Priority dates;Publication data including kind & date;Questel unique family ID (FAN);Family publication details;Priority numbers;WO parent publication number;Current assignees;Latest standardized assignees - inventors removed;Assignee country;Assignee address;Assignees - Count;Inventors;Inventor country;Inventor address;Title;Abstract;Claims;Object of invention;Advantages / Previous drawbacks;IPC - International classification;Independent claims;Technical concepts;Technology domains;Original document
2017-11-10;"CN107823639         A  2018-03-23 [CN107823639]
STG: (A) Published application
AP : 2017CN-1101293 2017-11-10";79182374;CN107823639         A  2018-03-23 [CN107823639];2017CN-1101293;;QILU ANIMAL HEALTH PRODUCTS;QILU ANIMAL HEALTH PRODUCTS;;;1;"XU LONGTAO
BI YUYU
GAO FENG
WANG LEI
MEI,LIU KONG";;;"(CN107823639)
Bovine viral diarrhoea virus inactivated vaccine and preparation method thereof";"(CN107823639)
The invention relates to an inactivated vaccine of a bovine viral diarrhoea virus (BVDV) and a preparation method of the inactivated vaccine, and belongs to the field of veterinary biological products. The vaccine is composed of four gene subtypes including BVDV I a, BVDV I b, BVDV II a and BVDV II b. The bovine viral diarrhoea inactivated vaccine is prepared by carrying out virus proliferation byusing a continuous cell line cultured by cell spinner bottles, full suspension and micro carriers, and optimizing a vaccine preparation process and the like. Safety and effectiveness testing resultsof the vaccine show that bovines are free of local and systemic adverse reactions after the bovine is immunized by the bovine viral diarrhoea virus inactivated vaccine; all the bovines receive immuneprotection; the vaccine is safe and reliable, and is capable of preventing diseases caused by different BVDV gene subtypes. The vaccine also comprises various types of monovalent inactivated vaccines,bivalent inactivated vaccines and tetravalent inactivated vaccines prepared from the four gene subtypes above.";"(CN107823639)
1. One bovine viral diarrhea inactivated vaccines, characterized in that killed vaccines are prepared by genetic subtypes four BVDV I a,BVDV I b,BVDV II a,BVDV II b Bovine Viral Diarrhea inactivated vaccine inactivated antigen.
2. Bovine viral diarrhea inactivated vaccine according to claim 1, characterized in with Bovine Viral Diarrhea Virus antigen is inactivated strain L, L2 strain bovine viral diarrhea virus, bovine viral diarrhea virus and bovine viral diarrhea virus strain T D strain prepared, wherein L is assumed to be strains 15 March 2017, other strains of (L2 strains, strain and strain T D) north star road No. 1 to No. 3 delivered 26 October 2017 beijing chaoyang district hospital China General Microbiological Culture Collection SHANGHAI microbial Institute Depository Center, accession numbers CGMCC No.13787,CGMCC No.14719,CGMCC No.14718 and the CGMCC No. 14720.
3. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in BVD BVDV I a subtype comprises means for causing an inactivated vaccine, inactivated vaccine subtypes BVDV I a i.e..
4. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in comprising means for causing inactivation of BVDV I b BVD vaccine subtypes, i.e. inactivated vaccine subtypes BVDV I b.
5. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in comprising means for BVDV II a subtype cause inactivation of BVD vaccine, inactivated vaccine subtypes BVDV II a i.e..
6. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in comprising means for causing inactivation of BVDV II b BVD vaccine subtypes, i.e. BVDV II b inactivated vaccine subtypes.
7. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in comprising means for BVDV I a, BVDV I b caused by BVD inactivated vaccine subtypes, i.e. inactivated vaccine divalent BVDV I a + b.
8. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in comprising means for BVDV II a, inactivated vaccine subtypes BVDV II b caused by BVD, i.e. inactivated vaccine divalent BVDV II a + b.
9. One bovine viral diarrhea inactivated vaccine according to claim 1, characterized in comprising means for BVDV I type, II type (each comprise a, subtypes b) caused by BVD vaccine inactivated, i.e. BVDV I (a + b), II (a + b) - type tetravalent inactivated vaccine.
10. One bovine viral diarrhea inactivated vaccine preparation method according to claim 1, characterized in that the method steps include:
(1) Cell culture: using MDBK cells were passaged and cultured;
(2) For propagating virus: L strain of the bovine viral diarrhea virus, bovine viral diarrhea virus L2 strains, bovine viral diarrhea virus and bovine viral diarrhea virus strain T D as a seed virus was inoculated bovine kidney cells were produced, and the preparation of a vaccine with virus antigen obtained through cell proliferation;
(3) Inactivating antigen: the prepared virus solution used is inactivated by inactivating agent;
(4) Dispensing shoot: the corresponding adjuvant and inactivated best antigens in a certain ratio with seedlings is performed.
11. One bovine viral diarrhea inactivated vaccine preparation method according to claim 1, characterized in MDBK cells using this method in the suspension culture or an adherent culture or/and the culture passaged and cultured in a manner/and micro carrier.";"(CN107823639)
It was found that the disease in the United States 1946 Olafson and the like, to the heat generation, characterized diarrhea and cough, referred to as bovine viral diarrhea.
The present invention relates to a bovine viral diarrhea virus (BVDV) an inactivated vaccine and its preparation method, which belongs to the veterinary field of biological products.
The present invention relates to a bovine viral diarrhea virus inactivated vaccine and its preparation method, which belongs to the veterinary field of biological products.";"(CN107823639)
MDBK cells may be four virus inoculation topathic creation, BVDV positive serum neutralization can be standard, BVDV IFA fluorescent antibody assay positive, reverse transcription polymerase chain reaction with reference to Bovine Viral Diarrhea disease such as Protocol protocol (SN/T 1905-2007), for BVDV 5'-UTR design specific primers, primer sequences are as follows:
The disease is widely distributed throughout the world, economic losses in cattle industry worldwide is caused by the primary etiological agent.";"A61K-039/12
A61K-039/295
A61K-039/39
A61P-031/14
C12N-007/00
C12N-007/06";"(CN107823639)
1. One bovine viral diarrhea inactivated vaccines, characterized in that killed vaccines are prepared by genetic subtypes four BVDV I a,BVDV I b,BVDV II a,BVDV II b Bovine Viral Diarrhea inactivated vaccine inactivated antigen.";"(CN107823639)
INACTIVATED VACCINE(100,27)
BOVINE VIRAL DIARRHEA(100,22)
BOVINE VIRAL DIARRHEA VIRUS(100,19)
INACTIVATED VACCINE SUBTYPE BVDV(100,4)
VIRUS INOCULATION TOPATHIC CREATION(82,1)
CULTURE MICROCARRIER VIRAL PROLIFERATION(65,1)
INACTIVATED VACCINE DIVALENT BVDV(64,2)
BVDV POSITIVE SERUM NEUTRALIZATION(51,1)
BVD INACTIVATED VACCINE SUBTYPE(50,1)
GENETIC SUBTYPE(49,1)
FLUORESCENT ANTIBODY ASSAY POSITIVE(40,1)
BVDV(38,109)
BVDV INACTIVATION(38,5)
COLLECTION SHANGHAI MICROBIAL INSTITUTE(38,1)
SERUM NEUTRALIZING ANTIBODY TITER(34,12)
BOVINE VIRAL DIARRHEA DISEASE(33,1)
KILLED VACCINE(32,5)
TETRAVALENT INACTIVATED VACCINE(32,1)
CATTLE INDUSTRY(30,1)
PRIMARY ETIOLOGICAL AGENT(30,1)
CHARACTERIZED DIARRHEA(29,1)
BVD BVDV(27,1)
NORTH STAR ROAD(26,3)
INACTIVATED GOOD ANTIGEN(25,1)
PRIMER SEQUENCE(25,1)
DISEASE(24,2)
ROLLER BOTTLE CELL(24,1)
BOVINE VIRAL DIARRHEA VIRUS ANTIGEN(23,1)
INACTIVATED BVDV ANTIGEN(22,6)
ADHERENT CULTURE(22,2)
BOVINE KIDNEY CELL(22,2)
DISPENSING SHOOT(22,2)
MARCH BVDV ANTIGEN AGE(20,5)
VIRUS PROPAGATION(20,5)
B BVD VACCINE SUBTYPE(20,1)
PRIMER(20,1)
SUBTYPE CAUSE INACTIVATION(20,1)
VIRUS INACTIVATED ANTIGEN(19,7)
ECONOMIC LOSS(19,2)
SEED VIRUS(19,2)
DISTRICT HOSPITAL CHINA GENERAL(19,1)
HEALTHY FEMALE GUINEA PIG(18,8)
NASAL SWAB(16,11)
BOVINE CALF SERUM(16,6)
CHINESE ANIMAL PHARMACOPEIA(16,4)
HEAT GENERATION(16,1)
WORLD(16,1)
INACTIVATED VACCINE INACTIVATED BVDV(15,3)
BIVALENT VACCINE HEALTHY LIVING(15,2)
B INACTIVATED VACCINE SUBTYPE(15,1)
COUGH(15,1)
DEPOSITORY CENTER(15,1)
REVERSE TRANSCRIPTION(15,1)
NECK MUSCLE INJECTION VACCINE(14,8)
DIVALENT INACTIVATED SHOOT(14,3)
VIRULENT CHALLENGE BVDV HEAD(14,3)
ANTIGEN(13,20)
ELISA DETECTION(13,16)
INCOME POISON(13,5)
FETAL BOVINE SERUM(13,4)
VIRUS SOLUTION PREPARATION(13,1)
VACCINE DOSAGE(12,6)
MICROBIAL SHANGHAI INSTITUTE(12,2)
SIGNIFICANT CLINICAL SIGN(11,7)
GUINEA PIG BVDV(11,5)
HEALTH SUSCEPTIBLE CALF(11,4)
MONOVALENT VACCINE DETECTION(11,4)
BIOLOGICAL PRODUCT VETERINARY FIELD(11,2)
SUBCUTANEOUSLY IMMUNIZED GUINEA PIG(11,2)
BVDV NEUTRALIZING ANTIBODY TITER(11,1)
NEUTRALIZING ANTIBODY TITER BVDV(11,1)
PREGNANCY FETAL MALFORMATION CREATION(11,1)
DOUBLE NEGATIVE ANTIBODY(10,10)
BVDV SERUM(10,4)
BOVINE VIRAL DIARRHEA VIRUS L(10,3)
MICROBIOLOGICAL CULTURE COLLECTION(10,2)
NEUTRALIZING ANTIBODY ASSAY(10,2)
CHINESE VETERINARY SPECIES DIRECTORY(10,1)
TETRAVALENT VACCINE SEEDLING(10,1)
BIOREACTOR INOCULATION(9,2)
CHAOYANG DISTRICT HOSPITAL(9,2)
VETERINARY PHARMACOPEIA(9,2)
BVDV MONOVALENT VACCINE(9,1)
BVDV VIRULENT STRAIN(9,1)
MONOVALENT VACCINE BVDV(9,1)
VACCINE BVDV ANTIGEN(9,1)
DAY POST CHALLENGE(8,4)
PATHOGEN DETECTION(8,4)
EMULSION ADJUVANT(8,3)
BIOREACTOR CULTURE(8,2)
CELL AGGREGATE DISAPPEARANCE(8,2)
CELL CULTURE VENOM POISONING(8,2)
CELL PROLIFERATION(8,2)
CONFLUENT MONOLAYER(8,2)
DIVALENT BVDV(8,2)
HARVESTED SUPERNATANT(8,2)
MINUTE OSCILLATION SUSPENSION CULTURE(8,2)
ROLLER BOTTLE CULTURE(8,2)
BOVINE IMMUNOGENIC VACCINE(8,1)
MONOVALENT INACTIVATED SHOOT(8,1)
MONOVALENT VACCINE EFFICACY(8,1)
PCR(8,1)
VIRUS INACTIVATION(8,1)
LEG MUSCLE INJECTION(7,9)
SNEEZE(7,9)
BOOSTER IMMUNIZATION(7,8)
CELL DENSITY(7,8)
CALF IMMUNE(7,2)
CELL CULTURE MEDIUM RESUSPENSION(7,2)
ERLENMEYER FLASK(7,2)
HEALTHY RABBIT(7,2)
NECK VACCINE(7,2)
PEOPLE REPUBLIC(7,2)
SUSPECTED ONSET(7,2)
VACCINE NECK MUSCLE INJECTION(7,2)
AGRICULTURE SCIENCE(7,1)
ATTACK VIRULENT STRAIN(7,1)
CULTURED BOVINE KIDNEY(7,1)
VACCINE EFFICACY TRIAL(7,1)
VERIFICATION APPENDIX PURITY(7,1)
BVDV D STRAIN ANTIGEN(6,7)
CULTURING CELL(6,4)
DAY CONTINUOUS OBSERVATION(6,4)
NEUTRALIZING ANTIBODY LEVEL(6,4)
NORMAL FOOD INTAKE(6,4)
BIVALENT VACCINE PREPARATION(6,1)
COW NOSTRIL(6,1)
IMMUNIZATION VACCINE INJECTION(6,1)
MONOVALENT VACCINE PREPARATION(6,1)
PESTIVIRUS GENUS(6,1)
STRANGE TOUCH NECK MUSCLE(6,1)
T D STRAIN(6,1)
TETRAVALENT VACCINE DETECTION(6,1)
TETRAVALENT VACCINE PREPARATION(6,1)
COW HEAD(5,4)
FULLY SUSPENDED CELL(5,4)
HEAD IMMUNE(5,4)
RESUSCITATION(5,4)
ANTIGEN PREPARATION(5,3)
GLUCOSE MEDIUM(5,3)
ACCESSION NUMBER(5,2)
CULTURE COMPLETION(5,2)
CULTURE FLASK(5,2)
DEACTIVATING DETECTION(5,2)
GIBCO COMPANY(5,2)
MICROCARRIER CHARGING(5,2)
PERIODIC OBSERVATION(5,2)
SUPERNATANT CULTURE MEDIUM(5,2)
VIRUS PARTICLE(5,2)
ACTIVE INGREDIENT BVDV(5,1)
BOVINE CHALLENGE(5,1)
BOVINE FECES(5,1)
BVDV GENOME(5,1)
BVDV SPLEEN(5,1)
CATTLE BVDV(5,1)
CATTLE DISEASE(5,1)
CENTURY YEAR(5,1)
CHINESE AGRICULTURE(5,1)
CHRONIC MUCOSAL DISEASE(5,1)
CLINICAL DIARRHEA(5,1)
COW MOUTH CHALLENGE MODE(5,1)
DAM ABORTION(5,1)
DISEASE PREVENTION(5,1)
FLAVIVIRIDAE FAMILY(5,1)
HARDENED MASS NECK(5,1)
HEALTH SENSE COW(5,1)
INACTIVATED VACCINE ANTIGEN(5,1)
INACTIVATION COMPLETION(5,1)
LI YOUMIN(5,1)
MULTIVALENT VACCINE(5,1)
PERSISTENT INFECTION(5,1)
RABBIT VACCINE INJECTION(5,1)
SEROLOGICAL SURVEY(5,1)
SUBGROUP BVDV(5,1)
VACCINE FINAL INSPECTION(5,1)
VETERINARY ASSOCIATION(5,1)
VIRUS INACTIVATING AGENT(5,1)
VIRUS INOCULATION(5,1)
VIRUS MULTIPLICATION(5,1)
ADJUVANT VOLUME RATIO(4,3)
INACTIVATED VACCINE EFFICIENCY UNIT(4,3)
STERILE TEST(4,3)
SUSPENSION CULTURE(4,3)
ANTIBODY DOUBLE NEGATIVE(4,2)
ARTIFICIAL SEQUENCE(4,2)
BIOREACTOR CELL CULTURE MEDIUM(4,2)
CELL INGROWTH(4,2)
CELL MORPHOLOGY(4,2)
FREEZING MEDIUM(4,2)
INOCULUM SAMPLE(4,2)
LEG INTRAMUSCULAR INJECTION(4,2)
LIQUID NITROGEN TANK SAVE(4,2)
MICROCARRIER CELL(4,2)
NECK INJECTION(4,2)
SAFETY TEST(4,2)
SEEDING CELL(4,2)
SERUM CONCENTRATION(4,2)
TEST EFFICACY(4,2)
UNIFORM SEEDING(4,2)
VENOM CELL CULTURE(4,2)
BOVINE IMMUNIZATION GROUP(4,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(4,1)
BVDV DETECTION(4,1)
BVDV L STRAIN CHALLENGE(4,1)
BVDV T STRAIN CHALLENGE(4,1)
CATTLE CONSUMING(4,1)
CELL DOMESTICATION(4,1)
CHALLENGE STRAIN(4,1)
FORMALDEHYDE WORKING CONCENTRATION(4,1)
INACTIVATED VACCINE PREPARATION(4,1)
MICROCARRIER SUSPENSION CULTURE(4,1)
SECURITY CHECK(4,1)
VACCINE SAFETY(4,1)
VIRUS ASSAY(4,1)
NEGATIVE CONTROL(3,23)
CONTROL RABBIT(3,4)
ANTIGEN MIAO(3,2)
BACTERIA(3,2)
BLIND PASS(3,2)
C FREEZE THAW CYCLING(3,2)
DISSOLVED OXYGEN CONTENT(3,2)
EDETIC ACID SOLUTION DIGESTION(3,2)
H INCUBATION(3,2)
INJECTION CELL CULTURE(3,2)
MEDIUM LITER(3,2)
MICROCARRIER CULTURE(3,2)
MYCOPLASMA(3,2)
NECK CONTROL GUINEA PIG(3,2)
PLUS CELL GROWTH SOLUTION(3,2)
PRESSURE HOMOGENIZER(3,2)
ROUND BOTTLE(3,2)
TOPATHIC MIAO(3,2)";Pharmaceuticals;Open
2017-11-09;"CN108570454         A  2018-09-25 [CN108570454]
STG: (A) Published application
AP : 2017CN-1098901 2017-11-09";81406930;CN108570454         A  2018-09-25 [CN108570454];2017CN-1098901;;JIANSHUN BIOSCIENCES;JIANSHUN BIOSCIENCES;;;1;"CAI SHIJUN
HOU RUIJUAN";;;"(CN108570454)
MDBK acclimation suspension method and two-stage virus production process";"(CN108570454)
The invention relates to an MDBK cell acclimation suspension method and a two-stage virus production process. According to the MDBK cell acclimation suspension method, adherent MDBK cells are acclimated to adapt to serum-free suspension culture and used as host cells for producing viruses which can have cytopathic effect or sensitivity on suspension MDBK cells by two-stage culture virus inoculation; when the cells grow to 2.0-20.0*10<6> cells/mL, diluting with a production culture medium by 1-5 times is performed to reach a density range of 1.0-10.0*10<6> cells/mL, and then virus inoculation is carried out or virus inoculation is performed before dilution. The suspension MDBK cells are adaptive to suspension growth in the serum-free chemical-defined culture medium, and the two-stage virusproduction process is simple and easy in amplification; liquid changing is avoided, and high culture medium utilization efficiency is achieved; production and growth culture media can be identical ornot and can be mixed proportionally to realize cell secondary growth and viral expression promotion.";"(CN108570454)
1. MDBK cell vaccine production of a suspension of the second-order culture method, comprising the steps of:
1) Cell Growth: MDBK cells suspended in growth medium to 2.0x106 cells/mL-20.0x106 cells/mL;
2) Resulted in elevated: inoculation amount at 10-1 -10-5 MOIbetween, or in step 3) after inoculation amount resulted in accordance with this;
3) Diluted/production medium supplemented with: diluted with production medium 1-5 times, after dilution cell density to 1.0x106 cells/mL-10.0x106 cells/mL;
4) the secondary growth: secondary growth of cells;
5) Optionally, harvesting the virus liquid was purified miao system.
2. MDBK cells cultured suspended second order of vaccine production method according to claim 1, wherein the suspension MDBK cells grow into the suspension tank culture, culture working volume of 30 L and above.
3. MDBK cell culturing the second-order vaccine production suspended method according to claim 1 or 2, wherein step 1) in cell density at 5.0x106 cells/mL-16.0x106 cells/mL, preferably, 6.0x106 cells/mL-15.0x106 cells/mL, most preferably, 10.0x106 cells/mL.
4. MDBK cells according to claim 1 to 3 according to any one of the two-step culture method suspended vaccine production, wherein step 2) in the cell inoculation amount at 10-1 -10-4 MOIbetween, more optimal ground, 10-1 -10-3 MOI,optimal grounding, 10-2 MOI.
5. MDBK cells according to claim 1 to 4 according to any one of the two-step culture method suspended vaccine production, wherein step 3) MDBK cells suspended in 1-4-fold diluted to a production medium, more preferably, 1-3-fold diluted, and most preferably 2-fold dilutions.
6. MDBK cells suspended in accordance with claim 1 to 5 according to any one of the two-stage culture vaccine production method, wherein step 3) resulted in the rear cell density in the 1.0x106 cells/mL-10.0x106 cells/mL, preferably, 4.0x106 cells/mL-10.0x106 cells/mL.
7. MDBK cells according to claim 1 to 6 according to any one of the two-step culture method suspended vaccine production, wherein the suspension MDBK cells is a vaccine produced as a suspending cells, MDBK cells adherent to or from the domestication, MDBK cells can be grown in suspension produced by suspending, preferably, suspended MDBK cells are transformed with adherent MDBK cells are acclimated to the domestication serum-free or low serum, serum-free acclimatization after acclimatization MDBK cells means that can be grown in a medium in absence of serum, proliferation, and the/or, preferably, suspended MDBK cells were suspended MDBK cells are transformed with adherent to the domestication.
8. MDBK cells according to claim 1 to 7 according to any one of the two-step culture method suspended vaccine production, wherein the virus is in the corresponding suspended MDBK cells sensitive, it is possible to produce a corresponding vaccine virus, preferably, selected from the group bovine diarrhea virus vaccine or infectious bovine rhinotracheitis vaccine viral.
9. MDBK cells suspended in accordance with claim 1 to 8 according to any one of the two-step culture method vaccine production, wherein the cell growth temperature at 35 °C-37 °C, resulted in elevated temperature after production of virus at 30 °C-37 °C.
10. MDBK cells according to any one of claim 1 to 9 suspension culturing the second-order vaccine production method, wherein the cell growth seeding density at 0.3x106 cells/mL-1.0x106 cells/mL cell, growing-degree days at 2-8 days at the highest cell density.";"(CN108570454)
The present invention also provides a suspension MDBK cells cultured associated second order of vaccine production method, comprising the steps of:
According to the present invention relates to a 1st aspect MDBK cell vaccine production method of a two-stage culture suspension, comprising the steps of:
According to the present invention relates to a 1st aspect MDBK cell vaccine production method of a two-stage culture suspension, comprising the steps of:
In other words, the present invention resides in the innovative: MDBK cells adherent with the present invention to low-serum, serum-free conditioned method and suspension acclimatization of acclimatization to the method, the obtained acclimatation cell growth state is stable, well dispersed, suitable for use in high-density, large scale culture, and facilitates viral replication and expression.
In other words, the present invention resides in the innovative: MDBK cells adherent with the present invention to low-serum, serum-free conditioned method and suspension acclimatization of acclimatization to the method, the obtained acclimatation cell growth state is stable, well dispersed, suitable for use in high-density, large scale culture, and facilitates viral replication and expression.";"(CN108570454)
Therefore, it is necessary to MDBK cell suspension acclimatization and serum-free conditioned method further study, and to overcome the above three drawbacks.
MDBK cells were acclimatized for suspended drawback of the prior art: 1, some not the full serum-free culture; 2, typically employ a two-step method of a rolling contact, that is first reduced to a serum-free suspension culture further, since the adherent culture medium applied is usually a basal medium in serum, based medium nutrient component is weak, the surface area/volume ratio generally adherent culture during acclimatization is small, limiting the nutritional intake, requiring a long time throughout the acclimatization procedure; 3, gene modified acclimatization, i.e. through genetic engineering, are in an adherent cell line is inserted into a gene fragment does not facilitate attachment, changing the original adherent culture, the cells were suspended growth, and then through continued optimization of the culture medium with serum-free high-density growth of the cells can be changed, this approach is easy to implement, but the insertion of the exogenous gene fragment, affecting the quality of the product.
is difficult to control, through Food and Drug Administration approval is difficult, and the suspension are relatively common for adherent culture serum-free culture, more cells can be grown per unit volume, it is possible to produce more biological products.
It is common practice in the case of adherent cell culture in a culture medium the cells grow adherently adding a predetermined amount of serum, and serum chemistry is not determined, and the quality is not stable, with a difference between batches, by means of which biological products produced by the cells, quality is difficult to control, through Food and Drug Administration approval is difficult, and the suspension are relatively common for adherent culture serum-free culture, more cells can be grown per unit volume, it is possible to produce more biological products.
In other words, the present invention is to overcome a technical problem solved by the disadvantages of prior art, adherent MDBK cells to provide a low serum, serum-free acclimatization and suspended habituation method, contacting the cell growth state is stable, well dispersed, suitable for large scale culture, and facilitates viral replication and expression.";"A61K-039/12
A61K-039/265
A61P-031/14
A61P-031/22
C12N-007/00
C12N-007/02";"(CN108570454)
1. MDBK cell vaccine production of a suspension of the second-order culture method, comprising the steps of: 1) Cell Growth: MDBK cells suspended in growth medium to 2.0x106 cells/mL-20.0x106 cells/mL;
2) Resulted in elevated: inoculation amount at 10-1 -10-5 MOIbetween, or in step 3) after inoculation amount resulted in accordance with this;
3) Diluted/production medium supplemented with: diluted with production medium 1-5 times, after dilution cell density to 1.0x106 cells/mL-10.0x106 cells/mL;
4) the secondary growth: secondary growth of cells;
5) Optionally, harvesting the virus liquid was purified miao system.";"(CN108570454)
ADHERENT CULTURE(100,3)
MDBK HABITUATION(100,1)
ORDER VIRAL PRODUCTION(100,1)
DRUG ADMINISTRATION APPROVAL(83,1)
VIRAL REPLICATION(80,2)
MDBK CELL(79,83)
EXOGENOUS GENE FRAGMENT(71,1)
ACCLIMATATION CELL GROWTH(70,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(69,3)
SUSPENSION ACCLIMATIZATION(64,1)
CULTURE CONTINUED OPTIMIZATION(59,1)
NUTRITIONAL INTAKE(54,1)
ADHERENT MDBK CELL(52,15)
GENE MODIFIED ACCLIMATIZATION(52,1)
NEWBORN CALF SERUM(51,26)
SUSPENSION CELL VACCINE PRODUCTION(48,1)
ACCLIMATIZATION(45,10)
ACCLIMATIZATION MDBK CELL(43,2)
SERUM CHEMISTRY(42,1)
VACCINE MDBK CELL(42,1)
VIRUS SUSCEPTIBILITY(42,1)
DILUTION CELL DENSITY(41,1)
ACCLIMATIZATION CULTURE(40,1)
SECONDARY VIRAL EXPRESSION(40,1)
BOVINE DIARRHEA VIRUS VACCINE(35,1)
ADHERENT CELL CULTURE(33,1)
SUSPENDED MDBK CELL SENSITIVE(33,1)
CELL GROWTH(32,18)
ADHERENT CULTURE MEDIUM(32,3)
SUSPENSION CULTURING(31,1)
SECONDARY CELL GROWTH(29,3)
CELL GROWTH SEEDING DENSITY(29,1)
GAUGE CULTURE DISH(25,8)
SECONDARY GROWTH(25,7)
MDBK CELL PRODUCED LESION(25,1)
MEDIUM NUTRIENT COMPONENT(25,1)
MEDIUM UTILIZATION EFFICIENCY(25,1)
SERUM FREE ACCLIMATIZATION(24,7)
MEDIUM SUSPENDED GROWTH(24,1)
SERUM FREE CULTURE(23,3)
VIRUS LIQUID(22,4)
BASAL MEDIUM(22,3)
BOVINE DIARRHEA VIRUS PRODUCTION(22,1)
PRODUCT QUALITY(22,1)
SUSPENSION SERUM FREE ADAPTATION(22,1)
CELL ML(21,146)
INOCULATION(21,10)
BIOLOGICAL PRODUCT(21,2)
SERUM ABSENCE(21,2)
HOST CELL(21,1)
PRODUCTION MEDIUM(20,14)
MOIBETWEEN(20,6)
BATCH(20,1)
FOOD(20,1)
ROLL(20,1)
CULTURE MEDIUM(19,7)
RPM SHAKER CULTURE(19,6)
SERUM FREE SUSPENSION CULTURE(19,2)
CULTURE VOLUME(18,26)
CO2 STATIONARY CULTURE(18,8)
SUSPENDED HABITUATION(18,2)
SERUM(17,12)
CELL MORPHOLOGY OBSERVATION(17,4)
OCCASIONAL REPLENISHMENT(17,4)
BIOLOGICAL STEADY CDSERY(17,3)
BIOLOGICAL AUTONOMOUS HABITUATION(17,2)
FULL SERUM FREE CULTURE(17,1)
TRYPSIN EDTA(16,6)
PRODUCTION CULTURE MEDIUM(16,2)
MIXING RATIO(16,1)
PRACTICE(16,1)
CULTURE VESSEL(15,8)
MICROSCOPE MDBK CELL(15,4)
REAR CELL DENSITY(15,1)
MASS CULTURE(14,3)
MDBK CELL ADHERENT CULTURE(14,2)
CELL VACCINE PRODUCTION(14,1)
QING COLLECTION(13,4)
SUSPENSION CULTURE FLASK(13,4)
CRYOPRESERVING MDBK CELL ADHERENT(13,1)
ELEVATED TEMPERATURE(13,1)
MDBK CELL ADHERENT ACCLIMATIZATION(13,1)
GLUCOSE(12,14)
MIAO(12,4)
CENTRIFUGE MDBK CELL(12,2)
DIGESTION SUBCULTURING(12,2)
ORDER VIRAL PMCROFION(12,2)
SHAKE FLASK CULTURE(12,2)
BVDV VIRUS INOCULATION(12,1)
ACCLIMATIZATION STAGE(11,4)
CELL CONDITION(11,4)
CELL RESUSCITATION(11,4)
PARTIAL CELL INOCULATION(11,4)
SHAKER FLASK(11,4)
GRADUALLY DECREASING SERUM(11,3)
BIOLOGICAL CDSERY(11,2)
DIGESTION SUBCULTURE(11,2)
GENTLY MDBK CELL(11,2)
MDBK CELL PELLET(11,2)
SCREENING ACCLIMATIZATION(11,2)
BVDV VIRUS MDBK CELL(11,1)
MDBK CELL BIOREACTOR CULTURE(11,1)
JSB DP(10,21)
LOW SERUM(10,12)
INCUBATOR(10,10)
NITROGEN TANK(10,9)
ANIMAL ORIGIN(10,5)
CELL GROWTH TEMPERATURE(10,3)
VIRUS REPLICATION(10,3)
BIOREACTOR TORRENT(10,1)
FROZEN ADHERENT MDBK CELL(10,1)
INVERTED MICROSCOPE MDBK GROWTH(10,1)
SUSPENDED MDBK GROWTH CULTURING(10,1)
SUPERNATANT(9,8)
BASAL MEDIUM DIGESTION(9,2)
CELL ML CELL(9,2)
CENTRIFUGAL PASSAGEWAY(9,2)
DAY MDBK CELL(9,2)
TANK MDBK CELL(9,2)
AGGLOMERATE(8,4)
GROWTH ENVIRONMENT(8,4)
LIVE CELL(8,4)
OPTIMAL GROWTH(8,4)
SURVIVING CELL(8,4)
ADHERENT CELL LINE(8,2)
CULTURE INFECTIOUS DOSE(8,1)
MDBK DOMESTICATION(8,1)
METHOD VACCINE PRODUCTION(8,1)
VIRAL ORDER(8,1)
DISPERSIBILITY(7,3)
SAMPLE COUNT(7,3)
BOVINE SERUM(7,2)
CELL GROWTH CULTURING(7,2)
CELL RESUSPENSION(7,2)
FLOTATION TANK(7,2)
FOLD DILUTION(7,2)
HARVESTED VIRUS LIQUID(7,2)
STERILE FILTRATION(7,2)
BIOPHARMACEUTICAL COMPANY(7,1)
BVDV MDBK CELL PRODUCTION(7,1)
CULTURE SUSPENSION MDBK CELL(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(7,1)
MEDIUM CD MDBK 21120L(7,1)
OPTIMIZED SUSPENSION MDBK CELL(7,1)
PERIODIC COUNT MDBK CELL(7,1)
PROGRESSIVE DECREASE(7,1)
RENAL EPITHELIAL CELL(7,1)
SERA MDBK CELL PROLIFERATION(7,1)
SUSPENDING MDBK CELL(7,1)
SUSPENSION DOMESTICATION(7,1)
FOLDING(6,8)
COOLING BOX(6,4)
CRYOTUBE(6,4)
DIGESTIVE JUICE(6,4)
FRONT ANCHORAGE(6,4)
GROWTH DENSITY(6,4)
REFRIGERATOR(6,4)
SERUM FREE CONDITIONED(6,4)
VITAMIN(6,4)
BIOLOGICAL STEADY SERIES(6,2)
CD HEK(6,2)
CD MDCK(6,2)
CENTRIFUGAL FLUID PASSAGE(6,2)
CULTURE MEDIUM PREPARATION(6,2)
CULTURE WORKING VOLUME(6,2)
DAY CULTURE CELL DENSITY(6,2)
DENSITY MODULATION(6,2)
GRADUAL DECREASE(6,2)
IRREGULAR PASSAGE(6,2)
MEDIUM MDBK CELL(6,2)
RECOVERED CELL(6,2)
RPM MIN CENTRIFUGATION(6,2)
SCREENING MEDIUM(6,2)
SECONDARY GROWTH START(6,2)
STABILIZATION(6,2)
SUSPENSION MEDIUM CULTURE(6,2)
ULTIMATELY INCREASING VIRAL YIELD(6,2)
ADVANCED INDUSTRIAL SCIENCE(6,1)
BOVINE KIDNEY CELL(6,1)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(6,1)
BVDV PICTURE(6,1)
BVDV VIRUS INFECTION(6,1)
CELL GROWING CULTURE(6,1)
CELL HIGH DENSITY GROWTH(6,1)
CULTURE PROLIFERATION(6,1)
LESION GROWTH(6,1)
MDBK CELL GROWTH(6,1)
NUMBERED JSB(6,1)
OPTIMIZED MDBK CELL(6,1)
REPLICATION COMPETENT VIRUS(6,1)
SEED VIRUS(6,1)
SLOW ACCLIMATATION(6,1)
SUSPENDED ACCLIMATIZATION(6,1)
TECHNOLOGICAL REQUIREMENT(6,1)
VACCINE MDBK CELL PRODUCING(6,1)
VACCINE PRODUCTION MDBK CELL(6,1)
VETERINARY VACCINE PRODUCTION(6,1)
VIRAL TITER(6,1)
DMEM(5,7)
HUMIDITY(5,6)
ROTATIONAL SPEED(5,6)
SINGLE CELL SUSPENSION(5,6)
MEDIUM SERUM CONCENTRATION(5,2)
ADHERENT CULTURE CONDITION(5,1)
ANCHORAGE DEPENDENT(5,1)
ANIMAL SERUM PLUS(5,1)
BIOLOGICAL STEADY MEDIUM(5,1)
CELL ADHESION(5,1)
CULTURE OTROPHIC COMPONENT(5,1)
DENSITY MDBK CELL(5,1)
DOWNSTREAM UNIVERSAL TECHNOLOGY(5,1)
FULLY COMPLIANT SUSPENSION CULTURE(5,1)
GENERATION ADAPTIVE PASSAGE(5,1)
GROWTH MEDIUM ADAPTATION(5,1)
INITIAL ACCLIMATATION GROWTH(5,1)
MDBK CELL DEVELOPMENT(5,1)
PRECIPITATE REMAINING MDBK CELL(5,1)
SUBCULTURED CELL(5,1)
SUSPENSION CULTURE CELL(5,1)
SUSPENSION CULTURE TECHNOLOGY(5,1)
TWO STAGE CULTURE SUSPENSION(5,1)
SURVIVAL RATE(4,5)
AFTER TRYPTIC DIGEST(4,4)
ATCC(4,4)
CELL VOLUME RATIO(4,4)
DISPERSED STATE(4,4)
ROOM TEMPERATURE DIGESTION(4,4)
ADSORPTION(4,2)
ANIMAL DERIVED CD(4,2)
CELL DISPERSION CONDITION(4,2)
CELL ML FROZEN CELL(4,2)
CHEMICAL COMPOSITION MDBK CELL(4,2)
CONFLUENT STATE(4,2)
CULTURE MEDIUM PRODUCTION(4,2)
DILUTED CELL DENSITY(4,2)
GENTLY COLLECTING STEP(4,2)
HYDROLYSIS PRODUCT(4,2)
INGREDIENT(4,2)
INITIAL GROWTH ARREST(4,2)
MLTIME(4,2)
OPTIMAL GROUND(4,2)
ORDER CULTURE(4,2)
PASSAGE STABLE GROWTH(4,2)
RETROVIRAL TEMPERATURE PRODUCTION(4,2)
STABLE CONTINUOUS GROWTH(4,2)
VIABILITY(4,2)
VOLUME CONCENTRATION PERCENTAGE(4,2)";Pharmaceuticals;Open
2017-08-30;"CN107569681         A  2018-01-12 [CN107569681]
STG: (A) Published application
AP : 2017CN-0764330 2017-08-30";78466673;CN107569681         A  2018-01-12 [CN107569681];2017CN-0764330;;"CHINA ANIMAL HUSBANDRY INDUSTRY
HARBIN VETERINARY RESEARCH INSTITUTE CAAS";"HARBIN VETERINARY RESEARCH INSTITUTE CAAS
CHINA ANIMAL HUSBANDRY INDUSTRY";;;2;"XU HEMIN
JIANG ZHIGANG
SHAO WEI
YU LI
PAN CHUNGANG
ZHANG AIMIN
LUO XIANYI
JIANG XIAOHONG
MA AIRONG
ZHOU JIANMIN";;;"(CN107569681)
Bivalent inactivated vaccine for bovine multocida pasteurellosis and preparation method of bivalent inactivated vaccine";"(CN107569681)
The invention relates to a bivalent inactivated vaccine for bovine multocida pasteurellosis, belonging to the technical field of preparation of veterinary biological products. The bivalent inactivatedvaccine provided by the invention is composed of antigens and a vaccine adjuvant, wherein the antigens are a bovine multocida pasteurellosis capsular type-A Pm-TJ strain and a bovine multocida pasteurellosis capsular type-B C45-2 strain. For the bivalent inactivated vaccine prepared by adopting the method provided by the invention, the concentration purifying process is adopted, the fermentationculture process of the bovine multocida pasteurellosis capsular type-B C45-2 strain is optimized, so that the fermentation time is shortened by one half, and the production efficiency is improved. Forthe bivalent inactivated vaccine provided by the invention, the bovine fibrinous and suppurative pneumonia and bovine hemorrhagic septicemia caused by bovine pasteurella multocida infection can be prevented through one-time injection immunization, and the bivalent inactivated vaccine has the features of safety, reliability and good immune effect.";"(CN107569681)
1. One M. Mannlaeimia Pap mannheimiosis divalent inactivated vaccines, characterized in, containing an antigen and an adjuvant, antigen is bovine P. multocida capsular A-Pm-TJ strain and B-type P. multocida capsular more cattle C45-2 strain, M. P. multocida capsular A-Pm-TJ accession number is CGMCC No. 3619 of strain, P. multocida capsular B-type bovine C45-2 CVCC 44502 an accession number of strain.
2. Bovine Mannlaeimia Pap mannheimiosis divalent inactivated vaccine according to claim 1, characterized in, M. P. multocida capsular A-type strain of Pm-TJ effective content 2.0-10.0 x109 CFU/mL;bovine P. multocida capsular B-type C45-2 strain of the active content of 2.0-10.0 x109 CFU/mL.
3. Bovine Mannlaeimia inactivated vaccine Pasteur mannheimiosis divalent according to claim 1, characterized in, M. P. multocida capsular A-type strain of Pm-TJ effective amount of 6.0x109 CFU/mL;bovine P. multocida capsular B-type strain of an effective amount of 4.0x10 C45-29 CFU/mL.
4. Claim 1-3 any bovine Mannlaeimia Pap mannheimiosis divalent inactivated vaccine preparation method, characterized in, comprises the following steps:
(1) A-type P. multocida capsular bovine Pm-TJ strain and B-type P. multocida capsular more cattle C45-2 strains were subjected to fermentation culture;
(2) Two strains of bacterial liquid was concentrated purified fermentation by centrifugation or hollow fibers, inactivated;
 (3) Two-killed bacterial liquid, according to a 2:1 volume ratio mixing, adding an adjuvant, mixed thoroughly, adding thimerosal solution, so that a final concentration of 0.005%, and the content of both antigens in the vaccine were not lower than 2.0x109 CFU/mL.
5. Preparation method according to claim 4, characterized in, step (1) A-type P. multocida capsular bovine strain of Pm-TJ is a method of fermentation medium: 1-2% of the Pm-TJ to strain in heart infusion broth was inoculated in the inoculation was of intellectual miao system, the amount of zo chase 35 C-37 C 6-10 hours incubation with progressive method, no more than 0.5 m and a maximum ventilation volume3 /h/10L.
6. Preparation method according to claim 4, characterized in, step (1) B-type P. multocida capsular bovine C45-2 strain of the fermentation culture method are: 1-2% C45-2 will be inoculated in the inoculation was with miao system containing 0.1% to strain in blood cells from whole blood is lysed broth Martin, 35 C-37 C 6-10 hours with progressive zo chase air amount of conditioned, no more than 0.5 m and a maximum aeration3 /h/10L;gradually zo chase air amount to 0-3 hours aeration rate was 0.1 m3 /h/10L,3-6hours aeration rate was 0.3 m3 /h/10L,6hours after aeration rate was 0.5 m3 /h/10L,not more than 0.5 m and a maximum ventilation volume3 /h/10L.
7. Preparation method according to claim 4, characterized in, step (1) two fermentation culture during the culture is performed in a non-uniform stirring.
8. In accordance with claim 4-7 either manufacturing method, characterized in, step (2) of the method to maintain a flow rate of bacterial suspension was centrifuged 2000-3000ml/min,8000-12000r/min continuous flow centrifuge, collecting bacterial sludge precipitated, resuspended in sterile PBS and washed with pH 7.2-7.4, 10-fold concentrated bacterial liquid was made.
9. In accordance with claim 4-7 either manufacturing method, characterized in, step (2) of the method to maintain a flow rate of bacterial liquid was centrifuged 2500ml/min,10000r/min continuous flow centrifuge, collecting bacterial sludge precipitated, resuspended in sterile PBS and washed with pH 7.2-7.4, 10-fold concentrated bacterial liquid was made.
10. In accordance with claim 4-7 either manufacturing method, characterized in, step (2) of a method for using 0.22 μm pore size hollow fiber concentrated purified hollow fiber was concentrated, controlling the pressure within 0.03 mpa, maintain the flow rate does not exceed 300 ml/min or less, so that it is concentrated to 1/10 the original times the bacterial suspension.
11. Claim 1-3 either bovine Mannlaeimia mice in Pap mannheimiosis divalent inactivated vaccine efficacy of the use of a check.
12. Application according to claim 11, characterized in, bovine Mannlaeimia Pap mannheimiosis inactivated vaccine immunization of mice at a dose of divalent to bovine immunogenic dose of 1/40 head parts.
13. Claim 1-3 rabbits in any one of bovine Mannlaeimia botulisms Pap test the efficacy of the use of divalent inactivated vaccines.
14. Application according to claim 13, characterized in, bovine Mannlaeimia Pap mannheimiosis inactivated vaccine dose of rabbits immunized with bovine bivalent immunogenic dose of 1/4 head parts.";"(CN107569681)
In order to achieve the purpose the present invention, the technical scheme of the present invention are as follows: one M.
The present invention relates to a pasteurized cow Mannlaeimia botulisms divalent inactivated vaccines, belongs to the veterinary biologic preparation technique field.
This patent describes the use of A-type by bacteria after culture BHI, an oil adjuvant is formulated to be inactivated vaccines, and the A.pg-A through a mouse model demonstrated to provide full protection to a virulent challenge, and with no cross-protection A.pg-B.";"(CN107569681)
In view of the immunologically cross-differential between different serotypes of P. multocida, existing products are commercially available A.pg-A may be required due to capsular prevention and bovine cellulosic purulent pneumonia, Pap mannheimiosis Mannlaeimia to cattle causes great difficulty in the prevention and control.
Thus, the best method is to make a pasteurized Mannlaeimia more cattle botulisms bivalent vaccine, which achieves its best preventive effect.
The present invention has the advantages of the present invention: (1) a divalent inactivated shoot to popular in China cellulosic purulent pneumonia and cattle out in hemorrhagic septicemia cattle can provide good immune protection efficacy.
The present invention make use of the batch 3 after vaccination cattle, both result in immune bovine obtain an effective protection of the virulent challenge, and the protective effect is not lower than monovalent vaccine of the same products, indicating that the present invention has a good immune protection of cattle against a vaccine prepared.
B-type bacteria single seedling can be effective in preventing bovine hemorrhagic septicemia, but the last two years of clinical applications in which, with a related article reports and individual subscriber's physical feedback, B-type bacteria single shoot injection bovine rear, there is a certain side effects, can result in severe cases death of the cattle; therefore B-type bacteria single shoot safety to be further improved.
In order to solve the problems in the prior art, the present invention Pasteur Mannlaeimia of the object is to provide one M. inactivated vaccine divalent mannheimiosis.
The disease belonging to the newly transmitted infectious disease in our country, province in China in recent years has spread to all areas of the major cattle, cattle industry has become a serious damage to the one of the diseases in China.";"A61K-039/102
A61K-039/116
A61P-007/04
A61P-011/00
A61P-031/04";"(CN107569681)
1. One M. Mannlaeimia Pap mannheimiosis divalent inactivated vaccines, characterized in, containing an antigen and an adjuvant, antigen is bovine P. multocida capsular A-Pm-TJ strain and B-type P. multocida capsular more cattle C45-2 strain, M. P. multocida capsular A-Pm-TJ accession number is CGMCC No. 3619 of strain, P. multocida capsular B-type bovine C45-2 CVCC 44502 an accession number of strain.";"(CN107569681)
MULTOCIDA(100,48)
STRAIN(100,36)
CATTLE(100,20)
DIVALENT INACTIVATED VACCINE(100,13)
PM TJ STRAIN(100,11)
BOVINE P(100,9)
ANTIGEN(100,7)
ADJUVANT(100,5)
ACCESSION(100,3)
MANNLAEIMIA(100,3)
B TYPE BOVINE C(100,2)
PM TJ ACCESSION(100,2)
INACTIVATED VACCINE PASTEUR MANNHEIMIOSIS(100,1)
MANNLAEIMIA PAP MANNHEIMIOSIS(100,1)
PASTEURIZED COW MANNLAEIMIA BOTULISM(100,1)
BOVINE MANNLAEIMIA PAP MANNHEIMIOSIS(95,4)
CATTLE BOTULISM BIVALENT VACCINE(67,1)
BOVINE CELLULOSIC PURULENT PNEUMONIA(61,1)
INACTIVATED VACCINE DIVALENT MANNHEIMIOSIS(46,1)
DIVALENT INACTIVATED SHOOT(41,1)
HEMORRHAGIC SEPTICEMIA CATTLE(38,3)
VIRULENT CHALLENGE PROTECTION(38,1)
CELLULOSIC PURULENT PNEUMONIA(34,5)
MULTOCIDA CAPSULAR BOVINE(33,1)
BOVINE HEMORRHAGIC SEPTICEMIA(32,1)
CATTLE IMMUNE PROTECTION(32,1)
BOVINE MANNLAEIMIA INACTIVATED VACCINE(31,1)
PAP MANNHEIMIOSIS(30,5)
CATTLE VACCINATION(29,1)
IMMUNE PROTECTION EFFICACY(29,1)
VIRULENT CHALLENGE(29,1)
CAPSULAR PREVENTION(27,1)
MONOVALENT VACCINE(27,1)
MOUSE INACTIVATED VACCINE IMMUNIZATION(27,1)
BIVALENT IMMUNOGENIC DOSE(26,1)
BOVINE MANNLAEIMIA MOUSE(26,1)
DIVALENT INACTIVATED VACCINE EFFICACY(26,1)
CAPSULAR BOVINE STRAIN(25,1)
TRANSMITTED INFECTIOUS DISEASE(25,1)
BOVINE CELLULOSIC FIBER(24,1)
BOVINE IMMUNE(22,1)
MANNLAEIMIA BOTULISM PAP TEST(22,1)
SUBSCRIBER PHYSICAL FEEDBACK(22,1)
VACCINE ADJUVANT(22,1)
ARTICLE REPORT(21,1)
BACTERIAL SLUDGE(20,5)
CATTLE INDUSTRY(20,1)
CATTLE STRAIN(20,1)
MULTOCIDA INFECTION(19,2)
PROGRESSIVE ZO CHASE AIR(19,1)
BOVINE IMMUNOGENIC DOSE(18,5)
OIL ADJUVANT(18,1)
INACTIVATED VACCINE(17,2)
INJECTION BOVINE REAR(16,1)
MOUSE MODEL(16,1)
BACTERIUM SINGLE SEEDLING(15,1)
VIRULENT BACTERIAL STRAIN(14,8)
DISEASE(14,3)
HOLLOW FIBER(13,15)
GRADUALLY ZO CHASE AIR(13,2)
SINGLE BACTERIUM(13,2)
CATTLE CAUSE GREAT DIFFICULTY(13,1)
CATTLE SEVERE CASE DEATH(13,1)
CHINESE ANIMAL PHARMACOPEIA(12,5)
PREVENTION(12,1)
PROVINCE(12,1)
STRAIN FERMENTATION CULTURE(12,1)
VACCINE(11,17)
ANTIGEN CONTENT(11,2)
FULL PROTECTION(11,1)
MAJOR CATTLE AREA(11,1)
MULTOCIDA CAPSULAR C(11,1)
MAXIMUM VENTILATION(10,5)
HOUR AERATION(10,4)
SEROTYPE(10,4)
BOVINE BIVALENT VACCINE IMMUNIZATION(10,2)
ACTIVE STRAIN(10,1)
INACTIVATED VACCINE PURIFICATION(10,1)
INTELLECTUAL MIAO(10,1)
CULTURE(9,19)
BEST PREVENTIVE EFFECT(9,1)
BACTERIA(8,10)
BOVINE EFFICACY(8,7)
BRAIN HEART INFUSION BROTH(8,2)
CLINICAL SYMPTOM MANNHEIMIOSIS(8,2)
BOVINE CELLULOSIC PURULENT PNEUMOCOCCUS(8,1)
NEEDLE(8,1)
PASTEUR MANNHEIMIOSIS CLINICAL SYMPTOM(8,1)
PM TJ EFFECTIVE CONTENT(8,1)
PROTECTIVE EFFECT(8,1)
BATCH(7,23)
CONTINUOUS FLOW CENTRIFUGE(7,5)
BOVINE IMMUNIZATION(7,4)
MAXIMUM AERATION(7,4)
POST CHALLENGE OBSERVATION(7,4)
CATTLE TRIAL NECK MUSCLE(7,3)
SEROTYPE POST CHALLENGE(7,3)
ACADEMY HARBIN VETERINARY STUDY(7,2)
CENTRIFUGATION(7,2)
VACCINE IMMUNIZATION BATCH(7,2)
BIOLOGIC PREPARATION TECHNIQUE FIELD(7,1)
CAPSULAR BOVINE C(7,1)
PAP MANNHEIMIOSIS CATTLE(7,1)
PAP MANNHEIMIOSIS PREVALENCE(7,1)
PASTEUR MANNHEIMIOSIS INACTIVATED VACCINE(7,1)
FOLDING(6,6)
MOUSE IMMUNIZATION(6,4)
ANIMAL HEALTH SENSE COW(6,3)
FINAL CONCENTRATION(6,3)
INACTIVATED VACCINE PREPARATION(6,3)
BIOPHARMACEUTICAL FACTORY(6,2)
CULTURE ASSAY VENTILATION(6,2)
MULTOCIDA BACTERIAL SUSPENSION(6,2)
CLINICAL APPLICATION(6,1)
HEART INFUSION AGAR SLANT(6,1)
INOCULATION BROTH MARTIN(6,1)
INOCULATION OVERDOSE VACCINE(6,1)
LIAO YANG SUNLIGHT(6,1)
MIXING VOLUME RATIO(6,1)
VACCINE IMMUNE MOUSE LOT(6,1)
ML MIN(5,8)
BROTH INOCULUM(5,3)
IMMUNE RABBIT(5,3)
LANZHOU PLANT(5,3)
CHINA AGRICULTURE(5,2)
CULTURE BACTERIAL VIABILITY COMPLETION(5,2)
HARVESTED BACTERIAL VIABILITY COUNT(5,2)
INACTIVATED VACCINE POTENCY(5,2)
RABBIT IMMUNIZATION(5,2)
VACCINE PREPARATION BATCH(5,2)
ADJUVANT GLUE ANTIGEN(5,1)
BOVINE CHALLENGE IMMUNIZATION(5,1)
BOVINE CLINICAL MANIFESTATION(5,1)
BOVINE DOSE IMMUNIZATION(5,1)
BRAIN HEART INFUSION AGAR(5,1)
CULTURE BROTH MARTIN(5,1)
FERMENTATION MEDIUM(5,1)
MANNLAEIMIA CALF BOVINE(5,1)
MARTIN BROTH AGAR(5,1)
PASTEUR COLI SEROTYPE(5,1)
RABBIT VACCINE EFFICACY(5,1)
VACCINE BATCH DOSE(5,1)
MILLILITER(4,6)
CENTRIFUGAL CONCENTRATION(4,4)
NODULE FORMATION(4,4)
PORE(4,4)
RESPIRATORY EVENT(4,4)
MINUTE STERILIZATION(4,3)
BOVINE CATTLE(4,2)
BOVINE HEAD IMMUNIZATION(4,2)
BOVINE MANNLAEIMIA PAP TEST(4,2)
P MLDMORE CATTLE(4,2)
RABBIT DEATH(4,2)
ANALYZED CALF MORBIDITY(4,1)
BIVALENT MANNHEIMIOSIS(4,1)
BOVINE ARTICLE PROTECTION IMMUNIZATION(4,1)
BOVINE RESPIRATORY DISEASE CANCER(4,1)
BUSS MANNHEIMIOSIS(4,1)
CATTLE BOTULISM(4,1)
CATTLE PM TJ STRAIN(4,1)
EPIDEMIC OUTBREAK(4,1)
KANG DAY LIVESTOCK(4,1)
MULTOCIDA INACTIVATED VACCINE(4,1)
MUSCLE INJECTION VACCINE(4,1)
PM TJ CHALLENGE STRAIN(4,1)
POST CHALLENGE SEEDLING(4,1)
REPEATED ADMINISTRATION CLINICAL MANIFESTATION(4,1)
TARGET ANIMAL OVERDOSE SAFETY(4,1)
TRACHEA INSTILLATION(4,1)
VACCINE PREPARATION IMMUNIZED MOUSE(4,1)
VIRULENT BACTERIAL SUSPENSION(4,1)
R MIN(3,10)
APPETITE(3,4)
MENTAL STATE(3,4)
MORTALITY(3,4)
PACK GROUP(3,4)
JITSUGYO CO(3,3)
STERILE GROWTH(3,3)
TARGET ANIMAL SAFETY TEST(3,3)
ABDOMINAL CAVITY INJECTION(3,2)
AERATION CULTURE CONDITION(3,2)
APPENDIX DETECTION(3,2)
BACTERIAL LIQUID BATCH(3,2)
BACTERIAL SUSPENSION FLOW RATE(3,2)
BATCH AERATION(3,2)
BOVINE P PREVENTION(3,2)
CALF MUSCLE INJECTION(3,2)
CONCENTRATED PURIFIED BACTERIAL COUNT(3,2)
OPTIMAL AERATION CONDITION(3,2)
PRIMARY SEED PROPAGATION(3,2)
PRODUCT COMPARATIVE EFFECTIVENESS(3,2)
SODIUM ETHYLMERCURITHIOSALICYLIC ACID SOLUTION(3,2)
VACCINE SUBCUTANEOUS INJECTION(3,2)
VIABLE CELL(3,2)
ANTIGEN STRAIN PREPARATION(3,1)
ASSAY EFFICACY(3,1)
BACTERIUM AERATION(3,1)
BEIJING GBU(3,1)
BEIJING OBO(3,1)
BIOLOGICAL PHARMACEUTICAL FACTORY PRODUCTION(3,1)
BIVALENT INACTIVATED VACCINE(3,1)
BLOOD AGAR(3,1)
BOVINE RANDOMIZATION(3,1)
BOVINE SEEDLING(3,1)
CATTLE BLEEDING(3,1)
CATTLE DEATH(3,1)
CHALLENGE DOSE(3,1)
CHALLENGE PROTECTION(3,1)
CLINICAL SCALE FARM(3,1)
CONCENTRATED BACTERIAL SUSPENSION(3,1)
CONCENTRATED PURIFIED FERMENTATION(3,1)
CROSS PROTECTION(3,1)
CULTURE INITIATION(3,1)
EXPANDED PM TJ STRAIN(3,1)
EXPERIMENTAL ANIMAL ASSOCIATION(3,1)
FERMENTER BROTH MEDIUM(3,1)
FINAL VACCINE ANTIGEN(3,1)
GROUP IMMUNIZED VACCINE BATCH(3,1)
HEALTHY ANIMAL SERUM(3,1)
HEART INFUSION AGAR PLATE(3,1)
IMMUNIZATION CHALLENGE(3,1)
IMMUNIZING DOSE(3,1)
IMMUNOGENIC CAPSULAR GOOD(3,1)
INACTIVATED VACCINE EFFICACY(3,1)
INOCULATED BRAIN(3,1)
MARTIN BROTH MEDIUM FORMULATION(3,1)
METERED DISPENSING(3,1)
MOUSE CORRELATION ANALYSIS(3,1)
NON UNIFORM STIRRING(3,1)
PM TJ STRAIN ANTIGEN(3,1)
PM TJ STRAIN IDENTIFICATION(3,1)
RABBIT CORRELATION ANALYSIS(3,1)
RABBIT POST CHALLENGE(3,1)
RECORDING CALF DEATH(3,1)
SEEDLING MARTIN(3,1)
SEGREGATED IDENTIFICATION(3,1)
SEROTYPE CULTURE(3,1)
STRAIN VIABLE COUNT(3,1)
SUCCESSFULLY ISOLATED PATHOGEN(3,1)
TEST RABBIT EFFECTIVENESS EFFICACY(3,1)
VACCINATION BATCH(3,1)
VACCINE MOUSE POTENCY TEST(3,1)
VACCINE PREPARED PAP(3,1)
VACCINE VIAL(3,1)
VIABLE BACTERIA CONCENTRATION(3,1)
WIDESPREAD BLEEDING(3,1)
CONTROL RABBIT(2,5)
EDITION(2,5)
BATCH CULTURE(2,4)
REACTOR(2,4)
BLOOD CELL LYSIS(2,3)
MOUSE GROUP(2,3)
MOUSE PROTECTION(2,3)
OBSERVATION PERIOD TEST BOVINE(2,3)
PURE CHECK(2,3)
ANTIGEN MIAO(2,2)
BACTERIAL LIQUID FLOW RATE(2,2)
BACTERIUM SINGLE SHOOT(2,2)
COLONY(2,2)
CORRELATION TEST(2,2)
HOMOGENEITY(2,2)
LYSED BLOOD CELL(2,2)
ONCE INOCULATED TEST(2,2)
PROTECTION RATIO(2,2)
SINGLE VACCINE DOSE(2,2)
SURVIVAL(2,2)
TEST COUNT(2,2)
ANIMAL EFFICACY TEST(2,1)
ANIMAL HUSBANDRY SHARE(2,1)
ARTICLE BATCH(2,1)
BACTERIAL CONCENTRATION(2,1)
BACTERIAL GROWTH CURVE(2,1)
BACTERIAL SPECIES(2,1)
BIOTECHNOLOGY CO(2,1)
BOVINE TEST DOSE(2,1)
BULK VACCINE(2,1)
CATTLE PROTECTION(2,1)
CLINICAL SIGN(2,1)
COMMERCIAL MONOVALENT VACCINE PRODUCT(2,1)
CREATING SHEAR(2,1)
EMULSION TANK(2,1)
HARVESTED BACTERIAL LIQUID(2,1)
INFECTIOUS DISEASE INTERNAL ORGAN(2,1)
LIQUID CULTURE FERMENTATION TANK(2,1)
LUNG PATHOLOGICAL CHANGE(2,1)
LYSED WHOLE BLOOD(2,1)
MOUSE IMMUNE(2,1)
ONCE INOCULATED OVERDOSE(2,1)
OPTIMAL INCUBATION(2,1)
OPTIMIZED CULTURE(2,1)
PM TJ STRAIN PREPARATION(2,1)
POISONING BACTERIUM P(2,1)
POURED BACKUP PLATE(2,1)
SERUM MARTIN(2,1)
STERILE CERTIFIED REAR(2,1)
TARGET ANIMAL PRODUCT GRANT(2,1)
TUBULAR CENTRIFUGE(2,1)
VACCINE INJECTION(2,1)
VACCINE PRODUCTION BATCH(2,1)
VIRULENT BACTERIAL LIQUID(2,1)
VOLUME STRAIN ANTIGEN(2,1)";Pharmaceuticals;Open
2017-08-28;"CN107586322         A  2018-01-16 [CN107586322]
STG: (A) Published application
AP : 2017CN-0748589 2017-08-28";78472435;CN107586322         A  2018-01-16 [CN107586322];2017CN-0748589;;HEILONGJIANG AUGUST FIRST LAND RECLAMATION UNIVERSITY;HEILONGJIANG AUGUST FIRST LAND RECLAMATION UNIVERSITY;;;1;NI HONGBO;;;"(CN107586322)
Infectious bovine rhinotracheitis virus gD protein antigen epitope polypeptide, and inhibitor, monoclonal antibody and application of polypeptide";"(CN107586322)
The invention belongs to the field of molecular biology and medicine, and specifically discloses an infectious bovine rhinotracheitis virus gD protein antigen epitope polypeptide and an application ofthe polypeptide in preparation of a reagent or a medicament for detecting or treating infectious bovine rhinotracheitis. The invention provides a monoclonal antibody for resisting the infectious bovine rhinotracheitis virus gD protein, and simultaneously the antigen epitope of the infectious bovine rhinotracheitis virus gD protein is screened out as <323>GEPKPGPSPDADRPE<337> (the shortest epitopesequence is 7 amino acid peptide fragments: <323>GEPKPGP<329>). The recombinant protein based on the antigen epitope can specifically be used to detect infectious bovine rhinotracheitis serum; in addition, a small-molecule inhibition drug designed based on the antigen epitope can block virus infection; and meanwhile, the multi-copy repeated epitope vaccine constructed on the basis of the antigenepitope can induce a high-titer gD protein antibody under the assistance of an appropriate adjuvant, and has a relatively high neutralizing antibody titer. The invention lays a foundation for establishing a detection method and researching and developing vaccines for the infectious bovine rhinotracheitis.";"(CN107586322)
1. One infectious bovine rhinotracheitis virus gD protein epitope polypeptide, characterized in, which comprises the amino acid sequence323 GEPKPGP329 fragments.
2. Claim 1 protein antigen epitopes with a polypeptide binding specificity of monoclonal antibodies such as anti-IBRV gD.
3. Claim 2 monoclonal antibodies secreted by the hybridoma cell strain.
4. Claim 1 epitope polypeptide for the manufacture of a reagent or infectious bovine rhinotracheitis detection application of the kit.
5. Claim 2 monoclonal antibody for the manufacture of a medicament for the treatment of infectious bovine rhinotracheitis application.
6. Claim 1 protein epitope of a polypeptide encoding nucleotide sequence.
7. One infectious bovine rhinotracheitis virus gD protein epitopes of a small molecule inhibitor, characterized in, small molecule inhibitors specific for the protein antigen epitope polypeptide according to claim 1, in combination with claim 1 protein epitope polypeptide inhibits the activity.
8. Inhibitor according to claim 7, characterized in, claim 1 protein epitope polypeptide binding to the inhibitor and inhibits the activity of the small molecule compound.
9. Claim 7 or 8 inhibitor for the manufacture of a medicament for the treatment of infectious bovine rhinotracheitis application.
10. Claim 1 protein epitope polypeptide in infectious bovine rhinotracheitis vaccine development of the application.";"(CN107586322)
Based on research, the present invention provides an infectious bovine rhinotracheitis virus gD protein epitope polypeptide, comprising an amino acid sequence of323 GEPKPGP329 (as shown in SEQ ID NO:1) fragments.
In order to achieve the purpose the present invention, the technical scheme of the present invention are as follows:
The present invention provides an anti-infectious bovine rhinotracheitis virus gD protein monoclonal antibody, while screening out infectious bovine rhinotracheitis virus gD protein epitope of an antigen323 GEPKPGPSPDADRPE337 (minimum epitope sequence of323 GEPKPGP329 7amino acids peptides), based on the antigenic epitope-specific detection of the recombinant protein can be infectious bovine rhinotracheitis serum; further based on the antigenic epitopes can be blocked for small molecule inhibitors of the designed medicaments viral infection; constructed based on the multiple copies of antigenic epitopes while repeating epitope vaccines, in a suitable adjuvant the aid, may induce high titer of gD protein antibody, and has a high neutralizing antibody titers.";"(CN107586322)
The present invention has the advantages that:
In order to solve the problems in the prior art, the present invention aims at resolving infectious bovine rhinotracheitis virus (IBRV) gD protein and screening for preparing a monoclonal antibody recognizing an epitope IBRV gD monoclonal antibody and the corresponding epitopes of the antigen, provide the basis for disease detection and treatment.";"A61K-039/265
A61K-039/42
A61K-045/00
A61P-011/00
A61P-031/22
C07K-014/06
C07K-016/08
C12N-005/20
G01N-033/569
G01N-033/68";"(CN107586322)
1. One infectious bovine rhinotracheitis virus gD protein epitope polypeptide, characterized in, which comprises the amino acid sequence323 GEPKPGP329 fragments.";"(CN107586322)
MONOCLONAL ANTIBODY(100,17)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,16)
INHIBITOR(100,7)
PROTEIN EPITOPE POLYPEPTIDE(100,5)
INFECTIOUS BOVINE RHINOTRACHEITIS SERUM(100,1)
ANTIGEN GD PROTEIN EPITOPE(87,1)
POLYPEPTIDE EPITOPE(78,4)
ANTIGENIC EPITOPE COPY(78,1)
REPEATING EPITOPE VACCINE(68,1)
INFECTIOUS BOVINE RHINOTRACHEITIS REAGENT(62,1)
NEUTRALIZING ANTIBODY TITER(60,2)
GD PROTEIN ANTIBODY(60,1)
GD PROTEIN(46,10)
MOLECULE INHIBITOR(46,4)
BOVINE RHINOTRACHEITIS VACCINE DEVELOPMENT(44,1)
GD PROTEIN MONOCLONAL ANTIBODY(42,3)
ANTIGENIC EPITOPE(42,2)
DESIGNED MEDICAMENT VIRAL INFECTION(37,1)
PROTEIN ANTIGEN EPITOPE POLYPEPTIDE(36,4)
GD MONOCLONAL ANTIBODY(36,1)
MONOCLONAL ANTIBODY RECOGNITION(36,1)
ANTIGEN EPITOPE(35,2)
AMINOACID PEPTIDE(34,1)
POLYPEPTIDE ENCODING(31,1)
MINIMUM EPITOPE SEQUENCE(29,1)
HYBRIDOMA CELL STRAIN(26,1)
MONOCLONAL ANTIBODY SPECIFICITY(26,1)
MEDICAMENT PREPARATION(25,1)
MEDICAMENT MANUFACTURE(24,4)
TITER(24,1)
FRAGMENT(22,3)
ADJUVANT(21,2)
INFECTIOUS BOVINE RHINOTRACHEITIS APPLICATION(20,3)
ANTIGENIC EPITOPE SPECIFIC DETECTION(20,1)
COMPOUND MOLECULE(16,1)
RECOMBINANT PROTEIN(15,3)
REAGENT MANUFACTURER(15,2)
AMINOACID SEQUENCE(14,4)
EPITOPE(12,6)
BOVINE RHINOTRACHEITIS SEROLOGICAL DIAGNOSIS(12,1)
BOVINE RHINOTRACHEITIS VACCINE CANDIDATE(12,1)
DISEASE DETECTION(12,1)
TETANUS TOXIN T CELL EPITOPE(12,1)
FOUNDATION(11,3)
INFECTIOUS BOVINE RHINOTRACHEITIS DETECTION(11,2)
INFECTIOUS BOVINE RHINOTRACHEITIS TREATMENT(11,2)
BOVINE RHINOTRACHEITIS DETECTION APPLICATION(11,1)
RUMINANT SIMPLEX VIRUS PROTEIN(10,1)
EPITOPE CONSERWD ANALYSIS(9,2)
IMMUNIZATION BLOOD COLLECTION(9,2)
HEI LONGJIANG PROVINCE(9,1)
IMMUNIZED MOUSE SPLEEN LYMPHOCYTE(9,1)
POLYPEPTIDE GD PROTEIN EPITOPE(9,1)
PROKARYOTIC RECOMBINANT GD PROTEIN(9,1)
ANTIBODY VACCINE TITER(8,1)
ANTIGENIC EPITOPE PRELIMINARY DETERMINATION(8,1)
DECREASE CHIMERIC EPITOPE VACCINE(8,1)
DEVELOPMENT ANTIGEN EPITOPE POLYPEPTIDE(8,1)
FREUND INCOMPLETE ADJUVANT(8,1)
GD PROTEIN BIOINFORMATICS(8,1)
LMLVIRUS CULTURE BROTH(8,1)
MOUSE RECOMBINANT PROKARYOTIC EXPRESSION(8,1)
POLYPEPTIDE PROTEIN EPITOPE EXPRESSION(8,1)
SUBCLASS IGG2A MONOCLONAL ANTIBODY(8,1)
CAPSULAR SAC(7,2)
ANTIGENIC EPITOPE IDENTIFICATION(7,1)
BLACK LONGJIANG EIGHTY(7,1)
CONJUNCTIVITIS SYMPTOM(7,1)
IPTG INDUCIBLE EXPRESSION(7,1)
NEUTRALIZATION TITER DILUTION FACTOR(7,1)
POLYPEPTIDE MOLECULE INHIBITOR(7,1)
SERUM NEUTRALIZING(7,1)
ARTIFICIAL SEQUENCE(6,4)
RECOMBINANT PROTEIN PURIFICATION(6,3)
SECONDARY ANTIBODY(6,3)
FLUORESCENCE MICROSCOPE(6,2)
STRAIN SECRETING(6,2)
EYEBALL BLOOD COLLECTION(6,1)
FETAL BOVINE SERUM(6,1)
INDIRECT ELISA SCREENING(6,1)
PROKARYOTIC EXPRESSION VECTOR(6,1)
REPETITION ENCODING GENE(6,1)
REPLICATION VIRAL PROTEIN(6,1)
SERUM ANTIBODY TITER(6,1)
SUCROSE GRADIENT CENTRIFUGATION(6,1)
WESTERN BLOT ASSAY(6,1)
ANTI GD PROTEIN(5,3)
PRIMARY ANTIBODY(5,3)
DRUG MOLECULE(5,2)
HRP LABELED GOAT(5,2)
ANTIBODY NEUTRALIZATION(5,1)
ANTIGEN DETECTION EPITOPE(5,1)
GD GC PROTEIN(5,1)
GD PROTEIN SEGMENT(5,1)
IDENTIFIED EPITOPE PEPTIDE(5,1)
IDENTIFIED EPITOPE POLYPEPTIDE(5,1)
INDIRECT IMMUNOFLUORESCENCE MAB(5,1)
MAB EPITOPE(5,1)
MAB REACTIVITY(5,1)
MATURE PROTEIN CREATION(5,1)
MEMBRANE PURIFIED VIRUS(5,1)
MONOCLONAL ANTIBODY SUBCLASS(5,1)
MOUSE BLOOD BIOCHEMICAL ANALYSIS(5,1)
NERVE GANGLIA(5,1)
PRECISE LOCATING EPITOPE(5,1)
RECLAMATION UNIVERSITY(5,1)
SUBCUTANEOUS IMMUNIZATION(5,1)
PGEX(4,6)
IGG ANTIBODY LEVEL(4,2)
MOLECULAR BIOLOGY FIELD(4,2)
MOUSE SERUM(4,2)
SERUM ANTIBODY LEVEL(4,2)
SERUM SEPARATION(4,2)
ANIMAL HERPES VIRUS(4,1)
ANIMAL TRADE(4,1)
ANTIBODY TITER EXPERIMENTAL GROUP(4,1)
BOVINE RESPIRATORY DISEASE(4,1)
CATTLE INDUSTRY(4,1)
CELL MONOLAYER(4,1)
CO2 INCUBATOR(4,1)
COMMERCIAL ELISA KIT(4,1)
CONSTRUCTION VACCINE EPITOPE(4,1)
ECORI SITE(4,1)
EPITOPE SCREENING(4,1)
EPTIPOE ATTACHMENT(4,1)
EXTREME DISCOMFORT(4,1)
FREUND COMPLETE ADJUVANT(4,1)
GD PEPTIDE(4,1)
GD RECOMBINANT PROTEIN(4,1)
GENE ENCODING(4,1)
HOMOLOGY MODELING(4,1)
IMMUNE PACKET(4,1)
IMMUNIZING DOSE(4,1)
IMMUNOLOGICAL ROUTE(4,1)
INDIRECT IMMUNOFLUORESCENCE EXPERIMENT(4,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS POLYPEPTIDE(4,1)
IPTG INDUCTION(4,1)
KBP FRAGMENT(4,1)
LATENT INFECTION(4,1)
MAB SHORT PEPTIDE REACTIVITY(4,1)
METHANOL FIXATION(4,1)
MONOCLONAL ANTIBODY CHARACTERIZATION(4,1)
MONOCLONAL ANTIBODY SCREENING(4,1)
NUCLEOTIDE SEQUENCE(4,1)
OUTSIDE WORLD DETOX(4,1)
PCR AMPLIFICATION(4,1)
PEPTIDE EPITOPE(4,1)
POSITIVE HYBRIDOMA CELL SCREENING(4,1)
PRECISE EPITOPE(4,1)
PRESS SPLEEN CELL(4,1)
REACTIVE MAB(4,1)
RECEPTOR PROTEIN(4,1)
RECOMBINANT PLASMID(4,1)
RECOMBINANT PROTEIN EXPRESSION(4,1)
RECOMBINANT PROTEIN REACTIVITY(4,1)
SECONDARY BACTERIAL INFECTION(4,1)
SERUM SAVE SEPARATION(4,1)
STERILE SPLEEN(4,1)
TAIL BLOOD(4,1)
TISSUE INJURY INFLAMMATORY CHANGE(4,1)
TISSUE SLICE(4,1)
TRUNCATED EXPRESSION(4,1)
TRUNCATED PCR(4,1)
VECTOR CONSTRUCT(4,1)
CELL FUSION(3,3)
CPG(3,3)
IDENTIFIED NEW EPITOPE(3,2)
IMMUNOGEN(3,2)
INDIRECT IMMUNOFLUORESCENCE ASSAY(3,2)
PROTEIN COATED ELISA PLATE(3,2)
ANTIBODY TITER LEVEL(3,1)
BIOCHEMICAL CO(3,1)
CELL CULTURE SUPERNATANT(3,1)
CELL LYSATE(3,1)
COATING ANTIGEN(3,1)
CREATION GOOD PROTECTION(3,1)
DETERMINATION KIT(3,1)
ECONOMIC LOSS DEVELOPMENT(3,1)
ELISA DETECTION(3,1)
GD ANALYSIS(3,1)
GENOME SEQUENCE(3,1)
INFECTED CELL(3,1)
INVERTED REPEAT REGION(3,1)
ISOLATED PEPTIDE SEQUENCE(3,1)
ITERATIVE SEQUENCE(3,1)
MONOCLONAL ANTIBODY REACTION(3,1)
MYELOMA CELL(3,1)
ORGAN OBSERVATION(3,1)";"Analysis of biological materials
Pharmaceuticals";Open
2017-07-10;"CN107299088         A  2017-10-27 [CN107299088]
STG: (A) Published application
AP : 2017CN-0560592 2017-07-10";77621177;CN107299088         A  2017-10-27 [CN107299088];2017CN-0560592;;INSTITUTE OF ANIMAL SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES;INSTITUTE OF ANIMAL SCIENCES CHINESE ACADEMY OF AGRICULTURAL SCIENCES;;;1;"CUI SHANGJIN
ZHAO ZHANZHONG
LIANG LIN";;;"(CN107299088)
IBRV-B (infectious bovine rhinotracheitis virus-B) strain and application thereof";"(CN107299088)
The invention discloses an IBRV-B (infectious bovine rhinotracheitis virus-B) strain and application thereof. The IBRV-B strain provided by the invention has the advantages of good immunogenicity and good culture characteristics. The IBRV-B strain is inoculated with MDBK cells; a culture material is harvested; beta-propiolactone is used for inactivation; then, the materials are mixed and emulsified with commercial Montanide<TM> ISA15AVG adjuvants of a French SEPPIC company to be made into an IBRV inactivated vaccine. Experiments prove that when the IBRV inactivated vaccine prepared by using the IBRV-B strain provided by the invention is used for immunizing ablactation health negative cow, the diseases caused by the IBRV can be prevented, so that the vaccine has the advantages of high safety, capability of fast antibody generation, long immunity period and the like.";"(CN107299088)
1. A strain of infectious bovine rhinotracheitis virus, characterized in, infectious bovine rhinotracheitis virus designated infectious bovine rhinotracheitis virus IBRV-B strain, deposited at the China General Microbiological Culture Collection Center, which species accession number: CGMCC No. 14294.
2. Claim 1 infectious bovine rhinotracheitis virus inactivating infectious bovine rhinotracheitis virus in the manufacture of a vaccine.
3. One infectious bovine rhinotracheitis virus inactivated vaccines, characterized in claim 1 comprising inactivated after infectious bovine rhinotracheitis virus.
4. Inactivated vaccine according to claim 3, characterized in inactivating means that the infectious bovine rhinotracheitis virus using 0.2% β - propiolactone inactivation at 4 °C under conditions of the 24 hours according to claim 1, and then inactivated β - propiolactone residual hydrolysis 24 hours at room temperature.
5. Claim 3 or 4 inactivated vaccine in the prevention of diseases caused by infectious bovine rhinotracheitis virus use of biological products.
6. Application according to claim 5, characterized in healthy female bovine respiratory disease condition to be generated.";"(CN107299088)
Further, the present invention also provides for the preparation of an inactivated vaccine be employed to prevent characterized in that after the present invention comprising inactivated infectious bovine rhinotracheitis virus diseases caused by the use of the biological products.
The present invention also provides infectious bovine rhinotracheitis virus inactivating infectious bovine rhinotracheitis virus in the manufacture of a vaccine.
The present invention is to provide a an object of the immunogenic good, the titer of the infectious bovine rhinotracheitis virus strain is stable; A second object of the present invention is to provide infectious bovine rhinotracheitis virus strain for the preparation of a vaccine; The present invention is to provide a further object of the strain produced by the infectious bovine rhinotracheitis virus vaccine; An object of the present invention is to provide a vaccine to a fifth embodiment for the manufacture of a medicament for the prevention of infectious bovine rhinotracheitis disease application.
In order to achieve the objective, the present invention adopts the following technical means:";"(CN107299088)
From the above results, in order to ensure good production of toxic immunogenic and safety, the present invention determines the passage of the virus in the maximum number of times generation 27, the original virus type is 7-11 generation, such as a virus based on the 12th-21 generation, the manufacture of up passage number is limited to 3 virus generation (22nd-25 generation) or less.
In view of the presence of other undesirable conditions in viral save time, assure viral shelf-life reliability, and therefore the infectious bovine rhinotracheitis virus IBRV-B strain at shidu-20 C is set at 12 months shelf life of, on the-70 C is set to 24 months of shelf-life of; to infectious bovine rhinotracheitis virus IBRV-B strain virus in freeze-20 C to save time is set to 36 months; lyophilized virus in-70 C to save time of 48 months.
Infectious bovine rhinotracheitis virus (Infectious bovine rhinotracheitisvirus,IBRV) can cause bovine suffering from an acute, febrile, contagious disease, appears as the upper respiratory tract inflammation and airway mucosa, respiratory distress, runny nose and other symptoms, can also cause pus cells of vulvitis, vaginitis, balanitis, conjunctivitis, abortion, young bovine meningitis, mastitis, metritis and other symptoms. 20 ** th century year 50 earliest the disease is found initially in Colorado, after other states are also successively finding that the disease.";"A61K-039/265
A61P-031/22
C12N-007/00
C12R-001/93";"(CN107299088)
1. A strain of infectious bovine rhinotracheitis virus, characterized in, infectious bovine rhinotracheitis virus designated infectious bovine rhinotracheitis virus IBRV-B strain, deposited at the China General Microbiological Culture Collection Center, which species accession number: CGMCC No. 14294.";"(CN107299088)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,57)
IBRV B STRAIN(100,15)
STRAIN(100,9)
CHINA GENERAL MICROBIOLOGICAL CULTURE(100,3)
COLLECTION CENTER(100,3)
SPECIES ACCESSION NUMBER(100,3)
INFECTIOUS BOVINE RHINOTRACHEITISVIRUS(100,1)
HEALTHY FEMALE CALF WEANING(81,1)
YOUNG BOVINE MENINGITIS(81,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS INACTIVATION(70,2)
VULVITIS PUS CELL(70,1)
TH CENTURY YEAR(64,1)
IMMUNITY LONG LASTING DURATION(63,1)
VIRAL SHELF LIFE RELIABILITY(57,1)
AIRWAY MUCOSA(56,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(56,1)
SHELF LIFE MONTH(52,1)
ANTIBODY QUICK CREATION(51,1)
BOVINE SUFFERING(50,1)
MONTH SHELF LIFE(50,1)
PROPIOLACTONE RESIDUAL HYDROLYSIS(50,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS DISEASE(48,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(47,1)
VACCINE MANUFACTURE(45,3)
INACTIVATED VACCINE PREPARATION(44,1)
MEDICAMENT MANUFACTURE(43,1)
LYOPHILIZED VIRUS(42,2)
SYMPTOM(42,2)
PROPIOLACTONE INACTIVATION(41,2)
VIRUS PASSAGE(40,1)
UPPER RESPIRATORY TRACT INFLAMMATION(36,1)
VACCINE PREPARATION(35,2)
CONJUNCTIVITIS(31,1)
RESPIRATORY DISTRESS(29,1)
VIRUS(28,12)
BOVINE RHINOTRACHEITIS DISEASE APPLICATION(28,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS INDUCED DISEASE(28,1)
SERUM NEUTRALIZING ANTIBODY TITER(27,4)
BALANITIS(27,1)
CONTAGIOUS DISEASE(27,1)
VAGINITIS(27,1)
VIRUS GENERATION(26,5)
ABORTION(26,1)
MASTITIS(26,1)
METRITIS(26,1)
COLORADO(25,1)
PREVENTION(25,1)
RUNNY NOSE(25,1)
VACCINE(24,15)
DISEASE(23,6)
SHIDU(22,1)
FREEZE(20,1)
CHINESE ANIMAL PHARMACOPEIA(19,3)
TITER(19,2)
OLD HEALTHY CALF(18,4)
MLINFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(18,1)
NEUTRALIZING TITER(17,5)
IMMUNOGENIC GOOD OBJECT(17,1)
BIOLOGICAL PRODUCT(16,2)
INTRANASAL SPRAY VACCINATION(16,2)
EXOGENOUS VIRAL CONTAMINATION(14,2)
MICROBIAL STUDY BEIJING(14,2)
VACCINE VIRUS SEED(14,2)
ACCLIMATIZATION DISEASED CATTLE(14,1)
DISPOSABLE OVERDOSE(13,3)
PREGNANT COW(13,3)
BOVINE RESPIRATORY DISEASE PREVENTION(13,2)
NORTH STAR ROAD(13,2)
VIRAL SAVE TIME(13,1)
VISCOUS PUS SEX NASAL(13,1)
ANTIBODY NEUTRALIZATION(12,3)
BOVINE VACCINE IMMUNIZATION(12,1)
CELLULOSIC EXUDATE PULMONARY EDEMA(12,1)
REED MUENCH(11,2)
IMMUNIZED ANTIBODY EBB(11,1)
SUBCLINICAL INFECTION SYMPTOM(11,1)
BOVINE NEUTRALIZING ANTIBODY(10,1)
DOSAGE IMMUNIZED CALF(10,1)
IMMUNE ANTIBODY TITER(10,1)
OLD HEALTHY SUSCEPTIBLE CALF(10,1)
PRIMORDIAL SEED BATCH(10,1)
SUSCEPTIBLE WEANED CALF(10,1)
VIRAL TITER MONTH(10,1)
INOCULATED SAFETY TEST(9,3)
VACCINE INJECTION(9,3)
BUBBLE ELIMINATION(9,2)
FOLD SERIAL DILUTION(9,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS INFECTED CATTLE(9,2)
LABORATORY PROTOTYPE(9,2)
VACCINE SAFETY(9,2)
VIRUS CULTURE(9,2)
ANTIBODY IMMUNE LAW(9,1)
BOVINE IMMUNIZATION(9,1)
BOVINE RESPIRATORY DISEASE SYNDROME(9,1)
DEEP MUSCLE INJECTION VACCINE(9,1)
EMULSIFICATION VACCINE PREPARATION(9,1)
HEALTHY FEMALE CALF(9,1)
IMMUNE HEALTH CALF(9,1)
LUNG TISSUE DESTRUCTION(9,1)
NEUTRALIZING ANTIBODY CORRELATION ANALYSIS(9,1)
NEUTRALIZING ANTIBODY TITER TEST(9,1)
POST IMMUNIZATION ANTIBODY(9,1)
PURULENT PNEUMONIA(9,1)
RHINOGARD USTRALIAN(9,1)
VIRUS INACTIVATING AGENT PROPAGATION(9,1)
COMMERCIAL VACCINE(8,2)
CYTOTOXIC GENERATION(8,2)
DEPOSIT DATE(8,2)
INACTIVATED VIRUS LIQUID(8,2)
OPTIMUM EMULSIFICATION(8,2)
POLY INTEGRATED BUNCH(8,2)
VIRAL INFECTION MAGNITUDE(8,2)
ACCLIMATIZATION STRAIN(8,1)
AUTOPSY LESION(8,1)
AVGADJUVANT EMULSION(8,1)
BEIJING CATTLE(8,1)
CAPSULAR SAC THICKNESS(8,1)
CHALLENGE PROTECTION CORRELATION(8,1)
CHINA AGRICULTURE(8,1)
EXOGENOUS TOXIC SPECIES(8,1)
EXPERIMENTAL ANIMAL GUINEA PIG(8,1)
FATTENING CATTLE(8,1)
FRANCE EMULSIFICATION(8,1)
FRENCH PHYSICIST(8,1)
IMMUNIZATION TITER(8,1)
IMMUNIZED GUINEA PIG(8,1)
INCOME POISON(8,1)
NECROTIC LESION(8,1)
NEUTRALIZING ANTIBODY DETECTION(8,1)
NOTE SHOOT CATTLE(8,1)
PURULENT SECRETION(8,1)
SUBUNIT VACCINE SEEDLING(8,1)
SYNCHRONIZATION SEEDING(8,1)
THREEDIMENSIONAL SYMMETRIC POSITIVE(8,1)
THYMUS LYMPHOCYTE(8,1)
TIME GENERATION(8,1)
TRACHEAL BLEEDING(8,1)
VACCINE LABORATORY PREPARATION(8,1)
VACCINE QUALITY CRITERIA(8,1)
VACCINE SHELF LIFE(8,1)
VETERINARY RESEARCH INSTITUTE SAVE(8,1)
VIRUS CULTURING(8,1)
PROPIOLACTONE(7,5)
INFLAMMATION CELL(7,2)
TITER PROLIFERATION(7,2)
IMMUNIZATION SCHEDULE(6,3)
ANTIBODY REACTION(6,2)
BATCH MIXING(6,2)
ABSCESS ABSENCE(6,1)
ADULT CATTLE(6,1)
ADULT GUINEA PIG(6,1)
BASAL CELL LIBRARY DISPENSING(6,1)
BOVINE IMMUNOGENIC GOOD(6,1)
CALF IMMUNE(6,1)
CHALLENGE PROTECTION REQUIREMENT(6,1)
COMMERCIAL MONTANIDETM(6,1)
DISPENSING BOTTLE(6,1)
EXPERIMENTAL VACCINE(6,1)
GENERATION VIRUS STRAIN(6,1)
HARVESTED VIRUS TITER(6,1)
HEALTHY CATTLE(6,1)
HEALTHY SURVIVAL(6,1)
IMMUNE CHALLENGE(6,1)
IMMUNE GUINEA PIG(6,1)
IMMUNIZATION DOSE(6,1)
IMMUNIZATION SERUM(6,1)
IMMUNIZED ANIMAL(6,1)
INACTIVATED VACCINE STRAIN(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS ATTACK(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS INFECTION(6,1)
KILLED VIRUS(6,1)
MADM VIRUS(6,1)
MULTIVALENT PLANTLET(6,1)
NERVE ATROPHY(6,1)
PERIOCULAR TISSUE(6,1)
SIGNIFICANT MACROSCOPIC LESION(6,1)
STANDARD POTENCY CUSTOMIZATION(6,1)
VACCINE EFFICACY(6,1)
VIRAL CHALLENGE(6,1)
VIRUS INOCULATION(6,1)
VOID MONOLAYER FORMATION(6,1)
ADULT BOVINE(5,1)
ANTIBODY ASSAY(5,1)
AQUEOUS FORMALDEHYDE(5,1)
BOLUS DOSE(5,1)
CLONED STRAIN(5,1)
CO2 INCUBATOR(5,1)
CULTURE OBSERVATION(5,1)
ELECTRON MICROSCOPE MORPHOLOGY(5,1)
HEALTH GUINEA PIG(5,1)
HIGHLY VIRULENT STRAIN(5,1)
IMMUNITY DURATION(5,1)
IMMUNIZATION SITE PRESENCE(5,1)
IMMUNOEFFICACY DETECTION(5,1)
INACTIVATED VACCINE DEVELOPMENT(5,1)
INOCULATION SITE(5,1)
INTERMEDIATE VACCINE BATCH(5,1)
LABORATORY BATCH PRODUCTION(5,1)
LOCAL OBSERVATION(5,1)
MARKER GENE DELETION(5,1)
MASTER CELL BANK(5,1)
MINIMUM IMMUNIZING DOSE(5,1)
OLD CALF(5,1)
PATIENT CALF(5,1)
PH PROPAGATION(5,1)
PLUS MONTANIDETM(5,1)
SAMPLE INSPECTION(5,1)
SEED LOT PRODUCTION(5,1)
SHELF LIFE DETERMINATION(5,1)
STERILE HOOD(5,1)
STRONG IRRITATING(5,1)
VIRUS ASSAY(5,1)
VIRUS SOLUTION TITER(5,1)
AQUEOUS PHASE(4,4)
APPENDIX(4,2)
COLONY(4,2)
CONTINUOUS STIRRING(4,2)
DISTRICT(4,2)
EMULSIFIER(4,2)
FINAL CONCENTRATION(4,2)
HOMOGENIZER(4,2)
STERILIZATION(4,2)
TEST EFFICACY(4,2)
VIRULENT EFFICIENCY UNIT(4,2)
ANTIBODY AVERAGE(4,1)
BASAL CELL BANK(4,1)
BLOOD COLLECTION(4,1)
BOOSTER IMMUNIZATION(4,1)
BRONCHIOLOPULMONARY WALL DAMAGE(4,1)
CLINICAL SYMPTOM DEGREE(4,1)
CULTURE SOLUTION PH(4,1)
DAY CONTINUOUS OBSERVATION(4,1)
DISEASE DEVELOPMENT(4,1)
DRAW BLOOD(4,1)
ECONOMIC LOSS(4,1)
FOOD INTAKE(4,1)
GENERATION VIRAL CONTENT(4,1)
INACTIVATED WHOLE(4,1)
INACTIVATION TEST(4,1)
INTERMEDIATE TRIAL BASIS(4,1)
LOCAL FLARE(4,1)
MYCOPLASMA TEST(4,1)
PERSISTENT REMAINS(4,1)
POST CHALLENGE(4,1)
PRODUCER CELL(4,1)
PROTECTION RATIO CHALLENGE(4,1)
SEPARATION OCCURRENCE(4,1)
STERILE GROWTH(4,1)
STERILE ROOM(4,1)
STRAIN GENERATION BASIS(4,1)";Pharmaceuticals;Open
2017-06-22;"KR10-2019-0000223   A  2019-01-02 [KR20190000223]
STG: (A) Published application
AP : 2017KR-0079300 2017-06-22
KR10-1938556        B1 2019-01-15 [KR101938556]
STG: (B1) Patent specification
AP : 2017KR-0079300 2017-06-22";83239514;"KR10-2019-0000223   A  2019-01-02 [KR20190000223]
KR10-1938556        B1 2019-01-15 [KR101938556]";2017KR-0079300;;REPUBLIC OF KOREA;REPUBLIC OF KOREA;;"(KR20190000223)
NAME=REPUBLIC OF KOREA(MANAGEMENT : RURAL DEVELOPMENT ADMINISTRATION) , REG=219981064455 
";1;"AHN, DONG JUN
HYUN BangHun
KIM, JAE JO
Choi
CHO, INN-SOO
SONG, JAE YOUNG
LIM, SEONG IN";"(KR101938556)
KR";"(KR101938556)
NAME=AHN, DONG JUN , COUNTRY=KR 

NAME=HYUN BangHun , COUNTRY=KR 

NAME=KIM, JAE JO , COUNTRY=KR 

NAME=Choi , COUNTRY=KR 

NAME=CHO, INN-SOO , COUNTRY=KR 

NAME=SONG, JAE YOUNG , COUNTRY=KR 

NAME=LIM, SEONG IN , COUNTRY=KR 
";"(KR101938556)
Vaccine Composition Containing Multiple Bovine Viral Diarrhoea Virus Vaccine Strains and Method of Preventing or Treating Bovine Viral Diarrhoea Virus Infection Diseases Using the Same";"(KR101938556)
The present invention relates to the consumer of the virus vaccine strain castle divers virus vaccine composition, and the consumer using the same stroke Castle disease virus infections of the present invention relates to a method for preventing or treating, and more particularly bovine kidney cells harvested by serial passage in different genotypes of the consumer (Genotype) virus vaccine strain castle divers virus (Bovine Viral Diarrhoea Virus, BVDV) at least one active ingredient 2 and the consumer is infected with the virus or viral castle divers to prevent viral infection of the virus for the treatment of consumer castle divers vaccine composition and the vaccine composition is used to castle disease virus consumer for preventing or treating viral infections of the stroke of the invention.";"(KR20190000223)
1. Bovine kidney cells harvested by continuous passage in a different virus genotype of the consumer (Genotype) virus vaccine strain castle divers at least 2 (Bovine Viral Diarrhoea Virus, BVDV) comprising as an active ingredient is the prevention or treatment of a viral infection of the consumer and the consumer castle divers virus vaccine composition for the treatment of viral infections castle divers.
2. Method according to claim 1, wherein the virus is of a different genotype castle divers virus vaccine strain is a consumer at the consumer (Wild field type) is open at the virus is a bovine kidney cells MDBK castle divers virus (Madin field Darby Bovine Kidney) inoculated 1x10 10 when two or more serial passaging6.0 -1x108.1 TCID50 /mlvirus viral titer of the virus with the consumer to castle divers to, composition.
3. Method according to claim 2, wherein the ratio of 15-30 is the number of serial passaging of the, composition.
4. Method according to claim 1, wherein the composition includes one or two or 2 of the 3 virus vaccine strain is castle divers consumer different virus genotype consumer castle divers virus vaccine strain is 1x104.0 TCID50 /ml has at least the viral titer, composition.
5. Method according to claim 1, wherein the consumer is different virus genotype 1a virus vaccine strain of genotype BVDV castle divers, genotype 2a and genotype 1b BVDV BVDV consisting of selected from the group consisting of the 2 and the at least one, composition.
6. Method according to claim 5, wherein the genotype of 1a is accession No. KCTC18531P as deposited under accession number BVDV BVD1a field JB (Bovine viral diarrhea virus) and, wherein the genotype of 1b is accession No. KCTC18532P as deposited under accession number BVDV BVD1b field JH (Bovine viral diarrhea virus) and, wherein the genotype of 2a is accession No. KCTC18533P as deposited under accession number BVDV BVD2a field CA characterized in that the (Bovine viral diarrhea virus), composition.
7. Method according to claim 1, wherein the composition is for ruminants virus constant consumer castle divers virus which is for inducing an immune response to the, composition.
8. Method according to claim 1, wherein the composition comprises IMS1313, carbopol ISA206 (Cabopol) and composed of at least one adjuvant selected from the group comprising 1 the, composition.
9. Method according to claim 9, wherein the composition is of a different genotype virus strain castle stroke volume of the consumer based on the viral vaccine adjuvant, 6-8:2-4 characterized in that it comprises, in the composition.
10. Method according to claim 1, wherein the composition comprises intramuscular, subcutaneous, intraperitoneal, intravenous, oral, dermal, ocular and brain selected from the group consisting of at least one route of administration of the 1 is administered through the, composition.
11. A vaccine according to any one of claims 1-10 method (with the proviso that, except for human) animal a composition for administration to a consumer of a different genotype is castle disease virus infection by divers in the prevention, protection, prevention, amelioration or treatment methods.";"(KR101938556)
Under such a technical background, the present inventors have found infection in agricultural and agricultural BVDV hanwoo cows continued to be generated by reducing the occurrence of persistent infectious disease sought solution to the distribution of genotype prevalence of recent National BVDV weeks and examined for their ability to cross protection between then, susceptible to infection with bovine BVDV, in particular for pregnancy BVDV MoW is effective for the production of protective antibodies to a variety of genotype BVDV for protection against high preventive vaccine to develop evenly=switch example as a result, the final selection of the particular vaccine strain is a genotype 3 BVDV serial passaging to passage number in an optimized BVDV were harvested and virus titer, each of the two or more kinds of different genotypes BVDV 2 vaccine strain inactivated mixture was then mixed, (e.g., IMS1313) ltadjuvanted mixed BVDV guinea pigs vaccinated with a preparation, mow and calves, the vaccine inoculation of mow BVDV colostrum ingestion of blood/serum neutralizing antibody titers in mail remarkably increased and maintained for a long period (guinea pig: postvaccination 12 weeks or more; calf: 16 weeks postvaccination) and has an extremely good protection against BVDV was confirmed, thereby completing the present invention.
It is an object of the present invention is constantly generated in Korea in different genotypes of the virus or viral infection of the consumer that the consumer divers castle virus vaccine composition for the treatment of viral infections divers castle of the device is provided.";"(KR101938556)
On the other hand, it can be seen from the viewpoint of industrial production, the cows are infected milk yield BVDV causes a decrease in the dairy industry because it leads to great problems.
Clinical symptoms are due to infection with BVDV six appears to be increased.
The present invention provides a viral vaccine strain of a plurality of consumer castle virus is a vaccine composition comprising a divers, and this virus is a viral infection using divers castle consumer treatment or prevention of diseases related to the method, and more particularly by serial passage in bovine kidney cells were harvested at different times of the viral Genotype the consumer is castle vaccine strain virus (Bovine Viral Diarrhoea Virus, BVDV) stroke of at least one of the 2 virus as an active ingredient in the consumer or consumer castle divers are infected with the virus in the viral infection of the virus and preventing stroke Castle Vaccine composition for use in the treatment, and the vaccine composition is a consumer using a Castle disease virus viral infection prophylaxis or treatment of stroke of the present invention relates to a method.
The cause of the disease in the body of a pestivirus of the Flaviviridae family (Flaviviridae) belonging to the genus RNA (pestivirus) virus cytopathic effect in cell lines and depending on whether or not causing cytopathic strain (Cytopathic BVDV: NADL, Singer, T20 weeks and the like) and the main [ ] (Non field Cytopathic BVDV: New York weeks etc.) biotype is classified as (Biotype).";"A61K-039/00
A61K-039/15
A61K-039/39";"(KR101938556)
1. KCTC18531P Deposited under accession number ECACC accession numbers castle divers virus vaccine strain is the consumer BVD1a field JB virus, KCTC18532P virus deposited under accession number ECACC accession number of the consumer is castle divers virus vaccine strain as deposited under accession number KCTC18533P and accession number BVD1b field JH virus vaccine strain of a consumer is castle divers BVD2a field CA virus selected from the group consisting of at least one consumer virus 2 virus is vaccine strain castle divers comprising as an active ingredient and a mixture of, wherein the genotype of 1a is BVD1a field JB castle divers virus and the virus is a consumer, the consumer is of genotype 1b BVD1b field JH castle divers virus and the virus, the 2a of genotype BVD2a field CA is castle divers virus virus is the consumer, the consumer is the prevention of infection of the virus or viral castle divers castle stroke for the treatment of viral infectious virus consumer vaccine composition.";"(KR20190000223)
VACCINE(100,110)
GENOTYPE(100,88)
BVDV(100,72)
CONSUMER(100,21)
BOVINE VIRAL DIARRHEA VIRUS(100,15)
BOVINE KIDNEY CELL(100,10)
VIRUS VACCINE(100,10)
CASTLE DIVER(100,4)
DIVER VIRUS VACCINE(100,3)
WATER(100,3)
CONSUMER VIRUS GENOTYPE(100,2)
CASTLE DISEASE VIRUS VIRAL INFECTION(100,1)
CONSUMER VIRUS CASTLE(100,1)
CONTINUOUS PASSAGE(100,1)
TREATING DIVER(100,1)
CONSUMER CASTLE DIVER(79,5)
BVDV COLOSTRUM INGESTION(67,1)
VIRAL INFECTION CASTLE DIVER(67,1)
ACCESSION NUMB BVDV BVD2A(63,1)
GENOTYPE BVDV CASTLE DIVER(62,1)
CASTLE REOVIRAL CONSUMER(59,1)
CASTLE VIRUS GENOTYPE(58,1)
CYTOPATHIC BVDV(56,2)
VIRAL INFECTION DISEASE VIRUS(55,2)
CASTLE DIVER VIRUS VACCINE(54,1)
DIGESTIVE TRACT MUCOSA INFECTION(54,1)
DIVER CASTLE VACCINE(54,1)
SYSTEMIC ORGAN INVOLVEMENT(52,1)
BVDV SERIAL PASSAGING(51,1)
CONSUMER VIRUS VACCINE(47,1)
RECENT NATIONAL BVDV WEEK(46,1)
GENOTYPE PREVALENCE DISTRIBUTION(44,1)
MLVIRUS VIRAL TITER(44,1)
DIVER CASTLE VIRUS(40,3)
DIARRHEIC MUCOSA(40,1)
STROKE CASTLE DISEASE VIRUS INFECTION(40,1)
CONSUMER DIVER CASTLE(39,5)
CASTLE DIVER CONSUMER(39,1)
GENOTYPE CONSUMER CASTLE(39,1)
FLAVIVIRIDAE FAMILY(38,1)
PREGNANCY BVDV(38,1)
WEEK POST VACCINATION(38,1)
CONSUMER CASTLE DISEASE(37,1)
RESPIRATORY SYSTEM LESION(37,1)
NEUTRALIZING ANTIBODY TITER(36,5)
BVDV DEFENSE(36,1)
DIVER CASTLE(33,4)
VACCINE INOCULATION(33,2)
PATHOLOGICAL CONDITION BULGING(33,1)
STRESS PARTOGRAM(33,1)
CYTOPATHIC STRAIN(32,1)
INFECTIOUS DISEASE SOUGHT SOLUTION(32,1)
OPTIMIZED BVDV(32,1)
ORAL MUCOSA ULCERATION(32,1)
VIRAL DIVER(32,1)
VIRAL INFECTION VIRUS TREATMENT(31,1)
RNA VIRUS GENUS(30,1)
DARBY BOVINE KIDNEY(29,5)
PREVENTION(28,7)
ACTIVE INGREDIENT(27,7)
CONSUMER CASTLE STROKE VOLUME(27,1)
EA VIRUS(27,1)
EPITHELIAL CELL(27,1)
PROTECTIVE ANTIBODY PRODUCTION(27,1)
CELL DEGENERATION(26,1)
RUMINANT VIRUS CONSTANT CONSUMER(26,1)
SEVERE PILOT(26,1)
CLINICAL SYMPTOM(25,14)
VIRAL INFECTION TREATMENT(25,4)
BVDV MIXTURE(25,1)
SEVERE DISEASE(25,1)
VIRAL VACCINE ADJUVANT(25,1)
CARBOPOL ISA(24,1)
INOCULATED 1X(24,1)
VIRUS PREVENTION(24,1)
INFECTIOUS DISEASE(23,3)
DIVER VIRUS(22,4)
GENOTYPE VARIETY(22,1)
PESTIVIRUS BODY(22,1)
GENOTYPE SPECIFIC VACCINE(21,1)
VIRUS(20,48)
1B GENOTYPE(20,1)
POST VACCINATION(20,1)
FLAVIVIRIDAE(19,1)
PESTIVIRUS(18,1)
INFECTION(17,12)
VIRUS DIVER CASTLE(17,5)
FLEXIBLE POLYMER(17,1)
IMMUNOPRECIPITATION ASSAY(16,10)
VIRAL INFECTION(16,4)
CONSUMER DIVER CASTLE VIRUS(16,3)
GINGIVA(16,1)
MORTALITY(16,1)
GUINEA PIG(15,20)
ADJUVANT(15,15)
DISEASE CAUSE(15,1)
EVENLY HIGH PREVENTIVE VACCINE(15,1)
SINGER(15,1)
STROKE CASTLE CONSUMER TISSUE(14,4)
2A GENOTYPE(14,3)
CATTLE(13,10)
BIOSCIENCE KOREA RESEARCH INSTITUTE(13,4)
HARD PALATE(13,1)
CONSUMER CASTLE VIRUS(12,3)
BIOTYPE(12,2)
BOVINE RESPIRATORY VIRUS VACCINE(12,2)
CYTOPATHIC EFFECT(12,2)
DIARRHEA(12,2)
GENOTYPE BVDV DIVER CASTLE(12,1)
PLACENTAL INFECTION LENTIGINOUS ATAXIA(12,1)
SECONDARY INFECTION(12,1)
COMPLEMENT FIXATION ASSAY(11,10)
IMMUNODIFFUSION ASSAY(11,5)
ORGANISM(11,2)
OUTDOOR SICK BVDV(11,2)
CASTLE VACCINE REOVIRAL CONSUMER(11,1)
VACCINE BVDV CALF INOCULATION(11,1)
TCID(10,19)
IMS(10,17)
POLYCLONAL ANTIBODY(10,5)
ANTIBODY NEUTRALIZATION(10,4)
FITC LABELED ANTI MOUSE(10,2)
ULCER(10,2)
BVDV VACCINATION GENOTYPE(10,1)
CASTLE REOVIRAL CONSUMER VIRUS(10,1)
DIVER CASTLE CONSUMER BVDV(10,1)
EFFORT RESULT(10,1)
GENETIC VACCINE INOCULATION BVDV(10,1)
GENOTYPE BVDV VIRAL TITER(10,1)
VIRAL INFECTION DIVER(10,1)
VIRUS TITER(9,10)
PROVISO(9,7)
WESTERN BLOTTING(9,5)
PERSISTENT INFECTION(9,4)
BLOOD SERUM(9,2)
FLUORESCENT ANTIBODY DIAGNOSTICS(9,2)
GENOTYPE VACCINE STRAIN(9,2)
INFECTION SERIAL PASSAGING(9,2)
VIRAL VACCINE STRAIN DIVER(9,2)
BIOCOM PATIBLE ADJUVANT(9,1)
BVDV VACCINE STRAIN IMS(9,1)
GENOTYPE BVDV VACCINE STRAIN(9,1)
REPRODUCTIVE DISORDER CLINICAL SYMPTOM(9,1)
VACCINE BVDV CALF SERUM(9,1)
VACCINE STRAIN BVDV INOCULATION(9,1)
CALF(8,6)
BOVINE(8,5)
SERIAL PASSAGE(8,5)
ANTIBODY SERUM(8,4)
SEPPIC WITTHAKER(8,2)
6LOG ANTIBODY TITER(8,1)
ACCESSION BVDV BIOTECHNOLOGY RESEARCH INSTITUTE(8,1)
ANTI MOUSE IMMUNOGLOBULIN ANTIBODY(8,1)
BVDV ANTIGEN DIAGNOSTIC KIT(8,1)
BVDV VACCINE COMPOSITION INOCULATEDMOW(8,1)
BVDV VACCINE INOCULATION(8,1)
CA IMPACTION ANTIBODY TITER(8,1)
COLOSTRUM INGESTION POE(8,1)
CONSUMER CASTLE VACCINE STRAIN(8,1)
DIABETES SYMPTOM CONGESTIBLE PLACENTA(8,1)
EXTINGUISHER VIRUS VACCINE(8,1)
EXTREME CASE(8,1)
FETAL THYMUS TISSUE DEFORMITY(8,1)
FLU UREIDO FLUORESCEIN(8,1)
INFECTED ANIMAL BVDV IDENTIFICATION(8,1)
INOCULATED BVDV GENOTYPE(8,1)
INOCULATING VIRUS BVDV(8,1)
MORPHOLOGICAL BVDV SPHERICAL MEMBRANE(8,1)
PREGNANT COW INFECTION(8,1)
REOVIRAL CASTLE VIRUS(8,1)
SECONDARY BIOTINYLATED ANTI MOUSE IGG(8,1)
SUCCESSIVE SUBCULTURE BVDV GENE(8,1)
SYMPTOMOLOGY SEROLOGICAL ASSAY(8,1)
VACCINATED BVDV ANTIBODY(8,1)
VACCINE INOCULATION MOURNING(8,1)
VIRAL TITER BVDV(8,1)
WEEK POST VACCINATION TITER(8,1)
POST(7,6)
WEEK INTERVAL(7,6)
ABC KIT(7,4)
BINARY ETHYLENEIMINE(7,2)
GENITAL INFECTION(7,2)
GENOTYPE 2A VACCINE(7,2)
HORSERADISH PEROXIDASE(7,2)
INFECTIOUS DISEASE DURATION(7,2)
INTRAPERITONEAL ADMINISTRATION(7,2)
LACTATING COW(7,2)
MONOCLONAL ANTIBODY BVDV(7,2)
MULTIVALENT VACCINE(7,2)
BOVINE GASTROINTESTINAL VIRUS(7,1)
BREATHING IMMINENT INFECTION(7,1)
BVDV INFECTED CATTLE(7,1)
BVDV INFECTION PERSISTENCE(7,1)
BVDV MDBK PROPAGATION(7,1)
BVDV VIRAL PROPAGATION(7,1)
BVDV VIRUS PROLIFERATION(7,1)
BVDV WEEK VACCINE(7,1)
CASTLE VIRUS VACCINE(7,1)
CULTURE BVDV GENOTYPE(7,1)
DIVER CASTLE DEBRIS(7,1)
GUINEA PIG BVDV SERUM(7,1)
GUINEA PIG INOCULATED BVDV(7,1)
IMMUNIZED MOTHER IMMUNE SERA(7,1)
MEASURING ANTIBODY TITER NEUTRALIZING(7,1)
PARENT ANTIBODY INOCULATION(7,1)
PREGNANCY II BVDV VACCINATION(7,1)
REOVIRAL CASTLE STROKE(7,1)
RESPIRATORY CLINICAL SYMPTOM(7,1)
TEMPORARILY COCLEA SYMPTOM(7,1)
VACCINE STRAIN GENOTYPE(7,1)
VACCINE STRAIN INOCULATION(7,1)
RADIOIMMUNOASSAY(6,10)
PROTEINCHIP ASSAY(6,5)
VACCINE FINAL SELECTION(6,4)
DISEASE PREVENTION(6,3)
VIRUS ISOLATION(6,3)
BOVINE HERPES VIRUS(6,2)
BVDV BEI(6,2)
FLUORESCENCE MICROSCOPE(6,2)
IMMUNOGLOBULIN MOLECULE(6,2)
NEUTRALIZATION ASSAY(6,2)
VACCINE FORMULATION(6,2)
VIRUS INFECTION(6,2)
ANIMAL INFECTION PERSISTENCE(6,1)
ANIMAL TOBVDV ANTIBODY(6,1)
ANTIBODY TITER IRRADIATION(6,1)
BOVINE ANIMAL GESTATION(6,1)
CASTLE CONSUMER CULTURE(6,1)
CASTLE CONSUMER WEEK(6,1)
CLINICALLY SEVERE DIARRHEA(6,1)
CONSUMER RNA DIVER(6,1)
CONSUMER VIRAL TITER(6,1)
DIVER VIRUS CONSUMER(6,1)
ESTABLISHED BVDV SERIAL PASSAGING(6,1)
EUROPE BVDV DISEASE(6,1)
FITC RABBIT IGG(6,1)
GENOTYPE COMPOSITION BVDV CULTURE(6,1)
GOAT IGG FITC(6,1)
MAIL ANTIBODY TITER(6,1)
MDBK BOVINE KIDNEY CELL(6,1)
NEUTRALIZING ANTIBODY ASSAY(6,1)
OUTDOOR SICK VIRUS(6,1)
SERIALLY PASSAGED CULTURE(6,1)
TARGET 1A BVDV GENOTYPE(6,1)
VACCINATION INOCULATION(6,1)
VIRAL INFECTION VIRUS VACCINE(6,1)
VIRUS CONSUMER DIVER(6,1)
VIRUS SERIAL PASSAGING(6,1)
RT PCR(5,3)
VACCINE MIXTURE(5,3)
10X DAB(5,2)
AGE MONTH(5,2)
LABELED REAGENT(5,2)
MAIL ADDRESS(5,2)
1A GENOTYPE BVDV(5,1)
1A VACCINE GENOTYPE(5,1)
1A WEEK GENOTYPE(5,1)
ABILITY INVERSEDDUETOTHE BVDV(5,1)
ACCESSION BVDV RESEARCH INSTITUTE(5,1)
ACCESSION GENOTYPE(5,1)
AGRICULTURAL DAIRY CATTLE(5,1)
ANDMATERNAL ANTIBODY(5,1)
ANTI MOUSE SECONDARY ANTIBODY(5,1)
ANTIBODY BVDV 1A CAPACITY(5,1)
ANTIGEN IMMUNOGENICITY(5,1)
BIOTINYLATED ANTI MOUSE IGG SOLUTION(5,1)
BIOTINYLATED SECONDARY ANTIBODY(5,1)
BIRMINGHAM HUNTSVILLE ALA(5,1)
BLOOD SERUM ANTIBODY TITER(5,1)
BOVINE FECES WEEK(5,1)
BOVINE PARAINFLUENZA(5,1)
BVDV BVD2A(5,1)
BVDV COUNTRY(5,1)
BVDV IMMUNODIPSTICK(5,1)
BVDV IMMUNOGENIC(5,1)
BVDV INFECTED CELL(5,1)
BVDV MIXED VACCINE(5,1)
BVDV VACCINE TREATMENT(5,1)
CALF VACCINE(5,1)
CEREBRAL HYPOPLASIA(5,1)
CHEMILUMINESCENT ENZYME SUBSTRATE(5,1)
COLOSTRUM THERAPY AGENT(5,1)
CONGENITAL PARTOGRAM(5,1)
CONSTANT CONSUMER RUMINANT VIRUS(5,1)
CONSUMER DIVER DETECTION(5,1)
COW INOCULATION(5,1)
CUSTODY AGRICULTURAL GOOD(5,1)
CYTOPATHOGENIC VIRUS(5,1)
DAIRY CATTLE FECES(5,1)
DEHYDRATION SYMPTOM(5,1)
DIGESTIVE EROSION(5,1)
DIGESTIVE TRACT COUGH(5,1)
DILUTION RECIPROCAL(5,1)
DISCONTINUITY APPETITE(5,1)
DOMESTIC EPIDEMICS(5,1)
DOSING SCHEDULE(5,1)
EARLY EMBRYONIC DEATH(5,1)
FLUORESCEIN ISOTHIOCYANATE(5,1)
GALENICA PHARMACEUTICAL(5,1)
GENETIC VACCINE STRAIN(5,1)
GENOTYPE 1A BVDV(5,1)
GENOTYPE 1A VACCINE(5,1)
GENOTYPE 1B BVDV(5,1)
GENOTYPE 1B CULTURE(5,1)
GENOTYPE 2A BVDV(5,1)
GENOTYPE 2B BVDV(5,1)
GENOTYPE IMMUNOGENICITY(5,1)
GENOTYPE IMS(5,1)
GENOTYPE NEUTRALIZATION(5,1)
GENOTYPE VIRUS(5,1)
GUINEA PIG ANTIBODY(5,1)
GUINEA PIG IMMUNIZATION(5,1)
GUINEA PIG SERA(5,1)
GUINEA PIG SERUM ANTIBODY(5,1)
HUMORAL IMMUNE RESPONSE INDUCTION(5,1)
IMMUNODIPSTICK CALF(5,1)
IMMUNOFLUORESCENCE ANTIBODY PERFORMANCE(5,1)
IMMUNOFLUORESCENCE ASSAY(5,1)
IMMUNOHISTOCHEMISTRY STAINING(5,1)
INACTIVATED BVDV(5,1)
INDIRECT FLUORESCENT ANTIBODY(5,1)
INDUCTIVE PHEWA ANALOG(5,1)
INFECTION SYMPTOMATOLOGY(5,1)
INOCULATING BOVINE(5,1)
INTERMITTENT DIARRHEA(5,1)
LABELING REAGENT IDENTIFICATION(5,1)
LACTATING CALF(5,1)
MAIL PREGNANCY II BVDV(5,1)
MLSERIAL PASSAGING(5,1)
MUMMY FETUS(5,1)
NEEDLELESS ADMINISTRATION(5,1)
NEUTROPENIA BVDV COMMON SYMPTOM(5,1)
NEWBORN SYMPTOM(5,1)
NITRO BLUE TETRAZOLIUM(5,1)
NUCLEOTIDE SEQUENCING ANALYSIS(5,1)
OCCASIONAL HUMP(5,1)
OCULAR MALFORMATION(5,1)
OUTDOOR SICK CELL(5,1)
PATHOGEN RESERVOIR HOST(5,1)
PICOCODE BILIRUBIN(5,1)
PLURONIC ISOTHIAZOLONE(5,1)
POLYVALENT VACCINE(5,1)
RESPIRATORY SYMPTOM(5,1)
SAMPLE TITER VIRUS(5,1)
SEROTYPE BVDV(5,1)
SURVIVAL PROLONGATION(5,1)
SWISS INCIDENCE(5,1)
SYMPTOMATIC THERAPY(5,1)
TETRA NITROBENZIDINE(5,1)
TISSUE CULTURE INFECTIVE(5,1)
TRAINED VETERINARIAN(5,1)
VACCINE ADMINISTRATION(5,1)
VACCINE COMPOSITION ADMINISTRATION(5,1)
VACCINE COMPOSITION GENOTYPE(5,1)
VACCINE COMPOSITION INOCULATION(5,1)
VACCINE COMPOSITIONTITER(5,1)
VACCINE IMMUNOGENICITY(5,1)
VACCINE MIXED BVDV(5,1)
VACCINE VACCINATION(5,1)
VIRUS CONCENTRATION REPLICATION(5,1)
WILD FIELD(5,1)
ENZYME LINKED IMMUNO SORBENT ASSAY(4,11)
BIOLOGICAL SAMPLE ANALYSIS(4,2)
CONSUMER SAMPLE(4,2)
ISOTONIC AGENT(4,2)
LATEX PARTICLE(4,2)
LEVEL ANTIBODY TITER(4,2)
PATHOGENIC CELL(4,2)
PEROXIDASE LINKED ASSAY(4,2)
SOLUTION 2DROPS(4,2)
SUSTAINED CAPACITY(4,2)
ADJUVANT IMS(4,1)
ADMINISTRATION SCHEDULE(4,1)
ALLEVIATING DISEASE PROGRESSION(4,1)
ALUMINUM HYDROXIDE GEL(4,1)
ATTENUATED STRAIN(4,1)
ATTENUATED VACCINE STRAIN(4,1)
ATTENUATED VIRAL VACCINE(4,1)
ATTENUATED VIRUS(4,1)
BOVINE DIARRHEA(4,1)
BRAIN HOMOGENATE(4,1)
BROAD SPECTRUM ANTIBIOTIC(4,1)
BVD RESISTING(4,1)
BVDV ANTIBODY REACTION(4,1)
BVDV DIAGNOSIS(4,1)
BVDV INTERSECTION(4,1)
BVDV VACCINE COMPOSITION MIXTURE(4,1)
BVDV VIRAL CONTENT(4,1)
CATTLE BVDV(4,1)
CHOLERA TOXIN(4,1)
CHROMOGENIC INDICATOR(4,1)
CROSS PROTECTION(4,1)
DOMESTIC BVDV(4,1)
DOMINANT STRAIN(4,1)
FARM BVDV PROPER TREATMENT(4,1)
FETAL INFECTION(4,1)
FITC LABELED ANTI GOAT(4,1)
FLUORESENT ASSAY(4,1)
GENETIC BVDV(4,1)
GENETIC STROKE(4,1)
GENOTYPE BVDV MIXTURE(4,1)
GENOTYPE DETERMINATION(4,1)
GUINEA PIG EXAMINATION(4,1)
HARDENING PHENOMENON(4,1)
IMMUNE ANTIBODY(4,1)
IMS CULTURE(4,1)
INFECTED CALF(4,1)
INOCULATED GUINEA PIG(4,1)
INOCULATION BLOOD(4,1)
INOCULATION SITE(4,1)
KOREA BVDV(4,1)
MILD EXOTHERM(4,1)
MILLION BVDV(4,1)
MLCASTLE VIRUS(4,1)
MOTHER COW(4,1)
NADL WEEK(4,1)
NECK REGION INTRAMUSCULAR ADMINISTRATION(4,1)
NOSE RIDGE(4,1)
NPLA BVDV(4,1)
PARENTERAL ADMINISTRATION(4,1)
PASSIVE IMMUNITY(4,1)
PATHOLOGICAL FINDING(4,1)
PLANT PRODUCTIVITY(4,1)
PLURONIC POLYOL(4,1)
PRIME BOOSTING(4,1)
RABBIT FITC(4,1)
REFRIGERATED FOOD(4,1)
RUMINANT ANIMAL(4,1)
SAPONIN DERIVATIVE(4,1)
SDFV FRAGMENT(4,1)
SEROLOGICAL STUDY(4,1)
STROKE GENOTYPE(4,1)
SUPPLEMENTAL ACTIVE INGREDIENT(4,1)
VACCINE DOSE(4,1)
VARIETY BVDV INFECTION(4,1)
VEHICLE ADMINISTRATION(4,1)
VETERINARILY ACCEPTABLE CARRIER(4,1)
VIRAL GENOTYPE(4,1)
VIRAL INFECTION PREVENTION(4,1)
VIRUS TITER 1X(4,1)
VIRUS TITRATION(4,1)
BVD1B FIELD(3,11)
SUBSTRATE SOLUTION(3,6)
FACS(3,5)
ABORTION(3,2)
ANTIBODY PRODUCTION CAPABILITY DURATION(3,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(3,2)
DEXTROSE(3,2)
FINAL CONCENTRATION(3,2)
GENTAMICIN(3,2)
KCTC18532P(3,2)
KCTC18533P(3,2)
LEUKOPENIA(3,2)
NAPHTHOL(3,2)
PI CH(3,2)
POLYANION(3,2)
RHINORRHEA(3,2)
RHODAMINE(3,2)
RUNNY NOSE(3,2)
SIDE EFFECT(3,2)
STABILIZER(3,2)
SUBCUTANEOUS ADMINISTRATION(3,2)
1M BEI(3,1)
1X CONCENTRATION(3,1)
300BP SITE(3,1)
AGE YEAR(3,1)
ANIMAL TISSUE(3,1)
ANTI FITC ANTIBODY(3,1)
ANTIBODY MOLECULE PRODUCTION(3,1)
ASSAY REAGENT(3,1)
ASSIGNED ACCESSION(3,1)
BACTERIUM SECONDARY INFECTION(3,1)
BASIC PHOSPHATIDYLINSITOSOL(3,1)
BEI PREPARATION(3,1)
BHV CYS(3,1)
BIOCHEMICAL ACTIVITY(3,1)
BOVINE BRAIN(3,1)
BRAIN EXTRACT(3,1)
BROWN STAINING(3,1)
BVDV RIGHT PREGNANCY(3,1)
BVDV ROLE(3,1)
BVDV SITUATION(3,1)
BVDV STRAIN(3,1)
BVDV TREATING(3,1)
BVDVOF SEPARATION(3,1)
CA BVD1B(3,1)
CALF TRANSPORT(3,1)
CANCER CALF(3,1)
CATTLE DEVELOPMENT(3,1)
CELL CYTOPLASM(3,1)
CHEMILUMINESCENT COMPOUND(3,1)
CLINICAL DISEASE(3,1)
COMMERCIAL VACCINE(3,1)
CULTURED HOST CELL(3,1)
CYTOTOXIC CELL(3,1)
DAIRY INDUSTRY(3,1)
DELAYING ABSORPTION(3,1)
DILUTED VIRAL SAMPLE(3,1)
DOSE BLOOD(3,1)
DYE SOL(3,1)
FOLD DILUTION(3,1)
GENOTYPE SELECTION(3,1)
IGG DILUTION(3,1)
IMMUNE CELL(3,1)
IMMUNE RESPONSE SENSITIVITY(3,1)
IMMUNOMODULATORY AGENT(3,1)
INDUCING ANTIBODY FORMATION BVDV(3,1)
INDUSTRIAL PRODUCTION VIEWPOINT(3,1)
LABEL DETECTION REAGENT(3,1)
LASTING ABILITY(3,1)
LYMPH NODE ADMINISTRATION(3,1)
MAMMAL SAMPLE(3,1)
NASAL MUCOUS MEMBRANE(3,1)
ORAL INFECTION(3,1)
OUTDOOR STRAIN(3,1)
PRIMARY ANTIBODY PBS(3,1)
PROLIFERATION ABSENCE(3,1)
PROPAGATION IDENTIFICATION(3,1)
SECONDARY CHALLENGE(3,1)
SECONDARY MONOCLONAL ANTIBODY(3,1)
SEVERE INFECTION(3,1)
SODIUM THIOSULFATE(3,1)
STERILE SALINE(3,1)
STRAIN TOLERANCE(3,1)
SUSCEPTIBLE ANIMAL(3,1)
SUSTAINED ACTIVITY(3,1)
TECHNICAL BACKGROUND(3,1)
TONSILLAR TISSUE EXTRACT(3,1)
TREATED MDBK CELL(3,1)
TREATMENT GOOD BVDV INFECTION(3,1)
UPPER SUBCLINICAL COW(3,1)
URINE LIFE(3,1)
VACCINE COMPOSITION BVDV COMPONENT(3,1)
VIRAL PARTICLE(3,1)
VIRUS STRAIN(3,1)
VIRUS TITER DETERMINATION(3,1)
CROSS TITER RESPONSE(2,4)
REVERSE TRANSCRIPTION PCR(2,4)
ACTIVITY DURATION(2,1)
ADJUVANT MIXTURE(2,1)
ANIMAL CONSUMPTION(2,1)
ANTIBODY HEAVY(2,1)
ANTIBODY IMMUNE RESPONSE ABILITY(2,1)
ANTIBODY PRODUCTION GAMEPLAYER(2,1)
ANTIBODY TITER VALUE(2,1)
BODILY FLUID SAMPLE(2,1)
BOOSTER IMMUNIZATION BLOOD SAMPLE(2,1)
BOVINE ABILITY(2,1)
BRIGHT GREEN(2,1)
BVDV CELL(2,1)
BVDV PRESENCE(2,1)
CELL LINE(2,1)
COMPOSITION CONSUMER(2,1)
CONSUMER IDENTIFICATION INFORMATION(2,1)
CONTINUED PRODUCTION(2,1)
CONTINUOUS SERIAL DILUTION(2,1)
DELIVERY VEHICLE(2,1)
DERIVED HEAT LABILE ENTEROTOXIN(2,1)
DETECTION REAGENT REACTION(2,1)
DIAMINOBENZIDINE(2,1)
DISEASE STATE(2,1)
DOSE 1X(2,1)
ECONOMY LOSS(2,1)
EQUALLY MIXED BVDV MIXTURE(2,1)
EXACT DOSAGE(2,1)
FLUORESCENT COMPOUND(2,1)
FORMABILITY(2,1)
FUNCTIONAL FRAGMENT(2,1)
GESTATION PERIOD DAY(2,1)
GOAT DERIVED ANTIBODY(2,1)
HEAD IMS(2,1)
HOST ANIMAL(2,1)
HUMAN ORIGIN(2,1)
IMMUNOSUPPRESSION(2,1)
IMS MIXTURE(2,1)
INACTIVATED VACCINE STRAIN(2,1)
INFECTION TREATMENT(2,1)
INOCULATED MIXTURE(2,1)
ISOLATED VIRUS(2,1)
LABELED CELL(2,1)
MAIL MIXTURE(2,1)
MINERAL GEL(2,1)
MIXTURE VIRAL CONTENT(2,1)
ML BVDV(2,1)
ML IMS(2,1)
ML VIRUS TITER(2,1)
MURAMYL DIPEPTIDE(2,1)
OCULAR FLUID(2,1)
PATHOGENIC VIRUS NATURE(2,1)
PBS AB SOLUTION(2,1)
PHYCOBILIPROTEIN(2,1)
PREGNANCY MIXTURE(2,1)
PRIMARY VACCINATION(2,1)
RABBIT DERIVED ANTIBODY(2,1)
RETAINING ABILITY(2,1)
SAMPLE DISPENSING(2,1)
SERA MIXTURE(2,1)
STRESS ABSENCE(2,1)
(KR101938556)
VACCINE(100,117)
VIRUS(100,50)
CONSUMER(100,25)
VIRUS VACCINE(100,6)
ACCESSION(100,3)
CASTLE DIVER VIRUS VACCINE(100,3)
DIVER VIRUS VACCINE(100,2)
WATER(100,2)
ACCESSION NUMBER KCTC18533P(100,1)
CA VIRUS(100,1)
CASTLE DIVER BVD2A(100,1)
CONSUMER BVD1A(100,1)
CONSUMER VIRUS CASTLE(100,1)
KCTC18532P VIRUS(100,1)
VIRUS INFECTION CASTLE DIVER(100,1)
CASTLE DIVER VIRUS(69,2)
BVDV COLOSTRUM INGESTION(47,1)
DIVER CASTLE STROKE(45,1)
RUMINANT VIRUS CASTLE DIVER(42,1)
CYTOPATHIC BVDV(40,2)
CONSUMER CASTLE DIVER(40,1)
VIRAL INFECTION DIVER CASTLE(39,1)
GENOTYPE BVD2A(38,1)
VIRAL INFECTIOUS VIRUS TREATMENT(38,1)
CASTLE DIVER(37,2)
OUTDOOR CASTLE DIVER VIRUS(37,1)
BVDV SERIAL PASSAGING(36,1)
DIVER CASTLE CONSUMER TREATMENT(35,1)
CASTLE DISEASE VIRUS(34,1)
RECENT NATIONAL BVDV WEEK(33,1)
GENOTYPE PREVALENCE DISTRIBUTION(31,1)
MLVIRUS VIRAL TITER(31,1)
STROKE CASTLE VACCINE(31,1)
CONSUMER VACCINE(29,1)
PREVENTIVE VACCINE(29,1)
VACCINE INOCULATION(29,1)
VIRAL CASTLE(29,1)
CONSUMER DIVER CASTLE(28,5)
CONSUMER CASTLE VIRUS(28,2)
CASTLE DISEASE VIRUS PREVENTION(28,1)
CONSUMER VIRUS(27,3)
CASTLE VACCINE(27,1)
FLAVIVIRIDAE FAMILY(27,1)
PREGNANCY BVDV(27,1)
WEEK POST VACCINATION(27,1)
NEUTRALIZING ANTIBODY TITER(26,6)
GENOTYPE BVDV VARIETY(25,1)
1A GENOTYPE(24,1)
MIXED BVDV GUINEA PIG(24,1)
OPTIMIZED BVDV(24,1)
VIRAL INFECTION PROPHYLAXIS(24,1)
BOVINE VIRAL DIARRHEA VIRUS(23,10)
BOVINE BVDV(23,1)
CYTOPATHIC STRAIN(23,1)
VIRUS VIRAL INFECTION(23,1)
INFECTION PREVENTION(22,2)
CONSUMER VIRAL INFECTION(22,1)
GENUS RNA(22,1)
INFECTIOUS DISEASE SOUGHT SOLUTION(22,1)
GENOTYPE BVDV(20,10)
BOVINE KIDNEY CELL(20,9)
DARBY BOVINE KIDNEY(20,5)
VIRUS GENOTYPE(20,4)
DAIRY INDUSTRY(20,1)
VIRAL VACCINE STRAIN(20,1)
INDUSTRIAL PRODUCTION VIEWPOINT(19,1)
PROTECTIVE ANTIBODY PRODUCTION(19,1)
CLINICAL SYMPTOM(18,13)
GENOTYPE CONSUMER(18,1)
GENOTYPE(17,95)
CARBOPOL ISA(17,1)
GENOTYPE 1B(16,21)
ACTIVE INGREDIENT(16,7)
PESTIVIRUS BODY(16,1)
INACTIVATED MIXTURE(15,1)
BVDV(14,68)
DISEASE PREVENTION(14,4)
BIOTYPE(14,3)
FLAVIVIRIDAE(14,1)
POST VACCINATION(14,1)
INFECTION(13,13)
PESTIVIRUS(13,1)
DIVER CASTLE CONSUMER TISSUE(12,4)
STROKE TREATMENT(12,2)
VACCINE STRAIN MIXTURE(12,2)
VIRUS CYTOPATHIC EFFECT(12,2)
IMMUNOPRECIPITATION ASSAY(11,10)
VIRUS DIVER CASTLE CONSUMER(11,3)
DIVER(10,5)
DISEASE CAUSE(10,1)
SINGER(10,1)
VIRUS MIXTURE(10,1)
GUINEA PIG(8,15)
COMPLEMENT FIXATION ASSAY(8,10)
IMMUNODIFFUSION ASSAY(8,5)
BVDV VACCINE INOCULATION(8,2)
RESPIRATORY VIRUS VACCINE STRAIN(8,2)
TOBVDV ANTIBODY VACCINE COMPOSITIONTITER(8,1)
VACCINE BVDV CALF INOCULATION(8,1)
VIRAL GENOTYPE TIME(8,1)
TCID(7,19)
IMS(7,16)
VIRUS TITER(7,10)
POLYCLONAL ANTIBODY(7,5)
VIRAL INFECTION(7,5)
COW(7,4)
FITC LABELED ANTI MOUSE(7,2)
OUTDOOR SICK BVDV(7,2)
CASTLE REOVIRAL CONSUMER VIRUS(7,1)
DEFENSE(7,1)
GENETIC VACCINE INOCULATION BVDV(7,1)
REOVIRAL CASTLE VIRUS CONSUMER(7,1)
YORK WEEK(7,1)
WESTERN BLOTTING(6,5)
ANTIBODY SERUM(6,4)
PERSISTENT INFECTION(6,4)
VACCINE FINAL SELECTION(6,4)
INACTIVATED BVDV(6,3)
BLOOD SERUM(6,2)
FLUORESCENT ANTIBODY DIAGNOSTICS(6,2)
MILK(6,2)
AGRICULTURAL HANWOO DAIRY CATTLE(6,1)
BIOCOM PATIBLE ADJUVANT(6,1)
BOVINE RESPIRATORY VIRUS VACCINE(6,1)
BVDV SYMPTOMATOLOGY SEROLOGICAL ANALYSIS(6,1)
BVDV VACCINE STRAIN IMS(6,1)
CA IMPACTION ANTIBODY TITER(6,1)
COLOSTRUM INGESTION POE(6,1)
CONSUMER DIVER CASTLE VIRUS(6,1)
CONSUMER REOVIRAL CASTLE(6,1)
DEAD ANIMAL COCLEA SYMPTOM(6,1)
DIVER CASTLE VIRUS CONSUMER(6,1)
EXTINGUISHER VIRUS VACCINE(6,1)
GENOTYPE BVDV VACCINE STRAIN(6,1)
GENOTYPE DOMESTIC EPIDEMICS(6,1)
MORPHOLOGICAL BVDV SPHERICAL MEMBRANE(6,1)
PREGNANCY BVDV VACCINATION(6,1)
RESEARCHER BVDV INFECTION(6,1)
VACCINE INOCULATION MOURNING(6,1)
VACCINE STRAIN BVDV INOCULATION(6,1)
VIRUS CASTLE CONSUMER DIVER(6,1)
VIRUS VACCINE GENOTYPE(6,1)
CALF(5,7)
POST(5,7)
WEEK INTERVAL(5,6)
ABC KIT(5,4)
ACCESSION GENOTYPE(5,2)
ANTIBODY NEUTRALIZATION(5,2)
BINARY ETHYLENEIMINE(5,2)
GENITAL INFECTION(5,2)
HORSERADISH PEROXIDASE(5,2)
INFECTION SYMPTOM(5,2)
INFECTIOUS DISEASE DURATION(5,2)
INTRAPERITONEAL ADMINISTRATION(5,2)
LACTATING COW(5,2)
MONOCLONAL ANTIBODY BVDV(5,2)
MULTIVALENT VACCINE(5,2)
6LOG ANTIBODY TITER(5,1)
ANTI MOUSE IMMUNOGLOBULIN ANTIBODY(5,1)
ANTIBODY FORMATIONSUSTAINED CAPACITY IRRADIATION(5,1)
ANTIBODY TITER IRRADIATION(5,1)
BIOTECHNOLOGY BVDV INSTITUTE(5,1)
BLOCKDATA LABELING REAGENT(5,1)
BVDV ANTIGEN DIAGNOSTIC KIT(5,1)
BVDV INFECTED CATTLE(5,1)
BVDV INFECTION PERSISTENCE(5,1)
BVDV MDBK PROPAGATION(5,1)
BVDV VACCINE COMPOSITION INOCULATEDMOW(5,1)
BVDV VIRAL TITER(5,1)
BVDV VIRUS GENOTYPE(5,1)
CASTLE DIVER CONSUMER(5,1)
CONSUMER CASTLE VACCINE(5,1)
COW BVDV VACCINE(5,1)
DIGESTIVE TRACT MUCOSA BOVINE(5,1)
DIVER CASTLE HYBRIDIZATION REACTION(5,1)
DIVER CASTLE RNA(5,1)
FLU UREIDO FLUORESCEIN(5,1)
GENOTYPE 1A BVDV CULTURE(5,1)
GUINEA PIG BVDV SERUM(5,1)
GUINEA PIG INOCULATED BVDV(5,1)
IMMUNIZED MOTHER IMMUNE SERA(5,1)
INOCULATING VIRUS BVDV(5,1)
MEASURING ANTIBODY TITER NEUTRALIZING(5,1)
PARENT ANTIBODY INOCULATION(5,1)
REOVIRAL CASTLE CONSUMER(5,1)
REOVIRAL CONSUMER 1A BVDV(5,1)
RESPIRATORY CLINICAL SYMPTOM(5,1)
RETENTION BVDV IMMUNODIPSTICK DURATION(5,1)
SECONDARY ANTIBODY ANTI MOUSE IGG(5,1)
STRAIN DIVER CASTLE(5,1)
STRAIN GENOTYPE CASTLE(5,1)
SYSTEMIC ORGAN INVOLVEMENT(5,1)
TEMPORARILY COCLEA SYMPTOM(5,1)
TEMPORARY CONGESTIBLE BUNDLE(5,1)
VACCINE STRAIN BOVINE DIGESTIVE(5,1)
VACCINE STRAIN GENOTYPE(5,1)
VIRAL TITER BVDV(5,1)
VIRUS CASTLE DIVER(5,1)
RADIOIMMUNOASSAY(4,10)
PROVISO(4,7)
PROTEINCHIP ASSAY(4,5)
2A GENOTYPE(4,4)
NEUTRALIZING ANTIBODY FORMATION(4,3)
VIRUS ISOLATION(4,3)
ADJUVANT IMS(4,2)
BOVINE HERPES VIRUS(4,2)
CULTURE BVDV(4,2)
FLUORESCENCE MICROSCOPE(4,2)
IMMUNOGLOBULIN MOLECULE(4,2)
LABELED REAGENT(4,2)
SUCCESSIVE SUBCULTURE(4,2)
VACCINE ADJUVANT(4,2)
VACCINE COMPOSITION BVDV(4,2)
VACCINE FORMULATION(4,2)
VACCINE VACCINATION(4,2)
1A GENOTYPE BVDV(4,1)
1A VACCINE GENOTYPE(4,1)
ABILITY INVERSEDDUETOTHE BVDV(4,1)
ANIMAL SYMPTOM BVDV(4,1)
ANTI MOUSE SECONDARY ANTIBODY(4,1)
ANTIGEN IMMUNOGENICITY(4,1)
BIOSCIENCE KOREA RESEARCH INSTITUTE(4,1)
BIOTINYLATED ANTI MOUSE IGG SOLUTION(4,1)
BIRMINGHAM HUNTSVILLE ALA(4,1)
BLOOD NEUTRALIZATION ASSAY(4,1)
BOOSTER IMMUNIZATION PEDIATRIC PAPER(4,1)
BOVINE ANIMAL GESTATION(4,1)
BOVINE FECES WEEK(4,1)
BVDV 1B GENOTYPE(4,1)
BVDV VACCINE MIXTURE VIRALTITER(4,1)
CEREBRAL HYPOPLASIA(4,1)
CLINICAL BVD RESISTING(4,1)
CLINICALLY SEVERE DIARRHEA(4,1)
CONGENITAL PARTOGRAM(4,1)
CONSUMER VIRAL TITER(4,1)
EARLY EMBRYONIC DEATH(4,1)
ESTABLISHED BVDV SERIAL PASSAGING(4,1)
FETAL THYMUS TISSUE(4,1)
FITC RABBIT IGG(4,1)
FLUORESCEIN ISOTHIOCYANATE(4,1)
GASTROINTESTINAL SYMPTOM(4,1)
GENOTYPE 2B BVDV(4,1)
GENOTYPE IMMUNOGENICITY(4,1)
GOAT IGG FITC(4,1)
GUINEA PIG SERUM ANTIBODY(4,1)
IMMUNODIPSTICK CALF(4,1)
INDUCTIVE PHEWA ANALOG(4,1)
INFECTED ANIMAL IDENTIFICATION(4,1)
INFECTED CATTLE FARM STRAIN(4,1)
INFECTION SERIAL PASSAGING(4,1)
INFECTIOUS DISEASE ANTIBODY(4,1)
INOCULATED GUINEA PIG SERUM(4,1)
LENTIGO MALIGNA ATAXIA(4,1)
MAIL ANTIBODY TITER(4,1)
NEUTROPENIA BVDV COMMON SYMPTOM(4,1)
NITRO BLUE TETRAZOLIUM(4,1)
OCULAR MALFORMATION(4,1)
OPTIMIZED VIRAL TITER(4,1)
OUTDOOR SICK VIRUS(4,1)
PATHOGEN RESERVOIR HOST(4,1)
PICOCODE BILIRUBIN(4,1)
PLURONIC ISOTHIAZOLONE(4,1)
PREVALENT ENHANCED NEUTRALIZING ANTIBODY(4,1)
SEPPIC WITTHAKER(4,1)
SERIAL PASSAGING VIRUS(4,1)
SERIALLY PASSAGED CULTURE(4,1)
SEROTYPE BVDV(4,1)
STILLBIRTH PLACENTAL(4,1)
STROKE CASTLE VIRUS DETECTION(4,1)
TARGET 1A BVDV GENOTYPE(4,1)
TISSUE CULTURE INFECTIVE(4,1)
VACCINATION BVDV(4,1)
VACCINATION INOCULATION(4,1)
VACCINE IMMUNOGENICITY(4,1)
VIRAL VACCINE GENOTYPE(4,1)
VIRUS BOVINE KIDNEY(4,1)
VIRUS TITER SERIAL PASSAGING(4,1)
WASTEWATER DEPARTMENT(4,1)
ENZYME LINKED IMMUNO SORBENT ASSAY(3,11)
SERIAL PASSAGE(3,5)
RT PCR(3,3)
10X DAB(3,2)
AGE MONTH(3,2)
CONSUMER SAMPLE(3,2)
MAIL ADDRESS(3,2)
PATHOGENIC CELL(3,2)
1A BVDV RESEARCH INSTITUTE(3,1)
1A CALF SERUM(3,1)
1A GENOTYPE CULTURE(3,1)
1B BVDV RESEARCH INSTITUTE(3,1)
1T GENOTYPE(3,1)
2A VACCINE STRAIN(3,1)
ADMINISTRATION MONTH(3,1)
ADMINISTRATION SCHEDULE(3,1)
AGRICULTURAL LAND(3,1)
ALLEVIATING DISEASE PROGRESSION(3,1)
ALUMINUM HYDROXIDE GEL(3,1)
ANDMATERNAL ANTIBODY TRANSFER(3,1)
ANTIBODY SUSTAINED ABILITY(3,1)
ANTIBODYTITER IRRADIATION(3,1)
ATTENUATED STRAIN(3,1)
ATTENUATED VIRAL VACCINE(3,1)
ATTENUATED VIRUS(3,1)
BIOSCIENCE RESEARCH INSTITUTE(3,1)
BIOTINYLATED SECONDARY ANTIBODY(3,1)
BLOOD SERUM ANTIBODY TITER(3,1)
BOVINE DIARRHEA(3,1)
BOVINE PARAINFLUENZA(3,1)
BRAIN HOMOGENATE(3,1)
BROAD SPECTRUM ANTIBIOTIC(3,1)
BUNDLE INFECTION(3,1)
BVDV 1A ANTIBODY(3,1)
BVDV BEI(3,1)
BVDV DIAGNOSIS(3,1)
BVDV INFECTED CELL(3,1)
BVDV INTERSECTION(3,1)
BVDV MIXED INOCULATION(3,1)
BVDV MIXED VACCINE(3,1)
BVDV SUSTAINED CAPACITY(3,1)
BVDV VACCINE TREATMENT(3,1)
CATTLE BVDV(3,1)
CELL CONSUMER DIVER(3,1)
CHEMILUMINESCENT ENZYME SUBSTRATE(3,1)
CHROMOGENIC INDICATOR(3,1)
CLINICAL MANIFESTATION(3,1)
COLOSTRUM THERAPY AGENT(3,1)
CONSUMER VIRUS INFECTION(3,1)
COUNTRY BVDV(3,1)
CROSS PROTECTION(3,1)
DAIRY COW FECES(3,1)
DIABETIC SYMPTOM(3,1)
DILUTION RECIPROCAL(3,1)
DISCONTINUITY APPETITE(3,1)
DISEASE SYMPTOM(3,1)
DIVER VIRUS(3,1)
DOMESTIC BVDV(3,1)
EARLY PREGNANCY STAGE(3,1)
EROSION COUGH(3,1)
EUROPE BVDV(3,1)
FETAL INFECTION(3,1)
FITC LABELED ANTI GOAT(3,1)
FLUORESENT ASSAY(3,1)
GALENICA PHARMACEUTICAL(3,1)
GENOTYPE 2A BVDV(3,1)
GENOTYPE 2A VACCINE(3,1)
GENOTYPE ANTIBODY(3,1)
GENOTYPE BVDV MIXTURE(3,1)
GENOTYPE DETERMINATION(3,1)
GENOTYPE DISCRIMINATION(3,1)
GENOTYPE IMS(3,1)
GENOTYPE NEUTRALIZATION(3,1)
GENOTYPE VIRUS(3,1)
GUINEA PIG EXAMINATION(3,1)
GUINEA PIG INOCULATION(3,1)
GUINEA PIG SERA(3,1)
HUMORAL IMMUNE RESPONSE INDUCTION(3,1)
IMMUNE ANTIBODY(3,1)
IMMUNE RESPONSE PERSISTENCE(3,1)
IMMUNOFLUORESCENCE ASSAY(3,1)
IMMUNOLOGICAL ASSAY(3,1)
IMMUNOTYPE ANTIBODY(3,1)
IMS CULTURE(3,1)
INDIRECT FLUORESCENT ANTIBODY(3,1)
INFECTED CALF(3,1)
INFECTED STRAIN TOLERANCE(3,1)
INOCULATING BOVINE(3,1)
INOCULATION SITE(3,1)
INTERMITTENT DIARRHEA(3,1)
KOREA BVDV(3,1)
MILD EXOTHERM(3,1)
ML BVDV MDBK CELL(3,1)
MLCASTLE VIRUS(3,1)
MLCULTURED GUINEA PIG(3,1)
MOTHER COW(3,1)
MUMMY FETUS(3,1)
NADL WEEK(3,1)
NECK REGION INTRAMUSCULAR ADMINISTRATION(3,1)
NEEDLELESS ADMINISTRATION(3,1)
NEWBORN INFECTION(3,1)
NONGJANG INFECTION TREATMENT(3,1)
NOSE RIDGE(3,1)
NPLA BVDV(3,1)
ORAL MUCOSA ULCERATION(3,1)
OUTDOOR BVDV(3,1)
PARENTERAL ADMINISTRATION(3,1)
PASSIVE IMMUNITY(3,1)
PATHOLOGICAL FINDING(3,1)
PLACENTAL INFECTION(3,1)
PLANT PRODUCTIVITY(3,1)
PLURONIC POLYOL(3,1)
POLYVALENT VACCINE(3,1)
PREGNANCY II COLOSTRUM(3,1)
PRIME BOOSTING(3,1)
PRODUCTION PERSISTENT(3,1)
RABBIT FITC(3,1)
REFRIGERATED FOOD(3,1)
REOVIRAL CONSUMER IDENTIFICATION INFORMATION(3,1)
REPRODUCTIVE DISORDER VARIETY(3,1)
RESPIRATORY SYMPTOM(3,1)
RESPIRATORY SYSTEM LESION(3,1)
RUMINANT ANIMAL(3,1)
SAPONIN DERIVATIVE(3,1)
SDFV FRAGMENT(3,1)
SEQUENCED GENE NUCLEIC ACID(3,1)
STRAIN DOMINANT GROWTH(3,1)
STRESS PARTOGRAM(3,1)
STROKE CASTLE TREATMENT(3,1)
STROKE GENOTYPE(3,1)
SUBCLINICAL MASTITIS(3,1)
SURVIVAL PROLONGATION(3,1)
SWISS INCIDENCE(3,1)
SYMPTOMATIC THERAPY(3,1)
TETRA NITROBENZIDINE(3,1)
TRAINED VETERINARIAN(3,1)
VACCINE ADMINISTRATION(3,1)
VACCINE COMPOSITION ADMINISTRATION(3,1)
VACCINE COMPOSITION GENOTYPE(3,1)
VACCINE COMPOSITION INOCULATION(3,1)
VACCINE COMPOSITION VIRAL INFECTION(3,1)
VACCINE DOSE(3,1)
VACCINE VIRUS(3,1)
VACCINE WEEK(3,1)
VEHICLE ADMINISTRATION(3,1)
VETERINARILY ACCEPTABLE CARRIER(3,1)
VIRAL REPLICATION(3,1)
VIRUS CONCENTRATION REPLICATION(3,1)
VIRUS INFECTION GENOTYPE(3,1)
VIRUS PROLIFERATION(3,1)
VIRUS TITER 1X(3,1)
VIRUS TITRATION(3,1)
SUBSTRATE SOLUTION(2,6)
FACS(2,5)
CROSS TITER RESPONSE(2,4)
ISA(2,4)
REVERSE TRANSCRIPTION(2,4)
INACTIVATION(2,3)
ABORTION(2,2)
ANTIBODY ABILITY(2,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(2,2)
CUSTODY(2,2)
CYTOKINE(2,2)
DEHYDRATION(2,2)
DEXTROSE(2,2)
FINAL CONCENTRATION(2,2)
GENTAMICIN(2,2)
ISOTONIC AGENT(2,2)
KCTC18531P(2,2)
LATEX PARTICLE(2,2)
LEUKOPENIA(2,2)
LEVEL ANTIBODY TITER(2,2)
NAPHTHOL(2,2)
PEROXIDASE LINKED ASSAY(2,2)
PI CH(2,2)
POLYANION(2,2)
PREGNANCY MIXTURE(2,2)
RHINORRHEA(2,2)
RHODAMINE(2,2)
SOLUTION 2DROPS(2,2)
STABILIZER(2,2)
SUBCUTANEOUS ADMINISTRATION(2,2)
TREATING(2,2)
VACCINE 2A CELL CULTURE(2,2)
WILD FIELD(2,2)
1A GUINEA PIG(2,1)
1M BEI(2,1)
1X CONCENTRATION(2,1)
300BP SITE(2,1)
ACTIVATION DETECTION(2,1)
ADJUVANT MIXTURE(2,1)
ADJUVANT ROLE(2,1)
AGE YEAR(2,1)
ANIMAL CONSUMPTION(2,1)
ANIMAL TISSUE(2,1)
ANTI FITC ANTIBODY(2,1)
ANTIBODY FORMATION BVDV(2,1)
ANTIBODY HEAVY(2,1)
ANTIBODY IMMUNE RESPONSE ABILITY(2,1)
ANTIBODY MOLECULE PRODUCTION(2,1)
ANTIBODY PRODUCTION GAMEPLAYER(2,1)
ASSAY REAGENT(2,1)
ASSIGNED ACCESSION(2,1)
BACTERIUM SECONDARY INFECTION(2,1)
BASIC PHOSPHATIDYLINSITOSOL(2,1)
BHV CYS(2,1)
BIOCHEMICAL ACTIVITY(2,1)
BIOLOGICAL ORIGIN(2,1)
BIOLOGICAL SAMPLE ANALYSIS(2,1)
BODILY FLUID SAMPLE(2,1)
BOOSTER IMMUNIZATION BLOOD SAMPLE(2,1)
BOVINE ABILITY(2,1)
BOVINE BRAIN(2,1)
BRAIN EXTRACT(2,1)
BRIGHT GREEN(2,1)
BROWN STAINING(2,1)
BVDV CELL(2,1)
BVDV CHEMICAL(2,1)
BVDV CONCENTRATION(2,1)
BVDV FIXING AGENT TREATMENT(2,1)
BVDV PRESENCE(2,1)
BVDV RIGHT PREGNANCY(2,1)
BVDV SECONDARY ANTIBODY RESPONSE(2,1)
BVDV STRAIN(2,1)
BVDVOF SEPARATION(2,1)
CA BVD1B(2,1)
CA KOREA RESEARCH INSTITUTE(2,1)
CALF TRANSPORT(2,1)
CANCER CALF(2,1)
CATTLE DEVELOPMENT(2,1)
CELL CYTOPLASM(2,1)
CELL LINE(2,1)
CHEMILUMINESCENT COMPOUND(2,1)
COMMERCIAL VACCINE(2,1)
COMPOSITION CONSUMER(2,1)
CONSUMER CULTURE(2,1)
CULTURED HOST CELL(2,1)
CYTOTOXIC CELL(2,1)
DELAYING ABSORPTION(2,1)
DIAMINOBENZIDINE(2,1)
DILUTED SECONDARY ANTIBODY CONCENTRATION(2,1)
DILUTED VIRAL SAMPLE(2,1)
DISEASE STATE(2,1)
DIVER CASTLE STATE(2,(...)";Pharmaceuticals;Open
2017-06-05;"CN108977413         A  2018-12-11 [CN108977413]
STG: (A) Published application
AP : 2017CN-0415514 2017-06-05";82456513;CN108977413         A  2018-12-11 [CN108977413];2017CN-0415514;;HUAZHONG AGRICULTURAL UNIVERSITY;HUAZHONG AGRICULTURAL UNIVERSITY;;;1;"GUO AIZHEN
LIU RUINING
DENG MINGLIANG
LI HANXIONG
CHEN YINGYU
HU ZHANGMIN
CHEN HUANCHUN";;;"(CN108977413)
Recombinant infectious bovine rhinotracheitis virus for expressing double-copy gD gene";"(CN108977413)
The invention belongs to the technical fields of animal virology and genetic engineering and particularly relates to a recombinant infectious bovine rhinotracheitis virus for expressing a double-copygD gene. An immunogenic gD gene extracellular region of the infectious bovine rhinotracheitis virus is inserted into a TK gene of a infectious bovine rhinotracheitis detalgG/detalTK dual-gene deletionstrain so as to express the double-copy gD gene. The proliferation of the recombinant virus is not changed, but the immunogenicity is improved. The recombinant infectious bovine rhinotracheitis virusIBRVdetagG/detaTK/gD+ is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO:V201552. The invention further discloses application of the recombinant infectious bovine rhinotracheitis virus IBRVdetagG/detaTK/gD+ in the preparation of engineering vaccines for the infectious bovine rhinotracheitis.";"(CN108977413)
1. A strain of recombinant infectious bovine rhinotracheitis virus gG / Δ TK/gD IBRV δ+, characterized in, containing the virus gD two copies of the gene, TK gene this deletion of the gD gene inserted into a copying position on the extracellular domain, the virus deposited at the China Type Culture Collection, accession number of CCTCC NO: V201552; gD gene nucleotide sequence of an extracellular region are as follows.
CAAGGGCCGACATTGGCCGTGCTGGGCGCGCTGCTCGCCGTTGCGGTGAGCTTGCCTACACCCGCGCCGCGGG TGACGGTATACGTCGACCCGCCGGCGTACCCGATGCCGCGATACAACTACACTGAACGCTGGCACACTACCGGGCCC ATACCGTCGCCCTTCGCAGACGGCCGCGAGCAGCCCGTCGAGGTGCGCTACGCGACGAGCGCGGCGGCGTGCGACAT GCTGGCGCTGATCGCAGACCCGCAGGTGGGGCGCACGCTGTGGGAAGCGGTACGCCGGCACGCGCGCGCGTACAACG CCACGGTCATATGGTACAAGATCGAGAGCGGGTGCGCCCGGCCGCTGTACTACATGGAGTACACCGAGTGCGAGCCC AGGAAGCACTTTGGGTACTGCCGCTACCGCACACCCCCGTTTTGGGACAGCTTCCTGGCGGGCTTCGCCTACCCCAC GGACGACGAGCTGGGACTGATTATGGCGGCGCCCGCGCGGCTCGTCGAGGGCCAGTACCGACGCGCGCTGTACATCG ACGGCACGGTCGCCTATACAGATTTCATGGTTTCGCTGCCGGCCGGGGACTGCTGGTTCTCGAAACTCGGCGCGGCT CGCGGGTACACCTTTGGCGCGTGCTTCCCGGCCCGGGATTACGAGCAAAAGAAGGTTCTGCGCCTGACGTATCTCAC GCAGTACTACCCGCAGGAGGCACACAAGGCCATAGTCGACTACTGGTTCATGCGCCACGGGGGCGTCGTTCCGCCGT ATTTTGAGGAGTCGAAGGGCTACGAGCCGCCGCCTGCCGCCGATGGGGGTTCCCCCGCGCCACCCGGCGACGACGAG GCCCGCGAGGATGAAGGGGAGACCGAGGACGGGGCAGCCGGGCGGGAGGGCAACGGCGGCCCCCCAGGACCCGAAGG CGACGGCGAGAGTCAGACCCCCGAAGCCAACGGAGGCGCCGAGGGCGAGCCGAAACCCGGCCCCAGCCCCGACGCCG ACCGCCCCGAAGGCTGGCCGAGCCTCGAAGCCATCACGCACCCCCCGCCCGCCCCCGCTACGCCCGCGGCCCCCGAC GCC.
2. Claim 1 gG / Δ TK/gD recombinant infectious bovine rhinotracheitis virus IBRV δ+ genetically engineered infectious bovine rhinotracheitis the preparation of a vaccine.
3. Claim 2 a strain of recombinant infectious bovine rhinotracheitis virus gG / Δ TK/gD IBRV δ+ strains genetically engineered infectious bovine rhinotracheitis virus in the manufacture of a recombinant virus.";"(CN108977413)
The present invention aims at obtaining an immunogenic better, induce the body's immune reaction with higher levels of recombinant viral infectious bovine rhinotracheitis for a longer duration of protection, genetically engineered attenuated vaccine development is highly safe to provide candidate vaccine strain.
The biological characteristics of this strain to the present invention are demonstrated immunogenic and rabbits, demonstrates that the recombinant viral propagation does not change, but its immunogenicity is enhanced.
For implementation purposes, the present invention adopts the following technical scheme:";"(CN108977413)
In addition, after the infected body IBRV latent infection in the trigeminal ganglion, when the body is subjected to stress factors stimulate proliferation of the virus is activated, cause scattering and propagation and pathogenesis, to control and eradication of the disease causes great difficulty (Nuotio et al.,2007).
In recent years, many authors have used a virus or bacteria gD gene expression as a carrier, such as vaccinia virus (Ferrer et al.,2011), adenovirus (Brownlie et al.,2015; Kumar et al.,2014), HSV(Blanc et al.,2012), Salmonella (Gnazzo et al.,2012), Newcastle disease virus (Khattar et al.,2010), BoHV-4(Donofrio et al.,2008; Donofrio et al.,2006), baculovirus (Peralta et al.,2007), tobacco Mosaic Virus (Perez Filgueira et al.,2003) and the like, may induce high levels of immune response, including humoral immunity and cellular immunity, and provide good protection.
ZL 2009102733576, the present application is not necessary to separately provide a biological deposit certificate).
Currently only a small number of European countries have eradicated the present disease, other countries are implementing extinguishing a plan, or the use of a marker vaccine distinguish between natural infection and vaccination of the groups, so as to be better monitored and safeguarded.
To further confirm the gD gene in a recombinant virus IBRV delta gG / TK/gD+ provide expression, viral infection after 24 h to 5 MOI MDBK cells, total cellular protein extracts for western blot detection, a primary antibody is a murine HA antibody, HRP-labeled goat antimouse IgG secondary antibody was.";"A61K-039/265
A61P-031/22
C12N-007/01
C12R-001/93";"(CN108977413)
1. A strain of recombinant infectious bovine rhinotracheitis virus gG / TK/gD IBRV +, characterized in, containing the virus gD two copies of the gene, TK gene this deletion of the gD gene inserted into a copying position on the extracellular domain, the virus deposited at the China Type Culture Collection, accession number of CCTCC NO: V201552; gD gene nucleotide sequence of an extracellular region are as follows. CAAGGGCCGACATTGGCCGTGCTGGGCGCGCTGCTCGCCGTTGCGGTGAGCTTGCCTACACCCGCGCCGCGGG TGACGGTATACGTCGACCCGCCGGCGTACCCGATGCCGCGATACAACTACACTGAACGCTGGCACACTACCGGGCCC ATACCGTCGCCCTTCGCAGACGGCCGCGAGCAGCCCGTCGAGGTGCGCTACGCGACGAGCGCGGCGGCGTGCGACAT GCTGGCGCTGATCGCAGACCCGCAGGTGGGGCGCACGCTGTGGGAAGCGGTACGCCGGCACGCGCGCGCGTACAACG CCACGGTCATATGGTACAAGATCGAGAGCGGGTGCGCCCGGCCGCTGTACTACATGGAGTACACCGAGTGCGAGCCC AGGAAGCACTTTGGGTACTGCCGCTACCGCACACCCCCGTTTTGGGACAGCTTCCTGGCGGGCTTCGCCTACCCCAC GGACGACGAGCTGGGACTGATTATGGCGGCGCCCGCGCGGCTCGTCGAGGGCCAGTACCGACGCGCGCTGTACATCG ACGGCACGGTCGCCTATACAGATTTCATGGTTTCGCTGCCGGCCGGGGACTGCTGGTTCTCGAAACTCGGCGCGGCT CGCGGGTACACCTTTGGCGCGTGCTTCCCGGCCCGGGATTACGAGCAAAAGAAGGTTCTGCGCCTGACGTATCTCAC GCAGTACTACCCGCAGGAGGCACACAAGGCCATAGTCGACTACTGGTTCATGCGCCACGGGGGCGTCGTTCCGCCGT ATTTTGAGGAGTCGAAGGGCTACGAGCCGCCGCCTGCCGCCGATGGGGGTTCCCCCGCGCCACCCGGCGACGACGAG GCCCGCGAGGATGAAGGGGAGACCGAGGACGGGGCAGCCGGGCGGGAGGGCAACGGCGGCCCCCCAGGACCCGAAGG CGACGGCGAGAGTCAGACCCCCGAAGCCAACGGAGGCGCCGAGGGCGAGCCGAAACCCGGCCCCAGCCCCGACGCCG ACCGCCCCGAAGGCTGGCCGAGCCTCGAAGCCATCACGCACCCCCCGCCCGCCCCCGCTACGCCCGCGGCCCCCGAC GCC.";"(CN108977413)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,25)
GENE(100,21)
VIRUS(100,12)
CULTURE COLLECTION(100,7)
STRAIN(100,7)
ACCESSION(100,5)
CCTCC(100,4)
EXTRACELLULAR DOMAIN(100,4)
GD IBRV(100,2)
GD GENE DELETION(100,1)
BOVINE RHINOTRACHEITIS(90,3)
RECOMBINANT VIRUS IBRV DELTA(85,1)
RECOMBINANT VIRAL PROPAGATION(80,3)
LABELED GOAT ANTI MOUSE(78,1)
INFECTIOUS BOVINE RHINOTRACHEITIS DELTA(76,1)
GD GENE(71,11)
CANDIDATE VACCINE STRAIN(71,1)
BIOLOGICAL DEPOSIT CERTIFICATE(70,1)
IMMUNOGENIC EXTRACELLULAR DOMAIN(65,1)
DISEASE ERADICATION(60,1)
MOI MDBK CELL(60,1)
CELLULAR PROTEIN EXTRACT(57,1)
VIRUS PROLIFERATION(57,1)
WESTERN BLOT DETECTION(55,1)
VACCINIA VIRUS(52,1)
EUROPEAN COUNTRY(51,1)
LATENT INFECTION(48,1)
VACCINE PREPARATION(46,2)
ATTENUATED VACCINE DEVELOPMENT(40,1)
RECOMBINANT VIRUS MANUFACTURE(39,1)
PROTECTION DURATION(38,1)
NATURAL INFECTION(37,1)
TRIGEMINAL GANGLION(36,1)
IMMUNOGENIC BETTER(35,1)
VACCINATION GROUP(32,1)
IMMUNOGENICITY(31,5)
SECONDARY ANTIBODY(30,2)
GD GENE EXPRESSION(29,4)
BODY INFECTION(28,1)
PATHOGENESIS(28,1)
EXTRACELLULAR REGION(27,5)
BACULOVIRUS(27,1)
DISEASE(27,1)
PRIMARY ANTIBODY(26,2)
ADENOVIRUS(26,1)
MARKER VACCINE(26,1)
SALMONELLA(26,1)
TOBACCO MOSAIC VIRUS(26,1)
BACTERIA(25,1)
DOUBLE COPY(25,1)
NEWCASTLE DISEASE VIRUS(25,1)
PROPAGATION(23,1)
GENETIC ENGINEERING TECHNOLOGY(22,2)
CAUSE SCATTERING(22,1)
HUMORAL IMMUNITY(20,3)
CELLULAR IMMUNITY(19,2)
VIRAL INFECTION(19,2)
IMMUNE RESPONSE LEVEL(19,1)
GD GENE EXPRESSION CASSETTE(17,5)
VACCINATED GD(17,5)
WUHAN UNIVERSITY(17,5)
EUKARYOTIC EXPRESSION PLASMID(17,3)
GD EXTRACELLULAR DOMAIN GENE(17,2)
IBRV VIRUS GENOMIC DNA(17,2)
BODY IMMUNE REACTION(17,1)
ANTIBODY(16,3)
PRIMESTAR MAX PREMIX(16,2)
VACCINETED WT BOHV(16,2)
ARTIFICIAL SEQUENCE(15,11)
GD PROTEIN GENE(15,3)
CMV PROMOTER(14,4)
NEWBORN CALF SERUM(14,2)
MDBK GENOME COTRANSFECTION(14,1)
RABBIT NEUTRALIZING ANTIBODY INOCULATION(14,1)
SHANGHAI PIK DAY BIOTECHNOLOGY(14,1)
RABBIT(13,6)
GLY ARG ALA(13,3)
IBRV GD GENE PRIMER(13,1)
IBRV INACTIVATED VACCINE ENHANCER(13,1)
CYS ALA ASP(12,2)
GLN ALA ARG(12,2)
LINEARIZED PCDNA(12,2)
MET ARG PRO ALA(12,2)
AGRICULTURAL MICROBIOLOGY COUNTRY(12,1)
BGLII RESTRICTION LINEARIZATION(12,1)
EXTRACELLULAR DOMAIN PCR AMPLIFICATION(12,1)
RECOMBINANT VIRUS IMMUNOGENICITY(12,1)
VIRAL IBRV CAPSULAR SAC(12,1)
VIRAL PLAQUE SCREEN OBSERVATION(12,1)
PRO ARG(11,6)
GENE DELETION VACCINE(11,3)
PARENTAL VIRUS(11,3)
CASSETTE GENE(11,2)
LEU ASP VAL(11,2)
PRO ASP ALA(11,2)
RECOMBINANT PLASMID(11,2)
VAL ALA ARG(11,2)
VAL PRO ALA(11,2)
ALA GLY ARG VAL(11,1)
ASP VAL TRP TYR(11,1)
BOHV NEUTRALIZING ANTIBODY(11,1)
CLEAVAGE ENZYME RNA LYSATE(11,1)
COMMERCIAL VACCINE IBR PREVENTION(11,1)
HERPES VIRUS VIRULENCE GENE(11,1)
IBRV GD DNA VACCINE(11,1)
LEU TRP PRO ALA(11,1)
LEU VAL LYS ALA(11,1)
PRO ALA LEU ARG(11,1)
RECOMBINANT VIRUS PROLIFERATION(11,1)
STRAIN GENE POSITION(11,1)
UTAH LOGAN CITY(11,1)
BOVINE RHINOTRACHEITIS GENETIC ENGINEERING(10,1)
EXTRACELLULAR DOMAIN AMPLIFICATION(10,1)
EXTRACELLULAR REGION IBRV G(10,1)
FREEZE THAW CYCLING(10,1)
GD PROTEIN CONNEXIN(10,1)
GREEN FLUORESCENCE SUPERIMPOSED OBSERVATION(10,1)
INACTIVATED WT BOHV(10,1)
LIVE VIRUS VECTOR EXPRESS(10,1)
PATHOGEN IBRV(10,1)
PERSISTENT INFECTION ROLE(10,1)
SEAMLESS CLONING KIT(10,1)
VACCINE DEVELOPMENT IMMUNOGENICITY(10,1)
VIRUS GD DEPLETION(10,1)
MONONUCLEAR CELL PROLIFERATION(9,3)
BOVINE HERPES VIRUS(9,2)
FLUORESCENCE OBSERVATION(9,2)
POST TRANSCRIPTIONAL REGULATORY ELEMENT(9,2)
RECOMBINANT TRANSFER PLASMID(9,2)
SECRETED PROTEIN(9,2)
UPSTREAM HOMOLOGY ARM(9,2)
VIRAL REPLICATION(9,2)
ALA CYS VAL(9,1)
ARG CYS ALA(9,1)
BOVINE RESPIRATORY DISEASE SYNDROME(9,1)
BOVINE RHINOTRACHEITIS DELTA(9,1)
CALF DECREASED VIRULENCE(9,1)
COTRANSFECTION EMPTY SPOT(9,1)
ECORI GD GENE(9,1)
GD EXPRESSION CASSETTE(9,1)
GD GENE PLASMID(9,1)
GD IMMUNOGENICITY(9,1)
GE DELETION MARKER VACCINE(9,1)
GENE UPSTREAM HOMOLOGY(9,1)
GENE VACCINE STRAIN(9,1)
IBRV DELTA GENE(9,1)
MOI IBRV DELTA(9,1)
NATIONAL LABORATORY IBRV DELTA(9,1)
PCR AMPLIFICATION PRIMER(9,1)
RECOMBINANT EXPRESSION CASSETTE(9,1)
SERUM NEUTRALIZING ANTIBODY DETECTION(9,1)
SUCROSE GRADIENT CENTRIFUGATION(9,1)
VACCINE IBRV DELTA(9,1)
VAL PHE PRO ALA(9,1)
VALIDATED PCDNA(9,1)
ARG LEU GLY ARG(8,2)
CYS ARG(8,2)
GLY VAL(8,2)
ISOAMYL ALCOHOL(8,2)
PRO TRP(8,2)
BLACK FONT(7,3)
DDH(7,3)
PRIMER SEQUENCE(7,3)
AGRICULTURAL UNIVERSITY CENTRAL CHINA(7,1)
CHEMOKINE INHIBITOR(7,1)
DISTINGUISHABLE IBRV(7,1)
GD INVOLVEMENT(7,1)
GENE DOWNSTREAM HOMOLOGY ARM(7,1)
GLYCOPROTEIN GD(7,1)
GOAT ANTI MOUSE(7,1)
HOMOLOGOUS RECOMBINATION(7,1)
IBRV EXTRACELLULAR REGION(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS IBRV(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(7,1)
INIMUNOGENICITY STUDY(7,1)
MONOCLONAL COLONY(7,1)
NECROTIC RHINITIS(7,1)
SUPPRESSING IMMUNOCOM(7,1)
TRANSFECTION SUPERNATANT(7,1)
VIRAL DRUG DETERMINATION(7,1)
VIRION STIMULATION(7,1)
VIRUS DILUTION(7,1)
VIRUS MDBK CELL(7,1)
WESTERN BLOTWITH(7,1)
FULL SEQUENCE(6,9)
ELECTROPHORESIS(6,4)
KOZAK SEQUENCE(6,2)
BOVINE INFECTION(6,1)
CRUDE ITALIC(6,1)
DIAGNOSIS ANTIGEN(6,1)
DILUTION AVERAGE PLAQUE(6,1)
ENZYMATIC CLEAVAGE(6,1)
G DELETION(6,1)
HOMOLOGOUS GD GENE INSERTION(6,1)
IBRV GENOME ENCODING BLOCK(6,1)
IMMUNOGENICITY STUDY(6,1)
ITALICIZED WORD(6,1)
MAIN CLINICAL MANIFESTATION(6,1)
NASAL SWAB(6,1)
NEUTRAL FORMALDEHYDE FULL COMPLEMENT(6,1)
NUCLEOTIDE SEQUENCE(6,1)
PLASMID PCDNA(6,1)
RABBIT PERIPHERAL BLOOD INOCULATION(6,1)
RECOMBINANT GENE(6,1)
RECOMBINANT VIRUS INFECTED CELL(6,1)
REPORTER GENE(6,1)
TK GD WPRE ENZYME(6,1)
TK GD WPRE PLASMID(6,1)
UNADSORBED VIRUS SOLUTION(6,1)
VACCINE STUDY(6,1)
VIRAL GENOME(6,1)
VIRUS ADSORPTION(6,1)
VIRUS CLASSIFICATION(6,1)
LANE(5,6)
TEMPLATE(5,5)
AMPLIFICATION PRODUCT(5,3)
PERIPHERAL BLOOD MONONUCLEAR CELL(5,3)
SEED(5,3)
PLAQUE DIAMETER(5,2)
AGAROSE COVERING(5,1)
ANHYDROUS ETHANOL(5,1)
BLACK RHINO(5,1)
BLOOD SERUM COLLECTION(5,1)
BP FRAGMENT(5,1)
CATTLE INDUSTRY(5,1)
CELLULAR PROTEIN(5,1)
CHALLENGE NEUTRALIZING ANTIBODY LEVEL(5,1)
CO2 INCUBATION(5,1)
CONSTRUCTING EXPRESSION(5,1)
DISCRIMINATION MAP CONSTRUCTION(5,1)
ENCODED PROTEIN SEQUENCE(5,1)
ENZYME CLEAVAGE(5,1)
ETIOLOGICAL AGENT(5,1)
EXTRACELLULAR REGION GENE(5,1)
FINGER SIDEWALL(5,1)
FOREIGN GENE DELETION(5,1)
G ABSENCE(5,1)
GC PROTECTION(5,1)
GD CODING REGION(5,1)
GENE DELETION MARKER VACCINE(5,1)
GLY ASN(5,1)
IMMUNE PROTECTION(5,1)
INOCULATION WT(5,1)
INVERTED REPEAT(5,1)
KD PROTEIN(5,1)
NASAL CAVITY INOCULATION(5,1)
NEEDLE PREVENTION(5,1)
NOSE JUICE(5,1)
PCR PRIMER(5,1)
PLAQUE COMPARISON(5,1)
PLUS CRYSTAL VIOLET(5,1)
POST INOCULATION(5,1)
PREPARED VIRUS GENOME(5,1)
PRO GLY ALA(5,1)
RED FLUORESCENCE(5,1)
RED FLUORESCENT(5,1)
SODIUM DODECYL SULFATE(5,1)
STRATEGY IDENTIFIED FIGURE(5,1)
STRONG ANTIGENICITY(5,1)
SUBUNIT VACCINE PREPARATION(5,1)
TARGET GENE DELETION(5,1)
UNDERLINED GROUND(5,1)
VAL ARG(5,1)
VIRAL PARTICLE(5,1)
VIRUS LIQUID FOLD DILUTION(5,1)
XTT CELL PROLIFERATION(5,1)
CODING REGION SEQUENCE(4,2)
COMPLETE GENOMIC SEQUENCE(4,2)
HOMOLOGY ARM SUPPORT(4,2)
PCR PRODUCT(4,2)
SHELL(4,2)
WHOLE SEQUENCE(4,2)
ABANDONED DYE(4,1)
ANHYDROUS DIETHYL ETHER(4,1)
ASP PRO(4,1)
ASSAY KIT(4,1)
BAMHI SEQUENCE(4,1)
BIG BOX(4,1)
CALCULATION(4,1)
CELL CULTURE INCUBATOR(4,1)
CELL FLASK(4,1)
CHINESE FEED(4,1)
COLLECTED BLOOD SEPARATION(4,1)
DETECTION MAP(4,1)
DOUBLE ANTIBODY(4,1)
DOUBLE GENE(4,1)
ESSENTIAL PROTEIN(4,1)
FINAL DRAW GROWTH CURVE(4,1)
GD COMPARISON(4,1)
GELLING TEMPERATURE AGAROSE(4,1)
HERPESVIRIDAE(4,1)
IBRV GENOME STRUCTURE(4,1)
IMMUNE RESPONSE INDUCTION(4,1)
IMMUNOSUPPRESSION(4,1)
MEASUREMENT PLOT(4,1)
NUCLEIC ACID METABOLISM(4,1)
PLAQUE FORMATION(4,1)
PLASMID TRANSFER(4,1)
POST CHALLENGE(4,1)
SCREENING NATURAL(4,1)";Pharmaceuticals;Open
2017-01-13;"CN107174660         A  2017-09-19 [CN107174660]
STG: (A) Published application
AP : 2017CN-0023617 2017-01-13";77282113;CN107174660         A  2017-09-19 [CN107174660];2017CN-0023617;;NOVO BIOTECH;NOVO BIOTECH;;;1;"QIAN HONG
WU YOUQIANG
BIAN GUANGLIN
ZHANG QIANG
CHA YINHE";;;"(CN107174660)
Bovine viral diarrhea-bovine infectious rhinotracheitis bivalent subunit vaccine and preparation method and application thereof";"(CN107174660)
The invention discloses a bovine viral diarrhea-bovine infectious rhinotracheitis bivalent subunit vaccine and a preparation method and application thereof, and belongs to the technical field of animal vaccines and animal biological products. The vaccine comprises bovine viral diarrhea virus E2 protein, bovine infectious rhinotracheitis virus gD protein and pharmaceutically acceptable adjuvant. The preparation method for the vaccine comprises the following steps that: 1) preparing the bovine viral diarrhea virus E2 protein and the bovine infectious rhinotracheitis virus gD protein; 2) mixing the bovine viral diarrhea virus E2 protein and the bovine infectious rhinotracheitis virus gD protein prepared in the 1) to prepare antigen liquid; 3) carrying out mixing emulsion on the anti-agent liquid with ISA 201VG at an volume ratio of 46:54. The vaccine has the advantages of high immunogenicity, high safety and no immunity interference; in addition, cows can be effectively prevented and protected from the infection of the bovine viral diarrhea virus and the bovine infectious rhinotracheitis virus, an effect of two prevention functions by one injection can be achieved, time and labor are saved, and cost is saved.";"(CN107174660)
1. Bovine viral diarrhea-infectious bovine rhinotracheitis units of vaccine, characterized in, bovine viral diarrhea virus E2 protein containing vaccine, infectious bovine rhinotracheitis virus gD protein, and pharmaceutically acceptable adjuvant.
2. Vaccine according to claim 1, characterized in, bovine viral diarrhea virus E2 protein to infectious bovine rhinotracheitis virus gD protein at equal mass ratio.
3. Vaccine according to claim 1 or 2, characterized in, bovine viral diarrhea virus E2 protein and infectious bovine rhinotracheitis virus gD protein concentration of 25μg/head parts-200μg/head parts, preferably bovine viral diarrhea virus E2 protein and infectious bovine rhinotracheitis virus gD protein concentration of 100μg/head parts.
4. Vaccine according to claim 1, characterized in, pharmaceutically acceptable adjuvant is ISA 201VG.
5. Claim 1-4 vaccine according to any one of claims, characterized in, vaccine also contains the immunopotentiator, and a preservative or /.
6. Vaccine according to claim 5, characterized in, Quil-A was Immunopotentlator, Quil-A at a concentration of 400μg/head parts-800μg/head parts, preferably 700μg/head parts.
7. Vaccine according to claim 5, characterized in, preservative is thimerosal, tihimerosal in an amount of 2μg/head parts.
8. Claim 1-7 A method of producing method according to any one of the vaccine, characterized in, comprises the following steps:
1) preparation of bovine viral diarrhea virus E2 protein and infectious bovine rhinotracheitis virus gD protein;
2) will be 1) bovine viral diarrhea virus E2 protein prepared in infectious bovine rhinotracheitis virus gD protein prepared against mixing and a stock solution; wherein, bovine viral diarrhea virus E2 protein to infectious bovine rhinotracheitis virus gD protein in accordance with equimass ratio;
3) with the antigen solution was 46:54 ISA 201VG that a volume ratio of the mixed emulsion.
9. Method according to claim 8, characterized in, / or a preservative enhancer and also include immune antigen solution was.
10. One such as claimed in any one claim 1-7 vaccine in the prevention and treatment of bovine viral diarrhea and infectious bovine rhinotracheitis in the application.";"(CN107174660)
It was found by the clinical case, BVDV and the IBRV often co-infection.
The present invention discloses a Bovine Viral Diarrhea-infectious bovine rhinotracheitis -unit vaccines and their preparation methods and uses, which belongs to the veterinary biologic to an animal vaccine art.
The present invention relates to a bovine viral diarrhea-infectious bovine rhinotracheitis -unit vaccine preparation and use of, biological products belonging to the technical field of veterinary vaccine to the animal.";"(CN107174660)
Therefore a need exists to develop a novel vaccine, strong immunogenicity of the vaccine, safety, low cost, and the vaccine is able to simultaneously prevent both types of disease.
In China 1983 has been reported for the first time occurrence of the disease, currently existing across the board 20 a plurality of province, city, a municipality BVD is present. 2008, People's Republic of Department of Agriculture published bulletin No.96, bovine viral diarrhea is defined as three classifications disease; world health organizations will also be listed as the disease animal veterinary diseases and animal embryos of the official report lists three types of disease pathogenic communication.
The disease is most earlier than found in U.S. 1946, explosion was after-demand a global epidemic.
The virus can also cause damage to the cow reproductive system, occurrence of abortion, stillbirth and the occurrence of inflammatory bowel disease and calf encephalitis, which may also be ocular conjunctivitis and keratitis.";"A61K-039/15
A61K-039/265
A61K-039/295
A61P-001/12
A61P-011/00
A61P-011/02
A61P-031/14
A61P-031/22";"(CN107174660)
1. Bovine viral diarrhea-infectious bovine rhinotracheitis units of vaccine, characterized in, bovine viral diarrhea virus E2 protein containing vaccine, infectious bovine rhinotracheitis virus gD protein, and pharmaceutically acceptable adjuvant.
8. Claim 1-7 A method of producing method according to any one of the vaccine, characterized in, comprises the following steps: 1) preparation of bovine viral diarrhea virus E2 protein and infectious bovine rhinotracheitis virus gD protein; 2) will be 1) bovine viral diarrhea virus E2 protein prepared in infectious bovine rhinotracheitis virus gD protein prepared against mixing and a stock solution; wherein, bovine viral diarrhea virus E2 protein to infectious bovine rhinotracheitis virus gD protein in accordance with equimass ratio; 3) with the antigen solution was 46:54 ISA 201VG that a volume ratio of the mixed emulsion.";"(CN107174660)
VACCINE(100,49)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,32)
PROTEIN(100,27)
BOVINE VIRAL DIARRHEA VIRUS E(100,22)
GD PROTEIN(100,19)
ADJUVANT(100,9)
BOVINE RHINOTRACHEITIS VACCINE(100,1)
VACCINE BOVINE RHINOTRACHEITIS UNIT(100,1)
DEPARTMENT PEOPLE REPUBLIC(47,1)
VACCINE STRONG IMMUNOGENICITY(41,1)
MUNICIPALITY BVD(39,1)
ANIMAL VETERINARY DISEASE(38,1)
OCULAR CONJUNCTIVITIS(37,1)
CALF ENCEPHALITIS(34,1)
GLOBAL EPIDEMIC(32,1)
DISEASE CLASSIFICATION(31,1)
DISEASE PATHOGENIC COMMUNICATION(30,1)
ABORTION OCCURRENCE(29,1)
BOVINE RHINOTRACHEITIS UNIT VACCINE(26,4)
ANIMAL EMBRYO(26,1)
GD PROTEIN CONCENTRATION(25,3)
OFFICIAL REPORT LIST(25,1)
INFLAMMATORY BOWEL DISEASE OCCURRENCE(24,1)
PRESERVATIVE ENHANCER(24,1)
EQUIMASS RATIO(22,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS INFECTION(19,2)
ANTIGEN SOLUTION(18,5)
STOCK SOLUTION(18,3)
CATTLE PROTECTION(18,2)
DISEASE(17,7)
BOVINE RHINOTRACHEITIS UNIT(17,3)
MIXED EMULSION VOLUME RATIO(17,2)
COINFECTION(17,1)
IMMUNE ANTIGEN SOLUTION(16,1)
STILLBIRTH(16,1)
VACCINE PREPARATION(15,4)
AGRICULTURE(15,1)
KERATITIS(15,1)
EXPLOSION(14,1)
IMMUNOPOTENTIATOR(14,1)
PROTEIN PREPARATION(13,2)
BULLETIN(13,1)
PROVINCE(12,2)
WORLD HEALTH ORGANIZATION(12,1)
BOVINE VIRAL DIARRHEA TREATMENT(11,2)
CITY(11,1)
VETERINARY VACCINE TECHNICAL FIELD(11,1)
BOVINE VIRAL DIARRHEA(10,7)
COW REPRODUCTIVE SYSTEM(10,1)
LIVE VACCINE(9,6)
VIRUS(9,4)
CAUSATIVE BOVINE FERTILITY BULL(9,1)
VIRAL SEX DIARRHEA TITER(9,1)
BVDV(8,6)
ANIMAL(8,4)
CREATION ANTIBODY TITER(8,2)
CLINICAL CASE(8,1)
FLAVIVIRUS GENUS PESTIVIRUS(8,1)
INTERFERENCE NON IMMUNE BENEFIT(8,1)
ANIMAL VACCINE ART(7,1)
BIOLOGICAL PRODUCT(7,1)
BOVINE RHINOTRACHEITIS SUBUNIT VACCINE(7,1)
BOVINE VIRAL SEX IMMUNIZING(7,1)
DIARRHEA CLINICAL MANIFESTATION(7,1)
DISEASE TIME OCCURRENCE(7,1)
NEUTRALIZING ANTIBODY CREATION STIMULATING(7,1)
VACCINE METHOD PREPARATION(7,1)
LABOR(6,2)
NEEDLE(6,2)
PRESERVATIVE THIMEROSAL(6,2)
IMMUNE BOVINE VIRAL SEX(6,1)
VACCINE ANTIBODY TITER(6,1)
VIRUS BVDV GENOME(6,1)
VACCINE VIRUS INFECTION(5,2)
BOVINE FATAL BACTERIAL PNEUMONIA(5,1)
CHINA MAJOR CATTLE INFECTION(5,1)
DETECTION ELISA ANTIBODY TITER(5,1)
ELISA DETECTION ANTIBODY TITER(5,1)
GD PROTEIN VACCINE(5,1)
INSECT BACULOVIRUS EXPRESSION(5,1)
PERSISTENT INFECTION MAJORITY(5,1)
PERSISTENT INFECTION RISK(5,1)
PROVINCE COW(5,1)
PURIFIED GD PROTEIN DILUTION(5,1)
RECOMBINANT VIRUS MUTATION(5,1)
TH CENTURY YEAR(5,1)
VACCINE CREATION DOSE(5,1)
VACCINE TIHIMEROSAL CONTENT(5,1)
VIRAL RECOMBINATION RISK(5,1)
DOUBLE SHOOT(4,3)
PROTEIN CONCENTRATION(4,3)
PROTEIN EXPRESSION PATTERN(4,2)
ANTIBODY NEUTRALIZATION(4,1)
BIOLOGICAL SAFETY CABINET(4,1)
GD GENE PREPARATION(4,1)
HERD IMMUNE(4,1)
INACTIVATED BVDV(4,1)
MERCURY PRESERVATIVE(4,1)
MUCOSAL DIAEASE(4,1)
PHYSIOLOGICAL SALINE INJECTION(4,1)
PREHEATED ADJUVANT(4,1)
REPRODUCTIVE DISORDER(4,1)
SUBUNIT VACCINE POTENCY(4,1)
SYNERGISTIC STIMULATION(4,1)
TITER TRACKING(4,1)
VACCINE IMMUNIZATION(4,1)
VACCINE IMMUNOASSAY(4,1)
VARIANT VIRUS RISK(4,1)
NUCLEIC ACID MOLECULE(3,4)
EQUAL MASS RATIO(3,3)
ALUMINA ADJUVANT(3,1)
ANTIBODY DETECTION KIT(3,1)
ANTIGEN ANTIBODY NEGATIVE(3,1)
BOVINE MUCOSAL DISEASE(3,1)
BOVINE VIRAL DIARRHEA VIRUS ANTIBODY(3,1)
BVDV INFECTED ANIMAL(3,1)
CATTLE GREAT CIRCLE(3,1)
COW MILK PRODUCTION(3,1)
CPG DNA(3,1)
CREATION HUMORAL IMMUNITY(3,1)
CREATION VACCINE POTENCY(3,1)
DISEASE NECROSIS(3,1)
DISEASE PREVENTION(3,1)
ELISA ANTIBODY DETECTION(3,1)
ENVELOPE PROTEIN(3,1)
EPIDEMIOLOGICAL SURVEY SHOW(3,1)
HRP LABELED ANTIBODY(3,1)
IMMUNE CELL(3,1)
IMMUNE SUPPRESSION(3,1)
IMMUNITY DURATION(3,1)
INLET SEEDLING(3,1)
KILLED VACCINE(3,1)
LIVE ATTENUATED VACCINE(3,1)
LOCAL MUCOSAL IMMUNITY(3,1)
MARKET BVDV(3,1)
MATURE PROTEIN(3,1)
MUCOUS MEMBRANE INFLAMMATION(3,1)
OLD CALF(3,1)
PREHEATED ANTIGEN LIQUID(3,1)
REGION DISTINCTION VIRUS INFECTION(3,1)
SECONDARY RESPIRATORY INFECTION(3,1)
STERILE TOOL PREPARATION(3,1)
THIMEROSAL ACCESSIBLE VOLUME(3,1)
VACCINE ANTIGEN SOLUTION(3,1)
VACCINE CREATION REGION(3,1)
VACCINE RISK(3,1)
VIRAL ANTIGEN PROTEIN(3,1)
VIRUS INFECTION CELLTITER(3,1)
VIRUS INFECTION TITER(3,1)
WIDELY POPULAR PROPAGATION(3,1)
VACCINE UNIT(2,4)
RELATIVE ANTIBODY TITER(2,2)
ADJUVANT VOLUME(2,1)
ANTIGEN DETECTION(2,1)
BIOSAFETY(2,1)
BOVINE RHINOTRACHEITIS UNIT PREPARATION(2,1)
BOVINE SUBUNIT SINGLE IMMUNIZATION(2,1)
CARBONATE BUFFER(2,1)
CAUSED CATTLE INDUSTRY(2,1)
CHROMOGENIC LIQUID(2,1)
COMBINED VACCINE TITER(2,1)
COMPLETE INACTIVATION(2,1)
IMMUNE RESPONSE RAPID INDUCTION(2,1)
INACTIVATED DOUBLE(2,1)
INOCULATION(2,1)
LINEAR DNA MOLECULE(2,1)
MAJOR STRUCTURAL PROTEIN(2,1)
MIN KNEADING(2,1)
MOLECULAR CELL VIRAL INFECTION(2,1)
OIL ADJUVANT(2,1)
POLYPROTEIN AMINOACID(2,1)
PROPOSED BOVINE VIRAL DIARRHEA(2,1)
RECOMBINANT NUCLEIC ACID(2,1)
SEALING MEMBRANE(2,1)
SUBUNIT VACCINE PROTECTION EFFECT(2,1)
TERM ABORTION(2,1)
UPPER RESPIRATORY INFLAMMATION(2,1)
VACCINE INFORMATION(2,1)
AGITATION(1,1)
ANTIBODY TITER RESULT(1,1)
BEAKER(1,1)
BOOSTED THREE WEEK(1,1)
BUFFALO(1,1)
CAMEL(1,1)";Pharmaceuticals;Open
2017-01-13;"CN107973840         A  2018-05-01 [CN107973840]
STG: (A) Published application
AP : 2017CN-0023620 2017-01-13";79532882;CN107973840         A  2018-05-01 [CN107973840];2017CN-0023620;;NOVO BIOTECH;NOVO BIOTECH;;;1;"QIAN HONG
WU YOUQIANG
BIAN GUANGLIN
ZHANG QIANG
WU SUFANG
CHE YING
SONG YUEHONG
LÜ YANGPING
CHEN BIN
CHA YINHE";;;"(CN107973840)
Preparation of CHO cell expressed infectious bovine rhinotracheitis virus protein gD and subunit vaccine thereof and application";"(CN107973840)
The invention discloses preparation of CHO cell expressed recombinant infectious bovine rhinotracheitis virus protein gD and a subunit vaccine thereof and an application and belongs to the technical fields of animal vaccines and veterinary biologicals. The condition that the vaccine can generate relatively high humoral immunity in bovine bodies is proven. The object of the invention is to providea preparation method capable of industrially producing the infectious bovine rhinotracheitis virus recombinant subunit vaccine on a large scale. The reparation method for the recombinant subunit vaccine comprises the following steps: 1) cloning an eukaryotic expression vector containing a protein gD coding gene; 2) transfecting CHO cells, and obtaining suspending CHO cell strains, which stably andefficiently express the protein gD, in a selecting, screening and acclimatizing manner; 3) subjecting the cell strains obtained in the step 2) to fermented culture, and carrying out purification, soas to obtain recombinant protein gD; and 4) uniformly mixing the recombinant protein gD and ISA 201 VG thoroughly, thereby obtaining the recombinant subunit vaccine. According to the method provided by the invention, target protein can be obtained from cell culture supernatant, the yield reaches up to 2g/L to 3g/L, the protein purification time is shortened, the vaccine production steps are simplified, and the vaccine production cost is greatly reduced.";"(CN107973840)
1. A recombinant infectious bovine rhinotracheitis virus gD protein preparation method, characterized in, preparation method comprising the steps of:
1) GD protein of the infectious bovine rhinotracheitis virus genes were cloned into eukaryotic expression vectors containing gene encoding gD protein obtained infectious bovine rhinotracheitis virus of the recombinant plasmid;
2) Re-containing infectious bovine rhinotracheitis virus gD recombinant plasmids were transfected into CHO of the gene encoding protein in a cell;
3) Through culture, screening, acclimatization 2) in the CHO cell strain was highly expressed cell line;
4) Fermentation culture 3) in the cell line, to obtain the recombinant infectious bovine rhinotracheitis virus gD protein.
2. Method according to claim 1, characterized in, containing infectious bovine rhinotracheitis virus gD protein-encoding gene of the recombinant plasmid includes applying the infectious bovine rhinotracheitis virus gD protein-encoding gene is codon optimized, and then cloned into eukaryotic expression vectors, recombinant plasmid was obtained.
3. Method according to claim 1 or 2, characterized in, infectious bovine rhinotracheitis virus gD protein-encoding gene as shown in SEQ ID NO:1.
4. Method according to claim 1 or 2, characterized in, eukaryotic expression vector is pEE12.4.
5. Method according to claim 1, characterized in, CHO-K1 cell is a CHO cell.
6. Comprising a recombinant infectious bovine rhinotracheitis virus gD protein subunit vaccine preparation method, characterized in, will produce recombinant infectious bovine rhinotracheitis virus gD protein method obtained with a pharmaceutically acceptable adjuvant mixed thoroughly according to claim 1, infectious bovine rhinotracheitis virus gD recombinant subunit vaccines obtained.
7. Method according to claim 6, characterized in, recombinant subunit vaccine adjuvants used as ISA 201 VG.
8. Method according to claim 6, characterized in, recombinant infectious bovine rhinotracheitis virus gD protein emulsified in a volume ratio mixed with an adjuvant ISA 201 VG 46:54.
9. Claim 1-8 one according to any of the recombinant infectious bovine rhinotracheitis virus gD protein and infectious bovine rhinotracheitis virus recombinant subunit vaccines and related diagnosis reagent for use in the manufacture.";"(CN107973840)
The present invention relates to a stable and efficient secretion of the protein expression of the infectious bovine rhinotracheitis virus gD CHO cell lines and infectious bovine rhinotracheitis virus gD protein subunit vaccine preparation method and application, which belongs to the technical field of veterinary biologic to an animal vaccine.
The present invention there is provided a CHO cell secretion of expressed proteins and gD infectious bovine rhinotracheitis virus subunit vaccine production method, comprising the steps of: 1) of the infectious bovine rhinotracheitis virus gD protein genes were cloned into eukaryotic expression vectors containing infectious bovine rhinotracheitis virus gD protein-encoding gene to obtain a recombinant plasmid; 2) and then a solution containing infectious bovine rhinotracheitis virus gD recombinant plasmids were transfected into CHO of the gene encoding the protein in a cell; 3) through the culture, screening, domesticated 2) in the CHO cell lines expressing cell lines to obtain a highly; 4) fermentation culture 3) in the cell line, to obtain the recombinant infectious bovine rhinotracheitis virus gD protein.
The present invention further provides a recombinant infectious bovine rhinotracheitis virus gD protein and recombinant subunit vaccines infectious bovine rhinotracheitis virus and related diagnosis for the preparation of a reagent.";"(CN107973840)
This cell line expresses an antigen of the infectious bovine rhinotracheitis virus vaccine may be prepared as a prophylactic to provide a novel, efficient prophylactic agent, it would have in China and even worldwide play an important role for preventing infectious bovine rhinotracheitis virus control.
With respect to the other expression systems, CHO cells have the following advantages: (1) has an exact post-transcriptional modification function, expression of the proteins in the molecular structure, chemical-physical properties and biological functionality to the closest to the natural protein molecules may be adherently growing ; (2), or may be in suspension culture, and has a high withstand shear forces and osmotic pressure capability with a high-efficiency amplification and the ability to express a recombinant gene ; (3), stable integration of an exogenous protein with a product secreted extracellularly function ; (4), and rarely secretion own endogenous protein, to facilitate separation and purification downstream products in serum-free or in suspension culture ; (5) can achieve a high-density culture medium, and the culture volume 1, 000L or more can be achieved, it is possible to mass production.
A main advantage of this system: (1) there is no need of the gene-deficient CHO-K1 cell line as a host cell CHO-K1 ; (2) cell more robust, easy to culture in a culture medium without the addition of glutamine ; (3), avoid glutamine decomposition causes a problem of high ammonia levels in the culture system, reduces the difficulty of control processes, and is effective to increase a time to live cells with a cell density and prolonged.
Epidemiological surveys show, 14 of the IBRV province in China major cattle infection rates of 33.3% on average, give me through the cattle industry can cause a huge economic loss.
The virus can also cause a cow reproductive system is compromised, resulting in abortion, stillbirth and the like, may also cause inflammatory bowel disease, bovine encephalitis, ocular conjunctivitis and keratitis and the like.";"A61K-039/265
A61P-031/22
C07K-014/06
C12N-005/10
C12N-015/85
G01N-033/569";"(CN107973840)
1. A recombinant infectious bovine rhinotracheitis virus gD protein preparation method, characterized in, preparation method comprising the steps of: 1) GD protein of the infectious bovine rhinotracheitis virus genes were cloned into eukaryotic expression vectors containing gene encoding gD protein obtained infectious bovine rhinotracheitis virus of the recombinant plasmid; 2) Re-containing infectious bovine rhinotracheitis virus gD recombinant plasmids were transfected into CHO of the gene encoding protein in a cell; 3) Through culture, screening, acclimatization 2) in the CHO cell strain was highly expressed cell line; 4) Fermentation culture 3) in the cell line, to obtain the recombinant infectious bovine rhinotracheitis virus gD protein.";"(CN107973840)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,40)
GD PROTEIN(100,23)
PROTEIN(100,11)
CHO CELL(100,10)
SUBUNIT VACCINE(100,5)
BOVINE RHINOTRACHEITIS VIRUS INFECTION(100,1)
GENE ENCODING GD PROTEIN(91,2)
EUKARYOTIC EXPRESSION VECTOR(89,8)
RECOMBINANT PLASMID(88,11)
RECOMBINANT SUBUNIT VACCINE(79,6)
GENE ENCODING PROTEIN CHO(79,1)
FERMENTATION CULTURE(76,3)
GD PROTEIN ENCODING GENE(62,7)
GD PROTEIN ACCLIMATIZATION(59,1)
CHINA MAJOR CATTLE INFECTION(58,1)
GENE ENCODING CHO(57,1)
OCULAR CONJUNCTIVITIS(53,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GENE(50,1)
EXOGENOUS PROTEIN STABLE INTEGRATION(49,1)
PROTEIN EXPRESSION SECRETION(49,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GD(47,3)
BOVINE ENCEPHALITIS(47,1)
RECOMBINANT GD PROTEIN(46,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(45,1)
EPIDEMIOLOGICAL SURVEY SHOW(42,1)
RECOMBINANT GENE(42,1)
GD PROTEIN GENE(41,2)
VACCINE PROTEIN PURIFICATION MANUFACTURE(41,1)
RECOMBINANT SUBUNIT VACCINE ADJUVANT(40,2)
ANIMAL VACCINE(40,1)
ENDOGENOUS PROTEIN(40,1)
HUGE ECONOMIC LOSS(40,1)
SUSPENSION CULTURE(38,4)
BIOLOGICAL FUNCTIONALITY(37,1)
CATTLE INDUSTRY(37,1)
WORLDWIDE PLAY(37,1)
PROTEIN MOLECULE(36,1)
CULTURE(35,7)
PROTEIN EXPRESSION(35,5)
PROPHYLACTIC AGENT EFFICIENT(33,1)
ACCLIMATIZATION(32,1)
REAGENT PREPARATION(31,1)
DIAGNOSIS REAGENT(30,1)
CELL CULTURE SUPERNATANT PROTEIN(29,1)
CHO CELL SECRETION(28,1)
PURIFICATION DOWNSTREAM PRODUCT(28,1)
STRONG HUMORAL IMMUNITY(27,1)
CULTURE VOLUME(25,1)
TRANSFECTED CHO CELL(24,1)
DIAGNOSIS(23,1)
L GLUTAMINE DECOMPOSITION(23,1)
PROPHYLACTIC(23,1)
RECOMBINANT CHO CELL(23,1)
STILLBIRTH(23,1)
KERATITIS(22,1)
VACCINE PRODUCTION(22,1)
ABORTION(21,1)
PROVINCE(21,1)
ANTIGEN(20,1)
INFLAMMATORY BOWEL DISEASE(20,1)
SECRETION(20,1)
ADSORPTION COLUMN(19,20)
PROTEIN SUBUNIT(19,3)
SHEAR FORCE(19,1)
VIRUS(19,1)
HOST CELL(17,3)
VACCINE PREPARATION(15,3)
OSMOTIC PRESSURE CAPABILITY(15,1)
POST TRANSCRIPTIONAL MODIFICATION FUNCTION(15,1)
ORBIT SHAKER INCUBATOR(14,2)
COW REPRODUCTIVE SYSTEM(14,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS CONTROL(14,1)
COOMMASSIE REAGENT(11,4)
TRYPSIN EDTA(11,4)
BIOLOGICAL SAFETY CABINET(11,3)
ANIMAL VACCINE TECHNICAL FIELD(11,1)
SHAKE FLASK FERMENTATION MONOCLONAL(11,1)
CELL SHRINKAGE MICROSCOPIC OBSERVATION(10,2)
SHANGHAI LIN YUAN(10,1)
SUBUNIT VACCINE PREPARATION(10,1)
GD PROTEIN ANTIGEN EXPRESSION(9,1)
OPTIMEM DILUTING PLASMID(9,1)
OPTIMIZED IBRV GD GENE(9,1)
SCREENING MONOCLONAL ESTABLISHMENT(9,1)
VACCINE ANTIBODY TITER(9,1)
VIABILITY COUNT(8,3)
BOVINE FATAL BACTERIAL PNEUMONIA(8,1)
CULTURE SUPERNATANT PROTEIN EXPRESSION(8,1)
ELISA DETECTION ANTIBODY TITER(8,1)
NEUTRALIZING ANTIBODY CREATION(8,1)
CELL LINE(7,11)
PRESSURIZED SCREENING(7,2)
SECRETION EXPRESSION(7,2)
ULTRAVIOLET IRRADIATION(7,2)
AMERICAN GIBCOM COMPANY(7,1)
HIGHLY EXPRESSED CELL LINE(7,1)
L GLUTAMINE ADDITION(7,1)
PROTEIN FERMENTATION CREATION(7,1)
PROVINCE COW(7,1)
TH CENTURY YEAR(7,1)
THERMO FISHER CORPORATION(7,1)
WHITE FLOCCULENT PRECIPITATE(7,1)
WASTE LIQUID(6,4)
BIOLOGICAL SAFETY COUNTER(6,2)
CHO CELL LINE(6,2)
SUSPENSION STABILIZER(6,2)
CONTROL PROCESS DIFFICULTY(6,1)
GD GENE PREPARATION(6,1)
HIGH EFFICIENCY AMPLIFICATION(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS IMMUNIZATION(6,1)
NICKEL COLUMN AFFINITY EXPRESSION(6,1)
PLASMID EXTRACTION REAGENT(6,1)
PROTEIN ASSAY KIT(6,1)
PURIFIED GD PROTEIN(6,1)
TRANSFECTION PRESSURIZATION(6,1)
TU MUSHROOM BACTERIAL LIQUID(6,1)
WESTERN BLOTTING(6,1)
XPB DIALYSIS(6,1)
ROOM TEMPERATURE(5,32)
BUFFERA(5,4)
H INCUBATION(5,4)
HOMOMIXER(5,4)
BIOTECHNOLOGY(5,2)
CORRECT CLONE(5,2)
FLASK CULTURE MEDIUM(5,2)
ICE BATH(5,2)
MEDIUM SUPERNATANT(5,2)
PROTEIN CONCENTRATION(5,2)
ANTIGEN ANTIBODY(5,1)
BIOCHEMICAL TRANSFORMATION(5,1)
BOVINE MUSCLE INJECTION(5,1)
CO2 CELL INCUBATOR(5,1)
CODON OPTIMIZATION(5,1)
COW MILK PRODUCTION(5,1)
CULTURED BACTERIA MIXTURE(5,1)
ENVELOPE GLYCOPROTEIN(5,1)
EUKARYOTIC VECTOR(5,1)
FERMENTATION FLASK(5,1)
FRAGMENT OPTI GD(5,1)
HIGH DENSITY CULTURE MEDIUM(5,1)
IBRV GD PROTEIN(5,1)
IMIDAZOLE ELUENT(5,1)
INTRACELLULAR AMMONIA(5,1)
LB AMPICILLIN(5,1)
LINKED GENE(5,1)
MOLECULAR STRUCTURE(5,1)
QUALIFIED SAVE(5,1)
SCALPEL DNA(5,1)
SCREEN MONOCLONAL(5,1)
SHAKER FLASK CELL(5,1)
START MONOCLONAL SCREENING(5,1)
RPM MIN(4,25)
RESERVE(4,5)
SAMPLE TUBE(4,4)
BLOCKING SOLUTION(4,3)
CELL VIABILITY(4,3)
CENTRIFUGATION(4,3)
GENOME(4,3)
OUTER STERILIZATION(4,3)
STANDING(4,3)
LARGE SCALE INDUSTRIAL PRODUCTION(4,2)
ADULT FEMALE(4,1)
AFFINITY CHROMATOGRAPHY(4,1)
BACTERIAL SUSPENSION(4,1)
BIOENGINEERED CELL(4,1)
BLOOD GLUCOSE(4,1)
BOVINE INJECTION(4,1)
CD CHO(4,1)
CELL INOCULATION(4,1)
CELL REACHED INTERSECTION(4,1)
CHROMATOGRAPHY PURIFICATION(4,1)
CO2 CELL CULTURE INCUBATOR(4,1)
CONTINUOUS GENTLE CENTRIFUGING TUBE(4,1)
CULTURE COLLECTION(4,1)
CULTURE FLASK(4,1)
DNA FRAGMENT(4,1)
ENDOTOXIN FREE PLASMID MAXI(4,1)
EPITHELIAL CELL(4,1)
EQUILIBRATION BUFFER(4,1)
GD GENE SEQUENCE(4,1)
HRP LABELED ANTIBODY(4,1)
IMMUNE CELL(4,1)
INSERT FEED SEQUENCING(4,1)
INTERMEDIATE CELL VISUALIZATION(4,1)
KB LADDER(4,1)
OVERNIGHT INCUBATION(4,1)
PCR AMPLIFICATION(4,1)
PIPETTE TIP(4,1)
PLASMID DILUTION(4,1)
PLASMID DNA(4,1)
PROTEIN PREPARATION PURITY(4,1)
PROTEIN PURIFICATION(4,1)
PROTEIN PURITY(4,1)
PURIFIED PROTEIN(4,1)
RECENT DEVELOPMENT YEAR(4,1)
SECONDARY RESPIRATORY INFECTION(4,1)
SEPARATED HAMSTER OVARY(4,1)
SHANGHAI SHANGAI LIFE SCIENCE(4,1)
SIGMA CORPORATION(4,1)
SUBCULTURE MEDIUM PREPARATION(4,1)
SUPERNATANT DISCARDED MEDIUM(4,1)
VACCINE MANUFACTURE(4,1)
ELUTION(3,4)
STRAIN(3,4)
WATER BATH(3,4)
CELL DENSITY(3,3)
FETCHING STEP(3,3)
SDS PAGE(3,3)
WARM WATER TANK(3,3)
BASAL MEDIUM(3,2)
EMULSIFICATION(3,2)
METHOTREXATE(3,2)
PCR PRODUCT(3,2)
PCR REACTION(3,2)
ADSORBENT FILM(3,1)
ADSORPTION FILM INTERMEDIATE(3,1)
AGAROSE GEL(3,1)
ANTIGEN DETECTION(3,1)
CARBONATE BUFFER(3,1)
CATTLE RELATIVE TITER(3,1)
CELL CULTURE DISH(3,1)
CELL HOMOGENIZATION(3,1)
CELL SUPERNATANT(3,1)
CELL SUSPENSION(3,1)
CHROMOGENIC LIQUID(3,1)
CO2 INCUBATOR TEMPERATURE(3,1)
COMMITTEE CELL(3,1)
COMPETENT CELL(3,1)
DEATH RAY(3,1)
DERIVED PROTEIN(3,1)
DIHYDROFOLATE REDUCTASE(3,1)
ELISA POSITIVE(3,1)
ENDOTOXIN FREE PLASMID EXTRACTION(3,1)
ENERGY HYDROLYSIS(3,1)
FEEDBACK ADJUSTMENT(3,1)
GENERATION CELL CULTURE VIABILITY(3,1)
HUNDRED GENERATION(3,1)
IMMEDIATELY REVERSED CENTRIFUGE TUBE(3,1)
IMMUNOGENIC GOOD(3,1)
KB GENE(3,1)
LINEAR DNA MOLECULE(3,1)
MAJOR STRUCTURAL PROTEIN(3,1)
MOLECULAR CELL VIRAL INFECTION(3,1)
OLD CALF(3,1)
OPTI GD SEQUENCE(3,1)
PRIMARY GLYCOPROTEIN(3,1)
PURITY DETERMINATION(3,1)
REMAINING SUPERNATANT CELL(3,1)
SAMPLE VIAL(3,1)
SEEDING DENSITY(3,1)
SUSPENSION TUBE(3,1)
UPPER RESPIRATORY INFLAMMATION(3,1)
WASTE COLLECTION TUBE(3,1)
WAVELENGTH MEASUREMENT SAMPLE(3,1)
WHITE PRECIPITATE(3,1)
ACCESSORY(2,1)
ADHERENT(2,1)";"Analysis of biological materials
Pharmaceuticals";Open
2016-12-28;"CN107970443         A  2018-05-01 [CN107970443]
STG: (A) Published application
AP : 2016CN-1239612 2016-12-28";79532531;CN107970443         A  2018-05-01 [CN107970443];2016CN-1239612;;NOVO BIOTECH;NOVO BIOTECH;;;1;"QIAN HONG
WU YOUQIANG
BIAN GUANGLIN
ZHANG QIANG
CHA YINHE";;;"(CN107970443)
Bovine viral diarrhea virus E2 protein subunit vaccine composition as well as preparation method and application thereof";"(CN107970443)
The invention discloses a bovine viral diarrhea virus E2 protein subunit vaccine composition as well as a preparation method and an application thereof, and belongs to the technical fields of animal vaccines and veterinary biological products. The vaccine composition consists of bovine viral diarrhea virus E2 protein of more than two subtypes and a pharmaceutically acceptable adjuvant. The preparation method of the vaccine composition comprises the following steps: 1) preparing an aqueous phase and an oil phase at the volume ratio of 46: 55; 2) pre-heating the aqueous phase and the oil phase to 32-34 DEG C; 3) adding the oil phase to a container, regulating the height and the speed of a stirrer, adding the aqueous phase to the oil phase in a stirring process, and continuing to conduct stirring for 10-20min; 4) keeping the vaccine composition, which is emulsified in the step 3), at 20 DEG C for 1h; 5) keeping the vaccine composition obtained in the step 4) at 4 DEG C for 24h; and 6) sub-packaging and labeling the vaccine composition obtained in the step 5). The vaccine composition can protect infections caused by the bovine viral diarrhea viruses of different subtypes; and the vaccine composition is simple to prepare and low in usage amount.";"(CN107970443)
1. Bovine viral diarrhea virus E2 protein subunit of a vaccine composition, characterized in, compositions comprise two subtypes or more bovine viral diarrhea virus E2 protein and a pharmaceutically acceptable adjuvant.
2. Composition according to claim 1, characterized in, bovine viral diarrhea virus E2 protein selected from the group of different subtypes of type BVDV GS5 1 a - E2, and the - E2 BVDV JL-1 1 b in the - E2 type at least one BVDV XJ-04 2 type.
3. Composition according to claim 1, characterized in, bovine viral diarrhea virus E2 protein of different subtypes in accordance with equimass ratio.
4. Composition according to claim 1, characterized in, bovine viral diarrhea virus E2 protein of different subtypes after mixing the protein concentration of 50 μg/head parts-200μg/head parts.
5. Composition according to claim 1, characterized in, adjuvant is ISA 201 VG.
6. In accordance with claim 1-5 composition according to any, characterized in, composition further containing the immunopotentiator, and the/or preservatives.
7. Composition according to claim 6, characterized in, Quil-A was Immunopotentlator, Quil-A at a concentration of 500 μg/head parts-750μg/head parts.
8. Composition according to claim 6, characterized in, preservative is thimerosal, tihimerosal in an amount of 0.01% per head parts in the vaccine composition below.
9. Claim 1-8 A method of producing composition according to any of the method, characterized in, method comprising the steps of:
1) Preparing an aqueous phase and oil phase, aqueous phase and oil phase in volume ratio of 46:55;
2) the water and oil are preheated to 33 °C ± 1 °C;
3) the oil phase was first placed in a vessel, adjusting the height and speed of the agitator preferably, the aqueous phase to oil phase in the course of the stirring, stirring was continued for 10 min-20 min;
4) Step 3) was allowed to stand for 1 h 20 °C vaccine composition is placed in good emulsification;
5) Will be 4) allowed to stand for 24 h in the vaccine composition is placed in 4 °C;
6) Will be 5) in the vaccine composition dispensing, labeling.
10. Method according to claim 9, characterized in, bovine viral diarrhea virus E2 of different subtypes of aqueous protein; ISA 201 VG oil phase is an adjuvant.
11. Method according to claim 10, characterized in, aqueous phase further comprises Immunopotentlator or preservative or both.
12. Method according to claim 9, characterized in, stirring speed of 350rpm/min-600rpm/min.
13. Claim 9-12 method according to any one of claims, characterized in, preparation materials and preparation procedures are carried out under sterile conditions.
14. Claim 1-9 A composition according to any one of a Bovine Viral Diarrhea the prevention and treatment.";"(CN107970443)
The present invention provides a bovine against bovine of different subtypes can be simultaneously protected viral diarrhea virus infection of the sub-unit vaccine composition.
The present invention provides a simultaneous protection of the calf from different typed can be bovine viral diarrhea virus infection in a sub-unit vaccine composition.
The present invention relates to a bovine viral diarrhea virus E2 protein a subunit vaccine composition and its preparation method and application, which belongs to the veterinary vaccines according to the technical field of animal biological products.";"(CN107970443)
As compared with the prior art, the present invention is able to protect cattle from different compositions of bovine viral diarrhea virus infection of the typing, and the composition is prepared in a simple, small amount.
The disease is most earlier than found in U.S. 1946, explosion was after-demand a global epidemic.
In China 1983 has been reported for the first time occurrence of the disease, currently existing across the board 20 a plurality of province, city, a municipality BVD is present. 2008, People's Republic of Department of Agriculture published bulletin No.96, bovine viral diarrhea is defined as three classifications disease; world health organizations will also be listed as the disease animal veterinary diseases and animal embryos of the official report lists three types of disease pathogenic communication.";"A61K-039/12
A61P-031/14";"(CN107970443)
1. Bovine viral diarrhea virus E2 protein subunit of a vaccine composition, characterized in, compositions comprise two subtypes or more bovine viral diarrhea virus E2 protein and a pharmaceutically acceptable adjuvant.";"(CN107970443)
BOVINE VIRAL DIARRHEA VIRUS E(100,17)
PROTEIN(100,13)
ADJUVANT(100,9)
SUBTYPE(100,9)
BOVINE VIRAL DIARRHEA VIRUS(100,8)
SUBUNIT VACCINE(100,5)
VACCINE COMPOSITION PROTEIN SUBUNIT(100,1)
DEPARTMENT PEOPLE REPUBLIC(75,1)
VIRAL DIARRHEA VIRUS INFECTION(68,1)
MUNICIPALITY BVD(63,1)
ANIMAL VETERINARY DISEASE(61,1)
VETERINARY VACCINE(59,1)
BOVINE VIRAL DIARRHEA VIRUS INFECTION(56,5)
ANIMAL VETERINARY VACCINE(56,1)
CALF SIMULTANEOUS PROTECTION(53,1)
GLOBAL EPIDEMIC(52,1)
DISEASE CLASSIFICATION(50,1)
DISEASE PATHOGENIC COMMUNICATION(48,1)
ANIMAL EMBRYO(43,1)
AQUEOUS PROTEIN SUBTYPE(40,1)
OFFICIAL REPORT LIST(40,1)
VACCINE COMPOSITION DISPENSING(34,1)
DISEASE(31,2)
AQUEOUS PHASE(29,12)
AGRICULTURE(25,1)
PROVINCE(24,1)
TYPING(24,1)
BOVINE VIRAL DIARRHEA(23,4)
VACCINE COMPOSITION PREPARATION(23,3)
EXPLOSION(23,1)
BULLETIN(22,1)
ANIMAL BIOLOGICAL PRODUCT(21,1)
EMULSIFICATION(21,1)
SUBTYPE BOVINE(21,1)
WORLD HEALTH ORGANIZATION(20,1)
ISOFORM(19,3)
PROTEIN CONCENTRATION(18,3)
OIL PHASE(17,7)
EQUIMASS RATIO(17,2)
CITY(17,1)
STIRRING COURSE(17,1)
BOVINE(16,2)
CATTLE(16,2)
LABELING(16,2)
SUBTYPE PROTEIN(15,5)
EMULSION(15,1)
AGITATION(14,2)
NEUTRALIZING ANTIBODY TITER(14,2)
STERILE CONDITION(14,2)
STIRRER(14,2)
COUNTRY BVDV EPIDEMICOLOGIC MOLECULE(14,1)
FLAVIVIRUS GENUS PESTIVIRUS(13,1)
VIRAL DIARRHEA VIRUS GENOTYPE(13,1)
DISEASE TIME OCCURRENCE(12,1)
STIRRING SPEED(11,2)
DIARRHEA CLINICAL MANIFESTATION(11,1)
HOG CHOLERA VIRUS(11,1)
ANTIBODY NEUTRALIZATION(10,2)
OIL VOLUME RATIO(10,2)
BVDV ANTIGEN ANTIBODY(10,1)
ISOLATED DISEASED BVDV2 VIRUS(10,1)
RPM MIN(9,6)
BVDV ENVELOPE PROTEIN(9,1)
C VACCINE(9,1)
CHINA DNASTAR SOFTWARE(9,1)
NEUTRALIZATION EXPERIMENT(8,2)
BRENNTAG BIOSECTOR(8,1)
MAJOR POPULAR BVDV STRAIN(8,1)
PERSISTENT INFECTION MAJORITY(8,1)
PESTIVIRUS GENUS(8,1)
PHYLOGENETIC ANALYSIS INVESTIGATION(8,1)
POLYPROTEIN ORF(8,1)
SHEEP BOUNDARY VIRUS(8,1)
SUBTYPE GROUP(8,1)
BOVINE VIRAL DIARRHEA VIRUS PREVENTION(7,2)
BIOLOGICAL SAFETY CABINET(7,1)
MERCURY PRESERVATIVE(7,1)
MUCOSAL DIAEASE(7,1)
PRESERVATIVE THIMEROSAL(7,1)
REPRODUCTIVE DISORDER(7,1)
SUBUNIT VACCINE COMPOSITION IMMUNOASSAY(7,1)
VIRAL INFECTION GENOTYPING(7,1)
ALUMINA ADJUVANT(6,1)
BVDV GENOME(6,1)
BVDV INFECTED ANIMAL(6,1)
CATTLE PROTECTION(6,1)
CREATION HUMORAL IMMUNITY(6,1)
DISEASE NECROSIS(6,1)
IMMUNE SUPPRESSION(6,1)
IMMUNOPOTENTIATOR CONCENTRATION(6,1)
MUCOUS MEMBRANE INFLAMMATION(6,1)
PROTEIN SIMILARITY(6,1)
PROTEIN VACCINE(6,1)
REAGENT VIAL(6,1)
SEROTYPE STRAIN DIFFERENCE(6,1)
STERILE TOOL PREPARATION(6,1)
WIDELY POPULAR PROPAGATION(6,1)
BIOLOGICAL PRODUCT TECHNICAL FIELD(5,1)
BOVINE MUCOSAL DISEASE(5,1)
CATTLE GREAT CIRCLE(5,1)
CATTLE INDUSTRY(5,1)
COMPOSITION SUBUNIT VACCINE PREPARATION(5,1)
CPG DNA(5,1)
FRENCH COMPANY(5,1)
MATURE PROTEIN(5,1)
NEUTRALIZATION TEST(5,1)
OLD CALF(5,1)
PROTEIN EXPRESSION PATTERN(5,1)
THIMEROSAL ACCESSIBLE VOLUME(5,1)
VACCINE COMPOSITION CONCENTRATION(5,1)
HOMOLOGY(4,2)
DETECTION EXPERIMENT(4,1)
ECONOMIC LOSS(4,1)
GENE ANALYSIS(4,1)
ISOLATED STRAIN(4,1)
OIL ADJUVANT(4,1)
PREHEATED OIL(4,1)
SUBPOPULATION(4,1)";Pharmaceuticals;Open
2016-12-23;"CN107973841         A  2018-05-01 [CN107973841]
STG: (A) Published application
AP : 2016CN-1208261 2016-12-23";79532514;CN107973841         A  2018-05-01 [CN107973841];2016CN-1208261;;NOVO BIOTECH;NOVO BIOTECH;;;1;"QIAN HONG
WU YOUQIANG
BIAN GUANGLIN
ZHANG QIANG
WU SUFANG
CHE YING
SONG YUEHONG
LÜ YANGPING
CHEN BIN
CHA YINHE";;;"(CN107973841)
Preparation methods for CHO cell expressed recombinant bovine viral diarrhea virus protein E2 and subunit vaccine and application";"(CN107973841)
The invention discloses preparation methods for CHO cell expressed recombinant bovine viral diarrhea virus protein E2 and a subunit vaccine and applications and belongs to the technical fields of animal vaccines and veterinary biologicals. The object of the invention is to provide a preparation method capable of industrially producing the bovine viral diarrhea virus recombinant subunit vaccine ona large scale. The preparation method for the recombinant subunit vaccine, provided by the invention, comprises the following steps: 1) cloning an eukaryotic expression vector containing a protein E2coding gene; 2) transfecting CHO cells, and performing selection, screening and acclimatizing to obtain suspending CHO cell strains, which stably and efficiently express the protein E2; 3) subjectingthe cell strains obtained in the step 2) to fermentation culture, and carrying out purification, so as to obtain recombinant protein E2; and 4) uniformly mixing the recombinant protein E2 and ISA 201VG thoroughly, thereby obtaining the recombinant subunit vaccine. According to the method provided by the invention, target protein can be obtained from cell culture supernatant, the yield reaches upto 500mg/L, the protein purification time is shortened, the vaccine production steps are simplified, and the vaccine production cost is greatly reduced.";"(CN107973841)
1. A recombinant bovine viral diarrhea virus E2 protein preparation method, characterized in, preparation method comprising the steps of:
1) Bovine viral diarrhea virus E2 protein was cloned into the eukaryotic expression vector containing bovine viral diarrhea virus E2 protein obtained in a recombinant plasmid encoding gene;
2) Containing bovine viral diarrhea virus E2 protein and the recombinant plasmids were transfected into CHO cells of the gene encoding;
3) Through culture, screening, acclimatization 2) CHO cell line obtained in a highly expressed cell line;
4) Fermentation culture 3) in the cell line, recombinant bovine viral diarrhea virus E2 protein was obtained after purification.
2. Preparation method according to claim 1, characterized in, E2 protein-encoding gene containing bovine viral diarrhea virus recombinant plasmid of bovine viral diarrhea virus E2 protein involves inserting codon-optimized gene encoding, and then cloned into eukaryotic expression vectors, recombinant plasmid was obtained.
3. Preparation method according to claim 1 or 2, characterized in, bovine viral diarrhea virus E2 protein-encoding gene as shown in SEQ ID NO:1.
4. Preparation method according to claim 1 or 2, characterized in, eukaryotic expression vector is pEE12.4.
5. Preparation method according to claim 1, characterized in, CHO-K1 cells are CHO cells.
6. Comprising a recombinant bovine viral diarrhea virus E2 protein subunit vaccine preparation method, characterized in, will produce recombinant bovine viral diarrhea virus E2 protein method obtained with a pharmaceutically acceptable adjuvant mixed thoroughly according to claim 1, bovine viral diarrhea virus E2 obtained recombinant subunit vaccine.
7. Preparation method according to claim 6, characterized in, recombinant subunit vaccine adjuvants used as ISA 201 VG.
8. Preparation method according to claim 6, characterized in, recombinant bovine viral diarrhea virus E2 protein in a volume ratio mixed with an adjuvant ISA 201 VG 46:54 emulsification.
9. Claim 1-8 any of the recombinant bovine viral diarrhea virus according to a bovine viral diarrhea virus E2 protein and recombinant subunit vaccines and related diagnosis reagent for use in the manufacture.";"(CN107973841)
The present invention relates to a stably expressing CHO cell lines of the bovine viral diarrhea virus E2 protein bovine viral diarrhea virus E2 protein and the preparation and use of subunit vaccines, animal vaccines and veterinary biologics which belongs to the technical field.
The present invention there is provided a CHO cells expressing bovine viral diarrhea virus E2 protein and secreted subunit vaccine production method, comprising the steps of: 1) bovine viral diarrhea virus E2 protein was cloned into the eukaryotic expression vector containing bovine viral diarrhea virus E2 obtained in a recombinant plasmid protein-encoding gene; 2) containing bovine viral diarrhea virus E2 protein and the recombinant plasmids were transfected into CHO cells of the gene encoding; 3) through the culture, screening, domesticated 2) CHO cell line is highly expressed in the cell lines obtained; 4) fermentation culture 3) in the cell line, recombinant bovine viral diarrhea virus E2 protein was obtained after purification.
The present invention further provides a recombinant bovine viral diarrhea virus E2 protein and bovine viral diarrhea virus recombinant subunit vaccines and related diagnosis for the preparation of a reagent.";"(CN107973841)
With respect to the other expression systems, CHO cells have the following advantages: (1) has an exact post-transcriptional modification function, expression of the proteins in the molecular structure, chemical-physical properties and biological functionality to the closest to the natural protein molecules may be adherently growing ; (2), or may be in suspension culture, and has a high withstand shear forces and osmotic pressure capability with a high-efficiency amplification and the ability to express a recombinant gene ; (3), stable integration of an exogenous protein with a product secreted extracellularly function ; (4), and rarely secretion own endogenous protein, to facilitate separation and purification downstream products in serum-free or in suspension culture ; (5) can achieve a high-density culture medium, and the culture volume 1, 000L or more can be achieved, it is possible to mass production.
A main advantage of this system: (1) there is no need of the gene-deficient CHO-K1 cell line as a host cell CHO-K1 ; (2) cell more robust, easy to culture in a culture medium without the addition of glutamine ; (3), avoid glutamine decomposition causes a problem of high ammonia levels in the culture system, reduces the difficulty of control processes, and is effective to increase a time to live cells with a cell density and prolonged.
A cell line expressing the antigen in bovine viral diarrhea virus vaccine may be prepared as a prophylactic to provide a novel, efficient prophylactic agent, bovine viral diarrhea virus worldwide in China and even to a preventive control can play an important role.
In China 1983 has been reported for the first time occurrence of the disease, currently existing across the board 20 a plurality of province, city, a municipality BVD is present. 2008, People's Republic of Department of Agriculture published bulletin No.96, bovine viral diarrhea is defined as three classifications disease; world animal Health Organization reported legal descriptions of the disease as well as veterinary diseases listed as AC pathogenic roster three types of disease animal embryo.
The disease is most earlier than found in U.S. 1946, explosion was after-demand a global epidemic.";"A61K-039/12
A61P-031/14
C07K-014/18
C12N-015/40
C12N-015/85";"(CN107973841)
1. A recombinant bovine viral diarrhea virus E2 protein preparation method, characterized in, preparation method comprising the steps of: 1) Bovine viral diarrhea virus E2 protein was cloned into the eukaryotic expression vector containing bovine viral diarrhea virus E2 protein obtained in a recombinant plasmid encoding gene; 2) Containing bovine viral diarrhea virus E2 protein and the recombinant plasmids were transfected into CHO cells of the gene encoding; 3) Through culture, screening, acclimatization 2) CHO cell line obtained in a highly expressed cell line; 4) Fermentation culture 3) in the cell line, recombinant bovine viral diarrhea virus E2 protein was obtained after purification.";"(CN107973841)
PROTEIN(100,41)
BOVINE VIRAL DIARRHEA VIRUS(100,31)
CHO CELL(100,15)
EUKARYOTIC EXPRESSION VECTOR(100,8)
PROTEIN PREPARATION(100,2)
SUBUNIT VACCINE PREPARATION(100,2)
RECOMBINANT PLASMID ENCODING GENE(97,1)
RECOMBINANT PLASMID(86,9)
FERMENTATION CULTURE(85,3)
RECOMBINANT SUBUNIT VACCINE(84,4)
VETERINARY BIOLOGICS(76,2)
DEPARTMENT PEOPLE REPUBLIC(75,1)
AC PATHOGENIC ROSTER(70,1)
GENE ENCODING CHO CELL(68,2)
WORLD ANIMAL HEALTH ORGANIZATION(65,1)
MUNICIPALITY BVD(62,1)
DISEASE ANIMAL EMBRYO(57,1)
VACCINATING ANIMAL(55,2)
EXOGENOUS PROTEIN STABLE INTEGRATION(55,1)
PROTEIN ENCODING GENE(53,5)
GLOBAL EPIDEMIC(52,1)
DISEASE CLASSIFICATION(50,1)
RECOMBINANT GENE(47,1)
VETERINARY DISEASE(47,1)
RECOMBINANT SUBUNIT VACCINE ADJUVANT(45,2)
ENDOGENOUS PROTEIN(45,1)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(43,1)
SUSPENSION CULTURE(42,4)
BIOLOGICAL FUNCTIONALITY(41,1)
PROTEIN MOLECULE(40,1)
CULTURE(39,7)
PURIFICATION(38,3)
CODON OPTIMIZED GENE ENCODING(37,1)
PROPHYLACTIC AGENT EFFICIENT(37,1)
ACCLIMATIZATION(36,1)
REAGENT PREPARATION(35,1)
DIAGNOSIS REAGENT(34,1)
CELL CULTURE SUPERNATANT PROTEIN(33,1)
PURIFICATION DOWNSTREAM PRODUCT(31,1)
PROTEIN EXPRESSION(30,3)
CULTURE VOLUME(28,1)
TRANSFECTED CHO CELL(27,1)
PROTEIN PURIFICATION(26,2)
DIAGNOSIS(26,1)
L GLUTAMINE DECOMPOSITION(26,1)
PROPHYLACTIC(26,1)
RECOMBINANT CHO CELL(26,1)
RECOMBINANT SUBUNIT VACCINE STEP(26,1)
SUBUNIT VACCINE(25,7)
AGRICULTURE(25,1)
PROVINCE(24,1)
EXPLOSION(23,1)
SECRETION(23,1)
ADSORPTION COLUMN(21,19)
BOVINE VIRAL DIARRHEA VIRUS E(21,19)
BULLETIN(21,1)
SHEAR FORCE(21,1)
HOST CELL(19,3)
BOVINE VIRAL DIARRHEA(17,3)
DISEASE(17,2)
CITY(17,1)
DROSOPHILA MELANOGASTER MARZOCCA MP(17,1)
OSMOTIC PRESSURE CAPABILITY(17,1)
POST TRANSCRIPTIONAL MODIFICATION FUNCTION(17,1)
PREVENTIVE CONTROL(17,1)
ORBIT SHAKER INCUBATOR(16,2)
ANTIGEN(15,4)
BIOLOGICAL SAFETY CABINET(14,4)
EMULSIFICATION(14,3)
ACCLIMATIZATION CHO CELL(13,1)
FLAVIVIRUS GENUS PESTIVIRUS(13,1)
TRYPSIN EDTA(12,4)
BVDV VACCINE INOCULATION(12,1)
DISEASE TIME OCCURRENCE(12,1)
SUBUNIT VACCINE PRODUCTION(12,1)
CELL SHRINKAGE MICROSCOPIC OBSERVATION(11,2)
BVDV INOCULATION ONSET(11,1)
DIARRHEA CLINICAL MANIFESTATION(11,1)
PROTEIN INSECT BACULOVIRUS EXPRESSION(11,1)
SHANGHAI LIN YUAN(11,1)
VIRUS NEUTRALIZING ANTIBODY INDUCTION(11,1)
IMIDAZOLE ELUTION(10,3)
FERMENTATION SUPERNATANT(10,2)
BVDV ANTIGEN ANTIBODY(10,1)
ENVELOPE GLYCOPROTEIN EXPRESSION OVERCOMING(10,1)
HAMSTER OVARY UNIVERSITY(10,1)
OPTIMEM DILUTING PLASMID(10,1)
PROTEIN IMMUNE ULOVILUS EXPRESSION(10,1)
VACCINE ANTIBODY TITER(10,1)
CELL LINE(9,7)
VIABILITY COUNT(9,3)
XSD SAMPLE BUFFER(9,3)
BOVINE CREATION IMMUNIZATION(9,1)
CODON OPTIMIZED BVDV(9,1)
MONOCLONAL SCREENING SETUP(9,1)
CHO CELL LINE(8,2)
POORLY DIGESTED CELL(8,2)
PRESSURIZED SCREENING(8,2)
QUALIFIED SAVE(8,2)
ULTRAVIOLET IRRADIATION(8,2)
AMERICAN GIBCOM COMPANY(8,1)
CATTLE PROTEIN EXPRESSION(8,1)
CHOICE VACCINE GENE(8,1)
COLUMN AFFINITY CHROMATOGRAPHY CHROMATOGRAM(8,1)
HIGHLY EXPRESSED CELL LINE(8,1)
L GLUTAMINE ADDITION(8,1)
PERSISTENT INFECTION MAJORITY(8,1)
PRODUCTION COST REDUCTION(8,1)
RACHIPLUSIA NUPERO(8,1)
THERMO FISHER CORPORATION(8,1)
VACCINE BVDV(8,1)
WEAK UNDISIRED PROTEIN(8,1)
WHITE FLOCCULENT PRECIPITATE(8,1)
SERUM(7,13)
BIOLOGICAL SAFETY COUNTER(7,2)
ANTIBODY NEUTRALIZATION(7,1)
ANTIBODY TITER MEASUREMENT(7,1)
CONTROL PROCESS DIFFICULTY(7,1)
FANXUE ZHENG(7,1)
HIGH EFFICIENCY AMPLIFICATION(7,1)
INACTIVATED SHOOT(7,1)
INJECTION PROTEIN SUBUNIT VACCINE(7,1)
MUCOSAL DIAEASE(7,1)
PLASMID EXTRACTION REAGENT(7,1)
PROTEIN ASSAY KIT(7,1)
PROTEIN GENE ENCODING(7,1)
PURIFYING PRECAUTION(7,1)
RECOMBINANT BACULOVIRUS(7,1)
REPRODUCTIVE DISORDER(7,1)
TRANSFECTION PRESSURIZATION(7,1)
VACCINE ANTIGEN PREPARATION(7,1)
XPB DIALYSIS(7,1)
SDS PAGE DETECTION(6,4)
WASTE LIQUID(6,4)
CORRECT CLONE(6,2)
AUXILIARY STERILIZING(6,1)
BIOCHEMICAL TRANSFORMATION(6,1)
BVDV GENOME(6,1)
BVDV INFECTED ANIMAL(6,1)
CO2 CELL INCUBATOR(6,1)
CREATION HUMORAL IMMUNITY(6,1)
CULTURED BACTERIA MIXTURE(6,1)
DISEASE LEGAL DESCRIPTION(6,1)
DISEASE NECROSIS(6,1)
EUKARYOTIC VECTOR(6,1)
FERMENTATION FLASK(6,1)
FOREIGN COUNTRY(6,1)
HIGH DENSITY CULTURE MEDIUM(6,1)
IMIDAZOLE ELUENT(6,1)
IMMUNE SUPPRESSION(6,1)
INFECTED CATTLE(6,1)
INTRACELLULAR AMMONIA(6,1)
LB AMPICILLIN(6,1)
LINKED GENE(6,1)
MOLECULAR STRUCTURE(6,1)
MUCOUS MEMBRANE INFLAMMATION(6,1)
PROTEIN ANTIGENICITY(6,1)
PROTEIN SECRETION EFFICIENCY(6,1)
RECOMBINANT EXPRESSION(6,1)
SCALPEL DNA(6,1)
SCREEN MONOCLONAL(6,1)
SECRETION EXPRESSION(6,1)
START MONOCLONAL SCREENING(6,1)
TRANSFORMED TU(6,1)
UNBOUND PROTEIN(6,1)
WIDELY POPULAR PROPAGATION(6,1)
XU XINGRAN(6,1)
ROOM TEMPERATURE(5,32)
RPM MIN(5,25)
BUFFERB(5,3)
CELL VIABILITY(5,3)
OUTER STERILIZATION(5,3)
STANDING(5,3)
BIOTECHNOLOGY(5,2)
ICE BATH(5,2)
LARGE SCALE INDUSTRIAL PRODUCTION(5,2)
MEDIUM SUPERNATANT(5,2)
PROTEIN CONCENTRATION(5,2)
ADULT FEMALE(5,1)
BACTERIAL SUSPENSION(5,1)
BIOENGINEERED CELL(5,1)
BLOOD GLUCOSE(5,1)
BOVINE MUCOSAL DISEASE(5,1)
CATTLE GREAT CIRCLE(5,1)
CATTLE INDUSTRY(5,1)
CD CHO(5,1)
CELL INOCULATION(5,1)
CELL REACHED INTERSECTION(5,1)
CO2 CELL CULTURE INCUBATOR(5,1)
CONTINUOUS GENTLE CENTRIFUGING TUBE(5,1)
CULTURE COLLECTION(5,1)
CULTURE FLASK(5,1)
DNA FRAGMENT(5,1)
DOWNSTREAM PURIFICATION(5,1)
ENDOTOXIN FREE PLASMID MAXI(5,1)
ENVELOPE PROTEIN(5,1)
EQUILIBRATION BUFFER(5,1)
GENE CLONING(5,1)
GENE CODING(5,1)
HPLC PURITY(5,1)
INEXPENSIVE VACCINE(5,1)
INSERT FEED SEQUENCING(5,1)
INTERMEDIATE CELL VISUALIZATION(5,1)
KB LADDER(5,1)
MATURE PROTEIN(5,1)
NATURAL ANTIGEN(5,1)
OLD CALF(5,1)
OVERNIGHT INCUBATION(5,1)
PCR AMPLIFICATION(5,1)
PIPETTE TIP(5,1)
PLASMID DILUTION(5,1)
PLASMID DNA(5,1)
PREVENTIVE MEASURE(5,1)
PROKARYOTIC EXPRESSION PRODUCT(5,1)
PROTEIN CODON(5,1)
RECENT DEVELOPMENT YEAR(5,1)
SHANGHAI SHANGAI LIFE SCIENCE(5,1)
SIGMA CORPORATION(5,1)
SUBCULTURE MEDIUM PREPARATION(5,1)
SUPERNATANT DISCARDED MEDIUM(5,1)
SUSPENSION STABILIZER(5,1)
TH CENTURY(5,1)
UV BASELINE FLAT WASH(5,1)
VACCINE INLET(5,1)
NAH(4,4)
SAMPLE TUBE(4,4)
FETCHING STEP(4,3)
BASAL MEDIUM(4,2)
DEAD CELL(4,2)
FINAL CONCENTRATION(4,2)
H INCUBATION(4,2)
METHOTREXATE(4,2)
PCR PRODUCT(4,2)
PCR REACTION(4,2)
RECOMBINANT PROTEIN(4,2)
ULTRAPURE WATER(4,2)
ADSORBENT FILM(4,1)
ADSORPTION FILM INTERMEDIATE(4,1)
AGAROSE GEL(4,1)
BATH PAN(4,1)
BVDV REGION(4,1)
CELL CULTURE DISH(4,1)
CELL HOMOGENIZATION(4,1)
CELL SUSPENSION(4,1)
CENTRIFUGE TUBE COVER(4,1)
CO2 INCUBATOR TEMPERATURE(4,1)
COMMITTEE CELL(4,1)
COMPETENT CELL(4,1)
DEATH RAY(4,1)
DERIVED PROTEIN(4,1)
DETECTION KIT(4,1)
DIHYDROFOLATE REDUCTASE(4,1)
ELISA POSITIVE(4,1)
ENDOTOXIN FREE PLASMID EXTRACTION(4,1)
ETHANOL PRESERVATION LIQUID(4,1)
FEEDBACK ADJUSTMENT(4,1)
FLASK CULTURE MEDIUM(4,1)
GENERATION CELL CULTURE VIABILITY(4,1)
HUNDRED GENERATION(4,1)
IMMEDIATELY REVERSED CENTRIFUGE TUBE(4,1)
IMMUNOGENIC GOOD(4,1)
KB GENE(4,1)
MODIFIED MAMMALIAN(4,1)
POLYPROTEIN AMINOACID(4,1)
PRELOADED COLUMN VOLUME(4,1)
PURITY DETERMINATION(4,1)
REMAINING SUPERNATANT CELL(4,1)
SAMPLE VIAL(4,1)
SEEDING CELL(4,1)
SEEDING DENSITY(4,1)
SMOOTH BASELINE(4,1)
SUSPENSION TUBE(4,1)
THOROUGH DRYING(4,1)
VIRUS INFECTED CELL(4,1)
WASTE COLLECTION TUBE(4,1)
WHITE PRECIPITATE(4,1)
CELL DENSITY(3,3)
NACL(3,3)
WARM WATER TANK(3,3)
RESERVE(3,2)
ACCESSORY(3,1)";Pharmaceuticals;Open
"2016-12-12
2017-01-11";"WO2018108772        A1 2018-06-21 [WO2018108772]
STG: (A1) Published application with search report
AP : 2017WO-EP82139 2017-12-11";80125604;WO2018108772        A1 2018-06-21 [WO2018108772];"2016US-62432803
2017NL-2018155";;"INTERVET INTERNATIONAL
MEDTRONIC INTERVET";"INTERVET INTERNATIONAL
MEDTRONIC INTERVET";"(WO2018108772)
NL; US";"(WO2018108772)
NAME=INTERVET INTERNATIONAL B.V. Wim de Körverstraat 35 5831 AN Boxmeer , POSTCODE=5831 AN , COUNTRY=NL 

NAME=INTERVET INC. 2 Giralda Farms Madison, NJ 07940 , POSTCODE=07940 , COUNTRY=US 
";2;"O'CONNELL KEVIN
VAIDYANATHAN SUBRAMANIAM
EDDY BRAD";"(WO2018108772)
US";"(WO2018108772)
NAME=O'CONNELL, Kevin 21401 West Center Road Elkhorn, NE 68022 , POSTCODE=68022 , COUNTRY=US 

NAME=VAIDYANATHAN, Subramaniam 35500 W 91 Street DeSoto, KS 66018 , POSTCODE=66018 , COUNTRY=US 

NAME=EDDY, Brad 21401 West Center Road Elkhorn, NE 68022 , POSTCODE=68022 , COUNTRY=US 
";"(WO2018108772)
Oral vaccine against ruminant respiratory disease comprising polyvinylpyrrolidone";"(WO2018108772)
The present invention relates to an oral vaccine against respiratory disease in ruminants, comprising live attenuated Mannheimia haemolytica bacteria and a Polyvinylpyrrolidone (PVP). The addition of PVP significantly improves the protective effect of vaccination on lung scores after a challenge infection. Further the PVP allows vaccination by a method of mass administration, such as by oral route via a drink. In addition the invention relates to methods for the preparation of such a vaccine, to methods for the vaccination of ruminants employing such a vaccine, and to medical uses of a composition comprising M. haemolytica bacteria.";"(WO2018108772)
Claims
1. Oral vaccine against respiratory disease in ruminants, the vaccine comprising live attenuated 
 Mannheimia haemolitica bacteria and a pharmaceutically acceptable carrier, wherein the vaccine also comprises Polyvinylpyrrolidone (PVP).
2. An oral vaccine according to claim 1 , wherein the live attenuated M. haemolytica bacteria are unable to express a virulent leukotoxin A protein.
3. An oral vaccine according to claims 1 or 2, wherein the ruminant is a bovine animal.
4. An oral vaccine according to anyone of claims 1 - 3, wherein the concentration of PVP is between about 0.3 and about 3 % w/v.
5. An oral vaccine according to anyone of claims 1 - 4, wherein the vaccine is in freeze-dried form.
6. An oral vaccine according to anyone of claims 1 - 5, wherein the PVP is of a combination of types of PVP.
7. An oral vaccine according to anyone of claims 1 - 6, wherein the oral vaccine also comprises at least one additional immunoactive component.
8. An oral vaccine according to claim 7, wherein the at least one additional immunoactive component are live attenuated Pasteurella multocida bacteria.
9. Method for the preparation of an oral vaccine according to any one of claims 1 - 8, comprising the step of admixing live attenuated M. haemolytica bacteria and a pharmaceutically acceptable carrier, with PVP.
10. Method for the vaccination of ruminants against respiratory disease, the method comprising the step of administering an oral vaccine according to any one of claims 1 - 8 to said ruminants by oral route. 
 1 1. Method according to claim 10, wherein the oral vaccine is admixed with milk and fed to ruminants.
12. An oral vaccine according to anyone of claims 1 - 8, for administration to a ruminant as a drink or with the feed.
13. An oral vaccine according to claim 12, wherein the drink is a dilution of the vaccine in milk, for 
 administration by feeding to young ruminants.
14. Milk drink for the vaccination by feeding of young ruminants against respiratory disease, the drink comprising a dilution of an oral vaccine according to any one of claims 1 - 8.
15. Use of an oral vaccine according to any one of claims 1 - 8 for the manufacture of a milk drink for the vaccination by feeding of young ruminants against respiratory disease.";"(WO2018108772)
It is an object of the present invention to overcome a disadvantage in the prior art, and to accommodate to a need in the field by providing a live attenuated bacterial vaccine against ruminant respiratory disease that can be administered by a more convenient and less stressful route of administration, while still inducing an effective immune-protection.
The present invention relates to the field of veterinary vaccinology; specifically the invention relates to an oral vaccine against respiratory disease in ruminants, comprising live attenuated Mannheimia haemolytica bacteria.
The present invention relates to the field of veterinary vaccinology; specifically the invention relates to an oral vaccine against respiratory disease in ruminants, comprising live attenuated Mannheimia haemolytica bacteria.
In addition the invention relates to methods for the preparation of such a vaccine, to methods for the vaccination of ruminants employing such a vaccine, and to medical uses of a composition comprising M. haemolytica bacteria.
Therefore in one aspect the invention relates to an oral vaccine against respiratory disease in ruminants, the vaccine comprising live attenuated Mannheimia haemolitica bacteria and a pharmaceutically acceptable carrier, wherein the vaccine also comprises Polyvinylpyrrolidone (PVP).
For the invention ""oral"" refers to a route of administration to a target ruminant via the oral cavity of the animal, typically: via the mouth, also known as: per os.";"(WO2018108772)
Although the inventors do not want to be bound by any theory or model that might explain these observations, they speculate that a PVP in some way or other associates with the bacteria in the vaccine, which allows these bacteria to more effectively establish a colonisation of the upper respiratory tract and/or results in a better exposure of these bacteria to the immune system.
This form has a number of advantages over a vaccine in liquid form, as it is lighter and therefore more economical to transport.
Not only does this provide good stabilisation, but an additional advantage is that its sweet taste makes the ingestion of the oral vaccine more pleasant to the ruminant, which helps to further reduce the stress of the vaccination for the ruminant animal.
disadvantage in the prior art, and to accommodate to a need in the field by providing a live attenuated bacterial vaccine against ruminant respiratory disease that can be administered by a more convenient and less stressful route of administration, while still inducing an effective immune-protection.
Of the bacterial pathogens involved in RRD, M. haemolytica is the major cause of disease.
In the animal husbandry of ruminants, one of the main veterinary problems is respiratory disease.
This is a complex syndrome of affections with serious negative effects on animal welfare and on economy of operation.
Several causes are considered to be relevant in ruminant respiratory disease (RRD): at the basis is infection by one or more bacteria and viruses, which is facilitated and aggravated by";"A61K-009/19
A61K-039/00
A61K-039/102
A61K-047/32";"(WO2018108772)
1. Oral vaccine against respiratory disease in ruminants, the vaccine comprising live attenuated Mannheimia haemolitica bacteria and a pharmaceutically acceptable carrier, wherein the vaccine also comprises Polyvinylpyrrolidone (PVP).";"(WO2018108772)
ATTENUATED MANNHEIMIA HAEMOLITICA BACTERIUM(100,2)
ATTENUATED MANNHEIMIA HAEMOLYTICA BACTERIUM(57,1)
ORAL VACCINE(55,82)
ADMINISTRATION STRESSFUL ROUTE(40,1)
ORAL VACCINE INGESTION(39,1)
YOUNG RUMINANT FEEDING(36,4)
HAEMOLYTICA BACTERIUM(33,33)
LIVE ATTENUATED BACTERIAL VACCINE(31,2)
RUMINANT VACCINATION(29,8)
ORAL VACCINE DILUTION(29,3)
AFFECTION COMPLEX SYNDROME(29,1)
RUMINANT ANIMAL HUSBANDRY(28,1)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(26,4)
VACCINE(24,99)
SWEET TASTE(24,1)
VACCINATION STRESS(24,1)
RUMINANT(23,35)
RESPIRATORY DISEASE(23,15)
BACTERIA EXPOSURE(22,1)
VACCINE PREPARATION(21,1)
RUMINANT RESPIRATORY DISEASE(20,11)
RUMINANT ANIMAL(19,2)
UPPER RESPIRATORY TRACT COLONIZATION(18,1)
POVIDONE(16,7)
MILK DRINK MANUFACTURER(15,2)
ANIMAL ORAL CAVITY(15,1)
BACTERIA(14,24)
ORAL VACCINE PREPARATION(14,3)
IMMUNOACTIVE COMPONENT(13,14)
VETERINARY VACCINOLOGY FIELD(13,1)
ASSOCIATE(12,1)
ANIMAL WELFARE(11,1)
BOVINE ANIMAL(10,5)
STABILIZATION(10,3)
MAJOR DISEASE CAUSE(10,1)
MOUTH(10,1)
ORAL ROUTE(9,9)
HAEMOLYTICA VACCINE(9,5)
BACTERIAL PATHOGEN(9,3)
LIGHTER(9,1)
CHALLENGE INFECTION(8,7)
OBSERVATION(8,5)
INFECTION(7,11)
AGE WEEK(7,9)
TARGET RUMINANT(7,7)
BOVINE VIRAL DIARRHEA VIRUS(7,3)
PNEUMONIC PASTEURELLOSIS(7,3)
COLOSTRUM DEPRIVED CALF(7,2)
EPIZOOTIC HEMORRHAGIC DISEASE VIRUS(7,1)
HAEMOLYTICA VACCINATION CHALLENGE EXPERIMENT(7,1)
NEGATIVE EFFECT(7,1)
ANIMAL DOSE VOLUME(6,9)
POST CHALLENGE DAY(6,7)
VIRUS(6,5)
VACCINE FORMULATION(6,4)
CLOSTRIDIA SPEC(6,3)
PNEUMONIC LESION(6,3)
LIVE ATTENUATED BACTERIUM(6,2)
VACCINE DOSE CONFIRMATION(6,2)
ATTENDING VETERINARIAN RECOMMENDATION(6,1)
HEALTHY CATTLE ORAL VACCINATION(6,1)
HIPPING FEVER PNEUMONIA(6,1)
OPERATION ECONOMY(6,1)
RUMINANT PLANNED TRANSPORTATION(6,1)
FREEZE DRIED VACCINE(5,8)
ORAL(5,5)
INTRANASAL ROUTE(5,3)
BOS TAURUS(5,2)
BRUCELLA SPEC(5,2)
FREEZE DRIED CAKE RECONSTITUTION(5,2)
HISTOPHILUS SOMNI(5,2)
IMMUNE(5,2)
IMMUNITY TRIAL DURATION(5,2)
MANNHEIMIA SPEC(5,2)
MULTOCIDA ANTIGEN(5,2)
MYCOBACTERIUM SPEC(5,2)
PASTEURELLA SPEC(5,2)
SPRINGER BERLIN(5,2)
BOVINE ECONOMIC RELEVANCE(5,1)
BOVINE PARAMYXOVIRUS(5,1)
EARLY VACCINATION CHALLENGE(5,1)
FIBRINOPURULENT BRONCHOPNEUMONIA(5,1)
H3N2 INFLUENZA VIRUS(5,1)
LEUKOTOXIN WILD TYPE VERSION(5,1)
LUNG LESION SEVERITY(5,1)
MULTOCIDA GENOMIC(5,1)
ORAL VACCINE RUMINANT(5,1)
PATHOGENIC BACTERIA STRAIN(5,1)
PETIT RUMINANT VIRUS(5,1)
PNEUMONIC LUNG TISSUE PERCENTAGE(5,1)
RUMINANT VACCINE PACKAGING(5,1)
VACCINATION CHALLENGE TRIAL(5,1)
VACCINE SERIAL TENFOLD DILUTION(5,1)
VACCINATED GROUP(4,10)
LIVE ATTENUATED P(4,5)
BIOLOGICALLY ACTIVE MOLECULE(4,3)
FREEZE DRYING STABILIZER(4,3)
STERILE TRYPTIC SOY BROTH(4,3)
VACCINE FULL DOSE(4,3)
ANIMAL CARETAKER(4,2)
ATTENUATED BACTERIAL VACCINE(4,2)
BACTERIAL ADJUVANT(4,2)
BOVINE CALF(4,2)
BOVINE HERPES VIRUS(4,2)
LIVE ATTENUATED VACCINE(4,2)
ORAL VACCINE FINAL VERSION(4,2)
ZEBU CATTLE(4,2)
ACAPSULAR MUTANT STRAIN(4,1)
ACAPSULAR PHENOTYPE(4,1)
ATTENUATING MUTATION(4,1)
AVIRULENT LEUKOTOXIN(4,1)
BACTERIA VACCINE STRAIN(4,1)
BACTERIUM TITER(4,1)
BACTERIUM UNATTENUATED VERSION(4,1)
BORRELIA BURGDORFERI(4,1)
CAPSULAR POLYSACCHARIDE(4,1)
CHALLENGE DOSE CONFIRMATION(4,1)
CLINICAL DISEASE SYMPTOM(4,1)
COMMERCIAL MILK REPLACER(4,1)
COMMERCIAL RUMINANT VACCINE(4,1)
CRYPTOSPORIDIUM SPEC(4,1)
DEER COMMERCIAL FARMING(4,1)
FACULTATIVE ANAEROBE(4,1)
FUSOBACTERIUM SPEC(4,1)
HAEMOLYTICA LEUKOTOXIN(4,1)
HAEMOLYTICA TITER(4,1)
IMMUNITY MONTH DURATION(4,1)
INACTIVATE ADJUVATED VACCINE(4,1)
INFECTION RUMINANT(4,1)
INFLAMMATORY AFFECTION(4,1)
INTRATRACHEAL INOCULATION(4,1)
LIVE ATTENUATED STRAIN(4,1)
LIVE BACTERIUM FINAL TITER(4,1)
LIVE VACCINE MICROORGANISM(4,1)
LUNG LESION DATA ANALYSIS(4,1)
MANNHEIMIA HAEMOLYTICA INFECTION(4,1)
MARKETING AUTHORIZATION(4,1)
MERCK VETERINARY MANUAL(4,1)
MUCOSAL ANTIGEN DELIVERY(4,1)
MULTOCIDA VACCINATION(4,1)
ORAL VACCINE ANIMAL DOSE(4,1)
ORAL VACCINE EFFECTIVENESS(4,1)
ORAL VACCINE EFFICACY(4,1)
POLYSACCHARIDE TRANSPORTER(4,1)
POLYVINYLPYRROLIDONE EXCIPIENT(4,1)
POVIDONE EXCIPIENT(4,1)
RELEVANCE RUMINANT(4,1)
RUMINANT TARGET AGE(4,1)
STABLY ATTENUATED BACTERIUM(4,1)
TAXONOMIC CLASSIFICATION(4,1)
TOXOPLASMA GONDII(4,1)
TURKEY IMMUNIZATION(4,1)
VACCINE DILUTION FEEDING(4,1)
VACCINE VIABILITY(4,1)
YOUNG RUMINANT TARGET(4,1)
SUCROSE(3,11)
PVP(3,5)
MEAN LUNG LESION SCORES(3,4)
PASTEURELLA MULTOCIDA(3,3)
POST CHALLENGE PERIOD(3,3)
RESPIRATORY DISEASE REDUCTION(3,3)
TARGET ANIMAL(3,3)
ANIMAL MOUTH(3,2)
APPROXIMATE TARGET DOSE(3,2)
BACTERIAL ISOLATION(3,2)
BLUE COLORANT(3,2)
CLINICAL OBSERVATION(3,2)
IMMUNE ENHANCING SUBSTANCE(3,2)
MASTER SEED(3,2)
MEDICATION TANK(3,2)
MODERATE AGITATION(3,2)
SEVERE CHALLENGE(3,2)
STABLE MUTATION(3,2)
ABNORMAL RESPIRATORY PATTERN(3,1)
ACAPSULAR DELETION(3,1)
ADMINISTRATION PERSONNEL(3,1)
ADMINISTRATION REGIME(3,1)
AGE RUMINANT(3,1)
AHYA MUTATION(3,1)
ALKTA STRAIN(3,1)
ANTIGENIC MOLECULE(3,1)
ASHLAND SPECIALTY CHEMICAL(3,1)
ASPECIFIC PROTEIN(3,1)
ASSURING VIABILITY(3,1)
BACTERIA DOSE(3,1)
BACTERIUM TITRATION(3,1)
BLUSHADOW DILUENT(3,1)
BOOSTER VACCINATION(3,1)
BOVINE PARAINFLUENZA VIRUS(3,1)
BOVINE ROTAVIRUS(3,1)
CAPSULAR ANTIGEN(3,1)
CAPSULE BIOSYNTHESIS(3,1)
CATTLE FARM(3,1)
CATTLE WEANING(3,1)
CERVINE ANIMAL(3,1)
CHALLENGE FOLD(3,1)
CHALLENGE INOCULUM(3,1)
CHLAMYDIA SPEC(3,1)
COLONY COUNT(3,1)
COXIELLA SPEC(3,1)
DAILY VETERINARY MONITORING(3,1)
DICTYOCAULUS SPEC(3,1)
DISEASE SIGN(3,1)
EXPERIMENT LAYOUT(3,1)
FEEDLOT FARM(3,1)
FINISHER FARM(3,1)
GLOBAL RELEVANCE(3,1)
GOVERNMENTAL REGULATION(3,1)
HAEMOLITICA CHALLENGE(3,1)
HAEMOLYTICA CULTURE(3,1)
HAEMOLYTICA ORGANISM(3,1)
HAEMOPHILUS SPEC(3,1)
HISTOPATHOLOGICAL SIGN(3,1)
HOLSTEIN BREED(3,1)
HOLSTEIN RACE(3,1)
HOST RUMINANT(3,1)
HYA GENE(3,1)
HYAE GENE(3,1)
IMMUNITY DURATION(3,1)
IMMUNIZING INFECTION(3,1)
IMMUNOGEN DELIVERY(3,1)
IMMUNOLOGICAL STATUS(3,1)
INACTIVATED BACTERIA(3,1)
INDIRECT ADMINISTRATION(3,1)
INFECTION PROGRESSION(3,1)
INFLUENZA INTRANASAL ADMINISTRATION(3,1)
INTRAGASTRIC ROUTE(3,1)
INTRANASAL VACCINE(3,1)
INTRATRACHEAL ROUTE(3,1)
IONIZING RADIATION(3,1)
LAMB WEANING(3,1)
LEPTOSPIRA SPEC(3,1)
LYOPHILIZED VACCINE(3,1)
MAXIMAL SCORE(3,1)
MEANING REPLICATIVE(3,1)
MERCK ANIMAL HEALTH(3,1)
MICROORGANISM CLASSIFICATION(3,1)
MOCK VACCINATED ANIMAL(3,1)
MUTANT BACTERIA(3,1)
NEOSPORA SPEC(3,1)
ORAL BACTERIA(3,1)
ORAL IMMUNIZATION(3,1)
ORAL VACCINE CONTAINER(3,1)
ORAL VACCINE ECONOMIC PRODUCTION(3,1)
OSTERTAGIA SPEC(3,1)
PAPILLOMA VIRUS(3,1)
PATHOLOGIC BEHAVIOR(3,1)
PHOSPHOLIPID SUBSTITUTION(3,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(3,1)
PLEASANT TASTE(3,1)
POLYMERIC MUCOADHESIVE(3,1)
POOL VACCINE(3,1)
POST VACCINATION ANIMAL(3,1)
POTASSIUM TELLURITE(3,1)
PROTEIN ANTIGEN(3,1)
REPLICATION DURATION(3,1)
REPLICATION ROUND(3,1)
REPLICATIVE VACCINE COMPONENT(3,1)
RUMINANT DISEASE(3,1)
RUMINANT LIFE(3,1)
RUMINANT SPECIES(3,1)
SALMONELLA SPEC(3,1)
SCHMALLENBERG VIRUS(3,1)
SORT APPLICATOR(3,1)
SORT STABILIZER(3,1)
STAPHYLOCOCCUS SPEC(3,1)
STUDY GROUPING CODE(3,1)
SUCTION NIPPLE(3,1)
SUSTAINED EFFICACY(3,1)
TOOTH ENAMEL(3,1)
TOXIFIED TOXIN(3,1)
TRANSPORTATION PLANNING(3,1)
TRYPTIC SOY AGAR PLATE(3,1)
VACCINATION CHALLENGE RESPONSE(3,1)
VACCINATION TIMING(3,1)
VACCINE AMPULE(3,1)
VACCINE BACTERIUM(3,1)
VACCINE DANGER(3,1)
VACCINE INGESTION(3,1)
VETERINARY HANDBOOK(3,1)
VETERINARY IMPORTANCE ANTIGENIC COMPONENT(3,1)
VETERINARY SCIENCE(3,1)
VIEWPOINT(3,1)
WEEK OLD CALF(3,1)
WILD TYPE PROTEIN(3,1)
WORLD COUNTRY(3,1)
ATTENUATION(2,4)
BLUETONGUE VIRUS(2,3)
BOVINE CORONAVIRUS(2,3)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(2,3)
MITIGATED FRACTION(2,3)
NECROPSY(2,3)
SHIPMENT(2,3)
ACTIVE ART(2,2)
ADMIXING(2,2)
BIOADHESIVE(2,2)
BOS INDICUS(2,2)
BUCKET(2,2)
BUFFALO(2,2)
CALF RECTAL TEMPERATURE(2,2)
CAPRINE(2,2)
COSMETICS(2,2)
DAY OBSERVATION(2,2)
DISINTEGRANT(2,2)
DOSING PUMP(2,2)
EMULSIFIER(2,2)
ENCODING REGION(2,2)
FOODSTUFF(2,2)
INCUBATION(2,2)
INFECTION REDUCTION(2,2)
LIQUID VACCINE(2,2)
MORTALITY ANALYSIS(2,2)
MYCOPLASMA BOVIS(2,2)
P MUTANT STRAIN(2,2)
PASTEURELLA HAEMOLYTICA(2,2)
PATHOLOGY(2,2)
PERSON ROUTINE CAPABILITY(2,2)
PHARMACOPEIA(2,2)
PHYSIOLOGICAL SALT SOLUTION(2,2)
PRESERVATIVE(2,2)
RECLASSIFICATION(2,2)
STANDARD BLOOD AGAR PLATE(2,2)
SUITABILITY(2,2)
SYNONYM(2,2)
SYNTHETIC POLYMER(2,2)
THICKENING(2,2)
THIMEROSAL(2,2)
VACCINATION PRIOR HISTORY(2,2)
WHOLE MILK(2,2)
WISENT(2,2)
ADHESION REDUCTION(2,1)
AFFECTED LUNG LOBE(2,1)
AFFECTION EXTENT(2,1)
AGE ANIMAL(2,1)
ANIMAL NATURAL TENDENCY(2,1)
ANIMAL PHYSICAL RESTRAINT(2,1)
ANTIBIOTIC AGENT(2,1)
BACTERIA QUANTITY(2,1)
BACTERIAL CULTURE MEDIUM(2,1)
BACTERIAL RE ISOLATION(2,1)
BACTERIAL RUMINANT RESPIRATORY DISEASE(2,1)
BACTERIOLOGICAL PRODUCTION(2,1)
BASELINE PARAMETER(2,1)
BOVINE SERUM ALBUMIN(2,1)
BULKING AGENT(2,1)
CHALLENGE INDUCED LUNG(2,1)
CHALLENGE PROTECTION(2,1)
CLINICAL MONITORING(2,1)
CLINICAL SCORE(2,1)
CMC(2,1)
COMMERCIAL VACCINE(2,1)
COMPLETE VACCINE(2,1)
CRYOPROTECTANT(2,1)
CULTURE DENSITY(2,1)
DAILY OBSERVATION(2,1)
DEATH PERCENT(2,1)
DENSITY CONFIDENCE INTERVAL(2,1)
DRIED FORMULATION(2,1)
EAR(2,1)
EARLY INFECTION(2,1)
ENVIRONMENTAL STRESS FACTOR(2,1)
EXPERIMENT COMPLETION(2,1)
EXPERIMENTAL ANIMAL(2,1)
EXTERNAL ORGANELLE(2,1)
EXTRANEOUS AGENT ABSENCE(2,1)
FAST MELT DOSING(2,1)
FOREIGN DNA(2,1)
FREEZE DRIED PELLET(2,1)
GENETIC RELATEDNESS LEVEL(2,1)
HEALTHY TARGET(2,1)
HEME DOSE(2,1)
HUT(2,1)
IMMEDIATE PROTECTION INDICATION(2,1)
IMMUNOSTIMULATORY NUCLEIC ACID(2,1)
IMPRESSIVE(2,1)
INFECTION EXTENT(2,1)
INFECTIVE CAPACITY(2,1)
INSUFFICIENT QUALITY(2,1)
INTERMEDIARY(2,1)
INTERMEDIATE DILUTION(2,1)
INTERNAL ORGANIZATION(2,1)
ISOLATED LUNG(2,1)
LIFE WEEK(2,1)
LIPOPOLYSACCHARIDE(2,1)
LIQUID NEBULIZATION(2,1)
LIQUID STABILIZER(2,1)
LIVE ATTENUATED MICROORGANISM(2,1)
LUNG LESION SIGNIFICANT DIFFERENCE(2,1)
LUNG PROPORTION(2,1)
LUNG TISSUE SAMPLE(2,1)
LYOPHILIZED SAMPLE(2,1)
MASTER GENERATION(2,1)
MICROBIAL ANTI ADHERENT AGENT(2,1)
MODIFIED LIVE VACCINE(2,1)
MOISTURE PROOF PACKAGING(2,1)
MYCOBACTERIUM BOVIS(2,1)
NATURAL HOST SPECIES(2,1)
NORMAL LUNG TISSUE(2,1)
NORMAL MILK FEEDING(2,1)
OCCASION(2,1)
OXIGEN PRESENCE(2,1)
PARENTAL STOCK(2,1)
PARENTERAL INJECTION(2,1)
PASSAGEING(2,1)
PASTEURELLACEAE FAMILY MEMBER(2,1)
PATHOGEN TARGET(2,1)
PHARMACEUTICAL COMPOUND DELIVERY(2,1)
PHARMACEUTICAL GRADE(2,1)
POSITIVE ISOLATION(2,1)
POST TRANSLATIONAL ACTIVATION(2,1)
POST VACCINATION PERIOD(2,1)
PRINCIPAL BACTERIAL PATHOGEN(2,1)
PROTECTING CALF(2,1)
PROTECTIVE IMMUNE RESPONSE(2,1)
PROTECTIVE IMMUNOLOGICAL RESPONSE(2,1)
RE CLASSIFIED BACTERIUM(2,1)
RECOMBINANT CARRIER MICROORGANISM(2,1)
RECOMBINANT DNA TECHNOLOGY(2,1)
REGION ENCODING PROTEIN(2,1)
RELEVANT ANTIGEN(2,1)
REPEATED ADMINISTRATION(2,1)
RESPIRATION FREQUENCY(2,1)
RICH CULTURE MEDIA(2,1)
RUMINANT MUZZLE AREA(2,1)
RUMINANT PREPARATION(2,1)
RUMINANT RESPIRATORY DISEASE ONSET(2,1)
RUMINANT RESPIRATORY DISEASE OUTBREAK(2,1)
SCIENTIFIC NAME(2,1)
SCORED LUNG LESION SCORES(2,1)
SEALED GLASS BOTTLE(2,1)
SHELF LIFE STABILITY(2,1)
SIGMA ALDRICH(2,1)
SKIMMED MILK POWDER(2,1)
STABLE GENETIC BASIS(2,1)
STANDARD BACTERIAL TITRATION(2,1)
STERILIZED STOCK SOLUTION(2,1)
SUBCUTANEOUS ROUTE(2,1)
SUPPLIER VARIETY(2,1)
TARGET RECOMBINANT DNA(2,1)
TARGET SPECIES(2,1)
TEST VACCINE(2,1)
THERAPEUTIC TREATMENT(2,1)
TREATMENT PLAN(2,1)
TRIAL PROPER PERFORMANCE(2,1)
UPPER RESPIRATORY TRACT COMMENSAL(2,1)
VACCINE DISTRIBUTION(2,1)
VACCINE PRODUCTION(2,1)
VACCINE QUALITY(2,1)
VETERINARY SERVICE(2,1)
VETERINARY TREATMENT(2,1)
VIRULENCE FACTOR EXPRESSION(2,1)
VISIBLE CONSOLIDATION(2,1)
WHOLE CULTURE(2,1)
WORDING(2,1)
YEAST EXTRACT(2,1)
PREVENTED FRACTION(1,4)
FOLDING(1,3)
MASS ADMINISTRATION(1,3)
ADDITIVE(1,1)
ADMIXTURE(1,1)
ADVANCED STATISTICAL ANALYSIS(1,1)
ANIMAL APPLICATION(1,1)
ANIMAL EFFECTIVE MASS VACCINATION(1,1)
ANIMAL RESPONSE(1,1)
ARGININE(1,1)
AVIRULENCE(1,1)
BACTERIAL GENOME(1,1)
BACTERIAL TOXIN(1,1)
BIJHLER(1,1)
BUFFERED SALINE SOLUTION(1,1)
BUHLER(1,1)
CARBOHYDRATE(1,1)
CARBOPOL(1,1)
CENTRIFUGATION(1,1)
CHANGE NUCLEOTIDE(1,1)
CHARACTERIZING FEATURE COMBINATION(1,1)
CHEMOKINE(1,1)
COMPLETE CULTURE(1,1)
CONCENTRATE(1,1)
CULTURE VOLUME(1,1)";Pharmaceuticals;Open
2016-09-14;"CN107815439         A  2018-03-20 [CN107815439]
STG: (A) Published application
AP : 2016CN-0824233 2016-09-14";79102984;CN107815439         A  2018-03-20 [CN107815439];2016CN-0824233;;HUA WEI TE BIOPHARMACEUTICAL;HUA WEI TE BIOPHARMACEUTICAL;;;1;"WANG WEI
LI ZHENGUANG
MENG QINGSEN
HUANG HUIWEN
SHI XINCHUAN
ZHANG SHUCHENG
WU HUA";;;"(CN107815439)
Bovine infectious rhinotuacheitis virus JSM strain and application thereof";"(CN107815439)
The invention relates to the fields of bioengineering and immunity, in particular relates to a bovine infectious rhinotuacheitis virus JSM strain and application thereof, and belongs to the field of veterinary biological products. According to the invention, the bovine infectious rhinotuacheitis virus JSM strain and a bovine viral diarrhea virus I type NMM strain are utilized to form a combined live vaccine, so that infection caused by the two viruses of cattle of different varieties can be prevented, and economic loss caused by the virus infection is reduced. After the vaccine is used, immunecattle have no local or general side effect, and 'prevention of the two viruses by virtue of one injection' is really realized, so that the bovine infectious rhinotuacheitis virus JSM strain is safeand reliable.";"(CN107815439)
1. A strain of infectious bovine rhinotracheitis virus strain, characterized in that, the strain designated infectious bovine rhinotracheitis virus JSM strain (IBRV JSM strain), and at 24 August 2016 in China General Microbiological Culture Collection common center collection, the accession number is: CGMCC No. 12666.
2. Claim 1 infectious bovine rhinotracheitis virus strain in the prevention of diseases caused by infectious bovine rhinotracheitis virus of a medicament for application.
3. A vaccine, wherein, the vaccine contains infectious bovine rhinotracheitis virus strain claim 1.
4. Vaccine according to claim 3, characterized in that, vaccine into a plurality of vaccines.
5. Vaccine according to claim 4, characterized in that, as a combined vaccine vaccines.
6. Vaccine according to claim 5, wherein, the vaccine further comprises bovine viral diarrhea virus I-type.
7. Vaccine according to claim 6, characterized in that, Bovine Viral Diarrhea Virus I-type BVDV I-type NMM strain entitled, and at 24 August 2016 in China General Microbiological Culture Collection common center collection, the accession number is: CGMCC No. 12664.
8. Claim 7 in the manufacture of I-type bovine viral diarrhea virus in the prevention of a disease caused by Bovine Viral Diarrhea Virus I-type of a medicament for application.
9. Application according to claim 8, wherein, the drug is a vaccine.
10. Preparation of bovine viral diarrhea, infectious bovine rhinotracheitis double method of live vaccines, characterized in that, comprising the steps of:
A) of the infectious bovine rhinotracheitis virus type I bovine viral diarrhea virus strains and JSM NMM strains were grown, harvested virus solution;
B) the two virus liquid was mixed;
C) was added to the hybrid virus liquid lyoprotectant, freeze-dried under vacuum, to give the double live vaccine.";"(CN107815439)
It was found by the clinical case, BVDV and the IBRV often co-infection.
The present invention first discloses a strain infectious bovine rhinotracheitis virus strain, the strain was named IBRV JSM strain, and to one of ordinary in China General Microbiological Culture Collection Center deposit 24 August 2016, the accession number is: CGMCC No. 12666.
The present invention relates to the field of biotechnology and immunity, and more particularly to infectious bovine rhinotracheitis virus strain JSM and the use thereof, which belongs to the veterinary field of biological products.";"(CN107815439)
For our country did for the first time found in New Zealand inlet bovine from 1980, now in most provinces cows, cattle and buffaloes has IBRV infection, causing a relatively large economic loss, the vaccine is one of main measures the disease prevention and control.
For the first time discovered and isolated BVDV 1946 Olafson and the like, at present, the disease has extensively throughout the world.
Infectious bovine rhinotracheitis (Infectious bovine rhinotracheitis,IBR) is a bovine herpes virus type I (BHV-1) caused by the bovine an acute, febrile, contagious disease, the clinical manifestations of upper respiratory and airway mucosal inflammation, respiratory distress, runny nose and other symptoms, can also cause pustular outer colpomycosis, balanitis, conjunctivitis, baby calf meningitis, mastitis, abortion and the like.";"A61K-039/12
A61K-039/265
A61K-039/295
A61P-031/14
A61P-031/22
C12N-007/00
C12R-001/93";"(CN107815439)
1. A strain of infectious bovine rhinotracheitis virus strain, characterized in that, the strain designated infectious bovine rhinotracheitis virus JSM strain (IBRV JSM strain), and at 24 August 2016 in China General Microbiological Culture Collection common center collection, the accession number is: CGMCC No. 12666.
10. Preparation of bovine viral diarrhea, infectious bovine rhinotracheitis double method of live vaccines, characterized in that, comprising the steps of: A) of the infectious bovine rhinotracheitis virus type I bovine viral diarrhea virus strains and JSM NMM strains were grown, harvested virus solution; B) the two virus liquid was mixed; C) was added to the hybrid virus liquid lyoprotectant, freeze-dried under vacuum, to give the double live vaccine.";"(CN107815439)
STRAIN(100,20)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,13)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(100,8)
INFECTIOUS BOVINE RHINOTRACHEITIS(100,6)
LIVE VACCINE(100,3)
BOVINE RHINOTRACHEITIS DOUBLE(100,1)
BOVINE VIRAL DIARRHEA PREPARATION(100,1)
AIRWAY MUCOUS MEMBRANE INFLAMMATION(94,1)
HYBRID VIRUS LIQUID LYOPROTECTANT(75,1)
PROVINCE COW(67,1)
CHINA GENERAL MICROBIOLOGICAL CULTURE(63,6)
DISEASE PREVENTION(58,5)
VACCINE(57,20)
CALF MENINGITIS(57,1)
CATTLE BREED(55,1)
DOUBLE LIVE VACCINE(53,2)
PUSTULAR OUTER COLPOMYCOSIS(53,1)
BOVINE HERPES VIRUS(49,1)
BOVINE IMMUNIZATION(48,1)
COUNTRY DID(45,1)
ACCESSION(43,4)
HARVESTED VIRUS SOLUTION(40,2)
ECONOMIC LOSS(40,1)
UPPER CLINICAL MANIFESTATION(39,1)
BOVINE VIRAL DIARRHEA VIRUS(37,21)
VIRUS LIQUID(35,1)
COINFECTION(31,1)
CONJUNCTIVITIS(31,1)
RESPIRATORY DISTRESS(30,1)
SYMPTOM(30,1)
BALANITIS(27,1)
CONTAGIOUS DISEASE(27,1)
ABORTION(26,1)
BUFFALO(26,1)
MASTITIS(26,1)
RUNNY NOSE(25,1)
 ZEALAND INLET BOVINE(24,1)
INFECTION(24,1)
SYSTEMIC ADVERSE REACTION(24,1)
MEDICAMENT(23,4)
WORLD(23,1)
BVDV(22,14)
MAIN MEASUREMENT(20,1)
VIRAL INFECTION(20,1)
BIOTECHNOLOGY FIELD(19,2)
BOVINE(19,2)
VIRUS NEUTRALIZATION ASSAY(18,4)
IMMUNITY(18,3)
COLLECTION CENTER(17,4)
IMMUNE(17,1)
VIRUS INOCULATION(16,6)
DISEASE(16,4)
PLAQUE CLONE PURIFIED VIRUS(16,2)
SCIENCE BEIJING CHINESE ACADEMY(16,1)
CATTLE(15,5)
BOVINE SERUM CHINA PROVINCE(15,1)
CLINICAL CASE(15,1)
HOSPITAL MICROBIAL STUDY BEIJING(15,1)
BIOLOGICAL PRODUCT VETERINARY FIELD(13,2)
HOSPITAL CHAOYANG DISTRICT(13,1)
SCIENCE ROAD CHINESE ACADEMY(13,1)
BVDV VIRUS VACCINE(12,1)
CHINA BVD VACCINE(12,1)
SAFE(12,1)
SUSPENSION CULTURE(11,4)
VIRUS ANTIGEN LIQUID(11,4)
TITER VIRUS CULTURE MEDIUM(11,2)
MUCOSAL EROSION ULCER(11,1)
VIRUS INOCULUM(10,2)
CATTLE INDUSTRY SHORTAGE(10,1)
DUPLEX LIVE VACCINE(10,1)
GB GENE RELATEDNESS(10,1)
SERIALLY PASSAGED VIRUS(10,1)
VIRAL F(9,8)
PCR AMPLIFICATION(9,2)
ANIMAL CLINICAL SYMPTOM(9,1)
CO2 SPINNER FLASK(9,1)
FETAL BOVINE SERUM(9,1)
NORTH STAR ROAD(9,1)
VACCINE DRUG SUBSTANCE(9,1)
BP FRAGMENT(8,2)
DEPOSIT DATE(8,2)
GB GENE AMPLIFICATION BAND(8,2)
PATHOGENIC ANALYSIS(8,2)
SUBCLONING PURIFIED VIRUS(8,2)
ABORTION PROMINENT FEATURE(8,1)
BOVINE TESTICULAR CELL(8,1)
BOVINE TURBINATE(8,1)
BVDV SPLEEN(8,1)
CATTLE DISEASE(8,1)
CELL CONFLUENT MONOLAYER(8,1)
CLINICAL ABNORMALITY(8,1)
FLAVIVIRIDAE FAMILY(8,1)
INOCULATED CATTLE(8,1)
LIVE VACCINE DOUBLE(8,1)
MALFORMED FETUS(8,1)
PREGNANT COW(8,1)
ROLLER BOTTLE CULTURE(8,1)
VIRUS GB GENE(8,1)
BIOREACTOR(7,3)
CELL DENSITY(6,4)
VIRULENCE(6,3)
VIRUS GENERATION(6,2)
ANTIBODY NEGATIVE HEALTHY CATTLE(6,1)
ANTIBODY NEGATIVE HEALTHY COW(6,1)
BOVINE NASAL(6,1)
BVDV INFECTION(6,1)
COMMERCIAL VACCINE(6,1)
CONTINUOUS CLINICAL SYMPTOM(6,1)
GENE HOMOLOGY COMPARISON(6,1)
GENE NUCLEOTIDE(6,1)
GENERATION VIRUS BOVINE(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS ANTIGEN(6,1)
INFECTIOUS DISEASE(6,1)
LI YOUMIN(6,1)
TOXIGENIC STRAIN(6,1)
TRYPSIN DIGESTION(6,1)
VACCINE BATCH(6,1)
VACCINE FORMULATION(6,1)
VACCINE VIAL(6,1)
VIRAL TITER(6,1)
BOVINE BLOOD(5,1)
BOVINE VIRAL DIARRHEA VIRUS ANTIGEN(5,1)
CHECK CELL MORPHOLOGY(5,1)
CO2 INCUBATOR(5,1)
COMBINED VACCINE LIVE VACCINE(5,1)
CULTURE MEDIUM SERUM(5,1)
DOWNSTREAM PRIMER(5,1)
EARLY AGE(5,1)
EPIDEMIC SITUATION(5,1)
HORSE SERUM(5,1)
LYOPROTECTANT MIXTURE(5,1)
LYOPROTECTANT UNIFORM(5,1)
PATHOGEN VACCINE COMPONENT(5,1)
POSITIVE STRANDED RNA GENOME(5,1)
PRIMARY RABBIT KIDNEY CELL(5,1)
SEED VIRUS PRODUCTION(5,1)
SYNTHETIC VIRUS(5,1)
UPSTREAM PRIMER(5,1)
VIRUS ISOLATION(5,1)
ACCLIMATIZATION(4,1)
AMPLIFIED SEQUENCE(4,1)
BOVINE VIRAL DIARRHEA DOUBLE(4,1)
BVDV POSITIVE(4,1)
CELL CULTURE BOTTLE(4,1)
CENTURY(4,1)
CULTURE CHAMBER(4,1)
GENERATION ONCE PURIFIED CLONE(4,1)
IMMUNOEFFICACY(4,1)
MEASURING TEST ANIMAL(4,1)
SIGNIFICANT THREAT(4,1)";Pharmaceuticals;Open
2016-08-29;"CN107779457         A  2018-03-09 [CN107779457]
STG: (A) Published application
AP : 2016CN-0768873 2016-08-29";79063178;CN107779457         A  2018-03-09 [CN107779457];2016CN-0768873;;PU LIKE BIO ENGINEERING;PU LIKE BIO ENGINEERING;;;1;"TIAN KEGONG
WANG TONGYAN
SUN JINZHONG
ZHANG XUKE";;;"(CN107779457)
Vaccine composition as well as preparation method and application thereof";"(CN107779457)
The invention provides an infectious bovine rhinotracheitis virus gB protein fragment, or a conservative variant thereof, or an active fragment thereof. The gB protein fragment has great expression quantity; a prepared subunit antigen has the better immune effect than gB protein. The invention also provides a subunit vaccine prepared by tandem expression of the gB protein fragment and gD protein.The vaccine has the advantages that the preparation method is simple; a better protection effect is achieved on the infectious bovine rhinotracheitis caused by the infectious bovine rhinotracheitis viruses.";"(CN107779457)
1. A nucleotide sequence, nucleotide sequence which are connected by the following sequential order:
Cooper strain corresponding to infectious bovine rhinotracheitis virus gB protein gene 202-357 which the nucleotide sequence, 955-1320 which the nucleotide sequence, 1423-1509 which the nucleotide sequence, 2230-2289 which the nucleotide sequence, with a flexible linker connected between four nucleotide sequence; preferably, nucleotide sequence encoding a protein the amino acid sequence SEQ ID NO:2 in the Sequence Listing.
2. Claim 1 from a nucleotide sequence encoding a infectious bovine rhinotracheitis virus gB protein fragment, or a conservative variant, or an active fragment thereof; preferably, gB protein fragment is SEQ ID NO Sequence Listing: an amino acid sequence shown 2; more preferably, in the sequence listing SEQ ID NO:1 gB protein fragment of the nucleotide sequence or degenerate sequence encoding.
3. One infectious bovine rhinotracheitis virus gB-gD protein, wherein, gB-gD protein including gB protein fragment according to claim 2, or a conservative variant, or active fragments thereof and gD protein; preferably, gB protein fragment, or a conservative variant, gD protein or an active fragment with a ratio of 1:1; preferably, gB protein fragment, or a conservative variant, or active fragments thereof with gD protein expression serial connection; preferably, gD protein amino acid sequence of SEQ ID NO Listing: 4 the amino acid sequence shown; more preferably, gD protein or nucleotide sequence shown in SEQ ID NO:3 by the nucleotide sequence encoding a degenerated sequence thereof.
4. One infectious bovine rhinotracheitis virus subunit vaccine composition, wherein, a subunit vaccine composition comprising immunogenic amount of gB protein fragment according to claim 2, or a conservative variant, or active fragments thereof, and pharmaceutically acceptable carrier; gB protein fragments of conservative variant thereof, or an active fragment of the gB protein fragments remain the same immunogenic.
5. A vaccine composition according to claim 4, wherein, gB protein fragment, or a conservative variant, or an active fragment content of 25-100 ug/ml; preferably, 25-100 μg/ml vaccine composition comprises a content of a sequence listing as SEQ ID NO:2 gB protein fragment of the amino acid sequence shown.
6. One infectious bovine rhinotracheitis virus subunit vaccine composition, wherein, a subunit vaccine composition comprising immunogenic amount of gB-gD protein and a pharmaceutically acceptable carrier; preferably according to claim 3, gB protein fragment, or a conservative variant, gD protein or an active fragment with a ratio of 1:1; preferably, gB protein fragment, or a conservative variant, or active fragments thereof with gD protein expression serial connection; preferably, gD protein is SEQ ID NO Sequence Listing: 4 the amino acid sequence shown; more preferably, as shown in SEQ ID NO:3 gD protein by the nucleotide sequence encoding nucleotides or degenerate sequences thereof.
7. A vaccine composition according to claim 6, wherein, gB-gD protein content of 25-100 ug/ml; preferably, gB-gD protein is a serial connection of the Sequence Listing SEQ ID NO expression: 2 of the Sequence Listing gB protein fragments and the amino acid sequence SEQ ID NO:4 amino acid sequence of gD protein shown, gB-gD protein antigens expressed by serial connection 25-100 ug/ml for content.
8. Claim 4-7 vaccine composition according to any one, wherein, a pharmaceutically acceptable carrier comprises an adjuvant,
Adjuvants include: (1) alumina adjuvant, saponin, alfuzosin aplidine, DDA-in-water emulsion ; (2), oil in water emulsions, water-in-oil-in-water emulsion; or (3) acrylate or methacrylate polymer, copolymers of maleic anhydride and alkenyl derivative; and RIBI adjuvant system, Block co-polymer,SAF-M, monophosphoryl lipid A, Avridine lipid-amine adjuvant, E. coli heat-labile enterotoxin, cholera toxin, IMS 1314, muramidyldipeptide, one or more adjuvant Gel;
Preferably, saponin as Quil A,QS-21,GPI-0100;
Preferably, emulsion to emulsion SPT, MF59 emulsions, or emulsions formed by the oil in combination with emulsifiers, emulsion may be based on a light liquid paraffin oil, oligomeric olefin oil due to the creation of isoprenoid (such as squalane or squalene oil, olefins, particularly isobutene or oligomeric undecylenes creation of oil), linear alkyl esters of acids or alcohol-containing (more particularly a vegetable oil, ethyl oleate, propylene glycol di-(caprylate/annuus acid ester), glycerol tris-(caprylate/annuus acid ester) or propylene glycol dioleate), esters of branched fatty acid or an alcohol (especially isostearate); emulsifiers are nonionic surface active agent (in particular polyoxyethylenated fatty acids (e.g. oleic acid) ester, sorbitan ester, a mannide ester (such as dry mannitol oleate), an aliphatic dihydric alcohol esters, glycerol esters, polyglycerol esters, propylene glycol and oleic esters, isostearic acid esters, ricinoleic acid esters or hydroxy stearic acid ester, the ester is obtained by ethoxylation, fatty alcohol and a polyhydric alcohol (such as oleyl alcohol) ethers, polyoxypropylene-polyoxyethylene block copolymer (particularly  particularly L121));
Preferably, acrylate or methacrylate polymers are cross-linked acrylate or methacrylate polymer, especially of the sugar polyol crosslinking compound of polyalkenic ether or carbomer, preferably Carbomer 974 P, 934 P and the 971 P;
Preferably, maleic anhydride and alkenyl derivative is a copolymer of maleic anhydride and copolymers of ethylene EMA;
Preferably, the adjuvant is an adjuvant 206;
5% To 50% V/V is in the range from the concentration of the adjuvant, preferably 50% V/V.
9. In accordance with claim 4-8 vaccine composition for preventing and/or treatment of infectious bovine rhinotracheitis virus-related disease or an infection caused by infectious bovine rhinotracheitis virus of a medicament for application.";"(CN107779457)
Of the 1st aspect of the present invention is to provide a nucleotide sequence, a nucleotide sequence which are connected by the following sequential order:
Of the 3rd aspect of the present invention is to provide an infectious bovine rhinotracheitis virus gB-gD protein, wherein, gB-gD protein includes a fragment of the gB protein, or a conservative variant, or active fragments thereof and gD protein.
Of the 2nd aspect of the present invention is to provide an infectious bovine rhinotracheitis virus gB protein fragment, or a conservative variant thereof, or an active fragment thereof, wherein a gB protein fragment consists of a nucleotide sequence encoding.";"(CN107779457)
The present invention relates to infectious bovine rhinotracheitis virus polypeptide, which is advantageously excited protective response in an animal.
A subunit vaccine does not contain a nucleic acid species, better safety, does not produce a persistent infection or latent infection after vaccination, can be distinguished from wild virus infection with the creation of an immune response, facilitates control and eradication of the disease, however, a hot research infectious bovine rhinotracheitis virus subunit vaccine production cost is high, low production efficiency, immunogenicity attenuated vaccines and killed vaccines or less than that, has had limited applications.
By infectious bovine rhinotracheitis virus results in reduced cellular immunity and immune suppression, often cause a secondary bacterial infection, making it difficult to the clinical diagnosis.
In order to solve the disadvantages of prior art, the present invention provides infectious bovine rhinotracheitis virus subunit vaccine composition and its preparation method, for infectious bovine rhinotracheitis vaccine composition through animal experiments demonstrated to have good immunity.";"A61K-039/265
A61P-031/22
C07K-014/06
C07K-019/00
C12N-015/38";"(CN107779457)
1. A nucleotide sequence, nucleotide sequence which are connected by the following sequential order: Cooper strain corresponding to infectious bovine rhinotracheitis virus gB protein gene 202-357 which the nucleotide sequence, 955-1320 which the nucleotide sequence, 1423-1509 which the nucleotide sequence, 2230-2289 which the nucleotide sequence, with a flexible linker connected between four nucleotide sequence; preferably, nucleotide sequence encoding a protein the amino acid sequence SEQ ID NO:2 in the Sequence Listing.";"(CN107779457)
VACCINE(100,34)
GB PROTEIN FRAGMENT(100,27)
CONSERVATIVE VARIANT(73,28)
BOVINE RHINOTRACHEITIS VACCINE(55,1)
GD PROTEIN(54,21)
NUCLEOTIDE SEQUENCE(49,8)
SUBUNIT ANTIGEN IMMUNIZATION(49,1)
GB GD PROTEIN(46,19)
ACTIVE FRAGMENT(45,29)
GB GD PROTEIN FRAGMENT(44,1)
IMMUNOGENICITY ATTENUATED VACCINE(43,1)
DISEASE ERADICATION(41,1)
OIL OLIGOMERIC UNDECYLENE CREATION(40,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(39,56)
KILLED VACCINE(38,1)
PERSISTENT INFECTION(38,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS POLYPEPTIDE(37,1)
IMMUNE SUPPRESSION(35,1)
SUGAR POLYOL CROSSLINKING(35,1)
SUBUNIT VACCINE(33,40)
GD PROTEIN EXPRESSION(33,6)
ALFUZOSIN APLIDINE(33,1)
LATENT INFECTION(33,1)
GB PROTEIN GENE(32,4)
CAPRYLATE ANNUUS ACID ESTER(32,2)
POLYOXYETHYLENE POLYOXYPROPYLENE(32,1)
WILD VIRUS INFECTION(32,1)
GB GD PROTEIN ANTIGEN(30,1)
IMMUNE RESPONSE CREATION(29,1)
SUBUNIT VACCINE EXPRESSION(29,1)
METHACRYLATE POLYMER(28,5)
AVRIDINE LIPID(27,1)
OLIGOMERIC OLEFIN(26,1)
SECONDARY BACTERIAL INFECTION(26,1)
ALKENYL DERIVATIVE(25,4)
MALEIC ANHYDRIDE COPOLYMER(25,3)
ALIPHATIC DIHYDRIC ALCOHOL ESTER(25,2)
ISOPRENOID CREATION(25,2)
MONOPHOSPHORYL LIPID(25,2)
DEGENERATE SEQUENCE ENCODING(25,1)
SUBUNIT VACCINE PRODUCTION(24,1)
COOPER STRAIN(23,8)
ADJUVANT GEL(23,1)
HOT RESEARCH(22,1)
ISOSTEARIC ACID ESTER(22,1)
FLEXIBLE LINKER(21,3)
GB PROTEIN PREPARATION(21,3)
ADJUVANT CONCENTRATION(21,1)
CHOLERA TOXIN(20,3)
MANNIDE ESTER(20,2)
POLYGLYCEROL ESTER(20,2)
DEGENERATED SEQUENCE(20,1)
ALUMINA ADJUVANT(19,3)
COLI HEAT LABILE ENTEROTOXIN(19,3)
POLYALKENIC ETHER(19,3)
IMMUNITY(19,1)
OLEIC ESTER(19,1)
OLEYL ALCOHOL(19,1)
CLINICAL DIAGNOSIS(18,1)
NUCLEIC ACID SPECIES(18,1)
POLYHYDRIC ALCOHOL(17,2)
SEQUENCE LISTING CONTENT(17,1)
SORBITAN ESTER(16,3)
ETHYLENE COPOLYMER(16,2)
IMMUNIZED COW CALF MORBIDITY(16,2)
DRY MANNITOL(16,1)
FATTY ALCOHOL(16,1)
RICINOLEIC ACID ESTER(15,3)
VACCINATION(15,2)
HYDROXYSTEARIC ACID ESTER(15,1)
ANIMAL EXPERIMENT(14,1)
BRANCHED FATTY ACID ESTER(14,1)
ISOSTEARATE(14,1)
PROTEIN(13,10)
EMULSIFIER(13,8)
CONSERVATIVE(13,7)
SAPONIN(13,5)
MURAMIDYLDIPEPTIDE(13,3)
PROPYLENE GLYCOL DIOLEATE(13,3)
ACID LINEAR ALKYL ESTER(13,1)
REDUCING CELLULAR IMMUNITY(13,1)
AMINOACID SEQUENCE(12,17)
PROTECTIVE RESPONSE(12,4)
ETHYL OLEATE(12,3)
PURULENT SECRETION EYE(12,3)
ISOBUTENE(12,1)
SEQUENCE LISTING SERIAL CONNECTION(12,1)
VACCINE ANTIGEN(11,4)
ETHOXYLATION(11,2)
SEQUENTIAL ORDER(11,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS RESULT(11,1)
MEDICAMENT(10,5)
COMPANY PROTEIN ASSAY KIT(10,3)
SQUALANE(10,3)
UG ML(10,3)
GENERATION RECONIBINANT ULOVILUS(10,2)
ANIMAL(9,7)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS INFECTION(9,4)
WATER EMULSION(9,3)
AFFINITY CHROMATOGRAPHY(8,3)
FLUSHING NOSE(8,3)
GBDEL PROTEIN(8,3)
RECOMBINANT BACMID CONSTRUCTION(8,3)
ANTIBODY TITER SERUM(8,2)
LIPID AMINE ADJUVANT(8,2)
NEUTRALIZING TITER MEASUREMENT(8,2)
COW CLINICAL SYMPTOM(8,1)
RECOMBINANT BACMID ROOT EXTRACTION(8,1)
VACCINE NEUTRALIZING POTENCY(8,1)
CONSERVATIVE AMINOACID SUBSTITUTION(7,5)
GPI(7,3)
IMS(7,3)
CAMBRIDGE BIOTECH INCORPORATION(7,1)
FRAGMENT ANTIGEN IMMUNIZATION(7,1)
GALENICA PHARMACEUTICAL INCORPORATION(7,1)
GB PROTEIN GENE BAMHI(7,1)
IMMUNOGENIC GB PROTEIN FRAGMENT(7,1)
PLASMID MINI KIT REAGENT(7,1)
POLYOL CROSSLINKING CARBOMER COMPOUND(7,1)
POLYOL CROSSLINKING SUGAR(7,1)
POLYPEPTIDE CONSERVATIVE VARIANT(7,1)
REGENTSPECIFICATION TRANSFECTION(7,1)
SERUM NEUTRALIZING TITER(7,1)
SYNTHESIZED GB PROTEIN BAMHI(7,1)
TRUNCATED GB PROTEIN EXPRESSION(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS RELATED DISEASE(6,6)
BIOLOGICAL ACTIVITY(6,4)
FUNCTIONAL DERIVATIVE(6,4)
NONIONIC SURFACTANT(6,3)
NUCLEOTIDE SEQUENCE FRAGMENT ACTIVITY(6,3)
PIK DAY(6,3)
VEGETABLE OIL(6,3)
PFASTBACI VECTOR(6,2)
SEGMENT(6,2)
ANTIGEN ANTIBODY NEGATIVE BOVINE(6,1)
COOPER GB PROTEIN(6,1)
CORRECT RECOMBINANT BACMID(6,1)
GB ANTIGEN VACCINE(6,1)
GENE FRAGMENT BAMHI(6,1)
LIVE VIRULENCE(6,1)
RECOMBINANT BACULOVIRUS GENERATION(6,1)
SERUM NEUTRALIZATION TITER DETECTION(6,1)
TISSUE CULTURE INFECTIVE(6,1)
WESTERN BLOT ASSAY(6,1)
WORLD ANIMAL HEALTH ORGANIZATION(6,1)
PREVENTION(5,6)
APPETITE LOSS(5,3)
LIQUID PARAFFIN OIL(5,3)
BOVINE SERUM(5,2)
DONOR PLASMID CONSTRUCTION(5,2)
ETHYLENICALLY UNSATURATED GROUP(5,2)
ALLYL PENTEK(5,1)
BAC COMPETENT CELL(5,1)
COMPARATIVE IMMUNOGENICITY(5,1)
DIGESTED PFASTBAC(5,1)
G ML VACCINE(5,1)
GD PROTEIN GENE SEQUENCE(5,1)
HERPES VIRUS GLYCOPROTEIN(5,1)
IMMUNIZED CHALLENGE(5,1)
ISOPRENOID OIL CREATION(5,1)
POST CHALLENGE CATTLE(5,1)
RECOMBINANT VIRUS GENERATION(5,1)
ROW LATE ONSET(5,1)
SYNTHETIC GB PROTEIN GENE(5,1)
TRUNCATED GB PROTEIN SEQUENCE(5,1)
VACCINE IMMUNIZATION(5,1)
DELETION(4,6)
CAPRYLATE ANNUUS(4,4)
METHACRYLIC ACID POLYMER(4,3)
BLOOD COLLECTION(4,2)
CORRECT POSITIVE PLASMID(4,2)
PARENT POLYPEPTIDE AMINOACID(4,2)
POLYOXYETHYLENE BLOCK COPOLYMER(4,2)
PROTECTION RATIO CHALLENGE(4,2)
ALANINE SUBSTITUTION(4,1)
BOVINE HERPES VIRUS(4,1)
CELL CULTURE INFECTIVE DOSE(4,1)
CENTRIFUGED SUPERNATANT(4,1)
CONSERVATIVE VARIANT SEQUENCE(4,1)
ECORI FRAGMENT(4,1)
EMERYVILLE CA(4,1)
GB PROTEIN ACTIVE FRAGMENT(4,1)
GB PROTEIN GENE SEQUENCE(4,1)
GB SUBUNIT VACCINE(4,1)
GENE SYNTHESIS COMPANY(4,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS ANTIGEN(4,1)
INOCULATED CELL CULTURE DISH(4,1)
LOGARITHMIC GROWTH SF9 CELL(4,1)
LYSINE SUBSTITUTION(4,1)
MATURE VIRION(4,1)
OLEFIN OLIGOMER OIL(4,1)
PARENT POLYPEPTIDE SEQUENCE(4,1)
POLYHYDROXYLATED COMPOUND(4,1)
PROTEIN SUBUNIT VACCINE(4,1)
RIBI INCORPORATION(4,1)
VACCINE COMPOSITION ADMINISTRATION(4,1)
ADMINISTRATION MODE(3,2)
ALKENYL GROUP(3,2)
AVRIDINE(3,2)
COW GROUP(3,2)
IMMUNE RESPONSE(3,2)
POLYPEPTIDE PROTEIN(3,2)
SYNTHETIC GENE SEQUENCE(3,2)
ACIDIC SOLUTION CREATION(3,1)
ADIUVANT(3,1)
ANGULAR SQUALENE OIL(3,1)
ANTIGEN ACTIVITY(3,1)
ARTIFICIAL SYNTHETIC(3,1)
BACTERIAL SUSPENSION(3,1)
BIRMINGHAM AL(3,1)
CAMBRIDGE MA(3,1)
CHALLENGE DOSE(3,1)
COMPOSITION IMMUNOGENICITY(3,1)
COMPOSITION SUBUNIT VACCINE PREPARATION(3,1)
CROSSLINKED ACRYLIC ACID(3,1)
DAY VACCINE(3,1)
DEISOBUTYLENIZER(3,1)
DONOR PLASMID SERIAL CONNECTION(3,1)
ESSENTIAL STRUCTURAL PROTEIN(3,1)
FUNCTIONAL FRAGMENT(3,1)
GB PROTEIN FRAGMENT CONDITION(3,1)
GD PROTEIN AMINOACID(3,1)
GROUP NEUTRALIZATION TITER(3,1)
HYDROGEN ATOM(3,1)
IDENTIFIED POSITIVE PLASMID(3,1)
IMMUNOGENIC RELATIVELY GB PROTEIN(3,1)
INFECTION ROUTE(3,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(3,1)
INJECTION COW(3,1)
LIGATION PRODUCT(3,1)
MUTAGENESIS(3,1)
PHYSIOLOGICAL PH(3,1)
POST TRANSFECTION(3,1)
PROTEIN SYNTHESIS(3,1)
VACCINE CONCENTRATION(3,1)
WHITE COLONY(3,1)
WRAPPING FOIL(3,1)";Pharmaceuticals;Open
2016-08-05;"RU2016132302        A  2018-02-08 [RU2016132302]
STG: (A) Application for invention
AP : 2016RU-0132302 2016-08-05
RU2644339           C2 2018-02-08 [RU2644339]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2016RU-0132302 2016-08-05";78817071;"RU2016132302        A  2018-02-08 [RU2016132302]
RU2644339           C2 2018-02-08 [RU2644339]";2016RU-0132302;;FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE NAUCHNOE UCHREZHDENIE VSEROSSIJSKIJ NAUCHNO ISSLEDOVATELSKIJ;FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE NAUCHNOE UCHREZHDENIE VSEROSSIJSKIJ NAUCHNO ISSLEDOVATELSKIJ;;;1;"SAMUJLENKO ANATOLIJ YAKOVLEVICH
KRASOCHKO PETR ALBINOVICH
EREMETS VLADIMIR IVANOVICH
ALBULOV ALEKSEJ IVANOVICH
GRIN SVETLANA ANATOLEVNA
KRASOCHKO PAVEL PETROVICH
EREMETS NATALYA KIREEVNA
BOBROVSKAYA IRINA VLADIMIROVNA
POPOVA VERA MIKHAJLOVNA
MURADYAN ZHORA YURIKOVICH
FROLOVA MARINA ALEKSEEVNA";;;"(RU2644339)
Sorbed inactive dry vaccine against infectious rhinotracheitis of cattle";"(RU2644339)
FIELD: veterinary medicine.SUBSTANCE: presented vaccine contains antigenic material from the Herpesvirus bovis 1 strain ""KMIEV - V123"" of the cattle IRT virus with biological activity of 7.3-7.8 lg TCD/ml, reproduced in the transplantable culture of VNK-21 cells, and contains a mixture of ethonia in the form of a 10% aqueous solution and chitosan succinate in the form of 2% solution in isotonic sodium chloride solution with pH 7.0-7.2 as an adjuvant.EFFECT: possibility of obtaining of a vaccine having high antigenic and immunogenic activity and harmlessness.2 cl, 4 tbl, 7 ex";"(RU2644339)
1. A vaccine against contagious rhino-tracheitis of cattle sorbirovannaya inactivated, dry containing material from antigenic strain bovis Herpesvirus 1 «virus»- KMIEV V123 IRT cattle, reproduced in the sensitive biological system and inactivation teotropinom in a concentration of 0.2% and the adjuvant of chitosan succinate that is characterized by the fact that the material it contains antigenic antigenic material from the strain of bovis Herpesvirus 1 «virus»- KMIEV V123 IRT cattle with biological activity 7,3-7,8 lg TTSD [50] /ml, reproduced in a culture of interwoven inc -21 cells and how the adjuvant contains a mixture of etoniya in the form of water solution and 10% of chitosan succinate as 2% of isotonic solution in the solution of sodium chloride with the launcher 7,0-7,2 taken in mass ratio, %:
2. Teotropin: 0.2:
Chitosan succinate: 0,25-0,5:
Etoniy: 0.4:
Antigenic material from the strain of Herpesvirus:
Bovis 1 «virus»- KMIEV V123 IRT cattle:
With biological activity 7,3-7,8 lg TTSD [50] /ml: The rest:
3. 2. The vaccine on page 1, characterized by what is also undergoing a process of sublimation drying, and as a protective environment for sublimation drying of chitosan regarding succinate, mass %:
4. Antigenic material: 100:
Teotropin: 0.2:
Chitosan succinate: 0,25-0,5:
Etoniy: 0.4:";;;"A61K-039/265
A61K-047/16";;;Pharmaceuticals;Open
2016-07-04;"CN105924506         A  2016-09-07 [CN105924506]
STG: (A) Published application
AP : 2016CN-0517156 2016-07-04";74124667;CN105924506         A  2016-09-07 [CN105924506];2016CN-0517156;;CHINA INSTITUTE OF VETERINARY DRUGS CONTROL;CHINA INSTITUTE OF VETERINARY DRUGS CONTROL;"(CN105924506)
CN";"(CN105924506)
NAME=CHINA INSTITUTE OF VETERINARY DRUGS CONTROL , COUNTRY=CN 
";1;"FAN XUEZHENG
ZHAO QIZU
YAO WENSHENG
DING JIABO
NING YIBAO
XU LU
WANG FANG
WANG QIN
ZOU XINGQI
ZHU YUANYUAN
ZHU LIANGQUAN
JIANG HUI";;;"(CN105924506)
Preparation method of bovine viral diarrhea virus E2 protein subunit vaccine";"(CN105924506)
The invention relates to a preparation method of a bovine viral diarrhea virus E2 protein subunit vaccine. The preparation method has the following advantages that: firstly, an expression method for obtaining BVDV E2 protein efficiently is set; and secondly, the E2 protein of the BVDV is used for expressing a supernatant immune rabbit, is proved to have good immunoreactions, and can be used for preparing BVDV subunit vaccine.";"(CN105924506)
1. Bovine viral diarrhea virus E2 protein a subunit vaccine preparation method, characterized in the vaccine is constructed has been designated alfalfa silver mosquito by californica nuclear polyhedrosis virus (baculovirus for short) is prepared as the production strain BacVDMoptiE 2 strain, the strain is assumed to be sent to Beijing No. 3 No. 1 01 June 2016 beichen west road chaoyang district hospital SHANGHAI microorganisms deposited under CGMCC Institute Committee for Type Culture Collection, accession numbers: CGMCC No. 12545.
2. Claim 1 bovine viral diarrhea virus E2 protein a subunit vaccine preparation method, characterized in the construction thereof is carried in a baculovirus BacVDMoptiE 2 strain MoptiE2-1 (sequence 1) and the MoptiE2-2 (sequence 2).
3. Claim 1 bovine viral diarrhea virus E2 protein as a subunit vaccine preparation method, characterized in baculovirus expression with its construction of the E2 protein BacVDMoptiE 2 was conducted to produce a soluble, inactivated, adjuvanted vaccine prepared suitable for use in subunit was added after emulsification.";"(CN105924506)
The present invention relates to a bovine viral diarrhea virus E2 protein subunit vaccine preparation method.
It has been found, different species of aminoacid codon usage frequency has a large difference, therefore, the present invention will be BVDV E2 gene codon optimized to insect baculovirus-preferred codons, to increase the amount of BVDV E2.
An object of the present invention is to create BVDV E2 protein or a subunit vaccine preparation method.
The present invention relates to bovine viral diarrhea virus (BVDV) E2 subunit vaccine production method and its protein expression, belongs to the field of veterinary biologics.";"(CN105924506)
The expansion will be identified in good passed by, for generations in mind P2Stock 2nd, 3rd to P3Stock generations in mind.
The expansion will be identified in good passed by, for generations in mind P2Stock 2nd, 3rd to P3Stock generations in mind.";"A61K-039/12
A61P-031/14
C07K-014/18
C12N-007/01
C12N-015/40
C12N-015/866";"(CN105924506)
1. Bovine viral diarrhea virus E2 protein a subunit vaccine preparation method, characterized in the vaccine is constructed has been designated alfalfa silver mosquito by californica nuclear polyhedrosis virus (baculovirus for short) is prepared as the production strain BacVDMoptiE 2 strain, the strain is assumed to be sent to Beijing No. 3 No. 1 01 June 2016 beichen west road chaoyang district hospital SHANGHAI microorganisms deposited under CGMCC Institute Committee for Type Culture Collection, accession numbers: CGMCC No. 12545.";"(CN105924506)
BOVINE VIRAL DIARRHEA VIRUS(100,50)
PROTEIN(100,14)
SUBUNIT VACCINE(100,11)
STRAIN(100,10)
BACULOVIRUS(100,6)
ALFALFA(100,5)
MOSQUITO(100,5)
ACCESSION NUMBER(100,4)
TYPE CULTURE(100,4)
BEICHEN WEST ROAD(100,3)
COMMITTEE(100,3)
DISTRICT HOSPITAL SHANGHAI MICROORGANISM(100,3)
VACCINE PREPARATION(100,3)
CALIFORNICA NUCLEAR POLYHEDROSIS VIRUS(100,2)
PROTEIN SUBUNIT(100,2)
STRAIN PRODUCTION(100,2)
VACCINE(100,2)
AMINOACID CODON USAGE FREQUENCY(54,1)
STOCK GENERATION(42,2)
ADJUVANTED VACCINE(38,1)
GENE CODON(37,1)
PROTEIN EXPRESSION(36,4)
SUPERNATANT PROTEIN EXPRESSION(36,2)
BACULOVIRUS BACVDMOPTIE(34,2)
RABBIT IMMUNIZATION(32,2)
PROTEIN BACVDMOPTIE(27,2)
BACULOVIRUS EXPRESSION(26,2)
MIND P(24,2)
STRAIN MOPTIE(24,2)
MIND(21,2)
VETERINARY BIOLOGICS FIELD(21,1)
FUSION GENE PLASMID(17,5)
EMULSIFICATION(17,1)
NUCLEAR POLYHEDROSIS VIRUS(16,3)
IMMUNE RESPONSE(16,2)
DROSOPHILA MELANOGASTER MARZOCCA MP(16,1)
SUBUNIT VACCINE PREPARATION(15,3)
TRANSFECTION REAGENT CELLFECTIN BDMOPTIE(15,1)
SHANGHAI HOSPITAL INSTITUTE COMMITTEE(14,1)
TRANSFECTION REAGENT CELLFECTIN BDME(14,1)
FUSION GENE CONSTRUCT PLASMID(12,2)
SERUM NEUTRALIZING TITER(12,2)
FLAVIVIRUS GENUS PESTIVIRUS(12,1)
INDUCTION OFVIRUS NEUTRALIZING ANTIBODY(12,1)
CULTURE SUPERNATANT(11,4)
BRIGHT GREEN FLUORESCENCE(11,3)
SUBUNIT VACCINE PRODUCTION(11,1)
INVITROGEN CORPORATION(10,3)
RECOMBINANT VIRUS(10,3)
RECONIBINANT ULOVILUS(10,2)
INSECT BACULOVIRUS PREFERRED CODON(10,1)
RESTRICTION FRAGMENT(9,4)
VECTOR PMD(9,4)
RECOMBINANT BACMID(9,2)
GENE RECOMBINANT BACULOVIRUS(9,1)
RECOMBINANT BACULOVIRUS GENOME(9,1)
RECOMBINANT BACULOVIRUS INFECTED CELL(9,1)
BAC BACTERIUM(8,2)
BACULOVIRUS TRANSFER VECTOR(8,2)
BAMHI RESTRICTION(8,2)
FLUORESCENCE MICROSCOPE(8,2)
NEUTRALIZING ANTIBODY PRODUCTION(8,2)
SMAI RESTRICTION(8,2)
VACCINE CANDIDATE(8,2)
BACULOVIRA BACVDMOPTIE(8,1)
DROSOPHILA MELANOGASTER CELL(8,1)
INFECTED CALF DELIVERY(8,1)
NEUTRALIZING ANTIBODY CREATION(8,1)
STRAIN SUGGESTED CLASSIFICATION DESIGNATION(8,1)
GENE SEQUENCE(7,6)
LINEAR PLASMID(7,4)
OVERLAP EXTENSION(7,4)
CHAOYANG DISTRICT(7,1)
LIFELONG STRIP VIRUS(7,1)
PEPTIDE MELS GENE FUSION(7,1)
SUBCUTANEOUS MULTIPOINT INJECTION(7,1)
SUBUNIT VACCINE FEASIBILITY(7,1)
VIRAL TITER DETERMINATION(7,1)
HINDIII SITE(6,2)
INSECT CELL(6,2)
LABELED GOAT(6,2)
VIRUS GENERATION(6,2)
WHOLE GENE SYNTHESIS(6,2)
ANTIBODY NEUTRALIZATION(6,1)
CLINICAL SYMPTOM(6,1)
FERRER F RACHIPLUSIA NUPERO BACULOVIRUS PROTEIN(6,1)
FETAL MALFORMATION(6,1)
PLASMID POPTIE(6,1)
PREGNANT COW(6,1)
RECOMBINANT VIRAL EXPRESSION ANALYSIS(6,1)
RT PCR(6,1)
VACCINE ANTIGEN PREPARATION(6,1)
PMOPTIE(5,3)
ANTI MOUSE ANTIBODY(5,2)
DNA OBTAINED TRANSPOSITION(5,2)
PREFIXATION SOLUTION(5,2)
RABBIT ILLUSTRATION(5,2)
SIGNAL PEPTIDE FUSION(5,2)
ANIMAL IMMUNIZATION(5,1)
BOVINE DIARRHEA(5,1)
CANDIDATE ANTIGEN(5,1)
CREATION HUMORAL IMMUNITY(5,1)
FLUORESCENT ANTIBODY FLUID(5,1)
FRESH EXPRESSFIVE MEDIUM(5,1)
IMMUNIZED ANIMAL(5,1)
IMMUNOGENICITY STUDY(5,1)
RECOMBINANT BACULOVIRUS CONSTRUCTION(5,1)
SEPARATED SERUM NEUTRALIZATION ASSAY(5,1)
STRAIN BACVDME(5,1)
SUSTAINED DETOX(5,1)
XU XING(5,1)
BIG EAR(4,1)
CARRIER PFB MOPTIE(4,1)
CATTLE INDUSTRY(4,1)
CONCENTRATED SUPERNATANT(4,1)
ENVELOPE PROTEIN(4,1)
FOREIGN GENE(4,1)
GENE CLONING(4,1)
H CULTURE INCUBATOR(4,1)
INFECTIOUS AGENT(4,1)
LMMOL FINAL CONCENTRATION(4,1)
MATURE PROTEIN(4,1)
MICROBIAL RESOURCE INFORMATION(4,1)
MICROORGANISM DEPOSIT(4,1)
POST HARVEST(4,1)
PROKARYOTIC EXPRESSION PRODUCT(4,1)
REPRODUCTIVE FAILURE(4,1)
RESTRICTION SITE(4,1)
SDS PAGE ELECTROPHORESIS(4,1)
SECRETORY SIGNAL PEPTIDE(4,1)
SUSPENSION CULTURE(4,1)
WEST ROAD(4,1)";Pharmaceuticals;Open
2016-04-07;"WO2017176519        A1 2017-10-12 [WO2017176519]
STG: (A1) Published application with search report
AP : 2017WO-US24669 2017-03-29";77463496;WO2017176519        A1 2017-10-12 [WO2017176519];2016US-62319320;;UNIVERSITY OF VIRGINIA;UNIVERSITY OF VIRGINIA;"(WO2017176519)
US";"(WO2017176519)
NAME=VIRGINIA COMMONWEALTH UNIVERSITY 800 East Leigh Street Suite 3000 Richmond, VA 23298 , POSTCODE=23298 , COUNTRY=US 
";1;CARLYON JASON A;"(WO2017176519)
US";"(WO2017176519)
NAME=CARLYON, Jason, A. 311 N. Meadow St. Richmond, VA 23220 , POSTCODE=23220 , COUNTRY=US 
";"(WO2017176519)
Ompa in vaccine compositions and as diagnostic targets";"(WO2017176519)
Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.";"(WO2017176519)
CLAIMS We claim:
1. An immunogenic composition including one or more isolated polypeptides in a vehicle or carrier suitable for administration to a subject, wherein at least one of said one or more polypeptides consists of 5 to 19 consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, wherein said at least one of said one or more polypeptides does not consist of 16 consecutive residues of SEQ ID NO: 84.
2. The immunogenic composition of claim 1, wherein said at least one of said one or more polypeptides is SEQ ID NO:81 or SEQ ID NO:85.
3. The immunogenic composition of claim 2, wherein said at least one of said one or more polypeptides is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87.
4. A pharmaceutical composition comprising an antibody or an antigen binding fragment thereof and a pharmaceutically acceptable carrier, wherein said antibody or antigen binding fragment thereof specifically recognizes at least one epitope consisting of 5 to 19 consecutive amino acids of SEQ ID NO: 84 including SEQ ID NO: 85, wherein said at least one epitope does not consist of 16 consecutive residues of SEQ ID NO: 84.
5. The pharmaceutical composition of claim 4, wherein said antigen binding fragment is selected from the group consisting of Fab fragments, Fab' fragments, F(ab')2fragments, Fd fragments, Fv fragments, scFv fragments, and combinations thereof.
6. The pharmaceutical composition of claim 4, wherein said at least one epitope is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO: 87
7. A method of protecting or treating a subject from a zoonotic disease comprising the step of administering to said subject an immunogenic composition including one or more isolated polypeptides, wherein at least one of said one or more polypeptides consists of 5 to 19 consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, wherein said at least one of said one or more polypeptides does not consist of 16 consecutive residues of SEQ ID NO:84.
8. The method of claim 7, wherein said at least one of said one or more polypeptides is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO: 87.
9. The method of claim 7, wherein said zoonotic disease is caused by an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of 
 Anaplasma phagocy tophi lum and Anaplasma marginale.
10. The method of claim 9, wherein said subject is a cow and said zoonotic disease is bovine anaplasmosis.
11. A method of protecting or treating a subject from a zoonotic disease comprising the step of administering to said subject a pharmaceutical composition including an antibody or an antigen binding fragment thereof that specifically recognizes at least one epitope consisting of 5 to 19 consecutive amino acids of SEQ ID NO: 84 including SEQ ID NO: 85, wherein said at least one epitope does not consist of 16 consecutive residues of SEQ ID NO:84.
12. The method of claim 11, wherein said antigen binding fragment is selected from the group consisting of Fab fragments, Fab' fragments, F(ab')2fragments, Fd fragments, Fv fragments, scFv fragments, and combinations thereof.
13. The method of claim 11, wherein said at least one epitope is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87.
14. The method of claim 11, wherein said zoonotic disease is caused by an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of 
 Anaplasma phagocy tophi lum and Anaplasma marginale.
15. The method of claim 14, wherein said subject is a cow and said zoonotic disease is bovine anaplasmosis.
16. A method of determining if a subject has been exposed to or is infected with an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of Anaplasma phagocy tophi lum and Anaplasma marginale, wherein said subject is suspected of having a zoonotic disease caused by an obligate intracellular 
 Anaplasmataceae bacterium, comprising the steps of 
 contacting a test sample from said subject, under conditions that allow 
 polypeptide-antibody complexes to form, with a composition that includes one or more polypeptides, at least one of which consists of sixteen to nineteen consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, wherein said at least one of said one or more polypeptides does not consist of 16 consecutive residues of SEQ ID NO:84, 
 detecting one or more polypeptide-antibody complexes in said test sample, wherein the detection is an indication that antibodies specific for Anaplasmataceae OmpA are present in the test sample, and 
 determining said subject has been exposed to or is infected with said 
 Anaplasmataceae bacterium if said antibodies specific for Anaplasmataceae OmpA are present in the test sample.
17. The method of claim 16, wherein said at least one of said one or more polypeptides is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87.
18. The method of claim 16, wherein said contacting and detecting steps are performed using an assay selected from the group consisting of an immunoblot and an enzyme- linked immunosorbent assay (ELISA).
19. The method of claim 16, wherein said subject is a cow and said zoonotic disease is bovine anaplasmosis.
20. The method of claim 16, wherein said test sample is a body fluid selected from the group consisting of blood, plasma, serum, urine, and saliva.";"(WO2017176519)
An aspect of the invention provides an immunogenic composition including one or more isolated polypeptides in a vehicle or carrier suitable for administration to a subject, wherein at least one of said one or more polypeptides consists of 5 to 19 consecutive residues of an Aph and A.
Another aspect of the invention provides a pharmaceutical composition comprising an antibody or an antigen binding fragment thereof and a pharmaceutically acceptable carrier, wherein said antibody or antigen binding fragment thereof specifically recognizes at least one epitope present in the Aph and A.
The invention generally relates to a vaccine and diagnostic for Anaplasmataceae infections.
In particular, the invention provides A. marginale and A. phagocy tophi lum outer surface protein A (OmpA) epitopes.";"(WO2017176519)
If it is desired to administer an oral form of the composition, various thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders and the like may be added.
A. marginale subsp. centrale is used as live vaccine against bovine anaplasmosis in some parts of the world, but this results in unreliable protection as immunity is not uniform against all strains and outbreaks have occurred in immunized populations.
Percent of infection in alanine substitution experiments that identified that OmpA aa59-74 are important for infection.
Recent studies demonstrated the importance of OmpA proteins to cellular invasion by A. phagocy tophi lum (Aph) and Ehrlichia chqffeensis, two Anaplasmataceae members that cause potentially fatal infections of humans and animals.";"A61K-038/17
A61K-039/02
A61K-039/40
C07K-016/12
G01N-033/569";"(WO2017176519)
CLAIMS We claim: 1. An immunogenic composition including one or more isolated polypeptides in a vehicle or carrier suitable for administration to a subject, wherein at least one of said one or more polypeptides consists of 5 to 19 consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, wherein said at least one of said one or more polypeptides does not consist of 16 consecutive residues of SEQ ID NO: 84.
4. A pharmaceutical composition comprising an antibody or an antigen binding fragment thereof and a pharmaceutically acceptable carrier, wherein said antibody or antigen binding fragment thereof specifically recognizes at least one epitope consisting of 5 to 19 consecutive amino acids of SEQ ID NO: 84 including SEQ ID NO: 85, wherein said at least one epitope does not consist of 16 consecutive residues of SEQ ID NO: 84.
7. A method of protecting or treating a subject from a zoonotic disease comprising the step of administering to said subject an immunogenic composition including one or more isolated polypeptides, wherein at least one of said one or more polypeptides consists of 5 to 19 consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, wherein said at least one of said one or more polypeptides does not consist of 16 consecutive residues of SEQ ID NO:84.
11. A method of protecting or treating a subject from a zoonotic disease comprising the step of administering to said subject a pharmaceutical composition including an antibody or an antigen binding fragment thereof that specifically recognizes at least one epitope consisting of 5 to 19 consecutive amino acids of SEQ ID NO: 84 including SEQ ID NO: 85, wherein said at least one epitope does not consist of 16 consecutive residues of SEQ ID NO:84.
16. A method of determining if a subject has been exposed to or is infected with an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of Anaplasma phagocy tophi lum and Anaplasma marginale, wherein said subject is suspected of having a zoonotic disease caused by an obligate intracellular Anaplasmataceae bacterium, comprising the steps of contacting a test sample from said subject, under conditions that allow polypeptide-antibody complexes to form, with a composition that includes one or more polypeptides, at least one of which consists of sixteen to nineteen consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, wherein said at least one of said one or more polypeptides does not consist of 16 consecutive residues of SEQ ID NO:84, detecting one or more polypeptide-antibody complexes in said test sample, wherein the detection is an indication that antibodies specific for Anaplasmataceae OmpA are present in the test sample, and determining said subject has been exposed to or is infected with said Anaplasmataceae bacterium if said antibodies specific for Anaplasmataceae OmpA are present in the test sample.";"(WO2017176519)
ZOONOTIC DISEASE(100,14)
INTRACELLULAR ANAPLASMATACEAE BACTERIUM(100,7)
IMMUNOGENIC(100,4)
CONSECUTIVE RESIDUE(87,10)
ANAPLASMA PHAGOCY TOPHI(82,5)
ISOLATED POLYPEPTIDE(56,3)
PHAGOCY TOPHI(51,2)
BOVINE ANAPLASMOSIS(43,10)
POLYPEPTIDE ANTIBODY COMPLEX(42,4)
OMPA PROTEIN IMPORTANCE(42,1)
EHRLICHIA CHQFFEENSIS(41,1)
ALANINE SUBSTITUTION EXPERIMENT(40,1)
FATAL HUMAN INFECTION(39,1)
MARGINALE SUBSP(37,1)
IMMUNIZED POPULATION(33,1)
ANAPLASMATACEAE BACTERIUM(32,4)
EPITOPE(31,27)
LIVE VACCINE(29,1)
ANTIGEN(28,15)
ANTIBODY(27,38)
SCFV FRAGMENT(27,3)
UNRELIABLE PROTECTION(25,1)
ANAPLASMA MARGINALE(24,6)
FD FRAGMENT(24,3)
CELL INVASION(23,2)
DISPERSING AID(21,1)
RECENT STUDY(20,1)
ANAPLASMATACEAE MEMBER(19,1)
CONSECUTIVE AMINOACID(18,5)
ADMINISTRATION(18,4)
THICKENING(18,1)
INFECTION PERCENT(16,3)
EMULSIFIER(15,1)
FLAVORING(15,1)
OUTBREAK(15,1)
ANAPLASMATACEAE INFECTION(13,7)
DILUENT(13,1)
IMMUNITY(13,1)
WORLD(13,1)
UNBOUND BACTERIA(12,7)
COW(11,9)
OMPA INVASIN DOMAIN(11,3)
BINDER(11,1)
INFECTION(10,32)
VACCINE(10,8)
CHIMERIC PEPTIDE(10,7)
BIPHASIC DEVELOPMENTAL CYCLE(10,4)
FAB FRAGMENT(10,4)
MARGINALE(10,4)
MARGINALE DC ORGANISM(10,4)
SCAPULARIS NYMPH(10,4)
DIFFERENTIAL TRANSCRIPTION PROFILING(10,3)
OMPA(9,27)
CHIMERIC PROTEIN(9,6)
NEUTRAVIDIN BEAD PLUS(9,3)
ALEXA FLUOR PERCENTAGE(9,2)
TICK CELL MARGINALE INFECTION(9,2)
CELLO SUBCELLULAR PREDICTION SERVER(9,1)
MARGINALE SENSU STRICTO STRAIN(9,1)
PHAGOCY TOPHI LUM HZ(9,1)
TRIPLICATE SAMPLE(8,7)
MAMMALIAN HOST CELL(8,6)
INFECTED CELL PERCENTAGE(8,5)
STRAIN(8,5)
IMMUNOBLOT(8,4)
TRANSMEMBRANE DOMAIN(8,4)
ANIMAL(8,3)
CONFORMATIONAL EPITOPE(8,3)
EHRLICHIA SPP(8,3)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY(8,3)
RECOMBINANT AMOMPA(8,3)
APH INFECTED MOUSE(8,2)
RICKETTSIALES BACTERIUM(8,2)
OMPA TARGET SIALYLATED GLYCOPROTEIN(8,1)
TERMINALLY SIALYLATED GLYCOPROTEIN(8,1)
INDEPENDENT EXPERIMENT(7,9)
LINKER SEQUENCE(7,8)
CELLULAR DEBRIS(7,5)
APH INFECTION CYCLE(7,4)
APH LYSATE(7,3)
PHAGOCYTOPHILUM INFECTION(7,2)
PROTEIN PURIFICATION LIGAND(7,2)
ANAPLASMA PLATY OX(7,1)
ANAPLASMATACEAE BACTERIUM UPTAKE(7,1)
APH INFECTED IXODE(7,1)
APH INFECTED NYMPH(7,1)
AUTODOCK VINA(7,1)
BOVINE ANAPLASMOSIS ETIOLOGIC AGENT(7,1)
MARGINALE OMPA CONSENSUS(7,1)
OMPA LINKER INSERTION MUTANT(7,1)
POLYCLONAL ANTISERUM TARGETING(7,1)
PREIMMUNE MOUSE SERUM DILUTION(7,1)
RAISING RABBIT POLYCLONAL ANTISERUM(7,1)
TOPHI LUM OMPA(7,1)
TSUTSUGAMUSHI OMPA PROTEIN(7,1)
HOST CELL INFECTION(6,4)
PREIMMUNE SERUM(6,3)
ANAPLASMA SPECIES(6,2)
ANAPLASMA SPP(6,2)
APH EFFECTOR(6,2)
APH INVASION(6,2)
APH POPULATION(6,2)
BIOTIN CARBOXYL CARRIER PROTEIN(6,2)
EXPERIMENTAL TIMELINE(6,2)
INFECTION INHIBITION(6,2)
INTACT APH DC ORGANISM(6,2)
INTACT DC BACTERIUM(6,2)
RECOMBINANT POLYPEPTIDE(6,2)
SPINNING DISC CONFOCAL MICROSCOPY(6,2)
UNFED TICK(6,2)
ANAPLASMATACEAE BACTERIUM EXPOSURE(6,1)
ANAPLASMATACEAE SPECIES BACTERIUM(6,1)
ANAPLASMATACEAE SPECIES GEOGRAPHICAL DISTRIBUTION(6,1)
BACTERIUM VACUOLAR MEMBRANE(6,1)
BOUND APH ORGANISM MAJORITY(6,1)
CANDIDATE GENE RECOMBINATION(6,1)
CONFOCAL MICROSCOPIC EXAMINATION(6,1)
EHRLICHIA SPECIES HOMOLOG(6,1)
ELUATE REVEALED ENRICHMENT(6,1)
EXPERIMENTALLY INOCULATED CALF(6,1)
JOHN HOPKINS UNIVERSITY(6,1)
MARGINALE OMPA SHARE(6,1)
MURINE POLYCLONAL ANTISERA GENERATION(6,1)
PATHOGEN VACUOLAR MEMBRANE(6,1)
QIAGEN RNEASY KIT(6,1)
RURAL POOR LIVELIHOOD(6,1)
TARGETING OMPA AA(6,1)
XBIT APH INFECTION(6,1)
GST ASPL(5,9)
BACTERIAL ADHESION(5,7)
DC INOCULUM(5,3)
ENZYME LINKED IMMUNO SORBENT ASSAY(5,3)
NATIVE OMPA SEQUENCE(5,2)
STATISTICAL SIGNIFICANCE(5,2)
TARGETING ANTIBODY(5,2)
ADHESIN TRIO(5,1)
AGAROSE AFFINITY CHROMATOGRAPHY(5,1)
AMOMPA COATED MICROSPHERE(5,1)
ANAPLASMATACEA BACTERIUM(5,1)
ANAPLASMATACEAE PATHOGEN(5,1)
ANTIBODY TITER DEFINITION(5,1)
ANTISERUM INVERSE DILUTION(5,1)
APH OMPA RESIDUE(5,1)
ASP TRANSCRIPTIONAL PROFILE(5,1)
ASPL UPREGULATION(5,1)
BACTERIAL CELLULAR ADHERENCE(5,1)
BIOTINYLATION ENRICHMENT(5,1)
CANDIDATE GENE ENTRY PLASMID(5,1)
CAPACITY NEUTRAVIDIN AGAROSE(5,1)
CAPTURED BIOTINYLATED PROTEIN(5,1)
CHIMERA EPITOPE(5,1)
CHIMERIC VACCINOGEN(5,1)
COLLECTIVE AVIDITY(5,1)
CONTAMINATING HOST MAJORITY(5,1)
CRITICAL CONSERVED EFFECTOR DOMAIN(5,1)
DC BACTERIAL INOCULUM(5,1)
DISCONTINUOUS RENOGRAFIN(5,1)
ELECTRON MICROSCOPIC EXAMINATION(5,1)
ENDOTHELIAL CELL MARGINALE INFECTION(5,1)
EPITOPE STERIC ISOLATION(5,1)
EXPERIMENTALLY INFECTED MOUSE(5,1)
GRAM NEGATIVE BACTERIA(5,1)
HOMOLOGY STRETCH(5,1)
IMMUNOHISTOCHEMICAL STAINING(5,1)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPE EXAMINATION(5,1)
IRRELEVANT APH PROTEIN(5,1)
MEDIATING BACTERIUM HOST CELL(5,1)
MULTIDIMENSIONAL PEPTIDE SEPARATION(5,1)
NEUTRAVIDIN AFFINITY CHROMATOGRAPHY(5,1)
OMP CANDIDATE GENE(5,1)
OMPA PREDICTED EXTRACELLULAR REGION(5,1)
OMPA PREPROTEIN(5,1)
OMPA PROTEIN ADMINISTRATION(5,1)
OMPA RELEVANCE(5,1)
ORGANISM CELL DEBRIS(5,1)
PEPTIDE ANTISERA BLOCKING(5,1)
POLYCLONAL ANTI OMPA ANTISERA(5,1)
PREDICTED EXTRACELLULAR DOMAIN(5,1)
PROTEIN PLAY HOUSEKEEPING ROLE(5,1)
PROTEIN STABILIZATION(5,1)
SCAPULARIS LARVA(5,1)
SIALIDASE COCKTAIL(5,1)
SLEX SIALIC ACID DETERMINANT(5,1)
T CELL EPITOPE(5,1)
TAGGED FUSION PROTEIN(5,1)
UNINFECTED HL60 CELL LYSATE(5,1)
VARIED SIALYLATED POLYSACCHARIDE(5,1)
ANTIBODY PRODUCTION(4,6)
REFSEQ(4,5)
DC WHOLE CELL LYSATE(4,3)
LINEAR EPITOPE(4,3)
PEPTIDE BOND(4,3)
ANAPLASMOSIS TREATMENT(4,2)
BACTERIAL SPECIES(4,2)
BINARY FISSION(4,2)
DIFFERENTIAL CENTRIFUGATION(4,2)
ESTABLISHED INFECTION(4,2)
PROTEIN IDENTIFICATION(4,2)
PROTEOME ANALYSIS(4,2)
PROTEOMIC ANALYSIS(4,2)
RRNA GENE TRANSCRIPT(4,2)
SLEX BLOCK SIALIC ACID(4,2)
SYMPTOM DEVELOPMENT(4,2)
ANTIBODY BLOCKING(4,1)
ANTIGEN FRAGMENT(4,1)
ANTIGENIC POLYPEPTIDE(4,1)
ANTISERUM SPECIFICITY(4,1)
APH DENVED MALTOSE(4,1)
APH OMPA SEQUENCE(4,1)
BACILLUS CHORISMATE(4,1)
BACTERIA PRETREATMENT(4,1)
BACTERIA UPTAKE(4,1)
BILLION DOLLAR(4,1)
BIOTINYLATED BACTERIUM(4,1)
BRACCO DIAGNOSTICS(4,1)
CHINESE HAMSTER OVARY CELL(4,1)
CLARIFIED LYSATE(4,1)
CLINICAL MANIFESTATION(4,1)
COMPOSITION ORAL FORM(4,1)
CONSERVATIVE SUBSTITUTION NATURE(4,1)
CYSTEINE ALKYLATION(4,1)
DEBILITATING INFECTION(4,1)
ELUATE PROTEIN CONCENTRATION(4,1)
EXPRESSION DATA ACCURACY(4,1)
FEBRILE ILLNESS(4,1)
FRESHLY PREPARED IODOACETAMIDE(4,1)
FUNCTIONALLY ESSENTIAL RESIDUE GLYCINE(4,1)
GLYCINE CONSERVATION(4,1)
GLYCOPROTEIN RECEPTOR(4,1)
HEJ FEMALE MOUSE(4,1)
HOMOLOGY ANALOGY RECOGNITION ENGINE(4,1)
HUGE REPERTOIRE(4,1)
IMMUNOACCESSIBLE DOMAIN(4,1)
IMMUNOSORBANT ASSAY(4,1)
INFECTED MOUSE SERUM(4,1)
INFECTION CYCLE KINETICS(4,1)
INTRACELLULAR BACTERIAL PATHOGEN(4,1)
INTRACELLULAR PATHOGEN(4,1)
INTRACELLULAR SIGNALING(4,1)
MAMMALIAN INFECTION(4,1)
MARGINALE EXPRESS(4,1)
MARGINALE ORGANISM(4,1)
MICROBE CONTINUOUS CULTIVATION(4,1)
MINNESOTA UNIVERSITY(4,1)
NATURAL OMPA PROTEIN(4,1)
OMPA FRAGMENT(4,1)
OMPA HOMOLOG(4,1)
PLASMID EXPRESSION VECTOR(4,1)
PRESUMABLY MULTIMERIC COMPLEX(4,1)
PROTEASE CLEAVAGE SITE(4,1)
REINITIATE INFECTION(4,1)
SCAPULARIS TICK(4,1)
SHADED STRETCH(4,1)
SLEX FUCOSE(4,1)
SOUTH AMERICAN CATTLE INDUSTRY(4,1)
STRAIN HZ GENOME(4,1)
TAGGED AMOMPA(4,1)
TRANSMEMBRANE HELIX(4,1)
TRYPSIN LYSATE(4,1)
UNIPROT APH DATABASE(4,1)
UNPUBLISHED OBSERVATION(4,1)
UNSTRUCTURED LINKER(4,1)
WESTERN BLOTTED GST OMPA(4,1)
YALE UNIVERSITY(4,1)
ARGININE(3,3)
CSLEXL(3,3)
FINAL CONCENTRATION(3,3)
IDENTITY REGION(3,3)
LINKED SIALIC ACID(3,3)
WEBSITE(3,3)
ACTIVE INGREDIENT(3,2)
ANTI MOUSE IGG(3,2)
ANTIGENIC REGION(3,2)
BACTERIAL ENTRY(3,2)
CELL DERIVED VACUOLE(3,2)
COMBINED SALIVARY GLAND(3,2)
DECOY DATABASE(3,2)
DIFFERENTIAL EXPRESSION(3,2)
DIFFERENTIAL GENE EXPRESSION(3,2)
HUMAN INFECTION(3,2)
IMMUNODOMINANT EPITOPE(3,2)
KDA BAND(3,2)
OMPA REGION(3,2)
SERA CONTINUED PRESENCE(3,2)
TARGET PROTEIN(3,2)
TRYPSIN TREATMENT(3,2)
VACCINATION(3,2)
AFFINITY CAPTURED DC PROTEIN(3,1)
AFFINITY PURIFIED SAMPLE ALIQUOT(3,1)
AGAROSE BEAD(3,1)
AL APH RECOGNITION(3,1)
ALANINE CODON(3,1)
AMOMPA BEAD(3,1)
ANTI OMPA STAINING(3,1)
ANTIBODY INCUBATION(3,1)
ANTIBODY SECRETION(3,1)
ANTIGEN ADMINISTRATION(3,1)
ANTIGEN MEANING(3,1)
ANTIGENIC PEPTIDE SEQUENCE(3,1)
ANTISERUM CONTINUED PRESENCE(3,1)
AP ORGANISM(3,1)
APH ADHESION(3,1)
APH DC BACTERIUM(3,1)
APH OMPA PROTEIN(3,1)
APH SEQUENCE LISTING(3,1)
APH WHOLE CELL LYSATE(3,1)
APOMPA DOMAIN(3,1)
APPROACH EFFICACY(3,1)
BACTERIA DETECTION(3,1)
BACTERIAL ENGAGEMENT(3,1)
BACTERIAL INTERACTION(3,1)
BACTERIAL INVASION(3,1)
BACTERIAL RECOGNITION(3,1)
BACTERIUM ANTIBODY CAUSE DEATH(3,1)
BACTERIUM PERIPHERY(3,1)
BIOLOGICAL SAMPLE ASSAY(3,1)
BLOOD CONTAMINATED FOMITE(3,1)
BRADFORD ASSAY(3,1)
CANDIDATE ENCODING GENE(3,1)
CATTLE INFECTION(3,1)
CELL ADHESION(3,1)
CELL LYSATE PROTEIN(3,1)
CHEMOTHERAPEUTIC AGENT(3,1)
CHRONIC INFECTION(3,1)
CONSERVED DOMAIN(3,1)
COURSE OIAPH INFECTION(3,1)
CULTURE HARBORING(3,1)
DIAGNOSTIC ASSAY(3,1)
DIAGNOSTIC TARGET(3,1)
DIAGNOSTIC TESTING(3,1)
EARLY STAGE GENE(3,1)
ECONOMIC IMPACT(3,1)
ELUTED PROTEIN(3,1)
ENDOTHELIAL CELL INVASION(3,1)
EPITOPE ACCESSIBILITY(3,1)
EXPRESSION CATEGORY(3,1)
EXTENSIVE APH REPLICATION PERIOD(3,1)
EXTRACELLULAR LOOP(3,1)
EXTRACT INTEGRAL MEMBRANE PROTEIN(3,1)
FIISION PEPTIDE(3,1)
FUSION POLYPEPTIDE(3,1)
GENE ENCODING(3,1)
GENE HOMOLOG(3,1)
GENE IDENTIFICATION(3,1)
GENE TRANSCRIPTION(3,1)
GFP POSITIVE DC ORGANISM(3,1)
GST OMPA INHIBITORY ACTION(3,1)
GST OMPA INTERACTION(3,1)
GST OMPA PURIFICATION(3,1)
GST TAGGED ASP(3,1)
HOMOLOG SEQUENCE LISTING(3,1)
HOST CELL ALIQUOT(3,1)
HOST CELL INVASION(3,1)
HOST INFECTION(3,1)
HTHYMIDINE INCORPORATION(3,1)
HUMAN MYELOID CELL INFECTION(3,1)
HUMIDIFIED ATMOSPHERE(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
HYPOTHETICAL PROTEIN(3,1)
IMMUNOFLUORESCENCE MICROSCOPY ANALYSIS(3,1)
INCOMPLETE GENE(3,1)
INFECTED HOST CELL(3,1)
INFECTION ASSAY(3,1)
INTERMOLECULAR INTERACTION(3,1)
IONIC INTERACTION(3,1)
LATE STAGE GENE(3,1)
LYSINE RESIDUE(3,1)
MAMMALIAN CELL INFECTION(3,1)
MANUFACTURER INSTRUCTION(3,1)
MATCHING FRAGMENT ION(3,1)
MATURE AMOMPA(3,1)
MATURE OMPA(3,1)
MATURE SEQUENCE MODEL(3,1)
MEAN FLUORESCENCE INTENSITY(3,1)
MISSED CLEAVAGE EVENT(3,1)
MOUSE ANTI ASPL(3,1)
MOUSE IGM(3,1)
MS GRADE SOLVENT(3,1)
NAIVE HOST CELL(3,1)
NAIVE MOUSE(3,1)
NASCENT HOST(3,1)
NATIVE PROTEIN(3,1)
NEUTRAVIDIN AFFINITY PURIFICATION(3,1)
OMPA ABILITY(3,1)
OMPA ANTIBODY(3,1)
OMPA CODING REGION(3,1)
OMPA CRITICAL REGION(3,1)
OMPA EXHIBIT(3,1)
OMPA EXPRESSION(3,1)
OMPA SEQUENCE ALIGNMENT(3,1)
OMPA SIALIC ACID INTERACTION(3,1)
OPTIMUM ADHESION(3,1)
ORGANISM PROTECTION(3,1)
OUTER SURFACE PROTEIN(3,1)
PATHOGEN ENTRY(3,1)
PATHOGEN EXHIBIT(3,1)
PATHOGEN PROTEIN REGION(3,1)
PCR MUTAGENESIS(3,1)
PEPTIDE EPITOPE(3,1)
PEPTIDE SERUM(3,1)
PHARMACOLOGICALLY ACCEPTABLE CARRIER(3,1)
PLATINUM PFX DNA POLYMERASE(3,1)
POLYPEPTIDE FRAGMENT(3,1)
POST INFECTION(3,1)
PREDICTED 3D(3,1)
PRETREATING HOST CELL(3,1)
PROTEIN INTERACTION(3,1)
PURIFIED DC ORGANISM(3,1)
PURIFIED POLYPEPTIDE(3,1)
RAT INFECTION(3,1)
RCS TRANSITION(3,1)
REACTIVITY FRACTION(3,1)
RECOMBINANT PEPTIDE(3,1)
RECOMBINANT PROTEIN BLOCKING(3,1)
RECOMBINANT PROTEIN EXPRESSION(3,1)
RECREATIONAL ANIMAL(3,1)
RESOURCE FACILITY(3,1)
RNA EXTRACTION(3,1)
RNA ISOLATION(3,1)
SCAPULARIS CELL(3,1)
SCAPULARIS TRANSMISSION FEEDING(3,1)
SCORING MODEL(3,1)
SEARCH PARAMETER(3,1)
SEQUENCE MULTITUDE(3,1)
SIALIC ACID CONTRIBUTION(3,1)
SIALIDASE TREATMENT(3,1)
SLEX SIALIC ACID RESIDUE(3,1)
SONI CATION(3,1)
SPACER PEPTIDE(3,1)
STRUCTURAL SIMILARITY(3,1)
SYNCHRONOUS INFECTION(3,1)
TANDEM MS PROTEIN ANALYSIS(3,1)
TANDEM REPEAT(3,1)
TARGET MRNA(3,1)
TICK BATCH(3,1)
TICK COLONY(3,1)
TMPRED(3,1)
TREATMENT MODALITY(3,1)
TRUNCATED VERSION(3,1)
TRYPSIN GOLD(3,1)
TRYPSIN SELECTIVITY(3,1)
ULTRASONIC PROCESSOR(3,1)
UNBOUND PROTEIN(3,1)
UNBOUND RECOMBINANT PROTEIN(3,1)
UNTRANSFECTED CHO CELL(3,1)
UNVACCINATED HOST(3,1)
UREA LYSIS BUFFER(3,1)
VACCINE INDUCED DISEASE RISK(3,1)
VACUOLE FORMATION(3,1)
VARIABLE METHIONINE OXIDATION(3,1)
VEHICLE TREATED APH ORGANISM(3,1)
VIRAL VECTOR(3,1)
WESTERN BLOTTING(3,1)
HL 60 CELL INFECTION(2,12)
AMV(2,5)
GENE SPECIFIC PRIMER(2,5)
PROLINE(2,5)
BODY FLUID(2,4)
CONSENSUS SEQUENCE(2,3)
PRIMARY SEQUENCE(2,3)
CALMODULIN(2,2)
COVERSLIP(2,2)
DEER(2,2)
DENSE CORED(2,2)
EXCIPIENT(2,2)
HEMAGLUTININ(2,2)
HYDROPHOBIC AMINOACID(2,2)
INFECTION COURSE(2,2)
MIDGUT(2,2)
NEGATIVELY CHARGED AMINOACID(2,2)
NEUTROPHIL(2,2)
POSITIVELY CHARGED AMINOACID(2,2)
PREDICTED TERTIARY STRUCTURE(2,2)
PREVENTION(2,2)
PROTEIN RATIO(2,2)
RECOMBINANT PROTEIN PRESENCE(2,2)
REDUCING INFECTION(2,2)
SUBSPECIE(2,2)
THIOREDOXIN(2,2)
UNIPROT SOURCE(2,2)
AMMONIUM BICARBONATE BUFFER(2,1)
AMPLITUDE SETTING(2,1)
ANTI OMPA SERUM(2,1)
ANTIGENIC SEQUENCE(2,1)
ANTISERA PRODUCTION(2,1)
APH DC PROTEIN(2,1)
APH ENGAGEMENT(2,1)
APH OUTER MEMBRANE(2,1)
AUXILIARY SUBSTANCE(2,1)
BACTERIA FILLED ORGANELLE(2,1)
BACTERIAL ACCESS(2,1)
BACTERIAL INFECTION PERCENT(2,1)
BANDING PATTERN COMPARISON(2,1)
BLOCK AP ADHESION(2,1)
CHEMICAL DOMAIN(2,1)
CLONING(2,1)
CLOSELY RELATED BACTERIUM FAMILY(2,1)
CLOSELY RELATED EHRLICHIA SPECIES(2,1)
CODING SEQUENCE(2,1)
COMPOSITION ADMINISTRATION(2,1)
COMPOSITION PROTEIN SEQUENCE(2,1)
DC ADHESION(2,1)
DETECTABLE EXPRESSION SIGNAL(2,1)
DETECTION REAGENT(2,1)
DIATRIZOATE(2,1)
DIFFERENTIAL APH GENE EXPRESSION(2,1)
DIGESTED SAMPLE(2,1)
DISEASE TRANSMISSION CHAIN(2,1)
ELECTRONIC SEQUENCE LISTING(2,1)
ENDOTHELIAL CELL MARKER(2,1)
ENZYME REMOVAL(2,1)
EUKARYOTIC CELL MEMBRANE(2,1)
EXPRESSION SITE(2,1)
FILE NAME(2,1)
FISHER CHEMICAL(2,1)
FREE PROTEASE INHIBITOR(2,1)
GEL SLURRY(2,1)
GENE CONVERSION(2,1)
IMMUNOGENIC RESPONSE(2,1)
INDEPENDENT INTERACTION(2,1)
INFECTION STAGE(2,1)
INSECT CELL(2,1)
LINEAR POLYPEPTIDE MIXTURE(2,1)
LINKER INSERTION MUTATION LOCATION(2,1)
MAL II LECTIN(2,1)
MID STAGE GENE EXPRESSION(2,1)
MILK PRODUCTION DECREASE(2,1)
MINIMUM PRECURSOR ION INTENSITY(2,1)
NATIVE SEQUENCE(2,1)
OMPA PRESENCE(2,1)
OUTER MEMBRANE PROTEIN CANDIDATE(2,1)
OVERLAPPING DOMAIN(2,1)
PAPER REMAINDER(2,1)
PATIENT SERUM(2,1)
PEPTIDE CHAIN(2,1)
PH BUFFERING(2,1)
PHENYLMETHYLSULFONYL FLUORIDE(2,1)
PRECISE ROLE(2,1)
PRIMARY ANTIBODY(2,1)
PROTEIN COMPLEX(2,1)
PROTEIN RECOGNITION(2,1)
RADIOIMMUNOPRECIPITATION ASSAY(2,1)
RECOMBINANT DNA TECHNOLOGY(2,1)
RECOMBINANT PROCESSING PROCEDURE ARTIFACT(2,1)
RECOMBINANT PROTEIN SEQUENCE(2,1)
RESEARCH TOOL(2,1)
RESPONSIVENESS(2,1)
SAMPLE MAJORITY(2,1)
SAMPLE REMAINDER(2,1)
SECONDARY ANTIBODY(2,1)
SEQUENCE ALTERATION(2,1)
SHORT PEPTIDE SEQUENCE ENCODING(2,1)
SOLUBILITY DECREASE(2,1)
SONICATED SAMPLE(2,1)
SUB OPTIMAL INFECTION(2,1)
SUPERNATANT REMOVAL(2,1)
SYNTHETIC PEPTIDE(2,1)
TANDEM MASS SPECTROMETER(2,1)
UNINFECTED INDIVIDUAL(2,1)
Z COLONY(2,1)
ABORTION(1,1)
ADHERENT(1,1)
ADHESIN FUNCTION(1,1)
ADJUNCT(1,1)
ADJUVANT(1,1)
ADMINISTRATION MODE(1,1)
ALHYDROGEL(1,1)
AMIDATION(1,1)
AMINOACID CONTIGUOUS CHAIN(1,1)
AMINOACID SEQUENCE IDENTITY(1,1)
AMINOACID SUBSTITUTION(1,1)
ANAPLASMATACEAE FAMILY MEMBER(1,1)
ANTIBIOTIC(1,1)
ANTIBODY SYNTHESIS(1,1)
ANTIGENIC AMINOACID SEQUENCE(1,1)
ANTIGENIC DETERMINANT(1,1)
ANTIGENICITY(1,1)
APH DC ORGANISM SURFACE BIOTINYLATION(1,1)
APH PSGL L INTERACTION(1,1)
BACTERIA FAMILY MEMBER(1,1)
BACTERIAL TICK CELL INTERACTION(1,1)
BLOCKADE(1,1)
BOVINE ANAPLASMOSIS RESULT(1,1)
CELL FREE APH ORGANISM(1,1)
CELL PREPARATION(1,1)
CELLULAR PROLIFERATION(1,1)";"Analysis of biological materials
Pharmaceuticals";Open
2016-01-06;"CN105641693         A  2016-06-08 [CN105641693]
STG: (A) Published application
AP : 2016CN-0007177 2016-01-06";73262268;CN105641693         A  2016-06-08 [CN105641693];2016CN-0007177;;"CHINA INSTITUTE OF VETERINARY DRUGS CONTROL
SPIRIT JINYU BIOLOGICAL PHARMACEUTICAL";"CHINA INSTITUTE OF VETERINARY DRUGS CONTROL
SPIRIT JINYU BIOLOGICAL PHARMACEUTICAL";;;2;"LANG HONGWU
LIU GUOYING
WU HUAWEI
FAN XIULI
HAO XUEBIN
Envy the East Fort
GAO JINYUAN
CHEN XIAOCHUN
DENG YONG
LIU DAN";;;"(CN105641693)
Preparation method of combined bovine viral diarrhea(BVD)/mucosal disease-infectious bovine rhinotracheitis(IBR) inactivated vaccine";"(CN105641693)
The invention relates to a combined bovine viral diarrhoea(BVD)-infectious bovine rhinotracheitis(IBR) inactivated vaccine and a preparation method thereof. According to the combined BVD-IBR inactivated vaccine provided by the invention, a method adaptive to microcarrier suspension culture cells MDBK(Madin-Darby Bovine Kidney) is adopted for reproducing BVDV NMG virus and IBRV LY virus. The method can well culture virus on cells cultured by the microcarrier, and solves the problems that the virus solution has carrier loss, non-uniform virus inoculation and even a nontoxic value with higher valence in the process of reproducing virus by the microcarrier cultured cells, the TCID50 is greater than 7.5, the microcarrier loss amount is small, cell growth is uniform, so the method is worth popularization and application.";"(CN105641693)
1. One bovine viral diarrhea/mucosal disease-infectious bovine rhinotracheitis duplex inactivated vaccines, characterized in that the vaccine contains inactivated bovine viral diarrhea/mucosal disease virus (BVDV) NMG strains and infectious bovine rhinotracheitis virus (IBRV) strain LY.
2. One bovine viral diarrhea/mucosal disease in double infectious bovine rhinotracheitis - of an inactivated vaccine production method according to claim 1, characterized in this method are:
As IBRVLY BVDVNMG strains of viruses and virus strains respectively (1) produced by kind of poison viral antigen vaccine is prepared through cell proliferation obtained;
Two viral (2) antigens were mixed in proportions formulated into an aqueous phase was inactivated;
Mixed with oil (3) is emulsified in duplex inactivated vaccine.
3. Mucosal disease - one bovine viral diarrhea/infectious bovine rhinotracheitis in double production of inactivated vaccines method according to claim 1, characterized in wherein BVDVNMG strain viruses and infectious bovine rhinotracheitis virus IBRVLY MDBK cells are passaged virus strain was used propagated.
4. Claim 2 A, 3 A Bovine Viral Diarrhea/mucosal disease in double infectious bovine rhinotracheitis - of an inactivated vaccine production method, characterized in which the viral antigen is respectively two viruses MDBK cells for passage through the bioreactor carrier is suspended Neurtrinos obtained after multiplication.
5. One bovine viral diarrhea/mucosal disease in double infectious bovine rhinotracheitis - of an inactivated vaccine production method according to claim 4, characterized in CytodexI micro carrier to be used therein.";"(CN105641693)
The present invention relates to a bovine viral diarrhea-infectious bovine rhinotracheitis duplex inactivated vaccines and its production method.
At the same time, the present invention there is provided a Bovine Viral Diarrhea/mucosal disease virus, infectious bovine rhinotracheitis virus accommodate a micro carrier suspension culture cells MDBK of a method.
The present invention relates to a bovine viral diarrhea/mucosal disease-infectious bovine rhinotracheitis duplex inactivated vaccine production method.";"(CN105641693)
Virus infection after a calf, may be latent in the nervous system, cause infections become are intermittent, persistent, and the disease bovine be long-term or life-long strip virus.
This method solves the cultured cell proliferation Bovine Viral Diarrhea/micro carrier mucosal disease virus, infectious bovine rhinotracheitis virus solution process presents a carrier loss, slow cell growth on microcarriers, a micro carrier cell growth on a non-uniform, serum did not clean, non-uniformity resulted in problems such as undesirable or even without drug price and the drug price.";"A61K-039/215
A61K-039/265
A61K-039/295
A61P-031/14
A61P-031/22";"(CN105641693)
1. One bovine viral diarrhea/mucosal disease-infectious bovine rhinotracheitis duplex inactivated vaccines, characterized in that the vaccine contains inactivated bovine viral diarrhea/mucosal disease virus (BVDV) NMG strains and infectious bovine rhinotracheitis virus (IBRV) strain LY.";"(CN105641693)
BOVINE VIRAL DIARRHEA(100,41)
INFECTIOUS BOVINE RHINOTRACHEITIS(100,19)
INACTIVATED VACCINE PRODUCTION(100,9)
INACTIVATED VACCINE(100,5)
INFECTIOUS BOVINE RHINOTRACHEITIS DUPLEX(100,5)
POISON VIRAL ANTIGEN VACCINE(31,1)
SUSPENSION CULTURE CELL(27,3)
DISEASE BOVINE(27,1)
DUPLEX INACTIVATED VACCINE(26,8)
DRUG PRICE(25,3)
MICROCARRIER(24,12)
SERUM NEUTRALIZING ANTIBODY TITER(23,10)
MICROCARRIER VIRUS(23,2)
CULTURED CELL PROLIFERATION(22,1)
VIRUS VECTOR CELL PROLIFERATION(22,1)
VIRUS TITER(20,2)
MICROCARRIER CELL GROWTH(20,1)
STRIP VIRUS(20,1)
VIRUS(18,24)
MUCOSAL DISEASE VIRUS(18,4)
ADAPTIVE MICROCARRIER(17,2)
CYTODEXI MICROCARRIER(17,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(15,55)
MICROBIOLOGICAL CULTURE(15,9)
STRAIN(14,26)
BIOREACTOR CARRIER(14,3)
VIRUS INFECTION(13,1)
CELL GROWTH(12,3)
CALF(12,1)
VACCINE(11,12)
CARRIER LOSS(11,2)
MICROCARRIER LOSS(11,2)
UNIFORM CELL GROWTH(11,2)
PRICE(11,1)
DRAINAGE OUTLET(10,10)
INFECTION(10,2)
NASAL SWAB(9,4)
COW NASAL CHALLENGE(9,2)
MULTIPLICATION(9,2)
SUSPECTED INFECTED CATTLE(9,2)
CHINESE ANIMAL PHARMACOPEIA COMMITTEE(9,1)
DISEASE COLORADO CATTLE FATTENING(9,1)
DOUBLE PRODUCTION(9,1)
BORN CALF SERUM(8,2)
BVDV ANTIGEN NEGATIVE AGED(8,2)
FLAVIVIRUS GENUS PESTIVIRUS(8,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(8,1)
SERUM(7,10)
GLUCOSE MEDIUM(7,8)
HEALTHY CATTLE SENSE(7,3)
FETAL BOVINE SERUM(7,2)
FOREIGN VIRAL CONTAMINATION(7,2)
HEALTHY FEMALE GUINEA PIG(7,2)
INJECTION VACCINE IMMUNIZATION(7,2)
LUOYANG HEN(7,2)
VACCINE INDUCED DEATH INJECTION(7,2)
VISCOUS HOMOGENEOUS EMULSION(7,2)
BOVINE RHINOTRACHEITIS SYMPTOM(7,1)
BVDV NEUTRALIZING ANTIBODY(7,1)
DENSE MONOLAYER TYPSINIZATION(7,1)
VIRAL REGRESSION VISCOUS SECRETION(7,1)
VIRULENT VIRUS STRAIN CHALLENGE(7,1)
AQUEOUS PHASE(6,5)
ANTIBODY ASSAY(6,4)
VACCINE SUBCUTANEOUS INJECTION(6,4)
POPULARIZATION(6,3)
VIRUS UNIFORM SEEDING(6,3)
CELL VIRUS INOCULATION(6,2)
EMULSIFYING ADJUVANT(6,2)
INACTIVATED SHOOT(6,2)
PALE PINK APPEARANCE(6,2)
BIOREACTOR SUSPENSION CULTURE PROPAGATION(6,1)
VIRULENT STRAIN VACCINE(6,1)
VIRUS INACTIVATION(6,1)
APPENDIX(5,7)
BOVINE CHALLENGED GROUP(5,3)
CONFLUENT CELL(5,3)
VIRAL PROPAGATION(5,3)
ANIMAL TESTED BVDV(5,2)
BOVINE VIRULENCE(5,2)
BVDV SERUM(5,2)
BVDV STRAIN(5,2)
CELL BOVINE KIDNEY(5,2)
FLUORESCENT ANTIBODY(5,2)
GUINEA PIG BVDV(5,2)
ADHERENT CULTURE EXPANDING(5,1)
AMERICAN VETERINARY ASSOCIATION(5,1)
BIOREACTOR BVDV(5,1)
BOVINE BVDV ONSET(5,1)
BOVINE FETAL SPLEEN(5,1)
BOVINE NASAL FLU(5,1)
GASTROINTESTINAL ULCER(5,1)
IBRVGB GENE FRAGMENT(5,1)
KILLED BUILT SEEDLING(5,1)
POST CHALLENGE DETOX(5,1)
POST INOCULATION ADSORPTION(5,1)
SOUTH STREET MANAGEMENT(5,1)
STEPWISE SPINNER FLASK(5,1)
STRAIN POISON ATTACK(5,1)
TH CENTURY YEAR(5,1)
VETERINARY PHARMACOPEIA(5,1)
VIRULENT CHALLENGE STRAIN(5,1)
VIRUS PROPAGATION STRAIN(5,1)
ZHONGGUANCUN HAIDIAN(5,1)
ZHOU TAI IMPACT(5,1)
STIRRING SPEED(4,9)
DISSOLVED OXYGEN CONTENT(4,6)
DISSOLVED OXYGEN SATURATED SOLUTION(4,6)
EDETIC ACID SOLUTION DIGESTION(4,6)
ROTATABLE FILTER(4,6)
RESUSCITATION(4,4)
CONTAINER MICROCARRIER(4,3)
ISOLATED STRAIN(4,3)
SEEDING CELL(4,3)
STIRRING BLADE(4,3)
BIOREACTOR CELL CULTURE(4,2)
FULL IMMUNE BOVINE(4,2)
MILKY WHITE(4,2)
NOSTRIL DROP(4,2)
PHYSICOCHEMICAL DETECTION(4,2)
VIRAL PARTICLE(4,2)
VIRUS ISOLATION(4,2)
BIOREACTOR CULTURE(4,1)
CAPSULAR SAC(4,1)
CHINESE AGRICULTURE(4,1)
CLASSICAL BVDV(4,1)
DAM ABORTION(4,1)
EPIDEMIOLOGICAL FINDING(4,1)
INACTIVATED ANTIGEN DETECTION(4,1)
ISOLATED SINGER STRAIN(4,1)
MIN QUANTITATIVE DISPENSING(4,1)
MYCOPLASMA BROTH(4,1)
NECROTIC RHINITIS(4,1)
NERVOUS SYSTEM(4,1)
OCULAR CONJUNCTIVITIS PRESENCE(4,1)
OCULAR SYMPTOM(4,1)
OCULAR TACKING(4,1)
PURULENT SECRETION(4,1)
QUBING VENOM(4,1)
REED MUENCH(4,1)
RESPIRATORY SYMPTOM(4,1)
VACCINE SYSTEMIC REACTION(4,1)
CHINA GENERAL(3,9)
ELISA(3,8)
WASHING(3,6)
BOTTLE(3,5)
HEAD PROTECTION(3,3)
MESH STAINLESS STEEL(3,3)
MICRO BARRIER CARRIER(3,3)
STERILE TEST(3,3)
STIRRING STOP(3,3)
ANTIGEN PREPARATION(3,2)
APPARENTLY LOCAL REACTION INJECTION(3,2)
CELL FLASK(3,2)
CENTRIFUGE TUBE(3,2)
DETECTION DISPLAY PURITY(3,2)
DRAIN OUTLET(3,2)
MICROCARRIER CELL(3,2)
NECK MUSCLE INJECTION(3,2)
ORAL DROP(3,2)
RT PCR(3,2)
STERILE GROWTH(3,2)
TEST EFFICACY(3,2)
ANIMAL REGRESSION(3,1)
ANTIGEN VIRAL CONTENT(3,1)
BATCH VOLUME DISPENSING(3,1)
BLACK RHINO(3,1)
BOVINE HERPES VIRUS(3,1)
BOVINE OCCURRENCE(3,1)
BOVINE ONSET(3,1)
BOVINE VIRUS(3,1)
BVDV DEVELOPMENT(3,1)
CASITONE AGAR MEDIUM(3,1)
CATTLE HEALTH(3,1)
CATTLE SERUM SAMPLE(3,1)
CELL SHEDDING CULTURE(3,1)
CHRONIC MUCOSAL DISEASE(3,1)
CLEAN PIPETTE(3,1)
CLINICAL SYMPTOM(3,1)
CLOSING POISON(3,1)
CULTURE COMPLETION(3,1)
DIARRHEA MAIN SYMPTOM(3,1)
EMULSIFICATION TANK(3,1)
EMULSION DISPENSING(3,1)
EXISTENT VISCOSITY(3,1)
FREEZE THAW(3,1)
IMMUNE CHALLENGED GROUP(3,1)
INACTIVATED ANTIGEN MIXTURE(3,1)
INACTIVATED PRODUCT INSPECTION(3,1)
INACTIVATED VIRUS FLUID(3,1)
INACTIVATION COMPLETION(3,1)
ISOLATED KMLE(3,1)
JILIN LI(3,1)
MICROBIAL RESOURCE INFORMATION(3,1)
MICROCARRIER BIOREACTOR(3,1)
MICROCARRIER SUSPENSION CULTURE(3,1)
PEOPLE REPUBLIC(3,1)
PERSISTENT INFECTION(3,1)
PRODUCT LABEL ALIQUOT(3,1)
REPORTER VIRUS(3,1)
SEASON DIVISION(3,1)
SECURITY CHECK(3,1)
SECURITY VERIFICATION(3,1)
STANDARD MALE SERUM NEUTRALIZATION(3,1)
STRAIN REQUIREMENT(3,1)
THERMO CORPORATION(3,1)
VACCINE ANTIGEN(3,1)
VACCINE FINAL INSPECTION(3,1)
VACCINE PREPARATION(3,1)
VACCINE STRAIN(3,1)
VECTOR SUSPENSION CULTURE(3,1)
VIRAL DIARRHEA(3,1)
VIRAL GROWTH REACTOR(3,1)
VIRULENT INFECTIOUS DISEASE CONTACT(3,1)
VIRUS INOCULUM SOLUTION STRAIN(3,1)
BVDV GROUP(2,2)
CARRIER SELECTION(2,2)
CLOUD SHAPED DIFFUSION(2,2)
CONDENSATION(2,2)
CULTURE PERIOD(2,2)
CYTODEXI(2,2)
DISCHARGED MIXTURE(2,2)
MEDIUM LITER(2,2)
MLBVDV(2,2)
MLIBRV(2,2)
POLYMERIZATION(2,2)
STRAIN PRODUCTION(2,2)
ALREADY PUBLISHED GENE(2,1)
BIOREACTOR MEDIUM(2,1)
BOVINEVIRALDIARRHEAVIRUS(2,1)
BVDV FEATURE(2,1)
CELL MAJORITY(2,1)
CELL OBSERVATION(2,1)
CELL PROPORTION(2,1)
CO EMULSIFIED DISPENSING(2,1)
CONJUNCTIVAL HYPEREMIA(2,1)
CONTENT BVDV(2,1)
CONTINUOUS INACTIVATION(2,1)
CULTURING CELL(2,1)
DETOXIFICATION PERIOD LAST(2,1)
DETOXIFICATION PERIOD MONITORING DISPLAY(2,1)
EFFICACY TEST AVERAGE MEET(2,1)
FOLD SERIAL DILUTION SOLUTION(2,1)
GENBANK SEQUENCE(2,1)
GENERATION CREATION CELL(2,1)
INACTIVATED SAMPLE(2,1)
MAINTENANCE MEDIUM REPLACEMENT(2,1)
MICROCARRIER CULTURED CELL(2,1)
MICROCARRIER TECHNOLOGY(2,1)
OFFICIAL REPORT ANIMAL DISEASE(2,1)
PASSAGED CELL(2,1)
PEPTONE MEDIUM(2,1)
PURIFIED ANTIGEN SOLUTION(2,1)
SEEDING DENSITY(2,1)
SPECIALTY CHEMICAL(2,1)
STERILE DETECTION(2,1)
STIRRED REACTOR(2,1)
VACCINE PRODUCTION(2,1)";Pharmaceuticals;Open
"2015-07-22
2016-07-22";"CA2993076           A1 2017-01-26 [CA2993076]
STG: (A1) Application laid open
AP : 2016CA-2993076 2016-07-22
WO2017011919        A1 2017-01-26 [WO201711919]
STG: (A1) Published application with search report
AP : 2016WO-CA50864 2016-07-22
WO2017011918        A1 2017-01-26 [WO201711918]
STG: (A1) Published application with search report
AP : 2016WO-CA50863 2016-07-22
US20190030153       A1 2019-01-31 [US20190030153]
STG: (A1) Application published
AP : 2016US-15746770 2016-07-22
FD :  Provisional Appl: US62/195,581 FDD=2015-07-22 [2015US-62195581]
FD : Provisional Appl: US62/195,602 FDD=2015-07-22 [2015US-62195602]";75209339;"CA2993076           A1 2017-01-26 [CA2993076]
WO2017011919        A1 2017-01-26 [WO201711919]
WO2017011918        A1 2017-01-26 [WO201711918]
US20190030153       A1 2019-01-31 [US20190030153]";"2015US-62195581
2015US-62195602
2016US-15746770
2016WO-CA50864";"(US20190030153)
WO2017011919
(CA2993076)
WO2017011919";"INT LIVESTOCK RESEARCH INSTITUTE
INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE
INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE ILRI
KENYA AGRICULTURE & LIVESTOCK RESEARCH ORGANIZATION
KENYA AGRICULTURE & LIVESTOCK RESEARCH ORGANIZATION KALRO
UNIVERSITY OF SASKATCHEWAN";"UNIVERSITY OF SASKATCHEWAN
INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE
KENYA AGRICULTURE & LIVESTOCK RESEARCH ORGANIZATION";"(US20190030153)
KE; CA
(WO201711919)
KE; CA
(WO201711918)
CA
(CA2993076)
KE; CA";"(US20190030153)
NAME=UNIVERSITY OF SASKATCHEWAN , CITY=Saskatoon , COUNTRY=CA 

NAME=KENYA AGRICULTURE AND LIVESTOCK RESEARCH ORGANIZATION (KALRO) , CITY=NAIROBI , COUNTRY=KE 

NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE (ILRI) , CITY=NAIROBI , COUNTRY=KE 

(WO201711919)
NAME=UNIVERSITY OF SASKATCHEWAN 120 Veterinary Road Saskatoon, Saskatchewan S7N 5E3 , POSTCODE=S7N 5E3 , COUNTRY=CA 

NAME=KENYA AGRICULTURE AND LIVESTOCK RESEARCH ORGANIZATION (KALRO) PO Box 57811, Kaptagat Road, Loresho Nairobi, 00200 , POSTCODE=00200 , COUNTRY=KE 

NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE (ILRI) PO Box 30709 Nairobi, 00100 , POSTCODE=00100 , COUNTRY=KE 

(WO201711918)
NAME=UNIVERSITY OF SASKATCHEWAN 120 Veterinary Road Saskatoon, Saskatchewan S7N 5E3 , POSTCODE=S7N 5E3 , COUNTRY=CA 

(CA2993076)
NAME=UNIVERSITY OF SASKATCHEWAN 120 Veterinary Road , CITY=SASKATOON , STATE=S1 , POSTCODE=S7N 5E3 , COUNTRY=CA 

NAME=KENYA AGRICULTURE AND LIVESTOCK RESEARCH ORGANIZATION (KALRO) PO BOX 57811, KAPTAGAT ROAD NAIROBI 00200 , CITY=LORESHO , POSTCODE=00200 , COUNTRY=KE 

NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE (ILRI) PO BOX 30709 00100 , CITY=NAIROBI , POSTCODE=00100 , COUNTRY=KE 
";3;"POTTER ANDREW
GERDTS VOLKER
PEREZ-CASAL JOSE
WANG YEJUN
WESONGA HEZRON
SOI REUBEN
NAESSENS JAN
JORES JOERG";"(US20190030153)
KE; CA";"(US20190030153)
NAME=POTTER Andrew , CITY=Saskatoon , COUNTRY=CA 

NAME=GERDTS Volker , CITY=Saskatoon , COUNTRY=CA 

NAME=PEREZ-CASAL Jose , CITY=Saskatoon , COUNTRY=CA 

NAME=WANG Yejun , CITY=Saskatoon , COUNTRY=CA 

NAME=WESONGA Hezron , CITY=Nairobi , COUNTRY=KE 

NAME=SOI Reuben , CITY=Nairobi , COUNTRY=KE 

NAME=NAESSENS Jan , CITY=Nairobi , COUNTRY=KE 

NAME=JORES Joerg , CITY=Nairobi , COUNTRY=KE 
";"(US20190030153)
Mycoplasma vaccines and uses thereof";"(US20190030153)
Immunogenic proteins comprising Mycoplasma mycoides subsp. mycoides and M. mycoides subsp. capri proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to prevent M. mycoides subsp. mycoides infections are disclosed.";"(CA2993076)
1. An immunogenic protein selected from:
(a) a fusion protein comprising two or more Mycoplasma mycoides proteins selected from M mycoides subsp. mycoides (Mmm) and M mycoides subsp. capri (Mmc) proteins;
(b) an Mmm or Mmc protein or fusion protein conjugated with an immunogenic carrier;
(c) variants of the proteins of (a) and (b); or (d) a protein corresponding to (a) or (b) from another Mycoplasma strain, species or subspecies.
2. The immunogenic protein of claim 1, wherein the Mmm or Mmc protein or fusion protein comprises an Mmm and/orMmc protein listed in Table 1 or Table 4, variants thereof, or the corresponding proteins from another Mycoplasma strain, species or subspecies.
3. The immunogenic protein of either one of claims 1 or 2, wherein the Mmm or Mmc protein or fusion protein comprises (a) a protein comprising the amino acid sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 18, 20, 22, 24, 26 or 28;
(b) an Mmm protein present in the fusion of SEQ ID NO:75;
(c) an Mmm protein present in the fusion of SEQ ID NO:77;
(d) variants of (a), (b) and (c); or (e) the corresponding protein from another Mycoplasma strain, species or subspecies.
4. The immunogenic protein of claim 1, wherein the fusion protein is selected from:
(a) a protein comprising the amino acid sequence of SEQ ID NO:51;
(b) a protein comprising the amino acid sequence of SEQ ID NO:53;
(c) a protein comprising amino acids 927-1421 of SEQ ID NO:75; (d) a protein comprising amino acids 927-1468 of SEQ ID NO:77; (e) variants of (a), (b), (c) and (d); or (f) a fusion protein comprising proteins corresponding to (a), (b), (c) and (d) from another Mycoplasma strain, species or subspecies.
5. The immunogenic protein of claim 1, wherein the Mmm or Mmc protein conjugated with a carrier comprises the amino acid sequence of an Mmm or Mmc protein listed in Table 4.
6. The immunogenic protein of any one of claims 1-5, wherein the carrier is an RTX toxin.
7. The immunogenic protein of claim 6, wherein the carrier is a detoxified leukotoxin molecule.
8. The immunogenic protein of claim 7, wherein the amino acid sequence of the protein conjugate comprises the amino acid sequence of SEQ ID NOS:55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79 or 81, or a variant thereof
9. A composition comprising at least one immunogenic protein according to any one of claims 1-8, and a pharmaceutically acceptable excipient.
10. A composition comprising at least two immunogenic Mycoplasma mycoides subspecies mycoides (Mmm) and/or Mycoplasma mycoides subspecies capri (Mmc) proteins selected from the Mmm and Mmc proteins listed in Tables 1 and 4, immunogenic fragments or variants thereof, or the corresponding Mycoplasma proteins from another Mycoplasma strain, species or subspecies, and a pharmaceutically acceptable excipient.
11. The composition of claim 10, wherein the Mycoplasma proteins are selected from two or more proteins comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28; a protein comprising amino acids 927-1421 of SEQ ID NO:75; a protein comprising amino acids 927-1468 of SEQ ID NO:77; or variants thereof.
12. The composition of either one of claims 10 or 11, comprising three to five Mycoplasma proteins.
13. The composition of either one of claims 10 or 11, comprising four or five Mycoplasma proteins.
14. The composition of any one of claims 10-13, wherein at least one of the proteins is selected from SEQ ID NOS:2, 4, 6, 8 or 10.
15. The composition of any one of claims 10-13, wherein at least one of the proteins is selected from SEQ ID NOS:12, 14, 16, 18 or 20.
16. The composition of any one of claims 10-13, wherein at least one of the proteins is selected from SEQ ID NOS:22, 24, 26 or 28.
17. The composition of any one of claims 10-16, wherein the two or more proteins are provided as a fusion protein.
18. The composition of any one of claims 10-17, wherein one or more of the proteins comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 or 28.
19. The composition of any one of claims 10-18, further comprising an immunological adjuvant.
20. The composition of claim 19, wherein the immunological adjuvant comprises (a) a polyphosphazine; (b) a CpG oligonucleotide or a poly (I:C); and (c) a host defense peptide.
21. A DNA molecule modified for expression in E. coli selected from: SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 or 27; or a DNA sequence that comprises a nucleotide sequence encoding an Mmm protein, wherein the DNA sequence is present in SEQ ID NOS: 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80.
22. A recombinant vector comprising:
(a) one or more DNA molecules according to claim 21; and
(b) control elements that are operably linked to said molecule whereby a coding sequence in said molecule can be transcribed and translated in a host cell.
23. A host cell transformed with the recombinant vector of claim 22.
24. A method of producing a Mycoplasma protein comprising:
(a) providing a population of host cells according to claim 23; and
(b) culturing said population of cells under conditions whereby the protein encoded by the DNA molecule present in said recombinant vector is expressed.
25. A method of treating or preventing a Mycoplasma infection in a vertebrate subject comprising administering a therapeutic amount of the composition of any one of claims 9-20, to the subject.
26. The method of claim 25, wherein the subject is a bovine subject.
27. The method of claim 26, wherein the Mycoplasma infection is contagious bovine pleuropneumonia.
28. Use of an immunogenic composition according to any one of claims 9-20, for treating or preventing a Mycoplasma infection in a vertebrate subject.
29. The use of claim 28, wherein the subject is a bovine subject.
30. The use of claim 29, wherein the Mycoplasma infection is contagious bovine pleuropneumonia.";"(US20190030153)
Also provided is a host cell transformed with the recombinant vector, as well as a method of producing a Mycoplasma protein comprising: (a) providing a population of such host cells; and (b) culturing said population of cells under conditions whereby the protein encoded by the DNA molecule present in said recombinant vector is expressed.
The present invention pertains generally to immunogenic compositions and methods for treating and/or preventing Mycoplasma infection.
In particular, the invention relates to the use of multiple Mycoplasma antigens in subunit vaccine compositions to elicit immune responses against Mycoplasma infections such as contagious bovine pleuropneumonia.
Accordingly, the invention is directed to isolated, immunogenic Mycoplasma proteins, fusions of one or more of these proteins, or conjugates of these proteins with immunogenic carriers and compositions comprising the same.";"(US20190030153)
In some cases it may be necessary to modify the coding sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the proper reading frame.
The vaccines are useful in vertebrate subj ects that are susceptible to Mycoplasma infection, including without limitation, animals such as farm animals, including cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; nondomestic animals such as elk, deer, mink and feral cats; humans; avian species, and other species that are raised for meat or egg production such as, but not limited to, chickens, turkeys, geese, ducks, pheasant, emu and ostrich.
Mycoplasma , belonging to the class Mollicutes, is a bacterium that lacks a cell wall and causes a number of diseases in humans, livestock, domestic animals and birds.
This strategy, however, does not prove realistic in some countries where it is considered too costly and logistically difficult to apply.
Stamping-out is also problematic because CBPP occurs among pastoral communities where movement control is difficult to implement.
Additionally, these vaccines are known to cause severe adverse effects postvaccination (Daleel, E.";"A61K-039/02
A61K-039/385
A61P-031/04
A61P-037/04
C07K-014/30
C07K-019/00
C12N-015/31
C12N-015/62
C12N-015/63
C12N-015/70
C12P-021/02";"(US20190030153)
1 . An immunogenic protein selected from: (a) a fusion protein comprising two or more Mycoplasma mycoides proteins selected from M. mycoides subsp. mycoides (Mmm) and M. mycoides subsp. capri (Mmc) proteins; (b) an Mmm or Mmc protein or fusion protein conjugated with an immunogenic carrier; (c) variants of the proteins of (a) and (b); or (d) a protein corresponding to (a) or (b) from another Mycoplasma strain, species or subspecies.
10 . A composition comprising at least two immunogenic Mycoplasma mycoides subspecies mycoides (Mmm) and/or Mycoplasma mycoides subspecies capri (Mmc) proteins selected from the Mmm and Mmc proteins listed in Tables 1 and 4, immunogenic fragments or variants thereof, or the corresponding Mycoplasma proteins from another Mycoplasma strain, species or subspecies, and a pharmaceutically acceptable excipient.
21 . A DNA molecule modified for expression in E. coli selected from: SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 or 27; or a DNA sequence that comprises a nucleotide sequence encoding an Mmm protein, wherein the DNA sequence is present in SEQ ID NOS: 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80.";"(US20190030153)
FUSION PROTEIN(100,24)
IMMUNOGENIC PROTEIN(100,8)
A DNA MOLECULE(100,2)
A DNA SEQUENCE(100,1)
MYCOPLASMA MYCOIDES SUBSPECIE MYCOIDE(100,1)
MYCOPLASMA VACCINE(100,1)
MYCOIDE SUBSP(76,6)
MYCOPLASMA STRAIN(62,11)
MYCOPLASMA MYCOIDES SUBSPECIE(62,1)
MYCOPLASMA PROTEIN(58,19)
MMC PROTEIN(54,19)
VERTEBRATE SUBJECT(50,3)
MYCOPLASMA MYCOIDES PROTEIN(50,1)
RECOMBINANT VECTOR(47,6)
PROTEIN(43,91)
PASTORAL COMMUNITY(43,1)
IMMUNOGENIC MYCOPLASMA PROTEIN(42,3)
HOST CELL POPULATION(39,2)
NUCLEOTIDE SEQUENCE(39,1)
DNA MOLECULE(37,4)
DETOXIFIED LEUKOTOXIN MOLECULE(35,2)
IMMUNOGENIC FRAGMENT(35,2)
IMMUNOGENIC CARRIER(34,4)
MMM PROTEIN(32,2)
MYCOPLASMA INFECTION(31,10)
PROTEIN VARIANT(31,2)
AVIAN SPECIES(30,1)
MYCOPLASMA ANTIGEN(29,9)
CELL POPULATION(29,2)
EXCIPIENT(27,4)
DOMESTIC MAMMAL(27,2)
FERAL(27,2)
CAPRI PROTEIN(27,1)
SUBSPECIE(26,24)
HOST DEFENSE PEPTIDE(26,2)
MYCOIDE INFECTION(26,2)
CPG OLIGONUCLEOTIDE(24,2)
HOST CELL(20,10)
CONTAGIOUS BOVINE PLEUROPNEUMONIA(20,9)
CODING SEQUENCE(19,16)
VACCINE(19,11)
SEVERE ADVERSE EFFECT POST VACCINATION(18,1)
STRATEGY(18,1)
FUSION(17,31)
MYCOIDE(17,10)
IMMUNOGENIC(17,6)
IMMUNOLOGICAL ADJUVANT(17,3)
LIVESTOCK(17,1)
MYCOPLASMA SPECIES(15,11)
SUBUNIT VACCINE(15,7)
DOMESTIC ANIMAL(15,1)
NON DOMESTIC ANIMAL(14,2)
RECALL ANTIGEN(13,9)
OSTRICH(13,2)
PHEASANT(13,2)
POLYPHOSPHAZINE(13,2)
AMINOACID SEQUENCE(12,74)
IMMUNE RESPONSE(12,11)
MYCOPLASMA(12,6)
BACTERIA(12,4)
BOVINE SUBJECT(12,3)
MEAT(12,1)
MYCOIDE PROTEIN(11,6)
PLASMID PAA(11,6)
CHICKEN(11,3)
BIRD(11,2)
DEER(11,2)
DUCK(11,2)
FARM ANIMAL(11,2)
GOOSE(11,2)
HORSE(11,2)
MINK(11,2)
MYCOPLASMA PROTEIN IMMUNOGENICITY(11,2)
MSC MODIFIED(10,8)
LKTA GENE(10,5)
MMC ANTIGEN(10,5)
ANTIGEN FUSION MOLECULE(10,3)
CARBOXY TERMINUS CONSENSUS(10,2)
ELK(10,2)
EMU(10,2)
TOXIN RTX FAMILY(10,2)
DISEASE(9,11)
CATTLE(9,6)
CBPP(9,4)
DOG(9,3)
GOAT(9,3)
IGG2 TITER(9,3)
PIG(9,3)
SHEEP(9,3)
THERAPEUTIC(9,3)
GENUS MYCOPLASMA SUBSPECIE(9,1)
IMMUNOGENIC LEUKOTOXIN POLYPEPTIDE(9,1)
IMMUNOGENIC MYCOPLASMA MOLECULE DISCOVERY(9,1)
PROPER READING FRAME(9,1)
ANIMAL(8,11)
DNA SEQUENCE(8,11)
IMMUNOLOGICAL RESPONSE(8,7)
WHITE CIRCLE(8,7)
VACCINIA VIRUS(8,3)
FUZED MYCOPLASMA PROTEIN(8,2)
GALLINACEOUS BIRD(8,2)
HOMOGENEOUS ANTIBODY POPULATION(8,2)
KERATOCONJUNCTIVITIS(8,2)
MYCOPLASMA MYCOIDES CLUSTER(8,2)
INFECTIOUS RESPIRATORY PATHOGEN(8,1)
INTRACELLULAR MICROBE DESTRUCTION(8,1)
MYCOPLASMA DISEASE PREVALENCE(8,1)
MYCOPLASMA POLYNUCLEOTIDE ENCODING(8,1)
PLACEBO GROUP(7,10)
CARRIER MOLECULE(7,6)
IGG1 TITER(7,3)
IMMUNOGENIC MOLECULE(7,3)
PBMC PROLIFERATIVE RESPONSE(7,3)
TERM RTX TOXIN(7,3)
BACILLUS SUBTILIS(7,2)
COLI ALPHA HEMOLYSIN(7,2)
MYCOIDE ANTIGEN(7,2)
REPRODUCTIVE DISORDER(7,2)
MMM EXPERIMENTAL CHALLENGE(7,1)
MYCOPLASMA FUSION PROTEIN(7,1)
MYCOPLASMA PROTEIN DISCOVERY(7,1)
PASTEURELLA HAEMOLYTICA LEUKOTOXIN(7,1)
RECOMBINANT LEUKOTOXIN GENE(7,1)
SIGNIFICANT DIFFERENCE(6,16)
BLACK CIRCLE(6,4)
BLACK TRIANGLE(6,3)
EPITOPE MAPPING(6,3)
PLACEBO SI(6,3)
SERUM IGG2 RESPONSE(6,3)
ANTIGEN DEFINITION(6,2)
CYTOPLASMIC DOMAIN(6,2)
NON VIRAL VECTOR(6,2)
TOXIN FAMILY(6,2)
ANTIGEN IMMUNOGENICITY(6,1)
AUTOGRAPHA CALIFORNICA(6,1)
BACTERIAL PLASMID VECTOR(6,1)
BACULOVIRUS EXPRESSION VECTOR(6,1)
CANINE INFECTIOUS RESPIRATORY DISEASE(6,1)
DIGESTED FRAGMENT DETERMINATION(6,1)
DITHIOPYRIDYL PROPIONATE(6,1)
DROSOPHILA MELANOGASTER(6,1)
EXOGENOUS DNA MOIETY(6,1)
EXPERIMENTAL IMMUNOLOGY HANDBOOK(6,1)
EXTRACHROMOSOMAL REPLICATION(6,1)
FOREIGN DNA UPTAKE(6,1)
HANSENULA POLYMORPHA(6,1)
HOST TRANSLATIONAL MACHINERY(6,1)
IMMUNOGENIC PROTEIN ANALOG(6,1)
KLUYVEROMYCE FRAGILIS(6,1)
KLUYVEROMYCE LACTIS(6,1)
LEUKOTOXIN POLYPEPTIDE CARRIER(6,1)
LEUKOTOXIN POLYPEPTIDE SEQUENCE(6,1)
LEUKOTOXIN SHORTENED VERSION(6,1)
LYSINE RESIDUE SUCCINYLATION(6,1)
MMC FUSION PROTEIN(6,1)
MMM ANTIGEN(6,1)
MONOSPECIFIC ANTISERA(6,1)
MYCOIDE FUSION PROTEIN(6,1)
MYCOPLASMA EPITOPE(6,1)
NATIVE MOLECULE CYTOTOXIC CHARACTER(6,1)
NATIVE RTX MOLECULE(6,1)
NON NUCLEOTIDIC BACKBONE(6,1)
PICHIA GUILLERIMONDII(6,1)
PLASMACYTOID LINEAGE(6,1)
POLYNUCLEOTIDE HYBRIDIZATION(6,1)
POLYPEPTIDE POST EXPRESSION MODIFICATION(6,1)
POST CHALLENGE PATHOLOGY(6,1)
PROGRAM COPY MPSRCH PACKAGE(6,1)
RECOMBINANT POLYNUCLEOTIDE EXPRESSION(6,1)
REGARDING MYCOPLASMA ANTIGEN(6,1)
REPLICATION ADENOVIRUS ORIGIN(6,1)
REPLICATION MAMMALIAN ORIGIN(6,1)
ROTAVIRUS POLYPEPTIDE(6,1)
RTX MOLECULE FAMILY(6,1)
RTX POLYPEPTIDE SEQUENCE(6,1)
SACCHAROMYCES CEREVISIAE(6,1)
SMITH HOMOLOGY(6,1)
SMITH LOCAL HOMOLOGY(6,1)
SMITH WATERMAN(6,1)
SOUTHERN HYBRIDIZATION EXPERIMENT(6,1)
SYNTHETIC PEPTIDE MIMOTOPE(6,1)
TEXAS AGRICULTURAL EXPERIMENT(6,1)
TRIMERIC ANTIBODY FRAGMENT CONSTRUCT(6,1)
TROPICAL ANIMAL HEALTH(6,1)
TRIAL(5,13)
ASTERISK(5,6)
CONJUGATE(5,6)
NUCLEIC ACID MOLECULE(5,6)
SYMBOL(5,6)
VALUE MEDIAN(5,6)
SPACER SEQUENCE(5,4)
ACTINOBACILLUS PLEUROPNEUMONIAE(5,3)
CONTROL SEQUENCE(5,3)
FUNCTIONAL FRAGMENT(5,3)
GRAM NEGATIVE BACTERIA(5,3)
PROTECTIVE IMMUNE RESPONSE(5,3)
RECOMBINANT PRODUCTION(5,3)
REGULATORY SEQUENCE(5,3)
SEQUENCE VARIANT(5,3)
STIMULATION INDEX STANDARD DEVIATION(5,3)
VACCINATED GROUP(5,3)
AFFINITY CHROMATOGRAPHY(5,2)
CONSTRUCTING EXPRESSION(5,2)
GENE DELIVERY EXPRESSION VECTOR(5,2)
POLYADENYLATION SEQUENCE(5,2)
RESTRICTION SITE(5,2)
RTX FAMILY MEMBER(5,2)
SERUM IGG1 RESPONSE(5,2)
TANDEM REPEAT(5,2)
VECTOR PAA(5,2)
AEDES AEGYPTI(5,1)
ANNUAL VACCINATION(5,1)
ANTI IDIOTYPE ANTIBODY(5,1)
BACTERIUM MYCOPLASMA(5,1)
BIOMEDICAL RESEARCH FOUNDATION(5,1)
BOMBYX MORI(5,1)
BOVINE PAPILLOMA VIRUS(5,1)
BOVIS INFECTION(5,1)
CANDIDA ALBICANS(5,1)
CANDIDA MALTOSA(5,1)
CATTLE IMMUNIZATION(5,1)
CELL DISPLAYING PEPTIDE ANTIGEN(5,1)
CHINESE HAMSTER OVARY(5,1)
CODON DICTIONARY(5,1)
COMPOSITION MYCOPLASMA PROTEIN(5,1)
CONFORMATIONAL EPITOPE(5,1)
DENOTING MICROORGANISM(5,1)
ETIOLOGICAL ROLE(5,1)
EXQUISITE SPECIFICITY(5,1)
EXTENSIVE VACCINATION PROGRAM(5,1)
HEXAMETHYLENEDIAMINE(5,1)
HOST CELL GENOMIC DNA(5,1)
INFECTION DIAGNOSIS(5,1)
LABORED BREATHING(5,1)
LIFE THREATENING(5,1)
LKT POLYPEPTIDE(5,1)
LUNG COLONIZATION(5,1)
MONKEY KIDNEY CELL(5,1)
MYCOPLASMA BACTERIUM PRESENCE(5,1)
NATIVE LEUKOTOXIN SEQUENCE(5,1)
NATIVE POLYPEPTIDE DELETION(5,1)
NON HUMAN PRIMATE(5,1)
NONINTEGRATED TRANSFERRED DNA(5,1)
NUCLEOTIDE SUBSTITUTION(5,1)
PARENT MONOCLONAL ANTIBODY MOLECULE(5,1)
PICHIA PASTORIS(5,1)
POLYNUCLEOTIDE SEQUENCE MYCOPLASMA(5,1)
POLYPEPTIDE FRAGMENT(5,1)
PURIFYING MOLECULE(5,1)
RESTRICTION ENDONUCLEASE SITE(5,1)
STAPHYLOCOCCAL PROTEIN(5,1)
STREPTOCOCCUS SPP(5,1)
SUBPHYLUM CHORDATUM MEMBER(5,1)
SUSCEPTIBLE ANIMAL TENDON SHEATH(5,1)
TERM LEUKOTOXIN POLYPEPTIDE(5,1)
TOXIN DISPLAY CYTOTOXIC ACTIVITY(5,1)
TRANSCRIPTION PROMOTER(5,1)
TRUNCATED LEUKOTOXIN(5,1)
UNICELLULAR ENTITY(5,1)
CLARITY(4,9)
N TERMINAL METHIONINE(4,9)
ANTIBODY PRODUCTION(4,3)
CLOSELY RELATED INFECTIOUS MYCOPLASMA(4,2)
DISORDER VARIETY(4,2)
MYCOPLASMA BACTERIUM BROAD RANGE(4,2)
MYCOPLASMA INFECTION PREVENTION(4,2)
TERM EPITOPE(4,2)
TRACHEOBRONCHITIS(4,2)
TRANSLATION STOP CODON(4,2)
WHOLE ORGANISM(4,2)
ANTIBODY COMPLEMENT(4,1)
ANTIGEN ANTIBODY(4,1)
ANTIGEN MOLECULE FUSION(4,1)
ANTIGEN PURIFICATION(4,1)
BACTERIOPHAGE T7 RNA POLYMERASE(4,1)
CELL CARCINOMA CELL(4,1)
ELDERLY POPULATION(4,1)
FUNDAMENTAL VIROLOGY(4,1)
GLYCINE SERINE(4,1)
HETEROLOGOUS GENE(4,1)
HYDROPATHY PLOT(4,1)
HYOPNEUMONIA CAUSE ENZOOTIC PNEUMONIA(4,1)
IMMUNIZED HOST(4,1)
IMMUNOGENIC COMPOSITION CONTEXT(4,1)
INFECTED CATTLE(4,1)
INFECTION INHIBITION(4,1)
INITIATION OPTIMIZATION(4,1)
INTACT PATHOGEN CELL(4,1)
INTERNUCLEOTIDE MODIFICATION(4,1)
ISOLATED MYCOPLASMA(4,1)
LIVE ANIMAL INTERNATIONAL TRADE(4,1)
LKT MOLECULE(4,1)
NCBI ACCESSION(4,1)
NCBI DATABASE(4,1)
NEGATIVELY CHARGED LINKAGE(4,1)
NEUTRALIZATION ASSAY(4,1)
NON COVALENT INTERACTION(4,1)
NON HUMAN ANIMAL(4,1)
NUCLEOTIDE SEQUENCE IDENTITY(4,1)
NUMEROUS PROTEIN ANTIGEN(4,1)
OMIGA VERSION(4,1)
PACKAGE SUITE(4,1)
PASSIVE IMMUNITY(4,1)
PCR AMPLIFICATION(4,1)
PENDANT MOIETY(4,1)
PEPTIDE UPTAKE(4,1)
PLASMID PCB(4,1)
PLURAL REFERENT(4,1)
POLYPEPTIDE MOIETY(4,1)
POSITIVELY CHARGED LINKAGE(4,1)
POXVIRUS(4,1)
PROTEIN SEQUENCE ATLAS(4,1)
RECEPTOR MOLECULE(4,1)
RECOMBINANT PROTEIN MULTITUDE(4,1)
REPLICATION ORIGIN(4,1)
SERUM IGG1 IMMUNE RESPONSE(4,1)
SHOW POLYNUCLEOTIDE ENCODING ANTIGEN(4,1)
SYMPTOM ELIMINATION(4,1)
TOLL ACTIVATION(4,1)
TRANSCRIPTION TERMINATION SEQUENCE(4,1)
TRANSFECTED DNA(4,1)
TRANSFERRED REPLICON EXPRESSION(4,1)
TRANSFORMED ORGANISM(4,1)
TRICHOPLUSIA NI(4,1)
UNCHARGED LINKAGE(4,1)
VIABLE OPTION(4,1)
MMM PROTEIN PRESENT(3,4)
VET(3,4)
ARTHRITIS(3,3)
BOOST(3,3)
CONTIGUOUS AMINOACID RESIDUE(3,3)
CURRENT EDITION(3,3)
INCUBATION(3,3)
MASTITIS(3,3)
ANTIGENIC DETERMINANT(3,2)
BIOCHEMISTRY(3,2)
BRONCHIOLITIS(3,2)
CHEMICAL SYNTHESIS(3,2)
CHEMOKINE(3,2)
HETEROLOGOUS SIGNAL SEQUENCE(3,2)
INTERNAL DELETION(3,2)
ION EXCHANGE CHROMATOGRAPHY(3,2)
METHYLATION(3,2)
N TERMINAL TRUNCATION(3,2)
N TERMINUS(3,2)
NATIVE SIGNAL SEQUENCE(3,2)
OTITIS(3,2)
PASSIVE IMMUNIZATION(3,2)
PELVIC INFLAMMATORY DISEASE(3,2)
PHARYNGITIS(3,2)
SIGNAL PEPTIDE(3,2)
STANDARD PURIFICATION(3,2)
STREPTOMYCES(3,2)
SYNOVITIS(3,2)
AFFECTED COUNTRY(3,1)
ALTERED ANTIBODY(3,1)
AMINOACID SPATIAL CONFORMATION(3,1)
AMINOALKLYPHOSPHORAMIDATE(3,1)
AMINOALKYLPHOSPHOTRIESTER(3,1)
ANOMERIC NUCLEIC ACID(3,1)
ANTI VIRALS(3,1)
ANTIBODY LINKED DNA(3,1)
ANTIGENIC PROTEIN REGION(3,1)
ATTENUATED STRAIN(3,1)
BACTERIAL EXPRESSION(3,1)
BACTERIAL HOST(3,1)
BIOLOGICAL MACROMOLECULE ABSENCE(3,1)
BIOLOGICAL SAMPLE(3,1)
BIOTECHNOLOGY INFORMATION(3,1)
CARRIER PARTICLE(3,1)
CARRIER POLYPEPTIDE(3,1)
CATTLE PRODUCTION(3,1)
CELL DISRUPTION(3,1)
CELL LYSATE(3,1)
CELL LYSIS(3,1)
CELLULAR DEBRIS(3,1)
CHIMERA EXPRESSION(3,1)
CHIMERIC MOLECULE(3,1)
CHOICE MATTER(3,1)
CODING SEQUENCE BOUNDARY(3,1)
CODING SEQUENCE EXPRESSION(3,1)
COLI GRAM NEGATIVE BACTERIUM(3,1)
COLUMN CHROMATOGRAPHY(3,1)
COMPOSITION ADMINISTRATION(3,1)
CONFERRED PROTECTION(3,1)
COVALENT BOND(3,1)
CTL HELP(3,1)
CTL PRODUCTION(3,1)
CYTOKINE PRODUCTION(3,1)
DAYHOFF ED(3,1)
DEFAULT PARAMETER(3,1)
DEFAULT SCORING TABLE(3,1)
DIRECT TRANSCRIPTION(3,1)
DISCRETE ANTIGEN(3,1)
DNA CLONING(3,1)
DNA TRANSFER(3,1)
ENZYME CLEAVAGE(3,1)
ETIOLOGIC AGENT(3,1)
EXPRESSION CASSETTE COMPONENT(3,1)
EXPRESSION REGULATION(3,1)
EXPRESSION VEHICLE(3,1)
FLANKING SEQUENCE(3,1)
FOREIGN GENE(3,1)
GAME BIRD(3,1)
GAP EXTENSION PENALTY(3,1)
GENE TRANSFER VECTOR(3,1)
GENOMIC DNA SEQUENCE(3,1)
GENOMIC SEQUENCE(3,1)
GROWING HOST CELL(3,1)
HIGHLY COMMUNICABLE LUNG DISEASE(3,1)
HIGHLY PREVALENT DISEASE(3,1)
HOMOLOGOUS REGION(3,1)
HOST CELL GROWTH(3,1)
HOST MUTATION(3,1)
HOST ORGANISM(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
HYOSYNOVIA LIFE(3,1)
IMMUNOADSORBENT(3,1)
IMMUNOPRECIPITATION(3,1)
INSERTED DNA(3,1)
INSULATING SUBSTANCE(3,1)
INTERNATIONAL OFFICE(3,1)
KAPLAN ED(3,1)
KDA LKT(3,1)
LINEAR EPITOPE(3,1)
LINKER SEQUENCE(3,1)
LKT SEQUENCE(3,1)
MAJOR CONSTRAINT(3,1)
MAMMAL INNATE IMMUNE(3,1)
MARKER(3,1)
MEMBRANE PROTEIN(3,1)
METHYLPHOSPHONATE(3,1)
MHC MOLECULE(3,1)
MMC POLYNUCLEOTIDE SEQUENCE(3,1)
MOIETY VARIETY(3,1)
MOLECULE ENCODING(3,1)
MONKEY SPECIES(3,1)
MONOCLONAL ANTIBODY PREPARATION(3,1)
MONOCYTE DENDRITIC CELL(3,1)
NATIVE SEQUENCE(3,1)
NEWBORN INDIVIDUAL(3,1)
NON ADAPTIVE IMMUNE RESPONSE CELL(3,1)
NONSPECIFIC EFFECTOR CELL(3,1)
OCULAR DISCHARGE(3,1)
OLD CHILD(3,1)
OLIGODEOXYRIBONUCLEOTIDE(3,1)
ORIGIN VIRTUE(3,1)
OVIPNEUMONIA CAUSE RESPIRATORY INFECTION(3,1)
OXFORD MOLECULAR GROUP(3,1)
PATHOGENIC ORGANISM MOLECULAR FEATURE(3,1)
PATHOGENIC PARTICLE(3,1)
PEPTIDE ATTACHMENT(3,1)
PHOSPHATE OXIDASE(3,1)
PHOSPHORODITHIOATE(3,1)
PHOSPHOROTHIOATE(3,1)
PHYSICAL STIMULUS(3,1)
PIG UPPER RESPIRATORY TRACK(3,1)
POLYDEOXYRIBONUCLEOTIDE(3,1)
POLYPEPTIDE DNA SEQUENCE(3,1)
POLYRIBONUCLEOTIDE(3,1)
POST TRANSLATIONAL PROCESSING(3,1)
PROLIFERATION REACTION(3,1)
PROTECTIVE ANTIGEN(3,1)
PROTEIN PURIFICATION(3,1)
RECOMBINANT HOST CELL(3,1)
REGULATORY COMPOUND PRESENCE(3,1)
REPRESENTATIVE MYCOPLASMA SEQUENCE(3,1)
REPRESENTATIVE SEQUENCE(3,1)
REVERSE VACCINOLOGY(3,1)
RNA HYBRID(3,1)
SAMPLE MAJORITY PERCENT(3,1)
SCHIZOSACCHAROMYCES POMBE(3,1)
SEVERE ECONOMIC LOSS(3,1)
SPODOPTERA FRUGIPERDA(3,1)
STABLE DUPLEX(3,1)
STANDARD ANTIGENICITY(3,1)
STANDARD IMMUNOASSAY(3,1)
STATION BULLETIN(3,1)
STREPTOMYCIN RESISTANT DERIVATIVE(3,1)
SWOLLEN JOINT(3,1)
SYNTHETIC ORIGIN(3,1)
SYSTEMATIC(3,1)
TEMPLATE BEARING(3,1)
TERM ANTIBODY(3,1)
TERM IMMUNOGEN(3,1)
TERM MONOCLONAL ANTIBODY(3,1)
TERM MYCOPLASMA MYCOIDES(3,1)
TERM PEPTIDE(3,1)
TERM TRANSFECTION(3,1)
TRANSCRIBED SEQUENCE(3,1)
TRANSCRIPTION TERMINATION SIGNAL(3,1)
TRANSFECT PLANT CELL(3,1)
TRANSIENT EXPRESSION(3,1)
TRANSLATION TERMINATION SEQUENCE(3,1)
VACCINE VECTOR(3,1)
VECTOR CONSTRUCT(3,1)
WATERMAN ADVANCE(3,1)
WHOLE CATTLE(3,1)
WHOLE IMMUNOGLOBULIN(3,1)
YARROWIA LIPOLYTICA(3,1)
YORK ACADEMY ANNALS(3,1)
ASN(2,3)
CONA(2,3)
COW(2,3)
PANEL TOP(2,3)
YEAST(2,3)
CARBOXYL(2,2)
ABORTION(2,1)
ACETYLATION(2,1)
ACRIDINE(2,1)
ADJUVANT(2,1)
ALIGNED SEQUENCE(2,1)
ALKYL SUBSTITUTED RNA(2,1)
ALKYLATOR(2,1)
ALPHAVIRUS(2,1)
AMINOACID ABBREVIATION(2,1)
AMINOACID KNOWLEDGE(2,1)
AMINOACID RESIDUE POLYMER(2,1)
ANOREXIA(2,1)
ARGININE(2,1)
ASPARAGINE(2,1)
BABY HAMSTER KIDNEY(2,1)
BASE PAIRING(2,1)
BIOINFORMATICS(2,1)
BIOLOGICAL RESPONSE(2,1)
(WO201711919)
FUSION PROTEIN(100,24)
IMMUNOGENIC PROTEIN(100,8)
A DNA MOLECULE(100,2)
A DNA SEQUENCE(100,1)
MYCOPLASMA MYCOIDES SUBSPECIE MYCOIDE(100,1)
MYCOPLASMA MYCOIDES SUBSPECIE(62,1)
MYCOPLASMA STRAIN(61,11)
MMC PROTEIN(55,18)
CONTAGIOUS BOVINE PI(50,2)
MYCOPLASMA PROTEIN(49,19)
MYCOPLASMA MYCOIDES PROTEIN(48,1)
PASTORAL COMMUNITY(45,1)
IMMUNOGENIC MYCOPLASMA PROTEIN(41,3)
PROTEIN(40,92)
MYCOIDE SUBSP(40,2)
ANDM MYCOIDE(39,2)
NUCLEOTIDE SEQUENCE(39,1)
DETOXIFIED LEUKOTOXIN MOLECULE(36,2)
MYCOPLASMA INFECTION(35,13)
IMMUNOGENIC FRAGMENT(35,2)
IMMUNOGENIC CARRIER(34,4)
MMM PROTEIN(32,2)
PROTEIN VARIANT(31,2)
AVIAN SPECIES(30,1)
MYCOPLASMA ANTIGEN(29,9)
VERTEBRATE SUBJECT(29,5)
CPG OLIGONUCLEOTIDE(29,1)
DOMESTIC MAMMAL(28,2)
EXCIPIENT(27,4)
FERAL(27,2)
SUBSPECIE(26,25)
HOST DEFENSE PEPTIDE(26,2)
RECOMBINANT VECTOR(25,6)
DNA MOLECULE(25,4)
IMMUNOGENIC(23,7)
CODING SEQUENCE(19,16)
HOST CELL POPULATION(19,2)
AMINOACID SEQUENCE(18,73)
BOVINE SUBJECT(18,4)
DOMESTIC ANIMAL(18,3)
STRATEGY(18,1)
FUSION(17,31)
IMMUNOLOGICAL ADJUVANT(17,3)
LIVESTOCK(17,1)
MYCOPLASMA SPECIES(16,12)
SUBUNIT VACCINE(15,7)
CONTAGIOUS BOVINE PLEUROPNEUMONIA(15,6)
VACCINE(14,12)
PHEASANT(14,2)
MYCOIDE(13,9)
RECALL ANTIGEN(13,9)
OSTRICH(13,2)
POLYPHOSPHAZINE(13,2)
IMMUNE RESPONSE(12,11)
MYCOPLASMA(12,6)
BACTERIA(12,4)
MEAT(12,1)
MYCOIDE PROTEIN(11,6)
CHICKEN(11,3)
MYCOPLASMA MYCOIDES SUBSP(11,3)
BIRD(11,2)
DEER(11,2)
DUCK(11,2)
FARM ANIMAL(11,2)
GOOSE(11,2)
HORSE(11,2)
MINK(11,2)
MYCOPLASMA PROTEIN IMMUNOGENICITY(11,2)
IKTA GENE(10,5)
MMC ANTIGEN(10,5)
TOXIN FAMILY(10,5)
CARBOXY TERMINUS CONSENSUS(10,2)
ELK(10,2)
EMU(10,2)
SHEEP(10,2)
DISEASE(9,11)
CATTLE(9,6)
DOG(9,3)
GOAT(9,3)
IGG2 TITER(9,3)
IGGL TITER(9,3)
PIG(9,3)
THERAPEUTIC(9,3)
GENUS MYCOPLASMA SUBSPECIE(9,1)
IMMUNOGENIC LEUKOTOXIN POLYPEPTIDE(9,1)
IMMUNOGENIC MYCOPLASMA MOLECULE DISCOVERY(9,1)
PROPER READING FRAME(9,1)
SCHIZO SACCHAROMYCES POMBE(9,1)
ANIMAL(8,11)
DNA SEQUENCE(8,11)
IMMUNOLOGICAL RESPONSE(8,7)
WHITE CIRCLE(8,7)
GRAM NEGATIVE BACTERIA(8,3)
VACCINIA VIRUS(8,3)
ANTIGEN FUSION MOLECULE(8,2)
GALLINACEOUS BIRD(8,2)
HOMOGENEOUS ANTIBODY POPULATION(8,2)
MYCOPLASMA MYCOIDES CLUSTER(8,2)
MYCOPLASMA PROTEIN FUSION(8,2)
COLI GRAM NEGATIVE BACTERIUM(8,1)
INFECTIOUS RESPIRATORY PATHOGEN(8,1)
INTRACELLULAR MICROBE DESTRUCTION(8,1)
MYCOPLASMA DISEASE PREVALENCE(8,1)
SHEEP ANDM CYNO(8,1)
CARRIER MOLECULE(7,6)
IMMUNOGENIC MOLECULE(7,3)
INFECTION PREVENTION(7,3)
BACILLUS SUBTILIS(7,2)
BACTERIUM MYCOPLASMA(7,2)
COLI ALPHA HEMOLYSIN(7,2)
GLYS LINKER(7,2)
HELPER T CELL(7,2)
MYCOIDE ANTIGEN(7,2)
REPRODUCTIVE DISORDER(7,2)
MMM EXPERIMENTAL CHALLENGE(7,1)
MYCOPLASMA POLYNUCLEOTIDE ENCODING(7,1)
MYCOPLASMA PROTEIN DISCOVERY(7,1)
PASTEURELLA HAEMOLYTICA LEUKOTOXIN(7,1)
PSTL RESTRICTION ENDONUCLEASE SITE(7,1)
RECOMBINANT LEUKOTOXIN GENE(7,1)
SUPPRESSOR T CELL ACTIVATION(7,1)
SIGNIFICANT DIFFERENCE(6,16)
PLACEBO GROUP(6,9)
BLACK CIRCLE(6,4)
BLACK TRIANGLE(6,3)
EPITOPE MAPPING(6,3)
PLACEBO SI(6,3)
SERUM IGG2 RESPONSE(6,3)
ANTIGEN DEFINITION(6,2)
CYTOPLASMIC DOMAIN(6,2)
REPLICATION ORIGIN(6,2)
ANTIGEN IMMUNOGENICITY(6,1)
AUTOGRAPHA CALIFORNICA(6,1)
BACTERIAL PLASMID VECTOR(6,1)
BACULOVIRUS EXPRESSION VECTOR(6,1)
BOVINE PAPILLOMA VIRUS(6,1)
CYTOLYTIC T CELL(6,1)
DIGESTED FRAGMENT DETERMINATION(6,1)
DITHIOPYRIDYL PROPIONATE(6,1)
DROSOPHILA MELANOGASTER(6,1)
EXOGENOUS DNA MOIETY(6,1)
EXPERIMENTAL IMMUNOLOGY HANDBOOK(6,1)
EXTRACHROMOSOMAL REPLICATION(6,1)
FOREIGN DNA UPTAKE(6,1)
GENBANK CD TRANSLATION(6,1)
GLUTATHIONE TRANSFERASE(6,1)
HANSENULA POLYMORPHA(6,1)
HOST TRANSLATIONAL MACHINERY(6,1)
IMMUNOGENIC PROTEIN ANALOG(6,1)
KLUYVEROMYCE FRAGILIS(6,1)
KLUYVEROMYCE LACTIS(6,1)
LEUKOTOXIN POLYPEPTIDE CARRIER(6,1)
LEUKOTOXIN POLYPEPTIDE SEQUENCE(6,1)
LEUKOTOXIN SHORTENED VERSION(6,1)
LIVE ATTENUATED STRAIN(6,1)
LYSINE RESIDUE SUCCINYLATION(6,1)
MMC FUSION PROTEIN(6,1)
MMM ANTIGEN(6,1)
MONOSPECIFIC ANTISERA(6,1)
MYCOIDE FUSION PROTEIN(6,1)
MYCOPLASMA ANTIGEN ENCODING(6,1)
MYCOPLASMA ANTIGEN ISOLATION(6,1)
MYCOPLASMA EPITOPE(6,1)
MYCOPLASMA FUSION PROTEIN(6,1)
NATIVE MOLECULE CYTOTOXIC CHARACTER(6,1)
NON NUCLEOTIDIC BACKBONE(6,1)
PICHIA GUILLERIMONDII(6,1)
PLASMACYTOID LINEAGE(6,1)
POLYNUCLEOTIDE HYBRIDIZATION(6,1)
POLYPEPTIDE POST EXPRESSION MODIFICATION(6,1)
POST CHALLENGE PATHOLOGY(6,1)
RECOMBINANT POLYNUCLEOTIDE EXPRESSION(6,1)
REGARDING MYCOPLASMA ANTIGEN(6,1)
REPLICATION ADENOVIRUS ORIGIN(6,1)
ROTAVIRUS POLYPEPTIDE(6,1)
SACCHAROMYCES CEREVISIAE(6,1)
SMITH HOMOLOGY(6,1)
SMITH LOCAL HOMOLOGY(6,1)
SMITH WATERMAN(6,1)
SYNTHETIC PEPTIDE MIMOTOPE(6,1)
TEXAS AGRICULTURAL EXPERIMENT(6,1)
TRANSMEMBRANE LA GLYCEROL(6,1)
TRIMERIC ANTIBODY FRAGMENT CONSTRUCT(6,1)
XRAY CRYSTALLOGRAPHY(6,1)
LTXA(5,13)
TRIAL(5,13)
ASTERISK(5,6)
CONJUGATE(5,6)
NUCLEIC ACID MOLECULE(5,6)
SYMBOL(5,6)
VALUE MEDIAN(5,6)
SPACER SEQUENCE(5,4)
ACTINOBACILLUS PLEUROPNEUMONIAE(5,3)
CONTROL SEQUENCE(5,3)
FUNCTIONAL FRAGMENT(5,3)
PROLIFERATIVE RESPONSE(5,3)
PROTECTIVE IMMUNE RESPONSE(5,3)
RECOMBINANT PRODUCTION(5,3)
REGULATORY SEQUENCE(5,3)
SEQUENCE VARIANT(5,3)
VACCINATED GROUP(5,3)
CONSTRUCTING EXPRESSION(5,2)
GENE DELIVERY EXPRESSION VECTOR(5,2)
POLYADENYLATION SEQUENCE(5,2)
RESTRICTION SITE(5,2)
TANDEM REPEAT(5,2)
VECTOR PAA(5,2)
AEDES AEGYPTI(5,1)
ANNUAL VACCINATION(5,1)
BIOMEDICAL RESEARCH FOUNDATION(5,1)
BOMBYX MORI(5,1)
CANDIDA ALBICANS(5,1)
CANDIDA MALTOSA(5,1)
CATTLE IMMUNIZATION(5,1)
CODON DICTIONARY(5,1)
COMPOSITION MYCOPLASMA PROTEIN(5,1)
CONFORMATIONAL EPITOPE(5,1)
DENOTING MICROORGANISM(5,1)
ETIOLOGICAL ROLE(5,1)
EXQUISITE SPECIFICITY(5,1)
EXTENSIVE VACCINATION PROGRAM(5,1)
HOST CELL GENOMIC DNA(5,1)
INFECTION DIAGNOSIS(5,1)
LABORED BREATHING(5,1)
LIFE THREATENING(5,1)
LUNG COLONIZATION(5,1)
MONKEY KIDNEY CELL(5,1)
MYCOIDE INFECTION(5,1)
MYCOPLASMA BACTERIUM PRESENCE(5,1)
MYCOPLASMA VACCINE(5,1)
NATIVE LEUKOTOXIN SEQUENCE(5,1)
NATIVE POLYPEPTIDE DELETION(5,1)
NONINTEGRATED TRANSFERRED DNA(5,1)
NUCLEOTIDE SUBSTITUTION(5,1)
PARENT MONOCLONAL ANTIBODY MOLECULE(5,1)
PICHIA PASTORIS(5,1)
PLASMID PAALOL(5,1)
POLYPEPTIDE FRAGMENT(5,1)
PURIFYING MOLECULE(5,1)
SHORT TERM IMMUNITY(5,1)
STAPHYLOCOCCAL PROTEIN(5,1)
STREPTOCOCCUS SPP(5,1)
SUBPHYLUM CHORDATUM MEMBER(5,1)
SUSCEPTIBLE ANIMAL TENDON SHEATH(5,1)
T CELL RECEPTOR(5,1)
TOXIN DISPLAY CYTOTOXIC ACTIVITY(5,1)
TRANSCRIPTION PROMOTER(5,1)
TRUNCATED LEUKOTOXIN(5,1)
UNICELLULAR ENTITY(5,1)
WITHM BOVIS(5,1)
CLARITY(4,9)
N TERMINAL METHIONINE(4,9)
ANTIBODY PRODUCTION(4,3)
CLOSELY RELATED INFECTIOUS MYCOPLASMA(4,2)
DISORDER VARIETY(4,2)
KERATOCONJUNCTIVITIS(4,2)
MYCOPLASMA BACTERIUM BROAD RANGE(4,2)
SERUM TGF LEVEL(4,2)
TRACHEOBRONCHITIS(4,2)
TRANSLATION STOP CODON(4,2)
WHOLE ORGANISM(4,2)
ANTIBODY COMPLEMENT(4,1)
ANTIGEN MOLECULE FUSION(4,1)
BACTERIOPHAGE T7 RNA POLYMERASE(4,1)
BOVIS INFECTION(4,1)
DMMC PROTEIN(4,1)
ELDERLY POPULATION(4,1)
FUNDAMENTAL VIROLOGY(4,1)
GLYCINE SERINE(4,1)
HETEROLOGOUS GENE(4,1)
HUMAN HEPATOCELLULAR CARCINOMA CELL(4,1)
HYBRIDIZATION EXPERIMENT(4,1)
HYDROPATHY PLOT(4,1)
HYOPNEUMONIA CAUSE ENZOOTIC PNEUMONIA(4,1)
IMMUNIZED HOST(4,1)
INFECTED CATTLE(4,1)
INITIATION OPTIMIZATION(4,1)
INTACT PATHOGEN CELL(4,1)
INTERNUCLEOTIDE MODIFICATION(4,1)
LIVE ANIMAL INTERNATIONAL TRADE(4,1)
MYCOPLASMA MULTIPLE ANTIGEN(4,1)
NEGATIVELY CHARGED LINKAGE(4,1)
NEUTRALIZATION ASSAY(4,1)
NUCLEOTIDE SEQUENCE IDENTITY(4,1)
NUMEROUS PROTEIN ANTIGEN(4,1)
OMIGA VERSION(4,1)
PACKAGE SUITE(4,1)
PCR AMPLIFICATION(4,1)
PENDANT MOIETY(4,1)
PEPTIDE ANTIGEN(4,1)
PEPTIDE UPTAKE(4,1)
PLASMID PCB(4,1)
PLURAL REFERENT(4,1)
POLYPEPTIDE MOIETY(4,1)
POSITIVELY CHARGED LINKAGE(4,1)
POXVIRUS(4,1)
PROTEIN SEQUENCE ATLAS(4,1)
RECEPTOR MOLECULE(4,1)
RECOMBINANT PROTEIN MULTITUDE(4,1)
REPRESENTATIVE LEUKOTOXIN(4,1)
RESISTANT DERIVATIVE TL SR(4,1)
SHOW POLYNUCLEOTIDE ENCODING ANTIGEN(4,1)
SYMPTOM ELIMINATION(4,1)
TOLL ACTIVATION(4,1)
TRANSCRIPTION TERMINATION SEQUENCE(4,1)
TRANSFECTED DNA(4,1)
TRANSFERRED REPLICON EXPRESSION(4,1)
TRANSFORMED ORGANISM(4,1)
TRICHOPLUSIA NI(4,1)
UNCHARGED LINKAGE(4,1)
VIABLE OPTION(4,1)
MMM PROTEIN PRESENT(3,4)
VET(3,4)
ARTHRITIS(3,3)
BOOST(3,3)
CONTIGUOUS AMINOACID RESIDUE(3,3)
CURRENT EDITION(3,3)
INCUBATION(3,3)
MAMMALIAN(3,3)
MASTITIS(3,3)
ANTIGENIC DETERMINANT(3,2)
BIOCHEMISTRY(3,2)
BRONCHIOLITIS(3,2)
CHEMICAL SYNTHESIS(3,2)
CHEMOKINE(3,2)
GENITALIUM(3,2)
HETEROLOGOUS SIGNAL SEQUENCE(3,2)
INTERNAL DELETION(3,2)
ION EXCHANGE CHROMATOGRAPHY(3,2)
METHYLATION(3,2)
NATIVE SIGNAL SEQUENCE(3,2)
OTITIS(3,2)
PASSIVE IMMUNIZATION(3,2)
PELVIC INFLAMMATORY DISEASE(3,2)
PHARYNGITIS(3,2)
SIGNAL PEPTIDE(3,2)
STANDARD PURIFICATION(3,2)
STREPTOMYCES(3,2)
SYNOVITIS(3,2)
5D SHOW SERUM(3,1)
ACCESSION NOS(3,1)
AFFECTED COUNTRY(3,1)
AFFINITY CHROMATOGRAPHY(3,1)
ALTERED ANTIBODY(3,1)
AMINOACID SPATIAL CONFORMATION(3,1)
AMINOALKLYPHOSPHORAMIDATE(3,1)
AMINOALKYLPHOSPHOTRIESTER(3,1)
ANOMERIC NUCLEIC ACID(3,1)
ANTIBODY LINKED DNA(3,1)
ANTIGENIC PROTEIN REGION(3,1)
BACTERIAL EXPRESSION(3,1)
BACTERIAL HOST(3,1)
BIOLOGICAL MACROMOLECULE ABSENCE(3,1)
BIOLOGICAL SAMPLE(3,1)
BIOTECHNOLOGY INFORMATION(3,1)
CARRIER PARTICLE(3,1)
CARRIER POLYPEPTIDE(3,1)
CATTLE PRODUCTION(3,1)
CELL DISPLAYING PEPTIDE(3,1)
CELL DISRUPTION(3,1)
CELL LYSATE(3,1)
CELL LYSIS(3,1)
CELLULAR DEBRIS(3,1)
CHIMERA EXPRESSION(3,1)
CHIMERIC MOLECULE(3,1)
CHOICE MATTER(3,1)
CODING SEQUENCE BOUNDARY(3,1)
CODING SEQUENCE EXPRESSION(3,1)
COLUMN CHROMATOGRAPHY(3,1)
COMPOSITION ADMINISTRATION(3,1)
CONFERRED PROTECTION(3,1)
COVALENT BOND(3,1)
CTL HELP(3,1)
CTL PRODUCTION(3,1)
CYTOKINE PRODUCTION(3,1)
DAYHOFF ED(3,1)
DEFAULT PARAMETER(3,1)
DEFAULT SCORING TABLE(3,1)
DEOXYRIBOSE(3,1)
DIRECT TRANSCRIPTION(3,1)
DISCRETE ANTIGEN(3,1)
DNA CLONING(3,1)
DNA TRANSFER(3,1)
ENZYME CLEAVAGE(3,1)
ETIOLOGIC AGENT(3,1)
EXPRESSION CASSETTE COMPONENT(3,1)
EXPRESSION REGULATION(3,1)
EXPRESSION VEHICLE(3,1)
FLANKING SEQUENCE(3,1)
FOREIGN GENE(3,1)
GAME BIRD(3,1)
GAP EXTENSION PENALTY(3,1)
GENE TRANSFER VECTOR(3,1)
GENOMIC DNA SEQUENCE(3,1)
GENOMIC SEQUENCE(3,1)
GROWING HOST CELL(3,1)
HIGHLY COMMUNICABLE LUNG DISEASE(3,1)
HIGHLY PREVALENT DISEASE(3,1)
HOMOLOGOUS REGION(3,1)
HOST CELL GROWTH(3,1)
HOST MUTATION(3,1)
HOST ORGANISM(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
HYOSYNOVIA LIFE(3,1)
IMMUNOADSORBENT(3,1)
IMMUNOPRECIPITATION(3,1)
INSULATING SUBSTANCE(3,1)
INTERNATIONAL OFFICE(3,1)
KAPLAN ED(3,1)
LINEAR EPITOPE(3,1)
LINKER SEQUENCE(3,1)
MAJOR CONSTRAINT(3,1)
MAMMAL INNATE IMMUNE(3,1)
MARKER(3,1)
MEMBRANE PROTEIN(3,1)
MEMORY EFFECTOR T CELL(3,1)
MMC POLYNUCLEOTIDE SEQUENCE(3,1)
MOIETY VARIETY(3,1)
MOLECULE ENCODING(3,1)
MOLECULE FAMILY(3,1)
MONKEY SPECIES(3,1)
MONOCLONAL ANTIBODY PREPARATION(3,1)
MONOCYTE DENDRITIC CELL(3,1)
NATIVE SEQUENCE(3,1)
NEWBORN INDIVIDUAL(3,1)
NONSPECIFIC EFFECTOR CELL(3,1)
OCULAR DISCHARGE(3,1)
OLD CHILD(3,1)
ORIGIN VIRTUE(3,1)
OVIPNEUMONIA CAUSE RESPIRATORY INFECTION(3,1)
OXFORD MOLECULAR GROUP(3,1)
PATHOGENIC ORGANISM MOLECULAR FEATURE(3,1)
PATHOGENIC PARTICLE(3,1)
PEPTIDE ANALYSIS(3,1)
PEPTIDE ATTACHMENT(3,1)
PHOSPHATE OXIDASE(3,1)
PHYSICAL STIMULUS(3,1)
PIG UPPER RESPIRATORY TRACK(3,1)
POLYDEOXYRIBONUCLEOTIDE(3,1)
POLYPEPTIDE DNA SEQUENCE(3,1)
POLYRIBONUCLEOTIDE(3,1)
POST VACCINATION(3,1)
PROGRAM PACKAGE(3,1)
PROLIFERATION REACTION(3,1)
PROTECTIVE ANTIGEN(3,1)
PROTEIN PURIFICATION(3,1)
RECOMBINANT HOST CELL(3,1)
REGULATORY COMPOUND PRESENCE(3,1)
REPRESENTATIVE MYCOPLASMA SEQUENCE(3,1)
REPRESENTATIVE SEQUENCE(3,1)
REVERSE VACCINOLOGY(3,1)
RNA HYBRID(3,1)
SAMPLE MAJORITY PERCENT(3,1)
SEVERE ECONOMIC LOSS(3,1)
SPODOPTERA FRUGIPERDA(3,1)
STABLE DUPLEX(3,1)
STANDARD ANTIGENICITY(3,1)
STANDARD IMMUNOASSAY(3,1)
STATION BULLETIN(3,1)
SUBSTITUTED RNA(3,1)
SULFANIDYLPHOSPHONOTHIOATE(3,1)
SWISS PROTEIN(3,1)
SWOLLEN JOINT(3,1)
SYNTHETIC ORIGIN(3,1)
SYSTEMATIC(3,1)
THIOPHOSPHATE(3,1)
TRANSCRIBED SEQUENCE(3,1)
TRANSCRIPTION TERMINATION SIGNAL(3,1)
TRANSFECT PLANT CELL(3,1)
TRANSIENT EXPRESSION(3,1)
TRANSLATION TERMINATION SEQUENCE(3,1)
VACCINE VECTOR(3,1)
VECTOR CONSTRUCT(3,1)
WATERMAN ADVANCE(3,1)
WHOLE CATTLE(3,1)
WHOLE IMMUNOGLOBULIN(3,1)
YARROWIA LIPOLYTICA(3,1)
YORK ACADEMY ANNALS(3,1)
ASN(2,3)
CONA(2,3)
COW(2,3)
DATABASE(2,3)
PANEL TOP(2,3)
STIMULATION INDEX(2,3)
YEAST(2,3)
CARBOXYL(2,2)
ABORTION(2,1)
ACETYLATION(2,1)
ACRIDINE(2,1)
ADJUVANT(2,1)
ALIGNED SEQUENCE(2,1)
ALKYLATOR(2,1)
ALPHAVIRUS(2,1)
AMINOACID ABBREVIATION(2,1)
AMINOACID LINKER(2,1)
ANOREXIA(2,1)
ANTIVIRAL(2,1)
ARGININE(2,1)
BABY HAMSTER KIDNEY(2,1)
BASE PAIRING(2,1)
BIOINFORMATICS(2,1)
BIOLOGICAL RESPONSE(2,1)
BIOTYPE SMALL COLONY(2,1)
CANINE INFECTIOUS RESPIRATORY DISEASE(2,1)
CARBAMATE(2,1)
CAUSE LAMENESS(2,1)
(WO201711918)
IMMUNOGENIC(100,19)
RECOMBINANT VECTOR(100,7)
A DNA MOLECULE(100,4)
IMMUNOGENIC MYCOPLASMA BOVIS PROTEIN(100,1)
IMMUNOGENIC FRAGMENT(78,4)
CONTAGIOUS BOVINE PI(69,2)
BOVIS INFECTION(61,7)
POLYARTHRITIS SYNDROME(60,1)
DNA MOLECULE(59,4)
MOREM BOVIS PROTEIN(54,1)
TRIPLE ADJUVANT FORMULATION(52,2)
MYCOPLASMA INFECTION(51,11)
MYCOPLASMA STRAIN(50,4)
MYCOPLASMA PROTEIN ISOLATION(50,3)
HOST DEFENSE PEPTIDE(49,5)
BOVIS PROTEIN(46,4)
AVIAN SPECIES(42,1)
EXCIPIENT(42,1)
MYCOPLASMA ANTIGEN(40,13)
VERTEBRATE SUBJECT(40,5)
MYCOPLASMA SPECIES(39,13)
IMMUNOLOGICAL ADJUVANT(38,8)
DOMESTIC MAMMAL(38,2)
FERAL(37,2)
LPPB(34,2)
PEPQ(34,2)
POLYPHOSPHAZINE(33,5)
PROTEIN(32,49)
CODING SEQUENCE(31,16)
OPPA(30,3)
SUBSPECIE(29,18)
PDHA(29,3)
DEOB(26,4)
HOST CELL POPULATION(26,2)
CHRONIC PNEUMONIA(26,1)
DOMESTIC ANIMAL(25,3)
HOST CELL(24,10)
BOVINE SUBJECT(24,4)
LIVESTOCK(24,1)
FUSION PROTEIN(23,9)
CONTAGIOUS BOVINE PLEUROPNEUMONIA(22,4)
PEPA(22,1)
SUBUNIT VACCINE(21,7)
IMMUNE RESPONSE(19,22)
VACCINE(19,14)
DISEASE(19,10)
PHEASANT(19,2)
OSTRICH(18,2)
MYCOPLASMA(17,6)
BACTERIA(17,4)
MEAT(17,1)
AMINOACID SEQUENCE(16,31)
CHICKEN(16,3)
GOOSE(16,2)
HORSE(16,2)
MYCOPLASMA PROTEIN IMMUNOGENICITY(16,2)
BIRD(15,2)
DEER(15,2)
DUCK(15,2)
FARM ANIMAL(15,2)
MINK(15,2)
EMULSION(14,9)
IKTA GENE(14,5)
TOXIN FAMILY(14,5)
ANTIGEN FUSION MOLECULE(14,3)
CATTLE(14,3)
CARBOXY TERMINUS CONSENSUS(14,2)
ELK(14,2)
EMU(14,2)
SHEEP(14,2)
TH2 IMMUNE RESPONSE(13,6)
GOAT(13,3)
IGA SERUM TITER(13,2)
POLYPHOSPHAZENES POLYELECTROLYTE(13,2)
GENUS MYCOPLASMA SUBSPECIE(13,1)
PROPER READING FRAME(13,1)
SCHIZO SACCHAROMYCES POMBE(13,1)
BOVIS(12,9)
DOG(12,3)
GRAM NEGATIVE BACTERIA(12,3)
PIG(12,3)
CROSSLINKED POLYPHOSPHAZENES POLYMER MICROPARTICLE(12,1)
IMMUNOGENIC MYCOPLASMA MOLECULE DISCOVERY(12,1)
UNMETHYLATED CPG OLIGONUCLEOTIDE(12,1)
ANIMAL(11,8)
SAMPLING DAY(11,8)
IMMUNOLOGICAL RESPONSE(11,7)
VACCINIA VIRUS(11,3)
GALLINACEOUS BIRD(11,2)
HOMOGENEOUS ANTIBODY POPULATION(11,2)
MYCOPLASMA PROTEIN FUSION(11,2)
COLI GRAM NEGATIVE BACTERIUM(11,1)
INFECTIOUS RESPIRATORY PATHOGEN(11,1)
INTRACELLULAR MICROBE DESTRUCTION(11,1)
MOREM BOVIS ANTIGEN(11,1)
MYCOPLASMA DISEASE PREVALENCE(11,1)
SHEEP ANDM CYNO(11,1)
VALUE MEDIAN(10,12)
IMMUNOGENIC MOLECULE(10,3)
BACILLUS SUBTILIS(10,2)
BACTERIUM MYCOPLASMA(10,2)
COLI ALPHA HEMOLYSIN(10,2)
HELPER T CELL(10,2)
LEUKOTOXIN MOLECULE(10,2)
REPRODUCTIVE DISORDER(10,2)
AGRICULTURAL EXPERIMENT STATION BULLETIN(10,1)
ASM BOVIS INFECTION(10,1)
EXPERIMENTAL BACTERIN VACCINE(10,1)
IMMUNOGENIC MYCOPLASMA PROTEIN(10,1)
MYCOPLASMA POLYNUCLEOTIDE ENCODING(10,1)
MYCOPLASMA PROTEIN DISCOVERY(10,1)
PASTEURELLA HAEMOLYTICA LEUKOTOXIN(10,1)
PSTL RESTRICTION ENDONUCLEASE SITE(10,1)
RECOMBINANT LEUKOTOXIN GENE(10,1)
SUPPRESSOR T CELL ACTIVATION(10,1)
COMPOSITION ADMINISTRATION(9,5)
THL IMMUNE RESPONSE(9,3)
ANITMICROBIAL AGENT REPERTOIRE(9,1)
AUTOGRAPHA CALIFORNICA(9,1)
BOVINE PAPILLOMA VIRUS(9,1)
EXPERIMENTAL IMMUNOLOGY HANDBOOK(9,1)
IMMUNIZING ANTIGEN SUSPENSION(9,1)
KLUYVEROMYCE FRAGILIS(9,1)
LEUKOTOXIN SHORTENED VERSION(9,1)
LYSINE RESIDUE SUCCINYLATION(9,1)
MYCOPLASMA ANTIGEN ENCODING(9,1)
MYCOPLASMA DISEASE PREVENTION(9,1)
NATIVE MOLECULE CYTOTOXIC CHARACTER(9,1)
NON RESORBABLE IMPERMEABLE POLYMER(9,1)
POLYPEPTIDE POST EXPRESSION MODIFICATION(9,1)
PROPHYLACTIC TREATME(...)";Pharmaceuticals;Open
2015-06-01;"CN104928260         A  2015-09-23 [CN104928260]
STG: (A) Published application
AP : 2015CN-0293093 2015-06-01
CN104928260         B  2018-10-23 [CN104928260B]
STG: (B) Granted patent for invention
AP : 2015CN-0293093 2015-06-01";70929414;"CN104928260         A  2015-09-23 [CN104928260]
CN104928260         B  2018-10-23 [CN104928260B]";2015CN-0293093;;SHANDONG NORMAL UNIVERSITY;SHANDONG NORMAL UNIVERSITY;;;1;"WANG HONGMEI
HOU PEILI
HE HONGBIN";;;"(CN104928260B)
Infectious bovine rhinotracheitis virus IBRV-JN03 isolates and uses thereof";"(CN104928260B)
The invention discloses an infectious bovine rhinotracheitis virus IBRV-JN03 isolate and application thereof. The preservation number of the infectious bovine rhinotracheitis virus is CGMCC No.10396 and the infectious bovine rhinotracheitis virus is preserved in the China General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and has relatively high virus titer and good immunogenicity; after calves are immunized by an aluminium hydroxide adjuvant inactivated vaccine prepared through the infectious bovine rhinotracheitis virus, relatively high antibodies are generated, so that the infectious bovine rhinotracheitis virus IBRV-JN03 isolate is a good infectious bovine rhinotracheitis vaccine candidate virus strain. Therefore, an infectious bovine rhinotracheitis diagnostic reagent, inactivated vaccine, attenuated vaccine and genetic engineering vaccine prepared on the basis of the virus can be used for diagnosis and vaccine prevention and control of the endemic infectious bovine rhinotracheitis and a wide market application prospect is realized.";"(CN104928260)
1. A strain infectious bovine rhinotracheitis virus IBRV-JN03 isolate, characterized in, isolated from the infectious bovine rhinotracheitis-prevelence, deposited with the China general microbiological culture collection center, accession number CGMCC No. 10396.
2. Infectious bovine rhinotracheitis virus IBRV-JN03 isolate according to claim 1, characterized in, comprising the nucleotide sequence, the nucleotide sequence as shown in SEQ ID NO:3.
3. Infectious bovine rhinotracheitis virus isolates IBRV-JN03 separation method according to claim 1, characterized in, comprising the steps of:
A. The onset of the sample collected from cattle, treated cells were inoculated MDBK, obtained by aseptic isolation cytopathic strains;
B. To IBR-F and the IBR-R as primers, amplifying PCR method for detecting, separating amplified infectious bovine rhinotracheitis virus strains specific fragments;
C. The isolated strain was added to a suspension of cells MDBK, employing Reed-Muench is calculated using the titer of the isolated strains;
D. Each of the isolated strain of a comparative analysis of immunogenicity: to prepare an inactivated antigen, immunizing mice and rabbits, leading to high levels of antibodies, screening for the best irnniunogenicity, that is obtained.
4. Infectious bovine rhinotracheitis virus IBRV-JN03 isolate in the preparation of vaccine for infectious bovine rhinotracheitis use according to claim 1 and 2, characterized in, infectious bovine rhinotracheitis vaccine is an inactivated whole virus, subunit vaccine, a live attenuated vaccine, or vaccine engineered DNA vaccine.
5. Infectious bovine rhinotracheitis virus isolates IBRV-JN03 preparation infectious bovine rhinotracheitis of an agent for diagnosis according to claim 1 or 2, characterized in: infectious bovine rhinotracheitis virus with a virulent pathogen antigen, antibody and nucleic acid is detected by an associated reagent.";"(CN104928260)
At the same time, the present invention is an infectious bovine rhinotracheitis diagnosis reagent of the foundation for the development.
The present invention relates to the field of biotechnology, in particular to an infectious bovine rhinotracheitis virus IBRV-JN03 strains and the use thereof.
The present invention discloses an infectious bovine rhinotracheitis virus IBRV-JN03 isolate and application thereof.";"(CN104928260)
Sequence analysis indicated that the isolated strain of the respective gene IBRV gB, gC gene, gD gene, on the other strains IBRV rigistration GenBank gE gene with a nucleotide homology of at least 95% or more, indicating that there is a difference IBRV strains, but can be protected from infection of a pandemic strains.";"A61K-039/265
A61P-031/22
C12N-007/00
C12Q-001/686
C12Q-001/70
C12R-001/93
G01N-033/569";"(CN104928260)
1. A strain infectious bovine rhinotracheitis virus IBRV-JN03 isolate, characterized in, isolated from the infectious bovine rhinotracheitis-prevelence, deposited with the China general microbiological culture collection center, accession number CGMCC No. 10396.";"(CN104928260)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,25)
IBRV JN(100,24)
STRAIN(100,17)
ACCESSION NUMBER(100,3)
BOVINE RHINOTRACHEITIS DIAGNOSIS REAGENT(100,2)
BOVINE RHINOTRACHEITIS PREVELENCE(100,1)
CHINA GENERAL MICROBIOLOGICAL CULTURE(100,1)
COLLECTION CENTER(100,1)
GEO DEMOGRAPHIC EPIDEMIC PREVENTION(74,1)
BOVINE RHINOTRACHEITIS VACCINE STRAIN(64,1)
PANDEMIC STRAIN INFECTION(60,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(56,2)
RIGISTRATION GENBANK(49,1)
VIRULENT PATHOGEN ANTIGEN(46,1)
AGENT INFECTIOUS BOVINE RHINOTRACHEITIS(45,1)
GENE ENGINEERING VACCINE(45,1)
NUCLEOTIDE HOMOLOGY(42,1)
ASEPTIC ISOLATION CYTOPATHIC STRAIN(40,2)
INACTIVATED VACCINE ADJUVANT(34,1)
INACTIVATED WHOLE VIRUS(28,1)
ISOLATED STRAIN TITER(27,2)
LIVE ATTENUATED VACCINE(27,1)
ENGINEERED DNA VACCINE(26,1)
GENE ISOLATED STRAIN(24,1)
INACTIVATED ANTIGEN(23,3)
VACCINE PREPARATION(23,1)
GD GENE(22,3)
IMMUNIZED MOUSE(21,2)
FOUNDATION(21,1)
GC GENE(20,4)
COMPARATIVE ANALYSIS ISOLATED STRAIN(19,2)
SAMPLE ONSET(18,2)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVENTION(16,2)
FREEZE THAW CYCLING(15,4)
FRAGMENT(15,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVELENCE(14,1)
BOVINE RHINOTRACHEITIS INACTIVATED VACCINE(13,2)
BOVINE DIARRHEIC STOOL SAMPLE(12,2)
SUBUNIT VACCINE(12,2)
BOVINE RHINOTRACHEITIS VACCINE CANDIDATE(12,1)
BOVINE TISSUE ONSET(11,3)
BIOTECHNOLOGY FIELD(11,1)
BOVINE RHINOTRACHEITIS CLINICAL ONSET(11,1)
COMPETITIVE BLOCKING HIPRA ESPAIIA(11,1)
REAGENT(10,4)
HERPES VIRUS PARTICLE MORPHOLOGY(10,3)
IMMUNOGENICITY COMPARATIVE ANALYSIS(10,3)
TREATED CELL(10,3)
DRUG(10,2)
AMPLIFICATION PCR(10,1)
MICROORGANISM MICROBIOLOGICAL CULTURE COLLECTION(10,1)
VACCINE CANDIDATE IMMUNOGENICITY(10,1)
GENE(9,4)
FETAL BOVINE SERUM(9,2)
VECTOR VACCINE(9,2)
APPLICATION PROSPECT(9,1)
BOVINE RHINOTRACHEITIS VACCINE DEVELOPMENT(9,1)
REED MUENCH COPOLAR(9,1)
BOVINE ROTAVIRUS(8,2)
CAPSULAR SAC(8,2)
PHYLOGENETIC TREE(8,2)
PLAQUE PURIFICATION ROUND(8,2)
INFECTIOUS BOVINE RHINOTRACHEITIS PREPARATION(8,1)
PATHOGENIC PATHOGEN ANTIGEN(8,1)
CIRCULATING PCR REACTION(7,3)
DOWNSTREAM PRIMER(7,3)
UPSTREAM PRIMER(7,3)
CDNA TEMPLATE(7,2)
FOLD SERIAL DILUTION(7,2)
FOREIGN VIRUS DETECTION(7,2)
VIRUS PROPAGATION(7,2)
AMPLIFIED VIRAL IBRV JN(7,1)
BOVINE NASAL SECRETION ONSET(7,1)
CHRONOSTRATIGRAPHIC CENTURY(7,1)
INACTIVATED VACCINE BATCH INOCULATION(7,1)
INACTIVATED VIRAL FLUID INOCULATION(7,1)
INFECTIOUS DISEASE PREVENTION(7,1)
INSTRUCTION MINIBEST VIRAL DNA(7,1)
INSTRUCTION MINIBEST VIRAL RNA(7,1)
RNASE INHIBITOR RNA(7,1)
STRAIN VIRUS PARTICLE MORPHOLOGY(7,1)
TAIL BLED WEEKLY(7,1)
VACCINE CANDIDATE STRAIN(7,1)
HORSE SERUM(6,2)
SHANGHAI BIOLOGICAL ENGINEERING CO(6,2)
XPCR BUFFER(6,2)
AMPLIFICATION GC GENE(6,1)
BEIJING CHAOYANG DISTRICT HOSPITAL(6,1)
BOVINE NASAL SWAB SAMPLE(6,1)
CHALLENGE VIRUS STRAIN(6,1)
GENE GE GD(6,1)
IBRV GENE GC(6,1)
IMMUNIZATION MOUSE ANTIBODY ANALYSIS(6,1)
NEGATIVE STAIN ELECTRON MICROSCOPY(6,1)
PALE BROWN SUSPENSION HOMOGENEITY(6,1)
RABBIT IMMUNE ANTIBODY(6,1)
SCREENED IRNNIUNOGENICITY(6,1)
STERILE TIP PICKED PLAQUE(6,1)
TRANSPARENT BOTTLE BROILER(6,1)
VACCINE VIRALLY INACTIVATED PREPARATION(6,1)
VIRUS CULTURE BROTH(6,1)
VIRUS IMMUNOGENICITY(6,1)
VIRUS RNA EXTRACTION(6,1)
WORLD ANIMAL HEALTH ORGANIZATION(6,1)
VACCINE PRODUCTION(5,3)
AGRICULTURE DEPARTMENT(5,1)
ALUMINUM HYDROXIDE ADJUVANT VACCINE(5,1)
ANTIBODY NEGATIVE HEALTHY CALF(5,1)
ANTIBODY NEUTRALIZATION(5,1)
ANTIBODY TITER(5,1)
BLOCKING ELISA DETECTION(5,1)
BOVINE HERPES VIRUS(5,1)
BOVINE SERUM CULTURE MEDIUM(5,1)
BROAD MARKET PROSPECT(5,1)
CHINA GENERAL CHINESE ACADEMY(5,1)
CLINICAL ABNORMALITY(5,1)
CONSERVED SEQUENCE GD GENE(5,1)
CULTURE INCUBATOR(5,1)
CYTOPATH PHENOMENON(5,1)
DISSEMINATED DISEASE(5,1)
EXOGENOUS VIRUS DETECTION(5,1)
EXPERIMENT GROUPING(5,1)
FOREIGN VACCINE INLET(5,1)
FUNCTIONAL GB GENE(5,1)
GENE AMPLIFICATION GE PCR(5,1)
GENETICALLY ENGINEERED VACCINE(5,1)
IMMUNE ANTIBODY DETECTION(5,1)
IMMUNE CATTLE(5,1)
IMMUNE SUPPRESSION(5,1)
IMMUNIZING ANIMAL EXPERIMENT(5,1)
IMMUNOGENICITY STRAIN(5,1)
INACTIVATION COMPLETION(5,1)
INFECTION INOCULUM(5,1)
ISOLATED STRAIN EXPANDED CULTURE(5,1)
ISOLATED VIRUS STRAIN(5,1)
LIVE VACCINE(5,1)
MOUSE INOCULATION(5,1)
NATIONAL COMMITTEE(5,1)
PARTICULATE LESION(5,1)
PCR DETECTION PRIMER(5,1)
PRELIMINARY DIAGNOSIS(5,1)
PREVALENT STRAIN REGION(5,1)
QUBING VENOM(5,1)
RT PCR CDNA(5,1)
RT PCR DETECTION(5,1)
RT PCR KIT(5,1)
STRONG TARGETED DIAGNOSIS(5,1)
TEMPLATE DNA(5,1)
VIRAL SUPERNATANT(5,1)
VIRAL TITER DETERMINATION(5,1)
VIRUS CHARACTERIZATION(5,1)
VIRUS POLYMERASE CHAIN REACTION DETECTION(5,1)
VIRUS STRAIN PCR DETECTION(5,1)
WHOLE VIRUS INACTIVATED VACCINE(5,1)
BLIND TRANSFER(4,3)
DENATURATION(4,3)
GENBANK(4,3)
DETECTION PURITY(4,2)
SEQUENCING ANALYSIS(4,2)
BCOV DETECTION(4,1)
CATTLE INDUSTRY PRODUCTION(4,1)
CELL GENERATION INACTIVATION(4,1)
CELL INOCULATION(4,1)
CHINESE MARKET(4,1)
CLONING VECTOR(4,1)
CONCEPT REQUIREMENT(4,1)
CONTINUOUS CULTURE VIRUS(4,1)
DILUTION PLUS(4,1)
DISEASE OCCURRENCE(4,1)
DNA VACCINE(4,1)
DOMESTIC STRAIN(4,1)
ELECTRON MICROSCOPE OBSERVATION(4,1)
ENZYME LA(4,1)
FOLD DILUTION(4,1)
GENE TYPING(4,1)
GIANT CELL NUCLEUS(4,1)
H INCOME POISON(4,1)
HARVESTED CELL CULTURE VIRUS(4,1)
IMMUNE PROTECTION(4,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(4,1)
ISOLATED STRAIN INDUCED CYTOPATH(4,1)
MINIBEST VIRAL RNA DNA(4,1)
POST VACCINATION(4,1)
REPRESENTATIVE STRAIN(4,1)
RNA VIRUS(4,1)
SAMPLE RNA EXTRACTION(4,1)
SERUM ANTIBODY(4,1)
TREATMENT CELL MONOLAYER(4,1)
VIRUS DILUTION(4,1)
VIRUS DOSE(4,1)
VIRUS GENERATION(4,1)
VIRUS GENOME(4,1)
VIRUS IDENTIFICATION(4,1)
VIRUS INACTIVATED LIQUID(4,1)
WEST ROAD(4,1)
WHOLE VIRUS ASSAY(4,1)
WIDESPREAD DISEASE(4,1)
BOVINE VIRAL DIARRHEA VIRUS(3,6)
ANNEALING TEMPERATURE(3,2)
BOOSTER IMMUNIZATION(3,2)
BOVINE ENTEROVIRUS(3,2)
CONTROLLED THERMAL CYCLER(3,2)
PENICILLIN(3,2)
STERILE TEST(3,2)
STERILIZATION(3,2)
STREPTOMYCIN(3,2)
BLOOD SAMPLE(3,1)
BOVINE RHINOTRACHEITIS VACCINE APPLICATION(3,1)
CELL CULTURE SUPERNATANT(3,1)
CELL DISEASE(3,1)
CELL SUSPENSION GROWTH(3,1)
CELL VIRUS(3,1)
CLINICAL SAMPLE VARIETY(3,1)
COPPER GRID(3,1)
CYTOPATHIC CONDITION(3,1)
ECONOMIC BENEFIT(3,1)
ECONOMIC LOSS(3,1)
EXCESS VIRAL SUSPENSION REMOVAL(3,1)
FORMALDEHYDE FINAL CONCENTRATION(3,1)
GE GENE SEQUENCE ANALYSIS(3,1)
H INACTIVATION TREATMENT(3,1)
HOMOLOGY ANALYSIS(3,1)
INFECTED CELL(3,1)
INITIAL IMMUNIZATION(3,1)
LESION PRESENCE(3,1)
MILK HERD ECONOMIC VALUE(3,1)
NEUTRALIZING ANTIBODY LEVEL(3,1)
PLAQUE FORMATION(3,1)
PRIMER SEQUENCE(3,1)
PROPER DILUTION(3,1)
PURE CULTURE(3,1)
SECONDARY BACTERIAL INFECTION(3,1)
SEVERE RESPIRATORY TRACT DISEASE(3,1)
STERILIZED WATER BALANCE(3,1)
SYNTHESIZING(3,1)
TUNGSTEN SOLUTION DROP(3,1)
VIRUS CONTENT MEASUREMENT(3,1)
VIRUS DISTRIBUTION UNIFORMITY(3,1)
VIRUS FLUID(3,1)
XGC BUFFER(3,1)
(CN104928260B)
IBRV JN(100,25)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,21)
STRAIN(100,17)
ACCESSION NUMBER(100,3)
CHINA GENERAL MICROBIOLOGICAL CULTURE(100,3)
COLLECTION CENTER(100,3)
DEPOSITION(100,2)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVELENCE(100,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(80,4)
SHANGHAI MICROBIAL INSTITUTE(69,1)
VIRUS NORTH STAR ROAD(65,1)
BOVINE RHINOTRACHEITIS VACCINE CANDIDATE(61,2)
INFECTIOUS BOVINE RHINOTRACHEITIS DIAGNOSIS(53,2)
ANTIBODY INACTIVATION CALF(53,1)
BOVINE RHINOTRACHEITIS DIAGNOSIS REAGENT(52,2)
IMMUNOGENIC STRONG IBRV(51,1)
GENETICALLY ENGINEERED VACCINE(48,2)
ANTIGEN VACCINE PRODUCTION(39,1)
BROAD MARKET PROSPECT(37,1)
MICROBIOLOGICAL CULTURE COLLECTION(37,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(35,1)
VACCINE DEVELOPMENT(35,1)
DISEASE OCCURRENCE(34,1)
ALUMINUM HYDROXIDE ADJUVANT VACCINE(32,2)
CATTLE INDUSTRY(32,1)
CLASSIFICATION NAME(32,1)
WHOLE VIRUS INACTIVATED VACCINE(30,1)
JUSTICE CHINA GENERAL(29,1)
LIVE ATTENUATED VACCINE(23,2)
DRUG(22,2)
DISTRICT HOSPITAL(22,1)
IMMUNOGENIC GOOD(19,1)
REGIONAL POPULAR PREVENTION CONTROL(19,1)
URGENT NEED(16,1)
ACCESSION(14,3)
BOVINE RHINOTRACHEITIS INACTIVATED VACCINE(13,2)
SPANISH HIPRA IBRV GB(13,1)
BOVINE TISSUE ONSET(12,3)
SEPARATE STRAIN(12,2)
SUBUNIT VACCINE(12,2)
IBRV ISOLATED STRAIN(11,3)
BOVINE DIARRHEA STOOL SAMPLE(11,2)
FREEZE THAW CYCLING(11,2)
IBRV GENBANK(11,2)
VACCINE CANDIDATE STRAIN(11,2)
BIOTECHNOLOGY FIELD(11,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVENTION(11,1)
TCID(10,8)
CAPSULAR SAC(10,3)
VIRUS PARTICLE MORPHOLOGY(10,3)
VECTOR VACCINE(9,2)
ANTIGENIC IBRV SUPERNATANT(9,1)
BOVINE RHINOTRACHEITIS VACCINE DEVELOPMENT(9,1)
CULTURED MONOLAYER PROLIFERATION(9,1)
CULTURING INCOME POISON(9,1)
IBRV IMMUNOGENICITY STRAIN(9,1)
IMMUNOGENIC VACCINE CANDIDATE(9,1)
BOVINE ROTAVIRUS(8,2)
CHINA PANDEMIC STRAIN(8,1)
CREATION TOPATHIC PHENOMENON(8,1)
FOREIGN IBRV VACCINE(8,1)
GENETIC EVOLUTIONARY TREE(8,1)
IBRV GB COMPETITION(8,1)
IMMUNE ANTIBODY ASSAY CALF(8,1)
IMMUNIZATION MOUSE ANTIBODY ASSAY(8,1)
KITINSTRUCTIONS RT PCR(8,1)
PATHOGENIC PATHOGEN ANTIGEN(8,1)
RABBIT IMMUNE ANTIBODY ASSAY(8,1)
CO2 CULTURE(7,3)
DOWNSTREAM PRIMER(7,3)
PCR CYCLING(7,3)
THERMAL CYCLER(7,3)
UPSTREAM PRIMER(7,3)
ANTIBODY NEUTRALIZATION(7,2)
FOLD SERIAL DILUTION(7,2)
FOREIGN VIRUS DETECTION(7,2)
FORMVAR MEMBRANE(7,2)
INACTIVATED ANTIGEN(7,2)
PLAQUE PURIFICATION(7,2)
AMPLIFIED VIRAL IBRV JN(7,1)
BOVINE NASAL SECRETION ONSET(7,1)
CLINICAL ABNORMALITY(7,1)
CO CONTAINING POST SOLIDIFICATION(7,1)
CO2 INCUBATOR CULTURING(7,1)
GC GENE AMPLIFICATION(7,1)
GENE CLADOGRAM TYPING ANALYSIS(7,1)
IBRV PCR DETECTION PRIMER(7,1)
INFECTION EPIDEMIC STRAIN(7,1)
REED MUENCH CALCULATION(7,1)
REVACCINATION MDBK CELL(7,1)
TITER VIRUS STRAIN(7,1)
VIRUS ASSAY TITER(7,1)
WHOLE VIRUS INACTIVATING VACCINE(7,1)
GENE GC(6,3)
STERILE DEIONIZED WATER(6,3)
CDNA TEMPLATE(6,2)
EXTRACTION KIT(6,2)
HORSE SERUM(6,2)
SEED VIRUS(6,2)
VIRUS PROPAGATION(6,2)
XPCR BUFFER(6,2)
AGRICULTURE DEPARTMENT(6,1)
CATTLE POPULATION(6,1)
CHINA PROVINCE(6,1)
CLINICAL BOVINE NASAL SECRETION(6,1)
COMPARATIVE ANALYSIS IMMUNOGENIC STRAIN(6,1)
CYCLING CELL CYTOTOXICITY(6,1)
FETAL BOVINE SERUM(6,1)
GC GENE STRAIN(6,1)
GENBANK HOMOLOGY(6,1)
GENE AMPLIFICATION GE PCR(6,1)
HERD FINISHING(6,1)
IBRV FORMALDEHYDE(6,1)
IBRV INACTIVATED VACCINE DEVELOPMENT(6,1)
IBRV JNDN IBRV(6,1)
IBRV LESION(6,1)
IMMUNIZED CALF(6,1)
INACTIVATED FORMALDEHYDE(6,1)
INACTIVATED IBRV(6,1)
INACTIVATED VACCINE CALF(6,1)
INCOME PURE CULTURE(6,1)
ISOLATED CYTOPATHIC STRAIN(6,1)
LA TAQ ENZYME(6,1)
NVSL CHALLENGE(6,1)
PARTICULATE LESION INFECTED CELL(6,1)
QUBING VENOM(6,1)
RABBIT INOCULATED MOUSE(6,1)
RT PCR PRIMER(6,1)
TITER ISOLATED STRAIN(6,1)
TOPATHIC MDBK CELL(6,1)
VACCINE VIRUS STRAIN(6,1)
VIRAL TITER(6,1)
VIRUS CHARACTERIZATION(6,1)
VIRUS GB GENE(6,1)
VIRUS INOCULATION(6,1)
VIRUS RNA EXTRACTION(6,1)
WORLD ANIMAL HEALTH ORGANIZATION(6,1)
CELL MONOLAYER(5,2)
COMPETITION ELISA DETECTION(5,2)
ANTIBODY TITER(5,1)
BOVINE DIAGNOSIS(5,1)
BOVINE HERPES VIRUS(5,1)
BOVINE ONSET(5,1)
CELL SUSPENSION CONFLUENCE(5,1)
CHINESE MARKET(5,1)
CONSERVED SEQUENCE GD GENE(5,1)
DIAGNOSTIC ANTIGEN(5,1)
DISSEMINATED DISEASE(5,1)
DROPWISE PIPET(5,1)
FAST CREATION ANTIBODY(5,1)
FOLD DILUTED VIRUS(5,1)
FOREIGN VACCINE INLET(5,1)
GENETICALLY ENGINEERED DNA VACCINE(5,1)
GRAY BROWN HOMOGENEOUS SUSPENSION(5,1)
HUGE ECONOMIC LOSS(5,1)
IBRV GENE(5,1)
IBRV INLET(5,1)
IBRV WHOLE VIRUS ANALYSIS(5,1)
IMMUNOGENIC COMPARATIVE ANALYSIS(5,1)
INACTIVATED VACCINE LOT(5,1)
INACTIVATION COMPLETION(5,1)
INTERNATIONAL CATTLE(5,1)
MINIBEST VIRAL DNA(5,1)
MINIBEST VIRAL RNA(5,1)
NASAL SWAB SAMPLE(5,1)
OVERSEAS MAIN IMMUNIZATION(5,1)
PLAQUE PURIFIED IBRV(5,1)
PRELIMINARY DIAGNOSIS(5,1)
PREVENTION EFFECTIVENESS(5,1)
RT PCR DETECTION(5,1)
SEVERE RESPIRATORY ILLNESS(5,1)
SYNTHESIZED CDNA(5,1)
VIRAL POLYMERASE CHAIN REACTION DETECTION(5,1)
VIRAL SUPERNATANT(5,1)
VIRUS ANTIBODY(5,1)
VIRUS GENOME(5,1)
VIRUS ISOLATION(5,1)
DENATURATION(4,3)
FINAL EXTENSION(4,3)
SIMPLEX(4,3)
DETECTION PURITY(4,2)
SEQUENCING ANALYSIS(4,2)
AMPLIFIED DNA(4,1)
AMPLIFIED FRAGMENT(4,1)
BCOV DETECTION(4,1)
BIOENGINEERED TECHNOLOGY CO(4,1)
BULL NOSE(4,1)
BVDV DETECTION(4,1)
CDNA SYNTHESIS(4,1)
CLONING VECTOR(4,1)
CULTURE BROTH(4,1)
DIFFERENCE IBRV STRAIN(4,1)
DMEM CULTURE MEDIUM(4,1)
ELISA DETERMINATION(4,1)
EXTRACTED RNA SAMPLE(4,1)
GENE GD(4,1)
HARVESTED CELL CULTURE VIRUS(4,1)
IBR R PCR AMPLIFICATION(4,1)
IBRV DETECTION(4,1)
IBRV PARTICLE(4,1)
IMMUNOLOGICALLY IGG ANTIBODY LEVEL(4,1)
INDUSTRY PRODUCTION TRADING(4,1)
MOUSE IMMUNE(4,1)
OLD IBRV(4,1)
PLAQUE STERILE TIP(4,1)
POLY INTEGRATED BUNCH(4,1)
POST BOOST(4,1)
PROCESSED MDBK CELL(4,1)
STRONG RELEVANCE(4,1)
TEMPLATE DNA(4,1)
TH CENTURY(4,1)
TOPATHIC CELL(4,1)
TRANSPARENT BOTTLE(4,1)
VIRAL BLIND(4,1)
VIRAL PARTICLE(4,1)
VIRUS CULTURE MEDIUM(4,1)
VIRUS DILUTION(4,1)
VIRUS IDENTIFICATION(4,1)
VIRUS SOLUTION ADSORPTION(4,1)
PBS(3,4)
ANNEALING TEMPERATURE(3,2)
BHV(3,2)
BLIND PASS(3,2)
BOVINE CORONAVIRUS(3,2)
BOVINE ENTEROVIRUS(3,2)
BOVINE VIRAL DIARRHEA VIRUS(3,2)
CULTURE SOLUTION(3,2)
MEMBRANE FILTER(3,2)
PENICILLIN(3,2)
STERILIZATION(3,2)
STREPTOMYCIN(3,2)
SUPERNATANT LIQUID(3,2)
ANTIBODY NEGATIVE HEALTH(3,1)
BEV DETECTION(3,1)
BREAKING TOOL(3,1)
CELL CULTURE INCUBATOR(3,1)
CELL CULTURE SUPERNATANT(3,1)
CLINICAL SAMPLE VARIETY(3,1)
COPPER GRID(3,1)
DETECTION REAGENT(3,1)
DMEM CELL MAINTENANCE MEDIUM(3,1)
DMEM INJECTION VOLUME(3,1)
EXCESS VIRUS SUSPENSION REMOVAL(3,1)
FECAL SAMPLE(3,1)
GE GENE SEQUENCE ANALYSIS(3,1)
IBRV CELL CULTURE(3,1)
IMMUNOSUPPRESSION(3,1)
INACTIVATION TREATMENT(3,1)";"Analysis of biological materials
Pharmaceuticals";Open
"2015-04-09
2016-04-08";"GB201506004         D0 2015-05-27 [GB201506004]
STG: (D0) Patent application filed
AP : 2015GB-0006004 2015-04-09
WO2016/162845       A1 2016-10-13 [WO2016162845]
STG: (A1) Published application with search report
AP : 2016WO-IB52008 2016-04-08
IL254970            A  2017-12-31 [IL-254970]
STG: (A) Application of patent for invention
AP : 2017IL-0254970 2016-04-08
EP3280438           A1 2018-02-14 [EP3280438]
STG: (A1) Application published with search report
AP : 2016EP-0718476 2016-04-08";69736478;"GB201506004         D0 2015-05-27 [GB201506004]
WO2016/162845       A1 2016-10-13 [WO2016162845]
IL254970            A  2017-12-31 [IL-254970]
EP3280438           A1 2018-02-14 [EP3280438]";"2015GB-0006004
2016WO-IB52008";"(EP3280438)
WO2016/162845
(IL-254970)
WO2016/162845";AGRICULTURAL RESEARCH COUNCIL;AGRICULTURAL RESEARCH COUNCIL;"(EP3280438)
ZA
(WO2016162845)
ZA";"(EP3280438)
NAME=Agricultural Research Council 1138 Park Street  Hatfield , CITY=0083 Pretoria , COUNTRY=ZA 

(WO2016162845)
NAME=AGRICULTURAL RESEARCH COUNCIL 1134 Park Street, Hatfield 0083 Pretoria , POSTCODE=0083 , COUNTRY=ZA 
";1;"WALLACE DAVID BRIAN
MATHER ARSHAD SALEH
KARA PRAVESH DEEPAK";"(EP3280438)
ZA";"(EP3280438)
NAME=WALLACE, David Brian 501 Pagel Street Pretoria North , CITY=0182 Pretoria , COUNTRY=ZA 

NAME=MATHER, Arshad Saleh 405 Bart Joubert Street Erasmia , CITY=0183 Centurion , COUNTRY=ZA 

NAME=KARA, Pravesh Deepak 36 Taj Street Laudium , CITY=0037 Pretoria , COUNTRY=ZA 
";"(EP3280438)
Recombinant lumpy skin disease virus knock-out mutant and uses thereof";"(EP3280438)
This invention relates to a live-attenuated recombinant lumpy skin disease virus knock-out mutant, wherein the interieukin-10-like gene or a functional part of the gene has been inactivated in the viral genome. The invention specifically relates to the recombinant lumpy skin disease virus knock-out mutant, pharmaceutical compositions comprising the knock-out mutant, methods of producing the knock out mutant and uses of the knock-out mutant.";"(WO2016162845)
1. CLAIMS 1. A lumpy skin disease virus (LSDV) knock-out mutant, wherein the interteukin-10- like gene or a functional part of the gene has been inactivated in the viral genome.
2. The LSDV knock-out mutant of claim 1 , wherein the interieukin-10-like gene or functional part thereof has been inactivated by deletion from the viral genome.
3. A pharmaceutical composition, comprising: i. a LSDV knock-out mutant, wherein the inteneukin-10-like gene or a functional part of the gene has been deleted from the viral genome; and 
 ii. a pharmaceutically acceptable diluent or excipient.
4. The pharmaceutical composition of claim 3, which further includes an adjuvant.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutical 
 composition is capable of eliciting a protective immune response in an animal against a disease caused by a virus from the viral genus Capripoxvirinae.
6. The pharmaceutical composition of claim 5, wherein the disease is selected from lumpy skin disease, sheep pox and goat pox.
7. The pharmaceutical composition of 5 or 6, wherein the animal is a ruminant.
8. The pharmaceutical composition of claim 7, wherein the ruminant is selected from the group consisting of cattle, sheep, goats and wild ungulates.
9. The pharmaceutical composition of any one of claims 5 to 8, which is formulated for intramuscular, intradermal, intravenous or subcutaneous administration. 10. The pharmaceutical composition of any one of claims 5 to 9, wherein the 
 composition is formulated for administration to the animal in a single dose. 11. The pharmaceutical composition of any one of claims 5 to 9, wherein the 
 composition is formulated for administration to the animal in two or more doses.
12. A method of producing a LSDV knock-out mutant wherein the interieukin-10-like gene or a functional part of the gene has been inactivated in the viral genome, the method comprising the steps of: i. infecting a host cell with a parental LSDV strain; ii. transfecting the host cell with an insertion vector containing a selection marker; and 
 iii. selecting recombinant LSDV knock-out mutants. 13. A LSDV knock-out mutant of claims 1 or 2 for use in a method of preventing a disease in an animal. 14. The LSDV knock-out mutant for use of claim 13, wherein the disease is caused by a virus from the viral genus Capripoxvirinae. 15. The LSDV knock-out mutant for use of claim 14, wherein the disease is selected from lumpy skin disease, sheep pox and goat pox. 16. The LSDV knock-out mutant for use of claim 14 or 15, wherein the animal is a ruminant. 17. The LSDV knock-out mutant for use of claim 16, wherein the ruminant is selected from the group consisting of cattle, sheep, goats and wild ungulates. 18. An insertion vector for obtaining a lumpy skin disease virus (LSDV) knock-out mutant, wherein the insertion vector inactivates an interieukin-10-like gene or a functional part of the gene to knock-out the gene. 19. The insertion vector of claim 1 , wherein the interieukin-10-like gene or a 
 functional part of the gene is inactivated by deletion from the viral genome on transfection of a cell containing an LSDV parental strain.";"(WO2016162845)
The purpose of the invention was to generate an improved live-attenuated LSDV vaccine using gene knockout technology targeting a putative LSDV immunomodulatory gene such as the interieukin-10-like gene.
This invention relates to a live-attenuated recombinant lumpy skin disease virus knock-out mutant, wherein the interleukin-10-like gene or a functional part of the gene has been inactivated in the viral genome.
The invention specifically relates to the recombinant lumpy skin disease virus knock-out mutant, pharmaceutical compositions comprising the knock-out mutant, methods of producing the knock out mutant and use of the knock-out mutant.
This invention relates to a virulent LSDV strain which has been attenuated through the disruption of its open reading frame 005 (ORF005), coding for a putative virulence factor with homology to interieukin-10 (IL-10) using homologous recombination.";"(WO2016162845)
It will be appreciated by those of skill in the art that genes may be inactivated by deletion, substitution, or by some other form of modification.
It will be appreciated that inactivation of the interieukin-10-like gene results In the production of a live attenuated lumpy skin disease virus strain.
It will be appreciated that the pharmaceutical composition may be formulated for administration to the animal in a single dose, alternatively the pharmaceutical composition may be formulated for administration to the animal in two or more doses.
Sheep pox (SPP) and goat pox (GTP) are also primary viral diseases affecting the small ruminant livestock industry in parts of Asia and Africa.
There are however times when the disease does cause death due to emaciation and secondary bacterial infections.
There is however no further information on these vaccines due to intellectual property protection rights so we are limited in our understanding of their development and efficacy.";"A61K
A61K-039/12";"(WO2016162845)
1. A lumpy skin disease virus (LSDV) knock-out mutant, wherein the interteukin-10- like gene or a functional part of the gene has been inactivated in the viral genome.
3. A pharmaceutical composition, comprising: i. a LSDV knock-out mutant, wherein the inteneukin-10-like gene or a functional part of the gene has been deleted from the viral genome; and ii. a pharmaceutically acceptable diluent or excipient.
7. The pharmaceutical composition of 5 or 6, wherein the animal is a ruminant.";"(WO2016162845)
KNOCKOUT MUTANT(100,36)
LUMPY SKIN DISEASE VIRUS(100,23)
VIRAL GENOME(68,12)
RUMINANT LIVESTOCK INDUSTRY(58,1)
INTERIEUKIN INACTIVATION(52,1)
TARGET GENE KNOCKOUT TECHNOLOGY(41,1)
SHEEP POX(39,7)
GENE(38,42)
INTERIEUKIN(36,13)
WILD UNGULATE(34,4)
IMMUNOMODULATORY GENE(33,3)
HOMOLOGOUS RECOMBINATION(31,3)
GENUS VIRUS(30,5)
RUMINANT(28,8)
INTERTEUKIN(28,1)
INTENEUKIN(27,1)
SECONDARY BACTERIAL INFECTION(27,1)
ANIMAL(26,31)
VECTOR INSERTION(25,9)
ADMINISTRATION(24,10)
UNDERSTANDING DEVELOPMENT(24,1)
DISEASE(22,17)
DILUENT(20,3)
DISRUPTION(20,1)
EMACIATION(20,1)
PRIMARY VIRAL DISEASE(20,1)
VACCINE(19,25)
LUMPY SKIN DISEASE VIRUS STRAIN(19,2)
PARENTAL STRAIN(19,2)
GENBANK ACCESSION(18,10)
CAPRIPOXVIRUS CHALLENGE(17,7)
DELETION(17,7)
HOMOLOGY(17,1)
SUBSTITUTION(17,1)
GOAT POX(16,9)
VIRULENCE FACTOR(16,1)
DOSE(15,5)
EXCIPIENT(15,3)
UNSTIMULATED PBMCS(14,4)
PROTECTIVE IMMUNE RESPONSE(14,2)
ASIA(14,1)
DEATH(14,1)
VIRAL CHALLENGE(13,7)
STRAIN(13,4)
AFRICA(13,2)
EMBRYONATED HEN EGG(13,2)
NEUTRALIZING ANTIBODY TITER(13,2)
SUBCUTANEOUS ADMINISTRATION(13,1)
DETECTABLE CAPRIPOXVIRUS NEUTRALIZING ANTIBODY(12,1)
EFFICACY(11,4)
UNVACCINATED GOAT(11,4)
JETPEI TRANSFECTION REAGENT(11,2)
VACCINATED UNVACCINATED SHEEP SEROCONVERSION(11,1)
DAY POST VACCINATION(10,5)
IL10(10,5)
REALTIME PCR(10,5)
VACCINIA VIRUS(10,3)
CLINICAL ILLNESS SIGN(10,2)
CANADIAN COUNCIL GUIDELINE(10,1)
ROMANIAN SHEEP POX STRAIN(10,1)
SOUTH AFRICA LIMPOPO PROVINCE(10,1)
VIRULENT CAPRIPOXVI RUSE(10,1)
PARENTAL VIRUS(9,4)
SINGLE DOSE(9,4)
UNVACCINATED ANIMAL(9,4)
MANUFACTURER GUIDELINE(9,3)
LIVE ATTENUATED VIRUS(9,2)
NUMEROUS POX SKIN LESION(9,2)
POLYPLUS TRANSFECTION(9,2)
SERUM NEUTRALIZATION TEST(9,2)
CAPRI POXVIRUS CHALLENGE(9,1)
CAPRIPOXVIRUS DNA QUANTIFICATION(9,1)
CAPRIPOXVIRUS INFECTION CLINICAL SIGN(9,1)
DETECTABLE CAPRIOOXVIRUS DMA(9,1)
GENE RESULT(9,1)
KEYHOLE LIMPET HEMOCYANIN(9,1)
KILLED CAPRIPOXVIRUS VACCINE(9,1)
PATHOGENIC CAPRIPOXVIRUS REPLICATION(9,1)
PMOSBLUE PLASMID BAMHI SITE(9,1)
RECOMBINANT CAPRIPOX VIRION(9,1)
SOUTH AFRICAN VET ASS(9,1)
VACCINATED GOAT PBMCS(9,1)
VIRULENT CAPRIPOXVIRUS STRAIN(9,1)
VIRUS NEUTRALIZING TITER(9,1)
COUNTING(8,6)
CLINICAL DISEASE(8,4)
LSD CHALLENGE(8,3)
POX LESION(8,3)
ANTIBODY NEUTRALIZATION(8,2)
CALF SERA(8,2)
CONFLUENT MONOLAYER(8,2)
SYMPTOM ONSET(8,2)
CAPRIPOXVIRUS ANTIBODY DETECTION ELISA(8,1)
CATTLE INAPPARENT DISEASE(8,1)
DOMINANT SELECTABLE MARKER GENE(8,1)
FREUND INCOMPLETE ADJUVANT(8,1)
HUMOURAL IMMUNITY SERUM(8,1)
KNOCKOUT RECOMBINANT VIRUS(8,1)
LAMB KIDNEY MONOLAYER(8,1)
LYMPHOCYTE PROLIFERATION ASSAY(8,1)
NEETHLING STRAIN VACCINE(8,1)
NEETHLING VACCINE STRAIN(8,1)
REALTIME QUANTITATIVE PCR(8,1)
RECOMBINANT CAPRIPOXVIRUS PROTEIN(8,1)
RECOMBINANT RLSDV SCREENING(8,1)
SHEEP POX CHALLENGE(8,1)
VIRUS TENFOLD SERIAL DILUTION(8,1)
GOAT SERA(7,3)
GOAT POX CHALLENGE(7,2)
CAPRI POXVIRUS ANTIGEN PRESENCE(7,1)
CLINICAL CAPRIPOXVIRUS DISEASE(7,1)
COLI GPT DOMINANT(7,1)
IGG ANTIBODY TITER(7,1)
QUANTITATIVE IFN KIT(7,1)
RECOMBINANT ANTIGEN ELISA(7,1)
RECOMBINANTLY EXPRESSED CAPRIPOX VIRION(7,1)
STRYDFONTEIN ABATTOIR(7,1)
TAQ DMA POLYMERASE(7,1)
VETERINARY DEPARTMENT ANNUAL REPORT(7,1)
VIRUS DILUTION ALIQUOT(7,1)
VIRUS STOCK TITER(7,1)
AGAROSE GEL(6,4)
CAPRIPOXVIRUS SPECIFIC IGG ANTIBODY(6,4)
TEST SERUM DILUTION(6,3)
ATTENUATED STRAIN(6,2)
CATTLE TRIAL(6,2)
DOSAGE REGIMEN(6,2)
EXPERIMENTAL CHALLENGE(6,2)
IFN SECRETION(6,2)
MANUFACTURER INSTRUCTION(6,2)
PBMCS PROLIFERATIVE RESPONSE(6,2)
PLASMID PMGE(6,2)
REPORTER GENE(6,2)
RESTRICTION RECOGNITION SITE(6,2)
ANIMAL HEALTH OLE BULLETIN(6,1)
BLU PHOS PHOSPHATASE SUBSTRATE(6,1)
CAPRIPOXVIRUS ORF BP REGION(6,1)
CEIL CULTURE FLASK(6,1)
INSECT BORNE INFECTIOUS DISEASE(6,1)
KENYAN VACCINE(6,1)
KNOCKOUT MUTANT GENERATION(6,1)
KNOCKOUT VIRUS GENERATION(6,1)
PEROXIDASE CONJUGATED PROTEIN DILUTION(6,1)
PERSON ADMINISTERING JUDGEMENT(6,1)
PLASMID NOTL SITE(6,1)
REDDENED NODULE(6,1)
RIDEAU ARCOTT SHEEP(6,1)
SCIENCE CENTER(6,1)
STERILE MICROPIPETTE TIP(6,1)
STERILE SCALPEL BLADE(6,1)
UNIVERSAL CLONING VECTOR PUL(6,1)
UNVACCINATED VACCINATED SHEEP(6,1)
YEMEN STRAIN INTRADERMAL INJECTION(6,1)
NEGATIVE SI(5,3)
OPEN READING FRAME(5,3)
DAY POST CHALLENGE(5,2)
EX TAQ DNA POLYMERASE(5,2)
HOST CELL SPECIES(5,2)
MUCOPURULENT NASAL DISCHARGE(5,2)
PRIMARY INOCULATION SITE(5,2)
SECRETED IFN LEVEL(5,2)
SITE NEUTRALIZATION(5,2)
UNIQUE RESTRICTION SITE(5,2)
VIRAL DNA DETECTION(5,2)
AFRICAN COUNTRY(5,1)
ANIMAL CARE COMMITTEE(5,1)
ANIMAL POST CHALLENGE(5,1)
ANNUAL VACCINATION(5,1)
CALF INOCULATION(5,1)
CELL MEDIATED IMMUNITY LYMPHOCYTE(5,1)
CHEMOKLNE RECEPTOR(5,1)
DISEASE OUTBREAK(5,1)
DISORDER SEVERITY(5,1)
ENDEMIC COUNTRY(5,1)
ENDPOINT TITER(5,1)
EXTRACTION PURIFICATION KIT(5,1)
FLUORESCING VIRUS(5,1)
GOAT QUANTIFICATION(5,1)
GPT GENE GIVING(5,1)
IMMUNOMODULATORY ARRAY(5,1)
INFECTION DIAGNOSIS(5,1)
KENYA GOVERNMENT(5,1)
LSD OUTBREAK(5,1)
LSD VACCINE(5,1)
MEASURE VIRAL REPLICATION(5,1)
PARO GPT PLASMID(5,1)
PMGE PLASMID(5,1)
POXVIRIDAE FAMILY(5,1)
PRETORIA NORM(5,1)
QIAGEN MIDI PREP KIT(5,1)
RECOMBINANT VIRUS GENERATION(5,1)
RUMINANT DOMESTIC(5,1)
SEVERE CLINICAL SIGN(5,1)
SHEEPPOX CHALLENGE(5,1)
VACCINE EFFICACY(5,1)
VETERINARY MICROBIOLOGY(5,1)
VIRAL GENE EXPRESSION INHIBITION(5,1)
VIRULENT STRAIN(5,1)
VIRUS HOST INTERACTION(5,1)
VIRUS PATHOGENESIS(5,1)
VIRUS TITER(5,1)
WARM BATH ANTIGEN(5,1)
WARMBATHS ANTIGEN(5,1)
CO2(4,8)
DETECTABLE ANTIBODY RESPONSE(4,4)
PROTEINASE(4,4)
BACKBONE(4,3)
CONJUNCTIVITIS(4,3)
ELECTROPHORESIS(4,3)
FETAL CALF SERUM(4,3)
GOAT POXVIRUS(4,3)
SEROLOGY(4,3)
SHEEP POXVIRUS(4,3)
CELL DEBRIS(4,2)
COMPOSITION DOSAGE(4,2)
DEVELOPED FEVER(4,2)
DISEASE TREATMENT(4,2)
HOST IMMUNE RESPONSE(4,2)
IMMUNOMODULATION(4,2)
MICROFUGE TUBE(4,2)
OPTIMUM THERAPEUTIC RESPONSE(4,2)
TREATED POPULATION(4,2)
AD LIBITUM(4,1)
ANIMAL CUBICLE(4,1)
ANIMAL OBSERVATION(4,1)
ANTIBIOTIC RESISTANCE MARKER GENE(4,1)
APOPTOSIS REGULATOR(4,1)
BOVINE IFN(4,1)
BOVINE MONOCLONAL ANTIBODY(4,1)
BOVINE SERUM ALBUMIN(4,1)
CAPRIPOXVIRUS ANTIGEN PRESENCE(4,1)
CAPRIPOXVIRUS DNA PRESENCE(4,1)
CATTLE PROTECTION(4,1)
CHOPPED TISSUE(4,1)
CLIMATIC CONDITION FAVORING(4,1)
CLINICAL SYMPTOM(4,1)
COMMERCIAL VACCINE(4,1)
DAILY EXAMINATION(4,1)
DAY POST INOCULATION(4,1)
DELAYING ABSORPTION(4,1)
DETERGENT SOLUTION PI(4,1)
DHUTED VIRUS VOLUME(4,1)
DIMETHYLDIOCTADECYLAZANIUM ALUMANE DIHYDROXIDE(4,1)
DISEASE PREVENTION(4,1)
DOSAGE UNIFORMITY(4,1)
EARLY DISEASE STAGE(4,1)
ECONOMIC IMPORTANCE(4,1)
EFFICACY TRIAL(4,1)
EXPERIMENTAL ANIMAL(4,1)
EXPERIMENTAL INFECTION(4,1)
FILTERED PIPETTE TIP(4,1)
GENE FRAGMENT(4,1)
GENE PRODUCT MULTITUDE(4,1)
GENTLE ASPIRATION(4,1)
GEOGRAPHICAL ORIGIN(4,1)
GOAT IFN(4,1)
GOAT INTERFERON GAMMA(4,1)
GPT GENE REMOVAL(4,1)
GROSS PATHOLOGY(4,1)
HEAT INACTIVATED CAPRIPOXVIRUS STRAIN(4,1)
HIGHLY PURE PTW UG(4,1)
HUMAN INTERVENTION(4,1)
HUMID ATMOSPHERE(4,1)
HUMIDIFIED ATMOSPHERE(4,1)
IFN CONCENTRATION(4,1)
IFN ELISA(4,1)
IL10 IIKE GENE(4,1)
IMMUNE RESPONSE ELICITATION(4,1)
INACTIVATED STRAIN(4,1)
INDIRECT ELISA(4,1)
INSERTION VECTOR DMA(4,1)
INTERFERON GAMMA QUANTIFICATION(4,1)
INTERNATIONAL OFFICE(4,1)
INVERTED FLUORESCENCE(4,1)
JETPEI DNA MIXTURE(4,1)
JETPEI REAGENT(4,1)
LIFELONG PROTECTION(4,1)
LSD SPREAD(4,1)
LUMPY SKIN DISEASE VACCINE(4,1)
MACULE APPEARANCE(4,1)
MARKER GENE SEQUENCE(4,1)
MEDICAL DISEASE(4,1)
MEDICAMENT MANUFACTURE(4,1)
MICROBETA SCINTILLATION COUNTER(4,1)
MOLECULAR CHARACTERIZATION(4,1)
MORBIDITY RANGING(4,1)
MUCOSAL DISCHARGE(4,1)
NASAL SWAB(4,1)
NATIONAL CENTER(4,1)
NAVE ANIMAL(4,1)
NEUTRALIZING ANTIBODY PRESENCE(4,1)
NIGERIAN INTRADERMAL INJECTION(4,1)
NOTIFIABLE DISEASE(4,1)
ONSET PREVENTION(4,1)
OPPOSITELY ORIENTATED SEQUENCE(4,1)
PARO GPT VECTOR(4,1)
PATHOLOGY DEVELOPMENT(4,1)
PBMCS ANALYSIS(4,1)
PCR FRAGMENT(4,1)
PCR SCREENING(4,1)
PEPTIDE ANALOG(4,1)
PLAQUE COUNT(4,1)
PLASMID PAGE(4,1)
PLASMID PGTE(4,1)
PMO VECTOR(4,1)
POSSIBILITY DIVERSITY(4,1)
POXVIRUS INFECTION FALL(4,1)
PROPHYLACTIC DOSE(4,1)
PURIFIED FRAGMENT(4,1)
PURIFIED LEUKOCYTE(4,1)
QIAGEN GEL(4,1)
QUANTITATIVE ELISA(4,1)
RECOMBINANT NUCLEIC ACID CONSTRUCT(4,1)
RECOMBINANT SELECTION(4,1)
RECOMBINANT VACCINE CONSTRUCT(4,1)
RECOMBINANT VACCINE VECTOR POTENTIAL(4,1)
RECOMBINANT VIRUS CONSTRUCTION(4,1)
RECONSTITUTED CELL(4,1)
RECOVERED SUPERNATANT(4,1)
REGULAR DAILY INTERVAL(4,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(4,1)
SELECTION MARKER PROTEIN(4,1)
SERIALLY DILUTED SHEEP(4,1)
SEVERE LETHARGY(4,1)
SEVERE SYMPTOM(4,1)
STERILE IMMUNITY(4,1)
SUBSTANCE ENCAPSULATION(4,1)
TAKARA EX(4,1)
TAQMAN ASSAY(4,1)
TENFOLD DILUTION(4,1)
TERRESTRIAL MANUAL(4,1)
TESTIS TISSUE(4,1)
THERAPEUTIC COMPOSITION EFFICACY(4,1)
THERAPEUTIC TOOL(4,1)
TISSUE CULTURE(4,1)
TREATMENT OUTCOME(4,1)
TRIAL CATTLE(4,1)
TWOFOLD DILUTION SERIES(4,1)
VACCINE FAILURE(4,1)
VACCINE FORMULATION(4,1)
VECTOR PHG(4,1)
VIRAL ANTIGEN STOCK(4,1)
VIRAL COPY(4,1)
VIRAL DMA PRESENCE(4,1)
VIRAL GENUS MEMBER(4,1)
VIRULENCE GENE(4,1)
VIRULENT VIRUS PRODUCING(4,1)
WOOL BRAKE(4,1)
XHCA SITE(4,1)
W P(3,8)
DPV(3,5)
HUNTER(3,5)
DPC(3,4)
FUNCTIONAL PART(3,3)
ABORTION(3,2)
CELLULAR RESPONSE(3,2)
CENTRIFUGATION(3,2)
CHORIOALLANTOIC MEMBRANE(3,2)
CONFLUENCY(3,2)
DEAD CELL(3,2)
DISEASE PROGRESSION(3,2)
FETAL BOVINE TESTIS(3,2)
GENE KNOCKOUT(3,2)
HERBIVACL(3,2)
HOMOGENEITY(3,2)
INFERTILITY(3,2)
KNIGHT(3,2)
NUCLEIC ACID MOLECULE(3,2)
PENICILLIN(3,2)
STREPTOMYCIN(3,2)
SUBLINGUAL ADMINISTRATION(3,2)
TRIPLICATE(3,2)
UNTREATED CONTROL POPULATION(3,2)
UNVACCINATED CONTROL SHEEP(3,2)
VACCINE GROUP(3,2)
WHOLE BLOOD(3,2)
ANIMAL PROTECTION(3,1)
ANIMAL STUDY(3,1)
ANIMAL TESTED NEGATIVE(3,1)
APPETITE LOSS(3,1)
CAPRIPOXVIRUS SPECIFIC NEUTRALIZING ANTIBODY(3,1)
CAPV(3,1)
CARBONATE BUFFER(3,1)
CELL PELLET(3,1)
COMPLETE BALANCED DIET(3,1)
COMPOSITION ADMINISTRATION(3,1)
DECREASED VIRUS REPLICATION(3,1)
DEVELOPED CRUST(3,1)
DILUTION FACTOR(3,1)
EARLY STUDY(3,1)
ESSENTIAL GENE(3,1)
EXPERIMENTAL SETTING(3,1)
FINAL INSERTION VECTOR(3,1)
FINAL UNIVERSAL CLONING VECTOR(3,1)
FLANKING REGION REPRESENTATIVE SEQUENCE(3,1)
FOREIGN ANIMAL DISEASE(3,1)
FROZEN CELL(3,1)
GREEN VISIBLE(3,1)
HOST RESPONSE INHIBITION(3,1)
IFN Y MEASUREMENT(3,1)
INFECTION TREATMENT(3,1)
KNOCKOUT MUTANT SHOWING(3,1)
LIPOSOME PRESENCE(3,1)
LISTED DISEASE(3,1)
LOCAL ECONOMY(3,1)
LOCAL FARM(3,1)
LYMPHADENOPATHY(3,1)
MPA SELECTION(3,1)
NEGATIVE ANTIGEN(3,1)
NEGATIVE OUTCOME(3,1)
NEGATIVE SHEEP(3,1)
NEUTRALIZING ANTIBODY LEVEL(3,1)
NUTRIENT MEDIUM(3,1)
PGEM T EASY VECTOR(3,1)
PHARMACEUTICALLY ACTIVE SUBSTANCE PREPARATION(3,1)
POST INFECTION(3,1)
POTENTIAL OUTCOME(3,1)
PRIMARY FBT FCE(3,1)
PRIMER SEQUENCE(3,1)
RELEVANT IMMUNE RESPONSE(3,1)
ROW SERVING(3,1)
SEVERE DISEASE(3,1)
SIGNIFICANT CAPRIPOXVIRUS(3,1)
STATISTICALLY RELEVANT LOW TITER(3,1)
STERILE POWDER(3,1)
STRONG CELLULAR IMMUNITY(3,1)
SUPERNATANT L(3,1)
T CELL RESPONSE(3,1)
TCIDSO ML VIRUS(3,1)
TERMINALLY LOCATED GENE(3,1)
TEST ANTIGEN MINUTE(3,1)
TEST SAMPLE LEUKOCYTE(3,1)
THERAPEUTICALLY EFFECTIVE DOSE(3,1)
TRANSFECTION COMPLEX(3,1)
TRANSFECTION MIXTURE(3,1)
TRYPSINZED MIXTURE(3,1)
UG ML XANTHINE(3,1)
UNVACCINATED CONTROL PBMCS(3,1)
VACCINATION GROUP(3,1)
VACUTAINER TUBE(3,1)
VIRAEMIA DETECTABLE LEVEL(3,1)
VIRAEMIA MEASURABLE DEGREE(3,1)
VIRAL LOAD(3,1)
VIRUS INFECTED CELL(3,1)
SIGMA(2,3)
STIMULATION INDEX(2,3)
FREEZE(2,2)
NON VACCINATED SHEEP(2,2)
ONDERSTEPOORT BIOLOGICAL PRODUCT(2,2)
TOXICITY(2,2)
ABSORBANCE(2,1)
AFRICAN HORSE SICKNESS VIRUS(2,1)
AMPLIFICATION PRODUCT(2,1)
ANIMAL EXPERIMENTATION(2,1)
ANTIBACTERIAL(2,1)
APPROVAL(2,1)
BACK TITRATED STOCK VIRUS(2,1)
BACTERIAL ARTIFICIAL CHROMOSOME(2,1)
BASAL RECTAL TEMPERATURE RANGING(2,1)
BEARD P(2,1)
BLOCKING SOLUTION(2,1)
CALF RECTAL TEMPERATURE(2,1)
CAPSULE(2,1)
CELL CULTURE ASSAY(2,1)";Pharmaceuticals;Open
2014-06-30;"EP2962696           A1 2016-01-06 [EP2962696]
STG: (A1) Application published with search report
AP : 2014EP-0382250 2014-06-30
WO2016001176        A1 2016-01-07 [WO201601176]
STG: (A1) Published application with search report
AP : 2015WO-EP64763 2015-06-29";71904711;"EP2962696           A1 2016-01-06 [EP2962696]
WO2016001176        A1 2016-01-07 [WO201601176]";2014EP-0382250;;"AQUILÓN CYL
UNIVERSITAT AUTONOMA DE BARCELONA";"AQUILÓN CYL
UNIVERSITAT AUTONOMA DE BARCELONA";"(EP2962696)
ES
(WO201601176)
ES";"(EP2962696)
NAME=Aquilón Cyl S.L. Facultad de Veterinaria  Campus de Vegazana s/n , CITY=24004 León , COUNTRY=ES 

NAME=Universitat Autònoma de Barcelona Edifici Eureka  Campus universitari s/n , CITY=08193 Bellaterra , COUNTRY=ES 

(WO201601176)
NAME=AQUILON CYL, S.L Aquilon CYL, S.l Campus vegazana s/n E-24004 León , COUNTRY=ES 

NAME=UNIVERSITAT AUTONOMA DE BARCELONA Universitat Autonoma de Barcelona Edifi. A - Campus Universitari s/n E-08193 Bellaterra (Barcelona) , COUNTRY=ES 
";2;"BARBÉ GARCIA JORDI
CAMPOY SÁNCHEZ SUSANA
LLAGOSTERA CASAS MONTSERRAT";"(EP2962696)
ES";"(EP2962696)
NAME=Barbé Garcia, Jordi C/ La Balsa, no. 1, casa 14 , CITY=08290 Cerfanyola del Vallès , COUNTRY=ES 

NAME=Campoy Sánchez, Susana C/ Joan Baptista Galí, no. 9 1ero 2da , CITY=08221 Terrassa , COUNTRY=ES 

NAME=Llagostera Casas, Montserrat C/ La Balsa, no. 1, casa 14 , CITY=08290 Cerdanyola del Vallès , COUNTRY=ES 
";"(EP2962696)
Novel veterinary vaccine compositions for use in the treatment of infectious diseases caused by or associated with Pasteurellaceae family bacteria";"(EP2962696)
Novel veterinary vaccine compositions for use in the treatment of infectious diseases caused by or associated with Pasteurellaceae family bacteria.The present invention provides vaccine compositions comprising as active ingredient Pasteurella multocida strain PM1094 or an outer-membrane protein extract thereof for the therapeutic and prophylactic treatment in animals of respiratory infections which are caused by or associated with bacteria belonging to the family Pasteurellaceae, to improve animal health and productivity.";"(EP2962696)
1. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use in the prophylactic and therapeutic treatment of respiratory infections in livestock animals caused by, or associated with at least one bacterial pathogen belonging to the Pasteurellaceae family other than any virulent strain and serotype of the bacterial species Pasteurella multocida.
2. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to claim 1, wherein the bacterial pathogen belonging to the Pasteurellaceae family is selected from the group consisting of: any virulent strain and/or serotype of Mannheimia sp., Haemophilius sp., Histophilus sp., Pasteurella sp. (other than Pasteurella multocida), and Actinobacillus sp..
3. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 and 2, wherein the bacterial pathogen belonging to the Pasteurellaceae family is selected from the group consisting of: any virulent strain and/or serotype of Manheimia haemolytica, Haemophilus parasuis, Actinobacillus pleuropneumoniae, Histophilus somni, Pasteurella trehalosi and Haemophilus paragallinarum.
4. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 3, wherein the respiratory infections caused by, or associated with at least one pathogen belonging to the Pasteurellaceae family are selected from the group consisting of: acute, subacute or chronic pneumonia, shipping fever, pleuropneumonia, porcine respiratory disease complex, bovine respiratory disease complex, upper respiratory tract infections, diphteria, lower respiratory tract infections, Grasser's disease, pasteurellosis.
5. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 4, in the prophylactic and therapeutic treatment of respiratory infections in livestock animals selected from the group consisting of: cattle, horses, pigs, birds, poultry, sheep, goat and rabbit.
6. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 5 in the prophylactic and therapeutic treatment of respiratory infections in pigs caused by or associated with Actinobacillus pleuropneumoniae.
7. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 5 in the prophylactic and therapeutic treatment of respiratory infections in pig, cattle or sheep caused by or associated with Manheimia haemolytica.
8. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 5 in the prophylactic and therapeutic treatment of respiratory infections in pigs caused by or associated with Haemophilus parasuis.
9. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 5 in the prophylactic and therapeutic treatment of respiratory infections in cattle caused by or associated with Histophilus somni.
10. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 5 in the prophylactic and therapeutic treatment of respiratory infections in sheep caused by or associated with Pasteurella trehalosi.
11. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use according to any of claims 1 to 5 in the prophylactic and therapeutic treatment of respiratory infections in poultry caused by or associated with Haemophilus paragallinarum.
12. A vaccine composition against respiratory infections in livestock animals caused by, or associated with at least one bacterial pathogen belonging to the Pasteurellaceae family other than any virulent strain and serotype of the bacterial species Pasteurella multocida comprising an immunogenically effective amount of Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom together with an acceptable carrier, vehicle and/or adjuvant.";"(EP2962696)
The present invention is therefore directed to provide vaccine compositions with improved effectiveness for the prevention and therapeutic treatment of infectious respiratory disease in livestock animals caused by, or being associated with bacterial pathogens belonging to the family of Pasteurellaceae bacteria.
According to a first aspect, the invention relates to Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use in the prophylactic and therapeutic treatment of respiratory infections in livestock animals caused by, or associated with at least one bacterial pathogen belonging to the Pasteurellaceae family other than any virulent strain and serotype of the bacterial species Pasteurella multocida.
According to a second aspect, the present invention relates to Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use as defined above, wherein the bacterial pathogen belonging to the Pasteurellaceae family is selected from the group consisting of: any virulent strain and/or serotype of Mannheimia sp., Haemophilius sp., Histophilus sp., Pasteurella sp.
The present invention relates to the field of vaccines, and their application as therapeutic and prophylactic agents in the veterinary industry, for the control of pathogen infections in livestock, caused by, or associated with bacteria belonging to the family Pasteurellaceae.
The present invention relates to the field of vaccines, and their application as therapeutic and prophylactic agents in the veterinary industry, for the control of pathogen infections in livestock, caused by, or associated with bacteria belonging to the family Pasteurellaceae.
In particular, the present invention provides new vaccine compositions for preventing the onset of, and therapeutically treating, respiratory infections in animals which are caused by, or are associated with bacterial pathogens belonging to the family Pasteurellaceae, to improve animal health and productivity.";"(EP2962696)
Several different approaches have been used so far in the treatment of respiratory diseases caused by bacterial pathogens in livestock, however there is still a need for further technical improvement in the present field, to increase efficiency of therapeutic treatments and prevention of the diseases.
difficult to
infections with these agents are mild and transient.
Porcine pleuropneumonia is one of the most important respiratory diseases of intensively raised swine throughout the world.
Although primary respiratory infectious agents can cause serious disease on their own, more often uncomplicated infections with these agents are mild and transient.
It is when these primary infections become complicated with opportunistic bacteria that more serious and chronic respiratory diseases result.
Carrier animals that may show no sign of disease, but are able to infect others, are difficult to identify and treat.
Even with modern drugs, bacteria and viruses in the upper respiratory tract are difficult to remove, making sick animals difficult to cure and susceptible to secondary infections.";"A61K-039/102
C07K-014/285
C12N-001/36";"(EP2962696)
1. Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom for use in the prophylactic and therapeutic treatment of respiratory infections in livestock animals caused by, or associated with at least one bacterial pathogen belonging to the Pasteurellaceae family other than any virulent strain and serotype of the bacterial species Pasteurella multocida.
12. A vaccine composition against respiratory infections in livestock animals caused by, or associated with at least one bacterial pathogen belonging to the Pasteurellaceae family other than any virulent strain and serotype of the bacterial species Pasteurella multocida comprising an immunogenically effective amount of Pasteurella multocida strain PM1094 or an outer-membrane protein extract prepared therefrom together with an acceptable carrier, vehicle and/or adjuvant.";"(EP2962696)
INFECTIOUS DISEASE TREATMENT(100,2)
PASTEURELLACEAE FAMILY BACTERIUM(100,2)
VETERINARY VACCINE(100,2)
BACTERIAL SPECIES PASTEURELLA MULTOCIDA(73,3)
PASTEURELLACEAE FAMILY(64,22)
VIRULENT STRAIN(58,11)
FAMILY PASTEURELLACEAE(58,4)
RESPIRATORY INFECTION TREATMENT THERAPEUTIC(52,15)
LIVESTOCK ANIMAL(44,9)
PASTEURELLA MULTOCIDA(43,28)
PORCINE PLEUROPNEUMONIA(41,1)
INTENSIVELY RAISED SWINE(39,1)
OPPORTUNISTIC BACTERIA(38,1)
PASTEURELLA MULTOCIDA STRAIN(37,10)
OUTER MEMBRANE PROTEIN EXTRACT(36,21)
MANHEIMIA HAEMOLYTICA(35,4)
VETERINARY INDUSTRY(34,1)
PASTEURELLA TREHALOSI(33,5)
BACTERIAL PATHOGEN(32,21)
PROPHYLACTIC(31,16)
HISTOPHILUS SOMNI(31,6)
ANIMAL HEALTH(30,2)
DISEASE PREVENTION(28,1)
PROPHYLACTIC AGENT(28,1)
PRIMARY RESPIRATORY INFECTIOUS AGENT(27,1)
ACTIVE INGREDIENT PASTEURELLA MULTOCIDA(26,1)
DISEASE SIGN(26,1)
SICK ANIMAL(26,1)
THERAPEUTIC(23,3)
VACCINE(22,28)
RESPIRATORY INFECTION ANIMAL(22,1)
RESPIRATORY INFECTION(21,7)
PROPHYLACTIC TREATMENT(21,3)
THERAPEUTIC TREATMENT EFFICIENCY(21,1)
PATHOGEN INFECTION CONTROL(20,1)
RESPIRATORY DISEASE TREATMENT(20,1)
PRODUCTIVITY(19,2)
GRASSER DISEASE(18,2)
ANIMAL CARRIER(18,1)
BACTERIA(17,14)
HAEMOPHILUS PARAGALLINARUM(17,4)
VACCINE FORMULATION(17,3)
LIVESTOCK(16,7)
HAEMOPHILUS PARASUIS(16,5)
PORCINE RESPIRATORY DISEASE(16,3)
MANNHEIMIA(15,6)
PASTEURELLA(15,6)
PASTEURELLACEAE BACTERIUM FAMILY(15,4)
DRUG(14,1)
ANIMAL(13,75)
VIRUS(12,1)
ADJUVANT(11,14)
RESPIRATORY DISEASE(11,9)
INFECTIOUS RESPIRATORY DISEASE(11,8)
NON VACCINATED ANIMAL(11,6)
POULTRY(11,5)
ONSET(11,2)
UPPER RESPIRATORY TRACT(11,2)
INFECTION(10,18)
ELISA ASSAY(10,9)
WORLD(10,2)
PRIMARY INFECTION(10,1)
VACCINE FIELD(10,1)
DISEASE(9,5)
MANHEMIA HAEMOLYTICA(9,3)
MOUSE SERA DILUTION(9,3)
MUTANT PASTEURELLA MULTOCIDA(9,3)
FUR GENE MUTATION(9,2)
SECONDARY INFECTION(9,2)
UNIVERSITAT AUT NOMA MICROBIOLOGY(9,1)
BACTERIAL STRAIN(8,5)
LUNG SCORE(8,5)
SHIPPING FEVER(8,5)
APP INFECTION(8,4)
CHRONIC PNEUMONIA(8,4)
HRP CONJUGATED ANTIBODY(8,4)
DIPHTERIA(8,3)
RESPIRATORY DISEASE RESULT(8,1)
SEVERE BOVINE PNEUMONIA LESION(8,1)
IMMUNOGLOBULIN(7,7)
CLINICAL RESPIRATORY SIGN(7,2)
HAEMOPHILUS INFLUENZAE(7,2)
INTRAPERITONEAL VACCINATION(7,2)
PLEUROPNEUMONIA INFECTION(7,2)
CATTLE COMMENSAL ORGANISM(7,1)
CHOCOLATE POLYVITEX AGAR(7,1)
HEALTHY RUMINANT RESPIRATORY TRACT(7,1)
PERICARDITIS MACROSCOPIC EXAMINATION(7,1)
RESPIRATORY INFECTIOUS DISEASE PREVENTION(7,1)
RESPIRATORY SIGN APPARITION(7,1)
VACCINE STRAIN ANTIGENICITY(7,1)
GOAT(6,5)
MANNHEIMIA HAEMOLYTICA(6,5)
AGE WEEK(6,4)
ANIMAL PERCENTAGE(6,4)
BIRD(6,3)
HORSE(6,3)
ANTIBODY ELICITATION(6,2)
INTRANASAL INOCULATION(6,2)
INTRAPERITONEAL ADMINISTRATION(6,2)
SALMONELLA ENTERICA STRAIN(6,2)
SERA DATA(6,2)
TONSILAR SWAB(6,2)
BACTERIUM PREVALENCE(6,1)
CLINICAL SIGN SEVERITY(6,1)
CLINICALLY EVIDENT ILLNESS(6,1)
EUTHANASIA APP DAY(6,1)
FIBRINOPURULENT BRONCHOPNEUMONIA(6,1)
FIBRINOUS POLYSEROSYTIS(6,1)
LUNG GROSS LESION(6,1)
NASOPHARYNGEAL MICROFLORA NORMAL CONSTITUENT(6,1)
PNEUMONIC PASTEURELLOSIS(6,1)
SERVER FARM FACILITY(6,1)
THROMBOTIC MENINGOENCEPHALITIS(6,1)
VIRULENT PASTEURELLA MULTOCIDA(6,1)
YOUNG GROWING CATTLE AGE(6,1)
CELL DISRUPTION(5,4)
NON VACCINATED GROUP(5,4)
SECONDARY ANTIBODY(5,4)
ANIMAL SUFFERING(5,3)
CLINICAL OBSERVATION(5,3)
ISOLATED COLONY(5,3)
PHYLOGENETIC DISTANCE(5,3)
STARTER FEED PROPORTION(5,2)
STUDY DIRECTOR(5,2)
ACTINOBACILLUS PLEUROPNEUMONIAE STRAIN(5,1)
APP CHALLENGE STRAIN(5,1)
FIBRINOUS PLEURISY(5,1)
GENERA HAEMOPHILUS(5,1)
HAEMOPHILUS SOMNUS(5,1)
INTRAPERITONEAL INOCULATION(5,1)
LOBE PLEURITIS(5,1)
MILD RESPIRATORY SIGN(5,1)
OPPORTUNISTIC INFECTIOUS AGENT(5,1)
PASTEURELLA VACCINE(5,1)
PATHOGEN SURVIVAL(5,1)
PIGLET ASSIGNMENT(5,1)
PORCINE PLEUROPNEUMONIA CLINICAL COURSE(5,1)
RESPIRATORY CLINICAL SIGN(5,1)
RUMINANT TONSIL(5,1)
SEVERE RESPIRATORY SIGN(5,1)
SODIUM PENTOBARBITAL INTRAVENOUS OVERDOSE(5,1)
SUBCUTANEOUS INNOCULATION(5,1)
VACCINE INACTIVATION(5,1)
ACETATE BUFFER(4,4)
BOVINE RESPIRATORY DISEASE COMPLEX(4,4)
HISTOPHILUS(4,4)
NONSENSE MUTATION(4,4)
PELLET(4,4)
SUPERNATANT(4,4)
SYRINGE(4,4)
GRAM NEGATIVE BACTERIA(4,3)
STATISTICAL DIFFERENCE(4,3)
BACTERIA QUANTITY(4,2)
BACTERIAL CULTURE(4,2)
CHOCOLATE AGAR PLATE(4,2)
LUNG LESION PRESENCE(4,2)
RABBIT IMMUNE RESPONSE(4,2)
TRUNCATED PROTEIN(4,2)
ACCLIMATIZATION DAY(4,1)
ACUTE OUTBREAK(4,1)
ACUTE SYSTEMIC DISEASE(4,1)
AD LIBITUM(4,1)
AFFECTED LUNG PROPORTION(4,1)
AGE PIG(4,1)
ANIMAL SEX(4,1)
APP BACTERIUM(4,1)
APP INOCULUM PREPARATION(4,1)
BACTERIAL BIOMASS(4,1)
BACTERIAL CHALLENGE SUSPENSION(4,1)
BACTERIAL SCORE(4,1)
BEEF PRODUCING COUNTRY(4,1)
CATTLE PATHOGEN(4,1)
CATTLE SHEEP(4,1)
CIRCULATING ANTIBODY(4,1)
CLINICAL DISEASE SIGN(4,1)
COMMERCIAL ELISA KIT(4,1)
DEAD ANIMAL PROTECTION(4,1)
DISEASE MAJOR ETIOLOGICAL AGENT(4,1)
DISEASE PREVALENCE(4,1)
DISEASE SEVERITY(4,1)
DISEASE SYMPTOM(4,1)
ECONOMICALLY IMPORTANT INFECTIOUS DISEASE(4,1)
EXPERIMENT AGE OBJECTIVE(4,1)
EXPERIMENT OUTCOME(4,1)
EXPERIMENT PIG(4,1)
EXPERIMENTAL FARM(4,1)
FATAL SEPTICEMIA(4,1)
FEEDLOT CATTLE(4,1)
FEVER EVALUATION(4,1)
FOWL CHOLERA(4,1)
FRESHLY STREAKED CHOCOLATE PLATE(4,1)
FUR ELIMINATION(4,1)
FUR MUTANT(4,1)
GENE DEREPRESSION(4,1)
GENE DISRUPTION(4,1)
GENETICS DEPARTMENT(4,1)
HEALTHY PIGLET(4,1)
HETEROLOGOUS CHALLENGE(4,1)
INACTIVATED STRAIN(4,1)
INFECTION LIKELY NATURAL ROUTE(4,1)
INTERMITTENT COUGH(4,1)
LATE CHALLENGE(4,1)
LESION ORIGIN(4,1)
LUNG INFLAMMATION(4,1)
LUNG LOBE(4,1)
MATERNAL ANTIBODY(4,1)
MEDICAL SIGN(4,1)
MOCK VACCINATION(4,1)
NEONATAL CALF(4,1)
OMPH GENE(4,1)
OMPH PROTEIN(4,1)
PASTEURELLA SPECIES(4,1)
PERICARDITIS PROPORTION(4,1)
PLEUROPNEUMONIA STRAIN(4,1)
PNEUMONIC SCORE(4,1)
POLYCLONAL ANTI SWINE IGG(4,1)
PRINCIPAL BACTERIUM(4,1)
RELEVANT OPPORTUNISTIC PATHOGEN(4,1)
REPRESSION ELIMINATION(4,1)
REPRESSOR FUR(4,1)
REPRODUCTION DISEASE(4,1)
REPRODUCTIVE TRACT DISEASE(4,1)
RESPIRATORY SIGN ABSENCE(4,1)
RESPIRATORY VIRUS(4,1)
SERIAL DILUTION PLATING(4,1)
SEVERE RESPIRATORY DISTRESS(4,1)
SHEEP BLOOD AGAR(4,1)
STATISTICAL SIGNIFICANCE(4,1)
STRAIN INACTIVATION(4,1)
SUBCUTANEOUS INOCULATION(4,1)
SURVIVAL PERCENTAGE(4,1)
SURVIVING ANIMAL(4,1)
VACCINE DOSE(4,1)
VACCINE EFFICACY(4,1)
VETERINARY BILL(4,1)
VETERINARY VACCINE PRACTICE(4,1)
YOUNG RUMINANT(4,1)
GROUP T(3,26)
SIGNIFICANT DIFFERENCE(3,5)
STRAIN OUTER MEMBRANE PROTEINS(3,5)
UPPER RESPIRATORY TRACT INFECTION(3,4)
ANIMAL GROUP(3,3)
GROUP ANIMAL(3,3)
LUNG SCORING(3,3)
RE ISOLATION(3,3)
CLINICAL CONDITION(3,2)
FARM ANIMAL(3,2)
LIPOPOLYSACCHRARIDE(3,2)
MONOPHOPHOLIPID(3,2)
MONOPHOSPHOLIPID(3,2)
PRIMARY PATHOGEN(3,2)
ACUTE ATTACK(3,1)
ACUTE FEBRILE COURSE(3,1)
ADEQUATELY CHARACTERIZED STRAIN(3,1)
AGE MONTH(3,1)
AGRICULTURAL SETTING(3,1)
BACTERIAL SPECIES(3,1)
BACTERIAL SUSPENSION(3,1)
BACTERIUM SPECIES(3,1)
BUFFERED PEPTONE(3,1)
CHALLENGE DAY(3,1)
CONCENTRATED STOCK CONCENTRATION(3,1)
DEPOSITED MUTANT(3,1)
DISEASE SYNDROME VARIETY(3,1)
DOMESTIC ANIMAL SPECIES(3,1)
ENZOOTIC PNEUMONIA COMPLEX(3,1)
EXACT BACTERIAL CONCENTRATION(3,1)
EXPERIMENTAL EVIDENCE(3,1)
FAMILY PASTEURELLACEAE MEMBER(3,1)
FEEDLOT DISEASE(3,1)
FINANCIAL COST ESTIMATE(3,1)
HETEROLOGOUS PROTECTION(3,1)
INACTIVATED CELL SUSPENSION(3,1)
IRON ACQUISITION(3,1)
LIVESTOCK INDUSTRY(3,1)
LOG RANK(3,1)
MEAN DYSPNEA(3,1)
MEAN SNEEZING(3,1)
MULTIFACTORIAL NATURE(3,1)
NATIVE PROTEIN(3,1)
NECROPSY DAY(3,1)
NUMERIC SCORE(3,1)
ONSET DAY(3,1)
OVERNIGHT INCUBATION(3,1)
PASTEURELLACEAE FAMILY MEMBER(3,1)
PIG INDUSTRY(3,1)
POSITIVE BACTERIAL ISOLATION(3,1)
POST INOCULATION(3,1)
PROTOCOL SOP(3,1)
REAL BACTERIAL CONCENTRATION(3,1)
RECOGNIZED DISEASE(3,1)
SECONDARY PNEUMONIA(3,1)
SERUM DILUTION(3,1)
STRAIN PROTECTIVE CAPACITY(3,1)
VIRULENCE(3,1)
YOUNG SHEEP(3,1)
ALUMINUM HYDROXIDE(2,9)
GAUGE(2,4)
LITHIUM CHLORIDE(2,4)
NON VACCINATED CONTROL(2,4)
UPPER PANEL(2,4)
ANTI RABBIT(2,2)
ANTIBIOTIC(2,2)
COADJUVANT(2,2)
COLISTIN(2,2)
FINAL CONCENTRATION(2,2)
HAEMOPHILIUS PARASUIS C(2,2)
MASTITIS(2,2)
MYCOPLASMA(2,2)
PROGRESSIVE CHANGE(2,2)
SEROTYPE(2,2)
TRANSPORTATION(2,2)
ABSCESS FORMATION(2,1)
ACCLIMATIZATION PERIOD(2,1)
ACUTE SIGN(2,1)
ANIMAL SHOWING DYSPNEA PROPORTION(2,1)
ANIMAL TREATMENT(2,1)
ANIMAL WELFARE REASON(2,1)
ANTI MOUSE IG(2,1)
APPETITE LOSS(2,1)
BACTERIAL AGENT(2,1)
BIOLOGICAL ACTIVITY(2,1)
BLOOD COLLECTION(2,1)
CELL INACTIVATION(2,1)
CELL SUSPENSION CONCENTRATION(2,1)
CHEST CAVITY(2,1)
CLOTTED BLOOD SAMPLE(2,1)
COMMON INHABITANT(2,1)
COMPROMISED PULMONARY DEFENSE(2,1)
CONDITION BACTERIAL GROWTH(2,1)
DECREASE GROWTH PARAMETER(2,1)
DIGITAL THERMOMETER(2,1)
DOUBLE MUTANT(2,1)
FINAL BLEEDING(2,1)
FISHER EXACT TEST(2,1)
FUR ACTION(2,1)
HEAT INACTIVATED PASTEURELLA MULTOCIDA(2,1)
HEMORRHAGIC SEPTICEMIA(2,1)
HOST ANIMAL(2,1)
IGG QUANTIFICATION(2,1)
INFECTED ANIMAL MORTALITY RATE(2,1)
IRON UPTAKE PROTEIN(2,1)
LABORATORY CULTURE MEDIA(2,1)
LAST CHALLENGE(2,1)
LUNG ABSCESS PRESENCE(2,1)
MAIN BACTERIUM(2,1)
MILD DELAY(2,1)
MOUSE IMMUNE RESPONSE(2,1)
NASAL PASSAGE NORMAL INHABITANT(2,1)
OBTAINING SERUM SAMPLE(2,1)
OBTAINING STRAIN(2,1)
PCR DETECTION(2,1)
PERICARDITIS PRESENCE(2,1)
PREVENTIVE(2,1)
PT PCT(2,1)
SECONDARY CRITERIA(2,1)
SERONEGATIVE(2,1)
(WO201601176)
VACCINE(100,41)
BACTERIAL PATHOGEN(100,26)
PASTEURELLA MULTOCIDA STRAIN(100,26)
PASTEURELLACEAE FAMILY(100,25)
OUTER MEMBRANE PROTEIN EXTRACT(100,24)
PROPHYLACTIC(100,17)
VIRULENT STRAIN(100,13)
THERAPEUTIC TREATMENT(100,12)
LIVESTOCK ANIMAL(100,11)
RESPIRATORY INFECTION CLINICAL SIGN(100,9)
RESPIRATORY INFECTION(100,8)
BACTERIAL SPECIES PASTEURELLA MULTOCIDA(100,4)
RESPIRATORY INFECTION TREATMENT THERAPEUTIC(64,8)
GRAM NEGATIVE BACTERIUM ACTINOBACILLUS PLEUROPNEUMONIAE(59,4)
FAMILY PASTEURELLACEAE(57,5)
PORCINE PLEUROPNEUMONIA(44,1)
PASTEURELLACEAE BACTERIUM FAMILY(42,5)
INTENSIVELY RAISED SWINE(42,1)
OPPORTUNISTIC BACTERIA(41,1)
UNCOMPLICATED INFECTION(40,1)
MANHEIMIA HAEMOLYTICA(36,5)
PASTEURELLA TREHALOSI(35,6)
HISTOPHILUS SOMNI(33,7)
RESPIRATORY DISEASE CLINICAL SIGN(33,2)
DISEASE PREVENTION(31,1)
VETERINARY INDUSTRY(30,1)
PRIMARY RESPIRATORY INFECTIOUS AGENT(29,1)
DISEASE SIGN(28,1)
SICK ANIMAL(28,1)
ANIMAL HEALTH(25,1)
PROPHYLACTIC AGENT(25,1)
CLINICAL SIGN(23,22)
THERAPEUTIC TREATMENT EFFICIENCY(23,1)
INFECTIOUS RESPIRATORY DISEASE(22,10)
RESPIRATORY DISEASE TREATMENT(22,1)
ANIMAL CARRIER(20,1)
GRASSER DISEASE(19,2)
HAEMOPHILUS PARAGALLINARUM(18,5)
PATHOGEN INFECTION CONTROL(18,1)
HAEMOPHILUS PARASUIS(17,6)
PORCINE RESPIRATORY DISEASE(17,3)
ANIMAL(16,104)
PASTEURELLA(16,8)
LIVESTOCK(16,7)
MANNHEIMIA(16,6)
BACTERIA(15,13)
DRUG(15,1)
PRODUCTIVITY(15,1)
UNIVERSITAT AUTONOMA MICROBIOLOGY(14,2)
VIRUS(13,1)
ADJUVANT(12,17)
RESPIRATORY DISEASE(12,9)
POULTRY(12,5)
ONSET(12,2)
PREVENTION(12,2)
UPPER RESPIRATORY TRACT(12,2)
INFECTION(11,27)
ELISA ASSAY(11,9)
MANHEMIA HAEMOLYTICA(11,4)
RESPIRATORY INFECTIOUS DISEASE(11,3)
THERAPEUTIC(11,3)
WORLD(11,2)
DISEASE(10,5)
HAEMOPHILUS INFLUENZAE(10,3)
MOUSE SERA DILUTION(10,3)
MUTANT PASTEURELLA MULTOCIDA(10,3)
PLEUROPNEUMONIA INFECTION(10,3)
BACTERIAL STRAIN OMP(10,2)
FUR GENE MUTATION(10,2)
PRIMARY INFECTION(10,1)
HRP CONJUGATED ANTIBODY(9,5)
SHIPPING FEVER(9,5)
CHRONIC PNEUMONIA(9,4)
CLINICAL DISEASE SIGN(9,3)
DIPHTERIA(9,3)
LUNG GROSS LESION(9,2)
SECONDARY INFECTION(9,2)
VIRULENT PASTEURELLA MULTOCIDA(9,2)
RESPIRATORY DISEASE RESULT(9,1)
VACCINE FIELD(9,1)
IMMUNOGLOBULIN(8,8)
AGE WEEK(8,5)
ANIMAL PERCENTAGE(8,5)
ISOLATED COLONY(8,5)
LUNG SCORE(8,5)
APP INFECTION(8,4)
CHRONIC LESION(8,3)
INTRANASAL INOCULATION(8,3)
ACTINOBACILLUS PLEUROPNEUMONIAE STRAIN(8,2)
BACTERIUM OMP(8,2)
CLINICAL RESPIRATORY SIGN(8,2)
HYDRATED ALUMINUM HYDROXY PHOSPHATE(8,2)
INTRAPERITONEAL VACCINATION(8,2)
LESION CHRONICITY(8,2)
LOBE PLEURITIS(8,2)
MILD RESPIRATORY SIGN(8,2)
PASTEURELLA VACCINE(8,2)
RESPIRATORY CLINICAL SIGN(8,2)
SEVERE RESPIRATORY SIGN(8,2)
SODIUM PENTOBARBITAL INTRAVENOUS OVERDOSE(8,2)
GRAM NEGATIVE BACTERIA FAMILY(8,1)
SEVERE BOVINE PNEUMONIA LESION(8,1)
BACTERIAL CULTURE(7,4)
CHALLENGE DAY(7,4)
CHOCOLATE AGAR PLATE(7,4)
CLINICAL OBSERVATION(7,4)
BIRD(7,3)
GLASSER DISEASE(7,3)
HORSE(7,3)
VACCINE FORMULATION(7,3)
ANTIBODY ELICITATION(7,2)
BACTERIAL BIOMASS(7,2)
GENETICS DEPARTMENT(7,2)
HEALTHY PIGLET(7,2)
HETEROLOGOUS CHALLENGE(7,2)
INTRAPERITONEAL ADMINISTRATION(7,2)
MATERNAL ANTIBODY(7,2)
PLEUROPNEUMONIA STRAIN(7,2)
PNEUMONIC SCORE(7,2)
POLYCLONAL ANTI SWINE IGG(7,2)
RESPIRATORY SIGN ABSENCE(7,2)
SALMONELLA ENTERICA STRAIN(7,2)
SERA DATA(7,2)
SERIAL DILUTION PLATING(7,2)
SHEEP BLOOD AGAR(7,2)
TONSILAR SWAB(7,2)
VACCINE EFFICACY(7,2)
VACCINE TITRATION(7,2)
ACTINOBACILLUS PLEUROPNEUMONIAE OMP(7,1)
CATTLE COMMENSAL ORGANISM(7,1)
CHOCOLATE POLYVITEX AGAR(7,1)
FARM SEROLOGICAL SCREENING(7,1)
FIBRINOPURULENT BRONCHOPNEUMONIA(7,1)
HEALTHY RUMINANT RESPIRATORY TRACT(7,1)
MEAN SNEEZING SCORESISTANDARD DEVIATION(7,1)
NONSPECIFIC INFLAMMATORY LESION(7,1)
PASTEURELLA MULTOCIDA STRAIN EFFICACY(7,1)
PASTEURELLACEAE FAMILY BACTERIUM(7,1)
PERICARDITIS MACROSCOPIC EXAMINATION(7,1)
RESPIRATORY SIGN APPARITION(7,1)
VACCINE STRAIN ANTIGENICITY(7,1)
ACTIVE AGENT(6,7)
GOAT(6,5)
MANNHEIMIA HAEMOLYTICA(6,5)
SECONDARY ANTIBODY(6,5)
ANIMAL SUFFERING(6,3)
COMMERCIAL ELISA KIT(6,2)
EXPERIMENTAL FARM(6,2)
FARM FACILITY(6,2)
FEVER EVALUATION(6,2)
LUNG LOBE(6,2)
STUDY DIRECTOR(6,2)
BACTERIUM PREVALENCE(6,1)
CLINICAL SIGN SEVERITY(6,1)
CLINICALLY EVIDENT ILLNESS(6,1)
FIBRINOUS POLYSEROSYTIS(6,1)
NASOPHARYNGEAL MICROFLORA NORMAL CONSTITUENT(6,1)
PLEUROPNEUMONIA APXIV(6,1)
PNEUMONIC PASTEURELLOSIS(6,1)
THROMBOTIC MENINGOENCEPHALITIS(6,1)
YOUNG GROWING CATTLE AGE(6,1)
CELL DISRUPTION(5,4)
NONSENSE MUTATION(5,4)
PHYLOGENETIC DISTANCE(5,3)
ANTI RABBIT IG(5,2)
BACTERIA QUANTITY(5,2)
CLINICAL RESPIRATORY DISEASE(5,2)
EXACT BACTERIAL CONCENTRATION(5,2)
EXCLUSION CRITERIA(5,2)
IMMUNE RESPONSE RABBIT(5,2)
INACTIVATED CELL SUSPENSION(5,2)
LUNG LESION PRESENCE(5,2)
NECROPSY DAY(5,2)
NUMERIC SCORE(5,2)
OVERNIGHT INCUBATION(5,2)
RABBIT IMMUNE RESPONSE(5,2)
REAL BACTERIAL CONCENTRATION(5,2)
SERUM DILUTION(5,2)
TAIL FISHER TEST(5,2)
TRUNCATED PROTEIN(5,2)
VACCINE PREPARATION(5,2)
ACUTE OUTBREAK(5,1)
ACUTE SYSTEMIC DISEASE(5,1)
AD LIBITUM(5,1)
ADJUVANT PROTECTION ANIMAL(5,1)
ANIMAL CLINICAL SIGN(5,1)
ANIMAL JUSTIFICATION(5,1)
ANIMAL SEX(5,1)
APP BACTERIUM(5,1)
APP CHALLENGE STRAIN(5,1)
APP INOCULUM PREPARATION(5,1)
BACTERIAL CHALLENGE SUSPENSION(5,1)
BLINDED TECHNICIAN(5,1)
CATTLE PATHOGEN(5,1)
CERTIFIED VETERINARIAN(5,1)
CLINICAL SIGN RECOVERY(5,1)
DISEASE PREVALENCE(5,1)
DYSPNEA SEVERITY(5,1)
ETHICAL COMMITTEE(5,1)
EXPERIMENT AGE OBJECTIVE(5,1)
EXPERIMENT OUTCOME(5,1)
FATAL SEPTICEMIA(5,1)
FEEDLOT CATTLE(5,1)
FIBRINOUS PLEURISY(5,1)
FIBRINOUS PLEURITIS(5,1)
FIBROUS ADHERENCE(5,1)
FOWL CHOLERA(5,1)
FREQUENTLY ACUTE LESION(5,1)
FRESHLY STREAKED CHOCOLATE PLATE(5,1)
GENE DEREPRESSION(5,1)
GENERA HAEMOPHILUS(5,1)
HAEMOPHILUS SOMNUS(5,1)
HEMORRHAGIC LESION(5,1)
INTERMITTENT COUGH(5,1)
INTRAPERITONEAL INOCULATION(5,1)
LESION ORIGIN(5,1)
LUNG INFLAMMATION(5,1)
LUNG LESION EVALUATION(5,1)
MOCK VACCINATION(5,1)
MULTOCIDA VACCINE(5,1)
NEONATAL CALF(5,1)
ONEWAY ANOVA ANALYSIS(5,1)
OPPORTUNISTIC INFECTIOUS AGENT(5,1)
PATHOGEN SURVIVAL(5,1)
PERICARDITIS PROPORTION(5,1)
PIGLET ASSIGNMENT(5,1)
PORCINE PLEUROPNEUMONIA CLINICAL COURSE(5,1)
PRESTARTER FEED PROPORTION(5,1)
REPRESSION ELIMINATION(5,1)
REPRESSOR FUR(5,1)
RUMINANT TONSIL(5,1)
SEVERE DYSPNEA DISTRIBUTION(5,1)
SPECIES PASTEURELLA MULTOCIDA(5,1)
SUBACUTE LESION(5,1)
SUBCUTANEOUS INNOCULATION(5,1)
SUBCUTANEOUS INOCULATION(5,1)
SYMPTOM SEVERITY(5,1)
VACCINE DISPENSER(5,1)
VACCINE INACTIVATION(5,1)
VETERINARY BILL(5,1)
VIRULENT BACTERIAL PATHOGEN(5,1)
YOUNG RUMINANT(5,1)
NON VACCINATED ANIMAL(4,8)
SYRINGE(4,5)
ACETATE BUFFER(4,4)
ANIMAL GROUP(4,4)
BOVINE RESPIRATORY DISEASE COMPLEX(4,4)
HISTOPHILUS(4,4)
LUNG SCORING(4,4)
PELLET(4,4)
PROGRESSIVE CHANGE(4,4)
RE ISOLATION(4,4)
SUPERNATANT(4,4)
ACCLIMATIZATION PERIOD(4,2)
ANIMAL FEED(4,2)
ANIMAL WELFARE REASON(4,2)
CELL INACTIVATION(4,2)
CELL SUSPENSION CONCENTRATION(4,2)
DIGITAL THERMOMETER(4,2)
FINAL BLEEDING(4,2)
LIPOPOLYSACCHRARIDE(4,2)
MONOPHOPHOLIPID(4,2)
MONOPHOSPHOLIPID(4,2)
PERICARDITIS PRESENCE(4,2)
PRIMARY PATHOGEN(4,2)
PROPHYLACTIC TREATMENT(4,2)
WHITE CIRCLE(4,2)
ACCLIMATIZATION DAY(4,1)
AFFECTED LUNG PROPORTION(4,1)
AGE PIG(4,1)
BACTERIAL SCORE(4,1)
BEEF PRODUCING COUNTRY(4,1)
CATTLE SHEEP(4,1)
CIRCULATING ANTIBODY(4,1)
DISCUSSION VACCINATION(4,1)
DISEASE MAJOR ETIOLOGICAL AGENT(4,1)
DISEASE SEVERITY(4,1)
DISEASE SYMPTOM(4,1)
ECONOMICALLY IMPORTANT INFECTIOUS DISEASE(4,1)
EXPERIMENT PIG(4,1)
FEEDLOT DISEASE(4,1)
FUR ELIMINATION(4,1)
FUR MUTANT(4,1)
GENE DISRUPTION(4,1)
HEAT INACTIVATED BACTERIN(4,1)
HUGE STATISTICAL DIFFERENCE(4,1)
INACTIVATED STRAIN(4,1)
INFECTION FAST RESOLUTION(4,1)
INFECTION LIKELY NATURAL ROUTE(4,1)
INFECTIOUS DISEASE TREATMENT(4,1)
INOCULATION ROUTE(4,1)
LESION PROGRESSION PHASE(4,1)
LUNG LESSION(4,1)
MEDICAL SIGN(4,1)
OMPH GENE(4,1)
OMPH PROTEIN(4,1)
PASTEURELLA SPECIES(4,1)
PIG LUNG(4,1)
PRINCIPAL BACTERIUM(4,1)
PURCHASED ANIMAL(4,1)
RELEVANT OPPORTUNISTIC PATHOGEN(4,1)
REPRODUCTION DISEASE(4,1)
REPRODUCTIVE TRACT DISEASE(4,1)
RESPIRATORY VIRUS(4,1)
SEVERE RESPIRATORY DISTRESS(4,1)
STATISTICAL SIGNIFICANCE(4,1)
STRAIN INACTIVATION(4,1)
SURVIVAL PERCENTAGE(4,1)
SURVIVING ANIMAL(4,1)
VACCINE DOSE(4,1)
VETERINARY VACCINE PRACTICE(4,1)
GROUP T(3,27)
ALUMINUM HYDROXIDE(3,12)
DPI(3,6)
SIGNIFICANT DIFFERENCE(3,6)
UPPER RESPIRATORY TRACT INFECTION(3,4)
COLISTIN(3,3)
FINAL CONCENTRATION(3,3)
GROUP ANIMAL(3,3)
SEROTYPE(3,3)
ANIMAL WEIGHT(3,2)
ANTIBIOTIC(3,2)
CARCASS(3,2)
CLASSIFICATION(3,2)
CLINICAL CONDITION(3,2)
COADJUVANT(3,2)
COMPLETE LUNG(3,2)
CONTAMINATION(3,2)
EUTHANASIA(3,2)
FARM ANIMAL(3,2)
HAEMOPHILIUS PARASUIS C(3,2)
INACTIVATED VACCINE(3,2)
INCINERATION(3,2)
LUNG CONSOLIDATION(3,2)
MASTITIS(3,2)
MYCOPLASMA(3,2)
PATHOGEN OMP(3,2)
PE ML(3,2)
RANDOMIZATION(3,2)
RECTUM(3,2)
REFRIGERATION(3,2)
TRANSPORTATION(3,2)
ACUTE ATTACK(3,1)
ACUTE FEBRILE COURSE(3,1)
ACUTE LESION PRESENCE(3,1)
ADEQUATELY CHARACTERIZED STRAIN(3,1)
AGE MONTH(3,1)
AGRICULTURAL SETTING(3,1)
BACTERIAL SPECIES(3,1)
BACTERIAL SUSPENSION(3,1)
BACTERIUM SPECIES(3,1)
CHALLENGE RECORD SHEET(3,1)
CHALLENGE STUDY(3,1)
CLINICAL EVALUATION(3,1)
CONCENTRATED STOCK CONCENTRATION(3,1)
DEPOSITED MUTANT(3,1)
DISEASE SYNDROME VARIETY(3,1)
DOMESTIC ANIMAL SPECIES(3,1)
EAR NUMBER(3,1)
ENZOOTIC PNEUMONIA COMPLEX(3,1)
EXPERIMENTAL ANIMAL(3,1)
EXPERIMENTAL EVIDENCE(3,1)
FAMILY PASTEURELLACEAE MEMBER(3,1)
FINANCIAL COST ESTIMATE(3,1)
HETEROLOGOUS PROTECTION(3,1)
IRON ACQUISITION(3,1)
LIVESTOCK INDUSTRY(3,1)
LOG RANK(3,1)
MEAN DYSPNEA(3,1)
MULTIFACTORIAL NATURE(3,1)
NATIVE PROTEIN(3,1)
ONSET DAY(3,1)
OVERNIGHT GROWTH(3,1)
PASTEURELLACEAE FAMILY MEMBER(3,1)
PIG IDENTIFICATION(3,1)
PIG INDUSTRY(3,1)
PIG PERCENTAGE(3,1)
POSITIVE BACTERIAL ISOLATION(3,1)
POST INOCULATION(3,1)
PROTOCOL SOP(3,1)
RECOGNIZED DISEASE(3,1)
SECONDARY PNEUMONIA(3,1)
STRAIN PROTECTIVE CAPACITY(3,1)
TRAINED PERSON(3,1)
VACCINATED PIG GROUP(3,1)
VIRULENCE(3,1)
YOUNG SHEEP(3,1)
GAUGE(2,4)
LITHIUM CHLORIDE(2,4)
NON VACCINATED PIG(2,4)
UPPER PANEL(2,4)
ABSCESS FORMATION(2,1)
ACUTE SIGN(2,1)
ANIMAL DISTRIBUTION(2,1)
ANIMAL HOUSE(2,1)
ANIMAL SHOWING DYSPNEA PROPORTION(2,1)
ANIMAL SHOWING SEVERE DYSPNEA(2,1)
ANIMAL TREATMENT(2,1)
ANTI MOUSE IG(2,1)
APPETITE LOSS(2,1)
BACTERIAL AGENT(2,1)
BIOLOGICAL ACTIVITY(2,1)
BLINDING(2,1)
BLOOD COLLECTION(2,1)
CHEST CAVITY(2,1)
CLOTTED BLOOD SAMPLE(2,1)
COMMON INHABITANT(2,1)
COMPROMISED PULMONARY DEFENSE(2,1)
CONDITION BACTERIAL GROWTH(2,1)
DEAD ANIMAL(2,1)
DECREASE GROWTH PARAMETER(2,1)
DOUBLE MUTANT(2,1)
ELISA TEST(2,1)
EXPERIMENTAL TREATMENT(2,1)
FEED CONSUMPTION(2,1)
FEEDING BAG(2,1)
FISHER EXACT TEST(2,1)
FUR ACTION(2,1)
HEAT INACTIVATED PASTEURELLA MULTOCIDA(2,1)
HEMORRHAGIC SEPTICEMIA(2,1)
HOST ANIMAL(2,1)
IGG QUANTIFICATION(2,1)
IMMUNE RESPONSE MOUSE(2,1)
IMMUNOGENIC AGENT(2,1)
INFECTED ANIMAL MORTALITY RATE(2,1)
INITIAL INOCULATION(2,1)
IRON UPTAKE PROTEIN(2,1)
LABORATORY CULTURE MEDIA(2,1)
LAST CHALLENGE(2,1)
LUNG ABSCESS PRESENCE(2,1)
MAIN BACTERIUM(2,1)
MILD DELAY(2,1)
MOUSE IMMUNE RESPONSE(2,1)
NASAL PASSAGE NORMAL INHABITANT(2,1)
OBTAINING SERUM SAMPLE(2,1)";Pharmaceuticals;Open
"2013-11-01
2014-10-30
2017-08-04";"US20150125487       A1 2015-05-07 [US20150125487]
STG: (A1) Application published
AP : 2014US-14528305 2014-10-30
WO2015/066292       A1 2015-05-07 [WO201566292]
STG: (A1) Published application with search report
AP : 2014WO-US63099 2014-10-30
EP3062816           A1 2016-09-07 [EP3062816]
STG: (A1) Application published with search report
AP : 2014EP-0800197 2014-10-30
US9757445           B2 2017-09-12 [US9757445]
STG: (B2) Granted patent as second publication
AP : 2014US-14528305 2014-10-30
FD :  Provisional Appl: US61/898,497 FDD=2013-11-01 [2013US-61898497]
FD : Previous publication: US20150125487 A1 2015-05-07 [US20150125487]
US20180015157       A1 2018-01-18 [US20180015157]
STG: (A1) Application published
AP : 2017US-15668946 2017-08-04
FD :  Continuation of: US14/528,305 FDD=2014-10-30 [2014US-14528305]
FD : Continuation of: US9757445 - 0 [US9757445]
FD : Provisional Appl: US61/898,497 FDD=2013-11-01 [2013US-61898497]";69279250;"US20150125487       A1 2015-05-07 [US20150125487]
WO2015/066292       A1 2015-05-07 [WO201566292]
EP3062816           A1 2016-09-07 [EP3062816]
US9757445           B2 2017-09-12 [US9757445]
US20180015157       A1 2018-01-18 [US20180015157]";"2013US-61898497
2014US-14528305
2014WO-US63099
2017US-15668946";"(EP3062816)
WO2015/066292";MERIAL;MERIAL;"(EP3062816)
US
(US20150125487)
US
(US9757445)
US
(US20180015157)
US
(WO201566292)
US";"(EP3062816)
NAME=Merial Inc. 3239 Satellite Boulevard, , CITY=Duluth, GA 30096 , COUNTRY=US 

(US20150125487)
NAME=MERIAL LIMITED , CITY=DULUTH , STATE=GA , COUNTRY=US , ATYP=US Company 

(US9757445)
NAME=MERIAL INC. , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US20180015157)
NAME=MERIAL INC. , CITY=DULUTH , STATE=GA , COUNTRY=US , ATYP=US Company 

(WO201566292)
NAME=MERIAL LIMITED 3239 Satellite Blvd. Duluth, GA 30096 , POSTCODE=30096 , COUNTRY=US 
";1;"LAWRENCE PAULRAJ KIRUBAKARAN
BEY RUSSELL F";"(US20150125487)
US
(US9757445)
US";"(US20150125487)
NAME=Lawrence Paulraj Kirubakaran , CITY=Worthington , STATE=MN , COUNTRY=US 

NAME=Bey Russell F. , CITY=Arden Hills , STATE=MN , COUNTRY=US 

(US9757445)
NAME=Lawrence Paulraj Kirubakaran , CITY=Worthington , STATE=MN , COUNTRY=US 

NAME=Bey Russell F. , CITY=Arden Hills , STATE=MN , COUNTRY=US 
";"(EP3062816)
Attenuated pasteurella multocida vaccines & methods of making & use thereof";"(EP3062816)
The present invention provides attenuated P. multocida strains that elicit an immune response in animal P. multocida, compositions comprising said strains, methods of vaccination against P. multocida, and kits for use with such methods and compositions. The invention further provides novel, genetically-engineered mutations in P. multocida hyaD and nanPU genes, which are useful in the production of novel attenuated P. multocida bacterial strains.";"(US20150125487)
What is claimed is:
1. Use of an attenuated Pasteurella multocida (P. multocida) strain in manufacturing an immunological composition that is capable of providing a safe and effective immune response in bovine against P. multocida or diseases caused by P. multocida, wherein the strain comprises deletions or partial deletions in its hyaD gene, nanPU genes, both genes, or homologs and orthologs thereof, relative to its virulent parental P. multocida strain.
2. The use of claim 1, wherein the strain, prior to deletion, comprised genes having at least 70% identity and comparable function to the sequences as set forth in SEQ ID NOs:1, 5, or both.
3. The use of claim 2, wherein the genes comprise nucleotides set forth in SEQ ID NOs:1 or 5.
4. The use of claim 3, wherein the strain expresses level(s) of HyaD and/or NanP, NanU peptide(s) that are significantly reduced or undetectable, relative to the strain's corresponding virulent parental strain.
5. The use of claim 1, characterized in that the strain has mutations in the same genes as does the strain deposited at the ATCC under the Patent Deposit Designation PTA-120624.
6. The use of claim 5, characterized in that the strain is the strain deposited at the ATCC under the Patent Deposit Designation PTA-120624.
7. The use of any one of claims 1 to 6, wherein the composition further comprises a pharmaceutically or veterinary acceptable vehicle, diluent or excipient.
8. The use of claim 7, wherein the composition further comprises an adjuvant.
9. The use of claim 8, wherein the adjuvant is inactivated bacteria, inactivated virus, fractions of inactivated bacteria, bacterial lipopolysaccharides, bacterial toxins, or derivatives or combinations thereof.
10. The use of claim 9, wherein the composition is a vaccine composition that provides a protective immune response in bovine against virulent P. multocida challenge.
11. The use of claim 9 or 10, wherein the composition further comprises at least one additional antigen associated with a bovine pathogen other than P. multocida.
12. The use of claim 11, wherein the at least one or more additional antigen(s) is capable of eliciting in a bovine an immune response against FMDV or BDV.
13. A method of vaccinating an animal comprising administering the composition described in any one of claims 1 to 7 or 8 to 10.
14. The method of claim 13, wherein the bovine is from about 4 weeks old to 6 weeks old.";"(US20150125487)
An object of this disclosure is to provide attenuated bacteria as well as methods for treatment and prophylaxis of infection by P. multocida.
The present disclosure further relates to efficacious field vaccines comprising attenuated P. multocida strains for use as vaccines in cattle.
The present invention provides attenuated P. multocida strains that elicit an immune response in animal P. multocida, compositions comprising said strains, methods of vaccination against P. multocida, and kits for use with such methods and compositions.
The invention further provides novel, genetically-engineered mutations in P. multocida hyaD and nanPU genes, which are useful in the production of novel attenuated P. multocida bacterial strains.
The present invention relates generally to attenuated bacterial vaccines, particularly those providing broad, safe, and effective protection to bovines against infections/disease caused by Pasteurella Multocida.
The invention further relates to methods of producing the attenuated bacteria, and to the identification of nucleic acid variations that are associated with decreased virulence of the attenuated bacteria.
The invention accordingly relates to immunogenic or vaccine compositions comprising the bacteria of the invention; e.g., live attenuated bacteria.
The invention therefore further relates to methods for preparing and/or formulating such compositions; e.g., culturing or growing or propagating the bacteria on or in suitable medium, harvesting the bacteria, optionally inactivating the bacteria, and optionally admixing the bacteria with a suitable veterinarily or pharmaceutically acceptable carrier, excipient, diluent or vehicle and/or an adjuvant and/or stabilizer.
Thus, the invention also relates to the use of the bacteria in formulating such compositions.";"(US20150125487)
The pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector (or protein expressed from an inventive vector in vitro); advantageously, the carrier, vehicle or excipient may facilitate transfection and/or improve preservation of the vector (or protein).
These mutants are useful for the production of live attenuated immunogenic compositions or live attenuated vaccines having a high degree of immunogenicity.
These mutants are also useful as vectors which can be useful for expression in vitro of expression products, as well as for reproduction or replication of nucleotide sequences (e.g., replication of DNA), and for in vivo expression products.
The kit may advantageously contain additional first or second vials for additional prime-vaccinations or additional boost-vaccinations.
It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as comprises , comprised , comprising and the like can have the meaning attributed to it in U.S. patent law; e.g., they can mean includes , included , including , and the like; and that terms such as consisting essentially of and consists essentially of have the meaning ascribed to them in U.S. patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
However, the field efficacy of these vaccines is questionable and none of the vaccines afford reliable protection.";"A61K-039/00
A61K-039/102
A61K-039/12
A61K-039/135
A61K-039/295
C12N-007/00
C12N-009/10";"(US20150125487)
1. Use of an attenuated Pasteurella multocida (P. multocida) strain in manufacturing an immunological composition that is capable of providing a safe and effective immune response in bovine against P. multocida or diseases caused by P. multocida, wherein the strain comprises deletions or partial deletions in its hyaD gene, nanPU genes, both genes, or homologs and orthologs thereof, relative to its virulent parental P. multocida strain.";"(US20150125487)
MULTOCIDA(100,45)
STRAIN(100,16)
BOVINE(100,13)
IMMUNE RESPONSE(100,9)
SAFE(100,5)
IMMUNOLOGICAL(100,3)
ATTENUATED PASTEURELLA MULTOCIDA(100,1)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(100,1)
DISEASE(100,1)
ATTENUATED BACTERIUM DECREASED VIRULENCE(62,1)
ATTENUATED BACTERIA(56,4)
MULTOCIDA BACTERIAL STRAIN(52,1)
GENETICALLY ENGINEERED MUTATION(39,1)
MULTOCIDA STRAIN(37,13)
ATTENUATED BACTERIAL VACCINE(36,1)
NANPU GENE(34,5)
INFECTION PROPHYLAXIS(31,1)
NUCLEOTIDE SEQUENCE REPLICATION(30,1)
MULTOCIDA HYAD(28,4)
BOOST VACCINATION(28,2)
LIVE ATTENUATED VACCINE(28,1)
VECTOR PRESERVATION(28,1)
DNA REPLICATION(27,1)
VECTOR ADMINISTRATION(26,1)
BACTERIA(25,15)
VIRULENT PARENTAL STRAIN(23,3)
INACTIVATED BACTERIA FRACTION(23,2)
MULTOCIDA CHALLENGE(22,1)
VACCINE(21,24)
HYAD GENE(20,6)
EXCIPIENT(19,9)
BACTERIAL LIPOPOLYSACCHARIDE(19,2)
NANU PEPTIDE(19,1)
VETERINARILY ACCEPTABLE CARRIER(18,5)
ORTHOLOG(18,1)
PARTIAL DELETION(17,2)
RELIABLE PROTECTION(17,1)
IMMUNOGENIC(16,2)
INACTIVATED VIRUS(16,2)
HOMOLOG(16,1)
MUTANT(15,5)
IMMUNOGENICITY(15,1)
PRODUCING NOVEL(15,1)
ADJUVANT(14,11)
PASTEURELLA MULTOCIDA(14,6)
PATENT LAW(14,2)
VETERINARY ACCEPTABLE VEHICLE(14,2)
TRANSFECTION(14,1)
PATENT DEPOSIT DESIGNATION(13,4)
REPRODUCTION(13,1)
VECTOR(12,6)
DELETION(12,5)
KIT(12,5)
AUTOCLAVED BRAIN HEART INFUSION(12,3)
COMPOUND FACILITATING COMBINATION(12,1)
COMPRISED GENE(12,1)
PROTECTIVE IMMUNE RESPONSE(12,1)
STABILIZER(12,1)
GENE(11,18)
ATTENUATED STRAIN(11,10)
DILUENT(11,3)
INFECTION DISEASE(11,2)
FIELD EFFECTIVE VACCINE(11,1)
VACCINE FIELD EFFICACY(11,1)
PROTEIN(10,17)
ATCC(10,4)
BACTERIA VIRULENCE ATTENUATION(10,2)
ANIMAL(9,20)
LUNG LESION(9,6)
BSSHII DIGESTED PBCSK(9,2)
SHEEP BLOOD(8,8)
MULTOCIDA INFECTION(8,4)
MULTOCIDA SEROGROUP(8,3)
VACCINATION(8,3)
BACTERIAL TOXIN(8,2)
CHILLED COLUMBIA BROTH(8,2)
PASTEURELLA MULTOCIDA VIRULENCE GENOTYPE(8,1)
CATTLE(7,6)
VIAL(7,5)
DYE TERMINATOR CHEMISTRY KIT(7,2)
TRUNCATED NANPU GENE(7,2)
VETERINARY LABORATORY AGENCY(7,2)
ACAPSULAR HYAD MUTANT(7,1)
BDV(7,1)
BOVINE PNEUMONIC PASTEURELLOSIS(7,1)
FMDV(7,1)
MULTOCIDA NANPU MUTANT(7,1)
PASTEURELLA MULTOCIDA VACCINE CANDIDATE(7,1)
SEVERE SUPPURATIVE BRONCHOPNEUMONIA(7,1)
WILD TYPEOBSERVE CLINICAL SIGN(7,1)
TSA PLATE(6,12)
INTEGRATED REPLACEMENT PLASMID(6,4)
BHI BROTH(6,3)
TRUNCATED NANPU PRESENCE(6,3)
VACCINE EFFICACY(6,3)
ANTIBIOTIC SUPPLEMENTATION(6,2)
COLUMBIA BLOOD AGAR(6,2)
ELECTROPORATION CUVETTE(6,2)
FETAL BOVINE SERUM(6,2)
PCT109GA REPLICATION(6,2)
PERKIN ELMER GENEAMP(6,2)
ANTIGENIC POLYPEPTIDE VARIANT(6,1)
CAPSULE BIOSYNTHETIC(6,1)
EXPERIMENTAL PNEUMONIA PASTEURELLOSIS(6,1)
KNOCKOUT NANPU(6,1)
MILD PURULENT LESION(6,1)
MUTANT LYOPHILIZED CULTURE(6,1)
PREDOMINATELY TRADITIONAL BACTERIN(6,1)
RANDOM SIGNATURE TAGGED MUTAGENESIS(6,1)
SEVERE PURULENT BRONCHOPNEUMONIA(6,1)
SWINE IMMUNODEFICIENCY VIRUS(6,1)
TRANSPORTER PERMEASE PROTEIN(6,1)
VIABLE ACAPSULAR PHENOTYPE(6,1)
IDENTITY(5,4)
COLONY PCR(5,3)
COMPARABLE FUNCTION(5,3)
LYOPHILIZED POWDER(5,3)
STERILE GLYCEROL(5,3)
STERILITY TESTING(5,3)
ABI PRISM(5,2)
AMES IOWA(5,2)
BOOST ADMINISTRATION(5,2)
BOOSTER ADMINISTRATION(5,2)
BOVINE CIRCOVIRUS(5,2)
CATTLE IMMUNITY(5,2)
COMPETENT BACTERIA(5,2)
CSCL CENTRIFUGATION(5,2)
DEXTROSE STARCH(5,2)
DNA SEQUENCER(5,2)
DOUBLE CROSSOVER MUTANT(5,2)
DOUBLE KNOCKOUT MUTANT(5,2)
GENE PULSER(5,2)
HYADR PRIMER(5,2)
IMMUNOGENIC FRAGMENT(5,2)
MUTANT COLONY(5,2)
NUCLEOTIDE REPLACEMENT(5,2)
PLASMID REPLICATION(5,2)
POLYPEPTIDE BIOLOGICAL ACTIVITY(5,2)
PRIME BOOST REGIMEN(5,2)
REPLACEMENT PLASMID LIGATION MIXTURE(5,2)
REPLACEMENT PLASMID RESOLUTION(5,2)
SIALIC ACID UPTAKE(5,2)
SYNDROME VIRUS(5,2)
VETERINARY MICROBIOLOGY(5,2)
ASSIGNED VETERINARIAN DISCRETION(5,1)
BACTERIA PATHOGENICITY(5,1)
BOOSTER VACCINE(5,1)
CLINICAL MICROBIOLOGY JOURNAL(5,1)
HYAD GENE DELETION MUTANT(5,1)
HYAD PARTIAL DELETION MUTANT(5,1)
MEMBRANE BOUND LYSOZYME INHIBITOR(5,1)
NORTH AMERICA CATTLE POPULATION(5,1)
PNEUMONIA CLINICAL SIGN(5,1)
RESTRICTION ENZYME BGLII(5,1)
SIALIC ACID DEFICIENT MUTANT(5,1)
UK CATTLE POPULATION(5,1)
UNCHARGED POLAR GLYCINE(5,1)
WILDLIFE DISEASE JOURNAL(5,1)
MASTER(4,13)
CLONE(4,6)
NON PERMISSIVE TEMPERATURE(4,4)
CULTURE REACHED LOG PHASE(4,3)
EPITOPE MAPPING(4,3)
PRIMARY ADMINISTRATION(4,3)
REGULATORY SEQUENCE(4,3)
AGE WEEK(4,2)
ELECTROPORATED CELL(4,2)
EXACT CFU(4,2)
EXPRESSION VECTOR(4,2)
FRESH GLYCEROL(4,2)
INFECTED HOST(4,2)
INTERNAL DIAGNOSTICS LABORATORY(4,2)
OVERNIGHT INCUBATION(4,2)
PROTEIN FRAGMENT(4,2)
PUBLISHED(4,2)
SIALIC ACID RESIDUE(4,2)
TN ABSENCE(4,2)
ACAPSULAR MUTANT(4,1)
ARGININE SUBSTITUTION(4,1)
ATTENUATED MUTANT(4,1)
ATTENUATED PHENOTYPE(4,1)
ATTENUATING MUTATION(4,1)
BACTERIAL INFECTION PATHOGENESIS(4,1)
BIG HORN SHEEP(4,1)
CALF VACCINATION(4,1)
CAPSULAR ANTIGEN(4,1)
CAPSULE BIOSYNTHESIS(4,1)
CATTLE PASTEURELLOSIS(4,1)
CHALLENGE ORGANISM RECOVERY(4,1)
CLINICAL DISEASE SEVERITY(4,1)
CLINICAL SIGN GRAVITY(4,1)
CONFORMATIONAL EPITOPE(4,1)
DAYOF CHALLENGE(4,1)
DELETED HYAD(4,1)
DELETED NANPU(4,1)
DERMONECROTIZING TOXIN(4,1)
ENDOBRONCHIAL POLY P(4,1)
EVENING POST CHALLENGE(4,1)
FACULTATIVE ANAEROBE(4,1)
FATAL PERITONITIS(4,1)
FILAMENTOUS HEMAGGLUTININ(4,1)
FOWL CHOLERA(4,1)
GENETICALLY DISTINCT ENTITY(4,1)
GLYCOSYLTRANSFERASE SYNTHESIS(4,1)
HARBORING BACTERIA(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
HETEROLOGOUS PROMOTER(4,1)
HISTOPHILUS SOMNI(4,1)
HYAD PRIMER(4,1)
HYAE VACCINE(4,1)
HYDROPHOBIC RESIDUE SUBSTITUTION(4,1)
IRON ACQUISITION PROTEIN(4,1)
KANAMYCIN SENSITIVE COLONY(4,1)
LICENSED VETERINARIAN(4,1)
LOCUS NANP(4,1)
LOCUS NANU(4,1)
LOWERED VIRAL TITER(4,1)
MANNHEIMA HAEMOLYTICA(4,1)
MERCK ANIMAL HEALTH(4,1)
METHYLATED NUCLEOTIDE(4,1)
MICROORGANISM ATTENUATION(4,1)
MONTH OLD CALF(4,1)
MUCOSAL ADJUVANT(4,1)
MULTOCIDA BACTERIUM(4,1)
MULTOCIDA GENOME(4,1)
MULTOCIDA HYAD NANPU(4,1)
MULTOCIDA IMMUNOLOGICAL(4,1)
MULTOCIDA OMP(4,1)
NANPU DELETION(4,1)
NANPU PRIMER(4,1)
NEWPORT LABORATORY RESEARCH(4,1)
NUCLEOTIDE SEQUENCE MUTATION(4,1)
OVIS ARIE(4,1)
OVIS CANADENSIS(4,1)
PASTEURELLA IMMUNOGEN(4,1)
PASTEURELLACEAE GENETIC ENGINEERING(4,1)
PBCSK HYADPM(4,1)
PBCSK NANPUPM(4,1)
PENTOBARBITAL INJECTION(4,1)
PERIPLASMIC PROTEIN SIAP(4,1)
PNEUMONIC LESION(4,1)
POLAR RESIDUE SUBSTITUTION(4,1)
POLYSACCHARIDE CAPSULE(4,1)
PRACTICING VETERINARIAN(4,1)
PROTEIN IMMUNOGENICITY(4,1)
RECOMBINANT PLASMID(4,1)
RECOMBINANT POLYNUCLEOTIDE(4,1)
REGULATORY AGENCY(4,1)
REPLACEMENT PLASMID INTEGRATION(4,1)
RESPIRATORY PASTEURELLOSIS(4,1)
SENSITIVE ACAPSULAR COLONY(4,1)
SIALIC ACID METABOLISM(4,1)
SYNTHESIZING OLIGONUCLEOTIDE(4,1)
SYSTEMIC PASTEURELLOSIS(4,1)
TABLE 2STUDY SCHEDULEAGEEVENT(4,1)
TRANSCRIPTION TERMINATOR(4,1)
TRIMETHYLATED CHITOSAN(4,1)
TRUNCATED HYAD GENE PRESENCE(4,1)
UNEQUIVOCAL DEMONSTRATION(4,1)
UNSUBSTITUTED POLYPEPTIDE(4,1)
VACCINATED CALF(4,1)
VIRULENCE GENE(4,1)
VIRULENT PARENT STRAIN(4,1)
SINGLE COLONY(3,10)
PCR PRODUCT(3,4)
CRYOVIAL(3,3)
ANTIBIOTIC SELECTION(3,2)
CELL PELLET(3,2)
ECORI SITE(3,2)
HEMORRHAGIC SEPTICEMIA(3,2)
HOST ANIMAL(3,2)
IGM PRODUCTION(3,2)
LIGATION PRODUCT GENERATING PLASMID(3,2)
MUTANT FORMATION(3,2)
NON SELECTION PLATE(3,2)
PCR KIT(3,2)
PCR REACTION(3,2)
REMAINING CALF(3,2)
REPLACEMENT PLASMID CONSTRUCTION(3,2)
WHOLE BACTERIA(3,2)
ACID ASPARTATE(3,1)
ACID TRANSFERASE ENZYME(3,1)
ALKENYL DERIVATIVE POLYMER(3,1)
ANNUAL BOOSTER(3,1)
ANTIGENIC DETERMINANT SITE(3,1)
AVIAN STRAIN(3,1)
BOVINE BACTERIAL PNEUMONIA(3,1)
BP DELETION(3,1)
BRANCHED POLYNUCLEOTIDE(3,1)
CATIONIC LIPID(3,1)
CFU VACCINE DOSE(3,1)
CHALLENGED ANIMAL(3,1)
COLI STRAIN(3,1)
COMMERCIAL VACCINE(3,1)
CONSERVATIVE REPLACEMENT(3,1)
COW DOSE VOLUME(3,1)
DISEASE STATUS(3,1)
DOMESTIC ANIMAL PATHOLOGY(3,1)
EXPRESSION REGULATION(3,1)
EXTRACELLULAR ENZYME(3,1)
GENE FRAGMENT(3,1)
GENETIC STABILITY(3,1)
HOMOLOGOUS PROTEIN(3,1)
HYAD EXPRESSION(3,1)
HYAE GENE(3,1)
IMMUNOGENIC PROTEIN(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
IMMUNOSTIMULATING SEQUENCE(3,1)
INFECTED ANIMAL(3,1)
INSTANT DISCLOSURE VACCINE(3,1)
LIVE STREPTOMYCIN DEPENDENT MUTANT(3,1)
LUNG TISSUE(3,1)
MAJOR PATHOGEN(3,1)
MANNHEIMIA HAEMOLYTICA TRANSMISSION(3,1)
METHIONINE CODON(3,1)
MICROORGANISM GENE(3,1)
MILD DYSPLASIA(3,1)
MOLECULAR CHARACTERIZATION(3,1)
MUTANT CULTURE(3,1)
MUTANT GENE(3,1)
MUTANT PHENOTYPE(3,1)
MUTANT STRAIN(3,1)
MUTATION IDENTIFICATION(3,1)
NANPUR PRIMER(3,1)
NATIVE CODING SEQUENCE(3,1)
NON POLAR ALANINE(3,1)
NUCLEIC ACID ENCODING PEPTIDE(3,1)
NUCLEOTIDE ANALOG(3,1)
NUCLEOTIDE BRANCH(3,1)
NUMEROUS VIRULENCE(3,1)
OLIGODEOXYRIBONUCLEOTIDE SEQUENCE(3,1)
ORGANISM CELL(3,1)
OXFORD STREET(3,1)
PARAMOUNT IMPORTANCE(3,1)
PHD THESIS(3,1)
PLATING COLONY(3,1)
PLURAL REFERENT(3,1)
POLYNUCLEOTIDE SEGMENT(3,1)
POTENTIAL VIRULENCE(3,1)
PRECISE DELETION(3,1)
PROTECTIVE IMMUNITY(3,1)
RANDOM MUTAGENESIS(3,1)
RECOMBINANT TECHNOLOGY(3,1)
RECOMBINANT VECTOR(3,1)
SALI SITE(3,1)
SEQUENCE RNA ISOLATION(3,1)
SERUM ANTIBODY(3,1)
SIALIC ACID TRAP(3,1)
SOMATIC ANTIGEN(3,1)
SPT EMULSION(3,1)
SUBCUTANEOUS ROUTE(3,1)
TARGET ANTIGEN(3,1)
TARGET GENE MODIFICATION(3,1)
TERMINAL BRONCHIOLE EPITHELIUM(3,1)
TERMINAL LIPOOLIGOSACCHARIDE(3,1)
THIOBARBITURIC ACID ASSAY(3,1)
TRANSCRIPTION INITIATION(3,1)
TRANSCRIPTION TERMINATION(3,1)
TRANSPOSON GENERATED MUTANT(3,1)
TRANSPOSON INSERTION(3,1)
TRANSPOSON TN(3,1)
TREATING PLASMID(3,1)
TRUNCATED HYAD PRESENCE(3,1)
US CATTLE(3,1)
VACCINE SAFETY(3,1)
VIRULENT STRAIN(3,1)
YEARLY TREND(3,1)
YOUNG ANIMAL(3,1)
YOUNG CALF(3,1)
APPLIED BIOSYSTEM(2,5)
BIO RAD(2,4)
BIOLOGICALLY SIMILAR RESIDUE(2,4)
KANAMYCIN RESISTANCE ELEMENT(2,4)
BIRD(2,3)
DILUTION(2,3)
MAMMAL(2,3)
NUCLEIC ACID SEQUENCE(2,3)
PIG(2,3)
STERILE DISTILLED WATER(2,3)
ADJUVANT INCREASE(2,2)
AGAR PLATE(2,2)
ASPARAGINE(2,2)
CHEMICAL SYNTHESIS(2,2)
CLOSTRIDIUM(2,2)
COLE(2,2)
COMMON POLYPEPTIDE(2,2)
CONJUGATION(2,2)
CONSTANT RANGING(2,2)
ELECTROPHORESIS(2,2)
ENCODED AMINOACID RESIDUE(2,2)
ESCHERICHIA(2,2)
FELINE(2,2)
GLUTAMINE(2,2)
HAPTEN(2,2)
IDENTIFICATION CONFIRMATION(2,2)
INTERVET(2,2)
INTRON(2,2)
ISOLATED GENE PRODUCT(2,2)
ISOLEUCINE(2,2)
LABELING COMPONENT(2,2)
NECROPSY(2,2)
NUCLEIC ACID FACILITY(2,2)
ORGANELLE(2,2)
PARASUIS(2,2)
PHENYLALANINE(2,2)
POULTRY(2,2)
PROVISO(2,2)
SALMONELLA(2,2)
SUBUNIT(2,2)
TEMPERATURE SENSITIVE PLASMID ORIGIN(2,2)
TEMPERATURE SENSITIVE REPLICATION ORIGIN(2,2)
THERMOCYCLER(2,2)
TRYPTOPHAN(2,2)
TYROSINE(2,2)
ACAPSULAR SINGLE CROSSOVER MUTANT(2,1)
ACRYLIC POLYMER(2,1)
AFRICA REGION(2,1)
AGAROSE GEL IMAGE(2,1)
ALUMINUM PHOSPHATE(2,1)
AMINOACID SPATIAL CONFORMATION(2,1)
ANTIBODY ABILITY(2,1)
ANTIBODY GENERATION(2,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(2,1)
ANTIBODY PRODUCTION(2,1)
ATROPHIC RHINITIS(2,1)
CALF SHOWING CLINICAL SIGN(2,1)
CAPSULE LOSS(2,1)
CODING SEQUENCE START CODON(2,1)
CODING SEQUENCE STOP CODON(2,1)
FEED INTAKE(2,1)
FUNCTIONAL RNA(2,1)
GENOMIC SEQUENCE(2,1)
GRAM NEGATIVE BACTERIA(2,1)
GREEN FLUORESCENT PROTEIN TAGGED ORGANISM(2,1)
IMMUNIZATION(2,1)
IMMUNOGENIC RESPONSE(2,1)
INTEGRATED DNA TECHNOLOGY(2,1)
INTERGENIC REGION(2,1)
IOWA STATE UNIVERSITY PRESS(2,1)
LINEAR EPITOPE(2,1)
LIPOPOLYSACCHARIDE(2,1)
MODIFIED NUCLEOTIDE(2,1)
MUTATED SEQUENCE(2,1)
NANPUPM1062KANR(2,1)
NATIVE SEQUENCE(2,1)
PHOSPHATE BUFFER(2,1)
POST VACCINATION(2,1)
PRELIMINARY WORK(2,1)
PROTECTIVE IMMUNOLOGICAL RESPONSE(2,1)
QUATERNARY AMMONIUM SALT(2,1)
REMAINING INOCULUM(2,1)
RNA DNA HYBRID(2,1)
SAIL(2,1)
SEQUENCE DNA ISOLATION(2,1)
STRUCTURAL ROLE(2,1)
SYNTHETIC ORIGIN(2,1)
TARGET ANIMAL(2,1)
TARGET SPECIES(2,1)
TERM EPITOPE(2,1)
TERM RECOMBINANT(2,1)
UNSUBSTITUTED PARENT AMINOACID(2,1)
WHOLE ORGANISM(2,1)
ACETYLATION(1,1)
ACTIVE FRAGMENT(1,1)
ADHESIN(1,1)
(US9757445)
ANIMAL(100,20)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(100,1)
PARENTAL STRAIN NANPU GENE(64,3)
PARENTAL STRAIN HYAD GENE(63,3)
ATTENUATED STRAIN(54,20)
VIRULENT PARENTAL STRAIN(54,5)
MULTOCIDA BACTERIAL STRAIN(52,1)
NANPU GENE(50,7)
ATTENUATED BACTERIUM DECREASED VIRULENCE(48,1)
ATTENUATED PASTEURELLA MULTOCIDA(45,1)
GENETICALLY ENGINEERED MUTATION(39,1)
ATTENUATED BACTERIA(35,4)
MULTOCIDA STRAIN(30,13)
NUCLEOTIDE SEQUENCE REPLICATION(30,1)
MULTOCIDA HYAD(28,4)
BOOST VACCINATION(28,2)
ATTENUATED BACTERIAL VACCINE(28,1)
LIVE ATTENUATED VACCINE(28,1)
VECTOR PRESERVATION(28,1)
DNA REPLICATION(27,1)
HYAD GENE(26,7)
VECTOR ADMINISTRATION(26,1)
MULTOCIDA(25,46)
BACTERIA(25,15)
TRUNCATED PROTEIN(24,2)
VACCINE(23,25)
INACTIVATED BACTERIA FRACTION(23,2)
PROTECTIVE IMMUNE RESPONSE(22,1)
EXCIPIENT(19,9)
BACTERIAL LIPOPOLYSACCHARIDE(19,2)
NANU PEPTIDE(19,1)
VETERINARILY ACCEPTABLE CARRIER(18,5)
NANU PROTEIN(18,1)
BOVINE(17,12)
PARTIAL DELETION(17,2)
RELIABLE PROTECTION(17,1)
IMMUNOGENIC(16,2)
INACTIVATED VIRUS(16,2)
DELETION(15,6)
MUTANT(15,5)
IMMUNOGENICITY(15,1)
PRODUCING NOVEL(15,1)
ADJUVANT(14,11)
IMMUNE RESPONSE(14,8)
PATENT LAW(14,2)
VETERINARY ACCEPTABLE VEHICLE(14,2)
TRANSFECTION(14,1)
PROTEIN(13,19)
PATENT DEPOSIT DESIGNATION(13,4)
DISEASE(13,1)
REPRODUCTION(13,1)
PASTEURELLA MULTOCIDA(12,6)
VECTOR(12,6)
KIT(12,5)
AUTOCLAVED BRAIN HEART INFUSION(12,3)
COMPOUND FACILITATING COMBINATION(12,1)
STABILIZER(12,1)
DILUENT(11,3)
VACCINE FIELD EFFICACY(11,1)
STRAIN(10,9)
BACTERIA VIRULENCE ATTENUATION(10,2)
LUNG LESION(9,6)
BSSHII DIGESTED PBCSK(9,2)
INFECTION DISEASE(9,2)
BOVINE RESPIRATORY DISEASE(9,1)
SHEEP BLOOD(8,8)
MULTOCIDA INFECTION(8,4)
MULTOCIDA SEROGROUP(8,3)
VACCINATION(8,3)
BACTERIAL TOXIN(8,2)
CHILLED COLUMBIA BROTH(8,2)
PASTEURELLA MULTOCIDA VIRULENCE GENOTYPE(8,1)
VIAL(7,5)
DYE TERMINATOR CHEMISTRY KIT(7,2)
TRUNCATED NANPU GENE(7,2)
VETERINARY LABORATORY AGENCY(7,2)
ACAPSULAR HYAD MUTANT(7,1)
BOVINE PNEUMONIC PASTEURELLOSIS(7,1)
MULTOCIDA NANPU MUTANT(7,1)
PASTEURELLA MULTOCIDA VACCINE CANDIDATE(7,1)
SEVERE SUPPURATIVE BRONCHOPNEUMONIA(7,1)
WILD TYPEOBSERVE CLINICAL SIGN(7,1)
TSA PLATE(6,12)
INTEGRATED REPLACEMENT PLASMID(6,4)
SAFE(6,4)
BHI BROTH(6,3)
TRUNCATED NANPU PRESENCE(6,3)
VACCINE EFFICACY(6,3)
ANTIBIOTIC SUPPLEMENTATION(6,2)
COLUMBIA BLOOD AGAR(6,2)
ELECTROPORATION CUVETTE(6,2)
FETAL BOVINE SERUM(6,2)
PCT109GA REPLICATION(6,2)
PERKIN ELMER GENEAMP(6,2)
ANTIGENIC POLYPEPTIDE VARIANT(6,1)
CAPSULE BIOSYNTHETIC(6,1)
EXPERIMENTAL PNEUMONIA PASTEURELLOSIS(6,1)
KNOCKOUT NANPU(6,1)
MILD PURULENT LESION(6,1)
MUTANT LYOPHILIZED CULTURE(6,1)
PREDOMINATELY TRADITIONAL BACTERIN(6,1)
RANDOM SIGNATURE TAGGED MUTAGENESIS(6,1)
SEVERE PURULENT BRONCHOPNEUMONIA(6,1)
SWINE IMMUNODEFICIENCY VIRUS(6,1)
TRANSPORTER PERMEASE PROTEIN(6,1)
VIABLE ACAPSULAR PHENOTYPE(6,1)
COLONY PCR(5,3)
LYOPHILIZED POWDER(5,3)
STERILE GLYCEROL(5,3)
STERILITY TESTING(5,3)
ABI PRISM(5,2)
AMES IOWA(5,2)
BOOST ADMINISTRATION(5,2)
BOOSTER ADMINISTRATION(5,2)
BOVINE CIRCOVIRUS(5,2)
CATTLE IMMUNITY(5,2)
COMPETENT BACTERIA(5,2)
CSCL CENTRIFUGATION(5,2)
DEXTROSE STARCH(5,2)
DNA SEQUENCER(5,2)
DOUBLE CROSSOVER MUTANT(5,2)
DOUBLE KNOCKOUT MUTANT(5,2)
GENE PULSER(5,2)
HYADR PRIMER(5,2)
IMMUNOGENIC FRAGMENT(5,2)
MUTANT COLONY(5,2)
NUCLEOTIDE REPLACEMENT(5,2)
PLASMID REPLICATION(5,2)
POLYPEPTIDE BIOLOGICAL ACTIVITY(5,2)
PRIME BOOST REGIMEN(5,2)
REPLACEMENT PLASMID LIGATION MIXTURE(5,2)
REPLACEMENT PLASMID RESOLUTION(5,2)
SIALIC ACID UPTAKE(5,2)
SYNDROME VIRUS(5,2)
VETERINARY MICROBIOLOGY(5,2)
ASSIGNED VETERINARIAN DISCRETION(5,1)
BACTERIA PATHOGENICITY(5,1)
BOOSTER VACCINE(5,1)
CLINICAL MICROBIOLOGY JOURNAL(5,1)
HYAD GENE DELETION MUTANT(5,1)
HYAD PARTIAL DELETION MUTANT(5,1)
MEMBRANE BOUND LYSOZYME INHIBITOR(5,1)
NORTH AMERICA CATTLE POPULATION(5,1)
PNEUMONIA CLINICAL SIGN(5,1)
RESTRICTION ENZYME BGLII(5,1)
SIALIC ACID DEFICIENT MUTANT(5,1)
UK CATTLE POPULATION(5,1)
UNCHARGED POLAR GLYCINE(5,1)
WILDLIFE DISEASE JOURNAL(5,1)
MASTER(4,13)
CLONE(4,6)
NON PERMISSIVE TEMPERATURE(4,4)
CULTURE REACHED LOG PHASE(4,3)
EPITOPE MAPPING(4,3)
PRIMARY ADMINISTRATION(4,3)
REGULATORY SEQUENCE(4,3)
AGE WEEK(4,2)
ELECTROPORATED CELL(4,2)
EXACT CFU(4,2)
EXPRESSION VECTOR(4,2)
FRESH GLYCEROL(4,2)
INFECTED HOST(4,2)
INTERNAL DIAGNOSTICS LABORATORY(4,2)
OVERNIGHT INCUBATION(4,2)
PROTEIN FRAGMENT(4,2)
PUBLISHED(4,2)
SIALIC ACID RESIDUE(4,2)
TN ABSENCE(4,2)
ACAPSULAR MUTANT(4,1)
ARGININE SUBSTITUTION(4,1)
ATCC DEPOSITORY(4,1)
ATTENUATED MUTANT(4,1)
ATTENUATED PHENOTYPE(4,1)
ATTENUATING MUTATION(4,1)
BACTERIAL INFECTION PATHOGENESIS(4,1)
BIG HORN SHEEP(4,1)
BUDAPEST TREATY(4,1)
CALF VACCINATION(4,1)
CAPSULAR ANTIGEN(4,1)
CAPSULE BIOSYNTHESIS(4,1)
CATTLE PASTEURELLOSIS(4,1)
CHALLENGE ORGANISM RECOVERY(4,1)
CLINICAL DISEASE SEVERITY(4,1)
CLINICAL SIGN GRAVITY(4,1)
CONFORMATIONAL EPITOPE(4,1)
DAYOF CHALLENGE(4,1)
DELETED HYAD(4,1)
DELETED NANPU(4,1)
DERMONECROTIZING TOXIN(4,1)
ENDOBRONCHIAL POLY P(4,1)
EVENING POST CHALLENGE(4,1)
FACULTATIVE ANAEROBE(4,1)
FATAL PERITONITIS(4,1)
FILAMENTOUS HEMAGGLUTININ(4,1)
FOWL CHOLERA(4,1)
GENETICALLY DISTINCT ENTITY(4,1)
GLYCOSYLTRANSFERASE SYNTHESIS(4,1)
HARBORING BACTERIA(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
HETEROLOGOUS PROMOTER(4,1)
HISTOPHILUS SOMNI(4,1)
HYAD PRIMER(4,1)
HYAE VACCINE(4,1)
HYDROPHOBIC RESIDUE SUBSTITUTION(4,1)
INFECTION PROPHYLAXIS(4,1)
IRON ACQUISITION PROTEIN(4,1)
KANAMYCIN SENSITIVE COLONY(4,1)
LICENSED VETERINARIAN(4,1)
LOCUS NANP(4,1)
LOCUS NANU(4,1)
LOWERED VIRAL TITER(4,1)
MANNHEIMA HAEMOLYTICA(4,1)
MERCK ANIMAL HEALTH(4,1)
METHYLATED NUCLEOTIDE(4,1)
MICROORGANISM ATTENUATION(4,1)
MONTH OLD CALF(4,1)
MUCOSAL ADJUVANT(4,1)
MULTOCIDA BACTERIUM(4,1)
MULTOCIDA GENOME(4,1)
MULTOCIDA HYAD NANPU(4,1)
MULTOCIDA IMMUNOLOGICAL(4,1)
MULTOCIDA OMP(4,1)
NANPU DELETION(4,1)
NANPU PRIMER(4,1)
NEWPORT LABORATORY RESEARCH(4,1)
NUCLEOTIDE SEQUENCE MUTATION(4,1)
OVIS ARIE(4,1)
OVIS CANADENSIS(4,1)
PASTEURELLA IMMUNOGEN(4,1)
PASTEURELLACEAE GENETIC ENGINEERING(4,1)
PBCSK HYADPM(4,1)
PBCSK NANPUPM(4,1)
PENTOBARBITAL INJECTION(4,1)
PERIPLASMIC PROTEIN SIAP(4,1)
PNEUMONIC LESION(4,1)
POLAR RESIDUE SUBSTITUTION(4,1)
POLYSACCHARIDE CAPSULE(4,1)
PRACTICING VETERINARIAN(4,1)
PROTEIN IMMUNOGENICITY(4,1)
RECOMBINANT PLASMID(4,1)
RECOMBINANT POLYNUCLEOTIDE(4,1)
REGULATORY AGENCY(4,1)
REPLACEMENT PLASMID INTEGRATION(4,1)
RESPIRATORY PASTEURELLOSIS(4,1)
SENSITIVE ACAPSULAR COLONY(4,1)
SIALIC ACID METABOLISM(4,1)
SYNTHESIZING OLIGONUCLEOTIDE(4,1)
SYSTEMIC PASTEURELLOSIS(4,1)
TABLE 2STUDY SCHEDULEAGEEVENT(4,1)
TRANSCRIPTION TERMINATOR(4,1)
TRIMETHYLATED CHITOSAN(4,1)
TRUNCATED HYAD GENE PRESENCE(4,1)
UNEQUIVOCAL DEMONSTRATION(4,1)
UNIVERSITY BLVD(4,1)
UNSUBSTITUTED POLYPEPTIDE(4,1)
VACCINATED CALF(4,1)
VIRULENCE GENE(4,1)
VIRULENT PARENT STRAIN(4,1)
WILD TYPE HYAD(4,1)
SINGLE COLONY(3,10)
PCR PRODUCT(3,4)
CRYOVIAL(3,3)
ANTIBIOTIC SELECTION(3,2)
CELL PELLET(3,2)
ECORI SITE(3,2)
HEMORRHAGIC SEPTICEMIA(3,2)
HOST ANIMAL(3,2)
IGM PRODUCTION(3,2)
LIGATION PRODUCT GENERATING PLASMID(3,2)
MUTANT FORMATION(3,2)
NON SELECTION PLATE(3,2)
PCR KIT(3,2)
PCR REACTION(3,2)
REMAINING CALF(3,2)
REPLACEMENT PLASMID CONSTRUCTION(3,2)
WHOLE BACTERIA(3,2)
ACID ASPARTATE(3,1)
ACID TRANSFERASE ENZYME(3,1)
ALKENYL DERIVATIVE POLYMER(3,1)
ANNUAL BOOSTER(3,1)
ANTIGENIC DETERMINANT SITE(3,1)
AVIAN STRAIN(3,1)
BOVINE BACTERIAL PNEUMONIA(3,1)
BP DELETION(3,1)
BRANCHED POLYNUCLEOTIDE(3,1)
CATIONIC LIPID(3,1)
CFU VACCINE DOSE(3,1)
CHALLENGED ANIMAL(3,1)
COLI STRAIN(3,1)
COMMERCIAL VACCINE(3,1)
CONSERVATIVE REPLACEMENT(3,1)
COW DOSE VOLUME(3,1)
DISEASE STATUS(3,1)
DOMESTIC ANIMAL PATHOLOGY(3,1)
EXPRESSION REGULATION(3,1)
EXTRACELLULAR ENZYME(3,1)
GENE FRAGMENT(3,1)
GENETIC STABILITY(3,1)
HOMOLOGOUS PROTEIN(3,1)
HYAD EXPRESSION(3,1)
HYAE GENE(3,1)
IMMUNOGENIC PROTEIN(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
IMMUNOSTIMULATING SEQUENCE(3,1)
INFECTED ANIMAL(3,1)
INSTANT DISCLOSURE VACCINE(3,1)
LIVE STREPTOMYCIN DEPENDENT MUTANT(3,1)
LUNG TISSUE(3,1)
MAJOR PATHOGEN(3,1)
MANNHEIMIA HAEMOLYTICA TRANSMISSION(3,1)
METHIONINE CODON(3,1)
MICROORGANISM GENE(3,1)
MILD DYSPLASIA(3,1)
MOLECULAR CHARACTERIZATION(3,1)
MUTANT CULTURE(3,1)
MUTANT GENE(3,1)
MUTANT PHENOTYPE(3,1)
MUTANT STRAIN(3,1)
MUTATION IDENTIFICATION(3,1)
NANPUR PRIMER(3,1)
NATIVE CODING SEQUENCE(3,1)
NON POLAR ALANINE(3,1)
NUCLEIC ACID ENCODING PEPTIDE(3,1)
NUCLEOTIDE ANALOG(3,1)
NUCLEOTIDE BRANCH(3,1)
NUMEROUS VIRULENCE(3,1)
OLIGODEOXYRIBONUCLEOTIDE SEQUENCE(3,1)
ORGANISM CELL(3,1)
OXFORD STREET(3,1)
PARAMOUNT IMPORTANCE(3,1)
PHD THESIS(3,1)
PLATING COLONY(3,1)
PLURAL REFERENT(3,1)
POLYNUCLEOTIDE SEGMENT(3,1)
POTENTIAL VIRULENCE(3,1)
PRECISE DELETION(3,1)
PROTECTIVE IMMUNITY(3,1)
RANDOM MUTAGENESIS(3,1)
RECOMBINANT TECHNOLOGY(3,1)
RECOMBINANT VECTOR(3,1)
SALI SITE(3,1)
SEQUENCE RNA ISOLATION(3,1)
SERUM ANTIBODY(3,1)
SIALIC ACID TRAP(3,1)
SOMATIC ANTIGEN(3,1)
SPT EMULSION(3,1)
SUBCUTANEOUS ROUTE(3,1)
TARGET ANTIGEN(3,1)
TARGET GENE MODIFICATION(3,1)
TERMINAL BRONCHIOLE EPITHELIUM(3,1)
TERMINAL LIPOOLIGOSACCHARIDE(3,1)
THIOBARBITURIC ACID ASSAY(3,1)
TRANSCRIPTION INITIATION(3,1)
TRANSCRIPTION TERMINATION(3,1)
TRANSPOSON GENERATED MUTANT(3,1)
TRANSPOSON INSERTION(3,1)
TRANSPOSON TN(3,1)
TREATING PLASMID(3,1)
TRUNCATED HYAD PRESENCE(3,1)
US CATTLE(3,1)
VACCINE SAFETY(3,1)
VIRULENT STRAIN(3,1)
YEARLY TREND(3,1)
YOUNG ANIMAL(3,1)
YOUNG CALF(3,1)
APPLIED BIOSYSTEM(2,5)
BIO RAD(2,4)
BIOLOGICALLY SIMILAR RESIDUE(2,4)
KANAMYCIN RESISTANCE ELEMENT(2,4)
BIRD(2,3)
DILUTION(2,3)
IDENTITY(2,3)
MAMMAL(2,3)
NUCLEIC ACID SEQUENCE(2,3)
PIG(2,3)
STERILE DISTILLED WATER(2,3)
ADJUVANT INCREASE(2,2)
AGAR PLATE(2,2)
ASPARAGINE(2,2)
CHEMICAL SYNTHESIS(2,2)
CLOSTRIDIUM(2,2)
COLE(2,2)
COMMON POLYPEPTIDE(2,2)
CONJUGATION(2,2)
CONSTANT RANGING(2,2)
ELECTROPHORESIS(2,2)
ENCODED AMINOACID RESIDUE(2,2)
ESCHERICHIA(2,2)
FELINE(2,2)
GLUTAMINE(2,2)
HAPTEN(2,2)
IDENTIFICATION CONFIRMATION(2,2)
INTERVET(2,2)
INTRON(2,2)
ISOLATED GENE PRODUCT(2,2)
ISOLEUCINE(2,2)
LABELING COMPONENT(2,2)
NUCLEIC ACID FACILITY(2,2)
ORGANELLE(2,2)
PARASUIS(2,2)
PHENYLALANINE(2,2)
POULTRY(2,2)
PROVISO(2,2)
SALMONELLA(2,2)
SUBUNIT(2,2)
TEMPERATURE SENSITIVE PLASMID ORIGIN(2,2)
TEMPERATURE SENSITIVE REPLICATION ORIGIN(2,2)
THERMOCYCLER(2,2)
TRYPTOPHAN(2,2)
TYROSINE(2,2)
ACAPSULAR SINGLE CROSSOVER MUTANT(2,1)
ACRYLIC POLYMER(2,1)
AFRICA REGION(2,1)
AGAROSE GEL IMAGE(2,1)
ALUMINUM PHOSPHATE(2,1)
AMINOACID SPATIAL CONFORMATION(2,1)
ANTIBODY ABILITY(2,1)
ANTIBODY GENERATION(2,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(2,1)
ANTIBODY PRODUCTION(2,1)
ATROPHIC RHINITIS(2,1)
CALF SHOWING CLINICAL SIGN(2,1)
CAPSULE LOSS(2,1)
CODING SEQUENCE START CODON(2,1)
CODING SEQUENCE STOP CODON(2,1)
FEED INTAKE(2,1)
FUNCTIONAL RNA(2,1)
GENOMIC SEQUENCE(2,1)
GRAM NEGATIVE BACTERIA(2,1)
GREEN FLUORESCENT PROTEIN TAGGED ORGANISM(2,1)
IMMUNIZATION(2,1)
IMMUNOGENIC RESPONSE(2,1)
INTEGRATED DNA TECHNOLOGY(2,1)
INTERGENIC REGION(2,1)
IOWA STATE UNIVERSITY PRESS(2,1)
LINEAR EPITOPE(2,1)
LIPOPOLYSACCHARIDE(2,1)
MODIFIED NUCLEOTIDE(2,1)
MUTATED SEQUENCE(2,1)
NANPUPM1062KANR(2,1)
NATIVE SEQUENCE(2,1)
PHOSPHATE BUFFER(2,1)
POST VACCINATION(2,1)
PRELIMINARY WORK(2,1)
PROTECTIVE IMMUNOLOGICAL RESPONSE(2,1)
QUATERNARY AMMONIUM SALT(2,1)
REMAINING INOCULUM(2,1)
RNA DNA HYBRID(2,1)
SAIL(2,1)
SEQUENCE DNA ISOLATION(2,1)
STRUCTURAL ROLE(2,1)
SYNTHETIC ORIGIN(2,1)
TARGET ANIMAL(2,1)
TARGET SPECIES(2,1)
TERM EPITOPE(2,1)
TERM RECOMBINANT(2,1)
UNSUBSTITUTED PARENT AMINOACID(2,1)
WHOLE ORGANISM(2,1)
ACETYLATION(1,1)
ACTIVE FRAGMENT(1,1)
ADHESIN(1,1)
ADHESION(1,1)
(US20180015157)
MULTOCIDA(100,45)
STRAIN(100,16)
BOVINE(100,13)
IMMUNE RESPONSE(100,9)
SAFE(100,5)
IMMUNOLOGICAL(100,3)
ATTENUATED PASTEURELLA MULTOCIDA(100,1)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(100,1)
DISEASE(100,1)
BACTERIA VIRULENCE ATTENUATION(42,2)
MICROORGANISM ATTENUATION(33,1)
MULTOCIDA BACTERIAL STRAIN(32,1)
EXPRESSION VECTOR(31,2)
ATTENUATING MUTATION(31,1)
NUCLEOTIDE SEQUENCE REPLICATION(30,1)
NANPU GENE(29,5)
IMMUNOGENIC(29,2)
BOOST VACCINATION(28,2)
LIVE ATTENUATED VACCINE(28,1)
VECTOR PRESERVATION(28,1)
DNA REPLICATION(27,1)
MULTOCIDA STRAIN(26,13)
VECTOR ADMINISTRATION(26,1)
POLYPEPTIDE BIOLOGICAL ACTIVITY(25,2)
GENETICALLY ENGINEERED MUTATION(24,1)
VIRULENT PARENTAL STRAIN(23,3)
INACTIVATED BACTERIA FRACTION(23,2)
MULTOCIDA CHALLENGE(22,1)
VACCINE(20,24)
HYAD GENE(20,6)
BACTERIAL LIPOPOLYSACCHARIDE(19,2)
NANU PEPTIDE(19,1)
VETERINARILY ACCEPTABLE CARRIER(18,5)
GRAM NEGATIVE BACTERIA(18,1)
ORTHOLOG(18,1)
PARTIAL DELETION(17,2)
RELIABLE PROTECTION(17,1)
INACTIVATED VIRUS(16,2)
HOMOLOG(16,1)
EXCIPIENT(15,9)
VECTOR(15,6)
MUTANT(15,5)
IMMUNOGENICITY(15,1)
PROTEIN(14,17)
BACTERIA(14,15)
ANTIGEN(14,12)
VETERINARY ACCEPTABLE VEHICLE(14,2)
TRANSFECTION(14,1)
GENE(13,18)
PATENT DEPOSIT DESIGNATION(13,4)
REPRODUCTION(13,1)
MUTATION(12,16)
PASTEURELLA MULTOCIDA(12,6)
DELETION(12,5)
AUTOCLAVED BRAIN HEART INFUSION(12,3)
COMPOUND FACILITATING COMBINATION(12,1)
COMPRISED GENE(12,1)
PROTECTIVE IMMUNE RESPONSE(12,1)
ATTENUATED STRAIN(11,10)
VACCINE FIELD EFFICACY(11,1)
KIT(10,5)
ATCC(10,4)
IMMUNOGEN(9,6)
LUNG LESION(9,6)
BSSHII DIGESTED PBCSK(9,2)
INFECTION DISEASE(9,2)
MICROORGANISM(9,2)
PRODUCING NOVEL(9,1)
EPITOPE(8,9)
SHEEP BLOOD(8,8)
MULTOCIDA INFECTION(8,4)
MULTOCIDA SEROGROUP(8,3)
BACTERIAL TOXIN(8,2)
CHILLED COLUMBIA BROTH(8,2)
PATENT LAW(8,2)
PASTEURELLA MULTOCIDA VIRULENCE GENOTYPE(8,1)
VIAL(7,5)
DYE TERMINATOR CHEMISTRY KIT(7,2)
TRUNCATED NANPU GENE(7,2)
VETERINARY LABORATORY AGENCY(7,2)
ACAPSULAR HYAD MUTANT(7,1)
BDV(7,1)
BOVINE PNEUMONIC PASTEURELLOSIS(7,1)
FMDV(7,1)
MULTOCIDA NANPU MUTANT(7,1)
PASTEURELLA MULTOCIDA VACCINE CANDIDATE(7,1)
SEVERE SUPPURATIVE BRONCHOPNEUMONIA(7,1)
WILD TYPEOBSERVE CLINICAL SIGN(7,1)
TSA PLATE(6,12)
INTEGRATED REPLACEMENT PLASMID(6,4)
BHI BROTH(6,3)
TRUNCATED NANPU PRESENCE(6,3)
VACCINE EFFICACY(6,3)
ANTIBIOTIC SUPPLEMENTATION(6,2)
COLUMBIA BLOOD AGAR(6,2)
ELECTROPORATION CUVETTE(6,2)
FETAL BOVINE SERUM(6,2)
PCT109GA REPLICATION(6,2)
PERKIN ELMER GENEAMP(6,2)
ANTIGENIC POLYPEPTIDE VARIANT(6,1)
ATTENUATED BACTERIUM DECREASED VIRULENCE(6,1)
CAPSULE BIOSYNTHETIC(6,1)
EXPERIMENTAL PNEUMONIA PASTEURELLOSIS(6,1)
KNOCKOUT NANPU(6,1)
MILD PURULENT LESION(6,1)
MUTANT LYOPHILIZED CULTURE(6,1)
PREDOMINATELY TRADITIONAL BACTERIN(6,1)
RANDOM SIGNATURE TAGGED MUTAGENESIS(6,1)
SEVERE PURULENT BRONCHOPNEUMONIA(6,1)
SWINE IMMUNODEFICIENCY VIRUS(6,1)
TRANSPORTER PERMEASE PROTEIN(6,1)
VIABLE ACAPSULAR PHENOTYPE(6,1)
IDENTITY(5,4)
COLONY PCR(5,3)
COMPARABLE FUNCTION(5,3)
DILUENT(5,3)
LYOPHILIZED POWDER(5,3)
STERILE GLYCEROL(5,3)
STERILITY TESTING(5,3)
ABI PRISM(5,2)
AMES IOWA(5,2)
BOOST ADMINISTRATION(5,2)
BOOSTER ADMINISTRATION(5,2)
BOVINE CIRCOVIRUS(5,2)
CATTLE IMMUNITY(5,2)
COMPETENT BACTERIA(5,2)
CSCL CENTRIFUGATION(5,2)
DEXTROSE STARCH(5,2)
DNA SEQUENCER(5,2)
DOUBLE CROSSOVER MUTANT(5,2)
DOUBLE KNOCKOUT MUTANT(5,2)
GENE PULSER(5,2)
HYADR PRIMER(5,2)
IMMUNOGENIC FRAGMENT(5,2)
MUTANT COLONY(5,2)
NUCLEOTIDE REPLACEMENT(5,2)
PLASMID REPLICATION(5,2)
PRIME BOOST REGIMEN(5,2)
REPLACEMENT PLASMID LIGATION MIXTURE(5,2)
REPLACEMENT PLASMID RESOLUTION(5,2)
SIALIC ACID UPTAKE(5,2)
SYNDROME VIRUS(5,2)
VETERINARY MICROBIOLOGY(5,2)
ASSIGNED VETERINARIAN DISCRETION(5,1)
BACTERIA PATHOGENICITY(5,1)
BOOSTER VACCINE(5,1)
CLINICAL MICROBIOLOGY JOURNAL(5,1)
HYAD GENE DELETION MUTANT(5,1)
HYAD PARTIAL DELETION MUTANT(5,1)
MEMBRANE BOUND LYSOZYME INHIBITOR(5,1)
NORTH AMERICA CATTLE POPULATION(5,1)
PNEUMONIA CLINICAL SIGN(5,1)
RESTRICTION ENZYME BGLII(5,1)
SIALIC ACID DEFICIENT MUTANT(5,1)
UK CATTLE POPULATION(5,1)
UNCHARGED POLAR GLYCINE(5,1)
WILDLIFE DISEASE JOURNAL(5,1)
MASTER(4,13)
CLONE(4,6)
NON PERMISSIVE TEMPERATURE(4,4)
CULTURE REACHED LOG PHASE(4,3)
EPITOPE MAPPING(4,3)
PRIMARY ADMINISTRATION(4,3)
REGULATORY SEQUENCE(4,3)
AGE WEEK(4,2)
ELECTROPORATED CELL(4,2)
EXACT CFU(4,2)
FRESH GLYCEROL(4,2)
INFECTED HOST(4,2)
INTERNAL DIAGNOSTICS LABORATORY(4,2)
OVERNIGHT INCUBATION(4,2)
PROTEIN FRAGMENT(4,2)
PUBLISHED(4,2)
SALI SITE(4,2)
SIALIC ACID RESIDUE(4,2)
TN ABSENCE(4,2)
ACAPSULAR MUTANT(4,1)
ARGININE SUBSTITUTION(4,1)
ATTENUATED MUTANT(4,1)
ATTENUATED PHENOTYPE(4,1)
BACTERIAL INFECTION PATHOGENESIS(4,1)
BIG HORN SHEEP(4,1)
CALF VACCINATION(4,1)
CAPSULAR ANTIGEN(4,1)
CAPSULE BIOSYNTHESIS(4,1)
CATTLE PASTEURELLOSIS(4,1)
CHALLENGE ORGANISM RECOVERY(4,1)
CLINICAL DISEASE SEVERITY(4,1)
CLINICAL SIGN GRAVITY(4,1)
CONFORMATIONAL EPITOPE(4,1)
DELETED HYAD(4,1)
DELETED NANPU(4,1)
DERMONECROTIZING TOXIN(4,1)
ENDOBRONCHIAL POLY P(4,1)
EVENING POST CHALLENGE(4,1)
FACULTATIVE ANAEROBE(4,1)
FATAL PERITONITIS(4,1)
FILAMENTOUS HEMAGGLUTININ(4,1)
FOWL CHOLERA(4,1)
GENETICALLY DISTINCT ENTITY(4,1)
GLYCOSYLTRANSFERASE SYNTHESIS(4,1)
HARBORING BACTERIA(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
HETEROLOGOUS PROMOTER(4,1)
HISTOPHILUS SOMNI(4,1)
HYAD PRIMER(4,1)
HYAE VACCINE(4,1)
HYDROPHOBIC RESIDUE SUBSTITUTION(4,1)
INFECTION PROPHYLAXIS(4,1)
IRON ACQUISITION PROTEIN(4,1)
KANAMYCIN SENSITIVE COLONY(4,1)
LICENSED VETERINARIAN(4,1)
LOCUS NANP(4,1)
LOCUS NANU(4,1)
LOWERED VIRAL TITER(4,1)
MANNHEIMA HAEMOLYTICA(4,1)
MERCK ANIMAL HEALTH(4,1)
METHYLATED NUCLEOTIDE(4,1)
MONTH OLD CALF(4,1)
MUCOSAL ADJUVANT(4,1)
MULTOCIDA BACTERIUM(4,1)
MULTOCIDA GENOME(4,1)
MULTOCIDA HYAD NANPU(4,1)
MULTOCIDA IMMUNOLOGICAL(4,1)
MULTOCIDA OMP(4,1)
NANPU DELETION(4,1)
NANPU PRIMER(4,1)
NEWPORT LABORATORY RESEARCH(4,1)
NUCLEOTIDE SEQUENCE MUTATION(4,1)
OVIS ARIE(4,1)
OVIS CANADENSIS(4,1)
PASTEURELLA IMMUNOGEN(4,1)
PASTEURELLACEAE GENETIC ENG(...)";Pharmaceuticals;Open
2013-07-29;"WO2015013739        A1 2015-02-05 [WO201513739]
STG: (A1) Published application with search report
AP : 2014WO-AU00750 2014-07-25";68500825;WO2015013739        A1 2015-02-05 [WO201513739];2013AU-0902802;;GRIFFITH UNIVERSITY;GRIFFITH UNIVERSITY;"(WO201513739)
AU";"(WO201513739)
NAME=GRIFFITH UNIVERSITY 170 Kessels Road Nathan, Queensland 4111 , COUNTRY=AU 
";1;GOOD MICHAEL;"(WO201513739)
AU";"(WO201513739)
NAME=GOOD, Michael 21 Brindabella Street Chapel Hill, Queensland 4069 , COUNTRY=AU 
";"(WO201513739)
Attenuated babesia vaccine";"(WO201513739)
An immunogenic composition and method of producing an immunogenic composition include isolated or purified blood-stage Babesia parasites, or red blood cells infected with blood-stage Babesia parasites, treated with tafuramycin A or an analog or derivative thereof. Typically, the blood-stage Babesia parasites are, or include, any form of the parasite that exists within red blood cells, including but not limited to merozoites. The immunogenic composition is used for the treatment or prophylaxis of babesiosis in mammals such as bovines.";"(WO201513739)
22 CLAIMS
1. A method of producing an immunogenic composition including the step of treating blood-stage Babesia parasites or red blood cells infected with said blood- stage Babesia parasites with tafuramycin A or an analog or derivative thereof, to thereby produce said immunogenic composition.
2. The method of Claim 1 , wherein the method excludes the step of including an adjuvant
3. The method of Claim 1 or Claim 2, wherein isolated or purified blood-stage parasites are treated with tafuramycin A or an analog or derivative thereof.
4. The method of Claim 3, wherein red blood cells are subsequently infected with the treated blood-stage parasites to produce parasitized red blood cells (pRBC).
5. The method of Claim 1 or Claim 2, wherein fed blood cells infected with blood-stage parasites (pRBC) are treated with tafuramycin A or an analog or derivative thereof.
6. The method of any preceding claim, which comprises red blood cells infected with the blood-stage Babesia parasites.
7. The method of Claim 6, wherein the red blood cells infected with said blood- stage Babesia parasites are intact.
8. The method of any preceding claim wherein the blood-stage parasites are merozoites, schizonts, trophozoites or rings.
9. An immunogenic composition obtainable by the method of any one of Claims 1-8.
10. An immunogenic composition comprising blood-stage Babesia parasites or red blood cells infected with said blood-stage Babesia parasites that have been treated with tafuramycin A or an analog or derivative thereof; and an immunologically acceptable carrier, diluent and/or excipient. 
 1 1. An immunogenic composition for use in preventing or treating babesiosis in an animal, said immunogenic composition comprising blood-stage Babesia parasites or red blood cells infected with said blood-stage Babesia parasites that have been treated with tafuramycin A or an analog or derivative thereof; and an immunologically acceptable carrier, diluent and/or excipient.
12. The immunogenic composition of any one of Claims 9-11, for use as a Babesia vaccine. 23
13. The immunogenic composition of Claim 12, for use as a blood-stage babesiosis vaccine.
14. The immunogenic composition of any one of Claims 9- 13, wherein the animal is a bovine.
15. The immunogenic composition of any one of Claims 9-14, which does not include an adjuvant.
16. The immunogenic composition of any one of Claims 9-15, which comprises Wood cells infected with the blood-stage Babesia parasites.
17. The immunogenic composition of Claim 16, wherein the red blood cells infected with said blood-stage Babesia parasites are intact.
18. The immunogenic composition of any one of Claims 9-17, wherein the blood-stage Babesia parasites comprise merozoites.
19. The immunogenic composition of any one of Claims 9-18, wherein administration of a single dose of the irnmunogenic composition prevents subsequent Babesia infection.
20. The immunogenic composition of any one of Claims 9-1 , which provides heterologous protection against infection by one or more other isolates, strains and/or species of Babesia.
21. The method or irnmunogenic composition of any preceding claim, wherein tafuramycin A or an analog or derivative thereof is a compound of Formula I:. 
 (I) 24 wherein, 
 Ri is either NHR or OR. where R is selected from H, benzyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyI and N'-methylpiperazin l-N-carbcmyl;
 R2 is selected rom H and Ci^ alkyl: 
 R¾ is selected from H and CM alkyl; 
 or R2and R.<, form a fused ring selected from the group consisting of a benzene ring, a pyrrole ring, a pyridine ring, a furan ring and a 5-methylfuran ring, which fused ring may be optionally substituted with Ci.*, alkyl. CF.< or C\* aJkyloxycarbonyl; 
 Y is an alkylene radical selected from -CH;-, -CH^CH;- or -CH;CH;CH2-; or Y may be -CH- to form a fi ve-raembered ring with R»; 
 X is an electrophilic leaving group 
 R4 is selected from H, Ci-6 alkyl, a -CHj- group bonded to Y to form a five- membered ring or a -CH;- group bonded to the -CH;- to which X is attached to form a six membered ring; 
 Rs is selected from the group consisting of: 
 (a) 
where Y| and Y; are independently selected from 0 and NH; 
 (b) 
25 
 (h) 26
; and 
 (i) t-butoxy, benzyloxy and 9-fhiorenylmethyloxy. 22. The method or immunogenic composition of Claim , wherein tafuramycin A or an analog or derivative thereof is a compound of Formula II: 

24. The method or immunogenic composition of any preceding claim, wherein the concentration of tafuramycin or analog or derivative thereof is 0.5-50 μ or preferably 2-20 μΜ.
25. A method of treating or preventing babesiosis in an animal, said method including the step of administering the immunogenic composition of any one of Claims 9-24 to an animal to thereby prevent or inhibit Babesia infection or treat an existing Babesia infection in said animal.
26. The method of Claim 25, wherein administration of a single dose of the immunogenic composition prevents subsequent Babesia infection.
27. The method of Claim 26, which provides heterologous protection against infection by one or more other isolates, strains and/or species of Babesia.
28. The method of any one of Claims 25-27, which excludes the step of administering adjuvant to the animal. 27
29. The method of any one of Claims 25-28» wherein the animal is a bovine.";"(WO201513739)
In another aspect, the invention provides an immunogenic composition comprising blood-stage Babesia parasites or red blood cells infected with said Wood- stage Babesia parasites that have been treated with tafuramycin A or an analog or derivative thereof; and an immunologically acceptable carrier, diluent or excipient.
In one aspect, the invention provides a method of producing an immunogenic composition including the step of treating blood-stage Babesia parasites or red blood cells infected with said blood-stage Babesia parasites with tafuramycin A or an analog or derivative thereof to thereby produce said immunogenic composition.
More particularly, this invention relates to the use of chemically-attenuated babesia parasites as a vaccine against babesia.";"(WO201513739)
It will be appreciated from the foregoing that one embodiment of the invention relates to in vitro treatment of isolated or purified blood-stage Babesia parasites or red blood ceils infected with blood-stage parasites, with tafuramycin A or an analog or derivative of tafuramycin A.
One preferred, unexpected advantage of the present invention is that the tafuramycin A-treated blood-stage Babesia parasites of a particular isolate, strain or species may, upon administration to an animal, immunize or vaccinate against infectio by heterologous Babesia isolates, strains and/or species.
Babesiosis is a group of diseases and conditions of mammals caused by, or otherwise associated, protozoan protists of the genus Babesia.
Typically the attenuated blood-stage Babesia parasites are not capable of proliferation, or are capable of only limited proliferation, following attenuation by treatment with tafuramycin A.";"A61K-039/018
A61P-033/00";"(WO201513739)
1. A method of producing an immunogenic composition including the step of treating blood-stage Babesia parasites or red blood cells infected with said blood- stage Babesia parasites with tafuramycin A or an analog or derivative thereof, to thereby produce said immunogenic composition.
10. An immunogenic composition comprising blood-stage Babesia parasites or red blood cells infected with said blood-stage Babesia parasites that have been treated with tafuramycin A or an analog or derivative thereof; and an immunologically acceptable carrier, diluent and/or excipient.
1 1. An immunogenic composition for use in preventing or treating babesiosis in an animal, said immunogenic composition comprising blood-stage Babesia parasites or red blood cells infected with said blood-stage Babesia parasites that have been treated with tafuramycin A or an analog or derivative thereof; and an immunologically acceptable carrier, diluent and/or excipient.
(I) 24 wherein, Ri is either NHR or OR. where R is selected from H, benzyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyI and";"(WO201513739)
BABESIA PARASITE(100,47)
IMMUNOGENIC(100,40)
ANIMAL(100,23)
TREATING BABESIOSIS(100,2)
GENUS BABESIA PROTOZOON PROTIST(62,2)
CHEMICALLY ATTENUATED BABESIA PARASITE(40,1)
BLOOD STAGE(39,29)
IMMUNOLOGICALLY ACCEPTABLE CARRIER(39,5)
TAFURAMYCIN(37,28)
BLOOD STAGE PARASITE(37,4)
BABESIA INFECTION(34,13)
HETEROLOGOUS BABESIA(25,2)
BLOOD STAGE TREATMENT(23,3)
HETEROLOGOUS PROTECTION(22,2)
BABESIOSIS VACCINE(22,1)
IRNMUNOGENIC(21,2)
RED BLOOD CEIL(21,2)
EXCIPIENT(19,6)
BENZYLOXYCARBONYL(18,1)
ATTENUATED BLOOD STAGE(16,3)
TAFURAMYCIN CONCENTRATION(16,1)
DILUENT(15,7)
TREATED BLOOD STAGE PARASITE(14,1)
WOOD STAGE(14,1)
STRAIN(13,8)
PROLIFERATION(13,1)
DISEASE GROUP(12,1)
BABESIOSIS(11,15)
BABESIA BIGEMENA(11,6)
SINGLE DOSE ADMINISTRATION(11,2)
BENZYL(11,1)
RED BLOOD CELL(10,28)
VACCINE(10,2)
LIMITED PROLIFERATION(10,1)
WOOD CELL(10,1)
TREATED BLOOD STAGE(9,4)
ADMINISTRATION(9,3)
SCHIZONT(9,1)
BABESIA(8,7)
BABESIA BOVIS(8,5)
ATTENUATION(8,4)
TROPHOZOITE(8,3)
MAMMAL(7,4)
PARASITIZED RED BLOOD CELL(7,3)
CHEMICALLY ATTENUATING BABESIA PARASITE(7,1)
GENUS PATHOGENIC PROTIST(7,1)
SHORTHORN SPLENECTORAISED CALF(7,1)
BABESIA CANIS(6,3)
BABESIA OCCULTAN(6,2)
PERSISTENT PARASITAEMIA(6,2)
ATTENUATED BABESIA VACCINE(6,1)
BABESIA PATHOGEIC SPECIES(6,1)
PARASITIZED RED BLOOD CEIL(6,1)
TICK BORNE BABESIA DIVERGEN(6,1)
BLOOD STAGE BABESIOSIS(5,3)
MICROSCOPIC EXAMINATION(5,3)
BABESIA OVIS(5,2)
BABESIOSIS THERAPEUTIC TREATMENT(5,2)
INFECTED TICK(5,2)
BABESIOSIS OUTBREAK(5,1)
CATTLE ARTHROPOD BORNE DISEASE(5,1)
CAUSATIVE BABESIA SPECIES(5,1)
INACCURATE PARASTTAEMIA COUNT(5,1)
INFECTED HOST MAMMAL BLOOD(5,1)
LIVE ATTENUATED VACCINE DIXIE(5,1)
MEROZOITE ESCAPING SIMULTANEOUS WAVE(5,1)
METABOLIZE EXCESS BILIRUBIN(5,1)
PARASITE REPLICATION INHIBITION(5,1)
PARASITEMIA RECRUDESCENCE(5,1)
STAINED TAIL TIP SMEAR(5,1)
SUSCEPTIBLE INTACT YEARLING(5,1)
VIRULENCE REVERSION RISK(5,1)
IMMUNIZATION(4,5)
ADJUVANT ABSENCE(4,3)
ADJUVANT ADMINISTRATION(4,2)
CATTLE POPULATION(4,2)
JUGULAR VEIN BLOOD SMEAR(4,2)
LITHIUM HEPARIN(4,2)
PATHOGENIC SPECIES(4,2)
THERAPEUTIC INTERVENTION(4,2)
BABESIA CABALLI(4,1)
BABESIA DIVERGETIS(4,1)
BABESIA EABALLI(4,1)
BABESIA INFECTION CYCLE(4,1)
BABESIA MEROZOITE(4,1)
BABESIA OVATA(4,1)
BOVINE BABESIOSIS FOLLOWED OBSERVATION(4,1)
CEREBRAL BABESIOSIS(4,1)
ERYTHROCYTE SLUDGING(4,1)
IMMUNOGENIC COMPOSITIOA(4,1)
MARKED CLINICAL DISTRESS(4,1)
TAFTIRAMYCM EFFICACY(4,1)
VACCINATION STRATEGY(4,1)
MESYLATE(3,4)
TOSYLATE(3,4)
BABESIA MICROTI(3,2)
BABESIOSIS TREATMENT(3,2)
BLOOD MEAL(3,2)
INTACT CELL(3,2)
MAMMALIAN HOST(3,2)
STOCK SOLUTION DILUTION(3,2)
ADULT CATTLE(3,1)
ATTENUATED DIXIE(3,1)
BABESI PARASITE(3,1)
BABESIA AV(3,1)
BABESIA MOIASI(3,1)
BABESIA MOTASI(3,1)
BEVT IRBCS(3,1)
BOS INDICA(3,1)
BOVINE MAMMAL MAIN PARASITE(3,1)
BREEDER HERD(3,1)
CALF ABORTION(3,1)
CATTLE FEVER(3,1)
CEREBRAL CAPILLARY(3,1)
CHALLENGE INOCULATION(3,1)
CHEMICALLY ATTENUATED WHOLE(3,1)
COCCYGEAL ARTERY VEIN(3,1)
DIRECT MEMORY ACCESS REGION RICH(3,1)
DISEASE PROGRESSION(3,1)
DISEASE SYMPTOM(3,1)
DIXIE EVIDENCE(3,1)
ERIA SPP(3,1)
ETERO GATIS(3,1)
EXCLUDED ADJUVANT(3,1)
EXPERIENCED PYREXIA(3,1)
FEMALE GAMETE(3,1)
FEVER SUCCESSIVE WAVE(3,1)
FREUND ADJUVANT(3,1)
HOMOLOGOUS DIXIE(3,1)
HOVIS ELISA(3,1)
IMMUNE RESPONSE ELICITATION(3,1)
INFECTED WI(3,1)
ISOTONIC SALINE(3,1)
IXODE RICM(3,1)
IXODE SPECIES(3,1)
LIVE VACCINE(3,1)
MAMMALIAN SUBFAMILY MEMBER(3,1)
MEROZOITE ADMINISTRATION(3,1)
OCCASIONAL FLUCTUATION(3,1)
PARASITAEMIA PERCENTAGE(3,1)
PRBC DOSE(3,1)
PREVENTATIVE THERAPY(3,1)
PROPHYLACTIC THERAPY(3,1)
PROTOZOON DISEASE(3,1)
PURIFIED BLOOD STAGE PARASITE(3,1)
REPHCATIVE BLOOD STAGE(3,1)
SC IZONT(3,1)
SEVERE HEMOLYTIC ANEMIA(3,1)
STATED INTEGER INCLUSION(3,1)
SUBSTANCE ENCAPSULATION(3,1)
SUDDEN DECLINE(3,1)
SYMPTOM ONSET(3,1)
SYSTEMIC ADMINISTRATION(3,1)
TAFURAMYCIN DOSE(3,1)
TH IMMUNOGENIC(3,1)
TISSUE CULTURE FLASK(3,1)
BROMO(2,4)
DONKEY(2,3)
SUPERNATANT(2,3)
B MICROSCOPIC EVIDENCE(2,2)
BUFFALO(2,2)
FINAL CONCENTRATION(2,2)
IMMUNITY(2,2)
INCUBATOR(2,2)
MALARIA(2,2)
MMUTE(2,2)
RED BLOOD CELL INFECTION(2,2)
ACARICIDE TREATMENT(2,1)
ALKYLOXYCARBCMYL(2,1)
ANIMAL RECOVERY(2,1)
APPETITE LOSS(2,1)
ASYMPTOMATIC CARRIER(2,1)
BINARY FISSION(2,1)
BLOOD DONOR(2,1)
BOVINE TREATMENT(2,1)
BOVIS PC(2,1)
BULK(2,1)
CALF TREATMENT(2,1)
CATTLE TRADE(2,1)
CORRECT DOSE(2,1)
DISSEMINATED INTRAVASCULAR COAGULATION(2,1)
ECONOMIC IMPACT(2,1)
ELECTROPHILIC LEAVING(2,1)
FINAL CENTRIFUGATION(2,1)
HEMOCYTOMETER(2,1)
HEMOGLOBINURIA(2,1)
HR DURATION(2,1)
HUMAN BABESIOSIS(2,1)
IMMUNOGENIC COMPOSITION COMPONENT(2,1)
INCUBATION COMPLETION(2,1)
INDUSTRIALIZING PRODUCTION(2,1)
INFECTED ANIMAL(2,1)
IRAUNOGENIC(2,1)
IRREGULAR INTERVAL(2,1)
JUGULAR VEIN EDETIC ACID(2,1)
LIMITATION TTHERETO(2,1)
LIVER FAILURE(2,1)
MAXIMUM PARASHAEMIA COUNT(2,1)
MAXIMUM PARASITAEMIA(2,1)
MEAT PRODUCTION(2,1)
MEROZOITE STAGE(2,1)
MEROZOITE TREATMENT(2,1)
MILK LOSS(2,1)
MONITORED DAILY(2,1)
NATURAL INFECTION(2,1)
PARASITE TREATMENT(2,1)
PARTIALLY PURIFIED PARASITE PREPARATION(2,1)
PCR ANALYSIS(2,1)
PH BUFFERING(2,1)
PLAUSIBILITY(2,1)
POSITIVE ERYTHROCYTE(2,1)
POST CHALLENGE SAMPLE(2,1)
PRODUCING SPOROZOITE(2,1)
RAPID DECLINE(2,1)
RECIPIENT ANIMAL(2,1)
SCIENTIFIC DOCUMENT(2,1)
SLOW DECLINE(2,1)
STAGE LIVER(2,1)
THICK TAIL TI(2,1)
THROMBOCYTOPENIA(2,1)
TREATED BLOOD STAGE BABESIA(2,1)
TRICHLOROETHANE RESIDUE(2,1)
UNEXPECTED BENEFIT(2,1)
UNREGISTERED PRODUCT(2,1)
UNTREATED BLOOD STAGE(2,1)
YELLOW MUCOUS MEMBRANE(2,1)
DEER(1,3)
DISORDER(1,3)
HORSE(1,3)
L CALF(1,3)
PIG(1,3)
SHEEP(1,3)
ACCURATE CELL(1,1)
ALKYLSULFONYL(1,1)
ANIMAL PACKED CELL VOLUME(1,1)
ANIMAR(1,1)
AUSTRALIA AREA(1,1)
AZANIUM(1,1)
BABESIA TREATED MEROZOITE(1,1)
BLOODSTREAM(1,1)
BUPARVAQUONE(1,1)
CATTLE RED BLOOD CELL(1,1)
CHAROLAIS(1,1)
CONTAMINATION(1,1)
DISCOVERY(1,1)
DISINTEGRANT(1,1)
DUOCARMYCIN(1,1)";Pharmaceuticals;Open
2013-06-27;"BR102013016531      A1 2013-07-09 [BR102013016531]
STG: (A1) Published application
AP : 2013BR-0016531 2013-06-27
BR102013016531      A2 2015-08-25 [BR102013016531]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2013BR-0016531 2013-06-27";70801942;"BR102013016531      A1 2013-07-09 [BR102013016531]
BR102013016531      A2 2015-08-25 [BR102013016531]";2013BR-0016531;;UFPEL-UNIVERSIDADE FEDERAL DE PELOTAS;UFPEL-UNIVERSIDADE FEDERAL DE PELOTAS;"(BR102013016531)
BR";"(BR102013016531)
NAME=UNIVERSIDADE FEDERAL DE PELOTAS , COUNTRY=BR 
";1;"RIZZI CAROLINE
BORSUK SIBELE
DELLAGOSTIN ODIR ANTÔNIO";;;"(BR102013016531)
Recombinant Cepa of bcg pasteur auxotrofico and its use as vaccine against the bovine tuberculosis";"(BR102013016531)
Recombinant Cepa of bcg pasteur auxotrofico and its use as vaccine against the bovine tuberculosis. Does the present invention mention to a vaccine cepa of mycobacterium bovis bcg recombinant expressing the antigen 85b of mycobacterium bovis (bcg? leud-85b). The vaccine cepa of the present invention is employed as vaccine against the bovine tuberculosis. The vaccine cepa is a auxotrofica cepa for the leucina amino acid derivative of the cepa bcg pasteur complemented for leucina after genetic transformation with the construction pup410:: fbpb? kan. The effectiveness of the cepa for the bovis control of the infection with mycobacterium on the basis of the expression of the recombinant antigen 85b in vivo is demonstrated in the present invention.";;;;"A61K-039/04
A61P-031/06
C12N-001/21
C12N-015/31
C12R-001/32";;;Pharmaceuticals;Open
2013-05-16;"CN104163858         A  2014-11-26 [CN104163858]
STG: (A) Published application
AP : 2013CN-0181740 2013-05-16
CN104163858         B  2017-05-17 [CN104163858B]
STG: (B) Granted patent for invention
AP : 2013CN-0181740 2013-05-16";67985370;"CN104163858         A  2014-11-26 [CN104163858]
CN104163858         B  2017-05-17 [CN104163858B]";2013CN-0181740;;PU LIKE BIO ENGINEERING;PU LIKE BIO ENGINEERING;;;1;"TIAN KEGONG
ZHANG XUKE
SUN JINZHONG
BAI CHAOYONG";;;"(CN104163858B)
P. multocida a cellular antigens, preparation method and use thereof";"(CN104163858B)
The invention relates to a pasteurella multocida acellular antigen, which is derived from deactivated supernate of pasteurella multocida culture medium, wherein the supernate contains polysaccharide and protein. The invention further provides a pasteurella multocida indirect hemagglutination test method, which is built on the basis of the antigen and has a very good specificity and sensitivity. The invention also provides a vaccine containing the antigen. The provided pasteurella multocida acellular antigen vaccine has the same immunity effect as that of whole cell vaccine, and has the advantages of no affection on animal growth, and little side effect on the vaccine injected part.";"(CN104163858)
1. A multocida cell-free antigen, characterized in, antigens from the inactivated multocida culture supernatant, the supernatant containing the polysaccharide and protein.
2. Antigen according to claim 1, characterized in, in a polysaccharide antigen 0.5-0.7 mg/ml in an amount, antigen protein content 8.8-10.6 mg/ml.
3. Antigen 1 according to claim or 2, characterized in, a cell antigen multocida cell-free antigen to animals and more p. multocida; preferably a pig, rabbit, chicken, cow or sheep.
4. A method of producing claim 1-3, any p. multocida cell-free method of antigen, characterized in, the method comprises: the p. multocida inoculated serum-containing medium, the cultured 30-40 °C 8-24 h, multocida culture obtained, the p. multocida culture inactivated after centrifugation or by direct precipitation, discarded cells, the supernatant is obtained with polysaccharides and proteins containing both multocida cell-free antigen.
5. The method according to claim 4, characterized in, the concentration of serum based medium is 2-20% (V/V).
6. The method according to claim 4 or 5, characterized in, Martin medium media is improved.
7. Claim 1-3, multocida antigen in any one of application in serological testing.
8. One p. multocida cell-free vaccine, characterized in, that has the claim 1-3, p. multocida in any one of a cellular antigens, adjuvants and preservatives.
9. Vaccine according to claim 8, characterized in, multocida cell-free vaccine antigen A final concentration 70-95% (V/V); 4-29% adjuvant in a vaccine in a final concentration (V/V); preservative is thimerosal, in a final concentration of vaccine 0.001-0.01% (V/V).
10. A method of cell-free preparation of multi p. multocida vaccine, characterized in, the method comprises: a serum-containing medium inoculated multocida, in cultured 30-40 °C 8-24 h, multocida obtained culture, the culture inactivated multocida after centrifugation or by direct precipitation, discarded cells, the supernatant is obtained with polysaccharides and protein multocida cell-free antigen, the antigen after certified by sterile, adjuvanted and thimerosal, after kneading is p. multocida cell-free vaccine.";"(CN104163858)
The present invention relates to the field of veterinary biologics, and particularly relates to a p. multocida cell-free antigen.
To achieve the purpose of the invention, the present invention provides a p. multocida cell-free antigen, wherein the antigen is derived from inactivated p. multocida culture supernatant, the supernatant containing the polysaccharide and protein.
The present invention relates to a multocida cell-free antigen, wherein the antigen is derived from inactivated multocida culture supernatant, the supernatant containing the polysaccharide and protein.
The present invention also provides a method utilizing antigen-established multocida indirect hemagglutination test method, the method has good specificity and sensitivity; the present invention also provides a vaccine comprising an antigen.";"(CN104163858)
In the last century, YUE-SHOUNG LU et al. then demonstrated that the p. multocida outer membrane protein in rabbits can give a good immune response, and is capable of homologous strains provided 100% protection of the challenge.
The present invention aims to solve the technical problems of the prior art is directed, to provide a p. multocida cell-free antigen, the antigen preparation method is simple, easy industrial-scale production, and has good irnniunogenicity; the of the present invention sensitized sheep red blood cells after the cell-free antigen, can be used to detect more p. multocida-specific antibody, the detection method specificity and stability are relatively good.
P. multocida (Pasteurell multoeida, Pm) can cause a variety of animal pasteurized mycobacterial diseases, such as avian species of fowl cholera, lung disease, bovine, rabbit animal hemorrhagic septicemia.
Both of which can give an immunogenic of outer membrane proteins, but the operation steps are complicated, difficult to achieve large scale production.";"A61K-039/102
A61P-031/04
C07K-014/285";"(CN104163858)
1. A multocida cell-free antigen, characterized in, antigens from the inactivated multocida culture supernatant, the supernatant containing the polysaccharide and protein.
10. A method of cell-free preparation of multi p. multocida vaccine, characterized in, the method comprises: a serum-containing medium inoculated multocida, in cultured 30-40 Ć 8-24 h, multocida obtained culture, the culture inactivated multocida after centrifugation or by direct precipitation, discarded cells, the supernatant is obtained with polysaccharides and protein multocida cell-free antigen, the antigen after certified by sterile, adjuvanted and thimerosal, after kneading is p. multocida cell-free vaccine.";"(CN104163858)
ANTIGEN(100,27)
MULTOCIDA CELL FREE ANTIGEN(100,22)
SUPERNATANT(100,16)
POLYSACCHARIDE(100,11)
PROTEIN(100,9)
MULTI P(100,3)
MULTOCIDA VACCINE(100,3)
INACTIVATED MULTOCIDA CULTURE SUPERNATANT(100,2)
CELL FREE PREPARATION(100,1)
CULTURE INACTIVATED MULTOCIDA(56,1)
FOWL CHOLERA AVIAN SPECIES(54,1)
MULTOCIDA VACCINE EFFICACY(37,1)
MEDIUM INOCULATED MULTOCIDA(36,1)
PASTEURELL MULTOEIDA(36,1)
MULTOCIDA CULTURE SUPERNATANT(34,2)
PROTEIN MULTOCIDA(33,1)
ANIMAL HEMORRHAGIC SEPTICEMIA(30,1)
MULTOCIDA INOCULATED SERUM(30,1)
MYCOBACTERIAL DISEASE(29,1)
YUE SHOUNG LU(29,1)
ANTIGEN ESTABLISHED MULTOCIDA(28,1)
DISCARDED CELL(23,2)
CHALLENGE PROTECTION(23,1)
CELL ANTIGEN(22,2)
MULTOCIDA ANTIGEN(21,1)
MULTOCIDA OBTAINED CULTURE(20,1)
HOMOLOGOUS STRAIN(18,3)
IMMUNE RESPONSE(18,2)
MULTOCIDA(16,31)
DIRECT PRECIPITATION(16,4)
ANTIGEN PROTEIN CONTENT(16,1)
SEROLOGICAL TESTING(16,1)
MULTOCIDA OUTER MEMBRANE PROTEIN(15,5)
VACCINE(14,24)
IRNNIUNOGENICITY(14,2)
ANIMAL VARIETY(14,1)
MULTOCIDA CELL FREE VACCINE(13,16)
THIMEROSAL(13,6)
MULTOCIDA INDIRECT HAEMAGGLUTINATION(13,3)
INACTIVATED P(13,1)
VACCINE FINAL CONCENTRATION(13,1)
CENTRIFUGATION(12,9)
POST RESUSCITATION SERUM(12,7)
ANIMAL GROWTH(12,3)
CENTURY(12,2)
VETERINARY BIOLOGICS FIELD(12,1)
RABBIT(11,14)
SERUM MODIFIED MARTIN BROTH(11,8)
SERUM CONCENTRATION(11,2)
LUNG DISEASE(11,1)
MULTOCIDA SPECIFIC ANTIBODY(11,1)
CELL FREE ANTIGEN(10,20)
OUTER MEMBRANE PROTEIN(10,6)
BOVINE(10,1)
MULTOCIDA STRAIN(9,8)
MULTOCIDA PM SERUM(9,3)
SEA BLOGGING BIOTECHNOLOGY INC(9,2)
CELL FREE VACCINE ANTIGEN(9,1)
INDIRECT HEMAGGLUTINATION TEST(9,1)
SERUM(8,19)
SHAKING CULTURE(8,9)
LYOPHILIZED BACTERIAL SPECIES(8,3)
DETECTION METHOD SPECIFICITY(8,1)
INDUSTRIAL SCALE PRODUCTION(7,2)
NEWBORN CALF SERUM(7,2)
ANTIGEN PREPARATION(7,1)
BRONCHIAL ELLA BB SERUM(7,1)
DISSECTION PALPABLE NODULE(7,1)
SERUM PM(6,5)
VACCINE EFFICACY COMPARISON(6,4)
VACCINE INJECTION SITE REACTION(6,3)
CHICKEN IMMUNIZATION(6,2)
MULTOCIDA IMMUNIZING(6,2)
PIG(6,2)
POST IMMUNIZATION RABBIT(6,2)
QINGDAO HITECH(6,2)
SHEEP TANNINS(6,2)
STERILE PHYSIOLOGICAL SALINE(6,2)
VACCINE WHOLE BACTERIAL STRAIN(6,2)
BRAIN HEART INFUSION BROTH(6,1)
COW(6,1)
DISEASE PASTEURELLA MULTOCIDA INACTIVATION(6,1)
FOWL CHOLERA VACCINE AGE(6,1)
OMPH JEONGMIN LEE(6,1)
POLYSACCHARIDE ANTIGEN UNRESPONSIVENESS(6,1)
UNINOCULATED CHICKEN FLU SELECTION(6,1)
VACCINE BACTERIUM IMMUNIZATION(6,1)
FORMALDEHYDE(5,10)
INDIRECT HAEMAGGLUTINATION TEST(5,3)
STRAIN ACCESSION(5,3)
RABBIT IMMUNIZATION(5,2)
SENSITIZED SHEEP PREPARATION(5,2)
BACTERIAL VACCINE IMMUNIZED RABBIT(5,1)
CHINESE VETERINARY DRUG COMPLIANCE(5,1)
FRESH HEPERANIZED SHEEP BLOOD(5,1)
GALOP TANNINS(5,1)
REDNESS INFFLAMMTATION(5,1)
TRYPTIC SOY BROTH(5,1)
VACCINE IMMUNE EFFICACY(5,1)
VACCINE RABBIT WHOLE BACTERIUM(5,1)
VIRULENT STRAIN SHEEP(5,1)
WHOLE BACTERIUM VACCINE EFFICACY(5,1)
ALUMINUM HYDROXIDE GEL(4,8)
STERILIZATION(4,6)
NEGATIVE SERA(4,3)
ANTIGEN ANTIBODY(4,2)
CHALLENGE SUBCUTANEOUS INJECTION(4,2)
DISEASE PREVENTION(4,2)
EQUIVALENT IMMUNE POTENCY(4,2)
ERYTHROCYTE SUSPENSION(4,2)
IMMUNIZATION ROUTE(4,2)
IMMUNOGENIC DOSE(4,2)
MINIMUM LETHAL DOSE(4,2)
MULTOCIDA SPECIES(4,2)
SERUM AGGLUTINATION REACTION(4,2)
BACTERIA COUNT(4,1)
BEIJING MERI(4,1)
BOOST IMMUNIZATION(4,1)
BOOSTER IMMUNIZATIONN(4,1)
BRENNTAG BIOSECTOR(4,1)
CAPSULAR POLYSACCHARIDE PREPARATION(4,1)
CHICKEN WHOLE BACTERIUM(4,1)
DISSECTION HARD NODULE(4,1)
ENGINEERED MICROBIAL CELL(4,1)
FOLIUM ILICIS(4,1)
GRAM NEGATIVE BACTERIA(4,1)
HEMAGGLUTINATION TITER(4,1)
HENAN KANG(4,1)
IMMUNIZATION EQUIVALENT EFFICACY(4,1)
INACTIVATED BACTERIAL SUSPENSION(4,1)
MAJOR PROTECTIVE ANTIGEN MULTOCIDA(4,1)
MULTOCIDA ANTIBODY(4,1)
MULTOCIDA NEGATIVE SERUM(4,1)
MULTOCIDA POLYSACCHARIDE(4,1)
NUTRITIONAL COMPONENT PROTEIN HYDROLYZATE(4,1)
NUTRITIONAL INGREDIENT(4,1)
PHENOMENON DISSECTION(4,1)
RABBIT INACTIVATED VACCINE(4,1)
RABBIT PAKISTAN(4,1)
RABBIT RANDOMIZATION(4,1)
SEROLOGICAL DIAGNOSIS PREPARATION(4,1)
STRAIN VIRULENCE(4,1)
SUPPURATIVE PHENOMENON(4,1)
TEST IMMUNE POTENCY CAPSULE(4,1)
THERMOSTATIC SHAKER(4,1)
VACCINE INJECTION INSPECTION(4,1)
VACCINE ORGANIZATION(4,1)
VACCINE WHOLE BACTERIUM(4,1)
WHOLE BACTERIUM VACCINE PROTECTION(4,1)
YOUNG ANIMAL AGE(4,1)
RED BLOOD CELL(3,13)
BACTERIAL VACCINE IMMUNIZED GROUP(3,5)
RED BLOOD CELL AGGLUTINATION(3,4)
MODIFIED MARTIN MEDIUM(3,3)
P SERUM(3,3)
SHEEP RED BLOOD CELL(3,3)
STERILE TEST(3,3)
VETERINARY MEDICINE(3,3)
BACTERIAL CONTENT(3,2)
GERM CONCENTRATION(3,2)
GLUTARALDEHYDE SOLUTION(3,2)
IMMUNOGENICITY(3,2)
P WHOLE BACTERIAL STRAIN(3,2)
TEST RABBIT(3,2)
ANTIGEN SENSITIZED SHEEP(3,1)
ANTIGENIC SUBSTANCE CONCENTRATION(3,1)
AVIGNON EXPERIMENTAL ANIMAL CO(3,1)
BACTERIA GROWTH(3,1)
CULTURE BROTH(3,1)
CULTURE SUPERNATANT(3,1)
ENORMOUS ECONOMIC LOSS(3,1)
FUR BEARING(3,1)
HEMAGGLUTINATION BOARD(3,1)
HETEROLOGOUS STRAIN(3,1)
HUMORAL IMMUNITY INDUCTION(3,1)
IMMUNE PRECURSOR(3,1)
IMMUNOGENIC STUDY(3,1)
IMMUNOLOGICAL EFFICACY TEST(3,1)
LIVE VACCINE(3,1)
MULTOCIDA BACTERIUM LIQUID(3,1)
MULTOCIDA ESTABLISHING(3,1)
MULTOCIDA POSITIVE SERUM(3,1)
P INACTIVATED BACTERIAL CULTURE(3,1)
PETRI DISH(3,1)
PROTEIN VACCINE(3,1)
RECORDING TEST CHICKEN DEATH(3,1)
SCORING CRITERIA(3,1)
SERUM ANTIBODY(3,1)
SERUM DILUTION(3,1)
VACCINATING ANIMAL(3,1)
VACCINE CLASS(3,1)
VACCINE SAFETY(3,1)
WASH COLONY(3,1)
RED BLOOD CELL SUSPENSION(2,6)
CELL FREE VACCINE PREPARATION(2,3)
SIGNIFICANT DIFFERENCE(2,3)
DAYTIME PERIOD(2,2)
P ANTIGEN(2,2)
PROPOLIS(2,2)
PROTEIN COMPONENT(2,2)
SENSITIZATION(2,2)
SEROLOGICAL DETECTION(2,2)
SOLID CULTURE(2,2)
ADDED PRESERVATIVE THIMEROSAL(2,1)
ADJUVANT FINAL CONCENTRATION(2,1)
AGAR DIFFUSION(2,1)
ANIMAL IMMUNOGENIC P(2,1)
ANTIBODY DETECTION(2,1)
ANTIGEN DEPENDENT(2,1)
ANTIGEN POSITIVE SERUM(2,1)
BACTERIAL SUSPENSION CONCENTRATION(2,1)
BOVINE SERUM ALBUMIN(2,1)
CIRCULAR DOT(2,1)
COAGULATION TEST(2,1)
COMMERCIAL CULTURE MEDIUM(2,1)
CRUDE EXTRACTION(2,1)
CULTIVATION LIQUID CULTURE(2,1)
CURRENT WHOLE BACTERIUM VACCINE(2,1)
DIRECT PROTEIN MEASUREMENT(2,1)
DISEASE OCCURRENCE(2,1)
DORSAL SUBCUTANEOUS INJECTION(2,1)
ENDOTOXIN CONCENTRATION(2,1)
EQUAL EFFICACY(2,1)
EXTENSIVE STUDY(2,1)
FRESHLY PREPARED TANNINS SOLUTION(2,1)
FUR QUALITY(2,1)
GENE EXPRESSION CLONING(2,1)
HOLE ROW(2,1)
IMMUNE DURATION(2,1)
IMMUNE PROTECTION(2,1)
IMMUNITY DURATION(2,1)
IMMUNIZED RABBIT TEST GROUP(2,1)
INTENSIVE STUDY(2,1)
JUDGEMENT CRITERIA(2,1)
JUN SUN(2,1)
LIQUID CULTIVATION(2,1)
LYSED WHOLE BLOOD(2,1)
MAGNETIC STIRRER(2,1)
MEAT PRODUCT(2,1)
MICRO OSCILLATOR(2,1)
MIN INCUBATION(2,1)
MODIFIED MARTIN AGAR PLATE(2,1)
NATURAL PRECIPITATION(2,1)
NEGATIVE SERUM PREPARATION(2,1)
NUCLEIC ACID PROTEIN ANALYZER(2,1)
P INOCULATION(2,1)
PASTEURELLA MULTOCIDA COMPONENT(2,1)
PASTEURELLA MULTOCIDA OUTER MEMBRANE(2,1)
POLYSACCHARIDE CONTENT MEASUREMENT(2,1)
POPULARIZATION(2,1)
PROPIOLACTONE(2,1)
RABBIT SERUM(2,1)
RABBIT TEST SCORE(2,1)
RAPID ONSET(2,1)
SAMPLE BATCH(2,1)
SERUM BB(2,1)
SEVERE INFLAMMATORY REACTION(2,1)
SHEEP BLOOD STORAGE STABILITY(2,1)
STERILE NORMAL SALINE(2,1)
STERILE SALINE WASH SOLUTION(2,1)
STRAIN ANTIGEN(2,1)
STRONG AGGREGATION(2,1)
TEST CHICKEN DAY(2,1)
TH CENTURY(2,1)
TISSUE MAP(2,1)
UNIFORM CONFLUENCE(2,1)
VACCINATION(2,1)
VACCINE INJECTION DETECTION(2,1)
VIABLE COUNT(2,1)
VISIBLE TRACE(2,1)
WHOLE BACTERIAL VACCINE PREPARATION(2,1)
YEAST EXTRACT(2,1)
ZHEJIANG DAY(2,1)
ATTENUATED VACCINE(1,1)
INDURATION(1,1)
(CN104163858B)
MULTOCIDA(100,81)
ANTIGEN(100,22)
CELL ANTIGEN(100,20)
MULTOCIDA ANTIGEN(100,6)
SEROLOGICAL DETECTION(100,2)
NON DIAGNOSTIC(100,1)
MULTOCIDA CULTURE(88,8)
INACTIVATED CULTURE SUPERNATANT(76,1)
INDIRECT HEMAGGLUTINATION(68,1)
MULTOCIDA VACCINE ANTIGEN(61,1)
CELL VACCINE(58,18)
ANTIGEN SENSITIZATION(48,1)
WHOLE BACTERIUM VACCINE(45,19)
WHOLE BACTERIA DEATH(44,1)
MULTOCIDA CELL FREE ANTIGEN(43,4)
CULTURE SUPERNATANT(42,2)
DIRECT PRECIPITATION(42,2)
POLYSACCHARIDE(40,12)
DEATH PHENOMENON(39,1)
IMMUNIZATION CHALLENGE(38,2)
SUPERNATANT(36,14)
PROTEIN ANTIGEN(35,2)
RAPID ONSET(35,1)
POLYSACCHARIDE CONTENT(30,2)
PROTEIN(29,7)
VACCINE(28,25)
ECONOMIC LOSS(28,1)
EQUIVALENT IMMUNOEFFICACY(28,1)
IMMUNOGENIC GOOD(28,1)
DISCARDING CELL(26,3)
MG ML ANTIGEN(26,1)
CENTRIFUGATION(25,8)
STERILE PHYSIOLOGICAL SALINE DISSOLUTION(24,7)
MORTALITY(24,1)
CELL FREE ANTIGEN PROTEIN(23,1)
INFLUENCE GROWTH(23,1)
ADJUVANT(21,5)
THIMEROSAL(20,10)
DISEASE(20,1)
FINAL CONCENTRATION(19,13)
BACTERIA(19,2)
PROTECTION RATIO(19,1)
RPM SHAKING(17,8)
VIRUS(17,1)
CELL VACCINE EFFICACY(16,5)
MULTOCIDA PM SERUM(16,4)
SERUM CONCENTRATION(16,2)
CONVERSION RATIO REDUCTION(16,1)
STRAIN(15,51)
SERUM(15,24)
RABBIT(15,13)
OUTER MEMBRANE PROTEIN(15,7)
INDUSTRIAL SCALE PRODUCTION(15,1)
SECONDARY INFECTION(15,1)
CELL VACCINE STRAIN(14,4)
CHINA VETERINARY MONITORING(14,4)
SHEEP RED BLOOD CELL(14,3)
CELLULAR VACCINE IMMUNOEFFICACY(14,2)
WHOLE BACTERIUM VACCINE IMMUNOEFFICACY(14,2)
ANTIGEN METHOD PREPARATION(14,1)
RABBIT IMMUNIZATION(13,5)
MULTOCIDA CULTURE SUPERNATANT(13,2)
SERUM MODIFIED MARTIN(12,7)
ANTIGEN PREPARATION(12,1)
TANNINS TANNING ACIDIFICATION(12,1)
BACTERIAL SPECIES(11,6)
STRAIN CELL FREE VACCINE(11,6)
DEATH(11,5)
MULTI P(11,3)
NEWBORN CALF SERUM(11,2)
CELLULAR VACCINE IMMUNIZED RABBIT(11,1)
MULTI DETECTION SPECIFIC ANTIBODY(11,1)
MULTOCIDA ANTIGEN SENSITIZATION(11,1)
POLYSACCHARIDE ANTIGEN UNRESPONSIVENESS(11,1)
RPM CENTRIFUGATION(10,5)
SERUM PM(10,5)
CATTLE(10,2)
QINGDAO HITECH(10,2)
SEA BLOG BIOTECHNOLOGY CO(10,2)
BRAIN HEART INFUSION BROTH(10,1)
ERYTHROCYTE SUSPENSION HYDROFORMYLATION(10,1)
ESTABLISHED TEST(10,1)
IMMUNIZED BIRD STATISTICS(10,1)
INOCULATED FOWL CHOLERA VACCINE(10,1)
POULTRY FOWL CHOLERA(10,1)
TANNING ACIDIFICATION SHEEP(10,1)
CAPSULAR POLYSACCHARIDE(9,3)
CAPSULAR VACCINE(9,2)
CELL VACCINE INJECTION(9,2)
CHICKEN IMMUNIZATION(9,2)
DISSECTION VACCINE(9,2)
MULTOCIDA ANTIBODY(9,2)
RABBIT WHOLE BACTERIUM(9,2)
IGM IMMUNOGLOBULIN CREATION(9,1)
MULTOCIDA VIRULENT STRAIN(9,1)
SENSITIZED SHEEP ERYTHROCYTE PREPARATION(9,1)
TRYPTONE SOY BROTH(9,1)
WHOLE BACTERIUM VACCINE IMMUNIZATION(9,1)
ALUMINUM HYDROXIDE GLUE(8,10)
FORMALDEHYDE(8,10)
BACTERIAL VACCINE IMMUNIZATION(8,3)
SERUM TITER(8,3)
VACCINE PREPARATION(8,2)
ANTIGEN ANTIBODY TITER(8,1)
ATTENUATED LIVE VACCINE(8,1)
BACTERIAL SUSPENSION MULTOCIDA(8,1)
CHICKEN IMMUNIZED TEST CHALLENGE(8,1)
INDIRECT HEMAGGLUTINATION ASSAY DETECTION(8,1)
RABBIT PAKISTAN POLE(8,1)
REMAINING NEGATIVE CONTROL(8,1)
TYPE ANIMAL(8,1)
VETERINARY BIOLOGICAL PRODUCT FIELD(8,1)
WHOLE BACTERIUM IMMUNIZED RABBIT(8,1)
RESUSCITATION(7,7)
NEGATIVE SERA(7,4)
TEST VACCINE(7,4)
WHOLE BACTERIAL VACCINE(7,4)
HOMOLOGOUS STRAIN(7,2)
INACTIVATED VACCINE DOSE(7,2)
MULTOCIDA POSITIVE SERUM(7,2)
PROTEIN VACCINE(7,2)
PUS PHENOMENON(7,2)
SERUM AGGLUTINATION REACTION(7,2)
VACCINE INJECTION SITE(7,2)
VACCINE WHOLE BACTERIAL PREPARATION(7,2)
BRENNTAG BIOSECTOR(7,1)
CELLULAR ANTIGEN PROTEIN(7,1)
DISEASE PREVENTION CONTRIBUTION(7,1)
FLARE INFFLAMMTATION(7,1)
GRAM NEGATIVE BACTERIA(7,1)
IMMUNIZED RABBIT CELL(7,1)
IMMUNIZED RABBIT SERUM TEST(7,1)
INDIRECT SEROLOGICAL TESTING(7,1)
NUTRITIVE SUBSTANCE FORMULATION(7,1)
PAP MANNHEIMIOSIS(7,1)
PASTEURELL MULTOEIDA(7,1)
RABBIT HEMORRHAGIC SEPTICEMIA(7,1)
RABBIT TEST CHALLENGE IMMUNIZATION(7,1)
STRAIN HOMOLOGOUS CHALLENGE(7,1)
MG ML(6,3)
DAY POST CHALLENGE(6,2)
FRESH ANTI SHEEP BLOOD(6,2)
MINIMUM LETHAL DOSE(6,2)
MULTOCIDA OUTER MEMBRANE PROTEIN(6,2)
STATISTIC ANALYSIS(6,2)
AGE YOUNG ANIMAL(6,1)
ANTIGENIC POLYSACCHARIDE CONTENT MEASUREMENT(6,1)
BEIJING MERI(6,1)
CENTURY YEAR(6,1)
CHICKEN FLU(6,1)
CHICKEN MORTALITY(6,1)
CULTURING COLONY(6,1)
DEPENDENT ANTIGEN POLYSACCHARIDE(6,1)
FEEDER ISOLATOR(6,1)
HENAN KANG(6,1)
MULTOCIDA ADJUVANT(6,1)
MULTOCIDA NEGATIVE SERUM(6,1)
MULTOCIDA VACCINE(6,1)
PRESERVATIVE THIMEROSAL(6,1)
SEROLOGICAL DIAGNOSIS(6,1)
STRAIN VIRULENCE(6,1)
UNSATISFACTORY IMMUNE(6,1)
VACCINE AUTOPSY(6,1)
VACCINE INJECTION EXAMINATION(6,1)
WHOLE BACTERIUM VACCINE INJECTION(6,1)
YUE SHOUNG LU(6,1)
CHICKEN P(5,4)
BACTERIAL CONTENT(5,2)
GLUTARALDEHYDE SOLUTION(5,2)
HARD NODULE(5,2)
INACTIVATION(5,2)
P CELLULAR ANTIGEN(5,2)
TANNINS SOLUTION(5,2)
ANIMAL ATTENUATED VACCINE(5,1)
ANTIGENIC SUBSTANCE CONCENTRATION(5,1)
AROUND INTERSPERSED AGGLUTINATING(5,1)
COLI INACTIVATED VACCINE(5,1)
CULTURE BROTH(5,1)
ENGINEERING CELL LYSIS(5,1)
IMMUNOGENIC DOSE(5,1)
IMMUNOGENIC STUDY(5,1)
MINIATURE OSCILLATOR(5,1)
MODIFIED MARTIN BROTH(5,1)
MULTOCIDA DIRECT PRECIPITATION(5,1)
MULTOCIDA STRAIN(5,1)
NODULE RECORD(5,1)
PREPARED SENSITIZING SHEEP(5,1)
SCORING CRITERIA(5,1)
SERUM DILUTION(5,1)
UNEXPECTED DISCOVERY(5,1)
UNEXPECTED FINDING(5,1)
RED BLOOD CELL SUSPENSION(4,6)
SAVE(4,6)
NEGATIVE CONTROL(4,5)
INCUBATION(4,3)
MODIFIED MARTIN MEDIUM(4,3)
PREIMMUINE(4,3)
AGAR DIFFUSION(4,1)
AGGLUTINATION STRENGTH(4,1)
ANTIGENIC PROTEIN CONTENT MEASUREMENT(4,1)
BACTERIAL CULTURE DIRECT EXTRACTION(4,1)
BACTERIAL GROWTH(4,1)
BACTERIAL SUSPENSION CONCENTRATION(4,1)
BOVINE SERUM ALBUMIN(4,1)
COMPANY EGG(4,1)
CONTINUOUS GENTLE SHAKING(4,1)
DECISION CRITERIA(4,1)
DISEASE OCCURRENCE(4,1)
DORSAL SUBCUTANEOUS INJECTION(4,1)
ENDOTOXIN CONCENTRATION(4,1)
EXTENSIVE STUDY(4,1)
FRESHLY PREPARED ALDEHYDE(4,1)
H QUICK BACTERIUM COUNT(4,1)
IMMUNE DURATION(4,1)
IMMUNE PROGENITOR WEIGHT(4,1)
IMMUNOEFFICACY EQUIVALENT(4,1)
INACTIVATED BACTERIAL LIQUID(4,1)
LYSED WHOLE BLOOD(4,1)
MAJOR PROTECTIVE ANTIGEN(4,1)
MARTIN AGAR PLATE(4,1)
MEAT PRODUCT(4,1)
MIN CENTRIFUGATION(4,1)
MODIFIED MARTIN AGAR(4,1)
P INACTIVATED CULTURE(4,1)
SERUM BB(4,1)
SEVERE INFLAMMATORY RESPONSE(4,1)
STERILE CERTIFIED REAR(4,1)
STERILE MINUS(4,1)
STERILE SALINE(4,1)
STRAIN ANTIGEN(4,1)
SUBCUTANEOUS INJECTION CHALLENGE(4,1)
SUN DIJUN(4,1)
SUSCEPTIBLE RABBIT(4,1)
VACCINE INJECTION LOCAL DETECTION(4,1)
VIABLE COUNT(4,1)
WHOLE BACTERIUM VACCINE DIFFERENCE(4,1)
YEAST EXTRACT(4,1)
ZHEJIANG DAY(4,1)
STRAIN CELL FREE ANTIGEN(3,4)
AGGREGATION(3,2)
IMMUNE RESPONSE(3,2)
INACTIVATED P(3,2)
PROPOLIS(3,2)
RED BLOOD CELL AGGLUTINATION(3,2)
STERILE TEST(3,2)
STRAIN CONTROL(3,2)
VACCINE CELL WEIGHT GAIN(3,2)
ANIMAL GROWTH(3,1)
ANIMAL IMMUNIZED GROUP(3,1)
CULTURCS(3,1)
DISCARDED CELL(3,1)
DURATION SAFETY(3,1)
ERYTHROCYTE SEDIMENTATION(3,1)
EXPERIMENTAL ANIMAL CO(3,1)
FUR QUALITY(3,1)
HOLE ROW(3,1)
IMMUNITY TEST(3,1)
IMMUNOGENICITY(3,1)
MAGNETIC STIRRER(3,1)
MARTIN PLATE(3,1)
MULTOCIDA COMPONENT(3,1)
MULTOCIDA CULTURE LIQUID MEDIUM(3,1)
MULTOCIDA FIVE(3,1)
NATURAL PRECIPITATION(3,1)
NEGATIVE HEMAGGLUTINATION PLATE(3,1)
NEGATIVE SERUM PREPARATION(3,1)
NUCLEIC ACID PROTEIN METER(3,1)
NUTRIENT COMPONENT(3,1)
OMPH IMMUNE PROTECTIVE EFFECT(3,1)
OUTER MEMBRANE PROTEIN GENE(3,1)
PAP COMPONENT(3,1)
POPULARIZATION(3,1)
PREIMMUNE RABBIT(3,1)
PROPIOLACTONE(3,1)
PROTECTION RATIO CHALLENGE(3,1)
REACTION SCORE(3,1)";Pharmaceuticals;Open
"2013-03-18
2014-03-17";"WO2014147001        A1 2014-09-25 [WO2014147001]
STG: (A1) Published application with search report
AP : 2014WO-EP55244 2014-03-17
AU2014234452        A1 2015-09-10 [AU2014234452]
STG: (A1) Open to public inspection
AP : 2014AU-0234452 2014-03-17
BR112015023870      A1 2015-12-08 [BR112015023870]
STG: (A1) Published application
AP : 2015BR-0023870 2014-03-17
MX2015013307        A  2016-01-25 [MX2015013307]
STG: (A) Patent application
AP : 2015MX-PA13307 2014-03-17
EP2976102           A1 2016-01-27 [EP2976102]
STG: (A1) Application published with search report
AP : 2014EP-0710302 2014-03-17
US20160287690       A1 2016-10-06 [US20160287690]
STG: (A1) Application published
AP : 2014US-14777672 2014-03-17
US9642905           B2 2017-05-09 [US9642905]
STG: (B2) Granted patent as second publication
AP : 2014US-14777672 2014-03-17
FD :  Previous publication: US20160287690 A1 2016-10-06 [US20160287690]
BR112015023870      A2 2017-07-18 [BR112015023870]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2015BR-0023870 2014-03-17
AU2014234452        B2 2018-02-22 [AU2014234452]
STG: (B2) Patent proceeded by OPI
AP : 2014AU-0234452 2014-03-17
MX357432            B  2018-07-09 [MX-357432]
STG: (B) Granted patent/ granted utility model
AP : 2015MX-PA13307 2014-03-17";67454633;"WO2014147001        A1 2014-09-25 [WO2014147001]
AU2014234452        A1 2015-09-10 [AU2014234452]
BR112015023870      A1 2015-12-08 [BR112015023870]
MX2015013307        A  2016-01-25 [MX2015013307]
EP2976102           A1 2016-01-27 [EP2976102]
US20160287690       A1 2016-10-06 [US20160287690]
US9642905           B2 2017-05-09 [US9642905]
BR112015023870      A2 2017-07-18 [BR112015023870]
AU2014234452        B2 2018-02-22 [AU2014234452]
MX357432            B  2018-07-09 [MX-357432]";"2013EP-0159665
2014EP-0710302
2014WO-EP55244";"(EP2976102)
WO2014147001
(US9642905)
WO2014147001
(BR112015023870)
WO2014147001
(AU2014234452)
WO2014147001
(MX-357432)
WO2014147001";"INTERVET INTERNATIONAL
MEDTRONIC INTERVET";MEDTRONIC INTERVET;"(EP2976102)
NL
(US20160287690)
US
(US9642905)
US
(WO2014147001)
NL; US
(BR112015023870)
NL
(MX-357432)
NL";"(EP2976102)
NAME=Intervet International B.V. P.O. Box 31  Wim De Körverstraat 35 , CITY=5831 AN Boxmeer , COUNTRY=NL 

(US20160287690)
NAME=INTERVET INC. , CITY=Madison , STATE=NJ , COUNTRY=US , ATYP=US Company 

(US9642905)
NAME=Intervet Inc. , CITY=Madison , STATE=NJ , COUNTRY=US , ATYP=US Company 

(WO2014147001)
NAME=INTERVET INTERNATIONAL B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer , COUNTRY=NL 

NAME=INTERVET INC. 556 Morris Avenue Summit, New Jersey 07901 , COUNTRY=US 

(BR112015023870)
NAME=INTERVET INT BV , COUNTRY=NL 

(MX-357432)
NAME=INTERVET INT BV , COUNTRY=NL 
";1;JACOBS ANTONIUS ARNOLDUS CHRISTIAAN;"(EP2976102)
NL";"(EP2976102)
NAME=JACOBS, Antonius Arnoldus Christiaan Wim de Körverstraat 35 , CITY=NL-5831 AN Boxmeer , COUNTRY=NL 
";"(EP2976102)
Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica";"(EP2976102)
The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by Mannheimia haemolytica, the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomisation of the vaccine.";"(WO2014147001)
1. Vaccine to protect a ruminant against pneumonia caused by Mannheimia haemolytica bacteria, the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomisation of the vaccine. 
 Vaccine according to claim 1 , characterised in that the atomisation provides a mist of vaccine particles having an average size below 50 μηη in diameter. 
 Vaccine according to any of the preceding claims, characterised in that the average particle size is between 20 and 40 μηη in diameter. 
 A vaccine according to any of the preceding claims, characterised in that it comprises live attenuated infectious bovine rhinotracheitis virus. 
 Use of live attenuated Mannheimia haemolytica bacteria, in combination with live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus for the manufacture of a vaccine which upon administration to the upper respiratory tract of a ruminant by intranasal atomisation of the vaccine provides protection against pneumonia caused by Mannheimia haemolytica bacteria. 
 A method to protect a ruminant against pneumonia caused by Mannheimia haemolytica bacteria, the method comprising administration of a vaccine comprising live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, to the upper respiratory tract of the ruminant by intranasal atomisation of the vaccine. 
 Live attenuated Mannheimia haemolytica bacteria, in combination with live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, for use in the method according to claim 6.";"(US20160287690)
The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by Mannheimia haemolytica, the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomisation of the vaccine.
The present invention pertains to a vaccine to protect a ruminant against pneumonia caused by Mannheimia haemolytica bacteria.
The invention also pertains to the manufacture of such a vaccine and a method for protecting a bovine against pneumonia caused by Mannheimia haemolytica bacteria.
The invention namely pertains to the surprising finding that an immune response against live attenuated Mannheimia haemolytica bacteria that provides protection against wild-type Mannheimia haemolytica bacteria, can be elicited even if these bacteria are administered to the upper respiratory tract (where wild-type Mannheimia haemolytica is present as a commensal and does not induce an immune response at all), when the administration takes place via atomisation in the presence of the viruses indicated above.
The object of the invention is therefor to provide a vaccine that protects a ruminant against pneumonic pasteurellosis caused by Mannheimia haemolytica, which vaccine is safe in young animals (younger than 3-4 weeks of age).";"(US20160287690)
Intranasal administration has proven to lead to a good mucosal immune response against the bacterium.
However, balancing safety and efficacy to find the desired attenuation does not relate to the abovementioned finding of the present invention.
It thus appears to be difficult to obtain actual protection against Mannheimia haemolytica (that is, actual reduction in lung lesion consolidation) which may be due to the fact that the disease, pasteurellosis, is a multifactorial disease.
This is a severe form of disease that develops in the complex of bovine respiratory diseases (Dagmara Kisiela et al. in Infect.";"A61K-039/00
A61K-039/102
A61K-039/155
A61K-039/265
A61K-039/295
C12N-007/00";"(US20160287690)
8. A method to protect a ruminant against pneumonia caused by Mannheimia haemolytica bacteria comprising administering a vaccine to the upper respiratory tract of the ruminant by intranasal atomisation of said vaccine; wherein said vaccine comprises live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus, and live attenuated bovine respiratory syncytial virus.";"(US20160287690)
VACCINE(100,45)
MANNHEIMIA HAEMOLYTICA BACTERIUM(100,15)
PNEUMONIA(100,14)
MANNHEIMIA HAEMOLYTICA(100,12)
RUMINANT(100,9)
ATTENUATED MANNHEIMIA HAEMOLYTICA BACTERIUM(100,8)
VACCINE INTRANASAL ATOMIZATION(89,1)
LUNG LESION CONSOLIDATION(55,1)
ATTENUATED PARAINFLUENZA(51,6)
RUMINANT UPPER RESPIRATORY TRACT(42,7)
INTRANASAL ATOMIZATION(41,2)
PNEUMONIC PASTEURELLOSIS(38,2)
MULTIFACTORIAL DISEASE(37,1)
BOVINE RESPIRATORY DISEASE COMPLEX(31,1)
VACCINE MANUFACTURE(28,2)
ADMINISTRATION(26,16)
VACCINE PARTICLE MIST(26,2)
YOUNG ANIMAL(26,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(20,8)
PASTEURELLOSIS(20,1)
BOVINE(19,4)
AGE WEEK(19,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(18,5)
COMMENSAL(18,1)
IMMUNE RESPONSE(17,16)
BACTERIA(17,11)
VIRUS PRESENCE(17,2)
ATOMIZATION(15,12)
NOSTRIL(14,6)
EFFICACY(14,1)
VIRUS(13,15)
ATTENUATION(13,4)
PATHOGENIC MANNHEIMIA HAEMOLYTICA BACTERIUM(13,2)
INTRANASAL ADMINISTRATION(12,3)
UPPER RESPIRATORY TRACT(11,10)
LIVE MANNHEIMIA HAEMOLYTICA(10,3)
PFIZER ANIMAL HEALTH(10,3)
SINGLE ADMINISTRATION VOLUME(10,2)
BOVINE PASTEURELLOSIS POTENTIATOR(10,1)
DISEASE(9,8)
WFI CANNULA ATOMIZATION(9,1)
MERCK ANIMAL HEALTH(8,3)
SEVERE CLINICAL SIGN(8,3)
VACCINE ATOMIZATION(8,2)
ATTENUATED MANNHEIMIA BACTERIUM(8,1)
BOVINE VIRAL DIARRHEA VIRUS(8,1)
COLOSTRUM DEPRIVED CALF(8,1)
LUNG LOBE FIBRINOUS PLEURITIS(8,1)
VACCINE PARTICLE SIZE(8,1)
VACCINATED ANIMAL(7,3)
CONSOLIDATION SCORE(7,2)
MUCOSAL IMMUNE RESPONSE(7,2)
VACCINATED CALF(7,2)
VACCINE ADMINISTRATION(7,2)
CHALLENGE CULTURE TITER(7,1)
INTRANASAL VACCINATION EFFICACY(7,1)
LMA MAD NASAL(7,1)
RHO BACF STABILIZER(7,1)
DRIED MANNHEIMIA HAEMOLYTICA(6,2)
AMERICAN HERITAGE MEDICAL DICTIONARY(6,1)
BACTERIN VACCINE(6,1)
FINE PARTICLE HEAVING MIST(6,1)
FROZEN LIVE BRSV(6,1)
MICROORGANISM INCAPABILITY(6,1)
WILD TYPE MANNHEIMIA HAEMOLYTICA(5,4)
ATTENUATED MICROORGANISM(5,2)
LIVE MH BRSV PI(5,2)
AEROSOL VACCINATION(5,1)
ATTENUATED BACTERIA(5,1)
BACTERIAL TITER(5,1)
BACTERIUM REMAINING VIRULENCE(5,1)
BLUE FLEX APPLICATOR NOZZLE(5,1)
COMMENSAL ORGANISM(5,1)
COMMERCIALLY OBTAINABLE VACCINE(5,1)
FROZEN LIVE PI(5,1)
LIVE ATTENUATED PARAINFLUENZA PRESENCE(5,1)
LIVE ATTENUATED STRAIN(5,1)
MAD CANNULA(5,1)
MERRIAM WEBSTER(5,1)
ONLINE DICTIONARY(5,1)
PATHOGENIC COUNTERPART(5,1)
PLEURITIS SCORE(5,1)
RESPIRATORY TRACT MUCOSA(5,1)
RISPOVAL APPLICATOR(5,1)
SEVERE DISEASE FORM(5,1)
TRANSTHORACIC CHALLENGE(5,1)
VACCINE EFFICACY(5,1)
VACCINE SPREADING(5,1)
VIRULENCE GENE(5,1)
POST CHALLENGE(4,2)
STATISTICALLY SIGNIFICANT REDUCTION(4,2)
ANIMAL MOUTH(4,1)
ANIMAL VACCINATION(4,1)
CLINICAL SIGN DEVELOPMENT(4,1)
CULTURE AIMING(4,1)
FINE MIST ORAL ADMINISTRATION(4,1)
HOUGHTON MIFFLIN COMPANY(4,1)
IMMUNE RESPONSE ADEQUATENESS(4,1)
JENCINE STRAIN(4,1)
LIVE BACTERIA(4,1)
LIVE VACCINE(4,1)
LUNG LESION REDUCTION(4,1)
NASALGEN IP(4,1)
PARTICLE VACCINE(4,1)
PERCENTAGE LUNG CONSOLIDATION(4,1)
RUMINANT PROTECTION(4,1)
STREPTOMYCIN DEPENDENT STRAIN(4,1)
SUBCUTANEOUS IMPLANT(4,1)
SYMPTOM FULL SUITE(4,1)
VACCINATION STUDY(4,1)
VIRAL PATHOGEN(4,1)
VIRUS ATTENUATION(4,1)
ANTIGEN(3,4)
LARYNX(3,2)
PHARYNX(3,2)
SEROTYPE(3,2)
AEROSOL ROUTE(3,1)
ANOVA REPEATED MEASUREMENT(3,1)
CHALLENGE DOSE(3,1)
CLEAN CATCH(3,1)
DISEASE INDUCTION(3,1)
DISEASED TISSUE(3,1)
EQUATION ESTIMATION(3,1)
EQUIVALENT LOBE SAMPLE(3,1)
EXPERIMENT OBJECTIVE(3,1)
GENESIS INDUSTRY(3,1)
LYOPHILIZED POWDER(3,1)
OLD CALF(3,1)
POST MORTEM SAMPLE(3,1)
PRINCIPAL BACTERIAL PATHOGEN(3,1)
RE ISOLATION DATA(3,1)
REPEATED MEASUREMENT ACCOUNTING(3,1)
STABILIZER MATRIX(3,1)
STATISTICAL PROGRAM(3,1)
VISCOSITY MODIFIER(3,1)
YOUNG CALF(3,1)
ACTIVE LEUKOTOXIN(2,1)
ALONE ADEQUATE PROTECTION(2,1)
BACTERIAL LOAD LOWERING(2,1)
BLOOD AGAR PLATE(2,1)
DETRIMENTAL HOST RESPONSE(2,1)
ELECTRIC SEDATION(2,1)
FREEZE DRIED VACCINE(2,1)
HALF LOBE(2,1)
HEALTH ABNORMALITY(2,1)
HUGE MUCOSAL AREA(2,1)
MAD ATOMIZATION(2,1)
MAXIMAL RESISTANCE(2,1)
(US9642905)
VACCINE(100,45)
MANNHEIMIA HAEMOLYTICA BACTERIUM(100,15)
PNEUMONIA(100,14)
MANNHEIMIA HAEMOLYTICA(100,12)
RUMINANT(100,9)
VACCINE INTRANASAL ATOMIZATION(100,1)
ATTENUATED MANNHEIMIA HAEMOLYTICA BACTERIUM(94,8)
LUNG LESION CONSOLIDATION(66,1)
ATTENUATED PARAINFLUENZA(61,6)
RUMINANT UPPER RESPIRATORY TRACT(50,7)
INTRANASAL ATOMIZATION(49,2)
PNEUMONIC PASTEURELLOSIS(45,2)
MULTIFACTORIAL DISEASE(44,1)
BOVINE RESPIRATORY DISEASE COMPLEX(37,1)
VACCINE PARTICLE MIST(31,2)
YOUNG ANIMAL(31,1)
NATIONAL STAGE ENTRY(28,1)
ADMINISTRATION(26,16)
VACCINE MANUFACTURE(26,2)
PASTEURELLOSIS(24,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(23,8)
AGE WEEK(23,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(21,5)
BOVINE(20,4)
NOSTRIL(17,6)
EFFICACY(17,1)
VIRUS(16,15)
ATTENUATION(15,4)
PATHOGENIC MANNHEIMIA HAEMOLYTICA BACTERIUM(15,2)
BACTERIA(14,11)
INTRANASAL ADMINISTRATION(14,3)
SINGLE ADMINISTRATION VOLUME(12,2)
BOVINE PASTEURELLOSIS POTENTIATOR(12,1)
LIVE MANNHEIMIA HAEMOLYTICA(11,3)
PFIZER ANIMAL HEALTH(11,3)
PCT(11,1)
WFI CANNULA ATOMIZATION(11,1)
DISEASE(10,8)
MERCK ANIMAL HEALTH(10,3)
SEVERE CLINICAL SIGN(10,3)
ATTENUATED MANNHEIMIA BACTERIUM(10,1)
BOVINE VIRAL DIARRHEA VIRUS(10,1)
COLOSTRUM DEPRIVED CALF(10,1)
LUNG LOBE FIBRINOUS PLEURITIS(10,1)
VACCINE PARTICLE SIZE(10,1)
VACCINATED ANIMAL(9,3)
VACCINE ATOMIZATION(9,2)
CHALLENGE CULTURE TITER(9,1)
INTRANASAL VACCINATION EFFICACY(9,1)
LMA MAD NASAL(9,1)
UPPER RESPIRATORY TRACT(8,10)
CONSOLIDATION SCORE(8,2)
MUCOSAL IMMUNE RESPONSE(8,2)
VACCINATED CALF(8,2)
VACCINE ADMINISTRATION(8,2)
RHO BACF STABILIZER(8,1)
DRIED MANNHEIMIA HAEMOLYTICA(7,2)
AMERICAN HERITAGE MEDICAL DICTIONARY(7,1)
BACTERIN VACCINE(7,1)
FINE PARTICLE HEAVING MIST(7,1)
FROZEN LIVE BRSV(7,1)
MICROORGANISM INCAPABILITY(7,1)
ATTENUATED MICROORGANISM(6,2)
LIVE MH BRSV PI(6,2)
AEROSOL VACCINATION(6,1)
ATTENUATED BACTERIA(6,1)
BACTERIAL TITER(6,1)
BACTERIUM REMAINING VIRULENCE(6,1)
BLUE FLEX APPLICATOR NOZZLE(6,1)
COMMENSAL ORGANISM(6,1)
COMMERCIALLY OBTAINABLE VACCINE(6,1)
FROZEN LIVE PI(6,1)
LIVE ATTENUATED PARAINFLUENZA PRESENCE(6,1)
LIVE ATTENUATED STRAIN(6,1)
MAD CANNULA(6,1)
MERRIAM WEBSTER(6,1)
ONLINE DICTIONARY(6,1)
PATHOGENIC COUNTERPART(6,1)
PLEURITIS SCORE(6,1)
RESPIRATORY TRACT MUCOSA(6,1)
RISPOVAL APPLICATOR(6,1)
SEVERE DISEASE FORM(6,1)
TRANSTHORACIC CHALLENGE(6,1)
VACCINE EFFICACY(6,1)
VACCINE SPREADING(6,1)
VIRULENCE GENE(6,1)
ANIMAL MOUTH(5,1)
ANIMAL VACCINATION(5,1)
CLINICAL SIGN DEVELOPMENT(5,1)
CULTURE AIMING(5,1)
FINE MIST ORAL ADMINISTRATION(5,1)
HOUGHTON MIFFLIN COMPANY(5,1)
IMMUNE RESPONSE ADEQUATENESS(5,1)
JENCINE STRAIN(5,1)
LIVE BACTERIA(5,1)
LIVE VACCINE(5,1)
LUNG LESION REDUCTION(5,1)
NASALGEN IP(5,1)
PARTICLE VACCINE(5,1)
PERCENTAGE LUNG CONSOLIDATION(5,1)
RUMINANT PROTECTION(5,1)
STREPTOMYCIN DEPENDENT STRAIN(5,1)
SUBCUTANEOUS IMPLANT(5,1)
SYMPTOM FULL SUITE(5,1)
VACCINATION STUDY(5,1)
VIRAL PATHOGEN(5,1)
VIRUS ATTENUATION(5,1)
ANTIGEN(4,4)
POST CHALLENGE(4,2)
STATISTICALLY SIGNIFICANT REDUCTION(4,2)
VIRUS PRESENCE(4,2)
AEROSOL ROUTE(4,1)
ANOVA REPEATED MEASUREMENT(4,1)
CHALLENGE DOSE(4,1)
CLEAN CATCH(4,1)
DISEASE INDUCTION(4,1)
DISEASED TISSUE(4,1)
EQUATION ESTIMATION(4,1)
EQUIVALENT LOBE SAMPLE(4,1)
EXPERIMENT OBJECTIVE(4,1)
GENESIS INDUSTRY(4,1)
LYOPHILIZED POWDER(4,1)
OLD CALF(4,1)
POST MORTEM SAMPLE(4,1)
PRINCIPAL BACTERIAL PATHOGEN(4,1)
RE ISOLATION DATA(4,1)
REPEATED MEASUREMENT ACCOUNTING(4,1)
STABILIZER MATRIX(4,1)
STATISTICAL PROGRAM(4,1)
VISCOSITY MODIFIER(4,1)
YOUNG CALF(4,1)
LARYNX(3,2)
PHARYNX(3,2)
SEROTYPE(3,2)
ACTIVE LEUKOTOXIN(3,1)
ALONE ADEQUATE PROTECTION(3,1)
BACTERIAL LOAD LOWERING(3,1)
BLOOD AGAR PLATE(3,1)
DETRIMENTAL HOST RESPONSE(3,1)
ELECTRIC SEDATION(3,1)
FREEZE DRIED VACCINE(3,1)
HALF LOBE(3,1)
HEALTH ABNORMALITY(3,1)
HUGE MUCOSAL AREA(3,1)
MAD ATOMIZATION(3,1)
MAXIMAL RESISTANCE(3,1)
(WO2014147001)
VACCINE(100,42)
MANNHEIMIA HAEMOLYTICA BACTERIUM(100,20)
VIRUS(100,17)
PROTECTION(100,16)
PNEUMONIA(100,15)
ADMINISTRATION(100,14)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(100,10)
RUMINANT(100,9)
ATTENUATED PARAINFLUENZA(100,8)
RUMINANT UPPER RESPIRATORY TRACT(100,7)
VACCINE INTRANASAL ATOMIZATION(100,3)
VACCINE MANUFACTURE(100,3)
ATTENUATED MANNHEIMIA HAEMOLYTICA BACTERIUM(78,7)
LUNG LESION CONSOLIDATION(37,1)
PNEUMONIC PASTEURELLOSIS(26,2)
MULTIFACTORIAL DISEASE(25,1)
VACCINE ADMINISTRATION(21,3)
BOVINE RESPIRATORY DISEASE COMPLEX(21,1)
VACCINE PARTICLE MIST(18,2)
YOUNG ANIMAL(18,1)
MANNHEIMIA HAEMOLYTICA(14,11)
AGE WEEK(13,3)
PASTEURELLOSIS(13,1)
COMMENSAL(12,1)
IMMUNE RESPONSE(11,16)
BACTERIA(11,11)
VIRUS PRESENCE(11,2)
ATOMIZATION(10,12)
PATHOGENIC MANNHEIMIA HAEMOLYTICA BACTERIUM(9,2)
EFFICACY(9,1)
ATTENUATION(8,4)
INTRANASAL ADMINISTRATION(8,3)
UPPER RESPIRATORY TRACT(7,10)
BOVINE(7,2)
DISEASE(6,8)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(6,3)
PFIZER ANIMAL HEALTH(6,3)
BOVINE PASTEURELLOSIS POTENTIATOR(6,1)
MERCK ANIMAL HEALTH(5,3)
SEVERE CLINICAL SIGN(5,3)
VACCINATED ANIMAL(5,3)
LIVE MANNHEIMIA HAEMOLYTICA(5,2)
VACCINE ATOMIZATION(5,2)
ATTENUATED MANNHEIMIA BACTERIUM(5,1)
BOVINE VIRAL DIARRHEA VIRUS(5,1)
CHALLENGE CULTURE TITER(5,1)
COLOSTRUM DEPRIVED CALF(5,1)
INTRANASAL VACCINATION EFFICACY(5,1)
LUNG LOBE FIBRINOUS PLEURITIS(5,1)
ATTENUATED MICROORGANISM(4,2)
CONSOLIDATION SCORE(4,2)
DRIED MANNHEIMIA HAEMOLYTICA(4,2)
MUCOSAL IMMUNE RESPONSE(4,2)
VACCINATED CALF(4,2)
AMERICAN HERITAGE MEDICAL DICTIONARY(4,1)
BACTERIN VACCINE(4,1)
FINE PARTICLE HEAVING MIST(4,1)
MICROORGANISM INCAPABILITY(4,1)
WILD TYPE MANNHEIMIA HAEMOLYTICA(3,4)
VACCINATION DAY(3,2)
AEROSOL VACCINATION(3,1)
ATTENUATED BACTERIA(3,1)
BACTERIAL TITER(3,1)
BACTERIUM REMAINING VIRULENCE(3,1)
CANNULA ATOMIZATION(3,1)
COMMENSAL ORGANISM(3,1)
COMMERCIALLY OBTAINABLE VACCINE(3,1)
FROZEN LIVE PI(3,1)
INTRANASAL ATOMIZATION(3,1)
LIVE ATTENUATED PARAINFLUENZA PRESENCE(3,1)
LIVE ATTENUATED STRAIN(3,1)
MAD CANNULA(3,1)
MERRIAM WEBSTER(3,1)
ONLINE DICTIONARY(3,1)
PATHOGENIC COUNTERPART(3,1)
PLEURITIS SCORE(3,1)
RESPIRATORY TRACT MUCOSA(3,1)
RISPOVAL APPLICATOR(3,1)
SEVERE DISEASE FORM(3,1)
STATISTICAL PROGRAM(3,1)
TRANSTHORACIC CHALLENGE(3,1)
VACCINE EFFICACY(3,1)
VACCINE SPREADING(3,1)
VIRULENCE GENE(3,1)
ANTIGEN(2,4)
NOSTRIL(2,4)
DROPLET(2,3)
LARYNX(2,2)
PHARYNX(2,2)
STATISTICALLY SIGNIFICANT REDUCTION(2,2)
AEROSOL ROUTE(2,1)
ANIMAL MOUTH(2,1)
ANIMAL VACCINATION(2,1)
ANOVA REPEATED MEASUREMENT(2,1)
APPLICATOR NOZZLE(2,1)
BACTERIAL RE ISOLATION(2,1)
CHALLENGE DOSE(2,1)
CLEAN CATCH(2,1)
CLINICAL SIGN DEVELOPMENT(2,1)
CULTURE AIMING(2,1)
DAY POST CHALLENGE(2,1)
DISEASE INDUCTION(2,1)
DISEASED TISSUE(2,1)
EQUATION ESTIMATION(2,1)
EQUIVALENT LOBE SAMPLE(2,1)
EXPERIMENT OBJECTIVE(2,1)
FINE MIST ORAL ADMINISTRATION(2,1)
GENESIS INDUSTRY(2,1)
HOUGHTON MIFFLIN COMPANY(2,1)
IMMUNE RESPONSE ADEQUATENESS(2,1)
LIVE BACTERIA(2,1)
LIVE MH BRSV PI(2,1)
LIVE VACCINE(2,1)
LUNG LESION REDUCTION(2,1)
LYOPHILIZED POWDER(2,1)
MAD NASAL(2,1)
MANNHEIMIA HAEMOLYTICA ML(2,1)
NASALGEN IP(2,1)
OLD CALF(2,1)
PARTICLE VACCINE(2,1)
PERCENTAGE LUNG CONSOLIDATION(2,1)
PRINCIPAL BACTERIAL PATHOGEN(2,1)
RE ISOLATION DATA(2,1)
REPEATED MEASUREMENT ACCOUNTING(2,1)
RUMINANT PROTECTION(2,1)
STABILIZER MATRIX(2,1)
STREPTOMYCIN DEPENDENT STRAIN(2,1)
SUBCUTANEOUS IMPLANT(2,1)
SYMPTOM FULL SUITE(2,1)
VACCINATION STUDY(2,1)
VIRAL PATHOGEN(2,1)
VIRUS ATTENUATION(2,1)
VISCOSITY MODIFIER(2,1)
YOUNG CALF(2,1)
ACTIVE LEUKOTOXIN(1,1)
ADMINISTRATION VOLUME(1,1)
ALONE ADEQUATE PROTECTION(1,1)
BACTERIAL LOAD LOWERING(1,1)
BLOOD AGAR PLATE(1,1)
DETRIMENTAL HOST RESPONSE(1,1)
ELECTRIC SEDATION(1,1)
FREEZE DRIED VACCINE(1,1)
HALF LOBE(1,1)
HEALTH ABNORMALITY(1,1)
HUGE MUCOSAL AREA(1,1)
MAD ATOMIZATION(1,1)
MAXIMAL RESISTANCE(1,1)
MUTATION(1,1)
NEGLIGIBLE REDUCTION(1,1)";Pharmaceuticals;Open
"2013-03-15
2014-03-13";"CA2907098           A1 2014-09-25 [CA2907098]
STG: (A1) Application laid open
AP : 2014CA-2907098 2014-03-13
WO2014151401        A1 2014-09-25 [WO2014151401]
STG: (A1) Published application with search report
AP : 2014WO-US25655 2014-03-13
AU2014234982        A1 2015-09-24 [AU2014234982]
STG: (A1) Open to public inspection
AP : 2014AU-0234982 2014-03-13
US20160008449       A1 2016-01-14 [US20160008449]
STG: (A1) Application published
AP : 2014US-14775741 2014-03-13
FD :  Provisional Appl: US61/791,571 FDD=2013-03-15 [2013US-61791571]
EP2983703           A1 2016-02-17 [EP2983703]
STG: (A1) Application published with search report
AP : 2014EP-0715511 2014-03-13
JP2016512841        A  2016-05-09 [JP2016512841]
STG: (A) Published application
AP : 2016JP-0501933 2014-03-13";73773430;"CA2907098           A1 2014-09-25 [CA2907098]
WO2014151401        A1 2014-09-25 [WO2014151401]
AU2014234982        A1 2015-09-24 [AU2014234982]
US20160008449       A1 2016-01-14 [US20160008449]
EP2983703           A1 2016-02-17 [EP2983703]
JP2016512841        A  2016-05-09 [JP2016512841]";"2013US-61791571
2014US-14775741
2014WO-US25655";"(EP2983703)
WO2014151401
(US20160008449)
WO2014151401
(JP2016512841)
WO2014151401
(CA2907098)
WO2014151401
(AU2014234982)
WO2014151401";"ZOETIS
ZOETIS SERVICES
ZOETISU SABISHIZU";ZOETIS SERVICES;"(EP2983703)
US
(US20160008449)
US
(WO2014151401)
US

(CA2907098)
US";"(EP2983703)
NAME=Zoetis Services LLC 100 Campus Drive , CITY=Florham Park, NJ 07932 , COUNTRY=US 

(US20160008449)
NAME=ZOETIS SERVICES LLC , CITY=Florham Park , STATE=NJ , COUNTRY=US 

(WO2014151401)
NAME=ZOETIS LLC 100 Campus Drive Florham Park, New Jersey 07932 , POSTCODE=07932 , COUNTRY=US 

(JP2016512841)
NAME=Zoetisu-Sabishizu LLC , REG=515230154 

(CA2907098)
NAME=ZOETIS SERVICES LLC 100 CAMPUS DRIVE , CITY=FLORHAM PARK , STATE=NJ , POSTCODE=07932 , COUNTRY=US 
";1;"BOWERSOCK TERRY LYNN
DUNN RYAN N
LEYH RANDY DEAN
OKKINGA KLAAS";"(EP2983703)
US";"(EP2983703)
NAME=BOWERSOCK, Terry Lynn c/o ZOETIS LLC 333 Portage Street , CITY=Kalamazoo, Michigan 49007 , COUNTRY=US 

NAME=DUNN, Ryan N. c/o ZOETIS LLC 100 Campus Drive , CITY=Florham Park, New Jersey 07932 , COUNTRY=US 

NAME=LEYH, Randy Dean c/o ZOETIS LLC 333 Portage Street , CITY=Kalamazoo, Michigan 49007 , COUNTRY=US 

NAME=OKKINGA, Klaas c/o ZOETIS LLC 100 Campus Drive , CITY=Florham Park, New Jersey 07932 , COUNTRY=US 
";"(EP2983703)
Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine";"(EP2983703)
The invention provides a method of protecting a bovine susceptible to Bibersteinia trehalosi, the method comprising administering to said bovine an effective amount of a vaccine comprising a Mannheimia haemolytica antigen, and further comprising one or more of Infectious Bovine Rhinotracheitis Virus, Bovine Viral Diarrhea Virus, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus.";"(CA2907098)
1. A method of protecting a bovine susceptible to Bibersteinia trehalosi, the method comprising administering to said bovine an effective amount of a vaccine comprising a Mannheimia haemolytica antigen, and further comprising one or more antigens of Infectious Bovine Rhinotracheitis Virus, Bovine Viral
Diarrhea
Virus, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus.
2. The method of claim 1, wherein the vaccine comprises antigens against
Infectious Bovine Rhinotracheitis Virus, Bovine Viral Diarrhea Virus,
Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus.
3. The method of any one of claims 1-2, wherein the Mannheimia haemolytica is killed or inactivated.
4. The method of any one of claims 1-3, where the vaccine further comprises an adjuvant.
5. The method of any one of claims 1-4, wherein the bovine is a bull, a steer, a calf, a cow, or a heifer.
6. The method of any one of claims 1-5, wherein the Mannheimia haemolytica antigen is a toxoid or a bacterin-toxoid.
7. The method of any one of claims 1-5, wherein the Mannheimia haemolytica antigen is a modified live antigen.";"(US20160008449)
In another preferred embodiment, the present invention contemplates the use of vaccine compositions comprising from about 1 mg/ml to about 60 mg/ml of antibiotic, and more preferably less than about 30 mg/ml of antibiotic.
For example, the present invention contemplates the vaccination of healthy cattle prior to six months of age and revaccination at six months of age.
The present invention also contemplates semiannual revaccinations with a single dose and possibly, a revaccination prior to breeding.";"(US20160008449)
Accordingly, there is a need in the art for compositions and methods to protect bovines against BRD caused by B. trehalosi.
The vaccines used in the methods of the instant invention may advantageously be formulated with veterinarily-acceptable carriers, including all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, immunomodulators, and the like.
BRD complex is a multifactorial infection, having many contributing pathogens, both viral and bacterial.
Most current anti-BRD vaccines on the market do not include antigens against B. trehalosi.";"A61K-039/02
A61K-039/102
A61K-039/12
A61K-039/155
A61K-039/265
A61K-039/39
A61P-031/00
A61P-031/12
A61P-037/04
C12N-007/00";"(US20160008449)
1. A method of protecting a bovine susceptible to Bibersteinia trehalosi, the method comprising administering to said bovine an effective amount of a vaccine comprising a Mannheimia haemolytica antigen, and further comprising one or more antigens of Infectious Bovine Rhinotracheitis Virus, Bovine Viral Diarrhea Virus, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus.";"(US20160008449)
BOVINE(100,8)
MANNHEIMIA HAEMOLYTICA ANTIGEN(100,5)
BIBERSTEINIA TREHALOSI(100,3)
MULTIVALENT VACCINE(100,2)
TREHALOSI INFECTION(100,2)
BOVINE CROSS PROTECTION(100,1)
HEALTHY CATTLE VACCINATION(87,1)
SEMI ANNUAL REVACCINATION(68,1)
MULTIFACTORIAL INFECTION(58,1)
CONTRIBUTING PATHOGEN(56,1)
AGE MONTH(49,4)
ADSORPTION DELAYING(48,1)
VACCINE(40,27)
REVACCINATION(40,2)
PARAINFLUENZA(34,6)
ANTIBIOTIC(32,2)
CURRENT ANTI BRD VACCINE(32,1)
BRD COMPLEX(31,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(30,7)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(29,7)
IMMUNOMODULATOR(29,1)
ANTIGEN(27,14)
BOVINE VIRAL DIARRHEA VIRUS(26,8)
TREHALOSI(26,5)
ISOTONIC AGENT(26,2)
ANTIBACTERIAL(25,1)
PRESERVATIVE(25,1)
BIBERSTEINIA TREHALOSI RESPIRATORY CHALLENGE(24,2)
VETERINARILY ACCEPTABLE CARRIER(24,2)
DISPERSION MEDIUM(24,1)
MODIFIED LIVE ANTIGEN(23,2)
ADJUVANT(20,13)
VIRUS(20,11)
ANTIFUNGAL AGENT(17,1)
DILUENT(16,2)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(16,1)
STABILIZING AGENT(15,1)
LEPTOSPIRA INTERROGAN POMONA(14,1)
BRD(13,2)
HEIFER(13,2)
IBR BVD CALF(12,1)
KILLED MANNHEIMIA HAEMOLYTICA ANTIGEN(12,1)
BULL(11,2)
STEER(11,2)
COW(10,2)
INACTIVATED TOXIN(10,2)
SINGLE DOSE(10,2)
INSUFFICIENT LUNG LESION SCORE(10,1)
VETERINARY RESEARCH NATIONAL INSTITUTE(10,1)
ACTIVE INGREDIENT(9,5)
ATTENUATED LIVE BACTERIUM(9,1)
BORGPETERSENII HARDJO BOVIS(9,1)
BOVINE RESPIRATORY DISEASE SYMPTOM(9,1)
HAEMOLYTICA LEUKOTOXIN(9,1)
LEPTOSPIRA GRIPPOTYPHOSA(9,1)
MANNHEIMIA HAEMOLYTICA EFFICACY(9,1)
MANNHEIMIA HAEMOLYTICA TOXOID(9,1)
MEDIAN LUNG LESION(9,1)
STRATIFIED MITIGATED FRACTION(9,1)
TRACHEA BIFURCATION(9,1)
TERM ANTIGEN(8,4)
CHALLENGE ADMINISTRATION(8,2)
PREVENTIVE FRACTION(8,2)
VACCINE ADMINISTRATION(8,2)
AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUND(8,1)
BOVI SHIELD GOLD(8,1)
CLINICAL SCORE DATA(8,1)
DECREASING LUNG LESION(8,1)
INACTIVATED BACTERIN(8,1)
LEPTOSPIRA CANICOLA(8,1)
MICROORGANISM INACTIVATION(8,1)
MICROORGANISM REPLICATION(8,1)
MITIGATED FRACTION ESTIMATE(8,1)
MYCOBACTERIUM TUBERCULOSIS(8,1)
RECONSTITUTED COMPOSITION PARENTERAL ADMINISTRATION(8,1)
RESIDUAL LIVE BACTERIA(8,1)
SYNTHETIC PEPTIDE MIMOTOPE(8,1)
TREHALOSI CHALLENGE CAUSED MORTALITY(8,1)
IBRV STRAIN(7,2)
LUNG TISSUE(7,2)
STUDY OBJECTIVE(7,2)
AFRICAN BUFFALO(7,1)
ANTI IDIOTYPE ANTIBODY(7,1)
BACTERIA INACTIVATION(7,1)
BACTERIAL LIPOPOLYSACCHARIDE(7,1)
CHOLERA TOXIN(7,1)
CLOVEN HOOF(7,1)
COMPLEX MULTIVALENT VACCINE(7,1)
INFECTION SYMPTOM(7,1)
KILLED BORDETELLA(7,1)
PATHOGENIC MICROORGANISM(7,1)
PERTUSSIS TOXIN(7,1)
PNEUMONIC LESION(7,1)
RESIDUAL LIVE VIRUS(7,1)
RESPIRATORY DISEASE CLINICAL SIGN(7,1)
SORBITAN TRIOLEATE(7,1)
SPIRAL HORNED ANTELOPE(7,1)
TS MUTANT STRAIN(7,1)
VACCINE FORMULATION(7,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(7,1)
VIRUS INACTIVATION(7,1)
ATOMIZER(6,4)
PRESSURIZED CONTAINER(6,2)
SYSTEMIC REACTION(6,2)
ADJUVANT MOLECULE(6,1)
AGRICULTURE UNITED STATES DEPARTMENT(6,1)
ANTIGEN SITE(6,1)
ANTIGENIC ACTIVITY(6,1)
ATCC ACCESSION(6,1)
BACTERIA SUSPENSION(6,1)
BACTERIN TOXOID FRACTION(6,1)
BIODEGRADABLE FORMULATION(6,1)
BIOLOGICAL ACTIVITY EFFECTIVENESS(6,1)
COSTIMULATORY MOLECULE(6,1)
CPG MOTIF(6,1)
DOMESTIC CATTLE(6,1)
HEALTH OBSERVATION(6,1)
IMMUNOGLOBULIN SUPERFAMILY MEMBER(6,1)
IMPLANTED DEPOT(6,1)
INSTANT VACCINE(6,1)
KILLED VIRUS(6,1)
LIVE ATTENUATED VIRUS(6,1)
LUNG SWAB(6,1)
MORIBUND ANIMAL(6,1)
NTX ANIMAL(6,1)
PENETRATION ENHANCER(6,1)
PLURONIC POLYOL(6,1)
PREVENTED FRACTION CONFIDENCE INTERVAL(6,1)
SERIAL PASSAGING(6,1)
SERINE REPLACEMENT(6,1)
SPARINGLY SOLUBLE POLYMER(6,1)
SPARINGLY SOLUBLE SALT(6,1)
SUBCUTANEOUS ADMINISTRATION MIDWAY(6,1)
TREHALOSI CULTURE(6,1)
ULTRAVIOLET IRRADIATION(6,1)
VACCINATED ANIMAL(6,1)
DISORDER(5,4)
CANNULA(5,3)
EPITOPE(5,3)
FORMALIN(5,3)
ANNUAL BASIS(5,2)
COMPLETE INACTIVATION(5,2)
ELECTROHYDRODYNAMICS(5,2)
FINE MIST(5,2)
POST CHALLENGE(5,2)
PROGRAMMED RELEASE(5,2)
PROPELLANT(5,2)
ADHESION MOLECULE(5,1)
AEROSOL SPRAY(5,1)
ALCOHOL WIPE(5,1)
ANIMAL AGE(5,1)
BACTERIAL GROWTH(5,1)
BEEF INDUSTRY(5,1)
BIOADHESIVE AGENT(5,1)
BRSV STRAIN(5,1)
BVDV PI(5,1)
COLI HEAT LABILE TOXIN(5,1)
DRY POWDER INHALER(5,1)
DUSTING POWDER(5,1)
EAR NOTCH(5,1)
FEMALE BOVINE(5,1)
HUMORAL IMMUNE RESPONSE(5,1)
IMMUNOGENIC ACTIVITY(5,1)
INACTIVATED BACTERIAL MIXTURE(5,1)
INACTIVATED VIRAL MIXTURE(5,1)
INFECTIOUS AGENT(5,1)
INTEGRIN FAMILY MEMBER(5,1)
LIPASE ACTIVITY(5,1)
LIPOSOMAL PREPARATION(5,1)
LUNG CULTURE(5,1)
MAGNESIUM STEARATE(5,1)
MAJOR BRONCHUS(5,1)
MEDIUM CULTURE FLUSH(5,1)
MICROORGANISM TRANSMISSION(5,1)
MODIFY LIVE VIRUS(5,1)
MULTOCIDA OUTER MEMBRANE PROTEIN(5,1)
OLIGOLACTIC ACID(5,1)
POLYACRYLIC POLYMER(5,1)
PURIFIED VIRUS(5,1)
QUATERNARY AMMONIUM(5,1)
RECEPTOR MOLECULE(5,1)
SERUM ANTIBODY(5,1)
SUSPENSION FORMULATION(5,1)
SYNTHETIC POLYNUCLEOTIDE(5,1)
VIRUS SUSPENSION(5,1)
LACTOSE(4,4)
ACTUATION VOLUME(4,2)
ANTIGENIC DETERMINANT(4,2)
DEXTROSE(4,2)
FINAL CONCENTRATION(4,2)
INHALATION(4,2)
MINERAL OIL(4,2)
MODIFIED RELEASE FORMULATION(4,2)
NEBULIZER(4,2)
OLIGONUCLEOTIDE(4,2)
SAPONIN(4,2)
VIRAL ANTIGEN(4,2)
ALUMINUM PHOSPHATE(4,1)
CAMPYLOBACTER FETUS(4,1)
CELL RECEPTOR(4,1)
CHEMICAL MUTAGENESIS(4,1)
CLINICAL SCORE REDUCED PERCENTAGE(4,1)
COMBINATION VACCINE HAEMOLYTICA FRACTION(4,1)
COMPOUND POWDER MIX(4,1)
COMPOUND SUSPENSION(4,1)
ENTERIC COATED TABLET(4,1)
EUTHANASIA NECROPSY(4,1)
EXCIPIENT(4,1)
FINAL BEA CONCENTRATION(4,1)
FINAL FORMALDEHYDE CONCENTRATION(4,1)
HYDROXYPROPYLMETHYLCELLULOSE(4,1)
IMMUNE MODULATING ACTIVITY(4,1)
INVESTIGATION(4,1)
LABORATORY ANALYSIS(4,1)
LOCAL ANESTHESIA SPOT(4,1)
MORTALITY REDUCTION(4,1)
MURAMYL DIPEPTIDE(4,1)
PERFORMANCE MODIFIER(4,1)
PHARMACOGENETICS(4,1)
POLYLACTIDE GLYCOSIDE(4,1)
PRIMARY EFFICACY(4,1)
PRIMARY INACTIVATING AGENT(4,1)
PRODUCTION CULTURE(4,1)
PROGRESSION EXTENT(4,1)
STABLE EMULSION(4,1)
SUSTAINED RELEASE(4,1)
SYNTHETIC LIPID(4,1)
TERM ADJUVANT(4,1)
TERM BACTERIN(4,1)
TERM IMMUNOGENIC(4,1)
TERM PATHOGEN(4,1)
TERM TOXOID(4,1)
TERM VETERINARILY ACCEPTABLE CARRIER(4,1)
TETRAFLUOROETHANE(4,1)
THIXOTROPIC LIQUID(4,1)
TRUE HORN(4,1)
VIRUS BEA MIXTURE(4,1)
WHOLE ORGANISM(4,1)
CAPSULE(3,3)
PROPYLENE GLYCOL(3,3)
ACTIVE RELEASE(3,1)
ALIQUOT(3,1)
ALUMINUM HYDROXIDE(3,1)
ALUMINUM SALT(3,1)
AQUEOUS ETHANOL(3,1)
ARGININE(3,1)
ATTENUATION(3,1)
BACTERIAL COMPONENT(3,1)
BANDAGE(3,1)
BLISTER(3,1)
CARTRIDGE(3,1)
CASPASE(3,1)
CHEMOKINE(3,1)
CHITOSAN(3,1)
CONFIDENCE LIMIT(3,1)
CPBVDV(3,1)
CYCLODEXTRIN(3,1)
CYTOKINE(3,1)
CYTOTOXIC(3,1)
DRESSING(3,1)
DRUG PRODUCT(3,1)
DRY BLENDING(3,1)
ELECTROPORATION(3,1)
ETHYLAMINE(3,1)
FLUID BED(3,1)
FRUCTOSE(3,1)
GLYCAM(3,1)
GLYCERIN(3,1)
HELMINTH(3,1)
HISTIDINE(3,1)
HYDROGEL(3,1)
ILLNESS(3,1)
IMPLANTATION(3,1)
INOCULATION(3,1)
INSUFFLATOR(3,1)
(WO2014151401)
BOVINE(100,7)
BIBERSTEINIA TREHALOSI(100,2)
HEALTHY CATTLE VACCINATION(84,1)
MANNHEIMIA HAEMOLYTICA ANTIGEN(83,4)
MULTIFACTORIAL INFECTION(56,1)
CONTRIBUTING PATHOGEN(54,1)
AGE MONTH(47,4)
ADSORPTION DELAYING(46,1)
VACCINE(39,28)
ANTIBIOTIC MG ML(36,2)
IMMUNOMODULATOR(28,1)
PARAINFLUENZA(27,5)
ANTIGEN(25,18)
ISOTONIC AGENT(25,2)
ANTIBACTERIAL(24,1)
PRESERVATIVE(24,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(23,6)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(23,6)
BIBERSTEINIA TREHALOSI RESPIRATORY CHALLENGE(23,2)
DISPERSION MEDIUM(23,1)
VETERINARILY ACCEPTABLE CARRIER(22,3)
MODIFIED LIVE ANTIGEN(22,2)
BOVINE VIRAL DIARRHEA VIRUS(21,7)
REVACCINATION(21,2)
ADJUVANT(19,14)
VIRUS(16,11)
ANTIFUNGAL AGENT(16,1)
DILUENT(15,2)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(15,1)
DISORDER(14,4)
INFECTION(14,3)
STABILIZING AGENT(14,1)
ANIMAL(13,27)
HEIFER(13,2)
LEPTOSPIRA INTERROGAN POMONA(13,1)
DISEASE(12,4)
BIBERSTEINIA TREHALOSI CHALLENGE(12,1)
IBR BVD(11,4)
BULL(11,2)
DIARRHEA PARAINFLUENZA(11,2)
STEER(11,2)
KILLED MANNHEIMIA HAEMOLYTICA ANTIGEN(11,1)
COW(10,2)
INACTIVATED TOXIN(9,2)
TREHALOSI INFECTION(9,2)
TS MUTANT STRAIN(9,2)
MULTIVALENT BOVINE VACCINE(9,1)
VETERINARY RESEARCH NATIONAL INSTITUTE(9,1)
ACTIVE INGREDIENT(8,5)
CHALLENGE ADMINISTRATION(8,2)
COMBINATION VACCINE(8,2)
VACCINE ADMINISTRATION(8,2)
ATTENUATED LIVE BACTERIUM(8,1)
BORGPETERSENII HARDJO BOVIS(8,1)
BOVINE RESPIRATORY DISEASE SYMPTOM(8,1)
HAEMOLYTICA LEUKOTOXIN(8,1)
LEPTOSPIRA GRIPPOTYPHOSA(8,1)
LUNG LESION MEDIAN PERCENT(8,1)
MANNHEIMIA HAEMOLYTICA EFFICACY(8,1)
MANNHEIMIA HAEMOLYTICA TOXOID(8,1)
MEDIAN LUNG LESION(8,1)
MG ML(8,1)
SEMI ANNUAL REVACCINATION(8,1)
STRATIFIED MITIGATED FRACTION(8,1)
TRACHEA BIFURCATION(8,1)
LUNG TISSUE(7,2)
MODIFIED LIVE VIRUS(7,2)
PREVENTIVE FRACTION(7,2)
STUDY OBJECTIVE(7,2)
AMINOALKYL GLUCOSAMINE(7,1)
BOVI SHIELD GOLD(7,1)
CLINICAL SCORE DATA(7,1)
DECREASING LUNG LESION(7,1)
INACTIVATED BACTERIN(7,1)
LEPTOSPIRA CANICOLA(7,1)
MICROORGANISM INACTIVATION(7,1)
MICROORGANISM REPLICATION(7,1)
MITIGATED FRACTION ESTIMATE(7,1)
MYCOBACTERIUM TUBERCULOSIS(7,1)
PERCENT PNEUMONIC LESION(7,1)
RECONSTITUTED COMPOSITION PARENTERAL ADMINISTRATION(7,1)
RESIDUAL LIVE BACTERIA(7,1)
SYNTHETIC PEPTIDE MIMOTOPE(7,1)
TREHALOSI CHALLENGE CAUSED MORTALITY(7,1)
PRESSURIZED CONTAINER(6,2)
SYSTEMIC REACTION(6,2)
AFRICAN BUFFALO(6,1)
BACTERIA INACTIVATION(6,1)
BACTERIAL LIPOPOLYSACCHARIDE(6,1)
CHOLERA TOXIN(6,1)
CLOVEN HOOF(6,1)
COMPLEX MULTIVALENT VACCINE(6,1)
CYTOTOXIC T CELL(6,1)
INFECTION SYMPTOM(6,1)
KILLED BORDETELLA(6,1)
PATHOGENIC MICROORGANISM(6,1)
QUATERNARY AZANIUM(6,1)
RESIDUAL LIVE VIRUS(6,1)
RESPIRATORY DISEASE CLINICAL SIGN(6,1)
SPIRAL HORNED ANTELOPE(6,1)
T CELL RECEPTOR(6,1)
TRACHEAL DOSING(6,1)
VACCINE FORMULATION(6,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(6,1)
VIRUS INACTIVATION(6,1)
ATOMIZER(5,4)
CANNULA(5,3)
EPITOPE(5,3)
ANNUAL BASIS(5,2)
COMPLETE INACTIVATION(5,2)
ELECTROHYDRODYNAMICS(5,2)
FINE MIST(5,2)
POST CHALLENGE(5,2)
PROGRAMMED RELEASE(5,2)
ADJUVANT MOLECULE(5,1)
AGRICULTURE UNITED STATES DEPARTMENT(5,1)
ANTIGEN SITE(5,1)
ANTIGENIC ACTIVITY(5,1)
BACTERIA SUSPENSION(5,1)
BACTERIN TOXOID FRACTION(5,1)
BINARY ETHYLENEIMINE(5,1)
BIODEGRADABLE FORMULATION(5,1)
BIOLOGICAL ACTIVITY EFFECTIVENESS(5,1)
CPG MOTIF(5,1)
DOMESTIC CATTLE(5,1)
EUTHANASIA DAY(5,1)
EUTHANASIA NECROPSY DAY(5,1)
HEALTH OBSERVATION(5,1)
IMMUNOGLOBULIN SUPERFAMILY MEMBER(5,1)
IMPLANTED DEPOT(5,1)
INSTANT VACCINE(5,1)
KILLED VIRUS(5,1)
LIVE ATTENUATED VIRUS(5,1)
LUNG SWAB(5,1)
MORIBUND ANIMAL(5,1)
PENETRATION ENHANCER(5,1)
PLURONIC POLYOL(5,1)
PREVENTED FRACTION CONFIDENCE INTERVAL(5,1)
SERIAL PASSAGING(5,1)
SPARINGLY SOLUBLE POLYMER(5,1)
SPARINGLY SOLUBLE SALT(5,1)
SUBCUTANEOUS ADMINISTRATION MIDWAY(5,1)
TREHALOSI CULTURE(5,1)
ULTRAVIOLET IRRADIATION(5,1)
VACCINATED ANIMAL(5,1)
ACTUATION VOLUME(4,2)
ANTIGENIC DETERMINANT(4,2)
DEXTROSE(4,2)
FINAL CONCENTRATION(4,2)
INHALATION(4,2)
MODIFIED RELEASE FORMULATION(4,2)
OLIGONUCLEOTIDE(4,2)
SAPONIN(4,2)
VIRAL ANTIGEN(4,2)
ADHESION MOLECULE(4,1)
AEROSOL SPRAY(4,1)
ALCOHOL WIPE(4,1)
ANIMAL AGE(4,1)
BACTERIAL GROWTH(4,1)
BEEF INDUSTRY(4,1)
BIOADHESIVE AGENT(4,1)
BVDV PI(4,1)
CHALLENGE DAY(4,1)
DRY POWDER INHALER(4,1)
DUSTING POWDER(4,1)
EAR NOTCH(4,1)
FEMALE BOVINE(4,1)
HUMORAL IMMUNE RESPONSE(4,1)
IMMUNOGENIC ACTIVITY(4,1)
INACTIVATED BACTERIAL MIXTURE(4,1)
INACTIVATED VIRAL MIXTURE(4,1)
INFECTIOUS AGENT(4,1)
INTEGRIN FAMILY MEMBER(4,1)
LIDOCAINE ML(4,1)
LIPASE ACTIVITY(4,1)
LIPOSOMAL PREPARATION(4,1)
LUNG CULTURE(4,1)
MAJOR BRONCHUS(4,1)
MICROORGANISM TRANSMISSION(4,1)
MODIFY LIVE VIRUS(4,1)
MULTOCIDA OUTER MEMBRANE PROTEIN(4,1)
OLIGOLACTIC ACID(4,1)
POLYACRYLIC POLYMER(4,1)
PURIFIED VIRUS(4,1)
RECEPTOR MOLECULE(4,1)
RECIPIENT IMMUNE RESPONSE(4,1)
SERUM ANTIBODY(4,1)
SUSPENSION FORMULATION(4,1)
SYNTHETIC POLYNUCLEOTIDE(4,1)
VIRUS SUSPENSION(4,1)
LACTOSE(3,4)
CAPSULE(3,3)
GLYCEROL(3,3)
CAMPYLOBACTER FETUS(3,1)
CHEMICAL MUTAGENESIS(3,1)
COMBINATION VACCINE HAEMOLYTICA FRACTION(3,1)
COMPOUND POWDER MIX(3,1)
COMPOUND SUSPENSION(3,1)
ENTERIC COATED TABLET(3,1)
EXCIPIENT(3,1)
FINAL FORMALDEHYDE CONCENTRATION(3,1)
HYDROXYPROPYLMETHYLCELLULOSE(3,1)
IMMUNE MODULATING ACTIVITY(3,1)
INVESTIGATION(3,1)
LABORATORY ANALYSIS(3,1)
LOCAL ANESTHESIA SPOT(3,1)
MORTALITY REDUCTION(3,1)
MURAMYL DIPEPTIDE(3,1)
PERFORMANCE MODIFIER(3,1)
PHARMACOGENETICS(3,1)
PHOSPHATIDYLCHOLINE(3,1)
POLYGLUTAMIC ACID MICROSPHERE(3,1)
POLYLACTIDE GLYCOSIDE(3,1)
PRIMARY EFFICACY(3,1)
PRIMARY INACTIVATING AGENT(3,1)
PRODUCTION CULTURE(3,1)
PROGRESSION EXTENT(3,1)
STABLE EMULSION(3,1)
SUSTAINED RELEASE(3,1)
THIXOTROPIC LIQUID(3,1)
TRUE HORN(3,1)
WHOLE ORGANISM(3,1)
ACTIVE RELEASE(2,1)
ALIQUOT(2,1)
ALUMINUM SALT(2,1)
ARGININE(2,1)
ATTENUATION(2,1)
AVRIDINE(2,1)
BACTERIAL COMPONENT(2,1)
BANDAGE(2,1)
BLISTER(2,1)
CARTRIDGE(2,1)
CASPASE(2,1)
CHEMOKINE(2,1)
CHITOSAN(2,1)
COLI HEAT(2,1)
CONFIDENCE LIMIT(2,1)
COSTIMULATORY MOLECULE(2,1)
CPBVDV(2,1)
CULTURE MEDIUM(2,1)
CYCLODEXTRIN(2,1)
CYTOKINE(2,1)
DRESSING(2,1)
DRUG PRODUCT(2,1)
DRY BLENDING(2,1)
ELECTROPORATION(2,1)
FLUID BED(2,1)
FRUCTOSE(2,1)
GLYCAM(2,1)
HELMINTH(2,1)
HYDROGEL(2,1)
ILLNESS(2,1)
(JP2016512841)
ANTIGEN(100,22)
MANNHEIMIA(100,9)
MULTIVALENT VACCINE(100,3)
BIBERSTEINIA TREHALOSI(100,2)
CATTLE PROTECTION(100,2)
BOVINE INFECTION(100,1)
STREPTOCOCCUM SUIS(76,1)
IMMUNOGENICITY ACTIVATOR(74,1)
MONTH OLD CALF HEALTH(64,1)
BACTERIUM(55,1)
OESTBERG HAEMOLYTICA ANTIGEN(53,1)
BOVINE PARAINFLUENZA(48,1)
VACCINE(40,26)
AGE MONTH(38,3)
MANNHEIMIA HAEMOLYTICA(38,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS NASAL(35,2)
CATTLE(34,2)
BOVINE VIRAL DIARRHEA VIRUS(33,8)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(33,5)
RE VACCINATION(32,4)
RHINOSCOPY(30,1)
VIRUS(28,15)
DOMESTIC(28,1)
COW(23,6)
NOSE(22,4)
BACTERIN(21,4)
PROTECTION INFECTION TOREHAROSHI(21,1)
VACCINATION(20,8)
BACTERIA(19,5)
CELL WALL COMPONENT(17,1)
VIRAL ANTIGEN(16,3)
VACCINE DOSAGE ADMINISTRATION(16,2)
ATTENUATED LIVE CHINA VIRUS(15,1)
CALVES BIBERUSUTINIA RESPIRATORY TOXICITY(15,1)
HAEMOLYTICA MULTOCIDA(14,2)
BACTERIUM INACTIVATED TOXIN(14,1)
LIVE MANNHEIMIA TOXOID ANTIGEN(14,1)
PULMONARY LESION RELAXATION(14,1)
REAL BOVINE UNGULATE SEX(14,1)
TRACHEA TOPICAL ANESTHESIA(14,1)
VIRUS BEI INACTIVATION(14,1)
VETERINARILY ACCEPTABLE CARRIER(13,3)
ACTIVE INGREDIENT(12,6)
BULL(12,2)
FORMALIN INACTIVATION(12,2)
VACCINE EFFECTIVENESS(12,2)
STRAIN NADL CPBVDV(12,1)
ATOMIZED MIST(11,2)
BOVINE RESPIRATORY DISEASE SYMPTOM(11,1)
CULTURED LUNG SWAB(11,1)
INSPECTING RESIDUAL LIVE VIRUS(11,1)
LIVE ATTENUATED BACTERIUM(11,1)
LIVE BACTERIUM INSPECTION(11,1)
TOREHAROSHI DISEASE(10,2)
BACTERIN TOXOID(10,1)
BOVI SHIELD GOLD(10,1)
CLINICAL SCORE DATA(10,1)
HAEMOLYTICA VACCINE(10,1)
INACTIVATED BACTERIN(10,1)
LUNG LESION PERCENTAGE(10,1)
MORI CHICA TOXOID(10,1)
MULTIFACTOR INFECTION(10,1)
MYCOBACTERIUM TUBERCULOSIS(10,1)
PHOSPHOLIPID PHOSPHATIDYLCHOLINE(10,1)
PROPHYLACTIC VACCINATION(10,1)
SYNTHETIC PEPTIDE MIMOTOPE(10,1)
TOXIN INACTIVATION(10,1)
LUNG TISSUE(9,2)
SODIUM THIOSULFATE(9,2)
SUSTAINED RELEASE(8,3)
ANTI IDIOTYPE ANTIBODY(8,1)
BACTERIA INACTIVATION(8,1)
COLI HEAT LABILE TOXIN(8,1)
HORN ANTELOPE(8,1)
HYDROXYPROPYL METHYL CELLULOSE(8,1)
INFECTION SYMPTOM(8,1)
KILLED BORDETELLA(8,1)
KILLING MANNHEIMIA(8,1)
MEDICAMENT INHALATION(8,1)
MICROORGANISM INACTIVATION(8,1)
MICROORGANISM PROPAGATION(8,1)
MICROORGANISM REPLICATION(8,1)
MONTH OLD ANIMAL(8,1)
MORTALITY CALCULATED CONFIDENCE INTERVAL(8,1)
MULTIVALENT BOVINE(8,1)
O DEACYLATED MONOPHOSPHORYL LIPID(8,1)
PATHOGENIC MICROORGANISM(8,1)
PERTUSSIS TOXIN(8,1)
RESPIRATORY DISEASE CLINICAL SIGN(8,1)
SORBITAN TRIOLEATE(8,1)
VACCINE EFFICACY(8,1)
VACCINE FORMULATION(8,1)
DELAYED RELEASE(7,2)
ISOTONIC AGENT(7,2)
PRESSURIZED CONTAINER(7,2)
PROGRAMMED RELEASE(7,2)
PULSED RELEASE(7,2)
ADJUVANT MOLECULE(7,1)
ADSORPTION DELAYING(7,1)
ANIMAL HAIR CUTTING(7,1)
ANIMAL INFECTION(7,1)
ANTIBODY TITER(7,1)
ANTIGENIC ACTIVITY(7,1)
ATTENUATED VIRUS(7,1)
BIOLOGICAL ACTIVITY EFFECTIVENESS(7,1)
BRD SYNDROME(7,1)
CHALLENGE NASAL(7,1)
CHOLERA TOXIN(7,1)
COSTIMULATORY MOLECULE(7,1)
ENTERIC TABLET(7,1)
EUTHANASIA DAY(7,1)
EUTHANIZED AUTOPSY DAY(7,1)
GAUGE TROCAR(7,1)
HOST COLONIZATION(7,1)
IBRV EBK(7,1)
INACTIVATED BACTERIA MIXTURE(7,1)
INTEGRIN FAMILY(7,1)
KILLED VIRUS(7,1)
MORIBUND ANIMAL(7,1)
PARENTERAL ADMINISTRATION(7,1)
PENETRATION ENHANCER(7,1)
PLURONIC POLYOL(7,1)
PNEUMONIA LESION RATIO(7,1)
PULMONARY FOCI(7,1)
SERUM ANTIBODY(7,1)
SPARINGLY SOLUBLE POLYMER(7,1)
SPARINGLY SOLUBLE SALT(7,1)
SUBUNIT ANTIGEN(7,1)
ULTRAVIOLET IRRADIATION(7,1)
VACCINATED ANIMAL(7,1)
VACCINATION STUDY(7,1)
VIRUS CHEMICAL INACTIVATION(7,1)
FINAL CONCENTRATION(6,3)
PROPELLANT(6,2)
ABNORMAL ANIMAL(6,1)
ADHESION MOLECULE(6,1)
ANIMAL ANTIBODY(6,1)
ANIMAL ATTACK(6,1)
ATCC DEPOSIT(6,1)
BACTERIAL GROWTH(6,1)
BEEF INDUSTRY(6,1)
BROMOETHYLAMINE SOLUTION(6,1)
BRSV PI(6,1)
BVDV PI(6,1)
CANNULA INSERTION(6,1)
DEMONSTRATED EFFICACY(6,1)
DRY POWDER INHALER(6,1)
DUSTING POWDER(6,1)
HUMORAL IMMUNE RESPONSE(6,1)
IMMUNOGENIC ACTIVITY(6,1)
IMMUNOMODULATORY AGENT(6,1)
INACTIVATED VIRUS MIXTURE(6,1)
INITIAL ADMINISTRATION PROPAGATION(6,1)
JAPANESE CATTLE(6,1)
LABORATORY ATTACK(6,1)
LIPASE ACTIVITY(6,1)
MAGNESIUM STEARATE(6,1)
NEBULIZER SOLUTION FORMULATION(6,1)
NTX ANIMAL(6,1)
POLYACRYLIC ACID POLYMER(6,1)
POST CHALLENGE(6,1)
PURIFIED VIRUS(6,1)
QUATERNARY AMMONIUM(6,1)
RECIPIENT IMMUNE RESPONSE(6,1)
RECONSTITUTED(6,1)
SHOULDER MIDDLE(6,1)
SUSPENSION FORMULATION(6,1)
SYNTHETIC POLYNUCLEOTIDE(6,1)
VACCINE BACTERIAL COMPONENT(6,1)
VIRAL SUSPENSION(6,1)
WEEKLY INTERVAL(6,1)
LACTOSE(5,4)
CAPSULE(5,3)
EPITOPE(5,3)
HEALTH(5,3)
ANTIGENIC DETERMINANT(5,2)
DEXTROSE(5,2)
LIPOSOME(5,2)
MINERAL OIL(5,2)
MODIFIED RELEASE FORMULATION(5,2)
OLIGONUCLEOTIDE(5,2)
OUTER MEMBRANE PROTEIN(5,2)
SAPONIN(5,2)
STABILIZER(5,2)
TOPICAL ADMINISTRATION(5,2)
ADMINISTRATION NORMAL ROUTE(5,1)
AEROSOL AGENT(5,1)
ALUMINUM PHOSPHATE(5,1)
ANIMAL DIE(5,1)
ANIMAL SYSTEMIC RESPONSE(5,1)
BIODEGRADABLE RELEASE FORMULATION(5,1)
CALF MIXING(5,1)
CHEMICAL MUTAGENESIS(5,1)
COMPOUND POWDER MIX(5,1)
ELECTRIC ATOMIZER(5,1)
EXCIPIENT(5,1)
FINAL FORMALDEHYDE CONCENTRATION(5,1)
IMPLANTATION AGENT(5,1)
INFECTIOUS FACTOR(5,1)
LABORATORY ANALYSIS(5,1)
MAIN BRONCHUS(5,1)
MORTALITY REDUCTION(5,1)
MURAMYL DIPEPTIDE(5,1)
PERFORMANCE MODIFIER(5,1)
PHARMACOGENOMICS(5,1)
POLYLACTIDE GLYCOSIDE(5,1)
POWDER PROJECT(5,1)
PRIMARY EFFICACY(5,1)
RE ADMINISTRATION(5,1)
SERUM SAMPLE(5,1)
SOLUBILIZING AGENT(5,1)
SPONGE AGENT(5,1)
STABLE EMULSION(5,1)
TETRAFLUOROETHANE(5,1)
VACCINATED GROUP(5,1)
WHOLE ORGANISM(5,1)
PROPYLENE GLYCOL(4,3)
TARGET(4,3)
ACTIVE RELEASE(3,1)
ALUMINUM HYDROXIDE(3,1)
ALUMINUM SALT(3,1)
AMINOACID VALINE(3,1)
ANIMAL SUBJECT(3,1)
ANTIBACTERIAL(3,1)
AQUEOUS ETHANOL(3,1)
ARGININE(3,1)
BANDAGE(3,1)
BLISTER(3,1)
BLOOD SAMPLE COLLECTION(3,1)
CANNULA MATERIAL ATTACK(3,1)
CARTRIDGE(3,1)
CASPASE(3,1)
CHEMOKINE(3,1)
CHITOSAN(3,1)
CONSTANT STIRRING(3,1)
CYCLODEXTRIN(3,1)
CYTOKINE(3,1)
DEPOT(3,1)
DERMIS(3,1)
DISPERSION MEDIUM(3,1)
DOWNWARD BEHIND(3,1)
DRESSING(3,1)
ELECTROPHORESIS LIGHT(3,1)
ELECTROPORATION(3,1)
FIBER AGENT(3,1)
FINAL DAY(3,1)
FINE POWDER(3,1)
FLUID BED(3,1)
FRUCTOSE(3,1)
GLYCAM(3,1)
GLYCERIN(3,1)
GLYCOLIC(3,1)
GRANULE(3,1)
HAEMOLYTICA GROUP(3,1)
HISTIDINE(3,1)
HYDROGEL(3,1)
(CA2907098)
BOVINE(100,3)
BIBERSTEINIA TREHALOSI(100,1)
BOVINE CROSS PROTECTION(100,1)
MULTIVALENT VACCINE(100,1)
TREHALOSI INFECTION(100,1)
MANNHEIMIA HAEMOLYTICA ANTIGEN(93,3)
PARAINFLUENZA(36,2)
VACCINE(35,3)
ANTIGEN(32,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(32,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(32,2)
BOVINE VIRAL DIARRHEA VIRUS(28,2)
MODIFIED LIVE ANTIGEN(27,1)
VIRUS(23,2)
ADJUVANT(15,1)
HEIFER(15,1)";Pharmaceuticals;Open
"2013-02-27
2014-02-27
2015-08-21
2018-06-12";"AR094912            A1 2015-09-09 [AR--94912]
STG: (A1) Independent patent application
AP : 2014AR-0100623 2014-02-27
US20160045593       A1 2016-02-18 [US20160045593]
STG: (A1) Application published
AP : 2015US-14832863 2015-08-21
US10029006          B2 2018-07-24 [US10029006]
STG: (B2) Granted patent as second publication
AP : 2015US-14832863 2015-08-21
FD :  Continuation of: WOPCT/EP2014/053855 FDD=2014-02-27 [2014WO-EP53855] PENDING
FD : Provisional Appl: US61/769,971 FDD=2013-02-27 [2013US-61769971]
FD : Previous publication: US20160045593 A1 2016-02-18 [US20160045593]
US20190000963       A1 2019-01-03 [US20190000963]
STG: (A1) Application published
AP : 2018US-16006472 2018-06-12
FD :  Continuation of: US14/832,863 FDD=2015-08-21 [2015US-14832863]
FD : Continuation of: US10029006 - 0 [US10029006]
FD : Continuation of: WOPCT/EP2014/053855 FDD=2014-02-27 [2014WO-EP53855] PENDING
FD : Provisional Appl: US61/769,971 FDD=2013-02-27 [2013US-61769971]";82836950;"AR094912            A1 2015-09-09 [AR--94912]
US20160045593       A1 2016-02-18 [US20160045593]
US10029006          B2 2018-07-24 [US10029006]
US20190000963       A1 2019-01-03 [US20190000963]";"2013EP-0156921
2013US-61769971
2014WO-EP53855
2015US-14832863
2018US-16006472";;"INSTITUTE NAC DE TECNOLOGIA AGROPECUARIA
INSTITUTO NACIONAL DE TECNOLOGÃ**A AGROPECUARIA
UNIVERSITY DE LIEGE";INSTITUTO NACIONAL DE TECNOLOGÃ**A AGROPECUARIA;"(US20160045593)
AR; BE
(US10029006)
AR
(US20190000963)
AR; BE";"(US20160045593)
NAME=UNIVERSITÉ DE LIÈGE , CITY=Liege , COUNTRY=BE 

NAME=INSTITUTO NACIONAL DE TECNOLOGÍA  AGROPECUARIA , CITY=Buenos Aires , COUNTRY=AR 

(US10029006)
NAME=INSTITUTO NACIONAL DE TECHNOLOGÍA AGROPECUARIA , CITY=Buenos Aries , COUNTRY=AR , ATYP=Non-US Company 

(US20190000963)
NAME=UNIVERSITÉ DE LIÈGE , CITY=Liege , COUNTRY=BE 

NAME=INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA , CITY=Buenos Aires , COUNTRY=AR 
";1;"WILLEMS LUC
TRONO KARINA";"(US20190000963)
AR; BE";"(US20190000963)
NAME=Willems Luc , CITY=Saint-Martin , COUNTRY=BE 

NAME=Trono Karina , CITY=Haedo , COUNTRY=AR 
";"(US20190000963)
Vaccine against bovine leukemia virus";"(US20190000963)
The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.";"(US20160045593)
1. A recombinant attenuated bovine leukemia virus (BLV) characterised in that the virus comprises: 
 a mutation in the nucleic acid sequence encoding the most N-terminal YXXL signalling motif of the cytoplasmic domain of the transmembrane subunit (TM) of the envelope protein, said mutation disrupting the signal transduction activity of the motif, 
 a mutation in G4 restricting the propagation of the BLV in vivo, and 
 a mutation in R3 restricting the propagation of the BLV in vivo.
2.-5. (canceled)
6. The recombinant attenuated BLV according to claim 1, further comprising: a mutation in the X region of the BLV nucleic acid sequence, said mutation abolishing the production of at least one or preferably all microRNA encoded by said X region.
7. The recombinant BLV according to claim 1, wherein the mutation in the nucleic acid sequence encoding the most N-terminal YXXL signalling motif of the cytoplasmic domain of the transmembrane subunit (TM) of the envelope protein results in a substitution of the tyrosine residue of the motif, preferably a substitution of the tyrosine residue with an aspartic acid residue.
8. The recombinant attenuated BLV according to claim 1, wherein the mutation in G4 restricting the propagation of the BLV in vivo abolishes the production of G4 polypeptide, or results in production of a C-terminally truncated G4 polypeptide lacking at least 20 or preferably at least 30 C-terminal amino acids of G4 polypeptide, or inactivates G4 polypeptide such as to at least abolish the oncogenic potential of G4 polypeptide.
9. The recombinant attenuated BLV according to claim 1, wherein the mutation in G4 restricting the propagation of the BLV in vivo is located in the X region of the BLV nucleic acid sequence.
10. The recombinant attenuated BLV according to claim 1, wherein the mutation in G4 restricting the propagation of the BLV in vivo is located in the region of the BLV nucleic acid sequence between the stop codon of R3 and the splice acceptor site of intron 2 of Tax/Rex.
11. The recombinant attenuated BLV according to claim 1, wherein the mutation in G4 restricting the propagation of the BLV in vivo comprises or consists of an insertion of an in-frame stop codon in the G4 open reading frame.
12. The recombinant attenuated BLV according to claim 1, wherein the mutation in G4 restricting the propagation of the BLV in vivo comprises or consists of an insertion of an in-frame stop codon in the G4 open reading frame in the region of the BLV nucleic acid sequence between the stop codon of R3 and the splice acceptor site of intron 2 of Tax/Rex, preferably between positions 6987 and 7007 of the BLV nucleic acid sequence.
13. The recombinant attenuated BLV according to claim 1, wherein the mutation in R3 restricting the propagation of the BLV in vivo abolishes the production of R3 polypeptide.
14. The recombinant attenuated BLV according to claim 1, wherein the mutation in R3 restricting the propagation of the BLV in vivo is located in the X region of the BLV nucleic acid sequence.
15. The recombinant attenuated BLV according to claim 1, wherein the mutation in R3 restricting the propagation of the BLV in vivo abolishes splicing at the intron 2-exon 3 boundary of R3 pre-messenger RNA, preferably wherein the mutation comprises or consists of a deletion of the splice acceptor site of intron 2 of R3.
16. The recombinant attenuated BLV according to claim 15, wherein the mutation in R3 restricting the propagation of the BLV in vivo is a deletion of at least a portion of the region of the BLV nucleic acid sequence between about 250 nucleotides upstream of the intron 2-exon 3 boundary of R3 and the splice acceptor site of intron 1 of G4, for example wherein the 5′ boundary of the deletion is located between about 209 and about 189 nucleotides upstream of the intron 2-exon 3 boundary of R3 and the 3′ boundary of the deletion is located between about 23 and about 3 nucleotides upstream of the intron 1-exon 2 boundary of G4.
17. The recombinant attenuated BLV according to claim 16, wherein the 5′ boundary of the deletion is located between positions 6604 and 6624 of the BLV nucleic acid sequence and the 3′ boundary of the deletion is located between positions 6838 and 6858 of the BLV nucleic acid sequence.
18. The recombinant attenuated BLV according to claim 1, wherein the mutation in G4 restricting the propagation of the BLV in vivo and the mutation in R3 restricting the propagation of the BLV in vivo abolish splicing at the intron 2-exon 3 boundary of R3 pre-messenger RNA and at the intron 1-exon 2 boundary of G4 pre-messenger RNA, preferably wherein the mutations comprise or consist of a deletion of the splice acceptor site of intron 2 of R3 and a deletion of the splice acceptor site of intron 1 of G4.
19. The recombinant attenuated BLV according to claim 18, wherein said mutations are a deletion of at least a portion of the region of the BLV nucleic acid sequence between about 250 nucleotides upstream of the intron 2-exon 3 boundary of R3 and the splice acceptor site of intron 2 of Tax/Rex, whereby the splice acceptor site of intron 2 of R3 and the splice acceptor site of intron 1 of G4 are deleted, for example wherein the 5′ boundary of the deletion is located between about 209 and about 189 nucleotides upstream of the intron 2-exon 3 boundary of R3 and the 3′ boundary of the deletion is located between about 55 and about 35 nucleotides upstream of the splice acceptor site of intron 2 of Tax/Rex.
20. The recombinant attenuated BLV according to claim 19, wherein the 5′ boundary of the deletion is located between positions 6604 and 6624 of the BLV nucleic acid sequence and the 3′ boundary of the deletion is located between positions 6987 and 7007 of the BLV nucleic acid sequence.
21. The recombinant attenuated BLV according to claim 2, wherein the mutation in the X region of the BLV nucleic acid sequence abolishing the production of at least one or preferably all microRNA encoded by said X region is a deletion of at least a portion of the region of the BLV nucleic acid sequence between the stop codon of TM and the splice acceptor site of intron 2 of R3, such as between the stop codon of TM and about 50 nucleotides upstream of the intron 2-exon 3 boundary of R3, for example wherein the 5′ boundary of the deletion is located between about 1 and about 11 nucleotides downstream of the stop codon of TM and the 3′ boundary of the deletion is located between about 92 and about 72 nucleotides upstream of the intron 2-exon 3 boundary of R3.
22. The recombinant attenuated BLV according to claim 21, wherein the 5′ boundary of the deletion is located between positions 6163 and 6173 of the BLV nucleic acid sequence and the 3′ boundary of the deletion is located between positions 6721 and 6741 of the BLV nucleic acid sequence.
23. The recombinant attenuated BLV according to claim 2, wherein the mutation in G4 restricting the propagation of the BLV in vivo and the mutation in R3 restricting the propagation of the BLV in vivo and the mutation in the X region of the BLV nucleic acid sequence abolishing the production of at least one or preferably all microRNA encoded by said X region are a deletion of at least a portion of the region of the BLV nucleic acid sequence between the stop codon of TM and the splice acceptor site of intron 2 of Tax/Rex, whereby the splice acceptor site of intron 2 of R3 and the splice acceptor site of intron 1 of G4 are deleted, for example wherein the 5′ boundary of the deletion is located between about 1 and about 11 nucleotides downstream of the stop codon of TM and the 3′ boundary of the deletion is located between about 55 and about 35 nucleotides upstream of the intron 2-exon 3 boundary of Tax/Rex.
24. The recombinant attenuated BLV according to claim 23, wherein the 5′ boundary of the deletion is located between positions 6163 and 6173 of the BLV nucleic acid sequence and the 3′ boundary of the deletion is located between positions 6987 and 7007 of the BLV nucleic acid sequence.
25. (canceled)
26. The recombinant attenuated BLV according to claim 1, wherein the BLV is derived from the BLV isolate 344 as encoded by the plasmid deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM™/LMBP Collection under accession number LMBP 8165 on Feb. 5, 2013.
27. The recombinant attenuated BLV according to claim 1, preferably wherein the BLV is derived from the BLV isolate 344 as encoded by the plasmid deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM™/LMBP Collection under accession number LMBP 8165 on Feb. 5, 2013, and wherein one of the following applies: 
 the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a deletion of the BLV nucleic acid sequence between positions 6614 and 6848; or 
 the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a double oligonucleotide segment comprising a stop codon inserted into the BamHI site at position 6997 of the BLV nucleic acid sequence such that said stop codon is in-frame to the G4 ORF, preferably wherein the double oligonucleotide segment is composed of two hybridised oligonucleotides each with the sequence 5′-GATCTAGGCTAGAATITCTAG CCTA-3′ (SEQ ID NO: 3), inserted into the BamHI site at position 6997 of the BLV nucleic acid sequence; or 
 the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a double oligonucleotide segment replacing the nucleic acid segment between XbaI site at position 6614 and BamHI site at position 6997 of the BLV nucleic acid sequence, preferably wherein the double oligonucleotide segment is composed of two hybridised oligonucleotides with the sequences 5′-CTAGAAAGCTTG-3′ (SEQ ID NO: 1) and 5′-GATCCAAGCTTT-3′ (SEQ ID NO: 2), respectively, replacing the nucleic acid segment between XbaI site at position 6614 and BamHI site at position 6997 of the BLV nucleic acid sequence; or 
 the recombinant attenuated BLV comprises a deletion of the BLV nucleic acid sequence between positions 6169 and 6997, preferably the recombinant attenuated BLV comprises the nucleic acid sequence 5′-TCTAGAAAG CTT-3′ (SEQ ID NO: 4) replacing the nucleic acid sequence from position 6170 to position 6996 of the BLV nucleic acid sequence; or 
 the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a deletion of the BLV nucleic acid sequence between positions 6169 and 6997, preferably the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises the nucleic acid sequence 5′-TCTAGAAAG CTT-3′ (SEQ ID NO: 4) replacing the nucleic acid sequence from position 6170 to position 6996 of the BLV nucleic acid sequence.
28. The recombinant attenuated BLV encoded by the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM™/LMBP Collection under accession number LMBP 8166 on Feb. 5, 2013.
29. A recombinant nucleic acid encoding the recombinant attenuated BLV according to claim 1.
30. The recombinant nucleic acid according to claim 29, wherein the nucleic acid is DNA.
31. A vector comprising the recombinant nucleic acid according to claim 29.
32. The plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM™/LMBP Collection under accession number LMBP 8166 on Feb. 5, 2013.
33. A recombinant nucleic acid encoding a recombinant attenuated BLV, wherein the recombinant nucleic acid comprises, consists essentially of or consists of the insert of the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM™/LMBP Collection under accession number LMBP 8166 on Feb. 5, 2013.
34. A vector comprising the recombinant nucleic acid according to claim 33.
35. A host cell comprising the recombinant attenuated BLV according to claim 1.
36. The host cell according to claim 35, wherein the host cell is a bacterial cell, a yeast cell, an animal cell, or a mammalian cell.
37. The host cell according to claim 35, wherein said host cell is inactivated.
38. A pharmaceutical composition comprising the recombinant attenuated BLV according to claim 1.
39. The pharmaceutical composition according to claim 38, wherein the pharmaceutical composition is a vaccine.
40. The vaccine according to claim 39 comprising one or more further immunogenic substance or composition.
41. A method of treatment, comprising: administering a recombinant attenuated BLV according to claim 1 to a subject.
42. A method of vaccination, comprising: 
 administering a recombinant attenuated BLV according to claim 1 to a subject.
43. A method of treatment of a BLV-associated disease, comprising: 
 administering a recombinant attenuated BLV according to claim 1 to a subject in need thereof.
44. The method of claim 43, wherein the subject is a bovid, preferably a bovine, more preferably cattle.
45. A non-human animal, preferably a non-human mammal, more preferably a bovid, even more preferably a bovine, such as cattle, to which the recombinant attenuated BLV according to claim 1, has been administered.
46. The non-human animal according to claim 45, which harbours in the genome of at least some of its cells, preferably in the genome of at least some of its peripheral blood mononuclear cells (PBMC), a provirus encoding the recombinant attenuated bovine leukemia virus according to claim 1.
47. A method for obtaining a non-human animal material which comprises obtaining material from the non-human animal according to claim 45, and optionally further processing said material into a non-human animal-derived product.
48. Non-human animal-derived material or a non-human animal-derived product obtainable or directly obtained from the non-human animal according to claim 45, wherein said non-human animal-derived material or said non-human animal-derived product comprises, consists of or is isolated from a secretion of the mammary gland of the non-human animal or a part thereof, in particular wherein the material or product comprises, consists of or is isolated from milk or colostrum.
49. (canceled)
50. A method of vaccination or treatment of a BLV-associated disease, comprising 
 administering a non-human animal-derived material or the non-human animal-derived product according to claim 48.";"(US20190000963)
As also already noted, aspect of the invention provides the recombinant attenuated BLV encoded by the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM /LMBP Collection under accession number LMBP 8167 on Feb. 5, 2013 (see Table 2C).
In certain embodiments, the invention provides the recombinant attenuated BLV as taught herein, preferably wherein the BLV is BLV isolate 344, and wherein one of the following applies: the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a deletion of the BLV nucleic acid sequence between positions 6614 and 6848; or the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a double oligonucleotide segment comprising a stop codon inserted into the BamHI site at position 6997 of the BLV nucleic acid sequence such that said stop codon is in-frame to the G4 ORF, preferably wherein the double oligonucleotide segment is composed of two hybridised oligonucleotides each with the sequence 5 -GATCTAGGCTAGAATTCTAGCCTA-3 (SEQ ID NO: 3), inserted into the BamHI site at position 6997 of the BLV nucleic acid sequence; or the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a double oligonucleotide segment replacing the nucleic acid segment between XbaI site at position 6614 and BamHI site at position 6997 of the BLV nucleic acid sequence, preferably wherein the double oligonucleotide segment is composed of two hybridised oligonucleotides with the sequences 5 -CTAGAAAGCTTG-3 (SEQ ID NO: 1) and 5 -GATCCAAGCTTT-3 (SEQ ID NO: 2), respectively, replacing the nucleic acid segment between XbaI site at position 6614 and BamHI site at position 6997 of the BLV nucleic acid sequence; or the recombinant attenuated BLV comprises a deletion of the BLV nucleic acid sequence between positions 6169 and 6997, preferably the recombinant attenuated BLV comprises the nucleic acid sequence 5 -TCTAGAAAGCTT-3 (SEQ ID NO: 4) replacing the nucleic acid sequence from position 6170 to position 6996 of the BLV nucleic acid sequence; or the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises a deletion of the BLV nucleic acid sequence between positions 6169 and 6997, preferably the recombinant attenuated BLV comprises a substitution of a T nucleotide at position 6073 of the BLV nucleic acid sequence with a G nucleotide and further comprises the nucleic acid sequence 5 -TCTAGAAAGCTT-3 (SEQ ID NO: 4) replacing the nucleic acid sequence from position 6170 to position 6996 of the BLV nucleic acid sequence.
As already noted, aspect of the invention provides the recombinant attenuated BLV encoded by the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM /LMBP Collection under accession number LMBP 8166 on Feb. 5, 2013 (see Table 2B).
Accordingly, in an aspect the invention provides a recombinant attenuated bovine leukemia virus (BLV) characterised in that the virus comprises: at least one mutation selected from the group consisting of: a mutation in the nucleic acid sequence encoding the most N-terminal YXXL signalling motif of the cytoplasmic domain of the transmembrane subunit (TM) of the envelope protein, said mutation disrupting the signal transduction activity of the motif, and a mutation in the X region of the BLV nucleic acid sequence, said mutation abolishing the production of at least one or preferably all microRNA encoded by said X region; and at least one mutation selected from the group consisting of: a mutation in G4 restricting the propagation of the BLV in vivo, and a mutation in R3 restricting the propagation of the BLV in vivo.";"(US20190000963)
Because exon 1 and 2 of R3 are common with the Tax/Rex mRNA, and the portion of R3 ORF present in exon 2 of R3 is identical to that of Rex, a suitable mutation in R3 restricting the propagation of the BLV may be advantageously located in the 3 portion of intron 2 of R3 or in exon 3 of R3.
Such premature stop codon may lead to production of a C-terminally truncated form of said polypeptide (this may preferably affect, such as diminish or abolish, some or all biological function(s) of the polypeptide) or, especially when the stop codon is introduced close to (e.g., about 20 or less, or about 10 or less amino acids downstream of) the translation initiation codon of the ORF, the stop codon may effectively abolish the production of the polypeptide.
Hence, such frame shift may lead to production of a form of the polypeptide having an alternative C-terminal portion and/or a C-terminally truncated form of said polypeptide (this may preferably affect, such as diminish or abolish, some or all biological function(s) of the polypeptide) or, especially when the mutation is introduced close to (e.g., about 20 or less, or about 10 or less amino acids downstream of) the translation initiation codon of the ORF, the frame shift may effectively abolish the production of the polypeptide.
Preferably such one or more other mutations do not interfere with replication of the BLV, in particular such one or more other mutations do not restrict the propagation of the BLV in vivo.";"A61K-039/00
A61K-039/12
A61K-039/21
A61P-035/02
C07K-014/005
C12N-005/10
C12N-007/00
C12N-007/04
C12N-015/48
C12N-015/867";"(US20190000963)
51 . A recombinant attenuated BLV encoded by the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM /LMBP Collection under accession number LMBP 8713 on Oct. 25, 2013.
55 . A plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM /LMBP Collection under accession number LMBP 8713 on Oct. 25, 2013.
56 . A recombinant nucleic acid encoding a recombinant attenuated BLV, wherein the recombinant nucleic acid comprises, consists essentially of or consists of the insert of the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM /LMBP Collection under accession number LMBP 8713 on Oct. 25, 2013.";"(US20160045593)
BOVINE LEUKEMIA VIRUS(100,101)
NUCLEIC ACID SEQUENCE(100,53)
PLASMID(100,25)
VACCINE(100,22)
ACCESSION NUMBER(100,19)
BUDAPEST TREATY(100,19)
LMBP COLLECTION(100,19)
MICROORGANISM BELGIAN COORDINATED COLLECTION(100,19)
RECOMBINANT NUCLEIC ACID ENCODING(100,11)
BAMHI SITE(100,8)
CYTOPLASMIC DOMAIN SIGNALING MOTIF(91,2)
DELETION BOUNDARY(68,75)
ORF TRANSLATION INITIATION CODON(64,2)
ATTENUATED PHENOTYPE(57,2)
MUTATION(53,224)
RECOMBINANT ATTENUATED BLV VIRUS(52,1)
OLIGONUCLEOTIDE HYBRIDIZATION(51,3)
INTRON SPLICE ACCEPTOR SITE(50,38)
RECOMBINANT BOVINE LEUKEMIA VIRUS(49,3)
NON HUMAN ANIMAL(45,7)
NUCLEOTIDE(44,96)
TRANSMEMBRANE SUBUNIT(38,15)
DOUBLE OLIGONUCLEOTIDE(38,8)
BLV REPLICATION(38,1)
PROPAGATION(37,65)
PRE MESSENGER RNA(34,9)
HOST CELL(30,19)
XBAI SITE(30,4)
BLV PROPAGATION(30,2)
SUBSTITUTION(28,21)
RECOMBINANT NUCLEIC ACID(27,23)
MUTATION DISRUPTING(27,12)
SPLICE ACCEPTOR SITE DELETION(27,6)
MAMMARY GLAND SECRETION(27,1)
EXON(25,104)
DELETION(25,49)
IMMUNOGENIC SUBSTANCE(25,1)
PROVIRUS ENCODING(24,1)
NUCLEIC ACID(23,19)
TERMINAL YXXL SIGNALING MOTIF(23,14)
PLASMID INSERT(23,7)
MUTATION ABOLISHING(22,11)
BLV NUCLEIC ACID SEQUENCE(21,58)
STOP CODON(21,29)
VECTOR(21,22)
ENVELOPE PROTEIN(21,15)
NON HUMAN MAMMAL(21,2)
TAX BOUNDARY(20,15)
VIRUS(20,10)
NON MUTATED BLV POLYPEPTIDE(20,6)
REX MRNA(20,4)
GENBANK(19,12)
SEQUENCE ABOLISHING(19,9)
NON HUMAN ANIMAL DERIVED PRODUCT(18,12)
RECOMBINANT BLV PROVIRUS(18,5)
MOTIF SIGNAL TRANSDUCTION ACTIVITY(16,13)
N TERMINAL YXXL(16,2)
PROPHYLACTIC TREATMENT(16,2)
MAMMALIAN CELL(16,1)
MOTIF RESIDUE(16,1)
TAX(15,37)
NUCLEIC ACID SEQUENCE ENCODING(15,17)
CYTOPLASMIC DOMAIN(15,14)
ONCOGENIC POTENTIAL(15,9)
INTRON NUCLEOTIDE(15,8)
BACTERIAL CELL(15,1)
RICE SEQUENCE NUMBER(14,12)
YEAST CELL(14,1)
BIOLOGICAL FUNCTION(13,5)
BOVID(13,4)
ANIMAL CELL(13,1)
VACCINE PREPARATION(13,1)
BLV ASSOCIATED DISEASE(12,19)
MIRNA MUTATION(12,5)
ENCODING NUCLEIC ACID(12,3)
ORF CODING(11,7)
PBLVDX PROVIRUS(11,4)
ENZOOTIC BOVINE LEUKOSIS(11,2)
ATTENUATED BLV PROVIRUS PBLVDX(11,1)
PREMATURE STOP CODON(11,1)
MIRNA ENCODING REGION(10,6)
NON MUTATED MIRNA(10,3)
PRE MRNA ENCODING SPLICING(10,2)
ORF(9,25)
FUNCTIONAL TAX PRODUCTION(9,7)
ASPARTIC ACID RESIDUE(9,4)
NUCLEOTIDE SUBSTITUTION(9,4)
MATURE MRNA ENCODING(9,3)
BLV PROVIRAL COPY(9,2)
ENVELOPE PROTEIN RESULT(9,1)
L TYROSINE RESIDUE(9,1)
PRE MRNA ENCODING NATIVE SPLICING(9,1)
INTRON EXON BOUNDARY(8,2)
VIRAL EXPRESSION POST TRANSCRIPTIONAL REGULATOR(8,1)
AMINOACID(7,10)
NON HUMAN ANIMAL DERIVED MATERIAL(7,10)
ABOLISHED BIOLOGICAL FUNCTION(7,8)
ACCESSORY PROTEIN(7,3)
VACCINATED ANIMAL(7,3)
NON HUMAN ANIMAL MATERIAL(7,2)
PROPHYLACTIC VACCINE MANUFACTURE(7,2)
TYROSINE RESIDUE SUBSTITUTION(7,2)
BENIGN POLYCLONAL PROLIFERATION(7,1)
CONSPICUOUS CLINICAL MANIFESTATION(7,1)
TRANSMEMBRANE CYTOPLASMIC TAIL(7,1)
COMPLETE PROVIRAL GENOME SEQUENCE(6,4)
MEDICAMENT MANUFACTURE(6,4)
BLV STRAIN(6,3)
GENETIC CONSTRUCT(6,3)
BLV MIRNA REGION(6,2)
CONSECUTIVE NUCLEOTIDE(6,2)
MILK(6,2)
REX POLYPEPTIDE(6,2)
ANTIVIRAL PASSIVE IMMUNITY(6,1)
ATTENUATED VIRUS PROPAGATION(6,1)
BLV GENOME ENV GENE(6,1)
BLV PROTEIN CELL EPITOPE(6,1)
BLV6073DX INFECTIVITY(6,1)
CELLULAR SPLICING MACHINERY(6,1)
CHEMICALLY INACTIVATED BLV(6,1)
CODON ENCODING ALANINE(6,1)
DOWNSTREAM EXON NUCLEOTIDE(6,1)
EXON INTRON BOUNDARY(6,1)
GENE EXPRESSION POST TRANSCRIPTIONAL REGULATION(6,1)
NUMEROUS ATTENUATED BLV MUTANT(6,1)
PROVIRUS INDUCED LEUKEMIA(6,1)
RAT EMBRYONIC FIBROBLAST(6,1)
RECOMBINANT VACCINIA VIRUS(6,1)
REGULATORY PROTEIN TAX(6,1)
TRANSMEMBRANE ENVELOPE PROTEIN(6,1)
UPSTREAM EXON NUCLEOTIDE(6,1)
CARE(5,9)
BLV NUCLEIC ACID REGION(5,7)
REX PROTEIN(5,7)
INTRON PORTION(5,4)
NUDEIC ACID SEQUENCE(5,4)
BOVINE LEUKEMIA VIRUS GENOME(5,2)
CHALLENGED HOST(5,2)
HOST CHALLENGE(5,2)
MUTATION RESTRICTING(5,2)
QUANTITATIVE PCR(5,2)
TRANSLATION INITIATION CODON(5,2)
BLV ENCODED MIRNA(5,1)
BLV ENVELOPE PROTEIN(5,1)
BLV GENE ENCODING(5,1)
DELTARETROVIRUS GENUS(5,1)
ENVELOPE PROTEIN DISRUPTION(5,1)
INFECTED COW(5,1)
LYMPHOID TUMOR DEVELOPMENT(5,1)
MATERNAL COLOSTRUM(5,1)
PERIPHERAL BLOOD MONONUCLEAR CELLS(5,1)
PERSISTENT LYMPHOCYTOSIS(5,1)
PRE MRNA SPLICING(5,1)
REGULATORY PROTEIN EARLY EXPRESSION(5,1)
RESTRICTION ENZYME DIGESTION(5,1)
SEVERE VIRAL INFECTION SYMPTOM(5,1)
UNINFECTED SENTINEL(5,1)
VACCINE CANDIDATE(5,1)
VIRUS ASYMPTOMATIC CARRIER(5,1)
FOLDING(4,11)
OPEN READING FRAME(4,7)
PATHOGENICITY(4,4)
RECOMBINANT DNA TECHNOLOGY(4,3)
HUMAN INTERVENTION(4,2)
INTRON SPLICE DONOR SITE(4,2)
NUCLEIC ACID ENCODING BLV(4,2)
PROVIRAL LOAD(4,2)
VIRUS VARIANT(4,2)
ADULT CATTLE(4,1)
ARTIFICIAL MUTATION(4,1)
BLV CLONE(4,1)
BLV GENOME REGION(4,1)
BLV GENOTYPE(4,1)
BLV INDUCED TUMOR(4,1)
BLV INFECTED ANIMAL(4,1)
BLV INFECTED BOVINE(4,1)
BLV INFECTED HOST CELL(4,1)
BLV NUCLEIC REGION(4,1)
BLV POLYPEPTIDE PRODUCTION(4,1)
BLV SUBUNIT(4,1)
BLV TUMOR(4,1)
CELL LEUKEMIA VIRUS(4,1)
CHIMERIC MOLECULE(4,1)
CONSERVED YXXL SEQUENCE(4,1)
DIVERSE OUTCOME(4,1)
DOMESTIC CATTLE(4,1)
EAR TATTOOING(4,1)
ENVELOPE GLYCOPROTEIN(4,1)
EXTRACELLULAR SUBUNIT(4,1)
FATAL LYMPHOMA(4,1)
GENE DELETION(4,1)
GEOGRAPHICAL ORIGIN(4,1)
HOMOLOGOUS RECOMBINATION(4,1)
IMMUNODEFICIENT MOUSE(4,1)
INFECTED NEEDLE(4,1)
LATENCY MONTH(4,1)
LATENT SPLICE(4,1)
LEF BVRE(4,1)
LYMPH NODE ENLARGEMENT(4,1)
MESSENGER RNA TRANSCRIPT(4,1)
MILD SYMPTOM(4,1)
MONTH POST VACCINATION(4,1)
MUT MICRORNA(4,1)
NATIVE SPLICING ABSENCE(4,1)
NEWBORN CALF(4,1)
NUCLEOTIDE NUMBER(4,1)
NUCLEOTIDE SEQUENCE(4,1)
NUCLEOTIDE TRIPLET(4,1)
ONCOVIRINAE SUBFAMILY MEMBER(4,1)
PATHOGENIC BLV(4,1)
PERSISTENT LYMPHOSIS(4,1)
PHRASE RESTRICTING(4,1)
PLASMID PBLV344H(4,1)
PLURAL REFERENT(4,1)
RECITED ENDPOINT(4,1)
REGION ENCODING MICRORNA(4,1)
REX ORF(4,1)
REX PRE MRNA(4,1)
RICE NUMBERING(4,1)
SATISFACTORY BIOSAFETY(4,1)
SPLICE ACCEPTOR CONSENSUS SEQUENCE(4,1)
SPLICE DONOR CONSENSUS SEQUENCE(4,1)
SURVIVING ANIMAL(4,1)
TAX ORF(4,1)
TERM TAX POLYPEPTIDE(4,1)
TERMINAL YXXL MOTIF(4,1)
TRANSACTIVATING PROTEIN(4,1)
TRANSLATIONAL REPRESSION(4,1)
TRANSMEMBRANE PROTEIN(4,1)
TRANSMEMBRANE SUBUNIT STOP CODON(4,1)
TRANSPOSON INSERTION(4,1)
VIRAL PARTICLE SYNTHESIS(4,1)
VIRAL TRANSCRIPTION(4,1)
VIRUS REPLICATION EFFICIENCY(4,1)
SHEEP(3,4)
BLV ASSOCIATED DISEASE PREVENTION(3,3)
BLV INFECTION(3,3)
LYMPHOSARCOMA(3,3)
MUTATION COMBINATION(3,3)
TRANSLATION PRODUCT(3,3)
ATTENUATED VACCINE(3,2)
BLV REGION(3,2)
IMMUNORECEPTOR(3,2)
INFECTIVITY SATISFACTORY LEVEL(3,2)
ORF START(3,2)
TERM MUTATION(3,2)
TRANSCRIPTION PRODUCTION(3,2)
ASP TYR(3,1)
BLV COMPLETE GENOMIC SEQUENCE(3,1)
BLV POLYPEPTIDE LEVEL(3,1)
CATTLE MANAGEMENT(3,1)
DISULFIDE BOND(3,1)
EXPRESSION VECTOR(3,1)
EXTENSIVE STUDY(3,1)
GENETICALLY MODIFIED HYBRID VIRUS(3,1)
HOST CELL GENOME(3,1)
HYDROXY L MOIETY(3,1)
INFECTED BLOOD TRANSFER(3,1)
INTRON PRECISE REMOVAL(3,1)
LATE EXPRESSION(3,1)
LIMITATION BLV(3,1)
MRNA GENOME(3,1)
MULTIMERIC COMPLEX(3,1)
MUTATION ACHIEVING(3,1)
MUTATION INTRODUCTION(3,1)
PERIODIC UPDATE(3,1)
PRE MRNA SEQUENCE(3,1)
PREVENTATIVE TREATMENT(3,1)
PURIFIED PROTEIN(3,1)
SHORT PEPTIDE MIMICKING(3,1)
TEMPORAL DURATION(3,1)
TRANSLATION TERMINATION CODON(3,1)
VACCINATED SUBJECT(3,1)
VAN DEN(3,1)
BLV ASSOCIATED DISEASE TREATMENT(2,4)
LTR(2,4)
DINUCLEOTIDE(2,2)
ORFS(2,2)
PERUSAL(2,2)
READER(2,2)
TYROSINE BASED ACTIVATION MOTIF(2,2)
ANTI BLV IMMUNE RESPONSE(2,1)
ANTIBODY PRODUCTION(2,1)
B LYMPHOTROPIC RETROVIRUS(2,1)
BLV INFECTED CELL TRANSFER(2,1)
BLV SEQUENCE(2,1)
BVL COMPLETE SEQUENCE(2,1)
COLD SPRING HARBOR(2,1)
CYTOKINE PRODUCTION(2,1)
DELETION ANALYSIS(2,1)
ECONOMIC LOSS(2,1)
GIVEN GENE SPLICING(2,1)
IDENTIFIED BLV OVERVIEW(2,1)
IMMUNE PROTECTION RAPID DECREASE(2,1)
INDEPENDENT TRANSCRIPTIONAL UNIT ENCODING(2,1)
LABORATORY PRESS(2,1)
MONOCYTE MACROPHAGE(2,1)
NUCLEIC ACID REPLICATION(2,1)
NUMERIC RANGE RECITATION(2,1)
(US10029006)
BOVINE LEUKEMIA VIRUS(100,155)
PLASMID(100,29)
ACCESSION NUMBER(100,16)
BUDAPEST TREATY(100,16)
LMBP COLLECTION(100,16)
MICROORGANISM BELGIAN COORDINATED COLLECTION(100,16)
RECOMBINANT NUCLEIC ACID ENCODING(100,8)
VACCINE(100,4)
RECOMBINANT ATTENUATED BLV(85,35)
CYTOPLASMIC DOMAIN SIGNALING MOTIF(77,3)
NUCLEIC ACID SEQUENCE(61,97)
DELETION BOUNDARY(52,75)
DOUBLE OLIGONUCLEOTIDE(49,10)
ORF TRANSLATION INITIATION CODON(49,2)
MUTATION(48,222)
BAMHI SITE(48,10)
OLIGONUCLEOTIDE HYBRIDIZATION(45,3)
BLV NUCLEIC ACID SEQUENCE(44,61)
INTRON SPLICE ACCEPTOR SITE(44,41)
NUCLEOTIDE(43,103)
SUSCEPTIBLE NON HUMAN ANIMAL(41,2)
TRANSMEMBRANE SUBUNIT(40,15)
RECOMBINANT ATTENUATED BLV VIRUS(40,1)
PROPAGATION(33,65)
XBAI SITE(32,5)
SUBSTITUTION(31,23)
MUTATION ABOLISHING(30,11)
BLV REPLICATION(29,1)
MUTATION DISRUPTING(28,11)
RECOMBINANT NUCLEIC ACID(26,21)
TERMINAL YXXL SIGNALING MOTIF(26,13)
PRE MESSENGER RNA(26,9)
DELETION(23,52)
BLV PROPAGATION(23,2)
RECOMBINANT BOVINE LEUKEMIA VIRUS(22,2)
ENVELOPE PROTEIN(21,14)
ATTENUATED PHENOTYPE(21,1)
EXON(20,105)
STOP CODON(20,31)
SPLICE ACCEPTOR SITE DELETION(20,6)
HOST CELL(19,17)
IMMUNOGENIC SUBSTANCE(19,1)
SEQUENCE ABOLISHING(18,10)
PLASMID INSERT(18,4)
MOTIF RESIDUE(18,2)
MICRORNA(17,22)
NUCLEIC ACID SEQUENCE ENCODING(17,17)
CYTOPLASMIC DOMAIN(17,13)
MOTIF SIGNAL TRANSDUCTION ACTIVITY(16,12)
REX MRNA(16,4)
NUCLEIC ACID(15,24)
TAX BOUNDARY(15,15)
NON MUTATED BLV POLYPEPTIDE(15,6)
BOVID(15,3)
PROPHYLACTIC TREATMENT(15,1)
GENBANK(14,12)
VIRUS(14,7)
TAX(13,38)
N TERMINAL YXXL(13,3)
MICRORNA PRODUCTION(13,1)
INTRON NUCLEOTIDE(12,8)
BLV ASSOCIATED DISEASE(12,2)
RICE SEQUENCE NUMBER(11,12)
ONCOGENIC POTENTIAL(11,9)
RECOMBINANT BLV(10,8)
BIOLOGICAL FUNCTION(10,5)
VACCINE PREPARATION(10,1)
MIRNA MUTATION(9,5)
OLIGONUCLEOTIDE(9,3)
YEAST EPISOMAL PLASMID(9,3)
BACTERIAL CELL(9,2)
ENVELOPE PROTEIN RESULT(9,2)
ENZOOTIC BOVINE LEUKOSIS(9,2)
ATTENUATED BLV PROVIRUS PBLVDX(9,1)
ORF(8,25)
ORF CODING(8,7)
NON MUTATED MIRNA(8,3)
YEAST CELL(8,3)
PRE MRNA ENCODING SPLICING(8,2)
RECOMBINANT ATTENUATED BLV PARTICLE(8,2)
CABBAGE LOOPER TRICHOPLUSIA NI(8,1)
PREMATURE STOP CODON(8,1)
BLV(7,7)
FUNCTIONAL TAX PRODUCTION(7,7)
MIRNA ENCODING REGION(7,6)
NUCLEOTIDE SUBSTITUTION(7,4)
MATURE MRNA ENCODING(7,3)
BLV PROVIRAL COPY(7,2)
ABOLISHED BIOLOGICAL FUNCTION(6,8)
ASPARTIC ACID RESIDUE(6,4)
AUXOTROPHIC RECIPIENT CELL(6,2)
INTRON EXON BOUNDARY(6,2)
SACCHAROMYCES CEREVISIAE(6,2)
TYROSINE RESIDUE SUBSTITUTION(6,2)
PRE MRNA ENCODING NATIVE SPLICING(6,1)
VIRAL EXPRESSION POST TRANSCRIPTIONAL REGULATOR(6,1)
AMINOACID(5,10)
COMPLETE PROVIRAL GENOME SEQUENCE(5,4)
GENETIC CONSTRUCT(5,4)
ACCESSORY PROTEIN(5,3)
BLV STRAIN(5,3)
CYTOPLASMIC TAIL(5,3)
YEAST PLASMID(5,3)
AUXOTROPHIC SELECTION MARKER(5,2)
BLV MIRNA REGION(5,2)
CONSECUTIVE NUCLEOTIDE(5,2)
HOMOLOGOUS RECOMBINATION(5,2)
REX POLYPEPTIDE(5,2)
BLV GENOME ENV GENE(5,1)
BLV PROVIRUS PLASMID(5,1)
CONDITIONALLY ESSENTIAL CHROMOSOMAL GENE(5,1)
GENERA SACCHAROMYCES YEAST(5,1)
RAT EMBRYONIC FIBROBLAST(5,1)
YEAST CENTROMERE PLASMID(5,1)
CARE(4,9)
OPEN READING FRAME(4,8)
BLV NUCLEIC ACID REGION(4,7)
REX PROTEIN(4,7)
INTRON PORTION(4,4)
BACTERIAL HOST(4,3)
TISSUE CULTURE(4,3)
VACCINATION(4,3)
BACTERIAL PLASMID(4,2)
BLV ENVELOPE(4,2)
BOVINE LEUKEMIA VIRUS GENOME(4,2)
CHALLENGED HOST(4,2)
HOST CHALLENGE(4,2)
MUTATION RESTRICTING(4,2)
QUANTITATIVE PCR(4,2)
TRANSLATION INITIATION CODON(4,2)
ATTENUATED VIRUS PROPAGATION(4,1)
BLV ENCODED MIRNA(4,1)
BLV6073DX INFECTIVITY(4,1)
BLV6073DX PROVIRUS(4,1)
BLV6073GPDX PROVIRUS(4,1)
BLVGPDX PROVIRUS(4,1)
CELLULAR SPLICING MACHINERY(4,1)
CODON ENCODING ALANINE(4,1)
DELTARETROVIRUS GENUS(4,1)
DOWNSTREAM EXON NUCLEOTIDE(4,1)
DROSOPHILA MELANOGASTER(4,1)
EMBRYONIC CALVARIUM(4,1)
ENVELOPE PROTEIN DISRUPTION(4,1)
EXON INTRON BOUNDARY(4,1)
GENE EXPRESSION POST TRANSCRIPTIONAL REGULATION(4,1)
GREEN MONKEY CHLOROCEBUS KIDNEY(4,1)
PBLV6073GPDX PLASMID(4,1)
PRE MRNA SPLICING(4,1)
REGULATORY PROTEIN EARLY EXPRESSION(4,1)
REGULATORY PROTEIN TAX(4,1)
REPLICATION YEAST ORIGIN(4,1)
RESTRICTION ENZYME DIGESTION(4,1)
SALMONELLA TYMPHIMURIUM(4,1)
SERRATIA MARCESCENS(4,1)
SEVERE VIRAL INFECTION SYMPTOM(4,1)
TERM YEAST CENTROMERIC PLASMID(4,1)
TERM YEAST INTEGRATIVE PLASMID(4,1)
TRANSMEMBRANE ENVELOPE PROTEIN(4,1)
UPSTREAM EXON NUCLEOTIDE(4,1)
VIRAL GENOME PACKAGING(4,1)
VIRION BUDDING(4,1)
FOLDING(3,11)
RECOMBINANT DNA TECHNOLOGY(3,3)
ATTENUATED VACCINE(3,2)
HUMAN INTERVENTION(3,2)
INFECTIVITY SATISFACTORY LEVEL(3,2)
INTRON SPLICE DONOR SITE(3,2)
NUCLEIC ACID ENCODING BLV(3,2)
ORF START(3,2)
PATHOGENICITY(3,2)
PROVIRAL LOAD(3,2)
TERM MUTATION(3,2)
TRANSCRIPTION PRODUCTION(3,2)
VIRUS VARIANT(3,2)
6073DX PLASMID(3,1)
ALKALI EARTH STEARATE(3,1)
ANTISENSE STRAND(3,1)
ARTIFICIAL MUTATION(3,1)
BACILLUS SUBTILIS(3,1)
BLV CLONE(3,1)
BLV GENE(3,1)
BLV GENOME REGION(3,1)
BLV GENOTYPE(3,1)
BLV INDUCED TUMOR(3,1)
BLV INFECTED HOST CELL(3,1)
BLV NUCLEIC REGION(3,1)
BLV POLYPEPTIDE PRODUCTION(3,1)
CELL LEUKEMIA VIRUS(3,1)
CHIMERIC MOLECULE(3,1)
CONSERVED YXXL SEQUENCE(3,1)
DERIVATISED NUCLEOTIDE BASIS(3,1)
DIVERSE OUTCOME(3,1)
DOMESTIC CATTLE(3,1)
EAR TATTOOING(3,1)
EXTRACELLULAR SUBUNIT(3,1)
GENE DELETION(3,1)
GEOGRAPHICAL ORIGIN(3,1)
GROWTH RESTORATION(3,1)
HARVESTED VIRAL PARTICLE(3,1)
HOST CELL DNA GENOME(3,1)
IMMUNODEFICIENT MOUSE(3,1)
INFECTED NEEDLE(3,1)
LATENT SPLICE(3,1)
LEF BVRE(3,1)
MESSENGER RNA TRANSCRIPT(3,1)
MICROBIOLOGICAL CULTURE(3,1)
MILD SYMPTOM(3,1)
MITOTIC SEGREGATION(3,1)
MUT MICRORNA(3,1)
NATIVE SPLICING ABSENCE(3,1)
NON HUMAN ANIMAL CELL(3,1)
NON HUMAN MAMMALIAN CELL(3,1)
NUCLEOTIDE NUMBER(3,1)
NUCLEOTIDE SEQUENCE(3,1)
NUCLEOTIDE TRIPLET(3,1)
ONCOVIRINAE SUBFAMILY MEMBER(3,1)
PATHOGENIC BLV(3,1)
PBLVGPDX PLASMID(3,1)
PERSISTENT LYMPHOSIS(3,1)
PHRASE RESTRICTING(3,1)
PICHIA PASTORIS(3,1)
PLASMID PBLV344H(3,1)
PLURAL REFERENT(3,1)
PROVIRAL SEQUENCE EXPRESSION(3,1)
RECITED ENDPOINT(3,1)
REGION ENCODING MICRORNA(3,1)
REPLICATION ORIGIN(3,1)
REX ORF(3,1)
REX PRE MRNA(3,1)
RICE NUMBERING(3,1)
SPLICE ACCEPTOR CONSENSUS SEQUENCE(3,1)
SPLICE DONOR CONSENSUS SEQUENCE(3,1)
SUPPRESSOR TRNA(3,1)
TAX ORF(3,1)
TERM TAX POLYPEPTIDE(3,1)
TERMINAL YXXL MOTIF(3,1)
TRANSACTIVATING PROTEIN(3,1)
TRANSLATIONAL REPRESSION(3,1)
TRANSMEMBRANE PROTEIN(3,1)
TRANSMEMBRANE SUBUNIT STOP CODON(3,1)
TRANSPOSON INSERTION(3,1)
VERTEBRATE ANIMAL CELL(3,1)
VIRAL PARTICLE SYNTHESIS(3,1)
VIRAL TRANSCRIPTION(3,1)
EXPERIMENTAL SECTION(2,6)
LTR(2,4)
SUGAR(2,4)
BREAST CANCER(2,3)
GLYCOPROTEIN(2,3)
MUTATION COMBINATION(2,3)
PROSTATE CANCER(2,3)
TRANSLATION PRODUCT(2,3)
AUTONOMOUS REPLICATION(2,2)
DINUCLEOTIDE(2,2)
ENCODING NUCLEIC ACID(2,2)
IRRADIATION(2,2)
ORFS(2,2)
PERIPHERAL BLOOD MONONUCLEAR CELL(2,2)
PERUSAL(2,2)
READER(2,2)
AMPICILLIN RESISTANCE GENE(2,1)
ARS SEQUENCE(2,1)
ASP TYR(2,1)
B LYMPHOTROPIC RETROVIRUS(2,1)
BACTERIOPHAGE DERIVED VECTOR(2,1)
BLV COMPLETE GENOMIC SEQUENCE(2,1)
BLV INFECTED CELL TRANSFER(2,1)
BLV POLYPEPTIDE LEVEL(2,1)
BLV SEQUENCE(2,1)
BVL COMPLETE SEQUENCE(2,1)
CARRIER SUBSTANCE(2,1)
CATTLE MANAGEMENT(2,1)
CELL ENCOMPASSING(2,1)
CELL INACTIVATION(2,1)
CENTROMERIC SEQUENCE(2,1)
CLONED SEQUENCE(2,1)
COLD SPRING HARBOR(2,1)
CYTOKINE PRODUCTION(2,1)
DELETION ANALYSIS(2,1)
DEOXYRIBONUCLEOTIDE(2,1)
DIRECT REPEAT RECOMBINATION(2,1)
DISULFIDE BOND(2,1)
ENVELOPE PROTEIN FORMATION(2,1)
ENZYMATIC DEGRADATION(2,1)
EXPRESSION VECTOR(2,1)
GENOMIC RNA(2,1)
GIVEN GENE SPLICING(2,1)
HOST CELL GENOME(2,1)
HOST GENOME(2,1)
HUMAN HELA(2,1)
HYDROXY L MOIETY(2,1)
IDENTIFIED BLV OVERVIEW(2,1)
IMPORTANCE FACTOR(2,1)
INDEPENDENT TRANSCRIPTIONAL UNIT ENCODING(2,1)
INFECTED BLOOD TRANSFER(2,1)
INSECT CELL(2,1)
INTRON PRECISE REMOVAL(2,1)
ISOLATED HOST CELL(2,1)
ISOLATED PROVIRUS(2,1)
KANAMYCIN RESISTANCE GENE(2,1)
LABORATORY PRESS(2,1)
LATE EXPRESSION(2,1)
LIMITATION BLV(2,1)
MAGNESIUM STEARATE(2,1)
MEDICAMENT PRODUCTION(2,1)
MONOCYTE MACROPHAGE(2,1)
MRNA GENOME(2,1)
MULTIMERIC COMPLEX(2,1)
MUTATION ACHIEVING(2,1)
MUTATION INTRODUCTION(2,1)
NATURAL INFECTION(2,1)
NUCLEIC ACID BACKBONE(2,1)
NUCLEIC ACID OLIGOMER(2,1)
NUCLEIC ACID REPLICATION(2,1)
NUMERIC RANGE RECITATION(2,1)
PERIODIC UPDATE(2,1)
PHEOCHROMOCYTOMA(2,1)
POL GENE SEQUENCE(2,1)
PRE MRNA SEQUENCE(2,1)
PRIMATE CELL(2,1)
PROPER SPLICING(2,1)
PYRIMIDINE BASE(2,1)
RECIPIENT CELL SELECTION(2,1)
RNA SPECIES(2,1)
SCHIZOSACCHAROMYCES POMBE(2,1)
SELF REPLICATED PLASMID(2,1)
SHORT RNA MOLECULE(2,1)
SODIUM SULFATE(2,1)
SPODOPTERA FRUGIPERDA(2,1)
STRUCTURAL(2,1)
SUBJECT SENSITIVITY ISSUE(2,1)
TEMPORAL DURATION(2,1)
TERM DELETION(2,1)
TERM ITAM(2,1)
TERM MICRORNA(2,1)
TERM OLIGONUCLEOTIDE(2,1)
TERM PRE MRNA(2,1)
TERM PROVIRUS(2,1)
TERM YEAST SHUTTLE VECTOR(2,1)
TRANSLATION TERMINATION CODON(2,1)
UNIQUE RESTRICTION SITE(2,1)
VACCINATED SUBJECT(2,1)
VAN DEN(2,1)
VECTOR COPY(2,1)
(US20190000963)
PLASMID(100,27)
BOVINE LEUKEMIA VIRUS(100,17)
ACCESSION NUMBER(100,14)
BUDAPEST TREATY(100,14)
LMBP COLLECTION(100,14)
MICROORGANISM BELGIAN COORDINATED COLLECTION(100,14)
RECOMBINANT NUCLEIC ACID ENCODING(100,8)
VACCINE(100,4)
RECOMBINANT ATTENUATED BLV(96,35)
ORF TRANSLATION INITIATION CODON(55,2)
OLIGONUCLEOTIDE HYBRIDIZATION(53,2)
BLV NUCLEIC ACID SEQUENCE(50,62)
RECOMBINANT ATTENUATED BLV VIRUS(45,1)
DOUBLE OLIGONUCLEOTIDE(43,4)
CYTOPLASMIC DOMAIN SIGNALING MOTIF(42,13)
BAMHI SITE(42,4)
MUTATION(35,193)
BLV REPLICATION(33,1)
BLV PROPAGATION(32,1)
NUCLEOTIDE(29,75)
XBAI SITE(28,2)
DELETION BOUNDARY(27,59)
NON HUMAN ANIMAL DERIVED PRODUCT(27,7)
TRANSMEMBRANE SUBUNIT(25,12)
ATTENUATED PHENOTYPE(24,1)
RECOMBINANT NUCLEIC ACID(23,19)
MAMMARY GLAND SECRETION(23,1)
SUBSTITUTION(22,14)
MUTATION ABOLISHING(22,9)
NON HUMAN ANIMAL WHOLE BLOOD(22,1)
HOST CELL(21,17)
MUTATION DISRUPTING(21,10)
PLASMID INSERT(21,4)
WHOLE BLOOD FRACTION(21,2)
IMMUNOGENIC SUBSTANCE(21,1)
NON HUMAN MAMMAL(21,1)
PROVIRUS ENCODING(21,1)
RECOMBINANT BOVINE LEUKEMIA VIRUS(21,1)
REX MRNA(18,4)
PROPAGATION(17,49)
NON MUTATED BLV POLYPEPTIDE(17,6)
NON HUMAN ANIMAL CELL(17,2)
ASSOCIATE DISEASE(17,1)
PROPHYLACTIC TREATMENT(17,1)
DELETION(16,43)
ENVELOPE PROTEIN(16,13)
GENBANK(16,12)
EXON(15,93)
INTRON SPLICE ACCEPTOR SITE(15,27)
NUCLEIC ACID SEQUENCE(14,17)
TAX BOUNDARY(13,14)
INTRON NUCLEOTIDE(13,8)
BLV ASSOCIATED DISEASE(13,2)
BOVID(13,2)
STOP CODON(12,20)
RICE SEQUENCE NUMBER(12,12)
MOTIF SIGNAL TRANSDUCTION ACTIVITY(12,11)
NON HUMAN ANIMAL DERIVED MATERIAL(12,5)
VACCINE PREPARATION(12,1)
MICRORNA(11,18)
NUCLEIC ACID(11,18)
RECOMBINANT BLV(11,8)
VIRUS(11,6)
BIOLOGICAL FUNCTION(11,5)
BACTERIAL CELL(11,2)
NUCLEIC ACID SEQUENCE ENCODING(10,14)
PRE MESSENGER RNA(10,6)
MIRNA MUTATION(10,5)
YEAST CELL(10,3)
YEAST EPISOMAL PLASMID(10,3)
ENZOOTIC BOVINE LEUKOSIS(10,2)
ATTENUATED BLV PROVIRUS PBLVDX(10,1)
COLOSTRUM(10,1)
ORF(9,23)
ORF CODING(9,7)
NON MUTATED MIRNA(9,3)
PRE MRNA ENCODING SPLICING(9,2)
CABBAGE LOOPER TRICHOPLUSIA NI(9,1)
PREMATURE STOP CODON(9,1)
RECOMBINANT ATTENUATED BLV PROVIRUS(9,1)
TAX(8,32)
ONCOGENIC POTENTIAL(8,8)
BLV(8,7)
MIRNA ENCODING REGION(8,6)
NUCLEOTIDE SUBSTITUTION(8,4)
MATURE MRNA ENCODING(8,3)
BLV PROVIRAL COPY(8,2)
NON HUMAN ANIMAL MATERIAL(8,1)
FUNCTIONAL TAX PRODUCTION(7,7)
SEQUENCE ABOLISHING(7,7)
VACCINATION(7,4)
INTRON EXON BOUNDARY(7,2)
PRE MRNA ENCODING NATIVE SPLICING(7,1)
SERUM(7,1)
VIRAL EXPRESSION POST TRANSCRIPTIONAL REGULATOR(7,1)
N TERMINAL YXXL(6,13)
AMINOACID(6,10)
ABOLISHED BIOLOGICAL FUNCTION(6,8)
COMPLETE PROVIRAL GENOME SEQUENCE(6,4)
GENETIC CONSTRUCT(6,4)
ACCESSORY PROTEIN(6,3)
CYTOPLASMIC TAIL(6,3)
YEAST PLASMID(6,3)
AUXOTROPHIC RECIPIENT CELL(6,2)
SACCHAROMYCES CEREVISIAE(6,2)
TYROSINE RESIDUE SUBSTITUTION(6,2)
BLV GENOME ENV GENE(6,1)
BLV PROVIRUS PLASMID(6,1)
CODING NUCLEOTIDE TRIPLET SUCCESSION(6,1)
CONDITIONALLY ESSENTIAL CHROMOSOMAL GENE(6,1)
GENERA SACCHAROMYCES YEAST(6,1)
RAT EMBRYONIC FIBROBLAST(6,1)
RECOMBINANT ATTENUATED BLV PARTICLE(6,1)
YEAST CENTROMERE PLASMID(6,1)
BACTERIAL HOST(5,3)
BLV STRAIN(5,3)
SPLICE ACCEPTOR SITE DELETION(5,3)
TISSUE CULTURE(5,3)
AUXOTROPHIC SELECTION MARKER(5,2)
BACTERIAL PLASMID(5,2)
BLV ENVELOPE(5,2)
BLV MIRNA REGION(5,2)
BOVINE LEUKEMIA VIRUS GENOME(5,2)
CHALLENGED HOST(5,2)
CONSECUTIVE NUCLEOTIDE(5,2)
HOMOLOGOUS RECOMBINATION(5,2)
HOST CHALLENGE(5,2)
MILK(5,2)
MUTATION RESTRICTING(5,2)
ORF NUCLEOTIDE(5,2)
QUANTITATIVE PCR(5,2)
REX POLYPEPTIDE(5,2)
ATTENUATED VIRUS PROPAGATION(5,1)
BLV6073DX INFECTIVITY(5,1)
BLV6073DX PROVIRUS(5,1)
BLV6073GPDX PROVIRUS(5,1)
CELLULAR SPLICING MACHINERY(5,1)
CODON ENCODING ALANINE(5,1)
DOWNSTREAM EXON NUCLEOTIDE(5,1)
EXON INTRON BOUNDARY(5,1)
GENE EXPRESSION POST TRANSCRIPTIONAL REGULATION(5,1)
GREEN MONKEY CHLOROCEBUS KIDNEY(5,1)
REGULATORY PROTEIN TAX(5,1)
REPLICATION YEAST ORIGIN(5,1)
TRANSMEMBRANE ENVELOPE PROTEIN(5,1)
UPSTREAM EXON NUCLEOTIDE(5,1)
VIRAL GENOME PACKAGING(5,1)
FOLDING(4,11)
CARE(4,9)
BLV NUCLEIC ACID REGION(4,7)
REX PROTEIN(4,7)
INTRON PORTION(4,4)
RECOMBINANT DNA TECHNOLOGY(4,3)
HUMAN INTERVENTION(4,2)
INTRON SPLICE DONOR SITE(4,2)
NUCLEIC ACID ENCODING BLV(4,2)
PROVIRAL LOAD(4,2)
TRANSLATION INITIATION CODON(4,2)
VIRUS VARIANT(4,2)
ARTIFICIAL MUTATION(4,1)
BACILLUS SUBTILIS(4,1)
BLV ENCODED MIRNA(4,1)
BLV GENOTYPE(4,1)
BLV POLYPEPTIDE PRODUCTION(4,1)
BLVGPDX PROVIRUS(4,1)
CONSERVED YXXL SEQUENCE(4,1)
DELTARETROVIRUS GENUS(4,1)
DERIVATISED NUCLEOTIDE BASIS(4,1)
DOMESTIC CATTLE(4,1)
DROSOPHILA MELANOGASTER(4,1)
EMBRYONIC CALVARIUM(4,1)
ENVELOPE PROTEIN DISRUPTION(4,1)
EXTRACELLULAR SUBUNIT(4,1)
HARVESTED VIRAL PARTICLE(4,1)
HOST CELL DNA GENOME(4,1)
IMMUNODEFICIENT MOUSE(4,1)
MESSENGER RNA TRANSCRIPT(4,1)
MICROBIOLOGICAL CULTURE(4,1)
MITOTIC SEGREGATION(4,1)
MUT MICRORNA(4,1)
NATIVE SPLICING ABSENCE(4,1)
NON HUMAN MAMMALIAN CELL(4,1)
NUCLEOTIDE NUMBER(4,1)
ONCOVIRINAE SUBFAMILY MEMBER(4,1)
PATHOGENIC BLV(4,1)
PBLV6073DX PLASMID(4,1)
PBLV6073GPDX PLASMID(4,1)
PBLVGPDX PLASMID(4,1)
PERIPHERAL BLOOD MONONUCLEAR CELLS(4,1)
PERSISTENT LYMPHOSIS(4,1)
PICHIA PASTORIS(4,1)
PLASMID PBLV344H(4,1)
PRE MRNA SPLICING(4,1)
PROVIRAL SEQUENCE EXPRESSION(4,1)
REGULATORY PROTEIN EARLY EXPRESSION(4,1)
RESTRICTION ENZYME DIGESTION(4,1)
REX PRE MRNA(4,1)
SALMONELLA TYMPHIMURIUM(4,1)
SERRATIA MARCESCENS(4,1)
SEVERE VIRAL INFECTION SYMPTOM(4,1)
SPLICE ACCEPTOR CONSENSUS SEQUENCE(4,1)
SUPPRESSOR TRNA(4,1)
TERM YEAST CENTROMERIC PLASMID(4,1)
TERM YEAST INTEGRATIVE PLASMID(4,1)
TRANSACTIVATING PROTEIN(4,1)
TRANSLATIONAL REPRESSION(4,1)
TRANSMEMBRANE SUBUNIT STOP CODON(4,1)
VIRAL PARTICLE SYNTHESIS(4,1)
VIRION BUDDING(4,1)
ASPARTIC ACID RESIDUE(3,3)
BREAST CANCER(3,3)
GLYCOPROTEIN(3,3)
MUTATION COMBINATION(3,3)
PROSTATE CANCER(3,3)
TRANSLATION PRODUCT(3,3)
ATTENUATED VACCINE(3,2)
INFECTIVITY SATISFACTORY LEVEL(3,2)
ORF START(3,2)
PATHOGENICITY(3,2)
TERM MUTATION(3,2)
TRANSCRIPTION PRODUCTION(3,2)
ANTISENSE STRAND(3,1)
ASP TYR(3,1)
BLV CLONE(3,1)
BLV COMPLETE GENOMIC SEQUENCE(3,1)
BLV GENE(3,1)
BLV GENOME REGION(3,1)
BLV INDUCED TUMOR(3,1)
BLV INFECTED HOST CELL(3,1)
BLV POLYPEPTIDE LEVEL(3,1)
CARRIER SUBSTANCE(3,1)
CATTLE MANAGEMENT(3,1)
CELL INACTIVATION(3,1)
CENTROMERIC SEQUENCE(3,1)
CHIMERIC MOLECULE(3,1)
DIRECT REPEAT RECOMBINATION(3,1)
DISULFIDE BOND(3,1)
DIVERSE OUTCOME(3,1)
EAR TATTOOING(3,1)
ENZYMATIC DEGRADATION(3,1)
EXPRESSION VECTOR(3,1)
GENE DELETION(3,1)
GENOMIC RNA(3,1)
GEOGRAPHICAL ORIGIN(3,1)
GROWTH RESTORATION(3,1)
HOST CELL GENOME(3,1)
HOST GENOME(3,1)
HUMAN HELA(3,1)
HYDROXY L MOIETY(3,1)
INFECTED BLOOD TRANSFER(3,1)
INFECTED NEEDLE(3,1)
INTRON PRECISE REMOVAL(3,1)
ISOLATED PROVIRUS(3,1)
LATE EXPRESSION(3,1)
LATENT SPLICE(3,1)
LEF BVRE(3,1)
LIMITATION BLV(3,1)
MILD SYMPTOM(3,1)
MOUSE MC3T(3,1)
MRNA GENOME(3,1)
MULTIMERIC COMPLEX(3,1)
MUTATION ACHIEVING(3,1)
MUTATION INTRODUCTION(3,1)
NUCLEOTIDE SEQUENCE(3,1)
PERIODIC UPDATE(3,1)
PHRASE RESTRICTING(3,1)
PLURAL REFERENT(3,1)
POLYPEPTIDE MRNA PRODUCTION(3,1)
PRE MRNA SEQUENCE(3,1)
RECIPIENT CELL SELECTION(3,1)
RECITED ENDPOINT(3,1)
REGION ENCODING MICRORNA(3,1)
REPLICATION ORIGIN(3,1)
REX ORF(3,1)
RICE NUMBERING(3,1)
SELF REPLICATED PLASMID(3,1)
SPLICE DONOR CONSENSUS SEQUENCE(3,1)
SUBJECT SENSITIVITY ISSUE(3,1)
TAX ORF(3,1)
TEMPORAL DURATION(3,1)
TERM TAX POLYPEPTIDE(3,1)
TERM YEAST SHUTTLE VECTOR(3,1)
TRANSLATION TERMINATION CODON(3,1)
TRANSMEMBRANE PROTEIN(3,1)
TRANSPOSON INSERTION(3,1)
UNIQUE RESTRICTION SITE(3,1)
VACCINATED SUBJECT(3,1)
VAN DEN(3,1)
VECTOR COPY(3,1)
VERTEBRATE ANIMAL CELL(3,1)
VIRAL TRANSCRIPTION(3,1)
EXPERIMENTAL SECTION(2,6)
LTR(2,4)
AUTONOMOUS REPLICATION(2,2)
COLD SPRING(2,2)
DINUCLEOTIDE(2,2)
ENCODING NUCLEIC ACID(2,2)
EXCIPIENT(2,2)
IRRADIATION(2,2)
ORFS(2,2)
PERUSAL(2,2)
READER(2,2)
AMPICILLIN RESISTANCE GENE(2,1)
ARS SEQUENCE(2,1)
B LYMPHOTROPIC RETROVIRUS(2,1)
BACTERIOPHAGE DERIVED VECTOR(2,1)
BLV INFECTED CELL TRANSFER(2,1)
BLV SEQUENCE(2,1)
BVL COMPLETE SEQUENCE(2,1)
CELL ENCOMPASSING(2,1)
CLONED SEQUENCE(2,1)
CYTOKINE PRODUCTION(2,1)
DELETION ANALYSIS(2,1)
DEOXYRIBONUCLEOTIDE(2,1)
ENVELOPE PROTEIN FORMATION(2,1)
GIVEN GENE SPLICING(2,1)
IDENTIFIED BLV OVERVIEW(2,1)
IMPORTANCE FACTOR(2,1)
INDEPENDENT TRANSCRIPTIONAL UNIT ENCODING(2,1)
INSECT CELL(2,1)
ISOLATED HOST CELL(2,1)
KANAMYCIN RESISTANCE GENE(2,1)
LABORATORY PRESS(2,1)
MEDICAMENT PRODUCTION(2,1)
MONOCYTE MACROPHAGE(2,1)
NATURAL INFECTION(2,1)
NUCLEIC ACID BACKBONE(2,1)
NUCLEIC ACID OLIGOMER(2,1)
NUCLEIC ACID REPLICATION(2,1)
NUMERIC RANGE RECITATION(2,1)
PHEOCHROMOCYTOMA(2,1)
POL GENE SEQUENCE(2,1)
PRIMATE CELL(2,1)
PROPER SPLICING(2,1)
PYRIMIDINE BASE(2,1)
RNA SPECIES(2,1)
SCHIZOSACCHAROMYCES POMBE(2,1)
SHORT RNA MOLECULE(2,1)
SPODOPTERA FRUGIPERDA(2,1)
STRUCTURAL(2,1)
TERM DELETION(2,1)
TERM ITAM(2,1)
TERM MICRORNA(2,1)
TERM OLIGONUCLEOTIDE(2,1)
TERM PRE MRNA(2,1)";Pharmaceuticals;Open
"2012-11-29
2013-11-28";"US20140147475       A1 2014-05-29 [US20140147475]
STG: (A1) Application published
AP : 2013US-14090178 2013-11-26
WO2014083091        A1 2014-06-05 [WO201483091]
STG: (A1) Published application with search report
AP : 2013WO-EP74930 2013-11-28
AU2013351213        A1 2015-05-21 [AU2013351213]
STG: (A1) Open to public inspection
AP : 2013AU-0351213 2013-11-28
BR112015012274      A1 2015-06-09 [BR112015012274]
STG: (A1) Published application
AP : 2015BR-0012274 2013-11-28
MX2015006797        A  2015-09-10 [MX2015006797]
STG: (A) Patent application
AP : 2015MX-PA06797 2013-11-28
EP2925354           A1 2015-10-07 [EP2925354]
STG: (A1) Application published with search report
AP : 2013EP-0795795 2013-11-28
US20150297704       A1 2015-10-22 [US20150297704]
STG: (A1) Application published
AP : 2013US-14647337 2013-11-28
RU2015125313        A  2017-01-11 [RU2015125313]
STG: (A) Application for invention
AP : 2015RU-0125313 2013-11-28
RU2613672           C2 2017-03-21 [RU2613672]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2015RU-0125313 2013-11-28
US9662382           B2 2017-05-30 [US9662382]
STG: (B2) Granted patent as second publication
AP : 2013US-14647337 2013-11-28
FD :  Previous publication: US20150297704 A1 2015-10-22 [US20150297704]
BR112015012274      A2 2017-07-11 [BR112015012274]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2015BR-0012274 2013-11-28
AU2013351213        B2 2017-10-19 [AU2013351213]
STG: (B2) Patent proceeded by OPI
AP : 2013AU-0351213 2013-11-28
MX356560            B  2018-06-04 [MX-356560]
STG: (B) Granted patent/ granted utility model
AP : 2015MX-PA06797 2013-11-28
EP2925354           B1 2018-06-06 [EP2925354]
STG: (B1) Patent specification
AP : 2013EP-0795795 2013-11-28
ES2676833           T3 2018-07-25 [ES2676833]
STG: (T3) Translation of granted European patent (former B3)
AP : 2013ES-0795795T 2013-11-28";66092466;"US20140147475       A1 2014-05-29 [US20140147475]
WO2014083091        A1 2014-06-05 [WO201483091]
AU2013351213        A1 2015-05-21 [AU2013351213]
BR112015012274      A1 2015-06-09 [BR112015012274]
MX2015006797        A  2015-09-10 [MX2015006797]
EP2925354           A1 2015-10-07 [EP2925354]
US20150297704       A1 2015-10-22 [US20150297704]
RU2015125313        A  2017-01-11 [RU2015125313]
RU2613672           C2 2017-03-21 [RU2613672]
US9662382           B2 2017-05-30 [US9662382]
BR112015012274      A2 2017-07-11 [BR112015012274]
AU2013351213        B2 2017-10-19 [AU2013351213]
MX356560            B  2018-06-04 [MX-356560]
EP2925354           B1 2018-06-06 [EP2925354]
ES2676833           T3 2018-07-25 [ES2676833]";"2012EP-0194759
2013EP-0795795
2013WO-EP74930";"(EP2925354)
WO2014083091
(US9662382)
WO2014083091
(RU2613672)
WO2014083091
(BR112015012274)
WO2014083091
(AU2013351213)
WO2014083091
(MX-356560)
WO2014083091
(ES2676833)
WO2014083091";"INTERVET INTERNATIONAL
MEDTRONIC INTERVET";INTERVET INTERNATIONAL;"(EP2925354)
NL
(EP2925354)
NL
(US20140147475)
NL
(US20150297704)
US
(US9662382)
US
(WO201483091)
NL; US
(BR112015012274)
NL
(MX-356560)
NL
(ES2676833)
NL";"(EP2925354)
NAME=Intervet International B.V. P.O. Box 31  Wim De Körverstraat 35 , CITY=5831 AN Boxmeer , COUNTRY=NL 

(EP2925354)
NAME=Intervet International B.V. P.O. Box 31  Wim De Körverstraat 35 , CITY=5831 AN Boxmeer , COUNTRY=NL , REG=101039064 

(US20140147475)
NAME=Jacobs Antonius Arnoldus Christiaan , CITY=Boxmeer , COUNTRY=NL 

(US20150297704)
NAME=INTERVET INC. , CITY=Summit , STATE=NJ , COUNTRY=US , ATYP=US Company 

(US9662382)
NAME=Intervet Inc. , CITY=Madison , STATE=NJ , COUNTRY=US , ATYP=US Company 

(WO201483091)
NAME=INTERVET INTERNATIONAL B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer , COUNTRY=NL 

NAME=INTERVET INC. 556 Morris Avenue Summit, New Jersey 07901 , COUNTRY=US 

(BR112015012274)
NAME=INTERVET INT BV , COUNTRY=NL 

(MX-356560)
NAME=INTERVET INT BV , COUNTRY=NL 

(ES2676833)
NAME=INTERVET INT BV , COUNTRY=NL 
";1;JACOBS ANTONIUS ARNOLDUS CHRISTIAAN;"(EP2925354)
NL
(EP2925354)
NL";"(EP2925354)
NAME=JACOBS, Antonius Arnoldus Christiaan Wim de Körverstraat 35 , CITY=NL-5831 AN Boxmeer , COUNTRY=NL 

(EP2925354)
NAME=JACOBS, Antonius Arnoldus Christiaan Wim de Körverstraat 35 , CITY=NL-5831 AN Boxmeer , COUNTRY=NL 
";"(EP2925354)
Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida";"(EP2925354)
The present invention pertains to a vaccine comprising live attenuated Pasteurella multocida bacteria for protection of a ruminant against pneumonia caused by P. multocida by administration of the vaccine to the upper respiratory tract of the ruminant via intranasal atomisation of the vaccine. The invention also pertains to a method to use the vaccine to protect a ruminant against pneumonia caused by P. multocida bacteria.";"(US20140147475)
1. A vaccine comprising live attenuated Pasteurella multocida bacteria for protection of a ruminant against pneumonia caused by Pasteurella multocida by administration of the vaccine to the upper respiratory tract of the ruminant via atomisation of the vaccine.
2. The vaccine of claim 1, wherein the administration takes place via intranasal atomisation.
3. The vaccine of claim 1, wherein the atomisation provides a mist of vaccine particles having an average size below 50 μm in diameter.
4. The vaccine of claim 3, wherein the average particle size is between 20 and 40 μm in diameter.
5. The vaccine of claim 1, wherein the vaccine additionally comprises live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus for protection against respiratory disease caused by parainfluenza virus and bovine respiratory syncytial virus.
6. The vaccine of claim 5, wherein it comprises live attenuated infectious bovine rhinotracheitis virus for protection against respiratory disease caused by infectious bovine rhinotracheitis virus.
7. A method to protect a ruminant against pneumonia caused by Pasteurella multocida bacteria, the method comprising administration of a vaccine comprising live attenuated Pasteurella multocida bacteria, to the upper respiratory tract of the ruminant by atomisation of the vaccine.";"(EP2925354)
The present invention pertains to a vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida.
The invention also pertains to the manufacture of such a vaccine and a method for protecting a ruminant against pneumonia caused by Pasteurella multocida.
The present invention pertains to those bacteria that cause such pneumonia in ruminants, in particular bovine.
The present invention pertains to those bacteria that cause such pneumonia in ruminants, in particular bovine.
The present invention pertains to a vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida.
The object of the invention is to provide a vaccine that protects, i.e. at least aids in preventing, ameliorates, actually prevents or cures, against pneumonia caused by Pasteurella multocida, which vaccine is safe in young animals.
The object of the invention is to provide a vaccine that protects, i.e. at least aids in preventing, ameliorates, actually prevents or cures, against pneumonia caused by Pasteurella multocida, which vaccine is safe in young animals.";"(EP2925354)
Intranasal administration has proven to lead to a good mucosal immune response against the bacterium.
In Tables 4 and 5, corresponding results are indicated for Group 2, vaccinated with the live vaccine administered to the upper respiratory tract by atomization of the vaccine and challenged with a heterologous PM (P. multocida) strain (which when compared to a homologous challenge typically makes it more difficult to obtain protection).
Certain serotypes, such as B:2 may cause haemorrhagic septicaemia, a systemic infection in ruminants, for example in bovine (i.e. animals that belong to the genus Bos, such as cows, steers, oxen, any other cattle, buffaloes etc).
Pneumonia is a local infection of the lower respiratory tract (in bovine often associated with bovine respiratory disease).
Pasteurella multocida bacteria in general may cause disease in wild and domesticated animals as well as humans.";"A01N-063/00
A61K-039/00
A61K-039/102
A61K-039/112
A61K-039/155
A61K-039/265
A61K-039/295
C12N-007/00";"(EP2925354)
1. Vaccine comprising live attenuated Pasteurella multocida bacteria for use in protection of a ruminant against pneumonia caused by P. multocida by administration of the vaccine to the upper respiratory tract of the ruminant via atomisation of the vaccine, characterised in that the administration takes place via intranasal atomisation and in that the P. multocida belong to serogroup A.";"(EP2925354)
VACCINE(100,38)
PNEUMONIA(100,21)
PASTEURELLA MULTOCIDA(100,12)
RUMINANT(100,9)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(100,8)
VACCINE ATOMIZATION(94,6)
INTRANASAL ATOMIZATION(79,2)
HOMOLOGOUS CHALLENGE(69,1)
SYSTEMIC INFECTION(65,1)
PASTEURELLA MULTOCIDA BACTERIUM(63,9)
RUMINANT PROTECTION(59,2)
BOVINE RESPIRATORY DISEASE(58,1)
VACCINE ADMINISTRATION(57,4)
ATTENUATED PARAINFLUENZA(57,3)
PARAINFLUENZA VIRUS(55,2)
HETEROLOGOUS P MULTOCIDA STRAIN(55,1)
VACCINE PARTICLE MIST(51,2)
LIVE VACCINE(48,3)
LOCAL INFECTION(48,1)
HEMORRHAGIC SEPTICEMIA(45,1)
VACCINE MANUFACTURE(43,2)
YOUNG ANIMAL(41,4)
MULTOCIDA(39,7)
RUMINANT UPPER RESPIRATORY TRACT(39,5)
BACTERIA(34,12)
DOMESTICATED ANIMAL(33,1)
BUFFALO(32,1)
SEROGROUP(28,3)
CATTLE(28,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(27,4)
STEER(27,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(26,6)
BOVINE(26,5)
SEROTYPE(26,4)
ADMINISTRATION(25,15)
COW(25,1)
INTRANASAL ADMINISTRATION(24,3)
WILD(23,1)
LIVE PASTEURALLA MULTOCIDA VACCINE(22,1)
UPPER RESPIRATORY TRACT(20,9)
LOW RESPIRATORY TRACT(20,1)
PFIZER ANIMAL HEALTH(19,3)
STREPTOMYCIN DEPENDENT STRAIN(19,1)
VACCINE INTRANASAL ATOMIZATION(18,1)
ANIMAL(16,12)
MERCK ANIMAL HEALTH(16,3)
LIVE PASTEURELLA MULTOCIDA VACCINE(16,1)
PASTEURELLA MULTOCIDA HYAE STRAIN(16,1)
DISEASE(15,10)
AGE WEEK(13,4)
AVIAN CHOLERA(13,2)
MUCOSAL IMMUNE RESPONSE(13,2)
RECONSTITUTED LIVE VACCINE(13,1)
AMERICAN HERITAGE MEDICAL DICTIONARY(12,1)
ANIMAL SYSTEMIC VACCINATION(12,1)
HETEROLOGOUS CHALLENGE CULTURE(12,1)
HOMOLOGOUS CHALLENGE CULTURE(12,1)
MICROORGANISM INCAPABILITY(12,1)
PASTEURELLA MULTOCIDA SEROTYPE(12,1)
LIVE BACTERIA(11,2)
LUNG LESION(11,2)
CANNULA ATOMIZATION(11,1)
PASTEURELLA BACTERIA(11,1)
RISPOVAL APPLICATOR(11,1)
CHALLENGE DOSE(10,2)
DROPLET(9,5)
EXPERIMENT(9,5)
ATTENUATED MICROORGANISM(9,2)
BACTERIUM REMAINING VIRULENCE(9,1)
BOOSTER VACCINATION(9,1)
COMMERCIALLY OBTAINABLE VACCINE(9,1)
CULTURE HETEROLOGOUS(9,1)
IMMUNOGENIC VIRUS(9,1)
KILLED VACCINE(9,1)
MAD CANNULA(9,1)
PASTEURELLA MULTOCIDA STRAIN(9,1)
PATHOGENIC COUNTERPART(9,1)
POST MORTEM SCORE(9,1)
RESPIRATORY TRACT MUCOSA(9,1)
SEVERE CLINICAL SIGN(9,1)
STATISTICAL UNCERTAINTY(9,1)
VACCINE EFFICACY(9,1)
VIRULENCE GENE(9,1)
ATTENUATION(8,4)
VACCINE GROUP(8,4)
ANIMAL MOUTH(8,1)
ATTENUATED STRAIN(8,1)
CLINICAL SIGN DEVELOPMENT(8,1)
FINE MIST ORAL ADMINISTRATION(8,1)
FINE PARTICLE MIST(8,1)
HOMOLOGOUS CULTURE(8,1)
KILLED BACTERIA(8,1)
MAD NASAL(8,1)
NASALGEN IP(8,1)
PARAINFLUENZA(8,1)
PARTICLE VACCINE(8,1)
SYMPTOM FULL SUITE(8,1)
VACCINE SAFETY(8,1)
VACCINE STRAIN(8,1)
ANTIGEN(7,4)
MUTATION(6,2)
APPLICATOR NOZZLE(6,1)
ATTENUATED PI(6,1)
CLINICAL SIGN RE(6,1)
DISEASE INDUCTION(6,1)
DISEASED TISSUE(6,1)
EQUIVALENT LOBE SAMPLE(6,1)
GENBANK(6,1)
GENESIS INDUSTRY(6,1)
HOUGHTON MIFFLIN CO(6,1)
LYOPHILIZED POWDER(6,1)
MATERNALLY DERIVED ANTIBODY PRESENCE(6,1)
OLD CALF(6,1)
PASTEURELLA OUTER MEMBRANE PROTEIN(6,1)
PERCENTAGE LUNG CONSOLIDATION(6,1)
POST MORTEM SAMPLE(6,1)
RE ISOLATION SCORE(6,1)
SECONDARY PATHOGEN(6,1)
STABILIZER MATRIX(6,1)
STATISTICAL PROGRAM(6,1)
UPPER RESPIRATORY TRACT COMMENSAL(6,1)
VISCOSITY MODIFIER(6,1)
YOUNG CALF(6,1)
LIVE P MULTOCIDA(5,4)
ADJUVANT(5,2)
INOCULATION(5,2)
LARYNX(5,2)
NOSTRIL(5,2)
PHARYNX(5,2)
ADMINISTRATION VOLUME(5,1)
ATROPHIC RHINITIS(5,1)
BLOOD AGAR PLATE(5,1)
CLEAN CATCH(5,1)
DETRIMENTAL HOST RESPONSE(5,1)
FREEZE DRIED VACCINE(5,1)
HALF LOBE(5,1)
LIVE ATTENUATED P(5,1)
LUNG BACTERIAL LOAD(5,1)
POOLED SAMPLE(5,1)
(US20140147475)
VACCINE(100,31)
PNEUMONIA(100,23)
PASTEURELLA MULTOCIDA(100,15)
PASTEURELLA MULTOCIDA BACTERIUM(100,11)
RUMINANT(100,11)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(100,9)
VACCINE ATOMIZATION(81,8)
VACCINE ADMINISTRATION(64,5)
RUMINANT PROTECTION(56,2)
RUMINANT UPPER RESPIRATORY TRACT(43,6)
HOMOLOGOUS CHALLENGE(35,1)
SYSTEMIC INFECTION(33,1)
INTRANASAL ATOMIZATION(30,1)
SECONDARY PATHOGEN(27,1)
VACCINE PARTICLE MIST(26,2)
CHALLENGE DOSE(25,2)
LIVE VACCINE(24,3)
ATTENUATED PARAINFLUENZA(24,2)
HEMORRHAGIC SEPTICEMIA(23,1)
VACCINE MANUFACTURE(22,2)
DOMESTICATED ANIMAL(17,1)
BACTERIA(16,12)
BUFFALO(16,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(15,3)
ADMINISTRATION(14,11)
CATTLE(14,2)
RESPIRATORY TRACT(14,2)
STEER(14,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(13,5)
SEROTYPE(13,4)
INTRANASAL ADMINISTRATION(13,2)
COW(12,1)
WILD(12,1)
DISEASE(11,10)
LIVE PASTEURALLA MULTOCIDA VACCINE(11,1)
UPPER RESPIRATORY TRACT(10,9)
PARAINFLUENZA VIRUS(10,2)
PFIZER ANIMAL HEALTH(9,3)
PASTEURALLA MULTOCIDA BACTERIUM(9,1)
WFI CANNULA ATOMIZATION(9,1)
ANIMAL(8,11)
STRAIN(8,5)
BOVINE(8,4)
MERCK ANIMAL HEALTH(8,3)
LIVE PASTEURELLA MULTOCIDA VACCINE(8,1)
PASTEURELLA MULTOCIDA HYAE STRAIN(8,1)
AGE WEEK(7,4)
YOUNG ANIMAL(7,4)
AVIAN CHOLERA(7,2)
MUCOSAL IMMUNE RESPONSE(7,2)
LMA MAD NASA(7,1)
RECONSTITUTED LIVE VACCINE(7,1)
LUNG LESION(6,2)
ANIMAL SYSTEMIC VACCINATION(6,1)
HETEROLOGOUS CHALLENGE CULTURE(6,1)
HOMOLOGOUS CHALLENGE CULTURE(6,1)
MICROORGANISM INCAPABILITY(6,1)
ATTENUATED MICROORGANISM(5,2)
BACTERIUM REMAINING VIRULENCE(5,1)
BLUE FLEX APPLICATOR NOZZLE(5,1)
COMMERCIALLY OBTAINABLE VACCINE(5,1)
CULTURE HETEROLOGOUS(5,1)
IMMUNOGENIC VIRUS(5,1)
KILLED VACCINE(5,1)
MAD CANNULA(5,1)
PASTEURELLA BACTERIA(5,1)
PASTEURELLA MULTOCIDA STRAIN(5,1)
PATHOGENIC COUNTERPART(5,1)
POST MORTEM SCORE(5,1)
RESPIRATORY TRACT MUCOSA(5,1)
RISPOVAL APPLICATOR(5,1)
SEVERE CLINICAL SIGN(5,1)
STATISTICAL UNCERTAINTY(5,1)
VACCINE EFFICACY(5,1)
VIRULENCE GENE(5,1)
EXPERIMENT(4,5)
ATTENUATION(4,4)
ANIMAL MOUTH(4,1)
ATTENUATED STRAIN(4,1)
CLINICAL SIGN DEVELOPMENT(4,1)
EMBL AAK(4,1)
FINE MIST ORAL ADMINISTRATION(4,1)
FINE PARTICLE MIST(4,1)
HOMOLOGOUS CULTURE(4,1)
LIVE BACTERIA(4,1)
NASALGEN IP(4,1)
STREPTOMYCIN DEPENDENT STRAIN(4,1)
SYMPTOM FULL SUITE(4,1)
VACCINE SAFETY(4,1)
VACCINE STRAIN(4,1)
ANTIGEN(3,4)
DROPLET(3,4)
ADJUVANT(3,2)
INOCULATION(3,2)
LARYNX(3,2)
MUTATION(3,2)
PHARYNX(3,2)
SEROGROUP(3,2)
ATTENUATED PI(3,1)
BOVINE RESPIRATORY DISEASE(3,1)
DISEASE INDUCTION(3,1)
DISEASED TISSUE(3,1)
EQUIVALENT LOBE SAMPLE(3,1)
GENESIS INDUSTRY(3,1)
LYOPHILIZED POWDER(3,1)
MATERNALLY DERIVED ANTIBODY PRESENCE(3,1)
OLD CALF(3,1)
PBS AIMING(3,1)
PERCENTAGE LUNG CONSOLIDATION(3,1)
POST MORTEM SAMPLE(3,1)
RE ISOLATION SCORE(3,1)
STABILIZER MATRIX(3,1)
STATISTICAL PROGRAM(3,1)
UPPER RESPIRATORY TRACT COMMENSAL(3,1)
VISCOSITY MODIFIER(3,1)
YOUNG CALF(3,1)
ADMINISTRATION VOLUME(2,1)
ATROPHIC RHINITIS(2,1)
BLOOD AGAR PLATE(2,1)
CLEAN CATCH(2,1)
DETRIMENTAL HOST RESPONSE(2,1)
FREEZE DRIED VACCINE(2,1)
HALF LOBE(2,1)
LOCAL INFECTION(2,1)
LUNG BACTERIAL LOAD(2,1)
POOLED SAMPLE(2,1)
POST CHALLENGE(2,1)
SPECIAL ATTENTION(2,1)
(US20150297704)
VACCINE(100,42)
PNEUMONIA(100,24)
PASTEURELLA MULTOCIDA(100,13)
RUMINANT(100,11)
PASTEURELLA MULTOCIDA BACTERIUM(100,10)
VACCINE INTRANASAL ATOMIZATION(100,1)
MULTOCIDA BACTERIUM(62,4)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(59,8)
INTRANASAL ATOMIZATION(54,3)
ATTENUATED PARAINFLUENZA(49,5)
HOMOLOGOUS CHALLENGE(40,1)
SYSTEMIC INFECTION(38,1)
RUMINANT UPPER RESPIRATORY TRACT(36,6)
RUMINANT PROTECTION(36,2)
VACCINE ADMINISTRATION(34,4)
VACCINE ATOMIZATION(32,6)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(31,8)
SECONDARY PATHOGEN(30,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(29,10)
CHALLENGE DOSE(29,2)
VACCINE PARTICLE MIST(29,2)
LIVE VACCINE(28,3)
RESPIRATORY DISEASE(26,10)
HEMORRHAGIC SEPTICEMIA(26,1)
VACCINE MANUFACTURE(25,2)
PARAINFLUENZA VIRUS(23,4)
MULTOCIDA(21,7)
BACTERIA(19,12)
DOMESTICATED ANIMAL(19,1)
BUFFALO(18,1)
CATTLE(16,2)
RESPIRATORY TRACT(16,2)
STEER(16,1)
SEROTYPE(15,4)
INTRANASAL ADMINISTRATION(14,3)
COW(14,1)
ADMINISTRATION(13,13)
DISEASE(13,10)
LIVE PASTEURELLA MULTOCIDA VACCINE(13,2)
WILD(13,1)
UPPER RESPIRATORY TRACT(12,9)
PFIZER ANIMAL HEALTH(11,3)
WFI CANNULA ATOMIZATION(10,1)
ANIMAL(9,11)
BOVINE(9,5)
STRAIN(9,5)
MERCK ANIMAL HEALTH(9,3)
PASTEURELLA MULTOCIDA HYAE STRAIN(9,1)
AGE WEEK(8,4)
YOUNG ANIMAL(8,4)
AVIAN CHOLERA(8,2)
MUCOSAL IMMUNE RESPONSE(8,2)
LMA MAD NASAL(8,1)
RECONSTITUTED LIVE VACCINE(8,1)
AMERICAN HERITAGE MEDICAL DICTIONARY(7,1)
ANIMAL SYSTEMIC VACCINATION(7,1)
HETEROLOGOUS CHALLENGE CULTURE(7,1)
HOMOLOGOUS CHALLENGE CULTURE(7,1)
MICROORGANISM INCAPABILITY(7,1)
LIVE BACTERIA(6,2)
LUNG LESION(6,2)
STREPTOMYCIN DEPENDENT STRAIN(6,2)
BLUE FLEX APPLICATOR NOZZLE(6,1)
PASTEURELLA BACTERIA(6,1)
RISPOVAL APPLICATOR(6,1)
EXPERIMENT(5,5)
ATTENUATED MICROORGANISM(5,2)
BACTERIUM REMAINING VIRULENCE(5,1)
COMMERCIALLY OBTAINABLE VACCINE(5,1)
CULTURE HETEROLOGOUS(5,1)
IMMUNOGENIC VIRUS(5,1)
KILLED VACCINE(5,1)
MAD CANNULA(5,1)
PASTEURELLA MULTOCIDA STRAIN(5,1)
PATHOGENIC COUNTERPART(5,1)
POST MORTEM SCORE(5,1)
RESPIRATORY TRACT MUCOSA(5,1)
SEVERE CLINICAL SIGN(5,1)
STATISTICAL UNCERTAINTY(5,1)
VACCINE EFFICACY(5,1)
VIRULENCE GENE(5,1)
ANTIGEN(4,4)
ATTENUATION(4,4)
DROPLET(4,4)
MUTATION(4,2)
AEROSOL EXPOSURE(4,1)
ANIMAL MOUTH(4,1)
ATTENUATED PI(4,1)
ATTENUATED STRAIN(4,1)
BOVINE RESPIRATORY DISEASE(4,1)
CLINICAL SIGN DEVELOPMENT(4,1)
DISEASE INDUCTION(4,1)
DISEASED TISSUE(4,1)
EMBL AAK(4,1)
EQUIVALENT LOBE SAMPLE(4,1)
FINE MIST ORAL ADMINISTRATION(4,1)
FINE PARTICLE MIST(4,1)
GENESIS INDUSTRY(4,1)
HOMOLOGOUS CULTURE(4,1)
HOUGHTON MIFFLIN CO(4,1)
KILLED BACTERIA(4,1)
LYOPHILIZED POWDER(4,1)
MATERNALLY DERIVED ANTIBODY PRESENCE(4,1)
NASALGEN IP(4,1)
OLD CALF(4,1)
PARTICLE VACCINE(4,1)
PASTEURELLA OUTER MEMBRANE PROTEIN(4,1)
PBS AIMING(4,1)
PERCENTAGE LUNG CONSOLIDATION(4,1)
POST MORTEM SAMPLE(4,1)
RE ISOLATION SCORE(4,1)
STABILIZER MATRIX(4,1)
STATISTICAL PROGRAM(4,1)
SYMPTOM FULL SUITE(4,1)
UPPER RESPIRATORY TRACT COMMENSAL(4,1)
VACCINE SAFETY(4,1)
VACCINE STRAIN(4,1)
VISCOSITY MODIFIER(4,1)
YOUNG CALF(4,1)
ADJUVANT(3,2)
INOCULATION(3,2)
LARYNX(3,2)
NOSTRIL(3,2)
PHARYNX(3,2)
POST MORTEM EXAMINATION(3,2)
SEROGROUP(3,2)
ADMINISTRATION VOLUME(3,1)
ATROPHIC RHINITIS(3,1)
BLOOD AGAR PLATE(3,1)
CLEAN CATCH(3,1)
DETRIMENTAL HOST RESPONSE(3,1)
FREEZE DRIED VACCINE(3,1)
HALF LOBE(3,1)
LOCAL INFECTION(3,1)
LUNG BACTERIAL LOAD(3,1)
POOLED SAMPLE(3,1)
POST CHALLENGE(3,1)
SAFETY EXAMINATION(3,1)
SPECIAL ATTENTION(3,1)
(US9662382)
VACCINE(100,42)
PNEUMONIA(100,24)
PASTEURELLA MULTOCIDA(100,13)
RUMINANT(100,11)
PASTEURELLA MULTOCIDA BACTERIUM(100,10)
VACCINE INTRANASAL ATOMIZATION(100,1)
MULTOCIDA BACTERIUM(66,4)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(63,8)
INTRANASAL ATOMIZATION(58,3)
ATTENUATED PARAINFLUENZA(52,5)
HOMOLOGOUS CHALLENGE(43,1)
SYSTEMIC INFECTION(40,1)
RUMINANT UPPER RESPIRATORY TRACT(38,6)
RUMINANT PROTECTION(38,2)
VACCINE ADMINISTRATION(37,4)
VACCINE ATOMIZATION(34,6)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(32,8)
SECONDARY PATHOGEN(32,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(31,10)
CHALLENGE DOSE(31,2)
VACCINE PARTICLE MIST(31,2)
LIVE VACCINE(29,3)
HEMORRHAGIC SEPTICEMIA(28,1)
NATIONAL STAGE ENTRY(28,1)
RESPIRATORY DISEASE(27,10)
VACCINE MANUFACTURE(26,2)
PARAINFLUENZA VIRUS(24,4)
MULTOCIDA(22,7)
DOMESTICATED ANIMAL(20,1)
BUFFALO(19,1)
CATTLE(17,2)
RESPIRATORY TRACT(17,2)
STEER(17,1)
SEROTYPE(16,4)
COW(15,1)
BACTERIA(14,12)
DISEASE(14,10)
INTRANASAL ADMINISTRATION(14,3)
LIVE PASTEURELLA MULTOCIDA VACCINE(14,2)
WILD(14,1)
ADMINISTRATION(13,13)
UPPER RESPIRATORY TRACT(12,9)
PFIZER ANIMAL HEALTH(11,3)
PCT(11,1)
WFI CANNULA ATOMIZATION(11,1)
BOVINE(10,5)
MERCK ANIMAL HEALTH(10,3)
PASTEURELLA MULTOCIDA HYAE STRAIN(10,1)
ANIMAL(9,11)
STRAIN(9,5)
LMA MAD NASAL(9,1)
AGE WEEK(8,4)
YOUNG ANIMAL(8,4)
AVIAN CHOLERA(8,2)
MUCOSAL IMMUNE RESPONSE(8,2)
RECONSTITUTED LIVE VACCINE(8,1)
LIVE BACTERIA(7,2)
LUNG LESION(7,2)
STREPTOMYCIN DEPENDENT STRAIN(7,2)
AMERICAN HERITAGE MEDICAL DICTIONARY(7,1)
ANIMAL SYSTEMIC VACCINATION(7,1)
HETEROLOGOUS CHALLENGE CULTURE(7,1)
HOMOLOGOUS CHALLENGE CULTURE(7,1)
MICROORGANISM INCAPABILITY(7,1)
ATTENUATED MICROORGANISM(6,2)
BACTERIUM REMAINING VIRULENCE(6,1)
BLUE FLEX APPLICATOR NOZZLE(6,1)
COMMERCIALLY OBTAINABLE VACCINE(6,1)
CULTURE HETEROLOGOUS(6,1)
IMMUNOGENIC VIRUS(6,1)
KILLED VACCINE(6,1)
MAD CANNULA(6,1)
PASTEURELLA BACTERIA(6,1)
PASTEURELLA MULTOCIDA STRAIN(6,1)
PATHOGENIC COUNTERPART(6,1)
POST MORTEM SCORE(6,1)
RESPIRATORY TRACT MUCOSA(6,1)
RISPOVAL APPLICATOR(6,1)
SEVERE CLINICAL SIGN(6,1)
STATISTICAL UNCERTAINTY(6,1)
VACCINE EFFICACY(6,1)
VIRULENCE GENE(6,1)
EXPERIMENT(5,5)
ATTENUATION(5,4)
ANIMAL MOUTH(5,1)
ATTENUATED STRAIN(5,1)
CLINICAL SIGN DEVELOPMENT(5,1)
EMBL AAK(5,1)
FINE MIST ORAL ADMINISTRATION(5,1)
FINE PARTICLE MIST(5,1)
HOMOLOGOUS CULTURE(5,1)
KILLED BACTERIA(5,1)
NASALGEN IP(5,1)
PARTICLE VACCINE(5,1)
SYMPTOM FULL SUITE(5,1)
VACCINE SAFETY(5,1)
VACCINE STRAIN(5,1)
ANTIGEN(4,4)
DROPLET(4,4)
MUTATION(4,2)
AEROSOL EXPOSURE(4,1)
ATTENUATED PI(4,1)
BOVINE RESPIRATORY DISEASE(4,1)
DISEASE INDUCTION(4,1)
DISEASED TISSUE(4,1)
EQUIVALENT LOBE SAMPLE(4,1)
GENESIS INDUSTRY(4,1)
HOUGHTON MIFFLIN CO(4,1)
LYOPHILIZED POWDER(4,1)
MATERNALLY DERIVED ANTIBODY PRESENCE(4,1)
OLD CALF(4,1)
PASTEURELLA OUTER MEMBRANE PROTEIN(4,1)
PBS AIMING(4,1)
PERCENTAGE LUNG CONSOLIDATION(4,1)
POST MORTEM SAMPLE(4,1)
RE ISOLATION SCORE(4,1)
STABILIZER MATRIX(4,1)
STATISTICAL PROGRAM(4,1)
UPPER RESPIRATORY TRACT COMMENSAL(4,1)
VISCOSITY MODIFIER(4,1)
YOUNG CALF(4,1)
ADJUVANT(3,2)
INOCULATION(3,2)
LARYNX(3,2)
NOSTRIL(3,2)
PHARYNX(3,2)
POST MORTEM EXAMINATION(3,2)
SEROGROUP(3,2)
ADMINISTRATION VOLUME(3,1)
ATROPHIC RHINITIS(3,1)
BLOOD AGAR PLATE(3,1)
CLEAN CATCH(3,1)
DETRIMENTAL HOST RESPONSE(3,1)
FREEZE DRIED VACCINE(3,1)
HALF LOBE(3,1)
LOCAL INFECTION(3,1)
LUNG BACTERIAL LOAD(3,1)
PCT CONTENT(3,1)
POOLED SAMPLE(3,1)
(WO201483091)
VACCINE(100,40)
PNEUMONIA(100,24)
ADMINISTRATION(100,15)
PASTEURELLA MULTOCIDA BACTERIUM(100,11)
RUMINANT(100,10)
PROTECTION(100,8)
RUMINANT UPPER RESPIRATORY TRACT(100,7)
MULTOCIDA BACTERIUM(100,4)
VACCINE MANUFACTURE(100,3)
VACCINE INTRANASAL ATOMIZATION(100,2)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(43,8)
VACCINE ATOMIZATION(39,7)
VACCINE ADMINISTRATION(38,5)
INTRANASAL ATOMIZATION(34,2)
HOMOLOGOUS CHALLENGE(30,1)
SYSTEMIC INFECTION(28,1)
RUMINANT PROTECTION(25,2)
BOVINE RESPIRATORY DISEASE(25,1)
PASTEURELLA MULTOCIDA(22,12)
VACCINE PARTICLE MIST(22,2)
LOCAL INFECTION(21,1)
LIVE VACCINE(20,3)
ATTENUATED PARAINFLUENZA(19,3)
HEMORRHAGIC SEPTICEMIA(19,1)
ATTENUATED P(16,1)
MULTOCIDA(15,7)
YOUNG ANIMAL(15,4)
BACTERIA(14,12)
DOMESTICATED ANIMAL(14,1)
BUFFALO(13,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(12,4)
CATTLE(12,2)
STEER(12,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(11,6)
BOVINE(11,5)
SEROTYPE(11,4)
INTRANASAL ADMINISTRATION(10,3)
COW(10,1)
WILD(10,1)
UPPER RESPIRATORY TRACT(9,9)
LIVE PASTEURALLA MULTOCIDA VACCINE(9,1)
LOW RESPIRATORY TRACT(9,1)
PFIZER ANIMAL HEALTH(8,3)
PARAINFLUENZA VIRUS(8,2)
MERCK ANIMAL HEALTH(7,3)
LIVE PASTEURELLA MULTOCIDA VACCINE(7,1)
PASTEURELLA MULTOCIDA AHYA STRAIN(7,1)
ANIMAL(6,11)
DISEASE(6,10)
STRAIN(6,5)
AGE WEEK(6,4)
RECONSTITUTED LIVE VACCINE(6,1)
ATTENUATED MICROORGANISM(5,2)
AVIAN CHOLERA(5,2)
LIVE BACTERIA(5,2)
LUNG LESION(5,2)
MUCOSAL IMMUNE RESPONSE(5,2)
STREPTOMYCIN DEPENDENT STRAIN(5,2)
AMERICAN HERITAGE MEDICAL DICTIONARY(5,1)
ANIMAL SYSTEMIC VACCINATION(5,1)
HETEROLOGOUS CHALLENGE CULTURE(5,1)
HOMOLOGOUS CHALLENGE CULTURE(5,1)
MICROORGANISM INCAPABILITY(5,1)
PASTEURELLA BACTERIUM(5,1)
PASTEURELLA MULTOCIDA SEROTYPE(5,1)
DROPLET(4,5)
EXPERIMENT(4,5)
CHALLENGE DOSE(4,2)
BACTERIUM REMAINING VIRULENCE(4,1)
CANNULA ATOMIZATION(4,1)
COMMERCIALLY OBTAINABLE VACCINE(4,1)
CULTURE HETEROLOGOUS(4,1)
IMMUNOGENIC VIRUS(4,1)
KILLED VACCINE(4,1)
LUNG CONSOLDIATION(4,1)
MAD CANNULA(4,1)
PASTEURELLA MULTOCIDA STRAIN(4,1)
PATHOGENIC COUNTERPART(4,1)
RESPIRATORY TRACT MUCOSA(4,1)
RISPOVAL APPLICATOR(4,1)
SEVERE CLINICAL SIGN(4,1)
STATISTICAL PROGRAM(4,1)
STATISTICAL UNCERTAINTY(4,1)
VACCINE EFFICACY(4,1)
VIRULENCE GENE(4,1)
ANTIGEN(3,4)
ATTENUATION(3,4)
AEROSOL EXPOSURE(3,1)
ANIMAL MOUTH(3,1)
APPLICATOR NOZZLE(3,1)
ATTENUATED PI(3,1)
ATTENUATED STRAIN(3,1)
CLINICAL SIGN DEVELOPMENT(3,1)
DAY POST CHALLENGE(3,1)
DISEASE INDUCTION(3,1)
DISEASED TISSUE(3,1)
EQUIVALENT LOBE SAMPLE(3,1)
FINE MIST ORAL ADMINISTRATION(3,1)
FINE PARTICLE MIST(3,1)
GENESIS INDUSTRY(3,1)
HOMOLOGOUS CULTURE(3,1)
HOUGHTON MIFFLIN CO(3,1)
KILLED BACTERIA(3,1)
LYOPHILIZED POWDER(3,1)
MAD NASAL(3,1)
MATERNALLY DERIVED ANTIBODY PRESENCE(3,1)
NASALGEN IP(3,1)
OLD CALF(3,1)
PARTICLE VACCINE(3,1)
PASTEURELLA OUTER MEMBRANE PROTEIN(3,1)
PERCENTAGE LUNG CONSOLIDATION(3,1)
POST MORTEM SCORE(3,1)
RE ISOLATION SCORE(3,1)
SECONDARY PATHOGEN(3,1)
STABILIZER MATRIX(3,1)
SYMPTOM FULL SUITE(3,1)
UPPER RESPIRATORY TRACT COMMENSAL(3,1)
VACCINE SAFETY(3,1)
VACCINE STRAIN(3,1)
VISCOSITY MODIFIER(3,1)
YOUNG CALF(3,1)
ADJUVANT(2,2)
INOCULATION(2,2)
LARYNX(2,2)
MUTATION(2,2)
NOSTRIL(2,2)
PHARYNX(2,2)
SEROGROUP(2,2)
VACCINE GROUP(2,2)
ADMINISTRATION VOLUME(2,1)
ATROPHIC RHINITIS(2,1)
BLOOD AGAR PLATE(2,1)
CLEAN CATCH(2,1)
DETRIMENTAL HOST RESPONSE(2,1)
FREEZE DRIED VACCINE(2,1)
HALF LOBE(2,1)
LIVE ATTENUATED P(2,1)
LUNG BACTERIAL LOAD(2,1)
POOLED SAMPLE(2,1)
SAFETY EXAMINATION(2,1)";"Basic materials chemistry
Pharmaceuticals";Open
"2012-11-08
2013-11-08
2015-11-06
2016-01-08
2016-03-21
2016-09-30
2017-04-10
2017-05-12
2017-06-15
2018-06-25";"CA2890466           A1 2014-05-15 [CA2890466]
STG: (A1) Application laid open
AP : 2013CA-2890466 2013-11-08
WO2014074817        A2 2014-05-15 [WO201474817]
STG: (A2) International application published with declaration under Article 17 (2) (a)
AP : 2013WO-US69144 2013-11-08
US20140170190       A1 2014-06-19 [US20140170190]
STG: (A1) Application published
AP : 2013US-14075169 2013-11-08
BR112015010364      A1 2015-05-19 [BR112015010364]
STG: (A1) Published application
AP : 2015BR-0010364 2013-11-08
AR093424            A1 2015-06-03 [AR--93424]
STG: (A1) Independent patent application
AP : 2013AR-0104119 2013-11-08
AU2013342269        A1 2015-06-04 [AU2013342269]
STG: (A1) Open to public inspection
AP : 2013AU-0342269 2013-11-08
WO2014074817        A3 2015-07-02 [WO201474817]
STG: (A3) Later publication of ISR with revised front page
AP : 2013WO-US69144 2013-11-08
EP2916863           A2 2015-09-16 [EP2916863]
STG: (A2) Application published without search report
AP : 2013EP-0853424 2013-11-08
HK1209317           A1 2016-04-01 [HK1209317]
STG: (A1) Patent application
AP : 2015HK-0109964 2015-10-13
US20160158336       A1 2016-06-09 [US20160158336]
STG: (A1) Application published
AP : 2015US-14934737 2015-11-06
FD :  Continuation of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
US9370561           B2 2016-06-21 [US9370561]
STG: (B2) Granted patent as second publication
AP : 2013US-14075169 2013-11-08
FD :  Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
FD : Previous publication: US20140170190 A1 2014-06-19 [US20140170190]
US20160199477       A1 2016-07-14 [US20160199477]
STG: (A1) Application published
AP : 2016US-14991003 2016-01-08
US20160243212       A1 2016-08-25 [US20160243212]
STG: (A1) Application published
AP : 2016US-14990995 2016-01-08
US20170022510       A1 2017-01-26 [US20170022510]
STG: (A1) Application published
AP : 2016US-15076140 2016-03-21
FD :  CIP of: US14/934,737 FDD=2015-11-06 [2015US-14934737]
FD : Continuation of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Continuation of: US9370561 - 0 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
AU2013342269        B2 2017-02-02 [AU2013342269]
STG: (B2) Patent proceeded by OPI
AP : 2013AU-0342269 2013-11-08
AU2017202354        A1 2017-05-11 [AU2017202354]
STG: (A1) Open to public inspection
AP : 2017AU-0202354 2017-04-10
US20170128560       A1 2017-05-11 [US20170128560]
STG: (A1) Application published
AP : 2016US-15281154 2016-09-30
FD :  Continuation of: US14/934,737 FDD=2015-11-06 [2015US-14934737]
FD : Continuation of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Continuation of: US9370561 - 0 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
US9675682           B2 2017-06-13 [US9675682]
STG: (B2) Granted patent as second publication
AP : 2016US-14991003 2016-01-08
FD :  Division of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Division of: US9370561 - 0 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
FD : Previous publication: US20160199477 A1 2016-07-14 [US20160199477]
US9744226           B2 2017-08-29 [US9744226]
STG: (B2) Granted patent as second publication
AP : 2016US-14990995 2016-01-08
FD :  Division of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Division of: US9370561 - 0 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
FD : Previous publication: US20160243212 A1 2016-08-25 [US20160243212]
US20170246286       A1 2017-08-31 [US20170246286]
STG: (A1) Application published
AP : 2017US-15594451 2017-05-12
US20170304424       A1 2017-10-26 [US20170304424]
STG: (A1) Application published
AP : 2017US-15624345 2017-06-15
EP2916863           B1 2018-05-30 [EP2916863]
STG: (B1) Patent specification
AP : 2013EP-0853424 2013-11-08
US10039819          B2 2018-08-07 [US10039819]
STG: (B2) Granted patent as second publication
AP : 2017US-15624345 2017-06-15
FD :  Continuation of: US14/990,995 FDD=2016-01-08 [2016US-14990995]
FD : Division of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Continuation of: US9744226 - 0 [US9744226]
FD : Division of: US9370561 - 0 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
FD : Previous publication: US20170304424 A1 2017-10-26 [US20170304424]
US10058601          B2 2018-08-28 [US10058601]
STG: (B2) Granted patent as second publication
AP : 2017US-15594451 2017-05-12
FD :  Continuation of: US14/991,003 FDD=2016-01-08 [2016US-14991003]
FD : Division of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Continuation of: US9675682 - 0 [US9675682]
FD : Division of: US9370561 - 2016-06-21 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
FD : Previous publication: US20170246286 A1 2017-08-31 [US20170246286]
BR112015010364      A2 2018-09-25 [BR112015010364]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2015BR-0010364 2013-11-08
ES2684556           T3 2018-10-03 [ES2684556]
STG: (T3) Translation of granted European patent (former B3)
AP : 2013ES-0853424T 2013-11-08
EP3384927           A1 2018-10-10 [EP3384927]
STG: (A1) Application published with search report
AP : 2018EP-0153297 2013-11-08
FD :  Division of: EP13853424 FDD=2013-11-08 [2013EP-0853424]
US20190000954       A1 2019-01-03 [US20190000954]
STG: (A1) Application published
AP : 2018US-16017314 2018-06-25
FD :  Division of: US15/281,154 FDD=2016-09-30 [2016US-15281154]
FD : Continuation of: US14/934,737 FDD=2015-11-06 [2015US-14934737]
FD : Continuation of: US14/075,169 FDD=2013-11-08 [2013US-14075169]
FD : Continuation of: US9370561 - 0 [US9370561]
FD : Provisional Appl: US61/723,979 FDD=2012-11-08 [2012US-61723979]
AU2017202354        B2 2019-02-21 [AU2017202354]
STG: (B2) Patent proceeded by OPI
AP : 2017AU-0202354 2017-04-10
FD :  Division of: AU2013342269 FDD=2013-11-08 [2013AU-0342269]";66336216;"CA2890466           A1 2014-05-15 [CA2890466]
WO2014074817        A2 2014-05-15 [WO201474817]
US20140170190       A1 2014-06-19 [US20140170190]
BR112015010364      A1 2015-05-19 [BR112015010364]
AR093424            A1 2015-06-03 [AR--93424]
AU2013342269        A1 2015-06-04 [AU2013342269]
WO2014074817        A3 2015-07-02 [WO201474817]
EP2916863           A2 2015-09-16 [EP2916863]
HK1209317           A1 2016-04-01 [HK1209317]
US20160158336       A1 2016-06-09 [US20160158336]
US9370561           B2 2016-06-21 [US9370561]
US20160199477       A1 2016-07-14 [US20160199477]
US20160243212       A1 2016-08-25 [US20160243212]
US20170022510       A1 2017-01-26 [US20170022510]
AU2013342269        B2 2017-02-02 [AU2013342269]
AU2017202354        A1 2017-05-11 [AU2017202354]
US20170128560       A1 2017-05-11 [US20170128560]
US9675682           B2 2017-06-13 [US9675682]
US9744226           B2 2017-08-29 [US9744226]
US20170246286       A1 2017-08-31 [US20170246286]
US20170304424       A1 2017-10-26 [US20170304424]
EP2916863           B1 2018-05-30 [EP2916863]
US10039819          B2 2018-08-07 [US10039819]
US10058601          B2 2018-08-28 [US10058601]
BR112015010364      A2 2018-09-25 [BR112015010364]
ES2684556           T3 2018-10-03 [ES2684556]
EP3384927           A1 2018-10-10 [EP3384927]
US20190000954       A1 2019-01-03 [US20190000954]
AU2017202354        B2 2019-02-21 [AU2017202354]";"2012US-61723979
2013AU-0342269
2013EP-0853424
2013US-14075169
2013WO-US69144
2015US-14934737
2016US-14990995
2016US-14991003
2016US-15076140
2016US-15281154
2017AU-0202354
2017US-15594451
2017US-15624345
2018US-16017314";"(EP2916863)
WO2014074817
(EP3384927)
WO2014074817
(CA2890466)
WO2014074817
(HK1209317)
WO2014074817
(AU2013342269)
WO2014074817
(ES2684556)
WO2014074817
(AU2017202354)
WO2014074817";"BIOTECHNOLOGY RESEARCH & DEVELOPMENT
BIOTECHNOLOGY RESEARCH & DEVELOPMENT COPORATION
MERIAL
US DEPARTMENT OF AGRICULTURE";"US DEPARTMENT OF AGRICULTURE
BIOTECHNOLOGY RESEARCH & DEVELOPMENT";"(EP2916863)
US
(EP2916863)
US
(EP3384927)
US
(US20160158336)
US
(US20140170190)
US
(US9370561)
US
(US20170022510)
US
(US20170128560)
US
(US20160199477)
US
(US9675682)
US
(US20160243212)
US
(US9744226)
US
(US20170304424)
US
(US10039819)
US
(US20170246286)
US
(US10058601)
US
(US20190000954)
US
(WO201474817)
US
(WO201474817)
US
(CA2890466)
US
(BR112015010364)
US";"(EP2916863)
NAME=Merial, Inc. 3239 Satellite Boulevard , CITY=Duluth, GA 30096 , COUNTRY=US 

(EP2916863)
NAME=Merial, Inc. 3239 Satellite Boulevard , CITY=Duluth, GA 30096 , COUNTRY=US , REG=101514329 

(EP3384927)
NAME=Merial Inc. 3239 Satellite Boulevard, Bldg. 500 , CITY=Duluth, GA 30096 , COUNTRY=US , REG=101537906 

(US20160158336)
NAME=Bey Russell F , CITY=Arden Hills , STATE=MN , COUNTRY=US 

NAME=Lawrence Paulraj Kirubakaran , CITY=Worthington , STATE=MN , COUNTRY=US 

NAME=Simonson Randy R , CITY=Worthington , STATE=MN , COUNTRY=US 

NAME=Briggs Robert E , CITY=Boone , STATE=IA , COUNTRY=US 

NAME=Tatum Fred M , CITY=Ames , STATE=IA , COUNTRY=US 

(US20140170190)
NAME=MERIAL LIMITED , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US9370561)
NAME=MERIAL, INC. , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US20170022510)
NAME=Biotechnology Research and Development Corporation , CITY=Peoria , STATE=IL , COUNTRY=US 

(US20170128560)
NAME=Biotechnology Research and Development Corporation , CITY=Peoria , STATE=IL , COUNTRY=US 

NAME=The United States of America as represented by the Secretary of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US 

(US20160199477)
NAME=Merial Inc. , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US9675682)
NAME=MERIAL, INC. , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US20160243212)
NAME=The United States of America, as Represented by the Secretary of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US , ATYP=US Company 

(US9744226)
NAME=The United States of America, as represented by the Secretary of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US , ATYP=US Government 

NAME=Biotechnology Research and Development Corporation , CITY=Peoria , STATE=IL , COUNTRY=US , ATYP=US Company 

(US20170304424)
NAME=Biotechnology Research and Development Corporation , CITY=Peoria , STATE=IL , COUNTRY=US 

NAME=The United States of America, as represented by the Secretary of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US 

(US10039819)
NAME=The United States of America, as represented by the Secretary of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US , ATYP=US Company 

NAME=Biotechnology Research and Development Corporation , CITY=Peoria , STATE=IL , COUNTRY=US , ATYP=US Company 

(US20170246286)
NAME=MERIAL INC. , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US10058601)
NAME=MERIAL INC. , CITY=Duluth , STATE=GA , COUNTRY=US , ATYP=US Company 

(US20190000954)
NAME=The United States of America, as represented by the Secretary of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US 

NAME=Biotechnology Research and Development Corporation , CITY=Peoria , STATE=IL , COUNTRY=US 

(WO201474817)
NAME=MERIAL LIMITED 3239 Satellite Blvd. Duluth, GA 30096 , POSTCODE=30096 , COUNTRY=US 

(WO201474817)
NAME=MERIAL, INC. 3239 Satellite Blvd. Duluth, GA 30096 , POSTCODE=30096 , COUNTRY=US 

(CA2890466)
NAME=MERIAL, INC. 3239 SATELLITE BLVD. , CITY=DULUTH , STATE=GA , POSTCODE=30096 , COUNTRY=US 

(BR112015010364)
NAME=MERIAL INC , COUNTRY=US 
";2;"BEY RUSSELL F
LAWRENCE PAULRAJ KIRUBAKARAN
SIMONSON RANDY R";"(EP3384927)
US";"(EP3384927)
NAME=BEY, Russell F. 1157 Amble Drive , CITY=Arden Hills, MN 55112 , COUNTRY=US 

NAME=LAWRENCE, Paulraj Kirubakaran 2257 Nobles Street , CITY=Worthington, MN 56187 , COUNTRY=US 

NAME=SIMONSON, Randy R. 28387 Cty Hwy 35 , CITY=Worthington, MN 56187 , COUNTRY=US 
";"(EP3384927)
Attenuated manheimia haemolytica vaccines and methods of making and use";"(EP3384927)
The present invention provides attenuated M. haemolitica strains that elicit an immune response in animal against M. haemolitica, compositions comprising said strains, methods of vaccination against M. haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to ""shipping fever"" or bovine respiratory disease.";"(CA2890466)
1. An attenuated Mannheimia haemolytica (M. haemolytica) strain capable of providing a safe and effective immune response in a bovine against M. haemolytica or diseases caused by
M haemolytica.
2. The strain of claim 1 having nucleic acid deletions in one or more virulence gene(s) relative to a virulent parental M. haemolytica strain.
3. The strain of claim 2 wherein the gene is a leukotoxin.
4. The strain of claim 3 wherein the gene is leukotoxin A.
5. The strain of claim 2 wherein the deletion results in a protein having a sequence encoded by the sequence as set forth in SEQ ID NO:16 or 17.
6. An immunological composition comprising the attenuated strain of any of claims 1 to 5.
7. The composition of claim 6 further comprising a pharmaceutically or veterinary acceptable vehicle, diluent or excipient.
8. The composition of claim 8 further comprising an adjuvant.
9. The composition of claim 9 wherein the adjuvant is inactivated bacteria, inactivated virus, fractions of inactivated bacteria, bacterial lipopolysaccharides, bacterial toxins, or derivatives or combinations thereof.
10. The composition of claim 6 which provides a protective immune response in bovine against virulent M. haemolytica challenge.
11. The composition of any one of claims 8 to 10 further comprising at least one additional antigen associated with a pathogen other than M. haemolytica.
12. The composition of claim 11 wherein the at least one or more additional antigen(s) is capable of eliciting in a bovine an immune response against M. haemolytica and other pathogen capable of infecting and causing illness or susceptibility to illness in a bovine.
13. A method of vaccinating an animal comprising at least one administration of the composition of any one of claims 6-12.
14. The method of claim 13 wherein the animal is a bovine.
15. The method of claim 14 wherein the bovine is a calf that is 28 days or older.
16. A live gene-deleted bacteria, to be used in combination with P.
multocida, M haemolytica and H. somni for the prevention of bovine respiratory disease caused by M
haemolytica,
H. somni, and P. multocida in calves 28 days and older.
17. The method of claim 13 wherein the vaccine is administered intranasally.
18. A deletion mutant bacterium having a deletion within the LktCA gene locus encoding acylase (LktC) and leukotoxinA (LktA).
19. The deletion mutant of claim 17, which secretes a truncated form a LktA
having an amino acid sequence encoded by the sequence as set forth in SEQ ID NO:16 or 17.
20. The deletion mutant of claim 17, which is attenuated relative to virulent wildtype parental bacterium, and wherein the parental bacterium is capable of causing typical
Fibrinous pleuropneumoniae in the lungs of affected cattle, and having the designation serotype A1
D153.
21. The deletion mutant of claim 18, which replicates primarily in a bovine's nasal passages to produce an immune response.
22. The deletion mutant of claim 21 wherein no shedding is observed in the animal's feces, saliva, or other body fluids.
23. The deletion mutant of claim 21 which causes no prolonged itching or irritation at the site of inoculation.";"(EP3384927)
The present invention relates generally to attenuated bacterial vaccines, particularly those providing broad, safe, and effective protection to production animals against infections/disease caused by gram-negative bacteria, including Mannheimia (Pasteurella) haemolytica.
The invention further relates to methods of producing the attenuated bacteria, and to PCR methods for differentiating among M. haemolitica serotypes A1 and A6, in vivo.
The invention accordingly relates to immunogenic or vaccine compositions comprising the bacteria of the invention; e.g., live attenuated bacteria.
The present invention provides attenuated M. haemolitica strains that elicit an immune response in animal against M. haemolitica, compositions comprising said strains, methods of vaccination against M. haemolitica, and kits for use with such methods and compositions.
The invention further provides multivalent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to ""shipping fever"" or bovine respiratory disease.
The invention therefore further relates to methods for preparing and/or formulating such compositions; e.g., culturing or growing or propagating the bacteria on or in suitable medium, harvesting the bacteria, optionally inactivating the bacteria, and optionally admixing the bacteria with a suitable veterinarily or pharmaceutically acceptable carrier, excipient, diluent or vehicle and/or an adjuvant and/or stabilizer.
Thus, the invention also relates to the use of the bacteria in formulating such compositions.";"(EP3384927)
These mutants are also useful as vectors which can be useful for expression in vitro of expression products, as well as for reproduction or replication of nucleotide sequences (e.g., replication of DNA), and for in vivo expression products.
The kit may advantageously contain additional first or second vials for additional prime-vaccinations or additional boost-vaccinations.
Thus, an embodiment of this disclosure provides useful RT-QPCR methods, which enable at least the following activities: a) identification of field isolates of M. haemolytica A1 and A6 quickly and screen large number of colonies; b) monitoring of vaccination/colonization of A1 and A6 in nasal cavities; c) elimination of the need for developing high titer antisera; and d) development of rapid, automated diagnostic test kits.
Under stress and in immunocompromised animals M. haemolytica descends into lungs and causes severe systemic disease resulting in pneumonic pasteurellosis or ""shipping fever"".
Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
Furthermore, cross-protection against M. haemolytica serotypes (either A6 or A2) has been difficult to achieve using conventional vaccine preparations (Purdy et al., 1993; Sabri et al., 2000).";"A01N-063/00
A61K
A61K-039/00
A61K-039/02
A61K-039/102
A61K-048/00
A61K-049/00
A61P-031/04
C07H-021/04
C07K
C07K-014/285
C12N
C12N-001/20
C12N-001/21
C12N-001/36
C12N-009/80
C12N-015/31
C12N-015/74";"(EP3384927)
1. A vaccine for use in vaccinating an animal against diseases caused by Mannheimia haemolytica, wherein the vaccine comprises bacteria containing an attenuating mutation in a gene, wherein the mutation modifies the expression and/or the biological activity of a polypeptide or protein encoded by the gene, resulting in attenuated virulence of the bacteria, wherein the mutation is an in-frame deletion resulting in the bacteria secreting a truncated leukotoxin (LktA), wherein the vaccine is administered at least once, further wherein the vaccine is administered intranasally.";"(EP2916863)
ATTENUATED MANNHEIMIA HAEMOLYTICA VACCINE(100,1)
BACTERIA VIRULENCE ATTENUATION(92,3)
MANNHEIMIA HAEMOLYTICA SEROTYPE(70,2)
LKTCA GENE(68,2)
POLYPEPTIDE BIOLOGICAL ACTIVITY(58,3)
ATTENUATING MUTATION(57,3)
BACTERIUM SECRETING(50,3)
ENCODING ACYLASE(48,2)
HISTOPHILUS SOMNI(48,2)
VACCINE(45,47)
TRUNCATED LEUKOTOXIN(44,4)
HAEMOLYTICA SEROTYPE(41,4)
MULTIVALENT VACCINE(40,1)
PNEUMONIC PASTEURELLOSIS(39,1)
HAEMOLITICA SEROTYPE(36,1)
ATTENUATED BACTERIAL VACCINE(34,1)
ATTENUATED BACTERIA(33,5)
SEVERE SYSTEMIC DISEASE(32,1)
IMMUNODEFICIENT ANIMAL(31,1)
BACTERIA(29,23)
MUTATION(29,9)
BOOST VACCINATION(28,2)
IMMUNOGENIC RESPONSE(26,3)
VACCINE PREPARATION(24,1)
INACTIVATED BACTERIA FRACTION(23,2)
HAEMOLYTICA(19,17)
HAEMOLYTICA VACCINE(19,3)
BACTERIAL LIPOPOLYSACCHARIDE(19,2)
LKTA(19,2)
LEUKOTOXIN(18,6)
ANIMAL PRODUCTION(18,1)
ANIMAL(17,23)
DELETION(17,10)
MULTOCIDA(17,3)
VIRULENCE GENE(17,2)
GRAM NEGATIVE BACTERIA(16,2)
INACTIVATED VIRUS(16,2)
PROTECTING BOVINE(16,1)
VETERINARY ACCEPTABLE CARRIER(16,1)
HAEMOLYTICA STRAIN(15,5)
VETERINARILY ACCEPTABLE CARRIER(14,5)
DISEASE(13,2)
SHIPPING FEVER(13,1)
PROTEIN(12,21)
GENE(11,14)
PASTEURELLA(11,6)
MANNHEIMIA(11,4)
INFECTION DISEASE(11,2)
EXCIPIENT(10,9)
AMINOACID SEQUENCE(10,3)
NECROTIZING BRONCHOPNEUMONIA(10,3)
INTRANASAL COLONIZATION EFFICACY(10,2)
DAY POST VACCINATION(9,7)
VIAL(9,4)
TRUNCATED LKTA SECRETION(9,2)
BACTERIAL TOXIN(8,2)
SAFE(8,2)
LYOPHILIZED MANNHEIMIA HAEMOLYTICA SEROTYPE(8,1)
NEONATAL DAIRY CALF PNEUMONIA(8,1)
LUNG(7,6)
KIT(7,5)
ANTIBODY NEUTRALIZATION(7,4)
COLUMBIA BROTH(7,4)
WESTERN BLOT(7,4)
BACTERIUM CHIEF CYTOTOXIN(7,1)
BOVINE PARAINFLUENZA VIRUS(7,1)
CATTLE INTRANASAL IMMUNIZATION(7,1)
LIVE MANNHEIMIA HAEMOLYTICA SEROTYPE(7,1)
PASTEURELLA HAEMOLYTICA SUBUNIT ANTIGEN(7,1)
RECOMBINANT MANNHEIMIA HAEMOLYTICA IMMUNOGENICITY(7,1)
LUNG LESION(6,3)
VACCINE EFFICACY(6,3)
FETAL BOVINE SERUM(6,2)
INTRANASAL VACCINATION(6,2)
PBCKAN LKTCARB(6,2)
PNEUMONIA SEVERE SIGN(6,2)
PCR(6,1)
VIRULENT PARENTAL BACTERIUM(6,1)
WILD MAMMAL INFECTIOUS DISEASE(6,1)
DILUENT(5,4)
ACYLASE ENZYME(5,2)
BOVINE HERPES VIRUS(5,2)
CHALLENGE ORGANISM(5,2)
FRESH GLYCEROL STOCK(5,2)
IMMUNITY STIMULATION(5,2)
IMMUNOGENIC FRAGMENT(5,2)
MANUFACTURER INSTRUCTION(5,2)
MUCOSAL ADJUVANT(5,2)
NUCLEOTIDE REPLACEMENT(5,2)
PNEUMONIC LESION(5,2)
ANTIGENIC POLYPEPTIDE VARIANT(5,1)
ATTENUATED MUTANT BACTERIUM(5,1)
BACTERIA PATHOGENICITY(5,1)
CHOLINE TRANSPORTER GENE(5,1)
COMMERCIAL VACCINE AUGMENTATION(5,1)
DEFIBRINATED SHEEP BLOOD(5,1)
GENERAT ING ANTIBODY(5,1)
INTRATRACHEAL CHALLENGE EXPOSURE(5,1)
KB DELETED LEUKOTOXIN INSERT(5,1)
LEUKOTOXIC CULTURE SUPERNATANT(5,1)
LEUKOTOXIN DEFICIENT MANNHEIMIA HAEMOLYTICA(5,1)
LEUKOTOXIN OPERON MOLECULAR EVOLUTION(5,1)
MANNHEIMIA OVINE STRAIN(5,1)
MANNHEIMIA SEROTYPING(5,1)
NATIVE LKTA GENE(5,1)
PASTEURELLA HAEMOLYTICA TRANSFERRIN(5,1)
PASTEURELLACEAE PHYLOGENY(5,1)
PBC PLASMID BACKBONE(5,1)
TRANSTHORACIC CHALLENGE EXPOSURE(5,1)
TRUNCATED LKTA PROTEIN(5,1)
VIRULENT PARENTAL STRAIN(5,1)
FEED INTAKE(4,4)
EPITOPE MAPPING(4,3)
AGE WEEK(4,2)
HISTOPATHOLOGICAL ANALYSIS(4,2)
INFECTED HOST(4,2)
LEUKOTOXIN GENE SPECIFIC DELETION(4,2)
PROTEIN FRAGMENT(4,2)
STUDY SCHEDULE(4,2)
VACCINE STRAIN(4,2)
ARGININE SUBSTITUTION(4,1)
BEEF CATTLE SHIPPING FEVER(4,1)
BMC GENOMICS(4,1)
BOVINE PRACTITIONER(4,1)
BOVINE RESPIRATORY DISEASE VACCINE(4,1)
CALF NASAL SECRETION(4,1)
CALF VACCINATION(4,1)
CATTLE LUNG(4,1)
CATTLE VACCINATION(4,1)
CLINICAL DISEASE SEVERITY(4,1)
CLINICAL SIGN CRITERIA(4,1)
CLINICAL SIGN GRAVITY(4,1)
COLI CLONING(4,1)
COMMENSAL ORGANISM(4,1)
CONCENTRATED CULTURE SUPERNATANT(4,1)
CONFORMATIONAL EPITOPE(4,1)
DAIRY HEIFER(4,1)
EFFICACIOUS VACCINE(4,1)
EXCLUSIVE COLONIZATION(4,1)
EXOTOXIN LEUKOTOXIN(4,1)
EXPERIMENTAL CHALLENGE EXPOSURE(4,1)
GENETICALLY DISTINCT ENTITY(4,1)
GOAT ANTI MOUSE(4,1)
HAEMOLYTICA BACTERIUM(4,1)
HAEMOLYTICA COLONY(4,1)
HAEMOLYTICA INFECTION(4,1)
HAEMOLYTICA LESION(4,1)
HAEMOLYTICA MUTANT(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
HETEROLOGOUS PROMOTER(4,1)
HOMOLOGOUS RECOMBINATION(4,1)
HOST ANIMAL NEUTROPHIL(4,1)
HYDROPHOBIC RESIDUE SUBSTITUTION(4,1)
INFECTION PROPHYLAXIS(4,1)
KDA PREDICTED PROTEIN(4,1)
LEUKOTOXIN NEGATIVE ISOGENIC MUTANT(4,1)
LKTC RBS(4,1)
LKTCADELR PRIMER(4,1)
LOGARITHMIC GROWTH(4,1)
LOWERED VIRAL TITER(4,1)
MANNHEIMIA HAEMOLYTICA GENOME SEQUENCE(4,1)
METHYLATED NUCLEOTIDE(4,1)
MONOCLONAL ANTI LEUKOTOXIN ANTIBODY(4,1)
MUTANT BACTERIA(4,1)
NEONATAL DAIRY CATTLE(4,1)
ORAL ATTENUATED VACCINE(4,1)
PARTIALLY DELETED LKTA GENE(4,1)
PASTEURELLA HAEMOLYTICA ISOLATION(4,1)
PASTEURELLA TREHALOSI(4,1)
PASTEURELLACEAE GENETIC ENGINEERING(4,1)
PBC SALI SITE(4,1)
PERCENT LUNG INVOLVEMENT(4,1)
POLAR RESIDUE SUBSTITUTION(4,1)
PROTEIN IMMUNOGENICITY(4,1)
QUATERNARY AZANIUM SALT(4,1)
RECOMBINANT POLYNUCLEOTIDE(4,1)
REPLACEMENT PLASMID INTEGRATION(4,1)
REPLACEMENT PLASMID RESOLUTION EXCISION(4,1)
SEROTYPE BACTERIUM(4,1)
SHAM VACCINE(4,1)
STRAW BEDDING(4,1)
SUSCEPTIBLE BOVINE ANIMAL(4,1)
TRANSCRIPTION TERMINATOR(4,1)
TRANSTRACHEAL ADMINISTRATION(4,1)
TRIMETHYLATED CHITOSAN(4,1)
TRUNCATED LKTCA(4,1)
UNSUBSTITUTED POLYPEPTIDE(4,1)
VACCINE INTRANASAL ADMINISTRATION(4,1)
VIRULENT CHALLENGE(4,1)
VIRULENT MANNHEIMIA HAEMOLYTICA(4,1)
VIRULENT PARENT STRAIN(4,1)
AMINOACID(3,5)
BA PLATE(3,3)
INTRON(3,3)
CALF SHOWING CLINICAL SIGN(3,2)
HUMANE REASON(3,2)
POST CHALLENGE(3,2)
REMAINING INOCULUM(3,2)
ALKENYL DERIVATIVE POLYMER(3,1)
ANNUAL BOOSTER(3,1)
ATTENUATED STRAIN(3,1)
BRANCHED POLYNUCLEOTIDE(3,1)
BROAD PROTECTIVE IMMUNITY(3,1)
CATIONIC LIPID(3,1)
CHALLENGED ANIMAL(3,1)
COMMERCIAL EXPERIMENTAL EVALUATION(3,1)
COMPLEX GENETIC MACHINERY(3,1)
CONSERVATIVE REPLACEMENT(3,1)
CROSS PROTECTION(3,1)
DELETION MUTATION ENGINEERING(3,1)
DIFCO LABORATORY(3,1)
EFFICACY EVALUATION(3,1)
FEEDLOT CALF(3,1)
FINAL LKTCA MUTANT(3,1)
GENOMIC SEQUENCE DELETION(3,1)
GENTLE SHAKING(3,1)
HAEMOLYTICA LKTCABD OPERON SHOWING(3,1)
HAEMOLYTICA VIRULENCE FACTOR(3,1)
HEALTHY CATTLE(3,1)
KANAMYCIN CASSETTE(3,1)
KANAMYCIN RESISTANCE GENE(3,1)
KIT MASTER MIX(3,1)
LESION REVIEW(3,1)
LEUKOTOXIN CA(3,1)
LEUKOTOXIN MOLECULAR EVOLUTION(3,1)
LIVE VACCINE(3,1)
LKTA ACTIVATION(3,1)
LYOPHILIZED CULTURE(3,1)
MODIFIED LIVE LEUKOTOXIN(3,1)
NASAL SWAB(3,1)
NUCLEOTIDE BRANCH(3,1)
OLIGODEOXYRIBONUCLEOTIDE SEQUENCE(3,1)
PARENTERAL ADMINISTRATION(3,1)
PLURAL REFERENT(3,1)
POLYNUCLEOTIDE SEGMENT(3,1)
POLYPEPTIDE FRAGMENT(3,1)
PROTEIN TBPA(3,1)
PTA LKTCA(3,1)
RECIPIENT STRAIN(3,1)
RECOMBINANT VECTOR(3,1)
RESPIRATORY DISEASE PREVENTION(3,1)
RUMINANT RESPIRATORY TRACT RESPONSE(3,1)
UNCHARGED POLAR(3,1)
UNMETHYLATED LIGATION PRODUCT(3,1)
VECTOR ADMINISTRATION(3,1)
VECTOR PRESERVATION(3,1)
VIRULENT STRAIN(3,1)
WEANED BEEF(3,1)
TRYPTICASE SOY AGAR(2,5)
BIOLOGICALLY SIMILAR RESIDUE(2,4)
DILUTION(2,4)
NASAL DISCHARGE(2,4)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(2,3)
EXON(2,3)
HAEMOLYTICA D(2,3)
LANE(2,3)
ANOREXIA(2,2)
BACTERIAL GENOME(2,2)
CHEMICAL SYNTHESIS(2,2)
CONJUGATION(2,2)
DYSPNEA(2,2)
ENCODED AMINOACID RESIDUE(2,2)
EXPERIMENT COURSE(2,2)
FELINE(2,2)
HAPTEN(2,2)
HISTOPATHOLOGY(2,2)
ISOLATED GENE PRODUCT(2,2)
LABELING COMPONENT(2,2)
LETHARGY(2,2)
LOBE(2,2)
LOG GROUP(2,2)
METHIONINE(2,2)
NECROPSY(2,2)
NITROCELLULOSE(2,2)
ORGANELLE(2,2)
PEN(2,2)
STABILIZER(2,2)
TEMPERATURE SENSITIVE PLASMID ORIGIN(2,2)
TRANSCRIPTION UNIT(2,2)
UPPER RESPIRATORY TRACT(2,2)
VIRAL INFECTION(2,2)
ACRYLIC POLYMER(2,1)
AGE DATE EVENT(2,1)
AMINOACID SPATIAL CONFORMATION(2,1)
ANTI LEUKOTOXIN MONOCLONAL ANTIBODY(2,1)
ANTIBODY ABILITY(2,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(2,1)
ANTIBODY PRODUCTION(2,1)
ANTIGENIC DETERMINANT SITE(2,1)
BEEF PRODUCTION(2,1)
BIOLOGICAL ACTIVITY(2,1)
CLONE(2,1)
COLUMBIA AGAR PLATE(2,1)
COMPARATIVE GENOMIC SEQUENCE ANALYSIS(2,1)
COMPETENT CELL(2,1)
DAY POST VAX(2,1)
DELETION SITE(2,1)
DIGESTED PREPARATION(2,1)
DOWNSTREAM REGULATORY SEQUENCE(2,1)
ECONOMIC LOSS(2,1)
ELICITED IMMUNE RESPONSE(2,1)
ENCODING SEQUENCE(2,1)
EXPERIMENTAL STUDY(2,1)
FUNCTIONAL ACYLASE(2,1)
FUNCTIONAL RNA(2,1)
GENBANK(2,1)
GENE CODING SEQUENCE(2,1)
GENE FRAGMENT(2,1)
GENE SEQUENCE(2,1)
GENOMIC MODIFICATION(2,1)
HOST CELL TRANSFORMATION(2,1)
IMMUNOGENIC COMPOSITION PRODUCTION(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
IMMUNOSTIMULATING SEQUENCE(2,1)
INFECTED ANIMAL(2,1)
INTRANASAL EXPOSURE(2,1)
INTRANASAL VACCINE COMBINATION(2,1)
LEUKOTOXOID INCREASED EXPRESSION(2,1)
LIFE MONTH(2,1)
LIGHT KILLED PASTEURELLA MULTOCIDA(2,1)
LINEAR EPITOPE(2,1)
LKTCA SEQUENCE(2,1)
LOGARITHMIC PHASE(2,1)
LUNG TISSUE(2,1)
MANNHEIMIA GLUCOSIDA(2,1)
METALLOENDOPEPTIDASE(2,1)
MODIFIED NUCLEOTIDE(2,1)
MOLECULAR CHARACTERIZATION(2,1)
NATIVE CODING SEQUENCE(2,1)
NATIVE SEQUENCE(2,1)
NATURAL COMPETENCE(2,1)
NON HEMOLYTIC COLONY(2,1)
NON HEMOLYTIC MUTANT(2,1)
NON METHYLATED CPG UNIT(2,1)
NUCLEOTIDE ANALOG(2,1)
ORGANISM CELL(2,1)
PHENOL CHLOROFORM(2,1)
PHOSPHATE BUFFER(2,1)
PIG DOSE VOLUME(2,1)
POLYADENYLATION SITE(2,1)
POVIDONE(2,1)
PRERUMINANT CALF(2,1)
PRIME BOOST(2,1)
PRODUCT SUPERNATANT(2,1)
PROTECTIVE IMMUNE RESPONSE(2,1)
PROTECTIVE IMMUNOLOGICAL RESPONSE(2,1)
PROTEIN ENRICHED FRACTION(2,1)
PVDF MEMBRANE(2,1)
RECOMBINANT TECHNOLOGY(2,1)
REDUCED NASOPHARYNGEAL COLONIZATION(2,1)
REPEAT SYRINGE(2,1)
REPRESENTATIVE COLONY(2,1)
REPRESENTATIVE MUTANT(2,1)
RESISTANCE CASSETTE(2,1)
RNA DNA HYBRID(2,1)
SECONDARY ANTIBODY(2,1)
SEQUENCE DIVERSITY(2,1)
SEQUENCE DNA ISOLATION(2,1)
SEQUENCE RNA ISOLATION(2,1)
SEVERE BACTERIAL PNEUMONIA(2,1)
SINGULAR TERM(2,1)
STRONG ANTISERA(2,1)
STRONG RBS(2,1)
SWINE(2,1)
SYNTHETIC ORIGIN(2,1)
TARGET ANTIGEN(2,1)
TARGET SPECIES(2,1)
TS ORI(2,1)
UNIQUE ECORI(2,1)
UNSUBSTITUTED PARENT AMINOACID(2,1)
VACCINATION DAY(2,1)
VACCINE MANUFACTURE(2,1)
VETERINARY ACCEPTABLE VEHICLE(2,1)
WHOLE ORGANISM(2,1)
WILD SHEEP(2,1)
ACETYLATION(1,1)
ACTIVE FRAGMENT(1,1)
ALKALINE PHOSPHATASE(1,1)
AMINOACID FAMILY(1,1)
AMINOACID SUBSTITUTION(1,1)
ANTI TOXIN(1,1)
ATTENUATION(1,1)
BACTERIA GROWTH RATE(1,1)
BACTERIAL ANTIGEN(1,1)
BACTERIAL PATHOGEN(1,1)
BACTERIN(1,1)
BARKER(1,1)
BIG(1,1)
BIOACTIVE COMPONENT(1,1)
CALF RESPONSE(1,1)
CANNULA(1,1)
CASSOWARY(1,1)
CENTRIFUGATION(1,1)
CHEETAH(1,1)
CHEMICAL MOIETY(1,1)
CHIEF COMPONENT(1,1)
COMPOSITION DOSE VOLUME(1,1)
CONSENSUS(1,1)
COYOTE(1,1)
CYSTINE(1,1)
(EP3384927)
VACCINE(100,40)
ANIMAL(100,23)
MANNHEIMIA HAEMOLYTICA(100,3)
DISEASE(100,2)
ATTENUATED MANHEIMIA HAEMOLYTICA VACCINE(100,1)
BACTERIA VIRULENCE ATTENUATION(37,2)
PNEUMONIC PASTEURELLOSIS(29,1)
HAEMOLITICA STRAIN(28,1)
HAEMOLITICA SEROTYPE(27,1)
BACTERIA(25,25)
ATTENUATED BACTERIA(25,5)
HAEMOLYTICA SEROTYPE(24,10)
BACTERIUM SECRETING(24,2)
MULTIVALENT VACCINE(24,2)
SEVERE SYSTEMIC DISEASE(24,1)
ATTENUATING MUTATION(23,2)
POLYPEPTIDE BIOLOGICAL ACTIVITY(23,2)
IMMUNODEFICIENT ANIMAL(23,1)
TITER ANTISERA(23,1)
NUCLEOTIDE SEQUENCE REPLICATION(22,1)
TRUNCATED LEUKOTOXIN(21,3)
BOOST VACCINATION(21,2)
ATTENUATED BACTERIAL VACCINE(21,1)
VACCINATION COLONIZATION MONITORING(21,1)
DNA REPLICATION(20,1)
VACCINE PREPARATION(18,1)
LKTCA GENE(17,2)
PROTECTIVE IMMUNITY(17,2)
SHIPPING FEVER(16,2)
BOVINE RESPIRATORY DISEASE(14,5)
MUTATION(12,7)
ENCODING ACYLASE(12,2)
NEGATIVE BACTERIA(12,2)
PROTECTING BOVINE(12,1)
VETERINARY ACCEPTABLE CARRIER(12,1)
HAEMOLYTICA STRAIN(11,7)
ANIMAL PRODUCTION(11,1)
RAPID DEVELOPMENT(11,1)
ADJUVANT(10,15)
EXCIPIENT(10,11)
STABILIZER(10,3)
DILUENT(9,6)
KIT(9,5)
AUTOMATED DIAGNOSTIC TEST KIT(9,1)
REPRODUCTION(9,1)
IMMUNE RESPONSE(8,8)
NASAL CAVITY(8,1)
NEED ELIMINATION(8,1)
HAEMOLYTICA(7,14)
DAY POST VACCINATION(7,7)
PASTEURELLA(7,6)
MANNHEIMIA(7,4)
MUTANT(7,4)
NECROTIZING BRONCHOPNEUMONIA(7,3)
STRAIN(7,3)
INFECTION DISEASE(7,2)
INTRANASAL COLONIZATION EFFICACY(7,2)
TRUNCATED LKTA SECRETION(7,2)
PROTEIN(6,21)
GENE(6,16)
COLONY(6,6)
VACCINATION(6,6)
VETERINARILY ACCEPTABLE CARRIER(6,5)
HAEMOLYTICA VACCINE(6,3)
PATENT LAW(6,2)
NEONATAL DAIRY CALF PNEUMONIA(6,1)
LUNG(5,6)
VECTOR(5,5)
ANTIBODY NEUTRALIZATION(5,4)
COLUMBIA BROTH(5,4)
VIAL(5,4)
WESTERN BLOT(5,4)
VACCINE EFFICACY(5,3)
VIRULENCE GENE(5,3)
FETAL BOVINE SERUM(5,2)
INACTIVATED BACTERIA FRACTION(5,2)
INTRANASAL VACCINATION(5,2)
PBCKAN LKTCARB(5,2)
PCT109GA189KAN LKTCARB(5,2)
PNEUMONIA SEVERE SIGN(5,2)
CATTLE INTRANASAL IMMUNIZATION(5,1)
LIVE MANNHEIMIA HAEMOLYTICA SEROTYPE(5,1)
PASTEURELLA HAEMOLYTICA SUBUNIT ANTIGEN(5,1)
RECOMBINANT MANNHEIMIA HAEMOLYTICA IMMUNOGENICITY(5,1)
PCR(4,12)
EXACT CFU(4,4)
LUNG LESION(4,3)
SAFE(4,3)
BACTERIAL LIPOPOLYSACCHARIDE(4,2)
CHIEF CYTOTOXIN(4,2)
IMMUNITY STIMULATION(4,2)
MUCOSAL ADJUVANT(4,2)
PNEUMONIC LESION(4,2)
RT QPCR(4,2)
ANTIGENIC POLYPEPTIDE VARIANT(4,1)
ATTENUATED MUTANT BACTERIUM(4,1)
BACTERIA PATHOGENICITY(4,1)
BCCT FAMILY BETAINE CARNITINE(4,1)
CHOLINE TRANSPORTER GENE(4,1)
COMMERCIAL VACCINE AUGMENTATION(4,1)
DEFIBRINATED SHEEP BLOOD(4,1)
DELETION MUTANT BACTERIUM(4,1)
FIELD IDENTIFICATION(4,1)
INTRATRACHEAL CHALLENGE EXPOSURE(4,1)
LEUKOTOXIC CULTURE SUPERNATANT(4,1)
LEUKOTOXIN DEFICIENT MANNHEIMIA HAEMOLYTICA(4,1)
LEUKOTOXIN OPERON MOLECULAR EVOLUTION(4,1)
LYOPHILIZED MANNHEIMIA HAEMOLYTICA(4,1)
MANNHEIMIA OVINE STRAIN(4,1)
MANNHEIMIA SEROTYPING(4,1)
NATIVE LKTA GENE(4,1)
PASTEURELLA HAEMOLYTICA TRANSFERRIN(4,1)
PASTEURELLACEAE PHYLOGENY(4,1)
PBC PLASMID BACKBONE(4,1)
TRANSTHORACIC CHALLENGE EXPOSURE(4,1)
TRUNCATED LKTA PROTEIN(4,1)
TRYPTICASE SOY AGAR(4,1)
VIRULENT PARENTAL BACTERIUM(4,1)
VIRULENT PARENTAL STRAIN(4,1)
WILD MAMMAL INFECTIOUS DISEASE(4,1)
FEED INTAKE(3,4)
EPITOPE MAPPING(3,3)
ACYLASE ENZYME(3,2)
AGE WEEK(3,2)
ATTENUATED STRAIN(3,2)
BOVINE HERPES VIRUS(3,2)
CHALLENGE ORGANISM(3,2)
COLUMBIA AGAR(3,2)
DELETION PCR(3,2)
FRESH GLYCEROL(3,2)
HISTOPATHOLOGICAL ANALYSIS(3,2)
IMMUNOGENIC FRAGMENT(3,2)
INACTIVATED VIRUS(3,2)
INFECTED HOST(3,2)
LEUKOTOXIN GENE(3,2)
LUNG INVOLVEMENT(3,2)
NUCLEOTIDE REPLACEMENT(3,2)
PCR AMPLIFICATION(3,2)
PROTEIN FRAGMENT(3,2)
STUDY SCHEDULE(3,2)
VACCINE STRAIN(3,2)
VETERINARY ACCEPTABLE VEHICLE(3,2)
AFFECTED CATTLE LUNG(3,1)
ARGININE SUBSTITUTION(3,1)
ATTENUATED MANNHEIMIA HAEMOLYTICA(3,1)
BEEF CATTLE SHIPPING FEVER(3,1)
BMC GENOMICS(3,1)
BOVINE PRACTITIONER(3,1)
BOVINE RESPIRATORY DISEASE PREVENTION(3,1)
BOVINE RESPIRATORY DISEASE VACCINE(3,1)
CALF NASAL SECRETION(3,1)
CALF VACCINATION(3,1)
CATTLE VACCINATION(3,1)
CLINICAL DISEASE SEVERITY(3,1)
CLINICAL SIGN CRITERIA(3,1)
CLINICAL SIGN GRAVITY(3,1)
COLI CLONING(3,1)
COMMENSAL ORGANISM(3,1)
CONCENTRATED CULTURE SUPERNATANT(3,1)
CONFORMATIONAL EPITOPE(3,1)
DAIRY HEIFER(3,1)
DELETED LEUKOTOXIN INSERT(3,1)
EFFICACIOUS VACCINE(3,1)
EXCLUSIVE COLONIZATION(3,1)
EXOTOXIN LEUKOTOXIN(3,1)
EXPERIMENTAL CHALLENGE EXPOSURE(3,1)
GENETICALLY DISTINCT ENTITY(3,1)
GOAT ANTI MOUSE(3,1)
HAEMOLYTICA BACTERIUM(3,1)
HAEMOLYTICA CHALLENGE(3,1)
HAEMOLYTICA COLONY(3,1)
HAEMOLYTICA INFECTION(3,1)
HAEMOLYTICA LESION(3,1)
HAEMOLYTICA MUTANT(3,1)
HETEROLOGOUS POLYNUCLEOTIDE(3,1)
HETEROLOGOUS PROMOTER(3,1)
HISTOPHILUS SOMNI(3,1)
HOST ANIMAL NEUTROPHIL(3,1)
HYDROPHOBIC RESIDUE SUBSTITUTION(3,1)
INFECTION PROPHYLAXIS(3,1)
KANAMYCIN CASSETTE(3,1)
KDA PREDICTED PROTEIN(3,1)
LEUKOTOXIN NEGATIVE ISOGENIC MUTANT(3,1)
LIVE GENE DELETED BACTERIUM(3,1)
LKTA TERMINAL DELETION(3,1)
LKTC RBS(3,1)
LKTCADELR PRIMER(3,1)
LOGARITHMIC GROWTH(3,1)
LOWERED VIRAL TITER(3,1)
MANNHEIMIA HAEMOLYTICA GENOME SEQUENCE(3,1)
METHYLATED NUCLEOTIDE(3,1)
MONOCLONAL ANTI LEUKOTOXIN ANTIBODY(3,1)
MUTANT BACTERIA(3,1)
MX3000P QPCR MACHINE(3,1)
NEONATAL DAIRY CATTLE(3,1)
ORAL ATTENUATED VACCINE(3,1)
PARTIALLY DELETED LKTA GENE(3,1)
PASTEURELLA HAEMOLYTICA ISOLATION(3,1)
PASTEURELLA TREHALOSI(3,1)
PASTEURELLACEAE GENETIC ENGINEERING(3,1)
PBC SALI SITE(3,1)
PCR KIT MASTER MIX(3,1)
POLAR RESIDUE SUBSTITUTION(3,1)
PROLONGED ITCHING(3,1)
PROTEIN IMMUNOGENICITY(3,1)
RECOMBINANT POLYNUCLEOTIDE(3,1)
REPLACEMENT PLASMID INTEGRATION(3,1)
REPLACEMENT PLASMID RESOLUTION EXCISION(3,1)
SEROTYPE BACTERIUM(3,1)
SHAM VACCINE(3,1)
STRAW BEDDING(3,1)
SUSCEPTIBLE BOVINE ANIMAL(3,1)
TRANSTRACHEAL ADMINISTRATION(3,1)
TRIMETHYLATED CHITOSAN(3,1)
TRUNCATED LKTCA(3,1)
UNSUBSTITUTED POLYPEPTIDE(3,1)
VACCINE INTRANASAL ADMINISTRATION(3,1)
VIRULENT CHALLENGE(3,1)
VIRULENT PARENT STRAIN(3,1)
BA PLATE(2,3)
INTRON(2,3)
CALF SHOWING CLINICAL SIGN(2,2)
HUMANE REASON(2,2)
POST CHALLENGE(2,2)
PROTECTIVE IMMUNE RESPONSE(2,2)
QUANTITATIVE PCR(2,2)
REMAINING INOCULUM(2,2)
ALKENYL DERIVATIVE POLYMER(2,1)
ANNUAL BOOSTER(2,1)
ANTI LEUKOTOXIN MONOCLONAL ANTIBODY(2,1)
ANTIBODY 2C(2,1)
ANTIGENIC DETERMINANT SITE(2,1)
BRANCHED POLYNUCLEOTIDE(2,1)
BROAD PROTECTIVE IMMUNITY(2,1)
CATIONIC LIPID(2,1)
CHALLENGED ANIMAL(2,1)
CLONE(2,1)
COLI DH11S(2,1)
COMMERCIAL EXPERIMENTAL EVALUATION(2,1)
COMPETENT CELL(2,1)
COMPLEX GENETIC MACHINERY(2,1)
CONSERVATIVE REPLACEMENT(2,1)
CROSS PROTECTION(2,1)
DAY POST VAX(2,1)
DELETION MUTATION ENGINEERING(2,1)
DELETION SITE(2,1)
DIFCO LABORATORY(2,1)
DOWNSTREAM REGULATORY SEQUENCE(2,1)
EFFICACY EVALUATION(2,1)
ELICITED IMMUNE RESPONSE(2,1)
EXPERIMENTAL STUDY(2,1)
FEEDLOT CALF(2,1)
FINAL LKTCA MUTANT(2,1)
FUNCTIONAL ACYLASE(2,1)
GENBANK(2,1)
GENE FRAGMENT(2,1)
GENOMIC MODIFICATION(2,1)
GENOMIC SEQUENCE DELETION(2,1)
GENTLE SHAKING(2,1)
HAEMOLYTICA LKTCABD OPERON SHOWING(2,1)
HAEMOLYTICA VIRULENCE FACTOR(2,1)
HEALTHY CATTLE(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
IMMUNOSTIMULATING SEQUENCE(2,1)
INFECTED ANIMAL(2,1)
INOCULATION SITE(2,1)
INTRANASAL EXPOSURE(2,1)
INTRANASAL VACCINE COMBINATION(2,1)
LESION REVIEW(2,1)
LEUKOTOXIN CA(2,1)
LEUKOTOXIN MOLECULAR EVOLUTION(2,1)
LIFE MONTH(2,1)
LIVE VACCINE(2,1)
LKTA ACTIVATION(2,1)
LKTCA SEQUENCE(2,1)
LKTRBSR PRIMER(2,1)
LUNG TISSUE(2,1)
LYOPHILIZED CULTURE(2,1)
MANUFACTURER INSTRUCTION(2,1)
MASTER SEED(2,1)
MODIFIED LIVE LEUKOTOXIN(2,1)
MODIFY LIVE MICROORGANISM(2,1)
MOLECULAR CHARACTERIZATION(2,1)
NASAL SWAB(2,1)
NATIVE CODING SEQUENCE(2,1)
NATURAL COMPETENCE(2,1)
NUCLEOTIDE ANALOG(2,1)
NUCLEOTIDE BRANCH(2,1)
OLIGODEOXYRIBONUCLEOTIDE SEQUENCE(2,1)
ORGANISM CELL(2,1)
OUTER MEMBRANE PROTEIN PLPE(2,1)
PARENTERAL ADMINISTRATION(2,1)
PCR PRODUCT ELECTROPHORESIS(2,1)
PHENOL CHLOROFORM(2,1)
PIG DOSE VOLUME(2,1)
PLURAL REFERENT(2,1)
POLYNUCLEOTIDE SEGMENT(2,1)
POLYPEPTIDE FRAGMENT(2,1)
PRIME BOOST(2,1)
PROTEIN TBPA(2,1)
PTA LKTCA(2,1)
QUANTITECT PROBE(2,1)
RECIPIENT STRAIN(2,1)
RECOMBINANT TECHNOLOGY(2,1)
RECOMBINANT VECTOR(2,1)
REDUCED NASOPHARYNGEAL COLONIZATION(2,1)
REPEAT SYRINGE(2,1)
REPRESENTATIVE COLONY(2,1)
REPRESENTATIVE MUTANT(2,1)
RUMINANT RESPIRATORY TRACT RESPONSE(2,1)
SDS GEL(2,1)
SEQUENCE RNA ISOLATION(2,1)
SEVERE BACTERIAL PNEUMONIA(2,1)
SPT EMULSION(2,1)
TARGET ANTIGEN(2,1)
TS ORI(2,1)
UNCHARGED POLAR(2,1)
UNMETHYLATED LIGATION PRODUCT(2,1)
VECTOR ADMINISTRATION(2,1)
VECTOR PRESERVATION(2,1)
VIRULENT STRAIN(2,1)
WEANED BEEF(2,1)
WILD SHEEP(2,1)
BIOLOGICALLY SIMILAR RESIDUE(1,4)
DILUTION(1,4)
NASAL DISCHARGE(1,4)
RPMI(1,4)
EXON(1,3)
LANE(1,3)
ANOREXIA(1,2)
ASPARAGINE(1,2)
BACTERIAL GENOME(1,2)
BACTERIAL TOXIN(1,2)
BHI MEDIUM(1,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(1,2)
CHEMICAL SYNTHESIS(1,2)
CONJUGATION(1,2)
CONSENSUS(1,2)
DYSPNEA(1,2)
ENCODED AMINOACID RESIDUE(1,2)
EUTHANIZE(1,2)
EXPERIMENT COURSE(1,2)
FELINE(1,2)
GLUTAMINE(1,2)
HAPTEN(1,2)
HISTOPATHOLOGY(1,2)
ILLNESS(1,2)
ISOLATED GENE PRODUCT(1,2)
ISOLEUCINE(1,2)
LABELING COMPONENT(1,2)
LETHARGY(1,2)
LOBE(1,2)
LOG GROUP(1,2)
METHIONINE(1,2)
NECROPSY(1,2)
NITROCELLULOSE(1,2)
NOSTRIL(1,2)
ORGANELLE(1,2)
PEN(1,2)
PHENYLALANINE(1,2)
TEMPERATURE SENSITIVE PLASMID ORIGIN(1,2)
TRYPTOPHAN(1,2)
TYROSINE(1,2)
UPPER RESPIRATORY TRACT(1,2)
VIRAL INFECTION(1,2)
ACETYLATION(1,1)
ACRYLIC POLYMER(1,1)
ACTIVE FRAGMENT(1,1)
AGE DATE EVENT(1,1)
ALKALINE PHOSPHATASE(1,1)
ALUMINUM HYDROXIDE(1,1)
ALUMINUM PHOSPHATE(1,1)
AMINOACID FAMILY(1,1)
AMINOACID RESIDUE POLYMER(1,1)
AMINOACID SPATIAL CONFORMATION(1,1)
ANTI TOXIN(1,1)
ANTIBODY ABILITY(1,1)
ANTIBODY GENERATION(1,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(1,1)
ANTIBODY PRODUCTION(1,1)
ASPARTATE(1,1)
ATTENUATION(1,1)
BACTERIA GROWTH RATE(1,1)
BACTERIAL ANTIGEN(1,1)
BACTERIAL PATHOGEN(1,1)
BACTERIN(1,1)
BARKER(1,1)
BEEF PRODUCTION(1,1)
BIG(1,1)
BIOACTIVE COMPONENT(1,1)
BIOLOGICAL ACTIVITY(1,1)
CALF RESPONSE(1,1)
CANNULA(1,1)
COMPARATIVE GENOMIC SEQUENCE ANALYSIS(1,1)
COMPOSITION ADMINISTRATION(1,1)
DIGESTED PREPARATION(1,1)
ECONOMIC LOSS(1,1)
FUNCTIONAL RNA(1,1)
GENE SEQUENCE(1,1)
IMMUNOGENIC COMPOSITION PRODUCTION(1,1)
IMMUNOGENIC RESPONSE(1,1)
KANAMYCIN RESISTANCE CASSETTE(1,1)
KANAMYCIN RESISTANCE GENE(1,1)
LEUKOTOXOID INCREASED EXPRESSION(1,1)
LIGHT KILLED PASTEURELLA MULTOCIDA(1,1)
LINEAR EPITOPE(1,1)
LOGARITHMIC PHASE(1,1)
MANNHEIMIA GLUCOSIDA(1,1)
METALLOENDOPEPTIDASE(1,1)
MODIFIED NUCLEOTIDE(1,1)
NATIVE SEQUENCE(1,1)
NON HEMOLYTIC COLONY(1,1)
NON HEMOLYTIC MUTANT(1,1)
NUCLEIC ACID DELETION(1,1)
PHOSPHATE BUFFER(1,1)
PRERUMINANT CALF(1,1)
PRODUCT SUPERNATANT(1,1)
PROTECTIVE IMMUNOLOGICAL RESPONSE(1,1)
PROTEIN ENRICHED FRACTION(1,1)
QUATERNARY AMMONIUM SALT(1,1)
RNA DNA HYBRID(1,1)
SECONDARY ANTIBODY(1,1)
SEQUENCE DIVERSITY(1,1)
SEQUENCE DNA ISOLATION(1,1)
SINGULAR TERM(1,1)
STRONG ANTISERA(1,1)
STRONG RBS(1,1)
SWINE(1,1)
SYNTHETIC ORIGIN(1,1)
TARGET SPECIES(1,1)
UNIQUE ECORI(1,1)
UNSUBSTITUTED PARENT AMINOACID(1,1)
VACCINE MANUFACTURE(1,1)
WHOLE ORGANISM(1,1)
(US20160158336)
VACCINE(100,32)
ATTENUATED MANNHEIMIA HAEMOLYTICA VACCINE(100,1)
DELETION MUTANT BACTERIUM MIXTURE(100,1)
DELETION MUTANT BACTERIUM(84,3)
HAEMOLYTICA STRAIN(60,10)
BACTERIA VIRULENCE ATTENUATION(52,1)
ATTENUATED STRAIN(51,8)
LKTCA GENE(48,1)
ATTENUATED MANNHEIMIA HAEMOLYTICA(45,1)
VIRULENT PARENTAL STRAIN(40,2)
PNEUMONIC PASTEURELLOSIS(39,1)
ENCODING ACYLASE(34,1)
POLYPEPTIDE BIOLOGICAL ACTIVITY(32,1)
SEVERE SYSTEMIC DISEASE(32,1)
MUTANT BACTERIA(31,2)
ATTENUATING MUTATION(31,1)
IMMUNODEFICIENT ANIMAL(31,1)
TITER ANTISERA(31,1)
VACCINE PROTECTIVE INTRANASAL DOSE(31,1)
NUCLEOTIDE SEQUENCE REPLICATION(29,1)
BOOST VACCINATION(28,2)
VACCINATION COLONIZATION MONITORING(28,1)
DNA REPLICATION(26,1)
STRAIN(25,9)
HAEMOLYTICA VACCINE(25,3)
ATTENUATED PASTEURELLA MULTOCIDA(25,1)
HAEMOLYTICA SEROTYPE(24,9)
INACTIVATED BACTERIA FRACTION(24,2)
VIRULENCE GENE(24,2)
VACCINE PREPARATION(24,1)
BOVINE RESPIRATORY DISEASE PREVENTION(23,1)
HAEMOPHILUS SOMNI(23,1)
PROTECTIVE IMMUNE RESPONSE(21,3)
MULTIVALENT VACCINE(21,2)
LEUKOTOXIN(20,6)
NUCLEIC ACID DELETION(20,1)
BACTERIAL LIPOPOLYSACCHARIDE(19,2)
BOVINE(18,12)
DELETION(18,10)
BACTERIA(17,20)
VETERINARILY ACCEPTABLE CARRIER(17,5)
SHIPPING FEVER(17,2)
INACTIVATED VIRUS(16,2)
RAPID DEVELOPMENT(15,1)
ANIMAL(14,19)
HAEMOLYTICA(14,10)
VETERINARY ACCEPTABLE VEHICLE(14,2)
AUTOMATED DIAGNOSTIC TEST KIT(13,1)
DISEASE(13,1)
REPRODUCTION(13,1)
EXCIPIENT(11,9)
KIT(10,5)
SAFE(10,4)
NECROTIZING BRONCHOPNEUMONIA(10,3)
INTRANASAL COLONIZATION EFFICACY(10,2)
NASAL CAVITY(10,1)
NEED ELIMINATION(10,1)
DAY POST VACCINATION(9,7)
COLONY(9,6)
MUTATION(9,5)
MUTANT(9,4)
TRUNCATED LKTA SECRETION(9,2)
NUCLEIC ACID SEQUENCE(8,4)
BACTERIAL TOXIN(8,2)
LKTA PROTEIN TRUNCATED FORM(8,2)
PATENT LAW(8,2)
NEONATAL DAIRY CALF PNEUMONIA(8,1)
PROTEIN(7,17)
GENE(7,11)
LUNG(7,6)
VECTOR(7,5)
ANTIBODY NEUTRALIZATION(7,4)
COLUMBIA BROTH(7,4)
VIAL(7,4)
PCT109GA189KAN LKTCARB(7,2)
CATTLE INTRANASAL IMMUNIZATION(7,1)
HAEMOLYTICA SEROTYPE AI(7,1)
PASTEURELLA HAEMOLYTICA SUBUNIT ANTIGEN(7,1)
RECOMBINANT MANNHEIMIA HAEMOLYTICA IMMUNOGENICITY(7,1)
LUNG LESION(6,3)
VACCINE EFFICACY(6,3)
WESTERN BLOT(6,3)
CHIEF CYTOTOXIN(6,2)
FETAL BOVINE SERUM(6,2)
INTRANASAL VACCINATION(6,2)
PBCKAN LKTCARB(6,2)
PNEUMONIA SEVERE SIGN(6,2)
RT QPCR(6,2)
TRUNCATED LEUKOTOXIN(6,2)
BCCT FAMILY BETAINE CARNITINE(6,1)
VIRULENT PARENTAL BACTERIUM(6,1)
WILD MAMMAL INFECTIOUS DISEASE(6,1)
DILUENT(5,4)
EXACT CFU(5,4)
ACYLASE ENZYME(5,2)
BOVINE HERPES VIRUS(5,2)
CHALLENGE ORGANISM(5,2)
COLUMBIA AGAR(5,2)
DELETION PCR(5,2)
IMMUNITY STIMULATION(5,2)
IMMUNOGENIC FRAGMENT(5,2)
LEUKOTOXIN GENE(5,2)
LUNG INVOLVEMENT(5,2)
MUCOSAL ADJUVANT(5,2)
NUCLEOTIDE REPLACEMENT(5,2)
PCR AMPLIFICATION(5,2)
PNEUMONIC LESION(5,2)
ANTIGENIC POLYPEPTIDE VARIANT(5,1)
ATTENUATED MUTANT BACTERIUM(5,1)
BACTERIA PATHOGENICITY(5,1)
CHOLINE TRANSPORTER GENE(5,1)
COMMERCIAL VACCINE AUGMENTATION(5,1)
DEFIBRINATED SHEEP BLOOD(5,1)
FIELD IDENTIFICATION(5,1)
INTRATRACHEAL CHALLENGE EXPOSURE(5,1)
LEUKOTOXIC CULTURE SUPERNATANT(5,1)
LEUKOTOXIN DEFICIENT MANNHEIMIA HAEMOLYTICA(5,1)
LEUKOTOXIN OPERON MOLECULAR EVOLUTION(5,1)
LYOPHILIZED MANNHEIMIA HAEMOLYTICA(5,1)
MANNHEIMIA HAEMOLYTICA SEROTYPE(5,1)
MANNHEIMIA OVINE STRAIN(5,1)
MANNHEIMIA SEROTYPING(5,1)
NATIVE LKTA GENE(5,1)
PASTEURELLA HAEMOLYTICA TRANSFERRIN(5,1)
PASTEURELLACEAE PHYLOGENY(5,1)
PBC PLASMID BACKBONE(5,1)
PBC SALL SITE(5,1)
TRANSTHORACIC CHALLENGE EXPOSURE(5,1)
TRYPTICASE SOY AGAR(5,1)
FEED INTAKE(4,4)
EPITOPE MAPPING(4,3)
AGE WEEK(4,2)
AMINOACID SEQUENCE(4,2)
FRESH GLYCEROL(4,2)
HISTOPATHOLOGICAL ANALYSIS(4,2)
INFECTED HOST(4,2)
PROTEIN FRAGMENT(4,2)
ARGININE SUBSTITUTION(4,1)
BACTERIUM SECRETING(4,1)
BEEF CATTLE SHIPPING FEVER(4,1)
BMC GENOMICS(4,1)
BOVINE PRACTITIONER(4,1)
BOVINE RESPIRATORY DISEASE VACCINE(4,1)
CALF NASAL SECRETION(4,1)
CALF VACCINATION(4,1)
CATTLE LUNG(4,1)
CATTLE VACCINATION(4,1)
CLINICAL DISEASE SEVERITY(4,1)
CLINICAL SIGN GRAVITY(4,1)
COLI CLONING(4,1)
COMMENSAL ORGANISM(4,1)
CONCENTRATED CULTURE SUPERNATANT(4,1)
CONFORMATIONAL EPITOPE(4,1)
DAIRY HEIFER(4,1)
DELETED LEUKOTOXIN INSERT(4,1)
EFFICACIOUS VACCINE(4,1)
EXCLUSIVE COLONIZATION(4,1)
EXOTOXIN LEUKOTOXIN(4,1)
EXPERIMENTAL CHALLENGE EXPOSURE(4,1)
GENETICALLY DISTINCT ENTITY(4,1)
GOAT ANTI MOUSE(4,1)
HAEMOLYTICA BACTERIUM(4,1)
HAEMOLYTICA COLONY(4,1)
HAEMOLYTICA INFECTION(4,1)
HAEMOLYTICA LESION(4,1)
HAEMOLYTICA MUTANT(4,1)
HAEMOPHILUS SOMNUS(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
HETEROLOGOUS PROMOTER(4,1)
HISTOPHILUS SOMNI(4,1)
HOST ANIMAL NEUTROPHIL(4,1)
HYDROPHOBIC RESIDUE SUBSTITUTION(4,1)
INFECTION PROPHYLAXIS(4,1)
KANAMYCIN CASSETTE(4,1)
KDA PREDICTED PROTEIN(4,1)
LEUKOTOXIN NEGATIVE ISOGENIC MUTANT(4,1)
LIVE MANNHEIMIA(4,1)
LKTA TERMINAL DELETION(4,1)
LKTC RBS(4,1)
LKTCADELR PRIMER(4,1)
LOGARITHMIC GROWTH(4,1)
LOWERED VIRAL TITER(4,1)
MANNHEIMIA HAEMOLYTICA GENOME SEQUENCE(4,1)
METHYLATED NUCLEOTIDE(4,1)
MONOCLONAL ANTI LEUKOTOXIN ANTIBODY(4,1)
MX3000P QPCR MACHINE(4,1)
NEONATAL DAIRY CATTLE(4,1)
ORAL ATTENUATED VACCINE(4,1)
PASTEURELLA HAEMOLYTICA ISOLATION(4,1)
PASTEURELLA TREHALOSI(4,1)
PASTEURELLACEAE GENETIC ENGINEERING(4,1)
PCR KIT MASTER MIX(4,1)
PCT109GA189KAN 1KTCA(4,1)
POLAR RESIDUE SUBSTITUTION(4,1)
PROTEIN IMMUNOGENICITY(4,1)
RECOMBINANT POLYNUCLEOTIDE(4,1)
SEROTYPE BACTERIUM(4,1)
SHAM VACCINE(4,1)
STRAW BEDDING(4,1)
SUSCEPTIBLE BOVINE ANIMAL(4,1)
TRANSTRACHEAL ADMINISTRATION(4,1)
TRIMETHYLATED CHITOSAN(4,1)
TRUNCATED LKTCA(4,1)
UNSUBSTITUTED POLYPEPTIDE(4,1)
VACCINE INTRANASAL ADMINISTRATION(4,1)
VIRULENT CHALLENGE(4,1)
VIRULENT PARENT STRAIN(4,1)
BA PLATE(3,3)
INTRON(3,3)
TERM GENE(3,3)
CALF SHOWING CLINICAL SIGN(3,2)
NEGATIVE BACTERIA(3,2)
POST CHALLENGE(3,2)
QUANTITATIVE PCR(3,2)
REMAINING INOCULUM(3,2)
ALKENYL DERIVATIVE POLYMER(3,1)
ANNUAL BOOSTER(3,1)
ATTENUATED BACTERIAL VACCINE(3,1)
BRANCHED POLYNUCLEOTIDE(3,1)
BROAD PROTECTIVE IMMUNITY(3,1)
CATIONIC LIPID(3,1)
CHALLENGED ANIMAL(3,1)
COLI DH11S(3,1)
COMMERCIAL EXPERIMENTAL EVALUATION(3,1)
COMPLEX GENETIC MACHINERY(3,1)
CONSERVATIVE REPLACEMENT(3,1)
CROSS PROTECTION(3,1)
DELETION MUTATION ENGINEERING(3,1)
DIFCO LABORATORY(3,1)
EFFICACY EVALUATION(3,1)
FEEDLOT CALF(3,1)
FINAL LKTCA MUTANT(3,1)
GENOMIC SEQUENCE DELETION(3,1)
GENTLE SHAKING(3,1)
HAEMOLYTICA VIRULENCE FACTOR(3,1)
HEALTHY CATTLE(3,1)
IMMUNOGENIC PROTEIN(3,1)
LESION REVIEW(3,1)
LEUKOTOXIN CA(3,1)
LEUKOTOXIN MOLECULAR EVOLUTION(3,1)
LIVE VACCINE(3,1)
LKTA ACTIVATION(3,1)
LKTRBSR PRIMER(3,1)
LYOPHILIZED CULTURE(3,1)
MANUFACTURER INSTRUCTION(3,1)
MODIFIED LIVE LEUKOTOXIN(3,1)
NASAL SWAB(3,1)
NUCLEOTIDE BRANCH(3,1)
OLIGODEOXYRIBONUCLEOTIDE SEQUENCE(3,1)
PARENTERAL ADMINISTRATION(3,1)
PLURAL REFERENT(3,1)
POLYNUCLEOTIDE SEGMENT(3,1)
PROTEIN TBPA(3,1)
PTA LKTCA(3,1)
QUANTITECT PROBE(3,1)
RECIPIENT STRAIN(3,1)
RECOMBINANT VECTOR(3,1)
RESPIRATORY DISEASE PREVENTION(3,1)
RUMINANT RESPIRATORY TRACT RESPONSE(3,1)
SPT EMULSION(3,1)
UNMETHYLATED LIGATION PRODUCT(3,1)
VACCINE STRAIN(3,1)
VECTOR ADMINISTRATION(3,1)
VECTOR PRESERVATION(3,1)
VIRULENT STRAIN(3,1)
WEANED BEEF(3,1)
BIOLOGICALLY SIMILAR RESIDUE(2,4)
DILUTION(2,4)
RPMI(2,4)
EXON(2,3)
ASPARAGINE(2,2)
BHI MEDIUM(2,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(2,2)
CHEMICAL SYNTHESIS(2,2)
CONJUGATION(2,2)
CONSENSUS(2,2)
ENCODED AMINOACID RESIDUE(2,2)
EXPERIMENT COURSE(2,2)
FELINE(2,2)
GLUTAMINE(2,2)
HAPTEN(2,2)
HISTOPATHOLOGY(2,2)
ISOLATED GENE PRODUCT(2,2)
ISOLEUCINE(2,2)
LABELING COMPONENT(2,2)
LETHARGY(2,2)
LOBE(2,2)
LOG GROUP(2,2)
METHIONINE(2,2)
NITROCELLULOSE(2,2)
NOSTRIL(2,2)
ORGANELLE(2,2)
PEN(2,2)
PHENYLALANINE(2,2)
STABILIZER(2,2)
TEMPERATURE SENSITIVE PLASMID ORIGIN(2,2)
TRYPTOPHAN(2,2)
TYROSINE(2,2)
UPPER RESPIRATORY TRACT(2,2)
VIRAL INFECTION(2,2)
ACRYLIC POLYMER(2,1)
ALUMINUM PHOSPHATE(2,1)
AMINOACID SPATIAL CONFORMATION(2,1)
ANTI LEUKOTOXIN MONOCLONAL ANTIBODY(2,1)
ANTIBODY 2C(2,1)
ANTIBODY ABILITY(2,1)
ANTIBODY GENERATION(2,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(2,1)
ANTIBODY PRODUCTION(2,1)
ANTI(...)";"Basic materials chemistry
Biotechnology
Pharmaceuticals";Open
2012-09-25;"RU2504400           C1 2014-01-20 [RU2504400]
STG: (C1) Patent for invention
AP : 2012RU-0140989 2012-09-25";61170586;RU2504400           C1 2014-01-20 [RU2504400];2012RU-0140989;;FEDERAL NOE G BJUDZHETNOE UCHREZHDENIE FEDERAL NYJ TS OKHRANY ZDOROV JA ZHIVOTNYKH FGBU VNIIZZH;FEDERAL NOE G BJUDZHETNOE UCHREZHDENIE FEDERAL NYJ TS OKHRANY ZDOROV JA ZHIVOTNYKH FGBU VNIIZZH;;;1;"MISHCHENKO VLADIMIR ALEKSANDROVICH
KONONOVA SVETLANA VLADIMIROVNA
KONONOV ALEKSANDR VLADIMIROVICH
DUMOVA VIKTORIJA VALENTINOVNA
KORPUSOVA TAT JANA IVANOVNA";;;"(RU2504400)
Inactivated emulsion associated vaccine for cattle parainfluenza-3, infectious rhinotracheitis and viral diarrhoea";"(RU2504400)
FIELD: medicine.SUBSTANCE: invention refers to veterinary virology and biotechnology. The vaccine contains an active substance and a target additive. As the active substance, the vaccine contains a mixture of an avirulent purified antigen material of the strain VGNKI-4 of PI-3 virus of the family Paramyxoviridae, the genus Parainfluenza, the subtype Parainfluenza virus 3, the collection of VGNKI No. VGNKI-4-DEP, of an avirulent purified antigen material of the strain VNIIZZh of cattle IRT virus of the family Herpesviridae, the genus Varicellavirus, of the collection of VGNKI VNIIZZh-DEP and of an avirulent purified antigen material of the strain NADL-VNIIZZh of cattle VD virus of the family Flaviviridae, of genus Pestivirus, of the collection FGU VGNKI NADL-VNIIZZh- DEP. The strains are taken in the relation of 1:1:1 in the amounts to provide the protective immune activity of each antigen in an animal's body after the target preparation is introduced.EFFECT: vaccine induces the high antibody level in immunised animals; the immunity in the immunised animals is formed 10-15 days after the repeated introduction of the vaccine and preserved for at least 6 months; when the above antigens are combined, a synergetic effect is observed that enables reducing the quantity of antigens in the preparations with the preserved and continuous immunity.27 cl, 9 tbl, 4 ex";"(RU2504400)
1. Vaccine associated against parainfluenza -3 (PG-3), infectious rhino-tracheitis (ИРТ) and virus diarrhea (ВД) of large livestock (КРС) emulsion inactivated, that contains active material and purposeful additives, that is characterized by the fact that as the active material it contains mixture from the avirulent purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, seven. Paramyxoviridae, the kind Of Parainfluenza, subtype Of Parainfluenza of virus 3, the collection VGNKI “OF VGNKI-4” - DEP, from the avirulent purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, seven. Herpesviridae, the kind Of Varicellavirus, the collection VGNKI “OF VNIIZZH-DEP” and from the avirulent purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, seven. Flaviviridae, the kind Of Pestivirus, the collection FGU “OF VGNKI” “OF NADL-VNIIZZH” - DEP, in an effective quantity.
2. Vaccine according to claim 1, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of the cells of mammals, in an effective quantity.
3. Vaccine according to claim 2, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of the cells of Syrian small hamster (VNK-21), in an effective quantity.
4. Vaccine according to claim 3, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of cells VNK-21 with the infectious activity not less than 6,5 lg TTSD [50] of /sm (3) and by the hemagglutinating activity is not below 5,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
5. Vaccine according to claim 2, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of the cells of the kidney of calf (MDBK), in an effective quantity.
6. Vaccine according to claim 5, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of cells MDBK with the infectious activity not less than 6,5 lg TTSD [50] of /sm (3) and by the hemagglutinating activity is not below 5,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
7. Vaccine according to claim 2, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of the cells of the kidney of calf (Taurus-2), in an effective quantity.
8. Vaccine according to claim 7, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VGNKI-4” of the virus PG-3 KRS, obtained in the interwoven culture of the cells Of Taurus-2 with the infectious activity not less than 6,5 lg TTSD [50] of /sm (3) and by the hemagglutinating activity is not below 5,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
9. Vaccine according to claim 1, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of the cells of mammals, in an effective quantity.
10. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of the cells of the gonad of goat (Ch-91), in an effective quantity.
11. Vaccine according to claim 10, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of the cells Of Ch-91 with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) before the inactivation, in quantity 10,0 mas.%.
12. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of cells MDBK, in an effective quantity.
13. Vaccine according to claim 12, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of cells MDBK with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) before the inactivation, in quantity 10,0 mas.%.
14. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of cells RBT, in an effective quantity.
15. Vaccine according to claim 14, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF VNIIZZH” of the virus IRT KRS, obtained in the interwoven culture of cells RBT with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) before the inactivation, in quantity 10,0 mas.%.
16. Vaccine according to claim 1, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of the cells of mammals, in an effective quantity.
17. Vaccine according to claim 16, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of the cells Of Taurus-2, in an effective quantity.
18. Vaccine according to claim 17, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of the cells Of Taurus-2 with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 6,65 logs [2] before the inactivation, in quantity 10,0 mas.%.
19. Vaccine according to claim 16, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of cells RBT, in an effective quantity.
20. Vaccine according to claim 19, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of cells RBT with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 6,65 logs [2] before the inactivation, in quantity 10,0 mas.%.
21. Vaccine according to claim 16, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of the cells of the kidney of saiga (ПС), in an effective quantity.
22. Vaccine according to claim 21, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven culture of cells PS with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 6,65 logs [2] before the inactivation, in quantity 10,0 mas.%.
23. Vaccine according to claim 1, that is characterized by the fact that from the purposeful additives it contains oil adjuvant.
24. Vaccine according to claim 23, that is characterized by the fact that it contains oil adjuvant in quantity 69,6 mas.%.
25. Vaccine according to claim 1, that is characterized by the fact that from the purposeful additives it contains additionally adjuvant saponin.
26. Vaccine according to claim 25, that is characterized by the fact that it contains saponin in quantity 0,4 mas.%.
27. Vaccine on any of pp. 1÷26, which is characterized by the fact that as the active material it contains the mixture of the avirulent and purified antigenic materials from the strain “OF VGNKI-4” of the virus PG-3 KRS, from the strain “OF VNIIZZH” of the virus IRT KRS and from the strain “OF NADL-VNIIZZH” of the virus VD KRS, obtained in the interwoven cultures of the cells of mammals, and the purposeful additives oil adjuvant and saponin in the relationship, mas.%:
28. Avirulent and purified antigenic material: :
from the strain “OF VGNKI-4” of the virus PG-3 KRS: :
obtained in the interwoven culture of the cells: :
be mammalianing, undertaken from the group, which contains: :
the culture of cells MDBK, the culture of cells VNK-21: :
and the culture of the cells Of Taurus-2 with the infectious: :
by activity not less than 6,5 lg TTSD [50] of /sm (3) and: :
by the hemagglutinating activity: :
not less than 5,0 logs [2] before the inactivation: 10,0:
Avirulent and purified antigenic material: :
from the strain “OF VNIIZZH” of the virus IRT KRS: :
obtained in the interwoven culture of the cells: :
be mammalianing, undertaken from the group, which contains: :
the culture of cells MDBK, the culture of the cells Of Ch-91 and: :
the culture of cells RBT with the infectious: :
by activity not less than 6,0 lg TTSD [50] of /sm (3) to: :
the inactivation: 10,0:
Avirulent and purified antigenic material: :
from the strain “OF NADL-VNIIZZH” of the virus VD KRS: :
obtained in the interwoven culture of the cells: :
be mammalianing, undertaken from the group, which contains: :
the culture of the cells Of Taurus-2, the culture of cells RBT: :
and the culture of cells PS with the infectious: :
by activity not less than 6,0 lg TTSD [50] of /sm (3) and: :
by activity in IFA not less than 6,65 logs [2] to: :
the inactivation: 10,0:
Oil adjuvant: 69,6:
Saponin: 0,4. :";;;"A61K-039/12
A61K-039/15
A61K-039/155
A61K-039/265
A61K-039/295";;;Pharmaceuticals;Open
2012-09-17;"RU2012139766        A  2014-03-27 [RU2012139766]
STG: (A) Application for invention
AP : 2012RU-0139766 2012-09-17
RU2515058           C1 2014-05-10 [RU2515058]
STG: (C1) Patent for invention
AP : 2012RU-0139766 2012-09-17";65036062;"RU2012139766        A  2014-03-27 [RU2012139766]
RU2515058           C1 2014-05-10 [RU2515058]";2012RU-0139766;;FEDERAL NOE G BJUDZHETNOE UCHREZHDENIE FEDERAL NYJ TS OKHRANY ZDOROV JA ZHIVOTNYKH FGBU VNIIZZH;FEDERAL NOE G BJUDZHETNOE UCHREZHDENIE FEDERAL NYJ TS OKHRANY ZDOROV JA ZHIVOTNYKH FGBU VNIIZZH;;;1;"MISHCHENKO VLADIMIR ALEKSANDROVICH
KONONOVA SVETLANA VLADIMIROVNA
KONONOV ALEKSANDR VLADIMIROVICH
DUMOVA VIKTORIJA VALENTINOVNA
KORPUSOVA TAT JANA IVANOVNA";;;"(RU2515058)
Associated inactivated emulsion bovine viral diarrhoea, rotavirus and coronavirus infections vaccine";"(RU2515058)
FIELD: medicine.SUBSTANCE: invention refers to veterinary virology and biotechnology, and concerns a bovine viral diarrhoea, rotavirus and coronavirus infections vaccine. The described vaccine contains an active substance and a target additive. As the active substance, the vaccine contains a mixture of an avirulent purified antigen material of the strain NADL-VNIIZZh-DEP of bovine viral diarrhoea of the family Flaviviridae, of the genus Pestivirus, an avirulent purified antigen material of the strain 101 VNIIZZh-DEP of bovine rotavirus of the family Reoviridae, of the genus Rotavirus, and an avirulent purified antigen material of the strain VNIIZZh-DEP of bovine coronavirus of the family Coronaviridae, of the genus Coronaivirus deposited in the Russian National Collection of Microorganism Strains used in veterinary science and animal industry. The strains are taken in the relation of 1:1:1 in the amounts to provide the protective immune activity of each antigen in an animal's body after the target preparation is introduced.EFFECT: vaccine induces a high antibody concentration and provides the expressed and long-lasting immunity in the immunised animals .31 cl, 9 tbl, 5 ex";"(RU2515058)
1. The Vaccine, associated against virus diarrhea (ВД), rotavirusnoy and koronavirusnoy infections of large livestock (КРС), emulsion inactivated, that contains active material and purposeful additives, that is characterized by the fact that as the active material it contains mixture from the avirulent purified antigenic material from the strain VD KRS, deposited in The All-Russian state collection of the strains of microorganisms, utilized in veterinary science and stock raising of № OF NADL-VNIIZZH-DEP, seven. Flaviviridae, the kind Of Pestivirus, from the avirulent purified antigenic material from the strain of rotavirusa KRS, deposited in The All-Russian state collection of the strains of microorganisms, utilized in veterinary science and stock raising of № 101 VNIIZZH-DEP, seven. Reoviridae, the kind Of Rotavirus and from the avirulent purified antigenic material from the strain of the corona virus KRS, deposited in The All-Russian state collection of the strains of microorganisms, utilized in veterinary science and stock raising of № VNIIZZH-DEP, seven. Coronaviridae, the kind Of Coronaivirus, in an effective quantity.
2. Vaccine according to claim 1, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of the cells of mammals, in an effective quantity.
3. Vaccine according to claim 2, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of the cells of the kidney of calf (Taurus-2), in an effective quantity.
4. Vaccine according to claim 3, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of the cells Of Taurus-2 with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 6,65 1og [2] before the inactivation, in quantity 10,0 mas.%.
5. Vaccine according to claim 2, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of the cells of the kidney of calf (RBT), in an effective quantity.
6. Vaccine according to claim 5, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of cells RBT with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 6,65 log [2] before the inactivation, in quantity 10,0 mas.%.
7. Vaccine according to claim 2, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of the cells of the kidney of saiga (ПС), in an effective quantity.
8. Vaccine according to claim 7, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of cells PS with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 6,65 log [2] before the inactivation, in quantity 10,0 mas.%.
9. Vaccine according to claim 1, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells of mammals, in an effective quantity.
10. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells of the kidney of the embryo of pig (SPEV), in an effective quantity.
11. Vaccine according to claim 10, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of cells SPEV with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 4,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
12. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells Of Taurus-2, in an effective quantity.
13. Vaccine according to claim 12, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells Of Taurus-2 with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 4,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
14. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells Of Vero, in an effective quantity.
15. Vaccine according to claim 14, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells of the kidney of green marmoset (Vero) with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 4,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
16. Vaccine according to claim 9, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells Of Mars-145, in an effective quantity.
17. Vaccine according to claim 16, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells of the kidney of the embryo of macaco (Mars-145) with the infectious activity not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA is not less than 4,0 log [2] before the inactivation, in quantity 10,0 mas.%.
18. Vaccine according to claim 1, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of the cells of mammals, in an effective quantity.
19. Vaccine according to claim 18, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of cells RBT, in an effective quantity.
20. Vaccine according to claim 19, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of cells RBT with the infectious activity not less than 5,0 lg TTSD [50] of /sm (3) and by activity in RGA is not less than 8,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
21. Vaccine according to claim 18, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of cells MDBK, in an effective quantity.
22. Vaccine according to claim 21, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of cells MDBK with the infectious activity not less than 5,0 lg TTSD [50] of /sm (3) and by activity in RGA is not less than 8,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
23. Vaccine according to claim 18, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of the cells Of Taurus-2, in an effective quantity.
24. Vaccine according to claim 23, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of the cells Of Taurus-2 with the infectious activity not less than 5,0 lg TTSD [50] of /sm (3) and by activity in RGA is not less than 8,0 log [2] before the inactivation, in quantity 10,0 mas.%.
25. Vaccine according to claim 18, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of the cells Of Vero, in an effective quantity.
26. Vaccine according to claim 25, that is characterized by the fact that it contains the avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of the cells Of Vero with the infectious activity not less than 5,0 lg TTSD [50] of /sm (3) and by activity in RGA is not less than 8,0 logs [2] before the inactivation, in quantity 10,0 mas.%.
27. Vaccine according to claim 1, that is characterized by the fact that from the purposeful additives it contains oil adjuvant.
28. Vaccine according to claim 27, that is characterized by the fact that it contains oil adjuvant in quantity 69,6 mas.%.
29. Vaccine according to claim 1, that is characterized by the fact that from the purposeful additives it contains additionally adjuvant saponin.
30. Vaccine according to claim 29, that is characterized by the fact that it contains saponin in quantity 0,4 mas.%.
31. Vaccine on any of pp. 1-30, that is characterized by the fact that as the active material it contains the mixture of the avirulent and purified antigenic materials from the strain VD KRS of №NADL-VNIIZZh-DEP, from the strain of rotavirusa KRS of №101 VNIIZZH-DEP and from the strain of the corona virus KRS of №VNIIZZh-DEP, obtained in the interwoven cultures of the cells of the mammals and the purposeful additives oil adjuvant and saponin in the relationship, mas.%:
32. The Avirulent and purified antigenic material from the strain OF NADL-VNIIZZH-DEP VD KRS, obtained in the interwoven culture of the cells of mammals, undertaken from the group, which contains the culture of the cells Of Taurus-2, the culture of cells RBT the culture of cells PS with the infectious activity is not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA not less than 6,65 logs [2] before the inactivation: 10,0:
The Avirulent and purified antigenic material from the strain 101 VNIIZZH-DEP of rotavirusa KRS, obtained in the interwoven culture of the cells of mammals, undertaken from the group, which contains the culture of cells SPEV, the culture of the cells Of Taurus-2, the culture of the cells Of Vero and the culture of the cells Of Mars-145 with the infectious activity is not less than 6,0 lg TTSD [50] of /sm (3) and by activity in IFA not less than 4,0 logs [2] before the inactivation: 10,0:
The Avirulent and purified antigenic material from the strain VNIIZZH-DEP of the corona virus KRS, obtained in the interwoven culture of the cells of mammals, undertaken from the group, which contains the culture of cells RBT, the culture of cells MDBK, the culture of the cells Of Taurus-2 and the culture of the cells Of Vero with the infectious activity is not less than 5,0 lg TTSD [50] of /sm (3) and by activity in RGA not less than 8,0 log2 before the inactivation: 10,0:
Oil adjuvant, in the quantity: 69,6:
Saponin, in the quantity: 0,4:";;;"A61K-039/15
A61K-039/215
A61K-039/295
C12N-007/00";;;Pharmaceuticals;Open
"2012-09-11
2013-09-11
2017-09-28";"WO2014043215        A1 2014-03-20 [WO201443215]
STG: (A1) Published application with search report
AP : 2013WO-US59235 2013-09-11
US20140079704       A1 2014-03-20 [US20140079704]
STG: (A1) Application published
AP : 2013US-14024019 2013-09-11
FD :  Provisional Appl: US61/699,563 FDD=2012-09-11 [2012US-61699563]
US20180094046       A1 2018-04-05 [US20180094046]
STG: (A1) Application published
AP : 2017US-15718385 2017-09-28
FD :  Continuation of: US14/024,019 FDD=2013-09-11 [2013US-14024019]
FD : Provisional Appl: US61/699,563 FDD=2012-09-11 [2012US-61699563]";64758040;"WO2014043215        A1 2014-03-20 [WO201443215]
US20140079704       A1 2014-03-20 [US20140079704]
US20180094046       A1 2018-04-05 [US20180094046]";"2012US-61699563
2013US-14024019
2017US-15718385";;TEXAS A & M UNIVERSITY;TEXAS A & M UNIVERSITY;"(US20140079704)
US
(US20180094046)
US
(WO201443215)
US";"(US20140079704)
NAME=The Texas A&M University System , CITY=College Station , STATE=TX , COUNTRY=US , ATYP=US Company 

(US20180094046)
NAME=The Texas A&M University System , CITY=College Station , STATE=TX , COUNTRY=US 

(WO201443215)
NAME=THE TEXAS A&M UNIVERSITY SYSTEM 3369 Tamu College Station, TX 77843-3369 , POSTCODE=77843-3369 , COUNTRY=US 
";1;"MWANGI WAITHAKA
WAGHELA SURYA
BERGHMAN LUC";"(US20180094046)
US";"(US20180094046)
NAME=Mwangi Waithaka , CITY=College Station , STATE=TX , COUNTRY=US 

NAME=Waghela Surya , CITY=College Station , STATE=TX , COUNTRY=US 

NAME=Berghman Luc , CITY=College Station , STATE=TX , COUNTRY=US 
";"(US20180094046)
Mosaic chimeric viral vaccine{[s]] particle";"(US20180094046)
The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.";"(WO201443215)
1. A bi-speciho di hodv comprising a viral antigen binding moiety fused in- frame wish a cell surface antigen binding moiety. 
 The diabody of Claim 1, wherein said viral antigen binding moiety is a single chain antibody moieeole thai binds to bovine viral diarrhea virus. 
 The diabody of Claim 2»wherein said single chain antibody molecule binds to the bov e viral diarrhea vims protein E2. 
 The diabody of Claim 1, wherein said ceil surface antigen binding moiety is a single ehai» antibody motecule that binds to dendritic cells. 
 The diabody of Claim 4, wherein said single chain antibody molecule binds to the bovine CD205 ar igeu receptor. 
 A composition comprising a recombinant adenovirus that expresses Pli3L;GM~ CSF and CD40I, 
 A composition compri sing a vaccine bound to the br-speeifk diabody of Claim 1. 
 The composition of Claim 7* wherein said vaccine is & bovine viral diarrhea virus I. vaccine. 
 The composition of Claim 7, wherein said, vaccine is a bovine viral diarrhea vims 2 vaccine. 
 The composition of Claim ?. wherein said vaccine is a mixtarc of bovine viral diarrhea virus I and bovine viral diarrhea virus 2 vaccines. The -composition of Claim 7, wherein said vaccine is a live vaccine. 
 The composition of Claim 1 1 , wherein said live vaccine is a modified live accine. 
 The composition of Claim ?, wherein said vaccine is a live vectored vaccine. A composition composing; 
 a) a vaccine bound to the hi-speciiic diabody of Claim C and 
 b) a. recombinant adenovirus that expresses Ph3L;GM-CSF and CD40L. 
 The composition of Claim 14, wherein said vaccine is a bovine viral diarrhea vims 1 vaccine. 
 The composition of Claim 14, wherein said vaccine is a. bo vine viral diarrhea vims 2 vaccine. 
 The composition, of Claim 1.4. wherein said vaccine is a mixture of bovine viral diarrhea, virus 1 and bovine viral diarrhea virus 2 vaccines. 
 The composition of Claim 14, wherein said vaccine is a live vaccine. 
 The composition of Claim 1 8, wherein said live vaccine is a modified live vaccine. 
 The composition of Claim 1 , wherein said vaccine is a live vectored vaccine. 
 A method, comprising: 
 a) providing: 
 i) a subject at r sk fo infection by a virus, and 
 ii) a vaccine bound to the bi-specific diabody of Claim. 1 ; and b) admkustermg said vaccine bound to said bi-speciftc diabody to said subject under conditions such that protective immunity s induced. 
 The method of Claim 2 ! , wherein said subject is a bovine. 
 The method of Claim 2 L wherein said subject is a neonatal calf 
 The method of Claim 21, wherein said subject has neutralizing antibodies for sa virus prior to administering said vaccine, 
 The method of Claim 24, wherein said neutralizing antibodies are maternal antibodies. 
 The method of Claim 24, wherein said neutralizing antibodies are bovine viral diarrhea virus 1 -specific antibodies. 
 The method of Claim 24, wherein said neutralising antibodies are bovine viral diarrhea virus 2-s eeir c antibodies. 
 The method of Claim 21 , wherein said vaccine is a bovine viral diarrhea virus 1 vaccine. 
 The method of Claim 21, wherein said vaccine is a bovine viral diarrhea virus 2 vaccine. 
 The method of Claim 21 , wherein said vaccine is a mixture of bo vine viral diarrhea virus 1 and bovine viral di rrhea virus 2 vaccines. 
 The method of Claim 21, wherein sai vaccine is a live vaccine, 
 The method of Claim. 31, wherein said live vaccine is a modified li ve vaccine. The method of Claim 21, wherein said vaccine is a li ve vectored vaccme. 
 A method, comprising: 
 a) providing; 
 i) a subject at risk for infection by a virus, 
 ii) a vaccine bound to the bi-specine diabod of Claim 1, and in) a. recombtna^t adenovirus that expresses F!t3L» GM-CSF and
 CD40L; and 
 b) administering said vaccine bound & said bi-specitlc diabody to said subject under conditions such that protective immunity is induced. 
 The method of Claim 34, wherein said subject is a bo viae. 
 The method of Claim 34, wherein said subject is a neonate! calf 
 The method of Claim 34, wherein said, vaccine is a bovine viral diarrhea virus 1. vaccine. 
 The method of Claim 34, wherein said vaccine is a bovine viral diarrhea virus 2 vaccine. 
 The method of Claim. 34. wherein said vaccine is a mixture of bovine viral diarrhea virus 1. and bovine viral, diarrhea, virus 2 vaccines. 
 The method of Claim 34»wherein said vaccine is a live vaccine. 
 The method of Claim 40, wherein said live vaccine is a modified live vaccine. 
 The method of Claim 34, wherein said vaccine is a live vectored vaccine. The method of Claim 34, wherein said subject has neutralising antibodies for said prior to administering said vaccine.";"(US20180094046)
In one embodiment, the present invention contemplates masking a MLV BVDV vaccine to protect it against complement lysis and thus allow targeting of the virus to the relevant antigen-presenting cells (APCs) for optimal induction of adaptive immunity.
In one embodiment, the present invention contemplates a vectored live vaccine expressing chimeric genes encoding protective BVDV antigens optimized for induction of robust effector/memory CD4+and CD8+ T cell responses that will induce cell-mediated immunity in neonatal calves in the presence of neutralizing maternal antibodies.
The present invention relates generally to the field of live and modified live, conventional and recombinant, vaccines.";"(US20180094046)
Consequently, there is a need to generate alternative BVDV vaccines that are efficacious, safe, cost-effective, and nonsusceptible to BVDV-specific antibody neutralization.
A significant proportion of cattle entering feedyards are PI, and since a chute side test to identify these individuals is currently unavailable these calves pose a great risk to unprotected cattle (12, 13).
Classical BVDV infections cause severe diarrhea and respiratory disease, which is the most common cause of morbidity and mortality in feedyards (1).
Despite their ability to induce long lasting neutralizing antibodies and cell-mediated immunity, MLV vaccines have been known to cause mucosal disease, immunosuppression and in utero infections.
MLV vaccines against BVDV prime protective antibody and T cell immunity but their efficacy is limited until neutralizing antibody levels have waned.";"A61K-035/76
A61K-039/00
A61K-039/42
C07K-016/08
C07K-016/10
C07K-016/28";"(US20180094046)
1. A mosaic chimeric viral vaccine particle comprising a plurality of antigenic sites derived from two or more of the bovine viral diarrhea virus proteins selected from the group consisting of Npror, capsid, Ems, E1, E2, NS2 and NS3.
18. A viral vaccine particle comprising at least one antigenic site, said at least one antigenic site is selected from the group consisting of Npro, capsid, Ems, E1, E2, NS2 and NS3.";"(US20140079704)
BISPECIFIC DIABODY(100,13)
VACCINE TARGET(100,1)
VACCINE(84,102)
RECOMBINANT LIVE VECTORED VACCINE(83,1)
ANTIBODY NEUTRALIZATION(82,35)
CLASSICAL BVDV INFECTION(82,1)
RECOMBINANT ADENOVIRUS(73,20)
VACCINE BOUND(60,4)
UNPROTECTED CATTLE(56,1)
MLV VACCINE(54,18)
MODIFIED LIVE VACCINE(52,8)
SEVERE DIARRHEA(45,1)
NEONATAL CALF IMMUNIZATION(43,11)
UTERO INFECTION(43,2)
CATTLE SIGNIFICANT PROPORTION(41,1)
PROTECTIVE ANTIBODY(41,1)
FEEDYARD(36,2)
MASKING MOTIF(34,11)
ANTIGENIC MOLECULE(33,4)
LONG LASTING NEUTRALIZING ANTIBODY(31,1)
MOIETY(30,26)
MASKING VACCINE(30,3)
VIRAL ANTIGEN(28,12)
DENDRITIC CELL RECRUITMENT(28,10)
MLV BVDV VACCINE VIRUS(28,3)
BOVINE VIRAL DIARRHEA VIRUS PROTEIN(27,1)
IMMUNE RESPONSE EFFICACY(26,3)
VIRUS(25,25)
BVDV(24,83)
CHIMERIC BVDV ANTIGEN(24,5)
NEONATAL CALF INTRADERMAL INOCULATION(24,2)
CELL MEDIATED IMMUNITY(23,12)
CELL IMMUNITY(23,10)
ANTI BVDV POLYCLONAL ANTIBODY(23,7)
EVADING NEUTRALIZING ANTIBODY(23,4)
MASKED MLV BVDV VACCINE(23,2)
MORTALITY(23,1)
RESPIRATORY DISEASE(23,1)
ANTIGENIC DETERMINANT(22,3)
IMMUNOSUPPRESSION(22,3)
CD40L(21,31)
FACTOR ACTIVATION(21,6)
TARGET ANTIGEN(20,10)
MORBIDITY COMMON CAUSE(20,1)
GMCSF(19,20)
AD CYTOKINE(19,9)
VIRAPOWER ADENOVIRAL GATEWAY(19,2)
RECOMBINANT ANTIGEN(18,8)
BVDV VACCINE IMMUNOGENICITY(18,2)
CONTEMPORARY BVDV VACCINE(18,2)
MUCOSAL DISEASE(18,2)
NON TARGETED BVDV ANTIGEN(18,2)
POLYVALENT DIABODY SCAFFOLD(18,2)
PROTECTIVE BVDV ANTIGEN CHIMERA(18,2)
BVDV STRAIN(17,6)
ADENOVIRUS VECTORED VACCINE(17,4)
ANTIBODY MEDIATED COMPLEMENT LYSIS(17,4)
CALF(16,22)
EFFICACY(16,5)
MLV VACCINE VIRION(16,2)
YOUNG SERONEGATIVE CALF IMMUNIZATION(16,1)
SINGLE CHAIN ANTIBODY MOLECULE(15,6)
VIRUS NEUTRALIZING(15,5)
DC ANTIGEN TARGETING(15,4)
VACCINE RECRUIT DENDRITIC CELL(15,3)
ACUTE BVDV INFECTION RESOLUTION(15,2)
BVDV NEUTRALIZATION ASSAY(15,2)
NEUTRALIZING ANTIBODY DECLINE(15,2)
PERSISTENT ANTIGEN STIMULUS(15,2)
BVDV NEUTRALIZING ANTIBODY TITER(15,1)
NEUTRALIZING MATERNAL ANTIBODY DECAY(15,1)
FLT3L GMCSF(14,21)
MOTIF(14,17)
PEPTIDE LINKER(14,5)
VIRUS VACCINE PARTICLE(14,3)
ADENOVIRUS VECTORED BVDV VACCINE(14,1)
BVDV VACCINE FORMULATION EFFICACY(14,1)
TARGETED MOSAIC BVDV ANTIGEN(14,1)
RECEPTOR(13,6)
1101 MATCHED CALF(13,4)
INTRADERMAL IMMUNIZATION SITE(13,2)
BVDV NEUTRALIZING MAB(13,1)
HYPOXANTHINE AMINOPTERIN THYMIDINE(13,1)
MULTICOMPONENT CHIMERIC BVDV(13,1)
RECOMBINANT ADENOVIRUS PFU DOSE(13,1)
BVDV MIXTURE(12,8)
ROBUST IFN(12,5)
AGE MATCHED NEONATAL CALF(12,2)
NEUTRALIZING ANTIBODY TARGET(12,2)
RECEPTOR MEDIATED ANTIGEN UPTAKE(12,2)
VACCINE CONTAMINATION RISK(12,2)
MAB TH97A(11,3)
ROBUST EFFECTOR MEMORY INDUCTION(11,3)
ANTIGENIC EPITOPE(11,2)
IC IR DIABODY(11,2)
SECRETING HYBRIDOMA(11,2)
EVADING ANTIBODY NEUTRALIZATION(11,1)
IMMUNOGENIC BVDV ANTIGEN(11,1)
KILLED BVDV VACCINE(11,1)
MARGINALE MSP1 ANTIGEN(11,1)
MLV BVDV EFFICACY(11,1)
PRE MADE SCFV ANTIBODY PHAGE(11,1)
RECOMBINANT VACCINIA VIRUS VECTOR(11,1)
SECONDARY BIOTINYLATED GOAT ANTI MOUSE(11,1)
USDA NASS STATISTICS(11,1)
IMMUNE(10,5)
CELL DETERMINANT(10,4)
FOREIGN ANTIGEN(10,3)
LIVE VIRUS(10,3)
ADVENTITIOUS VIRUS(10,2)
BVDV ANTIGEN LOADED DCS(10,2)
CD40L CYTOKINE(10,2)
DC ANTIGEN UPTAKE(10,2)
DC VACCINE INTERACTION(10,2)
LIVE VECTORED BVDV(10,2)
MOSAIC CHIMERA(10,2)
MOUSE SCFV MODULE(10,2)
POTENT MOLECULAR ADJUVANT(10,2)
ANTI FLAG AP CONJUGATED MAB(10,1)
BVDV ANTIGEN SPECIFICITY(10,1)
BVDV IMMUNE COW(10,1)
CHIMERIC MOSAIC ANTIGEN(10,1)
DRAINING LYMPHOID ORGAN(10,1)
EXPRESS BVDV ANTIGEN(10,1)
KDA PRECURSOR POLYPROTEIN(10,1)
MOSAIC CHIMERIC ANTIGEN(10,1)
TARGETED MLV VACCINE(10,1)
VACCINE OPTIMIZATION STRATEGY(10,1)
VECTORED LIVE VACCINE(10,1)
98 348BVDV VACCINE(9,5)
BVDV SPECIFIC NEUTRALIZING ANTIBODY(9,5)
IMMUNOCYTOCHEMISTRY(9,5)
205 TARGETED ANTIGEN(9,3)
CELL CYTOTOXICITY(9,3)
EXTENSIVE WASHING(9,3)
FREESTYLE CELL(9,3)
PROTECTIVE TITER(9,3)
BVDV INFECTED CELL(9,2)
CAPSID PROTEIN(9,2)
CELL MEDIATED CYTOTOXICITY ASSAY(9,2)
CELLULAR PATHWAY(9,2)
COSTIMULATORY MOLECULE(9,2)
DIFFERENCE NULL HYPOTHESIS(9,2)
DIVERSE MHC(9,2)
IFN SECRETION(9,2)
IMMATURE DCS(9,2)
IMMUNITY INDUCTION(9,2)
LIVE CHALLENGE(9,2)
NPRO ANTIGEN(9,2)
POST VACCINATION INTERVAL(9,2)
SCFV MOTIF(9,2)
AFFINITY NEUTRALIZING ANTIBODY(9,1)
ANTIGEN MICROARRAY ASSAY(9,1)
BVD VIRUS STRAIN(9,1)
CHUTE SIDE(9,1)
CYTOKINE ARC FLT3L(9,1)
INTRACELLULAR SIGNALING EVENT CASCADE(9,1)
INTRADENNAL IMMUNIZATION SITE(9,1)
MASK MLV VACCINE(9,1)
MOSAIC CHIMERIC POLYPEPTIDE SEQUENCE(9,1)
MOUSE HYBRIDOMA CLONE(9,1)
PASSIVE IMMUNITY DECLINE(9,1)
PROTECTIVE IMMUNITY PRIMING(9,1)
PURIFIED GOAT ANTI MOUSE(9,1)
RECEPTOR ABUNDANCE(9,1)
RECOMBINANT ADENOVIRUS ENCODING(9,1)
RECOMBINANT FUSION POLYPEPTIDE(9,1)
RECOMBINANT LIVE VACCINE(9,1)
SEQUENCED BVDV POLYPEPTIDE SEQUENCE(9,1)
TRANSIENT PASSIVE IMMUNITY(9,1)
BVDV SPECIFIC IMMUNE RESPONSE(8,17)
VACCINE FORMULATION SINGLE DOSE(8,7)
ANTIGEN PRESENTATION(8,4)
CELL EPITOPE(8,4)
CELL PRIMING(8,4)
DENDRITIC CELL ACTIVATION(8,4)
DIFFERENCE SIGNIFICANCE(8,4)
MOUSE MODEL(8,4)
SOLUBILITY(8,3)
CATTLE INDUSTRY(8,2)
ADENOVIRUS EXPRESSED BVDV ANTIGEN(8,1)
ANTI FLAG AGAROSE GEL(8,1)
ANTI FLAG AGAROSE RESIN(8,1)
BOVINE DC RECRUITMENT(8,1)
BVD VIRUS PROTECTION(8,1)
BVDV NEUTRALIZING ANTIBODY PRESENCE(8,1)
BVDV POLYPROTEIN(8,1)
BVDV SUBUNIT VACCINE(8,1)
BVDV VACCINE PROTECTION(8,1)
CC98MSP MINIMAL DOSE(8,1)
CHIMERIC GENE ENCODING(8,1)
COMMERCIAL BVDV VACCINE(8,1)
COMMERCIAL MLV VACCINE(8,1)
CONJUGATE TARGET BVDV(8,1)
CURRENT BVDV MLV VACCINE(8,1)
CYTOKINE ADENOVIRUS(8,1)
EUKARYOTIC EXPRESSION VECTOR(8,1)
EXPRESSED FLT3L BIOLOGICAL ACTIVITY(8,1)
EXTRACELLULAR ABUNDANCE(8,1)
HIGHLY SPECIALIZED PROFESSIONAL APCS(8,1)
HYPOTHESIS REJECTION(8,1)
IMMUNOGLOBULIN SPECIFICITY(8,1)
LOCAL CD40L SECRETION(8,1)
MDBK MONOLAYER(8,1)
NEONATAL CALF PROTECTION(8,1)
NEONATE IMMUNIZATION(8,1)
NONIMMUNOGENIC ANTIGEN(8,1)
OVINE BORDER DISEASE VIRUS(8,1)
POLYBODY SCAFFOLD(8,1)
PRO INFLAMMATORY CYTOKINE PRODUCTION(8,1)
QUANTITATIVE IMMUNOHISTOCHEMISTRY(8,1)
REPLICATION DEFECTIVE ADENOVIRUS VECTOR(8,1)
ROBUST DC RECRUITMENT(8,1)
STIMULATED LYMPHOBLAST(8,1)
STONEYPOINT AGRICORP(8,1)
VACCINE IMMUNIZATION(8,1)
YEARLING(7,6)
ADENOVIRUS SINGLE DOSE(7,5)
CTL RESPONSE(7,5)
CELL RECEPTOR(7,3)
DISEASE INDEX(7,3)
AFFINITY CHROMATOGRAPHY(7,2)
COATED VIRION(7,2)
COLOSTRUM DERIVED ANTIBODY(7,2)
EPITOPE(7,2)
EXPRESSION KIT(7,2)
FRESH PBMCS(7,2)
FUNCTIONAL ANTIGEN(7,2)
IC VARIABLE DOMAIN(7,2)
PROTEIN PURIFICATION(7,2)
ROBUST IMMUNE RESPONSE(7,2)
VACCINE DEVELOPMENT(7,2)
ACUTE INFECTION RESOLUTION(7,1)
ADAPTIVE IMMUNITY OPTIMAL INDUCTION(7,1)
ADCD40L VIRUS(7,1)
ADENOVIRUS GENOME(7,1)
ADLUCIFERASE VIRUS(7,1)
ANTI CANCER VACCINE(7,1)
ANTIGEN BOOST(7,1)
ANTIGEN REPERTOIRE(7,1)
AUTOLOGOUS BVDV(7,1)
BACTERIAL EXPRESSION VECTOR(7,1)
BIOLOGICALLY ACTIVE ADENOVIRUS PARTICLE(7,1)
BISPECIFIC ANTIBODY FRAGMENT(7,1)
BOVINE IGG RESIDUE(7,1)
BVDV EPITOPE(7,1)
BVDV IMMUNITY(7,1)
BVDV INCUBATION(7,1)
BVDV REPLICATION(7,1)
CATTLE HERD(7,1)
CHIMERA PURIFICATION(7,1)
CHIMERIC ADENOVIRUS(7,1)
CONTEMPORARY VACCINE(7,1)
CURRENT BVDV VACCINE EFFICACY(7,1)
CYTOKINE SECRETION(7,1)
CYTOKINE SUPPRESSION(7,1)
DCS MATURATION(7,1)
DIFFERENTIATION INDUCTION(7,1)
EMPTY VACCINE VECTOR(7,1)
ENDOSOME LYSOSOME COMPARTMENT(7,1)
EPITOPE PRESENTATION(7,1)
EVOLUTIONARY HISTORY(7,1)
FLAG(7,1)
FLAVIVIRIDAE FAMILY(7,1)
GENE DOWNREGULATION(7,1)
HEMAGGLUTININ(7,1)
HUMAN CVM PROMOTER(7,1)
HYDROPHILIC DOMAIN CONSERVED REGION(7,1)
IMMUNODOT BLOT(7,1)
INOCULATING CALF(7,1)
INTRANASAL INOCULATION(7,1)
INVENTOR PREVIOUS(7,1)
IRRELEVANT SCFV(7,1)
KILLED WHOLE BVDV(7,1)
MAB ANTIBODY(7,1)
MDBK CELL MONOLAYER(7,1)
MHC MOLECULE CONTEXT(7,1)
MLV VACCINE DIRECTED MASKING(7,1)
MSP1 CHIMERA(7,1)
NEONATAL CALF SIGNIFICANT PROPORTION(7,1)
NONSTRUCTURAL PROTEIN(7,1)
NPRO CAPSID(7,1)
PLASMID DNA ENCODING(7,1)
POLY HISTIDINE(7,1)
POTENTIAL MEC POOL(7,1)
POWERFUL INDUCER(7,1)
PRIME NA VE(7,1)
PRO INFLAMMATORY MOLECULE(7,1)
RAD LUCIFERASE(7,1)
RECOMBINANT DIABODY PRODUCTION(7,1)
RIC SCFV(7,1)
SUBUNIT ANTIGEN(7,1)
SUSTAINED ANTIGEN UPTAKE PRESENCE(7,1)
TERMINAL CD5 SECRETORY(7,1)
TLR SIGNALING(7,1)
UNCONJUGATED MAB(7,1)
VACCINE INACTIVATION(7,1)
VACCINE VEHICLE ATTRACTIVENESS(7,1)
VACCINE VIRUS PROTECTION(7,1)
VIRAL VACCINE PARTICLE ANTIGEN(7,1)
VIRUS TARGETING(7,1)
WEEK POST IMMUNIZATION(7,1)
CELL FUSION(6,5)
CD40L DIRECTED DC ACTIVATION(6,4)
BVDV SPECIFIC ANTIBODY NEUTRALIZATION(6,2)
CLONE 2C(6,2)
CODING SEQUENCE(6,2)
IFN PRODUCTION(6,2)
LC DERIVED DCS(6,2)
LINKER SEQUENCE(6,2)
RECALL RESPONSE ANALYSIS(6,2)
SEPARATE ASYMMETRIC PCR(6,2)
VULNERABILITY PERIOD(6,2)
205 TRANSFECTED 293A CELL(6,1)
ADAPTIVE IMMUNITY INITIATION(6,1)
ADENOVIRUS EXPRESSED CYTOKINE(6,1)
ANIMAL AGRICULTURE(6,1)
ANIMAL IMMUNIZATION(6,1)
ANIMAL SPLEEN(6,1)
ANTIGEN ACQUISITION(6,1)
ANTIGEN CAPTURE(6,1)
ANTIGEN PARTICLE(6,1)
ANTIGENIC PEPTIDE(6,1)
BIFUNCTIONAL CAPABILITY(6,1)
BOVINE CD40L(6,1)
BROADLY REPRESENTATIVE MOSAIC(6,1)
BVDV GENOME(6,1)
BVDV PROTEIN(6,1)
BVDV REACTIVE PBMCS(6,1)
BVDV1 PEPTIDE(6,1)
CAPSID ANTIGEN(6,1)
CDNA ENCODING(6,1)
CELL IMMUNOCYTOMETRIC ANALYSIS(6,1)
CELL PEPTIDE MOTIF(6,1)
CIRCULATING EFFECTOR(6,1)
COMPLEMENT MEDIATED LYSIS(6,1)
COMPREHENSIVE REPRESENTATION(6,1)
CPG MOTIF(6,1)
CPG ODN(6,1)
CTL EPITOPE(6,1)
CULTURE SUPERNATANT(6,1)
CYTOKINE EXPRESSION(6,1)
CYTOKINE INDUCTION(6,1)
DEPENDENT DC RECRUITMENT(6,1)
DERMAL DCS(6,1)
DIABODY DRUG(6,1)
DOMESTIC PET(6,1)
DOSE ESCALATION(6,1)
DRAINING LYMPH NODE(6,1)
ELISPOT ASSAY(6,1)
ENCODING NUCLEOTIDE(6,1)
EXOGENOUS ANTIGEN(6,1)
EXOGENOUS GENE(6,1)
EXPRESS CYTOKINE(6,1)
FETAL INFECTION(6,1)
FLAG TAGGED RCC(6,1)
FLAG TAGGED VACCINE(6,1)
GENUS PESTIVIRUS MEMBER(6,1)
GLOBULAR PROTEIN(6,1)
GLYCOPROTEIN MOLECULE(6,1)
HELPER ROLE(6,1)
HEPATITIS VIRAL ANTIGEN(6,1)
HYBRID POLYPEPTIDE(6,1)
HYBRID VACCINE(6,1)
IC 348BVDV VACCINE(6,1)
IGG2B MAB(6,1)
IMMUNE CATTLE(6,1)
IMMUNIZED ANIMAL(6,1)
INFECTED CELL CLEARANCE(6,1)
ISOTYPE MATCHED MAB(6,1)
KILLED VACCINE(6,1)
LABELED ANTI FLAG(6,1)
LINKER INTRODUCTION(6,1)
LIVE BVDV(6,1)
LOOSE IMMUNOGENICITY(6,1)
MACROPHAGE ACTIVATION(6,1)
MASKED VACCINE(6,1)
MATERNAL ANTIBODY NEUTRALIZING LEVEL(6,1)
MILLION CATTLE(6,1)
NEUTRALIZING ANTIBODY DECAY RATE(6,1)
NONCYTOPATHIC STRAIN(6,1)
OPTIMAL PROTEIN EXPRESSION(6,1)
OPTIMAL VACCINE(6,1)
ORGANISM SPECIES(6,1)
OVERLAP EXTENSION PCR(6,1)
PACKARD GAMMA COUNTER(6,1)
PARENTAL PROTEIN(6,1)
PEPTIDE ANTIGEN(6,1)
PHAGE DISPLAY LIBRARY(6,1)
POTENT ADJUVANT(6,1)
PRO BVDV(6,1)
PROLIFERATION ASSAY(6,1)
PROTECTIVE COLOSTRUM DERIVED BVDV(6,1)
PROTEIN CATEGORY(6,1)
PROTEIN EXPRESSION VECTOR(6,1)
RABBIT COMPLEMENT(6,1)
RECOMBINANT BOVINE(6,1)
REPRODUCTIVE DISEASE(6,1)
ROBUST ADAPTIVE IMMUNITY(6,1)
SCFV FRAGMENT(6,1)
SCFV PHAGE(6,1)
SCFV PROTEIN(6,1)
SERINE PROTEASE(6,1)
SINGULAR ENTITY(6,1)
SPLEEN CDNA(6,1)
SPLENOCYTE SUSPENSION(6,1)
TANDEM SCFV(6,1)
TARGET MOTIF(6,1)
TH2 CYTOKINE(6,1)
THERAPEUTIC ANTIBODY(6,1)
TLR LIGAND(6,1)
VACCINE FORMULATION POTENTIAL(6,1)
VH VL CHIMERA(6,1)
VIRAL PROTEASE(6,1)
WEEK POST CHALLENGE(6,1)
CRYOSTAT SECTION(5,6)
ISOTYPE MATCHED CONTROL(5,6)
HOST CELL(5,3)
LYMPHOCYTE(5,3)
CYTOKINE RELEASE(5,2)
DEMONSTRATION(5,2)
3H THYMIDINE INCORPORATION(5,1)
ADFLT3L POTENTIAL(5,1)
AGE MATCHED CALF(5,1)
ANTIBODY DIRECTED COMPLEMENT LYSIS(5,1)
ANTIGEN INTERACTION(5,1)
ANTIGENIC DETERMINANT COATING(5,1)
ANTIGENIC SUBSTANCE VARIETY(5,1)
ASYMMETRIC PCR PRODUCT(5,1)
BOVINE DCS(5,1)
BROAD CELL MEDIATED IMMUNITY(5,1)
CDNA SEQUENCE CODING(5,1)
CELL COMPLEMENT(5,1)
CHAIN DOMAIN(5,1)
CLONAL EXPANSION(5,1)
COMPLEMENT ACTIVITY(5,1)
CONSTRUCTING EXPRESSION(5,1)
CYTOKINE FUNCTION(5,1)
DCS PRODUCE IL12(5,1)
DENDRITIC CELL DIFFERENTIATION(5,1)
DEVELOPMENT STAGE DCS(5,1)
DIABODY DEPENDENT BVDV(5,1)
DIABODY PROTECTED VIRUS(5,1)
DIMERIC MOLECULE ASSEMBLY(5,1)
DNA CONSTRUCT(5,1)
ECONOMIC IMPORTANCE(5,1)
ENCODING BOVINE(5,1)
ENVELOPE PROTEIN(5,1)
EUKARYOTIC SECRETORY SIGNAL(5,1)
FEEDBACK INHIBITION(5,1)
FLAG(5,1)
FLAG PEPTIDE(5,1)
FLT3L ABILITY(5,1)
FOREIGN DNA(5,1)
FUSION PROTEIN PRODUCTION(5,1)
GAUGE NEEDLE(5,1)
GRAMMATICAL EQUIVALENT(5,1)
GST PROTEIN(5,1)
HOST ORGANISM(5,1)
INDEPENDENT DC ACTIVATION(5,1)
INFECTED SUBJECT(5,1)
INFECTION RISK(5,1)
INFECTION SITE(5,1)
ISOLATED CDNA(5,1)
ISOTYPE MATCHED MOUSE(5,1)
KDA PROTEIN(5,1)
KEY APCS(5,1)
LABELED ANTIGEN(5,1)
MAB GMCSF(5,1)
MAMMALIAN HOST(5,1)
MICROHEMAGGLUTINATION REACTION(5,1)
NON TRANSFECTED CELL(5,1)
NUCLEATED CELL(5,1)
PARTICLE VACCINE(5,1)
PATHOGEN INFECTED CELL(5,1)
PI CALF PRESENCE(5,1)
PIVOTAL ROLE(5,1)
PRE INOCULATION BIOPSY(5,1)
PRIORITY DISEASE(5,1)
PROTEIN COMPLEX ISOLATION(5,1)
PROTEIN INTERACTION(5,1)
PROTEIN LIBERATION(5,1)
RADCD40L INFECTED CELL(5,1)
SHORT LINKER PEPTIDE(5,1)
STRONG CYTOTOXIC(5,1)
TISSUE CULTURE(5,1)
VIRUS DETECTION(5,1)
ADCC(4,5)
CYTOKINE IC(4,5)
ANOVA(4,4)
BVDV SPECIFIC IFN(4,4)
DNA VACCINE(4,4)
ELISA(4,4)
IMMUNE CELL(4,4)
IMMUNE SYSTEM CELL(4,4)
SIGMA(4,4)
ACQUIRED IMMUNITY(4,2)
BVDV SPECIFIC ANTIBODY TITER(4,2)
CELL RESPONSE DATA(4,2)
CHEMOKINE(4,2)
CLASSICAL SWINE FEVER VIRUS(4,2)
ENDOCYTOSIS(4,2)
HAPLOTYPE(4,2)
IMIQUIMOD(4,2)
IMMUNE RESPONSE ANALYSIS(4,2)
LIVESTOCK(4,2)
OPSONIZATION(4,2)
OUTCOME(4,2)
PENICILLIN(4,2)
PROBABILITY(4,2)
PROTEIN FULL SEQUENCE(4,2)
STREPTOMYCIN(4,2)
TRANSLATION(4,2)
UNIQUE ABILITY(4,2)
98 348BVDB VACCINE(4,1)
ADENOVIRUS MIXTURE(4,1)
ANIMAL PROTECTION(4,1)
ANTIBODY DEPENDENT BVDV(4,1)
ANTIBODY MIXTURE(4,1)
ANTIGEN EPITOPE(4,1)
ANTIGENIC DIFFERENCE(4,1)
BISPECIFIC DIABODY PRODUCTION(4,1)
BOOSTING(4,1)
BOVINE CELL(4,1)
BOVINE GENERATION(4,1)
BRANCHED PROJECTION(4,1)
BROAD PROTECTION(4,1)
BVDV PRESENCE(4,1)
BVDV SPECIFIC ANTIBODY DECLINE(4,1)
CC98MSP MIXTURE(4,1)
CELL DELAY(4,1)
CELL RECOGNITION(4,1)
CELL VACCINE(4,1)
CELLULAR NETWORK(4,1)
CENTRAL HYPOTHESIS(4,1)
CLEAVAGE SITE(4,1)
CLOSELY RELATED PESTIVIRUS(4,1)
COBALT RESIN(4,1)
CODON OPTIMIZED SYNTHETIC GENE(4,1)
COLUMN CHROMATOGRAPHY(4,1)
CONGENITAL MALFORMATION(4,1)
CONTROL CHIMERA HYDROPATHIC PROFILE(4,1)
CRITICAL EVIDENCE(4,1)
CURRENT ADENOVIRUS VECTOR(4,1)
CYTOKINE PRODUCTION PATTERN(4,1)
DC ANTIGEN RECEPTOR(4,1)
DC BVDV(4,1)
DC MODULATION(4,1)
DCS FREQUENCY(4,1)
DENDRITIC CELL SPECIALIZATION(4,1)
DEPENDENT PRO INFLAMMATORY RESPONSE(4,1)
DISEASE DEVELOPMENT(4,1)
DISSOCIATION CONSTANT(4,1)
EARLY AGE(4,1)
EFFECTOR MEMORY PRIMING(4,1)
EFFICIENT TARGETING(4,1)
EXPERIMENTAL(4,1)
FLAG SEQUENCE(4,1)
FMS RELATED TYROSINE KINASE(4,1)
HUMAN ADENOVIRUS VECTOR(4,1)
HUMAN PATIENT(4,1)
HYBRID SELECTION(4,1)
HYBRIDOMA CELL(4,1)
HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE(4,1)
IMMUNOLOGICAL RESPONSE(4,1)
INDEPENDENT PATHWAY(4,1)
INFECTED CELL CULTURE(4,1)
INFLUENCE IMMUNE RESPONSE(4,1)
INNATE RESPONSE(4,1)
ISOTYPE MATCHED NEGATIVE(4,1)
LEVEL TRANSGENE EXPRESSION(4,1)
LINKED SEQUENCE ENCODING(4,1)
MAJOR ECONOMIC LOSS(4,1)
MHC CLASS(4,1)
MHC PEPTIDE COMPLEX(4,1)
MLV VACCINE SINGLE DOSE(4,1)
MONOCLONAL ANTIBODY PRODUCTION(4,1)
MYELOMA TUMOR CELL(4,1)
OPTIMUM EXPANSION(4,1)
PEPTIDE MHC COMPLEX FORMATION(4,1)
PERIPHERAL TISSUE(4,1)
PLUS VIRUS(4,1)
(US20180094046)
VIRAL VACCINE PARTICLE(100,31)
ANTIGENIC SITE(100,8)
MOSAIC(100,2)
CHIMERIC VIRAL VACCINE(100,1)
CHIMERIC VIRAL VACCINE PARTICLE(100,1)
PARTICLE(100,1)
BISPECIFIC DIABODY(88,16)
VECTORED LIVE VACCINE(81,1)
CLASSICAL BVDV INFECTION(79,1)
CHIMERIC GENE ENCODING(63,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(61,1)
MLV BVDV VACCINE(58,7)
ADAPTIVE IMMUNITY OPTIMAL INDUCTION(57,1)
VACCINE(54,81)
UNPROTECTED CATTLE(54,1)
MLV VACCINE(52,18)
ANTIBODY NEUTRALIZATION(51,30)
VIRUS TARGETING(51,1)
BOVINE RESPIRATORY VIRUS(49,1)
NEONATAL CALF(48,30)
MATERNAL ANTIBODY(48,20)
BOVINE VIRAL DIARRHEA VIRUS PROTEIN(45,1)
NEONATAL CALF IMMUNIZATION(44,13)
BOVINE HERPES VIRUS(44,2)
PROTECTIVE BVDV ANTIGEN(43,7)
SEVERE DIARRHEA(43,1)
BVDV VACCINE(41,8)
UTERO INFECTION(41,2)
BOVINE PARAINFLUENZA(39,1)
CATTLE SIGNIFICANT PROPORTION(39,1)
PROTECTIVE ANTIBODY(39,1)
FEEDYARD(35,2)
MODIFIED LIVE VACCINE(33,6)
ROBUST EFFECTOR MEMORY INDUCTION(33,3)
MOIETY(31,32)
CELL MEDIATED IMMUNITY(31,12)
LONG LASTING NEUTRALIZING ANTIBODY(30,1)
MASKING VACCINE(29,3)
PROTEIN FRAGMENT(29,1)
NEONATAL CALF INTRADERMAL INOCULATION(28,3)
MLV BVDV VACCINE VIRUS(27,3)
IMMUNE RESPONSE EFFICACY(25,3)
BVDV(24,85)
CHIMERIC BVDV ANTIGEN(23,5)
ADENOVIRUS VECTORED BVDV VACCINE(23,3)
BVDV SPECIFIC ANTIBODY NEUTRALIZATION(23,2)
CELL IMMUNITY(22,10)
ANTI BVDV POLYCLONAL ANTIBODY(22,7)
EVADING NEUTRALIZING ANTIBODY(22,4)
MASKED MLV BVDV VACCINE(22,2)
MORTALITY(22,1)
RESPIRATORY DISEASE(22,1)
IMMUNOSUPPRESSION(21,3)
CAPSID(20,14)
AD CYTOKINE(20,11)
MASKING MOTIF(20,11)
ADENOVIRUS VECTORED VACCINE(20,6)
HYDROPHILIC BVDV ANTIGEN CHIMERA(20,2)
TARGET ANTIGEN(19,10)
MORBIDITY COMMON CAUSE(19,1)
INTRADERMAL IMMUNIZATION SITE(18,4)
VIRAPOWER ADENOVIRAL GATEWAY(18,2)
LYSIS(18,1)
RECOMBINANT ANTIGEN(17,8)
CONTEMPORARY BVDV VACCINE(17,2)
MUCOSAL DISEASE(17,2)
NON TARGETED BVDV ANTIGEN(17,2)
POLYVALENT DIABODY SCAFFOLD(17,2)
PROTECTIVE BVDV ANTIGEN CHIMERA(17,2)
AUGMENTING BVDV VACCINE IMMUNOGENICITY(17,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(17,1)
DENDRITIC CELL RECRUITMENT(16,10)
BVDV STRAIN(16,6)
DC ANTIGEN TARGETING(16,5)
ANTIBODY MEDIATED COMPLEMENT LYSIS(16,4)
MLV VACCINE VIRION(16,2)
CELL RESPONSE(15,41)
CALF(15,22)
EFFICACY(15,5)
APCS(15,2)
YOUNG SERONEGATIVE CALF IMMUNIZATION(15,1)
FLT3L GMCSF(14,22)
VIRUS NEUTRALIZING(14,5)
VACCINE RECRUIT DENDRITIC CELL(14,3)
ACUTE BVDV INFECTION RESOLUTION(14,2)
BVDV NEUTRALIZATION ASSAY(14,2)
NEUTRALIZING ANTIBODY DECLINE(14,2)
PERSISTENT ANTIGEN STIMULUS(14,2)
BVDV NEUTRALIZING ANTIBODY TITER(14,1)
NEUTRALIZING MATERNAL ANTIBODY DECAY(14,1)
VIRUS VACCINE PARTICLE(13,3)
BVDV VACCINE FORMULATION EFFICACY(13,1)
TARGETED MOSAIC BVDV ANTIGEN(13,1)
ROBUST IFN(12,6)
1101 MATCHED CALF(12,4)
BVDV NEUTRALIZING MAB(12,1)
HYPOXANTHINE AMINOPTERIN THYMIDINE(12,1)
MULTICOMPONENT CHIMERIC BVDV(12,1)
RECOMBINANT ADENOVIRUS PFU DOSE(12,1)
BVDV MIXTURE(11,8)
AGE MATCHED NEONATAL CALF(11,2)
ANTIGENIC EPITOPE(11,2)
HYPOTHESIS REJECTION(11,2)
IC IR DIABODY(11,2)
NEONATE IMMUNIZATION(11,2)
NEUTRALIZING ANTIBODY TARGET(11,2)
RECEPTOR MEDIATED ANTIGEN UPTAKE(11,2)
REPLICATION DEFECTIVE ADENOVIRUS VECTOR(11,2)
SAFE(11,2)
SECRETING HYBRIDOMA(11,2)
VACCINE CONTAMINATION RISK(11,2)
EVADING ANTIBODY NEUTRALIZATION(11,1)
IMMUNOGENIC BVDV ANTIGEN(11,1)
KILLED BVDV VACCINE(11,1)
MARGINALE MSP1 ANTIGEN(11,1)
MLV BVDV EFFICACY(11,1)
PRE MADE SCFV ANTIBODY PHAGE(11,1)
RECOMBINANT VACCINIA VIRUS VECTOR(11,1)
SECONDARY BIOTINYLATED GOAT ANTI MOUSE(11,1)
USDA NASS STATISTICS(11,1)
BVDV SPECIFIC IMMUNE RESPONSE(10,25)
98 348BVDV VACCINE(10,6)
BVDV SPECIFIC NEUTRALIZING ANTIBODY(10,6)
FACTOR ACTIVATION(10,6)
CELL DETERMINANT(10,4)
LIVE VIRUS(10,3)
MAB TH97A(10,3)
PEPTIDE LINKER(10,3)
ADVENTITIOUS VIRUS(10,2)
BVDV ANTIGEN LOADED DCS(10,2)
CD40L CYTOKINE(10,2)
DC ANTIGEN UPTAKE(10,2)
DC VACCINE INTERACTION(10,2)
LIVE VECTORED BVDV(10,2)
MOSAIC CHIMERA(10,2)
MOUSE SCFV MODULE(10,2)
POTENT MOLECULAR ADJUVANT(10,2)
PRIME NA VE(10,2)
ANTI FLAG AP CONJUGATED MAB(10,1)
BVDV ANTIGEN SPECIFICITY(10,1)
BVDV IMMUNE COW(10,1)
CHIMERIC MOSAIC ANTIGEN(10,1)
DRAINING LYMPHOID ORGAN(10,1)
EXPRESS BVDV ANTIGEN(10,1)
KDA PRECURSOR POLYPROTEIN(10,1)
MOSAIC CHIMERIC ANTIGEN(10,1)
RECOMBINANT LIVE VECTORED VACCINE(10,1)
TARGETED MLV VACCINE(10,1)
VACCINE OPTIMIZATION STRATEGY(10,1)
IMMUNOCYTOCHEMISTRY(9,5)
205 TARGETED ANTIGEN(9,3)
CELL CYTOTOXICITY(9,3)
EXTENSIVE WASHING(9,3)
FOREIGN ANTIGEN(9,3)
FREESTYLE CELL(9,3)
PROTECTIVE TITER(9,3)
ROBUST IMMUNE RESPONSE(9,3)
AFFINITY NEUTRALIZING ANTIBODY(9,1)
ANTIGEN MICROARRAY ASSAY(9,1)
BVD VIRUS STRAIN(9,1)
CHUTE SIDE(9,1)
INTRACELLULAR SIGNALING EVENT CASCADE(9,1)
MASK MLV VACCINE(9,1)
MOSAIC CHIMERIC POLYPEPTIDE SEQUENCE(9,1)
MOUSE HYBRIDOMA CLONE(9,1)
PASSIVE IMMUNITY DECLINE(9,1)
PROTECTIVE IMMUNITY PRIMING(9,1)
PURIFIED GOAT ANTI MOUSE(9,1)
RECEPTOR ABUNDANCE(9,1)
RECOMBINANT ADENOVIRUS ENCODING(9,1)
RECOMBINANT LIVE VACCINE(9,1)
SEQUENCED BVDV POLYPEPTIDE SEQUENCE(9,1)
SUBUNIT PRO VACCINE(9,1)
TRANSIENT PASSIVE IMMUNITY(9,1)
VACCINE FORMULATION SINGLE DOSE(8,8)
CELL EPITOPE(8,4)
CELL PRIMING(8,4)
DENDRITIC CELL ACTIVATION(8,4)
DIFFERENCE SIGNIFICANCE(8,4)
MOUSE MODEL(8,4)
BVDV INFECTED CELL(8,2)
CAPSID PROTEIN(8,2)
CATTLE INDUSTRY(8,2)
CELL MEDIATED CYTOTOXICITY ASSAY(8,2)
COSTIMULATORY MOLECULE(8,2)
CPG ODN(8,2)
DENDRITIC CELL SURFACE ANTIGEN(8,2)
DIFFERENCE NULL HYPOTHESIS(8,2)
DIVERSE MHC(8,2)
IFN SECRETION(8,2)
IMMATURE DCS(8,2)
IMMUNITY INDUCTION(8,2)
LIVE CHALLENGE(8,2)
OVERLAP EXTENSION PCR(8,2)
POST VACCINATION INTERVAL(8,2)
SCFV MOTIF(8,2)
ADENOVIRUS EXPRESSED BVDV ANTIGEN(8,1)
ADENOVIRUS VECTORED CYTOKINE(8,1)
AGONISTIC ANTI BOVINE(8,1)
AGONISTIC DIABODY(8,1)
ANTI FLAG AGAROSE GEL(8,1)
ANTI FLAG AGAROSE RESIN(8,1)
BOVINE DC RECRUITMENT(8,1)
BVD VIRUS PROTECTION(8,1)
BVDV NEUTRALIZING ANTIBODY PRESENCE(8,1)
BVDV POLYPROTEIN(8,1)
BVDV SUBUNIT VACCINE(8,1)
CC98MSP MINIMAL DOSE(8,1)
COMMERCIAL BVDV VACCINE(8,1)
COMMERCIAL MLV VACCINE(8,1)
CONJUGATE TARGET BVDV(8,1)
CURRENT BVDV MLV VACCINE(8,1)
CYTOKINE ADENOVIRUS(8,1)
EUKARYOTIC EXPRESSION VECTOR(8,1)
EXPRESSED FLT3L BIOLOGICAL ACTIVITY(8,1)
EXTRACELLULAR ABUNDANCE(8,1)
HIGHLY SPECIALIZED PROFESSIONAL APCS(8,1)
IMMUNOGLOBULIN SPECIFICITY(8,1)
LOCAL CD40L SECRETION(8,1)
MDBK MONOLAYER(8,1)
NEONATAL CALF PROTECTION(8,1)
NONIMMUNOGENIC ANTIGEN(8,1)
OVINE BORDER DISEASE VIRUS(8,1)
POLYBODY SCAFFOLD(8,1)
PRO INFLAMMATORY CYTOKINE PRODUCTION(8,1)
QUANTITATIVE IMMUNOHISTOCHEMISTRY(8,1)
ROBUST DC RECRUITMENT(8,1)
STIMULATED LYMPHOBLAST(8,1)
STONEYPOINT AGRICORP(8,1)
VACCINE IMMUNIZATION(8,1)
YEARLING(7,6)
ANTIGEN PRESENTATION(7,3)
CELL RECEPTOR(7,3)
DISEASE INDEX(7,3)
ASYMMETRIC PCR PRODUCT(7,2)
BOVINE DCS(7,2)
COATED VIRION(7,2)
COLOSTRUM DERIVED ANTIBODY(7,2)
EXPRESSION KIT(7,2)
FRESH PBMCS(7,2)
FUNCTIONAL ANTIGEN(7,2)
IC VARIABLE DOMAIN(7,2)
MAMMALIAN HOST(7,2)
OPTIMAL INDUCTION(7,2)
VACCINE DEVELOPMENT(7,2)
VACCINE PROTECTION(7,2)
ACUTE INFECTION RESOLUTION(7,1)
ADCD40L VIRUS(7,1)
ADENOVIRUS GENOME(7,1)
ADLUCIFERASE VIRUS(7,1)
AGONISTIC MAB(7,1)
ANTIGEN BOOST(7,1)
ANTIGEN REPERTOIRE(7,1)
AUTOLOGOUS BVDV(7,1)
BACTERIAL EXPRESSION VECTOR(7,1)
BIOLOGICALLY ACTIVE ADENOVIRUS PARTICLE(7,1)
BISPECIFIC ANTIBODY FRAGMENT(7,1)
BOVINE IGG RESIDUE(7,1)
BVDV EPITOPE(7,1)
BVDV IMMUNITY(7,1)
BVDV INCUBATION(7,1)
BVDV REPLICATION(7,1)
CATTLE HERD(7,1)
CHIMERA PURIFICATION(7,1)
CHIMERIC ADENOVIRUS(7,1)
CONTEMPORARY VACCINE(7,1)
CURRENT BVDV VACCINE EFFICACY(7,1)
CYTOKINE SECRETION(7,1)
CYTOKINE SUPPRESSION(7,1)
DCS MATURATION(7,1)
DIFFERENTIATION INDUCTION(7,1)
EMPTY VACCINE VECTOR(7,1)
ENDOSOME LYSOSOME COMPARTMENT(7,1)
EPITOPE PRESENTATION(7,1)
EVOLUTIONARY HISTORY(7,1)
FLAG(7,1)
FLAVIVIRIDAE FAMILY(7,1)
GENE DOWNREGULATION(7,1)
HUMAN CVM PROMOTER(7,1)
HYDROPHILIC DOMAIN CONSERVED REGION(7,1)
IMMUNODOT BLOT(7,1)
INOCULATING CALF(7,1)
INTRANASAL INOCULATION(7,1)
INVENTOR PREVIOUS(7,1)
IRRELEVANT SCFV(7,1)
KILLED WHOLE BVDV(7,1)
MAB ANTIBODY(7,1)
MDBK CELL MONOLAYER(7,1)
MHC MOLECULE CONTEXT(7,1)
MLV VACCINE DIRECTED MASKING(7,1)
MSP1 CHIMERA(7,1)
NEONATAL CALF SIGNIFICANT PROPORTION(7,1)
NONSTRUCTURAL PROTEIN(7,1)
NPRO CAPSID(7,1)
PLASMID DNA ENCODING(7,1)
POTENTIAL MHC POOL(7,1)
POWERFUL INDUCER(7,1)
PRO INFLAMMATORY MOLECULE(7,1)
RAD LUCIFERASE(7,1)
RECOMBINANT DIABODY PRODUCTION(7,1)
RIC SCFV(7,1)
SUSTAINED ANTIGEN UPTAKE PRESENCE(7,1)
TERMINAL CD5 SECRETORY(7,1)
TLR SIGNALING(7,1)
UNCONJUGATED MAB(7,1)
VACCINE INACTIVATION(7,1)
VACCINE VEHICLE ATTRACTIVENESS(7,1)
VACCINE VIRUS PROTECTION(7,1)
VIRAL VACCINE PARTICLE ANTIGEN(7,1)
ADENOVIRUS SINGLE DOSE(6,5)
CELL FUSION(6,5)
CTL RESPONSE(6,5)
CD40L DIRECTED DC ACTIVATION(6,4)
DEMONSTRATION(6,4)
STRONG CYTOTOXIC(6,2)
205 TRANSFECTED 293A CELL(6,1)
ADAPTIVE IMMUNITY INITIATION(6,1)
ADENOVIRUS EXPRESSED CYTOKINE(6,1)
ANIMAL AGRICULTURE(6,1)
ANIMAL IMMUNIZATION(6,1)
ANIMAL SPLEEN(6,1)
ANTIGEN ACQUISITION(6,1)
ANTIGEN CAPTURE(6,1)
ANTIGENIC PEPTIDE(6,1)
BIFUNCTIONAL CAPABILITY(6,1)
BOVINE CD40L(6,1)
BROADLY REPRESENTATIVE MOSAIC(6,1)
BVDV GENOME(6,1)
BVDV PROTEIN(6,1)
BVDV REACTIVE PBMCS(6,1)
BVDV1 PEPTIDE(6,1)
CAPSID ANTIGEN(6,1)
CDNA ENCODING(6,1)
CELL IMMUNOCYTOMETRIC ANALYSIS(6,1)
CELL PEPTIDE MOTIF(6,1)
CELLULAR PATHWAY(6,1)
CIRCULATING EFFECTOR(6,1)
COMPLEMENT MEDIATED LYSIS(6,1)
COMPREHENSIVE REPRESENTATION(6,1)
CPG MOTIF(6,1)
CTL EPITOPE(6,1)
CULTURE SUPERNATANT(6,1)
CYTOKINE EXPRESSION(6,1)
CYTOKINE INDUCTION(6,1)
DEPENDENT DC RECRUITMENT(6,1)
DERMAL DCS(6,1)
DIABODY DRUG(6,1)
DOSE ESCALATION(6,1)
DRAINING LYMPH NODE(6,1)
ELISPOT ASSAY(6,1)
ENCODING NUCLEOTIDE(6,1)
EXOGENOUS ANTIGEN(6,1)
EXOGENOUS GENE(6,1)
EXPRESS CYTOKINE(6,1)
FETAL INFECTION(6,1)
FLAG TAGGED RCC(6,1)
GENUS PESTIVIRUS MEMBER(6,1)
GLOBULAR PROTEIN(6,1)
GLYCOPROTEIN MOLECULE(6,1)
HELPER ROLE(6,1)
HEPATITIS VIRAL ANTIGEN(6,1)
HYBRID POLYPEPTIDE(6,1)
HYBRID VACCINE(6,1)
IC 348BVDV VACCINE(6,1)
IGG2B MAB(6,1)
IMMUNE CATTLE(6,1)
IMMUNIZED ANIMAL(6,1)
INFECTED CELL CLEARANCE(6,1)
ISOTYPE MATCHED MAB(6,1)
KILLED VACCINE(6,1)
LINKER INTRODUCTION(6,1)
LIVE BVDV(6,1)
LOOSE IMMUNOGENICITY(6,1)
MACROPHAGE ACTIVATION(6,1)
MASKED VACCINE(6,1)
MATERNAL ANTIBODY NEUTRALIZING LEVEL(6,1)
MILLION CATTLE(6,1)
NEUTRALIZING ANTIBODY DECAY RATE(6,1)
NONCYTOPATHIC STRAIN(6,1)
NPRO ANTIGEN(6,1)
OPTIMAL PROTEIN EXPRESSION(6,1)
OPTIMAL VACCINE(6,1)
ORGANISM SPECIES(6,1)
PACKARD GAMMA COUNTER(6,1)
PARENTAL PROTEIN(6,1)
PEPTIDE ANTIGEN(6,1)
PHAGE DISPLAY LIBRARY(6,1)
POTENT ADJUVANT(6,1)
PROLIFERATION ASSAY(6,1)
PROTECTIVE COLOSTRUM DERIVED BVDV(6,1)
PROTEIN CATEGORY(6,1)
PROTEIN EXPRESSION VECTOR(6,1)
RABBIT COMPLEMENT(6,1)
RECOMBINANT BOVINE(6,1)
REPRODUCTIVE DISEASE(6,1)
ROBUST ADAPTIVE IMMUNITY(6,1)
SCFV FRAGMENT(6,1)
SCFV PHAGE(6,1)
SCFV PROTEIN(6,1)
SERINE PROTEASE(6,1)
SINGULAR ENTITY(6,1)
SPLEEN CDNA(6,1)
SPLENOCYTE SUSPENSION(6,1)
TANDEM SCFV(6,1)
TARGET MOTIF(6,1)
TH2 CYTOKINE(6,1)
THERAPEUTIC ANTIBODY(6,1)
TLR LIGAND(6,1)
VACCINE FORMULATION POTENTIAL(6,1)
VH VL CHIMERA(6,1)
VIRAL PROTEASE(6,1)
WEEK POST CHALLENGE(6,1)
CRYOSTAT SECTION(5,6)
ISOTYPE MATCHED CONTROL(5,6)
IMIQUIMOD(5,3)
LYMPHOCYTE(5,3)
CLONE 2C(5,2)
CODING SEQUENCE(5,2)
CYTOKINE RELEASE(5,2)
IFN PRODUCTION(5,2)
LC DERIVED DCS(5,2)
LINKER SEQUENCE(5,2)
QUICK RECALL RESPONSE(5,2)
RECALL RESPONSE ANALYSIS(5,2)
SEPARATE ASYMMETRIC PCR(5,2)
SOLUBILITY(5,2)
VULNERABILITY PERIOD(5,2)
3H THYMIDINE INCORPORATION(5,1)
ADFLT3L POTENTIAL(5,1)
AGE MATCHED CALF(5,1)
ANTIBODY DIRECTED COMPLEMENT LYSIS(5,1)
ANTIGEN INTERACTION(5,1)
BROAD CELL MEDIATED IMMUNITY(5,1)
CD40L MOUSE(5,1)
CELL COMPLEMENT(5,1)
CHAIN DOMAIN(5,1)
CLONAL EXPANSION(5,1)
COMPLEMENT ACTIVITY(5,1)
CONSTRUCTING EXPRESSION(5,1)
CYTOKINE FUNCTION(5,1)
DCS PRODUCE IL12(5,1)
DENDRITIC CELL DIFFERENTIATION(5,1)
DEVELOPMENT STAGE DCS(5,1)
DIABODY DEPENDENT BVDV(5,1)
DIABODY PROTECTED VIRUS(5,1)
DIMERIC MOLECULE ASSEMBLY(5,1)
DNA CONSTRUCT(5,1)
ECONOMIC IMPORTANCE(5,1)
ENCODING BOVINE(5,1)
ENVELOPE PROTEIN(5,1)
EUKARYOTIC SECRETORY SIGNAL(5,1)
FEEDBACK INHIBITION(5,1)
FLAG(5,1)
FLT3L ABILITY(5,1)
FOREIGN DNA(5,1)
FUSION PROTEIN PRODUCTION(5,1)
GAUGE NEEDLE(5,1)
INDEPENDENT DC ACTIVATION(5,1)
INDEPENDENT DC MODULATION(5,1)
INFECTION RISK(5,1)
INFECTION SITE(5,1)
ISOLATED CDNA(5,1)
ISOTYPE MATCHED MOUSE(5,1)
KDA PROTEIN(5,1)
KEY APCS(5,1)
LABELED ANTIGEN(5,1)
MAB GMCSF(5,1)
MICROHEMAGGLUTINATION REACTION(5,1)
NON TRANSFECTED CELL(5,1)
NUCLEATED CELL(5,1)
PARTICLE VACCINE(5,1)
PATHOGEN INFECTED CELL(5,1)
PI CALF PRESENCE(5,1)
PIVOTAL ROLE(5,1)
PRE INOCULATION BIOPSY(5,1)
PRIORITY DISEASE(5,1)
PROTEIN INTERACTION(5,1)
RADCD40L INFECTED CELL(5,1)
SHORT LINKER PEPTIDE(5,1)
TISSUE CULTURE(5,1)
VIRUS DETECTION(5,1)
ADCC(4,5)
CYTOKINE IC(4,5)
ANOVA(4,4)
BVDV SPECIFIC IFN(4,4)
DNA VACCINE(4,4)
ELISA(4,4)
IMMUNE CELL(4,4)
SIGMA(4,4)
SINGLE CHAIN ANTIBODY MOLECULE(4,4)
ACQUIRED IMMUNITY(4,2)
BVDV SPECIFIC ANTIBODY TITER(4,2)
CELL RESPONSE DATA(4,2)
CHEMOKINE(4,2)
CLASSICAL SWINE FEVER VIRUS(4,2)
ENDOCYTOSIS(4,2)
HAPLOTYPE(4,2)
HOST CELL(4,2)
IMMUNE RESPONSE ANALYSIS(4,2)
OPSONIZATION(4,2)
OUTCOME(4,2)
PENICILLIN(4,2)
PROBABILITY(4,2)
RESPONSE PRIMING(4,2)
SIGNIFICANT PROTECTION(4,2)
STREPTOMYCIN(4,2)
UNIQUE ABILITY(4,2)
ADENOVIRUS MIXTURE(4,1)
ANIMAL PROTECTION(4,1)
ANTIBODY DEPENDENT BVDV(4,1)
ANTIBODY MIXTURE(4,1)
ANTIGEN EPITOPE(4,1)
ANTIGENIC DIFFERENCE(4,1)
BISPECIFIC DIABODY PRODUCTION(4,1)
BOOSTING(4,1)
BOVINE CELL(4,1)
BOVINE GENERATION(4,1)
BRANCHED PROJECTION(4,1)
BROAD PROTECTION(4,1)
BVDV PRESENCE(4,1)
BVDV SPECIFIC ANTIBODY DECLINE(4,1)
CC98MSP MIXTURE(4,1)
CELL DELAY(4,1)
CELL RECOGNITION(4,1)
CELL VACCINE(4,1)
CELLULAR NETWORK(4,1)
CENTRAL HYPOTHESIS(4,1)
CLOSELY RELATED PESTIVIRUS(4,1)
CODON OPTIMIZED SYNTHETIC GENE(4,1)
COLUMN CHROMATOGRAPHY(4,1)
CONGENITAL MALFORMATION(4,1)
CONTROL CHIMERA HYDROPATHIC PROFILE(4,1)
CRITICAL EVIDENCE(4,1)
CURRENT ADENOVIRUS VECTOR(4,1)
CYTOKINE PRODUCTION PATTERN(4,1)
DC ANTIGEN RECEPTOR(4,1)
DC BVDV(4,1)
DCS FREQUENCY(4,1)
DENDRITIC CELL SPECIALIZATION(4,1)
DEPENDENT PRO INFLAMMATORY RESPONSE(4,1)
DISSOCIATION CONSTANT(4,1)
EARLY AGE(4,1)
EFFECTOR MEMORY PRIMING(4,1)
EFFICIEN(...)";Pharmaceuticals;Open
2012-07-27;"RU2012132044        A  2014-02-10 [RU2012132044]
STG: (A) Application for invention
AP : 2012RU-0132044 2012-07-27
RU2522780           C2 2014-07-20 [RU2522780]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2012RU-0132044 2012-07-27";61342584;"RU2012132044        A  2014-02-10 [RU2012132044]
RU2522780           C2 2014-07-20 [RU2522780]";2012RU-0132044;;G NAUCHNOE UCHREZHDENIE VRNII VETERINARNOJ SANITARII GIGIENY I EHKOLOGII ROSSIJSKOJ AKADEMII SKO;G NAUCHNOE UCHREZHDENIE VRNII VETERINARNOJ SANITARII GIGIENY I EHKOLOGII ROSSIJSKOJ AKADEMII SKO;;;1;"SMIRNOV ANATOLIJ MIKHAJLOVICH
BUTKO MIKHAIL PAVLOVICH
BELOUSOVA RAISA VASIL EVNA
FROLOV VIKTOR STEPANOVICH
TIGANOV VLADIMIR SEMENOVICH
PIMENOVA NATAL JA VLADIMIROVNA
TIGANOVA IRINA PETROVNA
FROLOV ALEKSEJ VIKTOROVICH
JAKIMCHUK VLADIMIR IVANOVICH
MAJSTRENKO EVGENIJA SEMENOVNA";;;"(RU2522780)
Method for preparing infectious bovine rhinotracheitis vaccine";"(RU2522780)
FIELD: medicine.SUBSTANCE: invention refers to veterinary microbiology, virology and biotechnology, and concerns a method for preparing an infectious bovine rhinotracheitis vaccine. The described method: preparing a virus material of the infectious bovine rhinotracheitis virus strain, infecting a continuous cell culture with the virus material, culturing the infectious bovine rhinotracheitis virus, collecting a virus fluid, inactivating it to prepare a fluid end product. The virus fluid is inactivated with an antioxidant solution prepared by electrolysis of 10.0-20.0% sodium chloride; electrolysis is continued until reaching pH 7.0-8.0, antioxidant concentration 0.7-0.9% and redox potential +1000±50 mV and an inactivator consumption 4.5-5.0 cmper 0.8-1.0 l of the virus fluid; the virus fluid inactivation is one-staged with the active chlorine concentration of Cac=200-300 mg/l for 60-70 min and at a temperature of 37-38°C at pH 7.2-7.4.EFFECT: presented invention can be used in developing agents for specific prevention, and particularly for preparing the infectious bovine rhinotracheitis vaccine.2 cl, 4 ex";"(RU2522780)
1. The Method of obtaining the vaccine against infectious rhino-tracheitis of large livestock, which includes the preparation of the virus-containing material from the strain of the virus of infectious rhino-tracheitis of large livestock, infection by the virus-containing material of the culture of the interwoven cells, the cultivation of the virus of infectious rhino-tracheitis of large livestock, the collection of the virus-containing liquid, its inactivation with the subsequent preparation of end product in the liquid form, that is characterized by the fact that the inactivation of the virus-containing liquid is carried out by the solution of oxidants, obtained by electrolysis 10, 0-20,0%- foot the solution of sodium chloride, moreover electrolysis they conduct to reaching of pH values 7,0-8,0, concentration of oxidants 0,7-0,9% and oxidation-reduction potential of +1000±50 mV and with the expenditure of the inactivating of resource 4,5-5,0 cm (3) on 0,8-1,0 l of the virus-containing liquid, moreover the inactivation of the virus-containing liquid is conducted into one stage with the content of active chlorine Of Sakh=200-300 mG/l during 60-70 min and at a temperature 37-38 (°) S with rN 7,2-7,4.
2. Method according to claim 1, that is characterized by the fact that as the strain of the virus of infectious rhino-tracheitis of large livestock is used the virus of infectious rhino-tracheitis of large livestock strain GKV 2333, the family Of Herpesviridae, subfamily Of Alphaherpesviridae or the strain “OF VNIIZZH” of the virus IRT KRS, seven. Herpesviridae, the kind Of Varicellavims, the collection FGU “OF VGNKI” “OF VNIIZZH-DEP”.";;;"A61K-039/265
C12N-007/00";;;Pharmaceuticals;Open
2012-07-27;"RU2502522           C1 2013-12-27 [RU2502522]
STG: (C1) Patent for invention
AP : 2012RU-0132042 2012-07-27";61169576;RU2502522           C1 2013-12-27 [RU2502522];2012RU-0132042;;G NAUCHNOE UCHREZHDENIE VRNII VETERINARNOJ SANITARII GIGIENY I EHKOLOGII ROSSIJSKOJ AKADEMII SKO;G NAUCHNOE UCHREZHDENIE VRNII VETERINARNOJ SANITARII GIGIENY I EHKOLOGII ROSSIJSKOJ AKADEMII SKO;;;1;"SMIRNOV ANATOLIJ MIKHAJLOVICH
BUTKO MIKHAIL PAVLOVICH
BELOUSOVA RAISA VASIL EVNA
FROLOV VIKTOR STEPANOVICH
TIGANOV VLADIMIR SEMENOVICH
PIMENOVA NATAL JA VLADIMIROVNA
TIGANOVA IRINA PETROVNA
FROLOV ALEKSEJ VIKTOROVICH
JAKIMCHUK VLADIMIR IVANOVICH
MAJSTRENKO EVGENIJA SEMENOVNA";;;"(RU2502522)
Method for preparing cattle viral diarrhoea vaccine";"(RU2502522)
FIELD: medicine.SUBSTANCE: invention refers to veterinary virology, microbiology and biotechnology and may be used in developing the agents for specific prevention, particularly for preparing cattle viral diarrhoea vaccine. To improve the quality of an end product by using an oxidant solution as an inactivating agent prepared by the electrolysis of sodium chloride solution, as well as to activate the method for preparing the cattle viral diarrhoea vaccine involving preparing a virus-containing material of the cattle viral diarrhoea vaccine strain, infecting a continuous cell culture with the virus-containing material, culturing the cattle viral diarrhoea virus, collecting a virus-containing fluid, inactivating and preparing the end product in the liquid form, with the cattle viral diarrhoea virus being inactivated by the oxidant solution prepared by electrolysis of 10.0-20.0% sodium chloride with the electrolysis carried out to pH 7.0-8.0, oxidant concentration 0.7-0.9% and redox potential +1000±50 mV; the processing is one-staged with the active chlorine content Cax=400-600 mg/l for 60-70 min with inactivating agent consumption 4.5-5.0 cmper 0.8-1.0 l of the virus-containing fluid.EFFECT: higher quality of the end product.3 ex";"(RU2502522)
1. The Method of obtaining the vaccine against virus diarrhea of large livestock, which includes the preparation of the virus-containing material from the strain of the virus of virus diarrhea of large livestock, infection by the virus-containing material of the culture of the interwoven cells, the cultivation of the virus of virus diarrhea of large livestock, the collection of the virus-containing liquid, inactivation with the subsequent preparation of end product in the liquid form, that is characterized by the fact that the inactivation of the virus of virus diarrhea of large livestock is carried out by the solution of oxidants, obtained by electrolysis 10, 0-20,0%- foot the solution of sodium chloride, moreover electrolysis they conduct before reaching of the values of rN 7,0-8,0, concentration of oxidants 0,7-0,9% and oxidation-reduction potential of +1000±50 mV, treatment is conducted into one stage with the content of active chlorine Of Sakh=400-600 mG/l during 60-70 min with the expenditure of the inactivating resource 4,5-5,0 cm (3) on 0,8-1,0 l of the virus-containing liquid.
2. Method according to claim 1, that is characterized by the fact that as the strain of the virus of virus diarrhea of large livestock are used the strain “Oregon” or the strain of the virus of diarrhea of large livestock GKV of 2336 families Of Flaviviridae of the kind Of Pestivirus.";;;"A61K-039/12
A61P-031/12
C12N-007/00";;;Pharmaceuticals;Open
"2012-06-27
2012-09-10
2013-06-24
2014-12-17
2015-12-14
2016-04-07
2017-03-30
2017-04-03
2018-05-17";"WO2014004378        A1 2014-01-03 [WO201404378]
STG: (A1) Published application with search report
AP : 2013WO-US47325 2013-06-24
EP2877196           A1 2015-06-03 [EP2877196]
STG: (A1) Application published with search report
AP : 2013EP-0809549 2013-06-24
US20150174226       A1 2015-06-25 [US20150174226]
STG: (A1) Application published
AP : 2013US-14408760 2013-06-24
US9248174           B2 2016-02-02 [US9248174]
STG: (B2) Granted patent as second publication
AP : 2013US-14408760 2013-06-24
FD :  Provisional Appl: US61/665,223 FDD=2012-06-27 [2012US-61665223]
FD : Provisional Appl: US61/698,979 FDD=2012-09-10 [2012US-61698979]
FD : Previous publication: US20150174226 A1 2015-06-25 [US20150174226]
EP2877196           A4 2016-04-06 [EP2877196]
STG: (A4) Supplementary search report
AP : 2013EP-0809549 2013-06-24
US20160146811       A1 2016-05-26 [US20160146811]
STG: (A1) Application published
AP : 2015US-14967687 2015-12-14
FD :  Division of: US14/408,760 FDD=2014-12-17 [2014US-14408760]
FD : Division of: US9248174 - 0 [US9248174]
FD : Division of: WOPCT/US2013/047325 FDD=2013-06-24 [2013WO-US47325]
FD : Provisional Appl: US61/665,223 FDD=2012-06-27 [2012US-61665223]
FD : Provisional Appl: US61/698,979 FDD=2012-09-10 [2012US-61698979]
US20170202941       A1 2017-07-20 [US20170202941]
STG: (A1) Application published
AP : 2017US-15477137 2017-04-03
US20170269080       A1 2017-09-21 [US20170269080]
STG: (A1) Application published
AP : 2017US-15474427 2017-03-30
US9945851           B2 2018-04-17 [US9945851]
STG: (B2) Granted patent as second publication
AP : 2017US-15474427 2017-03-30
FD :  CIP of: US14/967,687 FDD=2015-12-14 [2015US-14967687]
FD : Division of: US14/408,760 FDD=2014-12-17 [2014US-14408760]
FD : Division of: US9248174 - 0 [US9248174]
FD : Division of: US14408760 0
FD : Division of: WOPCT/US2013/047325 FDD=2013-06-24 [2013WO-US47325]
FD : Provisional Appl: US62/319,320 FDD=2016-04-07 [2016US-62319320]
FD : Provisional Appl: US61/665,223 FDD=2012-06-27 [2012US-61665223]
FD : Provisional Appl: US61/698,979 FDD=2012-09-10 [2012US-61698979]
FD : Previous publication: US20170269080 A1 2017-09-21 [US20170269080]
US10039815          B2 2018-08-07 [US10039815]
STG: (B2) Granted patent as second publication
AP : 2017US-15477137 2017-04-03
FD :  Division of: US14/967,687 FDD=2015-12-14 [2015US-14967687]
FD : Division of: US14/408,760 FDD=2014-12-17 [2014US-14408760]
FD : Division of: US14408760 0
FD : Division of: WOPCT/US2013/047325 FDD=2013-06-24 [2013WO-US47325]
FD : Division of: US9248174 - 2016-02-02 [US9248174]
FD : Provisional Appl: US61/665,223 FDD=2012-06-27 [2012US-61665223]
FD : Provisional Appl: US61/698,979 FDD=2012-09-10 [2012US-61698979]
FD : Previous publication: US20170202941 A1 2017-07-20 [US20170202941]
US20180264097       A1 2018-09-20 [US20180264097]
STG: (A1) Application published
AP : 2018US-15981950 2018-05-17
FD :  Division of: US15/477,137 FDD=2017-04-03 [2017US-15477137]
FD : Division of: US14/967,687 FDD=2015-12-14 [2015US-14967687]  abandoned
FD : Division of: US14/408,760 FDD=2014-12-17 [2014US-14408760]
FD : Division of: US10039815 - 0 [US10039815]
FD : Division of: US9248174 - 0 [US9248174]
FD : Division of: WOPCT/US2013/047325 FDD=2013-06-24 [2013WO-US47325]
FD : Provisional Appl: US61/665,223 FDD=2012-06-27 [2012US-61665223]
FD : Provisional Appl: US61/698,979 FDD=2012-09-10 [2012US-61698979]";61261504;"WO2014004378        A1 2014-01-03 [WO201404378]
EP2877196           A1 2015-06-03 [EP2877196]
US20150174226       A1 2015-06-25 [US20150174226]
US9248174           B2 2016-02-02 [US9248174]
EP2877196           A4 2016-04-06 [EP2877196]
US20160146811       A1 2016-05-26 [US20160146811]
US20170202941       A1 2017-07-20 [US20170202941]
US20170269080       A1 2017-09-21 [US20170269080]
US9945851           B2 2018-04-17 [US9945851]
US10039815          B2 2018-08-07 [US10039815]
US20180264097       A1 2018-09-20 [US20180264097]";"2012US-61665223
2012US-61698979
2013US-14408760
2013WO-US47325
2014US-14408760
2015US-14967687
2016US-62319320
2017US-15474427
2017US-15477137
2018US-15981950";"(EP2877196)
WO2014004378
(US9248174)
WO2014004378
(US20160146811)
WO2014004378
(US10039815)
WO2014004378";UNIVERSITY OF VIRGINIA;UNIVERSITY OF VIRGINIA;"(EP2877196)
US
(US20150174226)
US
(US9248174)
US
(US20160146811)
US
(US20170269080)
US
(US9945851)
US
(US20170202941)
US
(US10039815)
US
(US20180264097)
US
(WO201404378)
US";"(EP2877196)
NAME=Virginia Commonwealth University 800 East Leigh Street, Suite 113 , CITY=Richmond, VA 23219 , COUNTRY=US 

(US20150174226)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US 

(US9248174)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US , ATYP=US Company 

(US20160146811)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US 

(US20170269080)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US 

(US9945851)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US , ATYP=US Company 

(US20170202941)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US 

(US10039815)
NAME=VIRGINIA COMMONWEALTH UNIVERSITY , CITY=Richmond , STATE=VA , COUNTRY=US , ATYP=US Company 

(US20180264097)
NAME=Virginia Commonwealth University , CITY=Richmond , STATE=VA , COUNTRY=US 

(WO201404378)
NAME=VIRGINIA COMMONWEALTH UNIVERSITY 800 E. Leigh Street, Suite 3000 Richmond, VA 23219 , POSTCODE=23219 , COUNTRY=US 
";1;CARLYON JASON A;"(EP2877196)
US";"(EP2877196)
NAME=CARLYON, Jason, A. 311 N. Meadow St. , CITY=Richmond, VA 23220 , COUNTRY=US 
";"(EP2877196)
Ompa and asp14 in vaccine compositions and as diagnostic targets";"(EP2877196)
Anaplasma phagocytophilum surface proteins Asp 14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp 14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp 14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.";"(WO201404378)
What is claimed is:
1. An immunogenic composition including one or more isolated polypeptides in a vehicle or carrier suitable for administration to a subject, wherein at least one of said one or more polypeptides is or includes SEQ ID NO:03 or SEQ ID NO:06.
2. The immunogenic composition of claim 1, wherein said one or more polypeptides is linked to an amino acid spacer, an amino acid linker, a signal sequence, a stop transfer sequence, a transmembrane domain, a protein purification ligand, a heterologous protein, or one or more additional polypeptides comprising SEQ ID NO:01, 02, 03, 04, 05, 06, 07, 08, or 09, or a combination thereof.
3. The immunogenic composition of claim 2, wherein said one or more polypeptides is linked to said protein purification ligand and said protein purification ligand is selected from the group consisting of GST and His.
4. The immunogenic composition of claim 1 , wherein said at least one said one or more polypeptides is selected from the group consisting of SEQ ID NO:01 , SEQ ID NO:02, SEQ ID NO:03, SEQ ID NO:08, and SEQ ID NO:09.
5. The immunogenic composition of claim 1 , wherein said at least one said one or more polypeptides is selected from the group consisting of SEQ ID NO:04, SEQ ID NO:05, SEQ ID NO:06, and SEQ ID NO:07.
6. A method of protecting or treating a subject from a zoonotic disease by the step of administering to said subject an immunogenic composition including one or more isolated polypeptides, wherein at least one of said one or more polypeptides is or includes SEQ ID NO:03 or SEQ ID NO:06.
7. The method according to claim 6, wherein said one or more polypeptides is linked to an amino acid spacer, an amino acid linker, a signal sequence, a stop transfer sequence, a transmembrane domain, a protein purification ligand, a heterologous protein, or one or more additional polypeptides comprising SEQ ID NO:01, 02, 03, 04, 05, 06, 07, 08, or 09; or a combination thereof.
8. The method of claim 6, wherein said zoonotic disease is caused by an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of 
 Anaplasma phagocytophilum, Anaplasma marginale, Anaplasma platys, Ehrlichia chaffeensis, Ehrlichia canis, and Ehrlicia ruminatium.
9. The method of claim 6, wherein said subject is a human, and said zoonotic disease is human granulocytic anaplasmosis (HGA).
10. The method of claim 6, wherein said subject is an animal and said zoonotic disease is anaplasmosis.
11. The method of claim 6, said immunogenic composition is a cocktail containing two or more peptides selected from the group consisting of SEQ ID NO:01-66.
12. A method of detecting antibodies that specifically bind an Anaplasmataceae polypeptide in a test sample, comprising the steps of contacting a test sample, under conditions that allow polypeptide-antibody complexes to form, with a composition that includes at least one or more polypeptides encoding all or a portion of SEQ ID NO:01 or SEQ ID NO: 04, and detecting one or more polypeptide-antibody complexes in said test samples, wherein the detection is an indication that antibodies specific for 
 Anaplasmataceae Asp 14 or OmpA are present in the test sample.
13. The method of claim 1 1, wherein said method is an assay selected from the group consisting of an immunoblot and an enzyme-linked immunosorbent assay (ELISA).";"(US20150174226)
An embodiment of the invention is a composition including one or more isolated polypeptides, wherein at least one of said one or more polypeptides is or includes SEQ ID NO:03 or SEQ ID NO:06.
Aspects of the invention are related to diagnosing, preventing, and treating zoonotic diseases caused by Anaplasmataceae bacteria.
The invention generally relates to a vaccine and diagnostic for anaplasmosis in animals and humans.
In particular, the invention provides Anaplasma phagocytophilum outer surface protein A (OmpA) epitopes and/or Anaplasma phagocytophilum surface protein 14 (Asp14) epitopes.";"(US20150174226)
If it is desired to administer an oral form of the composition, various thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders and the like may be added.
In addition to Aph, the Anaplasmataceae family members include Anaplasma marginale, Anaplasma platys, Ehrlichia chaffeensis, Ehrlichia canis, and Ehrlichia ruminatium, among others, and all of these cause similar infections known collectively as ehrlichiosis.
No. 7,906,296 B2 to Beall et al teaches that Anaplasma platys (Apl), formerly known as Ehrlichia platys, causes tick-born anaplasmosis in dogs.
If only one sample is tested it can be difficult to interpret.";"A61K-038/16
A61K-038/17
A61K-039/00
A61K-039/02
A61K-039/40
A61P-033/02
C07K-016/12
G01N-033/569";"(US20150174226)
1. An immunogenic composition including one or more isolated polypeptides in a vehicle or carrier suitable for administration to a subject, wherein at least one of said one or more polypeptides is or includes SEQ ID NO:03 or SEQ ID NO:06.
6. A method of protecting or treating a subject from a zoonotic disease by the step of administering to said subject an immunogenic composition including one or more isolated polypeptides, wherein at least one of said one or more polypeptides is or includes SEQ ID NO:03 or SEQ ID NO:06.
12. A method of detecting antibodies that specifically bind an Anaplasmataceae polypeptide in a test sample, comprising the steps of contacting a test sample, under conditions that allow polypeptide-antibody complexes to form, with a composition that includes at least one or more polypeptides encoding all or a portion of SEQ ID NO:01 or SEQ ID NO:04, and detecting one or more polypeptide-antibody complexes in said test samples, wherein the detection is an indication that antibodies specific for Anaplasmataceae Asp14 or OmpA are present in the test sample.";"(US20150174226)
ANTIBODY(100,25)
ASP(100,21)
ZOONOTIC DISEASE(100,11)
VACCINE(100,8)
ANAPLASMA PLATY(100,5)
IMMUNOGENIC(100,4)
ANAPLASMATACEAE POLYPEPTIDE(100,2)
DIAGNOSTIC TARGET(100,1)
ISOLATED POLYPEPTIDE(98,4)
EHRLICHIA CHAFFEENSIS(85,3)
PROTEIN PURIFICATION LIGAND(83,10)
POLYPEPTIDE ANTIBODY COMPLEX(82,4)
EHRLICHIA RUMINATIUM(80,1)
CONSERVED INVASIN DOMAIN(76,1)
EHRLICHIA PLATY(74,1)
INTRACELLULAR ANAPLASMATACEAE BACTERIUM(72,2)
ANAPLASMATACEAE BACTERIUM(63,2)
ENCODING POLYPEPTIDE(63,2)
TICK BORN BACTERIUM(52,1)
HETEROLOGOUS PROTEIN(50,4)
CAUSE TICK BORN ANAPLASMOSIS(49,1)
TRANSMEMBRANE DOMAIN(48,8)
EHRLICIA RUMINATIUM(46,2)
HOMOLOGOUS GENE(46,1)
ANAPLASMA MARGINALE(41,3)
DISPERSING AID(41,1)
ANAPLASMA PHAGOCYTOPHILUM(39,5)
EHRLICHIA CANIS(38,3)
THICKENING(36,1)
ANAPLASMATACAEA INFECTION RANGE(34,1)
EHRLICHIOSIS(34,1)
AMINOACID LINKER(29,2)
EMULSIFIER(29,1)
FLAVORING(29,1)
ANAPLASMOSIS(28,18)
EPITOPE(26,20)
AMINOACID SPACER(25,2)
ANAPLASMATACAEA FAMILY MEMBER(25,1)
DILUENT(25,1)
ADMINISTRATION(24,3)
BINDER(23,1)
ANAPLASMA PHAGOCYTOPHILUM SURFACE PROTEIN(22,2)
ANAPLASMATACEAE FAMILY MEMBER(21,5)
CHIMERIC PEPTIDE(20,7)
EHRLICHIA SPP(20,5)
SCAPULARIS NYMPH(20,4)
ANTI ASP(19,14)
ANIMAL(19,7)
OMPA INVASIN DOMAIN(19,2)
CHIMERIC PROTEIN(18,6)
STOP TRANSFER SEQUENCE(18,6)
ALEXA FLUOR PERCENTAGE(18,2)
APH 16S RRNA GENE(18,2)
CELLO SUBCELLULAR PREDICTION SERVER(18,1)
CULTURE HARBORING TRANSGENIC HGE(18,1)
IMMUNOBLOT(17,4)
BIPHASIC DEVELOPMENTAL CYCLE(17,3)
HUMAN GRANULOCYTIC ANAPLASMOSIS(17,3)
NEUTRAVIDIN BEAD PLUS(17,3)
6A CELL(16,19)
CONFORMATIONAL EPITOPE(16,3)
APH INFECTED MOUSE(16,2)
RICKETTSIALES BACTERIUM(16,2)
NEUTROPHIL APH COLONIZATION(16,1)
OMPA TARGET SIALYLATED GLYCOPROTEIN(16,1)
SLEX CAPPED PSGL DETERMINANT(16,1)
TERMINALLY SIALYLATED GLYCOPROTEIN(16,1)
LINKED SIALIC ACID(15,6)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY(15,3)
INFECTION INHIBITION(15,3)
APH INFECTION DISSEMINATION(15,1)
GLUTATHIONE SEPHAROSE AFFINITY CHROMATOGRAPHY(15,1)
HEART MICROVASCULAR ENDOTHELIUM(15,1)
INTRAVACUOLAR APH COLONY(15,1)
PLASMID ENCODING PCR MUTAGENESIS(15,1)
PROTEIN LYNX GLOBAL SURVEYOR(15,1)
RAISING RABBIT POLYCLONAL ANTISERUM(15,1)
LINKER SEQUENCE(14,8)
CELLULAR DEBRIS(14,5)
DOG(14,5)
APH LYSATE(14,3)
ANAPLASMOSIS DIAGNOSIS(14,2)
HOST CELL PHAGOCYTOPHILUM INFECTION(14,2)
ANAPLASMATACAEA SURFACE PROTEIN(14,1)
ANAPLASMATASEAE FAMILY BACTERIUM(14,1)
ANNOTATED APH GENOME(14,1)
APH BACTERIUM UPTAKE(14,1)
APH INFECTED IXODE(14,1)
APH INFECTED NYMPH(14,1)
AUTODOCK VINA(14,1)
INTRACELLULAR APH ORGANISM(14,1)
MONOCYTOTROPIC EHRLICHIA SPECIES(14,1)
OMPA ENCOMPASSING FRAGMENT(14,1)
POLYCLONAL ANTISERUM TARGETING(14,1)
PREIMMUNE MOUSE SERUM DILUTION(14,1)
TRANSGENIC APH ORGANISM(14,1)
TSUTSUGAMUSHI OMPA PROTEIN(14,1)
GST ASP(12,22)
ANAPLASMA SPP(12,2)
APH EFFECTOR(12,2)
APH NCH(12,2)
APH POPULATION(12,2)
BIOTIN CARBOXYL CARRIER PROTEIN(12,2)
FASTA DATABASE(12,2)
INTACT APH DC ORGANISM(12,2)
INTACT DC BACTERIUM(12,2)
INTRACELLULAR BACTERIA(12,2)
RECOMBINANT OMPA(12,2)
RECOMBINANT POLYPEPTIDE(12,2)
SPINNING DISC CONFOCAL MICROSCOPY(12,2)
THIOREDOXIN(12,2)
UNBOUND BACTERIA(12,2)
UNFED TICK(12,2)
16S RRNA GENE TRANSCRIPT(12,1)
ANAPLASMATACEAE BACTERIUM EXPOSURE(12,1)
ANAPLASMATACEAE SPECIES BACTERIUM(12,1)
ANAPLASMATACEAE SPECIES GEOGRAPHICAL DISTRIBUTION(12,1)
BOUND APH ORGANISM MAJORITY(12,1)
CANDIDATE GENE RECOMBINATION(12,1)
CAUSE SIMILAR INFECTION(12,1)
CONFOCAL MICROSCOPIC EXAMINATION(12,1)
ELUATE REVEALED ENRICHMENT(12,1)
JOHN HOPKINS UNIVERSITY(12,1)
MURINE POLYCLONAL ANTISERA GENERATION(12,1)
NEUTRAVIDIN AGAROSE BEAD(12,1)
PSGL BACTERIAL RECOGNITION(12,1)
TARGETING OMPA AA(12,1)
DC INOCULUM(11,3)
HOST CELL INFECTION(11,3)
MAMMALIAN HOST CELL(11,3)
ANAPLASMA SPECIES(11,2)
ANAPLASMOSIS SYMPTOM(11,1)
ANTISERUM INVERSE DILUTION(11,1)
APH OMPA RESIDUE(11,1)
APH STRAIN HZ GENOME(11,1)
CANDIDATE GENE ENTRY PLASMID(11,1)
CAPTURED BIOTINYLATED PROTEIN(11,1)
EPITOPE STERIC ISOLATION(11,1)
EXPERIMENTALLY INFECTED MOUSE(11,1)
GLUTATHIONE AFFINITY CHROMATOGRAPHY(11,1)
IGM ANTIBODY EVALUATION(11,1)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPE EXAMINATION(11,1)
INFECTED C3H HEJ MOUSE(11,1)
IRRELEVANT APH PROTEIN(11,1)
NEUTRAVIDIN AFFINITY CHROMATOGRAPHY(11,1)
NEUTROPHIL BLOCKING INFECTION(11,1)
NON INFECTIOUS RETICULATE CELL(11,1)
OMP CANDIDATE GENE(11,1)
PREDICTED EXTRACELLULAR DOMAIN(11,1)
PROTEIN PLAY HOUSEKEEPING ROLE(11,1)
BACTERIAL ADHESION(10,7)
ANAPLASMATACEAE INFECTION(10,4)
ENZYME LINKED IMMUNO SORBENT ASSAY(10,4)
HYPOTHETICAL PROTEIN(10,2)
PROTEIN HOMOLOGY ANALOGY(10,2)
STATISTICAL SIGNIFICANCE(10,2)
TARGETING ANTIBODY(10,2)
VACUOLAR MEMBRANE(10,2)
3H THYMIDINE INCORPORATION(10,1)
ANTIBACTERIAL CHEMOTHERAPEUTIC AGENT(10,1)
ANTIBODY TITER DEFINITION(10,1)
APH INVASIN(10,1)
ASP TRANSCRIPTIONAL PROFILE(10,1)
BIOTINYLATION ENRICHMENT(10,1)
C3H HEJ FEMALE MOUSE(10,1)
CHIMERA EPITOPE(10,1)
CHIMERIC VACCINOGEN(10,1)
COLLECTIVE AVIDITY(10,1)
CONTAMINATING HOST MAJORITY(10,1)
DC BACTERIAL INOCULUM(10,1)
DISCONTINUOUS RENOGRAFIN(10,1)
EHRLICHIA COUNTERPART(10,1)
ELECTRON MICROSCOPIC EXAMINATION(10,1)
FATAL OPPORTUNISTIC INFECTION(10,1)
HEART MICROVASCULATURE(10,1)
HOMOLOGY STRETCH(10,1)
IMMUNOHISTOCHEMICAL STAINING(10,1)
MEDIATING BACTERIUM HOST CELL(10,1)
MULTIDIMENSIONAL PEPTIDE SEPARATION(10,1)
OMP CANDIDATE ENCODING GENE(10,1)
OMPA PREDICTED EXTRACELLULAR REGION(10,1)
OMPA PREPROTEIN(10,1)
OMPA RELEVANCE(10,1)
ORGANISM CELL DEBRIS(10,1)
PHAGOCYTOPHILUM BACTERIUM(10,1)
POLYCLONAL ANTI OMPA ANTISERA(10,1)
PROTEIN STABILIZATION(10,1)
PSGL BACTERIAL ENGAGEMENT(10,1)
QIAGEN RNEASY KIT(10,1)
SCAPULARIS LARVA(10,1)
SIALIDASE COCKTAIL(10,1)
SLEX SIALIC ACID RESIDUE(10,1)
TAGGED FUSION PROTEIN(10,1)
TRANSGENIC APH DC ORGANISM(10,1)
VARIED SIALYLATED GLYCAN(10,1)
PHYRE(9,8)
ANTIBODY PRODUCTION(9,6)
WEBSITE(9,6)
REFSEQ(9,5)
LINEAR EPITOPE(9,3)
APH ADHESION(9,2)
BACTERIAL SPECIES(9,2)
DIAGNOSTIC ASSAY(9,2)
DIFFERENTIAL CENTRIFUGATION(9,2)
ENDOTHELIAL CELL INFECTION(9,2)
ESTABLISHED INFECTION(9,2)
LINKER INSERTION(9,2)
PROTEIN IDENTIFICATION(9,2)
PROTEOMIC ANALYSIS(9,2)
RECOGNITION ENGINE(9,2)
SCORING MODEL(9,2)
SPY(9,2)
SS BIOTIN(9,2)
SYMPTOM DEVELOPMENT(9,2)
TRIPLICATE SAMPLE(9,2)
ANTI MOUSE IGG(9,1)
ANTIBODY BLOCKING(9,1)
ANTIGEN FRAGMENT(9,1)
ANTIGENIC POLYPEPTIDE(9,1)
APH INVASION(9,1)
APH OMPA SEQUENCE(9,1)
APL POLYPEPTIDE(9,1)
BACILLUS CHORISMATE(9,1)
BACTERIA PRETREATMENT(9,1)
BACTERIA UPTAKE(9,1)
BIOTINYLATED BACTERIUM(9,1)
BIOTINYLATION AFFINITY(9,1)
BRACCO DIAGNOSTICS(9,1)
CHINESE HAMSTER OVARY CELL(9,1)
CLARIFIED LYSATE(9,1)
COMPETITIVE AGONIST(9,1)
COMPOSITION ORAL FORM(9,1)
CONSERVATIVE SUBSTITUTION NATURE(9,1)
CYSTEINE ALKYLATION(9,1)
DEFINITIVE DIAGNOSIS(9,1)
DISEASE HALLMARK(9,1)
ELUATE PROTEIN CONCENTRATION(9,1)
EXPRESSION DATA ACCURACY(9,1)
FRANKLIN LAKE(9,1)
FRESHLY PREPARED IODOACETAMIDE(9,1)
GLYCOPROTEIN RECEPTOR(9,1)
HGA PATIENT SERUM(9,1)
HUGE REPERTOIRE(9,1)
IMMUNOACCESSIBLE DOMAIN(9,1)
INFECTED MOUSE SERUM(9,1)
INFECTED NEUTROPHIL(9,1)
INFECTION CYCLE KINETICS(9,1)
INTRACELLULAR PATHOGEN(9,1)
INTRACELLULAR SIGNALING(9,1)
ISE INFECTION(9,1)
MINNESOTA UNIVERSITY(9,1)
NON BIOTINYLATED PROTEIN(9,1)
OMPA ADMINISTRATION(9,1)
OMPA INSERTION MUTANT PROTEIN(9,1)
OMPA RECEPTOR(9,1)
PATHOLOGICAL FINDING(9,1)
PLASMID EXPRESSION VECTOR(9,1)
PLATINUM PA DNA POLYMERASE(9,1)
PLG SCORE(9,1)
POLYCLONAL ANTI GST SERUM(9,1)
PRESUMABLY MULTIMERIC COMPLEX(9,1)
PROTEASE CLEAVAGE SITE(9,1)
RABBIT ANTI GST ANTIBODY(9,1)
REINITIATE INFECTION(9,1)
RESIDENT BACTERIA(9,1)
SHADED STRETCH(9,1)
SIALIC ACID CONTRIBUTION(9,1)
SIALIC ACID DETERMINANT(9,1)
SLEX FUCOSE(9,1)
SNA LECTIN(9,1)
SUB OPTIMAL INFECTION(9,1)
TANDEM MS PROTEIN(9,1)
TICK SALIVARY GLAND(9,1)
TRANSMEMBRANE HELIX(9,1)
TRYPSIN LYSATE(9,1)
UNCHARACTERIZED PROTEIN(9,1)
UNIPROT APH DATABASE(9,1)
UNPUBLISHED OBSERVATION(9,1)
UNSTRUCTURED LINKER(9,1)
WESTERN BLOTTED GST OMPA(9,1)
YALE UNIVERSITY(9,1)
LINKER AMINOACID(8,5)
DC WHOLE CELL LYSATE(8,3)
PEPTIDE BOND(8,3)
SDS PAGE(7,8)
TRANSMISSION FEED(7,4)
ACTIVE INGREDIENT(7,2)
ANTIBIOTIC TREATMENT(7,2)
BACTERIAL ACCESS(7,2)
BACTERIAL CELL(7,2)
BACTERIAL ENTRY(7,2)
COMBINED SALIVARY GLAND(7,2)
DECOY DATABASE(7,2)
DIFFERENTIAL GENE EXPRESSION(7,2)
IMMUNODOMINANT EPITOPE(7,2)
INDEPENDENT EXPERIMENT(7,2)
KDA BAND(7,2)
OMPA REGION(7,2)
TARGET PROTEIN(7,2)
VACCINATION(7,2)
ALANINE CODON(7,1)
ALANINE SUBSTITUTION(7,1)
AMMONIUM BICARBONATE(7,1)
ANTIBODY INCUBATION(7,1)
ANTIBODY SECRETION(7,1)
ANTIGEN ADMINISTRATION(7,1)
ANTIGENIC PEPTIDE SEQUENCE(7,1)
ANTIGENIC REGION IMMUNOGEN(7,1)
APH INFECTION COURSE(7,1)
APH INFECTION CYCLE(7,1)
APH RECOGNITION(7,1)
BACTERIAL INVASION(7,1)
BACTERIAL SURVIVAL(7,1)
BACTERIUM ANTIBODY CAUSE DEATH(7,1)
BACTERIUM PERIPHERY(7,1)
BRADFORD ASSAY(7,1)
CELL LYSATE PROTEIN(7,1)
EIA ASSAY(7,1)
EPITOPE ACCESSIBILITY(7,1)
EXPRESS GST OMPA(7,1)
EXPRESS PSGL(7,1)
EXPRESSION CATEGORY(7,1)
EXTENSIVE APH REPLICATION PERIOD(7,1)
EXTRACT INTEGRAL MEMBRANE PROTEIN(7,1)
FATAL DISEASE(7,1)
FCS EXPRESS(7,1)
FUSION POLYPEPTIDE(7,1)
GENE HOMOLOG(7,1)
GENE TRANSCRIPTION(7,1)
GST ANTISERUM(7,1)
GST OMPA INHIBITORY ACTION(7,1)
GST OMPA PROTEIN BEARING(7,1)
GST OMPA PURIFICATION(7,1)
GST TAGGED APH(7,1)
HEALTHY PEOPLE(7,1)
HGA INFECTION(7,1)
HISTIDINE(7,1)
HOST CELL ALIQUOT(7,1)
IDENTIFIED APH PROTEIN(7,1)
IDENTITY TSUTSUGAMUSHI EXHIBIT REGION(7,1)
INCOMPLETE GENE(7,1)
INFECTED CELL PERCENTAGE(7,1)
INFECTED TICK BITE(7,1)
INTERMOLECULAR INTERACTION(7,1)
MAMMALIAN CELL INFECTION(7,1)
MARGINALE STRAIN(7,1)
MATCHING FRAGMENT ION(7,1)
MATURE OMPA(7,1)
MEDIATING INTERACTION(7,1)
MISSED CLEAVAGE EVENT(7,1)
NA VE MOUSE(7,1)
NON BIOTINYLATED DC WHOLE(7,1)
OMPA ANTIBODY(7,1)
OMPA CODING REGION(7,1)
OMPA DOMAIN(7,1)
OMPA EXPRESSION(7,1)
OMPA INTERACTION(7,1)
OMPA SIALIC ACID INTERACTION(7,1)
PEPTIDE CONJUGATE(7,1)
PEPTIDE EPITOPE(7,1)
PHAGOCYTOPHILUM HZ(7,1)
POLYPEPTIDE FRAGMENT(7,1)
POSITIVE APH ORGANISM(7,1)
PREIMMUNE SERUM(7,1)
PRETREATING HOST CELL(7,1)
PROTECTIVE NICHE(7,1)
PURIFIED DC ORGANISM(7,1)
PURIFIED GST OMPA(7,1)
PURIFIED POLYPEPTIDE(7,1)
RABBIT ANTISERUM(7,1)
RAT INFECTION(7,1)
RCS TRANSITION(7,1)
RECOMBINANT PEPTIDE(7,1)
RECREATIONAL ANIMAL(7,1)
RESOURCE FACILITY(7,1)
SPECIMEN PAIR(7,1)
SYNCHRONOUS INFECTION(7,1)
TERMINAL PEPTIDE DETERMINANT(7,1)
TICK BATCH(7,1)
TICK COLONY(7,1)
TMPRED(7,1)
TRYPSIN SELECTIVITY(7,1)
UNBOUND PROTEIN(7,1)
UNVACCINATED HOST(7,1)
UREA LYSIS(7,1)
VARIABLE METHIONINE OXIDATION(7,1)
WESTERN BLOTTING(7,1)
WORD IMMUNOGEN(7,1)
ASPARTATE(6,3)
FINAL CONCENTRATION(6,3)
ISOLEUCINE(6,3)
OMPA AMINOACID(6,3)
CONSERVED REGION(6,2)
AFFINITY CAPTURED DC PROTEIN(6,1)
AFFINITY PURIFIED SAMPLE ALIQUOT(6,1)
AMMONIUM FORMATE(6,1)
ANAPLASMOSIS TREATMENT(6,1)
ANTI OMPA STAINING(6,1)
ANTIGEN MEANING(6,1)
ANTISERUM CONTINUED PRESENCE(6,1)
AP ORGANISM(6,1)
APH DC BACTERIUM(6,1)
APH WHOLE CELL LYSATE(6,1)
APPROACH EFFICACY(6,1)
BACTERIA TRANSMISSION(6,1)
BINARY FISSION(6,1)
BIOLOGICAL SAMPLE ASSAY(6,1)
CELL ADHESION(6,1)
COMMERCIAL LABORATORY(6,1)
COOMASSIE BLUE(6,1)
DC POSITIVE ORGANISM(6,1)
DE NOVO SOFTWARE(6,1)
DIAGNOSTIC TESTING(6,1)
DISEASE SPREAD(6,1)
EARLY STAGE GENE(6,1)
ELUTED PROTEIN(6,1)
ENDOTHELIAL CELL INVASION(6,1)
FAIRLAWN(6,1)
FUSION PEPTIDE(6,1)
GENE ENCODING(6,1)
GENE IDENTIFICATION(6,1)
GFP POSITIVE DC ORGANISM(6,1)
GST OMPAK64A ABILITY(6,1)
HOST TISSUE(6,1)
HUMIDIFIED ATMOSPHERE(6,1)
HUMORAL IMMUNE RESPONSE(6,1)
IMMUNOFLUORESCENCE MICROSCOPY ANALYSIS(6,1)
INFECTED HOST CELL(6,1)
INFECTION ASSAY(6,1)
IONIC INTERACTION(6,1)
LATE STAGE GENE(6,1)
MAMMALIAN INFECTION COURSE(6,1)
MOUSE IGM(6,1)
MS GRADE SOLVENT(6,1)
MYELOID CELL INFECTION(6,1)
NASCENT HOST(6,1)
NATIVE PROTEIN(6,1)
OMPA ABILITY(6,1)
OMPA EXHIBIT(6,1)
OMPA SEQUENCE ALIGNMENT(6,1)
OPTIMUM ADHESION(6,1)
ORGANISM PROTECTION(6,1)
OUTER SURFACE PROTEIN(6,1)
PATHOGEN ENTRY(6,1)
PEPTIDE ENCODING(6,1)
PEPTIDE SERUM(6,1)
PEPTIDE SPACER(6,1)
PHARMACOLOGICALLY ACCEPTABLE CARRIER(6,1)
PLG SOFTWARE(6,1)
PROTEIN INTERACTION(6,1)
PROTEIN PURIFICATION(6,1)
PROTEOME ANALYSIS(6,1)
PSGL ABSENCE(6,1)
PURIFIED PEPTIDE(6,1)
REACTIVITY FRACTION(6,1)
RECOMBINANT PROTEIN EXPRESSION(6,1)
REGULATED ASP(6,1)
RIPA BUFFER(6,1)
RLT BUFFER TUBE(6,1)
RNA EXTRACTION(6,1)
RNA ISOLATION(6,1)
SCAPULARIS CELL(6,1)
SEARCH PARAMETER(6,1)
SEQUENCE MULTITUDE(6,1)
SIALIDASE TREATMENT(6,1)
SODIUM DODECYL SULFATE(6,1)
SODIUM ORTHOVANADATE(6,1)
STRAIN VARIANT(6,1)
TABLE 5APH DC PROTEIN(6,1)
TANDEM REPEAT(6,1)
TARGET MRNA(6,1)
TREATMENT MODALITY(6,1)
TRUNCATED VERSION(6,1)
TRYPSIN GOLD(6,1)
ULTRASONIC PROCESSOR(6,1)
UNTRANSFECTED CHO CELL(6,1)
VACCINATING ANIMAL(6,1)
VACUOLE FORMATION(6,1)
VEHICLE TREATED APH ORGANISM(6,1)
VIRAL VECTOR(6,1)
ZOONOTIC CYCLE(6,1)
GENE SPECIFIC PRIMER(5,5)
PBS(5,5)
CSLEX(5,4)
SPACER AMINOACID(5,4)
CHEMICAL SYNTHESIS(5,3)
DEER(5,3)
CALMODULIN(5,2)
CMR JCVI ORG(5,2)
EXCIPIENT(5,2)
HEMAGLUTININ(5,2)
HYDROPHOBIC AMINOACID(5,2)
MIDGUT(5,2)
NCBI NLM NIH(5,2)
PLATY(5,2)
POLY HISTIDINE(5,2)
STREPTAVIDIN(5,2)
TRANSFEREASE(5,2)
UNIPROT SOURCE(5,2)
AMPLITUDE SETTING(5,1)
ANAPLASMATACEAE MEMBER(5,1)
ANTI OMPA SERUM(5,1)
ANTIBODY PRESENCE(5,1)
ANTIGENIC SEQUENCE(5,1)
ANTISERA PRODUCTION(5,1)
APH OUTER MEMBRANE(5,1)
APH SEQUENCE(5,1)
APL SEQUENCE(5,1)
AUXILIARY SUBSTANCE(5,1)
BACTERIA FILLED ORGANELLE(5,1)
BACTERIUM MOVEMENT(5,1)
BANDING PATTERN COMPARISON(5,1)
BUFFERING AGENT(5,1)
CELL EPITOPE(5,1)
CHEMICAL DOMAIN(5,1)
CLONING(5,1)
CLOSELY RELATED BACTERIUM FAMILY(5,1)
CLOSELY RELATED EHRLICHIA SPECIES(5,1)
CODING SEQUENCE(5,1)
COMMERCIAL ASSAY(5,1)
COMPOSITION ADMINISTRATION(5,1)
COMPOSITION PROTEIN SEQUENCE(5,1)
DC ADHESION(5,1)
DETECTABLE EXPRESSION SIGNAL(5,1)
DETECTION REAGENT(5,1)
DIAGNOSTIC METHOD(5,1)
DIAGNOSTIC TOOL(5,1)
DIFFERENTIAL APH GENE EXPRESSION(5,1)
DIFFERENTIAL EXPRESSION(5,1)
DIGESTED SAMPLE(5,1)
DISEASE TRANSMISSION CHAIN(5,1)
DOG BLOOD SAMPLE(5,1)
EDTA FREE PROTEASE INHIBITOR(5,1)
ELECTRONIC SEQUENCE LISTING(5,1)
ELEVATED SERUM TRANSAMINASE(5,1)
ENZYME REMOVAL(5,1)
EUKARYOTIC CELL MEMBRANE(5,1)
EXPRESSION SITE(5,1)
FACS ANALYSIS(5,1)
FALSE POSITIVE(5,1)
FILE NAME(5,1)
FISHER CHEMICAL(5,1)
FLAG(5,1)
GEL SLURRY(5,1)
GENE CONVERSION(5,1)
GLUTATHIONE SERIES(5,1)
GRAM NEGATIVE BACTERIA(5,1)
HOST ANIMAL(5,1)
HZ STRAIN(5,1)
IGG ANTIBODY LEVEL(5,1)
IMMUNOGENIC RESPONSE(5,1)
INFECTION STAGE(5,1)
INSECT CELL(5,1)
LINEAR POLYPEPTIDE MIXTURE(5,1)
LIU EL AL(5,1)
MAL II LECTIN(5,1)
MID STAGE GENE EXPRESSION(5,1)
MINIMUM PRECURSOR ION INTENSITY(5,1)
NATIVE SEQUENCE(5,1)
OPPORTUNISTIC INFECTION RISK INCREASE(5,1)
PAPER REMAINDER(5,1)
PATHOGEN REGION(5,1)
PEPTIDE CHAIN(5,1)
PEPTIDE TERMINAL(5,1)
PHENYLMETHANESULFONYL FLUORIDE(5,1)
PRIMARY ANTIBODY(5,1)
PROTECTIVE VACCINE COMPONENT(5,1)
PROTEIN COMPLEX(5,1)
PROTEIN DETECTION(5,1)
PROTEIN RECOGNITION(5,1)
RADIOIMMUNOPRECIPITATION ASSAY(5,1)
RECOMBINANT DNA TECHNOLOGY(5,1)
RECOMBINANT PROCESSING PROCEDURE ARTIFACT(5,1)
RECOMBINANT PROTEIN SEQUENCE(5,1)
REGION DISRUPTION(5,1)
RESEARCH TOOL(5,1)
RESPONSIVENESS(5,1)
SAMPLE MAJORITY(5,1)
SAMPLE REMAINDER(5,1)
SECONDARY ANTIBODY(5,1)
SEQUENCE ALTERATION(5,1)
SERUM SAMPLE(5,1)
SHORT PEPTIDE SEQUENCE ENCODING(5,1)
SLEX MODIFIED PSGL(5,1)
SOLUBILITY DECREASE(5,1)
SONICATED SAMPLE(5,1)
SUPERNATANT REMOVAL(5,1)
SYNERGISTIC REDUCTION(5,1)
SYNTHETIC PEPTIDE(5,1)
TANDEM MASS SPECTROMETER(5,1)
TERM ANTIGEN(5,1)
TERM PEPTIDE(5,1)
TERMINAL GLUTATHIONE(5,1)
THROMBOCYTOPENIA(5,1)
TICK CELL(5,1)
UNINFECTED INDIVIDUAL(5,1)
VECTOR CYCLE(5,1)
FOLDING(4,3)
LINEAR SEQUENCE(4,3)
PRIMARY SEQUENCE(4,3)
SBG(4,3)
PROTEIN RATIO(4,2)
REDUCING INFECTION(4,2)
LINEAR AMINOACID SEQUENCE(3,4)
ADHERENT(3,1)
ADJUNCT(3,1)
ADJUVANT(3,1)
ADMINISTRATION MODE(3,1)
AFFECTED SUBJECT(3,1)
ALHYDROGEL(3,1)
AMIDATION(3,1)
AMPLICON(3,1)
ANIMAL TICK TRANSMITTED DISEASE(3,1)
ANTIBODY SYNTHESIS(3,1)
ANTIGENIC DETERMINANT(3,1)
(US9248174)
OMPA(100,42)
ASP(100,21)
ANAPLASMA PHAGOCYTOPHILUM(100,9)
VACCINE(100,8)
INTRACELLULAR ANAPLASMATACEAE BACTERIUM(100,2)
DIAGNOSTIC TARGET(100,1)
POLYPEPTIDE ANTIBODY COMPLEX(71,4)
ANAPLASMATACEAE ASP(58,2)
ANAPLASMATACEAE BACTERIUM(51,3)
INNOCCULATING DOG(47,2)
CONSERVED INVASIN DOMAIN(36,1)
ZOONOTIC DISEASE(34,6)
ANAPLASMA PLATY(31,3)
APH INFECTION(28,14)
BIOLOGICAL SAMPLE ASSAY(26,1)
MAMMALIAN HOST(26,1)
TICK BORN BACTERIUM(25,1)
ANTIBODY(24,24)
MAMMALIAN CELL INFECTION(24,2)
ANAPLASMOSIS TREATMENT(24,1)
HOMOLOGOUS GENE(22,1)
ANAPLASMOSIS(21,13)
APH GENE(19,3)
SIALIC ACID RESIDUE(19,2)
DISPERSING AID(19,1)
TICK CELL(19,1)
ANAPLASMA MARGINALE(17,2)
THICKENING(17,1)
ANAPLASMATACAEA INFECTION RANGE(16,1)
COLONIZATION(16,1)
INFECTED INDIVIDUAL(16,1)
SIALIDASE(15,1)
EMULSIFIER(14,1)
FLAVORING(14,1)
6A CELL(13,19)
MAMMAL(13,10)
AMINOACID SEQUENCE(13,9)
ADJUVANT(13,7)
ANAPLASMATACAEA FAMILY MEMBER(12,1)
DILUENT(12,1)
PREVENTION(12,1)
PRETREATMENT(11,2)
BINDER(11,1)
APH 16S RDNA(10,2)
ANTI ASP(9,15)
HGA(9,9)
CHIMERIC PEPTIDE(9,7)
CHIMERIC PROTEIN(9,6)
EHRLICHIA SPP(9,5)
SCAPULARIS NYMPH(9,4)
AUTODOCK VINA(9,2)
OMPA INVASIN DOMAIN(9,2)
TECHNOLOGY VETERINARY APPLICATION(9,1)
TRANSMEMBRANE DOMAIN(8,4)
BIPHASIC DEVELOPMENTAL CYCLE(8,3)
IMMUNOBLOT(8,3)
NEUTRAVIDIN BEAD PLUS(8,3)
ALEXA FLUOR PERCENTAGE(8,2)
APH 16S RRNA GENE(8,2)
HUMAN GRANULOCYTIC ANAPLASMOSIS(8,2)
CELLO SUBCELLULAR PREDICTION SERVER(8,1)
CULTURE HARBORING TRANSGENIC HGE(8,1)
NEUTROPHIL APH COLONIZATION(8,1)
OMPA TARGET SIALYLATED GLYCOPROTEIN(8,1)
SLEX CAPPED PSGL DETERMINANT(8,1)
TERMINALLY SIALYLATED GLYCOPROTEIN(8,1)
LINKER SEQUENCE(7,8)
LINKED SIALIC ACID(7,6)
APH LYSATE(7,3)
CONFORMATIONAL EPITOPE(7,3)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY(7,3)
INFECTION INHIBITION(7,3)
APH INFECTED MOUSE(7,2)
HOST CELL PHAGOCYTOPHILUM INFECTION(7,2)
PROTEIN PURIFICATION LIGAND(7,2)
RICKETTSIALES BACTERIUM(7,2)
APH INFECTION DISSEMINATION(7,1)
GLUTATHIONE SEPHAROSE AFFINITY CHROMATOGRAPHY(7,1)
HEART MICROVASCULAR ENDOTHELIUM(7,1)
INFECTED IXODE SCAPULARIS(7,1)
INTRAVACUOLAR APH COLONY(7,1)
PLASMID ENCODING PCR MUTAGENESIS(7,1)
PROTEIN LYNX GLOBAL SURVEYOR(7,1)
RAISING RABBIT POLYCLONAL ANTISERUM(7,1)
CELLULAR DEBRIS(6,5)
HUMORAL IMMUNE RESPONSE(6,4)
ANAPLASMA SPP(6,2)
APH EFFECTOR(6,2)
APH NCH(6,2)
APH POPULATION(6,2)
BIOTIN CARBOXYL CARRIER PROTEIN(6,2)
FASTA DATABASE(6,2)
INTACT APH DC ORGANISM(6,2)
INTACT DC BACTERIUM(6,2)
INTRACELLULAR BACTERIA(6,2)
MARGINALE OMPA(6,2)
RECOMBINANT OMPA(6,2)
RECOMBINANT POLYPEPTIDE(6,2)
SPINNING DISC CONFOCAL MICROSCOPY(6,2)
THIOREDOXIN(6,2)
UNBOUND BACTERIA(6,2)
UNFED TICK(6,2)
16S RRNA GENE TRANSCRIPT(6,1)
ANAPLASMATACAEA SURFACE PROTEIN(6,1)
ANAPLASMATACEAE BACTERIUM EXPOSURE(6,1)
ANAPLASMATACEAE SPECIES BACTERIUM(6,1)
ANAPLASMATACEAE SPECIES GEOGRAPHICAL DISTRIBUTION(6,1)
ANAPLASMATASEAE FAMILY BACTERIUM(6,1)
ANNOTATED APH GENOME(6,1)
APH BACTERIUM UPTAKE(6,1)
APH INFECTED IXODE(6,1)
APH INFECTED NYMPH(6,1)
BOUND APH ORGANISM MAJORITY(6,1)
CANDIDATE GENE RECOMBINATION(6,1)
CONFOCAL MICROSCOPIC EXAMINATION(6,1)
ELUATE REVEALED ENRICHMENT(6,1)
INTRACELLULAR APH ORGANISM(6,1)
JOHN HOPKINS UNIVERSITY(6,1)
MONOCYTOTROPIC EHRLICHIA SPECIES(6,1)
MURINE POLYCLONAL ANTISERA GENERATION(6,1)
NEUTRAVIDIN AGAROSE BEAD(6,1)
OMPA ENCOMPASSING FRAGMENT(6,1)
POLYCLONAL ANTISERUM TARGETING(6,1)
PREIMMUNE MOUSE SERUM DILUTION(6,1)
PSGL BACTERIAL RECOGNITION(6,1)
TARGETING OMPA AA(6,1)
TRANSGENIC APH ORGANISM(6,1)
TSUTSUGAMUSHI OMPA PROTEIN(6,1)
GST ASP(5,22)
BACTERIAL ADHESION(5,7)
DC INOCULUM(5,3)
ENDOTHELIAL CELL INFECTION(5,3)
ENZYME LINKED IMMUNO SORBENT ASSAY(5,3)
ANAPLASMA PHAGOCYTOPHILUM SURFACE PROTEIN(5,2)
ANAPLASMA SPECIES(5,2)
HYPOTHETICAL PROTEIN(5,2)
KLH CONJUGATED PEPTIDE(5,2)
POST TICK FEEDING(5,2)
PROTEIN HOMOLOGY ANALOGY(5,2)
QUANTITATIVE PCR(5,2)
RABBIT ANTISERUM(5,2)
SERUM ALIQUOT(5,2)
STATISTICAL SIGNIFICANCE(5,2)
TARGET PRIMER(5,2)
TARGETING ANTIBODY(5,2)
VACUOLAR MEMBRANE(5,2)
ANAPLASMOSIS SYMPTOM(5,1)
ANTISERUM INVERSE DILUTION(5,1)
APH OMPA AA(5,1)
APH OMPA RESIDUE(5,1)
APH STRAIN HZ GENOME(5,1)
CANDIDATE GENE ENTRY PLASMID(5,1)
CAPTURED BIOTINYLATED PROTEIN(5,1)
EPITOPE STERIC ISOLATION(5,1)
EXPERIMENTALLY INFECTED MOUSE(5,1)
GLUTATHIONE AFFINITY CHROMATOGRAPHY(5,1)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPE EXAMINATION(5,1)
INFECTED C3H HEJ MOUSE(5,1)
IRRELEVANT APH PROTEIN(5,1)
MILLION CATTLE INDUSTRY HUNDRED(5,1)
NEUTRAVIDIN AFFINITY CHROMATOGRAPHY(5,1)
NEUTROPHIL BLOCKING INFECTION(5,1)
NON INFECTIOUS RETICULATE CELL(5,1)
OMP CANDIDATE GENE(5,1)
PREDICTED EXTRACELLULAR DOMAIN(5,1)
PROTEIN PLAY HOUSEKEEPING ROLE(5,1)
PHYRE(4,8)
ANTIBODY PRODUCTION(4,6)
WEBSITE(4,6)
REFSEQ(4,5)
ANAPLASMATACEAE INFECTION(4,3)
DC WHOLE CELL LYSATE(4,3)
LINEAR EPITOPE(4,3)
PEPTIDE BOND(4,3)
APH ADHESION(4,2)
BACTERIA TRANSMISSION(4,2)
BACTERIAL SPECIES(4,2)
DIFFERENTIAL CENTRIFUGATION(4,2)
ESTABLISHED INFECTION(4,2)
LINKER INSERTION(4,2)
MURINE BETA ACTIN(4,2)
PROTEIN IDENTIFICATION(4,2)
PROTEOMIC ANALYSIS(4,2)
RECOGNITION ENGINE(4,2)
SCORING MODEL(4,2)
SPY(4,2)
SS BIOTIN(4,2)
SYMPTOM DEVELOPMENT(4,2)
TRIPLICATE SAMPLE(4,2)
3H THYMIDINE INCORPORATION(4,1)
ANAPLASMOSIS DIAGNOSIS(4,1)
ANTI MOUSE IGG(4,1)
ANTIBACTERIAL CHEMOTHERAPEUTIC AGENT(4,1)
ANTIBODY BLOCKING(4,1)
ANTIBODY TITER DEFINITION(4,1)
ANTIGEN FRAGMENT(4,1)
ANTIGENIC POLYPEPTIDE(4,1)
APH INVASIN(4,1)
APH INVASION(4,1)
APH OMPA SEQUENCE(4,1)
ASP TRANSCRIPTIONAL PROFILE(4,1)
BACILLUS CHORISMATE(4,1)
BACTERIA PRETREATMENT(4,1)
BACTERIA UPTAKE(4,1)
BIOTINYLATED BACTERIUM(4,1)
BIOTINYLATION AFFINITY(4,1)
BIOTINYLATION ENRICHMENT(4,1)
BRACCO DIAGNOSTICS(4,1)
C3H HEJ FEMALE MOUSE(4,1)
CHIMERA EPITOPE(4,1)
CHIMERIC VACCINOGEN(4,1)
CHINESE HAMSTER OVARY CELL(4,1)
CIRCULATING NEUTROPHIL(4,1)
CLARIFIED LYSATE(4,1)
COLLECTIVE AVIDITY(4,1)
COMPETITIVE AGONIST(4,1)
COMPOSITION ORAL FORM(4,1)
CONSERVATIVE SUBSTITUTION NATURE(4,1)
CONTAMINATING HOST MAJORITY(4,1)
CYSTEINE ALKYLATION(4,1)
DC BACTERIAL INOCULUM(4,1)
DISCONTINUOUS RENOGRAFIN(4,1)
DISEASE HALLMARK(4,1)
EHRLICHIA CHAFFEENSIS(4,1)
EHRLICHIA COUNTERPART(4,1)
EHRLICHIA RUMINATIUM(4,1)
ELECTRON MICROSCOPIC EXAMINATION(4,1)
ELUATE PROTEIN CONCENTRATION(4,1)
EXPRESSION DATA ACCURACY(4,1)
FATAL OPPORTUNISTIC INFECTION(4,1)
FRANKLIN LAKE(4,1)
FRESHLY PREPARED IODOACETAMIDE(4,1)
GLYCOPROTEIN RECEPTOR(4,1)
HEART MICROVASCULATURE(4,1)
HGA PATIENT SERUM(4,1)
HOMOLOGY STRETCH(4,1)
HUGE REPERTOIRE(4,1)
HUMAN APH INFECTION(4,1)
IMMUNOACCESSIBLE DOMAIN(4,1)
IMMUNOHISTOCHEMICAL STAINING(4,1)
INFECTED MOUSE SERUM(4,1)
INFECTED NEUTROPHIL(4,1)
INFECTION CYCLE KINETICS(4,1)
INTRACELLULAR PATHOGEN(4,1)
INTRACELLULAR SIGNALING(4,1)
ISE INFECTION(4,1)
MAMMALIAN HOST CELL INFECTION(4,1)
MARGINALE INFECTION(4,1)
MEDIATING BACTERIUM HOST CELL(4,1)
MICROBIAL KILLING CAPABILITY(4,1)
MINNESOTA UNIVERSITY(4,1)
MULTIDIMENSIONAL PEPTIDE SEPARATION(4,1)
NEUTROPHIL INITIAL COLONIZATION(4,1)
NON BIOTINYLATED PROTEIN(4,1)
OMP CANDIDATE ENCODING GENE(4,1)
OMPA ADMINISTRATION(4,1)
OMPA INSERTION MUTANT PROTEIN(4,1)
OMPA PREDICTED EXTRACELLULAR REGION(4,1)
OMPA PREPROTEIN(4,1)
OMPA RECEPTOR(4,1)
OMPA RELEVANCE(4,1)
ORGANISM CELL DEBRIS(4,1)
PATHOLOGICAL FINDING(4,1)
PHAGOCYTOPHILUM BACTERIUM(4,1)
PLASMID EXPRESSION VECTOR(4,1)
PLATINUM PA DNA POLYMERASE(4,1)
PLG SCORE(4,1)
POLYCLONAL ANTI GST SERUM(4,1)
POLYCLONAL ANTI OMPA ANTISERA(4,1)
PRESUMABLY MULTIMERIC COMPLEX(4,1)
PROTEASE CLEAVAGE SITE(4,1)
PROTEIN STABILIZATION(4,1)
PSGL BACTERIAL ENGAGEMENT(4,1)
QIAGEN RNEASY KIT(4,1)
RABBIT ANTI GST ANTIBODY(4,1)
REINITIATE INFECTION(4,1)
RESIDENT BACTERIA(4,1)
SCAPULARIS LARVA(4,1)
SHADED STRETCH(4,1)
SIALIC ACID CONTRIBUTION(4,1)
SIALIC ACID DETERMINANT(4,1)
SIALIDASE COCKTAIL(4,1)
SLEX FUCOSE(4,1)
SLEX SIALIC ACID RESIDUE(4,1)
SNA LECTIN(4,1)
SUB OPTIMAL INFECTION(4,1)
TAGGED FUSION PROTEIN(4,1)
TANDEM MS PROTEIN(4,1)
TICK SALIVARY GLAND(4,1)
TRANSGENIC APH DC ORGANISM(4,1)
TRANSMEMBRANE HELIX(4,1)
TRYPSIN LYSATE(4,1)
UNCHARACTERIZED PROTEIN(4,1)
UNIPROT APH DATABASE(4,1)
UNPUBLISHED OBSERVATION(4,1)
UNSTRUCTURED LINKER(4,1)
VARIED SIALYLATED GLYCAN(4,1)
WESTERN BLOTTED GST OMPA(4,1)
YALE UNIVERSITY(4,1)
SDS PAGE(3,9)
ELISA(3,5)
ANAPLASMATACEAE FAMILY MEMBER(3,4)
TRANSFERASE(3,4)
TRANSMISSION FEED(3,4)
ASPARTATE(3,3)
FINAL CONCENTRATION(3,3)
ISOLEUCINE(3,3)
LINKER AMINOACID(3,3)
OMPA AMINOACID(3,3)
ACTIVE INGREDIENT(3,2)
BACTERIAL ACCESS(3,2)
BACTERIAL CELL(3,2)
BACTERIAL ENTRY(3,2)
BIOLOGICAL SAMPLE(3,2)
COMBINED SALIVARY GLAND(3,2)
CONSERVED REGION(3,2)
DECOY DATABASE(3,2)
DIFFERENTIAL GENE EXPRESSION(3,2)
IMMUNODOMINANT EPITOPE(3,2)
INDEPENDENT EXPERIMENT(3,2)
INITIAL IMMUNIZATION(3,2)
KDA BAND(3,2)
OMPA REGION(3,2)
PATHOGEN LOAD(3,2)
TARGET PROTEIN(3,2)
AFFINITY CAPTURED DC PROTEIN(3,1)
AFFINITY PURIFIED SAMPLE ALIQUOT(3,1)
ALANINE CODON(3,1)
ALANINE SUBSTITUTION(3,1)
AMMONIUM BICARBONATE(3,1)
AMMONIUM FORMATE(3,1)
ANTI OMPA STAINING(3,1)
ANTIBODY INCUBATION(3,1)
ANTIBODY SECRETION(3,1)
ANTIGEN ADMINISTRATION(3,1)
ANTIGEN MEANING(3,1)
ANTIGENIC PEPTIDE SEQUENCE(3,1)
ANTIGENIC REGION IMMUNOGEN(3,1)
ANTISERUM CONTINUED PRESENCE(3,1)
AP ORGANISM(3,1)
APH DC BACTERIUM(3,1)
APH INFECTION COURSE(3,1)
APH INFECTION CYCLE(3,1)
APH RECOGNITION(3,1)
APH WHOLE CELL LYSATE(3,1)
APPROACH EFFICACY(3,1)
BACTERIAL INVASION(3,1)
BACTERIAL SURVIVAL(3,1)
BACTERIUM ANTIBODY CAUSE DEATH(3,1)
BACTERIUM PERIPHERY(3,1)
BINARY FISSION(3,1)
BLOOD UL(3,1)
BRADFORD ASSAY(3,1)
CELL ADHESION(3,1)
CELL LYSATE PROTEIN(3,1)
COOMASSIE BLUE(3,1)
DC POSITIVE ORGANISM(3,1)
DE NOVO SOFTWARE(3,1)
DIAGNOSTIC ASSAY(3,1)
DIAGNOSTIC TESTING(3,1)
DISEASE SPREAD(3,1)
DISSEMINATION STAGE(3,1)
EARLY STAGE GENE(3,1)
ELUTED PROTEIN(3,1)
ENDOTHELIAL CELL INVASION(3,1)
EPITOPE ACCESSIBILITY(3,1)
EXPRESS GST OMPA(3,1)
EXPRESS PSGL(3,1)
EXPRESSION CATEGORY(3,1)
EXTENSIVE APH REPLICATION PERIOD(3,1)
EXTRACT INTEGRAL MEMBRANE PROTEIN(3,1)
FAIRLAWN(3,1)
FATAL DISEASE(3,1)
FCS EXPRESS(3,1)
FUSION PEPTIDE(3,1)
FUSION POLYPEPTIDE(3,1)
GENE ENCODING(3,1)
GENE HOMOLOG(3,1)
GENE IDENTIFICATION(3,1)
GENE TRANSCRIPTION(3,1)
GFP POSITIVE DC ORGANISM(3,1)
GST ANTISERUM(3,1)
GST OMPA INHIBITORY ACTION(3,1)
GST OMPA PROTEIN BEARING(3,1)
GST OMPA PURIFICATION(3,1)
GST OMPAK64A ABILITY(3,1)
GST TAGGED APH(3,1)
HGA INFECTION(3,1)
HOST CELL ALIQUOT(3,1)
HOST TISSUE(3,1)
HUMIDIFIED ATMOSPHERE(3,1)
IDENTIFIED APH PROTEIN(3,1)
IDENTITY TSUTSUGAMUSHI EXHIBIT REGION(3,1)
IMMUNOFLUORESCENCE MICROSCOPY ANALYSIS(3,1)
INCOMPLETE GENE(3,1)
INFECTED CELL PERCENTAGE(3,1)
INFECTED HOST CELL(3,1)
INFECTED TICK BITE(3,1)
INFECTION ASSAY(3,1)
INHIBITED BACTERIAL INFECTION(3,1)
INTERMOLECULAR INTERACTION(3,1)
IONIC INTERACTION(3,1)
LATE STAGE GENE(3,1)
MAMMALIAN INFECTION COURSE(3,1)
MARGINALE OUTER MEMBRANE PROTEIN(3,1)
MARGINALE SHARE(3,1)
MARGINALE STRAIN(3,1)
MATCHING FRAGMENT ION(3,1)
MATURE OMPA(3,1)
MEDIATING INTERACTION(3,1)
MISSED CLEAVAGE EVENT(3,1)
MOUSE IGM(3,1)
MS GRADE SOLVENT(3,1)
MYELOID CELL INFECTION(3,1)
NA VE MOUSE(3,1)
NASCENT HOST(3,1)
NATIVE PROTEIN(3,1)
NITROCELLULOSE MEMBRANE(3,1)
NON BIOTINYLATED DC WHOLE(3,1)
OMPA ABILITY(3,1)
OMPA ANTIBODY(3,1)
OMPA CODING REGION(3,1)
OMPA DOMAIN(3,1)
OMPA EXHIBIT(3,1)
OMPA EXPRESSION(3,1)
OMPA INTERACTION(3,1)
OMPA SEQUENCE ALIGNMENT(3,1)
OMPA SIALIC ACID INTERACTION(3,1)
OPTIMUM ADHESION(3,1)
ORGANISM PROTECTION(3,1)
PATHOGEN ENTRY(3,1)
PEPTIDE CONJUGATE(3,1)
PEPTIDE EPITOPE(3,1)
PEPTIDE SERUM(3,1)
PEPTIDE SPACER(3,1)
PHAGOCYTOPHILUM HZ(3,1)
PHARMACOLOGICALLY ACCEPTABLE CARRIER(3,1)
PLG SOFTWARE(3,1)
POLYPEPTIDE FRAGMENT(3,1)
POSITIVE APH ORGANISM(3,1)
PREIMMUNE SERUM(3,1)
PRETREATING HOST CELL(3,1)
PROTECTIVE NICHE(3,1)
PROTEIN INTERACTION(3,1)
PROTEOME ANALYSIS(3,1)
PSGL ABSENCE(3,1)
PURIFIED DC ORGANISM(3,1)
PURIFIED GST OMPA(3,1)
PURIFIED PEPTIDE(3,1)
PURIFIED POLYPEPTIDE(3,1)
RAT INFECTION(3,1)
RCS TRANSITION(3,1)
REACTIVITY FRACTION(3,1)
RECOMBINANT PEPTIDE(3,1)
RECOMBINANT PROTEIN EXPRESSION(3,1)
RECREATIONAL ANIMAL(3,1)
REGULATED ASP(3,1)
RESOURCE FACILITY(3,1)
RIPA BUFFER(3,1)
RLT BUFFER TUBE(3,1)
RNA EXTRACTION(3,1)
RNA ISOLATION(3,1)
SCAPULARIS CELL(3,1)
SCID MOUSE INFECTION(3,1)
SEARCH PARAMETER(3,1)
SEQUENCE MULTITUDE(3,1)
SIALIDASE TREATMENT(3,1)
SODIUM DODECYL SULFATE(3,1)
SODIUM ORTHOVANADATE(3,1)
SYNCHRONOUS INFECTION(3,1)
TABLE 5APH DC PROTEIN(3,1)
TANDEM REPEAT(3,1)
TARGET MRNA(3,1)
TERMINAL PEPTIDE DETERMINANT(3,1)
TICK BATCH(3,1)
TICK COLONY(3,1)
TMPRED(3,1)
TREATMENT MODALITY(3,1)
TRUNCATED VERSION(3,1)
TRYPSIN GOLD(3,1)
TRYPSIN SELECTIVITY(3,1)
ULTRASONIC PROCESSOR(3,1)
UNBOUND PROTEIN(3,1)
UNTRANSFECTED CHO CELL(3,1)
UNVACCINATED HOST(3,1)
UREA LYSIS(3,1)
VACCINE PREPARATION(3,1)
VACUOLE FORMATION(3,1)
VARIABLE METHIONINE OXIDATION(3,1)
VEHICLE TREATED APH ORGANISM(3,1)
VIRAL VECTOR(3,1)
WESTERN BLOTTING(3,1)
WORD IMMUNOGEN(3,1)
ZOONOTIC CYCLE(3,1)
GENE SPECIFIC PRIMER(2,5)
PBS(2,5)
BOOST(2,4)
CSLEX(2,4)
PERIPHERAL BLOOD(2,4)
BODY FLUID(2,3)
CHEMICAL SYNTHESIS(2,3)
DEER(2,3)
FOLDING(2,3)
LINEAR SEQUENCE(2,3)
LIVER(2,3)
PRIMARY SEQUENCE(2,3)
SBG(2,3)
CALMODULIN(2,2)
CMR JCVI ORG(2,2)
EXCIPIENT(2,2)
HEMAGLUTININ(2,2)
HYDROPHOBIC AMINOACID(2,2)
IMMUNIZATION SCHEDULE(2,2)
MIDGUT(2,2)
NCBI NLM NIH(2,2)
PLATY(2,2)
POLY HISTIDINE(2,2)
PROTEIN RATIO(2,2)
REDUCING INFECTION(2,2(...)";"Analysis of biological materials
Pharmaceuticals";Open
2012-06-14;"KR20130140477       A  2013-12-24 [KR20130140477]
STG: (A) Published application
AP : 2012KR-0063911 2012-06-14
KR10-1876535        B1 2018-07-09 [KR101876535]
STG: (B1) Patent specification
AP : 2012KR-0063911 2012-06-14";61162984;"KR20130140477       A  2013-12-24 [KR20130140477]
KR10-1876535        B1 2018-07-09 [KR101876535]";2012KR-0063911;;VETALL;VETALL;;"(KR20130140477)
NAME=VETALL CO., LTD. , REG=120070091992 

(KR101876535)
NAME=VETALL CO., LTD. , REG=120070091992 
";1;"LEE, DAE EUN
YANG, MI YOUNG
Lee, Hun-Sik
KIM, JEONG MI";;;"(KR101876535)
Antibody for detecting of bovine viral diarrhea virusbvdv bvdv antigen detecting method and test kit using thereof";"(KR101876535)
The present invention relates to an epitope of the bovine viral diarrhea virus (BVDV), a vaccine composition comprising the epitope, an antibody and a fragment thereof prepared by using the epitope, a BVDV antigen detecting kit comprising the antibody or the fragment thereof, and a BVDV antigen detecting method using the kit. The present invention is very useful since the infection or non-infection of BVDV in the bovine blood is promptly detected and also tested outdoors. Especially, the BVDV antigen detecting kit can diagnose the bovine viral diarrhea at the early of infection as compared with antibody identification through a serological method. Therefore, the BVDV antigen detecting kit is regarded to help blocking the spread of BVDV, thereby contributing to an increase in the economical gain of bovine breeding farmhouses.";"(KR20130140477)
1. The amino acid sequence of SEQ ID NO:8 to 10 to 40 consecutive amino acids of the polypeptide consisting of the two including, bovine viral diarrhea virus E2 protein (BVDV, Bovine Viral Diarrhea Virus) having an antigenic determinant of a polypeptide molecule (epitope).
2. Method according to claim 1, the amino acid sequence of SEQ ID NO:7 consisting of the polypeptide, a polypeptide molecule.
3. Method according to claim 1, type 1a bovine viral diarrhea virus antigen type, 1b type and 2a type protein selected from the group consisting of at least one antigenic determinant of the 1 polypeptide molecule.
4. A second antigenic polypeptide molecule of claim 1, wherein the polypeptide molecule DNA molecule encoding, an expression vector comprising the DNA molecule, and wherein the transformed cell transformed with the expression vector selected from the group consisting of at least one 1 comprising as an active ingredient a virus or a bovine viral diarrhea (BVDV, Bovine Viral Diarrhea Virus) in a vaccine composition.
5. Claim 1 the first polypeptide molecule that specifically recognizes the antibody or fragment thereof.
6. Method according to claim 5, wherein the antibody is a monoclonal antibody or a polyclonal antibody, the antibody or fragment thereof.
7. Claim 5 antibody or fragment thereof of a second active ingredient or a bovine viral diarrheic diseases including viral prophylaxis or treatment of infection (BVDV, Bovine Viral Diarrhea Virus) composition.
8. The second antibody or fragment thereof of claim 5 comprising a bovine viral diarrheic diseases kit for the detection of viral antigen (BVDV, Bovine Viral Diarrhea Virus).
9. Method according to claim 8, wherein the kit comprises the antibody or fragment thereof is adsorbed as a test line comprises a membrane, the kit.
10. 8 Kit according to the first bovine viral diarrheic diseases using viral antigen (BVDV, Bovine Viral Diarrhea Virus) detection method.
11. Method according to claim 10, the method further silent blood, plasma, serum, lymph, tissue fluid, urine, tears, saliva, milk, vomitus, diarrhea in bovine viral or fecal virus type 1a (BVDV, Bovine Viral Diarrhea Virus) antigen type, 1b type, 2a and 1 in the form of one or more selected from the group consisting of detection methods.";"(KR101876535)
The subject of the present invention is preferably a bodily fluid or secretion of an animal to be diagnosed can be, for example of bovine blood, serum, plasma, lymph, tissue fluid or the like, or in vitro exudate that is secreted into the urine, tears, saliva, milk, vomitus, feces and blood and the like but preferably, but is not limited thereto.
The labeling reagent that is to say, the present invention is a labeled detection reagent is one of ordinary skill in the art will be well known to those skilled in the an can be used, for example the label can be a catalyst, an enzyme (e.g., phosphatase, peroxidase and the like, in a more specific example include enzyme substrates and bond together the basic phosphatidylinsitosols pertase and sheep chili using peroxidase or the like), an enzyme substrate (for example, nitro blue tetrazolium, 3, 5', 5, 5'-tetra nitrobenzidine, 4-- methoxy-1-naphthol, 4-chloro-1-naphthol, 5-- bromo - -4- - chloro - -3- - indolyl phosphate, chemiluminescent enzyme substrates include dioxetane, phewa derived and analogs thereof), a fluorescent compound (for example, flow ureido fluorescein, picocode bilirubin slawx (phycobiliprotein), rhodamine derivative and analogs thereof and the like), a chemiluminescent compound, a Metal sol, a Dye sol, latex particles (Particulate latex), a Color Indicator, liposomes (Color matter) contained in the color material, [ ] chemiluminescent compound, a Metal sol, a Dye sol, latex particles (Particulate latex), a Color Indicator, color material included in the liposomes (Color matter), base metals such as selenium and carbon sol sol 1 can be at least one selected from but not limited to.
The present invention relates to a bovine viral diarrhea virus (BVDV, Bovine Viral Diarrhea Virus) an antigenic determinant (epitope) of, a vaccine composition comprising the same, which can be produced by using the antibody or fragment thereof, wherein the antibody or fragment thereof comprising an antigen and a kit for detecting a virus or a bovine viral diarrheic diseases using the same method for detecting viral antigens or a bovine viral diarrheic diseases of the present invention.";"(KR101876535)
However these methods are cumbersome and must be tissue culture takes a long testing period, for analysis of specialized knowledge or expensive equipment to be problems.
In the present invention is to solve the problems of the prior art as to provide a system for, bovine viral diarrhea virus (BVDV, Bovine Viral Diarrhea Virus) to generate a neutralizing antibody against gp53/E2 protein known as protein structure and immunogenicity of the amino acid sequence has been found that particularly high amino acid sequence of the peptide was synthesized and made to an antibody against the, it can be used to quickly and easily on site in cattle BVDV diagnosed to be antigen detection kit using the same BVDV to provide a method for detection of the object.
The results of the detection method is to overcome the limitations of molecular biology assay is quick and simple and relatively low levels and necessary to control the extent of the detection method may be referred to.
The BVDV worldwide cause of diarrheic diseases bovine viral interspersed as, in addition to acute deaths due to diarrhea neutropenia, gastrointestinal mucosal hyperemia, ulceration, and respiratory tract lesions, pregnancy abortion or stillbirth addend, and the like alone and combined immunodeficiency virus form while, at the time of onset of a large amount of breeding agricultural economic harm and others.";"A61K-039/12
C07K-014/18
C07K-016/10
C12N-015/40";"(KR101876535)
8 An amino acid sequence of SEQ ID NO, bovine viral diarrhea virus E2 protein (BVDV, Bovine Viral Diarrhea Virus) having an antigenic determinant of a polypeptide molecule (epitope).
10. 8 Kit according to first use of a virus or a bovine viral diarrheic diseases (BVDV, Bovine Viral Diarrhea Virus) method for detecting an antigen.";"(KR20130140477)
BVDV(100,43)
BOVINE VIRAL DIARRHEA VIRUS(100,19)
KIT(100,17)
AMINOACID SEQUENCE(100,12)
BOVINE(100,6)
VIRAL DIARRHEIC DISEASE(100,4)
DETECTION KIT(100,2)
VIRAL ANTIGEN(100,2)
ANTIGEN DETECTION(100,1)
CONSUMER DETECTION(100,1)
VIRAL DIARRHEIC VIRUS ANTIBODY(100,1)
BOVINE VIRAL EPITOPE(52,1)
BOVINE VIRAL ANTIGEN(45,2)
POLYPEPTIDE MOLECULE ANTIGENIC DETERMINANT(39,2)
BASIC PHOSPHATIDYLINSITOSOL PERTASE(39,1)
VIRAL DIARRHEA(37,1)
LATEX PARTICLE(36,4)
PICOCODE BILIRUBIN(36,1)
DIARRHEA VIRUS(35,1)
NITRO BLUE TETRAZOLIUM(35,1)
VIRAL DIARRHEIC DISEASE KIT(34,1)
CHEMILUMINESCENT COMPOUND(33,2)
TETRA NITROBENZIDINE(32,1)
UREIDO FLUORESCEIN(32,1)
DYE SOL(31,2)
CHEMILUMINESCENT ENZYME SUBSTRATE(31,1)
VACCINE(29,5)
ANTIBODY NEUTRALIZATION(29,1)
SHEEP CHILI(29,1)
ANTIBODY(28,49)
SPECIALIZED KNOWLEDGE ANALYSIS(28,1)
RHODAMINE DERIVATIVE(26,1)
COLOR INDICATOR(25,2)
ENZYME SUBSTRATE(25,2)
AGRICULTURAL ECONOMIC BENEFIT(25,1)
INDOLYLPHOSPHATE(25,1)
POLYPEPTIDE MOLECULE DNA(25,1)
SERUM BVDV(25,1)
BREEDING CATTLE(23,1)
EXPRESSION VECTOR(22,2)
MOLECULAR BIOLOGY ASSAY LIMITATION(22,1)
LIPOSOME(21,2)
ANTIGEN ANTIBODY(21,1)
TISSUE CULTURE(21,1)
VIRAL PROPHYLAXIS(20,1)
LABELED REAGENT(19,3)
BVDV DIFFUSION(19,2)
LABEL DETECTION REAGENT(19,2)
PEROXIDASE(19,2)
POLYPEPTIDE CONSECUTIVE AMINOACID(19,2)
FLUORESCENT COMPOUND(19,1)
DIARRHEA(18,2)
NAPHTHOL(18,2)
EPITOPE(17,8)
BVDV INFECTION(17,3)
ACTIVE INGREDIENT(17,2)
METAL SOL(17,2)
BOVINE BLOOD PRESENCE(17,1)
PHYCOBILIPROTEIN(17,1)
SILENT BLOOD(16,1)
INFECTION EARLY DIAGNOSIS(15,2)
DNA MOLECULE(15,1)
INSPECTION PERIOD(15,1)
MOLECULE ENCODING(15,1)
ANTIGENIC DETERMINANT(14,10)
PROTEIN(14,8)
VIRUS(14,8)
DIOXETANE(14,1)
EXPENSIVE EQUIPMENT(14,1)
PHOSPHATASE(14,1)
VIRAL ANTIGEN DETECTION(14,1)
INFECTION TREATMENT(13,1)
TRANSFORMED CELL(13,1)
FRAGMENT(12,2)
LABEL(12,1)
PHEWA(12,1)
SELENIUM(12,1)
AMINOACID SEQUENCE IMMUNOGENICITY(10,1)
ANTIGEN BVDV DETECTION(10,1)
METHOXY(10,1)
ANTIGEN(9,20)
CATTLE(9,2)
ENZYME(9,2)
PEPTIDE AMINOACID SEQUENCE(9,1)
PROTEIN STRUCTURE(9,1)
TISSUE FLUID(8,3)
CONJUGATION PAD(7,6)
BOVINE VIRAL DIARRHEA(7,3)
CYTOPATHIC BVDV(7,3)
VOMITUS(7,3)
BOVINE VIRAL DIARRHEIC DISEASE(7,1)
DERMIS IMMUNOHISTOCHEMICAL STAINING(7,1)
GASTROINTESTINAL MUCOSAL HYPEREMIA(7,1)
POLYCLONAL ANTIBODY STUCKNITROCELLULOSE MEMBRANE(7,1)
SEPARATIST NCP BVDV(7,1)
SALIVA(6,3)
URINE(6,3)
FORESTRY QUARANTINE TEST(6,2)
TYPE ANTIGEN(6,2)
ANTI MOUSE IMMUNOGLOBULIN ANTIBODY(6,1)
BOVINE BVDV DIAGNOSIS(6,1)
CATTLE BVDV BLOOD(6,1)
CH RABBIT IGG FITC(6,1)
DIFFERENTIAL DEPOSITION(6,1)
PEPTIDE FORPOLYCLONAL ANTIBODY(6,1)
PRECIOUS METAL(6,1)
PREGNANCY BORN CALF(6,1)
SERUM COIIFOCA PCR(6,1)
STRIP INACTIVATED BVDV DOMESTIC(6,1)
LYMPH(5,3)
MILK(5,3)
TEAR(5,3)
ABSORBANCE SPECTRA(5,2)
DOMESTIC CATTLE(5,2)
GOLD PARTICLE SUSPENSION(5,2)
ACUTE DIARRHEA MORTALITY(5,1)
AGRICULTURAL ECONOMIC HARM(5,1)
BVDV POLYPEPTIDE MOLECULE(5,1)
IMMUNOAFFINITY CHROMATOGARPHY(5,1)
IMMUNOFLUORESCENCE ASSAY KIT(5,1)
INDIRECT IMMUNOFLUORESCENT ANTIBODY(5,1)
INFECTIOUS DISEASE SUSTAINED DURATION(5,1)
NEUTRALIZATION TEST SEROLOGIC DIAGNOSIS(5,1)
PBS FLUORESCENCE MICROSCOPE(5,1)
PROTEIN ANTIGEN BVDV(5,1)
TRANSLATIONAL MODIFICATION TRANSMEMBRANE DOMAIN(5,1)
ANALYTE(4,5)
GOLD SOLUTION(4,5)
SAMPLE PAD(4,5)
SURMODICS(4,5)
ANTIBODY PRODUCTION(4,3)
CELL LYSATE(4,3)
INFECTED CELL(4,3)
SODIUM BORATE(4,3)
1B TYPE(4,2)
ANTIGENIC SITE(4,2)
SODIUM TETRABORATE(4,2)
ANTI FITC ANTIBODY(4,1)
ANTI MOUSE ANTIBODY(4,1)
ANTI MOUSE IGG(4,1)
ANTIBODY CONCENTRATION BVDV BUFFER(4,1)
ANTIGEN BVDV ABSENCE(4,1)
ANTIGEN POLYPEPTIDE MOLECULE(4,1)
ANTIGEN REACTIVITY(4,1)
ASSAY STRIP SPECIMEN(4,1)
BVDV ANTIBODY GOLD CONJUGATE(4,1)
BVDV DIAGNOSTIC(4,1)
BVDV IMMUNODIPSTICK(4,1)
BVDV SEROTYPE(4,1)
BVDV1A BVDV1(4,1)
BVDV2 GENOTYPE(4,1)
CONJUGATED BSA CONCENTRATION(4,1)
DIAGNOSING BVDV(4,1)
DILUTED RABBIT IGG HRP(4,1)
EAR WEEK INTERVAL(4,1)
FLAVIVIRIDAE FAMILY(4,1)
FLORESCENT ANTIBODY(4,1)
FLUORESCEIN ISOTHIOCYANATE(4,1)
GOAT ANTI RABBIT(4,1)
GOLD PARTICLE ADSORPTION(4,1)
GOLD SENSITIZER PARTICLE(4,1)
IMMUNOAFFINITY CHROMATOGRAPHY(4,1)
IMMUNOPRECIPITATION KIT(4,1)
INFECTIOUS DISEASE ABSENCE(4,1)
INTRAPERITONEAL ADMINISTRATION(4,1)
LIMPET HEMOCYANIN(4,1)
LOW LEVEL(4,1)
MONOCLONAL ANTIBODY SEROTYPE(4,1)
MOUSE IGG VIRAL ANTIGEN(4,1)
NUCLEOTIDE BVDV(4,1)
PEPTIDE IMMUNIZATION(4,1)
PRE ACTIVATION PEPTIDE(4,1)
PREACTIVATED KLH(4,1)
PREPARATION BVDV ANTIGEN(4,1)
PROTEIN ANTIGENIC DETERMINANT(4,1)
RABBIT IMMUNIZATION(4,1)
SURVIVAL PROLONGATION(4,1)
SYMPTOM BVDV(4,1)
VIRAL TRANSCRIPTION DEVELOPMENT(4,1)
WESTERN BLOTTING(4,1)
LABORATORY(3,4)
ENZYME IMMUNOASSAY(3,3)
SAMPLE INLET(3,3)
DETECTION REAGENT(3,2)
FINAL PELLET(3,2)
PRIMARY ANTIBODY(3,2)
RED BAND(3,2)
SEALED CONTAINER(3,2)
SECONDARY ANTIBODY(3,2)
SPLEEN CELL(3,2)
1M GLYCINE(3,1)
AB ELISA(3,1)
AGAROSE BEAD(3,1)
ALLEVIATING DISEASE PROGRESSION(3,1)
ANIMAL SECRETION(3,1)
ANTI CH RABBIT(3,1)
ANTI IMMUNOGLOBULIN COLUMN(3,1)
ANTIBODY BVDV REACTION(3,1)
ANTIBODY COMPARISON(3,1)
ANTIBODY INSERT(3,1)
ANTIBODY PURIFICATION(3,1)
ANTIGEN DETERMINANT PRODUCTION(3,1)
ANTIGEN EFFICACY(3,1)
ANTIGEN GENE(3,1)
ANTIGENICITYPOLYPEPTJDE SEQUENCE(3,1)
BIOINFORMATICS PROGRAM(3,1)
BLOTTING KIT(3,1)
BORDER DISEASE VIRUS(3,1)
BOVINE BLOOD ANTIGEN POSITIVE(3,1)
BOVINE SERUM ALBUMIN(3,1)
BVDV ANTIBODY REACTION(3,1)
BVDV DETECTION KIT(3,1)
BVDV GOLD CONJUGATE(3,1)
BVDV1 GENE(3,1)
CLINICAL SYMPTOM VARIETY(3,1)
CO2 INCUBATOR(3,1)
COLUMN AFFINITY CHROMATOGRAPHY(3,1)
COMPOSITE MEMBRANE(3,1)
COVERING STRIP ASSAY(3,1)
CULTURE SUPERNATANT(3,1)
DARBY KIDNEY(3,1)
DETECTION METHOD DEGREE(3,1)
DIAGNOSTIC STRIP MANUFACTURE(3,1)
DNAMAN VERSION(3,1)
DOMAIN EXCLUSION ANALYSIS(3,1)
ELISA READER(3,1)
ETIOLOGICAL AGENT(3,1)
EXPERIMENTAL ANIMAL(3,1)
FINALLY PURE POLYCLONAL ANTIBODY(3,1)
GOLD CONJUGATE FINAL CONCENTRATION(3,1)
GOLD CONJUGATE TREATMENT(3,1)
IMMUNOASSAY SAMPLE DEVELOPING(3,1)
IMMUNOLOGICAL ANALYSIS(3,1)
INDIRECT IMMUNOFLUORESCENCE ANTIBODY(3,1)
INFECTION ABSENCE(3,1)
INFECTION PREVENTION(3,1)
INVERTED MICROSCOPE(3,1)
LABELED ANTIBODY(3,1)
LABELING AGENT IDENTIFICATION(3,1)
LYNNON CORPORATION(3,1)
MOUSE PERITONEAL CAVITY(3,1)
NAKED EYE(3,1)
PAD SURELINK(3,1)
PARENT ANTIBODY(3,1)
PHOSPHORUS FLAME(3,1)
POLYPEPTIDE MOLECULE IMMUNE RESPONSE(3,1)
POSITIVE SPECIMEN BVDV(3,1)
PRE CYS ACTIVATED KEYHOLE(3,1)
PURIFIED ANTIBODY(3,1)
RABBIT SERUM(3,1)
RECOMBINANT ANTIBODY SOLUTION(3,1)
REPRESENTATION ANTIGENIC DETERMINANT(3,1)
SAMPLE SPECIMEN PAD(3,1)
SERUM REACTION DILUTION(3,1)
STILLBIRTH RIGHT PREGNANCY(3,1)
SYNTHETIC PEPTIDE(3,1)
THERAPEUTIC COMPOSITION BVDV(3,1)
TREATED GOLD CONJUGATE(3,1)
VIRUS ANTIBODY(3,1)
VIRUS TYPE(3,1)
WEAK SENSITIVITY(3,1)
ABSORBENT PAD(2,5)
PRIMARY ANTIGEN ANTIBODY REACTION(2,4)
SIGMA(2,4)
DOSE(2,3)
DESICCANT(2,2)
PESTIVIRUS(2,2)
PHOTOMETA(2,2)
SOLUTION DEVELOPMENT(2,2)
WHOLE BLOOD(2,2)
ADHESIVE CARD(2,1)
AGRICULTURAL SOURCE ECONOMIC BENEFIT(2,1)
ANTIBODY TRANSFER(2,1)
ARYL MOUSE(2,1)
BODILY FLUID(2,1)
BVDV EXPLODED PERSPECTIVE(2,1)
CHARACTER DISPLAY(2,1)
CONJUGATE PREPARATION(2,1)
DETECTION METHOD RESULT(2,1)
DIAGNOSTIC TOOL(2,1)
DISEASE ANALYSIS(2,1)
DISEASE STATE(2,1)
DISPENSING(2,1)
FLUORESCENCE RESPONSE(2,1)
GOAT ANTI MOUSE IMMUNOGLOBULIN G(2,1)
GOLD PAD(2,1)
HYBRIDIZATION REACTION(2,1)
(KR101876535)
ANTIBODY(100,43)
BVDV(100,43)
ANTIGEN(100,25)
BOVINE VIRAL DIARRHEA VIRUS(100,23)
KIT(100,15)
AMINOACID SEQUENCE(100,12)
PROTEIN(100,12)
BOVINE(100,8)
EPITOPE(100,8)
VIRUS(100,7)
VIRAL DIARRHEIC DISEASE(100,5)
ANTIGEN DETECTION(100,2)
DETECTION KIT(100,2)
POLYPEPTIDE MOLECULE ANTIGENIC DETERMINANT(100,1)
VIRAL DIARRHEA VIRUS CONSUMER(100,1)
GASTROINTESTINAL MUCOSAL HYPEREMIA(60,1)
AGRICULTURAL ECONOMIC HARM(45,1)
DIARRHEIC DISEASE BOVINE(45,1)
BASIC PHOSPHATIDYLINSITOSOL PERTASE(42,1)
LATEX PARTICLE(39,4)
DIARRHEA NEUTROPENIA(39,1)
NITRO BLUE TETRAZOLIUM(39,1)
PICOCODE BILIRUBIN(39,1)
STILLBIRTH ADDEND(39,1)
CHEMILUMINESCENT COMPOUND(36,2)
TETRA NITROBENZIDINE(35,1)
UREIDO FLUORESCEIN(35,1)
DYE SOL(33,2)
CHEMILUMINESCENT ENZYME SUBSTRATE(33,1)
VIRAL DIARRHEIC VIRUS(33,1)
ANTIBODY NEUTRALIZATION(32,1)
RESPIRATORY TRACT LESION(32,1)
CATTLE BVDV(31,1)
SHEEP CHILI(31,1)
ANIMAL SECRETION(29,1)
ANTIGEN DETECTION KIT(29,1)
RHODAMINE DERIVATIVE(29,1)
SPECIALIZED KNOWLEDGE ANALYSIS(29,1)
COLOR INDICATOR(28,2)
ENZYME SUBSTRATE(27,2)
AGRICULTURAL ECONOMIC BENEFIT(27,1)
INDOLYLPHOSPHATE(27,1)
SERUM BVDV(27,1)
VACCINE(25,6)
ACUTE DEATH(25,1)
BREEDING CATTLE(25,1)
EXPRESSION VECTOR DNA MOLECULE(25,1)
ANTIBODY POLYPEPTIDE MOLECULE(24,2)
BVDV WORLDWIDE CAUSE(24,1)
MOLECULAR BIOLOGY ASSAY LIMITATION(24,1)
ANTIGEN ANTIBODY(23,1)
TISSUE CULTURE(23,1)
LIPOSOME(22,2)
POLYPEPTIDE MOLECULE DNA(22,2)
INTERSECTION NEUTRALIZING ABILITY(22,1)
VIRAL PROPHYLAXIS(22,1)
LABELED REAGENT(21,3)
BVDV DIFFUSION(21,2)
LABEL DETECTION REAGENT(21,2)
PEROXIDASE(21,2)
BOVINE VIRAL ANTIGEN(21,1)
FLUORESCENT COMPOUND(21,1)
BVDV INFECTION(20,2)
NAPHTHOL(20,2)
BOVINE BLOOD(19,2)
BODILY FLUID(19,1)
COMBINED IMMUNODEFICIENCY VIRUS(19,1)
PHYCOBILIPROTEIN(19,1)
ANTIGENIC DETERMINANT(18,15)
METAL SOL(18,2)
BOVINE BLOOD PRESENCE(18,1)
PREGNANCY ABORTION(17,1)
SILENT BLOOD(17,1)
ACTIVE INGREDIENT(16,3)
TISSUE FLUID(16,3)
INFECTION EARLY DIAGNOSIS(16,2)
MOLECULE ENCODING(16,1)
VOMITUS(15,3)
DIOXETANE(15,1)
EXPENSIVE EQUIPMENT(15,1)
PHOSPHATASE(15,1)
ULCER(15,1)
URINE(14,3)
INFECTION TREATMENT(14,1)
TRANSFORMED CELL(14,1)
SALIVA(13,3)
LABEL(13,1)
PHEWA(13,1)
SELENIUM(13,1)
TESTING PERIOD(13,1)
VIRAL ANTIGEN(13,1)
LYMPH(12,3)
MILK(11,3)
TEAR(11,3)
AMINOACID SEQUENCE IMMUNOGENICITY(11,1)
METHOXY(11,1)
ENZYME(10,2)
MONOCLONAL ANTIBODY(9,14)
SERUM(9,7)
FECES(9,2)
PEPTIDE AMINOACID SEQUENCE(9,1)
PROTEIN STRUCTURE(9,1)
CYTOPATHIC BVDV(8,3)
TYPE ANTIGEN(8,3)
FCONV PBS FLUORESCENCE MICROSCOPE(8,1)
POLYCLONAL ANTIBODY STUCKNITROCELLULOSE MEMBRANE(8,1)
SEPARATIST NCP BVDV(8,1)
CONJUGATION PAD(7,5)
FORESTRY QUARANTINE TEST(7,2)
ANTI MOUSE IMMUNOGLOBULIN ANTIBODY(7,1)
ANTIGEN BVDV EFFICACY(7,1)
BOVINE VIRAL VIRUS DIARRHEA(7,1)
BVDV ANTIGEN TYPE(7,1)
BVDV IMMUNODIPSTICK KIT(7,1)
BVDV INFECTED CATTLE(7,1)
INACTIVATED BVDV KOREAN(7,1)
OBJECT DETECTION(7,1)
SERUM COIIFOCA PCR(7,1)
BVDV ANTIBODY(6,2)
CATTLE BVDV BLOOD(6,1)
CH RABBIT IGG FITC(6,1)
DIFFERENTIAL DEPOSITION(6,1)
ONSET TIME(6,1)
PEPTIDE FORPOLYCLONAL ANTIBODY(6,1)
PREGNANCY BORN CALF(6,1)
1B TYPE(5,6)
DOMESTIC CATTLE(5,2)
GOLD PARTICLE SUSPENSION(5,2)
BASE METAL(5,1)
BVDV ANTIGEN DETECTION KIT(5,1)
BVDV POLYPEPTIDE MOLECULE(5,1)
CLINICAL SYMPTOM BVDV VARIETY(5,1)
CONJUGATED BSA KLH CONCENTRATION(5,1)
DERMIS STAINING(5,1)
DETECTION METHOD EXTENT(5,1)
FLUORESCEIN ISOTHIOCYANATE(5,1)
IMMUNOAFFINITY CHROMATOGARPHY(5,1)
IMMUNOHISTOLOGICAL STAINING(5,1)
INDIRECT IMMUNOFLUORESCENT ANTIBODY(5,1)
LABELING REAGENT IDENTIFICATION(5,1)
NAN IMMUNODIPSTICK(5,1)
NEUTRALIZATION TEST SEROLOGIC DIAGNOSIS(5,1)
PREACTIVATED KLH(5,1)
PREPARATION BVDV ANTIGEN(5,1)
SHEEP BORDER DISEASE VIRUS(5,1)
TRANSLATIONAL MODIFICATION TRANSMEMBRANE DOMAIN(5,1)
GOLD SOLUTION(4,5)
SURMODICS(4,5)
ANTIBODY PRODUCTION(4,3)
CELL LYSATE(4,3)
SODIUM BORATE(4,3)
PURIFIED ANTIBODY(4,2)
SECONDARY ANTIBODY(4,2)
SODIUM TETRABORATE(4,2)
ANTI FITC ANTIBODY(4,1)
ANTI MOUSE ANTIBODY(4,1)
ANTI MOUSE IGG(4,1)
ANTIBODY ANTIGENIC DETERMINANT(4,1)
ANTIBODY CONCENTRATION BVDV BUFFER(4,1)
ASSAY STRIP SPECIMEN(4,1)
BOVINE BLOOD ANTIGEN ABSENCE(4,1)
BVDV1 BVDV1A(4,1)
DIAGNOSING BVDV(4,1)
DIAGNOSTIC TECHNIQUE BVDV(4,1)
EAR WEEK INTERVAL(4,1)
FLAVIVIRIDAE FAMILY(4,1)
FLORESCENT ANTIBODY(4,1)
IMMUNOAFFINITY CHROMATOGRAPHY(4,1)
IMMUNOPRECIPITATION KIT(4,1)
INFECTIOUS DISEASE ABSENCE(4,1)
INTRAPERITONEAL ADMINISTRATION(4,1)
LIMPET HEMOCYANIN(4,1)
LOW LEVEL(4,1)
MOUSE IGG VIRAL ANTIGEN(4,1)
NUCLEOTIDE BVDV(4,1)
PROTEIN ANTIGENIC DETERMINANT(4,1)
SURELINK RABBIT(4,1)
SURVIVAL PROLONGATION(4,1)
VIRAL TRANSCRIPTION DEVELOPMENT(4,1)
ANALYTE(3,4)
LABORATORY(3,4)
2A TYPE(3,2)
DETECTION REAGENT(3,2)
FINAL PELLET(3,2)
INFECTED CELL(3,2)
SEALED CONTAINER(3,2)
SPLEEN CELL(3,2)
1M GLYCINE(3,1)
20UG ML BVDV(3,1)
ABSORBANCE SPECTRA(3,1)
ACCURATELY IDENTIFIED BVDV(3,1)
ACTIVATED PREPOLYMER(3,1)
AGAROSE BEAD(3,1)
ALLEVIATING DISEASE PROGRESSION(3,1)
ANTI CH RABBIT(3,1)
ANTI IMMUNOGLOBULIN COLUMN(3,1)
ANTIBODY COMPARISON(3,1)
ANTIBODY GOLD CONJUGATE(3,1)
ANTIBODY PRODUCING HYBRIDOMA(3,1)
ANTIBODY PURIFICATION(3,1)
ANTIGEN GENE(3,1)
ANTIGENIC SITE(3,1)
ANTIGENICITYPOLYPEPTJDE SEQUENCE(3,1)
BIOINFORMATICS PROGRAM(3,1)
BLOOD CLOT(3,1)
BLOTTING KIT(3,1)
BOVINE SERUM ALBUMIN(3,1)
BOVINE VIRAL DIARRHEA VIRUS TYPE(3,1)
BVDV ABSENCE(3,1)
BVDV GOLD CONJUGATE(3,1)
CAPILLARY PHENOMENON(3,1)
CO2 INCUBATOR(3,1)
COLUMN AFFINITY CHROMATOGRAPHY(3,1)
COVERING STRIP ASSAY(3,1)
CPE BVDV(3,1)
CULTURE SUPERNATANT(3,1)
DARBY KIDNEY(3,1)
DIAGNOSTIC KIT(3,1)
DIAGNOSTIC STRIP MANUFACTURE(3,1)
DNAMAN VERSION(3,1)
DOMAIN EXCLUSION ANALYSIS(3,1)
ELISA READER(3,1)
ENZYME IMMUNOASSAY KIT(3,1)
EXPERIMENTAL ANIMAL(3,1)
FINALLY PURE POLYCLONAL ANTIBODY(3,1)
GENE BVDV1(3,1)
GENE BVDV2(3,1)
GOLD CONJUGATE FINAL CONCENTRATION(3,1)
GOLD STAR(3,1)
HYBRIDOMA CELL(3,1)
IMMUNE RABBIT(3,1)
IMMUNE RESPONSE POLYPEPTIDE MOLECULE(3,1)
IMMUNOFLUORESCENCE TEST KIT(3,1)
IMMUNOLOGICAL ANALYSIS(3,1)
INDIRECT IMMUNOFLUORESCENCE ANTIBODY(3,1)
INFECTION ABSENCE(3,1)
INFECTION PREVENTION(3,1)
INVERTED MICROSCOPE(3,1)
LABELED ANTIBODY QUANTITY(3,1)
LYNNON CORPORATION(3,1)
MOISTURE ABSORBING PAD(3,1)
MOUSE PERITONEAL CAVITY(3,1)
NAKED EYE(3,1)
PARENT ANTIBODY(3,1)
PEPTIDE ANTIGEN(3,1)
PHOSPHATE FLAME(3,1)
PHOSPHORUS FLAME(3,1)
POSITIVE SPECIMEN BVDV(3,1)
PRE CYS ACTIVATED KEYHOLE(3,1)
RABBIT DILUTION(3,1)
SAMPLE SPECIMEN PAD(3,1)
SPECTRA ABSORBANCE(3,1)
SYNTHETIC PEPTIDE(3,1)
THERAPEUTIC COMPOSITION BVDV(3,1)
TREATED GOLD CONJUGATE(3,1)
VIRUS RESCUE(3,1)
WESTERN BLOT(3,1)
SIGMA(2,4)
DOSE(2,3)
DESICCANT(2,2)
IFA(2,2)
PESTIVIRUS(2,2)
PHOTOMETA(2,2)
SAMPLE INLET(2,2)
SOLUTION DEVELOPMENT(2,2)
WHOLE BLOOD(2,2)
ABSORBENT PAD OVERLAP(2,1)
ADHESIVE CARD(2,1)
AGRICULTURAL SOURCE ECONOMIC BENEFIT(2,1)
ANTIBODY TRANSFER(2,1)
CHARACTER DISPLAY(2,1)
CONJUGATE PREPARATION(2,1)
DETECTION METHOD RESULT(2,1)
DISEASE ANALYSIS(2,1)
DISEASE STATE(2,1)
DNA MOLECULE(2,1)
ELISA REACTION(2,1)
GOAT ANTI MOUSE IMMUNOGLOBULIN G(2,1)
GOLD PAD(2,1)
HYBRIDIZATION REACTION(2,1)
IGG MOUSE(2,1)
MEMBRANE COVERING(2,1)
MEMBRANE SUPPORT(2,1)
MIN REACTIVITY(2,1)
NEUTRALIZING ANTIBODY LEVEL(2,1)
PBS BUFFER(2,1)
PEPTIDE SEQUENCE(2,1)
RAPID TEST KIT(2,1)
REACTING SERUM(2,1)";Pharmaceuticals;Open
2011-12-29;"BRPI1101186         A1 2013-02-05 [BR201101186]
STG: (A1) Published application
AP : 2011BR-0001186 2011-12-29
WO2013097022        A2 2013-07-04 [WO201397022]
STG: (A2) International application published with declaration under Article 17 (2) (a)
AP : 2013WO-BR00006 2013-01-02
WO2013097022        A3 2013-10-10 [WO201397022]
STG: (A3) Later publication of ISR with revised front page
AP : 2013WO-BR00006 2013-01-02
BRPI1101186         A2 2015-07-14 [BR201101186]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2011BR-0001186 2011-12-29
BRPI1101186         A8 2017-09-05 [BRPI1101186]
STG: (A8) Modified first page
AP : 2011BR-0001186 2011-12-29
BRPI1101186         A8 2018-08-07 [BRPI1101186]
STG: (A8) Modified first page
AP : 2011BR-0001186 2011-12-29";45546938;"BRPI1101186         A1 2013-02-05 [BR201101186]
WO2013097022        A2 2013-07-04 [WO201397022]
WO2013097022        A3 2013-10-10 [WO201397022]
BRPI1101186         A2 2015-07-14 [BR201101186]
BRPI1101186         A8 2017-09-05 [BRPI1101186]
BRPI1101186         A8 2018-08-07 [BRPI1101186]";2011BR-0001186;;"FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE MINAS GERAIS FAPEMIG
GUIMARAES FONSECA FLAVIO
UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG";"UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG
GUIMARAES FONSECA FLAVIO";"(WO201397022)
BR
(WO201397022)
BR
(BR201101186)
BR
(BRPI1101186)
BR";"(WO201397022)
NAME=UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG Avenida Antônio Carlos, 6627 Unidade Administrativa II, Sala 2016 Pampulha CEP: 31270-90 Belo Horizonte, MG , COUNTRY=BR 

(WO201397022)
NAME=UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG Avenida Antônio Carlos, 6627 Unidade Administrativa II, Sala 2016 Pampulha CEP: 31270-90 Belo Horizonte, MG , COUNTRY=BR 

(BR201101186)
NAME=UNIVERSIDADE FEDERAL DE MINAS GERAIS , COUNTRY=BR 

NAME=FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE MINAS GERAIS - FAPEMIG , COUNTRY=BR 

(BRPI1101186)
NAME=UNIVERSIDADE FEDERAL DE MINAS GERAIS , COUNTRY=BR 

NAME=FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE MINAS GERAIS - FAPEMIG , COUNTRY=BR 
";2;"FIGUEIREDO BARBOSA STANCIOLI EDEL
GUIMARAES DA FONSECA FLAVIO
LAGUARDIA NASCIMENTO MATEUS
BORGES FERRARI AMANDA
SILVA BARBOSA ALINE APARECIDA";"(WO201397022)
BR
(WO201397022)
BR";"(WO201397022)
NAME=FIGUEIREDO BARBOSA STANCIOLI, Edel Rua Marechal Hermes, 340, apto. 504 Bairro Gutierrez CEP: 30430-030 Belo Horizonte, MG , COUNTRY=BR 

NAME=GUIMARÃES DA FONSECA, Flavio Rua Prof. Domicio Murta, 370, Apto.603 Bairro Ouro preto CEP: 31330-670 Belo Horizonte, MG , COUNTRY=BR 

NAME=LAGUARDIA NASCIMENTO, Mateus Rua Jornalista Lena santos, 445 Fernão Dias CEP: 31910-540 Belo Horizonte, MG , COUNTRY=BR 

NAME=BORGES FERRARI, Amanda Rua minas Novas, 109, apto. 101 Bairro Cruzeiro CEP: 31310-090 Belo Horizonte, MG , COUNTRY=BR 

NAME=SILVA BARBOSA, Aline Aparecida Rua João Fernades, 107 apto. 201 Bairro Liberdade CEP: 31270-250 Belo Horizonte, MG , COUNTRY=BR 

(WO201397022)
NAME=FIGUEIREDO BARBOSA STANCIOLI, Edel Rua Marechal Hermes, 340, apto. 504 Bairro Gutierrez CEP: 30430-030 Belo Horizonte, MG , COUNTRY=BR 

NAME=GUIMARÃES DA FONSECA, Flavio Rua Prof. Domicio Murta, 370, Apto.603 Bairro Ouro preto CEP: 31330-670 Belo Horizonte, MG , COUNTRY=BR 

NAME=LAGUARDIA NASCIMENTO, Mateus Rua Jornalista Lena santos, 445 Fernão Dias CEP: 31910-540 Belo Horizonte, MG , COUNTRY=BR 

NAME=BORGES FERRARI, Amanda Rua minas Novas, 109, apto. 101 Bairro Cruzeiro CEP: 31310-090 Belo Horizonte, MG , COUNTRY=BR 

NAME=SILVA BARBOSA, Aline Aparecida Rua João Fernades, 107 apto. 201 Bairro Liberdade CEP: 31270-250 Belo Horizonte, MG , COUNTRY=BR 
";"(WO201397022)
Recombinant proteins, polynucleotides and vaccines to combat bovine herpesvirus";"(WO201397022)
The present technology describes the production of a vaccine containing recombinant proteins comprising 4 epitopes of the main antigenic proteins of each of two bovine herpesviruses, namely BoHV-1 (Bovine herpesvirus 1) and BoHV-5 (Bovine herpesvirus 5), produced in a prokaryotic system and/or a eukaryotic system using recombinant virus generated on the MVA (Modified Vaccinia Ankara) platform. Specifically, each recombinant protein contains 4 epitopes produced linearly, one with the BoHV-1 epitopes and the other with the BoHV-5 epitopes, and the epitopes linked with the use of flexible glycine and serine rings to connect the desired regions and to allow suitable tertiary conformation of each fragment, resulting in two multi-epitope proteins with potential to immunize ruminants (especially bovines) against the BoHV-1 and BoHV-5 viruses, for controlling infection and viral dissemination and reducing the level of financial loss caused by two bovine diseases of great significance for the worldwide livestock sector, namely bovine infectious rhinotracheitis and bovine encephalitis.";"(WO201397022)
1. Recombinant Proteins characterized to understand the sequences represented for SEQ ID analogous, homologous and heterologas Nº1 and SEQ ID Nº2 and/or its.
2.
2. Polinucleotideos characterized to understand the sequences represented for SEQ ID analogous, homologous Nº3 and SEQ ID Nº4 and/or its and heterologos ones.
3.
3. Vaccine against Bovine Herpesvirus characterized to understand the recombinant protein represented by sequence SEQ ID Nº1 and/or the recombinant protein represented by sequence SEQ ID Nº2 and/or the polinucleotideo (SEQ ID Nº3) that it codifies the protein represented for sequence SEQ ID Nº1 and/or the polinucleotideo (SEQ ID Nº4) that it codifies the protein represented for sequence SEQ ID Nº2 and/or its analogous, homologous, heterologos ones and pharmacological and pharmaceutically acceptable excipients.
4.
4. Vaccine against Bovine Herpesvirus in accordance with claim 3 characterized by recombinant proteins represented by SEQ ID Nº1 and SEQ ID Nº 2 to be able to be produced in procariotos, eucariotos vectors and/or being used recombinant viruses produced for the expression in system eucarioto.
5.
5. Use of the vaccine against Bovine Herpesvirus in accordance with claims 3 and 4 characterized preferentially to be used in the control and prevention of the bovine Infectious Rinotraqueite and bovine Encephalitis.
6.
6. Use of the vaccine against Bovine Herpesvirus in accordance with claims 3 and 4, characterized to be in the immunization of bovines and/or other ruminants.
7.
7. Use of the vaccine against Bovine Herpesvirus in accordance with claims 3 and 4, characterized to be in the control and prevention of the infection for BoHV-1 and/or BoHV-5 in bovines and/or other ruminants.";;"(WO201397022)
It Enters the advantages of the i use of this system are highlighted: (i) the methods of genetic construction and manipulation are relatively simple, based mainly in the phenomenon of homologous recombination, process that occurs naturally during the response of poxvirus; (ii) the virus are capable to infect one varied gamma of cellular types efficiently; (iii) its genome support the insertion of huge amounts of exogenous DNA, being able to tolerate up to 25.000 Pb of additional DNA; (iv) the recombinant protein expression occur naturally in the cytoplasm, what it eliminates special petitions for nuclear processing and transport from RNA; (v) produced proteins processed and is carried from identical way what it occurs in the cells of origin of the studied gene, of form that the resulting proteins are biological active; (vi) the proteinic synthesis occurs in relatively high levels; (vii) the manipulation of the vector is insurance, Sendo that the vaccinia virus easily is contained inside of standards of bio-security of level 2 (Moss.
The MVA is a promising candidate for use vaccinates, due to its restricted specter of hosts, imunogenicidade and avirulencia in animal models and its excellent prognostic of security as vaccine for smallpox.
For BoHV-5, the few tested experimental vaccines had presented the same problems that BoHV-1 stops.
Such option is justified for the fact to deal with a protein of the integument turns over, not available large-scale for extracellular recognition, and that this does not dispose of studies in this respect in literature.";"A61K-039/245
A61K-039/265
A61P-031/22
A61P-037/02
C07K-014/035
C07K-019/00
C12N-015/38
C12R-001/19";"(WO201397022)
1. Recombinant Proteins characterized to understand the sequences represented for SEQ ID analogous, homologous and heterologas N1 and SEQ ID N2 and/or its.
2. Polinucleotideos characterized to understand the sequences represented for SEQ ID analogous, homologous N3 and SEQ ID N4 and/or its and heterologos ones.
3. Vaccine against Bovine Herpesvirus characterized to understand the recombinant protein represented by sequence SEQ ID N1 and/or the recombinant protein represented by sequence SEQ ID N2 and/or the polinucleotideo (SEQ ID N3) that it codifies the protein represented for sequence SEQ ID N1 and/or the polinucleotideo (SEQ ID N4) that it codifies the protein represented for sequence SEQ ID N2 and/or its analogous, homologous, heterologos ones and pharmacological and pharmaceutically acceptable excipients.";"(WO201397022)
PROTEIN(100,38)
RECOMBINANT PROTEIN(100,29)
VACCINE(100,18)
BOVINE HERPES VIRUS(100,9)
HETEROLOGO(100,2)
POLINUCLEOTIDEO(100,2)
EXCIPIENT(100,1)
HETEROLOGA N(100,1)
HOMOLOGOUS N(100,1)
HOMOLOGOUS RECOMBINATION PHENOMENON(90,1)
HOST RESTRICTED SPECTER(72,1)
SECURITY PROGNOSTIC(72,1)
INTEGUMENT PROTEIN(67,1)
EXTRACELLULAR RECOGNITION(60,1)
PROTEINIC SYNTHESIS(60,1)
VECTOR MANIPULATION(53,1)
EXOGENOUS DNA(52,1)
STUDYING GENE(51,1)
VACCINIA VIRUS(49,2)
BOVINE IMMUNIZATION(47,1)
RECOMBINANT PROTEIN EXPRESSION(46,1)
SPECIAL PETITION(46,1)
EXPERIMENTAL VACCINE(45,2)
EUCARIOTO VECTOR(41,1)
BOVINE PREVENTION(40,1)
INFECTION PREVENTION(40,1)
ORIGIN CELL(40,1)
POXVIRUS RESPONSE(40,1)
BOVINE ENCEPHALITIS(35,4)
IMUNOGENICIDADE(35,1)
AVIRULENCIA(32,1)
BIOACTIVE(32,1)
RECOMBINANT VIRUS(31,3)
CYTOPLASM(31,1)
DNA PB(30,1)
NUCLEAR PROCESSING(30,1)
INSURANCE(28,1)
SMALLPOX(28,1)
BOHV(26,53)
MANIPULATION(26,1)
BOHV EPITOPO(24,6)
WESTERN ESSAY(22,6)
STRONGLY REACTIVE ANIMAL SORO(22,4)
GENOME(22,2)
MOSS(22,1)
VIRUS(21,24)
WESTERN BLOTTING ESSAY(19,2)
CELL VIABILITY(18,6)
PROTEIN PRODUCTION(18,3)
RNA(18,1)
ANKARA VIRUS(17,4)
ANIMAL MODEL(17,1)
CHICKEN EMBRIONADO FIBROBLASTO(17,1)
ELECTION EPITOPO IMUNOGENICO(17,1)
BOHV PROTEIN(16,5)
COMPOSED DOSE REINFORCEMENT(16,5)
VIRUS DISSEMINATION(16,3)
ELISA ESSAY(15,3)
HOMOLOGOUS RECOMBINATION(15,3)
SORO PROCEEDING(15,3)
ANSWER LASTING PROTECTOR INDUCTION(15,1)
PROTEIN MULTIEPITOPO RUMINANT(15,1)
RECOMBINANT SUBUNIDADE VACCINE(15,1)
VACCINIA VIRUS ANCESTRY(15,1)
POLICLONAIS SORO(14,2)
VIRUS ERADICATION(14,2)
ESCHERICHIA BACTERIA(13,2)
RABBIT IMMUNIZATION(13,2)
VACCINATION STRATEGY(13,2)
BOVINE HERPES VIRUS BIOLOGY(13,1)
BOVINE VIRUS IMUNOGENO(13,1)
CELLULAR TOXICIDADE ESSAY(13,1)
CELLULAR TYPE VARIED GAMMA(13,1)
PURIFICADO VIRUS PROTEIN(13,1)
VIRUS TRANSCRICIONAIS ACTIVATOR(13,1)
ANTIGENIC PROTEIN(12,3)
CATTLE SECTOR(12,3)
GEIS RACE(12,2)
PURIFICADA PROTEIN(12,2)
BOVINE SOROTECA PROCEEDING(12,1)
CLINICAL DISEASE MANIFESTATION(12,1)
CONFERRED LASTING IMMUNITY(12,1)
COUNTRY BOVINE CASH(12,1)
EPITOPE PREDICTION HTTP(12,1)
EXPERIMENTAL FARM PROFESSOR(12,1)
FEDERAL UNIVERSITY VETERINARY MEDICINE(12,1)
FRAGMENT TERTIARY CONFORMATION(12,1)
GENETIC CONSTRUCTION(12,1)
IMUNO DOMINANT EPITOPO IDENTIFICATION(12,1)
MARGINAL EAR VEIN(12,1)
RECOMBINANT VACCINIA VIRUS(12,1)
SORO ANTIBODY PROCEEDING(12,1)
TH LYMPHOCYTE EPITOPE(12,1)
VIRUS PURIFICADO PROTEIN(12,1)
RECPBOHV(11,9)
ZEALAND RACE RABBIT(11,5)
BOHV ERADICATION(11,1)
EPITOPO EXHIBITION(11,1)
EXPRESSION BACTERIUM TRANSFORMATION(11,1)
GLYCOPROTEIN EPITOPO(11,1)
HUGE BIOTECHNOLOGICAL ADVANCE(11,1)
PLASMIDIO TRANSFECAO(11,1)
PROJECTED PROTEIN PURIFICACAO(11,1)
PROTEIN FRAGMENT CODER(11,1)
SEGMENT TERTIARY DOBRAMENTO(11,1)
SMALLPOX ERADICATION(11,1)
TOOL ONLINE MULTALIN(11,1)
TRANSFERENCE PLASMIDIO(11,1)
VIRUS IMUNOSSUPRESSORA(11,1)
COMMERCIAL ELISA(10,3)
IMPORTANCE BOVINE DISEASE(10,3)
SYSTEM EUCARIOTO(10,3)
CITOTOXICIDADE ABSENCE(10,2)
ECONOMIC IMPORTANCE(10,2)
HISTIDIN TAIL(10,2)
MAIN BOVINE EPITOPO(10,2)
VACCINATED ANIMAL(10,2)
AGRICULTURE MINISTRY(10,1)
ANTIGENIC SUBUNIDADE(10,1)
BOHV PREVALENCE(10,1)
BOVINE FETAL SERUM(10,1)
COMMERCIAL VACCINE MAJORITY(10,1)
EXPASY PLATFORM AID(10,1)
GENETICALLY ENGINEERED POXVIRUS(10,1)
HETEROLOGA RECOMBINANT PROTEIN EXPRESSION(10,1)
HUMORAL PROTECTOR(10,1)
IBR ERADICATION(10,1)
IDENTICAL WAY(10,1)
INFECTION BOVINE HOST(10,1)
INTRACELLULAR PATOGENO(10,1)
MULTIEPITOPE IMMUNOGEN(10,1)
PLASMIDEO PLW(10,1)
PREVALENCE FEE(10,1)
PROGRAM ONLINE CALCULATOR(10,1)
PURIFICADO BOHV(10,1)
RABBIT SORO PRIMARY ANTIBODY(10,1)
RIVER STEAMER(10,1)
RUMINANT FLOCK(10,1)
SCHOOL BIOTERIO(10,1)
SOROLOGICA DISCRIMINATION(10,1)
TICKET SERIADA(10,1)
UNCHAIN EPITOPO(10,1)
VACCINE DISSEMINATION(10,1)
VACCINE INEFFICIENCY(10,1)
SECONDARY ANTIBODY(9,3)
INTERVALADA(8,5)
VACCINE PRODUCTION(8,3)
CELL EPITOPO(8,2)
CLONING ANALYSIS(8,2)
EXPRESSION VECTOR(8,2)
FUSION PROTEIN(8,2)
INCUBATION PERIOD ENDING(8,2)
INSOLUBLE FRACTION(8,2)
NUCLEOTIDEO SEQUENCE(8,2)
SDS PAGE GEIS(8,2)
ALIVE VACCINE(8,1)
ANIMAL EUTHANASIA(8,1)
BACTERIA CULTURE(8,1)
BIOTERAPEUTICA PROTEIN(8,1)
BOVINE BLOOD COLLECTION(8,1)
BOVINE FLOCK(8,1)
BOVINE SOROTECA SAMPLE(8,1)
BRAZILIAN GOVERNMENT(8,1)
CAMPAIGN FINAL TRAINING(8,1)
CLONE VISUALIZATION(8,1)
CLONING CONFIRMATION(8,1)
DATA SCARCITY(8,1)
DOSAGE ESSAY(8,1)
EVALUATION EPIDEMIOLOGIST(8,1)
FLUORESCENT GREEN PROTEIN(8,1)
GERMANY SOUTH(8,1)
HERPES VIRUS PROTEIN(8,1)
IMMUNOMODULATORY PROTEIN(8,1)
INDUCED IMMUNE ANSWER(8,1)
INOCULATION EXPERIMENT(8,1)
INSERTO INTEGRITY(8,1)
LOCALIZATION EXPERIMENT(8,1)
MEDICINE SCHOOL(8,1)
MUCOSA ANTIBODY(8,1)
MULTIBRAVE FORMULATION(8,1)
PLASMATICA MEMBRANE(8,1)
PROTECTIVE CELLULAR ANSWER(8,1)
PROTEIN HIDROFOBICIDADE(8,1)
PROTEIN INOCULATION(8,1)
PROTEIN LOCALIZATION(8,1)
PROTEIN NUCLEOTIDEO(8,1)
PROTEINIC EXTRACT(8,1)
RATIONAL STRATEGY(8,1)
RECOMBINANT COLONY(8,1)
SATISFACTORY CELLULAR ANSWER(8,1)
SOROPOSITIVO ANIMAL(8,1)
VIRUS EXCRETION(8,1)
VIRUS GENOME(8,1)
WHITE PROTEIN CODER(8,1)
WORKED GENICO(8,1)
COMBAT(7,4)
ADJUVANT ALUMINUM HYDROXIDE(7,2)
BOVINE CELL(7,2)
ESPECTROFOTOMETRO(7,2)
IMUNOGENICA REGION(7,2)
MOLECULAR WEIGHT KALEIDOSCOPE MARKER(7,2)
PRODUCED MULTIEPITOPO RECOMBINANT PROTEIN(7,2)
RABBIT ANTI LGG TOTAL(7,2)
RECOMBINANT PROTEIN UNDERSTANDING(7,2)
AMPLIFICATION STUDY(7,1)
ANIMAL DEATH(7,1)
ANIMAL INOCULATION(7,1)
ANNUAL REINFORCEMENT(7,1)
ANSWER INDUCTION(7,1)
BACTERIAL PROTEIN CONTAMINANT(7,1)
BOHV GB(7,1)
BOHV GD(7,1)
BOVINE VACCINE(7,1)
CLONE EXPRESSION(7,1)
CONSTRUCTED GENICO CASSETTE(7,1)
CROSSED PROTECTION(7,1)
DEMONSTRATED IMMOBILIZED(7,1)
DIVERSE COUNTRY(7,1)
ELIMINATION STRATEGY(7,1)
ELUATO ANALYSIS(7,1)
EUROPEAN COUNTRY(7,1)
EXPERIMENTAL ADVERTISING(7,1)
EXPERIMENTAL ESSAY(7,1)
FLUORESCENCE MICROSCOPE(7,1)
GENE CODER(7,1)
GENICO CASSETTE DRAWING(7,1)
HIDROFOBICA CHOICE(7,1)
HORSE INJURY(7,1)
IMMUNE RECOGNITION(7,1)
IMMUNIZED ANIMAL(7,1)
INCLUSION AGGREGATE(7,1)
INCUBATION END(7,1)
INFECTED ANIMAL(7,1)
INFECTION CONTEXT(7,1)
LITERATURE STORY(7,1)
LOCALIZATION DETERMINATION(7,1)
MANUFACTURER INSTRUCTION(7,1)
MARKING GENE(7,1)
NARROW RIVER CITY(7,1)
NATIONAL SERVER(7,1)
PARENTAL VIRUS(7,1)
PROTECTIVE ANSWER DEVELOPMENT(7,1)
PROTEIN EPITOPO MULTIPLE(7,1)
PROTEIN PROCEEDING(7,1)
RABBIT BLOOD(7,1)
RABBIT SERUM(7,1)
REC BOHV EXPRESSION(7,1)
RECENT YEAR GROWING(7,1)
REPORTER PROTEIN(7,1)
RESTRICTION ENZYME(7,1)
SYSTEMIC IMMUNITY(7,1)
TAIL AFFINITY(7,1)
VECTOR PROCARIOTO(7,1)
VIRAL RESERVOIR(7,1)
VIRUS COMPONENT IMUNOGENICO(7,1)
VIRUS GENICA REGION(7,1)
YOUNG CATTLE(7,1)
RECBOHV(6,3)
BOARDING(6,2)
AFFECTED COUNTRY(6,1)
AFFINITY CHROMATOGRAPHY(6,1)
ANIMAL BLOOD(6,1)
BOHV SEQUENCE(6,1)
CARREADORE(6,1)
CELL CULTURE(6,1)
CHROMATOGRAPHY BEGINNING(6,1)
CLONE SELECTION(6,1)
CORRECT CLONING(6,1)
CULTURE EX ALIVE ANALYSIS(6,1)
DISEASE CLINICAL PRESENTATION(6,1)
DNA RIBBON(6,1)
DRAWN EPITOPO(6,1)
EVALUATION CRITERIA(6,1)
EXPERIMENT BEGINNING(6,1)
EXPRESS PROTEIN(6,1)
EXTRA PROTEIN(6,1)
FOREIGN COMPANY(6,1)
GENOMICA LOSS(6,1)
GEOGRAPHICAL DISTRIBUTION(6,1)
GLYCINE CHOICE(6,1)
GLYCINE FLEXIBLE HANDLE(6,1)
HISTIDIN SEQUENCE(6,1)
HUMAN VACCINE(6,1)
IMMUNE COVERING(6,1)
IMUNOENZIMATICO TEST(6,1)
IONIC INTERACTION(6,1)
MORTALITY INDEX(6,1)
PARAMETRIC ANALYSIS(6,1)
PORE MEMBRANE(6,1)
PREDICTION TOOL(6,1)
PRODUCED GENICO CASSETTE(6,1)
PROTECTIVE VACCINE(6,1)
PROTEIN GB(6,1)
RARE CODON(6,1)
REACTIVITY ANALYSIS(6,1)
RECOMBINANT DIFFERENTIAL(6,1)
RECOMBINANT GENE EXPRESSION(6,1)
RECOMBINANT VIRUS CONSTRUCTION(6,1)
REGION ELECTION(6,1)
SATISFACTORY ANSWER(6,1)
SAWING EFFICIENCY(6,1)
SEQUENCE ATTAINMENT(6,1)
STARTER SENSE(6,1)
SUCCESSIVE TICKET(6,1)
SYNTHETIC GENE CLONING(6,1)
THERMAL SHOCK PROTEIN(6,1)
VECTOR PLW(6,1)
VIRAL PROTEIN(6,1)
SIGMA(5,5)
LATENCY(5,4)
AGV BOHV(5,2)
HITECH(5,2)
INTRANASAL(5,2)
NARROW CHANNEL(5,2)
PROTEIN CONSTRUCTION(5,2)
REACTIVATION(5,2)
RECOMBINANT PROTEIN PRESENCE(5,2)
ANTI BOVINE IGG(5,1)
ANTIGEN PRODUCTION(5,1)
ANTIGENIC REGION(5,1)
BAND EXPRESSION(5,1)
CODON PRESENCE(5,1)
COLLECTION PIPE(5,1)
COMMERCIAL BOVINE(5,1)
COMMERCIAL VECTOR(5,1)
CONCENTRATION DOSAGE(5,1)
CULTURE TREATMENT(5,1)
DENATURING AGENT(5,1)
DRAWING FINISHING(5,1)
DRAWN CASSETTE(5,1)
ECONOMIC DAMAGE(5,1)
EFFICIENT ANSWER(5,1)
ELETROFORETICO(5,1)
FLASK CONTENT(5,1)
FUSION SEQUENCE(5,1)
IMPOSSIBILITY(5,1)
IMPROVEMENT NECESSITY(5,1)
INFECTED CELL(5,1)
JUSTIFICATION(5,1)
MARKET REQUIREMENT(5,1)
MILK PRODUCTION(5,1)
NATIVE PROTEIN THREEDIMENSIONAL STRUCTURE(5,1)
NI NTA(5,1)
NUMEROUS MUTATION(5,1)
PRODUCED PROTEIN REACTIVITY(5,1)
PRODUCED RECOMBINANT ANTIGEN(5,1)
PRODUCED RECOMBINANT PROTEIN IMUNOGENICIDADE(5,1)
PURE EXTREME(5,1)
REAL PROTECTION(5,1)
SAVAGE NITRIC OXIDE PRODUCTION(5,1)
SEQIIENCIAMENTO(5,1)
SEQUENCIAMENTO(5,1)
SIGNIFICANT COLLATERAL(5,1)
SOBRENADANTE(5,1)
SOLUBILIZACAO(5,1)
SUBCLONAGEM(5,1)
SUSCEPTIBLE CELL(5,1)";Pharmaceuticals;Open
2011-11-08;"MX2011011868        A  2013-05-13 [MX2011011868]
STG: (A) Patent application
AP : 2011MX-PA11868 2011-11-08
MX341611            B  2016-08-25 [MX-341611]
STG: (B) Granted patent/ granted utility model
AP : 2011MX-PA11868 2011-11-08";45655674;"MX2011011868        A  2013-05-13 [MX2011011868]
MX341611            B  2016-08-25 [MX-341611]";2011MX-PA11868;;CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I P N;;;;0;"GUADALUPE MIREYA DE LA GARZA AMAYA
VÍCTOR RUBÉN TENORIO GUTIÉRREZ
FRANCISCO SUÁREZ GÜEMES
CYNTHIA GONZÁLEZ RUÍZ
FRANCISCO JOSE TRIGO TAVERA";;;"(MX-341611)
Vaccine biological manufactured from micro vesicles (mvs) of mannheimia haemolytica serotype a2 of intranasal application in sheep.";"(MX-341611)
The pneumonic Mannheimiosis (Pasteurellosis) is a disease that affects ruminants in general, in cattle being a persistent and defiant problem. Nowadays, the disease has not been controlled nor prevented, since an effective biological has not been obtained. Mannheimia haemolytica is the main microbial agent associated with the development of this disease. The present invention refers to a vaccine biological, which comprises bacterium micro vesicles (MVs) isolated from a pathogen serotype A2, so as to prove the capacity thereof to awaken a suitable humoral immune response for preventing the individuals exposed to the field strains from developing pathological processes typical of the disease.";;;;"A61K-009/133
A61K-035/74
A61K-039/102
A61P-011/02";;;Pharmaceuticals;Open
2011-09-20;"RU2464999           C1 2012-10-27 [RU2464999]
STG: (C1) Patent for invention
AP : 2011RU-0138664 2011-09-20";36360591;RU2464999           C1 2012-10-27 [RU2464999];2011RU-0138664;;G NAUCHNOE UCHREZHDENIE NI VETERINARNYJ INSTITUTE NECHERNOZEMNOJ ZONY RF ROSSIJSKOJ AKADEMII SKOKHOZJ;G NAUCHNOE UCHREZHDENIE NI VETERINARNYJ INSTITUTE NECHERNOZEMNOJ ZONY RF ROSSIJSKOJ AKADEMII SKOKHOZJ;;;1;"SISJAGIN PAVEL NIKOLAEVICH
SISJAGINA ELENA PAVLOVNA
REDZHEPOVA GULJA REDZHEPOVNA
UBITINA IRINA VASIL EVNA
SAVIN ALEKSANDR VLADIMIROVICH";;;"(RU2464999)
Method for immunoprophylaxis of respiratory diseases in calves";"(RU2464999)
FIELD: medicine. ^ SUBSTANCE: invention refers to veterinary science. A method for immunoprophylaxis of respiratory diseases in calves involves immunisation with an associated vaccine for parainfluenza-3, infectious rhinotracheitis and bovine viral diarrhoea viruses in a combination with the use of an alcoholic solution of a herbal raw material as an agent for non-specific prophylaxis with the herbal raw material presented by a mixture of equal proportions of purple Echinacea herb and blossom clusters, Syrian rue herb, tillet blossom and common licorice roots which is imbedded in 70% ethanol in relation 1:10, kept in a dark place at temperature 18-20C for 7 days; the prepared tincture is prescribed orally in the form of 7-8% aqueous solution 1.5-2.0 ml/kg of animal's body weight for 15 days with immunising calves of 60 days old. ^ EFFECT: invention provides higher effectiveness of immunoprophylaxis. ^ 4 tbl, 3 ex";"(RU2464999)
1. The Method of immunoprophylaxis of the respiratory diseases of calves, which includes immunization by the associated vaccine against the viruses of parainfluenza -3, infectious rhino-tracheitis and virus diarrhea - disease of mucosas in combination with the application as the means of unspecific preventive maintenance of the alcohol liqueur of the vegetable raw material, that is characterized by the fact that as the vegetable raw material is used the mixture of equal quantities of grass and floscules of ekhinatsei of purple, grass of harmel peganum of usual, colors of the linden of small-leaved and roots of the licorice of naked, which they pour with ethyl alcohol 70% concentration with the relationship 1:10, maintain in the dark place at a temperature of 18-20°S during 7 days, moreover liqueur is assigned inside in the form 7-8% of aqueous solution in the dose 1,5-2,0 ml/kg of the living mass of animal during 15 days, moreover they immunize the calves of 60-day age.";;;"A61K-036/28
A61K-036/484
A61K-039/12
A61P-011/00";;;Pharmaceuticals;Open
"2011-07-05
2012-07-04
2016-05-31";"CA2839941           A1 2013-01-10 [CA2839941]
STG: (A1) Application laid open
AP : 2012CA-2839941 2012-07-04
WO2013003904        A1 2013-01-10 [WO201303904]
STG: (A1) Published application with search report
AP : 2012WO-AU00804 2012-07-04
AU2012278930        A1 2013-05-02 [AU2012278930]
STG: (A1) Open to public inspection
AP : 2012AU-0278930 2012-07-04
US20140147466       A1 2014-05-29 [US20140147466]
STG: (A1) Application published
AP : 2012US-14130904 2012-07-04
MX2014015649        A  2015-05-12 [MX2014015649]
STG: (A) Patent application
AP : 2014MX-PA15649 2012-07-04
EP2870251           A1 2015-05-13 [EP2870251]
STG: (A1) Application published with search report
AP : 2012EP-0807985 2012-07-04
CN104640991         A  2015-05-20 [CN104640991]
STG: (A) Published application
AP : 2012CN-80074502 2012-07-04
AU2012278930        B2 2016-01-14 [AU2012278930]
STG: (B2) Patent proceeded by OPI
AP : 2012AU-0278930 2012-07-04
US9381240           B2 2016-07-05 [US9381240]
STG: (B2) Granted patent as second publication
AP : 2012US-14130904 2012-07-04
FD :  Previous publication: US20140147466 A1 2014-05-29 [US20140147466]
US20160339096       A1 2016-11-24 [US20160339096]
STG: (A1) Application published
AP : 2016US-15169555 2016-05-31
BR112014033067      A1 2017-02-21 [BR112014033067]
STG: (A1) Published application
AP : 2014BR-0033067 2012-07-04
NZ703070            A  2017-07-28 [NZ-703070]
STG: (A) Published application
AP : 2012NZ-0703070 2012-07-04
BR112014033067      A2 2017-08-01 [BR112014033067]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2014BR-0033067 2012-07-04
EP2870251           A4 2017-08-30 [EP2870251]
STG: (A4) Supplementary search report
AP : 2012EP-0807985 2012-07-04
CN104640991         B  2017-09-19 [CN104640991B]
STG: (B) Granted patent for invention
AP : 2012CN-80074502 2012-07-04
US9999661           B2 2018-06-19 [US9999661]
STG: (B2) Granted patent as second publication
AP : 2016US-15169555 2016-05-31
FD :  Continuation of: US14/130,904 FDD=2012-07-04 [2012US-14130904]
FD : Continuation of: US9381240 - 0 [US9381240]
FD : Continuation of: US14130904 0
FD : Continuation of: WOPCT/AU2012/000804 FDD=2012-07-04 [2012WO-AU00804]
FD : Continuation of: US14/130,904 FDD=2014-02-03 [2014US-14130904]
FD : Previous publication: US20160339096 A1 2016-11-24 [US20160339096]";44691924;"CA2839941           A1 2013-01-10 [CA2839941]
WO2013003904        A1 2013-01-10 [WO201303904]
AU2012278930        A1 2013-05-02 [AU2012278930]
US20140147466       A1 2014-05-29 [US20140147466]
MX2014015649        A  2015-05-12 [MX2014015649]
EP2870251           A1 2015-05-13 [EP2870251]
CN104640991         A  2015-05-20 [CN104640991]
AU2012278930        B2 2016-01-14 [AU2012278930]
US9381240           B2 2016-07-05 [US9381240]
US20160339096       A1 2016-11-24 [US20160339096]
BR112014033067      A1 2017-02-21 [BR112014033067]
NZ703070            A  2017-07-28 [NZ-703070]
BR112014033067      A2 2017-08-01 [BR112014033067]
EP2870251           A4 2017-08-30 [EP2870251]
CN104640991         B  2017-09-19 [CN104640991B]
US9999661           B2 2018-06-19 [US9999661]";"2011AU-0902660
2012AU-0278930
2012US-14130904
2012WO-AU00804
2016US-15169555";"(EP2870251)
WO2013003904
(US9381240)
WO2013003904
(US9999661)
WO2013003904
(CA2839941)
WO2013003904
(MX2014015649)
WO2013003904
(AU2012278930)
WO2013003904
(NZ-703070)
WO2013003904
(BR112014033067)
WO2013003904
(CN104640991B)
WO2013003904";"AUSTRALIAN MEAT & LIVESTOCK
AUSTRALIAN MEAT & LIVESTOCK ASSOCIATION
MEAT & LIVESTOCK AUSTRALIA
QUEENSLAND DEPARTMENT OF AGRICULTURE FORESTRY & FORESTRY
STATE OF QUEENSLAND
STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE FISHERIES & FORESTRY
STATE OF QUEENSLAND ACTING THROUGH THE DEPT OF AGRICULTURE FISHERIES & FORESTRY
STATE OF QUEENSLAND ACTIONG THROUGH THE DEPT OF AGRICULTURE FISHERIES & FORESTRY";"MEAT & LIVESTOCK AUSTRALIA
STATE OF QUEENSLAND";"(EP2870251)
AU
(US20140147466)
AU
(US9381240)
AU
(US20160339096)
AU
(US9999661)
AU
(WO201303904)
AU
(CA2839941)
AU";"(EP2870251)
NAME=The State of Queensland acting through The  Department of Agriculture, Fisheries and Forestry 80 Ann Street , CITY=Brisbane, Queensland 4000 , COUNTRY=AU 

NAME=Meat & Livestock Australia Limited Level 1, 165 Walker Street , CITY=North Sydney, NSW 2060 , COUNTRY=AU 

(US20140147466)
NAME=THE STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE, FISHERIES AND FORESTRY , CITY=Queensland , COUNTRY=AU , ATYP=Non-US Company 

NAME=MEAT & LIVESTOCK AUSTRALIA LIMITED , CITY=NORTH SYDNEY, NEW SOUTH WALES , COUNTRY=AU , ATYP=Non-US Company 

(US9381240)
NAME=THE STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE AND FISHERIES , CITY=Brisbane, Queensland , COUNTRY=AU , ATYP=Non-US Company 

NAME=MEAT & LIVESTOCK AUSTRALIA LIMITED , CITY=North Sydney, New South Wales , COUNTRY=AU , ATYP=Non-US Company 

(US20160339096)
NAME=TH STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE AND FISH , CITY=BRISBANE , COUNTRY=AU 

NAME=MEAT & LIVESTOCK AUSTRALIA LIMTED , CITY=NORTH SYDNEY , COUNTRY=AU 

(US9999661)
NAME=The State of Queensland Acting Through the Department of Agriculture and Fisheries , CITY=Brisbane, Queensland , COUNTRY=AU , ATYP=Non-US Company 

NAME=Meat & Livestock Australia Limited , CITY=North Sydney, New South Wales , COUNTRY=AU , ATYP=Non-US Company 

(WO201303904)
NAME=THE STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE, FISHERIES AND FORESTRY 80 Ann Street Brisbane, Queensland 4000 , COUNTRY=AU 

NAME=MEAT & LIVESTOCK AUSTRALIA LIMITED Level 1 165 Walker Street North Sydney, New South Wales 2060 , COUNTRY=AU 

(CA2839941)
NAME=THE STATE OF QUEENSLAND ACTING THROUGH THE DEPARTMENT OF AGRICULTURE, FISHERIES AND FORESTRY 80 Ann Street Queensland 4000 , CITY=BRISBANE , COUNTRY=AU 

NAME=MEAT & LIVESTOCK AUSTRALIA LIMITED Level 1, 40 Mount Street NEW SOUTH WALES 2060 , CITY=NORTH SYDNEY , COUNTRY=AU 
";2;MAHONY TIMOTHY JOHN;"(EP2870251)
AU";"(EP2870251)
NAME=MAHONY, Timothy John 65 Church Road , CITY=Bellbowrie, Queensland 4070 , COUNTRY=AU 
";"(EP2870251)
Recombinant low virulence bovine herpesvirus 1 (bohv-1) vaccine vectors";"(EP2870251)
The present disclosure teaches generally in the field of vaccination and disease control in cattle and bovine animals. A recombinant bovine herpesvirus 1 (BoHV-1) vaccine vector is provided for efficient control of one or more bovine pathogens such as those associated with bovine respiratory disease complex, such as bovine viral diarrhoea virus (BVDV), and which ameliorates disease conditions caused thereby. Protocols for the management of confined or herded bovine animals are also enabled herein.";"(CA2839941)
1. A vaccine against at least one antigen from a bovine pathogen, said vaccine comprising a bovine herpes virus-1 (BoHV-1) genome from a low virulence BoHV-1
having genetic material encoding the at least one antigen which is heterologous to BoHV-1
inserted between two converging BoHV-1 genes wherein the insertion does not substantially down-regulate expression of the BoHV-1 genes and wherein the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a site selected from between 16600 to 16700; 22400
to 22500;
40,700 to 40,800; 58,000 to 59,000; 67,000 to 68,000; 74,000 to 76,000; 84,000
to 85,000;
90,000 to 91,000; and 96,000 to 97,000 of BoHV-1 reference sequence GenBank
Accession No, AJ004801 or at a functionally equivalent site in another BoHV-1.
2, The vaccine of Claim 1 wherein the genetic material encoding the at least one antigen is inserted into the BoHV-1 genome via GET recombination.
3. The vaccine of Claim 1 wherein the at least one antigen is inserted between two converging genes at a site selected from between 16600 to 16612; 22400 to
22493; 16602
to 16603; and 22421 to 22470.
4. The vaccine of Claim 1 wherein the at least one antigen is inserted between two converging genes at a site selected from between a site listed in Table 2.
5. The vaccine of any one of Claims 1 to 4 wherein the at least one antigen is selected from the list consisting of an antigen from bovine viral diarrhoea virus
(BVDV) an antigen from BoHV-1, an antigen from bovine parainfluenza3, an antigen from bovine respirator syncytial virus and an antigen from a microorganism.
6. The vaccine of Claim 5 wherein the BVDV antigen is selected from the list consisting of glycoprotein E0 and glycoprotein E2.
7. The vaccine of Claim 5 wherein the microorganism is selected from the list consisting of Mycoplasina bovis, a Salmonella species, Pasteurella multocida,
Mannhiemia haemolytica and Haemophilus somnus.
8. The vaccine of Claim 1 wherein the low virulence BoHV-1 strain is strain
V155.
9. The vaccine of any one of Claims 1 to 8 formulated in a pharmaceutical composition.
10. The vaccine of Claim 9 wherein the pharmaceutical composition is suitable for nasal administration.
11. A method for vaccinating a bovine animal against at least one antigen from a bovine pathogen, said method comprising administering to said bovine animal a humoral immunity-inducing or cell-mediated immunity-inducing effective amount of a vaccine according to any one of Claims 1 to 10.
12. The method of Claim 11 wherein administration is via intra-nasal, oral, intramuscular, sub-lingual, intravenous, subcutaneous, intra-arterial, skin spray, intravaginal or intra-rectal administration
13. A method of producing a vaccine against at least one antigen from a bovine pathogen, said method comprising:
(i) incorporating a BoHV-1 genome from a low virulence BoHV-1 into a bacterial artificial chromosome (BAC) vector to form a BoHV-1 pre-vector BAC
construct;
(ii) inserting genetic material encoding the at least one antigen into the
BoHV-1
pre-vector BAC construct via GET recombination to generate a recombinant BoHV-
BAC (rBoHV- 1 -BAC) vector, the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a site selected from between 16600 to 16700; 22400 to 22500; 40,700 to 40,800; 58,000 to
59,000;
67. 000 to 68,000; 74,000 to 76,000; 84,000 to 85,000; 90,000 to 91,000; a.nd
96,000 to
97,000 of BoHV-1 reference sequence GenBank Accession No. AJ004801 or at a functionally equivalent site in another BoHV-1;
(iii) transforming and amplifying the rBoHV-1-BAC vector in a bacterial host;
and
(iv) purifying and isolating the rBoHV-1-BAC vector from the bacterial host and formulating the vector into a vaccine composition.
14. The method of Claim 13 wherein the at least one antigen is inserted between two converging genes at a site selected from between 16600 to 16612; 22400 to
22493; 16602
to 16603; and 22421 to 22470.
15. The method of Claim 13 wherein the at least one antigen is inserted between two converging genes at a site selected from between a site listed in Table 2.
16. The method of any one of Claim 13 wherein the at least one antigen is selected from the list consisting of an antigen from bovine viral diarrhoea virus
(BVDV) an antigen from BoHV-1, an antigen from bovine parainfluenza3, an antigen from bovine respirator syncytial virus and an antigen from a microorganism.
17. The method of Claim 16 wherein the BVDV antigen is selected from the list consisting of glycoprotein E0 and glycoprotein E2.
18. The method of Claim 16 wherein the microorganism is selected from the list consisting of Mycoplasma bovis, a Salmonella species, Pasteurella multocida,
Mannhiemia haemolytica and Haemophilus somnus.
19. The method of Claim 13 wherein the low virulence BoHV-1 strain is strain V155.
20. A cultured cell transfected with the rBoHV-1-BAC vector of any one of
Claims 13
to 19.
21. Use of the vaccine of any one of Claims 1 to 10 in the manufacture of a medicament in the vaccination of cattle against a bovine pathogen.";"(US20140147466)
The present disclosure teaches generally in the field of vaccination and disease control in cattle and bovine animals.
Accordingly, another aspect enabled herein is a vaccine vector comprising a BoHV-1 genome from a low virulence BoHV-1 having genetic material encoding the at least one antigen which is heterologous to BoHV-1 inserted between two converging BoHV-1 genes wherein the insertion does not substantially down-regulate expression of the BoHV-1 genes.";"(US20140147466)
The present disclosure further enables a diagnostic assay to serologically distinguish between vaccinated and nonvaccinated bovine animals.
It was planned to administer the vaccine using a commercial applicator, however, due to problems in getting this to work, the vaccinations were delivered using a syringe as performed in previous research.
The use of a low virulence BoHV-1 rather than an inactivated or attenuated strain improves its ability to infect, replicate and produce a nonpathogenic infection and an effective immune response against BoHV-1 and any heterologous antigens.
The immune response in bovine animals is regarded, in an embodiment, as a protective immune response in that the immune response targets the protein on or produced by a pathogen and this facilitates a reduction in infection, colonization and/or symptoms of disease and/or transmission of pathogens and/or outcomes of infection such as morbidity or mortality.";"A61K-039/00
A61K-039/02
A61K-039/102
A61K-039/112
A61K-039/12
A61K-039/245
C12N-007/00
C12N-015/31
C12N-015/40
C12N-015/86
C12N-015/869";"(US20140147466)
62. A vaccine against at least one antigen from a bovine pathogen, said vaccine comprising a bovine herpes virus-1 (BoHV-1) genome from a low virulence BoHV-1 having genetic material encoding the at least one antigen which is heterologous to BoHV-1 inserted between two converging BoHV-1 genes wherein the insertion does not substantially down-regulate expression of the BoHV-1 genes and wherein the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a site selected from between 16600 to 16700; 22400 to 22500; 40,700 to 40,800; 58,000 to 59,000; 67,000 to 68,000; 74,000 to 76,000; 84,000 to 85,000; 90,000 to 91,000; and 96,000 to 97,000 of BoHV-1 reference sequence gen bank Accession No. AJ004801 or at a functionally equivalent site in another BoHV-1.
74. A method of producing a vaccine against at least one antigen from a bovine pathogen, said method comprising: (i) incorporating a BoHV-1 genome from a low virulence BoHV-1 into a bacterial artificial chromosome (BAC) vector to form a BoHV-1 pre-vector BAC construct; (ii) inserting genetic material encoding the at least one antigen into the BoHV-1 pre-vector BAC construct via GET recombination to generate a recombinant BoHV-1-BAC (rBoHV-1-BAC) vector, the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a site selected from between 16600 to 16700; 22400 to 22500; 40,700 to 40,800; 58,000 to 59,000; 67,000 to 68,000; 74,000 to 76,000; 84,000 to 85,000; 90,000 to 91,000; and 96,000 to 97,000 of BoHV-1 reference sequence gen bank Accession No. AJ004801 or at a functionally equivalent site in another BoHV-1; (iii) transforming and amplifying the rBoHV-1-BAC vector in a bacterial host; and (iv) purifying and isolating the rBoHV-1-BAC vector from the bacterial host and formulating the vector into a vaccine composition.";"(US20140147466)
BOHV(100,105)
ANTIGEN(100,73)
VACCINE(100,29)
BOVINE PATHOGEN(100,15)
CONVERGING GENE(100,14)
VACCINE VECTOR(100,8)
BOVINE HERPES VIRUS(100,6)
RECOMBINANT LOW VIRULENCE(100,1)
BACTERIAL ARTIFICIAL CHROMOSOME VECTOR(82,4)
NON PATHOGENIC INFECTION(74,1)
BOVINE ANIMAL(71,13)
CONVERGING BOHV(70,14)
RECOMBINANT BOVINE HERPES VIRUS(66,1)
INFECTION OUTCOME(63,1)
BOHV EXPRESSION(62,14)
BOVINE PARAINFLUENZA(62,3)
HAEMOPHILUS SOMNUS(61,5)
BACTERIAL ARTIFICIAL CHROMOSOME CONSTRUCT(60,2)
DISEASE SYMPTOM(59,1)
BACTERIAL HOST(58,7)
RECOMBINANT BOHV(58,3)
FUNCTIONALLY EQUIVALENT SITE(54,6)
DIAGNOSTIC ASSAY(53,1)
SALMONELLA SPECIES(48,4)
POLYADENYLATION(46,5)
PATHOGEN TRANSMISSION(46,1)
MICROORGANISM(42,6)
RBOHV(40,10)
COMMERCIAL APPLICATOR(40,2)
PROTECTIVE IMMUNE RESPONSE(40,1)
IMMUNE RESPONSE(38,16)
PASTEURELLA MULTOCIDA(36,3)
LOW VIRULENCE(35,25)
GLYCOPROTEIN(35,10)
VACCINATION(34,12)
BOVINE VIRAL DIARRHEA VIRUS(33,8)
COLONIZATION(33,1)
ACCESSION(32,9)
GENOME(31,32)
RECOMBINATION(31,6)
GENE(30,31)
MYCOPLASMA BOVIS(30,5)
MORBIDITY(29,1)
PATHOGEN(29,1)
MORTALITY(28,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(27,3)
ENCODING GENETIC MATERIAL(26,24)
CATTLE(24,33)
VECTOR(23,14)
DISEASE CONDITION(23,1)
HETEROLOGOUS ANTIGEN(22,4)
SYRINGE(22,2)
DISEASE CONTROL(22,1)
STRAIN(21,14)
VACCINATED CATTLE(21,5)
PROTEIN(21,2)
BACTERIAL ARTIFICIAL CHROMOSOME(20,5)
INTRANASAL INSTILLATION(20,4)
CLINICAL ASSESSMENT(19,6)
HOMOLOGOUS RECOMBINATION(18,4)
INFECTION(18,4)
RESTRICTION ENDONUCLEASE DIGESTION(18,2)
HYBAID SPRINT THERMOCYCLER(18,1)
ANIMAL TRIAL COMMENCEMENT(16,2)
NASAL ADMINISTRATION(16,2)
ROCHE MOLECULAR BIOSYSTEM(16,2)
NASAL TAMPON(15,4)
VIRUS PERSISTING(15,3)
VIRAL SUPERNATANT(14,3)
PATEURELLA MULTOCIDA(14,2)
PGETREC FACILITATED RECOMBINATION(14,1)
ENVIRONMENTAL SWAB(13,3)
RECOMBINANT VACCINE VECTOR(13,3)
GMBOHV EFFICACY(13,2)
REFERENCE SEQUENCE GEN(12,7)
VIRAL PELLET(12,3)
BAC VECTOR INSERTION(12,2)
TRANSFECTED MONOLAYER(12,2)
AUSTRALIAN VETERINARY JOURNAL(12,1)
BOHV GENETIC MANIPULATION(12,1)
BOVINE ANIMAL ECONOMIC VIABILITY(12,1)
CHALLENGE NASAL SWAB(12,1)
DUAL VACCINE FACILITATION(12,1)
CLINICAL SIGN(11,3)
BAC TK FRAGMENT(11,2)
CULTURED CELL(11,2)
TRANSGENE INSERTION(11,2)
VACCINE FORMULATION(11,2)
BOHV HINDIII PROFILE(11,1)
DONOR CALF SERA(11,1)
EFFICIENT CONTROL(11,1)
HERD SEROLOGICAL ANALYSIS(11,1)
PCR AMPLIFIED TRANSGENE(11,1)
POLYVALENT VACCINE VECTOR(11,1)
QIAGEN GENOMIC DNA(11,1)
RECE TRANSIENT EXPRESSION(11,1)
INDUCIBLE RECOMBINATION(10,7)
GENOMIC TIP(10,3)
PURIFIED BOHV(10,2)
BOHV RECOMBINATION(10,1)
CATTLE VACCINATION(10,1)
DH10B CELL HARBORING(10,1)
DIGESTED BAC VECTOR(10,1)
ELECTROPORATION ALIQUOT(10,1)
ELECTROPORATION CUVETTE(10,1)
ELECTROPORATION DH10B CELL(10,1)
GE GENE REPLACEMENT(10,1)
GFP EXPRESSION CASSETTE(10,1)
HETEROLOGOUS GENE ENCODING(10,1)
MANHIEMIA HAEMOLYTICA(10,1)
NSII SITE REMR(10,1)
PATHOGEN ANTIGEN(10,1)
PESTIVIRUS RESISTANT DERIVATIVE(10,1)
QIAGEN GEL EXTRACTION KIT(10,1)
QIAGEN PCR PURIFICATION COLUMN(10,1)
VIRAL GENOMIC DNA(10,1)
BOVINE RESPIRATORY DISEASE COMPLEX(9,3)
NATURAL HOST(9,3)
SAMPLE COLLECTION(9,3)
TRIGEMINAL GANGLIA(9,3)
BURIAL DEPTH(9,2)
CPE DEVELOPMENT(9,2)
EXPRESS PROTEIN(9,2)
IMMUNE RESPONSE STIMULATION(9,2)
PRE VECTOR BAC CONSTRUCT(9,2)
ARABINOSE INDUCTION(9,1)
BVDV IMMUNITY(9,1)
CLOSELY HOUSED CATTLE(9,1)
DIARY CATTLE(9,1)
EXTRACELLULAR VIRUS(9,1)
GENOMIC DNA EXTRACTION BUFFER(9,1)
HERD OWNER(9,1)
HERDED CATTLE(9,1)
HINDIII DIGESTION(9,1)
KANR CASSETTE(9,1)
MICROBIAL PATHOGEN(9,1)
MULTIFACTORIAL DISEASE(9,1)
MULTIVALENT VACCINE(9,1)
PROTOTYPE VACCINE(9,1)
SECONDARY CHALLENGE NASAL(9,1)
SOUTHERN BLOT(9,1)
SPEI DIGESTION(9,1)
UNIQUE RESTRICTION ENDONUCLEASE(9,1)
UNVACCINATED BOVINE(9,1)
VACCINATION EFFECTIVENESS(9,1)
CELL MONOLAYER(8,2)
FREEZE DRIED GMBOHV(8,2)
LYSIS BUFFER(8,2)
DAILY BASIS(7,4)
CO2 ATMOSPHERE(7,2)
POST VACCINATION(7,2)
AUDIBLE BREATHING(7,1)
BOHV SEGMENT(7,1)
BVDV ANTIGEN(7,1)
CAP RESISTANT COLONY(7,1)
CONVERGENT GENE(7,1)
DELETION FRAGMENT(7,1)
FEEDLOT CATTLE(7,1)
GENTLE ROCKING(7,1)
GENTLE SHAKING(7,1)
HETEROLOGOUS ANTIGEN EXPRESSION(7,1)
HETEROLOGOUS PROTEIN(7,1)
HYBRIDIZATION OVEN(7,1)
INFECTIOUS CLONE(7,1)
INTRACELLULAR VIRUS(7,1)
INTRANASAL ROUTE(7,1)
MANUFACTURER INSTRUCTION(7,1)
MATURE BOHV(7,1)
MURDOCH CHILDRENS RESEARCH INSTITUTE(7,1)
MYCOPLASMA SP(7,1)
NON CHARGED MEMBRANE(7,1)
PASTEURELLA SP(7,1)
PATHOGEN GENE(7,1)
PCR AMPLIFICATION(7,1)
PCR CYCLING(7,1)
PELLETED VIRUS(7,1)
PROPRIETARY(7,1)
PTKDEL VECTOR(7,1)
RECOMBINANT COLONY(7,1)
RECOMBINATION EXPERIMENT(7,1)
RUMINANT SPECIES(7,1)
SALMONELLA SP(7,1)
SHAKING PLATFORM(7,1)
THYMIDINE KINASE GENE(7,1)
TKRIGHT PCR PRODUCT(7,1)
TRANSGENE PRODUCT EXCISION(7,1)
VARIANT CRIB(7,1)
VIRAL GENE TRANSCRIPTION(7,1)
VIRUS FUNCTION(7,1)
GOAT(6,6)
SHEEP(6,6)
CARCASS(6,3)
DILUENT(6,3)
EXCIPIENT(6,3)
INCUBATION(6,3)
NOSTRIL(6,3)
NUCLEOTIDE(6,3)
OPTIMEM(6,3)
PLASMID(6,3)
TISSUE SAMPLE(6,3)
VALENCY(6,3)
BAC DNA(6,1)
BACTERIAL ALKALINE PHOSPHATASE(6,1)
BOVINE HOST(6,1)
CELL LYSIS(6,1)
COLI STRAIN(6,1)
DAILY SAMPLING(6,1)
DOUBLE RESISTANT DH10B CELL(6,1)
ELECTROCOMPETENT CELL(6,1)
EPICENTER TECHNOLOGY(6,1)
FILTER HYBRIDIZATION(6,1)
GENOMIC VIRAL DNA(6,1)
HUMORAL IMMUNE RESPONSE(6,1)
LB BROTH(6,1)
MARKER PROTEIN(6,1)
MEDICAMENT MANUFACTURE(6,1)
NUMERIC SCORE(6,1)
PCR ASSAY(6,1)
PCR TEMPLATE(6,1)
POST TRANSFECTION(6,1)
PRIMER PAIR CHLORAMF(6,1)
PROTEIN ANTIGEN(6,1)
RECOMBINATION ARM(6,1)
RESTRICTION ENZYME(6,1)
SEROLOGICAL TESTING(6,1)
SOC BROTH(6,1)
SPECIES ANIMAL(6,1)
SPREAD INCIDENCE(6,1)
TAQ POLYMERASE BUFFER(6,1)
TEMPLATE DNA(6,1)
TKLEFT PCR PRODUCT(6,1)
VACCINE PREPARATION(6,1)
VIRUS PARTICLE(6,1)
VIRUS PROPAGATION(6,1)
CENTRIFUGATION(5,2)
FREEZE DRIED PREPARATION(5,2)
MAINTENANCE MEDIUM(5,2)
SENTINEL GROUP(5,2)
TRANSFORMATION(5,2)
TRIPLICATE(5,2)
AGAROSE GEL(5,1)
ANTIBIOTIC ANTIMYOTIC(5,1)
ANTIBODY POSITIVE(5,1)
AUXILIARY SUBSTANCE(5,1)
BOTTLE ROTATION(5,1)
BUFFERING AGENT(5,1)
BVDV SPECIFIC ANTIBODY(5,1)
CAP RESISTANCE GENE(5,1)
CELL CULTURE SUPERNATANT(5,1)
CELL INFECTION(5,1)
CELL PELLET(5,1)
CHLORAMPHENICOL RESISTANCE GENE(5,1)
CHLORAMPHENICOL SELECTIVE PLATE(5,1)
CLINICAL NOTE(5,1)
CROSSOVER REGION(5,1)
DELETION INSERTION VECTOR(5,1)
EXCLUSION ELEMENT(5,1)
MANUFACTURE INSTRUCTION(5,1)
MDBK CELL(5,1)
MINIMAL KANAMYCIN RESISTANCE CASSETTE(5,1)
PCR DETECTION(5,1)
RE CONSTITUTION(5,1)
RECOVERED CELL(5,1)
SELECTIVE AGAR(5,1)
SODIUM PHOSPHATE(5,1)
STANDARD ANTIBODY ASSAY(5,1)
STANDARD VIROLOGICAL(5,1)
TARGET REGION(5,1)
(US9381240)
BOHV(100,125)
ANTIGEN(100,87)
VACCINE(100,34)
BOVINE PATHOGEN(100,24)
VACCINE VECTOR(100,11)
BOVINE HERPES VIRUS(100,10)
RECOMBINANT LOW VIRULENCE(100,1)
FAMILY HERPESVIRIDAE VIRUS(92,1)
ATTENUATED VIRUS(90,2)
LIFELONG LATENT INFECTION(88,1)
CONVERGING BOHV(78,21)
CONVERGING GENE(76,13)
BACTERIAL ARTIFICIAL CHROMOSOME VECTOR(76,4)
BOHV EXPRESSION(70,21)
VIRUS SHEDDING(62,1)
NEWBORN CALF(59,1)
CATTLE VACCINATION(57,2)
INACTIVATED VIRUS(57,1)
HAEMOPHILUS SOMNUS(56,6)
BACTERIAL ARTIFICIAL CHROMOSOME CONSTRUCT(56,2)
BOVINE ANIMAL(54,17)
BOVINE PARAINFLUENZA(54,4)
CATTLE DISEASE(54,1)
GENERALIZED DISEASE(53,1)
RECOMBINANT BOVINE HERPES VIRUS(51,2)
BACTERIAL HOST(50,11)
RECOMBINANT BOHV(49,5)
SALMONELLA SPECIES(44,4)
POLYADENYLATION(43,5)
ENTERITIS(40,2)
MICROORGANISM(39,6)
RBOHV(36,12)
MEDICAMENT MANUFACTURE(36,2)
HERPES VIRUS(36,1)
VACCINATION(35,7)
DISEASE CONDITION(34,2)
GENE(33,45)
PASTEURELLA MULTOCIDA(33,3)
BALANOPOSTHITIS(33,1)
MULTIPLICATION(33,1)
RHINOTRACHEITIS(33,1)
GENOME(32,43)
CONJUNCTIVITIS(32,1)
LOW VIRULENCE(31,35)
GLYCOPROTEIN(31,13)
BOVINE VIRAL DIARRHEA VIRUS(30,9)
ACCESSION(29,11)
RECOMBINATION(29,6)
MYCOPLASMA BOVIS(28,5)
VAGINITIS(28,1)
VIRAL ANTIGEN(27,1)
PRODUCTIVITY(26,1)
DISEASE CONTROL(25,2)
ENCODING GENETIC MATERIAL(24,34)
CATTLE(24,9)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(24,4)
ABORTION(22,2)
IMMUNE HOST(22,1)
VECTOR(21,20)
DEATH(21,1)
BVDV(19,8)
BACTERIAL ARTIFICIAL CHROMOSOME(18,7)
MORTALITY(18,4)
DISEASE(18,3)
EFFICIENT CONTROL(17,2)
RESTRICTION ENDONUCLEASE DIGESTION(17,2)
INFECTION(16,5)
HOMOLOGOUS RECOMBINATION(16,4)
HYBAID SPRINT THERMOCYCLER(16,1)
EXCIPIENT(15,4)
NASAL ADMINISTRATION(15,2)
POLYVALENT VACCINE VECTOR(15,2)
INFECTIOUS PUSTULAR VULVOVAGINITIS(15,1)
BVDV NONSTRUCTURAL PROTEIN(14,1)
DILUENT(13,4)
PATEURELLA MULTOCIDA(13,2)
BVDV CYTOPATHIC VARIANT(13,1)
INFECTIOUS BOVINE RHIBOTRACHEITIS(13,1)
MUCOSAL EROSION CLINICAL SIGN(13,1)
NONHOMOLOGOUS RNA RECOMBINATION(13,1)
BOVINE RESPIRATORY DISEASE COMPLEX(12,7)
PRE VECTOR BAC CONSTRUCT(12,4)
FEEDLOT CATTLE(12,3)
RECOMBINANT VACCINE VECTOR(12,3)
AUSTRALIAN VETERINARY JOURNAL(12,1)
BOHV GENETIC MANIPULATION(12,1)
BOVINE ANIMAL ECONOMIC VIABILITY(12,1)
BVDV MAJOR NEUTRALIZING EPITOPE(12,1)
DUAL VACCINE FACILITATION(12,1)
NEUTRALIZING ANTIBODY INDUCTION(12,1)
THYMIDINE KINASE DELETION MUTANT(12,1)
INDUCIBLE RECOMBINATION(11,10)
REFERENCE SEQUENCE GEN(11,8)
BAC VECTOR INSERTION(11,2)
CULTURED CELL(11,2)
TRANSFECTED MONOLAYER(11,2)
VIRAL SUPERNATANT(11,2)
FUNCTIONALLY EQUIVALENT SITE(10,5)
BAC TK FRAGMENT(10,2)
MANUFACTURER INSTRUCTION(10,2)
PERSISTENT INFECTION(10,2)
THYMIDINE KINASE GENE(10,2)
TRANSGENE INSERTION(10,2)
VACCINE FORMULATION(10,2)
BOHV HINDIII PROFILE(10,1)
DONOR CALF SERA(10,1)
GENETICALLY DISTINCT VIRUS APPEARANCE(10,1)
HERD SEROLOGICAL ANALYSIS(10,1)
PCR AMPLIFIED TRANSGENE(10,1)
QIAGEN GENOMIC DNA(10,1)
RECE TRANSIENT EXPRESSION(10,1)
GESTATION DAY(9,2)
PURIFIED BOHV(9,2)
BOHV GENOTYPE(9,1)
BOHV RECOMBINATION(9,1)
BVDV ANTIGENIC VARIABILITY(9,1)
DH10B CELL HARBORING(9,1)
DIGESTED BAC VECTOR(9,1)
EARLY EMBRYONIC DEATH(9,1)
EFFICACIOUS VACCINE(9,1)
ELECTROPORATION ALIQUOT(9,1)
ELECTROPORATION CUVETTE(9,1)
ELECTROPORATION DH10B CELL(9,1)
INFECTIOUS BALANOPOSTHITIS(9,1)
MANHIEMIA HAEMOLYTICA(9,1)
MONTH POST INFECTION(9,1)
NON PATHOGENIC INFECTION(9,1)
PASTEURELLA MUTOCIDA(9,1)
PATHOGEN ANTIGEN(9,1)
PESTIVIRUS RESISTANT DERIVATIVE(9,1)
QIAGEN GEL EXTRACTION KIT(9,1)
QIAGEN PCR PURIFICATION COLUMN(9,1)
VALENCY(8,6)
NUCLEOTIDE(8,5)
BACTERIAL SPECIES(8,2)
BOVINE HOST(8,2)
CPE DEVELOPMENT(8,2)
EXPRESS PROTEIN(8,2)
IMMUNE RESPONSE STIMULATION(8,2)
WILD TYPE VIRUS(8,2)
ARABINOSE INDUCTION(8,1)
BRDC SEVERITY(8,1)
CLOSELY HOUSED CATTLE(8,1)
DIARY CATTLE(8,1)
FLAVIVIRIDAE FAMILY(8,1)
GENOMIC DNA EXTRACTION BUFFER(8,1)
HERD OWNER(8,1)
HERDED CATTLE(8,1)
HINDIII DIGESTION(8,1)
MEDICATION PURCHASE(8,1)
MICROBIAL PATHOGEN(8,1)
MULTIFACTORIAL DISEASE(8,1)
MULTIVALENT VACCINE(8,1)
PAINFUL URINATION(8,1)
RUMINANT ORIGIN(8,1)
SEROLOGICAL SURVEY(8,1)
SEVERE CLINICAL DISEASE(8,1)
SPEI DIGESTION(8,1)
SWOLLEN VULVA(8,1)
UNIMMUNIZED ANIMAL(8,1)
UNIQUE RESTRICTION ENDONUCLEASE(8,1)
VACCINATION EFFECTIVENESS(8,1)
AUSTRALIAN STRAIN(7,1)
BOHV SEGMENT(7,1)
BOVINE ORIGIN CELL(7,1)
CAP RESISTANT COLONY(7,1)
CELL MEDIATED IMMUNITY INDUCTION(7,1)
COMPLICATED ETIOLOGY(7,1)
CONVERGENT GENE(7,1)
DAIRY FACILITY(7,1)
DELETION FRAGMENT(7,1)
DISEASE SYMPTOM(7,1)
GENITAL DISEASE(7,1)
GENTLE SHAKING(7,1)
HETEROLOGOUS ANTIGEN EXPRESSION(7,1)
HETEROLOGOUS PROTEIN(7,1)
HR POST INFECTION(7,1)
INFECTION OUTCOME(7,1)
INFECTIOUS CLONE(7,1)
INTRANASAL ROUTE(7,1)
KILLED VACCINE(7,1)
LIVESTOCK INDUSTRY(7,1)
MATURE BOHV(7,1)
MURDOCH CHILDRENS RESEARCH INSTITUTE(7,1)
MYCOPLASMA SP(7,1)
OCULAR DEFECT(7,1)
PASTEURELLA SP(7,1)
PATHOGEN GENE(7,1)
PCR AMPLIFICATION(7,1)
PCR CYCLING(7,1)
PELLETED VIRUS(7,1)
PRIMATE ORIGIN CELL(7,1)
PROPRIETARY(7,1)
PTKDEL VECTOR(7,1)
RECOMBINATION EXPERIMENT(7,1)
SALMONELLA SP(7,1)
TKRIGHT PCR PRODUCT(7,1)
TRANSGENE PRODUCT EXCISION(7,1)
VARIANT CRIB(7,1)
VIRAL GENE TRANSCRIPTION(7,1)
VIRAL PELLET(7,1)
VIRAL REPLICATION(7,1)
VIRUS FUNCTION(7,1)
VIRUS INFECTED CELL(7,1)
MORBIDITY(6,3)
OPTIMEM(6,3)
PLASMID(6,3)
APPETITE LOSS(6,2)
AGAROSE GEL(6,1)
BAC DNA(6,1)
BACTERIAL ALKALINE PHOSPHATASE(6,1)
CELL MONOLAYER(6,1)
COLI STRAIN(6,1)
CONTRIBUTING FACTOR(6,1)
CREATION DATE(6,1)
DIAGNOSTIC ASSAY(6,1)
DOUBLE RESISTANT DH10B CELL(6,1)
ELECTROCOMPETENT CELL(6,1)
GLYCOPROTEIN STRUCTURE(6,1)
HUMORAL IMMUNE RESPONSE(6,1)
HUMORAL IMMUNITY GENERATION(6,1)
LATENCY SITE(6,1)
LB BROTH(6,1)
MARKER PROTEIN(6,1)
PATHOGEN TRANSMISSION(6,1)
PCR ASSAY(6,1)
PCR TEMPLATE(6,1)
POST TRANSFECTION(6,1)
PRIMER PAIR CHLORAMF(6,1)
PROTEIN ANTIGEN(6,1)
RECOMBINATION ARM(6,1)
SEROLOGICAL TESTING(6,1)
SIGNIFICANT INFECTIOUS DISEASE(6,1)
SOC BROTH(6,1)
SPREAD INCIDENCE(6,1)
TARGET VIRUS(6,1)
TKLEFT PCR PRODUCT(6,1)
VACCINE CARRIER(6,1)
VACCINE DEVELOPMENT(6,1)
VACCINE PREPARATION(6,1)
VIRUS PARTICLE(6,1)
VIRUS PROPAGATION(6,1)
CENTRIFUGATION(5,2)
HAEMOPHILUS(5,2)
INCUBATION(5,2)
SUBGROUP(5,2)
TRANSFORMATION(5,2)
AEROSOL TRANSMISSION(4,1)
ANTIBIOTIC ANTIMYOTIC(4,1)
ASCII TEXT FILE NAME(4,1)
AUXILIARY SUBSTANCE(4,1)
BVDV SPECIFIC VACCINATION(4,1)
CAP RESISTANCE GENE(4,1)
CELL CULTURE SUPERNATANT(4,1)
CELL INFECTION(4,1)
CHLORAMPHENICOL RESISTANCE GENE(4,1)
CONFINED ENVIRONMENT(4,1)
CROSSOVER REGION(4,1)
DELETION INSERTION VECTOR(4,1)
EARLY EXPOSURE(4,1)
EXCLUSION ELEMENT(4,1)
FEED RESOURCE LOSS(4,1)
LYSIS BUFFER(4,1)
MDBK CELL(4,1)
PATHOGENIC AGENT(4,1)
PCR DETECTION(4,1)
PH BUFFERING(4,1)
POTENTIAL GENETIC(4,1)
PROTECTIVE IMMUNE RESPONSE(4,1)
PROTEIN SEQUENCE(4,1)
RABBIT CELL(4,1)
RE CONSTITUTION(4,1)
REPRODUCTIVE LOSS(4,1)
SELECTIVE AGAR(4,1)
SIGNIFICANT DISEASE RISK(4,1)
STANDARD ANTIBODY ASSAY(4,1)
TARGET REGION(4,1)
TRANSFECTION LIQUID(4,1)
TRANSFECTION MIXTURE(4,1)
VIRUS COMPARISON(4,1)
(US20160339096)
BOHV(100,106)
ANTIGEN(100,62)
VACCINE(100,28)
BOVINE PATHOGEN(100,14)
CONVERGING GENE(100,14)
VACCINE VECTOR(100,8)
BOVINE HERPES VIRUS(100,6)
RECOMBINANT LOW VIRULENCE(100,1)
FUNCTIONALLY EQUIVALENT SITE(94,12)
BACTERIAL ARTIFICIAL CHROMOSOME VECTOR(82,4)
NON PATHOGENIC INFECTION(74,1)
BOVINE ANIMAL(71,13)
CONVERGING BOHV(70,14)
RECOMBINANT BOVINE HERPES VIRUS(66,1)
INFECTION OUTCOME(63,1)
BOHV EXPRESSION(62,14)
BACTERIAL ARTIFICIAL CHROMOSOME CONSTRUCT(60,2)
DISEASE SYMPTOM(59,1)
BACTERIAL HOST(58,7)
RECOMBINANT BOHV(58,3)
DIAGNOSTIC ASSAY(53,1)
POLYADENYLATION(46,5)
PATHOGEN TRANSMISSION(46,1)
BOVINE VIRAL DIARRHEA VIRUS(45,7)
PATEURELLA MULTOCIDA(45,3)
HAEMOPHILUS SOMNUS(42,4)
RBOHV(40,10)
COMMERCIAL APPLICATOR(40,2)
PROTECTIVE IMMUNE RESPONSE(40,1)
IMMUNE RESPONSE(38,16)
MICROORGANISM(35,5)
VACCINATION(34,12)
INDUCIBLE RECOMBINATION(33,10)
COLONIZATION(33,1)
ACCESSION(32,9)
SALMONELLA SPECIES(32,3)
GENOME(31,32)
GENE(30,31)
LOW VIRULENCE(30,23)
MORBIDITY(29,1)
PATHOGEN(29,1)
MORTALITY(28,1)
ENCODING GENETIC MATERIAL(26,24)
CATTLE(24,33)
VECTOR(23,14)
GLYCOPROTEIN(23,8)
DISEASE CONDITION(23,1)
HETEROLOGOUS ANTIGEN(22,4)
SYRINGE(22,2)
DISEASE CONTROL(22,1)
VACCINATED CATTLE(21,5)
PROTEIN(21,2)
BACTERIAL ARTIFICIAL CHROMOSOME(20,5)
INTRANASAL INSTILLATION(20,4)
MYCOPLASMA BOVIS(20,4)
CLINICAL ASSESSMENT(19,6)
HOMOLOGOUS RECOMBINATION(18,4)
INFECTION(18,4)
RESTRICTION ENDONUCLEASE DIGESTION(18,2)
HYBAID SPRINT THERMOCYCLER(18,1)
ANIMAL TRIAL COMMENCEMENT(16,2)
NASAL ADMINISTRATION(16,2)
ROCHE MOLECULAR BIOSYSTEM(16,2)
NASAL TAMPON(15,4)
VIRUS PERSISTING(15,3)
STRAIN(14,12)
VIRAL SUPERNATANT(14,3)
PGETREC FACILITATED RECOMBINATION(14,1)
ENVIRONMENTAL SWAB(13,3)
MANUFACTURER INSTRUCTION(13,3)
RECOMBINANT VACCINE VECTOR(13,3)
GMBOHV EFFICACY(13,2)
REFERENCE SEQUENCE GEN(12,7)
VIRAL PELLET(12,3)
BAC VECTOR INSERTION(12,2)
TRANSFECTED MONOLAYER(12,2)
AUSTRALIAN VETERINARY JOURNAL(12,1)
BOHV GENETIC MANIPULATION(12,1)
BOVINE ANIMAL ECONOMIC VIABILITY(12,1)
CHALLENGE NASAL SWAB(12,1)
DUAL VACCINE FACILITATION(12,1)
CLINICAL SIGN(11,3)
BAC TK FRAGMENT(11,2)
CULTURED CELL(11,2)
TRANSGENE INSERTION(11,2)
VACCINE FORMULATION(11,2)
BOHV HINDIII PROFILE(11,1)
DONOR CALF SERA(11,1)
EFFICIENT CONTROL(11,1)
HERD SEROLOGICAL ANALYSIS(11,1)
PCR AMPLIFIED TRANSGENE(11,1)
POLYVALENT VACCINE VECTOR(11,1)
QIAGEN GENOMIC DNA(11,1)
RECE TRANSIENT EXPRESSION(11,1)
GENOMIC TIP(10,3)
PURIFIED BOHV(10,2)
BOHV RECOMBINATION(10,1)
CATTLE VACCINATION(10,1)
DH10B CELL HARBORING(10,1)
DIGESTED BAC VECTOR(10,1)
ELECTROPORATION ALIQUOT(10,1)
ELECTROPORATION CUVETTE(10,1)
ELECTROPORATION DH10B CELL(10,1)
GE GENE REPLACEMENT(10,1)
GFP EXPRESSION CASSETTE(10,1)
HETEROLOGOUS GENE ENCODING(10,1)
MANHIEMIA HAEMOLYTICA(10,1)
NSIL SITE REMR(10,1)
PATHOGEN ANTIGEN(10,1)
PESTIVIRUS RESISTANT DERIVATIVE(10,1)
QIAGEN GEL EXTRACTION KIT(10,1)
QIAGEN PCR PURIFICATION COLUMN(10,1)
VIRAL GENOMIC DNA(10,1)
BOVINE RESPIRATORY DISEASE COMPLEX(9,3)
NATURAL HOST(9,3)
SAMPLE COLLECTION(9,3)
TRIGEMINAL GANGLIA(9,3)
BURIAL DEPTH(9,2)
CPE DEVELOPMENT(9,2)
EXPRESS PROTEIN(9,2)
IMMUNE RESPONSE STIMULATION(9,2)
PRE VECTOR BAC CONSTRUCT(9,2)
ARABINOSE INDUCTION(9,1)
BOVINE PARAINFLUENZA(9,1)
BVDV IMMUNITY(9,1)
CLOSELY HOUSED CATTLE(9,1)
DIARY CATTLE(9,1)
EXTRACELLULAR VIRUS(9,1)
GENOMIC DNA EXTRACTION BUFFER(9,1)
HERD OWNER(9,1)
HERDED CATTLE(9,1)
HINDIII DIGESTION(9,1)
KANR CASSETTE(9,1)
MICROBIAL PATHOGEN(9,1)
MULTIFACTORIAL DISEASE(9,1)
MULTIVALENT VACCINE(9,1)
PROTOTYPE VACCINE(9,1)
SECONDARY CHALLENGE NASAL(9,1)
SOUTHERN BLOT(9,1)
SPEI DIGESTION(9,1)
UNIQUE RESTRICTION ENDONUCLEASE(9,1)
UNVACCINATED BOVINE(9,1)
VACCINATION EFFECTIVENESS(9,1)
CELL MONOLAYER(8,2)
FREEZE DRIED GMBOHV(8,2)
LYSIS BUFFER(8,2)
DAILY BASIS(7,4)
PROTEINASE(7,4)
CO2 ATMOSPHERE(7,2)
POST VACCINATION(7,2)
AUDIBLE BREATHING(7,1)
BOHV SEGMENT(7,1)
BVDV ANTIGEN(7,1)
CAP RESISTANT COLONY(7,1)
CONVERGENT GENE(7,1)
DELETION FRAGMENT(7,1)
FEEDLOT CATTLE(7,1)
GENTLE ROCKING(7,1)
GENTLE SHAKING(7,1)
HETEROLOGOUS ANTIGEN EXPRESSION(7,1)
HETEROLOGOUS PROTEIN(7,1)
HYBRIDIZATION OVEN(7,1)
INFECTIOUS CLONE(7,1)
INTRACELLULAR VIRUS(7,1)
INTRANASAL ROUTE(7,1)
MATURE BOHV(7,1)
MURDOCH CHILDRENS RESEARCH INSTITUTE(7,1)
MYCOPLASMA SP(7,1)
PASTEURELLA SP(7,1)
PATHOGEN GENE(7,1)
PCR AMPLIFICATION(7,1)
PCR CYCLING(7,1)
PELLETED VIRUS(7,1)
PROPRIETARY(7,1)
PTKDEL VECTOR(7,1)
RECOMBINANT COLONY(7,1)
RECOMBINATION EXPERIMENT(7,1)
RUMINANT SPECIES(7,1)
SHAKING PLATFORM(7,1)
THYMIDINE KINASE GENE(7,1)
TKRIGHT PCR PRODUCT(7,1)
TRANSGENE PRODUCT EXCISION(7,1)
VARIANT CRIB(7,1)
VIRAL GENE TRANSCRIPTION(7,1)
VIRUS FUNCTION(7,1)
GOAT(6,6)
SHEEP(6,6)
CARCASS(6,3)
DILUENT(6,3)
EXCIPIENT(6,3)
INCUBATION(6,3)
NOSTRIL(6,3)
NUCLEOTIDE(6,3)
OPTIMEM(6,3)
PLASMID(6,3)
TISSUE SAMPLE(6,3)
VALENCY(6,3)
AGAROSE GEL(6,1)
BAC DNA(6,1)
BACTERIAL ALKALINE PHOSPHATASE(6,1)
BOVINE HOST(6,1)
CELL LYSIS(6,1)
COLI STRAIN(6,1)
DAILY SAMPLING(6,1)
DOUBLE RESISTANT DH10B CELL(6,1)
ELECTROCOMPETENT CELL(6,1)
EPICENTER TECHNOLOGY(6,1)
FILTER HYBRIDIZATION(6,1)
GENOMIC VIRAL DNA(6,1)
HUMORAL IMMUNE RESPONSE(6,1)
LB BROTH(6,1)
MARKER PROTEIN(6,1)
MEDICAMENT MANUFACTURE(6,1)
NUMERIC SCORE(6,1)
PCR ASSAY(6,1)
PCR TEMPLATE(6,1)
POST TRANSFECTION(6,1)
PRIMER PAIR CHLORAMF(6,1)
PROTEIN ANTIGEN(6,1)
RECOMBINATION ARM(6,1)
RESTRICTION ENZYME(6,1)
SEROLOGICAL TESTING(6,1)
SOC BROTH(6,1)
SPECIES ANIMAL(6,1)
SPREAD INCIDENCE(6,1)
TAQ POLYMERASE BUFFER(6,1)
TEMPLATE DNA(6,1)
TKLEFT PCR PRODUCT(6,1)
VACCINE PREPARATION(6,1)
VIRUS PARTICLE(6,1)
VIRUS PROPAGATION(6,1)
CENTRIFUGATION(5,2)
FREEZE DRIED PREPARATION(5,2)
MAINTENANCE MEDIUM(5,2)
SENTINEL GROUP(5,2)
TRANSFORMATION(5,2)
TRIPLICATE(5,2)
ANTIBIOTIC ANTIMYOTIC(5,1)
ANTIBODY POSITIVE(5,1)
AUXILIARY SUBSTANCE(5,1)
BOTTLE ROTATION(5,1)
BUFFERING AGENT(5,1)
BVDV SPECIFIC ANTIBODY(5,1)
CAP RESISTANCE GENE(5,1)
CELL CULTURE SUPERNATANT(5,1)
CELL INFECTION(5,1)
CELL PELLET(5,1)
CHLORAMPHENICOL RESISTANCE GENE(5,1)
CHLORAMPHENICOL SELECTIVE PLATE(5,1)
CLINICAL NOTE(5,1)
CROSSOVER REGION(5,1)
DELETION INSERTION VECTOR(5,1)
EXCLUSION ELEMENT(5,1)
MDBK CELL(5,1)
MINIMAL KANAMYCIN RESISTANCE CASSETTE(5,1)
PASTEURELLA MULTOCIDA(5,1)
PCR DETECTION(5,1)
RE CONSTITUTION(5,1)
RECOVERED CELL(5,1)
SELECTIVE AGAR(5,1)
SODIUM PHOSPHATE(5,1)
STANDARD ANTIBODY ASSAY(5,1)
STANDARD VIROLOGICAL(5,1)
TARGET REGION(5,1)
TBE BUFFER(5,1)
(US9999661)
BOHV(100,104)
ANTIGEN(100,62)
VACCINE(100,28)
BOVINE PATHOGEN(100,14)
VACCINE VECTOR(100,8)
BOVINE HERPES VIRUS(100,6)
BACTERIAL ARTIFICIAL CHROMOSOME VECTOR(100,4)
RECOMBINANT LOW VIRULENCE(100,1)
NON PATHOGENIC INFECTION(89,1)
BOVINE ANIMAL(86,13)
CONVERGING BOHV(85,14)
RECOMBINANT BOVINE HERPES VIRUS(80,1)
CONVERGING GENE(79,10)
INFECTION OUTCOME(77,1)
BOHV EXPRESSION(76,14)
INSERTION SITE(73,5)
BACTERIAL ARTIFICIAL CHROMOSOME CONSTRUCT(73,2)
DISEASE SYMPTOM(72,1)
BACTERIAL HOST(70,7)
RECOMBINANT BOHV(70,3)
CONVERGENT GENE(69,2)
DIAGNOSTIC ASSAY(64,1)
POLYADENYLATION(56,5)
PATHOGEN TRANSMISSION(56,1)
BOVINE VIRAL DIARRHEA VIRUS(55,7)
FUNCTIONALLY EQUIVALENT SITE(54,6)
PATEURELLA MULTOCIDA(54,3)
HAEMOPHILUS SOMNUS(51,4)
RBOHV(49,10)
COMMERCIAL APPLICATOR(48,2)
PROTECTIVE IMMUNE RESPONSE(48,1)
IMMUNE RESPONSE(46,16)
GENOME(43,33)
MICROORGANISM(42,5)
VACCINATION(41,12)
INDUCIBLE RECOMBINATION(40,10)
COLONIZATION(40,1)
SALMONELLA SPECIES(39,3)
GENE(37,31)
LOW VIRULENCE(36,23)
MORBIDITY(36,1)
PATHOGEN(36,1)
MORTALITY(34,1)
ENCODING GENETIC MATERIAL(31,24)
CATTLE(29,33)
VECTOR(28,14)
GLYCOPROTEIN(28,8)
DISEASE CONDITION(28,1)
HETEROLOGOUS ANTIGEN(27,4)
VACCINATED CATTLE(26,5)
SYRINGE(26,2)
DISEASE CONTROL(26,1)
INTRANASAL INSTILLATION(25,4)
MYCOPLASMA BOVIS(25,4)
PROTEIN(25,2)
BACTERIAL ARTIFICIAL CHROMOSOME(24,5)
CLINICAL ASSESSMENT(23,6)
HOMOLOGOUS RECOMBINATION(22,4)
INFECTION(22,4)
RESTRICTION ENDONUCLEASE DIGESTION(22,2)
HYBAID SPRINT THERMOCYCLER(22,1)
ANIMAL TRIAL COMMENCEMENT(20,2)
NASAL ADMINISTRATION(20,2)
ROCHE MOLECULAR BIOSYSTEM(20,2)
VIRUS PERSISTING(19,3)
NASAL TAMPON(18,4)
STRAIN(17,12)
VIRAL SUPERNATANT(17,3)
PGETREC FACILITATED RECOMBINATION(17,1)
ENVIRONMENTAL SWAB(16,3)
MANUFACTURER INSTRUCTION(16,3)
RECOMBINANT VACCINE VECTOR(16,3)
GMBOHV EFFICACY(16,2)
VIRAL PELLET(15,3)
BAC VECTOR INSERTION(15,2)
TRANSFECTED MONOLAYER(15,2)
AUSTRALIAN VETERINARY JOURNAL(15,1)
BOHV GENETIC MANIPULATION(15,1)
BOVINE ANIMAL ECONOMIC VIABILITY(15,1)
CHALLENGE NASAL SWAB(15,1)
DUAL VACCINE FACILITATION(15,1)
CULTURED CELL(14,2)
BOHV HINDIII PROFILE(14,1)
DONOR CALF SERA(14,1)
EFFICIENT CONTROL(14,1)
HERD SEROLOGICAL ANALYSIS(14,1)
PCR AMPLIFIED TRANSGENE(14,1)
POLYVALENT VACCINE VECTOR(14,1)
QIAGEN GENOMIC DNA(14,1)
RECE TRANSIENT EXPRESSION(14,1)
CLINICAL SIGN(13,3)
BAC TK FRAGMENT(13,2)
TRANSGENE INSERTION(13,2)
VACCINE FORMULATION(13,2)
ACCESSION(12,7)
GENOMIC TIP(12,3)
PURIFIED BOHV(12,2)
BOHV RECOMBINATION(12,1)
CATTLE VACCINATION(12,1)
DH10B CELL HARBORING(12,1)
DIGESTED BAC VECTOR(12,1)
ELECTROPORATION ALIQUOT(12,1)
ELECTROPORATION CUVETTE(12,1)
ELECTROPORATION DH10B CELL(12,1)
GE GENE REPLACEMENT(12,1)
GFP EXPRESSION CASSETTE(12,1)
HETEROLOGOUS GENE ENCODING(12,1)
MANHIEMIA HAEMOLYTICA(12,1)
NSIL SITE REMR(12,1)
PATHOGEN ANTIGEN(12,1)
PESTIVIRUS RESISTANT DERIVATIVE(12,1)
QIAGEN GEL EXTRACTION KIT(12,1)
QIAGEN PCR PURIFICATION COLUMN(12,1)
VIRAL GENOMIC DNA(12,1)
BURIAL DEPTH(11,2)
CPE DEVELOPMENT(11,2)
EXPRESS PROTEIN(11,2)
IMMUNE RESPONSE STIMULATION(11,2)
PRE VECTOR BAC CONSTRUCT(11,2)
ARABINOSE INDUCTION(11,1)
BOVINE PARAINFLUENZA(11,1)
BVDV IMMUNITY(11,1)
CLOSELY HOUSED CATTLE(11,1)
DIARY CATTLE(11,1)
EXTRACELLULAR VIRUS(11,1)
GENOMIC DNA EXTRACTION BUFFER(11,1)
HERD OWNER(11,1)
HERDED CATTLE(11,1)
HINDIII DIGESTION(11,1)
KANR CASSETTE(11,1)
MICROBIAL PATHOGEN(11,1)
MULTIFACTORIAL DISEASE(11,1)
MULTIVALENT VACCINE(11,1)
PROTOTYPE VACCINE(11,1)
SECONDARY CHALLENGE NASAL(11,1)
SOUTHERN BLOT(11,1)
SPEI DIGESTION(11,1)
UNIQUE RESTRICTION ENDONUCLEASE(11,1)
UNVACCINATED BOVINE(11,1)
VACCINATION EFFECTIVENESS(11,1)
BOVINE RESPIRATORY DISEASE COMPLEX(10,3)
NATURAL HOST(10,3)
SAMPLE COLLECTION(10,3)
TRIGEMINAL GANGLIA(10,3)
CELL MONOLAYER(10,2)
FREEZE DRIED GMBOHV(10,2)
LYSIS BUFFER(10,2)
DAILY BASIS(9,4)
AUDIBLE BREATHING(9,1)
BOHV SEGMENT(9,1)
BVDV ANTIGEN(9,1)
CAP RESISTANT COLONY(9,1)
DELETION FRAGMENT(9,1)
FEEDLOT CATTLE(9,1)
GENTLE ROCKING(9,1)
GENTLE SHAKING(9,1)
HETEROLOGOUS ANTIGEN EXPRESSION(9,1)
HETEROLOGOUS PROTEIN(9,1)
HYBRIDIZATION OVEN(9,1)
INFECTIOUS CLONE(9,1)
INTRACELLULAR VIRUS(9,1)
INTRANASAL ROUTE(9,1)
MATURE BOHV(9,1)
MURDOCH CHILDRENS RESEARCH INSTITUTE(9,1)
MYCOPLASMA SP(9,1)
PASTEURELLA SP(9,1)
PATHOGEN GENE(9,1)
PCR AMPLIFICATION(9,1)
PCR CYCLING(9,1)
PELLETED VIRUS(9,1)
PROPRIETARY(9,1)
PTKDEL VECTOR(9,1)
RECOMBINANT COLONY(9,1)
RECOMBINATION EXPERIMENT(9,1)
RUMINANT SPECIES(9,1)
SHAKING PLATFORM(9,1)
THYMIDINE KINASE GENE(9,1)
TKRIGHT PCR PRODUCT(9,1)
TRANSGENE PRODUCT EXCISION(9,1)
VARIANT CRIB(9,1)
VIRAL GENE TRANSCRIPTION(9,1)
VIRUS FUNCTION(9,1)
CARCASS(8,3)
EXCIPIENT(8,3)
INCUBATION(8,3)
NOSTRIL(8,3)
NUCLEOTIDE(8,3)
OPTIMEM(8,3)
PLASMID(8,3)
TISSUE SAMPLE(8,3)
VALENCY(8,3)
CO2 ATMOSPHERE(8,2)
POST VACCINATION(8,2)
GOAT(7,6)
SHEEP(7,6)
DILUENT(7,3)
AGAROSE GEL(7,1)
BAC DNA(7,1)
BACTERIAL ALKALINE PHOSPHATASE(7,1)
BOVINE HOST(7,1)
CELL LYSIS(7,1)
COLI STRAIN(7,1)
DAILY SAMPLING(7,1)
DOUBLE RESISTANT DH10B CELL(7,1)
ELECTROCOMPETENT CELL(7,1)
EPICENTER TECHNOLOGY(7,1)
FILTER HYBRIDIZATION(7,1)
GENOMIC VIRAL DNA(7,1)
HUMORAL IMMUNE RESPONSE(7,1)
LB BROTH(7,1)
MARKER PROTEIN(7,1)
MEDICAMENT MANUFACTURE(7,1)
NUMERIC SCORE(7,1)
PCR ASSAY(7,1)
PCR TEMPLATE(7,1)
POST TRANSFECTION(7,1)
PRIMER PAIR CHLORAMF(7,1)
PROTEIN ANTIGEN(7,1)
RECOMBINATION ARM(7,1)
RESTRICTION ENZYME(7,1)
SEROLOGICAL TESTING(7,1)
SOC BROTH(7,1)
SPECIES ANIMAL(7,1)
SPREAD INCIDENCE(7,1)
TAQ POLYMERASE BUFFER(7,1)
TEMPLATE DNA(7,1)
TKLEFT PCR PRODUCT(7,1)
VACCINE PREPARATION(7,1)
VIRUS PARTICLE(7,1)
VIRUS PROPAGATION(7,1)
CENTRIFUGATION(6,2)
FREEZE DRIED PREPARATION(6,2)
MAINTENANCE MEDIUM(6,2)
SENTINEL GROUP(6,2)
TRANSFORMATION(6,2)
TRIPLICATE(6,2)
ANTIBIOTIC ANTIMYOTIC(6,1)
ANTIBODY POSITIVE(6,1)
AUXILIARY SUBSTANCE(6,1)
BOTTLE ROTATION(6,1)
BVDV SPECIFIC ANTIBODY(6,1)
CAP RESISTANCE GENE(6,1)
CELL CULTURE SUPERNATANT(6,1)
CELL INFECTION(6,1)
CELL PELLET(6,1)
CHLORAMPHENICOL RESISTANCE GENE(6,1)
CHLORAMPHENICOL SELECTIVE PLATE(6,1)
CLINICAL NOTE(6,1)
CROSSOVER REGION(6,1)
DELETION INSERTION VECTOR(6,1)
EXCLUSION ELEMENT(6,1)
MANUFACTURE INSTRUCTION(6,1)
MDBK CELL(6,1)
MINIMAL KANAMYCIN RESISTANCE CASSETTE(6,1)
PASTEURELLA MULTOCIDA(6,1)
PCR DETECTION(6,1)
PH BUFFERING(6,1)
RE CONSTITUTION(6,1)
RECOVERED CELL(6,1)
SELECTIVE AGAR(6,1)
SODIUM PHOSPHATE(6,1)
STANDARD ANTIBODY ASSAY(6,1)
STANDARD VIROLOGICAL(6,1)
TARGET REGION(6,1)
TBE BUFFER(6,1)
TRANSFECTION LIQUID(6,1)
TRANSFECTION MIXTURE(6,1)
BRAIN(5,3)
(WO201303904)
BOHV(100,149)
ANTIGEN(100,112)
GENOME(100,54)
GENE(100,51)
ENCODING GENETIC MATERIAL(100,41)
LOW VIRULENCE(100,40)
VACCINE(100,36)
CONVERGING GENE(100,26)
BOVINE PATHOGEN(100,24)
CONVERGING BOHV(100,24)
BOVINE HERPES VIRUS(100,10)
CATTLE(100,10)
BOVINE(100,9)
BOVINE RESPIRATORY DISEASE COMPLEX(100,7)
BOHV EXPRESSION(81,24)
RESTRICTION ENDONUCLEASE DIGESTION(80,6)
CATTLE VACCINATION(71,3)
PATEURELLA MULTOCIDA(69,6)
FAMILY HERPESVIRIDAE VIRUS(68,1)
ATTENUATED VIRUS(66,2)
LIFELONG LATENT INFECTION(65,1)
HAEMOPHILUS SOMNUS(61,8)
BVDV ANTIGEN(59,5)
SALMONELLA SPECIES(49,6)
POLYVALENT VACCINE VECTOR(48,2)
VIRUS SHEDDING(46,1)
MICROORGANISM(43,10)
NEWBORN CALF(43,1)
INACTIVATED VIRUS(42,1)
CATTLE DISEASE(40,1)
GENERALIZED DISEASE(39,1)
BACTERIAL HOST(37,11)
RECOMBINANT BOHV(37,4)
VACCINE VECTOR(36,10)
INDUCIBLE RECOMBINATION(35,18)
FUNCTIONALLY EQUIVALENT SITE(34,9)
MEDICAMENT MANUFACTURE(32,2)
MYCOPLASMA BOVIS(30,7)
POLYADENYLATION(30,7)
ENTERITIS(30,2)
HERPES VIRUS(26,1)
NASAL ADMINISTRATION(25,5)
VECTOR(24,35)
BOVINE ANIMAL(24,14)
BALANOPOSTHITIS(24,1)
CONJUNCTIVITIS(24,1)
MULTIPLICATION(24,1)
RHINOTRACHEITIS(24,1)
BOVINE VIRAL DIARRHEA VIRUS(23,8)
VAGINITIS(21,1)
DISEASE CONDITION(20,1)
MEDICAMENT(20,1)
VIRAL ANTIGEN(20,1)
PRODUCTIVITY(19,1)
RBOHV(18,3)
CONSTRUCT(17,10)
VACCINATION(16,6)
ABORTION(16,2)
DEATH(16,1)
IMMUNE HOST(16,1)
BACTERIAL ARTIFICIAL CHROMOSOME(15,6)
GENETIC MATERIAL ENCODING(13,7)
MORTALITY(13,4)
DISEASE(13,3)
HOMOLOGOUS RECOMBINATION(12,4)
RBOHV L BAC VECTOR(12,3)
HYBAID SPRINT THERMOCYCLER(12,1)
GLYCOPROTEIN E(11,7)
INFECTION(11,6)
THYMIDINE KINASE GENE(11,2)
DISEASE CONTROL(11,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(11,1)
THYMIDINE KINASE DELETION MUTANT(11,1)
REFERENCE SEQUENCE GENBANK ACCESSION(10,10)
BVDV(10,5)
FEEDLOT CATTLE(10,3)
RECOMBINANT VACCINE VECTOR(9,3)
BVDV CYTOPATHIC VARIANT(9,1)
EFFICIENT CONTROL(9,1)
INFECTIOUS BOVINE RHIBOTRACHEITIS(9,1)
MUCOSAL EROSION CLINICAL SIGN(9,1)
RECOMBINANT BOVINE HERPES VIRUS(9,1)
BOVINE PARAINFLUENZA(8,2)
CULTURED CELL(8,2)
TRANSFECTED MONOLAYER(8,2)
VIRAL SUPERNATANT(8,2)
AUSTRALIAN VETERINARY JOURNAL(8,1)
BOHV GENETIC MANIPULATION(8,1)
BOHV HINDLLL PROFILE(8,1)
BOVINE ANIMAL ECONOMIC VIABILITY(8,1)
BVDV MAJOR NEUTRALIZING EPITOPE(8,1)
CHIORAMF PRIMER(8,1)
CHLORAMR PRIMER(8,1)
DONOR CALF SERA(8,1)
DUAL VACCINE FACILITATION(8,1)
GENETICALLY DISTINCT VIRUS APPEARANCE(8,1)
HERD SEROLOGICAL ANALYSIS(8,1)
KANR FWD PRIMER(8,1)
KANR REV PRIMER(8,1)
NEUTRALIZING ANTIBODY INDUCTION(8,1)
PCR AMPLIFIED TRANSGENE(8,1)
QIAGEN GENOMIC DNA(8,1)
REALTIME PCR AMPLIFICATION(8,1)
RECE TRANSIENT EXPRESSION(8,1)
RBOHV L(7,6)
BAC TK FRAGMENT(7,2)
MANUFACTURER INSTRUCTION(7,2)
PERSISTENT INFECTION(7,2)
TRANSGENE IN(...)";Pharmaceuticals;Open
2011-05-24;"CN102337250         A  2012-02-01 [CN102337250]
STG: (A) Published application
AP : 2011CN-0137299 2011-05-24
CN102337250         B  2015-04-01 [CN102337250B]
STG: (B) Granted patent for invention
AP : 2011CN-0137299 2011-05-24";7491690;"CN102337250         A  2012-02-01 [CN102337250]
CN102337250         B  2015-04-01 [CN102337250B]";2011CN-0137299;;GREEN CORAL TECHNOLOGY;GREEN CORAL TECHNOLOGY;;;1;JIN YE;;;"(CN102337250B)
Infectious bovine rhinotracheitis virus strain and preparation method and application thereof";"(CN102337250B)
The invention discloses an infectious bovine rhinotracheitis virus strain and a preparation method and application thereof. A wild strain of infectious bovine rhinotracheitis virus is found. The preparation method comprises the following steps of: firstly, identifying a sample by a PCR (Polymerase Chain Reaction) and a fluorescence PCR; then adding bovine serum which is detected to be free of IBRV (Infectious Bovine Rhinotracheitis Virus) to MDBK (Madindarby Bovine Kidney) cells by means of a culture medium, cultivating for a certain period of time so as to grow single-layer cells; after inoculating the single-layer cells with the processed sample, observing the cytopathic effect; after taking a pathological cell sample and identifying the pathological cell to be positive by the PCR, measuring TCID50 (Tissue Culture Infective Dose) as 106.2, and carrying out the virus neutralization test, wherein the TCID is 27; then inoculating the sample into the single layer cells; and when 70 percent to 80 percent of cells undergo the cytopathic effect and storing the cells into a refrigerator at a temperature of -40 DEG C. The infectious bovine rhinotracheitis virus strain and the preparation method disclosed by the invention can be applied to preparation of an engineered vaccine for preventing the infectious bovine rhinotracheitis.";"(CN102337250)
1. Infectious bovine rhinotracheitis virus strains and preparation methods and uses, characterized in comprising the steps of: A, onset of bovine nasal secretions with sterile cotton swab was drawn down the laboratory studies, resulting cavity cotton swab sample; B, to gB -1 and the gB -2 as primers, PCR amplification method used to detect, amplify a sequence-specific fragment diseased, to gB-F, gB-R to primers and probes, PCR amplification by PCR and fluorescence detection method, infectious bovine rhinotracheitis virus identification, detection results are positive; C, through the medium of the IBRV MDBK cells without adding a detection in the bovine serum, incubated for a predetermined time after, MDBK cells grow as monolayers, with PCR and the PCR method for detection of the fluoresced MDBK cell cavity cotton swab samples were inoculated with a single layer, observation of a cytopathic, to be 70%-80% of cells were viral lesions, the cell revenue-40 °C refrigerator preservation.
2. Infectious bovine rhinotracheitis virus strains and preparation methods and uses according to claim 1, characterized in: the isolated infectious bovine rhinotracheitis virus strains, has been registered into the register number is CGMCC No. 4655 Culture Collection, entitled GD0109.
3. Infectious bovine rhinotracheitis virus strains and preparation methods and uses according to claim 1, characterized in: using a Reed-Muench method, the separated MDBK cell suspension was added strain, were monitored daily, TCID50 titer calculated strain of separate, isolated strains after freeze-thaw 3 dispensed, viral TCID50 was 106.2.
4. Infectious bovine rhinotracheitis virus strains and preparation methods and uses according to claim 1, characterized in: after mixing with the separated reference positive serum IBRV strains, observation of a cytopathic, IBRV reference positive serum neutralizing antibody titer of the isolated strain of 27.
5. Infectious bovine rhinotracheitis virus strains and preparation methods and uses according to claim 1, characterized in: in the prevention of bovine infectious bovine rhinotracheitis disease engineering application of a vaccine.";"(CN102337250)
The present invention relates to an infectious bovine rhinotracheitis virus, in particular to a method of preventing infectious bovine bovine rhinotracheitis disease cells engineered vaccines.
The present invention discloses infectious bovine rhinotracheitis virus strains and preparation methods and uses, infectious bovine rhinotracheitis virus field strains of the strain found, identified by PCR and the PCR after the first sample fluorescence, MDBK cells were detected without adding a culture medium is then IBRV bovine serum, incubated for a predetermined time, to grow a monolayer of cells, with the treated sample after inoculation, the observation of a cytopathic, taken after the cell-like lesion identified as positive PCR, 106.2 TCID50 was determined to be, virus neutralization assay, virus titer was 27, replated to a monolayer of cells, to be 70%-80% of the lesions having cells, the cell revenue-40 Ć save fridge, prevention of infectious bovine rhinotracheitis disease in cattle the engineering application of a vaccine.";"(CN102337250)
The present invention infectious bovine rhinotracheitis virus strains and preparation method and application has the following advantages and potential applications:
Infectious bovine rhinotracheitis disease is serious damage to the cattle industry worldwide one of the major viral infectious diseases.
There is a problem of latent infection infectious rhinotracheitis virus, a bovine or recovered after infection reveals over a long period, even life-long reveals, but are not shedding.";"A61K-039/265
A61P-031/22
C12N-007/00
C12Q-001/68
C12Q-001/70
C12R-001/93";"(CN102337250)
1. Infectious bovine rhinotracheitis virus strains and preparation methods and uses, characterized in comprising the steps of: A, onset of bovine nasal secretions with sterile cotton swab was drawn down the laboratory studies, resulting cavity cotton swab sample; B, to gB -1 and the gB -2 as primers, PCR amplification method used to detect, amplify a sequence-specific fragment diseased, to gB-F, gB-R to primers and probes, PCR amplification by PCR and fluorescence detection method, infectious bovine rhinotracheitis virus identification, detection results are positive; C, through the medium of the IBRV MDBK cells without adding a detection in the bovine serum, incubated for a predetermined time after, MDBK cells grow as monolayers, with PCR and the PCR method for detection of the fluoresced MDBK cell cavity cotton swab samples were inoculated with a single layer, observation of a cytopathic, to be 70%-80% of cells were viral lesions, the cell revenue-40 Ć refrigerator preservation.";"(CN102337250)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(100,12)
INFECTIOUS BOVINE RHINOTRACHEITIS DISEASE(100,4)
INFECTIOUS RHINOTRACHEITIS VIRUS(56,1)
REFRIGERATOR PRESERVATION(45,1)
VIRUS NEUTRALIZATION ASSAY(43,2)
DISEASE CELL ENGINEERED VACCINE(42,1)
VIRAL INFECTIOUS DISEASE(42,1)
BOVINE SERUM(41,3)
BOVINE NASAL SECRETION ONSET(38,3)
CELL MONOLAYER(38,3)
CELL REVENUE(36,3)
SAMPLE FLUORESCENCE(32,1)
CAVITY COTTON SWAB SAMPLE(31,2)
CELL CAVITY COTTON(29,1)
VIRAL LESION(28,2)
NEUTRALIZING ANTIBODY TITER(27,4)
CATTLE INDUSTRY(27,1)
PCR AMPLIFICATION(26,5)
LABORATORY STUDY(25,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS IDENTIFICATION(23,3)
OBSERVATION(22,5)
LESION(22,3)
STERILE COTTON(22,3)
INOCULATION(21,1)
TREATED SAMPLE(19,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(18,7)
BOVINE PREVENTION(18,2)
PCR POSITIVE(18,2)
FRIDGE(18,1)
MONOLAYER(18,1)
ISOLATED STRAIN(17,5)
CULTURE MEDIUM(17,2)
TITER CALCULATED STRAIN(17,2)
CULTURE COLLECTION(17,1)
PREVENTION(17,1)
VIRUS TITER(17,1)
PRIMER(16,5)
STRAIN(16,5)
FREEZE THAW(16,3)
CATTLE(16,1)
VACCINE APPLICATION ENGINEER(15,3)
INFECTION(14,1)
BOVINE(13,1)
PROBE(11,2)
OUTFLOWING SLURRYABILITY CLINICAL MANIFESTATION(11,1)
FLUORESCENCE DETECTION(10,1)
CELL SUSPENSION(9,4)
RT PCR KIT(8,3)
BOVINE NASAL COTTON SWAB(8,1)
THREEDIMENSIONAL SYMMETRICAL DIHEDRON(8,1)
REED MUENCH(7,3)
NESTED RT PCR(7,2)
SEQUENCE SPECIFIC FRAGMENT(6,3)
DNA EXTRACTION KIT(6,2)
BOVINE RHINOTRACHEITIS DISEASE CELL(6,1)
COTTON SWAB RINSE(6,1)
FLUORESCENCE PCR PRIMER(6,1)
INDIRECT HEMAGGLUTINATION ASSAY(6,1)
POTENTIAL APPLICATION(6,1)
XMASTER MIX(5,3)
LATENT INFECTION(5,2)
RT PCR DETECTION(5,2)
ANIMAL PEOPLE REPUBLIC(5,1)
INFECTIOUS RHINOTRACHEITIS(5,1)
INNOVATIVE VACCINE DEVELOPMENT(5,1)
TAQMAN PCR KIT(5,1)
CLOSING POISON(4,2)
EXTRACTED DNA(4,2)
GB F(4,2)
VIRUS CULTURE(4,2)
AMPLIFICATION FLUORESCENCE DETECTION(4,1)
BOVINE BLUETONGUE VIRUS(4,1)
BOVINE HERPES VIRUS(4,1)
BOVINE SALIVATION(4,1)
CAPSULAR SAC(4,1)
CLINICAL SYMPTOM(4,1)
CONFLUENT MONOLAYER(4,1)
COTTON SWAB SAMPLE(4,1)
DISEASE MORBIDITY(4,1)
DISEASE PRIMARY ETIOLOGICAL AGENT(4,1)
ENGINEERED VACCINE(4,1)
FLUORESCENT PCR DETECTION(4,1)
FLUORESCENT TAQMAN(4,1)
HERPESVIRIDAE FAMILY(4,1)
MAIN AIRWAY INFLAMMATION(4,1)
NIUS PCR(4,1)
PRELIMINARY DIAGNOSIS(4,1)
PURULENT SECRETION(4,1)
SERUM DILUTION(4,1)
TITER CALCULATION(4,1)
TRIGEMINAL GANGLION CELL(4,1)
VIRAL GENOME(4,1)
VIRUS SHEDDING PHENOMENON(4,1)
NUCLEIC ACID EXTRACTION KIT(3,2)
ACCESS PORT NIUS(3,1)
ACUTE UPPER RESPIRATORY INFLAMMATION(3,1)
AMPLIFICATION CURVE(3,1)
AMPLIFIED FRAGMENT(3,1)
CLINICAL PILOT(3,1)
CO2 CULTURE(3,1)
DISEASE BOVINE(3,1)
MIN CENTRIFUGATION(3,1)
NATURAL INFECTION(3,1)
NUCLEUS GIANT CELL(3,1)
PATIENT OCCURRENCE(3,1)
PERIPHERAL GANGLION NERVE CELL(3,1)
VIRUS ISOLATION(3,1)
BOVINE LEUKEMIA VIRUS(2,4)
HYPERTHERMIA(2,2)
STREPTOMYCIN(2,2)
SUPERNATANT(2,2)
AGAROSE GEL(2,1)
APPETITE LOSS(2,1)
BLIND TRANSFER(2,1)
BROAD TISSUE TROPISM(2,1)
CONJUNCTIVA(2,1)
CONTINUOUS FOLD SERIAL(2,1)
CURVE GENERATION(2,1)
DEAD CELL(2,1)
DETECTION SENSITIVITY(2,1)
EPIDEMIC(2,1)
FETUS(2,1)
MILK PRODUCTION DECREASE(2,1)
OUTER IMPACTING(2,1)
REFRIGERATOR STORAGE(2,1)
SAMPLE ONSET(2,1)
SEPARATED REFERENCE POSITIVE SERUM(2,1)
VIRUS FEATURE(2,1)
VIRUS SPECIFIC NEUTRALIZATION ASSAY(2,1)
(CN102337250B)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,13)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(100,6)
ACCESSION(100,1)
INFECTIOUS RHINOTRACHEITIS VIRUS(91,1)
VIRUS NEUTRALIZATION EXPERIMENT(90,1)
BOVINE RHINOTRACHEITIS DISEASE(79,1)
LATENT VIRUS INFECTION(72,1)
VIRAL TITER(65,1)
GENETIC ENGINEERING VACCINE(61,1)
PCR LESION(58,1)
CELL MONOLAYER(56,4)
DETOX PHENOMENON(50,1)
CELL INCOMING(43,1)
BOVINE SERUM(42,2)
ANTIBODY NEUTRALIZATION(38,1)
TITER ISOLATED STRAIN(37,1)
DETECTION SENSITIVITY(34,1)
INOCULATION(34,1)
VACCINE DISEASE CELL ENGINEERING(33,1)
PREVENTION(31,1)
TREATED SAMPLE(31,1)
CELL ENGINEERING VACCINE(28,2)
REFRIGERATOR(28,2)
INFECTION SOURCE(25,1)
OBSERVATION(24,5)
INFECTIOUS BOVINE RHINOTRACHEITIS DISEASE(24,3)
AFTER LONG TERM INFECTED CATTLE(24,1)
DETOX(22,1)
LESION(21,2)
NEUTRALIZING ANTIBODY TITER(19,3)
BOVINE APPLICATION(17,1)
CELL SUSPENSION(16,4)
DISADVANTAGE DEGREE(16,1)
FLUORESCENT RT PCR(12,2)
JACKETED RT PCR(12,2)
NASAL OUTFLOW REPULPABILITY(12,1)
REED MUENCH(11,3)
INDIRECT HEMAGGLUTINATION ASSAY(11,1)
SUBCLINICAL INFECTION SYMPTOM(11,1)
INCOME POISON(10,2)
CO2 CULTURE(9,3)
XMASTER MIX(9,3)
RT PCR DETECTION(9,2)
BOVINE NASAL SECRETION ONSET(9,1)
BOVINE NASAL SWAB(9,1)
DISEASE EPIDEMIC OCCURRENCE(9,1)
FLUORESCENCE PCR PRIMER(9,1)
ISOLATED VIRUS NEUTRALIZATION ASSAY(9,1)
POTENTIAL APPLICATION(9,1)
FLUORESCENT PCR(8,2)
CLINICAL PRELIMINARY DIAGNOSIS(8,1)
CONFLUENT CELL MONOLAYER(8,1)
FREEZE THAW KIT(8,1)
INFECTIOUS RHINOTRACHEITIS(8,1)
QUARANTINE BUREAU(8,1)
VIRAL INFECTIOUS DISEASE(8,1)
STERILE COTTON(7,2)
AIRWAY INFLAMMATION(7,1)
BOVINE SALIVATION(7,1)
BVDV TAQMAN(7,1)
DISEASE BOVINE EYE(7,1)
DNA EXTRACTION KIT(7,1)
EXTRACTION LABORATORY ONSET(7,1)
HERPESVIRIDAE FAMILY(7,1)
MATURE VIRUS PARTICLE(7,1)
NUCLEOCAPSID SYMMETRY(7,1)
REFERENCE POSITIVE SERUM TITER(7,1)
RT PCR KIT(7,1)
SAFEGUARDED DRUG(7,1)
SALICYLISM ATTACK(7,1)
VIRUS BROAD TISSUE TROPISM(7,1)
VIRUS LESION CELL(7,1)
NUCLEIC ACID EXTRACTION KIT(6,2)
BOVINE BLUETONGUE VIRUS(6,1)
BOVINE HERPES VIRUS(6,1)
BOVINE PREVENTION(6,1)
DISEASE PRIMARY ETIOLOGICAL AGENT(6,1)
EYE CONJUNCTIVA(6,1)
FREEZE ISOLATED STRAIN(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS POLYMERASE CHAIN REACTION(6,1)
LABORATORY DIAGNOSTICS(6,1)
MISCELLANEOUS BELT(6,1)
PCR AMPLIFICATION(6,1)
PCR AMPLIFIED DETECTION(6,1)
PEOPLE REPUBLIC(6,1)
PERIPHERAL GANGLIA(6,1)
POLYMERASE CHAIN REACTION FLUORESCENCE(6,1)
SERUM DILUTION(6,1)
SHEDDING DEATH(6,1)
THAWING TIME(6,1)
VIRAL GENOME(6,1)
VIRUS NEUTRALIZING(6,1)
ACUTE UPPER RESPIRATORY INFLAMMATION(5,1)
BVDV KIT(5,1)
CULTURE SEPARATION(5,1)
DILUTION PLUS(5,1)
DISEASE ONSET(5,1)
FLUORESCENCE DETECTION(5,1)
GENERATION PCR(5,1)
LATENT INFECTION(5,1)
MIXING CAVITY SWAB(5,1)
NATURAL INFECTION(5,1)
TITER STRAIN(5,1)
TRIGEMINAL GANGLIA CELL(5,1)
VIRUS DRUG(5,1)
VIRUS ISOLATION(5,1)
RINSE(4,2)
STREPTOMYCIN(4,2)
SUPERNATANT(4,2)
APPETITE LOSS(4,1)
BOVINE MAJOR FEATURE(4,1)
CAVITY COTTON(4,1)
CONTINUOUS POSITIVE SERA(4,1)
ECONOMIC BENEFIT(4,1)
IDENTIFIED PCR(4,1)
ISOLATED CULTURE(4,1)
NUCLEAR GIANT CELL(4,1)
PCR SAMPLE(4,1)
SAMPLE ONSET(4,1)
SEPARATION GENERATION(4,1)
VARIETY CLINICAL MANIFESTATION(4,1)
BOVINE LEUKEMIA VIRUS(3,4)
SAMPLE NUCLEIC ACID(3,3)";Pharmaceuticals;Open
2011-03-02;"CN102653731         A  2012-09-05 [CN102653731]
STG: (A) Published application
AP : 2011CN-0050501 2011-03-02";62015676;CN102653731         A  2012-09-05 [CN102653731];2011CN-0050501;;HUAZHONG AGRICULTURAL UNIVERSITY;HUAZHONG AGRICULTURAL UNIVERSITY;;;1;"GUO AIZHEN
ZHANG MINMIN
DENG MINGLIANG
Fu Shulin
LIU ZHENGFEI
XIE QIAN
CHEN HUANCHUN";;;"(CN102653731)
Recombined infectious bovine rhinotracheitis virus with deletion of gG, TK and gE genes";"(CN102653731)
The invention belongs to the technical fields of animal virology and animal genetic engineering, and particularly relates to a recombined infectious bovine rhinotracheitis virus with deletion of gG, TK and gE genes, genetic engineering vaccine and an application of the recombined infectious bovine rhinotracheitis virus. The strain of the recombined infectious bovine rhinotracheitis virus IBRV delta gG/TK/gE/EGFP + prepared by the invention is preserved in China Center For Type Culture Collection (CCTCC), with the preservation number of CCTCC NO: V201023, and the gG, TK and gE genes are deleted from the strain. A parent strain, namely the recombined infectious bovine rhinotracheitis virus IBRV delta gG/TK is preserved in the CCTCC, with the preservation number of CCTCC NO: V200915, and the gG and TK genes are deleted from the strain. The invention also discloses the preparation and application of the recombined infectious bovine rhinotracheitis virus IBRV delta gG/TK/gE/EGFP + in the genetic engineering vaccine of infectious bovine rhinotracheitis.";"(CN102653731)
1. Recombinant infectious bovine rhinotracheitis virus strains IBRV Δ gG/TK/gE/EGFP+, characterized in the strain deposited at the China Type Culture Collection, accession number of CCTCC NO: V201023 thereof, this strain has a deletion of the gG, TK, gE three genes.
2. Claim 1 strains containing IBRV Δ gG/TK/gE/EGFP+ of the infectious bovine rhinotracheitis genetically engineered vaccine.
3. Claim 1 strains for the preparation of recombinant virus genetically engineered infectious bovine rhinotracheitis virus application.
4. Claim 1 strains genetically engineered infectious bovine rhinotracheitis virus in the manufacture of a vaccine.";"(CN102653731)
The present invention further discloses a recombinant infectious bovine rhinotracheitis virus IBRV  gG/TK/gE/EGFP + to infectious bovine rhinotracheitis vaccine preparation and use of genetic engineering.
The present invention aims at obtaining an immunogenic better and better safeness genetically engineered infectious bovine rhinotracheitis virus of the weak strains.";"(CN102653731)
The main advantage of the present invention are:
TK gene deletion can occur after a decrease in virulence, and the ability to replicate in the non-dividing cells is also low, so that the latent virus is not easily activated, so that in the development of gene deletion vaccines, TK gene is a commonly available target gene (Kit S,Oavi H,Gaines JD,Billingsley P,McConnell S.Thymidine kinase-negative bovine herpes virus type 1 mutant is stable and highly attenuated in calves.Arch Virol,1985,86: 63-83).
GB: gB can cause cell fusion, in mammalian cell expression of cell fusion and formation of resorcinol showed gives rise, on viral replication necessarily, domestically it is achieved that the prokaryotic expression and the expression for the student of the product was analyzed antigenicity, immunogenicity of the expression in baculovirus than gC, gD weak; cell surface glycoprotein interactions, mediates virus adsorption starting, a plurality of transactivator may modulate the binding of the virus, but are not essential for virus infection; glycoprotein gB is necessary to perforation, and has been shown by invasive nerve and nerve propagation requires gB.
Currently only a small number of European countries have eradicated the present disease, other countries are implementing schemes could extinguish a fire, or the use of a marker vaccine having functions of the groups immunized with natural infection and, in order to be better monitored and safeguarded.";"A61K-039/265
A61P-031/20
C12N-007/00
C12N-007/01
C12R-001/93";"(CN102653731)
1. Recombinant infectious bovine rhinotracheitis virus strains IBRV  gG/TK/gE/EGFP +, characterized in the strain deposited at the China Type Culture Collection, accession number of CCTCC NO: V201023 thereof, this strain has a deletion of the gG, TK, gE three genes.";"(CN102653731)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,21)
STRAIN(100,10)
GE GENE(100,6)
CULTURE COLLECTION(100,5)
DELETION(100,5)
ACCESSION(100,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(100,2)
BOVINE RHINOTRACHEITIS VACCINE PREPARATION(100,1)
G DELETION(63,1)
EXPRESSION IMMUNOGENICITY(52,1)
GENE DELETION VACCINE DEVELOPMENT(52,1)
GENETICALLY ENGINEERED VACCINE(51,3)
PROKARYOTIC EXPRESSION(48,1)
INVASIVE NERVE(47,1)
EUROPEAN COUNTRY(46,1)
LATENT VIRUS(45,1)
MAMMALIAN CELL EXPRESSION(44,1)
NERVE PROPAGATION(44,1)
TARGET GENE(43,1)
RECOMBINANT VIRUS PREPARATION(37,1)
WEAK STRAIN(37,1)
VIRAL REPLICATION(34,3)
NATURAL INFECTION(34,1)
VIRUS ADSORPTION(33,3)
RESORCINOL FORMATION(32,1)
IMMUNOGENIC BETTER(31,1)
PRODUCT STUDENT(31,1)
BOVINE HERPES VIRUS(30,6)
G GENE(29,1)
SAFENESS(28,1)
TRANSACTIVATOR(28,1)
GE THREE GENE(26,1)
VACCINE MANUFACTURE(26,1)
ANTIGENICITY(25,1)
BACULOVIRUS(24,1)
GENE DELETION(23,3)
MARKER VACCINE(23,1)
PERFORATION(23,1)
GIVE RISE(21,1)
VIRUS INFECTION(21,1)
CELL FUSION(20,2)
MUTANT(19,1)
GLYCOPROTEIN(18,8)
DISEASE(18,2)
HUBEI PROVINCE WUHAN(18,2)
VIRULENCE(18,2)
FIRE(18,1)
GENE(15,6)
CALF(15,2)
ADISTINCT EQUID ALPHAHERPESVIRUS(15,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVENTION(14,1)
KIT(14,1)
RECOMBINANT INFECTIOUS BOVINE RHINOTRACHEITIS(14,1)
VIRUS(13,6)
DEFICIENT RECOMBINANT VIRUS(13,2)
DIVIDING CELL(13,1)
THREEDIMENSIONAL ICOSAHEDRAL SYMMETRY(13,1)
WUHAN UNIVERSITY(12,3)
G IMMUNOSUPPRESSIVE PROTEIN GENE(12,1)
PLASMID GENOME COTRANSFECTION(12,1)
FEVER PHENOMENON OCCURRENCE(11,2)
RIVER FARM VETERINARIAN(11,1)
SECRETED PROTEIN VIRAL REPLICATION(11,1)
CAPSULAR SAC(10,2)
HERPES VIRUS SEROLOGICAL DIAGNOSIS(10,1)
HERPES VIRUS VIRULENCE GENE(10,1)
PERSISTENT VIRUS INFECTION(10,1)
REPORTER GENE DOWNSTREAM HOMOLOGY(10,1)
GE GENE DELETION(9,2)
BOVINE RHINOTRACHEITIS DISEASE DEVELOPMENT(9,1)
FOREIGN FRAGMENT CUTAWAY(9,1)
G PROTEIN CHEMOKINE RECEPTOR(9,1)
GD GLYCOPROTEIN GENE(9,1)
GREEN FLUORESCENCE MICROSCOPE(9,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS APPLICATION(9,1)
PLASMID ENZYME DIGESTION(9,1)
VACCINE PREPARATION RECOMBINANT VIRUS(9,1)
VIRAL PLAQUE EXPRESSION(9,1)
VIRUS DISEASE INVASION(9,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GENOME(8,2)
VIRAL GENOME(8,2)
BOVINE RHINOTRACHEITIS DIFFERENTIAL DIAGNOSIS(8,1)
BP AMPLIFICATION PRIMER(8,1)
CELL SURFACE GLYCOPROTEIN INTERACTION(8,1)
GENETIC ENGINEERING TECHNIQUE FIELD(8,1)
GENETICALLY ENGINEERED RECOMBINANT STRAIN(8,1)
PCR AMPLIFIED FRAGMENT(8,1)
SUCROSE GRADIENT CENTRIFUGATION(8,1)
TAKARA BIO DALIAN CO(8,1)
VACCINE VIRULENCE(8,1)
VETERINARY MICROBIOGY(8,1)
VIRUS GE PROTEIN(8,1)
CATTLE INDUSTRY(7,2)
DOWNSTREAM PRIMER(7,2)
GE GENE AMPLIFICATION(7,2)
UPSTREAM PRIMER(7,2)
VIRAL PENETRATION(7,2)
ANTIBODY NEUTRALIZATION(7,1)
BULL FERTILITY(7,1)
CALF HAZARD(7,1)
CELL VIRUS INOCULATION(7,1)
CYTOTOXIC LYMPHOCYTE(7,1)
GENE ENGINEERING STRAIN(7,1)
HOMOLOGOUS RECOMBINATION(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(7,1)
JUNCTIONAL ADHERENCE(7,1)
KAI CHEONG(7,1)
NECROTIC RHINITIS(7,1)
NUCLEOTIDE SEQUENCE SPLICING(7,1)
PRECONSTRUCTED APPLICANT(7,1)
SEROLOGICAL SURVEY(7,1)
SUPERNATANT ADSORPTION(7,1)
VIRALLY INFECTED CELL(7,1)
VIRUS ADSORPTION TISSUE(7,1)
VIRUS THROWBACK ABILITY(7,1)
APOPTOSIS PREVENTION(6,1)
BOVINE KIDNEY CELL(6,1)
CHEN ZENG(6,1)
CHINA NATIONAL(6,1)
COW FEVER(6,1)
COW MILK PRODUCTION(6,1)
DIAGNOSTIC ANTIGEN(6,1)
DISEASE PREVALENCE(6,1)
DOWNSTREAM HOMOLOGY ARM(6,1)
EFFICIENTVIRAL GROWTH(6,1)
EQUINE HERPES VIRUS(6,1)
FATAL BOVINE(6,1)
GE CODING REGION DELETION(6,1)
GLYCOPROTEIN EXPRESSION(6,1)
HERPES VIRUS ANTIGEN(6,1)
HEXAGONAL EXTERIOR APPEARANCE(6,1)
HOMOLOGOUS GENE(6,1)
INFECTIOUS BACTERIAL ARTIFICIAL CHROMOSOME(6,1)
INFECTIOUS DISEASE(6,1)
LYSATE LYSIS(6,1)
MAJOR ENVELOPE GLYCOPROTEIN(6,1)
MARTIN BEER(6,1)
NATIONAL LABORATORY SEPARATION(6,1)
OVERNIGHT LIGATION(6,1)
PCR AMPLIFICATION(6,1)
PERSISTENT INFECTION(6,1)
PHOSPHORYLATED SUBSTRATE BROAD SPECTRUM(6,1)
RABBIT KIDNEY CELL(6,1)
RECOMBINANT PLASMID(6,1)
SPECTRUM CHEMOKINE(6,1)
UPSTREAM HOMOLOGY ARM(6,1)
VACCINE VIRUS INFECTION(6,1)
VIRUS EXISTENCE(6,1)
VIRUS GENE(6,1)
VIRUS PROPAGATION(6,1)
VIRUS RESEACH(6,1)
VIROLOGY(5,3)
DESIGNED ENZYME CLEAVAGE(5,2)
PLASMID TRANSFER(5,2)
VIRAL ENTRY(5,2)
BLACK DRAGON(5,1)
BRYANT NA(5,1)
CALF COW(5,1)
CAUSATIVE FORCE INFLUENCE(5,1)
CELL INFILTRATION(5,1)
COMPLEMENT LYSIS PRESENCE(5,1)
DISEASE BOVINE(5,1)
EXPRESSION CASSETTE(5,1)
GD GENE(5,1)
GE ELISA(5,1)
GENE DEFICIENT STRAIN(5,1)
GENETIC ENGINEERING STRAIN(5,1)
GENETICALLY ENGINEERED STRAIN PRODUCING(5,1)
GENOMIC DNA(5,1)
GREEN PLAQUE(5,1)
GREEN STAINED PLAQUE(5,1)
HARTLEY CA(5,1)
IMMUNOSUPPRESSIVE FACTOR(5,1)
KDA PROTEIN(5,1)
NERVOUS TISSUE(5,1)
NEUTRAL FORMALDEHYDE(5,1)
PARENT STRAIN(5,1)
PCR PRIMER(5,1)
PREPARED VIRUS GENOME(5,1)
RED RHINO(5,1)
RELIABLE MARKER(5,1)
RNA ENZYME(5,1)
SECONDARY BACTERIAL PNEUMONIA(5,1)
UNITED STATES INVITROGEN CORP(5,1)
VACCINE DEVELOPMENT(5,1)
VIRUS RELEASE(5,1)
GENBANK ACCESSION(4,2)
HINDIII(4,2)
TEMPLATE(4,2)
ALPHAHERPESVIRUSE(4,1)
AMPLIFICATION REACTION(4,1)
ANHYDROUS DIETHYL ETHER(4,1)
ANTI GD ANTIBODY(4,1)
ANTIVIRAL THERAPEUTIC AGENT DESIGN(4,1)
BIOLOGICAL ENGINEERING TECHNOLOGY(4,1)
CELL CULTURE(4,1)
CELL EFFECTIVE INTERDIFFUSION(4,1)
CHINESE PATENT GRANT(4,1)
EFFICIENT VACCINE(4,1)
FOREGROUND PRODUCING(4,1)
HERPES VIRUS HOTSPOT(4,1)
HOST CELL PROLIFERATION(4,1)
MEASURED POST CHALLENGE(4,1)
METHODDBCODE(4,1)
MOLECULAR BIOLOGY RESEARCH(4,1)
NUCLEIC ACID METABOLISM(4,1)
PLAQUE COMPARISON(4,1)
SEEDLING CONSTRUCTION(4,1)
SHELL(4,1)
STRUCTURAL PROTEIN(4,1)
TUMOR TREATMENT(4,1)
VIRUS INFECTED CELL(4,1)
WEEVREDISUTUCELBV(4,1)
LANE(3,2)";Pharmaceuticals;Open
2011-02-23;"CN102649948         A  2012-08-29 [CN102649948]
STG: (A) Published application
AP : 2011CN-0043444 2011-02-23
CN102649948         B  2016-05-25 [CN102649948B]
STG: (B) Granted patent for invention
AP : 2011CN-0043444 2011-02-23";62252643;"CN102649948         A  2012-08-29 [CN102649948]
CN102649948         B  2016-05-25 [CN102649948B]";2011CN-0043444;;HUAZHONG AGRICULTURAL UNIVERSITY;HUAZHONG AGRICULTURAL UNIVERSITY;;;1;"LIU ZHENGFEI
DING MINGFANG
FAN QIANG
GUO AIZHEN
GAO JUEJING
CHEN HUANCHUN";;;"(CN102649948B)
Infectious bovine rhinotracheitis Δ TK / Δ gE gene deletion flag live vaccines and preparation method";"(CN102649948B)
The invention belongs to the technical field of animal-borne disease genetic engineering and specifically relates to an infectious bovine rhinotracheitis delta TK/delta gE gene deletion mark live vaccine and a preparation method. The strain is preserved at China Center for Type Culture Collection and the preservation number is CCTCCNO: V201104. A recombined infectious bovine rhinotracheitis strain is lack of TK and gE genes and an EGFP (Enhanced Green Fluorescent Protein) express box is inserted. The toxicity of the prepared infectious bovine rhinotracheitis delta TK/delta gE gene deletion mark live vaccine is greatly reduced; the potential virus is difficult to activate; the safety is high; besides, except being lack of the TK and gE genes, the deletion strain can still express the other toxic genes; and the immunogenicity is excellent.";"(CN102649948)
1. One infectious bovine rhinotracheitis Δ TK / Δ gE gene deletion flag live strain BHV-1TK-/gE-/EGFP+, characterized in, deposited at the China Type Culture Collection live strain (CCTCC), and its accession number: CCTCC NO: V201104, a deletion of gE gene and the TK the live strains, EGFP expression cassette has been inserted.
2. Claim 1 of the live strain containing BHV-1TK-/gE-/EGFP+ of the infectious bovine rhinotracheitis genetically engineered vaccine.
3. Claim 1 live strain BHV-1TK-/gE-/EGFP+ genetically engineered infectious bovine rhinotracheitis the preparation of a vaccine.";"(CN102649948)
The present invention relates to the field of animal pathogens genetic engineering techniques.
The present invention aims at obtaining one infectious bovine rhinotracheitis  TK /  gE gene deletion flag strains, using the infectious bovine rhinotracheitis gene deletion flag strains and vaccine preparation of infectious bovine rhinotracheitis gene deletion flag of the infectious bovine rhinotracheitis gene deletion flag application of a vaccine.";"(CN102649948)
The main advantage of the present invention are:
Infectious bovine rhinotracheitis (Infectious Bovine Rhinotracheitis, IBR), commonly known as red nose disease (li zuobo, 2006), is made from bovine herpes virus 1 type (BHV-1) of bovine due to an acute, febrile, contagious disease, mainly caused by respiratory and reproductive diseases, such as an infectious rhinotracheitis, conjunctivitis, high thermal, infectious pustular outer colpomycosis, abortion and the like.
After virus in an infected calf, may be latent within on the nervous system, cause infections appear as intermittent, persistent.
Moreover disease bovine be long-term life of erase pulses reveals, when the resistance of the body is reduced, it is reactivated, detox outwardly therefrom, which is extremely difficult to eliminate the root cause of the disease.
Many years of clinical trials have shown, long-term use of conventional vaccines (inactivated shoot and attenuated attenuated vaccine) do not facilitate the extermination of vaccination and in combination with the present disease (wuchun tao, 2006), it is now the virus vaccine preparation method of genetically engineered vaccine is mainly employed.";"A61K-039/265
A61P-031/20
C12N-007/01
C12R-001/93";"(CN102649948)
1. One infectious bovine rhinotracheitis  TK /  gE gene deletion flag live strain BHV-1TK -/gE-/EGFP+, characterized in, deposited at the China Type Culture Collection live strain (CCTCC), and its accession number: CCTCC NO: V201104, a deletion of gE gene and the TK the live strains, EGFP expression cassette has been inserted.";"(CN102649948)
THYMIDINE KINASE(100,59)
GE GENE DELETION(100,20)
INFECTIOUS BOVINE RHINOTRACHEITIS(100,17)
LIVE STRAIN(100,5)
LIVE VACCINE(100,3)
ACCESSION NUMBER(100,1)
CULTURE COLLECTION LIVE STRAIN(100,1)
BOVINE RHINOTRACHEITIS GENE DELETION(63,3)
VACCINATION EXTERMINATION(34,1)
GENETICALLY ENGINEERED VACCINE(32,2)
INFECTIOUS RHINOTRACHEITIS(32,1)
INFECTIOUS PUSTULAR OUTER COLPOMYCOSIS(31,1)
INACTIVATED SHOOT(25,1)
INFECTED CALF(24,1)
WUCHUN TAO(21,2)
CLINICAL TRIAL YEAR(21,1)
LI ZUOBO(21,1)
VACCINE PREPARATION(20,3)
DISEASE BOVINE(20,1)
EXPRESSION CASSETTE(19,10)
ATTENUATED VACCINE(19,2)
LONG TERM LIFE(19,1)
BOVINE HERPES VIRUS(17,17)
GENETIC ENGINEERING(17,2)
GE STRAIN(15,1)
RED NOSE DISEASE(15,1)
DISEASE(14,6)
LATENT VIRUS(13,2)
CONJUNCTIVITIS(13,1)
STRAIN(12,6)
CONTAGIOUS DISEASE(12,1)
IMMUNOGENICITY(12,1)
VIRULENCE GENE STILL(12,1)
ABORTION(11,1)
RECOMBINANT VIRUS HOMOLOGOUS RECOMBINATION(10,3)
INFECTION(10,1)
VACCINE(9,6)
MASTER THESIS DISSERTATION(9,3)
FLAG STORAGE(9,1)
ROOT(9,1)
CONFLUENT MONOLAYER(8,5)
DETOX(8,2)
REDUCED VIRULENCE(8,2)
ANIMAL PATHOGEN FIELD(8,1)
BODY RESISTANCE(8,1)
CHINA UNIVERSITY HUBEI PROVINCE(8,1)
VIRUS VACCINE PREPARATION(8,1)
VIRUS INOCULATION(7,3)
BOVINE(7,2)
ANIMAL EPIDEMICS FIELD(7,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS GENE(7,1)
MYCOPLASMA NEWBORN CALF SERUM(7,1)
VACCINE APPLICATION(7,1)
VIRUS(6,16)
FLUORESCENCE MICROSCOPE(6,5)
HELPER PLASMID(6,4)
BOVINE RHINOTRACHEITIS DELETION STRAIN(6,1)
BOVINE RHINOTRACHEITIS INDIRECT ELISA(6,1)
CATTLE NEUTRALIZING ANTIBODY IMMUNE(6,1)
COW INFECTIOUS RHINOTRACHEITIS(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS STRAIN(6,1)
QUAIL POXVIRUS ATTENUATED VACCINE(6,1)
SAFETY DEGREE(6,1)
MOLECULAR MARKER(5,7)
RECOMBINANT VIRUS SCREENING(5,3)
SOUTHERN BLOT(5,3)
SUCCESSFUL RECOMBINATION(5,3)
ECTO PCR ASSAY(5,2)
IMMUNIZED COW(5,2)
VACCINE REACTIVATION(5,2)
BIOENGINEERED TREASURE(5,1)
BOVINE RHINOTRACHEITIS CLINICAL DIAGNOSIS(5,1)
BOVINE RHINOTRACHEITIS REPORTER(5,1)
INFECTIOUS BOVINE RHINOTRACHEITIS FALL(5,1)
KPNI HINDIII DIGESTION(5,1)
PLASMID RESTRICTION ENZYME DIGESTION(5,1)
RECOMBINANT VIRAL PCR VERIFICATION(5,1)
RECOMBINANT VIRUS CORRECTNESS(5,1)
SERUM NEUTRALIZING TITER(5,1)
LANE(4,15)
DIGESTIVE PASSAGE(4,3)
AGRICULTURAL UNIVERSITY LIBRARY(4,2)
DEFICIENT STRAIN(4,2)
DELETED VIRUS(4,2)
LESION PERCENTAGE(4,2)
NASAL SWAB(4,2)
NUCLEOTIDE BASE DELETION(4,2)
PCR AMPLIFICATION(4,2)
REPORTER GENE(4,2)
STERILE DDH(4,2)
VACCINE SAFETY(4,2)
ANTEROGRADE NEURONAL TRANSPORT(4,1)
CATTLE COHABITATION(4,1)
CHINESE VETERINARY SCIENCE(4,1)
CLONTEC LABORATORY(4,1)
DEXAMETHASONE REACTIVATION(4,1)
EAN METASTASIZE(4,1)
EUROPEAN COMMISSION HEALTH(4,1)
FARM VETERINARY SCIENCE(4,1)
FREEZE THAW EXTRACTION(4,1)
GD GLYCOPROTEIN EXPRESSION(4,1)
GE DOWNSTREAM HOMOLOGY(4,1)
GENE GE VERIFICATION(4,1)
GLYCOPROTEIN GE GENE(4,1)
HERPES VIRUS VIRULENCE GENE(4,1)
INDIRECT ELISA SETUP(4,1)
INFECTION COHABITATION EXPLANATION(4,1)
INFECTIOUS BOVINE RHINOTRACHEITIS CONSTRUCTION(4,1)
NASAL FOLD DILUTION(4,1)
RECOMBINANT VIRUS VERIFICATION(4,1)
RESTRICTION ENZYME XBAI(4,1)
SEROLOGICAL DIFFERENTIATION(4,1)
SEROLOGICAL SURVEY GANGCHA REGION(4,1)
SHANGHAI INSTITUTE CELL RESOURCE(4,1)
TEMPLATE ECTO PCR(4,1)
TH CENTURY YEAR(4,1)
TK RECOMBINANT VIRUS GENOME(4,1)
VACCINE SERONEUTRALIZATION(4,1)
VACCINE VIRULENCE(4,1)
CULTURE MEDIUM(3,5)
ECOR(3,5)
CENTRIFUGATION(3,4)
COTRANSFECTION(3,4)
CELL CO TRANSFECTED GENOME(3,3)
CLEAN BENCH(3,2)
FAST THAWING(3,2)
GENE EXPRESSION CASSETTE(3,2)
HYBRIDIZING BAND(3,2)
PLASMID VECTOR(3,2)
RECOMBINANT STRAIN(3,2)
AMPLIFICATION PRIMER(3,1)
BAMH PZF(3,1)
BIOKO BIOTECHNOLOGY(3,1)
BOVINE FERTILITY(3,1)
CANADIAN MANUFACTURE VIOLET(3,1)
CANDIDATE VACCINE(3,1)
CATTLE VACCINATION(3,1)
CENTRAL CHINA AGRICULTURAL UNIVERSITY(3,1)
CLEAR UNILLUMINATED PLAQUE(3,1)
DELETED SEQUENCE DELETION(3,1)
DELETION MUTANT(3,1)
DELETION VIRUS(3,1)
DISEASE DISCOVERY(3,1)
ENVELOPE GLYCOPROTEIN(3,1)
FAMILY VIRUS(3,1)
FLUORESCENT CLOUD(3,1)
FUCHUN PRESENTATION(3,1)
GE DELETION(3,1)
GENBANK ACCESSION(3,1)
GENE DEFICIENT RECOMBINANT VACCINE(3,1)
GENE DELETION FLAG STRAIN(3,1)
GENE DOWNSTREAM HOMOLOGY ARM(3,1)
GENE RECOMBINATION(3,1)
GENOME GENE(3,1)
GLYCOPROTEIN CARBOXYL TERMINAL TRUNCATION(3,1)
HAO BIOTECHNOLOGY(3,1)
HEALTHY BULL(3,1)
HERPES VIRUS SUBFAMILY(3,1)
HYCLONE LABORATORY(3,1)
IMMUNIZATION DAY(3,1)
IMMUNO INOCULATED CATTLE(3,1)
IMMUNOGENIC GOOD ANTIGEN(3,1)
INCUBATOR HOOD(3,1)
INFECTED CATTLE(3,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS ANTIBODY(3,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GC(3,1)
INOCULATED BOVINE(3,1)
INTERMITTENT COUGH(3,1)
INVITROGEN CORP(3,1)
LABELED PROBE BP PREPARATION(3,1)
LESION DILUTION(3,1)
LIU JINGHUA(3,1)
MALE COW IMMUNIZED GROUP(3,1)
MUCUS SYMPTOM(3,1)
NERVOUS SYSTEM(3,1)
NEUTRAL FORMALDEHYDE FULL COMPLEMENT(3,1)
PCR JUNCTION(3,1)
PLAQUE GREEN FLUORESCENCE REGION(3,1)
PLAQUE LESION(3,1)
PLAQUE PURIFICATION(3,1)
PLAQUE SCREENING(3,1)
PLASMID RECOMBINANT TRANSFER(3,1)
POISON EXPERIMENT(3,1)
POST DELIVERY NEWBORN(3,1)
POST IMMUNIZATION 7D(3,1)
PRENTICE HALL(3,1)
PREPARED GENETICALLY ENGINEERED VACCINE(3,1)
PURIFICATION SUCCESS(3,1)
RECOMBINANT VIRUS BASIS(3,1)
RECOMBINANT VIRUS SUCCESSFUL CONSTRUCTION(3,1)
REED MUENCH(3,1)
REFRIGERATOR RAPID MELTING(3,1)
RESPIRATORY PATHWAY(3,1)
RESTRICTION DIGESTION(3,1)
ROCHE PHARMACEUTICAL(3,1)
SCIENCE PUBLISHER(3,1)
SCIENTIFIC COMMITTEE(3,1)
SENSITIVITY SPECIFICITY(3,1)
SENSITIZED CELL SUSPENSION(3,1)
SEROLOGICAL ANTIBODY STATISTICAL ANALYSIS(3,1)
SERUM PRECIPITATION(3,1)
SIMPLEX VIRUS(3,1)
SUCCESSFUL ERADICATION(3,1)
TEST ANIMAL PATIENT ERADICATION(3,1)
TK MUTANT(3,1)
TK PURIFICATION(3,1)
UBIQUITOUS VIRUS PRESENCE(3,1)
UPSTREAM HOMOLOGY ARM(3,1)
VACCINE GENE DELETION(3,1)
VACCINE HOMEMADE COMMERCIAL PRODUCTION(3,1)
VIRAL REPLICATION(3,1)
VIRULENT STRAIN(3,1)
VIRUS DILUTED SERUM LAW(3,1)
VIRUS GENE DELETION(3,1)
WANG YANHUI(3,1)
WILD POISON CATTLE PHASE(3,1)
XIAO DINGHAN(3,1)
YANBANG FEN(3,1)
ZHU YUANMAO(3,1)
SAVE(2,5)
PHENOL(2,4)
CELL CULTURE FLASK(2,3)
VIRUS SOLUTION(2,3)
ADSORPTION(2,2)
EPP TUBE(2,2)
FLUORESCENT SIGNAL(2,2)
GENE AMPLIFICATION(2,2)
INACTIVATED VACCINE(2,2)
NORMAL CELL POPULATION(2,2)
NOSTRIL(2,2)
PCR PRODUCT DETECTION(2,2)
PROPER DILUTION(2,2)
SUPERNATANT(2,2)
AGGLUTINATION(2,1)
AMPLIFIED GE(2,1)
AMPLIFIER BAND(2,1)
ANTIGENICITY ANALYSIS(2,1)
ATTACHMENT PMD(2,1)
BASIC VIROLOGICAL TECHNIQUE MANUAL(2,1)
BLOOD COLLECTION(2,1)
BOVINE SAMPLE(2,1)
BOX GENE EXPRESSION(2,1)
BP DNA(2,1)
CALCIUM PHOSPHATE TRANSFECTION(2,1)
CATTLE INDUSTRY(2,1)
CAUSATIVE FORCE DUTY(2,1)
CELL LYSIS(2,1)
CLEAVAGE SITE(2,1)
CO2 INCUBATOR(2,1)
COHABITATION GROUP(2,1)
COHABITATION TEST(2,1)
COLLECTED NASAL(2,1)
CONSTRUCTED RECOMBINANT TRANSFER PLASMID(2,1)
CONTINUITY TEST PROTECTION(2,1)
DAY POST CHALLENGE(2,1)
DEATH SITUATION(2,1)
DILUTION RATIO LOGARITHM(2,1)
DISEASE OCCURRENCE(2,1)
DNA GENOME(2,1)
ERADICATION PROGRAM(2,1)
GE PZF(2,1)
GENE DELETION PRIMER(2,1)
GENE FRAGMENT(2,1)
GENOME COMPLETE(2,1)
GENOMIC DNA(2,1)
H INTERACTION INFECTION(2,1)
HERPES VIRUS KNOWLEDGE(2,1)
INFECTED CELL(2,1)
INOCULATION CHNGT WAVE RANGE(2,1)
INSECT FEEDING(2,1)
INSUFFICIENT PROTECTION(2,1)
LABELING KIT(2,1)
LESION PRESENCE(2,1)
LESION RATE PERCENTAGE(2,1)
LIVE VIRUS FLUID(2,1)
MARKER GENE(2,1)
MENTAL STATE MATCHING(2,1)
MODEL VACCINE(2,1)
MUTANT VIRUS(2,1)
NUCLEOTIDE SEQUENCE ANALYSIS(2,1)
PBLUESCRIPTII(2,1)
POST VACCINATION(2,1)
POTENTIAL EVOLUTIONARY RELATIONSHIP(2,1)
POTENTIAL TARGET ANIMAL RISK(2,1)
PPURIFICATION PROCESS SCREENING(2,1)
PRIMER SEQUENCE(2,1)
PROPAGATION VARIETY(2,1)
PROTECTIVE IMMUNITY(2,1)
REACTIVATED TEST(2,1)
RECOMBINANT VIRUS CONSTRUCTION(2,1)
REMAINING FRAGMENT(2,1)
RESIDUAL VIRULENCE(2,1)
RESTRICTION SITE(2,1)
RETRIEVED ATTACHMENT(2,1)
ROUNDED GREEN FLUORESCENCE REGION(2,1)
SAMPLE BATCH(2,1)
SCIENTIFIC RESEARCH(2,1)
SECONDARY BACTERIAL PNEUMONIA(2,1)
SECONDARY INFECTION CONJUNCTIVITIS(2,1)
SEGMENT GENE DELETION(2,1)
SERUM NEUTRALIZING ANTIBODY LEVEL(2,1)
SIGNIFICANT CYTOTOXIC(2,1)
SIGNIFICANT NASAL MUCUS(2,1)
SPREAD ROUTE(2,1)
STRONG RELEVANCE(2,1)
TEST PACKET ACTIVATION(2,1)
TK DNA(2,1)
TRANSFECTED HELA CELL(2,1)
TRANSFECTION VECTOR CONSTRUCTION(2,1)
TRANSFERRED SWAB(2,1)
TRUNCATED AL ACTIVITY(2,1)
UPSTREAM HOMOLOGY CONNECTION(2,1)
VACCINE PROTECTION(2,1)
VETERINARY RESEARCH INSTITUTE(2,1)
VIRAL INFECTION DEGRADATION(2,1)
VIRUS ATTACK(2,1)
VIRUS CELL(2,1)
VIRUS SUSPENSION(2,1)
WHOLE GENOME SEQUENCE(2,1)
WILD STRAIN(2,1)
(CN102649948B)
THYMIDINE KINASE(100,55)
INFECTIOUS BOVINE RHINOTRACHEITIS(100,17)
GE GENE DELETION(100,16)
LIVE VACCINE(100,4)
ACCESSION NUMBER(100,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(45,1)
LIVE STRAIN FLAG(30,3)
BOVINE RHINOTRACHEITIS GENE DELETION(29,1)
WILD POISON INFECTED CATTLE(29,1)
INFECTIOUS RHINOTRACHEITIS(25,1)
INFECTIOUS PUSTULAR OUTER COLPOMYCOSIS(24,1)
IMMUNO INOCULATED CATTLE(22,1)
TH CENTURY YEAR(22,1)
DISEASE ERADICATION(21,1)
FLAG MARKER GENE DELETION(21,1)
GENE DELETION FLAG STRAIN(20,1)
MUCUS SYMPTOM(20,1)
NUCLEOTIDE SEQUENCE INSERTION(20,1)
INFECTED CALF(19,1)
POST DELIVERY NEWBORN(19,1)
RESPIRATORY PATHWAY(19,1)
SEQUENCE LISTING DELETION(18,2)
GENE DELETION MARK(18,1)
VACCINE CATTLE PHASE(18,1)
RESIDUAL VIRULENCE(17,1)
DISEASE(16,4)
DISEASE BOVINE(16,1)
LI ZUOBO(16,1)
EXPRESSION CASSETTE(15,9)
VACCINE PREPARATION(15,2)
DISEASE PROPAGATION VARIETY(15,1)
GENE DELETION FLAG(15,1)
INSECT FEEDING(15,1)
SPREAD ROUTE(15,1)
GENETIC ENGINEERING(14,2)
ANIMAL DISEASE(14,1)
INFECTIOUSBOVINERHINOTRACHEITIS(14,1)
BOVINE HERPES VIRUS(13,13)
BP DNA(12,2)
CULTURE COLLECTION(12,1)
BLEEDING(11,1)
COMPLETE LIFETIME(11,1)
CONJUNCTIVITIS(11,1)
RED NOSE DISEASE(11,1)
STRONG(11,1)
LATENT VIRUS(10,2)
INACTIVATED VACCINE(10,1)
PROPAGATION PATH(10,1)
REDUCED VIRULENCE MARKER(10,1)
TRACHEA(10,1)
VACCINATION(10,1)
VERTICAL AXIS PROPAGATION(10,1)
VIRULENCE GENE STILL(10,1)
ATTENUATED VACCINE(9,2)
ABORTION(9,1)
CHEESE(9,1)
COLOSTRUM(9,1)
CONTAGIOUS DISEASE(9,1)
EXUDATE(9,1)
HORIZONTAL TRAVEL(9,1)
IMMUNOGENICITY(9,1)
NECROSIS(9,1)
ULCER(9,1)
RECOMBINANT VIRUS HOMOLOGOUS RECOMBINATION(8,3)
PFULIVE VIRUS INOCULATION DELETION(8,2)
TEST ANIMAL(8,2)
INFECTION(8,1)
STRAIN(7,4)
MASTER THESIS DISSERTATION(7,3)
STRONG PROTECTION(7,3)
BOVINE(7,1)
ROOT(7,1)
DETOX(6,2)
ANIMAL PATHOGEN FIELD(6,1)
BOVINE RHINOTRACHEITIS SEROLOGICAL SURVEY(6,1)
TECHNIQUE ROUTE(6,1)
DEFICIENT STRAIN(5,5)
FLUORESCENCE MICROSCOPE(5,5)
ANIMAL EPIDEMICS FIELD(5,1)
BOVINE RHINOTRACHEITIS INDIRECT ELISA(5,1)
DELETED VIRUS INOCULATION CHNGT(5,1)
MYCOPLASMA NEWBORN CALF SERUM(5,1)
VACCINE APPLICATION(5,1)
VIRUS(4,14)
CO2 INCUBATOR(4,4)
HELPER PLASMID(4,4)
SUCCESSFUL RECOMBINATION(4,3)
HUBEI PROVINCE(4,2)
RECOMBINANT VIRUS SCREENING(4,2)
SAFETY DEGREE(4,2)
WUCHUN TAO(4,2)
BOVINE RHINOTRACHEITIS CLINICAL DIAGNOSIS(4,1)
DILUTION CONFLUENT MONOLAYER(4,1)
ECORI RESTRICTION DOWNSTREAM HOMOLOGY(4,1)
ECORI RESTRICTION ENZYME HINDIII(4,1)
INFECTIOUS RHINOTRACHEITIS COW(4,1)
KILLING(4,1)
PLASMID RESTRICTION ENZYME DIGESTION(4,1)
PREPARATION METHOD FLAG(4,1)
QUAIL POXVIRUS ATTENUATED VACCINE(4,1)
RECOMBINANT VIRAL PCR VERIFICATION(4,1)
RECOMBINANT VIRUS CORRECTNESS(4,1)
REDUCED RESISTANCE BODY(4,1)
SERUM NEUTRALIZING TITER(4,1)
SOUTHERN BLOT VERIFICATION(4,1)
UPPER PROPAGATION WAY(4,1)
VECTOR PLASMID PBLUESCRIPTII(4,1)
LANE(3,14)
DNAMOLECULARMARKER(3,4)
AGRICULTURAL UNIVERSITY LIBRARY(3,2)
AMPLIFIED FRAGMENT(3,2)
LESION PERCENTAGE(3,2)
NASAL SWAB(3,2)
PCR AMPLIFICATION(3,2)
REPORTER GENE(3,2)
STERILE DDH(3,2)
TEMPLATE ECTOPCR TEST(3,2)
UPSTREAM HOMOLOGY ARM(3,2)
VACCINE SAFETY(3,2)
BOVINE HERPES VIRUS GENE(3,1)
CHINESE VETERINARY SCIENCE(3,1)
CLONING VECTOR PBLUESCRIPTII SK(3,1)
CONFLUENT CELL MONOLAYER(3,1)
DEXAMETHASONE REACTIVATION(3,1)
FAMILY VIRAL GENOME(3,1)
FARM VETERINARY SCIENCE(3,1)
FREEZE THAW EXTRACTION(3,1)
GE DOWNSTREAM HOMOLOGY(3,1)
GE UPSTREAM HOMOLOGY(3,1)
INFECTIOUS BOVINE RHINOTRACHEITIS CONSTRUCTION(3,1)
KB SPHI DIGESTION(3,1)
RESTRICTION ENZYME XBAI(3,1)
TK RECOMBINANT VIRUS GENOME(3,1)
TRUNCATED GLYCOPROTEIN GD AL(3,1)
VACCINE SERONEUTRALIZATION(3,1)
VACCINE VIRULENCE(3,1)
CULTURE MEDIUM(2,5)
REFRIGERATOR(2,5)
COTRANSFECTION(2,4)
CELL CO TRANSFECTED GENOME(2,3)
CELL CULTURE FLASK(2,3)
CELL DIGESTION(2,3)
CENTRIFUGATION(2,3)
INTERMEDIATE TRANSFER VECTOR(2,3)
CELL RESOURCE(2,2)
CLEAN BENCH(2,2)
DOUBLE DIGESTION(2,2)
EMPTY SPOT(2,2)
FAST THAWING(2,2)
FOLD DILUTION(2,2)
GREEN FLUORESCENCE(2,2)
HYBRIDIZING BAND(2,2)
KB FRAGMENT(2,2)
LIVE STRAIN(2,2)
MLEPP TUBE(2,2)
RECOMBINANT STRAIN(2,2)
RESTRICTION SITE(2,2)
AMPLIFICATION PRIMER(2,1)
ANTIBODY NEUTRALIZATION(2,1)
ANTIBODY VARIABLE RULE MEASUREMENT(2,1)
ANTICOAGULANT TUBE KNEADING(2,1)
ANTIGENICITY ANALYSIS(2,1)
ATTACHMENT PMD(2,1)
BIOKO BIOTECHNOLOGY(2,1)
BIOLOGICAL TECHNO CO(2,1)
BOVINE CAUSATIVE FORCE(2,1)
BULL FERTILITY(2,1)
CANDIDATE GENE DELETION(2,1)
CATTLE IMMUNIZED CHANGE(2,1)
CATTLE INDUSTRY(2,1)
CATTLE INOCULATION(2,1)
CATTLE VACCINATION(2,1)
CENTRAL CHINA AGRICULTURAL UNIVERSITY(2,1)
CLINICAL TRIAL YEAR(2,1)
CLONTECLABORATOTIES COMPANY(2,1)
COHABITATION TEST(2,1)
COLLECTED NASAL(2,1)
CONFLUENT MONOLAYER SHEET(2,1)
CONJUNCTIVITIS SECONDARY INFECTION CREATION(2,1)
CONTINUITY TEST PROTECTION(2,1)
DAY POST CHALLENGE(2,1)
DELETION MUTANT(2,1)
DELETION VIRUS CONCENTRATION(2,1)
DIGOXIGENIN LABELED KIT(2,1)
DISEASE DISCOVERY(2,1)
DISEASE OCCURRENCE(2,1)
DNA GENOME(2,1)
DNAECTO PCR(2,1)
DNAMOLECULAR MARKER(2,1)
ECTOPCR TEMPLATE(2,1)
ENVELOPE GLYCOPROTEIN(2,1)
ERADICATION PROGRAM(2,1)
EXPRESSION CASSETTE SEQUENCE(2,1)
FLUORESCENT CLOUD(2,1)
FOOD ANOREXIA(2,1)
FUCHUN PRESENTATION(2,1)
GE DELETION(2,1)
GENBANK ACCESSION(2,1)
GENE DEFICIENT RECOMBINANT VACCINE(2,1)
GENE DELIVERY WUHAN(2,1)
GENE DOWNSTREAM HOMOLOGY ARM(2,1)
GENE EXPRESSION CASSETTE(2,1)
GENE FRAGMENT(2,1)
GENE RECOMBINATION TECHNOLOGY(2,1)
GENOMIC DNA(2,1)
HEALTHY BULL(2,1)
HINDIII ECORI(2,1)
HYCLONE LABORATORY(2,1)
IMMUNIZED GROUP CREATION(2,1)
IMMUNOGENIC GOOD ANTIGEN(2,1)
INACTIVATED SHOOT(2,1)
INCUBATOR HOOD(2,1)
INFECTION COHABITATION(2,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS ANTIBODY(2,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GC(2,1)
INFLATED CIRCLE(2,1)
INTERMITTENT COUGH(2,1)
LABELED PROBE BP PREPARATION(2,1)
LIU JINGHUA(2,1)
LIVE VIRUS FLUID(2,1)
MALE COW IMMUNIZED GROUP(2,1)
MARKER GENE(2,1)
MODEL VACCINE(2,1)
NERVOUS SYSTEM(2,1)
NEUTRAL FORMALDEHYDE FULL COMPLEMENT(2,1)
PATIENT ERADICATION(2,1)
PCR JUNCTION(2,1)
PLAQUE LESION(2,1)
PLAQUE SCREENING(2,1)
PLASMID DIGESTION(2,1)
PLASMID VECTOR(2,1)
POISON EXPERIMENT(2,1)
POST IMMUNIZATION 7D(2,1)
POST VACCINATION(2,1)
POSTERIOR SLOPE(2,1)
PREPARED GENETICALLY ENGINEERED VACCINE(2,1)
PURIFICATION ROUND(2,1)
RECOMBINANT VIRUS BASIS(2,1)
RECOMBINANT VIRUS CONSTRUCTION(2,1)
RECOMBINANT VIRUS SUCCESSFUL CONSTRUCTION(2,1)
REED MUENCH(2,1)
RESPIRATORY TRACT INFECTION CREATION(2,1)
RESTRICTION DIGESTION(2,1)
RETRIEVED ATTACHMENT(2,1)
ROCHE PHARMACEUTICAL(2,1)
SAMPLE TESTED COHABITATION(2,1)
SCIENTIFIC RESEARCH(2,1)
SECONDARY BACTERIAL PNEUMONIA(2,1)
SENSITIZED CELL SUSPENSION(2,1)
SEROLOGICAL ANTIBODY STATISTICAL ANALYSIS(2,1)
SERUM NEUTRALIZING ANTIBODY LEVEL(2,1)
SERUM PRECIPITATION(2,1)
SHENZHEN ZHOU(2,1)
SPHI FRAGMENT(2,1)
STRONG RELEVANCE(2,1)
SUCCESSFUL ERADICATION(2,1)
SYMPTOM ABSENCE(2,1)
TEMPLATE DNA(2,1)
TEST PACKET ACTIVATION(2,1)
TESTING CATTLE(2,1)
TH CENTURY(2,1)
TK DNAA(2,1)
TK MUTANT(2,1)
TK PURIFICATION(2,1)
TRANSFECTION VECTOR CONSTRUCTION(2,1)
VACCINE GENE DELETION(2,1)
VACCINE HOMEMADE COMMERCIAL PRODUCTION(2,1)
VACCINE PROTECTION(2,1)
VERIFIED GENE(2,1)
VETERINARY RESEARCH INSTITUTE(2,1)
VIRAL INFECTION DEGRADATION(2,1)
VIRAL REPLICATION(2,1)
VIRULENT STRAIN(2,1)
VIRUS ATTACK(2,1)
VIRUS DILUTED SERUM LAW(2,1)
VIRUS GENE DELETION(2,1)
VIRUS SUSPENSION(2,1)
WANG YANHUI(2,1)
WEEK BLOOD COLLECTION(2,1)
WILD STRAIN(2,1)
WUHAN UNIVERSITY(2,1)
YUANPING HAO(2,1)
SAVE(1,5)
BAMHI(1,4)
PHENOL(1,4)
ADSORPTION(1,2)
FLUORESCENT SIGNAL(1,2)
GNAHCO(1,2)
NORMAL CELL POPULATION(1,2)
NOSTRIL(1,2)
PROPER DILUTION(1,2)
SUPERNATANT(1,2)
VIRAL SOLUTION(1,2)
AGGLUTINATION(1,1)
AMPLIFIER BAND(1,1)
BEEF SAMPLE(1,1)
BOVINE SAMPLE(1,1)
CALCIUM PHOSPHATE TRANSFECTION(1,1)
CARRIER PZF(1,1)
CO VACCINATION(1,1)
COLUMN COHABITATION GROUP(1,1)
CONSTRUCTED RECOMBINANT TRANSFER PLASMID(1,1)
CUSTOM INLET(1,1)
DEATH SITUATION(1,1)
FLUORESCENCE REGION(1,1)
FOLD SERIAL(1,1)
GE INTERMEDIATE TRANSFER DELETION(1,1)
GENE GE(1,1)
GENOME COMPLETE(1,1)
H INTERACTION INFECTION(1,1)
INFECTED CELL(1,1)
INSUFFICIENT PROTECTION(1,1)
LESION PRESENCE(1,1)
LESION RATE DILUTION(1,1)
LESION RATE PERCENTAGE(1,1)
LOST NORMAL MORPHOLOGY PIECE(1,1)
MENTAL STATE MATCHING(1,1)
PRIMER SEQUENCE(1,1)
REACTIVATED TEST(1,1)
SAMPLE LOT(1,1)
SIGNIFICANT NASAL MUCUS(1,1)
SIMPLEX VIRUS MEMBER(1,1)
TRANSFECTED HELA CELL(1,1)
WHOLE GENOME SEQUENCE(1,1)";Pharmaceuticals;Open
"2010-12-27
2011-12-21";"CA2822825           A1 2012-07-05 [CA2822825]
STG: (A1) Application laid open
AP : 2011CA-2822825 2011-12-21
WO2012/092053       A1 2012-07-05 [WO201292053]
STG: (A1) Published application with search report
AP : 2011WO-US66384 2011-12-21
AU2011352800        A1 2013-06-20 [AU2011352800]
STG: (A1) Open to public inspection
AP : 2011AU-0352800 2011-12-21
SG191396            A1 2013-08-30 [SG-191396]
STG: (A1) Patent Application
AP : 2013SG-0050117 2011-12-21
CO6761399           A2 2013-09-30 [CO6761399]
STG: (A2) Application derived from a PCT application
AP : 2013CO-0164014 2013-07-10
KR20130109220       A  2013-10-07 [KR20130109220]
STG: (A) Published application
AP : 2013KR-7019872 2011-12-21
CN103347534         A  2013-10-09 [CN103347534]
STG: (A) Published application
AP : 2011CN-80067439 2011-12-21
MX2013007584        A  2013-10-17 [MX2013007584]
STG: (A) Patent application
AP : 2013MX-PA07584 2011-12-21
US20130280294       A1 2013-10-24 [US20130280294]
STG: (A1) Application published
AP : 2011US-13995688 2011-12-21
FD :  Provisional Appl: US61/427,361 FDD=2010-12-27 [2010US-61427361]
EP2658570           A1 2013-11-06 [EP2658570]
STG: (A1) Application published with search report
AP : 2011EP-0813490 2011-12-21
JP2014502619        A  2014-02-03 [JP2014502619]
STG: (A) Published application
AP : 2013JP-0547556 2011-12-21
CL2013001877        A1 2014-03-07 [CL1877201300]
STG: (A1) Patent application
AP : 2013CL-0001877 2013-06-25
TH134799            A  2014-06-11 [TH-134799]
STG: (A) Published application
AP : 2013TH-1003605 2011-12-21
PE08712014          A1 2014-07-19 [PE201400871]
STG: (A1) Patent application
AP : 2013PE-0001482 2011-12-21
IN1093/MUMNP/2013   A  2014-08-22 [IN2013MN01093]
STG: (A) Application laid open
AP : 2013IN-MN01093 2013-06-11
RU2013128921        A  2015-02-10 [RU2013128921]
STG: (A) Application for invention
AP : 2013RU-0128921 2011-12-21
NZ611531            A  2015-04-24 [NZ-611531]
STG: (A) Published application
AP : 2011NZ-0611531 2011-12-21
AU2011352800        B2 2015-09-03 [AU2011352800]
STG: (B2) Patent proceeded by OPI
AP : 2011AU-0352800 2011-12-21
KR101554080         B1 2015-09-17 [KR101554080]
STG: (B1) Patent specification
AP : 2013KR-7019872 2011-12-21
CA2822825           C  2016-02-09 [CA2822825]
STG: (C) Patent (second level)
AP : 2011CA-2822825 2011-12-21
RU2595873           C2 2016-08-27 [RU2595873]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2013RU-0128921 2011-12-21
JP6053036           B2 2016-12-09 [JP6053036]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2013JP-0547556 2011-12-21
MX351380            B  2017-10-12 [MX-351380]
STG: (B) Granted patent/ granted utility model
AP : 2013MX-PA07584 2011-12-21
BR112013016503      A1 2018-04-03 [BR112013016503]
STG: (A1) Published application
AP : 2013BR-0016503 2011-12-21
BR112013016503      A2 2018-05-22 [BR112013016503]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2013BR-0016503 2011-12-21
CN103347534         B  2018-09-11 [CN103347534B]
STG: (B) Granted patent for invention
AP : 2011CN-80067439 2011-12-21
EP2658570           B1 2018-11-28 [EP2658570]
STG: (B1) Patent specification
AP : 2011EP-0813490 2011-12-21";7353217;"CA2822825           A1 2012-07-05 [CA2822825]
WO2012/092053       A1 2012-07-05 [WO201292053]
AU2011352800        A1 2013-06-20 [AU2011352800]
SG191396            A1 2013-08-30 [SG-191396]
CO6761399           A2 2013-09-30 [CO6761399]
KR20130109220       A  2013-10-07 [KR20130109220]
CN103347534         A  2013-10-09 [CN103347534]
MX2013007584        A  2013-10-17 [MX2013007584]
US20130280294       A1 2013-10-24 [US20130280294]
EP2658570           A1 2013-11-06 [EP2658570]
JP2014502619        A  2014-02-03 [JP2014502619]
CL2013001877        A1 2014-03-07 [CL1877201300]
TH134799            A  2014-06-11 [TH-134799]
PE08712014          A1 2014-07-19 [PE201400871]
IN1093/MUMNP/2013   A  2014-08-22 [IN2013MN01093]
RU2013128921        A  2015-02-10 [RU2013128921]
NZ611531            A  2015-04-24 [NZ-611531]
AU2011352800        B2 2015-09-03 [AU2011352800]
KR101554080         B1 2015-09-17 [KR101554080]
CA2822825           C  2016-02-09 [CA2822825]
RU2595873           C2 2016-08-27 [RU2595873]
JP6053036           B2 2016-12-09 [JP6053036]
MX351380            B  2017-10-12 [MX-351380]
BR112013016503      A1 2018-04-03 [BR112013016503]
BR112013016503      A2 2018-05-22 [BR112013016503]
CN103347534         B  2018-09-11 [CN103347534B]
EP2658570           B1 2018-11-28 [EP2658570]";"2010US-61427361
2011US-13995688
2011WO-US66384
2013TH-1003605";"(EP2658570)
WO2012/092053
(US20130280294)
WO2012/092053
(JP6053036)
WO2012/092053
(RU2595873)
WO2012092053
(SG-191396)
WO2012092053
(TH-134799)
WO2012092053
(IN2013MN01093)
WO2012/092053
(NZ-611531)
WO2012092053
(AU2011352800)
WO2012092053
(KR101554080)
WO2012/092053
(CA2822825)
WO2012/092053
(MX-351380)
WO2012092053
(BR112013016503)
WO2012092053
(CN103347534B)
WO2012/092053";"ELANCO
ELI LILLY
TEXAS VET LAB";ELANCO;"(EP2658570)
US
(EP2658570)
US
(US20130280294)
US
(WO201292053)
US


(CA2822825)
US
(CA2822825)
US";"(EP2658570)
NAME=Eli Lilly and Company Lilly Corporate Center , CITY=Indianapolis, IN 46285 , COUNTRY=US 

(EP2658570)
NAME=Elanco US Inc. 2500 Innovation Way , CITY=Greenfield, IN 46140 , COUNTRY=US , REG=101726847 

(US20130280294)
NAME=ELI LILLY AND COMPANY , CITY=Indianapolis , STATE=IN , COUNTRY=US , ATYP=US Company 

(WO201292053)
NAME=ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, Indiana 46285 , POSTCODE=46285 , COUNTRY=US 

(JP2014502619)
NAME=ELI LILLY & CO , REG=594197872 

(JP6053036)
NAME=ELI LILLY & CO , REG=594197872 

(KR20130109220)
NAME=ELI LILLY & CO. , REG=519952160210 

(KR101554080)
NAME=ELI LILLY & CO. , REG=519952160210 

(CA2822825)
NAME=ELI LILLY AND COMPANY Lilly Corporate Centre , CITY=INDIANAPOLIS , STATE=IN , POSTCODE=46285 , COUNTRY=US 

(CA2822825)
NAME=ELI LILLY AND COMPANY Lilly Corporate Centre , CITY=INDIANAPOLIS , STATE=IN , POSTCODE=46285 , COUNTRY=US 
";1;"WEISE DALE WADE
HARRIS JAMES ROBERT";"(EP2658570)
US
(EP2658570)
US";"(EP2658570)
NAME=WEISE, Dale, Wade c/o Eli Lilly and Company P. O. Box 6288 , CITY=Indianapolis, Indiana 46206-6288 , COUNTRY=US 

NAME=HARRIS, James, Robert c/o Eli Lilly and Company P.O. Box 6288 , CITY=Indianapolis, Indiana 46206-6288 , COUNTRY=US 

(EP2658570)
NAME=WEISE, Dale, Wade c/o Eli Lilly and Company P. O. Box 6288 , CITY=Indianapolis, Indiana 46206-6288 , COUNTRY=US 

NAME=HARRIS, James, Robert c/o Eli Lilly and Company P.O. Box 6288 , CITY=Indianapolis, Indiana 46206-6288 , COUNTRY=US 
";"(EP2658570)
Bovine viral diarrhea virus type 1b vaccine compositions and methods";"(EP2658570)
Disclosed are immunogenic compositions comprising a modified, live bovine viral diarrhea virus type lb (BVDV-lb), and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, managing, and/or ameliorating a viral or microbial infection, or one or more symptoms thereof, including, for example, those infections giving rise to shipping fever, bovine respiratory disease complex, and/or bovine viral diarrhea, particularly in susceptible or infected animals.";"(CA2822825)
1. An immunogenic composition comprising: a modified, live bovine viral diarrhea virus type 1 b (BVDV-1b), and a veterinary-acceptable carrier;
wherein the modified, live BVDV-1b is a TGAC strain of BVDV-1b altered by passaging in tissue culture cells.
2. The immunogenic composition of claim 1, wherein the modified, live bovine viral diarrhea virus is a cytopathic BVDV-1b virus.
3. The immunogenic composition of claim 1, further comprising one or more of:
a modified, live bovine respiratory syncytial virus (BRSV); wherein the modified, live
BRSV is an N375 strain of BRSV altered by passaging in tissue culture cells;
a modified, live bovine herpes virus (BHV-1); wherein the modified, live BHV-1
is a
Cooper strain of BHV-1 altered by passaging in tissue culture cells;
a modified, live bovine viral diarrhea virus (BVDV-1a); wherein the modified, live
BVDV-1a is a Singer strain of BVDV-1a altered by passaging in tissue culture cells;
a modified, live bovine viral diarrhea virus (BVDV-2); wherein the modified, live
BVDV-2 is a 125 strain of BVDV-2 altered by passaging in tissue culture cells; or a modified, live parainfluenza virus Type 3 (PI3); wherein the modified, live
PI3 is a
Reisinger SF4 strain of PI3 altered by passaging in tissue culture cells.
4. The immunogenic composition of claim 1, further comprising an immunologically effective amount of at least one additional antigen; wherein the at least one additional antigen is specific for Actinobacillus,
Actinomyces,
Bacillus, Bordetella, Brachyspira, Campylobacter, Clostridium, Ehrlichia,
Erysipelothrix, Escherichia, Histophilus, Leptospira, Listeria, Mannheimia,
Moraxella, Mycobacterium, Mycoplasma, Pasteurella, Salmonella, or
Streptococcus or a combination thereof.
5. A vaccine comprising the immunogenic composition of any one of claims 1
to
4, and an adjuvant;
wherein the immunogenic composition comprises at least 2x10 3 TCID50 of the modified, live BVDV-1b per dose.
6. The vaccine of claim 5, further comprising an immunologically-effective amount of at least one inactivated microbial pathogen.
7. A composition comprising a modified, live BVDV-1b virus and a veterinaryacceptable carrier for use in preventing shipping fever in an animal;
wherein the modified, live BVDV-1b is a TGAC strain of BVDV-1b altered by passaging in tissue culture cells; and wherein the composition comprises at least 2x10 3 TCID50 of the modified, live
BVDV-1b per dose.
8. The composition according to claim 7, wherein the composition is for use with an animal that is infected by, or susceptible to infection from, a pestivirus.
9. A composition comprising a modified, live BVDV-1 b virus and a pharmaceutically-acceptable carrier for use in preventing, treating, managing, or ameliorating one or more symptoms of a disease caused by a pestivirus in an animal susceptible to pestivirus infection;
wherein the modified, live BVDV-1b is a TGAC strain of BVDV-1b altered by passaging in tissue culture cells; and wherein the composition comprises at least 2x10 3 TCID50 of the modified, live
BVDV-1b per dose.
10. The composition according to claim 9, wherein the composition further comprises one or more of an immunogen derived from bovine rotavirus,
BRSV, BHV-1, bovine coronaviruses, PI3, bovine paramyxovirus, foot and mouth disease virus, BRV, BVDV-1a, BVDV-2, Mannheimia haemolytica type A1, Mannheimia haemolytica type A6, Pasteurella multocida,
Histophilus somni, or Mycoplasma bovis.
11. The composition according to any one of claims 7 to 10, wherein the composition is for use with an animal that is a bovid.
12. A composition comprising a modified, live BVDV-1b virus and a pharmaceutically-acceptable carrier, for use in protecting an animal against shipping fever, bovine respiratory disease complex or bovine viral diarrhea;
wherein the modified, live BVDV-1b is a TGAC strain of BVDV-1b altered by passaging in tissue culture cells; and wherein the composition comprises at least 2x10 3 TCID50 of the modified, live
BVDV-1b per dose.
13. The composition according to claim 12, wherein the composition is for use with one or more of an additional virus;
wherein said additional virus is a Bovine Rhinotracheitis Virus, a Bovine
Respiratory
Syncytial Virus, or a Parainfluenza 3 Virus; and wherein said additional virus is a modified, live virus or an inactivated virus.
14. The vaccine of claim 5, further comprising one or more of:
at least 5x10 3 TCID50 of a modified, live BHV-1 per dose;
at least 5x10 3 TC1D50 of a modified, live BVDV-1a per dose;
at least 3x10 3 TCID50 of a modified, live BVDV-2 per dose;
at least 6x10 4 TCID50 of a modified, live PI3 per dose; or at least 7x10 2 TCID50 of a modified, live BRSV per dose.";"(EP2658570)
The invention provides vaccine compositions that offer advantages over conventional formulations, and specifically provide ways of preventing or controlling diseases caused by one or more pestiviruses, and in particular, those caused by BVDV viruses including those of the Type 1b subgenotype (i.e., BVDV-1b).
The present invention relates generally to the fields of veterinary medicine and animal vaccines.
In particular embodiments, the present invention provides immunogenic compositions comprising modified, live BVDV-1b viruses, as well as pharmaceutical formulations containing them, and methods for using such vaccines in a variety of prophylactic regimens.";"(EP2658570)
Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
These PI cattle, which are highly predisposed to infection with microorganisms causing pneumonia or enteric disease, provide the necessary viral reservoirs for outbreaks of MD disease in cattle (see e.g., Liess et al., 1974; Barber et al., 1985; Malmquist, 1968; and Ross et al., 1986, each of which is specifically incorporated herein in its entirety by express reference thereto).
Thus, for these and other reasons inherent in the prior art, there is a need for BVDV vaccine formulations that elicit a vigorous and multi-faceted immune response, and particularly those that elicit an immune response against the Type 1b form of BVDV.
Because of the potential for great economic loss in unvaccinated herds, there is a need for cost-effective (and preferably, single-dose) vaccines containing modified, live BVDV-lb viruses that induce prophylaxis against BVDV infections in mammalian livestock populations.
Likewise, because contemporary polyvalent vaccines against multifactorial diseases such as BRDC and related shipping fever diseases are largely ineffective at preventing infection by BVDV-1b, there is also a need for improved vaccination modalities to better effect prophylaxis and control of disease outbreak in BVDV-1b-susceptible livestock.
The present invention encompasses new and useful compositions, as well as methods of employing them that may advantageously improve delivery of prophylactic and/or therapeutic agents to an animal in need thereof.
BRDC is a multifactorial disease complex that frequently afflicts stocker/feeder calves in market channels and at destination pasture or feed lot.
More particularly, it concerns immunogenic compositions, methods of making such compositions, and methods for preventing, treating, ameliorating, and/or managing microbial or viral infection, or a symptom thereof, and particularly respiratory infections in mammalian livestock, including multifactorial diseases such as bovine respiratory disease complex (BRDC).
Treatment of BVDV is problematic given the absence of antiviral therapeutics, and the mortality rate from pestivirus infection is high.";"A61K-039/12
A61K-039/15
A61K-039/155
A61K-039/245
A61K-039/39
A61P-001/00
A61P-031/12
A61P-031/14";"(EP2658570)
1. An immunogenic composition comprising: a modified, live, attenuated bovine viral diarrhea virus type 1b (BVDV1b), wherein the modified, live BVDV1b is a strain deposited under the ATCC accession number PTA-11553.";"(EP2658570)
IMMUNOGENIC(100,28)
BOVINE VIRAL DIARRHEA VIRUS(100,16)
1B VACCINE(100,1)
CONTEMPORARY POLYVALENT VACCINE(100,1)
LIVE BVDV LB VIRUS(95,1)
MAMMALIAN LIVESTOCK POPULATION(84,1)
MULTIFACTORIAL DISEASE(83,6)
BVDV VACCINE FORMULATION(83,1)
ANTIVIRAL THERAPEUTICS ABSENCE(74,1)
VACCINATION MODALITY(74,1)
ATCC ACCESSION(69,1)
UNVACCINATED HERD(69,1)
DESTINATION PASTURE(59,1)
STOCKER FEEDER CALF(58,1)
PROPHYLACTIC REGIMEN VARIETY(54,1)
VIRAL RESERVOIR(54,1)
BVDV VIRUS(53,1)
SHIPPING FEVER DISEASE(53,1)
SUSCEPTIBLE LIVESTOCK(52,1)
PI CATTLE(51,1)
PROPHYLACTIC DELIVERY(51,1)
GASTROINTESTINAL DISEASE(50,1)
VACCINATING ANIMAL(48,1)
LIVE BVDV 1B VIRUS(44,3)
MAMMALIAN LIVESTOCK(42,3)
VACCINE(41,39)
BVDV TREATMENT(40,1)
PHARMACEUTICAL FORMULATION(38,2)
DEVELOPMENT EFFORT(38,1)
BVDV INFECTION(37,6)
TCID(35,7)
LIVE BHV(33,1)
PESTIVIRUS(31,6)
MARKET CHANNEL(31,1)
SYMPTOM(30,24)
MULTI FACETED IMMUNE RESPONSE(30,1)
BVDV(29,68)
PREVENTABLE FRACTION(28,17)
BOVINE HERPES VIRUS(27,4)
ECONOMIC LOSS(27,2)
LIVE PERSISTENTLY INFECTED(27,1)
RESPIRATORY INFECTION(27,1)
ANIMAL(26,56)
PROPHYLAXIS(26,10)
DISEASE OUTBREAK(26,1)
INFECTION(25,22)
THERAPEUTIC AGENT(25,3)
SERUM NEUTRALIZING ANTIBODY TITER(24,3)
IMMUNE RESPONSE(23,23)
BOVINE RHINOTRACHEITIS VIRUS(22,3)
OUTBREAK(22,2)
ACTINOBACILLUS(22,1)
CAMPYLOBACTER(22,1)
ERYSIPELOTHRIX(22,1)
MICROBIAL PATHOGEN SPECIFIC ANTIGEN(22,1)
PESTIVIRUS INFECTION(21,3)
PNEUMONIA(21,2)
DISEASE(20,27)
BRDC(20,9)
PESTIVIRAL INFECTION(20,6)
FEEDLOT(20,4)
MICROORGANISM(20,3)
PEN DEAD CALF LUNG(20,3)
BRACHYSPIRA(20,1)
MYCOBACTERIUM(20,1)
STREPTOCOCCUS(20,1)
COASTAL BERMUDA HAY(19,2)
BORDETELLA(19,1)
CLOSTRIDIUM(19,1)
EHRLICHIA(19,1)
LEPTOSPIRA(19,1)
MORAXELLA(19,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(18,7)
NASAL SWAB(18,6)
VIRUS ISOLATION DATA(18,4)
BVDV1B FRACTION EFFICACY(18,3)
BVDV INFECTION SIGN(18,2)
ESCHERICHIA(18,1)
LISTERIA(18,1)
SALMONELLA(18,1)
NASAL SHEDDING(17,6)
VIRAL INFECTION(17,4)
POST CHALLENGE VIREMIA(17,3)
ACTINOMYCES(17,2)
TYPE 1B SUBGENOTYPE(17,1)
CLINICAL DISEASE SIGN(16,4)
DIARRHEA PARAINFLUENZA(16,3)
HAEMOPHILUS SOMNUS(16,3)
HISTOPHILUS SOMNI(16,3)
INTESTINAL MUCOSA ULCERATION(16,1)
STRAIN(15,5)
BVDV DEFINITIVE CLINICAL SIGN(15,1)
BVDV SERONEGATIVE CALF(15,1)
BVDV LA(14,6)
CATTLE(14,6)
EDTA VACUTAINER TUBE(14,4)
NONSTRUCTURAL PROTEIN(14,3)
BVDV CLINICAL SIGN(14,2)
BVDV1B INDUCED VIREMIA(14,2)
CHALLENGE VIRUS DILUTION(14,2)
SAS LEARNING EDITION(14,2)
VIRUS FROZEN ALIQUOT(14,2)
CULTURE VESSEL(13,6)
BOVINE RESPIRATORY DISEASE COMPLEX(13,4)
DISEASE PREVENTION(13,4)
MAMMALIAN POPULATION(13,3)
PROPHYLACTIC ADMINISTRATION(13,3)
COMMERCIAL STOCKER FEEDER CALF(13,2)
ORDINALLY SCALED TITER COMPARISON(13,2)
TVL BK CELL INOCULATION(13,2)
VIRULENCE CONSISTENCY(13,2)
COLOSTRUM DEPRIVED DAIRY CALF(13,1)
HEXAVALENT BRDC EFFECTIVENESS(13,1)
HEXAVALENT MLV VACCINE AID(13,1)
MORTALITY RATE(13,1)
PREGNANT CATTLE PLACENTA(13,1)
TVL BVDV1B MS DEPOSIT(13,1)
VETERINARY MEDICINE FIELD(13,1)
HORSE SERUM(12,3)
LEUKOPENIA DURATION(12,3)
ILLNESS SYMPTOM(12,2)
BVDV VIRUS SUBTYPE(12,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(12,1)
PREDOMINANT BVDV SUBTYPE(12,1)
TANNER(11,10)
BOVINE VIRAL DIARRHEA VIRUS TYPE(11,4)
CRYOPRESERVATION MEDIUM(11,4)
MODIFIED LIVE VIRUS(11,4)
MITIGATED FRACTION(11,3)
BVDV 1B ANTIBODY TITER(11,2)
BVDV SPECIES(11,2)
CONFLUENT TVL BK CELL(11,2)
DISEASE PROPHYLAXIS(11,2)
DISEASE SYMPTOM(11,2)
FROZEN PRODUCTION VIRUS INOCULUM(11,2)
GENERA BISON(11,2)
HARVESTED VIRAL FLUID BATCH(11,2)
IMMUNOGENIC POLYPEPTIDE(11,2)
INFECTION SEVERITY(11,2)
MATCHED RANDOMIZATION(11,2)
SORTING ALLY(11,2)
STERILE ULTRAFILTRATION(11,2)
VACCINATED CALF(11,2)
VIRAL INFECTION CLINICAL SIGN(11,2)
VIRAL PATHOGEN(11,2)
BVDV LB SHEDDING(11,1)
BVDV1B INDUCED LEUKOPENIA(11,1)
CALF PERSISTENT INFECTION(11,1)
INACTIVATED VIRUS VACCINE(11,1)
SHEDDING BVDV LB(11,1)
VACCINE BVDV1B FRACTION(11,1)
VACCINE EFFICACY ESTIMATE(11,1)
VETERINARY BIOLOGICS LABORATORY(11,1)
VETERINARY PRACTITIONER CARE(11,1)
HOST ANIMAL(10,5)
RT PCR(10,5)
ANTIMICROBIAL COMPOUND(10,3)
BVDV 1B INFECTION(10,3)
DETECTABLE IMMUNE RESPONSE(10,3)
POST CHALLENGE DAY(10,3)
STERILE FILTRATION(10,3)
4X CHALLENGE DOSE(10,1)
BBL CULTURE SWAB(10,1)
BUDAPEST TREATY PROVISION(10,1)
BVDV 1B CYTOPATHIC MORPHOLOGY(10,1)
BVDV LB EFFICACY(10,1)
BVDV1B CLINICAL SIGN(10,1)
CLINICAL DISEASE ETIOLOGY(10,1)
DISEASE BACTERIAL ETIOLOGIC AGENT(10,1)
EARLY RECOGNIZABLE CLINICAL SIGN(10,1)
FETUS MALFORMATION(10,1)
INFECTED TISSUE NECROSIS(10,1)
LIVE ATTENUATED VIRUS VACCINE(10,1)
PERSISTENTLY INFECTED ANIMAL(10,1)
PI CATTLE SUBTYPE(10,1)
STUDY SHED BVDV1B(10,1)
TEXAS VET LAB(10,1)
PROTECTIVE IMMUNE RESPONSE(9,4)
ROLLER BOTTLE(9,4)
1X TRYPSIN EDTA SOLUTION(9,2)
BVDV NEGATIVE CALF(9,2)
BVDV1B ISOLATION(9,2)
HARVEST BATCH(9,2)
INFECTIOUS DISEASE(9,2)
INOCULATED CULTURE(9,2)
LEUKOPENIA DEVELOPMENT(9,2)
LIVE VACCINE(9,2)
MAMMALIAN SPECIES(9,2)
MS GENETIC STABILITY(9,2)
RECURRENT INFECTION(9,2)
TARGET IMMUNOGEN(9,2)
TGAC STRAIN(9,2)
VIRAL CHALLENGE(9,2)
VIRUS INOCULUM VOLUME(9,2)
VIRUS PARTICLE(9,2)
ANTIGENIC EPITOPE(9,1)
BASELINE WBC COUNT(9,1)
BHV ANTIGENICITY(9,1)
BOVINE PATHOGENIC MICROBIAL SPECIES(9,1)
BOVINE VIRAL FORMULATION(9,1)
BVDV 1B MONOVALENT VACCINE(9,1)
BVDV DIFFERENTIATION(9,1)
BVDV OUTBREAK(9,1)
BVDV SUBGENOTYPE(9,1)
CLOVEN HOOFED MAMMAL(9,1)
FIBRINOUS PNEUMONIA(9,1)
IMMUNOGLOBULIN MOLECULE FRAGMENT(9,1)
IMMUNOHISTOCHEMICAL ASSAY(9,1)
INFECTION OUTBREAK(9,1)
LEUKOPENIA DATA ANALYSIS(9,1)
MS VIRUS IDENTITY(9,1)
NATIONAL VETERINARY SERVICE LABORATORY(9,1)
OBSERVER DISCRETION(9,1)
PESTIVIRUS GENUS(9,1)
PFIZER ANIMAL HEALTH(9,1)
POST CHALLENGE SHEDDING(9,1)
PRE VACCINATION BVDV(9,1)
RAW LEUKOCYTE DATA(9,1)
RECOVERED VIRUS ADMINISTRATION(9,1)
SEROLOGICALLY NEGATIVE CALF(9,1)
SUCCESSFUL BACKPASSAGE STUDY(9,1)
VACCINATED ANIMAL TISSUE(9,1)
VACCINATION STATUS KNOWLEDGE(9,1)
VACCINE SUBSERIAL(9,1)
VETERINARY MEDICAMENT MANUFACTURE(9,1)
VIRULENT PESTIVIRUS INFECTION(9,1)
WBC COUNT DATA(9,1)
GROWTH MEDIUM(8,6)
SUBCULTURE(8,6)
ANTIVIRAL(8,4)
ACTIVE INGREDIENT(8,3)
AFFECTED ANIMAL(8,3)
MEDIAN DIFFERENCE(8,3)
PASTEURELLA MULTOCIDA(8,3)
PREVENTED FRACTION(8,3)
ANTIGEN INTRODUCTION(8,2)
BLOOD SAMPLE BUFFY COAT(8,2)
BVDV DETECTION(8,2)
CALF SEQUENCE(8,2)
CULTURE FLASK(8,2)
DIFFERENTIATING FEATURE(8,2)
HARVEST DAY(8,2)
HUMORAL IMMUNE RESPONSE(8,2)
MAMMALIAN HOST(8,2)
MASTER SEED(8,2)
PRECHALLENGE CLINICAL OBSERVATION(8,2)
PRODUCTION VIRUS BATCH(8,2)
PROPORTION DATA(8,2)
PROTECTIVE IMMUNITY(8,2)
SHED VIRUS(8,2)
VIRUS PROPAGATION(8,2)
VIRUS SUSPENSION(8,2)
ANTIBODY TITER COMPARISON(8,1)
ANTIGENIC POLYPEPTIDE(8,1)
ATTENUATED PESTIVIRUS(8,1)
BILLION DOLLAR(8,1)
BIVALENT VACCINE(8,1)
BOS TAURUS(8,1)
BOVID LUNG(8,1)
BOVINE PARAMYXOVIRUS(8,1)
BRDC VACCINE(8,1)
BUDAPEST TREATY TERM(8,1)
BVBV 1B VACCINE DOSE(8,1)
BVDV 1B VACCINE DOSE(8,1)
BVDV IMMUNOGENIC(8,1)
BVDV1B INFECTION(8,1)
BVDV1B SHEDDING(8,1)
BVDV1B VIREMIA(8,1)
CANDIDATE STATUS MODIFICATION(8,1)
CAPRA HIRCUS(8,1)
CHALLENGE VIRUS EXPOSURE(8,1)
CLINICAL SYMPTOM(8,1)
COMMERCIAL VACCINE FORMULATION(8,1)
CONSECUTIVE DAY POST CHALLENGE(8,1)
CVB BIOMETRICS RANDOMIZATION TABLE(8,1)
CYTOPATHIC VARIANT(8,1)
DEVELOPED BVDV1B TITER(8,1)
DIFFERENTIAL WBC COUNT(8,1)
DOMESTIC FEEDLOT(8,1)
DOMESTIC LIVESTOCK(8,1)
ENVELOPE GLYCOPROTEIN(8,1)
FLAVIVIRIDAE FAMILY(8,1)
HEMORRHAGIC SYNDROME(8,1)
HEXAVALENT VACCINE COMPONENT(8,1)
HOMOGENEOUS POPULATION(8,1)
IMMUNOFLUORESCENCE ASSAY(8,1)
IMMUNOGENIC FORMULATION(8,1)
INFECTIOUS AGENT IDENTITY(8,1)
LIVE PESTIVIRUS(8,1)
MASTER GENETIC STABILITY(8,1)
MATERNAL ANTIBODY(8,1)
MICROORGANISM DEPOSIT(8,1)
MONOVALENT IMMUNOGENIC(8,1)
MULTIVALENT IMMUNOGENIC(8,1)
NASAL SECRETION ALIQUOT(8,1)
NON HUMAN PRIMATE(8,1)
OVIS ARIE(8,1)
PELLETED FEED RATION(8,1)
PESTIVIRUS SPECIES(8,1)
PHYLOGENETIC ANALYSIS(8,1)
POLYVALENT VACCINE(8,1)
PROPHYLACTIC IMMUNOGENIC COMPOUND(8,1)
QPCR METHODOLOGY(8,1)
RECIPIENT MAMMAL(8,1)
RESPIRATORY DISEASE CLINICAL SIGN(8,1)
SEPTICEMIC SYNDROME(8,1)
SHIPPING FEVER PATHOGENESIS(8,1)
STOCKER FEEDER CALF ENVIRONMENT(8,1)
SYMPTOM APPEARANCE(8,1)
TVL BVDV 1B MS(8,1)
UNIQUELY BVDV1B SEQUENCE(8,1)
UNIVERSITY BLVD(8,1)
USDA LICENSED VACCINE(8,1)
VACCINATION REGIMEN(8,1)
VACCINE EFFICACY ADJUSTED ESTIMATE(8,1)
VACCINE MEDICAMENT MANUFACTURE(8,1)
VERTEBRATE MAMMAL(8,1)
VIREMIA DATA(8,1)
VIRULENT BVDV(8,1)
VIRUS AMPOULE(8,1)
VIRUS GENETIC STABILITY(8,1)
VIRUS POPULATION(8,1)
VIRUS REPLICATION(8,1)
YEARLY INOCULATION(8,1)
ZOOLOGICAL SPECIMEN(8,1)
THERAPY(7,7)
CONSTANT VIRUS DECREASING SERUM(7,3)
MAXIMUM SHEDDING DAY(7,2)
TYPE 1B(7,2)
CO2(6,8)
EXPRESS REFERENCE(6,8)
KIT(6,7)
ANTIBIOTIC(6,3)
CALF GROUP(6,3)
CONTAINER END(6,3)
INSPIRATION(6,3)
LIQUID STUART MEDIUM(6,3)
NEOMYCIN(6,3)
NYSTATIN(6,3)
REPEATED MEASURE(6,3)
SUSCEPTIBILITY(6,3)
DAILY LEUKOCYTE COUNT RATIO(6,2)
DISPERSED CELL(6,2)
FINAL SUCROSE CONCENTRATION(6,2)
MANNHEIMIA HAEMOLYTICA(6,2)
MINIMUM INCUBATION(6,2)
MIXED BREED HEIFER(6,2)
MYCOPLASMA BOVIS(6,2)
OLFACTORY ORGAN SAMPLE(6,2)
PRECHALLENGE LEUKOCYTE(6,2)
VIRAL AGENT(6,2)
WORKING VIRUS(6,2)
ACTIVELY PROPAGATING CULTURE(6,1)
ACUTE OUTBREAK(6,1)
ACUTE PNEUMONIA(6,1)
ADVERSE EXTERNAL INFLUENCE PREDISPOSING(6,1)
ADVERSE POST VACCINATION REACTION(6,1)
AGE CATTLE(6,1)
AGRICULTURE UNITED STATES DEPARTMENT(6,1)
AIRWAY ACUTE INFLAMMATION(6,1)
ANIMAL VACCINATION(6,1)
ANTIBODY NEUTRALIZATION(6,1)
ATYPICAL CPE(6,1)
BLINDED PERSONNEL(6,1)
BRDC INFECTION(6,1)
BUFFY COAT SAMPLE(6,1)
BVD VIRUS(6,1)
BVDV INFECTED ANIMAL DETECTION(6,1)
BVDV STRAIN(6,1)
BVDV TITER(6,1)
CALF HEALTH(6,1)
CALF REMAINDER(6,1)
CAPSID PROTEIN(6,1)
CLINICAL ASSESSMENT(6,1)
CONFIDENCE INTERVAL(6,1)
CONTAMINATION EVIDENCE(6,1)
CULTURE PROPAGATION(6,1)
DAY POST VACCINATION(6,1)
DEPOSIT AVAILABILITY(6,1)
DISEASE SEVERITY(6,1)
DROOPING EAR(6,1)
FATAL MUCOSAL DISEASE(6,1)
FREEZE DRYER(6,1)
FROZEN TVL BK CELL(6,1)
HARVEST FLUID PURITY(6,1)
HEALTH INSPECTION SERVICE(6,1)
IDENTITY KNOWLEDGE(6,1)
IMMUNOGEN INJECTION(6,1)
IMMUNOGENIC PEPTIDE(6,1)
IMMUNOGENIC PROTEIN(6,1)
IMMUNOGENIC SUBSTANCE(6,1)
INCREASED BVDV1B ANTIBODY TITER(6,1)
INFECTED ANIMAL ABILITY(6,1)
INFECTED CATTLE(6,1)
INFECTION ELIMINATION(6,1)
INOCULATION DAY(6,1)
INTRANASAL ROUTE(6,1)
LB VACCINE(6,1)
LEUKOPENIA DETECTION(6,1)
MACROSCOPIC GROWTH ABSENCE(6,1)
MINIMUM INOCULUM TITER(6,1)
NASAL SECRETION SPECIMEN(6,1)
NATURAL EXPOSURE CLINICAL EVIDENCE(6,1)
NURSING CALF(6,1)
PAST THIRTY YEAR(6,1)
POKY FEEDER(6,1)
POOLED NASAL SECRETION(6,1)
POST CHALLENGE COUNT(6,1)
PROBE PRIMER SPECIFICITY(6,1)
PRONOUNCED FEVER(6,1)
PROTOCOL GENOTYPING(6,1)
QPCR ASSAY(6,1)
RECOGNIZABLE CYTOPATHOLOGICAL CHANGE(6,1)
RECOMBINANT VECTOR(6,1)
RECORD KEEPER(6,1)
SAS INSTITUTE(6,1)
SDFV FRAGMENT(6,1)
SEROLOGICAL EVALUATION(6,1)
STUDY INITIATION(6,1)
STUDY PRIMARY OUTCOME(6,1)
SUSCEPTIBLE ANIMAL TISSUE(6,1)
SUSCEPTIBLE CELL TISSUE CULTURE(6,1)
SYMPTOM ONSET(6,1)
THERAPEUTIC REGIMEN(6,1)
VACCINATION MAINTENANCE SCHEDULE(6,1)
VACCINE COMPOSITION ADMINISTRATION(6,1)
VACCINE EFFECTIVENESS(6,1)
VACCINE PREPARATION(6,1)
VERTEBRATE ANIMAL(6,1)
VIRAL PROTEASE(6,1)
VIRAL RESPIRATORY INFECTION(6,1)
VIRAL TITER(6,1)
VIRALLY MEDIATED DISEASE(6,1)
VIREMIA DURATION(6,1)
VIRUS MAJOR RESERVOIR(6,1)
WIDESPREAD AVAILABILITY(6,1)
YOUNG CATTLE(6,1)
HARVEST MATERIAL(5,5)
STATISTICAL ANALYSIS(5,5)
PLACEBO VACCINATED CONTROL PROPORTION(5,2)
PRESERVATIVE(5,2)
ADJUVANT ACTIVITY(5,1)
AGE MONTH(5,1)
ANIMAL SPECIES(5,1)
ANTI PESTIVIRUS ANTIBODY(5,1)
BEEF CATTLE INDUSTRY(5,1)
BIOLOGICAL ACTIVITY(5,1)
BORDER DISEASE VIRUS(5,1)
BOVINE KIDNEY(5,1)
BVDV 1B IMMUNOGENIC(5,1)
CLINICAL SIGN INCLUDED DIARRHEA(5,1)
COLLECTION DAY(5,1)
COMMERCIAL LIVESTOCK TREATMENT(5,1)
COMPOSITION FORMULATION(5,1)
DAILY PROPORTION(5,1)
DEPOSIT DATE(5,1)
DEPOSITED CULTURE(5,1)
ELABORATE TESTING(5,1)
ENZYME LINKED IMMUNOASSAY(5,1)
ESTIMATED ANNUAL LOSS(5,1)
EXCIPIENT(5,1)
HEALTHY FOUR VACCINATION(5,1)
HEAT KILLED VIRUS VACCINE(5,1)
IMMUNOGENIC AGENT(5,1)
INDICATOR VIRUS(5,1)
INFECTION COMPLETE INHIBITION(5,1)
INITIAL VACCINATION DAY(5,1)
MANAGEMENT PRACTICE(5,1)
MEDICAMENT PREPARATION(5,1)
MGB PROBE(5,1)
MICROSOFT WINDOW(5,1)
MODIFIED LIVE VIRAL PARTICLE(5,1)
MS DILUTION(5,1)
NAPHTHALENE DISULFONIC ACID(5,1)
NAPHTHALENESULFONIC ACID(5,1)
OCULAR DISCHARGE(5,1)
ORF CODE(5,1)
OXALIC ACID(5,1)
PASSAGE BVDV(5,1)
PATENT DISCLOSING GRANTING(5,1)
PI CALF(5,1)
POLYGALACTURONIC ACID(5,1)
PRESELECTED DOSE(5,1)
PRODUCT MATCHED PLACEBO VACCINE(5,1)
PURIFIED SUBUNIT(5,1)
RANDOMLY DRAWN EAR(5,1)
RAPID RESPIRATION(5,1)
RECENT REQUEST(5,1)
RELEVANT ANIMAL(5,1)
SAMPLE ALIQUOT(5,1)
SAMPLE FINISHING(5,1)
SEROLOGICAL ANALYSIS(5,1)
SPECIAL OUTLINE MODIFICATION(5,1)
SPSS VERSION(5,1)
STERILE DILUENT(5,1)
STERILE SALINE(5,1)
SUBCUTANEOUS DELIVERY(5,1)
SUBJECT CULTURE PUBLIC(5,1)
SUSCEPTIBLE MAMMAL(5,1)
THERAPEUTIC DRUG(5,1)
THERAPEUTIC IMMUNE RESPONSE(5,1)
TISSUE CULTURE CELL(5,1)
VETERINARY ACCEPTABLE MEDICAMENT MANUFACTURE(5,1)
VIRAL VECTOR(5,1)
VIRUS DETECTION(5,1)
APHIS(4,4)
DEPRESSION(4,4)
PROPORTIONING CONTROL(4,4)
MCS(4,3)
MICROBIAL SPECIFIC IMMUNOGEN(4,3)
ANTIBODY PRODUCTION(4,2)
BLACKLEG(4,2)
CHUTE(4,2)
COCCIDIOSTAT(4,2)
CRYOVIAL(4,2)
CYTOPATHOLOGICAL EFFECT(4,2)
EFFICACY SERIAL PASSAGE(4,2)
FINAL PRODUCT FABRICATION(4,2)
HARVESTER(4,2)
IMMUNIZATION(4,2)
MANIPULATION(4,2)
MAXIMUM INCUBATION(4,2)
MONOLAYER(4,2)
MYCOPLASMOSIS(4,2)
MYCOSTATIN(4,2)
NARIS(4,2)
OBSERVER GIVEN KNOWLEDGE(4,2)
PASTEURELLOSIS(4,2)
PORCINE(4,2)
PRIMARY CRITERIA(4,2)
PRODUCT DOSE(4,2)
PRODUCTION CELL(4,2)
PRODUCTION VESSEL(4,2)
PROLIFERATION(4,2)
PYREXIA(4,2)
REHYDRATE(4,2)
RESPIRATORY SYNCYTIAL VIRUS VACCINE(4,2)
SERIAL ASSEMBLY(4,2)
STABILIZER(4,2)
STERILE WATER(4,2)
STERILITY(4,2)
SUCROSE SOLUTION(4,2)
SUPERNATANT(4,2)
VIRUS PRODUCTION(4,2)
1B MSV(4,1)
ANIMAL RESISTANCE(4,1)
ANNUAL BASIS(4,1)
ANNUAL RE(4,1)
ANTI BVDV IMMUNE RESPONSE(4,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(4,1)
ANTIGENIC RESPONSE(4,1)
ANTIMICROBIAL RESISTANCE(4,1)
APPETITE LOSS(4,1)
AQUEOUS BUFFER(4,1)
BACTERIAL PATHOGEN TREATMENT(4,1)
BROAD PROTECTION(4,1)
BRSV COMPONENT(4,1)
BVDV 1B MASTER(4,1)
BVDV 1B VIRUS(4,1)
BVDV COMPONENT(4,1)
BVDV ISOLATION(4,1)
CALF REMAINS(4,1)
CAUSE ACUTE INFECTION(4,1)
CEFTIOFUR CRYSTALLINE FREE(4,1)
CONTEMPORARY TEXT(4,1)
CULTURE MEDIA SUBSTITUTING(4,1)
CULTURED POSITIVE(4,1)
DAY OBSERVATION(4,1)
DAY VIRUS(4,1)
DELIVERY VEHICLE(4,1)
DIBENZYLETHYLENEDIAMINE(4,1)
DISEASE AGENT(4,1)
DISEASE TREATMENT(4,1)
ECONOMICALLY IMPORTANT DISEASE(4,1)
FISH OIL(4,1)
FORWARD PRIMER(4,1)
GENETIC DIFFERENCE(4,1)
GOVERNMENTAL ACTION(4,1)
HARVEST FLUID SAMPLE(4,1)
HTL RESPONSE(4,1)
HUSBANDRY(4,1)
IMMUNOGENICITY(4,1)
IMMUNOLOGICAL FEATURE(4,1)
ISOLATED PEN(4,1)
ISOTONIC AGENT(4,1)
MINIMUM ACCEPTABLE HARVEST(4,1)
MINIMUM BVDV1B TCID(4,1)
MOLECULAR ENTITY(4,1)
MS WINDOW(4,1)
MULTIFACTORIAL CONDITION(4,1)
NAPHTHOIC ACID(4,1)
NASAL SECRETION SAMPLE(4,1)
ORGANIC CATION(4,1)
PARENT COMPOUND(4,1)
PASTEURELLA HAEMOLYTICA(4,1)
PATENT DEPOSITORY PERMANENT COLLECTION(4,1)
PATENT LAW CONVENTION(4,1)
PATHOGENIC AGENT(4,1)
PEANUT OIL(4,1)
PESTIVIRUS GROUP(4,1)
PHARMACEUTICAL FORMULATION COMPONENT(4,1)
POLYVALENT METAL CATION(4,1)
PRIMARY CAUSATIVE AGENT(4,1)
PROBE DETECTION(4,1)
PRODUCTION OUTLINE(4,1)
PROPHYLACTICALLY ACTIVE VACCINE(4,1)
PROTEIN SITE(4,1)
RAPID BREATHING(4,1)
REPEATED ADMINISTRATION(4,1)
REVERSE PRIMER(4,1)
RISK FACTOR(4,1)
SECONDARY BACTERIAL INFECTION(4,1)
SECONDARY CRITERIA(4,1)
SERUM ANTIBODY LEVEL(4,1)
SHIPPING FEVER PREVENTATIVE TREATMENT(4,1)
SUB SERIAL VACCINE(4,1)
SUCCESSIVE DOSE(4,1)
TANNIC ACID(4,1)
TERM EPITOPE(4,1)
TEST ANIMAL(4,1)
THERAPEUTIC COMPOUND(4,1)
TREATMENT REGIMEN(4,1)
UNDESIRED TOXICOLOGICAL EFFECT(4,1)
UNTOWARD REACTION(4,1)
VARIABLE OUTCOME(4,1)
VEHICLE(4,1)
VET RE(4,1)
(US20130280294)
ANIMAL(100,40)
BOVINE VIRAL DIARRHEA VIRUS(100,20)
DISEASE(100,13)
SHIPPING FEVER(100,8)
IMMUNOGENIC(100,6)
PESTIVIRUS(100,4)
1B VACCINE(100,1)
DISEASE SYMPTOM(100,1)
IBR PRESUMPTIVE DIAGNOSIS(100,1)
PESTIVIRUS INFECTION(100,1)
CALF PERSISTENT INFECTION(83,1)
1B VIRUS(70,4)
FETUS MALFORMATION(70,1)
PROPHYLACTIC PHARMACEUTICAL AGENT(69,1)
THERAPEUTIC ADMINISTRATION(61,1)
HEMORRHAGIC SYNDROME(58,1)
BILLION DOLLAR(57,1)
INFECTION GIVING(57,1)
PATHOLOGIC FINDING(56,1)
VIRAL RESERVOIR(51,1)
VETERINARY ACCEPTABLE CARRIER(49,2)
PI CATTLE(48,1)
GASTROINTESTINAL DISEASE(47,1)
YOUNG CATTLE(47,1)
ESTIMATED ANNUAL LOSS(45,1)
ADJUVANT(42,6)
BOVINE RHINOTRACHEITIS VIRUS DIARRHEA(41,7)
BOVINE PARAMYXOVIRUS(41,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(40,1)
HISTOPHILUS SOMNI(38,2)
BOVINE ROTAVIRUS(38,1)
DEVELOPMENT EFFORT(36,1)
ECONOMICALLY IMPORTANT DISEASE(36,1)
BOVINE VIRAL DIARRHEA(34,2)
LIVE IBRV(32,1)
INFECTION(31,14)
LIVE BHV(31,1)
CAUSE ACUTE INFECTION(30,1)
PREVENTABLE FRACTION(29,20)
BOVINE HERPES VIRUS(27,3)
SERUM NEUTRALIZING ANTIBODY TITER(26,4)
LIVE PERSISTENTLY INFECTED(26,1)
OUTBREAK(26,1)
SYMPTOM(25,10)
ABORTION(25,1)
CONFIDENCE(25,1)
FEEDLOT(25,1)
PREGNANCY(25,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(24,10)
CO ADMINISTRATION(24,1)
CATTLE(23,5)
DEATH MAJOR CAUSE(23,1)
ROSNER(23,1)
COASTAL BERMUDA HAY(22,3)
BVDV(21,54)
MYCOPLASMA BOVIS(21,1)
PARAINFLUENZA(21,1)
PASTEURELLA MULTOCIDA(20,2)
PNEUMONIA(20,2)
ACTINOBACILLUS(20,1)
BOVINE CORONAVIRUS(20,1)
CAMPYLOBACTER(20,1)
ERYSIPELOTHRIX(20,1)
MICROBIAL PATHOGEN SPECIFIC ANTIGEN(20,1)
IBR CLINICAL SIGN(19,4)
SAS LEARNING EDITION(19,4)
PEN DEAD CALF LUNG(19,3)
DIARRHEA(19,2)
BRACHYSPIRA(19,1)
MYCOBACTERIUM(19,1)
STREPTOCOCCUS(19,1)
MICROORGANISM(18,4)
HEXAVALENT MLV VACCINE AID(18,2)
RESPIRATORY SYNCYTIAL VACCINE(18,2)
BORDETELLA(18,1)
CLOSTRIDIUM(18,1)
EHRLICHIA(18,1)
LEPTOSPIRA(18,1)
MORAXELLA(18,1)
NASAL SWAB(17,6)
VIRUS ISOLATION DATA(17,4)
BOVINE RESPIRATORY DISEASE COMPLEX(17,3)
BVDV1B FRACTION EFFICACY(17,3)
BVDV INFECTION SIGN(17,2)
ESCHERICHIA(17,1)
LISTERIA(17,1)
SALMONELLA(17,1)
POST CHALLENGE VIREMIA(16,3)
ACTINOMYCES(16,2)
CLINICAL DISEASE SIGN(15,4)
RESPIRATORY DISEASE CLINICAL SIGN(15,4)
VACCINATED CALF(15,4)
COMMERCIAL STOCKER FEEDER CALF(15,3)
MANNHEIMIA HAEMOLYTICA TYPE(15,2)
NASAL LESION SEVERITY(15,2)
IBR GROSS NASAL LESION(15,1)
INTESTINAL MUCOSA ULCERATION(15,1)
ORDINALLY SCALED TITER DATA(15,1)
FEVER(14,3)
BVDV DEFINITIVE CLINICAL SIGN(14,1)
BVDV SERONEGATIVE CALF(14,1)
VIRAL SPECIFIC ANTIGEN(14,1)
BOVINE VIRAL DIARRHEA VIRUS TYPE(13,7)
MITIGATED FRACTION(13,5)
EDTA VACUTAINER TUBE(13,4)
MATCHED RANDOMIZATION(13,3)
NONSTRUCTURAL PROTEIN(13,3)
SORTING ALLY(13,3)
BBL CULTURE SWAB(13,2)
BRSV CLINICAL SIGN(13,2)
BRSV FRACTION EFFICACY(13,2)
BVDV CLINICAL SIGN(13,2)
BVDV1B INDUCED VIREMIA(13,2)
CHALLENGE VIRUS DILUTION(13,2)
VIRUS FROZEN ALIQUOT(13,2)
CALF SHEDDING BVDV(13,1)
COLOSTRUM DEPRIVED DAIRY CALF(13,1)
HEXAVALENT BRDC EFFECTIVENESS(13,1)
PREGNANT CATTLE PLACENTA(13,1)
TVL BVDV1B MS DEPOSIT(13,1)
CULTURE VESSEL(12,6)
DAY POST CHALLENGE(12,4)
CLINICAL SIGN OBSERVATION(12,2)
SEROLOGICALLY NEGATIVE CALF(12,2)
TVL BK CELL INOCULATION(12,2)
VACCINATION STATUS KNOWLEDGE(12,2)
VIRULENCE CONSISTENCY(12,2)
BRSV INFECTION CLINICAL SIGN(12,1)
POST VACCINATION SERUM NEUTRALIZATION(12,1)
PRE VACCINATION SERUM NEUTRALIZATION(12,1)
TANNER(11,12)
DISEASE PREVENTION(11,3)
HORSE SERUM(11,3)
IDENTITY KNOWLEDGE(11,3)
LEUKOPENIA DURATION(11,3)
OLFACTORY ORGAN LESION(11,3)
RECORD KEEPER(11,3)
SEROLOGICAL EVALUATION(11,3)
STUDY INITIATION(11,3)
ILLNESS SYMPTOM(11,2)
RT PCR(10,6)
CRYOPRESERVATION MEDIUM(10,4)
STERILE FILTRATION(10,4)
BVDV 1B ANTIBODY TITER(10,2)
CONFLUENT TVL BK CELL(10,2)
FROZEN PRODUCTION VIRUS INOCULUM(10,2)
HARVESTED VIRAL FLUID BATCH(10,2)
IMMUNOGENIC POLYPEPTIDE(10,2)
INFECTION SEVERITY(10,2)
STERILE ULTRAFILTRATION(10,2)
VIRAL INFECTION CLINICAL SIGN(10,2)
BRSV FRACTION ANTIGENICITY(10,1)
BVDV1B INDUCED LEUKOPENIA(10,1)
INACTIVATED VIRUS VACCINE(10,1)
NASAL SHEDDING PREVENTION(10,1)
ORDINALLY SCALED TITER COMPARISON(10,1)
VACCINE BRSV FRACTION(10,1)
VACCINE BVDV1B FRACTION(10,1)
VETERINARY BIOLOGICS LABORATORY(10,1)
VETERINARY PRACTITIONER CARE(10,1)
SUSCEPTIBILITY(9,8)
CONSTANT VIRUS DECREASING SERUM(9,5)
HOST ANIMAL(9,5)
CALF SEQUENCE(9,3)
CHALLENGE DOSE(9,3)
DATA COLLECTION(9,3)
DIFFERENTIATING FEATURE(9,3)
PRECHALLENGE CLINICAL OBSERVATION(9,3)
VISIBLE NASAL MUCOSA(9,3)
ADVERSE POST VACCINATION REACTION(9,2)
BLINDED PERSONNEL(9,2)
BVDV1B ISOLATION(9,2)
DAY POST VACCINATION(9,2)
INFECTIOUS DISEASE(9,2)
INOCULATED CULTURE(9,2)
LEUKOPENIA DEVELOPMENT(9,2)
MS GENETIC STABILITY(9,2)
PROBE PRIMER SPECIFICITY(9,2)
QPCR ASSAY(9,2)
TGAC STRAIN(9,2)
VIRAL CHALLENGE(9,2)
VIRUS CHALLENGE(9,2)
VIRUS INOCULUM VOLUME(9,2)
VIRUS PARTICLE(9,2)
BRSV HARVEST BATCH(9,1)
BUDAPEST TREATY PROVISION(9,1)
BVDV 1B CYTOPATHIC MORPHOLOGY(9,1)
BVDV1B CLINICAL SIGN(9,1)
CLINICAL DISEASE ETIOLOGY(9,1)
DOSE VACCINE ADMINISTRATION(9,1)
EARLY RECOGNIZABLE CLINICAL SIGN(9,1)
INFECTED TISSUE NECROSIS(9,1)
INFECTIOUS BOVINE RHINOTRACHEITIS REDUCTION(9,1)
LIVE ATTENUATED VIRUS VACCINE(9,1)
PERSISTENTLY INFECTED ANIMAL(9,1)
PSEUDOMEMBRANOUS EXUDATE(9,1)
STUDY SHED BRSV(9,1)
STUDY SHED BVDV1B(9,1)
TEXAS VET LAB(9,1)
GROWTH MEDIUM(8,6)
MEDIAN DIFFERENCE(8,4)
OLFACTORY ORGAN SAMPLE(8,4)
PREVENTED FRACTION(8,4)
ROLLER BOTTLE(8,4)
BVDV NEGATIVE CALF(8,2)
TARGET IMMUNOGEN(8,2)
ANTIGENIC EPITOPE(8,1)
BASELINE WBC COUNT(8,1)
BHV ANTIGENICITY(8,1)
BRSV CHALLENGE EXPOSURE(8,1)
BRSV VIRUS FRACTION(8,1)
BRSV VISUAL OBSERVATION(8,1)
BVDV 1B MONOVALENT VACCINE(8,1)
BVDV 1B VIREMIA(8,1)
BVDV DIFFERENTIATION(8,1)
BVDV OUTBREAK(8,1)
BVDV SUBGENOTYPE(8,1)
CALF NARIS(8,1)
FIBRINOUS PNEUMONIA(8,1)
FIBRONECROTIC EXUDATE(8,1)
HAEMOPHILUS SOMNUS(8,1)
IMMUNOGLOBULIN MOLECULE FRAGMENT(8,1)
IMMUNOHISTOCHEMICAL ASSAY(8,1)
LEUKOPENIA DATA ANALYSIS(8,1)
MS VIRUS IDENTITY(8,1)
NATIONAL VETERINARY SERVICE LABORATORY(8,1)
OBSERVER DISCRETION(8,1)
PESTIVIRUS GENUS(8,1)
PFIZER ANIMAL HEALTH(8,1)
POST CHALLENGE SHEDDING(8,1)
PRE VACCINATION BVDV(8,1)
PREVENTED BRSV SHEDDING(8,1)
RAW LEUKOCYTE DATA(8,1)
RECOVERED VIRUS ADMINISTRATION(8,1)
SUCCESSFUL BACKPASSAGE STUDY(8,1)
VACCINATED ANIMAL TISSUE(8,1)
VACCINE SUBSERIAL(8,1)
WBC COUNT DATA(8,1)
STATISTICAL ANALYSIS(7,12)
LIQUID STUART MEDIUM(7,5)
PRODUCT DOSE(7,5)
RESPIRATORY SYNCYTIAL VIRUS VACCINE(7,5)
ANTIBODY TITER GROUP COMPARISON(7,3)
TERM ANTIBODY(7,3)
AGE MONTH(7,2)
ANTIGEN INTRODUCTION(7,2)
BLOOD SAMPLE BUFFY COAT(7,2)
BVDV DETECTION(7,2)
COMMERCIAL CATTLE(7,2)
CULTURE FLASK(7,2)
DURATION DATA(7,2)
HUMORAL IMMUNE RESPONSE(7,2)
MASTER SEED(7,2)
MICROSOFT WINDOW(7,2)
PRODUCTION VIRUS BATCH(7,2)
PROPORTION DATA(7,2)
SECONDARY OUTCOME(7,2)
SHED VIRUS(7,2)
STERILE DILUENT(7,2)
TRYPSIN EDTA SOLUTION(7,2)
VIRUS PROPAGATION(7,2)
VIRUS SUSPENSION(7,2)
ANTIGENIC POLYPEPTIDE(7,1)
BHV CHALLENGE(7,1)
BOVID LUNG(7,1)
BRDC VACCINE(7,1)
BRSV DELETED PLACEBO(7,1)
BUDAPEST TREATY TERM(7,1)
BVBV 1B VACCINE DOSE(7,1)
BVDV 1B VACCINE DOSE(7,1)
BVDV FORMULATION(7,1)
BVDV SPECIES(7,1)
BVDV1B INFECTION(7,1)
BVDV1B SHEDDING(7,1)
CANDIDATE STATUS MODIFICATION(7,1)
CHALLENGE VIRUS EXPOSURE(7,1)
COMMERCIAL VACCINE FORMULATION(7,1)
CVB BIOMETRICS RANDOMIZATION TABLE(7,1)
CYTOPATHIC VARIANT(7,1)
DEVELOPED BVDV1B TITER(7,1)
DIFFERENTIAL WBC COUNT(7,1)
ENVELOPE GLYCOPROTEIN(7,1)
FLAVIVIRIDAE FAMILY(7,1)
FRANKLIN LAKE(7,1)
HELPER STIMULATION(7,1)
HEXAVALENT VACCINE COMPONENT(7,1)
HOMOGENEOUS POPULATION(7,1)
IBR PREVENTION(7,1)
IMMUNOFLUORESCENCE ASSAY(7,1)
INFECTIOUS AGENT IDENTITY(7,1)
MASTER GENETIC STABILITY(7,1)
MICROORGANISM DEPOSIT(7,1)
MODIFIED LIVE VIRUS VACCINE(7,1)
NASAL LESION ABSENCE(7,1)
NASAL SECRETION ALIQUOT(7,1)
NON HUMAN PRIMATE(7,1)
ORDINAL CATEGORY(7,1)
PELLETED FEED RATION(7,1)
PHYLOGENETIC ANALYSIS(7,1)
POST CHALLENGE OBSERVATION(7,1)
PROPHYLACTIC ADMINISTRATION(7,1)
QPCR METHODOLOGY(7,1)
SEPTICEMIC SYNDROME(7,1)
SHIPPING FEVER PATHOGENESIS(7,1)
STOCKER FEEDER CALF ENVIRONMENT(7,1)
TVL BVDV 1B MS(7,1)
UNIQUELY BVDV1B SEQUENCE(7,1)
UNIVERSITY BLVD(7,1)
VACCINATION REGIMEN(7,1)
VACCINE EFFICACY ADJUSTED ESTIMATE(7,1)
VACCINE ESTIMATE(7,1)
VIRAL PATHOGEN(7,1)
VIREMIA DATA(7,1)
VIRULENT BVDV(7,1)
VIRUS AMPOULE(7,1)
VIRUS GENETIC STABILITY(7,1)
VIRUS POPULATION(7,1)
VIRUS REPLICATION(7,1)
YEARLY INOCULATION(7,1)
ZOOLOGICAL SPECIMEN(7,1)
CO2(6,9)
HARVESTER(6,6)
ANTIBIOTIC(6,4)
CALF GROUP(6,4)
REPEATED MEASURE(6,4)
SUPERNATANT(6,4)
PLACEBO VACCINATED CONTROL PROPORTION(6,3)
ACTIVE INGREDIENT(6,2)
AFFECTED ANIMAL(6,2)
DAILY LEUKOCYTE COUNT RATIO(6,2)
DISPERSED CELL(6,2)
FINAL SUCROSE CONCENTRATION(6,2)
MINIMUM INCUBATION(6,2)
MIXED BREED HEIFER(6,2)
MS WINDOW(6,2)
PRECHALLENGE LEUKOCYTE(6,2)
SUCROSE SOLUTION FILTRATION(6,2)
TEST ANIMAL(6,2)
VARIABLE OUTCOME(6,2)
WORKING VIRUS(6,2)
ACTIVELY PROPAGATING CULTURE(6,1)
ACUTE PNEUMONIA(6,1)
ADVERSE EXTERNAL INFLUENCE PREDISPOSING(6,1)
AGRICULTURE UNITED STATES DEPARTMENT(6,1)
AIRWAY ACUTE INFLAMMATION(6,1)
ANTIBODY NEUTRALIZATION(6,1)
ATYPICAL CPE(6,1)
BHV ISOLATION(6,1)
BRSV ISOLATION FREQUENCY(6,1)
BRSV SERVING DETECTION(6,1)
BRSV STRAIN(6,1)
BRSV TITER(6,1)
BUFFY COAT SAMPLE(6,1)
BVD VIRUS(6,1)
BVDV INFECTED ANIMAL DETECTION(6,1)
BVDV STRAIN(6,1)
BVDV TITER(6,1)
CALF HEALTH(6,1)
CALF REMAINDER(6,1)
CAPSID PROTEIN(6,1)
CLINICAL ASSESSMENT(6,1)
CONFIDENCE INTERVAL(6,1)
CONTAMINATION EVIDENCE(6,1)
CULTURE PROPAGATION(6,1)
CYTOTOXIC ACTIVATION(6,1)
DECREASED CLINICAL SIGN(6,1)
DEPOSIT AVAILABILITY(6,1)
DISEASE SEVERITY(6,1)
DOSE ADMINISTRATION(6,1)
DROOPING EAR(6,1)
DUBELCOS MODIFIED EAGLE(6,1)
FATAL MUCOSAL DISEASE(6,1)
FREEZE DRYER(6,1)
FROZEN TVL BK CELL(6,1)
GENERALIZED MUCOSAL DISEASE(6,1)
HARVEST FLUID PURITY(6,1)
HAY AVAILABILITY(6,1)
HEALTH INSPECTION SERVICE(6,1)
IMMUNOGENIC PEPTIDE(6,1)
IMMUNOGENIC SUBSTANCE(6,1)
INCREASED BRSV ANTIBODY TITER(6,1)
INCREASED BVDV1B ANTIBODY TITER(6,1)
INFECTED ANIMAL ABILITY(6,1)
INFECTED CATTLE(6,1)
INFECTION ELIMINATION(6,1)
LEUKOPENIA DETECTION(6,1)
MACROSCOPIC GROWTH ABSENCE(6,1)
MINIMUM INOCULUM TITER(6,1)
NASAL SECRETION SPECIMEN(6,1)
NATURAL EXPOSURE CLINICAL EVIDENCE(6,1)
NEUTRALIZATION ASSAY(6,1)
PAST THIRTY YEAR(6,1)
POKY FEEDER(6,1)
POOLED NASAL SECRETION(6,1)
POST CHALLENGE COUNT(6,1)
PRONOUNCED FEVER(6,1)
RECOGNIZABLE CYTOPATHOLOGICAL CHANGE(6,1)
RECOMBINANT VECTOR(6,1)
SAS INSTITUTE(6,1)
SDFV FRAGMENT(6,1)
STUDY PRIMARY OUTCOME(6,1)
SUSCEPTIBLE ANIMAL TISSUE(6,1)
SUSCEPTIBLE CELL TISSUE CULTURE(6,1)
TERM IMMUNOGENIC PROTEIN(6,1)
TVL BRSV PO(6,1)
VACCINE COMPOSITION ADMINISTRATION(6,1)
VACCINE EFFECTIVENESS(6,1)
VERTEBRATE ANIMAL(6,1)
VIRAL PROTEASE(6,1)
VIRAL RESPIRATORY INFECTION(6,1)
VIRAL TITER(6,1)
VIREMIA DURATION(6,1)
VIRUS MAJOR RESERVOIR(6,1)
WIDESPREAD AVAILABILITY(6,1)
EXPRESS REFERENCE(5,8)
DAILY RECTAL TEMPERATURE(5,5)
BLACKLEG(5,3)
BUCKET(5,3)
CHUTE(5,3)
COCCIDIOSTAT(5,3)
CONTAINER END(5,3)
INSPIRATION(5,3)
MYCOPLASMOSIS(5,3)
OBSERVER GIVEN KNOWLEDGE(5,3)
PASTEURELLOSIS(5,3)
PLACEBO CONTROL VACCINE(5,3)
REHYDRATE(5,3)
SAMPLED FRAME(5,3)
MAXIMUM SHEDDING(5,2)
ANIMAL SPECIES(5,1)
BEEF CATTLE INDUSTRY(5,1)
BIOLOGICAL ACTIVITY(5,1)
BORDER DISEASE VIRUS(5,1)
BOVINE KIDNEY(5,1)
BRSV ABSENCE(5,1)
BRSV DETECTION(5,1)
BRSV SPECIFIC CPE OBSERVATION(5,1)
BVDV 1B EFFICACY(5,1)
BVDV 1B SHEDDING(5,1)
CLINICAL SIGN INCLUDED DIARRHEA(5,1)
DAILY PROPORTION(5,1)
DEPOSIT DATE(5,1)
DEPOSITED CULTURE(5,1)
ELABORATE TESTING(5,1)
ENZYME LINKED IMMUNOASSAY(5,1)
HEALTHY FOUR VACCINATION(5,1)
HEAT KILLED VIRUS VACCINE(5,1)
HOUSE STUDY(5,1)
IMMUNOGENIC AGENT(5,1)
INDICATOR VIRUS(5,1)
INFECTION COMPLETE INHIBITION(5,1)
LACRIMAL DISCHARGE(5,1)
MAMMALIAN HOST(5,1)
MAMMALIAN SPECIES(5,1)
MANAGEMENT PRACTICE(5,1)
MILD DEPRESSION(5,1)
MODIFIED LIVE VACCINE(5,1)
MS DILUTION(5,1)
NAPHTHALENE DISULFONIC ACID(5,1)
NAPHTHALENESULFONIC ACID(5,1)
NASAL PASSAGE EDEMA(5,1)
OCULAR DISCHARGE(5,1)
ORF CODE(5,1)
OXALIC ACID(5,1)
PASSAGE BVDV(5,1)
PATENT DISCLOSING GRANTING(5,1)
POLYGALACTURONIC ACID(5,1)
PRODUCT MATCHED PLACEBO VACCINE(5,1)
PROTOCOL GENOTYPING BOVINE VIRAL DIARRHEA VIRUS(5,1)
PURIFIED SUBUNIT(5,1)
RANDOMLY DRAWN EAR(5,1)
RAPID RESPIRATION(5,1)
RECENT REQUEST(5,1)
RELEVANT ANIMAL(5,1)
SAMPLE ALIQUOT(5,1)
SAMPLE FINISHING(5,1)
SCOTT CITY(5,1)
SECONDARY CRITERION(5,1)
SEROLOGICAL ANALYSIS(5,1)
SHEDDING ANALYSIS(5,1)
SPECIAL OUTLINE MODIFICATION(5,1)
SPSS VERSION(5,1)
STERILE SALINE(5,1)
STUDY DURATION(5,1)
SUBJECT CULTURE PUBLIC(5,1)
THERAPEUTIC IMMUNE RESPONSE(5,1)
TISSUE CULTURE CELL(5,1)
VIRAL FRACTION(5,1)
VIRAL VECTOR(5,1)
VIRUS DETECTION(5,1)
APHIS(4,5)
HARVEST MATERIAL(4,5)
PRECHALLENGE AVERAGE TEMPERATURE(4,5)
PROPORTIONING CONTROL(4,5)
ANOVA(4,4)
EFFECT MITIGATION(4,4)
EXPERIMENTAL UNIT(4,4)
LABORATORY PERSONNEL(4,4)
MCS(4,3)
ALLEY(4,2)
ANOREXIA(4,2)
ANTIBODY PRODUCTION(4,2)
BRSV PRESENCE ABSENCE(4,2)
CLEAR NASAL DISCHARGE(4,2)
CRYOVIAL(4,2)
CYTOPATHOLOGICAL EFFECT(4,2)
DAILY TEMPERATURE(4,2)
EFFICACY SERIAL PASSAGE(4,2)
FINAL PRODUCT FABRICATION(4,2)
IMMUNIZATION(4,2)
LYMPHOCYTE(4,2)
MANIPULATION(4,2)
MAXIMUM INCUBATION(4,2)
MONOLAYER(4,2)
MYCOSTATIN(4,2)
NEOMYCIN(4,2)
NYSTATIN(4,2)
PORCINE(4,2)
PRIMARY CRITERIA(4,2)
PRODUCTION CELL(4,2)
PRODUCTION CULTURE(4,2)
PRODUCTION VESSEL(4,2)
PROLIFERATION(4,2)
SAMPLE COLLECTION(4,2)
SERIAL ASSEMBLY(4,2)
STERILITY(4,2)
VIRUS PROD(...)";Pharmaceuticals;Open
2010-09-27;"UA60430             U  2011-06-25 [UA--60430U]
STG: (U) Declarative / pat. spec. for utility model
AP : 2010UA-U011489 2010-09-27";66191387;UA60430             U  2011-06-25 [UA--60430U];2010UA-U011489;;INSTITUTE EXPRM & CLINICAL VETERINA;INSTITUTE EXPRM & CLINICAL VETERINA;;;1;"KUCHERIAVENKO ROMAN OLEKSIIOVYCH
KUCHERIAVENKO VIKTORIIA VIKTORIVNA
DROZHZHIE ZHANNA MYKOLAIVNA
KUCHERIAVENKO LIUDMYLA ILLIVNA
TRYZNA LARYSA PETRIVNA";;;"(UA--60430U)
Strain of bovinae herpesvirus-1 ""bhv-1/bull-canada/kiyv/2007"" for production of vaccines and diagnostic preparations against infectious rhinotracheitis of bovine animals";"(UA--60430U)
A strain of bovinae herpesvirus-1 ""BHV-1/bull-Canada/Kiyv/2007"" for production of vaccines and diagnostic preparations against infectious rhinotracheitis of bovine animals, stored in collection of strains of microorganisms of laboratory of virology of the National scientific centre “Institute of experimental and clinical veterinary medicine” of the National Academy of agrarian sciences of Ukraine under the number of 60: family Herpesviridae, genius Varicellavirus, species Bovinae herpesvirus-1.";;;;"A61K-039/265
C12N-007/00";;;Pharmaceuticals;Open
"2010-09-21
2011-09-21";"CA2811243           A1 2012-03-29 [CA2811243]
STG: (A1) Application laid open
AP : 2011CA-2811243 2011-09-21
WO2012038454        A1 2012-03-29 [WO201238454]
STG: (A1) Published application with search report
AP : 2011WO-EP66377 2011-09-21
AU2011306957        A1 2013-04-11 [AU2011306957]
STG: (A1) Open to public inspection
AP : 2011AU-0306957 2011-09-21
MX2013003245        A  2013-05-22 [MX2013003245]
STG: (A) Patent application
AP : 2013MX-PA03245 2011-09-21
EP2618841           A1 2013-07-31 [EP2618841]
STG: (A1) Application published with search report
AP : 2011EP-0760764 2011-09-21
US20130195892       A1 2013-08-01 [US20130195892]
STG: (A1) Application published
AP : 2011US-13825050 2011-09-21
CN103338785         A  2013-10-02 [CN103338785]
STG: (A) Published application
AP : 2011CN-80055945 2011-09-21
BR112013006515      A1 2013-12-31 [BR112013006515]
STG: (A1) Published application
AP : 2013BR-0006515 2011-09-21
ZA201301950         B  2014-03-26 [ZA201301950]
STG: (B)
AP : 2013ZA-0001950 2013-03-14
AU2011306957        B2 2014-07-24 [AU2011306957]
STG: (B2) Patent proceeded by OPI
AP : 2011AU-0306957 2011-09-21
AU2011306957        C1 2014-08-28 [AU2011306957]
STG: (C1) Amended after Acceptance/Grant of a standard patent
AP : 2011AU-0306957 2011-09-21
RU2013118351        A  2014-10-27 [RU2013118351]
STG: (A) Application for invention
AP : 2013RU-0118351 2011-09-21
IN2395/DELNP/2013   A  2014-10-31 [IN2013DN02395]
STG: (A) Application laid open
AP : 2013IN-DN02395 2013-03-18
CN103338785         B  2015-01-14 [CN103338785B]
STG: (B) Granted patent for invention
AP : 2011CN-80055945 2011-09-21
RU2578943           C2 2016-03-27 [RU2578943]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2013RU-0118351 2011-09-21
BR112013006515      A2 2016-08-02 [BR112013006515]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2013BR-0006515 2011-09-21
EP2618841           B1 2016-10-19 [EP2618841]
STG: (B1) Patent specification
AP : 2011EP-0760764 2011-09-21
ES2606605           T3 2017-03-24 [ES2606605]
STG: (T3) Translation of granted European patent (former B3)
AP : 2011ES-0760764T 2011-09-21
MX347911            B  2017-05-17 [MX-347911]
STG: (B) Granted patent/ granted utility model
AP : 2013MX-PA03245 2011-09-21
US9878030           B2 2018-01-30 [US9878030]
STG: (B2) Granted patent as second publication
AP : 2011US-13825050 2011-09-21
FD :  Provisional Appl: US61/385,010 FDD=2010-09-21 [2010US-61385010]
FD : Previous publication: US20130195892 A1 2013-08-01 [US20130195892]
CA2811243           C  2019-03-05 [CA2811243]
STG: (C) Patent (second level)
AP : 2011CA-2811243 2011-09-21";44639929;"CA2811243           A1 2012-03-29 [CA2811243]
WO2012038454        A1 2012-03-29 [WO201238454]
AU2011306957        A1 2013-04-11 [AU2011306957]
MX2013003245        A  2013-05-22 [MX2013003245]
EP2618841           A1 2013-07-31 [EP2618841]
US20130195892       A1 2013-08-01 [US20130195892]
CN103338785         A  2013-10-02 [CN103338785]
BR112013006515      A1 2013-12-31 [BR112013006515]
ZA201301950         B  2014-03-26 [ZA201301950]
AU2011306957        B2 2014-07-24 [AU2011306957]
AU2011306957        C1 2014-08-28 [AU2011306957]
RU2013118351        A  2014-10-27 [RU2013118351]
IN2395/DELNP/2013   A  2014-10-31 [IN2013DN02395]
CN103338785         B  2015-01-14 [CN103338785B]
RU2578943           C2 2016-03-27 [RU2578943]
BR112013006515      A2 2016-08-02 [BR112013006515]
EP2618841           B1 2016-10-19 [EP2618841]
ES2606605           T3 2017-03-24 [ES2606605]
MX347911            B  2017-05-17 [MX-347911]
US9878030           B2 2018-01-30 [US9878030]
CA2811243           C  2019-03-05 [CA2811243]";"2010EP-0177931
2010US-61385010
2011EP-0760764
2011US-13825050
2011WO-EP66377";"(EP2618841)
WO2012038454
(US9878030)
WO2012038454
(RU2578943)
WO2012038454
(ZA201301950)
WO2012038454
(AU2011306957)
WO2012038454
(IN2013DN02395)
WO2012038454
(CN103338785B)
WO2012038454
(BR112013006515)
WO2012038454
(ES2606605)
WO2012038454
(MX-347911)
WO2012038454
(CA2811243)
WO2012038454";"INTERVET INTERNATIONAL
MEDTRONIC INTERVET";INTERVET INTERNATIONAL;"(EP2618841)
NL
(EP2618841)
NL
(US20130195892)
DE
(US9878030)
US
(WO201238454)
NL


(ES2606605)
NL
(MX-347911)
NL
(CA2811243)
NL
(CA2811243)
NL";"(EP2618841)
NAME=Intervet International B.V. Wim de Körverstraat 35 , CITY=5831 AN  Boxmeer , COUNTRY=NL 

(EP2618841)
NAME=Intervet International B.V. Wim de Körverstraat 35 , CITY=5831 AN  Boxmeer , COUNTRY=NL , REG=101190030 

(US20130195892)
NAME=Beer Martin , CITY=Greifswald-Insel Riems , COUNTRY=DE 

NAME=Reimann Ilona , CITY=Greifswald-Insel Riems , COUNTRY=DE 

NAME=Koenig Patricia , CITY=Greifswald-Insel Riems , COUNTRY=DE 

(US9878030)
NAME=Intervet Inc. , CITY=Madison , STATE=NJ , COUNTRY=US , ATYP=US Company 

(WO201238454)
NAME=INTERVET INTERNATIONAL B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer , COUNTRY=NL 

(ZA201301950)
NAME=INTERVET INTERNATIONAL BV Wim de Korverstraat 35~NL-5831 AN Boxmeer  NL 

(BR112013006515)
NAME=INTERVET INTERNATIONAL B.V. WIM DE KÖRVERSTRAAT 35, NL-5831 AN BOXMEER  NL 

(ES2606605)
NAME=INTERVET INT BV , COUNTRY=NL 

(MX-347911)
NAME=INTERVET INT BV , COUNTRY=NL 

(CA2811243)
NAME=INTERVET INTERNATIONAL B.V. Wim de Koerverstraat 35 NL-5831 , CITY=AN BOXMEER , COUNTRY=NL 

(CA2811243)
NAME=INTERVET INTERNATIONAL B.V. Wim de Koerverstraat 35 NL-5831 , CITY=AN BOXMEER , COUNTRY=NL 
";1;"BEER MARTIN
REIMANN ILONA
KOENIG PATRICIA";"(EP2618841)
DE";"(EP2618841)
NAME=BEER, Martin Suedufer 10 , CITY=17493 Greifswald-Insel Riems , COUNTRY=DE 

NAME=REIMANN, Ilona Suedufer 10 , CITY=17493 Greifswald-Insel Riems , COUNTRY=DE 

NAME=KOENIG, Patricia Suedufer 10 , CITY=17493 Greifswald-Insel Riems , COUNTRY=DE 
";"(EP2618841)
Bvdv vaccine";"(EP2618841)
The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.";"(CA2811243)
Claims
1) Bovine Viral Diarrhoea virus (BVDV) belonging to a first Type, characterised in that it is a chimeric BVDV, additionally carrying an E2 gene of a second BVDV Type.
2) Combination vaccine for the protection of susceptible ruminants against
BVDV, characterised in that the vaccine comprises a first BVDV belonging to a first
Type and carrying a BVDV E2 gene of said first Type, a second BVDV belonging to a first
Type, wherein the BVDV E2 gene belonging to said first Type is replaced by the BVDV
E2
gene belonging to a second Type, and a pharmaceutically acceptable carrier.
3) Combination vaccine according to claim 2, characterised in that, in addition, in the second BVDV the BVDV E1 gene belonging to said first Type is replaced by a
BVDV
E1 gene belonging to a second Type.
4) Combination vaccine according to claim 2 or 3, characterised in that the backbone of the first and second BVD virus belongs to Type 1 and the BVDV E2 gene of the second
BVD virus belongs to Type 2.
5) Combination vaccine according to claim 2 or 3, characterised in that the backbone of the first and second BVD virus belongs to Type 2 and the BVDV E2 gene of the second
BVD virus belongs to Type 1.
6) BVDV according to claim 1, characterised in that said BVDV is a live attenuated virus.
7) Combination vaccine according to any of claims 2-5, characterised in that said first and second BVDV are live attenuated viruses.
8) Vaccine for the protection of susceptible ruminants against BVDV, characterised in that the vaccine comprises a BVDV according to claim 1 or 6, and a pharmaceutically acceptable carrier.
9) Vaccine according to claim 8, characterised in that said BVDV comprises a deletion in the N pro gene and/or a deletion in the E rns gene.
10) Combination vaccine according to any of claims 2-5 or 7, characterised in that said first
BVDV and said second BVDV have the same backbone.
11. Combination vaccine according to claim 10, characterised in that said backbone is
BVDV Type 1.
12) Combination vaccine according to any of claims 2-5, 7, 10 or 11, characterised in that said first BVDV and/or said second BVDV comprises a deletion in the N pro gene and/or a deletion in the E rns gene.
13) Vaccine according to claim 8 or 9 or combination vaccine according to any of claims 2-
5, 7, 10, 11 or 12, characterized in that said vaccine or combination vaccine comprises an additional antigen of a virus or micro-organism pathogenic to ruminants, an antibody against said antigen or genetic information encoding an immunogenic polypeptide of said virus or micro-organism.
14) Vaccine or combination vaccine according to claim 13, characterized in that said virus or micro-organism pathogenic to ruminants is selected from the group of
Bovine Rotavirus, Bovine Herpesvirus, Parainfluenza Type 3 virus, Bovine
Paramyxovirus, Bluetongue virus, Foot and Mouth Disease virus, Pasteurella haemolytica and Bovine Respiratory Syncytial Virus.
15) Vaccine according to any of claim 8, 9, 13 or 14 or combination vaccine according to any of claims 2-5, 7 or 10-14, characterised in that it is in a freeze-dried form.
16) BVDV according to any of claims 1 or 6 for use as a medicament
17) BVDV according to any of claims 1 or 6 for use in the treatment of Bovine
Viral
Diarrhoea.
18) Method for the manufacture of a vaccine according to claim 8 or 9, characterised in that said method comprises the step of mixing a BVDV according to claim 1 or 6, and a
pharmaceutically acceptable carrier.
19) Method for the manufacture of a combination vaccine according to any of claims 2-5, 7
or 10-14, characterised in that said method comprises the step of mixing a first BVDV
belonging to a first Type and carrying a BVDV E2 gene of said first Type, a second
BVDV belonging to a first Type, wherein the BVDV E2 gene belonging to said first
Type is replaced by the BVDV E2 gene belonging to a second Type, and a pharmaceutically acceptable carrier.";"(EP2618841)
The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.
The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.
It was found however that, whereas BVDV Type 1 or 2 live attenuated vaccines when given as single vaccination provide excellent protection, a combination vaccine provides a significantly lower level of protection.
It is an objective of the present invention to provide improved BVDV vaccines, in which the disadvantages of mutual negative effects of e.g.";"(EP2618841)
Live attenuated vaccines have the advantage that they mimic a natural infection, and they have to be administered in most cases only once.
Therefore it is highly attractive, both for practical and economical reasons, to combine the combination vaccine according to the invention with an additional antigen of a virus or microorganism pathogenic to ruminants, an antibody against said antigen or genetic information encoding an immunogenic polypeptide of said virus or microorganism.
Thus, there is a need for improvement of BVDV combination vaccines.
Bovine viral diarrhea virus (BVDV), a member of the genus Pestivirus within the family Flaviviridae is the causative agent of bovine viral diarrhea, an economically important disease of cattle world-wide.
However, BVDV Type 1 and Type 2 are the common types causing disease.
The major economic losses caused by BVDV infections are due to reduced milk production, growth retardation, reduced reproductive performance, and increased occurrence of other diseases, such as Shipping Fever.";"A61K
A61K-039/00
A61K-039/12
A61K-039/295
A61K-039/40
A61K-039/42
A61P-031/12
C07K
C07K-014/005
C07K-014/18
C12N
C12N-007/00
C12N-007/04";"(EP2618841)
1. Combination vaccine for the protection of susceptible ruminants against BVDV, characterised in that the vaccine comprises a first BVDV belonging to a first Type and carrying a BVDV E2 gene of said first Type, a second BVDV belonging to a first Type, wherein the BVDV E2 gene belonging to said first Type is replaced by the BVDV E2 gene belonging to a second Type, and a pharmaceutically acceptable carrier, and wherein said first BVDV and said second BVDV have the same backbone.";"(EP2618841)
BOVINE VIRAL DIARRHEA VIRUS(100,233)
VACCINE(100,18)
BOVINE VIRAL DIARRHEA TREATMENT(100,1)
BVD VIRUS GENE(91,2)
BVD VIRUS(70,6)
FLAVIVIRIDAE FAMILY(64,1)
LIVE ATTENUATED VACCINE(61,5)
SUSCEPTIBLE RUMINANT PROTECTION(60,3)
VACCINE PREPARATION(59,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(53,1)
GENUS PESTIVIRUS MEMBER(53,1)
CAUSATIVE AGENT(43,1)
IMMUNOGENIC POLYPEPTIDE(38,2)
VIRUS ANTIGEN(38,2)
MUTUAL NEGATIVE(37,2)
MAJOR ECONOMIC LOSS(37,1)
BOVINE PARAMYXOVIRUS(36,3)
BOVINE ROTAVIRUS(36,2)
MEDICAMENT(36,1)
GENE(34,33)
NEUTRALIZING ANTIBODY TITER PEAKING(33,3)
NATURAL INFECTION(32,2)
INCREASED DISEASE OCCURRENCE(32,1)
BACKBONE(31,11)
NPRO GENE(31,3)
PARAINFLUENZA(31,3)
REPRODUCTIVE PERFORMANCE(31,2)
GENETIC INFORMATION ENCODING(31,1)
COMBINATION VACCINE(30,27)
ERNS GENE(30,4)
BOVINE HERPES VIRUS(29,3)
VIRUS(28,32)
CHALLENGE VIRUS VIREMIA(28,5)
BOVINE VIRAL DIARRHEA(28,1)
SHIPPING FEVER(28,1)
MICROORGANISM(27,9)
GROWTH RETARDATION(24,1)
BLOCKING ELISA(21,13)
PASTEURELLA HAEMOLYTICA(21,3)
VACCINATION CHALLENGE TRIAL(21,3)
SINGLE VACCINATION(21,1)
NASAL VIRUS SHEDDING(20,8)
NEUTRALIZATION ASSAY(20,6)
14D POST VACCINATION NEUTRALIZING ANTIBODY(20,1)
MILK PRODUCTION REDUCTION(20,1)
STERILE IMMUNITY(19,7)
CLINICAL DISEASE SIGN(19,5)
CLINICAL SCORE PEAKING(19,3)
NEUTRALIZING ANTIBODY PREDOMINANT INDUCER(19,1)
INFECTION(17,29)
IMMUNIZED ANIMAL(17,5)
DISEASE(17,2)
NPRO DELETION MUTANT(17,2)
SPORADIC COUGHING ALTERNATING(17,2)
VACCINE VIRUS NASAL EXCRETION(17,1)
ANIMAL TRIAL(16,6)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(16,3)
BSAI FRAGMENT(15,4)
CHALLENGE INFECTION NEUTRALIZING ANTIBODY(15,1)
NAIVE CALF(14,4)
MONOPHASIC DECLINE(14,3)
STAYED SERONEGATIVE(14,3)
VACCINE VIRUS SHEDDING(14,3)
PESTIVIRUS IMMUNODOMINANT PROTEIN(14,1)
CHALLENGE VIRUS SHEDDING(13,2)
CHIMERIC PESTIVIRUS(13,2)
LIVE ATTENUATED VIRUS(13,2)
RESTRICTION ENZYME DIGESTION(13,2)
COMBINATION VACCINE MANUFACTURE(13,1)
CULTURE IMMUNOFLUORESCENCE STAINING(13,1)
GOAT ANTI MOUSE FRAGMENT(13,1)
PERSISTENTLY INFECTED CALF GENERATION(13,1)
VIRUS VIREMIA SEROLOGY(13,1)
CLEAR BOOST(12,7)
ADVERSE CLINICAL REACTION(12,4)
CHALLENGE STRAIN(12,4)
WEEKLY INTERVAL(12,4)
DECREASED PARALLELING(12,3)
PHUSION PCR(12,3)
CEDI DIAGNOSTICS(12,2)
PURIFIED BLOOD LEUKOCYTE(12,2)
SUPERNATANT BLIND PASSAGE(12,2)
CHIMERA PARENTAL STRAIN(12,1)
CHIMERIC BVD VIRUS(12,1)
INFECTIOUS VIRUS PROGENY GENERATION(12,1)
MOCK VACCINATED ANIMAL(12,1)
PRE VACCINATION EXACERBATION(12,1)
BLUETONGUE VIRUS(11,3)
MAXIMUM TITER(10,8)
BIPHASIC RISE(10,3)
CHALLENGE DAY(10,3)
CLINICAL SIGN(10,3)
DAY SEROLOGY(10,3)
ELEVATED SCORE(10,3)
PURULENT NASAL DISCHARGE(10,3)
TRIPHASIC DECREASE(10,3)
BONE MARROW LAVAGE(10,2)
DAY POST VACCINATION(10,2)
ELISA ANTIBODY(10,2)
KILLED VACCINE(10,2)
MANUFACTURER INSTRUCTION(10,2)
PARENTAL VIRUS(10,2)
PLASMID PAFR(10,2)
PREGNANT ANIMAL(10,2)
SEVERE LEUKOPAENIA(10,2)
VACCINE CANDIDATE(10,2)
VIRAL BACKBONE(10,2)
VIRAL ENVELOPE(10,2)
WHOLE VIRAL GENOME(10,2)
ACUTELY INFECTED ANIMAL(10,1)
CHIMERIC VIRUS GENE(10,1)
CP SEQUENTIAL VACCINATION(10,1)
ERYTHROCYTE ALKALINE LYSIS(10,1)
FETAL BOVINE SERUM(10,1)
GLYCOSYLATED ENVELOPE PROTEIN(10,1)
LEUKOCYTE COUNT BIPHASIC DECLINE(10,1)
LOW PROTECTION LEVEL(10,1)
NONSTRUCTURAL AUTOPROTEASE(10,1)
NPRO DELETED VIRUS(10,1)
RE LATED PESTIVIRUS(10,1)
VACCINATION SEROLOGY(10,1)
YOUNG ANIMAL VACCINATION(10,1)
MAXIMAL DECREASE(9,4)
NON TRANSLATED REGION(9,4)
ANIMAL MILD NASAL(9,1)
BIG DYE TERMINATOR(9,1)
BIPHASIC SPIKED CURVE(9,1)
BLOOD PICTURE SEROLOGY(9,1)
CLEARLY DISCERNABLE VIRUS ISOLATION(9,1)
CLINICAL SCORE LEUKOCYTE COUNT(9,1)
CO CULTIVATION VIRUS REPLICATION DAY(9,1)
CO CULTURE VIRUS REPLICATION DAY(9,1)
CYTOPATHIC BIOTYPE(9,1)
FETAL ORGAN PANEL(9,1)
IMMUNIZED CALF(9,1)
NON DETECTABLE NEUTRALIZING TITER LEVEL(9,1)
PCR FRAGMENT INTEGRATION(9,1)
PERSON AMPLE GUIDANCE(9,1)
PESTIVIRAL VIRION(9,1)
PESTIVIRUS GENOME(9,1)
PESTIVIRUS GENUS(9,1)
PESTIVIRUS VACCINE(9,1)
PSEUDOVIRION VIREMIA(9,1)
SMAI PLASMID PA(9,1)
UNAFFECTED VIRUS ISOLATION(9,1)
WATERY DIARRHEA(9,1)
WEEK THROMBOCYTE COUNT(9,1)
SHADED BOX(8,3)
ACUTE INFECTION(8,2)
CLINICAL SCORE CLEAR RISE(8,2)
FAINT ELEVATION(8,2)
GENE ENCODING(8,2)
GENOMIC REGION ENCODING(8,2)
INDIRECT IMMUNOFLUORESCENCE TEST(8,2)
PLASMID PCR(8,2)
VACCINATED GROUP LEUKOCYTE COUNT(8,2)
ANIMAL LEUKOCYTE(8,1)
ANTIBODY NEUTRALIZATION(8,1)
ATTENUATING DELETION(8,1)
BOOSTER VACCINATION(8,1)
CLARIFIED SUPERNATANT(8,1)
CLINICAL REACTION POST VACCINATION(8,1)
CONDUCTED NEUTRALIZING ASSAY(8,1)
DAY POST CHALLENGE BOOST(8,1)
GROSS NECROPSY(8,1)
HIGHLY SUSCEPTIBLE MDBK CLONE(8,1)
MAJOR NEUTRALIZING EPITOPE(8,1)
MEAN CLINICAL SCORE(8,1)
MILD RESPIRATORY SYMPTOM SHORT(8,1)
MOCK VACCINATION(8,1)
MUCOSAL LESION(8,1)
NASAL SHEDDING(8,1)
NHEI LIGATION(8,1)
NONSTRUCTURAL GENE(8,1)
NPRO FETUS(8,1)
PESTIVIRAL PROTEIN(8,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(8,1)
PLASMID LINEARIZATION(8,1)
REPLICATION MACHINERY(8,1)
UNAFFECTED SEROLOGY(8,1)
VACCINATION REGIME(8,1)
VIROLOGY INSTITUTE(8,1)
VIRUS BACKBONE(8,1)
PHYSIOLOGICAL RANGE(7,9)
NEBULIZER(7,4)
488 CONJUGATED SECONDARY ANTIBODY(7,1)
ADVANCED MAZERATION(7,1)
ANIMAL SHED(7,1)
CHIMERIC CONSTRUCT(7,1)
CLINICAL BVD(7,1)
CLINICAL SYMPTOM(7,1)
CYCLE SEQUENCING KIT(7,1)
ENCODED POLYPROTEIN(7,1)
FLUORESCENCE MICROSCOPE(7,1)
FOLD SERIAL DILUTION(7,1)
GENE PULSER TRANSFECTION UNIT(7,1)
GENETIC ANALYZER(7,1)
HIGHLY COMPARABLE REPLICATION EFFICACY(7,1)
INFECTION SEVERITY(7,1)
INFECTIOUS CDNA CONSTRUCTION(7,1)
INOCULATED ANIMAL(7,1)
LEUKOCYTE COUNT MODERATE DROP(7,1)
LEUKOCYTE PICTURE(7,1)
MARKED LEUKOPAENIA(7,1)
MODERATE TITER(7,1)
NASAL SWAB SAMPLE(7,1)
NPRO VIRUS(7,1)
OVINE BORDER DISEASE VIRUS(7,1)
PLASMID FRAGMENT(7,1)
PLASMID PMA(7,1)
PLASMID SYN(7,1)
QIAGEN PLASMID(7,1)
RECOMBINANT VIRUS(7,1)
REPLICON ENCODING REGION(7,1)
RNA TRANSFECTION(7,1)
SEQUENTIAL VACCINE(7,1)
SEVERE SYMPTOM(7,1)
SMAI RESTRICTION(7,1)
STABILIZING VIRUS(7,1)
SUPERNATANT CONSECUTIVE PASSAGE(7,1)
UNINFECTED CELL CULTURE SUPERNATANT(7,1)
VIRUS EXCRETION(7,1)
VIRUS INOCULATION(7,1)
VIRUS TITER(7,1)
ABORTION(6,3)
HEIFER(6,3)
IMMUNIZATION(6,3)
PRE INFECTION COUNT(6,3)
PROTEIN REGION(6,3)
ANTIBODY DEVELOPMENT(6,2)
BOVINE CELL ANALYSIS(6,2)
LEUKOCYTE REDUCTION(6,2)
LIMITED VACCINE VIRUS VIREMIA(6,2)
MEDIUM TITER(6,2)
PROTECTIVE IMMUNE RESPONSE(6,2)
RAISED CLINICAL SCORE SHORT(6,2)
REMAINED NEGATIVE(6,2)
RESTRICTION SITE LOCATION(6,2)
STRUCTURAL PROTEIN(6,2)
SWAB FLUID(6,2)
ANIMAL PROTECTION(6,1)
ANIMAL SEROLOGICAL RESPONSE(6,1)
AUTOMATIC SEQUENCER(6,1)
BIPHASIC DROP(6,1)
BOVINE ROTAVIRUS GROUP(6,1)
CLEAR LEUKOPAENIA(6,1)
COMMON TYPE(6,1)
CONSTRUCTING CDNA(6,1)
DARK BLUE BOX(6,1)
DELETION BASIS(6,1)
ELEVATED COUNT INDICATION(6,1)
HUMIDIFIED ATMOSPHERE(6,1)
IMMUNOFLUORESCENCE ANALYSIS(6,1)
LB FRAGMENT(6,1)
LEUKOCYTE BLOOD COUNT(6,1)
LEUKOCYTE COUNT MARKED DECREASE(6,1)
MAJOR GENOTYPE(6,1)
MAJOR IMMUNOGEN(6,1)
MATURE PROTEIN(6,1)
MILD CLINICAL REACTION(6,1)
NPRO MUTANT COMBINATION(6,1)
NPRO STRAIN(6,1)
OCULAR DISCHARGE(6,1)
RNA MOLECULE(6,1)
RNA VIRUS(6,1)
SAN DIEGO(6,1)
SMAI SITE(6,1)
SUBCUTANEOUS ROUTE(6,1)
SYNTHETIC CLONE BASIS(6,1)
SYNTHETIC FRAGMENT(6,1)
THUMB RULE(6,1)
UNIQUE RESTRICTION SITE(6,1)
VACCINATION PERIOD WEEK(6,1)
VIRUS SPECIES(6,1)
WORKING DILUTION(6,1)
BLPI(5,5)
ELECTROPHORESIS(5,2)
HETERODIMER(5,2)
LEUKOCYTE COUNT SINGLE DECLINE(5,2)
MEAN REDUCTION(5,2)
MEGAPRIMER(5,2)
PMK RQ(5,2)
REDUCTION DAY(5,2)
SILENT MUTATION(5,2)
STABILIZER(5,2)
TRIAL NEUTRALIZING ANTIBODY END(5,2)
VIRULENCE(5,2)
WHOLE PERIOD(4,4)
BOOST EFFECT(4,3)
BSTBI(4,3)
DEPRESSION(4,3)
PGA(4,3)
REDUCING APPETITE(4,3)
SHOT(4,3)
TEMPLATE(4,3)
ATTENUATION LEVEL(4,2)
CALF CELL(4,1)
CARRIER PLASMID(4,1)
CELL BOUND VIREMIA(4,1)
CLINICAL SCORE SINGLE DECLINE(4,1)
DEGRADATION PRONE PROTEIN(4,1)
ELISA POSITIVE(4,1)
FREEZE DRIED VACCINE(4,1)
GASTROINTESTINAL DISORDER(4,1)
GRAY ARROW(4,1)
GROUP TITER(4,1)
IB STRAIN(4,1)
IDENTICAL BACKBONE(4,1)
ITALIC BNUCLEOTIDE POSITION(4,1)
LEUKOCYTE COUNT DECREASE(4,1)
MARGINAL INCREASE(4,1)
MAXIMAL REDUCTION(4,1)
MODERATE TEMPERATURE RISE(4,1)
NATURAL CONTEXT(4,1)
NET GMBH(4,1)
NPRO DID(4,1)
OBSERVED VACCINE VIRUS(4,1)
PEAK INCREASE(4,1)
PRE VACCINATION TEMPERATURE(4,1)
PROTRACTED COURSE(4,1)
REPLICATION CAPACITY(4,1)
RESPIRATORY DISORDER MILD INCREASE(4,1)
RT PCR(4,1)
SEROLOGICAL DIFFERENCE(4,1)
SHELF LIFE(4,1)
SOFTWARE VERSION(4,1)
SYNTHETIC CONSTRUCT(4,1)
TERMINAL PROTEASE(4,1)
VIRUS PREPARATION(4,1)
WHOLE VIRUS(4,1)
ACCESSION(3,1)
APPLIED ANTIBODY ELISA(3,1)
B NPRO GENOME(3,1)
BIOMER(3,1)
CAPSID(3,1)
(US20130195892)
BOVINE VIRAL DIARRHEA VIRUS(100,39)
COMBINATION VACCINE(100,38)
SUSCEPTIBLE RUMINANT PROTECTION(100,5)
BVDV VACCINE(100,2)
BVD VIRUS GENE(99,4)
BOVINE VIRAL DIARRHEA TREATMENT(98,3)
BVD VIRUS(84,9)
VACCINE PREPARATION(69,2)
IMMUNOGENIC POLYPEPTIDE(54,3)
VIRUS ANTIGEN(53,3)
FLAVIVIRIDAE FAMILY(49,1)
LIVE ATTENUATED VACCINE(47,5)
NPRO GENE(46,5)
ERNS GENE(44,6)
GENETIC INFORMATION ENCODING(41,2)
CATTLE ECONOMICALLY IMPORTANT DISEASE(41,1)
GENUS PESTIVIRUS MEMBER(41,1)
MEDICAMENT(35,3)
MICROORGANISM(33,11)
CAUSATIVE AGENT(33,1)
VACCINE(31,20)
BVDV INFECTION(30,5)
MUTUAL NEGATIVE(29,2)
MAJOR ECONOMIC LOSS(29,1)
VIRUS(28,34)
BOVINE PARAMYXOVIRUS(28,3)
GENE(26,32)
NEUTRALIZING ANTIBODY TITER PEAKING(26,3)
NATURAL INFECTION(25,2)
INCREASED DISEASE OCCURRENCE(25,1)
RUMINANT(24,8)
REPRODUCTIVE PERFORMANCE(24,2)
BVDV(23,107)
BOVINE HERPES VIRUS(22,3)
ANTIGEN(22,2)
BOVINE ROTAVIRUS GROUP(22,2)
BVDV COMBINATION VACCINE(22,1)
BOVINE VIRAL DIARRHEA(21,1)
SHIPPING FEVER(21,1)
CLINICAL SIGN(20,18)
ANTIBODY(18,8)
GROWTH RETARDATION(18,1)
BVDV NAVE CALF(17,3)
CHALLENGE VIRUS VIREMIA(17,3)
BLOCKING ELISA(16,12)
NASAL VIRUS SHEDDING(16,8)
CHIMERIC BVDV(16,6)
INTERFERON INCOMPETENT MDBK CELL(16,3)
PASTEURELLA HAEMOLYTICA(16,3)
MILK PRODUCTION REDUCTION(16,1)
SINGLE VACCINATION(16,1)
NEUTRALIZATION ASSAY(15,5)
NEUTRALIZING ANTIBODY PREDOMINANT INDUCER(15,1)
STERILE IMMUNITY(14,7)
CLINICAL DISEASE SIGN(14,5)
CLINICAL SCORE PEAKING(14,3)
890FL NPRO MUTANT(14,2)
ATTENUATED BVDV VACCINE(14,2)
CEDITEST BVDV ELISA(14,2)
IMMUNIZED ANIMAL(13,5)
LIVE ATTENUATED VIRUS(13,3)
STAYED SERONEGATIVE(13,3)
DISEASE(13,2)
NPRO DELETION MUTANT(13,2)
SPORADIC COUGHING ALTERNATING(13,2)
VACCINE VIRUS NASAL EXCRETION(13,1)
ANIMAL TRIAL(12,6)
BSAI FRAGMENT(12,4)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(12,3)
BVDV NA VE HEIFER(12,1)
CHALLENGE INFECTION NEUTRALIZING ANTIBODY(12,1)
MONOPHASIC DECLINE(11,3)
VACCINE VIRUS SHEDDING(11,3)
BVDV NASAL SHEDDING(11,1)
HETEROLOGOUS BVDV OUTCOME(11,1)
ORF ENCODED POLYPROTEIN(11,1)
PESTIVIRAL ORF PROTEIN(11,1)
PESTIVIRUS IMMUNODOMINANT PROTEIN(11,1)
VIRUS VIREMIA SEROLOGY(11,1)
CHALLENGE VIRUS SHEDDING(10,2)
RESTRICTION ENZYME DIGESTION(10,2)
VACCINATION BVDV(10,2)
BVDV VACCINE CANDIDATE(10,1)
CULTURE IMMUNOFLUORESCENCE STAINING(10,1)
GOAT ANTI MOUSE FRAGMENT(10,1)
NASAL BVDV EXCRETION(10,1)
NCP PURIFIED BLOOD LEUKOCYTE(10,1)
PERSISTENTLY INFECTED CALF GENERATION(10,1)
SEQUENTIAL VACCINATION CHALLENGE TRIAL(10,1)
ADVERSE CLINICAL REACTION(9,4)
CHALLENGE STRAIN(9,4)
WEEKLY INTERVAL(9,4)
DECREASED PARALLELING(9,3)
PARENTAL VIRUS(9,3)
BVDV GENOME(9,2)
CEDI DIAGNOSTICS(9,2)
HIGHLY VIRULENT BVDV(9,2)
PARENTAL BVDV(9,2)
SUPERNATANT BLIND PASSAGE(9,2)
CHIMERA PARENTAL STRAIN(9,1)
CHIMERIC BVD VIRUS(9,1)
INFECTIOUS VIRUS PROGENY GENERATION(9,1)
MOCK VACCINATED ANIMAL(9,1)
PCR PLASMID PGEM E1E2CS(9,1)
PRE VACCINATION EXACERBATION(9,1)
MAXIMUM TITER(8,8)
NPRO E2CS(8,8)
BIPHASIC RISE(8,3)
BLUETONGUE VIRUS(8,3)
BVDV STRUCTURAL PROTEIN REGION(8,3)
DAY SEROLOGY(8,3)
ELEVATED SCORE(8,3)
PURULENT NASAL DISCHARGE(8,3)
TRIPHASIC DECREASE(8,3)
BONE MARROW LAVAGE(8,2)
BVDV GENOMIC REGION(8,2)
BVDV NCP(8,2)
CLEAR BOOST BVDV(8,2)
DAY POST VACCINATION(8,2)
ELISA ANTIBODY(8,2)
KILLED VACCINE(8,2)
PHUSION PCR(8,2)
PLASMID PAFR(8,2)
PREGNANT ANIMAL(8,2)
RNA TRANSFECTION(8,2)
SEVERE LEUKOPAENIA(8,2)
VIRAL BACKBONE(8,2)
VIRAL ENVELOPE(8,2)
WHOLE VIRAL GENOME(8,2)
ACUTELY INFECTED ANIMAL(8,1)
CHIMERIC VIRUS GENE(8,1)
CP SEQUENTIAL VACCINATION(8,1)
ERYTHROCYTE ALKALINE LYSIS(8,1)
ETHIDIUM BROMIDE STAINING(8,1)
FETAL BOVINE SERUM(8,1)
GLYCOSYLATED ENVELOPE PROTEIN(8,1)
LEUKOCYTE COUNT BIPHASIC DECLINE(8,1)
LOW PROTECTION LEVEL(8,1)
NONSTRUCTURAL AUTOPROTEASE(8,1)
NPRO DELETED VIRUS(8,1)
YOUNG ANIMAL VACCINATION(8,1)
MAXIMAL DECREASE(7,4)
NON TRANSLATED REGION(7,4)
ANIMAL MILD NASAL(7,1)
BIG DYE TERMINATOR(7,1)
BIPHASIC SPIKED CURVE(7,1)
BLOOD PICTURE SEROLOGY(7,1)
BVDV 1B PROTOTYPE(7,1)
BVDV MAJOR IMMUNOGEN(7,1)
CHIMERIC PESTIVIRUS(7,1)
CLEARLY DISCERNABLE VIRUS ISOLATION(7,1)
CLINICAL SCORE LEUKOCYTE COUNT(7,1)
CO CULTIVATION VIRUS REPLICATION DAY(7,1)
CO CULTURE VIRUS REPLICATION DAY(7,1)
CYTOPATHIC BIOTYPE(7,1)
FETAL ORGAN PANEL(7,1)
IMMUNIZED CALF(7,1)
NON DETECTABLE NEUTRALIZING TITER LEVEL(7,1)
OVINE BORDER DISEASE VIRUS(7,1)
PCR FRAGMENT INTEGRATION(7,1)
PERSON AMPLE GUIDANCE(7,1)
PESTIVIRAL VIRION(7,1)
PESTIVIRUS GENOME(7,1)
PESTIVIRUS GENUS(7,1)
PESTIVIRUS VACCINE(7,1)
PSEUDOVIRION VIREMIA(7,1)
SMAI PLASMID PA(7,1)
UNAFFECTED VIRUS ISOLATION(7,1)
VACCINATION SEROLOGY(7,1)
WATERY DIARRHEA(7,1)
WEEK THROMBOCYTE COUNT(7,1)
BOVINE CELL(6,3)
LIMITED VACCINE VIRUS VIREMIA(6,3)
SHADED BOX(6,3)
ACUTE INFECTION(6,2)
CLINICAL SCORE CLEAR RISE(6,2)
FAINT ELEVATION(6,2)
GENE ENCODING(6,2)
GENOMIC REGION ENCODING(6,2)
INDIRECT IMMUNOFLUORESCENCE TEST(6,2)
VACCINATED GROUP LEUKOCYTE COUNT(6,2)
ALEXA FLUOR(6,1)
ANIMAL LEUKOCYTE(6,1)
ANTIBODY NEUTRALIZATION(6,1)
ATTENUATING DELETION(6,1)
BOOSTER VACCINATION(6,1)
BVDV BACKBONE(6,1)
CLARIFIED SUPERNATANT(6,1)
CLINICAL REACTION POST VACCINATION(6,1)
CONDUCTED NEUTRALIZING ASSAY(6,1)
DAY POST CHALLENGE BOOST(6,1)
ESCHERICHIA COLI DH10B CELL(6,1)
GGTACC SILENT MUTATION(6,1)
GROSS NECROPSY(6,1)
HARBORING PLASMID(6,1)
INFECTIOUS NCP(6,1)
MAJOR NEUTRALIZING EPITOPE(6,1)
MEAN CLINICAL SCORE(6,1)
MILD RESPIRATORY SYMPTOM SHORT(6,1)
MOCK VACCINATION(6,1)
MUCOSAL LESION(6,1)
NCP INOCULATION(6,1)
NHEI LIGATION(6,1)
NONSTRUCTURAL GENE(6,1)
NPRO FETUS(6,1)
PESTIVIRAL PROTEIN(6,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(6,1)
PLASMID LINEARIZATION(6,1)
REPLICATION MACHINERY(6,1)
TTCGAA SILENT MUTATION(6,1)
UNAFFECTED SEROLOGY(6,1)
VACCINATION REGIME(6,1)
VACCINE VACCINATION STRATEGY COMPARISON(6,1)
VIROLOGY INSTITUTE(6,1)
VIRUS BACKBONE(6,1)
PHYSIOLOGICAL RANGE(5,9)
PARAINFLUENZA TYPE(5,3)
ANTIBODY DEVELOPMENT(5,2)
LEUKOCYTE REDUCTION(5,2)
PROTECTIVE IMMUNE RESPONSE(5,2)
RAISED CLINICAL SCORE SHORT(5,2)
REMAINED NEGATIVE(5,2)
RESTRICTION SITE LOCATION(5,2)
SWAB FLUID(5,2)
488 CONJUGATED SECONDARY ANTIBODY(5,1)
ACC65I INSERTION(5,1)
ADVANCED MAZERATION(5,1)
ANIMAL DEVELOPED BVDV(5,1)
ANIMAL SHED(5,1)
BVDV CODING REGION(5,1)
CHIMERIC CONSTRUCT(5,1)
CLINICAL BVD(5,1)
CLINICAL SYMPTOM(5,1)
CYCLE SEQUENCING KIT(5,1)
D POST VACCINATION NEUTRALIZING ANTIBODY(5,1)
FATAL MUCOSAL DISEASE(5,1)
FLUORESCENCE MICROSCOPE(5,1)
FOLD SERIAL DILUTION(5,1)
GENE PULSER TRANSFECTION UNIT(5,1)
GENETIC ANALYZER(5,1)
GROUP BVDV TITER(5,1)
HIGHLY COMPARABLE REPLICATION EFFICACY(5,1)
INFECTION SEVERITY(5,1)
INFECTIOUS CDNA CONSTRUCTION(5,1)
INOCULATED ANIMAL(5,1)
LEUKOCYTE COUNT MODERATE DROP(5,1)
LEUKOCYTE PICTURE(5,1)
MARKED LEUKOPAENIA(5,1)
MEDIUM TITER BVDV(5,1)
MODERATE TITER(5,1)
NASAL SWAB SAMPLE(5,1)
NPRO VIRUS(5,1)
PLASMID FRAGMENT(5,1)
PLASMID PMA(5,1)
PLASMID SYN(5,1)
QIAGEN PLASMID(5,1)
RECOMBINANT VIRUS(5,1)
REPLICON ENCODING REGION(5,1)
SEVERE SYMPTOM(5,1)
SMAL RESTRICTION(5,1)
STABILIZING VIRUS(5,1)
SUPERNATANT CONSECUTIVE PASSAGE(5,1)
UNINFECTED CELL CULTURE SUPERNATANT(5,1)
VIRUS EXCRETION(5,1)
VIRUS INOCULATION(5,1)
VIRUS TITER(5,1)
BLPI(4,5)
IMMUNIZATION(4,3)
NEBULIZER(4,3)
PRE INFECTION COUNT(4,3)
CP DESIGN(4,2)
ELECTROPHORESIS(4,2)
HETERODIMER(4,2)
IMMUNIZED GROUP(4,2)
LEUKOCYTE COUNT SINGLE DECLINE(4,2)
MEAN REDUCTION(4,2)
MEGAPRIMER(4,2)
PMK RQ(4,2)
STABILIZER(4,2)
STERILE WATER(4,2)
TRIAL NEUTRALIZING ANTIBODY END(4,2)
VIRULENCE(4,2)
ANIMAL PROTECTION(4,1)
ANIMAL SEROLOGICAL RESPONSE(4,1)
AUTOMATIC SEQUENCER(4,1)
BIPHASIC DROP(4,1)
BVDV 1B FRAGMENT SEQUENCE(4,1)
CLEAR LEUKOPAENIA(4,1)
COMMON TYPE(4,1)
CONSTRUCTING CDNA(4,1)
DARK BLUE BOX(4,1)
DELETION BASIS(4,1)
ELEVATED COUNT INDICATION(4,1)
GRAVIDITY PERFORMANCE(4,1)
HUMIDIFIED ATMOSPHERE(4,1)
IMMUNOFLUORESCENCE ANALYSIS(4,1)
LEUKOCYTE BLOOD COUNT(4,1)
LEUKOCYTE COUNT MARKED DECREASE(4,1)
MATURE PROTEIN(4,1)
MILD CLINICAL REACTION(4,1)
NPRO MUTANT COMBINATION(4,1)
OCULAR DISCHARGE(4,1)
PBVDV GENERATION(4,1)
PLASMID PCR(4,1)
RNA MOLECULE(4,1)
RNA VIRUS(4,1)
SAN DIEGO(4,1)
SMAI SITE(4,1)
SUBCUTANEOUS ROUTE(4,1)
SYNTHETIC CLONE BASIS(4,1)
SYNTHETIC FRAGMENT(4,1)
THUMB RULE(4,1)
UNIQUE RESTRICTION SITE(4,1)
VACCINATION PERIOD WEEK(4,1)
VIRUS PROPAGATION(4,1)
WORKING DILUTION(4,1)
PGA(3,4)
WHOLE PERIOD(3,4)
BOOST EFFECT(3,3)
BSTBI(3,3)
DEPRESSION(3,3)
LOGIN(3,3)
REDUCING APPETITE(3,3)
ATTENUATION LEVEL(3,2)
1B SYNTH(3,1)
BVDV SEQUENCE(3,1)
CALF CELL(3,1)
CARRIER PLASMID(3,1)
CELL BOUND VIREMIA(3,1)
CLINICAL SCORE SINGLE DECLINE(3,1)
CLOSELY RELATED BVDV STRAIN(3,1)
DEGRADATION PRONE PROTEIN(3,1)
EDTA BLOOD(3,1)
ELISA POSITIVE(3,1)
FREEZE DRIED VACCINE(3,1)
GASTROINTESTINAL DISORDER(3,1)
GRAY ARROW(3,1)
IB STRAIN(3,1)
IDENTICAL BACKBONE(3,1)
LEUKOCYTE COUNT DECREASE(3,1)
MARGINAL INCREASE(3,1)
MAXIMAL REDUCTION(3,1)
MODERATE TEMPERATURE RISE(3,1)
NATURAL CONTEXT(3,1)
NET GMBH(3,1)
PEAK INCREASE(3,1)
PRE VACCINATION TEMPERATURE(3,1)
PROTRACTED COURSE(3,1)
REPLICATION CAPACITY(3,1)
RESPIRATORY DISORDER MILD INCREASE(3,1)
RT PCR(3,1)
SEQUENCE FRAGMENT(3,1)
SEQUENCECNUCLEOTIDE(3,1)
SEROLOGICAL DIFFERENCE(3,1)
SHELF LIFE(3,1)
SOFTWARE VERSION(3,1)
SYNTHETIC BVDV CONSTRUCTION(3,1)
SYNTHETIC CONSTRUCT(3,1)
TERMINAL PROTEASE(3,1)
TRIMESTER(3,1)
VIRUS PREPARATION(3,1)
WHOLE VIRUS(3,1)
(US9878030)
BOVINE VIRAL DIARRHEA VIRUS(100,89)
COMBINATION VACCINE(100,34)
PROTECTION(100,3)
BVDV VACCINE(100,2)
BOVINE VIRAL DIARRHEA TREATMENT(66,2)
BVD VIRUS GENE(66,2)
BVD VIRUS(61,7)
VACCINE PREPARATION(57,2)
IMMUNOGENIC POLYPEPTIDE(50,3)
VIRUS ANTIGEN(50,3)
FLAVIVIRIDAE FAMILY(46,1)
LIVE ATTENUATED VACCINE(44,5)
GENE(43,42)
GENETIC INFORMATION ENCODING(38,2)
CATTLE ECONOMICALLY IMPORTANT DISEASE(38,1)
GENUS PESTIVIRUS MEMBER(38,1)
NPRO GENE(34,4)
MEDICAMENT(34,2)
ERNS GENE(32,5)
MICROORGANISM(31,11)
CAUSATIVE AGENT(31,1)
BVDV INFECTION(28,5)
MAJOR ECONOMIC LOSS(27,1)
VIRUS(26,34)
BOVINE PARAMYXOVIRUS(26,3)
NEUTRALIZING ANTIBODY TITER PEAKING(24,3)
NATURAL INFECTION(23,2)
REPRODUCTIVE PERFORMANCE(23,2)
INCREASED DISEASE OCCURRENCE(23,1)
VACCINE(22,19)
RUMINANT(22,8)
BVDV(21,105)
BOVINE HERPES VIRUS(21,3)
ANTIGEN(21,2)
BOVINE ROTAVIRUS GROUP(21,2)
BVDV COMBINATION VACCINE(21,1)
VIRUS ISOLATION(20,21)
BOVINE VIRAL DIARRHEA(20,1)
SHIPPING FEVER(20,1)
CLINICAL SIGN(18,18)
ANTIBODY(17,8)
LIVE ATTENUATED TYPE(17,4)
GROWTH RETARDATION(17,1)
TYPE GENE(16,7)
CHALLENGE VIRUS VIREMIA(16,3)
BLOOD PICTURE(15,19)
BLOCKING ELISA(15,12)
ANIMAL TRIAL(15,11)
CHIMERIC BVDV(15,6)
INTERFERON INCOMPETENT MDBK CELL(15,3)
PASTEURELLA HAEMOLYTICA(15,3)
SINGLE VACCINATION(15,1)
NASAL VIRUS SHEDDING(14,8)
NEUTRALIZATION ASSAY(14,5)
SUSCEPTIBLE RUMINANT PROTECTION(14,4)
MILK PRODUCTION REDUCTION(14,1)
NEUTRALIZING ANTIBODY PREDOMINANT INDUCER(14,1)
STERILE IMMUNITY(13,7)
CLINICAL DISEASE SIGN(13,5)
IMMUNIZED ANIMAL(13,5)
CLINICAL SCORE PEAKING(13,3)
890FL NPRO MUTANT(13,2)
ATTENUATED BVDV VACCINE(13,2)
CEDITEST BVDV ELISA(13,2)
SEROLOGY(12,23)
LIVE ATTENUATED VIRUS(12,3)
STAYED SERONEGATIVE(12,3)
NPRO DELETION MUTANT(12,2)
SPORADIC COUGHING ALTERNATING(12,2)
VACCINE VIRUS NASAL EXCRETION(12,1)
BSAI FRAGMENT(11,4)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(11,3)
DISEASE(11,3)
BVDV NA VE HEIFER(11,1)
CHALLENGE INFECTION NEUTRALIZING ANTIBODY(11,1)
MONOPHASIC DECLINE(10,3)
VACCINE VIRUS SHEDDING(10,3)
BVDV NASAL SHEDDING(10,1)
HETEROLOGOUS BVDV OUTCOME(10,1)
ORF ENCODED POLYPROTEIN(10,1)
PESTIVIRAL ORF PROTEIN(10,1)
PESTIVIRUS IMMUNODOMINANT PROTEIN(10,1)
CHALLENGE STRAIN(9,4)
BVDV GENOME SCHEMATIC REPRESENTATION(9,3)
DECREASED PARALLELING(9,3)
PARENTAL VIRUS(9,3)
CHALLENGE VIRUS SHEDDING(9,2)
RESTRICTION ENZYME DIGESTION(9,2)
VACCINATION BVDV(9,2)
BVDV 1B NPRO GENOME(9,1)
BVDV VACCINE CANDIDATE(9,1)
CULTURE IMMUNOFLUORESCENCE STAINING(9,1)
GOAT ANTI MOUSE FRAGMENT(9,1)
NASAL BVDV EXCRETION(9,1)
NCP PURIFIED BLOOD LEUKOCYTE(9,1)
NPRO TRIAL TRANSPLACENTAL INFECTION(9,1)
PERSISTENTLY INFECTED CALF GENERATION(9,1)
SEQUENTIAL VACCINATION CHALLENGE TRIAL(9,1)
ADVERSE CLINICAL REACTION(8,4)
GENOMIC REGION ENCODING(8,4)
WEEKLY INTERVAL(8,4)
BLUETONGUE VIRUS(8,3)
CEDI DIAGNOSTICS(8,2)
HIGHLY VIRULENT BVDV(8,2)
PARENTAL BVDV(8,2)
SUPERNATANT BLIND PASSAGE(8,2)
CHIMERA PARENTAL STRAIN(8,1)
CHIMERIC BVD VIRUS(8,1)
INFECTIOUS VIRUS PROGENY GENERATION(8,1)
MOCK VACCINATED ANIMAL(8,1)
PRE VACCINATION EXACERBATION(8,1)
MAXIMUM TITER(7,8)
NPRO E2CS(7,8)
MAXIMAL DECREASE(7,4)
NON TRANSLATED REGION(7,4)
BIPHASIC RISE(7,3)
BVDV STRUCTURAL PROTEIN REGION(7,3)
ELEVATED SCORE(7,3)
PURULENT NASAL DISCHARGE(7,3)
TRIPHASIC DECREASE(7,3)
BONE MARROW LAVAGE(7,2)
BVDV GENOMIC REGION(7,2)
CHIMERIC CONSTRUCT(7,2)
CLEAR BOOST BVDV(7,2)
DAY POST VACCINATION(7,2)
ELISA ANTIBODY(7,2)
KILLED VACCINE(7,2)
PHUSION PCR(7,2)
PLASMID PAFR(7,2)
PREGNANT ANIMAL(7,2)
RNA TRANSFECTION(7,2)
SEVERE LEUKOPAENIA(7,2)
VIRAL BACKBONE(7,2)
VIRAL ENVELOPE(7,2)
WHOLE VIRAL GENOME(7,2)
ACUTELY INFECTED ANIMAL(7,1)
ANIMAL MILD NASAL(7,1)
BIG DYE TERMINATOR(7,1)
BIPHASIC SPIKED CURVE(7,1)
BVDV 1B PROTOTYPE(7,1)
BVDV MAJOR IMMUNOGEN(7,1)
CHIMERIC PESTIVIRUS(7,1)
CHIMERIC VIRUS GENE(7,1)
CLINICAL SCORE LEUKOCYTE COUNT(7,1)
CO CULTIVATION VIRUS REPLICATION DAY(7,1)
CO CULTURE VIRUS REPLICATION DAY(7,1)
CP SEQUENTIAL VACCINATION(7,1)
CYTOPATHIC BIOTYPE(7,1)
ERYTHROCYTE ALKALINE LYSIS(7,1)
ETHIDIUM BROMIDE STAINING(7,1)
FETAL BOVINE SERUM(7,1)
FETAL ORGAN PANEL(7,1)
GLYCOSYLATED ENVELOPE PROTEIN(7,1)
IMMUNIZED CALF(7,1)
LEUKOCYTE COUNT BIPHASIC DECLINE(7,1)
LOW PROTECTION LEVEL(7,1)
NON DETECTABLE NEUTRALIZING TITER LEVEL(7,1)
NONSTRUCTURAL AUTOPROTEASE(7,1)
NPRO DELETED VIRUS(7,1)
OVINE BORDER DISEASE VIRUS(7,1)
PCR FRAGMENT INTEGRATION(7,1)
PERSON AMPLE GUIDANCE(7,1)
PESTIVIRAL VIRION(7,1)
PESTIVIRUS GENOME(7,1)
PESTIVIRUS GENUS(7,1)
PESTIVIRUS VACCINE(7,1)
PSEUDOVIRION VIREMIA(7,1)
SMAI PLASMID PA(7,1)
WATERY DIARRHEA(7,1)
WEEK THROMBOCYTE COUNT(7,1)
YOUNG ANIMAL VACCINATION(7,1)
LIMITED VACCINE VIRUS VIREMIA(6,3)
SHADED BOX(6,3)
ACUTE INFECTION(6,2)
CLINICAL SCORE CLEAR RISE(6,2)
FAINT ELEVATION(6,2)
GENE ENCODING(6,2)
INDIRECT IMMUNOFLUORESCENCE TEST(6,2)
PLASMID PCR(6,2)
VACCINATED GROUP LEUKOCYTE COUNT(6,2)
ALEXA FLUOR(6,1)
ANIMAL LEUKOCYTE(6,1)
ANTIBODY NEUTRALIZATION(6,1)
ATTENUATING DELETION(6,1)
BOOSTER VACCINATION(6,1)
BVDV BACKBONE(6,1)
CHIMERA CONCLUSION(6,1)
CLARIFIED SUPERNATANT(6,1)
CLINICAL REACTION POST VACCINATION(6,1)
CONDUCTED NEUTRALIZING ASSAY(6,1)
DAY POST CHALLENGE BOOST(6,1)
ESCHERICHIA COLI DH10B CELL(6,1)
GGTACC SILENT MUTATION(6,1)
GROSS NECROPSY(6,1)
HARBORING PLASMID(6,1)
INFECTIOUS NCP(6,1)
MAJOR NEUTRALIZING EPITOPE(6,1)
MEAN CLINICAL SCORE(6,1)
MILD RESPIRATORY SYMPTOM SHORT(6,1)
MOCK VACCINATION(6,1)
MUCOSAL LESION(6,1)
NCP INOCULATION(6,1)
NHEI LIGATION(6,1)
NONSTRUCTURAL GENE(6,1)
NPRO FETUS(6,1)
NPRO VACCINATION(6,1)
PESTIVIRAL PROTEIN(6,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(6,1)
PLASMID LINEARIZATION(6,1)
REPLICATION MACHINERY(6,1)
TTCGAA SILENT MUTATION(6,1)
VACCINATION REGIME(6,1)
VACCINE VACCINATION STRATEGY COMPARISON(6,1)
VIROLOGY INSTITUTE(6,1)
VIRUS BACKBONE(6,1)
PHYSIOLOGICAL RANGE(5,9)
PARAINFLUENZA TYPE(5,3)
MUTUAL NEGATIVE(5,2)
STRAIN CP(5,2)
488 CONJUGATED SECONDARY ANTIBODY(5,1)
ACC65I INSERTION(5,1)
ADVANCED MAZERATION(5,1)
ANIMAL DEVELOPED BVDV(5,1)
ANIMAL SHED(5,1)
BVDV CODING REGION(5,1)
CLINICAL BVD(5,1)
CLINICAL SYMPTOM(5,1)
CYCLE SEQUENCING KIT(5,1)
D POST VACCINATION NEUTRALIZING ANTIBODY(5,1)
FATAL MUCOSAL DISEASE(5,1)
FLUORESCENCE MICROSCOPE(5,1)
FOLD SERIAL DILUTION(5,1)
GENE PULSER TRANSFECTION UNIT(5,1)
GENETIC ANALYZER(5,1)
GROUP BVDV TITER(5,1)
HIGHLY COMPARABLE REPLICATION EFFICACY(5,1)
INFECTION CONCLUSION(5,1)
INFECTION SEVERITY(5,1)
INFECTIOUS CDNA CONSTRUCTION(5,1)
INOCULATED ANIMAL(5,1)
LEUKOCYTE COUNT MODERATE DROP(5,1)
LEUKOCYTE PICTURE(5,1)
MARKED LEUKOPAENIA(5,1)
MEDIUM TITER BVDV(5,1)
MODERATE TITER(5,1)
NASAL SWAB SAMPLE(5,1)
NPRO VIRUS(5,1)
PLASMID FRAGMENT(5,1)
PLASMID PMA(5,1)
PLASMID SYN(5,1)
QIAGEN PLASMID(5,1)
RECOMBINANT VIRUS(5,1)
REPLICON ENCODING REGION(5,1)
SEVERE SYMPTOM(5,1)
SMAI RESTRICTION(5,1)
STABILIZING VIRUS(5,1)
SUPERNATANT CONSECUTIVE PASSAGE(5,1)
UNINFECTED CELL CULTURE SUPERNATANT(5,1)
VIRUS EXCRETION(5,1)
VIRUS INOCULATION(5,1)
VIRUS TITER(5,1)
BLPI(4,5)
ABORTION(4,3)
IMMUNIZATION(4,3)
NEBULIZER(4,3)
PRE INFECTION COUNT(4,3)
TIME SCALE(4,3)
ANTIBODY DEVELOPMENT(4,2)
LEUKOCYTE REDUCTION(4,2)
PROTECTIVE IMMUNE RESPONSE(4,2)
RAISED CLINICAL SCORE SHORT(4,2)
REMAINED NEGATIVE(4,2)
RESTRICTION SITE LOCATION(4,2)
SWAB FLUID(4,2)
ANIMAL PROTECTION(4,1)
ANIMAL SEROLOGICAL RESPONSE(4,1)
AUTOMATIC SEQUENCER(4,1)
BIPHASIC DROP(4,1)
BVDV 1B FRAGMENT SEQUENCE(4,1)
CLEAR LEUKOPAENIA(4,1)
COMMON TYPE(4,1)
CONSTRUCTING CDNA(4,1)
DARK BLUE BOX(4,1)
DELETION BASIS(4,1)
ELEVATED COUNT INDICATION(4,1)
GRAVIDITY PERFORMANCE(4,1)
HUMIDIFIED ATMOSPHERE(4,1)
IMMUNOFLUORESCENCE ANALYSIS(4,1)
LEUKOCYTE BLOOD COUNT(4,1)
LEUKOCYTE COUNT MARKED DECREASE(4,1)
MATURE PROTEIN(4,1)
MILD CLINICAL REACTION(4,1)
NPRO MUTANT COMBINATION(4,1)
OCULAR DISCHARGE(4,1)
PBVDV GENERATION(4,1)
RNA MOLECULE(4,1)
RNA VIRUS(4,1)
SAN DIEGO(4,1)
SMAI SITE(4,1)
SUBCUTANEOUS ROUTE(4,1)
SYNTHETIC CLONE BASIS(4,1)
SYNTHETIC FRAGMENT(4,1)
THUMB RULE(4,1)
UNIQUE RESTRICTION SITE(4,1)
VACCINATION PERIOD WEEK(4,1)
VIRUS PROPAGATION(4,1)
WORKING DILUTION(4,1)
PGA(3,4)
WHOLE PERIOD(3,4)
BOOST EFFECT(3,3)
BSTBI(3,3)
DEPRESSION(3,3)
ATTENUATION LEVEL(3,2)
ELECTROPHORESIS(3,2)
HETERODIMER(3,2)
LEUKOCYTE COUNT SINGLE DECLINE(3,2)
MEAN REDUCTION(3,2)
MEGAPRIMER(3,2)
PMK RQ(3,2)
STABILIZER(3,2)
STERILE WATER(3,2)
SUBSTITUTION(3,2)
TRIAL NEUTRALIZING ANTIBODY END(3,2)
VIRULENCE(3,2)
BOVINE CELL ANALYSIS(3,1)
BVDV SEQUENCE(3,1)
CALF CELL(3,1)
CARRIER PLASMID(3,1)
CELL BOUND VIREMIA(3,1)
CLINICAL SCORE SINGLE DECLINE(3,1)
CLOSELY RELATED BVDV STRAIN(3,1)
DEGRADATION PRONE PROTEIN(3,1)
EDTA BLOOD(3,1)
ELISA POSITIVE(3,1)
FREEZE DRIED VACCINE(3,1)
GASTROINTESTINAL DISORDER(3,1)
GRAY ARROW(3,1)
IB STRAIN(3,1)
IDENTICAL BACKBONE(3,1)
LEUKOCYTE COUNT DECREASE(3,1)
MARGINAL INCREASE(3,1)
MAXIMAL REDUCTION(3,1)
MODERATE TEMPERATURE RISE(3,1)
NATURAL CONTEXT(3,1)
NET GMBH(3,1)
PBVDV CONSTRUCTION(3,1)
PEAK INCREASE(3,1)
PRE VACCINATION TEMPERATURE(3,1)
PROTRACTED COURSE(3,1)
REPLICATION CAPACITY(3,1)
RESPIRATORY DISORDER MILD INCREASE(3,1)
RT PCR(3,1)
SEQUENCE FRAGMENT(3,1)
SEQUENCECNUCLEOTIDE(3,1)
SEROLOGICAL DIFFERENCE(3,1)
SHELF LIFE(3,1)
SOFTWARE VERSION(3,1)
SYNTHETIC BVDV CONSTRUCTION(3,1)
SYNTHETIC CONSTRUCT(3,1)
TERMINAL PROTEASE(3,1)
TRIMESTER(3,1)
VIRUS PREPARATION(3,1)
WHOLE VIRUS(3,1)
(WO201238454)
BVDV(100,77)
COMBINATION VACCINE(100,28)
BOVINE VIRAL DIARRHEA VIRUS(100,6)
SUSCEPTIBLE RUMINANT PROTECTION(100,6)
BVD VIRUS GENE(100,2)
BOVINE VIRAL DIARRHEA TREATMENT(95,3)
IMMUNOGENIC POLYPEPTIDE(77,3)
VIRUS ANTIGEN(76,3)
BVDV EL GENE(74,4)
BVD VIRUS(71,6)
FLAVIVIRIDAE FAMILY(70,1)
LIVE ATTENUATED VACCINE(66,5)
BVDV VACCINE(63,2)
GENETIC INFORMATION ENCODING(58,2)
CATTLE ECONOMICALLY IMPORTANT DISEASE(58,1)
GENUS PESTIVIRUS MEMBER(58,1)
VACCINE(54,25)
VACCINE PREPARATION(54,1)
CHIMERIC BVDV(53,7)
NPRO GENE(52,4)
BVDV INFECTION(51,2)
MICROORGANISM(49,11)
ERNS GENE(49,5)
CAUSATIVE AGENT(48,1)
LIVE ATTENUATED VIRUS(45,4)
MUTUAL NEGATIVE(41,2)
MAJOR ECONOMIC LOSS(41,1)
BOVINE PARAMYXOVIRUS(40,3)
BOVINE HERPES VIRUS(39,3)
NEUTRALIZING ANTIBODY TITER PEAKING(36,3)
INCREASED DISEASE OCCURRENCE(36,1)
NATURAL INFECTION(35,2)
GENE(34,22)
RUMINANT(34,8)
REPRODUCTIVE PERFORMANCE(34,2)
VIRUS(33,29)
MEDICAMENT(33,3)
BOVINE ROTAVIRUS GROUP(33,2)
MILD RESPIRATORY SYMPTOM(32,6)
ANTIGEN(32,2)
BVDV COMBINATION VACCINE(32,1)
VIRUS ISOLATION(31,22)
CHALLENGE VIRUS VIREMIA(31,5)
BOVINE VIRAL DIARRHEA(30,1)
SHIPPING FEVER(30,1)
BVDV NAIVE CALF(29,4)
CLINICAL SIGN(27,17)
THROMBOCYTE COUNT(27,12)
ANTIBODY(26,8)
GROWTH RETARDATION(26,1)
DETECTABLE NEUTRALIZING TITER(25,3)
BLOCKING ELISA(24,13)
ANTIBODY NEUTRALIZATION(24,7)
SINGLE VACCINATION(24,1)
PASTEURELLA HAEMOLYTICA(23,3)
BLOOD PICTURE(22,18)
BVDV2 STRAIN(22,8)
NASAL VIRUS SHEDDING(22,8)
MILK PRODUCTION REDUCTION(22,1)
ANIMAL TRIAL(21,9)
STERILE IMMUNITY(21,7)
NEUTRALIZING ANTIBODY PREDOMINANT INDUCER(21,1)
CLINICAL DISEASE SIGN(20,5)
CLINICAL SCORE PEAKING(20,3)
ATTENUATED BVDV VACCINE(20,2)
CEDITEST BVDV ELISA(20,2)
BVDV GENOME SCHEMATIC REPRESENTATION(19,6)
IMMUNIZED ANIMAL(19,5)
BLUETONGUE VIRUS(18,3)
STAYED SERONEGATIVE(18,3)
NPRO DELETION MUTANT(18,2)
SPORADIC COUGHING ALTERNATING(18,2)
VACCINE VIRUS NASAL EXCRETION(18,1)
DAY POST CHALLENGE(17,7)
BVDV TYPE GENE(17,5)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(17,3)
HETEROLOGOUS BVDV(...)";Pharmaceuticals;Open
"2010-07-29
2010-08-03
2011-07-29";"EP2412382           A1 2012-02-01 [EP2412382]
STG: (A1) Application published with search report
AP : 2010EP-0171304 2010-07-29
WO2012013939        A1 2012-02-02 [WO201213939]
STG: (A1) Published application with search report
AP : 2011WO-GB01154 2011-07-29
EP2598163           A1 2013-06-05 [EP2598163]
STG: (A1) Application published with search report
AP : 2011EP-0743576 2011-07-29
US20130216578       A1 2013-08-22 [US20130216578]
STG: (A1) Application published
AP : 2011US-13813100 2011-07-29
BR112013002199      A1 2013-12-31 [BR112013002199]
STG: (A1) Published application
AP : 2013BR-0002199 2011-07-29
EP2598163           B1 2017-01-18 [EP2598163]
STG: (B1) Patent specification
AP : 2011EP-0743576 2011-07-29
BR112013002199      A2 2017-06-27 [BR112013002199]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2013BR-0002199 2011-07-29
US9974846           B2 2018-05-22 [US9974846]
STG: (B2) Granted patent as second publication
AP : 2011US-13813100 2011-07-29
FD :  Provisional Appl: US61/370,223 FDD=2010-08-03 [2010US-61370223]
FD : Previous publication: US20130216578 A1 2013-08-22 [US20130216578]";15034421;"EP2412382           A1 2012-02-01 [EP2412382]
WO2012013939        A1 2012-02-02 [WO201213939]
EP2598163           A1 2013-06-05 [EP2598163]
US20130216578       A1 2013-08-22 [US20130216578]
BR112013002199      A1 2013-12-31 [BR112013002199]
EP2598163           B1 2017-01-18 [EP2598163]
BR112013002199      A2 2017-06-27 [BR112013002199]
US9974846           B2 2018-05-22 [US9974846]";"2010EP-0171304
2010US-61370223
2011EP-0743576
2011US-13813100
2011WO-GB01154";"(EP2598163)
WO2012013939
(US9974846)
WO2012013939
(BR112013002199)
WO2012013939";UNIVERSITY OF EDINBURGH;UNIVERSITY OF EDINBURGH;"(EP2412382)
GB
(EP2598163)
GB
(EP2598163)
GB
(US20130216578)
GB
(US9974846)
GB
(WO201213939)
GB
(BR112013002199)
GB";"(EP2412382)
NAME=University Court of the University of Edinburgh Old College,  South Bridge , CITY=Edinburgh EH8 9YL , COUNTRY=GB 

(EP2598163)
NAME=The University Court Of  The University of Edinburgh Old College  South Bridge , CITY=Edinburgh, Lothian EH8 9YL , COUNTRY=GB 

(EP2598163)
NAME=The University Court Of The University of Edinburgh Old College  South Bridge , CITY=Edinburgh, Lothian EH8 9YL , COUNTRY=GB , REG=101148416 

(US20130216578)
NAME=Matthews Keith Roland , CITY=Edinburgh , COUNTRY=GB 

(US9974846)
NAME=THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH , CITY=Edinburgh , COUNTRY=GB , ATYP=Non-US Company 

(WO201213939)
NAME=THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH Old College South Bridge Edinburgh EH8 9YL , COUNTRY=GB 

(BR112013002199)
NAME=UNIV COURT UNIV OF EDINBURGH , COUNTRY=GB 
";1;MATTHEWS KEITH ROLAND;"(EP2598163)
GB";"(EP2598163)
NAME=MATTHEWS, Keith, Roland Institute of Immunology and Infection Research Ashworth Laboratories University of Edinburgh West Mains Road , CITY=Edinburgh EH9 3JT , COUNTRY=GB 
";"(EP2598163)
Recombinant trypanosoma theileri parasite";"(EP2598163)
The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant Trypanosoma theileri parasite, preferably comprising a heterologous nucleic acid sequence that is capable of encoding a protein for instance an antigen, a cytokine, a hormone, an antimicrobial protein, or an antibody. Also disclosed are uses of and methods for making and using the recombinant T. theileri parasite in medical or non-curative treatments; in particular as a sustained delivery vector for proteins to bovine animals, e.g. as a vaccine.";"(EP2412382)
1. Recombinant Trypanosoma theileri parasite.
2. The recombinant T. theileri parasite according to claim 1, comprising at least one heterologous nucleic acid sequence.
3. The recombinant T. theileri parasite according to claim 2, wherein the heterologous nucleic acid sequence is capable of encoding at least one heterologous protein.
4. The recombinant T. theileri parasite according to claim 3, wherein the heterologous protein is a protein or protein-fragment selected from the group consisting of: an antigen, a cytokine, a hormone, an antimicrobial protein or an antibody.
5. Method for sustained delivery of a protein to a bovine animal, comprising the inoculation of said bovine animal with the recombinant T. theileri parasite according to any one of claims 1-4.
6. The recombinant T. theileri parasite according to any one of claims 1-4, for use as a sustained delivery vector for bovine animals.
7. Use of the recombinant T. theileri parasite according to any one of claims 1-4, for the manufacture of a composition comprising a sustained delivery vector for bovine animals.
8. Composition for the sustained delivery of a protein to a bovine animal, comprising the recombinant T. theileri parasite according to any one of claims 1-4 and a pharmaceutically acceptable carrier.
9. The recombinant T. theileri parasite according to any one of claims 1-4, for use as a medicament for bovine animals.
10. The recombinant T. theileri parasite according to any one of claims 1-4, for use as a vaccine for bovine animals.
11. Use of the recombinant T. theileri parasite according to any one of claims 1-4, for the manufacture of a vaccine for bovine animals.
12. Vaccine comprising the recombinant T. theileri parasite according to any one of claims 1-4 and a pharmaceutically acceptable carrier.
13. Method of vaccination of a bovine animal, comprising the step of inoculating said bovine animal with a vaccine according to claim 12.
14. Method for the preparation of the vaccine according to claim 12, said method comprising the admixing of the recombinant T. theileri parasite according to any one of claims 1-4 and a pharmaceutically acceptable carrier.
15. Method of non-curative treatment of bovine animals comprising the step of inoculating said bovine animal with a composition according to claim 8.
16. Use of the recombinant T. theileri parasite according to any one of claims 1-4, for a non-curative treatment of bovine animals.
17. Method for the preparation of the recombinant T. theileri parasite according to any one of claims 1-4, comprising the mutation of the genomic DNA of a T. theileri parasite.
18. The method according to claim 17, wherein the mutation comprises the insertion into the genomic DNA of a T. theileri parasite of a heterologous nucleic acid sequence capable of encoding at least one heterologous protein
19. The method according to any one of claims 17 or 18, comprising the steps of: 
 a. transfection of a T. theileri parasite with a DNA molecule comprising a heterologous nucleic acid sequence capable of encoding at least one heterologous protein, 
 b. allowing homologous recombination between said DNA molecule and the genomic DNA of said T. theileri parasite, and 
 c. selection of the desired recombinant T. theileri parasite.";"(EP2598163)
The present invention relates to the field of the veterinary medicine of bovine animals.
In particular the invention relates to a recombinant Trypanosoma theileri parasite, preferably comprising a heterologous nucleic acid sequence that is capable of encoding a protein for instance an antigen, a cytokine, a hormone, an antimicrobial protein, or an antibody.
Also disclosed are uses of and methods for making and using the recombinant T. theileri parasite in medical or non-curative treatments; in particular as a sustained delivery vector for proteins to bovine animals, e.g. as a vaccine.
For the invention, a ""bovine animal"" relates to domestic (taurine) cattle, but also to bison, buffalo, zebu, and yak.
Therefore the invention relates to a recombinant Trypanosoma theileri parasite for use in a method for the sustained delivery of a heterologous protein to a bovine animal as described in claims 1-8.
The present invention relates to the field of the veterinary medicine of bovine animals.";"(EP2598163)
This has advantageously allowed the parasite to replicate after inoculation into a bovine animal.
Also, because of the natural nonpathogenic character of the T. theileri parasite, there is no need for complex measures for its attenuation, and there is no chance of any back-mutation to a pathogenic state, even upon its prolonged existence in the host.
Such a recombinant T. theileri parasite has advantageously been used to comprise a heterologous nucleic acid, which was capable of encoding a heterologous protein.
However, as this does not change the microorganism involved or its characterising features, only its name or classification, such re-classified organisms are considered to remain within the scope of the invention.
It is therefore expected that T. theileri has developed some way to overcome the hosts' immune response, for instance by inducing immune-tolerance or immune-suppression in the host, or by applying immune-evasion mechanisms, but it is not known how this is accomplished, and for none of these routes there are clear indications: induction of immune-tolerance or -suppression is not likely as bovine carriers do not show any signs of such effect.
this does not change the microorganism involved or its characterising features, only its name or classification, such re-classified organisms are considered to remain within the scope of the invention.
The health aspect primarily regards the bovine health, but human health is also involved, as zoonoses from bovines to the human species are known; e.g. cross-species infections with bacteria such as Tuberculosis or E. coli 0157, with Rabies virus, or Cryptosporidium parasites.";"A61K-039/00
A61K-039/005
C07K-014/44
C12N-001/11
C12N-015/00";"(EP2598163)
1. A recombinant Trypanosoma theileri parasite for use in a method for the sustained delivery of a heterologous protein to a bovine animal, said method comprising inoculating said bovine animal with a sustained delivery vector comprising a recombinant T. theileri parasite, wherein the vector comprises a heterologous nucleic acid sequence encoding the heterologous protein and a resistance gene encoding a protein that provides resistance to an antiparasitic drug, the resistance gene being selected based on the natural sensitivity profile of the recombinant T. theileri.";"(EP2412382)
RECOMBINANT TRYPANOSOMA THEILERI PARASITE(100,5)
THEILERI PARASITE(45,147)
BOVINE ANIMAL(27,42)
SUSTAINED DELIVERY VECTOR(20,9)
ANTIMICROBIAL PROTEIN(17,9)
CRYPTOSPORIDIUM PARASITE(17,1)
RECOMBINANT T(16,105)
HETEROLOGOUS PROTEIN(16,29)
NATURAL NON PATHOGENIC CHARACTER(15,1)
PATHOGENIC PARASITE INFECTION(14,1)
HETEROLOGOUS NUCLEIC ACID SEQUENCE(12,25)
PROTEIN SUSTAINED DELIVERY(12,3)
GENOMIC DNA MUTATION(11,2)
PROLONGED EXISTENCE(11,1)
IMMUNE TOLERANCE INDUCTION(10,1)
RE CLASSIFIED ORGANISM(10,1)
VACCINE(9,50)
BOVINE HEALTH(9,2)
BOVINE CARRIER(8,1)
HUMAN HEALTH(8,1)
HUMAN SPECIES(8,1)
PROTEIN(7,63)
ANTIGEN(7,22)
HORMONE(7,15)
CYTOKINE(7,14)
ANTIBODY(7,11)
HOMOLOGOUS RECOMBINATION(7,8)
CLASSIFICATION(7,1)
CASSETTE INTEGRATION(6,19)
MEDICAL(6,3)
RECOMBINANT T ADMIXING(6,3)
IMMUNE EVASION(6,2)
VACCINE PREPARATION(6,2)
VETERINARY MEDICINE FIELD(6,2)
ATTENUATION(6,1)
CLEAR INDICATION(6,1)
MEASURING COMPLEX(6,1)
PATHOGENIC STATE(6,1)
TUBERCULOSIS(6,1)
ZOONOSIS(6,1)
PARASITE(5,24)
BOVINE(5,12)
MICROORGANISM(5,12)
HETEROLOGOUS NUCLEIC ACID(5,11)
INOCULATION(5,11)
THEILERI TRANSFERVECTOR(5,5)
T GENOMIC DNA(5,3)
BOVINE TREATMENT(5,2)
RABIESVIRUS(5,2)
VACCINE MANUFACTURE(5,2)
BACK MUTATION CHANCE(5,1)
BISON(5,1)
BUFFALO(5,1)
CROSS SPECIES INFECTION(5,1)
DOMESTIC(5,1)
EFFECT SIGN(5,1)
IMMUNE TOLERANCE(5,1)
SUPPRESSION(5,1)
ZEBU(5,1)
IMMUNE RESPONSE(4,11)
NON CURATIVE TREATMENT(4,7)
RECOMBINANT T PREPARATION(4,6)
BACTERIA(4,5)
ENCODED HETEROLOGOUS PROTEIN(4,4)
ANTIBODY DEPENDENT CYTOTOXICITY(4,1)
DEATH(4,1)
RECOMBINANT T REDUCED REPLICATION(4,1)
YAK(4,1)
DRUG RESISTANCE GENE(3,9)
PROTEIN DELIVERY(3,7)
ROUTE(3,6)
BOVINE HOST ANIMAL(3,5)
MEDICAMENT(3,5)
ANTIPARASITIC DRUG(3,4)
CATTLE(3,4)
PLASMID BACKBONE(3,4)
COMPOSITION MANUFACTURE(3,3)
THEILERI INFECTION(3,3)
BABESIA DIVERGENT(3,2)
MUTATIS MUTANDIS(3,2)
PROTOZOON PARASITE(3,2)
THEILERI GENOMIC DNA(3,2)
VETERINARY VACCINOLOGY(3,2)
BERZOFSKY AMPHIPHILICITY CRITERION(3,1)
CLASSICAL INACTIVATE ADJUVANTED VACCINE(3,1)
COMMENSAL INFECTION ESTABLISHMENT(3,1)
DICTYOCAULUS VIVIPARUS ACE(3,1)
GENUS LEISHMANIA PARASITE(3,1)
PARASITE REPLICATIVE MACHINERY(3,1)
POLYCISTRONIC GENOME ORGANIZATION(3,1)
THEILERI GENOME ORGANIZATION(3,1)
TRYPANOSOMA INFECTING CATTLE(3,1)
TRYPANOSOMATID GENOME ORGANIZATION(3,1)
UNSUCCESSFULLY TRANSFECTED PARASITE(3,1)
NUCLEIC ACID SEQUENCE(2,17)
MEAT QUALITY(2,5)
CASSETTE INSERTION(2,4)
LATED OUTPUT PARAMETER(2,4)
BLASTICIDIN RESISTANCE GENE(2,3)
PARASITOLOGY VOL(2,3)
SUSTAINED EXPRESSION(2,3)
ACCESSION NR(2,2)
ANTIGEN GENE(2,2)
EPISOMAL EXPRESSION(2,2)
INFECTION PROGRESSION(2,2)
PROTEIN PRESENTATION(2,2)
T CELL EPITOPE(2,2)
THEILERI RECOMBINANT(2,2)
TRANSIENT TRANSFECTION(2,2)
VACCINE DOSE(2,2)
ANTIGENIC EPITOPE FUSION PROTEIN(2,1)
ANTISENSE TRNA TRANSCRIPT(2,1)
ASPERGILLUS TERREUS(2,1)
BOVINE ANIMAL BLOODSTREAM(2,1)
BOVINE ANIMAL MICROORGANISM(2,1)
BOVINE ANIMAL NON THERAPEUTIC TREATMENT(2,1)
BOVINE ANIMAL VETERINARY MEDICINE(2,1)
BOVINE COMMENSAL MICROORGANISM(2,1)
BOVINE COMMENSAL PARASITE(2,1)
BOVINE HOST MANIPULATION(2,1)
BOVINE PATHOGEN ANTIGEN(2,1)
BOVINE PATHOGEN PROTECTIVE ANTIGEN(2,1)
BUFFY COAT ISOLATION(2,1)
CLINICAL DISEASE SYMPTOM(2,1)
COMMENSAL INFECTION EFFICIENT ESTABLISHMENT(2,1)
COMMENSAL LIFESTYLE(2,1)
COMMENSALISM UNIQUE BIOLOGY(2,1)
CRYPTOSPORIDIUM PARVUM CP(2,1)
DIVERSE SPECIES GROUPING(2,1)
DNA MOLECULE AMPLIFICATION(2,1)
DOWNSTREAM GENE TRANSCRIPTION(2,1)
DRUG RESISTANT GENOTYPE(2,1)
EFFICACIOUS IMMUNE PROTECTION(2,1)
ENCODED PROTEIN DELIBERATE TARGETING(2,1)
ENCODED PROTEIN TARGETING(2,1)
ESTRUM SYNCHRONIZATION(2,1)
FLAGELLUM MORPHOMETRICS(2,1)
FORMERLY INOCULATED ANIMAL(2,1)
GENOME ORGANIZATION FEATURE(2,1)
HETEROLOGOUS PROTEIN EXPRESSION(2,1)
INFECTIOUS METACYCLIC STAGE PARASITE(2,1)
LIVE RECOMBINANT CARRIER MICROORGANISM(2,1)
MANNHEIMIA HAEMOLYTICA LEUKOTOXIN(2,1)
MEGATRYPANUM TRYPANOSOME(2,1)
NATURALLY INFECTED BOVINE(2,1)
NEMATODE GUT(2,1)
NON PATHOGENIC PARASITE(2,1)
OSTERTAGIA OSTERTAGI ASP(2,1)
PARASITE PROLIFERATION(2,1)
PARASITE SURROUNDINGS(2,1)
PARASITE SUSTAINED EXISTENCE(2,1)
PARASITE VECTOR CLEARANCE(2,1)
PASSIVE IMMUNITY GENTLE PROVISION(2,1)
PATENTING AUTHORITY(2,1)
PCATR REPORTER PLASMID(2,1)
POLYMORPHONUCLEAR LEUCOCYTE(2,1)
RECOMBINANT PARASITE MAINTENANCE(2,1)
RECOMBINANT PARASITE QUALITY(2,1)
RESTRICTION ENZYME DIGESTION(2,1)
SALIVARIAN TRYPANOSOME SPECIES T(2,1)
SPLICE LEADER ACCEPTOR SITE(2,1)
STABLY TRANSFECTED PARASITE(2,1)
SUBUNIT PROTEIN ADMINISTRATION DOSE(2,1)
TARGET GENOME INTEGRATION(2,1)
TAXONOMIC CLASSIFICATION(2,1)
THEILERI INTEGRATION CASSETTE(2,1)
THEILERI PARASITE GENOME(2,1)
TRANSFECTED PARASITE RECOVERY(2,1)
TRYPANOSOMA PARASITE(2,1)
VACCINE COMPONENT(2,1)
VIABLE RECOMBINANT PARASITE(2,1)
NUCLEOTIDE(1,6)
HANDBOOK(1,5)
STABILIZER(1,5)
GENOME REGION(1,4)
MARKER VACCINE(1,4)
RECEPTOR(1,4)
RRNA GENE(1,4)
BLEOMYCIN(1,3)
ELISA(1,3)
INSERTED HETEROLOGOUS NUCLEIC ACID(1,3)
PARASITAEMIA LEVEL(1,3)
PARASITE SURFACE(1,3)
RNA POLYMERASE(1,3)
SIGNAL SEQUENCE(1,3)
SIGNIFICANT DIFFERENCE(1,3)
ADDITIVE(1,2)
ARTIFICIAL ORIGIN(1,2)
BETA TUBULIN GENE(1,2)
CODING REGION(1,2)
COMMERCIAL SUPPLIER(1,2)
CONDITIONED MEDIUM(1,2)
CONFORMATION(1,2)
DELETION(1,2)
DRUG SELECTION(1,2)
ENCODING NUCLEIC ACID(1,2)
ESCHERICHIA(1,2)
FEED CONVERSION(1,2)
GENBANK(1,2)
GLYCOSYLATION(1,2)
HETEROLOGOUS GENE EXPRESSION(1,2)
IMMUNOACTIVE COMPONENT(1,2)
IMMUNOLOGICAL RESPONSE(1,2)
INTERLEUKIN(1,2)
LIVE RECOMBINANT T(1,2)
LIVE T(1,2)
MEAT QUANTITY(1,2)
MILK QUALITY(1,2)
NEOMYCIN(1,2)
OPTIMIZATION(1,2)
PHLEOMYCIN(1,2)
PREVALENCE(1,2)
PRODUCTION RE(1,2)
PUROMYCIN(1,2)
RECOGNITION SITE(1,2)
RECOMBINANT T GENERATION(1,2)
RECOMBINANT T SELECTION(1,2)
SALMONELLA(1,2)
SECRETION(1,2)
STABLE INTEGRATION(1,2)
STREPTOCOCCUS(1,2)
SUBSPECIE(1,2)
SUBSTITUTION(1,2)
SUSTAINED DELIVERY VEHICLE(1,2)
SUSTAINED PRESENCE(1,2)
THIMEROSAL(1,2)
ABUNDANT GLUCOSE(1,1)
ACCEPTOR SIGNAL(1,1)
ACETYLCHOLINESTERASE(1,1)
ACTIVE CENTER(1,1)
ACTIVE IMMUNITY GENERATION(1,1)
ACTIVE MULTIMERIC MOLECULE(1,1)
ADDED RESTRICTION SITE(1,1)
ADENOSINE MONOPHOSPHATE SIGNAL(1,1)
ALBERT ED(1,1)
ALPHA TUBULIN GENE(1,1)
AMIDATION(1,1)
ANAPLASMA(1,1)
ANIMAL AFRICAN TRYPANOSOMIASIS(1,1)
ANIMAL HEALTH(1,1)
ANIMAL INFECTION(1,1)
ANIMAL RESISTANCE(1,1)
ANTI INFLAMMATORY DRUG(1,1)
ANTI SELF IMMUNITY(1,1)
ANTIBODY DELIVERY(1,1)
ANTIBODY PANEL(1,1)
ANTIGEN EXPRESSION(1,1)
ANTIGEN FOLDING(1,1)
ANTIGENIC COMPOUND(1,1)
ARTHROPOD VECTOR(1,1)
AUTOMATIC CELL(1,1)
BACULOVIRUS(1,1)
BEEF CATTLE(1,1)
BETA SUBUNIT(1,1)
BIOACTIVE MOLECULE ASSEMBLY(1,1)
BIOLOGICAL BEHAVIOR(1,1)
BIOLOGICAL EFFECT SUPPRESSION(1,1)
BIOLOGICAL EFFICACY(1,1)
BITING INSECT VECTOR(1,1)
BLOCKADE(1,1)
BOOPHILUS(1,1)
BOOSTER VACCINATION(1,1)
BOVINE ANIMAL TREATMENT(1,1)
BOVINE ANTIBODY(1,1)
BOVINE BLOOD ML(1,1)
BOVINE CELL(1,1)
BOVINE CYTOKINE(1,1)
BOVINE EPITHELIAL CELL(1,1)
BOVINE HERPES VIRUS(1,1)
BOVINE HOST BLOOD(1,1)
BOVINE HOST LIFETIME(1,1)
BOVINE INFECTION(1,1)
BOVINE INTERFERON(1,1)
BOVINE KIDNEY CELL(1,1)
BOVINE LUNGWORM(1,1)
BOVINE NEMATODE(1,1)
BOVINE PARAMETER(1,1)
BOVINE PARAMYXOVIRUS(1,1)
BOVINE POPULATION(1,1)
BOVINE PRODUCTION PARAMETER(1,1)
BOVINE TARGET ANIMAL(1,1)
BRUCEI PARASITE(1,1)
BRUCELLA(1,1)
CALF(1,1)
CALMODULIN(1,1)
CARBOHYDRATE(1,1)
CARBOXYLATION(1,1)
CATIONIC LIPOSOME(1,1)
CATTLE MALARIA(1,1)
CELL CULTURE TECHNOLOGY(1,1)
CELL DENSITY(1,1)
CELL MOLECULAR BIOLOGY(1,1)
CELLULAR IMMUNITY(1,1)
CELLULAR ORGANELLE PRESENCE(1,1)
CENTROMER(1,1)
CHALLENGE INFECTION(1,1)
CHAPERONIN(1,1)
CHEMICAL TRANSFECTION(1,1)
CHLORAMPHENICOL ACETYLTRANSFERASE GENE(1,1)
CHLORAMPHENICOL ACETYLTRANSFERASE PRODUCTION(1,1)
CHLORAMPHENICOL ACETYLTRANSFERASE PROTEIN(1,1)
CITROBACTER(1,1)
CLASSICAL SUBUNIT(1,1)
CLINICAL DISEASE SIGN(1,1)
CLINICAL SIGN INTENSITY(1,1)
CLONTECH LABORATORY(1,1)
COAGULATING BLOOD(1,1)
COLI CHLORAMPHENICOL ACETYLTRANSFERASE(1,1)
COLOSTRAL ANTIBODY(1,1)
COMMENSAL ORGANISM(1,1)
COMMENSAL STATUS(1,1)
COMMERCIAL CATTLE(1,1)
COMMERCIAL KIT(1,1)
COMPLETE PROTEIN EXPRESSION(1,1)
COMPLEX DISEASE RELEVANT PATHOGEN(1,1)
COMPLEX INTEGRATION CASSETTE(1,1)
COMPOUND ADMINISTRATION(1,1)
CONSTANT SYSTEMIC EXPRESSION(1,1)
CONSTRUCT TANDEM(1,1)
COUNTING CHAMBER(1,1)
COW BLOOD(1,1)
CPG MOTIF(1,1)
DELIBERATE GENETIC MODIFICATION(1,1)
DELIVERY ROUTE(1,1)
DETECTION REPORT(1,1)
DEVELOPMENTAL STAGE(1,1)
DISEASE PREVENTION(1,1)
DISEASE TREATMENT(1,1)
DNA LIGATION(1,1)
DOSE ADMINISTRATION(1,1)
DOSING(1,1)
DYING CELL(1,1)
DYING PARASITE(1,1)
EARLY INOCULATION(1,1)
ECONOMIC IMPORTANCE(1,1)
ECONOMIC PERFORMANCE(1,1)
ECONOMIC REASON(1,1)
EFFICIENT INTEGRATION(1,1)
EFFICIENT MONITORING(1,1)
EFFICIENT PCR ASSAY(1,1)
ENCODED PROTEIN QUALITY(1,1)
ENCODING GENE(1,1)
ENCODING SEQUENCE(1,1)
ESCAPE ROUTE(1,1)
ESTRUM MOMENT(1,1)
EUKARYOTIC CELL CULTURE(1,1)
EXPLICIT DIFFERENCE(1,1)
EXPRESSED ANTIGENIC PROTEIN(1,1)
EXTENSIVE TESTING(1,1)
EXTRACELLULAR T(1,1)
FD FRAGMENT(1,1)
FEEDER CELL UNFAVORABLE INTERFERENCE(1,1)
FERTILITY MANIPULATION(1,1)
FERTILITY REGULATION(1,1)
FERTILITY STIMULATION(1,1)
FLANKING REGION(1,1)
FLANKING SIGNAL EXCHANGE(1,1)
FOREIGN SEQUENCE(1,1)
FUNCTIONAL PROTEIN FRAGMENT(1,1)
GEL ELECTROPHORESIS(1,1)
GENE DISRUPTION(1,1)
GENE SEQUENCE(1,1)
GENEARRAY(1,1)
GENETIC INFORMATION MUTATION(1,1)
GENOME INSERTION(1,1)
GENOMIC NUCLEIC ACID(1,1)
GLOBAL SOCIAL(1,1)
GLYCEROL SHOCK(1,1)
GOVERNMENTAL REGULATION(1,1)
GROWTH PROMOTION(1,1)
HABITAT(1,1)
HAEMOPARASITE(1,1)
HEALTH REASON(1,1)
HEALTHY TARGET(1,1)
HEMOFLAGELLATE(1,1)
HETEROCHROMATIC REGION(1,1)
HETERODIMERIC PROTEIN(1,1)
HETEROLOGOUS GENE INSERT(1,1)
HETEROLOGOUS PROTEIN PRODUCTION(1,1)
HIDDEN ANTIGEN(1,1)
HIGHLY EXPRESSED GENE(1,1)
HORMONE TREATMENT(1,1)
HOST ORAL MUCOSA(1,1)
HOUSEKEEPING GENE REGION(1,1)
HUMAN APOLIPOPROTEIN(1,1)
HUMAN INTERVENTION(1,1)
IMMOBILIZED BD(1,1)
IMMUNE ENHANCING SUBSTANCE(1,1)
IMMUNE STIMULATORY MOLECULE(1,1)
IMMUNOFLUORESCENCE ASSAY(1,1)
IMMUNOGENIC FRAGMENT SELECTION(1,1)
IMMUNOGENIC PROTEIN(1,1)
IMMUNOLOGICAL QUALITY ASSESSMENT(1,1)
IMMUNOLOGICAL STATUS(1,1)
IMMUNOSTIMULATORY NUCLEIC ACID(1,1)
INEFFICIENT GLUCOSE(1,1)
INFECTED ANIMAL(1,1)
INFECTION PREVENTION(1,1)
INOCULATED BOVINE(1,1)
INOCULATION MOMENT(1,1)
INOCULUM DOSE(1,1)
INSECT CELL(1,1)
INSECT SALIVARY GLAND(1,1)
INSERTED HETEROLOGOUS GENE(1,1)
INSERTION MUTATION(1,1)
INTEGRATION CASSETTE CONSTRUCTION(1,1)
INTEGRATION EXACT LOCATION(1,1)
INTEGRATION REGION SELECTION(1,1)
INTERARRAY POSITIONAL DIFFERENCE(1,1)
INTERGENIC UNTRANSLATED REGION(1,1)
INTRACELLULAR KINETOPLAST LOCATION(1,1)
INTRACELLULAR T(1,1)
INTRACELLULARLY INSIDE MACROPHAGE(1,1)
IXODE SPEC(1,1)
JOINED CLASSIFICATION(1,1)
JURISDICTION(1,1)
LESION SEVERITY(1,1)
LIFE RECOMBINANT T DOSE(1,1)
LIFELONG IMMUNITY(1,1)
LINEAR EPITOPE(1,1)
LIPOFECTIN REAGENT(1,1)
LIVE INFECTIOUS STATE(1,1)
LIVE MICROORGANISM(1,1)
LYTIC FACTOR(1,1)
MAMMAL VARIETY(1,1)
MAMMALIAN DERIVED PROTEIN EXPRESSION(1,1)
MARKER GENE(1,1)
MATURE PROTEIN(1,1)
MICROBIOSTATIC ACTIVITY(1,1)
MICROORGANISM INACTIVATION(1,1)
MICROPLUS BM(1,1)
MILK CATTLE(1,1)
MILK QUANTITY(1,1)
ML PARASITE(1,1)
MOBILE GENETIC ELEMENT(1,1)
MODIFIED GENOTYPE(1,1)
MOLECULAR BIOLOGY CENTRAL DOGMA(1,1)
MRNA TRANSCRIPTION(1,1)
MRNA UNTRANSLATED REGION(1,1)
MUCOSAL EPITHELIUM(1,1)
MUSCLE GROWTH(1,1)
MUTATION POSITION(1,1)
MUTUAL COMPETITION(1,1)
NATURAL SENSITIVITY(1,1)
NESTED PCR ASSAY(1,1)
NON PATHOGENIC NATURE(1,1)
NON RECOMBINANT T(1,1)
OBSCURE SUBGROUP(1,1)
OPTIMAL GENOMIC INSERTION REGION(1,1)
OPTIMAL PARASITAEMIA(1,1)
OPTIMAL VIABILITY(1,1)
OPTIMIZED ASSAY(1,1)
OUTER ANTIGENIC COAT(1,1)
PARAFLAGELLAR ROD(1,1)
PARAINFLUENZA(1,1)
PARASITE DETECTION(1,1)
PARASITE GENOME SECTION(1,1)
PARASITE INSECT VECTOR(1,1)
PARASITE INTERNAL ORGAN(1,1)
PARASITE LIFELONG PRESENCE(1,1)
PARASITE ML BLOOD(1,1)
PARASITE SELECTION(1,1)
PARASITIC ORGANISM(1,1)
PARASITOLOGY RESEARCH(1,1)
PARENTERAL ROUTE(1,1)
PATHOGEN SPREAD(1,1)
PATHOGENIC SPECIES(1,1)
PBR PLASMID(1,1)
PCR PRIMER(1,1)
PERFORMANCE RE(1,1)
PERIPHERAL BLOOD LYMPHOCYTE CULTIVATION(1,1)
PHENOLIC COMPOUND(1,1)
PHYSIOLOGICAL BUFFER(1,1)
PLASMID CLONING(1,1)
POLYADENYLATION SIGNAL(1,1)
POLYCISTRONIC REPLICATION MODE(1,1)
POVIDONE(1,1)
PRIMER SELECTION(1,1)
PRIMING VACCINATION(1,1)
PRODUCTIVE INFECTION(1,1)
PRODUCTIVE REPLICATION(1,1)
PROLONGED EXPRESSION(1,1)
PROPER ACTIVE IMMUNIZATION(1,1)
PROPER BIOLOGICAL ACTIVITY(1,1)
PROPHYLACTIC EFFICACY(1,1)
PROTEIN ANTIGEN(1,1)
PROTEIN BIOLOGIC SOURCE(1,1)
PROTEIN CONTINUOUS DAILY EXPRESSION(1,1)
PROTEIN DEFINITION(1,1)
PROTEIN EXPRESSION TIMING(1,1)
PROTEIN POST TRANSLATIONAL PROCESSING(1,1)
PROTEIN SUBUNIT(1,1)
PUBLIC DATABASE(1,1)
RAISING ANTIBODY(1,1)
RECLASSIFICATION(1,1)
RECOMBINANT DNA MOLECULE(1,1)
RECOMBINANT MANIPULATION(1,1)
RECOMBINANT MICROORGANISM(1,1)
RECOMBINANT PHENOTYPE(1,1)
RECOMBINANT T AMPLIFICATION(1,1)
RECOMBINANT T CONTEXT(1,1)
RECOMBINANT T GENOME(1,1)
RECOMBINANT T INOCULATION(1,1)
RECOMBINANT T QUALITY(1,1)
RECOMBINANT T STUDYING(1,1)
RECOMBINANT T SURVIVAL(1,1)
RECOMBINANT T VIABILITY(1,1)
RECOMBINANT VECTOR(1,1)
RECOMBINATION VERIFICATION(1,1)
RELIANT INDICATOR(1,1)
RESISTANCE PHENOTYPE(1,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(1,1)
RNA TRANSCRIPTION DETECTION(1,1)
RNA TRANSCRIPTION LEVEL(1,1)
ROLLER BOTTLE(1,1)
ROUTINE PRACTITIONER SKILL(1,1)
SCIENCE PUBLISHER(1,1)
SCIENTIFIC LITERATURE(1,1)
SELECTIVE CRITERION(1,1)
SELECTIVE DRUG CONCENTRATION(1,1)
SENSITIVE PCR ASSAY(1,1)
SEPARATE SUBUNIT EXPRESSION(1,1)
SEQUENCE COMPETING(1,1)
SEQUENCE MUTATION(1,1)
SEROCONVERSION(1,1)
SEROLOGICAL ASSAY(1,1)
SEROLOGICAL PARAMETER(1,1)
SIMULTANEOUS INOCULATION(1,1)
SLEEPING DISEASE(1,1)
SOUTHERN AMERICA(1,1)
SPATIAL FOLDING(1,1)
SPECIAL VACUOLE(1,1)
SPECIALIZED MODIFICATION(1,1)
SPECIES DETERMINATION(1,1)
SPERM ANTIGEN(1,1)
STABLE TRANSFECTION SELECTION(1,1)
STAINED BLOOD SMEAR(1,1)
STERILE PHYSIOLOGICAL SALT SOLUTION(1,1)
SUB SAHARAN AFRICA(1,1)
SUBUNIT VACCINE COMMON DOSE(1,1)
SUCCESSFUL SURVIVAL(1,1)
SUMMER SEASON(1,1)
SYNTHETIC ORIGIN(1,1)
TANDEM GENE(1,1)
TARGET HOST(1,1)
TARGET ORGANISM(1,1)
TARGET RECOMBINATION REGION(1,1)
TAXONOMIC PLACING(1,1)
TETANUS TOXIN(1,1)
THEILERI ACTIN INTERGENIC REGION(1,1)
THEILERI CELL CULTURE MEDIUM(1,1)
THEILERI CULTURE MEDIUM(1,1)
THEILERI GENE(1,1)
THEILERI GENOMIC SEQUENCE INFORMATION(1,1)
THEILERI INCIDENCE(1,1)
THEILERI NEGATIVE ANIMAL(1,1)
THEILERI ORGANISM(1,1)
THEILERI PARASITE CELL CULTURE(1,1)
THEILERI SPECIES(1,1)
THEILERI STRAIN(1,1)
THERAPEUTIC VACCINATION(1,1)
TRANSFECTION EFFICIENCY(1,1)
TREATMENT NATURE(1,1)
TRIAL FULL DURATION(1,1)
TRYPANOSOMA CLASSIFICATION SECTION(1,1)
TRYPANOSOMA SPECIES(1,1)
TUBULIN INTERGENIC REGION(1,1)
TUMOR NECROSIS FACTOR(1,1)
UBIQUITOUS PRESENCE(1,1)
UNFAVORABLE ACTIVITY(1,1)
UNIQUE RESTRICTION ENZYME RECOGNITION(1,1)
UNIQUE RESTRICTION ENZYME SITE(1,1)
UNVACCINATED ANIMAL(1,1)
VACCINATION REACTION(1,1)
VACCINATION RESPONSE(1,1)
VACCINE ADMINISTRATION(1,1)
VACCINE COMPOSITION COMPONENT(1,1)
VACCINE EFFICACY(1,1)
VACCINE FORMULATION(1,1)
VACCINE PRODUCTION(1,1)
VACCINE SAFETY(1,1)
VECTOR ABILITY(1,1)
VECTOR BYTE(1,1)
VERIFICATION EXPERIMENT(1,1)
VERTEBRATE HOST(1,1)
WHOLE PROTEIN(1,1)
WHOLE TRANSFERVECTOR(1,1)
YOUNG AGE(1,1)
(EP2598163)
PARASITE(100,27)
RECOMBINANT TRYPANOSOMA THEILERI PARASITE(100,3)
RECOMBINANT TRYPANOSOMA(100,1)
THEILERI PARASITE(53,136)
HETEROLOGOUS PROTEIN SUSTAINED DELIVERY(52,3)
BOVINE ANIMAL(28,32)
CRYPTOSPORIDIUM PARASITE(27,1)
NATURAL NON PATHOGENIC CHARACTER(24,1)
RECOMBINANT T(23,106)
HETEROLOGOUS PROTEIN(23,28)
SUSTAINED DELIVERY VECTOR(23,6)
PATHOGENIC PARASITE INFECTION(23,1)
PROLONGED EXISTENCE(18,1)
THEILERI ACTIN INTERGENIC SEQUENCE(18,1)
ANTIMICROBIAL PROTEIN(17,8)
IMMUNE TOLERANCE INDUCTION(16,1)
RE CLASSIFIED ORGANISM(16,1)
BOVINE HEALTH(15,2)
RESISTANCE GENE ENCODING(14,2)
RESISTANCE GENE(13,3)
BOVINE CARRIER(13,1)
HUMAN SPECIES(13,1)
CASSETTE INTEGRATION(12,23)
CLASSIFICATION(12,1)
HUMAN HEALTH(12,1)
PROTEIN(11,66)
HETEROLOGOUS NUCLEIC ACID(11,12)
NATURAL SENSITIVITY(11,3)
INOCULATION MOMENT(11,2)
VACCINE(10,48)
HETEROLOGOUS NUCLEIC ACID SEQUENCE(10,21)
ANTIPARASITIC DRUG(10,6)
SIGNAL SEQUENCE(10,5)
IMMUNE EVASION(10,2)
NUCLEIC ACID SEQUENCE ENCODING(10,2)
ATTENUATION(10,1)
CLEAR INDICATION(10,1)
TUBERCULOSIS(10,1)
BOVINE(9,13)
BACK MUTATION CHANCE(9,1)
BUFFALO(9,1)
DOMESTIC(9,1)
MEASURING COMPLEX(9,1)
PATHOGENIC STATE(9,1)
SUPPRESSION(9,1)
ZOONOSIS(9,1)
ANTIGEN(8,21)
HORMONE(8,14)
CYTOKINE(8,13)
MICROORGANISM(8,12)
ANTIBODY(8,10)
THEILERI TRANSFERVECTOR(8,5)
BOVINE TREATMENT(8,2)
BISON(8,1)
CROSS SPECIES INFECTION(8,1)
EFFECT SIGN(8,1)
IMMUNE TOLERANCE(8,1)
PROTEINFRAGMENT(8,1)
ZEBU(8,1)
IMMUNE RESPONSE(7,11)
INOCULATION(7,11)
RNA PROCESSING(7,9)
HOMOLOGOUS RECOMBINATION(7,7)
RABIESVIRUS(7,2)
YAK(7,1)
ROUTE(6,6)
VECTOR(6,6)
BACTERIA(6,5)
ENCODED HETEROLOGOUS PROTEIN(6,4)
GENOMIC DNA MUTATION(6,2)
THEILERI GENOMIC DNA(6,2)
ANTIBODY DEPENDENT CYTOTOXICITY(6,1)
DEATH(6,1)
RECOMBINANT T REDUCED REPLICATION(6,1)
VETERINARY MEDICINE FIELD(6,1)
DRUG RESISTANCE GENE(5,9)
PROTEIN DELIVERY(5,7)
BOVINE HOST ANIMAL(5,5)
CATTLE(5,5)
PLASMID BACKBONE(5,4)
BABESIA DIVERGENT(5,3)
PHLEOMYCIN(5,3)
THEILERI INFECTION(5,3)
MEDICAL(5,2)
PROTOZOON PARASITE(5,2)
BERZOFSKY AMPHIPHILICITY CRITERION(5,1)
CLASSICAL INACTIVATE ADJUVANTED VACCINE(5,1)
COMMENSAL INFECTION ESTABLISHMENT(5,1)
DICTYOCAULUS VIVIPARUS ACE(5,1)
GENUS LEISHMANIA PARASITE(5,1)
MUTANT TRYPANOSOMATID PROTOZOA(5,1)
PARASITE REPLICATIVE MACHINERY(5,1)
POLYCISTRONIC GENOME ORGANIZATION(5,1)
THEILERI GENOME ORGANIZATION(5,1)
TRYPANOSOMA INFECTING CATTLE(5,1)
TRYPANOSOMATID GENOME ORGANIZATION(5,1)
UNSUCCESSFULLY TRANSFECTED PARASITE(5,1)
RECOMBINANT T PREPARATION(4,6)
CASSETTE INSERTION(4,4)
BLASTICIDIN RESISTANCE GENE(4,3)
PARASITOLOGY VOL(4,3)
RECOMBINANT T ADMIXING(4,3)
SUSTAINED EXPRESSION(4,3)
INFECTION PROGRESSION(4,2)
MUTATIS MUTANDIS(4,2)
PROTEIN SUSTAINED DELIVERY(4,2)
T CELL EPITOPE(4,2)
THEILERI RECOMBINANT(4,2)
VETERINARY VACCINOLOGY(4,2)
ANTIGENIC EPITOPE FUSION PROTEIN(4,1)
ANTISENSE TRNA TRANSCRIPT(4,1)
BOVINE ANIMAL MICROORGANISM(4,1)
BOVINE COMMENSAL MICROORGANISM(4,1)
BOVINE COMMENSAL PARASITE(4,1)
BOVINE PATHOGEN ANTIGEN(4,1)
BOVINE PATHOGEN PROTECTIVE ANTIGEN(4,1)
COMMENSAL INFECTION EFFICIENT ESTABLISHMENT(4,1)
ENCODED PROTEIN DELIBERATE TARGETING(4,1)
INFECTIOUS METACYCLIC STAGE PARASITE(4,1)
MANNHEIMIA HAEMOLYTICA LEUKOTOXIN(4,1)
PARASITE SUSTAINED EXISTENCE(4,1)
PCATR REPORTER PLASMID(4,1)
SPLICE LEADER ACCEPTOR SITE(4,1)
STABLY TRANSFECTED PARASITE(4,1)
THEILERI PARASITE GENOME(4,1)
TRANSFECTED PARASITE RECOVERY(4,1)
TRYPANOSOMA PARASITE(4,1)
VIABLE RECOMBINANT PARASITE(4,1)
NUCLEOTIDE(3,6)
MEAT QUALITY(3,5)
GENOME REGION(3,4)
LATED OUTPUT PARAMETER(3,4)
NON CURATIVE TREATMENT(3,4)
RRNA GENE(3,4)
ANTIGEN GENE(3,3)
ACCESSION NR(3,2)
ARTIFICIAL ORIGIN(3,2)
BETA TUBULIN GENE(3,2)
COMMERCIAL SUPPLIER(3,2)
EPISOMAL EXPRESSION(3,2)
GENBANK(3,2)
HETEROLOGOUS GENE EXPRESSION(3,2)
LIVE RECOMBINANT T(3,2)
NESTED PCR ASSAY(3,2)
PROTEIN PRESENTATION(3,2)
SUSTAINED DELIVERY VEHICLE(3,2)
SUSTAINED WAY(3,2)
T GENOMIC DNA(3,2)
TRANSIENT TRANSFECTION(3,2)
VACCINE DOSE(3,2)
VACCINE PREPARATION(3,2)
ANIMAL AFRICAN TRYPANOSOMIASIS(3,1)
ANTI INFLAMMATORY DRUG(3,1)
ASPERGILLUS TERREUS(3,1)
BOOSTER VACCINATION(3,1)
BOVINE ANIMAL BLOODSTREAM(3,1)
BOVINE ANIMAL NON THERAPEUTIC TREATMENT(3,1)
BOVINE ANIMAL VACCINATION(3,1)
BOVINE ANIMAL VETERINARY MEDICINE(3,1)
BOVINE EPITHELIAL CELL(3,1)
BOVINE HOST BLOOD(3,1)
BOVINE HOST LIFETIME(3,1)
BOVINE HOST MANIPULATION(3,1)
BOVINE INFECTION(3,1)
BOVINE LUNGWORM(3,1)
BOVINE NEMATODE(3,1)
BOVINE PARAMYXOVIRUS(3,1)
BOVINE POPULATION(3,1)
BOVINE TARGET ANIMAL(3,1)
BRUCEI PARASITE(3,1)
BUFFY COAT ISOLATION(3,1)
CATTLE MALARIA(3,1)
CLASSICAL SUBUNIT(3,1)
CLINICAL DISEASE SIGN(3,1)
CLINICAL DISEASE SYMPTOM(3,1)
CLINICAL SIGN INTENSITY(3,1)
COLOSTRAL ANTIBODY(3,1)
COMMENSAL LIFESTYLE(3,1)
COMMENSAL ORGANISM(3,1)
COMMENSAL STATUS(3,1)
COMMENSALISM UNIQUE BIOLOGY(3,1)
CRYPTOSPORIDIUM PARVUM CP(3,1)
DELIBERATE GENETIC MODIFICATION(3,1)
DIVERSE SPECIES GROUPING(3,1)
DNA MOLECULE AMPLIFICATION(3,1)
DOWNSTREAM GENE TRANSCRIPTION(3,1)
DRUG RESISTANT GENOTYPE(3,1)
DYING PARASITE(3,1)
EFFICACIOUS IMMUNE PROTECTION(3,1)
ENCODED PROTEIN TARGETING(3,1)
ENCODING GENE(3,1)
ESTRUM SYNCHRONIZATION(3,1)
EXPRESSED ANTIGENIC PROTEIN(3,1)
EXPRESSED PROTEIN TRAFFICKING(3,1)
FERTILITY MANIPULATION(3,1)
FERTILITY STIMULATION(3,1)
FLAGELLUM MORPHOMETRICS(3,1)
FORMERLY INOCULATED ANIMAL(3,1)
GENE DISRUPTION(3,1)
GENOME ORGANIZATION FEATURE(3,1)
HEME BIOSYNTHETIC PATHWAY(3,1)
HETERODIMERIC PROTEIN(3,1)
HETEROLOGOUS GENE INSERT(3,1)
HETEROLOGOUS PROTEIN EXPRESSION(3,1)
IMMOBILIZED BD(3,1)
IMMUNE ENHANCING SUBSTANCE(3,1)
IMMUNOFLUORESCENCE ASSAY(3,1)
IMMUNOGENIC FRAGMENT SELECTION(3,1)
IMMUNOLOGICAL QUALITY ASSESSMENT(3,1)
INOCULATED BOVINE(3,1)
INSECT SALIVARY GLAND(3,1)
INTRACELLULAR KINETOPLAST LOCATION(3,1)
LESION SEVERITY(3,1)
LIFELONG IMMUNITY(3,1)
LIVE MICROORGANISM(3,1)
LIVE RECOMBINANT CARRIER MICROORGANISM(3,1)
MAMMALIAN DERIVED PROTEIN EXPRESSION(3,1)
MEGATRYPANUM TRYPANOSOME(3,1)
MICROORGANISM INACTIVATION(3,1)
MICROPLUS BM(3,1)
MRNA TRANSCRIPTION(3,1)
MUCOSAL EPITHELIUM(3,1)
NATURALLY INFECTED BOVINE(3,1)
NEMATODE GUT(3,1)
NON PATHOGENIC PARASITE(3,1)
OBSCURE SUBGROUP(3,1)
OSTERTAGIA OSTERTAGI ASP(3,1)
PARASITE LIFELONG PRESENCE(3,1)
PARASITE PROLIFERATION(3,1)
PARASITE SURROUNDINGS(3,1)
PARASITE VECTOR CLEARANCE(3,1)
PASSIVE IMMUNITY GENTLE PROVISION(3,1)
PATENTING AUTHORITY(3,1)
PBR PLASMID(3,1)
POLYMORPHONUCLEAR LEUCOCYTE(3,1)
PRIMING VACCINATION(3,1)
PRODUCTIVE INFECTION(3,1)
PROPHYLACTIC EFFICACY(3,1)
RECOMBINANT PARASITE MAINTENANCE(3,1)
RECOMBINANT PARASITE QUALITY(3,1)
RECOMBINANT PHENOTYPE(3,1)
RECOMBINATION VERIFICATION(3,1)
REGULATEABLE EXPRESSION(3,1)
RESTRICTION ENZYME DIGESTION(3,1)
RNA TRANSCRIPTION DETECTION(3,1)
ROUTINE PRACTITIONER SKILL(3,1)
SALIVARIAN TRYPANOSOME SPECIES T(3,1)
SUBUNIT PROTEIN ADMINISTRATION DOSE(3,1)
TARGET GENOME INTEGRATION(3,1)
TAXONOMIC CLASSIFICATION(3,1)
THEILERI INCIDENCE(3,1)
THEILERI INTEGRATION CASSETTE(3,1)
THEILERI ORGANISM(3,1)
THEILERI PARASITE CELL CULTURE(3,1)
THERAPEUTIC VACCINATION(3,1)
TUMOR NECROSIS FACTOR(3,1)
VACCINE ADMINISTRATION(3,1)
VACCINE COMPONENT(3,1)
VACCINE COMPOSITION COMPONENT(3,1)
VACCINE EFFICACY(3,1)
VACCINE FORMULATION(3,1)
HANDBOOK(2,5)
STABILIZER(2,5)
MARKER VACCINE(2,4)
MEDICAMENT(2,4)
RECEPTOR(2,4)
BLEOMYCIN(2,3)
INSERTED HETEROLOGOUS NUCLEIC ACID(2,3)
PARASITAEMIA LEVEL(2,3)
RNA POLYMERASE(2,3)
CODING REGION(2,2)
CONDITIONED MEDIUM(2,2)
CONFORMATION(2,2)
DRUG SELECTION(2,2)
IMMUNOACTIVE COMPONENT(2,2)
IMMUNOLOGICAL RESPONSE(2,2)
MEAT QUANTITY(2,2)
MILK QUALITY(2,2)
PEPTIDE AGENT(2,2)
PREVALENCE(2,2)
RECOGNITION SITE(2,2)
RECOMBINANT T GENERATION(2,2)
RECOMBINANT T SELECTION(2,2)
STABLE INTEGRATION(2,2)
SUBSPECIE(2,2)
VACCINE PRODUCTION(2,2)
ABUNDANT GLUCOSE(2,1)
ACTIVE MULTIMERIC MOLECULE(2,1)
ALBERT ED(2,1)
ANIMAL HEALTH(2,1)
ANIMAL INFECTION(2,1)
ANTIBODY DELIVERY(2,1)
ANTIBODY PANEL(2,1)
ANTIGEN EXPRESSION(2,1)
ANTIGEN FOLDING(2,1)
ANTIGENIC COMPOUND(2,1)
BD COPY(2,1)
BETA SUBUNIT(2,1)
BIOACTIVE MOLECULE ASSEMBLY(2,1)
BIOLOGICAL BEHAVIOR(2,1)
BIOLOGICAL EFFICACY(2,1)
BITING INSECT VECTOR(2,1)
BOVINE ANIMAL TREATMENT(2,1)
BOVINE ANTIBODY(2,1)
BOVINE BLOOD ML(2,1)
BOVINE CELL(2,1)
BOVINE CYTOKINE(2,1)
BOVINE HERPES VIRUS(2,1)
BOVINE INTERFERON(2,1)
BOVINE KIDNEY CELL(2,1)
BOVINE PARAMETER(2,1)
BOVINE PRODUCTION PARAMETER(2,1)
CATIONIC LIPOSOME(2,1)
CELLULAR ORGANELLE PRESENCE(2,1)
CHALLENGE INFECTION(2,1)
CLONTECH LABORATORY(2,1)
COAGULATING BLOOD(2,1)
COMMERCIAL CATTLE(2,1)
COMPLEX DISEASE RELEVANT PATHOGEN(2,1)
COMPLEX INTEGRATION CASSETTE(2,1)
COMPOUND ADMINISTRATION(2,1)
CONDITIONALLY ACTIVE OPERATOR(2,1)
CONSTANT SYSTEMIC EXPRESSION(2,1)
CONSTRUCT TANDEM(2,1)
COW BLOOD(2,1)
CPG MOTIF(2,1)
DEVELOPMENTAL STAGE(2,1)
DISEASE PREVENTION(2,1)
DNA LIGATION(2,1)
DOSING(2,1)
EARLY INOCULATION(2,1)
ECONOMIC IMPORTANCE(2,1)
EFFICIENT PCR ASSAY(2,1)
ENCODED PROTEIN QUALITY(2,1)
ESCAPE ROUTE(2,1)
ESTRUM MOMENT(2,1)
EVENTUAL LYSIS(2,1)
FD FRAGMENT(2,1)
FEEDER CELL UNFAVORABLE INTERFERENCE(2,1)
FERTILITY REGULATION(2,1)
FUNCTIONAL PROTEIN FRAGMENT(2,1)
GEL ELECTROPHORESIS(2,1)
GENETIC INFORMATION MUTATION(2,1)
GENOME INSERTION(2,1)
GLOBAL SOCIAL(2,1)
GLYCEROL SHOCK(2,1)
GOVERNMENTAL REGULATION(2,1)
GROWTH PROMOTION(2,1)
HEALTHY TARGET(2,1)
HIDDEN ANTIGEN(2,1)
HOST ORAL MUCOSA(2,1)
HUMAN APOLIPOPROTEIN(2,1)
HUMAN INTERVENTION(2,1)
IMMUNE STIMULATORY MOLECULE(2,1)
IMMUNOGENIC PROTEIN(2,1)
IMMUNOLOGICAL STATUS(2,1)
INEFFICIENT GLUCOSE(2,1)
INFECTED ANIMAL(2,1)
INFECTION PREVENTION(2,1)
INOCULUM DOSE(2,1)
INSERTED HETEROLOGOUS GENE(2,1)
INSERTION MUTATION(2,1)
INTEGRATION CASSETTE CONSTRUCTION(2,1)
INTERARRAY POSITIONAL DIFFERENCE(2,1)
INTRACELLULARLY INSIDE MACROPHAGE(2,1)
IXODE SPEC(2,1)
JOINED CLASSIFICATION(2,1)
LIPOFECTIN REAGENT(2,1)
MARKER GENE(2,1)
MATURE PROTEIN(2,1)
MICROBIOSTATIC ACTIVITY(2,1)
MILK CATTLE(2,1)
MUTATION POSITION(2,1)
MUTUAL COMPETITION(2,1)
NON PATHOGENIC NATURE(2,1)
OPTIMAL PARASITAEMIA(2,1)
OPTIMAL VIABILITY(2,1)
OPTIMIZED ASSAY(2,1)
PARAFLAGELLAR ROD(2,1)
PARAINFLUENZA(2,1)
PARASITE DETECTION(2,1)
PARASITE INSECT VECTOR(2,1)
PARASITE SELECTION(2,1)
PARASITIC ORGANISM(2,1)
PARASITOLOGY RESEARCH(2,1)
PARENTERAL ROUTE(2,1)
PATHOGEN SPREAD(2,1)
PATHOGENIC SPECIES(2,1)
PCR PRIMER(2,1)
PHYSIOLOGICAL BUFFER(2,1)
PLASMID CLONING(2,1)
POLYCISTRONIC REPLICATION MODE(2,1)
PRIMER SELECTION(2,1)
PROLONGED EXPRESSION(2,1)
PROTEIN ANTIGEN(2,1)
PROTEIN CONTINUOUS DAILY EXPRESSION(2,1)
PROTEIN DEFINITION(2,1)
PROTEIN EXPRESSION TIMING(2,1)
PROTEIN POST TRANSLATIONAL PROCESSING(2,1)
PROTEIN SUBUNIT(2,1)
PUBLIC DATABASE(2,1)
RAISING ANTIBODY(2,1)
RECOMBINANT DNA MOLECULE(2,1)
RECOMBINANT MANIPULATION(2,1)
RECOMBINANT MICROORGANISM(2,1)
RECOMBINANT T AMPLIFICATION(2,1)
RECOMBINANT T CONTEXT(2,1)
RECOMBINANT T GENOME(2,1)
RECOMBINANT T INOCULATION(2,1)
RECOMBINANT T STUDYING(2,1)
RECOMBINANT T SURVIVAL(2,1)
RECOMBINANT T VIABILITY(2,1)
RECOMBINANT VECTOR(2,1)
RELIANT INDICATOR(2,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(2,1)
SCIENCE PUBLISHER(2,1)
SCIENTIFIC LITERATURE(2,1)
SELECTIVE CRITERION(2,1)
SELECTIVE DRUG CONCENTRATION(2,1)
SENSITIVE PCR ASSAY(2,1)
SEQUENCE COMPETING(2,1)
SEROLOGICAL ASSAY(2,1)
SEROLOGICAL PARAMETER(2,1)
SIMULTANEOUS INOCULATION(2,1)
SLEEPING DISEASE(2,1)
SOUTHERN AMERICA(2,1)
SPATIAL FOLDING(2,1)
SPECIAL VACUOLE(2,1)
SPECIALIZED MODIFICATION(2,1)
SPERM ANTIGEN(2,1)
STABLE TRANSFECTION SELECTION(2,1)
STAINED BLOOD SMEAR(2,1)
SUCCESSFUL SURVIVAL(2,1)
SUMMER SEASON(2,1)
TANDEM GENE(2,1)
TARGET ORGANISM(2,1)
TARGET RECOMBINATION REGION(2,1)
TAXONOMIC PLACING(2,1)
TETANUS TOXIN(2,1)
THEILERI ACTIN INTERGENIC REGION(2,1)
THEILERI CULTURE MEDIUM(2,1)
THEILERI GENE(2,1)
THEILERI GENOMIC SEQUENCE INFORMATION(2,1)
THEILERI NEGATIVE ANIMAL(2,1)
THEILERI SPECIES(2,1)
THEILERI STRAIN(2,1)
TRANSFECTION EFFICIENCY(2,1)
TRIAL FULL DURATION(2,1)
TRYPANOSOMA CLASSIFICATION SECTION(2,1)
TRYPANOSOMA SPECIES(2,1)
UNFAVORABLE ACTIVITY(2,1)
UNIQUE RESTRICTION ENZYME RECOGNITION(2,1)
UNIQUE RESTRICTION ENZYME SITE(2,1)
UNVACCINATED ANIMAL(2,1)
VACCINE ANTIGEN(2,1)
VACCINE MANUFACTURE(2,1)
VACCINE SAFETY(2,1)
VECTOR BYTE(2,1)
VERIFICATION EXPERIMENT(2,1)
VERTEBRATE HOST(2,1)
WHOLE TRANSFERVECTOR(2,1)
YOUNG AGE(2,1)
ELISA(1,3)
PARASITE SURFACE(1,3)
SIGNIFICANT DIFFERENCE(1,3)
ADDITIVE(1,2)
COMPOSITION MANUFACTURE(1,2)
DELETION(1,2)
ENCODING NUCLEIC ACID(1,2)
ESCHERICHIA(1,2)
FEED CONVERSION(1,2)
GLYCOSYLATION(1,2)
INTERLEUKIN(1,2)
LIVE T(1,2)
NEOMYCIN(1,2)
OPTIMIZATION(1,2)
PRODUCTION RE(1,2)
PUROMYCIN(1,2)
SALMONELLA(1,2)
SECRETION(1,2)
STREPTOCOCCUS(1,2)
SUBSTITUTION(1,2)
SUSTAINED PRESENCE(1,2)
THIMEROSAL(1,2)
ACCEPTOR SIGNAL(1,1)
ACETYLCHOLINESTERASE(1,1)
ACTIVE CENTER(1,1)
ACTIVE IMMUNITY GENERATION(1,1)
ADDED RESTRICTION SITE(1,1)
ADENOSINE MONOPHOSPHATE SIGNAL(1,1)
ALPHA TUBULIN GENE(1,1)
AMIDATION(1,1)
ANAPLASMA(1,1)
ANIMAL DERIVED COMPONENT(1,1)
ANIMAL PROTEIN(1,1)
ANIMAL RESISTANCE(1,1)
ANIMAL SERUM(1,1)
ANTI SELF IMMUNITY(1,1)
ARTHROPOD VECTOR(1,1)
AUTOMATIC CELL(1,1)
BACULOVIRUS(1,1)
BEEF CATTLE(1,1)
BIOLOGICAL EFFECT SUPPRESSION(1,1)
BLOCKADE(1,1)
BOOPHILUS(1,1)
BRUCELLA(1,1)
CALF(1,1)
CALMODULIN(1,1)
CARBOHYDRATE(1,1)
CARBOXYLATION(1,1)
CELL CULTURE TECHNOLOGY(1,1)
CELL DENSITY(1,1)
CELL MOLECULAR BIOLOGY(1,1)
CELLULAR IMMUNITY(1,1)
CENTROMER(1,1)
CHAPERONIN(1,1)
CHEMICAL TRANSFECTION(1,1)
CHLORAMPHENICOL ACETYLTRANSFERASE GENE(1,1)
CHLORAMPHENICOL ACETYLTRANSFERASE PRODUCTION(1,1)
CHLORAMPHENICOL ACETYLTRANSFERASE PROTEIN(1,1)
COLI CHLORAMPHENICOL ACETYLTRANSFERASE(1,1)
COMMERCIAL KIT(1,1)
COMPLETE PROTEIN EXPRESSION(1,1)
COUNTING CHAMBER(1,1)
DELIVERY ROUTE(1,1)
DETECTION REPORT(1,1)
DISEASE TREATMENT(1,1)
DOSE ADMINISTRATION(1,1)
DYING CELL(1,1)
ECONOMIC PERFORMANCE(1,1)
ECONOMIC REASON(1,1)
EFFICIENT INTEGRATION(1,1)
EFFICIENT MONITORING(1,1)
ENCODING SEQUENCE(1,1)
EUKARYOTIC CELL CULTURE(1,1)
EXPLICIT DIFFERENCE(1,1)
EXTENSIVE TESTING(1,1)
EXTRACELLULAR T(1,1)
FLANKING REGION(1,1)
FLANKING SIGNAL EXCHANGE((...)";Pharmaceuticals;Open
2010-07-05;"RU2010127726        A  2012-01-10 [RU2010127726]
STG: (A) Application for invention
AP : 2010RU-0127726 2010-07-05
RU2449013           C2 2012-04-27 [RU2449013]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2010RU-0127726 2010-07-05";36351931;"RU2010127726        A  2012-01-10 [RU2010127726]
RU2449013           C2 2012-04-27 [RU2449013]";2010RU-0127726;;FEDERAL NOE G UCHREZHDENIE FEDERAL NYJ TS OKHRANY ZDOROV JA ZHIVOTNYKH FGU VNIIZZH;FEDERAL NOE G UCHREZHDENIE FEDERAL NYJ TS OKHRANY ZDOROV JA ZHIVOTNYKH FGU VNIIZZH;;;1;"MISHCHENKO VLADIMIR ALEKSANDROVICH
PROKHVATILOVA LARISA BORISOVNA
LEVCHENKO SVETLANA VLADIMIROVNA
KONONOV ALEKSANDR VLADIMIROVICH
KORPUSOVA TAT JANA IVANOVNA";;;"(RU2449013)
Nadl-arriah virus strain of bovine viral diarrhoea for making biopreparations for diagnosis, specific prevention and treatment of bovine viral diarrhoea";"(RU2449013)
FIELD: chemistry. ^ SUBSTANCE: invention relates to veterinarian virology and biotechnology. A novel industrial strain NADL-ARRIAH of bovine viral diarrhoea is obtained. The strain is deposited in the microorganisms used in veterinary and animal husbandry of FGU VGNKI under registration number - industrial strain NADL-ARRIAH-DEP bovine viral diarrhoea. The strain is reproduced in passaged cultures of calf kidney cells, saiga finite cell line, intestinal mucus finite cell line, intraspecific swine embryo kidney hybrid finite cell line with swine splenocyte (A4ùC2) at 37C and in 72-96 hour of incubation, the virus accumulates therein in amount of 6.0-7.0 lg TCD50/cm3. The strain is stable and retains its properties for 10 passages. The strain is used to obtain hyperimmune blood serum to bovine viral diarrhoea on rabbit and guinea pigs, used for agent diagnosis and treating animal diseases.The invention can be used in veterinary. ^ EFFECT: inactivated emulsion vaccine derived from said strain protects immunised animals from direct infection by a virulent virus. ^ 1 dwg, 10 tbl, 7 ex";"(RU2449013)
1. Strain “OF NADL-VNIIZZH” of the virus of virus diarrhea of large livestock Of Diarrhea of virus of bovinum seven. Flaviviridae, the kind Of Pestivirus, deposited in the collection FGU “OF VGNKI” under the registration designation “OF NADL-VNIIZZH” - DEP, for preparing the biological preparations for diagnostics, specific preventive maintenance and the treatment of virus diarrhea of large livestock.";;;"A61K-039/12
C12N-007/00";;;Pharmaceuticals;Open
2010-03-06;"CN101934073         A  2011-01-05 [CN101934073]
STG: (A) Published application
AP : 2010CN-0120759 2010-03-06
CN101934073         B  2012-06-27 [CN101934073B]
STG: (B) Granted patent for invention
AP : 2010CN-0120759 2010-03-06";7166294;"CN101934073         A  2011-01-05 [CN101934073]
CN101934073         B  2012-06-27 [CN101934073B]";2010CN-0120759;;JILIN AGRICULTURAL UNIVERSITY;JILIN AGRICULTURAL UNIVERSITY;;;1;"GAO YUGANG
ZHANG LIANXUE
ZANG PU
LI FANYING
WANG NAN
LI RAN
DU RUI
WANG QUANKAI
LIU JIAJIA
YU WENYING
WANG YAXING";;;"(CN101934073B)
Bovine viral diarrhea virus (BVDV) transgenosis astragalus mongholicus vaccine and production method";"(CN101934073B)
The invention relates to a bovine viral diarrhea virus (BVDV) transgenosis Astragalus mongholicus vaccine and a production method which are used for preventing and curing animal bovine viral diarrhea virus, and overcoming the defects of poor immunogenicity and low protection of the existing inactivated vaccines and nucleic acid vaccines as well as unsafe application of the existing live poison vaccine. In the invention, BVDV RNA is taken as a template, a reverse transcription-polymerase chain reaction method is used for obtaining an E0 gene thereof, then a gene E0 recombination plant expression vector is constructed, a pollen tube pathway method is used for obtaining the BVDV E0 gene transgenosis Astragalus mongholicus, and the Astragalus mongholicus with immunogen transformed by the BVDVE0 gene is screened by an immunoblotting and an enzyme linked immunosorbent assay to obtain a vaccine product. The invention has the following beneficial effects: the BVDV E0 gene is expressed in theAstragalus mongholicus, which generates the protective antigen and adjuvant substance capable of increasing the immunization, thereby improving the antiviral effect of the Astragalus mongholicus and the optimun immunity of the vaccine; and the invnetion has the advangtages of easy production, convenient use, strong stability and no side effects.";"(CN101934073)
1 . Astragalus transgenic bovine viral diarrhea virus vaccine, characterized by reacting Bovine Viral Diarrhea Virus protective antigen gene in an edible anti-viral medicinal plants Astragalus expression in the host a vaccine produced product .
2 . Astragalus transgenic bovine viral diarrhea virus vaccine according to claim 1, characterized in that: first RNA as a template to bovine viral diarrhea virus using reverse transcription-polymerase chain reaction method to obtain E0 gene, enabling reconfiguration of Bovine Viral Diarrhea Virus gene E0 recombinant plant expression vector, and then uses the pollen tube pathway, bovine viral diarrhea virus gene E0 recombinant plant expression vector solution infused in the half open Astragalus stigma of a flower, seed was harvested seed matures to be Astragalus, planting the harvested seed yield shoots, respectively identified and reverse transcription polymerase chain reaction is carried out on the shoots-polymerase chain reaction method identification and protein electrophoresis identified, obtain a Bovine Viral Diarrhea Virus E0 gene transformation Astragalus, Western blotting and ELISA were screened by again through having immunogenic bovine viral diarrhea virus gene E0 transformed Astragalus, the resultant vaccine product .
3 . Bovine viral diarrhea virus vaccine method of producing transgenic milk vetch, characterized in that comprises the following steps: (1) Bovine Viral Diarrhea Virus gene E0 for obtaining a gene Conventional methods to extract RNA as a template RNA extracted bovine viral diarrhea virus genome, using reverse transcription-polymerase chain reaction amplified E0 gene, sequences of the primers used for amplification are as follows: upstream: 5 '-CCGGATCCACCATGGAAAACATAACACAGTGG-3' ; downstream: 5 '-GCGAGCTCTTAAGCGTATGCTCCAAACCACGT-3' , reverse transcription-polymerase chain reaction product was purified by agarose gel after electrophoresis, DNA extraction kit specification operation by witt jie, recovered E0 gene ; (2) Bovine Viral Diarrhea Virus gene E0 recombinant plant expression vector construction The step (1) to obtain DNA was digested with restriction enzyme double respectively gene of interest is gel-purified gene product of interest and plant expression vector DNA, T4 DNA ligase at 16 °C under conditions with connected 16h, an adequate amount ligation product was transformed competent E. coli engineered bacteria, transformed bacteria single colonies were picked and plasmids were extracted, identified and DNA by polymerase chain reaction restriction enzyme double after the enzyme digestion, by Bovine Viral Diarrhea Virus gene E0 recombinant plant expression vector sequence analysis, containing bovine viral diarrhea virus gene screening E0 engineered bacteria transformed with recombinant plant expression vectors, recombinant strains cultured in large amounts, mass-produced by the alkaline lysis solution for bovine viral diarrhea virus gene E0 recombinant plant expression vector, which is then diluted with buffer to a concentration of 1-2 ng / μl of the bovine viral diarrhea virus gene E0 recombinant plant expression vector ; (3) Bovine Viral Diarrhea Virus gene E0 pollen tube pathway transformed Astragalus Large amounts by culturing recombinant engineering bacteria, mass-produced by the alkaline lysis solution for bovine viral diarrhea virus gene E0 recombinant plant expression vector, during July in mid-, a plurality of selected flowers, large and uniform and biennial film pod Astragalus, with a syringe step (2) the resulting 1-2ng / μl of bovine viral diarrhea virus gene E0 recombinant plant expression vector of the semi-open tube into the solution, the flowers of vibrant colors over a stud, removes an already open, to brighten dark flower and flower color of an unopened flower still yet, harvesting seed to be seed matures, stored at room temperature, seed planting the harvested shoots obtained, respectively identified and reverse transcription polymerase chain reaction is carried out on the shoots-polymerase chain reaction method identification and protein electrophoresis identifying, screening the transgenic bovine viral diarrhea virus Astragalus ; (4) screening of transgenic bovine viral diarrhea virus vaccine Astragalus For Bovine Viral Diarrhea Virus transgenic medicinal plants, by Western blotting and ELISA were screened by having immunogenic bovine viral diarrhea virus gene E0 transformed Astragalus, the present invention vaccine product obtained.";"(CN101934073)
The present invention is a vaccine and a combination of medicinal plants, thus laying the foundation for developing new gene vaccine firm theoretical basis and to provide a new development path .
An object of the present invention is to provide a transgenic bovine viral diarrhea virus vaccine astragal, for use in animal Bovine Viral Diarrhea disease prevention, to overcome existing inactivated vaccine, a nucleic acid vaccine poorly immunogenic, low protection, the disadvantages of live virus vaccine unsafe for use .
The present invention is a Bovine Viral Diarrhea Virus protective antigen gene in an edible anti-viral medicinal plants Astragalus expression in the host a vaccine produced product .";"(CN101934073)
Pollen tube pathway has the advantage that does not rely on manual regenerating a plant tissue culture, the operation is simple, single-ovular and multi-ovular single dicotyledonous plant may be substituted, breeding time is short, the GluCl speed, transgenic plants can be directly obtained, the introduced DNA molecule is integrated efficiency is high, can be directly applied to a conventional breeding .
The present invention has the advantages that: bovine viral diarrhea virus E 0 gene in the expression of milk vetch, produce both an antigen and adjuvant substances produce enhanced protective immunity, enhancing the use of Astragalus antiviral effects of immunization and vaccination .
Bovine viral diarrhea virus can lead to the animal's viral diarrhea, mucosal disease, abortion, stillbirth, weak tires, fetal abnormalities, persistent infection, immune tolerance, thrombocytopenia and hemorrhage syndrome and the like more clinical symptoms, can also cause atypical swine fever, deer industry and the dairy industry and the pork industry to cause great harm; especially where a vaccine for human use is found in the virus, which is a potential threat to humans .
The virus causes a disease may occur throughout the year .
2, bovine viral diarrhea virus structural protein E 0 and the E 2 were capable of inducing the body to produce a protective response, but E 2 protein conserwd lower, antigenic variation is large, that results in viral escape rate high, low and a major cause of persistent infection vaccine protection, while E 0 the more highly conserved protein, an antigenic in turn, is more suitable for the development of genetically engineered plants .";"A61K-036/481
A61K-039/12
A61P-031/14
C12N-015/40
C12N-015/83";"(CN101934073)
1 . Astragalus transgenic bovine viral diarrhea virus vaccine, characterized by reacting Bovine Viral Diarrhea Virus protective antigen gene in an edible anti-viral medicinal plants Astragalus expression in the host a vaccine produced product .
3 . Bovine viral diarrhea virus vaccine method of producing transgenic milk vetch, characterized in that comprises the following steps: (1) Bovine Viral Diarrhea Virus gene E 0 for obtaining a gene Conventional methods to extract RNA as a template RNA extracted bovine viral diarrhea virus genome, using reverse transcription-polymerase chain reaction amplified E 0 gene, sequences of the primers used for amplification are as follows: upstream: 5 '-CCGGATCCACCATGGAAAACATAACACAGTGG-3' ; downstream: 5 '-GCGAGCTCTTAAGCGTATGCTCCAAACCACGT-3' , reverse transcription-polymerase chain reaction product was purified by agarose gel after electrophoresis, DNA extraction kit specification operation by witt jie, recovered E 0 gene ; (2) Bovine Viral Diarrhea Virus gene E 0 recombinant plant expression vector construction The step (1) to obtain DNA was digested with restriction enzyme double respectively gene of interest is gel-purified gene product of interest and plant expression vector DNA, T4 DNA ligase at 16 Ć under conditions with connected 16h, an adequate amount ligation product was transformed competent E. coli engineered bacteria, transformed bacteria single colonies were picked and plasmids were extracted, identified and DNA by polymerase chain reaction restriction enzyme double after the enzyme digestion, by Bovine Viral Diarrhea Virus gene E 0 recombinant plant expression vector sequence analysis, containing bovine viral diarrhea virus gene screening E 0 engineered bacteria transformed with recombinant plant expression vectors, recombinant strains cultured in large amounts, mass-produced by the alkaline lysis solution for bovine viral diarrhea virus gene E 0 recombinant plant expression vector, which is then diluted with buffer to a concentration of 1-2 ng / l of the bovine viral diarrhea virus gene E 0 recombinant plant expression vector ; (3) Bovine Viral Diarrhea Virus gene E 0 pollen tube pathway transformed Astragalus Large amounts by culturing recombinant engineering bacteria, mass-produced by the alkaline lysis solution for bovine viral diarrhea virus gene E 0 recombinant plant expression vector, during July in mid-, a plurality of selected flowers, large and uniform and biennial film pod Astragalus, with a syringe step (2) the resulting 1-2ng / l of bovine viral diarrhea virus gene E 0 recombinant plant expression vector of the semi-open tube into the solution, the flowers of vibrant colors over a stud, removes an already open, to brighten dark flower and flower color of an unopened flower still yet, harvesting seed to be seed matures, stored at room temperature, seed planting the harvested shoots obtained, respectively identified and reverse transcription polymerase chain reaction is carried out on the shoots-polymerase chain reaction method identification and protein electrophoresis identifying, screening the transgenic bovine viral diarrhea virus Astragalus ; (4) screening of transgenic bovine viral diarrhea virus vaccine Astragalus For Bovine Viral Diarrhea Virus transgenic medicinal plants, by Western blotting and ELISA were screened by having immunogenic bovine viral diarrhea virus gene E 0 transformed Astragalus, the present invention vaccine product obtained.";"(CN101934073)
BOVINE VIRAL DIARRHEA VIRUS(100,53)
PLANT RECOMBINANT EXPRESSION VECTOR(100,15)
VACCINE(100,14)
TRANSGENIC ASTRAGALUS(100,12)
ASTRAGALUS(100,10)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(100,10)
TRANSGENIC MILK VETCH(100,3)
BOVINE VIRAL DIARRHEA VIRUS GENE(73,31)
LIVE VIRUS VACCINE(63,2)
MEDICINAL PLANT ASTRAGALUS EXPRESSION(63,2)
RECOMBINANT ENGINEERING BACTERIUM(56,1)
PROTECTIVE ANTIGEN GENE(55,2)
BIENNIAL FILM POD ASTRAGALUS(50,2)
PERSISTENT INFECTION VACCINE PROTECTION(49,1)
ANIMAL VIRAL DIARRHEA(44,1)
GENE VACCINE FIRM(43,1)
PLANT EXPRESSION VECTOR DNA(43,1)
TRANSFORMED ASTRAGALUS(41,8)
COLI ENGINEERED BACTERIUM(41,3)
ENGINEERED BACTERIA(41,1)
WESTERN BLOTTING(38,3)
ASTRAGALUS ANTIVIRAL(38,1)
BOVINE VIRAL DIARRHEA VIRUS ASTRAGALUS(37,1)
PROTEIN ELECTROPHORESIS(36,3)
VACCINE ASTRAGALUS(36,2)
ENZYME DIGESTION(36,1)
TRANSGENIC MEDICINAL PLANT(36,1)
RESTRICTION ENZYME(35,4)
VIBRANT COLOR FLOWER(35,3)
ATYPICAL SWINE FEVER(35,1)
PLANTING SEED(35,1)
ADJUVANT SUBSTANCE(34,2)
FETAL ABNORMALITY(34,1)
HEMORRHAGE SYNDROME(34,1)
RECOMBINANT STRAIN(34,1)
POLLEN TUBE PATHWAY(33,5)
CLINICAL SYMPTOM(33,1)
DICOTYLEDONOUS PLANT(32,1)
PERSISTENT INFECTION(32,1)
UNOPENED FLOWER(31,3)
ALKALINE LYSIS SOLUTION(30,4)
ASTRAGALUS GENE CONVERSION(30,1)
DARK FLOWER(30,1)
DNA EXTRACTION KIT(29,3)
HARVESTED SHOOT(29,3)
GENE TRANSFORMATION ASTRAGALUS(29,2)
RECOMBINANT PLANT(28,4)
HIGHLY CONSERVED PROTEIN(28,1)
GENE(27,11)
PRIMER SEQUENCE(27,1)
WITT JIE(26,3)
ANIMAL BOVINE VIRAL DIARRHEA(26,1)
DAIRY INDUSTRY(26,1)
DISEASE PREVENTION(26,1)
GENE REASSEMBLY(26,1)
MANUAL REGENERATION(26,1)
PORK INDUSTRY(26,1)
PROTECTIVE IMMUNITY(26,1)
VACCINE ASTRAGAL(25,4)
SCREENING GENE(25,2)
DEER INDUSTRY(25,1)
TRANSFORMED BACTERIUM SINGLE COLONY(25,1)
VIRAL ESCAPE(25,1)
RNA TEMPLATE(24,3)
INTRODUCED DNA MOLECULE(24,1)
EDIBLE(23,2)
WEAK TIRE(23,1)
BOVINE VIRAL DIARRHEA VIRUS GENOME(22,3)
POTENTIAL THREAT(22,1)
VACCINE IMMUNE RESPONSE(22,1)
REVERSE TRANSCRIPTION(21,14)
TRANSGENIC ASTRAGALUS VACCINE(21,7)
FLOWER(20,7)
BREEDING(20,1)
GENETICALLY ENGINEERED PLANT DEVELOPMENT(20,1)
PLANT TISSUE CULTURE(20,1)
STRUCTURAL PROTEIN(20,1)
SHOOT(19,5)
VIRUS(19,2)
THEORETICAL BASIS(19,1)
THROMBOCYTOPENIA(19,1)
AMPLIFICATION(18,1)
GEL PURIFIED GENE PRODUCT(18,1)
GLUCL SPEED(18,1)
INACTIVATED VACCINE(17,4)
EXPRESSION VECTOR CONSTRUCTION(17,3)
BOVINE VIRAL DIARRHEA VIRUS RNA(17,2)
BOVINE VIRAL DIARRHEA DISEASE(16,3)
ANTIGEN(16,1)
ANTIVIRAL ACTION(16,1)
FOUNDATION(16,1)
STILLBIRTH(16,1)
VACCINATION(16,1)
VACCINE PRODUCTION(15,6)
ABORTION(15,1)
HARM(15,1)
DEVELOPMENT PATH(14,1)
EXPRESSION VECTOR SOLUTION(14,1)
HALF OPEN ASTRAGALUS STIGMA(14,1)
MUCOSAL DISEASE(14,1)
PROTECTIVE RESPONSE(14,1)
SYRINGE STEP(14,1)
TRANSGENIC PLANT(14,1)
RECOMBINANT ENGINEERED BACTERIUM(13,4)
IMMUNE TOLERANCE(13,1)
LEGUMINOUS PERENNIAL HERB ASTRAGALUS(13,1)
PCR(12,19)
ELISA(12,6)
ELECTROPHORESIS(12,5)
RNA(12,4)
TRANSGENIC ASTRAGALUS DEER(12,2)
AMOUNT LIGATION PRODUCT(12,1)
DISEASE(12,1)
MEDICINAL PLANT COMBINATION(12,1)
PROTEIN(12,1)
RECONFIGURATION(12,1)
DNA(11,6)
IMMUNIZATION(11,4)
NUCLEIC ACID VACCINE(11,3)
PLASMID(11,3)
T4 DNA LIGASE(11,2)
TRANSGENIC BVDV VACCINE ASTRAGAL(11,1)
AGAROSE(10,3)
STUD(10,3)
STRONG STABILITY(10,2)
GENE EXPRESSION(10,1)
SEED(9,8)
IMMUNIZATION VACCINE GROUP ASTRAGALUS(9,3)
IDENTIFICATION(9,2)
IMMUNE PIG HUMORAL ASTRAGAL(9,1)
IMMUNOREACTIVE TRANSGENIC ASTRAGAL(9,1)
LETTER REPRESENTATION(8,7)
CELLULAR IMMUNE ASSAY(8,3)
LOW PROTECTION(8,3)
ASTRAGALUS LARGE(8,1)
BVDV TRANSGENIC ASTRAGALUS(8,1)
DEER TRANSGENIC ASTRAGALUS(8,1)
MAJOR CAUSE(8,1)
MULTI OVULAR SINGLE(8,1)
SHEN NONG HERBAL CLASS IC(8,1)
INTERMEDIATE REPRESENTATION(7,7)
ASTRAGALUS POLYSACCHARIDE(7,2)
RESTRICTION ENZYME DIGESTION(7,2)
ASTRAGALUS HARVESTING SEED(7,1)
BOVINE TRANSGENIC ASTRAGAL(7,1)
VACCINE EXPRESSION HOST GINSENG(7,1)
ANTIBODY TITER(6,3)
BOVINE VIRAL DIARRHEA VIRUS TRANSGENE(6,3)
DAY PREIMMUINE(6,3)
PCR PRODUCT(6,3)
PATHWAY CONVERTED ASTRAGALUS(6,2)
TRANSGENIC HARVEST(6,2)
CHRONIC INFECTIOUS DISEASE PATIENT(6,1)
DEER SERUM FOLD DILUTION(6,1)
HEPARIN DEER BLOOD INJECTION(6,1)
MACROPHAGE PHAGOCYTOSIS(6,1)
MONGOLIAN ASTRAGALUS(6,1)
TRANSGENIC ASTRAGALUS FEEDING(6,1)
VIRUS VACCINE(6,1)
COMPETENT E(5,3)
HUMORAL IMMUNE RESPONSE(5,3)
JUGULAR VEIN BLOOD(5,3)
SEMI OPEN TUBE(5,3)
STRAW POWDER(5,3)
T CELL IMMUNE RESPONSE(5,3)
DULL FLOWER(5,2)
EXPRESSION VECTOR DNA(5,2)
BVDV VACCINE INDUCED BOVINE(5,1)
GLOBAL INFECTIOUS DISEASE(5,1)
HOUTTUYNIA CORDATA(5,1)
IMMUNIZATION ASTRAGALUS(5,1)
MISCELLANEOUS PLATELET(5,1)
OLD HEALTHY CALF(5,1)
OLD HEALTHY FAWN(5,1)
RECOMBINANT PLANT EXPRESSION VECTOR(5,1)
SECONDARY ANTIBODY CATTLE ENZYME(5,1)
TURMERIC ZEDOARIA(5,1)
CENTRIFUGE TUBE(4,3)
SERUM SEPARATION(4,3)
BOVINE VIRAL DIARRHEA VIRUS SCREENING(4,2)
CALF SERUM(4,2)
PROTEIN IDENTIFICATION(4,2)
ANIMAL HUSBANDRY PROSPERITY(4,1)
BLOOD IMMUNOGLOBULIN(4,1)
BOVINE VIRAL DIARRHEA VIRUS E(4,1)
DISEASE PREVALENCE(4,1)
DRAINAGE CARE DRUG(4,1)
FLOWER STIGMA(4,1)
FLUOROSPECTRO MINUTE(4,1)
HEALTHY PIGLET(4,1)
INVERTED MICROSCOPE COUNT(4,1)
LIVE VIRAL VACCINE(4,1)
MYOGENIC EFFICACY(4,1)
PLANT VACCINE(4,1)
POISON CATTLE(4,1)
RABBIT ANTI PIG ENZYME(4,1)
RABBIT FOLD DILUTION(4,1)
SHOOT IDENTIFICATION(4,1)
THEORETICAL SIGNIFICANCE(4,1)
TRANSGENIC PIG CELL(4,1)
VACCINE IMMUNIZATION(4,1)
VACCINE INDUCED ASTRAGAL(4,1)
WHOLE VIRUS ANTIGEN(4,1)
LECTIN(3,4)
CENTRIFUGATION(3,3)
ENZYME LINKED IMMUNO SORBENT ASSAY DETECTION(3,3)
FED ASTRAGALUS GROUP(3,3)
FEEDER(3,3)
INITIAL DAY(3,3)
INITIAL POST(3,3)
LYMPHOCYTE TRANSFORMATION LEVEL(3,3)
ROOM TEMPERATURE(3,3)
STIMULATION(3,3)
ANTIBODY NEGATIVE(3,2)
FEEDING ASTRAGALUS GROUP(3,2)
TARGET GENE(3,2)
BOVINE BLOOD(3,1)
BOVINE SERUM(3,1)
ENZYME LINKED IMMUNOADSORBENT(3,1)
FLUID DRAWN LYMPHOCYTE(3,1)
FLUID STRATIFICATION(3,1)
GENE SEQUENCE LISTING(3,1)
HEPATITIS PATIENT(3,1)
HORSE SERUM(3,1)
INJECTION ASTRAGALUS(3,1)
PIG BLOOD(3,1)
RABBIT ANTI SECONDARY ANTIBODY(3,1)
STERILE VIAL(3,1)
SUSCEPTIBLE ANIMAL(3,1)
SWINE SERUM(3,1)
TUBE LYMPHOCYTE ISOLATED CELL(3,1)
VACCINE INDUCED DEER(3,1)
WORLDWIDE DISTRIBUTION(3,1)
EXCEPTION(2,2)
SIGNIFICANT IGG RESPONSE(2,2)
SYRINGE(2,2)
TRANSPLANTATION(2,2)
(CN101934073B)
BOVINE VIRAL DIARRHEA VIRUS(100,52)
TRANSGENIC ASTRAGALUS(100,13)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(100,8)
VACCINE PRODUCTION(100,7)
PLANT RECOMBINANT EXPRESSION VECTOR(99,15)
LIVE VIRUS VACCINE(93,2)
BOVINE VIRAL DIARRHEA VIRUS GENE(83,33)
EDIBLE PROTECTIVE ANTIGEN(72,1)
ANIMAL VIRAL DIARRHEA(65,1)
GENE VACCINE FIRM(64,1)
PROTECTIVE ANTIGEN IMMUNIZATION(61,1)
MEDICINAL PLANT ASTRAGALUS EXPRESSION(59,1)
ASTRAGALUS ANTIVIRAL(57,1)
VACCINE ASTRAGALUS(54,3)
TRANSGENIC MILK VETCH(53,2)
ATYPICAL SWINE FEVER(52,1)
TRANSFORMED ASTRAGALUS(51,8)
HEMORRHAGE SYNDROME(51,1)
PROTECTIVE ANTIGEN GENE(51,1)
ASTRAGALUS GENE TRANSFORMATION(50,1)
FETAL ABNORMALITY(50,1)
CLINICAL SYMPTOM(49,1)
MANUAL REGENERATION(49,1)
VIRUS RESISTANT ASTRAGALUS(49,1)
DICOTYLEDONOUS PLANT(47,1)
PERSISTENT INFECTION(47,1)
RECOMBINANT ENGINEERING BACTERIUM(47,1)
ASTRAGALUS HARVESTING SEED(46,2)
BIENNIAL FILM POD ASTRAGALUS(46,2)
ASTRAGALUS GENE CONVERSION(45,1)
POLLEN TUBE PATHWAY(42,5)
WESTERN BLOTTING(42,3)
HIGHLY CONSERVED PROTEIN(41,1)
IMMUNE PROTECTIVE CREATION(41,1)
COLI ENGINEERED BACTERIUM(40,3)
DAIRY INDUSTRY(39,1)
GENE REASSEMBLY(39,1)
PORK INDUSTRY(39,1)
ANIMAL BOVINE VIRAL DIARRHEA(38,1)
DISEASE PREVENTION(38,1)
PROTEIN ELECTROPHORESIS(37,4)
DEER INDUSTRY(37,1)
VACCINE PROTECTION(37,1)
VIRAL ESCAPE(37,1)
VACCINE ASTRAGAL(36,5)
ENGINEERED BACTERIA(35,1)
INTRODUCED DNA MOLECULE(35,1)
TISSUE CULTURE(35,1)
VIBRANT COLOR FLOWER(34,3)
WEAK TIRE(34,1)
POTENTIAL THREAT(33,1)
ADJUVANT SUBSTANCE(31,1)
BOVINE VIRAL DIARRHEA VIRUS ASTRAGALUS(31,1)
UNOPENED FLOWER(30,3)
GENETICALLY ENGINEERED PLANT DEVELOPMENT(30,1)
VIRUS(29,2)
BREEDING(29,1)
HOST CELL(29,1)
PLANTING SEED(29,1)
STRUCTURAL PROTEIN(29,1)
HARVESTED SHOOT(28,3)
RECOMBINANT STRAIN(28,1)
THEORETICAL BASIS(28,1)
THROMBOCYTOPENIA(28,1)
GLUCL SPEED(27,1)
PERSISTENT INFECTION MAJOR CAUSE(27,1)
SCREENING GENE(27,1)
VACCINE(26,13)
TRANSGENIC ASTRAGALUS VACCINE(26,5)
ALKALINE LYSIS SOLUTION(26,4)
ANTI VIRUS ACTION(26,1)
REVERSE TRANSCRIPTION(25,14)
INACTIVATED VACCINE(25,4)
BOVINE VIRAL DIARRHEA VIRUS RNA(25,2)
BOVINE VIRAL DIARRHEA DISEASE(24,3)
RNA TEMPLATE(24,3)
FOUNDATION(24,1)
STILLBIRTH(24,1)
VACCINATION(24,1)
GENE(23,10)
IMMUNIZATION(23,5)
ABORTION(22,1)
HARM(22,1)
PRIMER SEQUENCE(22,1)
BOVINE VIRAL DIARRHEA VIRUS GENOME(21,3)
EDIBLE(21,1)
HALF OPEN ASTRAGALUS STIGMA(21,1)
PROTECTIVE RESPONSE(21,1)
DARK FLOWER(20,3)
DEVELOPMENT PATH(20,1)
EXPRESSION VECTOR SOLUTION(20,1)
MUCOSAL DISEASE(20,1)
TRANSGENIC PLANT(20,1)
RECOMBINANT ENGINEERED BACTERIUM(19,4)
GENE PRODUCT(19,1)
IMMUNE TOLERANCE(19,1)
TARGET GENE(18,3)
TRANSGENIC ASTRAGALUS DEER(18,2)
DISEASE(18,1)
GEL PURIFIED DNA(18,1)
MEDICINAL PLANT COMBINATION(18,1)
RECONFIGURATION(18,1)
TRANSFORMED BACTERIUM SINGLE COLONY(17,3)
PROTEIN(17,1)
EXPRESSION VECTOR CONSTRUCTION(16,3)
NUCLEIC ACID VACCINE(16,3)
STRONG STABILITY(16,2)
TRANSGENIC BVDV VACCINE ASTRAGAL(16,1)
ELISA(15,6)
ADJUVANT MATERIAL(14,1)
AMPLIFICATION(14,1)
GENE EXPRESSION(14,1)
LETTER REPRESENTATION(13,7)
IMMUNIZATION VACCINE GROUP ASTRAGALUS(13,3)
IMMUNE PIG HUMORAL ASTRAGAL(13,1)
IMMUNOREACTIVE TRANSGENIC ASTRAGAL(13,1)
CELLULAR IMMUNE ASSAY(12,3)
LOW PROTECTION(12,3)
STRAW POWDER FED T CELL(12,3)
BVDV TRANSGENIC ASTRAGALUS(12,1)
DEER TRANSGENIC ASTRAGALUS(12,1)
SYRINGE STEP(12,1)
ASTRAGALUS POLYSACCHARIDE(11,2)
ASTRAGALUS TRANSGENE(11,2)
RESTRICTION ENZYME DIGESTION(11,2)
MULTI OVULAR SINGLE(11,1)
SHEN NONG HERBAL CLASS IC(11,1)
VACCINE PRODUCTION ASTRAGALUS(11,1)
INTERMEDIATE REPRESENTATION(10,7)
AGAROSE(10,3)
ANTIBODY TITER(10,3)
BOVINE VIRAL DIARRHEA VIRUS TRANSGENE(10,3)
DAY PREIMMUINE(10,3)
PLASMID(10,3)
T4 DNA LIGASE(10,2)
BOVINE TRANSGENIC ASTRAGAL(10,1)
VACCINE EXPRESSION HOST GINSENG(10,1)
STUD(9,3)
DNA EXTRACTION KIT(9,2)
PATHWAY CONVERTED ASTRAGALUS(9,2)
AMOUNT LIGATION PRODUCT(9,1)
DEER SERUM FOLD DILUTION(9,1)
GENE TRANSFORMATION ASTRAGALUS(9,1)
HERB ASTRAGALUS FILM POD(9,1)
HUMORAL IMMUNE RESPONSE(8,3)
JUGULAR VEIN BLOOD(8,3)
EXPRESSION VECTOR DNA(8,2)
HARVESTING SEED(8,2)
WITT JIE(8,2)
CHRONIC INFECTIOUS DISEASE PATIENT(8,1)
HEPARIN DEER BLOOD INJECTION(8,1)
MACROPHAGE PHAGOCYTOSIS(8,1)
MONGOLIAN ASTRAGALUS(8,1)
OLD HEALTHY PIGLET(8,1)
TRANSGENIC ASTRAGALUS FEEDING(8,1)
VIRUS VACCINE(8,1)
BOVINE VIRAL DIARRHEA VIRUS SCREENING(7,2)
CALF SERUM(7,2)
VACCINE INDUCED DEER(7,2)
BVDV VACCINE INDUCED BOVINE(7,1)
GLOBAL INFECTIOUS DISEASE(7,1)
HOUTTUYNIA CORDATA(7,1)
IMMUNIZATION ASTRAGALUS(7,1)
LEGUMINOUS PERENNIAL(7,1)
MISCELLANEOUS PLATELET(7,1)
OLD HEALTHY CALF(7,1)
OLD HEALTHY FAWN(7,1)
RECOMBINANT PLANT EXPRESSION VECTOR(7,1)
SECONDARY ANTIBODY CATTLE ENZYME(7,1)
TURMERIC ZEDOARIA(7,1)
SERUM SEPARATION(6,3)
ANIMAL HUSBANDRY PROSPERITY(6,1)
CARE DRUG DRAINAGE(6,1)
DISEASE PREVALENCE(6,1)
FLOWER STIGMA(6,1)
RABBIT FOLD DILUTION(6,1)
TRANSGENIC PIG CELL(6,1)
VACCINE IMMUNIZATION(6,1)
LECTIN(5,4)
CENTRIFUGATION(5,3)
COMPETENT E(5,3)
ENZYME LINKED IMMUNO SORBENT ASSAY DETECTION(5,3)
FED ASTRAGALUS GROUP(5,3)
INITIAL DAY(5,3)
INITIAL POST(5,3)
LYMPHOCYTE TRANSFORMATION LEVEL(5,3)
PCR PRODUCT(5,3)
SEMI OPEN TUBE(5,3)
STIMULATION(5,3)
ANTIBODY NEGATIVE(5,2)
FEEDING ASTRAGALUS GROUP(5,2)
BLOOD IMMUNOGLOBULIN(5,1)
BOVINE VIRAL DIARRHEA VIRUS E(5,1)
FLUOROSPECTRO MINUTE(5,1)
INVERTED MICROSCOPE COUNT(5,1)
LIVE VIRAL VACCINE(5,1)
PLANT VACCINE(5,1)
POISON CATTLE(5,1)
RABBIT ANTI PIG ENZYME(5,1)
SHOOT IDENTIFICATION(5,1)
THEORETICAL SIGNIFICANCE(5,1)
VACCINE INDUCED ASTRAGAL(5,1)
WHOLE VIRUS ANTIGEN(5,1)
CELLULAR IMMUNE RESPONSE NIUS(4,2)
FEEDER(4,2)
TRAGACANTH(4,2)
BOVINE BLOOD(4,1)
BOVINE SERUM(4,1)
CENTRIFUGE TUBE DRAW(4,1)
ENZYME LINKED IMMUNOADSORBENT(4,1)
FLUID STRATIFICATION(4,1)
GENE SEQUENCE LISTING(4,1)
HEPATITIS PATIENT(4,1)
HORSE SERUM(4,1)
INJECTION ASTRAGALUS(4,1)
INTRACELLULAR CONCENTRATION(4,1)
PIG BLOOD(4,1)
PROTEIN IDENTIFICATION(4,1)
RABBIT ANTI SECONDARY ANTIBODY(4,1)
STERILE VIAL(4,1)
SUSCEPTIBLE ANIMAL(4,1)
SWINE SERUM(4,1)
TUBE LYMPHOCYTE ISOLATED CELL(4,1)
WORLDWIDE DISTRIBUTION(4,1)";Pharmaceuticals;Open
2010-02-26;"CN101892175         A  2010-11-24 [CN101892175]
STG: (A) Published application
AP : 2010CN-0115552 2010-02-26
CN101892175         B  2012-04-18 [CN101892175B]
STG: (B) Granted patent for invention
AP : 2010CN-0115552 2010-02-26";7134488;"CN101892175         A  2010-11-24 [CN101892175]
CN101892175         B  2012-04-18 [CN101892175B]";2010CN-0115552;;HARBIN VETERINARY RESEARCH INSTITUTE CAAS;HARBIN VETERINARY RESEARCH INSTITUTE CAAS;;;1;"YU LI
MA WENGE
JIANG ZHIGANG";;;"(CN101892175B)
Bovine capsular serotype A Pasteurella mutocida, validation identification and application thereof";"(CN101892175B)
The invention discloses bovine capsular serotype A Pasteurella mutocida and application thereof. The bovine capsular serotype A Pasteurella mutocida is separated from disease samples with haemorrhagic septicomia of cattle in six provinces (cities) with the microbial preservation number of CGMCC No.3619. The bovine capsular serotype A Pasteurella mutocida is cultured by BHI, oil adjuvant is adopted to prepare inactivated immunogen, and a mouse model proves that the bovine capsular serotype A Pasteurella mutocida has complete protecting function on serotype A Pm velogenic attck, and does not have crossing protection with serotype B Pm. Testing results prove that vaccine can be prepared by the bovine capsular serotype A Pasteurella mutocida for preventing the haemorrhagic septicomia of cattle caused by the capsular serotype A Pasteurella mutocida. The strain cannot cause diseases when inoculated to chicks, which proves that the strain is chicken isolated capsular serotype A Pasteurella mutocida.";"(CN101892175)
1. P. multocida Type A capsular bovine-derived a strain, a microbe given an accession number: CGMCC No. 3619.
2. Claim 1 P. multocida Type A capsular bovine-derived from bovine sources in the manufacture of P. multocida Type A control capsule of a medicament for use bovine hemorrhagic septicemia caused.
3. A method for controlling bovine the vaccine composition of hemorrhagic septicemia, from effective amounts of claim 1 P. multocida Type A and an adjuvant composition capsular bovine sources.
4. In accordance with the vaccine according to claim 3, characterized in: adjuvant is an oil adjuvant.
5. A method for identifying a bovine source of claim 1 P. multocida Type A to Type A capsular capsular synthetic gene is a primer, characterized in: the nucleotide sequence is SEQ IDNO: SEQ ID NO 1 and the: 2 shown.
6. Claim 1 bovine-derived Type A for identifying 16S rRNA gene of the P. multocida capsule of the primer sequence, characterized in: the nucleotide sequence is SEQ IDNO: 3 and the SEQ ID NO: 4 shown.
7. A culture method of claim 1 P. multocida Type A capsular bovine sources, comprising: using a BHI media alone.";"(CN101892175)
The present invention discloses a strain P. multocida Type A and its application to the capsular bovine sources.
An object of the present invention is to provide a strain bovine-derived capsular A P. multocida Type; A second object of the present invention is to P. multocida Type A applied to the control of bovine capsular bovine source of hemorrhagic septicemia; Is an object of the present invention is accomplished through the following technical scheme:
The present invention relates to a strain of Lactobacillus pastorianus, and more particularly to a strain of P. multocida Type A capsular bovine origin, bovine source of the present invention also relates to the capsular A P. multocida type multi-use of the control of bovine hemorrhagic septicemia, falls within a Pasteur coli pathogens and vaccine field.";"(CN101892175)
Can be advantageously, 5 to 10 years in China the disease in the future will be within one of the most serious infectious diseases to the cattle industry hazards.
The present invention will be vaccinated chicks P. multocida Type A capsular bovine sources do not cause disease, the test results show the present invention P. multocida Type A strain is a capsular non-chicken.";"A61K-039/102
A61P-031/04
C12N-001/20
C12N-015/11
C12Q-001/04
C12Q-001/68
C12R-001/01";"(CN101892175)
1. P. multocida Type A capsular bovine-derived a strain, a microbe given an accession number: CGMCC No. 3619.";"(CN101892175)
MULTOCIDA(100,33)
STRAIN(100,5)
ACCESSION NUMBER(100,2)
MICROBE(100,2)
LACTOBACILLUS PASTORIANUS STRAIN(100,1)
SEPARATE IDENTIFIER(100,1)
PASTEUR COLI PATHOGEN(91,1)
DISEASED COW HEMORRHAGIC SEPTICEMIA(90,1)
CAPSULAR BOVINE ORIGIN(79,1)
CAPSULAR BOVINE SOURCE(77,4)
CATTLE INDUSTRY HAZARD(69,1)
INFECTIOUS DISEASE(60,1)
PRIMER SEQUENCE MULTOCIDA CAPSULE(55,1)
CAPSULAR HEMORRHAGIC SEPTICEMIA(53,2)
HEMORRHAGIC SEPTICEMIA VACCINE(51,1)
MICROORGANISM DEPOSIT(45,1)
VIRULENT CHALLENGE(42,2)
CAPSULAR BOVINE DERIVED VACCINE(41,2)
OIL ADJUVANT(36,3)
HEMORRHAGIC SEPTICEMIA(36,1)
BOVINE HEMORRHAGIC SEPTICEMIA CONTROL(34,1)
ISOLATED BOVINE DERIVED CAPSULE(32,1)
CHICKEN(27,3)
DISEASE(26,4)
P STRAIN(25,1)
MOUSE MODEL(24,2)
CHICK(22,5)
MEDICAMENT CONTROL CAPSULE(21,1)
P RRNA GENE(20,1)
COMPLETE PROTECTION(19,1)
BLACK DRAGON RIVER(16,3)
P MANUFACTURE(15,1)
MULTOCIDA TYPE(14,1)
CAPSULAR BIOSYNTHETIC GENE(13,1)
CHICK PATHOGENICITY ASSAY(13,1)
HARBIN VETERINARY INSTITUTE(13,1)
VACCINE FIELD(13,1)
MILLION BACTERIA(12,3)
PCR TEMPLATE(12,3)
XG CENTRIFUGATION(11,2)
ACUTE BOVINE HEMORRHAGIC SEPTICEMIA(11,1)
CAPSULE BIOSYNTHESIS GENE(11,1)
CAPSULE BIOSYNTHETIC GENE(11,1)
INTERNATIONAL DEPOSITARY AUTHORITY(11,1)
SCIENCE CHINESE ACADEMY(11,1)
SCIENCE CHINESE AGRICULTURE(11,1)
WRIGHT STAINING BIPOLAR(11,1)
HEALTHY LIVING(10,2)
HYAD HYAC GENE(10,2)
MOUSE INOCULATION(10,2)
BEICHEN WEST ROAD(10,1)
BOVINE LUNG ONSET(10,1)
CATTLE ORAL SECRETION(10,1)
DISEASE BOVINE IETHALITY(10,1)
EPIDEMIC HEMORRHAGIC SEPTICEMIA(10,1)
MICRO BLUE FLASHING COLONY(10,1)
PM EVOLUTIONARY TREE(10,1)
BACTERIAL MICRO BIOCHEMICAL(9,1)
BOVINE INFECTIOUS DISEASE(9,1)
BRIGHT RED BLOOD AGAR(9,1)
HETEROGENEOUS SUBPOPULATION(9,1)
IMMUNITY HERD ABSENCE(9,1)
PASTEURELLA MUTOCIDA(9,1)
WRIGHT STAIN BLUE(9,1)
BCBD GENE(8,2)
DCBF GENE(8,2)
ECBJ GENE(8,2)
PHYLOGENETIC ANALYSIS(8,2)
UL STERILE DOUBLE(8,2)
ATTENUATED VIRULENCE(8,1)
CLONED KMT(8,1)
CONFLUENT LAWN(8,1)
DEFEAT NIUS(8,1)
DIDEOXYNUCLEOTIDE(8,1)
FOLD PRIME STAR(8,1)
GLUCOSE FERMENTATION(8,1)
ISOLATED CAPSULE RRNA GENE(8,1)
MOUSE IMMUNE PROTECTION ASSAY(8,1)
PATHOGEN CULTURE(8,1)
PATHOGEN VIRULENCE(8,1)
PATHOGENIC BACTERIUM CULTURE(8,1)
PREPARED IMMUNOGEN SEEDING(8,1)
PULMONARY LESION(8,1)
RANDOM CHALLENGE MENU(8,1)
TAQ DNA POLYMERASE(8,1)
GENBANK(7,4)
AVIAN PM(7,1)
BACTERIA CULTURE(7,1)
BACTERIAL CAPSULAR BOVINE SOURCE(7,1)
BACTERIAL CHALLENGE(7,1)
CAPSULAR BOVINE DERIVED SERUM(7,1)
CONSERVED GENE(7,1)
DISEASED LEFT PROVINCE(7,1)
FRANCE ADJUVANT VOLUME(7,1)
GENE HOMOLOGY(7,1)
HEALTHY SURVIVAL(7,1)
INDOPHENOL MATRIX(7,1)
INOCULATED PM TJ(7,1)
INTENSE STRESS OCCURRENCE(7,1)
KILLED PM TJ(7,1)
MARVIN GE(7,1)
MICROSCOPIC EXAMINATION(7,1)
MOUSE BACTERIUM(7,1)
NATIONAL ACADEMY(7,1)
PATHOGEN IDENTIFICATION(7,1)
PATHOGEN ISOLATION(7,1)
PM TJ CHICK(7,1)
SEROTYPE PM(7,1)
SMEAR STAINING(7,1)
SUSPENDED CONCUSSION(7,1)
SUSPENSION SUPERNATANT(7,1)
H DEATH(6,3)
PURE CULTURE(6,2)
T SYNONYMOUS MUTATION(6,2)
H CULTURE(5,2)
PCR PRODUCT(5,2)
ABDOMINAL CAVITY DISEASE(5,1)
ANIMAL ORIGIN(5,1)
BACTERIAL SUSPENSION(5,1)
BOVINE DERIVED TYPE(5,1)
BP KMT(5,1)
CATTLE INDUSTRY(5,1)
CHINA GENERAL MICROBIOLOGICAL CULTURE(5,1)
CLASSIFICATION NAME(5,1)
CULTURE CONDITION OPTIMIZATION(5,1)
CULTURED BACTERIAL MIXTURE(5,1)
DIED MIAO GROUP(5,1)
ELECTROPHORESIS DISPLAY(5,1)
H COLONY MORPHOLOGY(5,1)
H DEAD MOUSE LUNG(5,1)
HANGZHOU DAY(5,1)
MACCONKEY AGAR PLATE(5,1)
OPTIMAL AMPLIFICATION(5,1)
PCR AMPLIFICATION PRODUCT(5,1)
PM HOMOLOGY(5,1)
PM KMT(5,1)
POST VACCINATION(5,1)
PRELIMINARY STUDY(5,1)
PUBLISHED DOCUMENT(5,1)
SHAKING SUSPENSION(5,1)
STATISTICAL PROTECTION(5,1)
STERILE COLLECTION(5,1)
STERILE FILTRATE(5,1)
STRAIN BOVINE DERIVED CAPSULE(5,1)
VIABLE CELL GENERATION(5,1)
LIVER(4,3)
TYPE BIOSYNTHETIC GENE(4,3)
ASSAY ANALYSIS(4,1)
BLUE STAIN(4,1)
BOVINE DERIVED IMMUNOGENIC TEST(4,1)
BOVINE SOURCE CAPSULE(4,1)
CAPF PRIMER COMBINATION(4,1)
CATALASE POSITIVE(4,1)
COLI GRAM NEGATIVE CHARGE(4,1)
CULTURE BACTERIAL LIQUID(4,1)
DAILY EVENT(4,1)
EVOLUTIONARY TREE SETUP(4,1)
FRESH BLOOD AGAR PLATE(4,1)
HEART TISSUE(4,1)
HOMOLOGY ANALYSIS(4,1)
L ORNITHINE DECARBOXYLASE POSITIVE(4,1)
MICROBIAL AGENT(4,1)
PATHOGENIC TEST(4,1)
PCR PRIMER DESIGN(4,1)
SECONDARY MOUSE(4,1)
STAINED CELL(4,1)
TERMINAL TERMINATION(4,1)
(CN101892175B)
MULTOCIDA(100,31)
ACCESSION NUMBER(100,2)
MICROBE(100,2)
SEPARATE IDENTIFIER(100,2)
LACTOBACILLUS PASTORIANUS STRAIN(100,1)
STRAIN BOVINE DERIVED CAPSULE(100,1)
PASTEUR COLI PATHOGEN(91,1)
DISEASED COW HEMORRHAGIC SEPTICEMIA(90,1)
CAPSULAR BOVINE HEMORRHAGIC SEPTICEMIA(77,1)
CHINA ENDANGERING(66,1)
CAPSULAR BOVINE ORIGIN(63,2)
INFECTIOUS DISEASE(60,1)
CAPSULAR BOVINE SOURCE(58,3)
CAPSULAR HEMORRHAGIC SEPTICEMIA(53,2)
OIL ADJUVANT IMMUNOGEN(52,1)
HEMORRHAGIC SEPTICEMIA VACCINE(51,1)
BOVINE HEMORRHAGIC SEPTICEMIA(50,3)
MICROORGANISM DEPOSIT(45,1)
CAPSULAR BOVINE DERIVED VACCINE(41,2)
VIRULENT CHALLENGE(40,2)
BOVINE ORIGIN PREPARATION(38,1)
CATTLE INDUSTRY(37,2)
HEMORRHAGIC SEPTICEMIA(36,1)
STRAIN(32,4)
ISOLATED BOVINE DERIVED CAPSULE(32,1)
DISEASE(26,4)
CHICKEN(25,4)
P STRAIN(25,1)
CHICK(24,4)
MOUSE MODEL(24,2)
BOVINE SOURCE(23,2)
MEDICAMENT(20,1)
COMPLETE PROTECTION(19,1)
BLACK DRAGON RIVER(16,3)
BOVINE INFECTION PULMONARY LESION(15,1)
MULTOCIDA TYPE(14,1)
CAPSULAR BIOSYNTHETIC GENE(13,1)
CHICK PATHOGENICITY ASSAY(13,1)
CHINA AGRICULTURE ACADEMY(13,1)
VACCINE FIELD(13,1)
MILLION BACTERIA(12,3)
PCR TEMPLATE(12,3)
XG CENTRIFUGATION(11,2)
CAPSULE BIOSYNTHESIS GENE(11,1)
CAPSULE BIOSYNTHETIC GENE(11,1)
HARBIN VETERINARY STUDY(11,1)
INTERNATIONAL DEPOSITARY AUTHORITY(11,1)
SCIENCE CHINESE ACADEMY(11,1)
WRIGHT STAINING BIPOLAR(11,1)
TYPE CAPSULE(10,3)
HEALTHY LIVING(10,2)
HYAD HYAC GENE(10,2)
MOUSE INOCULATION(10,2)
PM INACTIVATED VACCINE(10,2)
BEICHEN WEST ROAD(10,1)
BOVINE LUNG ONSET(10,1)
CATTLE ORAL SECRETION(10,1)
CONTROL MULTOCIDA TYPE MULTIUSE(10,1)
DISEASE BOVINE IETHALITY(10,1)
EPIDEMIC HEMORRHAGIC SEPTICEMIA(10,1)
MICRO BLUE FLASHING COLONY(10,1)
PM EVOLUTIONARY TREE(10,1)
BACTERIAL MICRO BIOCHEMICAL(9,1)
BRIGHT RED BLOOD AGAR(9,1)
HETEROGENEOUS SUBPOPULATION(9,1)
IMMUNITY HERD ABSENCE(9,1)
PASTEURELLA MUTOCIDA(9,1)
TWIN DEOXYTERMINAL KMT(9,1)
WRIGHT STAIN BLUE(9,1)
DCBF GENE(8,2)
ECBJ GENE(8,2)
PHYLOGENETIC ANALYSIS(8,2)
PM HOMOLOGY(8,2)
PM KMT(8,2)
UL STERILE DOUBLE(8,2)
ATTENUATED VIRULENCE(8,1)
BOVINE DERIVED CAPSULE PATHOGENICITY(8,1)
CHOLERA PATHOGEN(8,1)
CONFLUENT LAWN(8,1)
DEFEAT NIUS(8,1)
FOLD PRIME STAR(8,1)
GLUCOSE FERMENTATION(8,1)
MOUSE IMMUNE PROTECTION ASSAY(8,1)
PATHOGEN CULTURE(8,1)
PATHOGEN VIRULENCE(8,1)
PATHOGENIC BACTERIUM CULTURE(8,1)
PREPARED IMMUNOGEN SEEDING(8,1)
RANDOM CHALLENGE MENU(8,1)
SPF GRADE MOUSE(8,1)
GENBANK(7,4)
PROVINCE(7,3)
BACTERIA CULTURE(7,1)
BACTERIAL CAPSULAR BOVINE SOURCE(7,1)
BACTERIAL CHALLENGE(7,1)
BLANK IMMUNIZING(7,1)
CLONE NUCLEOTIDE(7,1)
CONSERVED GENE(7,1)
FRANCE ADJUVANT VOLUME(7,1)
GENE HOMOLOGY(7,1)
HEALTHY SURVIVAL(7,1)
INDOPHENOL MATRIX(7,1)
INTENSE STRESS OCCURRENCE(7,1)
KILLED PM TJ(7,1)
MARVIN GE(7,1)
MICROSCOPIC EXAMINATION(7,1)
MOUSE BACTERIUM(7,1)
PATHOGEN IDENTIFICATION(7,1)
PATHOGEN ISOLATION(7,1)
PM TJ CHICK(7,1)
SEROTYPE PM(7,1)
SMEAR STAINING(7,1)
SUSPENDED CONCUSSION(7,1)
SUSPENSION SUPERNATANT(7,1)
H DEATH(6,3)
PURE CULTURE(6,2)
T SYNONYMOUS MUTATION(6,2)
H CULTURE(5,2)
MORTALITY(5,2)
ABDOMINAL CAVITY DISEASE(5,1)
ANIMAL ORIGIN(5,1)
AVIAN PM(5,1)
BACTERIAL SUSPENSION(5,1)
BCBD GENE(5,1)
BP KMT(5,1)
CHINA GENERAL MICROBIOLOGICAL CULTURE(5,1)
CLASSIFICATION NAME(5,1)
CULTURE CONDITION OPTIMIZATION(5,1)
CULTURED BACTERIAL MIXTURE(5,1)
ELECTROPHORESIS DISPLAY(5,1)
H COLONY MORPHOLOGY(5,1)
H DEAD MOUSE LUNG(5,1)
HANGZHOU DAY(5,1)
MACCONKEY AGAR PLATE(5,1)
OPTIMAL AMPLIFICATION(5,1)
PCR AMPLIFICATION PRODUCT(5,1)
POST VACCINATION(5,1)
PRELIMINARY STUDY(5,1)
PUBLISHED DOCUMENT(5,1)
SHAKING SUSPENSION(5,1)
STATISTICAL PROTECTION(5,1)
STERILE COLLECTION(5,1)
STERILE FILTRATE(5,1)
VIABLE CELL GENERATION(5,1)
ATTACK(4,3)
ASSAY ANALYSIS(4,1)
BIOCHEMICAL REACTION TUBE(4,1)
BLUE STAIN(4,1)
BOVINE DERIVED IMMUNOGENIC TEST(4,1)
CAPF PRIMER COMBINATION(4,1)
CATALASE POSITIVE(4,1)
CULTURE BACTERIAL LIQUID(4,1)
DAILY EVENT(4,1)
FRESH BLOOD AGAR PLATE(4,1)
HEART TISSUE(4,1)
HOMOLOGY ANALYSIS(4,1)
MICROBIAL AGENT(4,1)
PATHOGENIC TEST(4,1)
STAINED CELL(4,1)";Pharmaceuticals;Open
2009-12-24;"CN101818130         A  2010-09-01 [CN101818130]
STG: (A) Published application
AP : 2009CN-0273357 2009-12-24
CN101818130         B  2012-07-25 [CN101818130B]
STG: (B) Granted patent for invention
AP : 2009CN-0273357 2009-12-24";7072598;"CN101818130         A  2010-09-01 [CN101818130]
CN101818130         B  2012-07-25 [CN101818130B]";2009CN-0273357;;HUAZHONG AGRICULTURAL UNIVERSITY;HUAZHONG AGRICULTURAL UNIVERSITY;;;1;"GUO AIZHEN
ZHANG MINMIN
LIU ZHENGFEI
Fu Shulin
CHEN HUANCHUN";;;"(CN101818130B)
gG and TK gene-deleted recombinant infectious bovine rhinotracheitis virus and application";"(CN101818130B)
The invention belongs to the fields of animal virology and animal genetically engineered technology, and in particular relates to a gG and TK gene-deleted recombinant infectious bovine rhinotracheitis virus, a genetic engineering vaccine and application. The recombinant infectious bovine rhinotracheitis virus strain IBRV delta gG/delta TK prepared by the invention is preserved in China Center forType Culture Collection, with the preservation number of CCTCC No: V200915; and gG and TK genes are deleted in the strain, and the strain does not comprise foreign genes. An intermediate strain, namely recombinant infectious bovine rhinotracheitis virus GAZH-2009-01 is preserved in China Center for Type Culture Collection, with the preservation number of CCTCC No: V200910; and gG and TK genes are deleted in the strain and the strain comprises reporter gene EGFP. The invention also discloses application of the recombinant infectious bovine rhinotracheitis virus IBRV delta gG/delta TK in preparing the genetic engineering vaccine for the infectious bovine rhinotracheitis and preventing and controlling infectious bovine rhinotracheitis virus diseases.";"(CN101818130)
1. A deletion of the gene and the TK recombinant infectious bovine rhinotracheitis virus gG IBRV Δ gG / Δ TK, deposited at the China Type Culture Collection, accession number of CCTCC NO: V200915 thereof.
2. Recombinant infectious bovine rhinotracheitis virus strain according to claim 1, characterized in: (1) strains deleted for gG, TK gene; (2) strain is free of exogenous gene.
3. Claim 1 or 2 recombinant infectious bovine rhinotracheitis virus strain, characterized in: strain does not contain a reporter gene EGFP.
4. Claim 1 includes, 2 or 3 of the IBRV Δ gG / Δ TK gene-deleted recombinant infectious bovine rhinotracheitis virus vaccine.
5. Claim 1, 2 or 3 of the IBRV Δ gG / Δ TK is a recombinant infectious bovine rhinotracheitis virus vector vaccine prepared by genetic engineering.
6. A recombinant infectious bovine rhinotracheitis virus GAZH-2009-01, deposited at the China Type Culture Collection, accession number of CCTCC NO: V200910 thereof, characterized in: (1) strains deleted for gG, TK gene; (2) strain comprising a reporter gene EGFP.
7. Claim 1, 2 or 3 accession number of CCTCC N0: V200915 recombinant infectious bovine rhinotracheitis virus for the manufacture of a vaccine gene deletion.
8. Claim 5 accession number of CCTCC NO: V200910 recombinant infectious bovine rhinotracheitis virus in a recombinant virus application.";"(CN101818130)
The present invention further discloses a recombinant infectious bovine rhinotracheitis virus in the infectious bovine rhinotracheitis vaccine of the IBRV  gG /  TK a genetically engineered infectious bovine rhinotracheitis viral disease controlling the preparation of application and the application.
The present invention aims at obtaining one immunogenic property and the safety is a genetically engineered strain of the infectious bovine rhinotracheitis.";"(CN101818130)
The main advantage of the present invention are:
Currently only a small number of European countries have eradicated the present disease, other countries are implementing schemes could extinguish a fire, or the use of a marker vaccine having functions of the groups immunized with natural infection and, in order to be better monitored and safeguarded.
TK gene deletion can occur after a decrease in virulence, and the ability to replicate in the non-dividing cells is also low, so that the latent virus is not easily activated, so that in the development of gene deletion vaccines, TK gene is a commonly available target gene (Kit S,Oavi H,Gaines JD,Billingsley P,McConnell S.Thymidine kinase-negative bovine herpesvirus type 1 mutant is stable and highly attenuated in calves.Arch Virol,1985,86: 63-83).
GB: gB can cause cell fusion, in mammalian cells exhibiting expression of cell fusion and gives rise to form a multi-core, is essential for viral replication, it imparts a prokaryotic expression and the domestic optical pair of antigenic expression product was analyzed, in a baculovirus expression of the antigenic relatively gC, gD weak; cell surface glycoprotein interactions, mediates virus adsorption starting, a plurality of trans-activator may modulate the binding of the virus, but are not essential for virus infection; glycoprotein gB is necessary to perforation, and has been shown by invasive nerve and nerve propagation requires gB.";"A61K-039/265
A61P-031/20
C12N-007/00
C12N-007/01
C12R-001/93";"(CN101818130)
1. A deletion of the gene and the TK recombinant infectious bovine rhinotracheitis virus gG IBRV  gG /  TK, deposited at the China Type Culture Collection, accession number of CCTCC NO: V200915 thereof.
6. A recombinant infectious bovine rhinotracheitis virus GAZH-2009-01, deposited at the China Type Culture Collection, accession number of CCTCC NO: V200910 thereof, characterized in: (1) strains deleted for gG, TK gene; (2) strain comprising a reporter gene EGFP.";"(CN101818130)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,31)
GENE(100,17)
ACCESSION(100,7)
CULTURE COLLECTION(100,6)
STRAIN(100,6)
GENE DELETION(100,5)
DELETION(100,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(100,1)
BOVINE RHINOTRACHEITIS VIRAL DISEASE(60,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(55,36)
REPORTER GENE(37,9)
BOVINE HERPES VIRUS(36,1)
GENE DELETION VACCINE DEVELOPMENT(36,1)
EXOGENOUS GENE(33,2)
BACULOVIRUS EXPRESSION(33,1)
INVASIVE NERVE(32,1)
PROKARYOTIC EXPRESSION(32,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(31,2)
EUROPEAN COUNTRY(31,1)
LATENT VIRUS(31,1)
NERVE PROPAGATION(30,1)
TARGET GENE(29,1)
ANTIGEN EXPRESSION PRODUCT(24,1)
VIRAL REPLICATION(23,3)
VIRUS ADSORPTION(23,3)
G GENE DELETION(23,1)
NATURAL INFECTION(23,1)
VACCINE GENE DELETION MANUFACTURE(23,1)
GENETICALLY ENGINEERED STRAIN(22,4)
GENETICALLY ENGINEERED VACCINE(22,2)
MAMMALIAN CELL(22,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(20,3)
VACCINE VECTOR(20,1)
CELL FUSION EXPRESSION(19,1)
TRANSACTIVATOR(19,1)
DOMESTIC(17,1)
MARKER VACCINE(16,1)
PERFORATION(16,1)
VIRULENCE(16,1)
RECOMBINANT PLASMID(15,11)
INTERMEDIATE STRAIN(15,1)
VIRUS INFECTION(14,1)
DISEASE(13,2)
CALF(13,1)
MUTANT(13,1)
GLYCOPROTEIN(12,6)
FIRE(12,1)
BOVINE HERPES VIRUS SEROLOGICAL SURVEY(11,1)
RESTRICTION ENZYME(10,8)
ADISTINCT EQUID ALPHAHERPESVIRUS(10,1)
VIRUS(9,9)
ANTIBODY NEUTRALIZATION(9,4)
HUBEI PROVINCE(9,4)
CATTLE G PROTEIN BIOGRAPHY(9,1)
CELL FUSION(9,1)
DIVIDING CELL(9,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVENTION(9,1)
RECOMBINANT INFECTIOUS BOVINE RHINOTRACHEITIS(9,1)
THREEDIMENSIONAL ICOSAHEDRAL SYMMETRY(9,1)
BOVINE HERPES VIRUS MUTAGENESIS(8,1)
INFECTIOUS BACTERIAL ARTIFICIALCHROMOSOME(8,1)
JUNCTIONAL ADHERENCEAMONG INFECTED CELL(8,1)
SIMPLEX VIRUS VIRULENCE GENE(8,1)
CAPSULAR SAC(7,2)
WUHAN UNIVERSITY(7,2)
G PROTEIN POLYCLONAL ANTIBODY(7,1)
G UPSTREAM HOMOLOGY VECTOR(7,1)
HERPES VIRUS SEROLOGICAL DIAGNOSIS(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREPARATION(7,1)
INTRANASAL DRIP IRRIGATION(7,1)
NERVOUS TISSUE PERSISTENT INFECTION(7,1)
NEUTRALIZING ANTIBODY TITER(7,1)
REPORTER GENE CASSETTE AMPLIFICATION(7,1)
RIVER FARM VETERINARIAN(7,1)
SECRETED PROTEIN VIRAL REPLICATION(7,1)
RECOVERED FRAGMENT(6,3)
BOVINE KIDNEY CELL(6,2)
DOWNSTREAM HOMOLOGY ARM(6,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GENOME(6,2)
OVERNIGHT LIGATION(6,2)
RECOMBINANT TRANSFER PLASMID(6,2)
AMPLIFIABLE MARKER GENE(6,1)
BOVINE RHINOTRACHEITIS DISEASE DEVELOPMENT(6,1)
DAY FIGHT DEXAMETHASONE(6,1)
DELETION STRAIN GENOME DNA(6,1)
GD GLYCOPROTEIN GENE(6,1)
KBEGFP EXPRESSION CASSETTE(6,1)
PLASMID ENZYME DIGESTION(6,1)
RECOMBINANT VIRAL GENOME(6,1)
VACCINE PREPARATION RECOMBINANT VIRUS(6,1)
VIRAL PLAQUE EXPRESSION(6,1)
VIRUS DISEASE INVASION(6,1)
TEMPLATE(5,7)
CATTLE INDUSTRY(5,2)
GENOMIC DNA(5,2)
GREEN PLAQUE(5,2)
GREEN STAINED PLAQUE(5,2)
BOVINE RHINOTRACHEITIS DIFFERENTIAL DIAGNOSIS(5,1)
CELL SURFACE GLYCOPROTEIN INTERACTION(5,1)
CHINA VETERINARY MONITOR(5,1)
DELETED GENE PRIMER(5,1)
G DELETION STRAIN(5,1)
GENETIC ENGINEERING TECHNIQUE FIELD(5,1)
HERPES VIRUS DIAGNOSTIC ANTIGEN(5,1)
LANE CELL DEFICIENT STRAIN(5,1)
LANE TK DEFICIENT STRAIN(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
VACCINE VIRULENCE(5,1)
VETERINARY MICROBIOGY(5,1)
WHITE RABBIT BIG EAR(5,1)
ACCESSION NUMBER(4,3)
PLASMID TRANSFER(4,3)
AMPLIFICATION REACTION(4,2)
DESIGNED ENZYME CLEAVAGE(4,2)
T4 DNA LIGASE BUFFER(4,2)
VIRAL ENTRY(4,2)
XM BUFFER(4,2)
AGRICULTURAL UNIVERSITY CENTRAL CHINA(4,1)
AMPLIFIED UPSTREAM HOMOLOGY ARM(4,1)
APOPTOSISAND PREVENTION(4,1)
BARTHA NU(4,1)
BP SIZED FRAGMENT(4,1)
BULL FERTILITY(4,1)
CALF HAZARD(4,1)
CLEAVED PCDNA(4,1)
COLLECT CELL DISEASE(4,1)
CONFLUENT MONOLAYER(4,1)
COW MILK PRODUCTION(4,1)
CYTOTOXIC LYMPHOCYTE(4,1)
DELETION MONOLAYER(4,1)
DISEASE PREVALENCE(4,1)
DNA LIGASEBUFFER(4,1)
ENZYMATIC CLEAVAGE(4,1)
EXPERIMENTAL RABBIT(4,1)
FATAL BOVINE(4,1)
GE CODING REGION DELETION(4,1)
GENE UPSTREAM HOMOLOGY ARM(4,1)
GENOME COTRANSFECTION(4,1)
GLYCOPROTEIN EXPRESSION(4,1)
HEXAGONAL EXTERIOR APPEARANCE(4,1)
HOMOLOGOUS RECOMBINATION(4,1)
INFECTED RABBIT(4,1)
INFECTIOUS DISEASE(4,1)
KAI CHEONG(4,1)
LYSATE LYSIS(4,1)
MAJOR ENVELOPE GLYCOPROTEIN(4,1)
MARTIN BEER(4,1)
MATURE VIRION(4,1)
NECROTIC RHINITIS(4,1)
PARENTAL STRAIN(4,1)
PHOSPHORYLATED SUBSTRATE BROAD SPECTRUM(4,1)
RABBIT KIDNEY CELL(4,1)
REFRIGERATOR FREEZING(4,1)
REPORTER GENE KNOCKOUT(4,1)
RHINOTRACHEITIS VIRUS INFECTION(4,1)
STRAIN VIRULENCE(4,1)
THYMIDINE KINASE(4,1)
TRANSLATION SCHOOL(4,1)
VACCINE STRAIN BASIS(4,1)
VIRALLY INFECTED CELL(4,1)
VIRUS ADSORPTION TISSUE(4,1)
VIRUS DEPLETION(4,1)
VIRUS EXISTENCE(4,1)
VIRUS GENE(4,1)
VIRUS PROPAGATION(4,1)
VIRUS REPLICATION(4,1)
VIRUS RESEACH(4,1)
TK EGFP(3,3)
VIROLOGY(3,3)
GENBANK ACCESSION(3,2)
K BUFFER(3,2)
POSITIVE SERUM(3,2)
AMPLIFIED FRAGMENT(3,1)
ANIMAL GENETIC ENGINEERING(3,1)
BLACK DRAGON(3,1)
CELL INFILTRATION(3,1)
CLOSING POISON(3,1)
COMPLEMENT LYSIS PRESENCE(3,1)
DISEASE BOVINE(3,1)
DNA FRAGMENT(3,1)
DNA PRECIPITATION(3,1)
EFFICIENT VIRAL GROWTH(3,1)
EXPERIMENTAL ANIMAL(3,1)
G GENE AMPLIFICATION(3,1)
GD GENE(3,1)
GE ELISA(3,1)
GENE DELETION STRAIN(3,1)
GENETIC ENGINEERING STRAIN(3,1)
HARTLEY CA(3,1)
IMMUNE CELL(3,1)
JAPANESE WHITE RABBIT(3,1)
KDA PROTEIN(3,1)
PREPARED VIRUS GENOME(3,1)
PURIFIED PRIMER(3,1)
RED RHINO(3,1)
RELIABLE MARKER(3,1)
RNA ENZYME(3,1)
SECONDARY BACTERIAL PNEUMONIA(3,1)
VIRAL PARTICLE(3,1)
VIRAL PENETRATION(3,1)
VIRUS RELEASE(3,1)
DNA MARKER(2,4)
ANTI GD VIRUS(2,1)
BP G(2,1)
FOREGROUND PRODUCING(2,1)
HERPES VIRUS HOTSPOT(2,1)
HOST CELL PROLIFERATION(2,1)
INDUSTRY DEVELOPMENT(2,1)
KNOCKOUT REMOVAL(2,1)
MEASURED POST CHALLENGE(2,1)
MOLECULAR BIOLOGY RESEARCH(2,1)
NUCLEIC ACID METABOLISM(2,1)
PCR DETECTION(2,1)
PRIMARY ANTIBODY(2,1)
SEROLOGY POSITIVE(2,1)
VIRUS INFECTED CELL(2,1)
(CN101818130B)
GENE(100,15)
ACCESSION(100,6)
CULTURE COLLECTION(100,4)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS G(100,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(100,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(67,37)
BOVINE HERPES VIRUS(36,1)
EXPRESSION IMMUNOGENICITY(36,1)
GENE DELETION VACCINE DEVELOPMENT(36,1)
PROKARYOTIC EXPRESSION(33,1)
INVASIVE NERVE(32,1)
EUROPEAN COUNTRY(31,1)
LATENT VIRUS(31,1)
NERVE PROPAGATION(30,1)
GENETICALLY ENGINEERED VACCINE(29,1)
TARGET GENE(29,1)
G GENE DELETION(25,1)
EXOGENOUS GENE(24,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(23,26)
GENETICALLY ENGINEERED STRAIN(23,3)
VIRAL REPLICATION(23,3)
VIRUS ADSORPTION(23,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS STRAIN(23,1)
NATURAL INFECTION(23,1)
MAMMALIAN CELL(22,1)
PRODUCT STUDENT(21,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS VACCINE(20,3)
CELL FUSION EXPRESSION(19,1)
TRANSACTIVATOR(19,1)
VACCINE MANUFACTURE(18,1)
ANTIGENICITY(17,1)
BACULOVIRUS(17,1)
MARKER VACCINE(16,1)
PERFORATION(16,1)
VIRULENCE(16,1)
RECOMBINANT PLASMID(15,11)
GENE DELETION(15,6)
GENE ENGINEERING(14,1)
VIRUS INFECTION(14,1)
DISEASE(13,2)
CALF(13,1)
MUTANT(13,1)
GLYCOPROTEIN(12,6)
FIRE(12,1)
BOVINE HERPES VIRUS SEROLOGICAL SURVEY(11,1)
RESTRICTION ENZYME(10,8)
CATTLE RHINOTRACHEITIS VIRUS THYMIDINE(10,1)
VIRUS(9,8)
ANTIBODY NEUTRALIZATION(9,4)
HUBEI PROVINCE(9,4)
CELL FUSION(9,1)
DIVIDING CELL(9,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVENTION(9,1)
RECOMBINANT INFECTIOUS BOVINE RHINOTRACHEITIS(9,1)
THREEDIMENSIONAL ICOSAHEDRAL SYMMETRY(9,1)
VIRAL DISEASE APPLICATION(9,1)
BOVINE HERPES VIRUS MUTAGENESIS(8,1)
SIMPLEX VIRUS VIRULENCE GENE(8,1)
CAPSULAR SAC(7,2)
WUHAN UNIVERSITY(7,2)
G PROTEIN POLYCLONAL ANTIBODY(7,1)
HERPES VIRUS SEROLOGICAL DIAGNOSIS(7,1)
INTRANASAL DRIP IRRIGATION(7,1)
NERVOUS TISSUE PERSISTENT INFECTION(7,1)
NEUTRALIZING ANTIBODY TITER(7,1)
RECOMBINANT VIRUS G PROTEIN(7,1)
REPORTER GENE CASSETTE AMPLIFICATION(7,1)
RIVER FARM VETERINARIAN(7,1)
SECRETED PROTEIN VIRAL REPLICATION(7,1)
RECOVERED FRAGMENT(6,3)
BOVINE KIDNEY CELL(6,2)
DOWNSTREAM HOMOLOGY ARM(6,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS GENOME(6,2)
RECOMBINANT TRANSFER PLASMID(6,2)
AMPLIFIABLE MARKER GENE(6,1)
BOVINE RHINOTRACHEITIS DISEASE DEVELOPMENT(6,1)
DAY FIGHT DEXAMETHASONE(6,1)
DELETION STRAIN GENOME DNA(6,1)
EQUID ALPHAHERPESVIRUS(6,1)
GD GLYCOPROTEIN GENE(6,1)
KBEGFP EXPRESSION CASSETTE(6,1)
PLASMID ENZYME DIGESTION(6,1)
RECOMBINANT VIRAL GENOME(6,1)
VACCINE PREPARATION RECOMBINANT VIRUS(6,1)
VIRAL PLAQUE EXPRESSION(6,1)
VIRUS DISEASE INVASION(6,1)
TEMPLATE(5,7)
T4 DNA LIGASE BUFFER(5,4)
CATTLE INDUSTRY(5,2)
GENETIC ENGINEERING STRAIN(5,2)
GENOMIC DNA(5,2)
GREEN PLAQUE(5,2)
GREEN STAINED PLAQUE(5,2)
VIRAL PENETRATION(5,2)
BOVINE RHINOTRACHEITIS DIFFERENTIAL DIAGNOSIS(5,1)
CELL SURFACE GLYCOPROTEIN INTERACTION(5,1)
CHINA VETERINARY MONITOR(5,1)
DELETED GENE PRIMER(5,1)
G DELETION STRAIN(5,1)
HERPES VIRUS DIAGNOSTIC ANTIGEN(5,1)
LANE CELL DEFICIENT STRAIN(5,1)
LANE TK DEFICIENT STRAIN(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
VACCINE VIRULENCE(5,1)
VETERINARY MICROBIOGY(5,1)
WHITE RABBIT BIG EAR(5,1)
PLASMID TRANSFER(4,3)
AMPLIFICATION REACTION(4,2)
DESIGNED ENZYME CLEAVAGE(4,2)
VIRAL ENTRY(4,2)
XM BUFFER(4,2)
AGRICULTURAL UNIVERSITY CENTRAL CHINA(4,1)
AMPLIFIED UPSTREAM HOMOLOGY ARM(4,1)
APOPTOSIS PREVENTION(4,1)
BARTHA NU(4,1)
BP SIZED FRAGMENT(4,1)
BP UPSTREAM HOMOLOGY ARM(4,1)
BULL FERTILITY(4,1)
CALF HAZARD(4,1)
CHALLENGE ROUTE(4,1)
CLEAVED PCDNA(4,1)
COLLECT CELL DISEASE(4,1)
CONFLUENT MONOLAYER(4,1)
COW MILK PRODUCTION(4,1)
CYTOTOXIC LYMPHOCYTE(4,1)
DELETION MONOLAYER(4,1)
DISEASE PREVALENCE(4,1)
ENZYMATIC CLEAVAGE(4,1)
EXPERIMENTAL RABBIT(4,1)
FATAL BOVINE(4,1)
GE CODING REGION DELETION(4,1)
GENE UPSTREAM HOMOLOGY ARM(4,1)
GENOME COTRANSFECTION(4,1)
GLYCOPROTEIN EXPRESSION(4,1)
HEXAGONAL EXTERIOR APPEARANCE(4,1)
HOMOLOGOUS RECOMBINATION(4,1)
INFECTED RABBIT(4,1)
INFECTIOUS BACTERIAL ARTIFICIAL CHROMOSOME(4,1)
INFECTIOUS DISEASE(4,1)
JUNCTIONAL ADHERENCE(4,1)
KAI CHEONG(4,1)
LYSATE LYSIS(4,1)
MAJOR ENVELOPE GLYCOPROTEIN(4,1)
MARTIN BEER(4,1)
MATURE VIRION(4,1)
NECROTIC RHINITIS(4,1)
OVERNIGHT LIGATION(4,1)
PARENTAL STRAIN(4,1)
PHOSPHORYLATED SUBSTRATE BROAD SPECTRUM(4,1)
RABBIT KIDNEY CELL(4,1)
REFRIGERATOR FREEZING(4,1)
REPORTER GENE KNOCKOUT(4,1)
STRAIN VIRULENCE(4,1)
TRANSLATION SCHOOL(4,1)
VACCINE STRAIN BASIS(4,1)
VECTOR UPSTREAM HOMOLOGY(4,1)
VIRALLY INFECTED CELL(4,1)
VIRUS ADSORPTION TISSUE(4,1)
VIRUS DEPLETION(4,1)
VIRUS EXISTENCE(4,1)
VIRUS GENE(4,1)
VIRUS PROPAGATION(4,1)
VIRUS REPLICATION(4,1)
VIRUS RESEACH(4,1)
TK EGFP(3,3)
VIROLOGY(3,3)
GENBANK ACCESSION(3,2)
K BUFFER(3,2)
POSITIVE SERUM(3,2)
AMPLIFIED FRAGMENT(3,1)
ANIMAL GENETIC ENGINEERING(3,1)
BLACK DRAGON(3,1)
CELL INFILTRATION(3,1)
CLOSING POISON(3,1)
COMPLEMENT LYSIS PRESENCE(3,1)
DISEASE BOVINE(3,1)
DNA FRAGMENT(3,1)
DNA PRECIPITATION(3,1)
EFFICIENT VIRAL GROWTH(3,1)
EXPERIMENTAL ANIMAL(3,1)
GD GENE(3,1)
GE ELISA(3,1)
GENE DELETION STRAIN(3,1)
HARTLEY CA(3,1)
JAPANESE WHITE RABBIT(3,1)
KDA PROTEIN(3,1)
PBSK VECTOR(3,1)
PREPARED VIRUS GENOME(3,1)
PURIFIED PRIMER(3,1)
RED RHINO(3,1)
RELIABLE MARKER(3,1)
RNA ENZYME(3,1)
SECONDARY BACTERIAL PNEUMONIA(3,1)
VIRAL PARTICLE(3,1)
VIRUS RELEASE(3,1)
DNA MARKER(2,4)
ANHYDROUS DIETHYL ETHER(2,1)
ANTI GD VIRUS(2,1)
ANTIVIRAL THERAPEUTIC AGENT DESIGN(2,1)
BOVINE RHINOTRACHEITIS VACCINE APPLICATION(2,1)
BP G(2,1)
CAUSATIVE FORCE(2,1)
HERPES VIRUS HOTSPOT(2,1)
MEASURED POST CHALLENGE(2,1)
MOLECULAR BIOLOGY RESEARCH(2,1)
MONOCLONAL ANTIBODY COMPLEX(2,1)
NASAL SWAB INDEXING RESULT(2,1)
NUCLEIC ACID METABOLISM(2,1)
PCR DETECTION(2,1)
SAFETY EVALUATION(2,1)
TUMOR TREATMENT(2,1)";Pharmaceuticals;Open
"2009-11-23
2013-09-05";"AU2013224704        A1 2013-10-03 [AU2013224704]
STG: (A1) Open to public inspection
AP : 2013AU-0224704 2013-09-05
AU2013224704        B2 2016-06-30 [AU2013224704]
STG: (B2) Patent proceeded by OPI
AP : 2013AU-0224704 2013-09-05
FD :  Division of: AU2009323784 FDD=2009-11-23 [2009AU-0323784]";46094682;"AU2013224704        A1 2013-10-03 [AU2013224704]
AU2013224704        B2 2016-06-30 [AU2013224704]";"2009AU-0323784
2013AU-0224704";"(AU2013224704)
WO2010064164";ZOETIS SERVICES;ZOETIS SERVICES;;;1;"ANKENBAUER ROBERT GERARD
LUO YUGANG
WELCH SIAO-KUN WAN
YUAN YING";;;"(AU2013224704)
Bovine viral diarrhea virus with a modified Erns protein";"(AU2013224704)
The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines wherein said chimeric pestivirus comprises a bovine viral diarrhea virus which does not express its homologous Ems protein, furN4 ther wherein said chimeric pestivirus expresses a heterologous Ems protein derived from another pestivirus, or a natural, synthetic or genetic variant of said heterologous Ems protein. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.";"(AU2013224704)
1. A chimeric pestivirus, wherein said chimeric pestivirus comprises a bovine viral diarrhea virus which does not express its homologous Er"" protein, further wherein said chimeric pestivirus expresses a heterologous Ems protein derived from another pestivirus, or a natural, synthetic or genetic variant of said heterologous Er' protein.
2. The chimeric pestivirus of claim 1, wherein the heterologous Er' protein of said chimeric pestivirus, or the natural, synthetic or genetic variant of said heterologous Er' protein, is derived from a pestivirus selected from the group consisting of a reindeer pestivirus, a giraffe pestivirus, and a pronghorn antelope pestivirus.
3. The chimeric pestivirus of claim 1, wherein the heterologous Er' protein of said chimeric pestivirus has at least one Er' epitope which is not present in wild-type bovine viral diarrhea virus.
4. The chimeric pestivirus of claim 1, wherein the heterologous Er' protein of said chimeric pestivirus lacks at least one Er' epitope which is present in wild-type bovine viral diarrhea virus.
5. A culture of the chimeric pestivirus of claim 1.
6. A cell line or host cell comprising the chimeric pestivirus of claim 1.
7. A polynucleotide molecule encoding for the chimeric pestivirus of claim 1.
8. An immunogenic composition comprising the chimeric pestivirus of claim 1 and a veterinarily-acceptable carrier.
9. The immunogenic composition of claim 8, wherein the veterinarilyacceptable carrier is an adjuvant.
10. The immunogenic composition of claim 8, wherein said chimeric pestivirus is live attenuated.
11. The immunogenic composition of claim 8, wherein said chimeric pestivirus is inactivated.
12. The immunogenic composition of claim 8, further comprising one or more additional antigens useful for treating or preventing the spread of one or more additional pathogenic microorganisms in a bovine.
13. An immunogenic composition comprising the polynucleotide molecule of claim 7 and a veterinarily-acceptable carrier.
14. A vaccine comprising the chimeric pestivirus of claim 1 and a veterinarilyacceptable carrier.
15. The vaccine of claim 14, wherein the veterinarily-acceptable carrier is an adjuvant.
16. The vaccine of claim 14, wherein said chimeric pestivirus is live attenuated.
17. The vaccine of claim 14, wherein said chimeric pestivirus is inactivated.
18. A vaccine comprising the polynucleotide molecule of claim 7 and a veterinary acceptable carrier.
19. The vaccine of claim 14, further comprising one or more additional antigens useful for treating or preventing the spread of one or more additional pathogenic microorganisms in a bovine.
20. A kit comprising, in at least one container, the vaccine of claim 14.
21. A method of treating or preventing the spread of bovine viral diarrhea virus infection, wherein the vaccine of claim 14 is administered to an animal.
22. A method of vaccinating an animal, wherein a DIVA pestivirus vaccine is administered to said animal, and wherein said DIVA pestivirus vaccine comprises the chimeric pestivirus of claim 1, further wherein said chimeric pestivirus has at least one Erns epitope which is not present in wild-type bovine viral diarrhea virus.
23. A method of vaccinating an animal, wherein a DIVA pestivirus vaccine is administered to said animal, and wherein said DIVA vaccine comprises the chimeric pestivirus of claim 1, further wherein said chimeric pestivirus lacks at least one Erns epitope which is present in wild-type bovine viral diarrhea virus.
24. A method of differentiating between an animal vaccinated with the vaccine of claim 14 and an animal infected with wild type bovine viral diarrhea virus, wherein the animal vaccinated with said vaccine generates antibodies to at least one Ems epitope which is present in the chimeric pestivirus of said vaccine, but which is not present in wild-type bovine viral diarrhea virus, said method comprising the steps of: a) obtaining a serum sample from the animals; b) assaying said samples for the presence or absence of the antibodies; c) identifying the animal having said antibodies as having been vaccinated with said vaccine; and d) identifying the animal lacking said antibodies as having been infected with the wild type BVDV.
25. A method of differentiating between an animal infected with wild-type bovine viral diarrhea virus and an animal vaccinated with the vaccine of claim 14, wherein the animal infected with wild type bovine viral diarrhea virus generates antibodies to at least one Ems epitope which is present in wild-type bovine viral diarrhea virus, but which is not present in the chimeric pestivirus of said vaccine, said method comprising the steps of: a) obtaining a serum sample from the animals; b) assaying said samples for the presence or absence of the antibodies; c) identifying the animal having said antibodies as having been infected with the wild type BVDV; and d) identifying the animal lacking said antibodies as having been vaccinated with said vaccine.
26. A diagnostic kit for differentiating between an animal vaccinated with a vaccine comprising the chimeric pestivirus of claim 1 and an animal infected with wild type bovine viral diarrhea virus, said kit comprising reagents capable of detecting antibodies to at least one Ems epitope which is present in the chimeric pestivirus of the vaccine, but which is not present in wild-type bovine viral diarrhea virus.
27. A diagnostic kit for differentiating between an animal infected with wild type bovine viral diarrhea virus and an animal vaccinated with a vaccine comprising the chimeric pestivirus of claim 1, said kit comprising reagents capable of detecting antibodies to at least one Ems epitope which is present in wild-type bovine viral diarrhea virus, but which is not present in the chimeric pestivirus of the vaccine.
28. An antibody which recognizes an epitope of Er' which is present in the chimeric pestivirus of claim 1, but which epitope is not present in wild-type bovine viral diarrhea virus.
29. An antibody which recognizes an epitope present in wild-type bovine viral diarrhea virus, but which epitope is not present in the chimeric pestivirus of claim 1.";;;"A61K-039/12
C07K-014/18
C07K-016/10
C12N-007/04
C12N-015/86
G01N-033/50";;;"Analysis of biological materials
Pharmaceuticals";Open
2009-11-04;"CN102049043         A  2011-05-11 [CN102049043]
STG: (A) Published application
AP : 2009CN-0071135 2009-11-04";7282115;CN102049043         A  2011-05-11 [CN102049043];2009CN-0071135;;TIANJIN RINGPU BIOLOGY TECHNOLOGY;TIANJIN RINGPU BIOLOGY TECHNOLOGY;;;1;"MA LIWEI
SHEN HONGWANG
XIA XUELIN
LIU AILING";;;"(CN102049043)
Infectious bovine rhinotracheitis vaccine and preparation method thereof";"(CN102049043)
The invention relates to an infectious bovine rhinotracheitis vaccine and a preparation method thereof, belongs to the technical field of veterinary biological products, and is used for solving the problem to control the endemic infectious bovine rhinotracheitis by a vaccine. The vaccine is prepared by the following steps of: separating virus from a tissue of aborted fetus of cow infected with the infectious bovine rhinotracheitis; breeding; detecting titer; inactivating and emulsifying and the like. The vaccine can be used for controlling the endemic infectious bovine rhinotracheitis.";"(CN102049043)
1 . One infectious bovine rhinotracheitis vaccine, characterized in virus is infectious bovine rhinotracheitis virus, Infectious Bovine Rhinotracheitis Virus, simply referred to IBRV, lines from infectious bovine rhinotracheitis popular geographic regions identified .
2 . Infectious bovine rhinotracheitis vaccine according to claim 1, characterized in infectious bovine rhinotracheitis virus to diethyl ether, chloroform and trypsin sensitive; are not resistant to acid-base, and a 0.1 mol/L HCl solution are adjusted to pH3 with 0.1mol/LNaOH virus-containing fluid, and the pH9 1h pH11, 37 °C effect, i.e. can be virally-inactivated; may be IBRV positive serum neutralization, a neutralizing antibody titer of 2-7.9;TCID50 value of 10-6.65/100μl, 10-3.35/20μl .
3 . Infectious bovine rhinotracheitis vaccine according to claim 1, characterized in infectious bovine rhinotracheitis virus PCR amplified by specific primers may be used IBRV 339bp gB gene of the conserved region sequence of the high .
4 . Infectious bovine rhinotracheitis vaccine according to claim 3, characterized in IBRV specific primer has the sequence PB1: 5 '-GGC TCT ACC GCA CGG GCA CCT CT -3' ; PB2: 5 '-GCG GCT CTC GTC TCG CAG CAT TT -3' .
5 . One infectious bovine rhinotracheitis vaccine production method, characterized in preparation method comprises the following steps: A . Virus isolation: sterile collection IBR aborted fetus bovine liver, spleen, heart, kidney, placenta, lung, minced with scissors, milling, followed by 5-fold amount Hanks (200 IU/ml penicillin and 200μg/ml streptomycin containing), 10 ml centrifuge tube made of emulsions into, repeated freezing and thawing three times . To 10min 3000r/min centrifugation, the supernatants were sterilized by filtration . Hanks solution diluted with 10-fold, 100 fold, 1000-fold, were each inoculated grow into a compact monolayer and form an intact calves primary cells of the testes, serial passages 35-50 generation was isolated . B . Viral identification: IBRV with specific anti-virus neutralization assays were performed with standard male serum isolated, the isolate of the IBRV standard male serum neutralizing antibody titer of 2-8.1; extraction template DNA virus is isolated, amplified by PCR with specific primers of the IBRV 339bp gB gene is highly conserved region sequence, confirmation of the separation virus to IBRV . C . Viral propagation: grow dense monolayer and form of the virus was inoculated with intact primary cell testicular calves, timely harvested, the titers were determined, titers up to 106.5TCID50/0.1ml venom for built seedlings . D . Inactivating emulsion: 37% formaldehyde solution was added to a final concentration of 2 ‰ venom, 12 hours to inactivate, in a 4% added with Tween-80, containing 1% aluminum stearate with, 6% Span-80 mixed 1:2 in volume ratio of the white oil obtained by kneading the clay, 10000 revolutions/minute over 15 minutes by a high shear emulsifier emulsifies oil emulsion made inactivated vaccine .
6 . Infectious bovine rhinotracheitis vaccine production method according to claim 5, characterized in vaccine production method is applicable to all infectious bovine rhinotracheitis isolated strains of vaccine manufacturing .
7 . Infectious bovine rhinotracheitis vaccine production method according to claim 5, characterized in immunopotentiating adjuvant may be added during any preparation of a vaccine.";"(CN102049043)
An object of the present invention is to provide an infectious bovine rhinotracheitis vaccine and methods for their preparation, means for Solving the infectious bovine rhinotracheitis regional popular vaccine to prevent control problems .
The present invention relates to an infectious bovine rhinotracheitis vaccine and preparation method thereof, which belongs to the technical field of veterinary biologics .
The present invention relates to infectious bovine rhinotracheitis vaccine and its preparation method, which belongs to the veterinary biologic technology field, for solving the problem of the regional popular infectious bovine rhinotracheitis vaccine prevention control .";"(CN102049043)
These symptoms suggesting the presence of cattle population IBR, cattle population if there is a latent infection of the IBR, it is very difficult to eradicate, cattle industry will cause a great damage .
Due to the improvement of people's living standard and the intensified development for the livestock industry, the scale of the cattle industry in China extends continuously, the number of NIUs is significantly increased, but due to some major infectious diseases cannot be a radical, such as bovine respiratory group of viruses, including bovine herpes virus-I-type (BHV-1), bovine para-influenza virus (BPIV3), Bovine Respiratory Syndrome Virus (BRSV) and bovine viral diarrhea virus (BVDV) and the like, which increase no less popular and hazards with, resulting in huge economic losses to the cattle industry .
Cow reproductive system can also cause damage, abortion and fetal death occurs, and occurrence of inflammatory bowel disease and calf encephalitis, it sometimes happens that ocular conjunctivitis and keratitis, milk production in milking cows, bull fertility and the causative causative force has a large effect of cattle, and the acute IBR respiratory tract infection may occur secondary bovine lethal bacterial pneumonia, a major cause of economic loss may be caused by one of the cattle industry .";"A61K-039/265
A61P-031/20";"(CN102049043)
1 . One infectious bovine rhinotracheitis vaccine, characterized in virus is infectious bovine rhinotracheitis virus, Infectious Bovine Rhinotracheitis Virus, simply referred to IBRV, lines from infectious bovine rhinotracheitis popular geographic regions identified .
5 . One infectious bovine rhinotracheitis vaccine production method, characterized in preparation method comprises the following steps: A . Virus isolation: sterile collection IBR aborted fetus bovine liver, spleen, heart, kidney, placenta, lung, minced with scissors, milling, followed by 5-fold amount Hanks (200 IU/ml penicillin and 200g/ml streptomycin containing), 10 ml centrifuge tube made of emulsions into, repeated freezing and thawing three times . To 10min 3000r/min centrifugation, the supernatants were sterilized by filtration . Hanks solution diluted with 10-fold, 100 fold, 1000-fold, were each inoculated grow into a compact monolayer and form an intact calves primary cells of the testes, serial passages 35-50 generation was isolated . B . Viral identification: IBRV with specific anti-virus neutralization assays were performed with standard male serum isolated, the isolate of the IBRV standard male serum neutralizing antibody titer of 2 -8.1; extraction template DNA virus is isolated, amplified by PCR with specific primers of the IBRV 339bp gB gene is highly conserved region sequence, confirmation of the separation virus to IBRV . C . Viral propagation: grow dense monolayer and form of the virus was inoculated with intact primary cell testicular calves, timely harvested, the titers were determined, titers up to 10 6.5TCID50/0.1ml venom for built seedlings . D . Inactivating emulsion: 37% formaldehyde solution was added to a final concentration of 2  venom, 12 hours to inactivate, in a 4% added with Tween-80, containing 1% aluminum stearate with, 6% Span-80 mixed 1:2 in volume ratio of the white oil obtained by kneading the clay, 10000 revolutions/minute over 15 minutes by a high shear emulsifier emulsifies oil emulsion made inactivated vaccine .";"(CN102049043)
INFECTIOUS BOVINE RHINOTRACHEITIS(100,15)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(100,12)
INFECTIOUS BOVINE RHINOTRACHEITIS VACCINE(100,11)
VIRUS(100,7)
VACCINE PRODUCTION(100,6)
POPULAR GEOGRAPHIC REGION(100,1)
REGIONAL INFECTIOUS BOVINE RHINOTRACHEITIS(29,1)
BOVINE PARAINFLUENZA VIRUS(26,1)
NEUTRALIZING ANTIBODY TITER(25,5)
BOVINE RHINOTRACHEITIS(24,1)
REGIONAL POPULAR VACCINE(24,1)
ANTI VIRUS NEUTRALIZATION ASSAY(23,3)
CATTLE INDUSTRY(22,3)
SEPARATION VIRUS CONFIRMATION(22,1)
ABORTED FETUS BOVINE LIVER(20,3)
COW ABORTION VIRUS(20,1)
EXTRACTION TEMPLATE DNA VIRUS(20,1)
OCULAR CONJUNCTIVITIS(19,1)
SYMPTOM SUGGESTING(19,1)
STANDARD MALE SERUM(18,2)
CALF ENCEPHALITIS(17,1)
LETHAL BACTERIAL PNEUMONIA(17,1)
MILKING COW(17,1)
BULL FERTILITY(16,1)
BUILT SEEDLING(15,1)
CATTLE POPULATION(15,1)
MAJOR INFECTIOUS DISEASE(15,1)
VIRUS BOVINE RESPIRATORY GROUP(15,1)
BOVINE HERPES VIRUS(14,1)
CATTLE INDUSTRY SCALE(14,1)
CATTLE POPULATION PRESENCE(14,1)
HUGE ECONOMIC LOSS(14,1)
LATENT INFECTION(14,1)
LIVESTOCK INDUSTRY(14,1)
INACTIVATING EMULSION(13,3)
SHEAR EMULSIFIER(13,3)
INTENSIFIED DEVELOPMENT(13,1)
DENSE MONOLAYER(12,4)
COMPACT MONOLAYER(12,2)
INFLAMMATORY BOWEL DISEASE OCCURRENCE(12,1)
GB GENE(11,5)
VIRAL PROPAGATION(11,3)
VIRUS IDENTIFICATION(11,3)
SECONDARY BOVINE(11,1)
PRIMER(10,6)
STERILE COLLECTION(10,4)
PRIMARY CELL TESTICULAR CALF(10,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS POLYMERASE CHAIN REACTION(10,1)
LNAOH VIRUS(10,1)
FOLDING(9,9)
VIRUS ISOLATION(9,5)
VACCINE PREVENTION CONTROL(9,1)
TITER(8,7)
VENOM(8,4)
CENTRIFUGE TUBE(8,3)
INTACT CALF PRIMARY CELL(8,3)
HANK SOLUTION(8,2)
SERUM NEUTRALIZING(8,2)
KERATITIS(8,1)
PEOPLE LIVING STANDARD(8,1)
PROPAGATION PASSAGE(8,1)
EMULSION(7,6)
FORMALDEHYDE(7,3)
STREPTOMYCIN(7,3)
TRYPSIN SENSITIVE(7,2)
VACCINE MANUFACTURE(7,2)
ABORTION(7,1)
BOVINE RESPIRATORY SYNDROME VIRUS(7,1)
BOVINE VIRAL DIARRHEA VIRUS(7,1)
EMULSIFICATION(7,1)
RESPIRATORY TRACT INFECTION(7,1)
VETERINARY BIOLOGIC TECHNOLOGY FIELD(7,1)
HIGHLY CONSERVED REGION SEQUENCE(6,4)
PLACENTAL(6,4)
SUPERNATANT(6,4)
CENTRIFUGATION(6,3)
FINAL CONCENTRATION(6,3)
PENICILLIN(6,3)
TESTIS(6,3)
INFECTIOUS BOVINE NASAL AIRWAY(6,2)
SCISSORS(6,2)
FETAL DEATH(6,1)
NIUS(6,1)
RADICAL(6,1)
TITRATION(6,1)
VETERINARY BIOLOGICS TECHNICAL FIELD(6,1)
CLAY(5,3)
COW REPRODUCTIVE SYSTEM(5,1)
ECONOMIC LOSS MAJOR CAUSE(5,1)
INFECTIOUS BOVINE RHINOTRACHEITIS ENDEMIC(5,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVALENCE(5,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVELENCE(5,1)
INTRAMUSCULARLY INFECTIOUS BOVINE RHINOTRACHEITIS(5,1)
POPULAR PREVENTION CONTROL(5,1)
HANK(4,4)
HEART(4,4)
KIDNEY(4,4)
ALUMINUM STEARATE(4,3)
CATTLE(4,3)
LUNG(4,3)
SPAN(4,3)
WHITE OIL VOLUME RATIO(4,3)
BUILT SEEDLING VENOM(4,2)
BOVINE RHINOTRACHEITIS ABORTED FETUS(4,1)
FETAL TISSUE(4,1)
INFECTIOUS BOVINE RHINOTRACHEITIS PREVENTION(4,1)
SERIAL PASSAGE(3,3)
CHLOROFORM(3,2)
DIETHYL ETHER(3,2)
CATTLE POPULATION ABORTION(3,1)
COW DISEASE PATHOGENESIS(3,1)
ILLNESS ERADICATION(3,1)
LIVE VACCINE SANDU(3,1)
SERIALLY PASSAGED VIRUS(3,1)
TRIGEMINAL GANGLIA LATENT INFECTION(3,1)
IMMUNIZATION(2,6)
INACTIVATED VACCINE PREPARATION(2,3)
MINUTE OVER(2,3)
TWEEN 80(2,3)
ANTIBODY NEGATIVE ADULT COW(2,2)
VACCINE INJECTION(2,2)
BIOCHEMICAL CHARACTERIZATION(2,1)
BOVINE ANTIBODY(2,1)
CALF TESTICULAR CELL(2,1)
CELL ROUNDING VACCINATION(2,1)
CERTIFICATE ISOLATED VIRUS(2,1)
GENERATION EPISODE(2,1)
IMMUNE ENHANCING ADJUVANT PREPARATION(2,1)
IMMUNIZED ANTIBODY POSITIVE(2,1)
L HYDROGEN CHLORIDE SOLUTION(2,1)
LIFELONG STRIP VIRUS DISEASE(2,1)
OIL EMULSION INACTIVATED VACCINE(2,1)
PREGNANT COW(2,1)
SANDU RISK(2,1)
TOPATHIC REGULAR PATTERN(2,1)
VIRUS SEEDING(2,1)
POSITIVE SERA(1,2)
SYSTEMIC ADVERSE REACTION(1,2)
BOVINE LIVER(1,1)
DAY BLOOD COLLECTION(1,1)
LAG COMPARATIVE STUDY(1,1)
MODERATE VISCOSITY(1,1)
OLD CALF(1,1)
OLD COW(1,1)
SECURITY CHECK(1,1)
STERILE HANK SOLUTION(1,1)
STUDY BLANK(1,1)
SUCCESSFUL REPORT(1,1)
TEMPLATE DNA(1,1)
VIRAL DNA TEMPLATE(1,1)";Pharmaceuticals;Open
2009-08-31;"AR073249            A1 2010-10-20 [AR--73249]
STG: (A1) Independent patent application
AP : 2009AR-0103344 2009-08-31
BRPI1015901         A1 2012-09-25 [BR201015901]
STG: (A1) Published application
AP : 2010BR-0015901 2010-08-31
BRPI1015901         A2 2014-02-11 [BR201015901]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2010BR-0015901 2010-08-31";73158;"AR073249            A1 2010-10-20 [AR--73249]
BRPI1015901         A1 2012-09-25 [BR201015901]
BRPI1015901         A2 2014-02-11 [BR201015901]";2009AR-0103344;;"INSTITUTE NAC DE TECNOLOGIA AGROPECUARIA I N T A
INSTITUTE NAC DE TECNOLOGIA AGROPECUARIA INTA";INSTITUTE NAC DE TECNOLOGIA AGROPECUARIA INTA;"(BR201015901)
AR";"(BR201015901)
NAME=INSTITUTO NACIONAL DE TECNOLOGIA AGROPECUARIA (INTA) , COUNTRY=AR 
";1;"DUS SANTOS MARIA JOSE
PECORA ANDREA
WIGDOROVITZ ANDRES
ARDILA FERNANDO
PEREZ AGUIRREGURALDE MARIA SOL
ODEON ANSELMO
RIOS RAUL
GOMEZ CRISTINA
WOLMAN FEDERICO";;;"(BR201015901)
Vaccine against the virus of the bovine viral diarrhea ([vdvb]), procedures and methods of immunization";"(BR201015901)
VACCINE AGAINST the VIRUS OF the BOVINE VIRAL DIARRHEA ([VDVB]), PROCEDURES AND METHODS OF IMMUNIZATION Describes a vaccine against the virus of the bovine viral diarrhea ([VDVB]) that it understands a truncated recombinant [peptideo] ([E]2T) of [VDVB], where such [peptideo] was isolated of plants. The procedure in two phases for the [purificacao] of the recombinant [peptideo] truncated [E]2T of [VDVB] Expresso in plants and methods of immunization of mammals.";;;;"A61K-039/12
A61P-031/14
A61P-037/04
C07K-014/18
C12N-015/40
C12N-015/82";;;Pharmaceuticals;Open
2009-04-28;"CN102965348         A  2013-03-13 [CN102965348]
STG: (A) Published application
AP : 2012CN-0412082 2009-11-23
FD :  Division of: CN200980148483.7 FDD=2009-11-23 [2009CN-80148483]";8112538;CN102965348         A  2013-03-13 [CN102965348];2009US-61173363;;PFIZER;PFIZER;;;1;"Y LUO
YUAN YONG,ANDREWS MICHAEL,ARNOLD W. MICHAEL,MARLOW BARRY";;;"(CN102965348)
Bovine viral diarrhea-mucosal virus with modified erns protein";"(CN102965348)
The invention relates to a chimeric plague virus that can be used for an immunogenicity composition and a vaccine. The chimeric plague virus contains a bovine viral diarrhea-mucosal virus which is not expressing Erns protein with the same source, and expression of the chimeric plague virus is from allos Erns protein of another plague virus or a natrual, synthetic or genetic variant of the allos Erns protein. The invention also describes a method and a kit for treating or preventing transmission of infection of the bovine viral diarrhea-mucosal virus, and a method and a kit for differentiating vaccinal animals and wild infected animals.";"(CN102965348)
1. Chimeric blast virus, which do not express their cognate comprising chimeric pestivirus Eens protein of the Bovine Viral Diarrhea Virus, and wherein the chimeric pestivirus expression derived from another pestivirus in an heterologous Erns protein, or a heterologous Erns protein in its native, synthetic or genetic variants.
2. Chimeric pestivirus according to claim 1, wherein the heterologous chimeric blast virus Erns protein or heterologous Erns protein in its native, synthetic or genetically variant is derived from a virus selected from the group reindeer blast, pronghorn pestiviruses girafe pestiviruses and a pestivirus.
3. Chimeric pestivirus according to claim 1, wherein the heterologous chimeric blast virus Erns protein having at least one wild-type bovine viral diarrhea virus does not exist in that Erns epitope.
4. Chimeric pestivirus according to claim 1, wherein the heterologous chimeric blast virus Erns protein lacks at least one wild-type bovine viral diarrhea virus of the present Erns epitope.
5. Claim 1 of the chimeric blast cultures of virus.
6. Claim 1 comprises cell lines or host cells of viruses of the chimeric blast.
7. Claim 1 of the viral polynucleotide molecule encoding a chimeric blast.
8. Claim 1 of the viral and veterinarily acceptable chimeric blast comprising the vector of the immunogenic composition.
9. The immunogenic composition according to claim 8, wherein the veterinarily acceptable carrier is an adjuvant.
10. The immunogenic composition according to claim 8, wherein the virus is a live attenuated chimeric blast.
11. The immunogenic composition according to claim 8, wherein the chimeric pestivirus is inactivated.
12. The immunogenic composition according to claim 8, further comprising means for the treatment or prevention of one or more additional Bos taurus the propagation of one or more pathogenic microorganisms further antigens.
13. Claim 7 comprises the polynucleotide molecule and a veterinarily acceptable carrier immunogenic composition.
14. Claim 1 of the chimeric blast containing viruses and veterinarily acceptable carriers of the vaccine.
15. Vaccine according to claim 14, wherein the veterinarily acceptable carrier is an adjuvant.
16. Vaccine according to claim 14, wherein the virus is a live attenuated chimeric blast.
17. Vaccine according to claim 14, wherein the chimeric pestivirus is inactivated.
18. Claim 7 comprises a polynucleotide molecule and a veterinarily acceptable carrier which vaccine.
19. Vaccine according to claim 14, further comprising means for the treatment or prevention of one or more additional Bos taurus pathogenic microorganisms of the one or more additional propagation of an antigen.
20. Kits, wherein in at least one vessel contains a vaccine of claim 14.
21. Treating or preventing the spread of an infectious bovine viral diarrhea virus, wherein administering to the animal a vaccine of claim 14.
22. A method for vaccinating an animal, wherein the pestivirus vaccine DIVA administering to the animal, wherein the DIVA pestivirus vaccine comprises a chimeric pestivirus according to claim 1, and wherein the chimeric pestivirus has at least one is not present in wild-type bovine viral diarrhea virus in the Erns epitope.
23. A method for vaccinating an animal, wherein the pestivirus vaccine is administered to the animal DIVA, wherein DIVA vaccine comprising a chimeric pestivirus according to claim 1, and wherein at least one deletion chimeric blast occurring in wild type bovine viral diarrhea virus in a virus Erns epitope.
24. Distinguishing between vaccinated animals and animals infected with wild-type Bovine Viral Diarrhea Virus method according to claim 14, wherein the vaccinated animal to produce antibody, an antibody against the at least one of the chimeric pestivirus vaccine present in and absent from the wild-type bovine viral diarrhea virus in the Erns epitope, the method comprising the steps of: A) obtaining a serum sample from an animal; B) assaying the sample for the presence or absence of antibody; C) will be identified as having been subjected to vaccination of the animal having antibody; and D) have been identified as containing no BVDV-infected animals of the wild type antibody.
25. The wild-type Bovine Viral Diarrhea Virus infection in animals having functions and a vaccinated animal's method according to claim 14, wherein the wild-type Bovine Viral Diarrhea Virus infection of the animal to produce antibody, an antibody against the at least one wild-type bovine viral diarrhea virus present in the absence of either of the chimeric pestivirus of the vaccine to Erns epitope, the method comprising the steps of: A) obtaining a serum sample from an animal; B) assaying the sample for the presence or absence of antibody; C) will have a wild-type BVDV infection has been identified as an animal antibody; and D) has been identified as containing no antibody of animals vaccinated.
26. Are used to distinguish vaccinated comprising an animal infected with wild-type virus vaccine of chimeric blast with bovine viral diarrhea virus to an animal in a diagnostic kit according to claim 1, a kit comprises at least one of the fitting is capable of detecting a pestivirus vaccine against present in and absent from the wild-type bovine viral diarrhea virus in the Erns antibodies against an epitope of the agent.
27. Are used to distinguish infected with wild-type bovine viral diarrhea virus inoculation of the animals and containing a chimeric blast a diagnostic kit for an animal viral vaccines according to claim 1, the kit includes instructions that enable detection to at least one wild-type Bovine Viral Diarrhea Virus and there is no present in a vaccine for the chimeric pestivirus of the Erns antibodies against an epitope of the agent.
28. Identifying Erns epitope of an antibody, a chimeric pestivirus claim 1 epitope is present and absent from the wild-type bovine viral diarrhea virus.
29. An antibody recognizing the epitope, epitope is present and absent from the wild-type Bovine Viral Diarrhea Virus claim 1 of the chimeric pestivirus was.";"(CN102965348)
In one embodiment, the present invention provides a chimeric blast virus, wherein the chimeric pestivirus comprising Erns protein do not express a homologous bovine viral diarrhea virus, and wherein the chimeric pestivirus of heterologous expression derived from another pestivirus E rns protein, or a heterologous E rns protein in its native, synthetic or genetic variants.
The present invention relates to novel chimeric blast virus and their use in immunogenic compositions and vaccines for use.
The present invention also relates to methods for treating or preventing bovine viral diarrhea virus spread of infection of the methods and kits.
The present invention also relates to a chimeric pestivirus in the vaccinated animals and are used to distinguish between wild-type virus-infected animals use of methods and kits.
The present invention relates to chimeric blast can be used as immunogenic compositions and vaccines of the virus, wherein the chimeric pestivirus comprising does not express its cognate E rns protein of the Bovine Viral Diarrhea Virus, and wherein the baculoviral expression derived from another pestivirus of the chimeric pestivirus heterologous E rns protein, or a heterologous Erns protein natural, synthetic or genetic variants.
The present invention also describes the use to treat or prevent the spread of infection of a bovine viral diarrhea virus methods and kits, for distinguishing between vaccinated and infected animals and wild-type methods and kits.";"(CN102965348)
It may be desirable boost regimen, and can be adjusted to provide optimal immunization dosage regimen.
Although the vaccine appeared to protect the fetus from infection, but the guard is limited to homologous strains of the virus, and the antibody titer is no correlation between the guard.
To plague virus with the other (which is a sheep is border disease and swine of the swine fever (classical swine fever) of the causative agents) are closely related.
The terminology used herein is meant that the ""pathogenic microorganisms"" ""pathogen"" or can be in the host animal to induce or cause disease, diseased or abnormal state of the microorganism, such as viruses, bacteria, fungi, protozoa or parasite.";"A61K-039/12
A61K-048/00
A61P-031/14
C07K-016/10
C12N-001/15
C12N-001/19
C12N-001/21
C12N-005/10
C12N-007/01
C12N-015/40
G01N-033/569";"(CN102965348)
1. Chimeric blast virus, which do not express their cognate comprising chimeric pestivirus E ens protein of the Bovine Viral Diarrhea Virus, and wherein the chimeric pestivirus expression derived from another pestivirus in an heterologous E rns protein, or a heterologous E rns protein in its native, synthetic or genetic variants.";"(CN102965348)
BOVINE VIRAL DIARRHEA VIRUS(100,34)
CHIMERIC PESTIVIRUS(100,30)
CHIMERIC BLAST VIRUS(100,15)
PROTEIN(100,5)
COGNATE(100,1)
HETEROLOGOUS CHIMERIC BLAST VIRUS(75,3)
CHIMERIC PESTIVIRUS EXPRESSION(59,1)
BOS TAURUS PATHOGENIC MICROORGANISM(57,1)
HETEROLOGOUS ERNS PROTEIN NATURAL(57,1)
CHIMERIC BLAST(55,18)
HETEROLOGOUS EXPRESSION CHIMERIC PESTIVIRUS(49,3)
OPTIMAL IMMUNIZATION DOSAGE REGIMEN(49,1)
GENETIC VARIANT(46,5)
PATHOGENIC MICROORGANISM(46,2)
BACULOVIRAL EXPRESSION(43,1)
HOMOLOGOUS VIRUS STRAIN(43,1)
VIRUS CHIMERIC BLAST CULTURE(39,1)
IMMUNOGENIC(37,45)
VACCINE CHIMERIC PESTIVIRUS(37,2)
VETERINARILY ACCEPTABLE CHIMERIC BLAST(37,1)
VACCINATED ANIMAL(35,8)
BOOST REGIMEN(35,1)
SPREADING INFECTION(35,1)
DELETION CHIMERIC BLAST(34,1)
VIRUS VACCINE(33,2)
CLASSICAL SWINE FEVER(33,1)
ENS PROTEIN(33,1)
VIRAL POLYNUCLEOTIDE MOLECULE ENCODING(29,2)
ERNS PROTEIN(28,1)
HETEROLOGOUS E RN PROTEIN(27,7)
VACCINE(26,64)
ANIMAL(26,38)
ANTIBODY TITER(25,2)
VIRUS INFECTED ANIMAL(25,1)
ANIMAL ANTIBODY(24,3)
VACCINE VETERINARILY ACCEPTABLE CARRIER(23,2)
CAUSATIVE AGENT(23,1)
DIAGNOSTIC KIT(22,4)
BOVINE VIRAL DIARRHEA VIRUS INFECTION(22,3)
ANTIBODY RECOGNITION(22,1)
AGENT EPITOPE(21,3)
IMMUNOGENIC COMPOSITION VECTOR(21,1)
NATIVE(20,5)
ANTIBODY ABSENCE(20,3)
VIRUS(19,26)
KIT(19,24)
ANIMAL VIRAL VACCINE(19,1)
BOVINE VIRAL DIARRHEA VIRUS INOCULATION(19,1)
GROUP REINDEER BLAST(19,1)
GUARD(17,3)
BVDV INFECTED ANIMAL(17,2)
MICROORGANISM STATE(17,1)
SWINE FEVER(16,1)
PESTIVIRUS(15,8)
VIRUS HOST CELL(15,2)
CORRELATION(15,1)
CHIMERIC PESTIVIRUS VACCINE CANDIDATE(14,2)
BACTERIA(14,1)
PARASITE(14,1)
PATHOGEN(14,1)
COGNATE E RN PROTEIN(13,2)
MANUFACTURER INSTRUCTION(12,10)
OLIGO PRIMER(12,10)
BORDER DISEASE(12,1)
FUNGUS(12,1)
SWINE(12,1)
INFECTION(11,9)
METHYLATED PLASMID AMPLIFICATION(11,3)
PESTIVIRUS E RN PROTEIN(11,3)
PROTOZOA(11,2)
CATTLE CHIMERIC PESTIVIRUS VACCINATION(11,1)
PREGNANT COW BVDV PLACENTA(11,1)
PREVENTION(10,5)
FETUS(10,4)
PE RN GENE(10,4)
PE RN CHIMERA(10,3)
BOVINE ANTISERUM BVDV INOCULATION(10,1)
SHEEP(9,3)
E RN ANTIBODY(9,2)
IGG PEROXIDASE ABC(9,2)
ANTIBODY E RN EPITOPE(9,1)
BVDV VIRUS NEUTRALIZING EPITOPE(9,1)
CHIMERIC PESTIVIRUS VACCINATED ANIMAL(9,1)
NEUTRALIZING EPITOPE CHIMERIC VIRUS(9,1)
DISEASE(8,5)
BVDV FRAGMENT(8,3)
CHIMERIC BLAST VIRAL VACCINE(8,2)
QIAQUICK GEL EXTRACTION KIT(8,2)
VETERINARY LABORATORY AGENCY(8,2)
CHIMERIC BLAST VIRUS VACCINE(8,1)
ELISA WESTERN BLOT IMMUNOASSAY(8,1)
PE RN NEUTRALIZING TITER(8,1)
VIRUS INOCULATION CHIMERIC BLAST(8,1)
MARKER DETERMINANT(7,3)
ANTIBODY EPITOPE(7,2)
BVDV PESTIVIRUS(7,2)
MMESSAGE MMACHINE(7,2)
PLASMID DNA AMPLIFICATION(7,2)
BA BEIXI NEMATODE(7,1)
BOVINE PARAINFLUENZA VIRUS(7,1)
BVDV REINDEER CHIMERIC BLAST(7,1)
CHIMERIC BLAST MULTIPLICATION(7,1)
CHIMERIC NEUTRALIZATION TITER(7,1)
CHIMERIC PESTIVIRUS ANTIBODY(7,1)
CHIMERIC PESTIVIRUS EPITOPE(7,1)
CHIMERIC PESTIVIRUS GENOME(7,1)
COW ESTRUM ARTIFICIAL INSEMINATION(7,1)
FETAL ABORTION VIRUS ISOLATION(7,1)
INTRANASAL INOCULATION ATTACKING(7,1)
NANODROP SPECTROPHOTOMETER RNA GEL(7,1)
PATHOGENIC MICROORGANISM PROPAGATION(7,1)
PE RN VIRAL TRANSFECTION(7,1)
PESTIVIRUS PRONGHORN GENE(7,1)
RECOMBINANT BACULOVIRUS BVDV(7,1)
VACCINE ENCODING CHIMERIC BLAST(7,1)
VIRAL GENOME RNA TRANSCRIPT(7,1)
BLOCKING(6,6)
VECTOR LABORATORY(6,4)
VIRAL PARTICLE(6,4)
EXPRESSION BVDV(6,3)
FOLD SERIAL DILUTION(6,3)
VIRAL RNA ISOLATION KIT(6,3)
BVDV PROPAGATION(6,2)
GIARDIA SPP(6,2)
INFECTED CATTLE(6,2)
RD CELL CULTURE(6,2)
RE RN CHIMERA(6,2)
SEROLOGICAL CHARACTERIZATION(6,2)
VIP PEROXIDASE SUBSTRATE(6,2)
BVDV BVD VIRUS(6,1)
BVDV NEGATIVE SEMEN BREEDING(6,1)
BVDV PARENT TITER(6,1)
CHALLENGE INOCULUM INTRANASAL ADMINISTRATION(6,1)
CHIMERA PCR AMPLIFICATION(6,1)
CHIMERIC BLAST VIRUS MOLECULE(6,1)
CHIMERIC PESTIVIRUS VIRAL ANTIGEN(6,1)
COMPETITIVE ELISA BVDV(6,1)
FETUS VIRAL PROPAGATION(6,1)
MICROBIAL INFECTION SYMPTOM(6,1)
NEUTRALIZING ANTIBODY TITER(6,1)
PE RN GROWTH KINETICS(6,1)
PE RN SIMILARITY(6,1)
SYNTHESIZED STRAND NUCLEOTIDE MONOMER(6,1)
VACCINE VACCINATED ANIMAL(6,1)
WILD TYPE(5,31)
PROGRAMMED RELEASE(5,5)
QUICK RELEASE(5,5)
TARGETED RELEASE(5,5)
COLLECTED SUPERNATANT(5,3)
WILD TYPE BVDV INFECTION(5,3)
BVDV POSITIVE ANIMAL(5,2)
FETAL INFECTION(5,2)
INACTIVATED VIRUS(5,2)
LIPOFECTIN REAGENT(5,2)
PARENT BVDV(5,2)
PARENTERAL ADMINISTRATION(5,2)
WILD TYPE VIRUS VACCINE(5,2)
ABSORBABLE GEL SPONGE(5,1)
ALFUZOSIN APLIDINE(5,1)
ANTIBODY BOUND ANTIGEN(5,1)
ATTENDING VETERINARIAN(5,1)
BLACKWELL SCIENTIFIC PUBLICATION(5,1)
BLOOD SERUM NEUTRALIZATION TITER(5,1)
BORDET ELLA CAROTOBORA(5,1)
BOVI SHIELD GOLD(5,1)
BOVINE DIAGNOSTIC ASSAY(5,1)
BVDV ANTIGEN(5,1)
BVDV GIRAFFE PESTIVIRUS(5,1)
BVDV INDIRECT IMMUNOFLUORESCENCE(5,1)
BVDV RNA MOLECULE(5,1)
BVDV VACCINE PROTECTION(5,1)
BVDV VIRUS PARTICLE(5,1)
CHIMERA NEUTRALIZATION(5,1)
CHIMERIC BVDV TREATMENT(5,1)
CHIMERIC PESTIVIRUS DETECTION(5,1)
COW PREGNANCY STATUS(5,1)
CULLING INFECTED ANIMAL(5,1)
DAM METHYLTRANSFERASE(5,1)
DISEASE REMOVING BVDV THREAT(5,1)
DONOR BOVINE SERUM(5,1)
EXPRESSED CHIMERIC PESTIVIRUS(5,1)
FLAVIVIRIDAE BVDV(5,1)
FLAVIVIRIDAE PESTIVIRUS(5,1)
HAEMOPHILUS SOMNUS(5,1)
HAEMOPHILUS VISE PIG(5,1)
HERD BVDV(5,1)
HOMODIMERIC DISULFANE BOND FORMATION(5,1)
IMMUNE BOVINE SERUM(5,1)
IMMUNOFLUORESCENCE STAINING(5,1)
IMMUNOGENIC DETERMINANT(5,1)
IMMUNOHISTOCHEMICAL STAINING(5,1)
IUPAC IUB COMMISSION(5,1)
LIPID AMINE ADJUVANT(5,1)
MANNHEMIA HAEMOLYTICA(5,1)
METHIONINE METHYLSULFANIUM(5,1)
MICROORGANISM ACCELERATED CLEARANCE(5,1)
MICROORGANISM INACTIVATION(5,1)
NEOSPORA CANIUM(5,1)
NEUTRALIZING TITER SERUM(5,1)
OLIGONUCLEOTIDE PRIMER POLYMERASE CHAIN REACTION AMPLIFICATION(5,1)
ORAL MUCOSAL TRANSPORT(5,1)
PARENT VIRUS GROWTH KINETICS(5,1)
PARENTAL VIRUS BROAD SPECTRUM(5,1)
PE RN VIRUS(5,1)
PESTIVIRUS GIRAFFE(5,1)
PIGLET CAUSATIVE AGENT(5,1)
PRONGHORN ANTELOPE(5,1)
REGIONAL BVDV CLEARANCE(5,1)
RNA ENCODING AMPLIFICATION(5,1)
SALMONELLA ENTERICA SEROVAR(5,1)
SERUM NEUTRALIZATION ASSAY(5,1)
STREPTOCOCCUS UBERIS(5,1)
TOXOPLASMA GONDII(5,1)
TYPHOID SALMONELLA(5,1)
UNDILUTED BOVINE SERUM SAMPLE(5,1)
VIRUS CHIMERIC BLAST(5,1)
VIRUS NEUTRALIZATION ASSAY(5,1)
VIRUS RNA EXTRACTION(5,1)
LIPOSOME(4,5)
MODIFIED RELEASE FORMULATION(4,5)
PULSE RELEASE(4,5)
THERMOSCRIPT(4,3)
BOVINE VIRAL DIARRHEA VIRUS ANIMAL(4,2)
CDNA FRAGMENT(4,2)
DRY POWDER INHALER(4,2)
ELITE KIT(4,2)
HORSE SERUM(4,2)
HUMORAL IMMUNE RESPONSE(4,2)
MEDICAMENT MANUFACTURE(4,2)
MICROORGANISM TRANSMISSION(4,2)
PRESSURIZED CONTAINER(4,2)
RESIDUAL LIVE VIRUS MIXTURE(4,2)
RN GENE PROTEIN(4,2)
ADJUVANT IMMUNOGENIC(4,1)
ANTIBIOTIC IMMUNOGENIC(4,1)
BABESIA SPP(4,1)
BACILLUS ANTHRACIS(4,1)
BIOCHEMICAL NOMENCLATURE(4,1)
BIOTYPE CULTURE(4,1)
BONGO ANTELOPE(4,1)
BRUCELLA SPP(4,1)
BVDV POLYPEPTIDE(4,1)
BVDV TERMINUS(4,1)
CALF EFFICACY(4,1)
CATTLE INFECTION NATURE(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CHIMERIC PESTIVIRUS FLAT BOARD(4,1)
CHIMERIC PESTIVIRUS PRODUCTION(4,1)
CHLAMYDIA SPP(4,1)
CLONE CHIMERA(4,1)
CLOSTRIDIAL SPP(4,1)
DIFFERENTIAL DIAGNOSTIC ASSAY(4,1)
EIMERIA SPP(4,1)
ELECTROHYDRODYNAMIC(4,1)
ERNS EPITOPE(4,1)
FINE MIST ATOMIZER(4,1)
GENBANK ACCESSION(4,1)
GENOMIC ORGANIZATION(4,1)
GENUS EIMERIA(4,1)
HORSERADISH PEROXIDASE(4,1)
HUMORAL IMMUNITY INDUCTION(4,1)
HYDROXYPROPYL METHYLCELLULOSE(4,1)
HYDROXYPROPYLMETHYLCELLULOSE(4,1)
IMMUNOGENIC COMPOSITION ADMINISTRATION(4,1)
INOCULATED CATTLE(4,1)
MICROBE REPLICATION(4,1)
MUCOSA ULCERATION(4,1)
MUCOSAL DISORDER(4,1)
NADL BVDV(4,1)
NCP EXTENDED BIOTYPE(4,1)
PARASITIC NEMATODE(4,1)
PARENTAL BVDV(4,1)
PATHOGENIC FUNGUS(4,1)
PE RN DNA(4,1)
PHOSPHATIDYLCHOLINE(4,1)
POLYMORPHIC MARKER(4,1)
PRONGHORN BVDV(4,1)
RECOMBINANT PLASMID(4,1)
RNA TRANSCRIPT QUANTITY(4,1)
SERIALLY PASSAGED CELL(4,1)
STAPHYLOCOCCUS AUREUS(4,1)
UNIVERSITY BLVD(4,1)
UNIVERSITY BOULEVARD(4,1)
VACCINE EFFECTIVENESS(4,1)
VACCINE INOCULATION(4,1)
VACCINE MARKER(4,1)
VIRUS LIMITING DILUTION TITER(4,1)
WILD TYPE ANTIBODY(4,1)
SIGN(3,4)
ANTIGENIC DETERMINANT(3,3)
EXONUCLEASE(3,3)
MAGMAX(3,3)
NEBULIZER(3,3)
ANIMAL INFECTION(3,2)
BOVINE CELL CULTURE(3,2)
CELL MONOLAYER(3,2)
EXCIPIENT(3,2)
IMMUNOHISTOCHEMISTRY(3,2)
OLIGO PROCESSING(3,2)
PERSISTENTLY INFECTED(3,2)
PHOSPHOSERINE(3,2)
PRIMER OLIGO P(3,2)
PROPELLANT(3,2)
REVERSE TRANSCRIBED RNA(3,2)
RT PCR PRODUCT(3,2)
SEQUENCE SIMILARITY(3,2)
TEST ANTIGEN(3,2)
TEST EFFICACY(3,2)
ULTRA KIT(3,2)
AEROSOL SPRAY(3,1)
AMPLIFIED BVDV(3,1)
ANIMAL TISSUE(3,1)
ANTI BVDV INFECTION(3,1)
ANTIBIOTIC CLASS(3,1)
ANTIBODY DETERMINATION(3,1)
ANTIBODY GENERATION(3,1)
ANTIBODY SELECTION(3,1)
ANTIBODY STAINING(3,1)
ANTIBODY VIRAL PROTEIN(3,1)
ATTENUATED VIRUS(3,1)
AURAL ADMINISTRATION(3,1)
AUTHENTICITY SEQUENCE(3,1)
BINARY AZIRIDINE(3,1)
BIOADHESIVE AGENT(3,1)
BIOLOGICAL CLONING(3,1)
BLISTER PACK(3,1)
BOVINE HERPES VIRUS(3,1)
BOVINE RESPIRATORY DISEASE(3,1)
BOVINE TESTIS CELL(3,1)
BOWEL DISEASE(3,1)
BVDV ANTIBODY NEGATIVE SERUM(3,1)
BVDV BOVINE(3,1)
BVDV NEGATIVE COW(3,1)
BVDV TITER(3,1)
CASEIN SODIUM SALT(3,1)
CATIONIC LIPID(3,1)
CDNA AMPLIFICATION(3,1)
CELL DISEASE DEGENERATION(3,1)
CELLULAR IMMUNOLOGY(3,1)
CELLULAR UPTAKE(3,1)
CELLULOSIC POLYMER(3,1)
CHALLENGE DAY(3,1)
CHALLENGED ANIMAL(3,1)
CHIMERIC CONSTRUCT(3,1)
CHITOSAN POLYMER(3,1)
CHOLERA TOXIN(3,1)
CLINICAL PARAMETER(3,1)
CLINICAL SYMPTOM VARIETY(3,1)
COMPOUNDING(3,1)
CULTURE SUPERNATANT(3,1)
DAILY DOSAGE(3,1)
DAY POST CHALLENGE(3,1)
DEER SPECIES(3,1)
DEFINITION CONFLICT(3,1)
DELAYING ABSORPTION(3,1)
DEPOSITED PRONGHORN(3,1)
DETECTABLE MOIETY(3,1)
DIFFERENCE DISCORDANCE(3,1)
DIRECT PEPTIDE ELISA(3,1)
DISTINGUISHING ANIMAL(3,1)
ECONOMICAL DISRUPTION(3,1)
ELISA ANTIGEN(3,1)
ENVELOPE PROTEIN(3,1)
EPITOPE ABSENCE(3,1)
EYE EAR ADMINISTRATION(3,1)
FINE SPIROCHETE(3,1)
FLUORESCENCE DISCUSSION(3,1)
FLUTTER POWDER(3,1)
FORMALDEHYDE INACTIVATION(3,1)
FORMULA DILUTION(3,1)
FRACTIONAL DOSE(3,1)
FUSION DNA POLYMERASE(3,1)
GELAN GUM(3,1)
GESTATION DAY(3,1)
HEALTHY BOVINE(3,1)
HFC 227EA HEPTAFLUOROPROPANE(3,1)
HYDROPHOBIC MEMBRANE(3,1)
IDENTIFIED BVDV(3,1)
IMMUNIZED ANIMAL(3,1)
IMMUNOASSAY FORMAT(3,1)
IMMUNOGENIC ACTIVITY(3,1)
IMMUNOGENIC COMPOSITION INHALATION ADMINISTRATION(3,1)
IMMUNOGLOBULIN MOLECULE(3,1)
IMMUNOLOGICAL ASSAY(3,1)
IMMUNOSTIMULATORY AGENT(3,1)
IMPLANT LIBRARY(3,1)
INCUBATION DAY(3,1)
INFECTED SF21 CELL(3,1)
INOCULATED BOVINE(3,1)
INTACT IMMUNOGLOBULIN RECOMBINANT SOURCE(3,1)
LABELED MAB(3,1)
LATE ABORTION(3,1)
MAB STAINING(3,1)
MICROORGANISM ABILITY(3,1)
MODIFIED PEPTIDE BACKBONE(3,1)
MOTHER ANIMAL(3,1)
NEGATIVE BOVINE SERUM(3,1)
NUCELOCAPSID LIPID MEMBRANE(3,1)
OPTIMAL PROTEIN DILUTION(3,1)
OVERLAP PCR(3,1)
PARENTERAL FORMULATION(3,1)
PCR OLIGO(3,1)
PENETRATION ENHANCER(3,1)
PEPTIDOMIMETIC BIT LOCATION SYNTHESIS(3,1)
POLYNUCLEOTIDE ENCODING(3,1)
POLYPEPTIDE UNCONVENTIONAL AMINOACID(3,1)
POPULATION GROWTH(3,1)
POSITIVE BOVINE SERUM(3,1)
PREGNANT COW TEST(3,1)
PRINT INSTRUCTION(3,1)
PROSTAGLANDIN INJECTION(3,1)
PROTEIN EXPRESSION(3,1)
PURIFIED VIRUS(3,1)
RE RN GENOME(3,1)
REAGENT ABSENCE(3,1)
REAGENT FIT(3,1)
RECOMBINANT ORIGIN(3,1)
SAPONIN FRACTION(3,1)
SEROLOGICAL TESTING(3,1)
SHORT TERM IMMUNE RESPONSE(3,1)
SPONTANEOUS ABORTION OCCURRENCE(3,1)
STERILE SALINE(3,1)
SUBUNIT ANTIGEN(3,1)
SUPPOSITORY BASE(3,1)
SUSPENSION CULTURE(3,1)
SUSPENSION FORMULATION(3,1)
SYMPTOM RELIEF(3,1)
TEST VACCINE ADJUVANT(3,1)
THIXOTROPIC(3,1)
TISSUE INFECTION(3,1)
TITER DETERMINATION(3,1)
TRIMETHYL LYSINE(3,1)
UV IRRADIATION(3,1)
VACCINE DOSE(3,1)
VIBRIO SPP(3,1)
VIRAL DNA OLIGONUCLEOTIDE PRIMER(3,1)
VIRAL STOCK(3,1)
VIRAL SUSPENSION(3,1)
VIRAL TITER(3,1)
VIRUS DILUTION(3,1)
VIRUS MAINTENANCE(3,1)
VIRUS NEUTRALIZING ACTIVITY(3,1)
VIRUS OUTBREAK SOURCE(3,1)
VIRUS SUSPENSION(3,1)
BORDER DISEASE VIRUS(2,8)
BVDV E RN(2,5)
CONTROLLED RELEASE(2,5)
PRIMER OLIGO B(2,5)
AMINOACID ANALOG(2,3)
GLYCEROL(2,3)
ANCHOR(2,2)
BUFFALO(2,2)
CENTRIFUGATION(2,2)
CHIMERIC PESTIVIRUS E RN(2,2)
COLOR DEVELOPMENT(2,2)
CYCLODEXTRIN(2,2)
CYTOPATHIC EFFECT(2,2)
DAY INTERVAL(2,2)
DIFFERENTIATION(2,2)
DILUENT(2,2)
ENGLAND BIOLAB(2,2)
INFECTION REDUCTION(2,2)
IONTOPHORESIS(2,2)
MENTHOL(2,2)
MICRONEEDLE(2,2)
NORLEUCINE(2,2)
PCR PRODUCT PURIFICATION TREATMENT(2,2)
PLACEBO(2,2)
RNA VIRUS(2,2)
SURFACTANT(2,2)
SYRINGE(2,2)
VIRAL RNA SEQUENCE(2,2)
ABTS SUBSTRATE(2,1)
ACTINOBACILLUS PLEUROPNEUMONIAE(2,1)
AMNIOTIC FLUID(2,1)
ANCESTOR(2,1)
ANIMAL SPECIES(2,1)
ANTIBODY PRODUCTION(2,1)
ANTIGEN COATED ELISA(2,1)
BLOOD SAMPLE PAIR(2,1)
BLOT ANALYSIS(2,1)
BORDETELLA BRONCHISEPTICA(2,1)
BOVINE SERUM ANTIBODY SPECIFICITY(2,1)
BUFFERING AGENT(2,1)
BVDV GENOME LENGTH(2,1)
CARBOXYGLUTAMATE(2,1)
CELL SUSPENSION(2,1)
CHEMICAL MUTAGENESIS(2,1)
COMPLETE BVDV(2,1)
COMPOUND SOLUBILITY(2,1)
COMPOUND SUSPENSION(2,1)
CONFIRMATION SEQUENCE(2,1)
CROSSLINKED POLYACRYLIC ACID(2,1)
CRYPTOSPORIDIUM(2,1)
DEER VARIETY(2,1)
EAGLE CELL(2,1)
FORMALDEHYDE FINAL CONCENTRATION(2,1)
FROZEN STOCK SOLUTION(2,1)
GEL PURIFIED FRAGMENT(2,1)
GROWTH CURVE(2,1)
GROWTH MEDIUM(2,1)
HAEMOPHILUS PARASUIS(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
IMMUNOCHEMISTRY(2,1)
INCIDENCE REDUCTION(2,1)
INFUSION(2,1)
INJECTION DELIVERY(2,1)
INOCULUM REMOVAL(2,1)
ISOTONIC AGENT(2,1)
ISOTONIC PH(2,1)
L PE RN GENOME(2,1)
LACTOSE DRY MIXING(2,1)
MAIN GENOTYPE(2,1)
METHYL ARGININE(2,1)
MICROORGANISM REDUCTION(2,1)
MONOCLONAL ANTIBODY REACTION(2,1)
MURAMYL DIPEPTIDE(2,1)
MYCOBACTERIUM BOVIS(2,1)
MYCOBACTERIUM PARATUBERCULOSIS(2,1)
MYCOPLASMA BOVIS(2,1)
OLIGOMERIC LACTIC ACID(2,1)
ORGANIC POLYMER MOLECULE(2,1)
PARENTERAL SOLUTION PREPARATION(2,1)
PASTEURELLA MULTOCIDA(2,1)
PERFORMANCE MODIFIER(2,1)
POLYCLONAL MIXTURE(2,1)
PORCINE CELL(2,1)
PRESERVATION(2,1)
PROPIOLACTONE(2,1)
REAGENT POLYNUCLEOTIDE SEQUENCE(2,1)
RECOMBINANT VIRUS(2,1)
REFRIGERANT R134A(2,1)
SEQUENCE ENCODING(2,1)
SINGULAR TERM(2,1)
SPECIES SEPARATION(2,1)
STEREOISOMER AMINOACID(2,1)
SYNTHETIC PEPTIDE(2,1)
UNIQUE SPECIES(2,1)
UNIVERSITY R DONIS(2,1)
VIRAL SAMPLE(2,1)
VIRUS INFECTED CELL(2,1)
WHOLE ORGANISM(2,1)
ACTIVATION VOLUME(1,1)
ANIMAL SUBJECT(1,1)
ANTIBODY CREATION(1,1)
BOVINE CORONAVIRUS(1,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(1,1)
BOVINE TUBERCULOSIS(1,1)
CARBOXYL GROUP(1,1)
CLOSTRIDIUM(1,1)
COAT PROTEIN C CLOTHES(1,1)
COMPLETE GENOME(1,1)
DERIVED SEQUENCE(1,1)
DIVIDED DOSE(1,1)
ERYSIPELOTHRIX(1,1)
ESTRUM SYNCHRONIZATION(1,1)
FREEMAN(1,1)
GEL PURIFIED PCR PRODUCT(1,1)
GENE PRODUCT(1,1)
GENE SEQUENCE(1,1)
GENTAMICIN(1,1)
GLUTAMAX(1,1)
IMMUNE RESPONSE NATURE(1,1)
IMMUNOGEN AMINOACID SEQUENCE(1,1)
INFLUENZAE(1,1)
INTACT IMMUNOGLOBULIN IMMUNOREACTIVE PORTION(1,1)
LEPTOSPIRA(1,1)
MICROSPHERE(1,1)
MUCOSAL DISEASE(1,1)
MUCOUS MEMBRANE(1,1)
NATIONAL(1,1)
NEBRASKA(1,1)
OPTIMEM(1,1)
PATHOGENIC BACTERIUM(1,1)
PATHOGENIC VIRUS(1,1)
RABIESVIRUS(1,1)
RINDERPEST VIRUS(1,1)
SINGLE VIRAL LESION(1,1)
SWINE FEVER VIRUS(1,1)
TRANSDERMAL ADMINISTRATION(1,1)
WILD BOAR(1,1)";"Analysis of biological materials
Pharmaceuticals";Open
2009-03-05;"RU2396978           C1 2010-08-20 [RU2396978]
STG: (C1) Patent for invention
AP : 2009RU-0107929 2009-03-05";36319861;RU2396978           C1 2010-08-20 [RU2396978];2009RU-0107929;;MOSCOW STATE INSTITUTE OF ELECTRONIC TECHNOLOGY;MOSCOW STATE INSTITUTE OF ELECTRONIC TECHNOLOGY;;;1;"EVGLEVSKIJ ANATOLIJ ALEKSEEVICH
EVGLEVSKIJ DMITRIJ ANATOL EVICH";;;"(RU2396978)
Method for prevention of cattle leukosis development";"(RU2396978)
FIELD: medicine. ^ SUBSTANCE: invention refers to biotechnology. The method involves vaccination of animals with the vaccine prepared by inactivation of cultural leukosis virus and polymerisation of its glycoproteides with 0.2% formalin at 39-40C for 7-9 days and aluminium hydroxide sorption of the prepared suspension in amount 3-5 mg/ml. The vaccine is introduced subcutaneously, three times, every 14-15 days, in amount 3-5 ml. Herewith, 20-30 days prior to vaccination, tuberculosis anatoxin 4-5 ml and staphylococcal anatoxin-vaccine 4-5 ml are introduced subcutaneously. 8-9 months later, revaccination is performed as a single introduction of the leukosis vaccines preceded with introduction of tuberculosis anatoxin and staphylococcal anatoxin-vaccine in specified amount 20 days before. ^ EFFECT: method provides more effective protection of the animals vaccinated against leukosis. ^ 2 cl, 3 ex";"(RU2396978)
1. Method of the preventive maintenance of the development of the leucosis of large livestock, which includes the introduction of the inactivated vaccine against the leucosis, which is characterized by the fact that the vaccination of animals is carried out as far as the vaccine, obtained by the inactivation of the cultural virus of leucosis and by the polymerization of its glycoproteins by the 0,2%- by the solution of formalin with 39-40°С during 7-9 days and by the absorption of the obtained suspension on hydroxide of aluminum 3-5 mg/ml, vaccine introduces hypodermically, it is triple, with the interval of 14-15 days, before a volume of 3-5 ml, in this case tubercular anatoxin and staphylococcal anatoxin- vaccine on 4-5 ml preliminarily 20-30 days prior to vaccination hypodermically are introduced, and in 8-9 months is conducted revaccination by the single introduction of leucosis vaccine with the introduction of tubercular anatoxin and staphylococcal anatoxin- vaccine before the previous volumes preliminary in 20 days.
2. Method on п.1, which is characterized by the fact that the vaccinations subject the infected animals with the level of the caption of precipitating antibodies 1: 2-1: 4.";;;"A61K-039/12
A61K-039/295";;;Pharmaceuticals;Open
"2009-02-02
2010-02-02
2011-08-02
2015-07-31";"WO2010088691        A2 2010-08-05 [WO201088691]
STG: (A2) International application published with declaration under Article 17 (2) (a)
AP : 2010WO-US22932 2010-02-02
WO2010088691        A3 2011-01-06 [WO201088691]
STG: (A3) Later publication of ISR with revised front page
AP : 2010WO-US22932 2010-02-02
US20110296545       A1 2011-12-01 [US20110296545]
STG: (A1) Application published
AP : 2010US-13147578 2010-02-02
US9102925           B2 2015-08-11 [US9102925]
STG: (B2) Granted patent as second publication
AP : 2010US-13147578 2010-02-02
FD :  Provisional Appl: US61/149,278 FDD=2009-02-02 [2009US-61149278]
FD : Previous publication: US20110296545 A1 2011-12-01 [US20110296545]
US20150327522       A1 2015-11-19 [US20150327522]
STG: (A1) Application published
AP : 2015US-14815240 2015-07-31
FD :  Continuation of: US13/147,578 FDD=2011-08-02 [2011US-13147578]
FD : Continuation of: US9102925 - 0 [US9102925]
FD : Continuation of: WOPCT/US10/22932 FDD=2010-02-02 [2010WO-US22932]
FD : Provisional Appl: US61/149,278 FDD=2009-02-02 [2009US-61149278]";44375511;"WO2010088691        A2 2010-08-05 [WO201088691]
WO2010088691        A3 2011-01-06 [WO201088691]
US20110296545       A1 2011-12-01 [US20110296545]
US9102925           B2 2015-08-11 [US9102925]
US20150327522       A1 2015-11-19 [US20150327522]";"2009US-61149278
2010US-13147578
2010WO-US22932
2011US-13147578
2015US-14815240";"(US9102925)
WO2010088691";WASHINGTON STATE UNIVERSITY;WASHINGTON STATE UNIVERSITY;"(US20110296545)
US
(US9102925)
US
(US20150327522)
US
(WO201088691)
US
(WO201088691)
US";"(US20110296545)
NAME=Washington State University , CITY=Pullman , STATE=WA , COUNTRY=US , ATYP=US Company 

(US9102925)
NAME=Washington State University , CITY=Pullman , STATE=WA , COUNTRY=US , ATYP=US Company 

(US20150327522)
NAME=WASHINGTON STATE UNIVERSITY , CITY=Pullman , STATE=WA , COUNTRY=US , ATYP=US Company 

(WO201088691)
NAME=WASHINGTON STATE UNIVERSITY  1610 NE Eastgate Boulevard, Suite 650, Pullman, Washington 99163  , COUNTRY=US 

(WO201088691)
NAME=WASHINGTON STATE UNIVERSITY 1610 NE Eastgate Boulevard, Suite 650 Pullman, Washington 99163 , POSTCODE=99163 , COUNTRY=US 
";1;"SRIKUMARAN SUBRAMANIAM
SHANTHALINGAM SUDARVILI";"(US20110296545)
US
(US9102925)
US";"(US20110296545)
NAME=Srikumaran Subramaniam , CITY=Pullman , STATE=WA , COUNTRY=US 

NAME=Shanthalingam Sudarvili , CITY=Pullman , STATE=WA , COUNTRY=US 

(US9102925)
NAME=Srikumaran Subramaniam , CITY=Pullman , STATE=WA , COUNTRY=US 

NAME=Shanthalingam Sudarvili , CITY=Pullman , STATE=WA , COUNTRY=US 
";"(US9102925)
Compositions and methods for treating or preventing conditions and diseases associated with Mannheimia haemolytica";"(US9102925)
Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain ‘cleavage-inhibiting’ glutamine (Q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position −5 relative to the cleavage site. Mutagenesis of Q at position −5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(−5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods for treating conditions and/or diseases associated with M. haemolytica (e.g., pneumonic pasteurellosis), comprising administration of polypeptides comprising CD18 signal peptide sequences are also provided.";"(WO201088691)
CLAIMS
1. A purified or recombinant ruminant CD 18 polypeptide, comprising a ruminant CD 18 polypeptide, or portion thereof, having a cleavable signal peptide with a helix-breaking amino acid residue at amino acid position 18 (-5 with respect to signal peptide cleavage site).
2. The polypeptide of claim 1, wherein the amino acid residue at amino acid position 18 is selected from the group consisting of glycine, proline, arginine, and tyrosine.
3. The polypeptide of claim 1, wherein the ruminant is selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn and nilgai.
4. The polypeptide of claim 1, wherein the recombinant ruminant CD 18 polypeptide is one Q(-5)G CD18 mutant selected from the group consisting of SEQ ID NOS:57, 58, 60, 62, 64, 66, 68, 70 and CD 18 signal peptide-comprising portions thereof.
5. An isolated nucleic acid comprising a sequence that encodes the polypeptide of any one of claims 1 through 4.
6. An recombinant expression vector, comprising a nucleic acid comprising a sequence that encodes a polypeptide comprising a ruminant CD 18 polypeptide, or portion thereof, having a cleavable signal peptide with a helix-breaking amino acid residue at amino acid position 18 (-5 with respect to signal peptide cleavage site). 7. A recombinant or cloned ruminant cell or ruminant animal, comprising a ruminant cell capable of expressing a polypeptide comprising a ruminant CD 18 polypeptide, or portion thereof, having a cleavable signal peptide with a helix-breaking amino acid residue at amino acid position 18 (-5 with respect to signal peptide cleavage site).
8. The recombinant or cloned ruminant cell or ruminant animal of claim 7, wherein expressing a polypeptide comprising a ruminant CD 18 polypeptide having a cleavable signal peptide comprises expressing from a genomic locus, or from a recombinant expression vector.
9. The recombinant or cloned ruminant cell or ruminant animal of claim 7, wherein the cell or animal is less susceptible to, or resistant to the effects of M. haemolytica, relative to wild- type control cells.
10. The recombinant or cloned ruminant cell or ruminant animal of claim 7, wherein the cell or animal is that of a ruminant selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn and nilgai.
11. The recombinant or cloned ruminant cell or ruminant animal of claim 7, wherein, in the cell capable of expressing a polypeptide comprising a ruminant CD 18 polypeptide, or portion thereof, having a cleavable signal peptide, there is reduced or no expression of the endogenous wild-type CD 18 polypeptide having a non-cleavable signal peptide. 12. A method of providing a recombinant or cloned ruminant cell, comprising introduction into, or engineering within the ruminant cell, a nucleic acid comprising a sequence that encodes a polypeptide comprising a ruminant CD 18 polypeptide, or portion thereof, having a cleavable signal peptide with a helix-breaking amino acid residue at amino acid position 18 (-5 with respect to signal peptide cleavage site), wherein the cell is less susceptible to, or resistant to the effects of M. haemolytica, relative to wild-type control cells.
13. The method of claim 12, wherein the amino acid residue at amino acid position 18 is selected from the group consisting of glycine, proline, arginine, and tyrosine.
14. The method of claim 12, wherein the ruminant is selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn and nilgai.
15. The method of claim 12, wherein the recombinant ruminant CD 18 polypeptide is one Q(-5)G CD 18 mutant selected from the group consisting of SEQ ID NOS:57, 58, 60, 62, 64, 66, 68, 70 and CD 18 signal peptide-comprising portions thereof.
16. A method of providing a recombinant or cloned ruminant animal, comprising introduction into, or engineering within one or more cells of a ruminant animal, a nucleic acid comprising a sequence that encodes a polypeptide comprising a ruminant CD 18 polypeptide, or portion thereof, having a cleavable signal peptide with a helix-breaking amino acid residue at amino acid position 18 (-5 with respect to signal peptide cleavage site), wherein the recombinant or cloned ruminant animal is less susceptible to, or resistant to the effects of M. haemolytica, relative to wild-type control cells.
17. The method of claim 16, comprising the use of ruminant stem cells or enucleated ruminant cells.
18. The method of claim 16, wherein the amino acid residue at amino acid position 18 is selected from the group consisting of glycine, proline, arginine, and tyrosine. 19. The method of claim 16, wherein the ruminant is selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn and nilgai.
20. The method of claim 16, wherein the recombinant ruminant CD18 polypeptide is one Q(-5)G CD 18 mutant selected from the group consisting of SEQ ID NOS:57, 58, 60, 62, 64, 66, 68, 70 and CD 18 signal peptide-comprising portions thereof.
21. A method for treating or preventing conditions and diseases associated with M. haemolytica in ruminants, comprising administering to a ruminant subject in need thereof, an amount of a polypeptide comprising a CD 18 signal peptide, or portion thereof, suitable to treat, prevent or otherwise ameliorate a condition or disease associated with M. haemolytica in the ruminant.
22. The method of claim 21, wherein the polypeptide comprising a CD 18 signal peptide, or portion thereof, is a polypeptide comprising from about 13 to about 24 contiguous amino acid residues of the first 24 amino acids of the N-terminus of the native (full-length nascent) CD 18 sequence, wherein the polypeptide is suitable to provide for at least one of binding to M. haemolytica leukotoxin (Lkt) and abrogation of Lkt- induced cytolysis.
23. The method of claim 22, wherein the polypeptide comprises a contiguous portion of the CD 18 signal polypeptide beginning at amino acid residue 5.
24. The method of claim 23, wherein the polypeptide comprises residues 5 to 17 of the CD 18 signal polypeptide.
25. The method of claim 21, wherein the CD 18 sequence is selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn, nilgai, human, chimp, mouse, rat and pig.
26. The method of claim 21, wherein the CD 18 sequence is selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 21, 26, 57, 58, 60, 62, 64, 66, 68 and 70. 27. The method of any one of claims 21 through 24, wherein the CD 18 signal peptide sequence is selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn and nilgai, human, chimp, mouse, rat and pig.
28. The method of any one of claims 21 through 24, wherein the CD 18 signal peptide sequence is selected from the group consisting of SEQ ID NOS:28, 30, 32, 34, 36, 40,
 42, 44, 46, 48, 50, 52 and 54.
29. The method of claim 21, further comprising administration of an anti-leuko toxin antibody reagent or epitope-binding portion thereof.
30. The method of claim 21, wherein administering the amount of the polypeptide comprising a CD 18 signal peptide, or portion thereof, comprises administration to a ruminant previously vaccinated against M. haemolytica.
31. The method of claim 30, wherein vaccination against M. haemolytica comprises administration of M. haemolytica leukotoxin (Lkt) or a portion thereof.
32. An antibody specific for a CD 18 signal peptide, or portion thereof comprising from about 13 to about 24 contiguous amino acid residues of the first 24 amino acids of the N-terminus of the native (full-length nascent) ruminant CD 18 sequence, wherein the polypeptide is suitable to provide for at least one of binding to M. haemolytica leukotoxin (Lkt) and abrogation of Lkt-induced cytolysis.
33. The antibody of claim 32, wherein the polypeptide comprises a contiguous portion of the CD 18 signal polypeptide beginning at amino acid residue 5.
34. The antibody of claim 33, wherein the polypeptide comprises residues 5 to 17 of the CD 18 signal polypeptide. 35. The antibody of claim 32, wherein the CD 18 sequence is selected from the group consisting of cattle, bison, buffalo, goat, domestic sheep, big horn sheep, deer, elk, giraffes, yaks, camels, alpacas, llamas, wildebeest, antelope, pronghorn, nilgai, human, chimp, mouse, rat and pig.
36. The antibody of claim 32, wherein the CD 18 sequence is selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 21, 26, 57, 58, 60, 62, 64, 66,
 68 and 70.
37. A method for treating or preventing conditions and diseases associated with M. haemolytica in ruminants, comprising administering to a ruminant subject in need thereof, an amount of an antibody specific for a CD 18 signal peptide, or portion thereof comprising from about 13 to about 24 contiguous amino acid residues of the first 24 amino acids of the N- terminus of the native (full-length nascent) ruminant CD 18 sequence, wherein the polypeptide is suitable to provide for at least one of binding to M. haemolytica leukotoxin (Lkt) and abrogation of Lkt-induced cytolysis, wherein a method of treating for treating or preventing conditions and diseases associated with M. haemolytica in ruminants is provided. 38. The method of claim 37, wherein the antibody is according to any one of claims
 32-36.";"(US9102925)
For purposes of the present invention, target polypeptides and variants thereof are used to immunize an animal or transgenic animal as described above.
For purposes of the present invention, an effective dose will generally be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the SEQ ID NOS: 2, 4, 6, 8, 10, 12 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 57, 58, 60, 62, 64, 66, 68, and 70, sequences having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto polypeptide constructs in the individual to which it is administered.";"(US9102925)
Fusion proteins are useful for generating antibodies against amino acid sequences and for use in various targeting and assay systems.
In addition, it may be advantageous to incorporate an epitope tag or other moiety to facilitate affinity purification of the target protein.
Thus, it is not useful to specify an exact effective amount in advance.
Aggregation of proteins not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be immunogenic (see, e.g., Pinckard et al., Clin.
As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease or other indication, are ameliorated or otherwise beneficially altered.
For example, to generate cattle containing a CD18 molecule that had a Q( 5)G mutation (an exemplary mutation which results in limited binding of Lkt to CD18 signal sequence), a male Holstein primary fetal fibroblast line 6594 is transfected with vectors containing the mutated signal sequence to replace the native CD 18 coding region.";"A01K-067/027
A61K-038/00
A61K-039/395
C07K-014/705
C07K-016/28
C12N-005/16
C12N-015/85";"(US9102925)
1. A ruminant cell that is genetically engineered to contain a nucleic acid sequence encoding a ruminant CD18 protein having a cleavable signal peptide with a helix-breaking amino acid residue at an amino acid positioned 5 residues upstream of the signal peptide cleavage site.";"(US20110296545)
RUMINANT(100,66)
SIGNAL PEPTIDE(100,47)
ANTIBODY(100,23)
DISEASE(100,15)
RUMINANT CELL(100,9)
CLEAVABLE SIGNAL PEPTIDE(100,8)
RUMINANT ANIMAL(100,5)
MANNHEIMIA HAEMOLYTICA(100,2)
RECOMBINANT EXPRESSION VECTOR(100,2)
ISOLATED NUCLEIC ACID(100,1)
BIG HORN SHEEP(98,8)
HAEMOLYTICA LEUKOTOXIN(93,10)
TRANSFECTANT MEDIATED CYTOLYSIS(65,1)
RECOMBINANT RUMINANT(60,3)
RUMINANT LEUKOCYTE RENDERING(56,1)
RUMINANT CD(53,3)
INDUCED CYTOLYSIS(51,16)
CLEAVAGE(50,7)
HELIX(48,7)
AMINOACID RESIDUE(44,19)
ABROGATION(39,8)
WILDEBEEST(39,7)
EPITOPE(39,1)
CONTIGUOUS AMINOACID RESIDUE(38,6)
ALPACA(37,7)
ANTELOPE(37,7)
GIRAFFE(37,7)
N TERMINUS(36,4)
PHARMACEUTICAL FORMULATION(36,1)
TARGET PROTEIN AFFINITY PURIFICATION(36,1)
PNEUMONIC PASTEURELLOSIS(35,3)
CATTLE(34,13)
BOVINE PMN INDUCED CYTOLYSIS(34,11)
BUFFALO(34,7)
CAMEL(34,7)
LLAMA(34,7)
FETAL FIBROBLAST(34,2)
POLYPEPTIDE ADMINISTRATION(34,1)
DOMESTIC SHEEP(33,10)
PRONGHORN(33,5)
TARGET POLYPEPTIDE(33,1)
BISON(32,7)
NATIVE(32,5)
ANTI LEUKOTOXIN ANTIBODY REAGENT(32,1)
MALE HOLSTEIN PRIMARY(31,2)
YAK(30,7)
NILGAI(29,5)
DEER(27,9)
ELK(27,7)
ANTIBODY GENERATION(27,1)
CONDITION SYMPTOM(27,1)
NATIVE CD(26,2)
GOAT(25,9)
NUCLEIC ACID(25,3)
CLEAVAGE CONDUCIVE GLYCINE(24,3)
SIGNAL POLYPEPTIDE BEGINNING(24,2)
NON CLEAVABLE SIGNAL PEPTIDE(24,1)
MUTATION(23,13)
CLEAVAGE INHIBITING GLUTAMINE(23,3)
FUSION PROTEIN(22,7)
SIGNAL PEPTIDE SEQUENCE(22,4)
ACTIVITY LOSS(21,1)
MUTATED SIGNAL SEQUENCE(21,1)
AMINOACID POSITION(20,9)
AGGREGATION(20,1)
CHIMP(19,4)
MOIETY(19,1)
RUMINANT STEM CELL(19,1)
ARGININE(18,7)
PROLINE(17,6)
CYTOLYSIS ABROGATION(17,5)
SEQUENCE IDENTITY(17,5)
RUMINANT LEUKOCYTE INDUCED CYTOLYSIS(17,2)
CODING REGION(16,2)
TARGET(16,2)
PIG(15,4)
TRANSFECTANT INDUCED CYTOLYSIS(15,3)
DOSE(15,2)
ANIMAL(14,16)
CALF PNEUMONIC LUNG(14,2)
ERYTHROCYTE PELLET HYPOTONIC LYSIS(14,1)
PARENCHYMAL NECROSIS DISCREET FOCI(14,1)
POST INOCULATION(13,9)
TRANSGENIC ANIMAL(13,8)
HAEMOLYTICA INFECTION(13,5)
DISORDER(13,3)
PEPTIDE TERMINALLY TRUNCATED VERSION(13,2)
GROSS PULMONARY PATHOLOGY QUANTITATION(13,1)
GROSS PULMONARY LESION(12,2)
PURPLE FORMAZAN PRECIPITATE(12,2)
SMITH WATERMAN HOMOLOGY(12,2)
ALVEOLAR MACROPHAGE DEGRANULATION(12,1)
RUMINANT PMN INDUCED CYTOLYSIS(12,1)
SUBGENOMIC POLYNUCLEOTIDE ULTIMATE EFFICACY(12,1)
TARGET CELL INDUCED CYTOLYSIS(11,11)
DIPHENYL TETRAZOLIUM BROMIDE(11,2)
NON RUMINANT CDR CONFORMATION(11,1)
RUMINANT LEUKOCYTE SUSCEPTIBILITY(11,1)
AMINOACID(10,29)
VECTOR(10,6)
GRAY HISTOGRAM(10,4)
ANTIBODY NEUTRALIZATION(10,3)
CYTOLYSIS INHIBITION(10,3)
IRRELEVANT PEPTIDE(10,3)
L TYROSINE(10,3)
HEALTHY CATTLE NASOPHARYNX(10,1)
PREWARMED BRAIN HEART INFUSION(10,1)
PULMONARY TISSUE HISTOPATHOLOGICAL EXAMINATION(10,1)
RUMINANT LEUKOCYTE CYTOMETRIC ANALYSIS(10,1)
TRANSGENIC NON PRIMATE MAMMALIAN HOST(10,1)
BOVINE SIGNAL PEPTIDE(9,7)
MTT DYE REDUCTION(9,5)
CLINICAL SCORE(9,4)
CALF CHALLENGE(9,3)
RANDOMLY SCRAMBLED SEQUENCE(9,3)
SHADED HISTOGRAM(9,3)
ADJOINING PORTION(9,2)
ANTI LKT ANTIBODY(9,2)
FIBRINONECROTIC PNEUMONIA(9,2)
HAEMOLYTICA SEROTYPE(9,2)
UNIMMUNIZED CHICKEN(9,2)
ANTI FLAG EPITOPE ANTIBODY(9,1)
CRYSTALIZED DEXTRAN MICROSPHERE(9,1)
GROSS PNEUMONIC LESION(9,1)
OBSERVATIONAL DISEASE SCORE(9,1)
PHRASE RUMINANTIZED ANTIBODY(9,1)
POLYBRENE MEDIATED TRANSFECTION(9,1)
RUMINANT IMMUNOGLOBULIN(9,1)
SIGNAL SEQUENCE(8,7)
ASSAY(8,6)
BIOLOGICAL ACTIVITY(8,6)
FUSION PROTEIN CONSTRUCTION(8,3)
HAEMOLYTICA CULTURE(8,2)
KILLED ADENOVIRUS(8,2)
LEUCINE ISOLATED REPLACEMENT(8,2)
NECROTIC FOCI(8,2)
RUMINANT MONOCLONAL ANTIBODY(8,2)
SYNTHETIC PEPTIDE SPANNING(8,2)
DEGENERATE NEUTROPHIL DENSE BAND(8,1)
EXOGENOUS IMMUNOGLOBULIN(8,1)
NEUTRALIZING ANTIBODY TITER(8,1)
PARENT ANTIBODY CONFORMATION(8,1)
PARENT NON RUMINANT ANTIBODY(8,1)
PHRASE CHIMERIC ANTIBODY(8,1)
PNEUMONIC LUNG SCORE(8,1)
POLYPEPTIDE CARBOXY TERMINUS(8,1)
POLYPEPTIDE PEGYLATION(8,1)
RUMINANT ORIGIN ANTIBODY(8,1)
RUMINANTIZED SEQUENCE PREDICTED CONFORMATION(8,1)
SCREENING CDNA EXPRESSION LIBRARY(8,1)
VALIDATED PROTEIN INOCULATED ANIMAL(8,1)
SIGNAL PEPTIDE CLEAVAGE SITE(7,4)
TARGET TISSUE(7,4)
BOVINE EXPRESSION(7,3)
PROTEIN SEGMENT(7,3)
RUMINANT SIGNAL PEPTIDE(7,3)
WILD SHEEP(7,3)
ALLELIC VARIANT(7,2)
ANIMAL GENOTYPE(7,2)
ANIMAL INOCULATION(7,2)
BOVINE MINIMAL PEPTIDE SEQUENCE(7,2)
CLONE CATTLE(7,2)
COVALENT VARIANT(7,2)
DISEASE PROGRESSION(7,2)
DYE REDUCTION CYTOTOXICITY ASSAY(7,2)
EXPERIMENTAL INFECTION(7,2)
LUNG LESION(7,2)
MATURE PROTEIN(7,2)
MTT ASSAY(7,2)
NATIVE TERMINUS(7,2)
PURPLE COLOR INTENSITY(7,2)
TETRAZOLIUM DYE(7,2)
THERAPEUTIC AGENT ADMINISTRATION(7,2)
UNCHARGED POLAR(7,2)
ANTISERA UNAVAILABILITY(7,1)
BACTERIUM PRECISE SEROTYPE(7,1)
CLINICAL DISEASE SCORE(7,1)
CLINICAL DISEASE SCORING(7,1)
CLINICAL DISEASE SYMPTOM(7,1)
CLINICIAN JUDGEMENT(7,1)
COLORLESS RPMI UL(7,1)
COLOSTRUM DEPRIVED CALF(7,1)
CYTOTOXICITY INHIBITION ASSAY(7,1)
DILUTED INOCULUM ALIQUOT(7,1)
ENDOBRONCHIAL CHALLENGE(7,1)
ENDOGENOUS HEAVY INACTIVATION(7,1)
ENDOGENOUS IG(7,1)
ENDOGENOUS IMMUNOGLOBULIN ENCODING(7,1)
ER RESIDENT ENZYME(7,1)
EXACT EFFECTIVE(7,1)
EXHIBIT DIMINISHED IMMUNOGENICITY(7,1)
FETAL BOVINE SERUM(7,1)
FLAG EPITOPE EXPRESSION(7,1)
FLAG EPITOPE INTRODUCTION(7,1)
FUNCTIONAL ENDOGENOUS IMMUNOGLOBULIN(7,1)
HAEMOLYTICA BACTERIUM(7,1)
INFLUENZA HEMAGGLUTININ(7,1)
INSTITUTIONAL ANIMAL CARE(7,1)
INTERLOBULAR SEPTUM(7,1)
MINIGENE ENCODING(7,1)
NASCENT MEMBRANE PROTEIN(7,1)
NASOPHARYNGEAL FLORA(7,1)
NATIONAL HEALTH INSTITUTE(7,1)
NEUTRAL BUFFERED FORMALIN(7,1)
NON HUMAN MAMMALIAN HOST(7,1)
PARENTAL MOUSE MONOCLONAL ANTIBODY(7,1)
PHAGE MINOR COAT PROTEIN(7,1)
PHOTOAFFINITY LABELING(7,1)
PNEUMONIC LESION DEVELOPMENT(7,1)
POLYCATIONIC CONDENSED DNA(7,1)
POLYNUCLEOTIDE ENCAPSULATION(7,1)
POLYPEPTIDE TERMINUS AMINO(7,1)
POSITIVE ANTIBODY PIII PHAGE(7,1)
PROTEIN INHIBITOR ANTIBODY(7,1)
PROTEIN SPECIES HOMOLOG(7,1)
RUMINANT SUSCEPTIBILITY(7,1)
RUMINANTIZED SEQUENCE CONFORMATION(7,1)
STERILE COTTON SWAB(7,1)
STREAMING NUCLEUS COAT CELL(7,1)
VALIDATED PROTEIN ANTIGEN COLUMN(7,1)
ADJUVANT(6,6)
ACIDIC ISOPROPANOL(6,3)
ANAPLASMA MARGINALE(6,3)
INHIBITION DETECTION(6,3)
TARGET CELL CYTOLYSIS(6,3)
BACTERIAL CLEARANCE(6,2)
BIOLOGICALLY ACTIVE VARIANT(6,2)
BLACK HISTOGRAM(6,2)
CELL VIABILITY(6,2)
CODING SEQUENCE EXPRESSION(6,2)
FUNCTIONAL PROTEIN ACTIVITY(6,2)
LINKING FUNCTIONALITY(6,2)
LOGARITHMIC PHASE CULTURE(6,2)
MATURE CD(6,2)
PROTEIN VARIANT(6,2)
SPECIES VARIANT(6,2)
SUSCEPTIBILITY LOSS(6,2)
UNAVAILABLE TECHNOLOGY(6,2)
AGGREGATION PREVENTION(6,1)
ANTIBODY SPECIFICITY(6,1)
ANTIBODY SUITABILITY(6,1)
ASHWELL RECEPTOR(6,1)
AUTOFLUORESCENT PROTEIN(6,1)
BACTERIA CHARACTERIZATION(6,1)
BACTERIOLOGICAL EXAMINATION(6,1)
BACTERIUM PURE CULTURE(6,1)
BREAKING RESIDUE GLYCINE(6,1)
CALF PHENOTYPE(6,1)
CATHETERIZED ADMINISTRATION(6,1)
CHICKEN ANTISERUM(6,1)
CLINICAL DISEASE SIGN(6,1)
ENDOGENOUS WILD TYPE(6,1)
ENDOPLASMIC RETICULUM RESIDENT ENZYME(6,1)
ENZYME LINKED IMMUNOSORBANT ASSAY(6,1)
FICOLL PAQUE(6,1)
FLAG EPITOPE INSERTION(6,1)
GLUTAMINE MUTATION(6,1)
GROSSLY PNEUMONIC REGION(6,1)
HEART BLOOD CULTURE(6,1)
HETEROLOGOUS PROMOTER(6,1)
HISTOPATHOLOGICAL EVALUATION(6,1)
HOMOLOGOUS RECOMBINATION(6,1)
HORSERADISH PEROXIDASE(6,1)
LEUKOCYTE SUBSET(6,1)
LKT NEUTRALIZATION(6,1)
MAMMALIAN EXPRESSION VECTOR(6,1)
MURINE MASTOCYTOMA(6,1)
NATIVE IMMUNOGLOBULIN(6,1)
NECROPSY LUNG(6,1)
NON NATIVE GENE(6,1)
NON RUMINANT FRAMEWORK(6,1)
NON RUMINANT VARIABLE DOMAIN(6,1)
PARADIGM DICTATE(6,1)
PARENTAL ANTIBODY(6,1)
PASTEURELLA SPECIES(6,1)
PEPTIDE ALIQUOT(6,1)
PEPTIDE EFFICACY(6,1)
PEPTIDE POTENCY(6,1)
POLYPEPTIDE MEDIATED TARGETED DELIVERY(6,1)
PROTEIN AFFINITY CHROMATOGRAPHY(6,1)
PROTEIN TRANSLOCATION(6,1)
QUANTUM BIOTECHNOLOGY(6,1)
RECOMBINANT RETROVIRUS(6,1)
REPRESENTATIVE GROSS LESION(6,1)
RUMINANT SPECIES(6,1)
SANTA CRUZ BIOTECHNOLOGY(6,1)
SRP RECEPTOR(6,1)
TERM VACCINE VACCINATION(6,1)
THERAPEUTIC POLYNUCLEOTIDE(6,1)
THERAPEUTIC VACCINATION(6,1)
TOXIN PREPARATION UL(6,1)
TRANSFORMED CELL REIMPLANTATION(6,1)
UNDILUTED TOXIN PREPARATION(6,1)
UNPUBLISHED OBSERVATION(6,1)
UNTRANSFECTED PARENT CELL(6,1)
VACCINE ADMINISTRATION(6,1)
VIRUS PARTICLE(6,1)
INCUBATION(5,5)
ASPARTATE(5,4)
CONSTANT SHAKING(5,4)
EXCEPTION(5,4)
GLUTAMATE(5,4)
ISOLEUCINE(5,4)
MUTEIN(5,4)
PHENYLALANINE(5,4)
THREONINE(5,4)
TRYPTOPHAN(5,4)
WILD TYPE CONTROL CELL(5,3)
IMMUNIZATION(5,2)
ADSORPTION AFFINITY(5,1)
AMERSHAM(5,1)
ANAPHYLAXIS RISK(5,1)
ANTIBODY EXPRESSION(5,1)
BACTERIAL CULTURE(5,1)
BACTERIAL PELLET(5,1)
BOVINE CDNA(5,1)
CALCIUM PHOSPHATE PRECIPITATION(5,1)
CALF PRE INOCULATION STATUS(5,1)
CARRIER DEFINITION(5,1)
CASSETTE CONFERRING RESISTANCE(5,1)
CATTLE CLONING(5,1)
CLONED FETUS PRODUCTION(5,1)
CULTURE SUPERNATANT FLUID(5,1)
CYTOLYTIC ACTIVITY(5,1)
DELIVERED EX VIVO(5,1)
DETECTABLE THERAPEUTIC(5,1)
DEXTRAN MEDIATED TRANSFECTION(5,1)
DILUTION ALIQUOT(5,1)
DIRECT DNA MICROINJECTION(5,1)
EAR BIOPSY(5,1)
ELISA READER(5,1)
ENCODING NUCLEOTIDE(5,1)
ENDOGENOUS MAMMALIAN(5,1)
EX VIVO DELIVERY(5,1)
FUNCTIONAL HUMAN IG(5,1)
GENE THERAPEUTICS(5,1)
GESTATION DAY(5,1)
HANDHELD GENE(5,1)
HUMAN SERVICE NIH PUBLICATION(5,1)
HUMANIZED ANTIBODY CONTEXT(5,1)
HYBRIDOMA CLONE(5,1)
INHIBITION SPECIFICITY(5,1)
ISOLATING PMN(5,1)
ISOTONIC FORMULATION(5,1)
LUNG LOBE(5,1)
MEMBRANE LOCALIZATION(5,1)
MONOCLONAL ANTIBODY METHODOLOGY(5,1)
MOUSE MACROPHAGE(5,1)
MURINE ANTIBODY FRAGMENT(5,1)
NEUTRALIZING ABS(5,1)
NON RUMINANT HEAVY(5,1)
NON VIRAL DELIVERY VEHICLE(5,1)
PEPTIDE LINKAGE(5,1)
PHAGE ANTIBODY(5,1)
PHAGE DISPLAY ANTIBODY(5,1)
PHAGE LIBRARY(5,1)
PLASMA MEMBRANE PROTEIN PEPTIDE(5,1)
PLASMID VECTOR(5,1)
PNEUMONIC LUNG VOLUME(5,1)
POLYPEPTIDE ACTIVATION(5,1)
POLYPEPTIDE FRAGMENT(5,1)
POLYPEPTIDE VARIANT(5,1)
POSITIVE THERAPEUTIC OUTCOME(5,1)
PROMEGA CORPORATION(5,1)
PROTEIN(5,1)
PROTEIN HOMOLOG(5,1)
PROTEIN NON CRITICAL REGION(5,1)
PROTOPLAST FUSION(5,1)
PULMONARY ADMINISTRATION(5,1)
RECEPTOR EXPRESSION(5,1)
RECEPTOR LIGAND(5,1)
RUMINANT CD SIGNAL PEPTIDE(5,1)
SECRETED PROTEIN(5,1)
SEVERE PNEUMONIA(5,1)
SIGMA GENOSYS(5,1)
SIGNAL PEPTIDE PROMPTED EXAMINATION(5,1)
SILVER HISTOGRAM(5,1)
STANDARD POLYPEPTIDE NOMENCLATURE(5,1)
STUDY ONSET(5,1)
SUBSTANCE INOCULATION(5,1)
SUCCESSIVE ADMINISTRATION(5,1)
TARGET POLYPEPTIDE ISOLATION(5,1)
TARGET PROTEIN CDNA(5,1)
TETANUS TOXIN(5,1)
THERAPEUTIC INCLUSION(5,1)
THERAPEUTIC PEPTIDE(5,1)
TRANSFECTANT 2B(5,1)
TRANSFECTANT ANALYSIS(5,1)
TRANSFORMATION EFFICACY(5,1)
UNEXPECTED FINDING(5,1)
VALIDATED PROTEIN REGION(5,1)
AMINOACID SEQUENCE(4,8)
SERINE(4,5)
AMINOACID REPLACEMENT(4,3)
ANTI SIGNAL PEPTIDE SERUM(4,3)
GENE DELIVERY VEHICLE(4,3)
HISTIDINE(4,3)
LIPOSOME(4,3)
ANTIBODY AGENT(4,2)
CALF PHYSICAL EXAMINATION(4,2)
DELETION REGION(4,2)
DIMETHYLTHIAZOYL(4,2)
DIMETHYSULFOXIDE(4,2)
DOSE SCHEDULE(4,2)
HUMAN GENE THERAPY(4,2)
INTACT SIGNAL PEPTIDE(4,2)
PARTICLE GUN(4,2)
PEPTIDE BOND(4,2)
PNEUMONIC LESION AREA(4,2)
TOXIN UNTREATED CELL(4,2)
TRANSDUCTANT(4,2)
VIABLE CELL(4,2)
AFFINE GAP(4,1)
ALANINE SCANNING MUTAGENESIS(4,1)
AMINO TERMINUS(4,1)
ANTIGENIC MOLECULE VARIETY(4,1)
ASM PRESS PP(4,1)
AUTOANTIBODY PRODUCTION(4,1)
BACULOVIRUS SF9 CELL(4,1)
BHI AGAR PLATE(4,1)
BOVINE CD SIGNAL PEPTIDE(4,1)
BOVINE SERUM ALBUMIN(4,1)
BUFFERING SUBSTANCE(4,1)
CANCER GENE THERAPY(4,1)
CASSETTE SELECTION(4,1)
CLINICAL SIGN(4,1)
CODING SEQUENCE DELIVERY(4,1)
COLONY PCR(4,1)
CYSTEINE RESIDUE(4,1)
DISEASE CONTEXT(4,1)
DISULFIDE BOND(4,1)
DNA ADMINISTRATION(4,1)
DNA CONSTRUCT(4,1)
ELICITED IMMUNE RESPONSE(4,1)
ER RESIDENT SIGNAL PEPTIDASE(4,1)
FIBRIN DEPOSITION(4,1)
FIBROUS TISSUE(4,1)
FLUORESCENCE INTENSITY(4,1)
FOLD DILUTION(4,1)
FRESH CULTURE(4,1)
GAP EXTENSION PENALTY(4,1)
GENE GUN(4,1)
GENE INTRODUCTION(4,1)
GENOMIC PCR(4,1)
HCMV INFECTED CELL(4,1)
HUMAN IMMUNOGLOBULIN(4,1)
HUMAN MONOCLONAL ANTIBODY(4,1)
IMMUNE RESPONSE TREAT(4,1)
INDUCED CYTOTOXICITY(4,1)
INTERNATIONAL CORPORATION(4,1)
LOGARITHMIC GROWTH PHASE(4,1)
LUNG SAMPLE(4,1)
MACK PUB(4,1)
MOLECULAR BIOTECHNOLOGY(4,1)
MOLECULAR MODELING(4,1)
MOLECULE MODULATION(4,1)
MORPHOMETIC(4,1)
MUTANT CD(4,1)
MUTANT MOLECULE(4,1)
NUCLEAR DEBRIS(4,1)
ORGANISM MAJOR VIRULENCE FACTOR(4,1)
PARENTERAL INJECTION(4,1)
PEPTIDE ABSENCE(4,1)
PEPTIDE QUANTITY(4,1)
PHAGE PARTICLE(4,1)
PLATE GENTLE ROCKING(4,1)
POLYNUCLEOTIDE THERAPEUTIC COMPOSITION AGENT(4,1)
RECEPTOR MEDIATED DNA(4,1)
REPRESENTATIVE COLONY(4,1)
RESEARCH LAB(4,1)
RUMINANT TREATMENT(4,1)
SEROTYPING ANALYSIS(4,1)
SERUM DILUTION(4,1)
SERUM UL(4,1)
SIGNIFICANT LEUKOTOXIC ACTIVITY(4,1)
STUDY OBJECTIVE(4,1)
SUCCESSIVE PANNING(4,1)
TARGET PROTEIN PURIFICATION(4,1)
TERM PROTECTIVE IMMUNITY(4,1)
TOXIN BATCH(4,1)
TRANSFECT SF9 CELL(4,1)
UNIVERSITY MONOCLONAL ANTIBODY CENTER(4,1)
VIVO GENE THERAPY(4,1)
SITE DIRECTED MUTAGENESIS(3,6)
PHENOL RED(3,5)
CTERMINAL TRUNCATION(3,4)
FOLDING(3,4)
VALINE(3,4)
ANALOGY(3,3)
MAB(3,3)
ACUTE INFLAMMATION(3,2)
AMINOACID FAMILY(3,2)
ANTI BOVINE(3,2)
ARTERY(3,2)
ASPARAGINE(3,2)
CHIMPANZEE(3,2)
CONCENTRATION RANGING(3,2)
CONFORMATIONAL CHANGE(3,2)
CYSTINE(3,2)
GENETAILOR(3,2)
GLUTATHIONE(3,2)
LEUKOTOXIN(3,2)
MANNHEIMIA(3,2)
METHIONINE(3,2)
MOLECULAR BASIS(3,2)
PREDICTED SIGNAL SEQUENCE(3,2)
PROTEIN PRODUCTION(3,2)
SEQUENCE CONTEXT(3,2)
SIGNAL PEPTIDE PRESENCE(3,2)
TOXIN TREATED CELL(3,2)
WASHINGTON(3,2)
AA OVERLAP(3,1)
ADMINISTRATION MODE(3,1)
AGGLUTINATION PLATE(3,1)
AMINOACID SEQUENCE ANALYSIS(3,1)
ANTIBODY VARIABLE REGION(3,1)
ASEPTIC(3,1)
AUTOPHOSPHORYLATION(3,1)
AUXILIARY SUBSTANCE(3,1)
BACTERIAL CONCENTRATION(3,1)
BLOOD AGAR PLATE(3,1)
BOVINE CONSTANT(3,1)
BOVINE FLOW CYTOMETRIC ANALYSIS(3,1)
BOVINE LYMPHOMA CELL(3,1)
CAUSE PNEUMONIA(3,1)
CDR REGION(3,1)
CELL GROWTH MEASUREMENT(3,1)
CELL PELLET(3,1)
CHLORAMPHENICOL ACETYLTRANSFERASE(3,1)
CO ADMINISTRATION(3,1)
COMPOSITION EFFICACY(3,1)
COMPOSITION INGREDIENT(3,1)
CONCENTRATION DETERMINATION(3,1)
DEPHOSPHORYLATION(3,1)
DNA KIT(3,1)
ELICITATION(3,1)
ENCODING GENE PRODUCT(3,1)
EPITOPE BEARING FRAGMENT(3,1)
EXCIPIENT(3,1)
FUNCTIONAL VARIANT(3,1)
GENE TARGETING EVENT(3,1)
HUMAN MANIPULATION(3,1)
HYBRIDOMA BASED METHODOLOGY(3,1)
INFECTION TREATMENT(3,1)
INHIBITION COMPARISON(3,1)
INHIBITION FLOW CYTOMETRIC ANALYSIS(3,1)
INTERSTITIAL TISSUE SPACE(3,1)
ISOTYPE(3,1)
LOCAL ADMINISTRATION(3,1)
MDBK CELL(3,1)
MODIFIED ANTIBODY MOLECULE(3,1)
MODIFIED GENOTYPE(3,1)
MOLECULE ABILITY(3,1)
MONOCLONAL ANTIBODY PRESENCE(3,1)
MULTIMERIZATION(3,1)
MYELOMA CELL(3,1)
NATIVE SEQUENCE(3,1)
NATURAL FV REGION(3,1)
NATURAL MUTATION(3,1)
NATURE GENETICS(3,1)
NEOPLASTIC DISEASE TREATMENT(3,1)
ORAL TREATMENT(3,1)
PASTEURELLA MULTOCIDA(3,1)
PEPTIDE ABILITY(3,1)
PEPTIDE SPANNING AMINOACID(3,1)
PERCENT IDENTITY(3,1)
PHARMACEUTICAL CARRIER(3,1)
PHRASE AMINOACID RESIDUE(3,1)
PHYSICAL SYMPTOM(3,1)
POLYMORPHONUCLEAR LEUKOCYTE(3,1)
POLYPEPTIDE MEDIATED TREATMENT(3,1)
PROTEASE RESISTANCE(3,1)
PROTECTIVE IMMUNE RESPONSE(3,1)
RECOMBINANT DNA TECHNOLOGY(3,1)
RELEVANT FACTOR(3,1)
SERUM ABSENCE(3,1)
SERUM SAMPLE(3,1)
SF9 CELL CLONE(3,1)
SHORT PEPTIDE VERSION(3,1)
SIGNAL CD PEPTIDE(3,1)
SIGNAL PEPTIDE FAILURE(3,1)
SPLEEN CELL(3,1)
SUBJECT HUMANIZED ANTIBODY(3,1)
THERAPEUTIC COMPOSITION QUALITY(3,1)
TISSUE CULTURE PLATE(3,1)
TISSUE SAMPLE(3,1)
TRANSGENIC MOUSE IMMUNE CELL(3,1)
TRANSPARENT ACETATE(3,1)
TUMOR SITE(3,1)
VARIABLE REGION PIII(3,1)
(US9102925)
RUMINANT(100,44)
SIGNAL PEPTIDE(100,33)
AMINOACID(100,27)
PROTEIN(100,18)
DISEASE(100,11)
AMINOACID RESIDUE(100,10)
CLEAVAGE SITE(100,8)
RESIDUE(100,6)
HELIX(100,2)
MANNHEIMIA HAEMOLYTICA(100,2)
CLEAVABLE SIGNAL PEPTIDE(100,1)
NUCLEIC ACID SEQUENCE ENCODING(100,1)
RUMINANT CELL(100,1)
TRANSFECTANT MEDIATED CYTOLYSIS(100,1)
RUMINANT LEUKOCYTE RENDERING(85,1)
EPITOPE(60,1)
PHARMACEUTICAL FORMULATION(56,1)
TARGET PROTEIN AFFINITY PURIFICATION(56,1)
BOVINE PMN INDUCED CYTOLYSIS(53,11)
PNEUMONIC PASTEURELLOSIS(53,3)
POLYPEPTIDE ADMINISTRATION(52,1)
FETAL FIBROBLAST(51,2)
TARGET POLYPEPTIDE(50,1)
BIG HORN SHEEP(49,2)
MALE HOLSTEIN PRIMARY(47,2)
ANTIBODY GENERATION(41,1)
CONDITION SYMPTOM(41,1)
NATIVE CD(39,2)
CLEAVAGE CONDUCIVE GLYCINE(37,3)
NON CLEAVABLE SIGNAL PEPTIDE(37,1)
MUTATION(35,13)
CLEAVAGE INHIBITING GLUTAMINE(35,3)
FUSION PROTEIN(34,8)
ACTIVITY LOSS(33,1)
MUTATED SIGNAL SEQUENCE(32,1)
AGGREGATION(30,1)
CATTLE(29,7)
MOIETY(29,1)
HELIX BREAKING AMINOACID(28,1)
CYTOLYSIS ABROGATION(26,5)
HAEMOLYTICA LEUKOTOXIN(26,5)
SEQUENCE IDENTITY(26,5)
RUMINANT LEUKOCYTE INDUCED CYTOLYSIS(26,2)
TARGET(25,2)
CODING REGION(24,2)
TRANSFECTANT INDUCED CYTOLYSIS(23,3)
DOSE(23,2)
PARENCHYMAL NECROSIS DISCREET FOCI(22,1)
PRONGHORN(22,1)
WILDEBEEST(22,1)
CALF PNEUMONIC LUNG(21,2)
ALPACA(21,1)
ANTELOPE(21,1)
ERYTHROCYTE PELLET HYPOTONIC LYSIS(21,1)
GIRAFFE(21,1)
POST INOCULATION(20,9)
HAEMOLYTICA INFECTION(20,5)
DISORDER(20,3)
PEPTIDE TERMINALLY TRUNCATED VERSION(20,2)
BUFFALO(20,1)
CAMEL(20,1)
GROSS PULMONARY PATHOLOGY QUANTITATION(20,1)
LLAMA(20,1)
NILGAI(20,1)
TRANSGENIC ANIMAL(19,8)
SIGNAL PEPTIDE SEQUENCE(19,2)
CYTOLYSIS INHIBITION(18,4)
GROSS PULMONARY LESION(18,2)
PURPLE FORMAZAN PRECIPITATE(18,2)
SMITH WATERMAN HOMOLOGY(18,2)
ALVEOLAR MACROPHAGE DEGRANULATION(18,1)
BISON(18,1)
RUMINANT PMN INDUCED CYTOLYSIS(18,1)
SUBGENOMIC POLYNUCLEOTIDE ULTIMATE EFFICACY(18,1)
NON RUMINANT CDR CONFORMATION(17,1)
RUMINANT LEUKOCYTE SUSCEPTIBILITY(17,1)
YAK(17,1)
ANIMAL(16,14)
VECTOR(16,6)
DOMESTIC SHEEP(16,4)
GRAY HISTOGRAM(16,4)
ANTIBODY NEUTRALIZATION(16,3)
IRRELEVANT PEPTIDE(16,3)
DIPHENYL TETRAZOLIUM BROMIDE(16,2)
ELK(16,1)
HEALTHY CATTLE NASOPHARYNX(16,1)
PREWARMED BRAIN HEART INFUSION(16,1)
PULMONARY TISSUE HISTOPATHOLOGICAL EXAMINATION(16,1)
RUMINANT LEUKOCYTE CYTOMETRIC ANALYSIS(16,1)
TRANSGENIC NON PRIMATE MAMMALIAN HOST(16,1)
TARGET CELL INDUCED CYTOLYSIS(15,8)
FIBRINONECROTIC PNEUMONIA(15,2)
HAEMOLYTICA SEROTYPE(15,2)
UNIMMUNIZED CHICKEN(15,2)
BOVINE SIGNAL PEPTIDE(14,7)
MTT DYE REDUCTION(14,5)
CLINICAL SCORE(14,4)
ANTI LKT ANTIBODY(14,2)
ANTI FLAG EPITOPE ANTIBODY(14,1)
CRYSTALIZED DEXTRAN MICROSPHERE(14,1)
GROSS PNEUMONIC LESION(14,1)
OBSERVATIONAL DISEASE SCORE(14,1)
PHRASE RUMINANTIZED ANTIBODY(14,1)
POLYBRENE MEDIATED TRANSFECTION(14,1)
RUMINANT IMMUNOGLOBULIN(14,1)
SIGNAL SEQUENCE(13,7)
BIOLOGICAL ACTIVITY(13,6)
RUMINANT SIGNAL PEPTIDE(13,4)
CALF CHALLENGE(13,3)
DEER(13,3)
RANDOMLY SCRAMBLED SEQUENCE(13,3)
SHADED HISTOGRAM(13,3)
HAEMOLYTICA CULTURE(13,2)
KILLED ADENOVIRUS(13,2)
LEUCINE ISOLATED REPLACEMENT(13,2)
NECROTIC FOCI(13,2)
RUMINANT MONOCLONAL ANTIBODY(13,2)
SYNTHETIC PEPTIDE SPANNING(13,2)
DEGENERATE NEUTROPHIL DENSE BAND(13,1)
EXOGENOUS IMMUNOGLOBULIN(13,1)
NEUTRALIZING ANTIBODY TITER(13,1)
PARENT ANTIBODY CONFORMATION(13,1)
PARENT NON RUMINANT ANTIBODY(13,1)
PHRASE CHIMERIC ANTIBODY(13,1)
PNEUMONIC LUNG SCORE(13,1)
POLYPEPTIDE CARBOXY TERMINUS(13,1)
POLYPEPTIDE PEGYLATION(13,1)
RUMINANT ORIGIN ANTIBODY(13,1)
RUMINANTIZED SEQUENCE PREDICTED CONFORMATION(13,1)
SCREENING CDNA EXPRESSION LIBRARY(13,1)
VALIDATED PROTEIN INOCULATED ANIMAL(13,1)
ASSAY(12,6)
FUSION PROTEIN CONSTRUCTION(12,3)
GOAT(12,3)
BACTERIUM PRECISE SEROTYPE(12,1)
CLINICAL DISEASE SYMPTOM(12,1)
COLORLESS RPMI UL(12,1)
CYTOTOXICITY INHIBITION ASSAY(12,1)
DILUTED INOCULUM ALIQUOT(12,1)
ENDOGENOUS HEAVY INACTIVATION(12,1)
ENDOGENOUS IG(12,1)
ENDOGENOUS IMMUNOGLOBULIN ENCODING(12,1)
EXACT EFFECTIVE(12,1)
FLAG EPITOPE EXPRESSION(12,1)
NON HUMAN MAMMALIAN HOST(12,1)
PARENTAL MOUSE MONOCLONAL ANTIBODY(12,1)
POLYCATIONIC CONDENSED DNA(12,1)
RUMINANT SUSCEPTIBILITY(12,1)
STERILE COTTON SWAB(12,1)
BOVINE EXPRESSION(11,3)
WILD SHEEP(11,3)
ALLELIC VARIANT(11,2)
ANIMAL GENOTYPE(11,2)
ANIMAL INOCULATION(11,2)
BOVINE MINIMAL PEPTIDE SEQUENCE(11,2)
CLONE CATTLE(11,2)
COVALENT VARIANT(11,2)
DISEASE PROGRESSION(11,2)
DYE REDUCTION CYTOTOXICITY ASSAY(11,2)
EXPERIMENTAL INFECTION(11,2)
LUNG LESION(11,2)
MATURE PROTEIN(11,2)
MTT ASSAY(11,2)
NATIVE TERMINUS(11,2)
PURPLE COLOR INTENSITY(11,2)
RUMINANT ANIMAL(11,2)
TETRAZOLIUM DYE(11,2)
THERAPEUTIC AGENT ADMINISTRATION(11,2)
UNCHARGED POLAR(11,2)
ADJUVANT(10,6)
SIGNAL PEPTIDE CLEAVAGE SITE(10,4)
TARGET TISSUE(10,4)
PROTEIN SEGMENT(10,3)
BACTERIAL CLEARANCE(10,2)
ANTISERA UNAVAILABILITY(10,1)
CLINICAL DISEASE SCORE(10,1)
CLINICAL DISEASE SCORING(10,1)
CLINICIAN JUDGEMENT(10,1)
COLOSTRUM DEPRIVED CALF(10,1)
ENDOBRONCHIAL CHALLENGE(10,1)
ER RESIDENT ENZYME(10,1)
EXHIBIT DIMINISHED IMMUNOGENICITY(10,1)
FETAL BOVINE SERUM(10,1)
FLAG EPITOPE INTRODUCTION(10,1)
FUNCTIONAL ENDOGENOUS IMMUNOGLOBULIN(10,1)
INFLUENZA HEMAGGLUTININ(10,1)
INSTITUTIONAL ANIMAL CARE(10,1)
INTERLOBULAR SEPTUM(10,1)
MINIGENE ENCODING(10,1)
NASCENT MEMBRANE PROTEIN(10,1)
NASOPHARYNGEAL FLORA(10,1)
NATIONAL HEALTH INSTITUTE(10,1)
NEUTRAL BUFFERED FORMALIN(10,1)
PHAGE MINOR COAT PROTEIN(10,1)
PHOTOAFFINITY LABELING(10,1)
PNEUMONIC LESION DEVELOPMENT(10,1)
POLYNUCLEOTIDE ENCAPSULATION(10,1)
POLYPEPTIDE TERMINUS AMINO(10,1)
POSITIVE ANTIBODY PIII PHAGE(10,1)
PROTEIN INHIBITOR ANTIBODY(10,1)
PROTEIN SPECIES HOMOLOG(10,1)
RUMINANT VACCINATION(10,1)
RUMINANTIZED SEQUENCE CONFORMATION(10,1)
STREAMING NUCLEUS COAT CELL(10,1)
VALIDATED PROTEIN ANTIGEN COLUMN(10,1)
ACIDIC ISOPROPANOL(9,3)
ANAPLASMA MARGINALE(9,3)
INHIBITION DETECTION(9,3)
TARGET CELL CYTOLYSIS(9,3)
BIOLOGICALLY ACTIVE VARIANT(9,2)
BLACK HISTOGRAM(9,2)
CELL VIABILITY(9,2)
CODING SEQUENCE EXPRESSION(9,2)
FUNCTIONAL PROTEIN ACTIVITY(9,2)
LINKING FUNCTIONALITY(9,2)
LOGARITHMIC PHASE CULTURE(9,2)
PEPTIDE ABSENCE(9,2)
PROTEIN VARIANT(9,2)
SPECIES VARIANT(9,2)
SUSCEPTIBILITY LOSS(9,2)
UNAVAILABLE TECHNOLOGY(9,2)
AGGREGATION PREVENTION(9,1)
ANTIBODY SPECIFICITY(9,1)
ANTIBODY SUITABILITY(9,1)
ASHWELL RECEPTOR(9,1)
AUTOFLUORESCENT PROTEIN(9,1)
BACTERIA CHARACTERIZATION(9,1)
BACTERIOLOGICAL EXAMINATION(9,1)
BACTERIUM PURE CULTURE(9,1)
BREAKING RESIDUE GLYCINE(9,1)
CALF PHENOTYPE(9,1)
CATHETERIZED ADMINISTRATION(9,1)
CHICKEN ANTISERUM(9,1)
CLINICAL DISEASE SIGN(9,1)
CLONED RUMINANT(9,1)
ENDOGENOUS WILD TYPE(9,1)
ENDOPLASMIC RETICULUM RESIDENT ENZYME(9,1)
ENZYME LINKED IMMUNOSORBANT ASSAY(9,1)
FICOLL PAQUE(9,1)
FLAG EPITOPE INSERTION(9,1)
GLUTAMINE MUTATION(9,1)
GROSSLY PNEUMONIC REGION(9,1)
HEART BLOOD CULTURE(9,1)
HETEROLOGOUS PROMOTER(9,1)
HISTOPATHOLOGICAL EVALUATION(9,1)
HOMOLOGOUS RECOMBINATION(9,1)
HORSERADISH PEROXIDASE(9,1)
LEUKOCYTE SUBSET(9,1)
LKT NEUTRALIZATION(9,1)
MAMMALIAN EXPRESSION VECTOR(9,1)
MURINE MASTOCYTOMA(9,1)
NATIVE IMMUNOGLOBULIN(9,1)
NECROPSY LUNG(9,1)
NON NATIVE GENE(9,1)
NON RUMINANT FRAMEWORK(9,1)
NON RUMINANT VARIABLE DOMAIN(9,1)
PARADIGM DICTATE(9,1)
PARENTAL ANTIBODY(9,1)
PASTEURELLA SPECIES(9,1)
PEPTIDE ALIQUOT(9,1)
PEPTIDE EFFICACY(9,1)
PEPTIDE POTENCY(9,1)
POLYPEPTIDE MEDIATED TARGETED DELIVERY(9,1)
PROTEIN AFFINITY CHROMATOGRAPHY(9,1)
PROTEIN TRANSLOCATION(9,1)
QUANTUM BIOTECHNOLOGY(9,1)
RECOMBINANT RETROVIRUS(9,1)
REPRESENTATIVE GROSS LESION(9,1)
RUMINANT SPECIES(9,1)
SANTA CRUZ BIOTECHNOLOGY(9,1)
SRP RECEPTOR(9,1)
TERM VACCINE VACCINATION(9,1)
THERAPEUTIC POLYNUCLEOTIDE(9,1)
THERAPEUTIC VACCINATION(9,1)
TOXIN PREPARATION UL(9,1)
TRANSFORMED CELL REIMPLANTATION(9,1)
UNDILUTED TOXIN PREPARATION(9,1)
UNPUBLISHED OBSERVATION(9,1)
UNTRANSFECTED PARENT CELL(9,1)
VACCINE ADMINISTRATION(9,1)
VIRUS PARTICLE(9,1)
INCUBATION(8,5)
ARGININE(8,4)
ASPARTATE(8,4)
CONSTANT SHAKING(8,4)
EXCEPTION(8,4)
GLUTAMATE(8,4)
ISOLEUCINE(8,4)
MUTEIN(8,4)
PHENYLALANINE(8,4)
THREONINE(8,4)
TRYPTOPHAN(8,4)
TYROSINE(8,4)
IMMUNIZATION(8,2)
ADSORPTION AFFINITY(8,1)
AMERSHAM(8,1)
ANAPHYLAXIS RISK(8,1)
ANTIBODY EXPRESSION(8,1)
BACTERIAL CULTURE(8,1)
BACTERIAL PELLET(8,1)
BOVINE CDNA(8,1)
CALCIUM PHOSPHATE PRECIPITATION(8,1)
CALF PRE INOCULATION STATUS(8,1)
CARRIER DEFINITION(8,1)
CASSETTE CONFERRING RESISTANCE(8,1)
CATTLE CLONING(8,1)
CLONED FETUS PRODUCTION(8,1)
CULTURE SUPERNATANT FLUID(8,1)
CYTOLYTIC ACTIVITY(8,1)
DELIVERED EX VIVO(8,1)
DETECTABLE THERAPEUTIC(8,1)
DEXTRAN MEDIATED TRANSFECTION(8,1)
DILUTION ALIQUOT(8,1)
DIRECT DNA MICROINJECTION(8,1)
EAR BIOPSY(8,1)
ELISA READER(8,1)
ENCODING NUCLEOTIDE(8,1)
ENDOGENOUS MAMMALIAN(8,1)
EX VIVO DELIVERY(8,1)
FUNCTIONAL HUMAN IG(8,1)
GENE THERAPEUTICS(8,1)
GESTATION DAY(8,1)
HANDHELD GENE(8,1)
HUMAN SERVICE NIH PUBLICATION(8,1)
HUMANIZED ANTIBODY CONTEXT(8,1)
HYBRIDOMA CLONE(8,1)
INHIBITION SPECIFICITY(8,1)
ISOLATING PMN(8,1)
ISOTONIC FORMULATION(8,1)
LUNG LOBE(8,1)
MEMBRANE LOCALIZATION(8,1)
MONOCLONAL ANTIBODY METHODOLOGY(8,1)
MOUSE MACROPHAGE(8,1)
MURINE ANTIBODY FRAGMENT(8,1)
NEUTRALIZING ABS(8,1)
NON RUMINANT HEAVY(8,1)
NON VIRAL DELIVERY VEHICLE(8,1)
PEPTIDE LINKAGE(8,1)
PHAGE ANTIBODY(8,1)
PHAGE DISPLAY ANTIBODY(8,1)
PHAGE LIBRARY(8,1)
PLASMA MEMBRANE PROTEIN PEPTIDE(8,1)
PLASMID VECTOR(8,1)
PNEUMONIC LUNG VOLUME(8,1)
POLYPEPTIDE ACTIVATION(8,1)
POLYPEPTIDE FRAGMENT(8,1)
POLYPEPTIDE VARIANT(8,1)
POSITIVE THERAPEUTIC OUTCOME(8,1)
PROMEGA CORPORATION(8,1)
PROTEIN(8,1)
PROTEIN HOMOLOG(8,1)
PROTEIN NON CRITICAL REGION(8,1)
PROTOPLAST FUSION(8,1)
PULMONARY ADMINISTRATION(8,1)
RECEPTOR EXPRESSION(8,1)
RECEPTOR LIGAND(8,1)
SECRETED PROTEIN(8,1)
SEVERE PNEUMONIA(8,1)
SIGMA GENOSYS(8,1)
SIGNAL PEPTIDE PROMPTED EXAMINATION(8,1)
SILVER HISTOGRAM(8,1)
STANDARD POLYPEPTIDE NOMENCLATURE(8,1)
STUDY ONSET(8,1)
SUBSTANCE INOCULATION(8,1)
SUCCESSIVE ADMINISTRATION(8,1)
TARGET POLYPEPTIDE ISOLATION(8,1)
TARGET PROTEIN CDNA(8,1)
TETANUS TOXIN(8,1)
THERAPEUTIC INCLUSION(8,1)
THERAPEUTIC PEPTIDE(8,1)
TRANSFECTANT 2B(8,1)
TRANSFECTANT ANALYSIS(8,1)
TRANSFORMATION EFFICACY(8,1)
UNEXPECTED FINDING(8,1)
VALIDATED PROTEIN REGION(8,1)
SERINE(7,5)
ANTIBODY AGENT(7,2)
CALF PHYSICAL EXAMINATION(7,2)
DELETION REGION(7,2)
DIMETHYLTHIAZOYL(7,2)
DIMETHYSULFOXIDE(7,2)
DOSE SCHEDULE(7,2)
HUMAN GENE THERAPY(7,2)
INTACT SIGNAL PEPTIDE(7,2)
PARTICLE GUN(7,2)
PEPTIDE BOND(7,2)
PNEUMONIC LESION AREA(7,2)
TOXIN UNTREATED CELL(7,2)
VIABLE CELL(7,2)
AMINOACID SEQUENCE(6,8)
FOLDING(6,4)
AMINOACID REPLACEMENT(6,3)
ANTI SIGNAL PEPTIDE SERUM(6,3)
GENE DELIVERY VEHICLE(6,3)
HISTIDINE(6,3)
LIPOSOME(6,3)
TRANSDUCTANT(6,2)
AFFINE GAP(6,1)
ALANINE SCANNING MUTAGENESIS(6,1)
AMINO TERMINUS(6,1)
ANTIGENIC MOLECULE VARIETY(6,1)
ASM PRESS PP(6,1)
AUTOANTIBODY PRODUCTION(6,1)
BACULOVIRUS SF9 CELL(6,1)
BHI AGAR PLATE(6,1)
BOVINE CD SIGNAL PEPTIDE(6,1)
BOVINE SERUM ALBUMIN(6,1)
BUFFERING SUBSTANCE(6,1)
CANCER GENE THERAPY(6,1)
CASSETTE SELECTION(6,1)
CLINICAL SIGN(6,1)
CODING SEQUENCE DELIVERY(6,1)
COLONY PCR(6,1)
CYSTEINE RESIDUE(6,1)
DISEASE CONTEXT(6,1)
DISULFIDE BOND(6,1)
DNA ADMINISTRATION(6,1)
DNA CONSTRUCT(6,1)
ELICITED IMMUNE RESPONSE(6,1)
ER RESIDENT SIGNAL PEPTIDASE(6,1)
FIBRIN DEPOSITION(6,1)
FIBROUS TISSUE(6,1)
FLUORESCENCE INTENSITY(6,1)
FOLD DILUTION(6,1)
FRESH CULTURE(6,1)
GAP EXTENSION PENALTY(6,1)
GENE GUN(6,1)
GENE INTRODUCTION(6,1)
GENOMIC PCR(6,1)
HCMV INFECTED CELL(6,1)
HUMAN IMMUNOGLOBULIN(6,1)
HUMAN MONOCLONAL ANTIBODY(6,1)
IMMUNE RESPONSE TREAT(6,1)
INDUCED CYTOTOXICITY(6,1)
INTERNATIONAL CORPORATION(6,1)
LOGARITHMIC GROWTH PHASE(6,1)
LUNG SAMPLE(6,1)
MACK PUB(6,1)
MATURE CD(6,1)
MOLECULAR BIOTECHNOLOGY(6,1)
MOLECULAR MODELING(6,1)
MOLECULE MODULATION(6,1)
MORPHOMETIC(6,1)
MUTANT CD(6,1)
MUTANT MOLECULE(6,1)
NUCLEAR DEBRIS(6,1)
ORGANISM MAJOR VIRULENCE FACTOR(6,1)
PARENTERAL INJECTION(6,1)
PEPTIDE QUANTITY(6,1)
PHAGE PARTICLE(6,1)
PLATE GENTLE ROCKING(6,1)
POLYNUCLEOTIDE THERAPEUTIC COMPOSITION AGENT(6,1)
RECEPTOR MEDIATED DNA(6,1)
REPRESENTATIVE COLONY(6,1)
RESEARCH LAB(6,1)
RUMINANT TREATMENT(6,1)
SEROTYPING ANALYSIS(6,1)
SERUM DILUTION(6,1)
SERUM UL(6,1)
SIGNIFICANT LEUKOTOXIC ACTIVITY(6,1)
STUDY OBJECTIVE(6,1)
SUCCESSIVE PANNING(6,1)
TARGET PROTEIN PURIFICATION(6,1)
TERM PROTECTIVE IMMUNITY(6,1)
TOXIN BATCH(6,1)
TRANSFECT SF9 CELL(6,1)
UNIVERSITY MONOCLONAL ANTIBODY CENTER(6,1)
VIVO GENE THERAPY(6,1)
SITE DIRECTED MUTAGENESIS(5,6)
PHENOL RED(5,5)
CTERMINAL TRUNCATION(5,4)
VALINE(5,4)
MAB(5,3)
ACUTE INFLAMMATION(5,2)
AMINOACID FAMILY(5,2)
ANTI BOVINE(5,2)
ARTERY(5,2)
ASPARAGINE(5,2)
CHIMPANZEE(5,2)
CONCENTRATION RANGING(5,2)
CONFORMATIONAL CHANGE(5,2)
CONTIGUOUS AMINOACID RESIDUE(5,2)
CYSTINE(5,2)
GENETAILOR(5,2)
GLUTATHIONE(5,2)
MANNHEIMIA(5,2)
METHIONINE(5,2)
MOLECULAR BASIS(5,2)
PREDICTED SIGNAL SEQUENCE(5,2)
PROTEIN PRODUCTION(5,2)
SEQUENCE CONTEXT(5,2)
SIGNAL PEPTIDE PRESENCE(5,2)
TOXIN TREATED CELL(5,2)
WASHINGTON(5,2)
AA OVERLAP(5,1)
ADMINISTRATION MODE(5,1)
AGGLUTINATION PLATE(5,1)
AMINOACID SEQUENCE ANALYSIS(5,1)
ANTIBODY VARIABLE REGION(5,1)
ASEPTIC(5,1)
AUTOPHOSPHORYLATION(5,1)
AUXILIARY SUBSTANCE(5,1)
BACTERIAL CONCENTRATION(5,1)
BLOOD AGAR PLATE(5,1)
BOVINE CONSTANT(5,1)
BOVINE FLOW CYTOMETRIC ANALYSIS(5,1)
BOVINE LYMPHOMA CELL(5,1)
CAUSE PNEUMONIA(5,1)
CDR REGION(5,1)
CELL GROWTH MEASUREMENT(5,1)
CELL PELLET(5,1)
CHLORAMPHENICOL ACETYLTRANSFERASE(5,1)
CO ADMINISTRATION(5,1)
COMPOSITION EFFICACY(5,1)
COMPOSITION INGREDIENT(5,1)
CONCENTRATION DETERMINATION(5,1)
DEPHOSPHORYLATION(5,1)
DNA KIT(5,1)
ELICITATION(5,1)
ENCODING GENE PRODUCT(5,1)
EPITOPE BEARING FRAGMENT(5,1)
EXCIPIENT(5,1)
FUNCTIONAL VARIANT(5,1)
GENE TARGETING EVENT(5,1)
HUMAN MANIPULATION(5,1)
HYBRIDOMA BASED METHODOLOGY(5,1)
INFECTION TREATMENT(5,1)
INHIBITION COMPARISON(5,1)
INHIBITION FLOW CYTOMETRIC ANALYSIS(5,1)
INTERSTITIAL TISSUE SPACE(5,1)
ISOTYPE(5,1)
LOCAL ADMINISTRATION(5,1)
MDBK CELL(5,1)
MODIFIED ANTIBODY MOLECULE(5,1)
MODIFIED (...)";"Biotechnology
Other special machines
Pharmaceuticals";Open
"2009-01-09
2014-08-27";"US20100178301       A1 2010-07-15 [US20100178301]
STG: (A1) Application published
AP : 2009US-12351088 2009-01-09
US8846054           B2 2014-09-30 [US8846054]
STG: (B2) Granted patent as second publication
AP : 2009US-12351088 2009-01-09
FD :  Previous publication: US20100178301 A1 2010-07-15 [US20100178301]
US20140363466       A1 2014-12-11 [US20140363466]
STG: (A1) Application published
AP : 2014US-14469879 2014-08-27
FD :  Continuation of: US12/351,088 FDD=2009-01-09 [2009US-12351088]
FD : Continuation of: US8846054 - 0 [US8846054]";44279178;"US20100178301       A1 2010-07-15 [US20100178301]
US8846054           B2 2014-09-30 [US8846054]
US20140363466       A1 2014-12-11 [US20140363466]";"2009US-12351088
2014US-14469879";;BOEHRINGER INGELHEIM VETMEDICA;BOEHRINGER INGELHEIM VETMEDICA;"(US20100178301)
US
(US8846054)
US
(US20140363466)
US";"(US20100178301)
NAME=Boehringer Ingelheim Vetmedica, Inc. , CITY=Saint Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 

(US8846054)
NAME=Boehringer Ingelheim Vetmedica, Inc. , CITY=St. Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 

(US20140363466)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. , CITY=St. Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 
";1;"RINEHART CAROL L
JONES CRAIG
MYERS-KUHNHOFF JUDY
COLE WAYNE
OHNESORGE WILLIAM CHARLES";"(US20100178301)
US
(US8846054)
US";"(US20100178301)
NAME=Rinehart Carol L. , CITY=Saint Joseph , STATE=MO , COUNTRY=US 

NAME=Jones Craig , CITY=Saint Joseph , STATE=MO , COUNTRY=US 

NAME=Myers-Kuhnhoff Judy , CITY=Weatherby Lake , STATE=MO , COUNTRY=US 

NAME=Cole Wayne , CITY=St. Joseph , STATE=MO , COUNTRY=US 

NAME=Ohnesorge William Charles , CITY=Saint Joseph , STATE=MO , COUNTRY=US 

(US8846054)
NAME=Rinehart Carol L. , CITY=Saint Joseph , STATE=MO , COUNTRY=US 

NAME=Jones Craig , CITY=Saint Joseph , STATE=MO , COUNTRY=US 

NAME=Myers-Kuhnhoff Judy , CITY=Weatherby Lake , STATE=MO , COUNTRY=US 

NAME=Cole Wayne , CITY=Saint Joseph , STATE=MO , COUNTRY=US 

NAME=Ohnesorge William Charles , CITY=Saint Joseph , STATE=MO , COUNTRY=US 
";"(US8846054)
Method of treating pregnant cows and/or heifers";"(US8846054)
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.";"(US20100178301)
1. A method for safely vaccinating a pregnant cow, comprising administering a vaccine to the cow, wherein the vaccine comprises a modified live Infectious Bovine Rhinotracheitis (IBR) virus, modified live Bovine Viral Diarrhea Virus (BVD) Type 1, modified live BVD Type 2, or any combination thereof.
2. The method of claim 1, wherein said modified live BVDV Type 1 is derived from a Singer strain of BVDV.
3. The method of claim 2, wherein said modified live BVDV Type 1 Singer strain is the one that is included in the BREED-BACK™ FP5 vaccine.
4. The method of claim 1, wherein said modified live BVDV Type 2 is derived from Strain 296.
5. The method of claim 4, wherein said modified live BVDV Type 2 296 Strain is the one that is included in the BREED-BACK™ FP5 vaccine.
6. The method of claim 1, wherein said modified live IBR is derived from the IBR Colorado 1 Strain.
7. The method of claim 6, wherein said modified IBR is the one that is included in the BREED-BACK™ FP5 vaccine.
8. The method of claim 1, wherein said vaccine further comprises an immunological active component effective for treating or prophylaxis of an infection caused by Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus (BRSV).
9. The method of claim 1, wherein said vaccine further comprises an immunological active component effective for treating or prophylaxis of an infection caused by a Leptospira bacterium or Haemophilus somnus.
10. The method of claim 9, wherein said Leptospira bacterium is selected from the group consisting of: Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
11. The method of claim 9, wherein said Leptospira bacterium comprises Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
12. The method of claim 1, said vaccine being selected from the group consisting of BREED-BACK™ FP5, EXPRESS™5, EXPRESS™ FP5, BREED-BACK™ FP-HS, EXPRESS™5-HS, EXPRESS™ FP5-HS, BREED-BACK™ FP10, EXPRESS™10, BREEDBACK™ FP10-HS, EXPRESS™ FP10-HS, EXPRESS 10-HS®, and combinations thereof.
13. The method of claim 1, further comprising the step of administering said vaccine to the pregnant cow during the first, second or third trimester of pregnancy.
14. The method of claim 1, wherein the vaccine prevents the pregnant cow from the clinical signs of an infection caused by a microbe selected from the group consisting of a modified live Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof.
15. The method of claim 1, wherein the vaccine prevents the fetus of a pregnant cow from the clinical signs of an infection caused by a microbe selected from the group consisting of a modified live Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof.
16. The method of claim 1, wherein said method reduces the abortion rate in pregnant cows.
17. The method of claim 1, wherein the pregnant cow is a pregnant heifer.
18. The method of claim 1, further comprising the step of administering said vaccine to the cow prior to the pregnancy.
19. A method for safely vaccinating a pregnant cow, comprising administering a vaccine to the cow, wherein the vaccine comprises an immunological active component effective for treating or prophylaxis of an infection caused by a microbe selected from the group consisting of: Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVD) Type 1, BVD Type 2, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus (BRSV).
20. The method of claim 19, wherein the pregnant cow is in the first, second or third trimester of pregnancy.
21. The method of claim 19, wherein said vaccine comprises immunological active components effective for treating or prophylaxis of infections caused by Infectious Bovine Rhinotracheitis, BVD Type 1, BVD Type 2, Parainfluenza-3, Virus, and Bovine Respiratory Syncytial Virus.
22. The method of claim 19, further comprising the step of administering said vaccine to the cow prior to the pregnancy.
23. The method of claim 19, wherein said vaccine further comprises an immunological active component effective for treating or prophylaxis of an infection caused by a Leptospira bacterium or Haemophilus somnus.
24. The method of claim 19, wherein said Leptospira bacterium is selected from the group consisting of: Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
25. The method of claim 19, wherein said Leptospira bacterium comprises Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
26. The method of claim 22, wherein the pre-pregnancy administration of the vaccine was performed within 12 months of the pregnancy.
27. The method of claim 19, wherein said BVD Type 1 and said BVD Type 2 immunological active component are each a modified live virus.
28. The method of claim 19, wherein said IBR immunological active component is a modified live IBR.
29. The method of claim 19, wherein said vaccine prevents the pregnant cow from the clinical signs of an infection caused by a microbe selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVD) Type 1, BVD Type 2, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus (BRSV).
30. The method of claim 19, wherein the vaccine prevents the fetus of a pregnant cow from the clinical signs of an infection caused by a microbe selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVD) Type 1, BVD Type 2, Parainfluenza-3 Virus, and Bovine Respiratory Syncytial Virus (BRSV).
31. The method of claim 19, wherein said method reduces the abortion rate in pregnant cows.
32. The method of claim 19, wherein the pregnant cow is a pregnant heifer.";"(US8846054)
According to a further aspect the present invention relates to the vaccination of pregnant cows/heifers comprising the step of administering to a pregnant cow/heifer a modified live BVDV Type 1, preferably a cytopathic modified lived BVDV Type 1, which is derived from the Singer strain, a modified live BVDV Type 2, preferably a cytopathic modified live BVDV Type 2, which is derived from the 296 strain, and/or a modified live IBR which is derived from the IBR Colorado 1 Strain.
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections.
The invention also relates to a method of vaccinating a pregnant cow.
One aspect of the present invention provides a method for safely vaccinating a pregnant cow, wherein the method generally includes or comprises the step of administering a vaccine to the pregnant cow or pregnant heifer.
In other aspect the present invention also relates to a method for vaccinating pregnant cows/heifers comprising the step of administering to said pregnant cow/heifer a vaccine which comprises a vaccine composition and/or immunological active components of Haemophilus somnus, preferably in a bacterin form, in addition to the modified live BVDV Type 1, modified live BVDV Type 2, and/or modified live IBR, described above.";"(US8846054)
Accordingly, there is a need for safe methods of vaccinating pregnant cows.
The more classical BVDV type 1 strains and the more recently recognized BVDV type 2 strains display some limited but distinctive differences in nucleotide and amino acid sequences.
Additionally, administration of any vaccine composition noted above to a pregnant cow/heifer will not cause fetal infection by any pathogen having an immunological active component in the vaccine in more than 10%, more preferably 5%, still more preferably 4%, even more preferably 3%, still more preferably 2%, even more preferably 1% and most preferably no higher than unvaccinated cows/heifers.
According to a further aspect, the vaccine composition that can be used for the vaccination of pregnant cows/heifers as described herein further comprises at least one further immunological active component which can prevent the pregnant cow/heifer from microbiological infections of other cattle relevant pathogens or at least from the clinical signs caused by said other cattle relevant pathogens.";"A61K-039/00
A61K-039/102
A61K-039/12
A61K-039/265
A61K-039/295
C12N-007/00";"(US8846054)
1. A method of preventing abortion in a pregnant cow, comprising administering a vaccine to the pregnant cow, wherein the vaccine comprises a modified live Infectious Bovine Rhinotracheitis (IBR) virus that has been passaged at least 4 times in bovine embryo kidney cells, 22 times in ovine cells and once in MDBK cells, modified live Bovine Viral Diarrhea Virus (BVDV) Type 1 of a Singer strain that has been passaged at least twice in bovine turbinate cells, modified live BVDV Type 2 of Strain 296 that has been passaged in bovine testicular cells at least six times, or in embryonic swine kidney cells at least 23 times, or in MDBK cells at least 23 times, and Haemophilus somnus bacterin wherein the pregnant cow was vaccinated with a therapeutically effective amount of a vaccine comprising IBR, BVDV Type I and BVDV Type 2 prior to pregnancy.";"(US20100178301)
HEIFER(100,69)
PREGNANT COW(100,23)
PREGNANT COW HEIFER(64,14)
PREGNANT COW HEIFER VACCINATION(63,6)
CATTLE RELEVANT PATHOGEN(60,2)
LEPTOSPIRA BACTERIA(57,9)
SUBCLINICAL INFECTION SIGN(57,4)
PREGNANT COW FETUS(55,2)
INFECTION PROPHYLAXIS(53,8)
HAEMOPHILUS SOMNUS(51,3)
VACCINE(49,87)
PREGNANT HEIFER(49,3)
LEPTOSPIRA GRIPPOTYPHOSA(48,9)
LEPTOSPIRA POMONA(46,7)
LEPTOSPIRA CANICOLA(44,9)
LEPTOSPIRA HARDJO(44,9)
INFECTIOUS BOVINE RHINOTRACHEITIS(43,14)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(40,1)
PREGNANCY TRIMESTER(33,5)
UNVACCINATED COW HEIFER(31,2)
BOVINE VIRAL DIARRHEA VIRUS(29,27)
PARAINFLUENZA(29,6)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(27,6)
MICROBIOLOGICAL INFECTION(27,2)
MICROBIOLOGICAL INFECTION TREATMENT(27,1)
MODIFIED LIVE IBR(26,1)
SINGER STRAIN(25,7)
IBR COLORADO(25,3)
MICROBE(24,6)
VACCINE COMPOSITION ADMINISTRATION(22,3)
FETAL INFECTION(22,2)
VACCINE PRE PREGNANCY ADMINISTRATION(22,1)
IMMUNOLOGICAL ACTIVE COMPONENT(21,24)
PREGNANCY MONTH(20,2)
BVDV CAUSED INFECTION TREATMENT(19,1)
COW(18,87)
CLINICAL SIGN(17,7)
INFECTIOUS BOVINE RHINOTRACHEITIS COLORADO(17,1)
VIRUS(15,14)
CALVING OUTCOME(14,10)
BOVINE VIRAL DIARRHEA(14,7)
STRAIN(13,13)
MODIFIED LIVE VIRUS(13,3)
CALF NURSING PREGNANT CATTLE(13,2)
NUCLEOTIDE(13,1)
ENROLLED CATTLE(11,5)
HAEMOPHILUS SOMNUS BACTERIN(11,2)
BOVINE VIRAL DIARRHEA TYPE(10,7)
STUDY OUTCOME(10,7)
LICENSED BVDV MLV VACCINE(10,1)
GESTATION DAY(9,8)
PREGNANCY STATUS VERIFICATION(9,3)
POST MORTEM REPORT ADDENDUM(9,2)
TRIMESTER ENROLLED ANIMAL(9,2)
THENO NEGATIVEALBERTASTUDY PROTOCOL APPENDIX(9,1)
REPRESENTATIVE VACCINE(8,8)
NEBRASKA SITE(8,6)
BOOSTER VACCINATION(8,3)
CALF NURSING PREGNANT FEMALE(8,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(8,1)
PERSISTENTLY INFECTED CALF INDUCTION(8,1)
TRIMESTER PREGNANT COW(8,1)
VACCINATED COW PREGNANCY(8,1)
VACCINATED PREGNANT COW HEIFER(8,1)
TRIMESTER GROUP(7,8)
IMMUNOGENIC(7,7)
PRE BREEDING VACCINATION(7,5)
WEEK POST PARTUM(7,4)
ENROLLED CALF(7,3)
ENROLLMENT CRITERIA(7,3)
HEALTH LABORATORY ANIMAL(7,3)
VACCINE ADMINISTRATION(7,3)
BENCHMARK BIOLAB(7,2)
CALVING BLOOD SAMPLING(7,2)
POST CALVING DEATH(7,2)
SAMPLING SPREADSHEET RECORD(7,2)
SERUM NEUTRALIZATION ASSAY(7,2)
TRIMESTER HERD(7,2)
VACCINATION ENROLLMENT(7,2)
GUARDIAN SCOUR VACCINE(7,1)
INTHIRD TRIMESTERTHE CALF(7,1)
PREGNANT COW HEIFER PROPHYLAXIS(7,1)
PREGNANT COW PROPHYLAXIS(7,1)
PREGNANT COW VACCINATION(7,1)
SCOUR MILD OUTBREAK(7,1)
CALVING DIFFICULTY(6,3)
COW CALF RANCH(6,3)
ADULT HEIFER(6,2)
BOVINE TESTICULAR CELL(6,2)
COLOSTRUM FORCED FEEDING(6,2)
ENROLLED COW(6,2)
FLAVIVIRIDAE FAMILY(6,2)
POST PARTUM OBSERVATION(6,2)
VACCINATED CATTLE(6,2)
AGROUP APROTOCOL DEVIATION(6,1)
ANIMAL HEALTH FIELD(6,1)
ATTENUATED VIRUS VACCINE(6,1)
BRSV LIVE ATTENUATED STRAIN(6,1)
BVD IMMUNOHISTOCHEMISTRY TESTING(6,1)
BVDV SINGER STRAIN(6,1)
CALF POSTNATAL HEALTH(6,1)
ENROLLMENT PREGNANCY CHECK VACCINATION(6,1)
ENROLLMENT TRIMESTER PREGNANCY CHECK(6,1)
ENROLLMENT VACCINATION DAY(6,1)
HOG CHOLERA VIRUS(6,1)
INFECTION HISTOPATHOLOGICAL SIGN(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS DETECTION(6,1)
MICROBIAL INFECTION DIVERSITY(6,1)
NAIVE PREGNANT CATTLE(6,1)
ONTARIO VETERINARY COLLEGE(6,1)
POST PARTUM CALF HEALTH(6,1)
PREGNANT ANIMAL PLACENTA(6,1)
PREGNANT COW HEALTH(6,1)
VAGINAL PROLAPSE SURGICAL REPAIR(6,1)
POST MORTEM EXAMINATION(5,9)
MDBK CELL(5,5)
RT PCR(5,5)
DEAD CALF(5,3)
MEAN GESTATION(5,3)
TEST ANTIBODY(5,3)
BACTERIA CULTURE(5,2)
CALF 940Y(5,2)
CATEGORY FETAL LOSS(5,2)
GESTATION WINDOW(5,2)
HEALTHY BREEDING(5,2)
PLACEBO VACCINE(5,2)
PRE COLOSTRAL SEROLOGICAL STATUS(5,2)
PRE COLOSTRAL SERUM SAMPLING(5,2)
SAFE(5,2)
TISSUE COMPLIANCE(5,2)
VIRUS PATHOGEN(5,2)
WINTER MONTH(5,2)
ABSORBED COLOSTRAL ANTIBODY(5,1)
ALBERTA HERD(5,1)
ALKENE THEOLIGOMERIZATION(5,1)
ASSIGNED TRIMESTER VACCINATION(5,1)
BACTERIN FORM(5,1)
BOVINE EMBRYO KIDNEY CELL(5,1)
BREED BACK FP H(5,1)
BVD ENROLLMENT(5,1)
BVDV VACCINE(5,1)
BVDV VIRAL PROTEIN(5,1)
CALF ENROLLMENT TESTING(5,1)
CLINICAL SIGN HEIFER(5,1)
CLOPPER PEARSON CONFIDENCE INTERVAL(5,1)
CLOSTRIDIAL BACTERIN(5,1)
CORN STOCK PASTURE(5,1)
COWFETAL LOSS FORWA(5,1)
DAILY ACTIVITY CALENDAR LOG(5,1)
DAILY HERD OBSERVATION(5,1)
DIARRHEA PARAINFLUENZA(5,1)
EMBRYONIC SWINE KIDNEY CELL(5,1)
ENROLLED HEIFER(5,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(5,1)
FORT MACLEOD VETERINARY CLINIC(5,1)
HEALTHY SUSCEPTIBLE COW(5,1)
HERD ROUTINE MANAGEMENT(5,1)
IBR ATTENUATED STRAIN(5,1)
INACTIVATED ROTAVIRUS CORONAVIRUS(5,1)
INFERTILITY HISTORY(5,1)
MICROBIOLOGICAL GROWTH INHIBITION(5,1)
MODIFIED LIVE BVDV VIRULENCE(5,1)
NEBRASKA HERD(5,1)
NEBRASKA UNIVERSITY(5,1)
NECROPSIED FETUS(5,1)
PASTURE ASSIGNMENT(5,1)
PERSISTENT FETAL INFECTION(5,1)
PESTIVIRUS FAMILY VIRUS(5,1)
PESTIVIRUS GENUS(5,1)
PI LIVE ATTENUATED STRAIN(5,1)
POLYNUCLEOTIDE VACCINATION(5,1)
POLYOXYETHYLENE POLYOXYPROPYLENE(5,1)
POST MORTEM SAMPLE LABORATORY EXAMINATION(5,1)
PREDOMINANT CLINICAL PARAMETER(5,1)
RAINSTORM(5,1)
RAYMOND FINNEY HEIFER(5,1)
RAYMOND FINNEY HERD(5,1)
RAYMOND FINNEY RANCH(5,1)
RAYMOND HERD(5,1)
RAYMOND RANCH(5,1)
REPLICATION COMPENTENT(5,1)
RESEARCH DATA CALVING(5,1)
SERUM NEUTRALIZING ANTIBODY STATUS(5,1)
SERUM NEUTRALIZING TITER(5,1)
TISSUE CULTURE INFECTIVE(5,1)
TRIMESTER COW(5,1)
UNDIAGNOSED CALF LOSS(5,1)
VETERINARY DIAGNOSTIC LABORATORY(5,1)
VSM GUIDELINE(5,1)
WORKING COW CALF HERD(5,1)
ACRYLIC POLYMER(4,3)
EAR NOTCH(4,3)
VACCINE PRODUCTION ASSIGNMENT(4,3)
ADMINISTRATION SAFETY(4,2)
ADMINISTRATION TIMING(4,2)
CALF HEALTH STATUS(4,2)
EXPOSURE EVIDENCE(4,2)
HEALTH ISSUE(4,2)
IBR DETECTION(4,2)
LIVE CALF(4,2)
SERUM NEUTRALIZING ANTIBODY LEVEL(4,2)
STUDY OBJECTIVE(4,2)
ALBERTA CANADA TREATMENT(4,1)
AMINOACID SEQUENCE(4,1)
ATTENUATED MICROORGANISM(4,1)
AVRIDINE LIPID(4,1)
BOOSTER VACCINE(4,1)
BOVINE TURBINATE CELL(4,1)
BREEDING HERD(4,1)
BVD ABORTION(4,1)
CALF HEIFER(4,1)
CALVING SEASON(4,1)
CLASSICAL BVDV(4,1)
CLINICAL MANIFESTATION(4,1)
CYTEL STUDIO(4,1)
DYSTOCIA DIAGNOSIS(4,1)
FINAL BVD SEROLOGY(4,1)
GALENICA PHARMACEUTICAL(4,1)
IBR HISTORY(4,1)
INFECTION SYMPTOM(4,1)
LEPTO BACTERIN(4,1)
LEPTOSPIRA FA(4,1)
LEPTOSPIRA STRAIN(4,1)
MATERNAL ANTIBODY(4,1)
MICROBIOLOGICAL CONTAMINATION(4,1)
MONOPHOSPHORYL LIPID(4,1)
NEBRASKA TRIAL(4,1)
NONIONIC SURFACTANT(4,1)
PREGNANCY CONFIRMATION(4,1)
PREGNANCY VERIFICATION(4,1)
RAW DATA FILE(4,1)
RAYMOND HEIFER(4,1)
STILLBORN CALF(4,1)
TRIMESTER ASSIGNMENT(4,1)
UNSATURATED ALIPHATIC RADICAL(4,1)
VACCINATED DAM(4,1)
VIRULENT BVDV(4,1)
WILLIAMS HERD(4,1)
WILLIAMS RANCH(4,1)
IMMUNE RESPONSE(3,4)
SIGNIFICANT INCREASE(3,4)
COMBINATION VACCINE(3,3)
LIFE DAY(3,3)
PREGNANCY OUTCOME(3,3)
PRESERVATIVE(3,3)
PRODUCER(3,3)
ANIMAL SELECTION(3,2)
BLOOD COLLECTION(3,2)
ESK CELL(3,2)
FULL NECROPSY(3,2)
INVESTIGATOR OBSERVATION COMBINATION(3,2)
ISOTONIC AGENT(3,2)
LABORATORY TEST(3,2)
NEGATIVE ANTIBODY(3,2)
NUMERIC SCALE(3,2)
PAIRED SAMPLE(3,2)
SAMPLE TOXICITY CONTAMINATION(3,2)
STUDY START(3,2)
TERM BVDV(3,2)
TERM VACCINE(3,2)
TISSUE SAMPLE(3,2)
TRIMESTER ENROLLMENT VACCINATION TIME(3,2)
VIRUS DETECTION(3,2)
WAY LEPTOSPIRA BACTERIN(3,2)
ABORTING FRACTION(3,1)
ADJUVANT INSTANCE(3,1)
ADRD LABORATORY(3,1)
ADSORPTION DELAYING(3,1)
ADULT SERUM SAMPLE(3,1)
AEROBIC CULTURE(3,1)
AINSWORTH JOHNSTOWN NEBRASKA AREA(3,1)
ALKENYL DERIVATIVE(3,1)
AMINE ADJUVANT(3,1)
ANIMAL MANAGEMENT(3,1)
ANIMAL NEED(3,1)
ANIMAL PARITY(3,1)
ANTIBODY NEUTRALIZATION(3,1)
ANTIBODY REACTION NEUTRALIZATION(3,1)
ANTIGENIC SUBSTANCE(3,1)
ATTENUATED PARTICLE(3,1)
BIOCHEMICAL TEST(3,1)
BIRTH DATE(3,1)
BIVI FETAL PROTECTION PRODUCT(3,1)
BORN CALF LOSS(3,1)
BOVINE HERPES VIRUS(3,1)
BOVINE PATHOGEN(3,1)
BOVINE SERUM ALBUMIN(3,1)
BVD VIRUS AGENT(3,1)
BVDV DIVISION(3,1)
BVDV SEQUENCE(3,1)
BVDV STRAIN(3,1)
CALF 16Y(3,1)
CALF 53R(3,1)
CALF DEATH(3,1)
CALF FINAL OBSERVATION(3,1)
CALF LOSS DIAGNOSIS(3,1)
CALF SEX(3,1)
CALF TISSUE(3,1)
CALVING EAR(3,1)
CALVING EVENT(3,1)
CALVING LOSS ABORTION(3,1)
CALVING REMARK SECTION(3,1)
CHEMICALLY MODIFIED VIRUS(3,1)
CHOLERA TOXIN(3,1)
CLOTTED BLOOD TUBE(3,1)
COIN TOSS(3,1)
COLI VACCINE(3,1)
COW MAJORITY(3,1)
CULTURE GROWTH(3,1)
DAILY CALENDAR(3,1)
DECREASING SERUM ASSAY(3,1)
DIAGNOSTIC TESTING(3,1)
EFFICACY TRIAL(3,1)
ELEVATED FEVER(3,1)
EMERYVILLE CALIF(3,1)
ETHYLENICALLY UNSATURATED GROUP(3,1)
EXPRESS 5HS(3,1)
FEMALE BOVINE(3,1)
FETAL LOSS VISUAL SIGN(3,1)
FETAL TISSUE RECOVERY(3,1)
FETUS LOSS(3,1)
FINAL CALF SAMPLING(3,1)
FLUORESCENT ANTIBODY(3,1)
FOLD DILUTION(3,1)
HERD BOOK(3,1)
HERD MANAGEMENT(3,1)
HERD REMAINDER(3,1)
HOME PASTURE(3,1)
IMMUNITY DURATION(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
INFECTION SEVERITY(3,1)
INFLICTED INJURY(3,1)
INVESTIGATION SITE(3,1)
INVESTIGATOR DID(3,1)
KILLED VACCINE(3,1)
LABELED SAFETY PRECAUTION REGARDING(3,1)
LIKELY SIRE(3,1)
LIVE ANIMAL(3,1)
LIVING ORGANISM(3,1)
MALEIC ANHYDRIDE COPOLYMER(3,1)
MICROORGANISM FRACTION(3,1)
MINERAL SUPPLEMENT(3,1)
MISSING IDENTIFICATION(3,1)
MK 270A(3,1)
MLV IBR(3,1)
MODIFIED BVDV SINGER(3,1)
MULTIDOSE COMPOSITION PREPARATION(3,1)
MYCOLOGY CULTURE(3,1)
NAKED EYE(3,1)
NEBRASKA TREATMENT(3,1)
NURSING CALF(3,1)
OUTCOME RECORD(3,1)
PAIRED SERUM(3,1)
PCR ASSAY(3,1)
PENTAERYTHRITOL ALLYL(3,1)
PERSISTENT INFECTION(3,1)
PLASTIC EAR(3,1)
POLYHYDROXYLATED COMPOUND(3,1)
POLYMER DISSOLUTION(3,1)
POST CALVING LOSS(3,1)
POST PARTUM ILLNESS RATE(3,1)
PROPYLENE GLYCOL DIOLEATE(3,1)
RANCH COW(3,1)
RANCHER FAILURE(3,1)
RANDOMIZATION SOFTWARE(3,1)
REPLACEMENT HEIFER(3,1)
RURAL TECHNOLOGY(3,1)
SAMPLE VALIDITY(3,1)
SAN DIEGO(3,1)
SERUM ALIQUOT(3,1)
SERUM ANTIBODY(3,1)
SERUM COLLECTION(3,1)
SERUM SAMPLE INTEGRITY(3,1)
SERUM SAMPLE TOXICITY(3,1)
SITE VETERINARIAN(3,1)
SORBITAN ESTER(3,1)
SOUTH CENTRAL ALBERTA(3,1)
SPT EMULSION(3,1)
STUDY RECORD(3,1)
STUDY WRITTEN RECORD(3,1)
SUCROSE ALLYL(3,1)
SUGAR POLYALKENYL ETHER(3,1)
TERM LIVE VACCINE(3,1)
TEST VACCINE SERIAL(3,1)
THEIBR EXPOSURE(3,1)
UNSATURATED RADICAL(3,1)
UTERO EXPOSURE(3,1)
VACCINATION SAFETY(3,1)
VACCINATION TREATMENT(3,1)
VALIDITY QUESTION(3,1)
VIRION MOLECULAR(3,1)
VIRUS ISOLATION PERFORMANCE(3,1)
BVD TYPE(2,13)
CELL CULTURE FLUID(2,4)
COMBINED GROUP(2,3)
DILUENT(2,3)
ESTIMATED RANGE(2,3)
GROSS(2,3)
PLACEBO CONTROL(2,3)
RANDOMIZATION(2,3)
STEP ADMINISTRATION(2,3)
WAY VACCINE(2,3)
ANTIBIOTIC(2,2)
ANTIMICROBIOLOGICAL ACTIVE AGENT(2,2)
BLIZZARD(2,2)
CAPRYLATE(2,2)
CHUTE(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
EXCEPTION(2,2)
GLYCOPROTEIN(2,2)
GRASS(2,2)
IBRV BVDV(2,2)
LAMENESS(2,2)
LETHALITY(2,2)
LINCOLN(2,2)
NEOMYCIN(2,2)
PROTECTANT(2,2)
PURIFICATION(2,2)
PYREXIA(2,2)
RECTAL PALPATION(2,2)
RETEST(2,2)
ROUTE(2,2)
SEMEN(2,2)
SERONEGATIVE(2,2)
SITE PRACTICE(2,2)
STABILIZER(2,2)
SUSPECT(2,2)
WEATHER RELATED DEATH(2,2)
ADJUVANT SOLUTION(2,1)
AGE DAY(2,1)
ALUMINUM PHOSPHATE(2,1)
ANHYDROMANNITOL(2,1)
ANTIBODY TRANSFER(2,1)
ANTIGENICALLY RELATED ORGANISM(2,1)
ASEPTIC(2,1)
AUTOMATIC ANALYZER(2,1)
BALANOPOSTHITIS(2,1)
BLOODSAMPLE(2,1)
BROKEN LIMB(2,1)
BVD PRESENCE(2,1)
CALF TREATMENT(2,1)
CALVING LOSS REMOVAL(2,1)
CELL CULTURE SUPERNATANT(2,1)
CLOTTED BLOOD CELL(2,1)
COW GROUP(2,1)
DEATH RATE ESTIMATE(2,1)
ENCEPHALOMYELITIS(2,1)
ETHYL OLEATE(2,1)
FORFETAL LOSS(2,1)
GLUTAMYL TRANSPEPTIDASE(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
HISTOLOGICAL(2,1)
HUNDRED SEVEN(2,1)
HYDROGEN ATOM(2,1)
HYDROPERITONEUM(2,1)
IMMUNOLOGICAL RESPONSE(2,1)
INFECTED CELL CULTURE(2,1)
MAJOR ANTIGEN(2,1)
MLV VACCINE SINGLE DOSE(2,1)
MODIFIED LIVE VACCINE COMPONENT(2,1)
MURAMYL DIPEPTIDE(2,1)
NON AQUEOUS SOLUTION(2,1)
ORGANISM IMMUNOLOGICAL FUNCTION(2,1)
OVINE CELL(2,1)
PERFORMED VIRUS ISOLATION(2,1)
PLURONIC PRODUCT(2,1)
POLYPROTEIN(2,1)
PORCINE CELL(2,1)
POTENTIAL FETAL LOSS(2,1)
PRE COLOSTRAL SAMPLE STATUS(2,1)
PRE COLOSTRAL SERUM SAMPLE(2,1)
PRODUCTION RANCH(2,1)
RECENT HISTORY(2,1)
RESEARCH ANIMAL DISEASE(2,1)
RESPIRATORY DISEASE REDUCTION(2,1)
ROTATION SCHEDULE(2,1)
SERUM SEPARATION(2,1)
SHELF LIFE(2,1)
SOUTH DAKOTA STATE UNIVERSITY(2,1)
TREATMENT ASSIGNMENT(2,1)
TRIAL SITE(2,1)
VACCINATION GROUP(2,1)
VALID PRE COLOSTRAL SAMPLE(2,1)
VIRUS PARTICLE(2,1)
ALUMINUM HYDROXIDE(1,1)
ANTIBACTERIAL(1,1)
ANTIGENIC DIVERSITY(1,1)
ANTIPARASITIC(1,1)
ANTISENSE(1,1)
ARTIFICIAL INSEMINATION(1,1)
BEEF CATTLE(1,1)
BISHOP(1,1)
BLOOD SAMPLE PAIR(1,1)
BRANCHED FATTY ACID ESTER(1,1)
(US8846054)
HEIFER(100,69)
PREGNANT COW(100,18)
ABORTION(100,2)
PREGNANT COW HEIFER VACCINATION(62,6)
CATTLE RELEVANT PATHOGEN(58,2)
PREGNANT COW HEIFER(56,14)
HAEMOPHILUS SOMNUS BACTERIN(52,3)
PREGNANT HEIFER(48,2)
MICROBIOLOGICAL INFECTION TREATMENT(42,1)
EMBRYONIC SWINE KIDNEY CELL(41,2)
VACCINE(39,79)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(39,1)
LEPTOSPIRA BACTERIA(38,6)
PREGNANT COW FETUS(37,1)
BOVINE EMBRYO KIDNEY CELL(36,2)
HAEMOPHILUS SOMNUS(36,1)
LEPTOSPIRA GRIPPOTYPHOSA(32,7)
BOVINE TURBINATE CELL(31,2)
UNVACCINATED COW HEIFER(31,2)
LEPTOSPIRA POMONA(30,5)
LEPTOSPIRA CANICOLA(29,7)
LEPTOSPIRA HARDJO(29,7)
SINGER STRAIN(29,7)
BVDV CAUSED INFECTION TREATMENT(29,1)
CLINICAL SIGN(28,9)
BOVINE TESTICULAR CELL(27,3)
MICROBIOLOGICAL INFECTION(26,2)
MODIFIED LIVE IBR(26,1)
BOVINE VIRAL DIARRHEA VIRUS(25,24)
IBR COLORADO(25,3)
INFECTIOUS BOVINE RHINOTRACHEITIS COLORADO(24,2)
MDBK CELL(23,7)
INFECTIOUS BOVINE RHINOTRACHEITIS(22,6)
PREGNANCY TRIMESTER(22,4)
PROPHYLAXIS(21,5)
VACCINE COMPOSITION ADMINISTRATION(21,3)
FETAL INFECTION(21,2)
INFECTION PROPHYLAXIS(18,4)
OVINE CELL(18,2)
STRAIN(15,14)
CALVING OUTCOME(13,10)
CALF NURSING PREGNANT CATTLE(13,2)
NUCLEOTIDE(13,1)
MICROBE(12,3)
IMMUNOLOGICAL ACTIVE COMPONENT(11,17)
PREGNANCY(10,7)
INCIDENCE(10,6)
ENROLLED CATTLE(10,5)
BVDV(9,23)
CATTLE(9,12)
GESTATION DAY(9,8)
STUDY OUTCOME(9,7)
PREGNANCY STATUS VERIFICATION(9,3)
POST MORTEM REPORT ADDENDUM(9,2)
TRIMESTER ENROLLED ANIMAL(9,2)
LICENSED BVDV MLV VACCINE(9,1)
THENO NEGATIVEALBERTASTUDY PROTOCOL APPENDIX(9,1)
REPRESENTATIVE VACCINE(8,8)
NEBRASKA SITE(8,6)
CALF NURSING PREGNANT FEMALE(8,1)
PERSISTENTLY INFECTED CALF INDUCTION(8,1)
TRIMESTER PREGNANT COW(8,1)
VACCINATED COW PREGNANCY(8,1)
VACCINATED PREGNANT COW HEIFER(8,1)
TRIMESTER GROUP(7,8)
IMMUNOGENIC(7,7)
WEEK POST PARTUM(7,4)
BOOSTER VACCINATION(7,3)
ENROLLED CALF(7,3)
ENROLLMENT CRITERIA(7,3)
HEALTH LABORATORY ANIMAL(7,3)
VACCINE ADMINISTRATION(7,3)
BENCHMARK BIOLAB(7,2)
CALVING BLOOD SAMPLING(7,2)
POST CALVING DEATH(7,2)
SAMPLING SPREADSHEET RECORD(7,2)
SERUM NEUTRALIZATION ASSAY(7,2)
TRIMESTER HERD(7,2)
VACCINATION ENROLLMENT(7,2)
GUARDIAN SCOUR VACCINE(7,1)
INTHIRD TRIMESTERTHE CALF(7,1)
PREGNANT COW HEIFER PROPHYLAXIS(7,1)
PREGNANT COW PROPHYLAXIS(7,1)
PREGNANT COW VACCINATION(7,1)
SCOUR MILD OUTBREAK(7,1)
PRE BREEDING VACCINATION(6,5)
CALVING DIFFICULTY(6,3)
COW CALF RANCH(6,3)
ADULT HEIFER(6,2)
COLOSTRUM FORCED FEEDING(6,2)
ENROLLED COW(6,2)
FLAVIVIRIDAE FAMILY(6,2)
POST PARTUM OBSERVATION(6,2)
AGROUP APROTOCOL DEVIATION(6,1)
ATTENUATED VIRUS VACCINE(6,1)
BRSV LIVE ATTENUATED STRAIN(6,1)
BVD IMMUNOHISTOCHEMISTRY TESTING(6,1)
BVDV SINGER STRAIN(6,1)
CALF POSTNATAL HEALTH(6,1)
ENROLLMENT PREGNANCY CHECK VACCINATION(6,1)
ENROLLMENT TRIMESTER PREGNANCY CHECK(6,1)
ENROLLMENT VACCINATION DAY(6,1)
HOG CHOLERA VIRUS(6,1)
INFECTION HISTOPATHOLOGICAL SIGN(6,1)
INFECTIOUS BOVINE RHINOTRACHEITIS DETECTION(6,1)
MICROBIAL INFECTION DIVERSITY(6,1)
NAIVE PREGNANT CATTLE(6,1)
ONTARIO VETERINARY COLLEGE(6,1)
POST PARTUM CALF HEALTH(6,1)
PREGNANT ANIMAL PLACENTA(6,1)
PREGNANT COW HEALTH(6,1)
VAGINAL PROLAPSE SURGICAL REPAIR(6,1)
POST MORTEM EXAMINATION(5,9)
RT PCR(5,5)
COMBINATION VACCINE(5,3)
DEAD CALF(5,3)
MEAN GESTATION(5,3)
TEST ANTIBODY(5,3)
BACTERIA CULTURE(5,2)
CALF 940Y(5,2)
CATEGORY FETAL LOSS(5,2)
GESTATION WINDOW(5,2)
HEALTHY BREEDING(5,2)
PLACEBO VACCINE(5,2)
PRE COLOSTRAL SEROLOGICAL STATUS(5,2)
PRE COLOSTRAL SERUM SAMPLING(5,2)
SAFE(5,2)
TISSUE COMPLIANCE(5,2)
VIRUS PATHOGEN(5,2)
WINTER MONTH(5,2)
ABSORBED COLOSTRAL ANTIBODY(5,1)
ALKENE THEOLIGOMERIZATION(5,1)
ASSIGNED TRIMESTER VACCINATION(5,1)
BVDV VIRAL PROTEIN(5,1)
CALF ENROLLMENT TESTING(5,1)
CLINICAL SIGN HEIFER(5,1)
CLOPPER PEARSON CONFIDENCE INTERVAL(5,1)
DAILY HERD OBSERVATION(5,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(5,1)
HERD ROUTINE MANAGEMENT(5,1)
IBR ATTENUATED STRAIN(5,1)
INACTIVATED ROTAVIRUS CORONAVIRUS(5,1)
MODIFIED LIVE BVDV VIRULENCE(5,1)
PERSISTENT FETAL INFECTION(5,1)
PI LIVE ATTENUATED STRAIN(5,1)
RAYMOND FINNEY HEIFER(5,1)
RESEARCH DATA CALVING(5,1)
SERUM NEUTRALIZING ANTIBODY STATUS(5,1)
SERUM NEUTRALIZING TITER(5,1)
VETERINARY DIAGNOSTIC LABORATORY(5,1)
ACRYLIC POLYMER(4,3)
EAR NOTCH(4,3)
VACCINE PRODUCTION ASSIGNMENT(4,3)
ADMINISTRATION SAFETY(4,2)
EXPOSURE EVIDENCE(4,2)
HEALTH ISSUE(4,2)
IBR DETECTION(4,2)
LIVE CALF(4,2)
MODIFIED LIVE VIRUS(4,2)
SERUM NEUTRALIZING ANTIBODY LEVEL(4,2)
STUDY OBJECTIVE(4,2)
ALBERTA CANADA TREATMENT(4,1)
ALBERTA HERD(4,1)
AMINOACID SEQUENCE(4,1)
ATTENUATED MICROORGANISM(4,1)
AVRIDINE LIPID(4,1)
BACTERIN FORM(4,1)
BOOSTER VACCINE(4,1)
BREEDING HERD(4,1)
BVD ABORTION(4,1)
BVD ENROLLMENT(4,1)
BVDV VACCINE(4,1)
CALF HEIFER(4,1)
CALVING SEASON(4,1)
CLASSICAL BVDV(4,1)
CLINICAL MANIFESTATION(4,1)
CLOSTRIDIAL BACTERIN(4,1)
CORN STOCK PASTURE(4,1)
COWFETAL LOSS FORWA(4,1)
CYTEL STUDIO(4,1)
DAILY ACTIVITY CALENDAR LOG(4,1)
DIARRHEA PARAINFLUENZA(4,1)
DYSTOCIA DIAGNOSIS(4,1)
ENROLLED HEIFER(4,1)
FINAL BVD SEROLOGY(4,1)
FORT MACLEOD VETERINARY CLINIC(4,1)
GALENICA PHARMACEUTICAL(4,1)
HEALTHY SUSCEPTIBLE COW(4,1)
IBR HISTORY(4,1)
INFECTION SYMPTOM(4,1)
INFERTILITY HISTORY(4,1)
LEPTO BACTERIN(4,1)
LEPTOSPIRA FA(4,1)
LEPTOSPIRA STRAIN(4,1)
MATERNAL ANTIBODY(4,1)
MICROBIOLOGICAL CONTAMINATION(4,1)
MICROBIOLOGICAL GROWTH INHIBITION(4,1)
MONOPHOSPHORYL LIPID(4,1)
NEBRASKA HERD(4,1)
NEBRASKA TRIAL(4,1)
NEBRASKA UNIVERSITY(4,1)
NECROPSIED FETUS(4,1)
NONIONIC SURFACTANT(4,1)
PASTURE ASSIGNMENT(4,1)
PESTIVIRUS FAMILY VIRUS(4,1)
PESTIVIRUS GENUS(4,1)
POLYNUCLEOTIDE VACCINATION(4,1)
POLYOXYETHYLENE POLYOXYPROPYLENE(4,1)
POST MORTEM SAMPLE LABORATORY EXAMINATION(4,1)
PREDOMINANT CLINICAL PARAMETER(4,1)
PREGNANCY CONFIRMATION(4,1)
PREGNANCY MONTH(4,1)
PREGNANCY VERIFICATION(4,1)
RAINSTORM(4,1)
RAW DATA FILE(4,1)
RAYMOND FINNEY HERD(4,1)
RAYMOND FINNEY RANCH(4,1)
RAYMOND HEIFER(4,1)
RAYMOND HERD(4,1)
RAYMOND RANCH(4,1)
REPLICATION COMPENTENT(4,1)
STILLBORN CALF(4,1)
TISSUE CULTURE INFECTIVE(4,1)
TRIMESTER ASSIGNMENT(4,1)
TRIMESTER COW(4,1)
UNDIAGNOSED CALF LOSS(4,1)
UNSATURATED ALIPHATIC RADICAL(4,1)
VACCINATED CATTLE(4,1)
VACCINATED DAM(4,1)
VIRULENT BVDV(4,1)
VSM GUIDELINE(4,1)
WILLIAMS HERD(4,1)
WILLIAMS RANCH(4,1)
WORKING COW CALF HERD(4,1)
IMMUNE RESPONSE(3,4)
SIGNIFICANT INCREASE(3,4)
LIFE DAY(3,3)
PREGNANCY OUTCOME(3,3)
PRESERVATIVE(3,3)
PRODUCER(3,3)
ADMINISTRATION TIMING(3,2)
ANIMAL SELECTION(3,2)
BLOOD COLLECTION(3,2)
CALF HEALTH STATUS(3,2)
ESK CELL(3,2)
FULL NECROPSY(3,2)
INVESTIGATOR OBSERVATION COMBINATION(3,2)
ISOTONIC AGENT(3,2)
LABORATORY TEST(3,2)
NEGATIVE ANTIBODY(3,2)
NUMERIC SCALE(3,2)
PAIRED SAMPLE(3,2)
SAMPLE TOXICITY CONTAMINATION(3,2)
STUDY START(3,2)
TERM BVDV(3,2)
TERM VACCINE(3,2)
TISSUE SAMPLE(3,2)
TRIMESTER ENROLLMENT VACCINATION TIME(3,2)
VIRUS DETECTION(3,2)
WAY LEPTOSPIRA BACTERIN(3,2)
ABORTING FRACTION(3,1)
ADJUVANT INSTANCE(3,1)
ADRD LABORATORY(3,1)
ADSORPTION DELAYING(3,1)
ADULT SERUM SAMPLE(3,1)
AEROBIC CULTURE(3,1)
ALKENYL DERIVATIVE(3,1)
AMINE ADJUVANT(3,1)
ANIMAL MANAGEMENT(3,1)
ANIMAL NEED(3,1)
ANIMAL PARITY(3,1)
ANTIBODY NEUTRALIZATION(3,1)
ANTIBODY REACTION NEUTRALIZATION(3,1)
ANTIGENIC SUBSTANCE(3,1)
ATTENUATED PARTICLE(3,1)
BIOCHEMICAL TEST(3,1)
BIRTH DATE(3,1)
BIVI FETAL PROTECTION PRODUCT(3,1)
BORN CALF LOSS(3,1)
BOVINE PATHOGEN(3,1)
BOVINE SERUM ALBUMIN(3,1)
BVD VIRUS AGENT(3,1)
BVDV DIVISION(3,1)
BVDV SEQUENCE(3,1)
BVDV STRAIN(3,1)
CALF 16Y(3,1)
CALF 53R(3,1)
CALF DEATH(3,1)
CALF FINAL OBSERVATION(3,1)
CALF LOSS DIAGNOSIS(3,1)
CALF SEX(3,1)
CALF TISSUE(3,1)
CALVING EAR(3,1)
CALVING EVENT(3,1)
CALVING LOSS ABORTION(3,1)
CALVING REMARK SECTION(3,1)
CHEMICALLY MODIFIED VIRUS(3,1)
CHOLERA TOXIN(3,1)
CLOTTED BLOOD TUBE(3,1)
COIN TOSS(3,1)
COLI VACCINE(3,1)
COW MAJORITY(3,1)
CULTURE GROWTH(3,1)
DAILY CALENDAR(3,1)
DECREASING SERUM ASSAY(3,1)
DIAGNOSTIC TESTING(3,1)
EFFICACY TRIAL(3,1)
ELEVATED FEVER(3,1)
EMERYVILLE CALIF(3,1)
ETHYLENICALLY UNSATURATED GROUP(3,1)
EXPRESS 5HS(3,1)
FEMALE BOVINE(3,1)
FETAL LOSS VISUAL SIGN(3,1)
FETAL TISSUE RECOVERY(3,1)
FETUS LOSS(3,1)
FINAL CALF SAMPLING(3,1)
FLUORESCENT ANTIBODY(3,1)
FOLD DILUTION(3,1)
HERD BOOK(3,1)
HERD MANAGEMENT(3,1)
HERD REMAINDER(3,1)
HOME PASTURE(3,1)
IMMUNITY DURATION(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
INFECTION SEVERITY(3,1)
INFLICTED INJURY(3,1)
INVESTIGATION SITE(3,1)
INVESTIGATOR DID(3,1)
KILLED VACCINE(3,1)
LABELED SAFETY PRECAUTION REGARDING(3,1)
LIKELY SIRE(3,1)
LIVE ANIMAL(3,1)
LIVING ORGANISM(3,1)
MALEIC ANHYDRIDE COPOLYMER(3,1)
MICROORGANISM FRACTION(3,1)
MINERAL SUPPLEMENT(3,1)
MISSING IDENTIFICATION(3,1)
MK 270A(3,1)
MLV IBR(3,1)
MODIFIED BVDV SINGER(3,1)
MULTIDOSE COMPOSITION PREPARATION(3,1)
MYCOLOGY CULTURE(3,1)
NAKED EYE(3,1)
NEBRASKA TREATMENT(3,1)
NURSING CALF(3,1)
OUTCOME RECORD(3,1)
PAIRED SERUM(3,1)
PCR ASSAY(3,1)
PENTAERYTHRITOL ALLYL(3,1)
PERSISTENT INFECTION(3,1)
PLASTIC EAR(3,1)
POLYHYDROXYLATED COMPOUND(3,1)
POLYMER DISSOLUTION(3,1)
POST CALVING LOSS(3,1)
POST PARTUM ILLNESS RATE(3,1)
PROPYLENE GLYCOL DIOLEATE(3,1)
RANCH COW(3,1)
RANCHER FAILURE(3,1)
RANDOMIZATION SOFTWARE(3,1)
REPLACEMENT HEIFER(3,1)
RURAL TECHNOLOGY(3,1)
SAMPLE VALIDITY(3,1)
SERUM ALIQUOT(3,1)
SERUM ANTIBODY(3,1)
SERUM COLLECTION(3,1)
SERUM SAMPLE INTEGRITY(3,1)
SERUM SAMPLE TOXICITY(3,1)
SITE VETERINARIAN(3,1)
SORBITAN ESTER(3,1)
SOUTH CENTRAL ALBERTA(3,1)
SPT EMULSION(3,1)
STUDY RECORD(3,1)
STUDY WRITTEN RECORD(3,1)
SUCROSE ALLYL(3,1)
SUGAR POLYALKENYL ETHER(3,1)
TERM LIVE VACCINE(3,1)
TEST VACCINE SERIAL(3,1)
THEIBR EXPOSURE(3,1)
UNSATURATED RADICAL(3,1)
UTERO EXPOSURE(3,1)
VACCINATION SAFETY(3,1)
VACCINATION TREATMENT(3,1)
VALIDITY QUESTION(3,1)
VIRION MOLECULAR(3,1)
VIRUS ISOLATION PERFORMANCE(3,1)
BVD TYPE(2,13)
CELL CULTURE FLUID(2,4)
COMBINED GROUP(2,3)
DILUENT(2,3)
ESTIMATED RANGE(2,3)
GROSS(2,3)
PLACEBO CONTROL(2,3)
RANDOMIZATION(2,3)
STEP ADMINISTRATION(2,3)
WAY VACCINE(2,3)
ANTIBIOTIC(2,2)
ANTIMICROBIOLOGICAL ACTIVE AGENT(2,2)
BLIZZARD(2,2)
BOVINE VIRAL DIARRHEA(2,2)
CAPRYLATE(2,2)
CHUTE(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
EXCEPTION(2,2)
GLYCOPROTEIN(2,2)
GRASS(2,2)
IBRV BVDV(2,2)
LAMENESS(2,2)
LETHALITY(2,2)
LINCOLN(2,2)
NEOMYCIN(2,2)
PROTECTANT(2,2)
PURIFICATION(2,2)
PYREXIA(2,2)
RECTAL PALPATION(2,2)
RETEST(2,2)
ROUTE(2,2)
SEMEN(2,2)
SERONEGATIVE(2,2)
SITE PRACTICE(2,2)
STABILIZER(2,2)
SUSPECT(2,2)
WEATHER RELATED DEATH(2,2)
ADJUVANT SOLUTION(2,1)
AGE DAY(2,1)
ALUMINUM PHOSPHATE(2,1)
ANHYDROMANNITOL(2,1)
ANTIBODY TRANSFER(2,1)
ANTIGENICALLY RELATED ORGANISM(2,1)
ASEPTIC(2,1)
AUTOMATIC ANALYZER(2,1)
BLOODSAMPLE(2,1)
BROKEN LIMB(2,1)
BVD PRESENCE(2,1)
CALF TREATMENT(2,1)
CALVING LOSS REMOVAL(2,1)
CELL CULTURE SUPERNATANT(2,1)
CLOTTED BLOOD CELL(2,1)
COW GROUP(2,1)
DEATH RATE ESTIMATE(2,1)
ETHYL OLEATE(2,1)
FORFETAL LOSS(2,1)
GLUTAMYL TRANSPEPTIDASE(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
HISTOLOGICAL(2,1)
HUNDRED SEVEN(2,1)
HYDROGEN ATOM(2,1)
HYDROPERITONEUM(2,1)
IMMUNOLOGICAL RESPONSE(2,1)
INFECTED CELL CULTURE(2,1)
MAJOR ANTIGEN(2,1)
MLV VACCINE SINGLE DOSE(2,1)
MODIFIED LIVE VACCINE COMPONENT(2,1)
MURAMYL DIPEPTIDE(2,1)
NON AQUEOUS SOLUTION(2,1)
ORGANISM IMMUNOLOGICAL FUNCTION(2,1)
PERFORMED VIRUS ISOLATION(2,1)
PLURONIC PRODUCT(2,1)
POLYPROTEIN(2,1)
PORCINE CELL(2,1)
POTENTIAL FETAL LOSS(2,1)
PRE COLOSTRAL SAMPLE STATUS(2,1)
PRE COLOSTRAL SERUM SAMPLE(2,1)
PRODUCTION RANCH(2,1)
RECENT HISTORY(2,1)
RESEARCH ANIMAL DISEASE(2,1)
RESPIRATORY DISEASE REDUCTION(2,1)
ROTATION SCHEDULE(2,1)
SERUM SEPARATION(2,1)
SHELF LIFE(2,1)
SOUTH DAKOTA STATE UNIVERSITY(2,1)
TREATMENT ASSIGNMENT(2,1)
TRIAL SITE(2,1)
VACCINATION GROUP(2,1)
VALID PRE COLOSTRAL SAMPLE(2,1)
VIRUS PARTICLE(2,1)
ALUMINUM HYDROXIDE(1,1)
ANTIBACTERIAL(1,1)
ANTIGENIC DIVERSITY(1,1)
ANTIPARASITIC(1,1)
ANTISENSE(1,1)
ARTIFICIAL INSEMINATION(1,1)
BEEF CATTLE(1,1)
BISHOP(1,1)
BLOOD SAMPLE PAIR(1,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(1,1)
BRANCHED FATTY ACID ESTER(1,1)
BREED BACK 10HS(1,1)
(US20140363466)
HEIFER(100,69)
PREGNANT COW(100,17)
ABORTION(100,2)
PREGNANT COW HEIFER VACCINATION(73,6)
CATTLE RELEVANT PATHOGEN(69,2)
PREGNANT COW HEIFER(67,14)
HAEMOPHILUS SOMNUS(66,2)
LEPTOSPIRA BACTERIA(61,8)
PREGNANT HEIFER(57,2)
VACCINE(55,84)
MICROBIOLOGICAL INFECTION TREATMENT(49,1)
LEPTOSPIRA GRIPPOTYPHOSA(47,8)
LEPTOSPIRA POMONA(44,6)
PREGNANT COW FETUS(44,1)
LEPTOSPIRA CANICOLA(43,8)
LEPTOSPIRA HARDJO(43,8)
INFECTIOUS BOVINE RHINOTRACHEITIS COLORADO(41,4)
UNVACCINATED COW HEIFER(36,2)
SINGER STRAIN(35,7)
BVDV CAUSED INFECTION TREATMENT(34,1)
CLINICAL SIGN(33,9)
INFECTIOUS BOVINE RHINOTRACHEITIS(31,7)
INFECTION PROPHYLAXIS(31,5)
MICROBIOLOGICAL INFECTION(31,2)
BOVINE VIRAL DIARRHEA VIRUS(30,28)
MODIFIED LIVE IBR(30,1)
IBR COLORADO(29,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(29,1)
PREGNANCY TRIMESTER(26,4)
PROPHYLAXIS(25,5)
VACCINE COMPOSITION ADMINISTRATION(25,3)
FETAL INFECTION(25,2)
COW(21,86)
STRAIN(18,16)
CALVING OUTCOME(16,10)
NUCLEOTIDE(16,1)
CALF NURSING PREGNANT CATTLE(15,2)
MICROBE(14,3)
HAEMOPHILUS SOMNUS BACTERIN(13,2)
IMMUNOLICAL ACTIVE COMPONENT(13,1)
PREGNANCY(12,7)
INCIDENCE(12,6)
ENROLLED CATTLE(12,5)
BVDV(11,23)
IMMUNOLOGICAL ACTIVE COMPONENT(11,16)
STUDY OUTCOME(11,7)
PREGNANCY STATUS VERIFICATION(11,3)
POST MORTEM REPORT ADDENDUM(11,2)
TRIMESTER ENROLLED ANIMAL(11,2)
LICENSED BVDV MLV VACCINE(11,1)
THENO NEGATIVEALBERTASTUDY PROTOCOL APPENDIX(11,1)
CATTLE(10,12)
GESTATION DAY(10,8)
REPRESENTATIVE VACCINE(10,8)
NEBRASKA SITE(9,6)
WEEK POST PARTUM(9,4)
BOOSTER VACCINATION(9,3)
CALF NURSING PREGNANT FEMALE(9,1)
PERSISTENTLY INFECTED CALF INDUCTION(9,1)
TRIMESTER PREGNANT COW(9,1)
VACCINATED COW PREGNANCY(9,1)
VACCINATED PREGNANT COW HEIFER(9,1)
TRIMESTER GROUP(8,8)
IMMUNOGENIC(8,7)
PRE BREEDING VACCINATION(8,5)
COW CALF RANCH(8,3)
ENROLLED CALF(8,3)
ENROLLMENT CRITERIA(8,3)
HEALTH LABORATORY ANIMAL(8,3)
VACCINE ADMINISTRATION(8,3)
BENCHMARK BIOLAB(8,2)
CALVING BLOOD SAMPLING(8,2)
POST CALVING DEATH(8,2)
SAMPLING SPREADSHEET RECORD(8,2)
SERUM NEUTRALIZATION ASSAY(8,2)
TRIMESTER HERD(8,2)
VACCINATION ENROLLMENT(8,2)
AGROUP APROTOCOL DEVIATION(8,1)
ATTENUATED VIRUS VACCINE(8,1)
BRSV LIVE ATTENUATED STRAIN(8,1)
CALF POSTNATAL HEALTH(8,1)
ENROLLMENT TRIMESTER PREGNANCY CHECK(8,1)
GUARDIAN SCOUR VACCINE(8,1)
INFECTION HISTOPATHOLOGICAL SIGN(8,1)
INTHIRD TRIMESTERTHE CALF(8,1)
MICROBIAL INFECTION DIVERSITY(8,1)
NAIVE PREGNANT CATTLE(8,1)
ONTARIO VETERINARY COLLEGE(8,1)
PREGNANT COW HEIFER PROPHYLAXIS(8,1)
PREGNANT COW PROPHYLAXIS(8,1)
PREGNANT COW VACCINATION(8,1)
SCOUR MILD OUTBREAK(8,1)
CALVING DIFFICULTY(7,3)
ADULT HEIFER(7,2)
BOVINE TESTICULAR CELL(7,2)
COLOSTRUM FORCED FEEDING(7,2)
ENROLLED COW(7,2)
FLAVIVIRIDAE FAMILY(7,2)
POST PARTUM OBSERVATION(7,2)
VACCINATED CATTLE(7,2)
BVD IMMUNOHISTOCHEMISTRY TESTING(7,1)
BVDV SINGER STRAIN(7,1)
ENROLLMENT PREGNANCY CHECK VACCINATION(7,1)
ENROLLMENT VACCINATION DAY(7,1)
HOG CHOLERA VIRUS(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS DETECTION(7,1)
POST PARTUM CALF HEALTH(7,1)
PREGNANT ANIMAL PLACENTA(7,1)
PREGNANT COW HEALTH(7,1)
VAGINAL PROLAPSE SURGICAL REPAIR(7,1)
POST MORTEM EXAMINATION(6,9)
MDBK CELL(6,5)
RT PCR(6,5)
COMBINATION VACCINE(6,3)
DEAD CALF(6,3)
MEAN GESTATION(6,3)
TEST ANTIBODY(6,3)
BACTERIA CULTURE(6,2)
CALF 940Y(6,2)
CATEGORY FETAL LOSS(6,2)
GESTATION WINDOW(6,2)
HEALTHY BREEDING(6,2)
PLACEBO VACCINE(6,2)
PRE COLOSTRAL SEROLOGICAL STATUS(6,2)
PRE COLOSTRAL SERUM SAMPLING(6,2)
SAFE(6,2)
TISSUE COMPLIANCE(6,2)
VIRUS PATHOGEN(6,2)
WINTER MONTH(6,2)
ABSORBED COLOSTRAL ANTIBODY(6,1)
ALKENE THEOLIGOMERIZATION(6,1)
ASSIGNED TRIMESTER VACCINATION(6,1)
BVDV VIRAL PROTEIN(6,1)
CALF ENROLLMENT TESTING(6,1)
CLINICAL SIGN HEIFER(6,1)
CLOPPER PEARSON CONFIDENCE INTERVAL(6,1)
DAILY HERD OBSERVATION(6,1)
EMBRYONIC SWINE KIDNEY CELL(6,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(6,1)
HERD ROUTINE MANAGEMENT(6,1)
IBR ATTENUATED STRAIN(6,1)
INACTIVATED ROTAVIRUS CORONAVIRUS(6,1)
MODIFIED LIVE BVDV VIRULENCE(6,1)
PERSISTENT FETAL INFECTION(6,1)
PI LIVE ATTENUATED STRAIN(6,1)
RAYMOND FINNEY HEIFER(6,1)
RESEARCH DATA CALVING(6,1)
SERUM NEUTRALIZING ANTIBODY STATUS(6,1)
SERUM NEUTRALIZING TITER(6,1)
VETERINARY DIAGNOSTIC LABORATORY(6,1)
ACRYLIC POLYMER(5,3)
EAR NOTCH(5,3)
VACCINE PRODUCTION ASSIGNMENT(5,3)
ADMINISTRATION SAFETY(5,2)
EXPOSURE EVIDENCE(5,2)
HEALTH ISSUE(5,2)
IBR DETECTION(5,2)
LIVE CALF(5,2)
MODIFIED LIVE VIRUS(5,2)
SERUM NEUTRALIZING ANTIBODY LEVEL(5,2)
STUDY OBJECTIVE(5,2)
ALBERTA CANADA TREATMENT(5,1)
ALBERTA HERD(5,1)
AMINOACID SEQUENCE(5,1)
ATTENUATED MICROORGANISM(5,1)
AVRIDINE LIPID(5,1)
BACTERIN FORM(5,1)
BOOSTER VACCINE(5,1)
BOVINE EMBRYO KIDNEY CELL(5,1)
BOVINE TURBINATE CELL(5,1)
BREEDING HERD(5,1)
BVD ABORTION(5,1)
BVD ENROLLMENT(5,1)
BVDV VACCINE(5,1)
CALF HEIFER(5,1)
CALVING SEASON(5,1)
CLASSICAL BVDV(5,1)
CLINICAL MANIFESTATION(5,1)
CLOSTRIDIAL BACTERIN(5,1)
CORN STOCK PASTURE(5,1)
COWFETAL LOSS FORWA(5,1)
CYTEL STUDIO(5,1)
DAILY ACTIVITY CALENDAR LOG(5,1)
DIARRHEA PARAINFLUENZA(5(...)";Pharmaceuticals;Open
2009-01-09;"CA2648602           A1 2010-07-09 [CA2648602]
STG: (A1) Application laid open
AP : 2009CA-2648602 2009-01-09
CA2648602           C  2017-01-03 [CA2648602]
STG: (C) Patent (second level)
AP : 2009CA-2648602 2009-01-09";4136588;"CA2648602           A1 2010-07-09 [CA2648602]
CA2648602           C  2017-01-03 [CA2648602]";2009CA-2648602;;BOEHRINGER INGELHEIM VETMEDICA;BOEHRINGER INGELHEIM VETMEDICA;"(CA2648602)
US
(CA2648602)
US";"(CA2648602)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. 2621 North Belt Highway , CITY=ST. JOSEPH , STATE=MO , POSTCODE=64506-2002 , COUNTRY=US 

(CA2648602)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. 2621 North Belt Highway , CITY=ST. JOSEPH , STATE=MO , POSTCODE=64506-2002 , COUNTRY=US 
";1;"RINEHART CAROL L
JONES CRAIG
MYERS-KUHNHUFF JUDY
COLE WAYNE
OHNESORGE WILLIAM CHARLES";"(CA2648602)
US
(CA2648602)
US";"(CA2648602)
NAME=RINEHART, CAROL L. , COUNTRY=US 

NAME=JONES, CRAIG , COUNTRY=US 

NAME=MYERS-KUHNHUFF, JUDY , COUNTRY=US 

NAME=COLE, WAYNE , COUNTRY=US 

NAME=OHNESORGE, WILLIAM CHARLES , COUNTRY=US 

(CA2648602)
NAME=RINEHART, CAROL L. , COUNTRY=US 

NAME=JONES, CRAIG , COUNTRY=US 

NAME=MYERS-KUHNHUFF, JUDY , COUNTRY=US 

NAME=COLE, WAYNE , COUNTRY=US 

NAME=OHNESORGE, WILLIAM CHARLES , COUNTRY=US 
";"(CA2648602)
Method of treating pregnant cows and/or heifers";"(CA2648602)
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.";"(CA2648602)
1. A vaccine composition for use to prevent, in a pregnant cow,
(a) the incidence of one or more clinical signs of an infection caused by a microbe wherein the microbe is selected from the group consisting of
Infectious Bovine
Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof, or
(b) abortion in the pregnant cow, wherein the vaccine composition comprises a therapeutically effective amount of a modified live Infectious Bovine Rhinotracheitis (IBR) virus, a modified live Bovine Viral
Diarrhea Virus (BVDV) Type 1 of a Singer strain, a modified live BVDV Type 2
of
Strain 296, and a bacterin that is Haemophilus somnus bacterin.
2. The vaccine composition for use according to claim 1, wherein said modified live BVDV Type 1 is a Singer strain of BVDV that has been passaged at least twice in bovine turbinate cells.
3. The vaccine composition for use according to claim 1, wherein said modified live BVDV Type 1 Singer strain is the one that is included in the BREED-
BACK. TM. FP5
vaccine.
4. The vaccine composition for use according to claim 1, wherein said modified live BVDV Type 2 is Strain 296 of BVDV which has been passaged in bovine testicular cells at least six times, or in embryonic swine kidney cells at least 23 times, or in MDBK cells at least 23 times.
5. The vaccine composition for use according to claim 1, wherein said modified live BVDV Type 2 296 Strain is the one that is included in the BREED-BACK. TM.
FP5
vaccine.
6. The vaccine composition for use according to claim 1, wherein said modified live IBR virus is from the IBR Colorado 1 Strain.
7. The vaccine composition for use according to claim 6, wherein said modified live IBR virus is the one that is included in the BREED-BACK. TM. FP5 vaccine.
8. The vaccine composition for use according to claim 1, wherein said vaccine composition further comprises an attenuated microorganism, a killedmicroorganism or at least an immunologically active part of a microorganism effective for treating or prophylaxis of an infection caused by Parainfluenza-3 Virus, and Bovine Respiratory Syncytial
Virus (BRSV).
9. The vaccine composition for use according to claim 8, wherein the attenuated microorganism is a modified live virus (MLV).
10. The vaccine composition for use according to claim 1, wherein said vaccine composition further comprises an attenuated microorganism, a killedmicroorganism or at least an immunologically active part of a microorganism effective for treating or prophylaxis of an infection caused by a Leptospira bacterium.
1
1. The vaccine composition for use according to claim 10, wherein said
Leptospira bacterium is selected from the group consisting of: Leptospira canicola,
Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and
Leptospira pomona.
12. The vaccine composition for use according to claim 10, wherein said
Leptospira bacterium comprises Leptospira canicola, Leptospira grippotyphosa,
Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
13. A vaccine composition selected from the group consisting of
BREED-BACK. TM. FP5, EXPRESS. TM.5, EXPRESS. TM. FP5, BREED-BACK. TM. FP-HS,
EXPRESS. TM.5-HS, EXPRESS. TM. FP5-HS, BREED-BACK. TM. FP10, EXPRESS. TM.10,
BREEDBACK. TM. FP10-HS, EXPRESS. TM. FP10-HS, EXPRESS 10-HS, and combinations thereof, for use to prevent, in a pregnant cow,
(a) the incidence of one or more clinical signs of an infection caused by a microbe wherein the microbe is selected from the group consisting of
Infectious Bovine
Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof, or
(b) abortion in the pregnant cow.
14. The vaccine composition for use according to claim 1, wherein said vaccine composition is for administration to the pregnant cow during the first, second or third trimester of pregnancy.
15. The vaccine composition for use according to claim 1, wherein the vaccine composition prevents the fetus of a pregnant cow from the clinical signs of an infection caused by a microbe selected from the group consisting of a modified live Infectious
Bovine Rhinotracheitis
(IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof.
16. The vaccine composition for use according to claim 1, wherein the vaccine composition reduces the abortion rate in pregnant cows.
17. The vaccine composition for use according to claim 1, wherein the pregnant cow is a pregnant heifer.
18. The vaccine composition for use according to claim 1, wherein said vaccine composition is additionally for administration to the cow prior to the pregnancy.
19. Use of a vaccine composition for preventing, in a pregnant cow,
(a) the incidence of one or more clinical signs of an infection caused by a microbe wherein the microbe is selected from the group consisting of
Infectious Bovine
Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof, or
(b) abortion in the pregnant cow, wherein the vaccine composition comprises a therapeutically effective amount of a modified live Infectious Bovine Rhinotracheitis (IBR) virus, a modified live Bovine Viral
Diarrhea Virus (BVDV) Type 1 of a Singer strain, a modified live BVDV Type 2
of Strain
296, and a bacterin that is Haemophilus somnus bacterin.
20. The use according to claim 19, wherein the pregnant cow is in the first, second or third trimester of pregnancy.
21. The use according to claim 19, wherein said vaccine composition is additionally for administration to the cow prior to the pregnancy.
22. The use according to claim 19, wherein said vaccine composition further comprises an attenuated microorganism, a killed-microorganism or at least an immunologically active part of a microorganism effective for treating or prophylaxis of an infection caused by a Leptospira bacterium.
23. The use according to claim 22, wherein said Leptospira bacterium is selected from the group consisting of: Leptospira canicola, Leptospira grippotyphosa,
Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
24. The use according to claim 22, wherein said Leptospira bacterium comprises
Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
25. The use according to claim 19, wherein said vaccine composition is additionally for administration to the cow within 12 months before the pregnancy.
26. The use according to claim 19, wherein the vaccine composition prevents the fetus of a pregnant cow from the clinical signs of an infection caused by a microbe selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine
Viral Diarrhea
Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof.
27. The use according to claim 19, for reducing the abortion rate in pregnant cows.
28. The use according to claim 19, wherein the pregnant cow is a pregnant heifer.";"(CA2648602)
Still more particularly, the present invention relates to the use of such vaccines in pregnant cows/heifers.
One aspect of the present invention provides a method for safely vaccinating a pregnant cow, wherein the method generally includes or comprises the step of administering a vaccine to the pregnant cow or pregnant heifer.
One aspect of the present invention provides a method for safely vaccinating a pregnant cow, wherein the method generally includes or comprises the step of administering a vaccine to the pregnant cow or pregnant heifer.
More particularly, the present invention relates to the use of modified live BVDV Type 1 and BVDV Type 2 vaccines.
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections.
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections.
The invention also relates to a method of vaccinating a pregnant cow.
One aspect of the present invention provides a method for safely vaccinating a pregnant cow, wherein the method generally includes or comprises the step of administering a vaccine to the pregnant cow or pregnant heifer.
The present invention relates to the field of animal health and in particular to vaccines which comprise an attenuated bovine viral diarrhea virus (BVDV).
The present invention relates to the field of animal health and in particular to vaccines which comprise an attenuated bovine viral diarrhea virus (BVDV).";"(CA2648602)
However, Leptospira hardjo infections usually do not cause hemo lytic anemia, which makes diagnosis more difficult.
Accordingly, there is a need for safe methods of vaccinating pregnant cows.
This problem is probably due to the great antigenic diversity between type 1 and type 2 strains which is most pronounced in the glycoprotein E2, the major antigen for virus neutralization.
The division of BVDV into 2 species is based on significant differences at the level of genomic sequences (summarized in Heinz et al., 2000) which are also obvious from limited cross neutralizing antibody reactions.
Cattle with latent BHV-1 infections generally show no clinical signs when the virus is reactivated, but they do serve as a source of infection for other susceptible animals and thus perpetuate the disease.";"A61K-039/02
A61K-039/12
A61K-039/15
A61K-039/155
A61K-039/265
A61K-039/295
A61P-031/14
A61P-031/20
A61P-037/04";"(CA2648602)
1. A vaccine composition for use to prevent, in a pregnant cow, (a) the incidence of one or more clinical signs of an infection caused by a microbe wherein the microbe is selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof, or (b) abortion in the pregnant cow, wherein the vaccine composition comprises a therapeutically effective amount of a modified live Infectious Bovine Rhinotracheitis (IBR) virus, a modified live Bovine Viral Diarrhea Virus (BVDV) Type 1 of a Singer strain, a modified live BVDV Type 2 of Strain 296, and a bacterin that is Haemophilus somnus bacterin.
13. A vaccine composition selected from the group consisting of BREED-BACK. TM. FP5, EXPRESS. TM.5, EXPRESS. TM. FP5, BREED-BACK. TM. FP-HS, EXPRESS. TM.5-HS, EXPRESS. TM. FP5-HS, BREED-BACK. TM. FP10, EXPRESS. TM.10, BREEDBACK. TM. FP10-HS, EXPRESS. TM. FP10-HS, EXPRESS 10-HS, and combinations thereof, for use to prevent, in a pregnant cow, (a) the incidence of one or more clinical signs of an infection caused by a microbe wherein the microbe is selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof, or (b) abortion in the pregnant cow.
19. Use of a vaccine composition for preventing, in a pregnant cow, (a) the incidence of one or more clinical signs of an infection caused by a microbe wherein the microbe is selected from the group consisting of Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea Virus (BVDV) Type 1, BVDV Type 2, and any combination thereof, or (b) abortion in the pregnant cow, wherein the vaccine composition comprises a therapeutically effective amount of a modified live Infectious Bovine Rhinotracheitis (IBR) virus, a modified live Bovine Viral Diarrhea Virus (BVDV) Type 1 of a Singer strain, a modified live BVDV Type 2 of Strain 296, and a bacterin that is Haemophilus somnus bacterin.";"(CA2648602)
VACCINE(100,108)
HEIFER(100,74)
PREGNANT COW(100,27)
INFECTION(100,22)
CLINICAL SIGN(100,11)
MICROBE(100,9)
INCIDENCE(100,7)
HAEMOPHILUS SOMNUS BACTERIN(64,4)
PREGNANT HEIFER(51,4)
LEPTOSPIRA BACTERIA(44,9)
VACCINATING PREGNANT COW(43,1)
PREGNANT COW FETUS(42,2)
HEMO LYTIC ANEMIA(39,1)
LEPTOSPIRA GRIPPOTYPHOSA(37,9)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(36,6)
LEPTOSPIRA CANICOLA(35,8)
ATTENUATED MICROORGANISM(34,5)
BOVINE VIRAL DIARRHEA VIRUS ATTENUATION(34,2)
LEPTOSPIRA HARDJO INFECTION(34,2)
SUBCLINICAL INFECTION SIGN(31,2)
MICROBIOLOGICAL INFECTION TREATMENT(31,1)
PREGNANT COW PROPHYLAXIS(29,1)
SINGER STRAIN(27,10)
EXPRESS(27,6)
INFECTION PROPHYLAXIS(26,6)
PREGNANCY TRIMESTER(25,5)
BOVINE VIRAL DIARRHEA VIRUS(23,135)
CLINICAL SIGN HEIFER(23,1)
VIRUS NEUTRALIZING(23,1)
ANTIBODY REACTION NEUTRALIZATION(22,1)
BVDV CAUSED INFECTION TREATMENT(21,1)
LATENT BHV(21,1)
EMBRYONIC SWINE KIDNEY CELL(20,2)
PROPHYLAXIS(19,3)
SUSCEPTIBLE ANIMAL(19,1)
INFECTION SYMPTOM(17,1)
ABORTION(15,14)
PREGNANT COW HEIFER VACCINATION(15,6)
BOVINE TURBINATE CELL(15,2)
BVDV(15,2)
KILLEDMICROORGANISM(15,2)
MAJOR ANTIGEN(15,1)
BOVINE TESTICULAR CELL(14,3)
ANTIGENIC DIVERSITY(14,1)
BREEDBACK(14,1)
BACTERIN(13,8)
INFECTIOUS BOVINE RHINOTRACHEITIS(12,81)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHAEMORRHAGIAE POMONA BACTERIN(11,2)
INFECTION SOURCE(11,1)
STRAIN(10,23)
CALVING OUTCOME(10,10)
INFECTIOUS BOVINE RHINOTRACHEITIS COLORADO(10,4)
CALF NURSING PREGNANT CATTLE(10,2)
GLYCOPROTEIN(10,2)
GENOMIC SEQUENCE LEVEL(10,1)
CATTLE(9,19)
DEAD CALF(9,16)
VIRUS(8,13)
STUDY OUTCOME(8,8)
MDBK CELL(8,6)
ENROLLED CATTLE(8,5)
POSTPARTUM CALF DEATH(8,3)
LEPTOSPIRA POMONA INFECTION(8,2)
RHINOTRACHEITIS BOVINE VIRAL DIARRHEA PARAINFLUENZA(8,2)
ANIMAL HEALTH FIELD(8,1)
ENZOOTIC LEPTOSPIRA HARDJO INFECTION(8,1)
SIGNIFICANT DIFFERENCE(8,1)
TRIMESTER ENROLLMENT VACCINATION EAR(8,1)
STILLBORN CALF(7,5)
PREGNANCY STATUS VERIFICATION(7,3)
POSTMORTEM REPORT ADDENDUM(7,2)
TRIMESTER ENROLLED ANIMAL(7,2)
IMMUNOLOGICALLY DISTINCT LEPTOSPIRAL SEROVAR(7,1)
DISEASE(6,8)
NEBRASKA SITE(6,6)
EAR(6,4)
WEEK POSTPARTUM(6,4)
BOOSTER VACCINATION(6,3)
NEBRASKA HERD(6,3)
CATTLE RELEVANT PATHOGEN(6,2)
TRIMESTER HEIFER(6,2)
TRIMESTER POSTPARTUM TREATMENT(6,2)
INFECTIOUS PUSTULAR BALANOPOSTHITIS(6,1)
PERSISTENTLY INFECTED CALF INDUCTION(6,1)
PREGNANT COW HEIFER PROPHYLAXIS(6,1)
RHINOTRACHEITIS VIRAL DIARRHEA PARAINFLUENZA(6,1)
TRIMESTER CALVIN OUTCOME(6,1)
TRIMESTER PREGNANT COW(6,1)
VACCINATED COW PREGNANCY(6,1)
VACCINATED PREGNANT COW HEIFER(6,1)
SINGER(5,8)
TRIMESTER GROUP(5,8)
LIVE INFECTIOUS BOVINE RHINOTRACHEITIS(5,7)
MODIFIED LIVE VIRUS(5,7)
PRE BREEDING VACCINATION(5,6)
REPRESENTATIVE VACCINE(5,5)
CALVING DIFFICULTY(5,3)
COW CALF RANCH(5,3)
ENROLLED CALF(5,3)
ENROLLMENT CRITERIA(5,3)
HEALTH LABORATORY ANIMAL(5,3)
MEAN GESTATION DAY(5,3)
PERCENT CALF DEATH(5,3)
POSTPARTUM DEATH(5,3)
VACCINE ADMINISTRATION(5,3)
VACCINE COMPOSITION ADMINISTRATION(5,3)
WORKING COW CALF HERD(5,3)
BENCHMARK BIOLAB(5,2)
CALVING BLOOD SAMPLING(5,2)
LIVE ATTENUATED STRAIN(5,2)
POST CALVING DEATH(5,2)
SAMPLING SPREADSHEET RECORD(5,2)
SERUM NEUTRALIZATION ASSAY(5,2)
TRIMESTER HERD(5,2)
UNVACCINATED COW HEIFER(5,2)
VACCINATION ENROLLMENT(5,2)
ATTENUATED VIRUS VACCINE(5,1)
CALF POSTNATAL HEALTH(5,1)
CONCURRENT BACTERIAL BRONCHOPNEUMONIA(5,1)
ENDEMICALLY INFECTED HERD(5,1)
ENROLLMENT TRIMESTER PREGNANCY CHECK(5,1)
FORT MACLEOD VETERINARY CLINIC(5,1)
FP H(5,1)
GUARDIAN SCOUR VACCINE(5,1)
HEMO LYTIC CRISIS(5,1)
INFECTION HISTOPATHOLOGICAL SIGN(5,1)
MAMMARY INFLAMMATION EVIDENCE(5,1)
MICROBIAL INFECTION DIVERSITY(5,1)
NAIVE PREGNANT CATTLE(5,1)
NEBRASKA VETERINARY DIAGNOSTIC LABORATORY(5,1)
ONTARIO VETERINARY COLLEGE(5,1)
PREGNANT COW VACCINATION(5,1)
RAYMOND COW RANDOMIZATION(5,1)
SCOUR MILD OUTBREAK(5,1)
SUBCLINICALLY INFECTED BULL(5,1)
YEAR CALVING SEASON(5,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(4,21)
POSTMORTEM EXAMINATION(4,9)
EAR NOTCH(4,4)
IMMUNOGENIC(4,4)
LIVE CALF(4,4)
ANTIBODY TITER(4,3)
BOVINE VIRAL DIARRHEA VIRUS LIFE(4,3)
LACRIMAL DISCHARGE(4,3)
TEST ANTIBODY(4,3)
ABORTION STORM(4,2)
ADULT HEIFER(4,2)
ALBERTA TRIAL(4,2)
ANTIGENIC SUBTYPE(4,2)
BACTERIA CULTURE(4,2)
BREED BACKTM(4,2)
BREEDING HERD(4,2)
CALF 28Y(4,2)
CALF 940Y(4,2)
CATEGORY FETAL LOSS(4,2)
CATTLE POPULATION(4,2)
COLOSTRUM ADMINISTRATION(4,2)
COLOSTRUM FORCED FEEDING(4,2)
COMBINATION VACCINE(4,2)
DEATH LOSS CLARIFICATION(4,2)
DISEASE SEVERITY(4,2)
ENROLLED COW(4,2)
FLAVIVIRIDAE FAMILY(4,2)
GENITAL INFECTION(4,2)
GESTATION WINDOW(4,2)
HEALTHY BREEDING(4,2)
HERD REMAINDER(4,2)
INVESTIGATION SITE(4,2)
MICROBIOLOGICAL INFECTION(4,2)
NEBRASKA TRIAL(4,2)
PARAMYXOVIRUS FAMILY(4,2)
PLACEBO VACCINE(4,2)
POSTPARTUM OBSERVATION(4,2)
PRE COLOSTRAL SEROLOGICAL STATUS(4,2)
PRE COLOSTRAL SERUM SAMPLING(4,2)
SAFE(4,2)
STUDY WRITTEN RECORD(4,2)
TISSUE COMPLIANCE(4,2)
VACCINATED CATTLE(4,2)
VIRUS PATHOGEN(4,2)
WINTER MONTH(4,2)
ABSORBED COLOSTRAL ANTIBODY(4,1)
ALKENE THEOLIGOMERIZATION(4,1)
ALVEOLAR EPITHELIALIZATION(4,1)
ASSIGNED TRIMESTER VACCINATION(4,1)
BRONCHIOLAR EPITHELIUM DEGENERATION(4,1)
CALF ENROLLMENT TESTING(4,1)
CLOPPER PEARSON CONFIDENCE INTERVAL(4,1)
DAILY HERD OBSERVATION(4,1)
DAM INFLICTED INJURY(4,1)
ENROLLMENT PREGNANCY CHECK VACCINATION(4,1)
ENROLLMENT VACCINATION DAY(4,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(4,1)
HERD ROUTINE MANAGEMENT(4,1)
HOG CHOLERA VIRUS(4,1)
INACTIVATED ROTAVIRUS CORONAVIRUS(4,1)
MATURE COW(4,1)
PERSISTENT FETAL INFECTION(4,1)
POSTPARTUM CALF HEALTH(4,1)
PREGNANT ANIMAL PLACENTA(4,1)
PREGNANT COW HEALTH(4,1)
PURULENT BRONCHOPNEUMONIA(4,1)
RAYMOND FINNEY HEIFER(4,1)
SEROVAR LEPTOSPIRA(4,1)
SERUM NEUTRALIZING ANTIBODY STATUS(4,1)
SERUM NEUTRALIZING TITER(4,1)
STERILE ADJUVANTED DILUENT(4,1)
TRIMESTER NOSTNARTUM TREATMENT(4,1)
VAGINAL PROLAPSE SURGICAL REPAIR(4,1)
IMMUNOLOGICAL ACTIVE COMPONENT(3,16)
SUBGROUP(3,6)
EAR CHANGE(3,5)
PYREXIA(3,5)
TRIAL DESIGN(3,5)
INFECTIOUS BOVINE RHINOTRACHEITIS DETECTION(3,3)
SECONDARY BACTERIAL INFECTION(3,3)
VACCINE PRODUCTION ASSIGNMENT(3,3)
ADMINISTRATION SAFETY(3,2)
ADMINISTRATION TIMING(3,2)
CALF HEALTH STATUS(3,2)
ENROLLED PERCENT(3,2)
EXPOSURE EVIDENCE(3,2)
HEALTH ISSUE(3,2)
PROTOCOL DEVIATION(3,2)
SERUM NEUTRALIZING ANTIBODY LEVEL(3,2)
STUDY OBJECTIVE(3,2)
WEAK CALF(3,2)
YOUNG ANIMAL(3,2)
ALBERTA CANADA TREATMENT(3,1)
ALBERTA HERD(3,1)
ANHYDROMANNITOL OLEATE(3,1)
ATYPICAL INTERSTITIAL PNEUMONIA(3,1)
BACTERIAL ENTERITIS(3,1)
BACTERIAL PNEUMONIA ONSET(3,1)
BHV SUBTYPE(3,1)
BOOSTER VACCINE(3,1)
BOVINE EMBRYO KIDNEY CELL(3,1)
CALENDAR DAILY RECORD(3,1)
CALF BIRTH(3,1)
CALF HEIFER(3,1)
CALVING RECORD BOOK(3,1)
CLINICAL MANIFESTATION(3,1)
CLINICAL SIGN ONSET(3,1)
CLOSTRIDIAL BACTERIN(3,1)
CLOSTRIDIAL VACCINE(3,1)
CORN STOCK PASTURE(3,1)
CRANIOVENTRAL LUNG CONSOLIDATION(3,1)
DAILY ACTIVITY CALENDAR LOG(3,1)
DIED WITHJIN(3,1)
DIFFUSE INTERSTITIAL PNEUMONIA(3,1)
DIPHTHERITIC PLAQUE(3,1)
DYSTOCIA DIAGNOSIS(3,1)
ECCHYMOTIC HEMORRHAGE(3,1)
EMBRYONIC DEATH(3,1)
ENDONUCLEASE CLEAVAGE BASIS(3,1)
ENROLLED HEIFER(3,1)
ESOPHAGEAL ABSCESS(3,1)
FENITROTHION STUDIO(3,1)
FREQUENT URINATION(3,1)
GALENICA PHARMACEUTICAL(3,1)
GENERALIZED BHV(3,1)
HAEMOPHILUS SOMNUS(3,1)
HERD OWNER(3,1)
HISTOLOGIC EXAMINATION(3,1)
IBRV VIRUS ISOLATION(3,1)
INFECTED COW(3,1)
INFERTILITY HISTORY(3,1)
INFLAMED NARIS(3,1)
INTERSTITIAL EDEMA(3,1)
INVESTIGATOR REPORT(3,1)
LEPTO BACTERIN(3,1)
LIPID AMINE ADJUVANT(3,1)
LUNG PARENCHYMA(3,1)
MATERNAL ANTIBODY(3,1)
MICROBIOLOGICAL CONTAMINATION(3,1)
MICROBIOLOGICAL GROWTH INHIBITION(3,1)
NASOPHARYNX NORMAL INHABITANT(3,1)
NECROPSIED FETUS(3,1)
NECROPSY SEROLOGY(3,1)
NECROTIC LESION(3,1)
NONIONIC SURFACTANT(3,1)
NOTATION CLARIFICATION(3,1)
NOVARTIS ANIMAL HEALTH(3,1)
PASSIVELY DERIVED IMMUNITY(3,1)
PASTURE ASSIGNMENT(3,1)
PESTIVIRUS GENUS(3,1)
PHARMACEUTICAL COMPOSTION(3,1)
POLYNUCLEOTIDE VACCINATION(3,1)
POSTMORTEM SAMPLE LABORATORY EXAMINATION(3,1)
PREDOMINANT CLINICAL PARAMETER(3,1)
PREGNANCY CONFIRMATION(3,1)
PREGNANCY MONTH(3,1)
PREGNANCY VERIFICATION(3,1)
PREVALENT LEPTOSPIRA(3,1)
RAIN STORM(3,1)
RAW DATA FILE(3,1)
RAYMOND FINNEY HERD(3,1)
RAYMOND FINNEY RANCH(3,1)
RAYMOND HEIFER(3,1)
RAYMOND HERD(3,1)
RAYMOND RANCH(3,1)
REPLICATION COMPENTENT(3,1)
REPRODUCTIVE ORGAN(3,1)
SEROFIBRINOUS EXUDATE(3,1)
STUDY PROTOCOL APPENDIX(3,1)
SUBMUCOSAL HEMORRHAGE(3,1)
SUGAR POLYALKENYL(3,1)
TISSUE CULTURE INFECTIVE(3,1)
TL VACCINATION(3,1)
TRANSIENT INFERTILITY(3,1)
TRIMESTER ASSIGNMENT(3,1)
TRIMESTER COW(3,1)
UNDIAGNOSED CALF LOSS(3,1)
UNSATURATED ALIPHATIC RADICAL(3,1)
UTERUS INFLAMMATION(3,1)
VACCINATED DAM(3,1)
VSM GUIDELINE(3,1)
WILLIAMS HERD(3,1)
WILLIAMS RANCH(3,1)
ARTIFICIAL INSEMINATION(2,4)
HEMOGLOBINURIA(2,4)
ICTERUS(2,4)
IMMUNE RESPONSE(2,4)
LIVER(2,4)
SIGNIFICANT INCREASE(2,4)
CONJUNCTIVITIS(2,3)
DECISION(2,3)
DYSPNEA(2,3)
EXPRESSTM(2,3)
LIFE DAY(2,3)
PREGNANCY OUTCOME(2,3)
PRESERVATIVE(2,3)
PRODUCER(2,3)
SEMEN(2,3)
TRACHEA(2,3)
TRIMESTER ENROLLMENT VACCINATION TIME(2,3)
ACRYLIC POLYMER(2,2)
ANIMAL SELECTION(2,2)
ANOREXIA(2,2)
ANTIBIOTIC(2,2)
ANTIMICROBIOLOGICAL ACTIVE AGENT(2,2)
BLIZZARD(2,2)
BLOOD COLLECTION(2,2)
CALVING DEATH RATE(2,2)
CALVING OUTCOME RESULT(2,2)
DAIRY CATTLE(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
EROSION(2,2)
ESK CELL(2,2)
EXCEPTION(2,2)
FULL NECROPSY(2,2)
GRASS(2,2)
GROUP ASSIGNMENT(2,2)
HERD TRIMESTER(2,2)
INFECTIOUS PUSTULAR VULVOVAGINITIS(2,2)
INVESTIGATOR OBSERVATION COMBINATION(2,2)
ISOTONIC AGENT(2,2)
LABORATORY TEST(2,2)
LAMENESS(2,2)
LARYNX(2,2)
LEPTOSPIROSIS(2,2)
LETHALITY(2,2)
ML CULTURE(2,2)
MODIFIED INFECTIOUS BOVINE RHINOTRACHEITIS(2,2)
MORBIDITY(2,2)
NEGATIVE ANTIBODY(2,2)
NEOMYCIN(2,2)
NUMERIC SCALE(2,2)
PAIRED SAMPLE(2,2)
PERCENT CALF TREATMENT(2,2)
PERCENT FETAL LOSS(2,2)
PROTECTANT(2,2)
PURIFICATION(2,2)
RECTAL PALPATION(2,2)
RESPIRATORY RATE(2,2)
RETEST(2,2)
SAMPLE TOXICITY CONTAMINATION(2,2)
SERONEGATIVE(2,2)
SITE PRACTICE(2,2)
STABILIZER(2,2)
STILLBIRTH(2,2)
STUDY START(2,2)
SUSPECT(2,2)
SYMPTOM(2,2)
TISSUE SAMPLE(2,2)
VIRUS DETECTION(2,2)
WAY LEPTOSPIRA BACTERIN(2,2)
WEATHER RELATED DEATH(2,2)
ABNORMAL MILK(2,1)
ABORTING FRACTION(2,1)
ACUTE INFECTION(2,1)
ADJUVANT INSTANCE(2,1)
ADRD LABORATORY(2,1)
ADSORPTION DELAYING(2,1)
ADULT CATTLE(2,1)
ADULT SERUM SAMPLE(2,1)
AEROBIC CULTURE(2,1)
AINSWORTH JOHNSTOWN NEBRASKA AREA(2,1)
ALKENYL DERIVATIVE(2,1)
ANIMAL CONTAGIOUS DISEASE(2,1)
ANIMAL IDENTIFICATION(2,1)
ANIMAL MANAGEMENT(2,1)
ANIMAL NEED(2,1)
ANIMAL PARITY(2,1)
ANTIBODY NEUTRALIZATION(2,1)
ANTIGENIC SUBSTANCE(2,1)
ATTENUATED PARTICLE(2,1)
BACTERIAL PNEUMONIA ABSENCE(2,1)
BIOCHEMICAL TEST(2,1)
BIRTH DATE(2,1)
BIVI FETAL PROTECTION PRODUCT(2,1)
BORN CALF LOSS(2,1)
BOVINE HERPES VIRUS(2,1)
BOVINE PATHOGEN(2,1)
BOVINE VIRAL DIARRHEA ABORTION(2,1)
BOVINE VIRAL DIARRHEA ENROLLMENT(2,1)
BOVINE VIRAL DIARRHEA SEROLOGY(2,1)
BREEDING CATTLE(2,1)
CALF(2,1)
CALF 16Y(2,1)
CALF 51Y(2,1)
CALF 53R(2,1)
CALF FINAL OBSERVATION(2,1)
CALF LOSS DIAGNOSIS(2,1)
CALF SEX(2,1)
CALF TESTING(2,1)
CALF TISSUE(2,1)
CALVING EAR(2,1)
CALVING EVENT(2,1)
CALVING LOSS ABORTION(2,1)
CAMBRIDGE MA(2,1)
CHEMICALLY MODIFIED VIRUS(2,1)
CHOLERA TOXIN(2,1)
CLINICAL DISEASE(2,1)
CLOTTED BLOOD TUBE(2,1)
COIN TOSS(2,1)
COMPLETEDBETWEEN DAY(2,1)
COW KICK(2,1)
COW MAJORITY(2,1)
CULTURE GROWTH(2,1)
DAILY CALENDAR(2,1)
DAM IDENTIFICATION(2,1)
DECREASING SERUM ASSAY(2,1)
DIAGNOSTIC TESTING(2,1)
DUPLICATE EAR(2,1)
EFFICACY TRIAL(2,1)
ELEVATED FEVER(2,1)
EMERYVILLE CA(2,1)
ENROLLMENT ADJUSTMENT(2,1)
ETHYLENICALLY UNSATURATED GROUP(2,1)
EXTENSIVE PLEURITIS(2,1)
FEED LOT CATTLE(2,1)
FEMALE BOVINE(2,1)
FETAL LOSS VISUAL SIGN(2,1)
FETAL SHIPMENT(2,1)
FETAL TISSUE RECOVERY(2,1)
FETUS LOSS(2,1)
FINAL CALF SAMPLING(2,1)
FOLD DILUTION(2,1)
FREQUENT OCCURRENCE(2,1)
GENERALIZED DISEASE(2,1)
GENERALIZED VIRAL INFECTION(2,1)
GROSS LESION(2,1)
HERD BOOK(2,1)
HERD MANAGEMENT(2,1)
HOME PASTURE(2,1)
HYALINE MEMBRANE FORMATION(2,1)
ID DISCREPANCY(2,1)
IMMUNITY DURATION(2,1)
IMMUNOHISTOCHEMISTRY TESTING(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
INFECTED ANIMAL(2,1)
INFECTION SEVERITY(2,1)
INFECTIOUS BOVINE RHINOTRACHEITIS HISTORY(2,1)
INFECTIOUS BOVINE RHINOTRACHEITIS INFECTION(2,1)
INVESTIGATOR DID(2,1)
LABELED SAFETY PRECAUTION REGARDING(2,1)
LATE DISEASE STAGE(2,1)
LEPTOSPIRA FLUORESCENT ANTIBODY(2,1)
LIKELY SIRE(2,1)
LIMITED CROSS(2,1)
LIVE ANIMAL(2,1)
LIVING ORGANISM(2,1)
MALEIC ANHYDRIDE COPOLYMER(2,1)
MARKED CONGESTION(2,1)
MICROORGANISM FRACTION(2,1)
MILD INITIAL SIGN(2,1)
MINERAL SUPPLEMENT(2,1)
MISSING IDENTIFICATION(2,1)
MK 270A(2,1)
MULTIDOSE COMPOSITION PREPARATION(2,1)
MYCOLOGY CULTURE(2,1)
NAKED EYE(2,1)
NASAL CAVITY MUCOUS MEMBRANE(2,1)
NEBRASKA TREATMENT(2,1)
NECROPSY FLUID SAMPLE(2,1)
NURSING CALF(2,1)
OLD CATTLE(2,1)
ORGAN INFECTION(2,1)
OUTCOME RECORD(2,1)
PAIRED SERUM(2,1)
PERMECTRIN CD(2,1)
PERSISTENT INFECTION(2,1)
PLASTIC EAR(2,1)
POLYHYDROXYLATED COMPOUND(2,1)
POLYMER DISSOLUTION(2,1)
POST CALVING LOSS(2,1)
POSTPARTUM ILLNESS RATE(2,1)
PREGNANCY HALF(2,1)
PRELIMINARY EVIDENCE(2,1)
PURULENT VAGINAL DISCHARGE(2,1)
RANCH COW(2,1)
RANCHER FAILURE(2,1)
RANDOMIZATION SOFTWARE(2,1)
RESPIRATORY SIGN(2,1)
RURAL TECHNOLOGY(2,1)
SAMPLE VALIDITY(2,1)
SAN DIEGO(2,1)
SDSU LABORATORY(2,1)
SECONDARY BACTERIAL PNEUMONIA DEVELOPMENT(2,1)
SEPTICEMIC DISEASE(2,1)
SEROUS NASAL(2,1)
SERUM ALIQUOT(2,1)
SERUM ANTIBODY(2,1)
SERUM COLLECTION(2,1)
SERUM SAMPLE INTEGRITY(2,1)
SERUM SAMPLE TOXICITY(2,1)
SEVERE DEPRESSION(2,1)
SEVERE RESPIRATORY DISEASE(2,1)
SIGN SEVERITY(2,1)
SITE VETERINARIAN(2,1)
SORBITAN ESTER(2,1)
SOUTH CENTRAL ALBERTA(2,1)
SPT EMULSION(2,1)
STUDY RECORD(2,1)
SYNCYTIAL CELL FORMATION(2,1)
TAILHEAD ELEVATION(2,1)
TEST VACCINE SERIAL(2,1)
TI COW(2,1)
TI VACCINATION(2,1)
UNCOMPLICATED PERSISTENTLY INFECTED(2,1)
UNSATURATED RADICAL(2,1)
UTERO EXPOSURE(2,1)
VACCINATION SAFETY(2,1)
VACCINATION TREATMENT(2,1)
VALIDITY QUESTION(2,1)
VIRAL LESION(2,1)
VIRION MOLECULAR(2,1)
VIRUS ISOLATION PERFORMANCE(2,1)
VISIBLE LESION ABSENCE(2,1)
YOUNG BEEF(2,1)
YOUNG CALF(2,1)
ML CELL CULTURE FLUID(1,4)
ANEMIA(1,3)
APHIS PRODUCT CODE(1,3)
COMBINED GROUP(1,3)
ESTIMATED RANGE(1,3)
NASAL DISCHARGE(1,3)
PLACEBO CONTROL(1,3)
RANDOMIZATION(1,3)
WAY VACCINE(1,3)
GLYCEROL(1,2)
ROUTE(1,2)
ABORTED FETUS(1,1)
ADJUVANT SOLUTION(1,1)
ADMISSION(1,1)
AGE DAY(1,1)
AIRWAY(1,1)
ALVEOLITIS(1,1)
ANGUS CROSS BEEF CATTLE(1,1)
ANTEDATE(1,1)
ANTIBACTERIAL(1,1)
ANTIBODY TRANSFER(1,1)
ANTIGENICALLY RELATED ORGANISM(1,1)
ANTIPARASITIC(1,1)
ANTISENSE(1,1)
ASEPTIC(1,1)
ASPERGILLUS(1,1)
ATAXIA(1,1)
AUTOMATIC ANALYZER(1,1)
AVRIDINE(1,1)
BASELINE BLOOD SAMPLE(1,1)
BHV SINGLE SEROTYPE(1,1)
BIPHASIC DISEASE PATTERN(1,1)
BISHOP(1,1)
BLINDNESS(1,1)
BLOOD SAMPLE PAIR(1,1)
BOVINE SERUM ALBUMIN(1,1)
BOVINE VIRAL DIARRHEA PRESENCE(1,1)
BROKEN LIMB(1,1)
CALF ID(1,1)
CALF PRODUCTION(1,1)
CALVING LOSS REMOVAL(1,1)
CELL CULTURE SUPERNATANT(1,1)
CLOTTED BLOOD CELL(1,1)
COMBINATION VIRUS VACCINE(1,1)
COW GROUP(1,1)
COW REMOVAL(1,1)
DEATH RATE ESTIMATE(1,1)
DECREASED FEED INTAKE(1,1)
ENCEPHALOMYELITIS(1,1)
FED COLOSTRUM(1,1)
FETAL SAMPLE(1,1)
GAMMA GLUTAMYL TRANSPEPTIDASE ELEVATION(1,1)
HEAT LABILE ENTEROTOXIN(1,1)
HEIFER REMOVAL(1,1)
HISTOLOGICAL(1,1)
HUNDRED SEVEN(1,1)
HYDROGEN ATOM(1,1)
HYDROPERITONEUM(1,1)
IMMUNOLOGICAL RESPONSE(1,1)
INCREASED BREATH SOUND(1,1)
INFECTED CELL CULTURE(1,1)
INFECTIOUS BOVINE RHINOTRACHEITIS EXPOSURE(1,1)
INFECTIOUS BOVINE RHINOTRACHEITIS STRAIN(1,1)
LOWERED MILK(1,1)
LUNG RESULT SOMNUS INFECTION(1,1)
MILD VAGINAL DISCHARGE(1,1)
MINIMUM GESTATION(1,1)
MODIFIED LIVE BOVINE VIRAL DIARRHEA VIRUS(1,1)
MODIFIED LIVE VACCINE COMPONENT(1,1)
MURAMYL DIPEPTIDE(1,1)
NONAQUEOUS SOLUTION(1,1)
NORTH CENTRAL NEBRASKA(1,1)
OCCURRENCE FREQUENCY(1,1)
OCTANOATE DECANOATE(1,1)
ORGANISM IMMUNOLOGICAL FUNCTION(1,1)
OVINE CELL(1,1)
PARANASAL SINUS(1,1)
PENTEK(1,1)
PERFORMED VIRUS ISOLATION(1,1)
PHYSIOLOGICAL PH(1,1)
PLEURAL FLUID SAMPLE TOXICITY(1,1)
POLYOXYETHYLENE COPOLYMER BLOCK(1,1)
PORCINE CELL(1,1)
POTENTIAL FETAL LOSS(1,1)
PRE COLOSTRAL SAMPLE STATUS(1,1)
PRE COLOSTRAL SERUM SAMPLE(1,1)
PRODUCTION RANCH(1,1)
RECENT HISTORY(1,1)
RED DOT(1,1)
RED NOSE(1,1)
RESEARCH ANIMAL DISEASE(1,1)
ROTATION SCHEDULE(1,1)
SALIVATION(1,1)
SAMPLE SHIPMENT(1,1)
SECONDARY BACTERIAL PNEUMONIA PRESENCE(1,1)
SERUM SEPARATION(1,1)
SHELF LIFE(1,1)
SOUTH DAKOTA STATE UNIVERSITY(1,1)
SQUALENE OIL(1,1)
TREATMENT ASSIGNMENT(1,1)
TRIAL SITE(1,1)
UNDIAGNOSED PREGNANCY LOSS RATE(1,1)
VACCINATION GROUP(1,1)
VALID PRE COLOSTRAL SAMPLE(1,1)
VIRAL AGENT(1,1)
VIRUS PARTICLE(1,1)
WHITE FOCI(1,1)
(CA2648602)
VACCINE(100,108)
HEIFER(100,74)
PREGNANT COW(100,27)
INFECTION(100,22)
CLINICAL SIGN(100,11)
MICROBE(100,9)
INCIDENCE(100,7)
HAEMOPHILUS SOMNUS BACTERIN(66,4)
PREGNANT HEIFER(52,4)
LEPTOSPIRA BACTERIA(45,9)
VACCINATING PREGNANT COW(44,1)
PREGNANT COW FETUS(43,2)
HEMO LYTIC ANEMIA(40,1)
LEPTOSPIRA GRIPPOTYPHOSA(38,9)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(37,6)
LEPTOSPIRA CANICOLA(36,8)
ATTENUATED MICROORGANISM(35,5)
LEPTOSPIRA HARDJO INFECTION(35,2)
SINGER STRAIN(34,10)
PREGNANT COW HEIFER VACCINATION(33,6)
SUBCLINICAL INFECTION SIGN(31,2)
PREGNANT COW PROPHYLAXIS(29,1)
EXPRESS(28,6)
INFECTION PROPHYLAXIS(27,6)
BOVINE VIRAL DIARRHEA VIRUS ATTENUATION(27,2)
PREGNANCY TRIMESTER(26,5)
BOVINE VIRAL DIARRHEA VIRUS(24,135)
CLINICAL SIGN HEIFER(23,1)
VIRUS NEUTRALIZING(23,1)
ANTIBODY REACTION NEUTRALIZATION(22,1)
LATENT BHV(21,1)
EMBRYONIC SWINE KIDNEY CELL(20,2)
PREGNANT COW HEIFER(19,7)
INFECTIOUS BOVINE RHINOTRACHEITIS COLORADO(19,4)
SUSCEPTIBLE ANIMAL(19,1)
MICROBIOLOGICAL INFECTION TREATMENT(18,1)
INFECTION SYMPTOM(17,1)
ABORTION(15,14)
BOVINE TURBINATE CELL(15,2)
KILLEDMICROORGANISM(15,2)
MAJOR ANTIGEN(15,1)
STRAIN(14,23)
BACTERIN(14,8)
BOVINE TESTICULAR CELL(14,3)
ANTIGENIC DIVERSITY(14,1)
BREEDBACK(14,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(13,81)
BVDV(12,2)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHAEMORRHAGIAE POMONA BACTERIN(12,2)
BVDV CAUSED INFECTION TREATMENT(12,1)
CALVING OUTCOME(11,10)
INFECTION SOURCE(11,1)
CALF NURSING PREGNANT CATTLE(10,2)
GLYCOPROTEIN(10,2)
GENOMIC SEQUENCE LEVEL(10,1)
DEAD CALF(9,16)
CATTLE(8,19)
VIRUS(8,13)
STUDY OUTCOME(8,8)
MDBK CELL(8,6)
ENROLLED CATTLE(8,5)
POSTPARTUM CALF DEATH(8,3)
LEPTOSPIRA POMONA INFECTION(8,2)
RHINOTRACHEITIS BOVINE VIRAL DIARRHEA PARAINFLUENZA(8,2)
ANIMAL HEALTH FIELD(8,1)
ENZOOTIC LEPTOSPIRA HARDJO INFECTION(8,1)
SIGNIFICANT DIFFERENCE(8,1)
TRIMESTER ENROLLMENT VACCINATION EAR(8,1)
STILLBORN CALF(7,5)
PREGNANCY STATUS VERIFICATION(7,3)
POSTMORTEM REPORT ADDENDUM(7,2)
TRIMESTER ENROLLED ANIMAL(7,2)
IMMUNOLOGICALLY DISTINCT LEPTOSPIRAL SEROVAR(7,1)
DISEASE(6,8)
NEBRASKA SITE(6,6)
PRE BREEDING VACCINATION(6,6)
EAR(6,4)
WEEK POSTPARTUM(6,4)
BOOSTER VACCINATION(6,3)
COW CALF RANCH(6,3)
ENROLLED CALF(6,3)
ENROLLMENT CRITERIA(6,3)
HEALTH LABORATORY ANIMAL(6,3)
NEBRASKA HERD(6,3)
POSTPARTUM DEATH(6,3)
WORKING COW CALF HERD(6,3)
CATTLE RELEVANT PATHOGEN(6,2)
TRIMESTER HEIFER(6,2)
TRIMESTER POSTPARTUM TREATMENT(6,2)
INFECTIOUS PUSTULAR BALANOPOSTHITIS(6,1)
PERSISTENTLY INFECTED CALF INDUCTION(6,1)
PREGNANT COW HEIFER PROPHYLAXIS(6,1)
RHINOTRACHEITIS VIRAL DIARRHEA PARAINFLUENZA(6,1)
TRIMESTER CALVIN OUTCOME(6,1)
TRIMESTER PREGNANT COW(6,1)
VACCINATED COW PREGNANCY(6,1)
VACCINATED PREGNANT COW HEIFER(6,1)
SINGER(5,8)
TRIMESTER GROUP(5,8)
LIVE INFECTIOUS BOVINE RHINOTRACHEITIS(5,7)
MODIFIED LIVE VIRUS(5,7)
REPRESENTATIVE VACCINE(5,5)
CALVING DIFFICULTY(5,3)
MEAN GESTATION DAY(5,3)
PERCENT CALF DEATH(5,3)
VACCINE ADMINISTRATION(5,3)
VACCINE COMPOSITION ADMINISTRATION(5,3)
BENCHMARK BIOLAB(5,2)
CALVING BLOOD SAMPLING(5,2)
LIVE ATTENUATED STRAIN(5,2)
POST CALVING DEATH(5,2)
SAMPLING SPREADSHEET RECORD(5,2)
SERUM NEUTRALIZATION ASSAY(5,2)
TRIMESTER HERD(5,2)
UNVACCINATED COW HEIFER(5,2)
VACCINATION ENROLLMENT(5,2)
ATTENUATED VIRUS VACCINE(5,1)
CALF POSTNATAL HEALTH(5,1)
CONCURRENT BACTERIAL BRONCHOPNEUMONIA(5,1)
ENDEMICALLY INFECTED HERD(5,1)
ENROLLMENT TRIMESTER PREGNANCY CHECK(5,1)
FORT MACLEOD VETERINARY CLINIC(5,1)
FP H(5,1)
GUARDIAN SCOUR VACCINE(5,1)
HEMO LYTIC CRISIS(5,1)
INFECTION HISTOPATHOLOGICAL SIGN(5,1)
MAMMARY INFLAMMATION EVIDENCE(5,1)
MICROBIAL INFECTION DIVERSITY(5,1)
NAIVE PREGNANT CATTLE(5,1)
NEBRASKA VETERINARY DIAGNOSTIC LABORATORY(5,1)
ONTARIO VETERINARY COLLEGE(5,1)
PREGNANT COW VACCINATION(5,1)
RAYMOND COW RANDOMIZATION(5,1)
SCOUR MILD OUTBREAK(5,1)
SUBCLINICALLY INFECTED BULL(5,1)
YEAR CALVING SEASON(5,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(4,21)
POSTMORTEM EXAMINATION(4,9)
EAR NOTCH(4,4)
IMMUNOGENIC(4,4)
LIVE CALF(4,4)
ANTIBODY TITER(4,3)
BOVINE VIRAL DIARRHEA VIRUS LIFE(4,3)
LACRIMAL DISCHARGE(4,3)
TEST ANTIBODY(4,3)
ABORTION STORM(4,2)
ADULT HEIFER(4,2)
ALBERTA TRIAL(4,2)
ANTIGENIC SUBTYPE(4,2)
BACTERIA CULTURE(4,2)
BREED BACKTM(4,2)
BREEDING HERD(4,2)
CALF 28Y(4,2)
CALF 940Y(4,2)
CATEGORY FETAL LOSS(4,2)
CATTLE POPULATION(4,2)
COLOSTRUM ADMINISTRATION(4,2)
COLOSTRUM FORCED FEEDING(4,2)
DEATH LOSS CLARIFICATION(4,2)
DISEASE SEVERITY(4,2)
ENROLLED COW(4,2)
FLAVIVIRIDAE FAMILY(4,2)
GENITAL INFECTION(4,2)
GESTATION WINDOW(4,2)
HEALTHY BREEDING(4,2)
HERD REMAINDER(4,2)
INVESTIGATION SITE(4,2)
NEBRASKA TRIAL(4,2)
PARAMYXOVIRUS FAMILY(4,2)
PLACEBO VACCINE(4,2)
POSTPARTUM OBSERVATION(4,2)
PRE COLOSTRAL SEROLOGICAL STATUS(4,2)
PRE COLOSTRAL SERUM SAMPLING(4,2)
SAFE(4,2)
STUDY WRITTEN RECORD(4,2)
TISSUE COMPLIANCE(4,2)
VACCINATED CATTLE(4,2)
VIRUS PATHOGEN(4,2)
WINTER MONTH(4,2)
ABSORBED COLOSTRAL ANTIBODY(4,1)
ALKENE THEOLIGOMERIZATION(4,1)
ALVEOLAR EPITHELIALIZATION(4,1)
ASSIGNED TRIMESTER VACCINATION(4,1)
BRONCHIOLAR EPITHELIUM DEGENERATION(4,1)
CALF ENROLLMENT TESTING(4,1)
CLOPPER PEARSON CONFIDENCE INTERVAL(4,1)
DAILY HERD OBSERVATION(4,1)
DAM INFLICTED INJURY(4,1)
ENROLLMENT PREGNANCY CHECK VACCINATION(4,1)
ENROLLMENT VACCINATION DAY(4,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(4,1)
HERD ROUTINE MANAGEMENT(4,1)
HOG CHOLERA VIRUS(4,1)
INACTIVATED ROTAVIRUS CORONAVIRUS(4,1)
MATURE COW(4,1)
PERSISTENT FETAL INFECTION(4,1)
POSTPARTUM CALF HEALTH(4,1)
PREGNANT ANIMAL PLACENTA(4,1)
PREGNANT COW HEALTH(4,1)
PURULENT BRONCHOPNEUMONIA(4,1)
RAYMOND FINNEY HEIFER(4,1)
SEROVAR LEPTOSPIRA(4,1)
SERUM NEUTRALIZING ANTIBODY STATUS(4,1)
SERUM NEUTRALIZING TITER(4,1)
STERILE ADJUVANTED DILUENT(4,1)
TRIMESTER NOSTNARTUM TREATMENT(4,1)
VAGINAL PROLAPSE SURGICAL REPAIR(4,1)
IMMUNOLOGICAL ACTIVE COMPONENT(3,16)
SUBGROUP(3,6)
EAR CHANGE(3,5)
PYREXIA(3,5)
TRIAL DESIGN(3,5)
INFECTIOUS BOVINE RHINOTRACHEITIS DETECTION(3,3)
SECONDARY BACTERIAL INFECTION(3,3)
VACCINE PRODUCTION ASSIGNMENT(3,3)
ADMINISTRATION SAFETY(3,2)
ADMINISTRATION TIMING(3,2)
CALF HEALTH STATUS(3,2)
ENROLLED PERCENT(3,2)
EXPOSURE EVIDENCE(3,2)
HEALTH ISSUE(3,2)
PROTOCOL DEVIATION(3,2)
SERUM NEUTRALIZING ANTIBODY LEVEL(3,2)
STUDY OBJECTIVE(3,2)
WEAK CALF(3,2)
YOUNG ANIMAL(3,2)
ALBERTA CANADA TREATMENT(3,1)
ALBERTA HERD(3,1)
ANHYDROMANNITOL OLEATE(3,1)
ATYPICAL INTERSTITIAL PNEUMONIA(3,1)
BACTERIAL ENTERITIS(3,1)
BACTERIAL PNEUMONIA ONSET(3,1)
BHV SUBTYPE(3,1)
BOOSTER VACCINE(3,1)
BOVINE EMBRYO KIDNEY CELL(3,1)
CALENDAR DAILY RECORD(3,1)
CALF BIRTH(3,1)
CALF HEIFER(3,1)
CALVING RECORD BOOK(3,1)
CLINICAL MANIFESTATION(3,1)
CLINICAL SIGN ONSET(3,1)
CLOSTRIDIAL BACTERIN(3,1)
CLOSTRIDIAL VACCINE(3,1)
CORN STOCK PASTURE(3,1)
CRANIOVENTRAL LUNG CONSOLIDATION(3,1)
DAILY ACTIVITY CALENDAR LOG(3,1)
DIED WITHJIN(3,1)
DIFFUSE INTERSTITIAL PNEUMONIA(3,1)
DIPHTHERITIC PLAQUE(3,1)
DYSTOCIA DIAGNOSIS(3,1)
ECCHYMOTIC HEMORRHAGE(3,1)
EMBRYONIC DEATH(3,1)
ENDONUCLEASE CLEAVAGE BASIS(3,1)
ENROLLED HEIFER(3,1)
ESOPHAGEAL ABSCESS(3,1)
FENITROTHION STUDIO(3,1)
FREQUENT URINATION(3,1)
GALENICA PHARMACEUTICAL(3,1)
GENERALIZED BHV(3,1)
HAEMOPHILUS SOMNUS(3,1)
HERD OWNER(3,1)
HISTOLOGIC EXAMINATION(3,1)
IBRV VIRUS ISOLATION(3,1)
INFECTED COW(3,1)
INFERTILITY HISTORY(3,1)
INFLAMED NARIS(3,1)
INTERSTITIAL EDEMA(3,1)
INVESTIGATOR REPORT(3,1)
LEPTO BACTERIN(3,1)
LIPID AMINE ADJUVANT(3,1)
LUNG PARENCHYMA(3,1)
MATERNAL ANTIBODY(3,1)
MICROBIOLOGICAL CONTAMINATION(3,1)
MICROBIOLOGICAL GROWTH INHIBITION(3,1)
NASOPHARYNX NORMAL INHABITANT(3,1)
NECROPSIED FETUS(3,1)
NECROPSY SEROLOGY(3,1)
NECROTIC LESION(3,1)
NONIONIC SURFACTANT(3,1)
NOTATION CLARIFICATION(3,1)
NOVARTIS ANIMAL HEALTH(3,1)
PASSIVELY DERIVED IMMUNITY(3,1)
PASTURE ASSIGNMENT(3,1)
PESTIVIRUS GENUS(3,1)
PHARMACEUTICAL COMPOSTION(3,1)
POLYNUCLEOTIDE VACCINATION(3,1)
POSTMORTEM SAMPLE LABORATORY EXAMINATION(3,1)
PREDOMINANT CLINICAL PARAMETER(3,1)
PREGNANCY CONFIRMATION(3,1)
PREGNANCY MONTH(3,1)
PREGNANCY VERIFICATION(3,1)
PREVALENT LEPTOSPIRA(3,1)
RAIN STORM(3,1)
RAW DATA FILE(3,1)
RAYMOND FINNEY HERD(3,1)
RAYMOND FINNEY RANCH(3,1)
RAYMOND HEIFER(3,1)
RAYMOND HERD(3,1)
RAYMOND RANCH(3,1)
REPLICATION COMPENTENT(3,1)
REPRODUCTIVE ORGAN(3,1)
SEROFIBRINOUS EXUDATE(3,1)
STUDY PROTOCOL APPENDIX(3,1)
SUBMUCOSAL HEMORRHAGE(3,1)
SUGAR POLYALKENYL(3,1)
TISSUE CULTURE INFECTIVE(3,1)
TL VACCINATION(3,1)
TRANSIENT INFERTILITY(3,1)
TRIMESTER ASSIGNMENT(3,1)
TRIMESTER COW(3,1)
UNDIAGNOSED CALF LOSS(3,1)
UNSATURATED ALIPHATIC RADICAL(3,1)
UTERUS INFLAMMATION(3,1)
VACCINATED DAM(3,1)
VSM GUIDELINE(3,1)
WILLIAMS HERD(3,1)
WILLIAMS RANCH(3,1)
ARTIFICIAL INSEMINATION(2,4)
HEMOGLOBINURIA(2,4)
ICTERUS(2,4)
IMMUNE RESPONSE(2,4)
LIVER(2,4)
SIGNIFICANT INCREASE(2,4)
CONJUNCTIVITIS(2,3)
DECISION(2,3)
DYSPNEA(2,3)
EXPRESSTM(2,3)
LIFE DAY(2,3)
PREGNANCY OUTCOME(2,3)
PRESERVATIVE(2,3)
PRODUCER(2,3)
SEMEN(2,3)
TRACHEA(2,3)
TRIMESTER ENROLLMENT VACCINATION TIME(2,3)
ACRYLIC POLYMER(2,2)
ANIMAL SELECTION(2,2)
ANOREXIA(2,2)
ANTIBIOTIC(2,2)
ANTIMICROBIOLOGICAL ACTIVE AGENT(2,2)
BLIZZARD(2,2)
BLOOD COLLECTION(2,2)
CALVING DEATH RATE(2,2)
CALVING OUTCOME RESULT(2,2)
DAIRY CATTLE(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
EROSION(2,2)
ESK CELL(2,2)
EXCEPTION(2,2)
FULL NECROPSY(2,2)
GRASS(2,2)
GROUP ASSIGNMENT(2,2)
HERD TRIMESTER(2,2)
INFECTIOUS PUSTULAR VULVOVAGINITIS(2,2)
INVESTIGATOR OBSERVATION COMBINATION(2,2)
ISOTONIC AGENT(2,2)
LABORATORY TEST(2,2)
LAMENESS(2,2)
LARYNX(2,2)
LEPTOSPIROSIS(2,2)
LETHALITY(2,2)
ML CULTURE(2,2)
MODIFIED INFECTIOUS BOVINE RHINOTRACHEITIS(2,2)
MORBIDITY(2,2)
NEGATIVE ANTIBODY(2,2)
NEOMYCIN(2,2)
NUMERIC SCALE(2,2)
PAIRED SAMPLE(2,2)
PERCENT CALF TREATMENT(2,2)
PERCENT FETAL LOSS(2,2)
PROTECTANT(2,2)
PURIFICATION(2,2)
RECTAL PALPATION(2,2)
RESPIRATORY RATE(2,2)
RETEST(2,2)
SAMPLE TOXICITY CONTAMINATION(2,2)
SERONEGATIVE(2,2)
SITE PRACTICE(2,2)
STABILIZER(2,2)
STILLBIRTH(2,2)
STUDY START(2,2)
SUSPECT(2,2)
SYMPTOM(2,2)
TISSUE SAMPLE(2,2)
VIRUS DETECTION(2,2)
WAY LEPTOSPIRA BACTERIN(2,2)
WEATHER RELATED DEATH(2,2)
ABNORMAL MILK(2,1)
ABORTING FRACTION(2,1)
ACUTE INFECTION(2,1)
ADJUVANT INSTANCE(2,1)
ADRD LABORATORY(2,1)
ADSORPTION DELAYING(2,1)
ADULT CATTLE(2,1)
ADULT SERUM SAMPLE(2,1)
AEROBIC CULTURE(2,1)
AINSWORTH JOHNSTOWN NEBRASKA AREA(2,1)
ALKENYL DERIVATIVE(2,1)
ANIMAL CONTAGIOUS DISEASE(2,1)
ANIMAL IDENTIFICATION(2,1)
ANIMAL MANAGEMENT(2,1)
ANIMAL NEED(2,1)
ANIMAL PARITY(2,1)
ANTIBODY NEUTRALIZATION(2,1)
ANTIGENIC SUBSTANCE(2,1)
ATTENUATED PARTICLE(2,1)
BACTERIAL PNEUMONIA ABSENCE(2,1)
BIOCHEMICAL TEST(2,1)
BIRTH DATE(2,1)
BIVI FETAL PROTECTION PRODUCT(2,1)
BORN CALF LOSS(2,1)
BOVINE HERPES VIRUS(2,1)
BOVINE PATHOGEN(2,1)
BOVINE VIRAL DIARRHEA ABORTION(2,1)
BOVINE VIRAL DIARRHEA ENROLLMENT(2,1)
BOVINE VIRAL DIARRHEA SEROLOGY(2,1)
BREEDING CATTLE(2,1)
CALF(2,1)
CALF 16Y(2,1)
CALF 51Y(2,1)
CALF 53R(2,1)
CALF FINAL OBSERVATION(2,1)
CALF LOSS DIAGNOSIS(2,1)
CALF SEX(2,1)
CALF TESTING(2,1)
CALF TISSUE(2,1)
CALVING EAR(2,1)
CALVING EVENT(2,1)
CALVING LOSS ABORTION(2,1)
CAMBRIDGE MA(2,1)
CHEMICALLY MODIFIED VIRUS(2,1)
CHOLERA TOXIN(2,1)
CLINICAL DISEASE(2,1)
CLOTTED BLOOD TUBE(2,1)
COIN TOSS(2,1)
COMPLETEDBETWEEN DAY(2,1)
COW KICK(2,1)
COW MAJORITY(2,1)
CULTURE GROWTH(2,1)
DAILY CALENDAR(2,1)
DAM IDENTIFICATION(2,1)
DECREASING SERUM ASSAY(2,1)
DIAGNOSTIC TESTING(2,1)
DUPLICATE EAR(2,1)
EFFICACY TRIAL(2,1)
ELEVATED FEVER(2,1)
EMERYVILLE CA(2,1)
ENROLLMENT ADJUSTMENT(2,1)
ETHYLENICALLY UNSATURATED GROUP(2,1)
EXTENSIVE PLEURITIS(2,1)
FEED LOT CATTLE(2,1)
FEMALE BOVINE(2,1)
FETAL LOSS VISUAL SIGN(2,1)
FETAL SHIPMENT(2,1)
FETAL TISSUE RECOVERY(2,1)
FETUS LOSS(2,1)
FINAL CALF SAMPLING(2,1)
FOLD DILUTION(2,1)
FREQUENT OCCURRENCE(2,1)
GENERALIZED DISEASE(2,1)
GENERALIZED VIRAL INFECTION(2,1)
GROSS LESION(2,1)
HERD BOOK(2,1)
HERD MANAGEMENT(2,1)
HOME PASTURE(2,1)
HYALINE MEMBRANE FORMATION(2,1)
ID DISCREPANCY(2,1)
IMMUNITY DURATION(2,1)
IMMUNOHISTOCHEMISTRY TESTING(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
INFECTED ANIMAL(2,1)
INFECTION SEVERITY(2,1)
INFECTIOUS BOVINE RHINOTRACHEITIS HISTORY(2,1)
INFECTIOUS BOVINE RHINOTRACHEITIS INFECTION(2,1)
INVESTIGATOR DID(2,1)
LABELED SAFETY PRECAUTION REGARDING(2,1)
LATE DISEASE STAGE(2,1)
LEPTOSPIRA FLUORESCENT ANTIBODY(2,1)
LIKELY SIRE(2,1)
LIMITED CROSS(2,1)
LIVE ANIMAL(2,1)
LIVING ORGANISM(2,1)
MALEIC ANHYDRIDE COPOLYMER(2,1)
MARKED CONGESTION(2,1)
MICROORGANISM FRACTION(2,1)
MILD INITIAL SIGN(2,1)
MINERAL SUPPLEMENT(2,1)
MISSING IDENTIFICATION(2,1)
MK 270A(2,1)
MULTIDOSE COMPOSITION PREPARATION(2,1)
MYCOLOGY CULTURE(2,1)
NAKED EYE(2,1)
NASAL CAVITY MUCOUS MEMBRANE(2,1)
NEBRASKA TREATMENT(2,1)
NECROPSY F(...)";Pharmaceuticals;Open
2009-01-09;"MX2009000398        A  2010-07-15 [MX2009000398]
STG: (A) Patent application
AP : 2009MX-PA00398 2009-01-09";35428034;MX2009000398        A  2010-07-15 [MX2009000398];2009MX-PA00398;;BOEHRINGER INGELHEIM VETMEDICA;BOEHRINGER INGELHEIM VETMEDICA;;;1;"RINEART CAROL L
JONES CRAIG
MYERS JUDITH
COLE WAYNE
OHNESORGE WILLIAM CHARLES";;;"(MX2009000398)
Method of treating pregnant cows and/or heifers.";"(MX2009000398)
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.";;;;A61K-039/00;;;Pharmaceuticals;Open
"2008-12-03
2009-04-28
2009-11-23
2009-11-24
2017-02-13";"US20100136055       A1 2010-06-03 [US20100136055]
STG: (A1) Application published
AP : 2009US-12624473 2009-11-24
WO2010064164        A1 2010-06-10 [WO201064164]
STG: (A1) Published application with search report
AP : 2009WO-IB55291 2009-11-23
CA2744750           A1 2010-06-10 [CA2744750]
STG: (A1) Application laid open
AP : 2009CA-2744750 2009-11-23
AU2009323784        A1 2010-06-10 [AU2009323784]
STG: (A1) Open to public inspection
AP : 2009AU-0323784 2009-11-23
UY32274             A  2010-06-30 [UY--32274]
STG: (A) Patent application
AP : 2009UY-0032274 2009-11-30
TW201024416         A  2010-07-01 [TW201024416]
STG: (A) Laid open application for patent or patent of addition
AP : 2009TW-0141210 2009-12-02
AR075484            A1 2011-04-06 [AR--75484]
STG: (A1) Independent patent application
AP : 2009AR-0104645 2009-12-02
MX2011005820        A  2011-06-21 [MX2011005820]
STG: (A) Patent application
AP : 2011MX-PA05820 2009-11-23
KR20110091579       A  2011-08-11 [KR20110091579]
STG: (A) Published application
AP : 2011KR-7015168 2009-11-23
EP2373785           A1 2011-10-12 [EP2373785]
STG: (A1) Application published with search report
AP : 2009EP-0768236 2009-11-23
CN102239251         A  2011-11-09 [CN102239251]
STG: (A) Published application
AP : 2009CN-80148483 2009-11-23
IN4079/DELNP/2011   A  2012-04-06 [IN2011DN04079]
STG: (A) Application laid open
AP : 2011IN-DN04079 2011-05-31
JP2012510285        A  2012-05-10 [JP2012510285]
STG: (A) Published application
AP : 2011JP-0539129 2009-11-23
CO6440541           A2 2012-05-15 [CO6440541]
STG: (A2) Application derived from a PCT application
AP : 2011CO-0068897 2011-06-02
NZ592979            A  2012-08-31 [NZ-592979]
STG: (A) Published application
AP : 2009NZ-0592979 2009-11-23
ZA201104508         B  2012-11-28 [ZA201104508]
STG: (B)
AP : 2011ZA-0004508 2011-06-17
RU2011121044        A  2013-01-10 [RU2011121044]
STG: (A) Application for invention
AP : 2011RU-0121044 2009-11-23
ME01140             B  2013-03-20 [ME---1140]
STG: (B)
AP : 2011ME-0000097 2009-11-23
AU2009323784        B2 2013-08-15 [AU2009323784]
STG: (B2) Patent proceeded by OPI
AP : 2009AU-0323784 2009-11-23
UA103501            C2 2013-10-25 [UA-103501]
STG: (C2) Pat. grant. upon the USSR appl.,for which no pos. dec. made;grant. upon basis of national application
AP : 2011UA-0006460 2009-11-23
CN102239251         B  2014-04-23 [CN102239251B]
STG: (B) Granted patent for invention
AP : 2009CN-80148483 2009-11-23
RU2524426           C2 2014-07-27 [RU2524426]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2011RU-0121044 2009-11-23
KR101453146         B1 2014-10-27 [KR101453146]
STG: (B1) Patent specification
AP : 2011KR-7015168 2009-11-23
RU2013141044        A  2015-03-20 [RU2013141044]
STG: (A) Application for invention
AP : 2013RU-0141044 2013-09-06
JP5744748           B2 2015-05-15 [JP5744748]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2011JP-0539129 2009-11-23
TWI485248           B  2015-05-21 [TWI485248]
STG: (B) Granted patent or patent of addition
AP : 2009TW-0141210 2009-12-02
BRPI0920982         A2 2016-10-04 [BR200920982]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2009BR-0020982 2009-11-23
US9567375           B2 2017-02-14 [US9567375]
STG: (B2) Granted patent as second publication
AP : 2009US-12624473 2009-11-24
FD :  Provisional Appl: US61/119,594 FDD=2008-12-03 [2008US-61119594]
FD : Provisional Appl: US61/173,363 FDD=2009-04-28 [2009US-61173363]
FD : Previous publication: US20100136055 A1 2010-06-03 [US20100136055]
US20170151321       A1 2017-06-01 [US20170151321]
STG: (A1) Application published
AP : 2017US-15430837 2017-02-13
FD :  Continuation of: US12/624,473 FDD=2009-11-24 [2009US-12624473]
FD : Continuation of: US9567375 - 0 [US9567375]
FD : Provisional Appl: US61/173,363 FDD=2009-04-28 [2009US-61173363]
FD : Provisional Appl: US61/119,594 FDD=2008-12-03 [2008US-61119594]
EP2373785           B1 2018-06-27 [EP2373785]
STG: (B1) Patent specification
AP : 2009EP-0768236 2009-11-23
ES2681685           T3 2018-09-14 [ES2681685]
STG: (T3) Translation of granted European patent (former B3)
AP : 2009ES-0768236T 2009-11-23
CA2744750           C  2018-10-09 [CA2744750]
STG: (C) Patent (second level)
AP : 2009CA-2744750 2009-11-23";5202710;"US20100136055       A1 2010-06-03 [US20100136055]
WO2010064164        A1 2010-06-10 [WO201064164]
CA2744750           A1 2010-06-10 [CA2744750]
AU2009323784        A1 2010-06-10 [AU2009323784]
UY32274             A  2010-06-30 [UY--32274]
TW201024416         A  2010-07-01 [TW201024416]
AR075484            A1 2011-04-06 [AR--75484]
MX2011005820        A  2011-06-21 [MX2011005820]
KR20110091579       A  2011-08-11 [KR20110091579]
EP2373785           A1 2011-10-12 [EP2373785]
CN102239251         A  2011-11-09 [CN102239251]
IN4079/DELNP/2011   A  2012-04-06 [IN2011DN04079]
JP2012510285        A  2012-05-10 [JP2012510285]
CO6440541           A2 2012-05-15 [CO6440541]
NZ592979            A  2012-08-31 [NZ-592979]
ZA201104508         B  2012-11-28 [ZA201104508]
RU2011121044        A  2013-01-10 [RU2011121044]
ME01140             B  2013-03-20 [ME---1140]
AU2009323784        B2 2013-08-15 [AU2009323784]
UA103501            C2 2013-10-25 [UA-103501]
CN102239251         B  2014-04-23 [CN102239251B]
RU2524426           C2 2014-07-27 [RU2524426]
KR101453146         B1 2014-10-27 [KR101453146]
RU2013141044        A  2015-03-20 [RU2013141044]
JP5744748           B2 2015-05-15 [JP5744748]
TWI485248           B  2015-05-21 [TWI485248]
BRPI0920982         A2 2016-10-04 [BR200920982]
US9567375           B2 2017-02-14 [US9567375]
US20170151321       A1 2017-06-01 [US20170151321]
EP2373785           B1 2018-06-27 [EP2373785]
ES2681685           T3 2018-09-14 [ES2681685]
CA2744750           C  2018-10-09 [CA2744750]";"2008US-61119594
2009EP-0768236
2009US-12624473
2009US-61173363
2009US-61733363
2009WO-IB55291
2017US-15430837";"(EP2373785)
WO2010064164
(JP5744748)
WO2010064164
(RU2524426)
WO2010064164
(MX2011005820)
WO2010064164
(IN2011DN04079)
WO2010064164
(NZ-592979)
WO2010064164
(ZA201104508)
WO2010064164
(ME---1140)
WO2010064164
(AU2009323784)
WO2010064164
(UA-103501)
WO2010064164
(CN102239251B)
WO2010064164
(KR101453146)
WO2010064164
(BR200920982)
WO2010064164
(ES2681685)
WO2010064164
(CA2744750)
WO2010064164";"PFIZER
ZOETIS
ZOETIS SERVICES";ZOETIS SERVICES;"(EP2373785)
US
(EP2373785)
US
(US20100136055)
US
(US9567375)
US
(US20170151321)
US
(WO201064164)
US




(CA2744750)
US
(CA2744750)
US";"(EP2373785)
NAME=Pfizer Inc. 235 East 42nd Street , CITY=New York, NY 10017 , COUNTRY=US 

(EP2373785)
NAME=Zoetis Services LLC 10 Sylvan Way , CITY=Parsippany, NJ 07054 , COUNTRY=US , REG=101630447 

(US20100136055)
NAME=Pfizer Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

(US9567375)
NAME=Zoetis Services LLC , CITY=Parsippany , STATE=NJ , COUNTRY=US , ATYP=US Company 

(US20170151321)
NAME=ZOETIS SERVICES LLC , CITY=Parsippany , STATE=NJ , COUNTRY=US 

(WO201064164)
NAME=PFIZER INC.  235 East 42nd Street, New York, New York 10017  , COUNTRY=US 

(JP2012510285)
NAME=PFIZER INC. , REG=593141953 

(JP5744748)
NAME=ZOETIS LLC , REG=512261355 

(ZA201104508)
NAME=ZOETIS LLC US 

(KR101453146)
NAME=ZOETIS LLC , REG=520120585480 

(BR200920982)
NAME=PFIZER,INC 235 EST 42ND STREET - 20TH FLOOR 10017 NEW YORK US 

(CA2744750)
NAME=PFIZER INC. 235 EAST 42ND STREET , CITY=NEW YORK , STATE=NY , POSTCODE=10017 , COUNTRY=US 

(CA2744750)
NAME=PFIZER INC. 235 EAST 42ND STREET , CITY=NEW YORK , STATE=NY , POSTCODE=10017 , COUNTRY=US 
";1;"ANKENBAUER ROBERT GERARD
LUO YUGANG
WELCH SIAO-KUN WAN
YUAN YING";"(EP2373785)
US
(EP2373785)
US";"(EP2373785)
NAME=ANKENBAUER, Robert Gerard Pfizer Global Research and Development 7000 Portage Road , CITY=Kalamazoo, Michigan 49001 , COUNTRY=US 

NAME=LUO, Yugang Pfizer Global Research and Development 7000 PortageRoad , CITY=Kalamazoo, Michigan 49001 , COUNTRY=US 

NAME=WELCH, Siao-Kun Wan 9087 South 6th Street , CITY=Kalamazoo, Michigan 49009 , COUNTRY=US 

NAME=YUAN, Ying Pfizer Global Research and Development 7000 Portage Road , CITY=Kalamazoo, Michigan 49001 , COUNTRY=US 

(EP2373785)
NAME=ANKENBAUER, Robert Gerard Pfizer Global Research and Development 7000 Portage Road , CITY=Kalamazoo, Michigan 49001 , COUNTRY=US 

NAME=LUO, Yugang Pfizer Global Research and Development 7000 PortageRoad , CITY=Kalamazoo, Michigan 49001 , COUNTRY=US 

NAME=WELCH, Siao-Kun Wan 9087 South 6th Street , CITY=Kalamazoo, Michigan 49009 , COUNTRY=US 

NAME=YUAN, Ying Pfizer Global Research and Development 7000 Portage Road , CITY=Kalamazoo, Michigan 49001 , COUNTRY=US 
";"(EP2373785)
Bovine viral diarrhea virus with a modified erns protein";"(EP2373785)
The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines wherein said chimeric pestivirus comprises a bovine viral diarrhea virus which does not express its homologous Ems protein, further wherein said chimeric pestivirus expresses a heterologous Ems protein derived from another pestivirus, or a natural, synthetic or genetic variant of said heterologous Erns protein. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.";"(US20100136055)
We claim:
1. A chimeric pestivirus, wherein said chimeric pestivirus comprises a bovine viral diarrhea virus which does not express its homologous Ems protein, further wherein said chimeric pestivirus expresses a heterologous Ems protein derived from another pestivirus, or a natural, synthetic or genetic variant of said heterologous Ems protein.
2. The chimeric pestivirus of claim 1, wherein the heterologous Ems protein of said chimeric pestivirus, or the natural, synthetic or genetic variant of said heterologous Ems protein, is derived from a pestivirus selected from the group consisting of a reindeer pestivirus, a giraffe pestivirus, and a pronghorn antelope pestivirus.
3. The chimeric pestivirus of claim 1, wherein the heterologous Ems protein of said chimeric pestivirus has at least one Ems epitope which is not present in wild-type bovine viral diarrhea virus.
4. The chimeric pestivirus of claim 1, wherein the heterologous Ems protein of said chimeric pestivirus lacks at least one Ems epitope which is present in wild-type bovine viral diarrhea virus.
5. A culture of the chimeric pestivirus of claim 1.
6. A cell line or host cell comprising the chimeric pestivirus of claim 1.
7. A polynucleotide molecule encoding for the chimeric pestivirus of claim 1.
8. An immunogenic composition comprising the chimeric pestivirus of claim 1 and a veterinarily-acceptable carrier.
9. The immunogenic composition of claim 8, wherein the veterinarily-acceptable carrier is an adjuvant.
10. The immunogenic composition of claim 8, wherein said chimeric pestivirus is live attenuated.
11. The immunogenic composition of claim 8, wherein said chimeric pestivirus is inactivated.
12. The immunogenic composition of claim 8, further comprising one or more additional antigens useful for treating or preventing the spread of one or more additional pathogenic microorganisms in a bovine.
13. An immunogenic composition comprising the polynucleotide molecule of claim 7 and a veterinarily-acceptable carrier.
14. A vaccine comprising the chimeric pestivirus of claim 1 and a veterinarily-acceptable carrier.
15. The vaccine of claim 14, wherein the veterinarily-acceptable carrier is an adjuvant.
16. The vaccine of claim 14, wherein said chimeric pestivirus is live attenuated.
17. The vaccine of claim 14, wherein said chimeric pestivirus is inactivated.
18. A vaccine comprising the polynucleotide molecule of claim 7 and a veterinary acceptable carrier.
19. The vaccine of claim 14, further comprising one or more additional antigens useful for treating or preventing the spread of one or more additional pathogenic microorganisms in a bovine.
20. A kit comprising, in at least one container, the vaccine of claim 14.
21. A method of treating or preventing the spread of bovine viral diarrhea virus infection, wherein the vaccine of claim 14 is administered to an animal.
22. A method of vaccinating an animal, wherein a DIVA pestivirus vaccine is administered to said animal, and wherein said DIVA pestivirus vaccine comprises the chimeric pestivirus of claim 1, further wherein said chimeric pestivirus has at least one Ems epitope which is not present in wild-type bovine viral diarrhea virus.
23. A method of vaccinating an animal, wherein a DIVA pestivirus vaccine is administered to said animal, and wherein said DIVA vaccine comprises the chimeric pestivirus of claim 1, further wherein said chimeric pestivirus lacks at least one Ems epitope which is present in wild-type bovine viral diarrhea virus.
24. A method of differentiating between an animal vaccinated with the vaccine of claim 14 and an animal infected with wild type bovine viral diarrhea virus, wherein the animal vaccinated with said vaccine generates antibodies to at least one Ems epitope which is present in the chimeric pestivirus of said vaccine, but which is not present in wild-type bovine viral diarrhea virus, said method comprising the steps of: 
 a) obtaining a serum sample from the animals; 
 b) assaying said samples for the presence or absence of the antibodies; 
 c) identifying the animal having said antibodies as having been vaccinated with said vaccine; and 
 d) identifying the animal lacking said antibodies as having been infected with the wild type BVDV.
25. A method of differentiating between an animal infected with wild-type bovine viral diarrhea virus and an animal vaccinated with the vaccine of claim 14, wherein the animal infected with wild type bovine viral diarrhea virus generates antibodies to at least one Ems epitope which is present in wild-type bovine viral diarrhea virus, but which is not present in the chimeric pestivirus of said vaccine, said method comprising the steps of: 
 a) obtaining a serum sample from the animals; 
 b) assaying said samples for the presence or absence of the antibodies; 
 c) identifying the animal having said antibodies as having been infected with the wild type BVDV; and 
 d) identifying the animal lacking said antibodies as having been vaccinated with said vaccine.
26. A diagnostic kit for differentiating between an animal vaccinated with a vaccine comprising the chimeric pestivirus of claim 1 and an animal infected with wild type bovine viral diarrhea virus, said kit comprising reagents capable of detecting antibodies to at least one Ems epitope which is present in the chimeric pestivirus of the vaccine, but which is not present in wild-type bovine viral diarrhea virus.
27. A diagnostic kit for differentiating between an animal infected with wild type bovine viral diarrhea virus and an animal vaccinated with a vaccine comprising the chimeric pestivirus of claim 1, said kit comprising reagents capable of detecting antibodies to at least one Ems epitope which is present in wild-type bovine viral diarrhea virus, but which is not present in the chimeric pestivirus of the vaccine.
28. An antibody which recognizes an epitope of Ems which is present in the chimeric pestivirus of claim 1, but which epitope is not present in wild-type bovine viral diarrhea virus.
29. An antibody which recognizes an epitope present in wild-type bovine viral diarrhea virus, but which epitope is not present in the chimeric pestivirus of claim 1.";"(EP2373785)
The present disclosure further provides the chimeric BVDV as described above, wherein the heterologous Erns protein of said chimeric BVDV has at least one Erns epitope which is not present in wild-type bovine viral diarrhea virus.
The present disclosure provides the chimeric BVDV as described above, wherein the heterologous Erns protein of said chimeric BVDV lacks at least one Erns epitope which is present in wild-type bovine viral diarrhea virus.
In one embodiment, the present invention provides a chimeric pestivirus, wherein said chimeric pestivirus is a chimeric bovine viral diarrhea virus (BVDV) capable of differentiating between cattle vaccinated with said chimeric virus and cattle infected with a wild-type BVDV, which does not express its homologous Erns protein, further wherein said chimeric BVDV comprises a BVDV in which the full length Erns gene is replaced by the full length Erns gene of the pronghorn antelope pestivirus and which expresses a heterologous Erns protein derived from derived from a pronghorn antelope pestivirus (P- Erns).
In one embodiment, the present invention provides a chimeric pestivirus, wherein said chimeric pestivirus is a chimeric bovine viral diarrhea virus (BVDV) capable of differentiating between cattle vaccinated with said chimeric virus and cattle infected with a wild-type BVDV, which does not express its homologous Erns protein, further wherein said chimeric BVDV comprises a BVDV in which the full length Erns gene is replaced by the full length Erns gene of the pronghorn antelope pestivirus and which expresses a heterologous Erns protein derived from derived from a pronghorn antelope pestivirus (P- Erns).
The present disclosure further provides the chimeric BVDV as described above, wherein the heterologous Erns protein of said chimeric BVDV has at least one Erns epitope which is not present in wild-type bovine viral diarrhea virus.
The present invention relates to novel chimeric bovine viral diarrhea virus (BVDV) and their use in immunogenic compositions and vaccines.
The present invention relates to novel chimeric bovine viral diarrhea virus (BVDV) and their use in immunogenic compositions and vaccines.";"(EP2373785)
Such reagents are useful for analyzing a sample for the presence of antibodies, and are readily known and available to one of ordinary skill in the art.
Inasmuch as it may be desirable to administer an immunogenic composition or vaccine in combination with additional compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that an immunogenic composition or vaccine can conveniently be included in, or combined in, the form of a kit suitable for administration or coadministration of the compositions.
Thus, it is clear that a need exists for new vaccines for controlling the spread of BVDV.
However, existing MLV vaccines do not allow for the differentiation between vaccinated and naturally-infected animals.
Although this vaccine appears to protect fetuses from becoming infected, protection is limited to only the homologous strain of virus, and there is no correlation between antibody titers and protection.
BVDV infection in cattle can result in breeding problems, and can cause abortions or premature births.";"A61K
A61K-035/76
A61K-039/00
A61K-039/12
A61K-039/15
A61K-039/385
A61K-048/00
A61P-001/04
A61P-001/12
A61P-031/14
C07K
C07K-014/005
C07K-014/18
C07K-016/10
C12N
C12N-001/15
C12N-001/19
C12N-001/21
C12N-005/10
C12N-005/14
C12N-005/16
C12N-007/00
C12N-007/01
C12N-007/02
C12N-007/04
C12N-015/09
C12N-015/40
C12N-015/86
G01N
G01N-033/50
G01N-033/53
G01N-033/68";"(EP2373785)
1. A chimeric bovine viral diarrhea virus (BVDV) suitable for use in a vaccine against BVDV and allowing differentiation between cattle vaccinated with said chimeric virus and cattle infected with a wild-type BVDV, wherein the full length Erns gene is replaced by the full length Erns gene of the pronghorn antelope pestivirus (P-Erns) so that the chimeric BVDV expresses the Erns protein of pronghorn antelope pestivirus and does not express the BVDV Erns protein.";"(EP2373785)
BOVINE VIRAL DIARRHEA VIRUS(100,246)
PRONGHORN ANTELOPE PESTIVIRUS(100,11)
PROTEIN(100,7)
HETEROLOGOUS ERNS PROTEIN(51,5)
CHIMERIC BVDV(50,20)
HOMOLOGOUS ERNS PROTEIN(34,2)
CHIMERIC PESTIVIRUS(32,19)
ERNS PROTEIN EPITOPE(28,2)
CHIMERIC VIRUS(26,7)
HOMOLOGOUS VIRUS STRAIN(23,1)
ERNS EPITOPE(22,6)
IMMUNOGENIC(21,46)
ERNS PROTEIN(21,5)
FULL LENGTH ERNS GENE(20,6)
VACCINE(18,76)
CATTLE(18,19)
VETERINARILY ACCEPTABLE CARRIER(17,14)
ASSAYING SERUM SAMPLE(17,2)
BVDV(15,6)
ANTIBODY TITER(13,2)
DIFFERENTIATION(12,6)
ANTIBODY ABSENCE(12,3)
POLYNUCLEOTIDE MOLECULE ENCODING(12,3)
PESTIVIRUS ORIGIN(11,2)
BOVINE DIARRHEA VIRUS INFECTION(11,1)
INFECTION TREATMENT(10,3)
NATURALLY INFECTED ANIMAL(9,2)
EXPRESS(9,1)
CORRELATION(8,1)
PREMATURE BIRTH(8,1)
MANUFACTURER INSTRUCTION(7,10)
CHIMERIC PESTIVIRUS VACCINE(7,3)
ANTI MOUSE IGG PEROXIDASE ABC(7,2)
CHIMERIC PESTIVIRUS ERNS PROTEIN(7,2)
PRINT INSTRUCTION(7,2)
PRONGHORN ANTELOPE CHIMERIC PESTIVIRUS(7,1)
PRONGHORN ANTELOPE PESTIVIRUS CHIMERA(7,1)
P ERNS GENE(6,8)
METHYLATED PLASMID(6,6)
PREVENTION(6,4)
ABORTION(6,2)
INFECTION(5,11)
MARKER DETERMINANT(5,4)
CHIMERIC ERNS PROTEIN(5,3)
FETUS(5,3)
ANIMAL SUBJECT(5,2)
ERNS CHIMERIC VIRUS(5,2)
WILD TYPE BVDV(5,2)
INTESTINAL MUCOSA ULCERATION(5,1)
HOST CELL(4,5)
OLIGO PRIMER(4,5)
VIRUS PARTICLE(4,5)
GROWTH KINETICS(4,4)
PLASMID DNA(4,4)
HARVESTED SUPERNATANT(4,3)
INFECTION SYMPTOM(4,3)
PATHOGENIC MICROORGANISM(4,3)
VACCINATED CATTLE(4,3)
GIRAFFE PESTIVIRUS(4,2)
MICROORGANISM REPLICATION(4,2)
REINDEER PESTIVIRUS(4,2)
VETERINARY LABORATORY AGENCY(4,2)
VIRUS NEUTRALIZATION ASSAY(4,2)
ATTENDING VETERINARIAN SUPERVISION(4,1)
BIOCHEMICAL NOMENCLATURE COMMISSION(4,1)
BOVINE PARAINFLUENZA VIRUS(4,1)
CALF BIRTH(4,1)
CHIMERIC PESTIVIRUS GENOME(4,1)
GIRAFFE CHIMERIC PESTIVIRUS(4,1)
GIRAFFE ERNS GENE(4,1)
PREGNANT CATTLE PLACENTA(4,1)
REINDEER CHIMERIC PESTIVIRUS(4,1)
RESCUED RECOMBINANT VIRUS IDENTITY(4,1)
VIRAL GENOMIC RNA TRANSCRIPT(4,1)
VIRAL NEUTRALIZING EPITOPE RECOGNITION(4,1)
WILD TYPE(3,39)
BLOCKING(3,6)
PROGRAMMED RELEASE(3,5)
ENCODING FRAGMENT(3,4)
VECTOR LABORATORY(3,4)
DEPOSIT DESIGNATION(3,3)
MAGMAX AI(3,3)
MEDICAMENT PREPARATION(3,3)
PARENTAL VIRUS(3,3)
PARENTERAL ADMINISTRATION(3,3)
VIRAL RNA ISOLATION KIT(3,3)
WESTERN BLOTTING(3,3)
AURAL ADMINISTRATION(3,2)
BACULO ERNS LYSATE(3,2)
CHIMERIC ERNS REGION(3,2)
COMPETITIVE ELISA(3,2)
DEER SPECIES(3,2)
ERNS MONOCLONAL ANTIBODY(3,2)
ERNS PROTEIN COATING(3,2)
FLAVIVIRIDAE FAMILY(3,2)
IMMUNOLOGICAL ASSAY(3,2)
INFECTED CATTLE(3,2)
INFECTION INCIDENCE(3,2)
LIPOFECTIN REAGENT(3,2)
RD CELL CULTURE(3,2)
RESIDUAL LIVE VIRUS(3,2)
RNA TRANSCRIPT QUANTITY(3,2)
SUBUNIT ANTIGEN(3,2)
VIP PEROXIDASE SUBSTRATE(3,2)
VIRAL RNA TRANSFECTION(3,2)
ACTINOBACILLUS PLEUROPNEUMONIE(3,1)
BOVINE LEUKOSIS VIRUS(3,1)
BUNGOWANNAH PESTIVIRUS(3,1)
CHIMERA BIOLOGICAL CLONE(3,1)
CHIMERIC PESTIVIRUS VIRAL ANTIGEN(3,1)
COW DISPLAYING ESTRUM(3,1)
COW PREGNANCY STATUS(3,1)
FETAL INFECTION ETIOLOGIC AGENT(3,1)
INDIRECT IMMUNOFLUORESCENT ASSAY(3,1)
MAB OPTIMIZED DILUTION(3,1)
MICROORGANISM ACCELERATED ELIMINATION(3,1)
NEUTRALIZING ANTIBODY TITER RANGING(3,1)
QIAQUICK GEL EXTRACTION KIT(3,1)
RECOMBINANT BACULOVIRUS STOCK(3,1)
SALMONELLA ENTERICA SEROVAR(3,1)
SERUM NEUTRALIZING TITER(3,1)
UNDILUTED CATTLE SERUM(3,1)
MODIFIED RELEASE FORMULATION(2,5)
ANTIBODY PRESENCE(2,4)
ANTIGENIC DETERMINANT(2,4)
ATOMIZER(2,4)
P ERNS CHIMERA(2,4)
ANIMAL TEST POSITIVE(2,3)
COLOR DEVELOPMENT(2,3)
PFIZER GLOBAL MANUFACTURING(2,3)
PURIFIED PCR PRODUCT(2,3)
THERMOSCRIPT(2,3)
BOVINE CELL CULTURE(2,2)
BOVINE VIRAL DIARRHEA VIRUS INFECTION(2,2)
CELL MONOLAYER(2,2)
DETECTABLE MOIETY(2,2)
DIAGNOSTIC KIT(2,2)
DRY POWDER INHALER(2,2)
ELECTROHYDRODYNAMICS(2,2)
ELITE KIT(2,2)
ERNS GENE PROTEIN(2,2)
ERNS SPECIFIC MAB(2,2)
FINE MIST(2,2)
HORSE SERUM(2,2)
HPMCD(2,2)
HUMORAL IMMUNE RESPONSE(2,2)
INACTIVATED VIRUS MIXTURE(2,2)
METERED DOSE(2,2)
MICROORGANISM TRANSMISSION(2,2)
NUCLEOCAPSID(2,2)
PHOSPHOSERINE(2,2)
PRESSURIZED CONTAINER(2,2)
PRIMER OLIGO P(2,2)
RNA GEL(2,2)
RT PCR PRODUCT(2,2)
TEST ANTIGEN(2,2)
ABSORBABLE GEL SPONGE(2,1)
ABTS SUBSTRATE LL(2,1)
ADSORPTION DELAYING(2,1)
AGENT FACILITATING CELLULAR UPTAKE(2,1)
AMINOGLYCOSIDE CLASS(2,1)
ANTI IDIOTYPE ANTIBODY(2,1)
ANTIGEN SITE(2,1)
BABESIA SPP(2,1)
BACILLUS ANTHRACIS(2,1)
BACKBONE PESTIVIRUS(2,1)
BLACKWELL SCIENTIFIC PUBLICATION(2,1)
BOOSTING REGIMEN(2,1)
BORDER DISEASE CAUSATIVE AGENT(2,1)
BOVI SHIELD GOLD(2,1)
BOVINE HERPES VIRUS(2,1)
BOVINE SERUM SAMPLE(2,1)
BOVINE TESTICULAR CELL(2,1)
BRUCELLA SPP(2,1)
BVD VIRUS(2,1)
CATIONIC LIPID(2,1)
CATTLE SERUM DILUTION(2,1)
CATTLE SERUM SAMPLE(2,1)
CATTLE VACCINE(2,1)
CELLULAR IMMUNOLOGY(2,1)
CESAREAN DELIVERY(2,1)
CHALLENGE INOCULUM(2,1)
CHIMERA ENCODING REGION(2,1)
CHIMERA NEUTRALIZATION(2,1)
CHIMERIC PRONGHORN ERN REGION(2,1)
CHIMERIC VIRUS TITER(2,1)
CHLAMYDIA SPP(2,1)
CLOSTRIDIAL SPP(2,1)
COMPETITION ELISA(2,1)
CONFIRMED PREGNANCY(2,1)
CONJUGATION DISCUSSION(2,1)
CORNELL UNIVERSITY(2,1)
CULTURE SUPERNATANT(2,1)
DAM METHYLTRANSFERASE(2,1)
DIFFERENTIAL DIAGNOSTIC ASSAY(2,1)
DIVERGENT PESTIVIRUS(2,1)
DONOR CALF SERUM(2,1)
DOSAGE REGIMEN(2,1)
DULBECCO MODIFIED EAGLE(2,1)
EIMERIA SPP(2,1)
ELISA ANTIGEN PRODUCTION(2,1)
ENDOGENOUS WT REPLACEMENT(2,1)
ENVELOPE PROTEIN(2,1)
ENZYMATIC MOIETY(2,1)
ERNS MAB(2,1)
ERNS SUBSTITUTION(2,1)
GASTROINTESTINAL DISEASE(2,1)
GESTATION DAY(2,1)
GIARDIA SPP(2,1)
GROWING MICROORGANISM(2,1)
HAEMOPHILUS SOMNUS(2,1)
HEALTHY CALF(2,1)
HERD CERTIFICATION(2,1)
HETEROPOLYSACCHARIDE POLYMER(2,1)
HORSERADISH PEROXIDASE(2,1)
HYDROPHOBIC MEMBRANE ABSENCE(2,1)
IMMUNOASSAY FORMAT(2,1)
IMMUNOFLUORESCENT STAINING(2,1)
IMMUNOGENIC DETERMINANT(2,1)
IMMUNOGLOBULIN MOLECULE(2,1)
IMMUNOHISTOCHEMISTRY STAINING(2,1)
IMPLANTED DEPOT(2,1)
INOCULATED ANIMAL(2,1)
INTRANASAL INOCULATION(2,1)
LABELED MAB(2,1)
LEPTOSPIRA SPP(2,1)
LIVE BACTERIA(2,1)
MAB STAINING(2,1)
MANNHEMIA HAEMOLYTICA(2,1)
MARKED VACCINE(2,1)
METHIONINE METHYLSULFANIUM(2,1)
MICRONIZED SUSPENSION(2,1)
MMESSAGE MMACHINE(2,1)
MUCOSAL DISEASE OUTBREAK(2,1)
NANODROP SPECTROPHOTOMETER(2,1)
NEBRASKA UNIVERSITY(2,1)
NEOSPORA CANIUM(2,1)
NON INFECTED ANIMAL(2,1)
NON VACCINATED ANIMAL(2,1)
NUCLEOTIDE MONOMER(2,1)
OPTIMAL IMMUNIZATION(2,1)
PARENTERAL FORMULATION(2,1)
PATHOGENIC FUNGUS(2,1)
PENETRATION ENHANCER(2,1)
PESTIVIRUS GENUS(2,1)
PHOSPHATIDYLCHOLINE(2,1)
POST CHALLENGE ISOLATION(2,1)
POSTCHALLENGE INTERVAL(2,1)
RECOMBINANT PLASMID(2,1)
RERN GENE(2,1)
RNA MOLECULE ENCODING(2,1)
SERUM NEUTRALIZATION ASSAY(2,1)
SERUM SERIAL DILUTION(2,1)
STAPHYLOCOCCUS AUREUS(2,1)
STERILE ADJUVANT(2,1)
STREPTOCOCCUS UBERIS(2,1)
SYNTHETIC PEPTIDE MIMOTOPE(2,1)
T CELL PROLIFERATION(2,1)
T CELL RECEPTOR(2,1)
TOXOPLASMA GONDII(2,1)
TRADE ECONOMIC BENEFIT FREEDOM(2,1)
ULTRAVIOLET IRRADIATION(2,1)
UNCHALLENGED ANIMAL(2,1)
UNIQUE PESTIVIRUS SPECIES(2,1)
UNIVERSITY BOULEVARD(2,1)
VACCINE DOSE(2,1)
VACCINE EFFICACY(2,1)
VIBRIO SPP(2,1)
VIRAL GENOME(2,1)
VIRUS DISSEMINATION(2,1)
VIRUS FETAL TRANSMISSION(2,1)
WESTBROOK(2,1)
ANTIBIOTIC G ML(1,7)
BORDER DISEASE VIRUS(1,6)
PRIMER OLIGO B(1,5)
AMINOACID ANALOG(1,3)
BIOTYPE(1,3)
EXONUCLEASE(1,3)
FOLDING(1,3)
GLYCEROL(1,3)
LACTOSE(1,3)
LIPOSOME(1,3)
OVERLAPPING PCR(1,3)
P ERNS DNA(1,3)
P ERNS GENOME(1,3)
PCR PRODUCT TREATMENT(1,3)
ACTUATION VOLUME(1,2)
ALKALINE PHOSPHATASE(1,2)
AMINOACID MIMETICS(1,2)
ANTIBODY PRODUCTION(1,2)
ANTISERA(1,2)
ATTENUATION(1,2)
BUFFALO(1,2)
CARRIER VOLUME(1,2)
CLASSICAL SWINE FEVER VIRUS(1,2)
CONSTANT STIRRING(1,2)
DISCRIMINATION(1,2)
DIVIDED DOSE(1,2)
ENGLAND BIOLAB(1,2)
EXCIPIENT(1,2)
FREEMAN(1,2)
GLYCOPROTEIN(1,2)
HELMINTH(1,2)
HYDROXYPROLINE(1,2)
INACTIVATION(1,2)
INHALATION(1,2)
IONTOPHORESIS(1,2)
MENTHOL(1,2)
MICRONEEDLE(1,2)
NEBULIZER(1,2)
NORLEUCINE(1,2)
OINTMENT(1,2)
OLIGONUCLEOTIDE PRIMER(1,2)
P ERNS VIRUS(1,2)
PENTR ERN(1,2)
PLACEBO(1,2)
PRESERVATIVE(1,2)
PROPELLANT(1,2)
RNA VIRUS(1,2)
VIRAL RNA SEQUENCE(1,2)
ABORTED FETUS(1,1)
ACETYL LYSINE(1,1)
ACTIVE RELEASE(1,1)
AEROSOL SPRAY(1,1)
ALKALINE CONDITION(1,1)
ALLERGIC RESPONSE(1,1)
ALPACA(1,1)
AMNIOTIC FLUID(1,1)
ANIMAL SPECIES(1,1)
ANIMAL TISSUE(1,1)
ANOREXIA(1,1)
ANTELOPE(1,1)
ANTIBACTERIAL(1,1)
ANTIBODY DETECTION(1,1)
ANTIBODY LEVEL(1,1)
ANTIBODY PROPORTION(1,1)
ANTIGEN SOURCE(1,1)
ANTIMYCOTIC(1,1)
ARTIFICIAL INSEMINATION(1,1)
ASSAY DEVELOPMENT(1,1)
ASSAY VARIETY(1,1)
BACULODIRECT BACULOVIRUS EXPRESSION(1,1)
BANDAGE(1,1)
BIOADHESIVE AGENT(1,1)
BLISTER(1,1)
BLOOD SAMPLE PAIR(1,1)
BLOODSTREAM(1,1)
BLOT ANALYSIS(1,1)
BORDETELLA BRONCHISEPTICA(1,1)
BOVINE CORONAVIRUS(1,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(1,1)
BOVINE VIRAL DIARRHEA VIRUS SEQUENCE(1,1)
BOVINE VIRAL DIARRHEA VIRUSES(1,1)
BUFFERING AGENT(1,1)
CANDIDA(1,1)
CAPRINE(1,1)
CARBAPENEM(1,1)
CARBOHYDRATE(1,1)
CARBONATE BICARBONATE BUFFER(1,1)
CARBOXYL GROUP(1,1)
CARTRIDGE(1,1)
CASEIN SODIUM SALT(1,1)
CELL EXTRACT(1,1)
CELL POPULATION(1,1)
CELLULOSIC POLYMER(1,1)
CENTRIFUGATION(1,1)
CENTRIFUGE(1,1)
CEPHALOSPORINS(1,1)
CHALLENGE DAY(1,1)
CHAMOIS(1,1)
CHEMICAL COMPONENT(1,1)
CHEMICAL MUTAGENESIS(1,1)
CHEMICAL SYNTHESIS(1,1)
CHEMICALLY INDUCED MUTATION(1,1)
CHIMERA REGION(1,1)
CHIMERIC PESTIVIRUS SPECIFIC EPITOPE(1,1)
CHITOSAN(1,1)
CLINICAL PARAMETER(1,1)
CLINICAL SYNDROME VARIETY(1,1)
CO2 ENVIRONMENT(1,1)
COCOA BUTTER(1,1)
COLI K(1,1)
COLLAGEN(1,1)
COLORIMETRIC DETECTION(1,1)
COMPOUND POWDER MIX(1,1)
COMPOUND SUSPENSION(1,1)
CONFIRMATION SEQUENCE(1,1)
CONFLUENCY(1,1)
CONJUGATE(1,1)
CRYPTOSPORIDIUM PARVUM(1,1)
CYCLODEXTRIN(1,1)
DAY INCUBATION(1,1)
DECREASING SERUM ASSAY(1,1)
DERIVED SEQUENCE(1,1)
DEXTROSE(1,1)
DIRECT PEPTIDE ELISA(1,1)
DISPERSION MEDIUM(1,1)
DISTINCTION(1,1)
DISUBSTITUTED AMINOACID(1,1)
DISULFANE(1,1)
DIVIDED BOTTLE(1,1)
DIVIDED FOIL PACKET(1,1)
DOMESTIC(1,1)
DOSAGE INTERVAL(1,1)
DOSE MULTIPLE ADMINISTRATION(1,1)
DRESSING(1,1)
DRUG PRODUCT(1,1)
DRY BLENDING(1,1)
DUSTING POWDER(1,1)
EDITION(1,1)
ELECTROPORATION(1,1)
ELISA COATING(1,1)
ERADICATION PROGRAM(1,1)
ERYSIPELOTHRIX(1,1)
EXTENSIVE CYTOPATHIC EFFECT(1,1)
FASCIOLA(1,1)
FERRITIN(1,1)
FINAL CONCENTRATION(1,1)
FINAL FORMALDEHYDE CONCENTRATION(1,1)
FINAL SUPERNATANT(1,1)
FOLD DILUTION SERIES(1,1)
GELAN GUM(1,1)
GIVEN PROTEIN DERIVATION(1,1)
GROWTH MEDIUM(1,1)
HAEMOPHILUS PARASUIS(1,1)
HOST ANIMAL(1,1)
HYDROFLUOROCARBON 227EA(1,1)
HYDROXYETHYL CELLULOSE(1,1)
IMMUNITY DURATION(1,1)
IMMUNOCHEMISTRY(1,1)
IMMUNOGENIC ACTIVITY(1,1)
INDUCTION INDICATIVE(1,1)
INFECTED SUBJECT(1,1)
INFUSION(1,1)
ISOTONIC AGENT(1,1)
LAST VACCINATION(1,1)
LATE TERM ABORTION(1,1)
LATTER STRATEGY(1,1)
LETTER SYMBOL(1,1)
MAJOR GENOTYPE(1,1)
MICROORGANISM ABILITY(1,1)
MICROORGANISM PARTIAL PREPARATION(1,1)
MODIFIED PEPTIDE BACKBONE(1,1)
MUTATIONAL DIFFERENCE(1,1)
MYCOBACTERIUM BOVIS(1,1)
MYCOBACTERIUM PARATUBERCULOSIS(1,1)
MYCOPLASMA BOVIS(1,1)
NEGATIVE COW(1,1)
NEGATIVE SEMEN(1,1)
NEGATIVE SERUM(1,1)
NON MAMMALIAN CELL(1,1)
NON TRANSLATED REGION(1,1)
OLIGOLACTIC ACID(1,1)
ORGANIC POLYMER MOLECULE(1,1)
PASTEURELLA MULTOCIDA(1,1)
PERFORMANCE MODIFIER(1,1)
PEROXIDASE SUBSTRATE SOLUTION(1,1)
PLATINUM TAQ DNA POLYMERASE(1,1)
POLYCLONAL MIXTURE(1,1)
PORCINE CELL(1,1)
PORCINE SPECIES(1,1)
PROSTAGLANDIN INJECTION(1,1)
PURIFIED VIRUS(1,1)
R ERNS CHIMERA(1,1)
R ERNS RNA TRANSCRIPT(1,1)
REFRIGERANT R134A(1,1)
REPEATED PASSAGING(1,1)
RETROSPECTIVE SEROLOGICAL TEST(1,1)
SEQUENCE AUTHENTICITY(1,1)
SEQUENCE SIMILARITY(1,1)
SEROLOGIC TESTING(1,1)
SINGULAR TERM(1,1)
SPECIES ABSENCE(1,1)
STERILE NON AQUEOUS SOLUTION(1,1)
STERILE SALINE(1,1)
SUSPENSION CULTURE(1,1)
SUSPENSION FORMULATION(1,1)
TEST VACCINE(1,1)
THIXOTROPIC LIQUID(1,1)
THREE CHIMERA ERNS GENE(1,1)
TITER DETERMINATION(1,1)
UG ML GENTAMICIN(1,1)
ULTRA KIT(1,1)
VACCINE DEVELOPMENT(1,1)
VETERINARY ACCEPTABLE CARRIER(1,1)
VIRAL PROTEIN(1,1)
VIRAL SAMPLE(1,1)
VIRUS BEL MIXTURE(1,1)
VIRUS DILUTION(1,1)
VIRUS FORMALDEHYDE MIXTURE(1,1)
VIRUS ISOLATION(1,1)
VIRUS NEUTRALIZING ACTIVITY(1,1)
VIRUS SUSPENSION(1,1)
WHOLE ORGANISM(1,1)
(US20100136055)
CHIMERIC PESTIVIRUS(100,46)
HETEROLOGOUS EMS PROTEIN(88,12)
DIVA PESTIVIRUS VACCINE(58,4)
EMS EPITOPE(54,10)
VACCINE CHIMERIC PESTIVIRUS(54,2)
HOMOLOGOUS EMS PROTEIN(47,4)
HOMOLOGOUS VIRUS STRAIN(36,1)
IMMUNOGENIC(35,40)
BOVINE VIRAL DIARRHEA VIRUS(34,24)
VACCINE(33,49)
GENETIC VARIANT(33,5)
CHIMERIC PESTIVIRUS CULTURE(33,1)
PATHOGENIC MICROORGANISM(30,3)
COMPOSITION CO ADMINISTRATION(24,1)
DIAGNOSTIC KIT(23,2)
MLV VACCINE(23,2)
VETERINARILY ACCEPTABLE CARRIER(22,9)
ANTIBODY TITER(21,2)
BVDV INFECTION(21,2)
BVDV SPREAD(20,2)
POLYNUCLEOTIDE MOLECULE ENCODING(20,2)
PESTIVIRUS(19,11)
BOVINE VIRAL DIARRHEA VIRUS INFECTION(19,4)
ANTIBODY ABSENCE(18,3)
DIVA VACCINE(16,2)
VETERINARY ACCEPTABLE CARRIER(16,1)
NATURALLY INFECTED ANIMAL(15,2)
ADJUVANT(14,6)
CORRELATION(13,1)
PREMATURE BIRTH(13,1)
REAGENT(12,7)
ANTI MOUSE IGG PEROXIDASE ABC(12,2)
CHIMERIC PESTIVIRUS EMS PROTEIN(12,2)
OLIGO PRIMER(11,12)
ANTIBODY PRESENCE(11,5)
CHIMERIC PESTIVIRUS VACCINE(11,3)
PRONGHORN ANTELOPE PESTIVIRUS CHIMERA(11,1)
DIFFERENTIATION(10,3)
ABORTION(10,2)
PRONGHORN ANTELOPE CHIMERIC PESTIVIRUS(10,1)
METHYLATED PLASMID(9,6)
ADMINISTRATION(9,3)
BVDV NADL ENCODING FRAGMENT(9,3)
DISEASE(9,3)
FETUS(9,3)
VIRAL GENOMIC RNA TRANSCRIPT(9,2)
ANTIBIOTIC(8,10)
MARKER DETERMINANT(8,4)
BVDV FRAGMENT ENCODING(8,3)
CHIMERIC EMS PROTEIN(8,3)
CHIMERIC PESTIVIRUS GENOME(8,2)
CHIMERIC PESTIVIRUS VACCINATED ANIMAL(8,2)
EMS CHIMERIC VIRUS(8,2)
BVDV GIRAFFE CHIMERIC PESTIVIRUS(8,1)
BVDV REINDEER CHIMERIC PESTIVIRUS(8,1)
INTESTINAL MUCOSA ULCERATION(8,1)
VETERINARY LABORATORY AGENCY(7,2)
VIRUS NEUTRALIZATION ASSAY(7,2)
ATTENDING VETERINARIAN SUPERVISION(7,1)
CATTLE(6,8)
VIRUS PARTICLE(6,5)
GROWTH KINETICS(6,4)
PLASMID DNA(6,4)
HARVESTED SUPERNATANT(6,3)
INFECTION SYMPTOM(6,3)
BVDV VACCINATED CATTLE(6,2)
MICROORGANISM REPLICATION(6,2)
MMESSAGE MMACHINE(6,2)
NADL EMS GENE PROTEIN(6,2)
BIOCHEMICAL NOMENCLATURE COMMISSION(6,1)
BVDV NADL PARENTAL VIRUS(6,1)
GIRAFFE EMS GENE(6,1)
IMMUNOGENIC COMPOSITION CHIMERIC PESTIVIRUS(6,1)
MARKER IMMUNOGENIC DETERMINANT(6,1)
MLV BVDV VACCINE(6,1)
PREGNANT CATTLE PLACENTA(6,1)
REGIONAL BVDV ERADICATION PROGRAM(6,1)
RESCUED RECOMBINANT VIRUS IDENTITY(6,1)
VIRAL NEUTRALIZING EPITOPE RECOGNITION(6,1)
BLOCKING(5,6)
PROGRAMMED RELEASE(5,5)
TERM ANTIGEN(5,5)
VECTOR LABORATORY(5,4)
CHIMERIC BVDV CONSTRUCTION(5,3)
PARENTERAL ADMINISTRATION(5,3)
PTA DESIGNATION(5,3)
VIRAL RNA ISOLATION KIT(5,3)
WESTERN BLOTTING(5,3)
BACULO EMS LYSATE(5,2)
FLAVIVIRIDAE FAMILY(5,2)
PARENTAL BVDV(5,2)
PESTIVIRUS ORIGIN(5,2)
PFIZER GLOBAL MANUFACTURING(5,2)
RD CELL CULTURE(5,2)
RESIDUAL LIVE VIRUS(5,2)
RNA TRANSCRIPT QUANTITY(5,2)
VIP PEROXIDASE SUBSTRATE(5,2)
ACTINOBACILLUS PLEUROPNEUMONIE(5,1)
BOVINE LEUKOSIS VIRUS(5,1)
BUNGOWANNAH PESTIVIRUS(5,1)
BVDV DISEASE THREAT(5,1)
BVDV GIRAFFE PESTIVIRUS(5,1)
BVDV INFECTED ANIMAL DIFFERENTIATION(5,1)
BVDV NEGATIVE HEALTHY CALF(5,1)
BVDV NUCLEOCAPSID(5,1)
BVDV REINDEER PESTIVIRUS(5,1)
CHIMERA BIOLOGICAL CLONE(5,1)
CHIMERIC PESTIVIRUS VIRAL ANTIGEN(5,1)
COW DISPLAYING ESTRUM(5,1)
COW PREGNANCY STATUS(5,1)
FETAL INFECTION ETIOLOGIC AGENT(5,1)
INDIRECT IMMUNOFLUORESCENT ASSAY(5,1)
MAB OPTIMIZED DILUTION(5,1)
MICROORGANISM ACCELERATED ELIMINATION(5,1)
NEUTRALIZING ANTIBODY TITER RANGING(5,1)
QIAQUICK GEL EXTRACTION KIT(5,1)
RECOMBINANT BACULOVIRUS STOCK(5,1)
SALMONELLA ENTERICA SEROVAR(5,1)
SERUM NEUTRALIZING TITER(5,1)
UNDILUTED CATTLE SERUM(5,1)
WILD TYPE ANIMAL INFECTION(5,1)
MEDICAMENT PREPARATION(4,3)
AURAL ADMINISTRATION(4,2)
BORDER DISEASE VIRUS(4,2)
CHIMERIC EMS REGION(4,2)
COMPETITIVE ELISA(4,2)
DEER SPECIES(4,2)
DETECTABLE MOIETY(4,2)
DRY POWDER INHALER(4,2)
ELITE KIT(4,2)
EMS PROTEIN COATING(4,2)
HORSE SERUM(4,2)
HUMORAL IMMUNE RESPONSE(4,2)
IMMUNOLOGICAL ASSAY(4,2)
INACTIVATED VIRUS MIXTURE(4,2)
INFECTED CATTLE(4,2)
INFECTION INCIDENCE(4,2)
LIPOFECTIN REAGENT(4,2)
MARKED VACCINE(4,2)
METERED DOSE(4,2)
MICROORGANISM TRANSMISSION(4,2)
SUBUNIT ANTIGEN(4,2)
VIRAL RNA TRANSFECTION(4,2)
ABSORBABLE GEL SPONGE(4,1)
ACETYLL YSINE(4,1)
AGENT FACILITATING CELLULAR UPTAKE(4,1)
ANTI IDIOTYPE ANTIBODY(4,1)
BABESIA SPP(4,1)
BACILLUS ANTHRACIS(4,1)
BDV EMS MONOCLONAL ANTIBODY(4,1)
BLACKWELL SCIENTIFIC PUBLICATION(4,1)
BOOSTING REGIMEN(4,1)
BOVI SHIELD GOLD(4,1)
BOVINE HERPES VIRUS(4,1)
BOVINE PARAINFLUENZA VIRUS(4,1)
BOVINE TESTICULAR CELL(4,1)
BRUCELLA SPP(4,1)
BVDV ANTIGEN(4,1)
BVDV GENOME(4,1)
BVDV POLYPEPTIDE(4,1)
BVDV VIRION(4,1)
CATTLE SERUM DILUTION(4,1)
CATTLE VACCINE(4,1)
CERTIFIED BVDV NEGATIVE SEMEN(4,1)
CHALLENGE INOCULUM(4,1)
CHIMERA NEUTRALIZATION(4,1)
CHIMERIC PESTIVIRUS PRESENCE(4,1)
CHLAMYDIA SPP(4,1)
CLOSTRIDIAL SPP(4,1)
CONTRADICTORY DEFINITION(4,1)
CORNELL UNIVERSITY(4,1)
CP BIOTYPE(4,1)
DIFFERENTIAL DIAGNOSTIC ASSAY(4,1)
DIVERGENT PESTIVIRUS(4,1)
DONOR CALF SERUM(4,1)
EIMERIA SPP(4,1)
EMS SUBSTITUTION(4,1)
GIARDIA SPP(4,1)
HAEMOPHILUS SOMNUS(4,1)
HERD CERTIFICATION(4,1)
HORSERADISH PEROXIDASE(4,1)
IMMUNOFLUORESCENT STAINING(4,1)
IMMUNOHISTOCHEMISTRY STAINING(4,1)
INTRANASAL INOCULATION(4,1)
KIT FORM(4,1)
LEPTOSPIRA SPP(4,1)
MANNHEMIA HAEMOLYTICA(4,1)
METHIONINE METHYLSULFONIUM(4,1)
METHIONINE SULFOXIDE(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
NANODROP SPECTROPHOTOMETER(4,1)
NEBRASKA UNIVERSITY(4,1)
NEOSPORA CANIUM(4,1)
NON VACCINATED ANIMAL(4,1)
PATHOGENIC FUNGUS(4,1)
PESTIVIRUS GENUS(4,1)
POSTCHALLENGE INTERVAL(4,1)
RECOMBINANT PLASMID(4,1)
RESPONDING CYTOTOXIC DETECTION(4,1)
RNA MOLECULE ENCODING(4,1)
SERUM NEUTRALIZATION ASSAY(4,1)
SERUM SERIAL DILUTION(4,1)
SORBITAN TRIOLEATE(4,1)
STAPHYLOCOCCUS AUREUS(4,1)
STREPTOCOCCUS UBERIS(4,1)
SYNTHETIC PEPTIDE MIMOTOPE(4,1)
TOXOPLASMA GONDII(4,1)
TRADE ECONOMIC BENEFIT FREEDOM(4,1)
UNIQUE PESTIVIRUS SPECIES(4,1)
UNIVERSITY BOULEVARD(4,1)
VIRUS DISSEMINATION(4,1)
CDNA(3,11)
P EMS GENE(3,6)
ATCC(3,5)
MODIFIED RELEASE FORMULATION(3,5)
ANTIGENIC DETERMINANT(3,4)
ATOMIZER(3,4)
P EMS GENOME(3,4)
ANIMAL TEST POSITIVE(3,3)
COLOR DEVELOPMENT(3,3)
PURIFIED PCR PRODUCT(3,3)
THERMOSCRIPT(3,3)
BOVINE CELL CULTURE(3,2)
BVDV EMS SPECIFIC MAB(3,2)
BVDV ISOLATION(3,2)
CELL MONOLAYER(3,2)
ELECTROHYDRODYNAMICS(3,2)
FINE MIST(3,2)
HYDROXYPROPYLMETHYLCELLULOSE(3,2)
O PHOSPHOSERINE(3,2)
PRESSURIZED CONTAINER(3,2)
RNA GEL(3,2)
RT PCR PRODUCT(3,2)
TEST ANTIGEN(3,2)
ULTRA KIT(3,2)
ADSORPTION DELAYING(3,1)
AMINOGLYCOSIDE CLASS(3,1)
ANTIGEN SITE(3,1)
BDV EMS MAB(3,1)
BORDER DISEASE CAUSATIVE AGENT(3,1)
BOVINE SERUM SAMPLE(3,1)
BVD VIRUS(3,1)
BVDV ANTIBODY(3,1)
CAPSID PROTEIN(3,1)
CATIONIC LIPID(3,1)
CATTLE SERUM SAMPLE(3,1)
CELLULAR IMMUNOLOGY(3,1)
CESAREAN DELIVERY(3,1)
CHIMERA ENCODING REGION(3,1)
CHIMERIC PRONGHORN EM REGION(3,1)
CHIMERIC VIRUS TITER(3,1)
CONFIRMED PREGNANCY(3,1)
CONJUGATION DISCUSSION(3,1)
CULTURE SUPERNATANT(3,1)
DOSAGE REGIMEN(3,1)
ELISA ANTIGEN PRODUCTION(3,1)
ENVELOPE PROTEIN(3,1)
ENZYMATIC MOIETY(3,1)
GASTROINTESTINAL DISEASE(3,1)
GESTATION DAY(3,1)
GROWING MICROORGANISM(3,1)
HETEROPOLYSACCHARIDE POLYMER(3,1)
HYDROPHOBIC MEMBRANE ABSENCE(3,1)
IMMUNOASSAY FORMAT(3,1)
IMMUNOGLOBULIN MOLECULE(3,1)
IMPLANTED DEPOT(3,1)
INOCULATED ANIMAL(3,1)
LABELED MAB(3,1)
LIVE BACTERIA(3,1)
MAB STAINING(3,1)
MICRONIZED SUSPENSION(3,1)
MONOCLONAL ANTIBODY 15C(3,1)
NON INFECTED ANIMAL(3,1)
NUCLEOTIDE MONOMER(3,1)
OPTIMAL IMMUNIZATION(3,1)
PARENTERAL FORMULATION(3,1)
PENETRATION ENHANCER(3,1)
POST CHALLENGE ISOLATION(3,1)
STERILE ADJUVANT(3,1)
ULTRAVIOLET IRRADIATION(3,1)
UNCHALLENGED ANIMAL(3,1)
VACCINE DOSE(3,1)
VACCINE EFFICACY(3,1)
VIBRIO SPP(3,1)
VIRAL GENOME(3,1)
VIRUS FETAL TRANSMISSION(3,1)
WESTBROOK(3,1)
P EMS DNA(2,5)
EXONUCLEASE(2,3)
FULL LENGTH CHIMERIC BVDV(2,3)
HOST CELL(2,3)
LACTOSE(2,3)
LIPOSOME(2,3)
MAGMAX AL(2,3)
OVERLAPPING PCR(2,3)
P EMS CHIMERA(2,3)
PCR PRODUCT TREATMENT(2,3)
VIRUS INFECTION(2,3)
ACTUATION VOLUME(2,2)
ALKALINE PHOSPHATASE(2,2)
AMINOACID MIMETICS(2,2)
ANIMAL SUBJECT(2,2)
ANTIBODY PRODUCTION(2,2)
ANTISERA(2,2)
ATTENUATION(2,2)
BUFFALO(2,2)
CARRIER VOLUME(2,2)
CONSTANT STIRRING(2,2)
CPE(2,2)
DIVIDED DOSE(2,2)
ENGLAND BIOLAB(2,2)
EXCIPIENT(2,2)
FREEMAN(2,2)
GLYCOPROTEIN(2,2)
HELMINTH(2,2)
INACTIVATION(2,2)
INHALATION(2,2)
IONTOPHORESIS(2,2)
MICRONEEDLE(2,2)
MODIFIED EAGLE(2,2)
NEBULIZER(2,2)
NORLEUCINE(2,2)
OINTMENT(2,2)
OLIGONUCLEOTIDE PRIMER(2,2)
P EMS VIRUS(2,2)
PLACEBO(2,2)
PRESERVATIVE(2,2)
PREVENTION(2,2)
PROPELLANT(2,2)
R EMS CHIMERA(2,2)
R EMS GENE(2,2)
RNA VIRUS(2,2)
VIRAL RNA SEQUENCE(2,2)
ABT SUBSTRATE(2,1)
AEROSOL SPRAY(2,1)
AMNIOTIC FLUID(2,1)
ANIMAL SPECIES(2,1)
ANIMAL TISSUE(2,1)
ANTIBODY DETECTION(2,1)
ASSAY DEVELOPMENT(2,1)
BACULODIRECT BACULOVIRUS EXPRESSION(2,1)
BENZALKONIUM CHLORIDE(2,1)
BIOADHESIVE AGENT(2,1)
BLOT ANALYSIS(2,1)
BORDETELLA BRONCHISEPTICA(2,1)
BUFFERING AGENT(2,1)
BVDV NEGATIVE COW(2,1)
BVDV SPECIFIC MAB(2,1)
CARBONATE BICARBONATE BUFFER(2,1)
CASEIN SODIUM SALT(2,1)
CELL EXTRACT(2,1)
CELL POPULATION(2,1)
CELL RECEPTOR(2,1)
CELLULOSIC POLYMER(2,1)
CHEMICAL COMPONENT(2,1)
CHEMICAL MUTAGENESIS(2,1)
CHEMICALLY INDUCED MUTATION(2,1)
CHIMERA REGION(2,1)
CHIMERIC PESTIVIRUS SPECIFIC EPITOPE(2,1)
CLINICAL PARAMETER(2,1)
CLINICAL SYNDROME VARIETY(2,1)
CO2 ENVIRONMENT(2,1)
COLORIMETRIC DETECTION(2,1)
COMPOUND POWDER MIX(2,1)
COMPOUND SUSPENSION(2,1)
CONFIRMATION SEQUENCE(2,1)
CRYPTOSPORIDIUM PARVUM(2,1)
DAY INCUBATION(2,1)
DECREASING SERUM ASSAY(2,1)
DIVIDED BOTTLE(2,1)
DIVIDED FOIL PACKET(2,1)
DOSAGE INTERVAL(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
DUSTING POWDER(2,1)
ELISA COATING(2,1)
EXPANDED BVDV(2,1)
FINAL BEI CONCENTRATION(2,1)
FINAL FORMALDEHYDE CONCENTRATION(2,1)
FINAL SUPERNATANT(2,1)
FOLD DILUTION SERIES(2,1)
GELAN GUM(2,1)
GIVEN PROTEIN DERIVATION(2,1)
GROWTH MEDIUM(2,1)
HAEMOPHILUS PARASUIS(2,1)
HOST ANIMAL(2,1)
IMMUNITY DURATION(2,1)
IMMUNOCHEMISTRY(2,1)
IMMUNOGENIC ACTIVITY(2,1)
INDUCTION INDICATIVE(2,1)
INFECTED SUBJECT(2,1)
INFECTION TREATMENT(2,1)
INFUSION(2,1)
ISOTONIC AGENT(2,1)
LAST VACCINATION(2,1)
LATE TERM ABORTION(2,1)
LATTER STRATEGY(2,1)
LETTER SYMBOL(2,1)
MAB 15C(2,1)
MAGNESIUM STEARATE(2,1)
MAJOR GENOTYPE(2,1)
METHYLHISTIDINE(2,1)
METHYLTRANSFERASE(2,1)
MICROORGANISM ABILITY(2,1)
MICROORGANISM PARTIAL PREPARATION(2,1)
MOUTH DISEASE VIRUS(2,1)
MUTATIONAL DIFFERENCE(2,1)
MYCOBACTERIUM BOVIS(2,1)
MYCOBACTERIUM PARATUBERCULOSIS(2,1)
MYCOPLASMA BOVIS(2,1)
NEGATIVE SERUM(2,1)
NON MAMMALIAN CELL(2,1)
NON TRANSLATED REGION(2,1)
OLIGOLACTIC ACID(2,1)
ORGANIC POLYMER MOLECULE(2,1)
PASTEURELLA MULTOCIDA(2,1)
PEPTIDE BACKBONE MODIFICATION(2,1)
PEPTIDE ELISA(2,1)
PERFORMANCE MODIFIER(2,1)
PEROXIDASE SUBSTRATE SOLUTION(2,1)
POLYCLONAL MIXTURE(2,1)
PORCINE CELL(2,1)
PORCINE SPECIES(2,1)
PRINT INSTRUCTION(2,1)
PROSTAGLANDIN INJECTION(2,1)
PURIFIED VIRUS(2,1)
R EMS RNA TRANSCRIPT(2,1)
REPEATED PASSAGING(2,1)
SEQUENCE AUTHENTICITY(2,1)
SEQUENCE SIMILARITY(2,1)
SEROLOGIC TESTING(2,1)
SINGULAR TERM(2,1)
SODIUM THIOSULFATE(2,1)
SPECIES ABSENCE(2,1)
STERILE NON AQUEOUS SOLUTION(2,1)
STERILE SALINE(2,1)
SUSPENSION CULTURE(2,1)
SUSPENSION FORMULATION(2,1)
TERM ANTIBODY(2,1)
TERM BVDV(2,1)
TERM IMMUNOGENIC(2,1)
TERM PATHOGEN(2,1)
TERM PESTIVIRUS(2,1)
TERM POLYNUCLEOTIDE MOLECULE(2,1)
TERM VACCINE(2,1)
TEST VACCINE(2,1)
TETRAFLUOROETHANE(2,1)
THIXOTROPIC LIQUID(2,1)
THREE BVDV FROZEN STOCK(2,1)
THREE CHIMERA EMS GENE(2,1)
TITER DETERMINATION(2,1)
VIRAL PROTEIN(2,1)
VIRAL SAMPLE(2,1)
VIRUS BEI MIXTURE(2,1)
VIRUS DILUTION(2,1)
VIRUS FORMALDEHYDE MIXTURE(2,1)
VIRUS ISOLATION(2,1)
VIRUS NEUTRALIZING ACTIVITY(2,1)
VIRUS SUSPENSION(2,1)
WHOLE BVDV PRESENCE(2,1)
WHOLE ORGANISM(2,1)
AMINOACID ANALOG(1,3)
FOLDING(1,3)
PBS(1,3)
PROPYLENE GLYCOL(1,3)
ABORTED FETUS(1,1)
ACTIVE RELEASE(1,1)
ALKALINE CONDITION(1,1)
ALLERGIC RESPONSE(1,1)
ALPACA(1,1)
ANOREXIA(1,1)
ANTELOPE(1,1)
ANTIBACTERIAL(1,1)
ANTIBODY LEVEL(1,1)
ANTIBODY PROPORTION(1,1)
ANTIGEN SOURCE(1,1)
ANTIMYCOTIC(1,1)
AQUEOUS ETHANOL(1,1)
ARTIFICIAL INSEMINATION(1,1)
ASSAY VARIETY(1,1)
BANDAGE(1,1)
BIRTH(1,1)
BLISTER(1,1)
BLOOD SAMPLE PAIR(1,1)
BLOODSTREAM(1,1)
BOVINE CORONAVIRUS(1,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(1,1)
BOVINE VIRAL DIARRHEA VIRUS SEQUENCE(1,1)
CANDIDA(1,1)
CAPRINE(1,1)
CARBAPENEM(1,1)
CARBOHYDRATE(1,1)
CARBOXYL GROUP(1,1)
CARTRIDGE(1,1)
CENTRIFUGATION(1,1)
CENTRIFUGE(1,1)
CEPHALOSPORIN(1,1)
CHAMOIS(1,1)
CHEMICAL SYNTHESIS(1,1)
CHITOSAN(1,1)
CLASSICAL SWINE FEVER VIRUS(1,1)
COCOA BUTTER(1,1)
COLLAGEN(1,1)
CYCLODEXTRIN(1,1)
DERIVED SEQUENCE(1,1)
DEXTROSE(1,1)
DISCRIMINATION(1,1)
DISPERSION MEDIUM(1,1)
DISTINCTION(1,1)
DISUBSTITUTED AMINOACID(1,1)
DISULFIDE(1,1)
DOMESTIC(1,1)
DRESSING(1,1)
DRUG PRODUCT(1,1)
DRY BLENDING(1,1)
EDITION(1,1)
ELECTROPORATION(1,1)
ERYSIPELOTHRIX(1,1)
ETHYLAMINE(1,1)
EXTENSIVE CYTOPATHIC EFFECT(1,1)
FASCIOLA(1,1)
FERRITIN(1,1)
FINAL CONCENTRATION(1,1)
FLAVOR(1,1)
FLUID BED(1,1)
FLUORESCEIN(1,1)
FORMALIN(1,1)
FREEZE DRYING(1,1)
FRUCTOSE(1,1)
(US9567375)
CHIMERIC PESTIVIRUS(100,34)
BOVINE VIRAL DIARRHEA VIRUS(100,28)
DIVA PESTIVIRUS VACCINE(95,4)
PRONGHORN ANTELOPE PESTIVIRUS(83,3)
PRONGHORN ANTELOPE EMS PROTEIN(71,1)
HETEROLOGOUS EMS PROTEIN(66,6)
VACCINE CHIMERIC PESTIVIRUS(62,1)
HOMOLOGOUS VIRUS STRAIN(59,1)
IMMUNOGENIC(58,40)
PATHOGENIC MICROORGANISM(50,3)
EMS PROTEIN(47,5)
VACCINE(46,43)
HOMOLOGOUS EMS PROTEIN(45,3)
EMS EPITOPE(40,4)
COMPOSITION CO ADMINISTRATION(39,1)
MLV VACCINE(37,2)
VETERINARILY ACCEPTABLE CARRIER(36,9)
BVDV INFECTION(35,2)
ANTIBODY TITER(34,2)
BVDV SPREAD(33,2)
POLYNUCLEOTIDE MOLECULE ENCODING(33,2)
GENETIC VARIANT(27,3)
DIVA VACCINE(27,2)
DIAGNOSTIC KIT(27,1)
VETERINARY ACCEPTABLE CARRIER(26,1)
NATURALLY INFECTED ANIMAL(25,2)
ADJUVANT(23,6)
BOVINE VIRAL DIARRHEA VIRUS INFECTION(22,3)
CORRELATION(21,1)
PREMATURE BIRTH(21,1)
ISOLATED HOST CELL(20,1)
OLIGO PRIMER(19,12)
CHIMERIC PESTIVIRUS VACCINE(19,3)
ANTI MOUSE IGG PEROXIDASE ABC(19,2)
CHIMERIC PESTIVIRUS EMS PROTEIN(19,2)
ANTIBODY PRESENCE(18,5)
PRONGHORN ANTELOPE PESTIVIRUS CHIMERA(18,1)
PESTIVIRUS(17,9)
DIFFERENTIATION(17,3)
ABORTION(17,2)
PRONGHORN ANTELOPE CHIMERIC PESTIVIRUS(17,1)
METHYLATED PLASMID(16,6)
REAGENT(16,6)
BVDV NADL ENCODING FRAGMENT(16,3)
ADMINISTRATION(15,3)
DISEASE(15,3)
FETUS(15,3)
VIRAL GENOMIC RNA TRANSCRIPT(15,2)
ANTIBIOTIC(14,10)
BVDV FRAGMENT ENCODING(14,3)
CHIMERIC EMS PROTEIN(14,3)
CHIMERIC PESTIVIRUS GENOME(14,2)
MARKER DETERMINANT(13,4)
CHIMERIC PESTIVIRUS VACCINATED ANIMAL(13,2)
EMS CHIMERIC VIRUS(13,2)
BVDV GIRAFFE CHIMERIC PESTIVIRUS(13,1)
BVDV REINDEER CHIMERIC PESTIVIRUS(13,1)
INTESTINAL MUCOSA ULCERATION(13,1)
VIRUS NEUTRALIZATION ASSAY(12,2)
ATTENDING VETERINARIAN SUPERVISION(12,1)
CATTLE(11,8)
INFECTION SYMPTOM(11,3)
VETERINARY LABORATORY AGENCY(11,2)
PREGNANT CATTLE PLACENTA(11,1)
REGIONAL BVDV ERADICATION PROGRAM(11,1)
RESCUED RECOMBINANT VIRUS IDENTITY(11,1)
VIRAL NEUTRALIZING EPITOPE RECOGNITION(11,1)
VIRUS PARTICLE(10,5)
GROWTH KINETICS(10,4)
PLASMID DNA(10,4)
HARVESTED SUPERNATANT(10,3)
BVDV VACCINATED CATTLE(10,2)
MICROORGANISM REPLICATION(10,2)
MMESSAGE MMACHINE(10,2)
NADL EMS GENE PROTEIN(10,2)
BIOCHEMICAL NOMENCLATURE COMMISSION(10,1)
BVDV NADL PARENTAL VIRUS(10,1)
GIRAFFE EMS GENE(10,1)
IMMUNOGENIC COMPOSITION CHIMERIC PESTIVIRUS(10,1)
MARKER IMMUNOGENIC DETERMINANT(10,1)
MLV BVDV VACCINE(10,1)
BLOCKING(9,6)
VECTOR LABORATORY(9,4)
CHIMERIC BVDV CONSTRUCTION(9,3)
MAGMAX AI(9,3)
PARENTERAL ADMINISTRATION(9,3)
PTA DESIGNATION(9,3)
VIRAL RNA ISOLATION KIT(9,3)
WESTERN BLOTTING(9,3)
BACULO EMS LYSATE(9,2)
CHIMERIC TYPE(9,2)
FLAVIVIRIDAE FAMILY(9,2)
PARENTAL BVDV(9,2)
PESTIVIRUS ORIGIN(9,2)
PFIZER GLOBAL MANUFACTURING(9,2)
RD CELL CULTURE(9,2)
RESIDUAL LIVE VIRUS(9,2)
RNA TRANSCRIPT QUANTITY(9,2)
VIP PEROXIDASE SUBSTRATE(9,2)
BOVINE LEUKOSIS VIRUS(9,1)
BVDV DISEASE THREAT(9,1)
CHIMERA BIOLOGICAL CLONE(9,1)
CHIMERIC PESTIVIRUS VIRAL ANTIGEN(9,1)
INDIRECT IMMUNOFLUORESCENT ASSAY(9,1)
NEUTRALIZING ANTIBODY TITER RANGING(9,1)
UNDILUTED CATTLE SERUM(9,1)
WILD TYPE ANIMAL INFECTION(9,1)
PROGRAMMED RELEASE(8,5)
TERM ANTIGEN(8,5)
MEDICAMENT PREPARATION(8,3)
ACTINOBACILLUS PLEUROPNEUMONIE(8,1)
BUNGOWANNAH PESTIVIRUS(8,1)
BVDV GIRAFFE PESTIVIRUS(8,1)
BVDV INFECTED ANIMAL DIFFERENTIATION(8,1)
BVDV NEGATIVE HEALTHY CALF(8,1)
BVDV NUCLEOCAPSID(8,1)
BVDV REINDEER PESTIVIRUS(8,1)
COW DISPLAYING ESTRUM(8,1)
COW PREGNANCY STATUS(8,1)
FETAL INFECTION ETIOLOGIC AGENT(8,1)
MAB OPTIMIZED DILUTION(8,1)
MICROORGANISM ACCELERATED ELIMINATION(8,1)
QIAQUICK GEL EXTRACTION KIT(8,1)
RECOMBINANT BACULOVIRUS STOCK(8,1)
SALMONELLA ENTERICA SEROVAR(8,1)
SERUM NEUTRALIZING TITER(8,1)
AURAL ADMINISTRATION(7,2)
CHIMERIC EMS REGION(7,2)
COMPETITIVE ELISA(7,2)
DEER SPECIES(7,2)
DETECTABLE MOIETY(7,2)
EMS PROTEIN COATING(7,2)
IMMUNOLOGICAL ASSAY(7,2)
INFECTED CATTLE(7,2)
INFECTION INCIDENCE(7,2)
LIPOFECTIN REAGENT(7,2)
MARKED VACCINE(7,2)
SUBUNIT ANTIGEN(7,2)
VIRAL RNA TRANSFECTION(7,2)
ABSORBABLE GEL SPONGE(7,1)
BLACKWELL SCIENTIFIC PUBLICATION(7,1)
BOVI SHIELD GOLD(7,1)
BVDV ANTIGEN(7,1)
CERTIFIED BVDV NEGATIVE SEMEN(7,1)
CHIMERA NEUTRALIZATION(7,1)
DIVERGENT PESTIVIRUS(7,1)
DONOR CALF SERUM(7,1)
HAEMOPHILUS SOMNUS(7,1)
HERD CERTIFICATION(7,1)
IMMUNOFLUORESCENT STAINING(7,1)
IMMUNOHISTOCHEMISTRY STAINING(7,1)
MANNHEMIA HAEMOLYTICA(7,1)
METHIONINE METHYLSULFONIUM(7,1)
NANODROP SPECTROPHOTOMETER(7,1)
NEOSPORA(...)";"Analysis of biological materials
Biotechnology
Measurement
Pharmaceuticals";Open
"2008-10-31
2009-10-22";"WO2010051210        A1 2010-05-06 [WO201051210]
STG: (A1) Published application with search report
AP : 2009WO-US61610 2009-10-22
CA2740954           A1 2010-05-06 [CA2740954]
STG: (A1) Application laid open
AP : 2009CA-2740954 2009-10-22
AU2009309041        A1 2010-05-06 [AU2009309041]
STG: (A1) Open to public inspection
AP : 2009AU-0309041 2009-10-22
UY32208             A  2010-05-31 [UY--32208]
STG: (A) Patent application
AP : 2009UY-0032208 2009-10-29
AR074083            A1 2010-12-22 [AR--74083]
STG: (A1) Independent patent application
AP : 2009AR-0104219 2009-10-30
MX2011004316        A  2011-06-16 [MX2011004316]
STG: (A) Patent application
AP : 2011MX-PA04316 2009-10-22
KR20110089260       A  2011-08-05 [KR20110089260]
STG: (A) Published application
AP : 2011KR-7009366 2009-10-22
EP2362780           A1 2011-09-07 [EP2362780]
STG: (A1) Application published with search report
AP : 2009EP-0752247 2009-10-22
CN102202685         A  2011-09-28 [CN102202685]
STG: (A) Published application
AP : 2009CN-80142863 2009-10-22
BRPI0921748         A2 2011-12-06 [BR200921748]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2009BR-0021748 2009-10-22
CO6361948           A2 2012-01-20 [CO6361948]
STG: (A2) Application derived from a PCT application
AP : 2011CO-0058044 2011-05-11
JP2012507537        A  2012-03-29 [JP2012507537]
STG: (A) Published application
AP : 2011JP-0534628 2009-10-22
IN3345/DELNP/2011   A  2012-03-30 [IN2011DN03345]
STG: (A) Application laid open
AP : 2011IN-DN03345 2011-05-05
US20120093854       A1 2012-04-19 [US20120093854]
STG: (A1) Application published
AP : 2009US-13056501 2009-10-22
NZ591950            A  2012-12-21 [NZ-591950]
STG: (A) Published application
AP : 2009NZ-0591950 2009-10-22
BRPI0921748         A1 2013-10-08 [BR200921748]
STG: (A1) Published application
AP : 2009BR-0021748 2009-10-22
US8815255           B2 2014-08-26 [US8815255]
STG: (B2) Granted patent as second publication
AP : 2009US-13056501 2009-10-22
FD :  Provisional Appl: US61/110,286 FDD=2008-10-31 [2008US-61110286]
FD : Previous publication: US20120093854 A1 2012-04-19 [US20120093854]
SG10201506597R      A  2015-10-29 [SG10201506597R]
STG: (A) Patent Application / PCT entering national phase
AP : 2015SG-1006597R 2009-10-22
AU2009309041        B2 2016-02-04 [AU2009309041]
STG: (B2) Patent proceeded by OPI
AP : 2009AU-0309041 2009-10-22
CA2740954           C  2018-09-25 [CA2740954]
STG: (C) Patent (second level)
AP : 2009CA-2740954 2009-10-22";6822541;"WO2010051210        A1 2010-05-06 [WO201051210]
CA2740954           A1 2010-05-06 [CA2740954]
AU2009309041        A1 2010-05-06 [AU2009309041]
UY32208             A  2010-05-31 [UY--32208]
AR074083            A1 2010-12-22 [AR--74083]
MX2011004316        A  2011-06-16 [MX2011004316]
KR20110089260       A  2011-08-05 [KR20110089260]
EP2362780           A1 2011-09-07 [EP2362780]
CN102202685         A  2011-09-28 [CN102202685]
BRPI0921748         A2 2011-12-06 [BR200921748]
CO6361948           A2 2012-01-20 [CO6361948]
JP2012507537        A  2012-03-29 [JP2012507537]
IN3345/DELNP/2011   A  2012-03-30 [IN2011DN03345]
US20120093854       A1 2012-04-19 [US20120093854]
NZ591950            A  2012-12-21 [NZ-591950]
BRPI0921748         A1 2013-10-08 [BR200921748]
US8815255           B2 2014-08-26 [US8815255]
SG10201506597R      A  2015-10-29 [SG10201506597R]
AU2009309041        B2 2016-02-04 [AU2009309041]
CA2740954           C  2018-09-25 [CA2740954]";"2008US-61110286
2009US-13056501
2009WO-US61610";"(EP2362780)
WO2010051210
(US8815255)
WO2010051210
(JP2012507537)
WO2010051210
(MX2011004316)
WO2010051210
(KR20110089260)
WO2010051210
(CN102202685)
WO2010051210
(NZ-591950)
WO2010051210
(BR200921748)
WO2010051210
(AU2009309041)
WO2010051210
(CA2740954)
WO2010051210";"BOEHRING INGELHEIM VETMEDICA
BOEHRINGER INGELHEIM VETMEDICA";BOEHRINGER INGELHEIM VETMEDICA;"(EP2362780)
US
(US20120093854)
US
(US8815255)
US
(WO201051210)
US


(BR200921748)
US

(CA2740954)
US
(CA2740954)
US";"(EP2362780)
NAME=Boehringer Ingelheim Vetmedica, Inc. 2621 North Belt Highway , CITY=St. Joseph, MO 64506-2002 , COUNTRY=US 

(US20120093854)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. , CITY=St. Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 

(US8815255)
NAME=Boehringer Ingelheim Vetmedica, Inc. , CITY=St. Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 

(WO201051210)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC.  2621 North Belt Highway, St. Joseph, Missouri 64506-2002  , COUNTRY=US 

(JP2012507537)
NAME=Boehringer Ingelheim Fetomedika Incorporated , REG=503345374 

(KR20110089260)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. , REG=519986003585 

(BR200921748)
NAME=BOEHRING INGELHEIM VETMEDICA INC , COUNTRY=US 

(SG10201506597R)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. 2621 North Belt Highway St. Joseph, Missouri 64506-2002 US 

(CA2740954)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. 2621 North Belt Highway , CITY=ST. JOSEPH , STATE=MO , POSTCODE=64506-2002 , COUNTRY=US 

(CA2740954)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. 2621 North Belt Highway , CITY=ST. JOSEPH , STATE=MO , POSTCODE=64506-2002 , COUNTRY=US 
";1;"KNITTEL JEFFREY
BECK MICHAEL
HAYES PHILLIP WAYNE";"(EP2362780)
US";"(EP2362780)
NAME=KNITTEL, Jeffrey Boehringer Ingelheim Vetmedica Inc. 2621 North Belt Highway , CITY=St. Joseph, Missouri 64506-2002 , COUNTRY=US 

NAME=BECK, Michael Boehringer Ingelheim Vetmedica Inc. 2621 North Belt Highway , CITY=St. Joseph, Missouri 64506-2002 , COUNTRY=US 

NAME=HAYES, Phillip Wayne Boehringer Ingelheim Vetmedica Inc. 2621 North Belt Highway , CITY=St. Joseph, Missouri 64506-2002 , COUNTRY=US 
";"(EP2362780)
Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition";"(EP2362780)
The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least one M. bovis antigen, preferably the attenuated, avirulent M. bovis as provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.";"(WO201051210)
CLAIMS
1. An immunogenic composition for the treatment and/or prophylaxis of cattle against microbiological infections, wherein said immunogenic composition comprises a. one or more M. bovis antigens; and b. one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of microbiological infection in cattle caused by a cattle pathogen other than M. bovis.
2. The immunogenic composition according to claim 1, wherein the M. bovis antigen is an attenuated, avirulent M. bovis bacterium.
3. The immunogenic composition according to claims 1 or 2, wherein the M. bovis bacterium is passaged more than 10 times.
4. The immunogenic composition according to any of claims 1 to 3 , wherein the M. bovis bacterium is passaged more than 50 times.
5. The immunogenic composition according to any one of claims 1 to 4, wherein the M. bovis bacterium is selected from the group consisting of: the attenuated M. bovis bacteria strains deposited with the ATCC under accession numbers PTA-8694, PTA- 8695, or PTA-8696; any attenuated descendant M. bovis bacteria strains thereof; any attenuated, avirulent M. bovis bacterium strain having the same characteristics as any of the M. bovis bacteria strains deposited with the ATCC under accession numbers PTA-8694,
 PTA-8695 or PTA-8696, and combinations thereof.
6. The immunogenic composition according to any one of claims 1 to 5, wherein said microbiological infection in cattle caused by a cattle pathogen other than M. bovis is caused by one or more pathogens selected from the group consisting of:
 Bovine viral diarrhea virus (BVDV), Parainfluenza-3 Virus (PI-3), Infectious Bovine
 Rhinotracheitis virus (IBR), Bovine Respiratory Syncytial Virus (BRSV), Bovine Herpesvirus (BHV), Bovine Rotavirus (BRV), Bovine Enterovirus (BEV), Bovine
 Coronovirus (BCV), Bovine Rabies (BR), Bovine Parvovirus (BPV), Adenovirus
 Astro virus, Mannheimia haemolytica (formerly Pasteurella haemolytica), Pasteurella multocida, Haemophilus somnus (Histophilus ovis and Haemophilus agni),
 Actinomyces (Corynebacterium), Actinomyces pyogenes, Chlamydia psittaci, Campylobacter fetus venerealis and Campylobacter fetus fetus (formerly C fetus intestinalis ), Leptospira interrogans, Leptospira hardjo, Leptospira pomona, and
 Leptospira grippotyphosa, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo (Leptospira hardjopraμtno and Leptospira hardjo-bovis), Brucella abortus,
 Brucella suis and Brucella melitensis, Listeria monocytogenes, Chlamydia psittaci, Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordellii, Clostridium perfringens, Clostridium tetani, Moraxella bovis, Klebsiella spp, Klebsiella pneumoniae, Salmonella typhimurium; Salmonella newport, Mycobacterium avium paratuberculosis, Cryptsporidium parvum,
 Cryptsporidium hominis, Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus agalactiae, Escherichia coli, Mycoplasma spp,
 Mycoplasma dispar, and Ureaplasma spp., Tritrichomonas foetus, Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton sarkisovii, Neospora caninum (formerly Toxoplasma gondii), Babesia bigemina and Babesia bovis, Dictyocaulus viviparous (Lungworm disease), and combinations thereof.
7. The immunogenic composition according to any one of claims 1 to 6, wherein the further immunologically active component(s) is/are antigen(s) of one or more of the pathogens selected from the group consisting of:
 Bovine viral diarrhea virus (BVDV), Parainfluenza-3 Virus (PI-3), Infectious Bovine Rhinotracheitis virus (IBR), Bovine Respiratory Syncytial Virus (BRSV), Bovine Herpesvirus (BHV), Bovine Rotavirus (BRV), Bovine Enterovirus (BEV), Bovine Coronovirus (BCV), Bovine Rabies (BR), Bovine Parvovirus (PPV), Adenovirus Astro virus, Mannheimia haemolytica (formerly Pasteurella haemolytica), Pasteurella multocida, Haemophilus somnus (Histophilus ovis and Haemophilus agni),
 Actinomyces (Corynebacterium), Actinomyces pyogenes, Chlamydia psittaci, Campylobacter fetus venerealis and Campylobacter fetus fetus (formerly C fetus intestinalis ), Leptospira interrogans, Leptospira hardjo, Leptospira pomona, and Leptospira grippotyphosa, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo {Leptospira hardj opraμtno and Leptospira hardjo-bovis), Brucella abortus,
 Brucella suis and Brucella melitensis, Listeria monocytogenes, Chlamydia psittaci, Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordellii, Clostridium perfringens, Clostridium tetani, Moraxella bovis, Klebsiella spp, Klebsiella pneumoniae, Salmonella typhimurium; Salmonella newport, Mycobacterium avium paratuberculosis, Cryptsporidium parvum,
 Cryptsporidium hominis, Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, , Streptococcus agalactia, Escherichia coli, Mycoplasma spp, Mycoplasma dispar, and Ureaplasma spp., Tritrichomonas foetus, Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton sarkisovii, Neospora caninum (formerly Toxoplasma gondii), Babesia bigemina and Babesia bovis,
 Dictyocaulus viviparous (Lungworm disease), and combinations thereof.
8. The immunogenic composition according to any oe of claims 1 to 7, wherein the immunogenic composition is a combination vaccine.
9. The immunogenic composition according to claims 1 to 7 or the vaccine according to claim 8, wherein said immunogenic composition or vaccine is formulated for a single-dose administration.
10. A method of co-administration of two or more antigens to a cattle comprising, administering to said cattle M. bovis antigen and one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of infections caused by a further cattle relevant pathogen other than M. bovis.
11. The method according to claim 10, wherein the M. bovis antigen is an attenuated, avirulent M. bovis bacterium.
12. The method according to claim 10 or 11, wherein the M. bovis bacterium is passaged more than 10 times.
13. The method according to any one of claims 10 to 12, wherein the M. bovis bacterium is passaged more than 50 times.
14. The method according to any one of claims 10 to 13, wherein the M. bovis bacterium is selected from the group consisting of: the attenuated M. bovis bacteria strains deposited with the ATCC under accession numbers PTA-8694, PTA-8695 or PTA-8696; any attenuated descendant M. bovis bacteria strains thereof; any attenuated, avirulent M. bovis bacterium strain having the same characteristics as any of the M. bovis bacteria strains deposited with the ATCC under accession numbers PTA-8694, PTA-8695 or PTA-
 8696; and combinations thereof.
15. The method according to any one of claims 10 to 14, wherein the M. bovis antigen is inactivated.
16. The method according to any one of claims 10 to 15, wherein said infection caused by a further cattle relevant pathogen other than M. bovis is caused by at least one pathogen selected from the group consisting of:
 Bovine viral diarrhea virus (BVDV), Parainfluenza-3 Virus (PI-3), Infectious Bovine Rhinotracheitis virus (IBR), Bovine Respiratory Syncytial Virus (BRSV), Bovine Herpesvirus (BHV), Bovine Rotavirus (BRV), Bovine Enterovirus (BEV), Bovine Coronovirus (BCV), Bovine Rabies (BR), Bovine Parvovirus (PPV), Adenovirus Astro virus, Mannheimia haemolytica (formerly Pasteurella haemolytica), Pasteurella multocida, Haemophilus somnus (Histophilus ovis and Haemophilus agni),
 Actinomyces (Corynebacterium), Actinomyces pyogenes, Chlamydia psittaci, Campylobacter fetus venerealis and Campylobacter fetus fetus (formerly C fetus intestinalis ), Leptospira interrogans, Leptospira hardjo, Leptospira pomona, and Leptospira grippotyphosa, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo {Leptospira hardjoprajitno and Leptospira hardjo-bovis), Brucella abortus,
 Brucella suis and Brucella melitensis, Listeria monocytogenes, Chlamydia psittaci, Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordellii, Clostridium perfringens, Clostridium tetani, Moraxella bovis, Klebsiella spp, Klebsiella pneumoniae, Salmonella typhimurium; Salmonella newport, Mycobacterium avium paratuberculosis, Cryptsporidium parvum,
 Cryptsporidium hominis, Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus agalactiae, Escherichia coli, Mycoplasma spp, Mycoplasma dispar, and Ureaplasma spp., Tritrichomonas foetus, Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton sarkisovii, Neospora caninum (formerly Toxoplasma gondii), Babesia bigemina and Babesia bovis,
 Dictyocaulus viviparous (Lungworm disease), and combinations thereof.
17. The method according to any one of claims 10 to 16, wherein the further immunologically active component(s) is/are antigen(s) of one or more of the pathogens selected from the group consisting of:
 Bovine viral diarrhea virus (BVDV), Parainfluenza- 3 Virus (PI-3), Infectious Bovine Rhinotracheitis virus (IBR), Bovine Respiratory Syncytial Virus (BRSV), Bovine Herpesvirus (BHV), Bovine Rotavirus (BRV), Bovine Enterovirus (BEV), Bovine Coronovirus (BCV), Bovine Rabies (BR), Bovine Parvovirus (PPV), Adenovirus Astro virus, Mannheimia haemolytica (formerly Pasteurella haemolytica), Pasteurella multocida, Haemophilus somnus (Histophilus ovis and Haemophilus agni), Actinomyces (Corynebacterium), Actinomyces pyogenes, Chlamydia psittaci, Campylobacter fetus venerealis and Campylobacter fetus fetus (formerly C fetus intestinalis ), Leptospira interrogans, Leptospira hardjo, Leptospira pomona, and
 Leptospira grippotyphosa, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo (Leptospira hardjopraμtno and Leptospira hardjo-bovis), Brucella abortus, Brucella suis and Brucella melitensis, Listeria monocytogenes, Chlamydia psittaci, Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordellii, Clostridium perfringens, Clostridium tetani, Moraxella bovis, Klebsiella spp, Klebsiella pneumoniae, Salmonella typhimurium; Salmonella newport, Mycobacterium avium paratuberculosis, Cryptsporidium parvum, Cryptsporidium hominis, Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus agalactiae, Escherichia coli, Mycoplasma spp, Mycoplasma dispar, and Ureaplasma spp., Tritrichomonas foetus, Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton sarkisovii, Neospora caninum (formerly Toxoplasma gondii), Babesia bigemina and Babesia bovis, Dictyocaulus viviparous (Lungworm disease), and combinations thereof.
18. The method according to any one of claims 10 to 17, wherein the M. bovis antigen and the further immunologically active component(s) are administered separately.
19. The method according to claim 18, wherein the separate co-administration of the M. bovis antigen and the further immunologically active component(s) occurs within 2 days.
20. The method according to any one of claims 10 to 19, wherein the two or more antigens which comprise M. bovis antigen and one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of infections caused by a further cattle relevant pathogen other than M. bovis are formulated as fix-dose combination vaccine.
21. The method according to any one of claims 10 to 19, wherein the two or more antigens which comprise M. bovis antigen and one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of infections caused by a further cattle relevant pathogen other than M. bovis are administered to said cattle in one only dose.
22. The method according to any one of claims 10 to 21, wherein said administration is effective in lessening or reducing the signs of a M. bovis infection.
23. A combination of a M. bovis antigen and one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of infections caused by a further cattle relevant pathogen other than M. bovis for use as a medicament.";"(US20120093854)
According to a further aspect, the present invention relates to a combination vaccine and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against infections of the respiratory and/or reproductive system.
According to a further aspect, the present invention relates to a combination vaccine and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against infections of the respiratory and/or reproductive system caused by M. bovis, BVDV, PI-3, BRSV, IBR and/or BHV, wherein said vaccine comprises at least one M. bovis antigen, preferably the attenuated, avirulent M. bovis as described herein, and at least one further immunologically active component effective for the treatment and/or prophylaxis of infections caused by BVDV, PI-3, BRSV IBR and/or BHV.
The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen.
The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen.";"(US20120093854)
However, Leptospira hardjo infections usually do not cause hemo lytic anemia, which makes diagnosis more difficult.
The prior art is deficient in that killed M. bovis is not as effective or efficient in lessening the severity of clinical symptoms associated with a Mycoplasma bovis infection.
The division of BVDV into 2 serotypes is based on significant differences at the level of genomic sequences (summarized in Heinz et al., 2000) which are also obvious from limited cross neutralizing antibody reactions (Ridpath et al. 1994).
In general, Mycoplasmas are difficult to treat since they lack a cell wall or membrane, which tends to make them resistant to several classes of commonly used broad-spectrum antibiotic treatments.
Mycoplasmas differ from viruses in that Mycoplasmas are larger than most viruses and damage tissue cells by attaching to the surface of cells and destroying them, rather than by entering the cells.
Animals infected with M. bovis have depressed immune responses and can exhibit signs of M. bovis infection such as fever, depression, anorexia, labored breathing, nasal and ocular discharge, coughing, sneezing, gasping, grunting, lameness and swollen joints, mastitis, middle ear infections, abortions, recumbence and death.";"A61K-039/00
A61K-039/002
A61K-039/02
A61K-039/04
A61K-039/08
A61K-039/102
A61K-039/106
A61K-039/108
A61K-039/112
A61K-039/118
A61K-039/12
A61K-039/155
A61K-039/23
A61K-039/235
A61K-039/245
A61K-039/295
A61K-045/00
A61K-047/00
A61P-031/00
A61P-031/04
A61P-031/12
A61P-037/04
C12N-001/20
C12N-001/36
C12N-007/04
C12N-015/09";"(US20120093854)
1. An immunogenic composition for the treatment and/or prophylaxis of cattle against microbiological infections, wherein said immunogenic composition comprises. a. one or more M. bovis antigens; and b. one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of microbiological infection in cattle caused by a cattle pathogen other than M. bovis.
10. A method of coadministration of two or more antigens to a cattle comprising, administering to said cattle M. bovis antigen and one or more further immunologically active component(s) effective for the treatment and/or prophylaxis of infections caused by a further cattle relevant pathogen other than M. bovis.";"(US20120093854)
CATTLE(100,71)
IMMUNOGENIC(100,37)
ANTIGEN(100,29)
BOVIS BACTERIUM(100,22)
CO ADMINISTRATION(100,8)
CATTLE PROPHYLAXIS(100,7)
MICROBIOLOGICAL INFECTION(100,6)
MYCOPLASMA BOVIS ANTIGEN(100,1)
BOVIS ANTIGEN(79,23)
LEPTOSPIRA GRIPPOTYPHOSA(78,20)
MICROBIOLOGICAL INFECTION PROPHYLAXIS(75,1)
INFECTION PROPHYLAXIS(57,16)
TRICHOPHYTON MENTAGROPHYTE(57,9)
CAMPYLOBACTER FETUS VENEREALIS(56,10)
CRYPTSPORIDIUM HOMINIS(56,8)
LISTERIA MONOCYTOGENE(56,8)
LEPTOSPIRA HARDJOPRAJITNO(55,10)
TRICHOPHYTON SARKISOVII(55,9)
TRICHOPHYTON VERRUCOSUM(55,9)
LEPTOSPIRA HARDJO BOVIS(54,10)
CLOSTRIDIUM HAEMOLYTICUM(54,8)
CRYPTSPORIDIUM PARVUM(54,8)
LEPTOSPIRA INTERROGAN(53,12)
CLOSTRIDIUM SORDELLII(53,8)
CATTLE RELEVANT PATHOGEN(53,6)
BRUCELLA MELITENSIS(52,9)
LEPTOSPIRA HARDJO INFECTION(52,2)
BABESIA BIGEMINA(51,8)
LEPTOSPIRA CANICOLA(50,11)
FETUS INTESTINALIS(50,9)
HAEMOPHILUS SOMNUS(50,9)
HISTOPHILUS OVIS(50,9)
STREPTOCOCCUS UBERIS(50,9)
CLOSTRIDIUM NOVYI(50,8)
SALMONELLA TYPHIMURIUM(50,8)
HEMOLYTIC ANEMIA(48,2)
STAPHYLOCOCCUS AUREUS(47,9)
BABESIA BOVIS(46,9)
MYCOPLASMA SPP(46,7)
UREAPLASMA SPP(45,9)
BOVINE ROTAVIRUS(43,9)
KLEBSIELLA SPP(43,9)
CLINICAL SYMPTOM SEVERITY(43,2)
LUNGWORM DISEASE(40,8)
LABORED BREATHING(40,1)
MYCOPLASMA BOVIS INFECTION(40,1)
CHLAMYDIA PSITTACI(36,17)
ANTIBODY REACTION NEUTRALIZATION(34,1)
BRSV IBR(34,1)
BVDV DIVISION(32,1)
BOVIS INFECTION(31,17)
BOVIS(30,103)
ACTINOMYCES(30,18)
SWOLLEN JOINT(28,1)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS(27,11)
TRITRICHOMONAS FETUS(27,8)
CLOSTRIDIUM PERFRINGENS(26,9)
MANNHEIMIA HAEMOLYTICA(26,9)
PASTEURELLA HAEMOLYTICA(26,9)
PASTEURELLA MULTOCIDA(26,9)
BOVINE RABIES(26,8)
OCULAR DISCHARGE(26,1)
AVIRULENT(25,43)
CLOSTRIDIUM CHAUVOEI(25,9)
CLOSTRIDIUM SEPTICUM(25,9)
MORAXELLA BOVIS(25,8)
MYCOPLASMA DISPAR(24,9)
NEOSPORA CANINUM(24,9)
STREPTOCOCCUS AGALACTIAE(24,4)
BOVINE HERPES VIRUS(23,12)
CORYNEBACTERIUM(23,8)
INFECTION(22,44)
MYCOPLASMA(22,9)
PARAINFLUENZA(22,9)
BROAD SPECTRUM ANTIBIOTIC TREATMENT(22,1)
BRUCELLA SUIS(21,10)
BOVINE ENTEROVIRUS(21,8)
BOVINE PARVOVIRUS(21,8)
VIRUS(20,23)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(20,11)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(20,8)
ESCHERICHIA(19,9)
TISSUE CELL(19,1)
ATCC(18,11)
BOVINE VIRAL DIARRHEA VIRUS(18,11)
RECUMBENCE(18,1)
GENOMIC SEQUENCE LEVEL(16,1)
FIX DOSE(15,1)
VACCINE(14,13)
SEPARATE CO ADMINISTRATION(14,1)
LEPTOSPIRA BORGPETERSENII(13,4)
SIGNIFICANT DIFFERENCE(13,1)
BVDV(12,28)
ABORTION(12,17)
IMMUNE RESPONSE(12,7)
LAMENESS(12,3)
SEROTYPE(12,3)
DIAGNOSIS(12,2)
LEPTOSPIRA POMONA INFECTION(12,2)
ENZOOTIC LEPTOSPIRA HARDJO INFECTION(12,1)
INTERLOBULAR SEPTUM GELATINOUS THICKENING(12,1)
MIDDLE EAR INFECTION(12,1)
COMBINATION VACCINE(11,38)
ACTIVE COMPONENT(11,21)
MASTITIS(11,6)
ANOREXIA(11,5)
PATHOGEN ANTIGEN(11,5)
LEPTOSPIRA BOVIS(11,4)
LEPTOSPIRA PRAJITNO(11,4)
CATTLE MICROBIOLOGICAL INFECTION(11,2)
COCCIDIAN PARASITE CRYPTOSPORIDIUM PARVUM(11,1)
IMMUNOLOGICALLY DISTINCT LEPTOSPIRAL SEROVAR(11,1)
LEPTOSPIRA ICTEROHAEMORRHAGIA SEROVAR(11,1)
TRICHOPHYTON SPP MYCOSIS INFECTION(11,1)
YOUNG CALF INTRACISTERNAL INOCULATION(11,1)
ACCESSION NUMBER(10,8)
CHRONIC ENTERITIS(10,4)
MALIGNANT EDEMA(10,4)
DEPRESSION(10,3)
BRSV(10,2)
FIBRINOPURULENT BRONCHOPNEUMONIA(10,2)
NASAL(10,2)
INTRA ERYTHROCYTIC PROTOZOON PARASITE(10,1)
LEPTOSPIRA INTERROGAN SUBGROUP(10,1)
MUCOPURULENT ENDOMETRITIS(10,1)
PARASITIZED ERYTHROCYTE SLUDGING(10,1)
RETINAL NECROSIS GRAY FOCI(10,1)
ANIMAL(9,25)
FEVER(9,9)
BACTERIAL ORIGIN PATHOGEN(9,2)
INFECTED ANIMAL FECES(9,2)
VIRAL ORIGIN PATHOGEN(9,2)
AVIRULENT LIVE CULTURE VACCINE(9,1)
BABESIA INFECTED TICK INCURSION(9,1)
INFECTIOUS PUSTULAR BALANOPOSTHITIS(9,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(9,1)
YOUNG FLUKE MIGRATORY TRACK(9,1)
IBR(8,15)
DEATH(8,13)
BHV(8,5)
RELEVANT PATHOGEN(8,5)
BOVIS STRAIN(8,4)
CATTLE RELEVANT ANTIGEN(8,2)
CLINICAL SIGN SEVERITY(8,2)
FIBRINOUS PLEURITIS(8,2)
LEPTOSPIRA PONOMA(8,2)
RELEVANT CATTLE PATHOGEN(8,2)
RNASE ACTIVITY INACTIVATION(8,2)
SUPPURATIVE BRONCHITIS(8,2)
TRICHOMONA FETUS(8,2)
ACUTE FIBRINOUS BRONCHOPNEUMONIA(8,1)
ATTENUATED APATHOGENIC BVDV(8,1)
AVIRULENT LIVE CULTURE ADMINISTRATION(8,1)
BOVINE GENITAL CAMPYLOBACTERIOSIS(8,1)
BOVINE RHINOVIRUS SEROTYPE(8,1)
CALF PNEUMONIC LUNG(8,1)
CATTLE BABESIA BIGEMINA(8,1)
CATTLE VENEREAL PROTOZOAL DISEASE(8,1)
CHRONIC CONTAGIOUS ENTERITIS(8,1)
CLASS IC ENTERO TOXEMIA(8,1)
CLASS IC INFERTILITY SYNDROME(8,1)
COLONIC RIDGE ATROPHY(8,1)
COMPOSTED CATTLE MANURE(8,1)
CONCURRENT BACTERIAL BRONCHOPNEUMONIA(8,1)
DIFFERING VIRULENCE SEROTYPE(8,1)
ENDEMICALLY INFECTED HERD(8,1)
FATAL SEPTICEMIC INFECTION(8,1)
FREQUENT MYCOPLASMA PATHOGEN(8,1)
GENUS BRUCELLA BACTERIA(8,1)
HEALTHY CALF FECES(8,1)
HEMOLYTIC CRISIS(8,1)
INTRACELLULAR PROTOZOON PARASITE(8,1)
MAMMARY INFLAMMATION EVIDENCE(8,1)
NEONATAL DIARRHEA SYNDROME(8,1)
NONPNEUMONIC CALF RESPIRATORY TRACT(8,1)
OVINE SEPTICEMIA ETIOLOGIC AGENT(8,1)
PNEUMONIC CALF LUNG(8,1)
PROTRACTED CALVING SEASON(8,1)
RELIABLE ANTEMORTEM EVIDENCE(8,1)
ROTAVIRUS VIRULENT STRAIN(8,1)
SUBCLINICALLY INFECTED BULL(8,1)
UNCOMPLICATED IBR INFECTION(8,1)
YOUNG PIGLET SUSCEPTIBILITY(8,1)
COMBO(7,27)
ATTENUATED STRAIN(7,4)
ADULT CATTLE(7,3)
IMMUNOGENIC COMPOSITION ADMINISTRATION(7,3)
SIGN INCIDENCE(7,3)
ABORTION STORM(7,2)
BABESIA INFECTION(7,2)
BACTERIAL PNEUMONIA ONSET(7,2)
BOVIS VACCINE(7,2)
BUDAPEST TREATY TERM(7,2)
CATTLE POPULATION(7,2)
IBR ANTIGEN(7,2)
PARAMYXOVIRUS FAMILY(7,2)
PASSAGED STRAIN(7,2)
PREGNANT COW(7,2)
PREMONITORY SIGN(7,2)
ATTENUATED BVDV VIRUS(7,1)
BOVIS BACTERIUM STRAIN(7,1)
CLINICAL DISEASE ATTACK(7,1)
CONTAMINATED ANIMAL GENITAL(7,1)
COSMOPOLITAN DISTRIBUTION ENTEROCOLITIS(7,1)
FEMALE CATTLE VAGINA(7,1)
GENITAL INFECTION SIGN(7,1)
MYCOPLASMA PATHOGENIC SPECIES(7,1)
POLAR FLAGELLATED BACTERIUM(7,1)
PROLONGED CALVING SEASON(7,1)
RELEVANT GASTROINTESTINAL PATHOGEN(7,1)
SEVERE PERSISTENT COUGHING(7,1)
SEVERE VILLOUS ATROPHY(7,1)
SUSCEPTIBLE CATTLE BLOODSTREAM(7,1)
VULVA MARKED EDEMA(7,1)
WEANLING AGE CALF(7,1)
YOUNG CATTLE GRAZING(7,1)
LACRIMAL DISCHARGE(6,3)
OLD CATTLE(6,3)
REPRODUCTIVE SYSTEM(6,3)
SUSCEPTIBLE ANIMAL(6,3)
YOUNG ANIMAL(6,3)
ACUTE ENTERITIS(6,2)
ANIMAL INTESTINAL TRACT(6,2)
BOVINE ADENOVIRUS(6,2)
BRSV INFECTION(6,2)
DISEASE SEVERITY(6,2)
FEEDLOT CATTLE(6,2)
GROSS LESION(6,2)
INTRANASAL ROUTE(6,2)
LATENT SPORE(6,2)
LUNG PATHOLOGY(6,2)
PATHOGENIC STRAIN(6,2)
REPEAT BREEDING(6,2)
ACCIDENTAL LIVER PUNCTURE(6,1)
ACUTE PULMONARY LESION(6,1)
ALVEOLAR EPITHELIALIZATION(6,1)
ANIMAL PERACUTE DEATH(6,1)
ATTENUATED BVDV GENERATION(6,1)
BHV MANIFESTATION(6,1)
BOVINE RESPIRATORY VIRUS(6,1)
BOVIS INFECTED ANIMAL(6,1)
BRONCHIOLAR EPITHELIUM DEGENERATION(6,1)
BRONCHOINTERSTITIAL PNEUMONIA(6,1)
CAPILLARY EXTENSIVE RUPTURE(6,1)
CELL SURFACE(6,1)
CLINICAL SYMPTOM INCIDENCE(6,1)
CONGESTION BLUISH RED ZONE(6,1)
CRYPT IMMATURE CELL(6,1)
DICTYOCAULUS VIVIPARUS(6,1)
ENTEROCYTE SLOUGHING(6,1)
FEEDER PIG BARN(6,1)
FIBRINOPURULENT MENINGITIS(6,1)
GRAYISH BROWN CRANIOVENTRAL REGION(6,1)
HYPOTENSIVE SHOCK SYNDROME(6,1)
INFECTED COW PERCENTAGE(6,1)
INFECTIVE LARVA(6,1)
INTESTINAL DIGESTIVE ENZYME ACTIVITY(6,1)
INTESTINE ENTEROCYTE(6,1)
NECROSIS BROWN FOCI(6,1)
PATHOGENIC CLOSTRIDIA GROWTH(6,1)
SEVERE DEPRESSION SUDDEN ONSET(6,1)
SINGLE DOSE ADMINISTRATION(6,1)
SKIN ANTHROPOZOONOTIC DISEASE(6,1)
SUPERFAMILY TRICHOSTRONGYLOIDEA(6,1)
SUPPORTIVE LABORATORY EVIDENCE(6,1)
UNCOMPLICATED CRYPTOSPORIDIOSIS(6,1)
VULVA LACERATION(6,1)
HEMOGLOBINURIA(5,7)
CODING SEQUENCE(5,4)
PARATUBERCULOSIS(5,3)
SECONDARY BACTERIAL INFECTION(5,3)
AGE ANIMAL(5,2)
ELISA KIT(5,2)
PURULENT NASAL DISCHARGE(5,2)
SIGN DEVELOPMENT(5,2)
SUSCEPTIBLE COW(5,2)
UTERINE DISCHARGE(5,2)
WOUND CONTAMINATION(5,2)
ALVEOLITIS PROGRESSING(5,1)
AVIUM SUBSPECIE(5,1)
BACTERIAL PNEUMONIA CLINICAL SIGN(5,1)
BACTERIAL PNEUMONIA INITIATOR(5,1)
BEEF BREED(5,1)
BHV ANTIGEN(5,1)
BHV SUBTYPE(5,1)
BLACKLEG INFECTION(5,1)
BLACKLEG OUTBREAK(5,1)
BORN UNDERWEIGHT(5,1)
BOVINE REOVIRUS(5,1)
BOVIS IMMUNOGENIC(5,1)
BRAHMAN CATTLE(5,1)
BREED SUSCEPTIBILITY(5,1)
BREEDING HERD(5,1)
BRISKET EDEMA(5,1)
BRSV ANTIGEN(5,1)
BRUCELLA ABORTUS INFECTION(5,1)
BRUCELLA CONTAMINATED SEMEN(5,1)
BVDV ANTIGEN(5,1)
CATTLE ABORTION(5,1)
CATTLE GENITAL TRACT(5,1)
CATTLE HERD(5,1)
CATTLE LUNG(5,1)
CATTLE SUSCEPTIBILITY(5,1)
CATTLE VENEREAL DISEASE(5,1)
CAUSATIVE ORGANISM(5,1)
CHLAMYDIAL INFECTION PATHOGENESIS(5,1)
CLINICAL DISEASE INCIDENCE(5,1)
CLINICAL DISEASE RISK(5,1)
CLINICAL OUTBREAK(5,1)
CLINICAL SIGN DURATION(5,1)
CLINICAL SIGN ONSET(5,1)
CNS INVOLVEMENT(5,1)
COLOSTRAL ANTIBODY(5,1)
CONTAMINATED FEED INGESTION(5,1)
CONTAMINATED PASTURE(5,1)
CONTINUAL BUTTING(5,1)
CONTRACT BLACKLEG(5,1)
CRANIOVENTRAL LUNG CONSOLIDATION(5,1)
DIFFUSE INTERSTITIAL PNEUMONIA(5,1)
DIPHTHERITIC PLAQUE(5,1)
DRY HACKING COUGH(5,1)
EARLY EMBRYONIC DEATH(5,1)
ECCHYMOTIC HEMORRHAGE(5,1)
ENDONUCLEASE CLEAVAGE BASIS(5,1)
ENTERIC ORGANISM(5,1)
ERYTHROCYTE DESTRUCTION(5,1)
ERYTHROCYTIC STASIS(5,1)
ETIOLOGICAL ROLE(5,1)
EXTENSIVE REDDISH BLACK(5,1)
FARMED DEER(5,1)
FATAL DEHYDRATION(5,1)
FECAL SHEDDING(5,1)
FEED SUDDEN DEPRIVATION(5,1)
FIBRIN EXUDATION(5,1)
FREQUENT URINATION(5,1)
GENERALIZED ANEMIA(5,1)
GENERALIZED BHV(5,1)
GENUS BABESIA(5,1)
GESTATION MONTH(5,1)
HAEMOPHILUS AGNI(5,1)
HEAD EDEMATOUS SWELLING(5,1)
HEAVILY CONTAMINATED FEED(5,1)
HEMORRHAGIC ENTERITIS(5,1)
HEPATIC PARENCHYMA(5,1)
HISTOLOGIC EXAMINATION(5,1)
HISTOPHILUS SOMNI(5,1)
HYPEREMIC INTESTINAL MUCOSA(5,1)
IBR BHV PI(5,1)
INCIDENCE LESSENING(5,1)
INEFFECTIVE SERUM ANTIBODY(5,1)
INFECTION PREVALENCE(5,1)
INFECTIOUS MICROORGANISM(5,1)
INFECTIOUS NECROTIC HEPATITIS SUSPICION(5,1)
INFLAMED NARIS(5,1)
INTERSTITIAL EDEMA(5,1)
INTERSTITIAL THICKENING(5,1)
INTRACELLULAR PARASITE(5,1)
ISOSPORA SPP(5,1)
JOINT CLINICAL SYMPTOM(5,1)
KERATOCONJUNCTIVITIS(5,1)
LARYNX INFECTION(5,1)
LIVER LESION(5,1)
LIVESTOCK PRODUCTION INTENSIFICATION(5,1)
LUNG COLONIZATION(5,1)
LUNG PARENCHYMA(5,1)
LUSH PASTURE(5,1)
LYMPHOID CUFFING(5,1)
MAJOR SYNDROME SEPTICEMIA(5,1)
MAMMARY GLAND INFLAMMATION(5,1)
MESENTERIC TORSION(5,1)
MICROSPORUM SPP(5,1)
MILD RESPIRATORY DISEASE SIGN(5,1)
MLV VACCINE(5,1)
MUCOSA ULCERATION(5,1)
MYCOBACTERIUM SPP(5,1)
MYCOPLASMA EXACT ROLE(5,1)
MYCOPLASMA VACCINE(5,1)
NASOPHARYNX NORMAL INHABITANT(5,1)
NATURAL ORGANISM HABITAT(5,1)
NECROTIC LESION(5,1)
NECROTIZING TOXIN(5,1)
NEWBORN CALF(5,1)
NONGRAVID UTERUS(5,1)
NORTHWEST EUROPE(5,1)
NURSING UDDER(5,1)
ORGANISM INGESTION(5,1)
ORGANISM INVASION(5,1)
ORGANISM INVOLVEMENT(5,1)
ORGANISM PREVALENCE(5,1)
PARASITIC NEMATODE(5,1)
PASSIVELY DERIVED IMMUNITY(5,1)
PASTEURELLA SPP(5,1)
POSTERIOR FLAGELLUM(5,1)
PREDISPOSING INJURY(5,1)
PREVALENT LEPTOSPIRA(5,1)
PROTEOLYSIS INHIBITION(5,1)
PROTOTHECA SPP(5,1)
PULMONARY ABSCESSATION(5,1)
PURPLISH RED URINE(5,1)
REPRODUCTIVE DISORDER(5,1)
REPRODUCTIVE ORGAN(5,1)
SEROFIBRINOUS EXUDATE(5,1)
SEROLOGICAL HUMORAL IMMUNE RESPONSE(5,1)
SEVERE CLINICAL SIGN(5,1)
SEX REPRODUCTIVE TRACT(5,1)
SKIN INFECTION LOCALIZATION(5,1)
SOCIOECONOMIC IMPACT(5,1)
SOW COLOSTRUM(5,1)
SUBCLINICALLY INFECTED CARRIER(5,1)
SUBCUTANEOUS TISSUE EDEMA(5,1)
SUBMUCOSAL HEMORRHAGE(5,1)
SUPPURATIVE VAGINITIS(5,1)
SUSCEPTIBLE CATTLE INTRODUCTION(5,1)
TESTICULAR ABSCESS(5,1)
TETANUS INCIDENCE(5,1)
TETANUS TOXEMIA(5,1)
THICK GRANULAR BILE(5,1)
THRIFTY CALF(5,1)
TOXIN ANTIGENIC SPECIFICITY(5,1)
TOXOPLASMA GONDII(5,1)
TRANSIENT INFERTILITY(5,1)
UNCOMPLICATED ABORTION(5,1)
UNSANITARY VACCINATION(5,1)
UNVACCINATED HERD(5,1)
UTERINE INVOLUTION(5,1)
UTERUS INFLAMMATION(5,1)
VACCINE ADMINISTRATION(5,1)
VIVIPARUS INFECTION(5,1)
WATERY DIARRHEA(5,1)
WHOLE CELL INACTIVATED BACTERIN(5,1)
WILD RUMINANT(5,1)
YOUNG RUMINANT(5,1)
BRD(4,8)
BOVINE CORONAVIRUS(4,5)
ARTIFICIAL INSEMINATION(4,4)
CONVULSION(4,4)
DYSENTERY(4,4)
DYSPNEA(4,4)
ICTERUS(4,4)
MORTALITY(4,4)
MUTATION(4,4)
PYREXIA(4,4)
TRACHEA(4,4)
AFFECTED ANIMAL(4,2)
ANTIBODY TITER(4,2)
CHLAMYDIAL PNEUMONIA(4,2)
DERMATOPHYTOSIS(4,2)
LOCAL LESION(4,2)
MYCOPLASMA BOVIS(4,2)
NEURAL CELL(4,2)
NORMAL PARTURITION(4,2)
SEVERE DISEASE(4,2)
YOUNG RAM(4,2)
ACCESSORY SEX GLAND INFECTION(4,1)
ACUTE DIARRHEA(4,1)
ACUTE FASCIOLIASIS(4,1)
ACUTE LAMENESS(4,1)
AGE BULL(4,1)
AGE CATTLE(4,1)
ANIMAL CARCASS(4,1)
ANIMAL CONTAGIOUS DISEASE(4,1)
ANIMAL DISEASE(4,1)
BACTERIA STRAIN(4,1)
BACTERIA VIRULENCE FACTOR(4,1)
BARE FILAMENT(4,1)
BIRTH WEEK(4,1)
BLOOD CLOTTING(4,1)
BRAIN CAPILLARY(4,1)
BREATHING PATTERN(4,1)
BREEDING CATTLE(4,1)
BRITISH BREED(4,1)
CALF DIARRHEA(4,1)
CATTLE GI TRACT(4,1)
CLOUDY CSF(4,1)
CONCURRENT INFECTION(4,1)
CONTAMINATED INSTRUMENT(4,1)
CONTAMINATED PEN(4,1)
CONTAMINATED SOIL(4,1)
DISEASE SYNDROME(4,1)
DRUG ADMINISTRATION(4,1)
ENDEMIC STABILITY SITUATION(4,1)
ENVIRONMENTAL STRESSOR(4,1)
EXPERIMENTAL INFECTION(4,1)
EXTENSIVE PLEURITIS(4,1)
EXTENSIVE THROMBOSIS(4,1)
FREEZING SEMEN(4,1)
FRESHLY ISOLATED STRAIN(4,1)
GENERALIZED DISEASE(4,1)
GENERALIZED VIRAL INFECTION(4,1)
GRAYISH YELLOW(4,1)
HEAD SEVERE EDEMA(4,1)
HEALTHY CATTLE(4,1)
HOST SUPPRESSION(4,1)
HYALINE MEMBRANE FORMATION(4,1)
IGA ANTIBODY(4,1)
INFECTED ANIMAL TISSUE FLUID(4,1)
INFECTED DAM(4,1)
INFECTIOUS DISEASE(4,1)
INTESTINAL INFECTION(4,1)
LABORATORY CONFIRMATION(4,1)
LATE DISEASE STAGE(4,1)
LATENT BHV(4,1)
LETHAL TOXIN(4,1)
LIVER BIOPSY(4,1)
LIVER FLUKE INFECTION(4,1)
LOCALIZED LESION(4,1)
MALE PREPUCE(4,1)
MARKED CONGESTION(4,1)
MICROBICIDAL ACTIVITY(4,1)
MODERATE COUGHING(4,1)
MOIST COUGH(4,1)
MYCOPLASMA STRAIN(4,1)
NECROTIC TISSUE(4,1)
OCCASIONALLY CAUSED ABORTION(4,1)
ORGANISM CULTURE(4,1)
PI ANTIGEN(4,1)
PI ROLE(4,1)
PLEURA VESSEL(4,1)
POTENTIAL ZOONOTIC RISK(4,1)
PREGNANCY EXAMINATION(4,1)
PREGNANT ANIMAL(4,1)
REPLACEMENT HEIFER(4,1)
RESPIRATORY SIGN(4,1)
SEPTICEMIC DISEASE(4,1)
SERIAL PASSAGING(4,1)
SEROUS NASAL(4,1)
SEVERE DIARRHEA(4,1)
SEVERE ENTERITIS(4,1)
SEVERE INTESTINAL DAMAGE(4,1)
SEVERE TOXEMIA(4,1)
SKELETAL MUSCLE NECROSIS(4,1)
SOIL DISTURBANCE(4,1)
SPHERICAL SPORE(4,1)
STRAIN PREFERENCE(4,1)
SWOLLEN LIVER(4,1)
SYNERGISTIC ROLE(4,1)
TAILHEAD ELEVATION(4,1)
TESTED CATTLE PROPORTION(4,1)
TRYPSIN INHIBITOR(4,1)
UNCOMPLICATED PI(4,1)
UNDULATING MEMBRANE(4,1)
VAGINAL CULTURE(4,1)
VESSEL ENDOTHELIUM(4,1)
VETERINARILY ACCEPTABLE CARRIER(4,1)
VIRAL LESION(4,1)
VISIBLE LESION ABSENCE(4,1)
GROUND(3,7)
SHEEP(3,7)
HORSE(3,5)
LYMPH NODE(3,4)
BRONCHIOLITIS(3,3)
DAIRY CATTLE(3,3)
DERMATOMYCOSIS(3,3)
DIFFERENTIATION(3,3)
GRASS(3,3)
JAUNDICE(3,3)
MACROPHAGE(3,3)
MYOCARDIUM(3,3)
ABDOMINAL PAIN(3,2)
ABORTED FETUS(3,2)
AGGLUTININ(3,2)
ANAEROBIOSIS(3,2)
ATAXIA(3,2)
BIOVET(3,2)
BLINDNESS(3,2)
BRUSH BORDER(3,2)
CASTRATION(3,2)
EFFICACY(3,2)
EROSION(3,2)
FOCAL NECROSIS AREA(3,2)
INFARCTION(3,2)
INFECTION SOURCE(3,2)
INFERTILITY CAUSE(3,2)
LEPTOSPIROSIS(3,2)
MORBIDITY(3,2)
MULTOCIDA(3,2)
NECROPSY(3,2)
NEOMYCIN(3,2)
OPISTHOTONO(3,2)
ORGANISM SOURCE(3,2)
PARAINFLUENZA VIRUS(3,2)
RESPIRATORY DISTRESS(3,2)
SALMONELLA(3,2)
STILLBORN(3,2)
TACHYZOITE(3,2)
TEST KIT(3,2)
TRICHOMONIASIS(3,2)
ABNORMAL MILK(3,1)
ABORTED FETAL TISSUE(3,1)
ACARICIDE TREATMENT(3,1)
ACUTE INFECTION(3,1)
ANAEROBIC ENVIRONMENT(3,1)
ANIMAL SUSCEPTIBILITY(3,1)
ARTHRITIC JOINT(3,1)
BABESIA TRANSMISSION(3,1)
BACTERIAL PNEUMONIA ABSENCE(3,1)
BRONCHOPNEUMONIC PATTERN(3,1)
CAUSATIVE AGENT(3,1)
CLEAN HERD(3,1)
CLINICAL SIGN INCREASE SEVERITY(3,1)
COLLAGEN EXPOSURE(3,1)
COLOSTRAL DERIVED ANTIBODY(3,1)
CONSISTENT SIGN(3,1)
CULTURED STRAIN(3,1)
DEEP PUNCTURE WOUND(3,1)
DISCUSSION FOCUS(3,1)
DISEASE INTRODUCTION(3,1)
DISEASE SPECTRUM(3,1)
EARLY FETAL DEATH(3,1)
EDEMA DISEASE(3,1)
ENLARGED GALLBLADDER(3,1)
ENLARGED PERICARDIAL SAC(3,1)
ENTEROCYTE LOSS(3,1)
EXTENDED CALVING INTERVAL(3,1)
FATAL DISEASE(3,1)
FECAL ORAL ROUTE(3,1)
FREQUENT OCCURRENCE(3,1)
GESTATION STAGE(3,1)
INTESTINAL CONTENT SMEAR(3,1)
INTESTINAL CRYPT ABILITY(3,1)
JOINT PATHOLOGY(3,1)
LIFE FORM SPHERE(3,1)
LIMITED CROSS(3,1)
LIVE CALF(3,1)
LIVE MODIFIED VIRUS(3,1)
LIVE VIRUS(3,1)
LUNGWORM INFECTION RANGE SIGN(3,1)
MARKED DEPRESSION(3,1)
MODIFIED LIVE VACCINE(3,1)
NASAL CAVITY MUCOUS MEMBRANE(3,1)
NORTHERN ROCKY MOUNTAIN SECTION(3,1)
OBSERVED ABORTION(3,1)
ORGAN INFECTION(3,1)
ORGANISM GROWTH(3,1)
PLASMID PROFILE(3,1)
PLATELET ADHESION(3,1)
PULMONARY ABSCESS FORMATION(3,1)
PURULENT VAGINAL DISCHARGE(3,1)
RAPID RESPIRATION(3,1)
RECENT EXCAVATION(3,1)
RESPIRATORY DISEASE VIRUS(3,1)
SECONDARY BACTERIAL PNEUMONIA DEVELOPMENT(3,1)
SEVERE INTESTINAL DISEASE(3,1)
SEVERE RESPIRATORY DISEASE(3,1)
SEX NASAL PASSAGE(3,1)
SEXUALLY TRANSMITTED DISEASE TRANSMISSION(3,1)
SOFT SWELLING(3,1)
SOIL BORNE ORGANISM(3,1)
SPORADIC ABORTION CAUSE(3,1)
STRESSFUL SITUATION(3,1)
SUCCESSFUL LIVESTOCK PRODUCTION(3,1)
SYNCYTIAL CELL FORMATION(3,1)
THICKENED INTESTINAL WALL(3,1)
TISSUE CYST(3,1)
TISSUE NECROSIS(3,1)
TOXIN DETECTION(3,1)
UNTREATED ANIMAL(3,1)
VACCINE DEVELOPMENT(3,1)
VEGETATIVE CELL(3,1)
VIRAL INFECTION SIGN(3,1)
WEAK CALF(3,1)
WILD BIRD(3,1)
WORLDWIDE DISTRIBUTION(3,1)
WOUND HISTORY(3,1)
WOUND INFECTION(3,1)
YOUNG BEEF(3,1)
YOUNG MALE(3,1)
GOAT(2,3)
SUMMER(2,2)
ABATTOIR(2,1)
ABORTION MAJOR CAUSE(2,1)
AFFECTED AREA CONNECTIVE TISSUE(2,1)
AGENT IMPORTANCE(2,1)
AIRWAY(2,1)
AMPULLA(2,1)
ANAEROBE(2,1)
ANEMIC INFARCT(2,1)
ANIMAL INTESTINAL CONTENT(2,1)
ANIMAL PRODUCTION(2,1)
ANTIBIOTIC(2,1)
ANTISERUM(2,1)
APPRECIABLE REDUCTION(2,1)
ARCANOBACTERIUM(2,1)
ARTIFICIAL MEDIUM(2,1)
ASBESTOS(2,1)
ASEXUAL STAGE(2,1)
ATTENUATION(2,1)
AUSCULTATION(2,1)
BABESIOSIS(2,1)
BACTEREMIA(2,1)
BACTERIAL PNEUMONIA CAUSE(2,1)
BEEF CATTLE(2,1)
BHV SINGLE SEROTYPE(2,1)
BIOCHEMICAL REACTION(2,1)
BIOTYPE(2,1)
BIPHASIC DISEASE PATTERN(2,1)
BOVINE VIRAL DIARRHEA(2,1)
BRADYZOITE(2,1)
BREDA VIRUS(2,1)
BRONCHIOLE(2,1)
CALF PRODUCTION(2,1)
CELL MEDIATED IMMUNITY(2,1)
CLINICAL PATTERN(2,1)
CNS REGION(2,1)
CONSEQUENT DECREASE(2,1)
CONTINENT(2,1)
COOL ENVIRONMENT(2,1)
DARK BROWN(2,1)
DARK COLORED KIDNEY(2,1)
DEAD SHOW MANIA(2,1)
DECREASED FEED INTAKE(2,1)
DISEASE AGENT(2,1)
DISEASE PROTECTION(2,1)
DRY COUGH(2,1)
ENCEPHALOMYELITIS(2,1)
ENZYME PRODUCING ENTEROCYTE(2,1)
EPIDEMIOLOGY(2,1)
FIXED CARRIER(2,1)
GAS ACCUMULATION(2,1)
HAIRLOSS(2,1)
HEIFER GROUP(2,1)
HOST ANIMAL(2,1)
IMMUNE CARRIER(2,1)
IMMUNOCOMPROMISED INDIVIDUAL(2,1)
IMMUNOGENIC COMPOSITION COMPONENT(2,1)
IMMUNOGENIC COMPOSITION VACCINE(2,1)
IMMUNOGENIC RESPONSE(2,1)
IMMUNOLOGICAL RESPONSE(2,1)
INCREASED BREATH SOUND(2,1)
INCREASED BRONCHIAL SOUND(2,1)
INTRAVASCULAR HEMOLYSIS(2,1)
IRREGULAR ESTRAL CYCLE(2,1)
ISOLATION FREQUENCY(2,1)
LOCALIZED NECROSIS CAUSE(2,1)
LOCUS PRESENCE(2,1)
LOWERED MILK(2,1)
LUNG RESULT SOMNUS INFECTION(2,1)
MAJOR LESION(2,1)
MILD INITIAL SIGN(2,1)
MILD VAGINAL DISCHARGE(2,1)
MODIFIED BVDV(2,1)
MOIST ENVIRONMENT(2,1)
NATURAL CHALLENGE(2,1)
NATURAL RESERVOIR(2,1)
NEUROTOXIN(2,1)
NOCARDIA ASTEROIDES(2,1)
OCCURRENCE FREQUENCY(2,1)
OFFSPRING(2,1)
OLD ANIMAL(2,1)
ORGAN VARIETY(2,1)
PARANASAL SINUS(2,1)
PARASITE BODY(2,1)
PETECHIAL HEMORRHAGE(2,1)
POLYSEROSITIS(2,1)
POSITIVE SERUM AGGLUTINATION TEST(2,1)
PREGNANCY HALF(2,1)
PROLONGED LUTEAL PHASE(2,1)
PROLONGED TREATMENT(2,1)
PROTECTIVE IMMUNE RESPONSE(2,1)
RAPIDLY FATAL COURSE(2,1)
REDUCING SIGN(2,1)
SALIVATION(2,1)
SECONDARY BACTERIAL PNEUMONIA PRESENCE(2,1)
SEVERE OUTBREAK CAUSE(2,1)
SEVERITY REDUCTION(2,1)
SHALLOW RESPIRATORY RATE(2,1)
SKIN CELL(2,1)
SPOROZOITE(2,1)
THROMBOMENINGOENCEPHALITIS(2,1)
TONSILLAR CRYPT(2,1)
TRIMESTER(2,1)
UPPER RESPIRATORY TRACT EPITHELIUM(2,1)
VILLOUS HEIGHT(2,1)
WHITE FOCI(2,1)
YELLOWISH INTESTINAL CONTENT(2,1)
(US8815255)
ANTIGEN(100,95)
CATTLE(100,29)
IMMUNOGENIC(100,27)
MICROBIOLOGICAL INFECTION(100,7)
CO ADMINISTRATION(100,5)
CATTLE PROPHYLAXIS(100,4)
CATTLE TREATMENT(100,1)
MYCOPLASMA BOVIS ANTIGEN(100,1)
BOVIS BACTERIUM(99,18)
LEPTOSPIRA GRIPPOTYPHOSA(85,30)
ATTENUATED AVIRULENT(77,4)
TRICHOPHYTON MENTAGROPHYTE(73,8)
CAMPYLOBACTER FETUS VENEREALIS(72,8)
TRICHOPHYTON SARKISOVII(70,8)
TRICHOPHYTON VERRUCOSUM(70,8)
CRYPTSPORIDIUM HOMINIS(69,8)
LISTERIA MONOCYTOGENE(69,8)
CLOSTRIDIUM HAEMOLYTICUM(68,8)
CRYPTSPORIDIUM PARVUM(68,8)
BRUCELLA MELITENSIS(66,8)
LEPTOSPIRA HARDJO(65,24)
BOVIS ANTIGEN(65,13)
CLOSTRIDIUM SORDELLII(64,9)
BABESIA BIGEMINA(63,8)
FETUS INTESTINALIS(63,8)
HAEMOPHILUS SOMNUS(63,8)
HISTOPHILUS OVIS(63,8)
STREPTOCOCCUS UBERIS(63,8)
SALMONELLA TYPHIMURIUM(62,8)
LEPTOSPIRA INTERROGAN(60,14)
STAPHYLOCOCCUS AUREUS(60,8)
CLOSTRIDIUM NOVYI(59,9)
BABESIA BOVIS(59,8)
LEPTOSPIRA HARDJOPRAJITNO(58,19)
LEPTOSPIRA HARDJO BOVIS(57,19)
UREAPLASMA SPP(57,8)
LEPTOSPIRA CANICOLA(56,14)
BOVINE ROTAVIRUS(55,8)
KLEBSIELLA SPP(55,8)
MICROBIOLOGICAL INFECTION PROPHYLAXIS(54,1)
INFECTION PROPHYLAXIS(52,8)
MYCOPLASMA SPP(52,6)
LEPTOSPIRA POMONA(51,21)
LUNGWORM DISEASE(51,8)
CAMPYLOBACTER FETUS(50,17)
CATTLE PATHOGEN(49,3)
CHLAMYDIA PSITTACI(46,16)
CATTLE RELEVANT PATHOGEN(46,4)
BOVINE RABIES(40,8)
ACTINOMYCES(39,16)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS(37,8)
BOVINE HERPES VIRUS(36,8)
PATHOGEN ANTIGEN(35,3)
MANNHEIMIA HAEMOLYTICA(34,8)
MICROBIOLOGICAL INFECTION TREATMENT(34,1)
PATHOGEN(33,8)
TRITRICHOMONAS FETUS(33,8)
CLOSTRIDIUM CHAUVOEI(31,9)
CLOSTRIDIUM SEPTICUM(31,9)
BRUCELLA ABORTUS(31,8)
NEOSPORA CANINUM(31,8)
CLOSTRIDIUM PERFRINGENS(30,11)
MORAXELLA BOVIS(30,8)
MYCOPLASMA DISPAR(30,8)
BRUCELLA SUIS(29,8)
CORYNEBACTERIUM(29,8)
PARAINFLUENZA(29,8)
BOVINE ENTEROVIRUS(28,8)
STREPTOCOCCUS(28,8)
MYCOPLASMA BOVIS(28,3)
BOVIS(27,189)
PASTEURELLA HAEMOLYTICA(27,18)
PASTEURELLA MULTOCIDA(27,18)
BOVINE PARVOVIRUS(27,8)
BACTERIAL ORIGIN PATHOGEN(27,2)
VIRAL ORIGIN PATHOGEN(27,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(26,8)
HAEMOPHILUS(26,8)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(26,8)
KLEBSIELLA(26,8)
TOXOPLASMA(26,8)
ESCHERICHIA(26,7)
INFECTION TREATMENT(26,3)
CLOSTRIDIUM(24,10)
BOVINE VIRAL DIARRHEA VIRUS(23,8)
ATTENUATED BVDV(22,29)
AVIRULENT(21,84)
PTA(21,19)
BOVIS INFECTION(21,14)
BOVINE CORONAVIRUS(21,4)
STREPTOCOCCUS AGALACTIAE(21,4)
ORIGIN PATHOGEN(20,2)
BVDV(18,42)
ATCC(18,11)
VIRUS(17,10)
ANIMAL(17,9)
INFECTION(17,7)
COMPOSITION ADMINISTRATION(17,1)
IMMUNE RESPONSE(15,4)
ATTENUATED STRAIN(15,3)
SIGN DEVELOPMENT(15,2)
PATHOGENIC SPECIES(13,20)
ACCESSION NUMBER(12,8)
STRAIN(12,6)
ACTIVE COMPONENT(11,15)
VACCINE(11,9)
LEPTOSPIRA BORGPETERSENII(11,6)
PASTEURELLA HAEMOLYTICA BACTERIN(11,5)
LEPTOSPIRA BOVIS(10,6)
LEPTOSPIRA PRAJITNO(10,6)
PASTEURELLA MULTOCIDA BACTERIN(10,5)
FIX DOSE(10,1)
SEPARATE CO ADMINISTRATION(10,1)
COMBO(9,90)
CAMPYLOBACTER FETUS ANTIGEN(9,5)
ADENOVIRUS(9,2)
IBR ANTIGEN(8,6)
COMBINATION VACCINE(7,92)
SOMNUS(7,24)
LEPTOSPIRA POMONA BACTERIN(7,1)
RELEVANT CATTLE PATHOGEN(6,2)
AVIRULENT LIVE CULTURE ADMINISTRATION(6,1)
IMMUNOGENIC COMPOSITION ADMINISTRATION(5,3)
BRSV ANTIGEN(5,2)
BUDAPEST TREATY TERM(5,2)
PASSAGED STRAIN(5,2)
BOVIS BACTERIUM STRAIN(5,1)
NEOMYCIN(4,9)
PRESERVATIVE(4,9)
THIMEROSAL(4,7)
BOVIS STRAIN(4,2)
INTRANASAL ROUTE(4,2)
LUNG PATHOLOGY(4,2)
BOVIS INFECTED ANIMAL(4,1)
CLINICAL SIGN SEVERITY(4,1)
CLINICAL SYMPTOM INCIDENCE(4,1)
CLOSTRIDIUM PERFRINGENS TOXIN(4,1)
IBR BHV PI(4,1)
JOINT CLINICAL SYMPTOM(4,1)
LEPTOSPIRA BACTERIN(4,1)
SEROLOGICAL HUMORAL IMMUNE RESPONSE(4,1)
SINGLE DOSE ADMINISTRATION(4,1)
ELISA KIT(3,2)
LIVE MODIFIED VIRUS(3,2)
BHV ANTIGEN(3,1)
BOVIS IMMUNOGENIC(3,1)
BVDV ANTIGEN(3,1)
INCIDENCE LESSENING(3,1)
(WO201051210)
BOVIS(100,97)
CATTLE(100,73)
IMMUNOGENIC(100,34)
ANTIGEN(100,30)
BOVIS ANTIGEN(100,22)
BOVIS BACTERIUM(100,22)
ACTIVE COMPONENT(100,21)
INFECTION PROPHYLAXIS(100,16)
CO ADMINISTRATION(100,8)
CATTLE PROPHYLAXIS(100,7)
MICROBIOLOGICAL INFECTION(100,5)
MEDICAMENT(100,1)
ADENOVIRUS ASTRO VIRUS(82,4)
LEPTOSPIRA GRIPPOTYPHOSA(78,20)
MICROBIOLOGICAL INFECTION PROPHYLAXIS(75,1)
TRICHOPHYTON MENTAGROPHYTE(57,9)
CAMPYLOBACTER FETUS VENEREALIS(56,10)
CRYPTSPORIDIUM HOMINIS(56,8)
LEPTOSPIRA HARDJO BOVIS(56,8)
LISTERIA MONOCYTOGENE(56,8)
TRICHOPHYTON SARKISOVII(55,9)
TRICHOPHYTON VERRUCOSUM(55,9)
CLOSTRIDIUM HAEMOLYTICUM(54,8)
CRYPTSPORIDIUM PARVUM(54,8)
LEPTOSPIRA INTERROGAN(53,12)
CLOSTRIDIUM SORDELLII(53,8)
BRUCELLA MELITENSIS(52,9)
LEPTOSPIRA HARDJO INFECTION(52,2)
BABESIA BIGEMINA(51,8)
HISTOPHILUS OVIS(51,8)
LEPTOSPIRA HARDJ OPRATNO(51,1)
LEPTOSPIRA CANICOLA(50,11)
HAEMOPHILUS SOMNUS(50,9)
STREPTOCOCCUS UBERIS(50,9)
CLOSTRIDIUM NOVYI(50,8)
SALMONELLA TYPHIMURIUM(50,8)
STAPHYLOCOCCUS AUREUS(47,9)
LEPTOSPIRA HARDJOPRATNO(47,2)
BABESIA BOVIS(46,9)
MYCOPLASMA SPP(46,7)
UREAPLASMA SPP(45,9)
BOVINE ROTAVIRUS(43,9)
KLEBSIELLA SPP(43,9)
CLINICAL SYMPTOM SEVERITY(43,2)
BOVINE HERPES VIRUS(42,11)
LUNGWORM DISEASE(40,8)
LABORED BREATHING(40,1)
MYCOPLASMA BOVIS INFECTION(40,1)
CHLAMYDIA PSITTACI(36,17)
CATTLE RELEVANT PATHOGEN(35,5)
ANTIBODY REACTION NEUTRALIZATION(34,1)
BVDV DIVISION(32,1)
BOVIS INFECTION(31,17)
FORMERLY C FETUS INTESTINALIS(31,5)
ACTINOMYCES(30,18)
SWOLLEN JOINT(28,1)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS(27,11)
TRITRICHOMONAS FETUS(27,8)
LEPTOSPIRA HARDJOPRAJITNO(27,7)
CLOSTRIDIUM PERFRINGENS(26,9)
MANNHEIMIA HAEMOLYTICA(26,9)
PASTEURELLA HAEMOLYTICA(26,9)
PASTEURELLA MULTOCIDA(26,9)
OCULAR DISCHARGE(26,1)
CLOSTRIDIUM CHAUVOEI(25,9)
CLOSTRIDIUM SEPTICUM(25,9)
MORAXELLA BOVIS(25,8)
MYCOPLASMA DISPAR(24,9)
NEOSPORA CANINUM(24,9)
STREPTOCOCCUS AGALACTIAE(24,4)
AVIRULENT(23,42)
CORYNEBACTERIUM(23,8)
MYCOPLASMA(22,9)
PARAINFLUENZA(22,9)
BROAD SPECTRUM ANTIBIOTIC TREATMENT(22,1)
BRUCELLA SUIS(21,10)
BOVINE ENTEROVIRUS(21,8)
BOVINE PARVOVIRUS(21,8)
BOVINE RABIES(21,8)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(21,8)
VIRUS(20,23)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(20,11)
INFECTION(19,46)
ESCHERICHIA(19,9)
TISSUE CELL(19,1)
BOVINE VIRAL DIARRHEA VIRUS(18,11)
RECUMBENCE(18,1)
VACCINE(17,15)
GENOMIC SEQUENCE LEVEL(16,1)
HEMOLYTIC ANEMIA(15,2)
FIX DOSE(15,1)
LEPTOSPIRA BORGPETERSENII(13,4)
SIGNIFICANT DIFFERENCE(13,1)
ABORTION(12,17)
BVDV(12,16)
IMMUNE RESPONSE(12,7)
LAMENESS(12,3)
SEROTYPE(12,3)
DIAGNOSIS(12,2)
LEPTOSPIRA POMONA INFECTION(12,2)
ENZOOTIC LEPTOSPIRA HARDJO INFECTION(12,1)
INTERLOBULAR SEPTUM GELATINOUS THICKENING(12,1)
MIDDLE EAR INFECTION(12,1)
BOVIS STRAIN(11,7)
MASTITIS(11,6)
ANOREXIA(11,5)
PATHOGEN ANTIGEN(11,5)
LEPTOSPIRA BOVIS(11,4)
LEPTOSPIRA PRAJITNO(11,4)
CATTLE MICROBIOLOGICAL INFECTION(11,2)
COCCIDIAN PARASITE CRYPTOSPORIDIUM PARVUM(11,1)
IMMUNOLOGICALLY DISTINCT LEPTOSPIRAL SEROVAR(11,1)
LEPTOSPIRA ICTEROHAEMORRHAGIA SEROVAR(11,1)
TRICHOPHYTON SPP MYCOSIS INFECTION(11,1)
YOUNG CALF INTRACISTERNAL INOCULATION(11,1)
ACCESSION NUMBER(10,8)
CHRONIC ENTERITIS(10,4)
MALIGNANT EDEMA(10,4)
DEPRESSION(10,3)
FIBRINOPURULENT BRONCHOPNEUMONIA(10,2)
INTRA ERYTHROCYTIC PROTOZOON PARASITE(10,1)
LEPTOSPIRA INTERROGAN SUBGROUP(10,1)
PARASITIZED ERYTHROCYTE SLUDGING(10,1)
RETINAL NECROSIS GRAY FOCI(10,1)
SEPARATE CO ADMINISTRATION(10,1)
COMBINATION VACCINE(9,38)
ANIMAL(9,25)
FEVER(9,9)
BACTERIAL ORIGIN PATHOGEN(9,2)
BOVIS ELISA KIT(9,2)
INFECTED ANIMAL FECES(9,2)
VIRAL ORIGIN PATHOGEN(9,2)
AVIRULENT LIVE CULTURE VACCINE(9,1)
BABESIA INFECTED TICK INCURSION(9,1)
INFECTIOUS PUSTULAR BALANOPOSTHITIS(9,1)
YOUNG FLUKE MIGRATORY TRACK(9,1)
DEATH(8,13)
NASAL(8,4)
CATTLE RELEVANT ANTIGEN(8,2)
CLINICAL SIGN SEVERITY(8,2)
FIBRINOUS PLEURITIS(8,2)
LEPTOSPIRA PONOMA(8,2)
RELEVANT CATTLE PATHOGEN(8,2)
RNASE ACTIVITY INACTIVATION(8,2)
SUPPURATIVE BRONCHITIS(8,2)
TRICHOMONA FETUS(8,2)
ACUTE FIBRINOUS BRONCHOPNEUMONIA(8,1)
ATTENUATED APATHOGENIC BVDV(8,1)
AVIRULENT LIVE CULTURE ADMINISTRATION(8,1)
BOVINE GENITAL CAMPYLOBACTERIOSIS(8,1)
BOVINE RHINOVIRUS SEROTYPE(8,1)
CALF PNEUMONIC LUNG(8,1)
CATTLE BABESIA BIGEMINA(8,1)
CATTLE VENEREAL PROTOZOAL DISEASE(8,1)
CHRONIC CONTAGIOUS ENTERITIS(8,1)
CLASS IC INFERTILITY SYNDROME(8,1)
COLONIC RIDGE ATROPHY(8,1)
COMPOSTED CATTLE MANURE(8,1)
CONCURRENT BACTERIAL BRONCHOPNEUMONIA(8,1)
DIFFERING VIRULENCE SEROTYPE(8,1)
ENDEMICALLY INFECTED HERD(8,1)
FATAL SEPTICEMIC INFECTION(8,1)
FREQUENT MYCOPLASMA PATHOGEN(8,1)
GENUS BRUCELLA BACTERIA(8,1)
HEALTHY CALF FECES(8,1)
INTRACELLULAR PROTOZOON PARASITE(8,1)
MAMMARY INFLAMMATION EVIDENCE(8,1)
NEONATAL DIARRHEA SYNDROME(8,1)
NONPNEUMONIC CALF RESPIRATORY TRACT(8,1)
OVINE SEPTICEMIA ETIOLOGIC AGENT(8,1)
PNEUMONIC CALF LUNG(8,1)
PROTRACTED CALVING SEASON(8,1)
RELIABLE ANTEMORTEM EVIDENCE(8,1)
ROTAVIRUS VIRULENT STRAIN(8,1)
SUBCLINICALLY INFECTED BULL(8,1)
YOUNG PIGLET SUSCEPTIBILITY(8,1)
COMBO(7,28)
ADULT CATTLE(7,3)
IMMUNOGENIC COMPOSITION ADMINISTRATION(7,3)
SIGN INCIDENCE(7,3)
ABORTION STORM(7,2)
BABESIA INFECTION(7,2)
BACTERIAL PNEUMONIA ONSET(7,2)
BOVIS VACCINE(7,2)
BUDAPEST TREATY TERM(7,2)
CATTLE POPULATION(7,2)
CONTAMINATED SEMEN(7,2)
FEEDLOT CATTLE(7,2)
GENITAL INFECTION(7,2)
PARAMYXOVIRUS FAMILY(7,2)
PASSAGED STRAIN(7,2)
PREGNANT COW(7,2)
PREMONITORY SIGN(7,2)
ATTENUATED BVDV VIRUS(7,1)
BOVIS BACTERIUM STRAIN(7,1)
CLINICAL DISEASE ATTACK(7,1)
CONTAMINATED ANIMAL GENITAL(7,1)
COSMOPOLITAN DISTRIBUTION ENTEROCOLITIS(7,1)
FEMALE CATTLE VAGINA(7,1)
MYCOPLASMA PATHOGENIC SPECIES(7,1)
POLAR FLAGELLATED BACTERIUM(7,1)
PROLONGED CALVING SEASON(7,1)
RELEVANT GASTROINTESTINAL PATHOGEN(7,1)
SEVERE PERSISTENT COUGHING(7,1)
SEVERE VILLOUS ATROPHY(7,1)
SUSCEPTIBLE CATTLE BLOODSTREAM(7,1)
VULVA MARKED EDEMA(7,1)
WEANLING AGE CALF(7,1)
YOUNG CATTLE GRAZING(7,1)
ATTENUATED STRAIN(6,3)
LACRIMAL DISCHARGE(6,3)
OLD CATTLE(6,3)
SUSCEPTIBLE ANIMAL(6,3)
YOUNG ANIMAL(6,3)(...)";Pharmaceuticals;Open
"2008-10-03
2009-10-01";"WO2010039934        A1 2010-04-08 [WO201039934]
STG: (A1) Published application with search report
AP : 2009WO-US59196 2009-10-01
CA2738664           A1 2010-04-08 [CA2738664]
STG: (A1) Application laid open
AP : 2009CA-2738664 2009-10-01
AU2009298490        A1 2010-04-08 [AU2009298490]
STG: (A1) Open to public inspection
AP : 2009AU-0298490 2009-10-01
EP2337582           A1 2011-06-29 [EP2337582]
STG: (A1) Application published with search report
AP : 2009EP-0793230 2009-10-01
MX2011003535        A  2011-09-21 [MX2011003535]
STG: (A) Patent application
AP : 2011MX-PA03535 2009-10-01
CN102238961         A  2011-11-09 [CN102238961]
STG: (A) Published application
AP : 2009CN-80148786 2009-10-01
BRPI0920800         A2 2011-12-06 [BR200920800]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2009BR-0020800 2009-10-01
CO6361950           A2 2012-01-20 [CO6361950]
STG: (A2) Application derived from a PCT application
AP : 2011CO-0049498 2011-04-20
US20120034262       A1 2012-02-09 [US20120034262]
STG: (A1) Application published
AP : 2009US-13121566 2009-10-01
JP2012504417        A  2012-02-23 [JP2012504417]
STG: (A) Published application
AP : 2011JP-0530215 2009-10-01
RU2011117241        A  2012-11-10 [RU2011117241]
STG: (A) Application for invention
AP : 2011RU-0117241 2009-10-01
US8637046           B2 2014-01-28 [US8637046]
STG: (B2) Granted patent as second publication
AP : 2009US-13121566 2009-10-01
FD :  Provisional Appl: US61/195,102 FDD=2008-10-03 [2008US-61195102]
FD : Previous publication: US20120034262 A1 2012-02-09 [US20120034262]
JP5723280           B2 2015-04-03 [JP5723280]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2011JP-0530215 2009-10-01
CA2738664           C  2017-10-31 [CA2738664]
STG: (C) Patent (second level)
AP : 2009CA-2738664 2009-10-01";7201695;"WO2010039934        A1 2010-04-08 [WO201039934]
CA2738664           A1 2010-04-08 [CA2738664]
AU2009298490        A1 2010-04-08 [AU2009298490]
EP2337582           A1 2011-06-29 [EP2337582]
MX2011003535        A  2011-09-21 [MX2011003535]
CN102238961         A  2011-11-09 [CN102238961]
BRPI0920800         A2 2011-12-06 [BR200920800]
CO6361950           A2 2012-01-20 [CO6361950]
US20120034262       A1 2012-02-09 [US20120034262]
JP2012504417        A  2012-02-23 [JP2012504417]
RU2011117241        A  2012-11-10 [RU2011117241]
US8637046           B2 2014-01-28 [US8637046]
JP5723280           B2 2015-04-03 [JP5723280]
CA2738664           C  2017-10-31 [CA2738664]";"2008US-61195102
2009US-13121566
2009WO-US59196";"(EP2337582)
WO2010039934
(US8637046)
WO2010039934
(JP5723280)
WO2010039934
(RU2011117241)
WO2010039934
(AU2009298490)
WO2010039934
(MX2011003535)
WO2010039934
(CN102238961)
WO2010039934
(BR200920800)
WO2010039934
(CA2738664)
WO2010039934";"CORNELL UNIVERSITY
ELANCO TIERGESUNDHEIT
NOVARTIS";"CORNELL UNIVERSITY
ELANCO TIERGESUNDHEIT";"(EP2337582)
CH; US
(US20120034262)
CH; US
(US8637046)
CH; US
(WO201039934)
CH

(CA2738664)
CH; US
(CA2738664)
CH; US";"(EP2337582)
NAME=Novartis AG Lichtstrasse 35 , CITY=4056 Basel , COUNTRY=CH 

NAME=Cornell University Cornell Center For Technology Enterprise  And Commercialization  395 Pine Tree Road  Suite 310 , CITY=Ithaca, NY 14850 , COUNTRY=US 

(US20120034262)
NAME=NOVARTIS AG , CITY=Basel , COUNTRY=CH , ATYP=Non-US Company 

NAME=CORNELL UNIVERSITY , CITY=Ithaca , STATE=NY , COUNTRY=US , ATYP=US Company 

(US8637046)
NAME=Cornell University , CITY=Ithaca , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Novartis AG , CITY=Basel , COUNTRY=CH , ATYP=Non-US Company 

(WO201039934)
NAME=NOVARTIS AG  Lichstrasse 35, CH-4056 Basel  , COUNTRY=CH 

(JP2012504417)
NAME=Novartis AG , REG=506011618 

NAME=CORNELL UNIV , REG=510243539 

(JP5723280)
NAME=Novartis AG , REG=506011618 

NAME=UNIV CORNELL , REG=511040838 

(CA2738664)
NAME=NOVARTIS AG LICHTSTRASSE 35 CH-4056 , CITY=BASEL , COUNTRY=CH 

NAME=CORNELL UNIVERSITY 310 - 395 Pine Tree Road , CITY=ITHACA , STATE=NY , POSTCODE=14850 , COUNTRY=US 

(CA2738664)
NAME=NOVARTIS AG LICHTSTRASSE 35 CH-4056 , CITY=BASEL , COUNTRY=CH 

NAME=CORNELL UNIVERSITY 310 - 395 PINE TREE ROAD , CITY=ITHACA , STATE=NY , POSTCODE=14850 , COUNTRY=US 
";2;"RAJU SEETHARAMAN GOPINATH
HARLAND RICHARD
ALBEE II LEE DAVID
PATEL MAYUR NAVNITBHAI
OSTERRIEDER NIKOLAUS
KAUFER BENEDIKT B";"(EP2337582)
DE; US; CA";"(EP2337582)
NAME=RAJU SEETHARAMAN, Gopinath Novartis Animal Health US Inc. Larchwood Site 1447 140th Street , CITY=Larchwood, IA 51241 , COUNTRY=US 

NAME=HARLAND, Richard Novartis Animal Health Canada Inc. 2420 Palliswood Rd SW , CITY=Calgary, Alberta T2V 3P8 , COUNTRY=CA 

NAME=ALBEE II, Lee David Novartis Animal Health US Inc. Larchwood Site 1447 140th Street , CITY=Larchwood, IA 51241 , COUNTRY=US 

NAME=PATEL, Mayur Navnitbhai Novartis Animal Health US Inc. Larchwood Site 1447 140th Street , CITY=Larchwood, IA 51241 , COUNTRY=US 

NAME=OSTERRIEDER, Nikolaus Am Waldrand 226 , CITY=14482 Potsdam , COUNTRY=DE 

NAME=KAUFER, Benedikt B. Elberfelderstrasse 9 , CITY=10555 Berlin , COUNTRY=DE 
";"(EP2337582)
Bovine herpes virus -1 compositions, vaccines and methods";"(EP2337582)
The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.";"(WO201039934)
CLAIMS
1. A bovine herpes virus- 1 (BHV-I) that has modifications of two or more genes encoding proteins that suppress the immune system of an infected host, where the modifications relieve or prevent the immune system suppression.
2. The BHV-I of claim 1, where the genes encode proteins that cause down regulation of host MHC related proteins or evasion of a host immune response to BHV-I.
3. The BHV-I of claim 1, where the modifications relieve or prevent immune system suppression to an additional immunogen.
4. The BHV-I of claim 3, where the additional immunogen is co-administered with the BHV-I or administered to the host in a combination vaccine.
5. The BHV-I of claim 1, where the modifications are of genes that play a role in one or more of MHC class I expression, chemokine expression, MHC class II expression, development of latent infection and viral persistence, reactivation of latency, and expression of IgG-mediated immune response.
6. The BHV-I of claim 1, where the modifications are of one or more of UL49.5, UL41, Us4, Circ, LR-ORF-I, LR-ORF-2, Us9 and Us8.
7. The BHV-I of claim 1, where the modifications are of UL49.5 and UL41.
8. The BHV-I of claim 1, where the BHV-I background includes Cooper strain or GL756 strain.
9. A composition, comprising BHV-I and an additional immunogen, where the BHV-I contains a modification in a gene that suppresses an immune response to the additional immunogen in a host, and where the modification relieves the immune response suppression.
10. The BHV-I of claim 9, where the modification is in a gene that plays a role in one or more of MHC class I expression, chemokine expression, MHC class II expression, development of latent infection and viral persistence, reactivation of latency, and expression of IgG-mediated immune response.
11. The BHV-I of claim 9, where the modification is in a gene that plays a role in one of MHC class I expression and chemokine expression.
12. The BHV-I of claim 9, where the modification is in UL49.5, UL41, Us4, Circ, LR-ORF-I, LR-ORF-2, Us9 or Us8.
13. The BHV-I of claim 9, where the modification is in UL49.5 or UL41.
14. The BHV-I of claim 9, where the modification is in Us4.
15. The BHV-I of claim 9, where the modification is in UL49.5 and the BHV-I contains an additional modification in UL41 or Us4.
16. The BHV-I of claim 9, where the BHV-I background includes Cooper strain or GL756 strain.
17. The BHV-I of claim 9, where the additional immunogen includes a bacterial, viral or parasitic immunogen.
18. The BHV-I of claim 9, where the additional immunogen includes an immunogen from Bovine Viral Diarrhea Virus (BVDV) I, BVDV II, BVDV III, Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza 3 Virus (PI3), Rotavirus (BRV), Coronavirus (BCV), Mannheimia haemolytica, Histophilus somni, Mycoplasma bovis, Leptospira species, Vibrio species, Clostridia species, Pasteurella multocida, Fusobacterium necrophorum, E. coli O157:H7, Salmonella enterica, Neospora caninum or Trichomonas species.
19. The BHV-I of claim 9, where the additional immunogen includes LkT from Mannheimia haemolytica.
20. The BHV-I of claim 9, where the BHV-I is a modified live BHV-I vaccine strain.
21. The BHV- 1 of claim 9, where the BHV- l is a killed virus.
22. A method for eliciting an immunological response in a host, comprising administering to the host: a) an immunogen other than a BHV-I antigen (non-BHV-1 immunogen); and b) BHV-I containing a modification in a gene encoding a protein that can suppress a host immunological response to the non-BHV-1 immunogen .
23. The method of claim 22 where the gene includes UL49.5, UL41, Us4, Circ, LR-ORF-I, LR-ORF-2, Us9 or Us8.
24. The method of claim 22 where the gene includes UL49.5 and where the BHV- 1 contains an additional modification in UL41.
25. The method of claim 22 where the non-BHV-1 immunogen is from Bovine Viral Diarrhea Virus (BVDV) I, BVD IL BVD in, Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza 3 Virus (PI3), Rotavirus (BRV), Coronavirus (BCV), Mannheimia haemolytica, Histophilus somni, Mycoplasma bovis, Leptospira species, Vibrio species, Clostridia species, Pasteurella multocida, Fusobacterium necrophorum, E. coli O157:H7, Salmonella enterica, Neospora caninum or Trichomonas species.
26. The method of claim 22, where the non-BHV-1 immunogen and the BHV-I are co-administered or administered to the host in a combination vaccine.
27. The method of claim 22, where the host's immunological response to the non- BHV-1 immunogen is increased compared to the immunological response measured following wild-type BHV-I infection or infection with a commercially available BHV-I vaccine.
28. The method of claim 22, where the BHV-I containing the modification relieves down regulation of MHC class I expression, increases the ratio of IgGl to IgG2 for IgG specific for the non-BHV-1 immunogen, and/or increases IL-2 production following restimulation of blood cells with the non-BHV-1 immunogen, as compared to a wild-type BHV-I or a commercially available BHV-I vaccine strain.
29. A BHV-I containing a modification in a gene encoding a protein that depresses an immunological response in an infected ungulate, for use in eliciting an immunological response to BHV-I and a non-BHV-1 immunogen, in an ungulate host.
30. The use of claim 29, where the BHV-I contains a modification in at least two genes that encode proteins that depress an immunological response in an infected ungulate.
31. The use of claim 29, where the modifications are in UL49.5 and UL41.
32. The use of claim 29, where the gene encodes a protein that plays a role in one or more of MHC class I expression, chemokine expression, MHC class II expression, development of latent infection and viral persistence, reactivation of latency, and expression of IgG-mediated immune response.
33. The use of claim 29, where the gene encodes a protein that plays a role in one or more of MHC class I expression and chemokine expression.
34. The use of claim 29 where the modification is in UL49.5, UL41, Us4, Circ, LR-ORF-I, LR-ORF-2, Us9 or Us8.
35. The use of claim 29, where the modification is in Us4.
36. Use of a BHV-I containing a modification in a gene encoding a protein that depresses an immunological response in an infected ungulate, in the manufacture of a vaccine for eliciting an immunological response to BHV-I and a non-BHV-1 immunogen by co-administration or administration of a combination cocktail to an ungulate host.
37. The use of claim 36, where the modification is in Us4.
38. The use of claim 36, where the modification is in UL49.5 and where the BHV- 1 contains an additional modification in UL41.";"(US20120034262)
This application describes BHV-1 viruses that immunosuppress infected hosts to a lesser extent than normal, wild-type BHV-1 viruses.
Also disclosed are compositions containing the inventive BHV-1 viruses and additional immunogens.
Also disclosed are methods of using the inventive BHV-1 viruses, through coadministration to a host or through administration in a combination vaccine, to elicit an immune response in a host to BHV-1 and an additional immunogen.
The disclosure relates generally to the treatment or prevention of disease in cattle.
More particularly, the invention is directed to the production and use of modified bovine herpes virus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host.
In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through coadministration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease.";"(US20120034262)
This vaccine may be particularly useful in beef cattle females greater than one year of age.
BHV-1 viruses are known to cause immunosuppression of infected hosts.
Studies have established that the virus causes severe primary respiratory disease; that persistently infected cattle are a major source of infection for susceptible calves; and that BVD infects white cell reservoirs, causing profound and broad-based deficits in the immune system.
The ability to reactivate from latency results in recurrent disease and virus transmission.";"A61K-039/102
A61K-039/245
A61K-039/265
A61K-039/295
A61P-031/12
A61P-031/22
C07K-014/05
C12N-007/00
C12N-015/869";"(US20120034262)
39. A live bovine herpes virus-1 (BHV-1) that has modifications of UL49.
3 Virus (PI3), Rotavirus (BRV), Coronavirus (BCV), Mannheimia haemolytica, Histophilus somni, Mycoplasma bovis, Leptospira species, Vibrio species, Clostridia species, Pasteurella multocida, Fusobacterium necrophorum, E. coli O157:H7, Salmonella enterica, Neospora caninum or Trichomonas species.
5 and at least one additional gene encoding protein that can suppress the immune system of an infected host, where cells infected with the BHV-1 that has the modifications have at least partially restored MHC class I expression as compared to cells infected with a BHV-1 that does not have the modifications.
44. A composition, comprising: a) a live BHV-1 that has modifications of UL49.5 and at least one additional gene encoding protein that can affect a host immunological response to an immunogen; and b) an additional immunogen, where following administration of the composition to a host, a ratio of IgG1/IgG2 for IgG specific for the additional immunogen in the host is higher than a ratio of IgG1/IgG2 for IgG specific for the additional immunogen in a host administered a composition of live BHV-1 that does not have the modifications and the additional immunogen.
51. A method for eliciting an immunological response in a host, comprising administering to the host a composition including: a) an immunogen other than a BHV-1 antigen (non-BHV-1 immunogen); and b) a live BHV-1 that has modifications of UL49.5 and at least one additional gene encoding protein that can affect a host immunological response to an immunogen, where following administration of the composition to the host, a ratio of IgG1 to IgG2 in the host for IgG specific for the non-BHV-1 immunogen is higher than a ratio of IgG1 to IgG2 for IgG specific for the non-BHV-1 immunogen in a host administered a composition of the non-BHV-1 immunogen and live BHV-1 that does not have the modifications.
56. A live BHV-1 that has modifications of UL49.5 and one of UL41 or Us4, for use in eliciting an immunological response to BHV-1 and a non-BHV-1 immunogen in an ungulate host.";"(US20120034262)
BHV(100,174)
IMMUNOGEN(100,94)
VIRUS(100,75)
VACCINE(100,50)
CELL(100,47)
HOST(100,32)
IMMUNOLOGICAL RESPONSE(100,22)
LIVE BHV(100,15)
MANNHEIMIA HAEMOLYTICA(100,6)
MYCOPLASMA BOVIS(100,6)
PASTEURELLA MULTOCIDA(100,4)
FUSOBACTERIUM NECROPHORUM(100,3)
GENE ENCODING PROTEIN(100,3)
HISTOPHILUS SOMNI(100,3)
NEOSPORA CANINUM(100,3)
SALMONELLA ENTERICA(100,3)
BOVINE HERPES VIRUS(100,2)
CORONAVIRUS(100,2)
ROTAVIRUS(100,2)
UNGULATE HOST(100,2)
CLOSTRIDIA SPECIES(100,1)
INFECTED HOST IMMUNE(100,1)
LEPTOSPIRA SPECIES(100,1)
LIVE BOVINE HERPES VIRUS(100,1)
TRICHOMONAS SPECIES(100,1)
VIBRIO SPECIES(100,1)
PERSISTENTLY INFECTED CATTLE(53,1)
INFECTED HOST IMMUNOSUPPRESSION(46,1)
COMPOSITION ADMINISTRATION(42,5)
CATTLE PROTECTION(34,1)
DISEASE PREVENTION(33,1)
HOST BLOOD(32,4)
MODIFIED BOVINE HERPES VIRUS(31,1)
HOST IMMUNOLOGICAL RESPONSE(29,5)
BEEF CATTLE FEMALE(28,1)
RECURRENT DISEASE(28,1)
SUSCEPTIBLE CALF(26,1)
AGE YEAR(25,1)
CO ADMINISTRATION(24,4)
IGG1 RATIO(23,4)
SEVERE PRIMARY RESPIRATORY DISEASE(22,1)
MODIFIED BHV(19,21)
IGG1 IGG2 RATIO(19,11)
CELL SAMPLE(19,4)
INFECTED HOST(19,2)
VIRUS TRANSMISSION(19,1)
IGG(18,9)
IGG2(16,4)
LESSER EXTENT(16,1)
ADMINISTRATION(15,10)
COOPER STRAIN(15,3)
PARTIALLY RESTORED MHC(15,2)
IMMUNE RESPONSE(14,18)
CATTLE(14,7)
MAJOR INFECTION SOURCE(14,1)
WHITE CELL RESERVOIR(14,1)
DELETION MUTANT(12,9)
ANTIGEN(11,28)
MUTANT BHV(11,6)
UNDERLINED NUCLEOTIDE(11,6)
BOVINE VIRAL DIARRHEA VIRUS(11,5)
MDBK CELL(10,14)
CO ADMINISTERED VACCINE(10,4)
MYRISTYLATED TEGUMENT PROTEIN(10,2)
PARAINFLUENZA(10,2)
BROAD BASED DEFICIT(10,1)
INFECTION(9,19)
DISEASE(9,8)
LR ORF(9,8)
MARKER GENE(9,8)
CO ADMINISTERED ANTIGEN(9,3)
CO ADMINISTERED IMMUNOGEN(9,3)
MHC CLASS RESTORATION(9,3)
ZENON MOUSE IGG(9,3)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(9,2)
LATENCY RESULT(9,1)
NONCYTOPATHIC BVD BIOTYPE(9,1)
PERSISTENTLY INFECTED CALF BIRTH(9,1)
VACCINE STRAIN(8,4)
DELETION RECOMBINATION CONSTRUCT(8,2)
TARGETED GENE DELETION(8,2)
DUBLIN TYPHIMURIUM BACTERIN(8,1)
COMBINATION VACCINE(7,30)
BVD(7,9)
AGE MONTH(7,5)
NATIVE PROTEIN(7,5)
CELL MEDIATED IMMUNITY(7,4)
HOST IMMUNOLOGICAL RESPONSE DEPRESSION(7,4)
BHV SHEDDING(7,2)
RECOMBINANT VIRUS ISOLATION(7,2)
CATTLE LEPTOSPIRAL INFECTION(7,1)
EXOGENOUS CORTICOSTEROID ADMINISTRATION(7,1)
GENUS LEPTOSPIRA BACTERIUM(7,1)
IGG ISOTYPE SUBTYPE(7,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(7,1)
KLUWER ACADEMIC PUBLISHER(7,1)
NAIVE PREGNANT COW(7,1)
POLYPEPTIDE NEUTRALIZING EPITOPE(7,1)
GENE SEQUENCE(6,6)
VETERINARY ACCEPTABLE CARRIER(6,4)
INFECTED CELL CULTURE SUPERNATANT(6,3)
LIVE VIRUS VACCINE(6,3)
RECOMBINANT TRANSFER PLASMID(6,3)
VIRAL PLAQUE(6,3)
APOPTOSIS SUPPRESSION(6,2)
CLOSTRIDIAL ANTIGEN(6,2)
IMMUNIZED HOST PROTECTION(6,2)
IMMUNOMODULATORY MOLECULE(6,2)
LATENCY ESTABLISHMENT(6,2)
LKT ADMINISTRATION(6,2)
RECOMBINANT BHV(6,2)
RECOMBINANT LKT(6,2)
TARGET GENE DELETION(6,2)
UNMODIFIED BHV(6,2)
VIRAL INFECTIVITY(6,2)
DNA NON TRANSCRIBED STRAND(6,1)
EARLY EMBRYONIC DEATH PREVENTION(6,1)
EN PASSANT MUTAGENESIS(6,1)
FUSOBACTERIUM NECROPHORUM BACTERIN(6,1)
HOST MHC DOWNREGULATION(6,1)
INFECTIOUS VIRUS SHEDDING(6,1)
MADIN DARBY BOVINE KIDNEY(6,1)
ABORTION(5,7)
MONOCLONAL ANTIBODY(5,7)
IMMUNE(5,6)
GENE MODIFICATION(5,4)
INVITROGEN DETECTION TECHNOLOGY(5,3)
LABELING KIT(5,3)
PROTEIN FRAGMENT(5,3)
SECONDARY ANTIBODY(5,3)
ANTIBODY COMPLEMENT(5,2)
CIRC GENE(5,2)
DOSE ADMINISTRATION(5,2)
GENOME FRAGMENT(5,2)
IGG1 IGG2 SUBTYPE RATIO(5,2)
IGG2 ANTIBODY(5,2)
IMMUNOGENIC FRAGMENT(5,2)
INFECTED CELL CULTURE LYSATE(5,2)
LKT ANTIGEN(5,2)
LKT TITER(5,2)
RECALL ANTIGEN(5,2)
RECOMBINANT VIRUS PRODUCTION(5,2)
RELIEVING IMMUNOSUPPRESSION(5,2)
TRANSCRIPTION INITIATION(5,2)
TRANSCRIPTION TERMINATION SEQUENCE(5,2)
VACCINATED ANIMAL(5,2)
ARTIFICIAL CHROMOSOME INTRODUCTION(5,1)
BACTERIAL PATHOGEN FOREIGN IMMUNOGEN(5,1)
BHV MUTANT ANALOG(5,1)
BHV SYMPTOM(5,1)
BHV VIRULENCE(5,1)
BOVINE RESPIRATORY VIRUS(5,1)
CATTLE HERPES VIRUS DISEASE(5,1)
CATTLE LEPTOSPOROSIS(5,1)
CLOSTRIDIAL BACTERIN(5,1)
CLOSTRIDIUM HAEMOLYTICUM(5,1)
CLOSTRIDIUM NOVYI(5,1)
CLOSTRIDIUM SORDELLII(5,1)
CO ADMINISTERED BHV(5,1)
CONTAGIOUS MASTITIS(5,1)
EQUID HERPES VIRUS(5,1)
FATAL MANIFESTATION(5,1)
FETAL INFECTION PREVENTION(5,1)
GANGLION NEURON(5,1)
GREEN FLUORESCENCE VISUALIZATION(5,1)
HAEMOPHILUS SOMNUS(5,1)
HEMORRHAGIC BVD(5,1)
HISTOPHILUS SOMNI BACTERIN(5,1)
IGG1 IGG2 SUPPRESSION(5,1)
IGG2 SERUM ANTIBODY(5,1)
INFECTIOUS MUTANT VIRUS(5,1)
INTERROGAN SEROVAR(5,1)
INTRANASAL INSTILLATION(5,1)
KERATOCONJUNCTIVITIS(5,1)
LATENT INFECTION ESTABLISHMENT(5,1)
LEPTO HARDJO BOVIS(5,1)
LEPTOSPIRA GRIPPOTYPHOSA(5,1)
LEPTOSPIROSIS IMMUNOGEN(5,1)
MANNHEIMIA HAEMOLYTICA IMMUNOGEN(5,1)
MHC RESTORATION(5,1)
REDUNDANT CODON ENCODING(5,1)
SOUTHERN HYBRIDIZATION EXPERIMENT(5,1)
TRIGERMINAL GANGLIA(5,1)
VACCINE INABILITY(5,1)
VERTEBRATE CELL NUCLEUS(5,1)
VIRAL BOVINE HERPES VIRUS(5,1)
MODIFIED PROTEIN(4,6)
WILD TYPE BHV(4,4)
GENOME REGION(4,3)
MOCK INFECTED CELL(4,3)
MONOSACCHARIDE(4,3)
ACUTE INFECTION(4,2)
ANTIBODY CONCENTRATION(4,2)
ARTIFICIAL CHROMOSOME COMPONENT(4,2)
DELETION MODIFICATION(4,2)
DELETION RECOMBINATION SITE(4,2)
FOREIGN GENE(4,2)
FUNCTIONALLY EQUIVALENT PROTEIN(4,2)
FUSION PROTEIN(4,2)
LATENCY MAINTENANCE(4,2)
LKT ANIMAL(4,2)
MOLECULE EXPRESSION(4,2)
REPORTER GENE EXPRESSION(4,2)
REPORTER GENE PRODUCT(4,2)
ABUNDANT VIRAL GENE EXPRESSION(4,1)
ANTIBODY ISOTOPE(4,1)
ANTIBODY ISOTYPE(4,1)
BACTERIAL IMMUNOGEN(4,1)
BHV GENE(4,1)
BHV MODIFIED IMMUNOGEN(4,1)
BREED CATTLE(4,1)
CANINUM INFECTION(4,1)
CAT82A ANTIBODY(4,1)
COMPETITION IMMUNOASSAY(4,1)
DIVA VACCINE(4,1)
ECONOMICALLY SIGNIFICANT VIRAL PATHOGEN(4,1)
ENZYME LINKED IMMUNOADSORBENT ASSAY(4,1)
EUCARYOTIC MRNA(4,1)
EUCARYOTIC PROMOTER(4,1)
FATAL VIREMIA(4,1)
FETUS INFECTION(4,1)
GENE EXHIBIT HOMOLOGY(4,1)
GLYCOSYLATED POLYPEPTIDE(4,1)
HARDJO BOVIS ANTIGEN(4,1)
HERPESVIRIDAE FAMILY(4,1)
HIGHLY CONSERVED GLYCOPROTEIN(4,1)
HOMOLOGOUS RECOMBINATION(4,1)
HOST IMMUNOSUPPRESSION(4,1)
HYDROPHILICITY ALTERATION(4,1)
IGG1 SUBTYPE(4,1)
IMMUNOFLUORESCENCE ASSAY(4,1)
IMMUNOGEN ADMINISTRATION(4,1)
INFECTING BHV(4,1)
INFECTIOUS BHV(4,1)
ISOLATED SEGMENT ARTIFICIAL MANIPULATION(4,1)
LATENCY REACTIVATION CYCLE(4,1)
LATENT INFECTION DEVELOPMENT(4,1)
LIFELONG LATENCY(4,1)
MHC CLASS EXPRESSION(4,1)
MHC DECREASED EXPRESSION(4,1)
MHC EXPRESSION MEASUREMENT(4,1)
MODIFIED BHV IMMUNOGEN(4,1)
MONTANIDE ISA(4,1)
MUCOSAL EPITHELIUM(4,1)
NEONATE CALF(4,1)
NON LIQUID FORMULATION(4,1)
OCULAR SHEDDING REDUCTION(4,1)
PATHOGEN ANTIGEN(4,1)
POLYPEPTIDE FRAGMENT(4,1)
PREGNANT CATTLE(4,1)
PROCARYOTIC PROMOTER(4,1)
RECOMBINANT POLYPEPTIDE(4,1)
RESPIRATORY PNEUMONIA(4,1)
SERONEGATIVE CALF(4,1)
SEROVAR HARDJO(4,1)
SHINE DALGARNO SEQUENCE(4,1)
SUBTYPE IGG1(4,1)
SUBTYPE IGG2(4,1)
SUBUNIT ANTIGEN(4,1)
TERM IMMUNOGENIC POLYPEPTIDE(4,1)
TRICHOMONAS INFECTION PREVENTION(4,1)
TRICHOMONAS SPP(4,1)
UPSTREAM REGULATORY DOMAIN(4,1)
VACCINE ANTIGEN ABILITY(4,1)
INFECTED CELL SURFACE(3,6)
COMPLETE DELETION(3,4)
ISOTYPE MATCHED CONTROL ANTIBODY(3,4)
RECALL RESPONSE(3,4)
DELETION MUTATION(3,3)
IMMUNOLOGICAL RESPONSE COMPONENT(3,3)
MHC DOWN REGULATION(3,3)
POST INFECTION(3,3)
PRIMARY IMMUNE RESPONSE(3,3)
SERA(3,3)
SHIPPING FEVER(3,3)
UNDERLINED AMINOACID(3,3)
AGE DAY(3,2)
BENZYL ALCOHOL(3,2)
DELETION LOCATION(3,2)
INITIAL IMMUNIZATION(3,2)
ISOTONIC AGENT(3,2)
LATENCY PREVENTION REDUCTION(3,2)
PARTIAL DELETION(3,2)
PERIODIC BASIS(3,2)
PRIMARY ANTIBODY(3,2)
SERUM SAMPLE(3,2)
TRANSLATIONAL STOP CODON(3,2)
TRIGEMINAL GANGLIA(3,2)
ABORTED CALF(3,1)
ACUTE FEVER(3,1)
ADULT CATTLE(3,1)
ALTERED EXPRESSION(3,1)
ANTEROGRADE TRANSPORT(3,1)
ANTIBODY MOLECULE(3,1)
ANTIGEN CONCENTRATION(3,1)
ANTIGEN TRANSPORT(3,1)
ANTIGENIC DETERMINANT SITE(3,1)
APOPTOSIS ACTIVATION(3,1)
ASN SUBSTITUTION(3,1)
ATTENUATED VIRUS(3,1)
BACTERIAL ARTIFICIAL CHROMOSOME CONSTRUCT(3,1)
BACTERIAL ORIGIN SEQUENCE(3,1)
BACTERIAL REPLICATION ORIGIN SEQUENCE(3,1)
BACTERIAL STRAIN(3,1)
BEEF ANIMAL(3,1)
BHV COMPLEX(3,1)
BHV MODIFICATION(3,1)
BHV MODIFIED GENE(3,1)
BHV STRAIN(3,1)
BOVINE ANIMAL(3,1)
BOVINE CYTOKINE(3,1)
BOVINE HERPES VIRUS INFECTION(3,1)
BOVINE HOST(3,1)
BOVINE RESPIRATORY SYSTEM COMPLEX(3,1)
BREEDING FAILURE(3,1)
CAUDAL MUSCLE(3,1)
CAUSATIVE AGENT(3,1)
CELL COTRANSFECTION(3,1)
CELL CYTOPLASMIC EXPRESSION(3,1)
CELLULAR HOMOLOG(3,1)
CIRC CODING SEQUENCE(3,1)
CLINICAL DISEASE(3,1)
CLINICAL SYNDROME VARIETY(3,1)
CLOSTRIDIAL SPECIES(3,1)
CODING SEQUENCE BOUNDARY(3,1)
CODING SEQUENCE TRANSLATION(3,1)
COLI CLONE(3,1)
COMPLEMENT REGULATION(3,1)
CORTICOSTEROID INDUCED STRESS(3,1)
COVALENT BONDING(3,1)
DAIRY CATTLE FEMALE(3,1)
DAIRY HERD(3,1)
DISPOSABLE SYRINGE(3,1)
DNA REGULATORY SEQUENCE(3,1)
DOSE VIAL(3,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(3,1)
ENCODED PROTEIN ABILITY(3,1)
EVALUATING CYTOKINE(3,1)
EXOGENOUS DNA(3,1)
EXPRESSED MHC(3,1)
EYE SWAB(3,1)
FEVER ELIMINATION(3,1)
FLANKING PRIMER(3,1)
FLUORESCENT MARKER(3,1)
FUNCTIONALLY EQUIVALENT BHV(3,1)
GENE DELETION CONSTRUCT(3,1)
GENE ENCODING(3,1)
GFP EXPRESSION(3,1)
GLYCOSYLATED AMINOACID SUBSTITUTION(3,1)
GROWTH KINETICS(3,1)
HELIX BREAKER(3,1)
HETEROLOGOUS CELL(3,1)
HOST ACTIVATION(3,1)
HOST ANIMAL PROTEIN(3,1)
HOST IMMUNE RESPONSE ALTERATION(3,1)
HOST INABILITY(3,1)
HOST RESPONSE IMMUNOSUPPRESSION(3,1)
HOST RESPONSE MEASURING IMMUNOSUPPRESSION(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
IMMUNE DEPRESSION(3,1)
IMMUNE RESPONSE DEPRESSION(3,1)
IMMUNE RESPONSE RECALL(3,1)
IMMUNE RESPONSE SUPPRESSION(3,1)
IMMUNO EN(3,1)
IMMUNOGEN BIOLOGICAL RESPONSE(3,1)
IMMUNOMODULATORY CYTOKINE GROUP(3,1)
IMMUNOSUPPRESSIVE GENE COMBINATION(3,1)
IMMUNOTOLERANCE DEVELOPMENT(3,1)
INFECTED ANIMAL(3,1)
INFECTED CATTLE(3,1)
INTERFERON EXPRESSION(3,1)
INVERTED REPEAT(3,1)
ISOLATED BHV(3,1)
ISOLATED MOLECULE(3,1)
ISOLATED POLYPEPTIDE(3,1)
ISOSTERIC RESIDUE(3,1)
JOINT INFECTION(3,1)
LATE GESTATION(3,1)
LATENCY GENE(3,1)
LEUKOCYTE SUBSET(3,1)
LINEAR DNA MOLECULE(3,1)
LOCAL FOLDING ALTERATION(3,1)
METHYL GALACTURONATE(3,1)
METHYLPARABEN(3,1)
MHC CLASS MOLECULE(3,1)
MHC CONTEXT(3,1)
MHC IMMUNOGEN PROCESSING(3,1)
MHC MOLECULE(3,1)
MINERAL OIL EMULSION(3,1)
MODIFIED GENE EVALUATION(3,1)
MODIFIED LIVE BHV(3,1)
MODIFIED LIVE VACCINE(3,1)
MUTANT GENE(3,1)
NASAL SWAB(3,1)
NATIVE GENE(3,1)
NON AQUEOUS VEHICLE(3,1)
NON NATIVE PRODUCTION(3,1)
NUCLEOPROTEIN(3,1)
NUCLEOTIDE SEQUENCE(3,1)
ORAL VEHICLE(3,1)
PARENTERAL INJECTION(3,1)
PARENTERAL VEHICLE(3,1)
PARTIAL GENE DELETION(3,1)
PLURONIC POLYOL(3,1)
PNEUMONIA INCREASED SUSCEPTIBILITY(3,1)
PREGNANCY CHECKING(3,1)
PREGNANT ANIMAL(3,1)
PREGNANT FEMALE(3,1)
PROCARYOTIC SEQUENCE(3,1)
PROTEIN THOUGHT(3,1)
RESTRICTION DIGEST(3,1)
SAPONIN DERIVATIVE(3,1)
SEVERE RESPIRATORY INFECTION(3,1)
SODIUM BISULFITE(3,1)
SOLE INFECTIOUS AGENT(3,1)
STERILE DILUENT(3,1)
STRONG IMMUNOGEN(3,1)
SUPPRESSED MHC(3,1)
SUSCEPTIBLE ANIMAL(3,1)
SUSCEPTIBLE HOST(3,1)
SYSTEMIC IMMUNITY(3,1)
SYSTEMIC INFECTION(3,1)
TESTED BHV(3,1)
TONICITY ADJUSTMENT(3,1)
TREATMENT SUCCESSFULNESS(3,1)
UNDERGONE MODIFICATION(3,1)
UNINFECTED CELL(3,1)
VACCINATION ROUTE(3,1)
VACCINE PREPARATION(3,1)
VARICELLOVIRUS GENUS MEMBER(3,1)
VETERINARY ACCEPTABLE VEHICLE(3,1)
VIABLE VIRUS(3,1)
VIBRIO SPP(3,1)
VIRAL PERSISTENCE(3,1)
VIRUS INFECTED CELL(3,1)
VIRUS STRAIN(3,1)
VISCOSITY ENHANCING(3,1)
WESTERN BLOTTING(3,1)
WINTER WHEAT(3,1)
NECK(2,4)
TCID(2,4)
VECTOR(2,4)
BVDV(2,3)
MOLECULAR PROBE(2,3)
SDS PAGE(2,3)
SINGLE GENE(2,3)
SORBITOL(2,3)
TERMINUS(2,3)
ARABINOSE(2,2)
ARTIFICIAL COMBINATION(2,2)
BOOSTER IMMUNIZATION(2,2)
CARBOHYDRATE(2,2)
CHEMOKINE(2,2)
DOUBLE STRANDED DNA MOLECULE(2,2)
DRY POWDER(2,2)
ELISA PLATE(2,2)
FRUCTOSE(2,2)
IGG SUBTYPE SPECIFIC ANTIBODY(2,2)
IGG1 LEVEL(2,2)
LIPOPEPTIDE(2,2)
MHC RELATED PROTEIN(2,2)
PARASITE(2,2)
POLYADENYLATION SIGNAL(2,2)
PRESERVATIVE(2,2)
PROGRAMMED CELL DEATH(2,2)
RECOMBINANT DNA(2,2)
RNA POLYMERASE(2,2)
SECRETORY(2,2)
SEQUENCE INSERTION(2,2)
SINGLE NUCLEOTIDE DELETION(2,2)
STERILE WATER(2,2)
SUBCLASS(2,2)
576 INFECTED CELL(2,1)
ACETYLGLUCOSAMINE(2,1)
ADSORPTION AGENT(2,1)
ALPHAHERPESVIRUSE(2,1)
ALTERED HOST IMMUNE RESPONSE(2,1)
ANTI EN(2,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(2,1)
ANTIBODY PRODUCTION(2,1)
ARTHRITIC CONDITION(2,1)
BACTERIAL PNEUMONIA CAUSE(2,1)
BALANOPOSTHITIS(2,1)
BEEF QUALITY ASSURANCE(2,1)
BHV REGION(2,1)
BICARBONATE BUFFER(2,1)
BRACHIOCEPHALICUS(2,1)
CLOSTRIDIUM CHAUVOEI(2,1)
CLOSTRIDIUM SEPTICUM(2,1)
COLI CELL(2,1)
COMPONENT JUXTAPOSITION(2,1)
COUNTERING IMMUNOSUPPRESSION RESULT(2,1)
DELAYING AGENT(2,1)
DOUBLE STRANDED HELIX(2,1)
ETHYL OLEATE(2,1)
FALL WEANING(2,1)
FEED INTAKE DROP(2,1)
FEEDLOT(2,1)
GENOMIC DNA SEQUENCE(2,1)
HOST ANIMAL SAMPLE ANALYSIS(2,1)
HOST IMMUNOLOGICAL RESPONSE MEASUREMENT(2,1)
HOST LIFE(2,1)
HUMAN HERPES VIRUS(2,1)
IDENTICAL POLYPEPTIDE(2,1)
IFN TREATMENT(2,1)
IMMUNE RESPONSE INDICATOR(2,1)
IMMUNOPRECIPITATION(2,1)
IMMUNOSTIMULATION(2,1)
IMMUNOSUPRESSION(2,1)
INCORPORATION INSTANCE(2,1)
INITIAL INFECTION SITE(2,1)
INITIAL REPLICATION(2,1)
LATENCY RELATED GENE(2,1)
LATENCY RELATED ORF(2,1)
LIPOPOLYSACCHARIDE(2,1)
LIVE PREPARATION(2,1)
MHC CAUSE SUPPRESSION(2,1)
MINERAL GEL(2,1)
MODIFIED GENE ABILITY(2,1)
NEONATAL PERIOD(2,1)
NON GLYCOSYLATED AMINOACID(2,1)
NUCLEIC ACID COMPLEMENT(2,1)
NURSING INDIVIDUAL(2,1)
OLFACTORY ORGAN SITE(2,1)
ORGANISM ABILITY(2,1)
PARENTERAL PREPARATION(2,1)
PCR SCREEN(2,1)
PEPTIDE BOND(2,1)
PHOSPHATE BUFFER(2,1)
PLASTIC MICROTITRATION PLATE(2,1)
PLUS LKT GROUP(2,1)
PROTEIN ABSENCE(2,1)
PROTEIN PRODUCTION(2,1)
RECOMBINANT NUCLEIC ACID(2,1)
SECONDARY BACTERIAL INFECTION(2,1)
SECONDARY IMMUNE RESPONSE(2,1)
SENTENCE(2,1)
SEQUENCE ENCODING(2,1)
SEQUENCE RECOGNITION SITE(2,1)
SERUM ANTIBODY LEVEL(2,1)
STRONG IMMUNOLOGICAL RESPONSE(2,1)
SUBSTRATE REAGENT(2,1)
SUPERINFECTION(2,1)
SUPPRESSED IMMUNE RESPONSE(2,1)
SYNTHETIC PROTEIN(2,1)
SYNTHETIC SOLVENT(2,1)
TERM EPITOPE(2,1)
TESTED GENE(2,1)
TRANSLATION START CODON(2,1)
TRANSLATION STOP CODON(2,1)
TRIMESTER(2,1)
UNIQUE GENE(2,1)
VEGETABLE OIL EMULSION(2,1)
VIROLOGY(2,1)
ACTIVE GENE(1,1)
ACTIVE PROTEIN(1,1)
ACTIVE SUBSTANCE(1,1)
ADJUVANT COMBINATION(1,1)
AGALACTIA(1,1)
ALGINATE(1,1)
ALHYDROGEL(1,1)
ALUMINUM HYDROXIDE(1,1)
AMINOACID MUTATION(1,1)
AMPOULE(1,1)
AMYLOSE(1,1)
ANTIGEN PRESENTATION(1,1)
ANTIOXIDANT(1,1)
ANTISENSE(1,1)
BAYOLF(1,1)
BIO(1,1)
BIOPOLYMER(1,1)
BOVINE CORONAVIRUS(1,1)
BOVINE VIRAL DIARRHEA(1,1)
CARBOPOL(1,1)
CARRAGEENAN(1,1)
CELL GROWTH(1,1)
(US8637046)
VACCINE(100,57)
HOST(100,35)
IMMUNOLOGICAL RESPONSE(100,21)
LIVE BHV(100,9)
BOVINE HERPES VIRUS(100,2)
GENE ENCODING PROTEIN(82,2)
IMMUNOGEN(77,105)
LIVE BHV GENOME(76,1)
PERSISTENTLY INFECTED CATTLE(65,1)
INFECTED HOST IMMUNOSUPPRESSION(57,1)
COMPOSITION ADMINISTRATION(43,8)
FOREIGN GENE(42,4)
CATTLE PROTECTION(42,1)
DISEASE PREVENTION(41,1)
HOST BLOOD(40,4)
MODIFIED BOVINE HERPES VIRUS(39,1)
HOST IMMUNOLOGICAL RESPONSE(36,5)
RECURRENT DISEASE(35,1)
BHV(34,182)
BEEF CATTLE FEMALE(34,1)
SUSCEPTIBLE CALF(32,1)
IGG1 RATIO(31,3)
AGE YEAR(31,1)
CO ADMINISTRATION(29,4)
SEVERE PRIMARY RESPIRATORY DISEASE(27,1)
TRICHOMONAS SPECIES(26,1)
VIRUS(25,78)
CLOSTRIDIA SPECIES(25,1)
LEPTOSPIRA SPECIES(25,1)
MODIFIED BHV(24,22)
IGG1 IGG2 RATIO(24,11)
CELL SAMPLE(24,4)
INFECTED HOST(24,2)
VIBRIO SPECIES(24,1)
VIRUS TRANSMISSION(24,1)
IGG(22,9)
IGG2(22,3)
LESSER EXTENT(20,1)
IMMUNE RESPONSE(18,21)
ADMINISTRATION(18,12)
CATTLE(18,7)
MAJOR INFECTION SOURCE(17,1)
WHITE CELL RESERVOIR(17,1)
DELETION MUTANT(15,9)
ANTIGEN(13,28)
MARKER GENE(13,11)
MYCOPLASMA BOVIS(13,7)
MUTANT BHV(13,6)
UNDERLINED NUCLEOTIDE(13,6)
BOVINE VIRAL DIARRHEA VIRUS(13,5)
PASTEURELLA MULTOCIDA(13,4)
MDBK CELL(12,14)
LR ORF(12,10)
CO ADMINISTERED VACCINE(12,4)
NEOSPORA CANINUM(12,4)
SALMONELLA ENTERICA(12,4)
MYRISTYLATED TEGUMENT PROTEIN(12,2)
PARAINFLUENZA(12,2)
BROAD BASED DEFICIT(12,1)
PERSISTENTLY INFECTED CALF BIRTH(12,1)
INFECTION(11,20)
DISEASE(11,9)
GENOME(11,5)
CO ADMINISTERED ANTIGEN(11,3)
CO ADMINISTERED IMMUNOGEN(11,3)
ZENON MOUSE IGG(11,3)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(11,2)
ROTAVIRUS(11,2)
LATENCY RESULT(11,1)
NONCYTOPATHIC BVD BIOTYPE(11,1)
DELETION RECOMBINATION CONSTRUCT(10,2)
TARGETED GENE DELETION(10,2)
DUBLIN TYPHIMURIUM BACTERIN(10,1)
AGE MONTH(9,5)
HOST IMMUNOLOGICAL RESPONSE DEPRESSION(9,4)
HOST IMMUNOSUPPRESSION(9,3)
UNMODIFIED BHV(9,3)
BHV SHEDDING(9,2)
LEPTOSPIROSIS IMMUNOGEN(9,2)
RECOMBINANT VIRUS ISOLATION(9,2)
GENUS LEPTOSPIRA BACTERIUM(9,1)
IGG ISOTYPE SUBTYPE(9,1)
COMBINATION VACCINE(8,30)
BVD(8,10)
NATIVE PROTEIN(8,5)
CELL MEDIATED IMMUNITY(8,4)
INFECTED CELL CULTURE SUPERNATANT(8,3)
LIVE VIRUS VACCINE(8,3)
RECOMBINANT TRANSFER PLASMID(8,3)
VIRAL PLAQUE(8,3)
CATTLE LEPTOSPIRAL INFECTION(8,1)
DNA NON TRANSCRIBED STRAND(8,1)
EARLY EMBRYONIC DEATH PREVENTION(8,1)
EN PASSANT MUTAGENESIS(8,1)
EXOGENOUS CORTICOSTEROID ADMINISTRATION(8,1)
FUSOBACTERIUM NECROPHORUM BACTERIN(8,1)
HOST MHC DOWNREGULATION(8,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(8,1)
INFECTIOUS VIRUS SHEDDING(8,1)
KLUWER ACADEMIC PUBLISHER(8,1)
MADIN DARBY BOVINE KIDNEY(8,1)
NAIVE PREGNANT COW(8,1)
POLYPEPTIDE NEUTRALIZING EPITOPE(8,1)
GENE SEQUENCE(7,6)
GENE MODIFICATION(7,5)
VETERINARY ACCEPTABLE CARRIER(7,4)
APOPTOSIS SUPPRESSION(7,2)
BACTERIAL IMMUNOGEN(7,2)
CLOSTRIDIAL ANTIGEN(7,2)
IMMUNIZED HOST PROTECTION(7,2)
IMMUNOGENIC FRAGMENT(7,2)
IMMUNOMODULATORY MOLECULE(7,2)
LATENCY ESTABLISHMENT(7,2)
LKT ADMINISTRATION(7,2)
RECOMBINANT BHV(7,2)
RECOMBINANT LKT(7,2)
TARGET GENE DELETION(7,2)
TRICHOMONAS SPP(7,2)
VIRAL INFECTIVITY(7,2)
BACTERIAL PATHOGEN FOREIGN IMMUNOGEN(7,1)
BOVINE RESPIRATORY VIRUS(7,1)
CLOSTRIDIAL BACTERIN(7,1)
CO ADMINISTERED BHV(7,1)
FETAL INFECTION PREVENTION(7,1)
GREEN FLUORESCENCE VISUALIZATION(7,1)
HISTOPHILUS SOMNI BACTERIN(7,1)
IGG2 SERUM ANTIBODY(7,1)
INFECTIOUS MUTANT VIRUS(7,1)
LATENT INFECTION ESTABLISHMENT(7,1)
LEPTOSPIRA GRIPPOTYPHOSA(7,1)
MANNHEIMIA HAEMOLYTICA IMMUNOGEN(7,1)
SOUTHERN HYBRIDIZATION EXPERIMENT(7,1)
ABORTION(6,7)
MONOCLONAL ANTIBODY(6,7)
IMMUNE(6,6)
INVITROGEN DETECTION TECHNOLOGY(6,3)
LABELING KIT(6,3)
PROTEIN FRAGMENT(6,3)
SECONDARY ANTIBODY(6,3)
ANTIBODY COMPLEMENT(6,2)
CIRC GENE(6,2)
COOPER STRAIN(6,2)
DOSE ADMINISTRATION(6,2)
GENOME FRAGMENT(6,2)
IGG1 IGG2 SUBTYPE RATIO(6,2)
INFECTED CELL CULTURE LYSATE(6,2)
LKT TITER(6,2)
RECALL ANTIGEN(6,2)
RECOMBINANT VIRUS PRODUCTION(6,2)
RELIEVING IMMUNOSUPPRESSION(6,2)
TRANSCRIPTION INITIATION(6,2)
TRANSCRIPTION TERMINATION SEQUENCE(6,2)
VACCINATED ANIMAL(6,2)
ARTIFICIAL CHROMOSOME INTRODUCTION(6,1)
BHV MUTANT ANALOG(6,1)
BHV SYMPTOM(6,1)
BHV VIRULENCE(6,1)
CATTLE HERPES VIRUS DISEASE(6,1)
CATTLE LEPTOSPOROSIS(6,1)
CLOSTRIDIUM HAEMOLYTICUM(6,1)
CLOSTRIDIUM NOVYI(6,1)
CLOSTRIDIUM SORDELLII(6,1)
CONTAGIOUS MASTITIS(6,1)
EQUID HERPES VIRUS(6,1)
FATAL MANIFESTATION(6,1)
GANGLION NEURON(6,1)
HAEMOPHILUS SOMNUS(6,1)
HEMORRHAGIC BVD(6,1)
IGG1 IGG2 SUPPRESSION(6,1)
INTERROGAN SEROVAR(6,1)
INTRANASAL INSTILLATION(6,1)
KERATOCONJUNCTIVITIS(6,1)
LEPTO HARDJO BOVIS(6,1)
MHC CLASS RESTORATION(6,1)
MHC RESTORATION(6,1)
REDUNDANT CODON ENCODING(6,1)
TRIGERMINAL GANGLIA(6,1)
VACCINE INABILITY(6,1)
VERTEBRATE CELL NUCLEUS(6,1)
VIRAL BOVINE HERPES VIRUS(6,1)
MODIFIED PROTEIN(5,6)
WILD TYPE BHV(5,4)
GENOME REGION(5,3)
MONOSACCHARIDE(5,3)
ACUTE INFECTION(5,2)
ANTIBODY CONCENTRATION(5,2)
ARTIFICIAL CHROMOSOME COMPONENT(5,2)
DELETION MODIFICATION(5,2)
DELETION RECOMBINATION SITE(5,2)
FUNCTIONALLY EQUIVALENT PROTEIN(5,2)
FUSION PROTEIN(5,2)
LATENCY MAINTENANCE(5,2)
LKT ANIMAL(5,2)
MOLECULE EXPRESSION(5,2)
REPORTER GENE EXPRESSION(5,2)
REPORTER GENE PRODUCT(5,2)
ABUNDANT VIRAL GENE EXPRESSION(5,1)
ANTIBODY ISOTOPE(5,1)
ANTIBODY ISOTYPE(5,1)
BHV GENE(5,1)
BHV MODIFIED IMMUNOGEN(5,1)
BREED CATTLE(5,1)
BRSV IMMUNOGEN(5,1)
CANINUM INFECTION(5,1)
CAT82A ANTIBODY(5,1)
COMPETITION IMMUNOASSAY(5,1)
DIVA VACCINE(5,1)
ECONOMICALLY SIGNIFICANT VIRAL PATHOGEN(5,1)
ENZYME LINKED IMMUNOADSORBENT ASSAY(5,1)
EUCARYOTIC MRNA(5,1)
EUCARYOTIC PROMOTER(5,1)
FATAL VIREMIA(5,1)
FETUS INFECTION(5,1)
GENE EXHIBIT HOMOLOGY(5,1)
GLYCOSYLATED POLYPEPTIDE(5,1)
HARDJO BOVIS ANTIGEN(5,1)
HERPESVIRIDAE FAMILY(5,1)
HIGHLY CONSERVED GLYCOPROTEIN(5,1)
HOMOLOGOUS RECOMBINATION(5,1)
HYDROPHILICITY ALTERATION(5,1)
IGG1 SUBTYPE(5,1)
IMMUNOFLUORESCENCE ASSAY(5,1)
IMMUNOGEN ADMINISTRATION(5,1)
INFECTING BHV(5,1)
INFECTIOUS BHV(5,1)
ISOLATED SEGMENT ARTIFICIAL MANIPULATION(5,1)
LATENCY REACTIVATION CYCLE(5,1)
LATENT INFECTION DEVELOPMENT(5,1)
LIFELONG LATENCY(5,1)
MHC CLASS EXPRESSION(5,1)
MHC DECREASED EXPRESSION(5,1)
MHC EXPRESSION MEASUREMENT(5,1)
MODIFIED BHV IMMUNOGEN(5,1)
MONTANIDE ISA(5,1)
MUCOSAL EPITHELIUM(5,1)
NEONATE CALF(5,1)
NON LIQUID FORMULATION(5,1)
OCULAR SHEDDING REDUCTION(5,1)
PARASITIC IMMUNOGEN(5,1)
PATHOGEN ANTIGEN(5,1)
POLYPEPTIDE FRAGMENT(5,1)
PREGNANT CATTLE(5,1)
PROCARYOTIC PROMOTER(5,1)
RECOMBINANT POLYPEPTIDE(5,1)
RESPIRATORY PNEUMONIA(5,1)
SERONEGATIVE CALF(5,1)
SEROVAR HARDJO(5,1)
SHINE DALGARNO SEQUENCE(5,1)
SUBTYPE IGG1(5,1)
SUBTYPE IGG2(5,1)
SUBUNIT ANTIGEN(5,1)
TERM IMMUNOGENIC POLYPEPTIDE(5,1)
TRICHOMONAS INFECTION PREVENTION(5,1)
UPSTREAM REGULATORY DOMAIN(5,1)
VACCINE ANTIGEN ABILITY(5,1)
COMPLETE DELETION(4,4)
ISOTYPE MATCHED CONTROL ANTIBODY(4,4)
RECALL RESPONSE(4,4)
DELETION MUTATION(4,3)
IMMUNOLOGICAL RESPONSE COMPONENT(4,3)
MHC DOWN REGULATION(4,3)
POST INFECTION(4,3)
PRIMARY IMMUNE RESPONSE(4,3)
SHIPPING FEVER(4,3)
UNDERLINED AMINOACID(4,3)
AGE DAY(4,2)
BENZYL ALCOHOL(4,2)
COMBINATION COCKTAIL VACCINE(4,2)
DELETION LOCATION(4,2)
INITIAL IMMUNIZATION(4,2)
ISOTONIC AGENT(4,2)
LATENCY PREVENTION REDUCTION(4,2)
PARTIAL DELETION(4,2)
PRIMARY ANTIBODY(4,2)
SERUM SAMPLE(4,2)
TRANSLATIONAL STOP CODON(4,2)
TRIGEMINAL GANGLIA(4,2)
ABORTED CALF(4,1)
ACUTE FEVER(4,1)
ADULT CATTLE(4,1)
ALTERED EXPRESSION(4,1)
ANTEROGRADE TRANSPORT(4,1)
ANTIBODY MOLECULE(4,1)
ANTIGEN CONCENTRATION(4,1)
ANTIGEN TRANSPORT(4,1)
ANTIGENIC DETERMINANT SITE(4,1)
APOPTOSIS ACTIVATION(4,1)
ASN SUBSTITUTION(4,1)
ATTENUATED VACCINE STRAIN(4,1)
ATTENUATED VIRUS(4,1)
BACTERIAL ARTIFICIAL CHROMOSOME CONSTRUCT(4,1)
BACTERIAL ORIGIN SEQUENCE(4,1)
BACTERIAL REPLICATION ORIGIN SEQUENCE(4,1)
BACTERIAL STRAIN(4,1)
BEEF ANIMAL(4,1)
BHV COMPLEX(4,1)
BHV MODIFICATION(4,1)
BHV MODIFIED GENE(4,1)
BHV STRAIN(4,1)
BHV TREATMENT(4,1)
BOVINE ANIMAL(4,1)
BOVINE CYTOKINE(4,1)
BOVINE HERPES VIRUS INFECTION(4,1)
BOVINE HOST(4,1)
BOVINE RESPIRATORY SYSTEM COMPLEX(4,1)
BREEDING FAILURE(4,1)
CAUDAL MUSCLE(4,1)
CAUSATIVE AGENT(4,1)
CELL COTRANSFECTION(4,1)
CELL CYTOPLASMIC EXPRESSION(4,1)
CELLULAR HOMOLOG(4,1)
CIRC CODING SEQUENCE(4,1)
CLINICAL DISEASE(4,1)
CLINICAL SYNDROME VARIETY(4,1)
CLOSTRIDIAL SPECIES(4,1)
CODING SEQUENCE BOUNDARY(4,1)
CODING SEQUENCE TRANSLATION(4,1)
COLI CLONE(4,1)
COMPLEMENT REGULATION(4,1)
CORTICOSTEROID INDUCED STRESS(4,1)
COVALENT BONDING(4,1)
DAIRY CATTLE FEMALE(4,1)
DAIRY HERD(4,1)
DISPOSABLE SYRINGE(4,1)
DNA REGULATORY SEQUENCE(4,1)
DOSE VIAL(4,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(4,1)
ENCODED PROTEIN ABILITY(4,1)
EVALUATING CYTOKINE(4,1)
EXOGENOUS DNA(4,1)
EXPRESSED MHC(4,1)
EYE SWAB(4,1)
FEVER ELIMINATION(4,1)
FLANKING PRIMER(4,1)
FLUORESCENT MARKER(4,1)
FUNCTIONALLY EQUIVALENT BHV(4,1)
GENE DELETION CONSTRUCT(4,1)
GENE ENCODING(4,1)
GFP EXPRESSION(4,1)
GLYCOSYLATED AMINOACID SUBSTITUTION(4,1)
GROWTH KINETICS(4,1)
HELIX BREAKER(4,1)
HETEROLOGOUS CELL(4,1)
HOST ACTIVATION(4,1)
HOST ANIMAL PROTEIN(4,1)
HOST IMMUNE RESPONSE ALTERATION(4,1)
HOST INABILITY(4,1)
HOST RESPONSE IMMUNOSUPPRESSION(4,1)
HOST RESPONSE MEASURING IMMUNOSUPPRESSION(4,1)
HUMORAL IMMUNE RESPONSE(4,1)
IGG2 ANTIBODY(4,1)
IMMUNE DEPRESSION(4,1)
IMMUNE RESPONSE DEPRESSION(4,1)
IMMUNE RESPONSE RECALL(4,1)
IMMUNE RESPONSE SUPPRESSION(4,1)
IMMUNO EN(4,1)
IMMUNOGEN BIOLOGICAL RESPONSE(4,1)
IMMUNOMODULATORY CYTOKINE GROUP(4,1)
IMMUNOSUPPRESSIVE GENE COMBINATION(4,1)
IMMUNOTOLERANCE DEVELOPMENT(4,1)
INFECTED ANIMAL(4,1)
INFECTED CATTLE(4,1)
INTERFERON EXPRESSION(4,1)
INVERTED REPEAT(4,1)
ISOLATED BHV(4,1)
ISOLATED MOLECULE(4,1)
ISOLATED POLYPEPTIDE(4,1)
ISOSTERIC RESIDUE(4,1)
JOINT INFECTION(4,1)
LATE GESTATION(4,1)
LATENCY GENE(4,1)
LEUKOCYTE SUBSET(4,1)
LINEAR DNA MOLECULE(4,1)
LKT ANTIGEN(4,1)
LOCAL FOLDING ALTERATION(4,1)
METHYL GALACTURONATE(4,1)
METHYLPARABEN(4,1)
MHC CLASS MOLECULE(4,1)
MHC CONTEXT(4,1)
MHC IMMUNOGEN PROCESSING(4,1)
MHC MOLECULE(4,1)
MINERAL OIL EMULSION(4,1)
MODIFIED GENE EVALUATION(4,1)
MODIFIED LIVE BHV(4,1)
MODIFIED LIVE VACCINE(4,1)
MUTANT GENE(4,1)
NASAL SWAB(4,1)
NATIVE GENE(4,1)
NON AQUEOUS VEHICLE(4,1)
NON NATIVE PRODUCTION(4,1)
NUCLEOPROTEIN(4,1)
NUCLEOTIDE SEQUENCE(4,1)
ORAL VEHICLE(4,1)
PARENTERAL INJECTION(4,1)
PARENTERAL VEHICLE(4,1)
PARTIAL GENE DELETION(4,1)
PARTIALLY RESTORED MHC(4,1)
PLURONIC POLYOL(4,1)
PNEUMONIA INCREASED SUSCEPTIBILITY(4,1)
PREGNANCY CHECKING(4,1)
PREGNANT ANIMAL(4,1)
PREGNANT FEMALE(4,1)
PROCARYOTIC SEQUENCE(4,1)
PROTEIN THOUGHT(4,1)
RESTRICTION DIGEST(4,1)
SAPONIN DERIVATIVE(4,1)
SEVERE RESPIRATORY INFECTION(4,1)
SODIUM BISULFITE(4,1)
SOLE INFECTIOUS AGENT(4,1)
STERILE DILUENT(4,1)
STRONG IMMUNOGEN(4,1)
SUPPRESSED MHC(4,1)
SUSCEPTIBLE ANIMAL(4,1)
SUSCEPTIBLE HOST(4,1)
SYSTEMIC IMMUNITY(4,1)
SYSTEMIC INFECTION(4,1)
TESTED BHV(4,1)
TONICITY ADJUSTMENT(4,1)
TREATMENT SUCCESSFULNESS(4,1)
UNDERGONE MODIFICATION(4,1)
UNGULATE HOST(4,1)
UNINFECTED CELL(4,1)
VACCINATION ROUTE(4,1)
VACCINE PREPARATION(4,1)
VARICELLOVIRUS GENUS MEMBER(4,1)
VETERINARY ACCEPTABLE VEHICLE(4,1)
VIABLE VIRUS(4,1)
VIBRIO SPP(4,1)
VIRAL IMMUNOGEN(4,1)
VIRAL PERSISTENCE(4,1)
VIRUS INFECTED CELL(4,1)
VIRUS STRAIN(4,1)
VISCOSITY ENHANCING(4,1)
WESTERN BLOTTING(4,1)
WINTER WHEAT(4,1)
INFECTED CELL SURFACE(3,6)
NECK(3,4)
TCID(3,4)
VECTOR(3,4)
SERA(3,3)
ARABINOSE(3,2)
ARTIFICIAL COMBINATION(3,2)
BHV GROUP(3,2)
BOOSTER IMMUNIZATION(3,2)
CARBOHYDRATE(3,2)
CHEMOKINE(3,2)
DOUBLE STRANDED DNA MOLECULE(3,2)
DRY POWDER(3,2)
ELISA PLATE(3,2)
FRUCTOSE(3,2)
IGG SUBTYPE SPECIFIC ANTIBODY(3,2)
LIPOPEPTIDE(3,2)
MHC RELATED PROTEIN(3,2)
PARASITE(3,2)
PERIODIC BASIS(3,2)
POLYADENYLATION SIGNAL(3,2)
PRESERVATIVE(3,2)
PROGRAMMED CELL DEATH(3,2)
RECOMBINANT DNA(3,2)
RNA POLYMERASE(3,2)
SECRETORY(3,2)
SEQUENCE INSERTION(3,2)
SINGLE NUCLEOTIDE DELETION(3,2)
STERILE WATER(3,2)
SUBCLASS(3,2)
ACETYLGLUCOSAMINE(3,1)
ADSORPTION AGENT(3,1)
ALPHAHERPESVIRUSE(3,1)
ALTERED HOST IMMUNE RESPONSE(3,1)
ANTI EN(3,1)
ANTIBODY MEDIATED IMMUNE RESPONSE(3,1)
ANTIBODY PRODUCTION(3,1)
ARTHRITIC CONDITION(3,1)
BACTERIAL PNEUMONIA CAUSE(3,1)
BALANOPOSTHITIS(3,1)
BEEF QUALITY ASSURANCE(3,1)
BHV REGION(3,1)
BICARBONATE BUFFER(3,1)
BRACHIOCEPHALICUS(3,1)
CLOSTRIDIUM CHAUVOEI(3,1)
CLOSTRIDIUM SEPTICUM(3,1)
COLI CELL(3,1)
COMPONENT JUXTAPOSITION(3,1)
COUNTERING IMMUNOSUPPRESSION RESULT(3,1)
DELAYING AGENT(3,1)
DOUBLE STRANDED HELIX(3,1)
ETHYL OLEATE(3,1)
FALL WEANING(3,1)
FEED INTAKE DROP(3,1)
FEEDLOT(3,1)
GENOMIC DNA SEQUENCE(3,1)
HOST ANIMAL SAMPLE ANALYSIS(3,1)
HOST IMMUNOLOGICAL RESPONSE MEASUREMENT(3,1)
HOST LIFE(3,1)
HUMAN HERPES VIRUS(3,1)
IDENTICAL POLYPEPTIDE(3,1)
IFN TREATMENT(3,1)
IMMUNE RESPONSE INDICATOR(3,1)
IMMUNOPRECIPITATION(3,1)
IMMUNOSTIMULATION(3,1)
IMMUNOSUPRESSION(3,1)
INCORPORATION INSTANCE(3,1)
INITIAL INFECTION SITE(3,1)
INITIAL REPLICATION(3,1)
LATENCY RELATED GENE(3,1)
LATENCY RELATED ORF(3,1)
LIPOPOLYSACCHARIDE(3,1)
LIVE PREPARATION(3,1)
MHC CAUSE SUPPRESSION(3,1)
MINERAL GEL(3,1)
MODIFIED GENE ABILITY(3,1)
NEONATAL PERIOD(3,1)
NON GLYCOSYLATED AMINOACID(3,1)
NUCLEIC ACID COMPLEMENT(3,1)
NURSING INDIVIDUAL(3,1)
OLFACTORY ORGAN SITE(3,1)
ORGANISM ABILITY(3,1)
PARENTERAL PREPARATION(3,1)
PCR SCREEN(3,1)
PEPTIDE BOND(3,1)
PHOSPHATE BUFFER(3,1)
PLASTIC MICROTITRATION PLATE(3,1)
PLUS LKT GROUP(3,1)
PROTEIN ABSENCE(3,1)
PROTEIN PRODUCTION(3,1)
RECOMBINANT NUCLEIC ACID(3,1)
SECONDARY BACTERIAL INFECTION(3,1)
SECONDARY IMMUNE RESPONSE(3,1)
SENTENCE(3,1)
SEQUENCE ENCODING(3,1)
SEQUENCE RECOGNITION SITE(3,1)
SERUM ANTIBODY LEVEL(3,1)
STRONG IMMUNOLOGICAL RESPONSE(3,1)
SUBSTRATE REAGENT(3,1)
SUPERINFECTION(3,1)
SUPPRESSED IMMUNE RESPONSE(3,1)
SYNTHETIC PROTEIN(3,1)
SYNTHETIC SOLVENT(3,1)
TERM EPITOPE(3,1)
TESTED GENE(3,1)
TRANSLATION START CODON(3,1)
TRANSLATION STOP CODON(3,1)
TRIMESTER(3,1)
UNIQUE GENE(3,1)
VEGETABLE OIL EMULSION(3,1)
VIROLOGY(3,1)
BVDV(2,3)
MOLECULAR PROBE(2,3)
SDS PAGE(2,3)
SINGLE GENE(2,3)
SORBITOL(2,3)
TERMINUS(2,3)
ACTIVE GENE(2,1)
ACTIVE PROTEIN(2,1)
ACTIVE SUBSTANCE(2,1)
ADJUVANT COMBINATION(2,1)
AGALACTIA(2,1)
ALGINATE(2,1)
ALHYDROGEL(2,1)
ALUMINUM HYDROXIDE(2,1)
AMINOACID MUTATION(2,1)
AMPOULE(2,1)
AMYLOSE(2,1)
ANTIGEN PRESENTATION(2,1)
ANTIOXIDANT(2,1)
ANTISENSE(2,1)
BAYOLF(2,1)
BIO(2,1)
BIOPOLYMER(2,1)
BOVINE CORONAVIRUS(2,1)
BOVINE VIRAL DIARRHEA(2,1)
(WO201039934)
IMMUNOGEN(100,94)
PROTEIN(100,53)
IMMUNOLOGICAL RESPONSE(100,26)
HOST(100,25)
CO ADMINISTRATION(100,4)
A GENE ENCODING(100,3)
INFECTED UNGULATE(100,3)
UNGULATE HOST(100,3)
BOVINE HERPES VIRUS(100,2)
IMMUNE SYSTEM SUPPRESSION(100,2)
COMBINATION COCKTAIL ADMINISTRATION(100,1)
GENE ENCODING PROTEIN(100,1)
INFECTED HOST IMMUNE(100,1)
VACCINE MANUFACTURE(100,1)
CATTLE HERPES VIRUS DISEASE(78,1)
CHEMOKINE EXPRESSION(76,5)
LR ORF(61,22)
LATENCY REACTIVATION(58,5)
LATENT INFECTION DEVELOPMENT(56,4)
VIR(...)";Pharmaceuticals;Open
"2008-09-17
2009-09-16";"WO2010031783        A1 2010-03-25 [WO201031783]
STG: (A1) Published application with search report
AP : 2009WO-EP61989 2009-09-16
AU2009294654        A1 2010-03-25 [AU2009294654]
STG: (A1) Open to public inspection
AP : 2009AU-0294654 2009-09-16
AR073594            A1 2010-11-17 [AR--73594]
STG: (A1) Independent patent application
AP : 2009AR-0103544 2009-09-16
MX2011002870        A  2011-04-26 [MX2011002870]
STG: (A) Patent application
AP : 2011MX-PA02870 2009-09-16
EP2324112           A1 2011-05-25 [EP2324112]
STG: (A1) Application published with search report
AP : 2009EP-0783067 2009-09-16
CN102159705         A  2011-08-17 [CN102159705]
STG: (A) Published application
AP : 2009CN-80136090 2009-09-16
US20110229520       A1 2011-09-22 [US20110229520]
STG: (A1) Application published
AP : 2009US-13119458 2009-09-16
ZA201101666         B  2011-11-30 [ZA201101666]
STG: (B)
AP : 2011ZA-0001666 2011-03-03
JP2012502641        A  2012-02-02 [JP2012502641]
STG: (A) Published application
AP : 2011JP-0527309 2009-09-16
EP2324112           B1 2012-05-30 [EP2324112]
STG: (B1) Patent specification
AP : 2009EP-0783067 2009-09-16
ES2387637           T3 2012-09-27 [ES2387637]
STG: (T3) Translation of granted European patent (former B3)
AP : 2009ES-0783067T 2009-09-16
RU2011114984        A  2012-10-27 [RU2011114984]
STG: (A) Application for invention
AP : 2011RU-0114984 2009-09-16
CN102159705         B  2013-02-13 [CN102159705B]
STG: (B) Granted patent for invention
AP : 2009CN-80136090 2009-09-16
RU2483106           C2 2013-05-27 [RU2483106]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2011RU-0114984 2009-09-16
BRPI0919168         A2 2015-12-08 [BR200919168]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2009BR-0019168 2009-09-16";61901092;"WO2010031783        A1 2010-03-25 [WO201031783]
AU2009294654        A1 2010-03-25 [AU2009294654]
AR073594            A1 2010-11-17 [AR--73594]
MX2011002870        A  2011-04-26 [MX2011002870]
EP2324112           A1 2011-05-25 [EP2324112]
CN102159705         A  2011-08-17 [CN102159705]
US20110229520       A1 2011-09-22 [US20110229520]
ZA201101666         B  2011-11-30 [ZA201101666]
JP2012502641        A  2012-02-02 [JP2012502641]
EP2324112           B1 2012-05-30 [EP2324112]
ES2387637           T3 2012-09-27 [ES2387637]
RU2011114984        A  2012-10-27 [RU2011114984]
CN102159705         B  2013-02-13 [CN102159705B]
RU2483106           C2 2013-05-27 [RU2483106]
BRPI0919168         A2 2015-12-08 [BR200919168]";"2008EP-0164496
2009EP-0783067
2009WO-EP61989";"(EP2324112)
WO2010031783
(US20110229520)
WO2010031783
(JP2012502641)
WO2010031783
(RU2483106)
WO2010031783
(AU2009294654)
WO2010031783
(MX2011002870)
WO2010031783
(ZA201101666)
WO2010031783
(ES2387637)
WO2010031783
(CN102159705B)
WO2010031783
(BR200919168)
WO2010031783";"INTERVET INTERNATIONAL
INTEVET INT
JUSTUS LIEBIG UNIVERSITAT GIESSEN
MEDTRONIC INTERVET";"JUSTUS LIEBIG UNIVERSITAT GIESSEN
INTERVET INTERNATIONAL";"(EP2324112)
NL
(EP2324112)
NL
(WO201031783)
NL


";"(EP2324112)
NAME=Intervet International B.V. Wim de Körverstraat 31 , CITY=5831 AN Boxmeer , COUNTRY=NL 

(EP2324112)
NAME=Intervet International B.V. Wim de Körverstraat 31 , CITY=5831 AN Boxmeer , COUNTRY=NL , REG=100823718 

(WO201031783)
NAME=INTERVET INTERNATIONAL B.V.  Wim de Körverstraat 35, NL-5831 AN Boxmeer  , COUNTRY=NL 

(JP2012502641)
NAME=INTERVET INTERNATL BV , REG=506196247 

(ZA201101666)
NAME=INTEVET INTERNATIONAL B.V Wim de Korverstraat 35~NL-5831~AN Boxmeer  NL 

(BR200919168)
NAME=INTERVET INTERNATIONAL B.V. P.O. BOX 31,WIN DE KÖRVERSTRAAT 35, NL-5830 AN BOXMEER  NL 
";2;"THIEL HEINZ-JURGEN
RUEMENAPF HANS TILLMANN
HEIMANN MANUELA";"(EP2324112)
DE
(EP2324112)
DE";"(EP2324112)
NAME=THIEL, Heinz-Jurgen Justus-Liebig-Universitat Giessen Frankfurter Str. 107 35392 Giessen , COUNTRY=DE 

NAME=RUEMENAPF, Hans Tillmann Justus-Liebig-Universitat Giessen Frankfurter Str. 107 35392 Giessen , COUNTRY=DE 

NAME=HEIMANN, Manuela Justus-Liebig-Universitat Giessen Frankfurter Str. 107 35392 Giessen , COUNTRY=DE 

(EP2324112)
NAME=THIEL, Heinz-Jurgen Justus-Liebig-Universitat Giessen Frankfurter Str. 107 35392 Giessen , COUNTRY=DE 

NAME=RUEMENAPF, Hans Tillmann Justus-Liebig-Universitat Giessen Frankfurter Str. 107 35392 Giessen , COUNTRY=DE 

NAME=HEIMANN, Manuela Justus-Liebig-Universitat Giessen Frankfurter Str. 107 35392 Giessen , COUNTRY=DE 
";"(EP2324112)
Mutant pestivirus with mutations in core gene and ns3 region";"(EP2324112)
The present invention relates to mutant Pestiviruses, and vaccines containing said viruses.";"(WO201031783)
CLAIMS
1. Mutant Pestivirus, characterised in that the virus has a mutation in the gene encoding the Core protein, resulting in the virus being unable to express a functional Core protein, the virus further being characterised in that it contains one or more mutations in the C-terminal domain of the helicase domain of NS3.
2. Mutant Pestivirus according to claim 1, characterised in that the Pestivirus is Classical Swine Fever Virus (CSFV).
3. Mutant CSFV according to claim 2, characterised in that the mutation in the C-terminal domain of the helicase domain of NS3 is selected from the group consisting of As^mTyr, Glu2i6oGly, Prθ2i8sThr/Ala, Gln2i89Lys, Prθ22ooThr and Asn2256Asp.
4. Mutant CSFV according to claim 2 or 3, characterised in that the mutation in the C-terminal domain of the helicase domain of NS3 comprises the As^mTyr mutation.
5. Mutant Pestivirus according to claim 1, characterised in that the Pestivirus is Bovine Viral Diarrhea virus (BVDV).
6. Mutant BVDV according to claim 5, characterised in that the mutation in the C-terminal domain of the helicase domain of NS3 is selected from the group consisting of Glu2i89Lys, Leu2i9oPro, Thr2i9iAla, Asp2i92Glu, Pro2i94Leu, Tyr2204His, Asn226sTyr, Asn226sAsp.
7. Mutant BVDV according to claim 5 or 6, characterised in that the mutation in the C-terminal domain of the helicase domain of NS3 comprises the ASP2192GIU, Tyr2204His, Asn226sTyr, or Asn2265Asp mutation.
8. A vaccine characterised in that it comprises a mutant Pestivirus according to any of the preceding claims and a pharmaceutically acceptable carrier.";"(EP2324112)
The present invention relates to mutant Pestiviruses, and vaccines containing said viruses.
It was found that the defective CSFV genomes still replicated and could be packaged into viral particles when introduced in SK-6 cells together with helper A187-CAT RNA (Moser et al., J.Virol., 7787-7794, 1999).
The present invention relates to mutant Pestiviruses, and vaccines containing said viruses.
The present invention provides Mutant Pestiviruses that have a deletion in the gene encoding the Core protein, resulting in the virus being unable to express a functional Core protein, wherein the virus is further characterised in that it contains one or more mutations in the C-terminal domain of the helicase domain of NS3 that compensate for the lack of a functional core protein.";"(EP2324112)
Pestiviruses cause economically important diseases in animals worldwide.
BVDV-1 and BVDV-2 both cause acute infections in cattle (diarrhea, fever, hemorrhagic syndrome) as well as (if the infection occurs during pregnancy) abortion, malformation of the fetus and persistent infection of the calves.";"A61K
A61K-039/12
A61K-039/145
A61K-039/187
A61P-031/12
A61P-037/00
C07K
C07K-014/08
C12N
C12N-007/00
C12N-007/01
C12N-015/09";"(EP2324112)
1. Mutant Pestivirus, characterised in that the virus has a mutation in the gene encoding the Core protein, resulting in the virus being unable to express a functional Core protein, the virus further being characterised in that it contains one or more mutations in the C-terminal domain of the helicase domain of NS3 that compensate for the lack of a functional core protein.";"(EP2324112)
MUTATION(100,22)
MUTANT PESTIVIRUS(100,7)
CORE GENE(100,3)
CALF PERSISTENT INFECTION(57,1)
HELICASE DOMAIN(53,14)
FETUS MALFORMATION(48,1)
CORE PROTEIN FUNCTION(39,3)
HEMORRHAGIC SYNDROME(39,1)
VIRUS(28,9)
VIRAL PARTICLE(27,1)
GENE ENCODING(24,4)
ECONOMICALLY IMPORTANT DISEASE(24,1)
PESTIVIRUS(21,8)
CAUSE ACUTE INFECTION(21,1)
ASP MUTATION(19,2)
TYR MUTATION(19,2)
CORE PROTEIN(18,7)
VACCINE(17,5)
ABORTION(17,1)
PREGNANCY(17,1)
HELPER(15,1)
CRANIAL LOBE PNEUMONIA(13,2)
GENOME STILL(13,1)
BOVINE VIRAL DIARRHEA VIRUS(12,31)
ULCERATIVE GASTRITIS(12,4)
DIARRHEA(12,3)
INDEPENDENT MUTATION(12,2)
ANIMAL(11,44)
EUTHANASIA DAY(11,6)
ANTIBODY TITER(11,5)
CLASSICAL SWINE FEVER VIRUS(10,61)
INFECTION(10,15)
CATTLE(10,4)
THYMUS ATROPHY(10,3)
BOVINE TRANSMEMBRANE DOMAIN(10,2)
INFECTIOUS VIRUS PROGENY(10,2)
FEVER(9,4)
VIABLE INFECTIOUS VIRUS PARTICLE(9,2)
CUTIS PETECHIAL BLEEDING(9,1)
PESTIVIRUS DELETION MUTANT(9,1)
GROUP ANIMAL(8,15)
CORE GENE DELETION(8,2)
CRNA ELECTROPORATION(8,2)
MUTANT BVD VIRUS(8,1)
SEVERE CATARRHAL ENTERITIS(8,1)
SEVERE HEMORRHAGIC GASTRITIS(8,1)
CTERMINAL DOMAIN(7,13)
PARENTAL STRAIN(7,3)
NORTHERN BLOT(7,2)
CATTLE TRANSMISSIBLE DISEASE(7,1)
DEFECTIVE PESTIVIRUS GENOME(7,1)
EMS DELETION MUTANT(7,1)
INFECTIOUS VIRUS TITER RESCUE(7,1)
PESTIVIRUS CDNA COPY(7,1)
SEVERE INTESTINAL NEPHRITIS(7,1)
SEVERE NEUROLOGICAL SYMPTOM(7,1)
REMAINED NEGATIVE(6,4)
ALA(6,3)
VIRUS ISOLATION(6,3)
DAY POST INFECTION(6,2)
GENOMIC RNA(6,2)
PATHOLOGICAL SIGN(6,2)
RNA REPLICATION(6,2)
SEVERE LAMENESS(6,2)
SEVERE LEUCOPENIA(6,2)
VIRUS PARTICLE CONCENTRATION(6,2)
BIO RAD GENE PULSER(6,1)
BLOOD DILUTING PIPETTE(6,1)
CATARRHAL PNEUMONIA(6,1)
CATARRHAL PURULENT PNEUMONIA(6,1)
CLINICAL SIGN SEVERITY(6,1)
ENVELOPE PROTEIN GLYCOSYLATION(6,1)
INDIRECT IMMUNE LABELING(6,1)
INFECTIOUS VIRAL PARTICLE(6,1)
PATHOLOGICAL LESION INDICATIVE(6,1)
PESTIVIRUS GENUS(6,1)
PESTIVIRUS VIRION(6,1)
STRESSOR INTERPLAY(6,1)
TRANSLOCATED CELLULAR PROTEIN(6,1)
UNCHARACTERISTIC SYMPTOM(6,1)
POST CHALLENGE(5,3)
INFECTIOUS PARTICLE FORMATION(5,2)
REACHING TITER(5,2)
SKIN LESION(5,2)
VIABLE VIRUS(5,2)
ABSENT CORE COMPENSATION(5,1)
ANTIBODY NEUTRALIZATION(5,1)
ATTENUATED PHENOTYPE(5,1)
CLINICAL SIGN INDICATIVE(5,1)
COMMERCIAL PIG FARM(5,1)
CORE DELETION MUTANT(5,1)
ERYTHROCYTE LYSIS(5,1)
EU DIAGNOSTIC MANUAL(5,1)
EUROPEAN COMMISSION(5,1)
FLAVIVIRIDAE FAMILY(5,1)
INFECTIOUS VIRUS ALLOWED RECOVERY(5,1)
KIDNEY CORTEX(5,1)
NEUTRALIZATION DILUTION(5,1)
NEUTRALIZING ANTIBODY DETECTION(5,1)
PARTLY HEMORRHAGIC LYMPH NODE(5,1)
PERMANENT PORCINE KIDNEY CELL(5,1)
PEROXIDASE LINKED ANTIBODY ASSAY(5,1)
PESTIVIRUS ANTIBODY(5,1)
PESTIVIRUS MARKER VACCINE(5,1)
PESTIVIRUS PROPAGATION(5,1)
PESTIVIRUS REPLICATION(5,1)
POLYPROTEIN PRECURSOR(5,1)
STRONG COMPENSATING MUTANT(5,1)
WEANER PIG(5,1)
XHOI LIGATION(5,1)
NPLA(4,5)
DEVELOPED FEVER(4,2)
SEQUENCE SPANNING(4,2)
STRUCTURAL PROTEIN(4,2)
TYR EXCHANGE(4,2)
ANIMAL POST MORTEM EXAMINATION(4,1)
ANIMAL SERA(4,1)
BGLII FRAGMENT(4,1)
CLINICAL SIGN ABSENCE(4,1)
DIFFUSE DERMATITIS(4,1)
DISABLED CORE PROTEIN(4,1)
EMS PROTEIN N TERMINUS(4,1)
EXTENSIVE HEMORRHAGE(4,1)
FATAL DISEASE(4,1)
GALLBLADDER EDEMA(4,1)
GROUP SENTINEL PIG(4,1)
HCV ANTIGEN(4,1)
IDEXX LABORATORY(4,1)
INFECTIOUS COPY BASIS(4,1)
INFECTIOUS VIRUS PARTICLE FORMATION(4,1)
LETHAL CHALLENGE(4,1)
LIVE VACCINE(4,1)
LIVER CONGESTION(4,1)
MUTANT VIRUS(4,1)
MUTATION INTRODUCTION(4,1)
NCOI FRAGMENT(4,1)
NEUTRALIZATION ASSAY(4,1)
NEUTRALIZING ANTIBODY PRESENCE(4,1)
POST INFECTION REACHING(4,1)
RESCUING VIRUS(4,1)
RNA GENOME(4,1)
SEVERE DIARRHEA(4,1)
SWOLLEN LYMPH NODE(4,1)
VIRAL PROTEASE(4,1)
VIRAL PROTEIN(4,1)
VIRUS CHALLENGE(4,1)
VIRUS MUTANT TRANSMISSION(4,1)
VIRUS STRAIN(4,1)
FFU ML(3,5)
RIE(3,5)
DAY SEVEN(3,3)
PRIMER(3,3)
TRANSFECTION(3,3)
ALFORT P(3,2)
ANOREXIA(3,2)
CUVETTE(3,2)
EDETIC ACID BLOOD(3,2)
EXPERIMENT COURSE(3,2)
PIG REMAINING(3,2)
PLASTIC DISH(3,2)
RESPIRATORY TRACT(3,2)
SUBSTITUTION(3,2)
AD LIBITUM(3,1)
AFFECTED CATTLE(3,1)
AG ELISA(3,1)
ANIMAL FULL PROTECTION(3,1)
ANIMAL SHOWING CLINICAL SYMPTOM(3,1)
ANTIGEN DETECTION(3,1)
AUTHENTIC SEQUENCE(3,1)
BRONCHOPNEUMONIA(3,1)
CDNA CLONE(3,1)
CDNA TRANSCRIPT(3,1)
CLINICAL MANIFESTATION RANGE(3,1)
CLINICAL PATTERN(3,1)
COMMERCIAL SPECIES(3,1)
CONTAINMENT CONDITION(3,1)
CORE ABSENCE(3,1)
CORE CODING SEQUENCE(3,1)
COUNTING CHAMBER(3,1)
COVER CORE PROTEIN(3,1)
EAR(3,1)
ECONOMIC LOSS(3,1)
ENCODING GENE REGION(3,1)
ENDOCARDIUM(3,1)
EXPERIMENT BEGINNING(3,1)
EXPERIMENT BLOOD SAMPLE BEGINNING(3,1)
EXPERIMENT MAIN OBJECTIVE(3,1)
FUNCTIONAL IMPORTANCE(3,1)
GENE SEQUENCE(3,1)
GROWTH CURVE(3,1)
INITIAL SERUM DILUTION(3,1)
INSTITUTE CONTAINMENT UNIT(3,1)
LEUKOCYTE PREPARATION(3,1)
MINIMAL REQUIREMENT(3,1)
NATURAL HOST(3,1)
OVINE BORDER DISEASE VIRUS(3,1)
PEROXIDASE LINKED CONJUGATE(3,1)
PESTIVIRUS ASSEMBLY(3,1)
POLYPROTEIN PROCESSING(3,1)
POSITIVELY CHARGED CORE(3,1)
PYELONEPHIRITIS(3,1)
RNEASY KIT(3,1)
SAMPLE DILUTION(3,1)
SEVERE SYMPTOM(3,1)
SHOW VIRAL ATTENUATION(3,1)
SUB FEBRILE TEMPERATURE(3,1)
TRANSLOCATION SEQUENCE(3,1)
TRIAL BEGINNING(3,1)
VIRAL GENOME REGION(3,1)
VIRTUALLY FULL ATTENUATION(3,1)
VIRUS TRANSMISSION(3,1)
(US20110229520)
MUTATION(100,21)
MUTANT PESTIVIRUS(100,8)
CORE GENE(100,3)
HELICASE DOMAIN(65,17)
CALF PERSISTENT INFECTION(60,1)
FETUS MALFORMATION(50,1)
ASN2177TYR MUTATION(41,3)
HEMORRHAGIC SYNDROME(41,1)
VACCINE(40,14)
ASN2265ASP MUTATION(38,3)
PESTIVIRUS(32,7)
DEFECTIVE CSFV GENOME STILL(29,1)
VIRAL PARTICLE(28,1)
PARENTAL STRAIN(26,3)
ECONOMICALLY IMPORTANT DISEASE(26,1)
EXPERIMENT MAIN OBJECTIVE(26,1)
GENE ENCODING(24,5)
CORE PROTEIN FUNCTION(24,3)
CAUSE ACUTE INFECTION(22,1)
CLASSICAL SWINE FEVER VIRUS(21,11)
CORE SHOW ATTENUATION(21,1)
CORE PROTEIN(19,8)
ASP2192GLU(18,3)
ABORTION(18,1)
PREGNANCY(18,1)
HELPER(15,1)
BOVINE VIRAL DIARRHEA VIRUS(14,8)
CRANIAL LOBE PNEUMONIA(14,2)
BVDV(13,17)
VIRUS(13,7)
ULCERATIVE GASTRITIS(13,4)
ASN2256ASP(13,1)
PRO2200THR(13,1)
ANTIBODY TITER(12,5)
DIARRHEA(12,3)
ANIMAL(11,40)
INFECTION(11,13)
HIGHLY PATHOGENIC CSFV STRAIN(11,4)
BOVINE TRANSMEMBRANE DOMAIN(11,2)
GLU2189LYS(11,2)
INFECTIOUS VIRUS PROGENY(11,2)
CATTLE(10,4)
FEVER(10,4)
THYMUS ATROPHY(10,3)
MUTATION ASN2177TYR INTRODUCTION(10,2)
VIABLE INFECTIOUS VIRUS PARTICLE(10,2)
CUTIS PETECHIAL BLEEDING(10,1)
CTERMINAL DOMAIN(9,16)
GROUP ANIMAL(9,15)
PESTIVIRUS DELETION MUTANT(9,1)
MUTANT CSFV(8,3)
CORE GENE DELETION(8,2)
CRNA ELECTROPORATION(8,2)
PATHOLOGICAL SIGN ANIMAL(8,2)
MUTANT BVD VIRUS(8,1)
SEVERE CATARRHAL ENTERITIS(8,1)
SEVERE HEMORRHAGIC GASTRITIS(8,1)
NORTHERN BLOT(7,2)
BIO RAD GENE PULSER(7,1)
CATARRHAL PURULENT PNEUMONIA(7,1)
CATTLE TRANSMISSIBLE DISEASE(7,1)
CSFV ERNS PROTEIN(7,1)
DEFECTIVE PESTIVIRUS GENOME(7,1)
ENVELOPE PROTEIN GLYCOSYLATION(7,1)
ERNS DELETION MUTANT(7,1)
ERNS PROTEIN TERMINUS(7,1)
EUROPEAN COMMISSION DIAGNOSTIC MANUAL(7,1)
INDIRECT IMMUNE LABELING(7,1)
INFECTIOUS CSFV CDNA(7,1)
INFECTIOUS VIRUS TITER RESCUE(7,1)
MUTANT CSF VIRUS(7,1)
PATHOLOGICAL LESION INDICATIVE(7,1)
PESTIVIRUS CDNA COPY(7,1)
SEVERE INTESTINAL NEPHRITIS(7,1)
SEVERE NEUROLOGICAL SYMPTOM(7,1)
TRANSLOCATED CELLULAR PROTEIN(7,1)
CSFV CORE(6,4)
LEKALLAWAVITILLYQPVAA(6,4)
REMAINED NEGATIVE(6,4)
ALA(6,3)
VIRUS ISOLATION(6,3)
ASN2177TYR EXCHANGE(6,2)
CSFV MUTANT(6,2)
GENOMIC RNA(6,2)
RNA REPLICATION(6,2)
SEVERE LAMENESS(6,2)
SEVERE LEUCOPENIA(6,2)
VIRUS PARTICLE CONCENTRATION(6,2)
BLOOD DILUTING PIPETTE(6,1)
BVDV ANTIBODY DETECTION(6,1)
BVDV CDNA CODING SEQUENCE(6,1)
BVDV INFECTION CLINICAL PATTERN(6,1)
BVDV PESTIVIRUS ANTIBODY(6,1)
CATARRHAL PNEUMONIA(6,1)
CLINICAL SIGN SEVERITY(6,1)
CSFV ANTIBODY DETECTION(6,1)
INFECTIOUS VIRAL PARTICLE(6,1)
OVINE BORDER DISEASE VIRUS(6,1)
PESTIVIRUS GENUS(6,1)
PESTIVIRUS VIRION(6,1)
STRESSOR INTERPLAY(6,1)
UNCHARACTERISTIC SYMPTOM(6,1)
NPLA(5,7)
MDBK CELL(5,3)
POST CHALLENGE(5,3)
INDEPENDENT MUTATION(5,2)
INFECTIOUS PARTICLE FORMATION(5,2)
REACHING TITER(5,2)
SKIN LESION(5,2)
VIABLE VIRUS(5,2)
ABSENT CORE COMPENSATION(5,1)
ANTIBODY NEUTRALIZATION(5,1)
ATTENUATED PHENOTYPE(5,1)
CLASSICAL BVDV(5,1)
CLINICAL SIGN INDICATIVE(5,1)
COMMERCIAL PIG FARM(5,1)
CORE DELETION MUTANT(5,1)
CORE PROTEIN TERMINUS(5,1)
CSFV INFECTION(5,1)
ERYTHROCYTE LYSIS(5,1)
EU DIAGNOSTIC MANUAL(5,1)
FLAVIVIRIDAE FAMILY(5,1)
HERDCHEK CSFV(5,1)
HIGHLY VIRULENT CSFV(5,1)
INFECTIOUS VIRUS ALLOWED RECOVERY(5,1)
KIDNEY CORTEX(5,1)
LABOFUGE 400R(5,1)
MONOCLONAL ANTIBODY BVD(5,1)
MUTANT BVDV(5,1)
NEUTRALIZATION DILUTION(5,1)
NEUTRALIZING ANTIBODY DETECTION(5,1)
PARENTAL CSFV(5,1)
PARTLY HEMORRHAGIC LYMPH NODE(5,1)
PERMANENT PORCINE KIDNEY CELL(5,1)
PEROXIDASE LINKED ANTIBODY ASSAY(5,1)
PESTIVIRUS MARKER VACCINE(5,1)
PESTIVIRUS PROPAGATION(5,1)
PESTIVIRUS REPLICATION(5,1)
POLYPROTEIN PRECURSOR(5,1)
STRONG COMPENSATING MUTANT(5,1)
WEANER PIG(5,1)
XHOI LIGATION(5,1)
TRANSFECTION(4,3)
EDTA BLOOD(4,2)
SEQUENCE SPANNING(4,2)
STRUCTURAL PROTEIN(4,2)
ACUTE LETHAL CSF(4,1)
ANIMAL POST MORTEM EXAMINATION(4,1)
ANIMAL SERA(4,1)
BGLII FRAGMENT(4,1)
BVDV GENOME(4,1)
BVDV VIRUS(4,1)
CLINICAL SIGN ABSENCE(4,1)
CSF INFECTION(4,1)
DAY POST INFECTION(4,1)
DIFFUSE DERMATITIS(4,1)
DISABLED CORE PROTEIN(4,1)
EXTENSIVE HEMORRHAGE(4,1)
FATAL DISEASE(4,1)
GALLBLADDER EDEMA(4,1)
GROUP SENTINEL PIG(4,1)
IDEXX LABORATORY(4,1)
INFECTIOUS COPY BASIS(4,1)
INFECTIOUS VIRUS PARTICLE FORMATION(4,1)
LETHAL CHALLENGE(4,1)
LIVE VACCINE(4,1)
LIVER CONGESTION(4,1)
MUTANT VIRUS(4,1)
MUTATION INTRODUCTION(4,1)
NCOI FRAGMENT(4,1)
NEUTRALIZATION ASSAY(4,1)
NEUTRALIZING ANTIBODY PRESENCE(4,1)
POST INFECTION REACHING(4,1)
PRIMER BVT(4,1)
RESCUING VIRUS(4,1)
RNA GENOME(4,1)
SEVERE DIARRHEA(4,1)
SWOLLEN LYMPH NODE(4,1)
VIRAL PROTEASE(4,1)
VIRAL PROTEIN(4,1)
VIROLOGY ANIMAL(4,1)
VIRUS CHALLENGE(4,1)
VIRUS MUTANT TRANSMISSION(4,1)
VIRUS STRAIN(4,1)
RIE(3,5)
ORF(3,3)
ANOREXIA(3,2)
CPLWVTSC(3,2)
CUVETTE(3,2)
EXPERIMENT COURSE(3,2)
PIG REMAINING(3,2)
PLASTIC DISH(3,2)
RESPIRATORY TRACT(3,2)
AD LIBITUM(3,1)
AFFECTED CATTLE(3,1)
AG ELISA(3,1)
ANIMAL FULL PROTECTION(3,1)
ANIMAL SHOWING CLINICAL SYMPTOM(3,1)
ANTIGEN DETECTION(3,1)
AUTHENTIC SEQUENCE(3,1)
BRONCHOPNEUMONIA(3,1)
CDNA SYNTHESIS(3,1)
CDNA TRANSCRIPT(3,1)
CLINICAL MANIFESTATION RANGE(3,1)
COMMERCIAL SPECIES(3,1)
CONTAINMENT CONDITION(3,1)
CORE ABSENCE(3,1)
CORE CODING SEQUENCE(3,1)
COUNTING CHAMBER(3,1)
COVER CORE PROTEIN(3,1)
CSFV ALFORT P(3,1)
DEVELOPED FEVER ANIMAL(3,1)
EAR(3,1)
ECONOMIC LOSS(3,1)
ENCODING GENE REGION(3,1)
ENDOCARDIUM(3,1)
EXPERIMENT BEGINNING(3,1)
EXPERIMENT BLOOD SAMPLE BEGINNING(3,1)
FUNCTIONAL IMPORTANCE(3,1)
GENE SEQUENCE(3,1)
GROWTH CURVE(3,1)
INITIAL SERUM DILUTION(3,1)
INSTITUTE CONTAINMENT UNIT(3,1)
LEUKOCYTE PREPARATION(3,1)
MINIMAL REQUIREMENT(3,1)
NATURAL HOST(3,1)
PEROXIDASE LINKED CONJUGATE(3,1)
PIG EUTHANASIA(3,1)
POLYPROTEIN PROCESSING(3,1)
POSITIVELY CHARGED CORE(3,1)
RNEASY KIT(3,1)
SEVERE SYMPTOM(3,1)
SUBSTITUTION INTRODUCTION(3,1)
TRANSLOCATION SEQUENCE(3,1)
TRIAL BEGINNING(3,1)
UNRELATED GLYCOPROTEIN SIGNAL SEQUENCE(3,1)
VIRAL GENOME REGION(3,1)
VIRTUALLY FULL ATTENUATION(3,1)
(WO201031783)
MUTANT PESTIVIRUS(100,8)
HELICASE DOMAIN(75,15)
CALF PERSISTENT INFECTION(70,1)
FETUS MALFORMATION(59,1)
HEMORRHAGIC SYNDROME(49,1)
CORE PROTEIN FUNCTION(44,3)
GENE ENCODING(43,5)
VIRUS(41,11)
MUTATION(40,23)
MUTANT BVDV(39,3)
VIRAL PARTICLE(33,1)
MTYR MUTATION(32,1)
CORE PROTEIN(30,9)
ECONOMICALLY IMPORTANT DISEASE(30,1)
PESTIVIRUS(26,7)
CAUSE ACUTE INFECTION(25,1)
ASP MUTATION(23,2)
ABORTION(21,1)
PREGNANCY(21,1)
VACCINE(19,5)
HELPER(18,1)
CRANIAL LOBE PNEUMONIA(17,2)
STYR(17,2)
DELETION(16,2)
GENOME STILL(16,1)
INFECTION(15,42)
ULCERATIVE GASTRITIS(15,4)
ANIMAL(14,48)
ANTIBODY TITER(14,5)
DIARRHEA(14,3)
EUTHANASIA DAY(13,6)
INFECTIOUS VIRUS PROGENY(13,2)
PESTIVIRUS EL DELETION MUTANT(13,1)
CATTLE(12,4)
CLASSICAL SWINE FEVER VIRUS(12,4)
FEVER(12,4)
THYMUS ATROPHY(12,3)
CUTIS PETECHIAL BLEEDING(12,1)
OOTHR(12,1)
SASP(12,1)
STHR ALA(12,1)
CTERMINAL DOMAIN(11,14)
BOVINE VIRAL DIARRHEA VIRUS(11,5)
VIABLE INFECTIOUS VIRUS PARTICLE(11,2)
REGULAR TYPE L BVDV VIRUS(11,1)
GROUP ANIMAL(10,15)
BVDV(10,9)
VIRUS ISOLATION(10,5)
PEROXIDASE LINKED ANTIBODY ASSAY(10,3)
CORE GENE DELETION(10,2)
CRNA ELECTROPORATION(10,2)
MUTANT BVD VIRUS(10,1)
SEVERE CATARRHAL ENTERITIS(10,1)
SEVERE HEMORRHAGIC GASTRITIS(10,1)
XHOIZNCOI FRAGMENT LIGATION(10,1)
RNA(9,4)
IALA(9,2)
NORTHERN BLOT(9,2)
OGLY(9,2)
B VD(9,1)
BOVINE TRANSMEMBRANE DOMAIN(9,1)
CATTLE TRANSMISSIBLE DISEASE(9,1)
DEFECTIVE PESTIVIRUS GENOME(9,1)
ERNS DELETION MUTANT(9,1)
INFECTIOUS VIRUS TITER RESCUE(9,1)
PESTIVIRUS CDNA COPY(9,1)
SEVERE INTESTINAL NEPHRITIS(9,1)
SEVERE NEUROLOGICAL SYMPTOM(9,1)
CATARRHAL PURULENT PNEUMONIA(8,1)
ENVELOPE PROTEIN GLYCOSYLATION(8,1)
INDIRECT IMMUNE LABELING(8,1)
INFECTION SIX WEANER PIG(8,1)
PATHOLOGICAL LESION INDICATIVE(8,1)
TRANSLOCATED CELLULAR PROTEIN(8,1)
REMAINED NEGATIVE(7,4)
GENOMIC RNA(7,2)
PARENTAL STRAIN(7,2)
PATHOLOGICAL SIGN(7,2)
RNA REPLICATION(7,2)
SEVERE LAMENESS(7,2)
SEVERE LEUCOPENIA(7,2)
VIRUS PARTICLE CONCENTRATION(7,2)
BLOOD DILUTING PIPETTE(7,1)
BVDV ANTIBODY DETECTION(7,1)
BVDV CDNA CODING SEQUENCE(7,1)
BVDV INFECTION CLINICAL PATTERN(7,1)
BVDV PESTIVIRUS ANTIBODY(7,1)
CATARRHAL PNEUMONIA(7,1)
CLINICAL SIGN SEVERITY(7,1)
INFECTIOUS VIRAL PARTICLE(7,1)
PESTIVIRUS GENUS(7,1)
PESTIVIRUS VIRION(7,1)
STRESSOR INTERPLAY(7,1)
UNCHARACTERISTIC SYMPTOM(7,1)
POST CHALLENGE(6,3)
INDEPENDENT MUTATION(6,2)
INFECTIOUS PARTICLE FORMATION(6,2)
REACHING TITER(6,2)
SKIN LESION(6,2)
VIABLE VIRUS(6,2)
ABSENT CORE COMPENSATION(6,1)
ANTIBODY NEUTRALIZATION(6,1)
ATTENUATED PHENOTYPE(6,1)
CLASSICAL BVDV(6,1)
CLINICAL SIGN INDICATIVE(6,1)
COMMERCIAL PIG FARM(6,1)
CORE DELETION MUTANT(6,1)
ERYTHROCYTE LYSIS(6,1)
EU DIAGNOSTIC MANUAL(6,1)
EUROPEAN COMMISSION(6,1)
FLAVIVIRIDAE FAMILY(6,1)
GENEBANK ACCESSION(6,1)
INFECTIOUS VIRUS ALLOWED RECOVERY(6,1)
KIDNEY CORTEX(6,1)
NEUTRALIZATION DILUTION(6,1)
NEUTRALIZING ANTIBODY DETECTION(6,1)
PARTLY HEMORRHAGIC LYMPH NODE(6,1)
PERMANENT PORCINE KIDNEY CELL(6,1)
PESTIVIRUS MARKER VACCINE(6,1)
PESTIVIRUS PROPAGATION(6,1)
PESTIVIRUS REPLICATION(6,1)
POLYPROTEIN PRECURSOR(6,1)
STRONG COMPENSATING MUTANT(6,1)
SUBSTITUTION PRO INTRODUCTION(6,1)
XHOIZBGLII FRAGMENT(6,1)
NPLA(5,6)
CORE CODING SEQUENCE(5,2)
DEVELOPED FEVER(5,2)
STRUCTURAL PROTEIN(5,2)
TYR EXCHANGE(5,2)
ANIMAL SERA(5,1)
BVDV GENOME(5,1)
CLINICAL SIGN ABSENCE(5,1)
DIFFUSE DERMATITIS(5,1)
DISABLED CORE PROTEIN(5,1)
EDETIC ACID ANTICOAGULATED BLOOD(5,1)
ERNS PROTEIN N TERMINUS(5,1)
EXTENSIVE HEMORRHAGE(5,1)
FATAL DISEASE(5,1)
GALLBLADDER EDEMA(5,1)
GROUP SENTINEL PIG(5,1)
IDEXX LABORATORY(5,1)
INFECTIOUS COPY BASIS(5,1)
INFECTIOUS VIRUS PARTICLE FORMATION(5,1)
LETHAL CHALLENGE(5,1)
LIVE VACCINE(5,1)
LIVER CONGESTION(5,1)
MUTANT VIRUS(5,1)
MUTATION INTRODUCTION(5,1)
NEUTRALIZATION ASSAY(5,1)
NEUTRALIZING ANTIBODY PRESENCE(5,1)
PI TRANSCRIPT(5,1)
POST INFECTION REACHING(5,1)
RESCUING VIRUS(5,1)
RNA GENOME(5,1)
RNEASY KIT(5,1)
SEVERE DIARRHEA(5,1)
SWOLLEN LYMPH NODE(5,1)
TYR MUTATION(5,1)
VIRAL PROTEASE(5,1)
VIRAL PROTEIN(5,1)
VIRUS CHALLENGE(5,1)
VIRUS MUTANT TRANSMISSION(5,1)
VIRUS STRAIN(5,1)
ENZYME LINKED IMMUNO SORBENT ASSAY(4,5)
RIE(4,5)
DAY SEVEN(4,3)
PRIMER(4,3)
TRANSFECTION(4,3)
BORDER DISEASE VIRUS(4,2)
AB ELISA(4,1)
AD LIBITUM(4,1)
AFFECTED CATTLE(4,1)
AG ELISA(4,1)
AUTHENTIC SEQUENCE(4,1)
CDNA SYNTHESIS(4,1)
CDNA TRANSCRIPT(4,1)
COVER CORE PROTEIN(4,1)
EAR(4,1)
EXPERIMENT BEGINNING(4,1)
HOST CELLULAR SEQUENCE(4,1)
INITIAL SERUM DILUTION(4,1)
INSTITUTE CONTAINMENT UNIT(4,1)
LABORATORY EXAMINATION(4,1)
LEUKOCYTE PREPARATION(4,1)
PEROXIDASE LINKED CONJUGATE(4,1)
POLYPROTEIN PROCESSING(4,1)
POSITIVELY CHARGED CORE(4,1)
SEVERE SYMPTOM(4,1)
TRANSLOCATION SEQUENCE(4,1)
TRIAL BEGINNING(4,1)
UNRELATED GLYCOPROTEIN SIGNAL SEQUENCE(4,1)
VIRAL GENOME REGION(4,1)
VIRTUALLY FULL ATTENUATION(4,1)
ANOREXIA(3,2)
CUVETTE(3,2)
EDETIC ACID BLOOD(3,2)
EXPERIMENT COURSE(3,2)
ORF(3,2)
PATHOLOGY(3,2)
PIG REMAINING(3,2)
PLASTIC DISH(3,2)
RESPIRATORY TRACT(3,2)
ANIMAL FULL PROTECTION(3,1)
ANIMAL POST MORTEM EXAMINATION(3,1)
ANIMAL SHOWING CLINICAL SYMPTOM(3,1)
ANTIGEN DETECTION(3,1)
BRONCHOPNEUMONIA(3,1)
CLINICAL MANIFESTATION RANGE(3,1)
COMMERCIAL SPECIES(3,1)
CONTAINMENT CONDITION(3,1)
CORE ABSENCE(3,1)
COUNTING CHAMBER(3,1)
ECONOMIC LOSS(3,1)
ENCODING GENE REGION(3,1)
ENDOCARDIUM(3,1)
EXPERIMENT BLOOD SAMPLE BEGINNING(3,1)
EXPERIMENT MAIN OBJECTIVE(3,1)
FUNCTIONAL IMPORTANCE(3,1)
GENE SEQUENCE(3,1)
GROWTH CURVE(3,1)
MINIMAL REQUIREMENT(3,1)
NATURAL HOST(3,1)
PESTIVIRUS ASSEMBLY(3,1)
PYELONEPHIRITIS(3,1)
RNA PREPARATION(3,1)
SAMPLE DILUTION(3,1)
SEQUENCE SPANNING(3,1)
SHOW VIRAL ATTENUATION(3,1)
(JP2012502641)
MUTATION(100,19)
VIRUS(100,11)
MUTANT(100,8)
A GENE ENCODING(100,4)
HELICASE DOMAIN MUTATION(100,4)
PESTIVIRUS MUTATION(100,4)
PROTEIN(100,4)
CORE GENE(100,3)
LCP PESTIVIRUS(100,2)
PESTIVIRUS MUTATION REGION(100,1)
VAR CLOUATRE MELEE(100,1)
VIRAL CORE PROTEIN EXPRESSION(100,1)
PESTIVIRUS TRANS COMPLEMENTATION(71,1)
MUTATION PESTI(64,1)
SEQUENCE ENCODING BVDV GENOME(57,1)
PESTIVIRUS GENUS(53,1)
WORLD PESTIVIRUS(50,1)
DELETION MUTANT(45,1)
TERMINAL DOMAIN(41,4)
MUTANT CSFV(36,2)
CARRIER PESTIVIRUS(34,1)
ECONOMICALLY IMPORTANT DISEASE(32,1)
PESTIVIRUS(28,8)
PARENT STRAIN(27,3)
THRAND ASN(26,2)
TYROR ASN(25,2)
AUTONOMOUS REPLICATION(25,1)
VACCINE(22,7)
POST INFECTION ANIMAL(21,10)
GLU TYR(21,2)
LEU TYR(21,2)
ASN TYR(20,3)
ASP ALA(20,2)
GLU PRO(20,2)
LYSPRO(20,2)
GLY PRO(19,2)
HELICASE DOMAIN(18,9)
ATTENUATION(18,2)
CLASSICAL SWINE FEVER VIRUS(17,6)
ANIMAL(16,44)
BOVINE VIRAL DIARRHEA VIRUS(16,7)
EXPERIMENT(15,6)
CLASSICAL SWINE CHOLERA(15,2)
ULCERATIVE GASTRITIS(14,3)
ANTIBODY TITER(13,5)
INFECTIOUS VIRUS PROGENY(13,2)
CATARRHAL SUPPURATIVE PNEUMONIA(13,1)
INFECTIOUS CSFV CDNA DELETION(13,1)
BVDV(12,17)
CSFV(12,10)
VIABLE INFECTIOUS VIRUS PARTICLE(12,2)
PESTIVIRUS CSFV BVDV(12,1)
POST INFECTION UPSTAGING PIG(12,1)
PEROXIDASE CONJUGATED ANTIBODY ASSAY(11,2)
EUTHANASIA DAY(10,3)
CSFV ASN MUTATION(10,1)
DEFICIENT PESTIVIRUS GENOME(10,1)
MUTATION BVD VIRUS(10,1)
SEVERE CATARRHAL ENTERITIS(10,1)
RNA GENOME(9,3)
NEUTRALIZING ANTIBODY DETECTION(9,2)
NORTHERN BLOT(9,2)
REPLICATION CORE GENE(9,2)
ANTIBODY CSFV PIG DETECTION(9,1)
MILD THYMIC ATROPHY(9,1)
MUTANT CSFV SUBSTITUTION(9,1)
MUTATION CSF VIRUS(9,1)
PATHOGENIC CSFV STRAIN(9,1)
PESTIVIRUS VIRION STRUCTURAL PROTEIN(9,1)
PROTEIN ERNS MUTANT CSFV(9,1)
SEVERE HEMORRHAGIC GASTRITIS(9,1)
SEVERE THYMIC ATROPHY(9,1)
ANIMAL REMAINED NEGATIVE(8,3)
SEVERE DIARRHEA(8,2)
ANTIGEN ELISAVIRUS ISOLATION(8,1)
ATTENUATED VIRUS MUTANT(8,1)
BIO RAD GENE PULSER(8,1)
BOVINE TRANSMEMBRANE DOMAIN(8,1)
CELLULAR PROTEIN TRANSLOCATION(8,1)
FLAVIVIRIDAE PESTIVIRUS(8,1)
GENE ENCODING DELETION(8,1)
PEROXIDASE CONJUGATED ANTIBODY NEUTRALIZATION(8,1)
UPSTAGING PIG ANIMAL(8,1)
VIABLE VIRUS TITER(8,1)
VIRAL PROTEIN ORF(8,1)
WORLD ECONOMIC VIABILITY(8,1)
ACUTE LETHAL CSF(7,1)
BLOOD ANTICOAGULANT EDTA(7,1)
BLOOD DILUTION PIPETTE(7,1)
BVDV ERNS TRANSLOCATION SIGNAL(7,1)
BVDV INFECTION CLINICAL PATTERN(7,1)
CATARRHAL PNEUMONIA(7,1)
CLINICAL SIGN SEVERITY(7,1)
CORE CSFV ASN(7,1)
ELECTROPORATION CRNA(7,1)
ELECTROPORATION TYRCRNA(7,1)
EROSIVE DERMATITIS(7,1)
FETAL BOVINE SERUM(7,1)
GAP ELECTROPORATION CUVETTE(7,1)
INFECTIOUS COPY VIRUS(7,1)
INFECTIOUS VIRUS RECOVERY(7,1)
LYMPH NODE MILD SWELLING(7,1)
MONOCLONAL ANTIBODY PESTIVIRUS(7,1)
PERMANENT PIG KIDNEY(7,1)
PESTIVIRUS REPLICATION(7,1)
SEVERE WALKING DIFFICULTY ANIMAL(7,1)
STRONG COMPENSATORY MUTANT(7,1)
UNACCEPTABLE ANIMAL TEXAS(7,1)
VIRUS ISOLATIONSEPARATION(7,1)
BORDER DISEASE VIRUS(6,2)
INDEPENDENT MUTATION(6,2)
INFECTIOUS PARTICLE FORMATION(6,2)
VIRAL PARTICLE CONCENTRATION(6,2)
ANTERIOR LOBE PNEUMONIA(6,1)
ANTIBODY CSFV DETECTION(6,1)
ANTIBODY DETECTIONAFTER(6,1)
ATTENUATED PHENOTYPE(6,1)
BVDV COMPENSATION(6,1)
CDNA TRANSCRIPT(6,1)
CLASSICAL BVDV(6,1)
COMMISSION DECISION(6,1)
CORE DELETION MUTANT(6,1)
ENZYME LINKED IMMUNO SORBENT ANTIBODY(6,1)
EU DIAGNOSTIC MANUAL(6,1)
FETAL MALFORMATION(6,1)
FRAGMENT LIGATION(6,1)
GALLBLADDER HEMORRHAGE(6,1)
HEMORRHAGIC SYNDROME(6,1)
HERDCHEK CSFV(6,1)
HIGHLY VIRULENT CSFV(6,1)
LABOFUGE 400R(6,1)
MILD PNEUMONIA(6,1)
NEUTRALIZING INFECTION(6,1)
PATHOLOGICAL LESION(6,1)
PESTIVIRUS ANTIBODY(6,1)
PESTIVIRUS CDNA(6,1)
PESTIVIRUS RNA(6,1)
POLYPROTEIN PRECURSOR(6,1)
PORCINE UPSTAGING(6,1)
SHEEP PESTIVIRUS(6,1)
VIRAL GENOME ABSENCE(6,1)
WEANING PIG(6,1)
FFU MLREACHE(5,4)
ANIMAL EXPERIMENT(5,3)
EXOTHERM(5,3)
GROUP ANIMAL(5,3)
TRANSFECTION(5,3)
EXPERIMENT START(5,2)
LEKALLAWAVITILLYQPVAA(5,2)
ANIMAL POST MORTEM EXAMINATION(5,1)
ANIMAL SERA(5,1)
BGLII FRAGMENT(5,1)
BOVINE CONTAGIOUS DISEASE(5,1)
BOVINE SUFFERING(5,1)
BVDV CDNA(5,1)
BVDV NADL(5,1)
BVDV NPLA(5,1)
CHALLENGE INFECTION(5,1)
CLINICAL SIGN ABSENCE(5,1)
CLINICAL SYMPTOM VARIETY(5,1)
CORE PROTEIN FUNCTIONALITY(5,1)
CSFV ANTIBODY(5,1)
DISSOLUTION NEUBAUER COUNTING CHAMBER(5,1)
ENZYME LINKED IMMUNOSORBENTAG ELISAGROUP(5,1)
ERNS PROTEIN(5,1)
IDEXX LABORATORY(5,1)
INDIRECT LABELING(5,1)
INFECTIOUS VIRUS PARTICLE FORMATION(5,1)
INNATE INFLAMMATORY BOWEL DISEASE(5,1)
LETHAL CHALLENGE(5,1)
LIVE VACCINE(5,1)
LIVER CONGESTION(5,1)
LYMPH NODE SWELLING(5,1)
MAJORITY DELETION(5,1)
MANUFACTURER INSTRUCTION(5,1)
MILD SYMPTOM(5,1)
MUTANT VIRUS(5,1)
MUTATION ADDITIVE(5,1)
MUTATION INTRODUCTION(5,1)
NEUTRALIZATION ASSAY(5,1)
NEUTRALIZING ANTIBODY PRESENCE(5,1)
PESTIVIRUS GROWTH(5,1)
PORCINE ANIMAL(5,1)
SEQUENCE SPANNING TERMINUS(5,1)
SEVERE NEPHRITIS(5,1)
SEVERE SYMPTOM(5,1)
THOMA EDTA(5,1)
UPSTAGING ANIMAL(5,1)
VIRAL PROTEASE(5,1)
VIRAL REPLICATION(5,1)
VIRUS CHALLENGE(5,1)
VIRUS NEUTRALIZING(5,1)
ANOREXIA(4,2)
EXACT SEQUENCE(4,2)
EXPERIMENT COURSE(4,2)
INTESTINE(4,2)
LEUKOPENIA(4,2)
RESPIRATORY TRACT(4,2)
AB ELISA(4,1)
ACUTE INFECTION(4,1)
ALTERATION LOSS(4,1)
BOVINE AGE(4,1)
CDNA SYNTHESIS(4,1)
CODING SEQUENCE CORE(4,1)
COMMERCIAL SWINE(4,1)
CORE COMPENSATION(4,1)
CSFV ALFORT P(4,1)
EDTA BLOOD(4,1)
ENVELOPE PROTEIN(4,1)
EUTHANIZED MORIBUND STATE(4,1)
EXPERIMENT BEGINNING(4,1)
HEAT CLINICAL SIGN(4,1)
INITIAL SERUM DILUTION(4,1)
INSTITUTIONAL REASON(4,1)
LYMPH NODE PARTIAL SWELLING(4,1)
NATIVE BLOOD(4,1)
PCR PRIMER(4,1)
PERMANENT NPLA(4,1)
POLYPROTEIN PROCESSING(4,1)
POSITIVELY CHARGED CORE(4,1)
PRIMARY FETAL BOVINE(4,1)
PROTEIN EXPRESSION(4,1)
RNEASY KIT(4,1)
SKIN LESION(4,1)
VIABLE CONSTRUCT(4,1)
VIRAL STRAIN(4,1)
CATTLE(3,3)
ANIMAL HEAD(3,1)
ANIMAL SHOWING CLINICAL SYMPTOM(3,1)
ASN2265ASP(3,1)
ASP PRO(3,1)
BODY TEMPERATURESURVIVING(3,1)
BRONCHOPNEUMONIA(3,1)
CORE CODING SEQUENCE(3,1)
CORE FUNCTIONALITY(3,1)
CORE TYR(3,1)
DILUTED SAMPLE(3,1)
DOWNSTREAM PROCESSING STRAIN(3,1)
ECONOMIC LOSS(3,1)
ENCODING AMPLIFICATION PRODUCT(3,1)
FUNCTIONAL IMPORTANCE(3,1)
GROWTH CURVE(3,1)
KIDNEY CELL(3,1)
MODIFIED NCP(3,1)
MUTATION REGION(3,1)
NATURAL HOST(3,1)
NUCLEOCAPSID(3,1)
PHENOTYPIC DIFFERENCE(3,1)
PORCINE CELL(3,1)
POST INFECTION ANIMAL SUSPECT RESULT(3,1)
RENAL CELL(3,1)
RNA PREPARATION(3,1)
SIGNIFICANT TITER(3,1)
STILL DEFICIENT CSFV(3,1)
UNRELATED GLYCOPROTEIN SIGNAL SEQUENCE(3,1)
(CN102159705)
MUTATION(100,21)
VIRUS(100,16)
HELICASE DOMAIN(100,10)
MUTANT PESTIVIRUS(100,8)
A GENE(100,2)
CORE GENE(100,2)
CORE PROTEIN FUNCTION(100,2)
CORE PROTEIN ENCODING(100,1)
PERSISTENT INFECTION CALF(49,1)
INFECTIOUS PARTICLE FORMATION(37,2)
CLINICAL SYMPTOM ABSENCE(37,1)
FETAL MALFORMATION(36,1)
HEMORRHAGE SYNDROME(35,1)
FATAL DISEASE(32,1)
HELICASE DOMAIN MUTATION(29,2)
ASP MUTATION(28,3)
ACUTE INFECTION(28,1)
VACCINE(25,3)
ANIMAL PROTECTION(25,1)
ASN MUTATION(24,1)
ECONOMIC LOSS(23,1)
CORE PROTEIN(20,8)
TYR MUTATION(17,2)
MISCARRIAGE(17,1)
PREGNANCY(15,1)
VIRION(15,1)
INFECTION(13,35)
SWINE FEVER(12,2)
ASN GROUP(12,1)
DIARRHEA(11,3)
GENOME(11,2)
CLASSICAL SWINE FEVER VIRUS(10,58)
FEVER(10,2)
BOVINE VIRAL DIARRHEA VIRUS(9,31)
PIG(9,7)
EUTHANASIA DAY(9,5)
CATTLE(9,4)
PROGENY VIRAL TRANSFECTION(9,2)
B VD(8,1)
CATARRHAL PURULENT PNEUMONIA(8,1)
MUTANT VIRUS HELICASE DOMAIN(8,1)
NIUS TRANSMEMBRANE DOMAIN INTRODUCTION(8,1)
PIPETTE THOMA ASPIRATION(8,1)
SWINE NASAL VITALITY(8,1)
CTERMINAL DOMAIN(7,9)
RNA(7,6)
ANIMAL INFECTION(7,4)
ERNS PROTEIN(7,3)
CATARRHAL ENTERITIS(7,2)
GENOME TYR EXCHANGE(7,2)
BIO RAD GENE PULSER(7,1)
CHALLENGE FEBRILE ILLNESS(7,1)
CHALLENGE INFECTION SIGN(7,1)
JUSTICE VIRAL INSTITUTE(7,1)
MILD ULCERATIVE GASTRITIS(7,1)
NEUROLOGICAL DISEASE SYMPTOM(7,1)
ANTIBODY NEUTRALIZATION(6,2)
INFECTIOUS VIRAL PARTICLE RELEASE(6,2)
NORTHERN BLOT(6,2)
ANTI VIRUS ANTIBODY(6,1)
BOVINE INFECTION MORTALITY(6,1)
CONGENITAL BOWEL DISEASE(6,1)
DISEASE WORLDWIDE ECONOMIC IMPORTANCE(6,1)
ENVELOPE PROTEIN GLYCOSYLATION(6,1)
ENZYME LINKED IMMUNOSORBANT ASSAY(6,1)
ERNS DELETION MUTANT(6,1)
HOG CHOLERA VIRUS(6,1)
IMMORTALIZED PORCINE KIDNEY CELL(6,1)
MILD THYMIC ATROPHY(6,1)
OVERT CLINICAL SYMPTOM(6,1)
PATHOGENIC ATTACK KOSLOV HEIGHT(6,1)
PATHOLOGICAL LESION INDICATION(6,1)
PESTIVIRUS CDNA COPY(6,1)
PESTIVIRUS VIRAL PARTICLE(6,1)
SEVERE HEMORRHAGIC GASTRITIS(6,1)
SEVERE THYMIC ATROPHY(6,1)
STILL REMAINS(6,1)
VIRAL MUTANT DIVERGENCE(6,1)
VIRUS ANTIBODY TITER(6,1)
ALA(5,3)
ANTIBODY DETECTION(5,3)
DAY EUTHANASIA(5,2)
GENE DELETION(5,2)
RNA GENOME(5,2)
SEVERE LEUKOPENIA(5,2)
VIABLE VIRUS(5,2)
VIRAL REPLICATION(5,2)
VIRAL TITER(5,2)
VIRUS PARTICLE CONCENTRATION(5,2)
CATARRHAL PNEUMONIA(5,1)
CLINICAL SIGN SEVERITY(5,1)
FETAL BOVINE KIDNEY CELL(5,1)
FETAL BOVINE SERUM(5,1)
HEPATIC ENGORGEMENT(5,1)
INFECTION PORCINE STAND(5,1)
KIDNEY PETECHIAL HEMORRHAGE(5,1)
OVINE BORDER DISEASE VIRUS(5,1)
PATHOLOGY SYMPTOM(5,1)
PESTIVIRUS TYPING(5,1)
PROTECTION LETHAL CHALLENGE(5,1)
RENAL CORTEX PETECHIAL HEMORRHAGE(5,1)
SERUM DILUTION RECIPROCAL(5,1)
STAND ANTIBODY TITER(5,1)
VIRAL GENOME ENCODING(5,1)
WEANING PIGLET(5,1)
LAME LEG(4,2)
PARENT STRAIN(4,2)
ANIMAL WELLBEING(4,1)
ANTIBODY NPLA(4,1)
ARCHITECT DR(4,1)
ARTICLE VIRUS ISOLATION(4,1)
ATTENUATED MUTANT(4,1)
ATTENUATED PHENOTYPE(4,1)
ATYPICAL SYMPTOM(4,1)
AUTONOMOUS REPLICATION GENE(4,1)
BGLII FRAGMENT(4,1)
BLADDER INFLAMMATION(4,1)
COMMERCIALLY PURCHASED ANTIBODY(4,1)
CORE PROTEIN DELETION(4,1)
CORE PROTEIN FUSION(4,1)
CORE PROTEIN GENE ENCODING(4,1)
CYSTIC EDEMA(4,1)
DEFECT EFFICACY(4,1)
DISPLAY DIFFUSE DERMATITIS(4,1)
DISTEMPER VIRUS GENOME(4,1)
EU COMMISSION(4,1)
EU DIAGNOSTIC MANUAL(4,1)
EXHIBIT SEVERE SYMPTOM(4,1)
EXTENSIVE BLEEDING(4,1)
GENEBANK ACCESSION(4,1)
GENOMIC RNA(4,1)
HCV ANTIGEN(4,1)
HEMORRHAGIC LYMPH NODE(4,1)
INFECTED CATTLE EXHIBIT(4,1)
INFECTED RIE(4,1)
INFECTIOUS VIRAL PARTICLE FORMATION(4,1)
INFECTIOUS VIRUS TITER(4,1)
INFECTIOUSS VIRUS(4,1)
KOSLOV REMAINING PIG(4,1)
LEUKOCYTE DEPLETION(4,1)
LIVE VACCINE(4,1)
LYMPH NODE SLIGHT SWELLING(4,1)
MANUFACTURER INSTRUCTION(4,1)
NCOI FRAGMENT(4,1)
NEUTRALIZING ANTIBODY PRESENCE(4,1)
PATHOLOGICAL SIGN(4,1)
PEROXIDASE LINKED ANTIBODY ASSAY(4,1)
PESTIVIRUS ABSENCE(4,1)
PESTIVIRUS GENOME(4,1)
PIG KIDNEY(4,1)
PIG STAND GUARD(4,1)
PLAGUE VIRUS(4,1)
PNEUMONIA LUNG LOBE(4,1)
PORCINE STAND GUARD(4,1)
RESCUING VIRUS INFECTED CELL(4,1)
RNEASY KIT(4,1)
SEVERE DIARRHEA(4,1)
SEVERE INTERSTITIAL NEPHRITIS(4,1)
SHEEP BORDER DISEASE VIRUS(4,1)
STRONG COMPENSATION MUTANT(4,1)
TERMINAL AMINOACID FUSION(4,1)
THYMUS ATROPHY(4,1)
ULCERATIVE GASTRITIS OUTSIDE(4,1)
VACCINE MUTANT(4,1)
VIRAL PROTEASE(4,1)
VIRUS PROPAGATION(4,1)
FFU ML(3,5)
ALFORT P(3,3)
NUCLEOTIDE(3,3)
PRIMER(3,3)
CORE CODING SEQUENCE(3,2)
COUNTING CHAMBER(3,2)
DETECTION KIT(3,2)
AD LIBITUM(3,1)
CALCULATION EXPLANATION(3,1)
CDNA SYNTHESIS(3,1)
CLINICAL PRESENTATION SPECTRUM(3,1)
CO2 INCUBATOR(3,1)
DISPLAYED SWELLING(3,1)
EDETIC ACID BLOOD LEUKOCYTE(3,1)
ENLARGED EDEMA(3,1)
ENZYME ANTIGEN(3,1)
GENE ENCODING REGION(3,1)
GUARD PIG(3,1)
LUNG LOBE LIGHT PNEUMONIA(3,1)
LYSATE LARGE PRECURSOR POLYPROTEIN(3,1)
MEMBRANE SPANNING DOMAIN(3,1)
PIG PROTECTION(3,1)
POSITIVELY CHARGED CORE(3,1)
POST INFECTION DAY(3,1)
PROTEIN DERIVED TRANSMEMBRANE DOMAIN(3,1)
STRESSOR AFFECT(3,1)
STRUCTURAL PROTEIN GENE SEQUENCE(3,1)
VIRAL PROTEIN VARIETY(3,1)
VIRAL STRAIN(3,1)
WORLD ECONOMY(3,1)
ENZYME LINKED IMMUNO SORBENT ASSAY(2,9)
ANOREXIA(2,2)
EXPERIMENT COURSE(2,2)
LEUCOPENIA(2,2)
ACQUIRED SAMPLE(2,1)
ANIMAL DID(2,1)
ANIMAL SERUM(2,1)
ANTICOAGULANT EDETIC ACID(2,1)
CLEAVAGE SITE(2,1)
COMMUNICABILITY(2,1)
CONTAINMENT CONDITION(2,1)
DILUTION LIQUID(2,1)
ERNS N PRO(2,1)
EXPERIMENT MAIN OBJECTIVE(2,1)
EXPERIMENT START(2,1)
FLAVIVIRIDAE(2,1)
FUNCTION HELICASE DOMAIN(2,1)
FUNCTIONAL IMPORTANCE(2,1)
GROWTH CURVE(2,1)
INDEXING SEQUENCE(2,1)
NATURAL HOST(2,1)
NEUTRALIZATION TEST(2,1)
OBTAINING SERUM(2,1)
PANEL RESOLUTION(2,1)
PRIMARY NPLA(2,1)
PRO SITUATION(2,1)
RAW BLOOD(2,1)
RNA PREPARATION(2,1)
SEQUENCE ENCODING(2,1)
(CN102159705B)
MUTATION(100,19)
VIRUS(100,17)
HELICASE DOMAIN(100,8)
MUTANT PESTIVIRUS(100,8)
CORE PROTEIN FUNCTION(100,4)
A GENE(100,3)
CORE GENE(100,2)
CORE PROTEIN ENCODING(100,1)
MUTATION CTERMINAL DOMAIN(100,1)
VIRUS HELICASE(100,1)
PERSISTENT INFECTION CALF(49,1)
ASP MUTATION(43,3)
INFECTIOUS PARTICLE FORMATION(37,2)
CLINICAL SYMPTOM ABSENCE(37,1)
FETAL MALFORMATION(36,1)
HEMORRHAGE SYNDROME(35,1)
ACUTE INFECTION(28,1)
VACCINE(26,3)
ANIMAL PROTECTION(25,1)(...)";Pharmaceuticals;Open
"2008-06-25
2009-06-24";"WO2009156448        A1 2009-12-30 [WO2009156448]
STG: (A1) Published application with search report
AP : 2009WO-EP57911 2009-06-24
CA2729105           A1 2009-12-30 [CA2729105]
STG: (A1) Application laid open
AP : 2009CA-2729105 2009-06-24
AU2009264206        A1 2009-12-30 [AU2009264206]
STG: (A1) Open to public inspection
AP : 2009AU-0264206 2009-06-24
UY31930             A  2010-01-29 [UY--31930]
STG: (A) Patent application
AP : 2009UY-0031930 2009-06-23
AR072302            A1 2010-08-18 [AR--72302]
STG: (A1) Independent patent application
AP : 2009AR-0102333 2009-06-24
MX2010013437        A  2011-01-14 [MX2010013437]
STG: (A) Patent application
AP : 2010MX-PA13437 2009-06-24
EP2303320           A1 2011-04-06 [EP2303320]
STG: (A1) Application published with search report
AP : 2009EP-0769297 2009-06-24
KR20110036538       A  2011-04-07 [KR20110036538]
STG: (A) Published application
AP : 2010KR-7028302 2009-06-24
US20110117126       A1 2011-05-19 [US20110117126]
STG: (A1) Application published
AP : 2009US-13000962 2009-06-24
CO6280496           A2 2011-05-20 [CO6280496]
STG: (A2) Application derived from a PCT application
AP : 2010CO-0160843 2010-12-22
CN102076356         A  2011-05-25 [CN102076356]
STG: (A) Published application
AP : 2009CN-80124328 2009-06-24
IN9212/DELNP/2010   A  2012-03-02 [IN2010DN09212]
STG: (A) Application laid open
AP : 2010IN-DN09212 2010-12-24
JP2012530681        A  2012-12-06 [JP2012530681]
STG: (A) Published application
AP : 2011JP-0515376 2009-06-24
NZ589723            A  2013-01-25 [NZ-589723]
STG: (A) Published application
AP : 2009NZ-0589723 2009-06-24
CN103721250         A  2014-04-16 [CN103721250]
STG: (A) Published application
AP : 2014CN-0035977 2009-06-24
FD :  Division of: CN200980124328.1 FDD=2009-06-24 [2009CN-80124328]
SG2014010581        A  2014-05-29 [SG2014010581]
STG: (A) Patent Application / PCT entering national phase
AP : 2014SG-0010581 2009-06-24
EP2303320           B1 2014-09-10 [EP2303320]
STG: (B1) Patent specification
AP : 2009EP-0769297 2009-06-24
JP5642672           B2 2014-11-07 [JP5642672]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2011JP-0515376 2009-06-24
US8895026           B2 2014-11-25 [US8895026]
STG: (B2) Granted patent as second publication
AP : 2009US-13000962 2009-06-24
FD :  Previous publication: US20110117126 A1 2011-05-19 [US20110117126]
AU2009264206        B2 2014-12-18 [AU2009264206]
STG: (B2) Patent proceeded by OPI
AP : 2009AU-0264206 2009-06-24
BRPI0914560         A2 2015-12-15 [BR200914560]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2009BR-0014560 2009-06-24";68377;"WO2009156448        A1 2009-12-30 [WO2009156448]
CA2729105           A1 2009-12-30 [CA2729105]
AU2009264206        A1 2009-12-30 [AU2009264206]
UY31930             A  2010-01-29 [UY--31930]
AR072302            A1 2010-08-18 [AR--72302]
MX2010013437        A  2011-01-14 [MX2010013437]
EP2303320           A1 2011-04-06 [EP2303320]
KR20110036538       A  2011-04-07 [KR20110036538]
US20110117126       A1 2011-05-19 [US20110117126]
CO6280496           A2 2011-05-20 [CO6280496]
CN102076356         A  2011-05-25 [CN102076356]
IN9212/DELNP/2010   A  2012-03-02 [IN2010DN09212]
JP2012530681        A  2012-12-06 [JP2012530681]
NZ589723            A  2013-01-25 [NZ-589723]
CN103721250         A  2014-04-16 [CN103721250]
SG2014010581        A  2014-05-29 [SG2014010581]
EP2303320           B1 2014-09-10 [EP2303320]
JP5642672           B2 2014-11-07 [JP5642672]
US8895026           B2 2014-11-25 [US8895026]
AU2009264206        B2 2014-12-18 [AU2009264206]
BRPI0914560         A2 2015-12-15 [BR200914560]";"2008EP-0159009
2009EP-0769297
2009WO-EP57911";"(EP2303320)
WO2009156448
(US8895026)
WO2009156448
(JP5642672)
WO2009156448
(CA2729105)
WO2009156448
(MX2010013437)
WO2009156448
(KR20110036538)
WO2009156448
(CN102076356)
WO2009156448
(NZ-589723)
WO2009156448
(AU2009264206)
WO2009156448
(BR200914560)
WO2009156448";"BOEHRINGER INGELHEIM INTERNATIONAL
BOEHRINGER INGELHEIM PHARMACEUTICALS
BOEHRINGER INGELHEIM VETMEDICA";BOEHRINGER INGELHEIM VETMEDICA;"(EP2303320)
DE
(EP2303320)
DE
(US20110117126)
DE
(US8895026)
DE
(WO2009156448)
DE

(CA2729105)
DE

(IN2010DN09212)
DE

";"(EP2303320)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

(EP2303320)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE , REG=100089553 

(US20110117126)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , CITY=Ingelheim am Rhein , COUNTRY=DE , ATYP=Non-US Company 

(US8895026)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim am Rhein , COUNTRY=DE , ATYP=Non-US Company 

(WO2009156448)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH  Binger Strasse 173, 55216 Ingelheim am Rhein  , COUNTRY=DE 

(JP2012530681)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(JP5642672)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(CA2729105)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Str. 173 55216 , CITY=INGELHEIM AM RHEIN , COUNTRY=DE 

(KR20110036538)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=519980671421 

(IN2010DN09212)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH BINGER STRASSE 173, 55216 INGELHEIM AN RHEIN  , COUNTRY=DE 

(SG2014010581)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH BINGER STRAßE 173 55216 INGELHEIM AM RHEIN DE 

(BR200914560)
NAME=BOEHRINGER INGELHEIM INTERNATIONAL GMBH BINGER STRASSE 173, 55216 INGELHEIM  DE 
";1;"MEYERS GREGOR
TEWS BIRKE ANDREA
SCHUERMANN EVA-MARIA";"(EP2303320)
DE; FR";"(EP2303320)
NAME=MEYERS, Gregor Albstrasse 1 , CITY=72141 Walddorfhaeslach , COUNTRY=DE 

NAME=TEWS, Birke Andrea 13 rue Louis Bergot , CITY=F-59021 Lille , COUNTRY=FR 

NAME=SCHUERMANN, Eva-Maria Nauklerstrasse 58/1 , CITY=72074 Tuebingen , COUNTRY=DE 
";"(EP2303320)
Attenuated pestivirus";"(EP2303320)
The present invention relates to recombinant attenuated pestivurses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric Ems glycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well as to a method of attenuating a pestivirus comprising the step of modifying the Ems glycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric Ems glycoprotein.";"(WO2009156448)
CLAIMS:
1. An immunogenic composition comprising an attenuated pestivirus, wherein said attenuated pestivirus does not produce a dimeric Emsglycoprotein.
2. The immunogenic composition according to claim 1 , wherein the carboxy-terminus of the Emsglycoprotein of said attenuated pestivirus is modified by a deletion, insertion or substitution.
3. The immunogenic composition according to claim 1 or 2, wherein at least the last Cystein-residue of the Emsglyoprotein of said attenuated pestivirus is deleted or substituted by non-Cys amino acid residue.
4. The immunogenic composition according to claim 3, wherein the last Cystein-residue of the Emsglyoprotein of said attenuated pestivirus is deleted.
5. The immunogenic composition according to any one of claims 1 to 4, wherein said attenuated pestivirus is a Bovine viral diarrhea virus (BVDV), Classical swine fever virus (CSFV) or Border disease virus (BDV).
6. The immunogenic composition according claim 5: a. wherein at least the Cystein-residue of the Emsglyoprotein of said attenuated BVDV at amino acid position 441 according to SEQ ID NOs: 4 or 7 is deleted or substituted by a non Cystein-residue; b. wherein the Cystein-residue of the Erasglyoprotein of said attenuated CSFV at amino acid position 438 according to SEQ ID NO: 1 is deleted or substituted by a non Cystein-residue; c. wherein the Cystein-residue of the Emsglyoprotein of said attenuated BDV at amino acid position 439 according to SEQ ID NO: 10 is deleted or substituted by a non Cystein-residue.
7. The immunogenic composition according to any one claims 1 to 6, wherein said attenuated pestivirus further has at least a mutation in the Nproprotein, wherein said mutation in the Nproprotein leads to inactivation of said Nproprotein.
8. The immunogenic composition according to claim 7, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by the following formula:
 [Npro]χ-[PS]y-[C-term] and wherein:
 [Npr0] relates to the Nproportion of said polyprotein, wherein ""x"" represents the number of amino acids of the Npropresent in the polyprotein; and wherein
 [PS] relates to a processing signal selected from the group consisting of: ubiquitin, LC3, SUMO-I, NEDD8, GATE- 16 or GABA(A)RAP), Intein, picornavirus 3C, caridovirus 2A, or pi 5 of rabbit hemorrhagic disease virus; and wherein
 ""Y"" may be = 0, which means that no processing signal is present, or ""Y"" may be = 1, which means that a processing signal is present; and wherein
 [C-term] relates to the complete virus polyprotein except for TSf1^ but including the capsid (C)-protein, modified ERNSprotein and any other protein present in the virus polyprotein including the carboxyterminal NS5B; and wherein if ""y"" is = 0, then ""x"" is 0 to 12, (means no Nprospecific amino acid or 1 to 12 amino acids of Npr0are present); and wherein if ""y"" is = 1, then ""x"" is 0 to 168; (means no Nprospecific amino acid or 1 to all 168 amino acids of Npr0are present).
9. The immunogenic composition according to claim 8, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by the following formula:
 [Npro]4-[PS]o-[C-term]
10. The immunogenic composition according to claim 8, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by the following formula: [Npro]4-[PS]o-[C-term*], and wherein [C-term]* is = [C -term] wherein in the C-protein the amino acid at position 2 is changed from D to N.
11. The immunogenic composition according to claim 8, wherein said attenuated virus is BVDV, and wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by a formula selected from the group consisting of :
 [Npro]χ-[PS]o-MELF-[PS]o-[C-term*];
 and wherein [C-term]* is = [C-term] wherein in the C-protein the amino acid at position 2 is changed from D to N.
12. The immunogenic composition according to claim 8, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by a formula selected from the group consisting of :
 [ Npro]22-[PS]1-[C-term], and wherein PS is ubiquitin or LC3.
13. The immunogenic composition according to claim 12, wherein the [PS]o is replaced by [PS]], and wherein said PS is selected from the group of consisting of: ubiquitin, LC3, SUMO-I, NEDD8, GATE-16, GABA(A)RAP, Intein, picornavirus 3C, caridovirus 2A, aphtovirus 2A and pi 5 of rabbit hemorrhagic disease virus.
14. The immunogenic composition according to any one of claims 1 to 13, wherein said composition further comprises a pharmaceutically acceptable carrier or excipients.
15. The immunogenic composition according to any one of claims 1 or 14, wherein said composition comprises at least two attenuated pestiviruses of the same genus.
16. The immunogenic composition according to claim 15, wherein said attenuated pestiviruses are different isolates or subtypes of the same genus.
17. The immunogenic composition according to claim 15 or 16, wherein said attenuated pestiviruses are modified at same coding regions in such that none of the attenuated viruses can revert to a pathogenic pestivirus by recombination.
18. The immunogenic compositions according to any one of claims 1 to 17, wherein said immunogenic composition is a vaccine for the prophylaxis of a pestivirus infection.
19. An attenuated pestivirus, wherein said attenuated pestivirus does not produce a dimeric Emsglycoprotein and having at least a mutation in the Nproprotein, wherein said mutation in the Nproprotein leads to inactivation of said Nproprotein.
20. The attenuated pestivirus according to claim 19, wherein the carboxy-terminus of the Emsglycoprotein is modified by a deletion, insertion or substitution, and said mutation in the Nprois selected from the group of deletions, insertion mutations and/or substitution mutations.
21. The attenuated pestivirus according to claim 19 or 20, wherein at least the last Cystein-residue in the Erasglyoprotein is deleted or substituted by non-Cys amino acid residue.
22. The attenuated pestivirus according to any one of claims 19 to 21, wherein said attenuated pestivirus is a Bovine viral diarrhea virus (BVDV), Classical swine fever virus (CSFV) or Border disease virus (BDV).
23. The attenuated pestivirus according claim 22: a. wherein at least the Cystein-residue of the Emsglyoprotein of said attenuated BVDV at amino acid position 441 according to SEQ ID NOs: 4 or 7 is deleted or substituted by a non Cystein-residue; b. wherein the Cystein-residue of the Emsglyoprotein of said attenuated CSFV at amino acid position 438 according to SEQ ID NO: 1 is deleted or substituted by a non Cystein-residue; c. wherein the Cystein-residue of the Emsglyoprotein of said attenuated BDV at amino acid position 439 according to SEQ ID NO: 10 is deleted or substituted by a non Cystein-residue.
24. The attenuated virus according to any one of claims 30 to 38, wherein said mutation(s) in the Npr0lead to an encoded polyprotein as characterized by the following formula:
 [Npro]χ-[PS]y-[C-term] and wherein:
 [Npr0] relates to the Nproportion of said polyprotein, wherein ""x"" represents the number of amino acids of the Npropresent in the polyprotein; and wherein
 [PS] relates to a processing signal selected from the group consisting of: ubiquitin, LC3, SUMO-I, NEDD8, GATE- 16 or GABA(A)RAP), Intein, picornavirus 3 C, caridovirus 2A, aphtovirus 2 A or pi 5 of rabbit hemorrhagic disease virus; and wherein
 ""Y"" may be = 0, which means that no processing signal is present, or ""Y"" may be = 1, which means that a processing signal is present; and wherein
 [C-term] relates to the complete virus polyprotein except for Nproibut including the region of capsid (C)-protein, modified ERNSprotein and any other protein present in the virus polyprotein including the carboxyterminal NS5B; and wherein if ""y"" is = 0, then ""x"" is 0 to 12, (means no Nprospecific amino acid or 1 to 12 amino acids of Npr0are present); and wherein if ""y"" is = 1, then ""x"" is 0 to 168; (means no Nprospecific amino acid or 1 to all 168 amino acids of Npr0are present).
25. The attenuated virus according to claim 24, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by the following formula:
 [Npro]4-[PS]o-[C-terrn]
26. The attenuated virus according to claim 24, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by the following formula: [Npro]4-[PS]o-[C-term*], and wherein [C -term]* is = [C-term] wherein in the C-protein the amino acid at position 2 is changed from D to N.
27. The attenuated virus according to claim 24, wherein said mutation(s) in the Nprolead to an encoded polyprotein as characterized by the following formula:
 [Npro]χ-[PS],-[C-term] and wherein PS is selected from the group of ubiquitin or LC3.
28. A recombinant attenuated BVDV, wherein said attenuated BVDV does not produce a dimeric Emsglycoprotein.
29. The recombinant attenuated BVDV according to claim 28, wherein the carboxy- terminus of the Emsglycoprotein of said attenuated BVDV is modified by a deletion, insertion or substitution.
30. The recombinant attenuated BVDV according to claim 27or 28, wherein at least the last Cystein-residue of the Emsglyoprotein of said attenuated BVDV is deleted or substituted by non-Cys amino acid residue.
31. The recombinant attenuated BVDV according to any one of claims 28 to 30, wherein at least the Cystein-residue at amino acid position 441 according to SEQ ID NOs: 4 or 7 is deleted or substituted by a non Cystein-residue.
32. A method for attenuating a pestivirus, comprising modifying the Emsglycoprotein of said pestivirus in such that said attenuated pestivirus does not produce a dimeric Erasglycoprotein.
33. The method according to claim 32, wherein the carboxy-terminus of the Emsglycoprotein of said attenuated pestivirus is modified by a deletion, insertion or substitution.
34. The method according to claim 32 or 33, wherein at least the last Cystein-residue of the Emsglyoprotein of said attenuated pestivirus is deleted or substituted by non-Cys amino acid residue.";"(EP2303320)
The present invention relates to the field of animal health and in particular to attenuated pestiviruses such as classical swine fever virus (CSFV), bovine viral diarrhea virus (BVDV) or border disease virus (BDV).
Therefore, according to a further aspect, the present invention also relates to attenuated pestiviruses, wherein said attenuated pestiviruses do not produce a dimeric Erns glycoprotein by virtue of deletion or substitution by a noncysteine amino acid residue of the cysteine residue most carboxy-terminal of the ERNS glycoprotein, and having at least a mutation in the Npro protein, wherein said mutation in the Npro protein leads to inactivation of said Npro protein.
According to one aspect of the present invention, such attenuated pestiviruses can be formulated for use as modified live vaccine in a method of prophylaxis and/or treatment of pestivirus infections.
The present invention relates to the field of animal health and in particular to attenuated pestiviruses such as classical swine fever virus (CSFV), bovine viral diarrhea virus (BVDV) or border disease virus (BDV).";"(EP2303320)
However, in view of the importance of an effective and safe as well as detectable prophylaxis and treatment of pestiviral infections, there is a strong need for attenuated pestiviruses, such as BVDV, with a high potential for induction of immunity as well as a defined basis of attenuation which can also be distinguished from pathogenic pestiviruses, such as BVDV, as well as compositions and vaccines comprising said attenuated pestiviruses, such as BVDV.
Therefore, the technical problem underlying the present invention is to provide new attenuated pestiviruses, preferably an attenuated BVDV for use as live attenuated vaccines.
This problem is probably due to the great antigenic diversity between type 1 and type 2 strains which is most pronounced in the glycoprotein E2, the major antigen for virus neutralization (Tijssen et al., 1996).
The division of BVDV into 2 species is based on significant differences at the level of genomic sequences (summarized in Heinz et al., 2000) which are also obvious from limited cross neutralizing antibody reactions (Ridpath et al. 1994).
Pestiviruses are causative agents of economically important diseases of animals in many countries worldwide.";"A61K-039/00
A61K-039/12
A61K-039/15
A61K-039/187
A61P-031/12
A61P-037/00
C07K-014/005
C07K-014/18
C12N-007/00
C12N-007/01
C12N-007/04
C12N-015/09
C12N-015/33
C12N-015/40";"(EP2303320)
1. An attenuated pestivirus for use as a modified live vaccine in a method of prophylaxis and/or treatment of pestivirus infections, wherein at least the most C-terminal Cystein-residue of the Erns glycoprotein of said attenuated pestivirus is deleted or substituted by non-Cys amino acid residue and wherein said deletion or substitution of the most C-terminal Cystein-residue of the Erns glycoprotein results in a lack of homo dimer formation of the Erns glycoprotein and leads to an attenuated pestivirus.
10. An attenuated pestivirus, wherein at least the most C-terminal Cystein-residue of the Erns glycoprotein of said attenuated pestivirus is deleted or substituted by non-Cys amino acid residue and wherein said deletion or substitution of the most C-terminal Cysteinresidue of the Ems glycoprotein results in the lack of homo dimer formation of the Ems glycoprotein and leads to an attenuated pestivirus and wherein said attenuated pestivirus has at least another mutation in the Npro protein, wherein said mutation in the Npro protein leads to inactivation of said Npro protein.";"(EP2303320)
ATTENUATED PESTIVIRUS(100,52)
ERNS GLYCOPROTEIN RESIDUE(60,7)
NPRO PROTEIN(54,18)
DIMERIC ERNS GLYCOPROTEIN(35,9)
ENCODED POLYPROTEIN(35,6)
RECOMBINANT ATTENUATED PESTIVIRUS(29,3)
PATHOGENIC PESTIVIRUS(29,2)
ERNS DIMER(27,5)
VIRUS POLYPROTEIN(27,4)
ATTENUATED VIRUS(26,4)
EMS GLYCOPROTEIN(26,3)
ERNS GLYCOPROTEIN HOMODIMER(23,5)
ERNS GLYCOPROTEIN(22,30)
PESTIVIRAL INFECTION TREATMENT(22,1)
HOMODIMER FORMATION(21,5)
ATTENUATED BVDV(21,1)
EMS GLYOPROTEIN RESIDUE(21,1)
MUTATION(20,36)
PESTIVIRUS INFECTION TREATMENT(19,3)
DETECTABLE PROPHYLAXIS(19,1)
EMS GLYCOPROTEIN RESIDUE(19,1)
IMMUNITY INDUCTION(19,1)
LIVE ATTENUATED VACCINE(19,1)
VIRUS NEUTRALIZING(19,1)
PESTIVIRUS(18,68)
ANTIBODY REACTION NEUTRALIZATION(18,1)
SUBSTITUTION(17,33)
DELETION(17,25)
LIVE VACCINE(14,2)
CYSTEIN RESIDUE(13,8)
CAUSATIVE AGENT(13,1)
ECONOMICALLY IMPORTANT DISEASE(13,1)
EMS GLYCOPROTEIN RESULT(12,1)
ERNS GLYCOPROTEIN RESULT(12,1)
MAJOR ANTIGEN(12,1)
INACTIVATION(11,8)
MODIFIED LIVE VACCINE(11,6)
SUBSTITUTION MUTATION(11,2)
DELETION VIRTUE(11,1)
BOVINE VIRAL DIARRHEA VIRUS(10,102)
CARBOXY TERMINUS(10,5)
AMINOACID RESIDUE(10,4)
ATTENUATED BORDER DISEASE VIRUS(10,3)
ANTIGENIC DIVERSITY(10,1)
CLASSICAL SWINE FEVER VIRUS(9,53)
BORDER DISEASE VIRUS(9,26)
GLYCOPROTEIN(9,7)
HOG CHOLERA VIRUS(9,5)
CYSTEINE RESIDUE(9,2)
BVDV(9,1)
NON CYSTEINE AMINOACID RESIDUE(9,1)
IMMUNOGENIC(8,8)
CARIDOVIRUS(8,5)
INTERMOLECULAR DISULFANE BOND(8,5)
AMINOACID CYSTEINE(8,2)
CAPSID REGION(8,1)
GENOMIC SEQUENCE LEVEL(8,1)
ERNS HOMODIMER(7,5)
RNASE ACTIVITY INACTIVATION(7,5)
PROPHYLAXIS(7,4)
ERNS GLYCOPROTEIN MONOMER(7,3)
SIGNIFICANT DIFFERENCE(7,1)
VACCINE(6,17)
GABA(6,3)
ATTENUATED PATHOGENIC PESTIVIRUS(6,2)
DELETION GROUP(6,2)
ANIMAL HEALTH FIELD(6,1)
ATTENUATION DEFINED BASIS(6,1)
RECOMBINATION(6,1)
SIGNAL PROCESSING(5,11)
RABBIT HEMORRHAGIC DISEASE VIRUS(5,6)
FLAVIVIRIDAE FAMILY(5,4)
CELLULAR ANTIVIRAL DEFENSE(5,2)
FETAL INFECTION PREVENTION(5,2)
NPRO PORTION(5,2)
ATTENUATED PESTIVIRUS VIRULENCE(5,1)
CHALLENGE VIRUS TITER CONFIRMATION(5,1)
DIMERIZATION INCOMPETENT MUTANT(5,1)
ERNS GLYCOPROTEIN CONFORMATION(5,1)
MONOCLONAL NEUTRALIZING ANTIBODY AGAIST(5,1)
PERSISTENTLY INFECTED CALF INDUCTION(5,1)
PESTIVIRAL GLYCOPROTEIN MUTANT(5,1)
SACCHAROMYCES CEREVISIAE VACUOLAR MEMBRANE(5,1)
SAFE(5,1)
ANIMAL(4,15)
BIOLOGICAL ACTIVITY(4,8)
STRAIN(4,5)
NUCLEOTIDE SEQUENCE CODING(4,3)
PESTIVIRUS VIRION STRUCTURAL COMPONENT(4,3)
CODING SEQUENCE ENCODING GLYCOPROTEIN(4,2)
CONSERVED ERNS SEQUENCE(4,2)
EMS DIMER FORMATION PREVENTION(4,2)
INSERTION MUTATION(4,2)
NPRO SEQUENCE ELF(4,2)
PESTIVIRUS GENUS(4,2)
PESTIVIRUS GLYCOPROTEIN(4,2)
ATPASE INTEIN(4,1)
AUTOPHAGIC VESICLE MEMBRANE(4,1)
ERNS GLYCOPROTEIN DIMER(4,1)
ERNS GLYOPROTEIN RESIDUE(4,1)
MOMOMER HOMODIMER(4,1)
NPRO GENE DELETION(4,1)
PERSISTENTLY INFECTED LAMB(4,1)
PESTIVIRUS CDNA TRANSCRIPTION(4,1)
PICORNAVIRUS NONSTRUCTURAL PROTEIN(4,1)
POLYNUCLEOTIDE MOLECULE COMPRSING(4,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(4,1)
PREGNANT ANIMAL PLACENTA(4,1)
RECOMBINANT VACCINIA VIRUS(4,1)
UBIQUITIN CARBOXYL TERMINUS(4,1)
AMINOACID POSITION(3,24)
FUNCTIONAL VARIANT(3,6)
CONSTRUCTING CDNA(3,3)
ANCILLARY MOLECULE(3,2)
CLASSICAL SWINE FEVER PESTIVIRUS(3,2)
DAY POST INFECTION(3,2)
ERNS MONOMER(3,2)
MEMBRANE ANCHORING(3,2)
RNASE ASSAY(3,2)
VIRAL REPLICATION(3,2)
ANTIBODY TITER DETERMINATION(3,1)
CATALYTIC RESIDUE IDENTIFICATION(3,1)
CLINICAL SIGN OUTCOME(3,1)
ENVELOPE GLYCOPROTEIN EPITOPE MAPPING(3,1)
ERNS DIMERIZATION(3,1)
ERNS GLYCOPROTEIN CODING REGION(3,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(3,1)
FETUS ABORTION(3,1)
INFECTIOUS VIRUS RECOVERY(3,1)
INTERMOLECULAR BOND FORMATION(3,1)
LAMB INTRAUTERINE INFECTION(3,1)
MODIFIED LIVE PESTIVIRUS VACCINE(3,1)
MUSCLE BRACHIOCEPHALICUS(3,1)
NASCENT POLYPROTEIN(3,1)
PESTIVIRUS NEUTRALIZATION(3,1)
PESTIVIRUS NON TRANSLATED REGION(3,1)
PESTIVIRUS TERMINAL PROTEASE(3,1)
PHOSPHATIDYLETHANOLAMINE(3,1)
POLYNUCLEOTIDE MOLECULE CODING(3,1)
POLYNUCLEOTIDE VACCINATION(3,1)
PREDOMINANT CLINICAL PARAMETER(3,1)
PROBABLE IMMUNEMODULATING ACTIVITY(3,1)
REMINGTON PHARMACEUTICAL SCIENCE(3,1)
RNASE ACTIVITY ABROGATION(3,1)
SERUM NEUTRALIZATION ASSAY(3,1)
SYNTHESIZED POLYPROTEIN(3,1)
ACCESSION(2,6)
SUBTYPE(2,6)
FRAGMENT(2,4)
L CYSTEINE DELETION(2,4)
BORDER DISEASE VIRUS PESTIVIRUS(2,3)
PLACENTAL(2,3)
FUSION PROTEIN(2,2)
IMMUNOLOGICAL RESPONSE(2,2)
LIFE VACCINE(2,2)
NON AQUEOUS SOLUTION(2,2)
NUCLEIC ACID CODE DEGENERATION(2,2)
PESTIVIRUS SEQUENCE(2,2)
PROTEASE ACTIVITY(2,2)
PURIFICATION(2,2)
WT VIRUS(2,2)
ACCLIMATIZATION DAY(2,1)
ANIMAL NEED(2,1)
ANTIGENIC SUBSTANCE(2,1)
APHTOVIRUSE PROTEIN(2,1)
ATTENUATED PARTICLE(2,1)
ATTENUATED VIRAL PARTICLE(2,1)
ATTENUATED VIRULENCE(2,1)
ATTENUATION STRUCTURAL BASIS(2,1)
AUJESZKY DISEASE(2,1)
BACTERIOPHAGE T7 RNA POLYMERASE(2,1)
BINGEN MUTANT(2,1)
BIOCHEMICAL CHARACTERIZATION(2,1)
BIOCHEMICAL DATA(2,1)
BLOCKING ELISA(2,1)
BORDER DISEASE PESTIVIRUS(2,1)
BUFFY COAT PREPARATION(2,1)
CALICIVIRUS POLYPROTEIN PROCESSING(2,1)
CARBOXY TERMINAL CLEAVAGE(2,1)
CARBOXY TERMINAL GLYCIN(2,1)
CELLULAR PROTEASE(2,1)
CLINICAL MANIFESTATION(2,1)
CLINICAL SCORE INTENSITY(2,1)
COWORKER PRESENTED INDICATION(2,1)
CULTURE GROWTH(2,1)
CYSTEINE CODON(2,1)
CYSTEINE PROTEASE(2,1)
CYTOPATHOGENIC VIRUS(2,1)
DISCONTINUOUS TRANSLATION(2,1)
EMS RNASE ACTIVITY(2,1)
ENVELOPE PROTEIN(2,1)
ENVELOPED VIRUS(2,1)
ERNS GENE REGION(2,1)
ERNS MUTATION(2,1)
ERNS PROTEIN(2,1)
EVELOPE GLYCOPROTEIN PROCESSING(2,1)
FUNGAL ORIGIN(2,1)
FUSION MOLECULE(2,1)
GENETIC CODE DEGENERATIVE NATURE(2,1)
GENOME ORGANIZATION(2,1)
GENUS PESIVIRUS(2,1)
GENUS PESTIVIRUS MEMBER(2,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(2,1)
GP EPITOPE MAPPING(2,1)
HAIRY SHAKER(2,1)
HIGHLY CONSERVED CELLULAR PROTEIN(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
INFECTED HOST ANIMAL(2,1)
INFECTIOUS CLONE(2,1)
INT EH TERM(2,1)
INTERFERON RESPONSE INDUCTION(2,1)
INTRANASAL ROUTE(2,1)
INTRATHECAL ROUTE(2,1)
LATE EXPERIMENT STAGE(2,1)
LEADER PROTEINASE(2,1)
LEUKOCYTE COUNT(2,1)
LIMITED CROSS(2,1)
LINKED HETERODIMER(2,1)
LISTED MUTANT(2,1)
LIVE ATTENUATED VIRUS PRODUCTION(2,1)
LIVING ORGANISM(2,1)
MATERNAL ANTIBODY(2,1)
METABOLIZABLE OIL(2,1)
MODIFIED ATTENUATED PESTIVIRUS(2,1)
MODIFIED PESTIVIRUS(2,1)
MONOMER HOMODIMER FORMATION(2,1)
MOTIF IDENTITY(2,1)
MOUSE PRETREATMENT(2,1)
MUTATED POLYNUCLEOTIDE(2,1)
MUTATION ABROGATING(2,1)
MUTATION INTRODUCTION(2,1)
NEUBAUER CHAMBER(2,1)
NON PATHOGENIC VIRUS(2,1)
NUCLEOCAPSID PROTEIN(2,1)
NUCLEOTIDE EXCHANGE(2,1)
NUCLEOTIDE TRIPLET(2,1)
PARENTAL STRAIN(2,1)
PARENTERAL INJECTION(2,1)
PATHOLOGICAL SIGN(2,1)
PESTIVIRAL ORIGIN(2,1)
PESTIVIRUS CODING SEQUENCE(2,1)
PESTIVIRUS GENE EXPRESSION(2,1)
PESTIVIRUS POLYPROTEIN PROCESSING(2,1)
PESTIVIRUS PROTEIN(2,1)
PESTIVIRUS RNA(2,1)
PHARMACEUTICAL COMPOSTION(2,1)
PHENOTYPIC SELECTION(2,1)
PHYSIOLOGICALLY ACCEPTABLE SOLVENT(2,1)
PHYSIOLOGICALLY ACCEPTABLE STERILE SOLUTION(2,1)
PIG INFECTION(2,1)
PLANT RNASE(2,1)
POLYPEPTIDE CLEAVAGE(2,1)
PROLINE SUBSTITUTION(2,1)
PROTEIN CATABOLISM(2,1)
PROTEIN FUNDAMENTAL ROLE(2,1)
PROTEOLYTIC ACTIVITY(2,1)
RE LATED ORGANISM(2,1)
RE LATED SEQUENCE(2,1)
RECOMBINANT BIOENGINEERING(2,1)
RNASE NEGATIVE MUTANT(2,1)
RNASE NEGATIVE MUTATION(2,1)
SENSITIVE GLYCOPROTEIN(2,1)
SEVERE OUTBREAK(2,1)
SOFT FECES(2,1)
STABILIZING AGENT(2,1)
STUDY OBJECTIVE(2,1)
SURVIVING ANIMAL(2,1)
SYMPTOM SEVERITY(2,1)
TRANSLATIONAL DISCONTINUITY(2,1)
VACCINATED DAM(2,1)
VACCINATED PIG(2,1)
VACCINE CANDIDATE(2,1)
VACCINE STRAIN(2,1)
VETERINARY MICROBIOLOGY(2,1)
VIRAL GENOME CODE(2,1)
VIRAL PROTEIN(2,1)
VIREMIA DETECTION(2,1)
VIRION MOLECULAR(2,1)
VIRUS ATTENUATION(2,1)
VIRUS GROWTH RETARDATION(2,1)
VIRUS ISOLATION(2,1)
VIRUS NEUTRALIZING MONOCLONAL ANTIBODY(2,1)
VIRUS SUSPENSION(2,1)
DPI(1,6)
N TERMINAL METHIONINE(1,6)
ADJUVANT(1,2)
BOVINE SERUM ALBUMIN(1,2)
CHEMICAL DERIVATIVE(1,2)
DELETED REGION(1,2)
DISULFANE(1,2)
EXCIPIENT(1,2)
EXPERT(1,2)
GROUP ANIMAL(1,2)
IMMUNE RESPONSE(1,2)
INTERLEUKIN(1,2)
LETHALITY(1,2)
PESTIVIRUS INFECTION(1,2)
PYREXIA(1,2)
R GGLI(1,2)
RIBONUCLEASE(1,2)
RNASE ACTIVE SITE(1,2)
SEQUENCE DIVERSITY LEVEL(1,2)
SPERMIDINE(1,2)
STABILIZER(1,2)
VIRUS REPLICATION(1,2)
ANIMAL TREATMENT(1,1)
CELL CULTURE SUPERNATANT(1,1)
CLEAVAGE SITE(1,1)
COLD SPRING HARBOR(1,1)
COMPLETE PESTIVIRUS(1,1)
COVERED FECES(1,1)
DIRECT ENVIRONMENT CONFORMATION(1,1)
DNA COVERING(1,1)
DOUBLE EMULSION(1,1)
ENCODING NUCLEIC ACID MOLECULE(1,1)
ENVIRONMENT NEGATIVE POLARITY(1,1)
ERNS RNASE EFFECT(1,1)
HEMOCYTOMETER(1,1)
HOMODIMERISATION(1,1)
INFECTED CELL CULTURE(1,1)
INJECTABLE SOLUTION(1,1)
INSECT CELL(1,1)
INTEIN GROUP(1,1)
K GLYCOPROTEIN(1,1)
KEY PLAYER(1,1)
MARGINAL DIFFERENCE(1,1)
MICROTUBULE ASSOCIATED PROTEIN(1,1)
MODIFIED EXPRESSED POLYPEPTIDE(1,1)
MODIFIED POLYPEPTIDE(1,1)
NUCLEIC ACID MOLECULE ENCODING(1,1)
NUMB REDUCTION(1,1)
ORGANISM IMMUNOLOGICAL FUNCTION(1,1)
PESTIVIRUS REMAINING SEQUENCE(1,1)
PLASMA ISOLATION(1,1)
POST TRANSLATIONAL PROCESSING(1,1)
RNA CLEAVAGE ACTIVITY(1,1)
SEPARATE PROTEIN EXPRESSION(1,1)
SERUM PREPARATION(1,1)
SINGLE STRANDED RNA GENOME(1,1)
SITE DIRECTED MUTAGENESIS(1,1)
SPECIES PLUS(1,1)
STRETCH PRESENCE(1,1)
TARGET SPECIES(1,1)
TERM GLYCOPROTEIN(1,1)
TERMINAL AMINO(1,1)
TERMINAL GLYCINE(1,1)
TREATMENT EFFECTIVENESS(1,1)
UBIQUITIN GROUP(1,1)
VIRAL N DELETION(1,1)
VIRAL TRANSMISSION(1,1)
VIRUS CONCENTRATION(1,1)
VIRUS PARTICLE(1,1)
(US20110117126)
PESTIVIRUS(100,78)
ATTENUATED PESTIVIRUS(100,51)
C TERM(100,46)
IMMUNOGENIC(100,29)
BOVINE VIRAL DIARRHEA VIRUS(100,25)
DIMERIC EMS GLYCOPROTEIN(100,16)
VIRUS POLYPROTEIN(100,4)
EMS GLYCOPROTEIN CYSTEINE RESIDUE(96,10)
RECOMBINANT ATTENUATED PESTIVIRUS(77,6)
PESTIVIRUS EMS GLYCOPROTEIN(58,1)
ATTENUATED PESTIVIRUS NPRO PROTEIN(52,2)
RECOMBINANT ATTENUATED CSFV(47,1)
ENCODED POLYPROTEIN(42,24)
ATTENUATED VIRUS(39,6)
EMS GLYCOPROTEIN(38,32)
CARBOXY TERMINAL NS5B(37,7)
NON CYSTEINE RESIDUE(35,5)
PATHOGENIC PESTIVIRUS(35,2)
MODIFIED ERN PROTEIN(33,2)
PICORNAVIRUS 3C(32,6)
CARBOXY TERMINUS(28,6)
NPRO PROTEIN(27,14)
CARIDOVIRUS 2A(26,6)
NPRO PROTEIN INACTIVATION(26,1)
MUTATION(23,57)
DETECTABLE PROPHYLAXIS(23,1)
VIRUS NEUTRALIZING(23,1)
ANTIBODY REACTION NEUTRALIZATION(22,1)
IMMUNITY INDUCTION(22,1)
LIVE ATTENUATED VACCINE(22,1)
APHTOVIRUS 2A(21,3)
PESTIVIRAL INFECTION TREATMENT(21,2)
BVDV DIVISION(21,1)
PESTIVIRUS INFECTION PROPHYLAXIS(20,1)
POLYPROTEIN NPRO PORTION(19,2)
NON CYSTEINE AMINOACID(18,4)
ATTENUATED BVDV(18,3)
CAPSID REGION(18,1)
UBIQUITIN(17,13)
AMINOACID(16,28)
CAUSATIVE AGENT(16,1)
ECONOMICALLY IMPORTANT DISEASE(16,1)
POLYPROTEIN(15,9)
BORDER DISEASE VIRUS(15,6)
INTEIN(15,5)
MAJOR ANTIGEN(15,1)
PROTEIN(14,27)
SUBSTITUTION(14,23)
DELETION(14,22)
ATTENUATED BORDER DISEASE VIRUS(14,2)
BVDV(13,62)
RABBIT HEMORRHAGIC DISEASE VIRUS(13,7)
GABA(13,5)
NEDD(13,5)
SUMO(13,5)
SUBSTITUTION MUTATION(13,2)
ANTIGENIC DIVERSITY(13,1)
CLASSICAL SWINE FEVER VIRUS(12,17)
UBIQUITIN GROUP(12,3)
SIGNAL PROCESSING(11,8)
CYSTEIN RESIDUE(10,14)
EMS GLYOPROTEIN(10,8)
HOG CHOLERA VIRUS(10,5)
GENOMIC SEQUENCE LEVEL(10,1)
VACCINE(9,16)
CAPSID(9,3)
GLYCOPROTEIN(8,6)
EMS HOMODIMER(8,5)
RNASE ACTIVITY INACTIVATION(8,4)
EMS GLYCOPROTEIN MONOMER(8,3)
ATTENUATED APATHOGENIC PESTIVIRUS(8,2)
RECOMBINATION(8,1)
SIGNIFICANT DIFFERENCE(8,1)
CYSTEIN SERINE SUBSTITUTION(7,6)
FLAVIVIRIDAE FAMILY(7,5)
DELETION GROUP(7,2)
ATTENUATION DEFINED BASIS(7,1)
PESTIVIRUS POLYPROTEIN BVDV POLYPROTEIN(7,1)
RECOMBINANT ATTENUATED BVDV PESTIVIRUS(7,1)
C PROTEIN(6,15)
BDV(6,10)
SUBTYPE(6,8)
CYSTEIN DELETION(6,4)
BDV PESTIVIRUS(6,3)
CSFV PESTIVIRUS(6,3)
EXCIPIENT(6,3)
CELLULAR ANTIVIRAL DEFENSE(6,2)
CONSERVED EMS SEQUENCE SLHGIWPEKICTG(6,2)
FETAL INFECTION PREVENTION(6,2)
STRAIN(6,2)
ANIMAL HEALTH FIELD(6,1)
ATTENUATED PESTIVIRUS VIRULENCE(6,1)
CHALLENGE VIRUS TITER CONFIRMATION(6,1)
DIMERIZATION INCOMPETENT MUTANT(6,1)
PERSISTENTLY INFECTED CALF INDUCTION(6,1)
PESTIVIRAL GLYCOPROTEIN MUTANT(6,1)
SACCHAROMYCES CEREVISIAE VACUOLAR MEMBRANE(6,1)
SAFE(6,1)
STRONG NEED(6,1)
AMINOACID POSITION(5,24)
ANIMAL(5,15)
BIOLOGICAL ACTIVITY(5,8)
CSFV ATTENUATION(5,3)
NPPRO PROTEIN(5,3)
NUCLEOTIDE SEQUENCE CODING(5,3)
PESTIVIRUS VIRION STRUCTURAL COMPONENT(5,3)
EMS DIMER FORMATION PREVENTION(5,2)
INSERTION MUTATION(5,2)
PESTIVIRUS GENUS(5,2)
PESTIVIRUS GLYCOPROTEIN(5,2)
1STRAIN NADLNCBI GEN(5,1)
2STRAIN 890NCBI GEN(5,1)
AUTOPHAGIC VESICLE MEMBRANE(5,1)
DIMERIC ERN GLYCOPROTEIN(5,1)
EMS GLYCOPROTEIN CONFORMATION(5,1)
EMS GLYCOPROTEIN DIMER(5,1)
PERSISTENTLY INFECTED LAMB(5,1)
PESTIVIRUS CDNA TRANSCRIPTION(5,1)
PICORNAVIRUS NONSTRUCTURAL PROTEIN(5,1)
VIRUSSTRAIN BD31NCBI GEN(5,1)
ACCESSION(4,8)
TERMINAL METHIONINE(4,6)
MODIFIED LIVE VACCINE(4,4)
CONSTRUCTING CDNA(4,3)
ANCILLARY MOLECULE(4,2)
CODING SEQUENCE ENCODING GLYCOPROTEIN(4,2)
CSF PESTIVIRUS(4,2)
DAY POST INFECTION(4,2)
MEMBRANE ANCHORING(4,2)
PESTIVIRUS PROTEIN(4,2)
RAP(4,2)
RNASE ASSAY(4,2)
VIRAL REPLICATION(4,2)
ATPASE INTEIN(4,1)
BVDV LIFE VACCINE(4,1)
CLINICAL SIGN OUTCOME(4,1)
CYSTEINE CODON DELETION(4,1)
EMS GLYCOPROTEIN HOMODIMER FORMATION(4,1)
ENVELOPE GLYCOPROTEIN EPITOPE MAPPING(4,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(4,1)
HAIRY SHAKER SYNDROME(4,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(4,1)
MUTATED EMS PROTEIN(4,1)
NPRO GENE DELETION(4,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(4,1)
PREGNANT ANIMAL PLACENTA(4,1)
PROBABLE IMMUNEMODULATING ACTIVITY(4,1)
RECOMBINANT VACCINIA VIRUS(4,1)
RNASE ACTIVITY ABROGATION(4,1)
SERUM NEUTRALIZATION ASSAY(4,1)
STRAIN C413NCBI GEN(4,1)
STRAIN CP7NCBI GEN(4,1)
STRAIN X818NCBI GEN(4,1)
UBIQUITIN CARBOXYTERMINUS(4,1)
BOVINE SERUM ALBUMIN(3,2)
EMS MONOMER(3,2)
FUSION PROTEIN(3,2)
PESTIVIRUS INFECTION TREATMENT(3,2)
PESTIVIRUS SEQUENCE(3,2)
PROTEASE ACTIVITY(3,2)
ANTIBODY TITER DETERMINATION(3,1)
APHTOVIRUSE 2A PROTEIN(3,1)
ATTENUATED BVDV PARTICLE(3,1)
ATTENUATED CSFV(3,1)
ATTENUATED VIRAL PARTICLE(3,1)
ATTENUATED VIRULENCE(3,1)
BINGEN MUTANT(3,1)
BIOCHEMICAL CHARACTERIZATION(3,1)
BVDV VACCINE(3,1)
CALICIVIRUS POLYPROTEIN PROCESSING(3,1)
CARBOXY TERMINAL CLEAVAGE(3,1)
CARBOXY TERMINAL GLYCINE(3,1)
CATALYTIC RESIDUE IDENTIFICATION(3,1)
CLASSICAL BVDV(3,1)
CLINICAL MANIFESTATION(3,1)
CLINICAL SCORE INTENSITY(3,1)
CSF SIGN(3,1)
CSFV MUTANT(3,1)
CYSTEINE DELETION(3,1)
CYSTEINE PROTEASE(3,1)
CYTOPATHOGENIC VIRUS(3,1)
EMS DIMERIZATION(3,1)
EMS GLYCOPROTEIN CODING REGION(3,1)
EMS MUTATION(3,1)
EMS RNASE ACTIVITY(3,1)
ENVELOPED VIRUS(3,1)
EVELOPE GLYCOPROTEIN PROCESSING(3,1)
FETUS ABORTION(3,1)
GENUS PESIVIRUS(3,1)
INFECTED HOST ANIMAL(3,1)
INFECTIOUS CLONE(3,1)
INFECTIOUS VIRUS RECOVERY(3,1)
INTERMOLECULAR DISULFIDE FORMATION(3,1)
LAMB INTRAUTERINE INFECTION(3,1)
LEADER PROTEINASE(3,1)
LIVE ATTENUATED VIRUS PRODUCTION(3,1)
MATERNAL ANTIBODY(3,1)
MODIFIED LIVE PESTIVIRUS VACCINE(3,1)
MONOMER HOMODIMER FORMATION(3,1)
MOTIF IDENTITY(3,1)
MUSCLE BRACHIOCEPHALICUS(3,1)
MUTATED POLYNUCLEOTIDE(3,1)
MUTATION ABROGATING(3,1)
NASCENT POLYPROTEIN(3,1)
NON PATHOGENIC VIRUS(3,1)
NPRO SEQUENCE ELFSN(3,1)
NUCLEOCAPSID PROTEIN(3,1)
NUCLEOTIDE MOLECULE VARIANT(3,1)
NUCLEOTIDE TRIPLET(3,1)
PESTIVIRUS CODING SEQUENCE(3,1)
PESTIVIRUS NEUTRALIZATION(3,1)
PESTIVIRUS POLYPROTEIN PROCESSING(3,1)
PESTIVIRUS RNA(3,1)
PESTIVIRUS TERMINAL PROTEASE(3,1)
PHARMACEUTICAL COMPOSTION(3,1)
PLANT RNASE(3,1)
POLYNUCLEOTIDE MOLECULE CODING(3,1)
POLYNUCLEOTIDE VACCINATION(3,1)
POLYPEPTIDE CLEAVAGE(3,1)
PREDOMINANT CLINICAL PARAMETER(3,1)
PROLIN SUBSTITUTION(3,1)
PROTEIN FUNDAMENTAL ROLE(3,1)
RECOMBINANT BIOENGINEERING(3,1)
RNASE ACTIVITY TERM INACTIVATION(3,1)
RNASE NEGATIVE MUTANT(3,1)
RNASE NEGATIVE MUTATION(3,1)
STRAIN SD 1NCBI GEN(3,1)
SYMPTOM SEVERITY(3,1)
SYNTHESIZED POLYPROTEIN(3,1)
TRANSLATIONAL DISCONTINUITY(3,1)
VACCINATED DAM(3,1)
VACCINATED PIG(3,1)
VACCINE CANDIDATE(3,1)
VETERINARY MICROBIOLOGY(3,1)
VIRAL GENOME CODE(3,1)
VIRULENT BVDV(3,1)
WBC NUMB REDUCTION(3,1)
DPI(2,6)
FRAGMENT(2,4)
PROPHYLAXIS(2,4)
PLACENTAL(2,3)
ADJUVANT(2,2)
BDV X818(2,2)
CHEMICAL DERIVATIVE(2,2)
DELETED REGION(2,2)
EXPERT(2,2)
GROUP ANIMAL(2,2)
IMMUNE RESPONSE(2,2)
IMMUNOLOGICAL RESPONSE(2,2)
INTERLEUKIN(2,2)
LETHALITY(2,2)
NON AQUEOUS SOLUTION(2,2)
NUCLEIC ACID CODE DEGENERATION(2,2)
PURIFICATION(2,2)
PYREXIA(2,2)
RIBONUCLEASE(2,2)
RNASE ACTIVE SITE(2,2)
SEQUENCE DIVERSITY LEVEL(2,2)
SPERMIDINE(2,2)
STABILIZER(2,2)
TERM VACCINE(2,2)
VIRUS REPLICATION(2,2)
ACCLIMATIZATION DAY(2,1)
ANIMAL NEED(2,1)
ANTIGENIC SUBSTANCE(2,1)
ATTENUATED BDV(2,1)
ATTENUATED PARTICLE(2,1)
ATTENUATION STRUCTURAL BASIS(2,1)
BIOCHEMICAL DATA(2,1)
BLOCKING ELISA(2,1)
BUFFY COAT PREPARATION(2,1)
BVDV MUTANT(2,1)
BVDV SEQUENCE(2,1)
CELLULAR PROTEASE(2,1)
COMPLETE BVDV POLYPROTEIN(2,1)
COWORKER PRESENTED INDICATION(2,1)
CULTURE GROWTH(2,1)
CYSTEIN ENVIRONMENT MODIFICATION(2,1)
DISCONTINUOUS TRANSLATION(2,1)
DISULFIDE LINKED HETERODIMER(2,1)
DISULFIDE LINKED HOMODIMER(2,1)
EMS GENE REGION(2,1)
ENVELOPE PROTEIN(2,1)
FIBRIN COVERED FECES(2,1)
FORMULA BVDV(2,1)
FUNGAL ORIGIN(2,1)
FUSION MOLECULE(2,1)
GENETIC CODE DEGENERATIVE NATURE(2,1)
GENOME ORGANIZATION(2,1)
GENUS PESTIVIRUS MEMBER(2,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(2,1)
GP EPITOPE MAPPING(2,1)
HIGHLY CONSERVED CELLULAR PROTEIN(2,1)
HISTIDINE RESIDUE(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
INTERFERON RESPONSE INDUCTION(2,1)
INTRANASAL ROUTE(2,1)
INTRATHECAL ROUTE(2,1)
KILLED VACCINE(2,1)
LATE EXPERIMENT STAGE(2,1)
LEUKOCYTE COUNT(2,1)
LIMITED CROSS(2,1)
LISTED MUTANT(2,1)
LIVING ORGANISM(2,1)
METABOLIZABLE OIL(2,1)
MODIFIED ATTENUATED PESTIVIRUS(2,1)
MODIFIED PESTIVIRUS(2,1)
MOUSE PRETREATMENT(2,1)
MUTATION INTRODUCTION(2,1)
NEUBAUER CHAMBER(2,1)
NUCLEOTIDE EXCHANGE(2,1)
PARENTAL STRAIN(2,1)
PARENTERAL INJECTION(2,1)
PATHOLOGICAL SIGN(2,1)
PESTIVIRAL ORIGIN(2,1)
PESTIVIRUS GENE EXPRESSION(2,1)
PHENOTYPIC SELECTION(2,1)
PHYSIOLOGICALLY ACCEPTABLE SOLVENT(2,1)
PHYSIOLOGICALLY ACCEPTABLE STERILE SOLUTION(2,1)
PIG INFECTION(2,1)
PROTEIN CATABOLISM(2,1)
PROTEOLYTIC ACTIVITY(2,1)
SENSITIVE GLYCOPROTEIN(2,1)
SEVERE OUTBREAK(2,1)
SODIUM BISULFITE(2,1)
SOFT FECES(2,1)
STABILIZING AGENT(2,1)
STERILE PHYSIOLOGICALLY ACCEPTABLE SOLUTION(2,1)
STUDY OBJECTIVE(2,1)
SURVIVING ANIMAL(2,1)
TERM LIVE VACCINE(2,1)
VACCINE MANUFACTURE(2,1)
VACCINE STRAIN(2,1)
VIABLE CSFV(2,1)
VIRAL PROTEIN(2,1)
VIREMIA DETECTION(2,1)
VIRION MOLECULAR(2,1)
VIRUS ATTENUATION(2,1)
VIRUS GROWTH RETARDATION(2,1)
VIRUS ISOLATION(2,1)
VIRUS NEUTRALIZING MONOCLONAL ANTIBODY(2,1)
VIRUS SUSPENSION(2,1)
KID(1,4)
ANIMAL TREATMENT(1,1)
ANTIGENICALLY RELATED ORGANISM(1,1)
CARRIER SUBSTANCE(1,1)
CELL CULTURE SUPERNATANT(1,1)
CLEAVAGE SITE(1,1)
COLD SPRING HARBOR(1,1)
COMPLETE PESTIVIRUS(1,1)
DIRECT ENVIRONMENT CONFORMATION(1,1)
DNA COVERING(1,1)
DOUBLE EMULSION(1,1)
EMS RNASE EFFECT(1,1)
ENCODING NUCLEIC ACID MOLECULE(1,1)
ENVIRONMENT NEGATIVE POLARITY(1,1)
FACS ANALYSIS(1,1)
HEMOCYTOMETER(1,1)
HOMODIMER SHOW(1,1)
HOMODIMERISATION(1,1)
IMMUNOGENIC COMPOSITION FINAL PREPARATION(1,1)
INFECTED CELL CULTURE(1,1)
INJECTABLE SOLUTION(1,1)
INSECT CELL(1,1)
INTEIN GROUP(1,1)
KEY PLAYER(1,1)
LQRHEWNKHGWCNWFHIEPW(1,1)
MARGINAL DIFFERENCE(1,1)
MICROTUBULE ASSOCIATED PROTEIN(1,1)
MODIFIED EXPRESSED POLYPEPTIDE(1,1)
MODIFIED POLYPEPTIDE(1,1)
NUCLEIC ACID MOLECULE ENCODING(1,1)
ORGANISM IMMUNOLOGICAL FUNCTION(1,1)
PESTIVIRUS REMAINING SEQUENCE(1,1)
PHOSPHATIDYLETHANOLAMINE(1,1)
PLASMA ISOLATION(1,1)
POST TRANSLATIONAL PROCESSING(1,1)
RNA CLEAVAGE ACTIVITY(1,1)
SEPARATE PROTEIN EXPRESSION(1,1)
SERUM PREPARATION(1,1)
SINGLE STRANDED RNA GENOME(1,1)
SITE DIRECTED MUTAGENESIS(1,1)
SPECIES PLUS(1,1)
STRETCH PRESENCE(1,1)
TARGET SPECIES(1,1)
TERM BVDV(1,1)
TERM FUNCTIONAL VARIANT(1,1)
TERM GLYCOPROTEIN(1,1)
TERM MUTATION(1,1)
TERM PESTIVIRUS(1,1)
TREATMENT EFFECTIVENESS(1,1)
VIRAL TRANSMISSION(1,1)
VIRUS CONCENTRATION(1,1)
(US8895026)
PESTIVIRUS(100,70)
ATTENUATED PESTIVIRUS(100,46)
IMMUNOGENIC(100,25)
BOVINE VIRAL DIARRHEA VIRUS(100,21)
ERNS GLYCOPROTEIN CYSTEINE RESIDUE(100,9)
DIMERIC ERNS GLYCOPROTEIN(82,16)
RECOMBINANT ATTENUATED PESTIVIRUS(61,6)
PESTIVIRUS ERNS GLYCOPROTEIN(48,1)
ATTENUATED PESTIVIRUS NPRO PROTEIN(41,2)
ENCODED POLYPROTEIN(37,14)
RECOMBINANT ATTENUATED CSFV(37,1)
HOMOLOGOUS CYSTEINE RESIDUE(32,4)
ATTENUATED VIRUS(31,6)
PATHOGENIC PESTIVIRUS(27,2)
NON CYSTEINE AMINOACID(26,4)
NON CYSTEINE RESIDUE(22,3)
NPRO PROTEIN(21,14)
NPRO PROTEIN INACTIVATION(21,1)
ERNS GLYCOPROTEIN(20,27)
CARBOXY TERMINAL NS5B(19,7)
MUTATION(18,46)
DETECTABLE PROPHYLAXIS(18,1)
IMMUNITY INDUCTION(18,1)
LIVE ATTENUATED VACCINE(18,1)
VIRUS NEUTRALIZING(18,1)
PICORNAVIRUS 3C(17,6)
ANTIBODY REACTION NEUTRALIZATION(17,1)
PESTIVIRAL INFECTION TREATMENT(16,2)
BVDV DIVISION(16,1)
CARIDOVIRUS 2A(15,6)
MODIFIED ERN PROTEIN(15,2)
ATTENUATED BVDV(14,3)
BORDER DISEASE VIRUS(13,5)
CAUSATIVE AGENT(13,1)
APHTOVIRUS 2A(12,3)
ECONOMICALLY IMPORTANT DISEASE(12,1)
MAJOR ANTIGEN(12,1)
HOMOLOGY(11,4)
ATTENUATED BORDER DISEASE VIRUS(11,2)
BVDV(10,53)
CLASSICAL SWINE FEVER VIRUS(10,16)
ANTIGENIC DIVERSITY(10,1)
POLYPROTEIN NPRO PORTION(9,2)
CYSTEIN RESIDUE(8,14)
ERNS GLYOPROTEIN(8,8)
HOG CHOLERA VIRUS(8,5)
CAPSID REGION(8,1)
GENOMIC SEQUENCE LEVEL(8,1)
SUBSTITUTION(7,19)
DELETION(7,18)
RABBIT HEMORRHAGIC DISEASE VIRUS(7,7)
GABA(7,5)
NEDD(7,5)
SUMO(7,5)
ERNS GLYCOPROTEIN MONOMER(7,3)
ATTENUATED APATHOGENIC PESTIVIRUS(7,2)
VACCINE(6,15)
GLYCOPROTEIN(6,6)
ERNS HOMODIMER(6,5)
FLAVIVIRIDAE FAMILY(6,5)
RNASE ACTIVITY INACTIVATION(6,4)
SEQUENCE ALIGNMENT(6,4)
CONSERVED ERNS SEQUENCE SLHGIWPEKICTG(6,2)
UBIQUITIN GROUP(6,2)
ATTENUATION DEFINED BASIS(6,1)
PESTIVIRUS POLYPROTEIN BVDV POLYPROTEIN(6,1)
RECOMBINATION(6,1)
SIGNIFICANT DIFFERENCE(6,1)
C TERM(5,27)
SIGNAL PROCESSING(5,8)
CYSTEIN SERINE SUBSTITUTION(5,6)
CYSTEIN DELETION(5,4)
BDV PESTIVIRUS(5,3)
CSFV PESTIVIRUS(5,3)
STRAIN(5,2)
ANIMAL HEALTH FIELD(5,1)
ATTENUATED PESTIVIRUS VIRULENCE(5,1)
CHALLENGE VIRUS TITER CONFIRMATION(5,1)
DIMERIZATION INCOMPETENT MUTANT(5,1)
ERNS GLYCOPROTEIN CONFORMATION(5,1)
PERSISTENTLY INFECTED CALF INDUCTION(5,1)
PESTIVIRAL GLYCOPROTEIN MUTANT(5,1)
RECOMBINANT ATTENUATED BVDV PESTIVIRUS(5,1)
SACCHAROMYCES CEREVISIAE VACUOLAR MEMBRANE(5,1)
SAFE(5,1)
STRONG NEED(5,1)
AMINOACID POSITION(4,24)
ANIMAL(4,16)
BDV(4,11)
BIOLOGICAL ACTIVITY(4,8)
SUBTYPE(4,8)
CSFV ATTENUATION(4,3)
EXCIPIENT(4,3)
NPPRO PROTEIN(4,3)
NUCLEOTIDE SEQUENCE CODING(4,3)
PESTIVIRUS VIRION STRUCTURAL COMPONENT(4,3)
CELLULAR ANTIVIRAL DEFENSE(4,2)
ERNS DIMER FORMATION PREVENTION(4,2)
FETAL INFECTION PREVENTION(4,2)
PESTIVIRUS GENUS(4,2)
PESTIVIRUS GLYCOPROTEIN(4,2)
1STRAIN NADLNCBI GEN(4,1)
2STRAIN 890NCBI GEN(4,1)
AUTOPHAGIC VESICLE MEMBRANE(4,1)
DIMERIC ERN GLYCOPROTEIN(4,1)
ERNS GLYCOPROTEIN DIMER(4,1)
PERSISTENTLY INFECTED LAMB(4,1)
PESTIVIRUS CDNA TRANSCRIPTION(4,1)
PICORNAVIRUS NONSTRUCTURAL PROTEIN(4,1)
VIRUSSTRAIN BD31NCBI GEN(4,1)
C PROTEIN(3,13)
ACCESSION(3,8)
TERMINAL METHIONINE(3,6)
MODIFIED LIVE VACCINE(3,4)
CONSTRUCTING CDNA(3,3)
ANCILLARY MOLECULE(3,2)
CARBOXY TERMINUS(3,2)
CODING SEQUENCE ENCODING GLYCOPROTEIN(3,2)
CSF PESTIVIRUS(3,2)
DAY POST INFECTION(3,2)
ERNS MONOMER(3,2)
MEMBRANE ANCHORING(3,2)
PESTIVIRUS PROTEIN(3,2)
RAP(3,2)
RNASE ASSAY(3,2)
VIRAL REPLICATION(3,2)
ANTIBODY TITER DETERMINATION(3,1)
ATPASE INTEIN(3,1)
ATTENUATED BVDV PARTICLE(3,1)
BVDV LIFE VACCINE(3,1)
BVDV VACCINE(3,1)
CARBOXY TERMINAL CLEAVAGE(3,1)
CARBOXY TERMINAL GLYCINE(3,1)
CATALYTIC RESIDUE IDENTIFICATION(3,1)
CLINICAL SIGN OUTCOME(3,1)
CYSTEINE CODON DELETION(3,1)
ENVELOPE GLYCOPROTEIN EPITOPE MAPPING(3,1)
ERNS DIMERIZATION(3,1)
ERNS GLYCOPROTEIN CODING REGION(3,1)
ERNS GLYCOPROTEIN HOMODIMER FORMATION(3,1)
ERNS RNASE ACTIVITY(3,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(3,1)
FETUS ABORTION(3,1)
HAIRY SHAKER SYNDROME(3,1)
INFECTIOUS VIRUS RECOVERY(3,1)
LAMB INTRAUTERINE INFECTION(3,1)
MODIFIED LIVE PESTIVIRUS VACCINE(3,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(3,1)
MUSCLE BRACHIOCEPHALICUS(3,1)
MUTATED ERNS PROTEIN(3,1)
NASCENT POLYPROTEIN(3,1)
NPRO GENE DELETION(3,1)
NUCLEOTIDE MOLECULE VARIANT(3,1)
PESTIVIRUS NEUTRALIZATION(3,1)
PESTIVIRUS TERMINAL PROTEASE(3,1)
POLYNUCLEOTIDE MOLECULE CODING(3,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(3,1)
POLYNUCLEOTIDE VACCINATION(3,1)
PREDOMINANT CLINICAL PARAMETER(3,1)
PREGNANT ANIMAL PLACENTA(3,1)
PROBABLE IMMUNEMODULATING ACTIVITY(3,1)
RECOMBINANT VACCINIA VIRUS(3,1)
RNASE ACTIVITY ABROGATION(3,1)
SERUM NEUTRALIZATION ASSAY(3,1)
STRAIN C413NCBI GEN(3,1)
STRAIN CP7NCBI GEN(3,1)
STRAIN SD 1NCBI GEN(3,1)
STRAIN X818NCBI GEN(3,1)
SYNTHESIZED POLYPROTEIN(3,1)
UBIQUITIN CARBOXYTERMINUS(3,1)
FRAGMENT(2,4)
PROPHYLAXIS(2,4)
PLACENTAL(2,3)
BOVINE SERUM ALBUMIN(2,2)
FUSION PROTEIN(2,2)
IMMUNOLOGICAL RESPONSE(2,2)
LQRHEWNKHGWCNWFHIEPW(2,2)
NON AQUEOUS SOLUTION(2,2)
NUCLEIC ACID CODE DEGENERATION(2,2)
PESTIVIRUS INFECTION TREATMENT(2,2)
PESTIVIRUS SEQUENCE(2,2)
PROTEASE ACTIVITY(2,2)
TERM VACCINE(2,2)
ACCLIMATIZATION DAY(2,1)
ANIMAL NEED(2,1)
APHTOVIRUSE 2A PROTEIN(2,1)
ATTENUATED BDV(2,1)
ATTENUATED CSFV(2,1)
ATTENUATED VIRAL PARTICLE(2,1)
ATTENUATED VIRULENCE(2,1)
BINGEN MUTANT(2,1)
BIOCHEMICAL CHARACTERIZATION(2,1)
BIOCHEMICAL DATA(2,1)
BUFFY COAT PREPARATION(2,1)
BVDV MUTANT(2,1)
CALICIVIRUS POLYPROTEIN PROCESSING(2,1)
CELLULAR PROTEASE(2,1)
CLASSICAL BVDV(2,1)
CLINICAL MANIFESTATION(2,1)
CLINICAL SCORE INTENSITY(2,1)
COMPLETE BVDV POLYPROTEIN(2,1)
COWORKER PRESENTED INDICATION(2,1)
CSF SIGN(2,1)
CSFV MUTANT(2,1)
CYSTEIN ENVIRONMENT MODIFICATION(2,1)
CYSTEINE DELETION(2,1)
CYSTEINE PROTEASE(2,1)
CYTOPATHOGENIC VIRUS(2,1)
DISCONTINUOUS TRANSLATION(2,1)
DISULFIDE LINKED HETERODIMER(2,1)
DISULFIDE LINKED HOMODIMER(2,1)
ENVELOPED VIRUS(2,1)
ERNS MUTATION(2,1)
EVELOPE GLYCOPROTEIN PROCESSING(2,1)
GENOME ORGANIZATION(2,1)
GENUS PESIVIRUS(2,1)
GENUS PESTIVIRUS MEMBER(2,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(2,1)
GP EPITOPE MAPPING(2,1)
HIGHLY CONSERVED CELLULAR PROTEIN(2,1)
INFECTED HOST ANIMAL(2,1)
INFECTIOUS CLONE(2,1)
INTERFERON RESPONSE INDUCTION(2,1)
INTERMOLECULAR DISULFIDE FORMATION(2,1)
INTRANASAL ROUTE(2,1)
INTRATHECAL ROUTE(2,1)
KILLED VACCINE(2,1)
LATE EXPERIMENT STAGE(2,1)
LEADER PROTEINASE(2,1)
LEUKOCYTE COUNT(2,1)
LIVE ATTENUATED VIRUS PRODUCTION(2,1)
LIVING ORGANISM(2,1)
MATERNAL ANTIBODY(2,1)
MODIFIED ATTENUATED PESTIVIRUS(2,1)
MONOMER HOMODIMER FORMATION(2,1)
MOTIF IDENTITY(2,1)
MOUSE PRETREATMENT(2,1)
MUTATED POLYNUCLEOTIDE(2,1)
MUTATION ABROGATING(2,1)
NON PATHOGENIC VIRUS(2,1)
NPRO SEQUENCE ELFSN(2,1)
NUCLEOCAPSID PROTEIN(2,1)
NUCLEOTIDE EXCHANGE(2,1)
NUCLEOTIDE TRIPLET(2,1)
PARENTAL STRAIN(2,1)
PATHOLOGICAL SIGN(2,1)
PESTIVIRAL ORIGIN(2,1)
PESTIVIRUS CODING SEQUENCE(2,1)
PESTIVIRUS GENE EXPRESSION(2,1)
PESTIVIRUS POLYPROTEIN PROCESSING(2,1)
PESTIVIRUS RNA(2,1)
PHARMACEUTICAL COMPOSTION(2,1)
PIG INFECTION(2,1)
PLANT RNASE(2,1)
POLYPEPTIDE CLEAVAGE(2,1)
PROLIN SUBSTITUTION(2,1)
PROTEIN CATABOLISM(2,1)
PROTEIN FUNDAMENTAL ROLE(2,1)
RECOMBINANT BIOENGINEERING(2,1)
RNASE ACTIVITY TERM INACTIVATION(2,1)
RNASE NEGATIVE MUTANT(2,1)
RNASE NEGATIVE MUTATION(2,1)
SEVERE OUTBREAK(2,1)
SUBSTITUTION MUTATION(2,1)
SURVIVING ANIMAL(2,1)
SYMPTOM SEVERITY(2,1)
TERM LIVE VACCINE(2,1)
TRANSLATIONAL DISCONTINUITY(2,1)
VACCINATED DAM(2,1)
VACCINATED PIG(2,1)
VACCINE CANDIDATE(2,1)
VACCINE STRAIN(2,1)
VETERINARY MICROBIOLOGY(2,1)
VIABLE CSFV(2,1)
VIRAL GENOME CODE(2,1)
VIRULENT BVDV(2,1)
VIRUS ATTENUATION(2,1)
VIRUS GROWTH RETARDATION(2,1)
VIRUS NEUTRALIZING MONOCLONAL ANTIBODY(2,1)
WBC NUMB REDUCTION(2,1)
DPI(1,6)
KID(1,4)
ADJUVANT(1,2)
BDV X818(1,2)
CHEMICAL DERIVATIVE(1,2)
DELETED REGION(1,2)
EXPERT(1,2)
GROUP ANIMAL(1,2)
IMMUNE RESPONSE(1,2)
INTERLEUKIN(1,2)
LETHALITY(1,2)
PURIFICATION(1,2)
PYREXIA(1,2)
RIBONUCLEASE(1,2)
RNASE ACTIVE SITE(1,2)
SEQUENCE DIVERSITY LEVEL(1,2)
SPERMIDINE(1,2)
STABILIZER(1,2)
VIRUS REPLICATION(1,2)
ANIMAL TREATMENT(1,1)
ANTIGENIC SUBSTANCE(1,1)
ANTIGENICALLY RELATED ORGANISM(1,1)
ATTENUATED PARTICLE(1,1)
ATTENUATION STRUCTURAL BASIS(1,1)
BLOCKING ELISA(1,1)
BVDV SEQUENCE(1,1)
CARRIER SUBSTANCE(1,1)
CELL CULTURE SUPERNATANT(1,1)
CLEAVAGE SITE(1,1)
COLD SPRING HARBOR(1,1)
COMPLETE PESTIVIRUS(1,1)
CULTURE GROWTH(1,1)
DIRECT ENVIRONMENT CONFORMATION(1,1)
DNA COVERING(1,1)
DOUBLE EMULSION(1,1)
ENCODING NUCLEIC ACID MOLECULE(1,1)
ENVELOPE PROTEIN(1,1)
ENVIRONMENT NEGATIVE POLARITY(1,1)
ERNS GENE REGION(1,1)
ERNS RNASE EFFECT(1,1)
FACS ANALYSIS(1,1)
FIBRIN COVERED FECES(1,1)
FORMULA BVDV(1,1)
FUNGAL ORIGIN(1,1)
FUSION MOLECULE(1,1)
GENETIC CODE DEGENERATIVE NATURE(1,1)
HEMOCYTOMETER(1,1)
HISTIDINE RESIDUE(1,1)
HOMODIMER SHOW(1,1)
HOMODIMERISATION(1,1)
IMMUNOGENIC COMPOSITION FINAL PREPARATION(1,1)
IMMUNOLOGICAL ACTIVITY(1,1)
INFECTED CELL CULTURE(1,1)
INJECTABLE SOLUTION(1,1)
INSECT CELL(1,1)
INTEIN GROUP(1,1)
KEY PLAYER(1,1)
LIMITED CROSS(1,1)
LISTED MUTANT(1,1)
MARGINAL DIFFERENCE(1,1)
METABOLIZABLE OIL(1,1)
MICROTUBULE ASSOCIATED PROTEIN(1,1)
MODIFIED EXPRESSED POLYPEPTIDE(1,1)
MODIFIED PESTIVIRUS(1,1)
MODIFIED POLYPEPTIDE(1,1)
MUTATION INTRODUCTION(1,1)
NEUBAUER CHAMBER(1,1)
NUCLEIC ACID MOLECULE ENCODING(1,1)
ORGANISM IMMUNOLOGICAL FUNCTION(1,1)
PARENTERAL INJECTION(1,1)
PESTIVIRUS REMAINING SEQUENCE(1,1)
PHENOTYPIC SELECTION(1,1)
PHOSPHATIDYLETHANOLAMINE(1,1)
PHYSIOLOGICALLY ACCEPTABLE SOLVENT(1,1)
PHYSIOLOGICALLY ACCEPTABLE STERILE SOLUTION(1,1)
PLASMA ISOL(...)";Pharmaceuticals;Open
"2008-01-30
2009-01-29";"WO2009095518        A1 2009-08-06 [WO200995518]
STG: (A1) Published application with search report
AP : 2009WO-ES00046 2009-01-29
CA2714292           A1 2009-08-06 [CA2714292]
STG: (A1) Application laid open
AP : 2009CA-2714292 2009-01-29
AU2009209572        A1 2009-08-06 [AU2009209572]
STG: (A1) Open to public inspection
AP : 2009AU-0209572 2009-01-29
EP2256185           A1 2010-12-01 [EP2256185]
STG: (A1) Application published with search report
AP : 2009EP-0705071 2009-01-29
JP2011511630        A  2011-04-14 [JP2011511630]
STG: (A) Published application
AP : 2010JP-0544740 2009-01-29
US20110104205       A1 2011-05-05 [US20110104205]
STG: (A1) Application published
AP : 2009US-12865287 2009-01-29
BRPI0905753         A2 2011-08-30 [BR200905753]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2009BR-0005753 2009-01-29
EP2256185           A4 2012-08-08 [EP2256185]
STG: (A4) Supplementary search report
AP : 2009EP-0705071 2009-01-29
US8685413           B2 2014-04-01 [US8685413]
STG: (B2) Granted patent as second publication
AP : 2009US-12865287 2009-01-29
FD :  Previous publication: US20110104205 A1 2011-05-05 [US20110104205]
JP5547657           B2 2014-05-23 [JP5547657]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2010JP-0544740 2009-01-29
AU2009209572        B2 2014-07-31 [AU2009209572]
STG: (B2) Patent proceeded by OPI
AP : 2009AU-0209572 2009-01-29
EP2256185           B1 2014-09-10 [EP2256185]
STG: (B1) Patent specification
AP : 2009EP-0705071 2009-01-29
DK2256185           T3 2014-12-08 [DK2256185T]
STG: (T3) Translation of EP patent
AP : 2009DK-0705071 2009-01-29
ES2524468           T3 2014-12-09 [ES2524468]
STG: (T3) Translation of granted European patent (former B3)
AP : 2009ES-0705071T 2009-01-29
PT2256185           E  2014-12-18 [PT2256185]
STG: (E) Availability of national translation of European patent
AP : 2009PT-0705071T 2009-01-29
BRPI0905753         A1 2017-05-09 [BRPI0905753]
STG: (A1) Published application
AP : 2009BR-0005753 2009-01-29";1841066;"WO2009095518        A1 2009-08-06 [WO200995518]
CA2714292           A1 2009-08-06 [CA2714292]
AU2009209572        A1 2009-08-06 [AU2009209572]
EP2256185           A1 2010-12-01 [EP2256185]
JP2011511630        A  2011-04-14 [JP2011511630]
US20110104205       A1 2011-05-05 [US20110104205]
BRPI0905753         A2 2011-08-30 [BR200905753]
EP2256185           A4 2012-08-08 [EP2256185]
US8685413           B2 2014-04-01 [US8685413]
JP5547657           B2 2014-05-23 [JP5547657]
AU2009209572        B2 2014-07-31 [AU2009209572]
EP2256185           B1 2014-09-10 [EP2256185]
DK2256185           T3 2014-12-08 [DK2256185T]
ES2524468           T3 2014-12-09 [ES2524468]
PT2256185           E  2014-12-18 [PT2256185]
BRPI0905753         A1 2017-05-09 [BRPI0905753]";"2008ES-0000239
2009WO-ES00046";"(EP2256185)
WO2009095518
(US8685413)
WO2009095518
(JP5547657)
WO2009095518
(CA2714292)
WO2009095518
(AU2009209572)
WO2009095518
(DK2256185T)
WO2009095518
(ES2524468)
WO2009095518";"PEREZ DE ROZAS RUIZ DE GAUNA A
UNI AUT NOMA DE BARCELONA
UNIVERSITAT AUTONOMA DE BARCELONA";UNI AUT NOMA DE BARCELONA;"(EP2256185)
ES
(EP2256185)
ES
(US20110104205)
ES
(US8685413)
ES
(WO200995518)
ES

(CA2714292)
ES

(BRPI0905753)
ES";"(EP2256185)
NAME=Universitat Autònoma De Barcelona Edifici A - Campus Universitari s/n  Bellaterra , CITY=08193 Barcelona , COUNTRY=ES 

(EP2256185)
NAME=Universitat Autònoma de Barcelona Edifici A - Campus Universitari s/n  Bellaterra , CITY=08193 Barcelona , COUNTRY=ES , REG=101092096 

(US20110104205)
NAME=UNIVERSITAT AUTONOMA DE BARCELONA , CITY=Barcelona , COUNTRY=ES , ATYP=Non-US Company 

(US8685413)
NAME=Universitat Autonoma de Barcelona , CITY=Barcelona , COUNTRY=ES , ATYP=Non-US Company 

(WO200995518)
NAME=UNIVERSITAT AUTONOMA DE BARCELONA  Edifici A-Campus universitari s/n, E-08193 Bellaterra (Barcelona)  , COUNTRY=ES 

NAME=PEREZ DE ROZAS RUIZ DE GAUNA, Ana Ma  Edifici A-Campus universitari s/n, E-08193 Bellaterra (Barcelona)  , COUNTRY=ES 

(JP2011511630)
NAME=Uniberstitut Out Nomade de Barcelona; Spain, (Barcelona) E-0 8 1 9 3 Bellaterra, Eddiecea - Camps Universe Sitari Eze / Ene , REG=510207313 

(JP5547657)
NAME=UNIVERSITAT AUTONOMA DE BARCELONA , REG=510207313 

(CA2714292)
NAME=UNIVERSITAT AUTONOMA DE BARCELONA Edifici A-Campus de la UAB s/n 08193 , CITY=CERDANYOLA DEL VALLES , COUNTRY=ES 

(DK2256185T)
NAME=UNIVERSITAT AUTÒNOMA DE BARCELONA Edifici A - Campus Universitari s/n , Bellaterra,08193 Barcelona   ES 

(BRPI0905753)
NAME=UNIVERSITAT AUTONOMA DE BARCELONA , COUNTRY=ES 
";1;"BARBÉ GARCIA JORGE
BADIOLA SÁIZ
LLAGOSTERA CASAS MONTSERRAT
GARRIDO OCA A MA ELENA
BOSCH GALLEGO MONTSERRAT
PEREZ DE ROZAS RUIZ DE GAUNA ANA MA";"(EP2256185)
ES";"(EP2256185)
NAME=BARBE GARCIA, Jorge Edifici A-Campus universitari s/n , CITY=E-08193 Bellaterra (Barcelona) , COUNTRY=ES 

NAME=BADIOLA, Sáiz Edifici A-Campus universitari s/n , CITY=E-08193 Bellaterra (Barcelona) , COUNTRY=ES 

NAME=LLAGOSTERA CASAS, Montserrat Edifici A-Campus universitari s/n , CITY=E-08193 Bellaterra (Barcelona) , COUNTRY=ES 

NAME=GARRIDO OCAÑA, Ma Elena Edifici A-Campus universitari s/n , CITY=E-08193 Bellaterra (Barcelona) , COUNTRY=ES 

NAME=BOSCH GALLEGO, Montserrat Edifici A-Campus universitari s/n , CITY=E-08193 Bellaterra (Barcelona) , COUNTRY=ES 

NAME=PEREZ DE ROZAS RUIZ DE GAUNA, Ana Ma Edifici A-Campus universitari s/n , CITY=E-08193 Bellaterra (Barcelona) , COUNTRY=ES 
";"(EP2256185)
Heterologous protection against pasteurella multocida provided by p. multocida fur cells and the outer-membrane protein extracts thereof";"(EP2256185)
The invention relates to Pasteurella multocida mutants capable of providing heterologous protection against infection caused by virulent P . multocida. Said mutants are defective in fur ampH and fur ompH galE genes. The invention relates to Pasteurella multocida bacteria vaccine compositions containing fur ompH double mutants and fur ompH galE triple mutants obtained from P . multocida , or an extract of iron-regulated outer-membrane proteins (IROMPs) obtained from said mutants, and to an excipient and/or pharmaceutically acceptable adjuvants.";"(WO200995518)
1. Pasteurella multocida Bacteria wherein mutant is defective in genes / w ompHde so that there is no expression or ompHl defur and ompH2.
2.
2. Pasteurella multocida Bacteria according to claim 1, wherein in addition to being defective in genes ompH Fur and so is the galE gene in a way that optimizes the surface exposure of outer membrane proteins regulated by iron from cells of P. ompH multocida fur.
3.
3. Pasteurella multocida mutated bacteria according to claims 1-2, characterized as being defective in Fur wild gene interruption by integration in the same internal fragment of 394 bp of the fur gene amplified with primers and Furl
Fur2.
4.
4. Basteurella multocida mutant bacteria, according to claims 1-3, characterized as being defective in ompH, introducing a nonsense mutation in ompHl in position 76, and several nucleotide changes and a nonsense mutation at position 670 in ompH2.
5.
5. Pasteurella multocida Bacteria mutated, according to claims 1-4, characterized in that the ompHl mutation results in a stop codon instead of glutamine resulting in a truncated protein of 24 amino acids, and because ompH2 mutation leads to a protein truncated of 223 amino acids instead of 350 amino acids.
6.
6. Pasteurella multocida Bacteria mutated, according to claims 1-5, characterized by the absence of the major outer membrane protein 36-kDa due to nonsense mutations according to claims 4 and 5.
7.
7. Pasteurella multocida Bacteria mutated according to claim 2, characterized as being defective in galE gene interruption wild for integration into the same internal fragment of 495 bp galE. obtained by amplification with primers
GalEintup and GalEintp.
8.
8. Pasteurella multocida Bacteria mutated, according to claims 1-7, characterized for being inactivated.
9.
9. Pasteurella multocida Bacteria mutated, according to claim 8, characterized in that heat has been inactivated.
REPLACEMENT SHEET (Rule 26)
10.
10. Pasteurella multocida Bacteria mutated according to claim 8, characterized for being inactivated by sonication.
11.
11. Preparation of external membrane proteins of bacteria P. multocida mutant according to claims 1-10.
12.
12. Method for the preparation of a vaccine to protect animals from heterologous infection with P. multocida characterized it comprises:
 A. obtain mutants of P. multocida fur gene defect, or the fury ompH genes, or fur genes, galE ompHy, according to the claims
1. 10 and / or a preparation of outer membrane proteins to which these cells of P. multocida mutant result, according to claim 11; y
 B adequate preparation chosen method of giving the vaccine, comprising an extract of cells obtained in (a) containing an effective amount of mutant Fur, fur or fur ompH ompH galE and / or proteins of the outer membrane and a vehicle or pharmaceutically acceptable adjuvants.
13.
13. Method for the preparation of a vaccine to protect animals from heterologous infection with P. multocida, according to claim 12, characterized in that the fur mutant cells, the double mutant ompH fur or fur triple mutant ompHgalE iennicamenie have been inactivated.
14.
14. Method for preparing a vaccine for animals heierologa proieccion against infection with P. multocida, according to claim 12, characterized in that the fur mutant cells, the double mutant ompH fur or fur ompHgalE triple mutant have been inactivated by sonication.
15.
15. Composition of vaccine for animals heierologa proieccion against Pasteurella multocida infection caracierizada it comprises an immunogenic amount muianie fur, the fur ompH double mutant or triple mutant gal E ompH fur oy / or extract of external membrane proteins of According to the claims 12-14, a vehicle and / or pharmaceutically acceptable adjuvants.
16.
16. Vaccine composition according to claim 15, to protect animals from heterologous form illness P.multocida infection such as pneumonia in pigs and cattle, fowl cholera and pneumonia in small mammals like rabbits and hamsters.
REEMPUZO SHEET (Rule 26)
17.
17. Using Pastewella multocida fur mutant and / or an extract of external membrane proteins for the preparation of a vaccine to protect animals against heterologous Pastewella multocida infection according to claims 12-16.
18.
18. Using the double mutant Pasteurella multocida fur onψHy / or an extract from their membrane exieπia proieinas for the preparation of a vaccine for animals heterologous proieccion against Pasteurella multocida infection according to claims 12-16.
19.
19. Using the triple mutant Pasteurella multocida galE ompH fur and / or an extract of outer membrane proteins for the preparation of a vaccine to protect animals against heterologous Pasteurella multocida infection according to claims 12-16.
20.
20. REPLACEMENT SHEET (Rule 26)";"(EP2256185)
The invention relates to Pasteurella multocida mutants capable of providing heterologous protection against infection caused by virulent P. multocida.
The invention relates to Pasteurella multocida bacteria vaccine compositions containing fur ompH double mutants and fur ompH galE triple mutants obtained from P. multocida, or an extract of iron-regulated outer-membrane proteins (IROMPs) obtained from said mutants, and to an excipient and/or pharmaceutically acceptable adjuvants.
The invention relates to Pasteurella multocida mutants capable of providing heterologous protection against infection caused by virulent P. multocida.
The present invention relates to vaccine compositions against Pasteurella genus bacteria, specifically Pasteurella multocida, comprising fur ompH double mutants and fur ompH galE triple mutants, obtained from P. multocida or an extract of iron-regulated outer-membrane proteins (IROMPs) obtained from said mutants and an excipient and/or pharmaceutically acceptable adjuvants.
The present invention relates to vaccine compositions against Pasteurella genus bacteria, specifically Pasteurella multocida, comprising fur ompH double mutants and fur ompH galE triple mutants, obtained from P. multocida or an extract of iron-regulated outer-membrane proteins (IROMPs) obtained from said mutants and an excipient and/or pharmaceutically acceptable adjuvants.";"(EP2256185)
Each of these types of vaccines has its advantages and drawbacks; live attenuated vaccines produce protection under conditions similar to those of the natural disease.
Iron is a necessary element for almost all living cells.
Many iron-regulated outer-membrane proteins (IROMPs) are powerful antigens and factors that are essential for virulence during the infection process of some pathogens (Ratledge, C., and L.G.
Pasteurella multocida is a pathogenic bacterium which causes various infectious diseases, such as fowl cholera, bovine pneumonia and hemorrhagic septicemia, and atrophic rhinitis in pigs, in animals used for producing foods.
Bacterial infections are a major cause of diseases worldwide both in animals and in humans, especially in children.
The Pasteurella genus is among the disease-causing bacteria, and it currently includes 20 species, including Pasteurella multocida, which is a pathogenic bacterium which causes various infectious diseases such as fowl cholera, bovine pneumonia, hemorrhagic septicemia and atrophic rhinitis in pigs, in animals used for producing foods, so the control of the disease is very important for farmers dedicated to breeding this livestock.
are a major cause of diseases worldwide both in animals and in humans, especially in children.
diseases, such as fowl cholera, bovine pneumonia and hemorrhagic septicemia, and atrophic rhinitis in pigs, in animals used for producing foods.";"A61K-035/74
A61K-039/00
A61K-039/02
A61K-039/102
A61K-039/38
A61P-031/00
C07K-001/00
C07K-014/00
C07K-014/285
C07K-017/00
C12N-001/20
C12N-001/21
C12N-015/09
C12N-015/31
C12N-015/64";"(EP2256185)
1. A mutated Pasteurella multocida bacterium, characterized in that it is defective in fur and ompH genes such that the expression of fur or of ompH1 and ompH2 does not occur.";"(EP2256185)
OUTER MEMBRANE PROTEIN(100,31)
PASTEURELLA MULTOCIDA(100,21)
HETEROLOGOUS PROTECTION(100,15)
MUTATED PASTEURELLA MULTOCIDA BACTERIUM(100,9)
MULTOCIDA FUR CELL(100,2)
FUR OMPH GALE(75,12)
PASTEURELLA MULTOCIDA FUR(52,7)
PASTEURELLA MULTOCIDA MUTANT(50,2)
FUR OMPH DOUBLE MUTANT(48,5)
HETEROLOGOUS ANIMAL PROTECTION(45,7)
PASTEURELLA GENUS BACTERIUM(37,2)
BOVINE PNEUMONIA(34,2)
FOWL CHOLERA(30,6)
VIRULENT PASTEURELLA MULTOCIDA(30,2)
FUR OMPH GALE GENE(29,2)
BACTERIUM VACCINE(29,1)
FUR OMPH GALE MUTANT(27,6)
PASTEURELLA GENUS(26,1)
TRIPLE MUTANT(25,11)
FUR MUTANT CELL(25,2)
BACTERIA ATTENUATED VACCINE(24,1)
VACCINE(23,38)
OMPH GENE(22,9)
INFECTIOUS DISEASE(22,1)
MUTANT(21,28)
INFECTION(21,17)
ADJUVANT(21,9)
MULTOCIDA FUR OMPH CELL(21,2)
MULTOCIDA(20,43)
FUR OMPH(20,8)
FUR GENE BP(20,1)
POWERFUL ANTIGEN(20,1)
ATROPHIC RHINITIS(19,2)
FUR EXPRESSION(19,2)
HEMORRHAGIC SEPTICEMIA(18,3)
FOOD PRODUCT(17,2)
EXCIPIENT(16,10)
GALEINTP PRIMER(16,1)
RECA MUTATION(16,1)
FUR AMPH(15,1)
TRUNCATED PROTEIN(14,5)
LIVE ATTENUATED VACCINE(14,4)
DISEASE NATURE(14,1)
GALE INTERNAL FRAGMENT(14,1)
OMPH(13,28)
DISEASE(13,4)
MULTOCIDA FUR OMPH MUTANT(13,4)
PATHOGENIC BACTERIUM(13,4)
MULTOCIDA BACTERIUM(13,3)
VIRULENT P(12,8)
VACCINE PRODUCTION(12,2)
NONSENSE MUTATION(11,10)
ANIMAL(11,7)
CHILD(11,1)
IROMP(11,1)
BACTERIA(10,22)
PIG(10,5)
MULTOCIDA GALE MUTANT(10,4)
INTERRUPTION(10,2)
MULTOCIDA FUR OMPH GALE(10,2)
MUTATED P(10,2)
MAJOR DISEASE CAUSE(10,1)
FUR(9,20)
MULTOCIDA CELL(9,6)
LIVESTOCK(9,2)
CELL EXTRACT(9,1)
FARMER(9,1)
SONICATION(8,11)
PATHOGEN(8,3)
BACTERIAL INFECTION(8,2)
OUTER MEMBRANE PROTEIN PREPARATION(8,2)
PASTEURELLA MULTOCIDA OMPH GENE(8,2)
OUTER MEMBRANE PROTEIN EXTRACT(7,8)
HETEROLOGOUS CHALLENGE(7,6)
OMPH TRANSCRIPTION(7,4)
VIRULENCE(7,4)
DISEASE CONTROL(7,1)
FUR PROTEIN(6,6)
TRIPARENTAL MATING(6,6)
RT PCR ANALYSIS(6,5)
GALEINTUP(6,3)
MAMMAL(6,3)
MULTOCIDA RTOMPH(6,3)
MAIN ABSENCE(6,2)
MUTANT FUR OMPH GALE(6,1)
OMPHLAC PHOTOBACTERIUM SPL(6,1)
SEROTYPE EXISTENCE(6,1)
LIVE VACCINE(5,4)
BACTERIA CULTURE(5,3)
EPIDEMIC OUTBREAK(5,2)
HAMSTER(5,2)
LIVE ATTENUATED BACTERIUM(5,2)
MULTOCIDA VACCINATION(5,2)
NEISSERIA MENINGITIDIS(5,2)
OMPH GENE EXPRESSION(5,2)
RABBIT(5,2)
THERMALLY INACTIVATED FUR(5,2)
UNKNOWN ATTENUATION MARKER(5,2)
FUR OMPH MUTANT GENE(5,1)
OBTAINING P(5,1)
PASTEURELLA BACTERIA MUTATION(5,1)
PASTEURELLA MULTOCIDA FUR GENE(5,1)
PASTEURELLA MULTOCIDA FUR MUTANT(5,1)
PASTEURELLA MULTOCIDA GALE GENE(5,1)
PASTEURELLA MULTOCIDA RECA MUTANT(5,1)
PATHOGENIC YERSINIA ENTEROCOLITICA SURVIVAL(5,1)
SUICIDE PLASMID RECOMBINATION(5,1)
LANE(4,30)
AMINOACID(4,9)
INITIAL TRANSCRIPTION(4,5)
VACCINE DEVELOPMENT(4,4)
CATTLE(4,3)
MUTANT BACTERIA(4,3)
OMPH EXPRESSION(4,3)
PCR AMPLIFICATION(4,3)
MOUSE PERITONITIS(4,2)
ACAPSULAR PASTEURELLA MULTOCIDA(4,1)
ARTICLE OMPH MUTANT(4,1)
ATTENUATED BACTERIA IDENTIFICATION(4,1)
BACTERIAL SPECIES FUR MUTANT(4,1)
BACTERIAL STRAIN VIRULENCE(4,1)
BACTERIAL VIRULENT GENE(4,1)
BACTERIUM ENCODING TRANSCRIPTION FACTOR(4,1)
CHROMOSOMAL DNA PCR ANALYSIS(4,1)
CONTRA LA PASTEURELOSIS(4,1)
DEEP SEA BACTERIUM PHOTOBACTERIUM(4,1)
DEFECTIVE OMPH MUTANT(4,1)
DEPENDENT DNA(4,1)
DNA ENCODING PASTEURELLA MULTOCIDA(4,1)
FERRIC UPTAKE REGULATION(4,1)
FERRIC UPTAKE REGULATOR(4,1)
FUR GENE EXPRESSION(4,1)
FUR GENE NUCLEOTIDE(4,1)
FUR GENE TRANSCRIPTION(4,1)
FUR INDEPENDENT REGULATION(4,1)
FUR OMPH GALE CELL(4,1)
FUR OMPH STRAIN(4,1)
FUR OOMPH GALE(4,1)
FUR REINTERPRETATION(4,1)
FUR TITRATION ASSAY(4,1)
GALE MUTATION OBJECTIVE(4,1)
HARLAN IB RICA(4,1)
HOST ORGANISM MUCOSA(4,1)
INACTIVATED FUR OMPH CELL(4,1)
INCAPACITATED FOX GROWTH(4,1)
KDA OMPH PROTEIN(4,1)
MULTOCIDA FUR BACTERIUM(4,1)
OMPH GENE COPY(4,1)
OMPH PROTEIN ROLE(4,1)
PASTEURELLA MULTOCIDA BACTERIN(4,1)
PASTEURELLA MULTOCIDA CHARACTERIZATION(4,1)
PASTEURELLA MULTOCIDA EXBB(4,1)
PASTEURELLA MULTOCIDA MEMBRANE PROTEIN(4,1)
PATHOLOGICALLY IMPORTANT PASTEURELLA SEROTYPE(4,1)
SUBCLINICAL INFECTION SYMPTOM(4,1)
THERMALLY INACTIVATED MUTANT STRAIN(4,1)
TRANSCRIPTIONAL METALLOREGULATION(4,1)
WEEK SWISS FEMALE MOUSE(4,1)
BARB(3,16)
IRON REGULATED OUTER MEMBRANE PROTEINS(3,8)
HEMOGLOBIN(3,6)
DIVALENT CATION CHELATING AGENT(3,4)
OVEREXPRESSION(3,4)
PHAGE X DNA(3,4)
LIPOPOLYSACCHARIDE(3,3)
PLASMID INSERTION(3,3)
STOP CODON(3,3)
WILD TYPE GENE(3,3)
ADMINISTRATION(3,2)
BACTERIUM ENVIRONMENT(3,2)
CONSTRUCT PCR ANALYSIS(3,2)
DEFECTIVE FUR(3,2)
FUR MUTATION PRESENCE(3,2)
GALE MUTATION PRESENCE(3,2)
GRAM NEGATIVE BACTERIAL ORGANISM(3,2)
IRON RECEPTOR(3,2)
OMPH SEQUENCE(3,2)
PHAGE DNA(3,2)
PHYSIOLOGICAL SALINE(3,2)
PLASMID INTEGRATION(3,2)
TRANSCRIPTIONAL ANALYSIS(3,2)
VACCINE FORMULATION(3,2)
ANTIBACTERIAL VACCINE(3,1)
ATTENUATED BACTERIA STRAIN PRODUCTION(3,1)
BACTERIA CYTOPLASM(3,1)
BACTERIAL IRON UPTAKE PROTEIN(3,1)
BACTERIAL VIRULENCE(3,1)
BAROPHILIC BACTERIUM(3,1)
BIFUNCTIONAL UREASE(3,1)
CHICKEN HOMOLOGOUS PROTECTION(3,1)
CHROMOSOMAL DNA ANALYSIS(3,1)
FUR GENE ROLE(3,1)
FUR GENE SEQUENCE(3,1)
FUR HOMOLOG(3,1)
FUR MUTATION STABILITY(3,1)
GALE GENE INTERNAL FRAGMENT(3,1)
GALEINTRP OLIGONUCLEOTIDE(3,1)
GALEINTRP PRIMER(3,1)
GENE DISRUPTION(3,1)
HAEMOPHILUS INFLUENZAE(3,1)
HBPA GENE ENCODING(3,1)
HGBA GENE ENCODING(3,1)
HGBB FUNCTIONAL CHARACTERIZATION(3,1)
HOMOLOGOUS SEROTYPE(3,1)
IMMUNOGENIC HEMIN(3,1)
INACTIVATED PASTEURELLA WHOLE CELL(3,1)
INACTIVATION PROCESSA(3,1)
INACTIVATION STRATEGY(3,1)
INSERTING PLASMID PUA(3,1)
INTRAPERITONEAL INOCULATION(3,1)
KILLED PATHOGEN(3,1)
LIVE AROA DERIVATIVE(3,1)
MOB MOBILIZATION REGION(3,1)
MULTOCIDA MUTANT GIVE RISE(3,1)
MULTOCIDA SEROTYPE(3,1)
MULTOCIDA VACCINE(3,1)
MUTANT CHARACTERIZATION(3,1)
OMPH POLYPEPTIDE(3,1)
OUTER MEMBER PROTEIN(3,1)
PASTEURELLA MULTOCIDA PROTEIN(3,1)
PASTEURELLA ORGANISM(3,1)
PASTEUROLLOSIS VACCINE(3,1)
POLYVALENT VACCINE(3,1)
SEEDING BACTERIUM(3,1)
STRAIN THERMALLY INACTIVATED CELL(3,1)
THERMALLY INACTIVATED STRAIN(3,1)
TOXIN INACTIVE FORM(3,1)
URIDINE DIPHOSPHATE GALACTOSE EPIMERIZATION(3,1)
VACCINATION EFFICACY(3,1)
VACCINE EFFECTIVENESS(3,1)
VETERINARIAN VACCINE(3,1)
VIABLE BACTERIA CONCENTRATION(3,1)
VIRULENT BACTERIA(3,1)
PKO(2,5)
PRIMER POSITION(2,5)
ANTIBIOTIC(2,4)
IRON DEFICIENT MEDIUM(2,4)
MULTOCIDA OUTER MEMBRANE PROTEIN(2,3)
SELECTIVE PLATE(2,3)
COADJUVANT(2,2)
EXPOSURE SURFACE(2,2)
IRON REGULATED GENE(2,2)
MONOPHOSPHOLIPID(2,2)
PRIMER SEQUENCE(2,2)
TRANSCONJUGANT(2,2)
90D PRIMER(2,1)
AAD GENE(2,1)
AMERICAN SOCIETY(2,1)
ANIMAL IMMUNIZATION(2,1)
ANTIGEN PROTECTING(2,1)
ARO GENE(2,1)
ATTENUATED BACTERIUM CONSTRUCTION(2,1)
ATTENUATED STRAIN(2,1)
BACTERIAL CELL EXPERIENCE(2,1)
BIOLOGICALLY ACTIVE SUBUNIT(2,1)
BLOCKING TRANSCRIPTION(2,1)
CELL DISRUPTION(2,1)
CELL INACTIVATION(2,1)
CLONE OMPH(2,1)
COMA GENE(2,1)
DNA RECOGNITION(2,1)
ELECTROPHORETIC PROFILE(2,1)
ELLEN CHI(2,1)
ESCHERICHIA GENE(2,1)
FUNCTIONAL MUTATION(2,1)
FUR CFU ML(2,1)
FUR GENE PRODUCT(2,1)
GALE GENE PRODUCT(2,1)
GENE CLONING(2,1)
GENE DNA SEQUENCING(2,1)
GENE OMPH(2,1)
GENE RTOMPH(2,1)
GLUCOSE ABSENCE(2,1)
HEAT INACTIVATION(2,1)
HETEROLOGOUS ATTACK(2,1)
IMMUNITY STUDY(2,1)
INOCULATED EXTRACT VOLUME(2,1)
IRON METABOLISM(2,1)
IRON REGULATED PROTEIN EXPRESSION(2,1)
KDA PORIN(2,1)
KDA PROTEIN(2,1)
KILLED VACCINE(2,1)
LIVE PATHOGEN(2,1)
METABOLIC RESOURCE(2,1)
MULTOCIDA OUTER MEMBRANE PORIN(2,1)
MULTOCIDA STRAIN TABLE(2,1)
MUTANT ISOLATION(2,1)
NATIVE MODIFICATION(2,1)
NATIVE PROTEIN(2,1)
OBTAINING VACCINE(2,1)
OMPH STRAIN SELECTED UNDERPRESSURE(2,1)
P CLONED FRAGMENT(2,1)
PATHOGEN COMPONENT PURIFICATION(2,1)
PHARMACEUTICAL FORMULATION(2,1)
PHENOL REAGENT(2,1)
PIR PROTEIN(2,1)
POLYCLONAL ANTIBODY(2,1)
PRECISE DELETION(2,1)
PROGENITOR STRAIN(2,1)
PROTECTION STUDY(2,1)
PROTEIN GENE(2,1)
PUA INTERNAL FRAGMENT(2,1)
PURIFIED RECEPTOR(2,1)
PYRIMIDINE PATHWAY(2,1)
REPORTER GENE(2,1)
RNA EXTRACTION(2,1)
SEQDW PRIMER(2,1)
SHORT TRUNCATED PROTEIN(2,1)
SMAI INSERTION SITE(2,1)
STRAIN DERIVATIVE(2,1)
STREPTOMYCIN RESISTANCE GENE(2,1)
SUSPENSION DILUTION(2,1)
TONB GENE(2,1)
VACCINE DOSE(2,1)
VACCINE PREPARATION(2,1)
VIABLE CELL ABSENCE(2,1)
VIRULENCE REDUCTION(2,1)
WHOLE CELL LYSATE(2,1)
PROTECTION LEVEL(1,4)
LD50(1,3)
ACTIVE SUBSTANCE CONCENTRATION(1,2)
AUTHOR(1,2)
BSTEII(1,2)
COMPLETE GENOMIC SEQUENCE(1,2)
F REVERSE PRIMER(1,2)
GENOME(1,2)
IDENTITY(1,2)
NUCLEOTIDE CHANGE(1,2)
VETERINARY MEDICINE(1,2)
VIRULENCE LEVEL(1,2)
ANTIBACTERIAL AGENT IDENTIFICATION(1,1)
ANTIBODY PRESENCE(1,1)
ANTIBODY PRODUCTION(1,1)
ANTIGENICITY(1,1)
BIOLOGICAL PRODUCT ACTIVITY(1,1)
CELL SUSPENSION(1,1)
CHELATING AGENT PROPORTION(1,1)
DEVELOPMENT OBJECTIVE(1,1)
DOCUMENT FOCUS(1,1)
DOUBLE MUTANT(1,1)
FINAL GENETIC MODIFICATION(1,1)
FUR BOX(1,1)
FUR FORMATION(1,1)
FUR GENE INTERNAL REGION(1,1)
GRAM NEGATIVE PATHOGENIC BACTERIUM(1,1)
ICE BATH(1,1)
IMMUNOGENIC AGENT(1,1)
(EP2256185)
OUTER MEMBRANE PROTEIN(100,28)
PASTEURELLA MULTOCIDA(100,20)
HETEROLOGOUS PROTECTION(100,14)
MUTATED PASTEURELLA MULTOCIDA BACTERIUM(100,9)
MULTOCIDA FUR CELL(100,2)
FUR OMPH GALE(67,13)
PASTEURELLA MULTOCIDA FUR(56,8)
HETEROLOGOUS ANIMAL PROTECTION(45,7)
FUR OMPH DOUBLE MUTANT(42,8)
PASTEURELLA GENUS BACTERIUM(37,2)
BOVINE PNEUMONIA(34,2)
INFECTIOUS DISEASE(34,2)
FOWL CHOLERA(30,6)
VIRULENT PASTEURELLA MULTOCIDA(30,2)
FUR GENE EXPRESSION(29,1)
TRIPLE MUTANT(28,12)
PASTEURELLA MULTOCIDA MUTANT(28,1)
RECA MUTATION(28,1)
FUR OMPH GALE MUTANT(27,6)
NATIVE FUR GENE(26,1)
PASTEURELLA GENUS(26,1)
VACCINE(25,39)
BACTERIA ATTENUATED VACCINE(24,1)
OMPH GENE(21,11)
MULTOCIDA FUR OMPH CELL(21,2)
FUR GENE BP(20,1)
POWERFUL ANTIGEN(20,1)
INFECTION(19,16)
ATROPHIC RHINITIS(19,2)
ATTENUATED BACTERIA(19,2)
FUR EXPRESSION(19,2)
HEMORRHAGIC SEPTICEMIA(18,3)
FOOD PRODUCT(17,2)
FUR MUTANT CELL(17,1)
GALEINTUP PRIMER(17,1)
MULTOCIDA(16,43)
ADJUVANT(16,9)
MUTANT(14,23)
BACTERIA(14,21)
TRUNCATED PROTEIN(14,5)
LIVE ATTENUATED VACCINE(14,4)
BACTERIUM ENVIRONMENT(14,2)
DISEASE NATURE(14,1)
GALE INTERNAL FRAGMENT(14,1)
OMPH(13,26)
MULTOCIDA FUR OMPH MUTANT(13,4)
PATHOGENIC BACTERIUM(13,4)
GALEINTRP PRIMER(13,2)
EXCIPIENT(12,10)
VACCINE PRODUCTION(12,2)
NONSENSE MUTATION(11,9)
ANIMAL(11,8)
HOMOLOG(11,5)
CHILD(11,1)
GENBANK(11,1)
IROMP(11,1)
PIG(10,5)
MULTOCIDA GALE MUTANT(10,4)
INTERRUPTION(10,2)
MULTOCIDA FUR OMPH GALE(10,2)
MAJOR DISEASE CAUSE(10,1)
FUR(9,21)
MULTOCIDA CELL(9,6)
DISEASE(9,3)
LIVESTOCK(9,2)
CELL EXTRACT(9,1)
FARMER(9,1)
SONICATION(8,11)
PATHOGEN(8,3)
BACTERIAL INFECTION(8,2)
OUTER MEMBRANE PROTEIN PREPARATION(8,2)
PASTEURELLA MULTOCIDA OMPH GENE(8,2)
OUTER MEMBRANE PROTEIN EXTRACT(7,9)
VIRULENT P(7,7)
HETEROLOGOUS CHALLENGE(7,6)
OMPH TRANSCRIPTION(7,4)
VIRULENCE(7,4)
FUR OOMPH GALE(7,2)
DISEASE CONTROL(7,1)
MUTATED P(7,1)
FUR PROTEIN(6,6)
TRIPARENTAL MATING(6,6)
RT PCR ANALYSIS(6,5)
MAMMAL(6,3)
MULTOCIDA RTOMPH(6,3)
MAIN ABSENCE(6,2)
MUTANT FUR OMPH GALE(6,1)
OMPHLAC PHOTOBACTERIUM SPL(6,1)
SEROTYPE EXISTENCE(6,1)
LIVE VACCINE(5,4)
BACTERIA CULTURE(5,3)
EPIDEMIC OUTBREAK(5,2)
HAMSTER(5,2)
LIVE ATTENUATED BACTERIUM(5,2)
MULTOCIDA VACCINATION(5,2)
NEISSERIA MENINGITIDIS(5,2)
OMPH GENE EXPRESSION(5,2)
RABBIT(5,2)
THERMALLY INACTIVATED FUR(5,2)
UNKNOWN ATTENUATION MARKER(5,2)
FUR OMPH GALE GENE(5,1)
FUR OMPH MUTANT GENE(5,1)
OBTAINING P(5,1)
PASTEURELLA BACTERIA MUTATION(5,1)
PASTEURELLA MULTOCIDA FUR GENE(5,1)
PASTEURELLA MULTOCIDA FUR MUTANT(5,1)
PASTEURELLA MULTOCIDA GALE GENE(5,1)
PASTEURELLA MULTOCIDA RECA MUTANT(5,1)
PATHOGENIC YERSINIA ENTEROCOLITICA SURVIVAL(5,1)
SUICIDE PLASMID RECOMBINATION(5,1)
LANE(4,30)
AMINOACID(4,9)
INITIAL TRANSCRIPTION(4,5)
VACCINE DEVELOPMENT(4,4)
CATTLE(4,3)
MULTOCIDA STRAIN(4,3)
MUTANT BACTERIA(4,3)
OMPH EXPRESSION(4,3)
PCR AMPLIFICATION(4,3)
MOUSE PERITONITIS(4,2)
MULTOCIDA BACTERIUM(4,2)
VIRULENT GENE(4,2)
ACAPSULAR PASTEURELLA MULTOCIDA(4,1)
ARTICLE OMPH MUTANT(4,1)
ATTENUATED BACTERIA IDENTIFICATION(4,1)
BACTERIAL SPECIES FUR MUTANT(4,1)
BACTERIAL STRAIN VIRULENCE(4,1)
BACTERIUM ENCODING TRANSCRIPTION FACTOR(4,1)
CHROMOSOMAL DNA PCR ANALYSIS(4,1)
CONTRA LA PASTEURELOSIS(4,1)
DEEP SEA BACTERIUM PHOTOBACTERIUM(4,1)
DEFECTIVE OMPH MUTANT(4,1)
DEPENDENT DNA(4,1)
DNA ENCODING PASTEURELLA MULTOCIDA(4,1)
FERRIC UPTAKE REGULATION(4,1)
FERRIC UPTAKE REGULATOR(4,1)
FUR GENE NUCLEOTIDE(4,1)
FUR GENE TRANSCRIPTION(4,1)
FUR INDEPENDENT REGULATION(4,1)
FUR OMPH GALE CELL(4,1)
FUR OMPH STRAIN(4,1)
FUR REINTERPRETATION(4,1)
FUR TITRATION ASSAY(4,1)
GALE MUTATION OBJECTIVE(4,1)
HARLAN IB RICA(4,1)
HOST ORGANISM MUCOSA(4,1)
INACTIVATED FUR OMPH CELL(4,1)
INCAPACITATED FOX GROWTH(4,1)
KDA OMPH PROTEIN(4,1)
MULTOCIDA FUR BACTERIUM(4,1)
OMPH GENE COPY(4,1)
OMPH PROTEIN ROLE(4,1)
PASTEURELLA MULTOCIDA BACTERIN(4,1)
PASTEURELLA MULTOCIDA CHARACTERIZATION(4,1)
PASTEURELLA MULTOCIDA EXBB(4,1)
PASTEURELLA MULTOCIDA MEMBRANE PROTEIN(4,1)
PATHOLOGICALLY IMPORTANT PASTEURELLA SEROTYPE(4,1)
SUBCLINICAL INFECTION SYMPTOM(4,1)
THERMALLY INACTIVATED MUTANT STRAIN(4,1)
TRANSCRIPTIONAL METALLOREGULATION(4,1)
WEEK SWISS FEMALE MOUSE(4,1)
BARB(3,15)
HEMOGLOBIN(3,6)
OVEREXPRESSION(3,4)
PHAGE X DNA(3,4)
ADMINISTRATION(3,3)
DIVALENT CATION CHELATING AGENT(3,3)
LIPOPOLYSACCHARIDE(3,3)
PLASMID INSERTION(3,3)
STOP CODON(3,3)
WILD TYPE GENE(3,3)
ACCESSION NUMBER(3,2)
CONSTRUCT PCR ANALYSIS(3,2)
DEFECTIVE FUR(3,2)
FUR MUTATION PRESENCE(3,2)
GALE MUTATION PRESENCE(3,2)
GRAM NEGATIVE BACTERIAL ORGANISM(3,2)
IRON RECEPTOR(3,2)
OMPH SEQUENCE(3,2)
PHAGE DNA(3,2)
PHYSIOLOGICAL SALINE(3,2)
PLASMID INTEGRATION(3,2)
TRANSCRIPTIONAL ANALYSIS(3,2)
VACCINE FORMULATION(3,2)
ANTIBACTERIAL VACCINE(3,1)
ATTENUATED BACTERIA STRAIN PRODUCTION(3,1)
BACTERIA CYTOPLASM(3,1)
BACTERIAL IRON UPTAKE PROTEIN(3,1)
BACTERIAL VIRULENCE(3,1)
BAROPHILIC BACTERIUM(3,1)
BIFUNCTIONAL UREASE(3,1)
CHICKEN HOMOLOGOUS PROTECTION(3,1)
CHROMOSOMAL DNA ANALYSIS(3,1)
FUR GENE ROLE(3,1)
FUR GENE SEQUENCE(3,1)
FUR HOMOLOG(3,1)
FUR MUTATION STABILITY(3,1)
GALE GENE INTERNAL FRAGMENT(3,1)
GALEINTRP OLIGONUCLEOTIDE(3,1)
GENE DISRUPTION(3,1)
HAEMOPHILUS INFLUENZAE(3,1)
HBPA GENE ENCODING(3,1)
HGBA GENE ENCODING(3,1)
HGBB FUNCTIONAL CHARACTERIZATION(3,1)
HOMOLOGOUS SEROTYPE(3,1)
IMMUNOGENIC HEMIN(3,1)
INACTIVATED PASTEURELLA WHOLE CELL(3,1)
INACTIVATION PROCESSA(3,1)
INACTIVATION STRATEGY(3,1)
INSERTING PLASMID PUA(3,1)
INTRAPERITONEAL INOCULATION(3,1)
KILLED PATHOGEN(3,1)
LIVE AROA DERIVATIVE(3,1)
MOB MOBILIZATION REGION(3,1)
MULTOCIDA MUTANT GIVE RISE(3,1)
MULTOCIDA SEROTYPE(3,1)
MULTOCIDA VACCINE(3,1)
MUTANT CHARACTERIZATION(3,1)
OMPH POLYPEPTIDE(3,1)
PASTEURELLA MULTOCIDA PROTEIN(3,1)
PASTEURELLA ORGANISM(3,1)
PASTEUROLLOSIS VACCINE(3,1)
POLYVALENT VACCINE(3,1)
SEEDING BACTERIUM(3,1)
STRAIN THERMALLY INACTIVATED CELL(3,1)
THERMALLY INACTIVATED STRAIN(3,1)
TOXIN INACTIVE FORM(3,1)
URIDINE DIPHOSPHATE GALACTOSE EPIMERIZATION(3,1)
VACCINATION EFFICACY(3,1)
VACCINE EFFECTIVENESS(3,1)
VETERINARIAN VACCINE(3,1)
VIABLE BACTERIA CONCENTRATION(3,1)
VIRULENT BACTERIA(3,1)
IRON REGULATED OUTER MEMBRANE PROTEINS(2,7)
PRIMER POSITION(2,5)
ANTIBIOTIC(2,4)
IRON DEFICIENT MEDIUM(2,4)
MULTOCIDA OUTER MEMBRANE PROTEIN(2,3)
SELECTIVE PLATE(2,3)
COADJUVANT(2,2)
EXPOSURE SURFACE(2,2)
IRON REGULATED GENE(2,2)
MONOPHOSPHOLIPID(2,2)
PRIMER SEQUENCE(2,2)
TRANSCONJUGANT(2,2)
90D PRIMER(2,1)
AAD GENE(2,1)
AMERICAN SOCIETY(2,1)
ANIMAL IMMUNIZATION TABLE(2,1)
ANTIGEN PROTECTING(2,1)
ARO GENE(2,1)
ATTENUATED BACTERIUM CONSTRUCTION(2,1)
ATTENUATED STRAIN(2,1)
BACTERIAL CELL EXPERIENCE(2,1)
BIOLOGICALLY ACTIVE SUBUNIT(2,1)
BLOCKING TRANSCRIPTION(2,1)
CELL DISRUPTION(2,1)
CELL INACTIVATION(2,1)
CLONE OMPH(2,1)
COMA GENE(2,1)
DNA RECOGNITION(2,1)
DPDA FUR PRESENCE(2,1)
ELECTROPHORETIC PROFILE(2,1)
ELLEN CHI(2,1)
ESCHERICHIA GENE(2,1)
FUNCTIONAL MUTATION(2,1)
FUR CFU ML(2,1)
FUR GENE PRODUCT(2,1)
GALE GENE PRODUCT(2,1)
GENE CLONING(2,1)
GENE DNA SEQUENCING(2,1)
GENE OMPH(2,1)
GENE RTOMPH(2,1)
GLUCOSE ABSENCE(2,1)
HEAT INACTIVATION(2,1)
HETEROLOGOUS ATTACK(2,1)
IMMUNITY STUDY(2,1)
INOCULATED EXTRACT VOLUME(2,1)
IRON METABOLISM(2,1)
IRON REGULATED PROTEIN EXPRESSION(2,1)
KDA PORIN(2,1)
KDA PROTEIN(2,1)
KILLED VACCINE(2,1)
LIVE PATHOGEN(2,1)
METABOLIC RESOURCE(2,1)
MULTOCIDA OUTER MEMBRANE PORIN(2,1)
MUTANT ISOLATION(2,1)
NATIVE PROTEIN(2,1)
OMPH STRAIN SELECTED UNDERPRESSURE(2,1)
P CLONED FRAGMENT(2,1)
PATHOGEN COMPONENT PURIFICATION(2,1)
PHARMACEUTICAL FORMULATION(2,1)
PHENOL REAGENT(2,1)
PIR PROTEIN(2,1)
POLYCLONAL ANTIBODY(2,1)
PRECISE DELETION(2,1)
PROGENITOR STRAIN(2,1)
PROTECTION STUDY(2,1)
PROTEIN GENE(2,1)
PUA INTERNAL FRAGMENT(2,1)
PURIFIED RECEPTOR(2,1)
PYRIMIDINE PATHWAY(2,1)
REPORTER GENE(2,1)
RNA EXTRACTION(2,1)
SEQDW PRIMER(2,1)
SHORT TRUNCATED PROTEIN(2,1)
SMAI INSERTION SITE(2,1)
STRAIN DERIVATIVE(2,1)
STREPTOMYCIN RESISTANCE GENE(2,1)
SUSPENSION DILUTION(2,1)
TONB GENE(2,1)
VACCINE DOSE(2,1)
VACCINE PREPARATION(2,1)
VIABLE CELL ABSENCE(2,1)
VIRULENCE REDUCTION(2,1)
WHOLE CELL LYSATE(2,1)
PKO(1,4)
PROTECTION LEVEL(1,4)
LD50(1,3)
ACTIVE SUBSTANCE CONCENTRATION(1,2)
AUTHOR(1,2)
BSTEII(1,2)
COMPLETE GENOMIC SEQUENCE(1,2)
F REVERSE PRIMER(1,2)
GALEINTUP(1,2)
GENOME(1,2)
IDENTITY(1,2)
NUCLEOTIDE CHANGE(1,2)
VETERINARY MEDICINE(1,2)
VIRULENCE LEVEL(1,2)
ANTIBACTERIAL AGENT IDENTIFICATION(1,1)
ANTIBODY PRESENCE(1,1)
ANTIBODY PRODUCTION(1,1)
ANTIGENICITY(1,1)
BIOLOGICAL PRODUCT ACTIVITY(1,1)
CELL SUSPENSION(1,1)
CHELATING AGENT PROPORTION(1,1)
DEVELOPMENT OBJECTIVE(1,1)
DOCUMENT FOCUS(1,1)
DOUBLE MUTANT(1,1)
FINAL GENETIC MODIFICATION(1,1)
FUR BOX(1,1)
FUR FORMATION(1,1)
FUR GENE INTERNAL REGION(1,1)
GRAM NEGATIVE PATHOGENIC BACTERIUM(1,1)
ICE BATH(1,1)
(US20110104205)
MULTOCIDA(100,41)
VACCINE(100,39)
OUTER MEMBRANE PROTEIN(100,37)
PASTEURELLA MULTOCIDA(100,23)
INFECTION(100,17)
HETEROLOGOUS PROTECTION(100,14)
MUTATED PASTEURELLA MULTOCIDA BACTERIUM(100,9)
HETEROLOGOUS ANIMAL PROTECTION(100,7)
MULTOCIDA FUR CELL(100,2)
FUR OMPH GALE(57,13)
PASTEURELLA MULTOCIDA MUTANT(45,2)
FUR OMPH GALE MUTANT(37,5)
FUR OMPH DOUBLE MUTANT(33,5)
MULTOCIDA MUTANT(32,4)
INFECTIOUS DISEASE(31,2)
FUR EXPRESSION(30,3)
BOVINE PNEUMONIA(30,2)
FUR OMPH GALE GENE(29,2)
BACTERIUM VACCINE(29,1)
FUR OMPH(28,10)
FOWL CHOLERA(28,6)
OMPH GENE(26,8)
PASTEURELLA GENUS(26,1)
TRIPLE MUTANT(25,11)
FUR MUTANT CELL(25,2)
MULTOCIDA FUR OMPH CELL(21,2)
FUR GENE BP(20,1)
POWERFUL ANTIGEN(20,1)
ADJUVANT(18,10)
HEMORRHAGIC SEPTICEMIA(17,3)
ATROPHIC RHINITIS(17,2)
CELL EXTRACT(16,1)
GALEINTP PRIMER(16,1)
LIVE ATTENUATED VACCINE(15,3)
FOOD PRODUCT(15,2)
OMPH(14,23)
EXCIPIENT(14,11)
TRUNCATED PROTEIN(14,5)
DISEASE NATURE(14,1)
GALE INTERNAL FRAGMENT(14,1)
LIVING CELL(14,1)
MUTANT(13,27)
MULTOCIDA FUR MUTANT(13,7)
PATHOGENIC BACTERIUM(13,4)
MULTOCIDA BACTERIUM(13,3)
NONSENSE MUTATION(11,10)
MULTOCIDA FUR OMPH MUTANT(11,3)
OUTER MEMBRANE PROTEIN PREPARATION(11,2)
IROMP(10,8)
ANIMAL(10,7)
PIG(10,5)
INTERRUPTION(10,2)
MULTOCIDA FUR OMPH GALE(10,2)
FUR(9,18)
DISEASE(9,3)
LIVESTOCK(9,2)
CHILD(9,1)
FARMER(9,1)
MAJOR DISEASE CAUSE(9,1)
BACTERIA(8,22)
SONICATION(8,10)
PATHOGEN(8,3)
BACTERIAL INFECTION(8,2)
PASTEURELLA MULTOCIDA OMPH GENE(8,2)
VIRULENCE(7,4)
PASTEURELLA GENUS BACTERIUM(7,2)
DISEASE CONTROL(7,1)
FUR PROTEIN(6,6)
TRIPARENTAL MATING(6,6)
HETEROLOGOUS CHALLENGE(6,4)
GALEINTUP(6,3)
MAMMAL(6,3)
MUTANT FUR OMPH GALE(6,1)
OMPHLAC PHOTOBACTERIUM SPL(6,1)
PHAGE DNA(5,6)
MULTOCIDA CELL(5,5)
ADMINISTRATION(5,4)
BACTERIA CULTURE(5,3)
MAIN ABSENCE(5,3)
EPIDEMIC OUTBREAK(5,2)
HAMSTER(5,2)
LIVE ATTENUATED BACTERIUM(5,2)
MULTOCIDA VACCINATION(5,2)
NEISSERIA MENINGITIDIS(5,2)
OMPH GENE EXPRESSION(5,2)
RABBIT(5,2)
THERMALLY INACTIVATED FUR(5,2)
UNKNOWN ATTENUATION MARKER(5,2)
FUR OMPH MUTANT GENE(5,1)
MULTOCIDA GALE MUTANT(5,1)
PASTEURELLA BACTERIA MUTATION(5,1)
PASTEURELLA MULTOCIDA FUR GENE(5,1)
PASTEURELLA MULTOCIDA GALE GENE(5,1)
PASTEURELLA MULTOCIDA RECA MUTANT(5,1)
PATHOGENIC YERSINIA ENTEROCOLITICA SURVIVAL(5,1)
SUICIDE PLASMID RECOMBINATION(5,1)
AMINOACID(4,9)
VACCINE DEVELOPMENT(4,4)
CATTLE(4,3)
MULTOCIDA STRAIN(4,3)
MUTANT BACTERIA(4,3)
OMPH EXPRESSION(4,3)
PCR AMPLIFICATION(4,3)
MOUSE PERITONITIS(4,2)
ACAPSULAR PASTEURELLA MULTOCIDA(4,1)
ARTICLE OMPH MUTANT(4,1)
ATTENUATED BACTERIA IDENTIFICATION(4,1)
BACTERIA ATTENUATED VACCINE(4,1)
BACTERIAL SPECIES FUR MUTANT(4,1)
BACTERIAL STRAIN VIRULENCE(4,1)
BACTERIAL VIRULENT GENE(4,1)
BACTERIUM ENCODING TRANSCRIPTION FACTOR(4,1)
CATABOLITE ACTIVATOR PROTEIN(4,1)
CHROMOSOMAL DNA PCR ANALYSIS(4,1)
CONTRA LA PASTEURELOSIS(4,1)
DEEP SEA BACTERIUM PHOTOBACTERIUM(4,1)
DEFECTIVE OMPH MUTANT(4,1)
FERRIC UPTAKE REGULATION(4,1)
FERRIC UPTAKE REGULATOR(4,1)
FUR GENE EXPRESSION(4,1)
FUR GENE NUCLEOTIDE(4,1)
FUR GENE TRANSCRIPTION(4,1)
FUR OMPH GALE CELL(4,1)
FUR OMPH STRAIN(4,1)
FUR REINTERPRETATION(4,1)
FUR TITRATION ASSAY(4,1)
GALE MUTATION OBJECTIVE(4,1)
HARLAN IB RICA(4,1)
HOST ORGANISM MUCOSA(4,1)
INACTIVATED FUR OMPH CELL(4,1)
KDA OMPH PROTEIN(4,1)
MULTOCIDA FUR BACTERIUM(4,1)
MULTOCIDA LIVE VACCINE(4,1)
MUTANT OMPH STRAIN(4,1)
OMPH GENE COPY(4,1)
OMPH PROTEIN ROLE(4,1)
PASTEURELLA MULTOCIDA BACTERIN(4,1)
PASTEURELLA MULTOCIDA CHARACTERIZATION(4,1)
PASTEURELLA MULTOCIDA EXBB(4,1)
PASTEURELLA MULTOCIDA MEMBRANE PROTEIN(4,1)
PATHOLOGICALLY IMPORTANT PASTEURELLA SEROTYPE(4,1)
SUBCLINICAL INFECTION SYMPTOM(4,1)
THERMALLY INACTIVATED MUTANT STRAIN(4,1)
TRANSCRIPTIONAL METALLOREGULATION(4,1)
VIRULENT PASTEURELLA MULTOCIDA(4,1)
WEEK SWISS FEMALE MOUSE(4,1)
LANE(3,19)
BARB(3,14)
HEMOGLOBIN(3,6)
OUTER MEMBRANE PROTEIN EXTRACT(3,5)
OVEREXPRESSION(3,4)
DIVALENT CATION CHELATING AGENT(3,3)
LIPOPOLYSACCHARIDE(3,3)
MULTOCIDA OUTER MEMBRANE PROTEIN(3,3)
STOP CODON(3,3)
WILD TYPE GENE(3,3)
BACTERIUM ENVIRONMENT(3,2)
DEFECTIVE FUR(3,2)
FUR MUTATION PRESENCE(3,2)
GALE MUTATION PRESENCE(3,2)
IRON RECEPTOR(3,2)
NEGATIVE BACTERIAL ORGANISM(3,2)
PHYSIOLOGICAL SALINE(3,2)
PLASMID INSERTION(3,2)
PLASMID INTEGRATION(3,2)
TRANSCRIPTIONAL ANALYSIS(3,2)
VACCINE FORMULATION(3,2)
ALF SEQUENCER(3,1)
ANTIBACTERIAL VACCINE(3,1)
ATTENUATED BACTERIA STRAIN PRODUCTION(3,1)
BACTERIA CYTOPLASM(3,1)
BACTERIAL IRON UPTAKE PROTEIN(3,1)
BACTERIAL VIRULENCE(3,1)
BAROPHILIC BACTERIUM(3,1)
BIFUNCTIONAL UREASE(3,1)
CHICKEN HOMOLOGOUS PROTECTION(3,1)
CHROMOSOMAL DNA ANALYSIS(3,1)
DIPYRIDYL DPD(3,1)
ENTITLED LIVE ATTENUATED VACCINE(3,1)
FOLIN PHENOL REAGENT(3,1)
FUR GENE ROLE(3,1)
FUR GENE SEQUENCE(3,1)
FUR HOMOLOG(3,1)
FUR MUTATION STABILITY(3,1)
GALE GENE INTERNAL FRAGMENT(3,1)
GALEINTRP OLIGONUCLEOTIDE(3,1)
GALEINTRP PRIMER(3,1)
GENE DISRUPTION(3,1)
HAEMOPHILUS INFLUENZAE(3,1)
HBPA GENE ENCODING(3,1)
HGBA GENE ENCODING(3,1)
HGBB FUNCTIONAL CHARACTERIZATION(3,1)
HOMOLOGOUS SEROTYPE(3,1)
HYDRATED ALUMINUM HYDROXY PHOSPHATE(3,1)
IMMUNOGENIC HEMIN(3,1)
INACTIVATED PASTEURELLA WHOLE CELL(3,1)
INACTIVATION STRATEGY(3,1)
INTRAPERITONEAL INOCULATION(3,1)
KILLED PATHOGEN(3,1)
L GLUTAMINE(3,1)
LIVE AROA DERIVATIVE(3,1)
MOB MOBILIZATION REGION(3,1)
MULTOCIDA MUTANT GIVE RISE(3,1)
MULTOCIDA SEROTYPE(3,1)
MULTOCIDA VACCINE(3,1)
MUTANT CHARACTERIZATION(3,1)
NATIVE FUR GENE(3,1)
OMPH POLYPEPTIDE(3,1)
OMPH2SEQDW PRIMER(3,1)
OUTER MEMBER PROTEIN(3,1)
PASTEURELLA MULTOCIDA PROTEIN(3,1)
PASTEURELLA ORGANISM(3,1)
PASTEUROLLOSIS VACCINE(3,1)
POLYVALENT VACCINE(3,1)
RECA MUTATION(3,1)
SEEDING BACTERIUM(3,1)
STRAIN THERMALLY INACTIVATED CELL(3,1)
THERMALLY INACTIVATED STRAIN(3,1)
UDP GALACTOSE EPIMERIZATION(3,1)
VACCINATION EFFICACY(3,1)
VACCINE EFFECTIVENESS(3,1)
VETERINARIAN VACCINE(3,1)
VIABLE BACTERIA CONCENTRATION(3,1)
VIRULENT BACTERIA(3,1)
CFU(2,8)
PKO(2,5)
PRIMER POSITION(2,5)
ANTIBIOTIC(2,4)
GALEINT2UP(2,4)
IRON DEFICIENT MEDIUM(2,4)
ALUMINUM HYDROXIDE(2,3)
SBA PLATE(2,3)
SELECTIVE PLATE(2,3)
COADJUVANT(2,2)
EXPOSURE SURFACE(2,2)
IRON REGULATED GENE(2,2)
MONOPHOSPHOLIPID(2,2)
PRIMER SEQUENCE(2,2)
PROTECTION STUDY(2,2)
AMERICAN SOCIETY(2,1)
ANTIGEN PROTECTING(2,1)
ARO GENE(2,1)
ARTICLE ENTITLED EXPRESSION(2,1)
ATTENUATED BACTERIUM CONSTRUCTION(2,1)
ATTENUATED STRAIN(2,1)
BACTERIAL CELL EXPERIENCE(2,1)
BIOLOGICALLY ACTIVE SUBUNIT(2,1)
BLOCKING TRANSCRIPTION(2,1)
BUFFERED PEPTONE(2,1)
CELL DISRUPTION(2,1)
CELL INACTIVATION(2,1)
CLONE OMPH(2,1)
CLONED FRAGMENT(2,1)
COMA GENE(2,1)
DNA RECOGNITION(2,1)
DPD ABSENCE(2,1)
ELECTROPHORETIC PROFILE(2,1)
ELLEN CHI(2,1)
ENTITLED DNA ENCODING(2,1)
ESCHERICHIA GENE(2,1)
FUNCTIONAL MUTATION(2,1)
FUR GENE PRODUCT(2,1)
FUR REGULON(2,1)
GALE GENE PRODUCT(2,1)
GENE CLONING(2,1)
GENE DNA SEQUENCING(2,1)
GLUCOSE ABSENCE(2,1)
GLUTAMINE CODON(2,1)
HEAT INACTIVATION(2,1)
HETEROLOGOUS ATTACK(2,1)
IMMUNITY STUDY(2,1)
INOCULATED EXTRACT VOLUME(2,1)
IRON METABOLISM(2,1)
IRON REGULATED PROTEIN EXPRESSION(2,1)
KDA OMP PROTEIN(2,1)
KDA PORIN(2,1)
KDA PROTEIN(2,1)
KILLED VACCINE(2,1)
LIVE PATHOGEN(2,1)
METABOLIC RESOURCE(2,1)
MULTOCIDA OUTER MEMBRANE PORIN(2,1)
MUTANT ISOLATION(2,1)
NATIVE PROTEIN(2,1)
NEGATIVE PATHOGENIC BACTERIUM(2,1)
OBTAINING BACTERIN(2,1)
OBTAINING VACCINE(2,1)
OMPH SEQUENCE(2,1)
PATHOGEN COMPONENT PURIFICATION(2,1)
PHARMACEUTICAL FORMULATION(2,1)
PIR PROTEIN(2,1)
PLASMID PUA(2,1)
POLYCLONAL ANTIBODY(2,1)
PRECISE DELETION(2,1)
PROGENITOR STRAIN(2,1)
PROTEIN GENE(2,1)
PUA INTERNAL FRAGMENT(2,1)
PURIFIED RECEPTOR(2,1)
PYRIMIDINE PATHWAY(2,1)
REPORTER GENE(2,1)
RNA EXTRACTION(2,1)
RT PCR ANALYSIS(2,1)
SBA AGAR PLATE(2,1)
SHORT TRUNCATED PROTEIN(2,1)
STRAIN DERIVATIVE(2,1)
STREPTOMYCIN RESISTANCE GENE(2,1)
STREPTOMYCIN RESISTANT TRANSCONJUGANT(2,1)
SUSPENSION DILUTION(2,1)
THERMAL INACTIVATION(2,1)
TONB GENE(2,1)
VACCINE DOSE(2,1)
VACCINE PREPARATION(2,1)
VIABLE CELL ABSENCE(2,1)
VIRULENCE REDUCTION(2,1)
WHOLE CELL LYSATE(2,1)
PROTECTION LEVEL(1,4)
ACTIVE SUBSTANCE CONCENTRATION(1,2)
AUTHOR(1,2)
BSTEII(1,2)
COMPLETE GENOMIC SEQUENCE(1,2)
GENOME(1,2)
IDENTITY(1,2)
NUCLEOTIDE CHANGE(1,2)
RDENA(1,2)
RTOMPH2UP(1,2)
VETERINARY MEDICINE(1,2)
VIRULENCE LEVEL(1,2)
ALUMINUM PHOSPHATE(1,1)
ANTIBACTERIAL AGENT IDENTIFICATION(1,1)
ANTIBODY PRESENCE(1,1)
ANTIBODY PRODUCTION(1,1)
ANTIGENICITY(1,1)
BIOLOGICAL PRODUCT ACTIVITY(1,1)
CHELATING AGENT PROPORTION(1,1)
DEVELOPMENT OBJECTIVE(1,1)
DNA DEPENDENT(1,1)
DOCUMENT FOCUS(1,1)
DOUBLE MUTANT(1,1)
(US8685413)
MULTOCIDA(100,51)
OUTER MEMBRANE PROTEIN(100,34)
PASTEURELLA MULTOCIDA(100,23)
HETEROLOGOUS PROTECTION(100,14)
IMMUNOGENIC(100,10)
DEFECTIVE FUR GENE(100,5)
MULTOCIDA FUR CELL(100,2)
MUTANT STRAIN(100,2)
PASTEURELLA MULTOCIDA STRAIN(100,2)
COLECCI N(100,1)
REGISTRATION NUMBER(100,1)
DEFECTIVE OMPH GENE(83,3)
FUR OMPH GALE(62,11)
MULTOCIDA FUR OMPH GALE(61,4)
FUR GENE EXPRESSION(54,3)
FUR OMPH DOUBLE MUTANT(43,5)
DEFECTIVE GALE GENE(39,2)
BACTERIUM VACCINE(39,1)
FUR OMPH GALE GENE(38,2)
MUTANT(36,39)
PASTEURELLA MULTOCIDA MUTANT(36,2)
NONSENSE MUTATION(34,14)
TRIPLE MUTANT(33,11)
TRIPARENTAL MATING(31,8)
INTERNAL NUCLEOTIDE(30,3)
MUTATED MUTANT(29,2)
MULTOCIDA STRAIN(28,5)
FOWL CHOLERA(27,6)
OMPH(26,24)
FUR OMPH(26,9)
POWERFUL ANTIGEN(26,1)
ADJUVANT(24,10)
AMPLIFICATION(23,3)
INFECTIOUS DISEASE(23,2)
GENE(22,21)
BOVINE PNEUMONIA(22,2)
EXTRACTED CELL(22,1)
OBTAINING VACCINE(22,1)
INFECTION(21,12)
OUTER MEMBRANE PROTEIN PREPARATION(21,4)
GALEINTP PRIMER(21,1)
OMPH GENE(20,6)
LIVE ATTENUATED VACCINE(20,3)
ANIMAL(19,14)
TRUNCATED PROTEIN(19,5)
WILD TYPE FUR GENE(19,5)
NUCLEOTIDE(19,3)
DISEASE NATURE(19,1)
LIVING CELL(19,1)
EXCIPIENT(18,11)
MULTOCIDA BACTERIUM(18,3)
MULTOCIDA FUR MUTANT(17,7)
FUR OMPH GALE MUTANT(17,4)
OOMPH(17,1)
MULTOCIDA FUR OMPH MUTANT(15,3)
NUCLEOTIDE POSITION(15,3)
VACCINE(14,30)
DIPYRIDYL(14,1)
OMPH MAIN ABSENCE(14,1)
IROMP(13,8)
HEMORRHAGIC SEPTICEMIA(13,3)
ATROPHIC RHINITIS(13,2)
PRIMER(12,11)
DIVALENT CATION CHELATING AGENT(12,3)
BACTERIA(11,22)
PATHOGEN(11,3)
FOOD PRODUCT(11,2)
OMPH1GENE(11,1)
SONICATION(10,10)
PATHOGENIC BACTERIUM(10,4)
PASTEURELLA GENUS BACTERIUM(10,2)
PASTEURELLA MULTOCIDA OMPH GENE(10,2)
PIG(9,5)
INCREASING SURVIVAL(9,4)
VIRULENCE(9,4)
MUTANT OUTER MEMBRANE PROTEIN(9,2)
FUR PROTEIN(8,6)
HETEROLOGOUS CHALLENGE(8,4)
MUTANT FUR OMPH GALE(8,1)
OMPHLAC PHOTOBACTERIUM SPL(8,1)
FUR(7,15)
PHAGE DNA(7,6)
BACTERIA CULTURE(7,3)
GALEINTUP(7,3)
WILD TYPE GALE GENE(7,3)
HAMSTER(7,2)
LIVE ATTENUATED BACTERIUM(7,2)
NEISSERIA MENINGITIDIS(7,2)
OMPH GENE EXPRESSION(7,2)
THERMALLY INACTIVATED FUR(7,2)
FUR OMPH MUTANT GENE(7,1)
MULTOCIDA GALE MUTANT(7,1)
PASTEURELLA BACTERIA MUTATION(7,1)
PASTEURELLA MULTOCIDA FUR GENE(7,1)
PASTEURELLA MULTOCIDA GALE GENE(7,1)
PASTEURELLA MULTOCIDA RECA MUTANT(7,1)
PATHOGENIC YERSINIA ENTEROCOLITICA SURVIVAL(7,1)
SUICIDE PLASMID RECOMBINATION(7,1)
MULTOCIDA CELL(6,5)
CATTLE(6,3)
LIVE VACCINE(6,3)
MUTANT BACTERIA(6,3)
OMPH EXPRESSION(6,3)
PCR AMPLIFICATION(6,3)
EPIDEMIC OUTBREAK(6,2)
MULTOCIDA VACCINATION(6,2)
RABBIT(6,2)
UNKNOWN ATTENUATION MARKER(6,2)
BACTERIA ATTENUATED VACCINE(6,1)
BACTERIAL SPECIES FUR MUTANT(6,1)
CONTRA LA PASTEURELOSIS(6,1)
MULTOCIDA FUR BACTERIUM(6,1)
MULTOCIDA FUR OMPH CELL(6,1)
THERMALLY INACTIVATED MUTANT STRAIN(6,1)
LANE(5,19)
VACCINE DEVELOPMENT(5,4)
DEFECTIVE FUR(5,2)
FUR MUTATION PRESENCE(5,2)
GALE MUTATION PRESENCE(5,2)
MOUSE PERITONITIS(5,2)
NEGATIVE BACTERIAL ORGANISM(5,2)
PHYSIOLOGICAL SALINE(5,2)
PLASMID INTEGRATION(5,2)
VACCINE FORMULATION(5,2)
ACAPSULAR PASTEURELLA MULTOCIDA(5,1)
ARTICLE OMPH MUTANT(5,1)
ATTENUATED BACTERIA IDENTIFICATION(5,1)
BAC(...)";Pharmaceuticals;Open
"2007-10-31
2008-10-28";"WO2009056541        A1 2009-05-07 [WO200956541]
STG: (A1) Published application with search report
AP : 2008WO-EP64601 2008-10-28
EP2205275           A1 2010-07-14 [EP2205275]
STG: (A1) Application published with search report
AP : 2008EP-0845094 2008-10-28
US20100221275       A1 2010-09-02 [US20100221275]
STG: (A1) Application published
AP : 2008US-12682931 2008-10-28";14984651;"WO2009056541        A1 2009-05-07 [WO200956541]
EP2205275           A1 2010-07-14 [EP2205275]
US20100221275       A1 2010-09-02 [US20100221275]";"2007EP-0119742
2008EP-0845094
2008WO-EP64601";"(EP2205275)
WO2009056541
(US20100221275)
WO2009056541";"NOVARTIS
ROYAL VETERINARY COLLEGE";"NOVARTIS
ROYAL VETERINARY COLLEGE";"(EP2205275)
CH; GB
(US20100221275)
CH
(WO200956541)
CH; GB";"(EP2205275)
NAME=Novartis AG Lichtstrasse 35 , CITY=4056 Basel , COUNTRY=CH 

NAME=Royal Veterinary College Hawkshead Lane  North Mymms , CITY=AL9 7TA Hertfordshire Hatfield , COUNTRY=GB 

(US20100221275)
NAME=Novartis AG , CITY=Basel , COUNTRY=CH , ATYP=Non-US Company 

(WO200956541)
NAME=NOVARTIS AG  Lichtstrasse 35, CH-4056 Basel  , COUNTRY=CH 

NAME=ROYAL VETERINARY COLLEGE  Hawkshead Lane, North Mymms, Hatfield, Hertfordshire AL9 7TA  , COUNTRY=GB 
";2;"BROWNLIE JOE
COLLINS MARGARET
THOMAS CAROLE
THOMPSON IAN";"(EP2205275)
GB";"(EP2205275)
NAME=BROWNLIE, Joe 32 Bluebridge Road Brookmans Park , CITY=Hatfield Hertfordshire AL9 7SA , COUNTRY=GB 

NAME=COLLINS, Margaret 49 Cowbridge Road West , CITY=Cardiff South Wales CF5 5BQ , COUNTRY=GB 

NAME=THOMAS, Carole 43 Westbury Close , CITY=Hitchin Hertfordshire SC5 2NF , COUNTRY=GB 

NAME=THOMPSON, Ian The White House 41 Church Lane Lexden , CITY=Colchester Essex CO3 4AE , COUNTRY=GB 
";"(EP2205275)
Protection of an animal against pestivirus infection";"(EP2205275)
This invention involves compositions and methods for protecting animals from pestivirus infection and for treating animals infected with pestivirus. Pharmaceutical compositions containing E2 and NS3 from a pestivirus are used to protect animals or treat animals.";"(WO200956541)
1. CLAIMS Claim 1. A vaccine comprising recombinant NS3 and recombinant E2 from a pestivirus. Claim 2. The vaccine of Claim 1 wherein said pestivirus is selected from the group consisting of bovine viral diarrhea virus, classical swine fever virus, border disease virus and a combination thereof.
 Claim 3. The vaccine of Claim 1 further comprising an adjuvant. Claim 4. The vaccine of Claim 1 further comprising an antigen from an organism selected from the group consisting of bovine herpes virus type 1 (BHVl), parainfluenza virus type 3 (PI3), bovine respiratory syncytial virus (BRSV), porcine influenza virus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo- prajitno, Leptospira borgpetersenii hardjo-bovis, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira bratislava, Campylobacter fetus, Mannheimia haemolytica, Pasteurella multocida, Mycobacterium bovis,
 Mycobacterium dispar, Mycoplasma dispar, Mycoplasma bovis, Clostridium chauvoei, Clostridium haemolyticum, Clostridium septicum, Clostridium novyi, Clostridium perfringens type C, Clostridium perfringens type D, Clostridium sordellii, Clostridium tetani, Haemophilus somnus, Moraxella bovis, Escherichia coli, Salmonella typhimurium, Bacillus anthracis, Listeria monocytogenes, Actinomyces pyogenes, Ehrlichia bovis, Mycoplasma hyopneumoniae, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae, Leptospria ssp., Brachyspira pilosicoli, Brachyspira hyodysenteriae, Clostridium perfringens type A, swine influenza virus (SIV), porcine reproductive and respiratory syndrome virus (PRRSV), and porcine circovirus (PCV).
 Claim 5. The vaccine of Claim 1 wherein said NS3 and E2 are derived from bovine viral diarrhea virus selected from the group consisting of non-cytopathic bovine viral diarrhea virus, cytopathic bovine viral diarrhea virus and a combination thereof. Claim 6. The vaccine composition of Claim 1 wherein said recombinant NS3 comprises the amino acid sequence of SEQ ID NO: 2.
 Claim 7. The vaccine composition of Claim 1 wherein said recombinant E2 comprises the amino acid sequence of SEQ ID NO: 4. Claim 8. A method for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus, said method comprising: administering to said animal a pharmaceutically effective amount of a composition comprising recombinant NS3 and recombinant E2 from a pestivirus. Claim 9. The method of Claim 8 wherein said pestivirus is selected from the group consisting of bovine viral diarrhea virus, classical swine fever virus, border disease virus and a combination thereof.
 Claim 10. The method of Claim 8 wherein said composition further comprises an adjuvant. Claim 11. The method of Claim 8 wherein said composition further comprises at least one antigen from one other organism, said organism selected from the group consisting of bovine herpes virus type 1 (BHVl), parainfluenza virus type 3 (PI3), bovine respiratory syncytial virus (BRSV), bovine influenza virus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira borgpetersenii hardjo-bovis, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira bratislava, Campylobacter fetus, Mannheimia haemolytica, Pasteurella multocida, Mycobacterium bovis, Mycoplasma dispar, Mycoplasma bovis, Clostridium chauvoei, Clostridium haemolyticum, Clostridium septicum, Clostridium novyi, Clostridium perfringens type C, Clostridium perfringens type D, Clostridium sordellii, Clostridium tetani, Haemophilus somnus, Moraxella bovis, Escherichia coli, Salmonella typhimurium, Bacillus anthracis, Listeria monocytogenes, Actinomyces pyogenes, Ehrlichia bovis, Mycoplasma hyopneumoniae, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae, Leptospria ssp., Brachyspira pilosicoli, Brachyspira hyodys enter iae, Clostridium perfringens type A, swine influenza virus
 (SIV), porcine reproductive and respiratory syndrome virus (PRRSV), and porcine circovirus (PCV).
 Claim 12. The method of Claim 8 wherein said NS3 and E2 are derived from bovine viral diarrhea virus selected from the group consisting of non-cytopathic bovine viral diarrhea virus, cytopathic bovine viral diarrhea virus and a combination thereof.
 Claim 13. The method of Claim 8 wherein said recombinant NS3 comprises the amino acid sequence of SEQ ID NO: 2. Claim 14. The method of Claim 8 wherein said recombinant E2 comprises the amino acid sequence of SEQ ID NO: 4.
 Claim 15. A vaccine comprising a first polypeptide comprising the amino acid sequence of SEQ ID NO: 2 and second polypeptide comprising the amino acid sequence of SEQ ID NO: 4.
 Claim 16. The vaccine of Claim 15 further comprising an adjuvant.
 Claim 17. The vaccine of Claim 15 further comprising an antigen from an organism selected from the group consisting of bovine herpes virus type 1 (BHVl), parainfluenza virus type 3 (PB), bovine respiratory syncytial virus (BRSV), porcine influenza virus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo- prajitno, Leptospira borgpetersenii hardjo-bovis, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira bratislava, Campylobacter fetus, Mannheimia haemolytica, Pasteurella multocida, Mycobacterium bovis, Mycobacterium dispar, Mycoplasma dispar, Mycoplasma bovis, Clostridium chauvoei, Clostridium haemolyticum, Clostridium septicum, Clostridium novyi,
 Clostridium perfringens type C, Clostridium perfringens type D, Clostridium sordellii, Clostridium tetani, Haemophilus somnus, Moraxella bovis, Escherichia coli, Salmonella typhimurium, Bacillus anthracis, Listeria monocytogenes, Actinomyces pyogenes, Ehrlichia bovis, Mycoplasma hyopneumoniae, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae,
 Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae, Leptospria ssp., Brachyspira pilosicoli, Brachyspira hyodysenteriae, Clostridium perfringens type A, swine influenza virus (SIV), porcine reproductive and respiratory syndrome virus (PRRSV), and porcine circovirus (PCV). Claim 18. A vaccine comprising one expression vector comprising the nucleic acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3.
 Claim 19. The vaccine of Claim 18 further comprising an adjuvant.
 Claim 20. A vaccine comprising a first expression vector comprising the DNA sequence of
 SEQ ID NO: 1 and a second expression vector comprising the DNA sequence of SEQ ID NO: 3.
 Claim 21. The vaccine of Claim 20 further comprising an adjuvant.
 Claim 22. A method for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus, said method comprising: administering to said animal a pharmaceutically effective amount of a composition comprising one expression vector comprising the nucleic acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3.
 Claim 23. The method of Claim 22 wherein said composition further comprises an adjuvant. Claim 24. A method for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus, said method comprising: administering to said animal a pharmaceutically effective amount of a composition comprising a first expression vector comprising the DNA sequence of SEQ ID NO: 1 and a second expression vector comprising the DNA sequence of SEQ ID NO: 3. Claim 25. The method of Claim 24 wherein said composition further comprises an adjuvant.
 Claim 26. The method of Claim 24 wherein said first expression vector and said second expression vector are administered at the same time in one or two sites.
 Claim 27. The method of Claim 24 wherein said first expression vector and said second expression vector are administered within a short time period of each other. Claim 28. The method of Claim 27 wherein said short time  period is selected from the group consisting of less than one day, between one and seven days, between one week and four weeks.
 Claim 29. A method for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus, said method comprising: administering to said animal a pharmaceutically effective amount of a composition comprising NS3 with the amino acid sequence of SEQ ID NO: 2 and E2 with the amino acid sequence of SEQ ID NO: 4.
 Claim 30. The method of Claim 29 wherein said composition further comprises an adjuvant.
 Claim 31. The method of Claim 29 wherein said composition further comprises at least one antigen from one other organism, said organism selected from the group consisting of bovine herpes virus type 1 (BHVl), parainfluenza virus type 3 (PI3), bovine respiratory syncytial virus (BRSV), bovine influenza virus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira borgpetersenii hardjo-bovis, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira bratislava, Campylobacter fetus, Mannheimia haemolytica, Pasteurella multocida, Mycobacterium bovis, Mycoplasma dispar, Mycoplasma bovis, Clostridium chauvoei, Clostridium haemolyticum, Clostridium septicum, Clostridium novyi, Clostridium perfringens type C, Clostridium perfringens type D, Clostridium sordellii, Clostridium tetani, Haemophilus somnus, Moraxella bovis, Escherichia coli, Salmonella typhimurium, Bacillus anthracis, Listeria monocytogenes, Actinomyces pyogenes, Ehrlichia bovis, Mycoplasma hyopneumoniae, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae, Leptospria ssp., Brachyspira pilosicoli, Brachyspira hyodysenteriae, Clostridium perfringens type A, swine influenza virus (SIV), porcine reproductive and respiratory syndrome virus (PRRSV), and porcine circovirus (PCV). Claim 32. The use of recombinant E2 and recombinant NS3 from a pestivirus for the manufacture of a medicament for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus.
 Claim 33. The use of Claim 32 wherein said pestivirus is selected from the group consisting of bovine viral diarrhea virus, classical swine fever virus, border disease virus and a combination thereof.
 Claim 34. The use of Claim 32 wherein said recombinant NS3 comprises the amino acid sequence of SEQ ID NO: 2.
 Claim 35. The use of Claim 32 wherein said recombinant E2 comprises the amino acid sequence of SEQ ID NO: 4. Claim 36. The vaccine of Claim 1 wherein said NS3 and E2 are a fusion protein.
 Claim 37. The method of Claim 8 wherein said NS3 and E2 are a fusion protein.";"(US20100221275)
The present invention involves a vaccine (also called immunogenic composition ) against pestivirus, and more preferably against BVDV.
This invention pertains to a cell transfected with a recombinant gene in order to express a polypeptide of the invention.
The present invention further pertains to methods of producing the polypeptides of the invention.";"(US20100221275)
Whatever the reason for the failure, this work demonstrates that E2 and NS3, as individual antigens, did not protect cattle.
Vaccines can be used against bacteria, viruses, fungi, parasites, cancer, autoimmune diseases, and other types of diseases.
For this invention, one can use recombinantly produced E2 and NS3 proteins, E2 and NS3 purified from cells infected with a pestivirus, or DNA encoding E2 and NS3 to protect or treat an animal susceptible to a pestivirus infection, such as CSFV, BVDV, and BDV.";"A61K-039/00
A61K-039/12
A61K-039/295
A61P-031/04
A61P-031/12
A61P-037/04";"(US20100221275)
38. A vaccine comprising recombinant NS3 protein and recombinant E2 protein from a pestivirus.
2 and the E2 protein includes SEQ ID NO: 4.
47. A method for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus, comprising administering to said animal a pharmaceutically effective amount of a composition including recombinant NS3 protein and recombinant E2 protein from a pestivirus.
56. A vaccine comprising one or more expression vectors including the nucleic acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3.
60. A method for preventing or treating a disease caused by a pestivirus in an animal susceptible to infection with a pestivirus, comprising administering to said animal a pharmaceutically effective amount of a composition comprising one or more expression vectors including the nucleic acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3.";"(US20100221275)
PROTEIN(100,56)
ANIMAL(100,49)
PESTIVIRUS(100,42)
VACCINE(100,28)
INFECTION(100,13)
DISEASE(100,8)
PESTIVIRUS INFECTION(100,6)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(100,4)
ANIMAL PROTECTION(100,2)
EXPRESSION VECTOR(88,32)
BORGPETERSENII HARDJO BOVIS(58,4)
LEPTOSPIRA GRIPPOTYPHOSA(57,4)
BRACHYSPIRA PILOSICOLI(56,4)
LEPTOSPIRA INTERROGAN(56,4)
LISTERIA MONOCYTOGENE(56,4)
CLOSTRIDIUM HAEMOLYTICUM(54,4)
CLOSTRIDIUM SORDELLII(53,4)
LEPTOSPIRA CANICOLA(53,4)
SALMONELLA CHOLERAESUIS(52,4)
HAEMOPHILUS SOMNUS(51,4)
LEPTOSPIRA ICTEROHAEMINORRHAGIA(51,1)
CLOSTRIDIUM NOVYI(50,4)
EHRLICHIA BOVIS(50,4)
SALMONELLA TYPHIMURIUM(50,4)
BRACHYSPIRA HYODYSENTERIAC(48,1)
BACILLUS ANTHRACIS(47,4)
LEPTOSPRIA SSP(46,4)
RECOMBINANT GENE(46,1)
MYCOBACTERIUM DISPAR(43,1)
NUCLEIC ACID SEQUENCE(40,11)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(40,3)
BOVINE INFLUENZA VIRUS(39,3)
PASTEURELLA MULTOCIDA(38,8)
BOVINE HERPES VIRUS(37,4)
SYNDROME VIRUS(37,4)
PORCINE INFLUENZA VIRUS(36,1)
BOVINE VIRAL DIARRHEA VIRUS(35,30)
FUSION PROTEIN(32,15)
BORDER DISEASE VIRUS(30,8)
ACTINOBACILLUS PLEUROPNEUMONIAE(29,4)
ERYSIPELOTHRIX RHUSIOPATHIAE(29,4)
BORDETELLA BRONCHISEPTICA(28,4)
ANIMAL TREAT(28,1)
DNA ENCODING(27,7)
MANNHEIMIA HAEMOLYTICA(27,4)
TREATED ANIMAL(27,1)
CLOSTRIDIUM CHAUVOEI(26,4)
CLOSTRIDIUM SEPTICUM(26,4)
HAEMOPHILUS PARASUIS(26,4)
CAMPYLOBACTER FETUS(25,4)
MORAXELLA BOVIS(25,4)
MYCOPLASMA BOVIS(25,4)
MYCOPLASMA DISPAR(25,4)
PORCINE CIRCOVIRUS(25,4)
STREPTOCOCCUS SUIS(25,4)
IMMUNOGENIC(25,3)
MYCOBACTERIUM BOVIS(24,5)
ANTIGEN(23,20)
AUTOIMMUNE DISEASE(23,1)
ACTINOMYCES(21,4)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(21,4)
SWINE INFLUENZA VIRUS(21,4)
PARASITE(19,2)
CSFV(19,1)
FUNGUS(19,1)
CLASSICAL SWINE FEVER VIRUS(18,8)
FETAL BOVINE SERUM(18,4)
BRACHYSPIRA HYODYSENTERIAE(18,3)
CANCER(18,1)
BVDV(17,27)
CLOSTRIDIUM PERFRINGENS TYPE(17,8)
AMERSHAM BIOSCIENCE(17,2)
PRRSV(16,4)
BACTERIA(15,5)
CALF SERUM NEUTRALIZING TITER(15,1)
POST CHALLENGE(14,12)
BHV(14,4)
ORBITAL SHAKER INCUBATOR(14,2)
VIRUS(13,15)
VETERINARY LABORATORY AGENCY(13,2)
AMINOACID SEQUENCE(12,23)
VACCINATED GROUP(12,13)
CATTLE(12,7)
ANTIGEN PURIFICATION(12,4)
DNA VACCINATION(12,4)
HISTIDINE(12,4)
CYTOPLASMIC STAINING(12,3)
IMMUNOPEROXIDASE ASSAY(12,3)
NONSTRUCTURAL PROTEIN(12,3)
VIRUS NEUTRALIZING(12,2)
CHALLENGE NEUTRALIZING TITER(12,1)
NEUTRALIZING ANTIBODY TITER(12,1)
NONCYTOPATHIC VIRUS TITER(12,1)
PEROXIDASE CONJUGATED ANTI BOVINE IGG2(12,1)
VIRUS ISOLATION(11,5)
BACULOVIRUS EXPRESSION VECTOR(11,2)
CALF POST VACCINATION(11,2)
NI NTA AGAROSE(11,2)
NONCYTOPATHIC BVDV(11,2)
AUTOMATED HEMATOLOGIC ANALYZER(11,1)
GLYCOLYTIC ENZYME(11,1)
HORSERADISH PEROXIDASE CONJUGATED ANTI BOVINE(11,1)
PEROXIDASE CONJUGATED ANTI BOVINE IGG1(11,1)
PEROXIDASE CONJUGATED ANTI BOVINE IGM(11,1)
SIGMA(10,25)
BUFFY COAT(10,3)
NASAL SWAB(10,3)
PFU POLYMERASE(10,3)
ANTI BOVINE IGG CLONE(10,1)
BIOMETRA MINIGEL TANK(10,1)
CALF EXCRETING VIRUS(10,1)
LYMPHOCYTE PROLIFERATION ASSAY(10,1)
PESTIVIRUS GENOME(10,1)
RESTRICTION ENDONUCLEASE NDEI(10,1)
SUBUNIT ANTIGEN VACCINE(10,1)
TRANSFECTION SUPERNATANT DILUTION(10,1)
NASAL MUCOSA(9,9)
ANTIBIOTIC ANTIMYCOTIC(9,5)
MEAN STIMULATION(9,3)
PCR PRIMER(9,3)
VIRAL VECTOR(9,3)
WARM MEM(9,3)
ACUTE BVDV INFECTION(9,1)
BVDV NA VE(9,1)
COOMASSIE BRILLIANT BLUE(9,1)
HOMOLOGOUS ORGANISM PROTEIN(9,1)
POLYPEPTIDE MAXIMIZING EXPRESSION(9,1)
QIAQUICK GEL EXTRACTION KIT(9,1)
RUMINANT PATHOGEN(9,1)
SAMPLE NEUTRALIZING TITER(9,1)
WALLAC MICROBETA TRILUX(9,1)
WASHING(8,13)
AM BIOTECHNOLOGY(8,2)
BACULOVIRUS TRANSFER VECTOR(8,2)
COLI XLI BLUE CELL(8,2)
ELISA ANTIBODY(8,2)
HOMOLOGOUS VIRUS(8,2)
INSECT CELL INFECTION(8,2)
KY CODING SEQUENCE(8,2)
PURIFIED PROTEIN(8,2)
QIAGEN SPIN(8,2)
RECOMBINANT VIRUS(8,2)
SPRINGER VERLAG(8,2)
TITER STOCK(8,2)
VACCINE DOSE(8,2)
WESTERN BLOT(8,2)
ANTI BVDV HYPERIMMUNE SERUM(8,1)
ANTIBODY NEUTRALIZATION(8,1)
BACULOVIRUS COTRANSFECTION(8,1)
BAMHI DIGESTED INSERT(8,1)
BIOMETRA FASTBLOT(8,1)
BVDV MAJOR GENOTYPE(8,1)
BVDV VIRUS STRAIN(8,1)
CI 3H THYMIDINE(8,1)
DIMETHYLODECYLAMMONIUM BROMIDE(8,1)
FETAL BOVINE LUNG(8,1)
FINAL PLASMID DIGEST(8,1)
HOLSTEIN FRIESIAN CATTLE(8,1)
HOST ORGANISM TRANSFORMATION(8,1)
INFECTED CATTLE(8,1)
LINEARIZED PMELBAC(8,1)
LINEARIZED VECTOR DNA(8,1)
MURYAMYL DIPEPTIDE(8,1)
NA VE CALF(8,1)
NA VE CATTLE(8,1)
OPTIMAL MICROPLATE READER(8,1)
PESTIVIRUS GENUS(8,1)
PLASMID DNA EXTRACTION(8,1)
POLYPEPTIDE EPITOPE(8,1)
POLYPEPTIDE OVEREXPRESSION(8,1)
POXVIRUS PROTEIN(8,1)
RESTRICTION ENZYME DIGEST(8,1)
RUMINANT PESTIVIRUS INFECTION(8,1)
SALI RESTRICTION ENZYME SITE(8,1)
STREPTAVIDIN HORSERADISH(8,1)
SUPERFOS BIOSECTOR(8,1)
TRITERPENOID GLYCOSIDE(8,1)
VIRUS FOLD SERIAL DILUTION(8,1)
CENTRIFUGATION(7,6)
STATISTICALLY SIGNIFICANT DIFFERENCE(7,6)
CELL PELLET(7,3)
BAMHI INSERT(7,2)
ELEVATED SCORE(7,2)
ISOLATED POLYNUCLEOTIDE(7,2)
LB BROTH(7,2)
LIGATION BUFFER(7,2)
NORMAL PORCINE SERUM(7,2)
PLAQUE ASSAY(7,2)
RANDOM HEXAMER(7,2)
SECONDARY ANTIBODY(7,2)
STIMULATION INDEX(7,2)
UNINFECTED CELL(7,2)
ABBOTT CELL DYN(7,1)
AEROMONAS SPP(7,1)
ANTIGEN STIMULATION(7,1)
ANTISENSE PRIMER(7,1)
AVRIDINE LIPID(7,1)
BACULOVIRUS AGAROSE(7,1)
BAMHI CLONING SITE(7,1)
BIOTINYLATED MONOCLONAL(7,1)
BVDV INFECTED FBL CELL(7,1)
CALF DEMONSTRATING(7,1)
CALF SEROCONVERT(7,1)
CATTLE VACCINATION(7,1)
DAB PEROXIDASE SUBSTRATE(7,1)
DENSITOMETRIC ANALYSIS(7,1)
DNA ENCODING PROTEIN POLYPEPTIDE(7,1)
ESCHERICHIA SPP(7,1)
FD COAT PROTEIN(7,1)
FLAVIVIRIDAE FAMILY(7,1)
HETEROLOGOUS INFECTION(7,1)
IMMEDIATE EARLY PROMOTER(7,1)
IMMUNOAFFINITY PURIFICATION(7,1)
IMMUNOFLUORESCENCE ASSAY(7,1)
IMMUNOFLUORESCENT ASSAY(7,1)
INFECTED ANIMAL TISSUE(7,1)
INSECT CELL MONOLAYER(7,1)
INSECTIN LIPOSOME(7,1)
LABILE ENTEROTOXIN(7,1)
LYSATE VACCINE PREPARATION(7,1)
MONOPHOSORYL LIPID(7,1)
NI NTA SLURRY(7,1)
OPTIMIZED POLYNUCLEOTIDE(7,1)
PROPHYLACTIC EFFICACY(7,1)
PROTEIN ASSAY KIT(7,1)
RECOMBINANT BACULOVIRUS(7,1)
RECOMBINANT POLYPEPTIDE(7,1)
SALMONELLA SPP(7,1)
SHRIMP ALKALINE PHOSPHATASE(7,1)
SOFTMAX PRO VERSION(7,1)
SPEARMAN KARBER CALCULATION(7,1)
TISSUE CULTURE H2O(7,1)
TRANSMEMBRANE ANCHOR(7,1)
UNINFECTED SF9 CELL SUPERNATANT(7,1)
YEAST PROMOTER(7,1)
PCR PRODUCT(6,5)
PREGNANCY(6,5)
AMPICILLIN(6,4)
COLONY(6,4)
GLUTAMINE(6,4)
STERILE WATER(6,4)
BIOLOGICAL ACTIVITY(6,2)
ACID PHOSPHATASE PROMOTER(6,1)
ADSORPTION DELAYING(6,1)
AMMONIUM CHLORIDE LYSIS(6,1)
ANTIBIOTIC MARKER(6,1)
ANTIGEN DILUTION(6,1)
BACULOVIRAL DNA(6,1)
BETHYL LABORATORY(6,1)
CALF RESPONDING(6,1)
CARBOXY TERMINUS(6,1)
CDNA CLONE(6,1)
CELLULAR ORGANELLE(6,1)
CHIMERIC PROTEIN(6,1)
CHOLERA TOXIN(6,1)
CLEARED LYSATE(6,1)
CLINICAL SEVERITY(6,1)
CONSTRUCT INTEGRITY(6,1)
CONTAMINANT SPECIES(6,1)
CULTURE INFECTION(6,1)
CULTURE SUPERNATANT(6,1)
DAY POST INFECTION(6,1)
DISEASE SYMPTOM(6,1)
ELUTION BUFFER FRACTION(6,1)
ENCODED PROTEIN(6,1)
ENCODING EXPRESSION VECTOR(6,1)
ENZYME DIGESTION(6,1)
EUKARYOTIC EXPRESSION SEQUENCE(6,1)
EX VIVO SHELF LIFE(6,1)
GEL FILTRATION CHROMATOGRAPHY(6,1)
HETEROLOGOUS STRAIN(6,1)
HETEROLOGOUS VIRUS INFECTION(6,1)
INCOMPLETE ADJUVANT(6,1)
INTRA LYMPH NODE(6,1)
INTRANASAL ROUTE(6,1)
LEUCINE REPLACEMENT(6,1)
LOG FLASK(6,1)
LYMPHOCYTE DIRECT INFECTION(6,1)
MINPREP DNA(6,1)
PAA LABORATORY(6,1)
PBR 322 DERIVED PLASMID(6,1)
PHARMACOLOGICALLY ACCEPTABLE CARRIER(6,1)
PLAQUE STOCK(6,1)
PLASMID ENCODING(6,1)
POLYNUCLEOTIDE CONSTRUCT(6,1)
POLYPEPTIDE PURITY(6,1)
PROTEIN CONCENTRATION ESTIMATE(6,1)
PROTEOLYTIC DEGRADATION(6,1)
PURIFIED ANTIGEN SAMPLE(6,1)
PURIFIED LYMPHOCYTE(6,1)
PURIFIED POLYNUCLEOTIDE(6,1)
PURIFIED POLYPEPTIDE(6,1)
RECIPIENT PLASMID(6,1)
SALI DIGESTION(6,1)
SCINTILLATION ANALYZER(6,1)
SHIGELLA SPP(6,1)
SUBCUTANEOUS ROUTE(6,1)
SYNTHETIC GLYCOPEPTIDE(6,1)
TERM POLYPEPTIDE FRAGMENT(6,1)
TRANSCRIPTION TERMINATION SEQUENCE(6,1)
VACCINATED CALF RESPONSE(6,1)
VARIANT POLYPEPTIDE ABILITY(6,1)
VIRAL CHALLENGE(6,1)
VIRUS EXCRETION(6,1)
VIRUS TITRATION(6,1)
FALCON(5,6)
COMPARISON WINDOW(5,3)
CONSERVATIVE AMINOACID SUBSTITUTION(5,3)
HEIFER(5,3)
IGG2 LEVEL(5,3)
PRIMARY ANTIBODY(5,3)
TAQ POLYMERASE(5,3)
BACTERIAL CELL(5,2)
CARBONATE COATING(5,2)
HOST ANIMAL(5,2)
IGG2 RATIO RANGING(5,2)
IMMUNOGLOBULIN ISOTYPE(5,2)
ISOTONIC AGENT(5,2)
LB AGAR(5,2)
LIGASE BUFFER(5,2)
LYSIS BUFFER(5,2)
MODIFIED POLYPEPTIDE(5,2)
NORMAL RABBIT SERUM(5,2)
OPD SUBSTRATE(5,2)
PCR ANALYSIS(5,2)
SPIN COLUMN(5,2)
SYNTHETIC ORIGIN(5,2)
TERM REGULATORY SEQUENCE(5,2)
5M EDTA(5,1)
ACUTE INFECTION(5,1)
AGAROSE PLUG(5,1)
ALIPHATIC NON POLAR GROUP(5,1)
AMINE ADJUVANT(5,1)
AMINE FUNCTIONALITY(5,1)
BACTERIAL COMPONENT ADJUVANT(5,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(5,1)
BVDV STRAIN(5,1)
CALF SHOW PROLIFERATION(5,1)
CELLULAR DEBRIS(5,1)
CLINICAL EVALUATION(5,1)
CODING SEQUENCE EXPRESSION(5,1)
COMPUTATIONAL ANALYSIS(5,1)
DEXTRAN SULFATE(5,1)
DISEASE ANIMAL(5,1)
ESSENTIAL HOMOGENEITY(5,1)
ESTABLISHED LYMPHOCYTE PROLIFERATION RESPONSE(5,1)
EXPRESSION VECTOR CARRIER(5,1)
FUNCTIONAL HOMOLOG(5,1)
FUNCTIONAL POLYPEPTIDE EQUIVALENT(5,1)
GENOMIC DNA(5,1)
GLASSFIBRE FILTER(5,1)
GROUP EXPERIENCED PYREXIA(5,1)
GROUP VIRUS VACCINE(5,1)
HOST CELL CHOICE(5,1)
IGEPAL CA(5,1)
IGG1 CONCENTRATION(5,1)
IGM CONCENTRATION(5,1)
IMMUNOBLOT DETECTION(5,1)
ISOLATED POLYPEPTIDE(5,1)
JUNCTION INTEGRITY(5,1)
LEUCOPENIA EXTENT(5,1)
MAJOR CLINICAL SIGN(5,1)
MEAN NASAL DISCHARGE SCORE(5,1)
MEDICAMENT MANUFACTURE(5,1)
MOLECULAR DIAGNOSTICS(5,1)
MUCOSAL TISSUE UPTAKE(5,1)
NASAL DISCHARGE ONSET(5,1)
OBSERVATION REMAINDER(5,1)
PARTIAL PROTECTIVE IMMUNITY(5,1)
PCR DIRECTED MUTATION(5,1)
PCR ROUND(5,1)
PHAGE LAMBDA PROMOTER REGION(5,1)
PLAQUE DETECTION(5,1)
PLASMID PREPARATION(5,1)
POLYNUCLEOTIDE SEQUENCE TRANSCRIPTION(5,1)
PROTECTIVE ANTIGEN(5,1)
PROTEIN(5,1)
PSTI INSERT(5,1)
PTRCHIS DERIVED PLASMID(5,1)
PURITY DETERMINATION(5,1)
RADIOACTIVE COUNT(5,1)
RESTRICTION SITE(5,1)
SAMPLE NEUTRALIZATION ABILITY(5,1)
SAP ENZYME(5,1)
SEQUENCE CONSERVATION(5,1)
SEQUENCE IDENTITY PERCENTAGE(5,1)
SKIMMED MILK POWDER(5,1)
SODIUM PYRUVATE(5,1)
STRANDED RNA VIRUS(5,1)
SUPPLIED BSA DILUTION(5,1)
SUSPENSION CULTURE(5,1)
TERM CONSERVED RESIDUE(5,1)
THERAPEUTIC(5,1)
TISSUE CULTURE TECHNOLOGY(5,1)
TRNA MOLECULE(5,1)
VIRUS DETECTION(5,1)
VIRUS ESTABLISHMENT PERIOD(5,1)
GOAT(4,5)
REAGENT(4,5)
SHEEP(4,5)
DILUENT(4,4)
FINAL VOLUME(4,4)
HEPES(4,4)
NPS(4,4)
SEPARATE PROTEIN(4,4)
DNA VACCINE(4,3)
COVERSLIP(4,2)
DEXTROSE(4,2)
ELECTROPHORESIS(4,2)
FINAL CONCENTRATION(4,2)
MODIFIED EAGLE MEDIUM(4,2)
MOLAR BASIS(4,2)
MONOCLONAL ANTIBODY(4,2)
ORTHOLOG(4,2)
PARALOG(4,2)
PBLUEBACHISN(4,2)
PIGLET(4,2)
SEROCONVERSION(4,2)
SUBUNIT VACCINE(4,2)
SUPERSCRIPT UNIT(4,2)
VIRUS CLEARANCE RATE(4,2)
WHOLE BLOOD(4,2)
05M SODIUM ACETATE BUFFER(4,1)
ACIDIC FUNCTIONALITY(4,1)
ADAPTED SPODOPTERA FRUGIPERDA(4,1)
AGAROSE GEL(4,1)
ALUMINUM HYDROXIDE GEL(4,1)
ALUMINUM PHOSPHATE(4,1)
ANAMNESTIC RESPONSE(4,1)
ANIMAL CELL(4,1)
BACULOVIRUS SYSTEM POLYHEDRON PROMOTER(4,1)
BLUE DNA(4,1)
BVDV DNA SEQUENCE(4,1)
CALCULATION QUANTITY(4,1)
CDNA SAMPLE(4,1)
COLD PBS(4,1)
COLI CELL(4,1)
CORRECT INSERT ORIENTATION(4,1)
CORRECTED COUNT(4,1)
CYTOPATHOGENICITY(4,1)
EXPRESSION VECTOR DESIGN(4,1)
FINAL CALF(4,1)
FLUORESCENT MOUNTING(4,1)
FUNCTIONAL FRAGMENT(4,1)
FUSION SEQUENCE(4,1)
IMMUNODETECTION(4,1)
ISOPROPANOL VOLUME(4,1)
KINASE BUFFER(4,1)
LEUCOCYTE(4,1)
LIGATION MIXTURE(4,1)
LIMITING PYREXIA(4,1)
LOW NEUTRALIZING TITER(4,1)
LYSATE VOLUME(4,1)
MAJOR GLYCOPROTEIN(4,1)
MAMMALIAN CELL(4,1)
MINUTE WASH(4,1)
NATURAL ORIGIN(4,1)
OLFACTORY ORGAN TRANSPORT MEDIUM(4,1)
PCR CONDITION(4,1)
PCR REACTION(4,1)
PET DERIVED PLASMID(4,1)
PLANT OPTIMIZED VERSION(4,1)
PROLIFERATIVE RESPONSE(4,1)
PROPIONIBACTERIUM(4,1)
PUC DERIVED PLASMID(4,1)
PURIFIED FRACTION(4,1)
RECOMBINANT PROTEIN BAND(4,1)
RECOMBINANTLY PRODUCED PROTEIN(4,1)
REDUCED VIRUS ESTABLISHMENT(4,1)
RESPONDER(4,1)
REVERSE PRIMER(4,1)
ROLLER FLASK(4,1)
SAP BUFFER(4,1)
SCORING(4,1)
SDS LOADING(4,1)
SEQUENCE IDENTITY TERM PERCENTAGE(4,1)
SEQUENCE VERSION(4,1)
SERUM SAMPLE(4,1)
SF9 CELL LYSATE(4,1)
STANDARD CURVE DATA(4,1)
STEREOISOMER(4,1)
TAQ BUFFER(4,1)
TNM FH MEDIUM(4,1)
TRANSFER VECTOR GIVING(4,1)
VIRUS RE(4,1)
WASH BUFFER(4,1)
ACETONE(3,3)
AQUEOUS PHASE(3,3)
BOAR(3,3)
BULL(3,3)
CELL RESPONSE(3,3)
DNA LIGASE(3,3)
EUKARYOTIC CELL(3,3)
SOW(3,3)
STERILE DISTILLED WATER(3,3)
DELETION(3,2)
RECOMBINANT DNA(3,2)
TEMPLATE(3,2)
ADENOVIRUS(3,1)
ALIGNED SEQUENCE(3,1)
ALIPHATIC GROUP(3,1)
ALUMINUM SALT(3,1)
AMINOACID NORMALIZED FREQUENCY(3,1)
AMPHIBIAN(3,1)
ANIMAL OIL(3,1)
(WO200956541)
VACCINE(100,30)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(100,4)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(91,6)
BORGPETERSENII HARDJO BOVIS(91,5)
LEPTOSPIRA GRIPPOTYPHOSA(85,6)
BRACHYSPIRA PILOSICOLI(84,6)
LEPTOSPIRA INTERROGAN(84,6)
LISTERIA MONOCYTOGENE(84,6)
CLOSTRIDIUM HAEMOLYTICUM(81,6)
PESTIVIRUS(79,48)
CLOSTRIDIUM SORDELLII(79,6)
LEPTOSPIRA CANICOLA(79,6)
SALMONELLA CHOLERAESUIS(78,6)
HAEMOPHILUS SOMNUS(76,6)
CLOSTRIDIUM NOVYI(74,6)
EHRLICHIA BOVIS(74,6)
SALMONELLA TYPHIMURIUM(74,6)
BACILLUS ANTHRACIS(72,6)
EXPRESSION VECTOR(71,31)
CLOSTRIDIUM PERFRINGENS(70,18)
LEPTOSPRIA SSP(70,6)
BORDER DISEASE VIRUS(66,9)
BOVINE VIRAL DIARRHEA VIRUS(61,28)
MYCOBACTERIUM DISPAR(61,2)
BOVINE INFLUENZA VIRUS(59,4)
PASTEURELLA MULTOCIDA(57,12)
BOVINE HERPES VIRUS(56,6)
SYNDROME VIRUS(56,6)
PORCINE INFLUENZA VIRUS(51,2)
ACTINOBACILLUS PLEUROPNEUMONIAE(44,6)
ERYSIPELOTHRIX RHUSIOPATHIAE(44,6)
BORDETELLA BRONCHISEPTICA(42,6)
CLASSICAL SWINE FEVER VIRUS(40,9)
MANNHEIMIA HAEMOLYTICA(40,6)
CLOSTRIDIUM CHAUVOEI(39,6)
CLOSTRIDIUM SEPTICUM(39,6)
HAEMOPHILUS PARASUIS(39,6)
CAMPYLOBACTER FETUS(37,6)
MORAXELLA BOVIS(37,6)
MYCOPLASMA BOVIS(37,6)
MYCOPLASMA DISPAR(37,6)
PORCINE CIRCOVIRUS(37,6)
STREPTOCOCCUS SUIS(37,6)
MYCOBACTERIUM BOVIS(35,8)
BRACHYSPIRA HYODYSENTERIAE(35,5)
ACTINOMYCES(33,6)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(33,6)
SWINE INFLUENZA VIRUS(33,6)
ANIMAL(32,52)
FUSION PROTEIN(32,15)
DISEASE(30,11)
ANTIGEN(29,21)
INFECTION(29,16)
AMINOACID SEQUENCE(26,30)
CATTLE(26,7)
IMMUNOGENIC(25,3)
AUTOIMMUNE DISEASE(23,1)
MEDICAMENT MANUFACTURE(22,2)
SUBUNIT VACCINE(20,2)
RECOMBINANT E(19,10)
PARASITE(19,2)
FUNGUS(19,1)
PROTEIN(18,50)
DNA SEQUENCE(18,7)
CANCER(18,1)
PESTIVIRUS INFECTION(17,5)
VACCINATED CALF(16,5)
FETAL BOVINE SERUM(16,3)
BACTERIA(15,5)
CALF SERUM NEUTRALIZING TITER(15,1)
VIRUS(14,17)
NUCLEIC ACID SEQUENCE(14,5)
ORBITAL SHAKER INCUBATOR(14,2)
DAY POST CHALLENGE(13,7)
MAMMAL(13,7)
VETERINARY LABORATORY AGENCY(13,2)
VACCINATED GROUP(12,12)
ANTIGEN PURIFICATION(12,4)
DNA VACCINATION(12,4)
CYTOPLASMIC STAINING(12,3)
IMMUNOPEROXIDASE ASSAY(12,3)
PHOSPHATE BUFFERED SALINE(12,3)
AUTOMATED HAEMATO LOGICAL ANALYZER(12,1)
CHALLENGE NEUTRALIZING TITER(12,1)
NEUTRALIZING ANTIBODY TITER(12,1)
VIRUS ISOLATION(11,5)
BACULOVIRUS EXPRESSION VECTOR(11,2)
CALF POST VACCINATION(11,2)
NI NTA AGAROSE(11,2)
SIGMA(10,25)
REGULATORY SEQUENCE(10,6)
BUFFY COAT(10,3)
NASAL SWAB(10,3)
PFU POLYMERASE(10,3)
AMERSHAM BIOSCIENCE(10,2)
NCP INFECTED CELL(10,2)
BIOMETRA MINIGEL TANK(10,1)
CALF EXCRETING VIRUS(10,1)
FREUND INCOMPLETE ADJUVANT(10,1)
PESTIVIRUS GENOME(10,1)
PROTECTION AGAINT VIRAL CHALLENGE(10,1)
SUBUNIT ANTIGEN VACCINE(10,1)
TRANSFECTION SUPERNATANT DILUTION(10,1)
TRYPTOPHAN MICROPLATE READER(10,1)
VIRUS NEUTRALIZING SERUM(10,1)
WESTERN BLOT DENSITOMETRIC ANALYSIS(10,1)
NASAL MUCOSA(9,9)
MEAN STIMULATION(9,3)
NONSTRUCTURAL PROTEIN(9,3)
PCR PRIMER(9,3)
VIRAL VECTOR(9,3)
ACUTE BVDV INFECTION(9,1)
COOMASSIE BRILLIANT BLUE(9,1)
HOMOLOGOUS ORGANISM PROTEIN(9,1)
LEPTOSPIRA BORGPETERSENII(9,1)
PLAQUE PL STOCK(9,1)
POLYPEPTIDE MAXIMIZING EXPRESSION(9,1)
QIAQUICK GEL EXTRACTION KIT(9,1)
RUMINANT PATHOGEN(9,1)
SAMPLE NEUTRALIZING TITER(9,1)
WALLAC MICROBETA TRILUX(9,1)
WASHING(8,13)
ANTIBIOTIC ANTIMYCOTIC(8,4)
AM BIOTECHNOLOGY(8,2)
BACULOVIRUS TRANSFER VECTOR(8,2)
ELISA ANTIBODY(8,2)
HOMOLOGOUS VIRUS(8,2)
INSECT CELL INFECTION(8,2)
QIAGEN SPIN(8,2)
RECOMBINANT VIRUS(8,2)
TITER STOCK(8,2)
VACCINE DOSE(8,2)
ANTI BVDV HYPERIMMUNE SERUM(8,1)
ANTIBODY NEUTRALIZATION(8,1)
BACULOVIRUS COTRANSFECTION(8,1)
BAMHI DIGESTED INSERT(8,1)
BIOMETRA FASTBLOT(8,1)
BVDV MAJOR GENOTYPE(8,1)
BVDV NAVE(8,1)
BVDV VIRUS STRAIN(8,1)
DIMETHYLODECYLAMMONIUM BROMIDE(8,1)
FINAL PLASMID DIGEST(8,1)
FLUORESCENT IMMUNOASSAY(8,1)
HOLSTEIN FRIESIAN CATTLE(8,1)
HOST ORGANISM TRANSFORMATION(8,1)
INFECTED CATTLE(8,1)
LINEARIZED PMELBAC(8,1)
LINEARIZED VECTOR DNA(8,1)
LIPID AMINE ADJUVANT(8,1)
MURYAMYL DIPEPTIDE(8,1)
PLASMID DNA EXTRACTION(8,1)
POLYPEPTIDE EPITOPE(8,1)
RESTRICTION ENZYME DIGEST(8,1)
RUMINANT PESTIVIRUS INFECTION(8,1)
STREPTAVIDIN HORSERADISH(8,1)
SUPERFOS BIOSECTOR(8,1)
TRITERPENOID GLYCOSIDE(8,1)
CENTRIFUGATION(7,6)
STATISTICALLY SIGNIFICANT DIFFERENCE(7,6)
CELL PELLET(7,3)
CONSERVATIVE AMINOACID SUBSTITUTION(7,3)
NORMAL RABBIT SERUM(7,3)
BAMHI INSERT(7,2)
BVDV STRAIN(7,2)
ELEVATED SCORE(7,2)
ISOLATED POLYNUCLEOTIDE(7,2)
ISOLATED POLYPEPTIDE(7,2)
LB BROTH(7,2)
LIGATION BUFFER(7,2)
NORMAL PORCINE SERUM(7,2)
PLAQUE ASSAY(7,2)
RANDOM HEXAMER(7,2)
SECONDARY ANTIBODY(7,2)
SEQUENCE IDENTITY PERCENTAGE(7,2)
UNINFECTED CELL(7,2)
ABBOTT CELL DYN(7,1)
AEROMONAS SPP(7,1)
ANTIGEN STIMULATION(7,1)
ANTISENSE PRIMER(7,1)
BAMHI CLONING SITE(7,1)
BIOTINYLATED MONOCLONAL(7,1)
CALF DEMONSTRATING(7,1)
CALF SEROCONVERT(7,1)
DAB PEROXIDASE SUBSTRATE(7,1)
DNA ENCODING PROTEIN POLYPEPTIDE(7,1)
ESCHERICHIA SPP(7,1)
FD COAT PROTEIN(7,1)
GLYCOLYTIC ENZYME(7,1)
HETEROLOGOUS INFECTION(7,1)
IMMEDIATE EARLY PROMOTER(7,1)
IMMUNOAFFINITY PURIFICATION(7,1)
IMMUNOFLUORESCENCE ASSAY(7,1)
INFECTED ANIMAL TISSUE(7,1)
INSECT CELL MONOLAYER(7,1)
INSECTIN LIPOSOME(7,1)
LABILE ENTEROTOXIN(7,1)
LYSATE VACCINE PREPARATION(7,1)
MUTATION BACULOVIRUS(7,1)
NI NTA SLURRY(7,1)
OPTIMIZED POLYNUCLEOTIDE(7,1)
PEROXIDASE CONJUGATE(7,1)
POLYHEDRON PROMOTER(7,1)
PRIMER PMOL(7,1)
PROPHYLACTIC EFFICACY(7,1)
PROTEIN ASSAY KIT(7,1)
RECOMBINANT POLYPEPTIDE(7,1)
SALMONELLA SPP(7,1)
SPEARMAN KARBER CALCULATION(7,1)
TRANSMEMBRANE ANCHOR(7,1)
UNINFECTED SF9 CELL SUPERNATANT(7,1)
YEAST PROMOTER(7,1)
PCR PRODUCT(6,5)
PREGNANCY(6,5)
COLONY(6,4)
COMPARISON WINDOW(6,3)
BIOLOGICAL ACTIVITY(6,2)
LB AGAR(6,2)
ACID PHOSPHATASE PROMOTER(6,1)
ADSORPTION DELAYING(6,1)
ANTI BOVINE IGG CLONE(6,1)
ANTIBIOTIC MARKER(6,1)
ANTIGEN DILUTION(6,1)
BACULOVIRAL DNA(6,1)
BACULOVIRUS AGAROSE(6,1)
BETHYL LABORATORY(6,1)
CALF RESPONDING(6,1)
CARBOXY TERMINUS(6,1)
CDNA CLONE(6,1)
CELLULAR ORGANELLE(6,1)
CHIMERIC PROTEIN(6,1)
CHOLERA TOXIN(6,1)
CLEARED LYSATE(6,1)
CLINICAL SEVERITY(6,1)
CONSTRUCT INTEGRITY(6,1)
CONTAMINANT SPECIES(6,1)
CULTURE INFECTION(6,1)
CULTURE SUPERNATANT(6,1)
DEAE DEXTRAN(6,1)
DISEASE SYMPTOM(6,1)
ELUTION BUFFER FRACTION(6,1)
ENCODED PROTEIN(6,1)
ENCODING EXPRESSION VECTOR(6,1)
ENZYME DIGESTION(6,1)
EUKARYOTIC EXPRESSION SEQUENCE(6,1)
EX VIVO SHELF LIFE(6,1)
FUNCTIONAL HOMOLOG(6,1)
GEL FILTRATION CHROMATOGRAPHY(6,1)
HETEROLOGOUS STRAIN(6,1)
HETEROLOGOUS VIRUS INFECTION(6,1)
INTRANASAL ROUTE(6,1)
KY CODING SEQUENCE(6,1)
LOG FLASK(6,1)
LYMPHOCYTE DIRECT INFECTION(6,1)
MANUFACTURER INSTRUCTION(6,1)
MINPREP DNA(6,1)
NAVE CALF(6,1)
NAVE CATTLE(6,1)
PBR 322 DERIVED PLASMID(6,1)
PHARMACOLOGICALLY ACCEPTABLE CARRIER(6,1)
POLYNUCLEOTIDE CONSTRUCT(6,1)
POLYPEPTIDE FRAGMENT(6,1)
POLYPEPTIDE PURITY(6,1)
POXVIRUS PROTEIN(6,1)
PROTEIN CONCENTRATION ESTIMATE(6,1)
PROTEOLYTIC DEGRADATION(6,1)
PURIFIED ANTIGEN SAMPLE(6,1)
PURIFIED LYMPHOCYTE(6,1)
PURIFIED POLYNUCLEOTIDE(6,1)
PURIFIED POLYPEPTIDE(6,1)
PURIFIED PROTEIN(6,1)
RECIPIENT PLASMID(6,1)
RECOMBINANT BACULOVIRUS(6,1)
RECOMBINANT GENE(6,1)
RESPONSE LYMPHOPROLIFERATION ASSAY(6,1)
RESTRICTION ENDONUCLEASE(6,1)
RESTRICTION ENZYME SITE(6,1)
SCINTILLATION ANALYZER(6,1)
SHIGELLA SPP(6,1)
SOFTMAX PRO VERSION(6,1)
SPRINGER VERLAG(6,1)
SUBCUTANEOUS ROUTE(6,1)
SYNTHETIC GLYCOPEPTIDE(6,1)
TRANSCRIPTION TERMINATION SEQUENCE(6,1)
VARIANT POLYPEPTIDE ABILITY(6,1)
VIRUS EXCRETION(6,1)
VIRUS TITRATION(6,1)
FALCON(5,6)
HEIFER(5,3)
IGG2 LEVEL(5,3)
NONCYTOPATHIC BVDV(5,3)
PRIMARY ANTIBODY(5,3)
STERILE WATER(5,3)
TAQ POLYMERASE(5,3)
BACTERIAL CELL(5,2)
CARBONATE COATING BUFFER(5,2)
HOST ANIMAL(5,2)
IGG2 RATIO RANGING(5,2)
IMMUNOGLOBULIN ISOTYPE(5,2)
ISOTONIC AGENT(5,2)
LIGASE BUFFER(5,2)
MODIFIED POLYPEPTIDE(5,2)
PCR ANALYSIS(5,2)
REAGENT ML(5,2)
SPIN COLUMN(5,2)
STIMULATION INDEX(5,2)
SYNTHETIC ORIGIN(5,2)
ACUTE INFECTION(5,1)
AGAROSE PLUG(5,1)
ALIPHATIC NON POLAR GROUP(5,1)
AMINE FUNCTIONALITY(5,1)
ANTI BOVINE IGG2(5,1)
ANTI BOVINE IGGL(5,1)
BACTERIAL COMPONENT ADJUVANT(5,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(5,1)
CALF SHOW PROLIFERATION(5,1)
CELLULAR DEBRIS(5,1)
CHALLENGE DAY(5,1)
CODING SEQUENCE EXPRESSION(5,1)
COLI XLI BLUE CELL(5,1)
COMPUTATIONAL ANALYSIS(5,1)
CONSERVED RESIDUE(5,1)
DAY POST INFECTION(5,1)
DISEASE ANIMAL(5,1)
ESSENTIAL HOMOGENEITY(5,1)
ESTABLISHED LYMPHOCYTE PROLIFERATION RESPONSE(5,1)
EXPRESSION VECTOR CARRIER(5,1)
FREUND COMPLETE ADJUVANT(5,1)
GENOMIC DNA(5,1)
GLASSFBRE FILTER(5,1)
GROUP EXPERIENCED PYREXIA(5,1)
HOST CELL CHOICE(5,1)
IGGL CONCENTRATION(5,1)
IGM CONCENTRATION(5,1)
IMMUNOBLOT DETECTION(5,1)
ISOLEUCINE(5,1)
JUNCTION INTEGRITY(5,1)
LEUCOPENIA EXTENT(5,1)
MAJOR CLINICAL SIGN(5,1)
MEAN NASAL DISCHARGE SCORE(5,1)
MOLECULAR DIAGNOSTICS(5,1)
MUCOSAL TISSUE UPTAKE(5,1)
NASAL DISCHARGE ONSET(5,1)
OBSERVATION REMAINDER(5,1)
PARTIAL PROTECTIVE IMMUNITY(5,1)
PBST HORSERADISH PEROXIDASE(5,1)
PCR DIRECTED MUTATION(5,1)
PCR ROUND(5,1)
PHAGE LAMBDA PROMOTER REGION(5,1)
PLAQUE DETECTION(5,1)
PLASMID PREPARATION(5,1)
POLYNUCLEOTIDE SEQUENCE TRANSCRIPTION(5,1)
PROTECTIVE ANTIGEN(5,1)
PSTL INSERT(5,1)
PTRCHIS DERIVED PLASMID(5,1)
PURITY DETERMINATION(5,1)
RADIOACTIVE COUNT(5,1)
RESTRICTION SITE(5,1)
SAMPLE NEUTRALIZATION ABILITY(5,1)
SAP ENZYME(5,1)
SEQUENCE CONSERVATION(5,1)
SKIMMED MILK POWDER(5,1)
SUSPENSION CULTURE(5,1)
THERAPEUTIC(5,1)
TISSUE CULTURE TECHNOLOGY(5,1)
TRNA MOLECULE(5,1)
VIRUS DETECTION(5,1)
VIRUS ESTABLISHMENT PERIOD(5,1)
WASH CY(5,1)
RPM(4,15)
GOAT(4,5)
SHEEP(4,5)
DILUENT(4,4)
HEPES(4,4)
SEPARATE PROTEIN(4,4)
SUBJECT AMINOACID SEQUENCE(4,4)
DNA VACCINE(4,3)
COVERSLIP(4,2)
DEXTROSE(4,2)
ELECTROPHORESIS(4,2)
FINAL CONCENTRATION(4,2)
MODIFIED EAGLE MEDIUM(4,2)
MOLAR BASIS(4,2)
ORTHOLOG(4,2)
PARALOG(4,2)
PBLUEBACHISN(4,2)
PIGLET(4,2)
SEROCONVERSION(4,2)
SUPERSCRIPT UNIT(4,2)
VIRUS CLEARANCE RATE(4,2)
WHOLE BLOOD(4,2)
ACIDIC FUNCTIONALITY(4,1)
ADAPTED SPODOPTERA FRUGIPERDA(4,1)
AGAROSE GEL(4,1)
AMMONIUM CHLORIDE LYSIS BUFFER(4,1)
ANAMNESTIC RESPONSE(4,1)
ANIMAL CELL(4,1)
ANIMAL PROTECTION(4,1)
ANTI BOVINE IGM(4,1)
ANTIGEN SPECIFIC T CELL(4,1)
AU ANIMAL(4,1)
BLUE DNA(4,1)
CALCULATION QUANTITY(4,1)
CO DELIVERY(4,1)
COLI CELL(4,1)
CORRECT INSERT ORIENTATION(4,1)
CORRECTED COUNT(4,1)
CYTOPATHOGENICITY(4,1)
EXPRESSION VECTOR DESIGN(4,1)
FINAL CALF(4,1)
FLUORESCENT MOUNTING(4,1)
FUNCTIONAL FRAGMENT(4,1)
FUSION SEQUENCE(4,1)
GRACE MEDIUM(4,1)
IMMUNODETECTION(4,1)
KINASE BUFFER(4,1)
LEUCOCYTE(4,1)
LIGATION MIXTURE(4,1)
LIMITING PYREXIA(4,1)
LOW NEUTRALIZING TITER(4,1)
LYSATE VOLUME(4,1)
MAMMALIAN CELL(4,1)
MINUTE WASH(4,1)
NATURAL ORIGIN(4,1)
NONCYTOPATHIC VIRUS TITER(4,1)
NORMALIZED FREQUENCY(4,1)
OLFACTORY ORGAN TRANSPORT MEDIUM(4,1)
OX BUFFER(4,1)
PCR CONDITION(4,1)
PCR REACTION(4,1)
PET DERIVED PLASMID(4,1)
PLANT OPTIMIZED VERSION(4,1)
PROLIFERATIVE RESPONSE(4,1)
PROPIONIBACTERIUM(4,1)
PUC DERIVED PLASMID(4,1)
PURIFIED FRACTION(4,1)
RECOMBINANT PROTEIN BAND(4,1)
RECOMBINANTLY PRODUCED PROTEIN(4,1)
REDUCED VIRUS ESTABLISHMENT(4,1)
RESPONDER(4,1)
ROLLER FLASK(4,1)
SAP BUFFER(4,1)
SCORING(4,1)
SEQUENCE VERSION(4,1)
SERUM SAMPLE(4,1)
SF9 CELL LYSATE(4,1)
STANDARD CURVE DATA(4,1)
STEREOISOMER(4,1)
TEN FOLD SERIAL DILUTION(4,1)
TISSUE CULTURE H(4,1)
TNM FH MEDIUM(4,1)
TRANSFER VECTOR GIVING(4,1)
VIRUS RE(4,1)
WASH BUFFER(4,1)
ACETONE(3,3)
AQUEOUS PHASE(3,3)
BOAR(3,3)
BULL(3,3)
EUKARYOTIC CELL(3,3)
FINAL VOLUME(3,3)
SOW(3,3)
T4 DNA LIGASE(3,3)
DELETION(3,2)
RECOMBINANT DNA(3,2)
TEMPLATE(3,2)
ADENOVIRUS(3,1)
ALIGNED SEQUENCE(3,1)
ALIPHATIC GROUP(3,1)
ALUMINUM HYDROXIDE GEL(3,1)
ALUMINUM SALT(3,1)
AMINOACID MATCH PROPORTION(3,1)
AMPHIBIAN(3,1)
ANIMAL OIL(3,1)
ANTIBACTERIAL(3,1)
AVRIDINE(3,1)
BASE MATCH PROPORTION(3,1)";Pharmaceuticals;Open
2007-04-27;"RU2337706           C1 2008-11-10 [RU2337706]
STG: (C1) Patent for invention
AP : 2007RU-0116013 2007-04-27";36265822;RU2337706           C1 2008-11-10 [RU2337706];2007RU-0116013;;RUSSIAN ACADEMY OF AGRICULTURAL SCIENCES;RUSSIAN ACADEMY OF AGRICULTURAL SCIENCES;;;1;"KAZAKOV NIKOLAJ AFANAS EVICH
ZABLOTSKIJ VJACHESLAV TITOVICH
MUTUZKINA ZINAIDA PETROVNA";;;"(RU2337706)
Method of antigen production for cattle and small cattle anaplasmosis vaccine preparation, method of anaplasmosis vaccine preparation, anaplasmosis vaccine and method of cattle and small cattle anaplasmosis prevention";"(RU2337706)
FIELD: medicine; veterinary science. ^ SUBSTANCE: method of antigen production includes passage of agent Anaplasma marginale for susceptible cattle, cattle splenectomy followed by infection with infected Anaplasma marginale blood, exsanguination of infected animal and blood mixing with anticoagulant, centrifuge separation of plasma from erythrocytes, erythrocyte washing to remove remained plasma with physiologic saline, erythrocyte destruction, centrifuge removal of destroyed erythrocyte stroma and leukocytes. Thus centrifuge separation of plasma from erythrocytes is carried out at 3000 - 3500 rpm within 10-15 minutes. Erythrocyte washing to remove remained plasma in physiologic saline is triple centrifugation at the same modes. Erythrocyte destruction is carried out through triple freezing and defrosting. Produced lysed erythrocytes with released Anaplasmas are mixed with tenfold amount of sterile physiologic saline. Removal destroyed erythrocyte stroma and leukocytes is performed through triple centrifugation at g=5000-6000 during 45-60 min to have pure deposit Anaplasma marginale. Produced deposit is added with sterile physiologic saline. Mixture is shuttled within 3-6 hours, filtered, and anaplasma antigen is produced. Method of vaccine preparation includes suspending of produced antigen in concentration 55-75 billion anaplasmas in 1 ml with protein content 12-15 mg/ml in adjuvant. Produced suspension is additionally added with antibiotic. Vaccine contains produced antigen in amount 40-51.7 wt % and antibiotic. Animals are vaccinated with prepared vaccine hypodermically in dose 1-2 ml/gol or intradermally in dose 0.2 ml/gol twice every 30-45 days. ^ EFFECT: ecologically safe inactivated stable emulsified vaccine provides long and intense immunity. ^ 17 cl, 3 ex";"(RU2337706)
1. The Method of preparing the antigen for the preparation of vaccine against anaplasmosis of large and small livestock, which includes the passage of the agent Of Anaplasma of marginale on receptive large livestock, to splenektomiyu of large livestock with their subsequent infection by that infected Of Anaplasma of marginale by the blood, the exsanguination of the infected animal and mixing the blood with the anticoagulant, separation of plasma from erythrocytes by centrifugation, the washing of erythrocytes from the remainders of plasma by physiological solution, the destruction of erythrocytes, the removal of the stroma of the destroyed erythrocytes and leukocytes by centrifugation with obtaining of the anaplazmennogo antigen, that is characterized by the fact that the centrifugation with separation of plasma from erythrocytes is achieved with 3000-3500 r/min during 10-15 min, the washing of erythrocytes from the remainders of plasma in the physiological solution carry out by triple centrifugation with the same regimes, the destruction of erythrocytes accomplish by triple freezing and thawing, obtained thus the lizirovannye erythrocytes with the freed of them anaplasmas are mixed up with a 10-fold quantity of sterile physiological solution, the removal of the stroma of the destroyed erythrocytes and leukocytes is carried out by triple centrifugation with g=5000-6000 during 45-60 min before obtaining of clean sediment Of Anaplasma of marginale, sterile physiological solution is added into the obtained sediment, they shutteliruyut mixture for 3-6 h even they filter, obtaining thus the anaplazmennyy antigen.
2. Method according to claim 1, that is characterized by the fact that the exsanguination of the infected animal is achieved on the peak of the damage of the erythrocytes of the blood, which composes 40-90%.
3. Method according to claim 1, that is characterized by the fact that 15-25% solution of citric-acid sodium are used as the anticoagulant.
4. Method according to claim 1, that is characterized by the fact that freezing the infected erythrocytes is accomplished at a temperature (- 3÷-20) of °S for 10-14 h, and thawing - at room temperature.
5. Method according to claim 1, that is characterized by the fact that the sterile physiological solution into the sediment Of Anaplasma of marginale is added in the half volume from the volume of the erythrocytes undertaken for lizirovaniya.
6. The Method of preparing the vaccine against anaplasmosis of large and small livestock, which includes the suspension of the antigen Of Anaplasma of marginale in adyuvante, which is characterized by the fact that use the antigen, obtained on any of pp. 1-5, the concentrations of 55-75 billion anaplasmas in 1 ml with the content of protein 12-15 mg/ml, into the obtained suspension additionally introduce antibiotic.
7. Method according to claim 6, that is characterized by the fact that as the adjuvant is used the mixture of light mineral oil with the waterless lanoline in the relationship 6:1, with the relationship of antigen to the adjuvant - 1,07: 1.
8. Method according to claim 6, that is characterized by the fact that as the adjuvant use a mixture of markola - 52 with the emulsifier - 139 in the relationship 9:1, with the relationship of antigen to adjuvant 1:1.
9. Method according to claim 6, that is characterized by the fact that as the adjuvant is used the adjuvant VNIIZZH in quantity 57-60%.
10. Method according to claim 6, that is characterized by the fact that as the antibiotic is used gentamicin sulfate, either neomycin sulfate or the mixture of penicillin with streptomycin in relationship 1:1, in this case each of the antibiotics indicated introduce from the calculation 100-150 YED on 1 ml of vaccine.
11. Vaccine against anaplasmosis of large and small livestock, containing antigen Anaplasma of marginale and adjuvant, that is characterized by the fact that as the antigen it contains the antigen, obtained on any of pp. 1-5, in quantity 40-51,7 mas.%, and additionally antibiotic.
12. Vaccine according to claim 11, that is characterized by the fact that as the adjuvant it contains light mineral oil in quantity 41,4 mas.% and waterless lanoline - 6,9 mas.%, in this case the content of antigen in the vaccine composes 51,7 mas.%.
13. Vaccine according to claim 11, that is characterized by the fact that as the adjuvant it contains Markol - 52 in quantity 45 mas.% and emulsifier - 139-5 mas.%, in this case the content of antigen in the vaccine composes 50 mas.%.
14. Vaccine according to claim 11, that is characterized by the fact that as the adjuvant it contains adjuvant VNIIZZH in quantity 57-60 mas.%.
15. Vaccine on p. by 11, that is characterized by the fact that as the antibiotic it contains gentamicin sulfate, either neomycin sulfate or the mixture of penicillin with streptomycin in relationship 1:1, in this case antibiotic is contained from the calculation 100-150 YED on 1 ml of vaccine.
16. Vaccine according to claim 11, that is characterized by the fact that the content of protein is 3,7-4,1 mg/ml.
17. The Method of the preventive maintenance of anaplasmosis of large and small livestock by the vaccination of animals, that is characterized by the fact that vaccination achieve by the vaccine, described in pp. 11-16, in this case the vaccine of any adjuvant version introduce hypodermically at the dose 1-2 ml/gol or it is intracutaneous at the dose of 0.2 ml/gol doubly with the interval of 30-45 days.";;;A61K-039/00;;;Pharmaceuticals;Open
"2007-03-26
2008-03-25";"CL2008000856        A1 2008-05-30 [CL0856200800]
STG: (A1) Patent application
AP : 2008CL-0000856 2008-03-25
WO2008118902        A1 2008-10-02 [WO2008118902]
STG: (A1) Published application with search report
AP : 2008WO-US58109 2008-03-25
US20080241192       A1 2008-10-02 [US20080241192]
STG: (A1) Application published
AP : 2008US-12079117 2008-03-25
FD :  Provisional Appl: US60/919,997 FDD=2007-03-26 [2007US-60919997]
TW200902056         A  2009-01-16 [TW200902056]
STG: (A) Laid open application for patent or patent of addition
AP : 2008TW-0110845 2008-03-26";4699859;"CL2008000856        A1 2008-05-30 [CL0856200800]
WO2008118902        A1 2008-10-02 [WO2008118902]
US20080241192       A1 2008-10-02 [US20080241192]
TW200902056         A  2009-01-16 [TW200902056]";"2007US-60919997
2008US-12079117";;"HUI SHI
WYETH";WYETH;"(US20080241192)
US
(WO2008118902)
US";"(US20080241192)
NAME=Wyeth , CITY=Madison , STATE=NJ , COUNTRY=US , ATYP=US Company 

(WO2008118902)
NAME=WYETH  Five Giralda Farms, Madison, New Jersey 07940  , COUNTRY=US 

NAME=KUMAR, Mahesh  2910 22nd Avenue N., Fort Dodge, Iowa 50501  , COUNTRY=US 

NAME=ANSCHUTZ, Christine  305 East Vest Street, Jefferson, Iowa 50129  , COUNTRY=US 

NAME=TIAN, Jean Q.  3023 North 14th Street, Fort Dodge, Iowa 50501  , COUNTRY=US 
";1;"KUMAR MAHESH
ANSCHUTZ CHRISTINE
TIAN JEAN Q";"(US20080241192)
US";"(US20080241192)
NAME=Kumar Mahesh , CITY=Fort Dodge , STATE=IA , COUNTRY=US 

NAME=Anschutz Christine , CITY=Jefferson , STATE=IA , COUNTRY=US 

NAME=Tian Jean Q. , CITY=Fort Dodge , STATE=IA , COUNTRY=US 
";"(US20080241192)
Vaccination against multiple serotypes of pasteurella multocida";"(US20080241192)
The present invention provides methods for inducing cross-protective immunity against virulent strains of P. multocida in animals such as cattle and poultry. The methods of the invention include administering to an animal a mutant P. multocida strain, whereby the mutant P. multocida strain induces cross-protective immunity against one or more virulent P. multocida strains having serotypes that are different from the serotype of the mutant P. multocida strain. The mutant P. multocida strain will preferably contain one or more mutations that cause the cells to be acapsular and/or attenuated. Exemplary mutations include, e.g., mutations that impair the expression of one or more genes in the P. multocida capsule biosynthetic operon (e.g., phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hexB, and/or hexA).";"(WO2008118902)
WHAT IS CLAIMED IS:
1. A method for inducing cross-protective immunity against virulent P. multocida, said method comprising administering to an animal a mutant P. multocida;
 wherein said mutant P. multocida contains one or more mutations that cause said mutant P. multocida to be acapsular, and wherein said one or more mutations cause said mutant P. multocida to be attenuated;
 wherein said mutant P. multocida induces protective immunity in said animal against said virulent P. multocida; and
 wherein said virulent P. multocida has a serotype that is different from the serotype of said mutant P. multocida.
2. The method of claim 1 , wherein said mutant P. multocida additionally induces protective immunity in said animal against a virulent P. multocida having a serotype that is the same as the serotype of said mutant P. multocida.
3. The method of claim 1 , wherein said mutant P. multocida has a serotype selected from the group consisting of: A:1 , A:3, A:4, and A:3x4.
4. The method of claim 3, wherein said mutant P. multocida is an A:1 P. multocida strain.
5. The method of claim 4, wherein said virulent P. multocida is an A:3, A:4 or A:3x4 P. multocida strain.
6. The method of claim 5, wherein said mutant A:1 P. multocida strain additionally induces protective immunity in said animal against a virulent A:1 P. multocida strain.
7. The method of claim 4, wherein said mutant A:1 P. multocida strain induces protective immunity in said animal against virulent A:3, A:4 and A:3x4 P. multocida strains.
8. The method of claim 7, wherein said mutant A:1 P. multocida strain induces protective immunity in said animal against virulent A:1 , A:3, A:4 and A:3x4 P. multocida strains.
9. The method of claim 3, wherein said mutant P. multocida is an A:3 P. multocida strain.
10. The method of claim 9, wherein said virulent P. multocida is an A:1 , A:4 or A:3x4 P. multocida strain.
11. The method of claim 10, wherein said mutant A:3 P. multocida strain additionally induces protective immunity in said animal against a virulent A:3 P. multocida strain.
12. The method of claim 9, wherein said mutant A:3 P. multocida strain induces protective immunity in said animal against virulent A:1 , A:4 and A:3x4 P. multocida strains.
13. The method of claim 12, wherein said mutant A:3 P. multocida strain induces protective immunity in said animal against virulent A:1 , A:3, A:4 and A:3x4 P. multocida strains.
14. The method of claim 1 , wherein said animal is a bird.
15. The method of claim 1 , wherein said animal is an ungulate.
16. The method of claim 14, wherein said bird is a poultry bird.
17. The method of claim 16, wherein said poultry bird is a chicken, turkey, ostrich, game hen, squab, guinea fowl, pheasant, quail, duck, goose, or emu.
18. The method of claim 16, wherein said poultry bird is a chicken.
19. The method of claim 18, wherein said mutant P. multocida is an A:3 P. multocida strain.
20. The method of claim 2, wherein said poultry bird is a turkey.
21. The method of claim 20, wherein said mutant P. multocida is an A:1 P. multocida strain.
22. The method of claim 1 , wherein said one or more mutations is a mutation that impairs the expression of one or more genes in the P. multocida capsule biosynthetic operon.
23. The method of claim 8, wherein said one or more genes in the P. multocida capsule biosynthetic operon is a gene selected from the group consisting of phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hexB, and hexA.
24. The method of claim 8, wherein said one or more mutations is an insertion, substitution, or a deletion mutation within the coding sequence of a gene selected from the group consisting of phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hex B, and hex A.
25. The method of claim 8, wherein said one or more mutations is a deletion of all or part of the coding sequence of a gene selected from the group consisting of phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hexB, and hexA.
26. The method of claim 11 , wherein said one or more mutations is a deletion of all or part of the coding sequence of the hyaE gene.
27. A method for inducing cross-protective immunity in a chicken against a virulent A:1 P. multocida strain, said method comprising administering to said chicken an attenuated acapsular mutant A:3 P. multocida strain.
28. The method of claim 27, wherein said attenuated acapsular mutant A:3 P. multocida strain comprises a hyaE mutation in its genome.
29. A method for inducing cross-protective immunity in a turkey against a virulent A:3 P. multocida strain, said method comprising administering to said turkey an attenuated acapsular mutant A:1 P. multocida strain.
30. The method of claim 29, wherein said attenuated acapsular mutant A:1 P. multocida strain comprises a hyaE mutation in its genome.
31. A method for inducing cross-protective immunity against a virulent P. multocida, said method comprising administering to an animal a first dose of mutant P. multocida at a first time point, followed by administering to said animal a second dose of said mutant P. multocida at a second time point,
 wherein said mutant P. multocida contains one or more mutations that cause said mutant P. multocida to be acapsular, and wherein said one or more mutations cause said mutant P. multocida to be attenuated;
 wherein said mutant P. multocida induces protective immunity in said animal against said virulent P. multocida; and
 wherein said virulent P. multocida has a serotype that is different from the serotype of said mutant P. multocida.
32. The method of claim 31 , wherein said mutant P. multocida additionally induces protective immunity in said animal against a virulent P. multocida having a serotype that is the same as the serotype of said mutant P. multocida.
33. The method of claim 31 , wherein said mutant P. multocida has a serotype selected from the group consisting of A:1 , A:3, A:4, and A:3x4.
34. The method of claim 33, wherein said mutant P. multocida is an A:1 P. multocida strain.
35. The method of claim 34, wherein said virulent P. multocida is an A:3, A:4 or A:3x4 P. multocida strain.
36. The method of claim 35, wherein said mutant A:1 P. multocida strain additionally induces protective immunity in said animal against a virulent A:1 P. multocida strain.
37. The method of claim 34, wherein said mutant A:1 P. multocida strain induces protective immunity in said animal against virulent A:3, A:4 and A:3x4 P. multocida strains.
38. The method of claim 37, wherein said mutant A:1 P. multocida strain induces protective immunity in said animal against virulent A:1 , A:3, A:4 and A:3x4 P. multocida strains.
39. The method of claim 33, wherein said mutant P. multocida is an A:3 P. multocida strain.
40. The method of claim 39, wherein said virulent P. multocida is an A:1 , A:4 or A:3x4 P. multocida strain.
41. The method of claim 40, wherein said mutant A:3 P. multocida strain additionally induces protective immunity in said animal against a virulent A:3 P. multocida strain.
42. The method of claim 39, wherein said mutant A:3 P. multocida strain induces protective immunity in said animal against virulent A:1 , A:4 and A:3x4 P. multocida strains.
43. The method of claim 42, wherein said mutant A:3 P. multocida strain induces protective immunity in said animal against virulent A:1 , A:3, A:4 and A:3x4 P. multocida strains.
44. The method of claim 31 , wherein said animal is a bird.
45. The method of claim 31 , wherein said animal is an ungulate.
46. The method of claim 44, wherein said bird is a poultry bird.
47. The method of claim 46, wherein said poultry bird is a chicken, turkey, ostrich, game hen, squab, guinea fowl, pheasant, quail, duck, goose, or emu.
48. The method of claim 46, wherein said poultry bird is a chicken.
49. The method of claim 46, wherein said poultry bird is a turkey.
50. The method of claim 31 , wherein said one or more mutations is a mutation that impairs the expression of one or more genes in the P. multocida capsule biosynthetic operon.
51. The method of claim 50, wherein said one or more genes in the P. multocida capsule biosynthetic operon is a gene selected from the group consisting of phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hexB, and hexA.
52. The method of claim 50, wherein said one or more mutations is an insertion, substitution, or a deletion mutation within the coding sequence of a gene selected from the group consisting of phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hexB, and hex A.
53. The method of claim 50, wherein said one or more mutations is a deletion of all or part of the coding sequence of a gene selected from the group consisting of phyB, phyA, hyaE, hyaD, hyaC, hyaB, hexD, hexC, hexB, and hexA.
54. The method of claim 53, wherein said one or more mutations is a deletion of all or part of the coding sequence of the hyaE gene.
55. The method of claim 31 , wherein said first dose comprises from about 1x102to about 1x108cfu of mutant P. multocida.
56. The method of claim 55, wherein said first dose comprises from about 1x104to about 1x106cfu of mutant P. multocida.
57. The method of claim 56, wherein said first dose comprises about 1x106cfu of mutant P. multocida.
58. The method of claim 31 , wherein said second dose comprises from about 1x102to about 1x108cfu of mutant P. multocida.
59. The method of claim 58, wherein said second dose comprises from about 1x104to about 1x106cfu of mutant P. multocida.
60. The method of claim 59, wherein said second dose comprises about 1x106cfu of mutant P. multocida.
61. The method of claim 46, wherein said first time point occurs before said poultry bird is hatched, and said first dose is administered in ovo.
62. The method of claim 61 , wherein said first time point is between day 1 and day 26 of incubation of said poultry bird in ovo.
63. The method of claim 46, wherein said first time point is between 1 day of age and 10 weeks of age of said poultry animal.
64. The method of claim 63, wherein said first time point is between 4 weeks of age and 10 weeks of age of said poultry animal.
65. The method of claim 64, wherein said first time point is between 6 weeks of age and 8 weeks of age of said poultry animal.
66. The method of claim 46, wherein said second time point is between 1 day of age and 20 weeks of age of said poultry animal.
67. The method of claim 66, wherein said second time point is between 5 weeks of age and 20 weeks of age of said poultry animal.
68. The method of claim 67, wherein said second time point is between 12 weeks of age and 18 weeks of age of said poultry animal.";"(US20080241192)
The present invention relates to vaccines that are effective against virulent strains of P. multocida.
The present invention provides methods for inducing cross-protective immunity against virulent strains of P. multocida in animals such as cattle and poultry.
Accordingly, the present invention provides methods for inducing cross-protective immunity against multiple serotypes of P. multocida.
In one embodiment, the invention provides methods for inducing cross-protective immunity against a virulent P. multocida strain.";"(US20080241192)
The methods of the present invention are useful for inducing cross-protective immunity in animals against virulent P. multocida strains.
For example, there exists a need in the art for vaccination methods in which an attenuated strain of P. multocida provides cross-protective immunity against infection by virulent strains of P. multocida having serotypes that are different from the serotype of the attenuated P. multocida strain.
The methods of the present invention are useful for inducing protective immunity in animals such as birds, and ungulates.
For example, P. multocida is known to cause hemorrhagic septicemia in ungulates, atrophic rhinitis in swine, and fowl cholera in wild and domestic birds.";"A61K-039/102
A61P-031/04
C07K-014/32
C12N-015/31";"(US20080241192)
1. A method for inducing cross-protective immunity against virulent P. multocida, said method comprising administering to an animal a mutant P. multocida; wherein said mutant P. multocida contains one or more mutations that cause said mutant P. multocida to be acapsular, and wherein said one or more mutations cause said mutant P. multocida to be attenuated; wherein said mutant P. multocida induces protective immunity in said animal against said virulent P. multocida; and wherein said virulent P. multocida has a serotype that is different from the serotype of said mutant P. multocida.
27. A method for inducing cross-protective immunity in a chicken against a virulent A:1 P. multocida strain, said method comprising administering to said chicken an attenuated acapsular mutant A:3 P. multocida strain.
29. A method for inducing cross-protective immunity in a turkey against a virulent A:3 P. multocida strain, said method comprising administering to said turkey an attenuated acapsular mutant A:1 P. multocida strain.
31. A method for inducing cross-protective immunity against a virulent P. multocida, said method comprising administering to an animal a first dose of mutant P. multocida at a first time point, followed by administering to said animal a second dose of said mutant P. multocida at a second time point, wherein said mutant P. multocida contains one or more mutations that cause said mutant P. multocida to be acapsular, and wherein said one or more mutations cause said mutant P. multocida to be attenuated; wherein said mutant P. multocida induces protective immunity in said animal against said virulent P. multocida; and wherein said virulent P. multocida has a serotype that is different from the serotype of said mutant P. multocida.";"(US20080241192)
MULTOCIDA(100,133)
MULTOCIDA STRAIN(100,64)
VACCINATION(100,25)
CHICKEN(100,20)
CROSS PROTECTIVE IMMUNITY(100,19)
PASTEURELLA MULTOCIDA SEROTYPE(100,1)
MULTOCIDA CAPSULE BIOSYNTHETIC OPERON(75,10)
ATTENUATED ACAPSULAR MUTANT(72,4)
PROTECTIVE IMMUNITY(53,26)
POULTRY BIRD(47,12)
MUTATION(36,32)
AGE WEEK(35,14)
POULTRY ANIMAL(33,6)
SEROTYPE(32,32)
ANIMAL(29,41)
HYAE GENE CODING SEQUENCE(28,2)
MUTANT(27,56)
VIRULENT STRAIN(27,11)
GENE EXPRESSION(24,5)
HYAE MUTATION(24,2)
DOMESTIC BIRD(22,1)
DOSE(19,9)
FOWL CHOLERA(17,3)
UNGULATE(16,8)
MUTANT DOSE(16,6)
MUTANT SEROTYPE(16,4)
GAME HEN(16,3)
ATTENUATED STRAIN(16,2)
PHYB(15,6)
AGE DAY(14,2)
BIRD(11,37)
HEMORRHAGIC SEPTICEMIA(11,2)
ATROPHIC RHINITIS(10,2)
GENOME(10,2)
MULTOCIDA INFECTION(9,9)
DELETION MUTATION(9,4)
GUINEA FOWL(9,3)
MULTOCIDA HYAE MUTANT(9,3)
OSTRICH(9,3)
PHEASANT(9,3)
VACCINE(8,22)
MULTOCIDA CELL(8,13)
DISEASE SYMPTOM(8,6)
POULTRY(8,5)
GOOSE(8,3)
QUAIL(8,3)
SQUAB(8,3)
SEROTYPE MULTOCIDA ACAPSULAR MUTANT(8,1)
WILD(8,1)
CATTLE(7,4)
DUCK(7,3)
EMU(7,3)
MULTOCIDA MUTANT STRAIN(7,3)
PATHOLOGICAL LESION SEVERITY(7,2)
CAPSULE POLYSACCHARIDE DEPOLYMERIZATION(7,1)
MULTOCIDA HYAE DELETION MUTANT(7,1)
INFECTION(6,3)
ACAPSULAR MUTANT STRAIN(6,2)
SWINE(5,5)
INCUBATION(5,4)
VACCINATION REGIMEN(5,3)
EXTRACELLULAR POLYSACCHARIDE(5,2)
INFECTION MEASURABLE ALLEVIATION(5,1)
MULTOCIDA HYAE GENE(5,1)
SEROTYPE MULTOCIDA MUTANT(5,1)
ANIMAL PERCENTAGE(4,3)
BREAST MUSCLE(4,3)
MARKER GENE(4,3)
CHALLENGED BIRD(4,2)
DOSING REGIMEN(4,2)
LYOPHILIZED VIAL(4,2)
MUTANT CFU(4,2)
SUBCUTANEOUS VACCINATION(4,2)
CAPSULE BIOSYNTHETIC GENE(4,1)
HYAE GENE DELETION(4,1)
MULTOCIDA HEXA GENE(4,1)
COMMERCIAL TURKEY(3,2)
ORAL GAVAGE(3,2)
STUDY COMPLETION(3,2)
TARGET TITER(3,2)
ABDOMINAL BLEEDING(3,1)
ATTENUATED MUTANT(3,1)
CAPSULAR ANTIGEN(3,1)
CAPSULE BIOSYNTHESIS(3,1)
CAPSULE ORF(3,1)
EXPRESSION PROTECTIVE IMMUNITY(3,1)
HETEROLOGOUS SEROTYPE(3,1)
HEXA MUTATION(3,1)
INTRAMUSCULAR VACCINATION(3,1)
INTRATRACHEAL INOCULATION(3,1)
MULTOCIDA SEROTYPE(3,1)
MULTOCIDA VACCINE(3,1)
MUTANT CELL DOSE(3,1)
NUCLEOTIDE SUBSTITUTION(3,1)
OVO VACCINATION(3,1)
PASTEURELLOSIS SIGN(3,1)
SEROGROUP DESIGNATION(3,1)
SOMATIC LIPOPOLYSACCHARIDE(3,1)
SUSCEPTIBLE TARGET ANIMAL POPULATION(3,1)
VIRULENT CHALLENGE(3,1)
VIRUS PARTICLE(3,1)
WHITE LEGHORN CHICKEN(3,1)
WING WEB VACCINATION(3,1)
CFU DOSE(2,6)
ADULT(2,2)
CELLULAR IMMUNITY(2,2)
CODING REGION(2,2)
COMPANION ANIMAL(2,2)
HEALTH(2,2)
LIVESTOCK UNGULATE(2,2)
MIXED SEX(2,2)
PEN FLOOR(2,2)
POST CHALLENGE(2,2)
SCARIFICATION(2,2)
STUDY START(2,2)
ANIMAL SPECIES(2,1)
ANIMAL VACCINATION(2,1)
BOVINE ANIMAL(2,1)
CAPSULE ENZYMATIC REMOVAL(2,1)
CAPSULE EXPRESSION(2,1)
CAPSULE MAINTENANCE(2,1)
CHALLENGE STRAIN(2,1)
DISEASE CAUSATIVE AGENT(2,1)
EYE INOCULATION(2,1)
HEXA MUTANT(2,1)
IMMUNOREACTIVITY EFFICIENCY(2,1)
MANUFACTURER INSTRUCTION(2,1)
MEASURABLE PARAMETER(2,1)
MUTANT BACTERIA(2,1)
MUTATED GENE(2,1)
OVO ADMINISTRATION(2,1)
POLYVALENT VACCINE COMPONENT(2,1)
POST VACCINATION REACTION(2,1)
PRELIMINARY SAFETY(2,1)
REPEATED SUBCULTURING(2,1)
SURVIVAL PERCENTAGE(2,1)
VACCINE FORMULATION(2,1)
VACCINE PREPARATION(2,1)
VETERINARILY ACCEPTABLE CARRIER(2,1)
VETERINARILY ACCEPTABLE SALT(2,1)
EFFICACY(1,2)
ADJUVANT(1,1)
AIRSPRAY(1,1)
ANTIBODY PRODUCTION(1,1)
BUFFERING AGENT(1,1)
CELL MEDIATED IMMUNITY(1,1)
DISEASE DEVELOPMENT(1,1)
GENE PRODUCT DETECTION(1,1)
HOST ANIMAL(1,1)
INORGANIC SALT(1,1)
LABORATORY GROWTH MEDIUM(1,1)
PASTEURELLA MULTOCIDA(1,1)
POST HATCH(1,1)
PROTECTION INDUCTION(1,1)
PROTECTIVE IMMUNE RESPONSE(1,1)
REACTION SIGN(1,1)
TABLE VMORTALITY(1,1)
VACCINATED GROUP(1,1)
VIRUS LOAD(1,1)
(WO2008118902)
MULTOCIDA(100,140)
MULTOCIDA STRAIN(100,61)
VIRULENT P(100,26)
CHICKEN(100,21)
CROSS PROTECTIVE IMMUNITY(100,21)
ATTENUATED ACAPSULAR MUTANT(75,4)
MULTOCIDA CAPSULE BIOSYNTHETIC OPERON(67,9)
POULTRY BIRD(55,12)
PROTECTIVE IMMUNITY(54,28)
AGE WEEK(37,14)
MUTANT P(35,64)
POULTRY ANIMAL(35,6)
MUTATION(34,28)
SEROTYPE(30,29)
FOWL CHOLERA(30,3)
MUTANT P CFU(29,8)
HYAE GENE CODING SEQUENCE(29,2)
ANIMAL(27,40)
HYAE MUTATION(25,2)
DOMESTIC BIRD(23,1)
P VIRULENT STRAIN(22,10)
ATTENUATED P SEROTYPE(22,1)
GENE EXPRESSION(19,4)
DOSE(17,15)
GAME HEN(17,3)
PROTECTION INDUCTION(17,1)
PHYB(15,6)
AGE DAY(14,2)
UNGULATE(13,8)
MUTANT P DOSE(13,6)
P ATTENUATED STRAIN(13,2)
BIRD(12,36)
MUTANT(12,4)
HEMORRHAGIC SEPTICEMIA(12,2)
ANIMAL VARIETY(12,1)
ATROPHIC RHINITIS(11,2)
GENOME(11,2)
MULTOCIDA INFECTION(10,9)
DELETION MUTATION(10,3)
MULTOCIDA HYAE MUTANT(10,3)
VACCINATION(9,27)
VACCINE(9,24)
SWINE(9,5)
GUINEA FOWL(9,3)
OSTRICH(9,3)
PHEASANT(9,3)
MULTOCIDA CELL(8,13)
DISEASE SYMPTOM(8,6)
GOOSE(8,3)
QUAIL(8,3)
SQUAB(8,3)
SEROTYPE MULTOCIDA ACAPSULAR MUTANT(8,1)
WILD(8,1)
DUCK(7,3)
EMU(7,3)
INFECTION(7,3)
MULTOCIDA MUTANT STRAIN(7,3)
PATHOLOGICAL LESION SEVERITY(7,2)
CAPSULE POLYSACCHARIDE ENZYMATIC DEPOLYMERIZATION(7,1)
MULTOCIDA HYAE DELETION MUTANT(7,1)
CATTLE(6,3)
ACAPSULAR MUTANT STRAIN(6,2)
P STRAIN(5,22)
BREAST MUSCLE(5,3)
MUTANT P SEROTYPE(5,3)
VACCINATION REGIMEN(5,3)
EXTRACELLULAR POLYSACCHARIDE(5,2)
INFECTION MEASURABLE ALLEVIATION(5,1)
MULTOCIDA HYAE GENE(5,1)
SEROTYPE MULTOCIDA MUTANT(5,1)
ANIMAL PERCENTAGE(4,3)
MARKER GENE(4,3)
CHALLENGED BIRD(4,2)
DOSING REGIMEN(4,2)
LYOPHILIZED VIAL(4,2)
POST CHALLENGE OBSERVATION(4,2)
POST INOCULATION OBSERVATION(4,2)
SUBCUTANEOUS VACCINATION(4,2)
CAPSULE BIOSYNTHETIC GENE(4,1)
HYAE GENE DELETION(4,1)
LONG LASTING IMMUNITY GENERATION(4,1)
MULTOCIDA HEXA GENE(4,1)
MORTALITY(3,6)
ACAPSULAR P(3,5)
COMMERCIAL TURKEY(3,2)
ORAL GAVAGE(3,2)
STUDY COMPLETION(3,2)
TARGET TITER(3,2)
ABDOMINAL BLEEDING(3,1)
ATTENUATED MUTANT(3,1)
CAPSULAR ANTIGEN(3,1)
CAPSULE BIOSYNTHESIS(3,1)
CAPSULE ORF(3,1)
HETEROLOGOUS SEROTYPE(3,1)
HEXA MUTATION(3,1)
INTRAMUSCULAR VACCINATION(3,1)
INTRATRACHEAL INOCULATION(3,1)
MULTOCIDA SEROTYPE(3,1)
MULTOCIDA VACCINE(3,1)
MUTANT CELL DOSE(3,1)
NUCLEOTIDE SUBSTITUTION(3,1)
OVO VACCINATION(3,1)
PASTEURELLOSIS SIGN(3,1)
SEROGROUP DESIGNATION(3,1)
SOMATIC LIPOPOLYSACCHARIDE(3,1)
SUSCEPTIBLE TARGET ANIMAL POPULATION(3,1)
VIRULENT CHALLENGE(3,1)
VIRUS PARTICLE(3,1)
WHITE LEGHORN CHICKEN(3,1)
WING WEB VACCINATION(3,1)
POULTRY(2,4)
ADULT(2,2)
ANIMAL SELECTION(2,2)
ATTENUATED P(2,2)
CELLULAR IMMUNITY(2,2)
CODING REGION(2,2)
COMPANION ANIMAL(2,2)
HEALTH(2,2)
LIVESTOCK UNGULATE(2,2)
MIXED SEX(2,2)
PEN FLOOR(2,2)
RANDOMIZATION(2,2)
SCARIFICATION(2,2)
STUDY START(2,2)
ANIMAL SPECIES(2,1)
ANIMAL VACCINATION(2,1)
BIRD PERCENT(2,1)
BOVINE ANIMAL(2,1)
CAPSULAR P REPEATED SUBCULTURING(2,1)
CAPSULE ENZYMATIC REMOVAL(2,1)
CAPSULE EXPRESSION(2,1)
CAPSULE MAINTENANCE(2,1)
CHALLENGE STRAIN(2,1)
DAY POST CHALLENGE(2,1)
DESIGNATING P CONVENTION(2,1)
DISEASE CAUSATIVE AGENT(2,1)
EYE INOCULATION(2,1)
HEXA MUTANT(2,1)
IMMUNOREACTIVITY EFFICIENCY(2,1)
INCUBATION DAY(2,1)
MANUFACTURER INSTRUCTION(2,1)
MEASURABLE PARAMETER(2,1)
MUTANT BACTERIA(2,1)
MUTANT P ADMINISTRATION(2,1)
MUTATED GENE(2,1)
OVO ADMINISTRATION(2,1)
POLYVALENT VACCINE COMPONENT(2,1)
POST VACCINATION REACTION(2,1)
PRELIMINARY SAFETY(2,1)
SURVIVAL PERCENTAGE(2,1)
TURKEY PROTECTION(2,1)
VACCINE FORMULATION(2,1)
VACCINE PREPARATION(2,1)
VETERINARILY ACCEPTABLE CARRIER(2,1)
VETERINARILY ACCEPTABLE SALT(2,1)
VIRULENT P SEROTYPE(2,1)
ANTIBODY PRODUCTION(1,1)
DISEASE DEVELOPMENT(1,1)
GENE PRODUCT DETECTION(1,1)
HEX B(1,1)
HOST ANIMAL(1,1)
INORGANIC SALT(1,1)
LABORATORY GROWTH MEDIUM(1,1)
P DELETION MUTATION(1,1)
P MUTANT STRAIN(1,1)
P MUTATION(1,1)
PASTEURELLA MULTOCIDA(1,1)
PH BUFFERING(1,1)";Pharmaceuticals;Open
2007-03-09;"TW200836759         A  2008-09-16 [TW200836759]
STG: (A) Laid open application for patent or patent of addition
AP : 2007TW-0108321 2007-03-09
US20090246229       A1 2009-10-01 [US20090246229]
STG: (A1) Application published
AP : 2008US-12073306 2008-03-04
TWI328458           B  2010-08-11 [TWI328458]
STG: (B) Granted patent or patent of addition
AP : 2007TW-0108321 2007-03-09
US8084043           B2 2011-12-27 [US8084043]
STG: (B2) Granted patent as second publication
AP : 2008US-12073306 2008-03-04
FD :  Previous publication: US20090246229 A1 2009-10-01 [US20090246229]";38251875;"TW200836759         A  2008-09-16 [TW200836759]
US20090246229       A1 2009-10-01 [US20090246229]
TWI328458           B  2010-08-11 [TWI328458]
US8084043           B2 2011-12-27 [US8084043]";2007TW-0108321;;"NATIONAL CHUNG HSING UNIVERSITY
UNIVERSITY NATIONAL CHUNGHSING";NATIONAL CHUNG HSING UNIVERSITY;"(US8084043)
TW";"(US8084043)
NAME=National Chung-Hseng University , CITY=Taichung , COUNTRY=TW , ATYP=Non-US Company 
";1;"CHANG POA-CHUN
WU JIN-RU
SHIEN JUI-HUNG
SHIEH HAPPY K";"(US20090246229)
TW
(US8084043)
TW";"(US20090246229)
NAME=Chang Poa-Chun , CITY=Taichung , COUNTRY=TW 

NAME=Wu Jin-Ru , CITY=Taichung , COUNTRY=TW 

NAME=Shien Jui-Hung , CITY=Taichung , COUNTRY=TW 

NAME=Shieh Happy K. , CITY=Taichung , COUNTRY=TW 

(US8084043)
NAME=Chang Poa-Chun , CITY=Taichung , COUNTRY=TW 

NAME=Wu Jin-Ru , CITY=Taichung , COUNTRY=TW 

NAME=Shien Jui-Hung , CITY=Taichung , COUNTRY=TW 

NAME=Shieh Happy K. , CITY=Taichung , COUNTRY=TW 
";"(US8084043)
Subunit vaccine of Pasteurella multocida in veterinary uses";"(US8084043)
The present invention declaims the use of Pasteurella lipoprotein E (PlpE) as a subunit vaccine and the use of vaccines containing PlpE to protect animals from diseases caused by P. multocida. The results of vaccination and challenge experiments showed that mice and chickens immunized with PlpE were completely protected animals from challenge infection with 101-103 LD50 of P. multocida and no adverse effect was observed.";"(TW200836759)
1. Kinds for preventing and controlling are created animal disease's inferior unit vaccine constituent by P.multocida, its characteristic lies in contains P.multocida lipoprotein E (lipoprotein E, PlpE) to do is the antigen protein, and in veterinary science may accept the adjuvant.
2. According to the application patent scope 1st item of vaccine constituent, this P.multocida lipoprotein E has to choose the preface to tabulate SEQ ID the 1 to proteins of 6 listed aminoacid sequences.
3. According to the application patent scope 1st item of vaccine constituent, this PlpE antigen protein to have 1 to 6 one reaches over aminoacid of sequence 90% similarity protein with SEQ ID.
4. According to the application patent scope 1st item of vaccine constituent, should create the animal disease by P.multocida for the domesticated fowl acute defeat courage and uprightness disease.
5. According to the application patent scope 4th item of vaccine constituent, should create the animal disease by P.multocida for domesticated fowl Huo Luanbing.
6. According to the application patent scope 1st item of vaccine constituent, should create the animal disease by P.multocida for pig's atrophy rhinitis.
7. 1 kinds of Pasteur bacillus Pasteurella multocida lipoprotein E(PlpE) new use, it is for preventing and controlling creates the infectious disease by P.multocida, either its one or many kinds of related illness.
8. According to the application patent scope 7th new use, should create the infectious disease by Pasteur bacillus P.multocida for the domesticated fowl acute defeat courage and uprightness disease.
9. According to the application patent scope 8th new use, this domesticated fowl acute defeat courage and uprightness disease for fowl cholera.
10. According to the application patent scope 7th new use, this P.multocida infectious disease is occurred in the mammal.
11. According to the application patent scope 10th new use, this mammal for mouse class.
12. According to the application patent scope 10th new use, this P.multocida infectious disease initiates pig's atrophy rhinitis.";"(US8084043)
In one aspect, the present invention provides a subunit vaccine for protecting animal from diseases caused by P. multocida, which is characterized by comprising Pasteurella lipoprotein E (PlpE) as antigen, and a veterinary acceptable adjuvant.
In another aspect, the present invention provides a use of Pasteurella lipoprotein E in controlling infective diseases caused by P. multocida, or related disorders thereof.
The present invention relates to the use of Pasteurella lipoprotein E (PlpE) in a subunit vaccine, and the use of vaccines containing PlpE to protect animals from diseases caused by P. multocida.";"(US8084043)
In domestic birds, P. multocida causes acute septic disorders in turkey, chicken, duck, and goose, which may lead to a great loss in economy.";"A61K-038/00
A61K-039/00
A61K-039/02
A61K-039/102
A61P-031/04
C12N-015/31";"(US8084043)
1. A subunit vaccine composition for controlling animal diseases caused by P. multocida, the subunit vaccine composition comprising recombinant Pasteurella lipoprotein E (PlpE) as an antigen, and a veterinary acceptable adjuvant, wherein the Pasteurella lipoprotein E is a protein having the amino acid sequence identified by SEQ ID NO:2.";"(US20090246229)
MULTOCIDA(100,24)
PASTEURELLA LIPOPROTEIN(100,11)
INFECTIVE DISEASE(100,6)
SUBUNIT VACCINE(100,6)
ANIMAL DISEASE(100,5)
DISORDER(100,3)
PASTEURELLA MULTOCIDA SUBUNIT VACCINE(100,1)
VETERINARY(100,1)
VETERINARY ACCEPTABLE ADJUVANT(59,2)
PNEUMONIC PASTEURELLOSIS(52,3)
ACUTE SEPTIC DISORDER(43,1)
DOMESTIC BIRD(29,5)
HEMORRHAGIC SEPTICEMIA(21,7)
ANIMAL PROTECTION(19,1)
ANTIGEN(17,3)
VACCINE(16,3)
DISEASE(15,6)
ATROPHIC RHINITIS(15,5)
MULTOCIDA CAUSE(15,1)
MAMMALIAN(14,2)
GOOSE(13,1)
CHICKEN(12,13)
CATTLE(12,7)
ECONOMY(12,1)
PLPE(11,8)
ANIMAL(11,4)
DUCK(11,1)
PLPE GENE(10,5)
VACCINATION RESULT(9,1)
PIG(8,5)
SIMILARITY(8,3)
BACTERIN PROTECTIVE EFFICACY(8,2)
FOWL CHOLERA OUTBREAK(8,1)
AMINOACID SEQUENCE(7,9)
MULTOCIDA STRAIN(7,4)
RECOMBINANT PLASMID(7,3)
FOWL CHOLERA CAUSATIVE AGENT(7,1)
INFECTED CARNIVORE BITE(7,1)
PASTEURELLACEAE TAXONOMIC SITUATION(7,1)
MULTOCIDA INFECTION(6,2)
RECOMBINANT PLPB(6,2)
IMMUNIZED CHICKEN DEATH(6,1)
RECOMBINANT LIPOPROTEIN PURIFICATION(6,1)
RECOMBINANT PLPE PURIFICATION(6,1)
SURVIVAL RATE(5,7)
CHALLENGE STRAIN(5,2)
EMULSION ADJUVANT(5,2)
HISTIDINE MONOCLONAL ANTIBODY(5,2)
STRAIN LD50(5,2)
ACUTE SEPTIC SYMPTOM(5,1)
BACTERIAL GENOMIC DNA(5,1)
BIG DYE TERMINATOR(5,1)
DNEASY TISSUE KIT(5,1)
DUPLICATED GEL IMMUNOBLOT(5,1)
HAEMOLYTICA VACCINE(5,1)
NON EFFECTIVE SUBUNIT VACCINE(5,1)
OLD SPF CHICKEN(5,1)
PASTERURELLA MULTOCIDA(5,1)
PURPLE BACTERIUM GAMMA SUBGROUP(5,1)
QIAQUICK GEL EXTRACTION KIT(5,1)
RECOMBINANT PLPE PROTEIN(5,1)
COLI STRAIN(4,2)
PUBLISHED GENOME SEQUENCE(4,2)
SAS SOFTWARE(4,2)
ADVERSE SIDE EFFECT(4,1)
ANTIGENIC INDEX ASSAY(4,1)
DOMESTIC ANIMAL PATHOGEN(4,1)
FAMILY PASTEURELLACEAE(4,1)
GENOMIC DNA EXTRACTION(4,1)
GENUS PASTEURELLA(4,1)
GRAM NEGATIVE FACULTATIVE ANAEROBE(4,1)
HETEROLOGOUS CHALLENGE(4,1)
MULTOCIDA ANTIGEN(4,1)
PROTEIN ASSAY KIT(4,1)
WESTERN BLOTTING(4,1)
BOOSTER IMMUNIZATION(3,3)
IMIDAZOLE(3,3)
PURIFIED R PLPB(3,3)
REPORT(3,3)
SEROTYPE(3,3)
CHI SQUARED TEST(3,2)
GLM(3,2)
PRIMER SEQUENCE(3,2)
SEQUENCE IDENTITY(3,2)
3730XL DNA(3,1)
AGRICULTURAL RESEARCH(3,1)
ALUMINUM HYDROXIDE ADJUVANT(3,1)
AMINO TERMINI(3,1)
AMPLIFIED GENE(3,1)
ANTIGEN ADMINISTRATION(3,1)
APPENDING SEQUENCE LISTING(3,1)
AUTOMATIC SEQUENCER(3,1)
BACTERIAL STRAIN(3,1)
BLAST PROGRAM(3,1)
COMPLEMENT MEDIATED KILLING(3,1)
CULTURE COLLECTION(3,1)
DISADVANTAGE CALL(3,1)
DRUG INSPECTION(3,1)
EXPERIMENTAL CHALLENGE(3,1)
GENBANK(3,1)
GENETIC CLONING(3,1)
HUMAN OPPORTUNISTIC PATHOGEN(3,1)
IMMUNIZED ANIMAL(3,1)
INFECTION DOSE(3,1)
INSERT IDENTITY(3,1)
LASERGENE PACKAGE(3,1)
NICKEL CHROMATOGRAPHY(3,1)
POULTRY DISEASE(3,1)
PRIMER CONTAINED RESTRICTION ENZYME(3,1)
PROOF INSPECTION STANDARD(3,1)
PROTEAN PROGRAM(3,1)
RECOMBINANT PROTEIN PURITY(3,1)
RECOMBINANT VECTOR(3,1)
REVERSION(3,1)
SEQMAN PROGRAM(3,1)
SEQUENCING KIT(3,1)
SIGMA ALDRICH CO(3,1)
UNBOUND PROTEIN(3,1)
VACCINE ANTIGEN(3,1)
CFU(2,3)
KDA(2,3)
NACL(2,3)
PCR PRODUCT(2,2)
BLUE STAINED SDS PAGE(2,1)
DOUBLE EMULSION(2,1)
ELUTION(2,1)
EXPRESSION VECTOR CONSTRUCTION(2,1)
HUMAN INFECTION(2,1)
MANNHEIMIA HAEMOLYTICA(2,1)
MATURED R PLPB(2,1)
OLD MOUSE(2,1)
PASTEURELLA HAEMOLYTICA(2,1)
PASTEURELLA MULTOCIDA(2,1)
PRIMARY IMMUNIZATION(2,1)
PROTEIN CONCENTRATION(2,1)
R PLPB CONFERRED PROTECTION(2,1)
R PLPB CRUDE EXTRACT(2,1)
R PLPE CRUDE EXTRACT(2,1)
SIGNAL PEPTIDE CLEAVAGE(2,1)
UNDERLINED SEQUENCE(2,1)
WASHING(2,1)
WEEK INTERVAL(2,1)
ABSORBANCE(1,1)
(US8084043)
MULTOCIDA(100,21)
PASTEURELLA LIPOPROTEIN(100,8)
SUBUNIT VACCINE(100,7)
ANIMAL DISEASE(100,5)
PASTEURELLA MULTOCIDA SUBUNIT VACCINE(100,1)
VETERINARY(100,1)
RECOMBINANT PASTEURELLA LIPOPROTEIN(91,1)
VETERINARY ACCEPTABLE ADJUVANT(74,2)
ACUTE SEPTIC DISORDER(55,1)
PNEUMONIC PASTEURELLOSIS(54,2)
INFECTIVE DISEASE(30,2)
DOMESTIC BIRD(27,4)
ANIMAL PROTECTION(25,1)
ANTIGEN(24,3)
DISEASE(20,6)
VACCINE(20,3)
MULTOCIDA CAUSE(19,1)
DISORDER(17,2)
CHICKEN(16,13)
GOOSE(16,1)
ANIMAL(15,4)
DUCK(15,1)
ECONOMY(15,1)
HEMORRHAGIC SEPTICEMIA(14,5)
PLPE(13,8)
ATROPHIC RHINITIS(13,4)
PROTEIN(13,3)
PLPE GENE(12,5)
VACCINATION RESULT(11,1)
MULTOCIDA STRAIN(10,4)
BACTERIN PROTECTIVE EFFICACY(10,2)
FOWL CHOLERA OUTBREAK(10,1)
INFECTED CARNIVORE BITE(10,1)
RECOMBINANT PLASMID(9,3)
FOWL CHOLERA CAUSATIVE AGENT(9,1)
PASTEURELLACEAE TAXONOMIC SITUATION(9,1)
CATTLE(8,5)
MULTOCIDA INFECTION(8,2)
RECOMBINANT PLPB(8,2)
IMMUNIZED CHICKEN DEATH(8,1)
RECOMBINANT LIPOPROTEIN PURIFICATION(8,1)
RECOMBINANT PLPE PURIFICATION(8,1)
AMINOACID SEQUENCE(7,7)
PIG(7,4)
CHALLENGE STRAIN(7,2)
EMULSION ADJUVANT(7,2)
HISTIDINE MONOCLONAL ANTIBODY(7,2)
3730XL DNA ANALYZER(7,1)
ACUTE SEPTIC SYMPTOM(7,1)
DUPLICATED GEL IMMUNOBLOT(7,1)
OLD SPF CHICKEN(7,1)
PASTERURELLA MULTOCIDA(7,1)
PURPLE BACTERIUM GAMMA SUBGROUP(7,1)
RECOMBINANT PLPE PROTEIN(7,1)
SURVIVAL RATE(6,7)
STRAIN LD50(6,2)
BACTERIAL GENOMIC DNA(6,1)
BIG DYE TERMINATOR(6,1)
DNEASY TISSUE KIT(6,1)
HAEMOLYTICA VACCINE(6,1)
NON EFFECTIVE SUBUNIT VACCINE(6,1)
COLI STRAIN(5,2)
PUBLISHED GENOME SEQUENCE(5,2)
SAS SOFTWARE(5,2)
ADVERSE SIDE EFFECT(5,1)
AGRICULTURAL RESEARCH(5,1)
ALUMINUM HYDROXIDE ADJUVANT(5,1)
ANTIGEN ADMINISTRATION(5,1)
ANTIGENIC INDEX ASSAY(5,1)
APPENDING SEQUENCE LISTING(5,1)
COMPLEMENT MEDIATED KILLING(5,1)
DOMESTIC ANIMAL PATHOGEN(5,1)
EXPERIMENTAL CHALLENGE(5,1)
FAMILY PASTEURELLACEAE(5,1)
GENETIC CLONING(5,1)
GENOMIC DNA EXTRACTION(5,1)
GENUS PASTEURELLA(5,1)
GRAM NEGATIVE FACULTATIVE ANAEROBE(5,1)
HETEROLOGOUS CHALLENGE(5,1)
HUMAN OPPORTUNISTIC PATHOGEN(5,1)
IMMUNIZED ANIMAL(5,1)
LASERGENE PACKAGE(5,1)
MULTOCIDA ANTIGEN(5,1)
POULTRY DISEASE(5,1)
PRIMER CONTAINED RESTRICTION ENZYME(5,1)
PROTEIN ASSAY KIT(5,1)
RECOMBINANT VECTOR(5,1)
REVERSION(5,1)
SAS INSTITUTE(5,1)
UNBOUND PROTEIN(5,1)
VACCINE ANTIGEN(5,1)
WESTERN BLOTTING(5,1)
BOOSTER IMMUNIZATION(4,3)
IMIDAZOLE(4,3)
PURIFIED R PLPB(4,3)
REPORT(4,3)
SEROTYPE(4,3)
CHI SQUARED TEST(4,2)
GLM(4,2)
SEQUENCE IDENTITY(4,2)
AMINO TERMINI(4,1)
AMPLIFIED GENE(4,1)
AUTOMATIC SEQUENCER(4,1)
BACTERIAL STRAIN(4,1)
BLAST PROGRAM(4,1)
CULTURE COLLECTION(4,1)
DISADVANTAGE CALL(4,1)
DRUG INSPECTION(4,1)
EXTRACTION KIT(4,1)
GENBANK(4,1)
INFECTION DOSE(4,1)
INSERT IDENTITY(4,1)
NICKEL CHROMATOGRAPHY(4,1)
PROOF INSPECTION STANDARD(4,1)
PROTEAN PROGRAM(4,1)
RECOMBINANT PROTEIN PURITY(4,1)
SEQMAN PROGRAM(4,1)
SEQUENCING KIT(4,1)
SIGMA ALDRICH CO(4,1)
PCR PRODUCT(3,2)
SIMILARITY(3,2)
BLUE STAINED SDS PAGE(3,1)
DOUBLE EMULSION(3,1)
ELUTION(3,1)
EXPRESSION VECTOR CONSTRUCTION(3,1)
HUMAN INFECTION(3,1)
MANNHEIMIA HAEMOLYTICA(3,1)
MATURED R PLPB(3,1)
OLD MOUSE(3,1)
PASTEURELLA HAEMOLYTICA(3,1)
PASTEURELLA MULTOCIDA(3,1)
PRIMARY IMMUNIZATION(3,1)
PRIMER SEQUENCE(3,1)
PROTEIN CONCENTRATION(3,1)
R PLPB CONFERRED PROTECTION(3,1)
R PLPB CRUDE EXTRACT(3,1)
R PLPE CRUDE EXTRACT(3,1)
SIGNAL PEPTIDE CLEAVAGE(3,1)
UNDERLINED SEQUENCE(3,1)
WASHING(3,1)
WEEK INTERVAL(3,1)
CFU(2,3)
KDA(2,3)
NACL(2,3)";Pharmaceuticals;Open
2006-12-06;"TH115324            A  2012-07-31 [TH-115324]
STG: (A) Published application
AP : 2006TH-1006079 2006-12-06";64535256;TH115324            A  2012-07-31 [TH-115324];2006TH-1006079;;ZOE AWARD;ZOE AWARD;;;1;;;;"(TH-115324)
Virus vaccines of bovine viral diarrhea caused by species that have been marked.";"(TH-115324)
This invention is directed to a viral disease caused by a virus of calf diarrhea. Contains a mutation of the amino acids of the Helix domain case, at least one unit. The mutations in the NS 3 domains lead to a loss recognized by a monoclonal antibody in mono Cole has been created. Up against NS 3 primitive types. However, the increasing number of RNA viruses and the virus. Infection has been preserved. The invention is useful. For example, in the production of viral vaccines. Diarrhea caused by a virus of cattle that have been marked. Or to tell the difference between. Vaccinated animals And infected or not vaccinated.";"(TH-115324)
1. The virus of diarrhea caused by the virus of the cow consists of mutations. Amount of amino acids of at least one helicase domain. The mutation in NS domain helices. 3 resulted in a loss of recognition by monoclonal antibodies that were generated against NS 3 from the virus of diarrheal disease caused by traditional viral viruses. However, the increase in the RNA of the virus and the cause of the infected virus have been maintained.
2. The virus of diarrhea caused by the virus of the cow consists of mutations. Amino Acids of Helium Domains";;;"A61K-039/12
C12N-007/00";;;Pharmaceuticals;Open
2006-10-20;"UA26677             U  2007-10-10 [UA--26677U]
STG: (U) Declarative / pat. spec. for utility model
AP : 2006UA-U011089 2006-10-20";38626161;UA26677             U  2007-10-10 [UA--26677U];2006UA-U011089;;VOLOSIANKO OLENA VIKTORIVNA;;;;0;"VOLOSIANKO OLENA VIKTORIVNA
KASSICH VOLODYMYR YURIIOVYCH";;;"(UA--26677U)
A strain of infectious bovine rhinotracheitis virus kmiev-6 for making vaccine and diagnostic agents";"(UA--26677U)
A strain of infectious bovine rhinotracheitis virus KMIEV-6 for making vaccine and diagnostic agents.";;;;"A61K-039/265
C12N-007/00";;;Pharmaceuticals;Open
"2006-09-22
2007-09-20";"WO2008034857        A1 2008-03-27 [WO200834857]
STG: (A1) Published application with search report
AP : 2007WO-EP59923 2007-09-20
CA2663142           A1 2008-03-27 [CA2663142]
STG: (A1) Application laid open
AP : 2007CA-2663142 2007-09-20
UY30602             A1 2008-05-02 [UY--30602]
STG: (A1) Patent application (First publication level)
AP : 2007UY-0030602 2007-09-21
CL2007002704        A1 2008-05-30 [CL2704200700]
STG: (A1) Patent application
AP : 2007CL-0002704 2007-09-20
AR062917            A1 2008-12-17 [AR--62917]
STG: (A1) Independent patent application
AP : 2007AR-0104156 2007-09-20
EP2066342           A1 2009-06-10 [EP2066342]
STG: (A1) Application published with search report
AP : 2007EP-0820367 2007-09-20
US20090232846       A1 2009-09-17 [US20090232846]
STG: (A1) Application published
AP : 2007US-12441169 2007-09-20
JP2010504084        A  2010-02-12 [JP2010504084]
STG: (A) Published application
AP : 2009JP-0528717 2007-09-20
US8071108           B2 2011-12-06 [US8071108]
STG: (B2) Granted patent as second publication
AP : 2007US-12441169 2007-09-20
FD :  Provisional Appl: US60/846,662 FDD=2006-09-22 [2006US-60846662]
FD : Previous publication: US20090232846 A1 2009-09-17 [US20090232846]
EP2066342           B1 2014-07-23 [EP2066342]
STG: (B1) Patent specification
AP : 2007EP-0820367 2007-09-20
ES2508916           T3 2014-10-16 [ES2508916]
STG: (T3) Translation of granted European patent (former B3)
AP : 2007ES-0820367T 2007-09-20
JP5775665           B2 2015-07-10 [JP5775665]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2009JP-0528717 2007-09-20
CA2663142           C  2016-05-03 [CA2663142]
STG: (C) Patent (second level)
AP : 2007CA-2663142 2007-09-20";55631;"WO2008034857        A1 2008-03-27 [WO200834857]
CA2663142           A1 2008-03-27 [CA2663142]
UY30602             A1 2008-05-02 [UY--30602]
CL2007002704        A1 2008-05-30 [CL2704200700]
AR062917            A1 2008-12-17 [AR--62917]
EP2066342           A1 2009-06-10 [EP2066342]
US20090232846       A1 2009-09-17 [US20090232846]
JP2010504084        A  2010-02-12 [JP2010504084]
US8071108           B2 2011-12-06 [US8071108]
EP2066342           B1 2014-07-23 [EP2066342]
ES2508916           T3 2014-10-16 [ES2508916]
JP5775665           B2 2015-07-10 [JP5775665]
CA2663142           C  2016-05-03 [CA2663142]";"2006EP-0121147
2006US-60846662
2007EP-0820367
2007US-12441169
2007WO-EP59923";"(EP2066342)
WO2008034857
(US8071108)
WO2008034857
(JP5775665)
WO2008034857
(ES2508916)
WO2008034857
(CA2663142)
WO2008034857";INTERVET INTERNATIONAL;INTERVET INTERNATIONAL;"(EP2066342)
NL
(EP2066342)
NL
(US20090232846)
NL
(US8071108)
NL
(WO200834857)
NL

(CA2663142)
NL
(CA2663142)
NL";"(EP2066342)
NAME=Intervet International BV Wim de Körverstraat 35 , CITY=5831 AN  Boxmeer , COUNTRY=NL 

(EP2066342)
NAME=Intervet International BV Wim de Körverstraat 35 , CITY=5831 AN  Boxmeer , COUNTRY=NL , REG=100780526 

(US20090232846)
NAME=Intervet International B.V. , CITY=Boxmeer , COUNTRY=NL , ATYP=Non-US Company 

(US8071108)
NAME=Intervet International B.V. , CITY=Boxmeer , COUNTRY=NL , ATYP=Non-US Company 

(WO200834857)
NAME=INTERVET INTERNATIONAL B.V.  Wim de Körverstraat 35, NL-5831 AN Boxmeer  , COUNTRY=NL 

(JP2010504084)
NAME=Based Intanashiyonaru based Intabetsuto , REG=506196247 

(JP5775665)
NAME=INTERVET INT BV , REG=510000976 

(CA2663142)
NAME=INTERVET INTERNATIONAL B.V. P.O. Box 31 Wim de Koerverstraat 35 NL-5831 AN , CITY=BOXMEER , COUNTRY=NL 

(CA2663142)
NAME=INTERVET INTERNATIONAL B.V. P.O. Box 31 Wim de Koerverstraat 35 NL-5831 AN , CITY=BOXMEER , COUNTRY=NL 
";1;"BEER MARTIN
REIMANN ILONA
KOENIG PATRICIA";"(EP2066342)
DE";"(EP2066342)
NAME=BEER, Martin Suedufer10 , CITY=17493 Greifswald-Insel Riems , COUNTRY=DE 

NAME=REIMANN, Ilona Suedufer 10 , CITY=17493 Greifswald-Insel Riems , COUNTRY=DE 

NAME=KOENIG, Patricia Suedufer 10 , CITY=17493 Greifswald-Insel Riems , COUNTRY=DE 
";"(EP2066342)
Bovine Viral Diarrhea Virus mutant for use in a vaccine";"(EP2066342)
The present invention aims at providing new pestivirus mutants for use in vaccines. The present inventors worked with pestivirus mutants containing mutations in the coding region for the Npro protein of the virus. The mutants according to the present invention are characterized in that the mutant is based on a cp strain of the virus wherein part of the gene sequence encoding the Npro region is deleted, wherein said deleted part does not encompass the coding sequence for the N-terminal twelve amino acids of the Npro protein. Preferably the pestivirus is the Bovine Viral Diarrhea Virus (BVDV). Especially for BVDV it was found that a mutant according to the invention is a safe and efficient vaccine candidate.";"(WO200834857)
CLAIMS:
1. A mutant of a pestivirus which mutant is based on a cp strain of the virus wherein part of the gene sequence encoding the Npro region is deleted, characterised in that the deleted part does not encompass the coding sequence for the N-terminal twelve amino acids of the Npro protein.
2. A mutant according to claim 4, characterized in that the pestivirus is a cytopathogenic strain.
3. A mutant according to claim 1 or 2, characterized in that the pestivirus is the Bovine Viral Diarrhea Virus (BVDV).
4. A mutant according to claim 1 , characterised in that the mutant expresses all structural proteins of the virus.
5. A mutant according to claim 2, characterized that all of the Npro gene sequence, except for the coding sequence for the N-terminal twelve amino acids of the N-pro protein, is deleted.
6. A mutant according to claim 2 or 3, characterised in that the N-terminal twelve amino acids of the Npro protein are MELITNELLYKT-.
7. A mutant according to claim 6, characterized in that the pestivirus is BVDV strain CP7.
8. A vaccine for the protection of cattle against BVDV infection, characterized in that the vaccine comprises a mutant according to claim 1 , and a pharmaceutically acceptable carrier.
9. A vaccine according to claim 8, wherein the mutant is based on the CP7 BVDV strain, wherein all of the Npro gene, except for the coding sequence for the N-terminal twelve amino acids of the Npro protein, is deleted.
10. Use of a mutant according to any of claims 1 -7 in the manufacture of a vaccine to protect livestock against infection with a wild type pestivirus.
 1 1. Use of a mutant according to any of claims 1 -7 in a method for the manufacture of a vaccine to protect pregnant heifers against infection with BVDV.";"(EP2066342)
The present invention relates to a vaccine comprising a mutant of a pestivirus, said mutant expressing all structural proteins of the pestivirus and the use of said vaccine to protect life stock against infection with a pestivirus.
The present invention aims at providing new pestivirus mutants for use in vaccines.
The present invention aims at providing new pestivirus mutants for use in vaccines.
It was found that the defective CSFV genomes still replicated and could be packaged into viral particles when introduced in SK-6 cells together with helper A187-CAT RNA (Moser et al., J.Virol., 7787-7794, 1999).";"(EP2066342)
PI calves therefore are lifelong efficient shedders of the virus and are the most important cause of spreading of the virus in susceptible cattle world wide.
In summary, the experimental infection of pregnant heifers gives good evidence, that CP7 Npro is a highly attenuated and safe BVDV vaccine candidate.
BVDV infection also has the ability to cause persistent infection (PI) in the developing fetus.
Bovine viral diarrhea virus (BVDV), a member of the genus Pestivirus within the family Flaviviridae is the causative agent of bovine viral diarrhea, an economically important disease of cattle world-wide.";"A01N-063/00
A61K-035/76
A61K-039/00
A61K-039/12
A61P-031/12
C07K-014/07
C07K-014/18
C12N-001/00
C12N-007/00
C12N-007/04
C12N-015/09
C12N-015/39";"(EP2066342)
1. A vaccine for the protection of cattle against Bovine Viral Diarrhea Virus (BVDV) infection, characterized in that the vaccine comprises a mutant of BVDV which mutant is based on a cytopathogenic (cp) strain of the virus wherein all of the Npro gene sequence, except for the coding sequence for the N-terminal twelve amino acids of the Npro protein, is deleted, and wherein the mutant expresses all structural proteins of the virus, and a pharmaceutically acceptable carrier.";"(EP2066342)
VACCINE(100,26)
BOVINE VIRAL DIARRHEA VIRUS MUTANT(100,1)
PREGNANT HEIFER EXPERIMENTAL INFECTION(100,1)
FLAVIVIRIDAE FAMILY(54,1)
PESTIVIRUS MUTANT(46,4)
MUTANT EXPRESS(46,2)
VIRUS PROTEIN STRUCTURE(46,2)
FETUS DEVELOPMENT(45,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(44,1)
GENUS PESTIVIRUS MEMBER(44,1)
NPRO GENE SEQUENCE(40,3)
VACCINE CATEGORY(39,1)
NPRO PROTEIN AMINOACID(37,5)
CAUSATIVE AGENT(36,1)
VIRAL PARTICLE(36,1)
CATTLE PROTECTION(35,3)
VACCINE CANDIDATE(34,4)
NPRO DELETION MUTANT(26,7)
LIVE VACCINE(26,2)
MUTANT VIRUS(26,2)
MUTANT(25,30)
PERSISTENT INFECTION(25,1)
CODING SEQUENCE(24,4)
HOST ANIMAL(24,1)
BOVINE VIRAL DIARRHEA(23,1)
EVIDENCE(20,1)
HELPER(20,1)
BOVINE VIRAL DIARRHEA VIRUS(19,88)
INFECTION(19,24)
GENOME STILL(18,1)
PROTECTIVE IMMUNE RESPONSE(17,3)
NEUTRALIZING ANTIBODY TITER(17,2)
VIRUS(15,6)
PERSISTENTLY INFECTED FETUS EXCLUSION(15,1)
NASAL VIRUS SHEDDING(14,5)
MILD RESPIRATORY SYMPTOM(14,2)
VACCINE VIRUS NASAL EXCRETION(14,1)
VACCINE VIRUS NASAL SHEDDING(14,1)
VIRAL DISEASE(14,1)
N TERMINAL TWELVE(13,5)
PERSISTENTLY INFECTED(13,1)
IMMUNIZED ANIMAL(12,3)
VIRUS CP STRAIN(11,2)
BOVINE UBIQUITIN GENE FRAGMENT(11,1)
FETUS INFECTION PERSISTENCE(11,1)
PERSISTENTLY INFECTED CALF GENERATION(11,1)
PREGNANT HEIFER INFECTION(11,1)
INOCULATED ANIMAL(10,3)
CEDI DIAGNOSTICS(10,2)
NONSTRUCTURAL PROTEIN(10,2)
PURIFIED BLOOD LEUKOCYTE(10,2)
SUPERNATANT BLIND PASSAGE(10,2)
GESTATION TRIMESTER(10,1)
HEIFER CLINICAL SIGN(10,1)
MOCK VACCINATED ANIMAL(10,1)
PRE VACCINATION EXACERBATION(10,1)
QUESTIONABLE BONE MARROW LAVAGE(10,1)
UNSPECIFIC MILD OCULAR(10,1)
VACCINATION CHALLENGE TRIAL(10,1)
VIRAL GENOME REARRANGEMENT(10,1)
VIRUS NPRO PROTEIN(10,1)
CLINICAL SYMPTOM(9,2)
ANIMAL TRIAL SCHEDULE(9,1)
CONFERRING CYTOPATHOGENICITY(9,1)
ERYTHROCYTE ALKALINE LYSIS(9,1)
GLYCOSYLATED ENVELOPE PROTEIN(9,1)
GROWING VIRUS MUTANT(9,1)
NA VE HEIFER(9,1)
NONSTRUCTURAL AUTOPROTEASE(9,1)
UBIQUITIN PROTEOLYTIC ACTIVITY(9,1)
VIRUS ISOLATION(8,3)
WEEKLY INTERVAL(8,3)
CHALLENGE INFECTION(8,2)
CYTOPATHIC STRAIN(8,2)
INTRAMUSCULAR INFECTION(8,2)
STERILE IMMUNITY(8,2)
VIRAL REPLICATION(8,2)
CLINICAL DISEASE SIGN(8,1)
CO CULTIVATION VIRUS REPLICATION DAY(8,1)
DIGESTED PLASMID PA(8,1)
FETAL ORGAN PANEL(8,1)
FETOPATHOGENICITY VIRUS DETECTION(8,1)
IMMUNIZED CALF(8,1)
INFECTIOUS CLONE PA(8,1)
MOCK VACCINATION(8,1)
PESTIVIRAL VIRION(8,1)
PESTIVIRUS GENOME(8,1)
PESTIVIRUS REPLICATION(8,1)
SEROLOGICAL RESPONSE CLINICAL ABORTION(8,1)
SPORADIC COUGHING(8,1)
VIRUS ENVELOPE PROTEIN(8,1)
CLASSICAL SWINE FEVER VIRUS(7,10)
INDIRECT IMMUNOFLUORESCENCE TEST(7,2)
MUTANT STRAIN(7,2)
PCR FRAGMENT(7,2)
ANTIBODY NEUTRALIZATION(7,1)
ATTENUATED PHENOTYPE(7,1)
CLINICAL INVESTIGATION MONITORING(7,1)
COMMERCIAL ANTIGEN ELISA(7,1)
EFFICIENT VACCINE CANDIDATE(7,1)
ERNS MUTATION(7,1)
FETUS NUMEROUS ORGAN(7,1)
MUCOSAL LESION(7,1)
MURINE UBIQUITIN SEQUENCE(7,1)
NEUTRALIZATION ASSAY(7,1)
NPRO MUTATION(7,1)
PESTIVIRUS PROTEIN(7,1)
PREGNANT CATTLE(7,1)
RETARDED LEUKOCYTE REDUCTION(7,1)
RT PCR ASSAY(7,1)
SERUM NEUTRALIZATION TEST(7,1)
SUBGENOMIC RNA(7,1)
VACCINATED CALF CELL(7,1)
VACCINATION EFFICACY(7,1)
VIRAL GENOME SEQUENCE(7,1)
BIOTYPE(6,3)
BOVINE FRAGMENT(6,1)
BVDV INFECTION(6,1)
CLINICAL BVD(6,1)
CO CULTURE DAY(6,1)
DAY POST VACCINATION(6,1)
ENCODED POLYPROTEIN(6,1)
ERNS GENE(6,1)
ERNS PROTEIN(6,1)
GESTATION DAY(6,1)
INFECTIOUS VIRUS(6,1)
INOCULATED CULTURE(6,1)
INOCULATED PIG(6,1)
INOCULATION ROUTE(6,1)
LATE CP(6,1)
LIVE ATTENUATED VACCINE(6,1)
LIVE VACCINATION(6,1)
MARKED LEUKOPENIA(6,1)
MODERATE TITER(6,1)
NCP STRAIN(6,1)
NPRO CODING SEQUENCE(6,1)
NPRO MUTANT(6,1)
OVERLAPPING NUCLEOTIDE(6,1)
OVINE BORDER DISEASE VIRUS(6,1)
PATHOLOGICAL FINDING(6,1)
RESTRICTION FRAGMENT(6,1)
RNA DEPENDANT(6,1)
RT PCR ANALYSIS(6,1)
SAMPLE HOMOGENIZATION(6,1)
SERINE PROTEASE(6,1)
SUPERNATANT CONSECUTIVE PASSAGE(6,1)
UNINFECTED CELL CULTURE SUPERNATANT(6,1)
VIRAL GENOME EQUIVALENT(6,1)
VIRUS INOCULATION(6,1)
CODING REGION(5,3)
REPLICON(5,3)
BOVINE CELL(5,2)
CULTURED CELL INFECTION(5,2)
DOUBLE MUTANT(5,2)
SWAB FLUID(5,2)
ADVERSE CLINICAL REACTION(5,1)
ANIMAL SEROLOGICAL RESPONSE(5,1)
BLOCKING ELISA(5,1)
CELL LYSIS(5,1)
DIFFERENTIAL PCR(5,1)
EARLY PREGNANCY(5,1)
EFFICIENT CLEAVAGE(5,1)
FAINT ELEVATION(5,1)
GENE ENCODING(5,1)
GENE SEQUENCE ENCODING(5,1)
GROWTH KINETICS(5,1)
INCUBATION DAY(5,1)
INDUCED VIRAEMIA(5,1)
LEUKOCYTE COUNT MARKED DECREASE(5,1)
MATURE PROTEIN(5,1)
MINI KIT(5,1)
MODIFIED LIVE VIRUS(5,1)
MUTANT GROWTH(5,1)
PERSISTENTLY INFECTED SYNDROME(5,1)
PROTEIN CODING(5,1)
RESEARCH PROJECT(5,1)
RESTRICTED REPLICATION CAPACITY(5,1)
SEVERE DISEASE(5,1)
SUB GENOTYPE(5,1)
VACCINE MANUFACTURE(5,1)
VIRUS PROPAGATION(5,1)
VIRUS SPECIES(5,1)
AVIRULENT(4,2)
PRIMER(4,2)
CARRIER ADDITIVE(4,1)
CELL BOUND VIREMIA(4,1)
COMPLETE DELETION(4,1)
DETECTION CELL(4,1)
FLAVIVIRUS(4,1)
GASTROINTESTINAL DISORDER(4,1)
GENOMIC SEQUENCE(4,1)
IMMUNOGENICITY(4,1)
MAJOR ECONOMIC LOSS(4,1)
MINIMAL REQUIREMENT(4,1)
MODERATE DROP(4,1)
MODERATE TEMPERATURE RISE(4,1)
MUTANT CONSTRUCTION(4,1)
NON TRANSLATED REGION(4,1)
NPRO REGION(4,1)
PRE VACCINATION TEMPERATURE(4,1)
REMAINED NEGATIVE(4,1)
RNA POLYMERASE ACTIVITY(4,1)
SERUM PLUS(4,1)
SINGLE INTRAMUSCULAR IMMUNIZATION(4,1)
STRAIN CP(4,1)
STRETCH(4,1)
STRUCTURAL GENE(4,1)
(US20090232846)
VACCINE(100,18)
PESTIVIRUS MUTANT(100,7)
MUTANT PESTIVIRUS(100,2)
PREGNANT HEIFER EXPERIMENTAL INFECTION(92,1)
VIRUS LIFELONG EFFICIENT SHEDDER(76,1)
BVDV VACCINE CANDIDATE(73,1)
VIRUS CP STRAIN(64,4)
NPRO PROTEIN AMINOACID(50,3)
FLAVIVIRIDAE FAMILY(50,1)
GENE SEQUENCE ENCODING(45,3)
PERSISTENT INFECTION(45,1)
VIRUS SPREAD(43,1)
FETUS DEVELOPMENT(42,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(41,1)
GENUS PESTIVIRUS MEMBER(41,1)
MUTANT(40,32)
CODING SEQUENCE(39,7)
SUSCEPTIBLE CATTLE(39,1)
PESTIVIRUS(35,11)
NPRO REGION(35,3)
DELETED SEQUENCE(35,1)
CAUSATIVE AGENT(34,1)
CYTOPATHOGENIC STRAIN(34,1)
DEFECTIVE CSFV GENOME STILL(34,1)
VIRAL PARTICLE(34,1)
BVDV INFECTION(32,3)
EFFICIENT VACCINE CANDIDATE(32,2)
MUTANT EXPRESS(31,1)
BOVINE VIRAL DIARRHEA VIRUS(29,8)
VIRUS PROTEIN STRUCTURE(26,2)
BOVINE ANIMAL(26,1)
NPRO GENE SEQUENCE(25,2)
CATTLE PROTECTION(22,2)
BOVINE VIRAL DIARRHEA(21,1)
EVIDENCE(21,1)
N TERMINAL TWELVE(20,4)
INFECTION(18,22)
HELPER(18,1)
NEUTRALIZING ANTIBODY TITER(16,2)
BVDV(15,22)
CEDITEST BVDV ELISA(14,2)
BVDV NPRO DELETION MUTANT(14,1)
CSFV NPRO DELETION MUTANT(14,1)
PERSISTENTLY INFECTED FETUS EXCLUSION(14,1)
NASAL VIRUS SHEDDING(13,5)
MILD RESPIRATORY SYMPTOM(13,2)
VACCINE VIRUS NASAL EXCRETION(13,1)
VACCINE VIRUS NASAL SHEDDING(13,1)
TERMINAL TWELVE AMINOACID(12,4)
BVDV NA VE HEIFER(12,1)
PESTIVIRUS ALL STRUCTURAL PROTEIN(12,1)
IMMUNIZED ANIMAL(11,3)
BVDV NASAL SHEDDING(11,1)
ORF ENCODED POLYPROTEIN(11,1)
PESTIVIRAL ORF PROTEIN(11,1)
SAFE(10,2)
BOVINE UBIQUITIN GENE FRAGMENT(10,1)
CSFV NPRO MUTANT(10,1)
FETUS INFECTION PERSISTENCE(10,1)
NASAL BVDV EXCRETION(10,1)
PERSISTENTLY INFECTED CALF GENERATION(10,1)
PREGNANT HEIFER INFECTION(10,1)
INOCULATED ANIMAL(9,3)
BVDV IRE(9,2)
CEDI DIAGNOSTICS(9,2)
NONSTRUCTURAL PROTEIN(9,2)
PURIFIED BLOOD LEUKOCYTE(9,2)
SUPERNATANT BLIND PASSAGE(9,2)
CSFV STRAIN INDUCED VIRAEMIA(9,1)
DEFECTIVE BVDV GENOME(9,1)
GESTATION TRIMESTER(9,1)
HEIFER CLINICAL SIGN(9,1)
MOCK VACCINATED ANIMAL(9,1)
PRE VACCINATION EXACERBATION(9,1)
QUESTIONABLE BONE MARROW LAVAGE(9,1)
UNSPECIFIC MILD OCULAR(9,1)
VACCINATION CHALLENGE TRIAL(9,1)
VIRAL GENOME REARRANGEMENT(9,1)
VIRUS NPRO PROTEIN(9,1)
VIRUS ISOLATION(8,3)
WEEKLY INTERVAL(8,3)
CYTOPATHIC STRAIN(8,2)
INTRAMUSCULAR INFECTION(8,2)
LIVE VACCINE(8,2)
MUTANT VIRUS(8,2)
STERILE IMMUNITY(8,2)
VIRAL REPLICATION(8,2)
ANIMAL TRIAL SCHEDULE(8,1)
BVDV BIOTYPE(8,1)
BVDV CP STRAIN(8,1)
BVDV MUTANT STRAIN(8,1)
CONFERRING CYTOPATHOGENICITY(8,1)
ERYTHROCYTE ALKALINE LYSIS(8,1)
GLYCOSYLATED ENVELOPE PROTEIN(8,1)
GROWING VIRUS MUTANT(8,1)
INFECTIOUS CLONE PA BVDV(8,1)
INTERFERON INCOMPETENT MDBK CELL(8,1)
N PROPROTEIN AMINOACID(8,1)
NONSTRUCTURAL AUTOPROTEASE(8,1)
STRAIN CP PROPROTEIN(8,1)
UBIQUITIN PROTEOLYTIC ACTIVITY(8,1)
CLINICAL DISEASE SIGN(7,1)
CO CULTIVATION VIRUS REPLICATION DAY(7,1)
DIGESTED PLASMID PA BVDV(7,1)
FETAL ORGAN PANEL(7,1)
FETOPATHOGENICITY VIRUS DETECTION(7,1)
IMMUNIZED CALF(7,1)
MOCK VACCINATION(7,1)
NONCYTOPATHIC BVDV(7,1)
OVINE BORDER DISEASE VIRUS(7,1)
PESTIVIRAL VIRION(7,1)
PESTIVIRUS GENOME(7,1)
PESTIVIRUS REPLICATION(7,1)
SEROLOGICAL RESPONSE CLINICAL ABORTION(7,1)
SPORADIC COUGHING(7,1)
VIRUS ENVELOPE PROTEIN(7,1)
PROTECTIVE IMMUNE RESPONSE(6,3)
INDIRECT IMMUNOFLUORESCENCE TEST(6,2)
PART DELETION(6,2)
PCR FRAGMENT(6,2)
ANTIBODY NEUTRALIZATION(6,1)
ATTENUATED PHENOTYPE(6,1)
BVDV SUBTYPE(6,1)
CLINICAL INVESTIGATION MONITORING(6,1)
COMMERCIAL ANTIGEN ELISA(6,1)
CREATED BVDV MUTANT(6,1)
CSFV REPLICATION(6,1)
ERNS MUTATION(6,1)
FETUS NUMEROUS ORGAN(6,1)
HETEROLOGOUS BVDV(6,1)
MUCOSAL LESION(6,1)
MURINE UBIQUITIN SEQUENCE(6,1)
NEUTRALIZATION ASSAY(6,1)
NPRO GENE CODING REGION(6,1)
NPRO MUTATION(6,1)
OREGON C24V(6,1)
PESTIVIRUS PROTEIN(6,1)
PREGNANT CATTLE(6,1)
RETARDED LEUKOCYTE REDUCTION(6,1)
RT PCR ASSAY(6,1)
SERUM NEUTRALIZATION TEST(6,1)
SUBGENOMIC RNA(6,1)
VACCINATED CALF CELL(6,1)
VACCINATION EFFICACY(6,1)
VACCINE CATEGORY(6,1)
VIRAL GENOME SEQUENCE(6,1)
VIRULENT BVDV(6,1)
BOVINE CELL(5,2)
CULTURED CELL INFECTION(5,2)
DOUBLE MUTANT(5,2)
SWAB FLUID(5,2)
BOVINE FRAGMENT(5,1)
BVDV AG SERUM PLUS(5,1)
BVDV ANTIBODY(5,1)
BVDV ANTIGEN(5,1)
BVDV CDNA(5,1)
CHALLENGE INFECTION(5,1)
CLINICAL BVD(5,1)
CO CULTURE DAY(5,1)
CSFV MUTANT(5,1)
DAY POST VACCINATION(5,1)
ERNS GENE(5,1)
ERNS PROTEIN(5,1)
FATAL MUCOSAL DISEASE(5,1)
INFECTIOUS VIRUS(5,1)
INOCULATED CULTURE(5,1)
INOCULATED PIG(5,1)
INOCULATION ROUTE(5,1)
LATE CP(5,1)
LIVE ATTENUATED VACCINE(5,1)
LIVE VACCINATION(5,1)
MARKED LEUKOPENIA(5,1)
MODERATE TITER(5,1)
NCP STRAIN(5,1)
NCPBVDV STRAIN(5,1)
NUMEROUS CP BVDV(5,1)
OVERLAPPING NUCLEOTIDE(5,1)
PATHOLOGICAL FINDING(5,1)
PI SYNDROME(5,1)
RESTRICTION FRAGMENT(5,1)
RNA DEPENDANT(5,1)
RT PCR ANALYSIS(5,1)
SAMPLE HOMOGENIZATION(5,1)
SERINE PROTEASE(5,1)
SUPERNATANT CONSECUTIVE PASSAGE(5,1)
UNINFECTED CELL CULTURE SUPERNATANT(5,1)
VIRAL GENOME EQUIVALENT(5,1)
VIRUS INOCULATION(5,1)
REPLICON(4,3)
PRIMER(4,2)
WHOLE OBSERVATION PERIOD(4,2)
ADVERSE CLINICAL REACTION(4,1)
ANIMAL SEROLOGICAL RESPONSE(4,1)
BVDV IMMUNITY LEVEL(4,1)
BVDV PROTEIN PRESENCE(4,1)
CELL LYSIS(4,1)
DIFFERENTIAL PCR(4,1)
EARLY PREGNANCY(4,1)
EFFICIENT CLEAVAGE(4,1)
FAINT ELEVATION(4,1)
GENE ENCODING(4,1)
GROWTH KINETICS(4,1)
INCUBATION DAY(4,1)
LEUKOCYTE COUNT MARKED DECREASE(4,1)
MATURE PROTEIN(4,1)
MINI KIT(4,1)
MODIFIED LIVE VIRUS(4,1)
MUTANT GROWTH(4,1)
PROTEIN CODING(4,1)
RESEARCH PROJECT(4,1)
RESTRICTED REPLICATION CAPACITY(4,1)
SEVERE DISEASE(4,1)
SUB GENOTYPE(4,1)
VACCINE MANUFACTURE(4,1)
VIRUS PROPAGATION(4,1)
BVDV 2B(3,1)
BVDV SPECIFIC CLINICAL SYMPTOM(3,1)
CARRIER ADDITIVE(3,1)
CELL BOUND VIREMIA(3,1)
DETECTION CELL(3,1)
EDTA BLOOD(3,1)
FLAVIVIRUS(3,1)
GASTROINTESTINAL DISORDER(3,1)
GENE SEQUENCE(3,1)
GENOMIC SEQUENCE(3,1)
HOST ANIMAL(3,1)
IB STRAIN(3,1)
IMMUNOGENICITY(3,1)
MAJOR ECONOMIC LOSS(3,1)
MINIMAL REQUIREMENT(3,1)
MODERATE DROP(3,1)
MODERATE TEMPERATURE RISE(3,1)
MUTANT CONSTRUCTION(3,1)
NON TRANSLATED REGION(3,1)
PRE VACCINATION TEMPERATURE(3,1)
(US8071108)
VACCINE(100,18)
CODING SEQUENCE(100,7)
PESTIVIRUS MUTANT(100,7)
N TERMINAL TWELVE(100,4)
GENE SEQUENCE ENCODING(100,3)
NPRO PROTEIN AMINOACID(100,3)
NPRO REGION(100,3)
INTACT ERNS GENE(100,1)
MUTANT CYTOPATHOGENIC PESTIVIRUS(100,1)
PREGNANT HEIFER EXPERIMENTAL INFECTION(83,1)
CYTOPATHOGENIC PESTIVIRUS(71,1)
VIRUS LIFELONG EFFICIENT SHEDDER(69,1)
BVDV VACCINE CANDIDATE(66,1)
FLAVIVIRIDAE FAMILY(45,1)
PERSISTENT INFECTION(41,1)
VIRUS SPREAD(39,1)
VIRUS PROTEIN STRUCTURE(38,2)
FETUS DEVELOPMENT(38,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(37,1)
GENUS PESTIVIRUS MEMBER(37,1)
OVINE BORDER DISEASE VIRUS(35,2)
SUSCEPTIBLE CATTLE(35,1)
BOVINE VIRAL DIARRHEA VIRUS(33,9)
MUTANT PESTIVIRUS(33,1)
MUTANT(32,30)
VIRUS CP STRAIN(31,3)
DEFECTIVE CSFV GENOME STILL(31,1)
CAUSATIVE AGENT(30,1)
VIRAL PARTICLE(30,1)
BVDV INFECTION(29,3)
EFFICIENT VACCINE CANDIDATE(29,2)
PESTIVIRUS(28,10)
BOVINE ANIMAL(23,1)
NPRO GENE SEQUENCE(22,2)
CATTLE PROTECTION(20,2)
CLASSICAL SWINE FEVER VIRUS(19,2)
BOVINE VIRAL DIARRHEA(19,1)
EVIDENCE(19,1)
HELPER(17,1)
INFECTION(16,22)
NEUTRALIZING ANTIBODY TITER(14,2)
BVDV(13,21)
CEDITEST BVDV ELISA(13,2)
MILD RESPIRATORY SYMPTOM(12,2)
BVDV NPRO DELETION MUTANT(12,1)
CSFV NPRO DELETION MUTANT(12,1)
PERSISTENTLY INFECTED FETUS EXCLUSION(12,1)
NASAL VIRUS SHEDDING(11,5)
TERMINAL TWELVE AMINOACID(11,4)
BVDV NA VE HEIFER(11,1)
PESTIVIRUS ALL STRUCTURAL PROTEIN(11,1)
VACCINE VIRUS NASAL EXCRETION(11,1)
VACCINE VIRUS NASAL SHEDDING(11,1)
IMMUNIZED ANIMAL(10,3)
BVDV NASAL SHEDDING(10,1)
ORF ENCODED POLYPROTEIN(10,1)
PESTIVIRAL ORF PROTEIN(10,1)
SAFE(9,2)
BOVINE UBIQUITIN GENE FRAGMENT(9,1)
CSFV NPRO MUTANT(9,1)
FETUS INFECTION PERSISTENCE(9,1)
NASAL BVDV EXCRETION(9,1)
PERSISTENTLY INFECTED CALF GENERATION(9,1)
PREGNANT HEIFER INFECTION(9,1)
INOCULATED ANIMAL(8,3)
BVDV IRE(8,2)
CEDI DIAGNOSTICS(8,2)
NONSTRUCTURAL PROTEIN(8,2)
PURIFIED BLOOD LEUKOCYTE(8,2)
SUPERNATANT BLIND PASSAGE(8,2)
CSFV STRAIN INDUCED VIRAEMIA(8,1)
DEFECTIVE BVDV GENOME(8,1)
GESTATION TRIMESTER(8,1)
HEIFER CLINICAL SIGN(8,1)
MOCK VACCINATED ANIMAL(8,1)
PRE VACCINATION EXACERBATION(8,1)
QUESTIONABLE BONE MARROW LAVAGE(8,1)
UNSPECIFIC MILD OCULAR(8,1)
VACCINATION CHALLENGE TRIAL(8,1)
VIRAL GENOME REARRANGEMENT(8,1)
VIRUS NPRO PROTEIN(8,1)
VIRUS ISOLATION(7,3)
WEEKLY INTERVAL(7,3)
CYTOPATHIC STRAIN(7,2)
INTRAMUSCULAR INFECTION(7,2)
LIVE VACCINE(7,2)
MUTANT VIRUS(7,2)
STERILE IMMUNITY(7,2)
VIRAL REPLICATION(7,2)
ANIMAL TRIAL SCHEDULE(7,1)
BVDV BIOTYPE(7,1)
BVDV CP STRAIN(7,1)
BVDV MUTANT STRAIN(7,1)
CONFERRING CYTOPATHOGENICITY(7,1)
ERYTHROCYTE ALKALINE LYSIS(7,1)
GLYCOSYLATED ENVELOPE PROTEIN(7,1)
GROWING VIRUS MUTANT(7,1)
INFECTIOUS CLONE PA BVDV(7,1)
INTERFERON INCOMPETENT MDBK CELL(7,1)
N PROPROTEIN AMINOACID(7,1)
NONSTRUCTURAL AUTOPROTEASE(7,1)
STRAIN CP PROPROTEIN(7,1)
UBIQUITIN PROTEOLYTIC ACTIVITY(7,1)
INDIRECT IMMUNOFLUORESCENCE TEST(6,2)
PART DELETION(6,2)
PCR FRAGMENT(6,2)
CLINICAL DISEASE SIGN(6,1)
CO CULTIVATION VIRUS REPLICATION DAY(6,1)
DIGESTED PLASMID PA BVDV(6,1)
FETAL ORGAN PANEL(6,1)
FETOPATHOGENICITY VIRUS DETECTION(6,1)
IMMUNIZED CALF(6,1)
MOCK VACCINATION(6,1)
NONCYTOPATHIC BVDV(6,1)
PESTIVIRAL VIRION(6,1)
PESTIVIRUS GENOME(6,1)
PESTIVIRUS REPLICATION(6,1)
SEROLOGICAL RESPONSE CLINICAL ABORTION(6,1)
SPORADIC COUGHING(6,1)
VIRUS ENVELOPE PROTEIN(6,1)
PROTECTIVE IMMUNE RESPONSE(5,3)
ANTIBODY NEUTRALIZATION(5,1)
ATTENUATED PHENOTYPE(5,1)
BOVINE FRAGMENT(5,1)
BVDV AG SERUM PLUS(5,1)
BVDV ANTIBODY(5,1)
BVDV ANTIGEN(5,1)
BVDV CDNA(5,1)
BVDV SUBTYPE(5,1)
CHALLENGE INFECTION(5,1)
CLINICAL BVD(5,1)
CLINICAL INVESTIGATION MONITORING(5,1)
CO CULTURE DAY(5,1)
COMMERCIAL ANTIGEN ELISA(5,1)
CREATED BVDV MUTANT(5,1)
CSFV MUTANT(5,1)
CSFV REPLICATION(5,1)
DAY POST VACCINATION(5,1)
ERNS GENE(5,1)
ERNS MUTATION(5,1)
ERNS PROTEIN(5,1)
FATAL MUCOSAL DISEASE(5,1)
FETUS NUMEROUS ORGAN(5,1)
HETEROLOGOUS BVDV(5,1)
INFECTIOUS VIRUS(5,1)
INOCULATED CULTURE(5,1)
INOCULATED PIG(5,1)
INOCULATION ROUTE(5,1)
LATE CP(5,1)
LIVE ATTENUATED VACCINE(5,1)
LIVE VACCINATION(5,1)
MARKED LEUKOPENIA(5,1)
MODERATE TITER(5,1)
MUCOSAL LESION(5,1)
MURINE UBIQUITIN SEQUENCE(5,1)
NCP STRAIN(5,1)
NCPBVDV STRAIN(5,1)
NEUTRALIZATION ASSAY(5,1)
NPRO GENE CODING REGION(5,1)
NPRO MUTATION(5,1)
NUMEROUS CP BVDV(5,1)
OREGON C24V(5,1)
OVERLAPPING NUCLEOTIDE(5,1)
PATHOLOGICAL FINDING(5,1)
PESTIVIRUS PROTEIN(5,1)
PI SYNDROME(5,1)
PREGNANT CATTLE(5,1)
RESTRICTION FRAGMENT(5,1)
RETARDED LEUKOCYTE REDUCTION(5,1)
RNA DEPENDANT(5,1)
RT PCR ANALYSIS(5,1)
RT PCR ASSAY(5,1)
SAMPLE HOMOGENIZATION(5,1)
SERINE PROTEASE(5,1)
SERUM NEUTRALIZATION TEST(5,1)
SUBGENOMIC RNA(5,1)
SUPERNATANT CONSECUTIVE PASSAGE(5,1)
UNINFECTED CELL CULTURE SUPERNATANT(5,1)
VACCINATED CALF CELL(5,1)
VACCINATION EFFICACY(5,1)
VACCINE CATEGORY(5,1)
VIRAL GENOME EQUIVALENT(5,1)
VIRAL GENOME SEQUENCE(5,1)
VIRULENT BVDV(5,1)
VIRUS INOCULATION(5,1)
REPLICON(4,3)
BOVINE CELL(4,2)
CULTURED CELL INFECTION(4,2)
DOUBLE MUTANT(4,2)
SWAB FLUID(4,2)
ADVERSE CLINICAL REACTION(4,1)
ANIMAL SEROLOGICAL RESPONSE(4,1)
BVDV IMMUNITY LEVEL(4,1)
BVDV PROTEIN PRESENCE(4,1)
CELL LYSIS(4,1)
DIFFERENTIAL PCR(4,1)
EARLY PREGNANCY(4,1)
EFFICIENT CLEAVAGE(4,1)
FAINT ELEVATION(4,1)
GENE ENCODING(4,1)
GROWTH KINETICS(4,1)
INCUBATION DAY(4,1)
LEUKOCYTE COUNT MARKED DECREASE(4,1)
MATURE PROTEIN(4,1)
MINI KIT(4,1)
MODIFIED LIVE VIRUS(4,1)
MUTANT GROWTH(4,1)
PROTEIN CODING(4,1)
RESEARCH PROJECT(4,1)
RESTRICTED REPLICATION CAPACITY(4,1)
SEVERE DISEASE(4,1)
SUB GENOTYPE(4,1)
VACCINE MANUFACTURE(4,1)
VIRUS PROPAGATION(4,1)
PRIMER(3,2)
WHOLE OBSERVATION PERIOD(3,2)
BVDV 2B(3,1)
BVDV SPECIFIC CLINICAL SYMPTOM(3,1)
CARRIER ADDITIVE(3,1)
CELL BOUND VIREMIA(3,1)
DETECTION CELL(3,1)
EDTA BLOOD(3,1)
FLAVIVIRUS(3,1)
GASTROINTESTINAL DISORDER(3,1)
GENE SEQUENCE(3,1)
GENOMIC SEQUENCE(3,1)
HOST ANIMAL(3,1)
IB STRAIN(3,1)
IMMUNOGENICITY(3,1)
MAJOR ECONOMIC LOSS(3,1)
MINIMAL REQUIREMENT(3,1)
MODERATE DROP(3,1)
MODERATE TEMPERATURE RISE(3,1)
MUTANT CONSTRUCTION(3,1)
NON TRANSLATED REGION(3,1)
(WO200834857)
PREGNANT HEIFER EXPERIMENTAL INFECTION(100,1)
PESTIVIRUS MUTANT(87,6)
VIRUS LIFELONG EFFICIENT SHEDDER(82,1)
BVDV VACCINE CANDIDATE(79,1)
FLAVIVIRIDAE FAMILY(54,1)
VIRUS CP STRAIN(52,3)
NPRO PROTEIN AMINOACID(50,4)
PERSISTENT INFECTION(48,1)
BVDV INFECTION(47,4)
MUTANT(46,36)
VIRUS SPREAD(46,1)
FETUS DEVELOPMENT(45,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(44,1)
GENUS PESTIVIRUS MEMBER(44,1)
SUSCEPTIBLE CATTLE(42,1)
GENE SEQUENCE ENCODING(37,2)
VACCINE(36,19)
CODING SEQUENCE(36,6)
CAUSATIVE AGENT(36,1)
CYTOPATHOGENIC STRAIN(36,1)
VIRAL PARTICLE(36,1)
BVDV STRAIN(34,5)
VACCINE MANUFACTURE(33,3)
MUTANT EXPRESS(33,1)
PESTIVIRUS(32,10)
NPRO REGION(28,2)
VIRUS PROTEIN STRUCTURE(28,2)
NPRO GENE SEQUENCE(27,2)
BVDV NPRO DELETION MUTANT(25,3)
BOVINE VIRAL DIARRHEA VIRUS(24,3)
CATTLE PROTECTION(24,2)
BOVINE VIRAL DIARRHEA(23,1)
EVIDENCE(23,1)
HELPER(20,1)
INFECTION(19,23)
N TERMINAL TWELVE(19,6)
GENOME STILL(18,1)
PREGNANT BVDV NAVE HEIFER(18,1)
NEUTRALIZING ANTIBODY TITER(17,2)
CEDITEST BVDV ELISA(15,2)
PERSISTENTLY INFECTED FETUS EXCLUSION(15,1)
NASAL VIRUS SHEDDING(14,5)
MILD RESPIRATORY SYMPTOM(14,2)
VACCINE VIRUS NASAL EXCRETION(14,1)
VACCINE VIRUS NASAL SHEDDING(14,1)
LIVESTOCK(13,2)
PESTIVIRUS ALL STRUCTURAL PROTEIN(13,1)
LIVE VACCINE(12,4)
IMMUNIZED ANIMAL(12,3)
BVDV NASAL SHEDDING(12,1)
ORF ENCODED POLYPROTEIN(12,1)
PESTIVIRAL ORF PROTEIN(12,1)
N PROPROTEIN(11,2)
BOVINE UBIQUITIN GENE FRAGMENT(11,1)
BVDV NAVE CALF(11,1)
FETUS INFECTION PERSISTENCE(11,1)
NASAL BVDV EXCRETION(11,1)
PERSISTENTLY INFECTED CALF GENERATION(11,1)
PREGNANT HEIFER INFECTION(11,1)
INOCULATED ANIMAL(10,3)
CEDI DIAGNOSTICS(10,2)
NONSTRUCTURAL PROTEIN(10,2)
PART DELETION(10,2)
PURIFIED BLOOD LEUKOCYTE(10,2)
SUPERNATANT BLIND PASSAGE(10,2)
DEFECTIVE BVDV GENOME(10,1)
GESTATION TRIMESTER(10,1)
HEIFER CLINICAL SIGN(10,1)
MOCK VACCINATED ANIMAL(10,1)
QUESTIONABLE BONE MARROW LAVAGE(10,1)
UNSPECIFIC MILD OCULAR(10,1)
VACCINATION CHALLENGE TRIAL(10,1)
VIRAL GENOME REARRANGEMENT(10,1)
VIRUS NPRO PROTEIN(10,1)
ANIMAL TRIAL SCHEDULE(9,1)
BVDV BIOTYPE(9,1)
BVDV CP STRAIN(9,1)
BVDV MUTANT STRAIN(9,1)
CONFERRING CYTOPATHOGENICITY(9,1)
ERYTHROCYTE ALKALINE LYSIS(9,1)
GLYCOSYLATED ENVELOPE PROTEIN(9,1)
GROWING VIRUS MUTANT(9,1)
INFECTIOUS CLONE PA BVDV(9,1)
NONSTRUCTURAL AUTOPROTEASE(9,1)
UBIQUITIN PROTEOLYTIC ACTIVITY(9,1)
PLASMID PA BVDV(8,3)
VIRUS ISOLATION(8,3)
WEEKLY INTERVAL(8,3)
CYTOPATHIC STRAIN(8,2)
INTRAMUSCULAR INFECTION(8,2)
MUTANT VIRUS(8,2)
STERILE IMMUNITY(8,2)
VIRAL REPLICATION(8,2)
ANIMAL TRIAL SETUP(8,1)
CLINICAL DISEASE SIGN(8,1)
CO CULTIVATION VIRUS REPLICATION DAY(8,1)
FETAL ORGAN PANEL(8,1)
IMMUNIZED CALF(8,1)
MOCK VACCINATION(8,1)
NONCYTOPATHIC BVDV(8,1)
PESTIVIRAL VIRION(8,1)
PESTIVIRUS GENOME(8,1)
PESTIVIRUS REPLICATION(8,1)
SPORADIC COUGHING(8,1)
VIRUS ENVELOPE PROTEIN(8,1)
PROTECTIVE IMMUNE RESPONSE(7,3)
BLOCKING ELISA(7,2)
INDIRECT IMMUNOFLUORESCENCE TEST(7,2)
PCR FRAGMENT(7,2)
ANTIBODY NEUTRALIZATION(7,1)
ATTENUATED PHENOTYPE(7,1)
BVDV SUBTYPE(7,1)
COMMERCIAL ANTIGEN ELISA(7,1)
CREATED BVDV MUTANT(7,1)
DUPLEX REALTIME(7,1)
EFFICIENT VACCINE CANDIDATE(7,1)
ERNS MUTATION(7,1)
FETUS NUMEROUS ORGAN(7,1)
HETEROLOGOUS BVDV(7,1)
MUCOSAL LESION(7,1)
MURINE UBIQUITIN SEQUENCE(7,1)
NPRO MUTATION(7,1)
PESTIVIRUS PROTEIN(7,1)
PREGNANT CATTLE(7,1)
RETARDED LEUKOCYTE REDUCTION(7,1)
RNEASYOMINI KIT(7,1)
RT PCR ASSAY(7,1)
SERUM NEUTRALIZATION TEST(7,1)
STRAIN INDUCED VIRAEMIA(7,1)
VACCINATED CALF CELL(7,1)
VACCINATION EFFICACY(7,1)
VACCINE CATEGORY(7,1)
VIRAL GENOME SEQUENCE(7,1)
VIRULENT BVDV(7,1)
CODING REGION(6,4)
WILD TYPE PESTIVIRUS(6,2)
BOVINE FRAGMENT(6,1)
BVDV AG SERUM PLUS(6,1)
BVDV ANTIBODY(6,1)
BVDV ANTIGEN(6,1)
BVDV CDNA(6,1)
BVDV1 STRAIN(6,1)
BVDV2 STRAIN(6,1)
CHALLENGE INFECTION(6,1)
CLINICAL BVD(6,1)
CO CULTURE DAY(6,1)
COMPLETE BVDV NPRO(6,1)
ERNS GENE(6,1)
ERNS PROTEIN(6,1)
GESTATION DAY(6,1)
INFECTIOUS VIRUS(6,1)
INOCULATED CULTURE(6,1)
INOCULATED PIG(6,1)
INOCULATION ROUTE(6,1)
LATE CP(6,1)
LIVE ATTENUATED VACCINE(6,1)
LIVE VACCINATION(6,1)
MARKED LEUKOPENIA(6,1)
MODERATE TITER(6,1)
NCP STRAIN(6,1)
NCPBVDV STRAIN(6,1)
NPRO MUTANT(6,1)
NUMEROUS CP BVDV(6,1)
OVERLAPPING NUCLEOTIDE(6,1)
PATHOLOGICAL FINDING(6,1)
RESTRICTION FRAGMENT(6,1)
RNA DEPENDANT(6,1)
RT PCR ANALYSIS(6,1)
SAMPLE HOMOGENIZATION(6,1)
SERINE PROTEASE(6,1)
SEROLOGICAL RESPONSE CLINICAL ABORTION(6,1)
SUPERNATANT CONSECUTIVE PASSAGE(6,1)
UNINFECTED CELL CULTURE SUPERNATANT(6,1)
VIRAL GENOME EQUIVALENT(6,1)
VIRUS INOCULATION(6,1)
REPLICON(5,3)
BOVINE CELL(5,2)
CULTURED CELL INFECTION(5,2)
DOUBLE MUTANT(5,2)
SWAB FLUID(5,2)
ADVERSE CLINICAL REACTION(5,1)
ANIMAL SEROLOGICAL RESPONSE(5,1)
BVDV IMMUNITY LEVEL(5,1)
BVDV PROTEIN PRESENCE(5,1)
CELL LYSIS(5,1)
DIFFERENTIAL PCR(5,1)
EARLY PREGNANCY(5,1)
EFFICIENT CLEAVAGE(5,1)
FAINT ELEVATION(5,1)
GENE ENCODING(5,1)
GROWTH KINETICS(5,1)
HIGHLY SENSITIVE REALTIME(5,1)
INCUBATION DAY(5,1)
LEUKOCYTE COUNT MARKED DECREASE(5,1)
MATURE PROTEIN(5,1)
MODIFIED LIVE VIRUS(5,1)
MUTANT GROWTH(5,1)
PCR PRIMER(5,1)
PROTEIN CODING(5,1)
RESEARCH PROJECT(5,1)
RESTRICTED REPLICATION CAPACITY(5,1)
RESTRICTION ENZYME(5,1)
SEVERE DISEASE(5,1)
SUB GENOTYPE(5,1)
VIRUS PROPAGATION(5,1)
DAILY(4,4)
AVIRULENT(4,2)
BVDV SPECIFIC ANTIBODY DEVELOPMENT(4,2)
TRATSCHIN(4,2)
ANIMAL TRIAL DESIGN(4,1)
BVDV NEUTRALIZATION ASSAY RESULT(4,1)
BVDV SPECIFIC CLINICAL SYMPTOM(4,1)
CARRIER ADDITIVE(4,1)
CELL BOUND VIREMIA(4,1)
COMPLETE DELETION(4,1)
DETECTION CELL(4,1)
EXACERBATION(4,1)
FLAVIVIRUS(4,1)
GASTROINTESTINAL DISORDER(4,1)
GENE SEQUENCE(4,1)
GENOMIC SEQUENCE(4,1)
HOST ANIMAL(4,1)
IB STRAIN(4,1)
IMMUNOGENICITY(4,1)
MAJOR ECONOMIC LOSS(4,1)
MINIMAL REQUIREMENT(4,1)
MODERATE DROP(4,1)
MODERATE TEMPERATURE RISE(4,1)
MUTANT CONSTRUCTION(4,1)
(JP2010504084)
AMINOACID(100,10)
NPRO REGION(100,2)
A GENE SEQUENCE ENCODING(100,1)
MUTANT PESTIVIRUS VACCINE(100,1)
NPRO PORTION(100,1)
PESTIVIRUS VARIANT(100,1)
PROTEIN CODING SEQUENCE END(100,1)
VIRUS PPL(100,1)
GENUS PESTIVIRUS FLAVIVIRIDAE FAMILY(72,1)
PERFOITNED CYTOPATHIC PESTIVIRUS(47,1)
ATTENUATED LIVE VACCINE(44,1)
MUTANT PESTI(43,1)
EFFICIENT VACCINE CANDIDATE(42,1)
YOUNG COW EXPERIMENTAL INFECTION(39,1)
TERRNINUS PROTEIN(38,1)
BOVINE VIRAL DIARRHEA VIRUS PESTI(37,1)
ECONOMIC IMPORTANCE DISEASE(35,1)
GENOME MUTATION(34,1)
PROTEIN ARCHITECTURE(31,1)
VIRUS VARIANT(28,3)
PESTIVIRUS GENOME(28,2)
BOVINE VIRAL DIARRHEA(27,1)
VACCINE(26,19)
GENE SEQUENCE ENCODING(25,2)
SAFE BVDV(25,1)
MUTANT(24,5)
VACCINE CANDIDATE(22,5)
TERMINUS PROTEIN CODING SEQUENCE(22,1)
BOVINE VIRAL DIARRHEA VIRUS PESTIVIRUS(21,1)
HOST ANIMAL(21,1)
PROTEIN TERMINUS(20,1)
NPRO PROTEIN CODING REGION(19,1)
INFECTION(18,12)
CATTLE PROTECTION(18,1)
NPRO GENE SEQUENCE(17,2)
FLAVIVIRIDAE(17,1)
AMINOACID CODING(16,1)
ENVELOPE STILL ENCODING(16,1)
PATHOGEN(16,1)
PESTI(16,1)
BVDV(15,34)
BOVINE VIRAL DIARRHEA VIRUS(15,7)
VIRUS(15,7)
PESTIVIRUS(14,10)
PROTECTIVE IMMUNE RESPONSE(14,3)
NPRO PROTEIN AMINOACID(13,2)
VACCINE VIRUS APPLICATION(13,1)
PREGNANCY(12,9)
EVIDENCE(12,1)
VIRAL DISEASE(12,1)
MUTATION(11,6)
NEUTRALIZING ANTIBODY TITER(11,3)
CULTURED CELL(11,1)
MUSCULOSKELETAL SYSTEM FARM(11,1)
SAFE(11,1)
PROTEIN(10,14)
CEDITEST BVDV ELISA(10,2)
WORLD(10,2)
MILD RESPIRATORY SYMPTOM(9,2)
NASAL VACCINE VIRUS SHEDDING(9,2)
BVDV NPRO DELETION MUTANT(9,1)
NPRO DELETION MUTANT BVDV(9,1)
NPRO GENE DEFICIENT BVDV(9,1)
REPLICATING GENOME DEFECTIVE BVDV(9,1)
WILD TYPE BREEDER PESTIVIRUS(9,1)
ANIMAL(8,17)
YOUNG COW(8,4)
DEFECT CSFV GENOME(8,2)
ICTV(8,1)
PESTIVIRUS NPRO MUTANT(8,1)
VACCINATED ANIMAL(7,4)
BVDV NPRO NULL MUTANT(7,1)
FETUS INFECTION PERSISTENCE(7,1)
NONCYTOPATHIC BVDV COW(7,1)
NPRO DELETION MUTANT ANIMAL(7,1)
NPRO MUTANT BVDV(7,1)
PERSISTENTLY INFECTED CALF OCCURRENCE(7,1)
PERSISTENTLY INFECTED FETUS(7,1)
PESTIVIRUS DEFICIENT MUTANT(7,1)
PESTIVIRUS VARIANT ARCHITECTURE(7,1)
UNINFECTED VACCINATED CALF(7,1)
VIRAL GENOME REARRANGEMENT(7,1)
POST CHALLENGE(6,6)
IMMUNIZED ANIMAL(6,3)
LIVE VACCINE(6,3)
CEDI DIAGNOSTICS(6,2)
NONSTRUCTURAL PROTEIN(6,2)
RT PCR ASSAY(6,2)
STRAIN(6,2)
BVDV FETAL INFECTION(6,1)
BVDV NEUTRALIZATION ASSAY(6,1)
NASAL VIRUS SHEDDING WEEKLY(6,1)
NPRO VARIANT BVDV(6,1)
VACCINATION CHALLENGE TRIAL(6,1)
BLOCKING ELISA(5,2)
BVDV INFECTION(5,2)
INOCULATED ANIMAL(5,2)
VIRUS INOCULATION(5,2)
ANIMAL BVDV ELISA(5,1)
BVDV BIOTYPE(5,1)
BVDV IMMUNITY REQUEST(5,1)
BVDV IRE(5,1)
CLINICAL DISEASE SIGN(5,1)
CULTURE IMMUNOFLUORESCENCE ANALYSIS(5,1)
CULTURE VIRAL REPLICATION(5,1)
DEFICIENT NPRO GENE(5,1)
ELISA ANTIGEN(5,1)
ENVELOPE PROTEIN GLYCOSYLATION(5,1)
ERNS GENE VARIANT(5,1)
INDUCED IMMUNE STERILIZATION(5,1)
INFECTIOUS CLONE PA BVDV(5,1)
INTERNATIONAL PUBLICATION PAMPHLET(5,1)
MUCOSA LESION(5,1)
PESTIVIRUS ORF(5,1)
PESTIVIRUS REPLICATION(5,1)
PESTIVIRUS VIRION(5,1)
PLASMID PA BVDV FRAGMENT(5,1)
SUGAR CANE LINE(5,1)
UBIQUITIN PROTEOLYTIC ACTIVITY(5,1)
YOUNG COW CLINICAL SIGN(5,1)
YOUNG FEMALE CATTLE(5,1)
VIRUS ISOLATION(4,2)
CSFV REPLICATION(4,1)
FETUS ORGAN(4,1)
HETEROLOGOUS BVDV(4,1)
HIGHLY TOXIC CSFV VARIANT(4,1)
INDIRECT FLUORESCENT ANTIBODY TEST(4,1)
MISSING NPRO(4,1)
N PRO AMINOACID(4,1)
NON INFECTIOUS CELL CULTURE SUPERNATANT(4,1)
OREGON C24V(4,1)
PESTIVIRUS PROTEIN(4,1)
SPORADIC COUGH(4,1)
SUBTYPE BVDV1(4,1)
TERILIZATION IMMUNE(4,1)
UNINFECTED YOUNG COW(4,1)
VACCINATION EFFICACY(4,1)
VACCINE INFECTION(4,1)
VIREMIA YOUNG COW(4,1)
VIRUS GENOMIC SEQUENCE(4,1)
VIRUS PROTEASE(4,1)
VIRUS TITER VIREMIA(4,1)
WEEK POST IMMUNIZATION(4,1)
WEEK POST VACCINATION(4,1)
GENOTYPE(3,3)
OBSERVATION PERIOD(3,3)
REPLICON(3,3)
BOVINE CELL(3,2)
DOUBLE MUTANT(3,2)
POLYPROTEIN(3,2)
ADVERSE CLINICAL REACTION(3,1)
ALKALI SOLUBILITY(3,1)
ANIMAL VIREMIA(3,1)
ATTENUATED VIRUS(3,1)
BLIND PASSAGE(3,1)
BORDER DISEASE VIRUS(3,1)
BOVINE CATTLE(3,1)
BOVINE VIRUS(3,1)
BVDV AG SERUM PLUS(3,1)
BVDV ANTIBODY(3,1)
BVDV ANTIGEN(3,1)
BVDV FETAL TISSUE(3,1)
CAPSID PROTEIN(3,1)
CDNA CLONE(3,1)
CELL INFECTION(3,1)
CELL VIRUS(3,1)
CLINICAL BVD(3,1)
CLINICAL INVESTIGATION(3,1)
CP BVDV CYTOPATHIC EFFECT(3,1)
CP BVDV VARIETY(3,1)
CP INDUCTION(3,1)
DAY POST INFECTION(3,1)
EARLY PREGNANCY(3,1)
ELISA BVDV(3,1)
FALSE VACCINATION(3,1)
FETAL ABORTION(3,1)
FETAL ORGAN(3,1)
GENE FRAGMENT(3,1)
GROWTH KINETICS(3,1)
INFECTION PREVENTION(3,1)
INFECTIOUS VIRUS(3,1)
INOCULATION ROUTE(3,1)
KIDNEY RNA(3,1)
LEUKOCYTE 3X(3,1)
LIVE ATTENUATED VACCINE(3,1)
LIVE VACCINATION(3,1)
LIVE VIRUS(3,1)
MANUFACTURER INSTRUCTION(3,1)
MINI KIT(3,1)
MUTANT VIRUS(3,1)
NASAL DISCHARGE BVDV(3,1)
NPRO BVDV(3,1)
NUCLEOTIDE INSERTION(3,1)
OCULAR DISCHARGE(3,1)
PATHOLOGICAL FINDING(3,1)
PERSISTENT INFECTION(3,1)
PI CALF(3,1)
PRIMER CP7(3,1)
PROTEIN GENE(3,1)
PROTEIN ORF(3,1)
PURIFIED LEUKOCYTE(3,1)
RESEARCH PROJECT(3,1)
RESTRICTION ENZYME(3,1)
RESTRICTION FRAGMENT(3,1)
RT PCR ANALYSIS(3,1)
SCHEDULED ANIMAL(3,1)
SEA SAND(3,1)
SERINE PROTEASE(3,1)
SERUM NEUTRALIZING(3,1)
SEVERE DISEASE(3,1)
SLOW REPLICATION(3,1)
STERILE IMMUNITY(3,1)
STRUCTURAL PROTEIN ERN(3,1)
SUBGENOMIC RNA(3,1)
SUPERNATANT PASSAGE(3,1)
SYMPTOM TYPICAL BVDV(3,1)
THYMUS RN(3,1)
TISSUE CULTURE(3,1)
UNTREATED CALF(3,1)
VACCINE VARIANT(3,1)
VIABLE VIRUS(3,1)
VIRAL GENOME EQUIVALENT(3,1)
VIRAL PARTICLE(3,1)
VIRUS PROPAGATION(3,1)
GRAPH SHOWING(2,4)
ANIMAL CONDITION(2,2)
BVDV SPECIFIC ANTIBODY(2,2)
CO CULTURE(2,2)
INTRANASAL(2,2)
LIVESTOCK(2,2)
ANIMAL STUDY(2,1)
BVDV SPECIFIC CLINICAL SYMPTOM(2,1)
DESIGN DELETION VARIANT(2,1)
EDTA BLOOD(2,1)
FETOPATHOGENICITY(2,1)
FINAL TITER(2,1)
FLAVIVIRUS(2,1)
GENOME SEQUENCE(2,1)
IMPACT FREEZE(2,1)
INFECTED CELL CULTURE(2,1)
LAVAGE SAMPLE(2,1)
LEUKOCYTE SIGNIFICANT REDUCTION(2,1)
LOG10TCID50BVDV(2,1)
MAJOR ECONOMIC LOSS(2,1)
(JP5775665)
BOVINE VIRAL DIARRHEA VIRUS(100,96)
PROTEIN(100,16)
AMINO ACID(100,10)
PESTIVIRUS(100,10)
CARRIER(100,4)
PESTIVIRUS VARIANT(100,4)
GENE SEQUENCE ENCODING(100,2)
(...)";"Basic materials chemistry
Pharmaceuticals";Open
"2005-12-07
2006-11-24
2008-05-13
2011-06-22";"US20120021001       A1 2012-01-26 [US20120021001]
STG: (A1) Application published
AP : 2011US-13165877 2011-06-22
FD :  Division of: US11/995,779 FDD=2008-05-13 [2008US-11995779]  abandoned
FD : Division of: WOPCT/IB2006/003412 FDD=2006-11-24 [2006WO-IB03412]
FD : Provisional Appl: US60/748,312 FDD=2005-12-07 [2005US-60748312]";68308674;US20120021001       A1 2012-01-26 [US20120021001];"2005US-60748312
2006WO-IB03412
2008US-11995779
2011US-13165877";;ZOETIS;ZOETIS;"(US20120021001)
US";"(US20120021001)
NAME=PFIZER INC. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 
";1;"HUANG CHICHI
SHEPPARD MICHAEL G
CAO XUEMEI
ZYBARTH GABRIELE M";"(US20120021001)
AU; US";"(US20120021001)
NAME=Huang Chichi , CITY=Berwyn , STATE=PA , COUNTRY=US 

NAME=Sheppard Michael G. , CITY=Victoria , COUNTRY=AU 

NAME=Cao Xuemei , CITY=Scituate , STATE=MA , COUNTRY=US 

NAME=Zybarth Gabriele M. , CITY=Westport , STATE=MA , COUNTRY=US 
";"(US20120021001)
Marked bovine viral diarrhea virus vaccines";"(US20120021001)
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals.";"(US20120021001)
1. A bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein at least one mutation is within the SES loop of the helicase domain of NS3 and results in reduced binding by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus is retained.
2. The bovine viral diarrhea virus of claim 1, wherein the monoclonal antibody is selected from the group consisting of 20.10.6; 1.11.3; 21.5.8; and 24.8.
3. The bovine viral diarrhea virus of claim 1 wherein the virus comprises a single helicase domain amino acid mutation.
4. The bovine viral diarrhea virus of claim 1 comprising a helicase domain mutation within the IGR loop.
5. The bovine viral diarrhea virus of claim 4 comprising a helicase domain mutation within the IGR loop at amino acid residue 1841.
6. The bovine viral diarrhea virus of claim 4 comprising a helicase domain mutation within the IGR loop at amino acid residue 1843.
7. The bovine viral diarrhea virus of claim 4 comprising a helicase domain mutation within the IGR loop at amino acid residue 1845.
8. The bovine viral diarrhea virus of claim 1 comprising a helicase domain mutation within the KHP loop.
9. The bovine viral diarrhea virus of claim 8 comprising a helicase domain mutation within the KHP loop at amino acid residue 1867.
10. The bovine viral diarrhea virus of claim 8 comprising a helicase domain mutation within the KHP loop at amino acid residue 1868.
11. The bovine viral diarrhea virus of claim 8 comprising a helicase domain mutation within the KHP loop at amino acid residue 1869.
12. The bovine viral diarrhea virus of claim 1 comprising a helicase domain mutation within the SES loop.
13. The bovine viral diarrhea virus of claim 3, wherein the helicase domain mutation corresponds to at amino acid residue 1939 of SEQ ID NO: 1.
14. The bovine viral diarrhea virus of claim 3, wherein the helicase domain mutation corresponds to amino acid residue 1942 of SEQ ID NO: 1.
15. The bovine viral diarrhea virus of claim 1 wherein the virus comprises two, three, or four helicase domain amino acid mutations.
16. The bovine viral diarrhea virus of claim 15 comprising two helicase domain mutations.
17. The bovine viral diarrhea virus of claim 16 wherein the two helicase domain mutations are within the IGR loop.
18. The bovine viral diarrhea virus of claim 17 wherein the two helicase domain mutations within the IGR loop are at amino acid residues 1843 and 1845.
19. The bovine viral diarrhea virus of claim 16 wherein the two helicase domain mutations are within the SES loop.
20. The bovine viral diarrhea virus of claim 19 wherein the two helicase domain mutations within the SES loop correspond to amino acid residues 1939 and 1942 of SEQ ID NO: 1.
21. The bovine viral diarrhea virus of claim 15 comprising three helicase domain mutations.
22. The bovine viral diarrhea virus of claim 21 wherein the three helicase domain mutations are within the KHP loop.
23. The bovine viral diarrhea virus of claim 22 wherein the three helicase domain mutations within the KHP loop correspond to amino acid residues 1867, 1868, and 1869.
24. The bovine viral diarrhea virus of claim 21, wherein the three helicase domain mutations are within the IGR loop, the KHP loop, and the SES loop correspond to amino acid residues 1845, 1868, and 1939 of SEQ ID NO: 1.
25. A marked bovine viral diarrhea virus vaccine comprising the bovine viral diarrhea virus of claim 1.
26. A method of differentiating an animal infected with bovine diarrhea virus from an animal vaccinated with a bovine diarrhea virus vaccine wherein said bovine diarrhea virus vaccine is a marked vaccine comprising at least one helicase domain amino acid mutation, said method comprising; 
 (a) obtaining a test sample from a test animal; 
 (b) detecting bovine diarrhea virus in said test sample; and 
 (c) determining whether the bovine diarrhea virus contains the mutation.
27. The method of claim 26 wherein said method of detecting bovine diarrhea virus employs the use of at least one monoclonal antibody.
28. The method of claim 26 wherein the marked vaccine helicase domain amino acid mutation is in the helicase domain of NS3.
29. The method of claim 27 comprising the steps of: 
 (a) adding labeled antibody capable of detecting wild type bovine diarrhea virus or capable of detecting mutated bovine diarrhea virus to a test sample, wherein the test sample contains body fluid from test animal and; 
 (b) measuring the binding affinity of said labeled antibody to said wild type bovine diarrhea virus or to said mutated bovine diarrhea virus by contacting at least one monoclonal antibody to said wild type bovine diarrhea virus or to said mutated bovine diarrhea virus; and 
 (c) determining the vaccination status of test animal by comparing results of binding affinity using a monoclonal antibody directed to wild type BVDV versus BVDV with mutated NS3.
30. The method of claim 27 comprising the steps of: 
 (a) adding a labeled first antibody directed to a domain other than mutated NS3; and 
 (b) adding a labeled second antibody directed to a mutated portion of NS3.
31. The method of claim 30 wherein the first antibody is directed to a wild type virus.
32. The method of claim 30 wherein the second antibody is directed to the mutated portion of NS3.
33. The method of claim 32 wherein the second antibody is directed against NS3 and is selected from the group consisting of 20.10.6; 1.11.3; 21.5.8; and 24.8.
34. The method of claim 32 wherein the second antibody is directed to at least one mutated portion of the NS3 selected from the group consisting of the IGR loop, the KHP loop, and the SES loop.
35. The method of claim 34 wherein the bovine viral diarrhea virus comprises at least one helicase domain amino acid mutation within the IGR loop at an amino acid residue selected from the group consisting of 1841, 1843, and 1845.
36. The method of claim 34 wherein the bovine viral diarrhea virus comprises at least one helicase domain amino acid mutation within the KHP loop at an amino acid residue selected from the group consisting of 1867, 1868, and 1869.
37. The method of claim 34 wherein the bovine viral diarrhea virus comprises of at least one helicase domain amino acid mutation within the SES loop at an amino acid residue selected from the group consisting of 1939, and 1942.
38. The method of claim 34 wherein the bovine viral diarrhea virus comprises at least one helicase domain amino acid mutation within the IGR loop, the KHP loop, and the SES loop at amino acid residues 1845, 1868, and 1939.";"(US20120021001)
Accordingly, the present invention provides methods of treating infections in animal subjects caused by BDV viruses by administering to an animal a therapeutically effective amount of a mutated BVD virus of the present invention.
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained.
A further aspect of the present invention provides methods of determining the attenuated virus of a prior vaccination as the origin of the BVD virus present in an animal subject.";"(US20120021001)
It is desirable to delete an immunodominant epitope without significantly altering the function of the helicase.
Based on the above, it is clear that a need exists for new and more effective vaccines to control the spread of BVDV, Such a vaccine could be invaluable in future national or regional BVDV eradication programs, and could also be combined with other marked cattle vaccines, representing a substantial advance in livestock farming.
The term animal subjects, as used herein, is meant to include any animal that is susceptible to BVDV infections, such as bovine, sheep and swine.
Amplification and genetic manipulation of a full-length BVDV proviral molecular clone in Escherichia coli (E. coli) is difficult because the plasmid is unstable during propagation.
Therefore, a mutation at the same locus of the helicase domain of a variant BVD virus, or plasmid constructed to express a variant BVD virus, will result in an equivalent loss of recognition by antibodies raised against the variant, unmodified virus peptide.";"A61K-039/12
C12N-007/00
C12Q-001/70";"(US20120021001)
1. A bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein at least one mutation is within the SES loop of the helicase domain of NS3 and results in reduced binding by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus is retained.
26. A method of differentiating an animal infected with bovine diarrhea virus from an animal vaccinated with a bovine diarrhea virus vaccine wherein said bovine diarrhea virus vaccine is a marked vaccine comprising at least one helicase domain amino acid mutation, said method comprising; (a) obtaining a test sample from a test animal; (b) detecting bovine diarrhea virus in said test sample; and (c) determining whether the bovine diarrhea virus contains the mutation.";"(US20120021001)
BOVINE VIRAL DIARRHEA VIRUS(100,63)
HELICASE DOMAIN MUTATION(100,40)
ANIMAL(100,18)
BOVINE DIARRHEA VIRUS(100,14)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(100,5)
BOVINE DIARRHEA VIRUS VACCINE(100,3)
VARIANT BVD VIRUS(45,2)
REGIONAL BVDV ERADICATION PROGRAM(43,1)
HELICASE DOMAIN AMINOACID(40,7)
HELICASE DOMAIN(37,24)
BVD VIRUS ORIGIN(35,1)
KHP LOOP(34,17)
IGR LOOP(32,23)
UNMODIFIED VIRUS PEPTIDE(32,1)
INFECTIOUS VIRUS GENERATION(31,8)
MARKED CATTLE VACCINE(31,1)
PROVIRAL MOLECULAR CLONE(29,1)
MUTATION(27,35)
BVD VIRUS MUTATION(25,4)
REPLICATION VIRAL RNA(24,10)
MARKED VACCINE HELICASE DOMAIN(24,2)
MUTATED BOVINE DIARRHEA VIRUS(23,6)
BDV VIRUS(22,1)
BVDV SPREAD(22,1)
GENETIC MANIPULATION(21,1)
AMINOACID RESIDUE(20,34)
SE LOOP(19,18)
MONOCLONAL ANTIBODY(19,15)
BVDV INFECTION(17,3)
ANTIBODY(16,38)
MARKED VACCINE(16,4)
ANIMAL SUBJECT(14,4)
IMMUNODOMINANT EPITOPE(14,1)
RECOGNITION EQUIVALENT LOSS(14,1)
VACCINE(13,21)
TEST VACCINATION STATUS(13,2)
PRIOR VACCINATION ATTENUATED VIRUS(13,1)
TEST ANIMAL(12,4)
HELICASE FUNCTION(12,1)
RECOGNITION LOSS(11,9)
ESCHERICHIA(11,1)
NATIONAL(11,1)
TERM ANIMAL SUBJECT(11,1)
AMINOACID MUTATION(10,15)
PLASMID(10,7)
SWINE(9,1)
AMPLIFICATION(8,2)
HELICASE SUBDOMAIN(7,3)
PROPAGATION(7,3)
BVDV HELICASE DOMAIN(7,2)
SINGLE HELICASE DOMAIN(7,2)
SUBVIRAL REPLICON BACKBONE(7,2)
BVDV SUBVIRAL REPLICON CONTEXT(7,1)
TREATING INFECTION(7,1)
BOVINE(6,3)
SHEEP(6,3)
ATTENDING VETERINARIAN SUPERVISION(6,1)
CHYMOTRYPSIN SERINE PROTEASE FAMILY(6,1)
INFECTIOUS PROVIRAL PARENT PLASMID(6,1)
INTESTINAL MUCOSA ULCERATION(6,1)
MUTANT BVD VIRAL GENOME(6,1)
PROGENY MUTANT BVD VIRUS(6,1)
VECTASTAIN ELITE ABC KIT(6,1)
MUTATED PORTION(5,6)
DOMAIN RESULT(5,3)
PARENTERAL ADMINISTRATION(5,3)
NONSTRUCTURAL PROTEIN(5,2)
BIOCHEMICAL NOMENCLATURE COMMISSION(5,1)
BVDV CYTOPATHIC STRAIN(5,1)
BVDV IMMUNODOMINANT PROTEIN(5,1)
BVDV INFECTION SYMPTOM(5,1)
BVDV POLYPROTEIN ENCODING(5,1)
BVDV RNA REPLICATION(5,1)
FULL LENGTH BVDV(5,1)
MAB RECOGNITION ABOLISHMENT(5,1)
MAB RECOGNIZING BVDV(5,1)
MARKER IMMUNOGENIC DETERMINANT(5,1)
MLV BVDV VACCINE(5,1)
MUTANT R1942A DEMONSTRATED REACTIVITY(5,1)
MUTANT VIRAL HELICASE(5,1)
NCP BIOTYPE VIRUS(5,1)
PREGNANT CATTLE PLACENTA(5,1)
TNT RABBIT RETICULOCYTE(5,1)
TRUNCATED SUBVIRAL REPLICON(5,1)
PROGRAMMED RELEASE(4,5)
VETERINARILY ACCEPTABLE CARRIER(4,4)
GENOMIC NUCLEIC ACID MOLECULE(4,3)
11841A MUTATION(4,2)
1845A MUTATION(4,2)
1867A MUTATION(4,2)
ANTIBODY TITER(4,2)
AURAL ADMINISTRATION(4,2)
CAPSID PROTEIN(4,2)
CLASSICAL SWINE FEVER(4,2)
DOMAIN PEPTIDE SEQUENCE(4,2)
E1939A MUTATION(4,2)
EUKARYOTIC HOST CELL(4,2)
H1868A MUTATION(4,2)
INOCULATED ANIMAL(4,2)
INTRA LYMPH NODE(4,2)
MUTANT REPLICON(4,2)
MUTATED EPITOPE(4,2)
P1869A MUTATION(4,2)
PLASMID PROPAGATION(4,2)
PRESSURIZED CONTAINER(4,2)
PROKARYOTIC HOST CELL(4,2)
R1942A MUTATION(4,2)
WESTERN BLOT(4,2)
BOVINE DONOR CALF SERUM(4,1)
BVD DISEASE THREAT(4,1)
BVD VIRUS GENOME(4,1)
BVD VIRUS INDICATIVE(4,1)
BVDV INFECTION INCIDENCE(4,1)
BVDV NEGATIVE HEALTHY CALF(4,1)
BVDV NUCLEOCAPSID(4,1)
BVDV VIRULENT STRAIN(4,1)
CANDIDATE EPITOPE IDENTIFICATION(4,1)
CATALYTIC HELICASE ACTIVITY PRESERVATION(4,1)
COW PREGNANCY STATUS(4,1)
GENOMIC RNA PACKAGING(4,1)
HELIX SUBDOMAIN(4,1)
HOMOLOGOUS VIRUS STRAIN(4,1)
IMMUNOLOGICALLY DISTINCT EPITOPE(4,1)
INDIRECT IMMUNOFLUORESCENT ASSAY(4,1)
INTACT HELICASE PROTEIN(4,1)
MADIN DARBY BOVINE KIDNEY(4,1)
MARKED BVDV VACCINE STRAIN(4,1)
MARKED VIRUS GROWTH KINETICS(4,1)
MUTAGENIC OLIGONUCLEOTIDE PRIMER VIRTUE(4,1)
MUTANT PCR FRAGMENT(4,1)
MUTATED BDV VIRUS(4,1)
RD CELL TRANSFECTION(4,1)
RESIDUE R1843A MUTATION(4,1)
SERUM NEUTRALIZING TITER(4,1)
TRANSDERMAL PENETRATION ENHANCER(4,1)
VIRAL DIAHRREA VIRUS(4,1)
VIRUS NEUTRALIZATION ASSAY(4,1)
MODIFIED RELEASE FORMULATION(3,5)
ANTIBODY PRESENCE(3,3)
MDBK CELL(3,3)
DRY POWDER INHALER(3,2)
INFECTION RISK(3,2)
MOLECULAR MODELING(3,2)
MUTATED SEQUENCE(3,2)
OVERNIGHT INCUBATION(3,2)
PARENTERAL ROUTE(3,2)
REPLACEMENT MUTANT(3,2)
TRANSFECTED CELL(3,2)
TRANSLATED PROTEIN(3,2)
ABSORBABLE GEL SPONGE(3,1)
AGENT FACILITATING CELLULAR UPTAKE(3,1)
ALANINE REPLACEMENT FRAGMENT(3,1)
AMPHIGEN ADJUVANT(3,1)
AVRIDINE LIPID(3,1)
BVD GENOMIC SEQUENCE(3,1)
BVD VIRION(3,1)
BVDV HELICASE MOLECULAR MODEL(3,1)
BVDV IDENTIFICATION(3,1)
BVDV INFECTED CATTLE(3,1)
BVDV INFECTION DETECTION(3,1)
BVDV SUBTYPE(3,1)
CERTIFIED BVDV NEGATIVE SEMEN(3,1)
CHALLENGE INOCULUM(3,1)
COMPETITIVE IMMUNOASSAY(3,1)
CONTRADICTORY DEFINITION(3,1)
CYTOPATHIC BVDV(3,1)
DIFFERENTIAL DIAGNOSTIC ASSAY(3,1)
EFFICIENT VRNA REPLICATION(3,1)
ENVELOPED VIRION FORMATION(3,1)
EPITOPE CONFORMATION(3,1)
EPITOPE REFINEMENT(3,1)
EXPRESSIBLE GENE(3,1)
FLAVIVIRIDAE FAMILY(3,1)
FRESH RD CELL MONOLAYER(3,1)
HELICASE HELICAL SUBDOMAIN(3,1)
HELICASE PROTEASE(3,1)
HELICASE SUPERFAMILY(3,1)
HERD CERTIFICATION(3,1)
HETEROLOGOUS CDNA(3,1)
HETEROLOGOUS DNA(3,1)
HIGHLY CONSERVED HELICASE(3,1)
HOG CHOLERA(3,1)
HORSERADISH PEROXIDASE(3,1)
IMMUNOHISTOCHEMISTRY ASSAY(3,1)
INFECTIOUS VIRAL PARTICLE(3,1)
INITIATING TRANSLOCATION(3,1)
INTRANASAL INOCULATION(3,1)
LABELED ANTIBODY AFFINITY(3,1)
LIGATED REACTION ALIQUOT(3,1)
MAJOR BVDV IMMUNOGEN(3,1)
MARKED VACCINE CONTEXT(3,1)
MARKER DETERMINANT(3,1)
METHIONINE METHYLSULFONIUM(3,1)
METHIONINE SULFOXIDE(3,1)
MLV VACCINE(3,1)
MONOPHOSPHORYL LIPID(3,1)
MUCOSAL DISEASE OUTBREAK(3,1)
MUTANT R1843A(3,1)
NADL BVDV(3,1)
NUCLEOSIDE TRIPHOSPHATE(3,1)
OVERLAPPING FRAGMENT ENCODING(3,1)
OVERLAPPING PCR FRAGMENT(3,1)
OVERLAPPING PCR STRATEGY(3,1)
PESTIVIRUS GENUS(3,1)
PLASMID DNA PURIFICATION(3,1)
POSTCHALLENGE INTERVAL(3,1)
PROTEASE COFACTOR(3,1)
PROVIRAL PLASMID(3,1)
PURIFIED MUTATED VIRUS(3,1)
R1942A MUTANT(3,1)
RADIOLABELED METHIONINE(3,1)
RD CELL FRESH MONOLAYER(3,1)
RESPONDING CTL DETECTION(3,1)
RESTRICTION ENZYME DIGESTION(3,1)
RNA MOLECULE ENCODING(3,1)
RNA REPLICATION EFFICIENCY INDICATOR(3,1)
SERUM NEUTRALIZATION ASSAY(3,1)
SERUM SERIAL DILUTION(3,1)
SORBITAN TRIOLEATE(3,1)
SUCCESSFUL VIRUS VACCINE(3,1)
SUCROSE GRADIENT CENTRIFUGATION(3,1)
SYNTHESIZED POLYPROTEIN(3,1)
TEST FRAGMENT PCR AMPLIFICATION(3,1)
TISSUE CULTURE FLASK(3,1)
TITER VIRUS YIELD(3,1)
TRADE ECONOMIC BENEFIT FREEDOM(3,1)
TRANSCRIPT AMPLIFICATION(3,1)
TRUNCATED PROTEIN TRANSLATION(3,1)
UNPROCESSED POLYPROTEIN(3,1)
VACCINATED CATTLE(3,1)
VACCINE FETAL TRANSMISSION(3,1)
VETERINARY PHYSICIAN(3,1)
VIRAL PROTEIN EXPRESSION(3,1)
VIRUS ACCELERATED ELIMINATION(3,1)
VIRUS DISSEMINATION(3,1)
WISCONSIN UNIVERSITY(3,1)
WILD TYPE(2,20)
ATOMIZER(2,4)
LACTOSE(2,4)
OPTIMEM(2,4)
CLONE(2,3)
ELECTROPHORESIS(2,3)
LIPOSOME(2,3)
VAGINAL ADMINISTRATION(2,3)
ACTIVE INGREDIENT(2,2)
ALKALINE PHOSPHATASE(2,2)
AMINOACID MIMETICS(2,2)
BODY FLUID(2,2)
BOVINE CELL CULTURE(2,2)
BVDV ISOLATION(2,2)
COLONY(2,2)
CYSTEINE(2,2)
DEXTROSE(2,2)
DIARRHEA(2,2)
DIVIDED DOSE(2,2)
ELECTROHYDRODYNAMICS(2,2)
ENGLAND BIOLAB(2,2)
ESTRUM(2,2)
EXCIPIENT(2,2)
FINE MIST(2,2)
FRAGMENT SEQUENCE(2,2)
GLYCOPROTEIN(2,2)
HELICASE ACTIVE SITE(2,2)
HYDROXYPROPYLMETHYLCELLULOSE(2,2)
INHALATION(2,2)
INTRANASAL ADMINISTRATION(2,2)
IONTOPHORESIS(2,2)
ISOTONIC AGENT(2,2)
MICRONEEDLE(2,2)
NEBULIZER(2,2)
NON CONSERVATIVE AMINOACID SUBSTITUTION(2,2)
NORLEUCINE(2,2)
O PHOSPHOSERINE(2,2)
OINTMENT(2,2)
PHENYLALANINE(2,2)
PLACEBO(2,2)
PRESERVATIVE(2,2)
PROPELLANT(2,2)
PROTEIN COATING(2,2)
RECOMBINANT DNA(2,2)
SELECTIVE MEDIUM(2,2)
SILICON GRAPHICS(2,2)
TRYPTOPHAN(2,2)
TYROSINE(2,2)
VIRAL RNA SEQUENCE(2,2)
ADSORPTION DELAYING(2,1)
AEROSOL SPRAY(2,1)
AGAROSE GEL(2,1)
ALANINE RESIDUE(2,1)
ALLEGED VACCINE ASSOCIATED OUTBREAK(2,1)
AMINE ADJUVANT(2,1)
ARTIFICIAL CHROMOSOME(2,1)
BENZALKONIUM CHLORIDE(2,1)
BIOADHESIVE AGENT(2,1)
BORDER DISEASE CAUSATIVE AGENT(2,1)
BOVINE UBIQUITIN(2,1)
BVD VIRUS SEQUENCE(2,1)
BVDV NEGATIVE COW(2,1)
BVDV PRELIMINARY MOLECULAR MODEL(2,1)
BVDV STRAIN(2,1)
CATIONIC LIPID(2,1)
CATTLE SERUM SAMPLE(2,1)
CELL EXTRACT(2,1)
CELLULOSIC POLYMER(2,1)
CESAREAN DELIVERY(2,1)
CHOLERA TOXIN(2,1)
CLINICAL PARAMETER(2,1)
CLINICAL SYNDROME VARIETY(2,1)
COLORIMETRIC DETECTION(2,1)
COMPETITIVE ELISA(2,1)
COMPOSITION CO ADMINISTRATION(2,1)
CONFIRMED PREGNANCY(2,1)
DESIREABLE QUALITY(2,1)
DIAGNOSTIC LABORATORY(2,1)
DIRECT COMPETITIVE ASSAY(2,1)
DISULFIDE BOND(2,1)
DIVIDED FOIL PACKET(2,1)
DL FRAGMENT(2,1)
DNA SEGMENT(2,1)
DOSAGE INTERVAL(2,1)
DOSAGE REGIMEN(2,1)
DUSTING POWDER(2,1)
ELISA COATING(2,1)
EMERYVILLE CALIF(2,1)
ENCODED DOMAIN(2,1)
ENVELOPE PROTEIN(2,1)
ENZYME CLEAVAGE SITE(2,1)
EPITOPE RECOGNITION LOSS(2,1)
FETAL INFECTION(2,1)
FULLY MUTATED FRAGMENT(2,1)
GASTROINTESTINAL DISEASE(2,1)
GELAN GUM(2,1)
GENTLE ROCKING(2,1)
GESTATION DAY(2,1)
HCV PROTEIN REGION(2,1)
HELICASE CATALYTIC CENTER(2,1)
HETEROPOLYSACCHARIDE POLYMER(2,1)
HR POST INFECTION(2,1)
HYDROPHOBIC MEMBRANE ABSENCE(2,1)
IHC STAINING(2,1)
IMMUNITY DURATION(2,1)
IMMUNOASSAY FORMAT(2,1)
IMMUNOLOGICAL ASSAY(2,1)
IMMUNOMODULATORY AGENT(2,1)
IMPLANTED DEPOT(2,1)
INCOMPLETE ADJUVANT(2,1)
INDIRECT CONFIRMATION(2,1)
INDUCTION INDICATIVE(2,1)
ISOLEUCINE REPLACEMENT(2,1)
JPRED SERVER(2,1)
KEY EPITOPE(2,1)
LABELED MAB(2,1)
LETTER SYMBOL(2,1)
LIVE VIRUS(2,1)
LYSINE RESIDUE(2,1)
MAB PANEL(2,1)
MAGNESIUM STEARATE(2,1)
MAJOR GENOTYPE(2,1)
MARKER GENE(2,1)
MARKER MUTATION(2,1)
MEGASCRIPT(2,1)
METERED DOSE(2,1)
MODIFIED LIVE VIRAL VACCINE(2,1)
MONOCLONAL ANTIBODY PANEL(2,1)
MUTAGENESIS STUDY(2,1)
MUTANT SCREENING(2,1)
MUTANT VIRUS PRESENCE(2,1)
MUTATION INTRODUCTION(2,1)
MUTATION SITE(2,1)
NADL STRAIN(2,1)
NATIVE MOLECULE(2,1)
NON CONSERVATIVE AMINOACID REPLACEMENT(2,1)
NON INFECTED ANIMAL(2,1)
NS4A PROTEIN(2,1)
NUCLEOTIDE SEQUENCE(2,1)
OLIGOLACTIC ACID(2,1)
OPTIMAL IMMUNIZATION(2,1)
OPTIMIZED DILUTION(2,1)
OVERLAPPING PRIMER(2,1)
PARENTERAL FORMULATION(2,1)
PCR OVERLAP EXTENSION(2,1)
PEPTIDE BACKBONE MODIFICATION(2,1)
POLYCLONAL SERUM(2,1)
POLYPROTEIN REGION(2,1)
POST CHALLENGE ISOLATION(2,1)
PROGENY VIRUS(2,1)
PROSTAGLANDIN INJECTION(2,1)
PROTEASE BOUNDARY(2,1)
PROTEASE DOMAIN(2,1)
PROTEASE FRAGMENT(2,1)
PROTEASE ORIENTATION(2,1)
PROTOTYPICAL SEQUENCE(2,1)
PURIFIED DNA(2,1)
REACTIVITY TEST(2,1)
REPEATED PASSAGING(2,1)
REPLICATION ORIGIN(2,1)
REPLICATION RETENTION(2,1)
RESIDUE NUMBER(2,1)
RNA FARM(2,1)
RNA HELICASE(2,1)
RNA TRANSCRIPT(2,1)
RNA TRANSFECTION(2,1)
SAPONIN FRACTION(2,1)
SCANNING MUTANT(2,1)
SEED FLASK(2,1)
SEROLOGIC TESTING(2,1)
SERUM ANTIBODY(2,1)
SILENT NUCLEOTIDE CHANGE(2,1)
SOLUBILITY ENHANCING AGENT INCORPORATION(2,1)
STANDARD VIRUS TITRATION(2,1)
STERILE ADJUVANT(2,1)
STERILE NON AQUEOUS SOLUTION(2,1)
STERILE SALINE(2,1)
STOCK VIRUS TITER(2,1)
SUSPENSION FORMULATION(2,1)
TEMPLATE DNA(2,1)
TERM NAKED DNA(2,1)
TERM NON CONSERVATIVE(2,1)
TERTIARY CONFORMATION(2,1)
TRANSLATED BVD REGION(2,1)
TRANSLATION INITIATION CODON(2,1)
TRIPLE MUTANT(2,1)
UNCHALLENGED ANIMAL(2,1)
UNCHARGED POLAR(2,1)
UNIQUE BSMBI(2,1)
UNIQUE RESTRICTION ENZYME SITE(2,1)
VACCINATED ANIMAL(2,1)
VACCINE DOSE(2,1)
VACCINE EFFICACY(2,1)
VECTOR LABORATORY(2,1)
VECTOR PROPAGATION(2,1)
VIRAL PROTEOLYTIC ENZYME(2,1)
VIRAL REPLICATION(2,1)
VIRAL STRAIN(2,1)
VIRAL STRUCTURAL GENE(2,1)
VIRUS FETAL TRANSMISSION(2,1)
VIRUS ISOLATION(2,1)
VIRUS NEUTRALIZING ACTIVITY(2,1)
VIRUS PARTICLE(2,1)
WEAK HUMORAL IMMUNE RESPONSE(2,1)
AMINOACID ANALOG(1,3)
PROPYLENE GLYCOL(1,3)
ABORTED FETUS(1,1)
ACTIVE RELEASE(1,1)
ACTUATION VOLUME(1,1)
ALANINE MUTATION(1,1)
ALIGNED SEQUENCE(1,1)
ALKALINE CONDITION(1,1)
ALUMINUM HYDROXIDE GEL(1,1)
AMERICAN PUBLIC HEALTH ASSOCIATION PUBLICATION(1,1)
AMINOACID FAMILY(1,1)
AMNIOTIC FLUID(1,1)
AMPLIFICATION REACTION(1,1)
ANOREXIA(1,1)
ANTIBACTERIAL(1,1)
ANTIGEN SOURCE(1,1)
ANTIGENIC DETERMINANT(1,1)
ANTISERA(1,1)
AQUEOUS CARRIER(1,1)
AQUEOUS ETHANOL(1,1)
ARGININE(1,1)
ARTIFICIAL INSEMINATION(1,1)
ASPARAGINE(1,1)
ASPARTATE(1,1)
ASSAY VARIETY(1,1)
ATTENUATION(1,1)
BANDAGE(1,1)
BARBER(1,1)
BASIC PROTEIN(1,1)
BETA STRAND(1,1)
BLISTER(1,1)
BLOOD SAMPLE PAIR(1,1)
BLOODSTREAM(1,1)
BLOT ANALYSIS(1,1)
BUFFERING AGENT(1,1)
BVDV SEQUENCE ALIGNMENT(1,1)
CARBOHYDRATE(1,1)
CARBOXYL GROUP(1,1)
CARTRIDGE(1,1)
CATTLE CONDITION(1,1)
CHEMICAL COMPONENT(1,1)
CHEMICALLY INDUCED MUTATION(1,1)
CHITOSAN(1,1)
CHLAMYDIAL INFECTION(1,1)
COCOA BUTTER(1,1)
COGLYCOLIC(1,1)
COLI CELL(1,1)
COLLAGEN(1,1)
COLOR DEVELOPMENT(1,1)
COMPOUND POWDER MIX(1,1)
COMPOUND SOLUBILITY(1,1)
COMPOUND SUSPENSION(1,1)
CORRECT SEQUENCE(1,1)
CORRELATION(1,1)
CREATION(1,1)
CRITICAL RESIDUE(1,1)
CULTURE FLUID(1,1)
CYCLODEXTRIN(1,1)
CYTOKINE(1,1)
CYTOPATHIC EFFECT(1,1)
CYTOTOXIC(1,1)
DECREASING SERUM ASSAY(1,1)
DELIVERY VEHICLE(1,1)
DIFFERENTIAL IMMUNE RESPONSE(1,1)
DIRECT ASSAY(1,1)
DIRECTED MUTATION(1,1)
DIVIDED BOTTLE(1,1)
DOMAIN ABSENCE(1,1)
DOSE MULTIPLE ADMINISTRATION(1,1)
DOUBLE MUTANT(1,1)
DUAL BARREL FOLD(1,1)
EPITOPE SPECIFIC MUTATION(1,1)
FILE SEQUENCE(1,1)
FLAVIVIRUS(1,1)
FLAVOR(1,1)
GENETICALLY ENCODED AMINOACID(1,1)
GIVEN PEPTIDE ANTIBODY RECOGNITION(1,1)
HCV SEQUENCE(1,1)
HEAT LABILE ENTEROTOXIN(1,1)
HELICASE MOLECULE SEPARATED REGION(1,1)
HELICASE REGION(1,1)
HYDROPHOBIC REGION(1,1)
IMMUNOPRECIPITATE(1,1)
INFECTED SUBJECT(1,1)
INFUSION(1,1)
LAST VACCINATION(1,1)
LATE TERM ABORTION(1,1)
LIGATION MIXTURE(1,1)
LOOP IGP(1,1)
LOOP KHP(1,1)
MAMMALIAN CELL(1,1)
MEMBRANE ANCHORING REGION(1,1)
METHYLHISTIDINE(1,1)
MODIFIED NUCLEOTIDE(1,1)
MURAMYL DIPEPTIDE(1,1)
NON TRANSLATED REGION(1,1)
PARENTERAL SOLUTION PREPARATION(1,1)
PCR PRODUCT(1,1)
PERFORMANCE MODIFIER(1,1)
PLASMID PRESENCE(1,1)
PORCINE CELL(1,1)
PROTEASE MOLECULAR ORIENTATION(1,1)
PROTECTING GROUP INCLUSION(1,1)
RECOGNITION SITE(1,1)
RESTRICTION SITE(1,1)
RIBI INC(1,1)
RNA DEPENDENT NTP(1,1)
RNA PREPARATION(1,1)
SAFETY(1,1)
SEQUENCE COORDINATE(1,1)
SINGULAR TERM(1,1)
STRANDED NUCLEIC ACID(1,1)
STRONG HUMORAL RESPONSE(1,1)
STRONG STAINING(1,1)
TERM PLASMID(1,1)
TERM VACCINE(1,1)
TEST VACCINE(1,1)
TETRAFLUOROETHANE(1,1)
THIXOTROPIC LIQUID(1,1)
TRANSCRIPTION REACTION PRODUCT(1,1)
TRANSFECTION MIXTURE(1,1)
UNIQUE NOVEL RESTRICTION(1,1)
ZINC DEPENDENT PROTEASE(1,1)";Pharmaceuticals;Open
"2005-12-07
2006-11-24";"WO2007066188        A2 2007-06-14 [WO200766188]
STG: (A2) International application published without international search report
AP : 2006WO-IB03412 2006-11-24
CA2639074           A1 2007-06-14 [CA2639074]
STG: (A1) Application laid open
AP : 2006CA-2639074 2006-11-24
AU2006323028        A1 2007-06-14 [AU2006323028]
STG: (A1) Open to public inspection
AP : 2006AU-0323028 2006-11-24
TW200734463         A  2007-09-16 [TW200734463]
STG: (A) Laid open application for patent or patent of addition
AP : 2006TW-0145395 2006-12-06
AR057225            A1 2007-11-21 [AR--57225]
STG: (A1) Independent patent application
AP : 2006AR-0105386 2006-12-06
NO20081909          L  2008-05-21 [NO20081909]
STG: (L) Abstract
AP : 2008NO-0001909 2008-04-21
WO2007066188        A3 2008-06-05 [WO200766188]
STG: (A3) Later publication of ISR with revised front page
AP : 2006WO-IB03412 2006-11-24
KR10-2008-0065696   A  2008-07-14 [KR20080065696]
STG: (A) Published application
AP : 2008KR-7013580 2006-11-24
IN3899/DELNP/2008   A  2008-08-15 [IN2008DN03899]
STG: (A) Application laid open
AP : 2008IN-DN03899 2008-05-07
EP1973565           A2 2008-10-01 [EP1973565]
STG: (A2) Application published without search report
AP : 2006EP-0821006 2006-11-24
US20080305130       A1 2008-12-11 [US20080305130]
STG: (A1) Application published
AP : 2006US-11995779 2006-11-24
FD :  Provisional Appl: US60/748,312 FDD=2005-12-07 [2005US-60748312]
CN101355963         A  2009-01-28 [CN101355963]
STG: (A) Published application
AP : 2006CN-80050797 2006-11-24
JP2009519014        A  2009-05-14 [JP2009519014]
STG: (A) Published application
AP : 2008JP-0543931 2006-11-24
ZA200803558         B  2009-09-30 [ZA200803558]
STG: (B)
AP : 2008ZA-0003558 2008-04-23
RU2008120331        A  2010-01-20 [RU2008120331]
STG: (A) Application for invention
AP : 2008RU-0120331 2006-11-24
AU2006323028        B2 2010-02-25 [AU2006323028]
STG: (B2) Patent proceeded by OPI
AP : 2006AU-0323028 2006-11-24
RU2394594           C2 2010-07-20 [RU2394594]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2008RU-0120331 2006-11-24
KR10-2011-0045072   A  2011-05-03 [KR20110045072]
STG: (A) Published application
AP : 2011KR-7006546 2006-11-24
KR10-1045165        B1 2011-06-30 [KR101045165]
STG: (B1) Patent specification
AP : 2008KR-7013580 2006-11-24
NZ567668            A  2011-07-29 [NZ-567668]
STG: (A) Published application
AP : 2006NZ-0567668 2006-11-24
UA95619             C2 2011-08-25 [UA--95619]
STG: (C2) Pat. grant. upon the USSR appl.,for which no pos. dec. made;grant. upon basis of national application
AP : 2008UA-0007756 2006-11-24
BRPI0619566         A2 2011-10-04 [BR200619566]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2006BR-0019566 2006-11-24
KR101097547         B1 2011-12-22 [KR101097547]
STG: (B1) Patent specification
AP : 2011KR-7006546 2006-11-24
CN101355963         B  2012-03-21 [CN101355963B]
STG: (B) Granted patent for invention
AP : 2006CN-80050797 2006-11-24
HK1121698           A1 2012-12-14 [HK1121698]
STG: (A1) Patent application
AP : 2009HK-0101950 2009-03-02
EP1973565           B1 2013-05-15 [EP1973565]
STG: (B1) Patent specification
AP : 2006EP-0821006 2006-11-24
CA2639074           C  2013-10-08 [CA2639074]
STG: (C) Patent (second level)
AP : 2006CA-2639074 2006-11-24";5318986;"WO2007066188        A2 2007-06-14 [WO200766188]
CA2639074           A1 2007-06-14 [CA2639074]
AU2006323028        A1 2007-06-14 [AU2006323028]
TW200734463         A  2007-09-16 [TW200734463]
AR057225            A1 2007-11-21 [AR--57225]
NO20081909          L  2008-05-21 [NO20081909]
WO2007066188        A3 2008-06-05 [WO200766188]
KR10-2008-0065696   A  2008-07-14 [KR20080065696]
IN3899/DELNP/2008   A  2008-08-15 [IN2008DN03899]
EP1973565           A2 2008-10-01 [EP1973565]
US20080305130       A1 2008-12-11 [US20080305130]
CN101355963         A  2009-01-28 [CN101355963]
JP2009519014        A  2009-05-14 [JP2009519014]
ZA200803558         B  2009-09-30 [ZA200803558]
RU2008120331        A  2010-01-20 [RU2008120331]
AU2006323028        B2 2010-02-25 [AU2006323028]
RU2394594           C2 2010-07-20 [RU2394594]
KR10-2011-0045072   A  2011-05-03 [KR20110045072]
KR10-1045165        B1 2011-06-30 [KR101045165]
NZ567668            A  2011-07-29 [NZ-567668]
UA95619             C2 2011-08-25 [UA--95619]
BRPI0619566         A2 2011-10-04 [BR200619566]
KR101097547         B1 2011-12-22 [KR101097547]
CN101355963         B  2012-03-21 [CN101355963B]
HK1121698           A1 2012-12-14 [HK1121698]
EP1973565           B1 2013-05-15 [EP1973565]
CA2639074           C  2013-10-08 [CA2639074]";"2005US-60748312
2006US-11995779
2006WO-IB03412";"(EP1973565)
WO2007066188
(US20080305130)
WO2007066188
(JP2009519014)
WO2007066188
(RU2394594)
WO2007066188
(NO20081909)
WO2007066188
(AU2006323028)
WO2007066188
(KR101045165)
WO2007066188
(NZ-567668)
WO2007066188
(BR200619566)
WO2007066188
(KR101097547)
WO2007066188
(CN101355963B)
WO2007066188
(HK1121698)
WO2007066188
(CA2639074)
WO2007066188";"PAH USA 15
PFIZER
PFIZER PRODUCTS
ZOETIS";PAH USA 15;"(EP1973565)
US
(EP1973565)
US
(WO200766188)
US

(IN2008DN03899)
US


(CA2639074)
US
(CA2639074)
US";"(EP1973565)
NAME=Pfizer Products Incorporated Eastern Point Road , CITY=Groton, CT 06340 , COUNTRY=US 

(EP1973565)
NAME=Zoetis P LLC 100 Campus Drive , CITY=Florham Park, New Jersey 07932 , COUNTRY=US , REG=101384425 

(WO200766188)
NAME=PFIZER PRODUCTS INC.  Eastern Point Road, Groton, CT 06340  , COUNTRY=US 

(JP2009519014)
NAME=Pfizer Ink Products , REG=397067152 

(IN2008DN03899)
NAME=PFIZER PRODUCTS INC EASTERN POINT ROAD, GROTON, CONNECTICUT 06340, UNITED STATE OF AMERICA.  , COUNTRY=US 

(KR101045165)
NAME=PFIZER PRODUCTS INC. , REG=519986023423 

(KR20110045072)
NAME=PFIZER PRODUCTS INC. , REG=519986023423 

(KR101097547)
NAME=PFIZER PRODUCTS INC. , REG=519986023423 

(CA2639074)
NAME=PFIZER PRODUCTS INC. Eastern Point Road , CITY=GROTON , STATE=CT , POSTCODE=06340 , COUNTRY=US 

(CA2639074)
NAME=PFIZER PRODUCTS INC. Eastern Point Road , CITY=GROTON , STATE=CT , POSTCODE=06340 , COUNTRY=US 
";1;"HUANG CHICHI
SHEPPARD MICHAEL G
CAO XUEMEI
ZYBARTH GABRIELE";"(EP1973565)
AU; US";"(EP1973565)
NAME=HUANG, Chichi 69 Highpoint Drive , CITY=Berwyn, PA 19312 , COUNTRY=US 

NAME=SHEPPARD, Michael G. 9 The Eyrie , CITY=Eltham, VIC 3095 , COUNTRY=AU 

NAME=CAO, Xuemei 97 Stockbridge Road , CITY=Scituate, MA 02066 , COUNTRY=US 

NAME=ZYBARTH, Gabriele 6 Steeple View Road , CITY=Little Compton, Rhode Island 02837 , COUNTRY=US 
";"(EP1973565)
Marked bovine viral diarrhea virus";"(EP1973565)
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals.";"(WO200766188)
1. Claims We Claim: 1. A bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the helicase domain of NS3 results in a loss of recognition by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus is retained.
2. A bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein NS3 is not recognized by a monoclonal antibody to NS3,
. wherein the NS3 antibody is selected from the group consisting of 20.10.6;
 1.11.3; 21.5.8; and 24.8 but wherein viral RNA replication and the generation of infectious virus is retained.
3. The bovine viral diarrhea virus of Claim 1 wherein the virus vaccine comprises a single helicase domain amino acid mutation.
4. The bovine viral diarrhea virus of Claim 1 comprising a helicase domain mutation within the IGR loop.
5. The bovine viral diarrhea virus of Claim 4 comprising a helicase domain mutation within the IGR loop at amino acid residue 1841.
6. The bovine viral diarrhea virus of Claim 4 comprising a helicase domain mutation • within the IGR loop at amino acid residue 1843.
7. The bovine viral diarrhea virus of Claim 4 comprising a helicase domain mutation within the IGR loop at amino acid residue 1845.
8. The bovine viral diarrhea virus of Claim 1 comprising a helicase domain mutation within the KHP loop.
9. The bovine viral diarrhea virus of Claim 8 comp comprising a helicase domain mutation within the KHP loop at amino acid residue 1867.
10. The bovine viral diarrhea virus of Claim 8 comprising a helicase domain mutation within the KHP loop at amino acid residue 1868.
11. The bovine viral diarrhea virus of Claim 8 comprising a helicase domain mutation within the KHP loop at amino acid residue 1869.
12. The bovine viral diarrhea virus of Claim 1 comprising a helicase domain mutation within the SES loop.
13. The bovine viral diarrhea virus of Claim 12 comprising a helicase domain mutation within the SES loop at amino acid residue 1939.
14. The bovine viral diarrhea virus of Claim 12 comprising a helicase domain mutation within the SES loop at amino acid residue 1942.
15. The bovine viral diarrhea virus of Claim 1 wherein the virus comprises two, three, or four helicase domain amino acid mutations.
16. The bovine viral diarrhea virus of Claim 15 comprising two helicase domain mutations.
17. The bovine viral diarrhea virus of Claim 16 wherein the two helicase domain mutations are within the IGR loop.
18. The bovine viral diarrhea virus of Claim 17 wherein the two helicase domain mutations within the IGR loop are at amino acid residues 1843 and 1845.
19. The bovine viral diarrhea virus of Claim 16 wherein the two helicase domain mutations are within the SES loop.
20. The bovine viral diarrhea virus of Claim 19 wherein the two helicase domain mutations within the SES loop are at amino acid residues 1939 and 1942.
21. The bovine viral diarrhea virus of Claim 15 comprising three helicase domain mutations.
22. The bovine viral diarrhea virus of Claim 21 wherein the three helicase domain mutations are within the IGR loop.
23. The bovine viral diarrhea virus of Claim 22 wherein the three helicase domain mutations within the IGR loop are at amino acid residues 1867, 1868, and 1869.
24. The bovine viral diarrhea virus of Claim 21 comprising three helicase domain mutations within the IGR loop and the SES loop are at amino acid residues 1845, 1868, and 1939.
 25 A marked bovine viral diarrhea virus vaccine comprising bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the helicase domain of NS3 results in a loss of recognition by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus is retained. 26. A method of differentiating an animal infected with bovine diarrhea virus from an animal vaccinated with a bovine diarrhea virus vaccine wherein said bovine diarrhea virus vaccine is a marked vaccine comprising at least one helicase domain amino acid mutation, said method comprising; obtaining a test sample. from a test animal; detecting bovine diarrhea virus in said test sample; and determining whether the bovine diarrhea virus contains the mutation.
27. The method of Claim 26 wherein said method of detecting bovine diarrhea virus employs the use of at least one monoclonal antibody.
28. The method of Claim 26 wherein the marked vaccine helicase domain amino acid mutation is in the helicase domain of NS3.
29. The method of Claim 27 comprising the steps of: adding labeled antibody capable of detecting wild type bovine diarrhea virus or capable of detecting mutated bovine diarrhea virus to a test sample, wherein the test sample contains body fluid from test animal and; measuring the binding affinity of said labeled antibody to said wild type bovine diarrhea virus or to said mutated bovine diarrhea virus by contacting at least one monoclonal antibody to said wild type bovine diarrhea virus or to said mutated bovine diarrhea virus; determining the vaccination status of test animal by comparing results of binding affinity using a monoclonal antibody directed to wild type BVDV versus BVDV with mutated NS3.
30. The method of Claim 27 comprising the steps of: adding a labeled first antibody directed to a domain other than mutated NS3; and adding a labeled second antibody directed to a mutated portion of NS3.
31. The method of Claim 30 wherein the first antibody is directed to a wild type virus.
32. The method of Claim 30 wherein the second antibody is directed to the mutated portion of NS3.
33. The method of Claim 32 wherein the second antibody is directed against NS3 and is selected from the group consisting of 20.10.6; 1.11.3; 21.5.8; and 24.8.
34. The method of Claim 32 wherein the second antibody is directed to at least one mutated portion of the NS3 selected from the group consisting of the IGR loop, the KHP loop, and the SES loop.
35. The method of Claim 34 wherein the bovine viral diarrhea virus comprises at least one helicase domain amino acid mutation within the IGR loop at an amino acid residue selected from the group consisting of 1841 , 1843, and 1845.
36. The method of Claim 34 wherein the bovine viral diarrhea virus comprises at least one helicase domain amino acid mutation within the KHP loop at an amino acid residue selected from the group consisting of 1867, 1868, and 1869.
37. The method of Claim 34 wherein the bovine viral diarrhea virus comprises of at least one helicase domain amino acid mutation within the SES loop at an amino acid residue selected from the group consisting of 1939, and 1942.
38. The method of Claim 34 wherein the bovine viral diarrhea virus is comprises of at least one helicase domain amino acid mutation within the IGR loop and the SES loop at amino acid residues 1845, 1868, and 1939.";"(EP1973565)
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation, wherein the mutation in the helicase domain of NS3 is selected from the group consisting of: (a)a helicase domain mutation within the IGR loop at amino acid residue 1845; (b) a helicase domain mutation within the SES loop at amino acid residue 1939 or 1942; or (c) a helicase domain mutation within the IGR, KHP and SES loops at amino acid residues 1845, 1868 and 1939, respectively; and results in a loss of recognition by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus in retained; and wherein the amino acid residues are numbered according to SEQ ID NO: 1.
The present disclosure provides vectors in which the genomic nucleic acid sequence of a BVD virus as described herein above has been incorporated.
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation, wherein the mutation in the helicase domain of NS3 is selected from the group consisting of: (a)a helicase domain mutation within the IGR loop at amino acid residue 1845; (b) a helicase domain mutation within the SES loop at amino acid residue 1939 or 1942; or (c) a helicase domain mutation within the IGR, KHP and SES loops at amino acid residues 1845, 1868 and 1939, respectively; and results in a loss of recognition by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus in retained; and wherein the amino acid residues are numbered according to SEQ ID NO: 1.
The present disclosure provides immunogenic compositions in which one or more of the mutant BVD viruses described above have been included.
The present disclosure provides immunogenic compositions in which one or more of the mutant BVD viruses described above have been included.";"(EP1973565)
Based on the above, it is clear that a need exists for new and more effective vaccines to control the spread of BVDV.
It is desirable to delete an immunodominant epitope without significantly altering the function of the helicase.
Although this vaccine appears to protect fetuses from becoming infected, protection is limited to only the homologous strain of virus, and there is no correlation between antibody titers and protection.
BVDV infection can result in breeding problems in cattle, and can cause abortions or premature births.
results in a loss of recognition by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus in retained; and wherein the amino acid residues are numbered according to SEQ ID NO: 1.";"A61K
A61K-039/12
A61K-039/125
A61P-031/12
A61P-031/14
C07K
C07K-014/18
C12N
C12N-007/00
C12N-007/04
C12N-015/09
C12N-015/45
C12Q-001/70
G01N-033/53";"(EP1973565)
1. A bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation, wherein the mutation in the helicase domain of NS3 is selected from the group consisting of: (a) a helicase domain mutation within the IGR loop at amino acid residue 1845; (b) a helicase domain mutation within the SES loop at amino acid residue 1939 or 1942; or (d) a helicase domain mutation within the IGR, KHP and SES loops at amino acid residues 1845, 1868 and 1939, respectively; and results in a loss of recognition by a monoclonal antibody raised against NS3 from wild-type bovine viral diarrhea virus but wherein viral RNA replication and the generation of infectious virus is retained; and wherein the amino acid residues are numbered according to SEQ ID NO: 1.";"(EP1973565)
BOVINE VIRAL DIARRHEA VIRUS(100,8)
HELICASE DOMAIN MUTATION(100,6)
INFECTIOUS VIRUS GENERATION(47,4)
HELICASE DOMAIN(32,11)
REPLICATION VIRAL RNA(32,6)
HOMOLOGOUS VIRUS STRAIN(29,1)
AMINOACID RESIDUE(28,11)
MUTANT BVD VIRUS(26,4)
SE LOOP(25,6)
RECOGNITION LOSS(22,7)
HELICASE DOMAIN AMINOACID(19,1)
MONOCLONAL ANTIBODY(18,5)
ANTIBODY TITER(16,2)
BVDV INFECTION(15,3)
MUTATION(14,18)
IMMUNOGENIC(12,13)
BVD VIRUS MUTATION(11,6)
VACCINE(10,27)
CORRELATION(10,1)
PREMATURE BIRTH(10,1)
AMINOACID MUTATION(9,2)
ABORTION(8,2)
FETUS(7,3)
HELICASE SUBDOMAIN(7,3)
BVDV HELICASE DOMAIN(7,2)
SUBVIRAL REPLICON BACKBONE(7,2)
AMINOACID(6,22)
ANTIBODY RECOGNITION(6,5)
BVDV SUBVIRAL REPLICON CONTEXT(6,1)
INTESTINAL MUCOSA ULCERATION(6,1)
VECTASTAIN ELITE ABC KIT(6,1)
CATTLE(5,8)
ISOLATED GENOMIC NUCLEIC MOLECULE(5,2)
VARIANT BVD VIRUS(5,2)
ATTENDING VETERINARIAN SUPERVISION(5,1)
BVDV INFECTION SYMPTOM(5,1)
CALF BIRTH(5,1)
CHYMOTRYPSIN SERINE PROTEASE FAMILY(5,1)
INFECTIOUS PROVIRAL PARENT PLASMID(5,1)
MUTANT BVD VIRAL GENOME(5,1)
MUTANT VIRAL HELICASE(5,1)
PREGNANT CATTLE PLACENTA(5,1)
PROGENY MUTANT BVD VIRUS(5,1)
REGIONAL BVDV ERADICATION PROGRAM(5,1)
PROGRAMMED RELEASE(4,5)
GENOMIC NUCLEIC ACID MOLECULE(4,4)
PARENTERAL ADMINISTRATION(4,3)
CLASSICAL SWINE FEVER(4,2)
MUTANT REPLICON(4,2)
MUTATED EPITOPE(4,2)
NONSTRUCTURAL PROTEIN(4,2)
BIOCHEMICAL NOMENCLATURE COMMISSION(4,1)
BOVINE DONOR CALF SERUM(4,1)
BVD DISEASE THREAT(4,1)
BVD VIRUS GENOME(4,1)
BVD VIRUS INDICATIVE(4,1)
BVD VIRUS ORIGIN(4,1)
BVDV IMMUNODOMINANT PROTEIN(4,1)
BVDV INFECTION INCIDENCE(4,1)
BVDV NEGATIVE HEALTHY CALF(4,1)
BVDV NUCLEOCAPSID(4,1)
BVDV POLYPROTEIN ENCODING(4,1)
BVDV RNA REPLICATION(4,1)
BVDV VIRULENT STRAIN(4,1)
CANDIDATE EPITOPE IDENTIFICATION(4,1)
CATALYTIC HELICASE ACTIVITY PRESERVATION(4,1)
COW PREGNANCY STATUS(4,1)
GENOMIC RNA PACKAGING(4,1)
HELIX SUBDOMAIN(4,1)
IMMUNOLOGICALLY DISTINCT EPITOPE(4,1)
INDIRECT IMMUNOFLUORESCENT ASSAY(4,1)
INTACT HELICASE PROTEIN(4,1)
MAB RECOGNITION ABOLISHMENT(4,1)
MAB RECOGNIZING BVDV(4,1)
MARKED BVDV VACCINE STRAIN(4,1)
MARKED CATTLE VACCINE(4,1)
MARKED VIRUS GROWTH KINETICS(4,1)
MUTAGENIC OLIGONUCLEOTIDE PRIMER VIRTUE(4,1)
MUTANT PCR FRAGMENT(4,1)
RD CELL TRANSFECTION(4,1)
RNA DEPENDENT NTP(4,1)
SERUM NEUTRALIZING TITER(4,1)
TRANSDERMAL PENETRATION ENHANCER(4,1)
TRUNCATED SUBVIRAL REPLICON(4,1)
UNMODIFIED VIRUS PEPTIDE(4,1)
VIRUS NEUTRALIZATION ASSAY(4,1)
ZINC DEPENDENT PROTEASE(4,1)
ANIMAL SUBJECT(3,6)
MODIFIED RELEASE FORMULATION(3,5)
ANTIBODY PRESENCE(3,3)
NON CONSERVATIVE AMINOACID(3,3)
VETERINARILY ACCEPTABLE CARRIER(3,3)
AURAL ADMINISTRATION(3,2)
DRY POWDER INHALER(3,2)
EUKARYOTIC HOST CELL(3,2)
INFECTION RISK(3,2)
INOCULATED ANIMAL(3,2)
INTRA LYMPH NODE(3,2)
MOLECULAR MODELING(3,2)
MUTATED SEQUENCE(3,2)
OVERNIGHT INCUBATION(3,2)
PARENTERAL ROUTE(3,2)
PLASMID PROPAGATION(3,2)
PRESSURIZED CONTAINER(3,2)
PROKARYOTIC HOST CELL(3,2)
REPLACEMENT MUTANT(3,2)
TRANSLATED PROTEIN(3,2)
WESTERN BLOT(3,2)
ABOLISHED RECOGNITION(3,1)
ABSORBABLE GEL SPONGE(3,1)
AGENT FACILITATING CELLULAR UPTAKE(3,1)
ALANINE REPLACEMENT FRAGMENT(3,1)
BVD GENOMIC SEQUENCE(3,1)
BVD VIRION(3,1)
BVDV HELICASE MOLECULAR MODEL(3,1)
BVDV IDENTIFICATION(3,1)
BVDV INFECTED CATTLE(3,1)
BVDV INFECTION DETECTION(3,1)
BVDV INFECTION TREATMENT(3,1)
BVDV SUBTYPE(3,1)
CERTIFIED BVDV NEGATIVE SEMEN(3,1)
CHALLENGE INOCULUM(3,1)
COMPETITIVE IMMUNOASSAY(3,1)
CONTRADICTORY DEFINITION(3,1)
CYTOPATHIC BVDV(3,1)
DIFFERENTIAL DIAGNOSTIC ASSAY(3,1)
EFFICIENT VRNA REPLICATION(3,1)
ENVELOPED VIRION FORMATION(3,1)
EPITOPE CONFORMATION(3,1)
EPITOPE REFINEMENT(3,1)
EXPRESSIBLE GENE(3,1)
FLAVIVIRIDAE FAMILY(3,1)
FRESH RD CELL MONOLAYER(3,1)
HELICASE HELICAL SUBDOMAIN(3,1)
HELICASE PROTEASE(3,1)
HELICASE SUPERFAMILY(3,1)
HERD CERTIFICATION(3,1)
HETEROLOGOUS CDNA(3,1)
HETEROLOGOUS DNA(3,1)
HIGHLY CONSERVED HELICASE(3,1)
HOG CHOLERA(3,1)
HORSERADISH PEROXIDASE(3,1)
IMMUNOGENIC DETERMINANT(3,1)
IMMUNOHISTOCHEMISTRY ASSAY(3,1)
INFECTIOUS VIRAL PARTICLE(3,1)
INITIATING TRANSLOCATION(3,1)
INTRANASAL INOCULATION(3,1)
LIGATED REACTION ALIQUOT(3,1)
LIPID AMINE ADJUVANT(3,1)
MAJOR BVDV IMMUNOGEN(3,1)
MARKED VACCINE CONTEXT(3,1)
MARKER DETERMINANT(3,1)
METHIONINE METHYLSULFANIUM(3,1)
MUCOSAL DISEASE OUTBREAK(3,1)
NUCLEOSIDE TRIPHOSPHATE(3,1)
OVERLAPPING FRAGMENT ENCODING(3,1)
OVERLAPPING PCR FRAGMENT(3,1)
OVERLAPPING PCR STRATEGY(3,1)
PESTIVIRUS GENUS(3,1)
PHOSPHATIDYLCHOLINE(3,1)
PLASMID DNA PURIFICATION(3,1)
POSTCHALLENGE INTERVAL(3,1)
PROTEASE COFACTOR(3,1)
PROVIRAL MOLECULAR CLONE(3,1)
PROVIRAL PLASMID(3,1)
PURIFIED MUTATED VIRUS(3,1)
RADIOLABELED METHIONINE(3,1)
RD CELL FRESH MONOLAYER(3,1)
RESPONDING CTL DETECTION(3,1)
RESTRICTION ENZYME DIGESTION(3,1)
RNA MOLECULE ENCODING(3,1)
RNA REPLICATION EFFICIENCY INDICATOR(3,1)
SERUM NEUTRALIZATION ASSAY(3,1)
SERUM SERIAL DILUTION(3,1)
SUCCESSFUL VIRUS VACCINE(3,1)
SUCROSE GRADIENT CENTRIFUGATION(3,1)
SYNTHESIZED POLYPROTEIN(3,1)
T CELL PROLIFERATION(3,1)
TEST FRAGMENT PCR AMPLIFICATION(3,1)
TISSUE CULTURE FLASK(3,1)
TITER VIRUS YIELD(3,1)
TRADE ECONOMIC BENEFIT FREEDOM(3,1)
TRANSCRIPT AMPLIFICATION(3,1)
TRUNCATED PROTEIN TRANSLATION(3,1)
UNPROCESSED POLYPROTEIN(3,1)
VACCINATED CATTLE(3,1)
VACCINE STRAIN TRANSMISSION(3,1)
VETERINARY PHYSICIAN(3,1)
VIRAL PROTEIN EXPRESSION(3,1)
VIRUS ACCELERATED ELIMINATION(3,1)
VIRUS DISSEMINATION(3,1)
WISCONSIN UNIVERSITY(3,1)
WILD TYPE(2,11)
ATOMIZER(2,4)
MADIN DARBY BOVINE KIDNEY(2,4)
BIOTYPE(2,3)
CYSTEINE(2,3)
ELECTROPHORESIS(2,3)
LIPOSOME(2,3)
PNADLP(2,3)
VAGINAL ADMINISTRATION(2,3)
ACTIVE INGREDIENT(2,2)
BOVINE CELL CULTURE(2,2)
BVDV ISOLATION(2,2)
CONSERVATIVE AMINOACID SUBSTITUTION(2,2)
DISCLOSURE KIT(2,2)
ELECTROHYDRODYNAMICS(2,2)
EXCIPIENT(2,2)
FINE MIST(2,2)
FRAGMENT SEQUENCE(2,2)
GLYCOPROTEIN(2,2)
HPMCD(2,2)
ISOTONIC AGENT(2,2)
PHOSPHOSERINE(2,2)
PROPELLANT(2,2)
PROTEIN COATING(2,2)
SILICON GRAPHICS(2,2)
TRANSFECTED CELL(2,2)
ACETYL LYSINE(2,1)
ADSORPTION DELAYING(2,1)
AEROSOL SPRAY(2,1)
ALLEGED VACCINE ASSOCIATED OUTBREAK(2,1)
ARTIFICIAL CHROMOSOME(2,1)
BIOADHESIVE AGENT(2,1)
BORDER DISEASE CAUSATIVE AGENT(2,1)
BOVINE UBIQUITIN(2,1)
BVD VIRUS SEQUENCE(2,1)
BVDV NEGATIVE COW(2,1)
BVDV PRELIMINARY MOLECULAR MODEL(2,1)
BVDV STRAIN(2,1)
CATIONIC LIPID(2,1)
CATTLE SERUM SAMPLE(2,1)
CELL EXTRACT(2,1)
CELLULOSIC POLYMER(2,1)
CESAREAN DELIVERY(2,1)
CHALLENGE DAY(2,1)
CHOLERA TOXIN(2,1)
CLINICAL PARAMETER(2,1)
CLINICAL SYNDROME VARIETY(2,1)
COLORIMETRIC DETECTION(2,1)
COMPETITIVE ELISA(2,1)
COMPOSITION CO ADMINISTRATION(2,1)
CONFIRMED PREGNANCY(2,1)
DEMONSTRATED REACTIVITY(2,1)
DESIREABLE QUALITY(2,1)
DIAGNOSTIC LABORATORY(2,1)
DIRECT COMPETITIVE ASSAY(2,1)
DISULFANE BOND(2,1)
DIVIDED FOIL PACKET(2,1)
DNA SEGMENT(2,1)
DOSAGE INTERVAL(2,1)
DOSAGE REGIMEN(2,1)
DUSTING POWDER(2,1)
ELISA COATING(2,1)
EMERYVILLE CALIF(2,1)
ENCODED DOMAIN(2,1)
ENVELOPE PROTEIN(2,1)
ENZYME CLEAVAGE SITE(2,1)
EPITOPE RECOGNITION LOSS(2,1)
FETAL INFECTION(2,1)
FULLY MUTATED FRAGMENT(2,1)
GASTROINTESTINAL DISEASE(2,1)
GELAN GUM(2,1)
GENE MUTATION(2,1)
GENETIC MANIPULATION(2,1)
GENTLE ROCKING(2,1)
GESTATION DAY(2,1)
HELICASE CATALYTIC CENTER(2,1)
HETEROPOLYSACCHARIDE POLYMER(2,1)
HYDROFLUOROCARBON 227EA(2,1)
HYDROPHOBIC MEMBRANE ABSENCE(2,1)
IMMUNITY DURATION(2,1)
IMMUNOASSAY FORMAT(2,1)
IMMUNOLOGICAL ASSAY(2,1)
IMMUNOMODULATORY AGENT(2,1)
IMPLANTED DEPOT(2,1)
INDIRECT CONFIRMATION(2,1)
INDUCTION INDICATIVE(2,1)
JPRED SERVER(2,1)
KEY EPITOPE(2,1)
LABELED MAB(2,1)
LETTER SYMBOL(2,1)
MAB PANEL(2,1)
MAJOR GENOTYPE(2,1)
MANUFACTURER INSTRUCTION(2,1)
MARKER GENE(2,1)
MARKER MUTATION(2,1)
MEGASCRIPT(2,1)
METERED DOSE(2,1)
MODIFIED LIVE VIRAL VACCINE(2,1)
MODIFIED PEPTIDE BACKBONE(2,1)
MONOCLONAL ANTIBODY PANEL(2,1)
MUTAGENESIS STUDY(2,1)
MUTANT SCREENING(2,1)
MUTANT VIRUS PRESENCE(2,1)
MUTATION INTRODUCTION(2,1)
MUTATION SITE(2,1)
NAKED DNA(2,1)
NATIVE MOLECULE(2,1)
NON INFECTED ANIMAL(2,1)
NUCLEOTIDE SEQUENCE(2,1)
OLIGOLACTIC ACID(2,1)
OPTIMAL IMMUNIZATION(2,1)
OPTIMEM ML(2,1)
OPTIMIZED DILUTION(2,1)
OVERLAPPING PRIMER(2,1)
PARENTERAL FORMULATION(2,1)
PCR OVERLAP EXTENSION(2,1)
POLYCLONAL SERUM(2,1)
POLYPROTEIN REGION(2,1)
POST CHALLENGE ISOLATION(2,1)
PROGENY VIRUS(2,1)
PROSTAGLANDIN INJECTION(2,1)
PROTEASE BOUNDARY(2,1)
PROTEASE DOMAIN(2,1)
PROTEASE FRAGMENT(2,1)
PROTEASE ORIENTATION(2,1)
PROTOTYPICAL SEQUENCE(2,1)
PURIFIED DNA(2,1)
REACTIVITY TEST(2,1)
REPEATED PASSAGING(2,1)
REPLICATION ORIGIN(2,1)
RESIDUE NUMBER(2,1)
RNA HELICASE(2,1)
RNA TRANSCRIPT(2,1)
SAPONIN FRACTION(2,1)
SCANNING MUTANT(2,1)
SEED FLASK(2,1)
SEROLOGIC TESTING(2,1)
SERUM ANTIBODY(2,1)
SILENT NUCLEOTIDE CHANGE(2,1)
SOLUBILITY ENHANCING AGENT INCORPORATION(2,1)
STANDARD VIRUS TITRATION(2,1)
STERILE ADJUVANT(2,1)
STERILE NON AQUEOUS SOLUTION(2,1)
STERILE SALINE(2,1)
STOCK VIRUS TITER(2,1)
SUSPENSION FORMULATION(2,1)
TEMPLATE DNA(2,1)
TERTIARY CONFORMATION(2,1)
TRANSLATION INITIATION CODON(2,1)
TRIPLE MUTANT(2,1)
UNCHALLENGED ANIMAL(2,1)
UNCHARGED POLAR(2,1)
UNIQUE RESTRICTION ENZYME SITE(2,1)
VACCINATED ANIMAL(2,1)
VACCINE DOSE(2,1)
VACCINE EFFICACY(2,1)
VECTOR LABORATORY(2,1)
VECTOR PROPAGATION(2,1)
VIRAL PROTEOLYTIC ENZYME(2,1)
VIRAL REPLICATION(2,1)
VIRAL STRAIN(2,1)
VIRAL STRUCTURAL GENE(2,1)
VIRUS FETAL TRANSMISSION(2,1)
VIRUS ISOLATION(2,1)
VIRUS NEUTRALIZING ACTIVITY(2,1)
VIRUS PARTICLE(2,1)
WEAK HUMORAL IMMUNE RESPONSE(2,1)
LACTOSE(1,4)
AMINOACID ANALOG(1,3)
GLYCEROL(1,3)
SHEEP(1,3)
ALKALINE PHOSPHATASE(1,2)
AMINOACID MIMETICS(1,2)
ARGININE(1,2)
COLONY(1,2)
DEXTROSE(1,2)
DIARRHEA(1,2)
DIVIDED DOSE(1,2)
DOMAIN SEQUENCE(1,2)
ENGLAND BIOLAB(1,2)
ESTRUM(1,2)
HELICASE ACTIVE SITE(1,2)
HYDROXYPROLINE(1,2)
INHALATION(1,2)
INTRANASAL ADMINISTRATION(1,2)
IONTOPHORESIS(1,2)
MENTHOL(1,2)
MICRONEEDLE(1,2)
NEBULIZER(1,2)
NORLEUCINE(1,2)
OINTMENT(1,2)
PLACEBO(1,2)
PRESERVATIVE(1,2)
RECOMBINANT DNA(1,2)
SELECTIVE MEDIUM(1,2)
VIRAL RNA SEQUENCE(1,2)
ABORTED FETUS(1,1)
ACTIVE RELEASE(1,1)
ACTUATION VOLUME(1,1)
AGAROSE GEL(1,1)
ALIGNED SEQUENCE(1,1)
ALKALINE CONDITION(1,1)
ALUMINUM HYDROXIDE GEL(1,1)
AMERICAN PUBLIC HEALTH ASSOCIATION PUBLICATION(1,1)
AMINOACID FAMILY(1,1)
AMNIOTIC FLUID(1,1)
AMPLIFICATION REACTION(1,1)
ANOREXIA(1,1)
ANTIBACTERIAL(1,1)
ANTIGEN SOURCE(1,1)
ANTIGENIC DETERMINANT(1,1)
ANTISERA(1,1)
AQUEOUS CARRIER(1,1)
ARTIFICIAL INSEMINATION(1,1)
ASPARTATE(1,1)
ASSAY VARIETY(1,1)
ATTENUATION(1,1)
AVRIDINE(1,1)
BANDAGE(1,1)
BARBER(1,1)
BASIC PROTEIN(1,1)
BETA STRAND(1,1)
BLISTER(1,1)
BLOOD SAMPLE PAIR(1,1)
BLOODSTREAM(1,1)
BLOT ANALYSIS(1,1)
BUFFERING AGENT(1,1)
BVDV SEQUENCE ALIGNMENT(1,1)
CARBOHYDRATE(1,1)
CARBOXYL GROUP(1,1)
CARTRIDGE(1,1)
CATTLE CONDITION(1,1)
CHEMICAL COMPONENT(1,1)
CHEMICALLY INDUCED MUTATION(1,1)
CHITOSAN(1,1)
CHLAMYDIAL INFECTION(1,1)
COCOA BUTTER(1,1)
COLI CELL(1,1)
COLLAGEN(1,1)
COLOR DEVELOPMENT(1,1)
COMPOUND POWDER MIX(1,1)
COMPOUND SOLUBILITY(1,1)
COMPOUND SUSPENSION(1,1)
CORRECT SEQUENCE(1,1)
CREATION(1,1)
CRITICAL RESIDUE(1,1)
CULTURE FLUID(1,1)
CYCLODEXTRIN(1,1)
CYTOKINE(1,1)
CYTOPATHIC EFFECT(1,1)
DAM(1,1)
DECREASING SERUM ASSAY(1,1)
DELIVERY VEHICLE(1,1)
DIFFERENTIAL IMMUNE RESPONSE(1,1)
DIRECT ASSAY(1,1)
DIRECTED MUTATION(1,1)
DISCRIMINATION(1,1)
DISPERSION MEDIUM(1,1)
DISTINCTION(1,1)
DISUBSTITUTED AMINOACID(1,1)
DIVIDED BOTTLE(1,1)
DNA SEQUENCE PRIMER(1,1)
DOMAIN ABSENCE(1,1)
DOSE MULTIPLE ADMINISTRATION(1,1)
DOUBLE MUTANT(1,1)
DUAL BARREL FOLD(1,1)
EPITOPE SPECIFIC MUTATION(1,1)
FLAVIVIRUS(1,1)
FLAVOR(1,1)
HEAT LABILE ENTEROTOXIN(1,1)
HELICASE MOLECULE SEPARATED REGION(1,1)
HELICASE REGION(1,1)
HYDROPHOBIC REGION(1,1)
HYDROXYETHYL CELLULOSE(1,1)
IMMUNOPRECIPITATE(1,1)
INFECTED SUBJECT(1,1)
INFUSION(1,1)
LAST VACCINATION(1,1)
LATE TERM ABORTION(1,1)
LIGATION MIXTURE(1,1)
MAMMALIAN CELL(1,1)
MEMBRANE ANCHORING REGION(1,1)
MODIFIED NUCLEOTIDE(1,1)
MURAMYL DIPEPTIDE(1,1)
MUTANT K(1,1)
NON TRANSLATED REGION(1,1)
PARENTERAL SOLUTION PREPARATION(1,1)
PCR PRODUCT(1,1)
PERFORMANCE MODIFIER(1,1)
PLASMID PRESENCE(1,1)
PORCINE CELL(1,1)
PROTEASE MOLECULAR ORIENTATION(1,1)
PROTECTING GROUP INCLUSION(1,1)
RABBIT RETICULOCYTE LYSATE(1,1)
RECOGNITION EQUIVALENT LOSS(1,1)
RECOGNITION SITE(1,1)
REFRIGERANT R134A(1,1)
RESIDUE R MUTATION(1,1)
RESTRICTION SITE(1,1)
RNA PREPARATION(1,1)
SAFETY(1,1)
SEQUENCE COORDINATE(1,1)
STRANDED NUCLEIC ACID(1,1)
STRONG HUMORAL RESPONSE(1,1)
STRONG STAINING(1,1)
TEST VACCINE(1,1)
THIXOTROPIC LIQUID(1,1)
TRANSCRIPTION REACTION PRODUCT(1,1)
TRANSFECTION MIXTURE(1,1)
UNIQUE NOVEL RESTRICTION(1,1)
(US20080305130)
BOVINE VIRAL DIARRHEA VIRUS(100,65)
HELICASE DOMAIN MUTATION(100,40)
ANIMAL(100,18)
BOVINE DIARRHEA VIRUS(100,14)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(100,5)
BOVINE DIARRHEA VIRUS VACCINE(100,3)
HELICASE DOMAIN AMINOACID(50,9)
INFECTIOUS VIRUS GENERATION(49,10)
VARIANT BVD VIRUS(45,2)
HELICASE DOMAIN(43,25)
REPLICATION VIRAL RNA(37,12)
IGR LOOP(36,25)
BVD VIRUS ORIGIN(35,1)
MUTATION(33,38)
UNMODIFIED VIRUS PEPTIDE(32,1)
PROVIRAL MOLECULAR CLONE(29,1)
KHP LOOP(25,13)
BVD VIRUS MUTATION(25,4)
MONOCLONAL ANTIBODY(24,16)
MARKED VACCINE HELICASE DOMAIN(24,2)
MUTATED BOVINE DIARRHEA VIRUS(23,6)
RECOGNITION LOSS(22,11)
BDV VIRUS(22,1)
BVDV SPREAD(22,1)
GENETIC MANIPULATION(21,1)
AMINOACID RESIDUE(20,34)
SE LOOP(19,18)
ANTIBODY(18,39)
BVDV INFECTION(17,3)
MARKED VACCINE(16,4)
ANIMAL SUBJECT(14,4)
IMMUNODOMINANT EPITOPE(14,1)
RECOGNITION EQUIVALENT LOSS(14,1)
TEST VACCINATION STATUS(13,2)
PRIOR VACCINATION ATTENUATED VIRUS(13,1)
TEST ANIMAL(12,4)
HELICASE FUNCTION(12,1)
ESCHERICHIA(11,1)
TERM ANIMAL SUBJECT(11,1)
VACCINE(10,21)
AMINOACID MUTATION(10,15)
PLASMID(10,7)
SWINE(9,1)
AMPLIFICATION(8,2)
HELICASE SUBDOMAIN(7,3)
PROPAGATION(7,3)
BOVINE(7,2)
BVDV HELICASE DOMAIN(7,2)
SINGLE HELICASE DOMAIN(7,2)
SUBVIRAL REPLICON BACKBONE(7,2)
BVDV SUBVIRAL REPLICON CONTEXT(7,1)
TREATING INFECTION(7,1)
SHEEP(6,3)
ATTENDING VETERINARIAN SUPERVISION(6,1)
CHYMOTRYPSIN SERINE PROTEASE FAMILY(6,1)
INFECTIOUS PROVIRAL PARENT PLASMID(6,1)
INTESTINAL MUCOSA ULCERATION(6,1)
MUTANT BVD VIRAL GENOME(6,1)
PROGENY MUTANT BVD VIRUS(6,1)
VECTASTAIN ELITE ABC KIT(6,1)
MUTATED PORTION(5,6)
DOMAIN RESULT(5,3)
PARENTERAL ADMINISTRATION(5,3)
NONSTRUCTURAL PROTEIN(5,2)
BIOCHEMICAL NOMENCLATURE COMMISSION(5,1)
BVDV CYTOPATHIC STRAIN(5,1)
BVDV IMMUNODOMINANT PROTEIN(5,1)
BVDV INFECTION SYMPTOM(5,1)
BVDV POLYPROTEIN ENCODING(5,1)
BVDV RNA REPLICATION(5,1)
FULL LENGTH BVDV(5,1)
MAB RECOGNITION ABOLISHMENT(5,1)
MAB RECOGNIZING BVDV(5,1)
MARKER IMMUNOGENIC DETERMINANT(5,1)
MLV BVDV VACCINE(5,1)
MUTANT R1942A DEMONSTRATED REACTIVITY(5,1)
MUTANT VIRAL HELICASE(5,1)
NCP BIOTYPE VIRUS(5,1)
PREGNANT CATTLE PLACENTA(5,1)
REGIONAL BVDV ERADICATION PROGRAM(5,1)
TNT RABBIT RETICULOCYTE(5,1)
TRUNCATED SUBVIRAL REPLICON(5,1)
PROGRAMMED RELEASE(4,5)
VETERINARILY ACCEPTABLE CARRIER(4,4)
GENOMIC NUCLEIC ACID MOLECULE(4,3)
1845A MUTATION(4,2)
1867A MUTATION(4,2)
ANTIBODY TITER(4,2)
AURAL ADMINISTRATION(4,2)
CAPSID PROTEIN(4,2)
CLASSICAL SWINE FEVER(4,2)
DOMAIN PEPTIDE SEQUENCE(4,2)
E1939A MUTATION(4,2)
EUKARYOTIC HOST CELL(4,2)
H1868A MUTATION(4,2)
I1841A MUTATION(4,2)
INOCULATED ANIMAL(4,2)
INTRA LYMPH NODE(4,2)
MUTANT REPLICON(4,2)
MUTATED EPITOPE(4,2)
P1869A MUTATION(4,2)
PLASMID PROPAGATION(4,2)
PRESSURIZED CONTAINER(4,2)
PROKARYOTIC HOST CELL(4,2)
R1942A MUTATION(4,2)
WESTERN BLOT(4,2)
BOVINE DONOR CALF SERUM(4,1)
BVD DISEASE THREAT(4,1)
BVD VIRUS GENOME(4,1)
BVD VIRUS INDICATIVE(4,1)
BVDV INFECTION INCIDENCE(4,1)
BVDV NEGATIVE HEALTHY CALF(4,1)
BVDV NUCLEOCAPSID(4,1)
BVDV VIRULENT STRAIN(4,1)
CANDIDATE EPITOPE IDENTIFICATION(4,1)
CATALYTIC HELICASE ACTIVITY PRESERVATION(4,1)
COW PREGNANCY STATUS(4,1)
GENOMIC RNA PACKAGING(4,1)
HELIX SUBDOMAIN(4,1)
HOMOLOGOUS VIRUS STRAIN(4,1)
IMMUNOLOGICALLY DISTINCT EPITOPE(4,1)
INDIRECT IMMUNOFLUORESCENT ASSAY(4,1)
INTACT HELICASE PROTEIN(4,1)
MADIN DARBY BOVINE KIDNEY(4,1)
MARKED BVDV VACCINE STRAIN(4,1)
MARKED CATTLE VACCINE(4,1)
MARKED VIRUS GROWTH KINETICS(4,1)
MUTAGENIC OLIGONUCLEOTIDE PRIMER VIRTUE(4,1)
MUTANT PCR FRAGMENT(4,1)
MUTATED BDV VIRUS(4,1)
RD CELL TRANSFECTION(4,1)
RESIDUE R1843A MUTATION(4,1)
SERUM NEUTRALIZING TITER(4,1)
TRANSDERMAL PENETRATION ENHANCER(4,1)
VIRUS NEUTRALIZATION ASSAY(4,1)
MODIFIED RELEASE FORMULATION(3,5)
ANTIBODY PRESENCE(3,3)
MDBK CELL(3,3)
DRY POWDER INHALER(3,2)
INFECTION RISK(3,2)
MOLECULAR MODELING(3,2)
MUTATED SEQUENCE(3,2)
OVERNIGHT INCUBATION(3,2)
PARENTERAL ROUTE(3,2)
REPLACEMENT MUTANT(3,2)
TRANSFECTED CELL(3,2)
TRANSLATED PROTEIN(3,2)
ABSORBABLE GEL SPONGE(3,1)
AGENT FACILITATING CELLULAR UPTAKE(3,1)
ALANINE REPLACEMENT FRAGMENT(3,1)
AMPHIGEN ADJUVANT(3,1)
AVRIDINE LIPID(3,1)
BVD GENOMIC SEQUENCE(3,1)
BVD VIRION(3,1)
BVDV HELICASE MOLECULAR MODEL(3,1)
BVDV IDENTIFICATION(3,1)
BVDV INFECTED CATTLE(3,1)
BVDV INFECTION DETECTION(3,1)
BVDV SUBTYPE(3,1)
CERTIFIED BVDV NEGATIVE SEMEN(3,1)
CHALLENGE INOCULUM(3,1)
COMPETITIVE IMMUNOASSAY(3,1)
CONTRADICTORY DEFINITION(3,1)
CYTOPATHIC BVDV(3,1)
DIFFERENTIAL DIAGNOSTIC ASSAY(3,1)
EFFICIENT VRNA REPLICATION(3,1)
ENVELOPED VIRION FORMATION(3,1)
EPITOPE CONFORMATION(3,1)
EPITOPE REFINEMENT(3,1)
EXPRESSIBLE GENE(3,1)
FLAVIVIRIDAE FAMILY(3,1)
FRESH RD CELL MONOLAYER(3,1)
HELICASE HELICAL SUBDOMAIN(3,1)
HELICASE PROTEASE(3,1)
HELICASE SUPERFAMILY(3,1)
HERD CERTIFICATION(3,1)
HETEROLOGOUS CDNA(3,1)
HETEROLOGOUS DNA(3,1)
HIGHLY CONSERVED HELICASE(3,1)
HOG CHOLERA(3,1)
HORSERADISH PEROXIDASE(3,1)
IMMUNOHISTOCHEMISTRY ASSAY(3,1)
INFECTIOUS VIRAL PARTICLE(3,1)
INITIATING TRANSLOCATION(3,1)
INTRANASAL INOCULATION(3,1)
LABELED ANTIBODY AFFINITY(3,1)
LIGATED REACTION ALIQUOT(3,1)
MAJOR BVDV IMMUNOGEN(3,1)
MARKED VACCINE CONTEXT(3,1)
MARKER DETERMINANT(3,1)
METHIONINE METHYLSULFONIUM(3,1)
METHIONINE SULFOXIDE(3,1)
MLV VACCINE(3,1)
MONOPHOSPHORYL LIPID(3,1)
MUCOSAL DISEASE OUTBREAK(3,1)
MUTANT R1843A(3,1)
NADL BVDV(3,1)
NUCLEOSIDE TRIPHOSPHATE(3,1)
OVERLAPPING FRAGMENT ENCODING(3,1)
OVERLAPPING PCR FRAGMENT(3,1)
OVERLAPPING PCR STRATEGY(3,1)
PESTIVIRUS GENUS(3,1)
PLASMID DNA PURIFICATION(3,1)
POSTCHALLENGE INTERVAL(3,1)
PROTEASE COFACTOR(3,1)
PROVIRAL PLASMID(3,1)
PURIFIED MUTATED VIRUS(3,1)
R1942A MUTANT(3,1)
RADIOLABELED METHIONINE(3,1)
RD CELL FRESH MONOLAYER(3,1)
RESPONDING CTL DETECTION(3,1)
RESTRICTION ENZYME DIGESTION(3,1)
RNA MOLECULE ENCODING(3,1)
RNA REPLICATION EFFICIENCY INDICATOR(3,1)
SERUM NEUTRALIZATION ASSAY(3,1)
SERUM SERIAL DILUTION(3,1)
SORBITAN TRIOLEATE(3,1)
SUCCESSFUL VIRUS VACCINE(3,1)
SUCROSE GRADIENT CENTRIFUGATION(3,1)
SYNTHESIZED POLYPROTEIN(3,1)
TEST FRAGMENT PCR AMPLIFICATION(3,1)
TISSUE CULTURE FLASK(3,1)
TITER VIRUS YIELD(3,1)
TRADE ECONOMIC BENEFIT FREEDOM(3,1)
TRANSCRIPT AMPLIFICATION(3,1)
TRUNCATED PROTEIN TRANSLATION(3,1)
UNPROCESSED POLYPROTEIN(3,1)
VACCINATED CATTLE(3,1)
VACCINE FETAL TRANSMISSION(3,1)
VETERINARY PHYSICIAN(3,1)
VIRAL PROTEIN EXPRESSION(3,1)
VIRUS ACCELERATED ELIMINATION(3,1)
VIRUS DISSEMINATION(3,1)
WISCONSIN UNIVERSITY(3,1)
WILD TYPE(2,21)
ATOMIZER(2,4)
LACTOSE(2,4)
OPTIMEM(2,4)
CLONE(2,3)
ELECTROPHORESIS(2,3)
LIPOSOME(2,3)
VAGINAL ADMINISTRATION(2,3)
ACTIVE INGREDIENT(2,2)
ALKALINE PHOSPHATASE(2,2)
AMINOACID MIMETICS(2,2)
BODY FLUID(2,2)
BOVINE CELL CULTURE(2,2)
BVDV ISOLATION(2,2)
COLONY(2,2)
CYSTEINE(2,2)
DEXTROSE(2,2)
DIARRHEA(2,2)
DIVIDED DOSE(2,2)
ELECTROHYDRODYNAMICS(2,2)
ENGLAND BIOLAB(2,2)
ESTRUM(2,2)
EXCIPIENT(2,2)
FINE MIST(2,2)
FRAGMENT SEQUENCE(2,2)
GLYCOPROTEIN(2,2)
HELICASE ACTIVE SITE(2,2)
HYDROXYPROPYLMETHYLCELLULOSE(2,2)
INHALATION(2,2)
INTRANASAL ADMINISTRATION(2,2)
IONTOPHORESIS(2,2)
ISOTONIC AGENT(2,2)
MICRONEEDLE(2,2)
NEBULIZER(2,2)
NON CONSERVATIVE AMINOACID SUBSTITUTION(2,2)
NORLEUCINE(2,2)
O PHOSPHOSERINE(2,2)
OINTMENT(2,2)
PHENYLALANINE(2,2)
PLACEBO(2,2)
PRESERVATIVE(2,2)
PROPELLANT(2,2)
PROTEIN COATING(2,2)
RECOMBINANT DNA(2,2)
SELECTIVE MEDIUM(2,2)
SILICON GRAPHICS(2,2)
TRYPTOPHAN(2,2)
TYROSINE(2,2)
VIRAL RNA SEQUENCE(2,2)
ADSORPTION DELAYING(2,1)
AEROSOL SPRAY(2,1)
AGAROSE GEL(2,1)
ALANINE RESIDUE(2,1)
ALLEGED VACCINE ASSOCIATED OUTBREAK(2,1)
AMINE ADJUVANT(2,1)
ARTIFICIAL CHROMOSOME(2,1)
BENZALKONIUM CHLORIDE(2,1)
BIOADHESIVE AGENT(2,1)
BORDER DISEASE CAUSATIVE AGENT(2,1)
BOVINE UBIQUITIN(2,1)
BVD VIRUS SEQUENCE(2,1)
BVDV NEGATIVE COW(2,1)
BVDV PRELIMINARY MOLECULAR MODEL(2,1)
BVDV STRAIN(2,1)
CALORIMETRIC DETECTION(2,1)
CATIONIC LIPID(2,1)
CATTLE SERUM SAMPLE(2,1)
CELL EXTRACT(2,1)
CELLULOSIC POLYMER(2,1)
CESAREAN DELIVERY(2,1)
CHOLERA TOXIN(2,1)
CLINICAL PARAMETER(2,1)
CLINICAL SYNDROME VARIETY(2,1)
COMPETITIVE ELISA(2,1)
COMPOSITION CO ADMINISTRATION(2,1)
CONFIRMED PREGNANCY(2,1)
DIAGNOSTIC LABORATORY(2,1)
DIRECT COMPETITIVE ASSAY(2,1)
DISULFIDE BOND(2,1)
DIVIDED FOIL PACKET(2,1)
DNA SEGMENT(2,1)
DOSAGE INTERVAL(2,1)
DOSAGE REGIMEN(2,1)
DUSTING POWDER(2,1)
ELISA COATING(2,1)
EMERYVILLE CALIF(2,1)
ENCODED DOMAIN(2,1)
ENVELOPE PROTEIN(2,1)
ENZYME CLEAVAGE SITE(2,1)
EPITOPE RECOGNITION LOSS(2,1)
FETAL INFECTION(2,1)
FULLY MUTATED FRAGMENT(2,1)
GASTROINTESTINAL DISEASE(2,1)
GELAN GUM(2,1)
GENTLE ROCKING(2,1)
GESTATION DAY(2,1)
HCV PROTEIN REGION(2,1)
HELICASE CATALYTIC CENTER(2,1)
HETEROPOLYSACCHARIDE POLYMER(2,1)
HYDROPHOBIC MEMBRANE ABSENCE(2,1)
IHC STAINING(2,1)
IMMUNITY DURATION(2,1)
IMMUNOASSAY FORMAT(2,1)
IMMUNOLOGICAL ASSAY(2,1)
IMMUNOMODULATORY AGENT(2,1)
IMPLANTED DEPOT(2,1)
INCOMPLETE ADJUVANT(2,1)
INDIRECT CONFIRMATION(2,1)
INDUCTION INDICATIVE(2,1)
ISOLEUCINE REPLACEMENT(2,1)
JPRED SERVER(2,1)
KEY EPITOPE(2,1)
LABELED MAB(2,1)
LETTER SYMBOL(2,1)
LIVE VIRUS(2,1)
LYSINE RESIDUE(2,1)
MAB PANEL(2,1)
MAGNESIUM STEARATE(2,1)
MAJOR GENOTYPE(2,1)
MARKER GENE(2,1)
MARKER MUTATION(2,1)
MEGASCRIPT(2,1)
METERED DOSE(2,1)
MODIFIED LIVE VIRAL VACCINE(2,1)
MONOCLONAL ANTIBODY PANEL(2,1)
MUTAGENESIS STUDY(2,1)
MUTANT SCREENING(2,1)
MUTANT VIRUS PRESENCE(2,1)
MUTATION INTRODUCTION(2,1)
MUTATION SITE(2,1)
NADL STRAIN(2,1)
NATIVE MOLECULE(2,1)
NON CONSERVATIVE AMINOACID REPLACEMENT(2,1)
NON INFECTED ANIMAL(2,1)
NS4A PROTEIN(2,1)
NUCLEOTIDE SEQUENCE(2,1)
OLIGOLACTIC ACID(2,1)
OPTIMAL IMMUNIZATION(2,1)
OPTIMIZED DILUTION(2,1)
OVERLAPPING PRIMER(2,1)
PARENTERAL FORMULATION(2,1)
PCR OVERLAP EXTENSION(2,1)
PEPTIDE BACKBONE MODIFICATION(2,1)
POLYCLONAL SERUM(2,1)
POLYPROTEIN REGION(2,1)
POST CHALLENGE ISOLATION(2,1)
PROGENY VIRUS(2,1)
PROSTAGLANDIN INJECTION(2,1)
PROTEASE BOUNDARY(2,1)
PROTEASE DOMAIN(2,1)
PROTEASE FRAGMENT(2,1)
PROTEASE ORIENTATION(2,1)
PROTOTYPICAL SEQUENCE(2,1)
PURIFIED DNA(2,1)
REACTIVITY TEST(2,1)
REPEATED PASSAGING(2,1)
REPLICATION ORIGIN(2,1)
REPLICATION RETENTION(2,1)
RESIDUE NUMBER(2,1)
RNA HELICASE(2,1)
RNA TRANSCRIPT(2,1)
SAPONIN FRACTION(2,1)
SCANNING MUTANT(2,1)
SEED FLASK(2,1)
SEROLOGIC TESTING(2,1)
SERUM ANTIBODY(2,1)
SILENT NUCLEOTIDE CHANGE(2,1)
SOLUBILITY ENHANCING AGENT INCORPORATION(2,1)
STANDARD VIRUS TITRATION(2,1)
STERILE ADJUVANT(2,1)
STERILE NON AQUEOUS SOLUTION(2,1)
STERILE SALINE(2,1)
STOCK VIRUS TITER(2,1)
SUSPENSION FORMULATION(2,1)
TEMPLATE DNA(2,1)
TERM NAKED DNA(2,1)
TERM NON CONSERVATIVE(2,1)
TERTIARY CONFORMATION(2,1)
TRANSLATED BVDV REGION(2,1)
TRANSLATION INITIATION CODON(2,1)
TRIPLE MUTANT(2,1)
UNCHALLENGED ANIMAL(2,1)
UNCHARGED POLAR(2,1)
UNIQUE BSMBI(2,1)
UNIQUE RESTRICTION ENZYME SITE(2,1)
VACCINATED ANIMAL(2,1)
VACCINE DOSE(2,1)
VACCINE EFFICACY(2,1)
VECTOR LABORATORY(2,1)
VECTOR PROPAGATION(2,1)
VIRAL PROTEOLYTIC ENZYME(2,1)
VIRAL REPLICATION(2,1)
VIRAL STRAIN(2,1)
VIRAL STRUCTURAL GENE(2,1)
VIRUS FETAL TRANSMISSION(2,1)
VIRUS ISOLATION(2,1)
VIRUS NEUTRALIZING ACTIVITY(2,1)
VIRUS PARTICLE(2,1)
WEAK HUMORAL IMMUNE RESPONSE(2,1)
AMINOACID ANALOG(1,3)
PROPYLENE GLYCOL(1,3)
ABORTED FETUS(1,1)
ACTIVE RELEASE(1,1)
ACTUATION VOLUME(1,1)
ALANINE MUTATION(1,1)
ALIGNED SEQUENCE(1,1)
ALKALINE CONDITION(1,1)
ALUMINUM HYDROXIDE GEL(1,1)
AMERICAN PUBLIC HEALTH ASSOCIATION PUBLICATION(1,1)
AMINOACID FAMILY(1,1)
AMNIOTIC FLUID(1,1)
AMPLIFICATION REACTION(1,1)
ANOREXIA(1,1)
ANTIBACTERIAL(1,1)
ANTIGEN SOURCE(1,1)
ANTIGENIC DETERMINANT(1,1)
ANTISERA(1,1)
AQUEOUS CARRIER(1,1)
AQUEOUS ETHANOL(1,1)
ARGININE(1,1)
ARTIFICIAL INSEMINATION(1,1)
ASPARAGINE(1,1)
ASPARTATE(1,1)
ASSAY VARIETY(1,1)
ATTENUATION(1,1)
BANDAGE(1,1)
BARBER(1,1)
BASIC PROTEIN(1,1)
BETA STRAND(1,1)
BLISTER(1,1)
BLOOD SAMPLE PAIR(1,1)
BLOODSTREAM(1,1)
BLOT ANALYSIS(1,1)
BUFFERING AGENT(1,1)
BVDV SEQUENCE ALIGNMENT(1,1)
CARBOHYDRATE(1,1)
CARBOXYL GROUP(1,1)
CARTRIDGE(1,1)
CATTLE CONDITION(1,1)
CHEMICAL COMPONENT(1,1)
CHEMICALLY INDUCED MUTATION(1,1)
CHITOSAN(1,1)
CHLAMYDIAL INFECTION(1,1)
COCOA BUTTER(1,1)
COLI CELL(1,1)
COLLAGEN(1,1)
COLOR DEVELOPMENT(1,1)
COMPOUND POWDER MIX(1,1)
COMPOUND SOLUBILITY(1,1)
COMPOUND SUSPENSION(1,1)
CORRECT SEQUENCE(1,1)
CORRELATION(1,1)
CREATION(1,1)
CRITICAL RESIDUE(1,1)
CULTURE FLUID(1,1)
CYCLODEXTRIN(1,1)
CYTOKINE(1,1)
CYTOPATHIC EFFECT(1,1)
CYTOTOXIC(1,1)
DECREASING SERUM ASSAY(1,1)
DELIVERY VEHICLE(1,1)
DIFFERENTIAL IMMUNE RESPONSE(1,1)
DIRECT ASSAY(1,1)
DIRECTED MUTATION(1,1)
DISCRIMINATION(1,1)
DISPERSION MEDIUM(1,1)
DIVIDED BOTTLE(1,1)
DOMAIN ABSENCE(1,1)
DOSE MULTIPLE ADMINISTRATION(1,1)
DOUBLE MUTANT(1,1)
DUAL BARREL FOLD(1,1)
EPITOPE SPECIFIC MUTATION(1,1)
FILE SEQUENCE(1,1)
FLAVIVIRUS(1,1)
FLAVOR(1,1)
GENETICALLY ENCODED AMINOACID(1,1)
GIVEN PEPTIDE ANTIBODY RECOGNITION(1,1)
HCV SEQUENCE(1,1)
HEAT LABILE ENTEROTOXIN(1,1)
HELICASE MOLECULE SEPARATED REGION(1,1)
HELICASE REGION(1,1)
HYDROPHOBIC REGION(1,1)
IHC ANALYSIS(1,1)
IMMUNOPRECIPITATE(1,1)
INFECTED SUBJECT(1,1)
INFUSION(1,1)
LAST VACCINATION(1,1)
LATE TERM ABORTION(1,1)
LIGATION MIXTURE(1,1)
LOOP IGP(1,1)
LOOP KHP(1,1)
MAMMALIAN CELL(1,1)
MEMBRANE ANCHORING REGION(1,1)
METHYLHISTIDINE(1,1)
MODIFIED NUCLEOTIDE(1,1)
MURAMYL DIPEPTIDE(1,1)
NON TRANSLATED REGION(1,1)
PARENTERAL SOLUTION PREPARATION(1,1)
PCR PRODUCT(1,1)
PERFORMANCE MODIFIER(1,1)
PLASMID PRESENCE(1,1)
PORCINE CELL(1,1)
PROTEASE MOLECULAR ORIENTATION(1,1)
PROTECTING GROUP INCLUSION(1,1)
RECOGNITION SITE(1,1)
RESTRICTION SITE(1,1)
RIBI INC(1,1)
RNA DEPENDENT NTP(1,1)
RNA PREPARATION(1,1)
SAFETY(1,1)
SEQUENCE COORDINATE(1,1)
SINGULAR TERM(1,1)
STRANDED NUCLEIC ACID(1,1)
STRONG HUMORAL RESPONSE(1,1)
STRONG STAINING(1,1)
TERM PLASMID(1,1)
TERM VACCINE(1,1)
TEST VACCINE(1,1)
TETRAFLUOROETHANE(1,1)
THIXOTROPIC LIQUID(1,1)
TRANSCRIPTION REACTION PRODUCT(1,1)
TRANSFECTION MIXTURE(1,1)
UNIQUE NOVEL RESTRICTION(1,1)
ZINC DEPENDENT PROTEASE(1,1)
(WO200766188)
BOVINE VIRAL DIARRHEA VIRUS(100,61)
HELICASE DOMAIN MUTATION(100,40)
ANIMAL(100,17)
BOVINE DIARRHEA VIRUS(100,10)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(100,4)
BOVINE DIARRHEA VIRUS VACCINE(100,3)
INFECTIOUS VIRUS GENERATION(47,7)
HELICASE DOMAIN(38,15)
HELICASE DOMAIN AMINOACID(35,15)
REPLICATION VIRAL RNA(34,9)
HOMOLOGOUS VIRUS STRAIN(31,1)
MARKED VACCINE HELICASE DOMAIN(24,2)
MUTATED BOVINE DIARRHEA VIRUS(23,6)
MUTATION(22,57)
BVDV SPREAD(22,1)
AMINOACID RESIDUE(21,33)
MONOCLONAL ANTIBODY(20,15)
SE LOOP(19,16)
ANTIBODY(18,39)
MARKED VACCINE(18,3)
ANTIBODY TITER(18,2)
BVDV INFECTION(17,3)
HELJCASE DOMAIN AMINOACID(17,1)
IMMUNODOMINANT EPITOPE(14,1)
VACCINE(13,24)
TEST VACCINATION STATUS(13,2)
HELICASE FUNCTION(12,1)
STANDARD MONOCLONAL ANTIBODY(12,1)
CORRELATION(11,1)
PREMATURE BIRTH(11,1)
RECOGNITION LOSS(10,8)
BVD VIRUS MUTATION(9,4)
ABORTION(9,2)
FETUS(8,3)
BVDV(7,19)
ANTIBODY RECOGNITION(7,6)
HELICASE SUBDOMAIN(7,3)
ASSAY(7,2)
SINGLE HELICASE DOMAIN(7,2)
SUBVIRAL REPLICON BACKBONE(7,2)
BVDV SUBVIRAL REPLICON CONTEXT(7,1)
MUTANT SUBVIRAL REPLICON CHARACTERIZATION(7,1)
CATTLE(6,8)
AMINOACID MUTATION(6,3)
TEST ANIMAL(6,2)
VARIANT BVD VIRUS(6,2)
ATTENDING VETERINARIAN SUPERVISION(6,1)
CHYMOTRYPSIN SERINE PROTEASE FAMILY(6,1)
INFECTIOUS PROVIRAL PARENT PLASMID(6,1)
INTESTINAL MUCOSA ULCERATION(6,1)
MUTANT BVD VIRAL GENOME(6,1)
PROGENY MUTANT BVD VIRUS(6,1)
SUBVIRAL BVDV REPLICON(6,1)
VECTASTAIN ELITE ABC KIT(6,1)
MUTATED PORTION(5,6)
PARENTERAL ADMINISTRATION(5,4)
AURAL ADMINISTRATION(5,3)
NONSTRUCTURAL PROTEIN(5,2)
ALANINE REPLACEMENT MUTANT IMMUNOPRECIPITATION(5,1)
BIOCHEMICAL NOMENCLATURE COMMISSION(5,1)
BVDV CYTOPATHIC STRAIN(5,1)
BVDV IMMUNODOMINANT PROTEIN(5,1)
BVDV INFECTION SYMPTOM(5,1)
BVDV POLYPROTEIN ENCODING(5,1)
MAB RECOGNITION ABOLISHMENT(5,1)
MAB RECOGNIZING BVDV(5,1)
MUTANT VIRAL HELICASE(5,1)
PREGNANT CATTLE PLACENTA(5,1)
REGIONAL BVDV ERADICATION PROGRAM(5,1)
TNT RABBIT RETICULOCYTE(5,1)
TRUNCATED SUBVIRAL REPLICON(5,1)
PROGRAMMED RELEASE(4,5)
VETERINARILY ACCEPTABLE CARRIER(4,4)
GENOMIC NUCLEIC ACID MOLECULE(4,3)
ADI CLONING SITE(4,2)
CLASSICAL SWINE FEVER(4,2)
DOMAIN RESULT(4,2)
EUKARYOTIC HOST CELL(4,2)
INOCULATED ANIMAL(4,2)
MUTANT REPLICON(4,2)
MUTATED EPITOPE(4,2)
PLASMID PROPAGATION(4,2)
PRESSURIZED CONTAINER(4,2)
PROKARYOTIC HOST CELL(4,2)
VACCINE EFFICACY TESTING(4,2)
WESTERN BLOT(4,2)
BOVINE DONOR CALF SERUM(4,1)
BVD DISEASE THREAT(4,1)
BVD VIRUS GENOME(4,1)
BVD VIRUS INDICATIVE(4,1)
BVD VIRUS ORIGIN(4,1)
BVDV HELICASE DOMAIN GENERATION(4,1)
BVDV INFECTION INCIDENCE(4,1)
BVDV NEGATIVE HEALTHY CALF(4,1)
BVDV VIRULENT STRAIN(4,1)
CANDIDATE EPITOPE IDENTIFICATION(4,1)
CATALYTIC HELICASE ACTIVITY PRESERVATION(4,1)
COW PREGNANCY STATUS(4,1)
GENOMIC RNA PACKAGING(4,1)
HELIX SUBDOMAIN(4,1)
IMMUNOLOGICAL(...)";"Analysis of biological materials
Pharmaceuticals";Open
"2005-11-15
2006-11-13
2006-11-15";"UY29915             A1 2007-06-29 [UY--29915]
STG: (A1) Patent application (First publication level)
AP : 2006UY-0029915 2006-11-13
WO2007117303        A2 2007-10-18 [WO2007117303]
STG: (A2) International application published without international search report
AP : 2006WO-US60918 2006-11-15
CA2627952           A1 2007-10-18 [CA2627952]
STG: (A1) Application laid open
AP : 2006CA-2627952 2006-11-15
AU2006341564        A1 2007-10-18 [AU2006341564]
STG: (A1) Open to public inspection
AP : 2006AU-0341564 2006-11-15
AR057586            A1 2007-12-05 [AR--57586]
STG: (A1) Independent patent application
AP : 2006AR-0104998 2006-11-15
WO2007117303        A3 2008-01-24 [WO2007117303]
STG: (A3) Later publication of ISR with revised front page
AP : 2006WO-US60918 2006-11-15
EP1948229           A2 2008-07-30 [EP1948229]
STG: (A2) Application published without search report
AP : 2006EP-0850760 2006-11-15
KR10-2008-0072719   A  2008-08-06 [KR20080072719]
STG: (A) Published application
AP : 2008KR-7014460 2008-06-13
IN4723/DELNP/2008   A  2008-08-15 [IN2008DN04723]
STG: (A) Application laid open
AP : 2008IN-DN04723 2008-06-02
CN101360510         A  2009-02-04 [CN101360510]
STG: (A) Published application
AP : 2006CN-80051113 2006-11-15
US20090068223       A1 2009-03-12 [US20090068223]
STG: (A1) Application published
AP : 2006US-11559316 2006-11-13
FD :  Provisional Appl: US60/736,705 FDD=2005-11-15 [2005US-60736705]
JP2009516002        A  2009-04-16 [JP2009516002]
STG: (A) Published application
AP : 2008JP-0541465 2006-11-15
EP1948229           A4 2011-06-15 [EP1948229]
STG: (A4) Supplementary search report
AP : 2006EP-0850760 2006-11-15
BRPI0618593         A2 2011-09-06 [BR200618593]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2006BR-0018593 2006-11-15
NZ569016            A  2011-11-25 [NZ-569016]
STG: (A) Published application
AP : 2006NZ-0569016 2006-11-15
AU2006341564        B2 2012-05-03 [AU2006341564]
STG: (B2) Patent proceeded by OPI
AP : 2006AU-0341564 2006-11-15
AU2006341564        C1 2012-09-27 [AU2006341564]
STG: (C1) Amended after Acceptance/Grant of a standard patent
AP : 2006AU-0341564 2006-11-15
EP2712624           A1 2014-04-02 [EP2712624]
STG: (A1) Application published with search report
AP : 2013EP-0195822 2006-11-15
FD :  Division of: EP06850760 FDD=2006-11-15 [2006EP-0850760]
KR20140108603       A  2014-09-11 [KR20140108603]
STG: (A) Published application
AP : 2014KR-7024044 2006-11-15
IN286866            B  2017-09-01 [IN-286866]
STG: (B) Patent
AP : 2008IN-DN04723 2008-06-02";5323803;"UY29915             A1 2007-06-29 [UY--29915]
WO2007117303        A2 2007-10-18 [WO2007117303]
CA2627952           A1 2007-10-18 [CA2627952]
AU2006341564        A1 2007-10-18 [AU2006341564]
AR057586            A1 2007-12-05 [AR--57586]
WO2007117303        A3 2008-01-24 [WO2007117303]
EP1948229           A2 2008-07-30 [EP1948229]
KR10-2008-0072719   A  2008-08-06 [KR20080072719]
IN4723/DELNP/2008   A  2008-08-15 [IN2008DN04723]
CN101360510         A  2009-02-04 [CN101360510]
US20090068223       A1 2009-03-12 [US20090068223]
JP2009516002        A  2009-04-16 [JP2009516002]
EP1948229           A4 2011-06-15 [EP1948229]
BRPI0618593         A2 2011-09-06 [BR200618593]
NZ569016            A  2011-11-25 [NZ-569016]
AU2006341564        B2 2012-05-03 [AU2006341564]
AU2006341564        C1 2012-09-27 [AU2006341564]
EP2712624           A1 2014-04-02 [EP2712624]
KR20140108603       A  2014-09-11 [KR20140108603]
IN286866            B  2017-09-01 [IN-286866]";"2005US-60736705
2006EP-0850760
2006US-11559316
2006WO-US60918";"(EP1948229)
WO2007117303
(JP2009516002)
WO2007117303
(CA2627952)
WO2007117303
(KR20080072719)
WO2007117303
(CN101360510)
WO2007117303
(BR200618593)
WO2007117303
(NZ-569016)
WO2007117303
(AU2006341564)
WO2007117303
(KR20140108603)
WO2007117303
(IN-286866)
WO2007117303";BOEHRINGER INGELHEIM VETMEDICA;BOEHRINGER INGELHEIM VETMEDICA;"(EP1948229)
DE
(EP2712624)
DE
(US20090068223)
US
(WO2007117303)
DE; US

(CA2627952)
DE

(IN2008DN04723)
DE";"(EP1948229)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

(EP2712624)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

(US20090068223)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC. , CITY=St. Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 

(WO2007117303)
NAME=BOEHRINGER INGELHEIM VETMEDICA, INC.  2621 N. Belt Highway, St. Joseph, MO 64506  , COUNTRY=US 

NAME=BOEHRINGER INGELHIEM VETMEDICA GMBH  Binger Str. 173, D-55216 Ingelheim  , COUNTRY=DE 

(JP2009516002)
NAME=Boehringer Ingelheim vet Medica Gesellschaft mit Beshurenkuteru Hough Tsungu , REG=504225895 

(CA2627952)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 55216 , CITY=INGELHEIM , COUNTRY=DE 

(KR20140108603)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=519980671421 

(IN2008DN04723)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH BINGER STRASSE 173, 55216 INGELHEIM AM RHEIN  , COUNTRY=DE 
";1;"ELBERS KNUT
KNITTEL JEFFREY P
MEYERS GREGOR
TREMBLAY GREGOR
JONES CRAIG
LISCHEWSKI AXEL";"(EP2712624)
DE";"(EP2712624)
NAME=Elbers, Knut Boehringer Ingelheim GmbH,  Corporate Patents Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Knittel, Jeffrey P Boehringer Ingelheim GmbH,  Corporate Patents Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Meyers, Gregor Boehringer Ingelheim, Corporate Patents Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Tremblay, Gregor Boehringer Ingelheim GmbH,  Corporate Patents Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Jones, Craig Boehringer Ingelheim GmbH,  Corporate Patents Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Lischewski, Axel Boehringer Ingelheim GmbH,  Corporate Patents Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 
";"(EP2712624)
Combination vaccine comprising an attenuated bovine viral diharrhea virus";"(EP2712624)
The present invention relates to combinantion vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other than BVDV.";"(WO2007117303)
1. Cl -AIMS: 1 Λ comhsnauon vaccine IOΪ the treatment and'Ot pioph\ laxis oJ cattle against micsobioiogscal infections, wheiem said combinauon vaccine compiles
 > a one or more attenuated BVDV bat ing at least one mutation in the coding sequence foi gh eoprotem E™sand Oi at least anothei mutation in the coding sequence foi V"" uheiem said mutation in the coding sequence ioi gh copiotein Em"" leads to inacm αtion oi RNase acln m leading in C1™ and/υt said mutation m the coding sequence lor Kprøleads to mactnation oi said Nproand. tt> b one Oi more immunological activ e components') effectn e for the treatment and. or prophx la\is of microbiological infection in cattle caused b\ a bo\ me pathogen other than BVDY
 2 The \ accine according Io claim i \\ horan said combination compmcs
 15 a one oi more attenuated BVD\ ha\ ing at least one mutation m the coding sequence
 (oi gK coprotein Frasv herein wud mutatioii in the coding sequence for gh copiotcin FflB>leads to inactn ation of RNase actπ τi\ testdmg in bu"" and b one Oi more immunological activ e components) effectn e for the treatment and/or prophx la\is o( miciυbioioi-ical infection m cattle caused b^ a bo\ me pathogen othe;
 20 than BVD\
 1 Hie \ accine according to claim 1 wherein said combination compuses a one oi more attenuated BVD\ hax ing at least one mutation m the coding sequence for Npl"""" said mutation in the coding sequence foi \!fltleads to niaettuitton of said 2^ N311"" and b one ot moie immunological activ e component^) effectn e for the treatment and/oj prophy laxis of miciobioioyical infection in cattle caused h\ a bo\ mc pathogen othei than BVDΛ
 >{f 4 Hie x acctnc according to claim 1 wherein &aιd combination compuses a one or more attenuated BVDV ha\ ing at leant one mutation m the coding sequence for gh coproteui Emsand at least tuioihei mutation m the coding sequence for NJWuhejem satd mutation m the coding sequence foi gh coprotein Emvleads to
 S 27 inactivation of RNase activity residing in Emsand/or said mutation in the coding sequence for Nr'roleads to inactivation of said Nr'ro: and b. one or more immunological active component(s) effective for the treatment and/or prophylaxis of microbiological infection in cattle caused by a bovine pathogen other 5 than BVDV.
5. The vaccine according to any one of claims 1 to 4, wherein said combination vaccine comprises attenuated BVDV type 1 and attenuated BVDV type 2. both having at feast one mutation in the coding sequence for glycoprotein Emsand at least another mutation in the
 H) coding sequence for Npιt\ wherein said mutation in the coding sequence for glycoprotein Emsleads to inactivation of RNase activity residing in Emsand/or said mutation in the coding sequence for Npi"" leads to inactivation of said Npi"".
6. The combination vaccine according to any one of claims 1 to 5, wherein said infection in ! 5 cattle other than BVDV is caused by at least one pathogen selected from the group consisting of.
 Parainfluenza-^ Virus (Pϊ-3), Infectious Bovine Rhinotracheitis virus (I BR), Bovine Respiratory Syncytia! Virus (BRSV), Bovine Herpesvirus (BHV). Bovine Rotavirus (BRVK Bovine Enterovirus (BETV K Bovine Coronovirus (BCV)5Bovine Rabies
 20 (BR). Bovie Parvovirus (PPV), Adenovirus Astrovirus, Marmheimia haemolytica
 {formerly Pasteurella haemolytica). Pasteurel la muStocida, Haemophilus somnus (Histophilus ovis and Haemophilus agni). Actinomyces (Corynebacterium), Actinomyces pyogenes. Chlamydia psittaci, Campylobacter fetus venereahs and Campylobacter fetus fetus (formerly C fetus intestinahs ), Leptospira interrogans,
 25 Leptospira hardjo, Leptospira pomona. and Leptospira grippoiyphosa, Leptospira canicoia, Leptospira grippolyphosa, Leptospira hardjo (Leptospira hardjoprajitno and Leptospira hardjo-hovts). Brucella ahortus. Brucella suis and Brucella melitensis. Listeria monocytogenes, Chlamydia psittaci, Clostridium chauvoei, Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordelhi,
 3(5 Clostridium perfπngens. Clostridium tetani. Moraxeila bovis. Klebsiella spp.
 Klebsiella pneumoniae. Salmonella lyphimurium; Salmonella nex\port. Mycobacterium avium paratubercυiosis, Crj'ptsporidium paπ'um. Ciyptsporidium horainis. Staphylococcus aureus. Streptococcus dysgalactiae, Streptococcus uberus. Mycoplasma spp. Mycoplasma dispar, M> cop!asma bovis, and Ureaplasma spp,, Tri trichomonas foetus. Trichophyton verrucosus. Trichophyton nientagrophytes. Trichophyton sarkisovii, Neospora caninum (formerly Toxoplasma gondii), Babesia bigemina and Babesia bovis. and Diclyocaulυs viviparous (Lungworm disease).
 7 The combination vaccine according to any one of claims J to 6, wherein said immunological active component is an antigen of one at least one pathogen selected from the group consisting of:
 Parainfluenza-S Virus (Pf-3), Infectious Bovine Rhinolracheilis virus (IBR), Bovine Respirator)' Syncytia! Virus (BRSV). Bovine Herpesvirus (BHV). Bovine Rotavirus (BRV). Bovine Enterox iαis (BEV), Box ine Coronovirus (BCV). Bovine Rabies
 (BR). Bovie Parvovirus (PPV). Adenovirus Astrovirus. Mannheiinia haemolytica (formerly Pasteurella haeniolytiea). Pasteurella multocida, Haemophilus somnus (Histophilus ovis and Haemophilus agni). Actinomyces (Corynebacterium), Actinomyces pyogenes, Chlamydia psitiaci, Campylobacter fetus vεnerealis and Campylobacter fetus fetus (formerly C fetus intestinaiis ), Leptospira interrogans,
 Leptospira hardjo, Leptospira pomona. and Leptospira grippolyphosa. Leptospira canicola, Leptospira grippohphosa, Leptospira hardjo (Leptospira hardjoprajitno and Leptospira, hardjo-bovis), Brucella abortus. Brucella suis and Brucella melitensis. Listeria monocytogenes. Chlamydia psitiaci. Clostridium chauvoei. Clostridium septicum, Clostridium haemolyticum, Clostridium novyi, Clostridium sordellii,
 Clostridium perfringens, Clostridium tetani, MoraxeUa bovis, Klebsiella spp, Klebsiella pneumoniae. Salmonella typhi murium: Salmonella newport, Mycobacterium avium paratυberculosis. Cjyptsporidiuni panunx Cryptsporidiυm hominis. Staphylococcus aureus. Streptococcus dysgalactiae, Streptococcus uberus. Mycoplasma spp, Mycoplasma dispar. Mycoplasma bovis. and llreaplasma spp..
 Tϊϊtrichoraonas foetus. Trichophyton verrucosυm. Trichophyton menlagrophyies. Trichophyton sartisovii, Neospora caninum (formerly Toxoplasma gondii). Babesia bigemina and Babesia bovis, and Dictyocauhis viviparous (Lungworm disease)";"(EP2712624)
The invention also relates to methods for producing such combination vaccines.
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other than BVDV.
The present invention relates to the field of animal health and in particular to combination vaccines which comprise an attenuated bovine viral diarrhea virus (BVDV) and at least one further immunological active component for treating or preventing diseases or disorders in cattle caused by infectious agents.
The present invention relates to combination vaccines for the treatment and/or prophylaxis of cattle against microbiological infections, wherein one of the infections is caused by BVDV.
The present invention relates to combination vaccines for the treatment and/or prophylaxis of cattle against microbiological infections, wherein one of the infections is caused by BVDV.
The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections, and a further immunological active component for the prophylaxis and treatment of microbiological infections other than BVDV.";"(EP2712624)
It was particularly found that deletion or substitution of the histidine residue at position 349 (BVDV) leads to effective inactivation of Erns and therefore leads to particularly useful BVDV live vaccines.
However, Leptospira hardjo infections usually do not cause hemo lytic anemia, which makes diagnosis more difficult.
The attenuated BVDV as described herein can be advantageously used in combination vaccines for the treatment and/or prophylaxis of microbiological infections in cattle.
Although PI-3 is capable of causing disease, it is usually associated with mild to subclinical infections.
The division of BVDV into 2 species is based on significant differences at the level of genomic sequences (summarized in Heinz et al., 2000) which are also obvious from limited cross neutralizing antibody reactions (Ridpath et al. 1994).
This problem is probably due to the great antigenic diversity between type 1 and type 2 strains which is most pronounced in the glycoprotein E2, the major antigen for virus neutralization (Tijssen et al., 1996).";"A61K-039/00
A61K-039/02
A61K-039/12
A61K-039/15
A61K-039/155
A61K-039/265
A61K-039/295
A61P-031/00
A61P-031/12
A61P-043/00
C07K-014/005
C12N-007/00";"(EP2712624)
1. A combination vaccine for the prophylaxis of cattle against microbiological infections, wherein said combination vaccine comprises a. one or more attenuated BVDV, having at least one mutation in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro, wherein said mutation(s) in the coding sequence for glycoprotein Erns lead(s) to inactivation of RNase activity residing in Erns and said mutation(s) in the coding sequence for Npro lead(s) to inactivation of said Npro; and b. one or more immunological active component(s) effective for the prophylaxis of microbiological infection in cattle caused by a bovine pathogen other than BVDV.";"(EP2712624)
COMBINATION VACCINE(100,28)
MICROBIOLOGICAL INFECTION PROPHYLAXIS(100,2)
ATTENUATED BOVINE(100,1)
VIRAL DIHARRHEA VIRUS(100,1)
MICROBIOLOGICAL INFECTION TREATMENT(68,2)
LEPTOSPIRA GRIPPOTYPHOSA(61,6)
LEPTOSPIRA HARDJO INFECTION(52,2)
CODING SEQUENCE(50,46)
CATTLE PROPHYLAXIS(49,6)
HEMOLYTIC ANEMIA(48,2)
LEPTOSPIRA HARDJOPRAJITNO(48,2)
CRYPTSPORIDIUM HOMINIS(47,2)
LISTERIA MONOCYTOGENE(47,2)
CLOSTRIDIUM HAEMOLYTICUM(46,2)
CRYPTSPORIDIUM PARVUM(46,2)
MICROBIOLOGICAL INFECTION(45,8)
KLEBSIELLA SPP(45,3)
CLOSTRIDIUM SORDELLII(45,2)
TRICHOPHYTON MENTAGROPHYTE(44,3)
BOVIE PARVOVIRUS(43,2)
STREPTOCOCCUS UBERUS(43,2)
LEPTOSPIRA HARDJO BOVIS(42,3)
PROPHYLAXIS(42,3)
TRICHOPHYTON SARKISOVII(42,3)
TRICHOPHYTON VERRUCOSUM(42,3)
CLOSTRIDIUM NOVYI(42,2)
SALMONELLA TYPHIMURIUM(42,2)
RNASE ACTIVITY INACTIVATION(41,10)
BOVINE ROTAVIRUS(41,4)
CAMPYLOBACTER FETUS VENEREALIS(41,4)
STAPHYLOCOCCUS AUREUS(41,2)
BRUCELLA MELITENSIS(40,3)
LEPTOSPIRA CANICOLA(40,3)
PARAINFLUENZA(39,4)
HAEMOPHILUS SOMNUS(38,3)
HISTOPHILUS OVIS(38,3)
MUTATION(37,77)
BVDV(36,6)
BABESIA BOVIS(35,3)
VIRUS NEUTRALIZING(35,1)
UREAPLASMA SPP(34,3)
LUNGWORM DISEASE(34,2)
ANTIBODY REACTION NEUTRALIZATION(34,1)
VIRAL ORIGIN PATHOGEN(34,1)
MYCOPLASMA SPP(33,3)
BVDV CAUSED INFECTION TREATMENT(33,1)
NPRO LEAD(32,3)
INFECTIOUS AGENT(31,1)
BOVINE RABIES(30,3)
STREPTOCOCCUS UBERIS(30,1)
CHLAMYDIA PSITTACI(27,6)
LIVE VACCINE(26,2)
IMMUNOLOGICAL ACTIVE COMPONENT(24,7)
FORMERLY C FETUS INTESTINALIS(24,2)
BOVINE VIRAL DIARRHEA VIRUS(23,184)
BOVINE ENTEROVIRUS(23,3)
MANNHEIMIA HAEMOLYTICA(23,2)
TRITRICHOMONAS FETUS(23,2)
MAJOR ANTIGEN(23,1)
CATTLE(22,48)
INACTIVATION(22,12)
ACTINOMYCES(22,7)
ENCODED POLYPROTEIN(21,7)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(21,3)
MORAXELLA BOVIS(21,2)
CLOSTRIDIUM PERFRINGENS(20,3)
PASTEURELLA HAEMOLYTICA(20,3)
PASTEURELLA MULTOCIDA(20,3)
ANTIGENIC DIVERSITY(20,1)
DISORDER(20,1)
SUBCLINICAL INFECTION(20,1)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS(19,5)
CLOSTRIDIUM CHAUVOEI(19,3)
CLOSTRIDIUM SEPTICUM(19,3)
BRUCELLA ABORTUS(18,3)
MYCOPLASMA BOVIS(18,3)
MYCOPLASMA DISPAR(18,3)
NEOSPORA CANINUM(18,3)
INFECTION(17,46)
CORYNEBACTERIUM(17,3)
BRUCELLA SUIS(16,4)
GENOMIC SEQUENCE LEVEL(16,1)
DISEASE(15,31)
PREGNANT HEIFER(14,7)
HOG CHOLERA VIRUS(14,4)
ALFORT T BINGEN(13,4)
SERUM NEUTRALIZATION ASSAY(13,4)
ANIMAL HEALTH FIELD(13,1)
BOVINE PARVOVIRUS(13,1)
SIGNIFICANT DIFFERENCE(13,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(12,19)
GLYCOPROTEIN(12,7)
CONSERVED ERNS SEQUENCE(12,6)
BOVINE(12,3)
NPRO DELETION MUTANT(12,3)
CAPSID PROTEIN AMINOTERMINUS(12,2)
LEPTOSPIRA POMONA INFECTION(12,2)
ENZOOTIC LEPTOSPIRA HARDJO INFECTION(12,1)
INTERLOBULAR SEPTUM GELATINOUS THICKENING(12,1)
STRAIN(11,18)
DELETION(11,12)
ANTIBODY TITER(11,7)
NPRO PROTEIN CODING SEQUENCE(11,4)
SUBSTITUTION(11,3)
COCCIDIAN PARASITE CRYPTOSPORIDIUM PARVUM(11,1)
IMMUNOLOGICALLY DISTINCT LEPTOSPIRAL SEROVAR(11,1)
LEPTOSPIRA ICTEROHAEMORRHAGIA SEROVAR(11,1)
TRICHOPHYTON SPP MYCOSIS INFECTION(11,1)
YOUNG CALF INTRACISTERNAL INOCULATION(11,1)
NUCLEOTIDE SEQUENCE CODING(10,6)
INDIRECT IMMUNOFLUORESCENCE STAINING(10,4)
L HISTIDINE RESIDUE(10,4)
LIVE ATTENUATED STRAIN(10,3)
FIBRINOPURULENT BRONCHOPNEUMONIA(10,2)
CODON RNASE INACTIVATING DELETION(10,1)
INTRA ERYTHROCYTIC PROTOZOON PARASITE(10,1)
LEPTOSPIRA HARDJO PRAJITNO(10,1)
LEPTOSPIRA INTERROGAN SUBGROUP(10,1)
MONOCLONAL NEUTRALIZING ANTIBODY AGAIST(10,1)
MUCOPURULENT ENDOMETRITIS(10,1)
PARASITIZED ERYTHROCYTE SLUDGING(10,1)
RETINAL NECROSIS GRAY FOCI(10,1)
SACCHAROMYCES CEREVISIAE VACUOLAR MEMBRANE(10,1)
BOVINE VIRAL DIARRHEA ABORTION(9,7)
STUDY TERMINATION(9,6)
VIRUS ISOLATION(9,6)
ANTIBODY NEUTRALIZATION(9,3)
CHRONIC ENTERITIS(9,3)
MALIGNANT EDEMA(9,3)
CELLULAR ANTIVIRAL DEFENSE(9,2)
INFECTED ANIMAL FECES(9,2)
ATTENUATED PESTIVIRUS VIRULENCE(9,1)
BABESIA INFECTED TICK INCURSION(9,1)
ERNS RNASE INACTIVATION(9,1)
INFECTIOUS PUSTULAR BALANOPOSTHITIS(9,1)
PERSISTENTLY INFECTED CALF INDUCTION(9,1)
YOUNG FLUKE MIGRATORY TRACK(9,1)
BIOLOGICAL ACTIVITY(8,8)
ENDPOINT DILUTION(8,4)
ANIMAL INOCULATION(8,3)
FIBRINOUS PLEURITIS(8,2)
SUPPURATIVE BRONCHITIS(8,2)
TISSUE CULTURE INFECTIVE(8,2)
TRICHOMONA FETUS(8,2)
ACUTE FIBRINOUS BRONCHOPNEUMONIA(8,1)
AUTOPHAGIC VESICLE MEMBRANE(8,1)
BOVINE GENITAL CAMPYLOBACTERIOSIS(8,1)
BOVINE RHINOVIRUS SEROTYPE(8,1)
CALF PNEUMONIC LUNG(8,1)
CATTLE BABESIA BIGEMINA(8,1)
CATTLE VENEREAL PROTOZOAL DISEASE(8,1)
CLASS IC ENTERO TOXEMIA(8,1)
CLASS IC INFERTILITY SYNDROME(8,1)
COLONIC RIDGE ATROPHY(8,1)
COMPOSTED CATTLE MANURE(8,1)
CONCURRENT BACTERIAL BRONCHOPNEUMONIA(8,1)
COTYLEDON STAINED SMEAR(8,1)
DIFFERING VIRULENCE SEROTYPE(8,1)
EMBRYONATING CHICKEN EGG(8,1)
ENDEMICALLY INFECTED HERD(8,1)
GENUS BRUCELLA BACTERIA(8,1)
HEALTHY CALF FECES(8,1)
HEMOLYTIC CRISIS(8,1)
INTRACELLULAR PROTOZOON PARASITE(8,1)
MAMMARY INFLAMMATION EVIDENCE(8,1)
NEONATAL DIARRHEA SYNDROME(8,1)
NONPNEUMONIC CALF RESPIRATORY TRACT(8,1)
OVINE CHLAMYDIAL VACCINE(8,1)
OVINE SEPTICEMIA ETIOLOGIC AGENT(8,1)
PICORNAVIRUS NONSTRUCTURAL PROTEIN(8,1)
PNEUMONIC CALF LUNG(8,1)
PREGNANT COW INOCULATION(8,1)
PROTRACTED CALVING SEASON(8,1)
RELIABLE ANTEMORTEM EVIDENCE(8,1)
ROTAVIRUS VIRULENT STRAIN(8,1)
SUBCLINICALLY INFECTED BULL(8,1)
UBIQUITIN CARBOXYL TERMINUS(8,1)
YOUNG PIGLET SUSCEPTIBILITY(8,1)
BOVINE VIRAL DIARRHEA VIRAEMIA(7,4)
LIVE VIRUS(7,4)
ADULT CATTLE(7,3)
CARBOXY TERMINUS(7,3)
ERNS PROTEIN(7,3)
RECONSTITUTED SUSPENSION(7,3)
ABORTION STORM(7,2)
ANTIGENIC SUBTYPE(7,2)
BABESIA INFECTION(7,2)
BACTERIAL PNEUMONIA ONSET(7,2)
BREEDING HERD(7,2)
CATTLE POPULATION(7,2)
FLAVIVIRIDAE FAMILY(7,2)
GENITAL INFECTION(7,2)
GESTATION MONTH(7,2)
MANUFACTURER RECOMMENDATION(7,2)
NPRO SEQUENCE ELF(7,2)
PARAMYXOVIRUS FAMILY(7,2)
PREMONITORY SIGN(7,2)
TRAINED VETERINARIAN(7,2)
VACCINATED CATTLE(7,2)
WEEK POST VACCINATION(7,2)
ATPASE INTEIN(7,1)
CLINICAL DISEASE ATTACK(7,1)
CONTAMINATED ANIMAL GENITAL(7,1)
COSMOPOLITAN DISTRIBUTION ENTEROCOLITIS(7,1)
EXPERIMENTAL ANIMAL NECROPSY(7,1)
FEMALE CATTLE VAGINA(7,1)
NPRO GENE DELETION(7,1)
POLAR FLAGELLATED BACTERIUM(7,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(7,1)
PREGNANT ANIMAL PLACENTA(7,1)
PROLONGED CALVING SEASON(7,1)
RECOMBINANT VACCINIA VIRUS(7,1)
RELEVANT GASTROINTESTINAL PATHOGEN(7,1)
SERUM NEUTRALIZATION TITER(7,1)
SEVERE PERSISTENT COUGHING(7,1)
SEVERE VILLOUS ATROPHY(7,1)
SUSCEPTIBLE CATTLE BLOODSTREAM(7,1)
VULVA MARKED EDEMA(7,1)
WEANLING AGE CALF(7,1)
YOUNG CATTLE GRAZING(7,1)
FETAL TRANSMISSION(6,5)
FUNCTIONAL VARIANT(6,5)
CONSTRUCTING CDNA(6,3)
LACRIMAL DISCHARGE(6,3)
OLD CATTLE(6,3)
POST INOCULATION(6,3)
SUSCEPTIBLE ANIMAL(6,3)
ACUTE ENTERITIS(6,2)
ANIMAL INTESTINAL TRACT(6,2)
BACTERIA CULTURE(6,2)
BOVINE ADENOVIRUS(6,2)
BOVIS INFECTION(6,2)
CHALLENGE INFECTION(6,2)
CLINICAL DATA(6,2)
DATA LIBRARY(6,2)
DAY POST INFECTION(6,2)
DISEASE SEVERITY(6,2)
ENCODING TRIPLET(6,2)
FEEDLOT CATTLE(6,2)
FETAL INFECTION(6,2)
GROSS LESION(6,2)
LATENT SPORE(6,2)
MEMBRANE ANCHORING(6,2)
PATHOGENIC STRAIN(6,2)
PESTIVIRUS VIRION STRUCTURAL COMPONENT(6,2)
REPEAT BREEDING(6,2)
RESPIRATORY SIGN(6,2)
RNASE ASSAY(6,2)
STERILE SYRINGE(6,2)
ACCIDENTAL LIVER PUNCTURE(6,1)
ACUTE PULMONARY LESION(6,1)
ALVEOLAR EPITHELIALIZATION(6,1)
ANIMAL PERACUTE DEATH(6,1)
ATTENUATED VIRUS MUTANT(6,1)
BOVINE RESPIRATORY VIRUS(6,1)
BOVINE UBIQUITIN GENE(6,1)
BRONCHIOLAR EPITHELIUM DEGENERATION(6,1)
BRONCHOINTERSTITIAL PNEUMONIA(6,1)
CAPILLARY EXTENSIVE RUPTURE(6,1)
CONGESTION BLUISH RED ZONE(6,1)
CRYPT IMMATURE CELL(6,1)
DICTYOCAULUS VIVIPARUS(6,1)
ENTEROCYTE SLOUGHING(6,1)
ENVELOPE GLYCOPROTEIN EPITOPE MAPPING(6,1)
FEEDER PIG BARN(6,1)
FIBRINOPURULENT MENINGITIS(6,1)
FRESHLY SEEDED MDBK CELL(6,1)
GRAYISH BROWN CRANIOVENTRAL REGION(6,1)
HEIFER NECROPSY(6,1)
HUNDRED MICROLITER ALIQUOT(6,1)
HYPOTENSIVE SHOCK SYNDROME(6,1)
INFECTED COW PERCENTAGE(6,1)
INFECTIOUS CDNA CLONE(6,1)
INFECTIVE LARVA(6,1)
INTESTINAL DIGESTIVE ENZYME ACTIVITY(6,1)
INTESTINE ENTEROCYTE(6,1)
NECROSIS BROWN FOCI(6,1)
NPRO MUTATION BLOCKING(6,1)
PATHOGENIC CLOSTRIDIA GROWTH(6,1)
PROBABLE IMMUNEMODULATING ACTIVITY(6,1)
RNASE ACTIVITY INCATVATION(6,1)
SEROVAR LEPTOSPIRA(6,1)
SERUM NEUTRALIZING TITER(6,1)
SEVERE DEPRESSION SUDDEN ONSET(6,1)
SKIN ANTHROPOZOONOTIC DISEASE(6,1)
SOCIOECONOMIC IMPACT(6,1)
SUPERFAMILY TRICHOSTRONGYLOIDEA(6,1)
SUPPORTIVE LABORATORY EVIDENCE(6,1)
UNCOMPLICATED CRYPTOSPORIDIOSIS(6,1)
VIRUS INFECTED CONCLUSION(6,1)
VULVA LACERATION(6,1)
HEMOGLOBINURIA(5,7)
IMMUNE RESPONSE(5,7)
PYREXIA(5,6)
LEUKOCYTE COUNT(5,5)
APPETITE LOSS(5,3)
SECONDARY BACTERIAL INFECTION(5,3)
STRAIN CP(5,3)
TRIMESTER(5,3)
AGE ANIMAL(5,2)
CAPSID PROTEIN FUNCTION(5,2)
CORRECT AMINO TERMINUS(5,2)
ERNS GENE REGION(5,2)
FUSION PROTEIN(5,2)
GENBANK(5,2)
IMMEDIATE FREEZING(5,2)
NPRO PORTION(5,2)
PURULENT NASAL DISCHARGE(5,2)
STERILE VESSEL(5,2)
SUSCEPTIBLE COW(5,2)
UTERINE DISCHARGE(5,2)
VACCINE STRAIN(5,2)
WOUND CONTAMINATION(5,2)
YOUNG ANIMAL(5,2)
ABORTION SIGN(5,1)
ALVEOLITIS PROGRESSING(5,1)
AMINOTERMINUS RESIDUE(5,1)
ANIMAL BUFFY COAT PREPARATION(5,1)
ANIMAL INSEMINATION(5,1)
ATTENUATED MICROORGANISM(5,1)
ATTENUATED VIRAL PARTICLE(5,1)
ATYPICAL INTERSTITIAL PNEUMONIA(5,1)
AVIUM SUBSPECIE(5,1)
BACTERIAL PNEUMONIA CLINICAL SIGN(5,1)
BACTERIAL PNEUMONIA INITIATOR(5,1)
BEEF BREED(5,1)
BIOCHEMICAL CHARACTERIZATION(5,1)
BLACKLEG INFECTION(5,1)
BLACKLEG OUTBREAK(5,1)
BORN UNDERWEIGHT(5,1)
BOVINE REOVIRUS(5,1)
BRAHMAN CATTLE(5,1)
BREED SUSCEPTIBILITY(5,1)
BRISKET EDEMA(5,1)
BRUCELLA CONTAMINATED SEMEN(5,1)
CALICIVIRUS POLYPROTEIN PROCESSING(5,1)
CALICIVIRUS PROTEASE(5,1)
CATALYTIC RESIDUE IDENTIFICATION(5,1)
CATTLE ABORTION(5,1)
CATTLE GENITAL TRACT(5,1)
CATTLE HEALTHINESS(5,1)
CATTLE HERD(5,1)
CATTLE LUNG(5,1)
CATTLE SUSCEPTIBILITY(5,1)
CATTLE VENEREAL DISEASE(5,1)
CAUSATIVE ORGANISM(5,1)
CHLAMYDIAL INFECTION PATHOGENESIS(5,1)
CLINICAL DISEASE INCIDENCE(5,1)
CLINICAL DISEASE RISK(5,1)
CLINICAL MANIFESTATION(5,1)
CLINICAL OUTBREAK(5,1)
CLINICAL SIGN ANIMAL ID(5,1)
CLINICAL SIGN DURATION(5,1)
CLINICAL SIGN ONSET(5,1)
CLINICAL SIGN SERUM(5,1)
COLOSTRAL ANTIBODY(5,1)
CONIC ENTERITIS(5,1)
CONSERVED EPITOPE(5,1)
CONTAGIOUS ENTERITIS(5,1)
CONTAMINATED FEED INGESTION(5,1)
CONTAMINATED PASTURE(5,1)
CONTINUAL BUTTING(5,1)
CONTRACT BLACKLEG(5,1)
CRANIOVENTRAL LUNG CONSOLIDATION(5,1)
CYSTEINE PROTEASE(5,1)
CYTOPATHOGENIC PHENOTYPE(5,1)
CYTOPATHOGENIC VIRUS(5,1)
DIATRON MINICELL(5,1)
DIFFUSE INTERSTITIAL PNEUMONIA(5,1)
DIPHTHERITIC PLAQUE(5,1)
DRY HACKING COUGH(5,1)
EARLY EMBRYONIC DEATH(5,1)
ECCHYMOTIC HEMORRHAGE(5,1)
ENDONUCLEASE CLEAVAGE BASIS(5,1)
ENTERIC ORGANISM(5,1)
ERNS MUTATION(5,1)
ERYTHROCYTE DESTRUCTION(5,1)
ERYTHROCYTIC STASIS(5,1)
EVELOPE GLYCOPROTEIN PROCESSING(5,1)
EXTENSIVE REDDISH BLACK(5,1)
FARMED DEER(5,1)
FECAL SHEDDING(5,1)
FEED SUDDEN DEPRIVATION(5,1)
FETUS INFECTION(5,1)
FETUS RESORPTION(5,1)
FETUS TRANSPLACENTAL INFECTION(5,1)
FIBRIN EXUDATION(5,1)
FREQUENT URINATION(5,1)
GENERALIZED ANEMIA(5,1)
GENUS BABESIA(5,1)
GENUS PESIVIRUS(5,1)
GROSS PATHOLOGY ORGAN PANEL(5,1)
HAEMOPHILUS AGNI(5,1)
HEAD EDEMATOUS SWELLING(5,1)
HEAVILY CONTAMINATED FEED(5,1)
HEMORRHAGIC ENTERITIS(5,1)
HEPATIC PARENCHYMA(5,1)
HETEROLOGOUS CHALLENGE(5,1)
HISTOLOGIC EXAMINATION(5,1)
HYPEREMIC INTESTINAL MUCOSA(5,1)
INEFFECTIVE SERUM ANTIBODY(5,1)
INFECTION PREVALENCE(5,1)
INFECTIOUS CLONE(5,1)
INFECTIOUS NECROTIC HEPATITIS SUSPICION(5,1)
INFECTIOUS VIRUS RECOVERY(5,1)
INFLAMED NARIS(5,1)
INSANITARY VACCINATION(5,1)
INTERSTITIAL EDEMA(5,1)
INTERSTITIAL THICKENING(5,1)
INTRACELLULAR PARASITE(5,1)
INTRAMUSCULAR VACCINATION(5,1)
ISOSPORA SPP(5,1)
LARYNX INFECTION(5,1)
LATED ABORTION(5,1)
LEADER PROTEINASE(5,1)
LEPTOSPIRA BOVIS(5,1)
LEPTOSPIRA CANICO(5,1)
LEPTOSPIRA PONOMA(5,1)
LIVE ATTENUATED VIRUS PRODUCTION(5,1)
LIVER LESION(5,1)
LIVESTOCK PRODUCTION INTENSIFICATION(5,1)
LUNG COLONIZATION(5,1)
LUNG PARENCHYMA(5,1)
LUSH PASTURE(5,1)
LYMPHOID CUFFING(5,1)
LYOPHLIZED ANTIGEN(5,1)
LYPHILIZED ANTIGEN(5,1)
MAJOR SYNDROME SEPTICEMIA(5,1)
MAMMARY GLAND INFLAMMATION(5,1)
MANHEIMIA HAEMOLYTICA(5,1)
MATERNAL ANTIBODY(5,1)
MESENTERIC TORSION(5,1)
MICROSPORUM SPP(5,1)
MILD DISEASE SIGN(5,1)
MILD RESPIRATORY DISEASE SIGN(5,1)
MOTIF IDENTITY(5,1)
MUCOSA ULCERATION(5,1)
MUTANT VIRUS(5,1)
MUTATION ABROGATING(5,1)
MYCOBACTERIUM SPP(5,1)
MYCOPLASMA EXACT ROLE(5,1)
NASCENT POLYPROTEIN(5,1)
NASOPHARYNX NORMAL INHABITANT(5,1)
NATURAL ORGANISM HABITAT(5,1)
NECROPSY DIAGNOSIS(5,1)
NECROTIC LESION(5,1)
NECROTIZING TOXIN(5,1)
NEWBORN CALF(5,1)
NON PATHOGENIC VIRUS(5,1)
NON VIABLE FETUS(5,1)
NONGRAVID UTERUS(5,1)
NORTHWEST EUROPE(5,1)
NPRO SEQUENCE MUTATION(5,1)
NUCLEOCAPSID PROTEIN(5,1)
NUCLEOTIDE TRIPLET(5,1)
NURSING UDDER(5,1)
OBSERVATION POST VACCINATION(5,1)
OBSERVING VETERINARIAN(5,1)
ORGANISM INGESTION(5,1)
ORGANISM INVASION(5,1)
ORGANISM INVOLVEMENT(5,1)
ORGANISM PREVALENCE(5,1)
PARASITIC NEMATODE(5,1)
PASSIVELY DERIVED IMMUNITY(5,1)
PASTEURELLA SPP(5,1)
PESTIVIRUS FAMILY VIRUS(5,1)
PESTIVIRUS GENUS(5,1)
PESTIVIRUS GLYCOPROTEIN(5,1)
PESTIVIRUS NEUTRALIZATION(5,1)
PESTIVIRUS POLYPROTEIN PROCESSING(5,1)
PESTIVIRUS PROTEIN(5,1)
PESTIVIRUS RNA(5,1)
PESTIVIRUS TERMINAL PROTEASE(5,1)
PEYER PATCH(5,1)
PHARMACEUTICAL COMPOSTION(5,1)
PHOSPHATIDYLETHANOLAMINE(5,1)
PLANT RNASE(5,1)
POLYNUCLEOTIDE VACCINATION(5,1)
POLYPEPTIDE CLEAVAGE(5,1)
POSTERIOR FLAGELLUM(5,1)
PREDISPOSING INJURY(5,1)
PREDOMINANT CLINICAL PARAMETER(5,1)
PREVALENT LEPTOSPIRA(5,1)
PROTEASE ACTIVITY DESTRUCTION(5,1)
PROTEASE INACTIVATION(5,1)
PROTECTIVE VACCINE VIRUS(5,1)
PROTEIN FUNDAMENTAL ROLE(5,1)
PROTEOLYSIS INHIBITION(5,1)
PROTEOLYTIC PROTEIN ACTIVITY(5,1)
PROTOTHECA SPP(5,1)
PULMONARY ABSCESSATION(5,1)
PURPLISH RED URINE(5,1)
PYOGENES CAUSE SPORADIC ABORTION(5,1)
QUITE RESISTANT(5,1)
RE LATED ORGANISM(5,1)
RECONSTITUTED ANTIGEN(5,1)
REPLICATION COMPENTENT(5,1)
REPRODUCTIVE ORGAN(5,1)
RNASE ACTIVITY DESTRUCTION(5,1)
RNASE ENZYMATIC ACTIVITY(5,1)
RNASE NEGATIVE COUNTERPART(5,1)
RNASE NEGATIVE MUTANT(5,1)
SEROFIBRINOUS EXUDATE(5,1)
SEX REPRODUCTIVE TRACT(5,1)
SKIN INFECTION LOCALIZATION(5,1)
SOW COLOSTRUM(5,1)
STERILE SEA SAND(5,1)
SUBCLINICALLY INFECTED CARRIER(5,1)
SUBCUTANEOUS TISSUE EDEMA(5,1)
SUBMUCOSAL HEMORRHAGE(5,1)
SUPPURATIVE VAGINITIS(5,1)
SUSCEPTIBLE CATTLE INTRODUCTION(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
TESTICULAR ABSCESS(5,1)
TETANUS INCIDENCE(5,1)
TETANUS TOXEMIA(5,1)
THICK GRANULAR BILE(5,1)
THRIFTY CALF(5,1)
TOXIN ANTIGENIC SPECIFICITY(5,1)
TOXOPLASMA GONDII(5,1)
TRANSIENT INFERTILITY(5,1)
UNCOMPLICATED ABORTION(5,1)
UNVACCINATED HERD(5,1)
UTERINE INVOLUTION(5,1)
UTERUS INFLAMMATION(5,1)
VACCINATED DAM(5,1)
VACCINATED PIG(5,1)
VETERINARY MICROBIOLOGY(5,1)
VIRAL POLYPROTEIN(5,1)
VIRUS VACCINE(5,1)
VIVIPARUS INFECTION(5,1)
WATERY DIARRHEA(5,1)
WEEK POST INFECTION(5,1)
WILD RUMINANT(5,1)
YOUNG RUMINANT(5,1)
CONJUNCTIVITIS(4,5)
MORTALITY(4,5)
ANOREXIA(4,4)
ARTIFICIAL INSEMINATION(4,4)
CO CULTIVATION(4,4)
CONVULSION(4,4)
DYSENTERY(4,4)
DYSPNEA(4,4)
ICTERUS(4,4)
MASTITIS(4,4)
R GGLI(4,4)
TRACHEA(4,4)
AFFECTED ANIMAL(4,2)
ANIMAL STUDY(4,2)
CHLAMYDIAL PNEUMONIA(4,2)
COMPLETE POLYPROTEIN(4,2)
CONCLUSION BOVINE VIRAL DIARRHEA(4,2)
DERMATOPHYTOSIS(4,2)
DOUBLE MUTANT(4,2)
INVESTIGATION(4,2)
LIVE INFECTIOUS BOVINE RHINOTRACHEITIS(4,2)
LOCAL LESION(4,2)
MAB CODE(4,2)
NEURAL CELL(4,2)
NORMAL PARTURITION(4,2)
POST CHALLENGE(4,2)
SEVERE DISEASE(4,2)
VIRUS DOSE(4,2)
YOUNG RAM(4,2)
ABNORMAL BREATHING(4,1)
ACCESSORY SEX GLAND INFECTION(4,1)
ACUTE DIARRHEA(4,1)
ACUTE FASCIOLIASIS(4,1)
ACUTE LAMENESS(4,1)
AGE BULL(4,1)
ALFORT STRAIN(4,1)
ANCILLARY MOLECULE(4,1)
ANIMAL CARCASS(4,1)
ANIMAL CONTAGIOUS DISEASE(4,1)
ANIMAL DISEASE(4,1)
ANIMAL NEED(4,1)
AUJESZKY DISEASE(4,1)
BACTERIA VIRULENCE FACTOR(4,1)
BACTERIAL CONTAMINATION(4,1)
BACTERIOPHAGE T7 RNA POLYMERASE(4,1)
BARE FILAMENT(4,1)
BIRTH WEEK(4,1)
BLOOD CLOTTING(4,1)
BOVINE FRAGMENT(4,1)
BOVINE PATHOGEN(4,1)
BRAIN CAPILLARY(4,1)
BREATHING PATTERN(4,1)
BREEDING CATTLE(4,1)
BRITISH BREED(4,1)
CALF DIARRHEA(4,1)
CARBOXY TERMINAL CLEAVAGE(4,1)
CARBOXY TERMINAL GLYCINE(4,1)
CATTLE GI TRACT(4,1)
CELLULAR PROTEASE(4,1)
CLINICAL SYMPTOM PRESENCE(4,1)
CODON DELETION(4,1)
CONCURRENT INFECTION(4,1)
CONTAMINATED INSTRUMENT(4,1)
CONTAMINATED PEN(4,1)
CONTAMINATED SOIL(4,1)
COWORKER PRESENTED INDICATION(4,1)
CROHN DISEASE(4,1)
DEFINITE DATA(4,1)
DIET CONTENT(4,1)
DISEASE SYNDROME(4,1)
DISTINCTIVE LABEL(4,1)
DRUG ADMINISTRATION(4,1)
EFFICIENT TRANSLATION INITIATION(4,1)
ENDEMIC STABILITY SITUATION(4,1)
ENVIRONMENTAL STRESSOR(4,1)
EXPERIENCED VETERINARY SURGEON(4,1)
EXPERIMENTAL INFECTION(4,1)
EXTENSIVE PLEURITIS(4,1)
EXTENSIVE THROMBOSIS(4,1)
FETAL ABDOMINAL FLUID(4,1)
FETAL PNEUMONIA(4,1)
FREEZING SEMEN(4,1)
GENERALIZED DISEASE(4,1)
GENERALIZED VIRAL INFECTION(4,1)
GENOME ORGANIZATION(4,1)
GENOMIC DELETION(4,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(4,1)
GP EPITOPE MAPPING(4,1)
GRAYISH YELLOW(4,1)
HEAD SEVERE EDEMA(4,1)
HEALTHY CATTLE(4,1)
HIGHLY CONSERVED CELLULAR PROTEIN(4,1)
HOMOLOGOUS CHALLENGE(4,1)
HOOF EROSION(4,1)
HYALINE MEMBRANE FORMATION(4,1)
IGA ANTIBODY(4,1)
INACTIVE PROTEASE(4,1)
INFECTED ANIMAL TISSUE FLUID(4,1)
INFECTED DAM(4,1)
INFECTIOUS DISEASE(4,1)
INFECTIVE DOSE(4,1)
INOCULATION DATE(4,1)
INOCULATION DAY(4,1)
INTERFERON RESPONSE INDUCTION(4,1)
INTESTINAL INFECTION(4,1)
LABORATORY CONFIRMATION(4,1)
LATE DISEASE STAGE(4,1)
LETHAL TOXIN(4,1)
LIVE ATTENUATED VACCINE(4,1)
LIVER BIOPSY(4,1)
LIVER FLUKE INFECTION(4,1)
LIVING ORGANISM(4,1)
LOCALIZED LESION(4,1)
MALE PREPUCE(4,1)
MARKED CONGESTION(4,1)
MICROBICIDAL ACTIVITY(4,1)
MICROORGANISM FRACTION(4,1)
MILD COUGHING(4,1)
MODERATE COUGHING(4,1)
MOIST COUGH(4,1)
MOLECULAR UNIQUENESS(4,1)
MOUSE PRETREATMENT(4,1)
MUTATED POLYPROTEIN AMINOACID(4,1)
MUTATION INTRODUCTION(4,1)
NECROTIC TISSUE(4,1)
NPRO CODING SEQUENCE(4,1)
NUCLEOTIDE EXCHANGE(4,1)
OCCASIONALLY CAUSED ABORTION(4,1)
ORAL HEMORRHAGE(4,1)
ORGANISM CULTURE(4,1)
PARANASAL SINUS(4,1)
PARENTAL VIRUS(4,1)
PESTIVIRUS GENE EXPRESSION(4,1)
PESTIVIRUS MOLECULAR BIOLOGY(4,1)
PI ROLE(4,1)
PLEURA VESSEL(4,1)
POTENTIAL ZOONOTIC RISK(4,1)
PREGNANCY EXAMINATION(4,1)
PRELIMINARY EVIDENCE(4,1)
PROTEIN CATABOLISM(4,1)
RE LATED SPECIES(4,1)
RE LATED TISSUE(4,1)
RECTAL EXAMINATION(4,1)
REDDISH BROWN(4,1)
REPLACEMENT HEIFER(4,1)
REVERSION RISK(4,1)
RNASE POSITIVE VIRUS(4,1)
ROUTINE NECROPSY(4,1)
SEPTICEMIC DISEASE(4,1)
SEROUS NASAL(4,1)
SEVERE INTESTINAL DAMAGE(4,1)
SEVERE TOXEMIA(4,1)
SIGN SEVERITY(4,1)
SITE MUTATION ABSENCE(4,1)
SKELETAL MUSCLE NECROSIS(4,1)
SOIL DISTURBANCE(4,1)
SPHERICAL SPORE(4,1)
STERILE PIPETTE(4,1)
STRAIN PREFERENCE(4,1)
STUDY FETAL TISSUE TERMINATION(4,1)
STUDY INITIATION(4,1)
SWOLLEN LIVER(4,1)
SYNERGISTIC ROLE(4,1)
TAILHEAD ELEVATION(4,1)
TESTED CATTLE PROPORTION(4,1)
TRYPSIN INHIBITOR(4,1)
UNCOMPLICATED PI(4,1)
UNDULATING MEMBRANE(4,1)
UNUSED INOCULUM(4,1)
UNUSED VACCINE(4,1)
VAGINAL CULTURE(4,1)
VESSEL ENDOTHELIUM(4,1)
VIABLE MUTANT(4,1)
VIRAL LESION(4,1)
VIRAL PROTEIN(4,1)
VIRAL REPLICATION(4,1)
VIRUS ATTENUATION(4,1)
VIRUS CHALLENGE(4,1)
VIRUS NEUTRALIZING MONOCLONAL ANTIBODY(4,1)
VIRUS VIABILITY(4,1)
VISIBLE LESION ABSENCE(4,1)
GROUND(3,7)
N TERMINAL METHIONINE(3,7)
SHEEP(3,7)
HORSE(3,5)
RABBIT HEMORRHAGIC DISEASE VIRUS(3,5)
ASSAY CONDITION(3,3)
BRONCHIOLITIS(3,3)
DAIRY CATTLE(3,3)
DERMATOMYCOSIS(3,3)
DIFFERENTIATION(3,3)
GRASS(3,3)
JAUNDICE(3,3)
MACROPHAGE(3,3)
MYOCARDIUM(3,3)
NEOMYCIN(3,3)
NON VACCINATED CONTROL ANIMAL(3,3)
PREVENTION(3,3)
SERA(3,3)
ABDOMINAL PAIN(3,2)
ABORTED FETUS(3,2)
AGGLUTININ(3,2)
ANAEROBIOSIS(3,2)
ATAXIA(3,2)
BLINDNESS(3,2)
BRUSH BORDER(3,2)
BUNDESFORSCHUNGSANSTALT F R(3,2)
CARDOVIRUS(3,2)
CASTRATION(3,2)
CEREBELLUM(3,2)
DELETED REGION(3,2)
DISULFANE(3,2)
EXPERT(3,2)
FORMALDEHYDE(3,2)
GLASSWARE(3,2)
GROUP INOCULATION(3,2)
H STRAIN(3,2)
INFARCTION(3,2)
INFECTION SOURCE(3,2)
INFECTIOUS PUSTULAR VULVOVAGINITIS(3,2)
INFERTILITY CAUSE(3,2)
LEPTOSPIROSIS(3,2)
LESSER EXTENT(3,2)
LETHALITY(3,2)
LIKELIHOOD(3,2)
MESENTERIC LYMPH NODE(3,2)
MORBIDITY(3,2)
MULTOCIDA(3,2)
OBSERVATION PERIOD(3,2)
OPISTHOTONO(3,2)
ORGANISM SOURCE(3,2)
PERFRINGEN(3,2)
PLACENTITIS(3,2)
PRESERVATIVE(3,2)
PURIFICATION(3,2)
R MENAPF(3,2)
RESPIRATORY DISTRESS(3,2)
RETITRATION(3,2)
RIBONUCLEASE(3,2)
RNASE ACTIVE SITE(3,2)
SEROLOGY(3,2)
STERNUM(3,2)
STILLBORN(3,2)
TACHYZOITE(3,2)
TERMINAL AMINO(3,2)
TRICHOMONIASIS(3,2)
TRIPLICATE(3,2)
VIREMIA(3,2)
VIRUS REPLICATION(3,2)
ABNORMAL MILK(3,1)
ABORTED FETAL TISSUE(3,1)
ABSCESS DISCHARGE(3,1)
ACARICIDE TREATMENT(3,1)
ACUTE INFECTION(3,1)
ANAEROBIC ENVIRONMENT(3,1)
ANIMAL SUSCEPTIBILITY(3,1)
ANTIGENIC SUBSTANCE(3,1)
ARTHRITIC JOINT(3,1)
ATTENUATED PARTICLE(3,1)
BABESIA TRANSMISSION(3,1)
BACTERIAL PNEUMONIA ABSENCE(3,1)
BLOCKING ELISA(3,1)
BORDER DISEASE VIRUS(3,1)
BOVINE HERPES VIRUS ANTIGEN(3,1)
BOVINE HERPES VIRUS SUBTYPE(3,1)
BRONCHOPNEUMONIC PATTERN(3,1)
CAUSATIVE AGENT(3,1)
CHEMICALLY MODIFIED VIRUS(3,1)
CLEAN BENCH(3,1)
CLEAN HERD(3,1)
CLINICAL SIGN INCREASE SEVERITY(3,1)
CLINICAL SIGN PRESENCE(3,1)
CODING SEQUENCE REPLACING(3,1)
COLLAGEN EXPOSURE(3,1)
COLOSTRAL DERIVED ANTIBODY(3,1)
CONSISTENT SIGN(3,1)
CULTURE GROWTH(3,1)
DEEP PUNCTURE WOUND(3,1)
DISCUSSION FOCUS(3,1)
DISEASE INTRODUCTION(3,1)
DISEASE SPECTRUM(3,1)
DRIED BACTERIA CELL(3,1)
EARLY FETAL DEATH(3,1)
ENLARGED GALLBLADDER(3,1)
ENLARGED PERICARDIAL SAC(3,1)
ENTEROCYTE LOSS(3,1)
ENVELOPE PROTEIN(3,1)
EXTENDED CALVING INTERVAL(3,1)
FATAL DISEASE(3,1)
FECAL ORAL ROUTE(3,1)
FETAL ORGAN(3,1)
FREQUENT OCCURRENCE(3,1)
FUNGAL ORIGIN(3,1)
FUNGAL RNASE ACTIVE PROTEIN(3,1)
GENETIC CODE DEGENERATIVE NATURE(3,1)
GENOME REGION CODING(3,1)
GESTATION STAGE(3,1)
HEPARIN SODIUM(3,1)
HIGHLY ATTENUATED VIRUS(3,1)
HOMODIMER(3,1)
IMMUNITY DURATION(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
INFECTED HOST(3,1)
INFECTIOUS BOVINE RHINOTRACHEITIS INFECTION(3,1)
INTESTINAL CONTENT SMEAR(3,1)
INTESTINAL CRYPT ABILITY(3,1)
LIFE FORM SPHERE(3,1)
LIMITED CROSS(3,1)
LINKED HETERODIMER(3,1)
LISTED MUTANT(3,1)
LIVE CALF(3,1)
LUNGWORM INFECTION RANGE SIGN(3,1)
LYOPHILIZED INFECTIOUS BOVINE RHINOTRACHEITIS(3,1)
MAJOR DELETION(3,1)
MARKED DEPRESSION(3,1)
MINUTE PROTOZOON(3,1)
NASAL CAVITY MUCOUS MEMBRANE(3,1)
NECROPSY ROOM(3,1)
NORMAL COW MUCOUS MEMBRANE(3,1)
NORTHERN ROCKY MOUNTAIN SECTION(3,1)
OBSERVED ABORTION(3,1)
OCULAR DISCHARGE(3,1)
ORAL EROSION(3,1)
ORGAN INFECTION(3,1)
ORGANISM GROWTH(3,1)
PHENOTYPIC SELECTION(3,1)
PLASMID PROFILE(3,1)
PLATELET ADHESION(3,1)
PREGNANCY HALF(3,1)
PROTECTIVE IMMUNITY(3,1)
PROTEIN ROLE(3,1)
PROTEOLYTIC ACTIVITY(3,1)
PROTOCOL EXTRACT(3,1)
PULMONARY ABSCESS FORMATION(3,1)
PURULENT VAGINAL DISCHARGE(3,1)
RAPID RESPIRATION(3,1)
RECENT EXCAVATION(3,1)
RESPIRATORY DISEASE VIRUS(3,1)
SECONDARY BACTERIAL PNEUMONIA DEVELOPMENT(3,1)
SENSITIVE GLYCOPROTEIN(3,1)
SEVERE RESPIRATORY DISEASE(3,1)
SEX NASAL PASSAGE(3,1)
SEXUALLY TRANSMITTED DISEASE TRANSMISSION(3,1)
SIGNIFICANT CLINICAL SIGN(3,1)
SODIUM TIMERFONATE(3,1)
SOFT SWELLING(3,1)
SOIL BORNE ORGANISM(3,1)
SPORADIC ABORTION CAUSE(3,1)
STRESSFUL SITUATION(3,1)
SUCCESSFUL LIVESTOCK PRODUCTION(3,1)
SYNCYTIAL CELL FORMATION(3,1)
THICKENED INTESTINAL WALL(3,1)
TISSUE CYST(3,1)
TISSUE NECROSIS(3,1)
TOXIN DETECTION(3,1)
TRUE DELETION(3,1)
UNSTABLE PEPTIDE(3,1)
UNTREATED ANIMAL(3,1)
VACCINATED ANIMAL GROUP(3,1)
VEGETATIVE CELL(3,1)
VETERINARY PRACTICE(3,1)
VIRAL INFECTION SIGN(3,1)
VIRION MOLECULAR(3,1)
WEAK CALF(3,1)
WILD BIRD(3,1)
WORLDWIDE DISTRIBUTION(3,1)
WOUND HISTORY(3,1)
WOUND INFECTION(3,1)
YOUNG BEEF(3,1)
YOUNG MALE(3,1)
ML CELL CULTURE FLUID(2,4)
GOAT(2,3)
LIQUID NITROGEN(2,3)
NON INFECTED CONTROL CELL(2,3)
RNA VIRUS(2,3)
SINGLE MUTATION(2,3)
CYTOPATHIC EFFECT(2,2)
MORTAR(2,2)
SUMMER(2,2)
ABATTOIR(2,1)
ABNORMAL TEMPERATURE(2,1)
ABORTION MAJOR CAUSE(2,1)
ADJUVANT(2,1)
AFFECTED AREA CONNECTIVE TISSUE(2,1)
AGENT IMPORTANCE(2,1)
AIRWAY(2,1)
ALHYDROGEL(2,1)
AMINOACID CODON(2,1)
AMPULLA(2,1)
ANAEROBE(2,1)
ANEMIC INFARCT(2,1)
ANIMAL INTESTINAL CONTENT(2,1)
ANIMAL PRODUCTION(2,1)
ANTIBIOTIC(2,1)
ANTIGEN DETECTION(2,1)
ANTIPARASITIC(2,1)
ANTISENSE(2,1)
ANTISERUM(2,1)
APHTOVIRUSE(2,1)
ARTIFICIAL MEDIUM(2,1)
ASBESTOS(2,1)
ASEPTIC(2,1)
ASEXUAL STAGE(2,1)
ASPIRATION(2,1)
AUSCULTATION(2,1)
AUTOPHAGY(2,1)
AUTOPROTEASE(2,1)
B VIRULENT STRAIN(2,1)
BABESIOSIS(2,1)
BACTEREMIA(2,1)
BACTERIAL PNEUMONIA CAUSE(2,1)
BASELINE VALUE(2,1)
BECHER(2,1)
BEEF CATTLE(2,1)
BIOCHEMICAL REACTION(2,1)
BIOTYPE(2,1)
BIPHASIC DISEASE PATTERN(2,1)
BLEEDING(2,1)
BLOOD CELL DETERMINATION(2,1)
BLOOD ML(2,1)
BOVINE CORONAVIRUS(2,1)
BROWN COLOR(2,1)
CALF PRODUCTION(2,1)
CELL MEDIATED IMMUNITY(2,1)
CLEAVAGE SITE(2,1)
CLINICAL PATTERN(2,1)
COLD SPRING HARBOR(2,1)
COMPLETE NPRO CODING REGION(2,1)
COMPLETE PESTIVIRUS(2,1)
COMPLETE SEROCONVERSION(2,1)
CONSECUTIVE DAY(2,1)
CONSEQUENT DECREASE(2,1)
CONTINENT(2,1)
COOL ENVIRONMENT(2,1)
CORRECT TEST CONDUCTING(2,1)
DARK BROWN(2,1)
DARK COLORED KIDNEY(2,1)
DEAD SHOW MANIA(2,1)
DECREASED FEED INTAKE(2,1)
DISEASE AGENT(2,1)
DNA COVERING(2,1)
DOUBLE GENETIC MARKER(2,1)
DOUBLE MUTATION(2,1)
DRY COUGH(2,1)
ENCEPHALOMYELITIS(2,1)
ENCODING NUCLEIC ACID MOLECULE(2,1)
ENZYME PRODUCING ENTEROCYTE(2,1)
EPIDEMIOLOGY(2,1)
FETAL TISSUE SUSPENSION(2,1)
FIBRINOUS PERICARDITIS(2,1)
FIXED CARRIER(2,1)
FLANKING REGION(2,1)
GAS ACCUMULATION(2,1)
GENOME SEQUENCE(2,1)
HAEMOLYTICA REMAINS(2,1)
HAIRLOSS(2,1)
HEIFER GROUP(2,1)
HEPARIN BLOOD SAMPLE(2,1)
IMMUNE CARRIER(2,1)
IMMUNOCOMPROMISED INDIVIDUAL(2,1)
IMMUNOLOGICAL RESPONSE(2,1)
INCREASED BREATH SOUND(2,1)
INCREASED BRONCHIAL SOUND(2,1)
INFECTED CELL CULTURE(2,1)
INSECT CELL(2,1)
INTEIN GROUP(2,1)
INTRAVASCULAR HEMOLYSIS(2,1)
IRREGULAR ESTRAL CYCLE(2,1)
ISOLATION FREQUENCY(2,1)
K GLYCOPROTEIN(2,1)
KEY PLAYER(2,1)
LABELED CONTAINER(2,1)
LABORATORY ANALYSIS(2,1)
LATENT BOVINE HERPES VIRUS(2,1)
LOCALIZED NECROSIS CAUSE(2,1)
LOCUS PRESENCE(2,1)
LOWERED MILK(2,1)
LUNG RESULT SOMNUS INFECTION(2,1)
MAJOR LESION(2,1)
MBDK CELL(2,1)
MICROBIAL AGENT(2,1)
MICROTUBULE ASSOCIATED PROTEIN(2,1)
MILD INITIAL SIGN(2,1)
MILD VAGINAL DISCHARGE(2,1)
MODIFIED EXPRESSED POLYPEPTIDE(2,1)
MODIFIED POLYPEPTIDE(2,1)
NATURAL RESERVOIR(2,1)
NEGATIVE HERD(2,1)
NEUROTOXIN(2,1)
NOCARDIA ASTEROIDES(2,1)
NON AQUEOUS SOLUTION(2,1)
NON VACCINATED CONTROL FETUS(2,1)
NPRO REGION(2,1)
NUCLEIC ACID CODE DEGENERATION(2,1)
NUCLEIC ACID MOLECULE ENCODING(2,1)
OCCURRENCE FREQUENCY(2,1)
OFFSPRING(2,1)
OLD ANIMAL(2,1)
ORGAN VARIETY(2,1)
ORGANISM IMMUNOLOGICAL FUNCTION(2,1)
PARASITE BODY(2,1)
PARTIAL BLINDING(2,1)
PATHOLOGIST(2,1)
PERMISSIVE CELL CULTURE(2,1)
PETECHIAL HEMORRHAGE(2,1)
POLYSEROSITIS(2,1)
PORCINE CELL(2,1)
POSITIVE SERUM AGGLUTINATION TEST(2,1)
PROLONGED LUTEAL PHASE(2,1)
PROLONGED TREATMENT(2,1)
PROTEASE ACTIVE SITE RESIDUE(2,1)
RAPIDLY FATAL COURSE(2,1)
RECENT EXPERIMENT(2,1)
RED NOSE(2,1)
RNA CLEAVAGE ACTIVITY(2,1)
SALIVATION(2,1)
SAMPLE CHOICE(2,1)
SECONDARY BACTERIAL PNEUMONIA PRESENCE(2,1)
SEQUENCE VARIANT(2,1)
SEVERE OUTBREAK CAUSE(2,1)
SHALLOW RESPIRATORY RATE(2,1)
SITE DIRECTED MUTAGENESIS(2,1)
SKIN CELL(2,1)
SPECIAL ATTENTION(2,1)
SPOROZOITE(2,1)
STANDARD SEQUENCE DATA SEARCH(2,1)
STRETCH PRESENCE(2,1)
STUDY MONITOR(2,1)
SUSCEPTIBLE CELL(2,1)
TERM GLYCOPROTEIN(2,1)
THAWED SAMPLE(2,1)
THROMBOMENINGOENCEPHALITIS(2,1)
TISSUE SAMPLE ANALYSIS(2,1)
TONSILLAR CRYPT(2,1)
TRANSPORT TIMING(2,1)
UBIQUITIN GROUP(2,1)
UPPER RESPIRATORY TRACT EPITHELIUM(2,1)
VILLOUS HEIGHT(2,1)
VIRAL N DELETION(2,1)
VIRUS PARTICLE(2,1)
VIRUS TRANSMISSION(2,1)
WHITE FOCI(2,1)
YELLOWISH INTESTINAL CONTENT(2,1)
(US20090068223)
COMBINATION VACCINE(100,29)
BOVINE VIRAL DIARRHEA VIRUS(100,16)
MICROBIOLOGICAL INFECTION(100,14)
CATTLE PROPHYLAXIS(100,12)
MICROBIOLOGICAL INFECTION PROPHYLAXIS(100,6)
MICROBIOLOGICAL INFECTION TREATMENT(62,2)
LEPTOSPIRA GRIPPOTYPHOSA(53,6)
RNASE ACTIVITY INACTIVATION(51,10)
CODING SEQUENCE(47,52)
LEPTOSPIRA HARDJO INFECTION(46,2)
HEMOLYTIC ANEMIA(42,2)
CRYPTSPORIDIUM HOMINIS(41,2)
LISTERIA MONOCYTOGENE(41,2)
CLOSTRIDIUM HAEMOLYTICUM(40,2)
CRYPTSPORIDIUM PARVUM(40,2)
CLOSTRIDIUM SORDELLII(39,2)
PROPHYLAXIS(38,3)
TRICHOPHYTON MENTAGROPHYTE(38,3)
LEPTOSPIRA HARDJO BOVIS(37,3)
TRICHOPHYTON SARKISOVII(37,3)
TRICHOPHYTON VERRUCOSUM(37,3)
BOVIE PARVOVIRUS(37,2)
STREPTOCOCCUS UBERUS(37,2)
MUTATION(36,78)
CAMPYLOBACTER FETUS VENEREALIS(36,4)
CLOSTRIDIUM NOVYI(36,2)
SALMONELLA TYPHIMURIUM(36,2)
STAPHYLOCOCCUS AUREUS(36,2)
BRUCELLA MELITENSIS(35,3)
LEPTOSPIRA CANICOLA(33,4)
FETUS INTESTINALIS(33,3)
HAEMOPHILUS SOMNUS(33,3)
HISTOPHILUS OVIS(33,3)
BABESIA BOVIS(31,3)
HISTIDINE RESIDUE SUBSTITUTION(31,2)
VIRUS NEUTRALIZING(31,1)
ATTENUATED BVDV(30,29)
UREAPLASMA SPP(30,3)
LUNGWORM DISEASE(30,2)
ANTIBODY REACTION NEUTRALIZATION(30,1)
BVDV CAUSED INFECTION TREATMENT(30,1)
LEPTOSPIRA HARDJOPRAJITNO(30,1)
BOVINE ROTAVIRUS(29,3)
KLEBSIELLA SPP(29,3)
MYCOPLASMA SPP(29,3)
BVDV DIVISION(28,1)
INACTIVATION(24,13)
CHLAMYDIA PSITTACI(24,6)
LIVE VACCINE(23,2)
BVDV(22,35)
IMMUNOLOGICAL ACTIVE COMPONENT(22,10)
CATTLE(21,53)
MANNHEIMIA HAEMOLYTICA(20,2)
TRITRICHOMONAS FETUS(20,2)
MAJOR ANTIGEN(20,1)
ACTINOMYCES(19,7)
BOVINE(18,6)
BOVINE RABIES(18,4)
CLOSTRIDIUM PERFRINGENS(18,3)
PASTEURELLA HAEMOLYTICA(18,3)
PASTEURELLA MULTOCIDA(18,3)
MORAXELLA BOVIS(18,2)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS(17,5)
CLOSTRIDIUM CH(...)";Pharmaceuticals;Open
2005-10-06;"RU2292916           C1 2007-02-10 [RU2292916]
STG: (C1) Patent for invention
AP : 2005RU-0131025 2005-10-06";36215174;RU2292916           C1 2007-02-10 [RU2292916];2005RU-0131025;;G NAUCHNOE UCHREZHDENIE VSEROS;G NAUCHNOE UCHREZHDENIE VSEROS;;;1;"SHAKHOV ALEKSEJ GAVRILOVICH
RETSKIJ MIKHAIL ISAAKOVICH
ZOLOTAREV ALEKSANDR IVANOVICH
BRIGADIROV JURIJ NIKOLAEVICH
MAS JANOV JURIJ NIKOLAEVICH
PERSHINA SVETLANA IVANOVNA
BOJARINTSEV LEONID EVGEN EVICH
BOJARINTSEVA TAT JANA LEONIDOV
KLIMENKO VLADIMIR VASIL EVICH";;;"(RU2292916)
Method for immunoprophylaxis of acute respiratory diseases in calves";"(RU2292916)
FIELD: veterinary science. ^ SUBSTANCE: one should carry out immunization in down-calving cows with dry culture associated alive vaccine against paragrippe-3 and infectious rhinotracheitis in cattle at the dosage of 2 ml 1.5 mo before calving and simultaneously it is necessary to inject ligavirin subcutaneously at the dosage of 5 ml. In 14 d one should introduce ligavirin once more at the same dosage. Calves born in these cows should be once injected with ligavirin intramuscularly during 0.5-1 h after calving at the dosage of 1 ml. The innovation enables to increase efficiency of immunoprophylaxis of viral respiratory diseases in calves. ^ EFFECT: higher efficiency of immunoprophylaxis. ^ 3 ex, 6 tbl";"(RU2292916)
The Method of immunoprophylaxis of the acute respiratory diseases of calves, which includes the immunization of glubokostelnykh cows by vaccine against parainfluenza -3 and infectious rhino-tracheitis of large livestock dry that of cultural associated living at the dose 2 ml, which is characterized by the fact that additionally uses Ligavirin according to the following diagram: 1,5 months prior to calving of gubokostelnykh cows they immunize by vaccine against parainfluenza -3 and infectious rhino-tracheitis of large livestock of the dry of the cultural associated living and simultaneously hypodermically is introduced Ligavirin at the dose of 5 ml; in 14 days Of Ligavirin they introduce repeatedly at the same dose; to the calves, obtained from these cows, for 0,5-1 h after generation once intramuscularly is introduced Ligavirin at the dose of 1 ml";;;"A61K-039/155
A61K-039/265
A61K-039/295
A61K-047/38";;;Pharmaceuticals;Open
2005-08-18;"RU2005126087        A  2007-02-27 [RU2005126087]
STG: (A) Application for invention
AP : 2005RU-0126087 2005-08-18
RU2306334           C2 2007-09-20 [RU2306334]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2005RU-0126087 2005-08-18";36270699;"RU2005126087        A  2007-02-27 [RU2005126087]
RU2306334           C2 2007-09-20 [RU2306334]";2005RU-0126087;;GNU VRNII EHKSPERIMENTAL NOJ V;GNU VRNII EHKSPERIMENTAL NOJ V;;;1;"D JAKONOV LEV PETROVICH
SAVENKO NATAL JA BORISOVNA
SIMONOVA ALLA SERGEEVNA
BELOUSOVA RAISA VASIL EVNA
KLENOVITSKIJ PAVEL MIKHAJLOVIC";;;"(RU2306334)
INTERSPECIFIC HYBRID CELL LINE OF SHEEP KIDNEY (Ovis aries) WITH RABBIT LYMPHOCYTES FOR CULTIVATION OF INFECTIVE RHINOTRACHEITIS VIRUS AND CATTLE VIRAL DIARRHEA VIRUS";"(RU2306334)
FIELD: veterinary biotechnology. ^ SUBSTANCE: claimed strains of interspecific hybrid cells are obtained by fusion of non-breeding in culture rabbit lymphocytes with finite mutant cell line of sheep kidney. Described method may be used in virus investigation, virus cultivation and in producing of vaccines and diagnosticums. ^ EFFECT: strain with high sensitivity to viruses of infective rhinotracheitis and viral diarrhea. ^ 1 tbl";"(RU2306334)
The Line of the interspecies hybrid cells of the kidney of sheep (Ovis of aries) with the lymphocytes of the rabbit (PO- -Tk (-) ×LK) it is deposited in The Specialized Collection of the interwoven somatical cellular cultures of agricultural and trade animals (SKHZH RASKHN) under №62 for the cultivation of the viruses of infectious rhino-tracheitis and virus diarrhea - disease of mucosas of large livestock.";;;"A61K-039/12
C12N-005/07
C12N-007/00";;;Pharmaceuticals;Open
2005-07-13;"WO2007006101        A1 2007-01-18 [WO200706101]
STG: (A1) Published application with search report
AP : 2006WO-AU00990 2006-07-13";1823688;WO2007006101        A1 2007-01-18 [WO200706101];2005AU-0903721;;MONASH UNIVERSITY;MONASH UNIVERSITY;"(WO200706101)
AU";"(WO200706101)
NAME=MONASH UNIVERSITY  246 Clayton Road, Clayton, Victoria 3168  , COUNTRY=AU 

NAME=AL-HASANI, Keith  12/20 Pakington Street, Kew, Victoria 3101  , COUNTRY=AU 

NAME=ADLER, Ben  221 Lawrence Road, Mt Waverley, Victoria 3149  , COUNTRY=AU 

NAME=BOYCE, John, Dallas  11 Coronet Street, Flemington, Victoria 3031  , COUNTRY=AU 
";1;"AL-HASANI KEITH
ADLER BEN
BOYCE JOHN DALLAS";"(WO200706101)
AU";"(WO200706101)
NAME=AL-HASANI, Keith  12/20 Pakington Street, Kew, Victoria 3101  , COUNTRY=AU 

NAME=ADLER, Ben  221 Lawrence Road, Mt Waverley, Victoria 3149  , COUNTRY=AU 

NAME=BOYCE, John, Dallas  11 Coronet Street, Flemington, Victoria 3031  , COUNTRY=AU 
";"(WO200706101)
Surface proteins of pasteurella multocida";"(WO200706101)
This invention relates to bacterial proteins, and in particular to the identification of surface proteins of the bacterial pathogen Pasteurella multocida which are useful as antigens for vaccines. Immunogenic proteins which are able to elicit protective immunity are disclosed and claimed.";"(WO200706101)
CLAIMS
1. An isolated immunogenic P. multocida surface polypeptide or a biologically active fragment, derivative, or variant thereof, with the proviso that the polypeptide is not OmpH, P6-like protein (Omplδ, PmO966) , PIpB, GIpQ, Lpp, OmpA (PmO786) , or Oma87 (Pml992) .
2. A polypeptide according to claim 1, which is an outer membrane protein. 3. A polypeptide according to claim 1 or claim 2, which comprises an extracellular domain.
4. A polypeptide according to claim 2, in which the extracellular domain is from loop 2.
5. A polypeptide according to any one of claims 1 to 4, which is from P. multocida serotype A:l, A: 3, A: 4, or B : 2.
6. A polypeptide according to claim 5, selected from the group consisting of the proteins listed in Table 3. 7. A polypeptide according to any one of claims 1 to 6, which is selected from the group consisting of: a) a protein involved in transport of molecules across a P. multocida outer membrane; b) a protein involved in iron uptake; c) a protein involved in transport of nutrients; d) a protein involved in resistance of P. multocida to heavy metals; and e) a protein involved in synthesis or structural stability of the outer membrane. 8. A polypeptide according to any one of claims 1 to 7, which is expressed more strongly when the bacterium is grown a) in vitro under iron-depleted, anaerobic or amino acid-depleted conditions, or b) in vivo.
9. A polypeptide according to claim 8, which is expressed more strongly when the bacterium is grown in vivo.
10. A polypeptide according to any one of claims 1 to 5, which is selected from the group consisting of est, mglC, ompH_2, ompW, parC, pepP, pfhR, PM0300, PM0336, PM0337, PM0442, PM0527, PM0612, PM0803, PM0979, PM0998, PMl021, PM1064, PM1069, PM1426, PM1578, PM1600, PM1720, PM1809, rpS2, torD, trpB, tufA, tufB and vacJ.
11. A polypeptide according to claim 1, which is selected from the group consisting of PM0388, PM0442, PM0554, PM0659, PM0741, PM0786, PM0903, PM0966, PM0979, PM1050, PM1614, PM1614, PM1730, PM1979, PM1992, and PM1993.
12. A polypeptide according to claim 1, which is selected from the group consisting of PM0527, PM0680, PM1428, PM1426, PM1707, and PM1730. 13. A polypeptide according to any one of claims 1 to 12, which is fused to a heterologous polypeptide. 14. A polypeptide according to claim 13, in which the heterologous polypeptide is an immunogenic carrier polypeptide . 15. An antibody which specifically binds to a polypeptide according to any one of claims 1 to 12, or to a biologically-active fragment, derivative, or variant thereof .
16. An antibody according to claim 15, which is an avian, bovine, swine or rabbit antibody.
17. An antibody according to claim 15, which is a monoclonal antibody.
18. A composition comprising a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant thereof, together with a physiologically-acceptable carrier .
19. A vector comprising a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14.
20. A vector according to claim 19 which is an expression cassette.
21. A host cell comprising a vector according to claim 19 or claim 20.
22. A method of treating or preventing a disease or condition caused by P. multocida, comprising the step of administering a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant of any of these, to a subject suffering from, suspected to be suffering from or at risk of such a disease or condition.
23. A method of diagnosing a disease or condition caused by P. multocida, comprising the step of detecting a polypeptide according to any one of claims 1 to 12, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12, or a biologically-active fragment, derivative, or variant of any of these, in a biological sample from a subject suffering from, suspected to be suffering from, or at risk of such a disease or condition.
24. Use of a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant of any of these, in the treatment or prevention of a disease or condition caused by P. multocida.
25. Use of a polypeptide, antibody and/or nucleic acid molecule a polypeptide according to any one of claims 1 to 12, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12, or a biologically-active fragment, derivative, or variant of any of these, in the diagnosis of a disease or condition caused by P. multocida.
26. A composition comprising a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14 , or a biologically-active fragment, derivative, or variant of any of these, together with a pharmaceutically- or veterinarily- acceptable carrier.
27. A composition according to claim 26, comprising a polypeptide according to any one of claims 1 to 14.
28. A composition according to claim 27, in which the polypeptide is selected from the group consisting of
 PM0388, PM0442, PM0554, PM0659, PM0741, PM0786, PM0903, PM0966, PM0979, PM1050, PM1614, PMl614, PM1730, PM1979, PM1992, and PM1993.
29. A composition according to claim 27, in which the polypeptide is selected from the group consisting of
 PM0527, PM0680, PM1428, PM1426, PM1707, and PM1730.
30. A composition according to any one of claims 27 to 29, further comprising an adjuvant.
31. A composition according to any one of claims 27 to 29, which elicits an immune response which is protective against infection with P. multocida.
32. A composition according to any one of claims 27 to 31, which provides protection against at least two different serotypes of P. multocida. 33. A composition according to any one of claims 27 to 31, which elicits antibodies which bind specifically to a P. multocida surface polypeptide.
34. A kit comprising one or more of a polypeptide according to any one of claims 1 to 14, an antibody according to any one of claims 15 to 17, and/or a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 14, or a biologically-active fragment, derivative, or variant of any of these.
35. A kit according to claim 34 for detecting the presence of DNA associated with P. multocida in a sample, in which the kit comprises : a) a known amount of a first oligonucleotide which consists of at least about 7 to about 50 nucleotides, in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12; b) a known amount of a second oligonucleotide, in which the second oligonucleotide consists of at least about 7 to about 50 nucleotides, and in which the oligonucleotide has at least about 70% contiguous sequence identity to a nucleotide sequence which is complementary to a nucleic acid molecule which encodes a polypeptide according to any one of claims 1 to 12 and optionally c) reagents for nucleic acid amplification.
36. A kit according to claim 35, comprising two or more pairs of first and second oligonucleotides.
37. A method for detecting a nucleic acid molecule encoding a surface polypeptide of P. multocida, comprising the step of contacting a nucleic acid obtained from a biological sample of a subject with at least two oligonucleotides, under conditions effective to amplify the nucleic acid so as to yield an amount of amplified nucleic acid, in which a) at least one of the oligonucleotides is specific for a nucleic acid encoding a' surface polypeptide according to any one of claims 1 to 12, and b) the biological sample comprises cells suspected of containing a nucleic acid molecule encoding the immunogenic polypeptide .
38. A library of candidate immunogenic P. multocida outer membrane proteins, prepared by a method comprising the steps of a) subjecting the genomic DNA sequence of
 P. multocida to genomic analysis; b) selecting candidate open reading frames according to the vaccine potential of the corresponding proteins, on the basis of predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins ; e) cloning and expressing open reading frames identified in step(d); and f) isolating the expressed proteins.
39. A method of preparing a plurality of nucleic acid molecules encoding candidate P. multocida surface proteins, comprising: a) identifying P. multocida nucleic acid sequences, and b) cloning the nucleic acid sequences of a) , in which the identification is by one or more of: i) predicted cellular location of the encoded protein; ii) similarity of the encoded protein to a protein with a putative or confirmed role in infection and immunity; and iii) subtractive hybridisation of a nucleic acid sequence specific to a virulent P. multocida strain.
40. A method of identifying an immunogenic P. multocida outer membrane protein, comprising the steps of a) subjecting the genomic DNA sequence of
 P. multocida to genomic analysis; b) selecting candidate open reading frames according to the vaccine potential of the corresponding proteins, on the basis of predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing proteins encoded by the open reading frames identified in step(d); f) isolating the expressed proteins; and g) testing the isolated proteins for ability to protect a test animal from challenge with virulent P. multocida.
41. A method according to claim 39 or claim 40, in which the virulent P. multocida strain is from chickens, swine or cattle . 42. A method according to any one of claims 39 to
 41, in which the nucleic acid is specific to a strain from chickens .
43. A plurality of nucleic acid molecules prepared by a method according to any one of claims 39 to 42.";"(WO200706101)
In a first aspect the invention provides an isolated immunogenic P. multocida surface polypeptide, or a fragment, derivative, or variant thereof, with the proviso that the polypeptide is not OmpH_l, P6-like protein (also known as 0mpl6 or PmO966) , PIpB, GIpQ, Lpp, OmpA (also known as PmO786) , or Oma87 (also known as Pml992) .
In a second aspect the invention provides an antibody which specifically binds to a polypeptide of the invention, or to a biologically active fragment, derivative, or variant thereof.
In a third aspect the present invention provides a composition comprising a nucleic acid molecule which encodes a polypeptide of the invention, or a biologically active fragment, derivative, or variant thereof, together with a physiologically-acceptable carrier.
The invention further provides a vector comprising a nucleic acid molecule which encodes a polypeptide of the invention, or a biologically active fragment, derivative, or variant thereof, and a host cell comprising the vector.";"(WO200706101)
It will be appreciated that any convenient biological sample from the subject may be used, including but not limited to blood and other biological fluids, sputum, and tissue samples.
It will be appreciated that the invention is especially applicable to poultry, including chickens, turkeys, pheasants, ducks, geese, and guinea fowl, and to cattle, pigs and rabbits.
It will be appreciated that the diagnostic, therapeutic and prophylactic aspects of the invention are also applicable to subjects which have been exposed to an animal or bird infected with P. multocida.
The heterologous molecule may be any molecule which it is desired to provide as a surface polypeptide fusion protein, such as a molecule from a different serotype of P. multocida.
Haemorrhagic septicaemia is a fatal systemic disease of cattle and buffalos.
It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.
The bacterium also causes infections in humans, primarily through dog and cat bites.";"A61K-038/16
A61K-039/102
A61K-039/40
A61K-048/00
A61P-031/04
C07H-021/02
C07H-021/04
C07K-014/285
C07K-016/12";"(WO200706101)
CLAIMS 1. An isolated immunogenic P. multocida surface polypeptide or a biologically active fragment, derivative, or variant thereof, with the proviso that the polypeptide is not OmpH, P6-like protein (Ompl, PmO966) , PIpB, GIpQ, Lpp, OmpA (PmO786) , or Oma87 (Pml992) .
38. A library of candidate immunogenic P. multocida outer membrane proteins, prepared by a method comprising the steps of a) subjecting the genomic DNA sequence of P. multocida to genomic analysis; b) selecting candidate open reading frames according to the vaccine potential of the corresponding proteins, on the basis of predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins ; e) cloning and expressing open reading frames identified in step(d); and f) isolating the expressed proteins.
39. A method of preparing a plurality of nucleic acid molecules encoding candidate P. multocida surface proteins, comprising: a) identifying P. multocida nucleic acid sequences, and b) cloning the nucleic acid sequences of a) , in which the identification is by one or more of: i) predicted cellular location of the encoded protein; ii) similarity of the encoded protein to a protein with a putative or confirmed role in infection and immunity; and iii) subtractive hybridisation of a nucleic acid sequence specific to a virulent P. multocida strain.
40. A method of identifying an immunogenic P. multocida outer membrane protein, comprising the steps of a) subjecting the genomic DNA sequence of P. multocida to genomic analysis; b) selecting candidate open reading frames according to the vaccine potential of the corresponding proteins, on the basis of predicted cellular localisation of the proteins and their similarity to other proteins with putative or confirmed experimental roles in infection and immunity; c) identifying open reading frames specific to a virulent isolated P. multocida strain by subtractive hybridisation; d) identifying open reading frames unique to the virulent P. multocida strain which are predicted to encode outer membrane or secreted proteins; e) cloning and expressing proteins encoded by the open reading frames identified in step(d); f) isolating the expressed proteins; and g) testing the isolated proteins for ability to protect a test animal from challenge with virulent P. multocida.";"(WO200706101)
PROTEIN(100,52)
NUCLEIC ACID MOLECULE(100,39)
DERIVATIVE(100,34)
BIOLOGICALLY ACTIVE FRAGMENT(100,19)
MULTOCIDA SURFACE POLYPEPTIDE(100,6)
PMO(100,4)
MULTOCIDA OUTER MEMBRANE PROTEIN(100,3)
CANDIDATE IMMUNOGENIC P LIBRARY(100,2)
ENCODING CANDIDATE P(100,2)
IMMUNOGENIC P(100,2)
ISOLATED IMMUNOGENIC P(100,2)
MULTOCIDA SURFACE PROTEIN(100,2)
PROVISO(100,2)
SUBTRACTIVE HYBRIDIZATION(99,6)
PREDICTED CELLULAR LOCALIZATION BASIS(99,2)
CATTLE FATAL SYSTEMIC DISEASE(83,1)
MULTOCIDA STRAIN(65,9)
MULTOCIDA(61,84)
SECRETED PROTEIN(56,4)
ENCODED PROTEIN SIMILARITY(55,2)
VIRULENT P(49,10)
EXPERIMENTAL ROLE(48,4)
HETEROLOGOUS POLYPEPTIDE(46,3)
PROTEIN EXPRESSION(44,4)
HETEROLOGOUS MOLECULE(44,1)
GENOMIC ANALYSIS(42,4)
OLIGONUCLEOTIDE(41,24)
ANTIBODY(40,33)
VIRULENT ISOLATED P(39,4)
EXTRACELLULAR DOMAIN(37,5)
IMMUNOGENIC CARRIER POLYPEPTIDE(36,1)
CONTIGUOUS SEQUENCE IDENTITY(35,3)
ENCODED PROTEIN(35,2)
IMMUNITY(34,6)
INFECTION(33,14)
BIOLOGICAL SAMPLE(33,8)
SIMILARITY(32,4)
IMMUNOGENIC POLYPEPTIDE(31,2)
ISOLATED PROTEIN(31,2)
PREDICTED CELLULAR LOCATION(30,2)
RABBIT ANTIBODY(30,1)
P GENOMIC DNA SEQUENCE(29,4)
BIOLOGICAL FLUID(29,1)
MULTOCIDA NUCLEIC ACID SEQUENCE(28,2)
DISEASE DIAGNOSIS(26,2)
TISSUE SAMPLE(26,1)
VACCINE(24,18)
BACTERIA(24,12)
SEROTYPE(24,9)
SUBJECT SUFFERING(24,4)
VECTOR(23,20)
NUCLEIC ACID MOLECULE ENCODING(23,8)
DISEASE PREVENTION(23,2)
NUTRIENT TRANSPORT(23,2)
OPEN READING FRAME(22,17)
EXPRESSION CASSETTE(22,6)
HEMORRHAGIC SEPTICEMIA(22,3)
HOST CELL(21,18)
CHICKEN(21,15)
OUTER MEMBRANE(21,7)
BIOLOGICAL SUBJECT SAMPLE(20,1)
SPUTUM(20,1)
THERAPEUTIC(20,1)
NUCLEIC ACID SEQUENCE(19,9)
IRON UPTAKE(19,2)
TRANSPORTING MOLECULE(19,2)
SURFACE POLYPEPTIDE FUSION PROTEIN(19,1)
ADMISSION(18,2)
PHEASANT(18,2)
BUFFALO(17,2)
GUINEA FOWL(17,2)
VETERINARILY ACCEPTABLE CARRIER(17,2)
PML(16,2)
CATTLE(15,9)
GOOSE(15,2)
PROTEIN PREDICTED CELLULAR LOCALIZATION(15,2)
FRAGMENT(14,18)
SARCOSINE INSOLUBLE MEMBRANE FRACTION(14,6)
POULTRY(14,5)
BITE(14,2)
DUCK(14,2)
ENCODING NUCLEIC ACID(14,2)
SWINE(13,6)
NUCLEIC ACID AMPLIFICATION(13,5)
AMPLIFIED NUCLEIC ACID(12,3)
TEMPLATE STRAND(12,3)
ESTIMATED VACCINE ANTIGEN(12,2)
OUTER MEMBRANE STRUCTURAL STABILITY(12,2)
CHLORAMPHENICOL ACETYLTRANSFERASE GENE(12,1)
SONICATED SALMON SPERM DNA(12,1)
SOUTH ASIA HEMORRHAGIC SEPTICEMIA(12,1)
TORD(12,1)
TUFB(12,1)
VACJ(12,1)
BIRD(11,12)
RABBIT(11,9)
ANIMAL(11,8)
MPL(11,4)
POLYPEPTIDE DERIVATIVE(11,4)
SYSTEMIC ADMINISTRATION(11,4)
ANTIBODY NEUTRALIZATION(11,3)
PIG(11,3)
RPS(11,1)
TERMINALLY INFECTED CHICKEN BLOODSTREAM(11,1)
DETECTABLE LABEL(10,4)
CYTOPLASMIC DOMAIN(10,3)
DOG(10,3)
PASSIVE IMMUNITY(10,3)
NUCLEOTIDE SUBSTITUTION(10,2)
OMPW(10,2)
DOLLAR TURKEY INDUSTRY MILLION(10,1)
PROTEIN ACETONE TRYPTIC DIGEST(10,1)
DNA ENCODING(9,4)
ATTENUATED STRAIN(9,3)
OVO IMMUNIZATION(9,2)
OXIDATIVE CYCLIZATION(9,2)
TRANSMEMBRANE DOMAIN(9,2)
ALKYL CELLULOSE PHARMACEUTICAL GRADE(9,1)
ATTENDANT PHYSICIAN DISCRETION(9,1)
BIOPOLYMER PLASMA DESORPTION(9,1)
ENVISION POLYPEPTIDE VARIANT(9,1)
MATERNAL ANTIBODY ADMINISTRATION(9,1)
RECOMBINANT BACTERIUM DOSAGE(9,1)
UNGULATE HEMORRHAGIC SEPTICEMIA(9,1)
BIOLOGICAL ACTIVITY(8,5)
HETEROLOGOUS PROTECTION(8,3)
ANTISENSE MOLECULE(8,2)
ANTISENSE STRAND(8,2)
DAIRY CALF(8,2)
EXOGENOUS DNA(8,2)
HETERODUPLEX MOLECULE(8,2)
HOMOGENEOUS ANTIBODY POPULATION(8,2)
HOST CELL GENOME(8,2)
IMMUNOGENIC PROTEIN(8,2)
INFUSION BROTH(8,2)
MARKER GENE(8,2)
MATERNAL ANTIBODY TRANSFER(8,2)
P RESISTANCE(8,2)
RECITED POLYPEPTIDE(8,2)
RESTRICTION ENDONUCLEASE(8,2)
RNA SPECIES ABSENCE(8,2)
AUSTRALIAN POULTRY INDUSTRY(8,1)
COOMASSIE BRILLIANT BLUE(8,1)
ISOPYCNIC SUCROSE GRADIENT(8,1)
ONEDIMENSIONAL GEL ELECTROPHORESIS(8,1)
PRENTICE HALL INTERNATIONAL(8,1)
REMINGTON PHARMACEUTICAL SCIENCE(8,1)
REPORTER GENE EXPRESSION(8,1)
TAGGED FUSION POLYPEPTIDE(8,1)
WILD BIRD POPULATION(8,1)
IMMUNOGENICITY(7,4)
CYSTEINE RESIDUE(7,2)
DIAGNOSTIC ASSAY(7,2)
AUSTRALIAN CHICKEN INDUSTRY(7,1)
BACTERIN EFFICACY(7,1)
CORYNEBACTERIUM PARVUM(7,1)
EUKARYOTIC ORGANISM TISSUE(7,1)
EXUDATIVE CONJUNCTIVITIS(7,1)
FIBRINOUS PNEUMONIA(7,1)
HETERODUPLEX REPLICATION(7,1)
HOST ORGANISM TRANSFORMATION(7,1)
LIGAND AFFINITY CHROMATOGRAPHY(7,1)
MALDI TOF MS(7,1)
MULTOCIDA BACTERIUM(7,1)
MULTOCIDA MICROARRAY(7,1)
MULTOCIDA SEROTYPE(7,1)
MULTOCIDA VACCINE(7,1)
POLYACRYLAMIDE GEL ELECTROPHORESIS(7,1)
PRESELECTED DNA EXPRESSION(7,1)
RUFFLED FEATHER(7,1)
SARCOSINE DIFFERENTIAL SOLUBILITY(7,1)
SARCOSINE SOLUBILIZATION(7,1)
STANDARDIZED ALIQUOT(7,1)
SYNTHETIC OLIGONUCLEOTIDE ADAPTOR(7,1)
ACTIVE INGREDIENT(6,3)
GEL FILTRATION(6,3)
LIPOPOLYSACCHARIDE(6,3)
AMINOACID DEPLETED CONDITION(6,2)
AVIAN SPECIES(6,2)
BRAIN HEART(6,2)
DIAGNOSTIC KIT(6,2)
EGG LAYING ANIMAL(6,2)
FOREIGN DNA(6,2)
IRON STARVATION(6,2)
MULTOCIDA CELL(6,2)
ORAL FORMULATION(6,2)
RNA MOLECULE(6,2)
SARCOSINE INSOLUBLE FRACTION(6,2)
SEQUENCE SIMILARITY(6,2)
SOLUBLE PROTEIN FRACTION(6,2)
ACQUIRING INFECTION(6,1)
AFFINITY TRANSPORTER(6,1)
ASSAYABLE PROTEIN(6,1)
BINARY ANTIBODY ANTIGEN COMPLEX(6,1)
BIOPROCESS ENGINEERING(6,1)
CAPTIVE BIRD(6,1)
CELL BIOLOGICALLY PURE POPULATION(6,1)
CRUDE FRACTION CHROMATOGRAPHIC(6,1)
DESORPTION IONIZATION(6,1)
DOMESTIC POULTRY(6,1)
EGG IMMUNOGLOBULIN(6,1)
FREUND ADJUVANT(6,1)
GLUCURONIDASE GENE(6,1)
GRAM NEGATIVE BACTERIAL PATHOGEN(6,1)
IMMOBILIZED ANTIGEN(6,1)
IMMUNITY STIMULATION(6,1)
IMMUNIZING ANTIGEN(6,1)
IMMUNOFLUORESCENCE ASSAY(6,1)
IMMUNOGENIC EPITOPE(6,1)
INACTIVATED BACTERIA(6,1)
INFECTION SEVERITY(6,1)
INFECTIVE ORGANISM(6,1)
INTRANASAL AEROSOL(6,1)
LUCIFERASE GENE(6,1)
MULTISPECIFIC ANTIBODY(6,1)
MULTOCIDA OMP(6,1)
MULTOCIDA ORGANISM(6,1)
MYCOBACTERIAL PEPTIDE(6,1)
NORTHERN HYBRIDIZATION(6,1)
OMPH FRAGMENT(6,1)
PASSIVE IMMUNIZATION(6,1)
PEPTIDE MASS FINGERPRINTING(6,1)
PLASMID EXPRESSION VECTOR(6,1)
POLYOXYETHYLENE SORBITAN MONOOLEATE(6,1)
POLYPEPTIDE ANTIGEN(6,1)
POLYPEPTIDE FRAGMENT(6,1)
POLYPEPTIDE RESIDUE AMINO(6,1)
POLYSACCHARIDE CAPSULE(6,1)
POTENTIAL VACCINE CANDIDATE(6,1)
PREDOMINANT SYNDROME(6,1)
PROTEIN ASSAY REAGENT(6,1)
PROTEIN EXPRESSION EXPERIMENT(6,1)
QUESTIONABLE EFFICACY(6,1)
RABBIT COLONY(6,1)
RECOMBINANT POLYPEPTIDE(6,1)
SECRETORY LEADER(6,1)
SOMATIC SEROTYPE(6,1)
STERNAL BURSA(6,1)
SUBJECT MULTOCIDA INFECTION STATUS(6,1)
T CELL EPITOPE(6,1)
TRYPTIC DIGESTION(6,1)
VACCINE ADJUVANT(6,1)
VACCINE ANTIGEN POTENTIAL(6,1)
VIRAL EXPRESSION VECTOR(6,1)
EXCIPIENT(5,4)
LIPOSOME(5,4)
AMINOACID SEQUENCE VARIANT(5,3)
COLD SPRING(5,3)
FORMAMIDE(5,3)
IMMUNOASSAY(5,3)
LAGOMORPH(5,3)
MORTALITY(5,3)
MUTATION(5,3)
OLIGONUCLEOTIDE PRIMER(5,3)
SHIPPING FEVER(5,3)
TRIPLICATE(5,3)
AMPLIFIED DNA PRESENCE(5,2)
ANTIBODY PRESENCE(5,2)
ATROPHIC RHINITIS(5,2)
CARRIER CONJUGATED PEPTIDE(5,2)
KEYHOLE LIMPET HEMOCYANIN(5,2)
PASSIVE PROTECTION(5,2)
POVIDONE(5,2)
RT PCR(5,2)
SYNTHETIC PEPTIDE(5,2)
ACUTE DISEASE CLINICAL SIGN(5,1)
ADSORBED ANTISERA(5,1)
ADULT RABBIT(5,1)
ANTIBIOTIC GENE(5,1)
ANTIBODY CHARACTER(5,1)
BACTERIAL COLONY(5,1)
BACTERIOPHAGE M13 VECTOR(5,1)
BACTERIUM INTERACTION(5,1)
BIOCHEMICAL ASSAY(5,1)
BIOLOGICAL SAMPLE DUPLICATE GEL(5,1)
BOVINE PNEUMONIA(5,1)
CALCIUM PANTHOTHENATE(5,1)
CLOACAL FORMULATION(5,1)
COLI JMLOL(5,1)
CONTIGUOUS NUCLEOTIDE SEQUENCE HOMOLOGY(5,1)
CYCLIZED PEPTIDE(5,1)
DEGENERATE VARIANT(5,1)
DIDEOXY SEQUENCING(5,1)
DIMERIC PEPTIDE(5,1)
FOWL CHOLERA TERMINAL STAGE(5,1)
FRAGMENT IDENTIFICATION(5,1)
GELATIN CAPSULE(5,1)
HEALTH IMPAIRMENT(5,1)
HETEROLOGOUS DNA(5,1)
HETEROLOGOUS STRAIN(5,1)
HOMODUPLEX MOLECULE(5,1)
IMMUNOGENIC CARRIER PROTEIN(5,1)
INFECTION SIGN(5,1)
INOCULATION ROUTE(5,1)
KLENOW FRAGMENT(5,1)
LIVE BACTERIA(5,1)
LIVE VACCINE(5,1)
LOCALIZED INFECTION(5,1)
LONG TERM PROTECTION(5,1)
MANNITE ANHYDRIDE(5,1)
MATERNAL ANTIBODY PRODUCTION(5,1)
MEMBRANE PREPARATION PURIFICATION(5,1)
MOLECULE HYDROPHOBICITY(5,1)
MULTOCIDA OUTER MEMBRANE POLYPEPTIDE(5,1)
MULTOCIDA PROTEIN(5,1)
MUTATED DNA(5,1)
NATIVE OMP(5,1)
NEUTRAL AVRIDINE(5,1)
NI NTA RESIN(5,1)
NONSPECIFIC DIFFUSION(5,1)
NUMEROUS DISEASE CAUSATIVE AGENT(5,1)
OLIGONUCLEOTIDE ENCODING(5,1)
OPTIMAL OLIGONUCLEOTIDE(5,1)
OXFORD UNIVERSITY(5,1)
PARTICULATE CELL DEBRIS(5,1)
PCR MUTAGENESIS(5,1)
PEPTIDE BACKBONE(5,1)
PEPTIDE VACCINE(5,1)
PERIORBITAL SUBCUTANEOUS TISSUE(5,1)
PIPB PROTEIN(5,1)
PLASMID VECTOR(5,1)
PLASTIC AGGLUTINATION TRAY(5,1)
POLYCLONAL ANTIBODY(5,1)
POWDER INSUFFLATION(5,1)
PRIMER OLIGONUCLEOTIDE SEQUENCE(5,1)
PROTEIN ADMINISTRATION(5,1)
PROTEIN SPOT IDENTIFICATION(5,1)
RECIPIENT ORGANISM(5,1)
RECOMBINANT BACTERIAL CELL(5,1)
RECOMBINANT BACTERIAL PREPARATION(5,1)
RECOMBINANT MOLECULE(5,1)
RECOMBINANT PHAGE(5,1)
REGULAR OUTBREAK(5,1)
REGULATORY SEQUENCE FUNCTIONALITY(5,1)
REPLICATION ORIGIN(5,1)
RESTRICTION DIGEST(5,1)
STERILE INJECTABLE PREPARATION(5,1)
SUCROSE CUSHION(5,1)
SYPRO RUBY(5,1)
TEMPLATE DNA(5,1)
TERMINAL HEART PUNCTURE(5,1)
TRANSFECTED DNA(5,1)
TRANSFORMING DNA OPTIMAL PERFORMANCE(5,1)
TRYPTIC PEPTIDE(5,1)
UNPREDICTABLE EXPRESSION(5,1)
VACCINE FORMULATION(5,1)
LANE(4,4)
ACTIVE PROTECTION(4,2)
AUTHOR(4,2)
BEEF CATTLE(4,2)
COMMON BACTERIA(4,2)
COSMID(4,2)
EDITION(4,2)
EMBRYO(4,2)
ESCHERICHIA(4,2)
FEMALE SUBJECT(4,2)
HEAVY METAL(4,2)
INTERNAL DELETION(4,2)
P DIAGNOSIS(4,2)
PARTIAL ESTER(4,2)
PHOSPHOLIPID(4,2)
PROGENY(4,2)
STATIONARY PHASE(4,2)
STRINGENT CONDITION(4,2)
SUSCEPTIBLE SUBJECT(4,2)
VETERINARIAN(4,2)
ABNORMAL FUNCTIONING(4,1)
ACUTE DISEASE EVIDENCE(4,1)
ACYL HALIDE(4,1)
AGRICULTURAL INDUSTRY(4,1)
ANTIBODY ABSENCE(4,1)
ANTISENSE NUCLEIC ACID MOLECULE(4,1)
BACTERIA PREPARATION(4,1)
BACTERIAL ORIGIN(4,1)
BIOLOGICAL REPEAT(4,1)
BOLUS DOSE(4,1)
BOVINE SERUM ALBUMIN(4,1)
CAPSULE ABSENCE(4,1)
CARBOXYL ESTER(4,1)
CELL POPULATION(4,1)
CELLULAR RNA(4,1)
CENTRIFUGATION CYCLE(4,1)
CITED DOCUMENT(4,1)
CONDEMNATION LOSS(4,1)
COPY INSERTION(4,1)
CRUDE MEMBRANE(4,1)
CYCLICAL VARIANT(4,1)
DIGEST SEPARATION(4,1)
DISULFANE BOND(4,1)
DNA MARKER(4,1)
DOUBLE STRANDED PLASMID DNA(4,1)
ELISA ASSAY(4,1)
ENZYMATIC ACTIVITY(4,1)
EUKARYOTIC HOST(4,1)
EXPONENTIAL PHASE(4,1)
EXPRESS LANGUAGE(4,1)
EXTRACELLULAR DOMAIN BOUNDARY(4,1)
EXTRACELLULAR ENVIRONMENT(4,1)
FIBER STRIP(4,1)
FIBRINOPURULENT BRONCHOPNEUMONIA MAJOR CAUSE(4,1)
FLUORESCENT LABEL(4,1)
FREE HYDROXY ACYLATION(4,1)
GENE CLONING(4,1)
GENETIC ENGINEERING METHODOLOGY(4,1)
GENETIC ENVIRONMENT(4,1)
HETEROLOGOUS IMMUNITY GIVING(4,1)
HETEROLOGOUS NUCLEIC ACID MOLECULE(4,1)
INTRODUCED PRESELECTED DNA SEGMENT(4,1)
IRON STARVED BACTERIUM(4,1)
LIKELY ABILITY ESTIMATE(4,1)
MAJOR NATURAL HOST INFECTION(4,1)
MAJOR PROTECTIVE ANTIGEN(4,1)
MONOMER PEPTIDE(4,1)
MUCOUS DISCHARGE(4,1)
MULTOCIDA PREPARATION(4,1)
MULTOCIDA VIRULENCE FACTOR(4,1)
NUCLEIC ACID MOLECULE ANNEALING(4,1)
NUMEROUS BACTERIAL SPECIES(4,1)
PARENTERAL INJECTION(4,1)
PARTICLE BOMBARDMENT(4,1)
PEPTIDE CONCENTRATION(4,1)
PEPTIDE MASS MATCH(4,1)
PEPTIDE SYNTHESIS(4,1)
PEPTIDYL BOND(4,1)
PI PEPTIDE(4,1)
POLYPEPTIDE DETECTION(4,1)
PRESELECTED NUCLEIC ACID FRAGMENT(4,1)
PROTECTIVE ANTIBODY(4,1)
PROTECTIVE PROTEIN CAPACITY(4,1)
PROTEIN FALLING(4,1)
PROTEIN NUMBER(4,1)
PROTEIN POST TRANSLATIONAL MODIFICATION(4,1)
PROTEIN PROFILE(4,1)
RECOMBINANT NUCLEIC ACID MOLECULE(4,1)
RESTRICTION SITE(4,1)
RNA SPECIES PRESENCE(4,1)
ROUTINE CULTURE(4,1)
SARCOSINE SOLUBLE MEMBRANE FRACTION(4,1)
SEQUENTIAL STAINING(4,1)
SEVERE RESPIRATORY DISEASE(4,1)
SIGNIFICANT PERMEABILITY BARRIER(4,1)
SITE MEDIATED MUTAGENESIS(4,1)
STANDARD ACYLATING REAGENT(4,1)
STATISTICALLY SIGNIFICANT DIFFERENTIAL EXPRESSION(4,1)
STERILE INJECTABLE SOLUTION(4,1)
STRONG DIFFERENTIAL EXPRESSION(4,1)
SUBCELLULAR LOCALIZATION(4,1)
TARGET TRANSFORMATION(4,1)
TEMPLATE MOLECULE(4,1)
THEORETICAL MATCHING SEQUENCE(4,1)
UNLYSED CELL(4,1)
WING WEB INJECTION(4,1)
AMINOACID RESIDUE(3,4)
SDS PAGE(3,4)
ETHYLENE OXIDE CONDENSATION PRODUCT(3,3)
LABORATORY(3,3)
NATIVE SURFACE POLYPEPTIDE(3,3)
RNA SEQUENCE(3,3)
SIGMA(3,3)
SODIUM CITRATE(3,3)
DILUENT(3,2)
MOIETY(3,2)
REVERSE PHASE HPLC(3,2)
ADMINISTRATION MODE(3,1)
AFFINITY PURIFIED PROTEIN(3,1)
AGAROSE GEL(3,1)
ALANINEBETAINE(3,1)
ALKYLENE OXIDE CONDENSATION PRODUCT(3,1)
AMINO GROUP ACYL DERIVATIVE(3,1)
AMINOACID SUBSTITUTION VARIANT(3,1)
AMMONIUM SULFATE PRECIPITATION(3,1)
ANIMAL SERUM(3,1)
ANTIBODY DETECTION(3,1)
ANTIBODY PREPARATION(3,1)
ANTIGEN VARIETY(3,1)
AQUEOUS SUSPENSION MANUFACTURE(3,1)
AUXILIARY SUBSTANCE(3,1)
BACILLUS CALMETTE GUERIN(3,1)
BACTERIUM OUTER MEMBRANE FRACTION(3,1)
CALCIUM PHOSPHATE PRECIPITATION(3,1)
CAPSULAR GROUP(3,1)
CARBOXY SALT(3,1)
CARBOXYMETHYLATION(3,1)
CASAMINO ACID(3,1)
CELL LYSATE(3,1)
COMPANION ANIMAL TREATMENT(3,1)
CONSERVATIVE AMINOACID SUBSTITUTION(3,1)
CRC PRESS(3,1)
CYCLICAL REVERSE SEQUENCE(3,1)
DENATURING AGENT(3,1)
DISEASE COMPLETE CURE(3,1)
DNA SAMPLE(3,1)
EUKARYOTIC CELLULAR SOURCE(3,1)
EXOGENOUS NUCLEIC ACID(3,1)
FEEDING BIRD(3,1)
FINAL CONDENSATION(3,1)
FINAL DIPYRIDYL CONCENTRATION(3,1)
FUNCTIONAL ASSAY(3,1)
FUSION NUCLEIC ACID MOLECULE(3,1)
GEL PURIFIED FRAGMENT(3,1)
GEL SEPARATION(3,1)
GENE SEQUENCE(3,1)
HEMAGGLUTINATION(3,1)
HEPTADECAETHYLENOXYCETANOL(3,1)
HOST ENVIRONMENT(3,1)
HOST TISSUE(3,1)
HOST TRANSFORMATION(3,1)
HYBRIDIZATION CONDITION(3,1)
HYDROPHOBIC COMPOUND(3,1)
HYDROXYPROPYLMETHYLCELLULOSE(3,1)
IMMUNITY BASIS(3,1)
IMMUNOGENIC PRODUCT(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INCLUSIVE SENSE(3,1)
INCREASED IMMUNE RESPONSIVENESS(3,1)
INERT PARTICLE(3,1)
INFECTION TERMINAL STAGE(3,1)
INFECTIOUS AGENT(3,1)
INNER MEMBRANE PROTEIN ABUNDANCE(3,1)
INSTANCE PCR(3,1)
INTERMITTENT MIXING(3,1)
KILLED WHOLE CELL(3,1)
LEGHORN CROSS CHICKEN(3,1)
LINEAR PEPTIDE(3,1)
MICROTITRATION PLATE(3,1)
MOBILITY COMPARISON(3,1)
MOLECULAR BIOLOGICAL ASSAY(3,1)
MRNA STABILITY(3,1)
MS MASS SPECTROMETRY(3,1)
MUTATED REGION(3,1)
NOSE DROP(3,1)
NUCLEIC ACID ENCODING ISOLATION(3,1)
OPERABLY LINKED CODING SEQUENCE(3,1)
ORTHOLOGOUS GROUP(3,1)
OUTER MEMBRANE PROTEIN GENE(3,1)
PEPTIDE RESIN(3,1)
PHARMACEUTICAL CARRIER(3,1)
PHOSPHOTHREONINE(3,1)
PHOSPHOTYROSINE(3,1)
PHYSIOLOGICAL FLUID REMOVAL(3,1)
PLASMID SEQUENCE(3,1)
POLYOXYETHYLENE STEARIC ACID(3,1)
POWDER TABLET(3,1)
PRESELECTED NUCLEIC ACID MOLECULE(3,1)
PROPARGYLGLYCINE(3,1)
PROTEIN CHEMICAL MODIFICATION(3,1)
PROTEIN CONCENTRATION(3,1)
PROTEIN MODIFICATION(3,1)
RANDOM INTEGRATION(3,1)
RECIPIENT CELL(3,1)
RECOMBINANT DNA SEQUENCE(3,1)
RECOMBINANT DNA TECHNOLOGY(3,1)
REFRACTILE BODY(3,1)
REVERSE TRANSCRIPTION PCR(3,1)
RNA PRODUCT INTEGRITY(3,1)
RNA REVERSE TRANSCRIPTION(3,1)
SELFREPLICATION(3,1)
SUBJECT SERUM(3,1)
SUSTAINED RELEASE FORMULATION(3,1)
SYNTHETIC CYCLICAL PEPTIDE(3,1)
SYNTHETIC MONO(3,1)
TERPENE OIL(3,1)
THERAPEUTIC AGENT(3,1)
TRANSCRIPTION TRANSLATION REACTION(3,1)
TRANSFORMED CELL SELECTION(3,1)
UNIQUE PROTEIN(3,1)
VACCINE BASIS(3,1)
VARIANT NUCLEIC ACID MOLECULE(3,1)
VECTOR CAPACITY LOSS(3,1)
VETERINARY TREATMENT(3,1)
W MONOCLONAL ANTIBODY(3,1)
WHOLE KILLED CELL(3,1)
WING JOINT(3,1)
AGAROSE PLATE(2,1)
ALCOHOL PRESENCE(2,1)
AMIDATION(2,1)
AMIDE FORMATION(2,1)
AMINOACID ANALOG(2,1)
AMINOACID SUBSTITUTION FALLING(2,1)
AMINOLYSIS(2,1)
ANOREXIA(2,1)
ANTIBODY FRAGMENT(2,1)
ANTIGEN NARROW GROUP(2,1)
ASSAY VARIETY(2,1)
AUSTRALIAN PATENT(2,1)
BACTEREMIA LEVEL(2,1)
BACTERIAL ANTIGEN(2,1)
BASIC CONCEPT(2,1)
BEAK(2,1)
BENTONITE(2,1)
BICARBONATE BASE(2,1)
BISPECIFIC ANTIBODY(2,1)
BLAND FIXED OIL(2,1)
BOVID(2,1)
CANID(2,1)
CASSETTE MUTAGENESIS(2,1)
CHAIN OLEIC ACID(2,1)
CO TRANSFORMATION(2,1)
CODING REGION(2,1)
COLONIZATION(2,1)
COMPLEMENTARY SEQUENCE IDENTITY(2,1)
COMPLETE UNDERSTANDING(2,1)
CONSTANT AERATION(2,1)
CONTAMINANT(2,1)
CONTINUOUS STIRRING(2,1)
CULTURE MEDIUM(2,1)
CURRENT VACCINE(2,1)
CYANOSIS(2,1)
DEXTROSE(2,1)
DIACYLGLYCEROL(2,1)
DIARRHEA(2,1)
DISPERSION(2,1)
DISRUPTION(2,1)
DNA MOLECULE SOURCE(2,1)
DNA SEQUENCE ENCODING(2,1)
ELECTROPORATION(2,1)
EMACIATION(2,1)
ENHANCER(2,1)
ESTERIFICATION(2,1)
ETHIDIUM BROMIDE(2,1)
ETHYL ALCOHOL PRECIPITATION(2,1)
FELID(2,1)
FINAL RECOVERY(2,1)";Pharmaceuticals;Open
2005-07-08;"RU2287992           C1 2006-11-27 [RU2287992]
STG: (C1) Patent for invention
AP : 2005RU-0121585 2005-07-08";36264329;RU2287992           C1 2006-11-27 [RU2287992];2005RU-0121585;;G NAUCHNOE UCHREZHDENIE GNU VS;G NAUCHNOE UCHREZHDENIE GNU VS;;;1;"SHAKHOV ALEKSEJ GAVRILOVICH
RETSKIJ MIKHAIL ISAAKOVICH
ZOLOTAREV ALEKSANDR IVANOVICH
MAS JANOV JURIJ NIKOLAEVICH
PERSHINA SVETLANA IVANOVNA
BRIGADIROV JURIJ NIKOLAEVICH
KARDASHOV ALEKSEJ MIKHAJLOVICH
BIRJUKOV MAKSIM VLADIMIROVICH";;;"(RU2287992)
Method for immunoprophylaxis of viral respiratory diseases in calves";"(RU2287992)
FIELD: veterinary science. ^ SUBSTANCE: one should immunize down-calving cows 1.5 mo before calving with a live, dry culture associated vaccine against paragrippe-3 (PG) and infectious rhinotracheitis in cattle (IRT) and simultaneously it is necessary to introduce Ligfol per 5 ml/animal; in 14 d Ligfol should be introduced once more at the same dosage; for calves born form these cows for 0.5-1 h after the birth it is necessary to introduce Ligfol once intramuscularly at the dosage of 2 ml. The innovation decreases the quantity of diseases and accelerates the recovery in animals. ^ EFFECT: higher efficiency of immunoprophylaxis. ^ 3 ex, 6 tbl";"(RU2287992)
The Method of immunoprophylaxis of the virus respiratory diseases of calves, which includes the immunization of glubokostelnykh cows by vaccine against parainfluenza -3 and infectious rhino-tracheitis of large livestock dry that of cultural associated, living at the dose 2 ml, which is characterized by the fact that additionally uses Ligfol according to the following diagram: 1,5 months prior to calving of glubokostelnykh cows they immunize by vaccine against parainfluenza -3 and infectious rhino-tracheitis of large livestock of dry cultural of that associated, living, and simultaneously intramuscularly is introduced Ligfol on 5 ml to animal; in 14 days Of Ligfol they introduce repeatedly at the same dose; to the calves, obtained from these cows, for 0,5-1 h after generation once intramuscularly is introduced Ligfol at the dose of 2 ml";;;"A61K-035/00
A61K-036/00
A61K-038/36
A61K-039/12
A61K-039/155
A61K-039/265
A61K-039/395
A61K-039/42
A61P-031/12";;;Pharmaceuticals;Open
2005-07-08;"RU2287986           C1 2006-11-27 [RU2287986]
STG: (C1) Patent for invention
AP : 2005RU-0121582 2005-07-08";36264304;RU2287986           C1 2006-11-27 [RU2287986];2005RU-0121582;;G NAUCHNOE UCHREZHDENIE GNU VS;G NAUCHNOE UCHREZHDENIE GNU VS;;;1;"SHAKHOV ALEKSEJ GAVRILOVICH
RETSKIJ MIKHAIL ISAAKOVICH
ZOLOTAREV ALEKSANDR IVANOVICH
BELJAEV VASILIJ IVANOVICH
BRIGADIROV JURIJ NIKOLAEVICH
MAS JANOV JURIJ NIKOLAEVICH
PERSHINA SVETLANA IVANOVNA
KAVERIN NIKOLAJ NIKOLAEVICH";;;"(RU2287986)
Method for preventing respiratory diseases in calves";"(RU2287986)
FIELD: veterinary science. ^ SUBSTANCE: the present innovation deals with immunization of down-calving cows with a live dry culture associated vaccine against paragrippe-3 (PG) and infectious rhinotracheitis in cattle at the dosage of 2 ml 1.5 mo before calving at simultaneous intramuscular injection of Selecor at the dosage of 10 mcg/kg animal's body weight; in 14 d one should introduce Selecor once more at the same dosage; then Selecor should be once injected intramuscularly for calves born in above-mentioned cows for 0.5-1 h after their birth. The innovation increases colostral cell and humoral immunity in calves, decrease sickness rate and accelerates the recovery. ^ EFFECT: higher efficiency of prophylaxis. ^ 3 ex, 6 tbl";"(RU2287986)
The Method of the preventive maintenance of the respiratory diseases of calves, which includes the immunization of glubokostelnykh cows by vaccine against parainfluenza -3 and infectious rhino-tracheitis of large livestock dry that of cultural associated, living at the dose 2 ml, which is characterized by the fact that additionally uses Selekor according to the following diagram: 1,5 months prior to calving of glubokostelnykh cows they immunize by vaccine against parainfluenza -3 and infectious rhino-tracheitis of large livestock of dry cultural of that associated, living and simultaneously intramuscularly is introduced Selekor at the dose 10 g/kg of the mass of the body of animal, in 14 days Of Selekor they introduce repeatedly at the same dose, to the calves, obtained from these cows, for 0,5-1 h after generation once intramuscularly is introduced Selekor at the dose 10 g/kg of the mass of the body of animal.";;;"A61K-031/095
A61K-038/36
A61K-039/12
A61K-039/155
A61K-039/265
A61K-039/295
A61K-039/395
A61K-039/42
A61P-031/12";;;Pharmaceuticals;Open
"2005-07-07
2006-07-06";"US20070009545       A1 2007-01-11 [US20070009545]
STG: (A1) Application published
AP : 2005US-11176700 2005-07-07
WO2007006712        A2 2007-01-18 [WO200706712]
STG: (A2) International application published without international search report
AP : 2006WO-EP63948 2006-07-06
CA2614261           A1 2007-01-18 [CA2614261]
STG: (A1) Application laid open
AP : 2006CA-2614261 2006-07-06
AU2006268748        A1 2007-01-18 [AU2006268748]
STG: (A1) Open to public inspection
AP : 2006AU-0268748 2006-07-06
WO2007006712        A3 2007-04-05 [WO200706712]
STG: (A3) Later publication of ISR with revised front page
AP : 2006WO-EP63948 2006-07-06
EP1904096           A2 2008-04-02 [EP1904096]
STG: (A2) Application published without search report
AP : 2006EP-0777602 2006-07-06
CN101217974         A  2008-07-09 [CN101217974]
STG: (A) Published application
AP : 2006CN-80024567 2006-07-06
US20080193463       A1 2008-08-14 [US20080193463]
STG: (A1) Application published
AP : 2006US-11994677 2006-07-06
IN0085/CHENP/2008   A  2008-09-19 [IN2008CN00085]
STG: (A) Application laid open
AP : 2008IN-CN00085 2008-01-07
ZA200710724         B  2008-10-29 [ZA200710724]
STG: (B)
AP : 2007ZA-0010724 2007-12-10
JP2009500007        A  2009-01-08 [JP2009500007]
STG: (A) Published application
AP : 2008JP-0518870 2006-07-06
US7833536           B2 2010-11-16 [US7833536]
STG: (B2) Granted patent as second publication
AP : 2006US-11994677 2006-07-06
FD :  Continuation of: US11/176,700 FDD=2005-07-07 [2005US-11176700] ABANDONED
FD : Previous publication: US20080193463 A1 2008-08-14 [US20080193463]
NZ564286            A  2010-11-26 [NZ-564286]
STG: (A) Published application
AP : 2006NZ-0564286 2006-07-06
BRPI0612739         A2 2012-10-02 [BR200612739]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2006BR-0012739 2006-07-06";1804381;"US20070009545       A1 2007-01-11 [US20070009545]
WO2007006712        A2 2007-01-18 [WO200706712]
CA2614261           A1 2007-01-18 [CA2614261]
AU2006268748        A1 2007-01-18 [AU2006268748]
WO2007006712        A3 2007-04-05 [WO200706712]
EP1904096           A2 2008-04-02 [EP1904096]
CN101217974         A  2008-07-09 [CN101217974]
US20080193463       A1 2008-08-14 [US20080193463]
IN0085/CHENP/2008   A  2008-09-19 [IN2008CN00085]
ZA200710724         B  2008-10-29 [ZA200710724]
JP2009500007        A  2009-01-08 [JP2009500007]
US7833536           B2 2010-11-16 [US7833536]
NZ564286            A  2010-11-26 [NZ-564286]
BRPI0612739         A2 2012-10-02 [BR200612739]";"2005US-11176700
2006US-11994677
2006WO-EP63948";"(EP1904096)
WO2007006712
(US7833536)
WO2007006712
(JP2009500007)
WO2007006712
(CA2614261)
WO2007006712
(AU2006268748)
WO2007006712
(CN101217974)
WO2007006712
(IN2008CN00085)
WO2007006712
(NZ-564286)
WO2007006712
(BR200612739)
WO2007006712";"BERN UNIVERSITY OF
UNIVERSAL VISIBILITY OF BERN
UNIVERSITY OF BERN";UNIVERSITY OF BERN;"(EP1904096)
CH
(US7833536)
CH
(WO200706712)
CH

(CA2614261)
CH
(IN2008CN00085)
CH";"(EP1904096)
NAME=University of Bern Hochschulstrasse 4 , CITY=3012 Bern , COUNTRY=CH 

(US7833536)
NAME=University of Bern , CITY=Bern , COUNTRY=CH , ATYP=Non-US Company 

(WO200706712)
NAME=UNIVERSITY OF BERN  Hochschulstrasse 4, CH-3012 Bern  , COUNTRY=CH 

(JP2009500007)
NAME=Universal Visibility of Bern , REG=508004074 

(CA2614261)
NAME=UNIVERSITY OF BERN Hochschulstrasse 4 CH-3012 , CITY=BERN , COUNTRY=CH 

(IN2008CN00085)
NAME=UNIVERSITY OF BERN HOCHSCHULSTRASSE 4, CH-3012 BERN  , COUNTRY=CH 
";1;"FREY JOACHIM
VILEI EDIE M
PILO PAOLA";"(EP1904096)
CH";"(EP1904096)
NAME=FREY, Joachim Schreinerweg 9 , CITY=CH-3012 Bern , COUNTRY=CH 

NAME=VILEI, Edie M. Grubenstrasse 76 E , CITY=CH-3322 Urtenen-Schönbühl , COUNTRY=CH 

NAME=PILO, Paola 9, Rue Francois-Durafour , CITY=CH-1220 Geneve , COUNTRY=CH 
";"(EP1904096)
Mycoplasma subunit vaccine";"(EP1904096)
The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-a-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-a-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.";"(US20070009545)
1) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
2) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a live recombinant carrier encoding mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
3) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a host cell comprising a live recombinant carrier encoding mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
4) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a gene encoding mycoplasmal L-α-glycerophosphate oxidase or a part of said gene encoding an immunogenic fragment thereof, under the control of a functionally linked promoter and a pharmaceutically acceptable carrier.
5) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a host cell comprising a gene encoding mycoplasmal L-α-glycerophosphate oxidase or a part of said gene encoding an immunogenic fragment thereof, under the control of a functionally linked promoter and a pharmaceutically acceptable carrier.
6) Vaccine according to claims 1-5, characterised in that said vaccine additionally comprises one or more antigens derived from another micro-organism or virus that is pathogenic to the same host, antibodies against such antigens or genetic information encoding such antigens.
7) Vaccine according to claim 6, characterized in that said virus or micro-organism is selected from the group of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, another Mycoplasma spp., in particular, Mycoplasma hyopneumoniae, Brachyspira hyodysenteriae, Escherichia coli, Leptospira spp., Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Brachyspira hyodysenteriae, Shigella sp., Salmonella choleraesuis, Salmonella typhimurium, Salmonella enteritidis, Haemophilus parasui,s Lauwsonia, Pasteurella multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Staphylococcus hyicus and Clostridium perfringens.
8) Vaccine according to claim 6, characterized in that said virus or micro-organism is selected from the group consisting of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, Bovine Respiratory Syncytial Virus, porcine circo virus, porcine respiratory reproductive syndrome virus, another Mycoplasma spp., Pasteurella haemolytica, Staphylococcus aureus, Escherichia coli, Leptospira spp., Staphylococcus uberis, Theileria parva, Theileria annulata, Babesia bovis, Babesia bigemina, Babesia major, Trypanosoma species, Anaplasma marginale, Anaplasma centrale and Neospora caninum.
9) Vaccine according to claim 6, characterized in that said virus or micro-organism is selected from the group consisting of Fowlpox virus, Infectious Bronchitis virus, Infectious Bursal Disease (Gumboro), Marek's Disease Virus, Chicken Anaemia agent, Avian Reovirus, Turkey Rhinotracheitis virus, Chicken Poxvirus, Avian Encephalomyelitisvirus, Duck Plague virus, Newcastle Disease virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, another Mycoplasma spp. ia. Mycoplasma gallisepticum or Mycoplasma synoviae, Haemophilus paragallinarum (Coryza), Ornithobacterium rhinotracheale, Clostridium perfringens, Salmonella-, Campylobacter species, E. coli and Eimeria species.
10) Vaccine according to claim 6, characterized in that said virus or micro-organism is selected from the group consisting of influenza virus, measles virus, mumps paramyxovirus, Clostridium diphteriae, Clostridium tetani, Bordetella pertussis, and pox virus.
11) Vaccine for combating Mycoplasma infections, characterised in that it comprises antibodies against an mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
12) Vaccine according to claim 1-11, characterised in that it comprises an adjuvant.
13) Vaccine according to claim 1-12, characterised in that said mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof is the mycoplasmal L-α-glycerophosphate oxidase as encoded by M. bovis, M. sp. bovine group 7, M. mycoides subsp. Capri, M. penetrans, M. gallisepticum, M. synoviae, M. mobile, M. pulmonis, M. hyopneumoniae, M. pneumoniae, M. genitalium, M. mycoides S(mall) C(olony) strain Afadé or M. mycoides S(mall) C(olony) strain L2.
14) Mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof for use in a vaccine.
15) Use of mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof for the manufacturing of a vaccine for combating Mycoplasma infection.
16) Method for the preparation of a vaccine according to claim 1-14, said method comprising the admixing of mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof, as described in claim 1, a live recombinant carrier as described in claim 2, a gene or a part thereof as described in claim 4, a host cell as described in claims 3 and 5 or antibodies against mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof as described in claim 11, and a pharmaceutically acceptable carrier.
17) Diagnostic test for the discrimination between vaccination with a vaccine according to claims 1-14 on the one hand and vaccination with a whole cell vaccine or a field infection on the other hand, characterised in that said test comprises purified mycoplasmal L-α-glycerophosphate oxidase or an immunogenic fragment thereof.";"(US20070009545)
It was found now that contrary to all non-mycoplasmal bacteria, and apparently as a result of the lack of catalase, Mycoplasma has during evolution transferred its mycoplasmal L- -glycerophosphate oxidase from the intracellular space to the membrane, in such a way that it leads to the production of extracellular H2O2.
It is an objective of the present invention to provide a vaccine for combating Mycoplasma infection, that avoids or diminishes host cell damage, inflammation and disease.
The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L- -glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L- -glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.
The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L- -glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L- -glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.";"(US20070009545)
Vaccines according to the invention based upon live recombinant carriers as described above, capable of expressing the enzyme or immunogenic fragments thereof e.g. based upon a Salmonella carrier or a viral carrier infecting the enteric epithelium, or e.g. the respiratory epithelium have the advantage over subunit vaccines that they better mimic the natural way of infection of Mycoplasma.
When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl.
When the host cell is yeast, useful expression control sequences include, e.g., -mating factor.
Even more unexpectedly, it could be demonstrated that the formation of H2O2/ROS is the main, if not the only cause of tissue damage caused by Mycoplasma infection.
They are expected to damage the host either by directly impairing tissue cells or inducing host gene expression, e.g., proinflammatory genes via activation of NF- B, or via the Fenton reaction (Crichton, R.
Although diagnosis of mycoplasmal infections has improved significantly since the introduction of PCR methods and antigenic variability has been studied in detail in several Mycoplasma species, there is currently very little knowledge available on the molecular mechanisms and the effectors that allow pathogenic mycoplasmas to cause host cell damage, inflammation and disease.";"A61K
A61K-039/00
A61K-039/002
A61K-039/02
A61K-039/04
A61K-039/09
A61K-039/106
A61K-039/108
A61K-039/112
A61K-039/116
A61K-039/12
A61K-039/145
A61K-039/15
A61K-039/165
A61K-039/17
A61K-039/205
A61K-039/23
A61K-039/245
A61K-048/00
A61P
A61P-031/04
A61P-031/12
C07K-014/00
C12N-009/04
C12N-015/09
C12P-001/00
C12Q-001/26";"(US20070009545)
1) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises mycoplasmal L- -glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
2) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a live recombinant carrier encoding mycoplasmal L- -glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
3) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a host cell comprising a live recombinant carrier encoding mycoplasmal L- -glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
4) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a gene encoding mycoplasmal L- -glycerophosphate oxidase or a part of said gene encoding an immunogenic fragment thereof, under the control of a functionally linked promoter and a pharmaceutically acceptable carrier.
5) Vaccine for combating Mycoplasma infection, characterised in that said vaccine comprises a host cell comprising a gene encoding mycoplasmal L- -glycerophosphate oxidase or a part of said gene encoding an immunogenic fragment thereof, under the control of a functionally linked promoter and a pharmaceutically acceptable carrier.
11) Vaccine for combating Mycoplasma infections, characterised in that it comprises antibodies against an mycoplasmal L- -glycerophosphate oxidase or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
14) Mycoplasmal L- -glycerophosphate oxidase or an immunogenic fragment thereof for use in a vaccine.
15) Use of mycoplasmal L- -glycerophosphate oxidase or an immunogenic fragment thereof for the manufacturing of a vaccine for combating Mycoplasma infection.";"(US20070009545)
GLYCEROPHOSPHATE OXIDASE(100,63)
VACCINE(100,62)
IMMUNOGENIC FRAGMENT(100,28)
MYCOPLASMA INFECTION(100,17)
MYCOPLASMA SUBUNIT VACCINE(100,1)
ANIMAL DISCRIMINATION(58,2)
LIVE RECOMBINANT CARRIER ENCODING(55,3)
MYCOPLASMAL INFECTION DIAGNOSIS(54,1)
VACCINE PREPARATION(51,3)
ANIMAL SUFFERING(49,2)
CELL VACCINE(40,2)
MYCOIDE SUBSP(39,60)
INTESTINAL EPITHELIUM(38,1)
BOVINE VIRAL DIARRHEA VIRUS(36,2)
TRANSMISSIBLE GASTRO ENTERITIS VIRUS(35,2)
VIRAL CARRIER INFECTING(34,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(33,2)
EXTRACELLULAR H2O PRODUCTION(33,1)
GENE ENCODING(31,6)
PATHOGENIC MYCOPLASMA(31,2)
MAREK DISEASE VIRUS(31,1)
TRP PROMOTER(31,1)
INFECTIOUS BRONCHITIS VIRUS(30,2)
PORCINE CIRCO VIRUS(30,2)
LEPTOSPIRA SPP(29,4)
PRO INFLAMMATORY GENE(29,2)
REPRODUCTIVE SYNDROME VIRUS(29,2)
HOST GENE EXPRESSION INDUCTION(29,1)
IMPAIRING TISSUE CELL(29,1)
INFECTIOUS BURSAL DISEASE(28,2)
HOST CELL(27,21)
ORNITHOBACTERIUM RHINOTRACHEALE(27,2)
SALMONELLA CARRIER(25,1)
MYCOPLASMA(24,47)
MICROORGANISM(24,6)
MUMPS PARAMYXOVIRUS(24,2)
MYCOPLASMA GALLISEPTICUM(24,2)
BABESIA BIGEMINA(23,2)
BORDETELLA PERTUSSIS(23,2)
HAEMOPHILUS PARASUI(23,2)
SALMONELLA CHOLERAESUIS(23,2)
SALMONELLA ENTERITIDIS(23,2)
SALMONELLA TYPHIMURIUM(23,2)
STAPHYLOCOCCUS UBERIS(23,2)
FENTON REACTION(23,1)
STAPHYLOCOCCUS AUREUS(22,2)
MYCOPLASMA SPECIES(21,9)
FUNCTIONALLY LINKED PROMOTER CONTROL(21,4)
BABESIA BOVIS(21,2)
BOVINE PARAMYXOVIRUS(21,2)
CHICKEN ANEMIA AGENT(21,2)
DUCK PLAGUE VIRUS(20,2)
PORCINE INFLUENZA VIRUS(20,2)
TURKEY HERPES VIRUS(20,2)
BOVINE HERPES VIRUS(20,1)
CAMPYLOBACTER SPECIES(19,2)
BRACHYSPIRA HYODYSENTERIAE(18,4)
CHICKEN POXVIRUS(18,2)
MEASLES VIRUS(18,2)
TRYPANOSOMA SPECIES(18,2)
KNOWLEDGE(18,1)
MATING FACTOR(18,1)
RESPIRATORY EPITHELIUM(18,1)
INFLAMMATION(17,5)
CLOSTRIDIUM PERFRINGENS(17,4)
DIAGNOSTIC TEST(17,3)
EIMERIA SPECIES(17,2)
ANTIGENIC VARIABILITY(17,1)
ANTIBODY(16,18)
RECOMBINANT CARRIER(16,5)
CELL DAMAGE(16,4)
EFFECTOR(16,1)
WHOLE CELL VACCINE(16,1)
H2O FORMATION(15,3)
GENETIC INFORMATION ENCODING(14,2)
MOLECULAR(14,1)
TISSUE DAMAGE CAUSE(14,1)
INFECTION(13,16)
ACTINOBACILLUS PLEUROPNEUMONIAE(13,2)
BABESIA MAJOR(13,2)
ERYSIPELOTHRIX RHUSIOPATHIAE(13,2)
ANIMAL(12,10)
DISEASE(12,5)
ESCHERICHIA(12,5)
BORDETELLA BRONCHISEPTICA(12,2)
HAEMOPHILUS PARAGALLINARUM(12,2)
PASTEURELLA HAEMOLYTICA(12,2)
PASTEURELLA MULTOCIDA(12,2)
ECANEP CELL INFECTION(11,5)
ANAPLASMA CENTRALE(11,2)
ANAPLASMA MARGINALE(11,2)
EVOLUTION(11,2)
MYCOPLASMA SYNOVIAE(11,2)
NEOSPORA CANINUM(11,2)
NON MYCOPLASMAL BACTERIUM(11,2)
PORCINE PARVOVIRUS(11,2)
PSEUDORABIES VIRUS GROUP(11,2)
STAPHYLOCOCCUS HYICUS(11,2)
STREPTOCOCCUS SUIS(11,2)
THEILERIA ANNULATA(11,2)
THEILERIA PARVA(11,2)
TURKEY RHINOTRACHEITIS VIRUS(11,2)
ADMIXING(11,1)
INFECTION NATURAL WAY(11,1)
BACTERIA(10,7)
CATALASE(10,3)
MALL(10,3)
AVIAN REOVIRUS(10,2)
DECOMPLEMENTED MONOSPECIFIC RABBIT SERUM(10,1)
GENETIC RESOURCE DRASTIC ECONOMIZATION(10,1)
PCR METHOD INTRODUCTION(10,1)
PULMONIS(10,1)
MYCOPLASMA VACCINE(9,4)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(9,2)
ROTAVIRUS(9,2)
SHIGELLA(9,2)
YEAST(9,2)
ENZYME(8,12)
GLYCEROL METABOLISM(8,4)
BOVINE GROUP(8,3)
CORYZA(8,2)
NEWCASTLE DISEASE VIRUS(8,2)
BOVINE PATHOGENIC MYCOPLASMA SPECIES(8,1)
INTRACELLULAR SPACE(8,1)
MOBILE(8,1)
OVER SUBUNIT VACCINE(8,1)
PIG PATHOGENIC MYCOPLASMA SPECIES(8,1)
POULTRY PATHOGENIC MYCOPLASMA SPECIES(8,1)
BOVINE SERUM(7,4)
POLYCLONAL ANTIBODY(7,3)
SOUTHERN BLOT(7,3)
CYTOTOXIC ACTIVITY ASSESSMENT(7,2)
MYCOPLASMA SPECIES STRAIN(7,2)
CATTLE CBPP INFECTION(7,1)
CONTAGIOUS BOVINE ETIOLOGICAL AGENT(7,1)
GLYCOLYTIC PATHWAY(7,1)
MUTATED TGGTRP CODON(7,1)
POLYCLONAL MONOSPECIFIC SERUM(7,1)
RABBIT SUBCUTANEOUS IMMUNIZATION(7,1)
H2O PRODUCTION(6,5)
PBS BUFFER(6,5)
RAISING ANTIBODY(6,4)
CYTOTOXICITY INDUCTION(6,2)
EGG DROP SYNDROME VIRUS(6,2)
FILAMENTOUS PHAGE(6,2)
FLUORESCENCE MICROSCOPY(6,2)
MYCOPLASMAL PROTEIN(6,2)
VIABLE ECANEP CELL(6,2)
ACTIVE GLYCEROL TRANSPORTER GTSABC(6,1)
ANAWA BIOMEDICAL SERVICE(6,1)
BIOLOGICAL SAFETY LABORATORY FULFILLING(6,1)
BRITISH BIOCELL INTERNATIONAL(6,1)
CAMELID EXPRESSION LIBRARY(6,1)
CBPP ETIOLOGICAL AGENT(6,1)
CELL INJURY MEDIATOR(6,1)
CRANDELL FELINE KIDNEY CELL(6,1)
CYTOTOXICITY EXPERIMENT KINETICS(6,1)
ECANEP CELL INTRACELLULAR OXIDATION(6,1)
EXTRAORDINARY SOCIOECONOMIC IMPORTANCE(6,1)
GLPO GENE EXPRESSION(6,1)
GLYCEROL METABOLIC PATHWAY MODIFICATION(6,1)
GOLD CONJUGATED GOAT ANTI RABBIT(6,1)
HUMAN PATHOGENIC MYCOPLASMA SPECIES(6,1)
IMMUNOGENIC MYCOPLASMA PROTEIN(6,1)
IMMUNOPURE FAB PREPARATION KIT(6,1)
KLUWER ACADEMIC PLENUM PUBLISHER(6,1)
MYCOPLASMA MYCOIDES SUBSP(6,1)
MYCOPLASMA PATHOGENICITY(6,1)
POLY HISTIDINE TAILED FUSION PROTEIN(6,1)
RABBIT MONOSPECIFIC SERUM(6,1)
RABBIT PREIMMUNE SERUM(6,1)
RECOMBINANT GLPO EXPRESSION(6,1)
RECOMBINANT POLY HISTIDINE EXPRESSION(6,1)
STRAIN AFAD INFECTION(6,1)
GLYCEROL PRESENCE(5,8)
ANTI GLPO FAB FRAGMENT(5,3)
CACODYLATE BUFFER(5,3)
DNA ENCODING(5,2)
EMBRYONIC CALF(5,2)
EUROPEAN OUTBREAK(5,2)
MYCOPLASMA SUSPENSION(5,2)
TOPPRED SOFTWARE(5,2)
AMPHIPHILICITY CRITERION(5,1)
AXCELL BIOTECHNOLOGY(5,1)
CYTOPLASMIC GLPO ACTIVITY(5,1)
GENOMIC DNA EXTRACTION(5,1)
GLYCEROL PHOSPHATE KINASE(5,1)
GLYCEROL PHOSPHATE OXIDASE(5,1)
GTSABC TRANSPORTER(5,1)
MAMMAL VACCINATION(5,1)
MYCOPLASMA GENITALIUM(5,1)
MYCOPLASMA PRETREATMENT(5,1)
MYCOPLASMA VIABILITY(5,1)
MYCOPLASMAL VIRULENCE MOLECULAR BASIS(5,1)
PHAGOCYTE CELL SUGGESTING(5,1)
PRETREATED ECANEP CELL(5,1)
RABBIT ANTI CALCITONINE ANTIBODY(5,1)
TRITON IMMUNOBLOT ANALYSIS(5,1)
TRYPAN BLUE EXCLUSION(5,1)
MICROBIOLOGY(4,4)
PHYSIOLOGICAL CONCENTRATION PRESENCE(4,3)
ANTIBODY PANEL(4,2)
DIMINISHING HOST CELL DAMAGE(4,2)
FIELD INFECTION(4,2)
GLYCEROL ACTIVE UPTAKE(4,2)
PARAINFLUENZA TYPE(4,2)
SELF REPLICATING ORGANISM(4,2)
WEAK CYTOTOXIC(4,2)
AMERSHAM(4,1)
ANIMAL MYCOPLASMA(4,1)
ANTIBODY ADMINISTRATION(4,1)
ANTIBODY ENGINEERING PAGE(4,1)
ANTIGENIC FRAGMENT(4,1)
ATTENUATED MYCOPLASMA(4,1)
ATTENUATED SALMONELLA(4,1)
BACILLUS SUBTILIS(4,1)
BACKSCATTERED ELECTRON MICROGRAPH(4,1)
BACTERIA GENOME(4,1)
BACTERIAL EXPRESSION VECTOR(4,1)
BACULOVIRUS PROMOTER(4,1)
BVD VIRUS(4,1)
CAPRI STRAIN(4,1)
CBPP OUTBREAK(4,1)
CHELATION CHROMATOGRAPHY(4,1)
CHINESE HAMSTER OVARY CELL(4,1)
CULTURE SUPERNATANT(4,1)
DEOXY TERMINATOR(4,1)
DETECTABLE CM H2DCFDA OXIDATION(4,1)
DIACETATE ACETYL ESTER(4,1)
DICHLOROFLUORESCEIN FORMATION(4,1)
DNA FRAGMENT ENCODING(4,1)
EMBL DATABASE(4,1)
ESTER CLEAVAGE(4,1)
EUKARYOTIC HOST(4,1)
EUKARYOTIC ORIGIN(4,1)
EXPERIMENTAL HEMATOLOGY(4,1)
EXTRACELLULAR H2O(4,1)
EXTRACELLULAR PATHOGEN(4,1)
FARCHA LABORATORY(4,1)
FLUORESCENCE MICROGRAPH(4,1)
GENE ENCODING SEQUENCE(4,1)
GENETIC ANALYZER(4,1)
GLPO GENE SEQUENCE(4,1)
GLYCEROL FACILITATOR FACTOR(4,1)
GLYCEROL KINASE(4,1)
GLYCEROL RESIDUAL UPTAKE(4,1)
GLYCEROPHOSPHATE OXIDASE ACTIVITY(4,1)
GLYCEROPHOSPHATE OXIDASE PROTEIN(4,1)
GOLD CONJUGATED SECONDARY ANTIBODY(4,1)
GROWTH INHIBITION OBSERVATION(4,1)
H2O INDUCTION(4,1)
H2O MOLECULE(4,1)
H2O QUANTIFICATION(4,1)
HETEROLOGOUS PROMOTER(4,1)
HEXAMETHYLDISILAZANE EVAPORATION(4,1)
HIGHLY VIRULENT STRAIN(4,1)
HITRAP PROTEIN(4,1)
HOMOLOGOUS ENZYME(4,1)
IGG PURIFIED FAB FRAGMENT(4,1)
IMMUNOGLOBULIN PURIFICATION(4,1)
IMMUNOLOGICALLY IMPORTANT EPITOPE(4,1)
INCOMPLETE ADJUVANT(4,1)
INFECTED ANIMAL TISSUE(4,1)
INFECTED ECANEP CELL(4,1)
INFECTED HOST TISSUE(4,1)
INTRACELLULAR H2O DETECTION(4,1)
INTRACELLULAR H2O PRESENCE(4,1)
INTRACELLULAR ROS(4,1)
LACTOBACILLUS SPECIES(4,1)
LIPOPROTEIN MEMBRANE(4,1)
LRC VIRUS(4,1)
MARKED DISCREPANCY(4,1)
MYCOPLASMA BROTH MEDIUM(4,1)
MYCOPLASMA CULTURE MEDIUM(4,1)
MYCOPLASMAL CULTURE(4,1)
MYCOPLASMAL ENZYME(4,1)
MYCOPLASMAL MEMBRANE(4,1)
NASAL EPITHELIAL CELL(4,1)
NOTI CLEAVAGE SITE(4,1)
OXIDATIVE STRESS DETECTION(4,1)
PARASITIC LIFESTYLE(4,1)
PASSIVE VACCINATION(4,1)
PCR AMPLIFICATION(4,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(4,1)
PLANT VIRAL VECTOR(4,1)
PLATINUM SPUTTERED COVERSLIP(4,1)
POLY HISTIDINE TAILED PROTEIN(4,1)
POLYCLONAL IGG(4,1)
POLYCLONAL SERA(4,1)
PREWARMED INCUBATION(4,1)
PRIMARY ANTIBODY OMISSION(4,1)
PRIMER WALKING(4,1)
PROGRAM MOTIF SCAN(4,1)
RABBIT ANTI GLPO SERUM(4,1)
REACTION ASSAY ALIQUOT(4,1)
RECOMBINANT BACULOVIRUS(4,1)
RECOMBINANT CARRIER PARASITE(4,1)
RECOMBINANT CARRIER VIRUS(4,1)
RECOMBINANT VIRUS(4,1)
SECONDARY ELECTRON MICROGRAPH(4,1)
SEVERE INFECTIOUS DISEASE(4,1)
SPECIES VIRULENCE(4,1)
STRONG FLUORESCENCE INDUCTION(4,1)
UROGENITAL INFECTION(4,1)
VACCINE PACKAGING(4,1)
VACCINIA VIRUS(4,1)
MOI(3,6)
AFRICAN(3,3)
LRCS(3,3)
BOOSTER IMMUNIZATION(3,2)
CELL EPITOPE(3,2)
DIRECT VACCINATION(3,2)
GLPO PRESENCE(3,2)
H2O RELEASE(3,2)
HOST ANIMAL(3,2)
INSECT CELL(3,2)
MEM EARLE MEDIUM(3,2)
PATHOGENIC BACTERIUM(3,2)
STABILIZER(3,2)
ALUMINUM HYDROXIDE(3,1)
ANTI LPPC FAB FRAGMENT(3,1)
ANTIBODY GENERATION(3,1)
ANTIGEN IMMUNOBLOT ANALYSIS(3,1)
BOVINE SERA(3,1)
BOVINE SPECIES(3,1)
CARRIER IMMUNOGEN(3,1)
CHAIN ANTIBODY(3,1)
CHOICE VIRUS(3,1)
COMPOUND DETECTED INTRACELLULAR OXIDATION(3,1)
COVALENTLY BOUND(3,1)
CRYSTAL VIOLET(3,1)
DEGRADATION PRONE POLYPEPTIDE(3,1)
DISMUTASE ACTIVITY(3,1)
DJAM NA(3,1)
DYING CELL(3,1)
ECANEP CELL VIABILITY(3,1)
ENZYME ACTIVITY(3,1)
EUROPEAN STRAIN(3,1)
EXPRESSION INDUCTION(3,1)
FILTERED SUPERNATANT(3,1)
GENBANK(3,1)
GENE EXPRESSION PRODUCT(3,1)
GENE PROBE(3,1)
GLPO GENE FUNCTIONAL ANALYSIS(3,1)
GLPO INTERNAL PRIMER(3,1)
IMMUNODEFICIENT ANIMAL(3,1)
INBRED MOUSE(3,1)
INFLUENZA VIRUS GROUP(3,1)
INHIBITION ASSAY(3,1)
INTEGRAL MEMBRANE PROTEIN(3,1)
LIVESTOCK MAJOR LOSS(3,1)
LOCAL ABATTOIR(3,1)
MAIN VIRULENCE PATHWAY(3,1)
MAMMALIAN ORIGIN(3,1)
MYCOPLASMA AGAR PLATE(3,1)
MYCOPLASMA INTIMATE CONTACT(3,1)
MYCOPLASMAL GROWTH MEDIUM(3,1)
NTIS PUBLICATION(3,1)
RELEVANT ANTIGEN(3,1)
RESTRICTION SITE(3,1)
ROOM TEMPEARTURE(3,1)
SEQUENCING KIT(3,1)
SEVERE CATTLE DISEASE(3,1)
STOMACH HIGHLY ACIDIC ENVIRONMENT(3,1)
STOP MYCOPLASMA GROWTH(3,1)
VACCINE DEVELOPMENT(3,1)
VIRULENCE FACTOR ACQUISITION(3,1)
VIRUS VECTOR(3,1)
WHOLE MYCOPLASMA(3,1)
GLYCEROL ADDITION(2,9)
ECORI(2,4)
AXENIC CULTURE(2,2)
CROSSE(2,2)
CYTOSOL(2,2)
DETERGENT PHASE(2,2)
EMBL GEN(2,2)
EXOGENOUS H2O ADDITION(2,2)
LESS VIRULENT STRAIN(2,2)
MARKER VACCINE(2,2)
PETHIS(2,2)
POST INFECTION(2,2)
PRIMARY VIRULENCE FACTOR(2,2)
TRIANGLE(2,2)
ACTIVE VACCINATION(2,1)
ANIMAL CELL(2,1)
ANTIOXIDANT AGENT(2,1)
ASCENDING ETHANOL SERIES(2,1)
BOVINE CELL(2,1)
BOVINE HERPES VIRUS GROUP(2,1)
CELL VIABILITY ASSAY(2,1)
CO2 ATMOSPHERE(2,1)
CONFLUENT DENSITY(2,1)
CONTAINMENT SAFETY STANDARD(2,1)
CONTRAST MICROSCOPY(2,1)
CONTROLLED EXPERIMENTAL INFECTION(2,1)
DICHLORODIHYDROFLUORESCEIN(2,1)
ECANEP CELL CULTURE(2,1)
ELISA TEST(2,1)
ENZYME PRODUCTION(2,1)
ESSENTIAL REQUIREMENT(2,1)
FAB FRAGMENT ABSENCE(2,1)
FAB FRAGMENT PREPARATION(2,1)
FULL CELL MORTALITY(2,1)
GENETIC ANALYSIS(2,1)
GENETIC INFORMATION(2,1)
GENOME REDUCTION(2,1)
GLPO LOCATION(2,1)
GROWTH MEDIUM REACHING(2,1)
H2O GLYCEROL INDUCED PRODUCTION(2,1)
HYDROPHILICITY CRITERIA COMBINATION(2,1)
IMMUNE HOST RESPONSE(2,1)
IMMUNOGENIC RESPONSE(2,1)
INDEPENDENT MEASUREMENT(2,1)
INFLAMMATION CELL(2,1)
INTERSTITIAL FLUID(2,1)
LIVESTOCK PRODUCTION(2,1)
MID EXPONENTIAL GROWTH(2,1)
MURAMYL DIPEPTIDE(2,1)
MYCOPLASMA MAIN VIRULENCE FACTOR(2,1)
MYCOPLASMA PENETRANS(2,1)
MYCOPLASMA SPECIFIC TGATRP CODON(2,1)
NATURAL IMMUNE RESPONSE(2,1)
NUCLEIC ACID TRANSCRIPTION(2,1)
PARTITIONING PHASE(2,1)
PATHOGENICITY ISLAND(2,1)
PEROXIDE TEST(2,1)
PHAGE DISPLAY(2,1)
PROTEIN ANALYSIS(2,1)
PROTEIN CONCENTRATION(2,1)
PROTEIN IMMUNOLOGICALLY IMPORTANT REGION(2,1)
RECOMBINANT NUCLEIC ACID(2,1)
SCANNING ELECTRON MICROSCOPY PHOTOGRAPH(2,1)
(US20080193463)
IMMUNOGENIC FRAGMENT(100,23)
ANIMAL(100,16)
MYCOPLASMA INFECTION(100,16)
MYCOPLASMA SUBUNIT VACCINE(100,1)
GLYCEROPHOSPHATE OXIDASE(94,58)
LIVE RECOMBINANT CARRIER ENCODING(70,3)
MYCOPLASMAL INFECTION DIAGNOSIS(69,1)
ANIMAL DISCRIMINATION(66,2)
HETEROLOGOUS GENE ENCODING(66,1)
ANIMAL SUFFERING(57,2)
VACCINE PREPARATION(57,2)
MYCOIDE SUBSP(50,61)
VACCINE(50,40)
INTESTINAL EPITHELIUM(49,1)
BOVINE VIRAL DIARRHEA VIRUS(46,2)
CELL VACCINE(45,2)
TRANSMISSIBLE GASTRO ENTERITIS VIRUS(45,2)
VIRAL CARRIER INFECTING(44,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(42,2)
GENE ENCODING(39,6)
INFECTIOUS BRONCHITIS VIRUS(39,2)
PATHOGENIC MYCOPLASMA(39,2)
MAREK DISEASE VIRUS(39,1)
TRP PROMOTER(39,1)
LEPTOSPIRA SPP(38,4)
PORCINE CIRCO VIRUS(38,2)
HOST GENE EXPRESSION INDUCTION(38,1)
IMPAIRING TISSUE CELL(38,1)
PRO INFLAMMATORY GENE(37,2)
REPRODUCTIVE SYNDROME VIRUS(37,2)
ORNITHOBACTERIUM RHINOTRACHEALE(35,2)
HOST CELL(32,20)
SALMONELLA CARRIER(32,1)
MICROORGANISM(31,6)
MUMPS PARAMYXOVIRUS(31,2)
BABESIA BIGEMINA(30,2)
BORDETELLA PERTUSSIS(30,2)
SALMONELLA CHOLERAESUIS(30,2)
SALMONELLA ENTERITIDIS(30,2)
STAPHYLOCOCCUS UBERIS(30,2)
FENTON REACTION(30,1)
MYCOPLASMA(29,47)
SALMONELLA TYPHIMURIUM(29,2)
WHOLE CELL MYCOPLASMA PREPARATION(29,2)
MYCOPLASMA SPECIES(28,9)
STAPHYLOCOCCUS AUREUS(28,2)
FUNCTIONALLY LINKED PROMOTER CONTROL(27,4)
BABESIA BOVIS(27,2)
BOVINE PARAMYXOVIRUS(27,2)
CHICKEN ANEMIA AGENT(27,2)
BOVINE HERPES VIRUS(26,1)
DUCK PLAGUE VIRUS(25,2)
PORCINE INFLUENZA VIRUS(25,2)
TURKEY HERPES VIRUS(25,2)
CAMPYLOBACTER SPECIES(24,2)
RESPIRATORY EPITHELIUM(24,1)
BRACHYSPIRA HYODYSENTERIAE(23,4)
CHICKEN POXVIRUS(23,2)
MEASLES VIRUS(23,2)
TRYPANOSOMA SPECIES(23,2)
KNOWLEDGE(23,1)
MATING FACTOR(23,1)
INFLAMMATION(22,5)
CLOSTRIDIUM PERFRINGENS(22,4)
EIMERIA SPECIES(22,2)
ANTIGENIC VARIABILITY(22,1)
CELL DAMAGE(21,4)
EFFECTOR(21,1)
RECOMBINANT CARRIER(20,5)
H2O FORMATION(19,3)
DIAGNOSTIC TEST(19,2)
GENETIC INFORMATION ENCODING(19,2)
MOLECULAR(19,1)
ANTIBODY(18,17)
HAEMOPHILUS PARASUIS(18,1)
TISSUE DAMAGE CAUSE(18,1)
ACTINOBACILLUS PLEUROPNEUMONIAE(17,2)
BABESIA MAJOR(17,2)
ERYSIPELOTHRIX RHUSIOPATHIAE(17,2)
INFECTION(16,16)
DISEASE(16,5)
BORDETELLA BRONCHISEPTICA(16,2)
ESCHERICHIA(15,5)
ANAPLASMA CENTRALE(15,2)
ANAPLASMA MARGINALE(15,2)
HAEMOPHILUS PARAGALLINARUM(15,2)
PASTEURELLA HAEMOLYTICA(15,2)
PASTEURELLA MULTOCIDA(15,2)
THEILERIA ANNULATA(15,2)
ECANEP CELL INFECTION(14,5)
MALL(14,3)
NEOSPORA CANINUM(14,2)
PORCINE PARVOVIRUS(14,2)
STAPHYLOCOCCUS HYICUS(14,2)
STREPTOCOCCUS SUIS(14,2)
THEILERIA PARVA(14,2)
TURKEY RHINOTRACHEITIS VIRUS(14,2)
GENITATIUM(14,1)
INFECTION NATURAL WAY(14,1)
BACTERIA(13,7)
DECOMPLEMENTED MONOSPECIFIC RABBIT SERUM(13,1)
GENETIC RESOURCE DRASTIC ECONOMIZATION(13,1)
INFECTIOUS BURSAL DISEASE VIRUS(13,1)
PCR METHOD INTRODUCTION(13,1)
PULMONIS(13,1)
MYCOPLASMA VACCINE(12,4)
AVIAN REOVIRUS(12,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(12,2)
ROTAVIRUS(12,2)
CORYZA(11,2)
NEWCASTLE DISEASE VIRUS(11,2)
SHIGELLA(11,2)
YEAST(11,2)
OVER SUBUNIT VACCINE(11,1)
POULTRY PATHOGENIC MYCOPLASMA SPECIES(11,1)
ENZYME(10,11)
GLYCEROL METABOLISM(10,4)
BOVINE GROUP(10,3)
BOVINE PATHOGENIC MYCOPLASMA SPECIES(10,1)
MOBILE(10,1)
PIG PATHOGENIC MYCOPLASMA SPECIES(10,1)
BOVINE SERUM(9,4)
MYCOPLASMA SPECIES STRAIN(9,2)
CATTLE CBPP INFECTION(9,1)
CONTAGIOUS BOVINE ETIOLOGICAL AGENT(9,1)
GLYCOLYTIC PATHWAY(9,1)
MUTATED TGGTRP CODON(9,1)
POLYCLONAL MONOSPECIFIC SERUM(9,1)
RABBIT SUBCUTANEOUS IMMUNIZATION(9,1)
RAISING ANTIBODY(8,4)
CYTOTOXICITY INDUCTION(8,2)
FILAMENTOUS PHAGE(8,2)
FLUORESCENCE MICROSCOPY(8,2)
MYCOPLASMAL PROTEIN(8,2)
SOUTHERN BLOT(8,2)
VIABLE ECANEP CELL(8,2)
CRANDELL FELINE KIDNEY CELL(8,1)
CYTOTOXICITY EXPERIMENT KINETICS(8,1)
IMMUNOGENIC MYCOPLASMA PROTEIN(8,1)
KLUWER ACADEMIC PLENUM PUBLISHER(8,1)
RABBIT MONOSPECIFIC SERUM(8,1)
RABBIT PREIMMUNE SERUM(8,1)
RECOMBINANT POLY HISTIDINE EXPRESSION(8,1)
GLYCEROL PRESENCE(7,8)
PBS BUFFER(7,5)
ANTI GLPO FAB FRAGMENT(7,3)
CACODYLATE BUFFER(7,3)
DNA ENCODING(7,2)
EGG DROP SYNDROME VIRUS(7,2)
EMBRYONIC CALF(7,2)
EUROPEAN OUTBREAK(7,2)
MYCOPLASMA SUSPENSION(7,2)
POLYCLONAL ANTIBODY(7,2)
ANAWA BIOMEDICAL SERVICE(7,1)
BIOLOGICAL SAFETY LABORATORY FULFILLING(7,1)
BRITISH BIOCELL INTERNATIONAL(7,1)
CAMELID EXPRESSION LIBRARY(7,1)
CBPP ETIOLOGICAL AGENT(7,1)
CELL INJURY MEDIATOR(7,1)
ECANEP CELL INTRACELLULAR OXIDATION(7,1)
EXTRAORDINARY SOCIOECONOMIC IMPORTANCE(7,1)
GLPO GENE EXPRESSION(7,1)
GLYCEROL METABOLIC PATHWAY MODIFICATION(7,1)
GOLD CONJUGATED GOAT ANTI RABBIT(7,1)
HUMAN PATHOGENIC MYCOPLASMA SPECIES(7,1)
IMMUNOPURE FAB PREPARATION KIT(7,1)
MYCOPLASMA MYCOIDES SUBSP(7,1)
MYCOPLASMA PATHOGENICITY(7,1)
POLY HISTIDINE TAILED FUSION PROTEIN(7,1)
STRAIN AFAD INFECTION(7,1)
PHYSIOLOGICAL CONCENTRATION PRESENCE(6,3)
ANTIBODY PANEL(6,2)
DIMINISHING HOST CELL DAMAGE(6,2)
GLYCEROL ACTIVE UPTAKE(6,2)
PARAINFLUENZA TYPE(6,2)
SELF REPLICATING ORGANISM(6,2)
TOPPRED SOFTWARE(6,2)
WEAK CYTOTOXIC(6,2)
AMPHIPHILICITY CRITERION(6,1)
ANTIBODY ENGINEERING PAGE(6,1)
ATTENUATED MYCOPLASMA(6,1)
ATTENUATED SALMONELLA(6,1)
AXCELL BIOTECHNOLOGY(6,1)
BACILLUS SUBTILIS(6,1)
BACTERIA GENOME(6,1)
BACTERIAL EXPRESSION VECTOR(6,1)
BACULOVIRUS PROMOTER(6,1)
BOVINE EPITHELIAL CELL(6,1)
CBPP OUTBREAK(6,1)
CHINESE HAMSTER OVARY CELL(6,1)
CYTOPLASMIC GLPO ACTIVITY(6,1)
CYTOTOXIC ACTIVITY ASSESSMENT(6,1)
DEOXY TERMINATOR(6,1)
DIACETATE ACETYL ESTER(6,1)
DNA FRAGMENT ENCODING(6,1)
EXPERIMENTAL HEMATOLOGY(6,1)
EXTRACELLULAR PATHOGEN(6,1)
FLUORESCENCE MICROGRAPH(6,1)
GENOMIC DNA EXTRACTION(6,1)
GLPO GENE SEQUENCE(6,1)
GLYCEROL FACILITATOR FACTOR(6,1)
GLYCEROL PHOSPHATE KINASE(6,1)
GLYCEROL PHOSPHATE OXIDASE(6,1)
GLYCEROL RESIDUAL UPTAKE(6,1)
GLYCEROPHOSPHATE OXIDASE PROTEIN(6,1)
GROWTH INHIBITION OBSERVATION(6,1)
GTSABC TRANSPORTER(6,1)
HETEROLOGOUS PROMOTER(6,1)
HEXAMETHYLDISILAZANE EVAPORATION(6,1)
IGG PURIFIED FAB FRAGMENT(6,1)
INFECTED ANIMAL TISSUE(6,1)
INFECTED ECANEP CELL(6,1)
INFECTED HOST TISSUE(6,1)
INTRACELLULAR H2O DETECTION(6,1)
INTRACELLULAR ROS(6,1)
MAMMAL VACCINATION(6,1)
MYCOPLASMA GALLISEPTICUM(6,1)
MYCOPLASMA GENITALIUM(6,1)
MYCOPLASMA PRETREATMENT(6,1)
MYCOPLASMA VIABILITY(6,1)
MYCOPLASMAL CULTURE(6,1)
MYCOPLASMAL ENZYME(6,1)
MYCOPLASMAL MEMBRANE(6,1)
MYCOPLASMAL VIRULENCE(6,1)
NASAL EPITHELIAL CELL(6,1)
NOTI CLEAVAGE SITE(6,1)
PARASITIC LIFESTYLE(6,1)
PHAGOCYTE CELL SUGGESTING(6,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(6,1)
PLATINUM SPUTTERED COVERSLIP(6,1)
POLY HISTIDINE TAILED PROTEIN(6,1)
PRETREATED ECANEP CELL(6,1)
PREWARMED INCUBATION(6,1)
RABBIT ANTI CALCITONINE ANTIBODY(6,1)
RABBIT ANTI GLPO SERUM(6,1)
RECOMBINANT BACULOVIRUS(6,1)
RECOMBINANT CARRIER PARASITE(6,1)
RECOMBINANT GLPO(6,1)
SEVERE INFECTIOUS DISEASE(6,1)
SPECIES VIRULENCE(6,1)
STRONG FLUORESCENCE INDUCTION(6,1)
TGATP CODON(6,1)
TRITON IMMUNOBLOT ANALYSIS(6,1)
TRYPAN BLUE EXCLUSION(6,1)
UROGENITAL INFECTION(6,1)
US NTIS PUBLICATION(6,1)
VACCINE PACKAGING(6,1)
MICROBIOLOGY(5,4)
ACTIVE GLYCEROL TRANSPORTER(5,1)
AMERSHAM(5,1)
ANIMAL MYCOPLASMA(5,1)
ANTIBODY ADMINISTRATION(5,1)
ANTIGENIC FRAGMENT(5,1)
BACKSCATTERED ELECTRON MICROGRAPH(5,1)
BVD VIRUS(5,1)
CAPRI STRAIN(5,1)
CHELATION CHROMATOGRAPHY(5,1)
CULTURE SUPERNATANT(5,1)
DETECTABLE CM H2DCFDA OXIDATION(5,1)
DICHLOROFLUORESCEIN FORMATION(5,1)
EMBL DATABASE(5,1)
ESTER CLEAVAGE(5,1)
EUKARYOTIC HOST(5,1)
EUKARYOTIC ORIGIN(5,1)
EXTRACELLULAR H2O PRODUCTION(5,1)
FARCHA LABORATORY(5,1)
GENE ENCODING SEQUENCE(5,1)
GENETIC ANALYZER(5,1)
GLYCEROL KINASE(5,1)
GLYCEROPHOSPHATE OXIDASE ACTIVITY(5,1)
GTS ABC(5,1)
H2O INDUCTION(5,1)
H2O MOLECULE(5,1)
HIGHLY VIRULENT STRAIN(5,1)
HITRAP PROTEIN(5,1)
HOMOLOGOUS ENZYME(5,1)
IMMUNOLOGICALLY IMPORTANT EPITOPE(5,1)
INCOMPLETE ADJUVANT(5,1)
INTRACELLULAR H2O PRESENCE(5,1)
LACTOBACILLUS SPECIES(5,1)
LIPOPROTEIN MEMBRANE(5,1)
LIVE RECOMBINANT CARRIER(5,1)
LRC VIRUS(5,1)
MARKED DISCREPANCY(5,1)
MYCOPLASMA BROTH MEDIUM(5,1)
MYCOPLASMA CULTURE MEDIUM(5,1)
OXIDATIVE STRESS DETECTION(5,1)
PASSIVE VACCINATION(5,1)
PLANT VIRAL VECTOR(5,1)
POLYCLONAL IGG(5,1)
POLYCLONAL SERA(5,1)
PRIMARY ANTIBODY OMISSION(5,1)
PRIMER WALKING(5,1)
PROGRAM MOTIF SCAN(5,1)
REACTION ASSAY ALIQUOT(5,1)
RECOMBINANT CARRIER VIRUS(5,1)
RECOMBINANT VIRUS(5,1)
SECONDARY ELECTRON MICROGRAPH(5,1)
VACCINIA VIRUS(5,1)
MOI(4,6)
AFRICAN(4,3)
LRCS(4,3)
BOOSTER IMMUNIZATION(4,2)
CELL EPITOPE(4,2)
DIRECT VACCINATION(4,2)
GLPO PRESENCE(4,2)
H2O RELEASE(4,2)
HOST ANIMAL(4,2)
INSECT CELL(4,2)
MEM EARLE MEDIUM(4,2)
PATHOGENIC BACTERIUM(4,2)
STABILIZER(4,2)
ALUMINUM HYDROXIDE(4,1)
ANTI LPPC FAB FRAGMENT(4,1)
ANTIBODY GENERATION(4,1)
ANTIGEN IMMUNOBLOT ANALYSIS(4,1)
BA SI MOLECULE(4,1)
BOVINE SERA(4,1)
BOVINE SPECIES(4,1)
CARRIER IMMUNOGEN(4,1)
CHAIN ANTIBODY(4,1)
CHOICE VIRUS(4,1)
COLLOIDAL GOLD(4,1)
COMPOUND DETECTED INTRACELLULAR OXIDATION(4,1)
COVALENTLY BOUND(4,1)
CRYSTAL VIOLET(4,1)
DEGRADATION PRONE POLYPEPTIDE(4,1)
DISMUTASE ACTIVITY(4,1)
DYING CELL(4,1)
ECANEP CELL VIABILITY(4,1)
ENZYME ACTIVITY(4,1)
EUROPEAN STRAIN(4,1)
EXPRESSION INDUCTION(4,1)
FILTERED SUPERNATANT(4,1)
GENBANK(4,1)
GENE EXPRESSION PRODUCT(4,1)
GENE PROBE(4,1)
GLPO GENE FUNCTIONAL ANALYSIS(4,1)
GLPO INTERNAL PRIMER(4,1)
IMMUNODEFICIENT ANIMAL(4,1)
INBRED MOUSE(4,1)
INFLUENZA VIRUS GROUP(4,1)
INTEGRAL MEMBRANE PROTEIN(4,1)
LIVESTOCK MAJOR LOSS(4,1)
LOCAL ABATTOIR(4,1)
MAIN VIRULENCE PATHWAY(4,1)
MAMMALIAN ORIGIN(4,1)
MYCOPLASMA AGAR PLATE(4,1)
MYCOPLASMA INTIMATE CONTACT(4,1)
MYCOPLASMAL GROWTH MEDIUM(4,1)
RELEVANT ANTIGEN(4,1)
RESTRICTION SITE(4,1)
ROOM TEMPEARTURE(4,1)
SEQUENCING KIT(4,1)
SEVERE CATTLE DISEASE(4,1)
STOMACH HIGHLY ACIDIC ENVIRONMENT(4,1)
STOP MYCOPLASMA GROWTH(4,1)
VACCINE DEVELOPMENT(4,1)
VIRULENCE FACTOR ACQUISITION(4,1)
VIRUS VECTOR(4,1)
WHOLE MYCOPLASMA(4,1)
GLYCEROL ADDITION(3,9)
ECORI(3,4)
AXENIC CULTURE(3,2)
CROSSE(3,2)
CYTOSOL(3,2)
DETERGENT PHASE(3,2)
EMBL GEN(3,2)
EVOLUTION(3,2)
EXOGENOUS H2O ADDITION(3,2)
LESS VIRULENT STRAIN(3,2)
MARKER VACCINE(3,2)
NON MYCOPLASMAL BACTERIUM(3,2)
PETHIS(3,2)
POST INFECTION(3,2)
PRIMARY VIRULENCE FACTOR(3,2)
TRIANGLE(3,2)
ACTIVE VACCINATION(3,1)
ANIMAL CELL(3,1)
ANTIOXIDANT AGENT(3,1)
ASCENDING ETHANOL SERIES(3,1)
BOVINE CELL(3,1)
BOVINE HERPES VIRUS GROUP(3,1)
CELL VIABILITY ASSAY(3,1)
CO2 ATMOSPHERE(3,1)
CONFLUENT DENSITY(3,1)
CONTAINMENT SAFETY STANDARD(3,1)
CONTRAST MICROSCOPY(3,1)
CONTROLLED EXPERIMENTAL INFECTION(3,1)
DICHLORODIHYDROFLUORESCEIN(3,1)
ECANEP CELL CULTURE(3,1)
ELISA TEST(3,1)
ENZYME PRODUCTION(3,1)
ESSENTIAL REQUIREMENT(3,1)
FAB FRAGMENT ABSENCE(3,1)
FAB FRAGMENT PREPARATION(3,1)
FULL CELL MORTALITY(3,1)
GENETIC ANALYSIS(3,1)
GENETIC INFORMATION(3,1)
GENOME REDUCTION(3,1)
GLPO LOCATION(3,1)
GROWTH MEDIUM REACHING(3,1)
H2O GLYCEROL INDUCED PRODUCTION(3,1)
HYDROPHILICITY CRITERIA COMBINATION(3,1)
IMMUNE HOST RESPONSE(3,1)
IMMUNOGENIC RESPONSE(3,1)
INDEPENDENT MEASUREMENT(3,1)
INFLAMMATION CELL(3,1)
INTERSTITIAL FLUID(3,1)
LIVESTOCK PRODUCTION(3,1)
MID EXPONENTIAL GROWTH(3,1)
MURAMYL DIPEPTIDE(3,1)
MYCOPLASMA MAIN VIRULENCE FACTOR(3,1)
MYCOPLASMA PENETRANS(3,1)
MYCOPLASMA SPECIFIC TGATRP CODON(3,1)
MYCOPLASMA SYNOVIAE(3,1)
NATURAL IMMUNE RESPONSE(3,1)
NUCLEIC ACID TRANSCRIPTION(3,1)
PARTITIONING PHASE(3,1)
PATHOGENICITY ISLAND(3,1)
PEROXIDE TEST(3,1)
PHAGE DISPLAY(3,1)
PROTEIN ANALYSIS(3,1)
PROTEIN CONCENTRATION(3,1)
PROTEIN IMMUNOLOGICALLY IMPORTANT REGION(3,1)
PSEUDORABIES VIRUS GROUP(3,1)
RECOMBINANT NUCLEIC ACID(3,1)
SCANNING ELECTRON MICROSCOPY PHOTOGRAPH(3,1)
SECONDARY ANTIBODY(3,1)
(US7833536)
GLYCEROPHOSPHATE OXIDASE(100,54)
ANIMAL(100,13)
ANTIBODY PRODUCTION(100,1)
MYCOPLASMA SUBUNIT VACCINE(100,1)
MYCOPLASMA SPECIES GLPO GENE(93,2)
MYCOPLASMAL INFECTION DIAGNOSIS(80,1)
ANIMAL DISCRIMINATION(77,2)
ANIMAL SUFFERING(65,2)
VACCINE PREPARATION(65,2)
MYCOIDE SUBSP(62,61)
VACCINE(58,40)
INTESTINAL EPITHELIUM(57,1)
BOVINE VIRAL DIARRHEA VIRUS(53,2)
CELL VACCINE(53,2)
TRANSMISSIBLE GASTRO ENTERITIS VIRUS(52,2)
VIRAL CARRIER INFECTING(51,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(49,2)
MAREK DISEASE VIRUS(46,1)
TRP PROMOTER(46,1)
INFECTIOUS BRONCHITIS VIRUS(45,2)
PATHOGENIC MYCOPLASMA(45,2)
LEPTOSPIRA SPP(44,4)
PORCINE CIRCO VIRUS(44,2)
HOST GENE EXPRESSION INDUCTION(44,1)
IMPAIRING TISSUE CELL(44,1)
PRO INFLAMMATORY GENE(43,2)
REPRODUCTIVE SYNDROME VIRUS(43,2)
ORNITHOBACTERIUM RHINOTRACHEALE(41,2)
MYCOPLASMA INFECTION(39,10)
IMMUNOGENIC FRAGMENT(38,16)
SALMONELLA CARRIER(37,1)
MICROORGANISM(36,6)
MUMPS PARAMYXOVIRUS(36,2)
MYCOPLASMA SPP(36,1)
BORDETELLA PERTUSSIS(35,2)
SALMONELLA CHOLERAESUIS(35,2)
SALMONELLA ENTERITIDIS(35,2)
FENTON REACTION(35,1)
BABESIA BIGEMINA(34,2)
STAPHYLOCOCCUS UBERIS(34,2)
SALMONELLA TYPHIMURIUM(33,2)
WHOLE CELL MYCOPLASMA PREPARATION(33,2)
MYCOPLASMA SPECIES(32,9)
STAPHYLOCOCCUS AUREUS(32,2)
BABESIA BOVIS(31,2)
BOVINE PARAMYXOVIRUS(31,2)
CHICKEN ANEMIA AGENT(31,2)
BOVINE HERPES VIRUS(30,1)
DUCK PLAGUE VIRUS(29,2)
PORCINE INFLUENZA VIRUS(29,2)
TURKEY HERPES VIRUS(29,2)
CAMPYLOBACTER SPECIES(28,2)
RESPIRATORY EPITHELIUM(28,1)
BRACHYSPIRA HYODYSENTERIAE(27,4)
MEASLES VIRUS(27,2)
TRYPANOSOMA SPECIES(27,2)
KNOWLEDGE(27,1)
MATING FACTOR(27,1)
CHICKEN POXVIRUS(26,2)
EIMERIA SPECIES(26,2)
ANTIGENIC VARIABILITY(26,1)
MYCOPLASMA(25,44)
INFLAMMATION(25,5)
SALMONELLA SPECIES(25,2)
EFFECTOR(25,1)
EGG PROPANE(25,1)
HOST CELL(24,18)
CELL DAMAGE(24,4)
PENETRAN(24,2)
RECOMBINANT CARRIER(23,5)
H2O FORMATION(22,3)
DIAGNOSTIC TEST(22,2)
PULMONIS(22,2)
MOLECULAR(22,1)
HAEMOPHILUS PARASUIS(21,1)
TISSUE DAMAGE CAUSE(21,1)
INFECTION(19,16)
ACTINOBACILLUS PLEUROPNEUMONIAE(19,2)
BABESIA MAJOR(19,2)
BORDETELLA BRONCHISEPTICA(19,2)
ERYSIPELOTHRIX RHUSIOPATHIAE(19,2)
DISEASE(18,5)
ESCHERICHIA(18,5)
BOVINE GROUP(18,4)
HAEMOPHILUS PARAGALLINARUM(18,2)
PASTEURELLA HAEMOLYTICA(18,2)
PASTEURELLA MULTOCIDA(18,2)
CLOSTRIDIUM PERFRINGENS(17,3)
ANAPLASMA CENTRALE(17,2)
ANAPLASMA MARGINALE(17,2)
THEILERIA ANNULATA(17,2)
INFECTION NATURAL WAY(17,1)
ECANEP CELL INFECTION(16,5)
MALL(16,3)
MOBILE(16,2)
NEOSPORA CANINUM(16,2)
PORCINE PARVOVIRUS(16,2)
STAPHYLOCOCCUS HYICUS(16,2)
STREPTOCOCCUS SUIS(16,2)
THEILERIA PARVA(16,2)
TURKEY RHINOTRACHEITIS VIRUS(16,2)
PCR METHOD INTRODUCTION(16,1)
BACTERIA(15,7)
DECOMPLEMENTED MONOSPECIFIC RABBIT SERUM(15,1)
GENETIC RESOURCE DRASTIC ECONOMIZATION(15,1)
INFECTIOUS BURSAL DISEASE VIRUS(15,1)
MYCOPLASMA VACCINE(14,4)
AVIAN REOVIRUS(14,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(14,2)
ROTAVIRUS(14,2)
SHIGELLA(13,2)
YEAST(13,2)
OVER SUBUNIT VACCINE(13,1)
POLYHISTADINE TAILED FUSION PROTEIN(13,1)
POULTRY PATHOGENIC MYCOPLASMA SPECIES(13,1)
ENZYME(12,11)
GLYCEROL METABOLISM(12,4)
NEWCASTLE DISEASE VIRUS(12,2)
BOVINE PATHOGENIC MYCOPLASMA SPECIES(12,1)
EGG PROP SYNDROME VIRUS(12,1)
PIG PATHOGENIC MYCOPLASMA SPECIES(12,1)
SOUTHERN BLOT(11,3)
MYCOPLASMA SPECIES STRAIN(11,2)
CATTLE CBPP INFECTION(11,1)
CONTAGIOUS BOVINE ETIOLOGICAL AGENT(11,1)
ECANEP CELL FLUORESCENCE MICROGRAPH(11,1)
GLYCOLYTIC PATHWAY(11,1)
MUTATED TGGTRP CODON(11,1)
POLYCLONAL MONOSPECIFIC SERUM(11,1)
RABBIT SUBCUTANEOUS IMMUNIZATION(11,1)
BOVINE SERUM(10,4)
RAISING ANTIBODY(10,4)
CRANDELL FELINE KIDNEY CELL(10,1)
CYTOTOXICITY EXPERIMENT KINETICS(10,1)
IMMUNOGENIC MYCOPLASMA PROTEIN(10,1)
KLUWER ACADEMIC PLENUM PUBLISHER(10,1)
RABBIT MONOSPECIFIC SERUM(10,1)
RABBIT PREIMMUNE SERUM(10,1)
RECOMBINANT POLY HISTIDINE EXPRESSION(10,1)
CYTOTOXICITY INDUCTION(9,2)
FLUORESCENCE MICROSCOPY(9,2)
MYCOPLASMAL PROTEIN(9,2)
VIABLE ECANEP CELL(9,2)
ANAWA BIOMEDICAL SERVICE(9,1)
BIOLOGICAL SAFETY LABORATORY FULFILLING(9,1)
BRITISH BIOCELL INTERNATIONAL(9,1)
CAMELID EXPRESSION LIBRARY(9,1)
CBPP ETIOLOGICAL AGENT(9,1)
CELL INJURY MEDIATOR(9,1)
ECANEP CELL INTRACELLULAR OXIDATION(9,1)
EXTRAORDINARY SOCIOECONOMIC IMPORTANCE(9,1)
GLPO GENE EXPRESSION(9,1)
GLYCEROL METABOLIC PATHWAY MODIFICATION(9,1)
GOLD CONJUGATED GOAT ANTI RABBIT(9,1)
HUMAN PATHOGENIC MYCOPLASMA SPECIES(9,1)
IMMUNOPURE FAB PREPARATION KIT(9,1)
MYCOPLASMA MYCOIDES SUBSP(9,1)
MYCOPLASMA PATHOGENICITY(9,1)
STRAIN AFAD INFECTION(9,1)
GLYCEROL PRESENCE(8,8)
PBS BUFFER(8,5)
ANTI GLPO FAB FRAGMENT(8,3)
CACODYLATE BUFFER(8,3)
DNA ENCODING(8,2)
EMBRYONIC CALF(8,2)
EUROPEAN OUTBREAK(8,2)
MYCOPLASMA SUSPENSION(8,2)
POLYCLONAL ANTIBODY(8,2)
AMPHIPHILICITY CRITERION(8,1)
AXCELL BIOTECHNOLOGY(8,1)
CYTOPLASMIC GLPO ACTIVITY(8,1)
CYTOTOXIC ACTIVITY ASSESSMENT(8,1)
GENOMIC DNA EXTRACTION(8,1)
GLYCEROL PHOSPHATE KINASE(8,1)
GLYCEROL PHOSPHATE OXIDASE(8,1)
GTSABC TRANSPORTER(8,1)
IMMUNOGOLD LABELING(8,1)
MAMMAL VACCINATION(8,1)
MYCOPLASMA GALLISEPTICUM(8,1)
MYCOPLASMA GENITALIUM(8,1)
MYCOPLASMA PRETREATMENT(8,1)
MYCOPLASMA VIABILITY(8,1)
MYCOPLASMAL VIRULENCE(8,1)
PHAGOCYTE CELL SUGGESTING(8,1)
PRETREATED ECANEP CELL(8,1)
RABBIT ANTI CALCITONINE ANTIBODY(8,1)
TRITON IMMUNOBLOT ANALYSIS(8,1)
TRYPAN BLUE EXCLUSION(8,1)
ANTIBODY PANEL(7,2)
DIMINISHING HOST CELL DAMAGE(7,2)
GLYCEROL ACTIVE UPTAKE(7,2)
OXIDATIVE STRESS(7,2)
PARAINFLUENZA TYPE(7,2)
SELF REPLICATING ORGANISM(7,2)
TOPPRED SOFTWARE(7,2)
WEAK CYTOTOXIC(7,2)
ATTENUATED MYCOPLASMA(7,1)
ATTENUATED SALMONELLA(7,1)
BACILLUS SUBTILIS(7,1)
BACTERIA GENOME(7,1)
BACTERIAL EXPRESSION VECTOR(7,1)
BACULOVIRUS PROMOTER(7,1)
CBPP OUTBREAK(7,1)
CHINESE HAMSTER OVARY CELL(7,1)
DEOXY TERMINATOR(7,1)
DIACETATE ACETYL ESTER(7,1)
DNA FRAGMENT ENCODING(7,1)
EXPERIMENTAL HEMATOLOGY(7,1)
EXTRACELLULAR PATHOGEN(7,1)
FILAMENTOUS PHAGE(7,1)
GLPO GENE SEQUENCE(7,1)
GLYCEROL FACILITATOR FACTOR(7,1)
GLYCEROL RESIDUAL UPTAKE(7,1)
GLYCEROPHOSPHATE OXIDASE PROTEIN(7,1)
GROWTH INHIBITION OBSERVATION(7,1)
HETEROLOGOUS PROMOTER(7,1)
HEXAMETHYLDISILAZANE EVAPORATION(7,1)
IGG PURIFIED FAB FRAGMENT(7,1)
INFECTED ANIMAL TISSUE(7,1)
INFECTED ECAN(...)";Pharmaceuticals;Open
2005-05-30;"RU2292220           C1 2007-01-27 [RU2292220]
STG: (C1) Patent for invention
AP : 2005RU-0116282 2005-05-30";36212196;RU2292220           C1 2007-01-27 [RU2292220];2005RU-0116282;;GNU VNII VETERINARNOJ VIRUSOLO;GNU VNII VETERINARNOJ VIRUSOLO;;;1;"ZAKUTSKIJ NIKOLAJ IVANOVICH
ZUBAIROV MURTAZALI MUKHTAROVIC
KOTLJAROV VITALIJ MIKHAJLOVICH
KONAKOVA LJUDMILA DMITRIEVNA
DEEV NIKOLAJ IVANOVICH";;;"(RU2292220)
Method for preventing cattle against infectious rhinotracheitis and parainfluenza-3";"(RU2292220)
FIELD: veterinary medicine. ^ SUBSTANCE: method involves introducing associated inactivated vaccine against infectious rhinotracheitis and parainfluenza-3. Abactan-D and Abactan-R are given as prophylaxis at the same time with the first vaccination treatment and then at the second and the third day. ^ EFFECT: enhanced effectiveness of cattle protection against infectious rhinotracheitis and parainfluenza-3.";"(RU2292220)
The Method of the preventive maintenance of infectious rhino-tracheitis and parainfluenza -3 of large livestock, which is consisted in that introduce the inactivated associated vaccine against IRT and PG-3 of large livestock and chemical preparations “Abaktan- D” and “Abaktan- R” simultaneously with the 1st vaccination and further to 2 and 3 days in an effective quantity.";;;"A61K-031/00
A61K-039/155
A61K-039/265
A61P-031/00";;;Pharmaceuticals;Open
2005-02-17;"RU2005104190        A  2006-07-27 [RU2005104190]
STG: (A) Application for invention
AP : 2005RU-0104190 2005-02-17
RU2288007           C2 2006-11-27 [RU2288007]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2005RU-0104190 2005-02-17";36264405;"RU2005104190        A  2006-07-27 [RU2005104190]
RU2288007           C2 2006-11-27 [RU2288007]";2005RU-0104190;;GNU VNII VETERINARNOJ VIRUSOLO;GNU VNII VETERINARNOJ VIRUSOLO;;;1;"ZAKUTSKIJ NIKOLAJ IVANOVICH
ZHESTEREV VIKTOR IVANOVICH
KONAKOVA LJUDMILA DMITRIEVNA
TSYBANOV SODNOM ZHAM JANOVICH
CHERMASHENTSEVA NATAL JA ANATO
DEEV NIKOLAJ IVANOVICH
JURKOV SERGEJ GRIGOR EVICH";;;"(RU2288007)
Method for manufacturing associated inactivated culture vaccine against infectious rhinotracheitis and paragrippe-3 in cattle";"(RU2288007)
FIELD: biotechnology, veterinary virology. ^ SUBSTANCE: the present innovation deals with elaborating epizootically and ecologically safe associated inactivated vaccine that creates tense immunity simultaneously against IRT and PG-3 in cattle. The method deals with cultivating vaccine strains of IRT and PG-3 viruses in a cell culture, sampling virus-containing culture liquid, inactivation of virus and addition of an adjuvant. Moreover, as vaccine strains it is necessary to apply the strain of TC-A/C of IRT virus grown in passage cell culture MDVC, at activity of 7.5-8.0 lg TCD50/cu. cm, and the strain PG/C-2002 of PG-3 virus grown in passage cell culture PC at activity of 7.5-8.0 lg TCD50/cu. cm. On sampling virus-containing culture liquid one should carry out inactivation of virus of every strain with theotropin for about 5-7 d at 36.5-37.5° C, pH being 7.2-7.5. Moreover, one should add theotropin to virus-containing liquid of every strain at final concentration of 0.1%, and then mix inactivated virus-containing liquids of both strains at the ratio of 1:1 and add adjuvant at the quantity of 20% that consists of 6%-aluminum hydroxide and saponin gel. The innovation enables to obtain epizootically and ecologically safe vaccine that creates tense immunity in vaccinated animals, being stable at storage. ^ EFFECT: higher efficiency. ^ 2 ex, 1 tbl";"(RU2288007)
The Method of preparing the associated inactivated cultural vaccine against infectious rhino-tracheitis and parainfluenza -3 of large livestock, that includes the cultivation of the vaccine strains of the viruses of infectious rhino-tracheitis and parainfluenza -3 in the culture of cells, the collection of the virus-containing cultured fluid, the inactivation of virus and the addition of adjuvant, that is characterized by the fact that as the vaccine strains is used the strain TK-A/K of the virus of infectious rhino-tracheitis, grown in the interwoven culture of cells MDVK, with the activity 7,5-8,0 lg TTSD [50]/[cm] of (3), and the strain PG/K-2002 of the virus of parainfluenza -3, grown in the interwoven culture of cells PS, with the activity 7,5-8,0 lg TTSD [50]/[cm] of (3), after the collection of the virus-containing cultured fluid conduct the inactivation of the virus of each strain teotropinom during 5-7 days with to the temperature of 36,5-37,5°S, rN 7,2-7,5, moreover to the virus-containing liquid of each strain is added teopropin in final concentration 0,1%, and then are mixed up inactivated virus-containing liquids of both strains in relationship 1:1 and they add the adjuvant in quantity 20%, which consists of 6%- foot gel of hydroxide of aluminum and saponin.";;;"A61K-039/155
A61K-039/265
A61K-039/295
C12N-007/00";;;Pharmaceuticals;Open
2004-12-29;"RU2004138607        A  2006-06-10 [RU2004138607]
STG: (A) Application for invention
AP : 2004RU-0138607 2004-12-29
RU2279474           C1 2006-07-10 [RU2279474]
STG: (C1) Patent for invention
AP : 2004RU-0138607 2004-12-29";36229025;"RU2004138607        A  2006-06-10 [RU2004138607]
RU2279474           C1 2006-07-10 [RU2279474]";2004RU-0138607;;GNU VNII VETERINARNOJ VIRUSOLOGII I MIKROBIOLOGII;GNU VNII VETERINARNOJ VIRUSOLOGII I MIKROBIOLOGII;;;1;"ZAKUTSKIJ NIKOLAJ IVANOVICH
ZHESTEREV VIKTOR IVANOVICH
TSYBANOV SODNOM ZHAM JANOVICH
BALYSHEV VLADIMIR MIKHAJLOVICH
KONAKOVA LJUDMILA DMITRIEVNA
CHERMASHENTSEVA NATAL JA ANATO
JURKOV SERGEJ GRIGOR EVICH";;;"(RU2279474)
Strain of infection bovine rhinotracheitis (ibr) virus for production of vaccine and diagnostic preparations";"(RU2279474)
FIELD: veterinary virology and biotechnology. ^ SUBSTANCE: invention relates to new virus strain having high antigenic and immunogenic activity useful in preparation of inactivated vaccine against IBR. ^ EFFECT: IBR virus strain of increased antigenic and immunogenic activity. ^ 5 tbl, 3 ex";"(RU2279474)
Strain of the virus of infectious rhino-tracheitis of large livestock, the family Of Herpesviridae, the kind Of Varicello, the subtype Of Herpesvirus of bovis 1, collection VGNKI, “TK-A/K” - DEP, for preparing the vaccine and diagnostic preparations.";;;"A61K-039/265
C12N-007/00
C12R-001/93";;;Pharmaceuticals;Open
"2004-12-22
2005-12-21";"WO2006122586        A1 2006-11-23 [WO2006122586]
STG: (A1) Published application with search report
AP : 2005WO-EP56995 2005-12-21
CA2591624           A1 2006-11-23 [CA2591624]
STG: (A1) Application laid open
AP : 2005CA-2591624 2005-12-21
AU2005331860        A1 2006-11-23 [AU2005331860]
STG: (A1) Open to public inspection
AP : 2005AU-0331860 2005-12-21
MX2007007570        A  2007-07-24 [MX2007007570]
STG: (A) Patent application
AP : 2007MX-PA07570 2005-12-21
IN2702/CHENP/2007   A  2007-09-07 [IN2007CN02702]
STG: (A) Application laid open
AP : 2007IN-CN02702 2007-06-21
KR10-2007-0092290   A  2007-09-12 [KR20070092290]
STG: (A) Published application
AP : 2007KR-7016568 2007-07-19
EP1831248           A1 2007-09-12 [EP1831248]
STG: (A1) Application published with search report
AP : 2005EP-0857856 2005-12-21
CN101087803         A  2007-12-12 [CN101087803]
STG: (A) Published application
AP : 2005CN-80044494 2005-12-21
JP2008523840        A  2008-07-10 [JP2008523840]
STG: (A) Published application
AP : 2007JP-0547497 2005-12-21
ZA200705087         B  2008-08-27 [ZA200705087]
STG: (B)
AP : 2007ZA-0005087 2007-06-13
BRPI0519381         A1 2009-01-20 [BRPI0519381]
STG: (A1) Published application
AP : 2005BR-0019381 2005-12-21
BRPI0519381         A2 2009-01-20 [BR200519381]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2005BR-0019381 2005-12-21
RU2007128047        A  2009-01-27 [RU2007128047]
STG: (A) Application for invention
AP : 2007RU-0128047 2005-12-21
US20100062017       A1 2010-03-11 [US20100062017]
STG: (A1) Application published
AP : 2005US-11722476 2005-12-21
EP1831248           B1 2010-12-15 [EP1831248]
STG: (B1) Patent specification
AP : 2005EP-0857856 2005-12-21
AT491720            T  2011-01-15 [ATE491720]
STG: (T) EP patent valid in AT
AP : 2005AT-0857856T 2005-12-21
DE602005025404      D1 2011-01-27 [DE602005025404]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2005DE-60025404 2005-12-21
RU2415926           C2 2011-04-10 [RU2415926]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2007RU-0128047 2005-12-21
AU2005331860        B2 2011-08-11 [AU2005331860]
STG: (B2) Patent proceeded by OPI
AP : 2005AU-0331860 2005-12-21
CN101087803         B  2012-01-18 [CN101087803B]
STG: (B) Granted patent for invention
AP : 2005CN-80044494 2005-12-21
IN250650            B  2012-01-20 [IN-250650]
STG: (B) Patent
AP : 2007IN-CN02702 2007-06-21
JP4981684           B2 2012-04-27 [JP4981684]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2007JP-0547497 2005-12-21
US8309101           B2 2012-11-13 [US8309101]
STG: (B2) Granted patent as second publication
AP : 2005US-11722476 2005-12-21
FD :  Provisional Appl: US60/639,447 FDD=2004-12-22 [2004US-60639447]
FD : Previous publication: US20100062017 A1 2010-03-11 [US20100062017]";5365592;"WO2006122586        A1 2006-11-23 [WO2006122586]
CA2591624           A1 2006-11-23 [CA2591624]
AU2005331860        A1 2006-11-23 [AU2005331860]
MX2007007570        A  2007-07-24 [MX2007007570]
IN2702/CHENP/2007   A  2007-09-07 [IN2007CN02702]
KR10-2007-0092290   A  2007-09-12 [KR20070092290]
EP1831248           A1 2007-09-12 [EP1831248]
CN101087803         A  2007-12-12 [CN101087803]
JP2008523840        A  2008-07-10 [JP2008523840]
ZA200705087         B  2008-08-27 [ZA200705087]
BRPI0519381         A1 2009-01-20 [BRPI0519381]
BRPI0519381         A2 2009-01-20 [BR200519381]
RU2007128047        A  2009-01-27 [RU2007128047]
US20100062017       A1 2010-03-11 [US20100062017]
EP1831248           B1 2010-12-15 [EP1831248]
AT491720            T  2011-01-15 [ATE491720]
DE602005025404      D1 2011-01-27 [DE602005025404]
RU2415926           C2 2011-04-10 [RU2415926]
AU2005331860        B2 2011-08-11 [AU2005331860]
CN101087803         B  2012-01-18 [CN101087803B]
IN250650            B  2012-01-20 [IN-250650]
JP4981684           B2 2012-04-27 [JP4981684]
US8309101           B2 2012-11-13 [US8309101]";"2004US-60639447
2005US-11722476
2005WO-EP56995";"(EP1831248)
WO2006122586
(US8309101)
WO2006122586
(DE602005025404)
WO2006122586
(JP4981684)
WO2006122586
(RU2415926)
WO2006122586
(CA2591624)
WO2006122586
(MX2007007570)
WO2006122586
(KR20070092290)
WO2006122586
(BR200519381)
WO2006122586
(ATE491720)
WO2006122586
(AU2005331860)
WO2006122586
(CN101087803B)
WO2006122586";"INTERVET INTERNATIONAL
MEDTRONIC INTERVET";INTERVET INTERNATIONAL;"(EP1831248)
NL
(EP1831248)
NL
(US20100062017)
NL
(US8309101)
NL
(WO2006122586)
NL

(CA2591624)
NL

(BRPI0519381)
NL
(IN2007CN02702)
NL";"(EP1831248)
NAME=Intervet International BV Wim de Körverstraat 35 , CITY=5831 AN Boxmeer , COUNTRY=NL 

(EP1831248)
NAME=Intervet International BV Wim de Körverstraat 35 , CITY=5831 AN  Boxmeer , COUNTRY=NL , REG=100780526 

(US20100062017)
NAME=Wim de Korverstraat 35 , CITY=Boxmeer , COUNTRY=NL , ATYP=Non-US Company 

(US8309101)
NAME=Intervet International B.V. , CITY=Boxmeer , COUNTRY=NL , ATYP=Non-US Company 

(WO2006122586)
NAME=INTERVET INTERNATIONAL B.V.  Wim de Körverstraat 35, NL-5831 AN Boxmeer  , COUNTRY=NL 

(JP2008523840)
NAME=Based Intanashiyonaru based Intabetsuto , REG=506196247 

(JP4981684)
NAME=INTERVET INTERNATL BV , REG=506196247 

(CA2591624)
NAME=INTERVET INTERNATIONAL B.V. P.O. Box 31 Wim de Koerverstraat 35 NL-5831 AN , CITY=BOXMEER , COUNTRY=NL 

(KR20070092290)
NAME=INTERVET INTERNATIONAL B.V. , REG=519990598839 

(BRPI0519381)
NAME=INTERVET INTERNATIONAL B V , COUNTRY=NL 

(IN2007CN02702)
NAME=INTERVET INTERNATIONAL B V WIM DE KÖRVERSTRAAT 35, NL-5831 AN BOXMEER (NL)  , COUNTRY=NL 
";1;"LUO YUGANG
VERMEIJ PAUL
JACOBS ANTONIUS ARNOLDUS CHRISTIAAN";"(EP1831248)
US; NL
(EP1831248)
US; NL";"(EP1831248)
NAME=LUO, Yugang 43 Seabreeze Road , CITY=Ocean Pines, MD 21811 , COUNTRY=US 

NAME=VERMEIJ, Paul Lepelstraat 3 , CITY=NL-5845 BK St. Anthonis , COUNTRY=NL 

NAME=JACOBS, Antonius, Arnoldus, Christiaan Ondersteweg 2 , CITY=NL-5995 PS Kessel , COUNTRY=NL 

(EP1831248)
NAME=LUO, Yugang 43 Seabreeze Road Ocean Pines, MD 21811 , COUNTRY=US 

NAME=VERMEIJ, Paul Lepelstraat 3 NL-5845 BK St. Anthonis , COUNTRY=NL 

NAME=JACOBS, Antonius, Arnoldus, Christiaan Ondersteweg 2 NL-5995 PS Kessel , COUNTRY=NL 
";"(EP1831248)
Pasteurella multocida vaccine";"(EP1831248)
The present invention relates to live attenuated bacteria of the species Pasteurella multocida, to live attenuated vaccines comprising such live attenuated bacteria, to the use of such bacteria for the manufacture of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the detection of such bacteria.";"(WO2006122586)
1. Claims 1) Live attenuated Pasteurella multocida bacterium, said bacterium not being capable to express a functional Orf-15 protein.
 2) Live attenuated bacterium according to claim 1, characterized in that said bacterium is not capable to express a functional Orf-15 protein due to a mutation in the Orf-15 gene.
 3) Live attenuated bacterium according to claim 2, characterized in that the mutation comprises an insertion and/or a deletion.
 4) Live attenuated bacterium according to claims 1-3, characterized in that said bacterium carries a heterologous gene encoding one or more antigens selected from the group of viruses and microorganisms pathogenic to humans and/or animals.
 5) Live attenuated bacterium according to claim 4, characterized in that said heterologous gene is inserted in the gene encoding Orf-15.
 6) Live attenuated bacterium according to claim 4 or 5, characterized in that said one or more antigens are selected from the group consisting of Porcine Reproductive Respiratory Syndrome (PRRS) virus, Pseudorabies virus, Porcine Influenza virus, Porcine Parvovirus, Transmissible Gastroenteritis virus, rotavirus, Porcine Circovirus 1 or 2, Escherichia coli, Erysipelothrix rhusiopathiae, Bordetella bronchisepiica, Haemophilus par asuis, Mycoplasma hyopneumoniae and Streptococcus suis.
 7) Live attenuated bacterium according to claim 4 or 5, characterized in that said one or more antigens are selected from the group consisting of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, Pasteurella haemolytica, Staphylococcus aureus, Staphylococcus uberis, Escherichia coli,
 Bovine Respiratory Syncytial Virus, Theileria parva, Theileria annulata, Babesia bovis, Babesia bigemina, Babesia major, Trypanosoma species, Anaplasma marginale, Anaplasma centrale or Neospora caninum.
 8) Live attenuated bacterium according to claim 4 or 5, characterized in that said one or more antigens are selected from the group consisting of Fowlpox virus, Infectious Bronchitis virus,
 Infectious Bursal Disease, Marek's Disease Virus, Chicken Anaemia agent, Avian Reovirus, Mycoplasma gallisepticum, Turkey Rhinotracheitis virus, Haemophilus paragallinarum, Chicken Poxvirus, Avian Encephalomyelitisvirus, Duck Plague virus, Newcastle Disease virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, Ornithobacterium rhinotracheale, Mycoplasma synoviae, Clostridium perfringens, Salmonella species and E. coli.
 9) Live attenuated vaccine for the protection of animals or humans against Pasteurella multocida infection or the pathogenic effects thereof, characterized in that said vaccine comprises a live attenuated bacterium according to claims 1-8 and a pharmaceutically acceptable carrier.
 10) Live attenuated vaccine according to claim 9, characterized in that it comprises an adjuvant.
 11) Live attenuated vaccine according to claim 9 or 10, characterized in that it is in a freeze-dried form.
 12) Live attenuated vaccine according to claim 9-11, characterized in that it additionally comprises one or more antigens selected from the group of viruses and microorganisms pathogenic to humans and/or animals.
 13) Live attenuated bacterium according to claim 1-8 for use in a vaccine.
 14) Use of a live attenuated bacterium according to claim 1-8 for the manufacture of a vaccine for the protection of humans or animals against infection with a Pasteurella multocida bacterium or the pathogenic effects of infection. 15) Method for the preparation of a vaccine according to claims 9-12, characterized in that said method comprises the admixing of a live attenuated bacterium as defined in claims 1-8 and a pharmaceutically acceptable carrier.
 16) Diagnostic test for the detection olPasteurella multocida associated DNA or RNA characterised in that the test comprises a nucleic acid molecule as depicted in SEQ ID NO: 1 or a nucleic acid molecule that is complementary to said nucleic acid sequence, or a fragment thereof having a length of at least 12, preferably at least 15, more preferably at least 18 nucleotides.";"(EP1831248)
It was surprisingly found now, that the Orf-15 gene sequence is unique for Pasteurella multocida, and is not present in other Pasteurellaceae.
The present invention relates to live attenuated bacteria of the species Pasteurella multocida , to live attenuated vaccines comprising such live attenuated bacteria, to the use of such bacteria for the manufacture of such va ccines, to methods for the preparation of such vaccines and to diagnostic tests for the detection of such bacteria.
It is an objective of the present invention to provide a live attenuated Pasteurella multocida strain that fulfills these requirements.
It was surprisingly found now, that a novel, hitherto unknown gene of Pasteurella multocida, further referred to as the Orf-15 gene can be dele ted without impairing the immune reactivity of the strain, while at the same time dramatically decreasing the virulence of the bacterium.";"(EP1831248)
Bacterins are economically attractive, because they are inexpensive to produce.
Contrary to this, vaccination with live attenuated vaccine s gives a good cross -protection, not only against homologous serotypes but also against heterologous serotypes.
Moreover, it was found that live attenuated Pasteurella multocida strains missing the Orf-15 gene provide not only very good protection against their homologous serotype, but also a very good cross-protection against heterologous serotypes.
Pasteurella multocida is known i.a. to cause fowl cholera in poultry, haemorrhagic septicaemia in cattle and atrophic rhinitis in pigs.
Two kinds of disease are known: acute and chronic fowl cholera.
Haemorrhagic septicaemia is an acute disease characterized by a rapid course, edematous swelling in the head-throat-brisket region, swollen and haemorrhagic lymph nodes and the presence of numerous sub serous petechial haemorrhages.";"A61K
A61K-035/74
A61K-039/00
A61K-039/015
A61K-039/09
A61K-039/102
A61K-039/108
A61K-039/12
A61K-039/39
A61P-031/12
C07K
C07K-014/285
C12N
C12N-001/00
C12N-001/20
C12N-001/21
C12N-015/09
C12N-015/31
C12Q
C12Q-001/00
C12Q-001/68";"(EP1831248)
1. Live attenuated Pasteurella multocida bacterium, said bacterium not being capable to express a functional Orf-15 protein.";"(EP1831248)
PASTEURELLA MULTOCIDA VACCINE(100,5)
ATTENUATED BACTERIA(99,11)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(98,2)
HETEROLOGOUS SEROTYPE(88,2)
PASTEURELLA MULTOCIDA UNKNOWN GENE(84,1)
LIVE ATTENUATED BACTERIUM(77,8)
SEROUS PETECHIAL HEMORRHAGE(76,1)
HOMOLOGOUS SEROTYPE(75,3)
LIVE ATTENUATED PASTEURELLA MULTOCIDA(74,2)
BACTERIA VIRULENCE(69,1)
STRAIN IMMUNE REACTIVITY(69,1)
ATTENUATED PASTEURELLA MULTOCIDA(68,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(65,1)
LIVE ATTENUATED VACCINE(62,6)
FOWL CHOLERA(62,4)
BOVINE VIRAL DIARRHEA VIRUS(59,2)
INFECTIOUS BRONCHITIS VIRUS(59,1)
EDEMATOUS SWELLING(58,1)
INFECTIOUS BURSAL DISEASE(55,1)
ORNITHOBACTERIUM RHINOTRACHEALE(53,1)
MAREK DISEASE VIRUS(50,1)
GENE ENCODING ORF(48,1)
HETEROLOGOUS GENE ENCODING(48,1)
MYCOPLASMA GALLISEPTICUM(48,1)
CHICKEN ANEMIA AGENT(41,1)
HEAD THROAT BRISKET REGION(41,1)
HEMORRHAGIC SEPTICEMIA(40,4)
TURKEY INFECTION(39,1)
BABESIA BIGEMINA(38,2)
STAPHYLOCOCCUS UBERIS(38,2)
DUCK PLAGUE VIRUS(38,1)
PORCINE INFLUENZA VIRUS(38,1)
TURKEY HERPES VIRUS(38,1)
PASTEURELLA MULTOCIDA(37,16)
FUNCTIONAL ORF(37,11)
BABESIA BOVIS(35,2)
BOVINE PARAMYXOVIRUS(35,2)
STAPHYLOCOCCUS AUREUS(35,2)
CHICKEN POXVIRUS(35,1)
EIMERIA SPECIES(34,1)
PASTEURELLACEAE(34,1)
SALMONELLA SPECIES(33,1)
ORF(30,38)
PARAINFLUENZA(30,2)
TRYPANOSOMA SPECIES(30,2)
BOVINE HERPES VIRUS(28,2)
VACCINE MANUFACTURE(28,1)
BACTERIA(27,11)
ANIMAL PROTECTION(27,1)
VIRUS GROUP(26,2)
ERYSIPELOTHRIX RHUSIOPATHIAE(26,1)
BORDETELLA BRONCHISEPTICA(25,1)
NUMEROUS SUB PRESENCE(25,1)
CLOSTRIDIUM PERFRINGENS(24,1)
HAEMOPHILUS PARAGALLINARUM(24,1)
HAEMOPHILUS PARASUIS(23,1)
HUMAN PROTECTION(23,1)
MYCOPLASMA SYNOVIAE(23,1)
TRANSMISSIBLE GASTROENTERITIS VIRUS(23,1)
ATROPHIC RHINITIS(22,4)
ESCHERICHIA(22,3)
GENE SEQUENCE(22,3)
PORCINE CIRCOVIRUS(22,1)
PORCINE PARVOVIRUS(22,1)
STREPTOCOCCUS SUIS(22,1)
TURKEY RHINOTRACHEITIS VIRUS(22,1)
BABESIA MAJOR(21,2)
PASTEURELLA MULTOCIDA STRAIN(20,7)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(20,2)
PASTEURELLA HAEMOLYTICA(20,2)
ACUTE DISEASE(20,1)
DELE(20,1)
LYMPH NODE(20,1)
PORCINE REPRODUCTIVE RESPIRATORY SYNDROME(20,1)
RAPID COURSE(20,1)
GENE(19,27)
VACCINATION(19,18)
ANAPLASMA CENTRALE(19,2)
ANAPLASMA MARGINALE(19,2)
THEILERIA ANNULATA(19,2)
AVIAN REOVIRUS(19,1)
PSEUDORABIES VIRUS(19,1)
PASTEURELLA MULTOCIDA INFECTION(18,5)
VACCINE PROTECTION(18,4)
NEOSPORA CANINUM(18,2)
THEILERIA PARVA(18,2)
ROTAVIRUS(18,1)
PROTEIN(17,22)
LURIA BERTANI BROTH(17,9)
POULTRY(17,3)
CHRONICALLY INFECTED BIRD(17,2)
NEWCASTLE DISEASE VIRUS(16,1)
PATHOGENIC EFFECT(16,1)
SOMATIC SEROTYPE(15,4)
TRANSPOSON MUTANT(15,4)
CATTLE(15,3)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(15,2)
FIBRI NOSUPPURATIVE EXUDATE(15,1)
ADJUVANT(14,8)
ADMIXING(14,3)
DISEASE(14,3)
ACUTE FOWL CHOLERA SYMPTOM(14,1)
GENE ENCODING TRANSPOSITION ENZYM(14,1)
AEROSOL VACCINATION(13,3)
RESISTANT COLONY COUPLE(13,1)
VACCINE MORTALITY REISOLATION(13,1)
PIG(12,4)
PASTEURELLA MULTOCIDA ORF(12,2)
EGG DROP SYNDROME VIRUS(12,1)
NALIDIXIC RESISTANT(12,1)
LETHAL HETEROLOGOUS CHALLENGE(11,1)
MILD AIRSAC LESION(11,1)
NUMB ER DELETION(11,1)
PASTEURELLA MULTOCIDA FRESH CULTURE(11,1)
PCR PRIMER(10,3)
CROSS PROTECTION(10,2)
ORF CLONING(10,2)
PASTEURELLA SPECIES(10,2)
TRANSPOSON MEDIATED MUTANT(10,2)
TRANSPOSON MUTAGENESIS(10,2)
ATTENUATION BEHAVIOR(9,2)
DIGESTED PLASMID(9,2)
LIVE VACCINE(9,2)
PASTEURELLA MULTOCIDA DETECTION(9,2)
SOUTHERN BLOT(9,2)
VACCINE CULTURE(9,2)
CONNECTIVE TISSUE PROLIFERATION(9,1)
DIGESTED GENOMIC DNA(9,1)
MUTANT GENOMIC DNA(9,1)
PASTEURELLOSIS OUTBREAK(9,1)
PERIORBITAL SUBCUTANEOUS TISSUE(9,1)
SIZ ED PLASMID(9,1)
LURIA BERTANI PLATE(8,7)
DECREASE DEFINITION(8,4)
TRANSCONJUGANT(8,4)
CAPSULAR ANTIGEN GROUP(8,2)
TRANSPOSON INSERTION(8,2)
CHOICE GENE HETEROLOGOUS(8,1)
COLI THYA GENE(8,1)
DIG DNA LABELING(8,1)
DRY NON PRODUCTIVE COUGH(8,1)
EXUDATIVE CONJUNCTIVITIS(8,1)
GENE ACCORD ING(8,1)
LESION SERIOUSNESS(8,1)
LIGATED PCR(8,1)
LIVE ATTENUATED STRAIN(8,1)
NONHOMOLOGOUS RECOMBINATION(8,1)
NUCLEOTIDE DELETION(8,1)
ORF NONEXPRESSION(8,1)
POST VACCINATION OBSERVATION(8,1)
RESPIRATORY RA TE(8,1)
RESTRICTION ENZYME DIGESTION(8,1)
ROCHE MOLECULAR BIOCHEMICAL(8,1)
RUFFLED FEATHER(8,1)
SA FE VACCINE PREPARATION(8,1)
TISSUE PRO VIDE(8,1)
TRIMMED PCR FRAGMENT(8,1)
VACCINATION VACCINE(8,1)
VACCINE BEHAVIOR(8,1)
WATTLE SWELLING(8,1)
ANIMAL SPECIES(7,2)
CLINICAL SIGN(7,2)
BACTERIN VACCINATED ANIMAL(7,1)
BIRD VACCINATION(7,1)
CODON MUTATION(7,1)
CONTROLLED CONDITION(7,1)
CUMULATIVE MORTALITY COMPARISON(7,1)
MARKER GENE ENCODING(7,1)
NEWCASTLE DISEASE VACCINE(7,1)
NUCLEIC AC ID MOLECULE(7,1)
ORF FUNCTIONALITY(7,1)
ORF TRANSLATION(7,1)
PASTEURELLA MULTOCIDA RNA POLYMERASE(7,1)
PASTEURELLA MULTOCIDA SPECIES(7,1)
POST CHALLENGE OBSERVATION(7,1)
POULTRY PATHOGEN(7,1)
PROMOTER REGI(7,1)
RECOMBINANT CARRIER ADMINISTRATION(7,1)
SILENCING GENE(7,1)
SNOOT TWISTING(7,1)
STRAIN SEROTYPE(7,1)
SUB LETHAL INFECTION(7,1)
TRACHEA SWAB(7,1)
TRANSPOSITION MUTANT(7,1)
TRANSPOSON MUTATION(7,1)
UNIVERSAL ATTENUATION TARGET(7,1)
VACCINATION DOSE(7,1)
VETERINARY MICROBIOLOGY(7,1)
VIRUS SILENCING(7,1)
THYMINE MG ML(6,4)
CODING SEQUENCE(6,3)
IMMUNE RESPONSE(6,2)
RE LIGATION(6,2)
TRIMETHOPRIM MG ML(6,2)
ACUTE SEPTICEMIA(6,1)
ANIMAL PATHOGEN(6,1)
ATTENUATED BEHAVIOR NATURE(6,1)
BACTERIAL GENE HOMOLOGOUS(6,1)
BACTERIAL LAWN(6,1)
BACTERIUM EARLY DETECTION(6,1)
BIRD CHALL(6,1)
CHALLENGE CULTURE(6,1)
CHOICE VACCINE(6,1)
CLASSICAL MUTATION(6,1)
COMBINED VACCINE ADMINISTRATION(6,1)
DISEASE CAUSATIVE AGENT(6,1)
DISEASE SYMPTOM(6,1)
DISRUPTED GENE(6,1)
DNA TRANSCRIPTION(6,1)
DRINKING TOWER(6,1)
EFFICACIOUS ROUTE(6,1)
FA ILURE(6,1)
FOCAL NECROSIS(6,1)
FRESH DILUTED CULTURE(6,1)
GENE DIGESTION(6,1)
GENERAT ING ORF STEP(6,1)
HOMOLOGOUS PROMOTER(6,1)
IMMUNE STIMULATING(6,1)
KILLED VACCINE(6,1)
KLENOW ENZYME(6,1)
LABELING PROBE(6,1)
LOCALIZED INFECTION(6,1)
MANUFACTURER INSTRUCTION(6,1)
MUTANT GENE(6,1)
MUTATED GENE(6,1)
MUTATION RENDERING(6,1)
NATIVE ORF(6,1)
NUCLEOTIDE REPLACEMENT(6,1)
PAINT SPRAYER(6,1)
PCR TEXTBOOK(6,1)
PLASMID INTEG(6,1)
PRIMARY LESION SEVERITY(6,1)
PTT GENE(6,1)
QIAMP KIT(6,1)
RE LATED DISEASE(6,1)
REVERSION RISK(6,1)
STRAIN VIRULENCE(6,1)
TRANSFORMER KIT(6,1)
TRUNCATED ORF(6,1)
VACCINATION EXPERIMENT(6,1)
VIGOROUS SHAKING(6,1)
WILD TYPE STRAIN(6,1)
ANTISENSE RNA(5,3)
PNEUMONIA(5,3)
PCR TEST(5,2)
STABILIZER(5,2)
TRANSFORMANT(5,2)
ALLELE REPLACEMENT(5,1)
ALLELIC EXCHANGE(5,1)
ANTIBODY ABSENCE(5,1)
ANTIBODY DEVELOPMENT(5,1)
ATTRACTIVE(5,1)
BOVINE SERUM(5,1)
CATTLE PATHOGEN GROUP(5,1)
CHALLENGE DOSE(5,1)
CHOICE ORGAN(5,1)
DAY POST CHALLENGE(5,1)
DECREASED VIRULENCE(5,1)
ELEGANT(5,1)
ENCODED ANTIGEN(5,1)
ENDONUCLEASE TREATMENT(5,1)
EXPERIMENTAL(5,1)
EXTENSIVE DNA SEQUENCE HOMOLOGY(5,1)
EYE DROP ADMINISTRATION(5,1)
FISCHER EXACT TEST(5,1)
HUMAN PATHOGEN(5,1)
HYBRIDIZATION REACTION(5,1)
INFECTIOUS DOSE(5,1)
LUNG TISSUE(5,1)
MESSENGER RNA ENCODING(5,1)
MUCOSAL DISCHARGE(5,1)
MUTANT WIT H SELECTION(5,1)
ORF NUCLEIC ACID MOLECULE(5,1)
PASTEURELLA MULTOCIDA ASSOCIATED PROTEIN(5,1)
PATHOGENIC MICROORGANISM(5,1)
POST MORTEM(5,1)
PROTEIN EXPRESSION(5,1)
RAPID AMPLIFICATION(5,1)
TN INSERTION(5,1)
TN MUTANT(5,1)
VIRULENCE DECREASE(5,1)
NALIDIXIC ACID MG ML(4,5)
MRNA(4,4)
DSRNA(4,3)
BACTERIOLOGY(4,2)
BOOSTER(4,2)
SAPONIN(4,2)
AFFECTED LIVER(4,1)
AFFECTED LUNG(4,1)
CO MBINATION(4,1)
CO NSISTING(4,1)
DECREASED EXPRESSION(4,1)
DECREASED FUNCTIONALITY(4,1)
DECREASED VACCINATION COST REASON(4,1)
DETECTION KIT(4,1)
DIAGNOSTIC TOOL(4,1)
DNA MOBILITY(4,1)
DNA MOLECULE(4,1)
DNA REACTION(4,1)
DOSE RANGING(4,1)
ENSE CODE(4,1)
FE D AD LIBITUM(4,1)
FULL VIRULENCE(4,1)
FUNCTIONAL FRAGMENT(4,1)
GENE PRESENCE(4,1)
GRAM NEGATIVE BACTERIA(4,1)
HEART TISSUE(4,1)
HOST STRAIN(4,1)
IMMUNE HOST RESPONSE(4,1)
INSERTION SITE(4,1)
INTERFERING AGENT(4,1)
LABORATORY PRESS(4,1)
LOCALIZED SITE(4,1)
LURIA BERTANI AGAR PLATE(4,1)
MURAMYL DIPEPTIDE(4,1)
MUTAGENIC AGENT(4,1)
MUTATION NATURE(4,1)
NEGATIVE MUTANT(4,1)
OIL EMULSION(4,1)
ORF CONSTRUCTION(4,1)
ORF SELECTION(4,1)
PASTEURELLA MULTOCIDA GROUP(4,1)
PATHOGENICITY(4,1)
RECOMBINANT CARRIER CONSTRUCTION(4,1)
REPLACEMENT INSERTION(4,1)
SELECTIVE PCR REACTION(4,1)
SUSPENSION SYSTEM COLLECT(4,1)
TARGET DNA(4,1)
TISSUE REACTION(4,1)
VETERINARY PRACTICE(4,1)
WHOLE ORF(4,1)
WING JOINT(4,1)
DIAGNOSTIC TEST(3,4)
SIRNA(3,2)
(US20100062017)
PROTEIN(100,21)
LIVE ATTENUATED BACTERIUM(100,15)
BACTERIA(100,13)
FUNCTIONAL ORF(100,11)
DIAGNOSTIC TEST(100,8)
RNA(100,6)
PASTEURELLA MULTOCIDA BACTERIUM(100,5)
PASTEURELLA MULTOCIDA VACCINE(100,5)
PASTEURELLA MULTOCIDA ASSOCIATED DNA(100,2)
LIVE ATTENUATED VACCINE(60,9)
HETEROLOGOUS SEROTYPE(54,2)
PASTEURELLA MULTOCIDA UNKNOWN GENE(51,1)
SPECIES PASTEURELLA MULTOCIDA(46,2)
SEROUS PETECHIAL HEMORRHAGE(46,1)
HOMOLOGOUS SEROTYPE(45,3)
LIVE ATTENUATED PASTEURELLA MULTOCIDA(45,2)
BOVINE VIRAL DIARRHEA VIRUS(43,1)
BACTERIA VIRULENCE(42,1)
STRAIN IMMUNE REACTIVITY(42,1)
ATTENUATED PASTEURELLA MULTOCIDA(41,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(39,1)
FOWL CHOLERA(38,4)
VACCINE PREPARATION(38,3)
INFECTIOUS BRONCHITIS VIRUS(36,1)
BACTERIA DETECTION(35,2)
EDEMATOUS SWELLING(35,1)
ATTENUATED BACTERIA(33,5)
VACCINE MANUFACTURE(33,2)
INFECTIOUS BURSAL DISEASE(33,1)
ORNITHOBACTERIUM RHINOTRACHEALE(33,1)
MAREK DISEASE VIRUS(31,1)
GENE ENCODING ORF(29,1)
HETEROLOGOUS GENE ENCODING(29,1)
MYCOPLASMA GALLISEPTICUM(29,1)
BABESIA BIGEMINA(27,1)
PASTEURELLA MULTOCIDA INFECTION DETECTION(27,1)
STAPHYLOCOCCUS UBERIS(27,1)
HEAD THROAT BRISKET REGION(26,1)
STAPHYLOCOCCUS AUREUS(26,1)
BABESIA BOVIS(25,1)
BOVINE PARAMYXOVIRUS(25,1)
CHICKEN ANEMIA AGENT(25,1)
HEMORRHAGIC SEPTICEMIA(24,4)
DUCK PLAGUE VIRUS(23,1)
PORCINE INFLUENZA VIRUS(23,1)
TURKEY HERPES VIRUS(23,1)
TRYPANOSOMA SPECIES(22,1)
CHICKEN POXVIRUS(21,1)
BOVINE HERPES VIRUS(20,1)
EIMERIA SPECIES(20,1)
PASTEURELLACEAE(20,1)
SALMONELLA SPECIES(20,1)
PASTEURELLA MULTOCIDA(19,14)
ORF(18,38)
DIAGNOSTIC TOOL(18,2)
NUCLEIC ACID MOLECULE(17,10)
VIRUS GROUP(16,2)
ANIMAL PROTECTION(16,1)
BABESIA MAJOR(16,1)
ERYSIPELOTHRIX RHUSIOPATHIAE(16,1)
ESCHERICHIA(15,2)
BORDETELLA BRONCHISEPTICA(15,1)
NUMEROUS SUB PRESENCE(15,1)
ANAPLASMA CENTRALE(14,1)
ANAPLASMA MARGINALE(14,1)
CLOSTRIDIUM PERFRINGENS(14,1)
HAEMOPHILUS PARAGALLINARUM(14,1)
HAEMOPHILUS PARASUIS(14,1)
MYCOPLASMA SYNOVIAE(14,1)
PASTEURELLA HAEMOLYTICA(14,1)
THEILERIA ANNULATA(14,1)
TRANSMISSIBLE GASTROENTERITIS VIRUS(14,1)
PASTEURELLA MULTOCIDA STRAIN(13,8)
ATROPHIC RHINITIS(13,4)
GENE SEQUENCE(13,3)
FRAGMENT(13,2)
NEOSPORA CANINUM(13,1)
PORCINE CIRCOVIRUS(13,1)
PORCINE PARVOVIRUS(13,1)
STREPTOCOCCUS SUIS(13,1)
THEILERIA PARVA(13,1)
TURKEY RHINOTRACHEITIS VIRUS(13,1)
VACCINATION(12,18)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(12,2)
BACTERIN(12,2)
ACUTE DISEASE(12,1)
AVIAN REOVIRUS(12,1)
LYMPH NODE(12,1)
PORCINE REPRODUCTIVE RESPIRATORY SYNDROME(12,1)
PSEUDORABIES VIRUS(12,1)
RAPID COURSE(12,1)
GENE(11,28)
NUCLEOTIDE(11,9)
VACCINE PROTECTION(11,4)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(11,1)
ROTAVIRUS(11,1)
NALIDIXIC ACID(10,14)
POULTRY(10,3)
CHRONICALLY INFECTED BIRD(10,2)
NEWCASTLE DISEASE VIRUS(10,1)
PATHOGENIC EFFECT(10,1)
LB BROTH(9,8)
NUCLEIC ACID SEQUENCE(9,4)
SOMATIC SEROTYPE(9,4)
TRANSPOSON MUTANT(9,4)
CATTLE(9,3)
FIBRI NOSUPPURATIVE EXUDATE(9,1)
AEROSOL VACCINATION(8,3)
DISEASE(8,3)
ACUTE FOWL CHOLERA SYMPTOM(8,1)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(8,1)
MULTOCIDA TN MUTANT LIBRARY(8,1)
PIG(7,4)
PASTEURELLA MULTOCIDA DETECTION(7,3)
PASTEURELLA MULTOCIDA ORF(7,2)
EGG DROP SYNDROME VIRUS(7,1)
GENE ENCODING TRANSPOSITION ENZYME(7,1)
PCR PRIMER(6,3)
CROSS PROTECTION(6,2)
ORF CLONING(6,2)
PASTEURELLA SPECIES(6,2)
TRANSPOSON MEDIATED MUTANT(6,2)
TRANSPOSON MUTAGENESIS(6,2)
CODON(6,1)
CONNECTIVE TISSUE PROLIFERATION(6,1)
DIGESTED GENOMIC DNA(6,1)
LETHAL HETEROLOGOUS CHALLENGE(6,1)
MILD AIRSAC LESION(6,1)
MUTANT GENOMIC DNA(6,1)
PARAINFLUENZA TYPE(6,1)
PASTEURELLOSIS OUTBREAK(6,1)
PERIORBITAL SUBCUTANEOUS TISSUE(6,1)
STRAIN LPS SEROTYPE(6,1)
DECREASE DEFINITION(5,4)
TRANSCONJUGANT(5,4)
ATTENUATION BEHAVIOR(5,2)
CAPSULAR ANTIGEN GROUP(5,2)
DIGESTED PLASMID(5,2)
LIVE VACCINE(5,2)
LPS ANTIGEN(5,2)
PROTEIN EXPRESSION(5,2)
SOUTHERN BLOT(5,2)
TRANSPOSON INSERTION(5,2)
VACCINE CULTURE(5,2)
CHOICE GENE HETEROLOGOUS(5,1)
COLI THYA GENE(5,1)
DIG DNA LABELING(5,1)
DRY NON PRODUCTIVE COUGH(5,1)
EXUDATIVE CONJUNCTIVITIS(5,1)
LESION SERIOUSNESS(5,1)
LIVE ATTENUATED STRAIN(5,1)
NONHOMOLOGOUS RECOMBINATION(5,1)
NUCLEOTIDE DELETION(5,1)
ORF NONEXPRESSION(5,1)
PLASMID INTEGRATION MUTANT(5,1)
POST VACCINATION OBSERVATION(5,1)
RESTRICTION ENZYME DIGESTION(5,1)
ROCHE MOLECULAR BIOCHEMICAL(5,1)
RUFFLED FEATHER(5,1)
TISSUE PRO VIDE(5,1)
TRIMMED PCR FRAGMENT(5,1)
VACCINE BEHAVIOR(5,1)
WATTLE SWELLING(5,1)
THYMINE(4,5)
CLINICAL SIGN(4,2)
FRESH CULTURE(4,2)
ACUTE SEPTICEMIA(4,1)
ANIMAL PATHOGEN(4,1)
ATTENUATED BEHAVIOR NATURE(4,1)
BACTERIA DOSE(4,1)
BACTERIAL GENE HOMOLOGOUS(4,1)
BACTERIAL LAWN(4,1)
BACTERIN VACCINATED ANIMAL(4,1)
BACTERIUM EARLY DETECTION(4,1)
BIOCHEMICAL SCIENCE(4,1)
CHALLENGE CULTURE(4,1)
CHOICE VACCINE(4,1)
CHOLERA TOXIN(4,1)
CLASSICAL MUTATION(4,1)
COMBINED VACCINE ADMINISTRATION(4,1)
CUMULATIVE MORTALITY COMPARISON(4,1)
DISEASE CAUSATIVE AGENT(4,1)
DISEASE SYMPTOM(4,1)
DISRUPTED GENE(4,1)
DNA TRANSCRIPTION(4,1)
DRINKING TOWER(4,1)
EFFICACIOUS ROUTE(4,1)
FOCAL NECROSIS(4,1)
FRESH DILUTED CULTURE(4,1)
GENE DIGESTION(4,1)
HOMOLOGOUS PROMOTER(4,1)
IMMUNE STIMULATING(4,1)
INCOMPLETE ADJUVANT(4,1)
KILLED VACCINE(4,1)
KLENOW ENZYME(4,1)
LABELING PROBE(4,1)
LIGATED PCR(4,1)
LOCALIZED INFECTION(4,1)
MARKER GENE ENCODING(4,1)
MUTANT GENE(4,1)
MUTATED GENE(4,1)
MUTATION RENDERING(4,1)
NALIDIXIC RESISTANT STRAIN(4,1)
NATIVE ORF(4,1)
NEWCASTLE DISEASE VACCINE(4,1)
NUCLEOTIDE REPLACEMENT(4,1)
ORF FUNCTIONALITY(4,1)
ORF TRANSLATION(4,1)
PAINT SPRAYER(4,1)
PASTEURELLA MULTOCIDA RNA POLYMERASE(4,1)
PASTEURELLA MULTOCIDA SPECIES(4,1)
PCR TEXTBOOK(4,1)
POST CHALLENGE OBSERVATION(4,1)
POULTRY PATHOGEN(4,1)
PRIMARY LESION SEVERITY(4,1)
PTT GENE(4,1)
QIAMP KIT(4,1)
RECOMBINANT CARRIER ADMINISTRATION(4,1)
RESISTANT COLONY COUPLE(4,1)
REVERSION RISK(4,1)
SAFE VACCINE PREPARATION(4,1)
SILENCING GENE(4,1)
SNOOT TWISTING(4,1)
STRAIN VIRULENCE(4,1)
SUB LETHAL INFECTION(4,1)
TRACHEA SWAB(4,1)
TRANSFORMER KIT(4,1)
TRANSPOSITION MUTANT(4,1)
TRANSPOSON MUTATION(4,1)
TRUNCATED ORF(4,1)
TURKEY INFECTION(4,1)
UNIVERSAL ATTENUATION TARGET(4,1)
VACCINATION DOSE(4,1)
VACCINATION EXPERIMENT(4,1)
VIGOROUS SHAKING(4,1)
VIRUS SILENCING(4,1)
LB PLATE(3,6)
MRNA(3,4)
ANTISENSE RNA(3,3)
CODING SEQUENCE(3,3)
PNEUMONIA(3,3)
IMMUNE RESPONSE(3,2)
LB AGAR(3,2)
PCR TEST(3,2)
RE LIGATION(3,2)
STABILIZER(3,2)
TRANSFORMANT(3,2)
AD LIBITUM(3,1)
ADJUVANT ACTIVITY(3,1)
ALLELE REPLACEMENT(3,1)
ALLELIC EXCHANGE(3,1)
ANIMAL SPECIES(3,1)
ANTIBODY ABSENCE(3,1)
ANTIBODY DEVELOPMENT(3,1)
ATTRACTIVE(3,1)
BOVINE SERUM(3,1)
CHALLENGE DOSE(3,1)
CHOICE ORGAN(3,1)
COLI HEAT LABILE TOXIN(3,1)
DAY POST CHALLENGE(3,1)
DECREASED VIRULENCE(3,1)
ELEGANT(3,1)
ENCODED ANTIGEN(3,1)
ENDONUCLEASE TREATMENT(3,1)
EXPERIMENTAL(3,1)
EXTENSIVE DNA SEQUENCE HOMOLOGY(3,1)
EYE DROP ADMINISTRATION(3,1)
FISCHER EXACT TEST(3,1)
HUMAN PATHOGEN(3,1)
HYBRIDIZATION REACTION(3,1)
INFECTIOUS DOSE(3,1)
LUNG TISSUE(3,1)
MESSENGER RNA ENCODING(3,1)
MUCOSAL DISCHARGE(3,1)
MUTANT SELECTION(3,1)
NA LIDIXIC ACID(3,1)
NONSENSE CODE(3,1)
ORF NUCLEIC ACID MOLECULE(3,1)
PASTEURELLA MULTOCIDA ASSOCIATED PROTEIN(3,1)
PATHOGENIC MICROORGANISM(3,1)
POST MORTEM(3,1)
RAPID AMPLIFICATION(3,1)
TN INSERTION(3,1)
VIRULENCE DECREASE(3,1)
DSRNA(2,3)
RNAI(2,3)
SIRNA(2,3)
ADMIXING(2,2)
BACTERIOLOGY(2,2)
BOOSTER(2,2)
LESION LEVEL(2,2)
SAPONIN(2,2)
TRIMETHOPRIM(2,2)
AFFECTED LIVER(2,1)
AFFECTED LUNG(2,1)
ALUMINUM PHOSPHATE(2,1)
DECREASED EXPRESSION(2,1)
DECREASED FUNCTIONALITY(2,1)
DECREASED VACCINATION COST REASON(2,1)
DETECTION KIT(2,1)
DNA MOBILITY(2,1)
DNA MOLECULE(2,1)
DNA REACTION(2,1)
DOSE RANGING(2,1)
FULL VIRULENCE(2,1)
FUNCTIONAL FRAGMENT(2,1)
GENE PRESENCE(2,1)
GRAM NEGATIVE BACTERIA(2,1)
HEART TISSUE(2,1)
HOST STRAIN(2,1)
IMMUNE HOST RESPONSE(2,1)
INSERTION SITE(2,1)
INTERFERING AGENT(2,1)
LABORATORY PRESS(2,1)
LOCALIZED SITE(2,1)
MURAMYL DIPEPTIDE(2,1)
MUTAGENIC AGENT(2,1)
MUTATION NATURE(2,1)
NEGATIVE MUTANT(2,1)
OIL EMULSION(2,1)
ORF CONSTRUCTION(2,1)
ORF SELECTION(2,1)
PASTEURELLA MULTOCIDA GROUP(2,1)
PATHOGENICITY(2,1)
RECOMBINANT CARRIER CONSTRUCTION(2,1)
REPLACEMENT INSERTION(2,1)
SELECTIVE PCR REACTION(2,1)
SUSPENSION SYSTEM COLLECT(2,1)
TARGET DNA(2,1)
TISSUE REACTION(2,1)
TN VECTOR CONSTRUCTION(2,1)
VETERINARY PRACTICE(2,1)
WHOLE ORF(2,1)
WING JOINT(2,1)
(US8309101)
ORF(100,39)
GENE(100,29)
PROTEIN(100,21)
BACTERIA(100,12)
FUNCTIONAL ORF(100,10)
TRANSPOSON(100,10)
PASTEURELLA MULTOCIDA VACCINE(100,5)
PASTEURELLA MULTOCIDA BACTERIUM STRAIN(100,1)
HETEROLOGOUS SEROTYPE(81,2)
ATTENUATED BACTERIA(77,8)
PASTEURELLA MULTOCIDA UNKNOWN GENE(77,1)
SPECIES PASTEURELLA MULTOCIDA(69,2)
SEROUS PETECHIAL HEMORRHAGE(69,1)
HOMOLOGOUS SEROTYPE(68,3)
LIVE ATTENUATED PASTEURELLA MULTOCIDA(67,2)
LIVE ATTENUATED BACTERIUM(66,7)
LIVE ATTENUATED VACCINE(64,5)
BACTERIA VIRULENCE(63,1)
STRAIN IMMUNE REACTIVITY(63,1)
ATTENUATED PASTEURELLA MULTOCIDA(62,1)
FOWL CHOLERA(57,4)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(55,2)
EDEMATOUS SWELLING(53,1)
BACTERIA DETECTION(52,2)
VACCINE PREPARATION(52,2)
VACCINE MANUFACTURE(49,2)
PASTEURELLA MULTOCIDA INFECTION DETECTION(41,1)
HEAD THROAT BRISKET REGION(39,1)
HEMORRHAGIC SEPTICEMIA(37,4)
PASTEURELLA MULTOCIDA STRAIN(31,9)
PASTEURELLACEAE(31,1)
PASTEURELLA MULTOCIDA(29,15)
DIAGNOSTIC TOOL(27,2)
ANIMAL PROTECTION(25,1)
NUMEROUS SUB PRESENCE(23,1)
ATROPHIC RHINITIS(20,4)
GENE SEQUENCE(20,3)
BACTERIN(19,2)
ACUTE DISEASE(19,1)
LYMPH NODE(19,1)
RAPID COURSE(19,1)
VACCINATION(18,19)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(18,2)
VACCINE PROTECTION(17,4)
TRANSPOSON MUTANT(16,5)
NALIDIXIC ACID(15,14)
POULTRY(15,3)
CHRONICALLY INFECTED BIRD(15,2)
PATHOGENIC EFFECT(15,1)
LB BROTH(14,8)
SOMATIC SEROTYPE(14,4)
FIBRI NOSUPPURATIVE EXUDATE(14,1)
HETEROLOGOUS GENE(13,5)
CATTLE(13,3)
DISEASE(13,3)
ACUTE FOWL CHOLERA SYMPTOM(13,1)
MULTOCIDA TN MUTANT LIBRARY(13,1)
DIAGNOSTIC TEST(12,7)
AEROSOL VACCINATION(12,3)
PIG(11,4)
PASTEURELLA MULTOCIDA ORF(11,2)
GENE ENCODING TRANSPOSITION ENZYME(11,1)
PASTEURELLA MULTOCIDA DETECTION(10,3)
SOUTHERN BLOT(10,3)
VACCINE CULTURE(10,3)
CODON(10,1)
LETHAL HETEROLOGOUS CHALLENGE(10,1)
MILD AIRSAC LESION(10,1)
STRAIN LPS SEROTYPE(10,1)
PCR PRIMER(9,3)
CROSS PROTECTION(9,2)
ORF CLONING(9,2)
PASTEURELLA SPECIES(9,2)
TRANSPOSON MEDIATED MUTANT(9,2)
TRANSPOSON MUTAGENESIS(9,2)
CONNECTIVE TISSUE PROLIFERATION(9,1)
DIGESTED GENOMIC DNA(9,1)
MUTANT GENOMIC DNA(9,1)
PASTEURELLOSIS OUTBREAK(9,1)
PERIORBITAL SUBCUTANEOUS TISSUE(9,1)
DECREASE DEFINITION(8,4)
TRANSCONJUGANT(8,4)
ATTENUATION BEHAVIOR(8,2)
DIGESTED PLASMID(8,2)
LIVE VACCINE(8,2)
LPS ANTIGEN(8,2)
CHOICE GENE HETEROLOGOUS(8,1)
COLI THYA GENE(8,1)
DIG DNA LABELING(8,1)
DRY NON PRODUCTIVE COUGH(8,1)
EXUDATIVE CONJUNCTIVITIS(8,1)
LESION SERIOUSNESS(8,1)
LIVE ATTENUATED STRAIN(8,1)
NONHOMOLOGOUS RECOMBINATION(8,1)
NUCLEOTIDE DELETION(8,1)
ORF NONEXPRESSION(8,1)
PLASMID INTEGRATION MUTANT(8,1)
POST VACCINATION OBSERVATION(8,1)
RESTRICTION ENZYME DIGESTION(8,1)
ROCHE MOLECULAR BIOCHEMICAL(8,1)
RUFFLED FEATHER(8,1)
TISSUE PRO VIDE(8,1)
TRIMMED PCR FRAGMENT(8,1)
VACCINE BEHAVIOR(8,1)
WATTLE SWELLING(8,1)
CAPSULAR ANTIGEN GROUP(7,2)
CLINICAL SIGN(7,2)
FRESH CULTURE(7,2)
PROTEIN EXPRESSION(7,2)
TRANSPOSON INSERTION(7,2)
BACTERIN VACCINATED ANIMAL(7,1)
CUMULATIVE MORTALITY COMPARISON(7,1)
MARKER GENE ENCODING(7,1)
NALIDIXIC RESISTANT STRAIN(7,1)
NEWCASTLE DISEASE VACCINE(7,1)
ORF FUNCTIONALITY(7,1)
ORF TRANSLATION(7,1)
PASTEURELLA MULTOCIDA RNA POLYMERASE(7,1)
PASTEURELLA MULTOCIDA SPECIES(7,1)
POST CHALLENGE OBSERVATION(7,1)
POULTRY PATHOGEN(7,1)
RECOMBINANT CARRIER ADMINISTRATION(7,1)
RESISTANT COLONY COUPLE(7,1)
SILENCING GENE(7,1)
SNOOT TWISTING(7,1)
SUB LETHAL INFECTION(7,1)
TRACHEA SWAB(7,1)
TRANSPOSITION MUTANT(7,1)
TRANSPOSON MUTATION(7,1)
TURKEY INFECTION(7,1)
UNIVERSAL ATTENUATION TARGET(7,1)
VACCINATION DOSE(7,1)
VIRUS SILENCING(7,1)
THYMINE(6,5)
ACUTE SEPTICEMIA(6,1)
ANIMAL PATHOGEN(6,1)
ATTENUATED BEHAVIOR NATURE(6,1)
BACTERIA DOSE(6,1)
BACTERIAL GENE HOMOLOGOUS(6,1)
BACTERIAL LAWN(6,1)
BACTERIUM EARLY DETECTION(6,1)
BIOCHEMICAL SCIENCE(6,1)
CHALLENGE CULTURE(6,1)
CHOICE VACCINE(6,1)
CHOLERA TOXIN(6,1)
CLASSICAL MUTATION(6,1)
COMBINED VACCINE ADMINISTRATION(6,1)
DISEASE CAUSATIVE AGENT(6,1)
DISEASE SYMPTOM(6,1)
DISRUPTED GENE(6,1)
DNA TRANSCRIPTION(6,1)
DRINKING TOWER(6,1)
EFFICACIOUS ROUTE(6,1)
FOCAL NECROSIS(6,1)
FRESH DILUTED CULTURE(6,1)
GENE DIGESTION(6,1)
HOMOLOGOUS PROMOTER(6,1)
IMMUNE STIMULATING(6,1)
INCOMPLETE ADJUVANT(6,1)
KILLED VACCINE(6,1)
KLENOW ENZYME(6,1)
LABELING PROBE(6,1)
LIGATED PCR(6,1)
LOCALIZED INFECTION(6,1)
MUTANT GENE(6,1)
MUTATED GENE(6,1)
MUTATION RENDERING(6,1)
NATIVE ORF(6,1)
NUCLEOTIDE REPLACEMENT(6,1)
PAINT SPRAYER(6,1)
PCR TEXTBOOK(6,1)
PRIMARY LESION SEVERITY(6,1)
PTT GENE(6,1)
QIAMP KIT(6,1)
REVERSION RISK(6,1)
SAFE VACCINE PREPARATION(6,1)
STRAIN VIRULENCE(6,1)
TRANSFORMER KIT(6,1)
TRUNCATED ORF(6,1)
VACCINATION EXPERIMENT(6,1)
VIGOROUS SHAKING(6,1)
LB PLATE(5,6)
ANTISENSE RNA(5,3)
CODING SEQUENCE(5,3)
PNEUMONIA(5,3)
IMMUNE RESPONSE(5,2)
LB AGAR(5,2)
RE LIGATION(5,2)
AD LIBITUM(5,1)
ADJUVANT ACTIVITY(5,1)
ALLELE REPLACEMENT(5,1)
ALLELIC EXCHANGE(5,1)
ANIMAL SPECIES(5,1)
ANTIBODY ABSENCE(5,1)
ANTIBODY DEVELOPMENT(5,1)
ATTRACTIVE(5,1)
BOVINE SERUM(5,1)
CHALLENGE DOSE(5,1)
CHOICE ORGAN(5,1)
CIDA STRAIN(5,1)
COLI HEAT LABILE TOXIN(5,1)
DAY POST CHALLENGE(5,1)
DECREASED VIRULENCE(5,1)
ELEGANT(5,1)
ENCODED ANTIGEN(5,1)
ENDONUCLEASE TREATMENT(5,1)
EXPERIMENTAL(5,1)
EXTENSIVE DNA SEQUENCE HOMOLOGY(5,1)
EYE DROP ADMINISTRATION(5,1)
FISCHER EXACT TEST(5,1)
HUMAN PATHOGEN(5,1)
HYBRIDIZATION REACTION(5,1)
INFECTIOUS DOSE(5,1)
LUNG TISSUE(5,1)
MESSENGER RNA ENCODING(5,1)
MUCOSAL DISCHARGE(5,1)
MUTANT SELECTION(5,1)
NA LIDIXIC ACID(5,1)
NONSENSE CODE(5,1)
ORF NUCLEIC ACID MOLECULE(5,1)
PASTEURELLA MULTOCIDA ASSOCIATED DNA(5,1)
PASTEURELLA MULTOCIDA ASSOCIATED PROTEIN(5,1)
PATHOGENIC MICROORGANISM(5,1)
POST MORTEM(5,1)
RAPID AMPLIFICATION(5,1)
RESISTANT MUTANT(5,1)
TN INSERTION(5,1)
VIRULENCE DECREASE(5,1)
MRNA(4,4)
DSRNA(4,3)
SIRNA(4,3)
ADMIXING(4,2)
BACTERIOLOGY(4,2)
BOOSTER(4,2)
LESION LEVEL(4,2)
PCR TEST(4,2)
SAPONIN(4,2)
STABILIZER(4,2)
TRANSFORMANT(4,2)
TRIMETHOPRIM(4,2)
AFFECTED LIVER(4,1)
AFFECTED LUNG(4,1)
ALUMINUM PHOSPHATE(4,1)
DECREASED EXPRESSION(4,1)
DECREASED FUNCTIONALITY(4,1)
DECREASED VACCINATION COST REASON(4,1)
DETECTION KIT(4,1)
DNA MOBILITY(4,1)
DNA MOLECULE(4,1)
DNA REACTION(4,1)
DOSE RANGING(4,1)
FULL VIRULENCE(4,1)
FUNCTIONAL FRAGMENT(4,1)
GENE PRESENCE(4,1)
GRAM NEGATIVE BACTERIA(4,1)
HEART TISSUE(4,1)
HOST STRAIN(4,1)
IMMUNE HOST RESPONSE(4,1)
INSERTION SITE(4,1)
INTERFERING AGENT(4,1)
LABORATORY PRESS(4,1)
LOCALIZED SITE(4,1)
MURAMYL DIPEPTIDE(4,1)
MUTAGENIC AGENT(4,1)
MUTATION NATURE(4,1)
NEGATIVE MUTANT(4,1)
OIL EMULSION(4,1)
ORF CONSTRUCTION(4,1)
ORF SELECTION(4,1)
PASTEURELLA MULTOCIDA GROUP(4,1)
PATHOGENICITY(4,1)
RECOMBINANT CARRIER CONSTRUCTION(4,1)
REPLACEMENT INSERTION(4,1)
SELECTIVE PCR REACTION(4,1)
SUSPENSION SYSTEM COLLECT(4,1)
TARGET DNA(4,1)
TISSUE REACTION(4,1)
TN VECTOR CONSTRUCTION(4,1)
VETERINARY PRACTICE(4,1)
WHOLE ORF(4,1)
WING JOINT(4,1)
NUCLEIC ACID SEQUENCE(3,3)
RNAI(3,3)
ADMINISTRATION MODE(3,1)
AEROSOL GROUP(3,1)
AIR CIRCULATION(3,1)
ALUMINUM HYDROXIDE(3,1)
AMPICILLIN(3,1)
ANOREXIA(3,1)
APPROACH APPLICABILITY(3,1)
AVIRULENT(3,1)
BACTERIAL GENOME(3,1)
BASE ANALOG(3,1)
BAYOLF(3,1)
(WO2006122586)
PROTEIN(100,22)
BACTERIA(100,13)
ATTENUATED BACTERIA(100,12)
FUNCTIONAL ORF(100,11)
DIAGNOSTIC TEST(100,7)
RNA(100,6)
DNA(100,5)
ATTENUATED PASTEURELLA MULTOCIDA BACTERIUM(100,2)
DETECTION OLPASTEURELLA MULTOCIDA(100,1)
LIVE ATTENUATED BACTERIUM(86,10)
LIVE ATTENUATED VACCINE(81,8)
HETEROLOGOUS SEROTYPE(79,2)
PASTEURELLA MULTOCIDA UNKNOWN GENE(75,1)
SEROUS PETECHIAL HEMORRHAGE(68,1)
HOMOLOGOUS SEROTYPE(67,3)
LIVE ATTENUATED PASTEURELLA MULTOCIDA(66,2)
BACTERIA VIRULENCE(62,1)
ATTENUATED PASTEURELLA MULTOCIDA(61,1)
HAEMOPHILUS PAR ASUIS(60,1)
STRAIN IMMUNE REACTIVITY(60,1)
FOWL CHOLERA(56,4)
VA CCINE MANUFACTURE(54,1)
BOVINE VIRAL DIARRHEA VIRUS(53,2)
SPECIES PASTEURELLA MULTOCIDA(53,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(48,2)
ORNITHOBACTERIUM RHINOTRACHEALE(48,1)
VACCINE PREPARATION(47,2)
BORDETELLA BRONCHISEPIICA(45,1)
INFECTIOUS BRONCHITIS VIRUS(44,2)
GENE ENCODING ORF(43,1)
HETEROLOGOUS GENE ENCODING(43,1)
INFECTIOUS BURSAL DISEASE(41,2)
BACTERIA DETECTION(40,1)
PASTEURELLA MULTOCIDA INFECTION DETECTION(40,1)
MAREK DISEASE VIRUS(38,2)
HEAD THROAT BRISKET REGION(38,1)
HEMORRHAGIC SEPTICEMIA(36,4)
MYCOPLASMA GALLISEPTICUM(36,2)
BABESIA BIGEMINA(34,2)
STAPHYLOCOCCUS UBERIS(34,2)
PORCINE INFLUENZA VIRUS(34,1)
STAPHYLOCOCCUS AUREUS(32,2)
BABESIA BOVIS(31,2)
BOVINE PARAMYXOVIRUS(31,2)
CHICKEN ANEMIA AGENT(31,2)
CHICKEN POXVIRUS(31,2)
PASTEURELLACEAE(30,1)
PASTEURELLA MULTOCIDA(29,12)
DUCK PLAGUE VIRUS(29,2)
TURKEY HERPES VIRUS(29,2)
TRYPANOSOMA SPECIES(27,2)
ORF(26,38)
NUCLEIC ACID MOLECULE(25,9)
EIMERIA SPECIES(25,2)
SALMONELLA SPECIES(25,2)
ANIMAL PROTECTION(24,1)
VIRUS GROUP(23,2)
D IAGNOSTIC TOOL(23,1)
ERYSIPELOTHRIX RHUSIOPATHIAE(23,1)
NUMEROUS SUB PRESENCE(22,1)
VACCINE MANUFACTURE(21,2)
HAEMOPHILUS PARAGALLINARUM(21,1)
FRAGMENT(20,2)
TRANSMISSIBLE GASTROENTERITIS VIRUS(20,1)
ATROPHIC RHINITIS(19,4)
ESCHERICHIA(19,3)
GENE SEQUENCE(19,3)
BABESIA MAJOR(19,2)
PORCINE CIRCOVIRUS(19,1)
PORCINE PARVOVIRUS(19,1)
STREPTOCOCCUS SUIS(19,1)
THEILERIA PARVA(19,1)
VACCINATION(18,20)
PASTEURELLA MULTOCIDA STRAIN(18,7)
ATTENUATED PASTEURELLA MULTOCIDA VACCINE(18,2)
BACTERIN(18,2)
CLOSTRIDIUM PERFRINGENS(18,2)
PASTEURELLA HAEMOLYTICA(18,2)
ACUTE DISEASE(18,1)
DELE(18,1)
LYMPH NODE(18,1)
PORCINE REPRODUCTIVE RESPIRATORY SYNDROME(18,1)
RAPID COURSE(18,1)
GENE(17,28)
NUCLEOTIDE(17,9)
ANAPLASMA CENTRALE(17,2)
ANAPLASMA MARGINALE(17,2)
HUMAN PROTECTION(17,2)
MYCOPLASMA SYNOVIAE(17,2)
THEILERIA ANNULATA(17,2)
PSEUDORABIES VIRUS(17,1)
VACCINE PROTECTION(16,4)
NEOSPORA CANINUM(16,2)
TURKEY RHINOTRACHEITIS VIRUS(16,2)
ROTAVIRUS(16,1)
TRANSPOSON MUTANT(15,5)
NUCLEIC ACID SEQUENCE(15,3)
POULTRY(15,3)
CHRONICALLY INFECTED BIRD(15,2)
AVIAN REOVIRUS(14,2)
CLASSICAL MUTATION TECHN IQUE(14,1)
PATHOGENIC EFFECT(14,1)
ADJUVANT(13,8)
LB BROTH(13,8)
SOMATIC SEROTYPE(13,4)
ADMIXING(13,3)
CATTLE(13,3)
DISEASE(13,3)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(13,2)
FIBRI NOSUPPURATIVE EXUDATE(13,1)
NEWCASTLE DISEASE VIRUS(12,2)
ACUTE FOWL CHOLERA SYMPTOM(12,1)
GENE ENCODING TRANSPOSITION ENZYM(12,1)
MULTOCIDA TN MUTANT LIBRARY(12,1)
PASTEURELLA MULTOC IDA(12,1)
PASTEURELLA MULTODDA VACCINE(12,1)
AEROSOL VACCINATION(11,3)
PIG(11,3)
PASTEURELLA MULTOCIDA ORF(11,2)
VACCINE BEHAVIOR(11,1)
SOUTHERN BLOT(10,3)
LOCA LIZED INFECTION(10,1)
PASTEURELLA MULTODDA STRAIN(10,1)
PCR PRIMER(9,3)
CROSS PROTECTION(9,2)
EGG DROP SYNDROME VIRUS(9,2)
ORF CLONING(9,2)
POULTRY PATHOGEN(9,2)
TRANSPOSON MEDIATED MUTANT(9,2)
BAC TERIAL GENOME(9,1)
BOVINE HERPES VIRUS CO NSISTING(9,1)
EFFICAC IOUS ROUTE(9,1)
LETHAL HETEROLOGOUS CHALLENGE(9,1)
MILD AIRSAC LESION(9,1)
NUMB ER DELETION(9,1)
SPECI FIE STRAIN(9,1)
ANTISENSE RNA(8,3)
ATTENUATION BEHAVIOR(8,2)
DIGESTED PLASMID(8,2)
LIVE VACCINE(8,2)
PASTEURELLA MULTOCIDA DETECTION(8,2)
PASTEURELLA SPECIES(8,2)
VACCINE CULTURE(8,2)
CONNECTIVE TISSUE PROLIFERATION(8,1)
DIGESTED GENOMIC DNA(8,1)
MUTANT GENOMIC DNA(8,1)
OMITHOBACTERIUM RHINOTRACHEALE(8,1)
PASTEURELLOSIS OUTBREAK(8,1)
PASTEURETTA MULTOCIDA DETECTION(8,1)
POST VACCINATION OBSERVATIO(8,1)
SIZ ED PLASMID(8,1)
DECREASE DEFINITION(7,4)
TRANSCONJUGANT(7,4)
CAPSULAR ANTIGEN GROUP(7,2)
TRANSPOSON INSERTION(7,2)
CHOICE GENE HETEROLOGOUS(7,1)
COLI THYA GENE(7,1)
DIG DNA LABELING(7,1)
EXUDATIVE CONJUNCTIVITIS(7,1)
HEART TISSUE WOU ID(7,1)
LESION SERIOUSNESS(7,1)
LIVE ATTENUATED STRAIN(7,1)
NUCLEOTIDE DELETION(7,1)
PATHOGENIC MICROORGANISM(7,1)
QUICK AMPLIFI CATION(7,1)
RESTRICTION ENZYME DIGESTION(7,1)
ROCHE MOLECULAR BIOCHEMICAL(7,1)
RUFFLED FEATHER(7,1)
SA FE VACCINE PREPARATION(7,1)
TISSUE PRO VIDE(7,1)
TRIMMED PCR FRAGMENT(7,1)
WATTLE SWELLING(7,1)
ANIMAL SPECIES(6,2)
CLINICAL SIGN(6,2)
FRESH CULTURE(6,2)
PARAINFLUENZA TYPE(6,2)
BACTERIN VACCINATED ANIMAL(6,1)
CODON MUTATION(6,1)
CUMULATIVE MORTALITY COMPARISON(6,1)
FOWLPOXVIRUS CO NSISTING(6,1)
MARKER GENE ENCODING(6,1)
NALIDIXIC RESISTANT STRAIN(6,1)
NEWCASTLE DISEASE VACCINE(6,1)
NUCLEIC AC ID MOLECULE(6,1)
ORF FUNCTIONALITY(6,1)
ORF TRANSLATION(6,1)
PASTEURELLA MULTOCIDA RNA POLYMERASE(6,1)
PASTEURELLA MULTOCIDA SPECIES(6,1)
POST CHALLENGE OBSERVATION(6,1)
PROMOTER REGI(6,1)
RECOMBINANT CARRIER ADMINISTRATION(6,1)
RESISTANT COLONY COUPLE(6,1)
SILENCING GENE(6,1)
SNOOT TWISTING(6,1)
STRAIN SEROTYPE(6,1)
TNIO TRANSPOSON(6,1)
TRACHEA SWAB(6,1)
TRANSPOSITION MUTANT(6,1)
TRANSPOSON MUTAGENESIS(6,1)
TRANSPOSON MUTATION(6,1)
TURKEY INFECTION(6,1)
UNIVERSAL ATTENUATION TARGET(6,1)
VACCINATION D(...)";"Biotechnology
Pharmaceuticals";Open
2004-12-17;"UA7439              U  2005-06-15 [UA---7439U]
STG: (U) Declarative / pat. spec. for utility model
AP : 2004UA-U210400 2004-12-17";38542628;UA7439              U  2005-06-15 [UA---7439U];2004UA-U210400;;INSTITUTE EXPRM & CLINICAL VETERINA;INSTITUTE EXPRM & CLINICAL VETERINA;;;1;STEHNII BORYS TYMOFIIOVYCH;;;"(UA---7439U)
EPIZOOTIC STRAIN No. 12 PASTEURELLA MULTOCIDA, SEROLOGIC VARIANT A FOR PREPARING EMULSION INACTIVATED VACCINE AGAINST ENDOGENOUS PASTEURELLOSIS OF CALVES AND PIGLETS";"(UA---7439U)
Epizootic strain No. 12 Pasteurella Multocida, serologic variant A has been proposed for preparing the emulsion inactivated vaccine against endogenous pasteurellosis of the calves and the piglets.";;;;A61K-039/00;;;Pharmaceuticals;Open
2004-12-17;"UA7437              U  2005-06-15 [UA---7437U]
STG: (U) Declarative / pat. spec. for utility model
AP : 2004UA-U210398 2004-12-17";38542643;UA7437              U  2005-06-15 [UA---7437U];2004UA-U210398;;INSTITUTE EXPRM & CLINICAL VETERINA;INSTITUTE EXPRM & CLINICAL VETERINA;;;1;STEHNII BORYS TYMOFIIOVYCH;;;"(UA---7437U)
EPIZOOTIC STRAIN No. 3 PASTEURELLA MULTOCIDA, SEROLOGIC VARIANT D FOR PREPARING EMULSION INACTIVATED VACCINE AGAINST ENDOGENOUS PASTEURELLOSIS OF CALVES AND PIGLETS";"(UA---7437U)
Epizootic strain No. 3 Pasteurella Multocida, serologic variant D has been proposed for preparing the emulsion inactivated vaccine against endogenous pasteurellosis of the calves and the piglets.";;;;A61K-039/102;;;Pharmaceuticals;Open
2004-08-16;"UA6072              U  2005-04-15 [UA---6072U]
STG: (U) Declarative / pat. spec. for utility model
AP : 2004UA-U806878 2004-08-16";38537878;UA6072              U  2005-04-15 [UA---6072U];2004UA-U806878;;INSTITUTE EXPRM & CLINICAL VETERINA;INSTITUTE EXPRM & CLINICAL VETERINA;;;1;"STEHNII BORYS TYMOFIIOVYCH
STETSENKO VOLODYMYR IVANOVYCH
BABKIN MYKHAILO VALERIIOVYCH
KUCHERIAVENKO LIUDMYLA ILLIVNA
KUCHERIAVENKO ROMAN OLEKSIIOVY";;;"(UA---6072U)
Inactivated vaccine against viral diarrhea of the cattle";"(UA---6072U)
The inactivated vaccine against viral diarrhea of the cattle contains the productive strain of the virus VK-1M, the silicon emulsion KE 10-01 as an adjuvant, and formalin as an inactivating agent.";;;;A61K-039/00;;;Pharmaceuticals;Open
"2004-07-09
2005-07-11";"GB0415425           D0 2004-08-11 [GB200415425]
STG: (D0) Patent application filed
AP : 2004GB-0015425 2004-07-09
WO2006005943        A1 2006-01-19 [WO200605943]
STG: (A1) Published application with search report
AP : 2005WO-GB02732 2005-07-11
EP1766008           A1 2007-03-28 [EP1766008]
STG: (A1) Application published with search report
AP : 2005EP-0759229 2005-07-11
US20080226661       A1 2008-09-18 [US20080226661]
STG: (A1) Application published
AP : 2005US-11571855 2005-07-11";14883152;"GB0415425           D0 2004-08-11 [GB200415425]
WO2006005943        A1 2006-01-19 [WO200605943]
EP1766008           A1 2007-03-28 [EP1766008]
US20080226661       A1 2008-09-18 [US20080226661]";"2004GB-0015425
2004GB-0015428
2005WO-GB02732";"(EP1766008)
WO2006005943
(US20080226661)
WO2006005943";MOREDUN RESEARCH INSTITUTE;MOREDUN RESEARCH INSTITUTE;"(EP1766008)
GB
(WO200605943)
GB";"(EP1766008)
NAME=Moredun Research Institute Pentlands Science Park,  Bush Loan , CITY=Penicuik, Midlothian EH26 0PZ , COUNTRY=GB 

(WO200605943)
NAME=MOREDUN RESEARCH INSTITUTE  Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ  , COUNTRY=GB 
";1;"MARCH JOHN BERNARD
CLARK JASON";"(EP1766008)
GB; US";"(EP1766008)
NAME=MARCH, John, Bernard Moredun Research Institute Pentlands Science Park , CITY=Bush Loan Midlothian EH26 0PZ , COUNTRY=GB 

NAME=CLARK, Jason 17/6 Prestonfield Avenue , CITY=Edinburgh EH16 5EG , COUNTRY=US 
";"(EP1766008)
Phage screening assay";"(EP1766008)
The present invention relates to a method for identifying an agent for potential use in a vaccine. The present invention also provides agents identified by this method for use in a vaccine. The present further describes peptides of the pathogen Mycoplasma for use as a vaccine to treat or present diseases caused by Mycoplasma species, such as, Contagious bovine pleuropneumonia (CBPP).";"(WO200605943)
CLAIMS
1. A method for identifying a nucleic acid sequence or polypeptide for potential use in a vaccine, said method comprising: a) providing a genetically modified phage comprising nucleic acid from a disease causing agent or diseased cell; b) expressing a polypeptide(s) encoded by said nucleic acid sequence; c) contacting said expressed polypeptide(s) with antiserum from an animal which has previously been infected with said disease causing agent and/or has said diseased cell(s); and d) identifying said polypeptide(s) which specifically reacts with said antiserum.
2. The method according to claim 1 wherein the phage has been modified so as to be capable of expressing the polypeptide(s) in a cell to be infected by said phage and/or to express the polypeptide(s) on the surface of the phage particle, by the technique known as phage display.
3. The method according to either of claims 1 or 2 wherein the polypeptide(s) is expressed in a host cell transfected with said phage.
4. The method according to claim 3 wherein the host cell is Escherichia coli.
5. The method according to any preceding claim wherein the phage to be modified by introduction of said nucleic acid from a disease causing agent or diseased cells is λ-gtl 1 or λZAP express.
6. The method according to any preceding claim wherein the antiserum has been obtained from a mammal such as human, cow, sheep, pig, goat, rabbit, mouse or rat.
7. The method according to any one of claims 1 - 5 wherein the antiserum has been obtained from a bird, such as a chicken, duck or turkey or other farmed bird, or a fish, such as salmon, sea bass, trout or other farmed fish.
8. The method according to any preceding claim wherein the antiserum is brought into contact with said expressed polypeptides by first immobilising the phage to a substrate, such as nitrocellulase and lysing, if appropriate, the phage, in order to allow the polypeptide(s) to be exposed such that they are capable of coming into contact with said antiserum.
9. The method according to any preceding claim wherein polypeptides which specifically react with antibodies present in the antiserum are detected by Western blotting or immunoassay.
10. The method according to any preceding claim wherein the phage encoding the identified polypeptide is isolated and the polypeptide encoding nucleic acid sequenced in order to ascertain the identity of the polypeptide and/or nucleic acid.
11. Use of a polypeptide(s) or phage encoding said polypeptide(s) identified by the method according to any preceding claim for the manufacture of a vaccine for prophylactically or therapeutically vaccinating an animal.
12. Use according to claim 11 wherein the phage comprises appropriate transcription/translation regulators for controlling expressing of said polypeptide in a eukaryotic cell.
13. A vaccine formulation comprising a polypeptide(s) or phage encoding said polypeptide(s) identified by the method according to any preceding claim.
14. A modified phage expressing peptides of the pathogen Mycoplasma, e.g., Mycoplasma mycoides subsp. mycoides small colony type (MmmSC) for use as a vaccine to treat or prevent Contagious bovine pleuropneumonia (CBPP).
15. A modified phage(s) capable of expressing a polypeptide encoded by nucleotide sequence A8, or functional fragment, homologue or derivative thereof for use in a vaccine for the prevention of disease caused by the pathogen MmmSC, wherein A8 comprises the nucleotide sequence as shown in Figure 6c.
16. A modified phage(s) capable of expressing a polypeptide encoded by a nucleotide sequence Bl, or functional fragment, homologue or derivative thereof for use in a vaccine for the prevention of disease caused by the pathogen MmmSC, wherein Bl is the nucleotide sequence as shown in Figure 7a.
17. A modified phage(s) capable of expressing a polypeptide or functional fragment, homologue or derivative thereof for use in a vaccine for the prevention of disease caused by the pathogen MmmSC, wherein said polypeptide is at least one prolipoprotein as shown in Figures 6(d) or 7(d) or functional fragment, homologue or derivative thereof.
18. The modified phage according to any one of claims 14 — 17 identified by the method according to any one of claims 1 - 10.
19. Use of the polypeptides encoded by nucleotide sequences A8 and/or Bl and/or lipoproteins as shown in Figure 6d and/or 7d for the manufacture of vaccines for the prevention or treatment of Contagious bovine pleuropneumonia (CBPP) caused by the pathogen Mycoplasma mycoides subsp. mycoides small colony type (MmmSC).
20. A method of prophylactically treating CBPP using a polypeptide, prolipoprotein, lipoprotein and/or nucleic acid encoding a polypeptide, prolipoprotein or lipoprotein as shown in Figures 6d and/or 7d or functional fragment, homologue or derivative thereof, the method comprising administering to an animal an effective amount of said polypeptide, prolipoprotein or lipoprotein and/or nucleic acid encoding a polypeptide, prolipoprotein or lipoprotein such that a suitable immunogenic response to said polypeptide, prolipoprotein or lipoprotein is raised in said animal.";"(US20080226661)
It is amongst the objects of the present invention to obviate and/or mitigate at least one of the aforementioned disadvantages.
The present invention also provides agents identified by this method for use in a vaccine.
The present invention relates to a method for identifying an agent for potential use in a vaccine.
The present invention also provides agents identified by this method for use in a vaccine.
The present invention relates to a method for identifying an agent for potential use in a vaccine.";"(US20080226661)
Although it has been suggested that current live vaccines can be made considerably more stable and efficacious by following modifications to culture media and reconstitution procedures, it is apparent that a stable inexpensive and efficacious CBPP vaccine would offer many advantages, particularly if it offered a defined and recognisable antigenic profile, since this would allow the opportunity to differentiate between vaccinated and infected cattle, and would therefore be useful for control in Europe should the need arise.
Preferably, double stranded DNA phage is used, as such phage have the additional advantages of stability under high ambient conditions, ease and cheapness of production, together with providing a highly immunological signal (against the phage coat) which provides an easily assayed marker with which to check for vaccination.
ISCOM is an efficient mucosal delivery system for Mycoplasma mycoides subsp. mycoides (MmmSC) antigens inducing high mucosal and systemic antibody responses.
It has been suggested that C57BL/6 mice are resistant to infection with the human pathogen Mycoplasma pneumoniae because of an innate immunity associated with alveolar macrophages and humoral immunity (Hickman-Davis et al., 1997).
A major problem in designing an effective CBPP vaccine is the lack of understanding of the basic mechanism of immunity in cattle, although the apparent lack of correlation between antibody response and protection suggests that protection may be cell mediated, and the poor results with inactivated vaccines suggests that conformational epitopes may be important for protective efficacy.
One such exemplary pathogen is Mycoplasma mycoides subsp. mycoides small colony type (MmmSC), the causative agent of contagious bovine pleuropneumonia (CBPP), an economically important disease of cattle currently affecting much of Africa and parts of southern Europe.";"A61K-031/7052
A61K-035/66
A61K-038/02
A61K-038/16
A61K-039/00
A61K-039/02
A61P-031/04
C07K-014/30
C12N-007/00
C12N-015/10
C12N-015/63
C12Q-001/68
C12Q-001/70";"(US20080226661)
1. A method for identifying a nucleic acid sequence or polypeptide for potential use in a vaccine, said method comprising: a) providing a genetically modified phage comprising nucleic acid from a disease causing agent or diseased cell; b) expressing a polypeptide(s) encoded by said nucleic acid sequence; c) contacting said expressed polypeptide(s) with antiserum from an animal which has previously been infected with said disease causing agent and/or has said diseased cell(s); and d) identifying said polypeptide(s) which specifically reacts with said antiserum.
14. A modified phage expressing peptides of the pathogen Mycoplasma, e.g., Mycoplasma mycoides subsp. mycoides small colony type (MmmSC) for use as a vaccine to treat or prevent Contagious bovine pleuropneumonia (CBPP).
20. A method of prophylactically treating CBPP using a polypeptide, prolipoprotein, lipoprotein and/or nucleic acid encoding a polypeptide, prolipoprotein or lipoprotein as shown in FIGS. 6d and/or 7d or functional fragment, homologue or derivative thereof, the method comprising administering to an animal an effective amount of said polypeptide, prolipoprotein or lipoprotein and/or nucleic acid encoding a polypeptide, prolipoprotein or lipoprotein such that a suitable immunogenic response to said polypeptide, prolipoprotein or lipoprotein is raised in said animal.";"(US20080226661)
VACCINE(100,30)
CONTAGIOUS BOVINE PLEUROPNEUMONIA(100,17)
MYCOPLASMA MYCOIDES SUBSP(100,12)
HOMOLOG(100,11)
FUNCTIONAL FRAGMENT(100,10)
MODIFIED PHAGE(100,9)
NUCLEIC ACID SEQUENCE(100,7)
PROLIPOPROTEIN(100,7)
LIPOPROTEIN(100,5)
MYCOIDE SMALL COLONY TYPE(100,4)
PATHOGEN MYCOPLASMA PEPTIDE(100,4)
POTENTIAL(100,4)
ENCODING NUCLEIC ACID(100,3)
PHAGE SCREENING(100,1)
PROPHYLACTICALLY TREATING CBPP(100,1)
CBPP VACCINE(72,2)
HUMAN PATHOGEN MYCOPLASMA(57,1)
PATHOGEN MMMSC(52,6)
ALVEOLAR MACROPHAGE(52,1)
CONFORMATIONAL EPITOPE(52,1)
PHAGE ENCODING(48,3)
ASSAYED MARKER(45,1)
DISEASE PREVENTION(41,6)
ANTIGEN INDUCTION(41,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(41,1)
ANTISERUM(39,17)
DISEASED CELL(39,9)
ANTIGENIC PROFILE(36,1)
FARMED BIRD(36,1)
IMMUNOGENIC RESPONSE(35,1)
FISH FARMING(34,1)
PROTECTIVE EFFICACY(34,1)
PHAGE(33,36)
CAUSATIVE AGENT(33,1)
POLYPEPTIDE IDENTITY(33,1)
CURRENT LIVE VACCINE(32,1)
PRODUCTION CHEAPNESS(32,1)
RECONSTITUTION(31,1)
WESTERN BLOTTING(31,1)
VACCINE FORMULATION(29,1)
ANIMAL(27,13)
GENETICALLY MODIFIED PHAGE(27,2)
MYCOPLASMA SPECIES(27,2)
TRANSCRIPTION TRANSLATION REGULATOR(25,2)
INNATE IMMUNITY(25,1)
POLYPEPTIDE ENCODING NUCLEIC ACID(25,1)
DISEASE(24,15)
CONTAGIOUS CAPRINE PLEUROPNEUMONIA(24,3)
HUMORAL IMMUNITY(23,1)
POLYPEPTIDE IDENTIFICATION(23,1)
NUCLEOTIDE SEQUENCE B1(22,2)
SOUTHERN EUROPE(22,1)
HIGHLY IMMUNOLOGICAL SIGNAL(21,1)
AMBIENT CONDITION(20,1)
PHAGE DISPLAY(20,1)
DOUBLE STRANDED DNA PHAGE(19,2)
BASIC MECHANISM UNDERSTANDING(19,1)
CORRELATION(19,1)
PATHOGEN(18,4)
MYCOPLASMA CAPRICOLUMN SUBSP(18,2)
EUROPE(18,1)
CATTLE(17,7)
INACTIVATED VACCINE(17,3)
C57BL(17,1)
RUMINANT MYCOPLASMA(16,5)
IMMOBILIZATION(16,2)
MOUSE(15,40)
VACCINATION(15,4)
IMMUNOASSAY(15,1)
IMMUNITY(14,10)
MYCOIDE(14,8)
BOVINE CONVALESCENT SERA(14,2)
INACTIVATED CBPP VACCINE(14,2)
ISCOM(14,2)
CULTURE MEDIA(14,1)
EFFICIENT MUCOSAL DELIVERY(14,1)
GOAT ANTI MOUSE HORSERADISH PEROXIDASE(14,1)
MYCOPLASMA KILODALTON POLYPEPTIDE GENE(14,1)
MYCOPLASMA MYCOIDES SUBSPECIE MYCOIDE(14,1)
AFRICA(13,3)
INFECTION(12,13)
VETERINARY SCIENCE(12,5)
SMITH WATERMAN(12,4)
COMPARATIVE PATHOLOGY JOURNAL(12,3)
MEDICAL MICROBIOLOGY JOURNAL(12,3)
CHICKEN(12,2)
SUBSPECIE MYCOIDE VACCINE(12,1)
NUCLEIC ACID(11,14)
ANTIBODY RESPONSE(11,5)
RABBIT ANTISERUM(11,4)
FILAMENTOUS PHAGE(11,3)
PHAGE DNA VACCINATION(11,3)
CAPSULAR POLYSACCHARIDE ANALYSIS(11,2)
CLINICAL MICROBIOLOGY JOURNAL(11,2)
ALVEOLAR MACROPHAGE DEPLETION(11,1)
AMERSHAM BIOSCIENCE(11,1)
EUKARYOTIC CELL(11,1)
MYCOPLASMA MYCOIDES VAR ANTIGEN(11,1)
NEWINGS TRYPTOSE BROTH(11,1)
PHAGE PARTICLE SURFACE(11,1)
MOLECULAR GENETICS(10,5)
B1 CLONE PRIMER(10,2)
CATIONIC LIPID VECTOR(10,2)
MULTILAMELLAR VESICLE(10,2)
RESPIRATORY MYCOPLASMOSIS(10,2)
SALMON(10,2)
SEA BASS(10,2)
TROPICAL ANIMAL HEALTH(10,2)
TROUT(10,2)
CAPSULAR POLYSACCHARIDE EXTRACTION(10,1)
LIVE ATTENUATED MMMSC STRAIN(10,1)
LLOYDS CHEMIST PLC(10,1)
MYCOPLASMA MYCOIDES SUBSP GROWTH(10,1)
MYCOPLASMA SYNOVIAE LIVE VACCINE(10,1)
MAGNESIUM SULFATE(9,4)
CONTROLLABLE PROMOTER(9,3)
LIVE MYCOPLASMA(9,3)
MAMMAL(9,3)
NUCLEOTIDE QUERY SEQUENCE(9,3)
NUCLEOTIDE SEQUENCE DATABASE(9,3)
DUCK(9,2)
EUKARYOTIC PROMOTER(9,2)
INTRAPERITONEAL CHALLENGE(9,2)
SHEEP(9,2)
EXPRESS PATHOGEN POLYPEPTIDE(9,1)
MATHEMATICALLY RIGOROUS(9,1)
OBSERVING MYCOPLASMA COLONY(9,1)
ORGANISM AVIANISED STRAIN(9,1)
RABBIT HYPERIMMUNE SERUM(9,1)
RECOMBINANT MMMSC PROTEIN(9,1)
TAIL BLED PRE VACCINATION(9,1)
PIG(8,3)
VETERINARY RECORD(8,3)
COW(8,2)
VACCINE ANTIGEN(8,2)
ANIMAL PARASITE BIOLOGY(8,1)
CONJUGATED CARBOHYDRATE PROTEIN(8,1)
FETAL BOVINE SERUM(8,1)
GALACTOFURANOSE DISSACHARIDE(8,1)
IMMUNO BLOTTING MOUSE ANTISERA(8,1)
MYCOPLASMA ARTHRITIDIS MITOGEN(8,1)
MYCOPLASMA MYCOIDES ANTIGENICITY(8,1)
MYCOPLASMA MYCOIDES GALACTAN(8,1)
MYCOPLASMA SUPERANTIGEN(8,1)
PROTRACTED MYCOPLASMAEMIA(8,1)
RECEPTOR MEDIATED PHAGOCYTOSIS INITIATE(8,1)
VETERINARY MEDICAL SCIENCE JOURNAL(8,1)
SIGMA(7,16)
B1 PROTEIN(7,4)
POST CHALLENGE(7,4)
EXPERIMENTAL INFECTION(7,2)
LIVE ORGANISM(7,2)
MYCOPLASMA STRAIN(7,2)
PARENTERAL ROUTE(7,2)
PHARMACEUTICAL FORMULATION(7,2)
PROTEIN VACCINE(7,2)
RECIPIENT ANIMAL(7,2)
VIGOROUS AGITATION(7,2)
VIGOROUS SHAKING(7,2)
WHOLE BACTERIOPHAGE PARTICLE(7,2)
AGRICULTURE ORGANIZATION(7,1)
AMINOPHENOL GALACTOSIDE(7,1)
BACTERIOPHAGE PARTICLE PRECIPITATION(7,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA VACCINE(7,1)
EFFICACY REASSESSMENT(7,1)
EUKARYOTIC EXPRESSION CASSETTE(7,1)
GOAT IMMUNIZATION(7,1)
GROWTH INHIBITING ANTIBODY INDUCTION(7,1)
HBSAG BACTERIOPHAGE(7,1)
HEURISTIC SEARCH(7,1)
HYOPNEUMONIA INACTIVATED VACCINE(7,1)
IGG2B IMMUNOGLOBULIN(7,1)
IMMOBILIZED POLYPEPTIDE(7,1)
INACTIVATED MYCOPLASMA MYCOIDES(7,1)
INHIBITED MMMSC GROWTH(7,1)
INTRACELLULAR PROTEIN EXPRESSION(7,1)
INTRAPERITONEAL INOCULATION(7,1)
NATIONAL VETERINARY LABORATORY(7,1)
POST TRANSLATIONAL CLEAVAGE(7,1)
POST VACCINATION SERA(7,1)
PRE VACCINATION SERA(7,1)
CENTRIFUGATION(6,5)
DIAGNOSTICS(6,5)
EPIDEMIOLOGY(6,5)
PATHOGENICITY(6,5)
ADMINISTRATION MODE(6,4)
BLOCKING(6,3)
DRY SKIMMED MILK(6,3)
IMMUNE MOUSE RESPONSE(6,3)
COMPUTER HOMOLOGY(6,2)
GENOMIC DNA(6,2)
IMMUNOPROTECTIVE RESPONSE(6,2)
INJECTABLE CARRIER(6,2)
LABELED INSERTION SEQUENCE(6,2)
MOUSE INFECTION(6,2)
PUBLISHED GENOME SEQUENCE(6,2)
STIMULATION INDEX(6,2)
SUBCUTANEOUS ROUTE(6,2)
THALLOUS ACETATE(6,2)
ANTIGENIC STIMULUS(6,1)
BACTERIA VIRUS(6,1)
BACTERIOPHAGE GENOME(6,1)
BACTERIOPHAGE PELLET(6,1)
CAUSATIVE ORGANISM(6,1)
CAUSATIVE PATHOGEN(6,1)
CONFORMATIONALLY ACTIVE EPITOPE(6,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA PREVENTION(6,1)
CPG DINUCLEOTIDE(6,1)
ELISA TITER(6,1)
EPIZOOTIC DISEASE BULLETIN(6,1)
EUROPEAN BIOINFORMATICS(6,1)
FAO MEETING(6,1)
FEM IMMUNOLOGY(6,1)
HEURISTIC APPROXIMATION(6,1)
IMMUNOLOGICAL CHARACTERIZATION(6,1)
INFECTIOUS HUMAN DISEASE(6,1)
INTERNATIONAL CONGRESS(6,1)
INTRANASAL IMMUNIZATION(6,1)
ISCOM VACCINE(6,1)
LIVE WHOLE MYCOPLASMA(6,1)
MMMSC CHALLENGE(6,1)
MMMSC DOSE(6,1)
MMMSC PROTECTED MOUSE(6,1)
MYCOPLASMA BOVIS INFECTION(6,1)
MYCOPLASMA VACCINE(6,1)
PACKARD HARVESTER(6,1)
PEROXIDASE LABELED SECONDARY ANTIBODY(6,1)
PHAGE TRANSFECT(6,1)
POLYSACCHARIDE PROTEIN(6,1)
POSITIVE REACTIVE POLYPEPTIDE(6,1)
PRIMARY MOUSE ANTISERUM DILUTION(6,1)
PURE IGG1 ISOLATION(6,1)
RABBIT ANTI MMMSC SERUM(6,1)
RESPIRATORY TRACT MYCOPLASMA INFECTION(6,1)
SONICATED ANTIGEN(6,1)
TETANUS TOXOID(6,1)
VACCINE CANDIDATE IDENTIFICATION(6,1)
VIABLE SPLENOCYTE(6,1)
WEEK POST VACCINATION(6,1)
WHOLE MMMSC ANTIGEN(6,1)
WHOLE SONICATED MMMSC(6,1)
L DIOLEOYLPHOSPHATIDYL ETHANOLAMINE(5,2)
MOUSE SERUM(5,2)
MYCOIDE SMALL COLONY VARIANT(5,2)
VACCINATED GROUP(5,2)
01M GLYCINE(5,1)
16M AMMONIUM CHLORIDE(5,1)
ADJUVANT CHOICE(5,1)
ANTI MMMSC TITER(5,1)
ANTIBODY TITER(5,1)
AUSTRALIAN STRAIN(5,1)
BACTERIAL CONJUGATE VACCINE(5,1)
BACTERIAL PELLET(5,1)
BACTERIOPHAGE SUSPENSION(5,1)
BIOCHEMICAL JOURNAL(5,1)
CATTLE DISEASE(5,1)
CHALLENGE EXPERIMENT(5,1)
CHOICE CELL DISEASE(5,1)
CHOICE EXPRESSION VECTOR(5,1)
CLONE NUCLEOTIDE(5,1)
CLONE PROPORTION(5,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA DETECTION(5,1)
CYTOKINE MODULATOR(5,1)
CYTOTOXIC INDUCTION(5,1)
DIFF CATTLE(5,1)
EDISON ROAD(5,1)
EUKARYOTIC HOST CELL(5,1)
EXPERIMENTAL INACTIVATED VACCINE(5,1)
FASTA(5,1)
FINAL VACCINE CONSTITUTION(5,1)
FREEZE DRIED BROTH CULTURE(5,1)
GAL PROMOTER(5,1)
GALACTAN INFLUENCE(5,1)
GALACTAN INTRAVENOUS INJECTION(5,1)
GENE VACCINE(5,1)
GT TITRATION(5,1)
HOMOGENEOUS POLYACRYLAMIDE(5,1)
HYGIENE JOURNAL(5,1)
IMMUNOLOGICAL STUDY(5,1)
INCOMPLETE ADJUVANT(5,1)
INDIRECT ELISA(5,1)
INFECTIOUS AGENT PROTEIN(5,1)
INTERMITTENT SHAKING(5,1)
INTERNATIONAL IMMUNOLOGY(5,1)
LURIA BROTH AGAR(5,1)
LYSED CULTURE(5,1)
MANUFACTURER INSTRUCTION(5,1)
MATERNAL ANTIBODY(5,1)
MEMBRANE INCUBATION(5,1)
MOUSE IMMUNOBLOT(5,1)
MYCOPLASMA EVALUATION(5,1)
MYCOPLASMA SUBCUTANEOUS INJECTION(5,1)
MYCOPLASMAEMIA ABSENCE(5,1)
MYCOPLASMAEMIC MOUSE(5,1)
NITROCELLULOSE MEMBRANE(5,1)
NZCYM BROTH(5,1)
OBJECTIVE OVERVIEW(5,1)
OVERNIGHT CULTURE(5,1)
PASSIVE IMMUNITY(5,1)
PHAGE CLONE(5,1)
POLYCLONAL ANTIBODY(5,1)
POLYNUCLEOTIDE ENTRY(5,1)
POLYPEPTIDE GENE IDENTITY(5,1)
POLYPEPTIDE MAJORITY(5,1)
POLYPEPTIDE SEQUENCE SHARE(5,1)
PROTECTIVE ANTIGEN(5,1)
PROTEIN SUBUNIT VACCINE(5,1)
RABBIT ANTISERA(5,1)
RAINBOW MARKER(5,1)
RECOMBINANT PHAGE(5,1)
REVERSION(5,1)
RSV PROMOTER(5,1)
SEARCHING SEQUENCE DATABASE(5,1)
STERILE DILUTED ANTIGEN VOLUME(5,1)
STERILE MICROSCOPE SLIDE(5,1)
STIMULATION ASSAY(5,1)
STRAIN CHARACTERIZATION(5,1)
SUCCESSFUL IMMUNIZATION(5,1)
THERAPEUTIC ADMINISTRATION(5,1)
UNDILUTED SERUM(5,1)
UNVACCINATED MOUSE(5,1)
VACCINATION ROUTE(5,1)
VIABLE ORGANISM(5,1)
WESTERN BLOT(5,1)
WHOLE LIVE DEAD MYCOPLASMA(5,1)
PBST(4,7)
FLASK(4,6)
EUROPEAN UNION(4,5)
BUTTERY(4,3)
LIPOSOME(4,3)
1M HEPES(4,1)
AGE WEEK(4,1)
AMERICAN SOCIETY(4,1)
ANTIGENIC ACTIVITY(4,1)
B1 PLASMID(4,1)
B1 VACCINE(4,1)
BACTERIAL SUSPENSION(4,1)
BACTERIOPHAGE CONCENTRATION(4,1)
BLAST PROGRAM(4,1)
BLASTP PROGRAM(4,1)
CBPP CAUSAL AGENT(4,1)
CELL SUSPENSION DILUTION(4,1)
CHOICE PROMOTER(4,1)
COLI CULTURE(4,1)
COLI STRAIN(4,1)
COLI SUSPENSION(4,1)
COLLECTED SUPERNATANT(4,1)
CONCEPTUAL TRANSLATION PRODUCT(4,1)
ESCHERICHIA COLI MOUSE(4,1)
EXACT PROBABILITY(4,1)
EXPERIMENTAL MEDICINE JOURNAL(4,1)
EXPRESS LIBRARY(4,1)
EXPRESS VECTOR(4,1)
FAO PUBLICATION(4,1)
FUSION PROTEIN(4,1)
GENE ENCODING(4,1)
GENOMIC NUCLEIC ACID GENOME(4,1)
GT PURIFICATION(4,1)
HANK BALANCED SALT SOLUTION(4,1)
HOST GENOME(4,1)
IEM PLATE READER(4,1)
IMMUNOSTIMULATORY POLYNUCLEOTIDE SEQUENCE(4,1)
INFECTED ANIMAL(4,1)
INTERNATIONAL OFFICE(4,1)
LAMBDA GT(4,1)
LIVING CULTURE(4,1)
LYTIC GROWTH(4,1)
MODIFIED NEUBAUER COUNTING CHAMBER(4,1)
MULTISCREEN BLOTTING(4,1)
MYCOPLASMA RESISTANT C57BL MOUSE(4,1)
NAKED DNA(4,1)
PHAGE VECTOR(4,1)
PLASMID DNA(4,1)
PONCEAU RED(4,1)
PRELIMINARY STUDY(4,1)
PROTEIN QUERY SEQUENCE(4,1)
RABBIT SERUM(4,1)
RE EMERGENCE(4,1)
REACTING POLYPEPTIDE(4,1)
RECENT OUTBREAK(4,1)
RECENT VACCINATION(4,1)
RECOMBINANT PROTEIN EXPRESS(4,1)
SERIAL DILUTION(4,1)
SOLUBLE MANNAN(4,1)
SUBUNIT FRACTION(4,1)
SUGAR DETERMINATION(4,1)
SYNTHETIC MICROSPHERE(4,1)
TBLASTN PROGRAM(4,1)
TBLASTX PROGRAM(4,1)
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY(4,1)
UNIQUE ECOR(4,1)
VACCINE MANUFACTURE(4,1)
VACCINE PREPARATION(4,1)
VACCINE STRAIN(4,1)
VIABILITY COUNT(4,1)
VIRULENCE COMPARISON(4,1)
WHOLE MMMSC IMMUNE RESPONSE(4,1)
AFRICAN(3,2)
AMPICILLIN(3,2)
ANTI MYCOPLASMA(3,2)
BACTERIOLOGY(3,2)
CELL CONCENTRATION(3,2)
CELL MEDIATED IMMUNE RESPONSE(3,2)
CELLULAR PROLIFERATION(3,2)
CLONED NUCLEIC ACID(3,2)
CONSTRUCTING NUCLEIC ACID(3,2)
DRUG(3,2)
EXCIPIENT(3,2)
FINAL CONCENTRATION(3,2)
GENTAMYCIN(3,2)
GLUTERALDEHYDE(3,2)
IMMUNE CELL PROLIFERATIVE RESPONSE(3,2)
OBSERVATION(3,2)
PENICILLIN STREPTOMYCIN(3,2)
PYROGENIC WATER(3,2)
SERIES PHAGE(3,2)
STRONG IMMUNE RESPONSE(3,2)
TRIPLICATE(3,2)
VECTOR SEQUENCE(3,2)
05M SODIUM CARBONATE BUFFER(3,1)
ADDRESSEE(3,1)
AQUEOUS SUSPENSION INTRAVENOUS INJECTION(3,1)
BLOOD DROP(3,1)
CAPSULAR POLYSACCHARIDE SPECIFIC LATEX(3,1)
CELL DEBRIS(3,1)
CELL MEDIATED IMMUNITY(3,1)
CHOICE VECTOR(3,1)
CLONE B1(3,1)
CLONING VEHICLE K GT(3,1)
COLI CELL(3,1)
CONSULTATIVE GROUP(3,1)
CONSULTING(3,1)
CONTAGIOUS PLEUROPNEUMONIA(3,1)
CULTURE DAY(3,1)
CURRENT DISEASE SECURITY REQUIREMENT(3,1)
DAY INCUBATION(3,1)
DEOXYRIBONUCLEIC ACID(3,1)
DETECTION LATEX(3,1)
DIAMINOBENZIDINE(3,1)
DOUBLE STRANDED RNA PHAGE(3,1)
EFFICIENT DELIVERY VEHICLE(3,1)
EXOGENOUS NUCLEIC ACID(3,1)
FREEZE DRIED CULTURE(3,1)
GIVING SI(3,1)
GROWTH ABSENCE(3,1)
HEAT KILLED MYCOPLASMA MYCOIDES(3,1)
HOST ANIMAL(3,1)
IMMUNE HOST RESPONSE(3,1)
IMMUNOCHEMISTRY(3,1)
IMMUNOGENIC POLYPEPTIDE SCREENING(3,1)
LABORATORY PRESS(3,1)
LAMBDA B1(3,1)
LENS TISSUE(3,1)
LYSIS BUFFER(3,1)
MINUTE WASH(3,1)
MMMSC NUCLEIC ACID SEQUENCE(3,1)
MODIFIED POLYPEPTIDE(3,1)
MOUSE IMMUNE RESPONSE(3,1)
MOUSE PROTECTION(3,1)
MOUSE PROTECTIVE ANTIBODY(3,1)
O PHENYLENEDIAMINE DICHLORIDE(3,1)
OUTPUT CBPP VACCINE(3,1)
PATHOGEN NUCLEIC ACID SEQUENCE(3,1)
PHAGE NUCLEIC ACID(3,1)
PHENOL CHLOROFORM EXTRACTION(3,1)
PRIMARY SERUM(3,1)
PROTECTIVE IMMUNE RESPONSE(3,1)
PURIFIED DNA(3,1)
REPEATED VACCINATION(3,1)
SALINE BUFFER(3,1)
YORK ACADEMY ANNALS(3,1)
(WO200605943)
VACCINE(100,30)
HOMOLOG(100,7)
NUCLEIC ACID SEQUENCE(100,7)
FUNCTIONAL FRAGMENT(100,6)
LIPOPROTEIN(100,6)
PROLIPOPROTEIN(100,6)
MODIFIED PHAGE(100,5)
DISEASE PREVENTION(100,3)
ENCODING NUCLEIC ACID(100,3)
MYCOIDE SMALL COLONY TYPE(100,3)
PATHOGEN MMMSC(100,3)
POTENTIAL(100,3)
VACCINE MANUFACTURE(100,3)
CONTAGIOUS BOVINE PLEUROPNEUMONIA TREATMENT(100,1)
PATHOGEN MYCOPLASMA MYCOIDES(100,1)
PREVENTION(100,1)
DISEASED CELL(52,9)
CONFORMATIONAL EPITOPE(47,1)
ANTISERUM(44,17)
PHAGE ENCODING(43,3)
ASSAYED MARKER(41,1)
GENETICALLY MODIFIED PHAGE(40,2)
MYCOPLASMA MYCOIDES SUBSP(39,11)
INFECTIOUS AGENT PROTEIN(39,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(37,1)
ANTIGENIC PROFILE(33,1)
FARMED BIRD(33,1)
IMMUNOGENIC RESPONSE(33,1)
VACCINE PREPARATION(33,1)
DISEASE(31,13)
FISH FARMING(31,1)
PROTECTIVE EFFICACY(31,1)
CAUSATIVE AGENT(30,1)
POLYPEPTIDE IDENTITY(30,1)
PHAGE(29,36)
CURRENT LIVE VACCINE(29,1)
PRODUCTION CHEAPNESS(29,1)
CONTROLLABLE PROMOTER(28,3)
RECONSTITUTION(28,1)
WESTERN BLOTTING(28,1)
ANIMAL(27,12)
VACCINE FORMULATION(27,1)
PATHOGEN(25,4)
EXOGENOUS NUCLEIC ACID(24,1)
TRANSCRIPTION TRANSLATION REGULATOR(23,2)
CONTAGIOUS CAPRINE PLEUROPNEUMONIA(22,3)
POLYPEPTIDE ENCODING NUCLEIC ACID(22,1)
CONSTITUTIVE PROMOTER WAY(21,1)
POLYPEPTIDE IDENTIFICATION(21,1)
SOUTHERN EUROPE(20,1)
HIGHLY IMMUNOLOGICAL SIGNAL(19,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA(18,14)
DOUBLE STRANDED DNA PHAGE(18,2)
AMBIENT CONDITION(18,1)
PHAGE DISPLAY(18,1)
BASIC MECHANISM UNDERSTANDING(17,1)
CORRELATION(17,1)
CATTLE(16,7)
IMMUNOPROTECTIVE RESPONSE(16,2)
EUROPE(16,1)
NITROCELLULASE(16,1)
RUMINANT MYCOPLASMA(15,5)
INACTIVATED VACCINE(15,3)
IMMOBILIZATION(15,2)
IMMUNOASSAY(14,1)
NUCLEIC ACID(13,14)
VACCINATION(13,8)
BOVINE CONVALESCENT SERA(13,2)
CULTURE MEDIA(13,1)
IMMUNITY(12,8)
AFRICA(12,3)
MYCOPLASMA KILODALTON POLYPEPTIDE GENE(12,1)
MYCOPLASMA MYCOIDES SUBSPECIE MYCOIDE(12,1)
VETERINARY SCIENCE(11,5)
RABBIT ANTISERUM(11,4)
SMITH WATERMAN(11,4)
COMPARATIVE PATHOLOGY JOURNAL(11,3)
MEDICAL MICROBIOLOGY JOURNAL(11,3)
CHICKEN(11,2)
CAPRIPNEUMONIA CAPSULAR POLYSACCHARIDE(11,1)
SUBSPECIE MYCOIDE VACCINE(11,1)
PROTEIN(10,10)
DEAD MYCOPLASMA(10,4)
PHAGE DNA VACCINATION(10,3)
BL CLONE PRIMER(10,2)
CLINICAL MICROBIOLOGY JOURNAL(10,2)
MYCOPLASMA MYCOIDES GALACTAN(10,2)
ALVEOLAR MACROPHAGE DEPLETION(10,1)
EUKARYOTIC CELL(10,1)
MYCOPLASMA MYCOIDES VAR ANTIGEN(10,1)
NEWINGS TRYPTOSE BROTH(10,1)
PHAGE PARTICLE SURFACE(10,1)
POST CHALLENGE(9,8)
MOLECULAR GENETICS(9,5)
VETERINARY RECORD(9,5)
CATIONIC LIPID VECTOR(9,2)
MULTILAMELLAR VESICLE(9,2)
RESPIRATORY MYCOPLASMOSIS(9,2)
SALMON(9,2)
SEA BASS(9,2)
SHEEP(9,2)
TROPICAL ANIMAL HEALTH(9,2)
TROUT(9,2)
LLOYDS CHEMIST PLC(9,1)
MYCOPLASMA MYCOIDES SUBSP GROWTH(9,1)
MYCOPLASMA SYNOVIAE LIVE VACCINE(9,1)
PATHOGEN MYCOPLASMA PEPTIDE(9,1)
BL PROTEIN(8,4)
CHALLENGE EXPERIMENT(8,3)
MAMMAL(8,3)
NUCLEOTIDE QUERY SEQUENCE(8,3)
NUCLEOTIDE SEQUENCE DATABASE(8,3)
DUCK(8,2)
EUKARYOTIC PROMOTER(8,2)
FILAMENTOUS PHAGE ML(8,2)
GOURLAY BROTH(8,2)
INTRAPERITONEAL CHALLENGE(8,2)
WHOLE MMMSC ANTIGEN(8,2)
EXPRESS PATHOGEN POLYPEPTIDE(8,1)
FREUND INCOMPLETE ADJUVANT(8,1)
IMMUNOBLOTTING MOUSE ANTISERA(8,1)
MATHEMATICALLY RIGOROUS(8,1)
OBSERVING MYCOPLASMA COLONY(8,1)
ORGANISM AVIANISED STRAIN(8,1)
RABBIT HYPERIMMUNE SERUM(8,1)
RECOMBINANT MMMSC PROTEIN(8,1)
OMM MAGNESIUM SULFATE(7,3)
PIG(7,3)
POST VACCINATION(7,3)
CLONE NUCLEOTIDE(7,2)
COW(7,2)
EXPERIMENTAL INFECTION(7,2)
LIVE MYCOPLASMA(7,2)
LIVE ORGANISM(7,2)
MYCOPLASMA STRAIN(7,2)
PARENTERAL ROUTE(7,2)
PHARMACEUTICAL FORMULATION(7,2)
RABBIT ANTISERA(7,2)
RECIPIENT ANIMAL(7,2)
VACCINE ANTIGEN(7,2)
VIGOROUS AGITATION(7,2)
VIGOROUS SHAKING(7,2)
WHOLE BACTERIOPHAGE PARTICLE(7,2)
ANIMAL PARASITE BIOLOGY(7,1)
CONJUGATED CARBOHYDRATE PROTEIN(7,1)
MYCOPLASMA ARTHRITIDIS MITOGEN(7,1)
MYCOPLASMA CAPRICOLUM SUBSP(7,1)
MYCOPLASMA MYCOIDES ANTIGENICITY(7,1)
MYCOPLASMA SUPERANTIGEN(7,1)
PROTEIN SUBUNIT VACCINE(7,1)
PROTRACTED MYCOPLASMAEMIA(7,1)
RECEPTOR MEDIATED PHAGOCYTOSIS INITIATE(7,1)
VETERINARY MEDICAL SCIENCE JOURNAL(7,1)
SIGMA(6,16)
ANTIBODY RESPONSE(6,5)
IMMUNE MOUSE RESPONSE(6,4)
COMPUTER HOMOLOGY(6,2)
GENOMIC DNA(6,2)
INJECTABLE CARRIER(6,2)
LABELED INSERTION SEQUENCE(6,2)
MOUSE INFECTION(6,2)
MYCOPLASMAEMIA DETECTION(6,2)
PUBLISHED GENOME SEQUENCE(6,2)
SUBCUTANEOUS ROUTE(6,2)
THALLOUS ACETATE(6,2)
AGRICULTURE ORGANIZATION(6,1)
BACTERIOPHAGE PARTICLE PRECIPITATION(6,1)
CAPSULAR POLYSACCHARIDE ANALYSIS(6,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA VACCINE(6,1)
EFFICACY REASSESSMENT(6,1)
EUKARYOTIC EXPRESSION CASSETTE(6,1)
GOAT IMMUNIZATION(6,1)
GROWTH INHIBITING ANTIBODY INDUCTION(6,1)
HBSAG BACTERIOPHAGE(6,1)
HEURISTIC SEARCH(6,1)
HUMAN PATHOGEN MYCOPLASMA(6,1)
HYOPNEUMONIA INACTIVATED VACCINE(6,1)
IGG2B IMMUNOGLOBULIN(6,1)
IMMOBILIZED POLYPEPTIDE(6,1)
INACTIVATED MYCOPLASMA MYCOIDES(6,1)
INHIBITED MMMSC GROWTH(6,1)
INTRACELLULAR PROTEIN EXPRESSION(6,1)
INTRAPERITONEAL INOCULATION(6,1)
MMMSC STRAIN TI(6,1)
NATIONAL VETERINARY LABORATORY(6,1)
PHAGE SCREENING(6,1)
CENTRIFUGATION(5,5)
DIAGNOSTICS(5,5)
EPIDEMIOLOGY(5,5)
PATHOGENICITY(5,5)
ADMINISTRATION MODE(5,4)
ITALIC(5,4)
VECTOR SEQUENCE(5,4)
BLOCKING(5,3)
DRY SKIMMED MILK(5,3)
PRE VACCINATION SERA(5,2)
ADJUVANT CHOICE(5,1)
AMERSHAM BIOSCIENCE(5,1)
AMINOPHENOL SYNTHESIS(5,1)
ANTI MMMSC TITER(5,1)
ANTI MOUSE HORSERADISH PEROXIDASE(5,1)
ANTIBODY TITER(5,1)
ANTIGEN DETECTION LATEX(5,1)
ANTIGEN INDUCTION(5,1)
ANTIGENIC STIMULUS(5,1)
AUSTRALIAN STRAIN(5,1)
BACTERIA VIRUS(5,1)
BACTERIAL CONJUGATE VACCINE(5,1)
BACTERIAL PELLET(5,1)
BACTERIOPHAGE GENOME(5,1)
BACTERIOPHAGE GROWTH(5,1)
BACTERIOPHAGE PELLET(5,1)
BIOCHEMICAL JOURNAL(5,1)
BL PLASMID(5,1)
BL VACCINE(5,1)
CATTLE DISEASE(5,1)
CAUSATIVE ORGANISM(5,1)
CAUSATIVE PATHOGEN(5,1)
CHOICE CELL DISEASE(5,1)
CHOICE EXPRESSION VECTOR(5,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA DETECTION(5,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA PREVENTION(5,1)
CYTOKINE MODULATOR(5,1)
CYTOLYTIC T CELL RESPONSE(5,1)
DIFF CATTLE(5,1)
DISEASE RE EMERGENCE(5,1)
EDISON ROAD(5,1)
ELISA TITER(5,1)
EPIZOOTIC DISEASE BULLETIN(5,1)
EUKARYOTIC HOST CELL(5,1)
EUROPEAN BIOINFORMATICS(5,1)
EXPERIMENTAL INACTIVATED VACCINE(5,1)
FAO OIE MEETING(5,1)
FINAL VACCINE CONSTITUTION(5,1)
FISHER EXACT PROBABILITY(5,1)
FREEZE DRIED BROTH CULTURE(5,1)
GAL PROMOTER(5,1)
GENE VACCINE(5,1)
GTL PURIFICATION(5,1)
GTL TITRATION(5,1)
HEURISTIC APPROXIMATION(5,1)
HOMOGENEOUS POLYACRYLAMIDE GEL(5,1)
HYGIENE JOURNAL(5,1)
IMMUNOLOGICAL CHARACTERIZATION(5,1)
IMMUNOLOGICAL STUDY(5,1)
IMMUNOLOGY JOURNAL(5,1)
INDIRECT ELISA(5,1)
INFECTIOUS HUMAN DISEASE(5,1)
INTERMITTENT SHAKING(5,1)
INTERNATIONAL CONGRESS(5,1)
INTERNATIONAL IMMUNOLOGY(5,1)
INTRANASAL IMMUNIZATION(5,1)
ISCOM VACCINE(5,1)
L DIOLEOYLPHOSPHATIDYL ETHANOLAMINE(5,1)
LIVE WHOLE MYCOPLASMA(5,1)
LURIA BROTH AGAR(5,1)
LYSED CULTURE(5,1)
MAKRINA BLOT(5,1)
MANUFACTURER INSTRUCTION(5,1)
MATERNAL ANTIBODY(5,1)
MEMBRANE INCUBATION(5,1)
MMMSC CHALLENGE(5,1)
MMMSC DOSE(5,1)
MMMSC PROTECTED MOUSE(5,1)
MOUSE IMMUNIZATION(5,1)
MOUSE IMMUNOBLOT(5,1)
MYCOPLASMA BOVIS INFECTION(5,1)
MYCOPLASMA EVALUATION(5,1)
MYCOPLASMA SPECIES(5,1)
MYCOPLASMA SUBCUTANEOUS INJECTION(5,1)
MYCOPLASMA VACCINE(5,1)
MYCOPLASMAEMIA ABSENCE(5,1)
MYCOPLASMAEMIC MOUSE(5,1)
NITROCELLULOSE MEMBRANE(5,1)
OBJECTIVE OVERVIEW(5,1)
OVERNIGHT CULTURE(5,1)
PACKARD HARVESTER(5,1)
PASSIVE IMMUNITY(5,1)
PEROXIDASE LABELED SECONDARY ANTIBODY(5,1)
PHAGE CLONE(5,1)
PHAGE TRANSFECT(5,1)
POLYCLONAL ANTIBODY(5,1)
POLYNUCLEOTIDE ENTRY(5,1)
POLYPEPTIDE GENE IDENTITY(5,1)
POLYPEPTIDE MAJORITY(5,1)
POLYPEPTIDE SEQUENCE SHARE(5,1)
POSITIVE REACTIVE POLYPEPTIDE(5,1)
PRIMARY MOUSE ANTISERUM DILUTION(5,1)
PROTECTIVE ANTIGEN(5,1)
PROTEIN CONJUGATE VACCINE(5,1)
PROTEIN VACCINE(5,1)
PURE IGGL ISOLATION(5,1)
PURIFIED GTLL BACTERIOPHAGE SUSPENSION(5,1)
RABBIT ANTI MMMSC SERUM(5,1)
RAINBOW MARKER(5,1)
RECOMBINANT PHAGE(5,1)
RESPIRATORY TRACT MYCOPLASMA INFECTION(5,1)
REVERSION(5,1)
SEARCHING SEQUENCE DATABASE(5,1)
STERILE DILUTED ANTIGEN(5,1)
STERILE MICROSCOPE SLIDE(5,1)
STRAIN CHARACTERIZATION(5,1)
SUCCESSFUL IMMUNIZATION(5,1)
TECHNIQUE INVENTOR DISCOVERY(5,1)
TETANUS TOXOID(5,1)
THEREAPEUTIC ADMINISTRATION(5,1)
THYMIDINE INCORPORATION(5,1)
THYMIDINE KINASE(5,1)
TRANSLATIONAL CLEAVAGE(5,1)
UNDILUTED SERUM(5,1)
UNVACCINATED MOUSE(5,1)
VACCINATION ROUTE(5,1)
VACCINE CANDIDATE IDENTIFICATION(5,1)
VIABLE ORGANISM(5,1)
VIABLE SPLENOCYTE(5,1)
WESTERN BLOT(5,1)
WHOLE SONICATED MMMSC(5,1)
XL PRIMER(5,1)
FLASK(4,6)
BUTTERY(4,3)
LIPOSOME(4,3)
ANTI MYCOPLASMA IMMUNE RESPONSE(4,2)
MOUSE SERUM(4,2)
MYCOIDE SMALL COLONY VARIANT(4,2)
STIMULATION INDEX(4,2)
VACCINATED GROUP(4,2)
AGE WEEK(4,1)
AMERICAN SOCIETY(4,1)
ANTIGENIC ACTIVITY(4,1)
BACTERIAL SUSPENSION(4,1)
BACTERIOPHAGE CONCENTRATION(4,1)
BLAST PROGRAM(4,1)
CELL SUSPENSION DILUTION(4,1)
CHOICE PROMOTER(4,1)
CLONE CONTAINED TL(4,1)
COLI CULTURE(4,1)
COLI STRAIN(4,1)
COLI SUSPENSION(4,1)
COLLECTED SUPERNATANT(4,1)
CONCEPTUAL TRANSLATION PRODUCT(4,1)
ESCHERICHIA COLI MOUSE(4,1)
EXPERIMENTAL MEDICINE JOURNAL(4,1)
EXPRESS LIBRARY(4,1)
EXPRESS VECTOR(4,1)
F SONICATED ANTIGEN(4,1)
FREUND COMPLETE ADJUVANT(4,1)
FUSION PROTEIN(4,1)
GENE ENCODING(4,1)
GENOMIC NUCLEIC ACID GENOME(4,1)
GOURLAY AGAR PLATE(4,1)
HANK BALANCED SALT SOLUTION(4,1)
HOST GENOME(4,1)
IMMUNOSTIMULATORY POLYNUCLEOTIDE SEQUENCE(4,1)
INFECTED ANIMAL(4,1)
INTERNATIONAL OFFICE(4,1)
LAMBDA GTL(4,1)
LIVING CULTURE(4,1)
LYTIC GROWTH(4,1)
MODIFIED NEUBAUER COUNTING CHAMBER(4,1)
MYCOPLASMA RESISTANT C57BL MOUSE(4,1)
NAKED DNA(4,1)
PHAGE VECTOR(4,1)
PLASMID DNA(4,1)
PONCEAU RED(4,1)
PRELIMINARY STUDY(4,1)
PROTEIN QUERY SEQUENCE(4,1)
PYRO GENIE WATER(4,1)
RABBIT SERUM(4,1)
REACTING POLYPEPTIDE(4,1)
RECENT OUTBREAK(4,1)
RECENT VACCINATION(4,1)
RECOMBINANT PROTEIN EXPRESS(4,1)
SERIAL DILUTION(4,1)
SOLUBLE MANNAN(4,1)
SUBUNIT FRACTION(4,1)
SUGAR DETERMINATION(4,1)
SYNTHETIC MICROSPHERE(4,1)
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY(4,1)
UNIQUE ECOR(4,1)
VIABILITY COUNT(4,1)
VIRULENCE COMPARISON(4,1)
WHOLE MMMSC IMMUNE RESPONSE(4,1)
EUROPEAN UNION(3,5)
AFRICAN(3,2)
AMPICILLIN(3,2)
BACTERIOLOGY(3,2)
CELL CONCENTRATION(3,2)
CELLULAR PROLIFERATION(3,2)
CLONED NUCLEIC ACID(3,2)
CONSTRUCTING NUCLEIC ACID(3,2)
DRUG(3,2)
EXCIPIENT(3,2)
GENTAMICIN(3,2)
IMMUNE CELL PROLIFERATIVE RESPONSE(3,2)
OBSERVATION(3,2)
PENICILLIN STREPTOMYCIN(3,2)
STRONG IMMUNE RESPONSE(3,2)
TRIPLICATE(3,2)
ACTIVE EPITOPE(3,1)
ADDRESSEE(3,1)
AQUEOUS SUSPENSION INTRAVENOUS INJECTION(3,1)
BL CONSTRUCT RECOGNIZED SIZE(3,1)
BLOOD DROP(3,1)
CELL DEBRIS(3,1)
CELL MEDIATED IMMUNITY(3,1)
CHOICE VECTOR(3,1)
CONSULTATIVE GROUP(3,1)
CONSULTING(3,1)
CONTAGIOUS PLEUROPNEUMONIA(3,1)
CULTURE DAY(3,1)
CURRENT DISEASE SECURITY REQUIREMENT(3,1)
DAY INCUBATION(3,1)
DEOXYRIBO NUCLEIC ACID(3,1)
DOUBLE STRANDED RNA PHAGE(3,1)
EFFICIENT DELIVERY VEHICLE(3,1)
ELISA ANALYSIS(3,1)
FREEZE DRIED CULTURE(3,1)
GIVING SI(3,1)
GROWTH ABSENCE(3,1)
HEAT KILLED MYCOPLASMA MYCOIDES(3,1)
HOST ANIMAL(3,1)
IMMUNE HOST RESPONSE(3,1)
IMMUNOCHEMISTRY(3,1)
IMMUNOGENIC POLYPEPTIDE SCREENING(3,1)
INFECTIOUS AGENT(3,1)
INTERNAL PRIMING SITE(3,1)
LABORATORY PRESS(3,1)
LATEX AGGLUTINATION TEST(3,1)
LENS TISSUE(3,1)
LOOL VOLUME(3,1)
LYSIS BUFFER(3,1)
MINUTE WASH(3,1)
MMMSC NUCLEIC ACID SEQUENCE(3,1)
MODIFIED POLYPEPTIDE(3,1)
MOUSE IMMUNE RESPONSE(3,1)
MOUSE PROTECTION(3,1)
MOUSE PROTECTIVE ANTIBODY(3,1)
O PHENYLENEDIAMINE DICHLORIDE(3,1)
PATHOGEN NUCLEIC ACID SEQUENCE(3,1)
PHAGE NUCLEIC ACID(3,1)
PHENOL CHLOROFORM EXTRACTION(3,1)
POSITIVE CLONE(3,1)
PRIMARY SERUM(3,1)
PROLIPOPROTEIN AMINOACID(3,1)
PROTECTIVE IMMUNE RESPONSE(3,1)
PURIFIED DNA(3,1)
REPEATED VACCINATION(3,1)
SALINE BUFFER(3,1)
SEQUENCE IDENTITY(3,1)
SEQUENCE SIMILARITY(3,1)
SUBJECT INOCULATION(3,1)
YORK ACADEMY ANNALS(3,1)";Pharmaceuticals;Open
2004-07-09;"RU2004120861        A  2006-01-10 [RU2004120861]
STG: (A) Application for invention
AP : 2004RU-0120861 2004-07-09
RU2268747           C1 2006-01-27 [RU2268747]
STG: (C1) Patent for invention
AP : 2004RU-0120861 2004-07-09";36259550;"RU2004120861        A  2006-01-10 [RU2004120861]
RU2268747           C1 2006-01-27 [RU2268747]";2004RU-0120861;;FEDERAL NOE GOSUDARSTVENNOE UCHREZHDENIE FEDERAL NYJ TSENTR OKHRANY ZDOROV JA ZHIVOTNYKH;FEDERAL NOE GOSUDARSTVENNOE UCHREZHDENIE FEDERAL NYJ TSENTR OKHRANY ZDOROV JA ZHIVOTNYKH;;;1;"MISHCHENKO VLADIMIR ALEKSANDRO
GETMANSKIJ OLEG IVANOVICH
RUCHNOV JURIJ EVGEN EVICH
KOSTYRKIN JURIJ ALEKSEEVICH
NIKESHINA TAT JANA BORISOVNA
ZHBANOVA TAT JANA VALENTINOVNA";;;"(RU2268747)
Sorbed and inactivated vaccine against cattle infectious rhinotracheitis";"(RU2268747)
FIELD: veterinary virology, veterinary science, biotechnology. ^ SUBSTANCE: vaccine comprises antigenic material from the strain ""VNIIZZH-DEP"" of the cattle infectious rhinotracheitis virus reproduced in transplanted cells culture taken among transplanted cells BHK-21, MDBK and ZKG with the biological activity value at least 6.0 lg TCD50/cm3 and inactivated with aminoethylethyleneimine and also aluminum hydroxide as an adjuvant and, additionally, saponin taken in the effective ratios. The strain is deposited in the collection VGNKI at the registration code ""VNIIZZH-DEP"". Virus of the strain ""VNIIZZH-DEP"" is reproduced in transplanted cultures of cells BHK-21, MDBK and ZKG inducing cytopathic effect and virus is accumulated with the titer value 6.5-8.0 lg TCD50/cm3 for 48-96 h. Aminoethylethyleneimine is used in the concentration 0.1-0.2%, aluminum hydroxide is used as 3-4% gel in the amount 19.6-49.6 wt.-% and saponin is used as 10% aqueous solution in the amount 0.4 wt.-%. Vaccine shows high antigenic and immunogenic activity and harmless. ^ EFFECT: valuable properties of vaccine. ^ 18 cl, 8 tbl, 8 ex";"(RU2268747)
1. Vaccine against infectious rhino-tracheitis of large livestock sorbirovannaya inactivated, that contains antigenic material of the strain of the homologous virus, reproduced in the sensitive biological system and subjected to inactivation, and, at least, one adjuvant, that is characterized by the fact that as the antigenic material it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus of infectious rhino-tracheitis of large livestock (IRT KRS), seven. Herpesviridae, the kind Of Varicellavirus, the collection VGNKI “OF VNIIZZH-DEP”, in an effective quantity.
2. Vaccine according to claim 1, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells and subjected to inactivation.
3. Vaccine according to claim 2, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the homologous virus, reproduced in the interwoven culture of cells VNK-21 and inactivated aminoetiletileniminom (AEEI).
4. Vaccine according to claim 3, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells VNK-21 with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and inactivated AEEI.
5. Vaccine according to claim 4, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells VNK-21 with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and inactivated AEEI, in quantity 50,0-80,0 mas.%.
6. Vaccine according to claim 2, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells MDBK and inactivated AEEI.
7. Vaccine according to claim 6, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells MDBK with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and inactivated AEEI.
8. Vaccine according to claim 7, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells MDBK with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and inactivated AEEI, in quantity 50,0-80,0 mas.%.
9. Vaccine according to claim 2, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of the cells of 3KG and inactivated AEEI.
10. Vaccine according to claim 9, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of the cells of 3KG with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and inactivated AEEI.
11. Vaccine according to claim 10, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of the cells of 3KG with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and inactivated AEEI, in quantity 50,0-80,0 mas.%.
12. Vaccine according to claim 1, that is characterized by the fact that from the adjuvants it contains hydroxide of aluminum (GOA).
13. Vaccine according to claim 12, that is characterized by the fact that it contains GOA in the form 3-4% of gel.
14. Vaccine according to claim 13, that is characterized by the fact that it contains GOA in quantity 19,6-49,6 mas.%.
15. Vaccine according to claim 1, that is characterized by the fact that from the adjuvants it contains additionally saponin.
16. Vaccine according to claim 15, that is characterized by the fact that it contains saponin in the form of 10% aqueous solution.
17. Vaccine according to claim 16, that is characterized by the fact that it contains saponin in quantity 0,4 mas.%.
18. Vaccine according to claim 1, that is characterized by the fact that it contains antigenic material from the strain “OF VNIIZZH-DEP” of the virus IRT KRS, reproduced in the interwoven culture of cells, undertaken from the group, which consists of the interwoven culture of cells VNK-21, the interwoven culture of cells MDBK and of interwoven culture of the cells of 3KG, with the biological activity, at least, 6,0 Ig TTSD [50] /sm (3) and of the inactivated BY AEEI, the adjuvants GOA and saponin in the relationship, mas.%: Antigenic material
50. 0-80,0 GOA
19. 6-49,6 Saponin . 4";;;"A61K-039/265
A61P-031/12
C12N-007/00";;;Pharmaceuticals;Open
2004-05-31;"CN1704118           A  2005-12-07 [CN1704118]
STG: (A) Published application
AP : 2004CN-0046101 2004-05-31
CN100335129         C  2007-09-05 [CN100335129C]
STG: (C) Granted patent for invention
AP : 2004CN-0046101 2004-05-31";5227592;"CN1704118           A  2005-12-07 [CN1704118]
CN100335129         C  2007-09-05 [CN100335129C]";2004CN-0046101;;UNIVERSITY BEIJING;UNIVERSITY BEIJING;"(CN100335129C)
CN";"(CN100335129C)
NAME=PEKING UNIVERSITY , COUNTRY=CN 
";1;"CAI HONG
ZHU YUXIAN";;;"(CN100335129C)
Mycobacterium triple nucleic acid vaccine for cattle";"(CN100335129C)
The invention discloses a mycobacterium triple nucleic acid vaccine for cattle, whose preparation consists of fusing Ag85B, MPT-83 and MPT-64 genes or three genes of Ag85B, MPT-83 and MPT-64 with other nucleic acid sequences, then cloning the deletion partial sequence or partial mutated nucleic acid capable encoding nucleic acid sequences having the same reactive protein as Ag85B, MPT-83 and MPT-64 into eucaryon expressed carrying agent, then combining at least two of the prepared expression carriers for combination. The vaccine can be used from preventing and/or treating animal tuberculosis, in particular for preventing and/or treating ox, human and sheep's tuberculosis.";"(CN1704118)
1. One Mycobacterium bovis triple nucleic acid vaccine, is an Ag85B, MPT-83 and the MPT-64 gene or Ag85B, MPT-83 and the MPT-64 three gene fusion nucleic acid sequence corresponding to the other part of the nucleotide sequence or part thereof or deletion mutated and may be encoded with Ag85B, MPT-83 and the MPT-64 have the same nucleotide sequence of active protein, was cloned into a eukaryotic expression vector, the resultant jointly form a mixture of an expression vector.
2. Mycobacterium bovis triple nucleic acid vaccine according to claim 1, characterized in: a vaccine adjuvant DDA/or MPL and the guide plane and the/or Quil-A/or RIBI adjuvant and/or with physiological salt solution and/or aluminum adjuvant and/or Freund's adjuvant.
3. Mycobacterium bovis triple nucleic acid vaccine according to claim 2, characterized in: M. bovis triple nucleic acid vaccine nucleic acid vaccines with DDA in parts by weight ratio of 1-3:1.
4. Mycobacterium bovis triple nucleic acid vaccine according to claim 3, characterized in: M. bovis triple nucleic acid vaccine nucleic acid vaccines with DDA in parts by weight ratio of 3:1.
5. Mycobacterium bovis triple nucleic acid vaccine according to claim 1, characterized in: expression vector contains a promoter.
6. Mycobacterium bovis triple nucleic acid vaccine according to claim 5, characterized in: starting with pJW4303 son of the cytomegalovirus (CMV) early gene promoter or the promoter of the rat housekeeping genes.
7. According to claim 1 to 6 according to any one claim Mycobacterium bovis triple nucleic acid vaccine, characterized in: M. bovis triple nucleic acid vaccine to be Ag85B, MPT-83 and the MPT-64 genes was cloned into eukaryotic expression vectors and the expression product after pJW4303 in combination with a nucleic acid triplet Mycobacterium bovis vaccine.
8. Mycobacterium bovis triple nucleic acid vaccine according to claim 7, characterized in: M. bovis triple nucleic acid vaccine to the same parts by weight ratio of Ag85B, MPT-83 and the MPT-64 formed by the combination of the Mycobacterium bovis expression vector nucleic acid vaccine triplet.";"(CN100335129C)
An object of the present invention is to provide a superior immunogenic M. bovis triplex nucleic acid vaccines.
An object of the present invention is to provide a superior immunogenic M. bovis triplex nucleic acid vaccines.
An object of the present invention is to provide a superior immunogenic M. bovis triplex nucleic acid vaccines.
The present invention relates to a vaccine, particularly relates to a Mycobacterium bovis triplex nucleic acid vaccines.
The present invention provides Mycobacterium bovis triplex nucleic acid vaccine, is an Ag85B, MPT-83 and the MPT-64 gene or Ag85B, MPT-83 and the MPT-64 corresponding to the other three gene fusion nucleic acid sequence or partial sequence of the nucleotide mutation or deletion part thereof and may be encoded with Ag85B, MPT-83 and the MPT-64 have the same nucleotide sequence of the active protein, was cloned into a eukaryotic expression vector, the resulting mixture of an expression vector formed in combination.
The present invention relates to a vaccine, particularly relates to a Mycobacterium bovis triplex nucleic acid vaccines.";"(CN100335129C)
Mycobacterium bovis triplex nucleic acid vaccine the present invention significantly improves the large animal in particular to an animal (such as cattle, sheep and the like) protection efficiency, and eliminates a tuberculin sensitive reaction, enhance the safety of the vaccine.
The present invention to improve the immunity of animals and humans to Mycobacterium bovis, to more effectively control the spread of tuberculosis and popular, prosperity and enhance the human body mass with animal husbandry important theoretical significance and application value.
In addition, the choice of the DDA the present invention not only improves the efficiency of the vaccine adjuvant immunization, and allows for the immune response to a Th1-reaction is carried out.
But as indicated by inhalation, may also take place in exactly the same infection with M. tuberculosis, it is difficult to distinguish.";"A61K-039/04
A61K-048/00
A61P-031/06
C12N-015/31";"(CN100335129C)
1. One Mycobacterium bovis triple nucleic acid vaccine, is an Ag85B, MPT-83 and the MPT-64 gene, separately cloned into eukaryotic expression vectors, the resulting mixture was formed by a combination of the three types of expression vectors.";"(CN1704118)
MYCOBACTERIUM BOVIS(100,27)
TRIPLE NUCLEIC ACID VACCINE(100,22)
EUKARYOTIC EXPRESSION VECTOR(100,9)
GENE(100,8)
MYCOBACTERIUM BOVIS TRIPLEX(100,4)
ACTIVE PROTEIN(100,3)
NUCLEIC ACID SEQUENCE(100,3)
EXPRESSION VECTOR MIXTURE(100,2)
DELETION(100,1)
GENE FUSION(100,1)
MYCOBACTERIUM BOVIS VACCINE(73,2)
NUCLEOTIDE MUTATION(71,2)
VACCINE ADJUVANT IMMUNIZATION EFFICIENCY(65,1)
BOVIS TRIPLE(51,1)
AG FUSION(48,1)
OVINE TUBERCULOSIS(47,2)
BOVIS TRIPLEX(46,1)
RAT HOUSEKEEPING GENE PROMOTER(42,1)
THEORETICAL SIGNIFICANCE(42,1)
TUBERCULOSIS TREATMENT(41,1)
ANIMAL IMMUNITY(40,1)
MYCOBACTERIUM BOVIS EXPRESSION VECTOR(40,1)
EXPRESSION VECTOR(39,3)
VACCINE SAFETY(38,1)
CYTOMEGALOVIRUS SON(36,1)
TUBERCULOSIS SPREAD(33,2)
TRIPLE NUCLEIC ACID TREATMENT(29,1)
PREVENTION(27,4)
TUBERCULIN SENSITIVE REACTION(27,2)
NUCLEIC ACID VACCINE(26,16)
FREUND ADJUVANT(25,2)
FUSION NUCLEIC ACID SEQUENCE(22,1)
PROSPERITY(21,1)
ANIMAL HUSBANDRY(20,1)
INHALATION(20,1)
TRIPLEX NUCLEIC ACID VACCINE(18,9)
NUCLEIC ACID VACCINE TRIPLET(18,1)
ANIMAL(17,1)
NUCLEIC ACID TRIPLET(17,1)
PHYSIOLOGICAL SALT SOLUTION(17,1)
ALUMINUM ADJUVANT(16,2)
TUBERCULOSIS(15,14)
IMMUNE RESPONSE(15,4)
PROTECTION EFFICIENCY(15,4)
SHEEP(15,1)
INFECTION(14,2)
VACCINE(13,7)
BCG SUBCUTANEOUS INOCULATION(13,2)
FARM COMORBIDITY CHRONIC WASTING(13,1)
PART DELETION(13,1)
MYCOBACTERIUM TUBERCULOSIS PROTEIN(12,1)
CATTLE(11,13)
GUIDE PLANE(11,1)
MYCOBACTERIUM BOVIS BCG VACCINATION(11,1)
PPD BCG IMMUNIZATION(11,1)
VIRULENT MYCOBACTERIUM TUBERCULOSIS(11,1)
TUBERCULOSIS AG(10,4)
LESION HISTOPATHOLOGICAL EXAMINATION(10,1)
LUNG PARENCHYMA FIBROSIS(10,1)
VACCINE MYCOBACTERIUM BOVIS TRIPLE(10,1)
PHYSIOLOGICAL SALINE(9,3)
VIRULENT MYCOBACTERIUM BOVIS(9,2)
BOVINE IMMUNIZED TERPHENYLYL(9,1)
BOVINE INTRAMUSCULAR IMMUNIZATION(9,1)
BOVIS INFECTED CATTLE(9,1)
ENDOGENOUS PROTEASOME DEGRADATION(9,1)
IMMUNE BOVINE ANTIBODY TITER(9,1)
MISSING PORTION(9,1)
VACCINE ADJUVANT EFFICACY(9,1)
BOVINE TUBERCULOSIS LESION(8,2)
LUNG DAMAGE(8,2)
MONTH POST CHALLENGE(8,2)
RECOMBINANT SUBUNIT VACCINE(8,2)
ANESTHETIZED ANIMAL TRACHEA(8,1)
CATTLE ALVEOLAR TISSUE(8,1)
EXPERIMENTALLY INFECTED CATTLE(8,1)
MACROPHAGE MIXED LYMPHOCYTE INFILTRATION(8,1)
PEOPLE LIBERATION ARMY(8,1)
STEPWISE LUNG HOMOGENATE(8,1)
TISSUE BLOOD PLASMINOGEN ACTIVATOR(8,1)
TUBERCULOSIS INFECTION PREVENTION(8,1)
TUBERCULOSIS SECRETORY PROTEIN(8,1)
TUBERCULOSIS YEAR INCIDENCE(8,1)
NUCLEIC ACID VACCINE IMMUNIZATION(7,5)
IMMUNIZED PJW RESPONSE(7,2)
LUNG CULTURE POSITIVE TUMOR(7,2)
RECOMBINANT PLASMID(7,2)
ANTIGEN PLASMID DNA(7,1)
BCG IMMUNE CATTLE(7,1)
BOVINE DNA IMMUNIZATION(7,1)
CHRONIC INFECTIOUS DISEASE(7,1)
COSTIMULATORY MOLECULE EXPRESSION(7,1)
CULTURE INCUBATOR SUPERNATANT(7,1)
DERMOID MACROPPHAGE(7,1)
DNA VACCINE IMMUNE PJW(7,1)
HEPARINIZED BLOOD JUGULAR VEIN(7,1)
HORSERADISH PEROXIDASE LABELED GOAT(7,1)
HUMAN BODY(7,1)
INNATE IMMUNE EXPERIMENT ANALYSIS(7,1)
LUNG PARENCHYMA FRACTION(7,1)
LUNG PARENCHYMA SIGNIFICANT FIBROSIS(7,1)
NIUS PROTECTIVE EFFICACY(7,1)
PLASMID MAXI KIT(7,1)
POTENT ANTIGENICITY(7,1)
TUBERCULOSIS INFECTED MOUSE(7,1)
BACILLUS CALMETTE GUERIN(6,3)
HUMORAL IMMUNE RESPONSE(6,2)
ALLERGIC REACTION PPD CATTLE(6,1)
ANALYSIS AIRWAY PROTECTIVE EFFICACY(6,1)
ANTIGEN STIMULATION(6,1)
BACTERIA COUNTING(6,1)
BEIJING UNIVERSITY(6,1)
BOVINE IMMUNIZATION(6,1)
BOVINE PATHOGEN(6,1)
BOVINE POST CHALLENGE(6,1)
BOVINE PPD INJECTION(6,1)
BOVINE PULMONARY TISSUE DEVELOPMENT(6,1)
BOVINE VIRAL EXCHANGE(6,1)
BOVIS COLONY(6,1)
CATTLE IMMUNIZATION(6,1)
CYTOMEGALOVIRUS PROMOTER(6,1)
DEFATTED MILK(6,1)
DNA ENCODING(6,1)
DNA VACCINE TERPHENYLYL(6,1)
EUKARYOTIC EXPRESSION PROMOTER(6,1)
EXPERIMENT TUBERCULOSIS INFECTION COURSE(6,1)
EXTRACTING DNA GENOME(6,1)
EXTRACTION KIT(6,1)
GENETIC VACCINE CONSTRUCT(6,1)
HEPARINIZED BOVINE BLOOD(6,1)
HIV IMMUNE DEFICIENT PATIENT(6,1)
HOSPITAL TUBERCULOSIS(6,1)
HUMAN TUBERCULOSIS PATIENT(6,1)
IGG ANTIBODY REACTION SPECIFICITY(6,1)
IMMUNE BOVINE LUNG(6,1)
IMMUNIZED COW(6,1)
IMMUNOGLOBULIN SECRETION(6,1)
INFECTED T LYMPHOCYTE(6,1)
INTRADERMAL JUNCTION SPECIES(6,1)
JOB BOVINE TUBERCULOSIS(6,1)
LUNG GERM(6,1)
LYMPHOCYTE ALVEOLAR(6,1)
LYMPHOCYTIC INFILTRATION ABUNDANCE(6,1)
MACROPHAGE ANTIGEN(6,1)
MACROSCOPIC LUNG INJURY SITUATION(6,1)
MAMMALIAN EXPRESSION VECTOR(6,1)
MOUSE HOUSEKEEPING GENE PROMOTER(6,1)
MYCOBACTERIAL ANTIGEN(6,1)
MYCOBACTERIUM BOVIS CHALLENGE(6,1)
MYCOBACTERIUM BOVIS CULTURE(6,1)
MYCOBACTERIUM TUBERCULOSIS RELATION(6,1)
NONESSENTIAL AMINOACID(6,1)
NUTRITIONAL INGREDIENT(6,1)
PATIENT LYMPHOCYTE EARLY IDENTIFICATION(6,1)
POLYVALENT MYCOBACTERIUM BOVIS(6,1)
PULMONARY NODULE(6,1)
PULMONARY TUBERCULOSIS LESION(6,1)
RECOMBINANT EXPRESSION PLASMID(6,1)
RECOMBINANT STRAIN SCREENING(6,1)
RESTRICTION ENDONUCLEASE(6,1)
SECRETED PROTEIN STRUCTURAL GENE(6,1)
SERO DOMINANT ANTIGEN(6,1)
STRONG ANTIGEN REACTIVITY(6,1)
STRONG PROMOTER TRANSCRIPTION(6,1)
TENBROECK GRINDER(6,1)
TISSUE HISTOPATHOLOGICAL ANALYSIS(6,1)
TRACHEAL INTUBATION(6,1)
TRIPARTITE DNA VACCINE(6,1)
TUBERCULIN PPD(6,1)
ULTRAVIOLET SPECTROPHOTOMETER(6,1)
WEEK POST CHALLENGE(6,1)
ZHANGHUATONG TUBERCULOSIS(6,1)
ANTIBODY DILUTION(5,1)
BCG DNA VACCINE(5,1)
BCG PPD(5,1)
BLOOD LYMPHOCYTE(5,1)
BOVINE CHALLENGE(5,1)
BOVINE INTERFERON(5,1)
BOVINE PULMONARY FIBROSIS(5,1)
BOVINE TUBERCULOSIS INFECTION(5,1)
BOVIS INFECTION(5,1)
BOVIS TRIPLEX NUCLEIC ACID(5,1)
BUFFERED FORMALDEHYDE(5,1)
CHALLENGE EXPERIMENT(5,1)
CHINESE PEOPLE(5,1)
DIAGNOSTIC REAGENT DEVELOPMENT(5,1)
DIRECTIONAL CLONING(5,1)
DNA IMMUNIZED FIVE CATTLE(5,1)
DNA TRIPLET(5,1)
EMPTY VECTOR DNA VACCINE(5,1)
ENZYME DIGESTION(5,1)
EXPRESSION HETEROGENEITY(5,1)
HEMOLYSED BLOOD(5,1)
HUMAN ANIMAL TUBERCULOSIS TREATMENT(5,1)
IMMUNIZATION INJECTION(5,1)
IMMUNIZED ANIMAL CELL(5,1)
IMMUNOGENICITY STUDY(5,1)
INFECTION ROUTE(5,1)
INSERT SEQUENCE CORRECTNESS(5,1)
LIN ET VAN(5,1)
LIPOSOMAL GLYCOSYLATED PROTEIN CAUSE(5,1)
LOWENSTEIN JENSEN MEDIUM CULTURE(5,1)
MILLION CATTLE(5,1)
PBS TWEEN BUFFER(5,1)
PCR AMPLIFICATION(5,1)
PEOPLE BILLION(5,1)
PRECIPITATED MIXED PIPETTING(5,1)
QIAQUICK GEL(5,1)
RECOMBINANT VECTOR(5,1)
STIMULUS STRONG PROLIFERATIVE RESPONSE(5,1)
TERPHENYLYL DNA(5,1)
THORACIC LYMPH NODE(5,1)
TUBERCULOSIS DNA VACCINE(5,1)
TWOFOLD SERIAL(5,1)
BCG VACCINE(4,3)
COLLATERAL DAMAGE MINIMUM(4,3)
FIBROBLAST(4,3)
ARTIFICIAL SEQUENCE(4,2)
BOVINE LUNG SECTION SLICE(4,2)
CATTLE HEAD(4,2)
HUMORAL RESPONSE(4,2)
MYCOBACTERIUM TUBERCULOSIS H37RV(4,2)
PROLIFERATIVE RESPONSE DETECTION(4,2)
TOUR FORCE(4,2)
ADULT PROTECTION(4,1)
ALLERGY DETECTION(4,1)
ANIMAL HUSBANDRY RAPID DEVELOPMENT(4,1)
ANTI BOVINE ANTISERUM(4,1)
ANTIGEN ABSENCE(4,1)
ANTIGEN SOLUTION CULTURE(4,1)
BCG AG(4,1)
BCG IMMUNIZATION GROUP(4,1)
BOVINE AG(4,1)
BOVINE IGG(4,1)
BOVINE SERUM(4,1)
BOVIS EFFECTIVE IMMUNITY(4,1)
BRANCHED ACID TRANSFERASE ACTIVITY(4,1)
CATTLE AG(4,1)
CENTER YELLOW CALCIUM CHEESE(4,1)
CONTENT IMMUNIZATION(4,1)
DILUTED SERUM SAMPLE(4,1)
DNA VECTOR(4,1)
DOMESTIC DEVELOPMENT(4,1)
EARLY RECOGNITION(4,1)
EXOGENOUS GENE PRODUCT(4,1)
FINE CANNULA(4,1)
FOREIGN DATA(4,1)
FUSION PROTEIN(4,1)
HUMAN FIBRONECTIN(4,1)
INJURY SITE(4,1)
LIVESTOCK INDUSTRY(4,1)
LIVESTOCK WORKING(4,1)
MARKED BOVINE(4,1)
MEGA KIT(4,1)
MILLION DEATH(4,1)
NECK MUSCLE IMMUNIZATION MIXTURE(4,1)
PERSON CONTAMINATION(4,1)
POST STIMULUS(4,1)
POTENTIAL VIRULENCE(4,1)
PROTECTIVE IMMUNITY(4,1)
RESISTANT STRAIN GENERATION(4,1)
SALINE PROTECTION EFFICIENCY INJECTION(4,1)
TUBERCULOSIS TRANSMISSION(4,1)
VACCINE STUDY(4,1)
VECTOR PJW(4,1)
VIABLE COUNT(4,1)
WHOLE BLOOD CULTURE(4,1)
ANTIBODY LEVEL(3,2)
FOREIGN NUCLEIC ACID VACCINE(3,2)
INCUBATION(3,2)
PERIPHERAL BLOOD MONONUCLEAR CELL(3,2)
PJW MPT(3,2)
SHOT(3,2)
SIGNAL PEPTIDE(3,2)
BLOOD TISSUE(3,1)
CARBONATE BUFFER(3,1)
CATTLE TREATMENT(3,1)
CELL MEDIATED RESPONSE(3,1)
CPG SEQUENCE(3,1)
DAMAGE SCORE(3,1)
DIMETHYLTHIAZOL(3,1)
DNA VACCINE DEVELOPMENT(3,1)
EFFECTIVENESS(3,1)
EXTRACELLULAR SECRETORY SIGNAL SEQUENCE(3,1)
GENERATING CATTLE(3,1)
HILAR LYMPH NODE SAMPLE(3,1)
HUMAN HEALTH(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
LAST IMMUNIZATION(3,1)
LUNG CONTROL BOVINE TRACHEA(3,1)
LYMPH NODE TISSUE(3,1)
LYNIPHOPROLIFERATION(3,1)
MEDIASTINUM(3,1)
MYCOBACTERIAL CELL WALL SYNTHESIS(3,1)
NEGATIVE CULTURE(3,1)
NORMAL LUNG TISSUE(3,1)
NUCLEIC ACID IMMUNIZATION(3,1)
ORGAN FAILURE(3,1)
PPD POSITIVE COW(3,1)
PROTECTIVE IMMUNE RESPONSE(3,1)
SCAND J IMMUNOL(3,1)
SEQUENCE AMPLIFICATION(3,1)
SIGNIFICANT ANTIGEN IGG RESPONSE(3,1)
SUBSTRAIN(3,1)
TRANSFORMED BACTERIUM SINGLE COLONY(3,1)
TRAUMA DIAMETER(3,1)
VACCINE CONSTRUCTION(3,1)
VACCINE INDUCED IMMUNE RESPONSE(3,1)
VORDERMEIER ET(3,1)
WEAK POSITIVE AB(3,1)
(CN100335129C)
MPT(100,31)
MYCOBACTERIUM BOVIS(100,22)
TRIPLE NUCLEIC ACID VACCINE(100,21)
AG85B(100,8)
EUKARYOTIC EXPRESSION VECTOR(100,8)
EXPRESSION VECTOR(100,5)
GENE(100,5)
BOVIS TRIPLEX NUCLEIC ACID VACCINE(100,4)
MYCOBACTERIUM BOVIS TRIPLEX NUCLEIC ACID VACCINE(88,4)
MYCOBACTERIUM BOVIS TRIPLE VACCINE(73,1)
RAT HOUSEKEEPING GENE PROMOTER(61,1)
BOVINE ANIMAL TUBERCULOSIS(58,1)
CYTOMEGALOVIRUS SON(52,1)
FREUND ADJUVANT(37,2)
RIBI ADJUVANT(37,2)
PHYSIOLOGICAL SALINE(30,4)
INHALATION(28,1)
VACCINE(27,9)
7CFU VIRULENT MYCOBACTERIUM BOVIS(24,2)
ALUMINUM ADJUVANT(23,2)
REAR PJW(23,1)
TUBERCULOSIS(22,14)
NONIMMUNE BOVINE TRACHEAL INTUBATION(21,1)
INFECTION(20,2)
BACILLE CALMETTE GUERIN IMMUNIZATION(17,4)
MYCOBACTERIUM TUBERCULOSIS PROTEIN(17,1)
NUCLEIC ACID TREATMENT(17,1)
MYCOBACTERIUM TUBERCULOSIS VIRULENCE(16,1)
QIAGEN PLASMID MAXI KIT(16,1)
VIRULENT MYCOBACTERIUM TUBERCULOSIS(16,1)
IMMUNE CATTLE(15,4)
ANTIBODY ADJUVANT CREATION TITER(15,1)
LESION HISTOPATHOLOGICAL EXAMINATION(15,1)
LUNG PARENCHYMA FIBROSIS(15,1)
BOVINE IMMUNIZED TERPHENYLYL(13,1)
BOVINE INTRAMUSCULAR IMMUNIZATION(13,1)
CATTLE DNA VACCINATION(13,1)
NIUS ANTIGEN STIMULATION(13,1)
PROTEASOME DEGRADATION ENDOGENOUS SYNTHESIS(13,1)
VACCINE ADJUVANT DDA(13,1)
POST CHALLENGE(12,5)
BACILLE CALMETTE GUERIN VACCINE(12,3)
BOVINE IMMUNIZATION(12,2)
RECOMBINANT SUBUNIT VACCINE(12,2)
SUBCUTANEOUS INOCULATION(12,2)
TRIPARTITE DNA VACCINE(12,2)
ANESTHETIZED ANIMAL TRACHEA(12,1)
ANTIBODY IGG TITER(12,1)
CATTLE ALVEOLAR TISSUE(12,1)
EXPERIMENTALLY INFECTED CATTLE(12,1)
HORSERADISH PEROXIDASE LABELED ANTISERUM(12,1)
MACROPHAGE MIXED LYMPHOCYTE INFILTRATION(12,1)
MYCOBACTERIUM BOVIS SUBSTRAIN(12,1)
PEOPLE LIBERATION ARMY(12,1)
PROTEIN GENE DNA VACCINE IMMUNIZATION(12,1)
STEPWISE LUNG HOMOGENATE(12,1)
STERILIZED MILK INGESTION(12,1)
TISSUE BLOOD PLASMINOGEN ACTIVATOR(12,1)
TUBERCULOSIS AG85B DNA(12,1)
TUBERCULOSIS INFECTION PREVENTION(12,1)
TUBERCULOSIS SECRETORY PROTEIN(12,1)
TUBERCULOSIS YEAR INCIDENCE(12,1)
MYCO BACTERIAL ANTIGEN(11,2)
TUBERCULOSIS DNA VACCINE(11,2)
ANTIGEN PLASMID DNA(11,1)
BOVINE ANTIBODY TITER(11,1)
BOVINE DNA IMMUNIZATION(11,1)
CHRONIC INFECTIOUS DISEASE(11,1)
COSTIMULATORY MOLECULE EXPRESSION(11,1)
CULTURE INCUBATOR SUPERNATANT(11,1)
DERMOID MACROPPHAGE(11,1)
HEPARINIZED BLOOD JUGULAR VEIN(11,1)
INNATE IMMUNE EXPERIMENT ANALYSIS(11,1)
LUNG PARENCHYMA FRACTION(11,1)
LUNG PARENCHYMA SIGNIFICANT FIBROSIS(11,1)
NIUS PROTECTIVE EFFICACY(11,1)
POTENT ANTIGENICITY(11,1)
SERO DOMINANT ANTIGEN STATUS(11,1)
TUBERCULOSIS INFECTED MOUSE(11,1)
6CFU BACILLE CALMETTE GUERIN(10,2)
DIRECTIONAL CLONING(10,2)
LUNG DAMAGE(10,2)
RECOMBINANT PLASMID(10,2)
TRIPLEX NUCLEIC ACID VACCINE IMMUNIZATION(10,2)
AG85B EXPRESSION VECTOR(10,1)
BACTERIA COUNTING(10,1)
BOVINE PPD INJECTION(10,1)
BOVINE PULMONARY TISSUE DEVELOPMENT(10,1)
DNA ENCODING(10,1)
EUKARYOTIC EXPRESSION PROMOTER(10,1)
GENETIC VACCINE CONSTRUCT(10,1)
HEPARINIZED BOVINE BLOOD(10,1)
HOSPITAL TUBERCULOSIS(10,1)
LYMPHOCYTIC INFILTRATION ABUNDANCE(10,1)
MOUSE HOUSEKEEPING GENE PROMOTER(10,1)
MYCOBACTERIUM BOVIS CHALLENGE(10,1)
MYCOBACTERIUM BOVIS COLONY(10,1)
MYCOBACTERIUM TUBERCULOSIS RELATION(10,1)
PATIENT LYMPHOCYTE EARLY IDENTIFICATION(10,1)
POLYVALENT MYCOBACTERIUM BOVIS(10,1)
PULMONARY TUBERCULOSIS LESION(10,1)
RECOMBINANT EXPRESSION PLASMID(10,1)
RECOMBINANT STRAIN SCREENING(10,1)
SCORE BACILLE CALMETTE GUERIN(10,1)
TENBROECK GRINDER(10,1)
VACCINE MYCOBACTERIUM BOVIS TRIPLE NUCLEIC ACID VACCINE(10,1)
ZHANGHUATONG TUBERCULOSIS(10,1)
ALLERGIC REACTION PPD CATTLE(8,1)
ANALYSIS TRACHEA PROTECTIVE EFFICACY(8,1)
BEIJING UNIVERSITY(8,1)
BOVINE PATHOGEN(8,1)
BOVINE PATHOLOGICAL ANALYSIS(8,1)
BOVINE TUBERCULOSIS LESION(8,1)
BOVINE VIRAL EXCHANGE(8,1)
CATTLE IMMUNIZATION(8,1)
CENTRIFUGAL 20MIN(8,1)
DEFATTED MILK(8,1)
DIPHENYLTETRAZOLIUM BROMIDE(8,1)
DNA VACCINE TERPHENYLYL(8,1)
EXPERIMENT TUBERCULOSIS INFECTION COURSE(8,1)
EXTRACTION KIT(8,1)
GENOMIC DNA EXTRACTION(8,1)
GOAT ANTIBOVINE(8,1)
HIV IMMUNE DEFICIENT PATIENT(8,1)
IDENTIFICATION CORRECTNESS(8,1)
IMMUNIZED COW(8,1)
IMMUNOGLOBULIN SECRETION(8,1)
INTRADERMAL JUNCTION SPECIES(8,1)
JOB BOVINE TUBERCULOSIS(8,1)
LUNG GERM(8,1)
LYMPHOCYTE ALVEOLAR(8,1)
MACROPHAGE ANTIGEN(8,1)
MACROSCOPIC LUNG INJURY SITUATION(8,1)
MAMMALIAN EXPRESSION VECTOR(8,1)
MYCO BACTERIAL CELL(8,1)
MYCOBACTERIUM BOVIS CULTURE(8,1)
NONEMPTY PJW(8,1)
NUTRITIONAL INGREDIENT(8,1)
PPD DTH REACTION(8,1)
PULMONARY NODULE(8,1)
RESTRICTION ENDONUCLEASE(8,1)
SECRETED PROTEIN STRUCTURAL GENE(8,1)
STRONG ANTIGEN REACTIVITY(8,1)
STRONG PROMOTER TRANSCRIPTION(8,1)
TISSUE HISTOPATHOLOGICAL ANALYSIS(8,1)
ULTRAVIOLET SPECTROPHOTOMETER(8,1)
ARTIFICIAL SEQUENCE(7,2)
BOVINE LUNG SECTION SLICE(7,2)
BOVINE PERIPHERAL BLOOD MONONUCLEAR CELL(7,2)
HUMORAL RESPONSE(7,2)
MYCOBACTERIUM TUBERCULOSIS H37RV(7,2)
PROLIFERATIVE RESPONSE DETECTION(7,2)
AG85B GENE(7,1)
AG85B MPT(7,1)
ANTIBODY DILUTION(7,1)
BACILLE CALMETTE GUERIN IMMUNE(7,1)
BACILLE CALMETTE GUERIN PPD(7,1)
BLOOD LYMPHOCYTE(7,1)
BOVINE CHALLENGE(7,1)
BOVINE INTERFERON(7,1)
BOVINE PULMONARY FIBROSIS(7,1)
BOVINE TUBERCULOSIS INFECTION(7,1)
BOVIS INFECTION(7,1)
BUFFERED FORMALDEHYDE(7,1)
CHALLENGE EXPERIMENT(7,1)
CHEMI CON(7,1)
CHINESE PEOPLE(7,1)
CHRONIC WASTING(7,1)
COMPARATIVE SPECIFICITY(7,1)
DIAGNOSTIC REAGENT DEVELOPMENT(7,1)
DNA IMMUNIZED FIVE CATTLE(7,1)
DNA TRIPLET(7,1)
EMPTY VECTOR DNA VACCINE(7,1)
ENCODING AG85B(7,1)
HEMOLYSED BLOOD(7,1)
IMMUNE PJW(7,1)
IMMUNIZATION INJECTION(7,1)
IMMUNIZED ANIMAL CELL(7,1)
IMMUNIZED MOUSE(7,1)
IMMUNIZED PJW RESPONSE(7,1)
IMMUNOGENICITY STUDY(7,1)
INFECTION ROUTE(7,1)
LIN ET VAN(7,1)
LIPOSOMAL GLYCOSYLATED PROTEIN CAUSE(7,1)
LOWENSTEIN JENSEN MEDIUM CULTURE(7,1)
MICROPLATE READER(7,1)
MILLION CATTLE(7,1)
MPB HETEROGENOUS EXPRESSION(7,1)
PCR AMPLIFICATION(7,1)
PEOPLE BILLION(7,1)
PRECIPITATED MIXED PIPETTING(7,1)
PROTECTING TREATED CATTLE(7,1)
QIAQUICK GEL(7,1)
RECOMBINANT VECTOR(7,1)
STIMULUS STRONG PROLIFERATIVE RESPONSE(7,1)
TERPHENYLYL DNA(7,1)
THORACIC LYMPH NODE(7,1)
TRIPLE NUCLEIC ACID VACCINE IMMUNIZATION(7,1)
TRIPLE NUCLEIC ACID VACCINE MYCOBACTERIUM BOVIS(7,1)
TRIPLEX NUCLEIC ACID VACCINE CATTLE(7,1)
TUBERCULIN SKIN TEST(7,1)
TUBERCULOSIS PATIENT(7,1)
TUBERCULOSIS SPREAD(7,1)
COLLATERAL DAMAGE MINIMUM(6,3)
FIBROBLAST(6,3)
ANTIGEN ABSENCE(6,2)
CYTOMEGALOVIRUS(6,2)
MYCOBACTERIA(6,2)
TOUR FORCE(6,2)
1M CARBONATE BUFFER(6,1)
5M NACL(6,1)
ADULT PROTECTION(6,1)
ALLERGY DETECTION(6,1)
ANIMAL HUSBANDRY RAPID DEVELOPMENT(6,1)
ANTIBODY TITER IMMUNIZATION(6,1)
BOVINE IGG ANTIBODY RESPONSE(6,1)
BOVINE IMMUNE(6,1)
BOVINE SERUM(6,1)
BOVIS EFFECTIVE IMMUNITY(6,1)
BRANCHED ACID TRANSFERASE ACTIVITY(6,1)
CATTLE PROTECTION(6,1)
CENTER YELLOW CALCIUM CHEESE(6,1)
CONTENT IMMUNIZATION(6,1)
DNA VECTOR(6,1)
DOMESTIC DEVELOPMENT(6,1)
EARLY RECOGNITION(6,1)
EXOGENOUS GENE PRODUCT(6,1)
FINE CANNULA(6,1)
FOREIGN DATA(6,1)
FUSION PROTEIN(6,1)
HUMAN FIBRONECTIN(6,1)
INJURY SITE(6,1)
LEPRA 65KDA HEAT SHOCK(6,1)
LIVE BACILLE CALMETTE GUERIN(6,1)
LIVESTOCK INDUSTRY(6,1)
LIVESTOCK WORKING(6,1)
LUNG CULTURE POSITIVE TUMOR(6,1)
LYMPH NODE SHOULDER(6,1)
MARKED BOVINE(6,1)
MEGA KIT(6,1)
MILLION DEATH(6,1)
NECK MUSCLE IMMUNIZATION MIXTURE(6,1)
PERSON CONTAMINATION(6,1)
POST STIMULUS(6,1)
PROTECTIVE IMMUNITY(6,1)
RESISTANT STRAIN GENERATION(6,1)
TETRAMETHYLBENZIDINE(6,1)
TUBERCULIN SENSITIVE REACTION(6,1)
TUBERCULOSIS TRANSMISSION(6,1)
TUBERCULOSIS TREATMENT(6,1)
UNTIMELY TREATMENT(6,1)
VACCINE STUDY(6,1)
VECTOR PJW(6,1)
VIABLE COUNT(6,1)
WEAK POSITIVE AB(6,1)
WHOLE BLOOD CULTURE(6,1)
COCKLE(5,2)
FOREIGN NUCLEIC ACID VACCINE(5,2)
INCUBATION(5,2)
MICROSCOPE(5,2)
PJW MPT(5,2)
SHOT(5,2)
SIGNAL PEPTIDE(5,2)
ATTENUATED VACCINE INDUCED SECURITY(5,1)
BLOOD TISSUE(5,1)
CALMETTE GUERIN NUCLEIC ACID SEQUENCE(5,1)
CATTLE HEAD(5,1)
COW NONIMMUNE CONTROL(5,1)
DAMAGE SCORE(5,1)
DDA NUCLEIC ACID VACCINE(5,1)
DEVELOPING ACTIVE TUBERCULOSIS PERSON(5,1)
DIMETHYLTHIAZOL(5,1)
DNA VACCINE DEVELOPMENT(5,1)
EMPTY CARRIER INJECTION(5,1)
ENDOTRACHEAL TUBE(5,1)
EXPERIMENTAL SAMPLE(5,1)
EXTRACELLULAR SECRETORY SIGNAL SEQUENCE(5,1)
FARM CO MORBIDITY(5,1)
FOLD SERIAL(5,1)
GENERATING CATTLE(5,1)
GUINEA DTH REACTION(5,1)
HILAR LYMPH NODE SAMPLE(5,1)
HUMAN ANIMAL TREATMENT(5,1)
HUMAN HEALTH(5,1)
HUMORAL IMMUNE RESPONSE ANTIGEN(5,1)
IMMUNOLOGICAL RESPONSE(5,1)
LAST IMMUNIZATION(5,1)
LUNG CONTROL BOVINE TRACHEA(5,1)
LYMPH NODE TISSUE(5,1)
LYMPHOCYTE INFILTRATION CONTROL(5,1)
LYNIPHOPROLIFERATION(5,1)
MEDIASTINUM(5,1)
NATURAL MPT(5,1)
NEGATIVE CULTURE(5,1)
NORMAL LUNG TISSUE(5,1)
NUCLEIC ACID IMMUNIZATION(5,1)
ORGAN FAILURE(5,1)
PBS TWEEN BUFFER(5,1)
PPD POSITIVE COW(5,1)
PROTECTIVE IMMUNE RESPONSE(5,1)
PURIFIED NATURAL(5,1)
SALINE PROTECTION EFFICIENCY(5,1)
SCAND J IMMUNOL(5,1)
SEQUENCE AMPLIFICATION(5,1)
SERUM SAMPLE(5,1)
SIGNIFICANT ANTIGEN IGG RESPONSE(5,1)
T LYMPHOCYTE INFECTION(5,1)
TARGET GENE(5,1)
TRANSFORMED BACTERIUM SINGLE COLONY(5,1)
TRAUMA DIAMETER(5,1)
TUBERCULIN PPD SKIN TEST RESPONSE(5,1)
TUBERCULOSIS POSITIVE(5,1)
VACCINE CONSTRUCTION(5,1)
VACCINE INDUCED IMMUNE RESPONSE(5,1)";Pharmaceuticals;Open
"2004-05-19
2004-07-20
2005-05-18
2005-05-19";"WO2005111201        A1 2005-11-24 [WO2005111201]
STG: (A1) Published application with search report
AP : 2005WO-EP05377 2005-05-18
CA2561719           A1 2005-11-24 [CA2561719]
STG: (A1) Application laid open
AP : 2005CA-2561719 2005-05-18
AU2005243488        A1 2005-11-24 [AU2005243488]
STG: (A1) Open to public inspection
AP : 2005AU-0243488 2005-05-18
US20050287171       A1 2005-12-29 [US20050287171]
STG: (A1) Application published
AP : 2005US-11132686 2005-05-19
UY28905             A1 2005-12-30 [UY--28905]
STG: (A1) Patent application (First publication level)
AP : 2005UY-0028905 2005-05-18
DE102004025452      A1 2006-01-19 [DE102004025452]
STG: (A1) Doc. laid open (First publication)
AP : 2004DE-10025452 2004-05-19
AR049176            A1 2006-07-05 [AR--49176]
STG: (A1) Independent patent application
AP : 2005AR-0102032 2005-05-18
KR10-2007-0012862   A  2007-01-29 [KR20070012862]
STG: (A) Published application
AP : 2006KR-7026800 2005-05-18
EP1751276           A1 2007-02-14 [EP1751276]
STG: (A1) Application published with search report
AP : 2005EP-0741681 2005-05-18
MXPA06013298        A  2007-05-07 [MX2006PA013298]
STG: (A) Patent application
AP : 2006MX-PA13298 2005-05-18
CN1989240           A  2007-06-27 [CN1989240]
STG: (A) Published application
AP : 2005CN-80024345 2005-05-18
IN6428/DELNP/2006   A  2007-08-31 [IN2006DN06428]
STG: (A) Application laid open
AP : 2006IN-DN06428 2006-11-01
BRPI0510396         A  2007-11-13 [BR200510396]
STG: (A) Published application
AP : 2005BR-0010396 2005-05-18
BRPI0510396         A1 2007-11-13 [BR200510396]
STG: (A1) Published application
AP : 2005BR-0010396 2005-05-18
JP2007537740        A  2007-12-27 [JP2007537740]
STG: (A) Published application
AP : 2007JP-0517077 2005-05-18
EP1751276           B1 2009-01-14 [EP1751276]
STG: (B1) Patent specification
AP : 2005EP-0741681 2005-05-18
AT420949            T  2009-01-15 [ATE420949]
STG: (T) EP patent valid in AT
AP : 2005AT-0741681T 2005-05-18
PT1751276           E  2009-02-24 [PT1751276]
STG: (E) Availability of national translation of European patent
AP : 2005PT-0741681T 2005-05-18
DE602005012381      D1 2009-03-05 [DE602005012381]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2005DE-60012381 2005-05-18
DK1751276           T3 2009-05-18 [DK1751276T]
STG: (T3) Translation of EP patent
AP : 2005DK-0741681 2005-05-18
ES2321210           T3 2009-06-03 [ES2321210]
STG: (T3) Translation of granted European patent (former B3)
AP : 2005ES-0741681T 2005-05-18
SI1751276           T1 2009-06-30 [SI1751276T]
STG: (T1) Translation of EP claims
AP : 2005SI-0030619 2005-05-18
KR10-0908798        B1 2009-07-22 [KR100908798]
STG: (B1) Patent specification
AP : 2006KR-7026800 2005-05-18
US7572455           B2 2009-08-11 [US7572455]
STG: (B2) Granted patent as second publication
AP : 2005US-11132686 2005-05-19
FD :  Provisional Appl: US60/589,361 FDD=2004-07-20 [2004US-60589361]
FD : Previous publication: US20050287171 A1 2005-12-29 [US20050287171]
NZ552088            A  2009-10-30 [NZ-552088]
STG: (A) Published application
AP : 2005NZ-0552088 2005-05-18
RS50753             B  2010-08-31 [RS--50753]
STG: (B) Patent Specification
AP : 2009RS-0000106 2005-05-18
AU2005243488        B2 2011-07-07 [AU2005243488]
STG: (B2) Patent proceeded by OPI
AP : 2005AU-0243488 2005-05-18
BRPI0510396         A2 2012-03-20 [BR200510396]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2005BR-0010396 2005-05-18
JP2012061001        A  2012-03-29 [JP2012061001]
STG: (A) Published application
AP : 2011JP-0247652 2011-11-11
JP5006782           B2 2012-06-01 [JP5006782]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2007JP-0517077 2005-05-18
ME01119             B  2013-03-20 [ME---1119]
STG: (B)
AP : 2009ME-0000056 2005-05-18
CN1989240           B  2013-07-31 [CN1989240B]
STG: (B) Granted patent for invention
AP : 2005CN-80024345 2005-05-18
IN257379            B  2013-10-04 [IN-257379]
STG: (B) Patent
AP : 2006IN-DN06428 2006-11-01
CN103352030         A  2013-10-16 [CN103352030]
STG: (A) Published application
AP : 2013CN-0269097 2005-05-18
JP5562316           B2 2014-06-20 [JP5562316]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2011JP-0247652 2011-11-11
FD :  Division of: JP2007517077 FDD=2005-05-18 [2007JP-0517077]
CY1109036           T1 2014-07-02 [CY1109036]
STG: (T1) Translation of EP granted patent
AP : 2009CY-1100429 2009-04-10
CA2561719           C  2015-01-27 [CA2561719]
STG: (C) Patent (second level)
AP : 2005CA-2561719 2005-05-18
LU92748             I2 2015-11-02 [LU--92748]
STG: (I2) Supplementary protection certificate
AP : 2015LU-0092748 2015-06-19
LU92749             I2 2015-11-02 [LU--92749]
STG: (I2) Supplementary protection certificate
AP : 2015LU-0092749 2015-06-19
LU92747             I2 2015-11-02 [LU--92747]
STG: (I2) Supplementary protection certificate
AP : 2015LU-0092747 2015-06-19
NL300745            I1 2016-01-26 [NL-300745I]
STG: (I1) Suppl. protection certificate application
AP : 2015NL-C300745 2015-06-16
NL300745            I2 2016-01-26 [NL-300745I]
STG: (I2) Granted suppl. protection certificate
AP : 2015NL-C300745 2015-06-16
NL300744            I1 2016-01-26 [NL-300744I]
STG: (I1) Suppl. protection certificate application
AP : 2015NL-C300744 2015-06-16
NL300744            I2 2016-01-26 [NL-300744I]
STG: (I2) Granted suppl. protection certificate
AP : 2015NL-C300744 2015-06-16
NL300743            I1 2016-01-26 [NL-300743I]
STG: (I1) Suppl. protection certificate application
AP : 2015NL-C300743 2015-06-16
NL300743            I2 2016-01-26 [NL-300743I]
STG: (I2) Granted suppl. protection certificate
AP : 2015NL-C300743 2015-06-16
IN2508/DELNP/2013   A  2016-05-06 [IN2013DN02508]
STG: (A) Application laid open
AP : 2013IN-DN02508 2013-03-20
IN2509/DELNP/2013   A  2016-05-06 [IN2013DN02509]
STG: (A) Application laid open
AP : 2013IN-DN02509 2013-03-20
AR104448            A2 2017-07-19 [AR-104448]
STG: (A2) Divisional patent application
AP : 2016AR-0101219 2016-04-28
CN103352030         B  2018-08-10 [CN103352030B]
STG: (B) Granted patent for invention
AP : 2013CN-0269097 2005-05-18
FD :  Division of: CN200580024345 FDD=2005-05-18 [2005CN-80024345]";58049;"WO2005111201        A1 2005-11-24 [WO2005111201]
CA2561719           A1 2005-11-24 [CA2561719]
AU2005243488        A1 2005-11-24 [AU2005243488]
US20050287171       A1 2005-12-29 [US20050287171]
UY28905             A1 2005-12-30 [UY--28905]
DE102004025452      A1 2006-01-19 [DE102004025452]
AR049176            A1 2006-07-05 [AR--49176]
KR10-2007-0012862   A  2007-01-29 [KR20070012862]
EP1751276           A1 2007-02-14 [EP1751276]
MXPA06013298        A  2007-05-07 [MX2006PA013298]
CN1989240           A  2007-06-27 [CN1989240]
IN6428/DELNP/2006   A  2007-08-31 [IN2006DN06428]
BRPI0510396         A  2007-11-13 [BR200510396]
BRPI0510396         A1 2007-11-13 [BR200510396]
JP2007537740        A  2007-12-27 [JP2007537740]
EP1751276           B1 2009-01-14 [EP1751276]
AT420949            T  2009-01-15 [ATE420949]
PT1751276           E  2009-02-24 [PT1751276]
DE602005012381      D1 2009-03-05 [DE602005012381]
DK1751276           T3 2009-05-18 [DK1751276T]
ES2321210           T3 2009-06-03 [ES2321210]
SI1751276           T1 2009-06-30 [SI1751276T]
KR10-0908798        B1 2009-07-22 [KR100908798]
US7572455           B2 2009-08-11 [US7572455]
NZ552088            A  2009-10-30 [NZ-552088]
RS50753             B  2010-08-31 [RS--50753]
AU2005243488        B2 2011-07-07 [AU2005243488]
BRPI0510396         A2 2012-03-20 [BR200510396]
JP2012061001        A  2012-03-29 [JP2012061001]
JP5006782           B2 2012-06-01 [JP5006782]
ME01119             B  2013-03-20 [ME---1119]
CN1989240           B  2013-07-31 [CN1989240B]
IN257379            B  2013-10-04 [IN-257379]
CN103352030         A  2013-10-16 [CN103352030]
JP5562316           B2 2014-06-20 [JP5562316]
CY1109036           T1 2014-07-02 [CY1109036]
CA2561719           C  2015-01-27 [CA2561719]
LU92748             I2 2015-11-02 [LU--92748]
LU92749             I2 2015-11-02 [LU--92749]
LU92747             I2 2015-11-02 [LU--92747]
NL300745            I1 2016-01-26 [NL-300745I]
NL300745            I2 2016-01-26 [NL-300745I]
NL300744            I1 2016-01-26 [NL-300744I]
NL300744            I2 2016-01-26 [NL-300744I]
NL300743            I1 2016-01-26 [NL-300743I]
NL300743            I2 2016-01-26 [NL-300743I]
IN2508/DELNP/2013   A  2016-05-06 [IN2013DN02508]
IN2509/DELNP/2013   A  2016-05-06 [IN2013DN02509]
AR104448            A2 2017-07-19 [AR-104448]
CN103352030         B  2018-08-10 [CN103352030B]";"2004DE-10025452
2004US-60589361
2005CN-80024345
2005EP-0741681
2005US-11132686
2005WO-EP05377";"(EP1751276)
WO2005111201
(DE602005012381)
WO2005111201
(JP5006782)
WO2005111201
(MX2006PA013298)
WO2005111201
(DK1751276T)
WO2005111201
(SI1751276T)
WO2005111201
(KR100908798)
WO2005111201
(NZ-552088)
WO2005111201
(RS--50753)
WO2005111201
(AU2005243488)
WO2005111201
(BR200510396)
WO2005111201
(ME---1119)
WO2005111201
(CN1989240B)
WO2005111201
(CY1109036)
WO2005111201
(CA2561719)
WO2005111201
(NL-300745I)
WO2005111201
(NL-300744I)
WO2005111201
(NL-300743I)
WO2005111201
(IN2013DN02508)
WO2005111201
(IN2013DN02509)
WO2005111201
(CN103352030B)
WO2005111201";BOEHRINGER INGELHEIM VETMEDICA;BOEHRINGER INGELHEIM VETMEDICA;"(EP1751276)
DE
(EP1751276)
DE
(US20050287171)
DE
(US7572455)
DE
(WO2005111201)
DE
(DE102004025452)
DE


(BR200510396)
DE
(BR200510396)
DE
(IN2006DN06428)
DE
(CA2561719)
DE
(CA2561719)
DE


";"(EP1751276)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 , CITY=55218 Ingelheim am Rhein , COUNTRY=DE 

(EP1751276)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE , REG=100089553 

(US20050287171)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim , COUNTRY=DE , ATYP=Non-US Company 

(US7572455)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim , COUNTRY=DE , ATYP=Non-US Company 

(WO2005111201)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH  [DE/ DE] Binger Str. 173, 55216 Ingelheim  , COUNTRY=DE 

(DE102004025452)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim , POSTCODE=55218 , COUNTRY=DE 

(JP2007537740)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(JP5006782)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(JP2012061001)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(JP5562316)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(BR200510396)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , COUNTRY=DE 

(BR200510396)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , COUNTRY=DE 

(IN2006DN06428)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH BINGER STRASSE 173 55216 INGELHEIM  , COUNTRY=DE 

(CA2561719)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Str. 173 D-55216 , CITY=INGELHEIM , COUNTRY=DE 

(CA2561719)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Str. 173 D-55216 , CITY=INGELHEIM , COUNTRY=DE 

(NL-300745I)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Ingelheim 55216 DE 

(NL-300745I)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Ingelheim 55216 DE 

(NL-300744I)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Ingelheim 55216 DE 

(NL-300744I)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Ingelheim 55216 DE 

(NL-300743I)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Ingelheim 55216 DE 

(NL-300743I)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Ingelheim 55216 DE 
";1;"MEYERS GREGOR
EGE ANDREAS
MEYER CHRISTIANE
VON FREYBURG MARTINA";"(EP1751276)
DE";"(EP1751276)
NAME=MEYERS, Gregor Albstrasse 1 , CITY=72141 Walddorfhaeslach , COUNTRY=DE 

NAME=EGE, Andreas Gottlieb Olpp Str. 37 , CITY=72076 Tübingen , COUNTRY=DE 

NAME=MEYER, Christiane Treschowstrasse 31 , CITY=48163 Münster , COUNTRY=DE 

NAME=VON FREYBURG, Martina Schickhardtstr. 15 , CITY=74076 Heilbronn , COUNTRY=DE 
";"(EP1751276)
Vaccine comprising an attenuated pestivirus";"(EP1751276)
The present invention relates to attenuated pestivurses, in particular to attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Erns in addition to the inactivation of the (hypothesized) immunemodulating activity residing in Npro.The invention also relates to methods for attenuating pestiviruses such as BVDV, nucleic acids encoding said pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV of the invention.";"(WO2005111201)
CLAIMS:
1. An attenuated pestivirus, having at least one mutation in the coding sequence for glycoprotein Esand at least another mutation in the coding sequence for,- Npro.
2. The virus according to claim 1, wherein said mutation in-' the coding sequence for glycoprotein Emsleads to inactivation of RNase activity residing in Emsand/or said mutation in the coding sequence for Nproleads to inactivation of said Npro.
3. The virus according to claim 1 or 2, wherein sa d mutations are selected from the group of deletions, insertion mutations and/or substitution mutations.
4. The the virus according to any one of claims 1 to 3, wherein said mutation(s) are deletions.
5. The virus according to any one of claims 1 to 4, wherein said pestivirus is a Bovine viral diarrhea virus (BVDV).
6. The virus according to claim 5, wherein said mutation(s) in the coding sequence for glycoprotein Emsare located in the encoding nucleotide sequence corresponding to amino acids at position 298 to 310 and/or position 341 to 360.
7. The virus according to claim 5 or 6, wherein said mutation in the coding sequence for glycoprotein Emsis a deletion or substitution of the histidine at position 349.
8. The virus according to anyone of claims 1 to 7, wherein said mutation(s) in the coding sequence for glycoprotein Esare located in the nucleotide sequence coding for the conserved Emssequence SLHGIWPEKICTG and/or LQRHEWNKHGWCNWFHIEPW.
9. The virus according to any one of claims 1 to 8, wherein said mutation(s) in the coding sequence for glycoprotein Emslocated in the nucleotide sequence coding for the conserved Emssequence SLHGIWPEKIC and/or RHEWNKHGWCNW.
10. The virus according to anyone of claims 1 to 9, wherein said mutation(s) in the coding sequence for glycoprotein Emsare two mutations located in the nucleotide sequence coding for the conserved Emssequence SLHGIWPEKIC and/or RHEWNKHGWCNW.
11. The virus according to anyone of claims 1 to 10, wherein said mutation in the coding sequence for glycoprotein Emsis a single mutation located in the conserved Emssequence SLHGIWPEKIC or RHEWNKHGWCNW.
12. The virus according to any one of claims 1 to 11, wherein said mutation(s) in the coding sequence for Npr0lead to an encoded polyprotein as characterized by the following formula: [Npro]x-[PS]y-[C-term] and wherein: [Npro] relates to the Nproportion of said polyprotein, wherein ""x"" represents the number of amino acids of the Npropresent in the polyprotein; and wherein [PS] relates to a processing signal selected from the grpup consisting of: ubiquitin, LC3, SUMO-1, NEDD8, GATE-16 or GABA(A)RAP), Intein, picornavirus 3C, caridovirus 2A, or pl5 of rabbit hemorrhagic disease virus; and wherein
 ""Y"" may be = 0, which means that no processing signal is present, or ""Y"" may be = 1, which means that a processing signal is present; and wherein [C-term] relates to the complete virus polyprotein except for Npr0, but including the capsid (C)-protein and any other protein present in the virus polyprotein including the carboxyterminal NS5B; and wherein if ""y"" is = 0, then ""x"" is 0 to 12, (means no Nprospecific amino acid or 1 to 12 amino acids of Nproare present); and wherein if ""y"" is = 1, then ""x"" is 0 to 168; (means no Nprospecific amino acid or 1 to all 168 amino acids of Nproare present).
13. The virus according to claim 12, wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by the following formula: [NHHPSMC-term]
14. The virus according to claim 12, wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by the following formula: [Npro]3-[PS]o-[C-term] and wherein the definitions are as defined in claim 11.
15. The virus according to claim 12, wherein said mutation(s) in the coding sequence for Npr0lead to an encoded polyprotein as characterized by the following formula: [Npro]4-[PS]0-[C-term]
16. The virus according to claim 12, wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by the following formula: [Npro]6-[PS]0-[C-term]
17. The virus according to to claim 12, wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by the following formula: [Npro]4-[PS]o-[C-term*], and wherein [C-term]* is = [C-term] wherein in the C-protein the amino acid at position 2 is changed from D to N.
18. The virus according to claim 12, wherein said mutation (s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by the following formula: [NpI0]χ-[PS]ι-[C-term] and wherein PS is selected from the group of ubiquitin or LC3.
19. The virus according to claim 12, wherein said said virus is BVDV, and wherein mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by a formula selected from the group consisting of : M-[PS]0-[C-term]; MEL-[PS]o-[C-term]; MELF-[PS]o-[C-term]; MELFS-[PS]o-[C-term]; MELFSN-[PS]o-[C-term]; MELFSNE-[PS]o-[C-term]; MELFSNEL-[PS]0-[C-term] ; MELFSNELL-[PS]o-[C-term] ; MELFSNELLY-[PS]o-[C-term] ; MELFSNELLYK-[PS]0-[C-term] ; MELFSNELLYKT-[PS]o-[C-term]
20. The virus according to claim 12, wherein said said virus is BVDV, and wherein said mutation(s) in the coding sequence for Npr0lead to an encoded polyprotein as characterized by a formula selected from the group consisting of : MELI-[PS]o-[C-term]; MELIS-[PS]0-[C-term]; MELISN-[PS]0-[C-term]; MELISNE-[PS]o-[C-term] ; MELISNEL-[PS]0-[C-term] ; MELISNELL-[PS]0-[C-term]; MELISNELLY-[PS]o-[C-term] ; MELISNELLYK-[PS]0-[C-term] ; MELISNELLYKT-[PS]0-[C-term] ;
21. The virus according to claim 12, wherein said said virus is BVDV, and wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by a formula selected from the group consisting of : MELIT-[PS]0-[C-term]; MELITN- [PS]0-[C-term] ; MELΓΓNE- [PS]0-[C-term] ; MELITNEL-[PS]o-[C-term] ; MELITNELL-[PS]o-[C-term] ; MELITNELLY-[PS]o-[C-term] ; MELITNELLYK-[PS]0-[C-term] ; MELITNELLYKT-[PS]o-[C-term] ;
22. The virus according to claim 12, wherein said said virus is BVDV, and wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by a formula selected from the group consisting of : [Npro]χ-[PS]o-MELF-[PS]0-[C-term*]; and wherein [C-term]* is = [C-term] wherein in the C-protein the amino acid at position 2 is changed from D to N.
23. The virus according to claim 12, wherein said mutation(s) in the coding sequence for Nprolead to an encoded polyprotein as characterized by a formula selected from the group consisting of : [ NH^-PPSlHC-term], and wherein PS is ubiquitin or LC3.
24. The virus according to any one of claims 19 to 22, wherein the [PS]0is replaced by [PS]1}and wherein said PS is selected from the group of consisting of: ubiquitin, LC3, SUMO-1,
 NEDD8, GATE-16,GABA(A)RAP, Intein, picomavirus 3C, caridovirus 2A, and pl5 of rabbit hemorrhagic disease virus.
25. The BVDV according to any one of claims 5 to 24, wherein said BVDV is selected from the group of BVDV type 1 or BVDV type 2.
26. The BVDV according to any one of claims 5 to 25, wherein the BVDV corresponds to SEQ ID NO. 8 or a functional variant thereof.
27. A composition comprising the virus according to any one of claims 1 to 26 and a solution.
28. The composition according to claim 27, which induces an immunological response in an animal.
29. The composition according to claim 27 or 28, which is a vaccine.
30. The composition according to any one of claims 27 to 29, wherein said composition further comprises a pharmaceutically acceptable carrier or excipient.
31. Use of a virus according to any one of claims 1 to 26 in the manufacture of a vaccine for the prophylaxis and treatment of a pestivirus infection.
32. Use of a BVDV according to any one of claims 5 to 26 in the manufacture of a vaccine for the prophylaxis and treatment of a BVDV infection.
33. A nucleic acid molecule comprising the nucleic acid encoding a live attenuated BVDV according to any one of claims 5 to 26 or a fragment, functional variant, variant based on the degenerative nucleic acid code, fusion molecule or a chemical derivative thereof.
34. The nucleic acid molecule according to claim 33, wherein said nucleotide molecule is
 DNA.
35. The nucleic acid molecule according to claim 34, wherein said nucleotide molecule is RNA.
36. A method for attenuating a pestivirus, characterized in that at least one mutation in the coding sequence for glycoprotein Emsand at least another mutation in the coding sequence for Nprois generated in a pestivirus.
37. The method according to claim 36, comprising the following steps: a) reverse transcription of a wild-type pestivirus nucleotide sequence into a cDNA; b) cloning said cDNA; c) introducing mutations selected from the group of deletions, insertion mutations and/or substitution mutations into said cDNA, wherein said mutations are located in the coding sequence encoding glycoprotein Emsand the protease Npro, d) incorporating the cDNA into a plasmid or into a DNA virus capable of directing the transcription of pestivirus cDNA into RNA in vitro or upon infection of suitable cells.
38. The method according to claim 36 or 37, wherein said pestivirus is BVDV.
39. Method of treatment of disease caused by BVDV, wherein a BVDV according to any one of claims 4 to 26 or a composition according to claims 27 to 30, wherein the said BVDV or said composition is administered to an animal in need thereof at a suitable dosis as known to the skilled person and the reduction of symptoms of BVDV infection such as viremia and leukopenia and/or pyrexia and/or diarrhea is monitored.";"(EP1751276)
The present invention relates to the field of animal health and in particular to attenuated pestiviruses such as bovine viral diarrhea virus (BVDV).
The present invention relates to attenuated pestivivirus, preferably to attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Erns in addition to the inactivation of the (hypothesized) immunemodulating activity residing in Npro.
The invention also relates to methods for attenuating pestivirus in such that the attenuation results in an attenuated pestivirus, preferably in an attenuated BVDV, as described above.
The present invention furthermore relates to nucleic acids molecules encoding said attenuated pestiviruses, preferably encoding attenuated BVDV, compositions and vaccines comprising the attenuated pestivirus, preferably BVDV as disclosed herein.
A vaccine of the invention refers to a vaccine as defined above, wherein one immunologically active component is a BVDV or of pestiviral origin or derived from a nucleotide sequence that is more than 70% homologous to any known pestivirus sequence (sense or antisense).
The present invention relates to attenuated pestivivirus, preferably to attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Erns in addition to the inactivation of the (hypothesized) immunemodulating activity residing in Npro.
The present invention relates to the field of animal health and in particular to attenuated pestiviruses such as bovine viral diarrhea virus (BVDV).";"(EP1751276)
Furthermore, live vaccines with defined mutations as a basis for attenuation will allow to avoid the disadvantages of the present generation of vaccines, e.g. the risk of reversion to an mor pathogenic strain.
Because of the importance of an effective and safe as well as detectable prophylaxis and treatment of pestiviral infections, there is a strong need for improved attenuated pestiviruses, such as BVDV, with a high potential for induction of immunity as well as a defined basis of attenuation which can also be distinguished from pathogenic pestiviruses, such as BVDV, as well as compositions and vaccines comprising said attenuated pesitiviruses, such as BVDV.
Therefore, the technical problem underlying the present invention is to provide improved attenuated pestivirus, referably an attenuated BVDV for use as live attenuated vaccines.
A pestivirus, in particular BVDV attenuated in accordance with the present invention may be advantageously used in vaccines.
The division of BVDV into 2 species is based on significant differences at the level of genomic sequences (summarized in Heinz et al., 2000) which are also obvious from limited cross neutralizing antibody reactions (Ridpath et al. 1994).
This problem is probably due to the great antigenic diversity between type 1 and type 2 strains which is most pronounced in the glycoprotein E2, the major antigen for virus neutralization (Tijssen et al., 1996).
Pestiviruses are causative agents of economically important diseases of animals in many countries worldwide.";"A61K-035/76
A61K-039/00
A61K-039/12
A61K-039/15
A61K-039/187
A61K-039/42
A61K-049/00
A61P-031/12
A61P-031/14
C07K-014/005
C07K-014/08
C07K-014/705
C12N-007/00
C12N-007/04
C12N-015/01
C12N-015/09
C12N-015/12
C12N-015/86
C12P-013/04
C12Q-001/70
C12R-001/93";"(EP1751276)
1. An attenuated pestivirus, having at least one mutation in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro, wherein said mutation in the coding sequence for glycoprotein Ems leads to inactivation of RNase activity residing in Ems and said mutation in the coding sequence for Npro leads to inactivation of said Npro,
35. A method for attenuating a pestivirus, characterized in that at least one mutation in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro is generated in a pestivirus.";"(EP1751276)
VACCINE(100,25)
ATTENUATED PESTIVIRUS(100,18)
ENCODED POLYPROTEIN(86,14)
CODING SEQUENCE(78,48)
ATTENUATED BVDV(78,4)
MUTATION(58,85)
MOR PATHOGENIC STRAIN(52,1)
CONSERVED EMS SEQUENCE(50,4)
ATTENUATED PESTIVIVIRUS(50,1)
RNASE ACTIVITY INACTIVATION(44,8)
PATHOGENIC PESTIVIRUS(43,1)
ATTENUATING PESTIVIRUS(42,1)
ATTENUATED PESITIVIRUSE(41,1)
IMMUNEMODULATING ACTIVITY(40,1)
PESTIVIRUS(35,48)
PESTIVIRUS CDNA TRANSCRIPTION(35,3)
DETECTABLE PROPHYLAXIS(35,1)
IMMUNITY INDUCTION(34,1)
PESTIVIRAL ORIGIN(34,1)
VIRUS NEUTRALIZING(34,1)
ANTIBODY REACTION NEUTRALIZATION(33,1)
REVERSION RISK(32,1)
PESTIVIRAL INFECTION TREATMENT(31,2)
VACCINE GENERATION(31,1)
NUCLEOTIDE SEQUENCE CODING(30,9)
VACCINE MANUFACTURE(30,4)
SUBSTITUTION MUTATION(28,4)
LIVE ATTENUATED VACCINE(27,2)
BVDV(25,4)
BOVINE VIRAL DIARRHEA VIRUS(24,251)
CAUSATIVE AGENT(24,1)
ECONOMICALLY IMPORTANT DISEASE(24,1)
LIVE VACCINE(23,3)
MAJOR ANTIGEN(23,1)
PESTIVIRUS SEQUENCE(22,2)
CODING SEQUENCE ENCODING GLYCOPROTEIN(21,3)
INACTIVATION(20,10)
FUNCTIONAL VARIANT(19,36)
NUCLEIC ACID MOLECULE ENCODING(19,2)
ANTIGENIC DIVERSITY(19,1)
PESTIVIRUS INFECTION TREATMENT(18,1)
SYMPTOM REDUCTION(17,1)
PREGNANT HEIFER(16,9)
HOG CHOLERA VIRUS(16,5)
MUTATION INTRODUCTION(16,4)
ANTISENSE(16,1)
GENOMIC SEQUENCE LEVEL(16,1)
ERNS MUTATION(15,9)
DELETION GROUP(15,4)
CARIDOVIRUS(14,5)
SERUM NEUTRALIZATION ASSAY(14,5)
NPRO LEAD(14,1)
ANIMAL(13,51)
BOVINE VIRAL DIARRHEA ABORTION(13,14)
ALFORT T BINGEN(13,4)
CATTLE BREEDING STOCK(13,4)
SIGNIFICANT DIFFERENCE(13,1)
CONSERVED ERNS SEQUENCE(12,6)
GLYCOPROTEIN(12,6)
IMMUNOLOGICAL RESPONSE(12,3)
NPRO DELETION MUTANT(12,3)
CAPSID PROTEIN AMINOTERMINUS(12,2)
UBIQUITIN GROUP(12,2)
ANIMAL HEALTH FIELD(12,1)
VITUS(12,1)
STRAIN(11,15)
ATTENUATION(11,8)
FLAVIVIRIDAE FAMILY(11,5)
ATTENUATION DEFINED BASIS(11,1)
DEFINED MUTATION(11,1)
RABBIT HEMORRHAGIC DISEASE VIRUS(10,7)
STUDY TERMINATION(10,7)
ANTIBODY TITER(10,5)
FETAL PROTECTION INDUCTION(10,4)
GABA(10,4)
INDIRECT IMMUNOFLUORESCENCE STAINING(10,4)
INSERTION MUTATION(10,4)
NPRO PROTEIN CODING SEQUENCE(10,3)
LEUKOPENIA(10,2)
RE LATED COW MORTALITY(10,2)
ATTENUATION RESULT(10,1)
CODON RNASE INACTIVATING DELETION(10,1)
MONOCLONAL NEUTRALIZING ANTIBODY AGAIST(10,1)
SACCHAROMYCES CEREVISIAE VACUOLAR MEMBRANE(10,1)
VIRUS ISOLATION(9,7)
PYREXIA(9,3)
CELLULAR ANTIVIRAL DEFENSE(9,2)
INFECTIOUS CDNA CLONE(9,2)
ATTENUATED PESTIVIRUS VIRULENCE(9,1)
ERNS RNASE INACTIVATION(9,1)
PERSISTENTLY INFECTED CALF INDUCTION(9,1)
PESTIVIRAL GLYCOPROTEIN MUTANT(9,1)
GENE(8,10)
BIOLOGICAL ACTIVITY(8,8)
ENDPOINT DILUTION(8,4)
NPRO GENE(8,4)
ANTIBODY NEUTRALIZATION(8,3)
EXCIPIENT(8,3)
PLASMID(8,3)
NON VIABLE FETUS(8,2)
PESTIVIRUS GENUS(8,2)
RE LATED ABORTION(8,2)
SAFE(8,2)
TISSUE CULTURE INFECTIVE(8,2)
AUTOPHAGIC VESICLE MEMBRANE(8,1)
FORMERLY DESCIRBED MUTANT(8,1)
LIVER DEGENERATION FETUS(8,1)
PERIRENAL EDEMA(8,1)
PERSISTENTLY INFECTED HOST BIRTH(8,1)
PERSISTENTLY INFECTED LAMB(8,1)
PESTIVIRAL LIVE VACCINE(8,1)
PICORNAVIRUS NONSTRUCTURAL PROTEIN(8,1)
PREGNANT COW INOCULATION(8,1)
UBIQUITIN CARBOXYL TERMINUS(8,1)
PROCESSING SIGNAL(7,65)
BOVINE VIRAL DIARRHEA VIRAEMIA(7,4)
ANIMAL INOCULATION(7,3)
BACTERIAL CONTAMINATION(7,3)
CARBOXY TERMINUS(7,3)
ERNS PROTEIN(7,3)
PESTIVIRUS VIRION STRUCTURAL COMPONENT(7,3)
MANUFACTURER RECOMMENDATION(7,2)
NPRO SEQUENCE ELF(7,2)
RAP(7,2)
RNASE NEGATIVE MUTANT(7,2)
TRAINED VETERINARIAN(7,2)
VIRAL POLYPROTEIN(7,2)
WEEK POST VACCINATION(7,2)
ATPASE INTEIN(7,1)
EXPERIMENTAL ANIMAL NECROPSY(7,1)
HETEROLOGOUSLY EXPRESSED VIRAL PROTEIN(7,1)
POLYNUCLEOTIDE MOLECULE COMPRSING(7,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(7,1)
PREGNANT ANIMAL PLACENTA(7,1)
RECOMBINANT VACCINIA VIRUS(7,1)
SERUM NEUTRALIZATION TITER(7,1)
STUDY FETAL TISSUE TERMINATION(7,1)
COMPOSITION MANUFACTURE(6,8)
PREVENTION(6,8)
LEUKOCYTE COUNT(6,6)
COMPLETE NPRO CODING REGION(6,5)
FETAL TRANSMISSION(6,5)
SINGLE MUTATION(6,4)
CELL INFECTION(6,3)
CONSTRUCTING CDNA(6,3)
ABNORMAL BREATHING(6,2)
ANCILLARY MOLECULE(6,2)
CHALLENGE INFECTION(6,2)
CLINICAL DATA(6,2)
DATA LIBRARY(6,2)
DAY POST INFECTION(6,2)
EXPERIMENTAL FACILITY(6,2)
FETAL ORGAN(6,2)
MEMBRANE ANCHORING(6,2)
MUTANT VIRUS(6,2)
RESPIRATORY SIGN(6,2)
RNASE ASSAY(6,2)
ROUTINE NECROPSY(6,2)
STERILE SYRINGE(6,2)
STUDY INITIATION(6,2)
ATTENUATED VACCINE VIRUS(6,1)
ATTENUATED VIRUS MUTANT(6,1)
BOVINE UBIQUITIN GENE(6,1)
CODON CODING DELETION(6,1)
CODON CODING SUBSTITUTION(6,1)
ENVELOPE GLYCOPROTEIN EPITOPE MAPPING(6,1)
ETHYLENDIAMINTETRACETIC ACID ALKALISALT(6,1)
FETUS NECROPSY(6,1)
FRESHLY SEEDED MDBK CELL(6,1)
HEIFER NECROPSY(6,1)
HUNDRED MICROLITER ALIQUOT(6,1)
NPRO MUTATION BLOCKING(6,1)
PROBABLE IMMUNEMODULATING ACTIVITY(6,1)
REMINGTON PHARMACEUTICAL SCIENCE(6,1)
SERUM NEUTRALIZING TITER(6,1)
VACCINATION ANIMAL ID(6,1)
VIRUS INFECTED CONCLUSION(6,1)
NUCLEIC ACID SEQUENCE(5,15)
SIGNAL PROCESSING(5,10)
ACCESSION(5,6)
APPETITE LOSS(5,4)
ANIMAL STUDY(5,3)
STRAIN CP(5,3)
CAPSID PROTEIN FUNCTION(5,2)
CLINICAL SIGN PRESENCE(5,2)
CORRECT AMINO TERMINUS(5,2)
FETAL INFECTION PRESENCE(5,2)
FUSION PROTEIN(5,2)
GENBANK(5,2)
IMMEDIATE FREEZING(5,2)
NPRO PORTION(5,2)
STERILE VESSEL(5,2)
VACCINE STRAIN(5,2)
ABORTION SIGN(5,1)
AMINOTERMINUS RESIDUE(5,1)
ANIMAL BUFFY COAT PREPARATION(5,1)
ANIMAL HEALTH EXAMINATION(5,1)
ANIMAL INSEMINATION(5,1)
APPETITE SEROUS MEMBRANE LOSS(5,1)
ATTENUATED VIRAL PARTICLE(5,1)
AUTOLYSIS SIGN(5,1)
BIOCHEMICAL CHARACTERIZATION(5,1)
BREEDING HERD(5,1)
CALICIVIRUS POLYPROTEIN PROCESSING(5,1)
CALICIVIRUS PROTEASE(5,1)
CARBOXY TERMINAL GLYCIN(5,1)
CATALYTIC RESIDUE IDENTIFICATION(5,1)
CLINICAL MANIFESTATION(5,1)
CLINICAL OBSERVATION DATA(5,1)
CLINICAL SIGN ANIMAL ID(5,1)
CLINICAL SIGN BROAD SPECTRUM(5,1)
CLINICAL SIGN DURATION(5,1)
CONSERVED EPITOPE(5,1)
CYSTEINE PROTEASE(5,1)
CYTOPATHOGENIC PHENOTYPE(5,1)
CYTOPATHOGENIC VIRUS(5,1)
DAY LATE HEIFER(5,1)
DEHYDRATION LACHRYMATION(5,1)
DERIVED ATTENUATED VIRUS(5,1)
DIATRON MINICELL(5,1)
ENVELOPED VIRUS(5,1)
EVELOPE GLYCOPROTEIN PROCESSING(5,1)
FETAL ABDOMINAL FLUID(5,1)
FETAL TISSUE SUSPENSION(5,1)
FETUS ABORTION(5,1)
FETUS INFECTION(5,1)
FETUS RESORPTION(5,1)
FETUS TRANSPLACENTAL INFECTION(5,1)
GENUS PESIVIRUS(5,1)
HEIFER UTERUS(5,1)
HETEROLOGOUS CHALLENGE(5,1)
INFECTIOUS CLONE(5,1)
INFECTIOUS VIRUS RECOVERY(5,1)
INTRAMUSCULAR VACCINATION(5,1)
LAMB INTRAUTERINE INFECTION(5,1)
LEADER PROTEINASE(5,1)
LIVE ATTENUATED VIRUS PRODUCTION(5,1)
LUNG EDEMA(5,1)
MATERNAL ANTIBODY(5,1)
MILD DISEASE SIGN(5,1)
MOTIF IDENTITY(5,1)
MUTATED POLYNUCLEOTIDE(5,1)
MUTATION ABROGATING(5,1)
NASCENT POLYPROTEIN(5,1)
NECROPSY DIAGNOSIS(5,1)
NON PATHOGENIC VIRUS(5,1)
NPRO SEQUENCE MUTATION(5,1)
NRNS PROTEIN CODING SEQUENCE(5,1)
NUCLEOCAPSID PROTEIN(5,1)
NUCLEOTIDE TRIPLET(5,1)
OBSERVATION CLINICAL SIGN(5,1)
OBSERVING VETERINARIAN(5,1)
PESTIVIRUS GENOME(5,1)
PESTIVIRUS GLYCOPROTEIN(5,1)
PESTIVIRUS NEUTRALIZATION(5,1)
PESTIVIRUS NON TRANSLATED REGION(5,1)
PESTIVIRUS POLYPROTEIN PROCESSING(5,1)
PESTIVIRUS PROTEIN(5,1)
PESTIVIRUS RNA(5,1)
PESTIVIRUS TERMINAL PROTEASE(5,1)
PEYER PATCH(5,1)
PHARMACEUTICAL COMPOSTION(5,1)
PHOSPHATIDYLETHANOLAMINE(5,1)
PLANT RNASE(5,1)
POLYNUCLEOTIDE MOLECULE CODING(5,1)
POLYNUCLEOTIDE VACCINATION(5,1)
POLYPEPTIDE CLEAVAGE(5,1)
POST MORTEM FINDING(5,1)
POST VACCINATION SERUM(5,1)
PREDOMINANT CLINICAL PARAMETER(5,1)
PROGRESSED AUTOLYSIS(5,1)
PROTEASE ACTIVITY DESTRUCTION(5,1)
PROTEASE INACTIVATION(5,1)
PROTECTIVE VACCINE VIRUS(5,1)
PROTEIN FUNDAMENTAL ROLE(5,1)
PROTEOLYTIC PROTEIN ACTIVITY(5,1)
RE LATED ORGANISM(5,1)
RNASE ACTIVITY DESTRUCTION(5,1)
RNASE ENZYMATIC ACTIVITY(5,1)
RNASE NEGATIVE COUNTERPART(5,1)
SLAUGHTER EXAMINATION(5,1)
STERILE SEA SAND(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
TRIPLET ENCODING(5,1)
VACCINATED CATTLE(5,1)
VACCINATED DAM(5,1)
VACCINATED PIG(5,1)
VETERINARY MICROBIOLOGY(5,1)
VIRAL GENOME CODE(5,1)
VIREMIA ANIMAL ID DETECTION(5,1)
VIRUS VACCINE(5,1)
WEEK POST INFECTION(5,1)
BORDER DISEASE VIRUS(4,6)
ADMINISTRATION(4,4)
CO CULTIVATION(4,4)
R GGLI(4,4)
ANTIGEN DETECTION(4,2)
COMPLETE POLYPROTEIN(4,2)
CONCLUSION BOVINE VIRAL DIARRHEA(4,2)
DOUBLE MUTANT(4,2)
INVESTIGATION(4,2)
KILLED VACCINE(4,2)
MAB CODE(4,2)
MAIN EVALUATION PARAMETER(4,2)
NEGATIVE HERD(4,2)
NON AQUEOUS SOLUTION(4,2)
NUCLEIC ACID CODE DEGENERATION(4,2)
POSITIVE FETUS(4,2)
POST CHALLENGE(4,2)
VETERINARY PRACTICE(4,2)
VIRUS DOSE(4,2)
VIRUS LIFE(4,2)
ACTIVE ERNS RNASE(4,1)
ALFORT STRAIN(4,1)
ANIMAL INFECTION(4,1)
ANIMAL NEED(4,1)
AUJESZKY DISEASE(4,1)
BACTERIOPHAGE T7 RNA POLYMERASE(4,1)
BOVINE FRAGMENT(4,1)
CARBOXY TERMINAL CLEAVAGE(4,1)
CELLULAR PROTEASE(4,1)
CLINICAL ABORTION(4,1)
CLINICAL SYMPTOM PRESENCE(4,1)
CODON DELETION(4,1)
CODON SUBSTITUTION(4,1)
COWORKER PRESENTED INDICATION(4,1)
DEAD FETUS(4,1)
DEAD HEIFER(4,1)
DEFINITE DATA(4,1)
DISTINCTIVE LABEL(4,1)
EFFICIENT TRANSLATION INITIATION(4,1)
ENCODING TRIPLET(4,1)
EXPERIENCED VETERINARY SURGEON(4,1)
FETUS TISSUE SAMPLE ANALYSIS(4,1)
GENOME ORGANIZATION(4,1)
GENOMIC DELETION(4,1)
GENUS PESTIVIRUS MEMBER(4,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(4,1)
GP EPITOPE MAPPING(4,1)
GROSS PATHOLOGICAL FINDING(4,1)
HAIRY SHAKER(4,1)
HIGHLY CONSERVED CELLULAR PROTEIN(4,1)
HOMOLOGOUS CHALLENGE(4,1)
HOOF EROSION(4,1)
INACTIVE PROTEASE(4,1)
INFECTIVE DOSE(4,1)
INSEMINATION RECORD(4,1)
INTERFERON RESPONSE INDUCTION(4,1)
INTRATHECAL ROUTE(4,1)
LEUCINE CODON(4,1)
LIVING ORGANISM(4,1)
MILD COUGHING(4,1)
MOLECULAR UNIQUENESS(4,1)
MOUSE PRETREATMENT(4,1)
MUTATED POLYPROTEIN AMINOACID(4,1)
NPRO CODING SEQUENCE(4,1)
NUCLEOTIDE EXCHANGE(4,1)
ORAL HEMORRHAGE(4,1)
PARENTAL VIRUS(4,1)
PESTIVIRUS GENE EXPRESSION(4,1)
PESTIVIRUS MOLECULAR BIOLOGY(4,1)
PREGNANCY STATUS(4,1)
PROTEIN CATABOLISM(4,1)
RECTAL EXAMINATION(4,1)
RNASE POSITIVE VIRUS(4,1)
SERUM ANTIBODY(4,1)
SEVERE OUTBREAK(4,1)
SITE MUTATION ABSENCE(4,1)
STERILE PIPETTE(4,1)
UNUSED INOCULUM(4,1)
UNUSED VACCINE(4,1)
VIABLE MUTANT(4,1)
VIRAL REPLICATION(4,1)
VIRUS ATTENUATION(4,1)
VIRUS CHALLENGE(4,1)
VIRUS INOCULATION(4,1)
VIRUS NEUTRALIZING MONOCLONAL ANTIBODY(4,1)
VIRUS VIABILITY(4,1)
N TERMINAL METHIONINE(3,5)
ACTIVE COMPONENT(3,3)
ASCITE(3,3)
ASSAY CONDITION(3,3)
EXPERT(3,3)
NON VACCINATED CONTROL ANIMAL(3,3)
SERA(3,3)
SEROLOGY(3,3)
ABNORMAL TEMPERATURE(3,2)
BACKTITRATION(3,2)
BASELINE VALUE(3,2)
BOVINE SERUM ALBUMIN(3,2)
BUNDESFORSCHUNGSANSTALT F R(3,2)
CEREBELLUM(3,2)
CHEMICAL DERIVATIVE(3,2)
CONJUNCTIVITIS(3,2)
DELETED REGION(3,2)
DISULFANE(3,2)
FORMALDEHYDE(3,2)
GESTATION(3,2)
GLASSWARE(3,2)
GROUP INOCULATION(3,2)
INTERLEUKIN(3,2)
LETHALITY(3,2)
MAIN PARAMETER(3,2)
MESENTERIC LYMPH NODE(3,2)
POST MORTEM EXAMINATION(3,2)
PUBLISHED SEQUENCE(3,2)
PURIFICATION(3,2)
R MENAPF(3,2)
RE TITRATION(3,2)
RESPIRATORY RATE(3,2)
RIBONUCLEASE(3,2)
RNASE ACTIVE SITE(3,2)
SPERMIDINE(3,2)
STABILIZER(3,2)
STERILE CONDITION(3,2)
STERNUM(3,2)
SUBUNIT VACCINE(3,2)
SUPRA(3,2)
TERMINAL AMINO(3,2)
TRIAL(3,2)
TRIPLICATE(3,2)
VIRUS REPLICATION(3,2)
WEEK POST INOCULATION(3,2)
ANTIGENIC SUBSTANCE(3,1)
ATTENUATED PARTICLE(3,1)
ATTENUATION REMAINS UNKNOWN(3,1)
ATTENUATION STRUCTURAL BASIS(3,1)
BLOCKING ELISA(3,1)
CHALLENGE VIRUS TITRATION(3,1)
CLEAN BENCH(3,1)
CLINICAL PICTURE(3,1)
CODING SEQUENCE REPLACING(3,1)
CODON H DELETION(3,1)
CULTURE GROWTH(3,1)
ENVELOPE PROTEIN(3,1)
FUNGAL ORIGIN(3,1)
FUNGAL RNASE ACTIVE PROTEIN(3,1)
FUSION MOLECULE(3,1)
GENETIC CODE DEGENERATIVE NATURE(3,1)
GENETIC STABILITY(3,1)
GENOME REGION CODING(3,1)
HEPARIN SODIUM(3,1)
HIGHLY ATTENUATED VIRUS(3,1)
HOMODIMER(3,1)
ID TITER(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
INCLUSION CRITERIA(3,1)
INDUCED LESION(3,1)
INJECTION QSP(3,1)
LIMITED CROSS(3,1)
LINKED HETERODIMER(3,1)
LISTED MUTANT(3,1)
MAJOR DELETION(3,1)
METABOLIZABLE OIL(3,1)
NECROPSY ROOM(3,1)
NPRO AMINO TERMINAL SEQUENCE(3,1)
OBSERVED CLINICAL SIGN(3,1)
OCULAR DISCHARGE(3,1)
ORAL EROSION(3,1)
PARENTERAL INJECTION(3,1)
PHENOTYPIC SELECTION(3,1)
PHYSIOLOGICALLY ACCEPTABLE SOLVENT(3,1)
PHYSIOLOGICALLY ACCEPTABLE STERILE SOLUTION(3,1)
PROTECTIVE IMMUNITY(3,1)
PROTEIN ROLE(3,1)
PROTEOLYTIC ACTIVITY(3,1)
PROTOCOL EXTRACT(3,1)
SENSITIVE GLYCOPROTEIN(3,1)
SIGNIFICANT CLINICAL SIGN(3,1)
STABILIZING AGENT(3,1)
STERILE PHYSIOLOGICALLY ACCEPTABLE SOLUTION(3,1)
TRUE DELETION(3,1)
UNSTABLE PEPTIDE(3,1)
VACCINATED ANIMAL GROUP(3,1)
VIRION MOLECULAR(3,1)
VIRUS DETECTION DURATION(3,1)
L HISTIDINE RESIDUE(2,4)
WILD TYPE REVERSE TRANSCRIPTION(2,3)
ADJUVANT PRESENCE(2,1)
ASEPTIC(2,1)
BACK TITRATION DATA(2,1)
BASALINE(2,1)
BOVINE VIRAL DIARRHEA ANTIBODY(2,1)
BOVINE VIRAL DIARRHEA INFECTION(2,1)
CARRIER SUBSTANCE(2,1)
CELL CULTURE MEDIUM QSP(2,1)
CLEAVAGE SITE(2,1)
COLD SPRING HARBOR(2,1)
COMPLETE PESTIVIRUS(2,1)
COMPLETE SEROCONVERSION(2,1)
CONSECUTIVE DAY(2,1)
CORRECT TEST CONDUCTING(2,1)
DEATH REASON(2,1)
DNA COVERING(2,1)
DOUBLE EMULSION(2,1)
DOUBLE GENETIC MARKER(2,1)
DOUBLE MUTATION(2,1)
ENCODING NUCLEIC ACID MOLECULE(2,1)
FLANKING REGION(2,1)
FROZEN SAMPLE(2,1)
GENOME SEQUENCE(2,1)
GENOMIC SEQUENCE(2,1)
HEPARIN BLOOD SAMPLE(2,1)
INFECTED CELL CULTURE(2,1)
INJECTABLE SOLUTION(2,1)
INSECT CELL(2,1)
INTEIN GROUP(2,1)
K GLYCOPROTEIN(2,1)
KEY PLAYER(2,1)
LABELED CONTAINER(2,1)
LABORATORY ANALYSIS(2,1)
LIFE VACCINE(2,1)
MBDK CELL(2,1)
MEAN TITER(2,1)
MICROBIAL AGENT(2,1)
MICROTUBULE ASSOCIATED PROTEIN(2,1)
MODIFIED EXPRESSED POLYPEPTIDE(2,1)
MODIFIED POLYPEPTIDE(2,1)
NON VACCINATED CONTROL FETUS(2,1)
NPRO REGION(2,1)
ORGAN PANEL(2,1)
ORGANISM IMMUNOLOGICAL FUNCTION(2,1)
ORIGIN MOLECULE(2,1)
PARTIAL BLINDING(2,1)
PASSAGING(2,1)
PATHOLOGIST(2,1)
PERMISSIVE CELL CULTURE(2,1)
PESTIVIRUS REMAINING SEQUENCE(2,1)
PLACENTA REMAINS(2,1)
POST TRANSLATIONAL PROCESSING(2,1)
PROTEASE ACTIVE SITE RESIDUE(2,1)
RECENT EXPERIMENT(2,1)
RNA CLEAVAGE ACTIVITY(2,1)
SAMPLE CHOICE(2,1)
SEQUENCE VARIANT(2,1)
SINGLE STRANDED RNA GENOME(2,1)
SITE DIRECTED MUTAGENESIS(2,1)
SPECIAL ATTENTION(2,1)
SPECIES PLUS(2,1)
STANDARD SEQUENCE DATA SEARCH(2,1)
STRETCH PRESENCE(2,1)
STUDY MONITOR(2,1)
SUSCEPTIBLE CELL(2,1)
TERM GLYCOPROTEIN(2,1)
TERMINAL GLYCINE(2,1)
THAWED SAMPLE(2,1)
TRANSPORT TIMING(2,1)
TREATMENT EFFECTIVENESS(2,1)
VIRAL N DELETION(2,1)
VIRAL TRANSMISSION(2,1)
VIRUS PARTICLE(2,1)
(US20050287171)
MUTATION(100,103)
CODING SEQUENCE(100,64)
PESTIVIRUS(100,39)
FUNCTIONAL VARIANT(100,36)
BOVINE VIRAL DIARRHEA VIRUS(100,33)
ENCODED POLYPROTEIN(100,25)
VACCINE(100,19)
ATTENUATED PESTIVIRUS(100,17)
ATTENUATED BVDV(50,8)
PESTIVIRAL LIVE VACCINE(49,1)
ATTENUATING PESTIVIRUS(46,2)
SUBSTITUTION MUTATION(36,6)
RNASE ACTIVITY INACTIVATION(35,7)
CARBOXY TERMINAL NS5B(31,7)
PESTIVIRUS CDNA TRANSCRIPTION(30,3)
HISTIDINE RESIDUE SUBSTITUTION(29,2)
PATHOGENIC STRAIN(29,1)
PESTIVIRAL ORIGIN(29,1)
PICORNAVIRUS 3C(28,6)
CODING SEQUENCE ENCODING GLYCOPROTEIN(27,4)
CONSERVED ERNS SEQUENCE SLHGIWPEKICTG(27,3)
REVERSION RISK(27,1)
NUCLEOTIDE SEQUENCE CODING(25,9)
BVDV(24,91)
CARIDOVIRUS 2A(24,6)
LIVE VACCINE(22,2)
INACTIVATION(21,11)
MUTATION INTRODUCTION(20,4)
DELETION(19,16)
PESTIVIRUS SEQUENCE(19,2)
BOVINE VIRAL DIARRHEA VIRUS CDNA(17,1)
CROSSPROTECTION(17,1)
C TERM(16,65)
ENCODING NUCLEIC ACID(16,2)
RNASE ACTIVITY(15,8)
IMMUNOLOGICAL RESPONSE(15,4)
NUCLEIC ACID MOLECULE ENCODING(15,2)
INSERTION MUTATION(14,6)
INTEIN(14,5)
PREGNANT HEIFER(13,9)
POLYPROTEIN NPRO PORTION(13,3)
FUSION MOLECULE(13,2)
ANTISENSE(13,1)
ATTENUATION(13,1)
NUCLEOTIDE(13,1)
ERNS MUTATION(12,9)
RABBIT HEMORRHAGIC DISEASE VIRUS(12,6)
DELETION GROUP(12,4)
615CLINICAL BVD ABORTION618BVD ABORTION(12,1)
BVDV INFECTION(11,9)
GABA(11,6)
NEDD(11,6)
NPRO PROTEIN CODING SEQUENCE(11,5)
SUMO(11,5)
CATTLE BREEDING STOCK(11,4)
EXCIPIENT(11,4)
PLASMID(11,4)
NUCLEIC ACID CODE DEGENERATION(11,3)
MELFSNELLYKT(11,1)
MELISNELLYKT(11,1)
MELITNELLYKT(11,1)
STUDY TERMINATION(10,11)
NPRO MUTATION(10,6)
SINGLE MUTATION(10,6)
ANIMAL IDANIMAL IDCLINICAL SIGN158314381585LOSS(10,1)
PROCESSING SIGNAL(9,61)
AMINOACID(9,39)
PREGNANT ANIMAL(9,6)
BINGEN(9,3)
ATTENUATION RESULT(9,1)
DEFINED MUTATION(9,1)
LIVE VIRUS BVDV STRAINCOMPOSITION(9,1)
NON VIABLE FETUS588NORMAL608NORMAL619BVD ABORTION(9,1)
PESTIVIRUS POLYPROTEIN BVDV POLYPROTEIN(9,1)
BVD VIREMIA(8,4)
CSFV(8,4)
FETAL PROTECTION INDUCTION(8,4)
INDIRECT IMMUNOFLUORESCENCE STAINING(8,4)
CHEMICAL DERIVATIVE(8,3)
LIVE ATTENUATED BVDV(8,2)
ABORTION565EXPECTED BVD ABORTION(8,1)
CODON RNASE INACTIVATING DELETION(8,1)
BIOLOGICAL ACTIVITY(7,8)
VIRUS ISOLATION(7,6)
STRAIN(7,5)
CELL INFECTION(7,4)
ENDPOINT DILUTION(7,4)
ANTIBODY NEUTRALIZATION(7,3)
BVDV ATTENUATION(7,3)
FLAVIVIRIDAE FAMILY(7,3)
EMBL DATA LIBRARY(7,2)
SERUM NEUTRALIZING TITER(7,2)
ATTENUATED PESTIVIRUS VIRULENCE(7,1)
ATTENUATED VIRUS MUTANT BVDV(7,1)
CAPSID PROTEIN AMINOTERMINUS(7,1)
CONTAMINATED PLASTICOR GLASSWARE(7,1)
ERNS RNASE INACTIVATION(7,1)
PESTIVIRAL GLYCOPROTEIN MUTANT(7,1)
PREGNANT COW INOCULATION(7,1)
VIRUSSTRAIN BD31NCBI GEN(7,1)
TERMINAL METHIONINE(6,6)
TISSUE CULTURE(6,5)
NPRO GENE(6,3)
STUDY INITIATION(6,3)
BVDV NEGATIVE HERD(6,2)
CARBOXY TERMINAL GLYCINE(6,2)
PESTIVIRUS GENUS(6,2)
PESTIVIRUS PROTEIN(6,2)
RESPIRATORY RATE HOOF EROSION(6,2)
TRAINED VETERINARIAN(6,2)
VIRAL POLYPROTEIN(6,2)
WEEK POST VACCINATION(6,2)
ALIQUOT BEFOREIMMEDIATE FREEZING(6,1)
AUTOPHAGIC VESICLE MEMBRANE(6,1)
BVDV ANTIBODY TITER(6,1)
CSFV ALFORT STRAIN(6,1)
EXPERIMENTAL ANIMAL NECROPSY(6,1)
MUTATED POLYNUCLEOTIDE AMPLIFICATION(6,1)
NPRO DELETION MUTANT(6,1)
PKANE40A RNASE NEGATIVE MUTANT(6,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(6,1)
VIRULENT BVDV STRAIN(6,1)
C PROTEIN(5,13)
COMPOSITION MANUFACTURE(5,8)
SIGNAL PROCESSING(5,6)
COMPLETE NPRO CODING REGION(5,5)
RAP(5,3)
ANCILLARY MOLECULE(5,2)
BACTERIAL CONTAMINATION(5,2)
CHALLENGE INFECTION(5,2)
CLINICAL DATA(5,2)
CODON DELETION(5,2)
DAY POST INFECTION(5,2)
ENCODING TRIPLET(5,2)
EXPERIMENTAL FACILITY(5,2)
INFECTIOUS CDNA(5,2)
PESTIVIRUS VIRION STRUCTURAL COMPONENT(5,2)
RESPIRATORY SIGN(5,2)
RNASE ASSAY(5,2)
ROUTINE NECROPSY(5,2)
STERILE SYRINGE(5,2)
XIKE SAFETY(5,2)
10LACHRYMATION CONJUNCTIVITIS(5,1)
APPETITE LACHRYMATION(5,1)
ATTENUATED VACCINE VIRUS(5,1)
BOVINE UBIQUITIN GENE(5,1)
BVD ANTIGEN ASSAY(5,1)
BVD SERUM ANTIBODY(5,1)
CODON CODING DELETION(5,1)
CODON CODING SUBSTITUTION(5,1)
HEIFER CLINICAL OBSERVATION(5,1)
HEIFER NECROPSY(5,1)
IMPORTANCE AMINOACID(5,1)
LATE HEIFER DEVELOPED DIARRHEA(5,1)
MUTATED ERNS PROTEIN(5,1)
STRAIN C413NCBI GEN(5,1)
STRAIN CP7NCBI GEN(5,1)
STRAIN X818NCBI GEN(5,1)
SVANOVIR BVDV ANTIBODY TEST(5,1)
UBIQUITIN CARBOXYTERMINUS(5,1)
NUCLEIC ACID SEQUENCE(4,15)
PREVENTION(4,7)
CO CULTIVATION(4,5)
SEROLOGY(4,5)
ANIMAL STUDY(4,3)
APPETITE LOSS(4,3)
BVDV SPECIFIC ANTIBODY(4,3)
BOVINE SERUM ALBUMIN(4,2)
CLINICAL SIGN PRESENCE(4,2)
FETAL INFECTION PRESENCE(4,2)
FETAL ORGAN(4,2)
FUSION PROTEIN(4,2)
GENBANK(4,2)
INCLUSION CRITERIA(4,2)
STERILE VESSEL(4,2)
1210 13ABNORMAL BREATHING(4,1)
2469CLINICAL BVD(4,1)
598BVD ABORTION(4,1)
ABORTION SIGN(4,1)
AMINOTERMINUS RESIDUE(4,1)
ANIMAL BUFFY COAT PREPARATION(4,1)
ANIMAL GROUPNUMBER(4,1)
ANIMAL HEALTH EXAMINATION(4,1)
ANIMAL INSEMINATION(4,1)
ATTENUATED BVDV PARTICLE(4,1)
ATTENUATED VIRAL PARTICLE(4,1)
AUTOLYSIS SIGN(4,1)
BVD INFECTION(4,1)
BVD POSITIVE FETUS(4,1)
BVDV INDUCED LESION(4,1)
BVDV POSITIVE FETUS(4,1)
CARBOXY TERMINAL CLEAVAGE(4,1)
CLINICAL OBSERVATION DATA(4,1)
CLINICAL SIGN BROAD SPECTRUM(4,1)
CLINICAL SIGN DURATION(4,1)
CONSERVED EPITOPE(4,1)
CSFV POLYPROTEIN(4,1)
DIATRON MINICELL(4,1)
DISCARDING INORDER(4,1)
FETUS INFECTION(4,1)
FETUS RESORPTION(4,1)
FETUS TRANSPLACENTAL INFECTION(4,1)
GLYCOPROTEIN RNA CLEAVAGE ACTIVITY(4,1)
HEIFER DEVELOPED BVDV(4,1)
HEIFER INOCULATION(4,1)
HEIFER OBSERVATION(4,1)
HEIFER UTERUS(4,1)
HETEROLOGOUS BVDV(4,1)
HETEROLOGOUS CHALLENGE(4,1)
HOMOLOGOUS BVDV(4,1)
INACTIVATED BVDV(4,1)
INFECTIOUS CLONE(4,1)
L HISTIDINE(4,1)
LIVE ATTENUATED VIRUS PRODUCTION(4,1)
MATERNAL ANTIBODY(4,1)
MILD DISEASE SIGN(4,1)
MOTIF IDENTITY(4,1)
NECROPSY DIAGNOSIS(4,1)
NON PATHOGENIC VIRUS(4,1)
NONSTRUCTURAL PROTEIN(4,1)
NPRO SEQUENCE ELFSN(4,1)
NUCLEOTIDE MOLECULE VARIANT(4,1)
NUCLEOTIDE TRIPLET(4,1)
OBSERVING VETERINARIAN(4,1)
ORAL EROSION ORAL HEMORRHAGE(4,1)
ORAL HEMORRHAGE DIARRHEA(4,1)
PESTIVIRAL INFECTION TREATMENT(4,1)
PESTIVIRUS GENOME(4,1)
POLYNUCLEOTIDE MOLECULE CODING(4,1)
POLYNUCLEOTIDE VACCINATION(4,1)
POLYPEPTIDE CLEAVAGE(4,1)
POST INOCULATION OBSERVATION(4,1)
POST MORTEM FINDING(4,1)
PREDOMINANT CLINICAL PARAMETER(4,1)
PREGNANCY INTERRUPTION DETECTION(4,1)
PROGRESSED AUTOLYSIS(4,1)
PROTECTIVE VACCINE VIRUS(4,1)
PROTEIN FUNDAMENTAL ROLE(4,1)
RNASE ACTIVITY TERM INACTIVATION(4,1)
RNASE ENZYMATIC ACTIVITY(4,1)
SACRIFICED HEIFER(4,1)
SILENT ABORTION(4,1)
SLAUGHTER EXAMINATION(4,1)
STERILE SEA SAND(4,1)
STRAIN SD 1NCBI GEN(4,1)
SYNTHESIZED POLYPROTEIN(4,1)
THAWED SAMPLE ALIQUOT(4,1)
THEANIMAL INOCULATION(4,1)
VIRUS ANDCONTAMINATED PLASTICS(4,1)
WEEK POST INFECTION(4,1)
AMINOACID SEQUENCE(3,18)
ADMINISTRATION(3,4)
SERA(3,4)
ASSAY CONDITION(3,3)
EXPERT(3,3)
MORTALITY(3,3)
NON VACCINATED CONTROL ANIMAL(3,3)
ACTIVE COMPONENT(3,2)
ANTIGEN DETECTION(3,2)
BLOOD COLLECTION(3,2)
DOUBLE MUTANT(3,2)
FETAL TRANSMISSION(3,2)
MAB CODE(3,2)
MAIN EVALUATION PARAMETER(3,2)
NON AQUEOUS SOLUTION(3,2)
NPRO REGION(3,2)
POST CHALLENGE(3,2)
PURIFICATION(3,2)
TERM VACCINE(3,2)
UBIQUITIN GROUP(3,2)
VETERINARY PRACTICE(3,2)
WEEK PI(3,2)
WILD TYPE PESTIVIRUS(3,2)
ACTIVE ERNS RNASE(3,1)
ANIMAL INFECTION(3,1)
ANIMAL NEED(3,1)
ANTI BVDV VACCINATION(3,1)
ANTIGENIC SUBSTANCE(3,1)
ATTENUATED PARTICLE(3,1)
BINGEN STRAIN(3,1)
BOVINE FRAGMENT(3,1)
BVD ANTIBODY(3,1)
BVD VIRUS PRESENCE(3,1)
BVDV ANALYSIS(3,1)
BVDV MUTANT(3,1)
BVDV PUBLISHED SEQUENCE(3,1)
BVDV SEQUENCE(3,1)
BVDV TRANSMISSION(3,1)
CELLULAR PROTEASE(3,1)
CLEAN BENCH(3,1)
CLINICAL ABORTION(3,1)
CLINICAL PICTURE(3,1)
CLINICAL SYMPTOM PRESENCE(3,1)
CODING SEQUENCE REPLACING(3,1)
CODON SUBSTITUTION(3,1)
COMPLETE BVDV POLYPROTEIN(3,1)
CONJUNCTIVITIS NASAL DISCHARGE(3,1)
CORRECT AMINO TERMINUS(3,1)
CSFV GROWTH(3,1)
CSFV STRAIN(3,1)
CULTURE GROWTH(3,1)
DEAD HEIFER(3,1)
DEFINITE DATA(3,1)
DISTINCTIVE LABEL(3,1)
DISULFIDE BONDED HOMODIMER(3,1)
EFFICIENT TRANSLATION INITIATION(3,1)
ESTABLISHED BVDV(3,1)
ETHYLENDIAMINTETRACETIC ACID ALKALI SALT(3,1)
EXPERIENCED VETERINARY SURGEON(3,1)
FETAL ABDOMINAL FLUID(3,1)
FETAL TISSUE POST MORTEM EXAMINATION(3,1)
FUNGAL RNASE ACTIVE PROTEIN(3,1)
GENETIC CODE DEGENERATIVE NATURE(3,1)
GENOME REGION CODING(3,1)
GENOMIC DELETION(3,1)
GENUS PESTIVIRUS MEMBER(3,1)
GROSS PATHOLOGICAL FINDING(3,1)
HEPARIN SODIUM(3,1)
HIGHLY ATTENUATED VIRUS(3,1)
HIGHLY CONSERVED CELLULAR PROTEIN(3,1)
HISTIDINE RESIDUE(3,1)
HOMOLOGOUS CHALLENGE(3,1)
IMMEDIATE FREEZINGIN DRY ICE(3,1)
INFECTIVE DOSE(3,1)
INSEMINATION RECORD(3,1)
INTERFERON RESPONSE INDUCTION(3,1)
INTRATHECAL ROUTE(3,1)
KILLED VACCINE(3,1)
LEUCINE CODON(3,1)
LISTED MUTANT(3,1)
LIVE ATTENUATED VACCINE(3,1)
LIVING ORGANISM(3,1)
LOT A7B163A(3,1)
MAJOR DELETION(3,1)
MEMBRANE ANCHORING(3,1)
METABOLIZABLE OIL(3,1)
MILD COUGHING(3,1)
MOLECULAR UNIQUENESS(3,1)
MUTANT VIRUS(3,1)
MUTATED POLYPROTEIN AMINOACID(3,1)
MUTATION SITE(3,1)
NASAL DISCHARGE ORAL EROSION(3,1)
NECROPSY ROOM(3,1)
NPRO CODING SEQUENCE(3,1)
NUCLEOTIDE EXCHANGE(3,1)
OCULAR DISCHARGE(3,1)
PARENTAL VIRUS(3,1)
PARENTERAL INJECTION(3,1)
PASSAGED XIKE BBVD COMPONENT(3,1)
PESTIVIRUS MOLECULAR BIOLOGY(3,1)
PHYSIOLOGICALLY ACCEPTABLE SOLVENT(3,1)
PHYSIOLOGICALLY ACCEPTABLE STERILE SOLUTION(3,1)
PREGNANCY STATUS(3,1)
PROCEDURE FORBLINDING(3,1)
PROTEASE ACTIVITY(3,1)
PROTECTIVE IMMUNITY(3,1)
PROTEIN CATABOLISM(3,1)
PROTEIN ROLE(3,1)
RECTAL EXAMINATION(3,1)
SEROLOGICAL FINDING(3,1)
SIGNIFICANT CLINICAL SIGN(3,1)
SODIUM BISULFITE(3,1)
STERILE PHYSIOLOGICALLY ACCEPTABLE SOLUTION(3,1)
STERILE PIPETTE(3,1)
TERM LIVE VACCINE(3,1)
TRUE DELETION(3,1)
UNUSED INOCULUM(3,1)
UNUSED VACCINE(3,1)
VACCINATED ANIMAL GROUP(3,1)
VACCINE MANUFACTURE(3,1)
VACCINE STRAIN(3,1)
VIRAL GENOME(3,1)
VIRUS CHALLENGE(3,1)
VIRUS DETECTION DURATION(3,1)
TCID(2,5)
ABNORMAL TEMPERATURE(2,2)
ADJUVANT(2,2)
ALUMINUM HYDROXIDE(2,2)
BACKTITRATION(2,2)
BASELINE VALUE(2,2)
BVDV RELATED ABORTION(2,2)
CEREBELLUM(2,2)
DELETED REGION(2,2)
ELISA TEST(2,2)
FORMALDEHYDE SOLUTION(2,2)
GESTATION(2,2)
IMMUNE RESPONSE(2,2)
INTERLEUKIN(2,2)
INTRANASAL(2,2)
LETHALITY(2,2)
MAIN PARAMETER(2,2)
MESENTERIC LYMPH NODE(2,2)
PYREXIA(2,2)
RECOMMENDATION(2,2)
RNASE ACTIVE SITE(2,2)
SPERMIDINE(2,2)
STABILIZER(2,2)
STERILE CONDITION(2,2)
STERNUM(2,2)
SUPRA(2,2)
TRIAL(2,2)
TRIPLICATE(2,2)
ANTIGENICALLY RELATED ORGANISM(2,1)
APPROPRIATEVOLUME(2,1)
ASEPTIC(2,1)
BACK TITRATION DATA(2,1)
BVDV PRESENCE(2,1)
CARRIER SUBSTANCE(2,1)
CELL CULTURE SUPERNATANT(2,1)
COMPLETE PESTIVIRUS(2,1)
COMPLETE POLYPROTEIN(2,1)
COMPLETE SEROCONVERSION(2,1)
CORRECT TEST CONDUCTING(2,1)
DEATH REASON(2,1)
DNA COVERING(2,1)
DOUBLE EMULSION(2,1)
DOUBLE GENETIC MARKER(2,1)
DOUBLE MUTATION(2,1)
ENCODING NUCLEIC ACID MOLECULE(2,1)
FETAL TISSUE SUSPENSION(2,1)
FLANKING REGION(2,1)
FROZEN SAMPLE(2,1)
GENOME SEQUENCE(2,1)
GENOMIC SEQUENCE(2,1)
GROUP BEFOREINOCULATION(2,1)
HEPARIN BLOOD SAMPLE(2,1)
INFECTED CELL CULTURE(2,1)
INJECTABLE SOLUTION(2,1)
INOCULATIONOF GROUP(2,1)
INOCULATIONVIRUSGROUP(2,1)
INTEIN GROUP(2,1)
INVESTIGATION(2,1)
KEY PLAYER(2,1)
LABELED CONTAINER(2,1)
LABORATORY ANALYSIS(2,1)
LQRHEWNKHGWCNWFHIEPW(2,1)
MDBK CELL(2,1)
MICROBIAL AGENT(2,1)
MICROTUBULE ASSOCIATED PROTEIN(2,1)
MODIFIED EXPRESSED POLYPEPTIDE(2,1)
MODIFIED POLYPEPTIDE(2,1)
NEVERTHELESS BVD RELATED ABORTION(2,1)
NON VACCINATED CONTROL FETUS(2,1)
NOSTRILGROUP(2,1)
ORGANISM ELEMENT(2,1)
PATHOLOGIST(2,1)
PERMISSIVE CELL CULTURE(2,1)
PESTIVIRUS REMAINING SEQUENCE(2,1)
PHOSPHATIDYLETHANOLAMINE(2,1)
PLACENTA REMAINS(2,1)
PROTOCOLEXTRACT(2,1)
RECENT EXPERIMENT(2,1)
RETITRATIONPURPOSE(2,1)
SAMPLE CHOICE(2,1)
SERUM PREPARATION(2,1)
SPECIAL ATTENTION(2,1)
SPECIES PLUS(2,1)
STUDY MONITOR(2,1)
STUDYLOCATION(2,1)
SUSCEPTIBLE CELL(2,1)
(US7572455)
MUTATION(100,90)
CODING SEQUENCE(100,52)
BOVINE VIRAL DIARRHEA VIRUS(100,40)
FUNCTIONAL VARIANT(100,35)
VACCINE(100,19)
ATTENUATED PESTIVIRUS(100,16)
ENCODED POLYPROTEIN(89,16)
ATTENUATED BVDV(60,8)
PESTIVIRAL LIVE VACCINE(58,1)
ATTENUATING PESTIVIRUS(55,2)
RNASE ACTIVITY INACTIVATION(42,7)
ATTENUATED VIRUS(41,1)
SUBSTITUTION MUTATION(36,5)
HISTIDINE RESIDUE SUBSTITUTION(35,2)
PATHOGENIC STRAIN(35,1)
PESTIVIRAL ORIGIN(35,1)
REVERSION RISK(33,1)
NUCLEOTIDE SEQUENCE CODING(30,9)
BVDV(28,92)
CARBOXY TERMINAL NS5B(27,6)
PICORNAVIRUS 3C(26,5)
LIVE VACCINE(26,2)
INACTIVATION(25,11)
CARIDOVIRUS 2A(22,5)
CODING SEQUENCE ENCODING GLYCOPROTEIN(22,3)
PESTIVIRUS SEQUENCE(22,2)
PESTIVIRUS(21,31)
DELETION(20,15)
BOVINE VIRAL DIARRHEA VIRUS CDNA(20,1)
CROSSPROTECTION(20,1)
ENCODING NUCLEIC ACID(19,2)
RNASE ACTIVITY(18,8)
IMMUNOLOGICAL RESPONSE(18,4)
NUCLEIC ACID MOLECULE ENCODING(18,2)
C TERM(17,55)
PREGNANT HEIFER(16,9)
MUTATION INTRODUCTION(16,3)
ANTISENSE(16,1)
ATTENUATION(16,1)
DEGENERATIVE NUCLEIC ACID(16,1)
NUCLEOTIDE(16,1)
ANIMAL(15,50)
ERNS MUTATION(15,9)
DELETION GROUP(15,4)
INSERTION MUTATION(14,5)
BVDV INFECTION(13,9)
PLACENTAL(13,9)
NPRO PROTEIN CODING SEQUENCE(13,5)
CATTLE BREEDING STOCK(13,4)
EXCIPIENT(13,4)
MELFSNELLYKT(13,1)
MELISNELLYKT(13,1)
MELITNELLYKT(13,1)
STUDY TERMINATION(12,11)
NPRO MUTATION(12,6)
PESTIVIRUS CDNA TRANSCRIPTION(12,2)
VIRUS(11,16)
RABBIT HEMORRHAGIC DISEASE VIRUS(11,5)
SUMO(11,4)
BINGEN(11,3)
CONSERVED ERNS SEQUENCE SLHGIWPEKICTG(11,2)
ATTENUATION RESULT(11,1)
DEFINED MUTATION(11,1)
LIVE VIRUS BVDV STRAINCOMPOSITION(11,1)
PESTIVIRUS POLYPROTEIN BVDV POLYPROTEIN(11,1)
PROCESSING SIGNAL(10,47)
PREGNANT ANIMAL(10,6)
GABA(10,5)
NEDD(10,5)
BVD VIREMIA(10,4)
FETAL PROTECTION INDUCTION(10,4)
INDIRECT IMMUNOFLUORESCENCE STAINING(10,4)
LIVE ATTENUATED BVDV(10,2)
POLYPROTEIN NPRO PORTION(10,2)
CODON RNASE INACTIVATING DELETION(10,1)
AMINOACID(9,36)
SINGLE MUTATION(9,5)
STRAIN(9,5)
CSFV(9,4)
BVDV ATTENUATION(9,3)
EMBL DATA LIBRARY(9,2)
SERUM NEUTRALIZING TITER(9,2)
ATTENUATED PESTIVIRUS VIRULENCE(9,1)
ATTENUATED VIRUS MUTANT BVDV(9,1)
ERNS RNASE INACTIVATION(9,1)
PESTIVIRAL GLYCOPROTEIN MUTANT(9,1)
BIOLOGICAL ACTIVITY(8,8)
VIRUS ISOLATION(8,6)
TISSUE CULTURE(8,5)
ENDPOINT DILUTION(8,4)
ANTIBODY NEUTRALIZATION(8,3)
FLAVIVIRIDAE FAMILY(8,3)
PLASMID(8,3)
BVDV NEGATIVE HERD(8,2)
CARBOXY TERMINAL GLYCINE(8,2)
PESTIVIRUS GENUS(8,2)
ALIQUOT BEFOREIMMEDIATE FREEZING(8,1)
AUTOPHAGIC VESICLE MEMBRANE(8,1)
CAPSID PROTEIN AMINOTERMINUS(8,1)
CONTAMINATED PLASTICOR GLASSWARE(8,1)
CSFV ALFORT STRAIN(8,1)
MUTATED POLYNUCLEOTIDE AMPLIFICATION(8,1)
PREGNANT COW INOCULATION(8,1)
VIRUSSTRAIN BD31NCBI GEN(8,1)
TERMINAL METHIONINE(7,6)
NPRO GENE(7,3)
STUDY INITIATION(7,3)
PESTIVIRUS PROTEIN(7,2)
TRAINED VETERINARIAN(7,2)
VIRAL POLYPROTEIN(7,2)
WEEK POST VACCINATION(7,2)
BVDV ANTIBODY TITER(7,1)
EXPERIMENTAL ANIMAL NECROPSY(7,1)
NPRO DELETION MUTANT(7,1)
PKANE40A RNASE NEGATIVE MUTANT(7,1)
POLYNUCLEOTIDE MOLECULE SUBUNIT(7,1)
VIRULENT BVDV STRAIN(7,1)
LEUKOCYTE COUNT(6,9)
COMPOSITION MANUFACTURE(6,8)
COMPLETE NPRO CODING REGION(6,5)
CELL INFECTION(6,3)
RAP(6,3)
ANCILLARY MOLECULE(6,2)
BACTERIAL CONTAMINATION(6,2)
CHALLENGE INFECTION(6,2)
CLINICAL DATA(6,2)
CODON DELETION(6,2)
DAY POST INFECTION(6,2)
ENCODING TRIPLET(6,2)
EXPERIMENTAL FACILITY(6,2)
INFECTIOUS CDNA(6,2)
PESTI(...)";"Biotechnology
Pharmaceuticals";Open
"2004-05-14
2004-10-26
2005-05-12";"WO2005109991        A2 2005-11-24 [WO2005109991]
STG: (A2) International application published without international search report
AP : 2005WO-IN00154 2005-05-12
WO2005109991        A3 2006-03-30 [WO2005109991]
STG: (A3) Later publication of ISR with revised front page
AP : 2005WO-IN00154 2005-05-12
WO2005109991        A8 2006-08-24 [WO2005109991]
STG: (A8) Modified first page
AP : 2005WO-IN00154 2005-05-12
AP200603856         A0 2006-12-31 [AP200603856]
STG: (A0) Application filed, as announced in the Gazette published by this office
AP : 2006AP-0003856 2005-05-12
IL179254            A  2007-03-08 [IL-179254]
STG: (A) Application of patent for invention
AP : 2005IL-0179254 2005-05-12
MA28656             B1 2007-06-01 [MA--28656]
STG: (B1) Granted Patent
AP : 2006MA-0029521 2006-12-08
RU2006144451        A  2008-06-20 [RU2006144451]
STG: (A) Application for invention
AP : 2006RU-0144451 2005-05-12
RU2404800           C2 2010-11-27 [RU2404800]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2006RU-0144451 2005-05-12
IL179254            B  2011-12-29 [IL-179254]
STG: (B) Published Examined Application Laid Open for Public Inspection
AP : 2005IL-0179254 2005-05-12
AP2709              A  2013-07-30 [AP---2709]
STG: (A) Patent
AP : 2006AP-0003856 2005-05-12";54859240;"WO2005109991        A2 2005-11-24 [WO2005109991]
WO2005109991        A3 2006-03-30 [WO2005109991]
WO2005109991        A8 2006-08-24 [WO2005109991]
AP200603856         A0 2006-12-31 [AP200603856]
IL179254            A  2007-03-08 [IL-179254]
MA28656             B1 2007-06-01 [MA--28656]
RU2006144451        A  2008-06-20 [RU2006144451]
RU2404800           C2 2010-11-27 [RU2404800]
IL179254            B  2011-12-29 [IL-179254]
AP2709              A  2013-07-30 [AP---2709]";"2004IN-DE00880
2004IN-DE02103
2005WO-IN00154";"(RU2404800)
WO2005109991
(IL-179254)
WO2005109991
(AP---2709)
WO2005109991";"CHAUDHARY CHARAN SINGH HARYANA AGRICULTURAL UNIVERSITY
CHOUDHARY CHARAN SINGH HARYANA
NATIONAL RESEARCH DEVELOPMENT
SITY CHAUDHARY CHARAN SINGH HA";SITY CHAUDHARY CHARAN SINGH HA;"(WO2005109991)
IN
(IL-179254)
IN";"(WO2005109991)
NAME=CHAUDHARY CHARAN SINGH HARYANA AGRICULTURAL UNIVERSITY  Hisar - 125 004, Haryana  , COUNTRY=IN 

NAME=SHARMA, Rameshwar, Dass  College of Veterinary Sciences, Hisar - 125 004, Haryana  , COUNTRY=IN 

NAME=NICHANI, Anil, Kumar  College of Veterinary Sciences, Hisar - 125 004, Haryana  , COUNTRY=IN 

(IL-179254)
NAME=NATIONAL RESEARCH DEVELOPMENT CORPORATION GOVT. OF INDIA ENTERPRISE, 20-22  ZAMROODPUR COMMUNITY CENTER KAILASH COLONY EXTENSION, NEW DELHI 110 048 , COUNTRY=IN 

NAME=CHOUDHARY CHARAN SINGH HARYANA AGRICULTURAL UNIVERSITY, HISAR-125 004 HARYANA , COUNTRY=IN 
";1;"SHARMA RAMESHWAR DASS
NICHANI ANIL KUMAR";"(WO2005109991)
IN";"(WO2005109991)
NAME=SHARMA, Rameshwar, Dass  College of Veterinary Sciences, Hisar - 125 004, Haryana  , COUNTRY=IN 

NAME=NICHANI, Anil, Kumar  College of Veterinary Sciences, Hisar - 125 004, Haryana  , COUNTRY=IN 
";"(WO2005109991)
Anti-theileriosis vaccine";"(WO2005109991)
A process for the preparation of anti-theileriosis vaccine comprising the steps of isolating lymphoid cells infected with schizonts of Theileria annulata present in an infected animal, culturing the infected cells in a growth medium, subjecting said cultured cells to the step of in-vitro propagation by-serial passaging, developing cloned curltures from a single cell by limiting dilution technique and further passaging these, karyotyping the cells in the medium to ascertain the diploid character, and obtaining viable cells with maximum infectivity rates, determining macroschizont nuclear number, subjecting a number of viable cells with diploid character to the step of cryoprotectant in liquid nitrogen in the presence of a cryoprotectant in the said growth medium to obtain a suspension of viable cells, testing these cultures at different passages and in varying dose levels in groups of calves for ascertaining their pathogencity / antigenicity, determining passage level and dose for the safety and efficacy of candidate vaccine, its safe use in new born calves and pregnant cows, time taken to induce immunity, serological responses and erect on haematological parameters, and testing its efficacy under wide field conditions in the susceptible stock.";"(WO2005109991)
1. WE CLAIM 1. A process for the preparation of antMheileriosis vaccine comprising the steps of Isolating'lymphoid cells Infected with schizonts of Thelbrla annulata present . In an Infected animal, culturlng the infected cells In a growth medium, subjecting said cultured cells to the step of In-vitro propagation by-serial passaging, developing cloned cultures from a single cell by limiting dilution technique and further passaging these, karyotyping the cells in the medium to ascertain the diploid character, and obtaining viable cells with maximum Infecttvtty rates, determining i o macroschizont nuclear number, subjecting a number of viable cells with diploid character to the step of cryopreservation In liquid nitrogen in the presence of a cryoprotectant in the said growth medium to obtain a suspension of viable cells, testing these cultures at different passages and in varying dose levels in
 15 groups of carves for ascertaining their pathogenicity / antigenicity, determining passage level and dose for the safety and efficacy of candidate vaccine, its safe use in new born calves and pregnant cows, time taken to induce immunity, serological responses and effect on haematological parameters, 0 and testing Its efficacy under wide field conditions in the susceptible stock. 2. The process as claimed in claim 1 wherein the said growth medium used Is RPMI 1640: 10 to 20 % neonatal or normal bovine serum; antibiotics solution containing benzyl penicillin sodium @100 i. u. per ml, streptomycin sulphate @ 100 μg per ml. and mycostatin @10 i.u. per ml; 5 and also 200 mM of L- giutamine per ml. All the contents should be pre- sterillsed by filtration and should be free from any micro-organism contamination by standard procedures.
3. The process as claimed in claim 2, wherein the said growth medium Is pre-sterilized by filtration and made free from any micro-organism contamination by standard procedures. 4. The process as claimed In claim 1 , wherein said cryoprotectant is selected 5 from DMSO and glycerol. 5. The process as claimed in claim 4 wherein preferably said cryoprotectant used is DMSO. 6. The process as claimed In claim 1 , wherein the step of in vitro propagation of various cell lines of the parasite developed were tested at various l o passages i.e. 10, 20, 50, 100, 150 & 200 with varying dose levels and It was found that the cloned culture at its passage 200 with 5x10βcells per ml as a single dose was safe and immunogenic as a vaccine. 7. A process for the preparation of Ground-Up Tick Supernatant (GUTS) comprising:
 15 collecting infected ticks sterilizing the ticks with cetavJon solution, and normal saline and RPMI- 1640, freezing the sterilized ticks, grinding a known number of frozen ticks to obtain a fine paste , subjecting the paste to the step of sterilization ,
 20 adding antibiotics and albumin powder to the paste, subjecting the paste to the step of centrffugation to separate the supemate fluid, stlrlng the supernatant containing sporozoites of T. annulata in cryoprotectant to be used as Stabilate.
 25 8. The process as claimed in claim 1, wherein the cell concentration in said cell suspension Is adjusted to 10x10βviable celts per ml, the total volume is measured and mixed with equal quantity of growth medium containing 20% DMSO so as to make the final concentration of cells at 5x10Θviable cells per ml in growth medium containing 10% DMSO.
9. An antl theiieriosis vaccine comprising schizonts of T annulata in a cryoprotectants and In growth medium.
10. The antMheileriosis vaccine as claimed in claim 9, wherein the growth medium contains 20% DMSO so as to make the final concentration of 5x10Θviable cells per ml in growth medium containing 10% DMSO.
11. The antMheileriosis vaccine as claimed in claim 9 is protective and safe for the exotic and cross-bred cattle including new born calves and pregnant cows.";"(WO2005109991)
Still another object of the present invention Is to propose an antMheileriosis vaccine and a process of preparing the same for immunization of cattle against bovine tropical theiieriosis, which has no side reactions and can be safely used even In a few days old calves as well as in pregnant and high yielding cattle i o without any adverse effects.
Further object of the present invention is to propose an antMheileriosis vaccine and a process of preparing the same for immunization of cattle against bovine tropical theiieriosis, which is cost effective as it is based on indigenous ingredients.
This invention relates to an antMheeriosis vaccine and the process of preparing the same.";"(WO2005109991)
All calves were later challenged with infective Ground-Up Tick Supernates (GUTS)/ Stabilates so as to obtain a candidate cell culture line at appropriate passage and dose level, where it is unable tp produce disease but generates immunity in the susceptible stock.
The drawback is that, this is a drug for curative purposes and not a vaccine for prevention and control of the disease.
The limitation of the above preparation therefore, is that it is only suitable for 20 treating clinical cases of theiieriosis In cattle and sheep and has no preventive application.
The drawback of the above vaccine is that it contains only 0.1 to 3 million ceils as compared to present invention which contains 5 mfliion cells.";"A61K-039/00
A61K-039/018
A61P-033/02
C12N-005/06";"(WO2005109991)
1. A process for the preparation of antMheileriosis vaccine comprising the steps of Isolating 'lymphoid cells Infected with schizonts of Thelbrla annulata present . In an Infected animal, culturlng the infected cells In a growth medium, subjecting said cultured cells to the step of In-vitro propagation by-serial passaging, developing cloned cultures from a single cell by limiting dilution technique and further passaging these, karyotyping the cells in the medium to ascertain the diploid character, and obtaining viable cells with maximum Infecttvtty rates, determining i o macroschizont nuclear number, subjecting a number of viable cells with diploid character to the step of cryopreservation In liquid nitrogen in the presence of a cryoprotectant in the said growth medium to obtain a suspension of viable cells, testing these cultures at different passages and in varying dose levels in 15 groups of carves for ascertaining their pathogenicity / antigenicity, determining passage level and dose for the safety and efficacy of candidate vaccine, its safe use in new born calves and pregnant cows, time taken to induce immunity, serological responses and effect on haematological parameters, 0 and testing Its efficacy under wide field conditions in the susceptible stock.
9. An antl theiieriosis vaccine comprising schizonts of T annulata in a cryoprotectants and In growth medium.";"(WO2005109991)
ANTMHEILERIOSIS VACCINE PREPARATION(100,4)
ANTL THEIIERIOSIS VACCINE(100,1)
ANTMHEILERIOSIS VACCINE(74,9)
BOVINE TROPICAL THEIIERIOSIS(74,9)
CANDIDATE VACCINE EFFICACY(61,2)
T ANNULATA SCHIZONT(55,1)
CATTLE IMMUNIZATION(54,4)
ANTMHEERIOSIS VACCINE(53,1)
BORN CALF(50,3)
DIPLOID CHARACTER(48,5)
PREGNANT COW(44,6)
INDIGENOUS INGREDIENT(44,1)
DAY OLD CALF(43,1)
SUSCEPTIBLE STOCK(41,4)
HEMATOLOGIC PARAMETER(41,2)
VIABLE CELL(38,10)
VIABLE CELL SUSPENSION(34,2)
GROWTH MEDIUM(31,19)
INFECTED ANIMAL(31,3)
SEROLOGICAL RESPONSE(31,1)
MFLIION CELL(30,1)
UNABLE TP PRODUCE DISEASE(30,1)
VIABLE CELT(29,1)
CLONE CULTURE(28,7)
PATHOGENICITY ANTIGENICITY(28,2)
CRYOPROTECTANT PRESENCE(26,3)
MICROORGANISM CONTAMINATION(26,2)
IMMUNITY(25,3)
INFECTED CELL(22,5)
CRYOPRESERVATION STEP(21,2)
THERAPEUTIC(21,1)
CRYOPROTECTANT(20,4)
INFECTIVE(20,1)
CATTLE(19,10)
LIMITING DILUTION(19,3)
EFFICACY(19,2)
VACCINE(18,15)
PREVENTION(17,1)
MACROSCHIZONT NUCLEAR NUMBER(16,3)
THEIIERIOSIS CLINICAL CASE(15,3)
CULTURE(14,19)
ANTIBIOTIC SOLUTION(14,2)
DOSE LEVEL(14,1)
LAST CELL CONCENTRATION(14,1)
CEIL(13,2)
CULTURED CELL(13,2)
CEIL CULTURE VACCINE(12,2)
SHEEP(12,2)
PREVENTIVE APPLICATION(12,1)
THEIFERIA ANNULATA SCHIZONT(12,1)
THEILERIA ANNULATE SCHIZONT(12,1)
THELBRLA ANNULATA PRESENT SCHIZONT(12,1)
DIMETHYL SULFOXIDE(11,14)
DISEASE(11,9)
LIQUID NITROGEN(11,7)
LYMPHOID CELL(11,4)
TISSUE CULTURE FLASK(11,4)
DRUG(11,2)
FETAL BOVINE SERUM(11,2)
NEONATAL BOVINE SERUM(11,2)
CANDIDATE CELL CULTURE LINE(11,1)
DOSE(10,5)
ABOMASAL MUCOSA(10,2)
AGRICULTURAL RESEARCH INDIAN COUNCIL(10,1)
EXOTIC BREED CATTLE(10,1)
ORGANIZED LIVESTOCK FARM(10,1)
PASSAGE LEVEL(9,3)
ANNULATA SCHIZONT INFECTED CELL(9,1)
THEILERIA ANNULATA INFECTED CULTURE(9,1)
GROWTH MEDIUM QUANTITY(8,2)
INDIGENOUS CALF(8,2)
NECROTIC ULCER(8,2)
STANDARD(8,2)
ATTENUATED STRAIN SCHIZONT(8,1)
THRICE WEEKLY PASSAGED CULTURE(8,1)
VACCINE CANDIDATE(7,2)
ANNULATA INFECTIVE(7,1)
CAFF DEATH(7,1)
CATTLE LYMPHOLD CELL(7,1)
CHALLENGE INFECTION(7,1)
EXPERIMENTAL ANIMAL SHED(7,1)
INDIAN SUBCONTINENT(7,1)
LYMPH NODE BIOPSY SMEAR(7,1)
MACROSCHIZONT DEMONSTRATION(7,1)
MEDITERRANEAN LITTORAL(7,1)
NEO BORN CALF(7,1)
NONSPECIFIC IMMUNIZATION(7,1)
OLD CROSSBRED CALF(7,1)
PARASITAEMIA SCHIZONT DECREASE(7,1)
PEAK ANTIBODY TLTRE(7,1)
SERIAI PASSAGING(7,1)
SEVERE TICK CHALLENGE(7,1)
SKIN ERUPTION(7,1)
THEIIERIOSIS LESION(7,1)
THEILERIA SCHIZONT(7,1)
THELTERLA ANNULATE(7,1)
TROPICAL THEIIERIOSIS(7,1)
TWICE THRICE WEEKLY TIII(7,1)
VACCINATED ANIMAL CHALLENGE(7,1)
YOUNG CROSSBRED MALE(7,1)
SINGLE CELL(6,6)
VACCINE CELL CULTURE(6,3)
AGE MONTH(6,2)
PLACEBO INJECTED ANIMAL(6,2)
PROTECTIVE IMMUNITY(6,2)
STATIC CULTURE(6,2)
SUBCUTANEOUS ROUTE(6,2)
BOVINE ALBUMIN POWDER(6,1)
BULL BREEDING ABILITY(6,1)
CEREBRAL INVOLVEMENT(6,1)
DISEASE PREVALENCE(6,1)
DISEASE SYMPTOM(6,1)
DREADFUL DISEASE(6,1)
EPIDEMIOIOGICAL STUDY(6,1)
ETHANE SULPHOXLDE(6,1)
INDIAN COUNCIL COORDINATING UNIT(6,1)
INTENSIVE CROSS BREEDING(6,1)
INTERCURRENT DISEASE(6,1)
MICROSCOPE OIL IMMERSION TEN(6,1)
MILD THEIIERIOSIS(6,1)
POTENT CHALLENGE(6,1)
SEVERE CLINICAL DISEASE(6,1)
STERILIZED MORTAR(6,1)
SURVIVING CALF(6,1)
VACCINATED CALF(6,1)
VACCINATED DAM(6,1)
VACCINATION WEEK(6,1)
SAFE(5,7)
NORMAL BOVINE SERUM(5,2)
OLD CULTURE(5,2)
SCHIZONT CELL CULTURE(5,2)
SERIAL PASSAGING(5,2)
ADULT CATTLE(5,1)
ANIMAL TRIAL(5,1)
CANDIDATE CELL CULTURE VACCINE(5,1)
CLINICAL SYMPTOM(5,1)
CULTURE PLATING EFFICIENCY(5,1)
DURATL MAX(5,1)
ENORMOUS ECONOMIC LOSS(5,1)
IMMEDIATE THAWING(5,1)
INFECTED ADULT(5,1)
INFECTED TICK(5,1)
INFECTION INITIATION(5,1)
INFECTIVE DOSE(5,1)
INJECTING GUT(5,1)
LETHAL CHALLENGE(5,1)
LIVE VACCINE(5,1)
MAIN DISEASE SUFFERER(5,1)
NEWBORN CALF(5,1)
PERTINENT SIGN(5,1)
PROJECT COORDINATOR(5,1)
RAINY MONTH(5,1)
RARE SCHIZONT(5,1)
SCHIZONT GROWTH(5,1)
SEVERE THEIIERIOSIS(5,1)
SICK ANIMAL TREATMENT(5,1)
SUPPORTIVE THERAPY(5,1)
T EIBRIA ANNULATE(5,1)
VACCINATION EXPERIMENT(5,1)
VACCINATION STUDY(5,1)
VACCINE DOSE PREPARATION(5,1)
VISIBLE PARASITAEMIA(5,1)
VIABILITY(4,3)
ADVANCED DISEASE STAGE(4,1)
ANIMAL PERCENTAGE(4,1)
ANTIBODY DEVELOPMENT(4,1)
BIG FLASK(4,1)
BOVINE SERUM VOLUME(4,1)
BULL WORKING CAPACITY(4,1)
CATTLE LYMPHOID CELL(4,1)
CELL CLONE(4,1)
CELL ESTABLISHMENT(4,1)
CHEMOTHERAPEUTIC AGENT(4,1)
CULTURE EVALUATION(4,1)
CULTURE TEST(4,1)
DILUTED CULTURE(4,1)
DISEASE OCCURRENCE(4,1)
GROUND UP TICK SUPERNATES(4,1)
IMMUNITY DEVELOPMENT(4,1)
INDEPENDENT AGENCY(4,1)
MEDIATED IMMUNE RESPONSE(4,1)
PREGNANCY STAGE(4,1)
PROTECTIVE EFFICACY(4,1)
PROTRUSIVE EYEBALL(4,1)
REPEATED TICK INFESTATION(4,1)
RESIDUAL INFECTION(4,1)
SEA SAND(4,1)
STERILE CULTURE TUBE(4,1)
SUSCEPTIBLE ANIMAL(4,1)
SUSPENSION CULTURE(4,1)
UNUSUAL SIGN(4,1)
VACCINE DEVELOPMENT(4,1)
VACCINE INJECTED ANIMAL(4,1)
VACCINE INJECTION(4,1)
VACCINE ML(4,1)
VACCINE TESTING(4,1)
VITRO PROPAGATION(4,1)
YOUNG ANIMAL(4,1)
FEVER(3,4)
BUPARVAQUONE(3,2)
EXERCISE(3,2)
HEMATOLOGIC VALUE(3,2)
HOST RESPONSE(3,2)
NITROGEN CONTAINER(3,2)
PIROPLASM(3,2)
SEEDING RATE(3,2)
STREPTOMYCIN SULFATE(3,2)
CELL POPULATION(3,1)
COD FINAL CONCENTRATION(3,1)
CONTINUOUS FEEDING INTRIGUING FEATURE(3,1)
COUNTRY(3,1)
EXPONENTIAL GROWTH PHASE(3,1)
FINE PASTE(3,1)
GETTING NATURAL(3,1)
GROWTH MEDIUM MI(3,1)
HEMOCYTOMETER(3,1)
HEMOGLOBINURIA(3,1)
IMMUNOGENICITY(3,1)
LYMPHADENOPATHY(3,1)
MAIN SUSCEPTIBLE STOCK(3,1)
MIIK PRODUCTION(3,1)
NUTRIENT MEDIUM(3,1)
PATHOGENICITY ANTTQENLCLTV(3,1)
REPEATED INFECTIVE(3,1)
SROLOGTEAL RESPONSE(3,1)
STERILIZED GLASS TUBE(3,1)
SUPERNATANT FLUID(3,1)
SUSCEPTIBLE CALF GROUP(3,1)
THERAPEUTIC PREPARATION(3,1)
TICK EQUIVALENT GUT(3,1)
VECTOR TICK IMPRACTICABLE CONTROL(3,1)
WEEK POST(3,1)
(IL-179254)
VACCINE(100,19)
THEILERIA ANNULATE SCHIZONT(100,2)
ANTI THEILERIOSIS VACCINE PREPARATION(100,1)
BOVINE TROPICAL THELLERLOSIS(85,8)
CANDIDATE VACCINE EFFICACY(69,2)
CATTLE IMMUNIZATION(67,3)
ANTI THELLERLOSIS VACCINE(57,6)
DIPLOID CHARACTER(54,5)
INDIGENOUS INGREDIENT(49,1)
DAY OLD CALF(48,1)
VIABLE CELL(47,11)
SUSCEPTIBLE STOCK(46,4)
HEMATOLOGIC PARAMETER(46,2)
MICROORGANISM CONTAMINATION(45,3)
BORN CALF(45,2)
ANTI THEHERIOSIS VACCINE(44,1)
PATHOGENICITY ANTLGENICITY(42,1)
CLONE CULTURE(41,8)
STREPTOMYCIN CALIPHATE(40,1)
PREGNANT COW(39,5)
VIABLE CELL SUSPENSION(38,2)
STERILIZED TICK(36,1)
INFECTED ANIMAL(35,3)
T ANNULATA SCHIZONT(35,1)
UNABLE TP PRODUCE DISEASE(33,1)
GROWTH MEDIUM(32,20)
VACCINE DOSE(32,1)
CRYOPRESERVATLON STEP(30,1)
FROZEN TICK(30,1)
CRYOPROTECTANT PRESENCE(29,3)
SPOROZOITE PREPARATION(29,1)
IMMUNITY(28,3)
INFECTED CELL(28,3)
SEROLOGICAL RESPONSE(28,2)
INFECTED TICK(27,2)
THELLERIOSIS(26,1)
CALF GROUP(23,2)
STABUATE(23,1)
THERAPEUTIC(23,1)
LIMITING DILUTION(21,3)
EFFICACY(21,2)
MACROSCHIZONT NUCLEAR NUMBER(20,2)
MAXIMUM INFECTIVITY RATE(20,2)
PREVENTION(19,1)
CATTLE(18,7)
SUPERNATANT FLUID(18,2)
CRYSPROTECTANT(18,1)
DIMETHYL SULFOXIDE(17,13)
CULTURE(16,18)
ANTIBIOTIC SOLUTION(16,2)
BOVINE TROPICAL THEILERIOSIS(16,2)
CETAVION SOLUTION(16,2)
DOSE LEVEL(15,1)
STERILIZATION STEP(15,1)
STANDARD(14,3)
CULTURED CELL(14,2)
SHEEP(14,2)
CENTRIFUGING STEP(14,1)
FINAL CONCENTRATION(14,1)
LIQUID NITROGEN(13,7)
LYMPHOID CELL(13,4)
NYSTATIN(13,3)
DRUG(13,2)
LAST CELL CONCENTRATION(13,2)
INFECTIVE GROUND UP TICK(13,1)
PREVENTIVE APPLICATION(13,1)
DISEASE(12,9)
SAFE(12,9)
TISSUE CULTURE FLASK(12,4)
FETAL BOVINE SERUM(12,2)
NEONATAL BOVINE SERUM(12,2)
NORMAL SALINE(12,2)
CANDIDATE CELL CULTURE LINE(12,1)
THELLERLA ANNULATE ESTABLISHMENT(12,1)
DOSE(11,5)
ABOMASAL MUCOSA(11,2)
EXOTIC BREED CATTLE(11,1)
ORGANIZED LIVESTOCK FARM(11,1)
ANTI THELLERLOSIS VACCINE PREPARATION(10,3)
PASSAGE LEVEL(10,3)
SINGLE DOSE(10,3)
ANNULATE SCHIZONT INFECTED CELL(10,1)
CATTLE EXOTIC BREED(10,1)
O TREATING CLINICAL CASE(10,1)
ANNULATE INFECTED CELL(9,2)
GROWTH MEDIUM QUANTITY(9,2)
NECROTIC ULCER(9,2)
ATTENUATED STRAIN SCHIZONT(9,1)
THRICE WEEKLY PASSAGED CULTURE(9,1)
YOUNG INDIGENOUS CALF(9,1)
VACCINE CELL CULTURE(8,5)
VACCINE CANDIDATE(8,2)
GROUND UP TICK SUPERNATANT(8,1)
LYMPH NODE BIOPSY SMEAR(8,1)
MEDITERRANEAN LITTORAL(8,1)
NEO BORN CALF(8,1)
OLD CROSSBRED CALF(8,1)
PARASITEERNIA SCHIZONT DECREASE(8,1)
THELLERLOSIS LESION(8,1)
VACCINATED ANIMAL CHALLENGE(8,1)
SINGLE CELL(7,6)
SERIAL PASSAGING(7,4)
AGE MONTH(7,2)
CATTLE LYMPHOID CELL(7,2)
L GLUTAMINE(7,2)
PLACEBO INJECTED ANIMAL(7,2)
PROTECTIVE IMMUNITY(7,2)
STATIC CULTURE(7,2)
ANNULATE INFECTIVE(7,1)
CHALLENGE INFECTION(7,1)
EXPERIMENTAL ANIMAL SHED(7,1)
FTS PATHOGENICITY(7,1)
INDIAN SUBCONTINENT(7,1)
MEIN SUSCEPTIBLE STOCK(7,1)
NONSPECIFIC IMMUNIZATION(7,1)
PARASITE CELL LINE(7,1)
SEVERE TICK CHALLENGE(7,1)
SKIN ERUPTION(7,1)
THAILERIA ANNUASTA(7,1)
THEHERTA ANNULATE(7,1)
THEIHRIE SCHIZONT(7,1)
TROPICAL THELLERLOSIS(7,1)
WEEK POST VACCINATION(7,1)
PENICILLIN G SODIUM(6,2)
SCHIZONT CELL CULTURE(6,2)
BOVINE ALBUMIN POWDER(6,1)
BULL BREEDING ABILITY(6,1)
CALF DEATH(6,1)
CEREBRAL INVOLVEMENT(6,1)
CROSI BRED CATTLE(6,1)
CYTOSPIN SMEAR(6,1)
DISEASE PREVALENCE(6,1)
DISEASE SYMPTOM(6,1)
DREADFUL DISEASE(6,1)
DREADFUL TICK(6,1)
ETHANE SULPHOXLDE(6,1)
INDIAN COUNCIL COORDINATING UNIT(6,1)
INTERCURRENT DISEASE(6,1)
LATE PREGNANCY STAGE(6,1)
MICROSCOPE OIL IMMERSION LENS(6,1)
MILD THELLERLOSIS(6,1)
PEAK ANTIBODY TITER(6,1)
POTENT CHALLENGE(6,1)
SEVERE CLINICAL DISEASE(6,1)
STERILIZED MORTAR(6,1)
VACCINATED CALF(6,1)
VACCINATED DAM(6,1)
VACCINATION WEEK(6,1)
NORMAL BOVINE SERUM(5,2)
OLD CULTURE(5,2)
SUBCUTANEOUS ROUTE(5,2)
ADULT CATTLE(5,1)
ANIMAL TRIAL(5,1)
ANTI THELLERIOSIS VACCINE(5,1)
BORN CALF(5,1)
CANDIDATE CELL CULTURE VACCINE(5,1)
CLINICAL SYMPTOM(5,1)
CULTURE ERE(5,1)
CULTURE PLATING EFFICIENCY(5,1)
DOSE TITRATION(5,1)
ENORMOUS ECONOMIC LOSS(5,1)
GETTING NATURAL REPEATED INFECTIVE(5,1)
IMMEDIATE THAWING(5,1)
INFECTED ADULT(5,1)
INFECTION INITIATION(5,1)
INFECTIVE DOSE(5,1)
INJECTING GUT(5,1)
LETHAL CHALLENGE(5,1)
LIVE VACCINE(5,1)
MAIN DISEASE SUFFERER(5,1)
PERTINENT SIGN(5,1)
PROJECT COORDINATOR(5,1)
RAINY MONTH(5,1)
RARE SCHIZONT(5,1)
SCHIZONT GROWTH(5,1)
SEVERE THELLERIOSIS(5,1)
SICK ANIMAL TREATMENT(5,1)
SUPPORTIVE THERAPY(5,1)
VACCINATION EXPERIMENT(5,1)
VACCINATION STUDY(5,1)
VACCINE DOSE PREPARATION(5,1)
VISIBLE PARASLTAEMIA(5,1)
BUPARVAQUONE(4,2)
EXERCISE(4,2)
HEMATOLOGIC VALUE(4,2)
HOST RESPONSE(4,2)
NITROGEN CONTAINER(4,2)
PIROPLASM(4,2)
SEEDING RATE(4,2)
STREPTOMYCIN SULFATE(4,2)
VIABILITY(4,2)
ADVANCED DISEASE STAGE(4,1)
AGRICULTURAL RESEARCH(4,1)
ANIMAL PERCENTAGE(4,1)
ANTIBODY DEVELOPMENT(4,1)
BIG FLASK(4,1)
BOVINE SERUM VOLUME(4,1)
BULL WORKING CAPACITY(4,1)
CELL CLONE(4,1)
CELL ESTABLISHMENT(4,1)
CHEMOTHERAPEUTIC AGENT(4,1)
DILUTED CULTURE(4,1)
DISEASE OCCURRENCE(4,1)
DURAN MAX(4,1)
IMMUNITY DEVELOPMENT(4,1)
INDEPENDENT AGENCY(4,1)
INFECTIVITY RATE ASSESSMENT(4,1)
PL CULTURE(4,1)
PROTECTIVE EFFICACY(4,1)
PROTRUSIVE EYEBALL(4,1)
REPEATED TICK INFESTATION(4,1)
SEA SAND(4,1)
STERILE CULTURE TUBE(4,1)
SUSCEPTIBLE ANIMAL(4,1)
SUSPENSION CULTURE(4,1)
UNUSUAL SIGN(4,1)
VACCINE DEVELOPMENT(4,1)
VACCINE INJECTED ANIMAL(4,1)
VACCINE INJECTION(4,1)
VACCINE ML(4,1)
VACCINE TESTING(4,1)
YOUNG ANIMAL(4,1)
FEVER(3,4)
ANEMIA(3,2)
GROWING T(3,2)
CELL POPULATION(3,1)
CONTINUOUS FEEDING INTRIGUING FEATURE(3,1)
COUNTRY(3,1)
CULTURE O EVALUATION(3,1)
ENT PASSAGE(3,1)
EXPONENTIAL GROWTH PHASE(3,1)
FINE PASTE(3,1)
HEMOCYTOMETER(3,1)
LYMPHADENOPATHY(3,1)
NUTRIENT MEDIUM(3,1)
PATHOGENICITY ANTIGENICITY(3,1)
PATHOGENICITY ANTKIENLCITV(3,1)
POSTAL SERVICE MODEM(3,1)
STERILIZED GLASS TUBE(3,1)
SUSCEPTIBLE CALF GROUP(3,1)
THERAPEUTIC PREPARATION(3,1)
TICK EQUIVALENT GUT(3,1)
TRANSMITTED DISEASE(3,1)
VECTOR TICK IMPRACTICABLE CONTROL(3,1)
ALIQUOT(2,1)
CATTLE AGE GROUP(2,1)";Pharmaceuticals;Open
"2004-05-14
2004-05-17
2005-05-16
2006-12-13";"CA2467329           A1 2005-11-14 [CA2467329]
STG: (A1) Application laid open
AP : 2004CA-2467329 2004-05-14
WO2005111196        A1 2005-11-24 [WO2005111196]
STG: (A1) Published application with search report
AP : 2005WO-CA00745 2005-05-16
CA2565247           A1 2005-11-24 [CA2565247]
STG: (A1) Application laid open
AP : 2005CA-2565247 2005-05-16
AU2005243548        A1 2005-11-24 [AU2005243548]
STG: (A1) Open to public inspection
AP : 2005AU-0243548 2005-05-16
EP1747262           A1 2007-01-31 [EP1747262]
STG: (A1) Application published with search report
AP : 2005EP-0745406 2005-05-16
KR10-2007-0031936   A  2007-03-20 [KR20070031936]
STG: (A) Published application
AP : 2006KR-7026260 2006-12-13
PL381833            A1 2007-07-23 [PL2005381833]
STG: (A1) Application
AP : 2005PL-0381833 2005-05-16
CN101014698         A  2007-08-08 [CN101014698]
STG: (A) Published application
AP : 2005CN-80023509 2005-05-16
JP2007537307        A  2007-12-20 [JP2007537307]
STG: (A) Published application
AP : 2007JP-0511818 2005-05-16
BRPI0510882         A  2007-12-26 [BR200510882]
STG: (A) Published application
AP : 2005BR-0010882 2005-05-16
BRPI0510882         A1 2007-12-26 [BRPI0510882]
STG: (A1) Published application
AP : 2005BR-0010882 2005-05-16
US20080008723       A1 2008-01-10 [US20080008723]
STG: (A1) Application published
AP : 2005US-11569093 2005-05-16
EP1747262           A4 2009-02-11 [EP1747262]
STG: (A4) Supplementary search report
AP : 2005EP-0745406 2005-05-16
HU0700044           A2 2009-03-30 [HU200700044]
STG: (A2) Examined patent application
AP : 2007HU-0000044 2005-05-16
US7759070           B2 2010-07-20 [US7759070]
STG: (B2) Granted patent as second publication
AP : 2005US-11569093 2005-05-16
FD :  Provisional Appl: US60/571,489 FDD=2004-05-17 [2004US-60571489]
FD : Previous publication: US20080008723 A1 2008-01-10 [US20080008723]
BRPI0510882         A2 2011-03-29 [BR200510882]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2005BR-0010882 2005-05-16
EP1747262           B1 2012-09-26 [EP1747262]
STG: (B1) Patent specification
AP : 2005EP-0745406 2005-05-16
CA2565247           C  2014-03-25 [CA2565247]
STG: (C) Patent (second level)
AP : 2005CA-2565247 2005-05-16";4072662;"CA2467329           A1 2005-11-14 [CA2467329]
WO2005111196        A1 2005-11-24 [WO2005111196]
CA2565247           A1 2005-11-24 [CA2565247]
AU2005243548        A1 2005-11-24 [AU2005243548]
EP1747262           A1 2007-01-31 [EP1747262]
KR10-2007-0031936   A  2007-03-20 [KR20070031936]
PL381833            A1 2007-07-23 [PL2005381833]
CN101014698         A  2007-08-08 [CN101014698]
JP2007537307        A  2007-12-20 [JP2007537307]
BRPI0510882         A  2007-12-26 [BR200510882]
BRPI0510882         A1 2007-12-26 [BRPI0510882]
US20080008723       A1 2008-01-10 [US20080008723]
EP1747262           A4 2009-02-11 [EP1747262]
HU0700044           A2 2009-03-30 [HU200700044]
US7759070           B2 2010-07-20 [US7759070]
BRPI0510882         A2 2011-03-29 [BR200510882]
EP1747262           B1 2012-09-26 [EP1747262]
CA2565247           C  2014-03-25 [CA2565247]";"2004CA-2467329
2004US-60571489
2005CA-2565247
2005US-11569093
2005WO-CA00745
2006KR-7026260";"(EP1747262)
WO2005111196
(US7759070)
WO2005111196
(JP2007537307)
WO2005111196
(AU2005243548)
WO2005111196
(KR20070031936)
WO2005111196
(CN101014698)
WO2005111196
(HU200700044)
WO2005111196
(BR200510882)
WO2005111196
(CA2565247)
WO2005111196";NATIONAL RESEARCH COUNCIL OF CANADA;NATIONAL RESEARCH COUNCIL OF CANADA;"(EP1747262)
CA
(EP1747262)
CA
(US20080008723)
CA
(US7759070)
CA
(WO2005111196)
CA

(CA2467329)
CA

(BRPI0510882)
GB
(BR200510882)
GB
(CA2565247)
CA
(CA2565247)
CA";"(EP1747262)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA 1200 Montreal Road , CITY=Ottawa, Ontario K1A OR6 , COUNTRY=CA 

(EP1747262)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA 1200 Montréal Road , CITY=Ottawa, Ontario K1A 0R6 , COUNTRY=CA , REG=100184602 

(US20080008723)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA 1200 Montreal Road , CITY=Ottawa , STATE=ON , POSTCODE=K1A 0R6 , COUNTRY=CA , ATYP=Non-US Company 

(US7759070)
NAME=National Research Council of Canada , CITY=Ottawa, Ontario , COUNTRY=CA , ATYP=Non-US Company 

(WO2005111196)
NAME=NATIONAL RESEARCH COUNCIL CANADA  [CA/ CA] 1200 Montreal Road, Ottawa, Ontario K1A 0R6  , COUNTRY=CA 

(JP2007537307)
NAME=National Research Counsel Canada , REG=506379965 

(CA2467329)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA 1200 MONTREAL ROAD , CITY=OTTAWA , STATE=O1 , POSTCODE=K1A 0R6 , COUNTRY=CA 

(KR20070031936)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA , REG=519980599735 

(BRPI0510882)
NAME=NATIONAL RESEARCH COUNCIL CANADA , COUNTRY=GB 

(BR200510882)
NAME=NATIONAL RESEARCH COUNCIL CANADA , COUNTRY=GB 

(CA2565247)
NAME=NATIONAL RESEARCH COUNCIL CANADA 1200 Montreal Road , CITY=OTTAWA , STATE=O1 , POSTCODE=K1A 0R6 , COUNTRY=CA 

(CA2565247)
NAME=NATIONAL RESEARCH COUNCIL CANADA 1200 MONTREAL ROAD , CITY=OTTAWA , STATE=O1 , POSTCODE=K1A 0R6 , COUNTRY=CA 
";1;"COX ANDREW
RICHARDS JAMES C";"(EP1747262)
CA";"(EP1747262)
NAME=COX, Andrew 2160 Dutton Crescent , CITY=Ottawa, Ontario K1J 6K4 , COUNTRY=CA 

NAME=RICHARDS, James, C. 620-200 Rideau Terrace , CITY=Ottawa, Ontario K1M 0Z3 , COUNTRY=CA 
";"(EP1747262)
Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates";"(EP1747262)
A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.";"(CA2467329)
We Claim:
A lipopolysaccharide (""LPS"") having the structure:
wherein:
A method of making a vaccine comprising linking an LPS of claim 1 or a portion or variant thereof to an immunogenic carrier protein.
4. Use of the LPS of claim 1 in enhancing an immune response to bacterial infection.
5. A conjugate comprising an LPS f claim 1 or a portion thereof and an immunogenic carrier protein.
6. A vaccine comprising an LPS of claim 1 or a portion thereof.";"(EP1747262)
In an embodiment of the invention there is provided a method of inducing or increasing immunity in an animal, fish or bird against a bacterial pathogen comprising administering a conserved inner core LPS molecule.";"(EP1747262)
It would be useful to have a vaccine against the pathogenic bacteria of concern.
This structure is useful as a vaccine candidate that provides broad coverage to all strains.
In general however, this strategy is severely limited as the immune response remains serotype-restricted and fails to provide cross-protection against other serotypes.
Such approaches are not entirely satisfactory as effectiveness can be inadequate and there is a significant incidence of adverse effects.
There is currently no single vaccine available to provide cross-species protection against infections caused by these three species, Mh, Ap and Pm.
Taken together they cause diseases resulting in major economic losses to the animal farming industry.";"A61K-008/73
A61K-009/127
A61K-031/715
A61K-031/739
A61K-039/00
A61K-039/02
A61K-039/05
A61K-039/08
A61K-039/10
A61K-039/102
A61K-039/104
A61K-039/106
A61K-039/116
A61K-039/29
A61K-039/39
A61K-047/16
A61K-047/18
A61K-047/22
A61K-047/48
A61P-031/04
C07H-013/04
C07K-016/12
C08B-037/00
C12N-001/20
C12N-001/36
C12P-019/04
C12P-019/44
C12R-001/01
G01N-033/53
G01N-033/569";"(EP1747262)
1. An isolated lipopolysaccharide moiety having an inner core consisting of a conserved di-glucosyl-tetra-heptosyl inner-core moiety of Formula wherein Glc is glucose; Hep is heptose; Kdo is 3-deoxy-D-manno-2-octulosonic acid, and P is phosphate.
2. An isolated lipopolysaccharide moiety, wherein the inner core consists of a conserved di-glucosyl-tetra-heptosyl inner-core moiety of Formula wherein Glc is glucose; Hep is heptose; and Kdo is 3-deoxy-D-manno-2-octulosonic acid.";"(EP1747262)
CORE LIPOPOLYSACCHARIDE EPITOPE(100,1)
MULTI SPECIES VACCINE CANDIDATE(100,1)
ISOLATED LIPOPOLYSACCHARIDE MOIETY(80,2)
ACTINOBACILLUS PLEUROPNEUMONIAE APX EXOTOXOID(66,1)
MANNHEIMIA HAEMOLYTICA PLPE LIPOPROTEIN(60,1)
ANIMAL FARMING INDUSTRY(43,1)
MANNHEIMIA HAEMOLYTICA SIALOGLYCOPROTEASE(42,1)
ACTINOBACILLUS PLEUROPNEUMONIAE OMLA(41,1)
ACTINOBACILLUS PLEUROPNEUMONIAE TBPA(41,1)
MANNHEIMIA HAEMOLYTICA LEUKOTOXIN TOXOID(41,1)
OCTULOSONIC ACID(40,3)
KDA CAPSULAR PROTEIN(38,1)
PASTEURELLA MULTOCIDA PLPB(37,1)
IMMUNOGENIC CARRIER(36,3)
PASTEURELLA MULTOCIDA PIP(36,1)
CLOSTRIDIUM PERFRINGENS EXOTOXIN(32,2)
AERRUGINOSA TOXIN(31,1)
DIPHTHERIA TOXOID(31,1)
TETANUS TOXOID(29,1)
FORMULA INNER CORE MOIETY(26,2)
PERTUSSIS TOXIN TOXOID(26,2)
CHOLERA TOXIN TOXOID(25,2)
MAJOR ECONOMIC LOSS(24,1)
LINKER MOLECULE(23,1)
GLUCOSE(19,28)
FUNCTIONAL ANTIBODY(16,3)
STRATEGY(15,2)
ANIMAL(15,1)
SEROTYPE(14,18)
KDO(14,17)
CONSERVED INNER(14,4)
IMMUNE RESPONSE(14,4)
BACTERIAL PATHOGEN(13,4)
ANOMERIC PROTON RESONANCE(13,3)
GAL ANOMERIC PROTON(13,2)
BIRD(13,1)
FISH(13,1)
SINGLE VACCINE(13,1)
CORE OS NMR SPECTRUM(12,5)
IMMUNITY(12,4)
METHYLATION ANALYSIS DATA(12,4)
SEROTYPE CORE OS(12,4)
STRAIN MH LOSB(12,4)
SERUM BACTERICIDAL ASSAY(12,3)
DETOXIFIED P(12,2)
MANNHEIMIA HAEMOLYTICA MUTANT STRAIN(12,2)
VETERINARY BACTERIAL PATHOGEN LIPOPOLYSACCHARIDE(12,2)
ACTINOBACILLUS PLEUROPRIEUMONIA SEROTYPE(12,1)
CROSS SPECIES PROTECTION(12,1)
KDA CROSS PROTECTIVE LIPOPROTEIN(12,1)
MAJOR OUTER MEMBRANE PROTEIN(12,1)
KDO RESIDUE(11,8)
INFECTION(11,4)
INTER RESIDUE NOE(11,3)
BACTERIAL VETERINARY PATHOGEN(11,2)
RESPIRATORY SYNCYTIAL VIRUS F(11,2)
ROTAVIRUS(11,2)
CANDIDATE ANTIGEN EPITOPE(11,1)
HEXNAC RESIDUE ANOMERIC PROTON(11,1)
SIGNIFICANT ADVERSE EFFECT INCIDENCE(11,1)
VETERINARY PATHOGEN MANNHEIMIA HAEMOLYTICA(11,1)
DOUBLY CHARGED ION(10,5)
MONOCLONAL ANTIBODY(10,3)
ANTI IDIOTYPE VACCINE MIMICKING(10,1)
GLYCOCONJUGATE VACCINE INVESTIGATION(10,1)
HEPIV RESIDUE REVEALED DISUBSTITUTION(10,1)
MULTOCIDA HEPTOSYLTRANSFERASE MUTANT(10,1)
SEROTYPE CAPSULAR POLYSACCHARIDE(10,1)
DISEASE(9,9)
13C NMR ASSIGNMENT(9,6)
1D SELECTIVE EXPERIMENT(9,4)
LETTER DESIGNATION(9,4)
D MANNO(9,3)
PHOSPHOETHANOLAMINE RESIDUE(9,3)
ANOMERIC PROTON H RESONANCE(9,2)
HAEMOLYTICA SEROTYPE(9,2)
OLIGOSACCHARIDE EPITOPE(9,2)
VETERINARY ORGANISM(9,2)
CARBOHYDRATE ANTIGEN IMMUNOGENICITY(9,1)
ECONOMICALLY VIABLE VACCINE CANDIDATE(9,1)
LBGA GALACTOSYLTRANSFERASE GENE(9,1)
ELUTION FRACTION(8,4)
MOUSE DESIGNATION(8,4)
CORE OS RESIDUE(8,3)
ELECTROSPRAY MASS SPECTRUM(8,3)
HMQC TOCSY SPECTRUM(8,3)
INTER RESIDUE VIRTUE(8,3)
MH INFECTION(8,3)
SIMULATED SPECTRA(8,3)
ELECTROSPRAY IONIZATION(8,2)
ANOMERIC RESONANCE INTEGRATION(8,1)
BACKBONE OLIGOSACCHARIDE PARTIAL TRUNCATION(8,1)
BACTERICIDAL ASSAY DATA(8,1)
CANDIDATE VACCINE ANTIGEN(8,1)
COMPLEMENT MEDIATED BACTERICIDAL LYSIS(8,1)
DOUBLY UNDERLINED RESONANCE(8,1)
DOWNFIELD DOUBLET APPEARANCE(8,1)
GENERAT ING ANTIBODY(8,1)
GLYCOSYLTRANSFERASE TENTATIVE IDENTIFICATION(8,1)
HAEMOPHILUS INFLUENZAE STRAIN(8,1)
HEPTOSE MONOSACCHARIDE PROTON SPECTRA(8,1)
HOMOLOGOUS ENCAPSULATED BACTERIUM(8,1)
INTACT BACKBONE OLIGOSACCHARIDE(8,1)
INTENSE TRANSGLYCOSIDIC OCCURRENCE(8,1)
KDO METHYLENE PROTON(8,1)
MEDICINE BAYLOR COLLEGE(8,1)
OKLAHOMA UNIVERSITY HEALTH(8,1)
PERMETHYLATED ALDITOL ACETATE(8,1)
PHOSPHORYLATED KETODEOXYOCTONOATE RESIDUE(8,1)
POLYCLONAL SERA DILUTION(8,1)
PRODUCTION SPECTRUM(7,9)
SINGLY CHARGED PEAK(7,3)
ACETYLGALACTOSAMINE(7,2)
CONSERVED CARBOHYDRATE(7,2)
DOUBLY SELECTIVE EXPERIMENT(7,2)
ELECTROSPRAY CAPILLARY ELECTROPHORESIS(7,2)
FRACTIONATED CORE OS(7,2)
MASS SPECTROMETRIC(7,2)
SPECTROMETRIC ANALYSIS(7,2)
1D NOESY TOCSY EXPERIMENT(7,1)
ANOMERIC RESONANCE REMAINDER(7,1)
AP SEROTYPE SPECTRUM(7,1)
BACKBONE OLIGOSACCHARIDE FRACTION(7,1)
BACTERIAL MEMBRANE LEAFLET(7,1)
COMPLEMENTED MUTANT STRAIN(7,1)
FOWL CHOLERA DISEASE(7,1)
GAL PROTON RESONANCE(7,1)
GENOME SEQUENCED STRAIN(7,1)
KDO METHYLENE RESONANCE(7,1)
LIVE VACCINE RECENT VERSION(7,1)
LOSB MUTANT STRAIN(7,1)
MORAXELLA CATHARRHALIS(7,1)
MULTOCIDA MUTANT STRAIN(7,1)
PASTEURELLA MULTOCIDA STRAIN SPECTRUM(7,1)
PCHO RESIDUE MIGRATION(7,1)
SYNTHESIZED HEPTOSE PURITY(7,1)
T CELL DEPENDENT RESPONSE(7,1)
TRIPLE QUANTUM HOMO(7,1)
1H NMR DATA(6,4)
CONFORMATIONAL ANALYSIS(6,3)
GALNAC RESIDUE(6,3)
HUMAN SERUM ALBUMIN(6,3)
COZY SPECTRA(6,2)
HOMOLOGOUS STRAIN(6,2)
IMMUNE SERA DILUTION(6,2)
IMMUNOGENIC CARRIER PROTEIN(6,2)
KDO RESONANCE(6,2)
MAB DESIGNATION(6,2)
MH GENOME SEQUENCE(6,2)
OVERLAPPING RESONANCE(6,2)
SIGNIFICANT VETERINARY PATHOGEN(6,2)
SPIN SIMULATION(6,2)
VACCINATED MOUSE(6,2)
ANOMERIC 1H NMR RESONANCE(6,1)
ANTIGENIC LPS DERIVED OLIGOSACCHARIDE(6,1)
ATTENUATED PM STRAIN(6,1)
BACTERIAL SPECIES STRAIN(6,1)
CANDIDATE GLYCOSYLTRANSFERASE(6,1)
CARBOHYDRATE ANTIGEN EXPRESSION(6,1)
CONSERVED TRIHEPTOSYL(6,1)
DETOXIFIED LEUKOTOXIN(6,1)
FERMENTER GROWN BACTERIUM CULTURE(6,1)
GEL FILTRATION CHROMATOGRAPHY FRACTIONATION(6,1)
GLYCOFORM MINORITY(6,1)
GLYCOSIDIC LINKAGE VICINITY(6,1)
HETERONUCLEAR CORRELATED 2D(6,1)
HIGHLY LABILE APX TOXIN(6,1)
HOMOLOGOUS PM STRAIN(6,1)
KDO 1H NMR ASSIGNMENT(6,1)
KETOSIDIC BOND SENSITIVITY(6,1)
METHYLENE PROTON RESONANCE(6,1)
NARROW ANOMERIC RESONANCE(6,1)
NON TOXIC LEUKOTOXIN(6,1)
NUCLEAR CORRELATED EXPERIMENT(6,1)
PASSIVE PROTECTION EXPERIMENT DATA(6,1)
RARE ANTI CONFORMER(6,1)
RESEARCH COUNCIL(6,1)
STRUCTUAL CONSERVATION(6,1)
VACCINE PROTECTED CHICKEN(6,1)
VECTOR PLASMID PAL(6,1)
AMU(5,10)
2D REGION(5,6)
APPROXIMATE RATIO(5,6)
POSITIVE ION CAPILLARY ELECTROPHORESIS(5,5)
ASCITE FLUID(5,3)
ELECTROSPRAY MASS SPECTRA(5,3)
TERMINAL LD HEP(5,3)
ATTENUATED STRAIN(5,2)
BIOINFORMATICS(5,2)
CELLULOSE COLUMN CHROMATOGRAPHY(5,2)
CONFIGURED GALACTOSE RESIDUE(5,2)
CONSERVED INNER CORE EPITOPE(5,2)
EVIDENCE ABSENCE(5,2)
HEPV RESIDUE(5,2)
HYDROXY L PROTON(5,2)
KDO LINKAGE(5,2)
MAB PROVISION(5,2)
METROPOLIS MONTE CARLO CALCULATION(5,2)
MOUSE SERA(5,2)
PARENT STRAIN(5,2)
TERMINAL GAL RESIDUE(5,2)
1D NOESY NMR SPECTRUM(5,1)
AERUGINOSA TOXIN(5,1)
ANTIBODY NEUTRALIZATION(5,1)
AP ASSIGNMENT(5,1)
APP SEROTYPE(5,1)
BACTERIAL VIRULENCE(5,1)
BOVINE PASTURELLOSIS(5,1)
BRONCHOPNEUMONIA RESOLUTION(5,1)
BUTYL GLYCOSIDE DERIVATIVE(5,1)
CALF CHALLENGE MODEL(5,1)
CARBOHYDRATE EPITOPE(5,1)
CATTLE DEATH(5,1)
CLINICALLY RELEVANT STRAIN(5,1)
CONFIRMATORY DATA(5,1)
CONFIRMING HETEROGENEITY(5,1)
CONSERVED EPITOPE(5,1)
CORE OS EPITOPE(5,1)
DIPHTHERIA TOXIN TOXOID(5,1)
DISUBSTITUTED GAL(5,1)
DOG CAUSATIVE AGENT(5,1)
ELUTING CORE OS FRACTION(5,1)
EQUATORIAL PROTON(5,1)
FACILITATED PHAGOCYTOSIS(5,1)
FATTY ACYL SUBSTITUTION(5,1)
FRACTIONATED ACID HYDROLYSATE(5,1)
FREUND ADJUVANT(5,1)
GALACTO PYRANOSYL RESIDUE(5,1)
HETEROGENEOUS POPULATION(5,1)
HMQC TOCSY CORRELATION(5,1)
HMQC TOCSY SPECTRA(5,1)
HOST IMMUNIZATION(5,1)
IMMUNE STIMULATION(5,1)
IMMUNOGENIC EPITOPE(5,1)
IMMUNOLOGICAL STUDY(5,1)
INTER RESIDUE APPEARANCE(5,1)
INTERPROTON DISTANCE INN OCCURRENCE(5,1)
MAJOR BACKBONE OLIGOSACCHARIDE(5,1)
MANNHEIMIA HAEMOLYTICA DISPLAYING(5,1)
METHYLATION DATA(5,1)
MH CORE MOLECULE(5,1)
MHLOSB HSA CONJUGATE(5,1)
MICROBIOLOGY DEPARTMENT(5,1)
MINNESOTA UNIVERSITY(5,1)
MOLECULE CONFORMATION(5,1)
MULTIPLET PATTERN OBSERVATION(5,1)
MULTOCIDA CORE OS(5,1)
NOE OCCURRENCE(5,1)
OVINE PATHOGEN(5,1)
PHOSPHOCHOLINE MOIETY(5,1)
PM STRAIN CORE OLIGOSACCHARIDE(5,1)
PORCINE PATHOGEN(5,1)
PROTON NMR SPECTRUM(5,1)
PROTON SPECTRUM RESOLUTION(5,1)
RE LATED ORGANISM(5,1)
RESONANCE ASSIGNMENT(5,1)
RESONANCE CONNECTIVITY(5,1)
RESONANCE SELECTIVE EXCITATION(5,1)
SELECTIVE 1D TOCSY EXPERIMENT(5,1)
SPECTRA PEAK LISTING(5,1)
STRAIN THOROUGH KNOWLEDGE(5,1)
TETANUS TOXIN TOXOID(5,1)
TRANSPOSON MUTAGENESIS(5,1)
UNCHARACTERIZED PROTEIN(5,1)
UNUSUAL CONFORMATION(5,1)
VARIABLE OLIGOSACCHARIDE MOIETY(5,1)
VARIABLE POLYSACCHARIDE ANTIGEN(5,1)
O ANTIGEN ABSENCE(4,9)
13C NMR CHEMICAL SHIFT(4,7)
LANE(4,7)
GLCNAC(4,4)
COMPLEMENT DEFICIENT CONTROL(4,3)
CROSSPEAK(4,3)
HEPTOSIS(4,3)
SURVIVAL(4,3)
1H NMR SPECTRUM(4,2)
CARRIER MOLECULE(4,2)
CELL ELISA(4,2)
CORE OLIGOSACCHARIDE EXTENSION(4,2)
ESI MS(4,2)
H HMBC NMR SPECTRUM(4,2)
H HSQC NMR SPECTRUM(4,2)
LINKAGE SITE(4,2)
MASS MAJOR MOLECULE(4,2)
MH CELL(4,2)
ORIFICE VOLTAGE(4,2)
PAPER CHROMATOGRAPHY(4,2)
PHOSPHATE RESIDUE(4,2)
TERMINAL DD HEP(4,2)
13C NMR RESONANCE(4,1)
1D NOESY SPECTRUM(4,1)
1D NOESY TOCSY SPECTRUM(4,1)
1D ROESY EXPERIMENT(4,1)
1D SELECTIVE SEQUENCE(4,1)
1H NMR SPECTRA ESTABLISHING(4,1)
2D NMR EXPERIMENT(4,1)
2H2 DIHYDROGEN EXCHANGE(4,1)
AMICON CONCENTRATION CELL(4,1)
ANION EXCHANGE CHROMATOGRAPHY(4,1)
ANOMERIC PEAK(4,1)
ANOMERIC REGION SPECTRUM(4,1)
ANTIBACTERIAL DRUG(4,1)
AP STRAIN(4,1)
B1 PROTON CLOSE PROXIMITY(4,1)
BACTERIUM ADHESIVE ABILITY(4,1)
CELL IMMUNIZED MOUSE(4,1)
CHOLINE RESONANCE(4,1)
COLLISIONAL ACTIVATION(4,1)
COLORIMETRIC ANALYSIS(4,1)
COMPLEMENT MEDIATED LYSIS(4,1)
COMPUTATIONAL BIOLOGY CENTER(4,1)
CONFERRING PROTECTION(4,1)
CONFORMATION OCCURRENCE(4,1)
CORE BIOSYNTHESIS(4,1)
CORE CONFORMATION(4,1)
CORE OLIGOSACCHARIDE BIOSYNTHESIS(4,1)
CORE OS PRECURSOR ION(4,1)
CORE OS SUGAR ANALYSIS(4,1)
COVALENT BOND(4,1)
COZY SPECTRUM(4,1)
CRITERIA MAJORITY(4,1)
CROSS PROTECTION(4,1)
DEACYLATION PROCEDURE MODIFICATION(4,1)
DEL RESONANCE(4,1)
DGLCP LINKAGE(4,1)
DI GLUCOSYL MOIETY(4,1)
DI SUBSITUTED DD HEP(4,1)
DIPOLAR INTERACTION(4,1)
DISEASE MANAGEMENT STRATEGY(4,1)
DISEASE PREVENTION(4,1)
DISUBSTITUTED DD HEP(4,1)
DRYNESS UNDER REDUCED PRESSURE(4,1)
EARLY FRACTION ANALYSIS(4,1)
ELICITING HOST IMMUNE RESPONSE(4,1)
ENABLED IDENTIFICATION(4,1)
ES MS ANALYSIS(4,1)
ES MS SPECTRUM(4,1)
EXOCYCLIC CHAIN CLOSE PROXIMITY(4,1)
EXOCYCLIC CHAIN ORIENTATION(4,1)
EXTENSIVE ANTIGENIC DIVERSITY(4,1)
FAB MS ANALYSIS(4,1)
FRACTIONATED OS SAMPLE(4,1)
GENE CONSISTENT PRESENCE(4,1)
GENOME DATA(4,1)
GLC MS ANALYSIS(4,1)
GLUCOSAMINE RESIDUE(4,1)
GLYCINE RESIDUE(4,1)
GLYCOSIDIC BOND(4,1)
GLYCOSIDIC LINKAGE ANGLE(4,1)
GLYCOSYL RESIDUE SEQUENCE(4,1)
HEALTH ISSUE(4,1)
HEP HEX(4,1)
HEPI LINKAGE(4,1)
HEPI SUBSTITUTION PATTERN(4,1)
HEPIII RESIDUE(4,1)
HETEROGENEOUS MOLECULE MIXTURE(4,1)
HOD RESONANCE(4,1)
HOMOLOGOUS CHALLENGE(4,1)
HOMOLOGOUS ORGANISM(4,1)
INTRA RESIDUE CORRELATION(4,1)
INTRA RESIDUE NOE(4,1)
KDO GLCNII GLCNI SEQUENCE(4,1)
KDO H RESONANCE(4,1)
KDO HEXN(4,1)
KDO MOLECULE(4,1)
KDO OCCURRENCE(4,1)
KETOSE RESIDUE(4,1)
LATE FRACTION(4,1)
LBGB GENE SEQUENCE(4,1)
LD HEP RESIDUE(4,1)
LD HEPTOSE RESIDUE(4,1)
LEUKOLYTIC ACTIVITY(4,1)
LIPOPOLYSACCHARIDE PRODUCTION(4,1)
LIVE ORGANISM(4,1)
LIVE STRAIN(4,1)
LOSB GENE(4,1)
LPS PROTEIN COMPLEX(4,1)
MAIN SUBUNIT VACCINE CANDIDATE(4,1)
MAJOR ANTIGENIC DETERMINANT(4,1)
MEDIATED KILLING(4,1)
MEDIUM SIZED BRONCHUS LUMEN(4,1)
MEMBRANE ANCHORING(4,1)
MH ANTIGEN(4,1)
MH BIOLOGY(4,1)
MH CARBOHYDRATE REGION(4,1)
MH LOSB MASS SPECTRA(4,1)
MH WT STRAIN(4,1)
MILD ACID HYDROLYSIS(4,1)
MINIMIZED COORDINATE(4,1)
MOLECULAR GENETICS(4,1)
MOLECULAR MODELING(4,1)
MOLECULE CARRIER PROTEIN(4,1)
MONO REPLACEMENT(4,1)
MOUSE PROTECTION(4,1)
MULTOCIDA PARENT(4,1)
MUTAGENESIS STUDY(4,1)
MUTANT STRAIN CONSTRUCTION(4,1)
OBSERVED INTER RESIDUE(4,1)
OBSERVED NOE(4,1)
OS H RESONANCE(4,1)
OS NMR ANALYSIS(4,1)
OS SPECTRA(4,1)
PHOSPHOCHOLINE RESIDUE(4,1)
PM DISEASE(4,1)
PM RIBOSOME(4,1)
PORCINE IMMUNE RESPONSE(4,1)
PPM CORRELATING(4,1)
PRINCIPAL MICROORGANISM(4,1)
PROTECTIVE ANTIBODY(4,1)
PROTON SPECTRA SIMULATION(4,1)
QUADRUPOLE MASS SPECTROMETER(4,1)
RELEVANT PROTON(4,1)
REMAINING HEPTOSE RESIDUE(4,1)
RESIDUE DEFINITION(4,1)
RESIDUE RESONANCE(4,1)
RESOLVED RESIDUE(4,1)
RESONANCE ACCURATE MATCHING(4,1)
RESONANCE H PERMITTED ASSIGNMENT(4,1)
RESONANCE SPECTRA(4,1)
ROTAMER DISTRIBUTION(4,1)
SAMPLE HETEROGENEITY(4,1)
SAVED COORDINATE(4,1)
SEQUENTIAL RESIDUE(4,1)
SEROTYPE STRUCTURAL ANALYSIS(4,1)
SINGLY CHARGED ION(4,1)
SOMATIC ANTIGEN(4,1)
SPECTRA COMPLEXITY(4,1)
SPECTRAL PARAMETER(4,1)
SPENT SUPERNATANT(4,1)
STRAIN GENOME(4,1)
STRUCTURAL ANALYSIS DATA(4,1)
STRUCTURAL CONSERVATION(4,1)
STRUCTURAL RELATEDNESS(4,1)
SUBSTITUTION INDICATIVE(4,1)
TERM LIPOPOLYSACCHARIDE(4,1)
TERMINAL GLUCOSE RESIDUE(4,1)
TERMINALLY EXPOSED MOIETY(4,1)
TOCSY NOESY SPECTRUM(4,1)
UNEXPECTED FINDING(4,1)
VACCINE DEVELOPMENT(4,1)
VACCINE FORMULATION(4,1)
VACCINE MANUFACTURE(4,1)
VETERINARY DISEASE(4,1)
WESTERN BLOT(4,1)
SPECIES(3,17)
CHEMICAL SHIFT COMPARISON(3,5)
LIPID(3,4)
SHOWING CORRELATION(3,4)
BACTERIN(3,2)
CENTRIFUGATION(3,2)
COMPLETE ASSIGNMENT(3,2)
CONDENSATION(3,2)
CORE OLIGOSACCHARIDE REGION(3,2)
CURRENT VACCINE(3,2)
ELUANT(3,2)
FUSION(3,2)
GLUCOSE PRESENCE(3,2)
IGG RESPONSE(3,2)
IGM RESPONSE(3,2)
INTERNAL ACETONE(3,2)
NEGATIVE ION CAPILLARY ELECTROPHORESIS(3,2)
NEGATIVE ION ELECTROSPRAY(3,2)
NITROMETHANE(3,2)
NOMENCLATURE(3,2)
O CHAIN GALACTOSE RESIDUE(3,2)
STANDARD HOMO(3,2)
STRONG COUPLING(3,2)
STRUCTURAL DIFFERENCE(3,2)
TERMINAL PRESENCE(3,2)
TRIPLY(3,2)
1D 1H NMR(3,1)
ACETYLATED SAMPLE(3,1)
ALKALINE METHANOL(3,1)
ANTIGENIC POLYMERIC REPEATING UNIT(3,1)
AP PLAY(3,1)
AXIAL PROTON(3,1)
BLAST ANALYSIS(3,1)
CARBOHYDRATE RESIDUE UNIT(3,1)
CARBOHYDRATE SPECIFIC MAB(3,1)
CELL LYSATE(3,1)
CLEAR MULTIPLET PATTERN(3,1)
COLLISION ENERGY(3,1)
COLUMN PURIFICATION(3,1)
COMMON CORE OLIGOSACCHARIDE DETERMINANT(3,1)
COMPLEMENT PRESENCE(3,1)
CONSERVED INNER CORE OLIGOSACCHARIDE(3,1)
CORE MINIMUM ENERGY CONFORMER(3,1)
CORE OLIGOSACCHARIDE FRACTION(3,1)
CORE OS MS(3,1)
DIGITAL RESOLUTION(3,1)
DIHEDRAL ANGLE(3,1)
DOUBLY CHARGED REGION(3,1)
ESSENTIAL CRITERIA(3,1)
EXCESS HYDRAZINE(3,1)
GENETIC STABILITY(3,1)
GLUCOSE H RESONANCE(3,1)
GLYCOSIDIC ANGLE(3,1)
H SELECTIVE EXCITATION(3,1)
HAEMOPHILUS DUCREYI(3,1)
HAEMOPHILUS INFLUENZAE STRUCTURE(3,1)
HEPTOSE PRODUCT(3,1)
HOMOLOGY(3,1)
HOST ANIMAL(3,1)
HUMAN DISEASE(3,1)
IMMUNOCHEMISTRY(3,1)
INNER CORE LIPOPOLYSACCHARIDE EPITOPE(3,1)
INTERCONNECTIVITY(3,1)
INTERNAL DD HEP RESIDUE(3,1)
J 1D TOCSY(3,1)
LINKAGE PATTERN(3,1)
LINKING RESIDUE(3,1)
LIPOOLIGOSACCHARIDE(3,1)
MAGNETIZATION STOP(3,1)
MAGNETIZATION TRANSFER(3,1)
MAIN DISCREPANCY(3,1)
MAJOR OLIGOSACCHARIDE COMPONENT(3,1)
MAJOR SUBUNIT VACCINE(3,1)
MANNHEIMIA VARIETY(3,1)
MH STRAIN AL(3,1)
MH WHOLE CELL(3,1)
MINIMUM ENERGY CONFORMATION(3,1)
MOUSE MODEL(3,1)
MULTI SPECIES PATHOGEN(3,1)
MULTI SPECIES VACCINE PREPARATION(3,1)
MULTIPLET CONSTANT(3,1)
N ACETYL HEXOSAMINE RESIDUE(3,1)
NITROGEN SUBSTITUTED CARBON ATOM(3,1)
O ANTIGEN BIOSYNTHESIS(3,1)
O ANTIGENIC POLYSACCHARIDE(3,1)
OBSERVED SPECTRA(3,1)
PARTIAL ASSIGNMENT(3,1)
PARTIAL CLINICAL PROTECTION(3,1)
PASTEURELLA HAEMOLYTICA(3,1)
PFOS POTENTIAL(3,1)
PHOSPHATE MOLECULE(3,1)
POWERFUL TOOL(3,1)
PROTECTIVE IMMUNE RESPONSE(3,1)
PUBLICATION BASIS(3,1)
SELECTIVE PULSE(3,1)
SEROTYPE O ANTIGEN(3,1)
SHARP ANOMERIC SIGNAL(3,1)
SHORT CHAIN LIPOPOLYSACCHARIDE(3,1)
SIALOGLYCOPROTEASE(3,1)
SINGLY CHARGED REGION(3,1)
STANDARD VARIAN SOFTWARE(3,1)
STRUCTURAL DATA(3,1)
STRUCTURAL REPRESENTATION(3,1)
TERMINAL GALACTOSE MODEL COMPOUND(3,1)
TERMINAL GLUCOSE MODEL COMPOUND(3,1)
VIRTUAL COUPLING(3,1)
(US20080008723)
LIPOPOLYSACCHARIDE MOIETY(100,29)
ISOLATED LIPOPOLYSACCHARIDE MOIETY(100,3)
CORE LIPOPOLYSACCHARIDE EPITOPE(100,1)
MULTI SPECIES VACCINE CANDIDATE(100,1)
GLYCOSYLTRANSFERASE GENE(44,4)
PASTEURELLA MULTOCIDA MUTANT(34,2)
PORCINE FIBRINOHEMORRHAGIC NECROTIZING PLEUROPNEUMONIA(34,1)
OCTULOSONIC ACID(33,7)
PHOSPHOETHANOLAMINE(32,8)
SPECIES MANNHEIMIA HAEMOLYTICA(31,3)
BACTERIAL STRAIN(30,4)
MUTANT STRAIN(28,9)
ACTINOBACILLUS PLEUROPNEUMONIAE APX EXOTOXOID(26,1)
ACTINOBACILLUS PLEUROPNEUMONIAE MUTANT(26,1)
ACTINOBACILLUS PLEUROPNEUMONIAE(24,12)
MANNHEIMIA HAEMOLYTICA LEUKOTOXIN TOXOID(24,1)
MANNHEIMIA HAEMOLYTICA MUTANT(24,1)
MANNHEIMIA HAEMOLYTICA PLPE LIPOPROTEIN(24,1)
GLUCOSE(22,16)
SPECIES ACTINOBACILLUS PLEUROPNEUMONIAE(22,1)
PASTEURELLA MULTOCIDA(21,12)
VETERINARY BACTERIAL PATHOGEN LIPOPOLYSACCHARIDE(21,2)
SPECIES PASTEURELLA MULTOCIDA(21,1)
BOVINE PNEUMONIC PASTEURELLOSIS(20,1)
MANNHEIMIA HAEMOLYTICA(19,9)
FORMULA IC(19,3)
DIPHTHERIA TOXOID CRM(19,1)
KDO(17,7)
IMMUNOGENIC CARRIER(17,4)
FAMILY PASTEURELLACEAE(17,2)
ANIMAL FARMING INDUSTRY(17,1)
AVIAN FOWL CHOLERA(17,1)
IMMUNOGENIC EPITOPE(17,1)
MANNHEIMIA HAEMOLYTICA SIALOGLYCOPROTEASE(17,1)
INNER CORE MOIETY(16,11)
IMMUNOGENIC(16,2)
ACTINOBACILLUS PLEUROPNEUMONIAE OMLA(16,1)
ACTINOBACILLUS PLEUROPNEUMONIAE TBPA(16,1)
LPS BIOSYNTHETIC PATHWAY(16,1)
PATHOGENIC BACTERIUM(16,1)
CLOSTRIDIUM PERFRINGENS EXOTOXIN(15,1)
KDA CAPSULAR PROTEIN(15,1)
PASTEURELLA MULTOCIDA PLPB(15,1)
FORMULA ID(14,2)
LINKER MOLECULE(13,2)
BOVINE HEMORRHAGIC SEPTICEMIA(13,1)
CORE LIPOPOLYSACCHARIDE MOIETY(13,1)
MAMMAL IMMUNIZATION(13,1)
PORCINE ATROPHIC RHINITIS(13,1)
EPITOPE(12,7)
FUNCTIONAL ANTIBODY(12,3)
CHLOROHEXANOL ETHANE(12,1)
CONFERRING PROTECTION(12,1)
GENUS MANNHEIMIA(12,1)
LIPOPOLYSACCHARIDE PRODUCTION(12,1)
OVINE SEPTICEMIA(12,1)
PASTEURELLA MULTOCIDA STRAIN(12,1)
VACCINE(11,10)
ANTIBODY(11,6)
ANTIBODY GENERATION(11,2)
CORE OS EPITOPE(11,2)
MULTIVALENT VACCINE(11,1)
TETANUS TOXOID(11,1)
DISEASE(10,13)
INFECTION(10,7)
VACCINE CANDIDATE(10,6)
TERMINAL UNIT(10,4)
CHOLERA TOXIN TOXOID(10,2)
PERTUSSIS TOXIN TOXOID(10,2)
BROAD COVERAGE(10,1)
CONSERVED LPS INNER CORE(10,1)
HOST ANIMAL(10,1)
MUTANT BACTERIAL STRAIN CONSTRUCTION(10,1)
LIPOPOLYSACCHARIDE(9,4)
MEDICAMENT(9,3)
AERUGINOSA TOXIN(9,2)
MAJOR ECONOMIC LOSS(9,1)
D MANNO(8,7)
GLYCOCONJUGATE MIXTURE(8,1)
INNER CORE OLIGOSACCHARIDE EPITOPE(8,1)
TEST ANTIBODY(8,1)
VACCINE COMPONENT(8,1)
WHOLE BACTERIA CELL(8,1)
SEROTYPE(7,40)
HAEMOLYTICA SEROTYPE(7,8)
PM STRAIN(7,6)
IMMUNITY(7,4)
FUNCTIONAL CROSS REACTIVE ANTIBODY(7,3)
ADIPOHYDRAZIDE(7,1)
FORMULA INNER CORE MOIETY(7,1)
AP SEROTYPE(6,10)
CONSERVED INNER CORE(6,8)
MONOCLONAL ANTIBODY(6,4)
NOE CONNECTIVITY EXAMINATION(6,3)
OLIGOSACCHARIDE(6,3)
BACTERIAL VETERINARY PATHOGEN LPS(6,2)
STRATEGY(6,2)
ANIMAL(6,1)
ARCHAEOLIPID(6,1)
PENTOSE(6,1)
VARIABLE OUTER CORE OLIGOSACCHARIDE(6,1)
ADJUVANT(5,7)
METHYLATION ANALYSIS DATA(5,5)
BACTERIAL PATHOGEN(5,4)
IMMUNE RESPONSE(5,4)
SEROTYPE CORE OS(5,4)
INTER RESIDUE NOE VIRTUE(5,3)
GAL ANOMERIC PROTON(5,2)
AMINOHEXANOIC ACID(5,1)
ARCHAEOSOME(5,1)
BIRD(5,1)
CROSS SPECIES PROTECTION(5,1)
CYSTAMINE(5,1)
DUCREYI LBGA GALACTOSYLTRANSFERASE GENE(5,1)
FISH(5,1)
INTENSE TRANSGLYCOSIDIC NOE CONNECTIVITY(5,1)
LIPOSOME(5,1)
MAJOR OUTER MEMBRANE PROTEIN(5,1)
SHIPPING FEVER(5,1)
SINGLE VACCINE(5,1)
SQUARATE(5,1)
VARIABLE O ANTIGEN(5,1)
STRAIN(4,17)
LIPID(4,16)
GENE(4,11)
HMQC SPECTRUM(4,6)
DOUBLY CHARGED ION(4,5)
ANOMERIC 1H RESONANCE(4,2)
ANOMERIC PROTON RESONANCE(4,2)
HEPTOSE MONOSACCHARIDE(4,2)
HETERONUCLEAR CORRELATED 2D(4,2)
KDO RESIDUE REARRANGEMENT(4,2)
RESPIRATORY SYNCYTIAL VIRUS(4,2)
ROTAVIRUS(4,2)
ACETAL(4,1)
ANOMERIC PROTON 1H RESONANCE(4,1)
ANTI IDIOTYPE VACCINE MIMICKING(4,1)
ANTISERA(4,1)
CANDIDATE ANTIGEN EPITOPE(4,1)
CONSERVED LPS CARBOHYDRATE EPITOPE(4,1)
DEACYLATED LPS OLIGOSACCHARIDE(4,1)
GLYCOCONJUGATE VACCINE INVESTIGATION(4,1)
HEPIV RESIDUE REVEALED DISUBSTITUTION(4,1)
HEXNAC RESIDUE ANOMERIC PROTON(4,1)
INTER RESIDUE NOE CONNECTIVITY(4,1)
KDA CROSS PROTECTIVE LIPOPROTEIN(4,1)
MORAXELLA CATHARRHALIS LPS(4,1)
NEISSERIA MENINGITIDIS LPS(4,1)
PERMETHYLATED ALDITOL ACETATE DERIVATE(4,1)
SEROTYPE 5B CAPSULAR POLYSACCHARIDE(4,1)
SIGNIFICANT ADVERSE EFFECT INCIDENCE(4,1)
13C NMR ASSIGNMENT(3,6)
MH STRAIN(3,5)
SEROTYPE 5A(3,5)
ELUTION FRACTION(3,4)
ANHYDROUS HYDRAZINE(3,3)
DISEASE RANGE(3,3)
HMQC TOCSY SPECTRUM(3,3)
MH INFECTION(3,3)
PHOSPHOETHANOLAMINE RESIDUE(3,3)
POLYCLONAL SERA(3,3)
1H RESONANCE VIRTUE(3,2)
CONSERVED CARBOHYDRATE(3,2)
CORE LPS MOLECULE(3,2)
DOUBLY SELECTIVE EXPERIMENT(3,2)
FRACTIONATED CORE OS(3,2)
HAEMOPHILUS INFLUENZAE(3,2)
HMQC SPECTRA(3,2)
MASS SPECTROMETRIC(3,2)
SPECTROMETRIC ANALYSIS(3,2)
TERMINALLY EXPOSED STRUCTURE(3,2)
TRANSPOSON MUTAGENESIS(3,2)
VETERINARY ORGANISM(3,2)
13C 1H HSQC EXPERIMENT(3,1)
13C 1H HSQC SPECTRUM(3,1)
ACETYL HEXOSAMINE TRANSFERASE(3,1)
ANIMAL PATHOGEN VIRULENCE(3,1)
ANOMERIC RESONANCE INTEGRATION(3,1)
B CELL ACTIVATION(3,1)
BACTERICIDAL ASSAY DATA(3,1)
CANDIDATE VACCINE ANTIGEN(3,1)
CARBOHYDRATE ANTIGEN IMMUNOGENICITY(3,1)
COMPLEMENT MEDIATED BACTERICIDAL LYSIS(3,1)
DOUBLY UNDERLINED RESONANCE(3,1)
DOWNFIELD DOUBLET APPEARANCE(3,1)
ECONOMICALLY VIABLE VACCINE CANDIDATE(3,1)
GLYCOSYLTRANSFERASE TENTATIVE IDENTIFICATION(3,1)
HOMOLOGOUS ENCAPSULATED BACTERIUM(3,1)
HUMAN SERUM ALBUMIN(3,1)
INTACT BACKBONE OLIGOSACCHARIDE(3,1)
INTER RESIDUE NOE APPEARANCE(3,1)
LPS FACILITATED PHAGOCYTOSIS(3,1)
LPS GLYCOFORM POPULATION(3,1)
MEDICINE BAYLOR COLLEGE(3,1)
MUTANT LPS CORE OLIGOSACCHARIDE(3,1)
NOE CONNECTIVITY VIRTUE(3,1)
NUCLEAR OVERHAUSER(3,1)
OKLAHOMA UNIVERSITY HEALTH(3,1)
P NITROANILINE(3,1)
PHOSPHORYLATED KETODEOXYOCTONOATE RESIDUE(3,1)
PM RIBOSOME LPS VACCINE(3,1)
VETERINARY INFECTIOUS DISEASE ORGANIZATION(3,1)
AMU(2,10)
APPROXIMATE RATIO(2,6)
1H NMR DATA(2,4)
1D TOCSY EXPERIMENT(2,3)
ANOMERIC REGION(2,3)
AP LPS(2,3)
CONFORMATIONAL ANALYSIS(2,3)
ES MS(2,3)
MASS SPECTRUM(2,3)
MINIMUM ENERGY CONFORMER(2,3)
SINGLY CHARGED PEAK(2,3)
TERMINAL LD HEP(2,3)
13C SPECTRA(2,2)
1D NOESY EXPERIMENT(2,2)
1H SPECTRA(2,2)
31P HMQC(2,2)
ATTENUATED STRAIN(2,2)
BIOINFORMATICS(2,2)
CELLULOSE COLUMN CHROMATOGRAPHY(2,2)
CONFIGURED GALACTOSE RESIDUE(2,2)
CONSERVED INNER CORE EPITOPE(2,2)
CORE OLIGOSACCHARIDE EXTENSION(2,2)
CORE OLIGOSACCHARIDE STRUCTURAL ANALYSIS(2,2)
COZY SPECTRA(2,2)
DISUBSTITUTED DD HEP(2,2)
EVIDENCE ABSENCE(2,2)
FATTY ACYL(2,2)
HEPV RESIDUE(2,2)
HMBC SPECTRA(2,2)
HOMOLOGOUS STRAIN(2,2)
IMMUNOGENIC CARRIER PROTEIN(2,2)
INNER CORE OLIGOSACCHARIDE PORTION(2,2)
KDO LINKAGE(2,2)
LPS STRUCTURAL ANALYSIS(2,2)
MAB PROVISION(2,2)
MH GENOME SEQUENCE(2,2)
MOLECULAR MODELING(2,2)
MOUSE SERA(2,2)
OVERLAPPING RESONANCE(2,2)
PHOSPHATE RESIDUE ABSENCE(2,2)
PRECURSOR ION(2,2)
PROTEUS SPECIES(2,2)
PURIFIED LPS(2,2)
SIGNIFICANT VETERINARY PATHOGEN(2,2)
SIMULATED SPECTRA(2,2)
SPIN SIMULATION(2,2)
STRUCTURAL CONSERVATION(2,2)
TERMINAL GAL RESIDUE(2,2)
13C 1H HMBC EXPERIMENT(2,1)
1D NOESY TOCSY EXPERIMENT(2,1)
1H NOE MEASUREMENT(2,1)
1H RESONANCE ASSIGNMENT(2,1)
ACETYL HEXOSAMINE RESIDUE(2,1)
ACETYLGALACTOSAMINE RESIDUE(2,1)
ALDITOL ACETATE DERIVATIVE(2,1)
AMX SPECTROMETER(2,1)
ANOMERIC 1H NMR RESONANCE(2,1)
ANOMERIC RESONANCE REMAINDER(2,1)
ANTIBODY NEUTRALIZATION(2,1)
AP 5A OS SPECTRA(2,1)
ATTENUATED PM STRAIN(2,1)
BACKBONE OLIGOSACCHARIDE FRACTION(2,1)
BACTERIAL MEMBRANE LEAFLET(2,1)
BACTERIAL SPECIES STRAIN(2,1)
BACTERIAL VIRULENCE(2,1)
BOVINE PASTURELLOSIS(2,1)
BRAIN HEART INFUSION(2,1)
BSA CONJUGATE VACCINE(2,1)
BUTYL GLYCOSIDE DERIVATIVE(2,1)
CALF CHALLENGE MODEL(2,1)
CANDIDATE GLYCOSYLTRANSFERASE(2,1)
CARBOHYDRATE ANTIGEN EXPRESSION(2,1)
CATTLE DEATH(2,1)
CHROMATOGRAPHIC SPECIALTY(2,1)
CLINICALLY RELEVANT STRAIN(2,1)
CLOSTRIDIUM PERFRINGENS EXOTOXIN TOXOID(2,1)
CONFIRMATORY DATA(2,1)
CONFIRMING HETEROGENEITY(2,1)
CONSERVED EPITOPE(2,1)
CORE OLIGOSACCHARIDE ASSIGNMENT(2,1)
CORE OLIGOSACCHARIDE BIOSYNTHESIS(2,1)
CORE OLIGOSACCHARIDE FRACTION(2,1)
CORE OLIGOSACCHARIDE ORIENTATION(2,1)
DD HEP RESIDUE IDENTIFICATION(2,1)
DEFINITIVE DATA(2,1)
DETOXIFIED LEUKOTOXIN(2,1)
DFOR SEROTYPE(2,1)
DIPHTHERIA TOXIN TOXOID(2,1)
DISUBSTITUTED GAL(2,1)
DOG CAUSATIVE AGENT(2,1)
DUCREYI LPS(2,1)
ELECTROSPRAY IONIZATION(2,1)
ELUTING CORE OS FRACTION(2,1)
EQUATORIAL PROTON(2,1)
FERMENTER GROWN BACTERIUM CULTURE(2,1)
FOWL CHOLERA DISEASE(2,1)
FRACTIONATED ACID HYDROLYSATE(2,1)
GALACTO PYRANOSYL RESIDUE(2,1)
GEL FILTRATION CHROMATOGRAPHY FRACTIONATION(2,1)
GENOME SEQUENCED STRAIN(2,1)
GLYCOFORM MINORITY(2,1)
GLYCOSIDIC LINKAGE VICINITY(2,1)
GLYCOSYL OXONIUM ION(2,1)
HAEMOPHILUS DUCREYI STRAIN(2,1)
HETEROGENEOUS POPULATION(2,1)
HEX3HEP5KDO HEXN(2,1)
HIGHLY LABILE APX TOXIN(2,1)
HMQC TOCSY CORRELATION(2,1)
HMQC TOCSY SPECTRA(2,1)
HOD SUPPRESSION(2,1)
HOMOLOGOUS PM STRAIN(2,1)
HOST IMMUNIZATION(2,1)
IMMUNE STIMULATION(2,1)
IMMUNOLOGICAL STUDY(2,1)
INFLUENZAE LIPID(2,1)
INTACT LPS SUGAR ANALYSIS(2,1)
INTER NOE CONNECTIVITY(2,1)
KDO RESONANCE(2,1)
KETOSIDIC BOND SENSITIVITY(2,1)
LIPOPOLYSACCHARIDE PURIFICATION(2,1)
LIVE VACCINE RECENT VERSION(2,1)
LPS CORE OLIGOSACCHARIDE REGION(2,1)
LPS CORE OS(2,1)
LPS DEACYLATION(2,1)
LPS MIGRATION(2,1)
LPS MOLECULE CARRIER PROTEIN(2,1)
LYOPHILIZED OS(2,1)
LYOPHILIZED SUGAR(2,1)
MAJOR BACKBONE OLIGOSACCHARIDE(2,1)
MANNHEIMIA HAEMOLYTICA DISPLAYING(2,1)
METHYLATION DATA(2,1)
METHYLENE PROTON RESONANCE(2,1)
MH CORE MOLECULE(2,1)
MICROBIOLOGY DEPARTMENT(2,1)
MINNESOTA UNIVERSITY(2,1)
MOLECULE CONFORMATION(2,1)
MULTIPLET PATTERN OBSERVATION(2,1)
NARROW ANOMERIC RESONANCE(2,1)
NBS FERMENTER(2,1)
NOE OCCURRENCE(2,1)
NON TOXIC LEUKOTOXIN(2,1)
NUCLEAR CORRELATED EXPERIMENT(2,1)
OLIGOSACCHARIDE MUTANT(2,1)
ORGANISM POTENTIAL VIRULENCE(2,1)
OVINE PATHOGEN(2,1)
PASSIVE PROTECTION EXPERIMENT DATA(2,1)
PASTEURELLA HAEMOLYTICA LPS(2,1)
PHOSPHATE URIDYLTRANSFERASE(2,1)
PHOSPHOCHOLINE MOIETY(2,1)
PHOSPHOCHOLINE RESIDUE(2,1)
PIG TRACHEAL CELL(2,1)
PM LPS MOLECULE(2,1)
POLYSACCHARIDE ANTIGEN VARIABILITY(2,1)
PORCINE PATHOGEN(2,1)
PRESUMED HEXNAC RESIDUE(2,1)
PROTON SPECTRUM RESOLUTION(2,1)
PROXIMAL HEPTOSE RESIDUE(2,1)
QUADRUPOLE COLLISION CELL(2,1)
RARE ANTI CONFORMER(2,1)
RESEARCH COUNCIL(2,1)
RESONANCE CONNECTIVITY(2,1)
RESONANCE SELECTIVE EXCITATION(2,1)
SELECTIVE PULSE WIDTH(2,1)
SHARPLES CONTINUOUS CENTRIFUGE(2,1)
SHEWANELLA ONEIDENSIS(2,1)
SPECTRA PEAK LISTING(2,1)
SYNTHESIZED HEPTOSE PURITY(2,1)
TETANUS TOXIN TOXOID(2,1)
TRIPLE QUANTUM HOMO(2,1)
UNCHARACTERIZED PROTEIN(2,1)
UNUSUAL CONFORMATION(2,1)
VARIABLE OLIGOSACCHARIDE MOIETY(2,1)
VARIAN SATURN(2,1)
VARIOUSLY TRUNCATED CORE(2,1)
SPECIES(1,18)
O ANTIGEN ABSENCE(1,9)
13C NMR CHEMICAL SHIFT(1,7)
ATTACHMENT POINT(1,5)
CHEMICAL SHIFT COMPARISON(1,5)
CONSERVED STRUCTURE(1,5)
O CHAIN(1,5)
CENTRIFUGATION(1,4)
H2PO(1,4)
CROSSPEAK(1,3)
GALNAC(1,3)
STANDARD HOMO(1,3)
TOCSY STEP(1,3)
BACTERIN(1,2)
CARRIER MOLECULE(1,2)
CELL ELISA(1,2)
CROSS REACTIVE LPS EPITOPE(1,2)
CURRENT VACCINE(1,2)
DRIED SAMPLE(1,2)
ELUANT(1,2)
EXCESS HYDRAZINE(1,2)
FINAL CONCENTRATION(1,2)
GLCNAC(1,2)
HEPTOSIS(1,2)
HEXOSE(1,2)
HOMOLOGY(1,2)
INFERENCE(1,2)
LINKAGE PATTERN(1,2)
MASS MAJOR MOLECULE(1,2)
MH CELL(1,2)
MICRO MASS(1,2)
MS DATA(1,2)
NITROMETHANE(1,2)
PAPER CHROMATOGRAPHY(1,2)
PUBLICATION BASIS(1,2)
STRONG NOE(1,2)
TERMINAL DD HEP(1,2)
TERMINAL RESIDUE(1,2)
TRIPLY(1,2)
13C NMR RESONANCE(1,1)
1D 1H NMR(1,1)
1D NOESY SPECTRUM(1,1)
1D ROESY EXPERIMENT(1,1)
1D SELECTIVE EXPERIMENT(1,1)
1D SELECTIVE SEQUENCE(1,1)
1H NMR ASSIGNMENT(1,1)
1H NMR SPECTRA ESTABLISHING(1,1)
2D NOESY SPECTRUM(1,1)
5B CDATA(1,1)
5B SEROTYPE(1,1)
ACCURATE 1H(1,1)
ACETIC ANHYDRIDE(1,1)
ACETONE METHYL RESONANCE(1,1)
ACETYLATED SAMPLE(1,1)
ALKALINE METHANOL(1,1)
ALTERED MIGRATION(1,1)
AMICON CONCENTRATION CELL(1,1)
ANION EXCHANGE CHROMATOGRAPHY(1,1)
ANOMERIC PEAK(1,1)
ANTIBACTERIAL DRUG(1,1)
ANTIGENIC POLYMERIC REPEATING UNIT(1,1)
AP ADHERENCE(1,1)
AP PLAY(1,1)
AP STRAIN(1,1)
AQ AGNO(1,1)
AQUEOUS ACETONITRILE(1,1)
ASCITE FLUID(1,1)
AXIAL PROTON(1,1)
BACTERIUM ADHESIVE ABILITY(1,1)
BARE FUZED SILICA CAPILLARY(1,1)
BLAST ANALYSIS(1,1)
CALORIMETRIC ANALYSIS(1,1)
CAPILLARY OUTLET(1,1)
CARBOHYDRATE DATABASE(1,1)
CARBOHYDRATE RESIDUE UNIT(1,1)
CHOCOLATE AGAR PLATE(1,1)
COLLISION ACTIVATION(1,1)
COLLISION ENERGY(1,1)
COLLISIONAL ACTIVATION(1,1)
COLUMN FRACTIONATED LPS(1,1)
COMMON CORE OLIGOSACCHARIDE DETERMINANT(1,1)
COMPLEMENT MEDIATED LYSIS(1,1)
COMPLEMENT PRESENCE(1,1)
COMPUTATIONAL BIOLOGY CENTER(1,1)
CONFORMATION OCCURRENCE(1,1)
CONSERVED INNER CORE OLIGOSACCHARIDE(1,1)
CONSERVED LPS STRUCTURE(1,1)
CORE BIOSYNTHESIS(1,1)
CORE CONFORMATION(1,1)
CORE CONSERVATION(1,1)
CORE GLC RESIDUE(1,1)
CORE LD HEPTOSYL(1,1)
CORE OS REGION BIOSYNTHESIS(1,1)
CORE OS REGION PRESENTATION(1,1)
CORE OS RESIDUE(1,1)
CORE OS STRUCTURAL ANALYSIS(1,1)
CORE OS SUGAR ANALYSIS(1,1)
COZY SPECTRUM(1,1)
CRITERIA MAJORITY(1,1)
CROSS PROTECTION(1,1)
CUTOFF MEMBRANE(1,1)
DD HEPTOSYLTRANSFERASE(1,1)
DEACYLATION PROCEDURE MODIFICATION(1,1)
DECORATING(1,1)
DEFICIENT LPS(1,1)
DEUTERIUM EXCHANGE(1,1)
DGLCP LINKAGE(1,1)
DI GLUCOSYL MOIETY(1,1)
DIGITAL RESOLUTION(1,1)
DIHEDRAL ANGLE(1,1)
DISACCHARIDE MOIETY(1,1)
DISEASE MANAGEMENT STRATEGY(1,1)
DISEASE PREVENTION(1,1)
DRIED CELL WASHING(1,1)
DRYNESS UNDER REDUCED PRESSURE(1,1)
EARLY FRACTION ANALYSIS(1,1)
ELECTROSPRAY MASS SPECTROMETRY(1,1)
ELECTROSPRAY STAINLESS STEEL NEEDLE(1,1)
ELICITING HOST IMMUNE RESPONSE(1,1)
ENABLED IDENTIFICATION(1,1)
ESSENTIAL CRITERIA(1,1)
EXTENSIVE ANTIGENIC DIVERSITY(1,1)
FAB ANALYSIS DATA(1,1)
FAB DATA(1,1)
FAB MS ANALYSIS(1,1)
FRACTIONATED OS SAMPLE(1,1)
FRAGMENT ION(1,1)
FULLY ACYLATED LPS MOLECULE(1,1)
GAL PROTON(1,1)
GENE CONSISTENT PRESENCE(1,1)
GENETIC STABILITY(1,1)
GENOME DATA(1,1)
GLC III RESIDUE(1,1)
GLC MS ANALYSIS(1,1)
GLUCOSAMINE RESIDUE REDUCTION(1,1)
GLYCINE RESIDUE(1,1)
GLYCOSIDIC ANGLE(1,1)
GLYCOSIDIC BOND(1,1)
GLYCOSIDIC LINKAGE ANGLE(1,1)
GLYCOSYL RESIDUE SEQUENCE(1,1)
GRADUALLY COLD ACETONE(1,1)
HEALTH ISSUE(1,1)
HEP HEX(1,1)
HEPI LINKAGE(1,1)
HEPI SUBSTITUTION PATTERN(1,1)
HEPIII RESIDUE(1,1)
HEPTOSE PRODUCT(1,1)
HETEROGENEOUS MOLECULE MIXTURE(1,1)
HEX2HEP5KDO(1,1)
HEX3HEP5KDO1HEXN(1,1)
HEXNAC MOLECULE(1,1)
HEXNAC RESIDUE COMPLETE ASSIGNMENT(1,1)
HMBC SPECTRUM(1,1)
HMQCTOCSY SPECTRUM(1,1)
HOMOLOGOUS CHALLENGE((...)";"Analysis of biological materials
Macromolecular chemistry, polymers
Organic fine chemistry
Pharmaceuticals";Open
2004-04-13;"IN3859/DELNP/2005   A  2007-09-28 [IN2005DN03859]
STG: (A) Application laid open
AP : 2005IN-DN03859 2005-08-30";83851421;IN3859/DELNP/2005   A  2007-09-28 [IN2005DN03859];2004WO-IB01292;;PFIZER PRODUCTS;PFIZER PRODUCTS;"(IN2005DN03859)
US";"(IN2005DN03859)
NAME=PFIZER PRODUCTS INC EASTERN POINT ROAD, GROTON, CONNECTICUT 06340  , COUNTRY=US 
";1;"ELLSWORTH MICHAEL AARON
FICKEN MARTIN DALE
FERGEN BRIAN JAMES
TUCKER CASSIUS MCALLISTER";"(IN2005DN03859)
US";"(IN2005DN03859)
NAME=ELLSWORTH MICHAEL AARON , COUNTRY=US 

NAME=FICKEN MARTIN DALE , COUNTRY=US 

NAME=FERGEN BRIAN JAMES , COUNTRY=US 

NAME=TUCKER CASSIUS MCALLISTER , COUNTRY=US 
";"(IN2005DN03859)
Methods for preventing cattle reproductive diseases";"(IN2005DN03859)
The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by adminstering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.";;;;A61K-039/12;;;Pharmaceuticals;Open
"2004-03-17
2005-03-04";"WO2005089793        A1 2005-09-29 [WO200589793]
STG: (A1) Published application with search report
AP : 2005WO-IB00610 2005-03-04
CA2560532           A1 2005-09-29 [CA2560532]
STG: (A1) Application laid open
AP : 2005CA-2560532 2005-03-04
AU2005224179        A1 2005-09-29 [AU2005224179]
STG: (A1) Open to public inspection
AP : 2005AU-0224179 2005-03-04
TW200531701         A  2005-10-01 [TW200531701]
STG: (A) Laid open application for patent or patent of addition
AP : 2005TW-0108014 2005-03-16
AR048671            A1 2006-05-17 [AR--48671]
STG: (A1) Independent patent application
AP : 2005AR-0100998 2005-03-15
NO20063603          L  2006-09-08 [NO20063603]
STG: (L) Abstract
AP : 2006NO-0003603 2006-08-09
EP1727562           A1 2006-12-06 [EP1727562]
STG: (A1) Application published with search report
AP : 2005EP-0708706 2005-03-04
KR20060127199       A  2006-12-11 [KR20060127199]
STG: (A) Published application
AP : 2006KR-7019032 2006-09-15
CN1929859           A  2007-03-14 [CN1929859]
STG: (A) Published application
AP : 2005CN-80008271 2005-03-04
BRPI0508941         A  2007-08-14 [BR200508941]
STG: (A) Published application
AP : 2005BR-0008941 2005-03-04
BRPI0508941         A1 2007-08-14 [BRPI0508941]
STG: (A1) Published application
AP : 2005BR-0008941 2005-03-04
AU2005224179        B2 2007-08-23 [AU2005224179]
STG: (B2) Patent proceeded by OPI
AP : 2005AU-0224179 2005-03-04
IN4656/DELNP/2006   A  2007-08-24 [IN2006DN04656]
STG: (A) Application laid open
AP : 2006IN-DN04656 2006-08-11
JP2007529498        A  2007-10-25 [JP2007529498]
STG: (A) Published application
AP : 2007JP-0503432 2005-03-04
RU2006133328        A  2008-03-27 [RU2006133328]
STG: (A) Application for invention
AP : 2006RU-0133328 2005-03-04
JP4105220           B2 2008-04-04 [JP4105220]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2007JP-0503432 2005-03-04
KR20080036160       A  2008-04-24 [KR20080036160]
STG: (A) Published application
AP : 2008KR-7008843 2008-04-14
EP1727562           B1 2008-06-18 [EP1727562]
STG: (B1) Patent specification
AP : 2005EP-0708706 2005-03-04
AT398462            T  2008-07-15 [ATE398462]
STG: (T) EP patent valid in AT
AP : 2005AT-0708706T 2005-03-04
DE602005007584      D1 2008-07-31 [DE602005007584]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2005DE-60007584 2005-03-04
ZA200607132         B  2008-08-27 [ZA200607132]
STG: (B)
AP : 2006ZA-0007132 2006-08-25
PT1727562           E  2008-09-05 [PT1727562]
STG: (E) Availability of national translation of European patent
AP : 2005PT-0708706T 2005-03-04
DK1727562           T3 2008-09-15 [DK1727562T]
STG: (T3) Translation of EP patent
AP : 2005DK-0708706 2005-03-04
RU2335298           C2 2008-10-10 [RU2335298]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2006RU-0133328 2005-03-04
US20080260778       A1 2008-10-23 [US20080260778]
STG: (A1) Application published
AP : 2005US-10593134 2005-03-04
FD :  Provisional Appl: US60/553,867 FDD=2004-03-17 [2004US-60553867]
SI1727562           T1 2008-10-31 [SI1727562T]
STG: (T1) Translation of EP claims
AP : 2005SI-0030316 2005-03-04
ES2306101           T3 2008-11-01 [ES2306101]
STG: (T3) Translation of granted European patent (former B3)
AP : 2005ES-0708706T 2005-03-04
NZ549592            A  2008-12-24 [NZ-549592]
STG: (A) Published application
AP : 2005NZ-0549592 2005-03-04
TWI306404           B  2009-02-21 [TWI306404]
STG: (B) Granted patent or patent of addition
AP : 2005TW-0108014 2005-03-16
UA86405             C2 2009-04-27 [UA--86405]
STG: (C2) Pat. grant. upon the USSR appl.,for which no pos. dec. made;grant. upon basis of national application
AP : 2006UA-0009917 2005-03-04
BRPI0508941         A2 2012-05-15 [BR200508941]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2005BR-0008941 2005-03-04";55670;"WO2005089793        A1 2005-09-29 [WO200589793]
CA2560532           A1 2005-09-29 [CA2560532]
AU2005224179        A1 2005-09-29 [AU2005224179]
TW200531701         A  2005-10-01 [TW200531701]
AR048671            A1 2006-05-17 [AR--48671]
NO20063603          L  2006-09-08 [NO20063603]
EP1727562           A1 2006-12-06 [EP1727562]
KR20060127199       A  2006-12-11 [KR20060127199]
CN1929859           A  2007-03-14 [CN1929859]
BRPI0508941         A  2007-08-14 [BR200508941]
BRPI0508941         A1 2007-08-14 [BRPI0508941]
AU2005224179        B2 2007-08-23 [AU2005224179]
IN4656/DELNP/2006   A  2007-08-24 [IN2006DN04656]
JP2007529498        A  2007-10-25 [JP2007529498]
RU2006133328        A  2008-03-27 [RU2006133328]
JP4105220           B2 2008-04-04 [JP4105220]
KR20080036160       A  2008-04-24 [KR20080036160]
EP1727562           B1 2008-06-18 [EP1727562]
AT398462            T  2008-07-15 [ATE398462]
DE602005007584      D1 2008-07-31 [DE602005007584]
ZA200607132         B  2008-08-27 [ZA200607132]
PT1727562           E  2008-09-05 [PT1727562]
DK1727562           T3 2008-09-15 [DK1727562T]
RU2335298           C2 2008-10-10 [RU2335298]
US20080260778       A1 2008-10-23 [US20080260778]
SI1727562           T1 2008-10-31 [SI1727562T]
ES2306101           T3 2008-11-01 [ES2306101]
NZ549592            A  2008-12-24 [NZ-549592]
TWI306404           B  2009-02-21 [TWI306404]
UA86405             C2 2009-04-27 [UA--86405]
BRPI0508941         A2 2012-05-15 [BR200508941]";"2004US-60553867
2005EP-0708706
2005US-10593134
2005WO-IB00610";"(EP1727562)
WO2005089793
(US20080260778)
WO2005089793
(DE602005007584)
WO2005089793
(JP4105220)
WO2005089793
(RU2335298)
WO2005089793
(CA2560532)
WO2005089793
(NO20063603)
WO2005089793
(KR20060127199)
WO2005089793
(CN1929859)
WO2005089793
(AU2005224179)
WO2005089793
(KR20080036160)
WO2005089793
(ZA200607132)
WO2005089793
(DK1727562T)
WO2005089793
(SI1727562T)
WO2005089793
(NZ-549592)
WO2005089793
(BR200508941)
WO2005089793";"AUBURN UNIVERSITY
FALMASIA & UPJOHN
PHARMACIA & UPJOHN";PHARMACIA & UPJOHN;"(EP1727562)
US
(EP1727562)
US
(WO200589793)
US

(CA2560532)
US
(IN2006DN04656)
US
(BRPI0508941)
US
(BR200508941)
US";"(EP1727562)
NAME=Pharmacia & Upjohn Company LLC 7000 Portage Road , CITY=Kalamazoo, MI 49001-0199 , COUNTRY=US 

(EP1727562)
NAME=Pharmacia & Upjohn Company LLC 7000 Portage Road , CITY=Kalamazoo, MI 49001 , COUNTRY=US , REG=100813453 

(WO200589793)
NAME=PHARMACIA & UPJOHN COMPANY LLC  [US/ US] 301 Henrietta Street, Kalamazoo, MI 49001  , COUNTRY=US 

(JP2007529498)
NAME=PHARMACIA & UPJOHN CO LLC , REG=504396379 

(JP4105220)
NAME=Falmasia and Upjohn Company LLC; USA Michigan 4 9 0 0 1-0 1 9 9. Kalamazoo. Poty Jean Road 7 0 0 0 , REG=504396379 

(CA2560532)
NAME=PHARMACIA & UPJOHN COMPANY LLC 301 Henrietta Street , CITY=KALAMAZOO , STATE=MI , POSTCODE=49007 , COUNTRY=US 

(IN2006DN04656)
NAME=PHARMACIA & UPJOHN COMPANY LLC 301 HENRIETTA STREET, KALAMAZOO, MICHIGAN 49001  , COUNTRY=US 

(BRPI0508941)
NAME=PHARMACIA & UPJOHN COMPANY LLC , COUNTRY=US 

(BR200508941)
NAME=PHARMACIA & UPJOHN COMPANY LLC , COUNTRY=US 
";1;"ELLSWORTH MICHAEL AARON
TUCKER CASSIUS MCALLISTER";"(EP1727562)
US
(EP1727562)
US";"(EP1727562)
NAME=ELLSWORTH, Michael, Aaron c/o Pfizer Inc. Animal Health Group 601 West Cornhusker Highway , CITY=Lincoln, NE 68521 , COUNTRY=US 

NAME=TUCKER, Cassius, McAllister Pfizer Inc. Vet. Medicine Res. and Developm. 7000 Portage Road , CITY=Kalamazoo, MI 49001 , COUNTRY=US 

(EP1727562)
NAME=ELLSWORTH, Michael, Aaron c/o Pfizer Inc. Animal Health Group 601 West Cornhusker Highway Lincoln, NE 68521 , COUNTRY=US 

NAME=TUCKER, Cassius, McAllister Pfizer Inc. Vet. Medicine Res. and Developm. 7000 Portage Road Kalamazoo, MI 49001 , COUNTRY=US 
";"(EP1727562)
Method of vaccination against testicular bvdv infection";"(EP1727562)
The methods of the invention relate to methods for preventing testicular infection by bovine viral diarrhea virus by immunizing susceptible male animals against infection.";"(WO200589793)
What is claimed is:
1. A method of preventing testicular BVDV infection in a susceptible male animal comprising: administering to the animal an effective amount of a vaccine selected from the group consisting of an inactivated type 1 BVDV vaccine , an inactivated type 2 BVDV vaccine, a modified live type 1 BVDV vaccine, and a modified live type 2 BVDV vaccine.
2. The method of claim 1 wherein the animal is selected from the group consisting of bulls, rams and boars.
3. The method of claim 2 wherein the animal is a bull.
4. The method of claim 1 wherein the vaccine comprises both a modified live type 1 BVDV vaccine and a modified live type 2 BVDV vaccine.
5. The method of claim 4 wherein at least one modified live BVDV vaccine is derived from a cytopathogenic virus.
6. The method of claim 4 wherein at least one modified live BVDV vaccine is derived from a non-cytopathogenic virus.
7. The method of claim 4 wherein both modified live BVDV vaccines are derived from a cytopathogenic virus.
8. The method of claim 1-7 wherein the vaccine comprises at least one additional antigen selected from the group consisting of Bovine Herpes Virus (BHV-1); Parainfluenza Virus Type 3 (PIV3); . Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio- prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona,
 Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, Campylobacter fetus, Mannheimia (Pasteurella) haemolytica, Pasteurella multocida, Mycobacterium bovis, and Mycobacterium dispar.
9. The method of claim 8 wherein said additional antigens comprise Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), and Bovine Respiratory Syncytial Virus (BRSV).
10. The use of a vaccine selected from the group consisting of an inactivated type 1 BVDV vaccine, an inactivated type 2 BVDV vaccine, a modified live type 1 BVDV vaccine, and a modified live type 2 BVDV vaccine for manufacture of a medicament for preventing testicular BVDV infection in a susceptible male animal at increased risk of BVDV testicular infection
11. The method of claim 10 wherein the animal is selected from the group consisting of bulls, rams and boars.
12. The method of claim 11 wherein the animal is a bull.
13. The method of claim 10 wherein the vaccine comprises both a modified live type 1 BVDV vaccine and a modified live type 2 BVDV vaccine.
14. The method of claim 13 wherein at least one modified live BVDV vaccine is derived from a cytopathogenic virus.
15. The method of claim 13 wherein at least one modified live BVDV vaccine is derived from a non-cytopathogenic virus.
16. The method of claim 13 wherein both modified live BVDV vaccines are derived from a cytopathogenic virus.
17. The method of claim 10-16 wherein the vaccine comprises at least one additional antigen selected from the group consisting of Bovine Herpes Virus (BHV-1);
 Parainfluenza Virus Type 3 (PIV3); . Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio- prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, Campylobacter fetus, Mannheimia (Pasteurella) haemolytica, Pasteurella multocida, Mycobacterium bovis, and Mycobacterium dispar.
18. The method of claim 17 wherein said additional antigens comprise Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), and Bovine Respiratory Syncytial Virus (BRSV).";"(EP1727562)
Accordingly, the present invention provides methods of controlling or preventing infections in animal subjects caused by types 1 or 2 BVD viruses, or a combination of type 1 and type 2, by administering to an animal, an effective amount of a BVDV virus of the present invention.
The present invention provides a method of treating or preventing testicular infection and resultant shedding in semen by BVDV viruses in a susceptible male animal.
In addition, the objectives of the present invention can be accomplished by administering other antigens than BVDV types 1 and/or 2, (a ""combination vaccine"") such antigens include but are not limited to, BRSV, BHV-1, PIV3, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, Campylobacter fetus Mannheimia (Pasteurella) haemolytica, Pasteurella multocida, Mycobacterium bovis, and Mycobacterium dispar.
The present invention provides a method of treating or preventing testicular infection and resultant shedding in semen by BVDV viruses in a susceptible male animal.";"(EP1727562)
While subclinical infection is most common, signs such as depression, inappetence, oral erosions and ulcerations, diarrhea and death might be observed.
Semen collected on the day of exposure and 7 months after exposure did not cause infection in two additional sero negative calves.7
Two teams of investigators have also reported that acute infection of postpuberal bulls can cause a persistent BVDV infection that localizes in the testes.6,7 One unique case occurred in a sero positive, nonviremic bull maintained in an artificial insemination station in New Zealand.";"A61K
A61K-039/00
A61K-039/12
A61K-039/15
A61K-039/295
A61P-031/12
A61P-031/14
A61P-037/00";"(EP1727562)
1. Use of an effective amount of an antigen selected from the group consisting of an inactivated type 1 bovine viral diarrhea virus (BVDV), an inactivated type 2 BVDV, a modified live type 1 BVDV, and a modified live type 2 BVDV, for the manufacture of a vaccine for preventing testicular BVDV infection in a susceptible male animal.";"(EP1727562)
BOVINE VIRUS DIARRHEA VIRUS(100,170)
INFECTION(100,34)
VACCINATION(100,8)
POSTPUBERAL BULL ACUTE INFECTION(100,1)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(90,3)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(86,1)
HOMOLOGOUS VIRUS STRAIN(84,3)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(74,4)
BORGPETERSENII HARDJO BOVIS(72,4)
CAMPYLOBACTER FETUS MANNHEIMIA(72,1)
LEPTOSPIRA GRIPPOTYPHOSA(70,4)
LEPTOSPIRA INTERROGAN(69,4)
INVESTIGATOR TEAM(68,1)
LEPTOSPIRA CANICOLA(65,4)
HEALTHY CATTLE VACCINATION(64,1)
MYCOBACTERIUM DISPAR(63,4)
BVDV VIRUS(61,1)
PARAINFLUENZA VIRUS(58,5)
NONVIREMIC BULL(56,1)
SUSCEPTIBLE MALE ANIMAL(53,19)
SERONEGATIVE CALF(50,2)
VACCINE MANUFACTURE(50,1)
TESTICULAR INFECTION(47,20)
ARTIFICIAL INSEMINATION STATION(46,1)
ANTIGEN(45,9)
ORAL EROSION(44,1)
SHEDDING(38,1)
BOVINE HERPES VIRUS(37,5)
ANTIBIOTIC UG ML(36,2)
SEROPOSITIVE(35,1)
AGE MONTH(34,9)
PASTEURELLA MULTOCIDA(33,4)
EXPOSURE DAY(32,1)
MYCOBACTERIUM BOVIS(30,4)
SUBCLINICAL INFECTION(29,1)
INAPPETENCE(28,1)
PASTEURELLA(27,4)
ULCER(27,1)
LEPTOSPIRA(26,4)
DIARRHEA(23,1)
DEPRESSION(22,1)
ACUTELY INFECTED BULL(21,4)
SEMEN(20,25)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(20,10)
PERSISTENT TESTICULAR INFECTION(20,3)
DEATH(19,1)
BOVINE VIRAL DIARRHEA VIRUS(18,9)
TESTIS(18,3)
BOS TAURUS DNAJ(18,2)
INTRAMUSCULAR VACCINATION INTRANASAL CHALLENGE(16,1)
TESTICULAR SPECIMEN(15,4)
BOVI SHIELD GOLD(15,3)
MANNHEIMIA(14,3)
NONVIREMIC POSTPUBERAL BULL(14,1)
PREPUBERAL BULL VACCINATION(14,1)
VETERINARY ACCEPTABLE CARRIER(13,7)
PERSISTENTLY INFECTED ANIMAL(13,3)
VETERINARY PHYSICIAN(13,3)
COLOSTRUM DEPRIVED BEEF CALF(13,1)
INTACT BEEF BREED BULL(13,1)
RUMINANT PESTIVIRUS INFECTION DIAGNOSIS(13,1)
TESTICLE PERSISTENT INFECTION(13,1)
EARLY EMBRYONIC DEATH(12,2)
NON CYTOPATHOGENIC VIRUS(12,2)
INACTIVATED TYPE(11,16)
BOAR(11,3)
BULL SEMEN(11,2)
BULL INTRAMUSCULAR VACCINATION(11,1)
FETUS INFECTION PERSISTENCE(11,1)
PLACEBO VACCINATED BULL(11,1)
PREPUBERAL BULL CALF(11,1)
SERONEGATIVE POSTPUBERTAL BULL(11,1)
SUSCEPTIBLE HEIFER INSEMINATION(11,1)
TESTICULAR BIOPSY RT NPCR(11,1)
VACCINATING BULL EFFICACY(11,1)
ANNUAL BASIS(10,6)
IMMUNOGENIC(10,4)
AUBURN UNIVERSITY(10,2)
PERSISTENTLY INFECTED BULL(10,2)
VETERINARY MICROBIOLOGY(10,2)
CODON ENCODING NUCLEOTIDE(10,1)
PERSISTENT BOVINE PESTIVIRUS INFECTION(10,1)
SEMEN VIROLOGICAL STATUS(10,1)
SEVERE BVD OUTBREAK(10,1)
SUSCEPTIBLE INSEMINATED COW(10,1)
UNCASTRATED MALE CATTLE(10,1)
UNIQUE DISPLAY CASE(10,1)
VIRUS NEUTRALIZATION ASSAY(10,1)
MODIFIED LIVE TYPE(9,13)
IMMUNOHISTOCHEMISTRY(9,5)
FISHER EXACT TEST(9,3)
ATTENUATED CP(9,2)
BOVINE CYTOKINE(9,2)
CHALLENGED BULL(9,2)
DIADEM DEFECT(9,2)
IBR BVD(9,2)
INOCULATED ANIMAL(9,2)
INTRA LYMPH NODE(9,2)
PLURONIC POLYOL(9,2)
SAPONIN DERIVATIVE(9,2)
SEMEN RT NPCR(9,2)
ACUTE TESTICULAR INFECTION(9,1)
IMMUNOCOMPETENT SUSCEPTIBLE ANIMAL(9,1)
NONCYTOPATHIC BIOTYPE(9,1)
PFIZER ANIMAL HEALTH(9,1)
PROXIMAL DROPLET COINCIDING(9,1)
SEMI ANNUAL REVACCINATION(9,1)
UNINFECTED HERD(9,1)
VIRULENT STRAIN ATTENUATION(9,1)
SEMEN SAMPLE(8,3)
ARTIFICIALLY INDUCED INFECTION(8,1)
ASSESSING EFFICACY STUDY(8,1)
BULL CONTINUOUSLY SHED VIRUS(8,1)
BVD VIRUS PURIFICATION(8,1)
CATTLE ECONOMICALLY SIGNIFICANT PATHOGEN(8,1)
CATTLE INSEMINATION(8,1)
CEREBRAL HYPOPLASIA(8,1)
CHOLESTEROL AMPHIGEN(8,1)
HERD FERTILITY(8,1)
IMMUNOCOMPETENT BULL(8,1)
INSEMINATED HEIFER(8,1)
LIPID AMINE ADJUVANT(8,1)
MALE CATTLE SHEEP(8,1)
MORPHOLOGIC ABNORMALITY(8,1)
NEBRASKA LINCOLN(8,1)
PREGNANT HERDMATE(8,1)
PREPUBERAL VACCINATION(8,1)
PREVENTED TESTICULAR INFECTION(8,1)
SERONEGATIVE HEIFER(8,1)
SPERMATOZOON MORPHOLOGY(8,1)
SPERMATOZOON MOTILITY(8,1)
TESTICLE INFECTION(8,1)
VACCINE LICENSING(8,1)
VIRUS SHEDDING(8,1)
COMBINATION VACCINE(7,4)
THROMBOCYTOPENIA(7,3)
MEDICAMENT MANUFACTURE(7,2)
MINERAL OIL EMULSION(7,2)
RT NPCR TESTING(7,2)
SPERMATOZOAL HEAD(7,2)
SUSCEPTIBLE MALE(7,2)
TESTICULAR PROTECTION(7,2)
ABORTION STORM(7,1)
BOOSTING REGIMEN(7,1)
BULL TESTIS(7,1)
BVD VIRUS CAPACITY(7,1)
CHEMICALLY INDUCED MUTATION(7,1)
CLINICAL SCIENCE LABORATORY(7,1)
COMMERCIAL VACCINE MAJORITY(7,1)
CONFERENCE RE PROCEEDING(7,1)
DESCRIPTIVE STATISTIC(7,1)
EAR NOTCH BIOPSY SAMPLE(7,1)
FLAVIVIRIDAE FAMILY(7,1)
GALENICA PHARMACEUTICAL(7,1)
IMMUNOCOMPETENT ANIMAL(7,1)
INFECTED HEIFER(7,1)
INFECTION SYMPTOM(7,1)
LYOPHILIZED VACCINE(7,1)
NEEDLELESS ADMINISTRATION(7,1)
NONCYTOPATHIC STRAIN(7,1)
NONVIRAEMIC BULL(7,1)
PESTIVIRUS GENUS(7,1)
SEMI ANNUAL SUBSEQUENT VACCINE(7,1)
SERUM VIRUS ISOLATION(7,1)
TESTICULAR BIOPSY SPECIMEN POSITIVE(7,1)
TIMELY VACCINATION(7,1)
VACCINATED CATTLE(7,1)
VACCINE INGREDIENT(7,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(7,1)
VIRUS FETAL TRANSMISSION(7,1)
ACTIVE INGREDIENT(6,2)
CHALLENGE TREATMENT(6,2)
ISOTONIC AGENT(6,2)
MALE ANIMAL(6,2)
MINERAL GEL(6,2)
SAMPLING DAY(6,2)
VEGETABLE OIL EMULSION(6,2)
ADMINISTRATION SCHEDULE(6,1)
ADSORPTION DELAYING(6,1)
ANTIGEN CAPTURE COMPARISON(6,1)
ARTIFICIAL INSEMINATION FACILITY(6,1)
BOVI SHIELE GOLD(6,1)
BOVINE REPRODUCTIVE TRACT(6,1)
BULL FERTILITY(6,1)
CALF BIRTH(6,1)
CATTLE PERCENTAGE(6,1)
CHOLERA TOXIN(6,1)
CPNADL VIRUS(6,1)
DISEASE SYMPTOM(6,1)
DOSAGE REGIMEN(6,1)
EMERYVILLE CA(6,1)
EQUINE SERUM SODIUM BICARBONATE(6,1)
FETAL INFECTION(6,1)
GESTATION DAY(6,1)
HIGHLY SPECIALIZED LABORATORY FACILITY(6,1)
HIGHLY TRAINED TECHNICIAN(6,1)
HORSE SERUM(6,1)
IMMUNOCOMPETENCY DEVELOPMENT(6,1)
IMMUNOMODULATORY AGENT(6,1)
INFECTED TESTIS(6,1)
INFECTION ELEVATED RISK(6,1)
INTRAMUSCULAR ADMINISTRATION(6,1)
MINIMUM IMMUNIZING DOSE DETERMINATION(6,1)
NEUTRALIZING ANTIBODY PRESENCE(6,1)
OPTIMAL IMMUNIZATION(6,1)
PATHOGEN RESERVOIR(6,1)
PCR PLACEBO(6,1)
PROLONGED VIREMIA(6,1)
REPRODUCTIVE LOSS VIRTUE(6,1)
SAPONIN FRACTION(6,1)
SEROLOGICAL STUDY(6,1)
SPERMATOZOON CONCENTRATION(6,1)
SPREAD RAPIDITY(6,1)
SUSCEPTIBLE CELL MONOLAYER(6,1)
TESTICULAR VIRAL INFECTION(6,1)
TISSUE CULTURE(6,1)
VACCINATED ANIMAL(6,1)
VACCINE DOSE(6,1)
VIRUS EXCRETION(6,1)
LEUKOPENIA(5,3)
PLACEBO GROUP(5,3)
PRESERVATIVE(5,3)
AFFECTED HERD(5,1)
ANIMAL AGE(5,1)
ANIMAL BREEDING(5,1)
ANIMAL PROPORTION(5,1)
ANIMAL SUFFERING(5,1)
BOVINE VIRUS DIARRHEA VIRUS INFECTION(5,1)
CAMBRIDGE MA(5,1)
CATEGORICAL(5,1)
CATTLE INDUSTRY(5,1)
CELL CULTURE INFECTIVE DOSE(5,1)
COW CALF(5,1)
CP BVD(5,1)
DECREASED MOTILITY(5,1)
EARLE SALT(5,1)
EARLY REPRODUCTIVE LOSS(5,1)
ENZYME LINKED IMMUNOASSAY(5,1)
FEVER RANGING(5,1)
GENERALIZED RANDOMIZED BLOCK(5,1)
GLYCINE RESIDUE(5,1)
HIGHLY PATHOGENIC STRAIN(5,1)
HUMORAL IMMUNE RESPONSE(5,1)
IMMUNITY DURATION(5,1)
IMMUNOHISTOCHEMICAL ANALYSIS(5,1)
IMMUNOHISTOCHEMICAL DETECTION(5,1)
INFECTION RISK(5,1)
LIVE STRAIN(5,1)
MALE PIG(5,1)
MALE SHEEP(5,1)
MODIFIED LIVE ANTIGEN(5,1)
MODIFIED LIVE VACCINE PREPARATION(5,1)
PCR ASSAY(5,1)
SEVERE CHALLENGE(5,1)
SUSCEPTIBLE COW(5,1)
TESTICULAR SAMPLE(5,1)
VETERINARY DIAGNOSTIC CENTER(5,1)
VIRUS CONCENTRATION(5,1)
VIRUS PARTICLE(5,1)
VIRUS STRAIN(5,1)
INCREASED RISK(4,5)
ACTIVE SUBSTANCE(4,2)
ADJUVANT COMBINATION(4,2)
ALHYDROGEL(4,2)
ANIMAL SUBJECT(4,2)
CARBOPOL(4,2)
CODING SEQUENCE(4,2)
DEXTROSE(4,2)
EMULSIFIER(4,2)
GENOTYPE(4,2)
GENTAMICIN(4,2)
GLYCOSIDE(4,2)
LYSOLECITHIN(4,2)
NECROPSY(4,2)
POLYANION(4,2)
SYMPTOMOLOGY(4,2)
THIMEROSAL(4,2)
VACCINE PRODUCTION(4,2)
VAGINAL ADMINISTRATION(4,2)
ACUTE INFECTION SOURCE(4,1)
ANIMAL NECK REGION(4,1)
ANIMAL SERUM(4,1)
BVD COMPONENT(4,1)
BVD VIRUS PRESENCE ABSENCE(4,1)
CATTLE CONDITION(4,1)
CELL CULTURE IMMUNOPEROXIDASE TEST(4,1)
DEVELOPED VIREMIA(4,1)
DOSE MULTIPLE ADMINISTRATION(4,1)
ELISA TECHNOLOGY(4,1)
ENZYME LINKED ASSAY(4,1)
FUNCTIONALLY EQUIVALENT(4,1)
GENOMIC SITE(4,1)
HEAT LABILE ENTEROTOXIN(4,1)
IMMUNOTOLERANCE(4,1)
MURAMYL DIPEPTIDE(4,1)
NATURAL BREEDING(4,1)
PARAFFIN EMBEDDED TISSUE(4,1)
PORCINE CELL(4,1)
PRIMARY IMMUNIZATION(4,1)
QUALITY EVALUATION(4,1)
RT PCR(4,1)
SAS STAT SOFTWARE CHANGE(4,1)
SEROCONVERSION(4,1)
SEVERE DISEASE(4,1)
SIGNIFICANT CHALLENGE(4,1)
SIGNIFICANT ECONOMIC IMPACT(4,1)
SUCCESSFUL PROTECTION(4,1)
TESTING EFFORT(4,1)
TRANSMISSIBILITY(4,1)
TREATMENT KNOWLEDGE(4,1)
VET RE(4,1)
VIRAL LOAD(4,1)
VIRUS ML(4,1)
MODIFIED LIVE VIRUS VACCINE(3,2)
(US20080260778)
VACCINE(100,53)
ANIMAL(100,31)
PIV(100,9)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(100,8)
PARAINFLUENZA VIRUS TYPE 3(100,8)
TESTICULAR BVDV INFECTION(100,8)
VACCINATION(100,8)
BORGPETERSENII HARDJO BOVIS(100,6)
LEPTOSPIRA(100,6)
LEPTOSPIRA CANICOLA(100,6)
LEPTOSPIRA GRIPPOTYPHOSA(100,6)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(100,6)
LEPTOSPIRA INTERROGAN(100,6)
MYCOBACTERIUM BOVIS(100,6)
MYCOBACTERIUM DISPAR(100,6)
PASTEURELLA(100,6)
PASTEURELLA MULTOCIDA(100,6)
MANNHEIMIA(100,5)
CAMPYLOBACTER FETUS(100,4)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(100,3)
SUSCEPTIBLE MALE(100,3)
BOVINE VIRAL DIARRHEA VIRUS INFECTION(100,1)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(48,3)
BOVINE HERPES VIRUS(38,9)
CAMPYLOBACTER FETUS MANNHEIMIA(38,1)
HOMOLOGOUS VIRUS STRAIN(37,1)
TESTICULAR INFECTION(31,13)
ANTIGEN(29,12)
BVDV VACCINE(24,36)
SUSCEPTIBLE MALE ANIMAL(24,18)
BOVI SHIELD GOLD(23,26)
ORAL EROSION(23,1)
BOVINE VIRAL DIARRHEA VIRUS(22,21)
BVD VIRUS(19,14)
BVDV VIRUS(19,3)
BVDV INFECTION(18,6)
SHEDDING(16,1)
INAPPETENCE(15,1)
SUBCLINICAL INFECTION(15,1)
ULCER(14,1)
INFECTION(12,14)
DEPRESSION(12,1)
DIARRHEA(12,1)
ACUTELY INFECTED BULL(11,4)
PERSISTENT TESTICULAR INFECTION(11,3)
ANIMAL SUBJECT(11,2)
BRSV(11,1)
SWINE(11,1)
FETUS(10,2)
DEATH(10,1)
SERONEGATIVE POSTPUBERTAL BULL INOCULATION(10,1)
BVDV(9,42)
AGE MONTH(9,9)
BOS TAURUS DNAJ(9,2)
PWV(9,1)
SEMEN(8,24)
INACTIVATED TYPE(8,18)
SHEEP(8,2)
TESTICULAR BVDV INFECTION PREVENTION(8,1)
VETERINARY ACCEPTABLE CARRIER(7,7)
BOVINE(7,3)
BVDV CHALLENGE(7,3)
VETERINARY PHYSICIAN(7,3)
ATTENUATED CP BVDV(7,2)
PERSISTENTLY INFECTED ANIMAL(7,2)
ACUTE POSTPUBERAL BVDV INFECTION(7,1)
NONVIREMIC POSTPUBERAL BULL(7,1)
POSTPUBERAL BULL ACUTE INFECTION(7,1)
PREPUBERAL BULL VACCINATION(7,1)
BOAR(6,3)
BULL SEMEN(6,2)
EARLY EMBRYONIC DEATH(6,2)
NON CYTOPATHOGENIC VIRUS(6,2)
SERONEGATIVE CALF(6,2)
BVDV CPNADL VIRUS(6,1)
BVDV NONCYTOPATHIC STRAIN(6,1)
COLOSTRUM DEPRIVED BEEF CALF(6,1)
FETUS INFECTION PERSISTENCE(6,1)
HEALTHY CATTLE VACCINATION(6,1)
INTACT BEEF BREED BULL(6,1)
PLACEBO VACCINATED BULL(6,1)
PREPUBERAL BULL CALF(6,1)
RESPIRATORY SYNCITIAL VIRUS(6,1)
RUMINANT PESTIVIRUS INFECTION DIAGNOSIS(6,1)
SUSCEPTIBLE HEIFER INSEMINATION(6,1)
TESTICLE PERSISTENT INFECTION(6,1)
TESTICULAR BIOPSY RT NPCR(6,1)
TREATING BVDV TESTICULAR INFECTION(6,1)
VACCINATING BULL EFFICACY(6,1)
ANNUAL BASIS(5,6)
INCREASED RISK(5,5)
IMMUNOGENIC(5,4)
BVDV STRAIN(5,3)
AUBURN UNIVERSITY(5,2)
CHALLENGED BULL(5,2)
MONTANIDE ISA(5,2)
PERSISTENTLY INFECTED BULL(5,2)
VETERINARY MICROBIOLOGY(5,2)
ACUTE BVDV INFECTION(5,1)
ACUTE TESTICULAR INFECTION(5,1)
BVDV FETAL INFECTION(5,1)
BVDV INFECTION PERSISTENCE(5,1)
CODON ENCODING NUCLEOTIDE(5,1)
IMMUNOCOMPETENT SUSCEPTIBLE ANIMAL(5,1)
LA BVDV VIRUS STRAIN(5,1)
NONCYTOPATHIC BIOTYPE(5,1)
PERSISTENT BOVINE PESTIVIRUS INFECTION(5,1)
PFIZER ANIMAL HEALTH(5,1)
PROXIMAL DROPLET COINCIDING(5,1)
SEMEN VIROLOGICAL STATUS(5,1)
SEMI ANNUAL REVACCINATION(5,1)
SEVERE BVD OUTBREAK(5,1)
SUSCEPTIBLE INSEMINATED COW(5,1)
UNCASTRATED MALE CATTLE(5,1)
UNINFECTED HERD(5,1)
VIRULENT STRAIN ATTENUATION(5,1)
VIRUS NEUTRALIZATION ASSAY(5,1)
COMBINATION VACCINE(4,4)
BVDV TRANSMISSION(4,3)
IMMUNOHISTOCHEMISTRY(4,3)
SEMEN SAMPLE(4,3)
THROMBOCYTOPENIA(4,3)
BOVINE CYTOKINE(4,2)
BVDV DETECTION(4,2)
DIADEM DEFECT(4,2)
INOCULATED ANIMAL(4,2)
INTRA LYMPH NODE(4,2)
MEDICAMENT MANUFACTURE(4,2)
MINERAL OIL EMULSION(4,2)
PLURONIC POLYOL(4,2)
RT NPCR TESTING(4,2)
SAPONIN DERIVATIVE(4,2)
SEMEN RT NPCR(4,2)
SPERMATOZOAL HEAD(4,2)
ABORTION STORM(4,1)
AMPHIGEN ADJUVANT(4,1)
ARTIFICIALLY INDUCED INFECTION(4,1)
ASSESSING EFFICACY STUDY(4,1)
AVRIDINE LIPID(4,1)
BOOSTING REGIMEN(4,1)
BULL CONTINUOUSLY SHED VIRUS(4,1)
BVD VIRUS CAPACITY(4,1)
BVD VIRUS PURIFICATION(4,1)
BVDV BIOTYPE(4,1)
BVDV HIGHLY PATHOGENIC STRAIN(4,1)
BVDV INFECTION COMMON MANIFESTATION(4,1)
BVDV INFECTION DETECTION(4,1)
BVDV VACCINE MAIN CLASS(4,1)
CATTLE ECONOMICALLY SIGNIFICANT PATHOGEN(4,1)
CATTLE INSEMINATION(4,1)
CEREBRAL HYPOPLASIA(4,1)
CHALLENGE STUDY OVERVIEW(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CHOLESTEROL AMPHIGEN(4,1)
CLINICAL SCIENCE LABORATORY(4,1)
COMMERCIAL VACCINE MAJORITY(4,1)
CONFERENCE RE PROCEEDING(4,1)
DESCRIPTIVE STATISTIC(4,1)
EAR NOTCH BIOPSY SAMPLE(4,1)
FLAVIVIRIDAE FAMILY(4,1)
GALENICA PHARMACEUTICAL(4,1)
HERD FERTILITY(4,1)
HORSE SERUM SODIUM BICARBONATE(4,1)
IMMUNOCOMPETENT ANIMAL(4,1)
IMMUNOCOMPETENT BULL(4,1)
INFECTED HEIFER(4,1)
INFECTION SYMPTOM(4,1)
INSEMINATED HEIFER(4,1)
INVESTIGATOR TEAM(4,1)
LYOPHILIZED VACCINE(4,1)
MALE CATTLE SHEEP(4,1)
MONOPHOSPHORYL LIPID(4,1)
MORPHOLOGIC ABNORMALITY(4,1)
NADL SEQUENCE NUMBERING(4,1)
NEBRASKA LINCOLN(4,1)
NEEDLELESS ADMINISTRATION(4,1)
NONVIRAEMIC BULL(4,1)
NONVIREMIC BULL(4,1)
PESTIVIRUS GENUS(4,1)
PREGNANT HERDMATE(4,1)
PREPUBERAL VACCINATION(4,1)
PREVENTED TESTICULAR INFECTION(4,1)
SEMI ANNUAL SUBSEQUENT VACCINE(4,1)
SERONEGATIVE HEIFER(4,1)
SERUM VIRUS ISOLATION(4,1)
SPERMATOZOON MORPHOLOGY(4,1)
SPERMATOZOON MOTILITY(4,1)
TESTICLE BVDV(4,1)
TESTICLE INFECTION(4,1)
TESTICULAR BIOPSY SPECIMEN(4,1)
TESTICULAR SPECIMENSNO(4,1)
TIMELY VACCINATION(4,1)
VACCINATED CATTLE(4,1)
VACCINE INGREDIENT(4,1)
VACCINE LICENSING(4,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(4,1)
VIRUS FETAL TRANSMISSION(4,1)
VIRUS SHEDDING(4,1)
MODIFIED LIVE TYPE(3,12)
INTRANASAL(3,4)
ANTIBIOTIC(3,3)
LEUKOPENIA(3,3)
PLACEBO GROUP(3,3)
PRESERVATIVE(3,3)
ACTIVE INGREDIENT(3,2)
BVDV NUCLEIC ACID(3,2)
ISOTONIC AGENT(3,2)
MALE ANIMAL(3,2)
MINERAL GEL(3,2)
VEGETABLE OIL EMULSION(3,2)
ADMINISTRATION NECESSITY(3,1)
ADMINISTRATION SCHEDULE(3,1)
ADSORPTION DELAYING(3,1)
ANTIGEN CAPTURE COMPARISON(3,1)
ARTIFICIAL INSEMINATION FACILITY(3,1)
ARTIFICIAL INSEMINATION STATION(3,1)
BIOPSY IHC(3,1)
BOVINE REPRODUCTIVE TRACT(3,1)
BULL FERTILITY(3,1)
BVDV CONTEXT(3,1)
BVDV INFECTED ANIMAL DETECTION(3,1)
CALF BIRTH(3,1)
CATTLE PERCENTAGE(3,1)
CHOLERA TOXIN(3,1)
DISEASE SYMPTOM(3,1)
DOSAGE REGIMEN(3,1)
EMERYVILLE CALIF(3,1)
GESTATION DAY(3,1)
HIGHLY SPECIALIZED LABORATORY FACILITY(3,1)
HIGHLY TRAINED TECHNICIAN(3,1)
IMMUNOCOMPETENCY DEVELOPMENT(3,1)
IMMUNOMODULATORY AGENT(3,1)
INCOMPLETE ADJUVANT(3,1)
INFECTED TESTIS(3,1)
INFECTION ELEVATED RISK(3,1)
INTRAMUSCULAR ADMINISTRATION(3,1)
ISOLATING BVDV(3,1)
MINIMUM IMMUNIZING DOSE DETERMINATION(3,1)
NEUTRALIZING ANTIBODY PRESENCE(3,1)
OPTIMAL IMMUNIZATION(3,1)
PATHOGEN RESERVOIR(3,1)
PROLONGED VIREMIA(3,1)
REPRODUCTIVE LOSS VIRTUE(3,1)
SAPONIN FRACTION(3,1)
SAS INSTITUTE(3,1)
SEROLOGICAL STUDY(3,1)
SPERMATOZOON CONCENTRATION(3,1)
SPREAD RAPIDITY(3,1)
STRAIN NADL(3,1)
SUSCEPTIBLE CELL MONOLAYER(3,1)
TESTICULAR VIRAL INFECTION(3,1)
TISSUE CULTURE(3,1)
VACCINATED ANIMAL(3,1)
VACCINE DOSE(3,1)
VIRUS EXCRETION(3,1)
TCID(2,6)
ACTIVE SUBSTANCE(2,2)
ADJUVANT COMBINATION(2,2)
ALHYDROGEL(2,2)
BAYOLF(2,2)
BVDV COMPONENT(2,2)
CARBOPOL(2,2)
CODING SEQUENCE(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
GENOTYPE(2,2)
GENTAMICIN(2,2)
GLYCOSIDE(2,2)
LAND ANIMAL DISEASE(2,2)
LYSOLECITHIN(2,2)
MERTHIOLATE(2,2)
NECROPSY(2,2)
POLYANION(2,2)
SYMPTOMOLOGY(2,2)
VACCINE PRODUCTION(2,2)
VAGINAL ADMINISTRATION(2,2)
ACUTE INFECTION SOURCE(2,1)
AFFECTED HERD(2,1)
ALUMINUM HYDROXIDE GEL(2,1)
AMINE ADJUVANT(2,1)
ANIMAL AGE(2,1)
ANIMAL BREEDING(2,1)
ANIMAL NECK REGION(2,1)
ANIMAL PROPORTION(2,1)
ANIMAL SERUM(2,1)
ANIMAL SUFFERING(2,1)
BOVINE VIRUS DIARRHEA VIRUS INFECTION(2,1)
BRSV STRAIN(2,1)
BVD COMPONENT(2,1)
BVD VIRUS PRESENCE ABSENCE(2,1)
BVDV HORIZONTAL TRANSMISSION(2,1)
BVDV INFECTION CAUSE(2,1)
BVDV INFECTION RISK(2,1)
CATEGORICAL(2,1)
CATTLE CONDITION(2,1)
CATTLE INDUSTRY(2,1)
CELL CULTURE IMMUNOPEROXIDASE TEST(2,1)
CELL CULTURE INFECTIVE DOSE(2,1)
COW CALF(2,1)
DECREASED MOTILITY(2,1)
DEVELOPED VIREMIA(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
EARLY REPRODUCTIVE LOSS(2,1)
ELISA TECHNOLOGY(2,1)
ENZYME LINKED ASSAY(2,1)
ENZYME LINKED IMMUNOASSAY(2,1)
FEVER RANGING(2,1)
FUNCTIONALLY EQUIVALENT(2,1)
GENERALIZED RANDOMIZED BLOCK(2,1)
GENOMIC SITE(2,1)
GLYCINE RESIDUE(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
HUMORAL IMMUNE RESPONSE(2,1)
IHC TESTING(2,1)
IMMUNITY DURATION(2,1)
IMMUNOHISTOCHEMICAL ANALYSIS(2,1)
IMMUNOHISTOCHEMICAL DETECTION(2,1)
IMMUNOSUPPRESSION(2,1)
IMMUNOTOLERANCE(2,1)
LIVE STRAIN(2,1)
LIVE VIRUS(2,1)
MALE PIG(2,1)
MALE SHEEP(2,1)
MLV VACCINE SINGLE DOSE(2,1)
MODIFIED LIVE ANTIGEN(2,1)
MODIFIED LIVE BVDV PREPARATION(2,1)
MODIFIED LIVE VACCINE PREPARATION(2,1)
MURAMYL DIPEPTIDE(2,1)
NATURAL BREEDING(2,1)
PARAFFIN EMBEDDED TISSUE(2,1)
PCR ASSAY(2,1)
PI ANIMAL(2,1)
PORCINE CELL(2,1)
PRIMARY IMMUNIZATION(2,1)
QUALITY EVALUATION(2,1)
RT PCR(2,1)
SEROCONVERSION(2,1)
SEVERE CHALLENGE(2,1)
SEVERE DISEASE(2,1)
SIGNIFICANT CHALLENGE(2,1)
SUSCEPTIBLE COW(2,1)
TESTICULAR PROTECTION(2,1)
TESTICULAR SAMPLE(2,1)
TRANSMITTING BVDV(2,1)
VETERINARY DIAGNOSTIC CENTER(2,1)
VIRUS CONCENTRATION(2,1)
VIRUS PARTICLE(2,1)
WEEK LO(2,1)
(WO200589793)
VACCINE(100,54)
BVDV VACCINE(100,48)
SUSCEPTIBLE MALE ANIMAL(100,17)
TESTICULAR BVDV INFECTION(100,9)
LIVE BVDV VACCINE(98,6)
POSTPUBERAL BULL ACUTE INFECTION(72,1)
ACUTELY INFECTED BULL(66,4)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(65,5)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(65,3)
FETUS INFECTION PERSISTENCE(64,1)
BORGPETERSENII HARDJO BOVIS(63,5)
LEPTOSPIRA GRIPPOTYPHOSA(61,5)
LEPTOSPIRA INTERROGAN(60,5)
BVDV INFECTION PERSISTENCE(60,1)
LEPTOSPIRA CANICOLA(57,5)
MYCOBACTERIUM DISPAR(55,5)
CAMPYLOBACTER FETUS MANNHEIMIA(52,1)
BVDV TESTICULAR INFECTION(49,9)
INSEMINATED HEIFER(48,1)
PREGNANT HERDMATE(45,1)
INFECTED HEIFER(43,1)
BOVINE HERPES VIRUS(42,6)
NONVIREMIC BULL(40,1)
SERONEGATIVE CALF(39,2)
BULL FERTILITY(38,1)
ANTIBIOTIC UG ML(37,2)
REPRODUCTIVE LOSS VIRTUE(35,1)
PROXIMAL DROPLET(34,1)
SPERMATOZOON CONCENTRATION(34,1)
ANTIGEN(33,10)
ARTIFICIAL INSEMINATION STATION(33,1)
BOVI SHIELD GOLD(32,26)
ORAL EROSION(32,1)
TRANSMITTING BVDV(31,1)
PASTEURELLA MULTOCIDA(29,5)
DIADEM DEFECT(29,2)
BVDV HORIZONTAL TRANSMISSION(29,1)
TESTICULAR INFECTION(28,11)
MYCOBACTERIUM BOVIS(27,5)
NATURAL BREEDING(27,1)
BVD VIRUS(26,14)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(25,6)
SIGNIFICANT ECONOMIC IMPACT(25,1)
MEDICAMENT MANUFACTURE(24,3)
SPERMATOZOAL HEAD(24,2)
PASTEURELLA(23,5)
SUSCEPTIBLE MALE(23,4)
EXPOSURE DAY(23,1)
VIRUS ML(23,1)
LEPTOSPIRA(22,5)
SEROPOSITIVE(22,1)
TRANSMISSIBILITY(22,1)
ANIMAL(21,30)
MOTILITY(21,3)
INVESTIGATION(21,1)
SUBCLINICAL INFECTION(21,1)
BVDV TRANSMISSION(20,3)
INAPPETENCE(20,1)
UNCERTAINTY(20,1)
SEMEN(19,22)
ULCER(19,1)
DIARRHEA(17,1)
MORPHOLOGY(17,1)
BVDV(16,39)
DEPRESSION(16,1)
PERSISTENT TESTICULAR INFECTION(15,3)
INFECTION(14,13)
ANIMAL SUBJECT(14,3)
COW(14,1)
DEATH(14,1)
SERONEGATIVE POSTPUBERTAL BULL INOCULATION(14,1)
NON CYTOPATHOGENIC VIRUS(13,3)
TESTIS(13,3)
BOS TAURUS DNAJL(13,2)
INACTIVATED TYPE(12,18)
AGE MONTH(12,9)
BVDV CHALLENGE(12,5)
BOAR(12,4)
MODIFIED LIVE TYPE(11,16)
TESTICULAR BVDV INFECTION PREVENTION(11,1)
INCREASED RISK(10,5)
PERSISTENTLY INFECTED ANIMAL(10,2)
ACUTE POSTPUBERAL BVDV INFECTION(10,1)
NONVIREMIC POSTPUBERAL BULL(10,1)
PREPUBERAL BULL VACCINATION(10,1)
VETERINARY ACCEPTABLE CARRIER(9,7)
TESTICULAR SPECIMEN(9,3)
VETERINARY PHYSICIAN(9,3)
COLOSTRUM DEPRIVED BEEF CALF(9,1)
IBR BVDV1 BVDV2(9,1)
INTACT BEEF BREED BULL(9,1)
NEBRASKA LINCOLN UNIVERSITY(9,1)
RUMINANT PESTIVIRUS INFECTION DIAGNOSIS(9,1)
TESTICLE PERSISTENT INFECTION(9,1)
TREATING BVDV TESTICULAR INFECTION(9,1)
UG ML(9,1)
BVDV STRAIN(8,4)
BULL SEMEN(8,2)
EARLY EMBRYONIC DEATH(8,2)
SEMEN RT NPCR(8,2)
BVDV CPNADL VIRUS(8,1)
BVDV NONCYTOPATHIC STRAIN(8,1)
HEALTHY CATTLE VACCINATION(8,1)
PLACEBO VACCINATED BULL(8,1)
PREPUBERAL BULL CALF(8,1)
SUSCEPTIBLE HEIFER INSEMINATION(8,1)
TESTICULAR BIOPSY RT NPCR(8,1)
VACCINATING BULL EFFICACY(8,1)
ANNUAL BASIS(7,6)
IMMUNOHISTOCHEMISTRY(7,5)
IMMUNOGENIC(7,4)
AUBURN UNIVERSITY(7,2)
CHALLENGED BULL(7,2)
INTRAMUSCULAR INTRANASAL(7,2)
PERSISTENTLY INFECTED BULL(7,2)
ACUTE BVDV INFECTION(7,1)
ACUTE TESTICULAR INFECTION(7,1)
ATTENUATED CP BVDV1(7,1)
ATTENUATED CP BVDV2(7,1)
BULL VACCINATION CHALLENGE(7,1)
BVDV FETAL INFECTION(7,1)
CODON ENCODING NUCLEOTIDE(7,1)
HOMOLOGOUS VIRUS STRAIN(7,1)
IMMUNOCOMPETENT SUSCEPTIBLE ANIMAL(7,1)
LA BVDV VIRUS STRAIN(7,1)
NONCYTOPATHIC BIOTYPE(7,1)
PERSISTENT BOVINE PESTIVIRUS INFECTION(7,1)
PFIZER ANIMAL HEALTH(7,1)
PROXIMAL DROPLET COINCIDING(7,1)
SEMEN VIROLOGICAL STATUS(7,1)
SEMI ANNUAL REVACCINATION(7,1)
SERONEGATIVE HEIFER(7,1)
SEVERE BVD OUTBREAK(7,1)
SUSCEPTIBLE INSEMINATED COW(7,1)
UNCASTRATED MALE CATTLE(7,1)
UNINFECTED HERD(7,1)
UNIQUE DISPLAY CASE(7,1)
VIRULENT STRAIN ATTENUATION(7,1)
VIRUS NEUTRALIZATION ASSAY(7,1)
BOVINE VIRAL DIARRHEA VIRUS(6,7)
FISHER EXACT TEST(6,3)
BOVINE CYTOKINE(6,2)
INOCULATED ANIMAL(6,2)
PLURONIC POLYOL(6,2)
RT NPCR TESTING(6,2)
SAPONIN DERIVATIVE(6,2)
ARTIFICIALLY INDUCED INFECTION(6,1)
ASSESSING EFFICACY STUDY(6,1)
BULL CONTINUOUSLY SHED VIRUS(6,1)
BVD VIRUS PURIFICATION(6,1)
BVDV BIOTYPE(6,1)
BVDV HIGHLY PATHOGENIC STRAIN(6,1)
CATTLE ECONOMICALLY SIGNIFICANT PATHOGEN(6,1)
CATTLE INSEMINATION(6,1)
CEREBRAL HYPOPLASIA(6,1)
CHOLESTEROL AMPHIGEN(6,1)
HERD FERTILITY(6,1)
IMMUNOCOMPETENT BULL(6,1)
LIPID AMINE ADJUVANT(6,1)
MALE CATTLE SHEEP(6,1)
MOHOLOGIC ABNORMALITY(6,1)
PREPUBERAL VACCINATION(6,1)
SEMEN RT PCR(6,1)
SPERMATOZOON MORPHOLOGY(6,1)
SPERMATOZOON MOTILITY(6,1)
TESTICLE BVDV(6,1)
TESTICLE INFECTION(6,1)
VACCINE LICENSING(6,1)
VIRUS SHEDDING(6,1)
COMBINATION VACCINE(5,4)
SEMEN SAMPLE(5,3)
THROMBOCYTOPENIA(5,3)
BVDV DETECTION(5,2)
BVDV INFECTION RISK(5,2)
MALE ANIMAL(5,2)
MINERAL OIL EMULSION(5,2)
ABORTION STORM(5,1)
ADSOTION DELAYING AGENT(5,1)
BOOSTING REGIMEN(5,1)
BOVINE HEESVIRUS(5,1)
BULL TESTIS(5,1)
BVD VIRUS CAPACITY(5,1)
BVDV INFECTION COMMON MANIFESTATION(5,1)
BVDV INFECTION DETECTION(5,1)
BVDV VACCINE MAIN CLASS(5,1)
CHEMICALLY INDUCED MUTATION(5,1)
CLINICAL SCIENCE LABORATORY(5,1)
COMMERCIAL VACCINE MAJORITY(5,1)
CONFERENCE RE PROCEEDING(5,1)
CYTOTOXIC T CELL(5,1)
DESCRIPTIVE STATISTIC(5,1)
EAR NOTCH BIOPSY SAMPLE(5,1)
FLAVIVIRIDAE FAMILY(5,1)
HELPER T CELL(5,1)
IMMUNOCOMPETENT ANIMAL(5,1)
INFECTION SYMPTOM(5,1)
LYOPHILIZED VACCINE(5,1)
NEEDLELESS ADMINISTRATION(5,1)
NONVIRAEMIC BULL(5,1)
PESTIVIRUS GENUS(5,1)
SERUM VIRUS ISOLATION(5,1)
TESTICULAR BIOPSY SPECIMEN POSITIVE(5,1)
TIMELY VACCINATION(5,1)
TREATMENT VACCINATION CHALLENGE(5,1)
VACCINATED CATTLE(5,1)
VACCINE INGREDIENT(5,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(5,1)
VETERINARY MICROBIOLOGY(5,1)
VIRUS FETAL TRANSMISSION(5,1)
LEUKOPENIA(4,3)
PLACEBO GROUP(4,3)
PRESERVATIVE(4,3)
ACTIVE INGREDIENT(4,2)
BVDV NUCLEIC ACID(4,2)
ISOTONIC AGENT(4,2)
MINERAL GEL(4,2)
SAMPLING DAY(4,2)
VEGETABLE OIL EMULSION(4,2)
ADMINISTRATION NECESSITY(4,1)
ADMINISTRATION SCHEDULE(4,1)
ANTIGEN CAPTURE COMPARISON(4,1)
ARTIFICIAL INSEMINATION FACILITY(4,1)
BOVINE REPRODUCTIVE TRACT(4,1)
BVDV CONTEXT(4,1)
CALF BIRTH(4,1)
CATTLE PERCENTAGE(4,1)
CHOLERA TOXIN(4,1)
DISEASE SYMPTOM(4,1)
DOSAGE REGIMEN(4,1)
EMERYVILLE CA(4,1)
EQUINE SERUM SODIUM BICARBONATE(4,1)
GESTATION DAY(4,1)
HIGHLY SPECIALIZED LABORATORY FACILITY(4,1)
HIGHLY TRAINED TECHNICIAN(4,1)
HORSE SERUM(4,1)
IMMUNOCOMPETENCY DEVELOPMENT(4,1)
IMMUNOMODULATORY AGENT(4,1)
INFECTED TESTIS(4,1)
INFECTION ELEVATED RISK(4,1)
INTRAMUSCULAR ADMINISTRATION(4,1)
ISOLATING BVDV(4,1)
MINIMUM IMMUNIZING DOSE DETERMINATION(4,1)
NEUTRALIZING ANTIBODY PRESENCE(4,1)
OPTIMAL IMMUNIZATION(4,1)
PATHOGEN RESERVOIR(4,1)
PROLONGED VIREMIA(4,1)
SAPONIN FRACTION(4,1)
SEROLOGICAL STUDY(4,1)
SPREAD RAPIDITY(4,1)
SUSCEPTIBLE CELL MONOLAYER(4,1)
TESTICULAR VIRAL INFECTION(4,1)
TISSUE CULTURE(4,1)
VACCINATED ANIMAL(4,1)
VACCINE DOSE(4,1)
VIRUS EXCRETION(4,1)
O ML(3,3)
ACTIVE SUBSTANCE(3,2)
ADJUVANT COMBINATION(3,2)
ALHYDROGEL(3,2)
BAYOLF(3,2)
BPERCENT(3,2)
BVDV COMPONENT(3,2)
CARBOPOL(3,2)
CODING SEQUENCE(3,2)
DEXTROSE(3,2)
EMULSIFIER(3,2)
FETUS(3,2)
GENOTYPE(3,2)
GENTAMICIN(3,2)
GLYCOSIDE(3,2)
LYSOLECITHIN(3,2)
MEDICAMENT(3,2)
NECROPSY(3,2)
POLYANION(3,2)
SYMPTOMOLOGY(3,2)
THIMEROSAL(3,2)
VACCINE PRODUCTION(3,2)
VAGINAL ADMINISTRATION(3,2)
ACUTE INFECTION SOURCE(3,1)
AFFECTED HERD(3,1)
ANIMAL AGE(3,1)
ANIMAL BREEDING(3,1)
ANIMAL IDENTIFICATION(3,1)
ANIMAL NECK REGION(3,1)
ANIMAL PROPORTION(3,1)
ANIMAL SERUM(3,1)
ANIMAL SUFFERING(3,1)
BOVINE VIRUS DIARRHEA VIRUS INFECTION(3,1)
BVD COMPONENT(3,1)
BVD VIRUS PRESENCE ABSENCE(3,1)
BVDV INFECTION CAUSE(3,1)
CAMBRIDGE MA(3,1)
CATEGORICAL(3,1)
CATTLE CONDITION(3,1)
CATTLE INDUSTRY(3,1)
CELL CULTURE IMMUNOPEROXIDASE TEST(3,1)
CELL CULTURE INFECTIVE DOSE(3,1)
COW CALF(3,1)
DECREASED MOTILITY(3,1)
DEVELOPED VIREMIA(3,1)
DOSE MULTIPLE ADMINISTRATION(3,1)
EARLE SALT(3,1)
EARLY REPRODUCTIVE LOSS(3,1)
ELISA TECHNOLOGY(3,1)
ENZYME LINKED ASSAY(3,1)
ENZYME LINKED IMMUNOASSAY(3,1)
FEVER RANGING(3,1)
FUNCTIONALLY EQUIVALENT(3,1)
GENERALIZED RANDOMIZED BLOCK(3,1)
GENOMIC SITE(3,1)
GLYCINE RESIDUE(3,1)
HEAT LABILE ENTEROTOXIN(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
IMMUNITY DURATION(3,1)
IMMUNOHISTOCHEMICAL ANALYSIS(3,1)
IMMUNOHISTOCHEMICAL DETECTION(3,1)
IMMUNOSUPPRESSION(3,1)
IMMUNOTOLERANCE(3,1)
L CSTI ULAR PROTECTION(3,1)
LIVE STRAIN(3,1)
MALE PIG(3,1)
MALE SHEEP(3,1)
MODIFIED LIVE ANTIGEN(3,1)
MODIFIED LIVE BVDV PREPARATION(3,1)
MODIFIED LIVE VACCINE PREPARATION(3,1)
MURAMYL DIPEPTIDE(3,1)
PARAFFIN EMBEDDED TISSUE(3,1)
PCR ASSAY(3,1)
PI ANIMAL(3,1)
PORCINE CELL(3,1)
POSITIVE BVDV(3,1)
PRIMARY IMMUNIZATION(3,1)
QUALITY EVALUATION(3,1)
SAS STAT SOFTWARE CHANGE(3,1)
SEMI ANNUAL SUBSEQUENT VACCINE(3,1)
SEROCONVERSION(3,1)
SEVERE CHALLENGE(3,1)
SUSCEPTIBLE COW(3,1)
TESTICULAR SAMPLE(3,1)
VETERINARY DIAGNOSTIC CENTER(3,1)
VIRUS CONCENTRATION(3,1)
VIRUS PARTICLE(3,1)
(JP2007529498)
VACCINE(100,59)
INFECTION(100,30)
ANIMAL(100,25)
BOVINE VIRAL DIARRHEA VIRUS(100,23)
BOVINE(100,17)
MALE ANIMAL(100,12)
VACCINATION(100,8)
INACTIVATED VACCINE(100,6)
TESTICULAR INFECTION(100,4)
VIRAL DIARRHEA VIRUS(100,3)
MEDICAMENT MANUFACTURE(100,2)
INFECTION BVDV TESTIS(100,1)
SUSCEPTIBILITY INCREASED RISK(100,1)
TESTICULAR MALE(100,1)
TESTICULAR SENSITIVITY(100,1)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(80,1)
MICROPHONE TERRORISM HAEMOPHILUS RAJ(74,4)
LEPTOSPIRA BORGPETERSENII HARDIOPRAJITNO(67,4)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(59,5)
BORGPETERSENII HARDJO BOVIS(57,5)
LEPTOSPIRA INTERROGAN(54,5)
HARUJO AD BOVIS(54,2)
MYCOBACTERIUM DISPAR(50,5)
LEPTOSPIRA(47,41)
CAMPYLOBACTER FETUS MANNHEIMIA(47,1)
LEPTOSPIRA GRIPPOTYPHOSA(47,1)
BVDV INFECTION ANIMAL(45,1)
LEPTOSPIRA CANICOLA(43,1)
CHOLESTEROL AMPHIGEN(40,1)
NON PATHOGENIC VIRUS(37,2)
VIRAL DIARRHEA VIRUS INFECTION(37,1)
CATTLE IMMUNIZATION(30,1)
TESTIS PREVENTION(28,1)
PASTEURELLA MULTOCIDA(26,5)
ANTIGEN(24,10)
MYCOBACTERIUM BOVIS(24,5)
PASTEURELLOSIS(23,6)
INFECTION PREVENTION(23,3)
SHEEP MALE(23,3)
MOST CONSISTENT INFECTION SEMEN(22,1)
BVD VIRUS(21,11)
PASTEURELLA(21,5)
BOVI SHIELD GOLD(18,11)
MANNHEIMIA HAEMOLYTICA(18,4)
PIV(17,9)
SUSCEPTIBLE ANIMAL(17,7)
GEO PLASTICS(17,4)
IMMUNOGENIC(17,4)
HERPES(16,7)
COW(15,6)
JISUPARU ADDITIONAL ANTIGEN(15,1)
BULL(14,13)
VACCINE DOSAGE ADMINISTRATION(14,5)
LIVE VACCINE BVDV(14,4)
TESTICULAR BVDV INFECTION PREVENTION(14,2)
BVDV1(14,1)
ADJUVANT(13,13)
BRSV(13,1)
IMMUNE RESPONSE(12,5)
BOS TAURUS DNAJ(12,2)
TESTIS(11,7)
PIG(11,5)
INACTIVATED BVDV VACCINE(11,2)
PERSISTENT TESTICULAR INFECTION(11,2)
BVDV(10,28)
SUSCEPTIBLE MALE ANIMAL(10,6)
EYE TESTICULAR BIOPSY(10,2)
AGE COLOSTRUM DEPRIVATION MONTH(10,1)
TESTICULAR INFECTION BVD VIRUS(10,1)
RE VACCINATION(9,7)
VACCINE FORMULATION VIRUS(9,2)
BOVINE FEMALE USHIKO BVD(9,1)
GOLD 5BVDV TESTICULAR INFECTION(9,1)
HEALTHY CATTLE AGE VACCINATION(9,1)
IMMUNIZATION DOSE(8,4)
RT PCR ANALYSIS(8,4)
SHEEP(8,4)
PERSISTENT INFECTION ANIMAL(8,2)
FURABIBIRIDE PESTIVIRUS VIRUS(8,1)
IMMUNOCOMPETENT BULL TESTIS(8,1)
RUMINANT PESTIVIRUS INFECTION DIAGNOSIS(8,1)
TESTICULAR BVDV SUMMARIZING DETECTION(8,1)
SENSITIVE MALE ANIMAL(7,4)
LIVE BVDV(7,3)
ARTIFICIAL FERTILIZATION(7,2)
ACUTE BVDV INFECTION(7,1)
ARTIFICIAL ANIMAL BREEDING FACILITY(7,1)
BVDV CPNADL VIRUS(7,1)
BVDV INFECTION PERSISTENCE(7,1)
BVDV TESTICULAR INFECTION SENSITIVE(7,1)
BVDV VACCINE FORMULATION(7,1)
CALF BVDV BIRTH(7,1)
FETUS INFECTION PERSISTENCE(7,1)
IMMUNOCOMPETENT ANIMAL ACUTE INFECTION(7,1)
KILLED BVDV VACCINE(7,1)
TESTICULAR BVDV INFECTION TREATMENT(7,1)
TESTIS BVDV INFECTION(7,1)
TESTIS PERSISTENT INFECTION(7,1)
VACCINE INACTIVATED BVDV(7,1)
VIRUS NEUTRALIZATION ASSAY(7,1)
CALF HEAD(6,5)
VETERINARY ACCEPTABLE CARRIER(6,5)
FISHER EXACT TEST(6,3)
BVDV VIRUS(6,2)
FOOD ANIM PRACT(6,2)
PROXIMAL DROPLET(6,2)
SAPONIN DERIVATIVE(6,2)
VETERINARILY ACCEPTABLE CARRIER(6,2)
BOVINE MALE VACCINATION(6,1)
BVDV CLINICALLY SYMPTOMATIC REMAINS(6,1)
BVDV INFECTION STUDY(6,1)
CASTRATED MALE CATTLE(6,1)
CASTRATED MALE PIG(6,1)
CASTRATED MALE SHEEP(6,1)
CELL IMMUNOCOMPETENT INSENSITIVITY(6,1)
EXPRESSION BVDV INFECTION(6,1)
RT NPCR BVD VIRUS(6,1)
VACCINE VIRUS(6,1)
PLACEBO GROUP(5,7)
THROMBOCYTOPENIA(5,4)
BVDV TRANSMISSION(5,3)
ANIMAL AGE(5,2)
ANIMAL IDENTIFICATION(5,2)
BIOLOGICAL SIGN(5,2)
EARLY FETAL DEATH(5,2)
HORSE SERUM(5,2)
MAMMALIAN PATIENT(5,2)
SPERM CONCENTRATION(5,2)
SUBCUTANEOUS ROUTE(5,2)
ABORTION OUTB(...)";Pharmaceuticals;Open
2003-08-11;"RU2003124954        A  2005-02-10 [RU2003124954]
STG: (A) Application for invention
AP : 2003RU-0124954 2003-08-11
RU2255976           C2 2005-07-10 [RU2255976]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2003RU-0124954 2003-08-11";36207830;"RU2003124954        A  2005-02-10 [RU2003124954]
RU2255976           C2 2005-07-10 [RU2255976]";2003RU-0124954;;GOSUDARSTVENNOE NAUCHNOE UCHREZHDENIE INSTITUT EHKSPERIMENTAL NOJ VETERINARII SIBIRI I DAL NEGO VOSTOKA SIBIRSKOGO OTDELENIJA ROSSEL KHOZAKADEMII;GOSUDARSTVENNOE NAUCHNOE UCHREZHDENIE INSTITUT EHKSPERIMENTAL NOJ VETERINARII SIBIRI I DAL NEGO VOSTOKA SIBIRSKOGO OTDELENIJA ROSSEL KHOZAKADEMII;;;1;"GLOTOV A G
GLOTOVA T I";;;"(RU2255976)
Method for detecting virus-neutralizing antibodies at viral diarrhea as mucosal disease in cattle";"(RU2255976)
FIELD: veterinary science. ^ SUBSTANCE: the present innovation deals with serological diagnostics of infectious diseases in cattle, viral diarrhea as mucosal disease in cattle (cattle VD) and evaluation of immunity strength in vaccinated animals. The method deals with growing finite cell line of coronary vessels in cow's embryo in Eagle's MEM nutritive medium with 20 mg/ml kanamycin and 10% equine serum. Double dilutions of inactivated tested serumal samples (56 C, 30 min) should be mixed at equal volume (0.05 ml) with 100 TCD50/0.1 ml virus to be incubated for 1 h at 37 C in CO2-incubator. On finishing the incubation one should add 0.1 ml suspension of the above-mentioned finite cell line in Eagle's MEM nutritive medium containing 20 mg/ml kanamycin and 5% (2.5% final concentration) of equine serum. Cell concentration in the culture corresponds to 3.5 x 105. Reaction registration should be carried out in 3 d while cytopathogenic viral action appears in control holes containing working viral dosage. The innovation enables to widen the number of diagnostic immunological methods for veterinary purposes. ^ EFFECT: higher efficiency of detection. ^ 1 cl, 7 ex, 2 tbl";"(RU2255976)
1. The Method of the development of the virus-neutralizing antibodies with virus diarrhea of the mucous membranes of large livestock, which includes neutralization reaction with the antibodies of the blood serum of the animal cytotoxic action of virus in the culture of cells, that is characterized by the fact that the reaction is carried out by micromethod with the use of the interwoven line of the culture of the cells of the coronary vessels of the embryo of cow (KST)), preliminarily grown in nutrient medium Needle MEM with 20 mg/ml of Kanamycin and 10% of blood serum of horse, in this case incubate the serum of animals and 100 TTSTS 50/0,1 of ml of virus being investigated with 37°S WITH [2] - incubator, add 0,1 ml of the suspension of the culture of cells KST in the concentration of 3,5×10 in nutrient medium Needle, that contains 20 mg/ml of Kanamycin and 5% (2,5% final concentration) of the blood serum of horse respectively, and the calculation of reaction is carried out after 3 days.
2. Method according to claim 1, that is characterized by the fact that the reaction is carried out in the micro-plane-tables for the cultures of cells.";;;"A61K-039/00
C12N-005/00
G01N-033/50";;;"Analysis of biological materials
Pharmaceuticals";Open
"2003-07-29
2004-07-16
2004-07-26
2008-04-04";"WO2005021034        A2 2005-03-10 [WO200521034]
STG: (A2) International application published without international search report
AP : 2004WO-US24011 2004-07-26
CA2533877           A1 2005-03-10 [CA2533877]
STG: (A1) Application laid open
AP : 2004CA-2533877 2004-07-26
AU2004268514        A1 2005-03-10 [AU2004268514]
STG: (A1) Open to public inspection
AP : 2004AU-0268514 2004-07-26
US20050053621       A1 2005-03-10 [US20050053621]
STG: (A1) Application published
AP : 2004US-10893712 2004-07-16
TW200514568         A  2005-05-01 [TW200514568]
STG: (A) Laid open application for patent or patent of addition
AP : 2004TW-0122607 2004-07-28
WO2005021034        A3 2005-12-29 [WO200521034]
STG: (A3) Later publication of ISR with revised front page
AP : 2004WO-US24011 2004-07-26
IS8254              A  2006-01-23 [IS---8254]
STG: (A) Patent application made available to the public
AP : 2006IS-0008254 2006-01-23
NO20060931          L  2006-04-27 [NO20060931]
STG: (L) Abstract
AP : 2006NO-0000931 2006-02-27
EP1651263           A2 2006-05-03 [EP1651263]
STG: (A2) Application published without search report
AP : 2004EP-0801973 2004-07-26
IL173338            A  2006-06-11 [IL-173338]
STG: (A) Application of patent for invention
AP : 2004IL-0173338 2004-07-26
KR10-2006-0092198   A  2006-08-22 [KR20060092198]
STG: (A) Published application
AP : 2006KR-7002112 2006-01-31
BRPI0413107         A  2006-10-03 [BR200413107]
STG: (A) Published application
AP : 2004BR-0013107 2004-07-26
BRPI0413107         A1 2006-10-03 [BRPI0413107]
STG: (A1) Published application
AP : 2004BR-0013107 2004-07-26
EA200600121         A1 2006-10-27 [EA200600121]
STG: (A1) Public. of applic. with search report
AP : 2006EA-0000121 2004-07-26
JP2007500702        A  2007-01-18 [JP2007500702]
STG: (A) Published application
AP : 2006JP-0521967 2004-07-26
ZA200600585         B  2007-03-28 [ZA200600585]
STG: (B)
AP : 2006ZA-0000585 2006-01-20
CN1976717           A  2007-06-06 [CN1976717]
STG: (A) Published application
AP : 2004CN-80028362 2004-07-26
IN0342/DELNP/2006   A  2007-08-17 [IN2006DN00342]
STG: (A) Application laid open
AP : 2006IN-DN00342 2006-01-19
TNSN06031           A1 2007-10-03 [TN0600031]
STG: (A1) Application for a patent of invention
AP : 2006TN-0000031 2006-01-27
EA009391            B1 2007-12-28 [EA---9391]
STG: (B1) Patent
AP : 2006EA-0000121 2004-07-26
KR100810820         B1 2008-03-06 [KR100810820]
STG: (B1) Patent specification
AP : 2006KR-7002112 2006-01-31
US7361357           B2 2008-04-22 [US7361357]
STG: (B2) Granted patent as second publication
AP : 2004US-10893712 2004-07-16
FD :  Provisional Appl: US60/490,834 FDD=2003-07-29 [2003US-60490834]
FD : Previous publication: US20050053621 A1 2005-03-10 [US20050053621]
RS20060045          A  2008-06-05 [RS200600045]
STG: (A) Laid open patent application
AP : 2006YU-0000045 2004-07-26
US20080286302       A1 2008-11-20 [US20080286302]
STG: (A1) Application published
AP : 2008US-12098015 2008-04-04
NZ545612            A  2009-11-27 [NZ-545612]
STG: (A) Published application
AP : 2004NZ-0545612 2004-07-26
AU2004268514        B2 2010-01-21 [AU2004268514]
STG: (B2) Patent proceeded by OPI
AP : 2004AU-0268514 2004-07-26
IN239729            B  2010-04-09 [IN-239729]
STG: (B) Patent
AP : 2006IN-DN00342 2006-01-19
US7754222           B2 2010-07-13 [US7754222]
STG: (B2) Granted patent as second publication
AP : 2008US-12098015 2008-04-04
FD :  Continuation of: US10/893,712 FDD=2004-07-16 [2004US-10893712]
FD : Continuation of: US7361357 A 2008-04-22 [US7361357]
FD : Provisional Appl: US60/490,834 FDD=2003-07-29 [2003US-60490834]
FD : Previous publication: US20080286302 A1 2008-11-20 [US20080286302]
EP1651263           B1 2010-11-24 [EP1651263]
STG: (B1) Patent specification
AP : 2004EP-0801973 2004-07-26
AT489107            T  2010-12-15 [ATE489107]
STG: (T) EP patent valid in AT
AP : 2004AT-0801973T 2004-07-26
DE602004030253      D1 2011-01-05 [DE602004030253]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2004DE-60030253 2004-07-26
JP4662931           B2 2011-01-14 [JP4662931]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2006JP-0521967 2004-07-26
PT1651263           E  2011-01-25 [PT1651263]
STG: (E) Availability of national translation of European patent
AP : 2004PT-0801973T 2004-07-26
DK1651263           T3 2011-01-31 [DK1651263T]
STG: (T3) Translation of EP patent
AP : 2004DK-0801973 2004-07-26
EP1651263           B9 2011-02-16 [EP1651263]
STG: (B9) Corrected complete granted patent
AP : 2004EP-0801973 2004-07-26
SI1651263           T1 2011-02-28 [SI1651263T]
STG: (T1) Translation of EP claims
AP : 2004SI-0031575 2004-07-26
ES2355276           T3 2011-03-24 [ES2355276]
STG: (T3) Translation of granted European patent (former B3)
AP : 2004ES-0801973T 2004-07-26
ES2355276           T9 2011-03-25 [ES2355276]
STG: (T9) Corrected complete translated European patent application
AP : 2004ES-0801973T 2004-07-26
RS51456             B  2011-04-30 [RS--51456]
STG: (B) Patent Specification
AP : 2006YU-0000045 2004-07-26
TWI342783           B  2011-06-01 [TWI342783]
STG: (B) Granted patent or patent of addition
AP : 2004TW-0122607 2004-07-28
CA2533877           C  2011-09-06 [CA2533877]
STG: (C) Patent (second level)
AP : 2004CA-2533877 2004-07-26
BRPI0413107         A2 2012-03-13 [BR200413107]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2004BR-0013107 2004-07-26
CY1110995           T1 2015-06-11 [CY1110995]
STG: (T1) Translation of EP granted patent
AP : 2010CY-1101159 2010-12-16";5197143;"WO2005021034        A2 2005-03-10 [WO200521034]
CA2533877           A1 2005-03-10 [CA2533877]
AU2004268514        A1 2005-03-10 [AU2004268514]
US20050053621       A1 2005-03-10 [US20050053621]
TW200514568         A  2005-05-01 [TW200514568]
WO2005021034        A3 2005-12-29 [WO200521034]
IS8254              A  2006-01-23 [IS---8254]
NO20060931          L  2006-04-27 [NO20060931]
EP1651263           A2 2006-05-03 [EP1651263]
IL173338            A  2006-06-11 [IL-173338]
KR10-2006-0092198   A  2006-08-22 [KR20060092198]
BRPI0413107         A  2006-10-03 [BR200413107]
BRPI0413107         A1 2006-10-03 [BRPI0413107]
EA200600121         A1 2006-10-27 [EA200600121]
JP2007500702        A  2007-01-18 [JP2007500702]
ZA200600585         B  2007-03-28 [ZA200600585]
CN1976717           A  2007-06-06 [CN1976717]
IN0342/DELNP/2006   A  2007-08-17 [IN2006DN00342]
TNSN06031           A1 2007-10-03 [TN0600031]
EA009391            B1 2007-12-28 [EA---9391]
KR100810820         B1 2008-03-06 [KR100810820]
US7361357           B2 2008-04-22 [US7361357]
RS20060045          A  2008-06-05 [RS200600045]
US20080286302       A1 2008-11-20 [US20080286302]
NZ545612            A  2009-11-27 [NZ-545612]
AU2004268514        B2 2010-01-21 [AU2004268514]
IN239729            B  2010-04-09 [IN-239729]
US7754222           B2 2010-07-13 [US7754222]
EP1651263           B1 2010-11-24 [EP1651263]
AT489107            T  2010-12-15 [ATE489107]
DE602004030253      D1 2011-01-05 [DE602004030253]
JP4662931           B2 2011-01-14 [JP4662931]
PT1651263           E  2011-01-25 [PT1651263]
DK1651263           T3 2011-01-31 [DK1651263T]
EP1651263           B9 2011-02-16 [EP1651263]
SI1651263           T1 2011-02-28 [SI1651263T]
ES2355276           T3 2011-03-24 [ES2355276]
ES2355276           T9 2011-03-25 [ES2355276]
RS51456             B  2011-04-30 [RS--51456]
TWI342783           B  2011-06-01 [TWI342783]
CA2533877           C  2011-09-06 [CA2533877]
BRPI0413107         A2 2012-03-13 [BR200413107]
CY1110995           T1 2015-06-11 [CY1110995]";"2003US-60490834
2004EP-0801973
2004US-10893712
2004WO-US24011
2008US-12098015";"(EP1651263)
WO2005021034
(DE602004030253)
WO2005021034
(JP4662931)
WO2005021034
(IS---8254)
WO2005021034
(NO20060931)
WO2005021034
(IL-173338)
WO2005021034
(ZA200600585)
WO2005021034
(CN1976717)
WO2005021034
(TN0600031)
WO2005021034
(EA---9391)
WO2005021034
(KR100810820)
WO2005021034
(NZ-545612)
WO2005021034
(AU2004268514)
WO2005021034
(IN-239729)
WO2005021034
(ATE489107)
WO2005021034
(DK1651263T)
WO2005021034
(SI1651263T)
WO2005021034
(RS--51456)
WO2005021034
(CA2533877)
WO2005021034
(BR200413107)
WO2005021034
(CY1110995)
WO2005021034";"JECHEVIT
PFIZER
PFIZER PRODUCTS
ZOETIS
ZOETIS SERVICES";"PFIZER
ZOETIS SERVICES";"(EP1651263)
US
(EP1651263)
US
(EP1651263)
US
(US7361357)
US
(US20080286302)
US
(US7754222)
US
(WO200521034)
US


(IN2006DN00342)
US
(CA2533877)
US
(CA2533877)
US
(BRPI0413107)
US
(BR200413107)
US";"(EP1651263)
NAME=Welch, Siao-Kun Wan 9087 South 6th Street , CITY=Kalamazoo, MI 49009 , COUNTRY=US 

NAME=Calvert, Jay Gregory 27 Stonybrook Road , CITY=Gales Ferry, CT 06335 , COUNTRY=US 

NAME=O'Hara, Michael K. 1218 Oshtemo Trace , CITY=Kalamazoo, MI 49009 , COUNTRY=US 

NAME=Cao, Xuemei 97 Stockbridge Road , CITY=Scituate, MA 02066 , COUNTRY=US 

(EP1651263)
NAME=Zoetis Services LLC 10 Sylvan Way , CITY=Parsippany, NJ 07054 , COUNTRY=US , REG=101630447 

(EP1651263)
NAME=Pfizer Products Inc. Eastern Point Road , CITY=Groton, CT 06340 , COUNTRY=US , REG=100198232 

(US7361357)
NAME=Pfizer Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Pfizer Products Inc. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 

(US20080286302)
NAME=PFIZER INC. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=PFIZER PRODUCTS INC. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 

(US7754222)
NAME=Pharmacia & Upjohn Company, LLC , CITY=Kalamazoo , STATE=MI , COUNTRY=US , ATYP=US Company 

(WO200521034)
NAME=WELCH, Siao-Kun, Wan  [US/ US] 9087 South 6th Street, Kalamazoo, MI 49009  , COUNTRY=US 

NAME=CALVERT, Jay, Gregory  [US/ US] 27 Stonybrook Road, Gales Ferry, CT 06335  , COUNTRY=US 

NAME=O'HARA, Michael, K.  [US/ US] 1218 Oshtemo Trace, Kalamazoo, MI 49009  , COUNTRY=US 

NAME=CAO, Xuemei  [US/ US] 97 Stockbridge Road, Scituate, MA 02066  , COUNTRY=US 

(JP2007500702)
NAME=Pfizer Ink Products , REG=397067152 

(JP4662931)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(TN0600031)
NAME=PFIZER PRODUCTS INC. EASTERN POINT ROAD, GROTON, CONNECTICUT 06340 USA 

(IN2006DN00342)
NAME=PFIZER PRODUCTS INC EASTERN POINT ROAD, GROTON, CONNECTICUT 06340  , COUNTRY=US 

(CA2533877)
NAME=WELCH SIAO-KUN WAN 9087 South 6th Street, KALAMAZOO, MI, 49009 , COUNTRY=US 

NAME=CALVERT JAY GREGORY 27 Stonybrook Road, GALES FERRY, CT, 06335 , COUNTRY=US 

NAME=O'HARA MICHAEL K 1218 Oshtemo Trace, KALAMAZOO, MI, 49009 , COUNTRY=US 

NAME=CAO XUEMEI 97 Stockbridge Road, SCITUATE, MA, 02066 , COUNTRY=US 

(CA2533877)
NAME=WELCH SIAO-KUN WAN 9087 South 6th Street, KALAMAZOO, MI, 49009 , COUNTRY=US 

NAME=CALVERT JAY GREGORY 27 Stonybrook Road, GALES FERRY, CT, 06335 , COUNTRY=US 

NAME=O'HARA MICHAEL K 1218 Oshtemo Trace, KALAMAZOO, MI, 49009 , COUNTRY=US 

NAME=CAO XUEMEI 97 Stockbridge Road, SCITUATE, MA, 02066 , COUNTRY=US 

(BRPI0413107)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 

(BR200413107)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 
";2;"WELCH SIAO-KUN WAN
CALVERT JAY GREGORY
O'HARA MICHAEL K
CAO XUEMEI";"(EP1651263)
US
(EP1651263)
US";"(EP1651263)
NAME=Welch, Siao-Kun Wan 9087 South 6th Street Kalamazoo, MI 49009 , COUNTRY=US 

NAME=Calvert, Jay Gregory 27 Stonybrook Road Gales Ferry, CT 06335 , COUNTRY=US 

NAME=O'Hara, Michael K. 1218 Oshtemo Trace Kalamazoo, MI 49009 , COUNTRY=US 

NAME=Cao, Xuemei 97 Stockbridge Road Scituate, MA 02066 , COUNTRY=US 

(EP1651263)
NAME=Welch, Siao-Kun Wan 9087 South 6th Street Kalamazoo, MI 49009 , COUNTRY=US 

NAME=Calvert, Jay Gregory 27 Stonybrook Road Gales Ferry, CT 06335 , COUNTRY=US 

NAME=O'Hara, Michael K. 1218 Oshtemo Trace Kalamazoo, MI 49009 , COUNTRY=US 

NAME=Cao, Xuemei 97 Stockbridge Road Scituate, MA 02066 , COUNTRY=US 
";"(EP1651263)
Safe mutant viral vaccines";"(EP1651263)
The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.";"(WO200521034)
What is claimed is:
1. A vaccine composition comprising at least two live mutant viruses of the same family, wherein each virus contains a mutation in the viral genome, and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
2. The vaccine composition of claim 1 , wherein said family is the family of Flaviviridae.
3. The vaccine composition of claim 1 , wherein said two live mutant viruses are both from the genus of Pestivirus.
4. The vaccine composition of claim 1 , wherein the two mutant live viruses consist of a mutant BVDV-1 and a mutant BVDV-2.
5. The vaccine composition of claim 4, wherein the two mutant live viruses consist of a cytopathic (cp) BVDV-1 and a cp BVDV-2, and are both attenuated.
6. The vaccine composition of claim 5, wherein the cp BVDV-1 and the cp BVDV-2 both comprise a mutation in the NS2-3 region that results in a cytopathic biotype.
7. The vaccine composition of claim 6, wherein the cp BVDV-1 is BVDV-1 NADL, and the cp BVDV-2 is BVDV-2 53637.
8. The vaccine composition of claim 4, further comprising at least one of bovine herpesvirus- 1 , bovine respiratory syncytial virus, parainfluenza virus-3, Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, Leptospira pomona, or Mannhemia haemolytica.
9. The vaccine composition of claim 1 , further comprising a veterinarily-acceptable carrier.
10. A method of preparing a safe viral vaccine comprising selecting or constructing two live mutant viruses of the same family, wherein each virus contains a mutation and the mutations in the viruses reside in the same genomic site such that the mutant viruses can not undergo homologous recombination to eliminate the mutations.
11. The method of claim 10, wherein said mutation is selected from a deletion, an insertion, a substitution, or a combination thereof.
12. The method of claim 10, wherein said mutation confers a phenotype selected from attenuation of virulence, alteration of cellular tropism or biotype, alteration of species tropism, expression of a foreign gene cassette, or a combination thereof.
13. The method of claim 10, wherein said family is the family of Flaviviridae.
14. The method of claim 10, wherein said two live mutant viruses are from the genus of Pestivirus.
15. The method of claim 10, wherein the two mutant live viruses consist of a mutant BVDV-1 and a mutant BVDV-2.";"(EP1651263)
The present invention relates generally to vaccines suitable for administration to animals against viral infections.
More specifically, the present invention relates to safe vaccines and methods of preparing such vaccines.
The present invention provides safe vaccines which contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each virus or the encoding nucleic acid contains a mutation that confers a desirable phenotype, and the mutations In the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
The present invention provides safe vaccines which contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each virus or the encoding nucleic acid contains a mutation that confers a desirable phenotype, and the mutations In the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
The present invention relates generally to vaccines suitable for administration to animals against viral infections.
The present invention also provides a method of preparing a safe viral vaccine by selecting or constructing two or more live mutant viruses of the same family, genus or species, wherein each virus contains a mutation that confers a desirable phenotype, and the mutations in the viruses reside in the same genomic site such that the mutant viruses can not undergo homologous recombination to eliminate the mutations.";"(EP1651263)
It is desirable to prepare vaccines that provide protection against both BVDV-1 and BVDV-2.
It has been shown that a nucleotide identity as short as 15 nucleotides can lead to efficient homologous recombination (Nagy and Bujarski.
Where it is desired to include two attenuated mutant viruses from the same species, genus or family in a vaccine composition, there is a concern that the two viruses may recombine in the vaccinated animal thereby eliminating the attenuating mutations.
such that the mutant viruses cannot recombine with each other to eliminate the mutations.
The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations In the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
Wschr. 81:481-487 (1974)) and are highly predisposed to infection with microorganisms causing diseases such as pneumonia or enteric disease (Barber, et al., Vet.";"A61K
A61K-039/12
A61K-039/295
A61P-031/14
A61P-037/04
C07K-014/005
C07K-014/18";"(EP1651263)
1. A vaccine composition comprising at least two live mutant viruses of the same family, wherein each virus contains a mutation in the viral genome, and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations, and wherein two of the live mutant viruses consist of mutant Bovine Viral Diarrhea Viruses (BVDV).
8. A method of preparing a safe viral vaccine comprising selecting or constructing two live mutant viruses of the same family, wherein each virus contains a mutation and the mutations in the viruses reside in the same genomic site such that the mutant viruses can not undergo homologous recombination to eliminate the mutations, and wherein the viruses consist of mutant BVDV.";"(EP1651263)
LIVE MUTANT VIRUS(100,19)
SAFE MUTANT VIRAL VACCINE(100,1)
MUTANT VIRUS(90,12)
MUTANT LIVE VIRUS(71,3)
MUTATION(69,43)
ATTENUATED CP BVDV(58,2)
PARAINFLUENZA VIRUS(55,2)
LEPTOSPIRA GRIPPOTYPHOSA(54,2)
SAFE VACCINE(51,4)
LEPTOSPIRA CANICOLA(51,2)
VIRUS(50,41)
GENOMIC SITE(50,17)
LEPTOSPIRA HARDJO(49,2)
LEPTOSPIRA POMONA(49,2)
HOMOLOGOUS RECOMBINATION(46,8)
MANNHEMIA HAEMOLYTICA(46,3)
NUCLEIC ACID MOLECULE ENCODING(41,4)
SAFE VIRAL VACCINE(39,1)
NUCLEOTIDE IDENTITY(38,1)
GASTROINTESTINAL DISEASE(36,1)
ENCODING NUCLEIC ACID(35,2)
CELLULAR TROPISM ALTERATION(33,3)
VACCINE(32,23)
PHENOTYPE(32,5)
BOVINE HERPES VIRUS(32,3)
SPECIES TROPISM ALTERATION(32,3)
MUTANT(31,4)
VIRAL GENOME(29,10)
CYTOPATHIC BIOTYPE(28,3)
FOREIGN GENE CASSETTE(27,3)
FAMILY(25,13)
VIRULENCE ATTENUATION(25,3)
CP BIOTYPE(24,2)
CAMPYLOBACTER FETUS(23,2)
BOS TAURUS DNAJ(22,5)
ADMINISTRATION(22,1)
BOVINE VIRAL DIARRHEA VIRUSES(21,108)
VIRAL INFECTION(21,3)
MICROORGANISM(20,1)
PNEUMONIA(19,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(17,3)
BARBER(17,1)
ANIMAL(15,17)
PATHOGENIC VIRUS VERSION(15,4)
VETERINARILY ACCEPTABLE CARRIER(14,4)
NUCLEOTIDE(13,4)
INFECTION(13,2)
ANTIGENIC COMPONENT(12,3)
ATTENUATING MUTATION(11,4)
INTERTYPIC RECOMBINANT(11,4)
PESTIVIRUS GENUS(11,3)
CALF BIRTH(11,2)
HEMI NESTED RT PCR ASSAY(11,2)
DISEASE(10,4)
BOVINE PARAINFLUENZA VIRUS(10,1)
PREGNANT CATTLE PLACENTA(10,1)
VET(9,6)
VIRAL SEQUENCE DELETION(9,3)
NCP PESTIVIRUS(9,2)
VIRAL GENOMIC SITE(9,2)
CP PESTIVIRUS GENOME(9,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(9,1)
INFLUENZA VIRUS STRAIN(9,1)
INTERTYPIC RECOMBINATION PROBABILITY(9,1)
NONCYTOPATHIC CHIMERIC VIRUS(9,1)
NONCYTOPATHIC VIRUS EVIDENCE(9,1)
RETICULOENDOTHELIAL VIRUS(9,1)
ACUTE FATAL DISEASE(8,2)
NUCLEOTIDE SUBSTITUTION(8,2)
VIRUS VACCINE(8,2)
AVIAN LEUKOSIS VIRUS(8,1)
BOVINE LEUKOSIS VIRUS(8,1)
CANINE PARAINFLUENZA(8,1)
CHICKEN ANEMIA VIRUS(8,1)
CODON ENCODING NUCLEOTIDE(8,1)
FELINE CALICIVIRUS ATTENUATED STRAIN(8,1)
INFECTIOUS BRONCHITIS VIRUS(8,1)
TECHEN FEVER VIRUS(8,1)
UV IRRADIATION(7,3)
ABSENT FLANKING(7,2)
ATTENUATED CP(7,2)
NEWCASTLE DISEASE VIRUS(7,2)
RNA RECOMBINATION(7,2)
ACTINOBACILLUS PLEUROPNEUMONIE(7,1)
ATTENUATED LIVE VIRAL VACCINE(7,1)
ATTENUATED MUTANT VIRUS(7,1)
LISTERIA MONOCYTOGENE(7,1)
MAREK DISEASE VIRUS(7,1)
MOLECULE ENCODING MUTANT VIRUS(7,1)
SALMONELLA ENTERICA SEROVAR(7,1)
CATTLE WIDELY DISTRIBUTED PATHOGEN(6,1)
CYTOPATHIC PESTIVIRUS(6,1)
GENERA PESTIVIRUS(6,1)
HAEMOPHILUS PARASUL(6,1)
HAEMOPHILUS SOMNUS(6,1)
LIPID AMINE ADJUVANT(6,1)
MATURE VIRAL PROTEIN(6,1)
MYCOPLASMA GALANACIEUM(6,1)
MYCOPLASMA GALLISEPTICUM(6,1)
MYCOPLASMA HYOPNEUMONIA(6,1)
NEOSPORA CANIUM(6,1)
PRINCIPAL ATTENUATED VIRUS(6,1)
RESTRICTION ENZYME DIGESTION(6,1)
STREPTOCOCCUS UBERIS(6,1)
TOXOPLASMA GONDII(6,1)
VIRAL GENOMIC DNA(6,1)
VIRUS ACCELERATED ELIMINATION(6,1)
VIRUS PATHOGENICITY(6,1)
VIRUS RNA MOLECULE(6,1)
ACCESSION(5,4)
CELL INSERTION(5,3)
RT PCR PRODUCT(5,3)
BORDER DISEASE VIRUS(5,2)
MUTANT STRAIN(5,2)
PERCENT IDENTITY(5,2)
VIRAL PARTICLE(5,2)
ADSORPTION DELAYING(5,1)
ALIGNED VIRAL GENOME(5,1)
ATTENUATED PHENOTYPE(5,1)
ATTENUATED VIRULENCE(5,1)
BABESIA SPP(5,1)
BACILLUS ANTHRACIS(5,1)
BOOSTING REGIMEN(5,1)
BORRELIA SPP(5,1)
BRUCELLA SPP(5,1)
BVD VIRUS SEQUENCE(5,1)
CAMPYLOBACTER SPP(5,1)
CANINE HERPES VIRUS(5,1)
CATIONIC LIPID(5,1)
CELLULAR SEQUENCE DELETION(5,1)
CHLAMYDIA SPP(5,1)
CHOLERA TOXIN(5,1)
CLOSTRIDIAL SPP(5,1)
CO CULTIVATION DAY(5,1)
CONCOMITANT DELETION(5,1)
CP PHENOTYPE(5,1)
DISEASE SYMPTOM(5,1)
DOMESTIC WATERFOWL(5,1)
DOSAGE REGIMEN(5,1)
EHRLICHIA SPP(5,1)
EIMERIA SPP(5,1)
EMERYVILLE CA(5,1)
FETUS INFECTION(5,1)
FLANKING VIRAL SEQUENCE(5,1)
GENETIC ALTERATION(5,1)
GENOME ALTERATION(5,1)
GENOMIC REARRANGEMENT(5,1)
GENOMIC RNA(5,1)
GIARDIA SPP(5,1)
IMMUNOCOMPETENT ANIMAL(5,1)
IMMUNOMODULATORY AGENT(5,1)
INCOMPLETE DIGESTION(5,1)
INTRA LYMPH NODE(5,1)
LEPTOSPIRA SPP(5,1)
LIVE VECTORED VACCINE(5,1)
MILD DIARRHEA(5,1)
MUCOSAL DISEASE OUTBREAK(5,1)
MUTATION GENE GENOMIC LOCATION(5,1)
NCP VIRUS(5,1)
NORTH AMERICAN GENOTYPE(5,1)
OLL EMULSION(5,1)
OPTIMAL VACCINATION(5,1)
PATHOGENIC FUNGUS(5,1)
POTENTIAL NONCYTOPATHIC VIRUS(5,1)
PRRS VIRUS(5,1)
PSI BLAST PROGRAM(5,1)
PUBLISHED GENOMIC SEQUENCE GEN(5,1)
RE LATED GENOTYPE(5,1)
RE VIRULENCE(5,1)
REPLICATION ROUND(5,1)
RNA VACCINE(5,1)
SAPONIN FRACTION(5,1)
STAPHYLOCOCCUS AUREUS(5,1)
STRIKING SIMILARITY(5,1)
SYNDROME VIRUS(5,1)
UBIQUITIN CODING SEQUENCE(5,1)
VACCINATED ANIMAL(5,1)
VIBRIO SPP(5,1)
VIRAL INFECTION INCIDENCE(5,1)
VIRAL SEQUENCE DUPLICATION(5,1)
VIREMIC CALF(5,1)
VIRULENT STRAIN(5,1)
VIRUS ATTENUATION(5,1)
VIRUS GENOMIC SITE(5,1)
CELLULAR INSERTION LOCATION(4,2)
ISOTONIC AGENT(4,2)
RECOMBINATION SITE LOCATION(4,2)
THROMBOCYTOPENIA(4,2)
ANIMAL PROTECTION(4,1)
CAMBRIDGE MA(4,1)
CELLULAR INSERTION ALIGNMENT(4,1)
CELLULAR UPTAKE(4,1)
GENOMIC NUCLEIC ACID MOLECULE(4,1)
GLYCINE RESIDUE(4,1)
HETEROLOGOUS SEQUENCE INSERTION(4,1)
HUMORAL IMMUNE RESPONSE(4,1)
INACTIVATED WHOLE(4,1)
LIVE VIRUS(4,1)
MAB PANEL(4,1)
PARENTERAL ROUTE(4,1)
PCR ROUND(4,1)
POSITIVE STRAND RNA GENOME(4,1)
TISSUE CULTURE CELL(4,1)
VARIANT STRAIN(4,1)
VIRAL STRAIN(4,1)
VIRUS FAMILY(4,1)
VIRUS NUCLEIC ACID MOLECULE(4,1)
VIRUS PARTICLE(4,1)
VIRUS SHARE(4,1)
SERIAL PASSAGE(3,4)
CHEMICAL SYNTHESIS(3,2)
CLASSICAL SWINE FEVER VIRUS(3,2)
DEFINED GENOMIC ALTERATION(3,2)
DEXTROSE(3,2)
GENETIC ENGINEERING(3,2)
HEMORRHAGE(3,2)
INFECTIOUS BURSAL DISEASE VIRUS(3,2)
INSERTED SEQUENCE(3,2)
POLYPROTEIN(3,2)
ROUND PRODUCTION(3,2)
VIRAL RNA SEQUENCE(3,2)
ANTIGENICITY(3,1)
BORDETELLA BRONCHISEPTICA(3,1)
CANINE CORONAVIRUS(3,1)
CANINE PARVOVIRUS(3,1)
CELL DEBRIS(3,1)
CELL LYSIS(3,1)
CELLULAR SEQUENCE INSERTION(3,1)
CHEMICAL COMPONENT(3,1)
CLEAVAGE SITE(3,1)
CRYPTOSPORIDIUM PARVUM(3,1)
DELETED SEQUENCE(3,1)
EQUINE HERPES VIRUS COMBINATION(3,1)
FETUS REMAINING(3,1)
FUSOBACTERIUM NECROPHORUM(3,1)
GENOME ANALYSIS(3,1)
GESTATION PERIOD(3,1)
HEAT LABILE ENTEROTOXIN(3,1)
HOST ANIMAL(3,1)
IMMUNOCOMPETENCE(3,1)
INFECTED SUBJECT(3,1)
LAWSONIA INTRACELLULARIS(3,1)
LIVE CP(3,1)
LIVE FORM(3,1)
MURAMYL DIPEPTIDE(3,1)
MUTANT SEQUENCE(3,1)
MUTATION NATURE(3,1)
MYCOBACTERIUM BOVIS(3,1)
MYCOBACTERIUM PARATUBERCULOSIS(3,1)
MYCOPLASMA BOVIS(3,1)
OPTIMAL ALIGNMENT(3,1)
PARTIAL VIRUS PREPARATION(3,1)
PASTEURELLA MULTOCIDA(3,1)
PESTIVIRUS MEMBER(3,1)
PORCINE CIRCOVIRUS(3,1)
PORCINE PARVOVIRUS(3,1)
POTENTIAL NONCYTOPATHIC PRODUCT(3,1)
REVERSE PRIMER(3,1)
RIBI INC(3,1)
RICKETTSIA RICKETTSII(3,1)
STREPTOCOCCUS SUIS(3,1)
SUPERNATANT FLUID(3,1)
SUSCEPTIBLE CELL(3,1)
TRANSMISSIBLE GASTROENTERITIS VIRUS(3,1)
VENEZUELAN EQUINE ENCEPHALITIS VIRUS(3,1)
VETERINARIAN(3,1)
AMINOACID RESIDUE(2,3)
CHEMICAL TREATMENT(2,3)
SEROTYPE COMBINATION(2,3)
AFRICAN SWINE FEVER VIRUS(2,1)
ALUMINUM HYDROXIDE GEL(2,1)
ANTIBACTERIAL(2,1)
AVRIDINE(2,1)
BLOTYPE(2,1)
BOVINE CORONAVIRUS(2,1)
CANDIDA(2,1)
CANINE ADENOVIRUS(2,1)
(EP1651263)
LIVE MUTANT VIRUS(100,20)
SAFE MUTANT VIRAL VACCINE(100,1)
MUTANT VIRUS(85,12)
MUTATION(67,44)
MUTANT LIVE VIRUS(67,3)
ATTENUATED CP BVDV(55,2)
SAFE VACCINE(53,5)
PARAINFLUENZA VIRUS(52,2)
GENOMIC SITE(51,18)
LEPTOSPIRA GRIPPOTYPHOSA(51,2)
VIRUS(50,43)
LEPTOSPIRA CANICOLA(48,2)
LEPTOSPIRA HARDJO(47,2)
LEPTOSPIRA POMONA(47,2)
HOMOLOGOUS RECOMBINATION(44,8)
MANNHEMIA HAEMOLYTICA(44,3)
NUCLEIC ACID MOLECULE ENCODING(42,5)
SAFE VIRAL VACCINE(37,1)
NUCLEOTIDE IDENTITY(36,1)
GASTROINTESTINAL DISEASE(34,1)
ENCODING NUCLEIC ACID(33,2)
CELLULAR TROPISM ALTERATION(32,3)
VACCINE(31,23)
PHENOTYPE(30,5)
MUTANT(30,4)
BOVINE HERPES VIRUS(30,3)
SPECIES TROPISM ALTERATION(30,3)
VIRAL GENOME(27,10)
CYTOPATHIC BIOTYPE(26,3)
FAMILY(25,14)
FOREIGN GENE CASSETTE(25,3)
VIRULENCE ATTENUATION(23,3)
CP BIOTYPE(23,2)
CAMPYLOBACTER FETUS(22,2)
BOS TAURUS DNAJ(21,5)
ADMINISTRATION(21,1)
BOVINE VIRAL DIARRHEA VIRUSES(20,108)
VIRAL INFECTION(20,3)
MICROORGANISM(19,1)
PNEUMONIA(18,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(16,3)
BARBER(16,1)
ANIMAL(14,17)
PATHOGENIC VIRUS VERSION(14,4)
VETERINARILY ACCEPTABLE CARRIER(13,4)
NUCLEOTIDE(12,4)
INFECTION(12,2)
ATTENUATING MUTATION(11,4)
INTERTYPIC RECOMBINANT(11,4)
ANTIGENIC COMPONENT(11,3)
PESTIVIRUS GENUS(11,3)
CALF BIRTH(11,2)
HEMI NESTED RT PCR ASSAY(11,2)
DISEASE(9,4)
VIRAL SEQUENCE DELETION(9,3)
BOVINE PARAINFLUENZA VIRUS(9,1)
PREGNANT CATTLE PLACENTA(9,1)
VET(8,6)
NCP PESTIVIRUS(8,2)
VIRAL GENOMIC SITE(8,2)
CP PESTIVIRUS GENOME(8,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(8,1)
INFLUENZA VIRUS STRAIN(8,1)
INTERTYPIC RECOMBINATION PROBABILITY(8,1)
NONCYTOPATHIC CHIMERIC VIRUS(8,1)
NONCYTOPATHIC VIRUS EVIDENCE(8,1)
RETICULOENDOTHELIAL VIRUS(8,1)
ACUTE FATAL DISEASE(7,2)
NUCLEOTIDE SUBSTITUTION(7,2)
VIRUS VACCINE(7,2)
ACTINOBACILLUS PLEUROPNEUMONIE(7,1)
ATTENUATED LIVE VIRAL VACCINE(7,1)
ATTENUATED MUTANT VIRUS(7,1)
AVIAN LEUKOSIS VIRUS(7,1)
BOVINE LEUKOSIS VIRUS(7,1)
CANINE PARAINFLUENZA(7,1)
CHICKEN ANEMIA VIRUS(7,1)
CODON ENCODING NUCLEOTIDE(7,1)
FELINE CALICIVIRUS ATTENUATED STRAIN(7,1)
INFECTIOUS BRONCHITIS VIRUS(7,1)
LISTERIA MONOCYTOGENE(7,1)
MAREK DISEASE VIRUS(7,1)
MOLECULE ENCODING MUTANT VIRUS(7,1)
SALMONELLA ENTERICA SEROVAR(7,1)
TECHEN FEVER VIRUS(7,1)
UV IRRADIATION(6,3)
ABSENT FLANKING(6,2)
ATTENUATED CP(6,2)
NEWCASTLE DISEASE VIRUS(6,2)
RNA RECOMBINATION(6,2)
CATTLE WIDELY DISTRIBUTED PATHOGEN(6,1)
CYTOPATHIC PESTIVIRUS(6,1)
GENERA PESTIVIRUS(6,1)
HAEMOPHILUS PARASUL(6,1)
HAEMOPHILUS SOMNUS(6,1)
LIPID AMINE ADJUVANT(6,1)
MATURE VIRAL PROTEIN(6,1)
MYCOPLASMA GALANACIEUM(6,1)
MYCOPLASMA GALLISEPTICUM(6,1)
MYCOPLASMA HYOPNEUMONIA(6,1)
NEOSPORA CANIUM(6,1)
PRINCIPAL ATTENUATED VIRUS(6,1)
RESTRICTION ENZYME DIGESTION(6,1)
STREPTOCOCCUS UBERIS(6,1)
TOXOPLASMA GONDII(6,1)
VIRAL GENOMIC DNA(6,1)
VIRUS ACCELERATED ELIMINATION(6,1)
VIRUS PATHOGENICITY(6,1)
VIRUS RNA MOLECULE(6,1)
CELL INSERTION(5,3)
RT PCR PRODUCT(5,3)
BORDER DISEASE VIRUS(5,2)
MUTANT STRAIN(5,2)
PERCENT IDENTITY(5,2)
VIRAL PARTICLE(5,2)
ATTENUATED PHENOTYPE(5,1)
ATTENUATED VIRULENCE(5,1)
BABESIA SPP(5,1)
BACILLUS ANTHRACIS(5,1)
BOOSTING REGIMEN(5,1)
BORRELIA SPP(5,1)
BRUCELLA SPP(5,1)
CAMPYLOBACTER SPP(5,1)
CHLAMYDIA SPP(5,1)
CLOSTRIDIAL SPP(5,1)
CONCOMITANT DELETION(5,1)
DISEASE SYMPTOM(5,1)
DOMESTIC WATERFOWL(5,1)
EHRLICHIA SPP(5,1)
EIMERIA SPP(5,1)
FETUS INFECTION(5,1)
GENOMIC REARRANGEMENT(5,1)
GIARDIA SPP(5,1)
IMMUNOCOMPETENT ANIMAL(5,1)
LEPTOSPIRA SPP(5,1)
LIVE VECTORED VACCINE(5,1)
MUCOSAL DISEASE OUTBREAK(5,1)
MUTATION GENE GENOMIC LOCATION(5,1)
PATHOGENIC FUNGUS(5,1)
POTENTIAL NONCYTOPATHIC VIRUS(5,1)
PUBLISHED GENOMIC SEQUENCE GEN(5,1)
RE LATED GENOTYPE(5,1)
RE VIRULENCE(5,1)
STAPHYLOCOCCUS AUREUS(5,1)
VIRAL SEQUENCE DUPLICATION(5,1)
VIREMIC CALF(5,1)
VIRUS GENOMIC SITE(5,1)
ACCESSION(4,4)
CELLULAR INSERTION LOCATION(4,2)
ISOTONIC AGENT(4,2)
RECOMBINATION SITE LOCATION(4,2)
THROMBOCYTOPENIA(4,2)
ADSORPTION DELAYING(4,1)
ALIGNED VIRAL GENOME(4,1)
BVD VIRUS SEQUENCE(4,1)
CANINE HERPES VIRUS(4,1)
CATIONIC LIPID(4,1)
CELLULAR SEQUENCE DELETION(4,1)
CHOLERA TOXIN(4,1)
CO CULTIVATION DAY(4,1)
CP PHENOTYPE(4,1)
DOSAGE REGIMEN(4,1)
EMERYVILLE CA(4,1)
FLANKING VIRAL SEQUENCE(4,1)
GENETIC ALTERATION(4,1)
GENOME ALTERATION(4,1)
GENOMIC RNA(4,1)
IMMUNOMODULATORY AGENT(4,1)
INCOMPLETE DIGESTION(4,1)
INTRA LYMPH NODE(4,1)
MILD DIARRHEA(4,1)
NCP VIRUS(4,1)
NORTH AMERICAN GENOTYPE(4,1)
OLL EMULSION(4,1)
OPTIMAL VACCINATION(4,1)
PRRS VIRUS(4,1)
PSI BLAST PROGRAM(4,1)
REPLICATION ROUND(4,1)
RNA VACCINE(4,1)
SAPONIN FRACTION(4,1)
STRIKING SIMILARITY(4,1)
SYNDROME VIRUS(4,1)
UBIQUITIN CODING SEQUENCE(4,1)
VACCINATED ANIMAL(4,1)
VIBRIO SPP(4,1)
VIRAL INFECTION INCIDENCE(4,1)
VIRULENT STRAIN(4,1)
VIRUS ATTENUATION(4,1)
SERIAL PASSAGE(3,4)
CHEMICAL SYNTHESIS(3,2)
CLASSICAL SWINE FEVER VIRUS(3,2)
DEFINED GENOMIC ALTERATION(3,2)
DEXTROSE(3,2)
GENETIC ENGINEERING(3,2)
HEMORRHAGE(3,2)
INFECTIOUS BURSAL DISEASE VIRUS(3,2)
INSERTED SEQUENCE(3,2)
POLYPROTEIN(3,2)
ROUND PRODUCTION(3,2)
VIRAL RNA SEQUENCE(3,2)
ANIMAL PROTECTION(3,1)
ANTIGENICITY(3,1)
BORDETELLA BRONCHISEPTICA(3,1)
CAMBRIDGE MA(3,1)
CANINE CORONAVIRUS(3,1)
CANINE PARVOVIRUS(3,1)
CELL DEBRIS(3,1)
CELL LYSIS(3,1)
CELLULAR INSERTION ALIGNMENT(3,1)
CELLULAR SEQUENCE INSERTION(3,1)
CELLULAR UPTAKE(3,1)
CHEMICAL COMPONENT(3,1)
CLEAVAGE SITE(3,1)
CRYPTOSPORIDIUM PARVUM(3,1)
DELETED SEQUENCE(3,1)
EQUINE HERPES VIRUS COMBINATION(3,1)
FETUS REMAINING(3,1)
FUSOBACTERIUM NECROPHORUM(3,1)
GENOME ANALYSIS(3,1)
GENOMIC NUCLEIC ACID MOLECULE(3,1)
GESTATION PERIOD(3,1)
GLYCINE RESIDUE(3,1)
HEAT LABILE ENTEROTOXIN(3,1)
HETEROLOGOUS SEQUENCE INSERTION(3,1)
HOST ANIMAL(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
IMMUNOCOMPETENCE(3,1)
INACTIVATED WHOLE(3,1)
INFECTED SUBJECT(3,1)
LAWSONIA INTRACELLULARIS(3,1)
LIVE CP(3,1)
LIVE FORM(3,1)
LIVE VIRUS(3,1)
MAB PANEL(3,1)
MURAMYL DIPEPTIDE(3,1)
MUTANT SEQUENCE(3,1)
MUTATION NATURE(3,1)
MYCOBACTERIUM BOVIS(3,1)
MYCOBACTERIUM PARATUBERCULOSIS(3,1)
MYCOPLASMA BOVIS(3,1)
OPTIMAL ALIGNMENT(3,1)
PARENTERAL ROUTE(3,1)
PARTIAL VIRUS PREPARATION(3,1)
PASTEURELLA MULTOCIDA(3,1)
PCR ROUND(3,1)
PESTIVIRUS MEMBER(3,1)
PORCINE CIRCOVIRUS(3,1)
PORCINE PARVOVIRUS(3,1)
POSITIVE STRAND RNA GENOME(3,1)
POTENTIAL NONCYTOPATHIC PRODUCT(3,1)
REVERSE PRIMER(3,1)
RIBI INC(3,1)
RICKETTSIA RICKETTSII(3,1)
STREPTOCOCCUS SUIS(3,1)
SUPERNATANT FLUID(3,1)
SUSCEPTIBLE CELL(3,1)
TISSUE CULTURE CELL(3,1)
TRANSMISSIBLE GASTROENTERITIS VIRUS(3,1)
VARIANT STRAIN(3,1)
VENEZUELAN EQUINE ENCEPHALITIS VIRUS(3,1)
VETERINARIAN(3,1)
VIRAL STRAIN(3,1)
VIRUS FAMILY(3,1)
VIRUS NUCLEIC ACID MOLECULE(3,1)
VIRUS PARTICLE(3,1)
VIRUS SHARE(3,1)
AMINOACID RESIDUE(2,3)
CHEMICAL TREATMENT(2,3)
SEROTYPE COMBINATION(2,3)
AFRICAN SWINE FEVER VIRUS(2,1)
ALUMINUM HYDROXIDE GEL(2,1)
ANTIBACTERIAL(2,1)
AVRIDINE(2,1)
BLOTYPE(2,1)
BOVINE CORONAVIRUS(2,1)
CANDIDA(2,1)
CANINE ADENOVIRUS(2,1)
(US20050053621)
VACCINE(100,25)
LIVE MUTANT VIRUS(100,17)
SAFE VIRAL VACCINE(100,2)
SAFE MUTANT VIRAL VACCINE(100,1)
CYTOPATHIC BIOTYPE(80,6)
MUTANT LIVE VIRUS(80,4)
MUTANT VIRUS(78,12)
LEPTOSPIRA GRIPPOTYPHOSA(75,3)
BVDV GENOMIC SITE(72,4)
MUTATION(70,56)
LEPTOSPIRA CANICOLA(70,3)
LEPTOSPIRA HARDJO(68,3)
LEPTOSPIRA POMONA(68,3)
ATTENUATED CP BVDV(65,4)
MANNHEMIA HAEMOLYTICA(65,4)
MUTANT BVDV(57,4)
CYTOPATHIC BVDV(57,3)
GENOMIC SITE(55,19)
VIRULENCE ATTENUATION(55,6)
VIRUS(49,45)
CELLULAR TROPISM ALTERATION(49,4)
SPECIES TROPISM ALTERATION(47,4)
HOMOLOGOUS RECOMBINATION(46,8)
BOVINE HERPES VIRUS(45,4)
ATTENUATED MUTANT VIRUS(44,2)
EFFICIENT HOMOLOGOUS RECOMBINATION(44,1)
VIRAL GENOME(39,9)
FOREIGN GENE CASSETTE(39,4)
ATTENUATED VIRUS(38,7)
NUCLEOTIDE IDENTITY(38,1)
DNAJ CODING SEQUENCE(37,2)
BVDV(36,36)
REPLICATION ROUND(36,1)
CP BIOTYPE(33,2)
FAMILY(32,18)
CAMPYLOBACTER FETUS(32,3)
VACCINATED ANIMAL(31,2)
ATTENUATING MUTATION(30,5)
VETERINARILY ACCEPTABLE CARRIER(29,7)
HETEROLOGOUS SEQUENCE INSERTION(29,3)
PARAINFLUENZA VIRUS(29,3)
LEPTOSPIRA(28,3)
NUCLEIC ACID MOLECULE ENCODING(27,4)
NUCLEOTIDE(26,8)
NADL STRAIN(26,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(25,4)
BOS TAURUS DNAJ(22,5)
SAFE VACCINE(22,5)
GENUS(20,11)
SEQUENCE IDENTITY(19,3)
TISSUE TROPISM(17,1)
ANTIGENIC COMPONENT(16,3)
PATHOGENIC VIRUS VERSION(14,4)
ATTENUATION(14,2)
ANIMAL(13,17)
LIVE CYTOPATHIC BVDV(12,2)
CYTOPATHIC BVDV INCOMPLETE DIGESTION(12,1)
ATTENUATED BVDV(11,4)
INTERTYPIC RECOMBINANT(11,4)
PESTIVIRUS GENUS(11,3)
HEMI NESTED RT PCR ASSAY(11,2)
STRAIN(11,2)
WILD TYPE PATHOGENIC VERSION(11,1)
DISEASE(9,4)
VIRAL SEQUENCE DELETION(9,3)
GENERA PESTIVIRUS(9,2)
MATURE VIRAL PROTEIN(9,2)
NCP PESTIVIRUS(9,2)
VIRAL GENOMIC SITE(9,2)
BVDV VIRAL GENOME(9,1)
CODON ENCODING NUDEOTIDE(9,1)
CP PESTIVIRUS GENOME(9,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(9,1)
INFLUENZA VIRUS STRAIN(9,1)
INTERTYPIC RECOMBINATION PROBABILITY(9,1)
NONCYTOPATHIC CHIMERIC VIRUS(9,1)
NONCYTOPATHIC VIRUS EVIDENCE(9,1)
PREGNANT CATTLE PLACENTA(9,1)
RETICULOENDOTHELIAL VIRUS(9,1)
ACUTE FATAL DISEASE(8,2)
BVDV GENOME(8,2)
BVDV GENOMIC SEQUENCE(8,2)
NUCLEOTIDE SUBSTITUTION(8,2)
VIRUS VACCINE(8,2)
AVIAN LEUKOSIS VIRUS(8,1)
BOVINE LEUKOSIS VIRUS(8,1)
CHICKEN ANEMIA VIRUS(8,1)
FELINE CALICIVIRUS ATTENUATED STRAIN(8,1)
FLAVIVIRIDAE FAMILY VIRUS(8,1)
INFECTIOUS BRONCHITIS VIRUS(8,1)
TECHEN FEVER VIRUS(8,1)
VIRUS FAMILY FLAVIVIRIDAE(8,1)
UV IRRADIATION(7,3)
ABSENT FLANKING(7,2)
GENOMIC RNA(7,2)
RNA RECOMBINATION(7,2)
ACTINOBACILLUS PLEUROPNEUMONIE(7,1)
ATTENUATED LIVE VIRAL VACCINE(7,1)
LISTERIA MONOCYTOGENE(7,1)
SALMONELLA ENTERICA SEROVAR(7,1)
VACCINE COMPOSITION MUTANT VIRUS(7,1)
CALF BIRTH(6,1)
CANINE PARAINFLUENZA(6,1)
CATTLE WIDELY DISTRIBUTED PATHOGEN(6,1)
CYTOPATHIC BVDV2(6,1)
CYTOPATHIC PESTVIRUSE(6,1)
ENCODING MUTANT VIRUS(6,1)
HAEMOPHILUS SOMNUS(6,1)
MYCOPLASMA GALANACIEUM(6,1)
MYCOPLASMA GALLISEPTICUM(6,1)
MYCOPLASMA HYOPNEUMONIA(6,1)
NADL POLYPROTEIN(6,1)
NEOSPORA CANIUM(6,1)
NONCYTOPATHIC BVDV1(6,1)
PRINCIPAL ATTENUATED VIRUS(6,1)
RESTRICTION ENZYME DIGESTION(6,1)
STREPTOCOCCUS UBERIS(6,1)
TOXOPLASMA GONDII(6,1)
VIRAL GENOMIC DNA(6,1)
VIRUS ACCELERATED ELIMINATION(6,1)
VIRUS PATHOGENICITY(6,1)
VIRUS RNA MOLECULE(6,1)
CELL INSERTION(5,3)
RT PCR PRODUCT(5,3)
BORDER DISEASE VIRUS(5,2)
MUTANT STRAIN(5,2)
VIRAL PARTICLE(5,2)
AMPHIGEN ADJUVANT(5,1)
ATTENUATED PHENOTYPE(5,1)
ATTENUATED VIRULENCE(5,1)
AVRIDINE LIPID(5,1)
BABESIA SPP(5,1)
BACILLUS ANTHRACIS(5,1)
BOOSTING REGIMEN(5,1)
BORRELIA SPP(5,1)
BOVINE PARAINFLUENZA VIRUS(5,1)
BRUCELLA SPP(5,1)
BVDV1 NADL(5,1)
CAMPYLOBACTER SPP(5,1)
CHLAMYDIA SPP(5,1)
CLOSTRIDIAL SPP(5,1)
CONCOMITANT DELETION(5,1)
CP PESTVIRUSE(5,1)
DISEASE SYMPTOM(5,1)
DOMESTIC WATERFOWL(5,1)
EHRLICHIA SPP(5,1)
EIMERIA SPP(5,1)
FETUS INFECTION(5,1)
GENOMIC REARRANGEMENT(5,1)
GIARDIA SPP(5,1)
IMMUNOCOMPETENT ANIMAL(5,1)
LEPTOSPIRA SPP(5,1)
LIVE VECTORED VACCINE(5,1)
MONOPHOSPHORYL LIPID(5,1)
MUCOSAL DISEASE OUTBREAK(5,1)
NADL SEQUENCE NUMBERING(5,1)
PATHOGENIC FUNGUS(5,1)
POTENTIAL NONCYTOPATHIC VIRUS(5,1)
PUBLISHED GENOMIC SEQUENCE GEN(5,1)
RE VIRULENCE(5,1)
STAPHYLOCOCCUS AUREUS(5,1)
UBLIZING BLAST(5,1)
VIRAL SEQUENCE DUPLICATION(5,1)
VIREMIC CALF(5,1)
VIRUS GENOMIC SITE(5,1)
CELLULAR INSERTION LOCATION(4,2)
ISOTONIC AGENT(4,2)
RECOMBINATION SITE LOCATION(4,2)
THROMBOCYTOPENIA(4,2)
ADSORPTION DELAYING(4,1)
ALIGNED VIRAL GENOME(4,1)
AMINE ADJUVANT(4,1)
ANIMAL PROTECTION(4,1)
BVD VIRUS SEQUENCE(4,1)
BVDV CP(4,1)
CANINE HERPES VIRUS(4,1)
CATIONIC LIPID(4,1)
CELLULAR INSERTION ALIGNMENT(4,1)
CELLULAR SEQUENCE DELETION(4,1)
CELLULAR UPTAKE(4,1)
CHOLERA TOXIN(4,1)
CP PHENOTYPE(4,1)
DOSAGE REGIMEN(4,1)
EMERYVILLE CALIF(4,1)
FLANKING VIRAL SEQUENCE(4,1)
FLAVIVIRIDAE FAMILY MEMBER VIRION(4,1)
GASTROINTESTINAL DISEASE(4,1)
GENETIC ALTERATION(4,1)
GENOME ALTERATION(4,1)
GENOMIC NUCLEIC ACID MOLECULE(4,1)
GLYCINE RESIDUE(4,1)
HUMORAL IMMUNE RESPONSE(4,1)
IMMUNOMODULATORY AGENT(4,1)
INACTIVATED WHOLE(4,1)
INCOMPLETE ADJUVANT(4,1)
INTRA LYMPH NODE(4,1)
LIVE FORM(4,1)
LIVE VIRUS(4,1)
MAB PANEL(4,1)
MILD DIARRHEA(4,1)
MOLECULE ENCODING(4,1)
MOUTH DISEASE VIRUS(4,1)
MUTATION GENOMIC LOCATION(4,1)
NCP BVDV(4,1)
NCP VIRUS(4,1)
NONCYTOPATHIC BVDV DETECTABLE LEVEL(4,1)
NORTH AMERICAN GENOTYPE(4,1)
OPTIMAL VACCINATION(4,1)
PARENTERAL ROUTE(4,1)
POSITIVE STRAND RNA GENOME(4,1)
PRRS VIRUS(4,1)
PSI BLAST PROGRAM(4,1)
RNA VACCINE(4,1)
SAPONIN FRACTION(4,1)
STRAIN NADL(4,1)
STRIKING SIMILARITY(4,1)
SYNDROME VIRUS(4,1)
TISSUE CULTURE CELL(4,1)
UBIQUITIN CODING SEQUENCE(4,1)
VACCINE COMPOSITION TWO(4,1)
VARIANT STRAIN(4,1)
VIBRIO SPP(4,1)
VIRAL INFECTION INCIDENCE(4,1)
VIRAL STRAIN(4,1)
VIRULENT STRAIN(4,1)
VIRUS ATTENUATION(4,1)
VIRUS NUCLEIC ACID MOLECULE(4,1)
VIRUS PARTICLE(4,1)
SERIAL PASSAGE(3,4)
CHEMICAL SYNTHESIS(3,2)
CLASSICAL SWINE FEVER VIRUS(3,2)
DEFINED GENOMIC ALTERATION(3,2)
DEXTROSE(3,2)
FLAVIVIRUS(3,2)
GENETIC ENGINEERING(3,2)
HEMORRHAGE(3,2)
HEPACIVIRUS(3,2)
INFECTIOUS BURSAL DISEASE VIRUS(3,2)
INSERTED SEQUENCE(3,2)
PROTEASE(3,2)
VIRAL RNA SEQUENCE(3,2)
ALUMINUM HYDROXIDE GEL(3,1)
ANTIGENICITY(3,1)
BORDETELLA BRONCHISEPTICA(3,1)
BVDV REGION(3,1)
CANINE CORONAVIRUS(3,1)
CANINE PARVOVIRUS(3,1)
CELL DEBRIS(3,1)
CELL LYSIS(3,1)
CELLULAR SEQUENCE INSERTION(3,1)
CHEMICAL COMPONENT(3,1)
CLEAVAGE SITE(3,1)
CRYPTOSPORIDIUM PARVUM(3,1)
DELETED SEQUENCE(3,1)
EQUINE HERPES VIRUS COMBINATION(3,1)
FETUS REMAINING(3,1)
FUSOBACTERIUM NECROPHORUM(3,1)
GENOME ANALYSIS(3,1)
GESTATION PERIOD(3,1)
HAEMOPHILUS PARASUIS(3,1)
HEAT LABILE ENTEROTOXIN(3,1)
HOST ANIMAL(3,1)
IMMUNOCOMPETENCE(3,1)
INFECTED SUBJECT(3,1)
LAWSONIA INTRACELLULARIS(3,1)
MURAMYL DIPEPTIDE(3,1)
MUTANT SEQUENCE(3,1)
MUTATION NATURE(3,1)
MYCOBACTERIUM BOVIS(3,1)
MYCOBACTERIUM PARATUBERCULOSIS(3,1)
MYCOPLASMA BOVIS(3,1)
OPTIMAL ALIGNMENT(3,1)
PARTIAL VIRUS PREPARATION(3,1)
PASTEURELLA MULTOCIDA(3,1)
PESTIVIRUS MEMBER(3,1)
PORCINE CIRCOVIRUS(3,1)
PORCINE PARVOVIRUS(3,1)
POTENTIAL NONCYTOPATHIC PRODUCT(3,1)
REVERSE PRIMER(3,1)
RIBI INC(3,1)
RICKETTSIA RICKETTSII(3,1)
STREPTOCOCCUS SUIS(3,1)
SUPERNATANT FLUID(3,1)
SUSCEPTIBLE CELL(3,1)
TERM VACCINE(3,1)
TERM VIRUS(3,1)
TRANSMISSIBLE GASTROENTERITIS VIRUS(3,1)
VENEZUELAN EQUINE ENCEPHALITIS VIRUS(3,1)
VETERINARIAN(3,1)
AMINOACID RESIDUE(2,3)
CHEMICAL TREATMENT(2,3)
IDENTITY(2,3)
SEROTYPE COMBINATION(2,3)
AFRICAN SWINE FEVER VIRUS(2,1)
ANTIBACTERIAL(2,1)
(US7361357)
VACCINE(100,28)
SAFE MUTANT VIRAL VACCINE(100,1)
LIVE MUTANT VIRUS(99,19)
CYTOPATHIC BIOTYPE(65,4)
MUTANT VIRUS(64,13)
LEPTOSPIRA GRIPPOTYPHOSA(62,2)
LEPTOSPIRA CANICOLA(58,2)
LEPTOSPIRA HARDJO(56,2)
LEPTOSPIRA POMONA(56,2)
MUTATION(52,49)
MANNHEMIA HAEMOLYTICA(51,3)
ATTENUATED CP BVDV(47,4)
BVDV(46,43)
VIRAL GENOME(46,11)
GENOMIC SITE(45,20)
CYTOPATHIC BVDV(42,3)
VIRUS(39,47)
HETEROLOGOUS SEQUENCE INSERTION(36,3)
BOVINE HERPES VIRUS(35,3)
ATTENUATED MUTANT VIRUS(33,2)
DNAJ CODING SEQUENCE(33,1)
EFFICIENT HOMOLOGOUS RECOMBINATION(32,1)
BOVINE VIRAL DIARRHEA VIRUS(31,7)
HETEROLOGOUS SEQUENCE(30,3)
ATTENUATED VIRUS(28,7)
CAMPYLOBACTER FETUS(27,2)
NUCLEOTIDE IDENTITY(27,1)
REPLICATION ROUND(26,1)
FAMILY(24,17)
NUCLEOTIDE(24,8)
CP BIOTYPE(24,2)
LEPTOSPIRA(24,2)
PARAINFLUENZA VIRUS(24,2)
SAFE VACCINE(23,5)
VACCINATED ANIMAL(23,2)
ATTENUATING MUTATION(22,5)
HOMOLOGOUS RECOMBINATION(21,7)
NUCLEIC ACID MOLECULE ENCODING(20,4)
GENOME(19,6)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(19,3)
NADL STRAIN(19,2)
BOS TAURUS DNAJ(16,5)
MUTANT(15,1)
SEQUENCE IDENTITY(14,3)
TISSUE TROPISM(12,1)
ANTIGENIC COMPONENT(11,3)
PATHOGENIC VIRUS VERSION(10,4)
ATTENUATION(10,2)
ANIMAL(9,17)
LIVE CYTOPATHIC BVDV(9,2)
CYTOPATHIC BVDV INCOMPLETE DIGESTION(9,1)
ATTENUATED BVDV(8,4)
INTERTYPIC RECOMBINANT(8,4)
PESTIVIRUS GENUS(8,3)
CELLULAR TROPISM ALTERATION(8,2)
HEMI NESTED RT PCR ASSAY(8,2)
STRAIN(8,2)
WILD TYPE PATHOGENIC VERSION(8,1)
DISEASE(7,4)
VIRAL SEQUENCE DELETION(7,3)
SPECIES TROPISM ALTERATION(7,2)
PREGNANT CATTLE PLACENTA(7,1)
GENUS(6,7)
ACUTE FATAL DISEASE(6,2)
BVDV GENOME(6,2)
BVDV GENOMIC SEQUENCE(6,2)
FOREIGN GENE CASSETTE(6,2)
GENERA PESTIVIRUS(6,2)
MATURE VIRAL PROTEIN(6,2)
NCP PESTIVIRUS(6,2)
NUCLEOTIDE SUBSTITUTION(6,2)
VIRAL GENOMIC SITE(6,2)
VIRULENCE ATTENUATION(6,2)
VIRUS VACCINE(6,2)
AVIAN LEUKOSIS VIRUS(6,1)
BOVINE LEUKOSIS VIRUS(6,1)
BVDV VIRAL GENOME(6,1)
CHICKEN ANEMIA VIRUS(6,1)
CODON ENCODING NUDEOTIDE(6,1)
CP PESTIVIRUS GENOME(6,1)
FELINE CALICIVIRUS ATTENUATED STRAIN(6,1)
FLAVIVIRIDAE FAMILY VIRUS(6,1)
INFECTIOUS BRONCHITIS VIRUS(6,1)
INFECTIOUS LARYNGOTRACHEITIS VIRUS(6,1)
INFLUENZA VIRUS STRAIN(6,1)
INTERTYPIC RECOMBINATION PROBABILITY(6,1)
NONCYTOPATHIC CHIMERIC VIRUS(6,1)
NONCYTOPATHIC VIRUS EVIDENCE(6,1)
RETICULOENDOTHELIAL VIRUS(6,1)
TECHEN FEVER VIRUS(6,1)
VIRUS FAMILY FLAVIVIRIDAE(6,1)
UV IRRADIATION(5,3)
ABSENT FLANKING(5,2)
BOVINE VIRAL DIARRHEA VIRUS TYPE(5,2)
GENOMIC RNA(5,2)
RNA RECOMBINATION(5,2)
ACTINOBACILLUS PLEUROPNEUMONIE(5,1)
ATTENUATED LIVE VIRAL VACCINE(5,1)
LISTERIA MONOCYTOGENE(5,1)
SALMONELLA ENTERICA SEROVAR(5,1)
VACCINE COMPOSITION MUTANT VIRUS(5,1)
BIOTYPE(4,5)
CELL INSERTION(4,3)
RT PCR PRODUCT(4,3)
VETERINARILY ACCEPTABLE CARRIER(4,3)
BORDER DISEASE VIRUS(4,2)
MUTANT STRAIN(4,2)
POSITIVE STRAND RNA GENOME(4,2)
VIRAL PARTICLE(4,2)
AMPHIGEN ADJUVANT(4,1)
ATTENUATED PHENOTYPE(4,1)
ATTENUATED VIRULENCE(4,1)
AVRIDINE LIPID(4,1)
BABESIA SPP(4,1)
BACILLUS ANTHRACIS(4,1)
BOOSTING REGIMEN(4,1)
BORRELIA SPP(4,1)
BOVINE PARAINFLUENZA VIRUS(4,1)
BRUCELLA SPP(4,1)
BVDV1 NADL(4,1)
CALF BIRTH(4,1)
CAMPYLOBACTER SPP(4,1)
CANINE PARAINFLUENZA(4,1)
CATTLE WIDELY DISTRIBUTED PATHOGEN(4,1)
CHLAMYDIA SPP(4,1)
CLOSTRIDIAL SPP(4,1)
CONCOMITANT DELETION(4,1)
CP PESTVIRUSE(4,1)
CYTOPATHIC BVDV2(4,1)
CYTOPATHIC PESTVIRUSE(4,1)
DISEASE SYMPTOM(4,1)
DOMESTIC WATERFOWL(4,1)
EHRLICHIA SPP(4,1)
EIMERIA SPP(4,1)
ENCODING MUTANT VIRUS(4,1)
FETUS INFECTION(4,1)
GENOMIC REARRANGEMENT(4,1)
GIARDIA SPP(4,1)
HAEMOPHILUS SOMNUS(4,1)
IMMUNOCOMPETENT ANIMAL(4,1)
LEPTOSPIRA SPP(4,1)
LIVE VECTORED VACCINE(4,1)
MEDICINE NATIONAL LIBRARY(4,1)
MONOPHOSPHORYL LIPID(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
MYCOPLASMA GALANACIEUM(4,1)
MYCOPLASMA GALLISEPTICUM(4,1)
MYCOPLASMA HYOPNEUMONIA(4,1)
NADL POLYPROTEIN(4,1)
NADL SEQUENCE NUMBERING(4,1)
NEOSPORA CANIUM(4,1)
NONCYTOPATHIC BVDV1(4,1)
PATHOGENIC FUNGUS(4,1)
POTENTIAL NONCYTOPATHIC VIRUS(4,1)
PRINCIPAL ATTENUATED VIRUS(4,1)
PUBLISHED GENOMIC SEQUENCE GEN(4,1)
RE VIRULENCE(4,1)
RESTRICTION ENZYME DIGESTION(4,1)
STAPHYLOCOCCUS AUREUS(4,1)
STREPTOCOCCUS UBERIS(4,1)
TOXOPLASMA GONDII(4,1)
VIRAL GENOMIC DNA(4,1)
VIRAL SEQUENCE DUPLICATION(4,1)
VIREMIC CALF(4,1)
VIRUS ACCELERATED ELIMINATION(4,1)
VIRUS GENOMIC SITE(4,1)
VIRUS PATHOGENICITY(4,1)
VIRUS RNA MOLECULE(4,1)
CELLULAR INSERTION LOCATION(3,2)
ISOTONIC AGENT(3,2)
RECOMBINATION SITE LOCATION(3,2)
THROMBOCYTOPENIA(3,2)
ADSORPTION DELAYING(3,1)
ALIGNED VIRAL GENOME(3,1)
AMINE ADJUVANT(3,1)
ANIMAL PROTECTION(3,1)
BVD VIRUS SEQUENCE(3,1)
BVDV CP(3,1)
CANINE HERPES VIRUS(3,1)
CATIONIC LIPID(3,1)
CELLULAR INSERTION ALIGNMENT(3,1)
CELLULAR SEQUENCE DELETION(3,1)
CELLULAR UPTAKE(3,1)
CHOLERA TOXIN(3,1)
CP PHENOTYPE(3,1)
DOSAGE REGIMEN(3,1)
EMERYVILLE CALIF(3,1)
FLANKING VIRAL SEQUENCE(3,1)
FLAVIVIRIDAE FAMILY MEMBER VIRION(3,1)
GASTROINTESTINAL DISEASE(3,1)
GENETIC ALTERATION(3,1)
GENOME ALTERATION(3,1)
GENOMIC NUCLEIC ACID MOLECULE(3,1)
GLYCINE RESIDUE(3,1)
HUMORAL IMMUNE RESPONSE(3,1)
IMMUNOMODULATORY AGENT(3,1)
INACTIVATED WHOLE(3,1)
INCOMPLETE ADJUVANT(3,1)
INTRA LYMPH NODE(3,1)
LIVE FORM(3,1)
LIVE VIRUS(3,1)
MAB PANEL(3,1)
MILD DIARRHEA(3,1)
MOLECULE ENCODING(3,1)
MOUTH DISEASE VIRUS(3,1)
MUTATION GENOMIC LOCATION(3,1)
NCP BVDV(3,1)
NCP VIRUS(3,1)
NONCYTOPATHIC BVDV DETECTABLE LEVEL(3,1)
NORTH AMERICAN GENOTYPE(3,1)
OPTIMAL VACCINATION(3,1)
PARENTERAL ROUTE(3,1)
PRRS VIRUS(3,1)
PSI BLAST PROGRAM(3,1)
RNA VACCINE(3,1)
SAFE VIRAL VACCINE(3,1)
SAPONIN FRACTION(3,1)
STRAIN NADL(3,1)
STRIKING SIMILARITY(3,1)
SYNDROME VIRUS(3,1)
TISSUE CULTURE CELL(3,1)
UBIQUITIN CODING SEQUENCE(3,1)
VACCINE COMPOSITION TWO(3,1)
VARIANT STRAIN(3,1)
VIBRIO SPP(3,1)
VIRAL INFECTION INCIDENCE(3,1)
VIRAL STRAIN(3,1)
VIRULENT STRAIN(3,1)
VIRUS ATTENUATION(3,1)
VIRUS NUCLEIC ACID MOLECULE(3,1)
VIRUS PARTICLE(3,1)
SERIAL PASSAGE(2,4)
AMINOACID RESIDUE(2,3)
CHEMICAL TREATMENT(2,3)
IDENTITY(2,3)
SEROTYPE COMBINATION(2,3)
CHEMICAL SYNTHESIS(2,2)
CLASSICAL SWINE FEVER VIRUS(2,2)
DEFINED GENOMIC ALTERATION(2,2)
DEXTROSE(2,2)
FLAVIVIRUS(2,2)
GENETIC ENGINEERING(2,2)
HEMORRHAGE(2,2)
HEPACIVIRUS(2,2)
INFECTIOUS BURSAL DISEASE VIRUS(2,2)
INSERTED SEQUENCE(2,2)
PROTEASE(2,2)
VIRAL RNA SEQUENCE(2,2)
XBLAST(2,2)
ALUMINUM HYDROXIDE GEL(2,1)
ANTIGENICITY(2,1)
BORDETELLA BRONCHISEPTICA(2,1)
BVDV REGION(2,1)
CANINE CORONAVIRUS(2,1)
CANINE PARVOVIRUS(2,1)
CELL DEBRIS(2,1)
CELL LYSIS(2,1)
CELLULAR SEQUENCE INSERTION(2,1)
CHEMICAL COMPONENT(2,1)
CLEAVAGE SITE(2,1)
CRYPTOSPORIDIUM PARVUM(2,1)
DELETED SEQUENCE(2,1)
EQUINE HERPES VIRUS COMBINATION(2,1)
FETUS REMAINING(2,1)
FUSOBACTERIUM NECROPHORUM(2,1)
GENOME ANALYSIS(2,1)
GESTATION PERIOD(2,1)
HAEMOPHILUS PARASUIS(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
HOST ANIMAL(2,1)
IMMUNOCOMPETENCE(2,1)
INFECTED SUBJECT(2,1)
LAWSONIA INTRACELLULARIS(2,1)
MURAMYL DIPEPTIDE(2,1)
MUTANT SEQUENCE(2,1)
MUTATION NATURE(2,1)
MYCOBACTERIUM BOVIS(2,1)
MYCOBACTERIUM PARATUBERCULOSIS(2,1)
MYCOPLASMA BOVIS(2,1)
OPTIMAL ALIGNMENT(2,1)
PARTIAL VIRUS PREPARATION(2,1)
PASTEURELLA MULTOCIDA(2,1)
PESTIVIRUS MEMBER(2,1)
PORCINE CIRCOVIRUS(2,1)
PORCINE PARVOVIRUS(2,1)
POTENTIAL NONCYTOPATHIC PRODUCT(2,1)
REVERSE PRIMER(2,1)
RIBI INC(2,1)
RICKETTSIA RICKETTSII(2,1)
STREPTOCOCCUS SUIS(2,1)
SUPERNATANT FLUID(2,1)
SUSCEPTIBLE CELL(2,1)
TERM VACCINE(2,1)
TERM VIRUS(2,1)
TRANSMISSIBLE GASTROENTERITIS VIRUS(2,1)
UNITED STATES GOVERNMENT(2,1)
VENEZUELAN EQUINE ENCEPHALITIS VIRUS(2,1)
VETERINARIAN(2,1)
AFRICAN SWINE FEVER VIRUS(1,1)
ANTIBACTERIAL(1,1)
(US20080286302)
VACCINE(100,26)
MANNHEMIA HAEMOLYTICA(100,3)
CAMPYLOBACTER FETUS(100,2)
LEPTOSPIRA(100,2)
LEPTOSPIRA CANICOLA(100,2)
LEPTOSPIRA GRIPPOTYPHOSA(100,2)
LEPTOSPIRA HARDJO(100,2)
LEPTOSPIRA POMONA(100,2)
SAFE MUTANT VIRAL VACCINE(100,1)
LIVE MUTANT VIRUS(85,14)
CYTOPATHIC BVDV(67,3)
MUTANT VIRUS(65,10)
CYTOPATHIC BIOTYPE(62,3)
MUTATION(52,42)
ATTENUATED MUTANT VIRUS(52,2)
EFFICIENT HOMOLOGOUS RECOMBINATION(51,1)
GENOMIC SITE(50,18)
VIRUS(48,43)
VIR(...)";Pharmaceuticals;Open
"2003-07-14
2003-09-22
2004-07-14
2004-09-21";"WO2005007691        A2 2005-01-27 [WO200507691]
STG: (A2) International application published without international search report
AP : 2004WO-US22605 2004-07-14
CA2537896           A1 2005-01-27 [CA2537896]
STG: (A1) Application laid open
AP : 2004CA-2537896 2004-07-14
WO2005030802        A2 2005-04-07 [WO200530802]
STG: (A2) International application published without international search report
AP : 2004WO-US30831 2004-09-21
CA2539816           A1 2005-04-07 [CA2539816]
STG: (A1) Application laid open
AP : 2004CA-2539816 2004-09-21
WO2005007691        A3 2005-08-18 [WO200507691]
STG: (A3) Later publication of ISR with revised front page
AP : 2004WO-US22605 2004-07-14
WO2005030802        A3 2005-09-09 [WO200530802]
STG: (A3) Later publication of ISR with revised front page
AP : 2004WO-US30831 2004-09-21
WO2005007691        A8 2005-11-10 [WO200507691]
STG: (A8) Modified first page
AP : 2004WO-US22605 2004-07-14
AP200603513         A0 2006-02-28 [AP200603513]
STG: (A0) Application filed, as announced in the Gazette published by this office
AP : 2006AP-0003513 2004-07-14
AP200603513         D0 2006-02-28 [AP200603513]
STG: (D0) Patent application filed
AP : 2006AP-0003513 2004-07-14
AP200603594         A0 2006-04-30 [AP200603594]
STG: (A0) Application filed, as announced in the Gazette published by this office
AP : 2006AP-0003594 2004-09-21
EP1668029           A2 2006-06-14 [EP1668029]
STG: (A2) Application published without search report
AP : 2004EP-0786063 2004-07-14
EP1670820           A2 2006-06-21 [EP1670820]
STG: (A2) Application published without search report
AP : 2004EP-0784633 2004-09-21
MXPA06003169        A  2007-02-19 [MX2006PA003169]
STG: (A) Patent application
AP : 2006MX-PA03169 2004-09-21
ZA200603167         B  2008-03-26 [ZA200603167]
STG: (B)
AP : 2006ZA-0003167 2004-09-21
EP1670820           B1 2008-12-10 [EP1670820]
STG: (B1) Patent specification
AP : 2004EP-0784633 2004-09-21
AT417062            T  2008-12-15 [ATE417062]
STG: (T) EP patent valid in AT
AP : 2004AT-0784633T 2004-09-21
DE602004018347      D1 2009-01-22 [DE602004018347]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2004DE-60018347 2004-09-21
PT1670820           E  2009-03-13 [PT1670820]
STG: (E) Availability of national translation of European patent
AP : 2004PT-0784633T 2004-09-21
ES2320348           T3 2009-05-21 [ES2320348]
STG: (T3) Translation of granted European patent (former B3)
AP : 2004ES-0784633T 2004-09-21
ZA200601330         B  2010-10-27 [ZA200601330]
STG: (B)
AP : 2006ZA-0001330 2004-07-14
CA2539816           C  2012-01-03 [CA2539816]
STG: (C) Patent (second level)
AP : 2004CA-2539816 2004-09-21
EP1668029           B1 2013-12-25 [EP1668029]
STG: (B1) Patent specification
AP : 2004EP-0786063 2004-07-14
CA2537896           C  2014-03-25 [CA2537896]
STG: (C) Patent (second level)
AP : 2004CA-2537896 2004-07-14";26013;"WO2005007691        A2 2005-01-27 [WO200507691]
CA2537896           A1 2005-01-27 [CA2537896]
WO2005030802        A2 2005-04-07 [WO200530802]
CA2539816           A1 2005-04-07 [CA2539816]
WO2005007691        A3 2005-08-18 [WO200507691]
WO2005030802        A3 2005-09-09 [WO200530802]
WO2005007691        A8 2005-11-10 [WO200507691]
AP200603513         A0 2006-02-28 [AP200603513]
AP200603513         D0 2006-02-28 [AP200603513]
AP200603594         A0 2006-04-30 [AP200603594]
EP1668029           A2 2006-06-14 [EP1668029]
EP1670820           A2 2006-06-21 [EP1670820]
MXPA06003169        A  2007-02-19 [MX2006PA003169]
ZA200603167         B  2008-03-26 [ZA200603167]
EP1670820           B1 2008-12-10 [EP1670820]
AT417062            T  2008-12-15 [ATE417062]
DE602004018347      D1 2009-01-22 [DE602004018347]
PT1670820           E  2009-03-13 [PT1670820]
ES2320348           T3 2009-05-21 [ES2320348]
ZA200601330         B  2010-10-27 [ZA200601330]
CA2539816           C  2012-01-03 [CA2539816]
EP1668029           B1 2013-12-25 [EP1668029]
CA2537896           C  2014-03-25 [CA2537896]";"2003US-60486750
2003US-60504428
2004US-11022605
2004WO-US22605
2004WO-US30831";"(EP1670820)
WO2005030802
(EP1668029)
WO2005007691
(WO200530802)
WO2005007691
(DE602004018347)
WO2005030802
(AP200603513)
WO2005007691
(AP200603594)
WO2005030802
(ZA200603167)
WO2005030802
(ZA200601330)
WO2005007691
(CA2539816)
WO2005030802
(CA2537896)
WO2005007691";"INSTITUTE FOR GENOMIC RESEARCH
INTERNATIONAL LEVESTOCK RESEARCH INSTITUTE
INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE";INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE;"(EP1670820)
KE; US
(EP1670820)
KE; US
(EP1668029)
KE
(EP1668029)
KE
(WO200530802)
KE; US
(WO200507691)
KE
(CA2539816)
KE; US
(CA2539816)
KE; US
(CA2537896)
KE
(CA2537896)
KE";"(EP1670820)
NAME=International Livestock Research Institute ( ILRI) P.O. Box 30709 , CITY=00100 Nairobi , COUNTRY=KE 

NAME=THE INSTITUTE FOR GENOMIC RESEARCH 9712 Medical Center Drive , CITY=Rockville, Maryland 20850 , COUNTRY=US 

(EP1670820)
NAME=International Livestock Research Institute ( ILRI) P.O. Box 30709 , CITY=00100 Nairobi , COUNTRY=KE , REG=100148270 

NAME=J. Craig Venter Institute, Inc. 9704 Medical Center Drive , CITY=Rockville, MD 20850 , COUNTRY=US , REG=101020871 

(EP1668029)
NAME=International Livestock Research Institute P.O. Box 30709 , CITY=00100 Nairobi , COUNTRY=KE 

(EP1668029)
NAME=International Livestock Research Institute P.O. Box 30709 , CITY=00100 Nairobi , COUNTRY=KE , REG=100780625 

(WO200530802)
NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE  [KE/ KE] P.O. Box 30709, 00100 Nairobi  , COUNTRY=KE 

NAME=THE INSTITUTE FOR GENOMIC RESEARCH  [US/ US] 9712 Medical Center Drive, Rockville, MD 20850  , COUNTRY=US 

(WO200507691)
NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE  [KE/ KE] P.O. Box 30709, 00100 Nairobi  , COUNTRY=KE 

(CA2539816)
NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE P.O. Box 30709, 00100, NAIROBI , COUNTRY=KE 

NAME=THE INSTITUTE FOR GENOMIC RESEARCH 9212 Medical Center Drive, ROCKVILLE, MD, 20850 , COUNTRY=US 

(CA2539816)
NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE P.O. Box 30709 00100 , CITY=NAIROBI , COUNTRY=KE 

NAME=THE INSTITUTE FOR GENOMIC RESEARCH 9212 Medical Center Drive , CITY=ROCKVILLE , STATE=MD , POSTCODE=20850 , COUNTRY=US 

(CA2537896)
NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE P.O. Box 30709 00100 , CITY=NAIROBI , COUNTRY=KE 

(CA2537896)
NAME=INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE P.O. Box 30709 00100 , CITY=NAIROBI , COUNTRY=KE 
";1;"TARACHA EVANS
GARDNER MALCOLM J
NENE VISHVANATH";"(EP1670820)
KE; US
(EP1670820)
KE; US";"(EP1670820)
NAME=TARACHA, Evans Riara Villas, Riara Road , CITY=Lavington, Nairobi , COUNTRY=KE 

NAME=GARDNER, Malcolm, J. 10416 Overgate Place , CITY=Potomac, MD 20854 , COUNTRY=US 

NAME=NENE, Vishvanath 11601 Milbern Drive , CITY=Potomac, MD 20854 , COUNTRY=US 

(EP1670820)
NAME=TARACHA, Evans Riara Villas, Riara Road Lavington, Nairobi , COUNTRY=KE 

NAME=GARDNER, Malcolm, J. 10416 Overgate Place Potomac, MD 20854 , COUNTRY=US 

NAME=NENE, Vishvanath 11601 Milbern Drive Potomac, MD 20854 , COUNTRY=US 
";"(EP1670820)
Antigens for an east coast fever vaccine";"(EP1670820)
This invention relates, e.g., to DNA, protein, and peptide compositions and methods for identification of intracellular antigens of pathogens that stimulate animal cytotoxic lymphocytes in an antigen specific manner. Such antigens are prime candidates for the development of vaccines, useful for the prevention of intracellular pathogenic diseases such as East Coast Fever.";"(WO200507691)
1. We claim: 1. An isolated polypeptide, comprising a sequence represented by one of SEQ ED NO: 1 through SEQ ED NO:7; SEQ ED NO:9; or SEQ ED NO:14 through SEQ ED NO:17.
2. An isolated polypeptide of claim 1, comprising a sequence represented by one of SEQ ID NO:l through SEQ ED NO:7.
3. An isolated polypeptide of claim 1 , comprising a sequence represented by one of SEQ ED NO:9 or SEQ ED NO: 14 through SEQ ED NO: 17.
4. A pharmaceutical composition, comprising one or more polypeptides of claim 1 and a pharmaceutically acceptable carrier.
5. An immunogenic composition, comprising one or more polypeptides of claim 1 and, optionally, an adjuvant.
6. The immunogenic composition of claim 5, wliich stimulates cytotoxic T cells specific to the polypeptide.
7. The immunogenic composition of claim 5, which comprises an epitope that stimulates Thelieria pan>a (T. parva-) specific cytotoxic T cells.
8. A vaccine, comprising one or more polypeptides of claim 1 and, optionally, an adjuvant.
9. The vaccine of claim 8, which protects an animal against T. parva infection.
10. The polypeptide of claim 1, which is present in detectable amounts in isolates of T. parva.
11. The polypeptide of claim 1, comprising a T. parva antigen.
12. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO:l.
13. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO:2.
14. The polypeptide of claim 1 wherein the sequence is represented by SEQ ID NO:3.
15. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO:4.
16. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO:5.
17. The polypeptide of claim 1, wherein the sequence is represented by SEQ ID NO:6.
18. The polypeptide of claim 1, wherein the sequence is represented by SEQ ID NO:7.
19. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO:9.
20. The polypeptide of claim 1, wherein the sequence is represented by SEQ ID NO: 14.
21. The polypeptide of claim 1, wherein the sequence is represented by SEQ ID NO:15.
22. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO:16.
23. The polypeptide of claim 1, wherein the sequence is represented by SEQ ED NO: 17. 24. An isolated polynucleotide comprising: (a) a sequence represented by one of SEQ ED NO: 18 through SEQ ED NO:23 or SEQ ED NO:28 through SEQ ED NO:31; (b) a sequence which is at least about 90%> identical to a sequence of (a); (c) a sequence which hybridizes under conditions of high stringency to a polynucleotide which comprises a sequence of (a); (d) a sequence which encodes a polypeptide represented by SEQ ED NO:l tlirough SEQ ED NO:7; SEQ ED NO:9; or SEQ ED NO: 14 through SEQ ED NO: 17; or (e) a complement of any of (a), (b), (c) or (d).
25. The isolated polynucleotide of claim 24, wherein the polynucleotide comprises a sequence represented by one of SEQ ED NO: 18 through SEQ ED NO:23 or SEQ ED NO:28 through SEQ ED NO:31, or comprises a complement thereof.
26. The isolated polynucleotide of claim 24, wherein the polynucleotide comprises a sequence which is at least about 90%> identical to a sequence of (a), or comprises a complement thereof.
27. The isolated polynucleotide of claim 24, wherein the polynucleotide comprises a sequence which hybridizes under conditions of high stringency to a polynucleotide which comprises a sequence of (a), or which hybridizes under conditions of high stringency to a complement ofthe sequence of (a).
28. The isolated polynucleotide of claim 24, wherein the polynucleotide comprises a sequence which encodes a polypeptide represented by SEQ ED NO:l through SEQ ED NO:7; SEQ ED NO:9; or SEQ ED NO:14 through SEQ ED NO:17, or which comprises a complement ofthe encoding sequence.
29. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO: 18.
30. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO: 19.
31. The isolated polynucleotideof claim 24, wherein the sequence in (a) is represented by SEQ ED NO:20.
32. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO:21
33. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO:22.
34. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO:23.
35. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO:28.
36. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ID NO:29.
37. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO:30.
38. The isolated polynucleotide of claim 24, wherein the sequence in (a) is represented by SEQ ED NO:31.
39. A pharmaceutical composition comprising the polynucleotide of claim 24 and a pharmaceutically acceptable carrier or excipient.
40. A recombinant constract, comprising a polynucleotide of claim 24, operably linked to an expression control sequence.
41. A vector comprising the recombinant construct of claim 40.
42. The vector of claim 41, which further comprises one or more sequences encoding a selectable marker.
43. The vector of claim 41, which comprises a plasmid, a bacteriophage, a minichromosome or a eukaryotic virus vector.
44. A host cell comprising a vector of claim 41.
45. The host cell of claim 44, which is prokaryotic.
46. The host cell of claim 44, which is eukaryotic.
47. A method for producing a polypeptide which stimulates a T. αrvα-antigen specific cytotoxic lymphocyte (CTL), comprising culturing a host cell of claim 44 under conditions effective for producing a polypeptide encoded by the polynucleotide, and harvesting the polypeptide.
48. An antibody specific for the polypeptide of claim 1.
49. The antibody of claim 48, which is a polyclonal antibody.
50. The antibody of claim 48, which is a monoclonal antibody.
51. The antibody of claim 48, which is coupled to a carrier and/or a label.
52. A kit for detecting the presence of T. parva in a sample suspected of containing T. parva, or for purifying T. parva from a sample containing T. parva, comprising an antibody of claim 48.
53. The kit of claim 52, which further comprises means for performing an enzyme-linked or Western blot assay to detect the presence of T. parva.
54. The kit of claim 52, which further comprises means for binding the antibody to T. parva in the sample, and for releasing the organism from the antibody.
55. A method for protecting an animal against infection by T. parva, comprising administering to the animal a polypeptide of claim 1, under conditions effective for the animal to generate a protective antibody against the polypeptide.
56. A method for protecting an animal against infection by T. parva, comprising administering to the animal a polypeptide of claim 1, under conditions effective for the animal to generate T. /?αrv -antigen-specific CTLs.
57. A method for protecting an animal against infection by T. parva, comprising administering to the animal a host cell of claim 46 under conditions effective for the animal to generate a protective antibody against a polypeptide expressed by the polypeptide.
58. A method for protecting an animal against infection by T. parva, comprising administering to the animal a host cell of claim 46, under conditions effective for the animal to generate T. j^ rvα-antigen-specific CD4+ helper and CD8+ Cytotoxic T lymphocyte responses.
59. A method for detecting a pathogenic protozoan infection in a subject, comprising contacting peripheral blood monocytes from the subject with peptide-antigen pulsed cytotoxic T lymphocytes, wherein the cytotoxic T lymphocytes are obtained from an animal to which has been administered a polypeptide of claim 1, under conditions effective for the animal to generate T. j> rvα-antigen-specific CTLs.
60. A method for detecting a pathogenic protozoan infection in a subject, comprising contacting peripheral blood monocytes from the subject with peptide-antigen pulsed cytotoxic T lymphocytes, wherein the T lymphocytes are obtained from an animal to which has been administered a host cell of claim 46, under conditions effective for the animal to generate T. ^αrvα-antigen-specific CD4+ helper and CD8+ Cytotoxic T lymphocyte responses.
61. A method for detecting T. par>>a in a sample suspected of containing T. parva, comprising detecting in the sample a polynucleotide of claim 24.
62. The method of claim 61, which is high throughput.
63. A method for preparing a polyclonal antibody, comprising immunizing an animal with one or more polypeptides of claim 1.
64. A method for preparing a polyclonal antibody, comprising immunizing an animal with a host cell of claim 46.
65. A method for preparing a monoclonal antibody, comprising: (a) immunizing an animal with a polypeptide of claim 1, (b) recovering cells from the animal which produce antibody that binds to the polypeptide, (c) preparing a hybridoma with the cells isolated in (b), and (d) recovering a monoclonal antibody from the hybridoma that binds to the polypeptide in (a).
 66..A method for preparing a monoclonal antibody, comprising: (a) immunizing an animal with a host cell of claim 46, (b) recovering cells from the animal which produce antibody that binds to a polypeptide produced by the host cell, (c) preparing hybridomas with the cells isolated in (b), and (d) recovering a monoclonal antibody from the hybridoma that binds to the polypeptide in (b).
67. A method for identifying T. parva in a sample suspected of containing T. parva, comprising contacting the sample with an antibody of claim 48, under conditions effective for the antibody to bind specifically to its- cognate antigen, and detecting the presence of bound antibody.
68. The method of claim 67, wherein the detection is carried out by enzyme immunoassay, radioimmunoassay, fluorescence immunoassay, fiocculation, particle agglutination, flow microfluorimetryv a competition assay, or in situ chromogenic assay.
69. The method of claim 67, wherein the antibody is a polyclonal antibody.
70. The method of claim 67, wherein the antibody is a monoclonal antibody.
71. The method of claim 67, which'is quantitative.
72. The method of claim 67, which is high throughput.
73. A method for the identification of parasite antigens that are targets of cytotoxic T lymphocytes, comprising co-culturing immortalized fibroblast cell lines transfected with pooled cDNA harvested from a pathogen, with clones of lines of cytotoxic T cells, generated in an animal that has been immunized, by infection and treatment with the pathogen and assaying the supernatant from the co-culture for the presence of a soluble factor.
74. A method for a three-way matrix resolution for identification of a single cDNA clone from a pool of cDNAs, in high throughput procedures, comprising: (a) preparing a culture of transfonned cells by transforming bacterial cells with DNA from a pool of about 25 to about 500 cDNAs, wherein said pool has tested positive in a routine assay; (b) diluting the culture of transformed cells so as to yield a density of about 500- 5000 growth colonies per 150 cm2, when plated on agar-containing plates; (c) picking about 100 to 500 colonies from the growth cultures; (d) placing about 5 to 60 pools of about 10-100 individual cultures grown from the colonies, into numbered tubes, in such a manner such that each individual bacterial culture is present in more than one of said pools, so that tubes are labeled with a unique number and positioned so that a matrix of tubes is created so as to accommodate a multi-channel pipetting device; (e) creating a conesponding matrix table is by anaying the numbers on the conesponding tubes containing the pools into a matrix table; (f) testing the DNA from each ofthe tubes in a screening assay; and (g) identifying the individual positive colony by comparing the results with the matrix anay.
75. The method of claim 73, wherein the soluble factor is a cytokine.
76. The method of claim 75, wherein the cytokine is a gamma interferon.
77. The method of claim 74, wherein the screening assay causes the release of gamma interferon by CD 8+ cytotoxic T cells.
78. The method of claim 73 or claim 74, further comprising assaying the supernatant of co- cultured cells, for the presence of a soluble factor, secreted by the cytotoxic T cells.
79. The method of claim 73, wherein the pathogen is a protozoan organism.
80. The method of claim 73, wherein the fibroblast cell line is of bovine origin.
81. The method of claim 73, wherein the fibroblast cell line of bovine origin displays bovine Class I, MHC antigens.
82. The method of claim 79, wherein the protozoan organism is the macroscizhont stage of an organism in the genus Theileria.
83. The method of claim 82, wherein the organism is T. parva.
84. The method of claim 74, wherein the soluble factor is a cytokine.
85. The method of claim 84, wherein the cytokine is gamma interferon.";"(EP1670820)
Further, there is provided in another aspect of the present invention an antibody specific for the polypeptide of the present invention.
There is provided, in another aspect of the present invention, an immunogenic composition, comprising a polypeptide of the present invention and, optionally, an adjuvant, the composition being immunogenic.
In another aspect, the present invention provides a vaccine, comprising one or more polypeptides of the present invention and, optionally, an adjuvant; wherein said polypeptide is immunogenic.
In one aspect, the present invention provides an isolated polypeptide comprising a sequence represented by SEQ ID NO:1, or a variant thereof having greater than 90% identity thereto and having the same or similar biological activity as SEQ ID NO: 1, or any one of SEQ ID Nos 4 to 7.";"(EP1670820)
Such antibodies are useful for the detection of the presence of a stimulating antigen, in animals tissues and fluids.
The antibodies are also useful for the affinity purification of recombinantly produced peptides or proteins.
Such antibodies are also useful as diagnostic reagents for the qualitative and quantitative detection of protozoan diseases or in antibody-mediated tests and assays.
Theilerioses are a group of disease syndromes affecting cattle, sheep, goats and domestic buffalo caused by tick-borne haemo-protozoan parasites in the genus Theileria.
The most economically important diseases include East Coast fever (ECF), Mediterranean fever, and malignant theileriosis.
This is attributed to the failure of attenuated T. parva parasites to induce immunity.
T. parva is known to cause a lympho proliferative response in infected animals that resembles a variety of Tcell lynlphomas, leukemias and other lymphocytic cancers.";"A61K
A61K-038/00
A61K-039/00
A61K-039/002
A61K-039/018
C07K
C07K-014/435
C07K-014/44
C07K-016/18
C07K-016/20
C12N
C12N-015/00
C12N-015/10
C12N-015/30
C12Q-001/68
G01N
G01N-033/00
G01N-033/50
G01N-033/569";"(EP1670820)
1. An isolated polypeptide comprising a sequence represented by SEQ ID NO:1, or a variant thereof having greater than 90% identity thereto and having the same or similar biological activity as SEQ ID NO: 1, or any one of SEQ ID Nos 4 to 7.";"(EP1670820)
ANTIGEN(100,24)
EAST COAST FEVER VACCINE(100,1)
POLYNUCLEOTIDE ENCODING(85,12)
RECOMBINANT CONSTRUCT(78,12)
HAEMO PROTOZOON PARASITE(69,1)
POLYCLONAL ANTIBODY(62,8)
PARVA PARASITE(60,1)
T CELL LYNLPHOMA VARIETY(59,1)
PROTOZOON DISEASE DETECTION(58,1)
DOMESTIC BUFFALO(56,1)
MALIGNANT THEILERIOSIS(52,2)
MEDITERRANEAN FEVER(51,2)
GENUS THEILERIA(48,2)
LYMPHOCYTIC CANCER(48,2)
ANTIBODY(41,33)
NON HUMAN ANIMAL(41,4)
LYMPHOPROLIFERATIVE RESPONSE(41,2)
WESTERN BLOT ASSAY(39,2)
ECONOMICALLY IMPORTANT DISEASE(38,1)
DISEASE SYNDROME GROUP(37,1)
IMMUNOGENIC(36,5)
ATTENUATED T FAILURE(36,1)
DIAGNOSTIC REAGENT(35,2)
ISOLATED POLYPEPTIDE(34,4)
INFECTED ANIMAL(34,2)
ADJUVANT(33,10)
INFECTION DIAGNOSIS(32,2)
HYBRIDOMA(31,12)
PARVA INFECTION(31,2)
VACCINIA VIRUS(31,2)
YEAST EPISOME(31,2)
ANTIBODY MEDIATED TEST(30,1)
MEDICAMENT PREPARATION(30,1)
BACTERIAL PLASMID(29,2)
MONOCLONAL ANTIBODY(28,16)
BIOLOGICAL ACTIVITY(28,6)
VACCINE(27,10)
RECOVERED CELL(26,6)
AUTOLOGOUS IMMORTALIZED FIBROBLAST(26,4)
EXPRESSION CONTROL SEQUENCE(25,12)
RECOVERING SERUM(25,2)
YEAST CHROMOSOMAL ELEMENT(24,2)
INFECTION TREATMENT(24,1)
THEILERIOSE(23,2)
IMMUNITY(23,1)
ANTIGEN SPECIFIC CYTOTOXIC LYMPHOCYTE(22,3)
THERMOPHILIC BACTERIUM THERMUS AQUATICUS(21,1)
LEUKEMIA(19,2)
MODIFIED VACCINIA(18,3)
PEPTIDE(17,40)
IDENTITY(17,3)
IFN GAMMA ELISPOT(17,3)
FOWLPOXVIRUS(17,2)
PAPOVAVIRUS(17,2)
PSEUDORABIES VIRUS(17,2)
MER PEPTIDE(16,8)
PARASITIZED ERYTHROCYTE LETHAL DOSE(16,1)
EAST COAST FEVER(15,8)
PREVENTION(15,3)
GOAT(15,2)
IMMORTALIZED SKIN FIBROBLAST(15,2)
SHEEP(15,2)
RODENT MALARIA PLASMODIUM YOELII(15,1)
PURIFYING T(14,3)
RETROVIRUS(14,3)
PARVA ANTIGEN ENCODING POLYNUCLEOTIDE(14,1)
PARVA ANTIGEN POLYPEPTIDE VARIANT(14,1)
PLASMODIUM CHABAUDI ADAMI CHALLENGE(14,1)
CATTLE(13,7)
AUTOLOGOUS TPM(13,3)
PRELIMINARY CONTIG(13,3)
T CELL RECEPTOR(13,3)
CANARY POX VIRAL VECTOR(13,1)
LYMPHOPROLIFERATIVE DISORDER(13,1)
NUCLEOTIDE ENCODING PARASITE ANTIGEN(13,1)
PARVA CYTOTOXIC LYMPHOCYTE(13,1)
TICK ACARICIDAL DESTRUCTION(13,1)
TRITURATED TICK STABILITY(13,1)
WISCONSIN GENETIC COMPUTING UNIVERSITY(13,1)
ASSAY(12,6)
BOLA CLASS(12,5)
PARVA SPOROZOITE(12,2)
CANDIDATE PARASITE ANTIGEN IDENTIFICATION(12,1)
CATTLE EXPERIMENTAL IMMUNIZATION(12,1)
PARASITIC PROTOZOON ANTIGEN(12,1)
PARVA PARASITE POPULATION(12,1)
RESPONDING LYMPHOCYTE STIMULATION(12,1)
THEILERIA PARASITE PATHOGENIC STAGE(12,1)
PULSED CELL(11,7)
IFN GAMMA PRODUCTION(10,4)
ISOLATED POLYNUCLEOTIDE(10,3)
REPORTER MOLECULE(10,3)
BIOLOGICAL PROTEIN ACTIVITY(10,2)
MRNA POPULATION(10,2)
PLASMODIUM SPECIES(10,2)
SCHIZONT ANTIGEN(10,2)
SOUTHERN BLOT(10,2)
CELL UNDERGOING LYMPHOPROLIFERATION(10,1)
GENE ENCODING CANDIDATE ANTIGEN(10,1)
PARVA ANTIGEN POLYPEPTIDE ACTIVITY(10,1)
PARVA POLYPEPTIDE VARIANT(10,1)
PROTEIN NON REDUNDANT DATABASE(10,1)
VACCINE IMMUNIZING SPECTRUM(10,1)
IMMUNE RESPONSE(9,8)
PARVA NUCLEIC ACID(9,5)
RECOMBINANT NUCLEIC ACID(9,5)
PLASMID VECTOR(9,3)
TRANS ACTING FACTOR(9,3)
ANIMAL INFECTION(9,2)
ANTIGEN PEPTIDE(9,2)
ANTIGENIC SUBSTANCE(9,2)
HYBRIDIZATION PROBE(9,2)
IMMUNIZED ANIMAL(9,2)
LABELED NUCLEOTIDE(9,2)
MILLION CATTLE(9,2)
OLIGOPEPTIDE(9,2)
OPTIMIZED PROMOTER(9,2)
PARVA GENE(9,2)
PEPTIDE RECOGNITION(9,2)
UNCHARGED POLAR(9,2)
ANTIBODY ELISPOT ASSAY(9,1)
CATIONIC LIPID MEDIATED TRANSFECTION(9,1)
CLINICALLY DETECTABLE INFECTION EPISODE(9,1)
FARMER BUDGET(9,1)
HYDROXYLAPATITE CHROMATOGRAPHY(9,1)
IMMUNIZATION INFECTION DOSE(9,1)
IMMUNIZATION STRATEGY(9,1)
METALLOTHIONEIN GENE EXPRESSION(9,1)
PARVA GENOMIC DNA(9,1)
POLYPEPTIDE SEQUENCE DELETIONAL VARIANT(9,1)
RECOMBINANT NUCLEOTIDE VARIANT(9,1)
RECOMBINANT POLYPEPTIDE VARIANT(9,1)
SMITH WATERMAN(9,1)
WHOLE GENOME SHOTGUN STRATEGY(9,1)
LABORATORY PRESS(8,4)
EAST COAST FEVER DISEASE(8,3)
GENOME SCAN(8,2)
ANIMAL VACCINATION(8,1)
BACULOVIRUS EXPRESSION VECTOR(8,1)
CANDIDATE ANTIGEN ENCODING(8,1)
CONSTITUTIVELY EXPRESS CLASS(8,1)
DIRECTING MRNA TRANSCRIPTION(8,1)
DNA MOLECULE LIGATION(8,1)
EUKARYOTIC VIRUS VECTOR(8,1)
FRAGMENT ANTIBODY MOLECULE(8,1)
FRANK CLINICAL DISEASE DEVELOPMENT(8,1)
HYBRIDIZATION STRINGENCY(8,1)
INFECTION RATIONALE(8,1)
NONDENATURING DETERGENT(8,1)
PARASITE STAGE INFECTIVE(8,1)
PIROPLASM INFECTED ERYTHROCYTE(8,1)
PROBE DETECTABLE LABEL(8,1)
RCOMBINANT PLASMID(8,1)
RECOMBINANT VIRAL VECTOR(8,1)
RESTRICTION ENZYME DIGESTION(8,1)
SALMONELLA TYPHIMURIUM(8,1)
SCHIZONT INFECTED LYMPHOBLAST(8,1)
THEILERIA PARVA ANTIGEN(8,1)
TOXOPLASMA GONDII(8,1)
VACCINATION CAMPAIGN(8,1)
EQUIVALENT PROTEIN(7,5)
DUPLEX FORMATION(7,3)
PEPTIDE PERCENT(7,3)
SYNTHETIC CHEMISTRY(7,3)
BOVINE ORIGIN(7,2)
DNA ENCODING(7,2)
ENCODED PROTEIN(7,2)
EXEMPLIFIED PROTEIN(7,2)
FUSION VECTOR(7,2)
LB BROTH(7,2)
RECOMBINANT HOST CELL(7,2)
RECOMBINANT PROTEIN EXPRESSION(7,2)
SEQUENCE SIMILARITY(7,2)
TRANSLATION INITIATION REGION(7,2)
ADENOVIRUS ENHANCER(7,1)
ANNEALED PRIMER EXTENSION(7,1)
ANNOTATION DATABASE(7,1)
ANTIGEN LYSIS(7,1)
ANTISENSE TRANSCRIPT(7,1)
ATTENUATED PARASITE(7,1)
BABESIA SPP(7,1)
BIOLISTIC PARTICLE DELIVERY(7,1)
CATIONIC EXCHANGE CHROMATOGRAPHY(7,1)
CATTLE LYMPHOCYTE(7,1)
CATTLE WITCH(7,1)
CHIMERIC POLYPEPTIDE(7,1)
CLONED POLYNUCLEOTIDE(7,1)
CODON SUBSTITUTION(7,1)
COGNATE ANTIGEN(7,1)
COLI EXPRESSION VECTOR(7,1)
CONSENSUS GENE(7,1)
CYTOXAUZOON SPP(7,1)
DEGENERATE(7,1)
DELETIONAL MUTATION(7,1)
DISEASE PATHOGENESIS(7,1)
DNA VIRUS VECTOR(7,1)
DRUG SIMULTANEOUS ADMINISTRATION(7,1)
EIMERIA SPP(7,1)
ESTABLISHED CHROMOSOMAL MARKER(7,1)
EXPONENTIAL ACCUMULATION(7,1)
FLUORESCENCE IMMUNOASSAY(7,1)
FUSION EXPRESSION VECTOR(7,1)
FUSION MOIETY JUNCTION(7,1)
HOMOLOGOUS PARASITE(7,1)
IMMEDIATE EARLY ENHANCER(7,1)
IMMEDIATE EARLY PROMOTER(7,1)
IMMUNOGEN ADMINISTRATION(7,1)
INDUCIBLE PROMOTER(7,1)
INDUCING IMMUNOPROTECTION(7,1)
INTERCHAIN AFFINITY(7,1)
INTRACELLULAR PARASITE(7,1)
INVESTMENT DEAL(7,1)
KDA GLYCOPROTEIN(7,1)
LYMPHOCYTE PROLIFERATION(7,1)
MAMMALIAN EXPRESSION VECTOR(7,1)
MULTITRANSMEMBRANE DOMAIN(7,1)
NON CONSERVATIVE SUBSTITUTION(7,1)
NON RADIOACTIVE LABEL(7,1)
NUCLEOTIDE SEQUENCE MULTITUDE(7,1)
PARVA CONTIG(7,1)
PATHOGENIC PROTOZOON INFECTION(7,1)
PHENOTYPIC TRAIT(7,1)
PHOSPHOCELLULOSE CHROMATOGRAPHY(7,1)
POLYNUCLEOTIDE VARIANT(7,1)
POLYOMA ENHANCER(7,1)
PROTEOLYTIC CLEAVAGE(7,1)
PROTOZOON ORGANISM(7,1)
RECOMBINANT BACULOVIRUS(7,1)
RECOMBINANT PLASMID(7,1)
RECOMBINANT VECTOR CONSTRUCT(7,1)
RESTRICTION ENDONUCLEASE(7,1)
SOUTHEASTERN EUROPE(7,1)
SOUTHERN RUSSIA(7,1)
STIMULATORY ANTIGEN(7,1)
T CELL LYMPHOMA VARIETY(7,1)
THEILERIACIDAL DRUG(7,1)
TRAINED VETERINARIAN(7,1)
VACCINATION PROGRAM(7,1)
VACCINATION STRATEGY(7,1)
VARIANT HYBRIDIZATION(7,1)
VIRULENT PARASITE(7,1)
COMPLEMENTARITY(6,3)
ANTIBODY PRODUCTION(6,2)
BACTERIAL CELL(6,2)
BOVINE ENDOTHELIAL CELL(6,2)
CDNA SEQUENCE(6,2)
COLD SPRING HARBOR(6,2)
EXEMPLIFIED POLYNUCLEOTIDE SEQUENCE(6,2)
EXEMPLIFIED SEQUENCE(6,2)
FINAL PEPTIDE CONCENTRATION(6,2)
GENE MODEL(6,2)
MG ML DENATURED DNA(6,2)
POST CHALLENGE(6,2)
RESTRICTION SITE(6,2)
SOLUBLE FACTOR RELEASE(6,2)
UNKNOWN SEQUENCE(6,2)
ACTIVE POLYPEPTIDE FRAGMENT(6,1)
ALANINE SUBSTITUTION(6,1)
ANEMIC DISEASE(6,1)
ANIMAL IMMUNIZATION(6,1)
ANIMAL RESISTA(6,1)
ANNEALING PRIMER(6,1)
ANTIGEN PROTEOLYTIC PROCESSING(6,1)
ANTIGEN STIMULATION(6,1)
ANTIGENIC PROTEIN(6,1)
ANTISENSE RNA EXPRESSION(6,1)
ANTISENSE RNA TRANSCRIPTION(6,1)
BACULOVIRUS VECTOR(6,1)
BIOCHEMICAL CORP(6,1)
BOOSTER ADMINISTRATION(6,1)
CANDIDATE ANTIGEN PRODUCTION(6,1)
CATTLE PROTECTION(6,1)
CATTLE RECOVERING(6,1)
CDNA SUBTRACTION(6,1)
CHROMOSOMAL SPREAD(6,1)
CLONING VECTOR ASSORTMENT(6,1)
CLONTECH LABORATORY(6,1)
CODON CHOICE(6,1)
COMPETITION ASSAY(6,1)
CONSTITUTIVE EXPRESSION(6,1)
CULTURED INSECT CELL(6,1)
CYTOTOXIC ACTIVATION(6,1)
DNA VECTOR(6,1)
ENCOMPASSING FRAGMENT(6,1)
EUKARYOTIC HOST CELL(6,1)
FREEZE THAW(6,1)
GENE FINDING PROGRAM(6,1)
GENE PROPAGATION(6,1)
HETEROLOGOUS GENE(6,1)
HETEROLOGOUS HOST(6,1)
HOMOLOGOUS CHALLENGE(6,1)
IMMOBILIZED DNA HYBRIDIZATION(6,1)
IMMUNE CATTLE(6,1)
INCUBATING TP(6,1)
INDUCIBLE EXPRESSION(6,1)
INTRAVENOUS CHALLENGE(6,1)
IRRELEVANT PROTEIN(6,1)
LECTIN CHROMATOGRAPHY(6,1)
LETHAL CHALLENGE(6,1)
LIVE VACCINE(6,1)
LUCIFERASE GENE(6,1)
MATURE PROTEIN(6,1)
MINICHROMOSOME(6,1)
MODERATE STRINGENCY(6,1)
MOLECULE SECRETION(6,1)
MOUSE VACCINATION(6,1)
MUTANT SCREENING(6,1)
NATIVE GENOMIC SEQUENCE(6,1)
NICK TRANSLATION(6,1)
NUCLEOTIDE SEQUENCE CODING(6,1)
NUCLEOTIDE SIMILARITY EXTENT(6,1)
NUCLEOTIDE STRETCH(6,1)
NUCLEOTIDE SUBSTITUTION(6,1)
NUTRIENT ADDITIVE(6,1)
PARASITE PROTEIN(6,1)
PARASITE STRAIN(6,1)
PARTICLE AGGLUTINATION(6,1)
PARVA GENOME(6,1)
PARVA PROTEIN(6,1)
PEPTIDE BACKBONE(6,1)
PLURAL REFERENT(6,1)
PREDICTED GENE(6,1)
PRELIMINARY GENOME SEQUENCE(6,1)
PRIME CANDIDATE(6,1)
PROKARYOTIC HOST CELL(6,1)
PROTEIN PURIFICATION(6,1)
PROTEIN STAINING(6,1)
RARE TRANSCRIPT(6,1)
RE LATED MOLECULE(6,1)
REPLICATION ORIGIN(6,1)
RESTRICTION SELECTION MUTAGENESIS(6,1)
SHUFFLING GENE(6,1)
SIGNALING PATHWAY(6,1)
STRONG NON COVALENT BOND(6,1)
SUBPOPULATION SELECTION(6,1)
TARGET POLYNUCLEOTIDE(6,1)
THERMOSTABLE DNA POLYMERASE(6,1)
TRANSCRIPT ISOLATION(6,1)
TRANSCRIPTION INITIATION(6,1)
TRANSCRIPTION TERMINATION(6,1)
TRICHOPLUSIA NI(6,1)
UNIVERSAL PRIMER(6,1)
UNSUCCESSFUL ATTEMPT(6,1)
VIRAL REPLICATION(6,1)
LIGAND(5,5)
CYTOTOXIC T LYMPHOCYTES EPITOPE(5,3)
ELECTROPORATION(5,3)
GAMMA INTERFERON(5,3)
OLIGOMER(5,3)
TEMPLATE(5,3)
EXONUCLEASE(5,2)
ACTIVE PROTEIN FRAGMENT(5,1)
ADOPTIVE CELL(5,1)
AFFECTED COUNTRY(5,1)
AFFINITY CHROMATOGRAPHY(5,1)
ANTI BOLA(5,1)
ANTI CANCER(5,1)
ARTIFICIAL CHROMOSOME CONSTRUCTION(5,1)
ASEXUAL BLOOD(5,1)
BACTERIOPHAGE GENETIC ELEMENT(5,1)
BIOLOGICAL ANALYSIS AID(5,1)
BIOLOGICAL COMPOUND ACTIVITY(5,1)
BOVINE SKIN FIBROBLAST CELL(5,1)
BOVINE SPECIES(5,1)
CANDIDATE ANTIGEN SEQUENCE INFORMATION(5,1)
CHROMIUM RELEASE ASSAY(5,1)
CHROMOGENIC AGENT(5,1)
CHROMOSOME REGION(5,1)
CLONED DNA(5,1)
COVERAGE ASSUMING(5,1)
DIAGNOSTIC ASSAY(5,1)
DNA CONSTRUCT(5,1)
DNA FRAGMENT(5,1)
EAST COAST FEVER INFECTION(5,1)
EXEMPLIFIED PROBE(5,1)
EXPRESSED TP(5,1)
FC REGION FRAGMENT(5,1)
FUSION PROTEIN(5,1)
GENBANK(5,1)
GENE CONSTRUCT(5,1)
GENE PROBE(5,1)
GENETIC CODE REDUNDANCY(5,1)
GENETIC MAP(5,1)
GLYCOSYLATION PATTERN(5,1)
HOMOLOGOUS 250 KDA MOLECULE(5,1)
HOST BACTERIUM(5,1)
HOST CELL GENOME(5,1)
HUMAN MALARIA(5,1)
HYDROPHOBIC INTERACTION CHROMATOGRAPHY(5,1)
IMMORTALIZED FIBROBLAST CELL(5,1)
IMMUNE MOLECULE(5,1)
IMMUNIZATION PROTOCOL VARIETY(5,1)
INFECTED BLOOD(5,1)
INFECTIOUS AGENT(5,1)
INSECT HOST CELL(5,1)
INTERNATIONAL JOURNAL(5,1)
LABELED DNA(5,1)
LABELED PROTEIN(5,1)
LAMBDA PHAGE DERIVATIVE(5,1)
LATE PROMOTER(5,1)
LOCAL PARASITE(5,1)
LYSE TP(5,1)
MAINTENANCE PROPAGATION(5,1)
MARKER GENE(5,1)
MINIMAL HOMOLOGY(5,1)
MRNA PROBE PRODUCTION(5,1)
NATIVE MOLECULE(5,1)
NONONUCLEAR CELL(5,1)
NUCLEAR GENOME(5,1)
NUCLEOTIDE SEQUENCE CHROMOSOMAL LOCATION(5,1)
PARSING(5,1)
PET 11D(5,1)
POLYACRYLAMIDE GEL(5,1)
POLYNUCLEOTIDE PROBABLE ACTIVITY(5,1)
POLYPEPTIDE SEQUENCE VARIANT ACTIVITY(5,1)
POOLED CDNA(5,1)
PREDICTION SIGNAL(5,1)
PRIMED SYNTHESIS(5,1)
PROBE MOLECULE(5,1)
PURE PROTEIN(5,1)
PURIFIED PEPTIDE(5,1)
RANDOM MUTAGENESIS(5,1)
RE LATED SEQUENCE DETECTION(5,1)
RECOMBINANT PROTEIN SOLUBILITY(5,1)
RESTRICTION ENZYME VARIETY(5,1)
RETAINING FRAGMENT(5,1)
SCANNING MUTAGENESIS(5,1)
SCHIZONT INFECTED CELL(5,1)
SDS PAGE ELECTROPHORESIS(5,1)
SEGMENT AMPLIFICATION(5,1)
SEQUENCE NUCLEOTIDE(5,1)
SHORTED NAME(5,1)
SOLUBLE FACTOR SECRETION(5,1)
SUBUNIT VACCINE GENERATION(5,1)
SUCCESSIVE REFINEMENT(5,1)
TARGET CODON(5,1)
TARGET FRAGMENT(5,1)
TARGET SEQUENCE STRAND(5,1)
TP COMPLETE ORF(5,1)
TRANSFECT HOST(5,1)
TRANSIENT PORE(5,1)
UPSTREAM ENHANCER(5,1)
VE PEPTIDE(5,1)
WEAK ANTIBODY(5,1)
SKIN FIBROBLASTS(4,16)
ANTIGENIC DETERMINANT(4,2)
COLONY(4,2)
COSMID(4,2)
ENZYMOLOGY(4,2)
FINAL CONCENTRATION(4,2)
GENE EXPRESSION TECHNOLOGY(4,2)
INFECTIOUS T(4,2)
INVOLVEMENT(4,2)
KILODALTON(4,2)
LIPOFECTION(4,2)
NORTH AFRICA(4,2)
OLIGONUCLEOTIDE PROBE(4,2)
OVEREXPRESSION(4,2)
PHAGEMID(4,2)
PROTEASE(4,2)
SCANNING AMINOACID(4,2)
TRANSDUCTION(4,2)
VECTOR NUCLEIC ACID(4,2)
ACTIVE FRAGMENT(4,1)
AMMONIUM SULFATE PRECIPITATION(4,1)
ANIMAL ABILITY(4,1)
ANTIGEN PRESENCE(4,1)
BIOLOGICAL SAMPLE(4,1)
BOUND ANTIBODY PRESENCE(4,1)
BOVINE CLASS(4,1)
CALCIUM PHOSPHATE TRANSFECTION(4,1)
CELL DISTRIBUTION(4,1)
CELL LYSIS(4,1)
CELL MEMBRANE SOLUBILIZATION(4,1)
CHEMILUMINESCER(4,1)
CHEMOTHERAPY(4,1)
CHLORTETRACYCLINE(4,1)
CLASS EXPRESSION(4,1)
COMMERCIALLY VALUABLE(4,1)
CONSERVATIVE AMINOACID SUBSTITUTION(4,1)
CONSERVED REGION(4,1)
CONTIGUOUS SEQUENCE(4,1)
CRITICAL PROTEIN REGION(4,1)
CULTURING CELL(4,1)
CYTOMEGALOVIRUS(4,1)
CYTOTOXIC T LYMPHOCYTE RESPONSE(4,1)
DERIVATIZED FUNCTIONAL GROUP(4,1)
DIAGNOSTIC AID(4,1)
DIHYDROFOLATE REDUCTASE(4,1)
DISEASE DETECTION(4,1)
DISPLAY CELL(4,1)
DNA SEGMENT(4,1)
DNA SEQUENCE ENCODING(4,1)
DONOR CELL(4,1)
DOT BLOT(4,1)
DRUG COST(4,1)
EQUIVALENT BIOLOGICAL ACTIVITY(4,1)
EXOGENOUS FACTOR(4,1)
EXPRESSION VECTOR VARIETY(4,1)
EXTRACHROMOSOMAL ELEMENT(4,1)
FLUORESCENT COMPOUND(4,1)
FORMAT TECHNOLOGY(4,1)
FUNCTIONAL LINKAGE(4,1)
GENE GUN(4,1)
GENE SEQUENCE(4,1)
HYBRIDIZATION BUFFER SOLUTION(4,1)
IMMUNOREACTIVITY(4,1)
IMPAIRED CAPACITY(4,1)
ISOLATED PROTEIN(4,1)
KILOBASE(4,1)
LANE MW(4,1)
LINKAGE ANALYSIS(4,1)
LIVING CELL(4,1)
LOW VIRULENCE PARASITE(4,1)
LYSED CELL(4,1)
LYSING AGENT(4,1)
MAMMALIAN CELL CULTURE(4,1)
MAPPING(4,1)
MECHANICAL DISRUPTION(4,1)
METHOTREXATE RESISTANCE(4,1)
MODIFIED METHIONINE(4,1)
MODIFIED POLYPEPTIDE(4,1)
MUTATION PERFORMANCE(4,1)
NEOMYCIN RESISTANCE(4,1)
NI NTA(4,1)
NORTHERN ANALYSIS(4,1)
NUCLEIC ACID MANIPULATION(4,1)
NUCLEIC ACID MOLECULE VECTOR(4,1)
NUCLEIC ACID TRANSCRIPTION(4,1)
NUCLEOTIDE SEQUENCE VARIETY(4,1)
NUMEROUS REGULATORY SEQUENCE(4,1)
OLIGONUELCOTIDE(4,1)
PARTIAL FRAGMENT(4,1)
PARVA TRANSFER(4,1)
PASSAGE ATTENUATED CULTURE(4,1)
PERIPHERAL BLOOD MONOCYTE(4,1)
POLYPEPTIDE EPITOPE(4,1)
PRIMER EXTENSION PRODUCT(4,1)
PROBE CONCENTRATION(4,1)
PROBE GENERATION(4,1)
PROBE SEQUENCE(4,1)
PROTEIN ALIGNMENT(4,1)
PROTEIN PRODUCTION(4,1)
RECOMBINANT CELL CULTURE(4,1)
RECOMBINANT DNA TECHNIQUE ESTABLISHMENT(4,1)
RECOMBINANT DNA TECHNOLOGY(4,1)
RECOMBINANT PRODUCTION(4,1)
RESIDUE STRETCH(4,1)
SCREENING CELL(4,1)
SEQUENCE CONTIG(4,1)
SEQUENCE IDENTIFICATION(4,1)
SEQUENCE IDENTITY(4,1)
STANDARD TRIPLET GENETIC CODE(4,1)
SUPPLY COMMERCIAL KIT(4,1)
T BIOASSAY(4,1)
T CELL DERIVED SOLUBLE FACTOR(4,1)
T CELL REACTION(4,1)
T EXPRESSED GENE(4,1)
TARGET RECOMBINANT PROTEIN(4,1)
THERAPEUTIC(4,1)
TRANSCRIBED REGION(4,1)
UNDEFINED TERM(4,1)
WHOLE GENOME SEQUENCE(4,1)
XDENHARDT SOLUTION(4,1)
SPOT FORMING CELL(3,13)
CONTROL TP(3,3)
COOMASSIE BLUE(3,3)
MELTING TEMPERATURE(3,3)
POLYMERASE CHAIN REACTION AMPLIFICATION(3,3)
HORMONE(3,2)
WASHING(3,2)
ACARICIDE(3,1)
ACID EXTRACTION(3,1)
ACTIVATED CELL(3,1)
ADENO ASSOCIATED VIRAL VECTOR(3,1)
AFFECTED REGION(3,1)
AMINOACID IDENTITY SIMILARITY(3,1)
AMINOACID SEQUENCE VARIANT(3,1)
AMINOACID SIMILARITY(3,1)
AMPICILLIN(3,1)
ANALOG(3,1)
ANIMAL CELL(3,1)
ANNULATA(3,1)
ANTIBIOTIC(3,1)
ANTIBODY FRAGMENT(3,1)
ARTHROPOD(3,1)
ASSEMBLER(3,1)
AUTORADIOGRAPHY(3,1)
AVIAN POX BASED VECTOR(3,1)
BACTERIAL P(3,1)
BACTERIOPHAGE LAMBDA(3,1)
BIODEGRADABLE IMPLANT(3,1)
BIOLOGICAL PROTEIN PRODUCT ACTIVITY(3,1)
BUFFALO(3,1)
BULK CULTURE TECHNIQUE DEVELOPMENT(3,1)
BUPAVAQUONE(3,1)
CASSETTE MUTAGENESIS(3,1)
CELL LOCATION(3,1)
CELL PERCENT(3,1)
CHEMICAL INSERTION(3,1)
CHEMICAL MOIETY(3,1)
CO CULTURE(3,1)
CODON USAGE SPECIFIC MUTATION(3,1)
COMPARISON BASIS(3,1)
CONTIGUOUS AMINOACID RESIDUE(3,1)
CONTROL EXPERIMENTAL DATA(3,1)
COTRANSFECTION(3,1)
(EP1668029)
CYTOTOXIC T LYMPHOCYTES(100,23)
COGNATE ANTIGEN(100,5)
SCHIZONT ANTIGEN(100,2)
EAST COAST FEVER VACCINE(100,1)
BOUND ANTIBODY PRESENCE(66,5)
IMMUNOGENIC(56,4)
ANTIBODY(53,33)
HAEMO PROTOZOON PARASITE(53,1)
FRANK CLINICAL DISEASE DEVELOPMENT(51,1)
PATHOGENIC PROTOZOON INFECTION(49,3)
INFECTION RATIONALE(48,1)
THELIERIA PARVA(48,1)
PARVA PARASITE(47,1)
PROTOZOON DISEASE DETECTION(47,1)
ISOLATED POLYPEPTIDE(45,4)
RECOMBINANT CONSTRUCT(45,2)
ANTIGEN SPECIFIC CYTOTOXIC LYMPHOCYTE(44,3)
DOMESTIC BUFFALO(43,1)
THEILERIACIDAL DRUG(43,1)
POLYCLONAL ANTIBODY(41,6)
ISOLATED POLYNUCLEOTIDE(41,5)
MALIGNANT THEILERIOSIS(40,2)
MEDITERRANEAN FEVER(39,2)
GENUS THEILERIA(38,2)
PEPTIDE ANTIGEN(36,1)
MULTITRANSMEMBRANE DOMAIN(32,1)
EXCIPIENT(31,3)
ANIMAL(30,37)
EUKARYOTIC VIRUS VECTOR(30,2)
WESTERN BLOT ASSAY(30,2)
MONOCLONAL ANTIBODY(29,12)
DISEASE SYNDROME GROUP(29,1)
ECONOMICALLY IMPORTANT DISEASE(29,1)
CYTOTOXIC T LYMPHOCYTE RESPONSE(28,3)
PERIPHERAL BLOOD MONOCYTE(28,3)
PURIFYING T(28,3)
ATTENUATED T FAILURE(28,1)
DIAGNOSTIC REAGENT(27,2)
HYBRIDOMA(26,6)
COMPLEMENT(26,3)
FLUORESCENCE IMMUNOASSAY(26,2)
PULSED CYTOTOXIC T LYMPHOCYTE(24,3)
MINICHROMOSOME(24,2)
RECOVERED CELL(23,3)
COMPETITION ASSAY(23,2)
ANTIBODY MEDIATED TEST(23,1)
HOST CELL(22,27)
PARTICLE AGGLUTINATION(22,2)
ADOPTIVE CELL(21,1)
ADJUVANT(20,3)
PEPTIDE(18,42)
VECTOR(18,40)
THEILERIOSE(18,2)
IFN ELISPOT(17,9)
IMMUNITY(17,1)
THERMOPHILIC BACTERIUM THERMUS AQUATICUS(17,1)
EPITOPE(16,11)
KIT(16,6)
HELPER(16,4)
THROUGHPUT(15,8)
ANTIGEN SPECIFIC CTL(15,1)
INFECTION(14,12)
EXPRESSION CONTROL SEQUENCE(14,2)
TRANSFECTANT RECOGNITION(13,5)
RADIOIMMUNOASSAY(13,2)
CYTOTOXIC T LYMPHOCYTE(12,4)
RESTRICTION ENZYME DIGESTION(12,3)
FLOCCULATION(12,2)
GOAT(12,2)
SHEEP(12,2)
CYTOTOXIC T CELL(11,11)
EAST COAST FEVER(11,6)
OLIGOPEPTIDE(11,5)
PARVA SPOROZOITE(11,3)
ENZYME IMMUNOASSAY(11,2)
LETHAL DOSE OFPARASITIZED ERYTHROCYTE(11,1)
PARVA ANTIGEN POLYPEPTIDE VARIANT(11,1)
PLASMODIUM CHABAUDI ADAMI CHALLENGE(11,1)
RESOLVED SCHIZONT CDNA SCREENING(11,1)
RODENT MALARIA PLASMODIUM YOELII(11,1)
CATTLE(10,8)
ASSAY(10,7)
T CELL RECEPTOR(10,3)
MATURE ANTIGEN PEPTIDE(10,2)
PARASITE ANTIGEN IDENTIFICATION(10,2)
CANARY POX VIRAL VECTOR(10,1)
PARVA CYTOTOXIC LYMPHOCYTE(10,1)
RECOMBINANT IMMUNOGLOBULIN LIBRARY SCREENING(10,1)
SCHIZONT CDNA POOL SCREENING(10,1)
TICK ACARICIDAL DESTRUCTION(10,1)
TRITURATED TICK STABILITY(10,1)
CDNA ENCODING PARASITE ANTIGEN(9,1)
KEYHOLE LIMPET HEMOCYANIN(9,1)
PARASITIC PROTOZOON ANTIGEN(9,1)
PARVA PARASITE POPULATION(9,1)
RESPONDING LYMPHOCYTE STIMULATION(9,1)
THEILERIA PARASITE PATHOGENIC STAGE(9,1)
CLONTECH LABORATORY(8,3)
ANTIGEN PEPTIDE MOTIF(8,1)
CATTLE IMMUNIZATION EXPERIMENT(8,1)
CHARGE COUPLED DEVISE CAMERA(8,1)
DEPENDENT RECOGNITION(8,1)
IMMUNOGENIC PEPTIDE FRAGMENT(8,1)
PARVA ANTIGEN POLYPEPTIDE ACTIVITY(8,1)
PARVA POLYPEPTIDE VARIANT(8,1)
PROTEIN POST TRANSLATIONAL COVALENT MODIFICATION(8,1)
VACCINE IMMUNIZING SPECTRUM(8,1)
IFN PRODUCTION(7,5)
PARVA NUCLEIC ACID(7,5)
RECOMBINANT NUCLEIC ACID(7,5)
REPORTER MOLECULE(7,3)
RESTRICTED TP(7,3)
TRANS ACTING FACTOR(7,3)
BIOLOGICAL PROTEIN ACTIVITY(7,2)
GAMMA CARBOXYLATION(7,2)
IMMUNIZED ANIMAL(7,2)
LABELED NUCLEOTIDE(7,2)
MILLION CATTLE(7,2)
MRNA POPULATION(7,2)
OPTIMIZED PROMOTER(7,2)
PLASMODIUM SPECIES(7,2)
PROMOTERFINDER(7,2)
SOUTHERN BLOT(7,2)
TRANSFORMED CELL CULTURE(7,2)
UNCHARGED POLAR(7,2)
ANTIBODY ELISPOT ASSAY(7,1)
BIOLOGICAL ANTIGEN ACTIVITY(7,1)
CATIONIC LIPID MEDIATED TRANSFECTION(7,1)
CLINICALLY DETECTABLE INFECTION EPISODE(7,1)
CO CULTURED CELL SUPERNATENT(7,1)
ELECTROPHORESIS AUTORADIOGRAPH(7,1)
FARMER BUDGET(7,1)
HEME MOIETY ATTACHMENT(7,1)
HYDROXYLAPATITE CHROMATOGRAPHY(7,1)
IMMUNIZATION INFECTION DOSE(7,1)
IMMUNIZATION STRATEGY(7,1)
MATURE ANTIGEN PURIFICATION(7,1)
PEPTIDE EAST COAST FEVER(7,1)
PHOSPHOTIDYLINOSITOL COVALENT ATTACHMENT(7,1)
POLYPEPTIDE SEQUENCE DELETIONAL VARIANT(7,1)
RANDOMLY PRIMED LIBRARY(7,1)
RECOMBINANT NUCLEOTIDE VARIANT(7,1)
RECOMBINANT POLYPEPTIDE VARIANT(7,1)
SCHIZONT CDNA RESOLUTION(7,1)
POLYCLONAL CYTOTOXIC T LYMPHOCYTES(6,6)
LABORATORY PRESS(6,4)
EAST COAST FEVER DISEASE(6,3)
ANTI BOLA(6,2)
BOVINE ORIGIN(6,2)
EXEMPLIFIED PROTEIN(6,2)
FUSION VECTOR(6,2)
GENOMIC DNA(6,2)
RECOMBINANT HOST CELL(6,2)
RECOMBINANT PROTEIN EXPRESSION(6,2)
SCREENING ASSAY(6,2)
TRANSLATION INITIATION REGION(6,2)
AMPLIFIED CDNA PURIFICATION(6,1)
BACULOVIRUS EXPRESSION VECTOR(6,1)
CANDIDATE CDNA POOL(6,1)
CO CULTURED CELL SUPERNATANT(6,1)
CONSTUTIVELY EXPRESS CLASS(6,1)
DIRECTING MRNA TRANSCRIPTION(6,1)
DNA MOLECULE LIGATION(6,1)
FLAVIN COVALENT ATTACHMENT(6,1)
FOSTER CITY CALIF(6,1)
HYBRIDIZATION STRINGENCY(6,1)
LYMPHOPROLIFERATIVE DISORDER(6,1)
M13 PHAGE DNA BP(6,1)
NUCLEOTIDE RESIDUE STRETCH(6,1)
PARASITE STAGE INFECTIVE(6,1)
PIROPLASM INFECTED ERYTHROCYTE(6,1)
PROBE DETECTABLE LABEL(6,1)
RECOMBINANT VIRAL VECTOR(6,1)
SALMONELLA TYPHIMURIUM(6,1)
SCHIZONT INFECTED LYMPHOBLAST(6,1)
SECJUENCE SIMILARITY(6,1)
TARGETED GENE WALKING(6,1)
THEILERIA PARVA ANTIGEN(6,1)
TOXOPLASMA GONDII(6,1)
VACCINATION CAMPAIGN(6,1)
EQUIVALENT PROTEIN(5,5)
BACTERIAL CELL(5,3)
COMPLEMENTARITY(5,3)
SYNTHETIC CHEMISTRY(5,3)
FLOW MICROFLUORIMETRY(5,2)
RESTRICTION SITE(5,2)
ACTIVE POLYPEPTIDE FRAGMENT(5,1)
ADENOVIRUS ENHANCER(5,1)
ALANINE SUBSTITUTION(5,1)
ANEMIC DISEASE(5,1)
ANEMIC SYNDROME(5,1)
ANIMAL IMMUNIZATION(5,1)
ANIMAL INFECTION(5,1)
ANNEALED PRIMER EXTENSION(5,1)
ANNEALING PRIMER(5,1)
ANTIBODY INDUCTION(5,1)
ANTIGEN PROTEOLYTIC PROCESSING(5,1)
ANTIGENIC FRAGMENT(5,1)
ANTISENSE RNA EXPRESSION(5,1)
ANTISENSE RNA TRANSCRIPTION(5,1)
ANTISENSE TRANSCRIPT(5,1)
ATTENUATED PARASITE(5,1)
AUTOLOGOUS SKIN FIBROBLASTS(5,1)
BABESIA SPP(5,1)
BACTERIAL CLONE(5,1)
BACTERIAL CULTURE(5,1)
BACTERIAL PLASMID(5,1)
BACULOVIRUS VECTOR(5,1)
BIOCHEMICAL CORP(5,1)
BIOLOGICALLY ACTIVE FRAGMENT(5,1)
BOLA CONFIRMATION(5,1)
CANDIDATE ANTIGEN PRODUCTION(5,1)
CAPILLARY SEQUENCING(5,1)
CATIONIC EXCHANGE CHROMATOGRAPHY(5,1)
CATTLE LYMPHOCYTE(5,1)
CATTLE PROTECTION(5,1)
CATTLE RECOVERING(5,1)
CDNA SUBTRACTION(5,1)
CHIMERIC PEPTIDE(5,1)
CHIMERIC POLYPEPTIDE(5,1)
CHROMOSOMAL SPREAD(5,1)
CLONED POLYNUCLEOTIDE(5,1)
CLONING VECTOR ASSORTMENT(5,1)
CODON CHOICE(5,1)
CODON SUBSTITUTION(5,1)
COLI EXPRESSION VECTOR(5,1)
CONSTITUTIVE EXPRESSION(5,1)
COVALENT CROSSLINK FORMATION(5,1)
CULTURED INSECT CELL(5,1)
CYTOTOXIC ACTIVATION(5,1)
CYTOXAUZOON SPP(5,1)
DEGENERATE(5,1)
DELETIONAL MUTATION(5,1)
DISEASE PATHOGENESIS(5,1)
DIVERGENT PRIMER(5,1)
DNA VECTOR(5,1)
DNA VIRUS VECTOR(5,1)
DRUG SIMULTANEOUS ADMINISTRATION(5,1)
EIMERIA SPP(5,1)
ENCOMPASSING FRAGMENT(5,1)
ESTABLISHED CHROMOSOMAL MARKER(5,1)
EUKARYOTIC HOST CELL(5,1)
EXPONENTIAL ACCUMULATION(5,1)
FREEZE THAW(5,1)
FUSION EXPRESSION VECTOR(5,1)
FUSION MOIETY JUNCTION(5,1)
GAMMY INTERFERON(5,1)
GENE MOLECULE(5,1)
GENE PROPAGATION(5,1)
HETEROLOGOUS GENE(5,1)
HETEROLOGOUS HOST(5,1)
HOMOLOGOUS CHALLENGE(5,1)
HOMOLOGOUS PARASITE(5,1)
HYBRIDIZATION PROBE(5,1)
IDENTITY RESOLUTION(5,1)
IFN BIOACTIVITY(5,1)
IMMEDIATE EARLY ENHANCER(5,1)
IMMEDIATE EARLY PROMOTER(5,1)
IMMOBILIZED DNA HYBRIDIZATION(5,1)
IMMOBILIZED MEMBRANE(5,1)
IMMORTALIZED SKIN FIBROBLAST CELL(5,1)
IMMUNE BULL T CELL RESPONSE(5,1)
INCUBATING TP(5,1)
INDUCIBLE EXPRESSION(5,1)
INDUCIBLE PROMOTER(5,1)
INDUCING IMMUNOPROTECTION(5,1)
INFERIOR TRANSFECTION EFFICIENCY(5,1)
INTERCHAIN AFFINITY(5,1)
INTRACELLULAR PARASITE(5,1)
INTRAMOLECULAR LIGATION(5,1)
INTRAVENOUS CHALLENGE(5,1)
INTRON EXON JUNCTION(5,1)
INVENTIN POLYPEPTIDE(5,1)
INVESTMENT DEAL(5,1)
KDA GLYCOPROTEIN(5,1)
LECTIN CHROMATOGRAPHY(5,1)
LETHAL CHALLENGE(5,1)
LINKER PRIMER(5,1)
LIPID COVALENT ATTACHMENT(5,1)
LIVE VACCINE(5,1)
LYMPHOCYTE POPULATION(5,1)
MATURE PROTEIN(5,1)
MER PEPTIDE(5,1)
MODERATE STRINGENCY(5,1)
MOUSE VACCINATION(5,1)
MUTANT SCREENING(5,1)
NATIVE GENOMIC SEQUENCE(5,1)
NESTED PRIMER(5,1)
NICK TRANSLATION(5,1)
NON CONSERVATIVE SUBSTITUTION(5,1)
NON RADIOACTIVE LABEL(5,1)
NUCLEOTIDE COVALENT ATTACHMENT(5,1)
NUCLEOTIDE DERIVATIVE(5,1)
NUCLEOTIDE SEQUENCE CODING(5,1)
NUCLEOTIDE SEQUENCE MULTITUDE(5,1)
NUCLEOTIDE SIMILARITY EXTENT(5,1)
NUCLEOTIDE SUBSTITUTION(5,1)
NUTRIENT ADDITIVE(5,1)
PARASITE STRAIN(5,1)
PARVA INFECTION(5,1)
PEPTIDE RECOGNITION(5,1)
PHENOTYPIC TRAIT(5,1)
PHOSPHOCELLULOSE CHROMATOGRAPHY(5,1)
PLASMID LIBRARY(5,1)
PLURAL REFERENT(5,1)
POLYNUCLEOTIDE VARIANT(5,1)
POLYOMA ENHANCER(5,1)
PRIME CANDIDATE(5,1)
PROKARYOTIC HOST CELL(5,1)
PROTEIN PURIFICATION(5,1)
PROTEOLYTIC CLEAVAGE(5,1)
PROTOZOON ORGANISM(5,1)
RANDOM PRIMED LIBRARY(5,1)
RARE TRANSCRIPT(5,1)
RE LATED MOLECULE(5,1)
RECOMBINANT BACULOVIRUS(5,1)
RECOMBINANT VECTOR CONSTRUCT(5,1)
REPLICATION ORIGIN(5,1)
REPRODUCIBLE SEQUENCING(5,1)
RESTRICTION ENDONUCLEASE(5,1)
RESTRICTION SELECTION MUTAGENESIS(5,1)
SCIENTIFIC LITERATURE(5,1)
SHUFFLING GENE(5,1)
SOLUBLE PEPTIDE FRAGMENT(5,1)
SOUTHEASTERN EUROPE(5,1)
SOUTHERN RUSSIA(5,1)
STRONG NON COVALENT BOND(5,1)
SUBPOPULATION SELECTION(5,1)
SYNTHETIC PEPTIDE LIBRARY(5,1)
TARGET POLYNUCLEOTIDE(5,1)
THERMOSTABLE DNA POLYMERASE(5,1)
TP LYSIS(5,1)
TP RECOGNITION(5,1)
TP RESTRICTION(5,1)
TRAINED VETERINARIAN(5,1)
TRANSCRIPT ISOLATION(5,1)
TRANSCRIPTION INITIATION(5,1)
TRANSCRIPTION TERMINATION(5,1)
TRANSMEMBRANE DOMAIN(5,1)
TRICHOPLUSIA NI(5,1)
UNIVERSAL PRIMER(5,1)
UNSUCCESSFUL ATTEMPT(5,1)
VACCINATION PROGRAM(5,1)
VACCINATION STRATEGY(5,1)
VACCINIA VIRUS(5,1)
VIRAL REPLICATION(5,1)
VIRULENT PARASITE(5,1)
WESTERN BLOTTING(5,1)
YEAST EPISOME(5,1)
TPM(4,8)
LIGAND(4,5)
NUCLEIC ACID SEQUENCE(4,5)
CYTOTOXIC T LYMPHOCYTES EPITOPE(4,3)
OLIGOMER(4,3)
SOLUBLE FACTOR PRESENCE(4,3)
BOVINE ENDOTHELIAL CELL(4,2)
CDNA SEQUENCE(4,2)
DISEASE DEVELOPMENT(4,2)
DUPLEX FORMATION(4,2)
EXEMPLIFIED POLYNUCLEOTIDE SEQUENCE(4,2)
EXEMPLIFIED SEQUENCE(4,2)
EXONUCLEASE(4,2)
IFN RELEASE(4,2)
KILOBASE(4,2)
MG ML DENATURED DNA(4,2)
MODIFIED VACCINIA(4,2)
SOLUBLE FACTOR RELEASE(4,2)
SUBUNIT VACCINE(4,2)
ACTIVE PROTEIN FRAGMENT(4,1)
AFFECTED COUNTRY(4,1)
AFFINITY CHROMATOGRAPHY(4,1)
ANTIBODY MOLECULE(4,1)
ARTIFICIAL CHROMOSOME CONSTRUCTION(4,1)
ASEXUAL BLOOD(4,1)
BACTERIOPHAGE GENETIC ELEMENT(4,1)
BIOLOGICAL ANALYSIS AID(4,1)
BIOLOGICAL COMPOUND ACTIVITY(4,1)
BOVINE SKIN FIBROBLAST CELL(4,1)
BOVINE SPECIES(4,1)
CHROMOGENIC AGENT(4,1)
CHROMOSOME REGION(4,1)
CLINICAL DISEASE(4,1)
CLONE TP(4,1)
CLONED DNA(4,1)
COLONY GROWTH(4,1)
CULTURE GROWTH(4,1)
DIAGNOSTIC ASSAY(4,1)
DNA CONSTRUCT(4,1)
DNA FRAGMENT(4,1)
ELECTROPHORETIC SEPARATION(4,1)
EMITTED WAVELENGTH DETECTION(4,1)
ENCODED PROTEIN(4,1)
EXEMPLIFIED PROBE(4,1)
FC REGION FRAGMENT(4,1)
FLOWABLE POLYMER(4,1)
FUSION PROTEIN(4,1)
GENE CONSTRUCT(4,1)
GENE PROBE(4,1)
GENETIC CODE REDUNDANCY(4,1)
GENETIC MAP(4,1)
GLYCOSYLATION PATTERN(4,1)
HOMOLOGOUS 250 KDA MOLECULE(4,1)
HOST BACTERIUM(4,1)
HOST CELL GENOME(4,1)
HUMAN MALARIA(4,1)
HYDROPHOBIC INTERACTION CHROMATOGRAPHY(4,1)
IFN GAMMA(4,1)
IMMORTALIZED FIBROBLAST CELL(4,1)
IMMUNE RESPONSE STIMULATION(4,1)
IMMUNIZATION PROTOCOL VARIETY(4,1)
INFECTED BLOOD(4,1)
INFECTIOUS AGENT(4,1)
INSECT HOST CELL(4,1)
INVENITON HOST CELL(4,1)
LABELED DNA(4,1)
LABELED PROBE(4,1)
LAMBDA PHAGE DERIVATIVE(4,1)
LATE PROMOTER(4,1)
LIPID DERIVATIVE(4,1)
LOCAL PARASITE(4,1)
MAINTENANCE PROPAGATION(4,1)
MARKER GENE(4,1)
MINIMAL HOMOLOGY(4,1)
MRNA PROBE PRODUCTION(4,1)
NATIVE MOLECULE(4,1)
NUCLEOTIDE SEQUENCE CHROMOSOMAL LOCATION(4,1)
PEPTIDE PULSED P RECOGNITION(4,1)
PET 11D(4,1)
POLYNUCLEOTIDE PROBABLE ACTIVITY(4,1)
POOLED CDNA(4,1)
POSITIVE CDNA RESOLUTION(4,1)
POSITIVE COLONY(4,1)
PREDICTED DOMAIN(4,1)
PRIMED SYNTHESIS(4,1)
PROBE MOLECULE(4,1)
PROPROTEIN SEQUENCE(4,1)
PROSITE ANALYSIS(4,1)
PURE PROTEIN(4,1)
PURIFIED PEPTIDE(4,1)
PYROGLUTAMATE FORMATION(4,1)
RANDOM MUTAGENESIS(4,1)
RANDOM PRIMING(4,1)
RE LATED SEQUENCE DETECTION(4,1)
RECOMBINANT PROTEIN SOLUBILITY(4,1)
RESEARCH LITERATURE(4,1)
RESTRICTED EPITOPE(4,1)
RESTRICTION ENZYME VARIETY(4,1)
RETAINING FRAGMENT(4,1)
ROUTINE ASSAY(4,1)
SCANNING MUTAGENESIS(4,1)
SCHIZONT INFECTED CELL(4,1)
SEGMENT AMPLIFICATION(4,1)
SEQUENCE NUCLEOTIDE(4,1)
SEQUENCE SIMILARITY(4,1)
SHORTED NAME(4,1)
SOLUBLE FACTOR SECRETION(4,1)
SUCCESSIVE REFINEMENT(4,1)
TARGET ANTIGEN(4,1)
TARGET CODON(4,1)
TARGET FRAGMENT(4,1)
TARGET SEQUENCE STRAND(4,1)
TP MEASUREMENT(4,1)
TRANSFECT HOST(4,1)
UNTRANSFECTED CELL(4,1)
UPSTREAM ENHANCER(4,1)
WEAK ANTIBODY(4,1)
YEAST CHROMOSOMAL ELEMENT(4,1)
POLYMERASE CHAIN REACTION AMPLIFICATION(3,5)
SINGLE CDNA(3,4)
ADP RIBOSYLATION(3,2)
ANTIGENIC DETERMINANT(3,2)
CAPILLARY ELECTROPHORESIS(3,2)
COMMON MODIFICATION(3,2)
COMPLETE GENE(3,2)
COSMID(3,2)
COTRANSFECTION(3,2)
CYTOKINE(3,2)
ENZYMOLOGY(3,2)
FINAL CONCENTRATION(3,2)
GENE EXPRESSION TECHNOLOGY(3,2)
HYDROXYLATION(3,2)
INFECTIOUS T(3,2)
INVOLVEMENT(3,2)
LESTOQUARDI(3,2)
NORTH AFRICA(3,2)
OLIGONUCLEOTIDE PROBE(3,2)
PHAGEMID(3,2)
PROTEASE(3,2)
RNA POLYMERASE(3,2)
SCANNING AMINOACID(3,2)
SHORT STRETCH(3,2)
SULFATION(3,2)
TRANSDUCTION(3,2)
UBIQUITINATION(3,2)
VECTOR NUCLEIC ACID(3,2)
WASHING(3,2)
AA OVERLAP(3,1)
AMMONIUM SULFATE PRECIPITATION(3,1)
AMPLIFIED SEQUENCE(3,1)
ANTIGEN PEPTIDE HALF LIFE(3,1)
ANTIGEN PRESENCE(3,1)
ANTIGEN SEQUENCE(3,1)
BIOLOGICAL SAMPLE(3,1)
BOVINE CLASS(3,1)
CALCIUM PHOSPHATE TRANSFECTION(3,1)
CELL DISTRIBUTION(3,1)
CHEMILUMINESCER(3,1)
CHEMOTHERAPY(3,1)
CLASS EXPRESSION(3,1)
COLD SPRING HARBOR(3,1)
COMMERCIALLY VALUABLE(3,1)
CONSERVATIVE AMINOACID SUBSTITUTION(3,1)
CONSERVED REGION(3,1)
CONTIGUOUS SEQUENCE(3,1)
CRITICAL PROTEIN REGION(3,1)
CULTURING CELL(3,1)
CYSTINE FORMATION(3,1)
CYTOMEGALOVIRUS(3,1)
DIAGNOSTIC AID(3,1)
DIHYDROFOLATE REDUCTASE(3,1)
DISEASE DETECTION(3,1)
DNA SEGMENT(3,1)
DNA SEQUENCE ENCODING(3,1)(...)";"Analysis of biological materials
Pharmaceuticals";Open
"2003-07-02
2004-07-02";"WO2005003330        A2 2005-01-13 [WO200503330]
STG: (A2) International application published without international search report
AP : 2004WO-US21274 2004-07-02
CA2530779           A1 2005-01-13 [CA2530779]
STG: (A1) Application laid open
AP : 2004CA-2530779 2004-07-02
AU2004254619        A1 2005-01-13 [AU2004254619]
STG: (A1) Open to public inspection
AP : 2004AU-0254619 2004-07-02
WO2005003330        A3 2005-03-03 [WO200503330]
STG: (A3) Later publication of ISR with revised front page
AP : 2004WO-US21274 2004-07-02
US20050106185       A1 2005-05-19 [US20050106185]
STG: (A1) Application published
AP : 2004US-10882666 2004-07-02
KR10-2006-0020657   A  2006-03-06 [KR20060020657]
STG: (A) Published application
AP : 2005KR-7023127 2004-07-02
EP1638598           A2 2006-03-29 [EP1638598]
STG: (A2) Application published without search report
AP : 2004EP-0777430 2004-07-02
BRPI0410911         A  2006-06-27 [BR200410911]
STG: (A) Published application
AP : 2004BR-0010911 2004-07-02
BRPI0410911         A1 2006-06-27 [BRPI0410911]
STG: (A1) Published application
AP : 2004BR-0010911 2004-07-02
CN1798574           A  2006-07-05 [CN1798574]
STG: (A) Published application
AP : 2004CN-80015249 2004-07-02
EP1638598           B1 2006-12-06 [EP1638598]
STG: (B1) Patent specification
AP : 2004EP-0777430 2004-07-02
AT347373            T  2006-12-15 [ATE347373]
STG: (T) EP patent valid in AT
AP : 2004AT-0777430T 2004-07-02
DE602004003582      D1 2007-01-18 [DE602004003582]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2004DE-60003582 2004-07-02
HK1088561           A1 2007-03-09 [HK1088561]
STG: (A1) Patent application
AP : 2006HK-0110656 2006-09-25
DK1638598           T3 2007-03-26 [DK1638598T]
STG: (T3) Translation of EP patent
AP : 2004DK-0777430 2004-07-02
ZA200509533         B  2007-03-28 [ZA200509533]
STG: (B)
AP : 2005ZA-0009533 2004-07-02
PT1638598           E  2007-03-30 [PT1638598]
STG: (E) Availability of national translation of European patent
AP : 2004PT-0777430T 2004-07-02
SI1638598           T1 2007-04-30 [SI1638598T]
STG: (T1) Translation of EP claims
AP : 2004SI-0030197 2004-07-02
ES2278344           T3 2007-08-01 [ES2278344]
STG: (T3) Translation of granted European patent (former B3)
AP : 2004ES-0777430T 2004-07-02
JP2007524398        A  2007-08-30 [JP2007524398]
STG: (A) Published application
AP : 2006JP-0517833 2004-07-02
DE602004003582      T2 2007-09-20 [DE602004003582]
STG: (T2) Trans. of EP  patent
AP : 2004DE-60003582 2004-07-02
US7351416           B2 2008-04-01 [US7351416]
STG: (B2) Granted patent as second publication
AP : 2004US-10882666 2004-07-02
FD :  Provisional Appl: US60/608,931 FDD=2003-07-02 [2003US-60608931]
FD : Previous publication: US20050106185 A1 2005-05-19 [US20050106185]
NZ543771            A  2008-05-30 [NZ-543771]
STG: (A) Published application
AP : 2004NZ-0543771 2004-07-02
HRP20070084         T3 2008-09-30 [HRP20070084]
STG: (T3) Translation of an EP patent into Croatian
AP : 2007HR-0000084 2007-03-02
AU2004254619        B2 2009-05-21 [AU2004254619]
STG: (B2) Patent proceeded by OPI
AP : 2004AU-0254619 2004-07-02
JP2011024587        A  2011-02-10 [JP2011024587]
STG: (A) Published application
AP : 2010JP-0200481 2010-09-08
BRPI0410911         A2 2012-03-13 [BR200410911]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2004BR-0010911 2004-07-02
JP5001647           B2 2012-05-25 [JP5001647]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2006JP-0517833 2004-07-02
CA2530779           C  2012-06-05 [CA2530779]
STG: (C) Patent (second level)
AP : 2004CA-2530779 2004-07-02
KR10-1119216        B1 2013-03-18 [KR101119216]
STG: (B1) Patent specification
AP : 2005KR-7023127 2004-07-02
CN1798574           B  2013-12-11 [CN1798574B]
STG: (B) Granted patent for invention
AP : 2004CN-80015249 2004-07-02
BRPI0410911         B1 2014-07-08 [BR200410911]
STG: (B1) Granted patent / Granted pipeline patent
AP : 2004BR-0010911 2004-07-02
JP5649881           B2 2014-11-21 [JP5649881]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2010JP-0200481 2010-09-08
FD :  Division of: JP2006517833 FDD=2004-07-02 [2006JP-0517833]";5140853;"WO2005003330        A2 2005-01-13 [WO200503330]
CA2530779           A1 2005-01-13 [CA2530779]
AU2004254619        A1 2005-01-13 [AU2004254619]
WO2005003330        A3 2005-03-03 [WO200503330]
US20050106185       A1 2005-05-19 [US20050106185]
KR10-2006-0020657   A  2006-03-06 [KR20060020657]
EP1638598           A2 2006-03-29 [EP1638598]
BRPI0410911         A  2006-06-27 [BR200410911]
BRPI0410911         A1 2006-06-27 [BRPI0410911]
CN1798574           A  2006-07-05 [CN1798574]
EP1638598           B1 2006-12-06 [EP1638598]
AT347373            T  2006-12-15 [ATE347373]
DE602004003582      D1 2007-01-18 [DE602004003582]
HK1088561           A1 2007-03-09 [HK1088561]
DK1638598           T3 2007-03-26 [DK1638598T]
ZA200509533         B  2007-03-28 [ZA200509533]
PT1638598           E  2007-03-30 [PT1638598]
SI1638598           T1 2007-04-30 [SI1638598T]
ES2278344           T3 2007-08-01 [ES2278344]
JP2007524398        A  2007-08-30 [JP2007524398]
DE602004003582      T2 2007-09-20 [DE602004003582]
US7351416           B2 2008-04-01 [US7351416]
NZ543771            A  2008-05-30 [NZ-543771]
HRP20070084         T3 2008-09-30 [HRP20070084]
AU2004254619        B2 2009-05-21 [AU2004254619]
JP2011024587        A  2011-02-10 [JP2011024587]
BRPI0410911         A2 2012-03-13 [BR200410911]
JP5001647           B2 2012-05-25 [JP5001647]
CA2530779           C  2012-06-05 [CA2530779]
KR10-1119216        B1 2013-03-18 [KR101119216]
CN1798574           B  2013-12-11 [CN1798574B]
BRPI0410911         B1 2014-07-08 [BR200410911]
JP5649881           B2 2014-11-21 [JP5649881]";"2003US-60608931
2004EP-0777430
2004US-10882666
2004WO-US21274";"(EP1638598)
WO2005003330
(DE602004003582)
WO2005003330
(JP5001647)
WO2005003330
(HK1088561)
WO2005003330
(DK1638598T)
WO2005003330
(ZA200509533)
WO2005003330
(SI1638598T)
WO2005003330
(NZ-543771)
WO2005003330
(HRP20070084)
WO2005003330
(AU2004254619)
WO2005003330
(CA2530779)
WO2005003330
(KR101119216)
WO2005003330
(CN1798574B)
WO2005003330
(BR200410911)
WO2005003330";"& THE US SECRETARY UNITED STAT
BIOTECHNOLOGY RESEARCH & DEVELOPMENT
BIOTECHNOLOGY RESERCH & DEVELOPMENT
US BIOTECHNOLOGY RESEARCH & DEVELOPMENT
US DEPARTMENT OF AGRICULTURE
US DEPARTMENT OF COMMERCE
US GOVERNMENT
US SECRETARY OF AGRICULTURE";"US DEPARTMENT OF AGRICULTURE
BIOTECHNOLOGY RESEARCH & DEVELOPMENT";"(EP1638598)
US
(EP1638598)
US
(US7351416)
US
(WO200503330)
US
(DE602004003582)
US


(CA2530779)
US
(CA2530779)
US
(BRPI0410911)
US
(BR200410911)
US";"(EP1638598)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION 1815 North University Drive , CITY=Peoria, IL 61604 , COUNTRY=US 

NAME=THE UNITED STATES OF AMERICA as represented by THE  SECRETARY, UNITED STATES DEPARTMENT OF AGRICULTURE 1400 Indepedence Avenue SW , CITY=Washington, DC 20250-0302 , COUNTRY=US 

(EP1638598)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION 1815 North University Drive Peoria, IL 61604 , COUNTRY=US 

NAME=THE UNITED STATES OF AMERICA as represented by THE SECRETARY, UNITED STATES DEPARTMENT OF AGRICULTURE 1400 Indepedence Avenue SW Washington, DC 20250-0302 , COUNTRY=US 

(US7351416)
NAME=The United States of America as represented by the Department of Agriculture , CITY=Washington , STATE=DC , COUNTRY=US , ATYP=US Government 

(WO200503330)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION  [US/ US] 1815 North University Street, Peoria, IL 61604  , COUNTRY=US 

NAME=UNITED STATES OF AMERICA, as represented by THE DEPARTMENT OF AGRICULTURE  [US/ US] 1400 Independence Avenue SW, Washington, DC 20250-0003  , COUNTRY=US 

(DE602004003582)
NAME=Biotechnology Research and Development Corp. , CITY=Ill. , STATE=Peoria , COUNTRY=US 

NAME=The United States of America as represented by the Secretary  United States Department of Agriculture , CITY=D.C. , STATE=Washington , COUNTRY=US 

(JP2007524398)
NAME=USA GOVERNMENT , REG=503342591 

NAME=THE UNITED STATES OF AMERICA , REG=399036486 

(JP5001647)
NAME=Biotechnology Research and Development Corporation , REG=399036486 

NAME=USA GOVERNMENT , REG=503342591 

(JP5649881)
NAME=Biotechnology Research and Development Corporation , REG=399036486 

NAME=USA GOVERNMENT , REG=503342591 

(CA2530779)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION 1815 North University Street, PEORIA, IL, 61604 , COUNTRY=US 

NAME=UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF AGRICULTUR E 1400 Independence Avenue SW, WASHINGTON, DC, 20250-0003 , COUNTRY=US 

(CA2530779)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION 1815 North University Street , CITY=PEORIA , STATE=IL , POSTCODE=61604 , COUNTRY=US 

NAME=UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE 1400 Independence Avenue SW , CITY=WASHINGTON , STATE=DC , POSTCODE=20250-0003 , COUNTRY=US 

(BRPI0410911)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION , COUNTRY=US 

NAME=UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE , COUNTRY=US 

(BR200410911)
NAME=BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION , COUNTRY=US 

NAME=UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE , COUNTRY=US 
";2;"BRIGGS ROBERT E
TATUM FRED M";"(EP1638598)
US
(EP1638598)
US";"(EP1638598)
NAME=BRIGGS, Robert, E. 1071 X Avenue , CITY=Boone, IA 50036 , COUNTRY=US 

NAME=TATUM, Fred, M. Rural Route 2 Box 225F1 , CITY=Ames, IA 50010 , COUNTRY=US 

(EP1638598)
NAME=BRIGGS, Robert, E. 1071 X Avenue Boone, IA 50036 , COUNTRY=US 

NAME=TATUM, Fred, M. Rural Route 2 Box 225F1 Ames, IA 50010 , COUNTRY=US 
";"(EP1638598)
ACAPSULAR i P. MULTOCIDA HYAE /i DELETION MUTANTS";"(EP1638598)
A capsular hyaE deletion mutants of P. multocida can be administered to mammals, particularly ungulates, or birds to provide protective immunity against wild-type P. multocida, e.g., to prevent or reduce the severity of hemorrhagic septicemia or pneumonia in mammals, particularly livestock, ungulates, and companion animals, or fowl cholera in birds, particularly poultry.";"(WO200503330)
CLAIMS
1. An isolated Pasteurellaceae multocida (P. multocida) bacterium of serogroup A which comprises a deletion of all or a part of a hyaE gene, wherein the deletion attenuates the bacterium. 2. The bacterium of claim 1 which comprises no antibiotic resistance genes. 3. The bacterium of claim 1 which comprises no exogenous DNA. 4. The bacterium of claim 1 which is serotype A:3. 5. The bacterium of claim 1 which is serotype A:l. 6. The bacterium of claim 1 which is serotype A:4. 7. The bacterium of claim 1 wherein amino acids 239-359 of the hyaE protein are deleted. 8. The bacterium of claim 1 which comprises the nucleotide sequence shown in SEQ ID O-7. 9. The bacterium of claim 1 which comprises the nucleotide sequence shown in SEQ ID NO-8. 10. The bacterium of claim 1 which is live. 11. The bacterium of claim 1 which is lyophilized. 12. The bacterium of claim 1 which is killed. 13. A vaccine for inducing protective immunity against wild-type P. multocida comprising: the bacterium of claim 1 ; and a pharmaceutically acceptable vehicle.
14. The vaccine of claim 13 wherein the bacterium comprises no antibiotic resistance genes. 15. The vaccine of claim 13 wherein the bacterium comprises no exogenous DNA. 16. The vaccine of claim 13 wherein the bacterium is serotype A:3. 17. The vaccine of claim 13 wherein the bacterium is serotype A: 1. 18. The vaccine of claim 13 wherein the bacterium is serotype A:4. 19. The vaccine of claim 13 wherein amino acids 239-359 of the hyaE protein are deleted. 20. The vaccine of claim 13 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:7. 21. The vaccine of claim 13 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:8. 22. The vaccine of claim 13 wherein the bacterium is live. 23. The vaccine of claim 13 wherein the bacterium is lyophilized. 24. The vaccine of claim 13 wherein the bacterium is killed. 25. The vaccine of claim 13 which is packaged with instructions for administering the vaccine to an ungulate to confer protective immunity against wild-type P. multocida. 26. The vaccine of claim 13 which is packaged with instructions for administering the vaccine to a bird to confer protective immunity against wild-type P. multocida. 27. A feed suitable for ungulates comprising the bacterium of claim 1. 28. The feed of claim 27 wherein the bacterium comprises no antibiotic resistance genes.
29. The feed of claim 27 wherein the bacterium comprises no exogenous DNA. 30. The feed of claim 27 wherein the bacterium is serotype A:3. 31. The feed of claim 27 wherein the bacterium is serotype A: 1. 32. The feed of claim 27 wherein the bacterium is serotype A:4. 33. The feed of claim 27 wherein amino acids 239-359 of the hyaE protein are deleted. 34. The feed of claim 27 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:7. 35. The feed of claim 27 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:8. 36. The feed of claim 27 wherein the bacterium is live. 37. The feed of claim 27 wherein the bacterium is lyophilized. 38. The feed of claim 27 wherein the bacterium is killed. 39. The feed of claim 27 which is packaged with instructions for administering the feed to ungulates to confer protective immunity against wild-type P. multocida. 40. A feed suitable for a bird comprising the bacterium of claim 1. 41. The feed of claim 40 wherein the bacterium comprises no antibiotic resistance genes. 42. The feed of claim 40 wherein the bacterium comprises no exogenous DNA. 43. The feed of claim 40 wherein the bacterium is serotype A: 3. 44. The feed of claim 40 wherein the bacterium is serotype A: 1. 45. The feed of claim 40 wherein the bacterium is serotype A:4.
46. The feed of claim 40 wherein amino acids 239-359 of the hyaE protein are deleted. 47. The feed of claim 40 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:7. 48. The feed of claim 40 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:8. 49. The feed of claim 40 wherein the bacterium is live. 50. The feed of claim 40 wherein the bacterium is lyophilized. 51. , The feed of claim 40 wherein the bacterium is killed. 52. The feed of claim 40 which is packaged with instructions for administering the feed to a bird to confer protective immunity against wild-type P. multocida. 53. A method of inducing protective immunity against wild-type P. multocida comprising the step of: administering the bacterium of claim 1 to an ungulate or a bird, whereby the bacterium confers to the ungulate or bird protective immunity against wild-type P. multocida. 54. The method of claim 53 wherein the bacterium comprises no antibiotic resistance genes. 55. The method of claim 53 wherein the bacterium comprises no exogenous DNA. 56. The method of claim 53 wherein the bacterium is serotype A:3. 57. The method of claim 53 wherein the bacterium is serotype A: 1. 58. The method of claim 53 wherein the bacterium is serotype A:4.
59. The method of claim 53 wherein amino acids 239-359 of the hyaE protein are deleted. 60. The method of claim 53 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:7. 61. The method of claim 53 wherein the bacterium comprises the nucleotide sequence shown in SEQ ID NO:8. 62. The method of claim 53 wherein the bacterium is live. 63. The method of claim 53 wherein the bacterium is lyophilized. 64. The method of claim 53 wherein the bacterium is killed. 65. The method of claim 53 wherein the bacterium is administered to an ungulate. 66. The method of claim 65 wherein the ungulate is a bovine animal. 67. The method of claim 53 wherein the bacterium is administered to a bird. 68. The method of claim 53 wherein the bacterium is administered to a bird and the bird is a poultry bird. 69. The method of claim 53 wherein the bacterium is administered to a bird and the bird is a poultry bird is selected from the group consisting of chicken, turkey, ostrich, game hen, squab, guinea fowl, pheasant, quail, duck, goose, and emu. 70. The method of claim 53 wherein the bacterium is administered to a bird and the bird is a chicken. 71. The method of claim 53 wherein the bacterium is administered to a bird and the bird is a turkey. 72. The method of claim 53 wherein the bacterium is adrninistered subcutaneously.
73. The method of claim 53 wherein the bacterium is administered intramuscularly. 74. The method of claim 53 wherein the bacterium is administered orally. 75. The method of claim 53 wherein the bacterium is administered by top-dressing feed. 76. The method of claim 53 wherein the bacterium is administered intranasally. 77. The method of claim 53 wherein the bacterium is administered at a dose between about 104and about 109cfu. 78. The method of claim 53 wherein the dose is between about 104and about 106cfu.";"(EP1638598)
The invention thus provides tools and methods for inducing protective immunity against diseases caused by P. multocida.
One embodiment of the invention is an isolated Pasteurella multocida (P. multocida) bacterium of serogroup A which comprises a deletion of all or a part of a hyaE gene.
The invention relates to acapsular mutants of Pasteurella multocida and vaccines comprising the mutants.";"(EP1638598)
Acapsular hyaE deletion mutants of P. multocida serogroup A can be administered to mammals (including livestock, ungulates, and companion animals) and birds (including poultry) to provide protective immunity against wild-type P. multocida, e.g., to prevent or reduce the severity of diseases such as hemorrhagic septicemia or pneumonia in livestock, ungulates, and companion animals and to prevent or reduce the severity of fowl cholera in birds, especially poultry, respectively.
For example, for septiceaemic disease (such as fowl cholera), susceptible species can be exposed to wild-type organisms by intranasal, intravenous, intramuscular, or intraperitoneal routes, and the dosage required to cause disease between wild-type and mutant organisms can be compared.
cause disease between wild-type and mutant organisms can be compared.";"A23K-001/16
A61K
A61K-039/00
A61K-039/102
A61P-011/00
A61P-031/04
C07K-014/285
C12N
C12N-001/00
C12N-001/20
C12N-001/21
C12N-015/09";"(EP1638598)
1. An isolated Pasteurella multocida (P. multocida) bacterium of serogroup A which comprises a deletion of all or a part of a hyaE gene, wherein the deletion attenuates the bacterium.";"(EP1638598)
MULTOCIDA(100,26)
DELETION MUTANT(100,1)
PASTEURELLA MULTOCIDA ACAPSULAR MUTANT(100,1)
SEROGROUP BACTERIUM(90,2)
ACAPSULAR HYAE DELETION MUTANT(87,2)
FOWL CHOLERA SEVERITY(80,1)
PROTECTIVE IMMUNITY(75,12)
ISOLATED PASTEURELLA MULTOCIDA(72,2)
MULTOCIDA SEROGROUP(59,1)
MUTANT ORGANISM(53,1)
ADMINISTRATION(51,14)
BIRD(49,22)
SEPTICEAEMIC DISEASE(48,1)
HYAE GENE(45,8)
UNGULATE(44,14)
DISEASE SEVERITY(43,1)
INTRAPERITONEAL ROUTE(43,1)
POULTRY BIRD(41,3)
FOWL CHOLERA(39,2)
SUSCEPTIBLE SPECIES(33,1)
BACTERIA(32,18)
EXOGENOUS DNA(30,1)
DELETION(29,11)
VACCINE(26,15)
HEMORRHAGIC SEPTICEMIA(24,2)
GAME HEN(22,2)
LIVESTOCK(21,8)
BOVINE ANIMAL(21,2)
MEDICAMENT MANUFACTURE(21,2)
COMPANION ANIMAL(20,9)
POULTRY(20,7)
DISEASE CAUSE(20,1)
MUTANT BACTERIA(19,9)
SEROGROUP MULTOCIDA BACTERIUM(19,2)
DOSAGE(19,1)
CHICKEN(17,3)
PNEUMONIA(16,3)
ACAPSULAR PHENOTYPE(15,4)
INTRANASAL(15,4)
ANTIBIOTIC RESISTANCE GENE(15,2)
CFU(15,2)
DOSE(14,4)
MUTANT(14,4)
DISEASE(14,2)
GUINEA FOWL(13,2)
HYAE DELETION MUTANT(13,2)
OSTRICH(13,2)
PHEASANT(13,2)
GENERAT ING DELETION MUTANT(13,1)
PORCINE SEPTICEMIC PASTEURELLOSIS(13,1)
MAMMAL(12,5)
BOVINE SEPTICEMIC PASTEURELLOSIS(12,1)
CAPSULE BIOSYNTHETIC LOCUS GENE(12,1)
SEROGRUP MULTOCIDA BACTERIUM(12,1)
MULTOCIDA ACAPSULAR MUTANT(11,1)
COLUMBIA BROTH(10,3)
GOOSE(10,2)
QUAIL(10,2)
SQUAB(10,2)
DELETION EXCISING NUCLEOTIDE(10,1)
GENERAT ING PLASMID(10,1)
INDIAN INK STAINING ASSAY(10,1)
DUCK(9,2)
HYAE MUTANT(9,2)
MUTATED HYAE(9,2)
ORI HYAEKANR(9,2)
PATHOLOGIC LESION(9,2)
SUBCUTANEOUS VACCINATION(9,2)
ACAPSULAR MUTANT CULTURE(9,1)
CLINICAL SYMPTOM SEVERITY(9,1)
DELETION PRIMER ANNEAL(9,1)
STRAIN MULTOCIDA COLONY(9,1)
STRAIN MULTOCIDA MUTANT(9,1)
DEXTROSE STARCH(8,2)
DYE TERMINATOR CHEMISTRY KIT(8,1)
ECORV RESTRICTION DIGESTION(8,1)
GENERATED HYAEKANR(8,1)
HYAE GENE FRAGMENT(8,1)
TONSILLAR WASH SPECIMEN(8,1)
YEARLING MENINGOENCEPHALITIS(8,1)
WILD TYPE P(7,10)
ACAPSULAR BACTERIUM(7,1)
ANTIBIOTIC SUPPLEMENTATION(7,1)
COLONY EXHIBIT PEARL(7,1)
DONKEY SEPTICEMIA(7,1)
ELECTROPORATION CUVETTE(7,1)
ENCODED HYAE PROTEIN(7,1)
INTRATRACHEAL CHALLENGE(7,1)
MUCOSAL COLONIZATION(7,1)
PERKIN ELMER GENEAMP(7,1)
STRAIN STRUCTURAL HYAE GENE(7,1)
SWINE PASTEURELLOSIS(7,1)
UNIQUE HYAE REPLACEMENT PLASMID(7,1)
VIRULENT PARENT STRAIN(7,1)
WING WEB VACCINATION(7,1)
WILD TYPE LIFE FORM(6,3)
PLASMID VECTOR(6,2)
TARGET SPECIES EXPOSURE(6,2)
TOP DRESSING FEED(6,2)
ACAPSULAR COLONY(6,1)
COMPETENT BACTERIA(6,1)
CSCL CENTRIFUGATION(6,1)
DOSING REGIMEN(6,1)
DOUBLE CROSSOVER MUTANT(6,1)
ECORV DELETION(6,1)
HYAE GENE CODING REGION(6,1)
INTRAMUSCULAR VACCINATION(6,1)
MUCOID COLONY(6,1)
OVO VACCINATION(6,1)
PBCSK HYAEKANR(6,1)
REPLACEMENT PLASMID INTEGRATION(6,1)
SYNTHESIZING OLIGONUCLEOTIDE(6,1)
TRYPTICASE BROTH(6,1)
VIRUS PARTICLE(6,1)
PCR REACTION(5,2)
CLONED GENE(5,1)
DNA SEQUENCER(5,1)
ELICITED TRANSIENT(5,1)
ETHANE GLYCINE(5,1)
EYE INOCULATION(5,1)
FOLD SERIAL DILUTION(5,1)
GENE PULSER(5,1)
HYAE FRAGMENT(5,1)
HYDROXYETHYL PROPANE(5,1)
INTRAPULMONIC ROUTE(5,1)
INTRATONSILLAR ROUTE(5,1)
KANAMYCIN RESISTANCE GENE(5,1)
PACKED BACTERIUM(5,1)
PLASMID REPLICATION(5,1)
PLURONIC POLYOL(5,1)
PNEUMONIC DISEASE(5,1)
POLYVALENT VACCINE COMPONENT(5,1)
VACCINE FORMULATION(5,1)
VETERINARILY ACCEPTABLE CARRIER(5,1)
VETERINARILY ACCEPTABLE SALT(5,1)
ADULT(4,3)
ADJUVANT(4,2)
ANIMAL SUBJECT(4,2)
ATTENUATION(4,2)
SCARIFICATION(4,2)
BAMHI SITE(4,1)
CELL PLATING ARRAY(4,1)
COLUMBIA AGAR PLATE(4,1)
DELETION SITE(4,1)
DISC DIFFUSION ENZYME ASSAY(4,1)
ECORV SITE(4,1)
ELECTROPORATED CELL(4,1)
EXPONENTIAL GROWTH PHASE CULTURE(4,1)
FEED VACCINATION(4,1)
FOREIGN DNA(4,1)
GENE PCR(4,1)
HYAE FORWARD(4,1)
HYAE INSERT(4,1)
MAMMAL DEVELOPMENT(4,1)
PBCSK SITE(4,1)
PLASMID DNA(4,1)
START MET CODON(4,1)
SUSCEPTIBLE ANIMAL(4,1)
SUSCEPTIBLE TARGET SPECIES(4,1)
TN INSERTION(4,1)
TRIAL REMAINDER(4,1)
APPLIED BIOSYSTEM(3,3)
CALF(3,3)
ORGANISM(3,3)
WILD TYPE(3,2)
ACAPSULAR SINGLE CROSSOVER MUTANT(3,1)
ANTIBIOTIC SELECTION(3,1)
BLOCKED SYNTHESIS(3,1)
BROAD BREASTED WHITE(3,1)
CELL PELLET(3,1)
DAY FEVER(3,1)
DELIVERY(3,1)
DIMETHYLDIOCTADECYLAZANIUM BROMIDE(3,1)
ECORI SITE(3,1)
HOUR INCUBATION(3,1)
INORGANIC SALT(3,1)
INTEGRATED DNA TECHNOLOGY(3,1)
IOWA STATE UNIVERSITY(3,1)
LIGATION PRODUCT(3,1)
METHOXYHEXADECYLGLYCEROL(3,1)
MURAMYL DIPEPTIDE(3,1)
NON PERMISSIVE TEMPERATURE(3,1)
P MUTANT STRAIN(3,1)
PALATINE TONSIL(3,1)
PALMITAMINE(3,1)
PASTEURELLA MULTOCIDA(3,1)
PCR ANALYSIS(3,1)
PCR KIT(3,1)
PH BUFFERING(3,1)
PNEUMONIC CHANGE(3,1)
POST CHALLENGE(3,1)
REPLACEMENT PLASMID CONSTRUCTION(3,1)
REVERSE PRIMER(3,1)
STARCH AGAR PLATE(3,1)
TRANSFORMED CELL(3,1)
AIRSPRAY(2,1)
(US20050106185)
MULTOCIDA(100,32)
VACCINE(100,17)
SEROGROUP BACTERIUM(100,2)
ISOLATED PASTEURELLACEAE MULTOCIDA(100,1)
MULTOCIDA HYAE DELETION MUTANT(100,1)
BACTERIA(62,67)
PASTEURELLA MULTOCIDA ACAPSULAR MUTANT(51,1)
ACAPSULAR HYAE DELETION MUTANT(44,1)
PROTECTIVE IMMUNITY(41,13)
FOWL CHOLERA SEVERITY(41,1)
HYAE PROTEIN(33,7)
BIRD(27,24)
UNGULATE(27,18)
FOWL CHOLERA(27,3)
MULTOCIDA SEROGROUP(24,2)
HEMORRHAGIC SEPTICEMIA SEVERITY(24,1)
SEPTICEAEMIC DISEASE(24,1)
HYAE GENE(23,8)
ISOLATED PASTEURELLA MULTOCIDA(23,1)
DISEASE SEVERITY(22,1)
INTRAPERITONEAL ROUTE(22,1)
MUTANT ORGANISM(22,1)
POULTRY BIRD(21,3)
BIRD PROTECTIVE IMMUNITY(20,1)
ANTIBIOTIC RESISTANCE GENE(19,6)
DELETION MUTANT(18,2)
SUSCEPTIBLE SPECIES(17,1)
DELETION(15,10)
EXOGENOUS DNA(15,1)
LIVESTOCK(13,10)
POULTRY(13,8)
COMPANION ANIMAL(12,11)
SEROGROUP MULTOCIDA BACTERIUM(12,3)
HEMORRHAGIC SEPTICEMIA(12,2)
MAMMAL(11,7)
PNEUMONIA(11,4)
DISEASE(11,3)
BOVINE ANIMAL(11,2)
GAME HEN(11,2)
MUTANT BACTERIA(9,9)
CHICKEN(9,3)
DOSAGE(9,1)
MULTOCIDA ACAPSULAR MUTANT(8,2)
DOSE(7,6)
MUTANT(7,5)
ACAPSULAR PHENOTYPE(7,4)
INTRANASAL(7,4)
MEAN LUNG LESION SCORE(7,3)
HYAE DELETION MUTANT(7,2)
CFU(6,4)
GUINEA FOWL(6,2)
OSTRICH(6,2)
PHEASANT(6,2)
BOVINE SEPTICEMIC PASTEURELLOSIS(6,1)
CAPSULE BIOSYNTHETIC LOCUS GENE(6,1)
PORCINE SEPTICEMIC PASTEURELLOSIS(6,1)
COLUMBIA BROTH(5,3)
GOOSE(5,2)
QUAIL(5,2)
SQUAB(5,2)
ACAPSULAR HYAE DELETION GENERATION(5,1)
DELETION EXCISING NUCLEOTIDE(5,1)
INDIAN INK STAINING ASSAY(5,1)
MEDIAN LUNG LESION SCORE(5,1)
SEROGROUP DELETION MUTANT(5,1)
STEER CALF VACCINATION(5,1)
WILD TYPE(4,14)
DUCK(4,2)
HYAE MUTANT(4,2)
MULTOCIDA STRAIN(4,2)
MUTATED HYAE(4,2)
PATHOLOGIC LESION(4,2)
SUBCUTANEOUS VACCINATION(4,2)
ACAPSULAR MUTANT CULTURE(4,1)
CLINICAL SYMPTOM SEVERITY(4,1)
DELETION PRIMER ANNEAL(4,1)
DYE TERMINATOR CHEMISTRY KIT(4,1)
ECORV RESTRICTION DIGESTION(4,1)
HYAE GENE FRAGMENT(4,1)
STRAIN MULTOCIDA COLONY(4,1)
STRAIN MULTOCIDA MUTANT(4,1)
TONSILLAR WASH SPECIMEN(4,1)
YEARLING MENINGOENCEPHALITIS(4,1)
WILD TYPE LIFE FORM(3,3)
PLASMID VECTOR(3,2)
TARGET SPECIES EXPOSURE(3,2)
TOP DRESSING FEED(3,2)
ACAPSULAR BACTERIUM(3,1)
ACAPSULAR COLONY(3,1)
ANTIBIOTIC SUPPLEMENTATION(3,1)
COLONY EXHIBIT PEARL(3,1)
COMPETENT BACTERIA(3,1)
CSCL CENTRIFUGATION(3,1)
DONKEY SEPTICEMIA(3,1)
DOSING REGIMEN(3,1)
DOUBLE CROSSOVER MUTANT(3,1)
ECORV DELETION(3,1)
ELECTROPORATION CUVETTE(3,1)
ENCODED HYAE PROTEIN(3,1)
HYAE GENE CODING REGION(3,1)
INTRAMUSCULAR VACCINATION(3,1)
INTRATRACHEAL CHALLENGE(3,1)
MALE BOVINE CALF(3,1)
MUCOID COLONY(3,1)
MUCOSAL COLONIZATION(3,1)
OVO VACCINATION(3,1)
P192ORI HYAEKANR(3,1)
PBCSK HYAEKANR(3,1)
PERKIN ELMER GENEAMP(3,1)
REPLACEMENT PLASMID INTEGRATION(3,1)
STRAIN STRUCTURAL HYAE GENE(3,1)
SWINE PASTEURELLOSIS(3,1)
SYNTHESIZING OLIGONUCLEOTIDE(3,1)
TERM ACAPSULAR MUTANT(3,1)
TRYPTICASE BROTH(3,1)
TURKEY POULT VACCINATION(3,1)
UNIQUE HYAE REPLACEMENT PLASMID(3,1)
VIRULENT PARENT STRAIN(3,1)
VIRUS PARTICLE(3,1)
WING WEB VACCINATION(3,1)
ADULT(2,3)
AGAR PLATE(2,2)
ANIMAL SUBJECT(2,2)
ATTENUATION(2,2)
PCR REACTION(2,2)
SCARIFICATION(2,2)
ABI PRISM(2,1)
BAMHI SITE(2,1)
CELL PLATING ARRAY(2,1)
CLONED GENE(2,1)
COLUMBIA AGAR(2,1)
DELETION SITE(2,1)
DEXTROSE STARCH(2,1)
DISC DIFFUSION ENZYME ASSAY(2,1)
DNA SEQUENCER(2,1)
ECORV SITE(2,1)
ELECTROPORATED CELL(2,1)
ELICITED TRANSIENT(2,1)
EXPONENTIAL GROWTH PHASE CULTURE(2,1)
EYE INOCULATION(2,1)
FOLD SERIAL DILUTION(2,1)
FOREIGN DNA(2,1)
GENE PULSER(2,1)
GENERATED AHYAEKANR FRAGMENT(2,1)
HYAE FORWARD(2,1)
HYAE INSERT(2,1)
INTRAPULMONIC ROUTE(2,1)
INTRATONSILLAR ROUTE(2,1)
LIVE CULTURE(2,1)
MAMMAL DEVELOPMENT(2,1)
MONTH OLD CALF(2,1)
MUTANT STRAIN(2,1)
PACKED BACTERIUM(2,1)
PBCSK SITE(2,1)
PLASMID DNA(2,1)
PLASMID REPLICATION(2,1)
PNEUMONIC DISEASE(2,1)
POLYVALENT VACCINE COMPONENT(2,1)
START MET CODON(2,1)
STERILE PBS(2,1)
SUSCEPTIBLE ANIMAL(2,1)
SUSCEPTIBLE TARGET SPECIES(2,1)
TN INSERTION(2,1)
TRIAL REMAINDER(2,1)
VACCINE FORMULATION(2,1)
VACCINE PREPARATION(2,1)
VETERINARILY ACCEPTABLE CARRIER(2,1)
VETERINARILY ACCEPTABLE SALT(2,1)
APPLIED BIOSYSTEM(1,3)
ACAPSULAR SINGLE CROSSOVER MUTANT(1,1)
ANTIBIOTIC SELECTION(1,1)
BIRD TREATMENT(1,1)
BLOCKED SYNTHESIS(1,1)
BROAD BREASTED WHITE(1,1)
BUFFERING AGENT(1,1)
CELL PELLET(1,1)
DELIVERY(1,1)
ECORI SITE(1,1)
HOUR INCUBATION(1,1)
INORGANIC SALT(1,1)
INTEGRATED DNA TECHNOLOGY(1,1)
IOWA STATE UNIVERSITY(1,1)
KANAMYCIN RESISTANCE GENE(1,1)
LIGATION PRODUCT GENERATING PLASMID(1,1)
MAMMAL TREATMENT(1,1)
NON PERMISSIVE TEMPERATURE(1,1)
PALATINE TONSIL(1,1)
PASTEURELLA MULTOCIDA(1,1)
PCR ANALYSIS(1,1)
PCR KIT(1,1)
PNEUMONIC CHANGE(1,1)
POST CHALLENGE(1,1)
PRO ARG(1,1)
REPLACEMENT PLASMID CONSTRUCTION(1,1)
REVERSE PRIMER(1,1)
TRANSFORMED CELL(1,1)
(US7351416)
MULTOCIDA(100,31)
VACCINE(100,17)
SEROGROUP BACTERIUM(100,2)
ISOLATED PASTEURELLACEAE MULTOCIDA(100,1)
MULTOCIDA HYAE DELETION MUTANT(100,1)
HYAE GENE(65,23)
ACAPSULAR HYAE DELETION MUTANT(62,3)
BACTERIUM ACAPSULAR PHENOTYPE(57,1)
BACTERIA(56,59)
PASTEURELLA MULTOCIDA ACAPSULAR MUTANT(51,1)
HYAE PROTEIN(47,12)
PROTECTIVE IMMUNITY(41,13)
FOWL CHOLERA SEVERITY(41,1)
CODING REGION(31,11)
BIRD(27,24)
UNGULATE(27,18)
FOWL CHOLERA(27,3)
DELETION(26,19)
MULTOCIDA SEROGROUP(24,2)
HEMORRHAGIC SEPTICEMIA SEVERITY(24,1)
SEPTICEAEMIC DISEASE(24,1)
ISOLATED PASTEURELLA MULTOCIDA(23,1)
DISEASE SEVERITY(22,1)
INTRAPERITONEAL ROUTE(22,1)
MUTANT ORGANISM(22,1)
POULTRY BIRD(21,3)
BIRD PROTECTIVE IMMUNITY(20,1)
ANTIBIOTIC RESISTANCE GENE(19,6)
SUSCEPTIBLE SPECIES(17,1)
EXOGENOUS DNA(15,1)
LIVESTOCK(13,10)
POULTRY(13,8)
COMPANION ANIMAL(12,11)
SEROGROUP MULTOCIDA BACTERIUM(12,3)
HEMORRHAGIC SEPTICEMIA(12,2)
MAMMAL(11,7)
PNEUMONIA(11,4)
DISEASE(11,3)
BOVINE ANIMAL(11,2)
GAME HEN(11,2)
AMINOACID(9,15)
MUTANT BACTERIA(9,9)
CHICKEN(9,3)
DOSAGE(9,1)
MULTOCIDA ACAPSULAR MUTANT(8,2)
DELETION RESULT(8,1)
DOSE(7,6)
MUTANT(7,5)
ACAPSULAR PHENOTYPE(7,4)
INTRANASAL(7,4)
MEAN LUNG LESION SCORE(7,3)
HYAE DELETION MUTANT(7,2)
CFU(6,4)
GUINEA FOWL(6,2)
OSTRICH(6,2)
PHEASANT(6,2)
BOVINE SEPTICEMIC PASTEURELLOSIS(6,1)
CAPSULE BIOSYNTHETIC LOCUS GENE(6,1)
PORCINE SEPTICEMIC PASTEURELLOSIS(6,1)
COLUMBIA BROTH(5,3)
GOOSE(5,2)
QUAIL(5,2)
SQUAB(5,2)
DELETION EXCISING NUCLEOTIDE(5,1)
INDIAN INK STAINING ASSAY(5,1)
MEDIAN LUNG LESION SCORE(5,1)
WILD TYPE(4,14)
DUCK(4,2)
HYAE MUTANT(4,2)
MUTATED HYAE(4,2)
PATHOLOGIC LESION(4,2)
SUBCUTANEOUS VACCINATION(4,2)
ACAPSULAR MUTANT CULTURE(4,1)
CLINICAL SYMPTOM SEVERITY(4,1)
DELETION PRIMER ANNEAL(4,1)
DYE TERMINATOR CHEMISTRY KIT(4,1)
ECORV RESTRICTION DIGESTION(4,1)
HYAE GENE FRAGMENT(4,1)
STRAIN MULTOCIDA COLONY(4,1)
STRAIN MULTOCIDA MUTANT(4,1)
TONSILLAR WASH SPECIMEN(4,1)
YEARLING MENINGOENCEPHALITIS(4,1)
WILD TYPE LIFE FORM(3,3)
PLASMID VECTOR(3,2)
TARGET SPECIES EXPOSURE(3,2)
TOP DRESSING FEED(3,2)
ACAPSULAR BACTERIUM(3,1)
ACAPSULAR COLONY(3,1)
ANTIBIOTIC SUPPLEMENTATION(3,1)
COLONY EXHIBIT PEARL(3,1)
COMPETENT BACTERIA(3,1)
CSCL CENTRIFUGATION(3,1)
DONKEY SEPTICEMIA(3,1)
DOSING REGIMEN(3,1)
DOUBLE CROSSOVER MUTANT(3,1)
ECORV DELETION(3,1)
ELECTROPORATION CUVETTE(3,1)
ENCODED HYAE PROTEIN(3,1)
HYAE GENE CODING REGION(3,1)
INTRAMUSCULAR VACCINATION(3,1)
INTRATRACHEAL CHALLENGE(3,1)
MALE BOVINE CALF(3,1)
MUCOID COLONY(3,1)
MUCOSAL COLONIZATION(3,1)
OVO VACCINATION(3,1)
P192ORI HYAEKANR(3,1)
PBCSK HYAEKANR(3,1)
PERKIN ELMER GENEAMP(3,1)
REPLACEMENT PLASMID INTEGRATION(3,1)
STRAIN STRUCTURAL HYAE GENE(3,1)
SWINE PASTEURELLOSIS(3,1)
SYNTHESIZING OLIGONUCLEOTIDE(3,1)
TERM ACAPSULAR MUTANT(3,1)
TRYPTICASE BROTH(3,1)
UNIQUE HYAE REPLACEMENT PLASMID(3,1)
VIRULENT PARENT STRAIN(3,1)
VIRUS PARTICLE(3,1)
WING WEB VACCINATION(3,1)
ADULT(2,3)
AGAR PLATE(2,2)
ANIMAL SUBJECT(2,2)
ATTENUATION(2,2)
PCR REACTION(2,2)
SCARIFICATION(2,2)
SEROGROUP(2,2)
ABI PRISM(2,1)
BAMHI SITE(2,1)
CELL PLATING ARRAY(2,1)
CLONED GENE(2,1)
COLUMBIA AGAR(2,1)
DELETION SITE(2,1)
DEXTROSE STARCH(2,1)
DISC DIFFUSION ENZYME ASSAY(2,1)
DNA SEQUENCER(2,1)
ECORV SITE(2,1)
ELECTROPORATED CELL(2,1)
ELICITED TRANSIENT(2,1)
EXPONENTIAL GROWTH PHASE CULTURE(2,1)
EYE INOCULATION(2,1)
FOLD SERIAL DILUTION(2,1)
FOREIGN DNA(2,1)
GENE PULSER(2,1)
GENERATED HYAEKANR FRAGMENT(2,1)
HYAE FORWARD(2,1)
HYAE INSERT(2,1)
INTRAPULMONIC ROUTE(2,1)
INTRATONSILLAR ROUTE(2,1)
LIVE CULTURE(2,1)
MAMMAL DEVELOPMENT(2,1)
MUTANT STRAIN(2,1)
PACKED BACTERIUM(2,1)
PBCSK SITE(2,1)
PLASMID DNA(2,1)
PLASMID REPLICATION(2,1)
PNEUMONIC DISEASE(2,1)
POLYVALENT VACCINE COMPONENT(2,1)
START MET CODON(2,1)
STERILE PBS(2,1)
SUSCEPTIBLE ANIMAL(2,1)
SUSCEPTIBLE TARGET SPECIES(2,1)
TN INSERTION(2,1)
TRIAL REMAINDER(2,1)
VACCINE FORMULATION(2,1)
VACCINE PREPARATION(2,1)
VETERINARILY ACCEPTABLE CARRIER(2,1)
VETERINARILY ACCEPTABLE SALT(2,1)
APPLIED BIOSYSTEM(1,3)
ORGANISM(1,3)
ACAPSULAR SINGLE CROSSOVER MUTANT(1,1)
ACETYL D GLUCOSAMINE(1,1)
ANTIBIOTIC SELECTION(1,1)
BIRD TREATMENT(1,1)
BLOCKED SYNTHESIS(1,1)
BROAD BREASTED WHITE(1,1)
BUFFERING AGENT(1,1)
CELL PELLET(1,1)
DELIVERY(1,1)
ECORI SITE(1,1)
HOUR INCUBATION(1,1)
INORGANIC SALT(1,1)
INTEGRATED DNA TECHNOLOGY(1,1)
IOWA STATE UNIVERSITY(1,1)
KANAMYCIN RESISTANCE GENE(1,1)
LIGATION PRODUCT GENERATING PLASMID(1,1)
MAMMAL TREATMENT(1,1)
NON PERMISSIVE TEMPERATURE(1,1)
PALATINE TONSIL(1,1)
PASTEURELLA MULTOCIDA(1,1)
PCR ANALYSIS(1,1)
PCR KIT(1,1)
PNEUMONIC CHANGE(1,1)
POST CHALLENGE(1,1)
PRO ARG(1,1)
REPLACEMENT PLASMID CONSTRUCTION(1,1)
REVERSE PRIMER(1,1)
TRANSFORMED CELL(1,1)
(WO200503330)
BACTERIA(100,53)
MULTOCIDA(100,24)
SEROGROUP BACTERIUM(100,2)
ISOLATED PASTEURELLACEAE MULTOCIDA(100,1)
PASTEURELLA MULTOCIDA ACAPSULAR MUTANT(97,1)
FOWL CHOLERA SEVERITY(78,1)
PROTECTIVE IMMUNITY(59,8)
SEPTICEAEMIC DISEASE(47,1)
MULTOCIDA SEROGROUP(46,2)
ISOLATED PASTEURELLA MULTOCIDA(45,1)
BIRD(44,20)
HYAE GENE(44,8)
BOVINE ANIMAL(43,2)
UNGULATE(42,13)
DISEASE SEVERITY(42,1)
INTRAPERITONEAL ROUTE(42,1)
MUTANT ORGANISM(42,1)
POULTRY BIRD(40,3)
BIRD PROTECTIVE IMMUNITY(39,1)
FOWL CHOLERA(38,2)
P DELETION MUTANT(34,1)
ANTIBIOTIC RESISTANCE GENE(33,5)
SUSCEPTIBLE SPECIES(33,1)
EXOGENOUS DNA(29,1)
DELETION(28,11)
HEMORRHAGIC SEPTICEMIA(23,2)
SEROGROUP MULTOCIDA BACTERIUM(22,3)
GAME HEN(22,2)
ELEPHANT(22,1)
LIVESTOCK(21,9)
DISEASE(21,3)
POULTRY(20,7)
COMPANION ANIMAL(19,10)
VACCINE(18,13)
MUTANT BACTERIA(18,9)
BISON(18,1)
DOSAGE(18,1)
CHICKEN(17,3)
DEER(17,1)
SWINE(17,1)
YAK(17,1)
ACAPSULAR PHENOTYPE(15,4)
INTRANASAL(15,4)
PNEUMONIA(15,3)
DOSE(14,4)
MUTANT(14,4)
CATTLE(14,2)
CFU(14,2)
ACAPSULAR HYAE DELETION MUTANT(14,1)
SHEEP(13,2)
PORCINE SEPTICEMIC PASTEURELLOSIS(13,1)
GUINEA FOWL(12,2)
OSTRICH(12,2)
PHEASANT(12,2)
BOVINE SEPTICEMIC PASTEURELLOSIS(12,1)
CAPSULE BIOSYNTHETIC LOCUS GENE(12,1)
MAMMAL(11,5)
BASE PAIR SMA LINKER(11,1)
MULTOCIDA ACAPSULAR MUTANT(11,1)
WATER BUFFALO(11,1)
GOOSE(10,2)
QUAIL(10,2)
SQUAB(10,2)
ACAPSULAR HYAE DELETION GENERATION(10,1)
DELETION EXCISING NUCLEOTIDE(10,1)
INDIAN INK STAINING ASSAY(10,1)
SEROGROUP DELETION MUTANT(10,1)
STEER CALF VACCINATION(10,1)
COLUMBIA BROTH(9,3)
DUCK(9,2)
HYAE MUTANT(9,2)
MUTATED HYAE(9,2)
PATHOLOGIC LESION(9,2)
SUBCUTANEOUS VACCINATION(9,2)
ACAPSULAR MUTANT CULTURE(9,1)
CLINICAL SYMPTOM SEVERITY(9,1)
DELETION PRIMER ANNEAL(9,1)
ECOKY RESTRICTION DIGESTION(9,1)
STRAIN MULTOCIDA COLONY(9,1)
STRAIN MULTOCIDA MUTANT(9,1)
MULTOCIDA STRAIN(8,2)
DYE TERMINATOR CHEMISTRY KIT(8,1)
HYAE GENE FRAGMENT(8,1)
TONSILLAR WASH SPECIMEN(8,1)
YEARLING MENINGOENCEPHALITIS(8,1)
ACAPSULAR BACTERIUM(7,1)
ANTIBIOTIC SUPPLEMENTATION(7,1)
COLONY EXHIBIT PEARL(7,1)
DEXTROSE STARCH AGAR(7,1)
DONKEY SEPTICEMIA(7,1)
ELECTROPORATION CUVETTE(7,1)
ENCODED HYAE PROTEIN(7,1)
INTRATRACHEAL CHALLENGE(7,1)
MUCOSAL COLONIZATION(7,1)
STRAIN STRUCTURAL HYAE GENE(7,1)
SWINE PASTEURELLOSIS(7,1)
TENFOLD SERIAL DILUTION(7,1)
TURKEY POULT VACCINATION(7,1)
UNIQUE HYAE REPLACEMENT PLASMID(7,1)
VIRULENT PARENT STRAIN(7,1)
WING WEB VACCINATION(7,1)
WILD TYPE LIFE FORM(6,3)
HYAE INSERT(6,2)
PLASMID VECTOR(6,2)
TARGET SPECIES EXPOSURE(6,2)
TOP DRESSING FEED(6,2)
ACAPSULAR COLONY(6,1)
BSSRL GENERATED YEKANR FRAGMENT(6,1)
COMPETENT BACTERIA(6,1)
CSCL CENTRIFUGATION(6,1)
DOSING REGIMEN(6,1)
DOUBLE CROSSOVER MUTANT(6,1)
ECORV DELETION(6,1)
HYAE GENE CODING REGION(6,1)
INTRAMUSCULAR VACCINATION(6,1)
MUCOID COLONY(6,1)
OVO VACCINATION(6,1)
REPLACEMENT PLASMID INTEGRATION(6,1)
SYNTHESIZING OLIGONUCLEOTIDE(6,1)
TRYPTICASE BROTH(6,1)
VIRUS PARTICLE(6,1)
WILD TYPE P(5,8)
AHYA P(5,4)
SQ ID(5,2)
BAMEL SITE(5,1)
CLONED GENE(5,1)
DNA SEQUENCER(5,1)
ELICITED TRANSIENT(5,1)
EYE INOCULATION(5,1)
GENE PULSER(5,1)
GENERATING PLASMID PL(5,1)
HYA PROTEIN(5,1)
INTRAPULMONIC ROUTE(5,1)
INTRATONSILLAR ROUTE(5,1)
KANAMYCIN RESISTANCE GENE(5,1)
PACKED BACTERIUM(5,1)
PLASMID REPLICATION(5,1)
PNEUMONIC DISEASE(5,1)
POLYVALENT VACCINE COMPONENT(5,1)
VACCINE FORMULATION(5,1)
VETERINARILY ACCEPTABLE CARRIER(5,1)
VETERINARILY ACCEPTABLE SALT(5,1)
ADULT(4,3)
ANIMAL SUBJECT(4,2)
ATTENUATION(4,2)
SCARIFICATION(4,2)
CELL PLATING ARRAY(4,1)
COLL ORIGIN(4,1)
COLUMBIA AGAR PLATE(4,1)
CORV SITE(4,1)
DAY POST CHALLENGE(4,1)
DELETION SITE(4,1)
ELECTROPORATED CELL(4,1)
EXPONENTIAL GROWTH PHASE CULTURE(4,1)
FOREIGN DNA(4,1)
HYAE FORWARD(4,1)
MAMMAL DEVELOPMENT(4,1)
PBCSK SITE(4,1)
PLASMID DNA(4,1)
START MET CODON(4,1)
SUSCEPTIBLE ANIMAL(4,1)
SUSCEPTIBLE TARGET SPECIES(4,1)
TN INSERTION(4,1)
TRIAL REMAINDER(4,1)
VACCINE PREPARATION(4,1)
ACAPSULAR SINGLE CROSSOVER MUTANT(3,1)
ANTIBIOTIC SELECTION(3,1)
BIRD TREATMENT(3,1)
BLOCKED SYNTHESIS(3,1)
BROAD BREASTED WHITE(3,1)
CELL PELLET(3,1)
DAY FEVER(3,1)
DELIVERY(3,1)
ECORI SITE(3,1)
HOUR INCUBATION(3,1)
INORGANIC SALT(3,1)
INTEGRATED DNA TECHNOLOGY(3,1)
IOWA STATE UNIVERSITY(3,1)
LIGATION PRODUCT(3,1)
MAMMAL TREATMENT(3,1)
P MUTANT STRAIN(3,1)
PALATINE TONSIL(3,1)
PASTEURELLA MULTOCIDA(3,1)
PCR ANALYSIS(3,1)
PCR REACTION(3,1)
PH BUFFERING(3,1)
(JP2007524398)
HYAE GENE(100,2)
DELETION MUTANT MULTOCIDA(100,1)
NON CAPSULAR PASTEURELLA(100,1)
BACTERIUM SEROTYPE(96,12)
PASTEURELLOSIS MULTOCIDA SEROGROUP(94,1)
BACTERIA(68,51)
PROTECTIVE IMMUNITY(62,13)
PASTEURELLACEAE MULTOCIDA(56,1)
CAPSULAR HYAE MULTOCIDA(54,1)
POULTRY CHOLERA(51,2)
HYAE DELETION MUTANT(51,1)
GAVAGING MULTOCIDA UNGULATE(49,1)
HYAE PROTEIN(48,5)
VACCINE(46,25)
MULTOCIDA PROTECTIVE IMMUNITY(46,1)
AVIAN MULTOCIDA GAVAGING(45,1)
LIVE BACTERIA(43,4)
MULTOCIDA AVIAN VACCINE(42,1)
MULTOCIDA(40,16)
UNGULATE(40,14)
HEMORRHAGIC PNEUMONIA(40,1)
EXOGENOUS DNA(39,5)
ISOLATED PASTEURELLACEAE(38,1)
UNGULATE HEMORRHAGIC SEPTICEMIA(38,1)
VACCINE ADMINISTRATION(35,1)
DISEASE MULTOCIDA(34,1)
INTRAPERITONEAL ROUTE(32,1)
FREEZE DRIED BACTERIUM(31,4)
PASTEURELLOSIS(31,3)
INTRAMUSCULAR ROUTE(29,1)
INTRANASAL ROUTE(29,1)
LIVESTOCK(28,9)
BACTERIUM MULTOCIDA(28,3)
UNGULATE BACTERIUM(28,1)
ANTIBIOTIC RESISTANCE GENE(27,6)
INTRAVENOUS ROUTE(27,1)
MULTOCIDA VACCINE(27,1)
COMPANION ANIMAL DISEASE(26,1)
POULTRY(25,9)
AVIAN BACTERIUM(25,1)
BACTERIUM INTRANASAL ADMINISTRATION(25,1)
CHICKEN ENZYMOL(25,1)
POULTRY BIRD(23,1)
COMPANION ANIMAL(22,8)
SEVERITY(22,4)
DEAD BACTERIA(20,1)
EXOGENOUS BACTERIAL DNA(20,1)
MICROORGANISM(19,5)
DISEASE(19,4)
GAME HEN(19,1)
DELETION(18,6)
SEROTYPE(18,4)
BOVINE ANIMAL(18,1)
LABEL(18,1)
NON CAPSULAR VARIANT MULTOCIDA(17,2)
MAMMAL(16,6)
RESULT HYAE GENE DELETION(15,1)
MOTONEURON MULTOCIDA PASTEURELLA VACCINATION(14,1)
SEPSIS(13,1)
SEROGROUP(12,4)
ANIMAL SUBJECT(12,3)
DOSE(12,3)
NON CAPSULAR SEROGROUP(12,2)
MAMMALIAN(11,2)
CAPSULAR POLYSACCHARIDE BIOSYNTHESIS(11,1)
CFUBETWEEN(11,1)
SEROLOGY(11,1)
KIT(10,2)
MUTANT(10,2)
DIET(9,3)
GUINEA FOWL(9,2)
MUTATED HYAE FRAGMENT(9,2)
OSTRICH(9,2)
PHEASANT(9,2)
CFUIS(9,1)
GENE BACTERIUM HYAE DELETION(9,1)
HYAE CAPSULAR POLYSACCHARIDE(9,1)
SEPTIC SWINE PASTEURELLOSIS(9,1)
SQUAB(9,1)
ATTENUATED BACTERIA(8,3)
PLASMID P192ORI HYAEKAN(8,1)
GOOSE(7,2)
QUAIL(7,2)
CASTRATION MULTOCIDA STRAIN(7,1)
CLINICAL SYMPTOM PATHOLOGY(7,1)
MEURTHE FERN COLONY(7,1)
MUTANT MULTOCIDA CANDIDATE(7,1)
SEPTIC BOVINE PASTEURELLOSIS(7,1)
VIDEO GAME(7,1)
SUBCUTANEOUS VACCINATION(6,2)
BIOSYNTHESIS GENE(6,1)
DIMETHYL DIOCTADECYLAMMONIUM BROMIDE(6,1)
DISEASE SWINE PASTEURELLA(6,1)
FOWL CHOLERA DISEASE(6,1)
GENE HYAE DELETION(6,1)
HYAE GENE STRAND(6,1)
HYAE MICROBIAL COUNT(6,1)
HYAE TURKEY STRAIN(6,1)
HYDROXYETHYL PROPANEDIAMINE(6,1)
MULTOCIDA STRAIN ATTENUATION(6,1)
MUTANT STRAIN MULTOCIDA(6,1)
ORDER SEVERITY(6,1)
PLASMID HYAE DELETION(6,1)
PLASMID REPLICATION ANTIBIOTIC SELECTION(6,1)
PROTEIN HYAE DELETION(6,1)
SEQUENCER ABI PRISM(6,1)
TARGET SPECIES MUTANT BACTERIUM(6,1)
WILD TYPE SENSITIVE SPECIES(6,1)
DELETION PRIMER(5,2)
FOOD(5,2)
PLASMID VECTOR(5,2)
CAPSULAR TRAIT(5,1)
CLONED GENE ANNEAL(5,1)
CODING REGION HYAE DELETION(5,1)
CULTURE FOLD SERIAL DILUTION(5,1)
ECORV MULTOCIDA(5,1)
ELECTROPORATION CUVETTE(5,1)
ENCODED HYAE PROTEIN(5,1)
FIBER DOMESTIC LIVESTOCK(5,1)
INTRATRACHEAL INOCULATION(5,1)
LAMB LYMPH NODE FLAME(5,1)
MUCOSAL COLONIZATION(5,1)
PATHOGENIC PARENT STRAIN(5,1)
PERKIN ELMER GENEAMP(5,1)
RESTRICTION ENZYME DIGESTION(5,1)
STARCH GLUCOSE REPLICA(5,1)
WING MOTONEURON(5,1)
WING WEB VACCINATION(5,1)
WILD TYPE(4,14)
ADULT GROWTH(4,2)
DELETION SITE(4,2)
ELECTROPORATED CELL(4,2)
WILD TYPE PASTEURELLA(4,2)
1059AND PBCSK(4,1)
1059OR P192ORI(4,1)
1062HYA DELETION(4,1)
BACTERIAL MULTOCIDA(4,1)
BACTERIUM DELIVERY(4,1)
BAMHI SITE(4,1)
BROAD BREASTED WHITE(4,1)
COLUMBIA AGAR(4,1)
COMPETENT BACTERIA(4,1)
DONKEY SEPSIS(4,1)
DOSE MULTOCIDA(4,1)
DOSING REGIMEN(4,1)
ECORI CLONING(4,1)
GAME BIRD(4,1)
GENE PULSER(4,1)
GLUCOSAMINE SYNTHESIS(4,1)
HYAE DELETION MUTATION(4,1)
HYAE PCR(4,1)
INK STAIN(4,1)
INTRAMUSCULAR VACCINATION(4,1)
INTRATRACHEAL ROUTE(4,1)
IRIDESCENT PEARL(4,1)
KANAMYCIN BROTH(4,1)
LOGARITHMIC GROWTH(4,1)
METHOXY HEXADECYLGLYCEROL(4,1)
MULTIVALENT VACCINE COMPONENT(4,1)
MULTOCIDA VARIANT(4,1)
MUTANT BACTERIAL VACCINE(4,1)
NUCLEOTIDE EXCISION(4,1)
OVO VACCINATION(4,1)
PATHOLOGICAL LESION(4,1)
PBB SITE(4,1)
PLASMID PBCSK(4,1)
PLURONIC POLYOL(4,1)
SUBSTITUTED PLASMID INCORPORATION(4,1)
SYNTHESIZING OLIGONUCLEOTIDE(4,1)
TERMINATOR CHEMISTRY(4,1)
VACCINATED CALF(4,1)
VACCINATION ROUTE(4,1)
VACCINE ADJUVANT(4,1)
VACCINE FORMULATION(4,1)
VETERINARY ACCEPTABLE VEHICLE(4,1)
VIABLE BACTERIA(4,1)
ECORV SITE(3,2)
FORWARD PRIMER(3,2)
PCR REACTION(3,2)
DEXTRAN SULFATE(3,1)
ENZYME ASSAY DISC DIFFUSION(3,1)
GENE FRAGMENT(3,1)
HEXADECYL AMINE(3,1)
MUCOSAL VACCINATION(3,1)
NON CAPSULAR HYAE MULTOCIDA(3,1)
OLD TURKEY(3,1)
PCR FRAGMENT(3,1)
PLASMID DNA(3,1)
SENSITIVE TARGET SPECIES(3,1)
SUSCEPTIBLE ANIMAL(3,1)
UNGULATE TREATMENT(3,1)
VETERINARY ACCEPTABLE SALT(3,1)
NON CAPSULAR VARIANT(2,3)
CENTRIFUGATION(2,2)
COMPANION(2,2)
INTRANASAL(2,2)
NON CAPSULAR POLYSACCHARIDE(2,2)
NONVARIANT(2,2)
AMYGDALA(2,1)
ANTIBIOTIC FREE COLUMBIA BROTH(2,1)
APPARENT MUCOUS COLONY(2,1)
ATTRACTION(2,1)
BEARING CELL(2,1)
BUFFALO(2,1)
CAPSULE MAIN MEMBRANE COMPONENT(2,1)
CARBOPOL(2,1)
CELL PELLET(2,1)
CHILD(2,1)
CHROMOSOME(2,1)
COLONY FORMATION(2,1)
COMMENSAL MULTOCIDA MUCOSAL SURFACE(2,1)
DIMETHYLGLYCINE(2,1)
GENE CORRECT(2,1)
HEMORRHAGIC SEPTICEMIA(2,1)
INORGANIC SALT(2,1)
INTEGRATED DNA TECHNOLOGY(2,1)
IOWA STATE UNIVERSITY(2,1)
KANAMYCIN RESISTANCE GENE(2,1)
MAMMALIAN CELL(2,1)
MURAMYL DIPEPTIDE(2,1)
NECK SUBCUTANEOUS INJECTION(2,1)
NON CAPSULAR HYAE DELETION(2,1)
PALATINE TONSIL(2,1)
PARENT PCR PRODUCT(2,1)
PATHOLOGY EXTENT(2,1)
PCR KIT(2,1)
PLASMID INTEGRATION(2,1)
PNEUMONIA CHANGE(2,1)
POLY IC(2,1)
POLYACRYLIC ACID(2,1)
PRO ARG(2,1)
PRODUCED HYAEKAN FRAGMENT(2,1)
STRAIN HYAE GENE STRUCTURE(2,1)
TRANSFORMED CELL(2,1)
(JP5001647)
BACTERIA(100,29)
MULTOCIDA(100,18)
DELETION(100,7)
PROTECTIVE IMMUNITY(100,7)
WILD TYPE(100,7)
BACTERIUM SEROTYPE(100,6)
AMINOACID(100,4)
ANTIBIOTIC RESISTANCE GENE(100,4)
SEROGROUP(100,4)
ADMINISTRATION(100,3)
DNA(100,3)
ISOLATED PASTEURELLACEAE MULTOCIDA(100,3)
PORTION HYAE GENE DELETION(100,3)
EXOGENOUS BACTERIA(100,2)
FREEZE DRIED BACTERIUM(100,2)
LIVE BACTERIA(100,2)
MULTOCIDA HYAE DELETION MUTANT(100,2)
PASTEURELLOSIS SEROGROUP(100,2)
AVIAN MULTOCIDA GAVAGING(100,1)
GAVAGING MULTOCIDA UNGULATE(100,1)
HYAE PROTEIN(100,1)
NON CAPSULAR PASTEURELLA(100,1)
PASTEURELLACEAE MULTOCIDA(100,1)
HYAE GENE SEROGROUP(46,1)
POULTRY CHOLERA(42,2)
MULTOCIDA PROTECTIVE IMMUNITY(39,1)
CAPSULAR SEROGROUP(35,1)
HYAE DELETION MUTANT(34,2)
HEMORRHAGIC PNEUMONIA(33,1)
PASTEURELLOSIS(32,4)
VACCINE ADMINISTRATION(29,1)
INTRAPERITONEAL ROUTE(27,1)
INTRANASAL ROUTE(25,1)
UNGULATE(24,9)
INTRAMUSCULAR ROUTE(24,1)
SEPTIC DISEASE(24,1)
INTRAVENOUS ROUTE(23,1)
MULTOCIDA BACTERIUM(22,4)
COMPANION ANIMAL DISEASE(22,1)
GAVAGING ENZYMOL(22,1)
LIVESTOCK(21,8)
MULTOCIDA CAPSULAR FREE VARIANT(21,1)
POULTRY(19,8)
VACCINE(17,9)
COMPANION ANIMAL(16,7)
MICROORGANISM(16,5)
DISEASE(16,4)
SEVERITY(16,3)
SEROTYPE(15,4)
LABEL(15,1)
EXOGENOUS DNA(14,2)
MAMMALIAN(13,4)
SEPSIS(11,1)
ANIMAL SUBJECT(10,3)
CAPSULAR POLYSACCHARIDE BIOSYNTHETIC(9,1)
KIT(8,2)
MUTANT(8,2)
GENE BACTERIUM HYAE DELETION(8,1)
ATTENUATED BACTERIA(7,3)
DIET(7,3)
DOSE(7,3)
HYAE CAPSULAR POLYSACCHARIDE(7,1)
SEPTIC SWINE PASTEURELLOSIS(7,1)
DELETION MUTANT(6,3)
1062HYA MULTOCIDA CANDIDATE(6,1)
CLINICAL SYMPTOM PATHOLOGY(6,1)
MEURTHE FERN COLONY(6,1)
MULTOCIDA CAPSULAR VARIANT(6,1)
PLASMID P192ORI HYAEKAN(6,1)
SEPTIC BOVINE PASTEURELLOSIS(6,1)
SUBCUTANEOUS VACCINATION(5,2)
BIOSYNTHESIS GENE(5,1)
DIMETHYL DIOCTADECYLAMMONIUM BROMIDE(5,1)
DISEASE SWINE PASTEURELLA(5,1)
FOWL CHOLERA DISEASE(5,1)
GENE HYAE DELETION(5,1)
HYAE GENE STRAND(5,1)
HYAE MICROBIAL COUNT(5,1)
HYDROXYETHYL PROPANEDIAMINE(5,1)
MENINX ENCEPHALITIS(5,1)
MULTOCIDA MUTANT STRAIN(5,1)
MULTOCIDA STRAIN ATTENUATION(5,1)
MUTATED HYAE FRAGMENT(5,1)
PLASMID HYAE DELETION(5,1)
PLASMID REPLICATION ANTIBIOTIC SELECTION(5,1)
SENSITIVE WILD TYPE SPECIES(5,1)
SEQUENCER ABI PRISM(5,1)
STRAIN HYAE REPLACEMENT PLASMID(5,1)
TARGET SPECIES MUTANT BACTERIUM(5,1)
ADULT GROWTH(4,2)
DELETION PRIMER(4,2)
DELETION SITE(4,2)
ELECTROPORATED CELL(4,2)
PLASMID VECTOR(4,2)
1059AND PBCSK(4,1)
1059OR P192ORI(4,1)
CAPSULAR TRAIT(4,1)
CLONED GENE ANNEAL(4,1)
CODING REGION HYAE DELETION(4,1)
COMPETENT BACTERIA(4,1)
CULTURE FOLD SERIAL DILUTION(4,1)
DONKEY SEPSIS(4,1)
DOSING REGIMEN(4,1)
ELECTROPORATION CUVETTE(4,1)
ENCODED HYAE PROTEIN(4,1)
FIBER DOMESTIC LIVESTOCK(4,1)
HYAE DELETION MUTATION(4,1)
INK STAIN(4,1)
INTRAMUSCULAR VACCINATION(4,1)
INTRATRACHEAL INOCULATION(4,1)
IRIDESCENT PEARL(4,1)
LAMB LYMPH NODE FLAME(4,1)
METHOXY HEXADECYLGLYCEROL(4,1)
MUCOSAL COLONIZATION(4,1)
OVO VACCINATION(4,1)
PATHOGENIC PARENT STRAIN(4,1)
PATHOLOGICAL LESION(4,1)
PERKIN ELMER GENEAMP(4,1)
RESTRICTION ENZYME DIGESTION(4,1)
STARCH GLUCOSE REPLICA(4,1)
SUBSTITUTED PLASMID INCORPORATION(4,1)
SYNTHESIZING OLIGONUCLEOTIDE(4,1)
VACCINATION ROUTE(4,1)
VACCINE ADJUVANT(4,1)
WING MOTONEURON(4,1)
WING WEB VACCINATION(4,1)
ECORV SITE(3,2)
FORWARD PRIMER(3,2)
BACTERIUM DELIVERY(3,1)
BAMHI SITE(3,1)
BROAD BREASTED WHITE(3,1)
BSSH SITE(3,1)
GAME BIRD(3,1)
GENE PULSER(3,1)
GLUCOSAMINE SYNTHESIS(3,1)
HYAE PCR(3,1)
HYAEKAN FRAGMENT(3,1)
INTRATRACHEAL ROUTE(3,1)
KANAMYCIN BROTH(3,1)
LOGARITHMIC GROWTH(3,1)
MULTIVALENT VACCINE COMPONENT(3,1)
MUTANT BACTERIAL VACCINE(3,1)
NUCLEOTIDE EXCISION(3,1)
PLASMID PBCSK(3,1)
PLURONIC POLYOL(3,1)
TERMINATOR CHEMISTRY(3,1)
TURKEY STRAIN(3,1)
VACCINE FORMULATION(3,1)
VETERINARY ACCEPTABLE VEHICLE(3,1)
VIABLE BACTERIA(3,1)
CENTRIFUGATION(2,2)
COMPANION(2,2)
DEXTROSE(2,2)
INTRANASAL(2,2)
NONVARIANT(2,2)
PCR REACTION(2,2)
AMINOACID HYAE DELETION(2,1)
ANTIBIOTIC FREE CAPSULAR POLYSACCHARIDE(2,1)
ANTIBIOTIC FREE COLUMBIA BROTH(2,1)
APPARENT MUCOUS COLONY(2,1)
CELL PELLET(2,1)
COLONY FORMATION(2,1)
DEXTRAN SULFATE(2,1)
DIMETHYLGLYCINE(2,1)
ENZYME ASSAY DISC DIFFUSION(2,1)
GENE CORRECT(2,1)
HEMORRHAGIC SEPTICEMIA(2,1)
HEXADECYL AMINE(2,1)
INORGANIC SALT(2,1)
INTEGRATED DNA TECHNOLOGY(2,1)
IOWA STATE UNIVERSITY(2,1)
KANAMYCIN RESISTANCE GENE(2,1)
MALONIC ACID SALT(2,1)
MAMMALIAN CELL(2,1)
MOTONEURON MULTOCIDA VACCINATION RESULT(2,1)
MUCOSAL VACCINATION(2,1)
MURAMYL DIPEPTIDE(2,1)
NECK SUBCUTANEOUS INJECTION(2,1)
NON CAPSULAR HYAE DELETION(2,1)
NON CAPSULAR POLYSACCHARIDE VACCINE(2,1)
OLD TURKEY(2,1)
PALATINE TONSIL(2,1)
PARENT PCR PRODUCT(2,1)
PATHOLOGY EXTENT(2,1)
PCR FRAGMENT(2,1)
PCR KIT(2,1)
PLASMID DNA(2,1)
PLASMID INTEGRATION(2,1)
PNEUMONIA CHANGE(2,1)
POLY IC(2,1)
POLYACRYLIC ACID(2,1)
PRO ARG(2,1)
SENSITIVE TARGET SPECIES(2,1)
STRAIN HYAE GENE STRUCTURE(2,1)
SUSCEPTIBLE ANIMAL(2,1)
TRANSFORMED CELL(2,1)
UNGULATE TREATMENT(2,1)
VETER(...)";"Food chemistry
Pharmaceuticals";Open
2003-05-30;"UA65107             A  2004-03-15 [UA--65107]
STG: (A) Declarative patent spec. for invention
AP : 2003UA-0055019 2003-05-30";38564315;UA65107             A  2004-03-15 [UA--65107];2003UA-0055019;;"BONDAR TETIANA OLEKSANDRIVNA
DEMENTIEVA SVITLANA AVKSENTIIV
RYZHENKO HALYNA FEDORIVNA
RYZHENKO VASYL PETROVYCH";;;;0;"RYZHENKO VASYL PETROVYCH
RYZHENKO HALYNA FEDORIVNA
DEMENTIEVA SVITLANA AVKSENTIIV
BONDAR TETIANA OLEKSANDRIVNA";;;"(UA--65107)
Pasteurella multocida ""z-40/155"" strain for production of vaccine against pasteurellosis of livestock";"(UA--65107)
Pasteurella multocida ""Z-40/155"" strain is deposited in Collection of Microorganisms in State Research and Control Institute of Biotechnology and Strains of Microorganism under the entry No. 155. The strain is proposed for the production of the vaccine against pasteurellosis of the livestock.";;;;A61K-039/102;;;Pharmaceuticals;Open
2003-05-16;"SE0301436           D0 2003-05-16 [SE200301436]
STG: (D0) Patent application filed
AP : 2003SE-0001436 2003-05-16
WO2004101795        A1 2004-11-25 [WO2004101795]
STG: (A1) Published application with search report
AP : 2004WO-SE00753 2004-05-14";36858239;"SE0301436           D0 2003-05-16 [SE200301436]
WO2004101795        A1 2004-11-25 [WO2004101795]";2003SE-0001436;;"JOHANSSON KARL-ERIK
PERSSON ANJA
UHLEN MATHIAS
WESTBERG JOAKIM";;"(WO2004101795)
SE";"(WO2004101795)
NAME=WESTBERG, Joakim  [SE/ SE] Kratsbodavägen 25, S-168 65 Bromma  , COUNTRY=SE 

NAME=PERSSON, Anja  [SE/ SE] S:t Persgatan 39 F, S-753 29 Uppsala  , COUNTRY=SE 

NAME=UHLÉN, Mathias  [SE/ SE] Rådmansgatan 4, S-114 25 Stockholm  , COUNTRY=SE 

NAME=JOHANSSON, Karl-Erik  [SE/ SE] Västeråker-Högby, S-755 91 Uppsala  , COUNTRY=SE 
";0;"WESTBERG JOAKIM
PERSSON ANJA
UHLEN MATHIAS
JOHANSSON KARL-ERIK";"(WO2004101795)
SE";"(WO2004101795)
NAME=WESTBERG, Joakim  [SE/ SE] Kratsbodavägen 25, S-168 65 Bromma  , COUNTRY=SE 

NAME=PERSSON, Anja  [SE/ SE] S:t Persgatan 39 F, S-753 29 Uppsala  , COUNTRY=SE 

NAME=UHLÉN, Mathias  [SE/ SE] Rådmansgatan 4, S-114 25 Stockholm  , COUNTRY=SE 

NAME=JOHANSSON, Karl-Erik  [SE/ SE] Västeråker-Högby, S-755 91 Uppsala  , COUNTRY=SE 
";"(WO2004101795)
Variable proteins of mycoplasma mycoides, vaccines and process thereof";"(WO2004101795)
The invention relates to novel protein and nucleic acid sequences of variable surface proteins of Mycoplasma mycoides subsp. mycoides biotype small colony which causes Contagious bovine pleuropneumonia. In addition the invention relates to vaccine compositions comprising the proteins of the invention and methods for de-tecting the presence of the bacterium in diagnostic and epidemiological methods.";"(WO2004101795)
Claims
1. Variable protein of Mycoplasma mycoides subsp. mycoides biotype small colony chosen from:
 (a) proteins chosen from the group comprising SEQ ID No 22-23 and 26-42.
 (b) fragments having at least 20 consecutive amino acids in common with the proteins of (a); or
 (c) analogues or recombinant variants showing at least 50 %, preferably at least 70 %, more preferably at least 90 %, and most preferably at least 98 % ho- mology to the proteins of (a).
2. Variable protein of Mycoplasma mycoides subsp. mycoides biotype small colony chosen from:
 (a) proteins chosen from the group comprising SEQ ID No 22-23 and 25-42.
 (d) fragments having at least 20 consecutive amino acids in common with the proteins of (a); or
 (e) analogues or recombinant variants showing at least 70 %, preferably at least 90 %, and more preferably at least 98 % homology to the proteins of (a); for use in a vaccine.
3. Nucleic acid molecule encoding a variable protein of claim 1.
4. Nucleic acid molecule of claim 3, chosen from the group comprising SEQ ID No 1-2 and 5-21.
5. Recombinant vector comprising a nucleic acid molecule of claim 3 or 4.
6. Fusion protein comprising a variable protein of claim 1.
7. Fusion protein comprising at least two variable proteins of claim 1 or 2, and at least one linker molecule positioned between the proteins.
8. Host cell comprising the recombinant vector of claim 5.
9. Vaccine composition comprising at least one protein according to claim 1-2, preferably a mixture of more than one protein, and optionally additional components.
10. Vaccine composition according to claim 9, wherein at least one protein comprises at least 60 amino acids, preferably at least 80 amino acids, more preferably at least 100 amino acids, most preferably at least 150 amino acids.
11. Vaccine composition according to any one of claims 9-10, for use in preventing disease caused by Mycoplasma capricolum, gallisepticum, genitalium, hominis, hyopneumoniae, mycoides, pneumoniae, specifically Mycoplasma mycoides.
12. Use of at least one protein according to claim 1-2 for the preparation of a vaccine composition for use in preventing disease caused by Mycoplasma capricolum, gallisepticum, genitalium, hominis, hyopneumoniae, mycoides, pneumoniae, specifically Mycoplasma mycoides.
13. Affinity reagents, such as antibodies and affibodies, that specifically binds to at least one protein according to claim 1.
14. Use of at least one protein according to claim 1 for diagnosing the occurrence of Mycoplasma capricolum, gallisepticum, genitalium, hominis, hyopneumoniae, mycoides, pneumoniae, specifically Mycoplasma mycoides.
15. A process for preparing a protein according to claim 1 comprising the steps of a) introducing a vector according to claim 5 into a suitable host cell; b) culturing the host cell under conditions that allows the expression of a protein according to claim 1; and c) isolating the protein of step b) from the host cell or cell culture supernatant.";"(WO2004101795)
The invention also pertains to recombinant vectors comprising nucleic acid sequences of the present invention and host cells comprising such vectors.
The present invention pertains to novel protein- and nucleic acid sequences of variable surface proteins from Mycoplasma mycoides subsp. mycoides biotype small colony, the causative agent for Contagious bovine pleuropneumonia.
The present invention relates to the field of development of vaccines and diagnostic methods for combating Mycoplasma mycoides subsp. mycoides biotype small colony (MmymySC) which causes Contagious bovine pleuropneumonia.
In particular the invention relates to novel protein and nucleic acid sequences for variable surface proteins that are useful for the object of the present invention.";"(WO2004101795)
In conclusion, therefore, there is still a need for improved diagnostic tools and vaccines in order to be able to combat CBPP infections.
The background for this aspect is as follows: A vaccine containing a fusion protein including proteins, represented by the sequence of SEQ ID No 22-42 or parts thereof, has several advantages over a vaccine containing a cocktail of the same proteins, (i) It enhances the immunogenicity of the vaccine and the avidity between the antibody and the vaccine, (ii) It facilitates the production of the vaccine since fewer proteins have to be expressed and purified, (iii) It contributes to a more constant ratio between the amounts of antigen epitopes in the vaccine.
The use of pure protein preparations for vaccine purposes has several advantages over whole cell vaccines.
Also, the variation of surface antigens help the bacteria to escape the host immune system and is a major problem in the development of diagnostic tools and vaccines for prevention of CBPP The expression of variable surface protein genes can be regulated either on the transcriptional or the transla- tional level.
CBPP is the only bacterial disease included in the A-list of the World Organisation for Animal Health (http://www.oie.int) of prioritised communicable animal diseases, together with fourteen viral diseases.
Contagious bovine pleuropneumonia (CBPP) is the infectious disease that kills the largest number of cattle in Africa each year.";"A61K-039/00
A61K-048/00
C07K-014/30
C12N-015/31";"(WO2004101795)
Claims 1. Variable protein of Mycoplasma mycoides subsp. mycoides biotype small colony chosen from: (a) proteins chosen from the group comprising SEQ ID No 22-23 and 26-42.
(b) fragments having at least 20 consecutive amino acids in common with the proteins of (a); or (c) analogues or recombinant variants showing at least 50 %, preferably at least 70 %, more preferably at least 90 %, and most preferably at least 98 % ho- mology to the proteins of (a).
(d) fragments having at least 20 consecutive amino acids in common with the proteins of (a); or (e) analogues or recombinant variants showing at least 70 %, preferably at least 90 %, and more preferably at least 98 % homology to the proteins of (a); for use in a vaccine.
2. Variable protein of Mycoplasma mycoides subsp. mycoides biotype small colony chosen from: (a) proteins chosen from the group comprising SEQ ID No 22-23 and 25-42.";"(WO2004101795)
PROTEIN(100,55)
VARIABLE PROTEIN(100,10)
MYCOIDE BIOTYPE SMALL COLONY(100,8)
MYCOPLASMA MYCOIDES SUBSP(100,8)
PRIORITIZED COMMUNICABLE ANIMAL DISEASE(60,1)
VACCINE IMMUNOGENICITY(55,1)
VACCINE(54,32)
WORLD ORGANIZATION(45,1)
CONTAGIOUS BOVINE PLEUROPNEUMONIA(42,4)
ANTIGEN EPITOPE(41,1)
INFECTIOUS DISEASE(40,1)
RECOMBINANT VECTOR(38,3)
FUSION PROTEIN(35,9)
MYCOPLASMA CAPRICOLUM OCCURRENCE(32,1)
HOST CELL(31,11)
RECOMBINANT VARIANT SHOWING(30,4)
ANIMAL HEALTH(30,1)
PROTEIN PREPARATION(30,1)
VACCINE PRODUCTION(30,1)
CELL VACCINE(29,1)
CONSECUTIVE AMINOACID(26,4)
DIAGNOSTIC TOOL DEVELOPMENT(26,3)
CAUSATIVE AGENT(25,2)
ANALOG(24,5)
HOMINIS(24,3)
DIAGNOSTIC TOOL(22,4)
LINKER MOLECULE(22,2)
AVIDITY(22,1)
TRANSLA TIONAL LEVEL(22,1)
VACCINE COMPOSITION PREPARATION(22,1)
COCKTAIL(21,1)
PROTEIN EXPRESSION(20,4)
AFFINITY REAGENT(20,2)
NUCLEIC ACID SEQUENCE(19,11)
VIRAL DISEASE(19,1)
BACTERIAL DISEASE(18,1)
CELL CULTURE SUPERNATANT(18,1)
ANTIBODY(17,13)
NUCLEIC ACID MOLECULE ENCODING(16,2)
BACTERIA(15,8)
VECTOR(15,6)
HOMOLOGY(15,4)
AFFIBODY(15,1)
INFECTION(14,2)
CONSTANT RATIO(14,1)
PREVENTION(13,2)
CATTLE(12,3)
GROSS PATHOLOGICAL LESION SEVERITY(12,1)
SEQUENCED MOLLICUTE REPERTOIRE(12,1)
HOST IMMUNE(11,2)
MMYMYSC CODON USAGE(11,2)
MYCOPLASMA MYCOIODE MOLECULAR CHARACTERIZATION(11,1)
STEP PROTEIN(11,1)
URACIL PHOSPHORIBOSYLTRANSFERASE CATALYSIS(11,1)
GENE CODON(10,4)
HTTP(10,3)
VACCINE EFFICACY(10,3)
WWW(10,2)
BOVINE PATHOGEN MYCOPLASMA BOVIS(10,1)
DEOXYNUCLEOSIDE PHOSPHATE INTERCONVERSION(10,1)
ENZYME LINKED IMMUNOSOR BANT ASSAY(10,1)
MOLLICUTE SEQUENCED GENOME(10,1)
GENE ENCODING PROPROTEIN(9,1)
MMYMYSC AUSTRALIAN STRAIN(9,1)
MMYMYSC GENOME SEQUENCING(9,1)
PIE T CELL EPITOPE(9,1)
RIBOSOMAL PROTEIN OPERON(9,1)
TA REPEAT(8,4)
TRNA GENE(8,3)
EPIDEMIOLOGY STUDY(8,2)
PHOSPHATE URIDYLYLTRANSFERASE(8,2)
REPLICATION TERMINATION(8,2)
TRANSCRIPTIONAL REGULATION(8,2)
BIG DYE TERMINATOR CYCLE SEQUENCING(8,1)
FRAMESHIFT GENERATING TRUNCATED ORFS(8,1)
SYNONYMOUS ARGININE CODON(8,1)
VARIABLE SURFACE PROTEIN GENE(8,1)
EUROPEAN STRAIN(7,3)
GENE CLUSTER(7,3)
GENOMIC DNA(7,3)
ASYMMETRIC PCR(7,2)
INACTIVE COMPLEMENT(7,2)
PCR AMPLICON(7,2)
PLASMID CLONE(7,2)
POLYMERASE SLIPPAGE(7,2)
UTP GLUCOSE(7,2)
VACCINE STRAIN(7,2)
BACTERIA GENOME(7,1)
BACTERIAL EPIZOOTIC(7,1)
CAPSULE BIOSYNTHESIS GENE MIGHT(7,1)
CLINICAL DISEASE SYMPTOM(7,1)
DEOXYGUANOSINE KINASE(7,1)
DEVELOPMENT FIELD(7,1)
DNA METABOLIC PATHWAY(7,1)
EVOKED PULMONARY EDEMA(7,1)
EXOGENOUS NUCLEOBASE(7,1)
EXOGENOUS SUGAR GLUCOSE(7,1)
FUSION PROTEIN PURIFICATION(7,1)
GENE CODING OVERLAPPING FRAGMENT(7,1)
GENE ENCODING ANTIBIOTIC(7,1)
GLYCEROL UPTAKE CLUSTER(7,1)
GRAM POSITIVE BACTERIA(7,1)
HAEMOPHILUS INFLUENZAE(7,1)
IPPB GENE ENCODING(7,1)
MMYMYSC CELL LYSATE(7,1)
MMYMYSC LIPOPROTEIN(7,1)
MMYMYSC LIVE STRAIN(7,1)
MMYMYSC STRAIN SPECTRUM(7,1)
MTITYMYSC SPGCFIC ANTIGEN(7,1)
MYCOPLASMA GENITALIUM(7,1)
NUCLEOSIDE PHOSPHORYLATION(7,1)
NUCLEOSIDE PHOSPHOTRANSFERASE(7,1)
NUCLEOTIDE BIOSYNTHESIS(7,1)
ORGANISM VIRULENCE(7,1)
PAFFC EXPRESSION VECTOR(7,1)
PCR PRIMER DESIGNING(7,1)
RECOMBINANT PROTEIN VARIANT(7,1)
RESTRICTION FRAGMENT ELECTROPHORESIS(7,1)
RUMINATION CESSATION(7,1)
SEQUENCING PREMIX KIT(7,1)
SEVERE PLEURITIC PAIN(7,1)
STAPHYLOCOCCUS CARNOSUS(7,1)
STAPHYLOCOCCUS XYLOSUS(7,1)
STREPTAVIDIN BIOTIN INTERACTION(7,1)
THYMIDYLATE SYNTHASE(7,1)
TRANSMEMBRANE PROTEIN GENE(7,1)
UDP GALACTOSE MUTASE(7,1)
YERSINIA PESTIS(7,1)
VARIABLE SURFACE PROTEIN(6,6)
ORIC(6,4)
RESTRICTION SITE(6,3)
VACCINE DEVELOPMENT(6,3)
FUSION GENE(6,2)
GLYCOSYLTRANSFERASE(6,2)
SECONDARY ANTIBODY(6,2)
TANDEM REPEAT(6,2)
TRUNCATED COPY(6,2)
ABC TRANSPORTER GENE(6,1)
AMERSHAM BIOSCIENCE(6,1)
ANNUAL RE VACCINATION(6,1)
ARTHRITIC LESION(6,1)
ASCL OVERHANG(6,1)
BEAD AGGLUTINATION(6,1)
CAPSULAR CONTENT ASSOCIATE(6,1)
CATTLE IMMUNIZATION(6,1)
CLINICAL SYMPTOM(6,1)
CYTIDINE DEAMINASE(6,1)
DESIGNING OLIGONUCLEOTIDE(6,1)
DOCTORAL THESIS(6,1)
ESCHER ICHIA(6,1)
GENOME RESTRICTION MAP(6,1)
GENUS MYCOPLASMA(6,1)
GRAPHICAL DOTPLOT(6,1)
IMMUNOREACTIVITY STUDY(6,1)
INCOMPLETELY EXTENDED PRIMER(6,1)
LIPOPROTEIN PRECURSOR(6,1)
LIVE VACCINE(6,1)
MANNIDE OLEATE(6,1)
MINIMAL GENOME GENE(6,1)
MMYMYSC ANTIGEN(6,1)
MMYMYSC GENE(6,1)
MMYMYSC GENOME SEQUENCE(6,1)
MMYMYSC PATHOGENIC(6,1)
MOLLICUTE CONSERVED REGION(6,1)
MOLLICUTE GENOME(6,1)
MONONUCLEOTIDE STRETCH(6,1)
MYCOIDE CLUSTER(6,1)
NEBULIZED LIBRARY(6,1)
NON OXIDATIVE BRANCH(6,1)
NOTL OVERHANG(6,1)
NUCLEOSIDE KINASE(6,1)
NUCLEOTIDE SEQUENCE SIMILARITY(6,1)
ORGANISM REPLICATION(6,1)
OXI DATIVE BRANCH(6,1)
PARALOGOUS GENE(6,1)
PBSK PLASMID(6,1)
POLYVALENT VACCINE(6,1)
PROKARYOTE GENOME(6,1)
PROPROTEIN GENE(6,1)
PT TRANSPORTER(6,1)
PYRUVATE DEHYDROGENASE(6,1)
RABBIT IMMUNIZATION(6,1)
RECOMBINANT PLASMID(6,1)
REDUNDANT GENOME(6,1)
RIBOFLAVIN KINASE(6,1)
SPLICED PROMOTER(6,1)
SUPERPARAMAGNETIC BEAD(6,1)
SYNONYMOUS CODON(6,1)
TRANSMEMBRANE HELIX(6,1)
VACCINATION REGIME(6,1)
VACCINE ADJUVANT(6,1)
VACCINE VIABILITY(6,1)
VETERINARY MICROBIOLOGY(6,1)
WASHINGTON UNIVERSITY(6,1)
BACTERIAL GENOME(5,5)
UGA CODON(5,4)
TRANSPOSASE(5,3)
BACTERIAL CELL(5,2)
GENOME ANALYSIS(5,2)
PERSONAL COMMUNICATION(5,2)
PRIMARY ANTIBODY(5,2)
TRIVIAL NAME(5,2)
VARIABLE EXPRESSION(5,2)
ABC TRANSPORTER PROTEIN(5,1)
ACHOLEPLASMA SPECIES(5,1)
ALIMINIUM HYDROXIDE(5,1)
ANTIGENIC PROTEIN(5,1)
BACTERIA SPREAD(5,1)
BACTERIA STUDY(5,1)
CAPSULE SYNTHESIS(5,1)
CATEGORY GENE(5,1)
CHRONIC DISEASE CARRIER(5,1)
CLINICAL ASSESSMENT(5,1)
CLONE DNA SEQUENCING(5,1)
DEOC GENE(5,1)
DINUCLEOTIDE REPEAT(5,1)
DISEASE DIAGNOSIS(5,1)
DISEASE OUTBREAK(5,1)
DNA SEQUENCER(5,1)
DNAN GENE(5,1)
EVOLUTION STUDY(5,1)
EXTENSIVE VACCINATION(5,1)
FLUORESCENT MARKER(5,1)
GENE AMPLIFICATION(5,1)
GENE VICINITY(5,1)
GENOME SEQUENCE KNOWLEDGE(5,1)
GLY CEROL(5,1)
GLYCEROL KINASE(5,1)
HIGHLY CONTAGIOUS RESPIRATORY DISEASE(5,1)
IGG ANTIBODY(5,1)
ION AFFINITY CHROMATOGRAPHY(5,1)
MIC SEQUENCE SIMILARITY(5,1)
MMYMYSC PROTEIN(5,1)
PATHOGENIC STRAIN(5,1)
PENTOSE PHOSPHATE(5,1)
PET VECTOR(5,1)
PFAM DATABASE(5,1)
PHOSPHATE ALDOLASE(5,1)
PHYLOGENETIC STUDY(5,1)
PHYLOGENY STUDY(5,1)
PLASMID LIBRARY(5,1)
PLASMID PREPARATION KIT(5,1)
PLASMID PURIFICATION(5,1)
PLAUSIBLE EXPLANATION(5,1)
POTCD DOMAIN(5,1)
POTD GENE(5,1)
POTENTIAL CANDIDATE DRUG(5,1)
PROMOTER SPACER(5,1)
PROTEIN GROEL(5,1)
PROTEIN NATIVE FOLDING(5,1)
PROTEINASE K LYSIS(5,1)
PUBLISHED GENOME(5,1)
RECOMBINANT GENE(5,1)
RECOMBINANT VARIANT(5,1)
REPLICATION ORIGIN(5,1)
RESPIRATORY SIGN(5,1)
RESTRICTED BIOSYNTHETIC CAPACITY(5,1)
SUCCESSFUL VACCINATION(5,1)
SYNTHASE GENE(5,1)
SYSTEMIC INFECTION(5,1)
THYMIDINE KINASE(5,1)
TRANSLATIONAL REGULATION(5,1)
VARIABLE PROTEIN PROMOTER(5,1)
WESTERN BLOT(5,1)
WHOLE LIFE CELL VACCINE(5,1)
AFRICAN(4,3)
PCR REACTION(4,2)
PHYLUM(4,2)
AI LIBRARY(4,1)
ANTIBODY DEVELOPMENT(4,1)
ANTIGEN ARRAY(4,1)
ANTIGENIC SITE(4,1)
BACTERIAL PROMOTER REGION(4,1)
BIASED MUTATION(4,1)
BIOLOGICAL ROLE(4,1)
BIOSENSOR ANALYSIS(4,1)
BMHI RESTRICTED PUC(4,1)
CAPSULE INTRAVENOUS INJECTION(4,1)
CELL POPULATION(4,1)
COLORLESS SUBSTRATE(4,1)
CORI RESTRICTED PUC(4,1)
CORRECT PLASMID INSERT(4,1)
COSED PROGRAM(4,1)
COUGH DURATION(4,1)
DA BEAD COMPLEX(4,1)
DISEASE BREAK(4,1)
DISEASE INCUBATION PERIOD(4,1)
DISEASE RISK(4,1)
FREUND COMPLETE ADJUVANT(4,1)
FUNCTIONAL CATEGORY(4,1)
FUSION PROTEIN PRODUCTION(4,1)
GENE FRAGMENT(4,1)
GENOME PERCENT(4,1)
GLOBAL SOCIOECONOMIC PERSPECTIVE(4,1)
GLYCEROL TRANSPORT(4,1)
HOST DEFENSE(4,1)
INFECTED ANIMAL(4,1)
INTRAGENOMIC SEQUENCE COMPARISON(4,1)
ISS ABSENCE(4,1)
LIPID MOLECULE COMPLEX(4,1)
MICROARRAY TECHNOLOGY(4,1)
MMYMYSC ABILITY(4,1)
MMYMYSC DETECTION(4,1)
MMYMYSC LACK(4,1)
MOLECULAR DYNAMICS(4,1)
MYCOPLASMA POTENTIAL VIRULENCE FACTOR(4,1)
NAKED DNA(4,1)
NUCLEOSIDE MONOPHOSPHATE FORMATION(4,1)
NUCLEOTIDE INSERTION(4,1)
PATHOGENICITY POTENTIAL FACTOR(4,1)
PATHOLOGICAL POST MORTEM EXAMINATION(4,1)
PCR PRODUCT CLONING(4,1)
PHOSPHATE OXIDASE(4,1)
PROTEIN SEQUENCE KNOWLEDGE(4,1)
PUBLIC DATABASE SEQUENCE(4,1)
RAISING ANTIBODY(4,1)
RE COMBINANTVSP(4,1)
REPEAT MOTIF(4,1)
RVSP CAPACITY(4,1)
SELECTION MARKER(4,1)
SEVERE DISEASE(4,1)
SYMPTOMLESS CARRIER(4,1)
TRANSFERRING SUGAR(4,1)
UNIQUE HYBRIDIZATION PATTERN(4,1)
VACCINE COMPOSITION IMMUNE RESPONSE(4,1)
VECTOR SEQUENCE ELIMINATION(4,1)
WASH COUPLE(4,1)
KBP(3,5)
REPETITIVE SEQUENCE(3,5)
DIAGNOSTIC METHOD(3,3)
ELISA(3,3)
PAN(3,3)
ESCHERICHIA(3,2)
EVOLUTIONARY PRESSURE(3,2)
EXEMPLE(3,2)
FRUCTOSE(3,2)
GENOME ASSEMBLY(3,2)
HYDROGEN PEROXIDE PRODUCTION(3,2)
NONSENSE CODON(3,2)
PLACEBO(3,2)
PROTEIN MIXTURE(3,2)
ROUTE(3,2)
SIGNAL PEPTIDE SEQUENCE(3,2)
SPACER REGION(3,2)
STRAND(3,2)
SUBUNIT(3,2)
TEST SERUM(3,2)
TREHALOSE(3,2)
WHOLE CELL(3,2)
ACETYLGLUCOSAMINE(3,1)
ACTIVE SUBSTANCE PURITY(3,1)
ALIMINIUM N OCTADECANOATE(3,1)
ALKYL PHOSPHONATE(3,1)
ANOMALOUS PATTERN(3,1)
ANTIBIOTIC TREATMENT(3,1)
ANTIBODY PRESENCE(3,1)
AUXILIARY SUBSTANCE(3,1)
BASIC IDEA(3,1)
CAPSULE PRODUCTION(3,1)
CELL ANTIGENIC(3,1)
CELL DOSAGE(3,1)
CELL LIFE(3,1)
CODING DNA SEQUENCE(3,1)
COMPULSION(3,1)
DETERMINATION ACCURACY(3,1)
DIHYDROFOLATE REDUCTASE(3,1)
DIMETHYLDIOCTADECYLAZANIUM BROMIDE(3,1)
DIMETHYLGLYCINE(3,1)
DNAA REGION(3,1)
EMBDEN MEYERHOF PARNAS(3,1)
FACILIATE STORAGE(3,1)
FUNCTIONAL PROTEIN(3,1)
GC SKEW PATTERN(3,1)
GENE COMPARISON(3,1)
GRAM NEGATIVE BACTERIA(3,1)
HOMONUCLEOTIDE REGION(3,1)
IMMUNODOMINANT(3,1)
INFECTIOUS AGENT(3,1)
ISMMY HORIZONTAL TRANSFER(3,1)
LATEX AGGLUTINATION TEST(3,1)
LESION NATURE(3,1)
MAGNET SEPARATION(3,1)
METHOXYHEXADECYLGLYCEROL(3,1)
MICROCARRIER(3,1)
MISINCORPORATION(3,1)
MMYMYSC PRESENCE(3,1)
MODERATE CONCENTRATION(3,1)
MURAMYL DIPEPTIDE(3,1)
MYCOPLASMA PENETRANS(3,1)
MYCOPLASMA PULMONIS(3,1)
PATTERN DEVIATION(3,1)
PEANUT OIL(3,1)
PERMEASE COMPONENT(3,1)
PHENOL CHLOROFORM EXTRACTION(3,1)
PLURONIC ACID(3,1)
POTENTIAL MARKER(3,1)
PROLIPOPROTEIN CODING GENE STRUCTURE(3,1)
PROMOTER VARIABLE(3,1)
PROTEIN MODIFICATION(3,1)
PURE PROTEIN(3,1)
RANDOM LIBRARY CONSTRUCTION(3,1)
RED COLOR(3,1)
REPEAT RESIDUE(3,1)
RRNA SEQUENCE(3,1)
SCARCE ABILITY(3,1)
SCL SITE(3,1)
SEQUENCING REACTION(3,1)
SPERMIDINE PUTRESCINE(3,1)
SPIROPLASMA GROUP(3,1)
SPIROPLASMA MEMBER(3,1)
STANDARD VACCINATION(3,1)
STOP CO DON(3,1)
SYNTHETIC GENE TRANSLATION(3,1)
TISSUE ENVIRONMENT(3,1)
UNIVERSAL STOP CODON UGA(3,1)
UREAPLASMA PARVUM(3,1)
UREAPLASMA UREALYTICUM(3,1)
WHOLE GENOME(3,1)
WHOLE PROTEOME FUNCTIONAL ANALYSIS(3,1)
ABUNDANT AMINOACID(2,1)
ACETYL COA(2,1)
ACTIVE OXYGEN(2,1)
ADHESION(2,1)
AL RESTRICTION(2,1)
ALKALINE PHOSPHATASE(2,1)
ANDNCL(2,1)
ANNEALING TEMPERATURE(2,1)";Pharmaceuticals;Open
"2003-04-21
2004-04-13
2007-03-15";"CA2426280           A1 2004-10-21 [CA2426280]
STG: (A1) Application laid open
AP : 2003CA-2426280 2003-04-22
US20040208901       A1 2004-10-21 [US20040208901]
STG: (A1) Application published
AP : 2003US-10419661 2003-04-21
WO2004093904        A2 2004-11-04 [WO200493904]
STG: (A2) International application published without international search report
AP : 2004WO-IB01292 2004-04-13
AU2004231359        A1 2004-11-04 [AU2004231359]
STG: (A1) Open to public inspection
AP : 2004AU-0231359 2004-04-13
UY28274             A1 2004-11-30 [UY--28274]
STG: (A1) Patent application (First publication level)
AP : 2004UY-0028274 2004-04-21
WO2004093904        A3 2004-12-23 [WO200493904]
STG: (A3) Later publication of ISR with revised front page
AP : 2004WO-IB01292 2004-04-13
TW200505477         A  2005-02-16 [TW200505477]
STG: (A) Laid open application for patent or patent of addition
AP : 2004TW-0111107 2004-04-21
CL2004000799        A1 2005-04-22 [CL0799200400]
STG: (A1) Patent application
AP : 2004CL-0000799 2004-04-14
AR043892            A1 2005-08-17 [AR--43892]
STG: (A1) Independent patent application
AP : 2004AR-0101325 2004-04-20
MXPA05011278        A  2006-01-24 [MX2005PA011278]
STG: (A) Patent application
AP : 2005MX-PA11278 2004-04-13
EP1617866           A2 2006-01-25 [EP1617866]
STG: (A2) Application published without search report
AP : 2004EP-0727073 2004-04-13
KR20060013509       A  2006-02-10 [KR20060013509]
STG: (A) Published application
AP : 2005KR-7019938 2005-10-20
CO5611162           A2 2006-02-28 [CO5611162]
STG: (A2) Application derived from a PCT application
AP : 2005CO-0106970 2005-10-21
BRPI0409640         A  2006-04-25 [BR200409640]
STG: (A) Published application
AP : 2004BR-0009640 2004-04-13
BRPI0409640         A1 2006-04-25 [BRPI0409640]
STG: (A1) Published application
AP : 2004BR-0009640 2004-04-13
CN1777442           A  2006-05-24 [CN1777442]
STG: (A) Published application
AP : 2004CN-80010814 2004-04-13
RU2005128790        A  2006-06-10 [RU2005128790]
STG: (A) Application for invention
AP : 2005RU-0128790 2004-04-13
JP2006524224        A  2006-10-26 [JP2006524224]
STG: (A) Published application
AP : 2006JP-0506539 2004-04-13
US20070154943       A1 2007-07-05 [US20070154943]
STG: (A1) Application published
AP : 2007US-11724624 2007-03-15
FD :  Division of: US10/419,661 FDD=2003-04-21 [2003US-10419661]
US20070172877       A1 2007-07-26 [US20070172877]
STG: (A1) Application published
AP : 2007US-11724615 2007-03-15
FD :  Division of: US10/419,661 FDD=2003-04-21 [2003US-10419661]
BRPI0409640         A2 2009-04-14 [BR200409640]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2004BR-0009640 2004-04-13
US7563449           B2 2009-07-21 [US7563449]
STG: (B2) Granted patent as second publication
AP : 2003US-10419661 2003-04-21
FD :  Previous publication: US20040208901 A1 2004-10-21 [US20040208901]
AU2004231359        B2 2009-07-23 [AU2004231359]
STG: (B2) Patent proceeded by OPI
AP : 2004AU-0231359 2004-04-13
CA2426280           C  2014-11-18 [CA2426280]
STG: (C) Patent (second level)
AP : 2003CA-2426280 2003-04-22";32283;"CA2426280           A1 2004-10-21 [CA2426280]
US20040208901       A1 2004-10-21 [US20040208901]
WO2004093904        A2 2004-11-04 [WO200493904]
AU2004231359        A1 2004-11-04 [AU2004231359]
UY28274             A1 2004-11-30 [UY--28274]
WO2004093904        A3 2004-12-23 [WO200493904]
TW200505477         A  2005-02-16 [TW200505477]
CL2004000799        A1 2005-04-22 [CL0799200400]
AR043892            A1 2005-08-17 [AR--43892]
MXPA05011278        A  2006-01-24 [MX2005PA011278]
EP1617866           A2 2006-01-25 [EP1617866]
KR20060013509       A  2006-02-10 [KR20060013509]
CO5611162           A2 2006-02-28 [CO5611162]
BRPI0409640         A  2006-04-25 [BR200409640]
BRPI0409640         A1 2006-04-25 [BRPI0409640]
CN1777442           A  2006-05-24 [CN1777442]
RU2005128790        A  2006-06-10 [RU2005128790]
JP2006524224        A  2006-10-26 [JP2006524224]
US20070154943       A1 2007-07-05 [US20070154943]
US20070172877       A1 2007-07-26 [US20070172877]
BRPI0409640         A2 2009-04-14 [BR200409640]
US7563449           B2 2009-07-21 [US7563449]
AU2004231359        B2 2009-07-23 [AU2004231359]
CA2426280           C  2014-11-18 [CA2426280]";"2003US-10419661
2004WO-IB01292
2007US-11724615
2007US-11724624";"(EP1617866)
WO2004093904
(JP2006524224)
WO2004093904
(RU2005128790)
WO2004093904
(MX2005PA011278)
WO2004093904
(KR20060013509)
WO2004093904
(CN1777442)
WO2004093904
(BR200409640)
WO2004093904
(AU2004231359)
WO2004093904";"ELLSWORTH MICHAEL A
FERGEN BRIAN J
FICKEN MARTIN D
PFIZER
PFIZER PRODUCTS
TUCKER CASSIUS M
ZOETIS SERVICES";ZOETIS SERVICES;"(EP1617866)
US
(US20070154943)
US
(US20070172877)
US
(US7563449)
US
(WO200493904)
US

(BRPI0409640)
US
(BR200409640)
US
(CA2426280)
US
(CA2426280)
US";"(EP1617866)
NAME=Pfizer Products Inc. Eastern Point Road , CITY=Groton, Connecticut 06340 , COUNTRY=US 

(US20070154943)
NAME=Pfizer, Inc. , CITY=New york , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Pfizer Products, Inc. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 

(US20070172877)
NAME=Pfizer, Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Pfizer Products, Inc. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 

(US7563449)
NAME=Pfizer Inc, , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

(WO200493904)
NAME=PFIZER PRODUCTS INC.  [US/ US] Eastern Point Road, Groton, CT 06340  , COUNTRY=US 

(JP2006524224)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(BRPI0409640)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 

(BR200409640)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 

(CA2426280)
NAME=ELLSWORTH MICHAEL A 5510 Thistle Circle, LINCOLN, NE, 68516 , COUNTRY=US 

NAME=FICKEN MARTIN D 15015 Garden Street, BENNET, NE, 68317 , COUNTRY=US 

NAME=FERGEN BRIAN J 2532 Devoe Drive, LINCOLN, NE, 68506 , COUNTRY=US 

NAME=TUCKER CASSIUS M 2464 Sewel Drive, LINCOLN, NE, 68502 , COUNTRY=US 

(CA2426280)
NAME=ELLSWORTH MICHAEL A 5510 Thistle Circle, LINCOLN, NE, 68516 , COUNTRY=US 

NAME=FICKEN MARTIN D 15015 Garden Street, BENNET, NE, 68317 , COUNTRY=US 

NAME=FERGEN BRIAN J 2532 Devoe Drive, LINCOLN, NE, 68506 , COUNTRY=US 

NAME=TUCKER CASSIUS M 2464 Sewel Drive, LINCOLN, NE, 68502 , COUNTRY=US 
";1;"ELLSWORTH MICHAEL AARON
FICKEN MARTIN DALE
FERGEN BRIAN JAMES
TUCKER CASSIUS MCALLISTER";"(EP1617866)
US";"(EP1617866)
NAME=ELLSWORTH, Michael Aaron, Pfizer Global R & D 601 West Corhusker Highway , CITY=Lincoln, NE 68521 , COUNTRY=US 

NAME=FICKEN, Martin Dale, Pfizer Global R & D 601 West Corhusker Highway , CITY=Lincoln, NE 68521 , COUNTRY=US 

NAME=FERGEN, Brian, James 3043 Harrison Road , CITY=Ames, IA 50010 , COUNTRY=US 

NAME=TUCKER, Cassius McAllister, Pfizer Global R & D 301 Henrietta Street , CITY=Kalamazoo, MI 49001 , COUNTRY=US 
";"(EP1617866)
Modified live vaccines comprising bhv-1 (ibr) and/or bvdv for pregnant and nursing cattles";"(EP1617866)
The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by adminstering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.";"(CA2426280)
1. A vaccine composition that is safe for administration to a pregnant cow or a pregnant heifer comprising a therapeutically effective amount of a modified live
Bovine Herpes Virus Type-1 (BHV-1), a modified live Bovine Viral Diarrhea
Virus type
1 (BVDV-1), and a modified live Bovine Viral Diarrhea Virus type 2 (BVDV-2), wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding with a vaccine composition comprising a therapeutically effective amount of a modified live
BHV-1, a modified live BVDV-1, and a modified live BVDV-2.
2. A vaccine composition for preventing infection in a calf nursing a pregnant cow or nursing a pregnant heifer, comprising a therapeutically effective amount of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live
Bovine Viral Diarrhea Virus type 1 (BVDV-1), and a modified live Bovine Viral
Diarrhea Virus type 2 (BVDV-2), wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding and during pregnancy with a vaccine composition comprising a therapeutically effective amount of a modified live BHV-1, a modified live BVDV-1, and a modified live BVDV-2.
3. The vaccine composition of claim 1, further comprising one or more antigens selected from a modified live Parainfluenza Virus Type 3 (PIV3), a modified live Bovine Respiratory Syncytial Virus (BRSV), Leptospira canicola,
Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus.
4. The vaccine composition of claim 2, further comprising one or more antigens selected from a modified live Parainfluenza Virus Type 3 (PIV3), a modified live Bovine Respiratory Syncytial Virus (BRSV), Leptospira canicola,
Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus.
5. A vaccine composition for preventing infection in a calf nursing a pregnant cow or nursing a pregnant heifer, comprising a therapeutically effective amount of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live
Bovine Viral Diarrhea Virus type 1 (BVDV-1), and a modified live Bovine Viral
Diarrhea Virus type 2 (BVDV-2), wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding and during pregnancy with a vaccine composition comprising a therapeutically effective amount of a vaccine composition comprising a modified live BHV-1, a modified live BVDV-1, a modified live BVDV-2, and one or more antigens selected from a modified live PIV3, a modified live BRSV,
Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno,
Leptospira-icterohaemorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus.
6. A vaccine composition that is safe for administration to a pregnant cow or a pregnant heifer, comprising a therapeutically effective amount of a modified live
Bovine Herpes Virus Type-1 (BHV-1), a modified live Bovine Viral Diarrhea
Virus type
1 (BVDV-1), a modified live Bovine Viral Diarrhea Virus type 1 (BVDV-2), and one or more of a modified live Parainfluenza Virus Type 3 (PIV3), a modified live
Bovine
Respiratory Syncytial Virus (BRSV), Leptospira canicola, Leptospira grippotyphosa,
Leptospira borgpetersenii hardjo-prajitno, Leptospira-icterohaemorrhagia,
Leptospira interrogans pomona, and Campylobacter fetus bacterins, wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding with a vaccine composition comprising a therapeutically effective amount of modified live BHV-1, and a modified live BVDV-1, and a modified live BVDV-2.
7. A vaccine composition for preventing infection in a calf nursing a pregnant cow or nursing a pregnant heifer, comprising a therapeutically effective amount of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live
Bovine Viral Diarrhea Virus type 1 (BVDV-1), a modified live Bovine Viral
Diarrhea
Virus type 2 (BVDV-2), and one or more of a modified live Parainfluenza Virus
Type 3
(PIV3), a modified live Bovine Respiratory Syncytial Virus (BRSV), Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno,
Leptospira icterohaemorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, and Leptospira bratislava, wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding and during pregnancy with a vaccine composition comprising a therapeutically effective amount of a modified live
BHV-1, a modified live BVDV-1, and a modified live BVDV-2.
8. A vaccine composition that is safe for administration to a pregnant cow or a pregnant heifer, comprising a therapeutically effective amount of (a) a modified live Bovine Herpes Virus Type-1 (BHV-1), (b) a modified live Bovine Viral
Diarrhea
Virus type 1 (BVDV-1), and (c) a modified live Bovine Viral Diarrhea Virus type 2
(BVDV-2), wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding with a vaccine composition comprising a therapeutically effective amount of modified live BHV-1, a modified live BVDV-1, a modified live BVDV-2, and one or more antigens selected from a modified live PIV3, a modified live BRSV,
Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno,
Leptospira icterohaemorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus.
9. A vaccine composition as defined in claims 1 to 8, which is an intramuscular dosage form.
10. A vaccine composition as defined in claims 1 to 8, which is a subcutaneous dosage form.
11. A vaccine composition as defined in claims 1 to 8, containing from about 10 2 to about 10 10 TCID50 units BHV-1.
12. A vaccine composition as defined in claims 1 to 8, containing from about 10 2 to about 10 10 TCID50 units of each of said BVDV-1 and said BVDV-2.
13. A vaccine composition as defined in claims 3 to 8, containing from about 10 2 to about 10 10 TCID50 units of each virus.
14. A vaccine composition as defined in claims 1 to 13, having a unit volume of from about 0.1 to about 5.0 ml.
15. A vaccine composition as defined in claims 1 to 13, having a unit volume of about 5 ml.
16. A vaccine composition as defined in claims 1 to 13, having a unit volume of about 2 ml.
17. Use of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live Bovine Viral Diarrhea Virus type 1 (BVDV-1), and a modified live Bovine
Viral
Diarrhea Virus type 2 (BVDV-2), for safe administration to a pregnant cow or pregnant heifer, which cow or heifer has been vaccinated prebreeding with modified live BHV-1, a modified live BVDV-1, and a modified live BVDV-2.
18. Use of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live Bovine Viral Diarrhea Virus type 1 (BVDV-1), and a modified live Bovine
Viral
Diarrhea Virus type 2 (BVDV-2), and one or more of a modified live
Parainfluenza
Virus Type 3 (PIV3), a modified live Bovine Respiratory Syncytial Virus
(BRSV),
Leptospira canicola, Leptospira grippotyphosa; Leptospira borgpetersenii hardjoprajitno, Leptospira icterohaemorrhagia, Leptospira interrogans pomona,
Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus, for safe administration to a pregnant cow or a pregnant heifer, which cow or heifer has been vaccinated prebreeding with modified live BHV-1, a modified live BVDV-1, and a modified live BVDV-2.
19. Use of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live Bovine Viral Diarrhea Virus type 1 (BVDV-1), and a modified live Bovine
Viral
Diarrhea Virus type 1 (BVDV-2) for preventing infection in a calf nursing a pregnant cow or nursing a pregnant heifer, wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding and during pregnancy with modified live BHV-1, a modified live BVDV-1, and a modified live BVDV-2.
20. Use of a modified live Bovine Herpes Virus Type-1 (BHV-1), a modified live Bovine Viral Diarrhea Virus type 1 (BVDV-1), and a modified live Bovine
Viral
Diarrhea Virus type 2 (BVDV-2), and one or more of a modified live
Parainfluenza
Virus Type 3 (PIV3), a modified live Bovine Respiratory Syncytial Virus
(BRSV),
Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjoprajitno, Leptospira icterohaemorrhagia, Leptospira interrogans pomona,
Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus, for preventing infection in a calf nursing a pregnant cow or nursing a pregnant heifer, wherein the pregnant cow or pregnant heifer has been vaccinated prebreeding and during pregnancy with modified live BHV-1, a modified live BVDV-1, and modified live
BVDV-2.";"(US20040208901)
[0014] The present invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with at least one of BVDV Type 1 or Type 2, BHV-1, PIV3, BRSV, Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo-bovis and Leptospira interrogans pomona comprising administering to the animal, an effective amount of a combination vaccine.
[0001] The present invention relates to methods for safely vaccinating pregnant cows and calves nursing pregnant cows to prevent diseases or disorders, such as abortion caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus Type 3 (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo-bovis and Leptospira interrogans pomona by administering to the animal an effective amount of a combination vaccine.
The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.";"(US20040208901)
Studies have established that the virus causes severe primary respiratory disease; that persistently infected (PI) cattle are a major source of infection for susceptible calves; and that BVDV infects white cell reservoirs, causing profound and broad-based deficits in the immune system.
Wschr. 81:481-487 (1974) and are highly predisposed to infection with microorganisms causing diseases such as pneumonia or enteric disease (Barber, et al., Vet.";"A61K-039/00
A61K-039/12
A61K-039/145
A61K-039/15
A61K-039/155
A61K-039/235
A61K-039/245
A61K-039/265
A61K-039/295
A61K-039/38
A61P-015/00
A61P-015/06
A61P-031/04
A61P-031/12
A61P-031/22
C12N-007/01
C12N-007/04
C12P-021/06
C12Q-001/68
C12Q-001/70
G01N-033/53";"(US20040208901)
1. A method of preventing abortion in a pregnant animal, caused by a BHV-1 virus comprising administering to the pregnant animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1), wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1).
2. A method of preventing infection in an animal that is nursing a pregnant animal, comprising administering to the nursing animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1), wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1).
3. A method of preventing abortion in a pregnant animal, caused by a BHV-1 virus comprising administering to the pregnant animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1) and at least one antigen selected from the group consisting of: Bovine Viral Diarrhea Virus (BVDV); a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, and Campylobacter fetus; wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1).
4. A method of preventing infection in an animal that is nursing a pregnant animal, comprising administering to the nursing animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1) and at least one antigen selected from the group consisting of: Bovine Viral Diarrhea Virus (BVDV); a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, and Campylobacter fetus;), wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Herpes Virus (BHV-1).
14. A method of preventing abortion in a pregnant animal caused by a BVDV virus in an animal comprising administering to said animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV), wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV).
15. A method of preventing infection in an animal that is nursing a pregnant animal, comprising administering to the nursing animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV), wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV).
16. A method of preventing abortion in a pregnant animal, caused by a BVD virus comprising administering to the pregnant animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV) and at least one antigen selected from the group consisting of: Bovine Herpes Virus (BHV-1); a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, and Campylobacter fetus; wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV).
17. A method of preventing infection in an animal that is nursing a pregnant animal, comprising administering to the nursing animal a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV), wherein the pregnant animal is vaccinated pre-breeding with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV) and at least one antigen selected from the group consisting of: Bovine, Herpes Virus (BHV-1); a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, and Campylobacter fetus; wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising a modified live Bovine Viral Diarrhea Virus (BVDV).
27. A method of preventing abortion in a pregnant animal, caused by BHV-1 and BVDV viruses comprising administering to the pregnant animal a therapeutically effective amount of a vaccine composition comprising modified live Bovine Herpes Virus (BHV-1) and Bovine Viral Diarrhea viruses in combination with a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, and Campylobacter fetus bacterins, wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising at least one modified live Bovine Herpes Virus (BHV-1) and at least one modified live Bovine Viral Diarrhea virus.
28. A method of preventing infection in an animal that is nursing a pregnant animal, comprising administering to the nursing animal a therapeutically effective amount of a vaccine composition comprising modified live Bovine Herpes Virus (BHV-1) and Bovine Viral Diarrhea viruses in combination with a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardlo-bovis and Leptospira Bratislava, wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising at least one modified live Bovine Herpes Virus (BHV-1) and at least one modified live Bovine Viral Diarrhea virus.
29. A method of preventing abortion in a pregnant animal, caused by BHV-1 and BVDV viruses comprising administering to the pregnant animal a therapeutically effective amount of a vaccine composition comprising modified live Bovine Herpes Virus (BHV-1) and Bovine Viral Diarrhea viruses in combination with a modified live Parainfluenza Virus Type 3 (PIV3); a modified live Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira Bratislava, and Campylobacter fetus, wherein the pregnant animal is pre-vaccinated with a therapeutically effective amount of a vaccine composition comprising at least one modified live Bovine Herpes Virus (BHV-1) and at least one Bovine Viral Diarrhea virus.";"(US20070154943)
ANIMAL(100,119)
INFECTION(100,30)
PREGNANT ANIMAL(100,14)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(100,3)
CATTLE REPRODUCTIVE DISEASE(100,1)
LEPTOSPIRA GRIPPOTYPHOSA(47,10)
LEPTOSPIRA CANICOLA(45,9)
BORGPETERSENII HARDJO BOVIS(45,7)
LEPTOSPIRA INTERROGAN(42,8)
VACCINE(40,59)
PREGNANT COW(35,10)
CALF NURSING PREGNANT COW(35,5)
MULTIVALENT BACTERIN VACCINE(34,1)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(25,6)
LEPTOSPIRA HARDJ PRAJITNO(25,1)
BOVINE VIRAL DIARRHEA VIRUS(24,11)
LEPTOSPIRA HARDJO BOVIS(24,1)
LEPTOSPIRA(22,20)
GASTROINTESTINAL DISEASE(20,1)
CAMPYLOBACTER FETUS(19,15)
NURSING ANIMAL(19,2)
SUSCEPTIBLE CALF(19,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(18,4)
BOVINE HERPES VIRUS(17,3)
NURSING(17,3)
SEVERE PRIMARY RESPIRATORY DISEASE(16,1)
BVD VIRUS(15,11)
BOVINE RHINOTRACHEITIS VIRUS(15,9)
DISORDER(13,6)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(13,3)
ABORTION(12,37)
PIV(12,22)
DISEASE(12,10)
TRIMESTER PREGNANT ANIMAL(12,6)
DIARRHEA PARAINFLUENZA(11,9)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHAEMORRHAGIAE POMONA BACTERIN(11,5)
BVDV NEUTRALIZING ANTIBODY TITER(11,3)
MICROORGANISM(11,1)
VIRUS(10,28)
BHV(10,16)
LEPTOSPIRA BORGPETERSENLI HARDIO PRAJITNO(10,2)
LIVE VIRAL COMBINATION VACCINE(10,1)
MAJOR INFECTION SOURCE(10,1)
PNEUMONIA(10,1)
WHITE CELL RESERVOIR(10,1)
BVDV(9,46)
ANTIBODY NEUTRALIZATION(9,9)
PERSISTENT FETAL INFECTION(9,5)
RESPIRATORY INFECTION(9,2)
BARBER(9,1)
BRSV(8,11)
ANTIGEN(8,6)
SYNCYTIAL MODIFY LIVE VIRUS(8,5)
HEALTHY LIVE CALF(8,4)
PARAINFLUENZA VIRUS(8,2)
SERUM NEUTRALIZING ANTIBODY TITER(8,2)
VACCINATED PREGNANT CATTLE(8,2)
IMMUNOGENIC(7,11)
AGE MONTH(7,8)
ABORTING ANIMAL(7,7)
PREGNANCY STATUS(7,7)
BOVINE HERPES VIRUS TYPE(7,3)
IBRV NEUTRALIZING ANTIBODY(7,2)
INACTIVATED BVDV VACCINE(7,2)
RESPIRATORY SYNCITIAL VIRUS(7,2)
BROAD BASED DEFICIT(7,1)
LEPTOSPIRA BORGPETERSENLI HARDJO PRAJITNO(7,1)
LICENSED BVDV MLV VACCINE(7,1)
VIRULENT ORGANISM URINARY SHEDDING(7,1)
CATTLE(6,14)
BORGPETERSENLI HARDJO BOVIS(6,2)
HEIFER PREGNANCY(6,2)
IBRV ANTIBODY TITER(6,2)
SEMI ANNUAL REVACCINATION(6,2)
BOVINE ABORTION SEROLOGY EVALUATION(6,1)
CROSSBRED BEEF HEIFER RANGING(6,1)
GENUS LEPTOSPIRA SPIROCHETE(6,1)
INTESTINAL MUCOSA ULCERATION(6,1)
LEPTOSPIRA INTERROGAN POMONA(6,1)
LEPTOSPIRA SEROVAR HARDJO(6,1)
NONCYTOPATHIC BVDV BIOTYPE(6,1)
VET(5,17)
SST BLOOD SAMPLE(5,8)
VETERINARY ACCEPTABLE CARRIER(5,7)
ANIMAL BREEDING(5,6)
VACCINE COMPONENT SAFETY(5,6)
DAM PERCENTAGE(5,4)
HEALTHY CALF(5,4)
VETERINARY PHYSICIAN(5,3)
BOVI SHIELD VACCINE(5,2)
IMMUNE(5,2)
ANNUAL VACCINATION HISTORY(5,1)
BVDV CPNADL VIRUS(5,1)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHEMORRHAGIAE POMONA BACTERIN(5,1)
CATTLE LEPTOSPIRAL INFECTION(5,1)
CROSSBRED DAIRY HEIFER(5,1)
CYTOPATHIC VIRUS BIOTYPE(5,1)
HEALTHY CATTLE VACCINATION(5,1)
NEWBORN CALF HEALTH OBSERVATION(5,1)
PREGNANT CATTLE PLACENTA(5,1)
RIPPOTYPHOSA HARDJO ICTEROHEMORRHAGIA POMONA BACTERIN(5,1)
SYSTEMIC SYMPTOM MANIFESTATION(5,1)
COMBINATION VACCINE(4,22)
ANNUAL BASIS(4,6)
VACCINE TREATMENT(4,5)
ANIMAL STUDY(4,4)
ADVERSE LOCAL OBSERVATION(4,3)
ASSIGNED LOT DOSE(4,3)
FETAL PROTECTION(4,3)
IBRV INFECTION(4,3)
LOT BRSV COMPONENT(4,3)
STERILE DILUENT(4,3)
ABNORMAL CALF(4,2)
ATTENUATED VIRUS(4,2)
BOVINE CYTOKINE(4,2)
IBRV VIRUS(4,2)
INFECTION SYMPTOM(4,2)
INOCULATED ANIMAL(4,2)
INTRA LYMPH NODE(4,2)
LACTATING COW(4,2)
MODIFY LIVE VIRUS VACCINE(4,2)
MONTANIDE ISA(4,2)
NCP VIRUS(4,2)
NEOSPORA INFECTION(4,2)
PLACEBO DOSE(4,2)
PLURONIC POLYOL(4,2)
PRE BREEDING VACCINATION REGIMEN(4,2)
PRE NURSING NEUTRALIZING ANTIBODY(4,2)
REPRODUCTIVE DISEASE(4,2)
SAPONIN DERIVATIVE(4,2)
TEST VACCINE FORMULA ADMINISTRATION(4,2)
VACCINATED ANIMAL PREGNANCY(4,2)
VACCINE LOT(4,2)
BHV TRUNCATED VERSION(4,1)
BVDV FETAL INFECTION(4,1)
BVDV INFECTION PERSISTENCE(4,1)
BVDV VIRUS GROWTH STUDY(4,1)
CHEMICALLY INACTIVATED BVD(4,1)
CLASS IC SHIPPING FEVER SYNDROME(4,1)
L5IBRVBVDVPIV3BRSVTEST VACCINE(4,1)
MODIFY LIVE BVDV VACCINE(4,1)
PI CALF BIRTH(4,1)
VETERINARY DIAGNOSTIC LABORATORY(4,1)
VIRULENT STRAIN ATTENUATION(4,1)
VIRUS NEUTRALIZATION ASSAY(4,1)
GEOMETRIC(3,4)
PRE VACCINATION(3,4)
SERUM SEPARATION TUBE(3,4)
STERILE WATER DILUENT(3,4)
VACCINE LEPTOSPIRA(3,4)
PARTURITION PHASE(3,3)
POST VACCINATION REACTION TABLE(3,3)
PRETREATMENT PHASE(3,3)
ADVERSE SYSTEMIC REACTION(3,2)
BOVINE ANIMAL(3,2)
BRSV STRAIN(3,2)
CALF HEALTH STATUS(3,2)
HUMAN HANDLER(3,2)
HUMORAL IMMUNE RESPONSE(3,2)
INFECTION RISK(3,2)
MINERAL OIL EMULSION(3,2)
MLV COMPONENT DOSE(3,2)
MODIFIED LIVE ANTIGEN(3,2)
UTERO EXPOSURE(3,2)
ABORTION DATA(3,1)
ACUTE FATAL DISEASE(3,1)
ACUTE ONSET RESPIRATORY DISEASE(3,1)
ALPHAHERPESVIRIDA SUBFAMILY MEMBER(3,1)
AMPHIGEN ADJUVANT(3,1)
AVRIDINE LIPID(3,1)
BIPHASIC FEVER(3,1)
BOOSTING REGIMEN(3,1)
BVD VIRUS CAPACITY(3,1)
BVDV CPBVDV(3,1)
BVDV INCIDENCE(3,1)
BVDV INFECTION TREATMENT(3,1)
BVDV VIRUS STRAIN(3,1)
CALF MORTALITY(3,1)
CATTLE PESTIVIRUS(3,1)
CHOLESTEROL AMPHIGEN(3,1)
CLASSICAL SWINE FEVER(3,1)
CLINICAL SIGN EVIDENCE(3,1)
CLINICAL SYNDROME BROAD ARRAY(3,1)
COMPENDIUM COLLECTION(3,1)
CONVALESCENT SERA(3,1)
CONVALESCENT SERUM(3,1)
CROSSBRED BEEF CATTLE(3,1)
DIAGNOSTIC SEROLOGY TESTING(3,1)
EYE VITREOUS HUMOR(3,1)
FATAL MANIFESTATION(3,1)
FLAVIVIRIDAE FAMILY(3,1)
FROTHY SALIVA(3,1)
GALENICA PHARMACEUTICAL(3,1)
GIV GLYCOPROTEIN(3,1)
HACKING COUGH(3,1)
HEMORRHAGIC BVDV(3,1)
HERD FERTILITY(3,1)
HOLSTEIN HEIFER(3,1)
IMMUNOCOMPETENT ANIMAL(3,1)
INACTIVATED VIRAL VACCINE(3,1)
INCORRECT BREEDING DATE(3,1)
INFLAMED MUZZLE(3,1)
KIDNEY INFECTION(3,1)
LABORED BREATHING(3,1)
LEPTOSPIRA ANTIGEN(3,1)
LEPTOSPIRA INFECTION(3,1)
MEAN ANTIBODY TITER(3,1)
MONOPHOSPHORYL LIPID(3,1)
MUCOSAL DISEASE OUTBREAK(3,1)
NEEDLELESS ADMINISTRATION(3,1)
NEUTRALIZING ANTIBODY TITER TABLE(3,1)
NON HUMAN MAMMAL(3,1)
NON VACCINATED ANIMAL(3,1)
PESTIVIRUS GENUS(3,1)
PRE BREEDING VACCINATION HISTORY(3,1)
PREGNANT STUDY ANIMAL(3,1)
PURIFIED BVDV VIRUS(3,1)
REPRODUCTIVE DISORDER(3,1)
SEMI ANNUAL SUBSEQUENT VACCINE(3,1)
SEROLOGICAL TEST POTENCY(3,1)
SEVERELY AFFECTED CATTLE(3,1)
UNTOWARD SYSTEMIC REACTION(3,1)
VACCINATED CATTLE(3,1)
VACCINATION PRE BREEDING HISTORY(3,1)
VACCINE INGREDIENT(3,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(3,1)
VIRAL BIOTYPE(3,1)
VIRULENT BVDV(3,1)
VIRUS ACCELERATED ELIMINATION(3,1)
MODIFIED LIVE VIRUS COMPONENT(2,5)
NORMAL CALVING RATE(2,5)
COMMERCIAL DISTRIBUTION(2,4)
RECTAL PALPATION(2,4)
ABORTION CAUSE(2,3)
ADVERSE WEATHER CONDITION(2,3)
ANTIBIOTIC(2,3)
INTRANASAL(2,3)
PREGGUARD(2,3)
PRESERVATIVE(2,3)
SAMPLE COLLECTION(2,3)
ACTIVE INGREDIENT(2,2)
ACTIVE SUBSTANCE(2,2)
ADJUVANT COMBINATION(2,2)
ALHYDROGEL(2,2)
ANIMAL SUBJECT(2,2)
ANTIBODY PRESENCE(2,2)
BAYOLF(2,2)
CARBOPOL(2,2)
CONGENITAL DEFECT(2,2)
CYTOPATHIC EFFECT(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
GENTAMICIN(2,2)
GLYCOSIDE(2,2)
HEMORRHAGE(2,2)
IBRV COMPONENT(2,2)
ISOTONIC AGENT(2,2)
LAND ANIMAL DISEASE(2,2)
LIVE PREPARATION(2,2)
LOG10TCID(2,2)
LYSOLECITHIN(2,2)
MERTHIOLATE(2,2)
MINERAL GEL(2,2)
PLACEBO SUPPORTING(2,2)
POLYANION(2,2)
SEROLOGIC RESPONSE(2,2)
STUDY START(2,2)
VAGINAL ADMINISTRATION(2,2)
VEGETABLE OIL EMULSION(2,2)
ABORTED FETUS SAMPLE(2,1)
ACTIVE BVDV REPLICATION(2,1)
ACUTE FEVER(2,1)
ADMINISTRATION NECESSITY(2,1)
ADMINISTRATION SCHEDULE(2,1)
ADSORPTION DELAYING(2,1)
AMINE ADJUVANT(2,1)
ANIMAL AGE(2,1)
ANIMAL LIVE BIRTH(2,1)
BOVINE FETUS(2,1)
BOVINE RESPIRATORY DISEASE(2,1)
BREEDING FAILURE(2,1)
BVDV ANTIBODY(2,1)
BVDV DOSE(2,1)
CALVING INTERVAL(2,1)
CATTLE HERPES(2,1)
CHEMICALLY MODIFIED VIRUS(2,1)
CHOLERA TOXIN(2,1)
CLINICAL SYNDROME VARIETY(2,1)
CP BVDV(2,1)
CP VARIANT(2,1)
DAIRY HERD(2,1)
DAIRY INDUSTRY(2,1)
DEAD CALF(2,1)
DECREASED FOOD UPTAKE(2,1)
DOSAGE REGIMEN(2,1)
DYSTOCIA RELATED MORTALITY(2,1)
ECONOMIC IMPORTANCE(2,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(2,1)
EMERYVILLE CALIF(2,1)
EVALUATED DAILY(2,1)
EXCEEDED RELEASE REQUIREMENT(2,1)
EXCLUSION WITHDRAWAL CRITERIA(2,1)
FATAL MUCOSAL DISEASE(2,1)
GESTATION DAY(2,1)
GESTATION HALF(2,1)
HARSH COUGH(2,1)
IBRV DOSE(2,1)
IBRV STRAIN(2,1)
IMMUNITY DURATION(2,1)
IMMUNOMODULATORY AGENT(2,1)
IMMUNOTOLERANCE DEVELOPMENT(2,1)
INACTIVATED WHOLE(2,1)
INCOMPLETE ADJUVANT(2,1)
INFECTED CALF(2,1)
INFECTED CATTLE(2,1)
INFECTION SEVERITY(2,1)
INFECTIOUS DISEASE(2,1)
INTENSIVE SAFETY(2,1)
INTRAMUSCULAR ADMINISTRATION(2,1)
KEY VIRAL PROTEIN(2,1)
LACTATING ANIMAL(2,1)
LEPTOSPIRA CELL PREPARATION(2,1)
LIVE STRAIN(2,1)
MAJOR BHV(2,1)
MAJOR GENOTYPE(2,1)
MILD DIARRHEA(2,1)
MILD DISEASE(2,1)
MODIFIED LIVE BHV(2,1)
MODIFIED LIVE VACCINE PREPARATION(2,1)
MODIFY LIVE BHV(2,1)
MONOCLONAL ANTIBODY PANEL(2,1)
MUCOUS MEMBRANE NECROSIS(2,1)
MULTICOMPONENT(2,1)
NONSPECIFIC SIGN(2,1)
NURSING CALF(2,1)
NURSING STATUS(2,1)
OCULAR DISCHARGE(2,1)
OPTIMAL IMMUNIZATION(2,1)
PI ANIMAL(2,1)
PREDOMINANT STRAIN(2,1)
PREG GUARD(2,1)
PREGNANCY DAY(2,1)
PREGNANCY EXAMINATION(2,1)
PREGNANCY TREATMENT(2,1)
PULMONARY INFECTION(2,1)
RESEARCH WORKER CONFERENCE(2,1)
SAPONIN FRACTION(2,1)
SEROLOGIC STATUS(2,1)
SEROUS NASAL(2,1)
SERUM IGG CONCENTRATION(2,1)
STRAIN NADL(2,1)
SYSTEMIC INFECTION(2,1)
TEST VACCINE DOSE(2,1)
TREATMENT ASSIGNMENT KNOWLEDGE(2,1)
TREATMENT PREGNANCY(2,1)
VIRAL SUBUNIT(2,1)
VIRUS SAFETY(2,1)
WEEKLY HEALTH(2,1)
AGE DAY(1,1)
ALUMINUM HYDROXIDE GEL(1,1)
ANIMAL NECK REGION(1,1)
ANTIGEN VARIETY(1,1)
ANTIGENIC DIFFERENCE(1,1)
ANTIGENICITY(1,1)
BOVINE VIRAL DIARRHEA VIRUS PREPARATION(1,1)
BVDV PERMANENT SOURCE(1,1)
CAMPYLOBACTERIOSIS(1,1)
CATTLE CONDITION(1,1)
DISEASE TRANSMISSION(1,1)
FETAL DEVELOPMENT EARLY(1,1)
FOOD ANIMAL PRACTICE(1,1)
HEAT LABILE ENTEROTOXIN(1,1)
(US20070172877)
ANIMAL(100,119)
INFECTION(100,30)
PREGNANT ANIMAL(100,14)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(100,4)
CATTLE REPRODUCTIVE DISEASE(100,1)
BOVINE HERPES VIRUS(65,6)
LEPTOSPIRA GRIPPOTYPHOSA(52,10)
LEPTOSPIRA CANICOLA(50,9)
BORGPETERSENII HARDJO BOVIS(47,9)
LEPTOSPIRA INTERROGAN(46,8)
VACCINE(44,59)
CALF NURSING PREGNANT COW(39,5)
PREGNANT COW(38,10)
MULTIVALENT BACTERIN VACCINE(38,1)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(27,6)
LEPTOSPIRA HARDJ PRAJITNO(27,1)
LEPTOSPIRA HARDJO BOVIS(27,1)
LEPTOSPIRA(24,20)
GASTROINTESTINAL DISEASE(22,1)
CAMPYLOBACTER FETUS(21,15)
NURSING ANIMAL(21,2)
SUSCEPTIBLE CALF(21,1)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(20,4)
NURSING(19,3)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(18,5)
BOVINE RHINOTRACHEITIS VIRUS(17,9)
SEVERE PRIMARY RESPIRATORY DISEASE(17,1)
BVD VIRUS(16,11)
BOVINE VIRAL DIARRHEA VIRUS(15,6)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHAEMORRHAGIAE POMONA BACTERIN(14,6)
DISORDER(14,6)
ABORTION(13,37)
PIV(13,22)
DISEASE(13,10)
TRIMESTER PREGNANT ANIMAL(13,6)
MICROORGANISM(13,1)
DIARRHEA PARAINFLUENZA(12,9)
BVDV NEUTRALIZING ANTIBODY TITER(12,3)
LIVE VIRAL COMBINATION VACCINE(12,1)
PNEUMONIA(12,1)
VIRUS(11,28)
BHV(11,16)
ANTIBODY NEUTRALIZATION(11,9)
BARBER(11,1)
MAJOR INFECTION SOURCE(11,1)
WHITE CELL RESERVOIR(11,1)
BVDV(10,45)
PERSISTENT FETAL INFECTION(10,5)
RESPIRATORY INFECTION(10,2)
ANTIGEN(9,6)
SYNCYTIAL MODIFY LIVE VIRUS(9,5)
HEALTHY LIVE CALF(9,4)
BRSV(8,11)
IMMUNOGENIC(8,11)
ABORTING ANIMAL(8,7)
PREGNANCY STATUS(8,7)
BOVINE HERPES VIRUS TYPE(8,3)
IBRV NEUTRALIZING ANTIBODY(8,2)
INACTIVATED BVDV VACCINE(8,2)
PARAINFLUENZA VIRUS(8,2)
RESPIRATORY SYNCITIAL VIRUS(8,2)
SERUM NEUTRALIZING ANTIBODY TITER(8,2)
VACCINATED PREGNANT CATTLE(8,2)
BROAD BASED DEFICIT(8,1)
LICENSED BVDV MLV VACCINE(8,1)
AGE MONTH(7,8)
IBRV ANTIBODY TITER(7,2)
GENUS LEPTOSPIRA SPIROCHETE(7,1)
INTESTINAL MUCOSA ULCERATION(7,1)
LEPTOSPIRA INTERROGAN POMONA(7,1)
LEPTOSPIRA SEROVAR HARDJO(7,1)
LIVE VIRUS COMPONENTSLOG 10TCID(7,1)
NONCYTOPATHIC BVDV BIOTYPE(7,1)
VIRULENT ORGANISM URINARY SHEDDING(7,1)
VET(6,17)
CATTLE(6,14)
VETERINARY ACCEPTABLE CARRIER(6,7)
ANIMAL BREEDING(6,6)
VACCINE COMPONENT SAFETY(6,6)
DAM PERCENTAGE(6,4)
HEALTHY CALF(6,4)
VETERINARY PHYSICIAN(6,3)
HEIFER PREGNANCY(6,2)
SEMI ANNUAL REVACCINATION(6,2)
BOVINE ABORTION SEROLOGY EVALUATION(6,1)
CROSSBRED BEEF HEIFER RANGING(6,1)
CROSSBRED DAIRY HEIFER(6,1)
PREGNANT CATTLE PLACENTA(6,1)
SYSTEMIC SYMPTOM MANIFESTATION(6,1)
SST BLOOD SAMPLE(5,8)
ANNUAL BASIS(5,6)
ADVERSE LOCAL OBSERVATION(5,3)
ASSIGNED LOT DOSE(5,3)
IBRV INFECTION(5,3)
BOVI SHIELD VACCINE(5,2)
IMMUNE(5,2)
INFECTION SYMPTOM(5,2)
LACTATING COW(5,2)
MODIFY LIVE VIRUS VACCINE(5,2)
MONTANIDE ISA(5,2)
NEOSPORA INFECTION(5,2)
PRE BREEDING VACCINATION REGIMEN(5,2)
PRE NURSING NEUTRALIZING ANTIBODY(5,2)
VACCINATED ANIMAL PREGNANCY(5,2)
ANNUAL VACCINATION HISTORY(5,1)
BVDV CPNADL VIRUS(5,1)
BVDV FETAL INFECTION(5,1)
BVDV INFECTION PERSISTENCE(5,1)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHEMORRHAGIA POMONA BACTERIN(5,1)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHEMORRHAGIAE POMONA BACTERIN(5,1)
CATTLE LEPTOSPIRAL INFECTION(5,1)
CLASS IC SHIPPING FEVER SYNDROME(5,1)
CYTOPATHIC VIRUS BIOTYPE(5,1)
HEALTHY CATTLE VACCINATION(5,1)
NEWBORN CALF HEALTH OBSERVATION(5,1)
VIRUS NEUTRALIZATION ASSAY(5,1)
COMBINATION VACCINE(4,22)
VACCINE TREATMENT(4,5)
ANIMAL STUDY(4,4)
GEOMETRIC(4,4)
SERUM SEPARATION TUBE(4,4)
STERILE WATER DILUENT(4,4)
VACCINE LEPTOSPIRA(4,4)
FETAL PROTECTION(4,3)
LOT BRSV COMPONENT(4,3)
STERILE DILUENT(4,3)
ABNORMAL CALF(4,2)
ATTENUATED VIRUS(4,2)
BOVINE CYTOKINE(4,2)
IBRV VIRUS(4,2)
INOCULATED ANIMAL(4,2)
INTRA LYMPH NODE(4,2)
NCP VIRUS(4,2)
PLACEBO DOSE(4,2)
PLURONIC POLYOL(4,2)
REPRODUCTIVE DISEASE(4,2)
SAPONIN DERIVATIVE(4,2)
TEST VACCINE FORMULA ADMINISTRATION(4,2)
VACCINE LOT(4,2)
BHV TRUNCATED VERSION(4,1)
BVDV INFECTION TREATMENT(4,1)
BVDV VIRUS GROWTH STUDY(4,1)
BVDV VIRUS STRAIN(4,1)
CATTLE PESTIVIRUS(4,1)
CHEMICALLY INACTIVATED BVD(4,1)
CHOLESTEROL AMPHIGEN(4,1)
CLINICAL SIGN EVIDENCE(4,1)
DIAGNOSTIC SEROLOGY TESTING(4,1)
FATAL MANIFESTATION(4,1)
HEMORRHAGIC BVDV(4,1)
HERD FERTILITY(4,1)
HOLSTEIN HEIFER(4,1)
INCORRECT BREEDING DATE(4,1)
L5IBRVBVDVPIV3BRSVTEST VACCINE(4,1)
MODIFY LIVE BVDV VACCINE(4,1)
PESTIVIRUS GENUS(4,1)
PI CALF BIRTH(4,1)
PURIFIED BVDV VIRUS(4,1)
SEROLOGICAL TEST POTENCY(4,1)
SEVERELY AFFECTED CATTLE(4,1)
VETERINARY DIAGNOSTIC LABORATORY(4,1)
VIRULENT STRAIN ATTENUATION(4,1)
VIRUS ACCELERATED ELIMINATION(4,1)
NORMAL CALVING RATE(3,5)
COMMERCIAL DISTRIBUTION(3,4)
PRE VACCINATION(3,4)
RECTAL PALPATION(3,4)
PARTURITION PHASE(3,3)
POST VACCINATION REACTION TABLE(3,3)
PRETREATMENT PHASE(3,3)
ADVERSE SYSTEMIC REACTION(3,2)
BOVINE ANIMAL(3,2)
BRSV STRAIN(3,2)
CALF HEALTH STATUS(3,2)
HUMAN HANDLER(3,2)
HUMORAL IMMUNE RESPONSE(3,2)
INFECTION RISK(3,2)
MINERAL OIL EMULSION(3,2)
MLV COMPONENT DOSE(3,2)
MODIFIED LIVE ANTIGEN(3,2)
UTERO EXPOSURE(3,2)
ABORTION DATA(3,1)
ACTIVE BVDV REPLICATION(3,1)
ACUTE FATAL DISEASE(3,1)
ACUTE ONSET RESPIRATORY DISEASE(3,1)
ADMINISTRATION NECESSITY(3,1)
ADMINISTRATION SCHEDULE(3,1)
ADSORPTION DELAYING(3,1)
ALPHAHERPESVIRIDA SUBFAMILY MEMBER(3,1)
AMPHIGEN ADJUVANT(3,1)
ANIMAL LIVE BIRTH(3,1)
AVRIDINE LIPID(3,1)
BIPHASIC FEVER(3,1)
BOOSTING REGIMEN(3,1)
BOVINE FETUS(3,1)
BVD VIRUS CAPACITY(3,1)
BVDV ANTIBODY(3,1)
BVDV CPBVDV(3,1)
BVDV DOSE(3,1)
BVDV INCIDENCE(3,1)
CALF MORTALITY(3,1)
CALVING INTERVAL(3,1)
CATTLE HERPES(3,1)
CHOLERA TOXIN(3,1)
CLASSICAL SWINE FEVER(3,1)
CLINICAL SYNDROME BROAD ARRAY(3,1)
COMPENDIUM COLLECTION(3,1)
CONVALESCENT SERA(3,1)
CONVALESCENT SERUM(3,1)
CROSSBRED BEEF CATTLE(3,1)
DAIRY HERD(3,1)
DECREASED FOOD UPTAKE(3,1)
DOSAGE REGIMEN(3,1)
ECONOMIC IMPORTANCE(3,1)
EMERYVILLE CALIF(3,1)
EYE VITREOUS HUMOR(3,1)
FATAL MUCOSAL DISEASE(3,1)
FLAVIVIRIDAE FAMILY(3,1)
FROTHY SALIVA(3,1)
GALENICA PHARMACEUTICAL(3,1)
GESTATION DAY(3,1)
GIV GLYCOPROTEIN(3,1)
HACKING COUGH(3,1)
HARSH COUGH(3,1)
IBRV DOSE(3,1)
IMMUNOCOMPETENT ANIMAL(3,1)
IMMUNOMODULATORY AGENT(3,1)
IMMUNOTOLERANCE DEVELOPMENT(3,1)
INACTIVATED VIRAL VACCINE(3,1)
INCOMPLETE ADJUVANT(3,1)
INFECTED CALF(3,1)
INFECTED CATTLE(3,1)
INFECTION SEVERITY(3,1)
INFECTIOUS DISEASE(3,1)
INFLAMED MUZZLE(3,1)
INTRAMUSCULAR ADMINISTRATION(3,1)
KEY VIRAL PROTEIN(3,1)
KIDNEY INFECTION(3,1)
LABORED BREATHING(3,1)
LACTATING ANIMAL(3,1)
LEPTOSPIRA ANTIGEN(3,1)
LEPTOSPIRA INFECTION(3,1)
MEAN ANTIBODY TITER(3,1)
MILD DIARRHEA(3,1)
MONOPHOSPHORYL LIPID(3,1)
MUCOSAL DISEASE OUTBREAK(3,1)
MUCOUS MEMBRANE NECROSIS(3,1)
NEEDLELESS ADMINISTRATION(3,1)
NEUTRALIZING ANTIBODY TITER TABLE(3,1)
NON HUMAN MAMMAL(3,1)
NON VACCINATED ANIMAL(3,1)
NONSPECIFIC SIGN(3,1)
NURSING CALF(3,1)
OPTIMAL IMMUNIZATION(3,1)
PRE BREEDING VACCINATION HISTORY(3,1)
PREDOMINANT STRAIN(3,1)
PREG GUARD(3,1)
PREGNANCY EXAMINATION(3,1)
PREGNANT STUDY ANIMAL(3,1)
PULMONARY INFECTION(3,1)
REPRODUCTIVE DISORDER(3,1)
RESEARCH WORKER CONFERENCE(3,1)
SAPONIN FRACTION(3,1)
SEMI ANNUAL SUBSEQUENT VACCINE(3,1)
SEROLOGIC STATUS(3,1)
SEROUS NASAL(3,1)
SERUM IGG CONCENTRATION(3,1)
STRAIN NADL(3,1)
SYSTEMIC INFECTION(3,1)
TREATMENT ASSIGNMENT KNOWLEDGE(3,1)
UNTOWARD SYSTEMIC REACTION(3,1)
VACCINATED CATTLE(3,1)
VACCINATION PRE BREEDING HISTORY(3,1)
VACCINE INGREDIENT(3,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(3,1)
VIRAL BIOTYPE(3,1)
VIRAL SUBUNIT(3,1)
VIRULENT BVDV(3,1)
MODIFIED LIVE VIRUS COMPONENT(2,5)
ABORTION CAUSE(2,3)
ADVERSE WEATHER CONDITION(2,3)
ANTIBIOTIC(2,3)
INTRANASAL(2,3)
PREGGUARD(2,3)
PRESERVATIVE(2,3)
SAMPLE COLLECTION(2,3)
ACTIVE INGREDIENT(2,2)
ACTIVE SUBSTANCE(2,2)
ADJUVANT COMBINATION(2,2)
ALHYDROGEL(2,2)
ANIMAL SUBJECT(2,2)
ANTIBODY PRESENCE(2,2)
BAYOLF(2,2)
CARBOPOL(2,2)
CONGENITAL DEFECT(2,2)
CYTOPATHIC EFFECT(2,2)
DEXTROSE(2,2)
EMULSIFIER(2,2)
GENTAMICIN(2,2)
GLYCOSIDE(2,2)
HEMORRHAGE(2,2)
IBRV COMPONENT(2,2)
ISOTONIC AGENT(2,2)
LAND ANIMAL DISEASE(2,2)
LIVE PREPARATION(2,2)
LOG10TCID(2,2)
MERTHIOLATE(2,2)
MINERAL GEL(2,2)
PLACEBO SUPPORTING(2,2)
POLYANION(2,2)
SEROLOGIC RESPONSE(2,2)
STUDY START(2,2)
VAGINAL ADMINISTRATION(2,2)
VEGETABLE OIL EMULSION(2,2)
ABORTED FETUS SAMPLE(2,1)
ACUTE FEVER(2,1)
AGE DAY(2,1)
ALUMINUM HYDROXIDE GEL(2,1)
AMINE ADJUVANT(2,1)
ANIMAL AGE(2,1)
ANIMAL NECK REGION(2,1)
ANTIGEN VARIETY(2,1)
ANTIGENIC DIFFERENCE(2,1)
ANTIGENICITY(2,1)
BOVINE RESPIRATORY DISEASE(2,1)
BOVINE VIRAL DIARRHEA VIRUS PREPARATION(2,1)
BREEDING FAILURE(2,1)
BVDV PERMANENT SOURCE(2,1)
CAMPYLOBACTERIOSIS(2,1)
CATTLE CONDITION(2,1)
CHEMICALLY MODIFIED VIRUS(2,1)
CLINICAL SYNDROME VARIETY(2,1)
CP BVDV(2,1)
CP VARIANT(2,1)
DAIRY INDUSTRY(2,1)
DEAD CALF(2,1)
DISEASE TRANSMISSION(2,1)
DYSTOCIA RELATED MORTALITY(2,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(2,1)
EVALUATED DAILY(2,1)
EXCEEDED RELEASE REQUIREMENT(2,1)
EXCLUSION WITHDRAWAL CRITERIA(2,1)
FETAL DEVELOPMENT EARLY(2,1)
FOOD ANIMAL PRACTICE(2,1)
GESTATION HALF(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
IBRV STRAIN(2,1)
IMMUNITY DURATION(2,1)
INACTIVATED WHOLE(2,1)
INFECTED CELL(2,1)
INFECTED SUBJECT(2,1)
INTENSIVE SAFETY(2,1)
LEPTOSPIRA CELL PREPARATION(2,1)
LIVE STRAIN(2,1)
MAJOR BHV(2,1)
MAJOR GENOTYPE(2,1)
MILD DISEASE(2,1)
MODIFIED LIVE BHV(2,1)
MODIFIED LIVE VACCINE PREPARATION(2,1)
MODIFY LIVE BHV(2,1)
MONOCLONAL ANTIBODY PANEL(2,1)
MULTICOMPONENT(2,1)
NURSING STATUS(2,1)
OCULAR DISCHARGE(2,1)
PI ANIMAL(2,1)
PREGNANCY DAY(2,1)
PREGNANCY TREATMENT(2,1)
TEST VACCINE DOSE(2,1)
TREATMENT PREGNANCY(2,1)
VIRUS SAFETY(2,1)
WEEKLY HEALTH(2,1)
(US20040208901)
ANIMAL(100,133)
ABORTION(100,43)
PREGNANT ANIMAL(100,36)
INFECTION(100,33)
VIRUS(100,33)
BOVINE VIRAL DIARRHEA VIRUS(100,26)
BHV(100,20)
CATTLE REPRODUCTIVE DISEASE(100,1)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(95,7)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(81,8)
BOVINE HERPES VIRUS(80,14)
LEPTOSPIRA GRIPPOTYPHOSA(78,16)
LEPTOSPIRA CANICOLA(74,15)
LEPTOSPIRA INTERROGAN(72,14)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(69,12)
BORGPETERSENII HARDJO BOVIS(64,12)
VACCINE(59,75)
LIVE BOVINE HERPES VIRUS(47,3)
MULTIVALENT BACTERIN VACCINE(43,1)
PREGNANT COW(33,10)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(32,10)
LEPTOSPIRA HARDJ PRAJITNO(31,1)
LEPTOSPIRA HARDJO BOVIS(31,1)
CAMPYLOBACTER FETUS BACTERIN(30,1)
LEPTOSPIRA(29,25)
CALF NURSING PREGNANT COW(28,5)
CAMPYLOBACTER FETUS(27,19)
CALF NURSING(25,4)
BORGPETERSENII HARDLO BOVIS(24,2)
NURSING(23,6)
PIV(16,29)
GASTROINTESTINAL DISEASE(16,1)
ANTIGEN(15,9)
SUSCEPTIBLE CALF(15,1)
LIVE VIRAL COMBINATION VACCINE(13,1)
BOVINE RHINOTRACHEITIS VIRUS(12,9)
SEVERE PRIMARY RESPIRATORY DISEASE(12,1)
DISEASE(11,10)
DISORDER(11,6)
BVDV NEUTRALIZING ANTIBODY TITER(11,5)
DIARRHEA PARAINFLUENZA(9,9)
TRIMESTER PREGNANT ANIMAL(9,6)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHAEMORRHAGIAE POMONA BACTERIN(9,5)
PARAINFLUENZA VIRUS(9,2)
HERPES VIRUS(9,1)
MICROORGANISM(9,1)
BVDV(8,45)
MAJOR INFECTION SOURCE(8,1)
PNEUMONIA(8,1)
WHITE CELL RESERVOIR(8,1)
ANTIBODY NEUTRALIZATION(7,9)
PERSISTENT FETAL INFECTION(7,5)
BOVINE HERPES VIRUS TYPE(7,3)
BARBER(7,1)
SAFE(7,1)
IMMUNOGENIC(6,11)
SYNCYTIAL MODIFY LIVE VIRUS(6,5)
HEALTHY LIVE CALF(6,4)
SERUM NEUTRALIZING ANTIBODY TITER(6,2)
VACCINATED PREGNANT CATTLE(6,2)
BROAD BASED DEFICIT(6,1)
LICENSED BVDV MLV VACCINE(6,1)
AGE MONTH(5,8)
ABORTING ANIMAL(5,7)
PREG GUARD(5,5)
IBRV ANTIBODY TITER(5,2)
INACTIVATED BVDV VACCINE(5,2)
RESPIRATORY SYNCITIAL VIRUS(5,2)
GENUS LEPTOSPIRA SPIROCHETE(5,1)
IBRV NEUTRALIZING ANTIBODY TITER(5,1)
INTESTINAL MUCOSA ULCERATION(5,1)
LEPTOSPIRA INTERROGAN POMONA(5,1)
LEPTOSPIRA SEROVAR HARDJO(5,1)
NONCYTOPATHIC BVDV BIOTYPE(5,1)
VIRULENT ORGANISM URINARY SHEDDING(5,1)
VET(4,17)
CATTLE(4,14)
BRSV(4,11)
SST BLOOD SAMPLE(4,8)
BOVINE(4,7)
POST VACCINATION REACTION(4,7)
VETERINARY ACCEPTABLE CARRIER(4,7)
ANIMAL BREEDING(4,6)
VACCINE COMPONENT SAFETY(4,6)
DAM PERCENTAGE(4,4)
HEALTHY CALF(4,4)
VETERINARY PHYSICIAN(4,3)
BOVI SHIELD VACCINE(4,2)
HEIFER PREGNANCY(4,2)
IMMUNE(4,2)
SEMI ANNUAL REVACCINATION(4,2)
ANNUAL VACCINATION HISTORY(4,1)
BOVINE ABORTION SEROLOGY EVALUATION(4,1)
BVDV CPNADL VIRUS(4,1)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHEMORRHAGIA POMONA BACTERIN(4,1)
CANICOLA GRIPPOTYPHOSA HARDJO ICTEROHEMORRHAGIAE POMONA BACTERIN(4,1)
CANICOLA GRIPPOTYPHOSA HARDJO IETEROHAEMORRHAGIAE POMONA BACTERIN(4,1)
CATTLE LEPTOSPIRAL INFECTION(4,1)
CROSSBRED BEEF HEIFER RANGING(4,1)
CROSSBRED DAIRY HEIFER(4,1)
CYTOPATHIC VIRUS BIOTYPE(4,1)
HEALTHY CATTLE VACCINATION(4,1)
INTRAMUSCULAR DOSE PREGNANCY STATUS(4,1)
NEWBORN CALF HEALTH OBSERVATION(4,1)
NURSING SERUM ANTIBODY TITER(4,1)
PREGNANCY SERUM TRIMESTER(4,1)
PREGNANT ANIMAL POST VACCINATION(4,1)
PREGNANT CATTLE PLACENTA(4,1)
SYSTEMIC SYMPTOM MANIFESTATION(4,1)
COMBINATION VACCINE(3,22)
ANNUAL BASIS(3,6)
GEOMETRIC(3,6)
VACCINE TREATMENT(3,5)
ANIMAL STUDY(3,4)
SERUM SEPARATION TUBE(3,4)
STERILE WATER DILUENT(3,4)
VACCINE LEPTOSPIRA(3,4)
ADVERSE LOCAL OBSERVATION(3,3)
ASSIGNED LOT DOSE(3,3)
FETAL PROTECTION(3,3)
IBRV INFECTION(3,3)
LOT BRSV COMPONENT(3,3)
MLV COMPONENT DOSE(3,3)
PRE NURSE POST NURSE(3,3)
ABNORMAL CALF(3,2)
ATTENUATED VIRUS(3,2)
BOVINE CYTOKINE(3,2)
IBRV VIRUS(3,2)
INFECTION SYMPTOM(3,2)
INOCULATED ANIMAL(3,2)
INTRA LYMPH NODE(3,2)
LACTATING COW(3,2)
MODIFY LIVE VIRUS VACCINE(3,2)
MONTANIDE ISA(3,2)
NCP VIRUS(3,2)
NEOSPORA INFECTION(3,2)
PLACEBO DOSE(3,2)
PLURONIC POLYOL(3,2)
PRE BREEDING VACCINATION REGIMEN(3,2)
PRE NURSING NEUTRALIZING ANTIBODY(3,2)
REPRODUCTIVE DISEASE(3,2)
SAPONIN DERIVATIVE(3,2)
TEST VACCINE FORMULA ADMINISTRATION(3,2)
VACCINATED ANIMAL PREGNANCY(3,2)
VACCINE LOT(3,2)
BHV TRUNCATED VERSION(3,1)
BVDV FETAL INFECTION(3,1)
BVDV INFECTION PERSISTENCE(3,1)
BVDV INFECTION TREATMENT(3,1)
BVDV VIRUS GROWTH STUDY(3,1)
BVDV VIRUS STRAIN(3,1)
CATTLE PESTIVIRUS(3,1)
CHEMICALLY INACTIVATED BVD(3,1)
CHOLESTEROL AMPHIGEN(3,1)
CLASS IC SHIPPING FEVER SYNDROME(3,1)
CLINICAL SIGN EVIDENCE(3,1)
DELIVERED NEUTRALIZING ANTIBODY TITER(3,1)
DIAGNOSTIC SEROLOGY TESTING(3,1)
FATAL MANIFESTATION(3,1)
HEMORRHAGIC BVDV(3,1)
HERD FERTILITY(3,1)
HOLSTEIN HEIFER(3,1)
INCORRECT BREEDING DATE(3,1)
MODIFY LIVE BVDV VACCINE(3,1)
PESTIVIRUS GENUS(3,1)
PI CALF BIRTH(3,1)
PURIFIED BVDV VIRUS(3,1)
SEVERELY AFFECTED CATTLE(3,1)
STERILE DILUENT DAILY OBSERVATION(3,1)
TRIMESTER TART(3,1)
VACCINATION PREGNANCY(3,1)
VETERINARY DIAGNOSTIC LABORATORY(3,1)
VIRULENT STRAIN ATTENUATION(3,1)
VIRUS ACCELERATED ELIMINATION(3,1)
VIRUS NEUTRALIZATION ASSAY(3,1)
MODIFIED LIVE VIRUS COMPONENT(2,10)
NORMAL CALVING RATE(2,6)
COMMERCIAL DISTRIBUTION(2,4)
PRE VACCINATION(2,4)
RECTAL PALPATION(2,4)
PARTURITION PHASE(2,3)
PRETREATMENT PHASE(2,3)
ACTIVE INGREDIENT(2,2)
ADVERSE SYSTEMIC REACTION(2,2)
ANTIBODY PRESENCE(2,2)
BOVINE ANIMAL(2,2)
BRSV STRAIN(2,2)
CALF HEALTH STATUS(2,2)
HUMAN HANDLER(2,2)
HUMORAL IMMUNE RESPONSE(2,2)
INFECTION RISK(2,2)
ISOTONIC AGENT(2,2)
LIVE PREPARATION(2,2)
MINERAL GEL(2,2)
MINERAL OIL EMULSION(2,2)
MODIFIED LIVE ANTIGEN(2,2)
PLACEBO SUPPORTING(2,2)
SEROLOGIC RESPONSE(2,2)
STUDY START(2,2)
UTERO EXPOSURE(2,2)
VEGETABLE OIL EMULSION(2,2)
ABORTED CALF(2,1)
ABORTION DATA(2,1)
ACTIVE BVDV REPLICATION(2,1)
ACUTE FATAL DISEASE(2,1)
ACUTE ONSET RESPIRATORY DISEASE(2,1)
ADMINISTRATION NECESSITY(2,1)
ADMINISTRATION SCHEDULE(2,1)
ADSORPTION DELAYING(2,1)
ALPHAHERPESVIRIDA SUBFAMILY MEMBER(2,1)
AMPHIGEN ADJUVANT(2,1)
ANIMAL ABORTION(2,1)
ANIMAL LIVE BIRTH(2,1)
AVRIDINE LIPID(2,1)
BIPHASIC FEVER(2,1)
BOOSTING REGIMEN(2,1)
BOVINE FETUS(2,1)
BRSV TEST VACCINE(2,1)
BVD VIRUS CAPACITY(2,1)
BVDV ANTIBODY(2,1)
BVDV CPBVDV(2,1)
BVDV INCIDENCE(2,1)
CALF MORTALITY(2,1)
CALVING INTERVAL(2,1)
CATTLE HERPES(2,1)
CHOLERA TOXIN(2,1)
CLASSICAL SWINE FEVER(2,1)
CLINICAL SYNDROME BROAD ARRAY(2,1)
COMPENDIUM COLLECTION(2,1)
CONVALESCENT SERA(2,1)
CONVALESCENT SERUM(2,1)
CROSSBRED BEEF CATTLE(2,1)
DAIRY HERD(2,1)
DECREASED FOOD UPTAKE(2,1)
DOSAGE REGIMEN(2,1)
ECONOMIC IMPORTANCE(2,1)
EMERYVILLE CALIF(2,1)
EYE VITREOUS HUMOR(2,1)
FATAL MUCOSAL DISEASE(2,1)
FLAVIVIRIDAE FAMILY(2,1)
FROTHY SALIVA(2,1)
GALENICA PHARMACEUTICAL(2,1)
GESTATION DAY(2,1)
GIV GLYCOPROTEIN(2,1)
HACKING COUGH(2,1)
HARSH COUGH(2,1)
HISTORY ANIMAL DAY(2,1)
IBRV BVDV(2,1)
IBRV DOSE(2,1)
IMMUNOCOMPETENT ANIMAL(2,1)
IMMUNOMODULATORY AGENT(2,1)
IMMUNOTOLERANCE DEVELOPMENT(2,1)
INACTIVATED VIRAL VACCINE(2,1)
INCOMPLETE ADJUVANT(2,1)
INFECTED CALF(2,1)
INFECTED CATTLE(2,1)
INFECTION SEVERITY(2,1)
INFECTIOUS DISEASE(2,1)
INFLAMED MUZZLE(2,1)
INTRAMUSCULAR ADMINISTRATION(2,1)
KEY VIRAL PROTEIN(2,1)
KIDNEY INFECTION(2,1)
LABORED BREATHING(2,1)
LACTATING ANIMAL(2,1)
LEPTOSPIRA ANTIGEN(2,1)
LEPTOSPIRA INFECTION(2,1)
MEAN ANTIBODY TITER(2,1)
MILD DIARRHEA(2,1)
MONOPHOSPHORYL LIPID(2,1)
MUCOSAL DISEASE OUTBREAK(2,1)
MUCOUS MEMBRANE NECROSIS(2,1)
NEEDLELESS ADMINISTRATION(2,1)
NON HUMAN MAMMAL(2,1)
NON VACCINATED ANIMAL(2,1)
NONSPECIFIC SIGN(2,1)
NURSING CALF(2,1)
OPTIMAL IMMUNIZATION(2,1)
PRE BREEDING VACCINATION HISTORY(2,1)
PREDOMINANT STRAIN(2,1)
PREGNANCY EXAMINATION(2,1)
PREGNANT STUDY ANIMAL(2,1)
PULMONARY INFECTION(2,1)
REPRODUCTIVE DISORDER(2,1)
RESEARCH WORKER CONFERENCE(2,1)
SAMPLE COLLECTION TREATMENT POST VACCINATION(2,1)
SAPONIN FRACTION(2,1)
SEMI ANNUAL SUBSEQUENT VACCINE(2,1)
SEROLOGIC STATUS(2,1)
SEROUS NASAL(2,1)
SERUM IGG CONCENTRATION(2,1)
SERUM VACCINATION(2,1)
STRAIN NADL(2,1)
SYSTEMIC INFECTION(2,1)
TEST VACCINE POTENCY(2,1)
TREATMENT ASSIGNMENT KNOWLEDGE(2,1)
UNTOWARD SYSTEMIC REACTION(2,1)
VACCINATED CATTLE(2,1)
VACCINATION OBSERVATION(2,1)
VACCINATION PRE BREEDING HISTORY(2,1)
VACCINE INGREDIENT(2,1)
VETERINARY MEDICAL RESEARCH INSTITUTE(2,1)
VIRAL BIOTYPE(2,1)
VIRAL SUBUNIT(2,1)
VIRULENT BVDV(2,1)
ABORTION CAUSE(1,3)
ADVERSE WEATHER CONDITION(1,3)
ANTIBIOTIC(1,3)
INTRANASAL(1,3)
PREGGUARD(1,3)
PRESERVATIVE(1,3)
ACTIVE SUBSTANCE(1,2)
ADJUVANT COMBINATION(1,2)
ALHYDROGEL(1,2)
ANIMAL SUBJECT(1,2)
CARBOPOL(1,2)
CONGENITAL DEFECT(1,2)
CYTOPATHIC EFFECT(1,2)
DEXTROSE(1,2)
EMULSIFIER(1,2)
ETIOLOGY(1,2)
GENTAMICIN(1,2)
GLYCOSIDE(1,2)
HEMORRHAGE(1,2)
IBRV COMPONENT(1,2)
LAND ANIMAL DISEASE(1,2)
LYSOLECITHIN(1,2)
MERTHIOLATE(1,2)
POLYANION(1,2)
RESPIRATORY INFECTION(1,2)
VAGINAL ADMINISTRATION(1,2)
ABORTED FETUS SAMPLE(1,1)
ACUTE FEVER(1,1)
AGE DAY(1,1)
ALUMINUM HYDROXIDE GEL(1,1)
AMINE ADJUVANT(1,1)
ANIMAL AGE(1,1)
ANIMAL NECK REGION(1,1)
ANIMAL NORMAL CALF(1,1)
ANTIGEN VARIETY(1,1)
ANTIGENIC DIFFERENCE(1,1)
ANTIGENICITY(1,1)
BOVINE RESPIRATORY DISEASE(1,1)
BOVINE VIRAL DIARRHEA VIRUS PREPARATION(1,1)
BREEDING ANIMAL DAY DOSE(1,1)
BREEDING FAILURE(1,1)
BVD DOSE(1,1)
BVDV PERMANENT SOURCE(1,1)
CALF POSITIVE(1,1)
CAMPYLOBACTERIOSIS(1,1)
CATTLE CONDITION(1,1)
CHEMICALLY MODIFIED VIRUS(1,1)
CLINICAL SYNDROME VARIETY(1,1)
CP BVDV(1,1)
CP VARIANT(1,1)
DAIRY INDUSTRY(1,1)
DEAD CALF(1,1)
DISEASE TRANSMISSION(1,1)
DYSTOCIA RELATED MORTALITY(1,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(1,1)
EVALUATED DAILY(1,1)
EXCEEDED RELEASE REQUIREMENT(1,1)
EXCLUSION WITHDRAWAL CRITERIA(1,1)
FETAL DEVELOPMENT EARLY(1,1)
FOOD ANIMAL PRACTICE(1,1)
GESTATION HALF(1,1)
HEALTHY MORTALITY GROUP(1,1)
HEAT LABILE ENTEROTOXIN(1,1)
IBRV STRAIN(1,1)
IMMUNITY DURATION(1,1)
INACTIVATED WHOLE(1,1)
INFECTED CELL(1,1)
INTENSIVE SAFETY(1,1)
LEPTOSPIRA CELL PREPARATION(1,1)
LIVE STRAIN(1,1)
MAJOR BHV(1,1)
MAJOR GENOTYPE(1,1)
MILD DISEASE(1,1)
MODIFIED LIVE BHV(1,1)
MODIFIED LIVE VACCINE PREPARATION(1,1)
MODIFY LIVE BHV(1,1)
MONOCLONAL ANTIBODY PANEL(1,1)
MULTICOMPONENT(1,1)
NORMAL DYSTOCIA TREATMENT CALF(1,1)
NURSING STATUS(1,1)
OCULAR DISCHARGE(1,1)
PI ANIMAL(1,1)
PREGNANCY DAY(1,1)
PREGNANCY TREATMENT(1,1)
TEST VACCINE DOSE(1,1)
TREATMENT PREGNANCY(1,1)
VIRUS SAFETY(1,1)
WEEKLY HEALTH(1,1)
(US7563449)
PREGNANT ANIMAL(100,12)
L(...)";"Analysis of biological materials
Pharmaceuticals";Open
2003-04-01;"UA73377             C2 2004-10-15 [UA--73377]
STG: (C2) Pat. grant. upon the USSR appl.,for which no pos. dec. made;grant. upon basis of national application
AP : 2003UA-0042844 2003-04-01";38608224;UA73377             C2 2004-10-15 [UA--73377];2003UA-0042844;;"ZAVIRIUKHA ANATOLII IVANOVYCH
ZAVIRIUKHA HANNA ANATOLIIVNA";;;;0;"ZAVIRIUKHA ANATOLII IVANOVYCH
ZAVIRIUKHA HANNA ANATOLIIVNA";;;"(UA--73377)
Inactivated vaccine against leukemia of cattle";"(UA--73377)
The inactivated vaccine against leukemia of the cattle contains inactivated components from the blood of the sick animals and the products of the metabolism of vaccine strain Bacillus anthracis K-79Z, the virulent strain of the causative agent of colibacteriosis, Escherichia coli IBM-1, and the causative agent of pasteurellosis, Pasteurella multocida Z-84.";;;;"A61K-039/12
A61K-039/21
A61K-039/295";;;Pharmaceuticals;Open
2003-02-19;"WO2004073737        A1 2004-09-02 [WO200473737]
STG: (A1) Published application with search report
AP : 2003WO-IB01215 2003-02-19
CA2515978           A1 2004-09-02 [CA2515978]
STG: (A1) Application laid open
AP : 2003CA-2515978 2003-02-19
AU2003215835        A1 2004-09-09 [AU2003215835]
STG: (A1) Open to public inspection
AP : 2003AU-0215835 2003-02-19
MXPA05008756        A  2005-10-05 [MX2005PA008756]
STG: (A) Patent application
AP : 2005MX-PA08756 2003-02-19
EP1594537           A1 2005-11-16 [EP1594537]
STG: (A1) Application published with search report
AP : 2003EP-0815962 2003-02-19
BR0318114           A  2006-02-07 [BR200318114]
STG: (A) Published application
AP : 2003BR-0018114 2003-02-19
BRPI0318114         A1 2006-02-07 [BRPI0318114]
STG: (A1) Published application
AP : 2003BR-0018114 2003-02-19
NZ541879            A  2009-02-28 [NZ-541879]
STG: (A) Published application
AP : 2003NZ-0541879 2003-02-19
AU2003215835        B2 2009-12-10 [AU2003215835]
STG: (B2) Patent proceeded by OPI
AP : 2003AU-0215835 2003-02-19
BRPI0318114         A2 2011-04-05 [BR200318114]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2003BR-0018114 2003-02-19
EP1594537           B1 2012-10-24 [EP1594537]
STG: (B1) Patent specification
AP : 2003EP-0815962 2003-02-19
BR0318114           B1 2014-09-02 [BR200318114]
STG: (B1) Granted patent / Granted pipeline patent
AP : 2003BR-0018114 2003-02-19
BRPI0318114         B8 2014-09-02 [BR200318114]
STG: (B8) Modified first page patent/pipeline patent
AP : 2003BR-0018114 2003-02-19
BRPI0318114         B8 2015-07-21 [BR200318114]
STG: (B8) Modified first page patent/pipeline patent
AP : 2003BR-0018114 2003-02-19";1702768;"WO2004073737        A1 2004-09-02 [WO200473737]
CA2515978           A1 2004-09-02 [CA2515978]
AU2003215835        A1 2004-09-09 [AU2003215835]
MXPA05008756        A  2005-10-05 [MX2005PA008756]
EP1594537           A1 2005-11-16 [EP1594537]
BR0318114           A  2006-02-07 [BR200318114]
BRPI0318114         A1 2006-02-07 [BRPI0318114]
NZ541879            A  2009-02-28 [NZ-541879]
AU2003215835        B2 2009-12-10 [AU2003215835]
BRPI0318114         A2 2011-04-05 [BR200318114]
EP1594537           B1 2012-10-24 [EP1594537]
BR0318114           B1 2014-09-02 [BR200318114]
BRPI0318114         B8 2014-09-02 [BR200318114]
BRPI0318114         B8 2015-07-21 [BR200318114]";"2003BR-0018114
2003NZ-0541879
2003WO-IB01215";"(EP1594537)
WO2004073737
(CA2515978)
WO2004073737
(MX2005PA008756)
WO2004073737
(NZ-541879)
WO2004073737
(AU2003215835)
WO2004073737
(BR200318114)
WO2004073737";MERIAL;MERIAL;"(EP1594537)
FR
(EP1594537)
FR
(WO200473737)
FR
(CA2515978)
US
(BRPI0318114)
US
(BR200318114)
US";"(EP1594537)
NAME=MERIAL 17, rue Bourgelat , CITY=69002 Lyon , COUNTRY=FR 

(EP1594537)
NAME=MERIAL 29, Avenue Tony Garnier , CITY=69007 Lyon , COUNTRY=FR , REG=100176764 

(WO200473737)
NAME=MERIAL  [FR/ FR] 17, rue Bourgelat, F-69002 Lyon  , COUNTRY=FR 

(CA2515978)
NAME=MERIAL LIMITED 3239 Satellite Boulevard , CITY=DULUTH , STATE=GA , POSTCODE=30096 , COUNTRY=US 

(BRPI0318114)
NAME=MERIAL LIMITED , COUNTRY=US 

(BR200318114)
NAME=MERIAL LIMITED , COUNTRY=US 
";1;"AUDONNET JEAN-CHRISTOPHE FRANCIS
FISCHER LAURENT BERNARD
BARZU-LE-ROUX SIMONA";"(EP1594537)
FR";"(EP1594537)
NAME=AUDONNET, Jean-Christophe, Francis 119, rue de Crequi , CITY=F-69002 Lyon , COUNTRY=FR 

NAME=FISCHER, Laurent, Bernard 17, Chemin Vert , CITY=F-69110 Sainte Foy Les Lyon , COUNTRY=FR 

NAME=BARZU-LE-ROUX, Simona 461, route de Saint Bel , CITY=F-69210 Lentilly , COUNTRY=FR 
";"(EP1594537)
Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3";"(EP1594537)
Disclosed and claimed are methods and compositions and kits for the vaccination or immunization of an animal, such as a mammal, advantageously a bovine, involving a prime-boost regimen.";"(WO200473737)
WHAT IS CLAIMED IS:
1. A prime-boost vaccination method against a bovine pathogen, comprising administering to a bovine a first, priming vaccine or immunogenic or immunological composition against the bovine pathogen, wherein the first, priming vaccine or immunogenic or immunological composition comprises a DNA vaccine or immunological or immunogenic composition comprising nucleic acid molecule(s) encoding and expressing in vivo in the bovine at least one immunogen from the bovine pathogen, and thereafter administering a second, boosting vaccine or immunological or immunogenic composition against the bovine pathogen that is different than the first, priming vaccine or immunological or immunogenic composition, but contains or expresses at least one immunogen of the bovine pathogen which is the same immunogen of the bovine pathogen expressed by the first, priming vaccine or immunological or immunogenic composition.
2. The method according to claim 1, wherein the second, boosting immunological, immunogenic or vaccine composition comprises a recombinant live viral vector that contains and expresses in vivo nucleic acid molecule(s) encoding at least one immunogen of the bovine pathogen that is the same immunogen of the bovine pathogen expressed by the first, priming vaccine or immunological or immunogenic composition. 3. The method of claim 2, wherein the viral vector is a virus which is a poxvirus.
4. The method of claim 3, wherein the poxvirus is a canarypox virus.
5. The method according to claim 1, wherein the second, boosting immunological, immunogenic or vaccine composition comprises the bovine pathogen in inactivated or attenuated form.
6. The method according to claim 5, wherein the second, boosting immunological, immunogenic or vaccine composition comprises the bovine pathogen in inactivated form.
7. The method according to claim 1, wherein the second, boosting immunological, immunogenic or vaccine composition comprises the immunogen of the bovine pathogen expressed by the first, priming vaccine or immunological or immunogenic composition, as an isolated immunogen or subunit.
8. The method according to any one of claims 1-7 wherein the bovine pathogen is bovine respiratory syncytal virus (BRSV), bovine parainfluenza virus type-3 (bPI-3), bovine herpesvirus type-1 (BHV-1) or bovine viral diarrhea virus (BVDV), or combinations thereof.
9. The method of claim 8 wherein the bovine pathogen is BRSV.
10. The method of claim 8 wherein the bovine pathogen is bPI-3.
11. The method of claim 8 wherein the bovine pathogen is BHV- 1. 12. The method of claim 8 wherein the bovine pathogen is BVDV.
13. The method of claim 12 wherein the BVDV is BVDV-1.
14. The method of claim 12 wherein the BVDV is BVDV-2.
15. The method according to claim 8 wherein the immunogen is BRSV F, BRSV N, BRSV G, bPI-3 HN, bPI-3 F, BHV-1 gB, BHV-1 gC, BHV-1 gD, BVDV- 1 E0, BVDV-1 E2, BVDV-2 E0, BVDV-2 E2, or combinations thereof.
16. The method according to claim 15 wherein the immunogen is BRSV F, BRSV N, BRSV G, or combinations thereof.
17. The method according to claim 15 wherein the immunogen is bPI-3 HN, bPI-3 F, or combinations thereof. ' 18. The method according to claim 15 wherein the immunogen is BHV-1 gB, BHV-1 gC, BHV-1 gD, or combinations thereof.
19. The method according to claim 15 wherein the immunogen is BVDV-1 E0, BVDV-1 E2, BVDV-2 E0, BVDV-2 E2, or combinations thereof.
20. The method according to claim 8 wherein the immunogen is BRSV F, BRSV N, BRSV G, bPI-3 HN, bPI-3 F, BHV-1 gB, BHV-1 gC, BHV-1 gD, BVDV-
 1 E0, BVDV-1 E2, BVDV-2 E0, BVDV-2 E2, or epitopes thereof, or combinations thereof.
21. The method according to any one of claims 1-7 wherein the bovine is a calve that can have maternal antibodies against the bovine pathogen. 22. The method according to claim 8 wherein the bovine is a calve that can have maternal antibodies against the bovine pathogen.
23. The method according to claim 1, wherein the DNA vaccine is administered to the bovine from calving up to and including 12 weeks of age.
24. The method of claim 23 wherein the DNA vaccine is administered from calving up to and including 6 weeks of age. 25. The method of claim 23 wherein the DNA vaccine is admimstered from calving up to and including 4 weeks of age.
26. The method of claim 23 wherein the DNA vaccine is administered from calving up to and including 3 weeks of age.
27. The method according to claim 1, wherein the second, boosting vaccine or immunological or immunogenic composition is admimstered from about 2 weeks to about 5 months after the first, priming vaccine or immunological or immunogenic composition.
28. The method according to claim 27, wherein the second, boosting vaccine or immunological or immunogenic composition is administered from about 3 weeks to about 6 weeks after the first, priming vaccine or immunological or immunogenic composition.
29. The method according to claim 27, wherein the second, boosting vaccine or immunological or immunogenic composition is administered from about 4 weeks after the first, priming vaccine or immunological or immunogenic composition. 30. The method according to claim 1, including at least one additional administration of the second, boosting vaccine or immunological or immunogenic composition.
31. A kit for performing the method of claim 1 comprising (a) the first, priming vaccine or immunogenic or immunological composition, (b) the second, boosting vaccine or immunogenic or immunological composition; wherein (a) and (b) are in separate containers, optionally with instructions for administration or use.
32. The kit of claim 32, wherein (a) and (b) are in separate containers in the same package.
33. Use of a plasmid containing and expressing in vivo in a bovine such as cattle at least one immunogen from a bovine pathogen, selected from BRSV, bPI-3,
 BHV-1 and BVDV, for the preparation of a DNA vaccine intended to induce an immune response into young bovines such as calves which have or may have maternal antibodies against said bovine pathogen.
34. Use according to claim 33, wherein the DNA vaccine is intended to be administered to the young animal or bovine from calving up to and including 12 weeks of age, such as from calving up to and including 6 weeks of age, such as from calving up to and including 4 weeks of age, and especially from calving up to and including 3 weeks of age.
35. Use according to claim 33 or 34, wherein said DNA vaccine is intended to induce a priming immune response, such as with a IFN7+ memory T cell response specific for the expressed immunogen, which priming immune response can be boosted by a subsequent administration of an inactivated vaccine or a live recombinant vaccine comprising a viral vector, such as a live recombinant poxvirus, containing and expressing in vivo at least the same immunogen(s) than that expressed by the DNA vaccine. 36. Use of a bovine pathogenic agent, selected from BRSV, bPI-3, BHV-1 and BVDV, for the preparation of a priming DNA vaccine comprising a plasmid containing and expressing in vivo in a bovine such as cattle at least one immunogen from said pathogenic agent, and for the preparation of a second vaccine comprising said pathogenic agent under an inactivated form, wherein the DNA vaccine is intended to be administered to a bovine such as cattle first, such as to a young calve which have or may have maternal antibodies against said bovine pathogen, and the inactivated vaccine is intended to be administered after the DNA vaccine and to the same bovine such as cattle such as the young calve, to boost the immune response against said immunogen. 37. Use according to claim 36, wherein the DNA vaccine is intended to induce in the bovine such as cattle, such as the calve, an immune response against said immunogen(s), such as the gamma+ interferon memory T cell response specific for the expressed immunogen.
38. Use according to claim 36 or 37, wherein the DNA vaccine is intended to be administered to the young animal or bovine from calving up to and including 12 weeks of age, such as from calving up to and including 6 weeks of age, such as from calving up to and including 4 weeks of age, and especially from calving up to and including 3 weeks of age.
39. Use according to claim 36, 37 or 38, wherein the inactivated vaccine is intended to be administered from about 2 weeks to about 5 months after the priming administration, such as from about 3 to 6 weeks after, and such as about 4 weeks after the DNA vaccine was administered.
40. Use of a nucleotide sequence coding for at least one immunogen from a bovine pathogenic agent, selected from BRSV, bPI-3, BHV-1 and BVDV, for the preparation of a priming DNA vaccine comprising a plasmid containing and expressing in vivo said immunogen and for the preparation of a second vaccine comprising a live recombinant viral vector, such as a live recombinant poxvirus, containing and expressing in vivo at least said immunogen(s), wherein the DNA vaccine is intended to be administered to a bovine first, such as to a young calve which have or may have maternal antibodies against said bovine pathogen, and the viral vector-based vaccine is intended to be administered after the DNA vaccine and to the same bovine such as the calve, to boost the immune response against said immunogen.
41. Use according to claim 40, wherein the DNA vaccine is intended to induce a DNA vaccine induced immune response against said immunogen(s), such as the JFNγ+ memory T cell response specific for the expressed immunogen.
42. Use according to claim 40 or 41, wherein the DNA vaccine is intended to be administered to the young animal or bovine from calving up to and including 12 weeks of age, such as from calving up to and including 6 weeks of age, such as from calving up to and including 4 weeks of age, and especially from calving up to and including 3 weeks of age.
43. Use according to claim 40, 41 or 42, wherein the live viral vector-based vaccine is intended to be administered from about 2 weeks to about 5 months after the priming administration, such as from about 3 to 6 weeks after, and such as about 4 weeks after the DNA vaccine was admimstered. 44. Use of a bovine pathogenic agent, selected from BRSV, bPI-3, BHV-1 and BVDV, to prepare an inactivated vaccine intended to vaccinate a bovine against said pathogenic agent, wherein the bovine, such as a young calve which have or may have maternal antibodies against said bovine pathogen, has previously been immunized with a DNA vaccine expressing in vivo at least one immunogen from the same pathogenic agent and has developed a specific priming DNA vaccine induced immune response, such as the IFN7+ memory T cell response specific for the expressed immunogen.
45. Use according to claim 44, wherein the inactivated vaccine is intended to be administered from about 2 weeks to about 5 months, such as from about 3 to 6 weeks, and such as about 4 weeks after the bovine was administered with the DNA vaccine.
46. Use of a recombinant viral vector, such as a poxvirus vector, comprising and expressing in vivo at least one nucleotide sequence coding for at least one immunogen from a bovine pathogenic agent, selected from BRSV, bPI-3, BHV-1 and BVDV, to prepare a live recombinant vaccine intended to vaccinate a bovine against the pathogenic agent, wherein the bovine, such as a young calve which have or may have maternal antibodies against said bovine pathogen, has previously been immunized with a DNA vaccine expressing in vivo at least the same immunogen(s), has developed a priming DNA vaccine induced immune response, such as the IFNγ+ memory T cell response specific for the expressed immunogen. 47. Use according to claim 46, wherein the live viral vector-based vaccine is intended to be administered about 2 weeks to about 5 months, such as from about 3 to 6 weeks, and such as about 4 weeks after the bovine was administered with the DNA vaccine.
48. Prime-boost vaccination method of a bovine such as cattle against at least one bovine pathogen, wherein the bovine or cattle is first administered with a priming DNA vaccine comprising and expressing in vivo an immunogen from said pathogen , and then is boosted with a second type of vaccine presenting the same immunogen.
49. Method according to claim 48, wherem the boost is done with an inactivated vaccine.
50. Method according to claim 48, wherein the boost is done with a vaccine comprising a recombinant live viral vector, such as a recombinant poxvirus, comprising and expressing in vivo the said immunogen.
51. Method according to any one of claim 48 to 50, wherein the DNA vaccine is admimstered to a young calve that can have maternal antibodies against the pathogenic agent against which immunization or vaccination is directed.
52. Method according to any one of claim 48 to 51, wherein the DNA vaccine is admimstered to the young animal or bovine from calving up to and including 12 weeks of age, such as from calving up to and including 6 weeks of age, such as from calving up to and including 4 weeks of age, and especially from calving up to and including 3 weeks of age.
53. Method according to any one of claims 48 to 52, wherein the boost administration is administered from about 2 weeks to about 5 months after the priming administration, such as from about 3 to 6 weeks after, and such as about 4 weeks after.
54. Method according to any one of claims 48 to 53, wherein a second administration of the boost vaccine is done, such as when the bovine or calves are transferred to the finishing units.";"(EP1594537)
The present invention provides a kit for per forming a prime-boost vaccination method against a bovine pathogen comprising: (a) a first, priming vaccine, wherein the first, priming vaccine comprises a DNA vaccine comprising nucleic acid molecule(s) encoding and expressing in vivo in a bovine at least one immunogen from the bovine pathogen, wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and (b) a second, boosting vaccine wherein the second, boosting vaccine against the bovine pathogen is different to the first, priming vaccine, but contains or expresses at least one immunogen of the bovine pathogen which is the same immunogen of the bovine pathogen expressed by the first, priming vaccine, wherein the second, boosting vaccine is an inactivated pathogen wherein the pathogen is bovine respiratory syncytial virus (BRSV); wherein (a) and (b) are in separate containers, optionally with instructions for administration or use; and wherein the bovine pathogen is bovine respiratory syncytial virus (BRSV).
In another aspect, the present invention provides an inactivated vaccine for use in the treatment and/or prevention of BRSV; wherein the inactivated vaccine comprises a bovine pathogenic agent, wherein the bovine pathogenic agent is BRSV, and wherein the pathogenic agent is inactivated; wherein the inactivated vaccine is intended to be administered to a bovine that has previously been immunized with a DNA vaccine expressing in vivo at least one immunogen from the same pathogenic agent, wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and the bovine has developed a specific priming DNA vaccine induced immune response.
The present invention provides, in another aspect, the use of a bovine pathogenic agent, wherein the bovine pathogenic agent is BRSV, to prepare an inactivated vaccine intended to vaccinate a bovine against said pathogenic agent, wherein the bovine, has previously been immunized with a DNA vaccine expressing in vivo at least one immunogen from the same pathogenic agent, wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and the bovine has developed a specific priming DNA vaccine induced immune response.";"(EP1594537)
The present description relates to methods of vaccination or immunization of bovines, advantageously such methods involving a prime-boost regimen, as well as vaccines or immunological or immunogenic compositions, such as DNA vaccines or immunogenic or immunological compositions, which can be used such methods.
Knowledge in the field of in vitro transfection is not transposable to DNA vaccination, where the objective is to ensure an optimal, and advantageously protective, immune response.
Nature 1992. 356. 152-154) and liquid jet injectors which make it possible to transfect both skin cells and cells of underlying tissues (Furth et al.";"A61K-039/12
A61K-039/155
A61K-039/245
A61P-011/00
C12N-015/09
C12N-015/33
C12N-015/38
C12N-015/40
C12N-015/45";"(EP1594537)
1. A kit for per forming a prime-boost vaccination method against a bovine pathogen comprising: (a) a first; priming vaccine, wherein the first, priming vaccine comprises a DNA vaccine comprising nucleic acid molecule(s) encoding and expressing in vivo in a bovine at least one immunogen from the bovine pathogen, wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and (b) a second, boosting vaccine wherein the second, boosting vaccine against the bovine pathogen is different to the first, priming vaccine, but contains or expresses at least one immunogen of the bovine pathogen which is the same immunogen of the bovine pathogen expressed by the first, priming vaccine, wherein the second, boosting vaccine is an inactivated pathogen wherein the pathogen is bovine respiratory syncytial virus (BRSV); wherein (a) and (b) are in separate containers, optionally with instructions for administration or use; and wherein the bovine pathogen is bovine respiratory syncytial virus (BRSV).
3. Use of a bovine pathogenic agent, wherein the bovine pathogenic agent is BRSV, for the preparation of a priming DNA vaccine comprising a plasmid containing and expressing in vivo in a bovine at least one immunogen from said bovine pathogenic agent wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and for the preparation of a second vaccine comprising said bovine pathogenic agent under an inactivated form wherein the bovine pathogenic agent is bovine respiratory syncytial virus (BRSV), wherein the priming DNA vaccine is intended to be administered to a bovine first, and the inactivated vaccine is administered after the priming DNA vaccine and to the same bovine to boost the immune response against said immunogen.
8. Use of a bovine pathogenic agent, wherein the bovine pathogenic agent is BRSV, to prepare an inactivated vaccine for vaccinating a bovine against said pathogenic agent, wherein the bovine, has previously been immunized with a DNA vaccine expressing in vivo at least one immunogen from the same pathogenic agent, wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and the bovine has developed a specific priming DNA vaccine induced immune response.
14. A prime-boost vaccination for use in the treatment and/or prevention of BRSV; wherein a priming DNA vaccine comprises a plasmid containing and expressing in vivo in a bovine at least one immunogen from a bovine pathogenic agent wherein the bovine pathogenic agent is BRSV and wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof; and wherein a booster vaccine comprises a bovine pathogenic agent under an inactivated form wherein the bovine pathogenic agent is bovine respiratory syncytial virus (BRSV); wherein the priming DNA vaccine is intended to be administered to a bovine first, and the inactivated vaccine is intended to be administered after the priming DNA vaccine and to the same bovine to boost the immune response against said immunogen.
15. An inactivated vaccine for use in the treatment and/or prevention of BRSV; wherein the inactivated vaccine comprises a bovine pathogenic agent, wherein the bovine pathogenic agent is BRSV, and wherein the pathogenic agent is inactivated; wherein the inactivated vaccine is intended to be administered to a bovine that has previously been immunized with a DNA vaccine expressing in vivo at least one immunogen from the same pathogenic agent, wherein the immunogen is BRSV F or BRSV N or an epitope thereof or combinations thereof, and the bovine has developed a specific priming DNA vaccine induced immune response.";"(EP1594537)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(100,66)
BOVINE HERPES VIRUS(100,51)
BVDV(100,45)
VACCINATION(100,13)
IMMUNIZATION(100,9)
PRIME BOOST REGIMEN(100,8)
BOVINE PATHOGENIC AGENT(99,18)
BOVINE PATHOGEN IMMUNOGEN(73,2)
PRIMED DNA VACCINE(67,9)
PRIMING VACCINE(57,5)
PRIMING DNA VACCINE(45,2)
BOOSTING VACCINE(44,6)
BOVINE PATHOGEN(43,21)
INACTIVATED VACCINE(37,10)
IMMUNOGEN(34,89)
BOOSTER VACCINE(32,1)
PRIMING DNA VACCINE PREPARATION(31,1)
PRIME BOOST VACCINATION(30,2)
PATHOGENIC AGENT(28,16)
BOVINE IMMUNIZATION(27,1)
BOVINE(25,29)
PATHOGEN INACTIVATION(22,4)
INDUCED IMMUNE RESPONSE(22,3)
IMMUNE RESPONSE(21,23)
TRANSMEMBRANE DOMAIN DELETION(20,15)
VACCINE PREPARATION(20,2)
PREVENTION(18,2)
DNA VACCINE(17,98)
EPITOPE(17,49)
DNA VACCINATION(17,3)
JET INJECTOR(17,1)
MATERNAL ANTIBODY(16,9)
IMMUNOGEN EXPRESSION(16,7)
PLASMID(15,74)
BOVINE PATHOGEN EPITOPE(14,6)
INTERFERON MEMORY T CELL RESPONSE(14,1)
IMMUNOGENIC(13,41)
OLIGONUCLEOTIDE(12,62)
VACCINE(12,29)
DMRIE DOPE(12,17)
AGE WEEK(12,13)
YOUNG CALF(12,2)
BOVINE HOST CELL(11,21)
PLASMID EXPRESSION(11,13)
GENBANK DATABASE(11,7)
DNA DELETION(10,12)
DELETION FRAGMENT(10,9)
CANARY POXVIRUS(10,4)
ADMINISTRATION(9,18)
PATHOGEN(9,12)
NUCLEIC ACID MOLECULE(9,9)
SEPARATE CONTAINER(9,5)
BOOST VACCINE ADMINISTRATION(9,3)
CYTOPLASMIC TAIL DELETION(9,3)
KNOWLEDGE(9,1)
YOUNG ANIMAL(8,10)
EXPRESSION VECTOR VACCINE(8,6)
RABBIT BETA GLOBIN GENE(8,6)
BOVINE PARAINFLUENZA VIRUS(8,2)
CYTOSKELETON GENE PROMOTER(8,2)
LIVE RECOMBINANT POXVIRUS(8,2)
HUMAN TPA SIGNAL SEQUENCE(7,23)
PLASMID DNA(7,7)
VETERINARILY ACCEPTABLE VEHICLE(7,6)
BPI SUBSTITUTION(7,4)
PATHOGEN TARGET(7,4)
LIPOSOME FORMULATED VACCINE(7,2)
GENE ENCODING(6,6)
KIT(6,6)
ANTIGEN OPTIMIZATION(6,3)
ORIGIN HUMAN TPA(6,3)
DIOLEOYLPHOSPHATIDYL ETHANOLAMINE(6,2)
RABBIT GLOBIN GENE(6,2)
SKIN CELL(6,2)
EUKARYOTIC EXPRESSION PLASMID PVR(6,1)
FLAVIVIRIDAE FAMILY PESTIVIRUS(6,1)
INFLUENZA VIRUS HEMAGGLUTININ(6,1)
NUCLEIC ACID MOLECULE ENCODING(5,8)
F TRANSMEMBRANE DOMAIN(5,5)
IFN(5,4)
MALEIC ANHYDRIDE COPOLYMER(5,4)
INACTIVATED FORM(5,3)
INTRADERMAL ROUTE(5,3)
NUCLEOTIDE SEQUENCE CODING(5,3)
ACTIN PROMOTER(5,2)
ATTENUATED PATHOGEN(5,2)
DESMIN PROMOTER(5,2)
EXPRESSION VECTOR CONSTRUCT(5,2)
HUMAN TISSUE PLASMINOGEN ACTIVATOR(5,2)
NEEDLELESS INJECTOR VOLUME(5,2)
POXVIRUS VECTOR(5,2)
PRIMING VACCINE PREPARATION(5,2)
STABILIZING INTRON INSERTION(5,2)
ABERRANT MESSENGER RNA SPLICING(5,1)
ANTIGEN TRANSMEMBRANE DOMAIN(5,1)
ANTIGEN TRIGGERED SECRETION(5,1)
ATTENUATED VACCINIA VIRUS(5,1)
BICISTRONIC PLASMID ENCODING(5,1)
BPI HEMAGGLUTININ NEURAMINIDASE ANTIGEN(5,1)
CANARY POX FOWLPOXVIRUS(5,1)
CLINICAL SIGN SERIOUSNESS(5,1)
FOWL POXVIRUS ATTENUATION(5,1)
GENERAT ING PLASMID(5,1)
HEMAGGLUTININ NEURAMINIDASE TRANSMEMBRANE DOMAIN(5,1)
IMMUNOGEN TRANSMEMBRANE DOMAIN(5,1)
INFECTIOUS BOVINE RHINOTRACHITIS(5,1)
MONOCISTRONIC PLASMID ENCODING(5,1)
RECOMBINANT LIVE VIRAL VECTOR(5,1)
THEDESCRIPTIONIS PRIME BOOST REGIMEN(5,1)
EXCIPIENT(4,9)
ACCESSION(4,8)
PROTECTIVE IMMUNE RESPONSE(4,4)
ALKENYL DERIVATIVE(4,3)
BVDV PROTEIN(4,2)
BVDV VIRUS(4,2)
INTRANASAL ROUTE(4,2)
PHYSIOLOGICAL SALINE(4,2)
PREGNANT FEMALE(4,2)
PRIME BOOST IMMUNIZATION(4,2)
PRIMING IMMUNE RESPONSE(4,2)
ALKENE OLIGOMERIZATION(4,1)
AMPLIFIED FRAGMENT CLONING(4,1)
ANHYDROMANNITOL OLEATE(4,1)
ANTIGEN COMING LIKELIHOOD(4,1)
BOVINE GMCSF POLYPEPTIDE(4,1)
BOVINE PATHOGENIC AGENT EPITOPE(4,1)
CLONED DNA FRAGMENT(4,1)
CYTOKINE INHANCE(4,1)
CYTOMEGALOVIRUS EARLY PROMOTER(4,1)
EXPRESSION VECTOR PVR(4,1)
FUSION PROTEIN ADMINISTRATION(4,1)
GB TRANSMEMBRANE DOMAIN(4,1)
GUANIDINIUM THIOCYANATE(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
INTRAMUSCULAR ROUTE INDUCING(4,1)
MESSENGER RNA TRANSLATABILITY(4,1)
MURINE ROTAVIRUS(4,1)
NEEDLELESS INJECTOR AID(4,1)
POLYNUCLEOTIDE VACCINATION(4,1)
PROMOTER FUNCTIONAL SUBFRAGMENT(4,1)
PROTEIN TRANSMEMBRANE DOMAIN(4,1)
REMINGTON PHARMACEUTICAL SCIENCE(4,1)
RESTRICTION ENZYME SALI(4,1)
ST GD GENE(4,1)
SUGAR POLYALKENYL(4,1)
THYMIDINE KINASE GENE(4,1)
TRUNCATED GB GENE(4,1)
VACCINE ADMINISTRATION SUCCESSIVE(4,1)
VIRUS GENOMIC RNA(4,1)
SUBUNIT VACCINE(3,6)
HETEROLOGOUS SIGNAL SEQUENCE(3,5)
SYRINGE(3,4)
ADJUVANT SOLUTION(3,3)
FINAL VACCINE(3,3)
PLASMID MIXTURE(3,3)
ENCODING DNA VACCINE(3,2)
IMMUNE RESPONSE PRIMING(3,2)
MURINE ORIGIN(3,2)
PARAMYXOVIRIDAE FAMILY MEMBER(3,2)
PROMOTING ACTIVITY(3,2)
UPSTREAM REGION DELETION(3,2)
VACCINAL(3,2)
VACCINE VECTOR(3,2)
ACTIVATED DENDRIMER MOLECULE(3,1)
ACUTE CLINICAL SIGN(3,1)
ADENOVIRUS VECTOR(3,1)
ANIMAL IMMUNIZATION(3,1)
ANNUAL ADMINISTRATION(3,1)
ANTIGEN EPITOPE(3,1)
ANTIGEN SECRETION(3,1)
ATTENUATED VIRUS(3,1)
AVIPOXVIRUS(3,1)
BOVINE ADENOVIRUS(3,1)
BOVINE ANTIGEN(3,1)
BOVINE POPULATION(3,1)
BVDV DNA VACCINE(3,1)
BVDV IMMUNOGEN(3,1)
CATIONIC LIPID NEUTRAL LIPID(3,1)
CELLULAR MACHINERY(3,1)
CHOLERA TOXIN(3,1)
CLONING ORIGIN(3,1)
CODING SEQUENCE DISRUPTION(3,1)
COLORADO STRAIN(3,1)
CYTOPLASMIC DOMAIN(3,1)
DMRIB DOPE(3,1)
DNA PLASMID PREPARATION(3,1)
DNA VACCINE ADMINISTRATION(3,1)
DNA VACCINE EFFICACY(3,1)
DNA VACCINE FORMULATION(3,1)
DOVEPOX VIRUS(3,1)
ENCODED IMMUNOGEN(3,1)
ENZYME ECORV(3,1)
ETHIDIUM BROMIDE(3,1)
FETAL MALFORMATION(3,1)
FORMULA QUATERNARY AZANIUM SALT(3,1)
FUSION PROTEIN DIRECT ADMINISTRATION(3,1)
GD GLYCOPROTEIN(3,1)
GENOMIC DNA(3,1)
GLYCOPROTEIN GB SIGNAL PEPTIDE(3,1)
GLYCOPROTEIN GC(3,1)
HETEROLOGOUS TPA(3,1)
HUMAN ACQUIRED IMMUNODEFICIENCY VIRUS(3,1)
HYDROPATHY PROFILE BASIS(3,1)
IMMUNE REPONSE(3,1)
IMMUNE RESPONE(3,1)
IMMUNIZATION REGIMEN(3,1)
IMMUNOLOGICALLY ACTIVE PROTEIN(3,1)
INFECTIOUS DISEASE(3,1)
KDA PROMOTER(3,1)
MACK PUBLISHING(3,1)
MILD CLINICAL SIGN(3,1)
NEURAMINIDASE PROTEIN(3,1)
NONIONIC SURFACTANT(3,1)
NUCLEOTIDE DELETION(3,1)
NUCLEOTIDE SEQUENCE OPTIMIZATION(3,1)
PATHOGEN VACCINE(3,1)
PHARMACEUTICAL BIOTECHNOLOGY(3,1)
PLASMID ENCODING GAMMA INTERFERON(3,1)
PRIME BOO REGIMEN(3,1)
RECOMBINANT CANARY(3,1)
RECOMBINANT HERPES VIRUS(3,1)
RECOMBINANT VACCINIA(3,1)
RECOMBINANT VIRUS(3,1)
RESTRICTION SITE FACILITATING(3,1)
RNA MOLECULE ENCODING(3,1)
SPECIES CYTOKINE(3,1)
STRONG EUKARYOTIC PROMOTER(3,1)
SUBCUTANEOUS ROUTE(3,1)
THESIS GLYCOPROTEIN(3,1)
VAN DRUNEN LITTLE VAN DEN(3,1)
VIRAL GENOME(3,1)
VIRAL PROMOTER(3,1)
YOUNG BOVINE(3,1)
PLF(2,7)
PPB(2,7)
PFU(2,6)
BAMHI(2,5)
SIGNAL SEQUENCE INSERTION(2,5)
XHOI(2,5)
BOVINE GMCSF ADDITION(2,4)
COW(2,4)
ATTENUATED VACCINE(2,3)
BACTERIA(2,3)
EMULSION(2,3)
GLYCEROL(2,3)
GUINEA PIG(2,3)
HEMAGGLUTININ NEURAMINIDASE SIGNAL SEQUENCE(2,3)
METHACRYLIC ACID POLYMER(2,3)
RECOMBINANT VACCINE(2,3)
CAPRYLATE(2,2)
CO INJECTION(2,2)
CONCOMITANT(2,2)
DECANOATE(2,2)
EDITION(2,2)
EXTRACELLULAR MEDIUM(2,2)
F GLYCOPROTEIN(2,2)
INFECTIOUS BOVINE RHINOTRACHEITIS(2,2)
LINEAR ALIPHATIC RADICAL(2,2)
PARAMYXOVIRUS(2,2)
PHYSIOLOGICAL PH(2,2)
POLYPROTEIN(2,2)
ROUS SARCOMA VIRUS(2,2)
STOCK SOLUTION(2,2)
SV40 VIRUS(2,2)
ACTIVE INGREDIENT(2,1)
AGE ANIMAL(2,1)
ALLYLPENTAERYTHRITOL(2,1)
ALPHAHERPESVIRINAE FAMILY MEMBER(2,1)
ANOTHEREMBODIMENT(2,1)
ANTIGEN PRODUCTION(2,1)
AQUEOUS DEXTROSE(2,1)
BIOCHEMICAL AGENT(2,1)
BOOSTING(2,1)
BOVINE HERPES VIRUS STRAIN(2,1)
BPI F ANTIGEN(2,1)
BVDV NUCLEIC ACID MOLECULE(2,1)
CELLULAR PROMOTER(2,1)
CESIUM CHLORIDE(2,1)
COLD SPRING HARBOR(2,1)
COMPOSITION EXPRESS(2,1)
DIOLEOYLPHOSPHATIDYLCHOLINE(2,1)
DNA PELLET(2,1)
DNA QUANTITY(2,1)
DNA VACCINE IMMUNE RESPONSE(2,1)
DOPEA(2,1)
EARLY AGE(2,1)
EMODIMENT(2,1)
EMULSIFIER MIXTURE(2,1)
F ENCODING(2,1)
FUNCTIONAL FRAGMENT(2,1)
GB ANTIGEN(2,1)
GC ANTIGEN(2,1)
GD ANTIGEN(2,1)
GD PROTEIN(2,1)
GENE FRAGMENT(2,1)
GENECLEAN(2,1)
HUMAN ORIGIN(2,1)
HUMORAL IMMUNE RESPONSE(2,1)
HUMORAL RESPONSE(2,1)
IMMUNE CONTEXT(2,1)
IMMUNE PROTECTION(2,1)
IMMUNE RESPONSE INHIBITION(2,1)
ING AGENT(2,1)
INITIAL IMMUNOLOGICAL ACTIVITY LOSS(2,1)
INJECTABLE FLUID(2,1)
INTRON SEQUENCE(2,1)
ISOLATED PROTEIN(2,1)
LATTER FUSION PROTEIN(2,1)
MACVECTOR(2,1)
MELITTIN SIGNAL PEPTIDE(2,1)
MESSENGER RNA ENCODING(2,1)
METHADONE SALT(2,1)
MODIFIED VECTOR VACCINE(2,1)
MOUSE MODEL(2,1)
MUCOSAL DISEASE VIRUS(2,1)
NEUTRALIZING(2,1)
NON TRANSLATED REGION(2,1)
NUCLEIC ACID MOLECULE CODING(2,1)
NUCLEOTIDE SEQUENCE MODIFICATION(2,1)
OPTIMIZED GB(2,1)
OPTIMIZED GC(2,1)
OPTIMIZED GD(2,1)
ORAL ROUTE(2,1)
ORIGIN CELL(2,1)
PARTIAL DELETION(2,1)
PHOSPHATE BUFFER(2,1)
PLACE OFMURINE GMCSF(2,1)
PLASMID CONSTRUCTION(2,1)
POLYMER DISSOLUTION(2,1)
POLYOXYETHYLENE COPOLYMER BLOCK(2,1)
POXVIRUS SPECIFIC PROMOTER(2,1)
PRIME BOOST ADMINISTRATION(2,1)
PRINCIPAL ANTIGEN(2,1)
PROBE AID(2,1)
PRODUCTION STIMULATION(2,1)
PROMOTION(2,1)
PROTECTION EFFECTIVENESS(2,1)
PURIFIED PLASMID(2,1)
REACHING MATURITY(2,1)
RECOMBINANT VECTOR(2,1)
RECONSTITUTION(2,1)
SALI SITE(2,1)
SINGLE OPTIMIZED BVDV ANTIGEN(2,1)
SORBITAN ESTER(2,1)
STABILIZER PRESENCE(2,1)
STERILE ULTRAPURE WATER(2,1)
STRONG PROMOTER(2,1)
SUCCESSIVE ADMINISTRATION(2,1)
T LYMPHOCYTE MOBILIZATION(2,1)
TERM PLASMID(2,1)
TETRATETRACONTANE(2,1)
THEDESCRIPTIONINVOLVE(2,1)
THEDESCRIPTIONMAY(2,1)
THEDESCRIPTIONPROVIDE(2,1)
TPA SEQUENCE(2,1)
TRANSFECTED CELL(2,1)
UNSATURATED RADICAL(2,1)
VIRAL DNA FRAGMENT(2,1)
VIRAL ORIGIN(2,1)
VIRAL SUSPENSION(2,1)
YEAST VECTOR(2,1)
ADJUVANT EFFECT(1,3)
BULL(1,3)
CATTLE(1,3)
DOSAGE(1,3)
CHEMICAL COMPOUND(1,2)
(WO200473737)
IMMUNOGEN(100,98)
PLASMID(100,78)
BOVINE(100,42)
BOVINE PATHOGEN(100,36)
BVDV(100,35)
BPI(100,29)
IMMUNE RESPONSE(100,23)
MATERNAL ANTIBODY(100,16)
CATTLE(100,10)
BOVINE PATHOGENIC AGENT(100,9)
INACTIVATED VACCINE(100,8)
NUCLEOTIDE SEQUENCE CODING(100,5)
CALF(100,2)
POXVIRUS VECTOR(100,2)
PRIME BOOST VACCINATION(100,2)
PRIMING DNA VACCINE PREPARATION(100,2)
YOUNG BOVINE(100,2)
A DNA VACCINE PREPARATION(100,1)
RECOMBINANT VIRAL VECTOR(100,1)
BOVINE PATHOGEN IMMUNOGEN(90,5)
PRIMING VACCINE(81,11)
BOOSTING VACCINE(56,9)
AGE WEEK(55,32)
PRIMED DNA VACCINE(49,3)
LIVE RECOMBINANT VIRAL VECTOR(47,1)
LIVE RECOMBINANT POXVIRUS(44,4)
PATHOGENIC AGENT(36,18)
IMMUNOGEN EXPRESSION(36,10)
RECOMBINANT LIVE VIRAL VECTOR(35,3)
DNA VACCINE(33,116)
VACCINE PREPARATION(33,3)
LIVE RECOMBINANT VACCINE(33,2)
PRIMING DNA VACCINE(33,1)
INDUCED IMMUNE RESPONSE(26,4)
YOUNG ANIMAL(23,14)
PRIME BOOST REGIMEN(23,10)
VACCINE(22,35)
YOUNG(22,14)
BOOST VACCINE ADMINISTRATION(22,4)
BOVINE IMMUNIZATION(22,2)
TRANSMEMBRANE DOMAIN DELETION(21,15)
BOOST VACCINE(21,2)
PRIME BOOST IMMUNIZATION(20,2)
INACTIVATED VACCINE ADMINISTRATION(20,1)
DNA VACCINATION(18,3)
JET INJECTOR(18,1)
VIRAL VECTOR BASED VACCINE(16,1)
VACCINATION(15,17)
NUCLEIC ACID MOLECULE(15,10)
ANOTHEREMBODIMENT(15,1)
ISOLATED IMMUNOGEN(15,1)
IMMUNOGENIC(14,41)
IMMUNIZATION(14,11)
BOOST ADMINISTRATION(14,6)
BOVINE PATHOGEN EPITOPE(14,6)
ADMIMSTRATION(14,1)
ANTIGEN(13,81)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(13,1)
BOVINE HOST CELL(12,21)
PATHOGEN(12,12)
EPITOPE(11,44)
PLASMID EXPRESSION(11,13)
DMRIE DOPE(11,12)
DNA DELETION(11,12)
DELETION FRAGMENT(11,9)
SEPARATE CONTAINER(11,5)
IMMUNE RESPONSE PRIMING(11,3)
BOVINE VACCINATION(11,1)
IFN(10,3)
BOVINE IMMUNE(10,1)
KNOWLEDGE(10,1)
EXPRESSION VECTOR VACCINE(9,6)
RABBIT BETA GLOBIN GENE(9,6)
CYTOPLASMIC TAIL DELETION(9,3)
BOVINE RESPIRATORY SYNCYTAL VIRUS(9,1)
GENBANK DATABASE(8,7)
KIT(8,6)
VETERINARILY ACCEPTABLE VEHICLE(8,6)
RABBIT GLOBIN GENE(8,3)
ADMIXTURE(8,2)
CYTOSKELETON GENE PROMOTER(8,2)
HUMAN TPA SIGNAL SEQUENCE(7,23)
PLASMID DNA(7,7)
BPI SUBSTITUTION(7,4)
PATHOGEN TARGET(7,4)
BOVINE VIRAL DIARRHEA VIRUS(7,2)
LIPOSOME FORMULATED VACCINE(7,2)
NUCLEIC ACID MOLECULE ENCODING(6,8)
GENE ENCODING(6,6)
F TRANSMEMBRANE DOMAIN(6,5)
ANTIGEN OPTIMIZATION(6,3)
BULL(6,3)
ORIGIN HUMAN TPA(6,3)
PATHOGEN INACTIVATION(6,3)
PRIMING VACCINE PREPARATION(6,2)
SKIN CELL(6,2)
BOVINE HERPES VIRUS TYPE(6,1)
EUKARYOTIC EXPRESSION PLASMID PVR(6,1)
FLAVIVIRIDAE FAMILY PESTIVIRUS(6,1)
INFLUENZA VIRUS HEMAGGLUTININ(6,1)
MEMORY T CELL RESPONSE(5,9)
BVDV1 E(5,5)
BVDV2 E(5,5)
COW(5,4)
FINISHING UNIT(5,4)
MALEIC ANHYDRIDE COPOLYMER(5,4)
DMRJE DOPE(5,3)
DMRLE DOPE(5,3)
INTRADERMAL ROUTE(5,3)
ACTIN PROMOTER(5,2)
ATTENUATED PATHOGEN(5,2)
BVDV VIRUS(5,2)
DESMIN PROMOTER(5,2)
EXPRESSION VECTOR CONSTRUCT(5,2)
HUMAN TISSUE PLASMINOGEN ACTIVATOR(5,2)
NEEDLELESS INJECTOR VOLUME(5,2)
PHYSIOLOGICAL SALINE(5,2)
STABILIZING INTRON INSERTION(5,2)
ABERRANT MESSENGER RNA SPLICING(5,1)
ANTIGEN TRANSMEMBRANE DOMAIN(5,1)
ANTIGEN TRIGGERED SECRETION(5,1)
ATTENUATED VACCINIA VIRUS(5,1)
BICISTRONIC PLASMID ENCODING(5,1)
CLINICAL SIGN SERIOUSNESS(5,1)
IMMUNOGEN TRANSMEMBRANE DOMAIN(5,1)
INFECTIOUS BOVINE RHINOTRACHITIS(5,1)
MONOCISTRONIC PLASMID ENCODING(5,1)
PLASMID ATIONIC LIPID(5,1)
VIRAL GENOMIC RNA ISOLATION(5,1)
VIRUS ATTENUATED CANARY POX VIRUS(5,1)
EXCIPIENT(4,9)
SUBUNIT VACCINE(4,7)
GC GENE(4,5)
PROTECTIVE IMMUNE RESPONSE(4,4)
ALKENYL DERIVATIVE(4,3)
INACTIVATED FORM(4,3)
BVDV PROTEIN(4,2)
INTRANASAL ROUTE(4,2)
OLIGONUCLEOTIDE PAIR(4,2)
PARAMYXOVIRUS(4,2)
PREGNANT FEMALE(4,2)
PRIMING IMMUNE RESPONSE(4,2)
ALKENE OLIGOMERIZATION(4,1)
AMPLIFIED FRAGMENT CLONING(4,1)
ANHYDROMANNITOL OLEATE(4,1)
ANTIGEN COMING LIKELIHOOD(4,1)
APPLN CITED DOCUMENT(4,1)
BOVINE GMCSF POLYPEPTIDE(4,1)
BOVINE PATHOGENIC AGENT EPITOPE(4,1)
CLONED DNA FRAGMENT(4,1)
CYTOKINE INHANCE(4,1)
CYTOMEGALOVIRUS EARLY PROMOTER(4,1)
DIOLEOYL PHOSPHATIDYLETHANOLAMINE(4,1)
EXPRESSION VECTOR PVR(4,1)
FUSION PROTEIN ADMINISTRATION(4,1)
GB TRANSMEMBRANE DOMAIN(4,1)
GENOMIC DNA VIRAL SUSPENSION(4,1)
GUANIDINIUM THIOCYANATE(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
INTRAMUSCULAR ROUTE INDUCING(4,1)
MESSENGER RNA TRANSLATABILITY(4,1)
MURINE ROTAVIRUS(4,1)
NEEDLELESS INJECTOR AID(4,1)
POLYNUCLEOTIDE VACCINATION(4,1)
PRIMING ADMINISTRATOIN(4,1)
PROMOTER FUNCTIONAL SUBFRAGMENT(4,1)
PROTEIN TRANSMEMBRANE DOMAIN(4,1)
RECOMBINANT CANARY POX VIRUS VECTOR(4,1)
RECOMBINANT HERPES VIRUS(4,1)
REMINGTON PHARMACEUTICAL SCIENCE(4,1)
RESTRICTION ENZYME SAIL(4,1)
ST GD GENE(4,1)
SUGAR POLYALKENYL(4,1)
THYMIDINE KINASE GENE(4,1)
TRUNCATED GB GENE(4,1)
VACCINE ADMINISTRATION SUCCESSIVE(4,1)
VIRUS GENOMIC RNA(4,1)
HETEROLOGOUS SIGNAL SEQUENCE(3,5)
SYRINGE(3,4)
ADJUVANT SOLUTION(3,3)
FINAL VACCINE(3,3)
PLASMID MIXTURE(3,3)
ENCODING DNA VACCINE(3,2)
EXTRACELLULAR MEDIUM(3,2)
INFECTIOUS BOVINE RHINOTRACHEITIS(3,2)
INTRON SEQUENCE(3,2)
LINEAR ALIPHATIC RADICAL(3,2)
MURINE GMCSF(3,2)
PARAMYXOVIRIDAE FAMILY MEMBER(3,2)
PHYSIOLOGICAL PH(3,2)
PROMOTING ACTIVITY(3,2)
UPSTREAM REGION DELETION(3,2)
VACCINAL(3,2)
VACCINE VECTOR(3,2)
ACTIVATED DENDRIMER MOLECULE(3,1)
ACUTE CLINICAL SIGN(3,1)
ADENOVIRUS VECTOR(3,1)
ANIMAL IMMUNIZATION(3,1)
ANNUAL ADMINISTRATION(3,1)
ANTIGEN EPITOPE(3,1)
ANTIGEN SECRETION(3,1)
ATTENUATED FOWLPOXVIRUS(3,1)
AVIPOX VIRUS(3,1)
BAMHI BGLLL DIGESTION(3,1)
BAMHI HINDLLL FRAGMENT(3,1)
BIOCONJUGATE CHEMISTRY(3,1)
BOVINE ADENOVIRUS(3,1)
BOVINE ANTIGEN(3,1)
BOVINE POPULATION(3,1)
BPI ANTIGEN(3,1)
BVDV DNA VACCINE(3,1)
BVDV IMMUNOGEN(3,1)
CANARY POX FOWLPOXVIRUS(3,1)
CATIONIC LIPID NEUTRAL LIPID(3,1)
CELLULAR MACHINERY(3,1)
CHOLERA TOXIN(3,1)
CLINICAL SCORE(3,1)
CLONING ORIGIN(3,1)
CODING SEQUENCE DISRUPTION(3,1)
COLORADO STRAIN(3,1)
CYTOKINE IL LBETA(3,1)
CYTOPLASMIC DOMAIN(3,1)
DIGESTION FRAGMENT(3,1)
DNA PLASMID PREPARATION(3,1)
DNA VACCINE ADMINISTRATION(3,1)
DNA VACCINE EFFICACY(3,1)
DNA VACCINE FORMULATION(3,1)
DOVEPOX VIRUS(3,1)
ENCODED IMMUNOGEN(3,1)
ENZYME ECORV(3,1)
ETHIDIUM BROMIDE(3,1)
EXTRACELLULAR DOMAIN(3,1)
FETAL MALFORMATION(3,1)
FORMULA QUATERNARY AZANIUM SALT(3,1)
FUSION PROTEIN DIRECT ADMINISTRATION(3,1)
GB GLYCOPROTEIN(3,1)
GD GLYCOPROTEIN(3,1)
GENBANK ACCESSION(3,1)
GENERATING PLASMID PPB(3,1)
GLYCOPROTEIN GB SIGNAL PEPTIDE(3,1)
GLYCOPROTEIN GC(3,1)
HETEROLOGOUS TPA(3,1)
HUMAN ACQUIRED IMMUNODEFICIENCY VIRUS(3,1)
HYDROPATHY PROFILE BASIS(3,1)
IMMUNE REPONSE(3,1)
IMMUNE RESPONE(3,1)
IMMUNIZATION REGIMEN(3,1)
IMMUNOLOGICALLY ACTIVE PROTEIN(3,1)
INFECTIOUS DISEASE(3,1)
INTRON LI INSERTION(3,1)
KDA PROMOTER(3,1)
LUNG LESION(3,1)
MACK PUBLISHING(3,1)
MANUFACTURER INSTRUCTION(3,1)
MILD CLINICAL SIGN(3,1)
MULTIVALENT DNA VACCINE(3,1)
MURIN ORIGIN(3,1)
NEURAMINIDASE PROTEIN(3,1)
NONIONIC SURFACTANT(3,1)
NUCLEOTIDE DELETION(3,1)
NUCLEOTIDE SEQUENCE OPTIMIZATION(3,1)
PATHOGEN VACCINE(3,1)
PHARMACEUTICAL BIOTECHNOLOGY(3,1)
PLASMID ENCODING GAMMA INTERFERON(3,1)
PPB DIGESTION(3,1)
RECOMBINANT VACCINIA(3,1)
RECOMBINANT VIRUS(3,1)
RESTRICTION SITE FACILITATING(3,1)
RNA MOLECULE ENCODING(3,1)
SPECIES CYTOKINE(3,1)
STRONG EUKARYOTIC PROMOTER(3,1)
SUBCUTANEOUS ROUTE(3,1)
VAN DRUNEN LITTLE VAN DEN(3,1)
VIRAL GENOME(3,1)
VIRAL PROMOTER(3,1)
VIRUS EXCRETION(3,1)
XHOL FRAGMENT(3,1)
PLF(2,7)
PFU(2,6)
SIGNAL SEQUENCE INSERTION(2,5)
BOVINE GMCSF ADDITION(2,4)
FR AL(2,4)
ATTENUATED VACCINE(2,3)
BACTERIA(2,3)
EMULSION(2,3)
GUINEA PIG(2,3)
METHACRYLIC ACID POLYMER(2,3)
RECOMBINANT VACCINE(2,3)
CAPRYLATE(2,2)
CARBOMER(2,2)
CHEMOTACTIC PEPTIDE(2,2)
CO INJECTION(2,2)
CONCOMITANT(2,2)
DECANOATE(2,2)
EDITION(2,2)
F GLYCOPROTEIN(2,2)
PCR PRODUCT(2,2)
POLYPROTEIN(2,2)
ROUS SARCOMA VIRUS(2,2)
SHOW PLASMID(2,2)
STOCK SOLUTION(2,2)
SV40 VIRUS(2,2)
ACTIVE INGREDIENT(2,1)
AGE ANIMAL(2,1)
ALLYLPENTAERYTHRITOL(2,1)
ALPHAHERPESVIRINAE FAMILY MEMBER(2,1)
ANTIGEN PRODUCTION(2,1)
AQUEOUS DEXTROSE(2,1)
BAR VAC(2,1)
BASIC PLASMID(2,1)
BIOCHEMICAL AGENT(2,1)
BOOSTING(2,1)
BPI F ANTIGEN(2,1)
BVDV1 NUCLEIC ACID MOLECULE(2,1)
CELLULAR PROMOTER(2,1)
CESIUM CHLORIDE(2,1)
CLONING SITE(2,1)
COLD SPRING HARBOR(2,1)
COMPOSITION EXPRESS(2,1)
DIOLEOYLPHOSPHATIDYLCHOLINE(2,1)
DIOLEOYLPHOSPHATIDYLETHANOLAMINE(2,1)
DNA PELLET(2,1)
DNA QUANTITY(2,1)
DNA VACCINE IMMUNE RESPONSE(2,1)
EARLY AGE(2,1)
EMBODIEMENT(2,1)
EMODIMENT(2,1)
EMULSIFIER MIXTURE(2,1)
F ENCODING(2,1)
FUNCTIONAL FRAGMENT(2,1)
GB ANTIGEN(2,1)
GC ANTIGEN(2,1)
GD ANTIGEN(2,1)
GD PROTEIN(2,1)
GENE FRAGMENT(2,1)
HEMAGGLUTININ NEURAMINIDASE(2,1)
HUMAN ORIGIN(2,1)
HUMORAL IMMUNE RESPONSE(2,1)
HUMORAL RESPONSE(2,1)
IMMUNE CONTEXT(2,1)
IMMUNE PROTECTION(2,1)
IMMUNE RESPONSE INHIBITION(2,1)
INITIAL IMMUNOLOGICAL ACTIVITY LOSS(2,1)
INJECTABLE FLUID(2,1)
ISOLATED PROTEIN(2,1)
LATTER FUSION PROTEIN(2,1)
MACVECTOR(2,1)
MELITTIN SIGNAL PEPTIDE(2,1)
MESSENGER RNA ENCODING(2,1)
METHADONE SALT(2,1)
MODIFIED VECTOR VACCINE(2,1)
MOUSE MODEL(2,1)
MUCOSAL DISEASE VIRUS(2,1)
MURINE ORIGIN(2,1)
NEUTRALIZING(2,1)
NUCLEIC ACID MOLECULE CODING(2,1)
NUCLEOTIDE SEQUENCE MODIFICATION(2,1)
OLIGONUCELOTIDE(2,1)
OPTIMIZED GB(2,1)
OPTIMIZED GC(2,1)
OPTIMIZED GD(2,1)
ORAL ROUTE(2,1)
ORIGIN CELL(2,1)
PARTIAL DELETION(2,1)
PCR REACTION(2,1)
PHOSPHATE BUFFER(2,1)
PLASMID CONSTRUCTION(2,1)
POLYMER DISSOLUTION(2,1)
POLYOXYETHYLENE COPOLYMER BLOCK(2,1)
PRIME BOOST ADMINISTRATION(2,1)
PRINCIPAL ANTIGEN(2,1)
PROBE AID(2,1)
PRODUCTION STIMULATION(2,1)
PROMOTION(2,1)
PROTECTION EFFECTIVENESS(2,1)
PURIFIED PLASMID(2,1)
REACHING MATURITY(2,1)
RECOMBINANT VECTOR(2,1)
RECONSTITUTION(2,1)
RT PCR(2,1)
SINGLE OPTIMIZED BVDV ANTIGEN(2,1)
SORBITAN ESTER(2,1)
STABILIZER PRESENCE(2,1)
STERILE ULTRAPURE WATER(2,1)
STRONG PROMOTER(2,1)
SUCCESSIVE ADMINISTRATION(2,1)
SYNTHETIC FRAGMENT(2,1)
T LYMPHOCYTE MOBILIZATION(2,1)
TRANSFECTED CELL(2,1)
UNSATURATED RADICAL(2,1)
VIRAL DNA FRAGMENT(2,1)
VIRAL ORIGIN(2,1)
YEAST VECTOR(2,1)
YOUNG CALF(2,1)
(CA2515978)
IMMUNOGEN(100,97)
BOVINE VIRAL DIARRHEA VIRUS(100,86)
BOVINE HERPES VIRUS(100,84)
PLASMID(100,83)
BOVINE RESPIRATORY SENCITIAL VIRUS(100,53)
BOVINE(100,43)
BOVINE PATHOGEN(100,38)
BPI(100,27)
IMMUNE RESPONSE(100,23)
MATERNAL ANTIBODY(100,17)
VACCINATION(100,15)
CATTLE(100,10)
IMMUNIZATION(100,10)
PRIME BOOST REGIMEN(100,10)
BOVINE PATHOGENIC AGENT(100,9)
INACTIVATED VACCINE(100,8)
NUCLEOTIDE SEQUENCE CODING(100,4)
POX VIRUS VECTOR(100,3)
YOUNG BOVINE(100,3)
A DNA VACCINE PREPARATION(100,2)
CALF(100,2)
PRIME BOOST VACCINATION(100,2)
PRIMING DNA VACCINE PREPARATION(100,2)
RECOMBINANT VIRAL VECTOR(100,1)
BOVINE PATHOGEN IMMUNOGEN(91,5)
PRIMING VACCINE(82,11)
PRIMED DNA VACCINE(60,4)
AGE WEEK(56,32)
BOOSTING VACCINE(56,9)
LIVE RECOMBINANT POX VIRUS(51,4)
LIVE RECOMBINANT VIRAL VECTOR(48,1)
PATHOGENIC AGENT(37,18)
IMMUNOGEN EXPRESSION(37,10)
RECOMBINANT LIVE VIRAL VECTOR(35,3)
LIVE RECOMBINANT VACCINE(35,2)
DNA VACCINE(34,113)
VACCINE PREPARATION(34,3)
INDUCED IMMUNE RESPONSE(29,3)
BOVINE IMMUNIZATION(28,1)
YOUNG ANIMAL(24,14)
BOOST VACCINE ADMINISTRATION(23,4)
VACCINE(22,37)
YOUNG(22,14)
CANARY POX VIRUS(22,5)
TRANSMEMBRANE DOMAIN DELETION(21,15)
INFECTIOUS BOVINE RHINOTRACHEITIS(21,3)
BOOST VACCINE(21,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(21,2)
PRIME BOOST IMMUNIZATION(21,2)
INACTIVATED VACCINE ADMINISTRATION(20,1)
IFN(18,7)
GAMMA(18,5)
DNA VACCINATION(18,3)
JET INJECTOR(18,1)
IMMUNE RESPONSE PRIMING(17,4)
ANIMAL IMMUNIZATION(17,2)
VIRAL VECTOR BASED VACCINE(16,1)
ISOLATED IMMUNOGEN(15,1)
IMMUNOGENIC(14,41)
BOOST ADMINISTRATION(14,6)
BOVINE PATHOGEN EPITOPE(14,6)
ANTIGEN(13,87)
ADMINISTRATION(13,19)
PATHOGEN(13,12)
NUCLEIC ACID MOLECULE(13,8)
BOVINE HOST CELL(12,21)
ENCODING BOVINE GM CSF(12,10)
EPITOPE(11,43)
PLASMID EXPRESSION(11,13)
DNA DELETION(11,11)
DELETION FRAGMENT(11,9)
GEN BANK DATABASE(11,7)
SEPARATE CONTAINER(11,5)
ANOTHEREMBODIMENT(11,1)
BOVINE IMMUNE(11,1)
BOVINE VACCINATION(11,1)
EMODIMENT(11,1)
KNOWLEDGE(10,1)
KIT(9,8)
EXPRESSION VECTOR VACCINE(9,6)
RABBIT BETA GLOBIN GENE(9,6)
CYTOPLASMIC TAIL DELETION(9,3)
BOVINE RESPIRATORY SYNCYTAL VIRUS(9,1)
VETERINARILY ACCEPTABLE VEHICLE(8,6)
ADMIXTURE(8,2)
CYTOSKELETON GENE PROMOTER(8,2)
HUMAN TPA SIGNAL SEQUENCE(7,20)
PATHOGEN TARGET(7,4)
DIOLEOYLPHOSPHATIDYL ETHANOLAMINE(7,2)
LIPOSOME FORMULATED VACCINE(7,2)
MAMMAL(7,2)
RABBIT GLOBIN GENE(7,2)
SKIN CELL(7,2)
GENE ENCODING(6,6)
PLASMID DNA(6,6)
COW(6,4)
ANTIGEN OPTIMIZATION(6,3)
BPI SUBSTITUTION(6,3)
BULL(6,3)
ORIGIN HUMAN TPA(6,3)
PATHOGEN INACTIVATION(6,3)
ABERRANT MESSENGER RNA SPLICING(6,1)
CANARY POX FOWLPOXVIRUS(6,1)
EUKARYOTIC EXPRESSION PLASMID PVR(6,1)
FLAVIVIRIDAE FAMILY PESTIVIRUS(6,1)
IMMUNOGEN TRANSMEMBRANE DOMAIN(6,1)
INFECTIOUS BOVINE RHINOTRACHITIS(6,1)
INFLUENZA VIRUS HEMAGGLUTININ(6,1)
NUCLEIC ACID MOLECULE ENCODING(5,7)
FINISHING UNIT(5,4)
MALEIC ANHYDRIDE COPOLYMER(5,4)
INTRADERMAL ROUTE(5,3)
ACTIN PROMOTER(5,2)
ATTENUATED PATHOGEN(5,2)
DESMIN PROMOTER(5,2)
EXPRESSION VECTOR CONSTRUCT(5,2)
HUMAN TISSUE PLASMINOGEN ACTIVATOR(5,2)
NEEDLELESS INJECTOR VOLUME(5,2)
PPB DIGESTION(5,2)
STABILIZING INTRON INSERTION(5,2)
ANTIGEN TRANSMEMBRANE DOMAIN(5,1)
ANTIGEN TRIGGERED SECRETION(5,1)
ATTENUATED VACCINIA VIRUS(5,1)
BICISTRONIC PLASMID ENCODING(5,1)
BOVINE HERPES VIRUS TYPE(5,1)
BPI HEMAGGLUTININ NEURAMINIDASE ANTIGEN(5,1)
CLINICAL SIGN SERIOUSNESS(5,1)
FOWL POX VIRUS ATTENUATION(5,1)
HEMAGGLUTININ NEURAMINIDASE TRANSMEMBRANE DOMAIN(5,1)
MONOCISTRONIC PLASMID ENCODING(5,1)
VIRAL GENOMIC DNA EXTRACTION(5,1)
VIRAL GENOMIC RNA ISOLATION(5,1)
EXCIPIENT(4,9)
MEMORY T CELL RESPONSE(4,8)
ACCESSION(4,7)
SUBUNIT VACCINE(4,6)
PROTECTIVE IMMUNE RESPONSE(4,4)
ALKENYL DERIVATIVE(4,3)
INACTIVATED FORM(4,3)
PROMOTION(4,3)
EXTRACELLULAR DOMAIN(4,2)
INTRANASAL ROUTE(4,2)
LTR PROMOTER(4,2)
OLIGONUCLEOTIDE PAIR(4,2)
PHYSIOLOGICAL SALINE(4,2)
PREGNANT FEMALE(4,2)
RESTRICTION ENZYME(4,2)
ALKENE OLIGOMERIZATION(4,1)
AMPLIFIED FRAGMENT CLONING(4,1)
ANHYDROMANNITOL OLEATE(4,1)
ANTIGEN COMING LIKELIHOOD(4,1)
BOVINE GM CSF POLYPEPTIDE(4,1)
CLONED DNA FRAGMENT(4,1)
CYTOKINE INHANCE(4,1)
CYTOMEGALOVIRUS EARLY PROMOTER(4,1)
EXPRESSION VECTOR PVR(4,1)
FUSION PROTEIN ADMINISTRATION(4,1)
GB TRANSMEMBRANE DOMAIN(4,1)
GUANIDINIUM THIOCYANATE(4,1)
HETEROLOGOUS POLYNUCLEOTIDE(4,1)
INTRAMUSCULAR ROUTE INDUCING(4,1)
MESSENGER RNA TRANSLATABILITY(4,1)
MURINE ROTAVIRUS(4,1)
NEEDLELESS INJECTOR AID(4,1)
POLYNUCLEOTIDE VACCINATION(4,1)
PRIMING VACCINE PREPARATION(4,1)
PROMOTER FUNCTIONAL SUBFRAGMENT(4,1)
PROTEIN TRANSMEMBRANE DOMAIN(4,1)
REMINGTON PHARMACEUTICAL SCIENCE(4,1)
ST GD GENE(4,1)
SUGAR POLYALKENYL(4,1)
THYMIDINE KINASE GENE(4,1)
TRUNCATED CMV ACTIVITY(4,1)
TRUNCATED GB GENE(4,1)
TRUNCATED GC GENE(4,1)
VACCINE ADMINISTRATION SUCCESSIVE(4,1)
VIRUS GENOMIC RNA(4,1)
HETEROLOGOUS SIGNAL SEQUENCE(3,5)
SYRINGE(3,4)
ADJUVANT SOLUTION(3,3)
FINAL VACCINE(3,3)
PLASMID MIXTURE(3,3)
COINJECTION(3,2)
EMA PRODUCT(3,2)
ENCODING DNA VACCINE(3,2)
ENCODING GM CSF(3,2)
EXTRACELLULAR MEDIUM(3,2)
INTRON SEQUENCE(3,2)
LINEAR ALIPHATIC RADICAL(3,2)
MURINE GM CSF(3,2)
PARAMYXOVIRIDAE FAMILY MEMBER(3,2)
PARAMYXOVIRUS(3,2)
PHYSIOLOGICAL PH(3,2)
POLYHYDROXYLATED COMPOUND(3,2)
PRIMING IMMUNE RESPONSE(3,2)
UPSTREAM REGION DELETION(3,2)
VACCINAL(3,2)
VACCINE VECTOR(3,2)
5KDA PROMOTER(3,1)
ACTIVATED DENDRIMER MOLECULE(3,1)
ACUTE CLINICAL SIGN(3,1)
ADENOVIRUS VECTOR(3,1)
ANNUAL ADMINISTRATION(3,1)
ANTIGEN EPITOPE(3,1)
ANTIGEN SECRETION(3,1)
ATTENUATED VIRUS(3,1)
AVIPOXVIRUS(3,1)
BAMHI BGLII DIGESTION(3,1)
BAMHI HINDIII FRAGMENT(3,1)
BOVINE ADENOVIRUS(3,1)
BOVINE ANTIGEN(3,1)
BOVINE POPULATION(3,1)
BPI ANTIGEN(3,1)
CATIONIC LIPID NEUTRAL LIPID(3,1)
CELLULAR MACHINERY(3,1)
CHOLERA TOXIN(3,1)
CLINICAL SCORE(3,1)
CLONING ORIGIN(3,1)
CMV FUNCTIONAL FRAGMENT(3,1)
CODING SEQUENCE DISRUPTION(3,1)
COLORADO STRAIN(3,1)
CYTOKINE IL LBETA(3,1)
CYTOPLASMIC DOMAIN(3,1)
DIGESTION FRAGMENT(3,1)
DNA PLASMID PREPARATION(3,1)
DNA VACCINE ADMINISTRATION(3,1)
DNA VACCINE EFFICACY(3,1)
DOVEPOX VIRUS(3,1)
ENCODED IMMUNOGEN(3,1)
ENVELOPE GLYCOPROTEIN(3,1)
ENZYME ECORV(3,1)
FETAL MALFORMATION(3,1)
FORMULA QUATERNARY AZANIUM SALT(3,1)
FUSION PROTEIN DIRECT ADMINISTRATION(3,1)
GB GLYCOPROTEIN(3,1)
GC GLYCOPROTEIN(3,1)
GD GLYCOPROTEIN(3,1)
GENERATING PLASMID PPB(3,1)
GLYCOPROTEIN GB SIGNAL PEPTIDE(3,1)
GLYCOPROTEIN GC(3,1)
HETEROLOGOUS TPA(3,1)
HUMAN ACQUIRED IMMUNODEFICIENCY VIRUS(3,1)
HYDROPATHY PROFILE BASIS(3,1)
IDEC PHARMACEUTICAL(3,1)
IMMUNE REPONSE(3,1)
IMMUNE RESPONE(3,1)
IMMUNIZATION REGIMEN(3,1)
IMMUNOLOGICALLY ACTIVE PROTEIN(3,1)
INFECTIOUS DISEASE(3,1)
INTERFERON MEMORY T CELL RESPONSE(3,1)
LEUNG TACK(3,1)
LUNG LESION(3,1)
MACK PUBLISHING(3,1)
MESSENGER RNA ENCODING STABILITY(3,1)
MILD CLINICAL SIGN(3,1)
MURIN ORIGIN(3,1)
NEURAMINIDASE PROTEIN(3,1)
NONIONIC SURFACTANT(3,1)
NUCLEOTIDE DELETION(3,1)
NUCLEOTIDE SEQUENCE OPTIMIZATION(3,1)
PATHOGEN VACCINE(3,1)
PATHOGENIC AGENT EPITOPE(3,1)
PHARMACEUTICAL BIOTECHNOLOGY(3,1)
PLASMID ENCODING GAMMA INTERFERON(3,1)
PRODUCT CARBOPOL 974P(3,1)
RECOMBINANT CANARY(3,1)
RECOMBINANT HERPES VIRUS(3,1)
RECOMBINANT VACCINIA(3,1)
RECOMBINANT VIRUS(3,1)
RESTRICTION SITE FACILITATING(3,1)
RNA MOLECULE ENCODING(3,1)
SPECIES CYTOKINE(3,1)
STRONG EUKARYOTIC PROMOTER(3,1)
SUBCUTANEOUS ROUTE(3,1)
UNSATURATED ALIPHATIC RADICAL(3,1)
VAN DRUNEN LITTLE VAN DEN(3,1)
VIRAL GENOME(3,1)
VIRAL PROMOTER(3,1)
VIRUS EXCRETION(3,1)
PLF(2,7)
DMRIE(2,6)
XHOI(2,6)
SIGNAL SEQUENCE INSERTION(2,5)
TM CTER(2,5)
PSTI(2,4)
TEMPLATE(2,4)
ATTENUATED VACCINE(2,3)
BACTERIA(2,3)
EMULSION(2,3)
GLYCEROL(2,3)
GUINEA PIG(2,3)
METHACRYLIC ACID POLYMER(2,3)
RECOMBINANT VACCINE(2,3)
AMPLIFICATION PRODUCT(2,2)
CAPRYLATE(2,2)
COLD SPRING(2,2)
CONCOMITANT(2,2)
DECANOATE(2,2)
EDITION(2,2)
HEMAGGLUTININ NEURAMINIDASE SIGNAL SEQUENCE(2,2)
POLYPROTEIN(2,2)
RABIES VIRUS(2,2)
ROUS SARCOMA VIRUS(2,2)
SEPARATE PLASMID(2,2)
STOCK SOLUTION(2,2)
SV40 VIRUS(2,2)
TRANSCRIPTION UNIT(2,2)
ACTIVE INGREDIENT(2,1)
AGE ANIMAL(2,1)
ALLYLPENTAERYTHRITOL(2,1)
ALPHAHEIPESVIRINAE FAMILY MEMBER(2,1)
ANTIGEN PRODUCTION(2,1)
AQUEOUS DEXTROSE(2,1)
BAR VAC(2,1)
BASIC PLASMID(2,1)
BAV VECTOR(2,1)
BIOCHEMICAL AGENT(2,1)
BOOSTING(2,1)
BOVINE HERPES VIRUS STRAIN(2,1)
CELLULAR PROMOTER(2,1)
CESIUM CHLORIDE(2,1)
CLONING SITE(2,1)
COMPOSITION EXPRESS(2,1)
DIOLEOYLPHOSPHATIDYLCHOLINE(2,1)
DNA FORMULATION(2,1)
DNA INDUCED IMMUNE RESPONSE(2,1)
DNA PELLET(2,1)
DNA QUANTITY(2,1)
DOPEA(2,1)
EARLY AGE(2,1)
EMULSIFIER MIXTURE(2,1)
ENCODING FRAGMENT(2,1)
ETHYLENICALLY UNSATURATED GROUP(2,1)
GB ANTIGEN(2,1)
GC ANTIGEN(2,1)
GD PROTEIN(2,1)
GENE CLEAN(2,1)
GENE FRAGMENT(2,1)
HETEROLOGOUS NUCLEIC ACID(2,1)
HUMAN ORIGIN(2,1)
HUMORAL IMMUNE RESPONSE(2,1)
HUMORAL RESPONSE(2,1)
HYDROGEN ATOM(2,1)
IMMUNE CONTEXT(2,1)
IMMUNE PROTECTION(2,1)
IMMUNE RESPONSE INHIBITION(2,1)
INITIAL IMMUNOLOGICAL ACTIVITY LOSS(2,1)
INJECTABLE FLUID(2,1)
ISOLATED PROTEIN(2,1)
LATTER FUSION PROTEIN(2,1)
MAC VECTOR(2,1)
MELITTIN SIGNAL PEPTIDE(2,1)
METHADONE SALT(2,1)
MODIFIED VACCINIA(2,1)
MODIFIED VECTOR VACCINE(2,1)
MOUSE MODEL(2,1)
MUCOSAL DISEASE VIRUS(2,1)
MURINE ORIGIN(2,1)
NEUTRALIZING(2,1)
NONTRANSLATED REGION(2,1)
NUCLEIC ACID MOLECULE CODING(2,1)
NUCLEOTIDE SEQUENCE MODIFICATION(2,1)
NYCAC(2,1)
OLIGONUBLEOTIDE(2,1)
OLIGONUCELOTIDE(2,1)
OPTIMIZED GB(2,1)
OPTIMIZED GC(2,1)
OPTIMIZED GD(2,1)
ORAL ROUTE(2,1)
ORIGIN CELL(2,1)
PARTIAL DELETION(2,1)
PHOSPHATE BUFFER(2,1)
PLASMID CONSTRUCTION(2,1)
POLYMER DISSOLUTION(2,1)
POLYOXYETHYLENE COPOLYMER BLOCK(2,1)
POX VIRUS SPECIFIC PROMOTER(2,1)
PRIME BOOST ADMINISTRATION(2,1)
PRINCIPAL ANTIGEN(2,1)
PROBE AID(2,1)
PRODUCTION STIMULATION(2,1)
PROTECTION EFFECTIVENESS(2,1)
PURIFIED PLASMID(2,1)
REACHING MATURITY(2,1)
RECOMBINANT VECTOR(2,1)
RECONSTITUTION(2,1)
SALL SITE(2,1)
SHOW PLASMID PVR(2,1)
SIGNAL PEPTIDE(2,1)
STABILIZER PRESENCE(2,1)
STERILE ULTRAPURE WATER(2,1)
STRONG PROMOTER(2,1)
SUCCESSIVE ADMINISTRATION(2,1)
SYNTHETIC FRAGMENT(2,1)
TRANSFECTED CELL(2,1)
UNSATURATED RADICAL(2,1)
VIRAL DNA FRAGMENT(2,1)
VIRAL ORIGIN(2,1)
VIRAL SUSPENSION(2,1)
YEAST VECTOR(...)";Pharmaceuticals;Open
"2003-01-03
2004-01-05";"US20040185056       A1 2004-09-23 [US20040185056]
STG: (A1) Application published
AP : 2004US-10752482 2004-01-05";43996554;US20040185056       A1 2004-09-23 [US20040185056];"2003US-60437855
2004US-10752482";;UNIVERSITY OF NEBRASKA;UNIVERSITY OF NEBRASKA;;"(US20040185056)
NAME=Board of Regents, University of Nebraska-Lincoln , ATYP=US Company 
";1;JONES CLINTON J;"(US20040185056)
US";"(US20040185056)
NAME=Jones Clinton J. , CITY=Lincoln , STATE=NE , COUNTRY=US 
";"(US20040185056)
Vaccines containing bovine herpesvirus 1 attenuated by mutation in latency-related gene";"(US20040185056)
Vaccines for pathogenic strains of bovine herpesvirus 1 (BHV-1) which are based on attenuated BHV-1 having a mutation in the latency-related gene are provided. Live, attenuated vaccines are also provided which express antigens from other viral or bacterial pathogens and thus form the basis of a variety of vaccines.";"(US20040185056)
What is claimed and desired to be secured by Letters Patent is as follows:
1. A vaccine composition against a viral or bacterial pathogen, comprising a viral vector, wherein said viral vector is a mutant recombinant BHV-1 strain comprising: 
 a. a mutation in the latency-related (LR) gene, whereby no detectable reactivation from latency occurs; and 
 b. an expressable recombinant nucleic acid encoding an antigen from said viral or bacterial pathogen, wherein expression of said antigen induces immunological response against said viral or bacterial pathogen.
2. The vaccine composition of claim 1, wherein said viral vector comprises modified BHV-1 strain on deposit with the American Type Culture Collection as Accession No. ______.
3. The vaccine composition of claim 1, wherein said mutation in the LR gene is accomplished by chemical synthesis or artificial manipulation of isolated segments of nucleic acid.
4. The vaccine composition of claim 1, wherein said mutation in the LR gene is spontaneous or a selected, naturally occurring mutation.
5. The vaccine composition of claim 1, wherein the live, attenuated BHV-1 strain comprises a modified BHV-1 strain other than the BHV-1 strain on deposit with the American Type Culture Collection as Accession No. VR-864.
6. The vaccine composition of claim 1, wherein said mutated LR gene comprises the nucleotide sequence of SEQ ID NO:8.
7. The vaccine of claim 1, wherein said expressable recombinant nucleic acid is inserted in said mutated LR gene locus, whereby expression of the recombinant nucleic acid is driven by the LR promoter.
8. The vaccine of claim 1, wherein said expressable recombinant nucleic acid is inserted in a glycoprotein locus of the viral vector, whereby expression of the recombinant nucleic acid is driven by a heterologous promoter.
9. The vaccine composition of claim 1, wherein said vaccine is adapted for administration by a mode selected from the group consisting of intranasal instillation, intramuscular, ocular, intraperitoneal, and subcutaneous.
10. The vaccine composition of claim 1, wherein said viral or bacterial pathogen is selected from the group consisting of bovine herpesvirus 1, bovine viral diarrhea virus, bovine respiratory virus, bovine corona virus, Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus.
11. A method of modulating the immune response to a viral or bacterial infection, which comprises administering a vaccine composition according to claim 1.
12. A method of vaccinating a mammal in need thereof against a viral or bacterial pathogen, which comprises administering to said mammal a vaccine composition according to claim 1.
13. The method of claim 12, wherein said mammal is an ungulate.
14. The method of claim 13, wherein said ungulate is selected from the group consisting of bovines, buffalo, sheep, and deer.
15. The method of claim 12, wherein said viral or bacterial pathogen is selected from the group consisting of bovine herpesvirus 1, bovine viral diarrhea virus, bovine respiratory virus, bovine corona virus, Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus.
16. A recombinant viral vector comprising SEQ ID NO:8 and a recombinant nucleic acid fragment capable of encoding an antigen from a viral or bacterial pathogen.
17. The recombinant viral vector of claim 16, wherein said viral or bacterial pathogen is selected from the group consisting of bovine herpesvirus 1, bovine viral diarrhea virus, bovine respiratory virus, bovine corona virus, Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus.
18. A method for effecting the treatment of a viral or bacterial infection, which comprises administering to a mammal in need of said treatment, an effective amount of the vaccine of claim 1.
19. The method of claim 18, wherein said mammal is an ungulate.
20. The method of claim 19, wherein said ungulate is selected from the group consisting of bovines, buffalo, sheep, and deer.
21. The method of claim 18, wherein said viral or bacterial pathogen is selected from the group consisting of bovine herpesvirus 1, bovine viral diarrhea virus, bovine respiratory virus, bovine corona virus, Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus";"(US20040185056)
[0008] It is another object of the present invention to provide live viral vaccines based on BHV-1 attenuated by mutation in the LR gene which express recombinant immunogenic antigens.
[0007] It is an object of the present invention to provide live viral vaccines based on BHV-1 attenuated by mutation in the latency-related (LR) gene so that the BHV-1 does not reactivate from latency.
[0003] The present invention relates generally to vaccines based on live, attenuated viruses and to methods of using these vaccines.
More particularly, the present invention relates to vaccines based on bovine herpes virus 1, attenuated by mutation in the latency-related gene, and to methods for using these vaccines to induce immunological response to BHV-1 specific and/or recombinant immunogenic antigens without reactivation of the virus from latency.";"(US20040185056)
The vaccines of the present invention are useful with mammals, preferably ungulates, most preferably with sheep, bovines, deer, and buffalo.
The herpes simplex virus 2-kb latency associated transcript (LAT) leader sequence allows efficient expression of downstream proteins which is enhanced in neuronal cells: possible function of LAT ORFs.
These live, attenuated viral vaccines cause acute infection and produce sufficient viral titer to elicit a cell-mediated immune response.
Although modified live vaccines are available, there are disadvantages associated with the use of currently available vaccines, for example, they can cause disease in young calves or abortions in cows, and all have the potential to establish latency and reactivate from latency (Jones et al., 2000).
[0005] Bovine herpes virus 1 (BHV-1) is an important viral pathogen of cattle that can cause severe respiratory infection, conjunctivitis, abortions, vulvovaginitis, balanoposthitis, and systemic infection in neonate calves (Wyler et al., 1989).";"A61K-039/00
A61K-039/265
A61K-039/295
A61K-039/38
C12N-007/04
C12N-015/869";"(US20040185056)
1. A vaccine composition against a viral or bacterial pathogen, comprising a viral vector, wherein said viral vector is a mutant recombinant BHV-1 strain comprising: a. a mutation in the latency-related (LR) gene, whereby no detectable reactivation from latency occurs; and b. an expressable recombinant nucleic acid encoding an antigen from said viral or bacterial pathogen, wherein expression of said antigen induces immunological response against said viral or bacterial pathogen.
16. A recombinant viral vector comprising SEQ ID NO:8 and a recombinant nucleic acid fragment capable of encoding an antigen from a viral or bacterial pathogen.";"(US20040185056)
BOVINE HERPES VIRUS(100,35)
MUTATION(100,24)
VACCINE(100,23)
BACTERIAL PATHOGEN(100,18)
LATENCY RELATED GENE(100,17)
MUTANT RECOMBINANT BHV(100,1)
RECOMBINANT VIRAL VECTOR(100,1)
CATTLE VIRAL PATHOGEN(87,1)
BOVINE RESPIRATORY VIRUS(86,7)
HAEMOPHILUS SOMNUS(78,6)
VIRAL VECTOR(72,3)
DETECTABLE REACTIVATION(69,1)
LIVE VIRAL VACCINE(66,2)
RECOMBINANT IMMUNOGENIC ANTIGEN(63,2)
VIRAL VECTOR GLYCOPROTEIN(63,1)
VIRAL TITER(55,1)
NEONATE CALF(54,1)
EXPRESSABLE RECOMBINANT NUCLEIC ACID(49,2)
SYSTEMIC INFECTION(48,1)
LIVE VACCINE(47,1)
VIRUS REACTIVATION(46,2)
DOWNSTREAM PROTEIN EFFICIENT EXPRESSION(45,1)
YOUNG CALF(44,1)
ATTENUATED BHV(43,5)
UNGULATE(43,5)
IMMUNOGENIC ANTIGEN(43,2)
SEVERE RESPIRATORY INFECTION(43,1)
PASTEURELLA HAEMOLYTICA(41,6)
PASTEURELLA MULTOCIDA(41,6)
LAT ORFS FUNCTION(40,1)
RECOMBINANT NUCLEIC ACID(39,5)
INTRANASAL INSTILLATION(38,2)
HETEROLOGOUS PROMOTER(38,1)
BOVINE CORONAVIRUS(37,7)
MAMMAL(37,6)
EXPRESS ANTIGEN(37,1)
ATTENUATED VIRUS(35,3)
ABORTION(34,2)
BHV(32,56)
LATENCY(32,40)
IMMUNOLOGICAL RESPONSE(32,9)
ENCODING NUCLEIC ACID(32,1)
BUFFALO(31,3)
ISOLATED SEGMENT ARTIFICIAL MANIPULATION(31,2)
ANTIGEN(30,13)
ACUTE INFECTION(29,13)
BALANOPOSTHITIS(29,1)
VULVOVAGINITIS(29,1)
STRAIN(28,7)
NEURONAL CELL(28,2)
CONJUNCTIVITIS(28,1)
BOVINE VIRAL DIARRHEA VIRUS(27,7)
DEER(27,3)
SHEEP(27,3)
BOVINE(25,4)
ATTENUATED VIRAL VACCINE(24,3)
IMMUNE RESPONSE(22,7)
ACCESSION(22,2)
MODIFIED BHV(22,1)
LATENTLY INFECTED NEURON(20,3)
MUTANT VIRUS(19,13)
LATENCY ESTABLISHMENT(19,7)
COW(19,1)
GENE(18,35)
LATENCY REACTIVATION CYCLE(18,6)
HERPES SIMPLEX VIRUS(17,9)
TRANSIENTLY TRANSFECTED CELL(17,4)
LATENTLY INFECTED CALF TONSIL(17,1)
MUTATED LATENCY RELATED GENE(17,1)
VARIETY BASIS(17,1)
TRANSCRIPT(16,9)
ACUTE INTRANASAL INFECTION(16,3)
ACUTELY INFECTED CALF(15,2)
CALF SHEDDING OCULAR SWAB(15,1)
LEADER SEQUENCE(15,1)
NEUTRALIZING ANTIBODY TITER POST INFECTION(15,1)
BHV GENE(14,5)
RESCUING VIRUS(14,5)
AMERICAN TYPE CULTURE COLLECTION(14,3)
LAT(13,17)
DISEASE(13,3)
CATTLE ACUTE INFECTION(13,2)
RUMINANT HERPES VIRUS MOLECULAR VIROLOGY(13,1)
TRIGEMINAL GANGLION NEURON(13,1)
DEX TREATMENT(12,9)
BOVINE KIDNEY CELL(12,4)
CHEMICAL SYNTHESIS(12,3)
LAT NUCLEOTIDE(12,3)
RECOMBINANT ANTIGEN(12,3)
BHV REACTIVATION(12,2)
FETAL BOVINE SERUM(12,2)
LR RNA EXPRESSION(12,2)
BHV HINDIIID FRAGMENT(12,1)
LEUKOCYTE SUBPOPULATION DYNAMICS(12,1)
PERMISSIVE NEURON SURVIVAL(12,1)
DEX INJECTION(11,3)
LIVE ATTENUATED VACCINE(11,3)
ABUNDANT VIRAL TRANSCRIPT(11,1)
CALF OCULAR SWAB(11,1)
KLUWER ACADEMIC PUBLISHER(11,1)
LATENCY RELATED PROMOTER(11,1)
LATENTLY INFECTED CATTLE(11,1)
MCKRAE LAT NULL MUTANT(11,1)
SPONTANEOUS REACTIVATION PHENOTYPE(11,1)
SPHI SITE(10,3)
MDBK CELL INFECTION(10,2)
NEBRASKA UNIVERSITY(10,2)
PRIMARY LAT TRANSCRIPT(10,2)
UNIQUE PACI RESTRICTION(10,2)
BAMHI LINKER LIGATION(10,1)
BHV PATHOGENIC STRAIN(10,1)
BOVINE HERPES VIRUS REACTIVATION(10,1)
CLARIFIED VIRAL LYSATE(10,1)
DOLLAR CATTLE INDUSTRY MILLION(10,1)
IMPAIRED OCULAR SHEDDING(10,1)
INFECTIOUS VIRUS TITER(10,1)
LAT ANTI APOPTOTIC ACTIVITY(10,1)
PRODUCTIVE VIRAL REPLICATION(10,1)
SERUM TWOFOLD SERIAL DILUTION(10,1)
SYNTHETIC CORTICOSTEROID DEXAMETHASONE(10,1)
TRANSLATION INITIATION PHOSPHORYLATION(10,1)
AGAROSE GEL(9,4)
BACTERIAL STRAIN(9,3)
LATENCY MAINTENANCE(9,3)
LIVE BHV(9,3)
MODIFIED LIVE VACCINE(9,3)
PROTEIN EXPRESSION(9,3)
REACTIVATION EFFICIENCY(9,3)
VIRAL DNA COPY(9,3)
CALF INFECTION(9,2)
CLINICAL SYMPTOM(9,2)
DAY POSTREACTIVATION(9,2)
DEX INDUCED REACTIVATION(9,2)
GLYCOPROTEIN GENE(9,2)
HERPES SIMPLEX VIRUS LATENCY(9,2)
MUTANT GENOME(9,2)
MUTANT PLASMID(9,2)
NASAL SWAB(9,2)
PBLUEBACHIS VECTOR(9,2)
PEPTIDE ANTIBODY(9,2)
BOVINE MHC EXPRESSION(9,1)
BOVINE RHINOTRACHEITIS VULVOVAGINITIS(9,1)
CULTURED BOVINE EPITHELIAL CELL(9,1)
DEXAMETHASONE INDUCED REACTIVATION CHARACTERIZATION(9,1)
ETHIDIUM BROMIDE STAINING(9,1)
FINGER TRANSACTIVATOR PROTEIN(9,1)
FORMALDEHYDE BROMOPHENOL BLUE(9,1)
GENOMIC DNA FLANKING(9,1)
INFECTED CALF EYE(9,1)
LATENTLY INFECTED RABBIT TREATMENT(9,1)
MUTANT VIRAL GENOME(9,1)
NATIONAL VETERINARY SERVICE LABORATORY(9,1)
PACI RESTRICTION ENZYME SITE(9,1)
PCR MEDIATED MUTAGENESIS(9,1)
PLASMID ENCODING BICPO(9,1)
SEAPLAQUE AGAROSE(9,1)
SENSORY NEURON ACUTE INFECTION(9,1)
SERUM NEUTRALIZING(9,1)
HOMOGENATE(8,7)
LATENCY ASSOCIATED TRANSCRIPT GENE(8,4)
OCULAR ROUTE(8,2)
ALPHAHERPESVIRUS LATENCY(8,1)
BHV OCULAR GROWTH(8,1)
BHV STRAIN(8,1)
CALF ACUTE INFECTION(8,1)
CATTLE HERPES VIRUS DISEASE(8,1)
COMPREHENSIVE QUANTIFICATION(8,1)
CORE LAT PROMOTER(8,1)
DNA RESTRICTION FRAGMENT(8,1)
EFFICIENT SPONTANEOUS REACTIVATION(8,1)
FOREIGN GENE EXPRESSION(8,1)
GANGLION SENSORY NEURON(8,1)
HOST RESISTANT GENE KNOCKOUT(8,1)
INTACT BHV ISOLATION(8,1)
LATENT BOVINE HERPES VIRUS(8,1)
MUTANT GENE CONSTRUCT(8,1)
MUTANT OLIGONUCLEOTIDE INSERT(8,1)
PBLUEL SALI SITE(8,1)
PHENOTYPIC RESTORATION(8,1)
PLAQUE PURIFICATION ROUND(8,1)
RABBIT TRIGEMINAL GANGLIA(8,1)
REDUNDANT CODON ENCODING(8,1)
RESTRICTION ENZYME DIGESTION(8,1)
RIBONUCLEOTIDE REDUCTASE(8,1)
SEMI QUANTITATIVE PCR(8,1)
STRICT ISOLATION CONTAINMENT(8,1)
TISSUE CULTURE INFECTIOUS DOSE(8,1)
VACCINE STRAIN(8,1)
VIRAL GENE ABUNDANT EXPRESSION(8,1)
VIRAL GENOME CONTEXT(8,1)
VIRAL GENOME EFFICIENT AMPLIFICATION(8,1)
VIRAL PROMOTER CLASS(8,1)
VIRUS INDUCED NEURONAL APOPTOSIS(8,1)
SHIPPING FEVER(7,5)
GENE SEQUENCE(7,3)
PLAQUE FORMATION EFFICIENCY(7,3)
CALF NASAL CAVITY(7,2)
CRUCIAL ROLE(7,2)
FLUORESCENCE ASSAY(7,2)
PROTEIN FRAGMENT(7,2)
VETERINARY DIAGNOSTIC SERVICE(7,2)
ABUNDANT VIRAL GENE EXPRESSION(7,1)
ACTIN TRANSCRIPT(7,1)
ALPHAHERPESVIRINAE SUBFAMILY MEMBER(7,1)
APOPTOSIS INDUCTION(7,1)
APOPTOSIS INHIBITION(7,1)
ATTENUATED PHENOTYPE(7,1)
AVIRULENT ICP(7,1)
BHV MUTANT(7,1)
BIO RESEARCH AMERICAN(7,1)
BUDAPEST TREATY(7,1)
CALF NEURON(7,1)
CALF VACCINATION(7,1)
CLARIFIED LYSATE(7,1)
CONTAMINATING DNA DETECTION(7,1)
CROSSBRED CALF(7,1)
EFFICIENT HOMOLOGOUS RECOMBINATION(7,1)
FOREIGN PATHOGEN(7,1)
FRAGMENT TERMINI(7,1)
GLYCOPROTEIN CODING SEQUENCE(7,1)
HOMOLOGOUS RECOMBINATION EFFICIENCY(7,1)
INFECTIOUS DLAT(7,1)
INSERTION MUTANT OLIGONUCLEOTIDE SEQUENCE(7,1)
LAT DELETION(7,1)
LIFELONG LATENCY(7,1)
LR RESCUED VIRUS DID(7,1)
LYMPHOCYTE POPULATION DYNAMICS(7,1)
MUCOSAL EPITHELIUM(7,1)
MUNG BEAN EXONUCLEASE(7,1)
MUTANT RELEASED VIRUS(7,1)
NEURONAL SURVIVAL(7,1)
NEUTRALIZING ANTIBODY TITER MEASUREMENT(7,1)
PBLUEBACHISA VECTOR(7,1)
PBLUEL MLAT PLASMID(7,1)
PHARYNGEAL TONSIL GERMINAL CENTER(7,1)
RAT SENSORY GANGLIA(7,1)
REPORTER GENE INSERTION(7,1)
SACRAL DORSAL ROOT GANGLIA(7,1)
SHAWNEE MISSION(7,1)
SPHI FRAGMENT(7,1)
UNIVERSITY BOULEVARD(7,1)
VACCINE ADMINISTRATION(7,1)
VIRAL GENE EXPRESSION STIMULATION(7,1)
VIRAL GENOME ENTRY(7,1)
VIRUS SURVIVAL(7,1)
DPI(6,8)
EVIDENCE(6,5)
DEX INITIAL INTRAVENOUS INJECTION(6,2)
FORWARD PRIMER(6,2)
GC RNA(6,2)
HERPES SIMPLEX VIRUS REGION(6,2)
LAT REGION(6,2)
PCR ANALYSIS(6,2)
RECOMBINANT NUCLEIC ACID INSERTION(6,2)
REVERSE PRIMER(6,2)
RT PCR(6,2)
SECONDARY BACTERIAL INFECTION(6,2)
SURVIVING CELL(6,2)
ACUTE VIRUS GROWTH(6,1)
ALPHA GENE MRNA(6,1)
ALTERED PHENOTYPE(6,1)
ANIMAL VACCINATION(6,1)
ANTIVIRAL INHIBITOR(6,1)
BECKMAN LT(6,1)
BHV CONTEXT(6,1)
BHV FRAGMENT(6,1)
BHV HOMOLOGOUS NUCLEIC ACID(6,1)
BHV LR DNA(6,1)
BIOLOGICAL SIGNIFICANCE(6,1)
BLOCKING APOPTOSIS(6,1)
BOVINE GROWTH HORMONE GENE(6,1)
BOVINE HERPES VIRUS ANALYSIS(6,1)
BOVINE HERPES VIRUS DISTRIBUTION(6,1)
BOVINE RESPIRATORY SYSTEM COMPLEX(6,1)
CALF PERCENTAGE(6,1)
CULTURED BOVINE CELL(6,1)
DAY POST INFECTION(6,1)
DAY POSTTRANSFECTION(6,1)
DEX INTRAMUSCULAR INJECTION(6,1)
ECORI RESTRICTION SITE(6,1)
EXPERIMENTAL INVESTIGATION(6,1)
EXPLANT INDUCED REACTIVATION(6,1)
EXPRESS BHV(6,1)
EXPRESSION REPRESSION(6,1)
EXTENSIVE DELETION(6,1)
FINAL CHIMERIC VIRUS(6,1)
FOREIGN PROMOTER(6,1)
FREEZE THAW(6,1)
GENE TRANSCRIPT(6,1)
HEALTH INSPECTION SERVICE(6,1)
HINDIII SALI FRAGMENT(6,1)
INFECTIOUS BHV PRESENCE(6,1)
L3B PRIMER(6,1)
LABELING PROBE(6,1)
LABORATORY ANIMAL AMERICAN ASSOCIATION(6,1)
LAT GENE REGION(6,1)
LR NULL MUTANT(6,1)
LYMPHOCYTE MITOGENIC RESPONSE(6,1)
MAXILLARY ROUTE(6,1)
MOCK INFECTED CALF(6,1)
MUTANT BHV(6,1)
MUTANT INFECTED CALF(6,1)
MUTANT SHED(6,1)
NERVE CELL SPECIFICITY(6,1)
NUCLEOPROTEIN(6,1)
PACI LINKER(6,1)
PATHOGEN GENE(6,1)
PATHOGEN RECOMBINANT NUCLEIC ACID(6,1)
PEPTIDE TRANSPORT(6,1)
PSTI FRAGMENT PROPER ORIENTATION(6,1)
REACTIVATION EARLY STAGE(6,1)
RECURRENT DISEASE(6,1)
RESTRICTION DIGESTION(6,1)
ROBUST BHV(6,1)
SHED BHV(6,1)
SOLE INFECTIOUS AGENT(6,1)
TRIPLE PLAQUE(6,1)
UNIQUE ECORI RESTRICTION(6,1)
VIRAL DNA SEEDING(6,1)
VIRAL GENOME REGION(6,1)
VIRAL PLAQUE(6,1)
VIRAL SEQUENCE ENCOMPASSING(6,1)
VIRUS INOCULATION(6,1)
VIRUS SHEDDING(6,1)
VIRUS TITRATION(6,1)
STOP CODON(5,7)
SSC(5,6)
ANTISENSE(5,3)
CODING REGION(5,3)
DISCOVERY(5,3)
ELECTROPHORESIS(5,3)
PCR PRODUCT(5,3)
SECRETORY(5,3)
SUPERNATANT(5,3)
VIRAL DNA LEVEL DETECTION(5,3)
EPITOPE(5,2)
ANATOMICAL SITE DEPENDENT ESTABLISHMENT(5,1)
ATCC CCL(5,1)
BAND MIGRATION(5,1)
BAYER CORP(5,1)
BHV ANALYSIS(5,1)
BHV DETECTION(5,1)
BHV PRIMARY SITE(5,1)
BOVINE TISSUE(5,1)
CDNA SYNTHESIS(5,1)
CHLOROFORM EXTRACTION(5,1)
COOPER STRAIN(5,1)
CORTICOSTEROID INDUCED STRESS(5,1)
CORTICOSTEROID TREATMENT(5,1)
CYCLIN COMPLEX(5,1)
DIRECT CONJUGATE DILUTION(5,1)
DLAT ABILITY(5,1)
DNA EXTRACTION(5,1)
EYE DISEASE RECURRENCE(5,1)
EYE SWAB(5,1)
FOLD DILUTION(5,1)
FOREIGN EXPRESSION(5,1)
GAUGE NEEDLE(5,1)
HERPES SIMPLEX VIRUS INFECTED MOUSE(5,1)
HETEROLOGOUS CELL(5,1)
HOST INFECTION(5,1)
HUMAN CYTOMEGALOVIRUS PROMOTER(5,1)
INCUBATION DAY(5,1)
INDEPENDENT VERIFICATION(5,1)
INFECTED ANIMAL(5,1)
INFECTION EFFECTING TREATMENT(5,1)
INFECTIOUS VIRUS PRESENCE(5,1)
INSET PANEL(5,1)
ISOAMYL ALCOHOL(5,1)
ISOLATED MOLECULE(5,1)
ISOLATED POLYPEPTIDE(5,1)
LATENT INFECTION PHASE(5,1)
MR ASSOCIATION(5,1)
MUTANT SEED(5,1)
NATIVE PROTEIN(5,1)
NEURAL TISSUE(5,1)
PATHOGEN NUCLEIC ACID EXPRESSION(5,1)
PCR ASSAY CONDITION(5,1)
PCR PRIMER(5,1)
PLAQUE PURIFIED VIRUS(5,1)
PRELIMINARY STUDY(5,1)
PROTEIN SYNTHESIS(5,1)
RABBIT LUNG(5,1)
RABBIT SKIN FIBROBLAST(5,1)
RANDOM HEXAMER(5,1)
RECOMBINANT VIRUS CONSTRUCTION(5,1)
REPRESENTATIVE SAMPLE PCR(5,1)
SITE MUTATION(5,1)
SPONTANEOUS REACTIVATION LEVEL(5,1)
STOCK VIRUS(5,1)
SUCROSE TE CUSHION(5,1)
SUSCEPTIBLE ANIMAL(5,1)
SUSCEPTIBLE HOST(5,1)
TISSUE GRINDER(5,1)
TOO CONFLUENT DID(5,1)
UNIQUE ECORI SITE(5,1)
VIRAL STOCK(5,1)
VIRUS STOCK(5,1)
VISIBLE PLAQUE(5,1)
ZINC DEPENDANCE(5,1)
AMPLIFIED PRODUCT COMPLETE ELONGATION(4,2)
ARTIFICIAL COMBINATION(4,2)
BP PRODUCT(4,2)
CELL CYCLE PROGRESSION(4,2)
CELL MEDIATED IMMUNE RESPONSE(4,2)
GENETIC ENGINEERING(4,2)
HOT START(4,2)
HYPOTHESIS(4,2)
LATENCY RELATED TRANSCRIPT(4,2)
LINCOLN(4,2)
LIPOPEPTIDE(4,2)
PATHOGENIC VIRUS(4,2)
PBLUEL LAT(4,2)
PROGRAMMED CELL DEATH(4,2)
VIRION(4,2)
322 HINDIII L FRAGMENT(4,1)
BAMHI PLUS(4,1)
BAMHI SITE(4,1)
BICPO SEQUENCE(4,1)
BOVINE EPIDERMAL CELL(4,1)
BRACHIOCEPHALICUS(4,1)
CAUDAL MUSCLE MASS(4,1)
CELL MEDIATED IMMUNITY(4,1)
CELL MONOLAYER(4,1)
CELL PROTECTION(4,1)
CIP TREATMENT(4,1)
CLONING(4,1)
COLD SPRING HARBOR(4,1)
COMPLETE BHV(4,1)
COMPONENT JUXTAPOSITION(4,1)
CONJUGATE ANTIBODY STEP(4,1)
COTRANSFECTION(4,1)
DIGESTION SOUTHERN ANALYSIS(4,1)
DNA POSITIVE NEURON(4,1)
DNA SAMPLE(4,1)
DNASE TREATED RNA(4,1)
DRAMATIC DECREASE(4,1)
ENTRY INHIBITOR(4,1)
ETHANOL BATH(4,1)
FITC FILTER(4,1)
FUNCTIONAL PROTEIN(4,1)
GC DNA(4,1)
GENE DNA(4,1)
GENE PRODUCT IDENTIFICATION(4,1)
GROWING CELL(4,1)
HOST LIFE(4,1)
HYBRIDIZATION POSITIVE NEURON(4,1)
ICE COLD METHANOL ACETONE(4,1)
IMMEDIATE EARLY GENE EXPRESSION(4,1)
IMMEDIATE EARLY RNA(4,1)
IMMUNOSUPPRESSION(4,1)
INDEPENDENT ASSAY(4,1)
INDICATED VIRUS PFU(4,1)
INFECTED CELL(4,1)
INFECTIOUS VIRUS LEVEL(4,1)
INITIAL INFECTION SITE(4,1)
INITIAL REPLICATION(4,1)
KILOBASE LAT(4,1)
LAT DETECTABLE LEVEL(4,1)
LATENCY ANALYSIS(4,1)
LATENCY ASSOCIATED TRANSCRIPT MUTANT(4,1)
LATENCY STAGE(4,1)
LIPOPOLYSACCHARIDE(4,1)
MANIPULATION REGION(4,1)
MOUSE MODEL(4,1)
MURINE MHC DOWN REGULATION(4,1)
MUTANT PRESENCE(4,1)
MUTANT SELECTION(4,1)
MUTATED SEQUENCE(4,1)
NOTABLE DIFFERENCE(4,1)
NUCLEIC ACID COMPLEMENT(4,1)
NUCLEIC ACID TISSUE EXTRACTION(4,1)
NUMEROUS MUTANT(4,1)
PHENOTYPIC DIFFERENCE(4,1)
PRODUCTIVE INFECTION LEVEL(4,1)
PROPHYLACTIC TREATMENT(4,1)";Pharmaceuticals;Open
"2002-08-26
2003-08-14
2003-08-26
2007-08-30
2008-12-16
2010-06-22
2012-12-28";"WO2004017990        A1 2004-03-04 [WO200417990]
STG: (A1) Published application with search report
AP : 2003WO-IB03633 2003-08-14
CA2496750           A1 2004-03-04 [CA2496750]
STG: (A1) Application laid open
AP : 2003CA-2496750 2003-08-14
AU2003263390        A1 2004-03-11 [AU2003263390]
STG: (A1) Open to public inspection
AP : 2003AU-0263390 2003-08-14
UY27948             A1 2004-03-31 [UY--27948]
STG: (A1) Patent application (First publication level)
AP : 2003UY-0027948 2003-08-22
TW200404565         A  2004-04-01 [TW200404565]
STG: (A) Laid open application for patent or patent of addition
AP : 2003TW-0122872 2003-08-20
US20040081666       A1 2004-04-29 [US20040081666]
STG: (A1) Application published
AP : 2003US-10647919 2003-08-26
GT200300180         A  2004-05-18 [GT200300180]
STG: (A) Patent application / divisional patent application
AP : 2003GT-0000180 2003-08-25
PE04202004          A1 2004-07-24 [PE200400420]
STG: (A1) Patent application
AP : 2003PE-0000857 2003-08-22
IS7672              A  2005-01-27 [IS---7672]
STG: (A) Patent application made available to the public
AP : 2005IS-0007672 2005-01-27
NO20050603          L  2005-03-17 [NO20050603]
STG: (L) Abstract
AP : 2005NO-0000603 2005-02-03
AP200503238         A0 2005-03-31 [AP200503238]
STG: (A0) Application filed, as announced in the Gazette published by this office
AP : 2005AP-0003238 2003-08-14
AR041047            A1 2005-04-27 [AR--41047]
STG: (A1) Independent patent application
AP : 2003AR-0103054 2003-08-25
MA27388             A1 2005-06-01 [MA--27388]
STG: (A1) Patent of invention
AP : 2005MA-0028121 2005-02-25
MXPA05002255        A  2005-06-08 [MX2005PA002255]
STG: (A) Patent application
AP : 2005MX-PA02255 2003-08-14
EP1536830           A1 2005-06-08 [EP1536830]
STG: (A1) Application published with search report
AP : 2003EP-0792580 2003-08-14
KR20050062542       A  2005-06-23 [KR20050062542]
STG: (A) Published application
AP : 2005KR-7003230 2005-02-25
HRP20050192         A2 2005-06-30 [HRP20050192]
STG: (A2) Patent application without search report
AP : 2005HR-0000192 2005-02-28
BR0313806           A  2005-07-05 [BR200313806]
STG: (A) Published application
AP : 2003BR-0013806 2003-08-14
BRPI0313806         A1 2005-07-05 [BRPI0313806]
STG: (A1) Published application
AP : 2003BR-0013806 2003-08-14
EA200500275         A1 2005-08-25 [EA200500275]
STG: (A1) Public. of applic. with search report
AP : 2005EA-0000275 2003-08-14
CN1678346           A  2005-10-05 [CN1678346]
STG: (A) Published application
AP : 2003CN-0820316 2003-08-14
PA8581101           A1 2005-11-25 [PA8581101]
STG: (A1) Patent application
AP : 2003PA-8581101 2003-08-25
PL375548            A1 2005-11-28 [PL2003375548]
STG: (A1) Application
AP : 2003PL-0375548 2003-08-14
JP2006501237        A  2006-01-12 [JP2006501237]
STG: (A) Published application
AP : 2004JP-0530459 2003-08-14
IL166825            A  2006-01-15 [IL-166825]
STG: (A) Application of patent for invention
AP : 2003IL-0166825 2003-08-14
OA12915             A  2006-10-13 [OA--12915]
STG: (A) Patent of invention
AP : 2005OA-1000058 2003-08-14
KR20060116037       A  2006-11-13 [KR20060116037]
STG: (A) Published application
AP : 2006KR-7022893 2006-10-31
ZA200501171         B  2006-12-27 [ZA200501171]
STG: (B)
AP : 2005ZA-0001171 2005-02-09
EP1743652           A1 2007-01-17 [EP1743652]
STG: (A1) Application published with search report
AP : 2006EP-0122758 2003-08-14
TWI272105           B  2007-02-01 [TWI272105]
STG: (B) Granted patent or patent of addition
AP : 2003TW-0122872 2003-08-20
TNSN05059           A1 2007-05-14 [TN0500059]
STG: (A1) Application for a patent of invention
AP : 2005TN-0000059 2005-02-25
CN1315534           C  2007-05-16 [CN1315534C]
STG: (C) Granted patent for invention
AP : 2003CN-0820316 2003-08-14
RS20050177          A  2007-06-04 [RS200500177]
STG: (A) Laid open patent application
AP : 2005YU-0000177 2003-08-14
US20070298053       A1 2007-12-27 [US20070298053]
STG: (A1) Application published
AP : 2007US-11897421 2007-08-30
FD :  Continuation of: US10/647,919 FDD=2003-08-26 [2003US-10647919]
FD : Provisional Appl: US60/405,969 FDD=2002-08-26 [2002US-60405969]
HK1078457           A1 2008-01-25 [HK1078457]
STG: (A1) Patent application
AP : 2005HK-0110344 2005-11-18
NZ538394            A  2008-06-30 [NZ-538394]
STG: (A) Published application
AP : 2003NZ-0538394 2003-08-14
AU2003263390        B2 2008-12-18 [AU2003263390]
STG: (B2) Patent proceeded by OPI
AP : 2003AU-0263390 2003-08-14
NZ565206            A  2008-12-24 [NZ-565206]
STG: (A) Published application
AP : 2003NZ-0565206 2003-08-14
FD :  Division of: NZ53839403 FDD=2003-08-14 [2003NZ-0538394]
AU2008258154        A1 2009-01-08 [AU2008258154]
STG: (A1) Open to public inspection
AP : 2008AU-0258154 2008-12-16
IN0391/DELNP/2005   A  2009-03-27 [IN2005DN00391]
STG: (A) Application laid open
AP : 2005IN-DN00391 2005-02-02
EA011578            B1 2009-04-28 [EA--11578]
STG: (B1) Patent
AP : 2005EA-0000275 2003-08-14
JP2009215309        A  2009-09-24 [JP2009215309]
STG: (A) Published application
AP : 2009JP-0118662 2009-05-15
FD :  Division of: JP2004530459 0 [2004JP-0530459]
HRP20090271         A2 2009-11-30 [HRP20090271]
STG: (A2) Patent application without search report
AP : 2009HR-0000271 2009-05-14
US20100266629       A1 2010-10-21 [US20100266629]
STG: (A1) Application published
AP : 2010US-12820566 2010-06-22
IN243935            B  2010-11-12 [IN-243935]
STG: (B) Patent
AP : 2005IN-DN00391 2005-02-02
UA94689             C2 2011-06-10 [UA--94689]
STG: (C2) Pat. grant. upon the USSR appl.,for which no pos. dec. made;grant. upon basis of national application
AP : 2005UA-0001771 2003-08-14
AU2008258154        B2 2011-07-21 [AU2008258154]
STG: (B2) Patent proceeded by OPI
AP : 2008AU-0258154 2008-12-16
FD :  Division of: AU2003263390 FDD=2003-08-14 [2003AU-0263390]
EP1743652           B1 2011-11-16 [EP1743652]
STG: (B1) Patent specification
AP : 2006EP-0122758 2003-08-14
FD :  Division of: EP03792580 FDD=2003-08-14 [2003EP-0792580]
FD : Division of: EP1536830 - 0 [EP1536830]
AT533506            T  2011-12-15 [ATE533506]
STG: (T) EP patent valid in AT
AP : 2006AT-0122758T 2003-08-14
ME00810             B  2012-03-20 [ME----810]
STG: (B)
AP : 2009ME-0000213 2003-08-14
JP2012092126        A  2012-05-17 [JP2012092126]
STG: (A) Published application
AP : 2011JP-0275303 2011-12-16
US20130129779       A1 2013-05-23 [US20130129779]
STG: (A1) Application published
AP : 2012US-13729206 2012-12-28
FD :  Continuation of: US12/820,566 FDD=2010-06-22 [2010US-12820566]
FD : Division of: US10/647,919 FDD=2003-08-26 [2003US-10647919]  abandoned
FD : Provisional Appl: US60/405,969 FDD=2002-08-26 [2002US-60405969]
HRP20050192         B1 2014-02-14 [HRP20050192]
STG: (B1) Granted patent
AP : 2005HR-0000192 2005-02-28
PL216541            B1 2014-04-30 [PL-216541]
STG: (B1) Patent
AP : 2003PL-0375548 2003-08-14
CA2496750           C  2014-10-21 [CA2496750]
STG: (C) Patent (second level)
AP : 2003CA-2496750 2003-08-14
JP5785073           B2 2015-07-31 [JP5785073]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2011JP-0275303 2011-12-16
FD :  Division of: JP2004530459 FDD=2003-08-14 [2004JP-0530459]
JP2015172069        A  2015-10-01 [JP2015172069]
STG: (A) Published application
AP : 2015JP-0113008 2015-06-03
FD :  Division of: JP2011275303 FDD=2003-08-14 [2011JP-0275303]
US9662384           B2 2017-05-30 [US9662384]
STG: (B2) Granted patent as second publication
AP : 2010US-12820566 2010-06-22
FD :  Division of: US10/647,919 FDD=2003-08-26 [2003US-10647919]  abandoned
FD : Provisional Appl: US60/405,969 FDD=2002-08-26 [2002US-60405969]
FD : Previous publication: US20100266629 A1 2010-10-21 [US20100266629]
BRPI0313806         A2 2019-04-09 [BRPI0313806]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2003BR-0013806 2003-08-14";19510;"WO2004017990        A1 2004-03-04 [WO200417990]
CA2496750           A1 2004-03-04 [CA2496750]
AU2003263390        A1 2004-03-11 [AU2003263390]
UY27948             A1 2004-03-31 [UY--27948]
TW200404565         A  2004-04-01 [TW200404565]
US20040081666       A1 2004-04-29 [US20040081666]
GT200300180         A  2004-05-18 [GT200300180]
PE04202004          A1 2004-07-24 [PE200400420]
IS7672              A  2005-01-27 [IS---7672]
NO20050603          L  2005-03-17 [NO20050603]
AP200503238         A0 2005-03-31 [AP200503238]
AR041047            A1 2005-04-27 [AR--41047]
MA27388             A1 2005-06-01 [MA--27388]
MXPA05002255        A  2005-06-08 [MX2005PA002255]
EP1536830           A1 2005-06-08 [EP1536830]
KR20050062542       A  2005-06-23 [KR20050062542]
HRP20050192         A2 2005-06-30 [HRP20050192]
BR0313806           A  2005-07-05 [BR200313806]
BRPI0313806         A1 2005-07-05 [BRPI0313806]
EA200500275         A1 2005-08-25 [EA200500275]
CN1678346           A  2005-10-05 [CN1678346]
PA8581101           A1 2005-11-25 [PA8581101]
PL375548            A1 2005-11-28 [PL2003375548]
JP2006501237        A  2006-01-12 [JP2006501237]
IL166825            A  2006-01-15 [IL-166825]
OA12915             A  2006-10-13 [OA--12915]
KR20060116037       A  2006-11-13 [KR20060116037]
ZA200501171         B  2006-12-27 [ZA200501171]
EP1743652           A1 2007-01-17 [EP1743652]
TWI272105           B  2007-02-01 [TWI272105]
TNSN05059           A1 2007-05-14 [TN0500059]
CN1315534           C  2007-05-16 [CN1315534C]
RS20050177          A  2007-06-04 [RS200500177]
US20070298053       A1 2007-12-27 [US20070298053]
HK1078457           A1 2008-01-25 [HK1078457]
NZ538394            A  2008-06-30 [NZ-538394]
AU2003263390        B2 2008-12-18 [AU2003263390]
NZ565206            A  2008-12-24 [NZ-565206]
AU2008258154        A1 2009-01-08 [AU2008258154]
IN0391/DELNP/2005   A  2009-03-27 [IN2005DN00391]
EA011578            B1 2009-04-28 [EA--11578]
JP2009215309        A  2009-09-24 [JP2009215309]
HRP20090271         A2 2009-11-30 [HRP20090271]
US20100266629       A1 2010-10-21 [US20100266629]
IN243935            B  2010-11-12 [IN-243935]
UA94689             C2 2011-06-10 [UA--94689]
AU2008258154        B2 2011-07-21 [AU2008258154]
EP1743652           B1 2011-11-16 [EP1743652]
AT533506            T  2011-12-15 [ATE533506]
ME00810             B  2012-03-20 [ME----810]
JP2012092126        A  2012-05-17 [JP2012092126]
US20130129779       A1 2013-05-23 [US20130129779]
HRP20050192         B1 2014-02-14 [HRP20050192]
PL216541            B1 2014-04-30 [PL-216541]
CA2496750           C  2014-10-21 [CA2496750]
JP5785073           B2 2015-07-31 [JP5785073]
JP2015172069        A  2015-10-01 [JP2015172069]
US9662384           B2 2017-05-30 [US9662384]
BRPI0313806         A2 2019-04-09 [BRPI0313806]";"2002US-60405969
2003AU-0263390
2003EP-0792580
2003IL-0166825
2003NZ-0538394
2003US-10647919
2003WO-IB03633
2007US-11897421
2008AU-0258154
2010US-12820566
2012US-13729206";"(EP1536830)
WO2004017990
(JP2006501237)
WO2004017990
(IS---7672)
WO2004017990
(NO20050603)
WO2004017990
(AP200503238)
WO2004017990
(MX2005PA002255)
WO2004017990
(KR20050062542)
WO2004017990
(IL-166825)
WO2004017990
(KR20060116037)
WO2004017990
(ZA200501171)
WO2004017990
(TN0500059)
WO2004017990
(CN1315534C)
WO2004017990
(RS200500177)
WO2004017990
(HK1078457)
WO2004017990
(NZ-538394)
WO2004017990
(AU2003263390)
WO2004017990
(NZ-565206)
WO2004017990
(EA--11578)
WO2004017990
(HRP20090271)
WO2004017990
(IN-243935)
WO2004017990
(AU2008258154)
WO2004017990
(ME----810)
WO2004017990
(HRP20050192)
WO2004017990
(PL-216541)
WO2004017990
(CA2496750)
WO2004017990
(BRPI0313806)
WO2004017990";"PFIZER
PFIZER PRODUCTS
ZOETIS
ZOETIS SERVICES
ZOETISU";"PFIZER
ZOETIS SERVICES";"(EP1536830)
US
(EP1743652)
US
(EP1743652)
US
(US20070298053)
US
(US20130129779)
US
(US20100266629)
US
(US9662384)
US
(WO200417990)
US




(IN2005DN00391)
US
(CA2496750)
US
(CA2496750)
US
(BRPI0313806)
US
(BRPI0313806)
US";"(EP1536830)
NAME=Pfizer Products Inc. Eastern Point Road , CITY=Groton, Connecticut 06340 , COUNTRY=US 

(EP1743652)
NAME=Pfizer Products Inc. Eastern Point Road , CITY=Groton, Connecticut 06340 , COUNTRY=US 

(EP1743652)
NAME=Pfizer Products Inc. Eastern Point Road , CITY=Groton, CT 06340 , COUNTRY=US , REG=100198232 

(US20070298053)
NAME=Pfizer, Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Pfizer Products, Inc. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 

(US20130129779)
NAME=Dominowski Paul Joseph , CITY=Kalamazoo , STATE=MI , COUNTRY=US 

NAME=Goodyear Mark D. , CITY=Lincoln , STATE=NE , COUNTRY=US 

NAME=Huether Michael John , CITY=Lincoln , STATE=NE , COUNTRY=US 

(US20100266629)
NAME=PFIZER INC , CITY=Kalamazoo , STATE=MI , COUNTRY=US , ATYP=US Company 

(US9662384)
NAME=Zoetis Services LLC , CITY=Parsippany , STATE=NJ , COUNTRY=US , ATYP=US Company 

(WO200417990)
NAME=PFIZER PRODUCTS INC.  [US/ US] Eastern Point Road, Groton, CT 06340  , COUNTRY=US 

(JP2006501237)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(JP2009215309)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(JP5785073)
NAME=ZOETIS P LLC , REG=512268158 

(TN0500059)
NAME=PFIZER PRODUCTS INC EASTERN POINT ROAD, GROTON, CONNECTICUT 06340 USA 

(IN2005DN00391)
NAME=PFIZER PRODUCTS INC; EASTERN POINT ROAD, GROTON, CONNECTICUT 06340  , COUNTRY=US 

(CA2496750)
NAME=PFIZER PRODUCTS INC. Eastern Point Road , CITY=GROTON , STATE=CT , POSTCODE=06340 , COUNTRY=US 

(CA2496750)
NAME=PFIZER PRODUCTS INC. Eastern Point Road , CITY=GROTON , STATE=CT , POSTCODE=06340 , COUNTRY=US 

(BRPI0313806)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 

(BRPI0313806)
NAME=ZOETIS SERVICES LLC , COUNTRY=US 
";2;DOMINOWSKI PAUL JOSEPH;"(EP1743652)
US
(EP1743652)
US";"(EP1743652)
NAME=Dominowski, Paul Joseph Pfizer Global Research & Dev., Eastern Point Road , CITY=Groton, CT 06340 , COUNTRY=US 

(EP1743652)
NAME=Dominowski, Paul Joseph Pfizer Global Research & Dev., Eastern Point Road Groton, CT 06340 , COUNTRY=US 
";"(EP1743652)
Vaccine for respiratory and reproductive system infections in cattle";"(EP1743652)
The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by one or more of the following : Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.";"(WO200417990)
What is claimed is:
1. An immunogenic composition comprising: a modified live Bovine Herpes Virus (BHV-1); a modified live parainfluenza virus Type 3 (Pl3); a modified live Bovine Respiratory Syncytial Virus (BRSV); an adjuvant; at least one antigen;and a veterinary-acceptable carrier.
2. The immunogenic composition of Claim 1 , wherein said antigen is inactivated.
3. The immunogenic composition of Claim 1 , wherein said adjuvant comprises a saponin; a saponin containing oil-in-water emulsion; and/or Quil A, Amphigen and cholesterol.
4. The immunogenic composition of Claim 1, wherein said antigen comprises at least one antigen selected from the group consisting of Bovine Viral Diarrhea Virus (BVDV-1), Bovine Viral Diarrhea Virus (BVDV-2), Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, and Campylobacter fetus.
5. The immunogenic composition of Claim 4, wherein said Bovine Viral Diarrhea Virus (BVDV-1 ) is cytopathic or noncytopathic; and said Bovine Viral Diarrhea Virus (BVDV-2) is cytopathic or noncytopathic.
6. A method of inducing an immune response, in an animal subject, against at least one of the following:
 (a) Bovine Herpes Virus Type 1 ;
 (b) Bovine Viral Diarrhea Virus Type- 1 ; (c) Bovine Viral Diarrhea Virus Type- 2;
 (d) parainfluenza virus Type 3 (PI3);
 (e) Bovine Respiratory Syncytial Virus (BRSV);
 (f) Campylobacter fetus; or
 (g) an antigen selected from the group consisting of Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia,
 Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, Neospora caninum, Trichomonus fetus, Mycoplasma, bovis, Haemophilus somnus, Mannheimia haemolytica and Pasturella multocida, comprising administering an immunologically effective amount of the composition of Claim 1 and a veterinary-acceptable carrier.
7. A vaccine composition comprising: a modified live Bovine Herpes Virus (BHV-1); a modified live parainfluenza virus Type 3 (PI3); a modified live Bovine Respiratory Syncytial Virus (BRSV); an adjuvant; at least one antigen;and a veterinarly-acceptable carrier.
8. A method of preventing abortion caused by a virus selected from the group consisting of BHV-1 in an animal comprising administering to said animal a therapeutically effective amount of the vaccine composition of Claim 7.
9. The method of Claim 8, wherein said animal is a cow, a calf, a heifer, a steer or a bull.
10. A method of treating or preventing a disease or disorder in an animal caused by infection with a virus selected from the group consisting of BVDV Type 1 or Type 2, BHV- 1 , PI3 or BRSV comprising administering to said animal a therapeutically effective amount of the vaccine composition of Claim 7. 11. A method of treating or preventing a disease or disorder in an animal caused by infection with an antigen selected from the group consisting Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjobovis, Leptospira Bratislava, Campylobacter fetus, Neospora caninum, Trichomonus fetus, Mycoplasma, bovis, Haemophilus somnus, Mannheimia haemolytica and Pasturella multocida, comprising administering to said animal a therapeutically effective amount of the vaccine composition of Claim 7.
12. A method of preventing persistent fetal infection in an animal subject, comprising administering to said animal an effective amount of the vaccine composition of Claim 7.
13. A vaccine composition comprising: a modified live Bovine Herpes Virus (BHV-1); a modified live parainfluenza virus Type 3 (PI3); a modified live Bovine Respiratory Syncytial Virus (BRSV); a cytopathic BVD-2; a BVD-1 ; an adjuvant; at least one antigen selected from the group consisting of Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio-prajitno, Leptospira icterohaemmorrhagia, and Leptospira interrogans pomona, Leptospira borgpetersenii hardjobovis, Leptospira Bratislava and Campylobacter fetus; and a veterinary-acceptable carrier.";"(EP1743652)
The present invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with IBR, BVDV, P13, BRSV, Campylobacter fetus and/or Leptospirae by administering to the animal, an effective amount of a combination vaccine.
The present invention provides vaccines for the treatment and prevention of the major infectious causes of respiratory and reproductive disease in animals, such as cows and calves.
The present invention further provides immunogenic compositions and methods of treating or preventing diseases or disorders in animals.
The present invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with at least one of, BVDV Type 1 or Type 2, BHV-1, P13, BRSV, Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo-bovis and Leptospira interrogans pomona comprising administering to the animal, an effective amount of a combination vaccine.
The present invention provides vaccines for the treatment and prevention of the major infectious causes of respiratory and reproductive disease in animals, such as cows and calves.
The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Para influenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo-bovis and Leptospira interrogans pomona by administering to the animal an effective amount of a combination vaccine.";"(EP1743652)
Studies have established that the virus causes severe primary respiratory disease; that persistently infected (PI) cattle are a major source of infection for susceptible calves; and that BVDV infects white cell reservoirs, causing profound and broad-based deficits in the immune system.
Wschr. 81:481-487 (1974) and are highly predisposed to infection with microorganisms causing diseases such as pneumonia or enteric disease (Barber, et al., Vet.
Some inactivated BVDV vaccines provide protection against infection by type I BVDV only (Beer et al., Vet.
major source of infection";"A61K
A61K-009/107
A61K-039/00
A61K-039/02
A61K-039/12
A61K-039/155
A61K-039/245
A61K-039/265
A61K-039/295
A61K-039/39
A61K-047/02
A61K-047/18
A61K-047/24
A61K-047/28
A61K-047/44
A61P
A61P-011/00
A61P-015/00
A61P-015/06
A61P-031/04
A61P-031/12
A61P-031/14
A61P-031/20
A61P-031/22
A61P-037/02
A61P-037/04
A61P-039/00
C07K-014/005
C07K-014/115
C07K-014/135
C07K-014/18
C12N-001/00
C12N-001/20
C12N-007/01
C12P-019/34";"(EP1743652)
1. An immunogenic composition comprising a viral component, a bacterial component, and a veterinary-acceptable carrier, wherein the viral component comprises one or both antigens selected from a Bovine Viral Diarrhea Virus Type-1 (BVDV-1) and a Bovine Viral Diarrhea Virus Type-2 (BVDV-2), and wherein the bacterial component comprises one or both antigens selected from Leptospira interrogans pomona and Leptospira borgpetersenii hardjo-bovis.";"(EP1743652)
VACCINE(100,40)
CATTLE(100,19)
REPRODUCTIVE SYSTEM INFECTION(100,2)
LEPTOSPIRA INTERROGAN POMONA(99,2)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(92,2)
BORGPETERSENII HARDJO BOVIS(86,8)
LEPTOSPIRA INTERROGAN(59,6)
HEALTHY CATTLE VACCINATION(59,1)
MEDICAMENT MANUFACTURE(58,5)
PERSISTENTLY INFECTED CATTLE(57,1)
AGRICULTURE US DEPARTMENT(49,1)
LEPTOSPIRA GRIPPOTYPHOSA(45,6)
PERSISTENTLY INFECTED CALF(45,2)
BACTERIAL COMPONENT(44,2)
GASTROINTESTINAL DISEASE(43,1)
LEPTOSPIRA CANICOLA(42,5)
SUSCEPTIBLE CALF(41,1)
PERSISTENT FETAL INFECTION(38,5)
IMMUNOGENIC(37,10)
ANTIBIOTIC UG ML(34,2)
SEVERE PRIMARY RESPIRATORY DISEASE(34,1)
BOVINE VIRAL DIARRHEA VIRUS(33,259)
LEPTOSPIRA(33,16)
MAJOR INFECTIOUS CAUSE PREVENTION(33,1)
AGE MONTH(32,8)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(32,4)
DISEASE(31,11)
ETHANE DIOCTADECYLAZANIUM BROMIDE(31,2)
ANIMAL SUBJECT(30,7)
CALF NURSING PREGNANT COW(30,4)
ANIMAL(29,52)
ANTIGEN(27,8)
MAJOR INFECTION SOURCE(27,1)
VACCINE MANUFACTURE(26,1)
INFECTION(25,26)
MICROORGANISM(25,1)
COW(23,62)
CALF(23,5)
DISORDER(23,4)
PNEUMONIA(23,1)
VETERINARY ACCEPTABLE CARRIER(22,7)
ATTENDING VETERINARIAN SUPERVISION(22,3)
WHITE CELL RESERVOIR(22,1)
PLACEBO COW(21,12)
VIRAL COMPONENT(21,2)
BARBER(21,1)
VACCINATED COW(20,8)
CAMPYLOBACTER FETUS(20,7)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(20,2)
LEPTOSPIRA SEROVAR HARDJO(20,2)
GESTATION DAY(19,10)
LIVE PREPARATION(19,3)
BOVINE VIRAL DIARRHEA VIRUS TYPE(18,6)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(18,4)
CHORIONIC EPITHELIUM NECROSIS(18,2)
VIRUS(17,37)
BROAD BASED DEFICIT(16,1)
LEPTOSPIRA IMMUNIZING ANTIGEN POTENCY(16,1)
VET(15,17)
PARAINFLUENZA VIRUS(15,3)
SEROLOGIC ASSAY SERUM(15,3)
CORNELL UNIVERSITY COLLEGE(15,2)
FETAL CHALLENGE STUDY TERMINATION(15,2)
MICROFLUIDIZED(15,2)
REVEALED DIFFUSE NECROPURULENT PLACENTITIS(15,1)
VIRULENT ORGANISM URINARY SHEDDING(15,1)
BORGPETERSENII SEROVAR HARDJO(14,1)
GENUS LEPTOSPIRA SPIROCHETE(14,1)
IMMUNE(14,1)
INTESTINAL MUCOSA ULCERATION(14,1)
SASKATOON VETERINARY BIODIAGNOSTICS(14,1)
UNKNOWN FETUS(13,5)
DUPLICATE EAR(13,3)
HAEMOPHILUS SOMNUS(13,3)
PASTURELLA MULTOCIDA(13,3)
TRICHOMONUS FETUS(13,3)
AFFIRMED VACCINE ANTIGENICITY(13,1)
LEPTOSPIRE URINARY SHEDDING(13,1)
ANIMAL BREEDING(12,6)
RESPIRATORY SYNCYTIAL VIRUS VACCINE(12,4)
VIRUS ISOLATION ATTEMPT(12,4)
ANTIGEN IMMUNIZATION(12,3)
NATIONAL ANIMAL DISEASE CENTER(12,3)
NEBRASKA UNIVERSITY(12,3)
PARTIAL CELL(12,3)
PLACEBO VACCINE(12,3)
SERUM SERIAL DILUTION(12,3)
CHALLENGE VIRUS POTENCY(12,2)
COW PREGNANCY STATUS(12,2)
MIDWEST VETERINARY SERVICE(12,2)
POSTCHALLENGE VIRUS ISOLATION(12,2)
FETUS REVEALED PNEUMONIA EVALUATION(12,1)
IMMUNOTOLERANT FETUS INFECTION(12,1)
LEPTOSPIRA MONOVALENT VACCINE(12,1)
PREGNANT CATTLE PLACENTA(12,1)
SUBCUTANEOUS VACCINATION AABORTION(12,1)
ABORTION ETIOLOGY(11,2)
FETAL TISSUE HISTOPATHOLOGIC EVALUATION(11,2)
VETERINARY MEDICINE DIAGNOSTIC LABORATORY(11,2)
CATTLE LEPTOSPIRAL INFECTION(11,1)
COW VIREMIA INCIDENCE(11,1)
CYTOPATHIC VIRUS BIOTYPE(11,1)
DIFFUSE PURULENT PNEUMONIA(11,1)
INTENSE NEUTROPHILIC INFLAMMATION(11,1)
LEPTOSPIRA INFECTION INCIDENCE(11,1)
ADVENTITIOUS EXPOSURE(10,3)
BULK TITRATION(10,3)
CESAREAN DELIVERY(10,3)
COW BLOOD PERIPHERAL(10,3)
EXPERIMENTAL TEST VACCINE(10,3)
STATISTICAL SIGNIFICANCE(10,3)
STERILE ADJUVANT(10,3)
VIABLE CHALLENGE(10,3)
VIRUS CHALLENGE(10,3)
ANTICIPATED CALVING(10,2)
CHALLENGE INOCULUM(10,2)
CLOSTRIDIAL INFECTION(10,2)
COW FINAL PREGNANCY STATUS(10,2)
FAILED PREGNANCYC(10,2)
INFECTION SYMPTOM(10,2)
INTRANASAL INOCULATION(10,2)
NEARBY ISOLATION FACILITY(10,2)
QUALIFIED VETERINARY DIAGNOSTIC CENTER(10,2)
RECIPROCAL SERUM NEUTRALIZING TITER(10,2)
SEROLOGIC DATA(10,2)
TS MUTANT STRAIN(10,2)
VETERINARY PHYSICIAN(10,2)
BREEDING AGE HEIFER(10,1)
CLASS IC SHIPPING FEVER SYNDROME(10,1)
LEPTOSPIRA SHEDDING DURATION(10,1)
MARKED SUPPURATIVE INFLAMMATION(10,1)
POSTCHALLENGE VIREMIA ABSENCE(10,1)
VIRUS NEUTRALIZATION ASSAY(10,1)
COMBINATION VACCINE(9,26)
INFECTIOUS BOVINE RHINOTRACHEITIS(9,24)
LEPTOSPIROSIS(9,9)
TEST ANIMAL(9,9)
ANNUAL BASIS(9,6)
BOVINE CELL CULTURE(9,5)
IOWA(9,3)
ANTIBODY FLUORESCENCE MICROSCOPY(9,1)
CALF BIRTH(9,1)
EXTENSIVE FETAL AUTOLYSIS(9,1)
IMMUNITY SEVERE CHALLENGE(9,1)
INTERNATIONAL SYMPOSIUM PROCEEDING(9,1)
KIDNEY TISSUE HOMOGENATE(9,1)
NECROTIZING PLACENTITIS(9,1)
SEMI ANNUAL REVACCINATION(9,1)
SUPPURATIVE VASCULTISIS(9,1)
THORACIC FLUID SEROLOGIC ASSAY(9,1)
UNDETECTED ABORTION(9,1)
VIRULENT STRAIN ATTENUATION(9,1)
PLACEBO GROUP(8,8)
CHALLENGE DAY(8,3)
FETAL BRAIN(8,3)
FISHER EXACT TEST(8,3)
IMMUNOHISTOCHEMISTRY POSITIVE(8,3)
STUDY DURATION(8,3)
ASCITE DILUTION(8,2)
ATTENUATED VIRUS(8,2)
BFETAL TISSUE(8,2)
BOVINE CYTOKINE(8,2)
BRED COW(8,2)
BUFFY COAT CELL PREPARATION(8,2)
CONFIRMED PREGNANCY(8,2)
DESICCATED INFECTIOUS BOVINE RHINOTRACHEITIS(8,2)
FETAL PROTECTION STUDY(8,2)
FETUS EVALUATION(8,2)
HARDJO BOVIS STRAIN(8,2)
INOCULATED ANIMAL(8,2)
INTRA LYMPH NODE(8,2)
NCP VIRUS(8,2)
PERSISTENT INFECTION(8,2)
PLURONIC POLYOL(8,2)
POLYCLONAL ANTIBODY(8,2)
POSTCHALLENGE INTERVAL(8,2)
PRECHALLENGE INTERVAL(8,2)
REPRODUCTIVE DISEASE(8,2)
RT PCR ANALYSIS(8,2)
SAPONIN DERIVATIVE(8,2)
SERUM NEUTRALIZATION TITER(8,2)
SERUM SAMPLE PAIR(8,2)
STUDY OUTSET(8,2)
VETERINARY DIAGNOSITIC CENTER(8,2)
CATTLE PESTIVIRUS(8,1)
CESAREAN DERIVED FETUS PLUS(8,1)
CHOLESTEROL AMPHIGEN(8,1)
CLINICAL SIGN EVIDENCE(8,1)
FATAL MANIFESTATION(8,1)
FETUS ABORTION(8,1)
HARDJO BOVIS BACTERIN(8,1)
HARDJO BOVIS VACCINE(8,1)
HERD FERTILITY(8,1)
LEPTOSPIRA BACTERIA(8,1)
LEPTOSPIRA SERONEGATIVE(8,1)
LIPID AMINE ADJUVANT(8,1)
MULTIFOCAL THROMBOSIS(8,1)
NONCYTOPATHIC CHALLENGE(8,1)
PESTIVIRUS GENUS(8,1)
PLACENTAL LAMINA PROPRIA(8,1)
POSTCHALLENGE INCIDENCE(8,1)
PURULENT INFLAMMATION(8,1)
RE LATED ABORTION(8,1)
SEVERELY AFFECTED CATTLE(8,1)
UNOBSERVED ABORTION(8,1)
VACCINE DOSE ADMINISTRATION(8,1)
VACCINE EFFICACY MEASURE(8,1)
VIRUS ACCELERATED ELIMINATION(8,1)
BOVINE RESPIRATORY SYNCITIAL VIRUS(7,16)
PERSISTENTLY INFECTED(7,15)
DAM(7,6)
BOVINE ANIMAL(7,2)
COMMERCIAL VACCINE(7,2)
FETAL TISSUE HOMOGENIZATION(7,2)
HUMAN HANDLER(7,2)
HUMORAL IMMUNE RESPONSE(7,2)
IMMUNOHISTOCHEMISTRY EVALUATION(7,2)
INFECTION RISK(7,2)
MINERAL OIL EMULSION(7,2)
MODIFIED LIVE ANTIGEN(7,2)
PFIZER CENTRAL RESEARCH(7,2)
POSTCHALLENGE SAMPLE(7,2)
PROSTAGLANDIN INJECTION(7,2)
SEROLOGIC SAMPLE(7,2)
VIRUS IDENTITY(7,2)
ACUTE FATAL DISEASE(7,1)
ACUTE ONSET RESPIRATORY DISEASE(7,1)
ALPHAHERPESVIRIDA SUBFAMILY MEMBER(7,1)
BIPHASIC FEVER(7,1)
BOOSTING REGIMEN(7,1)
CATTLE URINE(7,1)
CLASSICAL SWINE FEVER(7,1)
CLINICAL SYNDROME BROAD ARRAY(7,1)
CLOSTRIDIAL DISEASE(7,1)
COLIFORM BACTERIUM(7,1)
COMPENDIUM COLLECTION(7,1)
EYE CONJUNCTIVAL SAC(7,1)
EYE VITREOUS HUMOR(7,1)
FETAL ORGAN(7,1)
FLAVIVIRIDAE FAMILY(7,1)
FROTHY SALIVA(7,1)
GALENICA PHARMACEUTICAL(7,1)
GIV GLYCOPROTEIN(7,1)
HACKING COUGH(7,1)
HAMSTER LETHALITY(7,1)
HARDJO CHALLENGE(7,1)
HISTOPATHOLOGIC EXAMINATION(7,1)
IMMUNOCOMPETENT ANIMAL(7,1)
INACTIVATED VIRAL VACCINE(7,1)
INFECTED CATTLE EXHIBIT(7,1)
INFLAMED MUZZLE(7,1)
INFLAMMATORY EXUDATE(7,1)
INFLAMMATORY FOCI(7,1)
INTRAMUSCULAR VACCINATION(7,1)
ISOLATION POSTCHALLENGE(7,1)
KIDNEY COLONIZATION(7,1)
KIDNEY INFECTION(7,1)
KILLED LEPTOSPIRE(7,1)
LABORED BREATHING(7,1)
LACTATING COW(7,1)
LEPTOSPIRA ANTIGEN(7,1)
LEPTOSPIRA FLUORESCENT ANTIBODY(7,1)
LEPTOSPIRA PROTECTION STUDY(7,1)
LEPTOSPIRA URINE(7,1)
MATERNAL DEATHA(7,1)
MONTH OLD CALF(7,1)
MUCOSAL DISEASE OUTBREAK(7,1)
NECROPSY FACILITY(7,1)
NEEDLELESS ADMINISTRATION(7,1)
NON HUMAN MAMMAL(7,1)
NON VACCINATED ANIMAL(7,1)
PAIRED POST ABORTION(7,1)
PAIRED SEROLOGY(7,1)
POMONA VACCINE(7,1)
PROTEUS VULGARIS(7,1)
SEROLOGIC EVIDENCE(7,1)
SEROPOSITIVE COW(7,1)
SERUM MICROSCOPIC AGGLUTINATION TITERS(7,1)
THORACIC FLUID SEROLOGY(7,1)
VACCINATED CATTLE(7,1)
VACCINE CHALLENGE(7,1)
VACCINE INGREDIENT(7,1)
VETERINARY MEDICINE COLLEGE(7,1)
VIRAL BIOTYPE(7,1)
SPONTANEOUS ABORTION(6,5)
ABORTED FETUS(6,4)
ESTRUM(6,4)
RECTAL PALPATION(6,4)
VACCINATION GROUP(6,4)
VACCINE GROUP(6,4)
CHALLENGE AGENT(6,3)
DECREASING SERUM ASSAY(6,3)
MANNHEIMIA HAEMOLYTICA(6,3)
MYCOPLASMA BOVIS(6,3)
NEOSPORA CANINUM(6,3)
SERUM NEUTRALIZING ASSAY(6,3)
STATISTICALLY SIGNIFICANT REDUCTION(6,3)
CONSECUTIVE DAY(6,2)
ACTIVE BVDV REPLICATION(6,1)
ADJUVANT FORMULATION(6,1)
ADMINISTRATION SCHEDULE(6,1)
ADSORPTION DELAYING(6,1)
AGRICULTURE UNITED STATES DEPARTMENT(6,1)
ANIMAL LIVE BIRTH(6,1)
BACTERIAL COCCI(6,1)
BOVINE FETUS(6,1)
CATTLE HERPES(6,1)
CHALLENGE POTENCY(6,1)
CHALLENGE ROUTE(6,1)
CHOLERA TOXIN(6,1)
CONNECTIVE TISSUE(6,1)
COW CALF(6,1)
COW NEGATIVE PERCENTAGE(6,1)
DAIRY HERD(6,1)
DEAD COW(6,1)
DOSAGE REGIMEN(6,1)
ECONOMIC IMPORTANCE(6,1)
EMERYVILLE CA(6,1)
FATAL MUCOSAL DISEASE(6,1)
HARDJOBOVIS ISOLATION DATA SHOW(6,1)
HARSH COUGH(6,1)
HEALTH OBSERVATION(6,1)
HUMORAL ANTIBODY(6,1)
IMMUNIZING DOSE(6,1)
IMMUNOMODULATORY AGENT(6,1)
IMMUNOTOLERANCE DEVELOPMENT(6,1)
INACTIVATED ANTIGEN(6,1)
INFECTED CALF(6,1)
INFECTION SEVERITY(6,1)
INFECTIOUS DISEASE(6,1)
ISOLATION URINE SAMPLE(6,1)
KEY VIRAL PROTEIN(6,1)
KIDNEY CULTURE NEGATIVE(6,1)
LACTATING ANIMAL(6,1)
LEPTOSPIRA DISEASE(6,1)
LEPTOSPIRE ISOLATION(6,1)
MANUFACTURER INSTRUCTION(6,1)
MILD DIARRHEA(6,1)
MUCOUS MEMBRANE NECROSIS(6,1)
NATURAL INFECTION ROUTE(6,1)
NURSING COW(6,1)
OPTIMAL IMMUNIZATION(6,1)
PHYSIOLOGICAL SALINE(6,1)
PLACENTAL TISSUE(6,1)
POSITIVE FETAL TISSUE IMMUNOHISTOCHEMISTRY(6,1)
POSITIVE SEROCONVERSION STATUS(6,1)
PRECHALLENGE SERUM NEUTRALIZING(6,1)
PREDOMINANT STRAIN(6,1)
PREGNANT ANIMAL(6,1)
PULMONARY INFECTION(6,1)
RECOVERED FETUS(6,1)
RESEARCH ISOLATION FACILITY(6,1)
RESEARCH WORKER CONFERENCE(6,1)
SALINE PLACEBO(6,1)
SAPONIN FRACTION(6,1)
SEROUS NASAL(6,1)
SERUM NEUTRALIZING TITER RANGING(6,1)
SOLE DETERMINANT(6,1)
VACCINE FORMULATION(6,1)
VETERINARY LABORATORY(6,1)
VIABLE ORGANISM(6,1)
VIRAL SUBUNIT(6,1)
VIREMIA NEGATIVE COW PERCENTAGE(6,1)
VIRUS GROWTH(6,1)
DAILY BASIS(5,3)
PRESERVATIVE(5,3)
RESPIRATORY INFECTION(5,3)
VACCINATED GROUP(5,3)
ACTIVE INGREDIENT(5,2)
ANEMNESTIC RESPONSE(5,2)
ANIMAL PERCENT(5,2)
ANTIBODY PRESENCE(5,2)
CAMPYLOBACTERIOSIS(5,2)
CHEMICAL INACTIVATION(5,2)
FOOD ANIMAL PRACTICE(5,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(5,2)
ISOTONIC AGENT(5,2)
MINERAL GEL(5,2)
NEGATIVE SEMEN(5,2)
PC INTERVAL(5,2)
SEROLOGIC RESPONSE(5,2)
SERUM NEUTRALIZING DATA(5,2)
STAPHYLOCOCCUS HYICUS(5,2)
TRIMESTER(5,2)
VEGETABLE OIL EMULSION(5,2)
ACUTE FEVER(5,1)
ANIMAL AGE(5,1)
BLOOD SAMPLE SEROLOGIC TESTING(5,1)
BOVINE RESPIRATORY DISEASE AGENT(5,1)
BREEDING FAILURE(5,1)
CAMBRIDGE MA(5,1)
CATTLE PROTECTION(5,1)
CESAREAN DERIVED CALF(5,1)
CLINICAL SYNDROME VARIETY(5,1)
CONTAMINATION(5,1)
CP VARIANT(5,1)
CURRENT VETERINARY THERAPY(5,1)
DAIRY INDUSTRY(5,1)
DOSE ANIMAL DOSING INTERVAL(5,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(5,1)
FIFTY YEAR REVIEW(5,1)
FOOD UPTAKE(5,1)
GESTATION HALF(5,1)
HANA VAN(5,1)
HARDJO BOVIS ORGANISM ML(5,1)
IMMUNITY DURATION(5,1)
INACTIVATED WHOLE(5,1)
KILLED COMBINATION BACTERIN(5,1)
LEPTOSPIRA CELL PREPARATION(5,1)
MAJOR GENOTYPE(5,1)
MARKED ANAMNESTIC RESPONSE(5,1)
MILD DISEASE(5,1)
MODIFIED LIVE VACCINE PREPARATION(5,1)
MONOCLONAL ANTIBODY PANEL(5,1)
MULTICOMPONENT(5,1)
OCULAR DISCHARGE(5,1)
PAIRED SERUM(5,1)
PC VIREMIA RATE(5,1)
POOLED FETAL TISSUE(5,1)
SEROLOGY DATA SHOW(5,1)
STATISTICALLY SIGNIFICANT DIFFERENCE FAVORING(5,1)
SYSTEMIC AFFECT(5,1)
THREE PRECHALLENGE SEROLOGIC STATUS(5,1)
TISSUE CULTURE(5,1)
TRUNCATED VERSION(5,1)
URINE KIDNEY CULTURE BASIS(5,1)
VIRUS ISOLATION NEGATIVE(5,1)
VIRUS STRAIN(5,1)
LUNG(4,5)
THYMUS(4,5)
MODIFIED LIVE VIRUS VACCINE(4,3)
ACTIVE SUBSTANCE(4,2)
ADJUVANT COMBINATION(4,2)
ALHYDROGEL(4,2)
ARTIFICIAL INSEMINATION(4,2)
ASPIRATION(4,2)
BAYOLF(4,2)
BLOOD SAMPLE PAIR(4,2)
CARBOPOL(4,2)
COW GROUP(4,2)
CYTOPATHIC EFFECT(4,2)
DEXTROSE(4,2)
DINOPROST TROMETHAMINE(4,2)
DIVIDED DOSE(4,2)
EMULSIFIER(4,2)
EXTRA(4,2)
FETAL RESORPTION(4,2)
GENTAMICIN(4,2)
GLYCOSIDE(4,2)
HEMORRHAGE(4,2)
INACTIVATED L(4,2)
INDIRECT IMMUNOFLUORESCENCE(4,2)
JUGULAR VEIN(4,2)
LEFT FLANK LAPAROTOMY(4,2)
LEPTOSPIRA COMBINATION VACCINE(4,2)
LYSOLECITHIN(4,2)
MONOVALENT L(4,2)
NOSTRIL(4,2)
POLYANION(4,2)
PREGNANCY GROUP TREATMENT(4,2)
PROTECTIVE RESPONSE(4,2)
REHYDRATION(4,2)
REPEATED MEASURE(4,2)
SEROTYPE(4,2)
SUPERNATANT(4,2)
THIMEROSAL(4,2)
UTERUS(4,2)
VAGINAL ADMINISTRATION(4,2)
VIBRIOSIS(4,2)
WHOLE BLOOD(4,2)
ANIMAL DOSE(4,1)
ANTIGEN VARIETY(4,1)
ANTIGENIC DIFFERENCE(4,1)
BOVINE VIRAL DIARRHEA VIRUS PREPARATION(4,1)
BRAINSTEM MIDBRAIN(4,1)
BVDV PERMANENT SOURCE(4,1)
CAFTLEMASTER PREGSURE(4,1)
CATTLE CONDITION(4,1)
CONSERVATIVE(4,1)
COW PERIPHERAL BLOOD(4,1)
CULTURE FLUID(4,1)
DISEASE TRANSMISSION(4,1)
(EP1743652)
CATTLE(100,33)
VACCINE(100,33)
INACTIVATED LEPTOSPIRA INTERROGAN POMONA(100,4)
REPRODUCTIVE SYSTEM INFECTION(100,2)
BORGPETERSENII HARDJO BOVIS(46,5)
DIMETHYLDIOCTADECYLAMMONIUM BROMIDE(34,1)
PERSISTENTLY INFECTED CATTLE(33,1)
VETERINARY ACCEPTABLE CARRIER(27,10)
IMMUNOGENIC(25,16)
GASTROINTESTINAL DISEASE(25,1)
SUSCEPTIBLE CALF(24,1)
BACTERIAL COMPONENT(23,2)
PROTECTIVE IMMUNE RESPONSE(21,3)
ANTIBIOTIC UG ML(20,2)
SEVERE PRIMARY RESPIRATORY DISEASE(20,1)
MAJOR INFECTIOUS CAUSE PREVENTION(19,1)
DISEASE(18,11)
BOVINE VIRAL DIARRHEA VIRUS(17,263)
DIMETHYLDIOCTADECYLAZANIUM BROMIDE(16,2)
MAJOR INFECTION SOURCE(15,1)
MEDICAMENT MANUFACTURE(15,1)
VACCINE MANUFACTURE(15,1)
COW(14,68)
LEPTOSPIRA(14,10)
CHOLESTEROL(14,7)
MICROORGANISM(14,1)
CALF(13,12)
ATTENDING VETERINARIAN SUPERVISION(13,3)
BVDV(13,3)
PNEUMONIA(13,1)
PLACEBO COW(12,12)
CALF NURSING PREGNANT COW(12,2)
BARBER(12,1)
WHITE CELL RESERVOIR(12,1)
INFECTION(11,24)
GESTATION DAY(11,10)
VACCINATED COW(11,8)
BOVINE VIRAL DIARRHEA VIRUS TYPE(11,4)
LEPTOSPIRA SEROVAR HARDJO(11,2)
VIRAL COMPONENT(11,2)
ANIMAL(10,42)
PERSISTENT FETAL INFECTION(10,4)
PROTECTIVE RESPONSE(10,4)
CHORIONIC EPITHELIUM NECROSIS(10,2)
VIRUS(9,34)
VET(9,15)
SEROLOGIC ASSAY SERUM(9,3)
CORNELL UNIVERSITY COLLEGE(9,2)
BROAD BASED DEFICIT(9,1)
LEPTOSPIRA IMMUNIZING ANTIGEN POTENCY(9,1)
AGE MONTH(8,7)
DISORDER(8,4)
DUPLICATE EAR(8,3)
FETAL CHALLENGE STUDY TERMINATION(8,2)
BORGPETERSENII SEROVAR HARDJO(8,1)
GENUS LEPTOSPIRA SPIROCHETE(8,1)
IMMUNE(8,1)
INTESTINAL MUCOSA ULCERATION(8,1)
LEPTOSIRA BORGPETERSENII HARDJO BOVIS(8,1)
LEPTOSPIRA INTERROGAN POMONA(8,1)
REVEALED DIFFUSE NECROPURULENT PLACENTITIS(8,1)
SASKATOON VETERINARY BIODIAGNOSTICS(8,1)
VIRULENT ORGANISM URINARY SHEDDING(8,1)
UNKNOWN FETUS(7,5)
RESPIRATORY SYNCYTIAL VIRUS VACCINE(7,4)
VIRUS ISOLATION ATTEMPT(7,4)
ANTIGEN IMMUNIZATION(7,3)
NEBRASKA UNIVERSITY(7,3)
PLACEBO VACCINE(7,3)
SERUM SERIAL DILUTION(7,3)
CHALLENGE VIRUS POTENCY(7,2)
COW PREGNANCY STATUS(7,2)
MIDWEST VETERINARY SERVICE(7,2)
POSTCHALLENGE VIRUS ISOLATION(7,2)
AFFIRMED VACCINE ANTIGENICITY(7,1)
FETUS REVEALED PNEUMONIA EVALUATION(7,1)
IMMUNOTOLERANT FETUS INFECTION(7,1)
LEPTOSPIRA MONOVALENT VACCINE(7,1)
LEPTOSPIRE URINARY SHEDDING(7,1)
PREGNANT CATTLE PLACENTA(7,1)
SUBCUTANEOUS VACCINATION AABORTION(7,1)
ADVENTITIOUS EXPOSURE(6,3)
BULK TITRATION(6,3)
CESAREAN DELIVERY(6,3)
COW BLOOD PERIPHERAL(6,3)
EXPERIMENTAL TEST VACCINE(6,3)
STATISTICAL SIGNIFICANCE(6,3)
STERILE ADJUVANT(6,3)
VIABLE CHALLENGE(6,3)
VIRUS CHALLENGE(6,3)
ABORTION ETIOLOGY(6,2)
FETAL TISSUE HISTOPATHOLOGIC EVALUATION(6,2)
LEPTOSPIRA BACTERIA(6,2)
VETERINARY MEDICINE DIAGNOSTIC LABORATORY(6,2)
CATTLE LEPTOSPIRAL INFECTION(6,1)
COW VIREMIA INCIDENCE(6,1)
CYTOPATHIC VIRUS BIOTYPE(6,1)
DIFFUSE PURULENT PNEUMONIA(6,1)
HEALTHY CATTLE VACCINATION(6,1)
INTENSE NEUTROPHILIC INFLAMMATION(6,1)
LEPTOSPIRA INFECTION INCIDENCE(6,1)
LEPTOSPIROSIS(5,9)
TEST ANIMAL(5,9)
PLACEBO GROUP(5,8)
BOVINE CELL CULTURE(5,5)
ANIMAL BREEDING(5,4)
IOWA(5,4)
BINARY ETHYLENEIMINE(5,3)
CHALLENGE DAY(5,3)
FETAL BRAIN(5,3)
FISHER EXACT TEST(5,3)
IMMUNOHISTOCHEMISTRY POSITIVE(5,3)
STUDY DURATION(5,3)
ANTICIPATED CALVING(5,2)
ASCITE DILUTION(5,2)
BFETAL TISSUE(5,2)
BOVINE CYTOKINE(5,2)
BRED COW(5,2)
BUFFY COAT CELL PREPARATION(5,2)
CHALLENGE INOCULUM(5,2)
CLOSTRIDIAL INFECTION(5,2)
CONFIRMED PREGNANCY(5,2)
COW FINAL PREGNANCY STATUS(5,2)
DESICCATED INFECTIOUS BOVINE RHINOTRACHEITIS(5,2)
FAILED PREGNANCYC(5,2)
FETAL PROTECTION STUDY(5,2)
FETUS EVALUATION(5,2)
HARDJO BOVIS STRAIN(5,2)
INFECTION SYMPTOM(5,2)
INOCULATED ANIMAL(5,2)
INTRA LYMPH NODE(5,2)
INTRANASAL INOCULATION(5,2)
NCP VIRUS(5,2)
NEARBY ISOLATION FACILITY(5,2)
PLURONIC POLYOL(5,2)
POLYCLONAL ANTIBODY(5,2)
POSTCHALLENGE INTERVAL(5,2)
PRECHALLENGE INTERVAL(5,2)
QUALIFIED VETERINARY DIAGNOSTIC CENTER(5,2)
RECIPROCAL SERUM NEUTRALIZING TITER(5,2)
RT PCR ANALYSIS(5,2)
SAPONIN DERIVATIVE(5,2)
SEROLOGIC DATA(5,2)
SERUM NEUTRALIZATION TITER(5,2)
SERUM SAMPLE PAIR(5,2)
STUDY OUTSET(5,2)
VETERINARY DIAGNOSITIC CENTER(5,2)
VETERINARY PHYSICIAN(5,2)
ANTIBODY FLUORESCENCE MICROSCOPY(5,1)
BREEDING AGE HEIFER(5,1)
CALF BIRTH(5,1)
CLASS IC SHIPPING FEVER SYNDROME(5,1)
EXTENSIVE FETAL AUTOLYSIS(5,1)
IMMUNITY SEVERE CHALLENGE(5,1)
INTERNATIONAL SYMPOSIUM PROCEEDING(5,1)
KIDNEY TISSUE HOMOGENATE(5,1)
LEPTOSPIRA SHEDDING DURATION(5,1)
MARKED SUPPURATIVE INFLAMMATION(5,1)
NECROTIZING PLACENTITIS(5,1)
PARAINFLUENZA VIRUS(5,1)
POSTCHALLENGE VIREMIA ABSENCE(5,1)
SEMI ANNUAL REVACCINATION(5,1)
SUPPURATIVE VASCULTISIS(5,1)
THORACIC FLUID SEROLOGIC ASSAY(5,1)
UNDETECTED ABORTION(5,1)
VIRULENT STRAIN ATTENUATION(5,1)
VIRUS NEUTRALIZATION ASSAY(5,1)
DAM(4,6)
ANNUAL BASIS(4,4)
CHALLENGE AGENT(4,3)
DECREASING SERUM ASSAY(4,3)
SERUM NEUTRALIZING ASSAY(4,3)
STATISTICALLY SIGNIFICANT REDUCTION(4,3)
BOVINE ANIMAL(4,2)
COMMERCIAL VACCINE(4,2)
FETAL TISSUE HOMOGENIZATION(4,2)
HUMAN HANDLER(4,2)
HUMORAL IMMUNE RESPONSE(4,2)
IMMUNOHISTOCHEMISTRY EVALUATION(4,2)
INFECTION RISK(4,2)
LIVE ANTIGEN(4,2)
MINERAL OIL EMULSION(4,2)
PFIZER CENTRAL RESEARCH(4,2)
POSTCHALLENGE SAMPLE(4,2)
PROSTAGLANDIN INJECTION(4,2)
SEROLOGIC SAMPLE(4,2)
VIRUS IDENTITY(4,2)
ACUTE FATAL DISEASE(4,1)
ACUTE ONSET RESPIRATORY DISEASE(4,1)
AMPHIGEN ADJUVANT(4,1)
BOOSTING REGIMEN(4,1)
CATTLE IMMUNIZATION(4,1)
CATTLE PESTIVIRUS(4,1)
CATTLE URINE(4,1)
CESAREAN DERIVED FETUS PLUS(4,1)
CLASSICAL SWINE FEVER(4,1)
CLINICAL SIGN EVIDENCE(4,1)
CLINICAL SYNDROME BROAD ARRAY(4,1)
CLOSTRIDIAL DISEASE(4,1)
COLIFORM BACTERIUM(4,1)
COMPENDIUM COLLECTION(4,1)
ETHANE DIOCTADECYLAZANIUM BROMIDE(4,1)
EYE CONJUNCTIVAL SAC(4,1)
EYE VITREOUS HUMOR(4,1)
FATAL MANIFESTATION(4,1)
FETAL ORGAN(4,1)
FETUS ABORTION(4,1)
FLAVIVIRIDAE FAMILY(4,1)
GALENICA PHARMACEUTICAL(4,1)
HAMSTER LETHALITY(4,1)
HARDJO BOVIS BACTERIN(4,1)
HARDJO BOVIS VACCINE(4,1)
HARDJO CHALLENGE(4,1)
HERD FERTILITY(4,1)
HISTOPATHOLOGIC EXAMINATION(4,1)
IMMUNOCOMPETENT ANIMAL(4,1)
INACTIVATED VIRAL VACCINE(4,1)
INFECTED CATTLE EXHIBIT(4,1)
INFLAMED MUZZLE(4,1)
INFLAMMATORY EXUDATE(4,1)
INFLAMMATORY FOCI(4,1)
INTRAMUSCULAR VACCINATION(4,1)
ISOLATION POSTCHALLENGE(4,1)
KIDNEY COLONIZATION(4,1)
KIDNEY INFECTION(4,1)
KILLED LEPTOSPIRE(4,1)
LABORED BREATHING(4,1)
LEPTOSPIRA ANTIGEN(4,1)
LEPTOSPIRA FLUORESCENT ANTIBODY(4,1)
LEPTOSPIRA PROTECTION STUDY(4,1)
LEPTOSPIRA SERONEGATIVE(4,1)
LEPTOSPIRA URINE(4,1)
LIPID AMINE ADJUVANT(4,1)
MATERNAL DEATHA(4,1)
MONTH OLD CALF(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
MULTIFOCAL THROMBOSIS(4,1)
NECROPSY FACILITY(4,1)
NEEDLELESS ADMINISTRATION(4,1)
NON VACCINATED ANIMAL(4,1)
NONCYTOPATHIC CHALLENGE(4,1)
PAIRED POST ABORTION(4,1)
PAIRED SEROLOGY(4,1)
PERSISTENTLY INFECTED CALF(4,1)
PESTIVIRUS GENUS(4,1)
PLACENTAL LAMINA PROPRIA(4,1)
POMONA VACCINE(4,1)
POSTCHALLENGE INCIDENCE(4,1)
PROTEUS VULGARIS(4,1)
PURULENT INFLAMMATION(4,1)
RE LATED ABORTION(4,1)
REPRODUCTIVE DISORDER(4,1)
SEROLOGIC EVIDENCE(4,1)
SEROPOSITIVE COW(4,1)
SERUM MICROSCOPIC AGGLUTINATION TITERS(4,1)
THORACIC FLUID SEROLOGY(4,1)
UNOBSERVED ABORTION(4,1)
VACCINATED CATTLE(4,1)
VACCINE CHALLENGE(4,1)
VACCINE DOSE ADMINISTRATION(4,1)
VACCINE EFFICACY MEASURE(4,1)
VACCINE INGREDIENT(4,1)
VETERINARY MEDICINE COLLEGE(4,1)
VIRAL BIOTYPE(4,1)
VIRUS ACCELERATED ELIMINATION(4,1)
SPONTANEOUS ABORTION(3,5)
ABORTED FETUS(3,4)
ESTRUM(3,4)
RECTAL PALPATION(3,4)
VACCINATION GROUP(3,4)
VACCINE GROUP(3,4)
ANIMAL SUBJECT(3,3)
DAILY BASIS(3,3)
PRESERVATIVE(3,3)
VACCINATED GROUP(3,3)
ACTIVE INGREDIENT(3,2)
ANEMNESTIC RESPONSE(3,2)
ANIMAL PERCENT(3,2)
ANTIBODY PRESENCE(3,2)
CAMPYLOBACTERIOSIS(3,2)
CONSECUTIVE DAY(3,2)
FOOD ANIMAL PRACTICE(3,2)
ISOTONIC AGENT(3,2)
MINERAL GEL(3,2)
NEGATIVE SEMEN(3,2)
PC INTERVAL(3,2)
SEROLOGIC RESPONSE(3,2)
SERUM NEUTRALIZING DATA(3,2)
STAPHYLOCOCCUS HYICUS(3,2)
TRIMESTER(3,2)
VEGETABLE OIL EMULSION(3,2)
ACTIVE BVDV REPLICATION(3,1)
ADJUVANT FORMULATION(3,1)
ADMINISTRATION NECESSITY(3,1)
ADMINISTRATION SCHEDULE(3,1)
ADSORPTION DELAYING(3,1)
AGRICULTURE UNITED STATES DEPARTMENT(3,1)
ANIMAL LIVE BIRTH(3,1)
ATTENUATED VIRUS(3,1)
BACTERIAL COCCI(3,1)
BOVINE FETUS(3,1)
CHALLENGE POTENCY(3,1)
CHALLENGE ROUTE(3,1)
CHOLERA TOXIN(3,1)
CONNECTIVE TISSUE(3,1)
COW CALF(3,1)
COW NEGATIVE PERCENTAGE(3,1)
DAIRY HERD(3,1)
DEAD COW(3,1)
DOSAGE REGIMEN(3,1)
ECONOMIC IMPORTANCE(3,1)
EMERYVILLE CA(3,1)
FATAL MUCOSAL DISEASE(3,1)
HARDJOBOVIS ISOLATION DATA SHOW(3,1)
HEALTH OBSERVATION(3,1)
HUMORAL ANTIBODY(3,1)
IMMUNIZING DOSE(3,1)
IMMUNOGENIC COMPOSITION DOSE(3,1)
IMMUNOMODULATORY AGENT(3,1)
IMMUNOTOLERANCE DEVELOPMENT(3,1)
INACTIVATED ANTIGEN(3,1)
INACTIVATED VIRUS(3,1)
INFECTIOUS DISEASE(3,1)
ISOLATION URINE SAMPLE(3,1)
KIDNEY CULTURE NEGATIVE(3,1)
LEPTOSPIRA DISEASE(3,1)
LEPTOSPIRE ISOLATION(3,1)
MANUFACTURER INSTRUCTION(3,1)
MILD DIARRHEA(3,1)
MUCOUS MEMBRANE NECROSIS(3,1)
NATURAL INFECTION ROUTE(3,1)
NURSING COW(3,1)
OPTIMAL IMMUNIZATION(3,1)
PERSISTENT INFECTION(3,1)
PHYSIOLOGICAL SALINE(3,1)
PLACENTAL TISSUE(3,1)
POSITIVE FETAL TISSUE IMMUNOHISTOCHEMISTRY(3,1)
POSITIVE SEROCONVERSION STATUS(3,1)
PRECHALLENGE SERUM NEUTRALIZING(3,1)
PREDOMINANT STRAIN(3,1)
PULMONARY INFECTION(3,1)
RECOVERED FETUS(3,1)
REPRODUCTIVE DISEASE(3,1)
RESEARCH ISOLATION FACILITY(3,1)
RESEARCH WORKER CONFERENCE(3,1)
SALINE PLACEBO(3,1)
SAPONIN FRACTION(3,1)
SERUM NEUTRALIZING TITER RANGING(3,1)
SOLE DETERMINANT(3,1)
VACCINE FORMULATION(3,1)
VETERINARY LABORATORY(3,1)
VIABLE ORGANISM(3,1)
VIREMIA NEGATIVE COW PERCENTAGE(3,1)
VIRUS GROWTH(3,1)
LUNG(2,5)
THYMUS(2,5)
MODIFIED LIVE VIRUS VACCINE(2,3)
ACTIVE SUBSTANCE(2,2)
ADJUVANT COMBINATION(2,2)
ALHYDROGEL(2,2)
ARTIFICIAL INSEMINATION(2,2)
ASPIRATION(2,2)
BAYOLF(2,2)
BLOOD SAMPLE PAIR(2,2)
CARBOPOL(2,2)
COW GROUP(2,2)
CYTOPATHIC EFFECT(2,2)
DEXTROSE(2,2)
DINOPROST TROMETHAMINE(2,2)
DIVIDED DOSE(2,2)
EMULSIFIER(2,2)
EXTRA(2,2)
FETAL RESORPTION(2,2)
GENTAMICIN(2,2)
GLYCOSIDE(2,2)
HEMORRHAGE(2,2)
INACTIVATED L(2,2)
INDIRECT IMMUNOFLUORESCENCE(2,2)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(2,2)
JUGULAR VEIN(2,2)
LEFT FLANK LAPAROTOMY(2,2)
LEPTOSPIRA COMBINATION VACCINE(2,2)
LYSOLECITHIN(2,2)
MONOVALENT L(2,2)
NOSTRIL(2,2)
POLYANION(2,2)
PREGNANCY GROUP TREATMENT(2,2)
REHYDRATION(2,2)
REPEATED MEASURE(2,2)
RESPIRATORY TRACT(2,2)
SEROTYPE(2,2)
SUPERNATANT(2,2)
THIMEROSAL(2,2)
UTERUS(2,2)
VAGINAL ADMINISTRATION(2,2)
VIBRIOSIS(2,2)
WHOLE BLOOD(2,2)
ACUTE FEVER(2,1)
ANIMAL AGE(2,1)
ANIMAL DOSE(2,1)
ANTIGEN VARIETY(2,1)
ANTIGENIC DIFFERENCE(2,1)
BLOOD SAMPLE SEROLOGIC TESTING(2,1)
BOVINE RESPIRATORY DISEASE AGENT(2,1)
BOVINE VIRAL DIARRHEA VIRUS PREPARATION(2,1)
BRAINSTEM MIDBRAIN(2,1)
BREEDING FAILURE(2,1)
BVDV PERMANENT SOURCE(2,1)
CAFTLEMASTER PREGSURE(2,1)
CAMBRIDGE MA(2,1)
CATTLE CONDITION(2,1)
CATTLE PROTECTION(2,1)
CESAREAN DERIVED CALF(2,1)
CLINICAL SYNDROME VARIETY(2,1)
CONSERVATIVE(2,1)
CONTAMINATION(2,1)
COW PERIPHERAL BLOOD(2,1)
CP VARIANT(2,1)
CULTURE FLUID(2,1)
CURRENT VETERINARY THERAPY(2,1)
DAIRY INDUSTRY(2,1)
DISEASE TRANSMISSION(2,1)
DOSE ANIMAL DOSING INTERVAL(2,1)
ECONOMICALLY IMPORTANT ZOONOTIC INFECTION(2,1)
FETAL DEVELOPMENT EARLY(2,1)
FIFTY YEAR REVIEW(2,1)
FOOD UPTAKE(2,1)
GESTATION HALF(2,1)
GRAM NEGATIVE COCCOBACILLI(2,1)
HANA VAN(2,1)
HARDJO BOVIS ORGANISM ML(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
IMMUNITY DURATION(2,1)
IMMUNOGENIC PRODUCT(2,1)
INACTIVATED WHOLE(2,1)
INFECTED CELL(2,1)
INFECTED SUBJECT(2,1)
KILLED COMBINATION BACTERIN(2,1)
LEPTOSPIRA PRESENCE(2,1)
MAJOR GENOTYPE(2,1)
MARKED ANAMNESTIC RESPONSE(2,1)
MILD DISEASE(2,1)
MODIFIED LIVE VACCINE PREPARATION(2,1)
MONOCLONAL ANTIBODY PANEL(2,1)
MULTICOMPONENT(2,1)
PAIRED SERUM(2,1)
PC VIREMIA RATE(2,1)
POOLED FETAL TISSUE(2,1)
SEROLOGY DATA SHOW(2,1)
STATISTICALLY SIGNIFICANT DIFFERENCE FAVORING(2,1)
SYSTEMIC AFFECT(2,1)
THREE PRECHALLENGE SEROLOGIC STATUS(2,1)
TISSUE CULTURE(2,1)
URINE KIDNEY CULTURE BASIS(2,1)
VIRUS ISOLATION NEGATIVE(2,1)
VIRUS STRAIN(2,1)
(US20040081666)
VACCINE(100,68)
IMMUNOGENIC(100,10)
LEPTOSPIRA BORGPETERSENII HARDIO PRAJITNO(100,10)
CATTLE REPRODUCTIVE DISEASE VACCINE(100,1)
LEPTOSPIRA BORGPETERSENII HARDJO PRAJITNO(82,3)
LEPTOSPIRA GRIPPOTYPHOSA(78,14)
BORGPETERSENII HARDJO BOVIS(74,13)
LEPTOSPIRA INTERROGAN(73,12)
LEPTOSPIRA CANICOLA(60,11)
LEPTOSPIRA ICTEROHAEMMORRHAGIA(60,10)
BOVINE HERPES VIRUS(47,6)
LACTATING COW(41,5)
INACTIVATED BVDV VACCINE(39,2)
LEPTOSPIRA(37,25)
CAMPYLOBACTER FETUS(37,16)
ANIMAL(34,96)
BOVINE VIRAL DIARRHEA VIRUS(34,34)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(34,7)
CYTOPATHIC BOVINE VIRAL DIARRHEA(34,3)
VETERINARY ACCEPTABLE CARRIER(32,14)
ANTIGEN(31,17)
LEPTOSPIRA HARDJ PRAJITNO(31,1)
LEPTOSPIRA HARDJO BOVIS(30,1)
PASTURELLA MULTOCIDA(29,5)
ANIMAL SUBJECT(27,10)
HAEMOPHILUS SOMNUS(27,5)
TRICHOMONUS FETUS(27,5)
IMMUNE RESPONSE(26,16)
DISEASE(26,13)
DISORDER(25,10)
GASTROINTESTINAL DISEASE(25,1)
SUSCEPTIBLE CALF(24,1)
PERSISTENT FETAL INFECTION(22,6)
VETERINARLY ACCEPTABLE CARRIER(22,2)
INFECTION(21,29)
SEVERE PRIMARY RESPIRATORY DISEASE(19,1)
COW(17,72)
ADJUVANT(17,21)
PERSISTENTLY INFECTED(17,5)
CALF NURSING PREGNANT COW(17,4)
MICROFLUIDIZED(17,4)
VIRUS(16,39)
STEER(16,4)
BVDV(15,46)
CALF(15,9)
BULL(15,5)
ATTENDING VETERINARIAN SUPERVISION(15,4)
BVDV IMMUNIZING ANTIGEN POTENCY(15,3)
MAJOR INFECTIOUS CAUSE PREVENTION(15,1)
MANNHEIMIA HAEMOLYTICA(14,5)
PARAINFLUENZA VIRUS(14,5)
VIRULENT BVDV INTRANASAL INOCULATION(14,2)
MICROORGANISM(14,1)
BHV(13,17)
NEOSPORA CANINUM(13,5)
CHOLESTEROL OIL(13,1)
PNEUMONIA(13,1)
PLACEBO COW(12,12)
SERUM NEUTRALIZING TITER(12,6)
BARBER(12,1)
MAJOR INFECTION SOURCE(12,1)
WHITE CELL RESERVOIR(12,1)
GESTATION DAY(11,10)
VACCINATED COW(11,8)
INFECTIOUS BOVINE RHINOTRACHEITIS(11,3)
LIVE PREPARATION(11,3)
LEPTOSPIRA SEROVAR HARDJO(11,2)
COMBINATION VACCINE(10,32)
CHORIONIC EPITHELIUM NECROSIS(10,2)
FETUS BVDV SEROTYPE(10,2)
VET(9,17)
BRSV(9,11)
VACCINE ADMINISTRATION(9,7)
DUPLICATE EAR(9,4)
BOVINE HERPES VIRUS TYPE(9,3)
CHALLENGE VIRUS POTENCY(9,3)
CORNELL UNIVERSITY COLLEGE(9,2)
EXPERIENCED BVDV VIREMIA(9,2)
BROAD BASED DEFICIT(9,1)
LEPTOSPIRA IMMUNIZING ANTIGEN POTENCY(9,1)
LICENSED BVDV MLV VACCINE(9,1)
POSTCHALLENGE BVDV VIREMIA INCIDENCE(9,1)
CATTLE(8,19)
AGE MONTH(8,8)
NEGATIVE BVDV ISOLATION(8,6)
BOVINE VIRAL DIARRHEA(8,4)
NEBRASKA UNIVERSITY(8,4)
ANTI BVDV POLYCLONAL ANTIBODY(8,3)
BVDV FETAL INFECTION(8,2)
POSTCHALLENGE BVDV ISOLATION(8,2)
GENUS LEPTOSPIRA SPIROCHETE(8,1)
INTESTINAL MUCOSA ULCERATION(8,1)
LEPTOSPIRA INTERROGAN POMONA(8,1)
NONCYTOPATHIC BVDV BIOTYPE(8,1)
PREGNANCY BVDV1 BVDV2 ISOLATION(8,1)
REVEALED DIFFUSE NECROPURULENT PLACENTITIS(8,1)
SASKATOON VETERINARY BIODIAGNOSTICS(8,1)
VIRULENT ORGANISM URINARY SHEDDING(8,1)
FETAL PROTECTION(7,7)
ANIMAL BREEDING(7,6)
UNKNOWN FETUS(7,5)
VIRUS ISOLATION ATTEMPT(7,5)
FAILED PREGNANCY(7,4)
FETAL TISSUE IMMUNOHISTOCHEMISTRY(7,4)
STATISTICAL SIGNIFICANCE(7,4)
CHALLENGE INOCULUM(7,3)
PARTIAL CELL(7,3)
PLACEBO VACCINE(7,3)
SERUM SERIAL DILUTION(7,3)
COW PREGNANCY STATUS(7,2)
MIDWEST VETERINARY SERVICE(7,2)
POSTCHALLENGE VIRUS ISOLATION(7,2)
SEMI ANNUAL REVACCINATION(7,2)
VIRUS ISOLATION POSTCHALLENGE(7,2)
FETUS REVEALED PNEUMONIA EVALUATION(7,1)
IMMUNOTOLERANT FETUS INFECTION(7,1)
LEPTOSPIRA MONOVALENT VACCINE(7,1)
LEPTOSPIRE URINARY SHEDDING(7,1)
PREGNANT CATTLE PLACENTA(7,1)
SERUM MICROSCOPIC AGGLUTINATION TITER(7,1)
SERUM VIRAL NEUTRALIZATION TITER(7,1)
SUBCUTANEOUS VACCINATION AABORTION(7,1)
VIRUS ISOLATION BVDV1 BVDV2(7,1)
IBR(6,10)
BOVINE CELL CULTURE(6,7)
ADVENTITIOUS EXPOSURE(6,3)
BUFFY COAT CELL PREPARATION(6,3)
BULK TITRATION(6,3)
CESAREAN DELIVERY(6,3)
COW BLOOD PERIPHERAL(6,3)
EXPERIMENTAL TEST VACCINE(6,3)
STERILE ADJUVANT(6,3)
STUDY OUTSET(6,3)
VIABLE CHALLENGE(6,3)
ABORTION ETIOLOGY(6,2)
ACUTE BVD VIRUS INFECTION(6,2)
BVDV LEPTOSPIRA(6,2)
CERTIFIED BVDV NEGATIVE SEMEN(6,2)
FETAL TISSUE HISTOPATHOLOGIC EVALUATION(6,2)
IMMUNE(6,2)
VETERINARY MEDICINE DIAGNOSTIC LABORATORY(6,2)
AGGLUTINATION ANTIBODY TITER(6,1)
BVDV INFECTED FETUS(6,1)
CATTLE LEPTOSPIRAL INFECTION(6,1)
COW VIREMIA INCIDENCE(6,1)
CYTOPATHIC VIRUS BIOTYPE(6,1)
DIFFUSE PURULENT PNEUMONIA(6,1)
HEALTHY CATTLE VACCINATION(6,1)
INTENSE NEUTROPHILIC INFLAMMATION(6,1)
LEPTOSPIRA INFECTION INCIDENCE(6,1)
TEST ANIMAL(5,11)
LEPTOSPIROSIS(5,9)
ANNUAL BASIS(5,6)
STUDY DURATION(5,4)
AMNIOTIC FLUID SAMPLE(5,3)
FETAL BRAIN(5,3)
ABNORMAL RESPIRATION(5,2)
AMPHIGEN ADJUVANT(5,2)
ANTICIPATED CALVING(5,2)
CLOSTRIDIAL INFECTION(5,2)
FETUS BACTERIN(5,2)
INFECTION SYMPTOM(5,2)
MONTANIDE ISA(5,2)
NEARBY ISOLATION FACILITY(5,2)
QUALIFIED VETERINARY DIAGNOSTIC CENTER(5,2)
REMAINED SERONEGATIVE((...)";Pharmaceuticals;Open
"2002-08-13
2003-08-12";"WO2004016794        A1 2004-02-26 [WO200416794]
STG: (A1) Published application with search report
AP : 2003WO-EP09031 2003-08-12
CA2495294           A1 2004-02-26 [CA2495294]
STG: (A1) Application laid open
AP : 2003CA-2495294 2003-08-12
AU2003258611        A1 2004-03-03 [AU2003258611]
STG: (A1) Open to public inspection
AP : 2003AU-0258611 2003-08-12
MXPA05001644        A  2005-04-19 [MX2005PA001644]
STG: (A) Patent application
AP : 2005MX-PA01644 2003-08-12
EP1534846           A1 2005-06-01 [EP1534846]
STG: (A1) Application published with search report
AP : 2003EP-0787795 2003-08-12
BR0313113           A  2005-06-28 [BR200313113]
STG: (A) Published application
AP : 2003BR-0013113 2003-08-12
BRPI0313113         A1 2005-06-28 [BRPI0313113]
STG: (A1) Published application
AP : 2003BR-0013113 2003-08-12
US20050208071       A1 2005-09-22 [US20050208071]
STG: (A1) Application published
AP : 2003US-10524210 2003-08-12
JP2005535338        A  2005-11-24 [JP2005535338]
STG: (A) Published application
AP : 2004JP-0528496 2003-08-12
US7244434           B2 2007-07-17 [US7244434]
STG: (B2) Granted patent as second publication
AP : 2003US-10524210 2003-08-12
FD :  Previous publication: US20050208071 A1 2005-09-22 [US20050208071]
JP4664072           B2 2011-01-14 [JP4664072]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2004JP-0528496 2003-08-12
CA2495294           C  2012-06-12 [CA2495294]
STG: (C) Patent (second level)
AP : 2003CA-2495294 2003-08-12
BRPI0313113         A2 2016-02-10 [BR200313113]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2003BR-0013113 2003-08-12";1720847;"WO2004016794        A1 2004-02-26 [WO200416794]
CA2495294           A1 2004-02-26 [CA2495294]
AU2003258611        A1 2004-03-03 [AU2003258611]
MXPA05001644        A  2005-04-19 [MX2005PA001644]
EP1534846           A1 2005-06-01 [EP1534846]
BR0313113           A  2005-06-28 [BR200313113]
BRPI0313113         A1 2005-06-28 [BRPI0313113]
US20050208071       A1 2005-09-22 [US20050208071]
JP2005535338        A  2005-11-24 [JP2005535338]
US7244434           B2 2007-07-17 [US7244434]
JP4664072           B2 2011-01-14 [JP4664072]
CA2495294           C  2012-06-12 [CA2495294]
BRPI0313113         A2 2016-02-10 [BR200313113]";"2002EP-0078357
2003EP-0787795
2003WO-EP09031";"(EP1534846)
WO2004016794
(US7244434)
WO2004016794
(JP4664072)
WO2004016794
(AU2003258611)
WO2004016794
(MX2005PA001644)
WO2004016794
(CA2495294)
WO2004016794
(BR200313113)
WO2004016794";"AKZO NOBEL
BASED INTANASHIYONARU BASED INTABETSUTO
INTERVET INTERNATIONAL";INTERVET INTERNATIONAL;"(EP1534846)
NL
(US7244434)
NL
(WO200416794)
NL

(CA2495294)
NL
(CA2495294)
NL
(BRPI0313113)
NL
(BR200313113)
NL";"(EP1534846)
NAME=Akzo Nobel N.V. Velperweg 76 , CITY=6824 BM  Arnhem , COUNTRY=NL 

(US7244434)
NAME=Intervet International B.V. , CITY=Boxmeer , COUNTRY=NL , ATYP=Non-US Company 

(WO200416794)
NAME=AKZO NOBEL N.V.  [NL/ NL] Velperweg 76, NL-6824 BM Arnhem  , COUNTRY=NL 

(JP2005535338)
NAME=AKZO NOBEL NV , REG=394010986 

(JP4664072)
NAME=Based Intanashiyonaru based Intabetsuto , REG=506196247 

(CA2495294)
NAME=AKZO NOBEL N V Velperweg 76, NL-6824 BM, ARNHEM , COUNTRY=NL 

(CA2495294)
NAME=AKZO NOBEL N.V. Velperweg 76 NL-6824 BM , CITY=ARNHEM , COUNTRY=NL 

(BRPI0313113)
NAME=AKZO NOBEL N V , COUNTRY=NL 

(BR200313113)
NAME=INTERVET INTERNATIONAL B V , COUNTRY=NL 
";1;"BEER MARTIN
REIMANN ILONA";"(EP1534846)
DE";"(EP1534846)
NAME=BEER, Martin Alwine-Wuthenow Ring 2b , CITY=17498 Neuenkirchen , COUNTRY=DE 

NAME=REIMANN, Ilona Riemser Weg 6E , CITY=17498 Gristow , COUNTRY=DE 
";"(EP1534846)
Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines";"(EP1534846)
The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be useful for vaccine purposes. The replicons encode most, preferably all, envelop proteins of the virus, while, on the other hand, it would not be capable of producing infectious progeny virus. The present invention provides a Pestiviral replicon, preferably from the Bovine Viral Diarrhea Virus (BVDV), which expresses all structural proteins except for a functional C or E1 protein. Preferably at least part of the coding sequence of the E1 or C protein has been deleted from said replicon. The present inventors proved for the first time, that both C and E1 structural proteins are essential for the formation of infectious pestiviruses. Furthermore it was shown that deletion of C and E1 does not impact the ability of RNA self-replication. By using cell lines constitutively expressing pestiviral structural proteins, Capsid- or E1-proteins can be efficiently trans-complemented. The resulting virions are able to infect bovine target cells and to transfer the replicons without generating replication-competent virus progeny. In other words, no infectious progeny virus is produced. The complemented virions are indistinguishable from wild-type Pestivirus.in virus neutralization experiments. Recombinations yielding infectious wild-type virus were not detected in any of the complementation experiments. The complemented viruses may be used for the safe and efficacious immunization against BVDV.";"(WO200416794)
CLAIMS:
1. A replicon of a pestivirus which is incapable of expressing one or more structural proteins of the virus, characterized in that said replicon expresses all structural proteins of a pestivirus except for a functional C and/or E1 protein.
2. A replicon according to claim 1 , characterized in that at least part of the coding sequence of the E1 or C protein has been deleted from said replicon.
3. A replicon according to claim 1 or 2, characterized in that said replicon does not encode a functional C protein.
4. A replicon according to claim 1 or 2, characterized in that said replicon is of the Bovine Viral Diarrhea Virus (BVDV).
5. A replicon according to claim 4, characterized in that the coding region encoding amino acid positions 201-243 of the C protein have been deleted.
6. A replicon according to claim 1 or 2, characterized in that said replicon does not encode a functional E1 protein.
7. A replicon according to claim 4, characterized in that the coding region encoding amino acid positions 498 to 653 of the E1 protein have been deleted.
8. Infectious viral particle of Pestivirus, characterized in that it contains a replicon according to any of claims 1-7.
9. A method for the production of viral particles of a Pestivirus according to claim 8, characterized in that said method comprises the following steps: a. Providing cells that are permissive for the Pestivirus and express Pestiviral E1 and/or C protein, b. Transfecting said cells with in-vitro transcribed RNA of a replicon according to any of claims 1 to 7, c. Culturing transfected cells obtained in step b, d. Harvesting the viral particles from the cultured cells.
10. A method according to claim 9, characterized in that said pestivirus is BVDV.
11. A method according to claim 10 or 11 , characterized in that said cells express the E1 and/or C protein of BVDV.
12. A vaccine containing infectious viral particles according to claim 8 and a pharmaceutically acceptable carrier.";"(US20050208071)
The present invention relates to replicons of Pestiviruses that do not express all structural proteins of the virus, infectious viral particles containing said replicons, a method for producing said infectious viral particles and vaccines containing said viral particles.
It was found that the defective CSFV genomes still replicated and could be packaged into viral particles when introduced in SK-6 cells together with helper A187-CAT RNA (Moser et al., J.
The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus.";"(US20050208071)
Such replicons can be useful for vaccine purposes.
While cp BVDV induce apoptosis and cell death and express nonstructural protein 3 (NS3), inoculation with ncp BVDV leads to persistent infection of cell cultures and NS3-expression is not detectable.
Bovine viral diarrhea virus (BVDV), a member of the genus Pestivirus within the family Flaviviridae is the causative agent of bovine viral diarrhea, an economically important disease of cattle world-wide.";"A01N-063/00
A61K-039/12
A61P-031/12
A61P-031/14
C07H-021/04
C07K-014/18
C12N-005/00
C12N-005/10
C12N-007/00
C12N-007/04
C12N-015/09
C12N-015/86";"(US20050208071)
1. A replicon of a pestivirus which is incapable of expressing one or more structural proteins of the virus, characterized in that said replicon expresses all structural proteins of a pestivirus except for a functional C and/or E1 protein, but wherein the coding sequences encoding the part of the C and/or the E1 protein essential for further downstream processing are retained or replaced by a coding sequence encoding analogous signal sequences from another pestiviral species.";"(US20050208071)
PROTEIN(100,40)
VACCINE(100,13)
STRUCTURAL PROTEIN(100,12)
INFECTIOUS VIRAL PARTICLE(100,8)
PESTIVIRUS REPLICON(100,4)
PESTVIRUSE REPLICON(100,1)
INFECTIOUS PROGENY VIRUS(76,5)
PESTIVIRAL RNA GENOME(67,2)
REPLICON(48,42)
EXPRESS NONSTRUCTURAL PROTEIN(47,1)
PESTIVIRAL SPECIES(41,1)
CODING SEQUENCE ENCODING(38,3)
MISSING PROTEIN(36,2)
FLAVIVIRIDAE FAMILY(35,1)
PESTIVIRUS INFECTIOUS VIRAL PARTICLE(34,2)
PESTIVIRAL REPLICON(33,1)
VIRUS PROTEIN STRUCTURE(32,1)
VIRAL PARTICLE(31,6)
REPLICATION COMPETENT VIRUS PROGENY(31,2)
CELL CULTURE INFECTION PERSISTENCE(31,1)
VIRUS NEUTRALIZATION EXPERIMENT(29,2)
CATTLE ECONOMICALLY IMPORTANT DISEASE(29,1)
GENUS PESTIVIRUS MEMBER(29,1)
NCP BVDV(25,2)
CULTURING TRANSFECTED CELL(25,1)
COMPLEMENTED VIRION(24,4)
IMMUNIZATION EFFECTIVENESS(24,2)
INFECTIOUS PESTIVIRUS FORMATION(24,2)
CAUSATIVE AGENT(24,1)
DEFECTIVE CSFV GENOME STILL(24,1)
PESTIVIRAL STRUCTURAL PROTEIN(23,2)
VIRUS COMPLEMENT(21,4)
CP BVDV(21,2)
BOVINE VIRAL DIARRHEA VIRUS(20,6)
ESSENTIAL PROTEIN(19,2)
CODING REGION ENCODING(18,4)
APOPTOSIS(15,1)
BOVINE VIRAL DIARRHEA(15,1)
BVDV(14,44)
VIRAL PARTICLE PRODUCTION(14,3)
RNA SELF REPLICATION ABILITY(14,2)
HELPER(13,1)
INFECTIOUS RECOMBINANT BVDV(12,3)
INDIRECT BVDV ANTIBODY ELISA(12,2)
BOVINE TARGET CELL(12,1)
VACCINATED ANIMAL(11,8)
INOCULATION(11,4)
RECOMBINATION(10,2)
BVDV REPLICON TRANS COMPLEMENTATION(10,1)
PESTIVIRUS ALL STRUCTURAL PROTEIN(10,1)
SEMLIKE FOREST VIRUS REPLICON(10,1)
VACCINATED CATTLE NASAL SWAB(10,1)
VIRUS(9,9)
PESTIVIRUS REPLICATION(9,3)
ANIMAL REMAINED BVDV ANTIBODY(9,2)
NEUTRALIZING ANTIBODY TITER(9,2)
CELL DEATH(9,1)
SIGNAL SEQUENCE(8,9)
NEUTRALIZING TITER(8,3)
TRANSFECTED PT SUPERNATANT(8,2)
AMERSHAM BIOSCIENCE(8,1)
BVD VIRUS RNA GENOME(8,1)
BVDV INFECTION SIGN(8,1)
CULTURED CELL(8,1)
INFECTIOUS WILD TYPE VIRUS(8,1)
REPLICATION INCOMPETENT PSEUDOVIRION(8,1)
SERUM HOMOLOGOUS NEUTRALIZATION TITER(8,1)
VIRUS ISOLATION(7,5)
BVDV STRAIN(7,4)
PLASMID EXPRESSION(7,4)
MANUFACTURER INSTRUCTION(7,3)
NEUTRALIZATION ASSAY(7,3)
BVDV ANTIGEN DETECTION(7,2)
NCP7 INOCULATION(7,2)
PESTIVIRUS GENOME(7,2)
SAFE(7,2)
BLOOD LEUKOCYTE CO CULTIVATION(7,1)
BVDV ERN ANTIGEN DETECTION(7,1)
MUTATED KUN REPLICON(7,1)
NASAL SWAB INOCULATION(7,1)
PERSISTENTLY INFECTED CALF GENERATION(7,1)
PROTOTYPE REPLICON RNA(7,1)
REPLICON RNA TRANSFECTION(7,1)
CELL PT(6,9)
INDIRECT ELISA(6,4)
SYN ORF(6,4)
GENE ENCODING(6,3)
BVDV ORF(6,2)
NCP SUPERNATANT(6,2)
PT PASSAGING(6,2)
RESPIRATORY SYMPTOM(6,2)
TRANS COMPLEMENTATION EXPERIMENT(6,2)
BVDV CLINICAL SIGN(6,1)
BVDV ERN EXPRESSION(6,1)
BVDV STRUCTURAL PROTEIN CAPSID(6,1)
CAPSID PROTEIN ANCHOR(6,1)
CAPSID PROTEIN TERMINUS(6,1)
CHECKIT BVD VIRUS(6,1)
DEFECTIVE BVDV GENOME(6,1)
DELETED BVDV GENOME(6,1)
ERNSE1E TRANSLOCATION(6,1)
ETHIDIUM BROMIDE STAINING(6,1)
FAMILY FLAVIVIRIDAE VIRUS(6,1)
GLYCOSYLATED ENVELOPE PROTEIN(6,1)
INDIRECT BVDV ELISA(6,1)
INFECTIOUS BVDV RECOVERY(6,1)
INFECTIOUS CLONE ESTABLISHMENT(6,1)
LETHAL CSFV CHALLENGE(6,1)
REVERTANT NCP OCCURRENCE(6,1)
SUBCLINICAL INFECTION SIGN(6,1)
THERMO SEQUENASE CYCLE SEQUENCING KIT(6,1)
TRANS COMPLEMENTED DEFECTIVE VIRION(6,1)
TRANS COMPLEMENTED RECOMBINANT BVDV(6,1)
TRANS COMPLEMENTED VIRUS TITER(6,1)
VIRUS CAPSID PROTEIN(6,1)
CELL CULTURE SUPERNATANT(5,4)
VIRUS SUSPENSION(5,3)
MARKED LEUKOPENIA(5,2)
NUCLEOTIDE SEQUENCING(5,2)
ABNORMAL CLINICAL SCORE(5,1)
BLOCKING BVDV ANTIBODY(5,1)
BVDV NEUTRALIZATION(5,1)
COMPLEMENTED BVDV(5,1)
CONSECUTIVE ELECTROPOARTION(5,1)
CRYPTICAL SPLICING SITE(5,1)
FETAL BOVINE SERUM(5,1)
INFECTIOUS VIRION GENERATION(5,1)
INFECTIOUS VIRUS PROGENY PRODUCTION(5,1)
NCP BVDV ALLOWED RECOVERY(5,1)
OVINE BORDER DISEASE VIRUS(5,1)
PERMANENT BOVINE KIDNEY(5,1)
PESTIVIRAL ORF(5,1)
PESTIVIRUS VIRION(5,1)
POSITIVE INOCULATION ANUMBER(5,1)
POSITIVE INOCULATION BNUMBER(5,1)
REPLICATING BVDV(5,1)
REPLICON CHARACTERIZATION(5,1)
RESTRICTION ENZYME DIGESTION(5,1)
ROCHE MOLECULAR BIOCHEMICAL(5,1)
STRUCTURAL PROTEIN TRANS COMPLEMENTATION(5,1)
POSITIVE SAMPLE(4,6)
CLONING(4,3)
KOP R CELL INFECTION(4,3)
ANIMAL VIRUS DISEASE(4,2)
FEDERAL RESEARCH(4,2)
GENOMIC REGION ENCODING(4,2)
MATURE PROTEIN(4,2)
VACCINE GROUP ANIMAL(4,2)
WILD TYPE PESTIVIRUS(4,2)
7C REPLICON(4,1)
AEROSOL DISPENSER(4,1)
ANTIGEN POSITIVE VIRUS PLAQUE(4,1)
BCATTLE SERUM(4,1)
BOOSTER VACCINATION(4,1)
BOVINE KIDNEY CELL(4,1)
BOVINE ORIGIN CELL(4,1)
BVDV GENOTYPE(4,1)
BVDV MUTANT(4,1)
BVDV NCP(4,1)
BVDV NEUTRALIZING ANTISERA(4,1)
BVDV PROPAGATION(4,1)
BVDV PROTEIN(4,1)
BVDV REPLICATION(4,1)
BVDV RNA(4,1)
CEDI DIAGNOSTICS(4,1)
CHECKIT BVDV III(4,1)
CLINICAL SYMPTOM(4,1)
COLI TOP10F CELL(4,1)
COMPLEMENTING PT CELL(4,1)
CONSTRUCT VARIANT(4,1)
CONTAINED EMS DELETED REPLICON(4,1)
CSFV ERN(4,1)
CSFV REPLICATION(4,1)
CSHEEP SERUM(4,1)
DBVDV ANTIBODY(4,1)
DELETION MUTANT(4,1)
DIPLOID BOVINE(4,1)
ERN DELETED REPLICON(4,1)
EXPRESSION PLASMID ENCODING(4,1)
FATAL MUCOSAL DISEASE(4,1)
HCMV PROMOTER(4,1)
HEALTHY CATTLE(4,1)
HUNDRED TCID(4,1)
INDIRECT IMMUNOFLUORESCENCE STAINING(4,1)
INOCULATED ANIMAL(4,1)
LI COR AUTOMATIC SEQUENCER(4,1)
LIVE VACCINE(4,1)
MUTANT BVDV(4,1)
MUTATED REPLICON(4,1)
MUTO SYRINGE(4,1)
NONSTRUCTURAL PROTEIN(4,1)
NUCLEAR PATHWAY(4,1)
PCR AMPLIFICATION(4,1)
PCR PRIMER(4,1)
PESTIVIRAL GENOME(4,1)
PESTIVIRUS CODING SEQUENCE(4,1)
PESTIVIRUS PROTEIN(4,1)
PESTIVIRUS SELF REPLICATING RNA(4,1)
PESTIVIRUS SPECIES SEQUENCE(4,1)
POLYPROTEIN EXPRESSION(4,1)
POOLED ANTI BVDV SERUM(4,1)
PROTEASE CLEAVAGE(4,1)
PT CELL TRANSFECTION(4,1)
PT MONOLAYER(4,1)
QIAGEN PLASMID(4,1)
RESTRICTION SITE KPNI(4,1)
RESTRICTION SITE NOTI(4,1)
REVERTANT BVDV(4,1)
RNA REPLICATION(4,1)
RNA TEMPLATE(4,1)
RT PCR ANALYSIS(4,1)
SEQUENCE ENCODING DELETION(4,1)
SUBGENOMIC RNA(4,1)
SYNTHESIZED CDNA(4,1)
THERMOSTABLE TAQ POLYMERASE(4,1)
TITRATION EXPERIMENT(4,1)
TRANS COMPLEMENTED NCP(4,1)
TRANS COMPLEMENTED REPLICON(4,1)
TRANS COMPLEMENTED VIRION(4,1)
TRIZOL REAGENT(4,1)
UNDILUTED SERUM(4,1)
UNDILUTED SUPERNATANT(4,1)
UNPUBLISHED DATA(4,1)
VIRAL TITER(4,1)
VIRUS DETECTION ASSAY(4,1)
VIRUS NEUTRALIZING(4,1)
VIRUS PLAQUE DETECTION(4,1)
PCDNA(3,3)
SEROLOGY(3,3)
418 RESISTANT COLONY(3,2)
TRANSFECTED CELL(3,2)
BLOCKING ELISA(3,1)
CAPSID ENCODING REGION(3,1)
CDNA CLONE(3,1)
CELL ALIQUOT(3,1)
CELL ELECTROPORATION(3,1)
CELL FOCI(3,1)
CLINICAL OBSERVATION(3,1)
COMMERCIAL ERN(3,1)
CORRECT DELETION(3,1)
DIPLOID CELL(3,1)
DNA RNA TRANSFECTION(3,1)
EASYJECT PLUS(3,1)
ELEVATED ELISA(3,1)
EXPERIMENT BEGINNING(3,1)
GENERATING VIRUS PROGENY ABILITY(3,1)
GIBCO LIFE TECHNOLOGY(3,1)
MARKED BOOSTER(3,1)
NA VE(3,1)
NUCLEOTIDE INSERTION(3,1)
PLASMID DNA(3,1)
PLASMID PA BVDV(3,1)
POLYPROTEIN PROCESSING(3,1)
PROTEIN CODING(3,1)
PROTEIN DELETION(3,1)
SELF REPLICATING RNA MOLECULE(3,1)
SEVERE DISEASE(3,1)
SPLICE SITE(3,1)
STANDARD SERUM NEUTRALIZATION TEST(3,1)
STRONG IMMUNOFLUORESCENCE(3,1)
STRUCTURAL PROTEIN SEQUENCE CODING(3,1)
SYNTHETIC ORF(3,1)
TRANS ACTING ELEMENT IDENTIFICATION(3,1)
TRANSIENT EXPRESSION(3,1)
VIRION PREPARATION(3,1)
VIRUS REPLICATION UNDERSTANDING(3,1)
WASHED LEUKOCYTE(3,1)
CELL CULTURE MEDIUM(2,4)
418 RESISTANT CELL(2,2)
FRAMESHIFT(2,2)
INCUBATION PERIOD(2,2)
INFECTIOUS UNIT(2,2)
MUTATION(2,2)
PCR PRODUCT(2,2)
REPORT(2,2)
TRIPLICATE(2,2)
VETERINARY MEDICINE(2,2)
ANTIBODY FREE CATTLE SERUM(2,1)
BIOTYPE(2,1)
BVDV NEGATIVE PT CELL(2,1)
BVDV SEQUENCE(2,1)
BVDV STRUCTURAL REGION(2,1)
CAPSID REGION(2,1)
CELL LYSATE(2,1)
CLEAR BOOSTER(2,1)
COLD SPRING HARBOR(2,1)
(US7244434)
PROTEIN(100,33)
VACCINE(100,13)
STRUCTURAL PROTEIN(100,10)
INFECTIOUS VIRAL PARTICLE(100,8)
PESTIVIRUS REPLICON(100,4)
PESTVIRUSE REPLICON(100,1)
PESTIVIRAL RNA GENOME(74,2)
INFECTIOUS PROGENY VIRUS(59,3)
EXPRESS NONSTRUCTURAL PROTEIN(52,1)
PESTIVIRAL SPECIES(46,1)
CODING SEQUENCE ENCODING(42,3)
REPLICON(41,34)
MISSING PROTEIN(40,2)
FLAVIVIRIDAE FAMILY(39,1)
PESTIVIRUS INFECTIOUS VIRAL PARTICLE(37,2)
VIRUS PROTEIN STRUCTURE(35,1)
VIRAL PARTICLE(34,6)
CELL CULTURE INFECTION PERSISTENCE(34,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(32,1)
GENUS PESTIVIRUS MEMBER(32,1)
POST TRANSLATIONAL PROCESSING(29,1)
NCP BVDV(27,2)
DEFECTIVE CSFV GENOME STILL(27,1)
CAUSATIVE AGENT(26,1)
INFECTIOUS VIRAL PARTICLE PRODUCTION(25,1)
CP BVDV(23,2)
ESSENTIAL PROTEIN(21,2)
BOVINE VIRAL DIARRHEA VIRUS(19,6)
APOPTOSIS(17,1)
BOVINE VIRAL DIARRHEA(17,1)
INFECTIOUS RECOMBINANT BVDV(14,3)
HELPER(14,1)
BVDV(13,41)
SIGNAL SEQUENCE(13,10)
CODING REGION ENCODING(13,3)
TRANSFECTED CELL(13,3)
INDIRECT BVDV ANTIBODY ELISA(13,2)
VACCINATED ANIMAL(12,8)
INOCULATION(12,4)
BVDV REPLICON TRANS COMPLEMENTATION(11,1)
PESTIVIRUS ALL STRUCTURAL PROTEIN(11,1)
SEMLIKE FOREST VIRUS REPLICON(11,1)
VACCINATED CATTLE NASAL SWAB(11,1)
VIRUS(10,9)
PESTIVIRUS REPLICATION(10,3)
ANIMAL REMAINED BVDV ANTIBODY(10,2)
NEUTRALIZING ANTIBODY TITER(10,2)
CELL DEATH(10,1)
NEUTRALIZING TITER(9,3)
TRANSFECTED PT SUPERNATANT(9,2)
BVD VIRUS RNA GENOME(9,1)
REPLICATION INCOMPETENT PSEUDOVIRION(9,1)
SERUM HOMOLOGOUS NEUTRALIZATION TITER(9,1)
VIRUS ISOLATION(8,5)
BVDV STRAIN(8,4)
NEUTRALIZATION ASSAY(8,3)
NCP7 INOCULATION(8,2)
AMERSHAM BIOSCIENCE(8,1)
BLOOD LEUKOCYTE CO CULTIVATION(8,1)
BVD VIRUS COMPLEMENT(8,1)
BVDV ERN ANTIGEN DETECTION(8,1)
BVDV INFECTION SIGN(8,1)
CULTURED CELL(8,1)
MUTATED KUN REPLICON(8,1)
NASAL SWAB INOCULATION(8,1)
PERSISTENTLY INFECTED CALF GENERATION(8,1)
POSITIVE INOCULATION BVDV SE5508ANUMBER(8,1)
PROTOTYPE REPLICON RNA(8,1)
REPLICON RNA TRANSFECTION(8,1)
INDIRECT ELISA(7,4)
PLASMID EXPRESSION(7,4)
SYN ORF(7,4)
MANUFACTURER INSTRUCTION(7,3)
BVDV ANTIGEN DETECTION(7,2)
BVDV ORF(7,2)
NCP SUPERNATANT(7,2)
PESTIVIRUS GENOME(7,2)
PT PASSAGING(7,2)
RESPIRATORY SYMPTOM(7,2)
TRANS COMPLEMENTATION EXPERIMENT(7,2)
BVDV ERN EXPRESSION(7,1)
CAPSID PROTEIN ANCHOR(7,1)
CAPSID PROTEIN TERMINUS(7,1)
CHECKIT BVD VIRUS(7,1)
DEFECTIVE BVDV GENOME(7,1)
DELETED BVDV GENOME(7,1)
FAMILY FLAVIVIRIDAE VIRUS(7,1)
INDIRECT BVDV ELISA(7,1)
INFECTIOUS CLONE ESTABLISHMENT(7,1)
LETHAL CSFV CHALLENGE(7,1)
REPLICATION COMPETENT VIRUS PROGENY(7,1)
REVERTANT NCP OCCURRENCE(7,1)
TRANS COMPLEMENTED DEFECTIVE VIRION(7,1)
TRANS COMPLEMENTED RECOMBINANT BVDV(7,1)
CELL PT(6,9)
GENE ENCODING(6,3)
VIRUS SUSPENSION(6,3)
MARKED LEUKOPENIA(6,2)
NUCLEOTIDE SEQUENCING(6,2)
BVDV CLINICAL SIGN(6,1)
BVDV STRUCTURAL PROTEIN CAPSID(6,1)
ERNSE1E TRANSLOCATION(6,1)
ETHIDIUM BROMIDE STAINING(6,1)
GLYCOSYLATED ENVELOPE PROTEIN(6,1)
INFECTIOUS BVDV RECOVERY(6,1)
SUBCLINICAL INFECTION SIGN(6,1)
THERMO SEQUENASE CYCLE SEQUENCING KIT(6,1)
TRANS COMPLEMENTED VIRUS TITER(6,1)
VIRUS CAPSID PROTEIN(6,1)
VIRUS NEUTRALIZATION EXPERIMENT(6,1)
CELL CULTURE SUPERNATANT(5,4)
CLONING(5,3)
KOP R CELL INFECTION(5,3)
ANIMAL VIRUS DISEASE(5,2)
FEDERAL RESEARCH(5,2)
GENOMIC REGION ENCODING(5,2)
MATURE PROTEIN(5,2)
VACCINE GROUP ANIMAL(5,2)
ABNORMAL CLINICAL SCORE(5,1)
ACOMPLEMENTED VIRUS(5,1)
ANTIGEN POSITIVE VIRUS PLAQUE(5,1)
BLOCKING BVDV ANTIBODY(5,1)
BOOSTER VACCINATION(5,1)
BVDV GENOTYPE(5,1)
BVDV MUTANT(5,1)
BVDV NEUTRALIZATION(5,1)
BVDV NEUTRALIZING ANTISERA(5,1)
BVDV REPLICATION(5,1)
CEDI DIAGNOSTICS(5,1)
CHECKIT BVDV III(5,1)
COLI TOP10F CELL(5,1)
COMPLEMENTED BVDV(5,1)
COMPLEMENTING PT CELL(5,1)
CONSECUTIVE ELECTROPOARTION(5,1)
CONTAINED EMS DELETED REPLICON(5,1)
CRYPTICAL SPLICING SITE(5,1)
CSFV REPLICATION(5,1)
ERN DELETED REPLICON(5,1)
EXPRESSION PLASMID ENCODING(5,1)
FETAL BOVINE SERUM(5,1)
HEALTHY CATTLE(5,1)
IMMUNIZATION EFFECTIVENESS(5,1)
INDIRECT IMMUNOFLUORESCENCE STAINING(5,1)
INFECTIOUS PESTIVIRUS FORMATION(5,1)
INFECTIOUS VIRION GENERATION(5,1)
INFECTIOUS VIRUS PROGENY PRODUCTION(5,1)
LI COR AUTOMATIC SEQUENCER(5,1)
MIXBVDVA BVD(5,1)
MUTATED REPLICON(5,1)
NCP BVDV ALLOWED RECOVERY(5,1)
NONSTRUCTURAL PROTEIN(5,1)
OVINE BORDER DISEASE VIRUS(5,1)
PERMANENT BOVINE KIDNEY(5,1)
PESTIVIRAL GENOME(5,1)
PESTIVIRAL ORF(5,1)
PESTIVIRAL STRUCTURAL PROTEIN(5,1)
PESTIVIRUS CODING SEQUENCE(5,1)
PESTIVIRUS PROTEIN(5,1)
PESTIVIRUS SELF REPLICATING RNA(5,1)
PESTIVIRUS SPECIES SEQUENCE(5,1)
PESTIVIRUS VIRION(5,1)
POLYPROTEIN EXPRESSION(5,1)
POOLED ANTI BVDV SERUM(5,1)
POSITIVE INOCULATION BNUMBER(5,1)
REPLICATING BVDV(5,1)
REPLICON CHARACTERIZATION(5,1)
RESTRICTION ENZYME DIGESTION(5,1)
RESTRICTION SITE KPNI(5,1)
RESTRICTION SITE NOTI(5,1)
REVERTANT BVDV(5,1)
ROCHE MOLECULAR BIOCHEMICAL(5,1)
STRUCTURAL PROTEIN TRANS COMPLEMENTATION(5,1)
SUBGENOMIC RNA(5,1)
THERMOSTABLE TAQ POLYMERASE(5,1)
TRANS COMPLEMENTED NCP(5,1)
TRANS COMPLEMENTED REPLICON(5,1)
TRANS COMPLEMENTED VIRION(5,1)
UNPUBLISHED DATA(5,1)
VIRAL TITER(5,1)
VIRUS PLAQUE DETECTION(5,1)
POSITIVE SAMPLE(4,6)
418 RESISTANT COLONY(4,2)
7C REPLICON(4,1)
AEROSOL DISPENSER(4,1)
ANTISERAIF ANALYSIS(4,1)
BCATTLE SERUM(4,1)
BOVINE KIDNEY CELL(4,1)
BOVINE ORIGIN CELL(4,1)
BVDV NCP(4,1)
BVDV PROPAGATION(4,1)
BVDV PROTEIN(4,1)
BVDV RNA(4,1)
CLINICAL SYMPTOM(4,1)
CONSTRUCT VARIANT(4,1)
CSFV ERN(4,1)
CSHEEP SERUM(4,1)
DBVDV ANTIBODY(4,1)
DELETION MUTANT(4,1)
DIPLOID BOVINE(4,1)
FATAL MUCOSAL DISEASE(4,1)
HCMV PROMOTER(4,1)
HUNDRED TCID(4,1)
INOCULATED ANIMAL(4,1)
LIVE VACCINE(4,1)
MUTANT BVDV(4,1)
MUTO SYRINGE(4,1)
NUCLEAR PATHWAY(4,1)
PCR AMPLIFICATION(4,1)
PCR PRIMER(4,1)
POSB BVD(4,1)
PROTEASE CLEAVAGE(4,1)
PT MONOLAYER(4,1)
QIAGEN PLASMID(4,1)
RNA REPLICATION(4,1)
RNA TEMPLATE(4,1)
RT PCR ANALYSIS(4,1)
SEQUENCE ENCODING DELETION(4,1)
SYNTHESIZED CDNA(4,1)
TITRATION EXPERIMENT(4,1)
TRIZOL REAGENT(4,1)
UNDILUTED SERUM(4,1)
VIRUS DETECTION ASSAY(4,1)
VIRUS NEUTRALIZING(4,1)
PCDNA(3,3)
SEROLOGY(3,3)
418 RESISTANT CELL(3,2)
FRAMESHIFT(3,2)
INCUBATION PERIOD(3,2)
INFECTIOUS UNIT(3,2)
MUTATION(3,2)
PCR PRODUCT(3,2)
REPORT(3,2)
TRIPLICATE(3,2)
VETERINARY MEDICINE(3,2)
BLOCKING ELISA(3,1)
CAPSID ENCODING REGION(3,1)
CDNA CLONE(3,1)
CELL ALIQUOT(3,1)
CELL ELECTROPORATION(3,1)
CELL FOCI(3,1)
CLINICAL OBSERVATION(3,1)
COMMERCIAL ERN(3,1)
CORRECT DELETION(3,1)
DIPLOID CELL(3,1)
DNA RNA TRANSFECTION(3,1)
EASYJECT PLUS(3,1)
ELEVATED ELISA(3,1)
EXPERIMENT BEGINNING(3,1)
GENERATING VIRUS PROGENY ABILITY(3,1)
GIBCO LIFE TECHNOLOGY(3,1)
MARKED BOOSTER(3,1)
NA VE(3,1)
NATIONAL PHASE FILING(3,1)
NUCLEOTIDE INSERTION(3,1)
PLASMID DNA(3,1)
PLASMID PA BVDV(3,1)
POLYPROTEIN PROCESSING(3,1)
PROTEIN CODING(3,1)
PROTEIN DELETION(3,1)
SELF REPLICATING RNA MOLECULE(3,1)
SEVERE DISEASE(3,1)
SPLICE SITE(3,1)
STANDARD SERUM NEUTRALIZATION TEST(3,1)
STRONG IMMUNOFLUORESCENCE(3,1)
STRUCTURAL PROTEIN SEQUENCE CODING(3,1)
SYNTHETIC ORF(3,1)
TRANS ACTING ELEMENT IDENTIFICATION(3,1)
TRANSIENT EXPRESSION(3,1)
VIRION PREPARATION(3,1)
VIRUS REPLICATION UNDERSTANDING(3,1)
WASHED LEUKOCYTE(3,1)
CELL CULTURE MEDIUM(2,4)
ANTIBODY FREE CATTLE SERUM(2,1)
BIOTYPE(2,1)
BVDV NEGATIVE PT CELL(2,1)
BVDV SEQUENCE(2,1)
BVDV STRUCTURAL REGION(2,1)
CAPSID REGION(2,1)
CELL LYSATE(2,1)
CLEAR BOOSTER(2,1)
COLD SPRING HARBOR(2,1)
CONTROL ANIMAL NASAL SWAB(2,1)
CYCLE VIRION(2,1)
FUNCTIONAL PROTEIN(2,1)
(WO200416794)
STRUCTURAL PROTEIN(100,9)
INFECTIOUS VIRAL PARTICLE(100,7)
PESTIVIRUS REPLICON(100,5)
PESTIVIRAL RNA GENOME(87,1)
EXPRESS NONSTRUCTURAL PROTEIN(78,1)
REPLICON(65,39)
INFECTIOUS PROGENY VIRUS(63,2)
PESTIVIRUS INFECTIOUS VIRAL PARTICLE(56,2)
VIRAL PARTICLE(51,6)
CELL CULTURE INFECTION PERSISTENCE(51,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(48,1)
GENUS PESTIVIRUS MEMBER(48,1)
FLAVIVIRIDAE FAMILY(47,2)
MISSING PROTEIN(47,1)
VIRUS PROTEIN STRUCTURE(42,2)
CULTURING TRANSFECTED CELL(42,1)
NCP BVDV(41,2)
CAUSATIVE AGENT(40,1)
CP BVDV(35,2)
CODING REGION ENCODING(30,4)
VACCINE(28,12)
BOVINE VIRAL DIARRHEA VIRUS(26,3)
APOPTOSIS(25,1)
BOVINE VIRAL DIARRHEA(25,1)
VIRAL PARTICLE PRODUCTION(23,3)
HELPER(22,1)
INFECTIOUS RECOMBINANT BVDV(21,3)
PROTEIN(20,19)
INDIRECT BVDV ANTIBODY ELISA(20,2)
GENOME STILL(20,1)
VACCINATED ANIMAL(18,8)
INOCULATION(17,8)
PESTIVIRUS ALL STRUCTURAL PROTEIN(17,1)
SEMLIKE FOREST VIRUS REPLICON(16,1)
VACCINATED CATTLE NASAL SWAB(16,1)
VIRUS(15,9)
PESTIVIRUS REPLICATION(15,3)
ANIMAL REMAINED BVDV ANTIBODY(15,2)
NEUTRALIZING ANTIBODY TITER(15,2)
BVDV FRAN COMPLEMENTATION(15,1)
CELL DEATH(15,1)
VIRUS ISOLATION(14,7)
BVDV STRAIN(14,5)
TRANSFECTED PT SUPERNATANT(14,2)
BVD VIRUS RNA GENOME(14,1)
SERUM HOMOLOGOUS NEUTRALIZATION TITER(14,1)
NEUTRALIZING TITER(13,3)
NONSTRUCTURAL PROTEIN(13,3)
BVDV INFECTION SIGN(13,1)
BVDV REPLICON CHARACTERIZATION(13,1)
CULTURED CELL(13,1)
EXPRESS PESTIVIRAL E(13,1)
SEROLOGY NEUTRALIZATION ASSAY(13,1)
POSITIVE INOCULATION ANUMBER(12,2)
POSITIVE INOCULATION BNUMBER(12,2)
BLOOD LEUKOCYTE CO CULTIVATION(12,1)
BVD VIRUS COMPLEMENT(12,1)
NASAL SWAB INOCULATION(12,1)
PERSISTENTLY INFECTED CALF GENERATION(12,1)
PROTOTYPE REPLICON RNA(12,1)
REPLICON RNA TRANSFECTION(12,1)
CELL PT(11,11)
RNA(11,10)
INDIRECT ELISA(11,4)
PLASMID EXPRESSION(11,4)
SYN ORF(11,4)
MANUFACTURER INSTRUCTION(11,3)
BVDV ANTIGEN DETECTION(11,2)
BVDV C PROTEIN(11,2)
BVDV ORF(11,2)
PESTIVIRUS GENOME(11,2)
PT PASSAGING(11,2)
RESPIRATORY SYMPTOM(11,2)
CAPSID PROTEIN ANCHOR(11,1)
CHECKIT BVD VIRUS(11,1)
DEFECTIVE BVDV GENOME(11,1)
DELETED BVDV GENOME(11,1)
INDIRECT BVDV ELISA(11,1)
INFECTIOUS CLONE ESTABLISHMENT(11,1)
REPLICATION COMPETENT VIRUS PROGENY(11,1)
TRANS COMPLEMENTED DEFECTIVE VIRION(11,1)
TRANS COMPLEMENTED RECOMBINANT BVDV(11,1)
POSITIVE SAMPLE(10,11)
GENE ENCODING(10,3)
FUNCTIONAL C(10,2)
BLOCKING BVDV ANTIBODY(10,1)
BVDV CLINICAL SIGN(10,1)
BVDV STRUCTURAL PROTEIN CAPSID(10,1)
GLYCOSYLATED ENVELOPE PROTEIN(10,1)
INFECTIOUS BVDV RECOVERY(10,1)
SUBCLINICAL INFECTION SIGN(10,1)
TRANS COMPLEMENTED VIRUS TITER(10,1)
VIRUS CAPSID PROTEIN(10,1)
VIRUS NEUTRALIZATION EXPERIMENT(10,1)
VIRUS PROGENY PASSAGE TITER(10,1)
VIRUS SUSPENSION(9,3)
MARKED LEUKOPENIA(9,2)
NUCLEOTIDE SEQUENCING(9,2)
TRANS COMPLEMENTATION EXPERIMENT(9,2)
CELL CULTURE SUPERNATANT(8,4)
ABNORMAL CLINICAL SCORE(8,1)
BVDV NEUTRALIZATION(8,1)
COMPLEMENTED BVDV(8,1)
CONSECUTIVE ELECTROPOARTION(8,1)
CRYPTICAL SPLICING SITE(8,1)
ETHIDIUM BROMIDE STAINING(8,1)
INFECTIOUS VIRION GENERATION(8,1)
INFECTIOUS VIRUS PROGENY PRODUCTION(8,1)
NCP BVDV ALLOWED RECOVERY(8,1)
NEUTRALIZATION INOCULATION(8,1)
PERMANENT BOVINE KIDNEY(8,1)
PESTIVIRAL ORF(8,1)
PESTIVIRUS VIRION(8,1)
PLASMID PA BVDV(8,1)
REPLICATING BVDV(8,1)
RESTRICTION ENZYME DIGESTION(8,1)
RNA SELFREPLICATION ABILITY(8,1)
ROCHE MOLECULAR BIOCHEMICAL(8,1)
SEQUENASE CYCLE SEQUENCING KIT(8,1)
VIRUS PROGENY PT CELL(8,1)
CLONING(7,3)
FUNCTIONAL C PROTEIN(7,3)
KOP R CELL INFECTION(7,3)
ANIMAL VIRUS DISEASE(7,2)
FEDERAL RESEARCH(7,2)
GENOMIC REGION ENCODING(7,2)
MATURE PROTEIN(7,2)
VACCINE GROUP ANIMAL(7,2)
AMERSHAM BIOSCIENCE(7,1)
ANTIGEN POSITIVE VIRUS PLAQUE(7,1)
BOOSTER VACCINATION(7,1)
BVDV GENOTYPE(7,1)
BVDV MUTANT(7,1)
BVDV NEUTRALIZING ANTISERA(7,1)
BVDV REPLICATION(7,1)
CATTLE IMMUNIZATION(7,1)
CEDI DIAGNOSTICS(7,1)
CHECKIT BVDV(7,1)
COMPLEMENTING PT CELL(7,1)
CONTAINED EMS DELETED REPLICON(7,1)
ERNS DELETED REPLICON(7,1)
EXPRESSION PLASMID ENCODING(7,1)
HEALTHY CATTLE(7,1)
IMMUNIZATION EFFECTIVENESS(7,1)
INDIRECT IMMUNOFLUORESCENCE STAINING(7,1)
INFECTIOUS PESTIVIRUS FORMATION(7,1)
MUTATED REPLICON(7,1)
PCR AMPLFICATION(7,1)
PESTIVIRAL GENOME(7,1)
PESTIVIRAL STRUCTURAL PROTEIN(7,1)
PESTIVIRUS CODING SEQUENCE(7,1)
PESTIVIRUS PROTEIN(7,1)
PESTIVIRUS SELF REPLICATING RNA(7,1)
PESTIVIRUS SPECIES SEQUENCE(7,1)
POLYPROTEIN EXPRESSION(7,1)
POOLED ANTI BVDV SERUM(7,1)
PT CELL TRANSFECTION(7,1)
REVERTANT BVDV(7,1)
SUBGENOMIC RNA(7,1)
THERMOSTABLE TAQ POLYMERASE(7,1)
TRANS COMPLEMENTED REPLICON(7,1)
TRANS COMPLEMENTED VIRION(7,1)
UNDILUTED SUPERNATANT(7,1)
UNPUBLISHED DATA(7,1)
VIRAL TITER(7,1)
VIRUS PLAQUE DETECTION(7,1)
W TRO TRANSCRIBED BVDV(7,1)
WRRO TRANSCRIBED RNA(7,1)
POSITIVE CELL(6,9)
SIGNAL SEQUENCE(6,8)
RESTRICTION SITE(6,2)
TRANSFECTED CELL(6,2)
AEROSOL DISPENSER(6,1)
BOVINE KIDNEY CELL(6,1)
BOVINE ORIGIN CELL(6,1)
BVDV PROPAGATION(6,1)
BVDV REPLICON CONSTRUCTION(6,1)
BVDV RNA(6,1)
CLINICAL SYMPTOM(6,1)
CONSTRUCT VARIANT(6,1)
DELETION MUTANT(6,1)
DIPLOID BOVINE(6,1)
HCMV PROMOTER(6,1)
IMMUNIZATION DAY(6,1)
INOCULATED ANIMAL(6,1)
KHRO YKH(6,1)
LIVE VACCINE(6,1)
MUTANT BVDV(6,1)
NUCLEAR PATHWAY(6,1)
PCR PRIMER(6,1)
PROTEASE CLEAVAGE(6,1)
PT MONOLAYER(6,1)
REVERTANT OCCURRENCE(6,1)
RNA REPLICATION(6,1)
RNA TEMPLATE(6,1)
RT PCR ANALYSIS(6,1)
SUPPLIER(6,1)
SYNTHESIZED CDNA(6,1)
TITRATION EXPERIMENT(6,1)
UNDILUTED SERUM(6,1)
VIRAL CONTAMINANT(6,1)
VIRUS DETECTION ASSAY(6,1)
VIRUS NEUTRALIZING(6,1)
WRO TRANSCRIBED RNA(6,1)
PCDNA(5,3)
AUTOMATIC SEQUENCER(5,1)
BLOCKING ELISA(5,1)
BVDV DETECTION(5,1)
CAPSID ENCODING REGION(5,1)
CAPTURE ELISA(5,1)
CDNA CLONE(5,1)
CELL ALIQUOT(5,1)
CELL ELECTROPORATION(5,1)
CELL FOCI(5,1)
CLINICAL OBSERVATION(5,1)
CODING SEQUENCE ENCODING(5,1)
CORRECT DELETION(5,1)
CYCLE VIRION(5,1)
DIPLOID CELL(5,1)
DNA RNA TRANSFECTION(5,1)
EASYJECT PLUS(5,1)
ELEVATED ELISA(5,1)
EXPERIMENT BEGINNING(5,1)
GENERATING VIRUS PROGENY ABILITY(5,1)
MARKED BOOSTER(5,1)
NUCLEOTIDE INSERTION(5,1)
PLASMID DNA(5,1)
POLYPROTEIN PROCESSING(5,1)
POSITIV SAMPLE(5,1)
PROTEIN CODING(5,1)
PROTEIN DELETION(5,1)
SELF REPLICATING RNA MOLECULE(5,1)
SEVERE DISEASE(5,1)
SPLICE SITE(5,1)
STRONG IMMUNOFLUORESCENCE(5,1)
STRUCTURAL PROTEIN SEQUENCE CODING(5,1)
SYNTHETIC ORF(5,1)
TRANS ACTING ELEMENT IDENTIFICATION(5,1)
TRANSIENT EXPRESSION(5,1)
VIRION PREPARATION(5,1)
VIRUS REPLICATION UNDERSTANDING(5,1)
WASHED LEUKOCYTE(5,1)
CELL CULTURE MEDIUM(4,4)
DARK(4,4)
FRAMESHIFT(4,2)
FUNCTIONAL E(4,2)
INCUBATION PERIOD(4,2)
LIFE TECHNOLOGY(4,2)
MUTATION(4,2)
N TERMINUS(4,2)
NASAL SECRETION(4,2)
PCR PRODUCT(4,2)
REPORT(4,2)
TRIPLICATE(4,2)
VETERINARY MEDICINE(4,2)
ANTIBODY FREE CATTLE SERUM(4,1)
BIOTYPE(4,1)
BVDV NEGATIVE PT CELL(4,1)
BVDV SEQUENCE(4,1)
BVDV STRUCTURAL REGION(4,1)
CAPSID REGION(4,1)
CEDI TEST(4,1)
CELL LYSATE(4,1)
CLEAR BOOSTER(4,1)
COLLECTION DAY(4,1)
CONTROL ANIMAL NASAL SWAB(4,1)
DILUTION FACTOR(4,1)
ESSENTIAL PROTEIN(4,1)
FUNCTIONAL PROTEIN(4,1)
GENE SEQUENCE(4,1)
GEOMETRIC(4,1)
GIBCO FE TECHNOLOGY(4,1)
HELPER CELL SUPERNATANT(4,1)
(JP2005535338)
REPLICON(100,37)
PROTEIN(100,31)
PESTIVIRUS(100,25)
STRUCTURAL PROTEIN(100,9)
INFECTIOUS VIRAL PARTICLE(100,7)
PESTIVIRUS REPLICON VACCINE(100,1)
REPLICON ECSO PESTIVIRUS(100,1)
INFECTIOUS PROGENY VIRUS(59,5)
CELL PACKAGED RNA GENOME(41,1)
RECOMBINANT INFECTIOUS BVDV(37,1)
PESTIVIRUS INFECTIOUS VIRAL PARTICLE(35,1)
COMPETENT VIRUS PROGENY(34,1)
CPBVDV APOTOSIS(33,1)
PESTIVIRUS PROTEIN STRUCTURE(32,1)
TRANSFECTING RNA REPLICON(32,1)
CELL CULTURE NCPBVDV INOCULATION(31,1)
MUTANT PROTEIN STRUCTURE(30,1)
PERSISTENT INFECTION(28,1)
AUTONOMOUS REPLICATION COMPETENT RNA DELETION(26,2)
GENE ENCODING(25,1)
MISSING PROTEIN(24,2)
NONSTRUCTURAL PROTEIN(24,2)
ENCODING MUTANT(24,1)
CAPSID PROTEIN(19,3)
PROTEIN SEQUENCE CODING(19,1)
VACCINATED ANIMAL(18,7)
VIRUS NEUTRALIZING(18,2)
PROTEIN FUNCTIONALITY(18,1)
ENVELOPE(17,2)
VIRAL PARTICLE PRODUCTION(17,2)
VIRION(16,7)
IMMUNE RESPONSE(16,4)
PESTI(16,3)
FUNCTIONAL REPLICON(16,1)
VACCINE(14,11)
REPLICATION GENERATION(14,1)
STILL ENVELOPE PROTEIN(14,1)
CODING REGION ENCODING(13,1)
ONH(12,1)
BVDV(11,39)
CODING SEQUENCE(11,6)
INFECTIOUS RECOMBINANT BVDV(11,3)
TRANSFECTED CELL(11,3)
DISEASE(11,1)
EXPRESS(11,1)
DELETION(10,10)
REPLICATION(10,5)
FULL COLOR PRINTHEAD(10,1)
IMMUNE RESPONSE CAUSE(10,1)
BVDV STRUCTURAL PROTEIN(9,5)
TARGET CELL INFECTION(9,2)
COMPLEMENTARITY BVDV REPLICON TRANSFORMER(9,1)
CELL DEATH(8,1)
COMMERCIAL VALUE(8,1)
PROGENY BVDV GENOME DELETION(8,1)
REPLICON REPLICATION COMPETENT VIRUS(8,1)
TRANS COMPLEMENTATION RECOMBINANT BVDV RECOVERY(8,1)
INFECTION(7,10)
INDIRECT ELISA(7,5)
PLASMID EXPRESSION(7,4)
CATTLE(7,2)
AMERSHAM BIOSCIENCE(7,1)
CULTURED CELL(7,1)
FLAVIVIRUS FAMILY TRANS COMPLEMENTATION(7,1)
GENOTYPE BVDV CHALLENGE(7,1)
MUTATION KUN REPLICON(7,1)
SERUM HOMOLOGOUS NEUTRALIZATION TITER(7,1)
VIRUS ISOLATION(6,5)
NCP7 INOCULATION(6,2)
VETERINARY FEDERAL RESEARCH(6,2)
AUTONOMOUS REPLICATION PESTIVIRUS RNA(6,1)
BVDV INFECTION SIGN(6,1)
CHALLENGED BVDV ANTIGEN(6,1)
CHALLENGED BVDV INFECTION(6,1)
COW NASAL VACCINATION(6,1)
EXPERIMENTALLY INFECTED BVDV(6,1)
GENOMIC BVDV CLEAVAGE(6,1)
INDIRECT IMMUNOFLUORESCENT STAINING(6,1)
REPLICATING REPLICON RNA MOLECULE(6,1)
TRANS BVDV CLINICAL SIGN(6,1)
SYN ORF(5,4)
BVDV ORF(5,2)
BVDV REPLICATION(5,2)
NEUTRALIZING TITER(5,2)
PESTIVIRUS PROTEIN(5,2)
RESPIRATORY SYMPTOM(5,2)
TRANS COMPLEMENTATION VIRUS INFECTION(5,2)
VIRAL POLYPROTEIN(5,2)
ANIMAL CHALLENGED BVDV(5,1)
ANTIBODY BVDV CHALLENGE(5,1)
AUTOMATED SEQUENCER LI COR(5,1)
BLOOD LEUKOCYTE CO CULTURE(5,1)
BVD VIRUS REPLICON(5,1)
BVDV ANTIBODY ELISA(5,1)
BVDV REPLICON RNA(5,1)
BVDV STRAIN CAPSID(5,1)
CALF PERSISTENT INFECTION(5,1)
DEFECTIVE BVDV GENOME(5,1)
DEFICIENT CSFV GENOME(5,1)
ENVELOPE PROTEIN GLYCOSYLATION(5,1)
ENVELOPE PROTEIN TRANSLOCATION(5,1)
ETHIDIUM BROMIDE STAINING(5,1)
HOG CHOLERA VIRUS(5,1)
INDIRECT BVDV ELISA(5,1)
INFECTION BVDV ANTIGEN(5,1)
INFECTIOUS CLONE ESTABLISHMENT(5,1)
INTERFERENCE DEFICIENCY CSFV(5,1)
MIDI MAXI KIT(5,1)
MUTO AEROSOL DISPENSER(5,1)
NASAL SWAB BVDV(5,1)
NCP BVDV RECOVERY(5,1)
NCP ENVELOPE PROTEIN(5,1)
NEUTRALIZING ANTIBODY TITER(5,1)
POLYPROTEIN TRANSLOCATION(5,1)
POST IMMUNE BLOOD LEUKOCYTE(5,1)
REPLICATIVE VIRAL PARTICLE(5,1)
REPLICON ECSO RESEARCH(5,1)
REPLICON TRANS COMPLEMENTATION(5,1)
RNA REPLICON SUPERNATANT(5,1)
SERONEGATIVE HEALTHY BOVINE HEAD(5,1)
STAINING TITRATION EXPERIMENT(5,1)
THERMO SEQUENASE CYCLE SEQUENCING KIT(5,1)
TRANS COMPLEMENTATION NCP(5,1)
TRANSFECTED PT SUPERNATANT(5,1)
VIRION FORMULATION IMMUNIZATION(5,1)
VIRUS GENOME RNA(5,1)
VIRUS NEUTRALIZATION EXPERIMENT(5,1)
VIRUS TITER VIRUS(5,1)
VIRUS VIRAL TITER(5,1)
CELL CULTURE SUPERNATANT(4,3)
POSITIVE SCORE(4,3)
ANIMAL VIRUS DISEASE(4,2)
BLOCKING ELISA(4,2)
BOVINE ORIGIN(4,2)
CELL RESISTANT CLONE(4,2)
CELL SUPERNATANT(4,2)
CELLULAR PROTEASE(4,2)
CLONE PT(4,2)
DELETION MUTANT(4,2)
DIPLOID BOVINE(4,2)
MATURE PROTEIN(4,2)
NUCLEOTIDE SEQUENCING(4,2)
SPLICE(4,2)
TRANS NCP(4,2)
ABNORMAL CLINICAL SCORE(4,1)
ANIMAL MARKED LEUKOPENIA(4,1)
ANIMAL REMAINED BVDV(4,1)
BLOOD LEUKOCYTE EDTA(4,1)
BOVINE ANTI BVDV SERUM(4,1)
BOVINE SERUM ANTIBODY(4,1)
BVD RNA MOLECULE(4,1)
BVDV MUTATION(4,1)
CEDI DIAGNOSTICS(4,1)
CELL REPLICON RNA(4,1)
CHECKIT BVDV III(4,1)
CODING SEQUENCE PORTION(4,1)
DELETION REPLICON(4,1)
DELETION VIRION(4,1)
EXPRESSION PLASMID ENCODING(4,1)
FETAL BOVINE SERUM(4,1)
FLAVIVIRUS GENUS(4,1)
IMMEDIATE EARLY PROMOTER(4,1)
IMMUNOPRECIPITATION EXPERIMENT(4,1)
INFECTION SEROLOGY(4,1)
INFECTIOUS BVDV(4,1)
INFECTIOUS PESTIVIRUS(4,1)
INFECTIOUS PROGENY(4,1)
INFECTIOUS VIRION PRODUCTION(4,1)
MAB BVDV(4,1)
METHIONINE CODON(4,1)
NEGATIVE SERUM BVDV ANTIBODY(4,1)
NEUTRALIZING ANTISERUM(4,1)
NON COMPLEMENTARY PT(4,1)
PERMANENT BOVINE KIDNEY(4,1)
PESTIVIRUS CODING SEQUENCE(4,1)
PESTIVIRUS ORF(4,1)
PESTIVIRUS REPLICATION(4,1)
PESTIVIRUS VIRION(4,1)
POLYPROTEIN EXPRESSION(4,1)
POST IMMUNE DATA(4,1)
PROTEIN CODING REGION(4,1)
PT BVDV INFECTION PATTERN(4,1)
PT IMMUNOFLUORESCENT(4,1)
REPLICON CELL EXPRESSION(4,1)
REPLICON MUTATION(4,1)
RESTRICTION ENZYME DIGESTION(4,1)
RESTRICTION SITE KPNI(4,1)
ROCHE MOLECULAR BIOCHEMICAL(4,1)
SERUM NEUTRALIZATION ASSAY(4,1)
STRUCTURAL PROTEIN BVDV(4,1)
SUBCLINICAL INFECTION SIGN(4,1)
TRANS ACTING ELEMENT PESTIVIRUS GENOME(4,1)
TRANS COMPLEMENTARITY(4,1)
TRANS COMPLEMENTATION DEFICIENCY(4,1)
TRANSFECTED REPLICON(4,1)
TRANSFORMER BVDV(4,1)
TRANSFORMER COMPLEMENTARITY(4,1)
UNPUBLISHED DATA(4,1)
VIRUS CAPSID PROTEIN(4,1)
VIRUS INOCULATION(4,1)
VIRUS SUSPENSION TITER(4,1)
WORLDWIDE ECONOMIC IMPORTANCE(4,1)
AMINOACID POSITION(3,4)
CELL PT(3,3)
ELECTROPORATION(3,3)
418 RESISTANT COLONY(3,2)
CLONING(3,2)
INITIAL IMMUNIZATION(3,2)
POST TRANSLATIONAL PROCESSING(3,2)
TRYPSIN SOLUTION(3,2)
BOVINE KIDNEY CELL(3,1)
BOVINE VIRAL DIARRHEA VIRUS REPLICON(3,1)
BVDV NEGATIVE PT(3,1)
BVDV REPLICON CONSTRUCTION(3,1)
BVDV VIRUS(3,1)
CLINICAL SYMPTOM(3,1)
CONSECUTIVE BHK(3,1)
CSFV CONDITION REPLICATION(3,1)
DIGESTED PLASMID(3,1)
EXPRESSION ESTABLISHMENT(3,1)
EYE INFECTION(3,1)
FALSE VIRION(3,1)
FUNCTIONAL PROTEIN EXPRESSION(3,1)
HCMV PROMOTER(3,1)
IMMUNIZED ANIMAL(3,1)
INACTIVATED SERUM(3,1)
INFECTED CELL EXPRESS(3,1)
INFECTIOUS VIRUS PARTICLE PRODUCTION(3,1)
INOCULATED ANIMAL(3,1)
LETHAL CHALLENGE(3,1)
LIVE VACCINE(3,1)
MUTANT BVDV(3,1)
PCR FRAGMENT(3,1)
PESTIVIRUS SHORT SPLICING SITE(3,1)
PLASMID DNA(3,1)
POST IMMUNE SERUM(3,1)
POST INFECTION DETECTION(3,1)
PROTEASE CLEAVAGE(3,1)
QIAGEN PLASMID(3,1)
RNA TEMPLATE(3,1)
RNA TRANSFECTION(3,1)
RT PCR ANALYSIS(3,1)
SERUM NEUTRALIZING(3,1)
STAINING INTENSITY(3,1)
SUBGENOMIC RNA(3,1)
TRANSFECTION KIT(3,1)
TRIZOL REAGENT(3,1)
VACCINE GROUP IMMUNIZATION(3,1)
VIRAL PLAQUE(3,1)
VIRAL REPLICATION(3,1)
VIRUS DETECTION ASSAY(3,1)
POSITIVE CELL(2,4)
COLLECTION SUBJECT(2,2)
FRAMESHIFT(2,2)
INCUBATION PERIOD(2,2)
KUNJIN VIRUS(2,2)
PCR PRODUCT(2,2)
RESISTANT CELL(2,2)
SIGNIFICANT ECONOMIC LOSS(2,2)
AGE MONTH(2,1)
ALTITUDE SENSITIVITY KOP R(2,1)
AMPLIFIED TAQ POLYMERASE(2,1)
ANIMAL ELISA(2,1)
ANIMAL HEAD(2,1)
ANTIBODY NEGATIVE(2,1)
BIOTYPE(2,1)
BLOCKING BVDV(2,1)
BORDER DISEASE VIRUS(2,1)
BOVINE IMMUNE(2,1)
BOVINE VIRAL DIARRHEA DISEASE(2,1)
BVDV PARTICLE(2,1)
BVDV RNA(2,1)
BVDV SAFE(2,1)
BVDV SEQUENCE(2,1)
CAPSID CODING REGION(2,1)
CAPTURE ELISA(2,1)
CELL ALIQUOT(2,1)
CE(...)";"Basic materials chemistry
Pharmaceuticals";Open
"2002-08-01
2003-07-30
2005-01-31";"WO2004013151        A2 2004-02-12 [WO200413151]
STG: (A2) International application published without international search report
AP : 2003WO-CA01156 2003-07-30
CA2494223           A1 2004-02-12 [CA2494223]
STG: (A1) Application laid open
AP : 2003CA-2494223 2003-07-30
AU2003254665        A1 2004-02-23 [AU2003254665]
STG: (A1) Open to public inspection
AP : 2003AU-0254665 2003-07-30
WO2004013151        A3 2004-07-01 [WO200413151]
STG: (A3) Later publication of ISR with revised front page
AP : 2003WO-CA01156 2003-07-30
EP1527080           A2 2005-05-04 [EP1527080]
STG: (A2) Application published without search report
AP : 2003EP-0766087 2003-07-30
BR0312896           A  2005-06-14 [BR200312896]
STG: (A) Published application
AP : 2003BR-0012896 2003-07-30
BRPI0312896         A1 2005-06-14 [BRPI0312896]
STG: (A1) Published application
AP : 2003BR-0012896 2003-07-30
CN1671722           A  2005-09-21 [CN1671722]
STG: (A) Published application
AP : 2003CN-0818185 2003-07-30
JP2005534752        A  2005-11-17 [JP2005534752]
STG: (A) Published application
AP : 2004JP-0525093 2003-07-30
US20060165728       A1 2006-07-27 [US20060165728]
STG: (A1) Application published
AP : 2003US-10523459 2003-07-30
US7598354           B2 2009-10-06 [US7598354]
STG: (B2) Granted patent as second publication
AP : 2003US-10523459 2003-07-30
FD :  Provisional Appl: US60/399,735 FDD=2002-08-01 [2002US-60399735]
FD : Previous publication: US20060165728 A1 2006-07-27 [US20060165728]
AU2003254665        B2 2010-01-28 [AU2003254665]
STG: (B2) Patent proceeded by OPI
AP : 2003AU-0254665 2003-07-30
AU2003254665        C1 2010-08-19 [AU2003254665]
STG: (C1) Amended after Acceptance/Grant of a standard patent
AP : 2003AU-0254665 2003-07-30
JP4718174           B2 2011-04-08 [JP4718174]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2004JP-0525093 2003-07-30
BRPI0312896         A2 2011-05-24 [BR200312896]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2003BR-0012896 2003-07-30
EP1527080           B1 2012-06-20 [EP1527080]
STG: (B1) Patent specification
AP : 2003EP-0766087 2003-07-30
CA2494223           C  2012-10-02 [CA2494223]
STG: (C) Patent (second level)
AP : 2003CA-2494223 2003-07-30
ES2391525           T3 2012-11-27 [ES2391525]
STG: (T3) Translation of granted European patent (former B3)
AP : 2003ES-0766087T 2003-07-30";1707276;"WO2004013151        A2 2004-02-12 [WO200413151]
CA2494223           A1 2004-02-12 [CA2494223]
AU2003254665        A1 2004-02-23 [AU2003254665]
WO2004013151        A3 2004-07-01 [WO200413151]
EP1527080           A2 2005-05-04 [EP1527080]
BR0312896           A  2005-06-14 [BR200312896]
BRPI0312896         A1 2005-06-14 [BRPI0312896]
CN1671722           A  2005-09-21 [CN1671722]
JP2005534752        A  2005-11-17 [JP2005534752]
US20060165728       A1 2006-07-27 [US20060165728]
US7598354           B2 2009-10-06 [US7598354]
AU2003254665        B2 2010-01-28 [AU2003254665]
AU2003254665        C1 2010-08-19 [AU2003254665]
JP4718174           B2 2011-04-08 [JP4718174]
BRPI0312896         A2 2011-05-24 [BR200312896]
EP1527080           B1 2012-06-20 [EP1527080]
CA2494223           C  2012-10-02 [CA2494223]
ES2391525           T3 2012-11-27 [ES2391525]";"2002US-60399735
2003WO-CA01156
2005US-10523459";"(EP1527080)
WO2004013151
(US7598354)
WO2004013151
(JP4718174)
WO2004013151
(CN1671722)
WO2004013151
(AU2003254665)
WO2004013151
(BR200312896)
WO2004013151
(CA2494223)
WO2004013151
(ES2391525)
WO2004013151";NATIONAL RESEARCH COUNCIL OF CANADA;NATIONAL RESEARCH COUNCIL OF CANADA;"(EP1527080)
CA
(EP1527080)
CA
(US7598354)
CA
(WO200413151)
CA

(BRPI0312896)
CA
(BR200312896)
CA
(CA2494223)
CA
(CA2494223)
CA";"(EP1527080)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA Intellectual Property Services, EG-12, Bldg. M-58, Montreal Road , CITY=Ottawa, Ontario K1A 0R6 , COUNTRY=CA 

(EP1527080)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA Intellectual Property Services,  EG-12, Bldg. M-58,  Montreal Road , CITY=Ottawa, Ontario K1A 0R6 , COUNTRY=CA , REG=100184605 

(US7598354)
NAME=National Research Council of Canada , CITY=Ottawa, Ontario , COUNTRY=CA , ATYP=Non-US Company 

(WO200413151)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA  [CA/ CA] Intellectual Property Services, Montreal Road, Bldg. M58, Room EG12, Ottawa, Ontario K1A 0R6  , COUNTRY=CA 

(JP2005534752)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA , REG=302046528 

(JP4718174)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA , REG=302046528 

(BRPI0312896)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA , COUNTRY=CA 

(BR200312896)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA , COUNTRY=CA 

(CA2494223)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA 1200 Montreal Road, OTTAWA, O1, K1A 0R6 , COUNTRY=CA 

(CA2494223)
NAME=NATIONAL RESEARCH COUNCIL OF CANADA 1200 Montreal Road , CITY=OTTAWA , STATE=O1 , POSTCODE=K1A 0R6 , COUNTRY=CA 
";1;"YOUNG NOEL M
BRISSON JEAN-ROBERT
KELLY JOHN FRANCIS
WATSON DAVID C
SZYMANSKI CHRISTINE M
JARRELL HAROLD C";"(EP1527080)
CA";"(EP1527080)
NAME=YOUNG, Noel, M. 51 East Park Drive , CITY=Ottawa, Ontario K1B 3Z6 , COUNTRY=CA 

NAME=BRISSON, Jean-Robert 14 Simcoe Street , CITY=Ottawa, Ontario K1S 1A2 , COUNTRY=CA 

NAME=KELLY, John, Francis 1106 Dunning Road, P.O. Box 64 , CITY=Ottawa, Ontario K4C 1E5 , COUNTRY=CA 

NAME=WATSON, David, C. 65 Melrose Avenue , CITY=Ottawa, Ontario K1Y 1T8 , COUNTRY=CA 

NAME=SZYMANSKI, Christine, M. 6573 Tooney Drive , CITY=Ottawa, Ontario K1C 6G3 , COUNTRY=CA 

NAME=JARRELL, Harold, C. 1340 Georges Vanier Drive , CITY=Ottawa, Ontario K4C 1R6 , COUNTRY=CA 
";"(EP1527080)
Campylobacter glycans and glycopeptides";"(EP1527080)
Multiple strains and species of Campylobacter were found to share a common glycan moitie which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1,4-GalNAc-a1,4-[Glc-ß1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.";"(WO200413151)
WE CLAIM:
1. A compound comprising a heptasaccharide of formula GalNAc- a1 ,4-GalNAc-a1 ,4-[Glc-β1 ,3]GalNAc-a1 ,4-GalNAc-a1 ,4-GalNAc-a1 ,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose or an immunologically active fragment thereof.
2. The compound as defined in claim 1 linked to an, amino acid or oligopeptide.
3. The compound as defined in claim 2 wherein said amino acid is asparagine.
4. The compound as defined in any of claims 1 , 2 or 3 derived from a glycoprotein isolated and purified from a campylobacter bacterium.
5. The compound as defined in claim 4, wherein said bacterium is selected from C. jejuni, C. coli and C. fetus ssp. venerealis.
6. A method of detecting a glycan moiety of a bacterial glycoprotein, the method comprising subjecting said sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy.
7. A pharmaceutical composition comprising a compound of any of claims 1 through 5 and a physiologically acceptable carrier.
8. The pharmaceutical composition as defined in claim 7, further comprising an immunogenic conjugate.
9. The pharmaceutical composition of claim 7 or 8, further comprising an immunostimulant.
10. Use of the pharmaceutical composition as defined in any one of claims 7 through 9 as a vaccine in an animal or a human.
11. An antibody or an antigen-binding fragment of an antibody that specifically binds with a compound comprising a glycan of the formula GalNAc- a1 ,4-GalNAc-a1 ,4-[Glc-β1 ,3]GalNAc-a1 ,4-GalNAc-a1 ,4-GalNAc-a1 ,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose or an immunologically active fragment thereof.
12. An antibody or an antigen-binding fragment of an antibody that specifically binds with a compound as defined in any of claims 1 through 6 5.
13. An antibody or an antigen-binding fragment of an antibody which specifically binds with a compound as defined in any one of claims 1 through 6 δderived from a gene isolated from a camelid.
14. The antibody or antigen-binding fragment thereof as defined in claim 13, wherein said camelid is selected from Camelus bactriamus, Camelus dromaderius, Lama pPaccos, Lama ggGlama and Lama vVicugna.
15. A pharmaceutical composition comprising the antibody or antigen- binding fragment as defined in any one of claims 11 through 14, and a physiologically acceptable carrier.
16. Use of the pharmaceutical composition as defined in claim 15 as a therapeutic agent in a human or an animal.
17. A method of reducing the presence of campylobacter pathogens from livestock, the method comprising administering to the livestock the antibody or antigen-binding fragment as defined in any one of claims 11 through 15.
18. A method as defined in claim 17, wherein said administration consists of feeding the livestock with feed mixed with said antibody or antigen- binding fragment.
19. The method as defined in claim 17 or 18, wherein said livestock is poultry.
20. A method of preventing campylobacter infections caused by campylobacter pathogens in a human, the method comprising removing said pathogens from livestock by the method as defined in claim 17.
21. A method of treating a disease caused by campylobacter pathogens in a human or an animal, the method comprising administering the antibody or antigen-binding fragment as defined in any one of claims 11 through 14.
22. A method of preventing ground water contamination by campylobacter pathogens, the method comprising reducing the presence of said pathogens from livestock by the method as defined in claim 17.
23. An animal feed or drink for livestock comprising the antibody or antigen-binding fragment as defined in any one of claims 11 through 14.
24. A feed or drink as defined in claim 23 comprising an additive comprising said antibody or fragment.
25. A feed as defined in claim 23 comprising a plant containing a genome modified to express said antibody or fragment.
26. A plant genome containing a gene capable of expressing the antibody or antibody fragment as defined in any of claims 11 through 14.
27. A plant cell containing the genome defined in claim 26.
28. A plant containing the cell defined in claim 27.
29. The plant genome of claim 26, wherein said gene is obtained by panning a library of camelid genes with a probe comprising the compound defined in claims 1 through 5, for camelid genes capable of expressing said antibody fragment and incorporating said gene in a plant genome.
30. A diagnostic kit for detecting the presence of campylobacter in animals or humans, said kit comprising the antibody or antibody fragment defined in any of claims 11-14.
31. A diagnostic kit for detecting the presence of campylobacter in a sample, said kit comprising the antibody or antibody fragment defined in any of claims 11-14.
32. The kit defined in claim 31 wherein said sample is selected from water, soil and manure.";"(EP1527080)
The present inventors have discovered that certain glycopeptides and gylcan moieties form an effective basis for vaccines and antibodies against multiple strains of campylobacter bacteria, by virtue of their ubiquitous presence on the surface of these bacteria in an invariant (or nearly invariant) form across multiple strains and species.
The invention is in the field of biologically active glycoproteins and glycan moieties of glyocoproteins as well as vaccines, antibodies and antibody fragments useful for combating campylobacter bacteria.
It is an object of the invention to provide a glycan which may exist either in isolation or linked to an oligo peptide, an amino acid and/or an immunogenic conjugate.
In accordance with one aspect, the invention provides a compound comprising a heptasaccharide of formula I: GaINAc-a1,4-GaINAc-a1,4-[Glc- 1,3]GaINAc-a1,4-GaINAc-a1,4-GaINAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose.
It is an object of the invention to provide a glycan which may exist either in isolation or linked to an oligo peptide, an amino acid and/or an immunogenic conjugate.";"(EP1527080)
It is thus desirable to provide strategies for combating its deleterious effects in humans.
While in general there is high degree of variance of glycoproteins and their glycan moieties in antigenic surface glycans between bacterial strains and re lated species, this is not always the case and such exceptions present suitable excellent candidates for antibody or vaccine-based strategies for eliminating bacteria.
It is also desirable to provide research tools having general application for studying protein glycosylation.
This conclusion is supported by the failure of these protein spots to react with the SBA/alkaline phosphatase conjugate following 2D PAGE and electroblotting (Table I).
failure of these protein spots to react with the SBA/alkaline phosphatase conjugate following 2D PAGE and electroblotting (Table I).";"A01H-005/00
A23K-001/16
A23K-001/18
A23L-001/30
A61K-039/02
A61K-039/106
A61K-039/395
A61K-047/48
A61P-031/04
C07H-003/06
C07K-014/205
C07K-016/12
C08B-037/00
C12N-005/04
C12N-005/10
C12N-015/09
C12N-015/10
G01N-024/08
G01N-033/483
G01N-033/569
G01N-033/68";"(EP1527080)
1. A compound comprising an isolated heptasaccharide of formula GalNAc- 1,4-GalNAc- 1,4-[Glc- 1,3]GalNAc- 1,4-GalNAc- 1,4-GalNAc- 1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose.";"(EP1527080)
GLYCOPEPTIDE(100,27)
CAMPYLOBACTER GLYCAN(100,1)
COMBATING CAMPYLOBACTER BACTERIUM(82,1)
CAMPYLOBACTER BACTERIA STRAIN(73,1)
FORMULA GALNAC ISOLATED HEPTASACCHARIDE(73,1)
CAMPYLOBACTER PATHOGEN GROUNDWATER CONTAMINATION(72,1)
GLYOCOPROTEIN POLYSACCHARIDE MOIETY(71,1)
BACTERIAL GLYCOPROTEIN GLYCAN MOIETY(60,1)
POLYSACCHARIDE PEPTIDE(59,1)
IMMUNOGENIC CONJUGATE(51,4)
ANTIBODY(48,49)
BIOLOGICALLY ACTIVE GLYCOPROTEIN(42,1)
ANTIBODY FRAGMENT(41,18)
GALNAC(41,5)
GYLCAN MOIETY(41,1)
ANTIGEN(38,22)
OLIGOPEPTIDE(38,7)
PROTEIN FAILURE(38,1)
CAMELUS DROMADERIUS(37,1)
LIVESTOCK(36,27)
CAMELUS BACTRIAMUS(36,1)
ALKALINE PHOSPHATASE CONJUGATE(35,2)
DIAGNOSTIC KIT(35,2)
UBIQUITOUS PRESENCE VIRTUE(35,1)
FORMULA GLYCAN MOIETY(33,1)
LAMA GGGLAMA(33,1)
LAMA PPACCO(33,1)
LAMA VVICUGNA(33,1)
CAMPYLOBACTER PATHOGEN PRESENCE(32,1)
FORMULA HEPTASACCHARIDE(31,2)
INVARIANT(29,2)
CAMPYLOBACTER BACTERIA PRESENCE(27,2)
FECAL MATTER ENTRY(27,1)
HR MA NMR(27,1)
GLYCAN(24,1)
VACCINE(23,8)
CAMPYLOBACTER PRESENCE(23,5)
DIACETAMIDO(22,1)
PROBABLE PERIPLASMIC PROTEIN(18,12)
ANOMERIC RESONANCE(18,9)
ACROSS MULTIPLE STRAIN(17,1)
POLYSACCHARIDE(15,13)
THERAPEUTIC AGENT(15,2)
FECAL SHEDDING RESULT(15,1)
IMMUNOSTIMULANT(14,3)
ALKALINE PHOSPHATASE(14,2)
AMERSHAM BIOSCIENCE(14,2)
NEISSERIA SPP PGL(14,1)
BACTERIA SURFACE(13,1)
CAMPYLOBACTER GLYCOPROTEIN POLYSACCHARIDE MOIETY(13,1)
FOODBOME PATHOGEN CAMPYLOBACTER(13,1)
CAMPYLOBACTER SPECIES(12,4)
CAMPYLOBACTER INFECTION(12,3)
ADDITIVE(12,1)
GOAT ANTI RABBIT ANTISERUM DILUTION(12,1)
AMINOACID(11,12)
BIO RAD LABORATORY(11,5)
DRINK(11,1)
STAININGB PGLB MUTANTC(11,1)
POULTRY(10,5)
ADMINISTRATION(10,3)
BACTERIUM FECAL SHEDDING(10,1)
COW VAGINAL MUCUS(10,1)
DOUBLY PROTONATED GLYCOPEPTIDE ION(10,1)
ENTERIC PATHOGEN CAMPYLOBACTER(10,1)
MUTANT CAPSULAR POLYSACCHARIDE(10,1)
PATHOGENIC CAMPYLOBACTER ORGANISM(10,1)
RESISTANT TRANSFORMANT(10,1)
2D PAGE(9,9)
SEARCHING DATABASE(9,3)
ROCHE MOLECULAR BIOCHEMICAL(9,2)
GENERAT ING PEAP(9,1)
ISOGENIC PGLB MUTANT(9,1)
MALCOLM LEVITT DECOUPLING CYCLE(9,1)
PARALYZED FLAGELLUM PROTEIN(9,1)
PGLB MUTANT CHARACTERIZATION(9,1)
PROBABLE SECRETED PROTEINASE(9,1)
TRYPSIN AUTOLYSIS PEPTIDE(9,1)
DISEASE(8,7)
PVDF MEMBRANE(8,4)
CORRELATION SPECTROSCOPY(8,2)
DA SUGAR MOIETY(8,2)
NAC RESONANCE(8,2)
SELECTIVE EXCITATION BANDWIDTH(8,2)
SOYBEAN AGGLUTININ(8,2)
BACTERIOPHAGE LIBRARY SCREENING(8,1)
PLASMID PPCR SCRIPT AMP(8,1)
DEUTERATED EDETIC ACID(7,4)
PROTEIN IDENTIFICATION(7,4)
LC PACKING(7,3)
MASS FINGERPRINT(7,3)
SELECTIVE EXPERIMENT(7,3)
SIGMA ALDRICH(7,3)
BACTERIAL CELL PROTON SPECTRA(7,2)
DEOXYCHOLATE PAGE(7,2)
GAINAC RESIDUE(7,2)
HOD RESONANCE(7,2)
MANUFACTURER INSTRUCTION(7,2)
MURINE MONOCLONAL ANTIBODY(7,2)
SPOT IDENTITY(7,2)
WESTERN BLOTTING(7,2)
2D GEL WESTERN BLOT(7,1)
AMPLITAQ CYCLE SEQUENCING KIT(7,1)
ANOMERIC SUGAR RESONANCE(7,1)
CAMELID LYMPHOCYTE(7,1)
CAMPLYLOBACTER JEJUNI(7,1)
CAMPYLOBACTER JEJUNI(7,1)
CAMPYLOBACTER OLIGOSACCHARIDE(7,1)
CAMPYLOBACTER TARGETING(7,1)
CE PUTATIVE CAPSULE(7,1)
CLONED GENE LIBRARY(7,1)
DOUBLY PROTONATED ION(7,1)
EXPERIMENTALLY INFECTED HUMAN VOLUNTEER(7,1)
FRACTION TRYPTIC DIGEST(7,1)
GLYCOPEPTIDE FRAGMENT ION(7,1)
GLYCOPROTEIN BIOSYNTHESIS(7,1)
GLYCOPROTEIN YIELD(7,1)
GRADIENT CRITERION SLAB GEL(7,1)
GUILAIN BARRE SYNDROME(7,1)
HEPTASACCHARIDE FRAGMENT(7,1)
HETERONUCLEAR MULTIPLE QUANTUM CORRELATION(7,1)
HEXNAC ION SIGNATURE(7,1)
IDENTIFIED GLYCOPROTEIN GLYCOSYLATION(7,1)
LECTIN AFFINITY CHROMATOGRAPHY(7,1)
LECTIN PROBING(7,1)
MATRIX ASSISTED LASER DESORPTION(7,1)
MICRO PRECOLUMN CARTRIDGE(7,1)
MUTANT CELL EXTRACT(7,1)
MUTANT NMR SPECTRUM(7,1)
MUTATED PLASMID DNA(7,1)
OXIDOREDUCTASE SUBUNIT(7,1)
PRONASE DIGEST MESH(7,1)
PRONASE DIGESTION ROUND(7,1)
PROTEIN MOIETY(7,1)
RE LATED FRAGEMENT(7,1)
RESIDUE ANOMERIC PROTON(7,1)
SINGLY PROTONATED FRAGMENT ION(7,1)
SUPEROXIDE DISMUTASE(7,1)
TRYPTIC DIGEST MASS SPECTROMETRY(7,1)
TRYPTIC GLYCOPEPTIDE(7,1)
VENEREALIS BIOTYPE(7,1)
ANIMAL SERUM(6,2)
COLLISION INDUCED DISSOCIATION(6,2)
COLUMN ELUATE(6,2)
DOWNFIELD SHIFT(6,2)
GAL AGAR(6,2)
HEX RESIDUE(6,2)
MHZ SPECTROMETER(6,2)
RE FRACTIONATION(6,2)
RECONSTRUCTED MASS PROFILE(6,2)
RESONANCE ASSIGNMENT(6,2)
UV ABSORBANCE(6,2)
1D TOCSY NOESY(6,1)
ANOMERICS RESONANCE(6,1)
BROADBAND DECOUPLING(6,1)
CAMPYLOBACTER STRAIN(6,1)
CAPSULAR RESONANCE(6,1)
CKANB PRIMER(6,1)
COMPOUND MOIETY(6,1)
ESI MS SPECTRUM(6,1)
EUKARYOTIC GLYCOPROTEIN(6,1)
GALNAC LECTIN(6,1)
GLYCOPEPTIDE PURIFICATION(6,1)
GLYCOSIDATION SITE(6,1)
GUILLAIN BARR SYNDROME(6,1)
HEPTASACCHARIDE MOIETY(6,1)
HEWLETT PACKARD CHROMATOGRAPH(6,1)
HOD SUPPRESSION(6,1)
HOMOGENEOUS POLYACRYLAMIDE GEL(6,1)
IMMUNOLOGIC STRATEGY(6,1)
INCOMING PLASMID DNA(6,1)
INTACT CAMPYLOBACTER CELL(6,1)
INTACT GLYCOPEPTIDE(6,1)
INTER RESIDUE CORRELATION(6,1)
INTESTINAL INFECTION(6,1)
ISOELECTRIC FOCUSING(6,1)
ISOGENIC MUTANT(6,1)
KD CHAPERONIN(6,1)
KSPM MUTANT(6,1)
LIVESTOCK MANURE(6,1)
MALDI ACQUISITION(6,1)
MASCOT DAEMON(6,1)
MUELLER HINTON AGAR(6,1)
MUELLER HINTON BROTH(6,1)
OLIGOSACCHARIDE RESIDUE SEQUENTIAL LOSS(6,1)
PATHOGEN ELIMINATION(6,1)
PATHWAY EVIDENCE(6,1)
PERIPLASMIC SOLUTE(6,1)
PGL PATHWAY(6,1)
PGLB MUTATION(6,1)
PROBABLE INTEGRAL MEMBRANE PROTEIN(6,1)
PROTEIN IMMUNODETECTION(6,1)
PROTEIN IMMUNOREACTIVITY(6,1)
SELECTIVE EXCITATION EXPERIMENT(6,1)
SINGLY CHARGED FRAGMENT ION(6,1)
TRYPTIC PEPTIDE ANALYSIS(6,1)
TRYPTIC PEPTIDE PLUS(6,1)
VARIAN SATURN(6,1)
VETERINARY PATHOGEN(6,1)
ACETONITRILE(5,4)
L ASPARAGINE(5,2)
ANTIBODY DOSE(5,1)
ANTIGEN DOSE(5,1)
ANTIGENIC PEPTIDE(5,1)
B3 OBSERVATION(5,1)
BOUND GLYCOPROTEIN(5,1)
CAMELID SPECIES(5,1)
CAMELLD SPECIES(5,1)
CARRIER TO HUMAN(5,1)
CATION EXCHANGE CHROMATOGRAPHY(5,1)
CJ GENE ANNOTATION(5,1)
CLONING EXPERIMENT(5,1)
COMMON POLYSACCHARIDE IDENTITY(5,1)
COMPOUND IMMUNOLOGICALLY ACTIVE FRAGMENT(5,1)
DNA SEQUENCER(5,1)
ESI MS ANALYSIS(5,1)
EUBACTERIA DOMAIN(5,1)
EUKARYOTIC PHENOMENON(5,1)
FAINT PROTEIN(5,1)
FETUS SSP(5,1)
FOCUS SPOT(5,1)
FORMULA MOIETY(5,1)
FROZEN CELL PELLET(5,1)
GENOME SEQUENCE DATABASE(5,1)
GLYCOPEPTIDE YIELD(5,1)
GLYCOPROTEIN EXTRACT PREPARATION(5,1)
GLYCOSIDATION SHIFT(5,1)
GLYCOSIDIC LINKAGE(5,1)
GLYCOSYLATED PROTEIN(5,1)
GROUNDWATER PROTECTION(5,1)
HEXNAC RESIDUE(5,1)
HEXNAC SEQUENTIAL LOSS(5,1)
HUMAN CONTAMINATION RISK(5,1)
HYPOTHETICAL PROTEIN(5,1)
IDENTICAL CAPSULAR REPEAT(5,1)
IMMUNOLOGIC TARGET(5,1)
INFECTION INCIDENCE(5,1)
ISOLATED GLYCOPEPTIDE(5,1)
JEJUNI STRAIN(5,1)
KANAMYCIN RESISTANCE CASSETTE(5,1)
KPSM MUTANT(5,1)
MAJOR ANTIGENIC PROTEIN(5,1)
MILLER FISHER SYNDROME(5,1)
MILLIPORE CORPORATION(5,1)
MOUSE COLONIZATION LOSS(5,1)
MUTANT SPECTRUM(5,1)
NMR ASSIGNMENT(5,1)
NMR EXPERIMENT(5,1)
PFU POLYMERASE(5,1)
PGL FOCUS(5,1)
PGL MUTATION(5,1)
PHARMACIA HR(5,1)
PROKARYOTIC ORGANISM DIVERSE GROUP(5,1)
PROMEGA MODIFIED TRYPSIN(5,1)
PROTEIN INTENSITY(5,1)
PROTEINASE K DIGEST(5,1)
PROTON ASSIGNMENT(5,1)
PURIFIED GLYCOPEPTIDE(5,1)
Q TOF MICRO ELECTROSPRAY INTERFACE(5,1)
QUADRUPLY CHARGED ION(5,1)
SEROTYPING SERUM(5,1)
SIGNIFICANT FOOD BORNE PATHOGEN(5,1)
TERMINATOR CHEMISTRY(5,1)
UNKNOWN PROTEIN(5,1)
UNUSUAL SUGAR(5,1)
WIDESPREAD PROTEIN GLYCOSYLATION(5,1)
XBAI RESTRICTION(5,1)
APPLIED BIOSYSTEM(4,6)
CARR PURCELL MEIBOOM GILL(4,4)
ANIMAL PRODUCTION(4,3)
BACILLOSAMINE(4,3)
CENTRIFUGATION(4,3)
COMMON RESONANCE(4,3)
NAC GROUP(4,3)
ARCHAEA(4,2)
CONJUGATE(4,2)
EXTERNAL ACETONE METHYL RESONANCE(4,2)
GRAM NEGATIVE BACTERIA(4,2)
LIPOOLIGOSACCHARIDE(4,2)
MS SPECTRA(4,2)
ORIFICE VOLTAGE(4,2)
REACHING HUMAN(4,2)
RECONSTRUCTED MOLECULAR MASS PROFILE(4,2)
SHARP PEAK(4,2)
WHOLE GENOME SEQUENCE(4,2)
13C NMR DATA(4,1)
AMERICAN SOCIETY(4,1)
ANTIBODY DOMAIN(4,1)
ASN LINKED GLYCOPEPTIDE(4,1)
B1 B3(4,1)
BACTERIAL STRAIN(4,1)
CAPLC PUMP(4,1)
CASSETTE ORIENTATION(4,1)
CHROMATOGRAPHY PURIFICATION(4,1)
COLLOIDAL COOMASSIE BLUE(4,1)
COOMASSIE BLUE STAIN(4,1)
DECREASED ADHESION(4,1)
FORMULA POLYSACCHARIDE(4,1)
GC MS ANALYSIS(4,1)
GENTLE STIRRING(4,1)
GLYCOPEPTIDE PREPARATION(4,1)
GRADIENT ELUTION(4,1)
HEXNAC ABSOLUTE CONFIGURATION(4,1)
IMMUNOGENIC ACTIVITY(4,1)
IMMUNOGENICITY LOSS(4,1)
INFUSION MS(4,1)
IRON UPTAKE(4,1)
JEJUNI WHOLE CELL(4,1)
LINKED CARBOHYDRATE(4,1)
MANURE SAMPLE(4,1)
MEDICAMENT PREPARATION(4,1)
MS COLLISION OFFSET(4,1)
OBTAINING ANTIBODY(4,1)
OVERLAPPING RESONANCE(4,1)
OXIDANIUM ION(4,1)
PEPTIDE EXTRACT(4,1)
POLYSACCHARIDE MAGIC ANGLE SPINNING(4,1)
PRECURSOR ION SCAN(4,1)
PROTEIN GIVING(4,1)
PROTEIN POST TRANSLATIONAL MODIFICATION(4,1)
QUADRUPOLE MASS SPECTROMETER(4,1)
RESIDUE RESONANCE(4,1)
SBA REACTIVE PROTEIN(4,1)
SCALAR INTERACTION PRESENCE(4,1)
SELECTIVE IRRADIATION(4,1)
SHALLOW GRADIENT(4,1)
SIMULTANEOUS EXCITATION(4,1)
SMOOTH TRUNCATION(4,1)
UNIDENTIFIED ION(4,1)
UNKNOWN SUGAR(4,1)
WHOLE GLYCINE EXTRACT(4,1)
NMR SPECTRA(3,4)
ABC TRANSPORT(3,3)
ACCORD(3,3)
AMMONIUM BICARBONATE(3,3)
DIPSI(3,3)
TANDEM MASS SPECTROMETRY(3,3)
1D SERIES(3,2)
ACETAMIDO GROUP(3,2)
AMPICILLIN(3,2)
CLEAVAGE(3,2)
CONCENTRATE(3,2)
DIGEST SOLUTION(3,2)
FINE GRADE(3,2)
MAGIC ANGLE SPINNING NUCLEAR MAGNETIC RESONANCE(3,2)
MICRO MASS(3,2)
MICROBIOLOGY(3,2)
POLYSACCHARIDE COMPONENT(3,2)
SDS PAGE BAND(3,2)
1D SDS PAGE(3,1)
AFFINITY CHROMATOGRAPHY PRODUCT(3,1)
AGAROSE COLUMN(3,1)
ANIMAL WASTE(3,1)
ANOMERIC CONFIGURATION(3,1)
ANTIBODY PREPARATION(3,1)
AQUEOUS METHANOL(3,1)
BIOGEL P COLUMN(3,1)
BROAD PEAK(3,1)
BROAD RESONANCE(3,1)
CAPILLARY COLUMN(3,1)
CARBON LINKAGE(3,1)
CINNAMIC ACID(3,1)
COMMON POLYSACCHARIDE RESONANCE(3,1)
DIAGNOSTIC TOOL(3,1)
ENANTIOMERIC CONFIGURATION(3,1)
EUKARYOTIC N LINKAGE CONSENSUS(3,1)
FRACTION GIVING(3,1)
FRACTION SDS PAGE ANALYSIS(3,1)
FRAGMENTATION SERIES(3,1)
FREEZE DRIED GLYCINE(3,1)
GAINAC COMPONENT(3,1)
GEL FILTRATION(3,1)
GENERATION PRODUCTION SPECTRUM(3,1)
GLUCOPYRANOSYL CONFIGURATION(3,1)
GLYCINE HCL BUFFER(3,1)
GLYCOPROTEIN ANALYSIS(3,1)
GRAY ARROW(3,1)
HETERONUCLEAR MULTIPLE BOND CORRELATION(3,1)
HOST STRAIN(3,1)
HUMAN RECIPIENT(3,1)
IDENTICAL PLS(3,1)
INDIRECT DETECTION(3,1)
LIFE DOMAIN(3,1)
LIGATION MIXTURE(3,1)
LINKAGE NATURE(3,1)
LIPOPOLYSACCHARIDE(3,1)
LIVESTOCK FOOD SOURCE(3,1)
LOSS FEAR(3,1)
MAJOR POLYSACCHARIDE(3,1)
MALDI MATRIX SOLUTION(3,1)
MASS PROTEIN(3,1)
MATRIX SCIENCE(3,1)
MEMBRANE FUSION COMPONENT PROBABILITY(3,1)
MIXED GLYCOPROTEIN(3,1)
MODULATION DEPTH(3,1)
MS ACQUISITION MODE(3,1)
N LINKED OLIGOSACCHARYLTRANSFERASE SUBUNIT(3,1)
N LINKED SUGAR PREPONDERANCE(3,1)
NANO NMR PROBE(3,1)
NARROW BANDWIDTH(3,1)
NMR STRUCTURAL WORK(3,1)
NMR STUDY(3,1)
NUMEROUS STRAIN(3,1)
ORGANISM PRESENCE(3,1)
OVERNIGHT GROWTH PLATE(3,1)
PARTIAL EXCITATION(3,1)
PATHOGEN PRESENCE(3,1)
PEPTIDE SEQUENCE(3,1)
PPM PEAK(3,1)
PROTEIN SPECIES(3,1)
PROTEIN TERMINAL SEQUENCING(3,1)
RECENT EFFORT(3,1)
SELECTIVE NMR COMPARISON(3,1)
SPOT MATRIX(3,1)
STANDARD VARIAN SOFTWARE(3,1)
TECHMIQUE(3,1)
THERAPEUTIC PREPARATION(3,1)
THIOREDOXIN PEROXIDASE(3,1)
TRANSGLYCOSYLASE(3,1)
VIABLE TARGET(3,1)
WATER SUPPLY(3,1)
WHOLE ANTIBODY(3,1)
2D GEL SPOT(2,1)
ABUNDANT COMPONENT(2,1)
ACONITATE(2,1)
ADIABICITY(2,1)
(US20060165728)
ANTIBODY(100,50)
GLYCOPEPTIDE(100,22)
ANTIBODY FRAGMENT(100,20)
ANTIGEN(100,20)
BACTERIAL GLYCOPROTEIN POLYSACCHARIDE MOIETY(100,1)
CAMPYLOBACTER GLYCAN(100,1)
COMBATING CAMPYLOBACTER BACTERIUM(82,1)
GALNAC(79,20)
IMMUNOLOGICALLY ACTIVE FRAGMENT(77,3)
GLYOCOPROTEIN GLYCAN MOIETY(77,1)
FORMULA GALNAC HEPTASACCHARIDE(75,1)
CAMPYLOBACTER BACTERIA STRAIN(73,1)
FORMULA GALNAC POLYSACCHARIDE(65,1)
GLYCOPROTEIN VARIANCE(47,1)
IMMUNOGENIC CONJUGATE(46,4)
CAMELID GENE LIBRARY(45,1)
BIOLOGICALLY ACTIVE GLYCOPROTEIN(42,1)
GYLCAN MOIETY(41,1)
OLIGOPEPTIDE(35,7)
DIAGNOSTIC KIT(35,2)
BACTERIA ELIMINATION(35,1)
INTACT GLYCOPROTEIN(35,1)
UBIQUITOUS PRESENCE VIRTUE(35,1)
LAMA VVICUGNA(33,1)
PROTEIN FAILURE(33,1)
LIVESTOCK(32,27)
GLYCAN(32,12)
CAMPYLOBACTER PATHOGEN PRESENCE(32,1)
GLYCAN MOIETY(31,4)
CAMELUS BACTRIAMUS(31,2)
CAMELUS DROMADERIUS(31,2)
FORMULA HEPTASACCHARIDE(31,2)
SBA ALKALINE PHOSPHATASE CONJUGATE(31,2)
VACCINE(29,11)
INVARIANT(29,2)
COMMON GLYCAN MOITIE(29,1)
CAMPYLOBACTER INFECTION(27,5)
BACTERIAL STRAIN(27,2)
LAMA GGGLAMA(27,2)
LAMA PPACCO(27,2)
CAMPYLOBACTER SPECIES(26,5)
DIACETAMIDO(25,3)
SPECTROSCOPY(24,3)
CAMPYLOBACTER PRESENCE(23,5)
HR MA NMR(23,4)
FETUS SSP(23,2)
ANTIGENIC SURFACE GLYCAN(19,1)
EXCEPTION(19,1)
ANOMERIC RESONANCE(18,9)
JEJUNI NCTC(18,9)
PLANT GENOME(18,4)
ACROSS MULTIPLE STRAIN(17,1)
DELETERIOUS EFFECT(17,1)
MAGIC ANGLE SPINNING NMR(17,1)
VACCINE BASED STRATEGY(17,1)
PROTEIN GLYCOSYLATION(16,7)
THERAPEUTIC AGENT(15,2)
NMR(14,4)
IMMUNOSTIMULANT(14,3)
STRATEGY(14,3)
AMERSHAM BIOSCIENCE(14,2)
CAMPYLOBACTER GLYCOPROTEIN GLYCAN MOIETY(14,1)
CAMPYLOBACTER PATHOGEN GROUNDWATER CONTAMINATION(14,1)
HUMAN FOOD CHAIN(14,1)
NEISSERIA SPP PGL(14,1)
BACTERIA SURFACE(13,1)
BIO RAD LABORATORY(12,6)
ADDITIVE(12,1)
GOAT ANTI RABBIT ANTISERUM DILUTION(12,1)
AMINOACID(11,12)
BACTERIAL GLYCOPROTEIN GLYCAN MOIETY(11,1)
DRINK(11,1)
POULTRY(10,5)
DEUTERATED EDTA(10,4)
NAC RESONANCE(10,3)
BACTERIUM FECAL SHEDDING(10,1)
COW VAGINAL MUCUS(10,1)
DOUBLY PROTONATED GLYCOPEPTIDE ION(10,1)
ENTERIC PATHOGEN CAMPYLOBACTER(10,1)
HEXNAC OXONIUM ION PRECURSOR(10,1)
MUTANT CAPSULAR POLYSACCHARIDE(10,1)
PATHOGENIC CAMPYLOBACTER ORGANISM(10,1)
SBA LECTIN AFFINITY CHROMATOGRAPHY(10,1)
SEARCHING DATABASE(9,3)
1D NOESY EXPERIMENT(9,2)
ADIABATIC WURST(9,2)
PRECAST IEF STRIP(9,2)
ROCHE MOLECULAR BIOCHEMICAL(9,2)
BORNE PATHOGEN CAMPYLOBACTER(9,1)
ISOGENIC PGLB MUTANT(9,1)
LINKED PGL GLYCAN RESONANCE(9,1)
PGLB MUTANT CHARACTERIZATION(9,1)
SACCHAROMYCES LINKED OLIGOSACCHARYLTRANSFERASE(9,1)
TRYPSIN AUTOLYSIS PEPTIDE(9,1)
2D PAGE(8,9)
DISEASE(8,8)
MA HR(8,5)
CAMPYLOBACTER BACTERIA PRESENCE(8,2)
CJ NUMBERING(8,2)
CORRELATION SPECTROSCOPY(8,2)
DA SUGAR MOIETY(8,2)
FORMULA GLYCAN MOIETY(8,2)
HR MA PROTON(8,2)
MEIBOOM GILL(8,2)
NCTC SPECTRA(8,2)
SELECTIVE EXCITATION BANDWIDTH(8,2)
SOYBEAN AGGLUTININ(8,2)
BACTERIOPHAGE LIBRARY SCREENING(8,1)
GLYCOPEPTIDE 1H SPECTRA(8,1)
PLASMID PPCR SCRIPT AMP(8,1)
AMMONIUM BICARBONATE(7,3)
LC PACKING(7,3)
MASS FINGERPRINT(7,3)
SELECTIVE EXPERIMENT(7,3)
SIGMA ALDRICH(7,3)
BACTERIAL CELL PROTON SPECTRA(7,2)
CAMELID SPECIES(7,2)
COLI DH10B(7,2)
DEOXYCHOLATE PAGE(7,2)
GALNAC RESIDUE(7,2)
HOD RESONANCE(7,2)
MURINE MONOCLONAL ANTIBODY(7,2)
SPOT IDENTITY(7,2)
WESTERN BLOTTING(7,2)
1D TOCSY EXPERIMENT(7,1)
2D GEL WESTERN BLOT(7,1)
AMPLITAQ CYCLE SEQUENCING KIT(7,1)
ANOMERIC SUGAR RESONANCE(7,1)
CAMELID LYMPHOCYTE(7,1)
CAMPYLOBACTER JEJUNI(7,1)
CAMPYLOBACTER TARGETING(7,1)
CLONED GENE LIBRARY(7,1)
COLLOIDAL COOMASSIE BLUE(7,1)
COOMASSIE BLUE STAIN(7,1)
DOUBLY PROTONATED ION(7,1)
EXPERIMENTALLY INFECTED HUMAN VOLUNTEER(7,1)
FRACTION TRYPTIC DIGEST(7,1)
GLYCAN MOIETY IDENTIFICATION(7,1)
GLYCOPEPTIDE FRAGMENTATION(7,1)
GLYCOPROTEIN BIOSYNTHESIS(7,1)
GLYCOPROTEIN YIELD(7,1)
GRADIENT CRITERION SLAB GEL(7,1)
HEPTASACCHARIDE FRAGMENT(7,1)
HETERONUCLEAR MULTIPLE QUANTUM CORRELATION(7,1)
HEXNAC ION SIGNATURE(7,1)
IDENTIFIED GLYCOPROTEIN GLYCOSYLATION(7,1)
ISOLATED GLYCOPEPTIDE BULK(7,1)
L ASPARAGINE(7,1)
LECTIN PROBING(7,1)
LINKED GLYCAN RESONANCE(7,1)
MALDI TOF MS SPECTRA(7,1)
MATRIX ASSISTED LASER DESORPTION(7,1)
MICRO PRECOLUMN CARTRIDGE(7,1)
MUTANT NMR SPECTRUM(7,1)
MUTATED PLASMID DNA(7,1)
NITRO BLUE TETRAZOLIUM CHLORIDE(7,1)
PEB CHROMATOGRAPHY PURIFICATION(7,1)
PLANT CELL(7,1)
POLYVINYLIDENE DIFLUORIDE(7,1)
PROBLOT PVDF MEMBRANE(7,1)
PRONASE DIGEST MESH(7,1)
PRONASE DIGESTION ROUND(7,1)
RESIDUE ANOMERIC PROTON(7,1)
SINGLY PROTONATED FRAGMENT ION(7,1)
TRYPTIC DIGEST MASS SPECTROMETRY(7,1)
TRYPTIC GLYCOPEPTIDE(7,1)
VENEREALIS BIOTYPE(7,1)
COCL(6,6)
1D SDS PAGE(6,3)
PROTEIN IDENTIFICATION(6,3)
ANIMAL SERUM(6,2)
COLLISION INDUCED DISSOCIATION(6,2)
COLUMN ELUATE(6,2)
DOWNFIELD SHIFT(6,2)
GAL AGAR(6,2)
HEX RESIDUE(6,2)
PEB ANALYSIS(6,2)
RE FRACTIONATION(6,2)
RECONSTRUCTED MASS PROFILE(6,2)
UV ABSORBANCE(6,2)
1D TOCSY NOESY(6,1)
ANOMERICS RESONANCE(6,1)
AUTHENTIC PEB(6,1)
BROADBAND DECOUPLING(6,1)
CAMPYLOBACTER STRAIN(6,1)
CAPSULAR RESONANCE(6,1)
CDN ISOTOPE(6,1)
CKANB PRIMER(6,1)
CPMG PULSEDURATION(6,1)
EUKARYOTIC GLYCOPROTEIN(6,1)
GALNAC LECTIN(6,1)
GLYCAN MOIETY DETECTION(6,1)
GLYCINE EXTRACT 2D GEL(6,1)
GLYCOPEPTIDE COMPLETE RESONANCE ASSIGNMENT(6,1)
GLYCOPEPTIDE PURIFICATION(6,1)
GLYCOSIDATION SITE(6,1)
GLYCOSYLATED PEB(6,1)
GUILLAIN BARR SYNDROME(6,1)
HEPTASACCHARIDE MOIETY(6,1)
HEWLETT PACKARD CHROMATOGRAPH(6,1)
HOD SUPPRESSION(6,1)
HOMOGENEOUS POLYACRYLAMIDE GEL(6,1)
HR MA SPECTRA(6,1)
IMMUNOLOGIC STRATEGY(6,1)
INCOMING PLASMID DNA(6,1)
INTACT CAMPYLOBACTER CELL(6,1)
INTACT GLYCOPEPTIDE(6,1)
INTER RESIDUE CORRELATION(6,1)
INTESTINAL INFECTION(6,1)
ISOELECTRIC FOCUSING(6,1)
ISOGENIC MUTANT(6,1)
JEJUNE NCTC(6,1)
KSPM MUTANT(6,1)
KTA EXPLORER(6,1)
LIVESTOCK MANURE(6,1)
MASCOT DAEMON(6,1)
MUELLER HINTON AGAR(6,1)
MUELLER HINTON BROTH(6,1)
MUTANT LOS MASS(6,1)
NOESY SPECTRA(6,1)
OLIGOSACCHARIDE RESIDUE SEQUENTIAL LOSS(6,1)
PATHOGEN ELIMINATION(6,1)
PATHWAY EVIDENCE(6,1)
PGL PATHWAY(6,1)
PGLB MUTATION(6,1)
PROTEIN IMMUNODETECTION(6,1)
PROTEIN IMMUNOREACTIVITY(6,1)
PURIFIED GLYCOPEPTIDE(6,1)
SBA LECTIN AGAROSE(6,1)
SELECTIVE EXCITATION EXPERIMENT(6,1)
SELECTIVE NOESY EXPERIMENT(6,1)
SELECTIVE TOCSY EXPERIMENT(6,1)
SHALLOW NACL GRADIENT(6,1)
SINGLY CHARGED FRAGMENT ION(6,1)
SURFACE EXPOSED GLYCOPROTEIN(6,1)
TRYPTIC PEPTIDE ANALYSIS(6,1)
TRYPTIC PEPTIDE PLUS(6,1)
VARIAN SATURN(6,1)
VETERINARY PATHOGEN(6,1)
ACETONITRILE(5,4)
13C RESONANCE(5,1)
1D TOCSY SEQUENCE(5,1)
4B NAC INTERPROTON(5,1)
ANTIBODY ADMINISTRATION(5,1)
ANTIBODY DOSE(5,1)
ANTIGEN DOSE(5,1)
B3 OBSERVATION(5,1)
BOUND GLYCOPROTEIN(5,1)
CATION EXCHANGE CHROMATOGRAPHY(5,1)
CJ1670C MS ANALYSIS(5,1)
CLONING EXPERIMENT(5,1)
COMPOUND IMMUNOLOGICALLY ACTIVE FRAGMENT(5,1)
DNA SEQUENCER(5,1)
EUBACTERIA DOMAIN(5,1)
EUKARYOTIC PHENOMENON(5,1)
FAINT PROTEIN(5,1)
FECAL MATTER ENTRY(5,1)
FOCUS SPOT(5,1)
FRACTION MS SPECTRUM(5,1)
FROZEN CELL PELLET(5,1)
GENOME SEQUENCE DATABASE(5,1)
GLYCAN MOIETY REMOVAL(5,1)
GLYCINE CHROMATOGRAPHY(5,1)
GLYCINE HCL(5,1)
GLYCOPEPTIDE GENERATION PRODUCTION SPECTRUM(5,1)
GLYCOPEPTIDE YIELD(5,1)
GLYCOPROTEIN EXTRACT PREPARATION(5,1)
GLYCOSIDATION SHIFT(5,1)
GLYCOSIDIC LINKAGE(5,1)
GLYCOSYLATED PROTEIN(5,1)
GROUNDWATER PROTECTION(5,1)
HEXNAC RESIDUE(5,1)
HEXNAC SEQUENTIAL LOSS(5,1)
HMBC CORRELATION(5,1)
HMBC SPECTRA(5,1)
HMQC EXPERIMENT(5,1)
HUMAN CONTAMINATION RISK(5,1)
IDENTICAL CAPSULAR REPEAT(5,1)
IMMUNOLOGIC TARGET(5,1)
INFECTION INCIDENCE(5,1)
JEJUNI STRAIN(5,1)
KANAMYCIN RESISTANT TRANSFORMANT(5,1)
KPSM MUTANT(5,1)
LINKAGE CONSENSUS(5,1)
LINKED GLYCOPEPTIDE(5,1)
MAJOR ANTIGENIC PROTEIN(5,1)
MALDI TOF MS ANALYSIS(5,1)
MILLER FISHER SYNDROME(5,1)
MILLIPORE CORPORATION(5,1)
MOUSE COLONIZATION LOSS(5,1)
MUTANT SPECTRUM(5,1)
NMR ASSIGNMENT(5,1)
NMR EXPERIMENT(5,1)
NOE EXPERIMENT(5,1)
PFU POLYMERASE(5,1)
PGL MUTATION(5,1)
PHARMACIA HR(5,1)
POTASSIUM FERRICYANIDE(5,1)
PROKARYOTIC ORGANISM DIVERSE GROUP(5,1)
PROMEGA MODIFIED TRYPSIN(5,1)
PROTEIN INTENSITY(5,1)
PROTON ASSIGNMENT(5,1)
Q TOF MICRO ELECTROSPRAY INTERFACE(5,1)
QUADRUPLY CHARGED ION(5,1)
SBA AFFINITY CHROMATOGRAPHY PRODUCT(5,1)
SBA CHROMATOGRAPHY(5,1)
SEROTYPING SERUM(5,1)
SIGNIFICANT FOOD BORNE PATHOGEN(5,1)
STRONG CPS RESONANCE(5,1)
TERMINATOR CHEMISTRY(5,1)
UNKNOWN PROTEIN(5,1)
UNUSUAL SUGAR(5,1)
WIDESPREAD PROTEIN GLYCOSYLATION(5,1)
XBAL RESTRICTION(5,1)
APPLIED BIOSYSTEM(4,6)
ANIMAL PRODUCTION(4,3)
BACILLOSAMINE(4,3)
CENTRIFUGATION(4,3)
COMMON RESONANCE(4,3)
NAC GROUP(4,3)
ARCHAEA(4,2)
CONJUGATE(4,2)
EXTERNAL ACETONE METHYL RESONANCE(4,2)
GLYCAN COMPONENT(4,2)
LIPOOLIGOSACCHARIDE(4,2)
NEGATIVE BACTERIA(4,2)
ORIFICE VOLTAGE(4,2)
REACHING HUMAN(4,2)
RECONSTRUCTED MOLECULAR MASS PROFILE(4,2)
SEQUON(4,2)
SHARP PEAK(4,2)
STRONG NOE(4,2)
WHOLE GENOME SEQUENCE(4,2)
13C NMR DATA(4,1)
AMERICAN SOCIETY(4,1)
ANTIBODY DOMAIN(4,1)
B1 B3(4,1)
B3 NOE(4,1)
BIOGEL COLUMN(4,1)
CAPLC PUMP(4,1)
CASSETTE ORIENTATION(4,1)
COMMON GLYCAN RESONANCE(4,1)
DECREASED ADHESION(4,1)
FOOD GLYCOME(4,1)
FRACTION MS ANALYSIS(4,1)
GC MS ANALYSIS(4,1)
GENTLE STIRRING(4,1)
GLYCAN DETECTION(4,1)
GLYCOPEPTIDE PREPARATION(4,1)
GRADIENT ELUTION(4,1)
HDO SIGNAL SUPPRESSION(4,1)
HEXNAC ABSOLUTE CONFIGURATION(4,1)
IMMUNOGENIC ACTIVITY(4,1)
IMMUNOGENICITY LOSS(4,1)
INFUSION MS(4,1)
IPG STRIP(4,1)
JEJUNI WHOLE CELL(4,1)
LINKED GLYCOSYLATION(4,1)
MAJOR GLYCAN(4,1)
MANURE SAMPLE(4,1)
MEDICAMENT PREPARATION(4,1)
MS COLLISION OFFSET(4,1)
NOE PATTERN COMPARISON(4,1)
OVERLAPPING RESONANCE(4,1)
PEB MS ANALYSIS(4,1)
PEPTIDE EXTRACT(4,1)
PRECURSOR ION SCAN(4,1)
PROTEIN GIVING(4,1)
PROTEIN POST TRANSLATIONAL MODIFICATION(4,1)
QUADRUPOLE MASS SPECTROMETER(4,1)
RESIDUE RESONANCE(4,1)
SBA AGAROSE COLUMN(4,1)
SBA REACTIVE PROTEIN(4,1)
SCALAR INTERACTION PRESENCE(4,1)
SELECTIVE IRRADIATION(4,1)
SERINE RESIDUE(4,1)
SHALLOW GRADIENT(4,1)
SIMULTANEOUS EXCITATION(4,1)
SMOOTH TRUNCATION(4,1)
SODIUM THIOSULFATE(4,1)
STANDARD 2D TOCSY(4,1)
UNIDENTIFIED ION(4,1)
UNKNOWN SUGAR(4,1)
WHOLE GLYCINE EXTRACT(4,1)
HIGH RESOLUTION MAGIC ANGLE SPINNING(3,5)
NMR SPECTRA(3,4)
13C CHEMICAL SHIFT(3,3)
DIPSI(3,3)
ACETAMIDO GROUP(3,2)
AMPICILLIN(3,2)
CLEAVAGE(3,2)
CONCENTRATE(3,2)
DIGEST SOLUTION(3,2)
FINE GRADE(3,2)
MICRO MASS(3,2)
MICROBIOLOGY(3,2)
O LINKAGE(3,2)
SDS PAGE BAND(3,2)
1D EXP(3,1)
1H ANALYSIS(3,1)
ANIMAL WASTE(3,1)
ANOMERIC CONFIGURATION(3,1)
ANTIBODY PREPARATION(3,1)
AQUEOUS METHANOL(3,1)
BROAD PEAK(3,1)
BROAD RESONANCE(3,1)
CAPILLARY COLUMN(3,1)
CARBON LINKAGE(3,1)
CELL EXTRACT(3,1)
COBALT CHLORIDE(3,1)
COMMON 1H RESONANCE(3,1)
COMMON GLYCAN SEQUENCE(3,1)
DIAGNOSTIC TOOL(3,1)
ENANTIOMERIC CONFIGURATION(3,1)
ESI MS(3,1)
FRACTION GIVING(3,1)
FRACTION SDS PAGE ANALYSIS(3,1)
FRAGEMENT(3,1)
FRAGMENTATION SERIES(3,1)
FREEZE DRIED GLYCINE(3,1)
GALNAC COMPONENT(3,1)
GEL FILTRATION(3,1)
GENERATING PEAP(3,1)
GLUCOPYRANOSYL CONFIGURATION(3,1)
GLYCOPEPTIDE DEDUCED STRUCTURE(3,1)
GLYCOPROTEIN ANALYSIS(3,1)
GRAY ARROW(3,1)
HETERONUCLEAR MULTIPLE BOND CORRELATION(3,1)
HOST STRAIN(3,1)
HUMAN RECIPIENT(3,1)
IDENTICAL PLS(3,1)
INDIRECT DETECTION(3,1)
KANAMYCIN RESISTANCE CASSETTE(3,1)
LIFE DOMAIN(3,1)
LIGATION MIXTURE(3,1)
LINKAGE NATURE(3,1)
LINKED SUGAR(3,1)
LIPOPOLYSACCHARIDE(3,1)
LIVESTOCK FOOD SOURCE(3,1)
LOSS FEAR(3,1)
MALDI MATRIX SOLUTION(3,1)
MASS PROTEIN(3,1)
MATRIX SCIENCE(3,1)
MIXED GLYCOPROTEIN(3,1)
MODULATION DEPTH(3,1)
MS ACQUISITION MODE(3,1)
MUTANT CELL(3,1)
NANO NMR PROBE(3,1)
NARROW BANDWIDTH(3,1)
NMR STRUCTURAL WORK(3,1)
NMR STUDY(3,1)
NUMEROUS STRAIN(3,1)
ORGANISM PRESENCE(3,1)
OVERNIGHT GROWTH PLATE(3,1)
PARTIAL EXCITATION(3,1)
PATHOGEN PRESENCE(3,1)
PBS COLUMN VOLUME(3,1)
PEB MOLECULAR MASS(3,1)
PEPTIDE SEQUENCE(3,1)
PROPANESULFONIC ACID BUFFER(3,1)
PROTEIN SPECIES(3,1)
PROTEIN TERMINAL SEQUENCING(3,1)
RECENT EFFORT(3,1)
SCIEX(3,1)
SELECTIVE NMR COMPARISON(3,1)
SODIUM AZIDE(3,1)
SODIUM PHOSPHATE(3,1)
SPOT MATRIX(3,1)
STANDARD VARIAN SOFTWARE(3,1)
(US7598354)
GLYCOPEPTIDE(100,22)
GALNAC(100,20)
FORMULA GALNAC HEPTASACCHARIDE(100,2)
CAMPYLOBACTER GLYCAN(100,1)
COMBATING CAMPYLOBACTER BACTERIUM(77,1)
GLYOCOPROTEIN GLYCAN MOIETY(72,1)
CAMPYLOBACTER BACTERIA STRAIN(69,1)
IMMUNOGENIC CONJUGATE(68,7)
CAMPYLOBACTER JEJUNI(45,3)
GLYCOPROTEIN VARIANCE(44,1)
OLIGOPEPTIDE(41,7)
DIACETAMIDO(41,5)
BIOLOGICALLY ACTIVE GLYCOPROTEIN(39,1)
GYLCAN MOIETY(38,1)
GLYCAN MOIETY(36,5)
DIAGNOSTIC KIT(33,2)
BACTERIA ELIMINATION(33,1)
INTACT GLYCOPROTEIN(33,1)
UBIQUITOUS PRESENCE VIRTUE(33,1)
IMMUNOLOGICALLY ACTIVE FRAGMENT(31,1)
PROTEIN FAILURE(31,1)
GLYCAN(30,12)
FORMULA HEPTASACCHARIDE(29,2)
SBA ALKALINE PHOSPHATASE CONJUGATE(29,2)
INVARIANT(28,2)
ANTIBODY(26,36)
BACTERIAL STRAIN(26,2)
VACCINE(25,10)
CAMPYLOBACTER SPECIES(25,5)
CAMPYLOBACTER PRESENCE(22,5)
HR MA NMR(21,4)
CAMPYLOBACTER COLI(21,2)
CAMPYLOBACTER INFECTION(20,4)
IMMUNOSTIMULANT(20,4)
ANTIGENIC SURFACE GLYCAN(18,1)
EXCEPTION(18,1)
ANOMERIC RESONANCE(17,9)
JEJUNI NCTC(17,9)
ACROSS MULTIPLE STRAIN(16,1)
DELETERIOUS EFFECT(16,1)
VACCINE BASED STRATEGY(16,1)
PROTEIN GLYCOSYLATION(15,7)
AMERSHAM BIOSCIENCE(14,2)
AMINOACID(13,13)
ANTIBODY FRAGMENT(13,13)
STRATEGY(13,3)
CAMPYLOBACTER GLYCOPROTEIN GLYCAN MOIETY(13,1)
CAMPYLOBACTER PATHOGEN GROUNDWATER CONTAMINATION(13,1)
HUMAN FOOD CHAIN(13,1)
NEISSERIA SPP PGL(13,1)
BIO RAD LABORATORY(12,6)
MAGIC ANGLE SPINNING NMR(12,2)
BACTERIA SURFACE(12,1)
GOAT ANTI RABBIT ANTISERUM DILUTION(11,1)
BACTERIAL GLYCOPROTEIN GLYCAN MOIETY(10,1)
DEUTERATED EDTA(9,4)
NAC RESONANCE(9,3)
1D NOESY EXPERIMENT(9,2)
ADIABATIC WURST(9,2)
PRECAST IEF STRIP(9,2)
ROCHE MOLECULAR BIOCHEMICAL(9,2)
BACTERIUM FECAL SHEDDING(9,1)
BORNE PATHOGEN CAMPYLOBACTER(9,1)
COW VAGINAL MUCUS(9,1)
DOUBLY PROTONATED GLYCOPEPTIDE ION(9,1)
ENTERIC PATHOGEN CAMPYLOBACTER(9,1)
HEXNAC OXONIUM ION PRECURSOR(9,1)
ISOGENIC PGLB MUTANT(9,1)
LINKED PGL GLYCAN RESONANCE(9,1)
MUTANT CAPSULAR POLYSACCHARIDE(9,1)
PATHOGENIC CAMPYLOBACTER ORGANISM(9,1)
PGLB MUTANT CHARACTERIZATION(9,1)
SACCHAROMYCES LINKED OLIGOSACCHARYLTRANSFERASE(9,1)
SBA LECTIN AFFINITY CHROMATOGRAPHY(9,1)
TRYPSIN AUTOLYSIS PEPTIDE(9,1)
2D PAGE(8,9)
SEARCHING DATABASE(8,3)
CAMPYLOBACTER BACTERIA PRESENCE(8,2)
CJ NUMBERING(8,2)
DA SUGAR MOIETY(8,2)
FORMULA GLYCAN MOIETY(8,2)
HR MA PROTON(8,2)
MEIBOOM GILL(8,2)
NCTC SPECTRA(8,2)
SELECTIVE EXCITATION BANDWIDTH(8,2)
SOYBEAN AGGLUTININ(8,2)
BACTERIOPHAGE LIBRARY SCREENING(8,1)
GLYCOPEPTIDE 1H SPECTRA(8,1)
PLASMID PPCR SCRIPT AMP(8,1)
MA HR(7,5)
AMMONIUM BICARBONATE(7,3)
LC PACKING(7,3)
MASS FINGERPRINT(7,3)
SELECTIVE EXPERIMENT(7,3)
SIGMA ALDRICH(7,3)
BACTERIAL CELL PROTON SPECTRA(7,2)
CAMELID SPECIES(7,2)
COLI DH10B(7,2)
CORRELATION SPECTROSCOPY(7,2)
DEOXYCHOLATE PAGE(7,2)
GALNAC RESIDUE(7,2)
HOD RESONANCE(7,2)
MURINE MONOCLONAL ANTIBODY(7,2)
SPOT IDENTITY(7,2)
WESTERN BLOTTING(7,2)
ANOMERIC SUGAR RESONANCE(7,1)
FRACTION TRYPTIC DIGEST(7,1)
GLYCAN MOIETY IDENTIFICATION(7,1)
GLYCOPEPTIDE FRAGMENTATION(7,1)
MICRO PRECOLUMN CARTRIDGE(7,1)
MUTATED PLASMID DNA(7,1)
PEB CHROMATOGRAPHY PURIFICATION(7,1)
PROBLOT PVDF MEMBRANE(7,1)
PRONASE DIGEST MESH(7,1)
PRONASE DIGESTION ROUND(7,1)
RESIDUE ANOMERIC PROTON(7,1)
SINGLY PROTONATED FRAGMENT ION(7,1)
PROTEIN IDENTIFICATION(6,3)
1D TOCSY EXPERIMENT(6,1)
AMPLITAQ CYCLE SEQUENCING KIT(6,1)
CAMELID LYMPHOCYTE(6,1)
CAMELUS BACTRIAMUS(6,1)
CAMELUS DROMADERIUS(6,1)
CAMPYLOBACTER TARGETING(6,1)
CLONED GENE LIBRARY(6,1)
COLLOIDAL COOMASSIE BLUE(6,1)
COOMASSIE BLUE STAIN(6,1)
DOUBLY PROTONATED ION(6,1)
EXPERIMENTALLY INFECTED HUMAN VOLUNTEER(6,1)
GLYCOPROTEIN BIOSYNTHESIS(6,1)
GLYCOPROTEIN YIELD(6,1)
GRADIENT CRITERION SLAB GEL(6,1)
HEPTASACCHARIDE FRAGMENT(6,1)
HETERONUCLEAR MULTIPLE QUANTUM CORRELATION(6,1)
HEXNAC ION SIGNATURE(6,1)
IDENTIFIED GLYCOPROTEIN GLYCOSYLATION(6,1)
ISOLATED GLYCOPEPTIDE BULK(6,1)
L ASPARAGINE(6,1)
LECTIN PROBING(6,1)
LINKED GLYCAN RESONANCE(6,1)
MALDI TOF MS SPECTRA(6,1)
MATRIX ASSISTED LASER DESORPTION(6,1)
MUTANT NMR SPECTRUM(6,1)
NITRO BLUE TETRAZOLIUM CHLORIDE(6,1)
POLYVINYLIDENE DIFLUORIDE(6,1)
TRYPTIC DIGEST MASS SPECTROMETRY(6,1)
TRYPTIC GLYCOPEPTIDE(6,1)
VENEREALIS BIOTYPE(6,1)
COCL(5,6)
1D SDS PAGE(5,3)
ANIMAL SERUM(5,2)
COLLISION INDUCED DISSOCIATION(5,2)
COLUMN ELUATE(5,2)
DOWNFIELD SHIFT(5,2)
GAL AGAR(5,2)
HEX RESIDUE(5,2)
PEB ANALYSIS(5,2)
RE FRACTIONATION(5,2)
RECONSTRUCTED MASS PROFILE(5,2)
UV ABSORBANCE(5,2)
1D TOCSY NOESY(5,1)
ANOMERICS RESONANCE(5,1)
AUTHENTIC PEB(5,1)
BROADBAND DECOUPLING(5,1)
CAMPYLOBACTER STRAIN(5,1)
CAPSULAR RESONANCE(5,1)
CDN ISOTOPE(5,1)
CKANB PRIMER(5,1)
CPMG PULSEDURATION(5,1)
EUKARYOTIC GLYCOPROTEIN(5,1)
GALNAC LECTIN(5,1)
GLYCAN MOIETY DETECTION(5,1)
GLYCINE EXTRACT 2D GEL(5,1)
GLYCOPEPTIDE COMPLETE RESONANCE ASSIGNMENT(5,1)
GLYCOPEPTIDE PURIFICATION(5,1)
GLYCOSIDATION SITE(5,1)
GLYCOSYLATED PEB(5,1)
GUILLAIN BARR SYNDROME(5,1)
HEPTASACCHARIDE MOIETY(5,1)
HEWLETT PACKARD CHROMATOGRAPH(5,1)
HOD SUPPRESSION(5,1)
HOMOGENEOUS POLYACRYLAMIDE GEL(5,1)
HR MA SPECTRA(5,1)
IMMUNOLOGIC STRATEGY(5,1)
INCOMING PLASMID DNA(5,1)
INTACT CAMPYLOBACTER CELL(5,1)
INTACT GLYCOPEPTIDE(5,1)
INTER RESIDUE CORRELATION(5,1)
INTESTINAL INFECTION(5,1)
ISOELECTRIC FOCUSING(5,1)
ISOGENIC MUTANT(5,1)
JEJUNE NCTC(5,1)
KSPM MUTANT(5,1)
KTA EXPLORER(5,1)
LAMA GGGLAMA(5,1)
LAMA PPACCO(5,1)
LIVESTOCK MANURE(5,1)
MASCOT DAEMON(5,1)
MUELLER HINTON AGAR(5,1)
MUELLER HINTON BROTH(5,1)
MUTANT LOS MASS(5,1)
NOESY SPECTRA(5,1)
OLIGOSACCHARIDE RESIDUE SEQUENTIAL LOSS(5,1)
PATHOGEN ELIMINATION(5,1)
PATHWAY EVIDENCE(5,1)
PGL PATHWAY(5,1)
PGLB MUTATION(5,1)
PROTEIN IMMUNODETECTION(5,1)
PROTEIN IMMUNOREACTIVITY(5,1)
PURIFIED GLYCOPEPTIDE(5,1)
SBA LECTIN AGAROSE(5,1)
SELECTIVE EXCITATION EXPERIMENT(5,1)
SELECTIVE NOESY EXPERIMENT(5,1)
SELECTIVE TOCSY EXPERIMENT(5,1)
SHALLOW NACL GRADIENT(5,1)
SINGLY CHARGED FRAGMENT ION(5,1)
SURFACE EXPOSED GLYCOPROTEIN(5,1)
TRYPTIC PEPTIDE ANALYSIS(5,1)
TRYPTIC PEPTIDE PLUS(5,1)
VARIAN SATURN(5,1)
VETERINARY PATHOGEN(5,1)
DISEASE(4,7)
APPLIED BIOSYSTEM(4,6)
ACETONITRILE(4,4)
POULTRY(4,4)
ANIMAL PRODUCTION(4,3)
BACILLOSAMINE(4,3)
CENTRIFUGATION(4,3)
COMMON RESONANCE(4,3)
NAC GROUP(4,3)
ARCHAEA(4,2)
CONJUGATE(4,2)
EXTERNAL ACETONE METHYL RESONANCE(4,2)
GLYCAN COMPONENT(4,2)
LIPOOLIGOSACCHARIDE(4,2)
NEGATIVE BACTERIA(4,2)
ORIFICE VOLTAGE(4,2)
REACHING HUMAN(4,2)
R(...)";"Analysis of biological materials
Food chemistry
Macromolecular chemistry, polymers
Pharmaceuticals";Open
2002-06-28;"RU2221040           C1 2004-01-10 [RU2221040]
STG: (C1) Patent for invention
AP : 2002RU-0117391 2002-06-28
RU2002117391        A  2004-01-27 [RU2002117391]
STG: (A) Application for invention
AP : 2002RU-0117391 2002-06-28";36144029;"RU2221040           C1 2004-01-10 [RU2221040]
RU2002117391        A  2004-01-27 [RU2002117391]";2002RU-0117391;;FEDERAL NOE GOSUDARSTVENNOE UCHREZHDENIE VSEROSSIJSKIJ NAUCHNO ISSLEDOVATEL SKIJ INSTITUT ZASHCHITY;FEDERAL NOE GOSUDARSTVENNOE UCHREZHDENIE VSEROSSIJSKIJ NAUCHNO ISSLEDOVATEL SKIJ INSTITUT ZASHCHITY;;;1;"MISHCHENKO V A
GUSEV A A
GETMANSKIJ O I
KOROPOVA N V
RUCHNOV JU E
KOSTYRKIN JU A";;;"(RU2221040)
Cattle infectious rhinotracheitis virus strain ""vniizzh"" for preparing vaccine and diagnostic preparations";"(RU2002117391)
FIELD: veterinary virology, biotechnology. SUBSTANCE: strain is deposited in collection of microorganism strains in VGNKI at code ""VNIIZZH-DEP"". The strain shows high biological, antigenic and immunogenic activity and can be used for preparing effective vaccine and diagnostic preparations. EFFECT: valuable properties of strain. 8 tbl, 3 ex";"(RU2221040)
Strain “OF VNIIZZH” of the virus of infectious rhino-tracheitis of large livestock seven. Herpesviridae, the kind Of Varicellavirus, the collection VGNKI “OF VNIIZZH-DEP”, for preparing the vaccine and diagnostic preparations.";;;"A61K-039/265
C12N-007/00
C12R-001/93";;;Pharmaceuticals;Open
"2001-09-06
2001-09-18
2002-09-05
2002-09-06
2006-09-20
2012-02-01";"WO03023041          A2 2003-03-20 [WO200323041]
STG: (A2) International application published without international search report
AP : 2002WO-EP09925 2002-09-05
CA2457441           A1 2003-03-20 [CA2457441]
STG: (A1) Application laid open
AP : 2002CA-2457441 2002-09-05
DE10143813          A1 2003-04-10 [DE10143813]
STG: (A1) Doc. laid open (First publication)
AP : 2001DE-1043813 2001-09-06
UY27434             A1 2003-04-30 [UY--27434]
STG: (A1) Patent application (First publication level)
AP : 2002UY-0027434 2002-09-05
WO03023041          A3 2003-11-20 [WO200323041]
STG: (A3) Later publication of ISR with revised front page
AP : 2002WO-EP09925 2002-09-05
US20040038198       A1 2004-02-26 [US20040038198]
STG: (A1) Application published
AP : 2002US-10236542 2002-09-06
KR20040039295       A  2004-05-10 [KR20040039295]
STG: (A) Published application
AP : 2004KR-7002362 2002-09-05
MXPA04002124        A  2004-07-08 [MX2004PA002124]
STG: (A) Patent application
AP : 2004MX-PA02124 2002-09-05
EP1440149           A2 2004-07-28 [EP1440149]
STG: (A2) Application published without search report
AP : 2002EP-0797952 2002-09-05
AR036432            A1 2004-09-08 [AR--36432]
STG: (A1) Independent patent application
AP : 2002AR-0103361 2002-09-06
BR0212312           A  2004-10-13 [BR200212312]
STG: (A) Published application
AP : 2002BR-0012312 2002-09-05
BRPI0212312         A1 2004-10-13 [BRPI0212312]
STG: (A1) Published application
AP : 2002BR-0012312 2002-09-05
HU0401585           A2 2004-11-29 [HU200401585]
STG: (A2) Examined patent application
AP : 2004HU-0001585 2002-09-05
CN1551913           A  2004-12-01 [CN1551913]
STG: (A) Published application
AP : 2002CN-0817511 2002-09-05
JP2005502361        A  2005-01-27 [JP2005502361]
STG: (A) Published application
AP : 2003JP-0527105 2002-09-05
HU0401585           A3 2005-02-28 [HU200401585]
STG: (A3) Imported patent application
AP : 2004HU-0001585 2002-09-05
PL368748            A1 2005-04-04 [PL2002368748]
STG: (A1) Application
AP : 2002PL-0368748 2002-09-05
EP1440149           B1 2006-08-02 [EP1440149]
STG: (B1) Patent specification
AP : 2002EP-0797952 2002-09-05
AT335074            T  2006-08-15 [ATE335074]
STG: (T) EP patent valid in AT
AP : 2002AT-0797952T 2002-09-05
DE60213639          D1 2006-09-14 [DE60213639]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2002DE-6013639 2002-09-05
US7135561           B2 2006-11-14 [US7135561]
STG: (B2) Granted patent as second publication
AP : 2002US-10236542 2002-09-06
FD :  Provisional Appl: US60/322,974 FDD=2001-09-18 [2001US-60322974]
FD : Previous publication: US20040038198 A1 2004-02-26 [US20040038198]
US20070015203       A1 2007-01-18 [US20070015203]
STG: (A1) Application published
AP : 2006US-11524356 2006-09-20
FD :  Continuation of: US10/236,542 FDD=2002-09-06 [2002US-10236542]
FD : Continuation of: US7135561 - 0 [US7135561]
FD : Provisional Appl: US60/322,974 FDD=2001-09-18 [2001US-60322974]
EP1749885           A2 2007-02-07 [EP1749885]
STG: (A2) Application published without search report
AP : 2006EP-0011790 2002-09-05
EP1749885           A3 2007-08-29 [EP1749885]
STG: (A3) Published search report
AP : 2006EP-0011790 2002-09-05
DE60213639          T2 2007-10-18 [DE60213639]
STG: (T2) Trans. of EP  patent
AP : 2002DE-6013639 2002-09-05
JP4416504           B2 2009-12-04 [JP4416504]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2003JP-0527105 2002-09-05
JP2009291203        A  2009-12-17 [JP2009291203]
STG: (A) Published application
AP : 2009JP-0180719 2009-08-03
FD :  Division of: JP2003527105 0 [2003JP-0527105]
BRPI0212312         A2 2011-02-08 [BR200212312]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2002BR-0012312 2002-09-05
US20120201850       A1 2012-08-09 [US20120201850]
STG: (A1) Application published
AP : 2012US-13364259 2012-02-01
EP1749885           B1 2012-12-05 [EP1749885]
STG: (B1) Patent specification
AP : 2006EP-0011790 2002-09-05
CA2457441           C  2013-01-08 [CA2457441]
STG: (C) Patent (second level)
AP : 2002CA-2457441 2002-09-05
EP1749885           B8 2013-01-16 [EP1749885]
STG: (B8) Modified first page granted patent
AP : 2006EP-0011790 2002-09-05
FD :  Division of: EP02797952 FDD=2002-09-05 [2002EP-0797952]
FD : Division of: EP1440149 - 0 [EP1440149]
DK1749885           T3 2013-03-11 [DK1749885T]
STG: (T3) Translation of EP patent
AP : 2006DK-0011790 2002-09-05
ES2401072           T3 2013-04-16 [ES2401072]
STG: (T3) Translation of granted European patent (former B3)
AP : 2006ES-0011790T 2002-09-05
US8778355           B2 2014-07-15 [US8778355]
STG: (B2) Granted patent as second publication
AP : 2012US-13364259 2012-02-01
FD :  Continuation of: US11/524,356 FDD=2006-09-20 [2006US-11524356]
FD : Continuation of: US10/236,542 FDD=2002-09-06 [2002US-10236542]
FD : Continuation of: US7135561 - 0 [US7135561]
FD : Provisional Appl: US60/322,974 FDD=2001-09-18 [2001US-60322974]
FD : Previous publication: US20120201850 A1 2012-08-09 [US20120201850]";64311;"WO03023041          A2 2003-03-20 [WO200323041]
CA2457441           A1 2003-03-20 [CA2457441]
DE10143813          A1 2003-04-10 [DE10143813]
UY27434             A1 2003-04-30 [UY--27434]
WO03023041          A3 2003-11-20 [WO200323041]
US20040038198       A1 2004-02-26 [US20040038198]
KR20040039295       A  2004-05-10 [KR20040039295]
MXPA04002124        A  2004-07-08 [MX2004PA002124]
EP1440149           A2 2004-07-28 [EP1440149]
AR036432            A1 2004-09-08 [AR--36432]
BR0212312           A  2004-10-13 [BR200212312]
BRPI0212312         A1 2004-10-13 [BRPI0212312]
HU0401585           A2 2004-11-29 [HU200401585]
CN1551913           A  2004-12-01 [CN1551913]
JP2005502361        A  2005-01-27 [JP2005502361]
HU0401585           A3 2005-02-28 [HU200401585]
PL368748            A1 2005-04-04 [PL2002368748]
EP1440149           B1 2006-08-02 [EP1440149]
AT335074            T  2006-08-15 [ATE335074]
DE60213639          D1 2006-09-14 [DE60213639]
US7135561           B2 2006-11-14 [US7135561]
US20070015203       A1 2007-01-18 [US20070015203]
EP1749885           A2 2007-02-07 [EP1749885]
EP1749885           A3 2007-08-29 [EP1749885]
DE60213639          T2 2007-10-18 [DE60213639]
JP4416504           B2 2009-12-04 [JP4416504]
JP2009291203        A  2009-12-17 [JP2009291203]
BRPI0212312         A2 2011-02-08 [BR200212312]
US20120201850       A1 2012-08-09 [US20120201850]
EP1749885           B1 2012-12-05 [EP1749885]
CA2457441           C  2013-01-08 [CA2457441]
EP1749885           B8 2013-01-16 [EP1749885]
DK1749885           T3 2013-03-11 [DK1749885T]
ES2401072           T3 2013-04-16 [ES2401072]
US8778355           B2 2014-07-15 [US8778355]";"2001DE-1043813
2001US-60322974
2002EP-0797952
2002US-10236542
2002WO-EP09925
2006US-11524356
2012US-13364259";"(EP1440149)
WO03023041
(DE60213639)
WO03023041
(JP4416504)
WO03023041
(KR20040039295)
WO03023041
(MX2004PA002124)
WO03023041
(CN1551913)
WO03023041
(HU200401585)
WO03023041
(BR200212312)
WO03023041
(CA2457441)
WO03023041";"BOEHRINGER INGELHEIM INTERNATIONAL
BOEHRINGER INGELHEIM VETMEDICA";BOEHRINGER INGELHEIM VETMEDICA;"(EP1440149)
DE
(EP1440149)
DE
(EP1749885)
DE
(EP1749885)
DE
(EP1749885)
DE
(EP1749885)
DE
(US7135561)
US
(US20120201850)
DE
(US8778355)
DE
(WO200323041)
DE
(DE10143813)
DE
(DE60213639)
DE

(BRPI0212312)
DE
(BR200212312)
DE
(CA2457441)
DE
(CA2457441)
DE";"(EP1440149)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 , CITY=55218 Ingelheim am Rhein , COUNTRY=DE 

(EP1440149)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE , REG=00531913 

(EP1749885)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE 

(EP1749885)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim am Rhein , COUNTRY=DE 

(EP1749885)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE , REG=100089557 

(EP1749885)
NAME=Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 , CITY=55216 Ingelheim am Rhein , COUNTRY=DE , REG=100089557 

(US20040038198)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=St. Joseph , STATE=MO , ATYP=Non-US Company 

(US7135561)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=St. Joseph , STATE=MO , COUNTRY=US , ATYP=US Company 

(US20120201850)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , CITY=Ingelheim am Rhein , COUNTRY=DE , ATYP=Non-US Company 

(US8778355)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim am Rhein , COUNTRY=DE , ATYP=Non-US Company 

(WO200323041)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH  [DE/ DE] Binger Str. 173, 55216 INGELHEIM  , COUNTRY=DE 

(DE10143813)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim , POSTCODE=55218 , COUNTRY=DE 

(DE60213639)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim , POSTCODE=55218 , COUNTRY=DE 

(JP2005502361)
NAME=Boehringer Ingelheim submitted Fetomedika Beshurenkuteru Hafutsungu Gesellschaft , REG=591091320 

(JP4416504)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , REG=504225895 

(BRPI0212312)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , COUNTRY=DE 

(BR200212312)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH , COUNTRY=DE 

(CA2457441)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 55216 , CITY=INGELHEIM AM RHEIN , COUNTRY=DE 

(CA2457441)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 55216 , CITY=INGELHEIM AM RHEIN , COUNTRY=DE 
";1;"ELBERS KNUT
FETZER CHRISTIANE
VON FREYBURG MARTINA
MEYERS GREGOR";"(EP1749885)
DE
(EP1749885)
DE
(EP1749885)
DE";"(EP1749885)
NAME=Elbers, Knut Caprino-Veronese-Strasse 4a 55435 Gau Algesheim , COUNTRY=DE 

NAME=Fetzer, Christiane Treschowstrasse 31 48163 MÃ¼nster , COUNTRY=DE 

NAME=von Freyburg, Martina Rathenaustrasse 6 55131 Mainz , COUNTRY=DE 

NAME=Meyers, Gregor Albstrasse 1 72141 Walddorfhaeslach , COUNTRY=DE 

(EP1749885)
NAME=Elbers, Knut Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173 55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Fetzer, Christiane Treschowstrasse 31 48163 Münster , COUNTRY=DE 

NAME=von Freyburg, Martina Rathenaustrasse 6 55131 Mainz , COUNTRY=DE 

NAME=Meyers, Gregor Strandstrasse 23d 17498 Neuenkirchen-Wampen , COUNTRY=DE 

(EP1749885)
NAME=Elbers, Knut Boehringer Ingelheim GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein , COUNTRY=DE 

NAME=Fetzer, Christiane Treschowstrasse 31 48163 MÃ¼nster , COUNTRY=DE 

NAME=von Freyburg, Martina Rathenaustrasse 6 55131 Mainz , COUNTRY=DE 

NAME=Meyers, Gregor Strandstrasse 23d 17498 Neuenkirchen-Wampen , COUNTRY=DE 
";"(EP1749885)
Infectious and attenuated bovine viral diarrhea virus vaccine";"(EP1749885)
The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.";"(WO200323041)
Claims
1. DNA molecule containing a nucleotide sequence complementary to a BVDV RNA, wherein said RNA, when introduced into susceptible host cells, induces the generation of infectious BVDV particles a) with the capability to induce viraemia and leukopenia in calves for a period of at least 1 day and at least one of the following clinical symptoms of the group comprising diarrhea and/or pyrexia lasting at least one day when infected with a dose of 6x106TCID5o; and/or b) with authentical virulence as compared to a wild-type BVDV isolate from which such DNA molecule has been derived; and/or c) which are, when BVDV naive calves are infected at a dose of 6x106TCID50with such particles, lethal for at least 30 % of such calves within a period of 21 days; and/or d) with a virulence of not less than 90 % of BVDV particles comprising an RNA with a sequence complementary to SEQ ID NO. 1 ; and/or e) comprising a sequence complementary to SEQ ID NO. 1.
2. Infectious BVDV clone, capable of serving as a template for transcription into an RNA, wherein said RNA, when introduced into susceptible host cells, induces the generation of infectious BVDV particles f) with the capability to induce viraemia and leukopenia in calves for a period of at least 1 day and at least one of the following clinical symptoms of the group comprising diarrhea and/or pyrexia lasting at least one day when infected with a dose of 6x106TCID5o; and/or g) with authentical virulence as compared to a wild-type BVDV isolate from which such DNA molecule has been derived; and/or h) which are, when BVDV naive calves aged from 3 to 6 months are infected at a dose of 6x106TCID50with such particles, lethal for at least 30 % of such calves within a period of 21 days after infection; and/or i) with a virulence of not less than 90 % of BVDV particles comprising an RNA with a sequence complementary to SEQ ID NO. 1 ; and/or j) comprising a sequence complementary to SEQ ID NO. 1.
3. DNA molecule according to claim 1 , wherein the pyrexia of step a) is at least 40
 °C.
4. BVDV particle generated by transcription using the DNA molecule according to claim 1 or 3 or the BVDV clone according to claim 2, the transfection of suitable cells or cell lines with said RNA and the collection of the resulting BVDV particles produced by said cells.
5. Infectious BVDV type 2 clone.
6. Infectious BVDV type 2 clone, capable of serving as a template for transcription into an RNA, wherein said RNA, when introduced into susceptible host cells, induces the generation of infectious BVDV particles k) with the capability to induce viraemia and leukopenia in calves for a period of at least 1 day and at least one of the following clinical symptoms of the group comprising diarrhea and/or pyrexia lasting at least one day when infected with a dose of 6x1 OsTCID5o; and/or I) with authentical virulence as compared to a wild-type BVDV isolate from which such DNA molecule has been derived; and/or m) which are, when BVDV naive calves aged from 3 to 6 months are infected at a dose of 6x106TCID5o with such particles, lethal for at least 30 % of such calves within a period of 21 days after infection; and/or n) with a virulence of not less than 90 % of BVDV particles comprising an RNA with a sequence complementary to SEQ ID NO. 1 ; and/or o) comprising a sequence complementary to SEQ ID NO. 1.
7. Infectious BVDV type 2 clone according to claim 5 or 6, as characterized by the DNA sequence of SEQ ID NO. 1 or a fragment, functional variant, variant based on the degenerative nucleic acid code, fusion molecule or a chemical derivative thereof.
8. BVDV type 2 particle generated by in vitro transcription of the BVDV clone according to any one of claims 5 to 7 into RNA, the transfection of suitable cells or cell lines with said RNA and the collection of the resulting BVDV particles produced by said cells.
9. DNA molecule containing a nucleotide sequence complementary to a full-length BVDV type 2 RNA.
10. DNA molecule according to claim 9, characterized by SEQ ID No. 1 or a fragment, functional variant, variant based on the degenerative nucleic acid code, fusion molecule or a chemical derivative thereof.
11. DNA molecule according to claim 9 or 10, consisting of the sequence as s characterized by SEQ ID No. 1.
12. RNA molecule complementary to the DNA molecule of claim 1 or claim 3 or any one of claims 9 to 11 , or to the BVDV clone of claim 2 or claim 4 or claim 5 to 7.
13. RNA molecule obtainable by transcription of the DNA molecule of claim 1 or claim 3 or any one of claims 9 to 1 1 , or the BVDV clone of claim 2 or claim 4 or o claim 5 to 7.
14. Method for the production of an infectious BVDV clone from a wild-type BVDV isolate, said infectious BVDV clone being complementary to a RNA having authentical virulence as compared to said wild-type isolate, comprising the steps of s p) isolating viral particles from an infected animal; q) passaging not more than twice on suitable cell culture cells; r) preparing RNA from the viral particles; s) generating full-length complementary DNA after reverse transcription of the RNA; wherein the reverse transcription includes a step at elevated 0 temperatures sufficient to break or reduce secondary structures of the RNA, and the use of a thermostable enzyme for this step, said enzyme being active at these elevated temperatures; t) incorporating the complementary DNA (cDNA) into a plasmid vector or into a DNA virus capable of directing the transcription of BVDV cDNA into RNA 5 upon infection of suitable cells.
15. Method for the production of an infectious BVDV clone from a wild-type BVDV isolate, said infectious BVDV clone being complementary to a RNA having a virulence of not less than 90 % of said wild-type isolate, comprising the steps of u) isolating viral particles from an infected animal; o v) preparing RNA from the viral particles; w) generating full-length complementary DNA after reverse transcription of the RNA; wherein the reverse transcription includes a step at elevated temperatures sufficient to break or reduce secondary structures of the RNA, and the use of a thermostable enzyme for this step, said enzyme being active at these""elevated temperatures; x) incorporating the complementary DNA (cDNA) into a plasmid or into a DNA virus capable of directing the transcription of BVDV cDNA into RNA upon infection of suitable cells.
16. The method of claim 14 or 15, wherein the 5' end of the RNA is transcribed using RACE.
17. The method of claim 16, wherein RACE is carried out with a thermostable polymerase allowing reaction temperatures of at least 42°C.
18. Method of BVDV attenuation, or comprising introducing one or more mutations into the DNA molecule of claim 1 or claim 3 or any one of claims 9 to 11 , or into the infectious BVDV clone of claim 2 or claim 4 or claim 5 to 7, wherein said mutation or mutations lead to or increase an attenuated phenotype of the recovered BVD virus.
19. Method of attenuation of a BVDV strain, comprising the steps of y) introducing one or more mutations into the DNA molecule of claim 1 or claim
 3 or any one of claims 9 to 11 , or into the infectious BVDV clone of claim 2 or claim 4 or claim 5 to 7; z) introducing the mutated DNA into susceptible host cells wherein said DNA is transcribed into RNA or introducing an RNA transcribed from said DNA into said cells; and aa) collecting viral particles produced by these cells; wherein said mutation or mutations results in attenuation.
20. Method of claims 18 or 19, wherein the mutation or mutations is a substitution, deletion, insertion, addition, or combination thereof.
21. Method of any one of claims 18 to 20, wherein the mutation or mutations is in the glycoprotein Ernsand causes impaired or loss of function of the mutated protein(s).
22. Method of claim 21 , wherein the mutation consists of bb) deletion of all or part of the glycoprotein Erns; and/or cc) deletion or substitution of histidine at position 300 of SEQ ID NO. 1 ; and/or dd) deletion or substitution of histidine at position 349 of SEQ ID NO. 1.
23. Attenuated BVDV clone or BVDV strain obtainable by a method according to any one of claims 18 to 22.
24. Vaccine comprising an attenuated BVDV clone or strain according to claim 23, optionally in combination with a pharmaceutically acceptable carrier or excipient.
25. Use of a attenuated BVDV clone or strain according to claim 23 in the manufacture of a vaccine for the prophylaxis and treatment of BVDV infections.";"(EP1749885)
The invention further relates to a BVDV type 2 particle generated by in vitro transcription of the BVDV clone according to the invention into RNA, the transfection of suitable cells or cell lines with said RNA and the collection of the resulting BVDV particles produced by said cells.
The invention provides infectious BVDV clones and methods to produce said BVDV clones.
The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.
Preferably, the invention relates to a BVDV type 2 clone obtainable by a method characterized by the following steps: aaa) a wild-type BVDV type 2 strain is isolated; bbb) said wild-type BVDV type 2 strain is passaged in cell-culture; ccc) said cell culture-passaged BVDV type 2 strain is used to infect bovine animals and a BVDV strain is re-isolated from the most severely infected animal; ddd) said re-isolated BVDV type 2 strain is passaged no more than twice, preferably-once, in cell culture; eee) said re-isolated BVDV type 2 strain is reverse-transcribed and cloned resulting in a full-length cDNA clone, preferably the 5' and 3' ends are cloned using the RACE-technology.";"(EP1749885)
The more classical BVDV type 1 strains and the more recently recognized BVDV type 2 strains display some limited but distinctive differences in nucleotide and amino acid sequences.
Therefore, the technical problem underlying this invention was to provide a BVDV, in particular a BVDV type 2, of defined genetic identity.
This problem is probably due to the great antigenic diversity between type 1 and type 2 strains which is most pronounced in the glycoprotein E2, the major antigen (Tijssen et al., 1996): most monoclonal antibodies against type 1 strains fail to bind to type 2 viruses (Ridpath et al., 1994).";"A01N-063/00
A61K-039/12
A61K-039/295
A61P-031/12
A61P-031/14
C07H-021/04
C07K-014/01
C07K-014/08
C07K-014/18
C12N-007/00
C12N-007/01
C12N-007/02
C12N-007/04
C12N-007/06
C12N-015/09
C12N-015/34
C12P-019/34
C12Q-001/68
C12Q-001/70";"(EP1749885)
1. DNA molecule containing a nucleotide sequence complementary to a BVDV RNA, wherein said RNA, when introduced into susceptible host cells, induces the generation of infectious BVDV particles a) with the capability to induce viraemia and leukopenia in calves for a period of at least 1 day and at least one of the following clinical symptoms of the group comprising diarrhea and/or pyrexia lasting at least one day when infected with a dose of 6 106TCID50; and/or b) with authentical virulence as compared to a wild-type BVDV isolate from which such DNA molecule has been derived; and/or c) which are, when BVDV naive calves are infected at a dose of 6 106TCID50 with such particles, lethal for at least 30 % of such calves within a period of 21 days; and/or d) with a virulence of not less than 90 % of BVDV particles comprising an RNA with a sequence complementary to SEQ ID NO. 1; and/or e) comprising a sequence complementary to SEQ ID NO. 1.
2. Infectious BVDV clone, capable of serving as a template for transcription into an RNA, wherein said RNA, when introduced into susceptible host cells, induces the generation of infectious BVDV particles f) with the capability to induce viraemia and leukopenia in calves for a period of at least 1 day and at least one of the following clinical symptoms of the group comprising diarrhea and/or pyrexia lasting at least one day when infected with a dose of 6x106TCID50; and/or g) with authentical virulence as compared to a wild-type BVDV isolate from which such DNA molecule has been derived; and/or h) which are, when BVDV naive calves aged from 3 to 6 months are infected at a dose of 6x106TCID50 with such particles, lethal for at least 30 % of such calves within a period of 21 days after infection; and/or i) with a virulence of not less than 90 % of BVDV particles comprising an RNA with a sequence complementary to SEQ ID NO. 1; and/or j) comprising a sequence complementary to SEQ ID NO. 1.
5. Infectious BVDV type 2 clone.
6. Infectious BVDV type 2 clone, capable of serving as a template for transcription into an RNA, wherein said RNA, when introduced into susceptible host cells, induces the generation of infectious BVDV particles k) with the capability to induce viraemia and leukopenia in calves for a period of at least 1 day and at least one of the following clinical symptoms of the group comprising diarrhea and/or pyrexia lasting at least one day when infected with a dose of 6 106TCID50; and/or I) with authentical virulence as compared to a wild-type BVDV isolate from which such DNA molecule has been derived; and/or m) which are, when BVDV naive calves aged from 3 to 6 months are infected at - a dose of 6 106TCID50 with such particles, lethal for at least 30 % of such calves within a period of 21 days after infection; and/or n) with a virulence of not less than 90 % of BVDV particles comprising an RNA with a sequence complementary to SEQ ID NO. 1; and/or o) comprising a sequence complementary to SEQ ID NO. 1.
9. DNA molecule containing a nucleotide sequence complementary to a full-length BVDV type 2 RNA.
14. Method for the production of an infectious BVDV clone from a wild-type BVDV isolate, said infectious BVDV clone being complementary to a RNA having authentical virulence as compared to said wild-type isolate, comprising the steps of p) isolating viral particles from an infected animal; q) passaging not more than twice on suitable cell culture cells; r) preparing RNA from the viral particles; s) generat ing full-length complementary DNA after reverse transcription of the RNA; wherein the reverse transcription includes a step at elevated temperatures sufficient to break or reduce secondary structures of the RNA, and the use of a thermostable enzyme for this step, said enzyme being active at these elevated temperatures; t) incorporating the complementary DNA (cDNA) into a plasmid vector or into a DNA virus capable of directing the transcription of BVDV cDNA into RNA upon infection of suitable cells.
15. Method for the production of an infectious BVDV clone from a wild-type BVDV isolate, said infectious BVDV clone being complementary to a RNA having a virulence of not less than 90 % of said wild-type isolate, comprising the steps of u) isolating viral particles from an infected animal; v) preparing RNA from the viral particles; w) generat ing full-length complementary DNA after reverse transcription of the RNA; wherein the reverse transcription includes a step at elevated temperatures sufficient to break or reduce secondary structures of the RNA, and the use of a thermostable enzyme for this step, said enzyme being active at these elevated temperatures; x) incorporating the complementary DNA (cDNA) into a plasmid or into a DNA virus capable of directing the transcription of BVDV cDNA into RNA upon infection of suitable cells.
26. A vaccine comprises an attenuated BVD virus type 1 combined with an attenuated BVD virus type 2 or any other antigenetic group and a pharmaceutically acceptable carrier or excipients.
27. A vaccine comprises an attenuated BVD virus type 1, wherein the RNase activity in its protein ERNS is inactivated, combined with an attenuated BVD virus type 2, wherein the RNase activity in its protein ERNS is inactivated, or any other antigenetic group wherein the RNase activity in its protein ERNS is inactivated, and a pharmaceutically acceptable carrier or excipients.";"(EP1440149)
BOVINE VIRAL DIARRHEA VIRUS(100,166)
FETAL INFECTION(100,7)
FETAL INFECTION PREVENTION(100,3)
BOVINE VIRAL DIARRHEA VIRUS CLONE(100,1)
HETEROLOGOLIS CHALLENGE VIRUS(91,1)
HETEROLOGOUS VIRUS(66,1)
BVDV STRAIN(58,1)
ATTENUATED CLONE(51,1)
INFECTED ANIMAL(50,5)
MEDICAMENT PRODUCTION(46,1)
MEDICAMENT PREPARATION(43,1)
BOVINE ANIMAL(40,2)
ANTIGEN GROUP(36,3)
MAJOR ANTIGEN(35,1)
L HISTIDINE CODON(33,1)
BVD VIRUS ATTENUATION(31,8)
STRAIN(30,9)
RACE TECHNOLOGY(29,4)
MONOCLONAL ANTIBODY(27,1)
NEUTRALIZING ANTIBODY TITER(23,4)
ANTIGENIC DIVERSITY(23,2)
VIRUS(21,22)
AUTHENTICAL VIRULENCE(21,6)
CELL CULTURE(21,4)
GLYCOPROTEIN(21,3)
CLONE(20,32)
VACCINE(20,22)
BVD ABORTION(20,7)
NUCLEOTIDE(17,11)
INFECTIOUS CDNA CLONE(17,3)
NUCLEOTIDE SEQUENCING(16,6)
PLASMID PKANE(16,6)
AMINOACID SEQUENCE(16,1)
IMMUNOFLUORESCENCE STAINING(15,3)
HOG CHOLERA VIRUS CHARACTERIZATION(15,1)
DNA MOLECULE(14,8)
CONJUGATED RABBIT ANTI MOUSE ANTIBODY(14,1)
PERSISTENTLY INFECTED CALF INDUCTION(14,1)
FULL LENGTH CDNA CLONE(13,4)
THERMOSTABLE ENZYME(13,3)
CDNA CLONE DELETION LIBRARY(13,1)
IMMUNOTOLERANT CALF BIRTH(13,1)
PHOSPHORYLATED OLIGONUCLEOTIDE PMOL(13,1)
PREGNANT COW PLACENTA(13,1)
BIOLOGICAL ACTIVITY(12,7)
FUNCTIONAL VARIANT(12,7)
VIRAL CYTOPATHOGENICITY(12,2)
AUTHENTIC VIRULENCE VIRUS(12,1)
CLASSICAL SWINE FEVER FIRUS(12,1)
FLECKED CATTLE FEMALE ANIMAL(12,1)
INDEPENDENT CDNA(12,1)
PREDOMINANT CLINICAL PARAMETER DIARRHEA(12,1)
RECOMBINANT VIRUS PAFIHOGENICITY(12,1)
CALF SERUM(11,3)
DAY POST INFECTION(11,3)
DEFINED GENETIC IDENTITY(11,3)
EXPERIMENTAL FACILITY(11,3)
LIVE VACCINE(11,3)
MANUFACTURER INSTRUCTION(11,3)
ACUTELY INFECTED CATTLE(11,1)
BOVINE DIARRHEA VIRUS(11,1)
GENOMIC REVERSION DANGER(11,1)
HEPARIN STABILIZED BLOOD ALIQUOT(11,1)
HETEROLOGOUS CHALLENGE VIRUS(11,1)
INFECTIOUS CLONE REPORT(11,1)
MILD RESPIRATORY SYMPTOM(11,1)
PREPARATIVE AGAROSE GEL ELECTROPHORESIS(11,1)
RE LATED COW MORTALITY(11,1)
VIRUS NASAL SHEDDING(11,1)
MADIN DARBY BOVINE KIDNEY(10,21)
ERNS CODING REGION(10,3)
ANTIBODY NEUTRALIZATION(10,2)
EUKARYOTIC PROMOTOR(10,2)
IMMUNOFLUORESCENCE ASSAY(10,2)
PRIMER PMOL(10,2)
PYREXIA LASTING(10,2)
FUSION MOLECULE(9,3)
PLASMID VECTOR(9,3)
RNA REVERSE TRANSCRIPTION(9,3)
CODON DELETION(9,2)
EXPERIMENTAL INFECTION(9,2)
GLUTEAL MUSCLE(9,2)
INOCULATION DAY(9,2)
MUTANT VIRUS(9,2)
NAIVE CALF(9,2)
PREGNANCY STATUS(9,2)
RNASE ACTIVITY DETERMINATION(9,2)
SERUM RECIPROCAL(9,2)
VIRUS GENOME(9,2)
ANIMAL FACILITY INSEMINATION(9,1)
ANIMAL NASAL SWAB(9,1)
BVD VIRUS GENE(9,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(9,1)
PKANE AATLI SITE(9,1)
RECOMBINANT VIRUS MUTANT(9,1)
DOSE(8,11)
ETHYL ALCOHOL PRECIPITATION(8,6)
SUSCEPTIBLE CELL(8,4)
ANIMAL BUFFY COAT PREPARATION(8,1)
ATTENUATED PESTIVIRUS(8,1)
BIG DYE TERMINATOR(8,1)
BORDER DISEASE VIRUS SUBGROUP(8,1)
BVD CAUSATIVE AGENT(8,1)
CDNA CLONE IDENTIFICATION(8,1)
CDNA CLONE INSERT(8,1)
CLONED POLIOVIRUS COMPLEMENTARY DNA(8,1)
DEGRADED RNA FRAGMENT(8,1)
DISEASE EPIDEMIOLOGY(8,1)
ELECTROPORATION CUVETTE(8,1)
FETUS RESORPTION(8,1)
INFECTIOUS VIRUS RECOVERY(8,1)
INTRAUTERINE INFECTION PATHOGENESIS(8,1)
LINEARIZED PKANE(8,1)
NUCLEOTIDE TRIPLET(8,1)
PATHOGENESIS REVIEW(8,1)
PESTIVIRUS GENUS(8,1)
POLYNUCLEOTIDE VACCINATION(8,1)
PREGNANT HEIFER(8,1)
RE LATED ABORTION(8,1)
RNA INFECTIVITY(8,1)
RNASE ACTIVITY INACTIVATION(8,1)
ROCHE MOLECULAR BIOCHEMICAL(8,1)
RT PCR SEQUENCING(8,1)
VACCINATED HEIFER(8,1)
VACCINATED HERD(8,1)
VENA JUGULARIS(8,1)
VIRUS ISOLATION DATA(8,1)
VIRUS ISOLATION INVESTIGATION(8,1)
VIRUS MUTANT GENE(8,1)
VIRUS PEROXIDASE ASSAY(8,1)
ADMINISTRATION(7,5)
NUCLEIC ACID CODE DEGENERATION(7,3)
CDNA SYNTHESIS(7,2)
CONSECUTIVE DAY(7,2)
CONSTRUCTING CDNA(7,2)
GROUP CLINICAL SYMPTOM(7,2)
KILLED VACCINE(7,2)
PARTIAL CDNA FRAGMENT(7,2)
PHENOL EXTRACTION(7,2)
SUSCEPTIBLE HOST CELL(7,2)
UNINFECTED CELL(7,2)
WELFARE REASON(7,2)
AATLI FRAGMENT(7,1)
ATTENUATED VIRAL PARTICLE(7,1)
BREEDING HERD(7,1)
BVD POSITIVE FETUS(7,1)
CATTLE VACCINATION(7,1)
CDNA NUCLEOTIDE(7,1)
CHARACTERIZING GENETIC RECOMBINATION(7,1)
CLINICAL MANIFESTATION(7,1)
CLINICAL SIGN BROAD SPECTRUM(7,1)
CORNELL UNIVERSITY(7,1)
CULTURE CELL REINFECTION(7,1)
CYTOPATHOGENIC VIRUS(7,1)
DERIVED ATTENUATED VIRUS(7,1)
ENCODED POLYPROTEIN(7,1)
ERNS MUTANT ANALYSIS(7,1)
FETUS BVD(7,1)
FLAVIVIRIDAE FAMILY(7,1)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY(7,1)
INFECTED CELL LYSATE(7,1)
INFECTION SYMPTOM(7,1)
INFECTIOUS CLONE BASIS(7,1)
INFECTIOUS COPY DERIVATIVE(7,1)
INFECTIOUS COPY DERIVED VIRUS(7,1)
INFECTIOUS TRANSCRIPT(7,1)
MANUFACTURER RECOMMENDATION(7,1)
MATERNAL ANTIBODY(7,1)
MONOSPECIFIC ANTIBODY(7,1)
MUTATION ABROGATING(7,1)
NEUTRALIZING ANTIBODY DETECTION(7,1)
NORTHERN BLOT(7,1)
NUCLEOTRAP KIT(7,1)
PESTIVIRUS GENETIC DIVERSITY(7,1)
PHARMACEUTICAL COMPOSTION(7,1)
PLASMID LINEARIZATION(7,1)
POLY DEGRADATION ENZYME(7,1)
PREGNANCY OBSERVATION(7,1)
PURIFIED VIRAL PROTEIN(7,1)
RE LATED ORGANISM(7,1)
REISOLATED VIRUS(7,1)
REVERTANT DETERMINATION(7,1)
STRONG CLINICAL SYMPTOM(7,1)
TFL POLYMERASE(7,1)
THERMOSTABLE POLYMERASE(7,1)
TISSUE CULTURE SUPERNATANT(7,1)
TRIAL HEIFER(7,1)
UBIQUITIN INTEGRATION(7,1)
UNIDIRECTIONAL DIGESTION(7,1)
UNUSUAL FLUCTUATION(7,1)
VACCINATED CATTLE(7,1)
VACCINATED DAM(7,1)
VETERINARY MEDICINE COLLEGE(7,1)
VETERINARY MICROBIOLOGY(7,1)
CHEMICAL DERIVATIVE(6,4)
COLD SPRING HARBOR(6,2)
LABORATORY PRESS(6,2)
MAIN EVALUATION PARAMETER(6,2)
NEGATIVE HERD(6,2)
STEP CLINICAL SYMPTOM(6,2)
AGE MONTH(6,1)
AMERSHAM(6,1)
ANCILLARY MOLECULE(6,1)
ANIMAL NEED(6,1)
ANTIBODY REACTION NEUTRALIZATION(6,1)
BACTERIOPHAGE T7 RNA POLYMERASE(6,1)
BASELINE LEUKOCYTE COUNT(6,1)
CDNA STABLE CLONE(6,1)
CHALLENGE EXPERIMENT(6,1)
CHALLENGE FACILITY(6,1)
CHALLENGE INFECTION(6,1)
CLINICAL PICTURE(6,1)
CODON SUBSTITUTION(6,1)
CULTURE CELL INFECTION(6,1)
DISTINCTIVE LABEL(6,1)
DNA OLIGONUCLEOTIDE(6,1)
ENDPOINT DILUTION(6,1)
FALSE NUCLEOTIDE(6,1)
FETAL ORGAN SAMPLE(6,1)
FLUORESCENT LABEL(6,1)
GENOMIC CDNA SEQUENCE(6,1)
IDENTITY PROOF(6,1)
INFECTED ANIMAL CELL(6,1)
INFECTED CULTURE CELL(6,1)
INFECTIOUS DNA(6,1)
INFECTIOUS RNA(6,1)
INITIAL CPNA LIBRARY(6,1)
INOCULATION ROUTE(6,1)
INTRANASAL ROUTE(6,1)
LABELING PROBE(6,1)
LIBRARY SCREENING(6,1)
LIVING ORGANISM(6,1)
MFEI FRAGMENT(6,1)
MOUSE PRETREATMENT(6,1)
MUTATED PROTEIN(6,1)
NUCLEOTIDE REPLACEMENT(6,1)
NUCLEOTIDE SUBSTITUTION(6,1)
ORIGIN HERD(6,1)
PCR TEMPLATE(6,1)
PEROXIDASE CONJUGATED GOAT(6,1)
PESTIVIRUS ABSENCE(6,1)
PLASMID CDNA(6,1)
PLASMID RESTRICTION(6,1)
POLY DA TAIL(6,1)
PROBE INCUBATION(6,1)
PSHAI FRAGMENT(6,1)
RECOMBINANT CDNA(6,1)
RNA OCCURING(6,1)
RNA TRANSCRIPTION(6,1)
RNASE ACTIVITY MEASUREMENT(6,1)
ROUTINE NECROPSY(6,1)
SACII FRAGMENT(6,1)
SEQUENTIAL PHENOL CHLOROFORM EXTRACTION(6,1)
SITE MUTATION ABSENCE(6,1)
SUCCESSFUL ATTENUATION(6,1)
TEST VIRUS ISOLATION(6,1)
TRIPLET CODING(6,1)
VACCINE CANDIDATE(6,1)
VACCINE STRAIN(6,1)
VIRAL CDNA(6,1)
VIRULENCE MARKER(6,1)
VIRUS CLONE(6,1)
VIRUS IDENTITY(6,1)
VIRUS INOCULATION(6,1)
VIRUS VACCINE(6,1)
ANIMAL EXPERIMENT(5,7)
ELEVATED TEMPERATURE(5,6)
EFFICACY(5,3)
ENGLAND BIOLAB(5,3)
EXCIPIENT(5,3)
GROUP HEIFER(5,3)
IMMUNIZATION(5,3)
L HISTIDINE SUBSTITUTION(5,3)
NOSTRIL(5,3)
PRODUCT ENCOMPASSING(5,3)
VIRAEMIA(5,3)
PURIFICATION(5,2)
AMPLIFIED RT PCR PRODUCT(5,1)
ANTIGENIC SUBSTANCE(5,1)
ATTENUATED PARTICLE(5,1)
ATTENUATION REMAINS UNKNOWN(5,1)
BOVINE SERUM ALBUMIN(5,1)
BOVINE TURBINAT CELL(5,1)
CALF LACK(5,1)
CAUSAL LINK(5,1)
CELL TRANSFECTION(5,1)
CHALLENGE DAY(5,1)
CLINICAL SIGN PRESENCE(5,1)
CULTURE GROWTH(5,1)
DAY VIREMIA(5,1)
DISPLAYTHERMO RT REVERSE TRANSCRIPTASE(5,1)
DNA VECTOR(5,1)
ENZYME MODIFICATION(5,1)
FETAL INFECTION PRESENCE(5,1)
GENETIC CODE DEGENERATIVE NATURE(5,1)
GENETIC STABILITY(5,1)
GENOME MODIFICATION(5,1)
GENOMIC INSERTION(5,1)
GROWTH FACTOR(5,1)
IMMUNE RESPONSE INDUCTION(5,1)
IMMUNOLOGICAL ACTIVITY(5,1)
INITIAL PHAGE LIBRARY(5,1)
KINASE MIX(5,1)
LEUCOCYTE DECREASE(5,1)
LIGASE MIX(5,1)
MOLECULE SOLUBILITY(5,1)
MUTATION INTRODUCTION(5,1)
NUCLEOTIDE EXCHANGE(5,1)
PREPARATION ALIQUOT(5,1)
PRIME IMPORTANCE(5,1)
RNA GENE(5,1)
RNA ISOLATION(5,1)
RNA LIGASE(5,1)
SEQUENCING KIT(5,1)
SEROLOGIC DETECTION(5,1)
SUPERNATANT MEASUREMENT(5,1)
TEMPLATE DNA(5,1)
TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE(5,1)
TESTED ORGAN(5,1)
TRANSCRIPTION MIX(5,1)
TRANSFECTED CELL(5,1)
TRANSFECTION TECHNOLOGY(5,1)
UNEXPACTED GENERATION(5,1)
VIREMIA DETECTION(5,1)
VIRUS CAPABILITY(5,1)
VIRUS GENERATION(5,1)
VIRUS IDENTIFICATION(5,1)
VIRUS NEUTRALIZING ANTIBODY PRESENCE(5,1)
VIRUS SPREAD(5,1)
DEAE(4,4)
BALTIMORE(4,2)
CELL CULTURE CELL(4,2)
CEREBELLUM(4,2)
CRUDE CELL EXTRACT(4,2)
DIANOVA(4,2)
DNA VIRUS(4,2)
EXCEPTION(4,2)
EXONUCLEASE(4,2)
HCL PH(4,2)
LETHALITY(4,2)
LIGATION(4,2)
MESENTERIC LYMPH NODE(4,2)
OBSERVATION PERIOD(4,2)
REPLICATION(4,2)
STATISTICALLY SIGNIFICANT DIFFERENCE(4,2)
STEP LEUKOPENIA(4,2)
STERNUM(4,2)
SUBUNIT VACCINE(4,2)
SUPRA(4,2)
ADJUVANT PRESENCE(4,1)
AMINOETHYLCARBAZOLE(4,1)
ANIMAL PASSAGE(4,1)
ANTIGENETIC GROUP(4,1)
ANTIGENETLC(4,1)
ANTISERUM(4,1)
ATTENUATION FUNCTIONAL(4,1)
CA SUSPENSION(4,1)
CALF GROUP(4,1)
CDNA UG(4,1)
CELLULAR INSERT(4,1)
CHEMICAL MOIETY(4,1)
CLOSE RESEMBLANCE(4,1)
CONGENITAL MALFORMATION(4,1)
DEXTRAN COMPLEX(4,1)
FETAL EXPOSURE(4,1)
FLUORESCEIN ISOTHIOCYANATE(4,1)
GENETIC MARKER SITE(4,1)
GENOME ANALYSIS(4,1)
GENOMIC SEQUENCE(4,1)
GENOTYPE UNTRANSLATED REGION(4,1)
GROWTH CURVE(4,1)
ICE COLD LYSIS(4,1)
IMMUNOLOGICAL RESPONSE(4,1)
INFECTION NORMAL ROUTE(4,1)
INFECTION PRODUCTION(4,1)
K MMERER(4,1)
LOW NEUTRALIZING ANTIBODY TITER(4,1)
LYSIS BUFFER(4,1)
MAB MIX(4,1)
MAJOR ECONOMICAL IMPACT(4,1)
MAMMALIAN CELL(4,1)
MEAN LEUKOCYTE COUNT(4,1)
MIXING RNA(4,1)
NATURAL HOST(4,1)
ORGANISM IMMUNOLOGICAL FUNCTION(4,1)
ORIGIN MOLECULE(4,1)
PARTICLE GENE(4,1)
PASSAGE STOCK(4,1)
PASSAGING(4,1)
PELLETED CELL(4,1)
PHOSPHOIMAGER(4,1)
POST CHALLENGE(4,1)
POST HYBRIDIZATION(4,1)
POST VACCINATION(4,1)
PRIMER SEQUENCE(4,1)
RELEASE MARKER(4,1)
REVERSE TRANSCRIPTION PCR(4,1)
RNA GUARD UNIT(4,1)
RNA PREPARATION(4,1)
RNA SEQUENCE(4,1)
RNASE FUNCTION DELETION(4,1)
SERONEGATIVE(4,1)
SERUM PRODUCTION(4,1)
SPECIES PLUS(4,1)
SPIN COLUMN(4,1)
SPUN COLUMN(4,1)
STRAIN CP(4,1)
TEST ENDPOINT(4,1)
TEST PLAQUE(4,1)
THAWED CELL(4,1)
TRANSPORT BUFFER(4,1)
VIRAL RNA CONCENTRATION(4,1)
VIRUS PARTICLE(4,1)
WHOLE VIRUS(4,1)
LEUCINE(3,3)
RNA SECONDARY STRUCTURE(3,3)
DEVIATION(3,2)
ECORV(3,2)
SERA(3,2)
XHOI(3,2)
(EP1749885)
BVD VIRUS ATTENUATION(100,6)
BOVINE VIRAL DIARRHEA VIRUS CLONE(100,1)
AUTHENTICAL VIRULENCE(73,10)
ATTENUATED BVDV CLONE(64,2)
PYREXIA LASTING(60,5)
DNA MOLECULE(58,17)
NAIVE CALF(55,5)
INFECTED ANIMAL(48,7)
VIRAL PARTICLE(46,13)
SUSCEPTIBLE HOST CELL(45,6)
GROUP CLINICAL SYMPTOM(44,5)
BOVINE VIRAL DIARRHEA VIRUS(43,184)
RNA(43,66)
THERMOSTABLE ENZYME(42,5)
CLONE(39,53)
ATTENUATED CLONE(39,2)
RNASE ACTIVITY(37,10)
ANTIGENETIC GROUP(35,2)
TRANSCRIPTION(31,12)
RNA REVERSE TRANSCRIPTION(30,5)
MUTATED PROTEIN(30,2)
CALF(28,21)
LEUKOPENIA(28,6)
PARTICLE GENE(28,4)
BVD VIRUS RECOVERY(28,1)
DNA MOLECULE TRANSCRIPTION(28,1)
VIRULENCE(27,12)
STRAIN(26,12)
EXCIPIENT(26,3)
VIRAEMIA(25,6)
PROTEIN(25,4)
ATTENUATED PHENOTYPE(24,1)
VACCINE(23,22)
DOSE(23,16)
RNA MOLECULE(23,2)
ELEVATED TEMPERATURE(22,10)
DIARRHEA(22,9)
PLASMID VECTOR(21,4)
MAJOR ANTIGEN(21,1)
FUSION MOLECULE(20,5)
THERMOSTABLE POLYMERASE(20,3)
BOVINE ANIMAL(20,2)
MUTATED DNA(20,1)
NUCLEIC ACID CODE DEGENERATION(18,5)
CDNA(17,18)
FUNCTIONAL VARIANT(16,9)
TEMPLATE(16,8)
COMPLEMENTARY DNA(16,5)
CELL TRANSFECTION(16,4)
MONOCLONAL ANTIBODY(16,1)
INFECTION(15,16)
REVERSE TRANSCRIPTION(15,5)
RNA SECONDARY STRUCTURE(15,5)
RACE TECHNOLOGY(15,4)
L HISTIDINE SUBSTITUTION(15,3)
NEUTRALIZING ANTIBODY TITER(14,4)
ANTIGENIC DIVERSITY(14,2)
VACCINE MANUFACTURE(14,2)
CELL INFECTION(13,7)
CHEMICAL DERIVATIVE(13,6)
CELL CULTURE CELL(13,3)
ENZYME(12,11)
BVD ABORTION(12,7)
GLYCOPROTEIN(12,3)
PLASMID(10,15)
NUCLEOTIDE(10,11)
CELL CULTURE(10,4)
AMINOACID SEQUENCE(10,1)
VIRUS(9,18)
NUCLEOTIDE SEQUENCING(9,6)
PLASMID PKANE(9,6)
PROPHYLAXIS(9,2)
STEP PYREXIA(9,2)
HOG CHOLERA VIRUS CHARACTERIZATION(9,1)
ANIMAL NASAL SWAB(8,2)
FUNCTION LOSS(8,2)
CDNA CLONE DELETION LIBRARY(8,1)
CONJUGATED RABBIT ANTI MOUSE ANTIBODY(8,1)
IMMUNOTOLERANT CALF BIRTH(8,1)
PERSISTENTLY INFECTED CALF INDUCTION(8,1)
PHOSPHORYLATED OLIGONUCLEOTIDE PMOL(8,1)
PREGNANT COW PLACENTA(8,1)
BIOLOGICAL ACTIVITY(7,7)
FULL LENGTH CDNA CLONE(7,4)
VIRAL CYTOPATHOGENICITY(7,2)
AUTHENTIC VIRULENCE VIRUS(7,1)
CLASSICAL SWINE FEVER FIRUS(7,1)
FLECKED CATTLE FEMALE ANIMAL(7,1)
INDEPENDENT CDNA(7,1)
PREDOMINANT CLINICAL PARAMETER DIARRHEA(7,1)
RECOMBINANT VIRUS PATHOGENICITY(7,1)
WILD TYPE(6,24)
FULL LENGTH COMPLEMENTARY DNA(6,7)
CALF SERUM(6,3)
DEFINED GENETIC IDENTITY(6,3)
ERNS CODING REGION(6,3)
LIVE VACCINE(6,3)
MANUFACTURER INSTRUCTION(6,3)
ANIMAL HEALTH FIELD(6,2)
ANTIBODY NEUTRALIZATION(6,2)
EUKARYOTIC PROMOTOR(6,2)
IMMUNOFLUORESCENCE ASSAY(6,2)
PRIMER PMOL(6,2)
ACUTELY INFECTED CATTLE(6,1)
BOVINE DIARRHEA VIRUS(6,1)
BVD VIRUS GENE(6,1)
GENOMIC REVERSION DANGER(6,1)
HEPARIN STABILIZED BLOOD ALIQUOT(6,1)
INFECTIOUS CDNA CLONE(6,1)
INFECTIOUS CLONE REPORT(6,1)
MILD RESPIRATORY SYMPTOM(6,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(6,1)
MUTATION RESULT(6,1)
PKANE AATLL SITE(6,1)
PREPARATIVE AGAROSE GEL ELECTROPHORESIS(6,1)
PROBE RADIOACTIVE LABELING(6,1)
RE LATED COW MORTALITY(6,1)
RECOMBINANT VIRUS MUTANT(6,1)
VIRUS NASAL SHEDDING(6,1)
MADIN DARBY BOVINE KIDNEY(5,16)
SUSCEPTIBLE CELL(5,4)
VIRUS ISOLATION(5,3)
CODON DELETION(5,2)
EXPERIMENTAL FACILITY(5,2)
EXPERIMENTAL INFECTION(5,2)
GLUTEAL MUSCLE(5,2)
MUTANT VIRUS(5,2)
SERUM RECIPROCAL(5,2)
VIRUS GENOME(5,2)
ANIMAL BUFFY COAT PREPARATION(5,1)
ATTENUATED PESTIVIRUS(5,1)
BIG DYE TERMINATOR(5,1)
BORDER DISEASE VIRUS SUBGROUP(5,1)
BVD CAUSATIVE AGENT(5,1)
CDNA CLONE IDENTIFICATION(5,1)
CDNA CLONE INSERT(5,1)
CLONED POLIOVIRUS COMPLEMENTARY DNA(5,1)
DEGRADED RNA FRAGMENT(5,1)
DISEASE EPIDEMIOLOGY(5,1)
ELECTROPORATION CUVETTE(5,1)
FETUS RESORPTION(5,1)
IMMUNOFLUORESCENCE STAINING(5,1)
INFECTIOUS VIRUS RECOVERY(5,1)
INTRAUTERINE INFECTION PATHOGENESIS(5,1)
LINEARIZED PKANE(5,1)
NUCLEOTIDE TRIPLET(5,1)
PATHOGENESIS REVIEW(5,1)
PESTIVIRUS GENUS(5,1)
POLYNUCLEOTIDE VACCINATION(5,1)
PREGNANT HEIFER(5,1)
RE LATED ABORTION(5,1)
RNA INFECTIVITY(5,1)
RNASE ACTIVITY INACTIVATION(5,1)
ROCHE MOLECULAR BIOCHEMICAL(5,1)
RT PCR SEQUENCING(5,1)
UL TRANSCRIPTION MIX(5,1)
VACCINATED HERD(5,1)
VENA JUGULARIS(5,1)
VIRUS MUTANT GENE(5,1)
VIRUS PEROXIDASE ASSAY(5,1)
ETHYL ALCOHOL PRECIPITATION(4,6)
ADMINISTRATION(4,4)
CONSECUTIVE DAY(4,2)
CONSTRUCTING CDNA(4,2)
KILLED VACCINE(4,2)
PARTIAL CDNA FRAGMENT(4,2)
PHENOL EXTRACTION(4,2)
UNINFECTED CELL(4,2)
WELFARE REASON(4,2)
AATLL FRAGMENT(4,1)
AGE MONTH(4,1)
AMERSHAM(4,1)
ANCILLARY MOLECULE(4,1)
ANIMAL NEED(4,1)
ANTIBODY REACTION NEUTRALIZATION(4,1)
ATTENUATED VIRAL PARTICLE(4,1)
BACTERIOPHAGE T7 RNA POLYMERASE(4,1)
BOVINE SERUM UG ML(4,1)
BREEDING HERD(4,1)
BVD POSITIVE FETUS(4,1)
CATTLE VACCINATION(4,1)
CDNA NUCLEOTIDE(4,1)
CDNA STABLE CLONE(4,1)
CHALLENGE EXPERIMENT(4,1)
CHARACTERIZING GENETIC RECOMBINATION(4,1)
CLINICAL MANIFESTATION(4,1)
CLINICAL PICTURE(4,1)
CLINICAL SIGN BROAD SPECTRUM(4,1)
CODON SUBSTITUTION(4,1)
CORNELL UNIVERSITY(4,1)
CULTURE CELL INFECTION(4,1)
CULTURE CELL REINFECTION(4,1)
CYTOPATHOGENIC VIRUS(4,1)
DAY POST INFECTION(4,1)
DERIVED ATTENUATED VIRUS(4,1)
DISTINCTIVE LABEL(4,1)
DNA OLIGONUCLEOTIDE(4,1)
ENDPOINT DILUTION(4,1)
ERNS MUTANT ANALYSIS(4,1)
FALSE NUCLEOTIDE(4,1)
FETAL ORGAN(4,1)
FETUS BVD(4,1)
FLAVIVIRIDAE FAMILY(4,1)
FLUORESCENT LABEL(4,1)
IDENTITY PROOF(4,1)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY(4,1)
INFECTED ANIMAL CELL(4,1)
INFECTED CELL LYSATE(4,1)
INFECTED CULTURE CELL(4,1)
INFECTION SYMPTOM(4,1)
INFECTIOUS CLONE BASIS(4,1)
INFECTIOUS DNA(4,1)
INFECTIOUS RNA(4,1)
INFECTIOUS TRANSCRIPT(4,1)
INOCULATION DAY(4,1)
LIVING ORGANISM(4,1)
MANUFACTURER RECOMMENDATION(4,1)
MATERNAL ANTIBODY(4,1)
MONOSPECIFIC ANTIBODY(4,1)
MOUSE PRETREATMENT(4,1)
MUTATION ABROGATING(4,1)
NEUTRALIZING ANTIBODY DETECTION(4,1)
NORTHERN BLOT(4,1)
NUCLEOTIDE REPLACEMENT(4,1)
NUCLEOTRAP KIT(4,1)
PCR TEMPLATE(4,1)
PEROXIDASE CONJUGATED GOAT(4,1)
PESTIVIRUS ABSENCE(4,1)
PESTIVIRUS GENETIC DIVERSITY(4,1)
PHARMACEUTICAL COMPOSTION(4,1)
PLASMID CDNA(4,1)
PLASMID LINEARIZATION(4,1)
PLASMID RESTRICTION(4,1)
POLY DA TAIL(4,1)
PREGNANCY STATUS(4,1)
PROBE INCUBATION(4,1)
PSHAI FRAGMENT(4,1)
PURIFIED VIRAL PROTEIN(4,1)
RE LATED ORGANISM(4,1)
RECOMBINANT CDNA(4,1)
REISOLATED VIRUS(4,1)
REVERTANT DETERMINATION(4,1)
RNA OCCURING(4,1)
RNA TRANSCRIPTION(4,1)
RNASE ACTIVITY DETERMINATION(4,1)
RNASE ACTIVITY MEASUREMENT(4,1)
ROUTINE NECROPSY(4,1)
SAALM LLER(4,1)
SEQUENTIAL PHENOL CHLOROFORM EXTRACTION(4,1)
SITE MUTATION ABSENCE(4,1)
STRONG CLINICAL SYMPTOM(4,1)
SUCCESSFUL ATTENUATION(4,1)
TFL POLYMERASE(4,1)
TISSUE CULTURE SUPERNATANT(4,1)
TRIPLET CODING(4,1)
UBIQUITIN INTEGRATION(4,1)
UNIDIRECTIONAL DIGESTION(4,1)
VACCINATED CATTLE(4,1)
VACCINATED DAM(4,1)
VACCINE STRAIN(4,1)
VETERINARY MEDICINE COLLEGE(4,1)
VETERINARY MICROBIOLOGY(4,1)
VIRAL CDNA(4,1)
VIRULENCE MARKER(4,1)
VIRUS ATTENUATION(4,1)
VIRUS CLONE(4,1)
VIRUS IDENTITY(4,1)
VIRUS INOCULATION(4,1)
ANIMAL EXPERIMENT(3,7)
CELL LINE(3,5)
LETHALITY(3,3)
PRODUCT ENCOMPASSING(3,3)
COLD SPRING HARBOR(3,2)
GENETIC MARKER SITE(3,2)
LABORATORY PRESS(3,2)
PURIFICATION(3,2)
STEP CLINICAL SYMPTOM(3,2)
AMPLIFIED RT PCR PRODUCT(3,1)
ANTIGENIC SUBSTANCE(3,1)
ATTENUATED PARTICLE(3,1)
ATTENUATION REMAINS UNKNOWN(3,1)
BOVINE SERUM ALBUMIN(3,1)
BOVINE TURBINAT CELL(3,1)
CALF LACK(3,1)
CAUSAL LINK(3,1)
CLINICAL SIGN PRESENCE(3,1)
CULTURE GROWTH(3,1)
DISPLAYTHERMO RT REVERSE TRANSCRIPTASE(3,1)
DNA VECTOR(3,1)
FETAL INFECTION PRESENCE(3,1)
GENETIC CODE DEGENERATIVE NATURE(3,1)
GENETIC STABILITY(3,1)
GENOME MODIFICATION(3,1)
GENOMIC INSERTION(3,1)
IMMUNE RESPONSE INDUCTION(3,1)
IMMUNOLOGICAL ACTIVITY(3,1)
INITIAL PHAGE LIBRARY(3,1)
KINASE MIX(3,1)
LEUCOCYTE DECREASE(3,1)
LIGASE MIX(3,1)
MOLECULE SOLUBILITY(3,1)
MUTATION INTRODUCTION(3,1)
NUCLEOTIDE EXCHANGE(3,1)
PREPARATION ALIQUOT(3,1)
PRIME IMPORTANCE(3,1)
RNA GENE(3,1)
RNA ISOLATION(3,1)
RNA LIGASE(3,1)
SEQUENCING KIT(3,1)
SEROLOGIC DETECTION(3,1)
SUPERNATANT MEASUREMENT(3,1)
TEMPLATE DNA(3,1)
TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE(3,1)
TRANSFECTED CELL(3,1)
TRANSFECTION TECHNOLOGY(3,1)
VIREMIA DETECTION(3,1)
VIRUS CAPABILITY(3,1)
VIRUS GENERATION(3,1)
VIRUS IDENTIFICATION(3,1)
VIRUS NEUTRALIZING ANTIBODY PRESENCE(3,1)
VIRUS SPREAD(3,1)
PHOSPHATE BUFFERED SALINE(2,7)
BASELINE(2,4)
DEAE(2,4)
LEUCINE(2,3)
PACYC(2,3)
BACTERIA(2,2)
BALTIMORE(2,2)
DIANOVA(2,2)
DNA VIRUS(2,2)
ENGLAND BIOLAB(2,2)
EXONUCLEASE(2,2)
LIGATION(2,2)
NOSTRIL(2,2)
R MENAPF(2,2)
REPLICATION(2,2)
ROUTE(2,2)
SERA(2,2)
STATISTICALLY SIGNIFICANT DIFFERENCE(2,2)
STEP LEUKOPENIA(2,2)
SUBUNIT VACCINE(2,2)
ACCESSION(2,1)
ADJUVANT PRESENCE(2,1)
ALFORT T BINGEN(2,1)
AMINOACID SUBSTITUTION(2,1)
AMINOETHYLCARBAZOLE(2,1)
ANIMAL PASSAGE(2,1)
ANOREXIA(2,1)
ANTIBIOTIC(2,1)
ANTISERUM(2,1)
ATTENUATION FUNCTIONAL(2,1)
CA SUSPENSION(2,1)
CALF GROUP(2,1)
CDNA SEQUENCE(2,1)
CDNA UG(2,1)
CELLULAR INSERT(2,1)
CHEMICAL MOIETY(2,1)
CLOSE RESEMBLANCE(2,1)
CONGENITAL MALFORMATION(2,1)
DEXTRAN COMPLEX(2,1)
FLUORESCEIN ISOTHIOCYANATE(2,1)
GENOME ANALYSIS(2,1)
GENOMIC SEQUENCE(2,1)
GENOTYPE UNTRANSLATED REGION(2,1)
GROWTH CURVE(2,1)
HOST CELL(2,1)
ICE COLD LYSIS(2,1)
IMMUNOLOGICAL RESPONSE(2,1)
K MMERER(2,1)
LOW NEUTRALIZING ANTIBODY TITER(2,1)
LYSIS BUFFER(2,1)
MAB MIX(2,1)
MAIN EVALUATION PARAMETER(2,1)
MAJOR ECONOMICAL IMPACT(2,1)
MAMMALIAN CELL(2,1)
MIXING RNA(2,1)
NATURAL HOST(2,1)
NEGATIVE HERD(2,1)
ORGANISM IMMUNOLOGICAL FUNCTION(2,1)
ORIGIN MOLECULE(2,1)
PASSAGE STOCK(2,1)
PASSAGING(2,1)
PELLETED CELL(2,1)
PHOSPHOIMAGER(2,1)
POST HYBRIDIZATION(2,1)
PRIMER SEQUENCE(2,1)
REVERSE TRANSCRIPTION PCR(2,1)
RNA GUARD UNIT(2,1)
RNA PREPARATION(2,1)
RNA SEQUENCE(2,1)
SERUM PRODUCTION(2,1)
SPECIES PLUS(2,1)
SPIN COLUMN(2,1)
SPUN COLUMN(2,1)
STRAIN CP(2,1)
TEST ENDPOINT(2,1)
TEST PLAQUE(2,1)
THAWED CELL(2,1)
TRANSPORT BUFFER(2,1)
TRIS HCI PH(2,1)
UNEXPECTED GENERATION(2,1)
VIRAL RNA CONCENTRATION(2,1)
VIRUS PARTICLE(2,1)
WHOLE VIRUS(2,1)
(EP1749885)
BVD VIRUS ATTENUATION(100,17)
BOVINE VIRAL DIARRHEA VIRUS VACCINE(100,1)
ATTENUATED BVDV CLONE(39,1)
RNASE ACTIVITY(33,15)
ATTENUATED CLONE(24,1)
TRIPLET CODING(22,2)
AUTHENTICAL VIRULENCE(21,7)
PROTEIN(19,9)
PYREXIA LASTING(19,3)
DNA MOLECULE(18,12)
CODING TRIPLET(18,1)
NAIVE CALF(17,3)
BOVINE VIRAL DIARRHEA VIRUS(16,162)
CLONE(16,39)
VACCINE(16,26)
MAJOR ANTIGEN(16,1)
EXCIPIENT(15,5)
DNA VIRUS(15,2)
L HISTIDINE CODON(15,1)
GROUP CLINICAL SYMPTOM(14,3)
PARTICLE GENE(14,2)
SUSCEPTIBLE HOST CELL(13,4)
MONOCLONAL ANTIBODY(13,1)
STRAIN(12,14)
CODON DELETION(12,3)
CODON SUBSTITUTION(12,2)
RNA(11,53)
MUTATION(11,16)
ANTIGENIC DIVERSITY(11,2)
CALF(10,17)
ATTENUATION(10,12)
NEUTRALIZING ANTIBODY TITER(10,4)
BVD ABORTION(9,7)
GLYCOPROTEIN(9,3)
L HISTIDINE DELETION(9,1)
UN CONNECTION(9,1)
DOSE(8,12)
NUCLEOTIDE(8,11)
VIRULENCE(8,9)
TRANSCRIPTION(8,8)
LEUKOPENIA(8,5)
VIRAEMIA(8,4)
VIRUS(7,18)
GENOME(7,10)
DIARRHEA(7,8)
NUCLEOTIDE SEQUENCING(7,6)
PLASMID PKANE(7,6)
TEMPLATE(7,6)
LEUCINE(7,5)
L HISTIDINE SUBSTITUTION(7,4)
AMINOACID SEQUENCE(7,1)
HOG CHOLERA VIRUS CHARACTERIZATION(7,1)
INFECTION(6,14)
CELL INFECTION(6,5)
L HISTIDINE(6,5)
THERMOSTABLE ENZYME(6,3)
ANIMAL NASAL SWAB(6,2)
CDNA CLONE DELETION LIBRARY(6,1)
CONJUGATED RABBIT ANTI MOUSE ANTIBODY(6,1)
IMMUNOTOLERANT CALF BIRTH(6,1)
PERSISTENTLY INFECTED CALF INDUCTION(6,1)
PHOSPHORYLATED OLIGONUCLEOTIDE PMOL(6,1)
PREGNANT COW PLACENTA(6,1)
BIOLOGICAL ACTIVITY(5,7)
FUNCTIONAL VARIANT(5,7)
CALF SERUM(5,3)
DEFINED GENETIC IDENTITY(5,3)
LIVE VACCINE(5,3)
MANUFACTURER INSTRUCTION(5,3)
ANTIBODY NEUTRALIZATION(5,2)
BVDV ATTENUATION(5,2)
EUKARYOTIC PROMOTOR(5,2)
IMMUNOFLUORESCENCE ASSAY(5,2)
THERMOSTABLE POLYMERASE(5,2)
VIRAL CYTOPATHOGENICITY(5,2)
ACUTELY INFECTED CATTLE(5,1)
AUTHENTIC VIRULENCE VIRUS(5,1)
BOVINE DIARRHEA VIRUS(5,1)
CLASSICAL SWINE FEVER FIRUS(5,1)
FLECKED CATTLE FEMALE ANIMAL(5,1)
GENOMIC REVERSION DANGER(5,1)
HEPARIN STABILIZED BLOOD ALIQUOT(5,1)
INDEPENDENT CDNA(5,1)
INFECTIOUS CLONE REPORT(5,1)
MILD RESPIRATORY SYMPTOM(5,1)
PREDOMINANT CLINICAL PARAMETER DIARRHEA(5,1)
PREPARATIVE AGAROSE GEL ELECTROPHORESIS(5,1)
PROBE RADIOACTIVE LABELING(5,1)
RE LATED COW MORTALITY(5,1)
RECOMBINANT VIRUS PATHOGENICITY(5,1)
VIRUS NASAL SHEDDING(5,1)
MADIN DARBY BOVINE KIDNEY(4,16)
SUPRA(4,10)
RACE TECHNOLOGY(4,4)
SUSCEPTIBLE CELL(4,4)
EMS CODING REGION(4,3)
FUSION MOLECULE(4,3)
PLASMID VECTOR(4,3)
RNA REVERSE TRANSCRIPTION(4,3)
VIRUS ISOLATION(4,3)
EXPERIMENTAL FACILITY(4,2)
EXPERIMENTAL INFECTION(4,2)
GLUTEAL MUSCLE(4,2)
MUTANT VIRUS(4,2)
PRIMER PMOL(4,2)
SERUM RECIPROCAL(4,2)
VIRUS GENOME(4,2)
ANIMAL BUFFY COAT PREPARATION(4,1)
ATTENUATED PESTIVIRUS(4,1)
BIG DYE TERMINATOR(4,1)
BORDER DISEASE VIRUS SUBGROUP(4,1)
BVD CAUSATIVE AGENT(4,1)
BVD VIRUS GENE(4,1)
CDNA BSRGI SITE(4,1)
CDNA CLONE IDENTIFICATION(4,1)
CDNA CLONE INSERT(4,1)
CLONED POLIOVIRUS COMPLEMENTARY DNA(4,1)
DEGRADED RNA FRAGMENT(4,1)
DISEASE EPIDEMIOLOGY(4,1)
DNA MOLECULE TRANSCRIPTION(4,1)
ELECTROPORATION CUVETTE(4,1)
FETUS RESORPTION(4,1)
IMMUNOFLUORESCENCE STAINING(4,1)
INFECTIOUS CDNA CLONE(4,1)
INFECTIOUS VIRUS RECOVERY(4,1)
INTRAUTERINE INFECTION PATHOGENESIS(4,1)
LINEARIZED PKANE(4,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(4,1)
NUCLEOTIDE TRIPLET(4,1)
PATHOGENESIS REVIEW(4,1)
PESTIVIRUS GENUS(4,1)
PKANE AATII SITE(4,1)
POLYNUCLEOTIDE VACCINATION(4,1)
PREGNANT HEIFER(4,1)
RE LATED ABORTION(4,1)
RECOMBINANT VIRUS MUTANT(4,1)
RNA INFECTIVITY(4,1)
RNASE ACTIVITY INACTIVATION(4,1)
ROCHE MOLECULAR BIOCHEMICAL(4,1)
RT PCR SEQUENCING(4,1)
UL TRANSCRIPTION MIX(4,1)
VACCINATED HERD(4,1)
VENA JUGPLARIS(4,1)
VIRUS MUTANT GENE(4,1)
VIRUS PEROXIDASE ASSAY(4,1)
ETHYL ALCOHOL PRECIPITATION(3,6)
ADMINISTRATION(3,4)
CHEMICAL DERIVATIVE(3,4)
NUCLEIC ACID CODE DEGENERATION(3,3)
BOVINE ANIMAL(3,2)
CONSECUTIVE DAY(3,2)
CONSTRUCTING CDNA(3,2)
KILLED VACCINE(3,2)
PARTIAL CDNA FRAGMENT(3,2)
PHENOL EXTRACTION(3,2)
RNA MOLECULE(3,2)
UNINFECTED CELL(3,2)
WELFARE REASON(3,2)
AATII FRAGMENT(3,1)
AGE MONTH(3,1)
AMERSHAM(3,1)
ANCILLARY MOLECULE(3,1)
ANIMAL NEED(3,1)
ANTIBODY REACTION NEUTRALIZATION(3,1)
ATTENUATED VIRAL PARTICLE(3,1)
BACTERIOPHAGE T7 RNA POLYMERASE(3,1)
BOVINE SERUM UG ML(3,1)
BREEDING HERD(3,1)
BVD POSITIVE FETUS(3,1)
CATTLE VACCINATION(3,1)
CDNA NUCLEOTIDE(3,1)
CDNA STABLE CLONE(3,1)
CHALLENGE EXPERIMENT(3,1)
CHARACTERIZING GENETIC RECOMBINATION(3,1)
CLINICAL MANIFESTATION(3,1)
CLINICAL PICTURE(3,1)
CLINICAL SIGN BROAD SPECTRUM(3,1)
CORNELL UNIVERSITY(3,1)
CULTURE CELL INFECTION(3,1)
CULTURE CELL REINFECTION(3,1)
CYTOPATHOGENIC VIRUS(3,1)
DAY POST INFECTION(3,1)
DERIVED ATTENUATED VIRUS(3,1)
DISTINCTIVE LABEL(3,1)
DNA OLIGONUCLEOTIDE(3,1)
EMS MUTANT ANALYSIS(3,1)
ENDPOINT DILUTION(3,1)
FALSE NUCLEOTIDE(3,1)
FETAL ORGAN(3,1)
FETUS BVD(3,1)
FLAVIVIRIDAE FAMILY(3,1)
FLUORESCENT LABEL(3,1)
IDENTITY PROOF(3,1)
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY(3,1)
INFECTED ANIMAL CELL(3,1)
INFECTED BOVINE(3,1)
INFECTED CELL LYSATE(3,1)
INFECTED CULTURE CELL(3,1)
INFECTION SYMPTOM(3,1)
INFECTIOUS CLONE BASIS(3,1)
INFECTIOUS DNA(3,1)
INFECTIOUS RNA(3,1)
INFECTIOUS TRANSCRIPT(3,1)
INOCULATION DAY(3,1)
LIVING ORGANISM(3,1)
MANUFACTURER RECOMMENDATION(3,1)
MATERNAL ANTIBODY(3,1)
MFEI FRAGMENT(3,1)
MONOSPECIFIC ANTIBODY(3,1)
MOUSE PRETREATMENT(3,1)
MUTATED DNA(3,1)
MUTATED PROTEIN(3,1)
MUTATION ABROGATING(3,1)
NEUTRALIZING ANTIBODY DETECTION(3,1)
NORTHERN BLOT(3,1)
NUCLEOTIDE REPLACEMENT(3,1)
NUCLEOTIDE SUBSTITUTION(3,1)
NUCLEOTRAP KIT(3,1)
PCR TEMPLATE(3,1)
PEROXIDASE CONJUGATED GOAT(3,1)
PESTIVIRUS ABSENCE(3,1)
PESTIVIRUS GENETIC DIVERSITY(3,1)
PHARMACEUTICAL COMPOSTION(3,1)
PLASMID CDNA(3,1)
PLASMID LINEARIZATION(3,1)
PLASMID RESTRICTION(3,1)
POLY DA TAIL(3,1)
PREGNANCY STATUS(3,1)
PROBE INCUBATION(3,1)
PSHAI FRAGMENT(3,1)
PURIFIED VIRAL PROTEIN(3,1)
RE LATED ORGANISM(3,1)
RECOMBINANT CDNA(3,1)
REISOLATED VIRUS(3,1)
REVERTANT DETERMINATION(3,1)
RNA OCCURING(3,1)
RNA TRANSCRIPTION(3,1)
RNASE ACTIVITY DETERMINATION(3,1)
RNASE ACTIVITY MEASUREMENT(3,1)
ROUTINE NECROPSY(3,1)
SAALM LLER(3,1)
SACI FRAGMENT(3,1)
SEQUENTIAL PHENOL CHLOROFORM EXTRACTION(3,1)
SITE MUTATION ABSENCE(3,1)
STRONG CLINICAL SYMPTOM(3,1)
SUCCESSFUL ATTENUATION(3,1)
TFL POLYMERASE(3,1)
TISSUE CULTURE SUPERNATANT(3,1)
UBIQUITIN INTEGRATION(3,1)
UNIDIRECTIONAL DIGESTION(3,1)
VACCINATED CATTLE(3,1)
VACCINATED DAM(3,1)
VACCINE STRAIN(3,1)
VETERINARY MEDICINE COLLEGE(3,1)
VETERINARY MICROBIOLOGY(3,1)
VIRAL CDNA(3,1)
VIRULENCE MARKER(3,1)
VIRUS ATTENUATION(3,1)
VIRUS CLONE(3,1)
VIRUS IDENTITY(3,1)
VIRUS INOCULATION(3,1)
ANIMAL EXPERIMENT(2,7)
ELEVATED TEMPERATURE(2,6)
DEAE(2,4)
FULL LENGTH CDNA CLONE(2,4)
CELL TRANSFECTION(2,3)
LETHALITY(2,3)
PRODUCT ENCOMPASSING(2,3)
BACTERIA(2,2)
BALTIMORE(2,2)
CELL CULTURE CELL(2,2)
COLD SPRING HARBOR(2,2)
DIANOVA(2,2)
ENGLAND BIOLAB(2,2)
EXONUCLEASE(2,2)
GENETIC MARKER SITE(2,2)
HCL PH(2,2)
LABORATORY PRESS(2,2)
LIGATION(2,2)
NOSTRIL(2,2)
PURIFICATION(2,2)
R MENAPF(2,2)
REPLICATION(2,2)
STATISTICALLY SIGNIFICANT DIFFERENCE(2,2)
STEP CLINICAL SYMPTOM(2,2)
STEP LEUKOPENIA(2,2)
SUBUNIT VACCINE(2,2)
ADJUVANT PRESENCE(2,1)
AMINOETHYLCARBAZOLE(2,1)
AMPLIFIED RT PCR PRODUCT(2,1)
ANIMAL PASSAGE(2,1)
ANTIGENETIC GROUP(2,1)
ANTIGENIC SUBSTANCE(2,1)
ANTISERUM(2,1)
ASPECT INCONNECTION(2,1)
ATTENUATED PARTICLE(2,1)
ATTENUATION FUNCTIONAL(2,1)
ATTENUATION REMAINS UNKNOWN(2,1)
BOVINE SERUM ALBUMIN(2,1)
BOVINE TURBINAT CELL(2,1)
CA SUSPENSION(2,1)
CALF GROUP(2,1)
CALF LACK(2,1)
CAUSAL LINK(2,1)
CDNA SEQUENCE(2,1)
CDNA UG(2,1)
CELLULAR INSERT(2,1)
CHEMICAL MOIETY(2,1)
CLINICAL SIGN PRESENCE(2,1)
CLOSE RESEMBLANCE(2,1)
CONGENITAL MALFORMATION(2,1)
CULTURE GROWTH(2,1)
DEXTRAN COMPLEX(2,1)
DISPLAYTHERMO RT REVERSE TRANSCRIPTASE(2,1)
DNA VECTOR(2,1)
DOSIS(2,1)
FETAL INFECTION PRESENCE(2,1)
FLUORESCEIN ISOTHIOCYANATE(2,1)
GENETIC CODE DEGENERATIVE NATURE(2,1)
GENETIC STABILITY(2,1)
GENOME ANALYSIS(2,1)
GENOME MODIFICATION(2,1)
GENOMIC INSERTION(2,1)
GENOMIC SEQUENCE(2,1)
GENOTYPE UNTRANSLATED REGION(2,1)
GROWTH CURVE(2,1)
HOST CELL(2,1)
ICE COLD LYSIS(2,1)
IMMUNE RESPONSE INDUCTION(2,1)
IMMUNOLOGICAL ACTIVITY(2,1)
IMMUNOLOGICAL RESPONSE(2,1)
INITIAL PHAGE LIBRARY(2,1)
K MMERER(2,1)
KINASE MIX(2,1)
LEUCOCYTE DECREASE(2,1)
LIGASE MIX(2,1)
LOW NEUTRALIZING ANTIBODY TITER(2,1)
LYSIS BUFFER(2,1)
MAB MIX(2,1)
MAIN EVALUATION PARAMETER(2,1)
MAJOR ECONOMICAL IMPACT(2,1)
MAMMALIAN CELL(2,1)
MIXING RNA(2,1)
MOLECULE SOLUBILITY(2,1)
MUTATION INTRODUCTION(2,1)
NATURAL HOST(2,1)
NEGATIVE HERD(2,1)
NUCLEOTIDE EXCHANGE(2,1)
ORGANISM IMMUNOLOGICAL FUNCTION(2,1)
ORIGIN MOLECULE(2,1)
PASSAGE STOCK(2,1)
PASSAGING(2,1)
PELLETED CELL(2,1)
PHOSPHOIMAGER(2,1)
POST HYBRIDIZATION(2,1)
PREPARATION ALIQUOT(2,1)
PRIME IMPORTANCE(2,1)
PRIMER SEQUENCE(2,1)
REVERSE TRANSCRIPTION PCR(2,1)
RNA GENE(2,1)
RNA GUARD UNIT(2,1)
RNA ISOLATION(2,1)
RNA LIGASE(2,1)
RNA PREPARATION(2,1)
RNA SEQUENCE(2,1)
SEQUENCING KIT(2,1)
SEROLOGIC DETECTI(...)";"Basic materials chemistry
Biotechnology
Pharmaceuticals";Open
"2001-08-28
2002-08-27";"US20030104612       A1 2003-06-05 [US20030104612]
STG: (A1) Application published
AP : 2002US-10228406 2002-08-27
US6974575           B2 2005-12-13 [US6974575]
STG: (B2) Granted patent as second publication
AP : 2002US-10228406 2002-08-27
FD :  Provisional Appl: US60/315,445 FDD=2001-08-28 [2001US-60315445]
FD : Previous publication: US20030104612 A1 2003-06-05 [US20030104612]";43448359;"US20030104612       A1 2003-06-05 [US20030104612]
US6974575           B2 2005-12-13 [US6974575]";"2001US-60315445
2002US-10228406";;"PFIZER
PFIZER PRODUCTS";"PFIZER
PFIZER PRODUCTS";"(US6974575)
US";"(US20030104612)
NAME=Pfizer Inc. , ATYP=US Company 

(US6974575)
NAME=Pfizer Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Pfizer Products Inc. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 
";2;"CAO XUEMEI
ZYBARTH GABRIELE M";"(US20030104612)
US
(US6974575)
US";"(US20030104612)
NAME=Cao Xuemei , CITY=East Lyme , STATE=CT , COUNTRY=US 

NAME=Zybarth Gabriele M. , CITY=Little Compton , STATE=RI , COUNTRY=US 

(US6974575)
NAME=Cao Xuemei , CITY=East Lyme , STATE=CT , COUNTRY=US 

NAME=Zybarth Gabriele M. , CITY=West Kingston , STATE=RI , COUNTRY=US 
";"(US6974575)
Generation of type I/type II hybrid form of bovine viral diarrhea virus for use as vaccine";"(US6974575)
The present invention provides genetically engineered type I/type II hybrid BVDV viruses. The hybrid viruses, as well as the hybrid viral genome, can be used in immunogenic compositions and vaccines for protecting cattle from BVDV infection.";"(US20030104612)
What is claimed is:
1. A hybrid BVD virus comprising a genome generated by substituting a portion of the genome of a type I BVD virus with the corresponding portion of the genome of a type II BVD virus.
2. The hybrid BVD virus of claim 1, wherein said portion of the viral genome is the E1-E2 region.
3. The hybrid BVD virus of claim 2, wherein said hybrid virus has the designation NADL890 and comprises a genome having the nucleotide sequence as set forth in SEQ ID NO: 10.
4. An isolated nucleic acid molecule comprising a sequence as set forth in SEQ ID NO: 10, or a degenerate variant thereof.
5. An isolated nucleic acid molecule comprising a sequence essentially as set forth in SEQ ID NO: 10, or a degenerate variant thereof.
6. A vector comprising a sequence essentially as set forth in SEQ ID NO: 10, or a degenerate variant thereof.
7. A vector designated as pNADL890 (ATCC #PTA-3098) (SEQ ID NO: 9).
8. A cell transformed or transfected with the nucleic acid molecule of claim 4 or 5.
9. A cell transformed or transfected with the vector of claim 6 or 7.
10. A progeny virus produced by the cell of claim 8.
11. A progeny virus produced by the cell of claim 9.
12. An immunogenic composition comprising the attenuated BVD virus of any of claims 1-3 and a veterinarily-acceptable carrier.
13. An immunogenic composition comprising the isolated nucleic acid molecule of claim 4 or 5 and a veterinarily-acceptable carrier.
14. A method of inducing an immune response against BVDV in an animal subject, comprising administering an immunologically effective amount of the hybrid BVD virus of any of claims 1-3 and a veterinarily-acceptable carrier.
15. A method of inducing an immune response against BVDV in an animal subject, comprising administering an immunologically effective amount of the isolated nucleic acid molecule of claim 4 or 5.
16. The method of claim 14, wherein said immune response is a cellular or humoral immune response.
17. The method of claim 15, wherein said immune response is a cellular or humoral immune response.
18. A vaccine composition comprising the attenuated BVD virus of any of claims 1-3 and a veterinarily-acceptable carrier.
19. A vaccine composition comprising the isolated nucleic acid molecule of claim 4 or 5 and a veterinarily-acceptable carrier.
20. A method of treating a BVDV infection in an animal, comprising administering to said animal, a therapeutically effective amount of the hybrid BVD virus of any of claims 1-3.
21. A method of treating a BVDV infection in an animal, comprising administering to said animal, a therapeutically effective amount of the isolated nucleic acid molecule of claim 4 or 5.
22. A method of identifying a BVD virus in an animal as a hybrid BVD virus of any of claims 1-3, said animal suspected of suffering a BVDV infection, comprising isolating the viral genomic nucleic acid from said animal, detecting the presence of a hybrid genomic nucleic acid sequence, thereby determining the isolated virus as identical to the hybrid BVD virus of any of claims 1-3.
23. A method of identifying a BVD virus in an animal as a hybrid BVD virus of any of claims 1-3, said animal suspected of suffering a BVDV infection, comprising isolating the virus from said animal, detecting the presence of viral proteins indicative of the said hybrid virus, thereby determining the isolated virus as identical to the attenuated BVD virus of any of claims 1-3.
24. A method of modifying a genome of an isolated type I BVD virus to make it suitable for use in a vaccine against both type I and type II BVD viruses, comprising substituting the E1-E2 region of the genome of said type I virus with the E1-E2 region of the genome of a type II virus, thereby obtaining a hybrid type I/type II virus suitable for use in a vaccine against both type I and type II BVD viruses.";"(US6974575)
The present invention provides genetically engineered type I/type II hybrid BVDV viruses.
The present invention provides genetically engineered type I/type II hybrid viruses using recombinant DNA technology.
The present invention further provides immunogenic compositions and vaccines formulated using the genetically engineered hybrid viruses.
One embodiment of the present invention provides genetically engineered type I/type II hybrid BVD viruses having a hybrid genome derived by substituting a portion of the genome of a type I BVD virus with the corresponding portion of the genome of a type II BVD virus.
In a preferred embodiment, the present invention provides hybrid viruses carrying a genome derived from the genome of NADL (a type I BVD virus, deposited with the American Type Culture Collection and designated as VR-534) wherein at least a portion of the E1-E2 region of the NADL genome is replaced with the corresponding portion of the E1-E2 region of the genome of 890 (a known type II BVD virus).
The present invention relates to genetically engineered type I/type II hybrid BVDV viruses.";"(US6974575)
Wschr. 81:481-487 (1974)) and are highly predisposed to infection with microorganisms causing diseases such as pneumonia or enteric disease (Barber, et al., Vet.
Some inactivated BVDV vaccines provide protection against infection by type I BVDV only (Beer et al., Vet.
Animal subjects as used herein include any animal that is susceptible to BVDV infections, such as bovine, sheep and swine.";"A61K-039/12
C12N-007/00
C12N-007/01";"(US6974575)
1. A hybrid BVD virus comprising a genome generated by substituting a portion of the genome of a type I BVD virus which comprises the E1-E2 region, with the corresponding portion of the genome of a type II BVD virus.";"(US20030104612)
VACCINE(100,26)
BOVINE VIRAL DIARRHEA VIRUS(100,19)
VECTOR(100,10)
ISOLATED NUCLEIC ACID MOLECULE(100,6)
HYBRID(100,3)
ATCC(100,1)
ISOLATED TYPE GENOME(100,1)
TYPE GENERATION(100,1)
HYBRID BVDV VIRUS(70,2)
BVDV INFECTION(67,10)
INACTIVATED BVDV VACCINE(56,2)
GENETICALLY ENGINEERED HYBRID VIRUS(53,1)
BVD VIRUS(50,35)
BVD VIRUS ORIGIN(47,2)
HYBRID VIRUS(46,23)
DEGENERATE(43,3)
HYBRID BVD VIRUS(39,14)
IMMUNOGENIC(36,14)
GASTROINTESTINAL DISEASE(36,1)
GENOME REGION(35,9)
HYBRID VIRAL GENOME(35,2)
PROGENY VIRUS(34,3)
VETERINARILY ACCEPTABLE CARRIER(33,9)
ANIMAL(32,27)
NADL GENOME REGION(31,2)
IMMUNE RESPONSE(30,11)
NADL GENOME(30,6)
BDV VIRUS(29,3)
ISOLATED VIRUS(29,2)
RECOMBINANT DNA TECHNOLOGY(26,1)
GENOME HYBRID(25,4)
CATTLE PROTECTION(23,2)
VIRAL GENOMIC NUCLEIC ACID(23,1)
VIRUS(22,68)
ANIMAL SUBJECT(22,8)
MICROORGANISM(21,1)
PRIOR VACCINATION HYBRID VIRUS(21,1)
VIRAL PROTEIN PRESENCE(21,1)
PNEUMONIA(19,1)
GENOME(18,17)
BARBER(17,1)
INFECTION(16,8)
GENETICALLY ENGINEERED TYPE(16,5)
BVDV(15,12)
GENOME PORTION(15,11)
DISEASE(15,1)
VET(13,13)
IMMUNOHISTOCHEMISTRY ASSAY(13,5)
DESIGNATION(13,1)
LICENSED BVDV MLV VACCINE(13,1)
NADL GENOME NUCLEOTIDE NUMBERING(12,1)
GENOMIC NUCLEIC ACID MOLECULE(11,8)
SWINE(11,3)
INTESTINAL MUCOSA ULCERATION(11,1)
VECTASTAIN ELITE ABC KIT(11,1)
BOVINE(10,4)
SHEEP(10,4)
ULTRASPEC RNA REAGENT(10,2)
BVDV INFECTED CATTLE SERUM(10,1)
BVDV INFECTION SYMPTOM(10,1)
HYBRID TYPE(10,1)
OLIGO 890E1A NUCLEOTIDE(10,1)
PREGNANT CATTLE PLACENTA(10,1)
PROGENY HYBRID BVD VIRUS(10,1)
VIRAL GENOME PORTION(10,1)
GIBCO BRL(9,5)
AMERICAN TYPE CULTURE COLLECTION(9,3)
PESTIVIRUS GENUS(9,2)
ATTENUATED BVD VIRUS(9,1)
CYTOPATHIC BVDV MARKER(9,1)
INFECTED MDBK MONOLAYER(9,1)
HR POST INFECTION(8,3)
IMMUNOPEROXIDASE ASSAY(8,2)
MADIN DARBY KIDNEY CELL(8,2)
TRANSFECTED CELL MONOLAYER(8,2)
VETERINARY PHYSICIAN(8,2)
BOVINE DONOR CALF SERUM(8,1)
BVDV INFECTION INCIDENCE(8,1)
BVDV RNA GENOME(8,1)
BVDV VIRULENT STRAIN(8,1)
NCP VIRUS REPLICATION(8,1)
PARENT VIRUS NADL(8,1)
PLASMID DNA PNADLP15A(8,1)
PLASMID PNADLP15A DNA(8,1)
RESCUED NADL GENOME SEQUENCE(8,1)
VIRAL GENOME NUCLEOTIDE(8,1)
VIRUS NEUTRALIZATION ASSAY(8,1)
INFECTION RISK(7,3)
DNA CLONE(7,2)
EUKARYOTIC HOST CELL(7,2)
INOCULATED ANIMAL(7,2)
INTRA LYMPH NODE(7,2)
PLASMID PROPAGATION(7,2)
PROKARYOTIC HOST CELL(7,2)
REPLICATION VIRAL RNA(7,2)
RNA TRANSCRIPT(7,2)
VIRAL GENOME REGION ENCODING(7,2)
ATTENUATED BVD STRAIN(7,1)
CHEMICALLY INACTIVATED BVD(7,1)
CHIMERIC PCR FRAGMENT(7,1)
FETAL EQUINE SERUM(7,1)
FRESH MDBK MONOLAYER(7,1)
MEGASCRIPT REAGENT(7,1)
NADL VIRAL GENOME(7,1)
RESTRICTION ENZYME BSABI(7,1)
SERUM ANTIBODY TITER(7,1)
VECTOR PLASMID PBVDDHX(7,1)
VIRAL PROTEIN NS4B(7,1)
CODING SEQUENCE(6,4)
REVERSE PRIMER(6,4)
BVD VIRAL PROTEIN DETECTION(6,1)
BVDV VACCINE DEVELOPMENT(6,1)
BVDV VIRUS STRAIN(6,1)
CALF DONOR SERUM(6,1)
HYBRID BDV VIRUS(6,1)
HYBRID BVDV GENOMIC SEQUENCE(6,1)
HYBRID VIRUS GENOMIC SEQUENCE(6,1)
IMMUNOHISTOCHEMISTRY STAINING(6,1)
SUCROSE GRADIENT CENTRIFUGATION(6,1)
VIRUS ACCELERATED ELIMINATION(6,1)
HOMOLOGY(5,4)
INFECTED CELL(5,3)
COLI STRAIN(5,2)
HUMORAL IMMUNE RESPONSE(5,2)
PARENTERAL ROUTE(5,2)
POST TRANSFECTION(5,2)
ACUTE FATAL DISEASE(5,1)
ADSORPTION DELAYING(5,1)
AGAROSE GEL PURIFICATION(5,1)
AGENT FACILITATING CELLULAR UPTAKE(5,1)
AMPHIGEN ADJUVANT(5,1)
ANTIBODY NEUTRALIZATION(5,1)
AVRIDINE LIPID(5,1)
BIOTECX LAB(5,1)
BOVINE CELL MONOLAYER(5,1)
BOVINE TURBINATE(5,1)
BVD GENOMIC SEQUENCE(5,1)
BVD PROTEIN(5,1)
BVD VIRUS SEQUENCE(5,1)
BVDV ENVELOPE REGION(5,1)
BVDV GENOME(5,1)
BVDV IDENTIFICATION(5,1)
BVDV PLAQUE(5,1)
BVDV SERUM(5,1)
BVDV STRAIN(5,1)
CATIONIC LIPID(5,1)
CHOLERA TOXIN(5,1)
CLASSICAL SWINE FEVER(5,1)
CONSERVED PROTEIN(5,1)
CONSTRUCT CLONING(5,1)
CP BIOTYPE(5,1)
DOSAGE REGIMEN(5,1)
EARLY PASSAGE VIRUS STOCK(5,1)
EMERYVILLE CALIF(5,1)
FLAVIVIRIDAE FAMILY(5,1)
GENOMIC RNA(5,1)
HYBRID GENOMIC(5,1)
HYBRID VIRUS PROTEIN(5,1)
IMMUNOCOMPETENT ANIMAL(5,1)
IMMUNOMODULATORY AGENT(5,1)
INACTIVATED VIRAL VACCINE(5,1)
INCOMPLETE ADJUVANT(5,1)
INTRACELLULAR EXTRACT(5,1)
LIGATION MIXTURE ALIQUOT(5,1)
MARKER GENE(5,1)
MILD DIARRHEA(5,1)
MONOCLONAL ANTIBODY 15C(5,1)
MONOPHOSPHORYL LIPID(5,1)
MUCOSAL DISEASE OUTBREAK(5,1)
NEUTRALIZING ANTIBODY PRODUCTION(5,1)
NOVA TECH(5,1)
OLIGO NADLNS2A(5,1)
OPTIMAL IMMUNIZATION(5,1)
PCR AMPLIFICATION(5,1)
PCR FRAGMENT ACCURACY(5,1)
PCR FRAGMENT YIELD(5,1)
POLYMERASE PFU(5,1)
PRIMER NADL890E2A(5,1)
PRIMER NADLC(5,1)
REPLICATION ORIGIN(5,1)
RESPONDING CTL DETECTION(5,1)
RNA MOLECULE ENCODING(5,1)
RNA STIMULATED NTP(5,1)
RNA TRANSFECTION(5,1)
SAPONIN FRACTION(5,1)
VACCINATED CATTLE(5,1)
VIRAL BIOTYPE(5,1)
VIRAL GENOMIC REGION ENCODING(5,1)
VIRAL PROTEASE(5,1)
VIRUS NEUTRALIZING(5,1)
VIRUS VIRION(5,1)
WESTERN BLOT(5,1)
PCR REACTION(4,3)
POLYPROTEIN(4,3)
ACTIVE INGREDIENT(4,2)
ANTIBODY PRESENCE(4,2)
FORWARD PRIMER(4,2)
ISOTONIC AGENT(4,2)
MDBK CELL(4,2)
PCR MIX(4,2)
PFU DNA POLYMERASE UNIT(4,2)
TRANSFORMANT(4,2)
ALLEGED VACCINE ASSOCIATED OUTBREAK(4,1)
AMINE ADJUVANT(4,1)
ANTIGENICITY FALL(4,1)
BSABI SITE(4,1)
CHEMICALLY MODIFIED VIRUS(4,1)
COLD PBS BUFFER(4,1)
CP VARIANT(4,1)
DUPLICATE CELL(4,1)
ENVELOPE PROTEIN(4,1)
FETAL PROTECTION(4,1)
GEL ELECTROPHORESIS(4,1)
GENERATING VIRUS STOCK(4,1)
GENOME SCHEMATIC REPRESENTATION(4,1)
HYBRID VIRUS PRESENCE(4,1)
IMMUNITY DURATION(4,1)
INDUCTION INDICATIVE(4,1)
INFECTED ANIMAL(4,1)
INFECTION TREATMENT(4,1)
MAB 15C(4,1)
MAB PANEL(4,1)
MAJOR GENOTYPE(4,1)
MFEI SITE(4,1)
MFEL SITE(4,1)
MODIFY LIVE VIRUS(4,1)
MUTATION INTRODUCTION(4,1)
NONSTRUCTURAL PROTEIN PROCESSING(4,1)
PI ANIMAL(4,1)
POLYMERASE CHAIN REACTION GENERATION(4,1)
PROTEASE ACTIVITY(4,1)
RECOGNITION ASSAY(4,1)
RNA HELICASE ACTIVITY(4,1)
RNA PURIFICATION(4,1)
VECTOR LABORATORY(4,1)
VECTOR PROPAGATION(4,1)
VIRAL STRAIN(4,1)
VIRUS ANALYSIS(4,1)
VIRUS PARTICLE(4,1)
ACETONE(3,4)
DILUTION(3,4)
NUCLEOTIDE POSITION(3,4)
CYTOPATHIC EFFECT(3,3)
TEMPLATE(3,3)
ATTENUATION(3,2)
DENATURATION(3,2)
DEXTROSE(3,2)
FINAL CONCENTRATION(3,2)
INTRANASAL(3,2)
PCR PRODUCT(3,2)
VAGINAL ADMINISTRATION(3,2)
VIRAL RNA SEQUENCE(3,2)
ALUMINUM HYDROXIDE GEL(3,1)
AMPLIFICATION CYCLE(3,1)
ANTIGENIC DIFFERENCE(3,1)
BLOT ANALYSIS(3,1)
CATTLE CONDITION(3,1)
CELL INFECTION SHOW PHENOTYPE(3,1)
CHEMICAL COMPONENT(3,1)
CODING REGION MIDDLE(3,1)
COMPLETE NADL(3,1)
CONSTRUCTING PLASMID STEP(3,1)
CORE PROTEIN(3,1)
DEGENERATE NUCLEIC ACID SEQUENCE(3,1)
ESSENTIAL ROLE(3,1)
EXTRA INSERTION(3,1)
FINAL CONSTRUCT GENERATION(3,1)
FINAL PCR GENERATION(3,1)
FRAGMENT SEQUENCE(3,1)
GENECLEAN(3,1)
GENETIC MODIFICATION(3,1)
GENETIC RECOMBINATION EVENT(3,1)
GENOTYPE ANALYSIS(3,1)
HEAT LABILE ENTEROTOXIN(3,1)
INFECTED SUBJECT(3,1)
INFECTION VIRUS(3,1)
MAMMALIAN CELL(3,1)
MLV VACCINE SINGLE DOSE(3,1)
MURAMYL DIPEPTIDE(3,1)
NADL REGION(3,1)
NADLN 2A(3,1)
OPTIMEM VOLUME(3,1)
PHENOTYPE ANALYSIS(3,1)
(US6974575)
VACCINE(100,23)
BOVINE VIRAL DIARRHEA VIRUS(100,11)
HYBRID(100,3)
HYBRID BVDV VIRUS(100,2)
TYPE GENERATION(100,1)
INACTIVATED BVDV VACCINE(62,2)
GENETICALLY ENGINEERED HYBRID VIRUS(59,1)
BVD VIRUS(56,35)
BVDV INFECTION(52,7)
HYBRID VIRUS(47,22)
HYBRID BVD VIRUS(43,14)
GASTROINTESTINAL DISEASE(40,1)
HYBRID VIRAL GENOME(39,2)
IMMUNOGENIC(35,13)
NADL GENOME REGION(35,2)
NADL GENOME(34,6)
RECOMBINANT DNA TECHNOLOGY(29,1)
VETERINARILY ACCEPTABLE CARRIER(28,7)
GENOME HYBRID(28,4)
CATTLE PROTECTION(26,2)
MICROORGANISM(23,1)
GENOME(21,17)
PNEUMONIA(21,1)
GENETICALLY ENGINEERED TYPE(20,5)
ANIMAL(19,19)
BARBER(19,1)
INFECTION(18,8)
GENOME REGION(18,7)
GENOME PORTION(17,11)
DISEASE(17,1)
VET(14,15)
BVDV(14,9)
IMMUNOHISTOCHEMISTRY ASSAY(14,5)
DESIGNATION(14,1)
LICENSED BVDV MLV VACCINE(14,1)
NADL GENOME NUCLEOTIDE NUMBERING(14,1)
GENOMIC NUCLEIC ACID MOLECULE(13,8)
INTESTINAL MUCOSA ULCERATION(13,1)
VECTASTAIN ELITE ABC KIT(13,1)
ANIMAL SUBJECT(12,7)
SWINE(12,3)
BVD VIRUS ORIGIN(12,2)
BOVINE(11,4)
SHEEP(11,4)
ULTRASPEC RNA REAGENT(11,2)
BVDV INFECTION SYMPTOM(11,1)
OLIGO 890E1A NUCLEOTIDE(11,1)
PREGNANT CATTLE PLACENTA(11,1)
PROGENY HYBRID BVD VIRUS(11,1)
GIBCO BRL(10,5)
AMERICAN TYPE CULTURE COLLECTION(10,3)
PESTIVIRUS GENUS(10,2)
ATTENUATED BVD VIRUS(10,1)
CYTOPATHIC BVDV MARKER(10,1)
INFECTED MDBK MONOLAYER(10,1)
HR POST INFECTION(9,3)
IMMUNOPEROXIDASE ASSAY(9,2)
MADIN DARBY KIDNEY CELL(9,2)
TRANSFECTED CELL MONOLAYER(9,2)
VETERINARY PHYSICIAN(9,2)
BOVINE DONOR CALF SERUM(9,1)
BVDV INFECTION INCIDENCE(9,1)
BVDV RNA GENOME(9,1)
BVDV VIRULENT STRAIN(9,1)
NCP VIRUS REPLICATION(9,1)
PARENT VIRUS NADL(9,1)
PLASMID DNA PNADLP15A(9,1)
PLASMID PNADLP15A DNA(9,1)
RESCUED NADL GENOME SEQUENCE(9,1)
VIRAL GENOME NUCLEOTIDE(9,1)
VIRUS NEUTRALIZATION ASSAY(9,1)
INFECTION RISK(8,3)
ATTENUATED BVD STRAIN(8,1)
CHEMICALLY INACTIVATED BVD(8,1)
CHIMERIC PCR FRAGMENT(8,1)
FETAL EQUINE SERUM(8,1)
FRESH MDBK MONOLAYER(8,1)
MEGASCRIPT REAGENT(8,1)
NADL VIRAL GENOME(8,1)
RESTRICTION ENZYME BSABI(8,1)
SERUM ANTIBODY TITER(8,1)
VECTOR PLASMID PBVDDHX(8,1)
VIRAL PROTEIN NS4B(8,1)
REVERSE PRIMER(7,4)
CATTLE SERUM(7,2)
DNA CLONE(7,2)
EUKARYOTIC HOST CELL(7,2)
INOCULATED ANIMAL(7,2)
INTRA LYMPH NODE(7,2)
PLASMID PROPAGATION(7,2)
PROKARYOTIC HOST CELL(7,2)
REPLICATION VIRAL RNA(7,2)
RNA TRANSCRIPT(7,2)
VIRAL GENOME REGION ENCODING(7,2)
BVD VIRAL PROTEIN DETECTION(7,1)
BVDV VACCINE DEVELOPMENT(7,1)
BVDV VIRUS STRAIN(7,1)
CALF DONOR SERUM(7,1)
HYBRID BDV VIRUS(7,1)
HYBRID BVDV GENOMIC SEQUENCE(7,1)
HYBRID VIRUS GENOMIC SEQUENCE(7,1)
IMMUNOHISTOCHEMISTRY STAINING(7,1)
SUCROSE GRADIENT CENTRIFUGATION(7,1)
VIRUS ACCELERATED ELIMINATION(7,1)
INFECTED CELL(6,3)
COLI STRAIN(6,2)
HUMORAL IMMUNE RESPONSE(6,2)
PARENTERAL ROUTE(6,2)
POST TRANSFECTION(6,2)
SUBCLONE GENERATION(6,2)
ACUTE FATAL DISEASE(6,1)
AGAROSE GEL PURIFICATION(6,1)
AGENT FACILITATING CELLULAR UPTAKE(6,1)
AMPHIGEN ADJUVANT(6,1)
AVRIDINE LIPID(6,1)
BOVINE CELL MONOLAYER(6,1)
BOVINE TURBINATE(6,1)
BVD GENOMIC SEQUENCE(6,1)
BVDV GENOME(6,1)
BVDV IDENTIFICATION(6,1)
BVDV PLAQUE(6,1)
CLASSICAL SWINE FEVER(6,1)
CP BIOTYPE(6,1)
FLAVIVIRIDAE FAMILY(6,1)
HYBRID GENOMIC(6,1)
HYBRID VIRUS PROTEIN(6,1)
IMMUNOCOMPETENT ANIMAL(6,1)
INACTIVATED VIRAL VACCINE(6,1)
MILD DIARRHEA(6,1)
MONOPHOSPHORYL LIPID(6,1)
MUCOSAL DISEASE OUTBREAK(6,1)
OLIGO NADLNS2A(6,1)
PCR FRAGMENT ACCURACY(6,1)
PRIMER NADL890E2A(6,1)
RESPONDING CTL DETECTION(6,1)
RNA MOLECULE ENCODING(6,1)
VACCINATED CATTLE(6,1)
VIRAL BIOTYPE(6,1)
VIRUS VIRION(6,1)
HOMOLOGY(5,4)
PCR REACTION(5,3)
POLYPROTEIN(5,3)
ACTIVE INGREDIENT(5,2)
ANTIBODY PRESENCE(5,2)
FORWARD PRIMER(5,2)
ISOTONIC AGENT(5,2)
MDBK CELL(5,2)
PCR MIX(5,2)
PFU DNA POLYMERASE UNIT(5,2)
TRANSFORMANT(5,2)
ADSORPTION DELAYING(5,1)
BIOTECX LAB(5,1)
BVD PROTEIN(5,1)
BVD VIRUS SEQUENCE(5,1)
BVDV ENVELOPE REGION(5,1)
BVDV SERUM(5,1)
CATIONIC LIPID(5,1)
CHOLERA TOXIN(5,1)
CONSERVED PROTEIN(5,1)
CONSTRUCT CLONING(5,1)
DOSAGE REGIMEN(5,1)
EARLY PASSAGE VIRUS STOCK(5,1)
EMERYVILLE CALIF(5,1)
GENOMIC RNA(5,1)
IMMUNOMODULATORY AGENT(5,1)
INCOMPLETE ADJUVANT(5,1)
INFECTED CATTLE(5,1)
INTRACELLULAR EXTRACT(5,1)
LIGATION MIXTURE ALIQUOT(5,1)
MARKER GENE(5,1)
MONOCLONAL ANTIBODY 15C(5,1)
NEUTRALIZING ANTIBODY PRODUCTION(5,1)
NOVA TECH(5,1)
OPTIMAL IMMUNIZATION(5,1)
PCR AMPLIFICATION(5,1)
PCR FRAGMENT YIELD(5,1)
POLYMERASE PFU(5,1)
PRIMER NADLC(5,1)
PROGENY VIRUS(5,1)
REPLICATION ORIGIN(5,1)
RNA STIMULATED NTP(5,1)
RNA TRANSFECTION(5,1)
SAPONIN FRACTION(5,1)
VIRAL GENOMIC REGION ENCODING(5,1)
VIRAL PROTEASE(5,1)
VIRUS NEUTRALIZING(5,1)
WESTERN BLOT(5,1)
DILUTION(4,4)
CYTOPATHIC EFFECT(4,3)
ALLEGED VACCINE ASSOCIATED OUTBREAK(4,1)
AMINE ADJUVANT(4,1)
ANTIGENICITY FALL(4,1)
BSABI SITE(4,1)
CHEMICALLY MODIFIED VIRUS(4,1)
CODING SEQUENCE MIDDLE(4,1)
COLD PBS BUFFER(4,1)
CP VARIANT(4,1)
DUPLICATE CELL(4,1)
ENVELOPE PROTEIN(4,1)
FETAL PROTECTION(4,1)
FINAL PCR FRAGMENT GENERATION(4,1)
GEL ELECTROPHORESIS(4,1)
GENERATING VIRUS STOCK(4,1)
HYBRID VIRUS PRESENCE(4,1)
IMMUNITY DURATION(4,1)
INDUCTION INDICATIVE(4,1)
INFECTED ANIMAL(4,1)
INFECTION TREATMENT(4,1)
MAB 15C(4,1)
MAB PANEL(4,1)
MAJOR GENOTYPE(4,1)
MFEI SITE(4,1)
MFEL SITE(4,1)
MODIFY LIVE VIRUS(4,1)
MUTATION INTRODUCTION(4,1)
NONSTRUCTURAL PROTEIN PROCESSING(4,1)
PI ANIMAL(4,1)
PROTEASE ACTIVITY(4,1)
RECOGNITION ASSAY(4,1)
RNA HELICASE ACTIVITY(4,1)
RNA PURIFICATION(4,1)
VECTOR LABORATORY(4,1)
VECTOR PROPAGATION(4,1)
VIRAL STRAIN(4,1)
VIRUS PARTICLE(4,1)
ACETONE(3,4)
NUCLEOTIDE POSITION(3,4)
TEMPLATE(3,3)
ATTENUATION(3,2)
DENATURATION(3,2)
DEXTROSE(3,2)
FINAL CONCENTRATION(3,2)
INTRANASAL(3,2)
PCR PRODUCT(3,2)
VAGINAL ADMINISTRATION(3,2)
VIRAL RNA SEQUENCE(3,2)
ALUMINUM HYDROXIDE GEL(3,1)
AMPLIFICATION CYCLE(3,1)
ANTIGENIC DIFFERENCE(3,1)
BLOT ANALYSIS(3,1)
CATTLE CONDITION(3,1)
CHEMICAL COMPONENT(3,1)
CODING REGION MIDDLE(3,1)
COMPLETE NADL(3,1)
CORE PROTEIN(3,1)
DEGENERATE NUCLEIC ACID SEQUENCE(3,1)
ESSENTIAL ROLE(3,1)
EXTRA INSERTION(3,1)
FINAL CONSTRUCT GENERATION(3,1)
FRAGMENT SEQUENCE(3,1)
GENECLEAN(3,1)
GENETIC MODIFICATION(3,1)
GENETIC RECOMBINATION EVENT(3,1)
GENOTYPE ANALYSIS(3,1)
HEAT LABILE ENTEROTOXIN(3,1)
INFECTED SUBJECT(3,1)
INFECTION VIRUS(3,1)
MAMMALIAN CELL(3,1)
MLV VACCINE SINGLE DOSE(3,1)
MURAMYL DIPEPTIDE(3,1)
NADL REGION(3,1)
NADLN 2A(3,1)
OPTIMEM VOLUME(3,1)
PHENOTYPE ANALYSIS(3,1)
PORCINE CELL(3,1)
PRIMARY IMMUNIZATION(3,1)
RIBI INC(3,1)
TERM VACCINE(3,1)
THROMBOCYTOPENIA(3,1)";Pharmaceuticals;Open
"2001-05-03
2002-05-03";"GB0110851           D0 2001-06-27 [GB200110851]
STG: (D0) Patent application filed
AP : 2001GB-0010851 2001-05-03
WO02089838          A1 2002-11-14 [WO200289838]
STG: (A1) Published application with search report
AP : 2002WO-GB02062 2002-05-03
CA2445997           A1 2002-11-14 [CA2445997]
STG: (A1) Application laid open
AP : 2002CA-2445997 2002-05-03
EP1387693           A1 2004-02-11 [EP1387693]
STG: (A1) Application published with search report
AP : 2002EP-0720307 2002-05-03
MXPA03010053        A  2004-03-09 [MX2003PA010053]
STG: (A) Patent application
AP : 2003MX-PA10053 2002-05-03
US20040170652       A1 2004-09-02 [US20040170652]
STG: (A1) Application published
AP : 2002US-10476508 2002-05-03
EP1387693           B1 2006-08-09 [EP1387693]
STG: (B1) Patent specification
AP : 2002EP-0720307 2002-05-03
AT335505            T  2006-09-15 [ATE335505]
STG: (T) EP patent valid in AT
AP : 2002AT-0720307T 2002-05-03
DE60213785          D1 2006-09-21 [DE60213785]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2002DE-6013785 2002-05-03
DK1387693           T3 2006-11-13 [DK1387693T]
STG: (T3) Translation of EP patent
AP : 2002DK-0720307 2002-05-03
PT1387693           E  2006-12-29 [PT1387693]
STG: (E) Availability of national translation of European patent
AP : 2002PT-0720307T 2002-05-03
ES2269672           T3 2007-04-01 [ES2269672]
STG: (T3) Translation of granted European patent (former B3)
AP : 2002ES-0720307T 2002-05-03
DE60213785          T2 2007-08-23 [DE60213785]
STG: (T2) Trans. of EP  patent
AP : 2002DE-6013785 2002-05-03
CY1107538           T1 2013-03-13 [CY1107538]
STG: (T1) Translation of EP granted patent
AP : 2006CY-1101522 2006-10-24";761007;"GB0110851           D0 2001-06-27 [GB200110851]
WO02089838          A1 2002-11-14 [WO200289838]
CA2445997           A1 2002-11-14 [CA2445997]
EP1387693           A1 2004-02-11 [EP1387693]
MXPA03010053        A  2004-03-09 [MX2003PA010053]
US20040170652       A1 2004-09-02 [US20040170652]
EP1387693           B1 2006-08-09 [EP1387693]
AT335505            T  2006-09-15 [ATE335505]
DE60213785          D1 2006-09-21 [DE60213785]
DK1387693           T3 2006-11-13 [DK1387693T]
PT1387693           E  2006-12-29 [PT1387693]
ES2269672           T3 2007-04-01 [ES2269672]
DE60213785          T2 2007-08-23 [DE60213785]
CY1107538           T1 2013-03-13 [CY1107538]";"2001GB-0010851
2002EP-0720307
2002WO-GB02062";"(EP1387693)
WO02089838
(US20040170652)
WO02089838
(DE60213785)
WO02089838
(CA2445997)
WO02089838
(MX2003PA010053)
WO02089838
(CY1107538)
WO02089838";"MINISTER OF AGRICULTURE FISHERIES & FOOD HER BRITANNIC MAJESTY S GOVERNMENT OF THE UNITED KI
NOVARTIS
SEC DEP FOR ENVIRONMENT FOOD
UK GOVERNMENT";NOVARTIS;"(EP1387693)
CH
(EP1387693)
CH
(WO200289838)
GB
(DE60213785)
CH
(CA2445997)
CH";"(EP1387693)
NAME=Novartis AG Lichtstrasse 35 , CITY=4056 Basel , COUNTRY=CH 

(EP1387693)
NAME=Novartis AG Lichtstrasse 35 4056 Basel , COUNTRY=CH 

(WO200289838)
NAME=THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD & RURAL AFFAIRS  [GB/ GB] (Defra), Nobel House, 17 Smith Square, London SW1P 3JR  , COUNTRY=GB 

NAME=NICHOLAS, Robin, Ashley, John  [GB/ GB] Department of Bacterial Diseases, Veterinary Laboratories Agency (Weybridge), New Haw, Addlestone, Surrey, Kent KT15 3NB  , COUNTRY=GB 

(DE60213785)
NAME=Novartis AG , CITY=Basel , COUNTRY=CH 

(CA2445997)
NAME=NOVARTIS AG Lichtstrasse 35 CH-4056 , CITY=BASEL , COUNTRY=CH 
";1;NICHOLAS ROBIN ASHLEY JOHN;"(EP1387693)
GB
(EP1387693)
GB";"(EP1387693)
NAME=NICHOLAS, Robin Ashley John, Vet.Labs Agency Dept. of Bacterial Diseases, New Haw, Addlestone , CITY=Surrey, Kent KT15 3NB , COUNTRY=GB 

(EP1387693)
NAME=NICHOLAS, Robin Ashley John, Vet.Labs Agency Dept. of Bacterial Diseases, New Haw, Addlestone Surrey, Kent KT15 3NB , COUNTRY=GB 
";"(EP1387693)
Saponin inactivated mycoplasma vaccine";"(EP1387693)
A strain of Mycoplasma which is a causative agent of bovine pneumonias, which has been inactivated by treatment with an agent, which disrupts cel membranes such as saponin, is described. Preferably, the strain is Mycoplasma bovis or Mycoplasma mycoides subsp.mycoides SC. These strains can be used as vaccines. Veterinary compositions, methods of preparing these and their use in prophylaxis is also described and claimed.";"(WO200289838)
Claims
1. A strain of Mycoplasma which is a causative agent of bovine pneumonias which has been inactivated by treatment with an agent which disrupts cell membranes.
2. A strain according to claim 1 wherein the strain is Mycoplasma bovis.
3. A strain according to claim 1 wherein the strain is Mycoplasma mycoides subsp. mycoides SC.
4. A strain according to any one of claims 1 to 3 wherein the agent which disrupts cell membranes is saponin.
5. A veterinary composition comprising an inactivated strain of Mycoplasma which is a causative agent of bovine pneumonias as claimed in any one of claims 1 to 4, in combination with a veterinarily acceptable carrier.
6. A composition according to claim 5 wherein the strain is Mycoplasma bovis.
7. A composition according to claim 5 wherein the strain is Mycoplasma mycoides subsp. mycoides SC.
8. A composition according to any one of claims 5 to 7, which is suitable for parenteral administration.
9. A composition according to any one of claim 5 to 8 wherein the veterinary acceptable carrier is a liquid carrier.
10. A composition according to any one of claims 5 to 9 which further comprises one or more of a dispersing agent, a wetting agent or a suspending agent.
11. A composition according to any one of claims 5 to 10, which further comprises an adjuvant.
12. A composition according to claim 11 wherein the adjuvant is saponin.
13. A method of preparing an inactivated strain of Mycoplasma, which is a causative agent of bovine pneumomas as described above, which method comprises incubating a strain of Mycoplasma, which is a causative agent of bovine pneumonias in the presence of an agent which disrupts cell membranes.
14. A method according to claim 13 wherein the strain is Mycoplasma bovis.
15. A method according to claim 13 wherein the strain is Mycoplasma mycoides subsp. mycoides SC.
16. A method according to any one of claims 13 to 15 wherein the agent which disrupts cell membranes is saponin.
17. A method according to claim 16 wherein the saponin is present in the incubation culture in an amount of from about 0.5-lOmg/ml.
18. A method according to claim 17 wherein the saponin is present in an amount of about 2mg/ml.
19. A method of preventing disease in cattle caused by a strain of Mycoplasma, which is a causative agent of bovine pneumonias, said method comprising administering to the cattle an inactivated strain of Mycoplasma, which is a causative agent of bovine pneumonias according to any one of claims 1 to 4 or a veterinary composition as according to any one of claims 5 to 12.
20. The use of a strain of Mycoplasma, which is a causative agent of bovine pneumonias according to any one of claims 1 to 4 in the preparation of a medicament for the treatment of animals.
21. A strain of Mycoplasma, which is a causative agent of bo ine pneumonias substantially as hereinbefore described with reference to the examples.";"(EP1387693)
Thus, a further aspect of the invention comprises a veterinary composition comprising an inactivated strain of Mycoplasma bovis, which is a causative agent of bovine pneumonia as described above, in combination with a veterinarily acceptable carrier.
According to the present invention, there is provided a strain of Mycoplasma bovis, which is a causative agent of bovine pneumonia, which has been inactivated by treatment with saponin.
The present invention relates to an inactivated strain of Mycoplasma bovis, which is a causative agent of bovine pneumonia, which is useful as a vaccine in cattle, to methods of producing it and to its use.
The present invention relates to an inactivated strain of Mycoplasma bovis, which is a causative agent of bovine pneumonia, which is useful as a vaccine in cattle, to methods of producing it and to its use.
The present invention particularly relates to an inactivated strain of Mycoplasma bovis.";"(EP1387693)
Recent strains of Mycoplasma bovis are showing increased resistance to a range of antibiotics (Ayling R et al (2000) Veterinary record 146, 745-747) and there is, therefore, a need for an effective vaccine.
An advantage of the present invention is that it is surprisingly a highly effective vaccine.
The pathogenic microorganism is treated with a chemical, such as formaldehyde, which damages the organism to such an extent that it cannot cause infective disease in the animal to which it is administered.
A formalised M bovis vaccine against calf arthritis incorporating saponin as an adjuvant was immunogenic and reduced spread of infection to other joints in a small number of calves (Poumarat F et al (1999) Proceedings of International Symposium of Ruminant Mycoplasmas, Toulouse, June 1999 p65).
Mycoplasma bovis is a primary cause of calf pneumonia, arthritis, mastitis, eye disease and other conditions worldwide and has been estimated to cost the cattle industry millions of pounds in mortality and setback losses annually.
Calf pneumonia is a complex syndrome involving bacteria, viruses and mycoplasmas.
cause infective disease in the animal to which it is administered.";"A61K-039/02
A61P-031/04
C12N-001/20";"(EP1387693)
1. A strain of Mycoplasma bovis which is a causative agent of bovine pneumonia and which has been in activated by treatment with saponin.
8. A method of preparing an inactivated strain of Mycoplasma bovis, which is a causative agent of bovine pneumonia, which method comprises incubating a strain of Mycoplasma bovis which is a causative agent of bovine pneumonia in the presence of saponin.";"(EP1387693)
SAPONIN(100,17)
MYCOPLASMA BOVIS INACTIVATED STRAIN(100,6)
MYCOPLASMA VACCINE(100,1)
BOVINE PNEUMONIA CAUSATIVE AGENT(98,12)
MYCOPLASMA BOVIS STRAIN(53,10)
POUND CATTLE INDUSTRY MILLION(39,1)
VETERINARILY ACCEPTABLE CARRIER(33,3)
BOVINE PNEUMONIA PROPHYLAXIS(31,1)
MYCOPLASMA BOVIS RECENT STRAIN(31,1)
PATHOGENIC MICROORGANISM(30,1)
CALF ARTHRITIS(24,1)
BOVIS VACCINE(22,2)
SPREADING INFECTION(21,1)
CAUSE INFECTIVE DISEASE(20,1)
SAPONIN PRESENCE(20,1)
VETERINARY(18,4)
CALF PNEUMONIA(18,3)
SETBACK LOSS(18,1)
COMPLEX SYNDROME(17,1)
VETERINARY RECORD(16,3)
CALF PNEUMONIA PRIMARY CAUSE(15,1)
MEDICAMENT PREPARATION(15,1)
CULTURE INCUBATION(14,2)
VACCINE(13,18)
ADJUVANT(13,7)
PARENTERAL ADMINISTRATION(13,3)
MASTITIS(12,1)
ORGANISM(12,1)
ANIMAL TREATMENT(11,1)
ARTHRITIS(11,1)
MORTALITY(11,1)
MYCOPLASMA BOVIS(10,6)
ANTIBIOTIC RANGE(10,1)
VIRUS(10,1)
BACTERIA(9,2)
FORMALDEHYDE(9,2)
MYCOPLASMA(8,9)
EYE DISEASE(8,1)
ANIMAL(7,5)
CATTLE(7,5)
CALF(7,4)
INCREASED RESISTANCE(7,1)
LIQUID CARRIER(5,2)
DISPERSING AGENT(5,1)
EXPERIMENTAL QUADRIVALENT VACCINE(5,1)
FREUND INCOMPLETE ADJUVANT(5,1)
INACTIVATED MYCOPLASMA STRAIN(5,1)
SUSPENDING AGENT(4,3)
WETTING AGENT(4,3)
CALF LUNG(4,2)
EATON BROTH MEDIUM(4,2)
ORGANISM KEY ANTIGENIC REGION(4,2)
BOVINE PNEUMONIA STRAIN(4,1)
FORMALDEHYDE KILLED ANTIGEN(4,1)
FORMALIZED VACCINE(4,1)
INACTIVATED MYCOPLASMA BOVIS(4,1)
INACTIVATED VIRUS STRAIN(4,1)
MANNHEIMA HAEMOLYTICA(4,1)
MASTER FROZEN ALIQUOT(4,1)
ORGANISM POTENT STRAIN(4,1)
PNEUMONIA CLINICAL SIGN(4,1)
SAPOGENIN GLYCOSIDE(4,1)
UNHEATED HORSE SERUM(4,1)
ACTIVE INGREDIENT(3,3)
CAUSATIVE AGENT(3,2)
PRESERVATIVE(3,2)
ADMINISTRATION WEEK(3,1)
AEROSOL ADMINISTRATION(3,1)
CATTLE LUNG(3,1)
CHICKEN EGG YOLK(3,1)
COMBATING INACTIVATION(3,1)
CONGRESS PROCEEDING(3,1)
DIFCO PPLO BROTH BASE(3,1)
EXPERIMENTAL VACCINE(3,1)
FORMALDEHYDE INACTIVATED VACCINE(3,1)
FRESHLY PREPARED YEAST EXTRACT(3,1)
HUMAN MYCOPLASMA(3,1)
INACTIVATING AGENT CLASS(3,1)
INTRAMUSCULAR DOSING(3,1)
LUNG LESION(3,1)
MYCOPLASMA BOVIS STRAIN PASSAGE(3,1)
QUILLAGA BARK(3,1)
STERILE INJECTABLE PREPARATION(3,1)
VACCINE FORMULATION(3,1)
VACCINE MLS(3,1)
VIRULENT CHALLENGE(3,1)
CELL MEMBRANE(2,4)
DISPERSION(2,2)
EXCIPIENT(2,2)
IMMUNE RESPONSE(2,2)
PENICILLIN(2,2)
7H3SF(2,1)
AGE WEEK(2,1)
AGENT EFFICACY(2,1)
ANIMAL AGE(2,1)
ANTIBODY INDUCING ACTIVITY(2,1)
AQUEOUS SUSPENSION PREPARATION(2,1)
ARACHIS OIL(2,1)
BETA LACTAMINE GROUP ANTIBIOTIC(2,1)
CATTLE GROUP(2,1)
CHOLESTEROL QUANTITY(2,1)
COMPLEX ORGANISM(2,1)
CONSECUTIVE DAY(2,1)
DISEASE PREVENTION(2,1)
DISPERSIBLE POWDER(2,1)
EATON MEDIUM VOLUME(2,1)
ENZYME PRODUCTION(2,1)
ESSENTIAL PROTEIN(2,1)
F INACTIVATED STRAIN(2,1)
HPMCD(2,1)
LYTIC ACTIVITY(2,1)
MICROORGANISM NATURE(2,1)
MYCOPLASMA AGALACTIAE(2,1)
MYCOPLASMA CELL(2,1)
OILY SUSPENSION(2,1)
ORGANISM ABILITY(2,1)
POVIDONE(2,1)
PROPYL PARABEN(2,1)
STERILE INJECTABLE SOLUTION(2,1)
STRAIN CONCENTRATION(2,1)
STRAIN PRECISE NATURE(2,1)
UNIVERSAL CONTAINER(2,1)
YOUNG CALF(2,1)
(US20040170652)
BOVINE PNEUMONIA CAUSATIVE AGENT(100,18)
SAPONIN(100,17)
MYCOPLASMA STRAIN(100,12)
CELL MEMBRANE(100,10)
MYCOPLASMA INACTIVATED STRAIN(100,6)
MYCOPLASMA VACCINE(100,1)
MYCOPLASMA MYCOIDES SUBSP(46,9)
MYCOPLASMA BOVIS INACTIVATED STRAIN(37,1)
MYCOPLASMA BOVIS RECENT STRAIN(28,1)
CATTLE INDUSTRY MILLION(27,1)
PATHOGENIC MICROORGANISM(27,1)
VETERINARILY ACCEPTABLE CARRIER(25,2)
VETERINARY(23,6)
CALF ARTHRITIS(22,1)
INFECTIVE DISEASE(21,1)
MYCOPLASMA BOVIS(19,10)
BOVIS VACCINE(19,2)
SPREADING INFECTION(18,1)
CALF PNEUMONIA(16,3)
VETERINARY RECORD(16,2)
CEL MEMBRANE(16,1)
SETBACK LOSS(16,1)
COMPLEX SYNDROME(15,1)
MYCOIDE(14,16)
INACTIVATED STRAIN(14,6)
VACCINE(13,22)
CALF PNEUMONIA PRIMARY CAUSE(13,1)
MEDICAMENT PREPARATION(13,1)
VETERINARY ACCEPTABLE CARRIER(13,1)
ADJUVANT(12,7)
PARENTERAL ADMINISTRATION(12,3)
CULTURE INCUBATION(12,2)
HIGHLY EFFICACIOUS VACCINE(11,1)
MASTITIS(11,1)
ORGANISM(11,1)
CATTLE(10,9)
ANIMAL TREATMENT(10,1)
ARTHRITIS(10,1)
FORMALDEHYDE(10,1)
MORTALITY(10,1)
ANTIBIOTIC RANGE(9,1)
PROPHYLAXIS(9,1)
VIRUS(9,1)
BACTERIA(8,2)
CONTAGIOUS BOVINE PLEUROPNEMONIA(8,2)
MYCOPLASMA(7,8)
EYE DISEASE(7,1)
ANIMAL(6,5)
CALF(6,5)
INACTIVATED MYCOPLASMA STRAIN(6,2)
INCREASED RESISTANCE(6,1)
STAIN(6,1)
MYCOIDE SUBSP(5,3)
LIQUID CARRIER(5,2)
EXPERIMENTAL QUADRIVALENT VACCINE(5,1)
SUSPENDING AGENT(4,3)
CALF LUNG(4,2)
CATTLE LUNG(4,2)
MG ML(4,2)
ORGANISM KEY ANTIGENIC REGION(4,2)
BOTSWANAN OUTBREAK(4,1)
BOVINE PNEUMONIA STRAIN(4,1)
DISPERSING AGENT(4,1)
FORMALIN KILLED ANTIGEN(4,1)
INACTIVATED VIRUS STRAIN(4,1)
MASTER FROZEN ALIQUOT(4,1)
MYCOPLASMA MYCOIDES SUBSP PREPARATION(4,1)
ORGANISM POTENT STRAIN(4,1)
PNEUMONIA CLINICAL SIGN(4,1)
UNHEATED HORSE SERUM(4,1)
VETERINARY LABORATORY AGENCY(4,1)
ACTIVE INGREDIENT(3,3)
WETTING AGENT(3,3)
CAUSATIVE AGENT(3,2)
COMBATING INACTIVATION(3,1)
CONGRESS PROCEEDING(3,1)
EGG PASSAGED LIVE STRAIN(3,1)
FORMALIN INACTIVATED VACCINE(3,1)
FORMALIZED VACCINE(3,1)
INTRAMUSCULAR DOSING(3,1)
MANNHEIMA HAEMOLYTICA(3,1)
MYCOPLASMA BOVIS STRAIN(3,1)
MYCOPLASMA BOVIS VACCINE PREPARATION(3,1)
PNEUMONIA MYCOPLASMA BOVIS(3,1)
QUILLAGA BARK(3,1)
SAPOGENIN GLYCOSIDE(3,1)
SUDANESE COUNTRY(3,1)
VIRULENT CHALLENGE(3,1)
BIOLOGICAL TESTING(2,2)
BROTH MEDIUM(2,2)
DISPERSION(2,2)
EXCIPIENT(2,2)
IMMUNE RESPONSE(2,2)
PENICILLIN(2,2)
PRESERVATIVE(2,2)
ADMINISTRATION WEEK(2,1)
AEROSOL ADMINISTRATION(2,1)
AGE WEEK(2,1)
AGENT EFFICACY(2,1)
ANIMAL AGE(2,1)
CHICKEN EGG YOLK(2,1)
CHOLESTEROL QUANTITY(2,1)
DIFCO PPLO BROTH BASE(2,1)
DISPERSIBLE POWDER(2,1)
ECONOMIC IMPORTANCE(2,1)
FRESHLY PREPARED YEAST EXTRACT(2,1)
HUMAN MYCOPLASMA(2,1)
INACTIVATING AGENT CLASS(2,1)
INCOMPLETE ADJUVANT(2,1)
INFECTED CATTLE(2,1)
LUNG LESION(2,1)
LYTIC ACTIVITY(2,1)
MICROORGANISM NATURE(2,1)
MYCOPLASMA BOVIS PASSAGE(2,1)
MYCOPLASMA CELL(2,1)
OILY SUSPENSION(2,1)
RESIDUAL VIRULENCE(2,1)
STERILE INJECTABLE PREPARATION(2,1)
STERILE INJECTABLE SOLUTION(2,1)
UNIVERSAL CONTAINER(2,1)
VACCINE FORMULATION(2,1)
VACCINE MLS(2,1)
VACCINE STRAIN(2,1)
YOUNG CALF(2,1)
ANTIBODY INDUCING ACTIVITY(1,1)
AQUEOUS SUSPENSION PREPARATION(1,1)
ARACHIS OIL(1,1)
BETA LACTAMINE GROUP ANTIBIOTIC(1,1)
CATTLE GROUP(1,1)
CELL MEMBRANE DISRUPTER(1,1)
COMPLEX ORGANISM(1,1)
ENZYME PRODUCTION(1,1)
ESSENTIAL PROTEIN(1,1)
HYDROXYPROPYLMETHYLCELLULOSE(1,1)
ORGANISM ABILITY(1,1)
SODIUM ALGINATE(1,1)
STRAIN CONCENTRATION(1,1)
STRAIN PRECISE NATURE(1,1)
(WO200289838)
BOVINE PNEUMONIA CAUSATIVE AGENT(100,15)
MYCOPLASMA STRAIN(100,11)
CELL MEMBRANE(100,10)
MYCOPLASMA INACTIVATED STRAIN(100,6)
CAUSATIVE AGENT(100,2)
BO INE PNEUMONIA(100,1)
BOVINE PNEUMOMA CAUSATIVE AGENT(100,1)
MYCOPLASMA BOVIS INACTIVATED STRAIN(46,1)
POUND CATTLE INDUSTRY MILLION(42,1)
MYCOPLASMA MYCOIDES SUBSP(39,6)
MYCOPLASMA BOVIS RECENT STRAIN(34,1)
PATHOGENIC MICROORGANISM(33,1)
VETERINARILY ACCEPTABLE CARRIER(31,2)
CALF ARTHRITIS(27,1)
INFECTIVE DISEASE(26,1)
VETERINARY(24,5)
SPREADING INFECTION(23,1)
SAPONIN(22,17)
MYCOPLASMA BOVIS(21,9)
CALF PNEUMONIA(20,3)
SETBACK LOSS(20,1)
VETERINARY RECORD(19,2)
COMPLEX SYNDROME(19,1)
INACTIVATED STRAIN(18,6)
F MYCOPLASMA MYCOIDES(17,1)
VACCINE(16,24)
MYCOIDE(16,13)
CALF PNEUMONIA PRIMARY CAUSE(16,1)
MEDICAMENT PREPARATION(16,1)
VETERINARY ACCEPTABLE CARRIER(16,1)
ADJUVANT(15,7)
PARENTERAL ADMINISTRATION(15,3)
CULTURE INCUBATION(15,2)
ARTHRITIS(13,1)
HIGHLY EFFICACIOUS VACCINE(13,1)
MASTITIS(13,1)
MORTALITY(13,1)
ORGANISM(13,1)
CATTLE(12,9)
ANIMAL TREATMENT(12,1)
ANTIBIOTIC RANGE(11,1)
VIRUS(11,1)
BACTERIA(10,2)
CONTAGIOUS BOVINE PLEUROPNEMONIA(10,2)
FORMALDEHYDE(10,2)
MYCOPLASMA(9,8)
EYE DISEASE(9,1)
CALF(8,4)
INACTIVATED MYCOPLASMA STRAIN(8,2)
ANIMAL(7,5)
DIFCO PPLO BROTH BA(7,1)
INCREASED RESISTANCE(7,1)
MVCOYLASMA MYCOIDE SUBSP MVCOIDES PREPARATION(7,1)
LIQUID CARRIER(6,2)
EXPERIMENTAL QUADRIVALENT VACCINE(6,1)
MYCOPLASMA MYCOIDES SUBSP STRAIN(6,1)
SUSPENDING AGENT(5,3)
CALF LUNG(5,2)
CATTLE LUNG(5,2)
EATON BROTH MEDIUM(5,2)
LOMG ML(5,2)
ORGANISM KEY ANTIGENIC REGION(5,2)
BOTSWANAN OUTBREAK(5,1)
BOVINE PNEUMONIA STRAIN(5,1)
DISPERSING AGENT(5,1)
FORMALDEHYDE KILLED ANTIGEN(5,1)
FREUND INCOMPLETE ADJUVANT(5,1)
INACTIVATED VIRUS STRAIN(5,1)
MASTER FROZEN ALIQUOT(5,1)
ORGANISM POTENT STRAIN(5,1)
PNEUMONIA CLINICAL SIGN(5,1)
UNHEATED HORSE SERUM(5,1)
VETERINARY LABORATORY AGENCY(5,1)
WETTING AGENT(4,3)
COMBATING INACTIVATION(4,1)
CONGRESS PROCEEDING(4,1)
EGG PASSAGED LIVE STRAIN(4,1)
FORMALIZED VACCINE(4,1)
INTRAMUSCULAR DOSING(4,1)
MANNHEIMA HAEMOLYTICA(4,1)
MYCOPLASMA BOVIS STRAIN PASSAGE(4,1)
MYCOPLASMA BOVIS VACCINE PREPARATION(4,1)
QUILLAGA BARK(4,1)
SAPOGENIN GLYCOSIDE(4,1)
SUDANESE COUNTRY(4,1)
VIRULENT CHALLENGE(4,1)
ACTIVE INGREDIENT(3,3)
BIOLOGICAL TESTING(3,2)
PRESERVATIVE(3,2)
ADMINISTRATION WEEK(3,1)
AEROSOL ADMINISTRATION(3,1)
CHICKEN EGG YOLK(3,1)
FORMALDEHYDE INACTIVATED VACCINE(3,1)
FRESHLY PREPARED YEAST EXTRACT(3,1)
HUMAN MYCOPLASMA(3,1)
INACTIVATING AGENT CLASS(3,1)
INFECTED CATTLE(3,1)
LUNG LESION(3,1)
STERILE INJECTABLE PREPARATION(3,1)
VACCINE FORMULATION(3,1)
DISPERSION(2,2)
EXCIPIENT(2,2)
IMMUNE RESPONSE(2,2)
AGE WEEK(2,1)
AGENT EFFICACY(2,1)
ANIMAL AGE(2,1)
ANTIBODY INDUCING ACTIVITY(2,1)
AQUEOUS SUSPENSION PREPARATION(2,1)
ARACHIS OIL(2,1)
BETA LACTAMINE GROUP ANTIBIOTIC(2,1)
CATTLE GROUP(2,1)
CELL MEMBRANE DISRUPTER(2,1)
CHOLESTEROL QUANTITY(2,1)
COMPLEX ORGANISM(2,1)
CONSECUTIVE DAY(2,1)
DISPERSIBLE POWDER(2,1)
EATON MEDIUM VOLUME(2,1)
EAUSATIVE AGENT(2,1)
ECONOMIC IMPORTANCE(2,1)
ENZYME PRODUCTION(2,1)
ESSENTIAL PROTEIN(2,1)
HEMOLYTIC ACTIVITY(2,1)
HYDROXYPROPYLMETHYLCELLULOSE(2,1)
MICROORGANISM NATURE(2,1)
MYCOPLASMA CELL(2,1)
OILY SUSPENSION(2,1)
ORGANISM ABILITY(2,1)
POLYVINYLPYRROLIDONE(2,1)
PROPYL PARABEN(2,1)
RESIDUAL VIRULENCE(2,1)
SAPONIN CONTAUIING RANGE(2,1)
STERILE INJECTABLE SOLUTION(2,1)
STRAIN CONCENTRATION(2,1)
STRAIN PRECISE NATURE(2,1)
STRONG SEROLOGICAL RESPONSE(2,1)
UNIVERSAL CONTAINER(2,1)
VACCINE STRAIN(2,1)
YOUNG CALF(2,1)
(CA2445997)
SAPONIN(100,17)
BOVINE PNEUMONIA CAUSATIVE AGENT(100,16)
MYCOPLASMA STRAIN(100,11)
MYCOPLASMA INACTIVATED STRAIN(100,6)
MYCOPLASMA VACCINE(100,1)
MYCOPLASMA MYCOIDES SUBSP(40,7)
INCUBATION CULTURE IRE(40,1)
MYCOPLASMA BOVIS INACTIVATED STRAIN(37,1)
POUND CATTLE INDUSTRY MILLION(34,1)
VETERINARILY ACCEPTABLE CARRIER(29,3)
MYCOPLASMA BOVIS RECENT STRAIN(27,1)
PATHOGENIC MICROORGANISM(27,1)
VETERINARY(26,6)
INFECTIVE DISEASE(26,1)
MYCOPLASMA MYCOIDES SUBSP MYCOIDES(26,1)
CALF ARTHRITIS(21,1)
MYCOPLASMA BOVIS(19,10)
BOVIS VACCINE(19,2)
SAPONIN PRESENCE(18,1)
SPREADING INFECTION(18,1)
CALF PNEUMONIA(16,3)
CEL MEMBRANE(16,1)
SETBACK LOSS(16,1)
VETERINARY RECORD(15,2)
COMPLEX SYNDROME(15,1)
CATTLE(14,9)
INACTIVATED STRAIN(14,6)
MYCOIDE 5C(14,1)
VACCINE(13,23)
CAUSATIVE AGENT(13,3)
CALF PNEUMONIA PRIMARY CAUSE(13,1)
MEDICAMENT PREPARATION(13,1)
ADJUVANT(12,7)
PARENTERAL ADMINISTRATION(12,3)
MYCOIDE(11,11)
ARTHRITIS(10,1)
MASTITIS(10,1)
MORTALITY(10,1)
ORGANISM(10,1)
ANIMAL TREATMENT(9,1)
ANTIBIOTIC RANGE(9,1)
PROPHYLAXIS(9,1)
VIRUS(9,1)
BACTERIA(8,2)
CONTAGIOUS BOVINE PLEUROPNEMONIA(8,2)
FORMALDEHYDE(8,2)
10MG ML(8,1)
MYCOPLASMA(7,8)
EYE DISEASE(7,1)
CELL MEMBRANE(6,6)
ANIMAL(6,5)
CALF(6,5)
INCREASED RESISTANCE(6,1)
LIQUID CARRIER(5,2)
EXPERIMENTAL QUADRIVALENT VACCINE(5,1)
MYCOPLASMA MYCOIDES SUBSP STRAIN(5,1)
SUSPENDING AGENT(4,3)
CALF LUNG(4,2)
CATTLE LUNG(4,2)
EATON BROTH MEDIUM(4,2)
MYCOPLASMA BOVIS STRAIN(4,2)
ORGANISM KEY ANTIGENIC REGION(4,2)
BOTSWANAN OUTBREAK(4,1)
BOVINE PNEUMONIA STRAIN(4,1)
DISPERSING AGENT(4,1)
FORMALDEHYDE KILLED ANTIGEN(4,1)
FREUND INCOMPLETE ADJUVANT(4,1)
INACTIVATED MYCOPLASMA STRAIN(4,1)
INACTIVATED VIRUS STRAIN(4,1)
MASTER FROZEN ALIQUOT(4,1)
MYCOPLASMA MYCOIDES SUBSP MYCOIDES PREPARATION(4,1)
ORGANISM POTENT STRAIN(4,1)
PNEUMONIA CLINICAL SIGN(4,1)
UNHEATED HORSE SERUM(4,1)
VETERINARY LABORATORY AGENCY(4,1)
ACTIVE INGREDIENT(3,3)
WETTING AGENT(3,3)
COMBATING INACTIVATION(3,1)
EGG PASSAGED LIVE STRAIN(3,1)
FORMALIZED VACCINE(3,1)
INTRAMUSCULAR DOSING(3,1)
MYCOPLASMA BOVIS VACCINE PREPARATION(3,1)
QUILLAGA BARK(3,1)
SAPOGENIN GLYCOSIDE(3,1)
SUDANESE COUNTRY(3,1)
VIRULENT CHALLENGE(3,1)
BIOLOGICAL TESTING(2,2)
DISPERSION(2,2)
EXCIPIENT(2,2)
IMMUNE RESPONSE(2,2)
PENICILLIN(2,2)
PRESERVATIVE(2,2)
ADMINISTRATION WEEK(2,1)
AEROSOL ADMINISTRATION(2,1)
AGE WEEK(2,1)
AGENT EFFICACY(2,1)
ANIMAL AGE(2,1)
CHICKEN EGG YOLK(2,1)
CHOLESTEROL QUANTITY(2,1)
CULTURE INCUBATION(2,1)
DIFCO PPLO BROTH BASE(2,1)
DISPERSIBLE POWDER(2,1)
ECONOMIC IMPORTANCE(2,1)
FRESHLY PREPARED YEAST EXTRACT(2,1)
HUMAN MYCOPLASMA(2,1)
INACTIVATING AGENT CLASS(2,1)
INFECTED CATTLE(2,1)
LUNG LESION(2,1)
LYTIC ACTIVITY(2,1)
MICROORGANISM NATURE(2,1)
MYCOPLASMA BOVIS PASSAGE(2,1)
MYCOPLASMA CELL(2,1)
OILY SUSPENSION(2,1)
RESIDUAL VIRULENCE(2,1)
STERILE INJECTABLE PREPARATION(2,1)
STERILE INJECTABLE SOLUTION(2,1)
STRAIN LMG(2,1)
UNIVERSAL CONTAINER(2,1)
VACCINE FORMULATION(2,1)
VACCINE STRAIN(2,1)
YOUNG CALF(2,1)
7H3SF(1,1)
ANTIBODY INDUCING ACTIVITY(1,1)
AQUEOUS SUSPENSION PREPARATION(1,1)
ARACHIS OIL(1,1)
BETA LACTAMINE GROUP ANTIBIOTIC(1,1)
CATTLE GROUP(1,1)
CELL MEMBRANE DISRUPTER(1,1)
COMPLEX ORGANISM(1,1)
CONSECUTIVE DAY(1,1)
DOSAGE UNIT FORNIS(1,1)
EATON MEDIUM VOLUME(1,1)
ENZYME PRODUCTION(1,1)
ESSENTIAL PROTEIN(1,1)";Pharmaceuticals;Open
2000-12-15;"RU2202367           C2 2003-04-20 [RU2202367]
STG: (C2) Patent for invention ( 2nd publ.)
AP : 2000RU-0131304 2000-12-15";36137001;RU2202367           C2 2003-04-20 [RU2202367];2000RU-0131304;;"HKSPERIMENTAL NOJ VETERINARII
VRNII";"VRNII
HKSPERIMENTAL NOJ VETERINARII";;;2;"KRIKUN V A
GULJUKIN M I
SIMONOV A V";;;"(RU2202367)
Method for preparing inactivated vaccine against cattle leucosis";"(RU2202367)
FIELD: veterinary science. SUBSTANCE: the present method deals with cultivation of virus-containing peripheral blood leucocytes in leucosis-suffering cattle, inactivation and antigen obtaining. Cultivation of leucocytes is carried out for 24-36 h at inoculation concentration equal to 5-10x106 cells/ml medium. Then leucocytes should be deposited due to centrifuging. Suspension should be prepared upon Eagle's medium at concentration of 10 mln cells/ml medium, leucocytes are fixed to inactivate the virus inside by adding 5 volumes of 2-3%-glutaric aldehyde solution. Incubation is carried out at room temperature for 30-40 min. Leucocytes should be thrice washed in buffered physiological solution at pH=7.2-7.4, resuspended in Eagle's medium at 100 mln leucocytes/ml to be used as immunizing agent. Vaccine obtained due to the suggested method provides accelerated terms of sanitation in leucosis-suffering farms by 2-3 times and decreased expenses necessary for sanitation. EFFECT: higher efficiency. 2 ex, 1 tbl";"(RU2202367)
The Method of the preparation of the inactivated vaccine against the leucosis of large livestock, which includes the cultivation of the virussoderashchikh leukocytes of the peripheral blood of large livestock of the patient with leucosis, inactivation and obtaining of antigen, that is characterized by the fact that, the cultivation of leukocytes conduct 24-26 h with sowing concentration 5-10•10(6) cells on 1 ml of medium, then precipitate leukocytes by centrifugation, is prepared suspension on Wednesday Needle with the concentration of 10 million cells on 1 ml of medium, they fix leukocytes and inactivate the being contained in them virus by adding 5 volumes 2nd-3%- foot solution of glutaraldehyde, they incubate at room temperature during 30-40 min, leukocytes three times wash clean in the buffered physiological solution from rN 7,2-7,4, they resuspend on Wednesday Needle from the calculation of 100 million leukocytes in 1 ml and are used they as the immunizing agent.";;;A61K-039/12;;;Pharmaceuticals;Open
2000-11-29;"TH62362             A  2004-06-07 [TH--62362]
STG: (A) Published application
AP : 2000TH-1004623 2000-11-29";64515036;TH62362             A  2004-06-07 [TH--62362];2000TH-1004623;;SAINT JOHN BARRINGER THE NEW YORK SPIRIT OF PROGRAMMING HIGHLIGHTS MEDICINE CROW;SAINT JOHN BARRINGER THE NEW YORK SPIRIT OF PROGRAMMING HIGHLIGHTS MEDICINE CROW;;;1;;;;"(TH--62362)
The viral diarrhea virus of cattle that has weakened immensely safe for use in pregnant cows.";"(TH--62362)
This invention relates to the use of viruses, BVD (diarrhea virus of cattle), whose life was. The softening effect of vaccines specifically for the preparation for the defense. And / or BVDV infection in cattle, cattle, cows pregnant. And for the protection of the unborn child. Pregnant cows.";"(TH--62362)
1. The use of live BVDV (virus that causes diarrhea from cattle virus) by the presence of RNase in glycoproteins. It has been depleted. For the preparation of vaccines. Life for protection And / or treatment of BVDV infection in cattle, cattle, cattle.
2. The use of BVDV in accordance with claim 1 for protection. And / or treatment of BVDV infection in pregnant cows.
3. Use of BVDV according to claim 1 for induction of BVDV infection in pregnant cows.";;;"A61K-039/12
A61P-031/14
C07K-007/04
C07K-014/18
C12N-015/40";;;Pharmaceuticals;Open
"2000-11-22
2000-12-18
2001-11-21";"CA2363493           A1 2002-05-22 [CA2363493]
STG: (A1) Application laid open
AP : 2001CA-2363493 2001-11-20
US20040146854       A1 2004-07-29 [US20040146854]
STG: (A1) Application published
AP : 2001US-09989933 2001-11-21
CA2363493           C  2006-06-06 [CA2363493]
STG: (C) Patent (second level)
AP : 2001CA-2363493 2001-11-20";4042895;"CA2363493           A1 2002-05-22 [CA2363493]
US20040146854       A1 2004-07-29 [US20040146854]
CA2363493           C  2006-06-06 [CA2363493]";"2000US-60252513
2000US-60256515
2001US-09989933";;"PFIZER
PFIZER PRODUCTS";"PFIZER
PFIZER PRODUCTS";"
(CA2363493)
US
(CA2363493)
US";"(US20040146854)
NAME=Pfizer Inc. , ATYP=US Company 

(CA2363493)
NAME=PFIZER PRODUCTS INC Eastern Point Road, GROTON , COUNTRY=US 

(CA2363493)
NAME=PFIZER PRODUCTS INC. Eastern Point Road , CITY=GROTON , STATE=CT , POSTCODE=06340 , COUNTRY=US 
";2;"CAO XUEMEI
ZYBARTH GABRIELE M";"(US20040146854)
US";"(US20040146854)
NAME=Cao Xuemei , CITY=East Lyme , STATE=CT , COUNTRY=US 

NAME=Zybarth Gabriele M. , CITY=West Kingston , STATE=RI , COUNTRY=US 
";"(US20040146854)
Attenuated forms of bovine viral diarrhea virus";"(US20040146854)
The present invention relates to attenuated forms of bovine viral diarrhea (BVD) viruses. In particular, the present invention relates to attenuated BVD viruses made by mutating the N
protease gene and inserting a bovine ubiquitin coding sequence. The attenuated viruses of the present invention can be used to raise antibodies against BVDV. Immunogenic compositions and vaccine compositions, as well as therapeutic and diagnosis methods, are also provided by the present invention.";"(CA2363493)
1. An attenuated bovine viral diarrhea (BVD) virus, wherein said virus carries in the viral genome, a mutated 3'
region of a N pro coding sequence and a sequence coding for a monomeric bovine ubiquitin, wherein the ubiquitin coding sequence is operably placed between the 3' end of said mutated N pro coding sequence and the 5' end of the coding sequence for the viral core protein, and the 5' region of the N pro coding sequence is intact.
2. The attenuated BVD virus of claim 1, comprising a genomic nucleic acid sequence as set forth in SEQ ID NO: 11, or a degenerate variant thereof.
3. An isolated nucleic acid molecule comprising the genomic sequence of an attenuated BVD virus, wherein said virus carries in the viral genome, a mutated 3' region of a
N pro coding sequence and a sequence coding for a monomeric bovine ubiquitin, wherein the ubiquitin coding sequence is operably placed between the 3' end of said mutated N pro coding sequence and the 5' end of the coding sequence for the viral core protein, and the 5' region of the N pro coding sequence is intact.
4. An isolated nucleic acid molecule comprising a sequence as set forth in SEQ ID NO: 11, or a degenerate variant thereof.
5. A vector comprising a sequence as set forth in
SEQ ID NO: 11, or a degenerate variant thereof.
6. A vector designated as pBVDdN6 (ATCC No. PTA-2532)
(SEQ ID NO: 12).
7. A cell transformed or transfected with any of the nucleic acid molecules of claims 3 or 4.
8. A method of modifying the genomic nucleic acid molecule of an isolated wild type BVD virus, comprising introducing a mutation into the 3' region of the N pro protease gene wherein said mutation renders the N pro protein inactive, and inserting a sequence coding for a monomeric bovine ubiquitin between the mutated N pro coding sequence and the coding sequence of the core protein.
9. A method of attenuating an isolated wild type BVD
virus, comprising isolating the genomic nucleic acid molecule from said virus, introducing a mutation into the 3'
region of the N pro protease gene in the viral genome, wherein said mutation renders the N pro protein inactive; inserting a sequence coding for a monomeric bovine ubiquitin between the mutated N pro coding sequence and the coding sequence of the core protein; and producing from the modified genome an attenuated virus suitable for use in a vaccine.
10. An immunogenic composition comprising the attenuated BVD virus of claim 1 or 2 and a veterinarilyacceptable carrier.
11. An immunogenic composition comprising the isolated nucleic acid molecule of claim 3 or 4 and a veterinarilyacceptable carrier.
12. A use of an immunologically effective amount of the attenuated BVD virus (BVDV) defined in claim 1 or 2, and a veterinarily-acceptable carrier, for inducing an immune response against BVDV in an animal subject.
13. A vaccine composition comprising the isolated nucleic acid molecule of claim 3 or 4 and a veterinarilyacceptable carrier.
14. A use of a therapeutically effective amount of the attenuated BVD virus defined in claim 1 or 2 for treating a
BVDV infection in an animal.
15. A method of identifying a BVD virus in an animal as an attenuated BVD virus of any one of claims 1-3, said animal suspected of suffering a BVDV infection, comprising isolating the virus from said animal, detecting the presence of the ubiquitin coding sequence, thereby determining the isolated virus as identical to the attenuated BVD virus of claim 1 or 2.
16. Use, for inducing an immune response against BVDV
in an animal subject, of an immunologically effective amount of the attenuated BVD virus of claim 1 or 2.
17. Use, in the preparation of a medicament for inducing an immune response against BVDV in an animal subject, of an immunologically effective amount of the attenuated BVD virus of claim 1 or 2.
18. Use, for treating a BVDV infection in an animal, of a therapeutically effective amount of the attenuated BVD
virus of claim 1 or 2.
19. Use, in the preparation of a medicament for treating a BVDV infection in an animal, of a therapeutically effective amount of the attenuated BVD virus of claim 1
or 2.
20. A kit comprising the immunogenic composition of claim 10 or 11 and instructions for use of said composition for inducing an immune response against BVDV in an animal subject.
21. A kit comprising the vaccine composition of claim 13 and instructions for use of said composition as a vaccine for preventing or treating a BVDV infection in an animal.";"(US20040146854)
[0010] One embodiment of the present invention provides attenuated BVD viruses which carry in the viral genome, a mutated Npro coding sequence having an intact 5 region, and a sequence coding for a monomeric bovine ubiquitin, wherein the ubiquitin coding sequence is operably placed between the 3 end of the mutated Npro coding sequence and the 5 end of the core protein coding sequence.
[0009] The present invention provides attenuated BVD virus carrying a deletion of only a portion of the Npro coding sequence in the 3 region of the Npro gene, and an insertion of the coding region of a bovine ubiquitin gene.
[0001] The present invention relates to attenuated bovine viral diarrhea (BVD) viruses and methods of making the same by modifying the viral genome.";"(US20040146854)
The methods of the present invention allow discrimination between vaccinated and infected animals, and permit the identification of the origin of a BVD virus in the event of alleged vaccine-associated outbreaks.
For prokaryotic cells, the GM2rb3 strain of E. coli (NEB) has been found to give the best results for propagating the plasmid, and is generally preferred.
[0007] A clear need exists for new and effective vaccines to control the spread of the BVD virus.
Given that the disease caused by this virus is one of the most widespread and economically important diseases of cattle, such vaccines would represent a substantial advance in livestock farming.
Wschr. 81:481-487 (1974)) and are highly predisposed to infection with microorganisms causing diseases such as pneumonia or enteric disease (Barber, et al., Vet Rec. 117:459-464 (1985)).
Unfortunately, only one such vaccine appears to protect fetuses from infection and this protection is limited to one strain of homologous virus.";"A61K-039/12
C07K-016/08
C12N-005/10
C12N-007/00
C12N-007/01
C12N-007/04
C12N-015/33
C12Q-001/70
G01N-033/569";"(US20040146854)
1. An attenuated bovine viral diarrhea (BVD) virus, wherein said virus carries in the viral genome, a mutated Npro coding sequence comprising an intact 5 region, and a sequence coding for a monomeric bovine ubiquitin, wherein the ubiquitin coding sequence is operably placed between the 3 end of said mutated Npro coding sequence and the 5 end of the coding sequence for the viral core protein.
4. An isolated nucleic acid molecule comprising the genomic sequence of an attenuated BVD virus, wherein said virus carries in the viral genome, a mutated Npro coding sequence comprising an intact 5 region, and a sequence coding for a monomeric bovine ubiquitin, wherein the ubiquitin coding sequence is operably placed between the 3 end of said mutated Npro coding sequence and the 5 end of the coding sequence for the viral core protein.
5. An isolated nucleic acid molecule comprising a sequence as set forth in SEQ ID NO: 11, or a degenerate variant thereof.
6. An isolated nucleic acid molecule comprising a sequence essentially as set forth in SEQ ID NO: 11, or a degenerate variant thereof.
7. A vector comprising a sequence essentially as set forth in SEQ ID NO: 11, or a degenerate variant thereof.
8. A vector designated as pBVDdN6 (ATCC No. PTA-2532) (SEQ ID NO: 12).
13. A method of modifying the genomic nucleic acid molecule of an isolated wild type BVD virus, comprising introducing a mutation into the 3 region of the Npro protease gene wherein said mutation renders the Npro protein inactive, and inserting a sequence coding for a monomeric bovine ubiquitin between the mutated Npro coding sequence and the coding sequence of the core protein.
15. A method of attenuating an isolated wild type BVD virus, comprising isolating the genomic nucleic acid molecule from said virus, introducing a mutation into the 3 region of the Npro protease gene in the viral genome, wherein said mutation renders the Npro protein inactive; inserting a sequence coding for a monomeric bovine ubiquitin between the mutated Npro coding sequence and the coding sequence of the core protein; and producing from the modified genome an attenuated virus suitable for use in a vaccine.";"(US20040146854)
VIRUS(100,44)
MUTATED NPRO CODING SEQUENCE(100,16)
BOVINE VIRAL DIARRHEA VIRUS(100,15)
VECTOR(100,14)
GENOMIC NUCLEIC ACID MOLECULE(100,11)
ISOLATED NUCLEIC ACID MOLECULE(100,7)
BOVINE VIRAL DIARRHEA(100,5)
ATTENUATED FORM(100,2)
WILD TYPE INSULATION(100,2)
PTA(100,1)
MONOMERIC BOVINE UBIQUITIN(95,11)
NPRO PROTEASE GENE(75,6)
VIRAL GENOME(54,13)
BVD VIRUS ATTENUATION(53,24)
UBIQUITIN CODING SEQUENCE(47,6)
BVD VIRUS SPREAD(41,1)
HOMOLOGOUS VIRUS STRAIN(40,1)
CORE PROTEIN CODING SEQUENCE(39,6)
NPRO PROTEIN(37,5)
DEGENERATE(35,5)
CODING SEQUENCE(32,20)
BOVINE UBIQUITIN GENE(32,3)
VACCINE(29,29)
BOVINE UBIQUITIN CODING SEQUENCE(29,1)
ATTENUATED BOVINE VIRAL DIARRHEA(28,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(27,1)
GASTROINTESTINAL DISEASE(27,1)
ORIGIN IDENTIFICATION(26,1)
MUTATION(25,15)
VETERINARILY ACCEPTABLE CARRIER(25,9)
IMMUNOGENIC(22,13)
ATTENUATED VIRUS(22,11)
ISOLATED VIRUS(22,2)
MODIFIED GENOME(22,1)
ANIMAL(21,33)
BVD VIRUS(21,17)
NPRO GENE REGION(19,5)
ALLEGED VACCINE ASSOCIATED OUTBREAK(19,2)
DISEASE(17,2)
GENOMIC NUCLEIC ACID SEQUENCE(17,2)
GENOMIC SEQUENCE(15,6)
ANTIBODY PRODUCTION(15,4)
CODING REGION INSERTION(15,2)
GM2RB(15,1)
MICROORGANISM(15,1)
VIRAL CORE PROTEIN(14,3)
PNEUMONIA(14,1)
UBIQUITIN CODING SEQUENCE PRESENCE(13,2)
BARBER(13,1)
FETUS(13,1)
ANIMAL SUBJECT(12,9)
INFECTION(12,7)
BVDV INFECTIOUS CLONE(12,3)
QIAQUICK PCR PURIFICATION KIT(12,3)
DISCRIMINATION(12,2)
DELETION(11,13)
BVD(11,4)
MUTATION PRESENCE(11,2)
PLASMID PBVDDN GENERATION(10,4)
BVD VIRUS ORIGIN(10,3)
BVDV INFECTION SYMPTOM(10,2)
CODING SEQUENCE END(10,2)
STRAIN(10,1)
THERAPEUTIC(10,1)
PLASMID(9,16)
PCR FRAGMENT GENERATION(9,6)
IMMUNOHISTOCHEMISTRY ASSAY(9,5)
RESTRICTION ENZYME DIGESTION(9,3)
BVDV NPRO PROTEIN(9,2)
VIRUS NEUTRALIZING SERUM ANTIBODY(9,2)
INFECTIOUS VIRUS PARTICLE(8,3)
VIRUS GROWTH KINETICS(8,3)
BVDV VIRULENT STRAIN(8,2)
DNA PLASMID POPULATION(8,2)
NPRO CODING SEQUENCE PORTION(8,2)
PLASMID P15AD1UBIN MODIFICATION(8,2)
PROKARYOTIC CELL(8,2)
INTESTINAL MUCOSA ULCERATION(8,1)
PROGENY ATTENUATED BVD VIRUS(8,1)
VIRAL GENOME NPRO GENE(8,1)
VIRAL POLYPROTEIN PRECURSOR TRANSLATION(8,1)
MDBK CELL(7,9)
EXTRA NUCLEOTIDE(7,5)
RNA TRANSFECTION(7,4)
LIGATION REACTION ALIQUOT(7,3)
IMMUNE RESPONSE RESULT(7,2)
ROCHE MOLECULAR BIOCHEMICAL(7,2)
SUBVIRAL REPLICON(7,2)
BVDV GENOME NUCLEOTIDE(7,1)
NCP BIOTYPE VIRUS(7,1)
PREGNANT CATTLE PLACENTA(7,1)
BOVINE POLYUBIQUITIN SEQUENCE(6,2)
BVDDN GENOMIC SEQUENCE(6,2)
HETEROLOGOUS COLONY(6,2)
IMMUNOHISTOCHEMICAL ASSAY(6,2)
TRANSFECTED CELL MONOLAYER(6,2)
ATTENUATED BDV VIRUS(6,1)
BOVINE DONOR CALF SERUM(6,1)
BOVINE UBIQUITIN CLONING(6,1)
BOVINE UBIQUITIN GENE INSERTION(6,1)
BVD VIRAL GENOME(6,1)
BVD VIRUS GENOME(6,1)
BVDV INFECTION INCIDENCE(6,1)
BVDV RNA TRANSCRIPTION(6,1)
CLEAR NEED(6,1)
DIAGNOSIS(6,1)
GENETICALLY ENGINEERED BVD VIRUS(6,1)
INFECTED RD MONOLAYER(6,1)
MONOMERIC BOVINE UBIQUITIN INSERTION(6,1)
MUTATED BVD GENOME(6,1)
NPRO GENE MUTATION(6,1)
NPRO UBIQUITIN FUSION(6,1)
PATHOGENIC BVD VIRUS(6,1)
QIAQUICK KIT PURIFIED FRAGMENT(6,1)
PFU DNA POLYMERASE UNIT(5,5)
INFECTION RISK(5,3)
NPRO CODING SEQUENCE REGION(5,3)
BVDV CONSTRUCT(5,2)
HR POST INFECTION(5,2)
INOCULATED ANIMAL(5,2)
INTRA LYMPH NODE(5,2)
PARENT PLASMID(5,2)
PARTIAL BVDV GENOMIC SEQUENCE(5,2)
PLASMID PBVDDN CONSTRUCTION(5,2)
BVD GENOMIC SEQUENCE INCORPORATION(5,1)
BVD VIRUS STRAIN(5,1)
BVDDN GENOME(5,1)
BVDV CODING REGION NTR(5,1)
BVDV SEQUENCE NTR(5,1)
CHIMERIC VIRAL GENOME(5,1)
DNA FRAGMENT LIGATION(5,1)
ELITE ABC KIT(5,1)
EMBRYONIC BOVINE TRACHEA CELL(5,1)
FETAL EQUINE SERUM(5,1)
FRAGMENT PCR AMPLIFICATION(5,1)
FRESH MDBK MONOLAYER(5,1)
MADIN DARBY KIDNEY CELL(5,1)
MEGASCRIPT REAGENT(5,1)
MONOMERIC UBIQUITIN INTRODUCTION(5,1)
NPRO GENE PARTIAL DELETION(5,1)
OLIGONUCLEOTIDE NADLC(5,1)
PCR FRAGMENT SYNTHESIS(5,1)
PESTIVIRUS GENUS(5,1)
PLASMID PVVNADLD1UBIN(5,1)
PROGENY VIRUS ATTENUATION(5,1)
RESTRICTION ENZYME SAC(5,1)
SUBCONFLUENT MONOLAYER(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
ULTRASPEC RNA REAGENT(5,1)
VIRUS ACCELERATED ELIMINATION(5,1)
VIRUS GROWTH PHENOTYPE(5,1)
FINAL CONCENTRATION(4,6)
NUCLEIC ACID MOLECULE(4,6)
AUTOEXTENSION(4,5)
GENECLEAN(4,3)
DETECTED VIRAL PROTEIN(4,2)
HUMORAL IMMUNE RESPONSE(4,2)
MINI DNA PURIFICATION(4,2)
PARENTERAL ROUTE(4,2)
POST TRANSFECTION(4,2)
SUPPORTED VIRAL RNA REPLICATION(4,2)
VIRAL REPLICATION RATE(4,2)
VIRUS REPLICATION(4,2)
AGENT FACILITATING CELLULAR UPTAKE(4,1)
AMPHIGEN ADJUVANT(4,1)
AVRIDINE LIPID(4,1)
BOVINE TESTICULAR CELL(4,1)
BOVINE TURBINATE CELL(4,1)
BOVPOUBA SEQUENCE NUMBERING(4,1)
BVD VACCINE(4,1)
BVDV GENOME SEQUENCE(4,1)
BVDV IDENTIFICATION(4,1)
BVDV PLAQUE(4,1)
BVDV STRUCTURAL GENE(4,1)
BVDVNADL CODING SEQUENCE(4,1)
BVDVNADL CORE PROTEIN(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CLASSICAL SWINE FEVER(4,1)
CLEANED VECTOR FRAGMENT(4,1)
CLONE PNADLP15A(4,1)
CONFERENCE RE PROCEEDING(4,1)
FLANKING SEQUENCE ENCOMPASSING(4,1)
FLAVIVIRIDAE FAMILY(4,1)
MONOPHOSPHORYL LIPID(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
NADLP15A CLONE(4,1)
NUCLEOTIDE DELETION(4,1)
PCR AMPLIFICATION ROUND(4,1)
PLASMID P15ADI(4,1)
PLASMID PVVNADLD1NS(4,1)
PROTEOLYTIC CLEAVAGE(4,1)
PVVNADL DERIVATIVE(4,1)
RESCUED VIRUS NATURE(4,1)
RESPONDING CTL DETECTION(4,1)
ROUND PCR AMPLIFICATION(4,1)
RT PCR BEAD(4,1)
SELF NON SELF DISCRIMINATION SCIENCE(4,1)
UBIQUITIN SEQUENCE FUSION(4,1)
UBIQUITIN TERMINUS(4,1)
ULTRACENTRIFUGATION PRECIPITATION(4,1)
VACCINATED CATTLE(4,1)
VETERINARY PHYSICIAN(4,1)
VIRUS FETAL TRANSMISSION(4,1)
SHEEP(3,6)
ENGLAND BIOLAB(3,4)
GENOMIC NUCLEIC ACID(3,3)
RD CELL(3,3)
SUBSTITUTION(3,3)
VIRUS TITER(3,3)
ACTIVE INGREDIENT(3,2)
AGAROSE GEL(3,2)
ANTIBODY PRESENCE(3,2)
COLI CELL(3,2)
COMPLETE BVDDN(3,2)
IMMUNOGENICITY(3,2)
ISOTONIC AGENT(3,2)
OLIGONUCLEOTIDE PRIMER SEQUENCE(3,2)
OVERLAPPING SEQUENCE(3,2)
PARTIAL NPRO CODING SEQUENCE(3,2)
PHENOTYPE ANALYSIS(3,2)
PLASMID STABILITY(3,2)
ADSORPTION DELAYING(3,1)
AMERSHAM(3,1)
AMINE ADJUVANT(3,1)
AMPLIFIED FRAGMENT(3,1)
ANIMAL DISEASE NATIONAL LABORATORY(3,1)
ANTIBODY TITER(3,1)
BIOTECX LABORATORY(3,1)
BOVINE POLYUBIQUITIN DNA SEQUENCE(3,1)
BP FRAGMENT(3,1)
BVD INFECTION(3,1)
BVD PROTEIN(3,1)
BVD VIRUS SEQUENCE(3,1)
BVDVNADL CORE CODING REGION(3,1)
BVNDN VIRAL RNA(3,1)
CATIONIC LIPID(3,1)
CELL ACTIVATION ASSAY(3,1)
CELLULAR RNA ALIQUOT(3,1)
CELLULAR UBIQUITIN(3,1)
CHOLERA TOXIN(3,1)
CLINICAL SYNDROME VARIETY(3,1)
CLONE AMPLIFICATION(3,1)
CONSTRUCT DERIVATIVE(3,1)
CORRECT DELETION(3,1)
DELETION SITE(3,1)
DIGESTED FRAGMENT(3,1)
DOSAGE REGIMEN(3,1)
EARLY PASSAGE VIRUS STOCK(3,1)
EFFICIENT TRANSLATION INITIATION(3,1)
EMERYVILLE CALIF(3,1)
ENVELOPE PROTEIN(3,1)
EUKARYOTIC HOST CELL(3,1)
FOLD GREAT AFFINITY(3,1)
GEL ELECTROPHORESIS(3,1)
GENERATING VIRUS STOCK(3,1)
GENOMIC ELEMENT DELETION(3,1)
GENOMIC RNA(3,1)
GENTLE ROCKING(3,1)
GIBCO BRL(3,1)
IMMUNITY DURATION(3,1)
IMMUNOMODULATORY AGENT(3,1)
INCOMPLETE ADJUVANT(3,1)
INDUCTION INDICATIVE(3,1)
INFECTED CATTLE(3,1)
INFECTED CELL CLUSTER(3,1)
INFECTION ROUND(3,1)
INFECTIVITY FALL(3,1)
INJECTION SCHEDULE(3,1)
INTESTINAL ALKALINE PHOSPHATASE(3,1)
INTRACELLULAR EXTRACT(3,1)
ISOLATING BVDDN(3,1)
LIVE VIRUS(3,1)
MAJOR GENOTYPE(3,1)
MARKER GENE(3,1)
MODIFIED LIVE VIRAL VACCINE(3,1)
MODIFIED VIRAL GENOME(3,1)
MUTATION INTRODUCTION(3,1)
NEIGHBOR CELL(3,1)
NPRO CODING REGION SEQUENCE(3,1)
OPTIMAL IMMUNIZATION(3,1)
PARENT VIRUS(3,1)
PARENTAL RNA(3,1)
PCR TEMPLATE(3,1)
PLAQUE ASSAY(3,1)
PLASMID P15AD1UBIN CONSTRUCTION(3,1)
PLASMID PROPAGATION(3,1)
PLASMID VECTOR(3,1)
PROKARYOTIC HOST CELL(3,1)
PROTEIN EXPRESSION(3,1)
RAISING ANTIBODY(3,1)
RANDOM MUTAGENESIS(3,1)
REPLICATION ORIGIN(3,1)
RNA ENCODING(3,1)
RNA MOLECULE(3,1)
RNA POLYMERASE PROMOTER(3,1)
SAPONIN FRACTION(3,1)
TEMPLATE DNA(3,1)
TISSUE CULTURE FLASK(3,1)
TRANSFECTION RNA LIPID MIXTURE(3,1)
UBIQUITIN CODING SEQUENCE INSERTION(3,1)
UNIQUE PINA(3,1)
UNIQUE RESTRICTION ENZYME(3,1)
VECTOR LABORATORY(3,1)
VECTOR PBVDDN CONSTRUCTION(3,1)
VECTOR PLASMID PREPARATION(3,1)
VECTOR PROPAGATION(3,1)
VECTOR PVVNADLD1NS(3,1)
VIRAL ENZYME(3,1)
VIRAL STRAIN(3,1)
VIRICIDAL AGENT(3,1)
VIRUS TITRATION(3,1)
WESTERN BLOT(3,1)
PARENT WILD TYPE VIRUS(2,5)
WILD TYPE BVD VIRUS(2,5)
NPRO CODING SEQUENCE END(2,4)
BVDV CAUSED INFECTION(2,2)
COLD SPRING(2,2)
DEXTROSE(2,2)
DISTINCTION(2,2)
IMMUNOLOGY(2,2)
INTRANASAL(2,2)
PRIOR VACCINATION ATTENUATED VIRUS(2,2)
PURIFIED FRAGMENT EQUAL VOLUME(2,2)
VAGINAL ADMINISTRATION(2,2)
VIRAL INFECTION(2,2)
VIRAL RNA SEQUENCE(2,2)
ALUMINUM HYDROXIDE GEL(2,1)
BLOT ANALYSIS(2,1)
BVD PRESENCE(2,1)
CARBOXYL TERMINAL HYDROLASE(2,1)
CATTLE CONDITION(2,1)
CELL LYSATE(2,1)
CHEMICAL COMPONENT(2,1)
CHEMICAL MUTAGEN(2,1)
CONSTRUCT GENERATION(2,1)
DEGENERATE NUCLEIC ACID SEQUENCE(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
DRAMATIC REDUCTION(2,1)
FUSION SEQUENCE(2,1)
GENOTYPE ANALYSIS(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
INFECTED SUBJECT(2,1)
LABORATORY SAMPLE(2,1)
LESS ATTENUATED BVDV VIRUS(2,1)
MAMMALIAN CELL(2,1)
MLV VACCINE SINGLE DOSE(2,1)
MOLECULAR CLONE(2,1)
MONOCLONAL ANTIBODY TECHNOLOGY(2,1)
MURAMYL DIPEPTIDE(2,1)
NON TRANSLATED REGION(2,1)
NPRO PROTEIN FUNCTION(2,1)
OPTIMEM VOLUME(2,1)
P15ADI REGION(2,1)
PARTIAL CODING SEQUENCE(2,1)
PARTIAL NPRO SEQUENCE(2,1)
(CA2363493)
BOVINE VIRAL DIARRHEA VIRUS(100,66)
BOVINE VIRAL DIARRHEA(100,61)
VIRUS(100,52)
GENOMIC NUCLEIC ACID MOLECULE(100,15)
VECTOR(100,15)
BVD VIRUS ATTENUATION(100,6)
ISOLATED NUCLEIC ACID MOLECULE(100,4)
ATTENUATED FORM(100,3)
WILD TYPE INSULATION(100,3)
PTA(100,1)
MONOMERIC BOVINE UBIQUITIN(98,12)
HOMOLOGOUS VIRUS STRAIN(87,3)
PRO CODING(86,8)
PRO PROTEASE GENE(69,3)
BVD VIRUS ORIGIN(63,4)
VIRAL GENOME(56,15)
UBIQUITIN CODING SEQUENCE(48,7)
CODING SEQUENCE(45,44)
CORE PROTEIN CODING SEQUENCE(40,7)
BOVINE UBIQUITIN GENE(38,3)
VACCINE(37,30)
ATTENUATED BVD VIRUS(36,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(34,1)
IMMUNOGENIC COMPOSITION(31,1)
VETERINARILY ACCEPTABLE CARRIER(30,8)
MUTATED NR(29,2)
DEGENERATE(28,3)
PROPROTEIN(28,2)
GASTROINTESTINAL DISEASE(27,1)
BOVINE UBIQUITIN CODING SEQUENCE(26,1)
MEDICAMENT PREPARATION(25,2)
MUTATION(23,16)
MODIFIED GENOME(23,1)
ANIMAL SUBJECT(22,14)
ATTENUATED VIRUS(22,11)
ATTENUATED BOVINE VIRAL DIARRHEA(22,4)
CODING REGION INSERTION(19,2)
DISEASE(18,2)
ISOLATED VIRUS(16,1)
MICROORGANISM(16,1)
GENOMIC SEQUENCE(15,9)
PRIOR VACCINATION ATTENUATED VIRUS(15,3)
BVD(15,2)
NI REGION(15,2)
GM2RB(15,1)
VIRAL CORE PROTEIN(14,3)
FETUS(14,1)
PNEUMONIA(14,1)
INFECTION(13,8)
BVDV INFECTIOUS CLONE(13,3)
UBIQUITIN CODING SEQUENCE PRESENCE(13,2)
BARBER(13,1)
BOVINE VIRAL DIARRHEA DN(12,39)
GENOMIC NUCLEIC ACID SEQUENCE(12,1)
THERAPEUTIC(11,1)
DELETION(10,11)
IMMUNOHISTOCHEMISTRY ASSAY(10,5)
BVDV INFECTION SYMPTOM(10,2)
VIRUS NEUTRALIZING SERUM ANTIBODY(10,2)
PLASMID(9,16)
RESTRICTION ENZYME DIGESTION(9,3)
BVDV VIRULENT STRAIN(9,2)
INTESTINAL MUCOSA ULCERATION(9,1)
ARTIFICIAL SEQUENCE(8,12)
INFECTIOUS VIRUS PARTICLE(8,3)
ISOLATED GENOMIC NUCLEIC MOLECULE(8,3)
DNA PLASMID POPULATION(8,2)
PLASMID P15ADLUBIN MODIFICATION(8,2)
PROKARYOTIC CELL(8,2)
ALLEGED VACCINEASSOCIATED OUTBREAK EVENT(8,1)
VIRAL POLYPROTEIN PRECURSOR TRANSLATION(8,1)
VET(7,10)
GENE(7,9)
MDBK CELL(7,9)
EXTRA NUCLEOTIDE(7,5)
RNA TRANSFECTION(7,4)
STRAIN(7,4)
LIGATION REACTION ALIQUOT(7,3)
UBIQUITIN MONOMER(7,3)
ROCHE MOLECULAR BIOCHEMICAL(7,2)
SUBVIRAL REPLICON(7,2)
BVDV GENOME NUCLEOTIDE(7,1)
CALF BIRTH(7,1)
PREGNANT CATTLE PLACENTA(7,1)
QIAQUICK KIT PURIFIED FRAGMENT(7,1)
PLASMID GENERATION(6,4)
PARENT PLASMID(6,3)
BOVINE POLYUBIQUITIN SEQUENCE(6,2)
HETEROLOGOUS COLONY(6,2)
IMMUNOHISTOCHEMICAL ASSAY(6,2)
TRANSFECTED CELL MONOLAYER(6,2)
VIRUS GROWTH KINETICS(6,2)
ATTENUATED BDV VIRUS(6,1)
BOVINE DONOR CALF SERUM(6,1)
BOVINE UBIQUITIN CLONING(6,1)
BOVINE UBIQUITIN GENE INSERTION(6,1)
BVDV INFECTION INCIDENCE(6,1)
BVDV RNA TRANSCRIPTION(6,1)
CHIMERIC VIRAL GENOME(6,1)
DIAGNOSIS(6,1)
INFECTED RD MONOLAYER(6,1)
MONOMERIC BOVINE UBIQUITIN INSERTION(6,1)
POLYMERASE CHAIN REACTION FRAGMENT(5,20)
INFECTION RISK(5,3)
PURIFICATION KIT(5,3)
VIRUS BOVINE VIRAL DIARRHEA(5,3)
BVDV CONSTRUCT(5,2)
BVDV PROTEIN(5,2)
INOCULATED ANIMAL(5,2)
INTRALYMPH NODE(5,2)
MANUFACTURER INSTRUCTION(5,2)
PARTIAL BVDV GENOMIC SEQUENCE(5,2)
16HRS POSTINFECTION(5,1)
48HRS POSTINFECTION(5,1)
BVDV INFECTION TREATMENT(5,1)
DNA FRAGMENT LIGATION(5,1)
DNE VIRAL CLONE(5,1)
ELITE ABC KIT(5,1)
EMBRYONIC BOVINE TRACHEA CELL(5,1)
FRESH MDBK MONOLAYER(5,1)
ISOLATED WILD TYPE GENOME(5,1)
LIPID AMINE ADJUVANT(5,1)
MADIN DARBY KIDNEY CELL(5,1)
MONOMERIC UBIQUITIN INTRODUCTION(5,1)
OLIGONUCLEOTIDE NADLC(5,1)
OLIGONUDEOTIDE PRIMER SEQUENCE(5,1)
PESTIVIRUS GENUS(5,1)
PROGENY VIRUS ATTENUATION(5,1)
RESTRICTION ENZYME SAC(5,1)
SUBCONFLUENT MONOLAYER(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
VECTOR PLASMID PVV(5,1)
VIRAL GENOME GENE(5,1)
VIRUS ACCELERATED ELIMINATION(5,1)
NATIONAL ANIMAL DISEASE LABORATORY(4,38)
POLYMERASE CHAIN REACTION AMPLIFICATION(4,12)
TOPOLOGY(4,12)
FINAL CONCENTRATION(4,6)
NUCLEIC ACID MOLECULE(4,6)
AUTOEXTENSION(4,5)
ENGLAND BIOLAB(4,5)
GENE CLEAN(4,3)
PHENOTYPE ANALYSIS(4,3)
DETECTED VIRAL PROTEIN(4,2)
HUMORAL IMMUNE RESPONSE(4,2)
MINI DNA PURIFICATION(4,2)
PARENTERAL ROUTE(4,2)
PROTEASE GENE(4,2)
SUPPORTED VIRAL RNA REPLICATION(4,2)
VIRAL REPLICATION RATE(4,2)
VIRUS REPLICATION(4,2)
950BP FRAGMENT(4,1)
ADMINISTRATIONCAN ROUTE(4,1)
AGENT FACILITATING CELLULAR UPTAKE(4,1)
AMPHIGEN ADJUVANT(4,1)
BOVINE TURBINATE CELL(4,1)
BOVPOUBA SEQUENCE NUMBERING(4,1)
BVDV GENOME SEQUENCE(4,1)
BVDV IDENTIFICATION(4,1)
BVDV PLAQUE(4,1)
BVDV STRUCTURAL GENE(4,1)
BVDVNADL CODING SEQUENCE(4,1)
BVDVNADL CORE PROTEIN(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CLASSICAL SWINE FEVER(4,1)
CLEANED VECTOR FRAGMENT(4,1)
CONFERENCE RE PROCEEDING(4,1)
DONE PVV AMPLIFICATION(4,1)
FLANKING SEQUENCE ENCOMPASSING(4,1)
FLAVIVIRIDAE FAMILY(4,1)
INFECTED CATTLE EXHIBIT(4,1)
LABILE ENTEROTOXIN(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
NUCLEOTIDE DELETION(4,1)
PC DOS MS DOS(4,1)
PLASMID P15ADI(4,1)
PROTEOLYTIC CLEAVAGE(4,1)
RESCUED VIRUS NATURE(4,1)
RESPONDING CTL DETECTION(4,1)
UBIQUITIN SEQUENCE FUSION(4,1)
ULTRACENTRIFUGATION PRECIPITATION(4,1)
VACCINATED CATTLE(4,1)
VETERINARY PHYSICIAN(4,1)
VIRUS FETAL TRANSMISSION(4,1)
SHEEP(3,6)
BIOTYPE(3,3)
MONOCLONAL ANTIBODY(3,3)
PLASMID CONSTRUCTION(3,3)
R CODING SEQUENCE(3,3)
RD CELL(3,3)
STRANDEDNESS(3,3)
SUBSTITUTION(3,3)
VIRUS TITER(3,3)
ACTIVE INGREDIENT(3,2)
AGAROSE GEL(3,2)
ANTIBODY PRESENCE(3,2)
COIL STRAIN(3,2)
IMMUNOGENICITY(3,2)
INTACT N TERMINUS(3,2)
ISOTONIC AGENT(3,2)
OVERLAPPING SEQUENCE(3,2)
PLASMID STABILITY(3,2)
VIRAL RNA SEQUENCE(3,2)
ADSORPTION DELAYING(3,1)
AMPLIFIED FRAGMENT(3,1)
ANTIBODY TITER(3,1)
BIOTECX LABORATORY(3,1)
BOVINE POLYUBIQUITIN DNA SEQUENCE(3,1)
BOVINE VIRAL DIARRHEA INCORPORATION(3,1)
BOVINE VIRAL DIARRHEA VACCINE(3,1)
BVDV CODING REGION(3,1)
BVDV STRAIN(3,1)
BVDVNADL CORE CODING REGION(3,1)
BVNDN VIRAL RNA(3,1)
CAMBRIDGE MA(3,1)
CATIONIC LIPID(3,1)
CELL DUSTER(3,1)
CELLULAR RNA ALIQUOT(3,1)
CELLULAR UBIQUITIN(3,1)
CHOLERA TOXIN(3,1)
CLINICAL SYNDROME VARIETY(3,1)
CONSTRUCT DERIVATIVE(3,1)
CORRECT DELETION(3,1)
CORRESPONDENCE ADDRESS(3,1)
DELETION SITE(3,1)
DIGESTED FRAGMENT(3,1)
DL UBIN(3,1)
DOSAGE REGIMEN(3,1)
EARLY PASSAGE VIRUS STOCK(3,1)
EFFICIENT TRANSLATION INITIATION(3,1)
EMERYVILLE CA(3,1)
ENVELOPE PROTEIN(3,1)
EUKARYOTIC HOST CELL(3,1)
FOLD GREAT AFFINITY(3,1)
GEL ELECTROPHORESIS(3,1)
GENERATING VIRUS STOCK(3,1)
GENOMIC ELEMENT DELETION(3,1)
GENOMIC RNA(3,1)
GENTLE ROCKING(3,1)
GROWTH PHENOTYPE(3,1)
IM GENE(3,1)
IMMUNITY DURATION(3,1)
IMMUNOMODULATORY AGENT(3,1)
INDUCTION INDICATIVE(3,1)
INFECTED CELL CLUSTER(3,1)
INFECTION ROUND(3,1)
INFECTIVITY FALL(3,1)
INJECTION SCHEDULE(3,1)
INTESTINAL ALKALINE PHOSPHATASE(3,1)
INTRACELLULAR EXTRACT(3,1)
MAJOR GENOTYPE(3,1)
MARKER GENE(3,1)
MEGA SCRIPT(3,1)
MODIFIED LIVE VIRAL VACCINE(3,1)
MODIFIED VIRAL GENOME(3,1)
MUTATED NIP(3,1)
MUTATION INTRODUCTION(3,1)
NEIGHBOR CELL(3,1)
NI REGION CODING(3,1)
OPTIMAL IMMUNIZATION(3,1)
P15A CLONE(3,1)
PARENT VIRUS(3,1)
PARENTAL RNA(3,1)
PI 5A VECTOR(3,1)
PLAQUE ASSAY(3,1)
PLASMID P15AD1UBIN CONSTRUCTION(3,1)
PLASMID PROPAGATION(3,1)
POLYMERASE PROMOTER(3,1)
POST TRANSFECTION(3,1)
PROKARYOTIC HOST CELL(3,1)
PROTEIN EXPRESSION(3,1)
PW DERIVATIVE(3,1)
RAISING ANTIBODY(3,1)
RANDOM MUTAGENESIS(3,1)
REPLICATION ORIGIN(3,1)
RNA ENCODING(3,1)
RNA MOLECULE(3,1)
RNA REAGENT(3,1)
SAPONIN FRACTION(3,1)
TEMPLATE DNA(3,1)
TISSUE CULTURE FLASK(3,1)
TRANSFECTION RNA LIPID MIXTURE(3,1)
UBIQUITIN CODING REGION(3,1)
UBIQUITIN CODING SEQUENCE INSERTION(3,1)
UBIQUITIN FUSION REGION(3,1)
UBIQUITIN FUSION SEQUENCE(3,1)
UNIQUE PINA(3,1)
UNIQUE RESTRICTION ENZYME(3,1)
VECTOR LABORATORY(3,1)
VECTOR PLASMID PREPARATION(3,1)
VECTOR PROPAGATION(3,1)
VECTOR PVV(3,1)
VIRAL ENZYME(3,1)
VIRAL STRAIN(3,1)
VIRICIDAL AGENT(3,1)
VIRUS TITRATION(3,1)
WESTERN BLOT(3,1)
D1NS(2,5)
PARENT WILD TYPE VIRUS(2,5)
COLD SPRING(2,2)
DEXTROSE(2,2)
DISTINCTION(2,2)
INTRANASAL(2,2)
PHI DNA POLYMERASE UNIT(2,2)
PURIFIED FRAGMENT EQUAL VOLUME(2,2)
VAGINAL ADMINISTRATION(2,2)
VIRAL INFECTION(2,2)
VIROLOGY(2,2)
ANTIBODY TECHNOLOGY(2,1)
BLOT ANALYSIS(2,1)
BOVINE VIRAL DIARRHEA GENOME(2,1)
BOVINE VIRAL DIARRHEA INFECTION(2,1)
BOVINE VIRAL DIARRHEA PROTEIN(2,1)
BVDV SEQUENCE(2,1)
CARBOXYL TERMINAL HYDROLASE(2,1)
CATTLE CONDITION(2,1)
CELL LYSATE(2,1)
CHEMICAL COMPONENT(2,1)
CHEMICAL MUTAGEN(2,1)
CLONED NUCLEIC ACID(2,1)
COLI CELL(2,1)
CONSTRUCT GENERATION(2,1)
DEGENERATE NUCLEIC ACID SEQUENCE(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
DRAMATIC REDUCTION(2,1)
FILING DATE(2,1)
FORWARD PRIMER(2,1)
FULL CODING SEQUENCE DELETION(2,1)
GENOTYPE ANALYSIS(2,1)
IBM PC(2,1)
INFECTED SUBJECT(2,1)
LABORATORY SAMPLE(2,1)
LESS ATTENUATED BVDV VIRUS(2,1)
MAMMALIAN CELL(2,1)
MOLECULAR CLONE(2,1)
MURAMYL DIPEPTIDE(2,1)
MUTATION PRESENCE(2,1)
NONTRANSLATED REGION(2,1)
OLIGONUCLEOTIDE PRIMER SEQUENCE(2,1)
OPTIMEM VOLUME(2,1)
P15ADI REGION(2,1)
P1O SEQUENCE(2,1)
PARTIAL CODING SEQUENCE(2,1)
PARTIAL DELETION(2,1)
PFIZER PRODUCT INC(2,1)
PFU DNA POLYMERASE UNIT(2,1)
PLASMID SEQUENCE FULL(2,1)
PLATINUM COMPLEX(2,1)
PORCINE CELL(2,1)
PR CODING REGION(2,1)
PRIMARY IMMUNIZATION(2,1)
PROGENY PRODUCTION(2,1)
RIBI INC(2,1)
SAFETY(2,1)
SITE DIRECTED MUTAGENESIS(2,1)
(CA2363493)
BOVINE VIRAL DIARRHEA VIRUS(100,66)
BOVINE VIRAL DIARRHEA(100,60)
VIRUS(100,52)
GENOMIC NUCLEIC ACID MOLECULE(100,15)
VECTOR(100,15)
BVD VIRUS ATTENUATION(100,6)
ISOLATED NUCLEIC ACID MOLECULE(100,4)
ATTENUATED FORM(100,3)
WILD TYPE INSULATION(100,3)
PTA(100,1)
MONOMERIC BOVINE UBIQUITIN(89,12)
HOMOLOGOUS VIRUS STRAIN(86,3)
PRO CODING(85,8)
PRO PROTEASE GENE(81,3)
BVD VIRUS ORIGIN(62,4)
VIRAL GENOME(51,15)
BOVINE UBIQUITIN CODING SEQUENCE(47,1)
UBIQUITIN CODING SEQUENCE(42,7)
CODING SEQUENCE(40,44)
BOVINE UBIQUITIN GENE(38,3)
VACCINE(37,30)
ATTENUATED BVD VIRUS(36,1)
CORE PROTEIN CODING SEQUENCE(35,7)
CATTLE ECONOMICALLY IMPORTANT DISEASE(33,1)
IMMUNOGENIC COMPOSITION(31,1)
VETERINARILY ACCEPTABLE CARRIER(30,8)
DEGENERATE(28,3)
PROPROTEIN(28,2)
GASTROINTESTINAL DISEASE(27,1)
MEDICAMENT PREPARATION(25,2)
MUTATION(23,16)
MODIFIED GENOME(23,1)
ANIMAL SUBJECT(22,14)
ATTENUATED VIRUS(22,11)
ATTENUATED BOVINE VIRAL DIARRHEA(22,4)
BVD(18,2)
CODING REGION INSERTION(18,2)
DISEASE(18,2)
MUTATED NR(17,2)
GENOMIC SEQUENCE(15,9)
PRIOR VACCINATION ATTENUATED VIRUS(15,3)
NI REGION(15,2)
GM2RB(15,1)
ISOLATED VIRUS(15,1)
MICROORGANISM(15,1)
VIRAL CORE PROTEIN(14,3)
FETUS(14,1)
PNEUMONIA(14,1)
INFECTION(13,8)
UBIQUITIN CODING SEQUENCE PRESENCE(13,2)
BARBER(13,1)
BVDV INFECTIOUS CLONE(12,3)
GENOMIC NUCLEIC ACID SEQUENCE(12,1)
BOVINE VIRAL DIARRHEA DN(11,39)
DELETION(10,11)
IMMUNOHISTOCHEMISTRY ASSAY(10,5)
BVDV INFECTION SYMPTOM(10,2)
THERAPEUTIC(10,1)
PLASMID(9,16)
RESTRICTION ENZYME DIGESTION(9,3)
BVDV VIRULENT STRAIN(9,2)
VIRUS NEUTRALIZING SERUM ANTIBODY(9,2)
ARTIFICIAL SEQUENCE(8,12)
INFECTIOUS VIRUS PARTICLE(8,3)
ISOLATED GENOMIC NUCLEIC MOLECULE(8,3)
DNA PLASMID POPULATION(8,2)
PLASMID P15ADLUBIN MODIFICATION(8,2)
PROKARYOTIC CELL(8,2)
ALLEGED VACCINEASSOCIATED OUTBREAK EVENT(8,1)
INTESTINAL MUCOSA ULCERATION(8,1)
VIRAL POLYPROTEIN PRECURSOR TRANSLATION(8,1)
VET(7,10)
GENE(7,9)
MDBK CELL(7,9)
EXTRA NUCLEOTIDE(7,5)
RNA TRANSFECTION(7,4)
STRAIN(7,4)
LIGATION REACTION ALIQUOT(7,3)
UBIQUITIN MONOMER(7,3)
ROCHE MOLECULAR BIOCHEMICAL(7,2)
SUBVIRAL REPLICON(7,2)
BVDV GENOME NUCLEOTIDE(7,1)
CALF BIRTH(7,1)
PREGNANT CATTLE PLACENTA(7,1)
QIAQUICK KIT PURIFIED FRAGMENT(7,1)
PLASMID GENERATION(6,4)
PARENT PLASMID(6,3)
BOVINE POLYUBIQUITIN SEQUENCE(6,2)
HETEROLOGOUS COLONY(6,2)
IMMUNOHISTOCHEMICAL ASSAY(6,2)
TRANSFECTED CELL MONOLAYER(6,2)
VIRUS GROWTH KINETICS(6,2)
ATTENUATED BDV VIRUS(6,1)
BOVINE DONOR CALF SERUM(6,1)
BOVINE UBIQUITIN CLONING(6,1)
BOVINE UBIQUITIN GENE INSERTION(6,1)
BVDV INFECTION INCIDENCE(6,1)
BVDV RNA TRANSCRIPTION(6,1)
CHIMERIC VIRAL GENOME(6,1)
DIAGNOSIS(6,1)
INFECTED RD MONOLAYER(6,1)
MONOMERIC BOVINE UBIQUITIN INSERTION(6,1)
POLYMERASE CHAIN REACTION FRAGMENT(5,20)
INFECTION RISK(5,3)
PURIFICATION KIT(5,3)
VIRUS BOVINE VIRAL DIARRHEA(5,3)
BVDV CONSTRUCT(5,2)
BVDV PROTEIN(5,2)
INOCULATED ANIMAL(5,2)
INTRALYMPH NODE(5,2)
MANUFACTURER INSTRUCTION(5,2)
PARTIAL BVDV GENOMIC SEQUENCE(5,2)
16HRS POSTINFECTION(5,1)
48HRS POSTINFECTION(5,1)
BVDV INFECTION TREATMENT(5,1)
DNA FRAGMENT LIGATION(5,1)
DNE VIRAL CLONE(5,1)
ELITE ABC KIT(5,1)
EMBRYONIC BOVINE TRACHEA CELL(5,1)
FRESH MDBK MONOLAYER(5,1)
ISOLATED WILD TYPE GENOME(5,1)
LIPID AMINE ADJUVANT(5,1)
MADIN DARBY KIDNEY CELL(5,1)
MONOMERIC UBIQUITIN INTRODUCTION(5,1)
OLIGONUCLEOTIDE NADLC(5,1)
OLIGONUDEOTIDE PRIMER SEQUENCE(5,1)
PESTIVIRUS GENUS(5,1)
PROGENY VIRUS ATTENUATION(5,1)
RESTRICTION ENZYME SAC(5,1)
SUBCONFLUENT MONOLAYER(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
VECTOR PLASMID PVV(5,1)
VIRAL GENOME GENE(5,1)
VIRUS ACCELERATED ELIMINATION(5,1)
NATIONAL ANIMAL DISEASE LABORATORY(4,38)
POLYMERASE CHAIN REACTION AMPLIFICATION(4,12)
TOPOLOGY(4,12)
FINAL CONCENTRATION(4,6)
NUCLEIC ACID MOLECULE(4,6)
AUTOEXTENSION(4,5)
ENGLAND BIOLAB(4,5)
GENE CLEAN(4,3)
PHENOTYPE ANALYSIS(4,3)
DETECTED VIRAL PROTEIN(4,2)
HUMORAL IMMUNE RESPONSE(4,2)
MINI DNA PURIFICATION(4,2)
PARENTERAL ROUTE(4,2)
PROTEASE GENE(4,2)
SUPPORTED VIRAL RNA REPLICATION(4,2)
VIRAL REPLICATION RATE(4,2)
VIRUS REPLICATION(4,2)
950BP FRAGMENT(4,1)
ADMINISTRATIONCAN ROUTE(4,1)
AGENT FACILITATING CELLULAR UPTAKE(4,1)
AMPHIGEN ADJUVANT(4,1)
BOVINE TURBINATE CELL(4,1)
BOVPOUBA SEQUENCE NUMBERING(4,1)
BVDV GENOME SEQUENCE(4,1)
BVDV IDENTIFICATION(4,1)
BVDV PLAQUE(4,1)
BVDV STRUCTURAL GENE(4,1)
BVDVNADL CODING SEQUENCE(4,1)
BVDVNADL CORE PROTEIN(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CLASSICAL SWINE FEVER(4,1)
CLEANED VECTOR FRAGMENT(4,1)
CONFERENCE RE PROCEEDING(4,1)
DONE PVV AMPLIFICATION(4,1)
FLANKING SEQUENCE ENCOMPASSING(4,1)
FLAVIVIRIDAE FAMILY(4,1)
INFECTED CATTLE EXHIBIT(4,1)
LABILE ENTEROTOXIN(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
NUCLEOTIDE DELETION(4,1)
PC DOS MS DOS(4,1)
PLASMID P15ADI(4,1)
PROTEOLYTIC CLEAVAGE(4,1)
RESCUED VIRUS NATURE(4,1)
RESPONDING CTL DETECTION(4,1)
UBIQUITIN SEQUENCE FUSION(4,1)
ULTRACENTRIFUGATION PRECIPITATION(4,1)
VACCINATED CATTLE(4,1)
VETERINARY PHYSICIAN(4,1)
VIRUS FETAL TRANSMISSION(4,1)
SHEEP(3,6)
BIOTYPE(3,3)
MONOCLONAL ANTIBODY(3,3)
PLASMID CONSTRUCTION(3,3)
R CODING SEQUENCE(3,3)
RD CELL(3,3)
STRANDEDNESS(3,3)
SUBSTITUTION(3,3)
VIRUS TITER(3,3)
ACTIVE INGREDIENT(3,2)
AGAROSE GEL(3,2)
ANTIBODY PRESENCE(3,2)
COIL STRAIN(3,2)
IMMUNOGENICITY(3,2)
INTACT N TERMINUS(3,2)
ISOTONIC AGENT(3,2)
OVERLAPPING SEQUENCE(3,2)
PLASMID STABILITY(3,2)
VIRAL RNA SEQUENCE(3,2)
ADSORPTION DELAYING(3,1)
AMPLIFIED FRAGMENT(3,1)
ANTIBODY TITER(3,1)
BIOTECX LABORATORY(3,1)
BOVINE POLYUBIQUITIN DNA SEQUENCE(3,1)
BOVINE VIRAL DIARRHEA INCORPORATION(3,1)
BOVINE VIRAL DIARRHEA VACCINE(3,1)
BVDV CODING REGION(3,1)
BVDV STRAIN(3,1)
BVDVNADL CORE CODING REGION(3,1)
BVNDN VIRAL RNA(3,1)
CAMBRIDGE MA(3,1)
CATIONIC LIPID(3,1)
CELL DUSTER(3,1)
CELLULAR RNA ALIQUOT(3,1)
CELLULAR UBIQUITIN(3,1)
CHOLERA TOXIN(3,1)
CLINICAL SYNDROME VARIETY(3,1)
CONSTRUCT DERIVATIVE(3,1)
CORRECT DELETION(3,1)
CORRESPONDENCE ADDRESS(3,1)
DELETION SITE(3,1)
DIGESTED FRAGMENT(3,1)
DL UBIN(3,1)
DOSAGE REGIMEN(3,1)
EARLY PASSAGE VIRUS STOCK(3,1)
EFFICIENT TRANSLATION INITIATION(3,1)
EMERYVILLE CA(3,1)
ENVELOPE PROTEIN(3,1)
EUKARYOTIC HOST CELL(3,1)
FOLD GREAT AFFINITY(3,1)
GEL ELECTROPHORESIS(3,1)
GENERATING VIRUS STOCK(3,1)
GENOMIC ELEMENT DELETION(3,1)
GENOMIC RNA(3,1)
GENTLE ROCKING(3,1)
GROWTH PHENOTYPE(3,1)
IM GENE(3,1)
IMMUNITY DURATION(3,1)
IMMUNOMODULATORY AGENT(3,1)
INDUCTION INDICATIVE(3,1)
INFECTED CELL CLUSTER(3,1)
INFECTION ROUND(3,1)
INFECTIVITY FALL(3,1)
INJECTION SCHEDULE(3,1)
INTESTINAL ALKALINE PHOSPHATASE(3,1)
INTRACELLULAR EXTRACT(3,1)
MAJOR GENOTYPE(3,1)
MARKER GENE(3,1)
MEGA SCRIPT(3,1)
MODIFIED LIVE VIRAL VACCINE(3,1)
MODIFIED VIRAL GENOME(3,1)
MUTATED NIP(3,1)
MUTATION INTRODUCTION(3,1)
NEIGHBOR CELL(3,1)
NI REGION CODING(3,1)
OPTIMAL IMMUNIZATION(3,1)
P15A CLONE(3,1)
PARENT VIRUS(3,1)
PARENTAL RNA(3,1)
PI 5A VECTOR(3,1)
PLAQUE ASSAY(3,1)
PLASMID P15AD1UBIN CONSTRUCTION(3,1)
PLASMID PROPAGATION(3,1)
POLYMERASE PROMOTER(3,1)
POST TRANSFECTION(3,1)
PROKARYOTIC HOST CELL(3,1)
PROTEIN EXPRESSION(3,1)
PW DERIVATIVE(3,1)
RAISING ANTIBODY(3,1)
RANDOM MUTAGENESIS(3,1)
REPLICATION ORIGIN(3,1)
RNA ENCODING(3,1)
RNA MOLECULE(3,1)
RNA REAGENT(3,1)
SAPONIN FRACTION(3,1)
TEMPLATE DNA(3,1)
TISSUE CULTURE FLASK(3,1)
TRANSFECTION RNA LIPID MIXTURE(3,1)
UBIQUITIN CODING REGION(3,1)
UBIQUITIN CODING SEQUENCE INSERTION(3,1)
UBIQUITIN FUSION REGION(3,1)
UBIQUITIN FUSION SEQUENCE(3,1)
UNIQUE PINA(3,1)
UNIQUE RESTRICTION ENZYME(3,1)
VECTOR LABORATORY(3,1)
VECTOR PLASMID PREPARATION(3,1)
VECTOR PROPAGATION(3,1)
VECTOR PVV(3,1)
VIRAL ENZYME(3,1)
VIRAL STRAIN(3,1)
VIRICIDAL AGENT(3,1)
VIRUS TITRATION(3,1)
WESTERN BLOT(3,1)
D1NS(2,5)
PARENT WILD TYPE VIRUS(2,5)
COLD SPRING(2,2)
DEXTROSE(2,2)
DISTINCTION(2,2)
INTRANASAL(2,2)
PHI DNA POLYMERASE UNIT(2,2)
PURIFIED FRAGMENT EQUAL VOLUME(2,2)
VAGINAL ADMINISTRATION(2,2)
VIRAL INFECTION(2,2)
VIROLOGY(2,2)
ANTIBODY TECHNOLOGY(2,1)
BLOT ANALYSIS(2,1)
BOVINE VIRAL DIARRHEA GENOME(2,1)
BOVINE VIRAL DIARRHEA INFECTION(2,1)
BOVINE VIRAL DIARRHEA PROTEIN(2,1)
BVDV SEQUENCE(2,1)
CARBOXYL TERMINAL HYDROLASE(2,1)
CATTLE CONDITION(2,1)
CELL LYSATE(2,1)
CHEMICAL COMPONENT(2,1)
CHEMICAL MUTAGEN(2,1)
CLONED NUCLEIC ACID(2,1)
COLI CELL(2,1)
CONSTRUCT GENERATION(2,1)
DEGENERATE NUCLEIC ACID SEQUENCE(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
DRAMATIC REDUCTION(2,1)
FILING DATE(2,1)
FORWARD PRIMER(2,1)
FULL CODING SEQUENCE DELETION(2,1)
GENOTYPE ANALYSIS(2,1)
IBM PC(2,1)
INFECTED SUBJECT(2,1)
LABORATORY SAMPLE(2,1)
LESS ATTENUATED BVDV VIRUS(2,1)
MAMMALIAN CELL(2,1)
MOLECULAR CLONE(2,1)
MURAMYL DIPEPTIDE(2,1)
MUTATION PRESENCE(2,1)
NONTRANSLATED REGION(2,1)
OLIGONUCLEOTIDE PRIMER SEQUENCE(2,1)
OPTIMEM VOLUME(2,1)
P15ADI REGION(2,1)
P1O SEQUENCE(2,1)
PARTIAL CODING SEQUENCE(2,1)
PARTIAL DELETION(2,1)
PFIZER PRODUCT INC(2,1)
PFU DNA POLYMERASE UNIT(2,1)
PLASMID SEQUENCE FULL(2,1)
PLATINUM COMPLEX(2,1)
PORCINE CELL(2,1)
PR CODING REGION(2,1)
PRIMARY IMMUNIZATION(2,1)
PROGENY PRODUCTION(2,1)
RIBI INC(2,1)
SAFETY(2,1)
SITE DIRECTED MUTAGENESIS(2,1)";"Analysis of biological materials
Pharmaceuticals";Open
"2000-07-13
2002-12-18";"US6541013           B1 2003-04-01 [US6541013]
STG: (B1) Granted patent as first publication
AP : 2000US-09615179 2000-07-13
US20030152593       A1 2003-08-14 [US20030152593]
STG: (A1) Application published
AP : 2002US-10325664 2002-12-18
US7135173           B2 2006-11-14 [US7135173]
STG: (B2) Granted patent as second publication
AP : 2002US-10325664 2002-12-18
FD :  CIP of: US09/615,179 FDD=2000-07-13 [2000US-09615179]
FD : CIP of: US6541013 A 0 [US6541013]
FD : Previous publication: US20030152593 A1 2003-08-14 [US20030152593]";43295928;"US6541013           B1 2003-04-01 [US6541013]
US20030152593       A1 2003-08-14 [US20030152593]
US7135173           B2 2006-11-14 [US7135173]";"2000US-09615179
2002US-10325664";;IDAHO RESEARCH FOUNDATION;IDAHO RESEARCH FOUNDATION;"(US6541013)
US
(US7135173)
US";"(US6541013)
NAME=Idaho Research Foundation, Inc. , CITY=Moscow , STATE=ID , COUNTRY=US , ATYP=US Company 

(US20030152593)
NAME=Idaho Research Foundation, Inc. , ATYP=US Company 

(US7135173)
NAME=Idaho Research Foundation, Inc. , CITY=Moscow , STATE=ID , COUNTRY=US , ATYP=US Company 
";1;"BOHACH CAROLYN H
FERENS WITOLD A";"(US20030152593)
US
(US7135173)
US";"(US20030152593)
NAME=Bohach Carolyn H. , CITY=Moscow , STATE=ID , COUNTRY=US 

NAME=Ferens Witold A. , CITY=Moscow , STATE=ID , COUNTRY=US 

(US7135173)
NAME=Bohach Carolyn H. , CITY=Moscow , STATE=ID , COUNTRY=US 

NAME=Ferens Witold A. , CITY=Moscow , STATE=ID , COUNTRY=US 
";"(US7135173)
Antiviral activity of Shiga toxin";"(US7135173)
The present invention provides methods and compositions for eliminating virally-infected cells by administering a Shiga-toxin composition, and the present invention provides methods and compositions for suppressing bovine leukemia-related cell proliferation. In the methods, a Shiga-toxin composition is administered in an amount effective to suppress bovine leukemia-related cell proliferation. The Shiga-toxin composition can include a Shiga-toxin polypeptide; a probiotic microorganism expressing a Shiga-toxin polypeptide; or a transgenic plant expressing a Shiga-toxin polypeptide. In one embodiment, the Shiga-toxin polypeptide is Stx1A and, in another embodiment, the Shiga-toxin polypeptide is Stx1 holotoxin. In yet a further embodiment, the Shiga-toxin polypeptide comprises Stx2.";"(US6541013)
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A method for suppressing bovine leukemia virus-related cell proliferation in an animal subject, comprising administering an amount of a composition comprising a Stx1A polypeptide to the animal effective to suppress bovine leukemia virus-related cell proliferation.
2. The method of claim 1, wherein the animal subject is a ruminant.
3. A method for treating a bovine leukemia virus-related disorder in an animal subject, comprising administering to the animal subject an amount of a composition comprising a Stx1A polypeptide effective to suppress bovine leukemia virus-related cell proliferation in the animal subject.
4. The method of claim 3, wherein the bovine leukemia virus-related disorder comprises persistent lymphocytosis.
5. The method of claim 3, wherein the bovine leukemia virus-related disorder comprises malignant lymphoma.
6. The method of claim 3, wherein the bovine leukemia virus-related disorder comprises the progression of viral infection.
7. The method of claim 3, wherein the animal subject is a ruminant.
8. A method for treating a cell, comprising administering to the cell an amount of a Stx1A polypeptide effective to suppress bovine leukemia virus-related cell proliferation.
9. The method of claim 8, wherein the cell is infected with bovine leukemia virus.";"(US7135173)
The present invention provides methods and compositions for eliminating virally-infected cells by administering a Shiga-toxin polypeptide having antiviral activity.
Thus, present invention provides methods and compositions for eliminating cells infected with virus by the administration of Stx polypeptides.
In one aspect, the invention provides methods for eliminating virally-infected cells in a mammalian subject, including administering to a mammalian subject infected with a virus an amount of a Shiga-toxin composition effective to eliminate virally-infected cells.
In another embodiment, the invention provides methods for treating a virus infection in a mammal, including administering to a mammal infected with a virus an amount of a Shiga-toxin composition effective to treat the virus infection.
The present invention provides methods and compositions for suppressing BLV-related cell proliferation by administering a Shiga-toxin polypeptide having antiviral activity.
In one aspect of the invention, methods for suppressing BLV-related lymphocyte proliferation are provided.";"(US7135173)
It will be appreciated that other suitable microorganisms that are harmless to ruminants can be used.
Accordingly, it is desirable to utilize control sequences that are subject to environmental conditions.
BLV infections in cattle are chronic and, in most animals, the disease does not progress to the malignant stage.
Inhibition of SLP by anti-gp51 was due to a specific interaction with viral proteins, because this antibody did not affect IL-2-induced proliferation of BLV-negative PBMC, and control monoclonal antibody of the same isotype had no effect on SLP.
Immun. 67(5):2209 17) and, consequently, the presence of Stx in tissues or body fluids of cattle harboring BLV could benefit these animals, for example, by causing deletion of the BLV-expressing cells, by inhibiting viral expression and propagation, or by inhibiting the transmission of BLV between animals.";"A61K-038/00
A61K-038/16
A61K-038/43
A61K-039/00
A61K-039/02";"(US7135173)
1. A method for eliminating virally-infected cells in a mammalian subject, comprising administering to a mammalian subject infected with a virus an amount of a Shiga-toxin composition consisting essentially of a Shiga-toxin A subunit or an euzymatically-active portion thereof effective to eliminate virally-infected cells, and an acceptable carrier.
8. A method for treating a virus infection in a mammal, comprising administering to a mammal infected with a virus an amount of a Shiga-toxin composition consisting essentially of a Shiga-toxin A subunit or an enzymatically-active portion thereof effective to treat the virus infection, and an acceptable carrier.
15. A method for eliminating virally-infected cells in a ruminant, comprising administering to a ruminant infected with a virus an amount of a Shiga toxin holotoxin effective to eliminate virally-infected cells.
19. A method for treating a virus infection in a ruminant, comprising administering to a ruminant infected with a virus an amount of a Shiga toxin holotoxin effective to treat the virus infection.";"(US6541013)
SHIGA TOXIN POLYPEPTIDE(100,83)
CELL PROLIFERATION(100,15)
BOVINE LEUKEMIA VIRUS(100,11)
A CELL(100,4)
BOVINE LEUKEMIA VIRUS RELATED DISORDER(100,4)
ANIMAL SUBJECT(100,3)
STX1A POLYPEPTIDE(65,3)
BLV INFECTED LYMPHOCYTE(43,2)
BLV DELETION(30,1)
INFECTED COW(26,1)
PROLIFERATION SUPPRESSION(24,2)
ANTIVIRAL ACTIVITY(23,36)
VIRAL EXPRESSION(22,1)
ANIMAL(19,26)
SLP INHIBITION(18,7)
BLV NEGATIVE PBMC(16,2)
VIRAL PROTEIN(15,8)
MALIGNANCY STAGE(15,2)
VIRAL INFECTION PROGRESSION(15,2)
CATTLE HARBORING BODY FLUID(14,1)
RUMINANT(13,16)
BLV RELATED LYMPHOCYTE PROLIFERATION(13,4)
NORMAL BOVINE(13,1)
BLV INFECTED COW(12,9)
HOLOTOXIN SUBUNIT(12,7)
DISEASE(12,1)
MICROORGANISM(11,17)
SLP POTENT SUPPRESSOR(10,3)
POKEWEED ANTIVIRAL PROTEIN(10,2)
BLV INFECTION(9,5)
CYTOTOXIC(9,3)
MONOCLONAL ANTIBODY(9,3)
TRITIATED THYMIDINE INCORPORATION(9,3)
ISOTYPE(9,2)
PROPAGATION(9,2)
PERIPHERAL BLOOD MONONUCLEAR CELL(8,6)
CULTURE PROLIFERATION(8,4)
BLV INFECTED CATTLE EXPRESS(8,2)
BLV PROTEIN DISSEMINATION(8,2)
INFECTION PERSISTENTLY LYMPHOCYTOTIC STAGE(8,2)
PROBIOTIC MICROORGANISM ADMINISTRATION(8,2)
SPONTANEOUS PROLIFERATION INITIATION(8,2)
VIRAL PROTEIN DE NOVO SYNTHESIS(8,2)
VIRAL PROTEIN DISSEMINATION(8,2)
POKEWEED MITOGEN INHIBITION(8,1)
RICINUS COMMUNIS LECTIN(8,1)
SPONTANEOUS LYMPHOCYTE PROLIFERATION SUPPRESSION(8,1)
CULTURE(7,15)
ANTIBODY(7,10)
BLV POSITIVE PBMC CULTURE(7,5)
SLP INITIATION(7,4)
MALIGNANT LYMPHOSARCOMA(7,3)
POTENT SLP INHIBITOR(7,2)
VIRAL PARTICLE DISSEMINATION(7,2)
GUANYLYL CYCLASE DISRUPTION(7,1)
HOG CHOLERA VIRUS PURIFICATION(7,1)
LYMPHOCYTE SPONTANEOUS BLASTOGENESIS(7,1)
PBMC DONOR BLV STATUS(7,1)
SLP(6,14)
CATTLE(6,11)
BLV RELATED CELL PROLIFERATION(6,4)
BACTERIA TRANSFORMATION(6,3)
AGROBACTERIUM TUMIFACIEN(6,2)
BLV EXPRESSION ASSAY(6,2)
BLV PARTICLE EXPRESSION(6,2)
CAULIFLOWER MOSAIC VIRUS(6,2)
NON LETHAL SUPPRESSION(6,2)
RIBOSOME INACTIVATION(6,2)
BLOOD LYMPHOCYTE POPULATION CHARACTERIZATION(6,1)
BLV INFECTION ALLEVIATING SYMPTOM(6,1)
BLV KDA GLYCOPROTEIN(6,1)
BOVINE LYMPHOCYTE SUBPOPULATION PROLIFERATION(6,1)
ENVIRONMENTAL CONDITION(6,1)
IDAHO DAIRY UNIVERSITY(6,1)
INHIBITOR HERBICIDE PHOSPHINOTHRICIN(6,1)
PLANT NUCLEUS DNA(6,1)
SHIGA TOXIN TRANSLOCATION(6,1)
SLP STX1A SUPPRESSION(6,1)
TOXIN MICROBIAL PATHOGENESIS(6,1)
TRANSCRIPTION PHYTOHEMAGGLUTININ ACTIVATION(6,1)
UNSTIMULATED EX VIVO PBMC(6,1)
NON TRANSLATED REGION(5,6)
IMMUNOSTIMULATION(5,5)
MARKER GENE(5,3)
ANTIVIRAL ANTIBODY ABILITY(5,2)
ASYMPTOMATIC INFECTION STAGE(5,2)
BLV INFECTION PROGRESSION(5,2)
BLV NEGATIVE PBMC CULTURE(5,2)
ENVELOPE GLYCOPROTEIN(5,2)
EUKARYOTIC RIBOSOME(5,2)
INOCULANT PASTE(5,2)
MRNA TRANSLATION(5,2)
SLP SUPPRESSION(5,2)
SLP SUSCEPTIBILITY(5,2)
STX1A EXPRESSION(5,2)
TRANSCRIPTION TERMINATION(5,2)
UNINFECTED COW(5,2)
ANTIVIRAL ACTIVITY DEMONSTRATION(5,1)
BLV EXPRESSION SUPPRESSION(5,1)
BOVINE LYMPHOCYTE SUBPOPULATION ACTIVATION(5,1)
CARBOHYDRATE MOIETY VIROLOGY(5,1)
CULTURE EXCEEDED PROLIFERATION(5,1)
CYTOPLASMIC ACCUMULATION POTENTIAL CYTOTOXICITY(5,1)
ENGINEERED MICROORGANISM STRAIN(5,1)
ESCHERICHIA COLI PLASMID TRANSFORMATION(5,1)
EXOGENOUS RNA ONCOGENIC VIRUS(5,1)
EXPRESS RICIN TOXIN(5,1)
GENERIC NON PATHOGENIC BOVINE(5,1)
GENETIC VARIABILITY VIROLOGY(5,1)
HETEROLOGOUS DNA REPLICATION(5,1)
HETEROLOGOUS DNA TRANSCRIPTION(5,1)
HIV REPLICATION INHIBITION(5,1)
HORMONE SOMATOSTATIN SCIENCE(5,1)
LIVE MICROBIAL FEED SUPPLEMENT(5,1)
MAXIMAL SLP SENSITIVITY(5,1)
MOLONEY LEUKEMIA VIRUS(5,1)
NON IMMUNOGLOBULIN PLASMA PROTEIN CHARACTERIZATION(5,1)
PERSISTENT LYMPHOCYTOSIS DEVELOPMENT(5,1)
PROBABLY MINOR SUBPOPULATION(5,1)
PROPAGATION BLV EXPRESSION(5,1)
RECA MINUS LAB STRAIN(5,1)
RIBOSOMAL INHIBITORY PROTEIN(5,1)
RIBOSOME INACTIVATING PROTEIN FAMILY(5,1)
RIBOSOME INACTIVATING PROTEIN PAP(5,1)
RICE ACTIN INTRON(5,1)
RIP ANTIVIRAL ACTIVITY(5,1)
SHIGA TOXIN GENE(5,1)
SLP MEDIATED INHIBITION(5,1)
STAPHYLOCOCCAL ENTEROTOXIN(5,1)
STRONGLY AUGMENTED PROLIFERATION(5,1)
SUBGENOMIC MRNA PROMOTER(5,1)
THERAPEUTIC STRATEGY FEASIBILITY(5,1)
TRYPTOPHAN COMPETITIVE INHIBITION(5,1)
BLV POSITIVE CULTURE(4,4)
TREATED COW(4,4)
BOVINE LEUKEMIA VIRUS EXPRESSION(4,3)
DNA SPLICING(4,3)
TOXIN CONCENTRATION(4,3)
AGROBACTERIUM TRANSFORMATION(4,2)
ANTI HIV ACTIVITY(4,2)
BLV P EXPRESSION(4,2)
BLV PARTICLE RELEASE(4,2)
BOVINE LEUKEMIA VIRUS GENOME(4,2)
BOVINE LEUKEMIA VIRUS INFECTED CATTLE(4,2)
CONFIDENCE INTERVAL(4,2)
CULTURE EVIDENCE(4,2)
ESTABLISHED SLP EVENT(4,2)
GLYCOSIDASE ACTIVITY(4,2)
HOST CHROMOSOME(4,2)
LATENT HERPES SIMPLEX VIRUS(4,2)
MAGNESIUM STEARATE(4,2)
MARGINAL IMPACT(4,2)
MEASURING EXPERIMENT(4,2)
MRNA MOLECULE(4,2)
MURINE MONOCLONAL ANTIBODY(4,2)
NON TRANSLATED LEADER SEQUENCE(4,2)
NUTRITIONAL BENEFIT(4,2)
PLANT EXPRESSION VECTOR(4,2)
PROLIFERATION INDUCTION(4,2)
RETROVIRAL REVERSE TRANSCRIPTASE(4,2)
SPURIOUS INHIBITOR(4,2)
STX1A ABILITY(4,2)
STX1A ACTIVITY(4,2)
STX1A IMPACT(4,2)
STX1B MOLAR CONCENTRATION(4,2)
TOXIN PREPARATION(4,2)
TRANSFORMED PLANT(4,2)
UNINFECTED CELL(4,2)
WESTERN BLOT(4,2)
30B EXPRESSION VECTOR(4,1)
ANTI MOUSE ANTIBODY(4,1)
ANTIBODY NEUTRALIZATION(4,1)
BACTERIUM METH(4,1)
BLV CORE PROTEIN EXPRESSION(4,1)
BLV INDUCED SLP INHIBITOR(4,1)
BLV INFECTED CELL PROLIFERATION(4,1)
BLV INFECTION MANIFESTATION(4,1)
BLV REPLICATION(4,1)
BOVINE LEUKOSIS VIRUS PRODUCTION(4,1)
CARBOXYLASE OXYGENASE(4,1)
CELL LYSATE IMMUNOBLOT ANALYSIS(4,1)
CHEMICALLY SYNTHESIZED GENE(4,1)
COAT PROTEIN HETEROLOGOUS(4,1)
DE NOVO PROTEIN SYNTHESIS(4,1)
DOWNER GROVE(4,1)
EUCARYOTIC GENE(4,1)
EX VIVO EXPRESSION(4,1)
EXPRESSION VECTOR INTRODUCTION(4,1)
FETAL BOVINE SERUM(4,1)
FIGWORT MOSAIC VIRUS(4,1)
FREQUENT MALIGNANCY(4,1)
GENETICALLY TRUE BREEDING POPULATION(4,1)
HETEROLOGOUS DNA INSERTION(4,1)
HEWLETT PACKARD DENSITOMETER(4,1)
HOLSTEIN CATTLE(4,1)
HOST CHROMOSOMAL DNA(4,1)
INFECTION DIAGNOSIS(4,1)
INTEGRASE INHIBITION(4,1)
INTESTINAL MICROBIAL BALANCE(4,1)
JUGULAR VENIPUNCTURE(4,1)
KAN GENE ENCODING RESISTANCE(4,1)
LYMPHOCYTE ACTIVATOR(4,1)
MICROBIAL PROMOTER(4,1)
MICROORGANISM VIABILITY(4,1)
MITOGENIC STIMULATION(4,1)
NEOPLASTIC TRANSFORMATION(4,1)
NITRO BLUE TETRAZOLIUM(4,1)
NOPALINE SYNTHASE(4,1)
ONCOGENIC RETROVIRUS(4,1)
OPTIMAL MICROBIAL STRAIN SELECTION(4,1)
PARADOXICAL PHENOTYPE(4,1)
PBMC METABOLISM(4,1)
PBMC SUBPOPULATION(4,1)
PHENOTYPIC TRAIT(4,1)
PLANT ANTI HIV PROTEIN GAP(4,1)
PLANT ANTIVIRAL ACTIVITY(4,1)
PLANT TRANSFORMATION STRATEGY(4,1)
PLANT TRANSFORMATION VECTOR(4,1)
POLARIZED INTESTINAL CELL(4,1)
POLYPEPTIDE TOXIN(4,1)
POTENT CYTOTOXIN(4,1)
PROBIOTIC MICROORGANISM VARIETY(4,1)
PROKARYOTE TRANSFORMATION(4,1)
PROLIFERATION PERCENTAGE INHIBITION(4,1)
PROSPECT BIOTECHNOLOGY(4,1)
PROTEIN SYNTHESIS INHIBITION(4,1)
RECEPTOR PENTAMER(4,1)
REGENERATED SOYBEAN(4,1)
REGULATABLE PROMOTER(4,1)
RIBULOSE SUBUNIT(4,1)
RUMEN CANNULA(4,1)
SALMONELLA TYPHIMURIUM(4,1)
SCREENABLE GENE(4,1)
STX1A CELLULAR TARGET(4,1)
STX1A DOSE(4,1)
STX1A INCREASINGLY GREAT DOSE(4,1)
STX1B SUBUNIT(4,1)
SUBCLINICAL INFECTION STAGE(4,1)
SUBSEQUENCE EVALUATION(4,1)
SUBUNIT PROTEIN EXPRESSION(4,1)
SUPPRESSED VIRAL PROTEIN SYNTHESIS(4,1)
SYMPTOM ALLEVIATION(4,1)
TERM PROBIOTIC MICROORGANISM(4,1)
TISSUE CULTURE EXPERIMENT(4,1)
TOXIN FRAGMENT(4,1)
TOXIN SEQUENCE DELAYING EXPRESSION(4,1)
TRANSCRIPTION REGULATION(4,1)
TRANSGENIC TRAIT(4,1)
TRYPAN BLUE INCLUSION(4,1)
VIRAL REPRESSION(4,1)
VIRUS SUPPRESSION(4,1)
FERRER(3,5)
CELLULAR PROLIFERATION(3,4)
INGREDIENT(3,4)
PREMISE(3,4)
AMPLIFICATION(3,3)
POLYADENYLATION(3,3)
VACCINE(3,3)
ADVERSE IMPACT(3,2)
ANTI STX1A IMMUNE SERUM(3,2)
BLV POSITIVE COW(3,2)
CELL PROLIFERATION PERCENTAGE(3,2)
CHENOPODIUM QUINOA(3,2)
DNA INTRODUCTION(3,2)
INERT DILUENT(3,2)
LIKELY EXPLANATION(3,2)
LIPOPOLYSACCHARIDE(3,2)
REGENERATION(3,2)
SHELF LIFE(3,2)
THERAPEUTICALLY EFFECTIVE DOSE(3,2)
TRANSCRIPTION REACTION(3,2)
WESTERN ANALYSIS(3,2)
AMMONIUM SULFATE PRECIPITATION(3,1)
ANTIBIOTIC MARKER(3,1)
ANTIBIOTIC TOLERANCE(3,1)
ANTIGEN EXPRESSION(3,1)
BETA VULGARIS PLANT(3,1)
BIO RAD ASSAY(3,1)
BIOLOGICALLY ACTIVE EPITOPE(3,1)
BLV INFECTED DAM(3,1)
BLV POSITIVE CATTLE EXPRESS(3,1)
BLV PROPAGATION(3,1)
BOVINE ALBUMIN(3,1)
BOVINE LEUKEMIA VIRUS DESTRUCTION(3,1)
BOVINE LEUKEMIA VIRUS GLYCOPROTEIN(3,1)
COSTLY IMPEDIMENT(3,1)
CULTURED PLANT HOST CELL(3,1)
DIFCO LABORATORY(3,1)
DNA MARKER(3,1)
DOMESTIC CATTLE(3,1)
EXPRESS SCD(3,1)
FOREIGN DNA INSERTION(3,1)
GRAND ISLAND(3,1)
HELPER VIRUS VIROLOGY(3,1)
HETEROLOGOUS DNA PIECE(3,1)
HETEROLOGOUS SEQUENCE INTEGRATION(3,1)
HIV INFECTION INHIBITION(3,1)
HUMAN GLOMERULAR ENDOTHELIAL CELL(3,1)
INTACT POLARIZED HUMAN(3,1)
INTRACELLULAR EXPRESSION(3,1)
MAIZE ADH(3,1)
MOLECULAR ANALYZER ANALYTICAL PROGRAM(3,1)
MOUSE DIHYDROFOLATE REDUCTASE(3,1)
NATIVE GENE LEADER SEQUENCE(3,1)
PHENOTYPIC EXPRESSION(3,1)
PLANT INOCULATION(3,1)
PLASMID COPY(3,1)
POLYCLONAL ANTIBODY(3,1)
POLYPEPTIDE INHIBITION(3,1)
POLYPEPTIDE PURIFICATION(3,1)
PRECLINICAL EVALUATION(3,1)
PROKARYOTIC HOST CELL(3,1)
PROKARYOTIC VECTOR(3,1)
PROLIFERATION INHIBITION(3,1)
PROPHYLACTIC ADMINISTRATION(3,1)
PROTEIN IMMUNOBLOT(3,1)
PROTOPLAST FUSION(3,1)
PROVIRAL BOVINE LEUKEMIA VIRUS(3,1)
PUBLIC OPPOSITION(3,1)
PURIFIED STX1A(3,1)
RECENT SPECULATION(3,1)
REPRESENTATIVE PROBIOTIC(3,1)
RESTRICTION ENZYME(3,1)
RNA COPY(3,1)
SCINTILLATION SPECTROSCOPY(3,1)
SELECTIVE ANTIVIRAL(3,1)
SONICATED EXTRACT(3,1)
SOYBEAN 7S STORAGE(3,1)
STATISTICAL SIGNIFICANCE(3,1)
STX ANTIBODY(3,1)
STX1A CODING SEQUENCE(3,1)
SUCCESSFUL CULTURING(3,1)
TOXIN FAMILY(3,1)
TRANSCRIBED MRNA SEQUENCE(3,1)
TRANSCRIPTION INITIATION(3,1)
TRANSFORMATION SUCCESS(3,1)
TRANSGENE EXPRESSION(3,1)
TRP PROMOTER(3,1)
UNINFECTED ANIMAL(3,1)
UNIVERSITY LABORATORY(3,1)
VECTOR AUTONOMOUS REPLICATION(3,1)
VECTOR SEQUENCE RECOMBINATION(3,1)
VIRAL PROLIFERATION(3,1)
VIRUS INFECTED PROTOPLAST(3,1)
YIELD DECLINE(3,1)
CONTROL CULTURE(2,4)
LEE(2,4)
PBS(2,4)
SHEEP(2,4)
ADMINISTRATION MODE(2,2)
ADMIXTURE(2,2)
BLV RELATED DISORDER(2,2)
CALCIUM PHOSPHATE(2,2)
CALF(2,2)
CELL CULTURE BEGINNING(2,2)
CELL CULTURE HR(2,2)
CELL CULTURE START(2,2)
DEXTROSE(2,2)
DIGESTIVE TRACT(2,2)
DIRECT EXPRESSION(2,2)
ELECTROPORATION(2,2)
EMULSION(2,2)
INCREASED PROLIFERATION(2,2)
INCUBATION(2,2)
INTRANASAL(2,2)
KANAMYCIN(2,2)
LETHAL EFFECT(2,2)
NITROCELLULOSE(2,2)
PALATABILITY(2,2)
PENICILLINASE(2,2)
PLANT CELL TRANSFORMATION(2,2)
PLANT CLASS(2,2)
PRECULTURE(2,2)
PROCARYOTE(2,2)
PROGENY(2,2)
PROVIRUS(2,2)
TERMINATION REGION(2,2)
TRYPTOPHAN LEVEL(2,2)
WHOLE PLANT(2,2)
ACD MIX(2,1)
AGROBACTERIUM CELL(2,1)
AMMONIUM CHLORIDE(2,1)
ANTAGONISTIC ACTIVITY(2,1)
ANTI BLV SERUM(2,1)
ANTI HIV PLANT PROTEIN(2,1)
ANTI STX1A SERUM(2,1)
ANTI TOXIN ABILITY(2,1)
ANTIBIOTIC PRESENCE(2,1)
ANTIBIOTIC RESISTANCE SELECTABLE MARKER(2,1)
ANTIGP 51 MEDIATED INHIBITION(2,1)
ANTIRETROVIRAL AGENT AIDS RE(2,1)
ANTIVIRAL COMPOSITION ACTIVITY(2,1)
ASYMPTOMATIC PERIOD(2,1)
BIOTHERAPEUTIC TREATMENT(2,1)
BLOOD BORNE DISEASE TRANSMISSION(2,1)
BLOOD DONOR(2,1)
BLV EXPRESSION LEVEL(2,1)
BLV FREE PBMC PROLIFERATION(2,1)
BLV NEGATIVE DONOR(2,1)
BLV POSITIVE DONOR(2,1)
BLV POSITIVE PBMC ABILITY(2,1)
BLV RELATED DISEASE SEVERITY(2,1)
BLV TARGET(2,1)
BLV TRANSMISSION(2,1)
BOVINE CELL(2,1)
BOVINE LEUKEMIA VIRUS INFECTION(2,1)
BOVINE LEUKEMIA VIRUS INHIBITION(2,1)
BUFFERING AGENT(2,1)
CANCER RE(2,1)
CATTLE PRODUCTION(2,1)
CAULIMOVIRUS(2,1)
CELL AGGLUTINATION(2,1)
CELL HARVESTER(2,1)
CELL LYSATE ANALYSIS(2,1)
CELL PROLIFERATION ASSAY(2,1)
CELL PROMOTER(2,1)
CELL RECEPTOR(2,1)
CELL SHRINKAGE(2,1)
CELLULAR PATHWAY(2,1)
CHIMERIC PLANT GENE(2,1)
CLONED DNA(2,1)
CODING SEQUENCE MODIFICATION(2,1)
COLD SPRING HARBOR(2,1)
COLI RNA POLYMERASE(2,1)
COMPOSITION ADMINISTRATION(2,1)
COMPOUNDING(2,1)
CONA INDUCED BOVINE(2,1)
CORRECT UTILIZATION(2,1)
CRITICAL IMPORTANCE(2,1)
CULTURE DISH(2,1)
CULTURE REDUCED THYMIDINE INCORPORATION(2,1)
DEFECTIVE RNA(2,1)
DELIVERY MODIFIER(2,1)
DEVELOPMENT PROBABILITY(2,1)
DIRECT MICROINJECTION(2,1)
DNA SEGMENT(2,1)
ECONOMIC IMPACT(2,1)
ENTERIC COATING(2,1)
ENTEROTOXIN RESISTANT MOUSE(2,1)
EQUIVALENT MOLAR CONCENTRATION(2,1)
ESCHERICHIA COLI PROTEIN EXPRESSION(2,1)
ETHANOL PRECIPITATION(2,1)
EXPRESSION ENHANCEMENT ELEMENT(2,1)
EXPRESSION VECTOR CONSTRUCTION(2,1)
FAT YIELD(2,1)
FES BUFFER(2,1)
FRESH PLANT TISSUE(2,1)
FULL CITATION(2,1)
FUSION PROTEIN(2,1)
GENE CODING(2,1)
GENETIC ENGINEERING OFFER(2,1)
GENETIC INFORMATION(2,1)
GLUFOSINATE AMMONIUM SALT(2,1)
GLUTAMINE SYNTHETASE ACTION(2,1)
HELPER TI PLASMID(2,1)
HIV DISEASE(2,1)
HOST CELL CULTURE(2,1)
HUMAN PATHOGEN(2,1)
IMMUNODOMINANT EPITOPE(2,1)
INDUCED NEOPLASIA(2,1)
INFLUENCE IMMUNE RESPONSE(2,1)
INSERTED FOREIGN DNA(2,1)
INTERFERING FACTOR(2,1)
KDA PROTEIN(2,1)
LABORATORY SETTING(2,1)
LYMPHOMA DEVELOPMENT(2,1)
MALIGNANT LYMPHOMA INDUCTION(2,1)
MAMMALIAN CELL(2,1)
MATREX GEL(2,1)
MEASUREMENT SE(2,1)
MICROFUGE TUBE(2,1)
MINIMAL ESSENTIAL CODING SEQUENCE(2,1)
MINIMAL IMPACT(2,1)
MODULATED CELL DIVISION TRAIT(2,1)
NACL GRADIENT(2,1)
NEGATIVE BACTERIA(2,1)
NEUTRALIZING ABILITY(2,1)
NORMAL BOVINE PBMC(2,1)
NORMAL PBMC CULTURE(2,1)
OPERABLY LINKED SEQUENCE EXPRESSION(2,1)
PARTICLE BOMBARDMENT(2,1)
PATHOLOGICAL EFFECT NEUTRALIZATION(2,1)
PBMC PREPARATION(2,1)
PERIPHERAL CIRCULATION(2,1)
PERIPLASMIC PROTEIN CONCENTRATION(2,1)
PEST RESISTANCE(2,1)
PHENOL CHLOROFORM EXTRACTION(2,1)
PHENOTYPIC SELECTION(2,1)
PHENYLMETHYLSULFONYL FLUORIDE(2,1)
PLANT LEAF(2,1)
PLANT RIP(2,1)
PLANT SPECIES VARIETY(2,1)
PLASMID GENE(2,1)
PLASMID VECTOR(2,1)
POISONOUS LECTIN(2,1)
POLYLINKER REGION(2,1)
POTENT ANTIVIRAL AGENT(2,1)
PROTECTIVE ROLE(2,1)
PROTEIN GENE(2,1)
PROTEIN MOLECULE(2,1)
PURIFYING LECTIN(2,1)
PWM INDUCED PROLIFERATION(2,1)
RECENT PUBLICATION(2,1)
REPEATED FREEZE THAW CYCLE(2,1)
REPLICATION SITE(2,1)
REPRESENTATIVE ASSAY(2,1)
REPRESENTATIVE EXPERIMENT(2,1)
RESTRICTION SITE(2,1)
RIBOSOMAL RNA SEQUENCE(2,1)
RIBOSOME INHIBITING PROTEIN(2,1)
RICIN CHAIN(2,1)
RICIN INJECTION(2,1)
RIP FAMILY MEMBER(2,1)
SCIENTIFIC CORP(2,1)
SDS LOADING BUFFER(2,1)
SELECTIVE TROPISM(2,1)
SEQUENTIAL ATTACHMENT(2,1)
SHARP CONTRAST(2,1)
SHIGA TOXIN LOW DOSE(2,1)
SLP ALMOST COMPLETE SUPPRESSION(2,1)
SODIUM CARBOXYMETHYLCELLULOSE(2,1)
SOLUBLE PROTEIN(2,1)
STRONG RISK FACTOR(2,1)
STRUCTURAL SIMILARITY(2,1)
STX1A PRODUCTION(2,1)
STX1B CONCENTRATION(2,1)
SUCCESSFUL EXPRESSION(2,1)
TARGET TRANSGENE(2,1)
TERM BIOTHERAPEUTIC AGENT(2,1)
TERM EXPRESSION VECTOR(2,1)
TERM REPLICON(2,1)
TERM TRANSFORMATION(2,1)
TEST ANTIVIRAL ACTIVITY(2,1)
THICKENING(2,1)
TISSUE CULTURE CELL(2,1)
TOBACCO PLANT(2,1)
TOPOLOGICAL ACTIVITY(2,1)
TOXIN ACTIVITY(2,1)
TOXIN MOVEMENT(2,1)
TOXIN RECEPTOR LEVEL(2,1)
TRANSFORMED CELL(2,1)
TRANSGENE ABILITY(2,1)
TRANSGENIC PLANT ADMINISTRATION(2,1)
TRANSGENIC PLANT DOSE(2,1)
TRANSGENIC PLANT REPRESENTATION(2,1)
TRANSMISSION PROBABILITY(2,1)
VERO TOXIN ACTION(2,1)
VIRAL ORIGIN(2,1)
VISCOSITY REGULATOR(2,1)
VITRO EXPRESSION(2,1)
CULTURED CELL(1,3)
FOLDING(1,3)
INHIBITORY EFFECT(1,3)
LIQUID CARRIER(1,3)
PILL(1,3)
SIGMA(1,3)
TABLET(1,3)
VET(1,3)
ACCURATE CHEMICAL(1,1)
ADDITIVE(1,1)
AGAROSE(1,1)
AMPICILLIN(1,1)
ANGIOSPERM(1,1)
APOPTOSIS(1,1)
ARCHETYPE(1,1)
ARITHMETIC MEAN STANDARD ERROR(1,1)
(US20030152593)
SHIGA TOXIN POLYPEPTIDE(100,90)
VIRALLY INFECTED CELL(100,16)
CELL PROLIFERATION(100,12)
MAMMALIAN SUBJECT(100,10)
MAMMAL(100,8)
ANIMAL SUBJECT(100,6)
VIRUS INFECTION(100,6)
A CELL(100,4)
BOVINE LEUKEMIA VIRUS RELATED DISORDER(100,4)
SHIGA TOXIN ANTIVIRAL ACTIVITY(100,1)
SHIGA TOXIN(97,63)
RESPIRATORY SYNCITIAL VIRUS(38,5)
VIRUS(26,25)
COSTLY IMPEDIMENT(26,1)
SHIGA TOXIN TYPE(25,10)
CATTLE PRODUCTION(17,1)
VIRAL INFECTION PROGRESSION(16,2)
PICOMA VIRUS(15,3)
MALIGNANCY STAGE(15,2)
BOVINE LEUKEMIA VIRUS RELATED LYMPHOCYTE PROLIFERATION(15,1)
RUMINANT(14,18)
BLV INFECTION(14,5)
BLV RELATED LYMPHOCYTE PROLIFERATION(13,4)
BLV INFECTED COW(12,9)
HOLOTOXIN SUBUNIT(12,7)
VESICULAR STOMATITIS VIRUS(12,5)
CELL ELIMINATION(12,2)
HUMAN SUBJECT(12,2)
DISEASE(12,1)
MICROORGANISM(11,17)
CORONAVIRUS(11,5)
ROTAVIRUS(11,5)
TOGAVIRUS(11,5)
HEPATITIS VIRUS(11,4)
SLP POTENT SUPPRESSOR(11,3)
CELL PERMEABILITY INCREASE(11,2)
SLP INHIBITION(10,8)
ADENOVIRUS(10,5)
HERPES VIRUS(10,5)
SEMLIKI(10,5)
VACCINIA(10,5)
SPONTEANEOUS LYMPHOCYTE PROLIFERATION(10,2)
ADMINISTRATION(9,6)
BLV PROTEIN DISSEMINATION(9,2)
INFECTION PERSISTENTLY LYMPHOCYTOTIC STAGE(9,2)
PICORNAVIRUS(9,2)
PROBIOTIC MICROORGANISM ADMINISTRATION(9,2)
ANIMAL(8,21)
CULTURE PROLIFERATION(8,4)
BLV EXPRESSION ASSAY(8,3)
MALIGNANT LYMPHOSARCOMA(8,3)
ANTIVIRAL AGENT(8,2)
BLV INFECTED CATTLE EXPRESS(8,2)
BOVINE IMMUNODEFICIENCY VIRUS(8,2)
ENZYMATIC MUTANT E167D(8,2)
SPONTANEOUS PROLIFERATION INITIATION(8,2)
VIRAL PROTEIN DE NOVO SYNTHESIS(8,2)
VIRAL PROTEIN DISSEMINATION(8,2)
POKEWEED MITOGEN INHIBITION(8,1)
SPONTANEOUS LYMPHOCYTE PROLIFERATION SUPPRESSION(8,1)
CATTLE(7,14)
BLV POSITIVE PBMC CULTURE(7,5)
SLP INITIATION(7,4)
BACTERIA TRANSFORMATION(7,3)
ASSOCIATION MUTANT STX1A(7,2)
POTENT SLP INHIBITOR(7,2)
VIRAL PARTICLE DISSEMINATION(7,2)
ENVIRONMENTAL CONDITION(7,1)
INHIBITOR HERBICIDE PHOSPHINOTHRICIN(7,1)
PBMC DONOR BLV STATUS(7,1)
POKEWEED ANTIVIRAL PROTEIN(7,1)
STEC INTESTINAL COLONIZATION(7,1)
UNIVERSITY DAIRY HERD(7,1)
MURINE MONOCLONAL ANTIBODY(6,3)
RECEPTOR MEDIATED CYTOTOXICITY(6,3)
STX VARIANT(6,3)
AGROBACTERIUM TUMIFACIEN(6,2)
BLV INDUCED SLP INHIBITOR(6,2)
BLV PARTICLE EXPRESSION(6,2)
CAULIFLOWER MOSAIC VIRUS(6,2)
FETAL BOVINE SERUM(6,2)
NITRO BLUE TETRAZOLIUM(6,2)
NON LETHAL SUPPRESSION(6,2)
PROLIFERATION PERCENTAGE INHIBITION(6,2)
PROTEIN SYNTHESIS INHIBITION ASSAY(6,2)
BLV INFECTION ALLEVIATING SYMPTOM(6,1)
BLV KDA GLYCOPROTEIN(6,1)
IDAHO DAIRY UNIVERSITY(6,1)
PLANT NUCLEUS DNA(6,1)
RABBIT RETICULOCYTE LYSATE(6,1)
RNASIN RIBONUCLEASE INHIBITOR(6,1)
SLP STX1A SUPPRESSION(6,1)
NON TRANSLATED REGION(5,6)
BLV POSITIVE CULTURE(5,5)
COLD SPRING HARBOR(5,5)
IMMUNOSTIMULATION(5,5)
DNA SPLICING(5,3)
MARKER GENE(5,3)
AMMONIUM SULFATE PRECIPITATION(5,2)
ANTI MOUSE ANTIBODY(5,2)
ANTIBODY NEUTRALIZATION(5,2)
ANTIVIRAL ANTIBODY ABILITY(5,2)
ASYMPTOMATIC INFECTION STAGE(5,2)
BLV INFECTED LYMPHOCYTE(5,2)
BLV INFECTION PROGRESSION(5,2)
BLV NEGATIVE PBMC CULTURE(5,2)
BLV PARTICLE RELEASE(5,2)
DOWNER GROVE(5,2)
ENVELOPE GLYCOPROTEIN(5,2)
GLYCOLIPID RECEPTOR(5,2)
HEWLETT PACKARD DENSITOMETER(5,2)
INOCULANT PASTE(5,2)
MOLECULAR ANALYZER ANALYTICAL PROGRAM(5,2)
MRNA TRANSLATION(5,2)
PLANT EXPRESSION VECTOR(5,2)
PLANT HEMITOXIN(5,2)
POLYCLONAL ANTIBODY(5,2)
POLYPEPTIDE TOXIN(5,2)
SCINTILLATION SPECTROSCOPY(5,2)
SLP SUPPRESSION(5,2)
SLP SUSCEPTIBILITY(5,2)
SPURIOUS INHIBITOR(5,2)
STX1A EXPRESSION(5,2)
STX1A IMPACT(5,2)
STX1B MOLAR CONCENTRATION(5,2)
TRANSCRIPTION TERMINATION(5,2)
UNINFECTED COW(5,2)
VIRALLY INFECTED ANIMAL CELL(5,2)
WESTERN BLOT(5,2)
ANTIVIRAL ACTIVITY CONJECTURE(5,1)
ANTIVIRAL ACTIVITY DEMONSTRATION(5,1)
BLV EXPRESSION SUPPRESSION(5,1)
BOVINE CRYPT EPITHELIAL CELL(5,1)
BOVINE GASTROINTESTINAL MUCOSA(5,1)
CULTURE EXCEEDED PROLIFERATION(5,1)
CYTOPLASMIC ACCUMULATION POTENTIAL CYTOTOXICITY(5,1)
ENGINEERED MICROORGANISM STRAIN(5,1)
ENZYMATIC MUTANT EL(5,1)
EXPRESS RICIN TOXIN(5,1)
HETEROLOGOUS DNA REPLICATION(5,1)
HETEROLOGOUS DNA TRANSCRIPTION(5,1)
HIV REPLICATION INHIBITION(5,1)
HOG CHOLERA VIRUS(5,1)
INFLUENZA VIRUS PROTEIN(5,1)
KDA FLUORESCENT DEXTRAN(5,1)
LIVE MICROBIAL FEED SUPPLEMENT(5,1)
MAXIMAL SLP SENSITIVITY(5,1)
MOLONEY LEUKEMIA VIRUS(5,1)
PERSISTENT LYMPHOCYTOSIS DEVELOPMENT(5,1)
PLANT RIP CYTOTOXIC ACTIVITY(5,1)
PROBABLY MINOR SUBPOPULATION(5,1)
PROPAGATION BLV EXPRESSION(5,1)
RIBOSOME INACTIVATING PROTEIN FAMILY(5,1)
RICE ACTIN INTRON(5,1)
RIP ANTIVIRAL ACTIVITY(5,1)
SHIGA TOXIN GENE(5,1)
SLP MEDIATED INHIBITION(5,1)
STEC EXPRESS TOXIN(5,1)
STRONGLY AUGMENTED PROLIFERATION(5,1)
STX POLYPEPTIDE ADMINISTRATION(5,1)
STX1A MUTANT ACTIVITY(5,1)
SUBGENOMIC MRNA PROMOTER(5,1)
THERAPEUTIC STRATEGY FEASIBILITY(5,1)
TRYPTOPHAN COMPETITIVE INHIBITION(5,1)
UNIFORMED SERVICE UNIVERSITY(5,1)
VIRAL GENE TRANSCRIPTION DEREPRESSION(5,1)
VIRAL INFECTION SYMPTOM ALLEVIATION(5,1)
VET(4,13)
VIROLOGY(4,7)
TREATED COW(4,4)
AMPLIFICATION(4,3)
AGROBACTERIUM TRANSFORMATION(4,2)
BLV P EXPRESSION(4,2)
CELL TRAFFICKING MUTANT(4,2)
CONFIDENCE INTERVAL(4,2)
CULTURE EVIDENCE(4,2)
ESTABLISHED SLP EVENT(4,2)
HOST CHROMOSOME(4,2)
MAGNESIUM STEARATE(4,2)
MARGINAL IMPACT(4,2)
MATREX GEL(4,2)
MEASURING EXPERIMENT(4,2)
MRNA MOLECULE(4,2)
NON TRANSLATED LEADER SEQUENCE(4,2)
NUTRITIONAL BENEFIT(4,2)
PROLIFERATION INDUCTION(4,2)
REPEATED FREEZE THAW CYCLE(4,2)
SCIENTIFIC CORP(4,2)
STX1A ABILITY(4,2)
STX1A ACTIVITY(4,2)
TOXIN CONCENTRATION(4,2)
TOXIN PREPARATION(4,2)
TRANSFORMED PLANT(4,2)
UNINFECTED CELL(4,2)
30B EXPRESSION VECTOR(4,1)
BIO RAD MICROASSAY(4,1)
BLV CORE PROTEIN EXPRESSION(4,1)
BLV DELETION(4,1)
BLV INFECTED CELL PROLIFERATION(4,1)
BLV INFECTION MANIFESTATION(4,1)
BLV PROTEIN EXPRESSION(4,1)
BLV REPLICATION(4,1)
BOVINE VASCULATURE(4,1)
CARBOXYLASE OXYGENASE(4,1)
CELL LYSATE IMMUNOBLOT ANALYSIS(4,1)
CLINICAL DISEASE STAGE(4,1)
COAT PROTEIN HETEROLOGOUS(4,1)
DEFICIENT ENZYMATIC ACTIVITY(4,1)
DENSITY ACCU PAQUE LYMPHOCYTE(4,1)
EUCARYOTIC GENE(4,1)
EXPRESSION VECTOR INTRODUCTION(4,1)
FIGWORT MOSAIC VIRUS(4,1)
FREQUENT MALIGNANCY(4,1)
GENETICALLY TRUE BREEDING POPULATION(4,1)
HETEROLOGOUS DNA INSERTION(4,1)
HOST CHROMOSOMAL DNA(4,1)
HOST MEMBRANE PERMEABILITY(4,1)
HUMAN HYDROPHOBIC PROTEIN(4,1)
INTESTINAL MICROBIAL BALANCE(4,1)
JUGULAR VENIPUNCTURE(4,1)
KAN GENE ENCODING RESISTANCE(4,1)
LUCIFERASE ASSAY REAGENT(4,1)
MICROBIAL PROMOTER(4,1)
MICROORGANISM VIABILITY(4,1)
MITOGENIC STIMULATION(4,1)
NEOPLASTIC TRANSFORMATION(4,1)
NOPALINE SYNTHASE(4,1)
ONCOGENIC RETROVIRUS(4,1)
OPTIMAL MICROBIAL STRAIN SELECTION(4,1)
PBMC ALIQUOT(4,1)
PBMC METABOLISM(4,1)
PBMC SUBPOPULATION(4,1)
PHENOTYPIC TRAIT(4,1)
PLANT ANTIVIRAL ACTIVITY(4,1)
PLANT TRANSFORMATION STRATEGY(4,1)
PLANT TRANSFORMATION VECTOR(4,1)
POLIOVIRUS POLYPEPTIDE(4,1)
POTENT CYTOTOXIN(4,1)
PROBIOTIC MICROORGANISM VARIETY(4,1)
PROKARYOTE TRANSFORMATION(4,1)
RECEPTOR PENTAMER(4,1)
REGENERATED SOYBEAN(4,1)
REGULATABLE PROMOTER(4,1)
RIBOSOME INACTIVATION(4,1)
RIBULOSE SUBUNIT(4,1)
RUMEN CANNULA(4,1)
SALMONELLA TYPHIMURIUM(4,1)
SCREENABLE GENE(4,1)
STX1A CELLULAR TARGET(4,1)
STX1A DOSE(4,1)
STX1A INCREASINGLY GREAT DOSE(4,1)
STX1B SUBUNIT(4,1)
SUBSEQUENCE EVALUATION(4,1)
SUPPRESSED VIRAL PROTEIN SYNTHESIS(4,1)
TERM PROBIOTIC MICROORGANISM(4,1)
TISSUE CULTURE EXPERIMENT(4,1)
TOXIN ACTIVITY ENZYME(4,1)
TOXIN FRAGMENT(4,1)
TOXIN SEQUENCE DELAYING EXPRESSION(4,1)
TRANSCRIPTION REGULATION(4,1)
TRANSGENIC TRAIT(4,1)
TRANSMEMBRANE GLYCOPROTEIN(4,1)
TRYPAN BLUE INCLUSION(4,1)
VIRAL EFFECTION(4,1)
VIRAL INFECTION MANIFESTATION(4,1)
VIRAL REPRESSION(4,1)
VIRUS SUPPRESSION(4,1)
BIOTECHNOLOGY(3,6)
CELLULAR PROLIFERATION(3,4)
INGREDIENT(3,4)
MUTATION(3,4)
PERIPHERAL BLOOD MONONUCLEAR CELL(3,4)
PREMISE(3,4)
AIDS RE(3,3)
MOLAR BASIS(3,3)
POLYADENYLATION(3,3)
ADVERSE IMPACT(3,2)
ANTI STX1A IMMUNE SERUM(3,2)
BLV POSITIVE COW(3,2)
CANCER RE(3,2)
CELL HARVESTER(3,2)
CHENOPODIUM QUINOA(3,2)
DNA INTRODUCTION(3,2)
INERT DILUENT(3,2)
LIKELY EXPLANATION(3,2)
LIPOPOLYSACCHARIDE(3,2)
PHENYLMETHYLSULFONYL FLUORIDE(3,2)
REGENERATION(3,2)
SHELF LIFE(3,2)
THERAPEUTICALLY EFFECTIVE DOSE(3,2)
TRANSCRIPTION REACTION(3,2)
WESTERN ANALYSIS(3,2)
28S RRNA(3,1)
ACID CITRATE DEXTROSE(3,1)
ADENINE RESIDUE(3,1)
ANTI HIV ACTIVITY(3,1)
ANTIBIOTIC MARKER(3,1)
ANTIBIOTIC TOLERANCE(3,1)
ANTIGEN EXPRESSION(3,1)
ANTIVIRAL ASSAY(3,1)
BETA VULGARIS PLANT(3,1)
BIO RAD ASSAY(3,1)
BLV INFECTED DAM(3,1)
BLV POSITIVE CATTLE EXPRESS(3,1)
BLV PROPAGATION(3,1)
BOVINE ALBUMIN(3,1)
BOVINE LEUKEMIA VIRUS DESTRUCTION(3,1)
BUFFY COAT CELL(3,1)
CAPSID PROTEIN(3,1)
CARBOXY TERMINUS(3,1)
COLI GLYCOPROTEIN(3,1)
CULTURED PLANT HOST CELL(3,1)
DIFCO LABORATORY(3,1)
DIFFERENTIAL PROTEOLYSIS(3,1)
DNA MARKER(3,1)
DOMESTIC CATTLE(3,1)
EXPRESS SCD(3,1)
FOREIGN DNA INSERTION(3,1)
GB RECENT FINDING(3,1)
GLYCOSIDASE ACTIVITY(3,1)
GRAND ISLAND(3,1)
HARVESTED CULTURE(3,1)
HETEROLOGOUS DNA PIECE(3,1)
HETEROLOGOUS SEQUENCE INTEGRATION(3,1)
HIV INFECTION INHIBITION(3,1)
HUMAN GLOMERULAR ENDOTHELIAL CELL(3,1)
INTACT POLARIZED HUMAN(3,1)
INTRACELLULAR EXPRESSION(3,1)
LATENT HERPES SIMPLEX VIRUS(3,1)
LUCIFERASE RNA(3,1)
MAIZE ADH(3,1)
NATIVE GENE LEADER SEQUENCE(3,1)
PLANT INOCULATION(3,1)
PLASMID COPY(3,1)
POLYPEPTIDE INHIBITION(3,1)
POLYPEPTIDE PURIFICATION(3,1)
PROKARYOTIC HOST CELL(3,1)
PROKARYOTIC VECTOR(3,1)
PROMEGA CORPORATION(3,1)
PROPHYLACTIC ADMINISTRATION(3,1)
PROTEIN IMMUNOBLOT(3,1)
PROTOPLAST FUSION(3,1)
PUBLIC OPPOSITION(3,1)
PURIFIED STX1A(3,1)
RECENT SPECULATION(3,1)
REOVIRUS PROTEIN(3,1)
REPRESENTATIVE PROBIOTIC(3,1)
RESTRICTION ENZYME(3,1)
RIP RICIN(3,1)
RNA COPY(3,1)
SELECTIVE ANTIVIRAL(3,1)
SENSITIZED ANIMAL(3,1)
SONICATED EXTRACT(3,1)
SOYBEAN 7S STORAGE(3,1)
STATISTICAL SIGNIFICANCE(3,1)
STX ANTIBODY(3,1)
STX1A CODING SEQUENCE(3,1)
STX1A HYDROPHOBIC REGION(3,1)
STX1A INTERACTION(3,1)
SUCCESSFUL CULTURING(3,1)
TOXIN FAMILY(3,1)
TRANS GOLGI NETWORK(3,1)
TRANSCRIBED MRNA SEQUENCE(3,1)
TRANSCRIPTION INITIATION(3,1)
TRANSFORMATION SUCCESS(3,1)
TRANSGENE EXPRESSION(3,1)
TRP PROMOTER(3,1)
UNINFECTED ANIMAL(3,1)
UNIVERSITY LABORATORY(3,1)
VECTOR AUTONOMOUS REPLICATION(3,1)
VECTOR SEQUENCE RECOMBINATION(3,1)
VIRAL PROLIFERATION(3,1)
BLV RELATED CELL PROLIFERATION(2,4)
CONTROL CULTURE(2,4)
FOLDING(2,4)
PBS(2,4)
SHEEP(2,4)
SIGMA(2,4)
ALKALINE PHOSPHATASE(2,3)
ACCURATE CHEMICAL(2,2)
ADMINISTRATION MODE(2,2)
ADMIXTURE(2,2)
BLV RELATED DISORDER(2,2)
CELL CULTURE BEGINNING(2,2)
CELL CULTURE HR(2,2)
CELL CULTURE START(2,2)
CYTOSOL(2,2)
DIGESTIVE TRACT(2,2)
ELECTROPORATION(2,2)
GASTROINTESTINAL TRACT(2,2)
INCREASED PROLIFERATION(2,2)
INTRANASAL(2,2)
ISOTYPE(2,2)
KANAMYCIN(2,2)
LECTIN(2,2)
MICROBIOL(2,2)
MONKEY(2,2)
NITROCELLULOSE(2,2)
NUMEROUS FACTOR(2,2)
PALATABILITY(2,2)
PENICILLINASE(2,2)
PROCARYOTE(2,2)
PROVIRUS(2,2)
RODENT(2,2)
STREPTOMYCIN(2,2)
SUBSTITUTION(2,2)
TERMINATION REGION(2,2)
TRYPTOPHAN LEVEL(2,2)
VACCINE(2,2)
WASHINGTON(2,2)
WHOLE PLANT(2,2)
ACD MIX(2,1)
AGAROSE COLUMN(2,1)
AGROBACTERIUM CELL(2,1)
ALANINE CATALYTIC CENTER(2,1)
AMMONIUM CHLORIDE(2,1)
ANTAGONISTIC ACTIVITY(2,1)
ANTI BLV SERUM(2,1)
ANTI STX1A SERUM(2,1)
ANTI TOXIN ABILITY(2,1)
ANTIBIOTIC PRESENCE(2,1)
ANTIBIOTIC RESISTANCE SELECTABLE MARKER(2,1)
ANTIGP 51 MEDIATED INHIBITION(2,1)
ANTIVIRAL COMPOSITION ACTIVITY(2,1)
ASYMPTOMATIC PERIOD(2,1)
BERTHOLD TECHNOLOGY(2,1)
BIOLOGICAL ACTIVITY(2,1)
BIOTHERAPEUTIC TREATMENT(2,1)
BLOOD BORNE DISEASE TRANSMISSION(2,1)
BLOOD DONOR(2,1)
BLV EXPRESSION LEVEL(2,1)
BLV FREE PBMC PROLIFERATION(2,1)
BLV NEGATIVE DONOR(2,1)
BLV POSITIVE DONOR(2,1)
BLV POSITIVE PBMC ABILITY(2,1)
BLV RELATED DISEASE SEVERITY(2,1)
BLV TARGET(2,1)
BLV TRANSMISSION(2,1)
BOVINE CELL(2,1)
BOVINE SERUM ALBUMIN(2,1)
BUFFERING AGENT(2,1)
CAULIMOVIRUS(2,1)
CELL CULTURE COMMENCEMENT(2,1)
CELL CULTURE SUPERNATANT(2,1)
CELL INTERNALIZATION(2,1)
CELL LYSATE ANALYSIS(2,1)
CELL MEMBRANE PERMEABILITY(2,1)
CELL PROLIFERATION ASSAY(2,1)
CELL PROLIFERATION INHIBITION(2,1)
CELL RECEPTOR(2,1)
CELL SHRINKAGE(2,1)
CHEMILUMINESCENCE(2,1)
CHIMERIC PLANT GENE(2,1)
CLONED DNA(2,1)
CODING SEQUENCE MODIFICATION(2,1)
COMPLETE RETROGRADE TRANSPORT(2,1)
COMPOSITION ADMINISTRATION(2,1)
COMPOUNDING(2,1)
CONA INDUCED BOVINE(2,1)
CORRECT UTILIZATION(2,1)
CRITICAL IMPORTANCE(2,1)
CULTURE DISH(2,1)
CULTURE REDUCED THYMIDINE INCORPORATION(2,1)
CYTOMETRIC ANALYSIS(2,1)
DELIVERY MODIFIER(2,1)
DEVELOPMENT PROBABILITY(2,1)
DIRECT MICROINJECTION(2,1)
DNA SEGMENT(2,1)
DNA SYNTHESIS(2,1)
ECONOMIC IMPACT(2,1)
ENTERIC COATING(2,1)
ENZYMATIC ACTIVITY LOSS(2,1)
EQUIVALENT MOLAR CONCENTRATION(2,1)
ETHANOL PRECIPITATION(2,1)
EX VIVO(2,1)
EXPRESSION ENHANCEMENT ELEMENT(2,1)
EXPRESSION VECTOR CONSTRUCTION(2,1)
FAT YIELD(2,1)
FECAL SAMPLE(2,1)
FES BUFFER(2,1)
FRESH PLANT TISSUE(2,1)
FUSION PROTEIN(2,1)
GB ABSENCE(2,1)
GENE CODING(2,1)
GENETIC ENGINEERING OFFER(2,1)
GENETIC INFORMATION(2,1)
GLUFOSINATE AMMONIUM SALT(2,1)
GLUTAMINE SYNTHETASE ACTION(2,1)
HEALTH SCIENCE(2,1)
HELPER TI PLASMID(2,1)
HOST CELL CULTURE(2,1)
HUMAN DISEASE(2,1)
HUMAN INTESTINAL EPITHELIUM(2,1)
HUMAN PATHOGEN(2,1)
HYDROPHILIC MOLECULE(2,1)
IMMUNODIFFUSION(2,1)
INDISCRIMINATE CELL DEATH(2,1)
INDUCED NEOPLASIA(2,1)
INFLUENCE IMMUNE RESPONSE(2,1)
INSERTED FOREIGN DNA(2,1)
INTERFERING FACTOR(2,1)
KDA AL FRAGMENT(2,1)
KDA PROTEIN(2,1)
KIDNEY ENDOTHELIAL CELL(2,1)
LABORATORY SETTING(2,1)
LEUK RE(2,1)
LUMAT LB(2,1)
LYMPHOMA DEVELOPMENT(2,1)
MALIGNANT LYMPHOMA INDUCTION(2,1)
MAMMALIAN CELL(2,1)
MICROFUGE TUBE(2,1)
MINIMAL ESSENTIAL CODING SEQUENCE(2,1)
MINIMAL IMPACT(2,1)
MODULATED CELL DIVISION TRAIT(2,1)
MOLECULE MOTIF(2,1)
MOUSE IGG1(2,1)
NACL GRADIENT(2,1)
NEGATIVE BACTERIA(2,1)
NEGATIVE CATTLE(2,1)
NEUTRALIZING ABILITY(2,1)
NORMAL BOVINE PBMC(2,1)
NORMAL PBMC CULTURE(2,1)
OAK RIDGE(2,1)
OPERABLY LINKED SEQUENCE EXPRESSION(2,1)
PARTICLE BOMBARDMENT(2,1)
PATHOLOGICAL EFFECT NEUTRALIZATION(2,1)
PBMC PREPARATION(2,1)
PERIPHERAL CIRCULATION(2,1)
PERIPLASMIC PROTEIN CONCENTRATION(2,1)
PERKIN ELMER LIFE SCIENCE(2,1)
PEST RESISTANCE(2,1)
PHENOL CHLOROFORM EXTRACTION(2,1)
PHENOTYPIC SELECTION(2,1)
PINOCYTIC ACTIVITY(2,1)
PLANT CELL TRANSFORMATION(2,1)
PLANT LEAF(2,1)
PLANT MOL(2,1)
PLANT SPECIES VA(...)";Pharmaceuticals;Open
"2000-06-27
2001-06-15";"WO200200881         A1 2002-01-03 [WO200200881]
STG: (A1) Published application with search report
AP : 2001WO-EP06738 2001-06-15
CA2414339           A1 2002-01-03 [CA2414339]
STG: (A1) Application laid open
AP : 2001CA-2414339 2001-06-15
AU8386201           A  2002-01-08 [AU200183862]
STG: (A) Open to public inspection
AP : 2001AU-0083862 2001-06-15
EP1170367           A1 2002-01-09 [EP1170367]
STG: (A1) Application published with search report
AP : 2000EP-0113088 2000-06-27
KR20030032969       A  2003-04-26 [KR20030032969]
STG: (A) Published application
AP : 2002KR-7017425 2001-06-15
BR0112020           A  2003-05-13 [BR200112020]
STG: (A) Published application
AP : 2001BR-0012020 2001-06-15
BRPI0112020         A1 2003-05-13 [BRPI0112020]
STG: (A1) Published application
AP : 2001BR-0012020 2001-06-15
US20030129744       A1 2003-07-10 [US20030129744]
STG: (A1) Application published
AP : 2001US-10312062 2001-06-15
JP2004501644        A  2004-01-22 [JP2004501644]
STG: (A) Published application
AP : 2002JP-0506196 2001-06-15
ZA200210354         B  2004-04-20 [ZA200210354]
STG: (B)
AP : 2002ZA-0010354 2002-12-20
MXPA02012593        A  2004-05-17 [MX2002PA012593]
STG: (A) Patent application
AP : 2002MX-PA12593 2001-06-15
KR10-2008-0038457   A  2008-05-06 [KR20080038457]
STG: (A) Published application
AP : 2008KR-7009258 2001-06-15
KR10-0909846        B1 2009-07-29 [KR100909846]
STG: (B1) Patent specification
AP : 2002KR-7017425 2001-06-15
KR10-0939050        B1 2010-02-11 [KR100939050]
STG: (B1) Patent specification
AP : 2008KR-7009258 2001-06-15
BRPI0112020         A2 2010-10-19 [BR200112020]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2001BR-0012020 2001-06-15
EP2365082           A1 2011-09-14 [EP2365082]
STG: (A1) Application published with search report
AP : 2010EP-0181849 2000-06-27
FD :  Division of: EP00113088 FDD=2000-06-27 [2000EP-0113088]
FD : Division of: EP1170367 - 0 [EP1170367]
JP4856351           B2 2011-11-04 [JP4856351]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2002JP-0506196 2001-06-15
CA2414339           C  2012-09-04 [CA2414339]
STG: (C) Patent (second level)
AP : 2001CA-2414339 2001-06-15";1558355;"WO200200881         A1 2002-01-03 [WO200200881]
CA2414339           A1 2002-01-03 [CA2414339]
AU8386201           A  2002-01-08 [AU200183862]
EP1170367           A1 2002-01-09 [EP1170367]
KR20030032969       A  2003-04-26 [KR20030032969]
BR0112020           A  2003-05-13 [BR200112020]
BRPI0112020         A1 2003-05-13 [BRPI0112020]
US20030129744       A1 2003-07-10 [US20030129744]
JP2004501644        A  2004-01-22 [JP2004501644]
ZA200210354         B  2004-04-20 [ZA200210354]
MXPA02012593        A  2004-05-17 [MX2002PA012593]
KR10-2008-0038457   A  2008-05-06 [KR20080038457]
KR10-0909846        B1 2009-07-29 [KR100909846]
KR10-0939050        B1 2010-02-11 [KR100939050]
BRPI0112020         A2 2010-10-19 [BR200112020]
EP2365082           A1 2011-09-14 [EP2365082]
JP4856351           B2 2011-11-04 [JP4856351]
CA2414339           C  2012-09-04 [CA2414339]";"2000EP-0113088
2001WO-EP06738";"(US20030129744)
WO200200881
(JP4856351)
WO200200881
(AU200183862)
WO200200881
(MX2002PA012593)
WO200200881
(KR100909846)
WO200200881
(KR100939050)
WO200200881
(BR200112020)
WO200200881
(CA2414339)
WO200200881";"BAYER
EDE LELYYSTAT BETH LOTEN FENOTECHAP
ID LELYSTAD
PFIZER ANIMAL HEALTH
PFIZER ANIMAL HEALTH SOCIETE ANONYM";"PFIZER ANIMAL HEALTH
ID LELYSTAD";"(EP1170367)
NL
(EP2365082)
BE; NL
(WO200200881)
DE; NL



(BRPI0112020)
DE; NL
(BR200112020)
DE; NL
(CA2414339)
DE; NL
(CA2414339)
DE; NL";"(EP1170367)
NAME=BAYER AG 51368 Leverkusen (DE) 

NAME=ID-Lelystad B.V. Edelhertweg 15 , CITY=8219 PH Lelystad , COUNTRY=NL 

(EP2365082)
NAME=Pfizer Animal Health S.A. Rue Laid Buriat, 1 , CITY=1348 Ottignies, , COUNTRY=BE 

NAME=ID-Lelystad B.V. Edelhertweg 15 , CITY=8219 PH Lelystad , COUNTRY=NL 

(WO200200881)
NAME=BAYER AKTIENGESELLSCHAFT  [DE/ DE] 51368 Leverkusen  , COUNTRY=DE 

NAME=ID-LELYSTAD B.V.  [NL/ NL] Edelhertweg 15, NL-8219 PH Lelystad  , COUNTRY=NL 

(JP4856351)
NAME=Pfizer Animal Health Societe Anonym , REG=510089546 

NAME=Ede - Lelyystat Beth Loten Fenotechap , REG=503010922 

(KR20030032969)
NAME=BAYER AKTIENGESELLSCHAFT , REG=519981076737 

(KR100939050)
NAME=BAYER AKTIENGESELLSCHAFT , REG=519981076737 

(BRPI0112020)
NAME=BAYER AKTIENGESELLSCHAFT , COUNTRY=DE 

NAME=ID-LELYSTAD B V , COUNTRY=NL 

(BR200112020)
NAME=BAYER AKTIENGESELLSCHAFT , COUNTRY=DE 

NAME=ID-LELYSTAD B V , COUNTRY=NL 

(CA2414339)
NAME=BAYER AKTIENGESELLSCHAFT D 51368, LEVERKUSEN , COUNTRY=DE 

NAME=ID-LELYSTAD B V Edelhertweg 15, NL 8219, LELYSTAD , COUNTRY=NL 

(CA2414339)
NAME=BAYER AKTIENGESELLSCHAFT D 51368 , CITY=LEVERKUSEN , COUNTRY=DE 

NAME=ID-LELYSTAD B.V. Edelhertweg 15, NL 8219 , CITY=LELYSTAD , COUNTRY=NL 
";2;"SCHLAPP TOBIAS
RIJSEWIJK FRANCISCUS ANTONIUS MARIA";"(EP2365082)
DE; NL";"(EP2365082)
NAME=Schlapp, Tobias Gerstenkamp 10 , CITY=51061 Köln , COUNTRY=DE 

NAME=Rijsewijk, Franciscus Antonius Maria Schermer 9 , CITY=8244 AK Lelystad , COUNTRY=NL 
";"(EP2365082)
BVDV virus-like particles";"(EP2365082)
The present invention relates to bovine viral diarrhea virus (BVDV) virus-like particles, a polycistronic RNA and DNA corresponding thereto encoding a polyprotein of BVDV structural proteins that are sufficient to form BVDV virus-like particles, a viral vector encoding factors and structural proteins for the assembly of BVDV virus-like particles, a vaccine comprising BVDV virus-like particles, a diagnostic kit and methods for preparing BVDV virus-like particles.";"(WO200200881)
Claims
1. BVDV virus-like particles.
2. BVDV virus-like particles according to claim 1 comprising the BVDV structural proteins N, Ems, El and E2.
3. Polycistronic RNA molecule comprising a ribonucleotide sequence encoding a polyprotein consisting of the BVDV structural proteins N, Ems, El and E2, said RNA molecule being not spliced in the cell nucleus within its polyprotein encoding part.
4. RNA molecule according to claim 3 encoding a polyprotein having the amino acid sequence according to SEQ LD NO: 2 provided that said RNA molecule does not contain strong potential splice sites.
5. RNA molecule according to claim 4 comprising a ribonucleotide sequence corresponding to the polynucleotide sequence from Nucleotide No. 17 to Nucleotide No. 2710 according to SEQ ID NO: 1
6. DNA fragment corresponding to the RNA molecule according to any of claims 3 to 5.
7. DNA fragment according to claim 6 comprising the polynucleotide sequence from Nucleotide No. 17 to Nucleotide No. 2710 according to SEQ ID NO: 1.
8. DNA construct comprising the DNA according to claim 6 or 7 operably linked to cis-regulatory sequences capable of controlling the expression of the polyprotein encoded by said DNA.
. DNA construct according to claim 8 further comprising a terminator sequence.
10. DNA construct according to claim 8 or 9 wherein the cis-regulatory sequences are derived from the human cytomegalovirus immediate early 1 promoter and 5 ' untranslated leader.
11. DNA construct according to claim 9 wherein the terminator sequence is derived from the bovine growth hormone terminator sequence.
12. Viral vector encoding factors for the assembly of BVDV virus-like particles, said viral vector comprising the DNA construct according to any of claims 8 to ll.
13. Viral vector according to claim 12 which is BHV-1 or a BHV-1 deletion mutant.
14. Viral vector according to claim 13 which is Difivac-1 deposited under Accession No. 1-1213.
15. Viral vector according to any of claims 12 to 14 wherein said BHV-1 vector carries said DNA construct within the sequence coding for glycoprotein gE or at the position within a mutant BHV-1 vector where the sequence coding for glycoprotein gE is deleted.
16. Viral vector according to claim 15 which is A9-SV-1F9 deposited under the CNCM accession No. 1-2488.
17. Host cell containing the vector according to any of claims 12 to 16.
18. Vaccine comprising BVDV virus-like particles according to claim 1 or 2 and a pharmaceutically acceptable carrier or diluent.
19. Vaccine according to claim 18 further comprising BHV- 1.
20. Vaccine according to claim 19 wherein said BHV-1 lacks glycoprotein gE.
21. Vaccine according to claim 20 wherein said BHV-1 is Difivac-1 deposited under CNCM accession No. 1-1213.
22. Vaccine comprising recombinant viruses encoded by and including the vector according to any of claims 12 to 16 and a pharmaceutically acceptable carrier or diluent.
23. Diagnostic kit containing BVDV virus-like particles according to claim 1 or
 2.
24. Diagnostic kit according to claim 23 further containing BVDV NS3 and/or BVDV p80 protein or immunogenic fragments thereof.
25. Diagnostic kit according to claim 23 or 24 further containing BHV-1 gE protein and/or BHV-1 gl/gE protein complex or immunogenic fragments thereof.
26. Method for preparing BVDV virus-like particles comprising
 (a) inserting the DNA construct according to any of claims 8 to 11 into a viral vector encoding factors for the assembly of BVDV virus-like particles, (b) infecting suitable host cells capable of expressing the polyprotein encoded by said DNA, and
 (c) culturing said host cells under appropriate conditions.
27. Method for preparing recombinant viruses encoded by and including the vector according to any of claims 12 to 16 comprising
 (a) infecting suitable host cells with a viral vector according to 12 to 16,
 (b) culturing said host cells under appropriate conditions, and optionally
 (c) isolating the recombinant viruses.
28. Method for preparing a vaccine according to claim 22 comprising admixing the recombinant viruses with a pharmaceutically acceptable carrier.";"(EP2365082)
The present invention provides BVDV virus-like particles.
The invention contemplates BVDV virus-like particles which can be derived from various naturally occurring BVDV strains such as BVDV type I A strains (represented by the NADL strain), BVDV type I B strains (represented by the Osloss strain) and BVDV type II strains (represented by the 890 strain) including the cytopathic strain 87-2552 [Reddy et al. (1995), Antigenic differences between a field isolate and vaccine strains of bovine viral diarrhea virus, J.
The present invention relates to bovine viral diarrhea virus (BVDV) virus-like particles, a polycistronic RNA and DNA corresponding thereto encoding a polyprotein of BVDV structural proteins that are sufficient to form BVDV virus-like particles, a viral vector encoding factors and structural proteins for the assembly of BVDV virus-like particles, a vaccine comprising BVDV virus-like particles, a diagnostic kit and methods for preparing BVDV virus-like particles.
The present invention relates to bovine viral diarrhea virus (BVDV) virus-like particles, a polycistronic RNA and DNA corresponding thereto encoding a polyprotein of BVDV structural proteins that are sufficient to form BVDV virus-like particles, a viral vector encoding factors and structural proteins for the assembly of BVDV virus-like particles, a vaccine comprising BVDV virus-like particles, a diagnostic kit and methods for preparing BVDV virus-like particles.
The present invention provides BVDV virus-like particles.";"(EP2365082)
To prepare the BVDV virus-like particles according to the present invention it is favourable to use host cells which contain the information for synthesising the structural proteins from a DNA template.
In BVDV strain PT810 the first amino acid of the N protein is a serine but to allow efficient translation of the synthetic coding region, this amino acid was replaced by a methionine and preceded by a Kozak consensus sequence.
To allow easy cloning, the sequence recognised by the Stu I restriction enzyme, was added to both sides of the synthetic sequence bringing the total length to 2715 nucleotides.
Vaccines based on E2 of only one BVDV type are more restricted in their cross protection [Bolin and Ridpath (1996), Glycoprotein E2 of bovine viral diarrhea virus expressed in insect cells provides calves limited protection from systemic infection and disease, Arch.
However, upon interaction with the host cell, virus-like particles do not produce progeny viruses, because the proper nucleic acid sequences are not present in these particles.";"A61K-039/12
A61K-039/15
A61P-031/12
C07K-014/18
C12N-005/02
C12N-005/10
C12N-007/00
C12N-007/01
C12N-007/04
C12N-015/09
C12N-015/40
C12N-015/869";"(EP2365082)
1. BVDV virus-like particles.
3. Polycistronic RNA molecule comprising a ribonucleotide sequence encoding a polyprotein consisting of the BVDV structural proteins N, Erns, E1 and E2, said RNA molecule being not spliced in the cell nucleus within its polyprotein encoding part.";"(EP1170367)
BOVINE VIRAL DIARRHEA VIRUS(100,126)
VIRUS LIKE PARTICLE(100,21)
POLYCISTRONIC RNA MOLECULE(100,1)
VIRAL VECTOR ENCODING FACTOR(86,4)
RNA MOLECULE(70,8)
DIAGNOSTIC KIT(69,4)
RECOMBINANT VIRUS(67,9)
HOST CELL(63,17)
RIBONUCLEOTIDE SEQUENCE(59,4)
IMMUNOGENIC FRAGMENT(59,2)
CYTOPATHIC STRAIN(59,1)
GLYCOPROTEIN GE(57,2)
PROGENY VIRUS(56,1)
SYSTEMIC INFECTION(56,1)
POLYPROTEIN EXPRESSION(46,1)
VACCINE(45,26)
STRUCTURAL PROTEIN(43,18)
POLYPROTEIN(43,13)
BVDV STRUCTURAL PROTEIN(43,1)
RESTRICTION ENZYME(39,2)
DELETION MUTANT(39,1)
SYNTHETIC SEQUENCE BRINGING(39,1)
NUCLEOTIDE(38,10)
UNTRANSLATED LEADER(38,2)
ANTI BVDV ANTIBODY ABSENCE(37,1)
ANTIGENIC DIFFERENCE(37,1)
GE PROTEIN COMPLEX(33,1)
STRAIN(32,10)
KOZAK CONSENSUS SEQUENCE(32,3)
REGULATORY SEQUENCE(30,10)
INSECT CELL(30,2)
DNA CONSTRUCT(30,1)
ACCESSION(28,5)
CODING SEQUENCE(28,5)
METHIONINE(28,1)
NASAL FLUID SAMPLE(27,1)
BIOLOGICAL SAMPLE(25,1)
CODING REGION(24,3)
BIOLOGICAL FLUID SAMPLE(24,1)
DISEASE(22,1)
POLYPROTEIN ENCODING PART(21,2)
SERUM SAMPLE(21,2)
TRANSLATION(20,2)
PROPER NUCLEIC ACID SEQUENCE(20,1)
DILUENT(19,3)
CELL NUCLEUS(19,2)
BVDV VIRUS LIKE PARTICLE(18,5)
PESTIVIRUS GENOMIC ORGANIZATION(17,1)
GROWTH HORMONE TERMINATOR SEQUENCE(16,4)
PESTIVIRUS GENUS SUBDIVISION(16,1)
STRONG POTENTIAL(15,3)
ARCH(14,4)
BOVINE HERPES VIRUS(14,4)
PROKARYOTIC PLASMID(14,3)
N PROTEIN AMINOACID(14,2)
LIMITED PROTECTION(14,1)
NONESSENTIAL GLYCOPROTEIN DELETION(14,1)
VIRUS VACCINE(13,2)
INFECTIOUS BOVINE RHINO TRACHEITIS(13,1)
ZA STRAIN GENOMIC DNA(13,1)
CATTLE VACCINATION(12,2)
NONSTRUCTURAL PROTEIN(12,2)
BOVINE DIARRHEA VIRUS(12,1)
BVDV RECOMBINANT VIRUS(12,1)
CONCOMITANT DUPLICATION INVERSION(12,1)
EMBRYONIC BOVINE TRACHEA(12,1)
FLANKING RECOMBINATION FRAGMENT(12,1)
INFECTIOUS CULTURE SUPERNATANT(12,1)
L SERINE(12,1)
MRNA TRANSCRIPTION TERMINATION(12,1)
ENVELOPE GLYCOPROTEIN(11,2)
EXON INTRON JUNCTION(11,1)
INTRON EXON JUNCTION(11,1)
MURINE LEUKEMIA VIRUS(11,1)
TRANSPLACENTAL TRANSMISSIBILITY(11,1)
ZA GE(11,1)
ZA STRAIN GENOME(11,1)
PLASMID PVR(10,2)
TRANSCRIPTION INITIATION(10,2)
GLYCOPROTEIN E(9,3)
NUCLEOCAPSID PROTEIN N(9,3)
ATTENUATED GLYCOPROTEIN(9,1)
DELETED ZA STRAIN(9,1)
EUKARYOTIC EXPRESSION VECTOR(9,1)
INFECTIOUS BALANOPOSTITIS(9,1)
RE LATED FLAVIVIRUS(9,1)
RECOMBINANT VIRAL VECTOR(9,1)
RECOMBINATION EXPRESSION CASSETTE PLASMID(9,1)
TRANSMEMBRANE GLYCOPROTEIN(9,1)
SUBUNIT VACCINE(8,5)
SPLICEOSOME(8,4)
BOVINE CELL(8,3)
INDUCED DISEASE(8,3)
ETIOLOGICAL AGENT(8,2)
UNIQUE ECOR(8,2)
VACCINE VECTOR(8,2)
BOVINE GROWTH HORMONE TERMINATOR(8,1)
CORTICOTROPIN ADMINISTRATION(8,1)
CROSS PROTECTION(8,1)
DIGESTED PLASMID(8,1)
ESCHERICHIA BACTERIA(8,1)
EXPRESSION CASSETTE INSERTION(8,1)
FLANKING RECOMBINATION SEQUENCE(8,1)
FLAVIVIRIDAE FAMILY(8,1)
GENOME SEGMENT EXPRESSION(8,1)
INCUBATION FRESH TISSUE(8,1)
INDUCIBLE PROMOTER(8,1)
MARKER VACCINE EFFECTIVENESS(8,1)
NATURAL GE DELETION(8,1)
NEUTROPHIL SUPPRESSION(8,1)
PROMOTER LEADER(8,1)
RABBIT ALPHA GLOBIN GENE(8,1)
RECOMBINATION CASSETTE(8,1)
SPONTANEOUS MUTANT(8,1)
UTERO INFECTION(8,1)
VACCINE CANDIDATE(8,1)
VIRUS REPLICATION(8,1)
AMINOACID(7,6)
ADENOVIRUS VECTOR(7,1)
BOVINE GROWTH HORMONE GENE(7,1)
EUKARYOTIC GENE(7,1)
EUKARYOTIC MRNA(7,1)
GE ANTIBODY(7,1)
GENOMIC RNA(7,1)
GENUS PESTIVIRUS MEMBER(7,1)
HETEROLOGOUS GENE(7,1)
HOMOLOGOUS CHALLENGE(7,1)
HOST DISCRIMINATION(7,1)
IRRELEVANT RNA(7,1)
KILLED VACCINE(7,1)
LINEARIZED PS(7,1)
LIVE VACCINE(7,1)
MATERNAL ANTIBODY PRESENCE(7,1)
MUTANT ZA(7,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(7,1)
TISSUE CULTURE FLASK(7,1)
VACCINAL STRAIN(7,1)
VACCINATED HOST(7,1)
VIRUS PROTEIN STRUCTURE(7,1)
INSERTED GENE(6,3)
RNA POLYMERASE(6,3)
VIROLOGY(6,3)
ADJUVANT ACTIVITY(6,1)
BOVINE SERUM(6,1)
CDNA ENCODING(6,1)
CELL MONOLAYER(6,1)
CODING REGION TERMINUS(6,1)
COTRANSFECTION CELL(6,1)
ENVELOPE PROTEIN(6,1)
FETAL PROTECTION(6,1)
GE US REGION(6,1)
GENOME REGION CODING(6,1)
GI GENE(6,1)
HUMAN CYTOMEGALOVIRUS PROMOTER ENHANCER(6,1)
INVERTED REPEAT(6,1)
METHIONINE RESIDUE(6,1)
MRNA SYNTHESIS(6,1)
POSITIVE STRANDED RNA GENOME(6,1)
PS ECOR V SITE(6,1)
RECOMBINATION ANALYSIS(6,1)
ROUND PLAQUE(6,1)
SPLICE JUNCTION(6,1)
TITER RANGING(6,1)
TRANSCRIPTION COMPLEX(6,1)
MADIN DARBY BOVINE KIDNEY(5,4)
CULTURE MEDIUM(5,2)
GE COMPLEX(5,2)
MICROBIOL(5,2)
POLYADENYLATION(5,2)
PREVALENCE(5,2)
ZA RECOMBINATION POINT(5,2)
ACCEPTOR SEQUENCE(4,1)
ALPHAHERPESVIRUSE MEMBER(4,1)
BP LONG FRAGMENT ENCODING(4,1)
CELL DEBRIS(4,1)
CODING POTENTIAL(4,1)
DONOR SEQUENCE(4,1)
EFFICIENT TERMINATION(4,1)
ENDOPLASMATIC RETICULUM(4,1)
ESSENTIAL ROLE(4,1)
EXPRESSION STABILITY(4,1)
HATCHED BOX(4,1)
HOST SIGNAL PEPTIDASE(4,1)
IMMUNE SYSTEM T CELL COMPARTMENT(4,1)
IMMUNOSUPPRESSION(4,1)
INFECTED CELL(4,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(4,1)
INTRACELLULAR PRODUCTION(4,1)
LETTER CODE(4,1)
PC GENE VERSION(4,1)
PESTIVIRUS TAXONOMIC PERSPECTIVE(4,1)
POSITIVE PLAQUE(4,1)
(EP2365082)
BOVINE VIRAL DIARRHEA VIRUS(100,121)
VIRUS LIKE PARTICLE(100,23)
BVDV STRUCTURAL PROTEIN POLYPROTEIN(100,1)
VIRAL VECTOR ENCODING FACTOR(94,5)
POLYCISTRONIC RNA MOLECULE(83,1)
DIAGNOSTIC KIT(76,5)
POLYCISTRONIC RNA(70,1)
RNA MOLECULE(58,8)
RECOMBINANT VIRUS(56,9)
HOST CELL(53,17)
RIBONUCLEOTIDE SEQUENCE(49,4)
IMMUNOGENIC FRAGMENT(49,2)
CYTOPATHIC STRAIN(49,1)
GLYCOPROTEIN GE(48,2)
PROGENY VIRUS(47,1)
SYSTEMIC INFECTION(47,1)
STRUCTURAL PROTEIN(44,19)
VACCINE(43,27)
BVDV(42,4)
DNA(40,18)
POLYPROTEIN EXPRESSION(39,1)
POLYPROTEIN(36,13)
RESTRICTION ENZYME(32,2)
UNTRANSLATED LEADER(32,2)
DELETION MUTANT(32,1)
SYNTHETIC SEQUENCE BRINGING(32,1)
NUCLEOTIDE(31,10)
ANTI BVDV ANTIBODY ABSENCE(30,1)
ANTIGENIC DIFFERENCE(30,1)
STRAIN(27,10)
GE PROTEIN COMPLEX(27,1)
BVDV VIRUS LIKE PARTICLE(26,8)
KOZAK CONSENSUS SEQUENCE(26,3)
REGULATORY SEQUENCE(25,10)
INSECT CELL(25,2)
DNA CONSTRUCT(25,1)
ACCESSION(23,5)
CODING SEQUENCE(23,5)
METHIONINE(23,1)
NASAL FLUID SAMPLE(22,1)
BIOLOGICAL SAMPLE(21,1)
CODING REGION(20,3)
BIOLOGICAL FLUID SAMPLE(20,1)
POLYPROTEIN ENCODING PART(18,2)
SERUM SAMPLE(18,2)
DISEASE(18,1)
TRANSLATION(17,2)
PROPER NUCLEIC ACID SEQUENCE(17,1)
DILUENT(16,3)
CELL NUCLEUS(16,2)
PESTIVIRUS GENOMIC ORGANIZATION(14,1)
GROWTH HORMONE TERMINATOR SEQUENCE(13,4)
STRONG POTENTIAL(13,3)
PESTIVIRUS GENUS SUBDIVISION(13,1)
BOVINE HERPES VIRUS(12,4)
PROKARYOTIC PLASMID(12,3)
N PROTEIN AMINOACID(12,2)
LIMITED PROTECTION(12,1)
NONESSENTIAL GLYCOPROTEIN DELETION(12,1)
ARCH(11,4)
ZA STRAIN GENOMIC DNA(11,1)
CATTLE VACCINATION(10,2)
NONSTRUCTURAL PROTEIN(10,2)
VIRUS VACCINE(10,2)
BOVINE DIARRHEA VIRUS(10,1)
BVDV RECOMBINANT VIRUS(10,1)
CONCOMITANT DUPLICATION INVERSION(10,1)
EMBRYONIC BOVINE TRACHEA(10,1)
FLANKING RECOMBINATION FRAGMENT(10,1)
INFECTIOUS CULTURE SUPERNATANT(10,1)
L SERINE(10,1)
MRNA TRANSCRIPTION TERMINATION(10,1)
ENVELOPE GLYCOPROTEIN(9,2)
EXON INTRON JUNCTION(9,1)
INTRON EXON JUNCTION(9,1)
MURINE LEUKEMIA VIRUS(9,1)
TRANSPLACENTAL TRANSMISSIBILITY(9,1)
ZA GE(9,1)
ZA STRAIN GENOME(9,1)
PLASMID PVR(8,2)
TRANSCRIPTION INITIATION(8,2)
ATTENUATED GLYCOPROTEIN(8,1)
DELETED ZA STRAIN(8,1)
EUKARYOTIC EXPRESSION VECTOR(8,1)
INFECTIOUS BALANOPOSTITIS(8,1)
RE LATED FLAVIVIRUS(8,1)
RECOMBINANT VIRAL VECTOR(8,1)
RECOMBINATION EXPRESSION CASSETTE PLASMID(8,1)
TRANSMEMBRANE GLYCOPROTEIN(8,1)
BOVINE CELL(7,3)
GLYCOPROTEIN E(7,3)
INDUCED DISEASE(7,3)
NUCLEOCAPSID PROTEIN N(7,3)
ETIOLOGICAL AGENT(7,2)
UNIQUE ECOR(7,2)
VACCINE VECTOR(7,2)
BOVINE GROWTH HORMONE TERMINATOR(7,1)
CORTICOTROPIN ADMINISTRATION(7,1)
CROSS PROTECTION(7,1)
DIGESTED PLASMID(7,1)
ESCHERICHIA BACTERIA(7,1)
EXPRESSION CASSETTE INSERTION(7,1)
FLANKING RECOMBINATION SEQUENCE(7,1)
FLAVIVIRIDAE FAMILY(7,1)
GENOME SEGMENT EXPRESSION(7,1)
INCUBATION FRESH TISSUE(7,1)
INDUCIBLE PROMOTER(7,1)
MARKER VACCINE EFFECTIVENESS(7,1)
NATURAL GE DELETION(7,1)
NEUTROPHIL SUPPRESSION(7,1)
PROMOTER LEADER(7,1)
RABBIT ALPHA GLOBIN GENE(7,1)
RECOMBINATION CASSETTE(7,1)
SPONTANEOUS MUTANT(7,1)
UTERO INFECTION(7,1)
VACCINE CANDIDATE(7,1)
VIRUS REPLICATION(7,1)
AMINOACID(6,6)
SUBUNIT VACCINE(6,5)
SPLICEOSOME(6,4)
ADENOVIRUS VECTOR(6,1)
BOVINE GROWTH HORMONE GENE(6,1)
EUKARYOTIC GENE(6,1)
EUKARYOTIC MRNA(6,1)
GE ANTIBODY(6,1)
GENOMIC RNA(6,1)
GENUS PESTIVIRUS MEMBER(6,1)
HETEROLOGOUS GENE(6,1)
HOMOLOGOUS CHALLENGE(6,1)
HOST DISCRIMINATION(6,1)
IRRELEVANT RNA(6,1)
KILLED VACCINE(6,1)
LINEARIZED PS(6,1)
LIVE VACCINE(6,1)
MATERNAL ANTIBODY PRESENCE(6,1)
MUTANT ZA(6,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(6,1)
TISSUE CULTURE FLASK(6,1)
VACCINAL STRAIN(6,1)
VACCINATED HOST(6,1)
VIRUS PROTEIN STRUCTURE(6,1)
INSERTED GENE(5,3)
RNA POLYMERASE(5,3)
VIROLOGY(5,3)
ADJUVANT ACTIVITY(5,1)
BOVINE SERUM(5,1)
CDNA ENCODING(5,1)
CELL MONOLAYER(5,1)
CODING REGION TERMINUS(5,1)
COTRANSFECTION CELL(5,1)
ENVELOPE PROTEIN(5,1)
FETAL PROTECTION(5,1)
GE US REGION(5,1)
GENOME REGION CODING(5,1)
GI GENE(5,1)
HUMAN CYTOMEGALOVIRUS PROMOTER ENHANCER(5,1)
INVERTED REPEAT(5,1)
METHIONINE RESIDUE(5,1)
MRNA SYNTHESIS(5,1)
POSITIVE STRANDED RNA GENOME(5,1)
PS ECOR V SITE(5,1)
RECOMBINATION ANALYSIS(5,1)
ROUND PLAQUE(5,1)
SPLICE JUNCTION(5,1)
TITER RANGING(5,1)
TRANSCRIPTION COMPLEX(5,1)
MADIN DARBY BOVINE KIDNEY(4,4)
CULTURE MEDIUM(4,2)
GE COMPLEX(4,2)
MICROBIOL(4,2)
POLYADENYLATION(4,2)
PREVALENCE(4,2)
ZA RECOMBINATION POINT(4,2)
ACCEPTOR SEQUENCE(4,1)
ALPHAHERPESVIRUSE MEMBER(4,1)
BP LONG FRAGMENT ENCODING(4,1)
CELL DEBRIS(4,1)
CODING POTENTIAL(4,1)
DONOR SEQUENCE(4,1)
EFFICIENT TERMINATION(4,1)
ENDOPLASMATIC RETICULUM(4,1)
ESSENTIAL ROLE(4,1)
EXPRESSION STABILITY(4,1)
HATCHED BOX(4,1)
HOST SIGNAL PEPTIDASE(4,1)
IMMUNE SYSTEM T CELL COMPARTMENT(4,1)
IMMUNOSUPPRESSION(4,1)
INFECTED CELL(4,1)
INFECTIOUS BOVINE RHINOTRACHEITIS(4,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(4,1)
INTRACELLULAR PRODUCTION(4,1)
LETTER CODE(4,1)
PC GENE VERSION(4,1)
PESTIVIRUS TAXONOMIC PERSPECTIVE(4,1)
POSITIVE PLAQUE(4,1)
(US20030129744)
BOVINE VIRAL DIARRHEA VIRUS(100,21)
VIRUS LIKE PARTICLE(100,20)
BVDV VIRUS LIKE PARTICLE(100,18)
BVDV STRUCTURAL PROTEIN POLYPROTEIN(100,5)
POLYCISTRONIC RNA MOLECULE(100,2)
VIRAL VECTOR ENCODING FACTOR(95,6)
POLYCISTRONIC RNA(90,2)
DIAGNOSTIC KIT(89,6)
RNA MOLECULE(76,8)
RECOMBINANT VIRUS(73,9)
STRUCTURAL PROTEIN(70,10)
IMMUNOGENIC FRAGMENT(64,2)
CYTOPATHIC STRAIN(64,1)
CNCM ACCESSION(63,3)
GLYCOPROTEIN GE(62,2)
PROGENY VIRUS(61,1)
SYSTEMIC INFECTION(61,1)
RIBONUCLEOTIDE SEQUENCE(60,5)
NADL STRAIN(60,1)
BVDV(59,32)
VACCINE(59,25)
HOST CELL(57,19)
POLYPROTEIN EXPRESSION(50,1)
DNA CONSTRUCT(47,2)
MUTANT BHV(45,1)
DNA(43,17)
RESTRICTION ENZYME(42,2)
DELETION MUTANT(42,1)
EFFICIENT TRANSLATION(42,1)
SYNTHETIC SEQUENCE BRINGING(42,1)
NUCLEOTIDE(41,10)
POLYPROTEIN(41,10)
UNTRANSLATED LEADER(41,2)
ANTIGENIC DIFFERENCE(40,1)
GE PROTEIN COMPLEX(36,1)
KOZAK CONSENSUS SEQUENCE(34,3)
REGULATORY SEQUENCE(33,10)
INSECT CELL(33,2)
STRAIN(32,6)
METHIONINE(32,1)
GLYCOPROTEIN(30,6)
CODING SEQUENCE(30,5)
DNA FRAGMENT(30,2)
SERINE(28,1)
CODING REGION(24,4)
DISEASE(24,1)
SV 1F(23,5)
CLONE(23,2)
PROPER NUCLEIC ACID SEQUENCE(22,1)
PROTEIN(20,17)
DILUENT(20,4)
POLYPROTEIN ENCODING PART(20,3)
BVDV NONSTRUCTURAL PROTEIN(20,2)
BVDV NUCLEOCAPSID PROTEIN(20,2)
FATHER(20,1)
BVDV VACCINE(18,4)
GROWTH HORMONE TERMINATOR SEQUENCE(18,4)
CELL NUCLEUS(18,3)
PESTIVIRUS GENOMIC ORGANIZATION(18,1)
STRONG POTENTIAL(17,3)
BVDV RECOMBINATION EXPRESSION CASSETTE(17,2)
INFECTIOUS PUSTULAR VULVOVAGINITIS(17,1)
PESTIVIRUS GENUS SUBDIVISION(17,1)
BOVINE HERPES VIRUS(16,4)
BVDV INDUCED DISEASE(16,3)
PROKARYOTIC PLASMID(16,3)
LIMITED PROTECTION(16,1)
NONESSENTIAL GLYCOPROTEIN DELETION(16,1)
AMINOACID(15,6)
ARCH(15,4)
VIRUS VACCINE(14,2)
DIGESTING PLASMID BSM(14,1)
FETAL BVDV INFECTION(14,1)
INFECTIOUS BOVINE RHINO TRACHEITIS(14,1)
ZA STRAIN GENOMIC DNA(14,1)
CATTLE VACCINATION(13,2)
BVDV RECOMBINANT VIRUS(13,1)
CONCOMITANT DUPLICATION INVERSION(13,1)
EMBRYONIC BOVINE TRACHEA(13,1)
FLANKING RECOMBINATION FRAGMENT(13,1)
INFECTIOUS CULTURE SUPERNATANT(13,1)
MADIN DARBY BOVINE KIDNEY(13,1)
MRNA TRANSCRIPTION TERMINATION(13,1)
ENVELOPE GLYCOPROTEIN(12,2)
BVDV CDNA ENCODING(12,1)
BVDV EXPRESSION CASSETTE(12,1)
BVDV GENOME STRUCTURAL PROTEIN(12,1)
BVDV STRAIN ATTENUATION(12,1)
ENDOPLASMATIC RETICULUM(12,1)
EXON INTRON JUNCTION(12,1)
INACTIVATED BVDV STRAIN(12,1)
INTRON EXON JUNCTION(12,1)
ISOLATED BVDV GLYCOPROTEIN(12,1)
MURINE LEUKEMIA VIRUS(12,1)
TRANSPLACENTAL TRANSMISSIBILITY(12,1)
ZA GE(12,1)
ZA STRAIN GENOME(12,1)
PLASMID PVR(11,2)
TRANSCRIPTION INITIATION(11,2)
ATTENUATED GLYCOPROTEIN(10,1)
BACULOVIRUS BVDV(10,1)
DELETED ZA STRAIN(10,1)
EUKARYOTIC EXPRESSION VECTOR(10,1)
INFECTIOUS BALANOPOSTITIS(10,1)
MDBK CELL MONOLAYER(10,1)
OPTION SPLICE JUNCTION(10,1)
RECOMBINANT VIRAL VECTOR(10,1)
RECOMBINANT VIRUS EXPRESSION(10,1)
RECOMBINATION EXPRESSION CASSETTE PLASMID(10,1)
TRANSMEMBRANE GLYCOPROTEIN(10,1)
BOVINE CELL(9,3)
ETIOLOGICAL AGENT(9,2)
VACCINE VECTOR(9,2)
ACTH ADMINISTRATION(9,1)
ATTENUATED BVDV(9,1)
BHV GENOME(9,1)
BOVINE GROWTH HORMONE TERMINATOR(9,1)
BVDV CAPSID(9,1)
BVDV VIRION(9,1)
CROSS PROTECTION(9,1)
ESCHERICHIA BACTERIA(9,1)
EXPRESSION CASSETTE INSERTION(9,1)
FLANKING RECOMBINATION SEQUENCE(9,1)
FLAVIVIRIDAE FAMILY(9,1)
GENOME SEGMENT EXPRESSION(9,1)
INCUBATION FRESH TISSUE(9,1)
INDUCIBLE PROMOTER(9,1)
MARKER VACCINE EFFECTIVENESS(9,1)
NATURAL GE DELETION(9,1)
NEUTROPHIL SUPPRESSION(9,1)
PROMOTER LEADER(9,1)
RABBIT ALPHA GLOBIN GENE(9,1)
RECOMBINATION CASSETTE(9,1)
SPONTANEOUS BHV(9,1)
SPONTANEOUS MUTANT(9,1)
UTERO INFECTION(9,1)
VACCINE CANDIDATE(9,1)
VIRUS REPLICATION(9,1)
SUBUNIT VACCINE(8,5)
SPLICEOSOME(8,4)
ADENOVIRUS VECTOR(8,1)
ANTI BVDV ANTIBODY ABSENCE(8,1)
BHV ISOLATION(8,1)
BOVINE GROWTH HORMONE GENE(8,1)
BVDV GENE(8,1)
BVDV PERCENTAGE(8,1)
EUKARYOTIC GENE(8,1)
EUKARYOTIC MRNA(8,1)
GE ANTIBODY(8,1)
GENOMIC RNA(8,1)
GENUS PESTIVIRUS MEMBER(8,1)
HETEROLOGOUS GENE(8,1)
HOMOLOGOUS CHALLENGE(8,1)
HOST DISCRIMINATION(8,1)
IRRELEVANT RNA(8,1)
KILLED VACCINE(8,1)
LINEARIZED PS(8,1)
LIVE VACCINE(8,1)
MATERNAL ANTIBODY PRESENCE(8,1)
MUTANT STRUCTURAL PROTEIN(8,1)
MUTANT ZA(8,1)
NATION ALE(8,1)
PESTIVIRUS TAXONOMIC PERSPECTIVE(8,1)
PUBLISHED BVDV SEQUENCE(8,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(8,1)
TISSUE CULTURE FLASK(8,1)
VACCINAL STRAIN(8,1)
VACCINATED HOST(8,1)
VIRUS PROTEIN STRUCTURE(8,1)
PS SITE(7,2)
SERUM SAMPLE(7,2)
ECOR(6,3)
INSERTED GENE(6,3)
RNA POLYMERASE(6,3)
VIROLOGY(6,3)
ACCIDENTAL SPLICING SIGNAL(6,1)
ADJUVANT ACTIVITY(6,1)
ALUMINUM HYDROXIDE(6,1)
BHV PRODUCTION(6,1)
BOVINE SERUM(6,1)
BVDV RNA(6,1)
CODING REGION TERMINUS(6,1)
COTRANSFECTION CELL(6,1)
ENVELOPE PROTEIN(6,1)
FETAL PROTECTION(6,1)
GENOME REGION CODING(6,1)
GI GENE(6,1)
HUMAN CYTOMEGALOVIRUS PROMOTER ENHANCER(6,1)
INVERTED REPEAT(6,1)
METHIONINE RESIDUE(6,1)
MRNA SYNTHESIS(6,1)
POSITIVE STRANDED RNA GENOME(6,1)
RECENT BVDV(6,1)
RECOMBINATION ANALYSIS(6,1)
ROUND PLAQUE(6,1)
SERINE RESIDUE(6,1)
TITER RANGING(6,1)
TRANSCRIPTION COMPLEX(6,1)
BOVINE VIRAL DIARRHEA(5,2)
CULTURE MEDIUM(5,2)
GE COMPLEX(5,2)
POLYADENYLATION(5,2)
PREVALENCE(5,2)
ZA RECOMBINATION POINT(5,2)
ACCEPTOR SEQUENCE(5,1)
BHV CONSTRUCTION(5,1)
BIOLOGICAL FLUID SAMPLE(5,1)
BIOLOGICAL SAMPLE(5,1)
BP LONG FRAGMENT ENCODING(5,1)
BVDV MEDIUM(5,1)
CELL DEBRIS(5,1)
CODING POTENTIAL(5,1)
DONOR SEQUENCE(5,1)
EFFICIENT TERMINATION(5,1)
ESSENTIAL ROLE(5,1)
EXPRESSION STABILITY(5,1)
FLAVIVIRUS(5,1)
GL GE(5,1)
HATCHED BOX(5,1)
HOST SIGNAL PEPTIDASE(5,1)
IMMUNOSUPPRESSION(5,1)
INFECTED CELL(5,1)
INTRACELLULAR PRODUCTION(5,1)
(WO200200881)
BVDV VIRUS LIKE PARTICLE(100,18)
POLYCISTRONIC RNA MOLECULE(100,2)
VIRAL VECTOR ENCODING FACTOR(94,5)
DIAGNOSTIC KIT(91,5)
RNA MOLECULE(89,8)
RECOMBINANT VIRUS(85,9)
BVDV STRUCTURAL PROTEIN(76,13)
IMMUNOGENIC FRAGMENT(75,2)
CYTOPATHIC STRAIN(75,1)
GLYCOPROTEIN GE(73,2)
PROGENY VIRUS(72,1)
SYSTEMIC INFECTION(72,1)
RIBONUCLEOTIDE SEQUENCE(70,5)
HOST CELL(67,18)
BVDV(65,24)
VACCINE(65,24)
STRUCTURAL PROTEIN(63,8)
POLYPROTEIN(59,11)
POLYPROTEIN EXPRESSION(59,1)
DNA CONSTRUCT(55,2)
RESTRICTION ENZYME(50,2)
DELETION MUTANT(50,1)
EFFICIENT TRANSLATION(50,1)
SYNTHETIC SEQUENCE BRINGING(50,1)
NUCLEOTIDE(48,10)
UNTRANSLATED LEADER(48,2)
ANTIGENIC DIFFERENCE(47,1)
STRAIN(44,8)
BOVINE VIRAL DIARRHEA VIRUS(42,9)
GE PROTEIN COMPLEX(42,1)
KOZAK CONSENSUS SEQUENCE(40,3)
REGULATORY SEQUENCE(38,10)
INSECT CELL(38,2)
ACCESSION(37,4)
METHIONINE(36,1)
CODING SEQUENCE(35,5)
DNA FRAGMENT(35,2)
CODING REGION(29,4)
DISEASE(28,1)
BVDV STRUCTURAL PROTEIN POLYPROTEIN(27,3)
CLONE(27,2)
VIRUS LIKE PARTICLE(26,16)
PROPER NUCLEIC ACID SEQUENCE(26,1)
POLYPROTEIN ENCODING PART(24,3)
DILUENT(23,4)
BVDV VACCINE(21,4)
GROWTH HORMONE TERMINATOR SEQUENCE(21,4)
CELL NUCLEUS(21,3)
PESTIVIRUS GENOMIC ORGANIZATION(21,1)
INFECTIOUS PUSTULAR VULVOVAGINITIS(20,1)
PESTIVIRUS GENUS SUBDIVISION(20,1)
BVDV INDUCED DISEASE(19,3)
PROKARYOTIC PLASMID(19,3)
STRONG POTENTIAL(19,3)
ARCH(18,4)
N PROTEIN AMINOACID(18,2)
INFECTIOUS BOVINE RHINO TRACHEITIS(18,1)
LIMITED PROTECTION(18,1)
BVDV GLYCOPROTEIN(17,2)
BVDV NUCLEOCAPSID PROTEIN(17,1)
FETAL BVDV INFECTION(17,1)
RABBIT ALPHAGLOBIN GENE(17,1)
TRANSMEMBRANE GLYCOPROTEIN EL(17,1)
VIRUS VACCINE(16,2)
CATTLE VACCINATION(15,2)
BVDV RECOMBINANT VIRUS(15,1)
CONCOMITANT DUPLICATION INVERSION(15,1)
EMBRYONIC BOVINE TRACHEA(15,1)
FLANKING RECOMBINATION FRAGMENT(15,1)
INFECTIOUS CULTURE SUPERNATANT(15,1)
L SERINE(15,1)
MRNA TRANSCRIPTION TERMINATION(15,1)
ENVELOPE GLYCOPROTEIN(14,2)
BVDV CDNA ENCODING(14,1)
BVDV EXPRESSION CASSETTE(14,1)
BVDV GENOME STRUCTURAL PROTEIN(14,1)
BVDV RECOMBINATION EXPRESSION CASSETTE(14,1)
EXON INTRON JUNCTION(14,1)
INACTIVATED BVDV STRAIN(14,1)
INTRON EXON JUNCTION(14,1)
MURINE LEUKEMIA VIRUS(14,1)
TRANSPLACENTAL TRANSMISSIBILITY(14,1)
ZA STRAIN GENOME(14,1)
GLYCOPROTEIN E(13,2)
TRANSCRIPTION INITIATION(13,2)
ADENOVIRUS VECTOR(12,1)
ATTENUATED GLYCOPROTEIN(12,1)
BACULOVIRUS BVDV(12,1)
BOVINE HERPES VIRUS NEGATIVE STRAIN(12,1)
DELETED ZA STRAIN(12,1)
EUKARYOTIC EXPRESSION VECTOR(12,1)
FLANKING RECOMBI NATION SEQUENCE(12,1)
INFECTIOUS BALANOPOSTITIS(12,1)
RECOMBINANT VIRAL VECTOR(12,1)
RECOMBINANT VIRUS EXPRESSION(12,1)
RECOMBINATION EXPRESSION CASSETTE PLASMID(12,1)
EL PROTEIN(11,2)
ETIOLOGICAL AGENT(11,2)
UNIQUE ECOR(11,2)
VACCINE VECTOR(11,2)
SUBUNIT VACCINE(10,5)
SPLICEOSOME(10,4)
BOVINE CELL(10,3)
ATTENUATED BVDV(10,1)
BOVINE GROWTH HORMONE TERMINATOR(10,1)
CORTICOTROPIN ADMINISTRATION(10,1)
CROSS PROTECTION(10,1)
ESCHERICHIA BACTERIA(10,1)
EXPRESSION CASSETTE INSERTION(10,1)
FLAVIVIRIDAE FAMILY(10,1)
GENOME SEGMENT EXPRESSION(10,1)
INCUBATION FRESH TISSUE(10,1)
INDUCIBLE PROMOTER(10,1)
MARKER VACCINE EFFECTIVENESS(10,1)
NATURAL GE DELETION(10,1)
NEUTROPHIL SUPPRESSION(10,1)
PROMOTER LEADER(10,1)
RECOMBINATION CASSETTE(10,1)
SPONTANEOUS MUTANT(10,1)
UTERO INFECTION(10,1)
VACCINE CANDIDATE(10,1)
VIRUS REPLICATION(10,1)
AMINOACID(9,5)
ANTI BVDV ANTIBODY ABSENCE(9,1)
BOVINE GROWTH HORMONE GENE(9,1)
EUKARYOTIC GENE(9,1)
EUKARYOTIC MRNA(9,1)
GE ANTIBODY(9,1)
GENUS PESTIVIRUS MEMBER(9,1)
HETEROLOGOUS GENE(9,1)
HOMOLOGOUS CHALLENGE(9,1)
HOST DISCRIMINATION(9,1)
IRRELEVANT RNA(9,1)
KILLED VACCINE(9,1)
LINEARIZED PS(9,1)
LIVE VACCINE(9,1)
MATERNAL ANTIBODY PRESENCE(9,1)
MUTANT STRUCTURAL PROTEIN(9,1)
MUTANT ZA(9,1)
NEIGHBORING US(9,1)
PLASMID PNR(9,1)
PLASMID PVR(9,1)
PUBLISHED BVDV SEQUENCE(9,1)
RESTRICTION ENZYME RECOGNITION SEQUENCE(9,1)
TISSUE CULTURE FLASK(9,1)
VACCINAL STRAIN(9,1)
VACCINATED HOST(9,1)
VIRUS PROTEIN STRUCTURE(9,1)
INSERTED GENE(8,3)
RNA POLYMERASE(8,3)
VIROLOGY(8,3)
SERUM SAMPLE(8,2)
ADJUVANT ACTIVITY(7,1)
BOVINE SERUM(7,1)
BVDV LA(7,1)
BVDV RNA(7,1)
CELL MONOLAYER(7,1)
CODING REGION TERMINUS(7,1)
COTRANSFECTION CELL(7,1)
ENVELOPE PROTEIN(7,1)
FETAL PROTECTION(7,1)
GENOME REGION CODING(7,1)
GL GENE(7,1)
HUMAN CYTOMEGALOVIRUS PROMOTER ENHANCER(7,1)
INVERTED REPEAT(7,1)
METHIONINE RESIDUE(7,1)
MRNA SYNTHESIS(7,1)
NUCLEOCAPSID PROTEIN N(7,1)
PLASMID ENCODING(7,1)
RECENT BVDV(7,1)
RECOMBINATION ANALYSIS(7,1)
ROUND PLAQUE(7,1)
SPLICE JUNCTION(7,1)
TITER RANGING(7,1)
TRANSCRIPTION COMPLEX(7,1)
BOVINE VIRAL DIARRHEA(6,2)
BVDV NONSTRUCTURAL PROTEIN(6,2)
CULTURE MEDIUM(6,2)
GE COMPLEX(6,2)
POLYADENYLATION(6,2)
PREVALENCE(6,2)
ZA RECOMBINATION POINT(6,2)
ACCEPTOR SEQUENCE(6,1)
BIOLOGICAL FLUID SAMPLE(6,1)
BIOLOGICAL SAMPLE(6,1)
BP LONG FRAGMENT ENCODING(6,1)
CELL DEBRIS(6,1)
CODING POTENTIAL(6,1)
DONOR SEQUENCE(6,1)
EBTR CELL(6,1)
ECOR V SITE(6,1)
EFFICIENT TERMINATION(6,1)
ENDOPLASMATIC RETICULUM(6,1)
ESSENTIAL ROLE(6,1)
EXPRESSION STABILITY(6,1)
FLAVIVIRUS(6,1)
HATCHED BOX(6,1)
HOST SIGNAL PEPTIDASE(6,1)
INFECTED CELL(6,1)
INTRACELLULAR PRODUCTION(6,1)
LETTER CODE(6,1)
MAJOR GLYCOPROTEIN(6,1)
NASAL FLUID SAMPLE(6,1)
NONESSENTIAL GLYCOPROTEIN DELETION(6,1)
PC GENE VERSION(6,1)
PESTIVIRUS TAXONOMIC PERSPECTIVE(6,1)
(JP2004501644)
BOVINE VIRAL DIARRHEA VIRUS(100,22)
VIRUS LIKE PARTICLE(100,20)
POLYPROTEIN(100,4)
VIRUS LIKE PARTICLE BVDV(100,2)
E1E(100,1)
PESTIVIRUS GENUS SUBDIVISION(100,1)
POLYCISTRONIC RNA(67,1)
RNA MOLECULE CODING(63,1)
RIBONUCLEOTIDE MOLECULE(62,1)
RECOMBINANT VIRUS(61,6)
POLYCISTRONIC RNA ENCODING(60,1)
NEUTROPHIL SUPPRESSION(58,1)
RNA MOLECULE(57,3)
BVDV STRAIN ATTENUATION(56,2)
SUBUNIT VACCINE BVDV(56,1)
READYIDENTIFICATION RNA MOLECULE(54,1)
ACTH ADMINISTRATION(53,1)
VIRAL VECTOR ENCODING FACTOR(52,2)
FETAL SHEEP MODEL(52,1)
HOMOLOGOUS CHALLENGE(52,1)
IMMUNOGENIC FRAGMENT(51,2)
INTRAUTERINE INFECTION(51,1)
MUTANT STRUCTURAL PROTEIN(50,1)
VACCINAL STRAIN(50,1)
SYSTEMIC INFECTION(48,1)
MATERNAL ANTIBODY PRESENCE(47,1)
NONSTRUCTURAL PROTEIN FACTOR(44,1)
VACCINE VECTOR(44,1)
BVDV STRUCTURAL PROTEIN(42,2)
VACCINE(41,22)
PROTEIN EXPRESSION(39,3)
ENVELOPE GLYCOPROTEIN(38,3)
TERMINATION SEQUENCE(38,3)
FETAL PROTECTION(38,1)
MUTANT GLYCOPROTEIN(38,1)
SEQUENCE DIVERSITY(38,1)
HOST CELL(37,11)
REGULATORY SEQUENCE(36,8)
NON TRANSLATED LEADER(36,2)
DEFICIENT MUTANT(35,1)
DNA VECTOR(35,1)
GE GLYCOPROTEIN(35,1)
DNA(34,10)
DILUENT VACCINE(34,1)
POLY RNA MOLECULE(34,1)
GLYCOPROTEIN(32,7)
SEQ DNA POLYNUCLEOTIDE SEQUENCE(32,1)
TRANSLATION START CODON(31,1)
IMMUNOGENICITY(30,1)
INTENDED BVDV STRUCTURAL PROTEIN(29,1)
GE PROTEIN COMPLEX(28,1)
VECTOR ENCODING CONSTRUCTION(27,1)
INSECT CELL(26,2)
DNA CONSTRUCT(26,1)
BACULOVIRUS(25,1)
BVDV(24,33)
PROTEIN(24,12)
DNA FRAGMENT(24,2)
CODING SEQUENCE(23,2)
POLY CIS(23,1)
BOVINE VIRUS DIARRHEA VIRUS(22,1)
DELETION(22,1)
LYMPHOCYTE FUNCTION(22,1)
TRANSLATION(22,1)
SPLICE SITE(21,2)
DIAGNOSIS(20,3)
TRANSCRIPTION(20,2)
SV 1F(19,7)
SUBUNIT VACCINE(19,3)
DISEASE(19,1)
POLYPROTEIN PORTION(19,1)
SHEEP(19,1)
DIAGNOSING BVDV(18,1)
VIROLOGY(17,3)
2707BP EXPRESSION CASSETTE ENCODING(16,2)
AMP(15,1)
RECOMBINANT BHV(14,4)
CONSTRUCTION ERROR(14,1)
DETECTED LEVEL(14,1)
PESTIVIRUS GENOMIC ORGANIZATION(14,1)
INFECTION(13,6)
CNCM(13,2)
NUCLEOTIDE NUMBER(13,2)
ARCH(12,4)
PROKARYOTIC PLASMID(12,3)
RECOMBINANT EXPRESSION CASSETTE(12,2)
STRAIN BVDV STRUCTURAL PROTEIN(12,2)
VAN(12,2)
LIMITED PROTECTION(12,1)
AMINOACID SUBSTITUTION(11,1)
ENVELOPE TRANSMEMBRANE GLYCOPROTEIN(11,1)
GENE BVDV GE(11,1)
E1AND(10,4)
BVDV VACCINE(10,2)
CATTLE VACCINATION(10,2)
NUCLEOCAPSID PROTEIN(10,2)
BOVINE DIARRHEA VIRUS(10,1)
EMBRYONIC BOVINE TRACHEA(10,1)
GE BHV 1GE BVDV(10,1)
MADIN DARBY BOVINE KIDNEY(10,1)
SEQUENCE ENCODING POSITION(10,1)
STRUCTURAL PROTEIN BVDV POLYPROTEIN(10,1)
BOVINE HERPES VIRUS(9,2)
NATURAL GE DELETION(9,2)
RECOMBINANT FRAGMENT(9,2)
ACCESSION NUMBER(9,1)
BVDV CDNA ENCODING(9,1)
BVDV RECOMBINANT ZA STRAIN(9,1)
CASSETTE GE(9,1)
DNA POLYCISTRONIC RNA(9,1)
EXON INTRON JUNCTION(9,1)
INTRON EXON JUNCTION(9,1)
ISOLATED BVDV GLYCOPROTEIN(9,1)
STRAIN ZA GENOME(9,1)
TRANSCRIPTION MRNA TERMINATION(9,1)
TRANSPLACENTAL TRANSMISSIBILITY(9,1)
AMINOACID SEQUENCE(8,2)
ATTENUATED GLYCOPROTEIN(8,1)
ENDOPLASMIC RETICULUM LUMEN(8,1)
NONESSENTIAL GLYCOPROTEIN(8,1)
PESTIVIRUS GENUS(8,1)
PLAQUE PURIFIED VIRUS(8,1)
PRE MRNA INTRON(8,1)
RECOMBINANT VIRAL VECTOR(8,1)
STRAIN GENOME DNA(8,1)
ANTI BVDV E2MAB(7,2)
BVDV STRAIN(7,2)
CELL MONOLAYER(7,2)
GENE FRAGMENT LOCATION(7,2)
2707BP FRAGMENT(7,1)
ANTIGENIC BVDV(7,1)
BOVINE GROWTH HORMONE TERMINATOR(7,1)
BOVINE VIRAL DIARRHEA PATHOGENESIS(7,1)
BVDV CAPSID(7,1)
BVDV STINFO(7,1)
BVDV VIRION(7,1)
COTRANSFECTION EXPERIMENT(7,1)
END KOZAK CONSENSUS SEQUENCE(7,1)
FRAGMENT 8KBP(7,1)
HETEROLOGUS GENE(7,1)
INACTIVATED BVDV(7,1)
INDUCIBLE PROMOTER(7,1)
NATURAL MUTANT DELETION(7,1)
NONSTRUCTURAL PROTEIN(7,1)
PLAQUE BVDV(7,1)
RABBIT ALPHA GLOBIN GENE(7,1)
SPONTANEOUS BHV(7,1)
TISSUE CULTURE FLASK(7,1)
UNTRANSLATED LEADER(7,1)
VACCINE CANDIDATE(7,1)
MDBK CELL(6,2)
NASAL FLUID(6,2)
RECOGNITION SEQUENCE(6,2)
SHORT UNIQUE ECOR(6,2)
1GE BHV(6,1)
ADENOVIRUS VECTOR(6,1)
ANTI BVDV ANTIBODY ABSENCE(6,1)
BVDV EXPRESSION(6,1)
CARBOXY TERMINUS(6,1)
CODING REGION ENCODING EXON(6,1)
CYTOPATHIC STRAIN(6,1)
DIAGNOSTIC KIT ABSENCE(6,1)
EUKARYOTIC MRNA(6,1)
EUROPE BVDV(6,1)
EXPRESSION CASSETTE INSERTION(6,1)
GE ANTIBODY(6,1)
GENOME BHV(6,1)
IRRELEVANT RNA(6,1)
NUCLEOTIDE SEQUENCE STRAIN(6,1)
PLASMID PVR(6,1)
PROGENY VIRUS(6,1)
PROTEIN STRUCTURE PORTION(6,1)
RECOMBINANT CASSETTE(6,1)
STRUCTURAL STRAIN BVDV(6,1)
TRANSCRIPTION INITIATION(6,1)
TRANSCRIPTION TERMINATION(6,1)
UNIVERSAL GENETIC CODE TRANSLATION(6,1)
UPSTREAM KOZAK CONSENSUS SEQUENCE(6,1)
VACCINATED HOST(6,1)
VIRUS REPLICATION(6,1)
VIRUS VACCINE(6,1)
BVDV VIRUS LIKE PARTICLE(5,6)
NUCLEUS(5,3)
RNA POLYMERASE(5,3)
BOVINE SERUM(5,1)
BVDV INDUCED BHV(5,1)
BVDV RNA(5,1)
CIS REGULATORY ELEMENT(5,1)
COMPOUND ADJUVANT ACTIVITY(5,1)
DEFICIENT GE CONSTRUCTION(5,1)
DNA VACCINE(5,1)
DOUBLE MARKER(5,1)
ENCODING PROTEIN(5,1)
ENVELOPE PROTEIN(5,1)
FRESH TISSUE CULTURE MEDIUM(5,1)
GENOME ENCODING(5,1)
GENOMIC RNA(5,1)
HUMAN CYTOMEGALOVIRUS PROMOTER(5,1)
INFECTED HOST(5,1)
INITIATION SITE(5,1)
INTERSECTION PROTECTION(5,1)
METHIONINE RESIDUE(5,1)
MRNA SYNTHESIS(5,1)
PLASMID PS(5,1)
PROTEIN SYNTHESIS(5,1)
PUBLISHED BVDV(5,1)
SERINE RESIDUE(5,1)
SIMULTANEOUS OVERLAPPING(5,1)
SPLICEOSOME COLOR(5,1)
STRAIN PROTEIN(5,1)
TRANSCRIPTIONAL COMPLEX(5,1)
UNIQUE SMAI SITE(5,1)
VIRAL VECTOR ENCODING CONSTRUCTION(5,1)
VIRUS FAMILY(5,1)
FLAVIVIRUS(4,2)
GROWTH HORMONE TERMINATOR SEQUENCE(4,2)
MICROBIOL(4,2)
STRAIN RECOMBINATION STRUCTURE(4,2)
ACCEPTOR SEQUENCE(4,1)
ALUMINUM PHOSPHATE(4,1)
ANTI BVDV HOST(4,1)
ANTIBODY PRESENCE(4,1)
ANTIGENIC DIFFERENCE(4,1)
BIOLOGICAL SAMPLE(4,1)
BVDV FACTOR(4,1)
CELL COMPARTMENT(4,1)
CELL DEBRIS(4,1)
CHARACTER CODE(4,1)
CIS DNA(4,1)
CLEAR TERMINATION(4,1)
CODING POTENTIAL(4,1)
DONOR SEQUENCE(4,1)
EFFICIENT TRANSLATION(4,1)
EXPRESSION STABILITY(4,1)
HOST SIGNAL PEPTIDASE(4,1)
INFECTED CELL(4,1)
MEDIUM PFU(4,1)
PESTIVIRUS TAXONOMIC PERSPECTIVE(4,1)
PLASMID BSM STRUCTURE(4,1)
(JP4856351)
BOVINE VIRAL DIARRHEA VIRUS(100,18)
STRUCTURAL PROTEIN(100,6)
POLYPROTEIN(100,3)
VIRUS LIKE PARTICLE BVDV(100,2)
E1E(100,1)
NUCLEOTIDE NUMBER(100,1)
PESTIVIRUS GENUS SUBDIVISION(100,1)
ISOLATED DNA(71,5)
CNCM INSTITUT PASTEUR ACCESSION(64,2)
ISOLATED POLYNUCLEOTIDE(61,2)
GE LOCUS POLYPROTEIN(59,1)
NEUTROPHIL SUPPRESSION(58,1)
BVDV STRAIN ATTENUATION(56,2)
SUBUNIT VACCINE BVDV(56,1)
RECOMBINANT VIRUS(53,5)
ACTH ADMINISTRATION(53,1)
MUTANT PROTEIN STRUCTURE(53,1)
FETAL SHEEP MODEL(52,1)
HOMOLOGOUS CHALLENGE(52,1)
INTRAUTERINE INFECTION(51,1)
VACCINAL STRAIN(50,1)
SYSTEMIC INFECTION(48,1)
MATERNAL ANTIBODY PRESENCE(47,1)
CODING SEQUENCE(46,4)
VACCINE(45,22)
PPL VIRAL VECTOR(44,1)
VACCINE VECTOR(44,1)
POLYNUCLEOTIDE SEQUENCE(39,1)
BVDV STRUCTURAL PROTEIN(38,3)
ENVELOPE GLYCOPROTEIN(38,3)
FETAL PROTECTION(38,1)
SEQUENCE DIVERSITY(38,1)
GLYCOPROTEIN(36,8)
REGULATORY SEQUENCE(36,8)
NON TRANSLATED LEADER(36,2)
DNA VECTOR(35,1)
ISOLATED POLYNUCLEOTIDE TERMINATION SEQUENCE(35,1)
VIRAL INFECTED CELL(35,1)
TRANSLATION START CODON(31,1)
IMMUNOGENICITY(30,1)
INTENDED BVDV STRUCTURAL PROTEIN(29,1)
SPLICE(29,1)
DNA MOLECULE(28,1)
INSECT CELL(26,2)
ENCODED PROTEIN(26,1)
BACULOVIRUS(25,1)
BVDVTHE SEQUENCE(25,1)
PROTEIN EXPRESSION(24,2)
COMPLEMENTARY RNA MOLECULE(24,1)
HOST ANIMAL(23,1)
BOVINE VIRUS DIARRHEA VIRUS(22,1)
DELETION(22,1)
LYMPHOCYTE FUNCTION(22,1)
TRANSLATION(22,1)
PROTEIN(21,10)
1A VIRUS(21,1)
HOST CELL(20,8)
TRANSCRIPTION(20,2)
BVH(20,1)
BVDV(19,29)
SV 1F(19,7)
NUCLEOTIDE(19,5)
SUBUNIT VACCINE(19,3)
DISEASE(19,1)
SHEEP(19,1)
INFECTION(18,7)
VIROLOGY(17,3)
2707BP EXPRESSION CASSETTE ENCODING(16,2)
DNA(15,3)
AMP(15,1)
RECOMBINANT BHV(14,4)
DETECTED LEVEL(14,1)
PESTIVIRUS GENOMIC ORGANIZATION(14,1)
ARCH(12,3)
PROKARYOTIC PLASMID(12,3)
STRAIN BVDV STRUCTURAL PROTEIN(12,2)
VAN(12,2)
LIMITED PROTECTION(12,1)
PRE MRNA SPLICEOSOME NUCLEUS(12,1)
SPLICE ACCEPTOR SITE(12,1)
SPLICE DONOR SITE(12,1)
STRUCTURAL PROTEIN PORTION(12,1)
VIRAL DNA(12,1)
AMINOACID SUBSTITUTION(11,1)
ENVELOPE TRANSMEMBRANE GLYCOPROTEIN(11,1)
GENE BVDV GE(11,1)
RECOMBINANT 40BP GENOME(11,1)
BVDV VACCINE(10,2)
CATTLE VACCINATION(10,2)
BOVINE DIARRHEA VIRUS(10,1)
EMBRYONIC BOVINE TRACHEA(10,1)
GE BHV 1GE BVDV(10,1)
MADIN DARBY BOVINE KIDNEY(10,1)
STRUCTURAL PROTEIN BVDV POLYPROTEIN(10,1)
BVDV STRAIN(9,3)
BOVINE HERPES VIRUS(9,2)
NATURAL GE DELETION(9,2)
RECOMBINANT FRAGMENT(9,2)
BVDV CDNA ENCODING(9,1)
BVDV RECOMBINANT ZA STRAIN(9,1)
CASSETTE GE(9(...)";Pharmaceuticals;Open
"2000-04-21
2001-04-17";"BRPI0101523         A1 2001-05-22 [BR200101523]
STG: (A1) Published application
AP : 2001BR-0001523 2001-04-19
CA2342305           A1 2001-10-21 [CA2342305]
STG: (A1) Application laid open
AP : 2001CA-2342305 2001-04-20
EP1149901           A1 2001-10-31 [EP1149901]
STG: (A1) Application published with search report
AP : 2001EP-0201388 2001-04-17
BR0101523           A  2001-11-20 [BR200101523]
STG: (A) Published application
AP : 2001BR-0001523 2001-04-19
US20020086033       A1 2002-07-04 [US20020086033]
STG: (A1) Application published
AP : 2001US-09839796 2001-04-19
JP2002325575        A  2002-11-12 [JP2002325575]
STG: (A) Published application
AP : 2001JP-0122200 2001-04-20
MXPA01003968        A  2003-08-20 [MX2001PA003968]
STG: (A) Patent application
AP : 2001MX-PA03968 2001-04-20
EP1149901           B1 2006-04-05 [EP1149901]
STG: (B1) Patent specification
AP : 2001EP-0201388 2001-04-17
AT322541            T  2006-04-15 [ATE322541]
STG: (T) EP patent valid in AT
AP : 2001AT-0201388T 2001-04-17
US7037508           B2 2006-05-02 [US7037508]
STG: (B2) Granted patent as second publication
AP : 2001US-09839796 2001-04-19
FD :  Previous publication: US20020086033 A1 2002-07-04 [US20020086033]
DE60118456          D1 2006-05-18 [DE60118456]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 2001DE-6018456 2001-04-17
DK1149901           T3 2006-07-31 [DK1149901T]
STG: (T3) Translation of EP patent
AP : 2001DK-0201388 2001-04-17
DE60118456          T2 2006-08-24 [DE60118456]
STG: (T2) Trans. of EP  patent
AP : 2001DE-6018456 2001-04-17
PT1149901           E  2006-08-31 [PT1149901]
STG: (E) Availability of national translation of European patent
AP : 2001PT-0201388T 2001-04-17
ES2261329           T3 2006-11-16 [ES2261329]
STG: (T3) Translation of granted European patent (former B3)
AP : 2001ES-0201388T 2001-04-17
CA2342305           C  2010-11-09 [CA2342305]
STG: (C) Patent (second level)
AP : 2001CA-2342305 2001-04-20
BRPI0101523         A2 2010-12-28 [BR200101523]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 2001BR-0001523 2001-04-19
JP4937460           B2 2012-03-02 [JP4937460]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2001JP-0122200 2001-04-20";810423;"BRPI0101523         A1 2001-05-22 [BR200101523]
CA2342305           A1 2001-10-21 [CA2342305]
EP1149901           A1 2001-10-31 [EP1149901]
BR0101523           A  2001-11-20 [BR200101523]
US20020086033       A1 2002-07-04 [US20020086033]
JP2002325575        A  2002-11-12 [JP2002325575]
MXPA01003968        A  2003-08-20 [MX2001PA003968]
EP1149901           B1 2006-04-05 [EP1149901]
AT322541            T  2006-04-15 [ATE322541]
US7037508           B2 2006-05-02 [US7037508]
DE60118456          D1 2006-05-18 [DE60118456]
DK1149901           T3 2006-07-31 [DK1149901T]
DE60118456          T2 2006-08-24 [DE60118456]
PT1149901           E  2006-08-31 [PT1149901]
ES2261329           T3 2006-11-16 [ES2261329]
CA2342305           C  2010-11-09 [CA2342305]
BRPI0101523         A2 2010-12-28 [BR200101523]
JP4937460           B2 2012-03-02 [JP4937460]";"2000EP-0201421
2001EP-0201388";;"AKZO NOBEL
INTERVET INTERNATIONAL
MEDTRONIC INTERVET";INTERVET INTERNATIONAL;"(EP1149901)
NL
(EP1149901)
NL
(US7037508)
NL
(DE60118456)
NL

(CA2342305)
AN
(CA2342305)
NL
(BR200101523)
NL
(BR200101523)
NL";"(EP1149901)
NAME=Akzo Nobel N.V. Velperweg 76 , CITY=6824 BM  Arnhem , COUNTRY=NL 

(EP1149901)
NAME=Akzo Nobel N.V. Velperweg 76 , CITY=6824 BM  Arnhem , COUNTRY=NL , REG=100073762 

(US7037508)
NAME=Akzo Nobel NV , COUNTRY=NL , ATYP=Non-US Company 

(DE60118456)
NAME=Akzo Nobel N.V. , CITY=Arnheim/Arnhem , COUNTRY=NL 

(JP2002325575)
NAME=AKZO NOBEL NV , REG=394010986 

(JP4937460)
NAME=INTERVET INTERNATL BV , REG=506196247 

(CA2342305)
NAME=AKZO NOBEL N V Velperweg 76, P.O. Box 9300, 6300 SB, ARNHEM , COUNTRY=AN 

(CA2342305)
NAME=AKZO NOBEL N.V. Velperweg 76 NL-6824 BM , CITY=ARNHEM , COUNTRY=NL 

(BR200101523)
NAME=AKZO NOBEL N V , COUNTRY=NL 

(BR200101523)
NAME=INTERVET INTERNATIONAL B V , COUNTRY=NL 
";1;"THIEL HEINZ-JUERGEN
BECHER PAUL
ORLICH MICHAELA";"(EP1149901)
DE";"(EP1149901)
NAME=Thiel, Heinz-Jürgen Sandfeld 15 , CITY=35396 Giessen , COUNTRY=DE 

NAME=Becher, Paul Bahnhofstrasse 31 , CITY=35112 Fronhausen , COUNTRY=DE 

NAME=Orlich, Michaela Händelstrasse 6 , CITY=35392 Giessen , COUNTRY=DE 
";"(EP1149901)
Pestivirus mutants and vaccines containing the same";"(EP1149901)
The present invention is directed to attenuated pestivirus mutants, which have a reduced ability to replicate as exhibited by a small plaque size. The mutations are in the 5' nontranslated region of the viral genome. These mutant viruses are useful as live vaccines in the control of bovine viral diarrhea, border disease and classical swine fever.";"(CA2342305)
1. A pestivirus which contains one or more mutations in the region containing stem-loops Ia and Ib of the 5' nontranslated region (NTR) of the pestivirus genome, which mutation results in a small plaque size phenotype as compared to wild-type pestivirus, and in which the expression of the viral polyprotein is under the control of a homologous internal ribosome entry site
(IRES) and the sequence at the 5' end of the genome is GUAU.
2. The pestivirus according to claim 1, wherein the pestivirus has more than one mutation in the 5'NTR.
3. The pestivirus according to claim 1, wherein the mutation is a deletion of one or more nucleotides.
4. The pestivirus according to claim 3, wherein the mutation is a deletion of stem-loop Ia.
5. The pestivirus according to claim 4, wherein the mutation is a deletion of stem-loop Ia and part of stem-loop Ib.
6. The pestivirus according to claim 4, wherein the mutation is a deletion of stem-loops Ia and Ib, provided that the 5' terminal sequence is
GUAUAU or GUAUCCU.
7. The pestivirus according to any one of claims 1-4, wherein if the loop portion of stem-loop Ib is present, then the loop consists of five adenosine
(A)
residues.
8. The pestivirus according to any one of claims 1-7, wherein the pestivirus is BVDV-1 or BVDV-2.
9. A vaccine comprising a live attenuated pestivirus according to any one of claims 1- 8, and a pharmaceutically acceptable carrier or diluent.
10. The vaccine according to claim 9, which contains an adjuvant.
11. The vaccine according to claim 9, which is in freeze-dried or frozen form.
12. The vaccine according to claim 9, wherein the live attenuated pestivirus is a live attenuated BVDV virus, which vaccine further comprises an immunogen derived from one or more of bovine rotavirus, bovine respiratory syncytial virus, bovine herpesvirus type 1, bovine coronaviruses, parainfluenza type 3 virus, bovine paramyxovirus, foot and mouth disease virus, infectious bovine rhinotracheitis virus and Pasteurella hemolytica.
13. Use, for immunizing an animal against a pestivirus-induced disease, of the vaccine according to any one of claims 9-12.
14. A method of making a vaccine for the protection of an animal against a pestivirus, comprising mixing together the pestivirus according to any one of claims 1-8 with a pharmaceutically acceptable carrier.
15. The vaccine according to any one of claims 9-12, for use in immunizing an animal against a pestivirus-induced disease.
16. Use, in the manufacture of a medicament for immunizing an animal against a pestivirus-induced disease, of a live attenuated pestivirus according to any one of claims 1-8.";"(EP1149901)
More specifically, the present invention is directed to a pestivirus which contains one or more mutations in the region containing stem-loops Ia and Ib of the 5' nontranslated region (NTR) of the pestivirus genome, which mutation results in a small plaque size phenotype, in which the expression of the viral polyprotein is under the control of a homologous internal ribosome entry site (IRES) and the sequence GUAU is at the 5' end of the pestivirus genome.
The invention is particularly directed to attenuated bovine viral diarrhea viruses that have been genetically engineered for reduced replication in the host, and which are useful in live vaccines for cattle.
More specifically, the present invention is directed to a pestivirus which contains one or more mutations in the region containing stem-loops Ia and Ib of the 5' nontranslated region (NTR) of the pestivirus genome, which mutation results in a small plaque size phenotype, in which the expression of the viral polyprotein is under the control of a homologous internal ribosome entry site (IRES) and the sequence GUAU is at the 5' end of the pestivirus genome.
The present invention is directed to attenuated pestivirus mutants, which have a reduced ability to replicate, which is exhibited by a small plaque size.
The present invention is directed to attenuated pestivirus mutants, which have a reduced ability to replicate, which is exhibited by a small plaque size.";"(EP1149901)
Such viruses are useful as live vaccines in the control of bovine viral diarrhea, classical swine fever and border disease of sheep.
Because of the importance of a safe and effective prophylaxis and treatment of pestivirus infections, there is a strong need for live and specifically attenuated vaccines with a high potential for induction of immunity as well as a defined basis of attenuation resulting in a significant reduction in the ability to replicate in the host.
Therefore, the technical problem underlying the present invention is to provide safe, specifically attenuated pestiviruses for use as live attenuated vaccines with an ability to induce protective immunity.
The solution to the above technical problem is achieved by the present invention, which provides an attenuated pestivirus which contains a mutation in the 5'nontranslated region (NTR) of the pestivirus genome.
A live vaccine strain with defined mutations resulting in a strong attenuation would avoid the disadvantages of the present generation of vaccines.
BVDV-1 and BVDV-2 both cause acute infections in cattle (diarrhea, fever, hemorrhagic syndrome) as well as (if the infection occurs during pregnancy) abortion, malformation of the fetus and persistent infection of the calves.
However, these strains may still lead to transplacental infection and thereby cause fetal death, growth malformation, and persistant infection in the offspring.
Pestiviruses cause economically important diseases in animals worldwide.";"A01N-063/00
A61K-039/12
A61K-039/135
A61K-039/155
A61K-039/187
A61K-039/20
A61K-039/215
A61K-039/245
A61K-039/39
A61P-031/12
A61P-031/14
A61P-031/20
A61P-031/22
C07H-021/04
C07K-014/18
C12N-007/00
C12N-007/01
C12N-007/02
C12N-007/04
C12N-007/08
C12N-015/09
C12Q-001/70";"(EP1149901)
1. A pestivirus which contains one or more mutations in the region containing stem-loops la and Ib of the 5' nontranslated region (NTR) of the pestivirus genome, which mutation results in a small plaque size phenotype, and in which the expression of the viral polyprotein is under the control of a homologous internal ribosome entry site (IRES) and the sequence at the 5' end of the genome is GUAU.";"(EP1149901)
VACCINE(100,23)
PESTIVIRUS MUTANT(100,3)
ATTENUATED PESTIVIRUS MUTANT(100,2)
PESTIVIRUS GENOME(92,4)
VIRAL POLYPROTEIN EXPRESSION(83,1)
ATTENUATED PESTIVIRUS(77,2)
CALF PERSISTENT INFECTION(68,1)
PESTIVIRUS(59,28)
NON TRANSLATED REGION(59,3)
FETUS MALFORMATION(58,1)
LIVE VACCINE(53,6)
HEMORRHAGIC SYNDROME(48,1)
PERSISTANT INFECTION(48,1)
MUTATION(45,22)
VIRAL GENOME NON TRANSLATED REGION(45,1)
IMMUNITY INDUCTION(42,1)
LIVE ATTENUATED VACCINE(42,1)
GROWTH MALFORMATION(39,1)
LIVE ATTENUATED PESTIVIRUS(38,3)
VACCINE GENERATION(38,1)
PROTECTIVE IMMUNITY(36,1)
SAFE IMPORTANCE(35,1)
PESTIVIRUS INFECTION TREATMENT(34,3)
STEM LOOP LA DELETION(30,4)
STRONG ATTENUATION(30,1)
ECONOMICALLY IMPORTANT DISEASE(29,1)
NUCLEOTIDE DELETION(28,3)
BOVINE PARAMYXOVIRUS(28,2)
CLASSICAL SWINE FEVER(28,2)
STEM LOOP IA DELETION(27,1)
BOVINE ROTAVIRUS(26,2)
PARAINFLUENZA(25,2)
CAUSE ACUTE INFECTION(25,1)
PROPHYLAXIS(24,4)
PESTIVIRUS INDUCED DISEASE(24,1)
BOVINE HERPES VIRUS(23,2)
OFFSPRING(23,1)
ANIMAL PROTECTION(22,1)
ATTENUATED VACCINE(22,1)
PLAQUE SIZE(20,3)
ABORTION(20,1)
PREGNANCY(20,1)
DIARRHEA(19,1)
CATTLE(18,5)
STEM LOOP IA(18,4)
FETAL DEATH(18,1)
REDUCING AGENT REPLICATION(18,1)
INDEPENDENT CLONE(17,3)
PHENOTYPE(17,3)
FEVER(17,1)
INFECTIOUS CLONE(16,9)
STEM LOOP LA(16,9)
ANIMAL(16,8)
INFECTION(16,2)
PASTEURELLA HEMOLYTICA(16,2)
SIGNIFICANT REDUCTION(16,1)
STEM LOOP IB(16,1)
PLAQUE(15,15)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(15,1)
MUTATION RESULT(15,1)
BOVINE VIRAL DIARRHEA VIRUS(14,66)
GENOME(14,7)
PLAQUE PHENOTYPE(14,5)
BOVINE CORONAVIRUS(14,2)
TISSUE CULTURE INFECTIOUS DOSIS(14,2)
ATTENUATION DEFINED BASIS(14,1)
DEFINED MUTATION(14,1)
REDUCED ABILITY(13,3)
TRANSCRIBED RNA PHOTOMETRIC QUANTIFICATION(13,1)
INFECTIOUS VIRUS RECOVERY(12,3)
VIRAL GENOMIC RNA(12,3)
ADENOSINE(12,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(12,2)
PESTIVIRUS POLYPROTEIN TRANSLATION INITIATION(12,1)
VACCINE VIRUS(11,2)
LINEARIZED PLASMID DNA MICROGRAM(11,1)
GENETIC STABILITY(10,6)
MUTANT RNA(10,4)
RNA TRANSFECTION(10,3)
CLONED CDNA FRAGMENT(10,2)
RNA INFECTIVITY(10,2)
BOVINE VIRAL DIARRHEA CONTROL(10,1)
GLYOXYLATED RNA MICROGRAM(10,1)
PESTIVIRUS MUTANT GENOME(10,1)
HORSE SERUM(9,4)
PEAK TITER(9,4)
PLAQUE ASSAY(9,4)
RNA LIGATION(9,3)
RNA POLYMERASE PROMOTER(9,3)
AUTHENTIC INFECTIOUS CDNA(9,1)
HOG CHOLERA VIRUS(9,1)
INFECTIOUS VIRUS TITER(9,1)
PASSAGED VIRUS MUTANT(9,1)
PESTIVIRUS GENOME POLYPROTEIN REGION(9,1)
PROBE RADIOACTIVE LABELING(9,1)
VIRAL PROTEIN NONEXPRESSION(9,1)
DILUENT(8,4)
ANTISENSE PRIMER(8,2)
DELETION MUTANT(8,2)
PHOSPHORIMAGER(8,2)
RELEASED VIRUS TITER(8,2)
VIRUS MUTANT DELTA(8,2)
CDNA FRAGMENT AMPLIFICATION(8,1)
GENOME CDNA CLONING(8,1)
HAIRPIN LA DELETION(8,1)
HAIRPIN LA MUTANT(8,1)
INDEPENDENT SEQUENCE(8,1)
NESTED RT PCR ASSAY(8,1)
PERSISTENTLY INFECTED ANIMAL(8,1)
POLYPROTEIN AUG INITIATION CODON(8,1)
PREDICTED HAIRPIN LA(8,1)
VIRUS VACCINE(8,1)
BOVINE CELL(7,4)
BACTERIAL VECTOR(7,3)
RESIDUE DELETION(7,3)
AGAROSE OVERLAY(7,2)
ATTENUATED STRAIN(7,2)
DAY POST INFECTION(7,2)
FOLD SERIAL DILUTION(7,2)
GROWTH KINETICS DETERMINATION(7,2)
INVESTIGATED CLONE(7,2)
NUCLEOTIDE SUBSTITUTION(7,2)
PLAQUE GENE(7,2)
RNA TRANSCRIPTION(7,2)
RT PCR ANALYSIS(7,2)
SECONDARY MUTATION ABSENCE(7,2)
ANTI MOUSE IMMUNOGLOBULIN(7,1)
DURALON UV MEMBRANE(7,1)
GENETIC RELATEDNESS(7,1)
LAMB INTRAUTERINE INFECTION(7,1)
LIVE PESTIVIRUS PREPARATION(7,1)
LIVE VIRUS DOSE(7,1)
MUTANT PESTIVIRUS(7,1)
MUTANT TITER(7,1)
PESTIVIRUS GENUS(7,1)
PESTIVIRUS NON TRANSLATED REGION(7,1)
PESTIVIRUS PROTEIN FULL COMPLEMENT(7,1)
PESTIVIRUS REPLICATION(7,1)
PESTIVIRUS RNA(7,1)
PHENOMENON CHARACTERIZATION(7,1)
RECOVERED INFECTIOUS VIRUS(7,1)
RECOVERED MUTANT VIRUS(7,1)
RNA NORTHERN BLOT ANALYSIS(7,1)
SUPERNATANT PASSAGING(7,1)
TEMPLATE DNA DEGRADATION(7,1)
VIRULENT PESTIVIRUS(7,1)
VIRUS MUTANT QUANTITY(7,1)
CELL CULTURE SUPERNATANT(6,3)
INCUBATION DAY(6,2)
NHEL SITE(6,2)
PHENOL CHLOROFORM(6,2)
SIGMA ALDRICH(6,2)
ATTENUATED VIRUS MAXIMUM IMMUNOGENICITY(6,1)
CATTLE VACCINE(6,1)
CONSERVED NUCLEOTIDE(6,1)
FLAVIVIRIDAE FAMILY(6,1)
GENETICALLY STABLE CDNA(6,1)
GENOME TERMINUS(6,1)
INTRACUTANE ADMINISTRATION(6,1)
MUTANT CDNA GENERATION(6,1)
MUTANT EMERGENCE(6,1)
MUTANT VIRUS GROWTH RESTRICTION(6,1)
PESTIVIRUS REVIEW(6,1)
PESTIVIRUS SPECIES(6,1)
PORCINE KIDNEY CELL(6,1)
REPLICATION KINETICS(6,1)
SUBGENOMIC CDNA(6,1)
TRANSFECTED CELL DILUTION(6,1)
TRANSFECTED CELL INFECTION(6,1)
TRANSFECTION SUPERNATANT(6,1)
INTERNAL RIBOSOME ENTRY SITE(5,35)
OL SL(5,8)
PCP(5,8)
BAND INTENSITY(5,2)
SEMI SOLID MEDIUM(5,2)
VIRUS YIELD(5,2)
AGE MONTH(5,1)
ANIMAL POPULATION(5,1)
BOVINE KIDNEY CELL(5,1)
CLONING STRATEGY(5,1)
CYTOPATHOLOGY DEVELOPMENT(5,1)
FATAL MUCOSAL DISEASE(5,1)
GENETICALLY STABLE VARIANT(5,1)
GROWTH CURVE ESTABLISHMENT(5,1)
GROWTH RESTRICTED VIRUS(5,1)
MUTANT ANALYZED GENOMIC REGION(5,1)
MUTATED VIRUS(5,1)
NUCLEOTIDE SEQUENCING(5,1)
PEROXIDASE CONJUGATED GOAT(5,1)
PROGENY VIRUS PRODUCTION(5,1)
TRANSCRIPT DERIVED PARENT VIRUS(5,1)
VACCINATED ANIMAL(5,1)
VACCINE STRAIN(5,1)
VIRAL CDNA(5,1)
VIRAL POLYPEPTIDE(5,1)
VIRAL REPLICATION(5,1)
VIRAL RNA TERMINUS(5,1)
VIRUS MAJOR RESERVOIR(5,1)
CLASSICAL SWINE FEVER VIRUS(4,11)
FOLDING(4,5)
STABILIZER(4,3)
VACCINATION(4,3)
MICROORGANISM(4,2)
PRESERVATIVE(4,2)
STEM LOOP PORTION(4,2)
ADJUVANT ACTIVITY(4,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(4,1)
CELL TRANSFECTION(4,1)
CELLULAR RNA(4,1)
CONFLUENT CELL(4,1)
DELTA RNA(4,1)
GENOMIC REGION ENCODING(4,1)
GROWTH KINETICS DIFFERENCE(4,1)
IB SUPPORTED REPLICATION(4,1)
IMMUNFLUORESCENCE ANALYSIS(4,1)
LACK NUCLEOTIDE(4,1)
LOOP APEX(4,1)
MUTANT VIRUS TERMINAL SEQUENCE(4,1)
MUTATED SEQUENCE(4,1)
PEROXIDASE SUBSTRATE(4,1)
RECOVERED VIRUS(4,1)
RNA ACCUMULATION(4,1)
SENSE PRIMER SEQUENCE(4,1)
VACCINE COMPOSITION PREPARATION(4,1)
VIRAL RNA SYNTHESIS ANALYSIS(4,1)
VIRAL YIELD DETERMINATION(4,1)
IMMUNITY(3,2)
INTRANASAL(3,2)
MONOLAYER(3,2)
NUCLEOTIDE SEQUENCE ANALYSIS(3,2)
THIMEROSAL(3,2)
TITRATION(3,2)
ACTINOBACILLUS PLEUROPNEUMONIAE(3,1)
CDNA DERIVED(3,1)
CHLAMYDIA PSITTACI(3,1)
CONSERVED SEQUENCE MOTIF(3,1)
FROZEN FORM(3,1)
GENOMIC SEQUENCE(3,1)
GROWTH RESTRICTED PHENOTYPE(3,1)
IB LOOP REGION(3,1)
IMMUNOFLUORESCENCE(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INDEPENDENTLY PRODUCED VIRAL PLAQUE(3,1)
INFECTED CELL(3,1)
INSEMINATION(3,1)
NUCLEOTIDE DIFFERENCE(3,1)
NUCLEOTIDE INSERTION(3,1)
OSLOSS SEQUENCE(3,1)
PASTEURELLA MULTOCIDA(3,1)
PRECISE DOSAGE(3,1)
REACH TITER(3,1)
REPLICATION ABILITY(3,1)
REVERSE GENETIC ENGINEERING(3,1)
ROLLER BOTTLE(3,1)
SAMPLE STAINING(3,1)
SEQUENCE AU(3,1)
(EP1149901)
VACCINE(100,22)
PESTIVIRUS GENOME(100,4)
PESTIVIRUS MUTANT(100,3)
ATTENUATED PESTIVIRUS MUTANT(97,1)
VIRAL POLYPROTEIN EXPRESSION(90,1)
ATTENUATED PESTIVIRUS(84,2)
CALF PERSISTENT INFECTION(74,1)
PESTIVIRUS(64,28)
NON TRANSLATED REGION(64,3)
FETUS MALFORMATION(63,1)
HEMORRHAGIC SYNDROME(52,1)
STEM LOOP IA DELETION(51,3)
LIVE VACCINE(48,5)
MUTATION(46,21)
IMMUNITY INDUCTION(46,1)
LIVE ATTENUATED VACCINE(46,1)
LIVE ATTENUATED PESTIVIRUS(42,3)
VACCINE GENERATION(42,1)
PROTECTIVE IMMUNITY(39,1)
SAFE IMPORTANCE(38,1)
PESTIVIRUS INFECTION TREATMENT(37,3)
STRONG ATTENUATION(33,1)
ECONOMICALLY IMPORTANT DISEASE(32,1)
NUCLEOTIDE DELETION(31,3)
BOVINE PARAMYXOVIRUS(31,2)
BOVINE ROTAVIRUS(29,2)
PARAINFLUENZA(27,2)
CAUSE ACUTE INFECTION(27,1)
STEM LOOP LA(26,12)
PROPHYLAXIS(26,4)
BOVINE HERPES VIRUS(25,2)
ANIMAL PROTECTION(24,1)
ATTENUATED VACCINE(24,1)
ABORTION(22,1)
PREGNANCY(22,1)
DIARRHEA(21,1)
CATTLE(20,5)
REDUCING AGENT REPLICATION(19,1)
INFECTIOUS CLONE(18,9)
INDEPENDENT CLONE(18,3)
PHENOTYPE(18,3)
PASTEURELLA HEMOLYTICA(18,2)
PLAQUE SIZE(18,2)
FEVER(18,1)
PLAQUE(17,15)
INFECTION(17,2)
SIGNIFICANT REDUCTION(17,1)
STEM LOOP IB(17,1)
STEM LOOP LB(17,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(16,1)
MUTATION RESULT(16,1)
BOVINE VIRAL DIARRHEA VIRUS(15,66)
GENOME(15,7)
PLAQUE PHENOTYPE(15,5)
BOVINE CORONAVIRUS(15,2)
TISSUE CULTURE INFECTIOUS DOSIS(15,2)
ATTENUATION DEFINED BASIS(15,1)
DEFINED MUTATION(15,1)
ANIMAL(14,7)
TRANSCRIBED RNA PHOTOMETRIC QUANTIFICATION(14,1)
INFECTIOUS VIRUS RECOVERY(13,3)
VIRAL GENOMIC RNA(13,3)
ADENOSINE(13,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(13,2)
PESTIVIRUS POLYPROTEIN TRANSLATION INITIATION(13,1)
VACCINE VIRUS(12,2)
LINEARIZED PLASMID DNA MICROGRAM(12,1)
GENETIC STABILITY(11,6)
MUTANT RNA(11,4)
RNA TRANSFECTION(11,3)
CLONED CDNA FRAGMENT(11,2)
REDUCED ABILITY(11,2)
RNA INFECTIVITY(11,2)
GLYOXYLATED RNA MICROGRAM(11,1)
PESTIVIRUS MUTANT GENOME(11,1)
PLAQUE ASSAY(10,4)
RNA LIGATION(10,3)
RNA POLYMERASE PROMOTER(10,3)
INFECTIOUS VIRUS TITER(10,1)
DILUENT(9,4)
HORSE SERUM(9,4)
PEAK TITER(9,4)
ANTISENSE PRIMER(9,2)
DELETION MUTANT(9,2)
PHOSPHORIMAGER(9,2)
RELEASED VIRUS TITER(9,2)
VIRUS MUTANT DELTA(9,2)
AUTHENTIC INFECTIOUS CDNA(9,1)
HOG CHOLERA VIRUS(9,1)
PASSAGED VIRUS MUTANT(9,1)
PESTIVIRUS GENOME POLYPROTEIN REGION(9,1)
PROBE RADIOACTIVE LABELING(9,1)
VIRAL PROTEIN NONEXPRESSION(9,1)
BACTERIAL VECTOR(8,3)
RESIDUE DELETION(8,3)
AGAROSE OVERLAY(8,2)
DAY POST INFECTION(8,2)
FOLD SERIAL DILUTION(8,2)
GROWTH KINETICS DETERMINATION(8,2)
INVESTIGATED CLONE(8,2)
RNA TRANSCRIPTION(8,2)
RT PCR ANALYSIS(8,2)
SECONDARY MUTATION ABSENCE(8,2)
CDNA FRAGMENT AMPLIFICATION(8,1)
GENOME CDNA CLONING(8,1)
HAIRPIN LA DELETION(8,1)
HAIRPIN LA MUTANT(8,1)
INDEPENDENT SEQUENCE(8,1)
NESTED RT PCR ASSAY(8,1)
PERSISTENTLY INFECTED ANIMAL(8,1)
POLYPROTEIN AUG INITIATION CODON(8,1)
PREDICTED HAIRPIN IA(8,1)
VIRUS VACCINE(8,1)
BOVINE CELL(7,4)
ATTENUATED STRAIN(7,2)
NUCLEOTIDE SUBSTITUTION(7,2)
PLAQUE GENE(7,2)
ANTI MOUSE IMMUNOGLOBULIN(7,1)
DURALON UV MEMBRANE(7,1)
GENETIC RELATEDNESS(7,1)
LAMB INTRAUTERINE INFECTION(7,1)
LIVE PESTIVIRUS PREPARATION(7,1)
LIVE VIRUS DOSE(7,1)
MUTANT PESTIVIRUS(7,1)
MUTANT TITER(7,1)
PESTIVIRUS GENUS(7,1)
PESTIVIRUS NON TRANSLATED REGION(7,1)
PESTIVIRUS PROTEIN FULL COMPLEMENT(7,1)
PESTIVIRUS REPLICATION(7,1)
PESTIVIRUS RNA(7,1)
PHENOMENON CHARACTERIZATION(7,1)
RECOVERED INFECTIOUS VIRUS(7,1)
RECOVERED MUTANT VIRUS(7,1)
RNA NORTHERN BLOT ANALYSIS(7,1)
SUPERNATANT PASSAGING(7,1)
TEMPLATE DNA DEGRADATION(7,1)
VIRULENT PESTIVIRUS(7,1)
VIRUS MUTANT QUANTITY(7,1)
INTERNAL RIBOSOME ENTRY SITE(6,35)
CELL CULTURE SUPERNATANT(6,3)
OI DELTA(6,3)
INCUBATION DAY(6,2)
PHENOL CHLOROFORM(6,2)
SIGMA ALDRICH(6,2)
STEM LOOP LA DELETION(6,2)
ATTENUATED VIRUS MAXIMUM IMMUNOGENICITY(6,1)
CATTLE VACCINE(6,1)
CONSERVED NUCLEOTIDE(6,1)
FLAVIVIRIDAE FAMILY(6,1)
GENETICALLY STABLE CDNA(6,1)
GENOME TERMINUS(6,1)
INTRACUTANE ADMINISTRATION(6,1)
MUTANT CDNA GENERATION(6,1)
MUTANT EMERGENCE(6,1)
MUTANT VIRUS GROWTH RESTRICTION(6,1)
PESTIVIRUS REVIEW(6,1)
PESTIVIRUS SPECIES(6,1)
PORCINE KIDNEY CELL(6,1)
REPLICATION KINETICS(6,1)
SUBGENOMIC CDNA(6,1)
TRANSFECTED CELL DILUTION(6,1)
TRANSFECTED CELL INFECTION(6,1)
TRANSFECTION SUPERNATANT(6,1)
OI SL(5,8)
PCP(5,8)
STABILIZER(5,3)
VACCINATION(5,3)
BAND INTENSITY(5,2)
SEMI SOLID MEDIUM(5,2)
VIRUS YIELD(5,2)
AGE MONTH(5,1)
ANIMAL POPULATION(5,1)
BOVINE KIDNEY CELL(5,1)
CLONING STRATEGY(5,1)
CYTOPATHOLOGY DEVELOPMENT(5,1)
FATAL MUCOSAL DISEASE(5,1)
GENETICALLY STABLE VARIANT(5,1)
GROWTH CURVE ESTABLISHMENT(5,1)
GROWTH RESTRICTED VIRUS(5,1)
LOOP PORTION(5,1)
MUTANT ANALYZED GENOMIC REGION(5,1)
MUTATED VIRUS(5,1)
NUCLEOTIDE SEQUENCING(5,1)
PEROXIDASE CONJUGATED GOAT(5,1)
PROGENY VIRUS PRODUCTION(5,1)
TRANSCRIPT DERIVED PARENT VIRUS(5,1)
VACCINATED ANIMAL(5,1)
VACCINE STRAIN(5,1)
VIRAL CDNA(5,1)
VIRAL POLYPEPTIDE(5,1)
VIRAL REPLICATION(5,1)
VIRAL RNA TERMINUS(5,1)
VIRUS MAJOR RESERVOIR(5,1)
XHOI FRAGMENT(5,1)
CLASSICAL SWINE FEVER VIRUS(4,11)
FOLDING(4,5)
IMMUNITY(4,2)
INTRANASAL(4,2)
MICROORGANISM(4,2)
MONOLAYER(4,2)
NUCLEOTIDE SEQUENCE ANALYSIS(4,2)
PRESERVATIVE(4,2)
THIMEROSAL(4,2)
TITRATION(4,2)
ADJUVANT ACTIVITY(4,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(4,1)
CELL TRANSFECTION(4,1)
CELLULAR RNA(4,1)
CONFLUENT CELL(4,1)
DELTA RNA(4,1)
GENOMIC REGION ENCODING(4,1)
GROWTH KINETICS DIFFERENCE(4,1)
IB SUPPORTED REPLICATION(4,1)
IMMUNFLUORESCENCE ANALYSIS(4,1)
LACK NUCLEOTIDE(4,1)
LOOP APEX(4,1)
MUTANT VIRUS TERMINAL SEQUENCE(4,1)
MUTATED SEQUENCE(4,1)
NHEL SITE(4,1)
PEROXIDASE SUBSTRATE(4,1)
RECOVERED VIRUS(4,1)
RNA ACCUMULATION(4,1)
SENSE PRIMER SEQUENCE(4,1)
VACCINE COMPOSITION PREPARATION(4,1)
VIRAL RNA SYNTHESIS ANALYSIS(4,1)
VIRAL YIELD DETERMINATION(4,1)
ACTINOBACILLUS PLEUROPNEUMONIAE(3,1)
CDNA DERIVED(3,1)
CHLAMYDIA PSITTACI(3,1)
CONSERVED SEQUENCE MOTIF(3,1)
FROZEN FORM(3,1)
GENOMIC SEQUENCE(3,1)
GROWTH RESTRICTED PHENOTYPE(3,1)
IB LOOP REGION(3,1)
IMMUNOFLUORESCENCE(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INDEPENDENTLY PRODUCED VIRAL PLAQUE(3,1)
INFECTED CELL(3,1)
INSEMINATION(3,1)
NUCLEOTIDE DIFFERENCE(3,1)
NUCLEOTIDE INSERTION(3,1)
OSLOSS SEQUENCE(3,1)
PASTEURELLA MULTOCIDA(3,1)
PRECISE DOSAGE(3,1)
REACH TITER(3,1)
REPLICATION ABILITY(3,1)
REVERSE GENETIC ENGINEERING(3,1)
ROLLER BOTTLE(3,1)
SAMPLE STAINING(3,1)
SEQUENCE AU(3,1)
SEQUENCE REPLICATION(3,1)
STRUCTURAL PROTEIN(3,1)
TRANSCRIPT DERIVED VIRUS(3,1)
(US20020086033)
PESTIVIRUS(100,23)
VACCINE(100,22)
MUTATION(100,21)
PLAQUE(100,21)
STEM LOOP LA(100,11)
PHENOTYPE(100,5)
PESTIVIRUS MUTANT(100,4)
GENOME END(100,3)
NON TRANSLATED REGION(100,3)
PESTIVIRUS GENOME(100,3)
ATTENUATED PESTIVIRUS MUTANT(100,2)
CONTROL(100,2)
INTERNAL RIBOSOME ENTRY SITE(100,2)
MUTATION RESULT(100,2)
VIRAL POLYPROTEIN EXPRESSION(100,2)
ATTENUATED PESTIVIRUS(65,2)
CALF PERSISTENT INFECTION(58,1)
LIVE VACCINE(54,7)
FETUS MALFORMATION(48,1)
CLASSICAL SWINE FEVER(43,3)
HEMORRHAGIC SYNDROME(40,1)
VIRAL GENOME NON TRANSLATED REGION(38,1)
PERSISTENT INFECTION(36,1)
IMMUNITY INDUCTION(35,1)
LIVE ATTENUATED VACCINE(35,1)
STEM LOOP LA DELETION(33,5)
GROWTH MALFORMATION(33,1)
LIVE ATTENUATED PESTIVIRUS(32,3)
SHEEP BORDER DISEASE(31,1)
PROTECTIVE IMMUNITY(30,1)
SAFE IMPORTANCE(29,1)
ECONOMICALLY IMPORTANT DISEASE(25,1)
STRONG ATTENUATION(25,1)
NUCLEOTIDE DELETION(24,3)
BOVINE PARAMYXOVIRUS(24,2)
BOVINE ROTAVIRUS(22,2)
CAUSE ACUTE INFECTION(21,1)
TRANSPLACENTAL INFECTION(21,1)
PESTIVIRUS INFECTION TREATMENT(20,3)
PLAQUE SIZE(20,3)
PESTIVIRUS INDUCED DISEASE(20,1)
BOVINE HERPES VIRUS(19,2)
STEM LOOP LB(19,2)
ANIMAL PROTECTION(19,1)
ATTENUATED VACCINE(19,1)
OFFSPRING(19,1)
PESTIVIRUS CAUSE(18,1)
ABORTION(17,1)
PREGNANCY(17,1)
BOVINE VIRAL DIARRHEA VIRUS(16,5)
DIARRHEA(16,1)
CATTLE(15,5)
BOVINE VIRAL DIARRHEA CONTROL(15,2)
FETAL DEATH(15,1)
REDUCING AGENT REPLICATION(15,1)
PROPHYLAXIS(14,4)
PASTEURELLA HEMOLYTICA(14,2)
FEVER(14,1)
BVDV(13,24)
NTR MUTANT(13,9)
VIRUS(13,9)
REDUCED ABILITY(13,3)
INFECTION(13,2)
SIGNIFICANT REDUCTION(13,1)
ATTENUATION DEFINED BASIS(12,1)
DEFINED MUTATION(12,1)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(12,1)
ANIMAL(11,8)
PLAQUE PHENOTYPE(11,5)
BOVINE CORONAVIRUS(11,2)
BVDV INFECTIOUS CLONE(11,2)
TISSUE CULTURE INFECTIOUS DOSIS(11,2)
TRANSCRIBED RNA PHOTOMETRIC QUANTIFICATION(11,1)
INFECTIOUS VIRUS RECOVERY(10,3)
MDBK CELL TRANSFECTION(10,3)
VIRAL GENOMIC RNA(10,3)
ADENOSINE(10,2)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(10,2)
PESTIVIRUS POLYPROTEIN TRANSLATION INITIATION(10,1)
BVDV NTR(9,3)
VACCINE VIRUS(9,2)
PESTIVIRUS GENOME NTR(9,1)
PESTIVIRUS IRE BORDER(9,1)
STRONG NEED(9,1)
GENETIC STABILITY(8,6)
PLAQUE ASSAY(8,5)
RNA LIGATION(8,3)
RNA TRANSFECTION(8,3)
CLONED CDNA FRAGMENT(8,2)
PESTIVIRUS NTR(8,2)
RNA INFECTIVITY(8,2)
CSFV INFECTIOUS CLONE(8,1)
INFECTIOUS VIRUS TITER(8,1)
DILUENT(7,4)
HORSE SERUM(7,4)
PEAK TITER(7,4)
RNA POLYMERASE PROMOTER(7,3)
AGAROSE OVERLAY(7,2)
ANTISENSE PRIMER(7,2)
DELETION MUTANT(7,2)
INFECTIOUS CDNA GENERATION(7,2)
PHOSPHORIMAGER(7,2)
RELEASED VIRUS TITER(7,2)
VIRUS MUTANT DELTA(7,2)
AUTHENTIC INFECTIOUS CDNA(7,1)
BDV INFECTIOUS CLONE(7,1)
BVDV INFECTIVITY(7,1)
BVDV MUTANT RNA(7,1)
HOG CHOLERA VIRUS(7,1)
PASSAGED VIRUS MUTANT(7,1)
PESTIVIRUS GENOME POLYPROTEIN REGION(7,1)
PROBE RADIOACTIVE LABELING(7,1)
VIRAL PROTEIN NONEXPRESSION(7,1)
BOVINE CELL(6,4)
BACTERIAL VECTOR(6,3)
RESIDUE DELETION(6,3)
DAY POST INFECTION(6,2)
FOLD SERIAL DILUTION(6,2)
GROWTH KINETICS DETERMINATION(6,2)
INVESTIGATED CLONE(6,2)
RNA TRANSCRIPTION(6,2)
RT PCR ANALYSIS(6,2)
SECONDARY MUTATION ABSENCE(6,2)
ANTI MOUSE IMMUNOGLOBULIN(6,1)
BVDV GENETICALLY STABLE VARIANT(6,1)
BVDV HCV CHIMERA(6,1)
BVDV OSLOSS SEQUENCE(6,1)
BVDV STRAIN ATTENUATION(6,1)
CDNA FRAGMENT AMPLIFICATION(6,1)
DURALON UV MEMBRANE(6,1)
GENETIC RELATEDNESS(6,1)
GENOME CDNA CLONING(6,1)
HAIRPIN LA DELETION(6,1)
HAIRPIN LA MUTANT(6,1)
HETEROLOGOUS BVDV(6,1)
LAMB INTRAUTERINE INFECTION(6,1)
LINEARIZED PLASMID DNA(6,1)
LIVE PESTIVIRUS PREPARATION(6,1)
LIVE VIRUS DOSE(6,1)
MUTANT PESTIVIRUS(6,1)
MUTANT TITER(6,1)
NESTED RT PCR ASSAY(6,1)
PERSISTENTLY INFECTED ANIMAL(6,1)
PESTIVIRUS GENUS(6,1)
PESTIVIRUS NON TRANSLATED REGION(6,1)
PESTIVIRUS PROTEIN FULL COMPLEMENT(6,1)
PESTIVIRUS REPLICATION(6,1)
PESTIVIRUS RNA(6,1)
PHENOMENON CHARACTERIZATION(6,1)
POLYPROTEIN AUG INITIATION CODON(6,1)
PREDICTED HAIRPIN LA(6,1)
RECOVERED BVDV MUTANT(6,1)
RECOVERED INFECTIOUS VIRUS(6,1)
RECOVERED MUTANT VIRUS(6,1)
RNA NORTHERN BLOT ANALYSIS(6,1)
SAMPLE ETHIDIUM BROMIDE STAINING(6,1)
SUPERNATANT PASSAGING(6,1)
TEMPLATE DNA DEGRADATION(6,1)
VIRULENT PESTIVIRUS(6,1)
VIRUS MUTANT QUANTITY(6,1)
VIRUS VACCINE(6,1)
CELL CULTURE SUPERNATANT(5,3)
INDEPENDENT CLONE(5,3)
OI DELTA(5,3)
BORDER DISEASE VIRUS(5,2)
BVDV SEQUENCE(5,2)
INCUBATION DAY(5,2)
MOUTH DISEASE VIRUS(5,2)
NHEL SITE(5,2)
NUCLEOTIDE SUBSTITUTION(5,2)
PARAINFLUENZA TYPE(5,2)
PHENOL CHLOROFORM(5,2)
SIGMA ALDRICH(5,2)
ATTENUATED VIRUS MAXIMUM IMMUNOGENICITY(5,1)
BVDV GENOME(5,1)
BVDV GENOMIC SEQUENCE(5,1)
BVDV PROPAGATION(5,1)
BVDV TERMINUS(5,1)
BVDV VACCINE(5,1)
CATTLE VACCINE(5,1)
CLASSICAL BVDV(5,1)
CONSERVED NUCLEOTIDE(5,1)
CSFV IRE(5,1)
FLAVIVIRIDAE FAMILY(5,1)
GENETICALLY STABLE BVDV(5,1)
GENETICALLY STABLE CDNA(5,1)
GENOME TERMINUS(5,1)
GLYOXYLATED RNA(5,1)
HOMOLOGOUS IRE(5,1)
INFECTIOUS BVDV(5,1)
INTRACUTANE ADMINISTRATION(5,1)
MUTANT CDNA GENERATION(5,1)
MUTANT EMERGENCE(5,1)
MUTANT VIRUS GROWTH RESTRICTION(5,1)
NOTL NSIL FRAGMENT(5,1)
PESTIVIRUS REVIEW(5,1)
PESTIVIRUS SPECIES(5,1)
PORCINE KIDNEY CELL(5,1)
REPLICATION KINETICS(5,1)
SUBGENOMIC CDNA(5,1)
TRANSFECTED CELL DILUTION(5,1)
TRANSFECTED CELL INFECTION(5,1)
TRANSFECTION SUPERNATANT(5,1)
UNTREATED MDBK CELL(5,1)
OI SL(4,8)
PCP(4,8)
BAND INTENSITY(4,2)
GUAU SEQUENCE(4,2)
NTR SEQUENCE(4,2)
SEMI SOLID MEDIUM(4,2)
VIRUS YIELD(4,2)
AGE MONTH(4,1)
ANIMAL POPULATION(4,1)
ATTENUATED STRAIN(4,1)
BOVINE KIDNEY CELL(4,1)
BVDV IRE ELEMENT(4,1)
BVDV PUBLISHED SEQUENCE(4,1)
BVDV STEM LOOP LA(4,1)
CLONING STRATEGY(4,1)
CSFV MUTANT(4,1)
CYTOPATHOLOGY DEVELOPMENT(4,1)
FATAL MUCOSAL DISEASE(4,1)
GROWTH CURVE ESTABLISHMENT(4,1)
GROWTH RESTRICTED VIRUS(4,1)
GUAU RETENTION(4,1)
HANDBUCH DER(4,1)
LOOP PORTION(4,1)
MUTANT ANALYZED GENOMIC REGION(4,1)
MUTATED VIRUS(4,1)
NTR CLONE(4,1)
NUCLEOTIDE SEQUENCING(4,1)
PEROXIDASE CONJUGATED GOAT(4,1)
PLASMID HHDI(4,1)
PROGENY VIRUS PRODUCTION(4,1)
STRAIN NADL(4,1)
TRANSCRIPT DERIVED PARENT VIRUS(4,1)
VACCINATED ANIMAL(4,1)
VACCINE STRAIN(4,1)
VIRAL CDNA(4,1)
VIRAL POLYPEPTIDE(4,1)
VIRAL REPLICATION(4,1)
VIRAL RNA TERMINUS(4,1)
VIRUS MAJOR RESERVOIR(4,1)
XHOI FRAGMENT(4,1)
FOLDING(3,5)
STABILIZER(3,3)
VACCINATION(3,3)
CLASSICAL SWINE FEVER VIRUS(3,2)
IMMUNITY(3,2)
INTRANASAL(3,2)
MICROORGANISM(3,2)
MONOLAYER(3,2)
NUCLEOTIDE SEQUENCE ANALYSIS(3,2)
PRESERVATIVE(3,2)
REVERSE GENETICS(3,2)
TITRATION(3,2)
VIROLOGY(3,2)
ACTINOBACILLUS PLEUROPNEUMONIAE(3,1)
ADJUVANT ACTIVITY(3,1)
BDV IRE ELEMENT(3,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(3,1)
BVDV ANTIGEN POSITIVE CELL(3,1)
BVDV MIXTURE(3,1)
BVDV TERMINAL SEQUENCE(3,1)
CDNA DERIVED(3,1)
CELLULAR RNA(3,1)
CHLAMYDIA PSITTACI(3,1)
CONFLUENT CELL(3,1)
CONSERVED SEQUENCE MOTIF(3,1)
DELTA RNA(3,1)
ETHYLCARBAZOLE(3,1)
FROZEN FORM(3,1)
GENERATION(3,1)
GENOMIC REGION ENCODING(3,1)
GROWTH KINETICS DIFFERENCE(3,1)
GROWTH RESTRICTED PHENOTYPE(3,1)
HHDI BASIS(3,1)
IMMUNFLUORESCENCE ANALYSIS(3,1)
IMMUNOFLUORESCENCE(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INDEPENDENTLY PRODUCED VIRAL PLAQUE(3,1)
INDICATED MUTANT BVDV STRAIN(3,1)
INFECTED CELL(3,1)
INSEMINATION(3,1)
IRE ACTIVITY(3,1)
LACK NUCLEOTIDE(3,1)
LOOP APEX(3,1)
METHANOL ACETONE(3,1)
MUTANT VIRUS TERMINAL SEQUENCE(3,1)
MUTATED SEQUENCE(3,1)
NTR STEM LOOP LA(3,1)
NUCLEOTIDE DIFFERENCE(3,1)
NUCLEOTIDE INSERTION(3,1)
PA BVDV BASIS(3,1)
PASTEURELLA MULTOCIDA(3,1)
PEROXIDASE SUBSTRATE(3,1)
PESTIVIRUS SEQUENCE(3,1)
PRECISE DOSAGE(3,1)
RECOVERED VIRUS(3,1)
RNA ACCUMULATION(3,1)
VACCINE COMPOSITION PREPARATION(3,1)
VIRAL RNA SYNTHESIS ANALYSIS(3,1)
VIRAL YIELD DETERMINATION(3,1)
(US7037508)
VACCINE(100,28)
PESTIVIRUS MUTANT(100,6)
GROWTH RESTRICTED PHENOTYPE(100,3)
VIRAL POLYPROTEIN EXPRESSION(100,2)
ATTENUATED ISOLATED PESTIVIRUS(100,1)
WILD TYPE PESTIVIRUS(100,1)
PESTIVIRUS GENOME(91,3)
ATTENUATED PESTIVIRUS MUTANT(89,2)
ATTENUATED PESTIVIRUS(73,2)
CALF PERSISTENT INFECTION(65,1)
LIVE VACCINE(61,7)
FETUS MALFORMATION(55,1)
NON TRANSLATED REGION(52,3)
CLASSICAL SWINE FEVER(49,3)
HEMORRHAGIC SYNDROME(45,1)
MUTATION(44,21)
VIRAL GENOME NON TRANSLATED REGION(43,1)
BOVINE PARAMYXOVIRUS(41,3)
PERSISTENT INFECTION(41,1)
IMMUNITY INDUCTION(40,1)
LIVE ATTENUATED VACCINE(40,1)
BOVINE ROTAVIRUS(38,3)
GROWTH MALFORMATION(37,1)
IMMUNOGENICALLY ACTIVE ISOLATED PESTIVIRUS(35,1)
SHEEP BORDER DISEASE(35,1)
STEM LOOP 1A DELETION(34,3)
PROTECTIVE IMMUNITY(34,1)
SAFE IMPORTANCE(33,1)
PESTIVIRUS(32,15)
BOVINE HERPES VIRUS(32,3)
STRONG ATTENUATION(29,1)
ECONOMICALLY IMPORTANT DISEASE(28,1)
NUCLEOTIDE DELETION(27,3)
CAUSE ACUTE INFECTION(24,1)
TRANSPLACENTAL INFECTION(24,1)
BOVINE VIRAL DIARRHEA VIRUS(23,7)
PASTEURELLA HEMOLYTICA(23,3)
STEM LOOP 1A(23,2)
IMMUNOGENICALLY EFFECTIVE DOSAGE(23,1)
PESTIVIRUS INFECTION TREATMENT(22,3)
OFFSPRING(22,1)
ANIMAL PROTECTION(21,1)
ATTENUATED VACCINE(21,1)
BOVINE CORONAVIRUS(20,3)
INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS(20,2)
ABORTION(19,1)
PREGNANCY(19,1)
MUTANT(18,25)
ANIMAL(18,10)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(18,3)
PLAQUE SIZE(18,3)
STEM LOOP 1B(18,2)
DIARRHEA(18,1)
PLAQUE(17,21)
VIRUS(17,10)
CATTLE(17,5)
PHENOTYPE(17,5)
BOVINE VIRAL DIARRHEA CONTROL(17,2)
FETAL DEATH(17,1)
PESTIVIRUS GENOME END(17,1)
REDUCING AGENT REPLICATION(17,1)
PROPHYLAXIS(16,4)
FEVER(16,1)
NTR MUTANT(15,9)
INFECTION(15,2)
SIGNIFICANT REDUCTION(15,1)
BVDV(14,23)
STEM LOOP LA(14,10)
PLAQUE PHENOTYPE(13,5)
ADENOSINE(13,2)
BVDV INFECTIOUS CLONE(13,2)
TISSUE CULTURE INFECTIOUS DOSIS(13,2)
ATTENUATION DEFINED BASIS(13,1)
DEFINED MUTATION(13,1)
DILUENT(12,5)
GENOME(12,4)
LIVE ATTENUATED PESTIVIRUS(12,2)
MUTATION RESULT(12,1)
PESTIVIRUS POLYPROTEIN TRANSLATION INITIATION(12,1)
TRANSCRIBED RNA PHOTOMETRIC QUANTIFICATION(12,1)
IRE(11,5)
INFECTIOUS VIRUS RECOVERY(11,3)
MDBK CELL TRANSFECTION(11,3)
REDUCED ABILITY(11,3)
VIRAL GENOMIC RNA(11,3)
METHOD INDUCING IMMUNITY(11,1)
PESTIVIRUS GENOME NTR(11,1)
STRONG NEED(11,1)
PLAQUE ASSAY(10,5)
GENOME END(10,4)
BVDV NTR(10,3)
INTERNAL RIBOSOME ENTRY SITE(10,2)
VACCINE VIRUS(10,2)
PESTIVIRUS IRE BORDER(10,1)
GENETIC STABILITY(9,6)
PARAINFLUENZA TYPE(9,3)
RNA LIGATION(9,3)
RNA TRANSFECTION(9,3)
CLONED CDNA FRAGMENT(9,2)
PESTIVIRUS NTR(9,2)
RNA INFECTIVITY(9,2)
CSFV INFECTIOUS CLONE(9,1)
INFECTIOUS VIRUS TITER(9,1)
HORSE SERUM(8,4)
PEAK TITER(8,4)
RNA POLYMERASE PROMOTER(8,3)
AGAROSE OVERLAY(8,2)
INFECTIOUS CDNA GENERATION(8,2)
PHOSPHORIMAGER(8,2)
RELEASED VIRUS TITER(8,2)
VIRUS MUTANT DELTA(8,2)
AUTHENTIC INFECTIOUS CDNA(8,1)
BDV INFECTIOUS CLONE(8,1)
BVDV INFECTIVITY(8,1)
BVDV MUTANT RNA(8,1)
HOG CHOLERA VIRUS(8,1)
PASSAGED VIRUS MUTANT(8,1)
PESTIVIRUS GENOME POLYPROTEIN REGION(8,1)
PROBE RADIOACTIVE LABELING(8,1)
VIRAL PROTEIN NONEXPRESSION(8,1)
BACTERIAL VECTOR(7,3)
RESIDUE DELETION(7,3)
ANTISENSE PRIMER(7,2)
DAY POST INFECTION(7,2)
DELETION MUTANT(7,2)
FOLD SERIAL DILUTION(7,2)
GROWTH KINETICS DETERMINATION(7,2)
INVESTIGATED CLONE(7,2)
RNA TRANSCRIPTION(7,2)
RT PCR ANALYSIS(7,2)
SECONDARY MUTATION ABSENCE(7,2)
BVDV GENETICALLY STABLE VARIANT(7,1)
BVDV STRAIN ATTENUATION(7,1)
CDNA FRAGMENT AMPLIFICATION(7,1)
GENOME CDNA CLONING(7,1)
HAIRPIN LA DELETION(7,1)
HAIRPIN LA MUTANT(7,1)
LINEARIZED PLASMID DNA(7,1)
NESTED RT PCR ASSAY(7,1)
PERSISTENTLY INFECTED ANIMAL(7,1)
POLYPROTEIN AUG INITIATION CODON(7,1)
PREDICTED HAIRPIN LA(7,1)
RECOVERED BVDV MUTANT(7,1)
VIRUS VACCINE(7,1)
BOVINE CELL(6,4)
BORDER DISEASE VIRUS(6,2)
BVDV SEQUENCE(6,2)
INCUBATION DAY(6,2)
MOUTH DISEASE VIRUS(6,2)
NUCLEOTIDE SUBSTITUTION(6,2)
PHENOL CHLOROFORM(6,2)
SIGMA ALDRICH(6,2)
STEM LOOP LA DELETION(6,2)
ANTI MOUSE IMMUNOGLOBULIN(6,1)
ATTENUATED VIRUS MAXIMUM IMMUNOGENICITY(6,1)
BVDV GENOME(6,1)
BVDV GENOMIC SEQUENCE(6,1)
BVDV HCV CHIMERA(6,1)
BVDV OSLOSS SEQUENCE(6,1)
BVDV PROPAGATION(6,1)
BVDV TERMINUS(6,1)
BVDV VACCINE(6,1)
CATTLE VACCINE(6,1)
CLASSICAL BVDV(6,1)
CONSERVED NUCLEOTIDE(6,1)
CSFV IRE(6,1)
DURALON UV MEMBRANE(6,1)
FLAVIVIRIDAE FAMILY(6,1)
GENETIC RELATEDNESS(6,1)
GENETICALLY STABLE BVDV(6,1)
GENETICALLY STABLE CDNA(6,1)
GENOME TERMINUS(6,1)
GLYOXYLATED RNA(6,1)
HETEROLOGOUS BVDV(6,1)
HOMOLOGOUS IRE(6,1)
INFECTIOUS BVDV(6,1)
INTRACUTANE ADMINISTRATION(6,1)
LAMB INTRAUTERINE INFECTION(6,1)
LIVE PESTIVIRUS PREPARATION(6,1)
LIVE VIRUS DOSE(6,1)
MUTANT CDNA GENERATION(6,1)
MUTANT EMERGENCE(6,1)
MUTANT PESTIVIRUS(6,1)
MUTANT TITER(6,1)
MUTANT VIRUS GROWTH RESTRICTION(6,1)
NOTL NSIL FRAGMENT(6,1)
PESTIVIRUS GENUS(6,1)
PESTIVIRUS NON TRANSLATED REGION(6,1)
PESTIVIRUS PROTEIN FULL COMPLEMENT(6,1)
PESTIVIRUS REPLICATION(6,1)
PESTIVIRUS REVIEW(6,1)
PESTIVIRUS RNA(6,1)
PESTIVIRUS SPECIES(6,1)
PHENOMENON CHARACTERIZATION(6,1)
PORCINE KIDNEY CELL(6,1)
RECOVERED INFECTIOUS VIRUS(6,1)
RECOVERED MUTANT VIRUS(6,1)
REPLICATION KINETICS(6,1)
RNA NORTHERN BLOT ANALYSIS(6,1)
SAMPLE ETHIDIUM BROMIDE STAINING(6,1)
SUBGENOMIC CDNA(6,1)
SUPERNATANT PASSAGING(6,1)
TEMPLATE DNA DEGRADATION(6,1)
TRANSFECTED CELL DILUTION(6,1)
TRANSFECTED CELL INFECTION(6,1)
TRANSFECTION SUPERNATANT(6,1)
UNTREATED MDBK CELL(6,1)
VIRULENT PESTIVIRUS(6,1)
VIRUS MUTANT QUANTITY(6,1)
CELL CULTURE SUPERNATANT(5,3)
INDEPENDENT CLONE(5,3)
OI DELTA(5,3)
AGE MONTH(5,1)
ANIMAL POPULATION(5,1)
ATTENUATED STRAIN(5,1)
BOVINE KIDNEY CELL(5,1)
BVDV IRE ELEMENT(5,1)
BVDV PUBLISHED SEQUENCE(5,1)
BVDV STEM LOOP LA(5,1)
CLONING STRATEGY(5,1)
CSFV MUTANT(5,1)
CYTOPATHOLOGY DEVELOPMENT(5,1)
FATAL MUCOSAL DISEASE(5,1)
GROWTH CURVE ESTABLISHMENT(5,1)
GROWTH RESTRICTED VIRUS(5,1)
GUAU RETENTION(5,1)
HANDBUCH DER(5,1)
LOOP PORTION(5,1)
MUTANT ANALYZED GENOMIC REGION(5,1)
MUTATED VIRUS(5,1)
NTR CLONE(5,1)
NUCLEOTIDE SEQUENCING(5,1)
PEROXIDASE CONJUGATED GOAT(5,1)
PLASMID HHDI(5,1)
PROGENY VIRUS PRODUCTION(5,1)
STRAIN NADL(5,1)
THERAPEUTIC EFFECT(5,1)
TRANSCRIPT DERIVED PARENT VIRUS(5,1)
VACCINATED ANIMAL(5,1)
VACCINE STRAIN(5,1)
VIRAL CDNA(5,1)
VIRAL POLYPEPTIDE(5,1)
VIRAL REPLICATION(5,1)
VIRAL RNA TERMINUS(5,1)
VIRUS MAJOR RESERVOIR(5,1)
XHOI FRAGMENT(5,1)
OI SL(4,8)
PCP(4,8)
STABILIZER(4,3)
VACCINATION(4,3)
BAND INTENSITY(4,2)
GUAU SEQUENCE(4,2)
MICROORGANISM(4,2)
NTR SEQUENCE(4,2)
PRESERVATIVE(4,2)
SEMI SOLID MEDIUM(4,2)
VIRUS YIELD(4,2)
ADJUVANT ACTIVITY(4,1)
BDV IRE ELEMENT(4,1)
BOVINE VIRAL DIARRHEA VIRUS STRAIN(4,1)
BVDV TERMINAL SEQUENCE(4,1)
CELLULAR RNA(4,1)
CONFLUENT CELL(4,1)
DELTA RNA(4,1)
ETHYLCARBAZOLE(4,1)
GENOMIC REGION ENCODING(4,1)
GROWTH KINETICS DIFFERENCE(4,1)
IMMUNFLUORESCENCE ANALYSIS(4,1)
INDICATED MUTANT BVDV STRAIN(4,1)
IRE ACTIVITY(4,1)
LACK NUCLEOTIDE(4,1)
LOOP APEX(4,1)
MUTANT VIRUS TERMINAL SEQUENCE(4,1)
MUTATED SEQUENCE(4,1)
NHEL SITE(4,1)
NTR STEM LOOP LA(4,1)
PEROXIDASE SUBSTRATE(4,1)
RECOVERED VIRUS(4,1)
RNA ACCUMULATION(4,1)
SENSE PRIMER SEQUENCE(4,1)
VACCINE COMPOSITION PREPARATION(4,1)
VIRAL RNA SYNTHESIS ANALYSIS(4,1)
VIRAL YIELD DETERMINATION(4,1)
FOLDING(3,5)
CLASSICAL SWINE FEVER VIRUS(3,2)
INTRANASAL(3,2)
MONOLAYER(3,2)
NUCLEOTIDE SEQUENCE ANALYSIS(3,2)
REVERSE GENETICS(3,2)
TITRATION(3,2)
VIROLOGY(3,2)
ACTINOBACILLUS PLEUROPNEUMONIAE(3,1)
BVDV ANTIGEN POSITIVE CELL(3,1)
BVDV MIXTURE(3,1)
CDNA DERIVED(3,1)
CHLAMYDIA PSITTACI(3,1)
CONSERVED SEQUENCE MOTIF(3,1)
GENERATION(3,1)
HHDI BASIS(3,1)
IMMUNOFLUORESCENCE(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INDEPENDENTLY PRODUCED VIRAL PLAQUE(3,1)
INFECTED CELL(3,1)
INSEMINATION(3,1)
METHANOL ACETONE(3,1)
NUCLEOTIDE DIFFERENCE(3,1)
NUCLEOTIDE INSERTION(3,1)
PA BVDV BASIS(3,1)
PASTEURELLA MULTOCIDA(3,1)
PRECISE DOSAGE(3,1)
REACH TITER(3,1)
REPLICATION ABILITY(3,1)
(JP2002325575)
PESTIVIRUS(100,30)
PLAQUE(100,23)
VACCINE(100,21)
MUTATION(100,16)
IRE(100,11)
PHENOTYPE(100,6)
GENOME(100,5)
PESTIVIRUS GENOME(100,5)
STEM LOOP LA(100,4)
UNTRANSLATED REGION(100,4)
CONTROL(100,2)
VIRAL POLYPROTEIN EXPRESSION(100,2)
HULFNG GUAU(100,1)
MUTANT PESTIVIRUS(100,1)
MUTATION RESULT(100,1)
PESTIVIRUS REGION(100,1)
IRE VARIANT BVDV(94,1)
VIRUS DIARRHEIC LIVE CATTLE(74,1)
REPLICATION ATTENUATED PESTIVIRUS(66,1)
GUA UCCU GUAUAU(57,1)
VIRUS RHINOBRONCHITIS CALF(53,1)
PESTIVIRUS VARIANT(49,2)
LIVE VACCINE(43,7)
AVIRULENT PESTIVIRUS(42,1)
BARBA PASTEURELLOSIS(41,1)
INFECTION PREVENTION(41,1)
AVIRULENT BVDV(37,1)
BVDV 1OR BVDV(36,1)
ANIMAL PESTIVIRUS(35,2)
CATTLE PARAMYXOVIRUS(32,2)
IRE FACTO(...)";"Basic materials chemistry
Pharmaceuticals";Open
2000-04-17;"RU2162339           C1 2001-01-27 [RU2162339]
STG: (C1) Patent for invention
AP : 2000RU-0109667 2000-04-17";36131628;RU2162339           C1 2001-01-27 [RU2162339];2000RU-0109667;;"ASHCHITY ZHIVOTNYKH
VRNII Z";"ASHCHITY ZHIVOTNYKH
VRNII Z";;;2;"GUSEV A A
RUSALEEV V S
SOSNITSKIJ A I
GNEVASHEV V M
PRUNTOVA O V";;;"(RU2162339)
Method of emulsion antipasteurellosis vaccine preparing";"(RU2162339)
veterinary microbiology, biotechnology. SUBSTANCE: industrial strains of Pasteurella multicida of serotypes A, D and B are cultured in nutrient media containing Hottinger broth with addition of 10-15% cattle serum at pH 7.6-7.8 and index of amine nitrogen 200-250 mg%. Obtained bacterial mass is subjected for inactivation with aminoethylethyleneimine which is added to bacterial suspension up to concentration 0.5-4%. Mixture is incubated at 37-38 C for 12-16 h and prepared antigen is added to sucrose-gelatin medium. Then antigen is combined with oily adjuvant in the ratio 3:7, respectively. EFFECT: enhanced immunogenic activity and specific safety of vaccine. 5 cl, 4 tbl, 8 ex";"(RU2162339)
1. The Method of preparing the emulsion anti-pasteurellosis vaccine, which includes obtaining the suspension of the culture of Pasteurella, at least, one serotype, the inactivation of the obtained culture and the connection of bacterial antigen with the oil adjuvant, that is characterized by the fact that as inaktivanta is used aminoetiletilenimin, which is introduced into the suspension of culture to concentration 0,5 - 4%, and at the end of inactivation the obtained antigen is introduced into the stabilizing medium.
2. Method according to claim 1, that is characterized by the fact that inactivation conduct for 12- 16 h with 37 - 38 (o) C.
3. Method according to claim 1, that is characterized by the fact that at the end of inactivation they precipitate bacterial antigen by centrifugation.
4. Method according to claim 1, that is characterized by the fact that the sugar- gelatinous medium is used as the stabilizing medium.
5. Method according to claim 1, that is characterized by the fact that antigen and oil adjuvant they connect up relationship 3: 7.";;;"A61K-039/102
A61L-002/16
C12N-001/00";;;"Medical technology
Pharmaceuticals";Open
"1999-11-30
1999-12-14
2000-11-29";"WO200139801         A2 2001-06-07 [WO200139801]
STG: (A2) International application published without international search report
AP : 2000WO-EP11940 2000-11-29
CA2388678           A1 2001-06-07 [CA2388678]
STG: (A1) Application laid open
AP : 2000CA-2388678 2000-11-29
AU2509101           A  2001-06-12 [AU200125091]
STG: (A) Open to public inspection
AP : 2001AU-0025091 2000-11-29
WO200139801         A3 2002-02-07 [WO200139801]
STG: (A3) Later publication of ISR with revised front page
AP : 2000WO-EP11940 2000-11-29
EP1237572           A2 2002-09-11 [EP1237572]
STG: (A2) Application published without search report
AP : 2000EP-0988765 2000-11-29
MXPA02004236        A  2003-01-28 [MX2002PA004236]
STG: (A) Patent application
AP : 2002MX-PA04236 2000-11-29
NZ519786            A  2003-10-31 [NZ-519786]
STG: (A) Published application
AP : 2000NZ-0519786 2000-11-29
AU777991            B2 2004-11-11 [AU-777991]
STG: (B2) Patent proceeded by OPI
AP : 2001AU-0025091 2000-11-29";73600657;"WO200139801         A2 2001-06-07 [WO200139801]
CA2388678           A1 2001-06-07 [CA2388678]
AU2509101           A  2001-06-12 [AU200125091]
WO200139801         A3 2002-02-07 [WO200139801]
EP1237572           A2 2002-09-11 [EP1237572]
MXPA02004236        A  2003-01-28 [MX2002PA004236]
NZ519786            A  2003-10-31 [NZ-519786]
AU777991            B2 2004-11-11 [AU-777991]";"1999EP-0123767
1999US-60170616
2000EP-0988765
2000WO-EP11940";"(EP1237572)
WO200139801
(CA2388678)
WO200139801
(MX2002PA004236)
WO200139801
(NZ-519786)
WO200139801
(AU-777991)
WO200139801";BOEHRINGER INGELHEIM VETMEDICA;BOEHRINGER INGELHEIM VETMEDICA;"(EP1237572)
DE
(WO200139801)
DE
(CA2388678)
DE";"(EP1237572)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Postfach 2 00 , CITY=55216 Ingelheim , COUNTRY=DE 

(WO200139801)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH [DE / DE]  55216 Ingelheim am Rhein  , COUNTRY=DE 

(CA2388678)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Str. 173 55216 , CITY=INGELHEIM AM RHEIN , COUNTRY=DE 
";1;"MEYERS GREGOR
ELBERS KNUT";"(EP1237572)
DE";"(EP1237572)
NAME=MEYERS, Gregor Albstrasse 1 , CITY=72141 Walddorfhaeslach , COUNTRY=DE 

NAME=ELBERS, Knut Caprino-Veronese-Str. 4a , CITY=55435 Gau Algesheim , COUNTRY=DE 
";"(EP1237572)
Safe attenuated bovine viral diarrhea viruses for use in pregnant cows";"(EP1237572)
This invention relates to the use of specifically attenuated live BVD (bovine viral diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.";"(WO200139801)
1. Claims: Use of a live BVDV (bovine viral diarrhea virus), wherein the RNase activity residing in its glycoprotein ERNSis inactivated for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle.
2. Use of a BVDV according to claim 1 for use in the prevention and/or treatment of BVDV infections in pregnant cows.
3. Use of a BVDV according to claim 1 for inducing fetal protection against BVDV infections in pregnant cows.
 - 4. Use of a BVDV according to any one of claims 1 to 3 for use in the prevention and/or treatment of BVDV type I infections.
5. Use of a BVDV according to any one of claims 1 to 3 for use in the prevention and/or treatment of BVDV type II infections.
6. Use of a BVDV according to any one of claims 1 to 5, wherein said RNase activity is inactivated by deletions and/or mutations of at least one amino acid of said glycoprotein.
7. Use of a BVD virus according to any one of claims 1 to 6 comprising a BVDV pestivirus, wherein said RNase activity is inactivated by the deletion of the histidine residue at position 349, as described in figure 1 for the CP7 strain in an exemplary manner or corresponding thereto in other BVDV strains, of said glycoprotein.";"(WO200139801)
The present invention relates to the use of specifically attenuated live BVD (Bovine Viral Diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.
Therefore, in one aspect, the present invention relates the unexpected use of a live BVDV (bovine viral diarrhea virus), wherein the RNase activity residing in its glycoprotein ERNS is inactivated, for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle.
This application discloses an attenuated live vaccine that is superior in its efficacy of induction of immunity to subunit and killed vaccines as well as superior to conventionally attenuated vaccines which are molecularly undefined, unmarked and unpredictable with respect to mutants.";"(WO200139801)
Live vaccines with defined mutations as a basis for attenuation would allow to avoid the disadvantages of the present generation of attenuated vaccines.
The invention also relates to a method of treatment and/or prevention of BVDV infections in the above named group of cattle.
The more classical BVDV type I strains and the more recently recognized BVDV type II strains display some limited but distinctive differences in nucleotide and amino acid sequences.
Therefore, the technical problem underlying this invention was to provide safely attenuated and live BVDV vaccines that can be used for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections of pregnant cows or cattle in the presence of pregnant cows.";"A61K-039/12
A61P-031/12
A61P-031/14
C07K-007/04
C07K-014/18
C12N-007/04
C12N-015/40";"(WO200139801)
Claims: Use of a live BVDV (bovine viral diarrhea virus), wherein the RNase activity residing in its glycoprotein ERNS is inactivated for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle.";"(WO200139801)
BOVINE VIRAL DIARRHEA VIRUS(100,9)
CATTLE BREEDING STOCK(100,4)
BVDV INFECTION TREATMENT(89,7)
LIVE VACCINE PREPARATION(70,6)
PREGNANT COW(65,15)
BVDV INFECTION PREVENTION(62,1)
ATTENUATED LIVE VACCINE(60,1)
CLASSICAL BVDV(51,1)
BVDV VACCINE(44,1)
RNASE ACTIVITY(43,15)
RECENTLY RECOGNIZED BVDV(42,1)
PREVENTION(41,10)
PREGNANT COW PRESENCE(41,1)
INDUCTION EFFICACY(40,1)
VACCINE PREPARATION(34,1)
FETAL PROTECTION(33,3)
ATTENUATED VACCINE(31,2)
BVDV PESTIVIRUS(31,2)
BVDV TREATMENT(31,2)
KILLED VACCINE(29,3)
GLYCOPROTEIN(28,16)
LIVE VACCINE(27,4)
BVD VIRUS(25,2)
BVDV STRAIN(22,5)
CATTLE GROUP(22,1)
BOVINE VIRAL DIARRHEA(21,1)
NUCLEOTIDE(19,1)
IMMUNITY(18,1)
SUBUNIT(17,1)
DELETION(15,6)
RNASE ACTIVITY INACTIVATION(14,4)
DEFINED MUTATION(14,1)
ATTENUATION(13,4)
ATTENUATED LIVE BVDV REVERTANT(13,1)
MUTANT(12,3)
LIVE BVDV VACCINE(12,2)
BVDV INFECTION MANIFESTATION(12,1)
L HISTIDINE RESIDUE(12,1)
MONOCLONAL NEUTRALIZING ANTIBODY AGAIST(12,1)
SERONEGATIVE HEIFER PLACENTA(12,1)
VIRUS(11,12)
CATTLE(11,5)
BACTERIAL COLONY HARBORING PLASMID(11,1)
PERSISTENTLY INFECTED CALF INDUCTION(11,1)
ATTENUATED PESTIVIRUS(10,2)
BRANSON SONIFIER B12(10,1)
BVDV MUTANT VIABILITY(10,1)
IMMUNOTOLERANT CALF BIRTH(10,1)
PREGNANT COW PLACENTA(10,1)
QIAAMP VIRAL MINI KIT(10,1)
AMINOACID SEQUENCE(9,4)
ACUTE SERO FIBRINOUS INFLAMMATION(9,1)
BVDV MUTANT RNASE ACTIVITY(9,1)
CHILD BEARING HOST ANIMAL PLACENTA(9,1)
FETAL BVDV INFECTION RISK(9,1)
FETAL INFECTION CHALLENGE VIRUS(9,1)
PERSISTENTLY INFECTED BULL(9,1)
PLASMID DNA(8,4)
CONSTRUCTING CDNA(8,3)
MANUFACTURER RECOMMENDATION(8,2)
BOVINE DIARRHEA VIRUS(8,1)
BOVINE KIDNEY TRANSFECTION(8,1)
BVDV ANTIBODY TITER(8,1)
BVDV FETAL CHALLENGE(8,1)
PREGNANT COW VICINITY(8,1)
RECOMBINANT VACCINIA VIRUS(8,1)
VIRUS ISOLATION(7,3)
MUTANT VIRUS(7,2)
RNASE ACTIVITY DETERMINATION(7,2)
ABROGATED RNASE ACTIVITY(7,1)
ANTIBODY ELISA DATA(7,1)
ATTENUATED BVDV(7,1)
ATTENUATED LIVE VIRUS(7,1)
BVD CAUSATIVE AGENT(7,1)
BVDV NEGATIVE HERD(7,1)
BVDV SEROPOSITIVE(7,1)
COLOSTRUM INGESTION(7,1)
COW ABORTED FETUS(7,1)
DISEASE EPIDEMIOLOGY(7,1)
ENZYME CATALYTIC CENTER(7,1)
FETAL INFECTION PREVENTION(7,1)
FETUS NECROPSY(7,1)
FETUS RESORPTION(7,1)
INFECTIOUS VIRUS RECOVERY(7,1)
INTRAUTERINE INFECTION PATHOGENESIS(7,1)
JACKSON IMMUNO RESEARCH(7,1)
LIVE ATTENUATED VIRUS(7,1)
NONCYTOPATHOGENIC BVDV(7,1)
ORGANISM GROWTH CULTURE(7,1)
PATHOGENESIS REVIEW(7,1)
PATHOGENIC PESTIVIRUS(7,1)
PESTIVIRUS GENUS(7,1)
POLYMERASE SEQUENCING KIT(7,1)
POLYNUCLEOTIDE VACCINATION(7,1)
PORCINE PESTIVIRUS(7,1)
PREGNANT HEIFER(7,1)
REVERTANT OUTBREAK(7,1)
RNASE ENZYMATIC ACTIVITY(7,1)
RNEASY MINI KIT(7,1)
RT PCR AMPLIFICATION(7,1)
SVANOVIR BVDV ANTIBODY TEST(7,1)
BVDV DETECTION(6,2)
BREEDING HERD(6,1)
BROMID STAINING(6,1)
CATTLE VACCINATION(6,1)
CLINICAL MANIFESTATION(6,1)
CONJUGATED ANTISERUM(6,1)
CYTOPATHOGENIC VIRUS(6,1)
DERIVED ATTENUATED VIRUS(6,1)
EPPENDORF CENTRIFUGE(6,1)
IMMUNOFLUORESCENCE ASSAY(6,1)
INFECTIOUS CRNA(6,1)
NEGATIVE FRO BVDV(6,1)
NON INFECTIOUS RNA(6,1)
PCR SEQUENCING(6,1)
PESTIVIRUS GENETIC DIVERSITY(6,1)
PHARMACEUTICAL COMPOSTION(6,1)
PREGNANCY MONTH(6,1)
PREGNANT CATTLE(6,1)
PRIMER PMOL(6,1)
PURIFIED VIRAL PROTEIN(6,1)
REINVESTIGATING SERUM(6,1)
RNASE NEGATIVE BVDV MUTANT(6,1)
SEROLOGICAL DATA(6,1)
VACCINA VIRUS VTF(6,1)
VACCINATED CATTLE(6,1)
VETERINARY MICROBIOLOGY(6,1)
VIRAL POIYPROTEIN(6,1)
VIROLOGICAL EXAMINATION(6,1)
ANCILLARY MOLECULE(5,1)
ANIMAL NEED(5,1)
ANTIBODY REACTION NEUTRALIZATION(5,1)
ANTISENSE PRIMER(5,1)
AQUA DEST(5,1)
ATTENUATED ORGANISM(5,1)
BACTERIOPHAGE T7 RNA POLYMERASE(5,1)
BORN CALF(5,1)
BOVINE KIDNEY CELL(5,1)
BUFFY COAT PREPARATION(5,1)
BVDV ANTIBODY PRESENCE(5,1)
CLINICAL SYMPTOM(5,1)
DATA LIBRARY(5,1)
DISTINCTIVE LABEL(5,1)
EMS GENE(5,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(5,1)
IMMUNITY INDUCTION(5,1)
LIVING ORGANISM(5,1)
MOLECULAR UNIQUENESS(5,1)
MOUSE PRETREATMENT(5,1)
NESTED AMPLIFICATION(5,1)
NORTHERN BLOT(5,1)
NUCLEOTIDE SEQUENCING(5,1)
PARENT VIRUS ABILITY(5,1)
PESTIVIRUS DETECTION(5,1)
PESTIVIRUS MOLECULAR BIOLOGY(5,1)
PLASMID DISPLAYING(5,1)
RNASE ASSAY BUFFER(5,1)
RUMINANT IDENTIFICATION(5,1)
SERUM POSITIVITY(5,1)
SMAL CRNA(5,1)
STERILE PIPETTE(5,1)
TRANSFECTION EXPERIMENT(5,1)
UNTRANSLATED CDNA REGION(5,1)
VIRAL GENOME(5,1)
VIRAL RNA CHARACTERIZATION(5,1)
EXPERT(4,3)
TRIAL(4,3)
BVDV POSITIVE(4,2)
CLINICAL SAMPLE(4,2)
SERUM SAMPLE(4,2)
ABORTION SAMPLE(4,1)
AMPICILLIN SELECTION(4,1)
APPROPATE CELL(4,1)
BOLD CHARACTER(4,1)
BOVINE SERUM ALBUMIN(4,1)
BP LADDER(4,1)
BVDV MAJOR ANTIGENIC GROUP(4,1)
CALF LACK(4,1)
CLINICAL OBSERVATION(4,1)
CLINICAL SIGN PRESENCE(4,1)
COMPLETE LIVE ORGANISM(4,1)
CRNA TRANSFECTION(4,1)
CUP HORN(4,1)
DISH CELL(4,1)
FUNGAL RNASE ACTIVE PROTEIN(4,1)
GENETIC STABILITY REMAINS UNKNOWN(4,1)
GENOMIC MODIFICATION(4,1)
GEY BUFFER TREATMENT(4,1)
GLYCOPROTEIN ABILITY(4,1)
IMMUNOLOGICAL ACTIVITY(4,1)
INFECTION DAY(4,1)
MOUSE FITC(4,1)
MUTANT PA BVDV(4,1)
NON INFECTED CELL(4,1)
PCR PRODUCT SPECIFICITY(4,1)
PHENOTYPIC SELECTION(4,1)
PLACENTAL TRANSMISSION(4,1)
PREGNANCY DAY(4,1)
RECOMBINANT MODIFICATION(4,1)
RECOVERED VIRUS CELL(4,1)
RT PCR CYCLE(4,1)
SPECIES BVDV(4,1)
SPLITTING CELL(4,1)
STERILE VESSEL(4,1)
SYNTHETIC OLIGONUCLEOTIDE(4,1)
TRANSFECTED CELL(4,1)
TRANSIENT ASSAY(4,1)
VIABILITY ACTIVITY(4,1)
VIRUS PREPARATION(4,1)
VIRUS PROPAGATION(4,1)
VIRUS SPREAD(4,1)
ROUTE(3,3)
ANTIBIOTIC(3,2)
ELISA TEST(3,2)
INTRANASAL(3,2)
NESTED PCR(3,2)
OBSERVATION PERIOD(3,2)
PURIFICATION(3,2)
SUBUNIT VACCINE(3,2)
ADJUVANT PRESENCE(3,1)
AMPLIFICATE(3,1)
BVDV FEATURE(3,1)
BVDV SPECIFIC IMMUNOFLUORESCENCE(3,1)
CELL CULTURE ALIQUOT(3,1)
CELL LYSATE(3,1)
CENTRIFUGING STEP SUPERNATANT(3,1)
CLEAR EVIDENCE(3,1)
CLONE B2(3,1)
COLUMN CHROMATOGRAPHY(3,1)
CONGENITAL MALFORMATION(3,1)
DIETHYLPYROCARBONAT(3,1)
ERYTHROCYTE PHASE(3,1)
FRESH BLOOD(3,1)
GEL FILTRATION(3,1)
HORIZONTAL AGAROSE(3,1)
IMMUNOFLUORESCENCE MICROSCOPY(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INFECTED CELL CULTURE(3,1)
INSUFFICIENT OXYGEN(3,1)
INTERNAL PRIRNER SEQUENCE(3,1)
LOW NEUTRALIZING ANTIBODY TITER(3,1)
LYSIS BUFFER(3,1)
MAIN EVALUATION PARAMETER(3,1)
MAJOR ECONOMICAL IMPACT(3,1)
MIXTURE ALIQUOT(3,1)
MONTHLY BASIS(3,1)
ORGANISM IMMUNOLOGICAL FUNCTION(3,1)
ORIGIN MOLECULE(3,1)
PASSAGING(3,1)
PCR BUFFER(3,1)
PHENOL CHLOROFORM EXTRACTION(3,1)
SENSE PMOL(3,1)
SPECIES PLUS SUBSEQUENT ISOLATION(3,1)
TERM GLYCOPROTEIN(3,1)
TISSUE SUSPENSION(3,1)
ULTRACENTRIFUGATION(3,1)
WHOLE ORGANISM(3,1)
WHOLE VIRUS(3,1)
ACETATE EDETIC ACID(2,1)
ADMINISTRATION(2,1)
ANIMAL GROUP(2,1)
ANTIPARASITIC(2,1)
BLOOD ML(2,1)
BVDV INFECTION STILL TREATMENT(2,1)
BVDV RELATED ABORTION(2,1)
CDNA PROBE(2,1)
CELL SUSPENSION(2,1)
CHORION(2,1)
CLASSIFICATION(2,1)
CNANGE(2,1)
CONTAMINATION(2,1)
CYCLOPHOSPHAMIDE(2,1)
DAY PI(2,1)
(CA2388678)
BOVINE VIRAL DIARRHEA VIRU(100,106)
PREGNANT COW(100,11)
SAFE ATTENUATED BOVINE VIRAL DIARRHEA VIRUS(100,1)
ATTENUATED LIVE VACCINE(97,1)
CATTLE BREEDING STOCK(89,3)
PREGNANT COW INFECTION(87,1)
LIVE VACCINE PREPARATION(82,3)
INDUCTION EFFICACY(64,1)
PREGNANT COW PRESENCE(52,1)
RNASE ACTIVITY(51,15)
BVD VIRUS(50,1)
BVDV STRAIN(48,2)
PREVENTION(47,8)
ATTENUATED VACCINE GENERATION(46,1)
KILLED VACCINE(44,3)
BVDV INFECTION TREATMENT(40,1)
INDUCING FETAL PROTECTION(40,1)
LIVE VACCINE(35,4)
ATTENUATED VACCINE(33,1)
INFECTION(31,15)
GLYCOPROTEIN(29,16)
IMMUNITY(29,1)
SUBUNIT(28,1)
NUCLEOTIDE(24,1)
GIYCOPROTEIN(22,1)
PROPHYLAXIS(21,1)
STRAIN(19,12)
DELETION(19,7)
RNASE ACTIVITY INACTIVATION(18,4)
VACCINE(17,12)
BOVINE VIRAL DIARRHEA(17,5)
ATTENUATION(17,4)
DEFINED MUTATION(17,1)
MUTANT(16,6)
BACTERIAL COLONY HARBORING PIASMID(16,1)
SERONEGATIVE HEIFER PLACENTA(15,1)
CATTLE(14,5)
PERSISTENTLY INFECTED CALF INDUCTION(14,1)
ATTENUATED PESTIVIRUS(13,2)
BRANSON SONIFIER B12(13,1)
IMMUNOTOLERANT CALF BIRTH(13,1)
PREGNANT COW PLACENTA(13,1)
QLAAMP VIRAL MINI KIT(13,1)
VACCINATING PREGNANT COW(13,1)
L HISTIDINE RESIDUE(12,2)
ACUTE SERO FIBRINOUS INFLAMMATION(12,1)
CHILDBEARING HOST ANIMAL PLACENTA(12,1)
FETAL INFECTION CHALLENGE VIRUS(12,1)
PERSISTENTLY INFECTED BULL(12,1)
AMINO ACID SEQUENCE(11,4)
PLASMID DNA(11,4)
CLINICAL MANIFESTATION(11,2)
MANUFACTURER RECOMMENDATION(11,2)
BOVINE DIARRHEA VIRUS(11,1)
BOVINE KIDNEY TRANSFECTION(11,1)
EMSL DATA LIBRARY(11,1)
PREGNANT COW VICINITY(11,1)
RECOMBINANT CYTOPATHOGENIC SWINE FEVER VIRUS(11,1)
RECOMBINANT VACCINIA VIRUS(11,1)
CONSTRUCTING CDNA(10,3)
ABROGATED RNASE ACTIVITY(10,1)
ANTIBODY ELISA DATA(10,1)
ATTENUATED LIVE VIRUS(10,1)
COLOSTRUM INGESTION(10,1)
FETAL INFECTION PREVENTION(10,1)
LIVE ATTENUATED VIRUS(10,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(10,1)
MOUSE FITC CONJUGATED ANTISERUM(10,1)
MUTANT PA VIABILITY ACTIVITY(10,1)
POLYMERASE SEQUENCING KIT(10,1)
REVERTANT OUTBREAK(10,1)
MUTANT VIRUS(9,2)
RNASE ACTIVITY DETERMINATION(9,2)
BUFFY COAT(8,2)
COW ABORTED FETUS(8,1)
DISEASE EPIDEMIOLOGY(8,1)
ENZYME CATALYTIC CENTER(8,1)
FETUS NECROPSY(8,1)
FETUS RESORPTION(8,1)
INFECTIOUS VIRUS RECOVERY(8,1)
INTRAUTERINE INFECTION PATHOGENESIS(8,1)
MDBK CLONE B2(8,1)
ORGANISM GROWTH CULTURE(8,1)
PATHOGENESIS REVIEW(8,1)
PATHOGENIC PESTIVIRUS(8,1)
PESTIVIRUS GENUS(8,1)
POLYNUCLEOTIDE VACCINATION(8,1)
PORCINE PESTIVIRUS(8,1)
PREGNANCY MONTH(8,1)
PREGNANT HEIFER(8,1)
RNASE ENZYMATIC ACTIVITY(8,1)
VIRUS ISOLATION(7,2)
BREEDING HERD(7,1)
CATTLE VACCINATION(7,1)
CYTOPATHOGENIC VIRUS(7,1)
DERIVED ATTENUATED VIRUS(7,1)
EPPENDORF CENTRIFUGE(7,1)
FLAVIVIRIDAE FAMILY(7,1)
IMMUNOFLUORESCENCE ASSAY(7,1)
IMMUNORESEARCH LABORATORY(7,1)
INFECTIOUS CRNA(7,1)
MUTANT RNASE ACTIVITY(7,1)
NONINFECTIOUS RNA(7,1)
PESTIVIRUS GENETIC DIVERSITY(7,1)
PHARMACEUTICAL COMPOSTION(7,1)
PHENOUCHLOROFORM EXTRACTION(7,1)
PREGNANT CATTLE(7,1)
PURIFIED VIRAL PROTEIN(7,1)
REINVESTIGATING SERUM SAMPLE(7,1)
RN EASY MINI KIT(7,1)
SEROLOGICAL DATA(7,1)
VACCINA VIRUS VTF(7,1)
VACCINATED CATTLE(7,1)
VETERINARY MICROBIOLOGY(7,1)
VIRAL POLYPROTEIN(7,1)
VIROLOGICAL EXAMINATION(7,1)
CLINICAL SAMPLE(6,2)
AGAIST BOVINE VIRAL DIARRHEA VIRUS(6,1)
ANCILLARY MOLECULE(6,1)
ANIMAL NEED(6,1)
ANTIBODY REACTION NEUTRALIZATION(6,1)
ANTISENSE PRIMER(6,1)
ATTENUATED ORGANISM(6,1)
BACTERIOPHAGE T7 RNA POLYMERASE(6,1)
BGLIL FRAGMENT(6,1)
BORN CALF(6,1)
BOVINE KIDNEY CELL(6,1)
BUFFV COAT PREPARATION(6,1)
CO2 INCUBATOR(6,1)
DAY POSTINFECTION(6,1)
DISTINCTIVE LABEL(6,1)
FETAL CHALLENGE(6,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(6,1)
IMMUNITY INDUCTION(6,1)
LIVING ORGANISM(6,1)
MOLECULAR UNIQUENESS(6,1)
MOUSE PRETREATMENT(6,1)
MUTAGENESIS KIT(6,1)
NESTED AMPLIFICATION(6,1)
NORTHERN BLOT(6,1)
NUCLEOTIDE SEQUENCING(6,1)
PARENT VIRUS ABILITY(6,1)
PESTIVIRUS DETECTION(6,1)
PESTIVIRUS MOLECULAR BIOLOGY(6,1)
PLASMID DISPLAYING(6,1)
RNASE ASSAY BUFFER(6,1)
RUMINANT IDENTIFICATION(6,1)
SERUM POSITIVITY(6,1)
SMAL CRNA(6,1)
STERILE PIPETTE(6,1)
TRANSFECTION EXPERIMENT(6,1)
UNTRANSLATED CDNA REGION(6,1)
VIRAL GENOME(6,1)
VIRAL RNA CHARACTERIZATION(6,1)
VIRUS RECOVERY PASSAGE(6,1)
EXPERT(5,3)
MONOCLONAL ANTIBODY(5,3)
TRIAL(5,3)
ABORTION SAMPLE(5,1)
AMPICILLIN SELECTION(5,1)
BOLD CHARACTER(5,1)
BOVINE SERUM ALBUMIN(5,1)
CALF LACK(5,1)
CAUSATIVE AGENT(5,1)
CLINICAL OBSERVATION(5,1)
CLINICAL SIGN PRESENCE(5,1)
COMPLETE LIVE ORGANISM(5,1)
CRNA TRANSFECTION(5,1)
CUP HORN(5,1)
DISH CELL(5,1)
FETAL PROTECTION(5,1)
FETAL TRANSMISSION EVALUATION(5,1)
FUNGAL RNASE ACTIVE PROTEIN(5,1)
GEN BANK(5,1)
GENETIC STABILITY REMAINS UNKNOWN(5,1)
GENOMIC MODIFICATION(5,1)
GEY BUFFER TREATMENT(5,1)
GLYCOPROTEIN ABILITY(5,1)
IMMUNOLOGICAL ACTIVITY(5,1)
INFECTION DAY(5,1)
NONINFECTED CELL(5,1)
PHAGE STRAND(5,1)
PHENOTYPIC SELECTION(5,1)
PL SUSPENSION(5,1)
PLACENTAL TRANSMISSION(5,1)
PREGNANCY DAY(5,1)
PUFFY COAT(5,1)
RECOMBINANT MODIFICATION(5,1)
RECOVERED VIRUS(5,1)
SPLITTING CELL(5,1)
STERILE VESSEL(5,1)
SUPERNATANT PI(5,1)
SYNTHETIC OLIGONUCLEOTIDE(5,1)
TRANSFECTED CELL(5,1)
TRANSIENT ASSAY(5,1)
VACCINE PREPARATION(5,1)
VIRUS PREPARATION(5,1)
VIRUS PROPAGATION(5,1)
VIRUS SPREAD(5,1)
ROUTE(4,3)
ANTIBIOTIC(4,2)
ELISA TEST(4,2)
INTRANASAL(4,2)
OBSERVATION PERIOD(4,2)
PURIFICATION(4,2)
SUBUNIT VACCINE(4,2)
25P VOLUME(4,1)
50P VOLUME(4,1)
ACETONEIMETHANOL(4,1)
ADJUVANT PRESENCE(4,1)
AMPLIFICATE(4,1)
CELL CULTURE ALIQUOT(4,1)
CELL LYSATE(4,1)
CLEAR EVIDENCE(4,1)
COLUMN CHROMATOGRAPHY(4,1)
CONGENITAL MALFORMATION(4,1)
ERYTHROCYTE PHASE(4,1)
EXTERNAL PRIMER SEQUENCE(4,1)
FRESH BLOOD(4,1)
GEL FILTRATION(4,1)
HORIZONTAL AGAROSE(4,1)
IMMUNOFLUORESCENCE MICROSCOPY(4,1)
IMMUNOLOGICAL RESPONSE(4,1)
INFECTED CELL CULTURE(4,1)
INSUFFICIENT OXYGEN(4,1)
INTERNAL PRIMER SEQUENCE(4,1)
LOW NEUTRALIZING ANTIBODY TITER(4,1)
LYSIS BUFFER(4,1)
MAIN EVALUATION PARAMETER(4,1)
MAJOR ECONOMICAL IMPACT(4,1)
MIXTURE ALIQUOT(4,1)
MONTHLY BASIS(4,1)
MS GENE(4,1)
NEGATIVE HERD(4,1)
ORGANISM IMMUNOLOGICAL FUNCTION(4,1)
ORIGIN MOLECULE(4,1)
PASSAGING(4,1)
SPECIES PLUS SUBSEQUENT ISOLATION(4,1)
SUFFOCATION(4,1)
TERM GLYCOPROTEIN(4,1)
TISSUE SUSPENSION(4,1)
ULTRACENTRIFUGATION(4,1)
WHOLE ORGANISM(4,1)
WHOLE VIRUS(4,1)
NCP(3,2)
ACETATE EDETIC ACID(3,1)
ADMINISTRATION(3,1)
ANTIPARASITIC(3,1)
BLOOD CELL DETERMINATION(3,1)
BLOOD ML(3,1)
CELL SUSPENSION(3,1)
CENTRIFUGING STEP(3,1)
CHORION(3,1)
CLASSIFICATION(3,1)
CONTAMINATION(3,1)
DAY PI(3,1)
DEDUCED AMINO ACID SEQUENCE(3,1)
DISH DIAMETER(3,1)";Pharmaceuticals;Open
"1999-11-30
1999-12-14
2000-11-06";"EP1104676           A1 2001-06-06 [EP1104676]
STG: (A1) Application published with search report
AP : 1999EP-0123767 1999-11-30
UY26450             A1 2001-07-31 [UY--26450]
STG: (A1) Patent application (First publication level)
AP : 2000UY-0026450 2000-11-27
AR026637            A1 2003-02-19 [AR--26637]
STG: (A1) Independent patent application
AP : 2000AR-0106270 2000-11-29
CO5280138           A1 2003-05-30 [CO5280138A1]
STG: (A1) Published Application
AP : 2000CO-0091439 2000-11-29
US6610305           B1 2003-08-26 [US6610305]
STG: (B1) Granted patent as first publication
AP : 2000US-09706649 2000-11-06
FD :  Provisional Appl: US60/170,616 FDD=1999-12-14
FD : Provisional Appl: US60/170,616 FDD=1999-12-14 [1999US-60170616]";18528;"EP1104676           A1 2001-06-06 [EP1104676]
UY26450             A1 2001-07-31 [UY--26450]
AR026637            A1 2003-02-19 [AR--26637]
CO5280138           A1 2003-05-30 [CO5280138A1]
US6610305           B1 2003-08-26 [US6610305]";"1999EP-0123767
1999US-60170616
2000US-09706649";;"BOEHRINGER INGELHEIM
BOEHRINGER INGELHEIM VETMEDICA";BOEHRINGER INGELHEIM VETMEDICA;"(EP1104676)
DE
(US6610305)
DE";"(EP1104676)
NAME=BOEHRINGER INGELHEIM VETMEDICA GMBH Binger Strasse 173 , CITY=55218 Ingelheim am Rhein , COUNTRY=DE 

(US6610305)
NAME=Boehringer Ingelheim Vetmedica GmbH , CITY=Ingelheim , COUNTRY=DE , ATYP=Non-US Company 
";1;"MEYERS GREGOR DIPL-BIOCHEM
ELBERS KNUT";"(EP1104676)
DE";"(EP1104676)
NAME=Meyers, Gregor, Dipl.-Biochem. Albstrasse 1 , CITY=72141 Walddorfhaeslach , COUNTRY=DE 

NAME=Elbers, Knut Caprino-Veronese-Strasse 4a , CITY=55435 Gau-Algesheim , COUNTRY=DE 
";"(EP1104676)
Safe attenuated bovine viral diarrhea viruses for use in pregnant cows";"(EP1104676)
This invention relates to the use of specifically attenuated live BVD (bovine viral diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.";"(EP1104676)
1. Use of a live BVDV (bovine viral diarrhea virus), wherein the RNase activity residing in its glycoprotein ERNS is inactivated for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle.
2. Use of a BVDV according to claim 1 for use in the prevention and/or treatment of BVDV infections in pregnant cows.
3. Use of a BVDV according to claim 1 for inducing fetal protection against BVDV infections in pregnant cows.
4. Use of a BVDV according to any one of claims 1 to 3 for use in the prevention , and/or treatment of BVDV type I infections.
5. Use of a BVDV according to any one of claims 1 to 3 for use in the prevention and/or treatment of BVDV type II infections.
6. Use of a BVDV according to any one of claims 1 to 7, wherein said RNase activity is inactivated by deletions and/or mutations of at least one amino acid of said glycoprotein.
7. Use of a BVD virus according to any one of claims 1 to 8 comprising a BVDV pestivirus, wherein said RNase activity is inactivated by the deletion of the histidine residue at position 349, as described in figure 1 for the CP7 strain in an exemplary manner or corresponding thereto in other BVDV strains, of said glycoprotein.";"(EP1104676)
The present invention relates to the use of specifically attenuated live BVD (Bovine Viral Diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.
This invention relates to the use of specifically attenuated live BVD (bovine viral diarrhea) viruses for the preparation of a vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle, pregnant cows and for fetal protection in pregnant cows.";"(EP1104676)
Live vaccines with defined mutations as a basis for attenuation would allow to avoid the disadvantages of the present generation of attenuated vaccines.
Therefore, the technical problem underlying this invention was to provide safely attenuated and live BVDV vaccines that can be used for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections of pregnant cows or cattle in the presence of pregnant cows.
The invention also relates to a method of treatment and/or prevention of BVDV infections in the above named group of cattle.
The more classical BVDV type I strains and the more recently recognized BVDV type II strains display some limited but distinctive differences in nucleotide and amino acid sequences.";"A61K-039/12
A61P-031/12
A61P-031/14
C07K-007/04
C07K-014/18
C12N-007/04
C12N-015/00
C12N-015/40";"(EP1104676)
1. Use of a live BVDV (bovine viral diarrhea virus), wherein the RNase activity residing in its glycoprotein ERNS is inactivated for the preparation of a live vaccine for use in the prevention and/or treatment of BVDV infections in breeding stocks of cattle.";"(EP1104676)
BOVINE VIRAL DIARRHEA VIRUS(100,97)
PREGNANT COW(100,10)
CATTLE BREEDING STOCK(100,2)
SAFE(100,1)
PREGNANT COW INFECTION(85,1)
LIVE VACCINE PREPARATION(80,3)
ATTENUATED LIVE VACCINE(53,1)
RNASE ACTIVITY(51,12)
PREGNANT COW PRESENCE(51,1)
BVD VIRUS(49,1)
PREVENTION(48,7)
BVDV STRAIN(47,2)
ATTENUATED VACCINE GENERATION(44,1)
BVDV INFECTION TREATMENT(39,1)
INDUCTION EFFICACY(36,1)
LIVE VACCINE(34,4)
GLYCOPROTEIN(33,15)
INFECTION(31,14)
BOVINE VIRAL DIARRHEA(28,5)
KILLED VACCINE(27,3)
FETAL PROTECTION(27,1)
NUCLEOTIDE(24,1)
BOVINE VIRAL DIARRHEA VIRU(23,3)
PROPHYLAXIS(20,1)
DELETION(19,6)
RNASE ACTIVITY INACTIVATION(18,4)
VACCINE(17,12)
DEFINED MUTATION(17,1)
ATTENUATION(16,4)
L HISTIDINE RESIDUE(15,1)
MONOCLONAL NEUTRALIZING ANTIBODY AGAIST(15,1)
BACTERIAL COLONY HARBORING PLASMID(14,1)
PERSISTENTLY INFECTED CALF INDUCTION(14,1)
CATTLE(13,5)
ATTENUATED PESTIVIRUS(13,2)
BRANSON SONIFIER B12(13,1)
IMMUNOTOLERANT CALF BIRTH(13,1)
PREGNANT COW PLACENTA(13,1)
QIAAMP VIRAL MINI KIT(13,1)
SERONEGATIVE HEIFER PLACENTA(13,1)
ACUTE SERO FIBRINOUS INFLAMMATION(12,1)
CHILD BEARING HOST ANIMAL PLACENTA(12,1)
PERSISTENTLY INFECTED BULL(12,1)
AMINOACID SEQUENCE(11,5)
PLASMID DNA(10,4)
CONSTRUCTING CDNA(10,3)
CLINICAL MANIFESTATION(10,2)
MANUFACTURER RECOMMENDATION(10,2)
BOVINE DIARRHEA VIRUS(10,1)
BOVINE KIDNEY TRANSFECTION(10,1)
PREGNANT COW VICINITY(10,1)
RECOMBINANT VACCINIA VIRUS(10,1)
MUTANT VIRUS(9,2)
RNASE ACTIVITY DETERMINATION(9,2)
ABROGATED RNASE ACTIVITY(9,1)
ANTIBODY ELISA DATA(9,1)
FETAL INFECTION PREVENTION(9,1)
LATED CLINICAL SIGN(9,1)
LIVE ATTENUATED VIRUS(9,1)
POLYMERASE SEQUENCING KIT(9,1)
REVERTANT OUTBREAK(9,1)
BUFFY COAT(8,2)
ATTENUATED LIVE VIRUS(8,1)
COW ABORTED FETUS(8,1)
DISEASE EPIDEMIOLOGY(8,1)
ENZYME CATALYTIC CENTER(8,1)
FETUS NECROPSY(8,1)
FETUS RESORPTION(8,1)
INFECTIOUS VIRUS RECOVERY(8,1)
JACKSON IMMUNO RESEARCH(8,1)
ORGANISM GROWTH CULTURE(8,1)
PATHOGENESIS REVIEW(8,1)
PATHOGENIC PESTIVIRUS(8,1)
PESTIVIRUS GENUS(8,1)
POLYNUCLEOTIDE VACCINATION(8,1)
PORCINE PESTIVIRUS(8,1)
PREGNANT HEIFER(8,1)
RE LATED ABORTION(8,1)
RNASE ENZYMATIC ACTIVITY(8,1)
RT PCR AMPLIFICATION(8,1)
VIRUS ISOLATION(7,2)
BREEDING HERD(7,1)
CATTLE VACCINATION(7,1)
CONJUGATED ANTISERUM(7,1)
CYTOPATHOGENIC VIRUS(7,1)
DERIVED ATTENUATED VIRUS(7,1)
EPPENDORF CENTRIFUGE(7,1)
FLAVIVIRIDAE FAMILY(7,1)
IMMUNOFLUORESCENCE ASSAY(7,1)
INFECTIOUS CRNA(7,1)
MUTANT RNASE ACTIVITY(7,1)
NON INFECTIOUS RNA(7,1)
PCR SEQUENCING(7,1)
PESTIVIRUS GENETIC DIVERSITY(7,1)
PHARMACEUTICAL COMPOSTION(7,1)
PREGNANCY MONTH(7,1)
PRIMER PMOL(7,1)
PURIFIED VIRAL PROTEIN(7,1)
REINVESTIGATING SERUM SAMPLE(7,1)
VACCINA VIRUS VTF(7,1)
VACCINATED CATTLE(7,1)
VETERINARY MICROBIOLOGY(7,1)
VIRAL POLYPROTEIN(7,1)
VIROLOGICAL EXAMINATION(7,1)
ANCILLARY MOLECULE(6,1)
ANIMAL NEED(6,1)
ANTIBODY REACTION NEUTRALIZATION(6,1)
ANTISENSE PRIMER(6,1)
AQUA DEST(6,1)
ATTENUATED ORGANISM(6,1)
BACTERIOPHAGE T7 RNA POLYMERASE(6,1)
BOVINE KIDNEY CELL(6,1)
CO2 INCUBATOR(6,1)
DATA LIBRARY(6,1)
DAY POST INFECTION(6,1)
DISTINCTIVE LABEL(6,1)
ERNS GENE(6,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(6,1)
IMMUNITY INDUCTION(6,1)
LIVING ORGANISM(6,1)
MOLECULAR UNIQUENESS(6,1)
MOUSE PRETREATMENT(6,1)
NESTED AMPLIFICATION(6,1)
NORTHERN BLOT(6,1)
NUCLEOTIDE SEQUENCING(6,1)
PARENT VIRUS ABILITY(6,1)
PESTIVIRUS DETECTION(6,1)
PESTIVIRUS MOLECULAR BIOLOGY(6,1)
PLASMID DISPLAYING(6,1)
RNASE ASSAY BUFFER(6,1)
RUMINANT IDENTIFICATION(6,1)
SERUM POSITIVITY(6,1)
SMAL CRNA(6,1)
STERILE PIPETTE(6,1)
TRANSFECTION EXPERIMENT(6,1)
UNTRANSLATED CDNA REGION(6,1)
VIRAL GENOME(6,1)
VIRAL RNA CHARACTERIZATION(6,1)
VIRUS RECOVERY PASSAGE(6,1)
EXPERT(5,3)
MONOCLONAL ANTIBODY(5,3)
TRIAL(5,3)
ABORTION SAMPLE(5,1)
AMPICILLIN SELECTION(5,1)
BOLD CHARACTER(5,1)
BOVINE SERUM ALBUMIN(5,1)
BP LADDER(5,1)
CALF LACK(5,1)
CAUSATIVE AGENT(5,1)
CLINICAL SIGN PRESENCE(5,1)
COMPLETE LIVE ORGANISM(5,1)
CRNA TRANSFECTION(5,1)
CUP HORN(5,1)
DISH CELL(5,1)
EXTERNAL PRIMER GENE(5,1)
FETAL TRANSMISSION EVALUATION(5,1)
FUNGAL RNASE ACTIVE PROTEIN(5,1)
GENBANK(5,1)
GENETIC STABILITY REMAINS UNKNOWN(5,1)
GENOMIC MODIFICATION(5,1)
GEY BUFFER TREATMENT(5,1)
GLYCOPROTEIN ABILITY(5,1)
HEPARIN SODIUM(5,1)
IMMUNOLOGICAL ACTIVITY(5,1)
INFECTION DAY(5,1)
INTERNAL PRIMER GENE(5,1)
MOUSE FITC(5,1)
NON INFECTED CELL(5,1)
PCR PRODUCT SPECIFICITY(5,1)
PHENOTYPIC SELECTION(5,1)
PLACENTAL TRANSMISSION(5,1)
PREGNANCY DAY(5,1)
RECOMBINANT MODIFICATION(5,1)
RECOVERED VIRUS(5,1)
RT PCR CYCLE(5,1)
SPLITTING CELL(5,1)
STERILE VESSEL(5,1)
SYNTHETIC OLIGONUCLEOTIDE(5,1)
TRANSFECTED CELL(5,1)
VIRUS PREPARATION(5,1)
VIRUS PROPAGATION(5,1)
VIRUS SPREAD(5,1)
ROUTE(4,3)
ANTIBIOTIC(4,2)
INTRANASAL(4,2)
NESTED PCR(4,2)
OBSERVATION PERIOD(4,2)
PURIFICATION(4,2)
SUBUNIT VACCINE(4,2)
VIABILITY(4,2)
ADJUVANT PRESENCE(4,1)
AMPLIFICATE(4,1)
CELL CULTURE ALIQUOT(4,1)
CELL LYSATE(4,1)
CENTRIFUGING STEP SUPERNATANT(4,1)
CLEAR EVIDENCE(4,1)
CLINICAL SAMPLE(4,1)
CLONE B2(4,1)
COLUMN CHROMATOGRAPHY(4,1)
CONGENITAL MALFORMATION(4,1)
DIETHYLPYROCARBONAT(4,1)
ERYTHROCYTE PHASE(4,1)
EXTERNAL PRIMER SEQUENCE(4,1)
FRESH BLOOD(4,1)
GEL FILTRATION(4,1)
HORIZONTAL AGAROSE(4,1)
IMMUNOFLUORESCENCE MICROSCOPY(4,1)
IMMUNOLOGICAL RESPONSE(4,1)
INFECTED CELL CULTURE(4,1)
INSUFFICIENT OXYGEN(4,1)
INTERNAL PRIMER SEQUENCE(4,1)
LOW NEUTRALIZING ANTIBODY TITER(4,1)
LYSIS BUFFER(4,1)
MAIN EVALUATION PARAMETER(4,1)
MAJOR ECONOMICAL IMPACT(4,1)
MIXTURE ALIQUOT(4,1)
MONTHLY BASIS(4,1)
NEGATIVE HERD(4,1)
ORGANISM IMMUNOLOGICAL FUNCTION(4,1)
ORIGIN MOLECULE(4,1)
PASSAGING(4,1)
PCR BUFFER(4,1)
PHENOL CHLOROFORM EXTRACTION(4,1)
SENSE PMOL(4,1)
SEROPOSITIVE(4,1)
SPECIES PLUS SUBSEQUENT ISOLATION(4,1)
SUFFOCATION(4,1)
TERM GLYCOPROTEIN(4,1)
TISSUE SUSPENSION(4,1)
ULTRACENTRIFUGATION(4,1)
WHOLE ORGANISM(4,1)
WHOLE VIRUS(4,1)
ANIMAL GROUP(3,2)
ACETATE EDETIC ACID(3,1)
ADMINISTRATION(3,1)
ANTIPARASITIC(3,1)
BGIII(3,1)
BLOOD CELL DETERMINATION(3,1)
BLOOD ML(3,1)
CDNA PROBE(3,1)
CELL SUSPENSION(3,1)
CHORION(3,1)
CLASSIFICATION(3,1)
CONTAMINATION(3,1)
DAY PI(3,1)
DEDUCED AMINOACID SEQUENCE(3,1)
DISH DIAMETER(3,1)
EFFICACY(3,1)
(US6610305)
BOVINE VIRAL DIARRHEA VIRU(100,22)
PREGNANT COW(100,17)
BOVINE VIRAL DIARRHEA VIRUS(100,9)
FETAL INFECTION(100,4)
PREGNANT COW INFECTION(100,2)
BVDV INFECTION MANIFESTATION(100,1)
COW TO CALF TRANSMISSION(100,1)
SAFE(100,1)
GLYCOPROTEIN ERN(92,14)
RNASE ACTIVITY(81,18)
LIVE VACCINE PREPARATION(77,5)
CATTLE BREEDING STOCK(68,4)
BVDV INFECTION TREATMENT(66,6)
CLASSICAL BVDV(56,1)
GLYCOPROTEIN ERN AMINOACID(50,3)
BVDV STRAIN(48,4)
RECENTLY RECOGNIZED BVDV(47,1)
FETAL PROTECTION(46,4)
DELETION(36,10)
BVDV INFECTION(32,4)
LIVE BVDV(31,4)
BVDV FEATURE(31,1)
LIVE VACCINE(30,4)
PREVENTION(27,7)
L HISTIDINE RESIDUE(27,4)
PLACENTAL BARRIER(22,1)
NUCLEOTIDE(21,1)
BVDV(20,24)
ATTENUATED VACCINE(19,2)
VIRUS(17,16)
VACCINE(16,9)
FETUS(15,5)
ATTENUATION(15,4)
DEFINED MUTATION(15,1)
RNASE ACTIVITY INACTIVATION(14,3)
ATTENUATED LIVE BVDV REVERTANT(14,1)
LIVE BVDV VACCINE(13,2)
SERONEGATIVE HEIFER PLACENTA(13,1)
BACTERIAL COLONY HARBORING PLASMID(12,1)
PERSISTENTLY INFECTED CALF INDUCTION(12,1)
ATTENUATED PESTIVIRUS(11,2)
BRANSON SONIFIER B12(11,1)
BVDV MUTANT VIABILITY(11,1)
IMMUNOTOLERANT CALF BIRTH(11,1)
PREGNANT COW PLACENTA(11,1)
QIAAMP VIRAL MINI KIT(11,1)
BUFFY COAT(10,4)
KILLED VACCINE(10,3)
ACUTE SERO FIBRINOUS INFLAMMATION(10,1)
BVDV MUTANT RNASE ACTIVITY(10,1)
CHILD BEARING HOST ANIMAL PLACENTA(10,1)
FETAL BVDV INFECTION RISK(10,1)
PERSISTENTLY INFECTED BULL(10,1)
PLASMID DNA(9,4)
CONSTRUCTING CDNA(9,3)
BOVINE DIARRHEA VIRUS(9,1)
BOVINE KIDNEY TRANSFECTION(9,1)
BVDV ANTIBODY TITER(9,1)
BVDV INFECTION PREVENTION(9,1)
PREGNANT COW VICINITY(9,1)
RECOMBINANT VACCINIA VIRUS(9,1)
VIRUS ISOLATION(8,3)
BGLII FRAGMENT(8,2)
RNASE ACTIVITY DETERMINATION(8,2)
ABROGATED RNASE ACTIVITY(8,1)
ANTIBODY ELISA DATA(8,1)
ATTENUATED LIVE VACCINE(8,1)
BVD VIRUS(8,1)
BVDV PESTIVIRUS(8,1)
COLOSTRUM INGESTION(8,1)
EMBL DATA LIBRARY(8,1)
ETHIDIUM BROMIDE STAINING(8,1)
FETAL INFECTION PREVENTION(8,1)
IMPORTANCE AMINOACID(8,1)
LIVE ATTENUATED VIRUS(8,1)
MONOCLONAL NEUTRALIZING ANTIBODY DEVELOPMENT(8,1)
MOUSE FITC CONJUGATED ANTISERUM(8,1)
NONCYTOPATHOGENIC BVDV(8,1)
POLYMERASE SEQUENCING KIT(8,1)
REVERTANT OUTBREAK(8,1)
SVANOVIR BVDV ANTIBODY TEST(8,1)
AMINOACID(7,7)
SUPERNATANT(7,6)
ATTENUATED BVDV(7,1)
ATTENUATED LIVE VIRUS(7,1)
BVD CAUSATIVE AGENT(7,1)
BVDV NEGATIVE HERD(7,1)
BVDV SEROPOSITIVE(7,1)
COW ABORTED FETUS(7,1)
DISEASE EPIDEMIOLOGY(7,1)
ENZYME CATALYTIC CENTER(7,1)
FETUS NECROPSY(7,1)
FETUS RESORPTION(7,1)
GLYCOPROTEIN ERN ABILITY(7,1)
IMMUNE FLUORESCENCE ASSAY(7,1)
INFECTIOUS VIRUS RECOVERY(7,1)
INTRAUTERINE INFECTION PATHOGENESIS(7,1)
JACKSON IMMUNO RESEARCH(7,1)
MDBK CLONE B2(7,1)
NON INFECTED MDBK CELL(7,1)
ORGANISM GROWTH CULTURE(7,1)
PATHOGENESIS REVIEW(7,1)
PATHOGENIC PESTIVIRUS(7,1)
PESTIVIRUS GENUS(7,1)
POLYMERASE CHAIN READTION(7,1)
POLYNUCLEOTIDE VACCINATION(7,1)
PORCINE PESTIVIRUS(7,1)
PREGNANT HEIFER(7,1)
RNASE ENZYMATIC ACTIVITY(7,1)
RT PCR AMPLIFICATION(7,1)
BVDV DETECTION(6,2)
BREEDING HERD(6,1)
CATTLE VACCINATION(6,1)
CLINICAL MANIFESTATION(6,1)
CYTOPATHOGENIC VIRUS(6,1)
DERIVED ATTENUATED VIRUS(6,1)
EPPENDORF CENTRIFUGE(6,1)
FLAVIVIRIDAE FAMILY(6,1)
HEIFER RANKING(6,1)
IMMUNOFLUORESCENCE ASSAY(6,1)
INDIRECT IMMUNE FLUORESCENCE TEST(6,1)
INFECTIOUS CRNA(6,1)
MANUFACTURER RECOMMENDATION(6,1)
MODIFIED GLYCOPROTEIN ERN(6,1)
NON INFECTIOUS RNA(6,1)
PCR SEQUENCING(6,1)
PESTIVIRUS GENETIC DIVERSITY(6,1)
PREGNANCY MONTH(6,1)
PREGNANT CATTLE(6,1)
PURIFIED VIRAL PROTEIN(6,1)
REINVESTIGATING SERUM SAMPLE(6,1)
RNASE ACTIVITY TERM INACTIVATION(6,1)
SEROLOGICAL DATA(6,1)
VACCINA VIRUS VTF(6,1)
VACCINATED CATTLE(6,1)
VETERINARY MICROBIOLOGY(6,1)
VIRAL POLYPROTEIN(6,1)
VIROLOGICAL EXAMINATION(6,1)
PA BVDV(5,7)
EXPERT(5,3)
TRIAL(5,3)
BVDV POSITIVE(5,2)
CLINICAL SAMPLE(5,2)
ANCILLARY MOLECULE(5,1)
ANIMAL NEED(5,1)
ANTIBODY REACTION NEUTRALIZATION(5,1)
ANTISENSE PRIMER(5,1)
AQUA DEST(5,1)
ATTENUATED ORGANISM(5,1)
BORN CALF(5,1)
BOVINE KIDNEY CELL(5,1)
CLINICAL SYMPTOM(5,1)
CO2 INCUBATOR(5,1)
DAY POST INFECTION(5,1)
DISTINCTIVE LABEL(5,1)
ERN GENE(5,1)
GLYCOPROTEIN STRUCTURE IDENTIFICATION(5,1)
IMMUNITY INDUCTION(5,1)
INDUCTION EFFICACY(5,1)
LIVING ORGANISM(5,1)
MOLECULAR UNIQUENESS(5,1)
MOUSE PRETREATMENT(5,1)
MUTANT VIRUS(5,1)
NCOI FRAGMENT(5,1)
NESTED AMPLIFICATION(5,1)
NORTHERN BLOT(5,1)
NUCLEOTIDE SEQUENCING(5,1)
PARENT VIRUS ABILITY(5,1)
PESTIVIRUS DETECTION(5,1)
PESTIVIRUS MOLECULAR BIOLOGY(5,1)
PLASMID DISPLAYING(5,1)
PREGNANT COW PRESENCE(5,1)
RNASE ASSAY BUFFER(5,1)
RNASE MOTIF(5,1)
RUMINANT IDENTIFICATION(5,1)
SERUM POSITIVITY(5,1)
SMAI CRNA(5,1)
STERILE PIPETTE(5,1)
TERM LIVE VACCINE(5,1)
TRANSFECTION EXPERIMENT(5,1)
UNTRANSLATED CDNA REGION(5,1)
VIRAL GENOME(5,1)
VIRAL RNA CHARACTERIZATION(5,1)
VIRUS RECOVERY PASSAGE(5,1)
WEST GROVE(5,1)
AMINOACID SEQUENCE(4,4)
ROUTE(4,4)
ANTIBIOTIC(4,2)
DITHIOTHREITOL(4,2)
ELISA TEST(4,2)
INTRANASAL(4,2)
NESTED PCR(4,2)
OBSERVATION PERIOD(4,2)
PURIFICATION(4,2)
SUBUNIT VACCINE(4,2)
ACETATE EDTA(4,1)
AMPICILLIN SELECTION(4,1)
BOLD CHARACTER(4,1)
BOVINE SERUM ALBUMIN(4,1)
BP LADDER(4,1)
BVDV MAJOR ANTIGENIC GROUP(4,1)
CALF LACK(4,1)
CLINICAL OBSERVATION(4,1)
CLINICAL SIGN PRESENCE(4,1)
COMPLETE LIVE ORGANISM(4,1)
CRNA TRANSFECTION(4,1)
CUP HORN(4,1)
ERN CONSERVED SEQUENCE(4,1)
FETAL TRANSMISSION EVALUATION(4,1)
FUNGAL RNASE ACTIVE PROTEIN(4,1)
GENBANK(4,1)
GENETIC STABILITY REMAINS UNKNOWN(4,1)
GENOMIC MODIFICATION(4,1)
HEPARIN SODIUM(4,1)
IMMUNOLOGICAL ACTIVITY(4,1)
NON INFECTED CELL(4,1)
PBS RAB(4,1)
PCR PRODUCT SPECIFICITY(4,1)
PHAGE STRAND(4,1)
PHENOTYPIC SELECTION(4,1)
PLACENTAL TRANSMISSION(4,1)
RECOMBINANT MODIFICATION(4,1)
RECOVERED VIRUS(4,1)
RT PCR CYCLE(4,1)
SODIUM DODECYL SULFATE(4,1)
SPECIES BVDV(4,1)
SPLITTING CELL(4,1)
STERILE VESSEL(4,1)
SYNTHETIC OLIGONUCLEOTIDE(4,1)
TRANSFECTED CELL(4,1)
TRANSIENT ASSAY(4,1)
VIRUS PREPARATION(4,1)
VIRUS PROPAGATION(4,1)
VIRUS SPREAD(4,1)
XHOI(3,3)
NCP(3,2)
ADJUVANT PRESENCE(3,1)
AMPLIFICATE(3,1)
BVDV SPECIFIC ANTIBODY(3,1)
BVDV SPECIFIC IMMUNOFLUORESCENCE(3,1)
CELL CULTURE ALIQUOT(3,1)
CELL LYSATE(3,1)
CLEAR EVIDENCE(3,1)
COLD ETHANOL(3,1)
COLUMN CHROMATOGRAPHY(3,1)
CONGENITAL MALFORMATION(3,1)
ERYTHROCYTE PHASE(3,1)
EXTERNAL PRIMER SEQUENCE(3,1)
FRESH BLOOD(3,1)
GEL FILTRATION(3,1)
HORIZONTAL AGAROSE(3,1)
IMMUNOFLUORESCENCE MICROSCOPY(3,1)
IMMUNOLOGICAL RESPONSE(3,1)
INFECTED CELL CULTURE(3,1)
INSUFFICIENT OXYGEN(3,1)
INTERNAL PRIMER SEQUENCE(3,1)
LOW NEUTRALIZING ANTIBODY TITER(3,1)
LYSIS BUFFER(3,1)
MAIN EVALUATION PARAMETER(3,1)
MAJOR ECONOMICAL IMPACT(3,1)
MIXTURE ALIQUOT(3,1)
MONTHLY BASIS(3,1)
ORGANISM IMMUNOLOGICAL FUNCTION(3,1)
ORIGIN MOLECULE(3,1)
PASSAGING(3,1)
PCR BUFFER(3,1)
PHENOL CHLOROFORM EXTRACTION(3,1)
PI MONTH(3,1)
SUFFOCATION(3,1)
TERM BVDV(3,1)
TERM GLYCOPROTEIN(3,1)
TERM VACCINE(3,1)
TISSUE SUSPENSION(3,1)
ULTRACENTRIFUGATION(3,1)
WHOLE ORGANISM(3,1)
WHOLE VIRUS(3,1)
ADMINISTRATION(2,1)
ANIMAL GROUP(2,1)
ANTIPARASITIC(2,1)
BACTERIOPHAGE(2,1)
BUFFER TREATMENT(2,1)
BVDV INFECTION STILL TREATMENT(2,1)
BVDV RELATED ABORTION(2,1)
CATTLE GROUP(2,1)
CDNA PROBE(2,1)";Pharmaceuticals;Open
"1999-08-19
2000-08-18
2002-06-17
2008-08-26";"AUPQ233799          A0 1999-09-09 [AU-233799]
STG: (A0)
AP : 1999AU-0002337 1999-08-19
WO200114411         A1 2001-03-01 [WO200114411]
STG: (A1) Published application with search report
AP : 2000WO-AU00988 2000-08-18
CA2382176           A1 2001-03-01 [CA2382176]
STG: (A1) Application laid open
AP : 2000CA-2382176 2000-08-18
AU6671100           A  2001-03-19 [AU200066711]
STG: (A) Open to public inspection
AP : 2000AU-0066711 2000-08-18
EP1212349           A1 2002-06-12 [EP1212349]
STG: (A1) Application published with search report
AP : 2000EP-0954158 2000-08-18
IL148191            A  2002-09-12 [IL-148191]
STG: (A) Application of patent for invention
AP : 2000IL-0148191 2000-08-18
ZA200201458         B  2002-10-30 [ZA200201458]
STG: (B)
AP : 2002ZA-0001458 2002-02-21
AR025342            A1 2002-11-20 [AR--25342]
STG: (A1) Independent patent application
AP : 2000AR-0104312 2000-08-18
CN1382153           A  2002-11-27 [CN1382153]
STG: (A) Published application
AP : 2000CN-0814551 2000-08-18
JP2003507052        A  2003-02-25 [JP2003507052]
STG: (A) Published application
AP : 2001JP-0518740 2000-08-18
NZ517211            A  2003-08-29 [NZ-517211]
STG: (A) Published application
AP : 2000NZ-0517211 2000-08-18
AU776439            B2 2004-09-09 [AU-776439]
STG: (B2) Patent proceeded by OPI
AP : 2000AU-0066711 2000-08-18
JP3803293           B2 2006-05-12 [JP3803293]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2001JP-0518740 2000-08-18
EP1212349           A4 2006-05-31 [EP1212349]
STG: (A4) Supplementary search report
AP : 2000EP-0954158 2000-08-18
IN0211/DELNP/2002   A  2008-07-25 [IN2002DN00211]
STG: (A) Application laid open
AP : 2002IN-DN00211 2002-02-20
US7494785           B1 2009-02-24 [US7494785]
STG: (B1) Granted patent as first publication
AP : 2000US-10049953 2000-08-18
US20090136536       A1 2009-05-28 [US20090136536]
STG: (A1) Application published
AP : 2008US-12198572 2008-08-26
FD :  Division of: US10/049,953 FDD=2002-06-17 [2002US-10049953]
FD : Division of: US7494785 A 0 [US7494785]
FD : Division of: WOPCT/AU00/00988 FDD=2000-11-18 [2000WO-AU00988]
IN245420            B  2011-01-21 [IN-245420]
STG: (B) Patent
AP : 2002IN-DN00211 2002-02-20
EP1212349           B1 2011-08-10 [EP1212349]
STG: (B1) Patent specification
AP : 2000EP-0954158 2000-08-18
AT519775            T  2011-08-15 [ATE519775]
STG: (T) EP patent valid in AT
AP : 2000AT-0954158T 2000-08-18";13401;"AUPQ233799          A0 1999-09-09 [AU-233799]
WO200114411         A1 2001-03-01 [WO200114411]
CA2382176           A1 2001-03-01 [CA2382176]
AU6671100           A  2001-03-19 [AU200066711]
EP1212349           A1 2002-06-12 [EP1212349]
IL148191            A  2002-09-12 [IL-148191]
ZA200201458         B  2002-10-30 [ZA200201458]
AR025342            A1 2002-11-20 [AR--25342]
CN1382153           A  2002-11-27 [CN1382153]
JP2003507052        A  2003-02-25 [JP2003507052]
NZ517211            A  2003-08-29 [NZ-517211]
AU776439            B2 2004-09-09 [AU-776439]
JP3803293           B2 2006-05-12 [JP3803293]
EP1212349           A4 2006-05-31 [EP1212349]
IN0211/DELNP/2002   A  2008-07-25 [IN2002DN00211]
US7494785           B1 2009-02-24 [US7494785]
US20090136536       A1 2009-05-28 [US20090136536]
IN245420            B  2011-01-21 [IN-245420]
EP1212349           B1 2011-08-10 [EP1212349]
AT519775            T  2011-08-15 [ATE519775]";"1999AU-0002337
2000AU-0066711
2000WO-AU00988
2002US-10049953
2008US-12198572";"(EP1212349)
WO200114411
(US7494785)
WO200114411
(US20090136536)
WO200114411
(JP3803293)
WO200114411
(CA2382176)
WO200114411
(IL-148191)
WO200114411
(ZA200201458)
WO200114411
(CN1382153)
WO200114411
(NZ-517211)
WO200114411
(AU-776439)
WO200114411
(IN-245420)
WO200114411
(ATE519775)
WO200114411";"FERROSAN
MINI FOR AGRICULTURE MINISTER
MINI FOR AGRICULTURE MINISTER FOR LAND & WATER CONSERVATION FOR & ON BEHALF OF THE STATE OF NEW
MINISTER FOR AGRICULTURE & MINISTER FOR LAND & WATER CONSERVATION FOR & ON BEHALF OF THE STATE OF NEW SOUTH WALES
MINISTER FOR AGRICULTURE & MINISTER FOR LAND & WATER CONSERVATION SYNDEY
MINISTER FOR AGRICULTURE MINISTER FOR LAND & WA
MINISTER FOR AGRICULTURE MINISTER FOR LAND & WATER CONSERVATION
MINISTER FOR AGRICULTURE MINISTER FOR LAND & WATER CONSERVATION FOR ANDON BEHALF OF THE STATE OF NEW SOUTH WALES
MINISTER STAR FOR AGRICULTURE MINISTER STAR FOR LAND & WATER CONCERTION FOR & ON BEE HALF OF THE STATE OVE NEW SOUTH WALES AUSTRALIA NEW SOUTH WALES 2 0 0 0 SYDNEY LIVERPOOL STREET 1 5 7 PARKVIEW REVER 1 7
OF NEW SOUTH WALES
TER CONSERVATION FOR & ON BEHALF OF THE STATE";MINI FOR AGRICULTURE MINISTER FOR LAND & WATER CONSERVATION FOR & ON BEHALF OF THE STATE OF NEW;"(EP1212349)
AU
(EP1212349)
AU
(US7494785)
GB
(US20090136536)
AU
(WO200114411)
AU

(CA2382176)
AU
(IN2002DN00211)
AU
(IN-245420)
AU";"(EP1212349)
NAME=Minister for Agriculture, Minister for Land and Water Conservation for and on behalf of The State of New South Wales Level 17 ""Parkview"", 157 Liverpool Street , CITY=Sydney, New South Wales 2000 , COUNTRY=AU 

(EP1212349)
NAME=Minister for Agriculture, Minister for Land and Water Conservation for and on behalf of The State of New South Wales Level 17 ""Parkview"",  157 Liverpool Street , CITY=Sydney,New South Wales 2000 , COUNTRY=AU , REG=100179188 

(US7494785)
NAME=Minister for Agriculture and Minister for Land and Water Conservation , CITY=Syndey , COUNTRY=GB , ATYP=Non-US Company 

(US20090136536)
NAME=MINISTER FOR AGRICULTURE AND MINISTER FOR LAND AND WATER CONSERVATION , CITY=Sydney , COUNTRY=AU , ATYP=Non-US Company 

(WO200114411)
NAME=MINISTER FOR AGRICULTURE, MINISTER FOR LAND AND WATER CONSERVATION for and on behalf of THE STATE OF [AU / AU]   NEW SOUTH WALES; Level 17 ""Parkview"" 157 Liverpool Street Sydney, New South Wales 2000  , COUNTRY=AU 

(JP3803293)
NAME=Minister star for agriculture, Minister star for land and water concertion for and on bee half of the state Ove New South Wales; Australia New South Wales 2 0 0 0, Sydney, Liverpool Street 1 5 7, &quot;Parkview&quot; Rever 1 7 , REG=502059870 

(CA2382176)
NAME=MINISTER FOR AGRICULTURE, MINISTER FOR LAND AND WATER CONSERVATION FOR A ND ON BEHALF OF THE STATE OF NEW SOUTH WALES Level 17 ""Parkview"", 157 Liverpool Street Sydney , CITY=NEW SOUTH WALES , COUNTRY=AU 

(IN2002DN00211)
NAME=MINISTER FOR AGRICULTURE MINISTER FOR LAND AND WATER CONSERVATION LEVEL 17 ""PARKVIEW"", 157 LIVERPOOL STREET, SYDNEY, NEW SOUTH WALES 2000  , COUNTRY=AU 

(IN-245420)
NAME=Minister For Agriculture Minister For Land and Water Conservation , COUNTRY=AU 
";1;"SHANNON ANTHONY DOUGLAS
COLACO CAMILO ANTHONY LEO SELWYN
FROST MELINDA JANE";"(EP1212349)
AU; GB
(EP1212349)
AU; GB";"(EP1212349)
NAME=SHANNON, Anthony, Douglas 12 Propsting Street Curtin, Australian Capital Territory 260 , COUNTRY=AU 

NAME=COLACO, Camilo Anthony Leo Selwyn 107 Foster Road Trumpington Cambridge Cambridgeshire CB2 2JN , COUNTRY=GB 

NAME=FROST, Melinda, Jane 96C Cumberland Road Ingleburn, New South Wales 2565 , COUNTRY=AU 

(EP1212349)
NAME=SHANNON, Anthony, Douglas 12 Propsting Street Curtin, Australian Capital Territory 2605 , COUNTRY=AU 

NAME=COLACO, Camilo Anthony Leo Selwyn 107 Foster Road Trumpington Cambridge Cambridgeshire CB2 2JN , COUNTRY=GB 

NAME=FROST, Melinda, Jane 96C Cumberland Road Ingleburn, New South Wales 2565 , COUNTRY=AU 
";"(EP1212349)
Recombinant subunit vaccine";"(EP1212349)
A method is provided of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a cell which cell has been subjected to a stimulus which causes the induction of a heat shock response in said cells; and (b) recovering the antigenic polypeptide coupled to one or more hsps from said cell or the culture medium. Also provided are immunogenic compositions comprising a heat shock protein (hsp) derived from a non-mammalian eukaryote coupled to a heterologous antigenic polypeptide which composition is capable of inducing an immune response to said antigenic polypeptide in a human or animal.";"(WO200114411)
CLAIMS
1. A method of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises:
 (a) expressing the antigenic polypeptide in a cell which cell has been subjected to a stimulus which causes the induction of a heat shock response in said cells; and
 (b) recovering the antigenic polypeptide coupled to one or more hsps from said cell or the culture medium.
2. A method according to claim 1 wherein the cell is a non-mammalian cell and the hsp is a non-mammalian hsp.
3. A method according to claim 2 wherein the cell is a non-mammalian eukaryotic cell and the hsp is a non-mammalian eukaryotic hsp.
4. A method according to claim 3 wherein the cell is an insect cell and the hsp is an insect hsp.
5. A method according to any one of the preceding claims wherein the antigenic polypeptide is an antigen of a pathogenic organism, or a fragment or derivative thereof.
6. A method according to claim 5 wherein the pathogenic organism is a virus or a bacterium.
7. A method according to claim 6 wherein the virus is a pestivirus.
8. A method according to claim 7 wherein the virus is bovine viral diarrhoea virus (BVDV).
9. A method according to any one of the preceding claims wherein the antigenic polypeptide is expressed in the cell by the introduction into the cell of a polynucleotide encoding the antigenic polypeptide operably linked to a regulatory control sequence capable of directing expression of the polypeptide in the cell.
10. A method according to claim 9 wherein the polynucleotide is part of a virus or viral vector.
 11 . A method according to claim 10 wherein the cell is an insect cell and the virus or viral vector is a baculovirus or baculovirus vector.
12. A composition comprising an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide obtained by the method of any one of claims 1 to 11.
13. A composition comprising a heat shock protein (hsp) derived from a non- mammalian eukaryote coupled to a heterologous antigenic polypeptide which composition is capable of inducing an immune response to said antigenic polypeptide in an animal or human.
14. A composition according to claim 13 wherein the hsp is an insect hsp.
15. A composition according to claim 13 or claim 14 wherein the antigenic polypeptide is an antigen of a pathogenic organism, or a fragment or derivative thereof.
16. A composition according to any one of claims 13 to 15 wherein the pathogenic organism is a virus or a bacterium.
17. A composition according to claim 16 wherein the virus is a pestivirus.
18. A composition according to claim 17 wherein the virus is bovine viral diarrhoea virus (BVDV).
19. A composition comprising a pestivirus antigen coupled to a heat shock protein.
20. A pharmaceutical composition comprising an immunogenic amount of a composition according to any one of claims 12 to 19 together with a pharmaceutically acceptable carrier or diluent.
 21 . A method for inducing immunocompetence in an animal against a pathogen, said method comprising the steps of: administering to an animal a therapeutically effective amount of a pharmaceutical composition according to claim 20.";"(EP1212349)
The present invention generally relates to a method of producing an immunogenic composition comprising a nonmammalian heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a nonmammalian cell which cell has been subjected to a heat stimulus which causes the induction of a heat shock response in said cells; and (b) recovering the antigenic polypeptide coupled to one or more nonmammalian hsps induced by the heat shock reponse from said cell or from the culture medium.
The present invention seeks to provide an improved therapeutic vaccine which ameliorates at least some of the disadvantages over existing prior art.
The present invention relates generally to the field of therapeutics and the development thereof for use in animals including mammals, humans, birds and fish.
The present invention seeks to provide an improved therapeutic vaccine which ameliorates at least some of the disadvantages over existing prior art.
The present invention generally relates to a method of producing an immunogenic composition comprising a nonmammalian heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a nonmammalian cell which cell has been subjected to a heat stimulus which causes the induction of a heat shock response in said cells; and (b) recovering the antigenic polypeptide coupled to one or more nonmammalian hsps induced by the heat shock reponse from said cell or from the culture medium.";"(EP1212349)
However, it may be desirable to include an hsp/antigenic polypeptide which does not provoke an antibody response and prevents or reduces the generation of an immune response to that particular antigen when the vaccinated host is subsequently infected by the corresponding natural pathogen.
This provides a useful marker for vaccinated subjects.
Thus, there is need for therapeutics and methods that can lead to CD8+ CTL response by vaccination with nonlive materials such as proteins in a specific manner.
However it is not necessary for the cells to carry out precisely the same posttranslational modifications as would be performed in a mammalian cell.
In fact, in modern medicine, immunotherapy including vaccination has eradicated smallpox and virtually eradicated diseases such as polio, tetanus, tuberculosis, chicken pox, and measles.
There are, however, several limitations associated with subunit vaccines.
This poses a practical problem, for the only certain way to achieve a CTL response is to use live agents that are themselves pathogenic.
The problem is generally circumvented by using attenuated viral and bacterial strains or by killing whole cells that can be used for vaccination.
poses a practical problem";"A61K-009/00
A61K-039/00
A61K-039/12
A61K-039/15
A61K-039/385
A61K-039/44
A61K-047/42
A61P-031/12
A61P-037/02
C07K-002/00
C07K-014/005
C07K-014/18
C07K-014/435
C07K-019/00
C12N-015/09
C12N-015/12
C12N-015/866
C12P-021/02
C12P-025/00
C12R-001/93";"(EP1212349)
1. A method of producing an immunogenic complex comprising a nonmammalian heat shock protein coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the heterologous antigenic polypeptide in a nonmammalian cell; and (b) subjecting said cell to a heat stimulus which causes the induction of a heat shock response in said cells; and (c) recovering heterologous antigenic polypeptides coupled to one or more nonmammalian heat shock proteins induced by the heat shock response from said cell or from the culture medium.";"(EP1212349)
HETEROLOGOUS ANTIGENIC POLYPEPTIDE(100,6)
RECOMBINANT SUBUNIT VACCINE(100,2)
ANTIGENIC POLYPEPTIDE(46,40)
NON MAMMALIAN HSP(38,2)
VIRTUALLY ERADICATED DISEASE(37,1)
NON MAMMALIAN HEAT SHOCK PROTEIN(36,2)
THERAPEUTIC VACCINE(29,2)
NON MAMMALIAN CELL(28,6)
HEAT STIMULUS(27,2)
IMMUNOGENIC COMPLEX(25,1)
CULTURE MEDIUM(24,3)
INVITROGEN MAXBAC BACULOVIRUS(20,7)
VACCINATION(20,7)
POLYPEPTIDE DIRECTING EXPRESSION(20,2)
NON MAMMALIAN(19,4)
VACCINATED SUBJECT(19,1)
VIRAL VECTOR(18,4)
POLYNUCLEOTIDE ENCODING CELL(18,2)
IMMUNOGENIC(17,3)
PATHOGENIC ORGANISM ANTIGEN(17,2)
LIVE AGENT(16,1)
IMMUNOTHERAPY(15,1)
NON MAMMALIAN EUKARYOTIC CELL(14,12)
BACULOVIRUS VECTOR(14,4)
THERAPEUTICS(14,1)
TUBERCULOSIS(14,1)
NON MAMMALIAN EUKARYOTIC HSP(13,3)
CHICKEN POX(13,1)
MEASLES(13,1)
POSE(13,1)
SMALLPOX(13,1)
TETANUS(13,1)
HEAT SHOCK PROTEIN(12,11)
HSP ANTIGENIC PEPTIDE(12,9)
EUKARYOTIC HEAT SHOCK PROTEIN(12,1)
WHOLE CELL(12,1)
SUBUNIT VACCINE(11,20)
MODERN MEDICINE(11,1)
POLIO(11,1)
HEAT SHOCK RESPONSE INDUCTION(10,3)
BIOTINYLATED ANTI MOUSE IGG(10,2)
INSECT HEAT SHOCK PROTEIN(10,2)
PROTEIN(9,28)
WHOLE VIRUS GENOME(9,7)
VIRUS CHALLENGE(9,5)
MARKER(9,4)
BIOTINYLATED GOAT ANTISERUM(9,2)
RECOMBINANT PESTIVIRUS PROTEIN EXPRESSION(9,2)
INSECT CELL HSP(8,4)
ANTIGENIC HETEROLOGOUS PEPTIDE(8,2)
ANTIGENIC POLYPEPTIDE EXPRESSION(8,2)
HETEROLOGOUS POLYPEPTIDE EXPRESSION(8,2)
RECOMBINANT BACULOVIRUS ENCODING(8,2)
MANUFACTURER INSTRUCTION(7,5)
VACCINATED ANIMAL(7,5)
CDNA AMPLIFICATION(7,4)
RECOMBINANT VIRUS(7,4)
STRAIN(7,3)
COMMONWEALTH SERUM LABORATORY(7,2)
NON LIVE MATERIAL(7,2)
REMINGTON PHARMACEUTICAL SCIENCE(7,2)
CATIONIC LIPOSOME MEDIATED TRANSFECTION(7,1)
HETEROLOGOUS POLYPEPTIDE GLYCOSYLATION(7,1)
IMMUNOGENIC STRESS PROTEIN PEPTIDE VACCINE(7,1)
VENTOLIN METERED DOSE INHALER(7,1)
UG ML FREEZE(6,7)
PLAQUE ASSAY(6,5)
INFECTIOUS VIRUS(6,3)
INVITROGEN CORPORATION(6,3)
NON MAMMALIAN EUKARYOTE(6,2)
NON MAMMALIAN VERTEBRATE CELL(6,2)
INVITROGEN TA CLONING KIT(6,1)
UNCOMPLEXED ANTIGENIC PEPTIDE(6,1)
BOVINE VIRAL DIARRHEA VIRUS(5,32)
LEUPEPTIN(5,10)
ACCESSION(5,9)
HEAT SHOCK(5,4)
CONICAL FLASK(5,3)
REGULATORY CONTROL SEQUENCE(5,3)
STOMACH ENVIRONMENT(5,3)
THERAPEUTIC FORMULATION(5,3)
ACETYL MURAMYL(5,2)
ANTI PESTIVIRUS ANTISERUM(5,2)
ANTIBODY NEUTRALIZATION(5,2)
ANTIGENIC FRAGMENT(5,2)
ANTISENSE PRIMER(5,2)
BACTERIAL CONTAMINATION(5,2)
CATTLE HERD(5,2)
CULTURE SUPERNATANT(5,2)
EXPERIMENTAL VACCINE(5,2)
ISOCOMATRIX ADJUVANT(5,2)
LIVE ATTENUATED VACCINE(5,2)
MACK PUBLISHING(5,2)
NON COVALENT BONDING(5,2)
PESTIVIRUS RECOMBINANT PROTEIN(5,2)
PROPHYLACTICALLY(5,2)
THERAPEUTIC REGIMEN(5,2)
TISSUE CULTURE FLASK(5,2)
WHOLE ORGANISM VACCINE(5,2)
ANTIGENIC POLYPEPTIDE OPTIMUM EXPRESSION(5,1)
ANTIGENIC POLYPEPTIDE SYNTHESIS(5,1)
CDNA DIRECTIONAL CLONING(5,1)
FREUND INCOMPLETE ADJUVANT(5,1)
GENOME ENCODING CDNA(5,1)
INFECTIOUS DISEASE PROGRESSION(5,1)
NON MAMMALIAN EUKAROTIC CELL(5,1)
NON TOXIC EXCIPIENT(5,1)
NUCLEAR POLYHEDROSIS VIRUS(5,1)
PESTIVIRUS PROTEIN PRIMER(5,1)
PESTIVIRUS THERAPEUTICS(5,1)
POLYPEPTIDE ANTIGENIC MOLECULE(5,1)
PROTEIN EXPRESSION POST INFECTION(5,1)
RECOMBINANT BACULOVIRUS STOCK TITER(5,1)
RESIDUAL INFECTIOUS BACULOVIRUS(5,1)
SERINE PROTEASE ENZYME(5,1)
SPINHALER POWDER INHALER(5,1)
SUBUNIT PROTEIN VACCINE(5,1)
SUBUNIT VACCINE REC ANTIGEN(5,1)
SUPERNATANT CLOVER LANE(5,1)
T CELL RECEPTOR RECOGNITION(5,1)
DILUENT(4,8)
ANTIBODY CONCENTRATION(4,4)
SHAKING CELL(4,4)
ENTERIC COATING(4,3)
HSP COMPLEX(4,3)
THERMAL SEQUENCER(4,3)
DENATURATION CYCLE(4,2)
GAUGE NEEDLE(4,2)
INFECTED ANIMAL(4,2)
INVERTEBRATE CELL(4,2)
MEDIATED IMMUNE RESPONSE(4,2)
ORAL FORMULATION(4,2)
POWDERED GUM(4,2)
VACCINE DOSE(4,2)
ANIMAL IMMUNOCOMPETENCE(4,1)
ANTIGEN RECOGNITION MOLECULE(4,1)
ANTIGENIC POLYPEPTIDE PRODUCTION(4,1)
ANTIGENIC PROTEIN YIELD(4,1)
AUSTRALIAN VIRUS(4,1)
BACTERIA TRANSFORMATION(4,1)
BACULOVIRUS INACTIVATION(4,1)
BBOTH SUPERNATANT(4,1)
BENCH CENTRIFUGE(4,1)
BORDETELLA PERTUSSIS(4,1)
CLAYSON INCUBATOR(4,1)
COMMERCIAL ANIMAL HERD(4,1)
COMPATIBLE COHESIVE OVERHANG(4,1)
CONFLUENT MONOLAYER(4,1)
CONTINUAL BOOSTER INJECTION(4,1)
CORYNEBACTERIUM PARVUM(4,1)
COW INFECTION(4,1)
CYTOKINE IFN(4,1)
CYTOTOXIC T CELL CASCADE(4,1)
DIOCTYL SODIUM SULFONATE(4,1)
DISRUPTED PATHOGEN PREPARATION(4,1)
EXPORT ABATTOIR(4,1)
GENOME FRAGMENT(4,1)
HYDRATED SILICOALUMINATE(4,1)
HYDROXYPROPYLMETHYLCELLULOSE(4,1)
IMMUNODEFICIENCY VIRUS(4,1)
INDUCING IMMUNOCOMPETENCE(4,1)
INFECTIOUS DISEASE PREVENTION(4,1)
INSECT CELL INFECTION(4,1)
INSECT CELL POLYPEPTIDE(4,1)
INSECT SUPERNATANT FRACTION(4,1)
INTRACELLULAR PATHOGEN(4,1)
ISCOMATRIX ADJUVANT(4,1)
LIPOSOMAL ENCAPSULATION(4,1)
MANNITOL PHARMACEUTICAL GRADE(4,1)
MASTER VIRUS STOCK(4,1)
METHYLHYDROXYETHYL CELLULOSE(4,1)
MICROSPHERE ENCAPSULATION(4,1)
MITOCHONDRIAL HSP(4,1)
MOIST MASSING(4,1)
NON MAMMALIAN CELL CULTURE(4,1)
NON PREGNANT HEIFER(4,1)
NONSTRUCTURAL POLYPEPTIDE(4,1)
NUCLEOPROTEIN(4,1)
ORBITAL SHAKER(4,1)
OVERSEAS PESTIVIRUS(4,1)
PATHOGENIC BACTERIUM CULTURE(4,1)
PBLUEBACHIS BACULOVIRUS TRANSFER VECTOR(4,1)
PELLET EXTRACT SERIAL DILUTION(4,1)
PESTIVIRUS ANTIBODY NEGATIVE(4,1)
PHENOTYPIC VARIANT(4,1)
PLASMID PURIFICATION KIT(4,1)
POLYPEPTIDE CORRECT FOLDING(4,1)
POLYPEPTIDE SUBUNIT(4,1)
PRETREATED HSP(4,1)
PROPIONOBACTERIUM ACNE(4,1)
PROTEIN AGGREGATION INDUCTION(4,1)
PROTEINOID ENCAPSULATION(4,1)
PROTEINOID MICROSPHERE(4,1)
PROTEOLYSIS INHIBITION(4,1)
RECIPIENT HEALTH(4,1)
RECOGNIZED PHARMACOPEIA(4,1)
RECOMBINANT BACULOVIRUS INFECTED CELL(4,1)
RECOMBINANT BACULOVIRUS PRODUCTION(4,1)
RECOMBINANT EXPRESSED SUBUNIT VACCINE(4,1)
RECOMBINANT VIRAL STOCK(4,1)
REFRIGERATED BEVERAGE(4,1)
REGULATORY AGENCY(4,1)
SECRETED POLYPEPTIDE(4,1)
SF CULTURING(4,1)
STRESSFUL STIMULUS(4,1)
T CELL EPITOPE(4,1)
TABLET TRITURATE(4,1)
TRANSPLACENTAL TRANSFER INHIBITION(4,1)
TRUNCATED PESTIVIRUS(4,1)
ULTRAVENT NEBULIZER(4,1)
VACCINATED CATTLE(4,1)
VACCINE EFFECTIVENESS(4,1)
VACCINE REGISTRATION(4,1)
VIRALLY INFECTED MAMMALIAN CELL(4,1)
VIROLOGY DEPARTMENT(4,1)
VIRUS TRANSPLACENTAL TRANSMISSION(4,1)
PARTIAL SEQUENCE(3,7)
SF9 CELL(3,7)
ACTIVE INGREDIENT(3,3)
ADMINISTRATION MODE(3,3)
BLOODSTREAM(3,3)
CENTRIFUGATION(3,3)
HPMCP(3,3)
INTESTINE(3,3)
MONOCLONAL ANTIBODY(3,3)
PARASITE(3,3)
SUPPOSITORY(3,3)
THIMEROSAL(3,3)
ANTIGENIC REGION(3,2)
CELL LYSATE(3,2)
COMPLEX ADMINISTRATION(3,2)
CYTOTOXIC T CELL RESPONSE(3,2)
ELIZABETH MACARTHUR AGRICULTURAL INSTITUTE(3,2)
FUNGAL CELL(3,2)
HPMCD(3,2)
INSECT CELL CULTURE(3,2)
INTRACELLULAR CONCENTRATION(3,2)
MAJOR IMMUNOGENIC REGION(3,2)
PHARMACEUTICAL CARRIER(3,2)
POVIDONE(3,2)
PROTECTIVE IMMUNE RESPONSE(3,2)
RECOMBINANT PROTEIN PREPARATION(3,2)
SPODOPTERA FRUGIPERDA(3,2)
STRESSED CELL(3,2)
THERAPEUTIC AGENT(3,2)
VACCINE MIXTURE(3,2)
VACCINE PRODUCTION(3,2)
YEAST CELL(3,2)
ACTIVE IMMUNOGENIC INGREDIENT(3,1)
ADJUVANT EFFECTIVENESS(3,1)
ANIMAL CELL INFECTION(3,1)
ANIONIC DETERGENT(3,1)
ANTIGEN ELIMINATION(3,1)
ANTIGENIC PROTEIN COUPLING(3,1)
ATHESE PROTEIN(3,1)
ATTENUATED VIRUS(3,1)
BACTERIAL CLONE(3,1)
BACTERIAL ENDOTOXIN(3,1)
BIOTEX LABORATORY(3,1)
CAPSULE ADMINISTRATION(3,1)
CATIONIC DETERGENT(3,1)
CATTLE SERUM(3,1)
COMMERCIAL DISINTEGRANT(3,1)
COMPLEX PULMONARY DELIVERY(3,1)
DEGENERATING MATRIX(3,1)
DEVELOPING FETUS(3,1)
DIFCO LABORATORY(3,1)
EFFICACY OBJECTIVE MEASUREMENT(3,1)
ENDOGENOUS HSP PRESENCE(3,1)
EXPERIMENTAL SUBUNIT VACCINE(3,1)
EXPRESSED PROTEIN DEGRADATION(3,1)
EXPRESSION INDUCTION(3,1)
FETAL PROTECTION(3,1)
FINE MULTIPARTICULATE(3,1)
FISONS CORP(3,1)
FOLDED POLYPEPTIDE(3,1)
FOREIGN PATHOGEN(3,1)
FROZEN CELL ALIQUOT(3,1)
GROWING COLONY(3,1)
HELPER T CELL RESPONSE(3,1)
HOST INDIVIDUAL IMMUNOCOMPETENCE(3,1)
HSP ANTIGENIC MOLECULE COMPLEX(3,1)
IMMUNE RESPONSE ENHANCER(3,1)
IMMUNOGEN PROPORTION(3,1)
INFECTED CATTLE(3,1)
INFECTED CULTURE(3,1)
INFECTION LIKELIHOOD(3,1)
INSECT CELL SUSPENSION CULTURE(3,1)
INSECT HSP(3,1)
INSOLUBLE CATIONIC EXCHANGE RESIN(3,1)
KIT VIAL(3,1)
LEPIDOPTERAN SPECIES(3,1)
LIGHTLY COMPRESSED PLUG(3,1)
MAMMAL TREATMENT THERAPEUTIC(3,1)
MEASLES VIRUS(3,1)
MERCK ADJUVANT(3,1)
MONOLAYER CULTURE(3,1)
NEBULIZER FORMULATION(3,1)
NORMAL PROTEIN EXPORT PATHWAY(3,1)
NOTABLE EXCEPTION(3,1)
NUCLEOTIDE SEQUENCE TRANSLATION(3,1)
PAN COATER(3,1)
PEST INFECTION(3,1)
PLAQUE PURIFICATION(3,1)
POST TRANSLATION MODIFICATION(3,1)
POTENTIAL NONIONIC DETERGENT(3,1)
POWDER DISPERSION(3,1)
PREGNANT ANIMAL(3,1)
PRESELECTED PATHOGEN(3,1)
PROTEIN MAJORITY(3,1)
PROTEIN STABILIZATION(3,1)
PVAP CELLULOSE ACETATE PHTHALATE(3,1)
RECOMBINANT PLASMID(3,1)
RECOMBINANT PROTEIN HARVEST(3,1)
RNA PELLET DRYING(3,1)
RUBELLA VIRUS(3,1)
SODIUM CARBOXYMETHYLCELLULOSE(3,1)
SOYA LECITHIN(3,1)
STATED INTEGER INCLUSION(3,1)
STERILE DIETHYL PYROCARBONATE(3,1)
SUBUNIT VACCINE SUBCELLULAR COMPONENT(3,1)
SUSTAINED RELEASE FORMULATION(3,1)
T CELL ANTIGEN RECEPTOR(3,1)
THERAPEUTIC DISSOLUTION(3,1)
TRIANGLE PARK(3,1)
TRIZOL REAGENT(3,1)
UNINFECTED SF(3,1)
VIRAL CHALLENGE(3,1)
VIRULENT STRAIN(3,1)
VIRUS TITER(3,1)
MOLECULAR BIOLOGY(2,5)
PROKARYOTIC CELL(2,5)
TNF(2,5)
LACTOSE(2,4)
SHEEP(2,4)
ANIMAL IMMUNE(2,3)
BINDER(2,3)
FINAL VOLUME(2,3)
FUNGUS(2,3)
HEAT SHOCK RESPONSE(2,3)
TAQ DNA POLYMERASE UNIT(2,3)
ALHYDROGEL(2,2)
ANIMAL GROUP(2,2)
ANTIBODY SOLUTION(2,2)
CACHET(2,2)
CELL DENSITY(2,2)
CELL MEDIATING FUNCTION(2,2)
CELLSB(2,2)
CHEMICAL MODIFICATION(2,2)
CHEMICAL SYNTHESIS(2,2)
COLORANT(2,2)
DEIONIZED WATER(2,2)
DEXTROSE SOLUTION(2,2)
EDWARD(2,2)
ELISA WASH PLATE(2,2)
ESTRUM(2,2)
FINAL EXTENSION(2,2)
FRESH MEDIUM(2,2)
GLIDANT(2,2)
LOZENGE(2,2)
NUCLEIC ACID MOLECULE(2,2)
PENICILLIN(2,2)
PLURONIC(2,2)
PLUS CELL(2,2)
POLOXALENE(2,2)
PRESERVATIVE(2,2)
PROPIOLACTONE(2,2)
RECOMBINANT PROTEIN LOCATION(2,2)
RICKETTSIA(2,2)
STRATEGY(2,2)
STREPTOMYCIN(2,2)
THERMOMETER(2,2)
TRAGACANTH(2,2)
TRIAL(2,2)
7H3SF(2,1)
ACID CMC(2,1)
ADENOSINE TRIPHOSPHATE PRESENCE(2,1)
ADMINISTRATIVE TECHNIQUE VARIETY(2,1)
AGAROSE GEL(2,1)
AGE WEEK(2,1)
AL2O3 BASIS(2,1)
ALZA CORP(2,1)
AMICON ULTRAFILTRATION CELL STEP(2,1)
AMPHIBIAN CELL(2,1)
AMPLIFICATION REACTION(2,1)
ANTI FRICTIONAL AGENT(2,1)
AQUEOUS DEXTROSE(2,1)
ATTENUATED STRAIN(2,1)
ATTENUATING AGENT(2,1)
AUXILIARY SUBSTANCE(2,1)
BACTERIAL ANTIGEN EXPRESSION(2,1)
BENZETHOMIUM CHLORIDE(2,1)
BIOLOGICAL RESPONSE MODIFIER(2,1)
BIOLOGICALLY ACTIVE MOLECULE(2,1)
BIOLOGICALLY ACTIVE PROTEIN(2,1)
BLOCKED COPOLYMER(2,1)
BLOCKING ELISA(2,1)
BLUE PLAQUE(2,1)
BROAD PROTECTION(2,1)
BULK SUBSTANCE(2,1)
CANCER TREATMENT(2,1)
CELL PELLET(2,1)
CELL POPULATION(2,1)
CENTRICON TUBE(2,1)
CHALLENGE STRAIN(2,1)
CHEMICALLY MODIFIED PROTEIN(2,1)
COATING PAN(2,1)
CODE FRAGMENT(2,1)
COMPETENT CELL PREPARATION(2,1)
COMPLEX DISPENSING(2,1)
COMPLEX FORMULATION(2,1)
COMPLEX NASAL DELIVERY(2,1)
COMPLEX SUGAR(2,1)
COMPLEX UPTAKE(2,1)
CONCENTRATED PREPARATION(2,1)
COUPLED RECOMBINANT PROTEIN EXPRESSION(2,1)
CULTURE ASSAY(2,1)
CYTOTOXIC T LYMPHOCYTE(2,1)
DAILY SAMPLE(2,1)
DEMONSTRATED REQUIREMENT(2,1)
DESIGN VERSION(2,1)
DICHLOROTETRAFLUOROETHANOL(2,1)
DISACCHARIDE(2,1)
DISEASE SPREAD(2,1)
DISTAL LUNG(2,1)
DRY THERAPEUTIC DELIVERY(2,1)
ECONOMICAL STANDARD METHODOLOGY(2,1)
EDIBLE PAPER(2,1)
ENDOGENOUS HEAT SHOCK PROTEIN(2,1)
ENDOPLASMIC RETICULUM(2,1)
ETHYLENE GLYCOL COPOLYMER(2,1)
EXPRESSED PROTEIN VACCINE PREPARATION(2,1)
FERRIC HYDROXIDE(2,1)
GENTLE MIXING(2,1)
GLYCOPROTEIN STRUCTURE(2,1)
GLYOXAL IC(2,1)
HARD TABLET(2,1)
HETEROLOGOUS PROTECTION(2,1)
HIGHLY EFFICACIOUS VACCINE(2,1)
HIGHLY VARIABLE ANTIGENIC DETERMINANT(2,1)
HOMOLOGOUS PROTECTION(2,1)
HR INCUBATION(2,1)
HR INTERVAL(2,1)
HSP ANTIGEN COMPLEX(2,1)
HUMAN SUBJECT WEIGHING(2,1)
HYDROCHLOROFLUOROCARBON(2,1)
HYDROFLUOROCARBON(2,1)
HYDROXYPHOSPHORYLOXY(2,1)
HYLAURONIC ACID(2,1)
IDENTIFIED SUBUNIT VACCINE(2,1)
IMMUNE RESPONSE INTENSITY(2,1)
IMMUNOGEN FINAL CONCENTRATION(2,1)
INCLUSION COMPLEX(2,1)
INERT MATRIX(2,1)
INFECTED CELL CULTURE FLASK(2,1)
INFECTION CYCLE(2,1)
INFECTION RISK(2,1)
INFECTIOUS AGENT(2,1)
INORGANIC SALT(2,1)
INTRACELLULAR COMPLEX(2,1)
INTRACELLULAR ENVIRONMENT(2,1)
LEACHING(2,1)
LYOPHILIZATION PERMIT(2,1)
MAJOR HISTOCOMPATIBILITY(2,1)
MAJOR HSP(2,1)
MAMMALIAN CELL GOLGI BODY(2,1)
MARQUEST MEDICAL PRODUCT(2,1)
MAXBAC BACULOVIRUS EXPRESSION(2,1)
MAXIMUM PROTEIN RECOVERY(2,1)
MERCURIC COMPOUND(2,1)
MIXED LYMPHOCYTE(2,1)
MOLDED TABLET(2,1)
MOLECULAR ENTITY(2,1)
MURAMYL DIPEPTIDE(2,1)
NATURAL INFECTION(2,1)
NATURAL SPONGE(2,1)
NON COVALENTLY ASSOCIATED MOLECULAR CHAPERON(2,1)
NON MAMMALIAN EUKARYOTIC CELL VARIETY(2,1)
ORAL DELIVERY(2,1)
PACKAGED ALCOHOL PAD(2,1)
PEANUT OIL(2,1)
PELLETED CELL FRACTION(2,1)
PH BUFFERING(2,1)
PHARMACEUTICAL USAGE(2,1)
PLUS INSECT CELL(2,1)
POLYALKYLENE ETHYLENE GLYCOL(2,1)
POLYETHYLENE GLYCOL MOIETY(2,1)
POLYMERIC COMPOUND PARTICULATE PREPARATION(2,1)
POLYNUCLEOTIDE SEQUENCE(2,1)
POLYRIBONUCLEOTIDE(2,1)
PROGEN INDUSTRY(2,1)
PROTEIN ANTIGEN(2,1)
PROTEIN CLASS(2,1)
PROTEIN PASSAGE(2,1)
PROTEIN STABILITY(2,1)
PUBLISHED SEQUENCE CONSERVED REGION(2,1)
PURIFIED PROTEIN(2,1)
PYROGENIC SILICA(2,1)
RECOMBINANT PROTEIN CULTURE(2,1)
RECOMBINANT PROTEIN MIX(2,1)
RECOMBINANT PROTEIN YIELD(2,1)
RECOVERED HSP(2,1)
REFRIGERANT R134A(2,1)
RESTRICTION ENZYME(2,1)
RHODES ED(2,1)
SEC DOSE(2,1)
SECRETED COMPLEX(2,1)
SHELF LIFE(2,1)
SODIUM STARCH(2,1)
SOFT GELATIN(2,1)
SOLUBILIZING AGENT(2,1)
SOLUBLE LUBRICANT(2,1)
SOLUTION ATOMIZATION(2,1)
SOYBEAN OIL(2,1)
STANDARD CLONING(2,1)
STERILE CONTAINER(2,1)
STERILE FLUID(2,1)
STERILE SALINE(2,1)
STRESS STIMULUS(2,1)
STRONG CELL MEDIATED IMMUNITY(2,1)
STRONG HUMORAL IMMUNITY(2,1)
STRUCTURAL PROTEIN(2,1)
SUGAR COATING(2,1)
SURFACTANT AID(2,1)
SURFACTANT MIGHT(2,1)
SYNTHETIC ADJUVANT(2,1)
SYNTHETIC ORIGIN(2,1)
TERM VACCINE(2,1)
THERAPEUTIC CONTEXT(2,1)
THERAPEUTIC VOLUME(2,1)
THERAPEUTICS DEVELOPMENT(2,1)
THICK STARCH(2,1)
TISSUE DEPOT(2,1)
TRANSFECTION REACTION(2,1)
TRANSFER VECTOR VIRUS(2,1)
TREHALOSE DIMYCOLATE(2,1)
TRICHLOROFLUOROMETHANE(2,1)
ULTRAMYLOPECTIN(2,1)
UNTOWARD REACTION(2,1)
VACCINE BASIS(2,1)
VACCINE VECTOR(2,1)
VIRAL PELLET(2,1)
WHOLE CULTURE(2,1)
WORKING STOCK(2,1)
YIELD STRESS PROTEIN PEPTIDE COMPLEX(2,1)
CELL ML(1,9)
RPM(1,9)
BORDER DISEASE VIRUS(1,6)
PESTIVIRUS ANTIGEN CAPTURE ELISA(1,5)
ACORN(1,1)
ADENOVIRUS(1,1)
ADMISSION(1,1)
AEROSOL(1,1)
ALCOHOLIC SOLUTION(1,1)
ALIGNMENT STRUCTURE(1,1)
ALLIGATOR(1,1)
AMINOACID CONSTITUTION(1,1)
ANIMAL SUBJECT(1,1)
ANTIOXIDANT(1,1)
AQUEOUS ENVIRONMENT(1,1)
ARBOVIRUS(1,1)
AUSTRALIAN QUARANTINE INSPECTION SERVICE(1,1)
AZANIUM(1,1)
BANKER(1,1)
BENTONITE(1,1)
BIOMEDICAL(1,1)
BUFFERED SOLUTION(1,1)
CALCIUM SALT(1,1)
CALCIUM TRIPHOSPHATE(1,1)
CAP WAKO(1,1)
CARBOHYDRATE(1,1)
CATHETERIZATION(1,1)
CELL STRESS RESPONSE(1,1)
CHAPERONIN(1,1)
CHICKEN(1,1)
CHLAMYDIA(1,1)
CLINICIAN(1,1)
COATING MIXTURE(1,1)
COCCIDIA(1,1)
COMMON INERT INGREDIENT(1,1)
COMPLEX PROTECTION(1,1)
COMPLEX STABILITY(1,1)
COMPRESSION COATING(1,1)
CONSTITUENT SUBUNIT(1,1)
CONTROL VACCINE FORMULATION(1,1)
CORRECT SIZED INSERT(1,1)
COXSACKIEVIRUS(1,1)
CROCODILE(1,1)
CULTURE PRODUCTION(1,1)
CURRENT SUBUNIT VACCINE(1,1)
CYCLODEXTRAN(1,1)
CYTOMEGALOVIRUS(1,1)
DEAE DEXTRAN(1,1)
DIOXOLANE(1,1)
DIZZINESS(1,1)
DRIED POWDER(1,1)
DUODENUM(1,1)
ECHINOVIRUS(1,1)
ECHOVIRUS(1,1)
EDIBLE PRODUCT(1,1)
EGG ROOM(1,1)
EMPLOYED EXCIPIENT(1,1)
EMPLOYED HSP(1,1)
EMULSIFIER(1,1)
(US7494785)
HETEROLOGOUS ANTIGENIC POLYPEPTIDE(100,6)
IMMUNOGENIC COMPLEX(100,2)
RECOMBINANT SUBUNIT VACCINE(100,2)
ANTIGENIC POLYPEPTIDE(80,47)
INVITROGEN TA CLONING KIT(68,1)
VIRTUALLY ERADICATED DISEASE(52,1)
PBLUEBACHIS BACULOVIRUS TRANSFER VECTOR(50,1)
NON MAMMALIAN EUKARYOTE(46,3)
SUBUNIT VACCINATED SHEEP(45,1)
NON MAMMALIAN EUKARYOTIC HSP(43,4)
CATTLE SUBUNIT VACCINE(42,1)
HETEROLOGOUS VIRUS(40,1)
COMMERCIAL ADJUVANT PREPARATION(34,1)
VACCINATED CATTLE(32,3)
INVITROGEN MAXBAC BACULOVIRUS(28,7)
POLYPEPTIDE DIRECTING EXPRESSION(28,2)
INVITROGEN CORPORATION(27,3)
NON MAMMALIAN CELL(25,5)
CULTURE MEDIUM(25,4)
VIRAL VECTOR(25,4)
IMMUNOGENIC(25,3)
POLYNUCLEOTIDE ENCODING CELL(25,2)
HSP(24,52)
PATHOGENIC ORGANISM ANTIGEN(24,2)
IMMUNOTHERAPY(21,1)
STIMULUS(20,5)
BACULOVIRUS VECTOR(20,3)
THERAPEUTICS(20,1)
TUBERCULOSIS(20,1)
VACCINATION(19,16)
NON MAMMALIAN EUKARYOTIC CELL(19,11)
BOVINE VIRAL DIARRHEA VIRUS(19,3)
CHICKEN POX(19,1)
SMALLPOX(19,1)
HEAT SHOCK PROTEIN(18,21)
MEASLES(18,1)
TETANUS(18,1)
MODERN MEDICINE(16,1)
POLIO(16,1)
IMMUNE RESPONSE(15,12)
INFECTION RATE(15,3)
PREGNANT VACCINATED HEIFER(15,2)
BVD VIRUS(14,4)
CTL RESPONSE(14,4)
ANTIGENIC HETEROLOGOUS PEPTIDE(14,3)
BIOTINYLATED ANTI MOUSE IGG(14,2)
ELIZABETH MACARTHUR AGRICULTURAL INSTITUTE(14,2)
CELL VIABILITY(14,1)
ANIMAL(13,25)
EVIDENCE(13,3)
PROTEIN(12,32)
TRIAL(12,10)
WHOLE VIRUS GENOME(12,7)
VACCINATED ANIMAL(12,6)
BIOTINYLATED GOAT ANTISERUM(12,2)
BIRD(12,2)
RECOMBINANT PESTIVIRUS PROTEIN EXPRESSION(12,2)
GRAMIN FETAL TISSUESVACCINATEDCONTROL(12,1)
SHEEP(11,23)
PLASMID(11,8)
VACCINE DOSE(11,6)
CDNA AMPLIFICATION(11,5)
RECOMBINANT VIRUS(11,5)
HEAT SHOCK RESPONSE INDUCTION(11,4)
INSECT CELL HSP(11,4)
MAMMAL(11,3)
NEUTRALIZING ANTIBODY CONCENTRATION(11,3)
ANTIGENIC POLYPEPTIDE EXPRESSION(11,2)
FISH(11,2)
HETEROLOGOUS POLYPEPTIDE EXPRESSION(11,2)
LIVE VIRUS REPLICATION(11,2)
HETEROLOGOUS CHALLENGE VIRUS GLEN(11,1)
PLAQUE PURIFYING RECOMBINANT BACULOVIRUS(11,1)
VACCINATED EWE FETUS(11,1)
DAY POST CHALLENGE(10,6)
COMMONWEALTH SERUM LABORATORY(10,2)
NON LIVE MATERIAL(10,2)
CATIONIC LIPOSOME MEDIATED TRANSFECTION(10,1)
PREGNANT HEIFER VACCINATION(10,1)
THERAPEUTICS FIELD(10,1)
SUSPENSION CULTURE(9,5)
WEEK POST CHALLENGE(9,4)
ANTIGEN CAPTURE ELISA(9,2)
HETEROLOGOUS PESTIVIRUS(9,2)
NON MAMMALIAN VERTEBRATE CELL(9,2)
ANTIGENIC POLYPEPTIDE INDUCIBLE EXPRESSION(9,1)
CATTLE PESTIVIRUS CHALLENGE(9,1)
HETEROLOGOUS BVDV CHALLENGE(9,1)
HETEROLOGOUS POLYPEPTIDE GLYCOSYLATION(9,1)
PESTIVIRUS ENVELOPE GLYCOPROTEIN(9,1)
RECOMBINANT BACULOVIRUS INACTIVATION(9,1)
SUBUNIT PESTIVIRUS VACCINE(9,1)
UNCOMPLEXED ANTIGENIC PEPTIDE(9,1)
PCR(8,11)
DEVELOPING FETUS(8,3)
INFECTIOUS VIRUS(8,3)
MACK PUBLISHING(8,3)
NS4A ANTIGEN(8,3)
ANTIBODY NEUTRALIZATION(8,2)
AUSTRALIAN VIRUS(8,2)
INFECTED ANIMAL(8,2)
ISOCOMATRIX ADJUVANT(8,2)
PROTEIN RESULT(8,2)
THERAPEUTIC VACCINE(8,2)
UNPROTECTED EWE(8,2)
BACULOVIRUS PLASMID TRANSFORMATION(8,1)
BDV CLOVER LANE(8,1)
BEGA BVDV VIRUS(8,1)
CATIONIC LIPOSOME TRANSFECTION(8,1)
CATTLE SUBUNIT TRIAL(8,1)
EUKARYOTIC HSP ANTIGENIC PEPTIDE(8,1)
GLEN INNES VIRUS(8,1)
LIVE HETEROLOGOUS BVDV(8,1)
NUCLEAR POLYHEDROSIS VIRUS(8,1)
RECOMBINANT BACULOVIRUS ENCODING(8,1)
TOTALLY UNRELATED BVDV(8,1)
TOTALLY UNRELATED LIVE VIRUS(8,1)
SF9 CELL CULTURE(7,5)
REGULATORY CONTROL SEQUENCE(7,4)
CONICAL FLASK(7,3)
ANTI PESTIVIRUS ANTISERUM(7,2)
ANTIGENIC FRAGMENT(7,2)
ANTISENSE PRIMER(7,2)
BACTERIAL CLONE(7,2)
BACTERIAL CONTAMINATION(7,2)
CULTURE SUPERNATANT(7,2)
EXPERIMENTAL SUBUNIT VACCINE(7,2)
EXPERIMENTAL VACCINE(7,2)
FETAL ASSAY(7,2)
NON COVALENT BONDING(7,2)
PESTIVIRUS RECOMBINANT PROTEIN(7,2)
SNT ASSAY(7,2)
TISSUE CULTURE FLASK(7,2)
VIRUS TITER(7,2)
ANTIGENIC POLYPEPTIDE OPTIMUM EXPRESSION(7,1)
ANTIGENIC POLYPEPTIDE SYNTHESIS(7,1)
CDNA DIRECTIONAL CLONING(7,1)
CHALLENGE LIVE VIRUS(7,1)
GENOME ENCODING CDNA(7,1)
INACTIVATED WHOLE VIRUS VACCINE(7,1)
INFECTIOUS DISEASE PROGRESSION(7,1)
NON MAMMALIAN EUKAROTIC CELL(7,1)
PCR FRAGMENT CLONING(7,1)
PESTIVIRUS PROTEIN ENCODING(7,1)
PROTEIN EXPRESSION POST INFECTION(7,1)
RECOMBINANT BACULOVIRUS INFECTED CULTURE(7,1)
RECOMBINANT BACULOVIRUS STOCK TITER(7,1)
RESIDUAL INFECTIOUS BACULOVIRUS(7,1)
SUBUNIT PROTEIN VACCINE(7,1)
WHOLE CLOVER LANE VIRUS(7,1)
FINAL CONCENTRATION(6,6)
VACCINE PRODUCTION(6,4)
ANAMNESTIC RESPONSE(6,3)
VIRUS ISOLATION(6,2)
ANTIGEN RECOGNITION MOLECULE(6,1)
AUSTRALIAN PESTIVIRUS(6,1)
BORDETELLA PERTUSSIS(6,1)
CHALLENGED BVDV(6,1)
COMPATIBLE COHESIVE OVERHANG(6,1)
CONTINUAL BOOSTER INJECTION(6,1)
CORYNEBACTERIUM PARVUM(6,1)
DETECTABLE PESTIVIRUS ABSENCE(6,1)
DIAGNOSTIC RT PCR(6,1)
DISRUPTED PATHOGEN PREPARATION(6,1)
EXOGENOUS MOLECULE ADMINISTRATION(6,1)
EXPORT ABATTOIR(6,1)
INFECTIOUS DISEASE PREVENTION(6,1)
INSECT SUPERNATANT FRACTION(6,1)
MITOCHONDRIAL HSP(6,1)
MLISCOMATRIX ADJUVANT(6,1)
NON INFECTED FETUS(6,1)
NON MAMMALIAN CELL CULTURE(6,1)
NON MAMMALIAN HSP(6,1)
NON PREGNANT HEIFER(6,1)
NONSTRUCTURAL POLYPEPTIDE(6,1)
OVERSEAS PESTIVIRUS(6,1)
PELLET EXTRACT SERIAL DILUTION(6,1)
PHRASE NON MAMMALIAN(6,1)
PLASMID PURIFICATION KIT(6,1)
POSTULATED EARLY ONSET(6,1)
PRIMER DESIGN VERSION(6,1)
PROPIONOBACTERIUM ACNE(6,1)
RECOMBINANT VIRAL STOCK(6,1)
SUBUNIT PROTEIN DOSE(6,1)
SUBUNIT VACCINATED EWE(6,1)
TRUNCATED PESTIVIRUS(6,1)
VACCINE EFFICACY(6,1)
ANTIBODY RESPONSE(5,8)
PLASMID TRANSFER(5,3)
THERMAL SEQUENCER(5,3)
BORDER DISEASE VIRUS(5,2)
CATTLE IMMUNE RESPONSE(5,2)
DENATURATION CYCLE(5,2)
FETAL PROTECTION(5,2)
GAUGE NEEDLE(5,2)
INVERTEBRATE CELL(5,2)
PHARMACEUTICAL CARRIER(5,2)
SUBUNIT PREPARATION(5,2)
ANTIBODY TITER(5,1)
ANTIGENIC POLYPEPTIDE PRODUCTION(5,1)
AUSTRALIAN BVDV(5,1)
AUSTRALIAN CATTLE(5,1)
BACTERIA TRANSFORMATION(5,1)
BENCH CENTRIFUGE(5,1)
BVDV POLYPEPTIDE(5,1)
BVDV PROTEIN(5,1)
CLAYSON INCUBATOR(5,1)
CONFLUENT MONOLAYER(5,1)
COW INFECTION(5,1)
CROSS PROTECTION(5,1)
CULTURE WEREGROWN(5,1)
CYTOTOXIC STIMULATION(5,1)
DISTANT BVD(5,1)
FETAL PROTECTIVE INDEX(5,1)
FREEZER INBLOCK(5,1)
GENOME FRAGMENT(5,1)
HARVESTING SUPERNATANT(5,1)
ICN BIOMEDICAL(5,1)
INDUCING IMMUNOCOMPETENCE(5,1)
INSECT CELL POLYPEPTIDE(5,1)
INSUFFICIENT VIRUS CIRCULATING(5,1)
LIVE PESTIVIRUS TRANSFER(5,1)
MASTER VIRUS STOCK(5,1)
NONSTRUCTURAL PROTEIN(5,1)
NS4A POLYPEPTIDE(5,1)
ORBITAL SHAKER(5,1)
PATHOGENIC BACTERIUM CULTURE(5,1)
PCR SPINCLEAN COLUMN(5,1)
PESTIVIRUS ANTIBODY NEGATIVE(5,1)
PESTIVIRUS ANTIGEN(5,1)
PHENOTYPIC VARIANT(5,1)
PLAQUE PURIFICATION ROUND(5,1)
POLYPEPTIDE CORRECT FOLDING(5,1)
POLYPEPTIDE SUBUNIT(5,1)
PRETREATED HSP(5,1)
PURIFIED RECOMBINANT BACULOVIRUS PRODUCTION(5,1)
RECOGNIZED PHARMACOPEIA(5,1)
RECOMBINANT BACULOVIRUS INFECTED CELL(5,1)
RECOMBINANT EXPRESSED SUBUNIT VACCINE(5,1)
REGULATORY AGENCY(5,1)
RT PCR ASSAY(5,1)
SF CULTURING(5,1)
SHEEP BDV(5,1)
SHEEP PESTIVIRUS(5,1)
STRESSFUL STIMULUS(5,1)
SUBUNIT VACCINATED CATTLE(5,1)
SUBUNIT VACCINATION(5,1)
TRANGIE VIRUS(5,1)
TRUNCATED BVDV(5,1)
UNPROTECTED SHEEP(5,1)
VACCINE EFFECTIVENESS(5,1)
VIRALLY INFECTED MAMMALIAN CELL(5,1)
VIROLOGY DEPARTMENT(5,1)
WEEK POST VACCINATION(5,1)
MGCL2(4,7)
MOLECULAR BIOLOGY(4,7)
PARTIAL SEQUENCE(4,7)
DILUENT(4,6)
ANIMAL GROUP(4,4)
CENTRIFUGATION(4,3)
EXCIPIENT(4,3)
FTS(4,3)
LEUPEPTIN(4,3)
PBLUEBACHIS(4,3)
PLURONIC(4,3)
ADMINISTRATION MODE(4,2)
CARBOXYMETHYLCELLULOSE(4,2)
CELL LYSATE(4,2)
FUNGAL CELL(4,2)
GENOMIC REGION(4,2)
HSP COMPLEX(4,2)
INTRACELLULAR CONCENTRATION(4,2)
MODIFIED PACE(4,2)
PCR BUFFER(4,2)
RECOMBINANT PROTEIN PREPARATION(4,2)
REDUCED VIRAL REPLICATION(4,2)
SPODOPTERA FRUGIPERDA(4,2)
STRESSED CELL(4,2)
VIROLOGY JOURNAL(4,2)
WORKING STOCK(4,2)
YEAST CELL(4,2)
ACTIVE IMMUNOGENIC INGREDIENT(4,1)
AGE WEEK(4,1)
AMPHIBIAN CELL(4,1)
ANTIBODY ASSAY(4,1)
ANTIBODY BEGINNING(4,1)
ANTIGENIC PEPTIDE POLYPEPTIDE COMPLEX(4,1)
ANTIGENIC PROTEIN COUPLING(4,1)
ATTENUATED STRAIN(4,1)
BACTERIAL ANTIGEN EXPRESSION(4,1)
BACTERIAL ENDOTOXIN(4,1)
BACULOVIRUS POLYHEDRIN PROMOTER CONTROL(4,1)
BACULOVIRUS TRANSFER VECTOR(4,1)
BERYLLIUM SULFATE(4,1)
BIOTEX LABORATORY(4,1)
BLOCKED COPOLYMER(4,1)
BLOCKING ELISA(4,1)
BLUE PLAQUE(4,1)
BULK SUBSTANCE(4,1)
BVDV ANTIGEN(4,1)
BVDV GLEN(4,1)
BVDV INFECTION PRESENCE(4,1)
BVDV NADL(4,1)
BVDV STRAIN(4,1)
CATTLE TRIAL(4,1)
CDNA ENCODING(4,1)
CELL RECEPTOR RECOGNITION(4,1)
CHALLENGE STRAIN(4,1)
CLONED VIRUS PASS(4,1)
COMMERCIAL VIABILITY(4,1)
COMPETENT CELL PREPARATION(4,1)
CULTURE ASSAY(4,1)
DAILY SAMPLE(4,1)
DIFCO LABORATORY(4,1)
DISEASE SPREAD(4,1)
DNA CLONING(4,1)
DOSESCONTROL CELL PREPARATION(4,1)
ECONOMICAL STANDARD METHODOLOGY(4,1)
ENDOGENOUS HSP PRESENCE(4,1)
ENGINEERED BACULOVIRUS(4,1)
EWESEWESNUMBER POSITIVE(4,1)
EXPRESSED PROTEIN DEGRADATION(4,1)
EXPRESSION INDUCTION(4,1)
EXTRAORDINARY CONCENTRATION(4,1)
FETUS DEVELOPMENT(4,1)
FOLDED POLYPEPTIDE(4,1)
FOREIGN PATHOGEN(4,1)
FROZEN CELL ALIQUOT(4,1)
GENTLE MIXING(4,1)
GIBCO BRL(4,1)
GLOVER ED(4,1)
GLYCOPROTEIN STRUCTURE(4,1)
GROWING COLONY(4,1)
HEIFER VACCINATED GROUP(4,1)
HETEROLOGOUS PROTECTION(4,1)
HIGHLY EFFICACIOUS VACCINE(4,1)
HOMOLOGOUS PROTECTION(4,1)
HOST INDIVIDUAL IMMUNOCOMPETENCE(4,1)
IMMUNOGENIC PROTEIN(4,1)
INCOMPLETE ADJUVANT(4,1)
INFECTED CELL CULTURE FLASK(4,1)
INSECT CELL SUSPENSION(4,1)
INSECT HSP(4,1)
INTRACELLULAR ENVIRONMENT(4,1)
LEPIDOPTERAN SPECIES(4,1)
LIVE ATTENUATED VACCINE(4,1)
LIVE BVDV(4,1)
MAMMAL TREATMENT THERAPEUTIC(4,1)
MAMMALIAN CELL GOLGI BODY(4,1)
MARKER VACCINE DEVELOPMENT(4,1)
MERCK ADJUVANT(4,1)
MHC MOLECULE(4,1)
MONOCLONAL ANTIBODY PANEL(4,1)
MONOLAYER CULTURE(4,1)
NATURAL PATHOGEN(4,1)
NORMAL PROTEIN EXPORT PATHWAY(4,1)
NOTABLE EXCEPTION(4,1)
NS4A PROTEIN REMAINS(4,1)
NUCLEOTIDE SEQUENCE TRANSLATION(4,1)
PCR PRIMER(4,1)
PEST INFECTION(4,1)
PLAQUE ASSAY SERIES(4,1)
PLUS INSECT CELL(4,1)
POLYMERIC COMPOUND PARTICULATE PREPARATION(4,1)
POSITIVE FETUS(4,1)
POST TRANSLATION MODIFICATION(4,1)
PRESELECTED PATHOGEN(4,1)
PRIMED ANIMAL(4,1)
PROBABLE ROLE(4,1)
PROGEN INDUSTRY(4,1)
PROTECTED FETUS(4,1)
PROTEIN CLASS(4,1)
PROTEIN HYDROPHOBIC TAIL REGION(4,1)
PROTEIN MAJORITY(4,1)
PROTEIN SUBUNIT(4,1)
PURIFIED PROTEIN(4,1)
RANGING VACCINE(4,1)
RAPID ANAMNESTIC RISE(4,1)
RECOMBINANT PLASMID(4,1)
RECOMBINANT PROTEIN CULTURE(4,1)
RECOMBINANT PROTEIN HARVEST(4,1)
RECOMBINANT PROTEIN PRODUCTION OPTIMIZATION(4,1)
RECOVERED HSP(4,1)
RNA PELLET DRYING(4,1)
SERUM NEUTRALIZING(4,1)
SF ADAPTATION(4,1)
SF CULTURE(4,1)
SHEEP TRIAL(4,1)
SINGLE PESTIVIRUS SUBUNIT GLYCOPROTEIN(4,1)
SODIUM METABISULFITE(4,1)
SPECIES BARRIER(4,1)
STATED INTEGER INCLUSION(4,1)
STERILE DIETHYL PYROCARBONATE(4,1)
STRESS STIMULUS(4,1)
STRONG HUMORAL IMMUNITY(4,1)
SUBUNIT VACCINE DEVELOPMENT(4,1)
SUBUNIT VACCINE PREPARATION(4,1)
SUBUNIT VACCINE SUBCELLULAR COMPONENT(4,1)
SYNTHETIC ADJUVANT(4,1)
TERM HETEROLOGOUS POLYPEPTIDE(4,1)
THERAPEUTIC FORMULATION(4,1)
THERAPEUTIC REGIMEN(4,1)
THERAPEUTICS DEVELOPMENT(4,1)
TISSUE DEPOT(4,1)
TITER MAGNITUDE(4,1)
TRANSFER VECTOR VIRUS(4,1)
TRANSFERRING VIRUS MAXIMUM CHANCE(4,1)
TRIAL FORMAT(4,1)
TRIZOL REAGENT(4,1)
UNINFECTED SF(4,1)
UNTOWARD REACTION(4,1)
VACCINATED HOST(4,1)
VACCINE BASIS(4,1)
VACCINE VECTOR(4,1)
VIRAL CHALLENGE(4,1)
VIRAL PELLET(4,1)
VIRAL RNA EXTRACTION(4,1)
VIRULENT STRAIN(4,1)
VIRUS FETAL TRANSFER(4,1)
VIRUS PARTICLE(4,1)
WHOLE ORGANISM VACCINE(4,1)
WIDESPREAD PROTECTION(4,1)
PROKARYOTIC CELL(3,5)
REVERSE TRANSCRIPTASE(3,4)
TREND(3,3)
ANTIBODY SOLUTION(3,2)
BETA PROPIOLACTONE(3,2)
CELL DENSITY(3,2)
CHEMICAL SYNTHESIS(3,2)
DEIONIZED WATER(3,2)
EDWARD(3,2)
ELISA WASH PLATE(3,2)
ESTRUM(3,2)
FINAL EXTENSION(3,2)
FRESH MEDIUM(3,2)
INACTIVATED VACCINE(3,2)
NUCLEIC ACID MOLECULE(3,2)
PENICILLIN(3,2)
PLACENTAL(3,2)
PLUS CELL(3,2)
PRESERVATIVE(3,2)
STRATEGY(3,2)
STREPTOMYCIN(3,2)
THERMOMETER(3,2)
THIMEROSAL(3,2)
ACTIVE INGREDIENT(3,1)
ADENOSINE TRIPHOSPHATE PRESENCE(3,1)
ADMINISTRATIVE TECHNIQUE VARIETY(3,1)
AGAROSE GEL(3,1)
ALUMINUM PHOSPHATE(3,1)
ALUMINUM POTASSIUM SULFATE(3,1)
AMICON ULTRAFILTRATION CELL STEP(3,1)
AMPLIFICATION REACTION(3,1)
ANIMAL GIVING(3,1)
AQUEOUS DEXTROSE(3,1)
ATTENUATING AGENT(3,1)
AUXILIARY SUBSTANCE(3,1)
BENZYL ALCOHOL(3,1)
BOTHSUPERNATANT(3,1)
BROAD PROTECTION(3,1)
BUFFERING AGENT(3,1)
CATTLE PRODUCING COUNTRY(3,1)
CELL ANTIGEN RECEPTOR(3,1)
CELL PELLET(3,1)
CENTRICON TUBE(3,1)
CLEAR EVIDENCE(3,1)
CLONING STAGE(3,1)
COMPLEX SUGAR(3,1)
CONCENTRATED PREPARATION(3,1)
CORRECT GENETIC INFORMATION(3,1)
CORRECT ORIENTATION(3,1)
COUPLED RECOMBINANT PROTEIN EXPRESSION(3,1)
DOSEFINAL VOLUME(3,1)
ENDOGENOUS HEAT SHOCK PROTEIN(3,1)
ENDOPLASMIC RETICULUM(3,1)
ENHANCER(3,1)
EXCESS ATP(3,1)
FINAL PROTEIN YIELD(3,1)
HEAT SHOCK PROTEIN INDUCTION(3,1)
HIGHLY VARIABLE ANTIGENIC DETERMINANT(3,1)
HR INCUBATION(3,1)
HR INTERVAL(3,1)
HSP ANTIGEN COMPLEX(3,1)
HYLAURONIC ACID(3,1)
IMMUNE RESPONSE GENERATION(3,1)
IMMUNE RESPONSE INTENSITY(3,1)
IMMUNOPEROXIDASE(3,1)
INFECTIOUS AGENT(3,1)
INSECT HEAT SHOCK PROTEIN(3,1)
INSPECTION SERVICE(3,1)
INTRACELLULAR COMPLEX(3,1)
LABORATORY PRESS(3,1)
LIMITINGDILUTION(3,1)
LIVE AGENT(3,1)
MAJOR HSP(3,1)
MAJOR IMMUNOGENIC REGION(3,1)
MAXBAC BACULOVIRUS EXPRESSION(3,1)
MAXIMUM PROTEIN RECOVERY(3,1)
MERCURIC COMPOUND(3,1)
MIXED LYMPHOCYTE(3,1)
MODIFIED PESTIVIRUS(3,1)
MOLECULAR ENTITY(3,1)
MRL PRESS(3,1)
MURAMYL DIPEPTIDE(3,1)
NATURAL INFECTION(3,1)
NON MAMMALIAN EUKARYOTIC CELL VARIETY(3,1)
NS4A COMPLEX(3,1)
PCR REACTION(3,1)
PEANUT OIL(3,1)
PELLETED CELL FRACTION(3,1)
POLYNUCLEOTIDE SEQUENCE(3,1)
POLYRIBONUCLEOTIDE(3,1)
PREGNANT CONTROL HEIFER(3,1)
PROTECTIVE IMMUNE RESPONSE(3,1)
PUBLISHED SEQUENCE CONSERVED REGION(3,1)
SECRETED COMPLEX(3,1)
SHELF LIFE(3,1)
SODIUM ALGINATE(3,1)
SOLUBILIZING AGENT(3,1)
SOYBEAN OIL(3,1)
STANDARD CLONING(3,1)
STATISTICALLY SIGNIFICANT DECREASE(3,1)
STRONG CELL MEDIATED IMMUNITY(3,1)
STRONG PRIMING RESPONSE(3,1)
(US20090136536)
HETEROLOGOUS ANTIGENIC POLYPEPTIDE(100,7)
RECOMBINANT SUBUNIT VACCINE(100,2)
ANTIGENIC POLYPEPTIDE(78,49)
NON MAMMALIAN EUKARYOTE(44,4)
PESTIVIRUS ANTIGEN(41,1)
VIRTUALLY ERADICATED DISEASE(39,1)
NON MAMMALIAN EUKARYOTIC HSP(32,4)
IMMUN(...)";"Biotechnology
Pharmaceuticals";Open
"1999-04-29
2000-04-25";"NO20002213          D0 2000-04-28 [NO200002213]
STG: (D0) Patent application filed
AP : 2000NO-0002213 2000-04-28
HU0001701           D0 2000-07-28 [HU200001701]
STG: (D0) Filing application
AP : 2000HU-0001701 2000-04-28
NO20002213          L  2000-10-30 [NO20002213]
STG: (L) Abstract
AP : 2000NO-0002213 2000-04-28
EP1050541           A1 2000-11-08 [EP1050541]
STG: (A1) Application published with search report
AP : 2000EP-0201485 2000-04-25
HU0001701           A2 2002-06-29 [HU200001701]
STG: (A2) Examined patent application
AP : 2000HU-0001701 2000-04-28
HU0001701           A3 2005-05-30 [HU200001701]
STG: (A3) Imported patent application
AP : 2000HU-0001701 2000-04-28
NO327859            B1 2009-10-05 [NO-327859]
STG: (B1) Granted patents
AP : 2000NO-0002213 2000-04-28";14765424;"NO20002213          D0 2000-04-28 [NO200002213]
HU0001701           D0 2000-07-28 [HU200001701]
NO20002213          L  2000-10-30 [NO20002213]
EP1050541           A1 2000-11-08 [EP1050541]
HU0001701           A2 2002-06-29 [HU200001701]
HU0001701           A3 2005-05-30 [HU200001701]
NO327859            B1 2009-10-05 [NO-327859]";"1999EP-0201322
2000EP-0201485";;"AKZO NOBEL
INTERVET INTERNATIONAL";INTERVET INTERNATIONAL;"(EP1050541)
NL";"(EP1050541)
NAME=Akzo Nobel N.V. Velperweg 76 , CITY=6824 BM  Arnhem , COUNTRY=NL 
";1;"SCHETTERS THEODORUS PETRUS MAR
CARCY BERNARD
GORENFLOT ANDRE
PRECIGOUT ERIC
VALLET ALEXINA";"(EP1050541)
FR; NL";"(EP1050541)
NAME=Schetters, Theodorus Petrus Maria Heggerank 17 , CITY=5432 CD  Cuyk , COUNTRY=NL 

NAME=Carcy, Bernard 15, rue de Suez , CITY=34070 Montpellier , COUNTRY=FR 

NAME=Gorenflot, André 424, rue de l'Aiguelongue , CITY=34090 Montpellier , COUNTRY=FR 

NAME=Précigout, Eric 64, rue du Vieux-Prades , CITY=34730 Prades Le Lez , COUNTRY=FR 

NAME=Vallet, Alexina Les Guettes du Leman, Appt. 10 Poese , CITY=St. Paul en Chablais , COUNTRY=FR 
";"(EP1050541)
Babesia vaccine";"(EP1050541)
The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of Babesia divergens. Furthermore, the invention relates to recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences and host cells comprising such nucleic acid sequences. Yet another embodiment of the invention relates to vaccines against Babesia divergens comprising proteins of the 37 kD protein family, nucleic acid sequence of genes encoding proteins of the 37 kD protein family of Babesia divergens, recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences, host cells comprising such nucleic acid sequences, antibodies against proteins of the 37 kD protein family and methods for the preparation of such vaccines. Additionally, diagnostic kits for the detection of Babesia divergens, diagnostic kits for the detection of antibodies against Babesia divergens and methods for the detection of Babesia divergens and antibodies against Babesia divergens are disclosed. Finally, an embodiment relates to the use of a protein of the 37 kD protein family or a mixture of such proteins for the manufacture of vaccines.";"(EP1050541)
1. Nucleic acid sequence of Babesia divergens characterised in that it encodes a protein of the 37 kD protein family or an immunogenic fragment thereof.
2. Nucleic acid sequence according to claim 1, characterised in that the protein has a molecular weight of 37 kD.
3. Nucleic acid sequence according to claim 1, characterised in that the protein has a molecular weight of 35 kD.
4. Nucleic acid sequence according to claim 2, characterised in that it comprises the sequence shown in SEQ ID NO 1.
5. Nucleic acid sequence according to claim 3, characterised in that it comprises the sequence shown in SEQ ID NO 2 or 3.
6. Nucleic acid sequence encoding a protein of the 37 kD protein family that is capable of binding to the monoclonal antibody F42F8.
7. Recombinant DNA molecule characterised in that it comprises a nucleic acid sequence according to claims 1-6 and regulating sequences enabling expression of said nucleic acid sequence.
8. Live recombinant carrier micro-organism comprising a nucleic acid sequence according to claims 1-7.
9. Live recombinant carrier according to claim 8, characterised in that said carrier additionally comprises a heterologous gene encoding an antigen of a cattle-pathogen, which is able to elicit an immune response.
10. Live recombinant carrier according to claim 9, characterised in that said cattle pathogen is selected from the group of cattle pathogens, consisting of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, Pasteurella haemolytica, Bovine Respiratory Syncytial Virus, Theileria parve, Theileria annulata, Babesia bovis, Babesia bigemina, Babesia major, Trypanosoma species, Anaplasma marginale, Anaplasma centrale or Neospora caninum
11. Host cell comprising a nucleic acid sequence according to claims 1-6, a recombinant DNA molecule according to claim 7 or a live recombinant carrier according to claims 8-10.
12. Vaccine inducing protection against infection of cattle with B. divergens or the clinical manifestations of the infection, characterised in that it comprises at least one protein of the 37 kD protein family or an immunogenic fragment thereof and a pharmaceutically acceptable carrier.
13. Vaccine according to claim 12, characterised in that it comprises two or more different proteins of the 37 kD protein family.
14. Vaccine according to claim 13, characterised in that it comprises 50-75% of a 37 kD member of the 37 kD protein family and 50-25% of a 35 kD protein member of the 37 kD protein family.
15. Vaccine inducing protection against infection of cattle with B. divergens or the clinical manifestations of the infection, characterised in that it comprises a nucleic acid sequence according to claims 1-6, a recombinant DNA molecule according to claim 7, a live recombinant carrier according to claims 8-10 or a host cell according to claim 11.
16. Vaccine protecting against infection of cattle with B. divergens or the clinical manifestations of the infection, characterised in that it comprises antibodies against a protein of the 37 kD family.
17. Method for the preparation of a vaccine according to claim 12, 15 or 16, characterised in that said method comprises the admixing of a protein of the 37 kD protein family or an immunogenic fragment thereof, antibodies against a protein of the 37 kD family, a nucleic acid sequence according to claims 1-6, a recombinant DNA molecule according to claim 7, a live recombinant carrier according to claims 8-10 or a host cell according to claim 11 and a pharmaceutically acceptable carrier.
18. Method for the preparation of a vaccine according to claim 13, characterised in that said method comprises the admixing of two different proteins of the 37 kD protein family or immunogenic fragments thereof and a pharmaceutically acceptable carrier.
19. Diagnostic kit for the detection of antibodies against Babesia divergens, said kit comprising purified protein of the 37 kD protein family or fragments thereof still comprising an antigenic determinant.
20. Diagnostic kit for the detection of Babesia divergens, said kit comprising antibodies reactive with an antigenic determinant on a protein the 37 kD protein family.
21. Method for the detection of antibodies against Babesia divergens, said method comprising incubating serum with a protein of the 37 kD protein family or an antigenic fragment thereof.
22. Method for the detection of Babesia divergens parasites, said method comprising incubating serum with antibodies against a protein of the 37 kD protein family.
23. Use of a protein of the 37 kD protein family or a mixture of such proteins for the manufacture of a vaccine inducing protection against infection of cattle with B. divergens or the clinical manifestations of the infection";"(EP1050541)
Additionally, diagnostic kits for the detection of Babesia divergens, diagnostic kits for the detection of antibodies against Babesia divergens and methods for the detection of Babesia divergens and antibodies against Babesia divergens are disclosed.
The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of Babesia divergens.
Furthermore, the invention relates to recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences and host cells comprising such nucleic acid sequences.
The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of Babesia divergens, recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences, host cells comprising such nucleic acid sequences, vaccines against Babesia divergens comprising proteins of the 37 kD protein family, methods for the preparation of such vaccines, methods for the detection of antibodies against a protein of the 37 kD protein family, diagnostic kits for the detection of Babesia divergens, diagnostic kits for the detection of antibodies against Babesia divergens and methods for the detection of Babesia divergens.
The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of Babesia divergens.
The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of Babesia divergens, recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences, host cells comprising such nucleic acid sequences, vaccines against Babesia divergens comprising proteins of the 37 kD protein family, methods for the preparation of such vaccines, methods for the detection of antibodies against a protein of the 37 kD protein family, diagnostic kits for the detection of Babesia divergens, diagnostic kits for the detection of antibodies against Babesia divergens and methods for the detection of Babesia divergens.";"(EP1050541)
It is an objective of the present invention to provide an novel and efficient vaccine component against Babesia divergens infection in cattle, or at least against the clinical manifestations of the infection.
When the host cell is yeast, useful expression control sequences include, e.g., -mating factor.
When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl.
The disease is also called ""red water"" since in a progressed state it causes bloody urine.
This is due to their variable infectivity and morbidity: in unhealthy animals an attenuated live vaccine causes a virulent infection leading to sickness.
It was now surprisingly found, that an immunological response that provides immunity against infection with the Babesia parasite, or at least an immunological response that sufficiently reduces the level of clinical manifestations upon infection (as shown e.g. by a decrease of the haematocrit value), can be obtained by vaccination with vaccines comprising a protein of the 37 kD protein family or an immunogenic fragment thereof.";"A61K
A61K-039/00
A61K-039/018
C07K-014/44
C07K-016/20
C12N-001/19
C12N-001/21
C12N-015/30
G01N-033/569";"(EP1050541)
1. Nucleic acid sequence of Babesia divergens characterised in that it encodes a protein of the 37 kD protein family or an immunogenic fragment thereof.
6. Nucleic acid sequence encoding a protein of the 37 kD protein family that is capable of binding to the monoclonal antibody F42F8.
12. Vaccine inducing protection against infection of cattle with B. divergens or the clinical manifestations of the infection, characterised in that it comprises at least one protein of the 37 kD protein family or an immunogenic fragment thereof and a pharmaceutically acceptable carrier.
16. Vaccine protecting against infection of cattle with B. divergens or the clinical manifestations of the infection, characterised in that it comprises antibodies against a protein of the 37 kD family.
19. Diagnostic kit for the detection of antibodies against Babesia divergens, said kit comprising purified protein of the 37 kD protein family or fragments thereof still comprising an antigenic determinant.
20. Diagnostic kit for the detection of Babesia divergens, said kit comprising antibodies reactive with an antigenic determinant on a protein the 37 kD protein family.
21. Method for the detection of antibodies against Babesia divergens, said method comprising incubating serum with a protein of the 37 kD protein family or an antigenic fragment thereof.
22. Method for the detection of Babesia divergens parasites, said method comprising incubating serum with antibodies against a protein of the 37 kD protein family.
23. Use of a protein of the 37 kD protein family or a mixture of such proteins for the manufacture of a vaccine inducing protection against infection of cattle with B. divergens or the clinical manifestations of the infection";"(EP1050541)
BABESIA DIVERGENT DETECTION(100,5)
BABESIA VACCINE(100,1)
KD PROTEIN FAMILY(96,77)
BABESIA DIVERGENT(93,23)
SUBCLINICAL INFECTION MANIFESTATION(63,12)
DIAGNOSTIC KIT(57,8)
CATTLE INFECTION(48,6)
ANTIBODY DETECTION(47,7)
IMMUNOGENIC FRAGMENT(41,17)
RECOMBINANT MOLECULE(41,3)
BABESIA DIVERGENT PARASITE DETECTION(40,4)
NUCLEIC ACID SEQUENCE(37,38)
RECOMBINANT CARRIER(37,5)
ATTENUATED LIVE VACCINE(36,1)
SERUM INCUBATION(34,3)
VACCINE PROTECTION INDUCTION(33,3)
GENE ENCODING(31,16)
VACCINE PREPARATION(29,7)
PROTEIN(28,116)
BOVINE VIRAL DIARRHEA VIRUS(28,2)
RECOMBINANT DNA MOLECULE(26,4)
VIRULENT INFECTION(26,1)
VACCINE INDUCING PROTECTION MANUFACTURE(25,2)
LIVE RECOMBINANT CARRIER(24,7)
UNHEALTHY ANIMAL(24,1)
BABESIA PARASITE(23,3)
HETEROLOGOUS GENE ENCODING(23,1)
HOST CELL(22,14)
VACCINE PROTECTION(22,2)
HEMATOCRIT DECREASE(22,1)
ANTIGENIC FRAGMENT(21,3)
IMMUNOLOGICAL RESPONSE(21,2)
THEILERIA PARVE(21,1)
ANTIBODY(20,29)
DIVERGENT(20,10)
VARIABLE INFECTIVITY(20,1)
RECOMBINANT CARRIER MICROORGANISM(19,1)
KD FAMILY(18,12)
ANTIGENIC DETERMINANT(18,5)
PROTEIN MIXTURE(18,3)
BABESIA BIGEMINA(18,2)
VACCINE(17,45)
PROTEIN ADMIXING(16,3)
BABESIA BOVIS(16,2)
BOVINE PARAMYXOVIRUS(16,2)
PURIFIED PROTEIN(15,4)
VACCINE MANUFACTURE(15,1)
CLINICAL MANIFESTATION LEVEL(14,2)
PARAINFLUENZA(14,2)
TRYPANOSOMA SPECIES(14,2)
BOVINE HERPES VIRUS(13,2)
CATTLE PATHOGEN GROUP(12,2)
BLOODY URINE(12,1)
MORBIDITY(12,1)
PROGRESS STATE(12,1)
SICKNESS(12,1)
KIT(10,4)
BABESIA MAJOR(10,2)
HOMOLOGOUS BABESIA DIVERGENT STRAIN(10,2)
KD PROTEIN MEMBER(10,1)
VIRULENT BABESIA DIVERGENT PARASITE(10,1)
MONOCLONAL ANTIBODY(9,14)
INFECTION(9,12)
KDA PROTEIN FAMILY(9,7)
NUCLEIC ACID SEQUENCE ENCODING(9,7)
ANAPLASMA CENTRALE(9,2)
ANAPLASMA MARGINALE(9,2)
PASTEURELLA HAEMOLYTICA(9,2)
THEILERIA ANNULATA(9,2)
VACCINATION(8,11)
IMMUNITY(8,3)
NEOSPORA CANINUM(8,2)
PATHOGEN IMMUNOGENIC PROTEIN(8,2)
BABESIA DIVERGENT INFECTION DIAGNOSIS(8,1)
RED WATER(8,1)
IMMUNE RESPONSE(7,5)
DISEASE(7,3)
BOVINE RESPIRATORY SYNCYTIAL VIRUS(7,2)
DIVERGENT PARASITIZED ERYTHROCYTE(7,1)
ENCODER MEMBER(7,1)
KD MEMBER(7,1)
PARASITE BABESIA DIVERGENT(7,1)
RECOMBINANT BD(6,4)
BERZOFSKY AMPHIPHILICITY CRITERION(6,1)
DIVERGENT INFECTED ERYTHROCYTE(6,1)
PLASMODIUM YOELII CIRCUMSPOROZOITE GENE(6,1)
POLYCLONAL ANTIBODY(5,3)
ANTISENSE OLIGONUCLEOTIDE(5,2)
LIVE VACCINE(5,2)
T CELL EPITOPE(5,2)
ANIMAL BABESIA INFECTION STATUS(5,1)
BABESIA DIVERGENT ANTIBODY DETECTION(5,1)
BABESIA DIVERGENT PROTEIN BAND(5,1)
CRANDELL FELINE KIDNEY CELL(5,1)
DENATURATED LABELED PROBE(5,1)
GOAT ANTI RABBIT IGG(5,1)
KD MEROZOITE MEMBRANE PROTEIN(5,1)
LIVE VIRAL VECTOR VACCINE(5,1)
NEUTRALIZING ANTIBODY INDUCTION(5,1)
NON INFECTED INSECT CELL LYSATE(5,1)
PATHOGENIC BABESIA SPECIES(5,1)
POLYCLONAL ANTISERUM INDUCTION(5,1)
WESTERN BLOT INCUBATION(5,1)
NON INFECTED CELL(4,3)
PROTEIN EXPRESSION(4,3)
BIOMAX MR(4,2)
DNA VACCINATION(4,2)
HETEROLOGOUS STRAIN(4,2)
HOMOLOGOUS CHALLENGE(4,2)
IMMUNITY INDUCTION(4,2)
PHENOL CHLOROFORM EXTRACTION(4,2)
RECOMBINANT BAC BD(4,2)
ACUTELY INFECTED ANIMAL(4,1)
ANTI IDIOTYPIC ANTIBODY GENERATION(4,1)
ANTI PARASITE VACCINE(4,1)
ANTIGEN IMMUNOPRECIPITATION(4,1)
BABESIA ANTIGEN ABSENCE(4,1)
BD FUSION PROTEIN(4,1)
CATTLE VACCINATION(4,1)
EXPRESS CDNA SYNTHESIS KIT(4,1)
GENE ENCODING FAMILY(4,1)
GERBIL IMMUNOGLOBULIN(4,1)
HERRING SPERM DNA(4,1)
HETEROLOGOUS CHALLENGE EXPERIMENT(4,1)
KBP CDNA FRAGMENT(4,1)
KD PROTEIN ANTIBODY(4,1)
LOCAL VETERINARY AUTHORITY(4,1)
METALLOTHIONEIN PROMOTER(4,1)
PARASITIC VESICLE MEMBRANE(4,1)
RECOMBINANT VECTOR LB(4,1)
TRIPHOSPHATE DEOXYRIBONUCLEOSIDE EXCESS(4,1)
HCL PH(3,4)
NUCLEIC ACID MOLECULE ENCODING(3,3)
DIAGNOSTIC TOOL(3,2)
ENCODED PROTEIN(3,2)
GENOMIC DNA(3,2)
NET RANK(3,2)
RAISING ANTIBODY(3,2)
STRAIN ENCODING(3,2)
SUPERCOMPETENT CELL(3,2)
TRANSLATION KIT(3,2)
WEEK INTERVAL(3,2)
ACTIVE IMMUNIZATION(3,1)
ACUTE BABESIOSIS(3,1)
AGAROSE ELECTROPHORESIS(3,1)
ANIMAL DISEASE(3,1)
ANTIBODY ADMINISTRATION(3,1)
ATTENUATED SALMONELLA(3,1)
BABESIA STRAIN(3,1)
BABESIOSIS INFECTION(3,1)
BACILLUS SUBTILUS(3,1)
BACTERIA GENOME(3,1)
BACTERIAL CULTURE(3,1)
BACTERIAL EXPRESSION VECTOR(3,1)
BACULOVIRUS PROMOTER(3,1)
BAMHI RESTRICTION SITE(3,1)
BD CORRECT ORIENTATION(3,1)
BIOTINYLATED OLIGO(3,1)
BOOSTER INFECTION(3,1)
BOVINE BABESIOSIS(3,1)
CATTLE POPULATION(3,1)
CDNA ENCODING SEQUENCE(3,1)
CDNA LIBRARY RECOMBINANT(3,1)
CDNA LIBRARY SCREENING(3,1)
CHALLENGE INOCULUM(3,1)
CHINESE HAMSTER OVARY CELL(3,1)
CLONTECH LABORATORY(3,1)
CULTURE CENTRIFUGATION(3,1)
CULTURE SUPERNATANT(3,1)
DEGENERACY PHENOMENON(3,1)
DEVELOPING BABESIOSIS(3,1)
DIAGNOSTIC IMMUNOASSAY(3,1)
DIVERGENT ANTIGEN(3,1)
DNA FRAGMENT ENCODING(3,1)
DOMESTIC ANIMAL BABESIOSIS(3,1)
ECORI ADAPTOR(3,1)
EFFICACIOUS VACCINE(3,1)
ETHANE GLYCINE(3,1)
EUKARYOTIC BACULOVIRUS(3,1)
EUKARYOTIC ORIGIN(3,1)
EXCISED CDNA(3,1)
EXPERIMENTAL HEMATOLOGY(3,1)
EXPERIMENTAL INFECTION(3,1)
GELMAN SCIENCE(3,1)
GENUS BABESIA(3,1)
GERBIL HUMORAL RESPONSE(3,1)
GERBIL SURVIVAL(3,1)
GROVEMONT CIRCLE(3,1)
HELPER PHAGE(3,1)
HEMOGLOBINURIA OCCURRENCE(3,1)
HERPES VIRUS CARRIER VIRUS(3,1)
HOMOLOGOUS PROTEIN(3,1)
HYBRIDIZATION EXPERIMENT(3,1)
HYDROPHILICITY PROFILE ANALYSIS(3,1)
IMMUNE MODULATOR(3,1)
IMMUNE PRESENTATION(3,1)
IMMUNIZING ANTIGEN(3,1)
IMMUNODEFICIENT ANIMAL(3,1)
IMMUNOLOGICALLY IMPORTANT EPITOPE(3,1)
INCOMPLETE ADJUVANT(3,1)
INSIDE PARASITIC VESICLE(3,1)
INTESTINAL ALKALINE PHOSPHATASE(3,1)
IXODE RICINUS(3,1)
KANAMYCIN RESISTA(3,1)
KDA ANTIBODY(3,1)
LABELED ANTIBODY(3,1)
LABELING KIT(3,1)
LACTOBACILLUS SPECIES(3,1)
LACZ PROMOTER(3,1)
LIVE ATTENUATED VACCINE(3,1)
MAMMAL SERUM(3,1)
MOLECULE CLEAVAGE(3,1)
MONOCLONAL ANTIBODY IGG2A(3,1)
NATIVE PGEX(3,1)
NITROCELLULOSE MEMBRANE(3,1)
NON FAT MILK(3,1)
NUCLEOTIDE PROBE(3,1)
PALO ALTO(3,1)
PARAMAGNETIC PARTICLE(3,1)
PARASITE GROWTH(3,1)
PASSIVE VACCINATION(3,1)
PGEX PRIMER(3,1)
PHAGEMID VECTOR(3,1)
PHYSIOLOGICALLY ACCEPTABLE DILUENT(3,1)
PLANT VIRAL VECTOR(3,1)
PLASMID MINIPREP(3,1)
POLYATRACT MRNA(3,1)
POLYCLONAL SERA(3,1)
POSITIVE RECOMBINANT PGEX(3,1)
PREFERENCE ANTIBODY(3,1)
PRIMER PMOL(3,1)
PRIMER USEFUF(3,1)
PROPHYLACTICALLY(3,1)
PROTEIN ANTIGENIC DETERMINANT(3,1)
PROTEIN EXTREMITY(3,1)
PROTEIN IMMUNOGENICITY(3,1)
PROTEIN SEQUENCE ATLAS(3,1)
PURIFIED RECOMBINANT VECTOR(3,1)
RECOMBINANT BACULOVIRUS(3,1)
RECOMBINANT CARRIER ENCODING(3,1)
RECOMBINANT CARRIER PARASITE(3,1)
RECOMBINANT CARRIER VIRUS(3,1)
RECOMBINANT DNA MOLECULE ENCODING(3,1)
RECOMBINANT LAMBDA PHAGE(3,1)
RECOMBINANT MICROORGANISM(3,1)
RECOMBINANT VIRUS(3,1)
RELEVANT MAMMALIAN ANTIBODY(3,1)
REPETITIVE MOTIF(3,1)
RESTRICTION SITE ECORI(3,1)
SECRETED PROTEIN(3,1)
SECRETED VESICLE(3,1)
STERILE IMMUNITY(3,1)
STRAIN VIRULENCE(3,1)
TRIGGERING ANTIBODY(3,1)
VACCINATION ASSAY(3,1)
VACCINE ADMINISTRATION(3,1)
VACCINIA VIRUS(3,1)
VARIANT TRIPLET CODE(3,1)
VECTOR IMMUNOGEN(3,1)
VETERINARY SURVEILLANCE(3,1)
XHOI RESTRICTION SITE(3,1)
DIAGNOSTIC TEST(2,6)
FINAL VOLUME(2,5)
LANE(2,4)
XSSC(2,4)
ELECTRO ELUTION(2,3)
ETHYL ALCOHOL PRECIPITATION(2,3)
FULL PROTECTION(2,3)
ALIQUOT(2,2)
CLONE(2,2)
CYTOKINE(2,2)
DENATURATION(2,2)
DIRECT VACCINATION(2,2)
ELISA PLATE(2,2)
FINAL CONCENTRATION(2,2)
HOST ANIMAL(2,2)
INTERFERON(2,2)
ISOTYPE(2,2)
LIFE TECHNOLOGY(2,2)
NUCLEIC ACID HOMOLOGY(2,2)
PGEM T VECTOR(2,2)
PROTECTION INDUCTION(2,2)
RELEVANT VACCINE COMPONENT(2,2)
STABILIZER(2,2)
AD LIBITUM(2,1)
AGAROSE BEAD(2,1)
AGE WEEK(2,1)
ANIMAL HEALTH(2,1)
ANIMAL RECEIVED FOOD(2,1)
ANNEALING(2,1)
ANTIBIOTIC(2,1)
ANTIBODY ABSENCE(2,1)
ANTIBODY CONCENTRATION(2,1)
ANTIBODY INJECTION(2,1)
BAC VECTOR(2,1)
BAMHI CUT PHOSPHATASE(2,1)
BAMHI RESTRICTION ENZYME UNIT(2,1)
BD INJECTION(2,1)
BEAD COLUMN(2,1)
BIOLOGICAL ACTIVITY(2,1)
BLOT ANALYSIS(2,1)
BOOSTER INJECTION(2,1)
BOVINE SERUM ALBUMIN(2,1)
CARRIER CATTLE(2,1)
CARRIER MOLECULE(2,1)
CATTLE PROTECTION(2,1)
CDNA REGION CODING(2,1)
CELL CULTURE EUROPEAN COLLECTION(2,1)
CHALLENGE DOSE VOLUME(2,1)
CHOICE PROTEIN(2,1)
CHOICE VIRUS(2,1)
COLI VECTOR(2,1)
COVALENTLY BOUND(2,1)
DEGRADATION PRONE POLYPEPTIDE(2,1)
DESOXYRIBONUCLEOTIDE(2,1)
DEXTRANSULPHATE(2,1)
DNA EXTRACTION(2,1)
DNA PELLET(2,1)
DOSAGE FORMULATION(2,1)
EFFICIENCY COMPETENT CELL(2,1)
ELISA TEST(2,1)
ENZYME BUFFER(2,1)
ESSENTIAL REQUIREMENT(2,1)
EXPRESS VECTOR(2,1)
EXPRESSION INDUCTION(2,1)
FUNCTIONAL SIMILARITY(2,1)
GENE ENCODING SEQUENCE ANALYSIS(2,1)
GENETIC INFORMATION(2,1)
GIGAPACK(2,1)
H POST INFECTION(2,1)
HETEROLOGOUS DNA SEQUENCE ENCODING(2,1)
HOST CELL PROTEIN(2,1)
HOST ORGANISM(2,1)
HYBRIDOMA PRODUCTION(2,1)
HYDROPHILICITY CRITERIA COMBINATION(2,1)
HYDROPHOBIC SEGMENT PRESENCE(2,1)
HYDROPHOBIC SEQUENCE(2,1)
IMMUNE HOST RESPONSE(2,1)
IMMUNE STIMULATING COMPLEX(2,1)
IMMUNOBLOTTING(2,1)
IMMUNOFLUORESCENCE PATTERN(2,1)
IMMUNOGENIC RESPONSE(2,1)
IMMUNOPROTECTION(2,1)
INBRED MOUSE(2,1)
INSERT SEQUENCING(2,1)
INTEGRATION SITE(2,1)
INTERGENIC REGION(2,1)
KDA RECOMBINANT PROTEIN(2,1)
KEY ROLE(2,1)
LIGATION REACTION(2,1)
LIVE INFECTION(2,1)
LRC GENE(2,1)
LYSIS BUFFER VOLUME(2,1)
LYTIC AGENT(2,1)
MAMMALIAN ORIGIN(2,1)
MARKER PROTEIN(2,1)
MEMBRANE FILTER(2,1)
MIXED VACCINE(2,1)
MONOCLONAL ANTIBODY PREPARATION(2,1)
MURAMYL DIPEPTIDE(2,1)
NATURAL MUTATION(2,1)
NUCLEIC ACID DELETION(2,1)
PACKAGING EXTRACT(2,1)
PARASITE CARRIER(2,1)
PGEM VECTOR(2,1)
PLASMID DNA(2,1)
POSITIVE PARASITEMIA(2,1)
POVIDONE(2,1)
PREHYBRIDIZATION SOLUTION(2,1)
PRIMER BD(2,1)
PROTECTIVE ACTIVITY(2,1)
PROTEIN BASIS(2,1)
PROTEIN IMMUNOLOGICALLY IMPORTANT REGION(2,1)
PROTEIN REACTION(2,1)
PROTEIN REGION(2,1)
RECOMBINANT DNA MOLECULE MIXTURE(2,1)
RECOMBINANT DNA PRODUCTION(2,1)
RECOMBINANT PROTEIN DOSE(2,1)
RECOMBINANT PROTEIN QUANTITY(2,1)
RELEVANT ANTIGEN(2,1)
REPEATED ADMINISTRATION(2,1)
SAPONIN GROUP(2,1)
SCORE ANALYSIS(2,1)
SENSITIVE PROTEIN COMPARISON(2,1)
SEVERE ECONOMICAL LOSS(2,1)
SF9 CELL INFECTION(2,1)
SHELF LIFE(2,1)
SILENT MODIFICATION(2,1)
SPIN COLUMN(2,1)
STERILE PHYSIOLOGICAL SALT SOLUTION(2,1)
STRONG HUMORAL RESPONSE(2,1)
TE BUFFER(2,1)
TERMINATION SEQUENCE(2,1)
THEILERIA PARVA(2,1)
TRANSFORMATION REACTION(2,1)
UNVACCINATED GROUP(2,1)
VIRUS VECTOR(2,1)
WHITE COLONY(2,1)
WHOLE POLYPEPTIDE(2,1)
YEAST CELL(2,1)
YEAST EXTRACT(2,1)
DILUTION(1,3)
IPTG(1,3)
PARASITE SURFACE(1,3)
SYNERGISTIC EFFECT(1,3)
ECACC(1,2)
FLASK(1,2)
ACTIVE SUBSTANCE(1,1)
AGAR PLATE(1,1)
AMIDATION(1,1)
AMINOACID LEUCINE(1,1)
AMINOACID SUBSTITUTION(1,1)
AMPICILLIN(1,1)
AMYLASE(1,1)
ANEMIA(1,1)
ANTIBODY SOURCE(1,1)
ANTISERA(1,1)
BACTERIOLOGY(1,1)
BACTERIOPHAGE(1,1)
BACTOTRYPTONE(1,1)";"Analysis of biological materials
Pharmaceuticals";Open
1999-02-02;"CA2297507           A1 2000-08-02 [CA2297507]
STG: (A1) Application laid open
AP : 2000CA-2297507 2000-01-31";4023085;CA2297507           A1 2000-08-02 [CA2297507];1999EP-0200304;;AKZO NOBEL;AKZO NOBEL;"(CA2297507)
NL";"(CA2297507)
NAME=AKZO NOBEL NV Velperweg 76 NL-6824 BM , CITY=ARNHEM , COUNTRY=NL 
";1;KEIL GUNTHER MICHAEL;"(CA2297507)
DE";"(CA2297507)
NAME=KEIL, GUNTHER MICHAEL , COUNTRY=DE 
";"(CA2297507)
Synthetic gene of bovine viral diarrhoea virus";"(CA2297507)
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpesvirus recombinants carrying such genes, Bovine Herpesvirus recombinant virus particles carrying the proteins encoded by such genes, vaccines based on these recombinants, methods for the preparation of such recombinants and methods for the preparation of such vaccines and to diagnostic tools.";"(CA2297507)
1. Synthetic BVDV-gene, characterised in that said BVDV-gene has a not naturally occurring nucleotide sequence encoding a naturally occurring amino acid sequence.
2. Synthetic BVDV-gene according to claim 1, characterised in that said BVDVgene encodes the BVDV E2 protein.
3. Synthetic BVDV-gene according to claim 1 or 2, characterised in that in said BVDV-gene at least one naturally occurring putative splice-donor- or -acceptor site is removed.
4. Synthetic BVDV-gene according to claim 2 or 3, characterised in that said BVDV gene has a GC-content between 48 and 60 %, preferably between 48 and 50% %.
5. Synthetic BVDV-gene according to claim 4, characterised in that said BVDV gene has a GC-content of approximately 48 %.
6. Synthetic BVDV-gene according to claim 2, characterised in that said BVDV gene has the nucleic acid sequence presented in the overview of replacements in the sequence of SEQ ID NO: 14.
7. Synthetic BVDV-gene according to claims 1 to 6, characterised in that said BVDV gene is under the control of the MCMVie1-promoter, the MCMVe1-promoter, the HCMVie1-promoter or the BHV gE-promoter.
8. Live attenuated recombinant BHV carrier virus, characterised in that it carries a synthetic BVDV-gene according to claims 1 to 7.
9. Live attenuated recombinant BHV carrier virus according to claim 8, characterised in that said BHV-recombinant is a BHV-1 recombinant. 45
10. Live attenuated recombinant BHV carrier virus according to claim 9, characterised in that the synthetic BVDV-gene is inserted in the gE-gene of said BHV recombinant.
11. Live attenuated recombinant BHV carrier virus according to claim 9, characterised in that the synthetic BVDV-gene is inserted in the gl-gene of said BHV recombinant.
12. Live attenuated recombinant BHV carrier virus according to claims 8 to 11, characterised in that it comprises an additional gene encoding an antigen from a micro-organism or virus that is pathogenic for cattle.
13. Live attenuated recombinant BHV carrier virus according to claim 12, characterised in that the gene is chosen from the group of cattle pathogens, consisting of Bovine Rotavirus, Bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, Bovine Respiratory Syncytium virus and Pasteurella haemolytica.
14. Inactivated Recombinant BHV carrier virus particle, characterised in that it carries the BVDV E2 glycoprotein on its surface.
15. Vaccine for the protection of cattle against virus infection, characterised in that said vaccine comprises a live attenuated recombinant BHV carrier virus according to claims 8 to 13 and/or the DNA thereof and/or a BHV-recombinant virus particle according to claim 14 and a pharmaceutically acceptable carrier.
16. Vaccine according to claim 15, characterised in that it is formulated for intranasal administration.
17. Method for the preparation of a vaccine according to claim 15 or 16, characterised in that said method comprises the admixing of a live attenuated BHV-recombinant according to claims 8 to 13 and/or the DNA thereof and/or a BHV-recombinant virus particle according to claim 14 and a pharmaceutically acceptable carrier.
18. Method for the preparation of a live attenuated BHV-recombinant according to claims 8 to 13, said method comprising bringing together in a suitable host cell isolated BHVDNA and a 46 vector comprising the synthetic BVDV-gene, placed under the control of a suitable promoter and flanked by 3' and 5' flanking regions that share homology with BHV-sequences.
19. Method for the preparation of a live attenuated BHV-recombinant according to claims 8 to 13, said method comprising bringing into a suitable host cell a vector comprising the synthetic BVDV-gene, placed under the control of a suitable promoter and flanked by 3' and 5' flanking regions that share homology with BHV-sequences, followed by infection of said suitable host cell with BHV.
20. Diagnostic test for the discrimination between sera from cattle infected with BVDV field strains and cattle vaccinated with a vaccine according to claim 15 or 16, said test being characterised in that the test comprises purified BVDV E2 protein. 21 Use of inactivated BHV carrier viruses according to the invention for the manufacture of vaccines for booster vaccination against BVDV-infection.";"(CA2297507)
Thus the invention relates to vaccines suitable for booster vaccination that comprise inactivated BHV carrier viruses according to the invention.
Moreover, the invention relates to the use of inactivated BHV carrier viruses according to the invention for the manufacture of vaccines for booster vaccination against BVDV-infection.
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpes virus recombinants, live attenuated and inactivated Bovine Herpes virus recombinants carrying such genes, vaccines based on these live attenuated recombinants, methods for the preparation of such live attenuated recombinants and to methods for the preparation of such vaccines.
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpes virus recombinants, live attenuated and inactivated Bovine Herpes virus recombinants carrying such genes, vaccines based on these live attenuated recombinants, methods for the preparation of such live attenuated recombinants and to methods for the preparation of such vaccines.
Therefore, in a preferred form, the present invention provides live attenuated recombinant BHV carrier viruses comprising, next to a BVDV-gene, a gene encoding an antigen from microorganisms or viruses that are pathogenic for cattle.";"(CA2297507)
Promising live recombinant vector virus candidates however would be the live attenuated bovine herpesviruses (BHV), since such bovine herpesviruses, if expressing the BVDV E2-gene, would have the following advantages: they are host-specific: they only infect bovine species
Thus there is a clear need for improved, efficacious vaccines against BVDV.
Since BVDV-infection leads to high economic losses, there is a substantial need for vaccines against BVDV.
BVD is an acute postnatal infection in seronegative immunocompetent cattle.
Acute BVDV infection enhances clinical diseases caused by other pathogens and is an important component of the bovine respiratory disease complex.
The failure to respond to BVDV infection until around day 125 of gestation can result in embryonic death, resorption, and stillbirths or, more frequently, in a whole array of non fatal teratogenic effects
Two main problems are known to exist when genes of a cytoplasmatically replicating virus are expressed in the nucleus, which is an evident consequence of cloning into the genome of a virus that replicates in the nucleus, e.g.
main problems";"A61K-039/12
C12N-007/01
C12N-015/33
C12N-015/86
C12Q-001/70
G01N-033/569";"(CA2297507)
1. Synthetic BVDV-gene, characterised in that said BVDV-gene has a not naturally occurring nucleotide sequence encoding a naturally occurring amino acid sequence.
14. Inactivated Recombinant BHV carrier virus particle, characterised in that it carries the BVDV E2 glycoprotein on its surface.";"(CA2297507)
BOVINE VIRAL DIARRHEA VIRUS(100,142)
GENE(100,74)
SYNTHETIC(100,22)
VIRUS PARTICLE(100,5)
SYNTHETIC GENE(100,4)
BOVINE HERPES VIRUS RECOMBINANT(100,3)
RECOMBINANT BHV CARRIER(100,3)
RECOMBINANT BHV CARRIER VIRUS(95,10)
SERONEGATIVE IMMUNOCOMPETENT CATTLE(87,1)
SYNTHETIC BOVINE VIRAL DIARRHEA(84,2)
LIVE ATTENUATED RECOMBINANT(74,1)
BOOSTER VACCINATION(72,3)
INACTIVATED BHV CARRIER VIRUS(71,2)
LIVE ATTENUATED RECOMBINANT PREPARATION(68,1)
RECOMBINANT VECTOR VIRUS CANDIDATE(64,1)
BOVINE HERPES VIRUS(63,4)
ACUTE POSTNATAL INFECTION(61,1)
BOVINE RESPIRATORY SYNCYTIUM VIRUS(58,1)
ACUTE BVDV INFECTION(55,1)
BHV RECOMBINANT VIRUS PARTICLE(48,2)
EFFICACIOUS VACCINE(46,1)
NUCLEOTIDE SEQUENCE(44,1)
VIRUS GENOME(42,1)
VACCINE PREPARATION(41,6)
BVDV INFECTION(41,1)
EMBRYONIC DEATH(40,1)
VIRUS GENE(39,3)
VACCINE MANUFACTURE(38,2)
VACCINE(35,19)
BHV CARRIER VIRUS(34,2)
CLINICAL DISEASE(33,1)
BOVINE PARAMYXOVIRUS(32,1)
BOVINE SPECIES(31,1)
BOVINE ROTAVIRUS(30,1)
VIRUS REPLICATION(29,4)
ECONOMIC LOSS(27,1)
HOST CELL(25,7)
CATTLE PATHOGEN GROUP(24,1)
MISC DIFFERENCE(23,48)
STILLBIRTH(22,1)
INFECTION(21,13)
FLANKING REGION(21,3)
REPLACEMENT OVERVIEW(20,3)
CATTLE PROTECTION(20,2)
DIAGNOSTIC TOOL(20,1)
GESTATION(20,1)
RESORPTION(20,1)
NUCLEUS(19,7)
WHOLE ARRAY(19,1)
PASTEURELLA HAEMOLYTICA(18,1)
NUCLEOTIDE AGCT(17,8)
HOMOLOGY(16,3)
GLYCOPROTEIN(15,12)
PATHOGEN(15,4)
BVD(14,1)
NON FATAL TERATOGENIC EFFECT(13,1)
DISCRIMINATION(12,3)
ADMIXING(12,2)
INTRANASAL ADMINISTRATION(12,2)
LIVE RECOMBINANT VECTOR VIRUS(12,2)
MCMV EL PROMOTER(12,2)
MICROORGANISM(12,2)
BHVDNA(12,1)
IMMUNOCOMPETENT CATTLE POSTNATAL EXPOSURE(12,1)
MCMVIE CONTROL(12,1)
HCMV IE(11,4)
BHV DRAMATIC MANIFESTATION(11,1)
BOVINE RESPIRATORY DISEASE COMPLEX(11,1)
FRAGMENT INTEGRATION(10,4)
MCMVE(10,4)
HOMOLOGOUS RECOMBINATION(10,3)
AMINO ACID SEQUENCE(9,7)
BOOSTER IMMUNIZATION(9,2)
MCMV IEL PROMOTER(9,1)
MCMV PROMOTER IEL(9,1)
INDICATED SEQUENCE(8,24)
GENETIC CODE DEGENERACY(8,4)
BHV GE PROMOTER(8,3)
PLASMID PNH(8,3)
VACCINE STRAIN(8,3)
VIRAL PROTEIN(8,3)
BHV INCORPORATION(8,2)
CLEAVING PSP(8,2)
E2SYN VIRION(8,2)
KLENOW POLYMERASE(8,2)
RECOMBINANT VIRION(8,2)
BOVINE VIRAL DIARRHEA(8,1)
CATTLE TRANSMISSIBLE DISEASE(8,1)
GENOTYPICALLY GD POSITIVE VIRION(8,1)
OMBINANT BHV CARRIER VIRUS(8,1)
VIROLOGY INTERNATIONAL CONGRESS(8,1)
WESTERN BLOT INCUBATION(8,1)
SERA(7,3)
INFECTED CALF(7,2)
PLASMID PCF(7,2)
PURIFIED VIRION(7,2)
RECOMBINANT CARRIER VIRUS(7,2)
SYNTHETIC DNA FRAGMENT(7,2)
ATTENUATED CARRIER BHV VIRUS(7,1)
BACULOVIRUS EXPRESSED GLYCOPROTEIN(7,1)
BHVRECOMBINANT VIRUS PARTICLE(7,1)
CONCYTOPATHIC BIOTYPE(7,1)
LIVE RECOMBINANT VIRUS(7,1)
PARAINFLUENZA TYPE(7,1)
PSEUDORABIES TKPROMOTER(7,1)
THYMIDINE KINASE GENE(7,1)
NAME KEY(6,53)
VACCINATION(6,6)
CSFV STRAIN(6,2)
KB FRAGMENT(6,2)
RABBIT SERUM(6,2)
BAMHL RESTRICTION SITE(6,1)
BHV CHARACTERIZATION(6,1)
BHV ENVELOPE PROTEIN(6,1)
BHV VIRUS PARTICLE(6,1)
BHV VSIS(6,1)
BRSV GLYCOPROTEIN(6,1)
COMPELEMTARY STRAND(6,1)
DNA NUCLEOTIDE(6,1)
EMBL GENE BANK(6,1)
ENCODING TRIPLET(6,1)
FOREIGN DNA INTEGRATION(6,1)
GENE ENCODING ANTIGEN(6,1)
HERPES VIRUS NOMENCLATURE(6,1)
HOST MAMMAL SERUM(6,1)
IMMUNOGENIC PROTEIN(6,1)
INFECTED MDBK CELL(6,1)
INTRACUTANE ADMINISTRATION(6,1)
ISOLATED MCMV EL(6,1)
LIVE VACCINE PREPARATION(6,1)
MAMMALIAN CELL NUCLEUS(6,1)
MINIMAL MUCOSAL LESION(6,1)
NATURALLY ACQUIRED BVD(6,1)
NONESSENTIAL GENE(6,1)
NUCLECTIDE TOGA(6,1)
NUCLEOTIDE CATG(6,1)
NUCLEOTIDE TOGA(6,1)
PLASMID PROMESIG(6,1)
PLASMID PSPE2SYN(6,1)
PURIFIED BAMHL XHOL INSERT(6,1)
RECOMBINANT VACCINIA(6,1)
RESTRICTION ENZYME CLEAVAGE SITE(6,1)
STRESSOR INTERPLAY(6,1)
TRANSIENT LEUKOPENIA(6,1)
VACCINIA VIRUS VECTOR(6,1)
VCOMPLEMENTARY STRAND(6,1)
VECTOR VIRUS GENE(6,1)
VIRUS MATURATION(6,1)
VIRUS PARTICLE DOSE(6,1)
DIAGNOSTIC TEST(5,4)
MISC FEATURE(5,3)
ANTIGEN INCORPORATION(5,1)
ANTIGENIC VARIANT(5,1)
BHV RECOMBINANT VIRUS(5,1)
BOVINE ANIMAL PROTECTION(5,1)
BOVINE KIDNEY CELL(5,1)
BOVINE PATHOGEN(5,1)
CLINICAL BVD(5,1)
DELETION MUTANT(5,1)
GD POLYA FRAGMENT(5,1)
HERPESSPECIFIC TARGETING SIGNAL(5,1)
IMMUNE MODULATOR(5,1)
LACZ EXPRESSION(5,1)
LACZ GENE EXPRESSION(5,1)
NATURAL INFECTION ROUTE(5,1)
NUCLEAR RNASPLICING(5,1)
PC DOS MS DOS(5,1)
PLASMID PCA(5,1)
PLASMID PCB(5,1)
PREFERENCE VECTOR(5,1)
PROMI MAP(5,1)
SDSPOLYACRYLAMIDE GEL(5,1)
STRAIN SCHONBOKEN INFECTED CELL(5,1)
SYNTHETIC GCCONTENT(5,1)
UNEXPECTED INCORPORATION(5,1)
VACCINE DOSAGE(5,1)
VIABLE BHV(5,1)
VIRAL REPLICATION(5,1)
VIRUS STRAIN(5,1)
VIRUS VACCINE(5,1)
STICKY END(4,24)
LANE(4,8)
IMMUNITY(4,3)
INACTIVATED VACCINE(4,3)
MORBIDITY(4,3)
AGAROSE GEL(4,2)
CDNA SEQUENCE(4,2)
LYSED CELL(4,2)
PHYSIOLOGICAL SALT SOLUTION(4,2)
PROTECTIVE IMMUNE RESPONSE(4,2)
WHOLE GENE(4,2)
ADJUVANT ACTIVITY(4,1)
AFFECTED CATTLE(4,1)
AGGU CONSENSUS SEQUENCE(4,1)
BHV GC CONTENT(4,1)
BOVINE HERPES VIRUS INFECTION(4,1)
CARRIED GENE HETEROLOGOUS PROTEIN(4,1)
COMPARABLE INFECTION(4,1)
CORRESPONDENCE ADDRESS(4,1)
CPE DEVELOPMENT(4,1)
DNA MANIPULATION(4,1)
ENCODED PROTEIN(4,1)
EXPRESSION VECTOR POTENTIAL(4,1)
FOREIGN GENE(4,1)
GALACTOSIDASE SEQUENCE(4,1)
GENE CODING(4,1)
HERPES SIMPLE VIRUS(4,1)
HETEROLOGOUS GENE PRODUCT(4,1)
INFECTED ANIMAL(4,1)
ISOLATED VIRION(4,1)
LABOR INTENSIVE TASK(4,1)
LATE PROMOTER(4,1)
MAMMALIAN SPECIES(4,1)
MILD RESPIRATORY DISEASE(4,1)
MURINE CYTOMEGALOVIRUS SEQUENCE(4,1)
NAKED DNA(4,1)
NATIVE PROTEIN(4,1)
NITROCELLULOSE FILTER(4,1)
POTENTIAL SPLICE SITE(4,1)
PROTEIN EXPRESSION(4,1)
PROTEIN GENE(4,1)
SDS POLYACRYLAMIDE GEL(4,1)
SEVERE INFECTION(4,1)
SPLICE CONSENSUS SEQUENCE(4,1)
SPLICE DONOR SEQUENCE REMOVAL(4,1)
SYNTHETIC BRSV(4,1)
SYNTHETIC OLIGONUCLEOTIDE(4,1)
VACCINATING ANIMAL(4,1)
VACCINE DEVELOPMENT(4,1)
VACCINE VECTOR(4,1)
MOLECULE TYPE(3,16)
CYTOKINE(3,2)
CYTOPLASM(3,2)
FLUOROGRAPHY(3,2)
FRAMEWORK(3,2)
HERD(3,2)
MOUSE CYTOMEGALOVIRUS(3,2)
NUCLEIC ACID SEQUENCE ENCODING(3,2)
PESTIVIRUS SIGNAL SEQUENCE(3,2)
POLYLINKER(3,2)
RECEIVED FRAGMENT(3,2)
RESPIRATORY TRACT(3,2)
AKZO NOVEL(3,1)
ANTI GD SERUM(3,1)
ANTIBODY PRESENCE(3,1)
BOVINE EMBRYONIC CELL(3,1)
CELL CULTURE SUPERNATANT(3,1)
CELL PROTEIN(3,1)
CHANGED CODON(3,1)
CHARACTERERIZATION(3,1)
CHOICE CARRIER(3,1)
CLINICAL MANIFESTATION RANGE(3,1)
CLINICAL PATTERN(3,1)
COMMON MANIFESTATION(3,1)
CORRECT TRANSPORT(3,1)
CRYPTICAL SPLICE SIGNAL PRESENCE(3,1)
DNA SYNTHESIS(3,1)
DOHERTY ML(3,1)
DONOR CONSENSUS SEQUENCE(3,1)
ECONOMICAL LOSS(3,1)
ELISA TEST(3,1)
EMULSIFIER(3,1)
ENCODING GENE PRODUCT(3,1)
FILING DATE(3,1)
GENETIC INFORMATION(3,1)
IBM PC(3,1)
INSERTING SYNTHETIC(3,1)
INTEGRATION SITE(3,1)
MUCOSAL FLUID(3,1)
NATIVE GC CONTENT(3,1)
NUCLEOTIDE SEQUENCE COMPARISON(3,1)";"Analysis of biological materials
Pharmaceuticals";Open
"1999-02-02
2000-01-27
2000-04-26";"EP1026252           A1 2000-08-09 [EP1026252]
STG: (A1) Application published with search report
AP : 2000EP-0200281 2000-01-27
CA2304991           A1 2001-10-26 [CA2304991]
STG: (A1) Application laid open
AP : 2000CA-2304991 2000-04-26";4034934;"EP1026252           A1 2000-08-09 [EP1026252]
CA2304991           A1 2001-10-26 [CA2304991]";"1999EP-0200304
2000CA-2304991
2000EP-0200281";;AKZO NOBEL;AKZO NOBEL;"(EP1026252)
NL
(CA2304991)
NL";"(EP1026252)
NAME=Akzo Nobel N.V. Velperweg 76 , CITY=6824 BM  Arnhem , COUNTRY=NL 

(CA2304991)
NAME=AKZO NOBEL NV Velperweg 76 NL-6824 BM , CITY=ARNHEM , COUNTRY=NL 
";1;GUNTHER MICHAEL;"(EP1026252)
DE";"(EP1026252)
NAME=Keil, Gunther Michael Boddenblick 9b 17498 Insel Riems , COUNTRY=DE 
";"(EP1026252)
Synthetic gene of bovine viral diarrhoea virus";"(EP1026252)
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpesvirus recombinants carrying such genes, Bovine Herpesvirus recombinant virus particles carrying the proteins encoded by such genes, vaccines based on these recombinants, methods for the preparation of such recombinants and methods for the preparation of such vaccines and to diagnostic tools.";"(EP1026252)
1. Synthetic BVDV-gene, characterised in that said BVDV-gene has a not naturally occurring nucleotide sequence encoding a naturally occurring amino acid sequence.
2. Synthetic BVDV-gene according to claim 1, characterised in that said BVDV-gene encodes the BVDV E2 protein.
3. Synthetic BVDV-gene according to claim 1 or 2, characterised in that in said BVDV-gene at least one naturally occurring putative splice-donor- or -acceptor site is removed.
4. Synthetic BVDV-gene according to claim 2 or 3, characterised in that said BVDV gene has a GC-content between 48 and 60 %, preferably between 48 and 50% %.
5. Synthetic BVDV-gene according to claim 4, characterised in that said BVDV gene has a GC-content of approximately 48 %.
6. Synthetic BVDV-gene according to claim 2, characterised in that said BVDV gene has the nucleic acid sequence presented in the overview of replacements in the sequence of SEQ ID NO: 14.
7. Synthetic BVDV-gene according to claims 1 to 6, characterised in that said BVDV gene is under the control of the MCMVie1-promoter, the MCMVe1-promoter, the HCMVie1-promoter or the BHV gE-promoter.
8. Live attenuated recombinant BHV carrier virus, characterised in that it carries a synthetic BVDV-gene according to claims 1 to 7.
9. Live attenuated recombinant BHV carrier virus according to claim 8, characterised in that said BHV-recombinant is a BHV-1 recombinant.
10. Live attenuated recombinant BHV carrier virus according to claim 9, characterised in that the synthetic BVDV-gene is inserted in the gE-gene of said BHV recombinant.
11. Live attenuated recombinant BHV carrier virus according to claim 9, characterised in that the synthetic BVDV-gene is inserted in the gI-gene of said BHV recombinant.
12. Live attenuated recombinant BHV carrier virus according to claims 8 to 11, characterised in that it comprises an additional gene encoding an antigen from a micro-organism or virus that is pathogenic for cattle.
13. Live attenuated recombinant BHV carrier virus according to claim 12, characterised in that the gene is chosen from the group of cattle pathogens, consisting of Bovine Rotavirus, Bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, Bovine Respiratory Syncytium virus and Pasteurella haemolytica.
14. Inactivated Recombinant BHV carrier virus particle, characterised in that it carries the BVDV E2 glycoprotein on its surface.
15. Vaccine for the protection of cattle against virus infection, characterised in that said vaccine comprises a live attenuated recombinant BHV carrier virus according to claims 8 to 13 and/or the DNA thereof and/or a BHV-recombinant virus particle according to claim 14 and a pharmaceutically acceptable carrier.
16. Vaccine according to claim 15, characterised in that it is formulated for intranasal administration.
17. Method for the preparation of a vaccine according to claim 15 or 16, characterised in that said method comprises the admixing of a live attenuated BHV-recombinant according to claims 8 to 13 and/or the DNA thereof and/or a BHV-recombinant virus particle according to claim 14 and a pharmaceutically acceptable carrier.
18. Method for the preparation of a live attenuated BHV-recombinant according to claims 8 to 13, said method comprising bringing together in a suitable host cell isolated BHV-DNA and a vector comprising the synthetic BVDV-gene, placed under the control of a suitable promoter and flanked by 3' and 5' flanking regions that share homology with BHV-sequences.
19. Method for the preparation of a live attenuated BHV-recombinant according to claims 8 to 13, said method comprising bringing into a suitable host cell a vector comprising the synthetic BVDV-gene, placed under the control of a suitable promoter and flanked by 3' and 5' flanking regions that share homology with BHV-sequences, followed by infection of said suitable host cell with BHV.
20. Diagnostic test for the discrimination between sera from cattle infected with BVDV field strains and cattle vaccinated with a vaccine according to claim 15 or 16, said test being characterised in that the test comprises purified BVDV E2 protein.
21. Use of inactivated BHV carrier viruses according to the invention for the manufacture of vaccines for booster vaccination against BVDV-infection.";"(EP1026252)
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpes virus recombinants, live attenuated and inactivated Bovine Herpes virus recombinants carrying such genes, vaccines based on these live attenuated recombinants, methods for the preparation of such live attenuated recombinants and to methods for the preparation of such vaccines.
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpes virus recombinants carrying such genes, Bovine Herpes virus recombinant virus particles carrying the proteins encoded by such genes, vaccines based on these recombinants, methods for the preparation of such recombinants and methods for the preparation of such vaccines and to diagnostic tools.
Therefore, in a preferred form, the present invention provides live attenuated recombinant BHV carrier viruses comprising, next to a BVDV-gene, a gene encoding an antigen from microorganisms or viruses that are pathogenic for cattle.
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpes virus recombinants carrying such genes, Bovine Herpes virus recombinant virus particles carrying the proteins encoded by such genes, vaccines based on these recombinants, methods for the preparation of such recombinants and methods for the preparation of such vaccines and to diagnostic tools.
The present invention refers to synthetic Bovine Viral Diarrhoea virus genes, live attenuated Bovine Herpes virus recombinants, live attenuated and inactivated Bovine Herpes virus recombinants carrying such genes, vaccines based on these live attenuated recombinants, methods for the preparation of such live attenuated recombinants and to methods for the preparation of such vaccines.";"(EP1026252)
Thus there is a clear need for improved, efficacious vaccines against BVDV.
Since BVDV-infection leads to high economic losses, there is a substantial need for vaccines against BVDV.
Promising live recombinant vector virus candidates however would be the live attenuated bovine herpesviruses (BHV), since such bovine herpesviruses, if expressing the BVDV E2-gene, would have the following advantages: they are host-specific: they only infect bovine species; they protect against two different diseases: Bovine herpes virus infection and BVDV-infection.
The failure to respond to BVDV infection until around day 125 of gestation can result in embryonic death, resorption, and stillbirths or, more frequently, in a whole array of non fatal teratogenic effects (H.
Two main problems are known to exist when genes of a cytoplasmatically replicating virus are expressed in the nucleus, which is an evident consequence of cloning into the genome of a virus that replicates in the nucleus, e.g.
BVD is an acute postnatal infection in sero negative immunocompetent cattle.
Acute BVDV infection enhances clinical diseases caused by other pathogens and is an important component of the bovine respiratory disease complex.";"A61P-031/12
C07K-014/18
C12N-015/40";"(EP1026252)
1. Synthetic BVDV-gene, characterised in that said BVDV-gene has a not naturally occurring nucleotide sequence encoding a naturally occurring amino acid sequence.
14. Inactivated Recombinant BHV carrier virus particle, characterised in that it carries the BVDV E2 glycoprotein on its surface.
21. Use of inactivated BHV carrier viruses according to the invention for the manufacture of vaccines for booster vaccination against BVDV-infection.";"(EP1026252)
BOVINE VIRAL DIARRHEA VIRUS(100,117)
BOVINE HERPES VIRUS RECOMBINANT(100,3)
SYNTHETIC GENE(100,3)
SYNTHETIC BOVINE VIRAL DIARRHEA(92,2)
LIVE ATTENUATED RECOMBINANT(85,2)
BOVINE HERPES VIRUS(62,4)
SERONEGATIVE IMMUNOCOMPETENT CATTLE(62,1)
RECOMBINANT VECTOR VIRUS CANDIDATE(55,1)
ACUTE POSTNATAL INFECTION(51,1)
BOVINE RESPIRATORY SYNCYTIUM VIRUS(50,1)
RECOMBINANT VIRUS PARTICLE(49,1)
ACUTE BVDV INFECTION(47,1)
VACCINE PREPARATION(44,5)
VIRUS GENE(42,3)
CARRIER VIRUS(40,15)
EFFICACIOUS VACCINE(39,1)
GENE(38,71)
NUCLEOTIDE SEQUENCE(38,1)
BHV RECOMBINANT VIRUS PARTICLE(37,3)
EMBRYONIC DEATH(34,1)
RECOMBINANT PREPARATION(34,1)
BOOSTER VACCINATION(33,3)
DIAGNOSTIC TOOL(31,1)
BOVINE HERPES VIRUS INFECTION(30,1)
VACCINE(29,17)
BOVINE PARAMYXOVIRUS(28,1)
CLINICAL DISEASE(28,1)
BOVINE SPECIES(27,1)
CARRIER VIRUS PARTICLE(26,2)
VACCINE MANUFACTURE(26,2)
BOVINE ROTAVIRUS(25,1)
INFECTION(24,13)
PARAINFLUENZA(24,1)
ECONOMIC LOSS(23,1)
RECOMBINANT(23,1)
HOST CELL(21,7)
BHV SEQUENCE(21,3)
CATTLE PATHOGEN GROUP(21,1)
CATTLE PROTECTION(21,1)
STILLBIRTH(19,1)
FLANKING REGION(18,3)
REPLACEMENT OVERVIEW(18,2)
GI GENE(17,2)
GESTATION(17,1)
RESORPTION(17,1)
WHOLE ARRAY(17,1)
BHV DNA(16,2)
PASTEURELLA HAEMOLYTICA(16,1)
PROTEIN(14,28)
HOMOLOGY(14,3)
GLYCOPROTEIN(13,12)
PATHOGEN(12,4)
BVD(12,1)
DISEASE(11,4)
STRAIN SCH NB KEN(11,4)
DISCRIMINATION(11,2)
NON FATAL TERATOGENIC EFFECT(11,1)
ADMIXING(10,2)
INTRANASAL ADMINISTRATION(10,2)
LIVE RECOMBINANT VECTOR VIRUS(10,2)
MICROORGANISM(10,2)
IMMUNOCOMPETENT CATTLE POSTNATAL EXPOSURE(10,1)
MCMVIE CONTROL(10,1)
HCMV IE(9,4)
MCMVE(9,4)
BOVINE RESPIRATORY DISEASE COMPLEX(9,1)
AMINOACID SEQUENCE(8,7)
HOMOLOGOUS RECOMBINATION(8,3)
VIRUS REPLICATION(8,3)
BOOSTER IMMUNIZATION(8,2)
NONESSENTIAL BHV GENE(8,1)
GENETIC CODE DEGENERACY(7,4)
BHV GE PROMOTER(7,3)
FRAGMENT INTEGRATION(7,3)
PLASMID PNH(7,3)
VACCINE STRAIN(7,3)
VIRAL PROTEIN(7,3)
CLEAVING PSP(7,2)
KLENOW POLYMERASE(7,2)
RECOMBINANT VIRION(7,2)
SDS POLYACRYLAMIDE GEL(7,2)
SERA(7,2)
BOVINE VIRAL DIARRHEA(7,1)
CATTLE TRANSMISSIBLE DISEASE(7,1)
GENOTYPICALLY GD POSITIVE VIRION(7,1)
RECOMBINANT BHV VIRUS(7,1)
VIROLOGY INTERNATIONAL CONGRESS(7,1)
WESTERN BLOT INCUBATION(7,1)
INFECTED CALF(6,2)
PLASMID PCF(6,2)
PURIFIED VIRION(6,2)
RECOMBINANT CARRIER VIRUS(6,2)
SYN VIRION(6,2)
SYNTHETIC DNA FRAGMENT(6,2)
BACULOVIRUS EXPRESSED GLYCOPROTEIN(6,1)
CONCYTOPATHIC BIOTYPE(6,1)
LIVE RECOMBINANT VIRUS(6,1)
THYMIDINE KINASE GENE(6,1)
VACCINATION(5,6)
DIAGNOSTIC TEST(5,3)
KB FRAGMENT(5,2)
RABBIT SERUM(5,2)
BAMHI RESTRICTION SITE(5,1)
DNA NUCLEOTIDE(5,1)
DRAMATIC MANIFESTATION(5,1)
ENCODING TRIPLET(5,1)
FOREIGN DNA INTEGRATION(5,1)
GENE ENCODING ANTIGEN(5,1)
HERPES VIRUS NOMENCLATURE(5,1)
HOST MAMMAL SERUM(5,1)
IMMUNOGENIC PROTEIN(5,1)
INTRACUTANE ADMINISTRATION(5,1)
LIVE VACCINE PREPARATION(5,1)
MAMMALIAN CELL NUCLEUS(5,1)
MINIMAL MUCOSAL LESION(5,1)
NATURALLY ACQUIRED BVD(5,1)
NONESSENTIAL GENE(5,1)
PLASMID PROMESIG(5,1)
RECOMBINANT VACCINIA(5,1)
RESTRICTION ENZYME CLEAVAGE SITE(5,1)
STRESSOR INTERPLAY(5,1)
TRANSIENT LEUKOPENIA(5,1)
VACCINIA VIRUS VECTOR(5,1)
VECTOR VIRUS GENE(5,1)
VIRUS MATURATION(5,1)
VIRUS PARTICLE DOSE(5,1)
LANE(4,8)
AGAROSE GEL(4,2)
INFECTED CELL(4,2)
LYSED CELL(4,2)
PHYSIOLOGICAL SALT SOLUTION(4,2)
PROTECTIVE IMMUNE RESPONSE(4,2)
PSEUDORABIES(4,2)
WHOLE GENE(4,2)
ANTIGEN INCORPORATION(4,1)
ANTIGENIC VARIANT(4,1)
BHV INFECTION(4,1)
BHV RECOMBINANT VIRUS(4,1)
BOVINE ANIMAL PROTECTION(4,1)
BOVINE KIDNEY CELL(4,1)
BOVINE PATHOGEN(4,1)
BVDV INFECTION(4,1)
CLINICAL BVD(4,1)
DELETION MUTANT(4,1)
GD POLYA FRAGMENT(4,1)
HERPESSPECIFIC TARGETING SIGNAL(4,1)
IMMUNE MODULATOR(4,1)
LACZ EXPRESSION(4,1)
LACZ GENE EXPRESSION(4,1)
NATURAL INFECTION ROUTE(4,1)
PLASMID PAMB(4,1)
PLASMID PCA(4,1)
PLASMID PCB(4,1)
PLASMID PSPE(4,1)
PREFERENCE VECTOR(4,1)
PROMI MAP(4,1)
PURIFIED BAMHI XHOI INSERT(4,1)
TK PROMOTER(4,1)
UNEXPECTED INCORPORATION(4,1)
VACCINE DOSAGE(4,1)
VIRAL REPLICATION(4,1)
VIRUS STRAIN(4,1)
VIRUS VACCINE(4,1)
BGLII(3,6)
HINDIII(3,3)
IMMUNITY(3,3)
INACTIVATED VACCINE(3,3)
MORBIDITY(3,3)
CYTOKINE(3,2)
CYTOPLASM(3,2)
FLUOROGRAPHY(3,2)
FRAMEWORK(3,2)
HERD(3,2)
MOUSE CYTOMEGALOVIRUS(3,2)
NUCLEIC ACID SEQUENCE ENCODING(3,2)
POLYLINKER(3,2)
RESPIRATORY TRACT(3,2)
ADJUVANT ACTIVITY(3,1)
AFFECTED CATTLE(3,1)
CARRIED GENE HETEROLOGOUS PROTEIN(3,1)
COMPARABLE INFECTION(3,1)
DNA MANIPULATION(3,1)
ENCODED PROTEIN(3,1)
ENCODING GENE PRODUCT PROTEIN(3,1)
ENVELOPE PROTEIN(3,1)
FOREIGN GENE(3,1)
GALACTOSIDASE SEQUENCE(3,1)
GENE CODING(3,1)
GENEBANK(3,1)
HERPES SIMPLE VIRUS(3,1)
HETEROLOGOUS GENE PRODUCT(3,1)
INFECTED ANIMAL(3,1)
ISOLATED VIRION(3,1)
LABOR INTENSIVE TASK(3,1)
LATE PROMOTER(3,1)
MAMMALIAN SPECIES(3,1)
MILD RESPIRATORY DISEASE(3,1)
MURINE CYTOMEGALOVIRUS SEQUENCE(3,1)
NAKED DNA(3,1)
NATIVE PROTEIN(3,1)
NITROCELLULOSE FILTER(3,1)
POTENTIAL EXPRESSION VECTOR(3,1)
POTENTIAL SPLICE SITE(3,1)
PROTEIN GENE(3,1)
SEVERE INFECTION(3,1)
SPLICE CONSENSUS SEQUENCE(3,1)
SPLICE DONOR SEQUENCE REMOVAL(3,1)
VACCINATING ANIMAL(3,1)
VACCINE DEVELOPMENT(3,1)
VACCINE VECTOR(3,1)
XHOI RECEIVED FRAGMENT(3,1)
ANTI GD SERUM(2,1)
ANTIBODY PRESENCE(2,1)
BOVINE EMBRYONIC CELL(2,1)
CDNA SEQUENCE(2,1)
CELL CULTURE SUPERNATANT(2,1)
CELL PROTEIN(2,1)
CHANGED CODON(2,1)
CHARACTERERIZATION(2,1)
CHOICE CARRIER(2,1)
CLINICAL MANIFESTATION RANGE(2,1)
CLINICAL PATTERN(2,1)
COMMON MANIFESTATION(2,1)
CORRECT TRANSPORT(2,1)
CRYPTICAL SPLICE SIGNAL PRESENCE(2,1)
DNA SYNTHESIS(2,1)
DOHERTY ML(2,1)
DONOR CONSENSUS SEQUENCE(2,1)
ECONOMICAL LOSS(2,1)
ELISA TEST(2,1)
EMULSIFIER(2,1)
FRAGMENT F INTEGRATION(2,1)
GENETIC INFORMATION(2,1)
INSERTING SYNTHETIC(2,1)
INTEGRATION SITE(2,1)
MDBK CELL(2,1)
MUCOSAL FLUID(2,1)
NUCLEOTIDE SEQUENCE COMPARISON(2,1)
OLIGONUCLEOTIDE(2,1)
POTENTIAL VACCINE(2,1)
PROMI CONSTRUCTION(2,1)
RECOMBINANT DNA TECHNOLOGY(2,1)
SPLICING(2,1)
STABILIZER(2,1)
SUSCEPTIBLE CELL(2,1)
(CA2304991)
BOVINE VIRAL DIARRHEA VIRUS(100,141)
GENE(100,72)
SYNTHETIC(100,22)
VIRUS PARTICLE(100,5)
SYNTHETIC GENE(100,4)
BOVINE HERPES VIRUS RECOMBINANT(100,3)
RECOMBINANT BHV CARRIER(100,3)
RECOMBINANT BHV CARRIER VIRUS(95,10)
SERONEGATIVE IMMUNOCOMPETENT CATTLE(87,1)
SYNTHETIC BOVINE VIRAL DIARRHEA(84,2)
LIVE ATTENUATED RECOMBINANT(74,1)
BOOSTER VACCINATION(72,3)
INACTIVATED BHV CARRIER VIRUS(71,2)
LIVE ATTENUATED RECOMBINANT PREPARATION(68,1)
RECOMBINANT VECTOR VIRUS CANDIDATE(64,1)
BOVINE HERPES VIRUS(63,4)
ACUTE POSTNATAL INFECTION(61,1)
BOVINE RESPIRATORY SYNCYTIUM VIRUS(58,1)
ACUTE BVDV INFECTION(55,1)
BHV RECOMBINANT VIRUS PARTICLE(48,2)
EFFICACIOUS VACCINE(46,1)
NUCLEOTIDE SEQUENCE(44,1)
VACCINE PREPARATION(41,6)
BVDV INFECTION(41,1)
EMBRYONIC DEATH(40,1)
VIRUS GENE(39,3)
VACCINE MANUFACTURE(38,2)
BOVINE HERPES VIRUS INFECTION(35,1)
BHV CARRIER VIRUS(34,2)
VACCINE(33,18)
CLINICAL DISEASE(33,1)
BOVINE PARAMYXOVIRUS(32,1)
BOVINE SPECIES(31,1)
BOVINE ROTAVIRUS(30,1)
ECONOMIC LOSS(27,1)
INFECTION(25,13)
HOST CELL(25,7)
MISC DIFFERENCE(24,52)
CATTLE PATHOGEN GROUP(24,1)
STILLBIRTH(22,1)
FLANKING REGION(21,3)
REPLACEMENT OVERVIEW(21,2)
CATTLE PROTECTION(20,2)
DIAGNOSTIC TOOL(20,1)
GESTATION(20,1)
RESORPTION(20,1)
WHOLE ARRAY(19,1)
HCMVIE1PROMOTER(18,1)
PASTEURELLA HAEMOLYTICA(18,1)
NUCLEOTIDE AGCT(17,8)
HOMOLOGY(16,3)
GLYCOPROTEIN(15,12)
PATHOGEN(15,4)
BVD(14,1)
O VACCINE(14,1)
DISEASE(13,4)
NON FATAL TERATOGENIC EFFECT(13,1)
DISCRIMINATION(12,3)
ADMIXING(12,2)
INTRANASAL ADMINISTRATION(12,2)
LIVE RECOMBINANT VECTOR VIRUS(12,2)
MCMV EL PROMOTER(12,2)
MICROORGANISM(12,2)
GHVDNA(12,1)
IMMUNOCOMPETENT CATTLE POSTNATAL EXPOSURE(12,1)
MCMVIE CONTROL(12,1)
BHV DRAMATIC MANIFESTATION(11,1)
BOVINE RESPIRATORY DISEASE COMPLEX(11,1)
FRAGMENT INTEGRATION(10,4)
MCMVE(10,4)
HOMOLOGOUS RECOMBINATION(10,3)
VIRUS REPLICATION(10,3)
AMINO ACID SEQUENCE(9,7)
BOOSTER IMMUNIZATION(9,2)
MCMV IEL PROMOTER(9,1)
MCMV PROMOTER IEL(9,1)
INDICATED SEQUENCE(8,24)
GENETIC CODE DEGENERACY(8,4)
BHV GE PROMOTER(8,3)
PLASMID PNH(8,3)
VACCINE STRAIN(8,3)
VIRAL PROTEIN(8,3)
BHV INCORPORATION(8,2)
CLEAVING PSP(8,2)
E2SYN VIRION(8,2)
KLENOW POLYMERASE(8,2)
RECOMBINANT VIRION(8,2)
BOVINE VIRAL DIARRHEA(8,1)
CATTLE TRANSMISSIBLE DISEASE(8,1)
GENOTYPICALLY GD POSITIVE VIRION(8,1)
VIROLOGY INTERNATIONAL CONGRESS(8,1)
WESTERN BLOT INCUBATION(8,1)
SERA(7,3)
INFECTED CALF(7,2)
PLASMID PCF(7,2)
PURIFIED VIRION(7,2)
RECOMBINANT CARRIER VIRUS(7,2)
SYNTHETIC DNA FRAGMENT(7,2)
ATTENUATED CARRIER BHV VIRUS(7,1)
BACULOVIRUS EXPRESSED GLYCOPROTEIN(7,1)
BHVRECOMBINANT VIRUS PARTICLE(7,1)
CONCYTOPATHIC BIOTYPE(7,1)
LIVE RECOMBINANT VIRUS(7,1)
PARAINFLUENZA TYPE(7,1)
PSEUDORABIES TKPROMOTER(7,1)
THYMIDINE KINASE GENE(7,1)
NAME KEY(6,57)
VACCINATION(6,6)
KB FRAGMENT(6,2)
RABBIT SERUM(6,2)
BAMHL RESTRICTION SITE(6,1)
BHV CHARACTERIZATION(6,1)
BHV ENVELOPE PROTEIN(6,1)
BHV VIRUS PARTICLE(6,1)
BRSV GLYCOPROTEIN(6,1)
COMPELEMTARY STRAND(6,1)
CSFV STRAIN AL FORT(6,1)
DNA NUCLEOTIDE(6,1)
EMBL GENE BANK(6,1)
ENCODING TRIPLET(6,1)
FOREIGN DNA INTEGRATION(6,1)
GENE ENCODING ANTIGEN(6,1)
HERPES VIRUS NOMENCLATURE(6,1)
HOST MAMMAL SERUM(6,1)
IMMUNOGENIC PROTEIN(6,1)
INFECTED MDBK CELL(6,1)
INTRACUTANE ADMINISTRATION(6,1)
ISOLATED MCMV EL(6,1)
LIVE VACCINE PREPARATION(6,1)
MAMMALIAN CELL NUCLEUS(6,1)
MINIMAL MUCOSAL LESION(6,1)
NATURALLY ACQUIRED BVD(6,1)
NONESSENTIAL GENE(6,1)
NUCLEOTIDE CATG(6,1)
NUCLEOTIDE TOGA(6,1)
PLASMID PROMESIG(6,1)
PLASMID PSPE2SYN(6,1)
PURIFIED BAMHL XHOL INSERT(6,1)
RECOMBINANT VACCINIA(6,1)
RESTRICTION ENZYME CLEAVAGE SITE(6,1)
STRESSOR INTERPLAY(6,1)
TRANSIENT LEUKOPENIA(6,1)
VACCINIA VIRUS VECTOR(6,1)
VECTOR VIRUS GENE(6,1)
VIRUS MATURATION(6,1)
VIRUS PARTICLE DOSE(6,1)
DIAGNOSTIC TEST(5,4)
MISC FEATURE(5,3)
ANTIGEN INCORPORATION(5,1)
ANTIGENIC VARIANT(5,1)
BHV RECOMBINANT VIRUS(5,1)
BOVINE ANIMAL PROTECTION(5,1)
BOVINE KIDNEY CELL(5,1)
BOVINE PATHOGEN(5,1)
CLINICAL BVD(5,1)
DELETION MUTANT(5,1)
GD POLYA FRAGMENT(5,1)
HERPESSPECIFIC TARGETING SIGNAL(5,1)
IMMUNE MODULATOR(5,1)
LACZ EXPRESSION(5,1)
LACZ GENE EXPRESSION(5,1)
NATURAL INFECTION ROUTE(5,1)
NUCLEAR RNASPLICING(5,1)
PC DOS MS DOS(5,1)
PLASMID PCA(5,1)
PLASMID PCB(5,1)
PREFERENCE VECTOR(5,1)
PROMI MAP(5,1)
SDSPOLYACRYLAMIDE GEL(5,1)
STRAIN SCHTINBEIKEN INFECTED CELL(5,1)
SYNTHETIC GCCONTENT(5,1)
UNEXPECTED INCORPORATION(5,1)
VACCINE DOSAGE(5,1)
VIABLE BHV(5,1)
VIRAL REPLICATION(5,1)
VIRUS STRAIN(5,1)
VIRUS VACCINE(5,1)
STICKY END(4,24)
LANE(4,8)
HCMV IE(4,3)
IMMUNITY(4,3)
INACTIVATED VACCINE(4,3)
MORBIDITY(4,3)
AGAROSE GEL(4,2)
CDNA SEQUENCE(4,2)
LYSED CELL(4,2)
PHYSIOLOGICAL SALT SOLUTION(4,2)
PROTECTIVE IMMUNE RESPONSE(4,2)
WHOLE GENE(4,2)
ADJUVANT ACTIVITY(4,1)
AFFECTED CATTLE(4,1)
AGGU CONSENSUS SEQUENCE(4,1)
BHV ANALYSIS(4,1)
BHV GC CONTENT(4,1)
CARRIED GENE HETEROLOGOUS PROTEIN(4,1)
COMPARABLE INFECTION(4,1)
CORRESPONDENCE ADDRESS(4,1)
CPE DEVELOPMENT(4,1)
DNA MANIPULATION(4,1)
ENCODED PROTEIN(4,1)
EXPRESSION VECTOR POTENTIAL(4,1)
FOREIGN GENE(4,1)
GALACTOSIDASE SEQUENCE(4,1)
GENE CODING(4,1)
HERPES SIMPLE VIRUS(4,1)
HETEROLOGOUS GENE PRODUCT(4,1)
INFECTED ANIMAL(4,1)
ISOLATED VIRION(4,1)
LABELED PROBE(4,1)
LABOR INTENSIVE TASK(4,1)
LATE PROMOTER(4,1)
MAMMALIAN SPECIES(4,1)
MILD RESPIRATORY DISEASE(4,1)
MURINE CYTOMEGALOVIRUS SEQUENCE(4,1)
NAKED DNA(4,1)
NATIVE PROTEIN(4,1)
NITROCELLULOSE FILTER(4,1)
POTENTIAL SPLICE SITE(4,1)
PROTEIN EXPRESSION(4,1)
PROTEIN GENE(4,1)
SDS POLYACRYLAMIDE GEL(4,1)
SEVERE INFECTION(4,1)
SPLICE CONSENSUS SEQUENCE(4,1)
SPLICE DONOR SEQUENCE REMOVAL(4,1)
SYNTHETIC BRSV(4,1)
SYNTHETIC OLIGONUCLEOTIDE(4,1)
VACCINATING ANIMAL(4,1)
VACCINE DEVELOPMENT(4,1)
VACCINE VECTOR(4,1)
MOLECULE TYPE(3,16)
BGLIL(3,4)
CYTOKINE(3,2)
CYTOPLASM(3,2)
FLUOROGRAPHY(3,2)
FRAMEWORK(3,2)
HERD(3,2)
MOUSE CYTOMEGALOVIRUS(3,2)
NUCLEIC ACID SEQUENCE ENCODING(3,2)
PESTIVIRUS SIGNAL SEQUENCE(3,2)
POLYLINKER(3,2)
RECEIVED FRAGMENT(3,2)
RESPIRATORY TRACT(3,2)
ANTI GD SERUM(3,1)
ANTIBODY PRESENCE(3,1)
BOVINE EMBRYONIC CELL(3,1)
CELL CULTURE SUPERNATANT(3,1)
CELL PROTEIN(3,1)
CHANGED CODON(3,1)
CHARACTERERIZATION(3,1)
CHOICE CARRIER(3,1)
CLINICAL MANIFESTATION RANGE(3,1)
CLINICAL PATTERN(3,1)
COMMON MANIFESTATION(3,1)
CORRECT TRANSPORT(3,1)
CRYPTICAL SPLICE SIGNAL PRESENCE(3,1)
DNA SYNTHESIS(3,1)
DOHERTY ML(3,1)
DONOR CONSENSUS SEQUENCE(3,1)
ECONOMICAL LOSS(3,1)
ELISA TEST(3,1)
EMULSIFIER(3,1)
ENCODING GENE PRODUCT(3,1)
FILING DATE(3,1)
GENETIC INFORMATION(3,1)
IBM PC(3,1)
INSERTING SYNTHETIC(3,1)
INTEGRATION SITE(3,1)
MUCOSAL FLUID(3,1)
NATIVE GC CONTENT(3,1)
NUCLEOTIDE SEQUENCE COMPARISON(3,1)
POTENTIAL VACCINE(3,1)";"Biotechnology
Pharmaceuticals";Open
"1999-01-08
1999-12-24
2001-09-13
2012-03-14";"AUPP807399          A0 1999-02-04 [AU-807399]
STG: (A0)
AP : 1999AU-0008073 1999-01-08
WO200041720         A1 2000-07-20 [WO200041720]
STG: (A1) Published application with search report
AP : 1999WO-AU01167 1999-12-24
CA2660344           A1 2000-07-20 [CA2660344]
STG: (A1) Application laid open
AP : 1999CA-2660344 1999-12-24
FD :  Division of: CA2359111 FDD=1999-12-24 [1999CA-2359111]
CA2359111           A1 2000-07-20 [CA2359111]
STG: (A1) Application laid open
AP : 1999CA-2359111 1999-12-24
AU2526300           A  2000-08-01 [AU200025263]
STG: (A) Open to public inspection
AP : 2000AU-0025263 1999-12-24
WO200041720         A8 2000-11-09 [WO200041720]
STG: (A8) Modified first page
AP : 1999WO-AU01167 1999-12-24
EP1140165           A1 2001-10-10 [EP1140165]
STG: (A1) Application published with search report
AP : 1999EP-0968288 1999-12-24
JP2002534480        A  2002-10-15 [JP2002534480]
STG: (A) Published application
AP : 2000JP-0593330 1999-12-24
NZ512011            A  2002-12-20 [NZ-512011]
STG: (A) Published application
AP : 1999NZ-0512011 1999-12-24
ZA200105543         B  2003-01-22 [ZA200105543]
STG: (B)
AP : 2001ZA-0005543 2001-07-05
AU758133            B2 2003-03-13 [AU-758133]
STG: (B2) Patent proceeded by OPI
AP : 2000AU-0025263 1999-12-24
TW533079            B  2003-05-21 [TW-533079]
STG: (B) Granted patent or patent of addition
AP : 1999TW-0123010 1999-12-27
EP1140165           A4 2005-01-05 [EP1140165]
STG: (A4) Supplementary search report
AP : 1999EP-0968288 1999-12-24
EP1946773           A2 2008-07-23 [EP1946773]
STG: (A2) Application published without search report
AP : 2008EP-0005701 1999-12-24
EP1946773           A3 2008-07-30 [EP1946773]
STG: (A3) Published search report
AP : 2008EP-0005701 1999-12-24
FD :  Division of: EP1140165 - 0 [EP1140165]
FD : Division of: EP99968288.3 FDD=1999-12-24 [1999EP-0968288]
EP1140165           B1 2008-10-08 [EP1140165]
STG: (B1) Patent specification
AP : 1999EP-0968288 1999-12-24
AT410183            T  2008-10-15 [ATE410183]
STG: (T) EP patent valid in AT
AP : 1999AT-0968288T 1999-12-24
DE69939706          D1 2008-11-20 [DE69939706]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 1999DE-6039706 1999-12-24
PT1140165           E  2009-01-13 [PT1140165]
STG: (E) Availability of national translation of European patent
AP : 1999PT-0968288T 1999-12-24
DK1140165           T3 2009-02-16 [DK1140165T]
STG: (T3) Translation of EP patent
AP : 1999DK-0968288 1999-12-24
ES2317708           T3 2009-04-16 [ES2317708]
STG: (T3) Translation of granted European patent (former B3)
AP : 1999ES-0968288T 1999-12-24
JP4949555           B2 2012-03-16 [JP4949555]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2000JP-0593330 1999-12-24
JP2012072157        A  2012-04-12 [JP2012072157]
STG: (A) Published application
AP : 2011JP-0242133 2011-11-04
FD :  Division of: JP2000593330 0 [2000JP-0593330]
US20120251566       A1 2012-10-04 [US20120251566]
STG: (A1) Application published
AP : 2012US-13420082 2012-03-14
CA2359111           C  2014-02-18 [CA2359111]
STG: (C) Patent (second level)
AP : 1999CA-2359111 1999-12-24
US9149520           B2 2015-10-06 [US9149520]
STG: (B2) Granted patent as second publication
AP : 2012US-13420082 2012-03-14
FD :  Continuation of: US09/857,797 FDD=2001-09-13 [2001US-09857797]
FD : Continuation of: US09857797 0  PENDING
FD : Continuation of: WOPCT/AU99/01167 FDD=1999-12-24 [1999WO-AU01167]
FD : Previous publication: US20120251566 A1 2012-10-04 [US20120251566]
US9579379           B1 2017-02-28 [US9579379]
STG: (B1) Granted patent as first publication
AP : 1999US-09857797 1999-12-24";912755;"AUPP807399          A0 1999-02-04 [AU-807399]
WO200041720         A1 2000-07-20 [WO200041720]
CA2660344           A1 2000-07-20 [CA2660344]
CA2359111           A1 2000-07-20 [CA2359111]
AU2526300           A  2000-08-01 [AU200025263]
WO200041720         A8 2000-11-09 [WO200041720]
EP1140165           A1 2001-10-10 [EP1140165]
JP2002534480        A  2002-10-15 [JP2002534480]
NZ512011            A  2002-12-20 [NZ-512011]
ZA200105543         B  2003-01-22 [ZA200105543]
AU758133            B2 2003-03-13 [AU-758133]
TW533079            B  2003-05-21 [TW-533079]
EP1140165           A4 2005-01-05 [EP1140165]
EP1946773           A2 2008-07-23 [EP1946773]
EP1946773           A3 2008-07-30 [EP1946773]
EP1140165           B1 2008-10-08 [EP1140165]
AT410183            T  2008-10-15 [ATE410183]
DE69939706          D1 2008-11-20 [DE69939706]
PT1140165           E  2009-01-13 [PT1140165]
DK1140165           T3 2009-02-16 [DK1140165T]
ES2317708           T3 2009-04-16 [ES2317708]
JP4949555           B2 2012-03-16 [JP4949555]
JP2012072157        A  2012-04-12 [JP2012072157]
US20120251566       A1 2012-10-04 [US20120251566]
CA2359111           C  2014-02-18 [CA2359111]
US9149520           B2 2015-10-06 [US9149520]
US9579379           B1 2017-02-28 [US9579379]";"1999AU-0008073
1999CA-2359111
1999WO-AU01167
2000AU-0025263
2001US-09857797
2012US-13420082";"(EP1946773)
WO200041720
(EP1140165)
WO200041720
(US9579379)
WO200041720
(DE69939706)
WO200041720
(JP4949555)
WO200041720
(CA2660344)
WO200041720
(NZ-512011)
WO200041720
(ZA200105543)
WO200041720
(AU-758133)
WO200041720
(DK1140165T)
WO200041720
(CA2359111)
WO200041720";"CSL
PFIZER
ZOETIS SERVICES";ZOETIS SERVICES;"(EP1946773)
AU
(EP1946773)
US
(EP1140165)
AU
(EP1140165)
AU
(US20120251566)
US
(US9149520)
US
(US9579379)
US
(WO200041720)
AU

(CA2660344)
AU
(CA2359111)
AU
(CA2359111)
AU";"(EP1946773)
NAME=CSL Limited 45 Poplar Road , CITY=Parkville, VIC 3052 , COUNTRY=AU 

(EP1946773)
NAME=Pfizer Inc. 235 East 42nd Street New York, NY 10017 , COUNTRY=US 

(EP1140165)
NAME=CSL LIMITED 45 Poplar Road , CITY=Parkville, VIC 3052 , COUNTRY=AU 

(EP1140165)
NAME=CSL Limited 45 Poplar Road Parkville, VIC 3052 , COUNTRY=AU 

(US20120251566)
NAME=Pfizer Inc. , CITY=Madison , STATE=NJ , COUNTRY=US , ATYP=US Company 

(US9149520)
NAME=Zoetis Services LLC , CITY=Florham Park , STATE=NJ , COUNTRY=US , ATYP=US Company 

(US9579379)
NAME=Zoetis Services LLC , CITY=Parsippany , STATE=NJ , COUNTRY=US , ATYP=US Company 

(WO200041720)
NAME=CSL LIMITED [AU / AU]  45 Poplar Road Parkville, Victoria 3052  , COUNTRY=AU 

(JP4949555)
NAME=PFIZER INC. , REG=593141953 

(CA2660344)
NAME=CSL LIMITED 45 Poplar Road Victoria 3052 , CITY=PARKVILLE , COUNTRY=AU 

(CA2359111)
NAME=CSL LIMITED 45 Poplar Road VIC 3052 , CITY=PARKVILLE , COUNTRY=AU 

(CA2359111)
NAME=CSL LIMITED 45 Poplar Road VIC 3052 , CITY=PARKVILLE , COUNTRY=AU 
";1;WALKER JOHN;"(EP1946773)
AU
(EP1946773)
AU";"(EP1946773)
NAME=Walker, John 26 Clapham Street , CITY=Balwyn Victoria 3103 , COUNTRY=AU 

(EP1946773)
NAME=Walker, John 26 Clapham Street Balwyn Victoria 3103 , COUNTRY=AU 
";"(EP1946773)
Improved saponin adjuvant compositions and methods relating thereto";"(EP1946773)
An immunogenic composition comprises (1) an LHRH-diphtheria toxoid conjugate, and (2) an immunostimulating complex that itself optionally includes an additional protein, but the composition does not contain an ionic polysaccharide as adjuvant. The composition is for use in a method of eliciting in an animal an effective immune response. The immune response may inhibit the reproductive capacity of the animal. It is further provided a vaccine against bovine viral diarrhea virus (BVDV) comprising as adjuvant a combination of DEAE-dextran and an immunostimulating complex (ISCOM).";"(WO200041720)
CLAIMS:
1. An adjuvant composition which comprises an ionic macromolecule component and a saponin component.
2. A composition according to claim 1 , wherein the saponin component is an immunostimulatory complex.
3. A composition according to claim 1 , wherein the ionic macromolecule is an ionic polysaccharide.
4. A composition according to claim 3, wherein the ionic polysaccharide is an ionic dextran.
5. A composition according to claim 4, wherein the ionic dextran is DEAE-dextran.
6. A composition according to claim 2, wherein the immunostimulatory complex is a protein-free immunostimulatory complex.
7. A composition according to claim 2, wherein the immunostimulatory complex comprises Quil A, cholesterol and a phospholipid.
8. A composition according to claim 2, wherein the mass ratio of ionic macromolecule component to immunostimulating complex component is in the range of 50 to 300, preferably in the range of 100 to 140.
9. A composition according to claim 8, wherein the mass ratio is about 125.
10. A composition according to claim 1 , comprising about 10mg DEAE-dextran and about 80μg immunostimulating complex.
11. A composition according to claim 1 , comprising about 100mg DEAE-dextran and about 800μg immunostimulating complex.
12. A composition according to claim 1 , comprising about 150 mg DEAE-dextran and about 500 μg immunostimulating complex.
13. An immunogenic composition comprising an immunogen and an adjuvant composition, wherein said adjuvant composition is a composition according to any one of claims 1 to 12.
14. An immunogenic composition according to claim 13, wherein said immunogen comprises LHRH.
15. An immunogenic composition according to claim 14, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.
16. An immunogenic composition according to claim 15 comprising 5-500μg of LHRH-diphtheria toxoid conjugate in 5-500mg ionic polysaccharide and 40- 4000μg immunostimulating complex.
17. A pharmaceutical composition comprising an immunostimulating composition according to any of claims 13 to 16, together with one or more pharmaceutically acceptable carriers and/or diluents.
18. A method of eliciting, in an animal, an effective immune response, said method comprising administering to said animal an effective amount of an immunogenic composition according to any of claims 13 to 16.
9. Use of an adjuvant composition according to any of claims 1 to 12 in the manufacture of a composition for eliciting an effective immune response in an animal. 
 AMENDED CLAIMS
 [received by the International Bureau on 8 May 2000 (08.05.00); original claims 2 and 3 cancelled; original claims 1, 6, 7, 8 and 17 amended; remaining claims unchanged (3 pages)]
1. (Amended) An adjuvant composition which comprises an ionic polysaccharide component and a saponin component, wherein the saponin component is an immunostimulating complex.
2. (Deleted).
3. (Deleted).
4. A composition according to claim 1 , wherein the ionic polysaccharide is an ionic dextran.
5. A composition according to claim 4, wherein the ionic dextran is DEAE- dextran.
6. (Amended) A composition according to claim 1 , wherein the immunostimulating complex is a protein-free immunostimulating complex.
7. (Amended) A composition according to claim 1 , wherein the immunostimulating complex comprises Quil A, cholesterol and a phospholipid.
8. (Amended) A composition according to claim 1 , wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of 50 to 300, preferably in the range of 100 to 140.
9. A composition according to claim 8, wherein the mass ratio is about 125.
10. A composition according to claim 1 , comprising about 10mg DEAE-dextran and about 80μg immunostimulating complex.
11. A composition according to claim 1, comprising about 100mg DEAE-dextran and about 800μg immunostimulating complex.
12. A composition according to claim 1 , comprising about 150 mg DEAE-dextran and about 500 μg immunostimulating complex.
13. An immunogenic composition comprising an immunogen and an adjuvant composition, wherein said adjuvant composition is a composition according to any one of claims 1 to 12.
14. An immunogenic composition according to claim 13, wherein said immunogen comprises LHRH.
15. An immunogenic composition according to claim 14, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.
16. An immunogenic composition according to claim 15 comprising 5-500μg of LHRH-diphtheria toxoid conjugate in 5-500mg ionic polysaccharide and 40- 4000μg immunostimulating complex.
17. (Amended) A pharmaceutical composition comprising an immunogenic composition according to any of claims 13 to 16, together with one or more pharmaceutically acceptable carriers and/or diluents.
18. A method of eliciting, in an animal, an effective immune response, said method comprising administering to said animal an effective amount of an immunogenic composition according to any of claims 13 to 16.
9. Use of an adjuvant composition according to any of claims 1 to 12 in the manufacture of a composition for eliciting an effective immune response in an animal.";"(EP1946773)
In yet another aspect there is provided an adjuvant composition which comprises an ionic polysaccharide component and a saponin component, particularly an immunostimulating complex component.
In still yet another aspect there is provided an adjuvant composition which comprises an ionic polysaccharide component and a saponin component, particularly a protein-free immunostimulating complex component.
In a further aspect of the present invention there is provided an immunogenic composition comprising an immunogen and an adjuvant composition, which adjuvant composition comprises an ionic macromolecule component and a saponin component, particularly an immunostimulating complex component.
In another further aspect there is provided an immunogenic composition comprising an immunogen and an adjuvant composition, which adjuvant composition comprises an ionic polysaccharide component and a saponin component, particularly an immunostimulating complex component.
In still another further aspect there is provided an immunogenic composition comprising an immunogen and an adjuvant composition, which adjuvant composition comprises an ionic polysaccharide component and a saponin component, particularly a protein-free immunostimulating complex component.
In still another further aspect of the present invention there is provided a pharmaceutical composition comprising an immunogenic composition as broadly described above, together with one or more pharmaceutically acceptable carriers and/or diluents.
Another aspect of the present invention relates to a method of eliciting, in an animal, an effective immune response, said method comprising administering to said animal an effective amount of an immunogenic composition as broadly described above.
In yet another aspect, the present invention provides the use of an adjuvant composition as broadly described above in the manufacture of a composition for eliciting an effective immune response in an animal.
The present invention relates generally to an adjuvant composition having high adjuvant properties and low reactogenicity.
The present invention relates generally to an adjuvant composition having high adjuvant properties and low reactogenicity.
One aspect of the present invention relates to an adjuvant composition which comprises an ionic macromolecule component and a saponin component, particularly an immunostimulating complex component.
One aspect of the present invention relates to an adjuvant composition which comprises an ionic macromolecule component and a saponin component, particularly an immunostimulating complex component.
One aspect of the present invention relates to an adjuvant composition which comprises an ionic macromolecule component and a saponin component, particularly an immunostimulating complex component.";"(EP1946773)
The adjuvant composition of the present invention is useful where the development of reactogenicity following administration of an immunogenic composition is unacceptable, for example, but not limited to, administration of an LHRH composition as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of domestic pets or livestock destined for consumption.
It will be appreciated that known adjuvants offer a range of abilities to stimulate an immune response, most usually defined in terms of antibody response to the immunising antigen.
It will be appreciated that some adjuvants, for example the oil in water and water in oil emulsions, are widely considered as strong adjuvants as they stimulate high levels of antibody, but the reactogenicity of such adjuvants precludes their routine use in many animal species or in man.
The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
The polysaccharide may be selected from any one of a number of such molecules, preferably soluble molecules to aid in sterilisation for example by filtration, but the polysaccharide is not restricted to soluble polysaccharides, as insoluble materials may be sterilised by irradiation, wet or dry heat or other processes that do not rely on solubility.
Thus reduction of LH and FSH levels leads to loss of reproductive function.";"A61K-039/00
A61K-039/12
A61K-039/39
A61K-039/395
A61K-047/18
A61P-015/08
A61P-015/16
A61P-015/18
A61P-037/04
A61P-043/00
C07K-007/06
C07K-014/575";"(EP1946773)
1. An immunogenic composition comprising (1) an LHRH-diphtheria toxoid conjugate, and (2) an immunostimulating complex that itself optionally includes an additional protein, wherein said composition does not contain an ionic polysaccharide as adjuvant.
18. A vaccine against bovine viral diarrhea virus (BVDV) comprising a BVDV component, and DEAE dextran and Isomatrix as combined adjuvant.";"(EP1946773)
DIPHTHERIA TOXOID CONJUGATE(100,7)
SAPONIN ADJUVANT(100,1)
IMMUNOGENIC(95,11)
ADJUVANT(86,49)
IONIC MACROMOLECULE COMPONENT(66,4)
SAPONIN COMPONENT(61,13)
IONIC POLYSACCHARIDE COMPONENT(55,10)
IMMUNE RESPONSE(47,18)
IMMUNOSTIMULATING COMPLEX COMPONENT(46,11)
IONIC POLYSACCHARIDE(46,7)
IMMUNOGENIC COMPOSITION ADMINISTRATION(46,1)
PHOSPHATIDYLCHOLINE(43,5)
FERTILITY MODIFICATION(40,1)
SOLUBLE POLYSACCHARIDE(40,1)
BODILY HEALTH(39,1)
ANIMAL(38,22)
ANIMAL REPRODUCTIVE CAPACITY(38,1)
REACTOGENICITY DEVELOPMENT(35,2)
SOLUBLE MOLECULE(35,1)
ANIMAL SEXUAL MATURATION(34,1)
DIRECTLY DEPENDENT(34,1)
LIVESTOCK(33,8)
IMMUNOGEN(33,6)
DIPALMITOYL PHOSPHATIDYL(33,3)
DOMESTIC PET(33,2)
DISEASE TREATMENT(30,1)
BOVINE VIRAL DIARRHEA VIRUS(29,4)
ISOMATRIX(29,1)
THERAPEUTIC AGENT(29,1)
DISEASE CONDITION(27,1)
STERILIZATION(26,1)
DEAE DEXTRAN(25,8)
POLYSACCHARIDE(25,6)
IMMUNOSTIMULATING COMPLEX(24,31)
COMPOSITION MANUFACTURE(23,1)
VACCINE(22,25)
MIXTURE MICROGRAM(22,1)
CHOLESTEROL(21,12)
PROTEIN(21,8)
PHOSPHOLIPID(21,3)
BEHAVIOR(21,1)
IRRADIATION(21,1)
ADJUVANT COMBINATION(20,22)
REPRODUCTIVE FUNCTION LOSS(20,1)
PROPHYLACTIC(19,2)
FSH LEVEL(19,1)
SOLUBILITY(19,1)
PLANT ORIGIN(18,2)
DILUENT(17,5)
MOLAR RATIO(17,3)
LUTEINISING HORMONE RELEASING HORMONE(16,71)
DIPHTHERIA TOXOID T CELL EPITOPE(16,1)
DEAE COMBINATION(14,2)
DRY HEAT(14,1)
MEAT(14,1)
ADMINISTRATION(13,5)
STERILE PHOSPHATE BUFFERED SALINE(13,3)
IGG ISOTYPE SERUM TITER(13,1)
ISCOMATRIX ADJUVANTED VACCINE(13,1)
LOW REACTOGENICITY(12,6)
THIMEROSAL(12,6)
DOSAGE UNIT(12,5)
VACCINE FORMULATION DEAE(12,2)
INSOLUBLE MATERIAL(12,1)
ISCOM ADJUVANTED VACCINE(12,1)
CARRIER PROTEIN(11,9)
DEXTRAN DEAE(11,4)
UNACCEPTABLE REACTOGENICITY(11,2)
VACCINATED CATTLE(11,2)
CONJUGATE PREPARATION(10,5)
GOAT(10,2)
HYPOTHALMIC PEPTIDE HORMONE(10,1)
IMMUNOSTIMULATORY ADJUVANT EFFECTIVENESS(10,1)
ISCOM VACCINE MLS(10,1)
REPRODUCTIVE ORGAN TUMOR(10,1)
SHEEP(9,11)
WEEK POST BOOST(9,4)
ACCESSORY SEX ORGAN(9,1)
ACCESSORY SEXUAL ORGAN(9,1)
ACTIVE MATERIAL(9,1)
IGM ANTIBODY TITER(9,1)
INACTIVATED VIRUS MLS(9,1)
IONIC POLYSACCHARIDE ADJUVANT(9,1)
POWERFUL ADJUVANT DEAE(9,1)
REACTOGENICITY QUANTITATIVE INDICATION(9,1)
PROTEIN ASSAY(8,3)
DEXTRAN ALONE FORMULATION(8,2)
PEPTIDE CONJUGATE(8,2)
UNBOUND PEPTIDE(8,2)
JUGULAR VENEPUNCTURE(8,1)
REACTOGENICITY POST BOOST(8,1)
SURFACE ACTIVE GLYCOSIDE(8,1)
VACCINE REACTOGENICITY(8,1)
REACTION SITE(7,6)
ADULT BOVINE SERUM(7,1)
BEAGLE FOXHOUND(7,1)
CHARGED SAPONIN INCORPORATION(7,1)
DIPHTHERIA TOXIOD(7,1)
HORMONE ANTERIOR PITUITARY(7,1)
HYPOTHALAMIC HORMONE LUTEINISING HORMONE(7,1)
IMMUNOGENIC COMPOSITION REACTOGENICITY(7,1)
INFLUENZA ENVELOPE PROTEIN(7,1)
INJECTION SITE CAREFUL PALPATION(7,1)
KEYHOLE LIMPET HEMOCYANIN ANTIGEN(7,1)
LIVESTOCK ANIMAL MANAGEMENT(7,1)
POSTPRIMARY VACCINATION(7,1)
REPEATING VACCINATION GUN(7,1)
REPRODUCTIVE ORGAN ACTIVITY(7,1)
SOLUBLE ANTIGEN OVUM(7,1)
SYSTEMIC REACTOGENICITY(7,1)
THOROUGH MANUAL PALPATION(7,1)
VACCINE FORMULATION WEEK(7,1)
VAL LYS ARG(7,1)
OVALBUMIN(6,5)
PRESERVATIVE(6,5)
PROTEIN CONCENTRATION(6,3)
THERAPEUTIC EFFECT(6,3)
ADJUVANT ACTIVITY(6,2)
ADMINISTRATION SITE(6,2)
COM STARCH(6,2)
FEMALE CATTLE(6,2)
GLUCOSE RESIDUE(6,2)
SERUM DILUTION(6,2)
STRONG ADJUVANT(6,2)
TEST POPULATION PROPORTION(6,2)
TRP TYR(6,2)
VISIBLE SWELLING(6,2)
ANTIGENIC POLYSACCHARIDE(6,1)
APPROXIMATE ISOTONICITY(6,1)
ASSIMILABLE EDIBLE CARRIER(6,1)
BALANCED DIET(6,1)
CANINE VACCINE(6,1)
DEAE DEXTRAN SITE REACTIVITY(6,1)
DELETIONAL VARIANT(6,1)
DETECTABLE SYMPTOM(6,1)
DEXTRAN PLUS ANTIGEN(6,1)
DIPHTHERIA TOXIN CONJUGATE(6,1)
DOMESTIC LIVESTOCK(6,1)
HRH DIPHTHERIA(6,1)
IMMUNOGENIC FORMULATION(6,1)
INFLAMMATION SYMPTOM(6,1)
ISCOM ATRIX(6,1)
MICROORGANISM CONTAMINATING ACTION(6,1)
MMUNO STIMULATING COMPLEX(6,1)
MOUSE IMMUNIZATION(6,1)
NECK SCRUFF(6,1)
NONSTRUCTURAL PROTEIN(6,1)
PHYSIOLOGICAL OSMOLARITY(6,1)
PRODUCTION GAIN(6,1)
REACTOGENICITY OCCURRENCE(6,1)
REPRODUCTIVE IMMUNOLOGY(6,1)
SEXUAL BEHAVIOR(6,1)
SEXUAL MATURITY(6,1)
VACCINATION EFFICACY(6,1)
VACCINE CONSTITUENT ION(6,1)
CHEMICAL EQUIVALENT(5,7)
HEIFER(5,4)
TRIAL(5,4)
COMPANION ANIMAL(5,3)
DETERGENT(5,3)
DISPERSION MEDIUM(5,3)
REACTOGENICITY DEGREE(5,3)
DIALYSIS(5,2)
STERILE POWDER(5,2)
ADJUVANT COMBINATION VACCINE(5,1)
ADJUVANT FORMULATION(5,1)
AEROSOL ADMINISTRATION(5,1)
BUCCAL TABLET(5,1)
BULK PLASTIC PILLOW PACK(5,1)
CARBOXY TERMINUS(5,1)
CHICKEN EGG ALBUMIN(5,1)
CONTINUING VACCINATION(5,1)
DEAE DEXTRAN FORMULATION(5,1)
DEXTRAN ADJUVANT(5,1)
DEXTRAN VACCINE(5,1)
DIET FOOD(5,1)
DOSE SITE REACTIVITY(5,1)
EQUINE VIRUS(5,1)
EXTENSIVE EXPERIMENTATION(5,1)
FEMALE GONAD(5,1)
GONAD MAINTENANCE(5,1)
INDOOR PEN(5,1)
INFECTED CATTLE(5,1)
INSOLUBLE ALUMINUM SALT(5,1)
IONIC MACROMOLECULE(5,1)
LIPID ANTIGEN(5,1)
MULTIDOSE CONTAINER(5,1)
NON NATURAL RESIDUE(5,1)
PARTICULATE ANTIGEN(5,1)
PEPTIDE HAPTEN(5,1)
POSITIVELY CHARGED DEAE DEXTRAN(5,1)
PREFORMED ADJUVANT(5,1)
PROPRIOLACTONE ML LITER(5,1)
PUBLISHED CONCLUSION(5,1)
QAE DEXTRAN(5,1)
REPRODUCTIVE RESEARCH(5,1)
SAPONIN DERIVATIVE(5,1)
SCIENTIFIC LITERATURE(5,1)
SEVERE ABSCESSED REACTION(5,1)
SITE REACTOGENICITY COMPARISON(5,1)
SOLUBLE PROTEIN ANTIGEN(5,1)
STATED INTEGER INCLUSION(5,1)
STRONG IMMUNOSTIMULANT(5,1)
TITER DEAE(5,1)
VACCINATED ANIMAL(5,1)
VACCINE ADJUVANT(5,1)
VACCINE DOSE(5,1)
VACCINE EFFICACY(5,1)
VETERINARILY ACTIVE SUBSTANCE(5,1)
VIRUS STRAIN(5,1)
AMINOACID SUBSTITUTION(4,2)
ANTIBACTERIAL(4,2)
COLTER(4,2)
DEAE LEVEL(4,2)
EXCIPIENT(4,2)
HOMOLOG(4,2)
MLS LITER(4,2)
MONKEY(4,2)
REPTILE(4,2)
SIMILARITY(4,2)
TROCHE(4,2)
ULTRAFILTRATION(4,2)
VISIBLE REACTION(4,2)
ADJUVANT TECHNOLOGY(4,1)
AGE MONTH(4,1)
AGENT DELAYING ABSORPTION(4,1)
ASN GIN(4,1)
BULK VACCINE(4,1)
CAPTIVE WILD ANIMAL(4,1)
CHOICE ANTIGEN(4,1)
CHOICE DILUENT(4,1)
CIRCULATING ANTIBODY PRESENCE(4,1)
COMBINATION ADJUVANT VACCINEOR(4,1)
DEAE DOSE(4,1)
DEXTRAN LINKED ALPHA(4,1)
DISINTEGRATION(4,1)
DOG CLOSE EXAMINATION(4,1)
DRUG DELIVERY(4,1)
EARLY IGM(4,1)
EXTEMPORANEOUS PREPARATION(4,1)
FILTERED STERILIZATION(4,1)
FUNCTIONAL ANALOG(4,1)
FUSION PROTEIN(4,1)
GAUGE NEEDLE(4,1)
GELATIN CAPSULE(4,1)
GLN ASN(4,1)
GLU ALA(4,1)
GLUCOSE POLYMER(4,1)
IMMUNOGENIC PREPARATION(4,1)
IMMUNOSTIMULAFING COMPLEX(4,1)
IMMUNOSTIMULATING COMPLEX DERIVATIVE(4,1)
IMMUNOSTIMUTATING COMPLEX(4,1)
INERT DILUENT(4,1)
INJECTABLE COMPOSITION DELAYED RELEASE(4,1)
INJECTION SITE PHYSICAL PALPATION(4,1)
IONIC POLYSACCHARIDE MASS RATIO(4,1)
ISCOMATRIX BASED VACCINE(4,1)
MALE PIG(4,1)
NEGATIVELY CHARGED POLYSACCHARIDE COMPONENT(4,1)
PHARMACEUTICAL CARRIER(4,1)
POSITIVELY CHARGED IMMUNOSTIMULATING COMPLEX(4,1)
POST BOOST VACCINATION(4,1)
POTATO STARCH(4,1)
PRIMARY IMMUNIZATION(4,1)
PROLONGED ABSORPTION(4,1)
PROTEIN INCORPORATION(4,1)
PROTEIN REMAINDER(4,1)
REACTOGENICITY COMPLETE ABSENCE(4,1)
REPRODUCTIVE ACTIVITY(4,1)
RESIDUE EXEMPLARY SUBSTITUTION(4,1)
SAPONIN FRACTION MIXTURE(4,1)
SAPONIN PREPARATION(4,1)
SCORE SEVERE SITE REACTION(4,1)
SECONDARY VACCINATION(4,1)
SEMI QUANTITATIVE SCALE(4,1)
SEVERE PAIN(4,1)
SEVERITY INDICATION(4,1)
SEX SIGNIFICANT PROPORTION(4,1)
SITE REACTION DATA(4,1)
SOLUBLE ADJUVANT(4,1)
SOLUBLE DEXTRAN(4,1)
SOUTH AMERICAN TREE(4,1)
STERILE INJECTABLE SOLUTION PREPARATION(4,1)
STERILE MIXING VESSEL(4,1)
SUBSTITUTIONAL AMINOACID VARIANT(4,1)
T CELL HELP(4,1)
TAIL VEIN(4,1)
TOXOID CONJUGATE SHOW(4,1)
UNITARY DOSAGE(4,1)
VACCINE MANUFACTURE(4,1)
VACCINE PREPARATION(4,1)
VACCINE SITE(4,1)
VISIBLE ABSCESS FORMATION(4,1)
VISUAL INSPECTION(4,1)
WEEKLY INTERVAL(4,1)
BOTTLE(3,3)
EYE(3,3)
HORSE(3,3)
PROTEIN FREE IMMUNOSTIMULATING COMPLEX(3,3)
ELIXIR(3,2)
LHRH(3,2)
TOXICITY(3,2)
ACTION PREVENTION(3,1)
ACTIVE INGREDIENT PLUS(3,1)
ADJUVANT COMPONENT ACTIVITY(3,1)
ADJUVANT COMPOUND(3,1)
AMINOACID INSERTIONAL DERIVATIVE(3,1)
ANTIGEN COMPLEX(3,1)
ANTIGEN CONTENT(3,1)
ANTIGEN SPECIFIC ELISA ASSAY(3,1)
ANTIGEN VOLUME(3,1)
BIBLIOGRAPHY(3,1)
CHOLESTEROL SOLUTION(3,1)
CLOSE VISUAL EXAMINATION(3,1)
COMBINATION ADJUVANT DEAE(3,1)
COMBINATION ADJUVANT MLS(3,1)
COMPOSITION PERCENTAGE(3,1)
CONSISTENT IMMUNE RESPONSE(3,1)
DEAE VOLUME(3,1)
DIETHYLAMINOETHYL(3,1)
DISORDER TREATMENT(3,1)
EFFICACIOUS VACCINE DEVELOPMENT(3,1)
FREQUENT SITE REACTION(3,1)
HEPES BUFFER(3,1)
IMMUNE RESPONSE DURATION(3,1)
IMMUNOSTIMULATING COMPLEX FINAL FORMULATION(3,1)
IMMUNOSTIMULATING COMPLEX PARTICLE(3,1)
INVNETION(3,1)
ISOTONIC AGENT(3,1)
LABORATORY TEST ANIMAL(3,1)
LED REACTION VESSEL(3,1)
MAGNETIC STIRRER(3,1)
MAGNETIC STIRRING BAR(3,1)
MINIMUM TITER(3,1)
MODIFIED DEXTRAN(3,1)
OUTDOOR RUN(3,1)
PHOSPHOLIPID RATIO(3,1)
PHYLUM(3,1)
POLYSACHARIDE(3,1)
PRINCIPAL ACTIVE INGREDIENT(3,1)
PROPER FLUIDITY(3,1)
QUILLAJA SAPONARIA(3,1)
REACTOGENCICITY(3,1)
REACTOGENIC COMPONENT(3,1)
RECENT REVIEW(3,1)
SENSITIVE ANIMAL(3,1)
SIGNIFICANT ADJUVANT(3,1)
STERILE VEHICLE(3,1)
STRINGENT TEST(3,1)
STRONG IMMUNE RESPONSE(3,1)
TERMINAL FUSION(3,1)
VACCINE COMPONENT(3,1)
WEAK ACTIVITY(3,1)
WHOLE FORMULATION(3,1)
WHOLE VIRUS(3,1)
ALPHA LINKED(2,1)
AMINOACID PEPTIDE(2,1)
AMINOACID SEQUENCE VARIANT(2,1)
ANTIBODY RESPONSE DURATION(2,1)
ASTERISK(2,1)
BANTAM(2,1)
BIOTECHNOLOGY(2,1)
BREAST CANCER(2,1)
CAGE(2,1)
CELL LYTIC EFFECT(2,1)
CENTRIFUGATION(2,1)
CHLOROBUTANOL(2,1)
CONJUGATE VACCINE(2,1)
CORRECT CONCENTRATION(2,1)
CORRECT VOLUME(2,1)
COUNTERION(2,1)
DAY INTERVAL(2,1)
(EP1140165)
SAPONIN ADJUVANT(100,1)
IMMUNOGENIC(79,10)
ADJUVANT(67,44)
DIPHTHERIA TOXOID CONJUGATE(66,7)
SAPONIN COMPONENT(62,15)
IONIC POLYSACCHARIDE COMPONENT(60,11)
IMMUNOGENIC COMPOSITION ADMINISTRATION(48,1)
FERTILITY MODIFICATION(42,1)
SOLUBLE POLYSACCHARIDE(42,1)
IONIC DEXTRAN(39,2)
REACTOGENICITY DEVELOPMENT(37,2)
FIGHTING INFECTION(37,1)
SOLUBLE MOLECULE(37,1)
IMMUNOSTIMULATING COMPLEX(35,41)
IMMUNOGEN(35,8)
POLYSACCHARIDE(34,7)
ANTIGENIC SUBSTANCE(34,2)
DOMESTIC PET(34,2)
THERAPEUTIC AGENT(30,1)
IMMUNE RESPONSE(28,13)
CARBOXY TERMINUS(27,2)
STERILIZATION(27,1)
MEDICAMENT MANUFACTURE(26,1)
COMPOSITION MANUFACTURE(24,1)
ANTIBODY(23,4)
FERTILITY(23,1)
BEHAVIOR(22,1)
IRRADIATION(22,1)
REPRODUCTIVE FUNCTION LOSS(21,1)
PROPHYLACTIC(20,2)
FSH LEVEL(20,1)
SOLUBILITY(20,1)
ANIMAL(18,13)
DILUENT(18,5)
DIPHTHERIA TOXOID T CELL EPITOPE(17,1)
LIVESTOCK(16,4)
DRY HEAT(15,1)
ADMINISTRATION(14,5)
GNRH(14,2)
IONIC POLYSACCHARIDE ADJUVANT(14,2)
IGG ISOTYPE SERUM TITER(14,1)
ISCOMATRIX ADJUVANTED VACCINE(14,1)
LUTEINISING HORMONE RELEASING HORMONE(13,69)
LOW REACTOGENICITY(13,6)
STERILE PHOSPHATE BUFFERED SALINE(13,3)
INSOLUBLE MATERIAL(13,1)
ISCOM ADJUVANTED VACCINE(13,1)
CARRIER PROTEIN(12,9)
DEXTRAN DEAE(12,4)
VACCINE FORMULATION DEAE(12,2)
DIPALMITOYL PHOSPHATIDYL(11,2)
POLYCATIONIC ADJUVANT(11,2)
UNACCEPTABLE REACTOGENICITY(11,2)
VACCINATED CATTLE(11,2)
HYPOTHALMIC PEPTIDE HORMONE(11,1)
IMMUNOSTIMULATORY ADJUVANT EFFECTIVENESS(11,1)
ISCOM VACCINE MLS(11,1)
REPRODUCTIVE ORGAN TUMOR(11,1)
CONJUGATE PREPARATION(10,5)
IMMUNOSTIMULATING COMPLEX COMPONENT(10,3)
ACCESSORY SEX ORGAN(10,1)
ACCESSORY SEXUAL ORGAN(10,1)
IGM ANTIBODY TITER(10,1)
INACTIVATED VIRUS MLS(10,1)
POWERFUL ADJUVANT DEAE(10,1)
REACTOGENICITY QUANTITATIVE INDICATION(10,1)
WEEK POST BOOST(9,4)
ABSCESSED REACTION VACCINE FORMULATION(9,1)
BVDV VIRUS STRAIN(9,1)
JUGULAR VENEPUNCTURE(9,1)
REACTOGENICITY POST BOOST(9,1)
SERUM IGG TITER(9,1)
VACCINE REACTOGENICITY(9,1)
PROTEIN FREE IMMUNOSTIMULATING COMPLEX(8,5)
PROTEIN ASSAY(8,3)
DEXTRAN ALONE FORMULATION(8,2)
PEPTIDE CONJUGATE(8,2)
UNBOUND PEPTIDE(8,2)
ADULT BOVINE SERUM(8,1)
BEAGLE FOXHOUND(8,1)
CHARGED SAPONIN INCORPORATION(8,1)
DIPHTHERIA TOXIOD(8,1)
HORMONE ANTERIOR PITUITARY(8,1)
HYPOTHALAMIC HORMONE LUTEINISING HORMONE(8,1)
IMMUNOGENIC COMPOSITION REACTOGENICITY(8,1)
INFLUENZA ENVELOPE PROTEIN(8,1)
INJECTION SITE CAREFUL PALPATION(8,1)
KEYHOLE LIMPET HEMOCYANIN ANTIGEN(8,1)
LIVESTOCK ANIMAL MANAGEMENT(8,1)
POSTPRIMARY VACCINATION(8,1)
REPEATING VACCINATION GUN(8,1)
REPRODUCTIVE ORGAN ACTIVITY(8,1)
SOLUBLE ANTIGEN OVUM(8,1)
SYSTEMIC REACTOGENICITY(8,1)
THOROUGH MANUAL PALPATION(8,1)
VAL LYS ARG(8,1)
REACTION SITE(7,6)
ADJUVANT ACTIVITY(7,2)
ADMINISTRATION SITE(7,2)
CORN STARCH(7,2)
FEMALE CATTLE(7,2)
GLUCOSE RESIDUE(7,2)
SERUM DILUTION(7,2)
STRONG ADJUVANT(7,2)
TEST POPULATION PROPORTION(7,2)
TRP TYR(7,2)
VISIBLE SWELLING(7,2)
ANTIGENIC POLYSACCHARIDE(7,1)
APPROXIMATE ISOTONICITY(7,1)
ASSIMILABLE EDIBLE CARRIER(7,1)
BALANCED DIET(7,1)
CANINE VACCINE(7,1)
DEAE DEXTRAN SITE REACTIVITY(7,1)
DELETIONAL VARIANT(7,1)
DETECTABLE SYMPTOM(7,1)
DEXTRAN PLUS ANTIGEN(7,1)
DIPHTHERIA TOXIN CONJUGATE(7,1)
DOMESTIC LIVESTOCK(7,1)
IMMUNOGENIC FORMULATION(7,1)
INFLAMMATION SYMPTOM(7,1)
ISCOM ATRIX(7,1)
MICROORGANISM CONTAMINATING ACTION(7,1)
MOUSE IMMUNIZATION(7,1)
NECK SCRUFF(7,1)
NONSTRUCTURAL PROTEIN(7,1)
PHYSIOLOGICAL OSMOLARITY(7,1)
REACTOGENICITY OCCURRENCE(7,1)
REPRODUCTIVE IMMUNOLOGY(7,1)
SEXUAL BEHAVIOR(7,1)
SEXUAL MATURITY(7,1)
VACCINATION EFFICACY(7,1)
VACCINE CONSTITUENT ION(7,1)
SHEEP(6,10)
HEIFER(6,5)
OVALBUMIN(6,5)
PRESERVATIVE(6,5)
THIMEROSAL(6,5)
TRIAL(6,4)
PROTEIN CONCENTRATION(6,3)
ADJUVANT COMBINATION VACCINE(6,1)
ADJUVANT FORMULATION(6,1)
AEROSOL ADMINISTRATION(6,1)
ANTIGEN FORMULATION(6,1)
BUCCAL TABLET(6,1)
BULK PLASTIC PILLOW PACK(6,1)
CHICKEN EGG ALBUMIN(6,1)
CONTINUING VACCINATION(6,1)
DEAE DEXTRAN FORMULATION(6,1)
DEXTRAN ADJUVANT(6,1)
DEXTRAN VACCINE(6,1)
DIET FOOD(6,1)
DOSE SITE REACTIVITY(6,1)
EQUINE VIRUS(6,1)
EXTENSIVE EXPERIMENTATION(6,1)
FEMALE GONAD(6,1)
GONAD MAINTENANCE(6,1)
INDOOR PEN(6,1)
INFECTED CATTLE(6,1)
INSOLUBLE ALUMINUM SALT(6,1)
LIPID ANTIGEN(6,1)
MULTIDOSE CONTAINER(6,1)
NON NATURAL RESIDUE(6,1)
PARTICULATE ANTIGEN(6,1)
PEPTIDE HAPTEN(6,1)
POSITIVELY CHARGED DEAE DEXTRAN(6,1)
PREFORMED ADJUVANT(6,1)
PUBLISHED CONCLUSION(6,1)
QAE DEXTRAN(6,1)
REPRODUCTIVE RESEARCH(6,1)
SAPONIN DERIVATIVE(6,1)
SCIENTIFIC LITERATURE(6,1)
SEVERE ABSCESSED REACTION(6,1)
SITE REACTOGENICITY COMPARISON(6,1)
SOLUBLE PROTEIN ANTIGEN(6,1)
STATED INTEGER INCLUSION(6,1)
STRONG IMMUNOSTIMULANT(6,1)
TITER DEAE(6,1)
VACCINATED ANIMAL(6,1)
VACCINE ADJUVANT(6,1)
VACCINE DOSE(6,1)
VACCINE EFFICACY(6,1)
VETERINARILY ACTIVE SUBSTANCE(6,1)
CHEMICAL EQUIVALENT(5,7)
COMPANION ANIMAL(5,3)
DETERGENT(5,3)
DISPERSION MEDIUM(5,3)
REACTOGENICITY DEGREE(5,3)
VISIBLE REACTION(5,3)
DIALYSIS(5,2)
STERILE POWDER(5,2)
ADJUVANT TECHNOLOGY(5,1)
AGE MONTH(5,1)
AGENT DELAYING ABSORPTION(5,1)
BODILY HEALTH(5,1)
BULK VACCINE(5,1)
CAPTIVE WILD ANIMAL(5,1)
CHOICE ANTIGEN(5,1)
CHOICE DILUENT(5,1)
CIRCULATING ANTIBODY PRESENCE(5,1)
COMBINATION ADJUVANT VACCINEOR(5,1)
DEAE DOSE(5,1)
DEXTRAN LINKED ALPHA(5,1)
DISINTEGRATION(5,1)
DOG CLOSE EXAMINATION(5,1)
DRUG DELIVERY(5,1)
EARLY IGM(5,1)
EXTEMPORANEOUS PREPARATION(5,1)
FILTERED STERILIZATION(5,1)
FUNCTIONAL ANALOG(5,1)
FUSION PROTEIN(5,1)
GAUGE NEEDLE(5,1)
GELATIN CAPSULE(5,1)
GLN ASN(5,1)
GLU ALA(5,1)
GLUCOSE POLYMER(5,1)
IMMUNOGENIC PREPARATION(5,1)
IMMUNOSTIMULATING COMPLEX DERIVATIVE(5,1)
INERT DILUENT(5,1)
INJECTABLE COMPOSITION DELAYED RELEASE(5,1)
INJECTION SITE PHYSICAL PALPATION(5,1)
IONIC POLYSACCHARIDE MASS RATIO(5,1)
ISCOMATRIX BASED VACCINE(5,1)
MALE PIG(5,1)
NEGATIVELY CHARGED POLYSACCHARIDE COMPONENT(5,1)
PHARMACEUTICAL CARRIER(5,1)
POSITIVELY CHARGED IMMUNOSTIMULATING COMPLEX(5,1)
POST BOOST VACCINATION(5,1)
POTATO STARCH(5,1)
PRIMARY IMMUNIZATION(5,1)
PROLONGED ABSORPTION(5,1)
PROTEIN INCORPORATION(5,1)
PROTEIN REMAINDER(5,1)
REACTOGENICITY COMPLETE ABSENCE(5,1)
REPRODUCTIVE ACTIVITY(5,1)
RESIDUE EXEMPLARY SUBSTITUTION(5,1)
SAPONIN FRACTION MIXTURE(5,1)
SAPONIN PREPARATION(5,1)
SCORE SEVERE SITE REACTION(5,1)
SECONDARY VACCINATION(5,1)
SEMI QUANTITATIVE SCALE(5,1)
SEVERE PAIN(5,1)
SEVERITY INDICATION(5,1)
SEX SIGNIFICANT PROPORTION(5,1)
SITE REACTION DATA(5,1)
SOLUBLE ADJUVANT(5,1)
SOLUBLE DEXTRAN(5,1)
SOUTH AMERICAN TREE(5,1)
STERILE INJECTABLE SOLUTION PREPARATION(5,1)
STERILE MIXING VESSEL(5,1)
SUBSTITUTIONAL AMINOACID VARIANT(5,1)
T CELL HELP(5,1)
TAIL VEIN(5,1)
TOXOID CONJUGATE SHOW(5,1)
UNITARY DOSAGE(5,1)
VACCINATION DAY(5,1)
VACCINE IMPROVED LONGEVITY(5,1)
VACCINE MANUFACTURE(5,1)
VACCINE PREPARATION(5,1)
VACCINE SITE(5,1)
VISIBLE ABSCESS FORMATION(5,1)
VISUAL INSPECTION(5,1)
WEEKLY INTERVAL(5,1)
DOSAGE UNIT(4,5)
AMINOACID SUBSTITUTION(4,2)
ANTIBACTERIAL(4,2)
COLTER(4,2)
DEAE LEVEL(4,2)
EXCIPIENT(4,2)
MONKEY(4,2)
REPTILE(4,2)
SIMILARITY(4,2)
TROCHE(4,2)
ULTRAFILTRATION(4,2)
ACTION PREVENTION(4,1)
ACTIVE INGREDIENT PLUS(4,1)
ADJUVANT COMPONENT ACTIVITY(4,1)
ADJUVANT COMPOUND(4,1)
AMINOACID INSERTIONAL DERIVATIVE(4,1)
ANTIGEN COMPLEX(4,1)
ANTIGEN CONTENT(4,1)
ANTIGEN SPECIFIC ELISA ASSAY(4,1)
ANTIGEN VOLUME(4,1)
BIBLIOGRAPHY(4,1)
CHOLESTEROL SOLUTION(4,1)
CLOSE VISUAL EXAMINATION(4,1)
COMBINATION ADJUVANT DEAE(4,1)
COMBINATION ADJUVANT MLS(4,1)
COMPOSITION PERCENTAGE(4,1)
CONSISTENT IMMUNE RESPONSE(4,1)
DEAE VOLUME(4,1)
DIETHYLAMINOETHYL(4,1)
DIRECTLY DEPENDENT(4,1)
DISEASE TREATMENT(4,1)
DISORDER TREATMENT(4,1)
EFFICACIOUS VACCINE DEVELOPMENT(4,1)
FREQUENT SITE REACTION(4,1)
IMMUNE RESPONSE DURATION(4,1)
IMMUNOSTIMULATING COMPLEX FINAL FORMULATION(4,1)
IMMUNOSTIMULATING COMPLEX PARTICLE(4,1)
INVNETION(4,1)
ISOTONIC AGENT(4,1)
LABORATORY TEST ANIMAL(4,1)
LED REACTION VESSEL(4,1)
MACROMOLECULE(4,1)
MAGNETIC STIRRER(4,1)
MAGNETIC STIRRING BAR(4,1)
MINIMUM TITER(4,1)
MODIFIED DEXTRAN(4,1)
OUTDOOR RUN(4,1)
PHOSPHOLIPID RATIO(4,1)
PHYLUM(4,1)
PLANT ORIGIN(4,1)
POLYSACHARIDE(4,1)
PRIMARY STRUCTURAL HOMOLOGY(4,1)
PRINCIPAL ACTIVE INGREDIENT(4,1)
PROPER FLUIDITY(4,1)
QUILLAJA SAPONARIA(4,1)
REACTOGENCICITY(4,1)
REACTOGENIC COMPONENT(4,1)
RECENT REVIEW(4,1)
SENSITIVE ANIMAL(4,1)
SIGNIFICANT ADJUVANT(4,1)
STERILE VEHICLE(4,1)
STRINGENT TEST(4,1)
STRONG IMMUNE RESPONSE(4,1)
TERMINAL FUSION(4,1)
VACCINE COMPONENT(4,1)
WEAK ACTIVITY(4,1)
WHOLE FORMULATION(4,1)
WHOLE VIRUS(4,1)
EYE(3,3)
HORSE(3,3)
BOTTLE(3,2)
ELIXIR(3,2)
LHRH(3,2)
TOXICITY(3,2)
ALPHA LINKED(3,1)
AMINOACID PEPTIDE(3,1)
AMINOACID SEQUENCE VARIANT(3,1)
ANTIBODY RESPONSE DURATION(3,1)
ASTERISK(3,1)
BANTAM(3,1)
BICARBONATE(3,1)
BIOTECHNOLOGY(3,1)
BREAST CANCER(3,1)
CAGE(3,1)
CELL LYTIC EFFECT(3,1)
CENTRIFUGATION(3,1)
CHLOROBUTANOL(3,1)
CONJUGATE VACCINE(3,1)
CORRECT CONCENTRATION(3,1)
CORRECT VOLUME(3,1)
COUNTERION(3,1)
DAY INTERVAL(3,1)
DEAE COMBINATION(3,1)
DEAE DEXTRAN COMPONENT(3,1)
DEAE GROUP(3,1)
DEAE MASS RATIO(3,1)
DEAE RATIO(3,1)
DISEASE CONDITION(3,1)
DISSOLUTION(3,1)
DONKEY(3,1)
EARLY STAGE(3,1)
(US20120251566)
ADJUVANT(100,51)
SAPONIN ADJUVANT(100,1)
SAPONIN COMPONENT(97,19)
IONIC POLYSACCHARIDE COMPONENT(95,16)
IMMUNOGENIC(87,9)
DIPHTHERIA TOXOID CONJUGATE(85,2)
ADJUVANT REACTOGENICITY(67,1)
IMMUNIZING ANTIGEN(57,1)
IMMUNOGEN(52,11)
IMMUNOSTIMULATORY COMPLEX(51,1)
LHRH COMPOSITION ADMINISTRATION(51,1)
IONIC DEXTRAN(49,3)
IMMUNOGENIC COMPOSITION ADMINISTRATION(49,1)
IMMUNOSTIMULATING COMPLEX COMPONENT(48,13)
IONIC MACROMOLECULE COMPONENT(47,3)
FERTILITY MODIFICATION(42,1)
SOLUBLE POLYSACCHARIDE(42,1)
IMMUNE RESPONSE(41,15)
BODILY HEALTH(41,1)
REACTOGENICITY DEVELOPMENT(37,2)
SOLUBLE MOLECULE(37,1)
DOMESTIC PET(35,2)
ANIONIC MACROMOLECULE COMPONENT(32,1)
ANIMAL(31,17)
DISEASE TREATMENT(31,1)
THERAPEUTIC AGENT(30,1)
ANIMAL SPECIES(29,2)
POLYSACCHARIDE(28,6)
DISEASE CONDITION(28,1)
STERILIZATION(27,1)
STRONG ADJUVANT(25,3)
COMPOSITION MANUFACTURE(24,1)
ANTIBODY LEVEL(22,1)
BEHAVIOR(22,1)
IRRADIATION(22,1)
REPRODUCTIVE FUNCTION LOSS(21,1)
PROPHYLACTIC(20,2)
FSH LEVEL(20,1)
SOLUBILITY(20,1)
LHRH DIPHTHERIA(19,7)
IMMUNOSTIMULATORY COMPLEX FORM(19,3)
CAGE(18,2)
LIVESTOCK(16,4)
LUTEINISING HORMONE RELEASING HORMONE(16,4)
DRY HEAT(15,1)
BCA PROTEIN ASSAY(14,3)
IONIC POLYSACCHARIDE ADJUVANT(14,2)
IGG ISOTYPE SERUM TITER(14,1)
ISCOMATRIX ADJUVANTED VACCINE(14,1)
DILUENT(13,4)
DIPALMITOYL PHOSPHATIDYLCHOLINE(13,2)
INSOLUBLE MATERIAL(13,1)
ISCOM ADJUVANTED VACCINE(13,1)
DOSAGE UNIT(12,5)
DEAE DEXTRAN FORMULATION(12,4)
ISCOMATRIX FORMULATION(12,3)
KEYHOLE LIMPET HEMOCYANIN(12,1)
CARRIER PROTEIN(11,8)
LOW REACTOGENICITY(11,7)
UNACCEPTABLE REACTOGENICITY(11,2)
VACCINATED CATTLE(11,2)
HYPOTHALMIC PEPTIDE HORMONE LHRH(11,1)
IMMUNOSTIMULATORY ADJUVANT EFFECTIVENESS(11,1)
ISCOM VACCINE MLS(11,1)
REPRODUCTIVE ORGAN TUMOR(11,1)
MAN(10,4)
LHRH PEPTIDE(10,3)
SEVERE ABSCESSED REACTION(10,3)
ACCESSORY SEX ORGAN(10,1)
ACCESSORY SEXUAL ORGAN(10,1)
ACTIVE MATERIAL(10,1)
IGM ANTIBODY TITER(10,1)
INACTIVATED VIRUS MLS(10,1)
REACTOGENICITY QUANTITATIVE INDICATION(10,1)
BVDV VIRUS STRAIN(9,1)
DEAE DEXTRAN REACTOGENCICITY(9,1)
JUGULAR VENEPUNCTURE(9,1)
LHRH CONJUGATE PREPARATION REACTOGENICITY(9,1)
LHRH REACTOGENICITY(9,1)
REACTOGENICITY POST BOOST(9,1)
SERUM IGG TITER(9,1)
VACCINE REACTOGENICITY(9,1)
REACTION SITE(8,7)
PROTEIN FREE IMMUNOSTIMULATING COMPLEX(8,4)
ANTIBODY RESPONSE(8,3)
STERILE PHOSPHATE(8,3)
ADJUVANT DEAE DEXTRAN(8,2)
DEAE DEXTRAN ALONE FORMULATION(8,2)
PEPTIDE CONJUGATE(8,2)
UNBOUND PEPTIDE(8,2)
VACCINE DOSE(8,2)
WEEK POST BOOST(8,2)
ADULT BOVINE SERUM(8,1)
ANTI LHRH ANTIBODY TITER(8,1)
BEAGLE FOXHOUND(8,1)
CHARGED SAPONIN INCORPORATION(8,1)
DIPHTHERIA TOXIOD(8,1)
HORMONE ANTERIOR PITUITARY(8,1)
HYPOTHALAMIC HORMONE LUTEINISING HORMONE(8,1)
IMMUNOGENIC COMPOSITION REACTOGENICITY(8,1)
INFLUENZA ENVELOPE PROTEIN(8,1)
INJECTION SITE CAREFUL PALPATION(8,1)
LHRH FUNCTIONAL ANALOG(8,1)
LHRH HOMOLOG(8,1)
LIVESTOCK ANIMAL MANAGEMENT(8,1)
POSTPRIMARY VACCINATION(8,1)
REPEATING VACCINATION GUN(8,1)
SOLUBLE ANTIGEN OVUM(8,1)
SYSTEMIC REACTOGENICITY(8,1)
THOROUGH MANUAL PALPATION(8,1)
CELL EPITOPE(7,3)
PROTEIN CONCENTRATION(7,3)
THERAPEUTIC EFFECT(7,3)
ADJUVANT ACTIVITY(7,2)
ADMINISTRATION SITE(7,2)
FEMALE CATTLE(7,2)
GLUCOSE RESIDUE(7,2)
SERUM DILUTION(7,2)
TEST POPULATION PROPORTION(7,2)
VISIBLE SWELLING(7,2)
APPROXIMATE ISOTONICITY(7,1)
ASSIMILABLE EDIBLE CARRIER(7,1)
BALANCED DIET(7,1)
CANINE VACCINE(7,1)
DEAE DEXTRAN PLUS ANTIGEN(7,1)
DEAE DEXTRAN SITE REACTIVITY(7,1)
DELETIONAL VARIANT(7,1)
DETECTABLE SYMPTOM(7,1)
DOMESTIC LIVESTOCK(7,1)
IMMUNOGENIC FORMULATION(7,1)
IMMUNOGENIC LHRH(7,1)
INFLAMMATION SYMPTOM(7,1)
ISCOMATRIX DEAE DEXTRAN(7,1)
ISCOMATRIX VACCINE FORMULATION GROUP(7,1)
LHRH HAPTEN(7,1)
LHRH VACCINE(7,1)
MICROORGANISM CONTAMINATING ACTION(7,1)
MOUSE IMMUNIZATION(7,1)
NECK SCRUFF(7,1)
NONSTRUCTURAL PROTEIN(7,1)
PHYSIOLOGICAL OSMOLARITY(7,1)
POLYSACCHARIDE ANTIGEN(7,1)
REACTOGENICITY OCCURRENCE(7,1)
REPRODUCTIVE IMMUNOLOGY(7,1)
SEXUAL BEHAVIOR(7,1)
SEXUAL MATURITY(7,1)
VACCINATION EFFICACY(7,1)
VACCINE IONIC POLYSACCHARIDE COMPONENT(7,1)
SHEEP(6,10)
OVALBUMIN(6,5)
PRESERVATIVE(6,5)
THIOMERSAL(6,4)
TRIAL(6,4)
VISIBLE REACTION(6,4)
ADJUVANT COMBINATION VACCINE(6,1)
ADJUVANT FORMULATION(6,1)
AEROSOL ADMINISTRATION(6,1)
BUCCAL TABLET(6,1)
BULK PLASTIC PILLOW PACK(6,1)
CARBOXY TERMINUS(6,1)
CHICKEN EGG ALBUMIN(6,1)
CONTINUING VACCINATION(6,1)
DEAE DEXTRAN VACCINE(6,1)
DICALCIUM PHOSPHATE(6,1)
DIET FOOD(6,1)
DIETHYLAMINOETHYL(6,1)
DOSE SITE REACTIVITY(6,1)
EQUINE VIRUS(6,1)
EXTENSIVE EXPERIMENTATION(6,1)
FEMALE GONAD(6,1)
FMOC CHEMISTRY(6,1)
GONAD MAINTENANCE(6,1)
INDOOR PEN(6,1)
INFECTED CATTLE(6,1)
INSOLUBLE ALUMINUM SALT(6,1)
LIPID ANTIGEN(6,1)
MULTIDOSE CONTAINER(6,1)
NON NATURAL RESIDUE(6,1)
PARTICULATE ANTIGEN(6,1)
PEPTIDE HAPTEN(6,1)
POSITIVELY CHARGED DEAE DEXTRAN(6,1)
POWERFUL ADJUVANT(6,1)
PREFORMED ADJUVANT(6,1)
PUBLISHED CONCLUSION(6,1)
REPRODUCTIVE RESEARCH(6,1)
ROUTINE(6,1)
SAPONIN DERIVATIVE(6,1)
SCIENTIFIC LITERATURE(6,1)
SEVERITY INDICATION(6,1)
SITE REACTOGENICITY COMPARISON(6,1)
SOLUBLE PROTEIN ANTIGEN(6,1)
STATED INTEGER INCLUSION(6,1)
STRONG IMMUNOSTIMULANT(6,1)
TERM REPRODUCTIVE ORGAN(6,1)
VACCINATED ANIMAL(6,1)
VACCINE ADJUVANT(6,1)
VACCINE EFFICACY(6,1)
VETERINARILY ACTIVE SUBSTANCE(6,1)
COMPANION ANIMAL(5,3)
DEAE DEXTRAN COMPONENT(5,3)
DETERGENT(5,3)
DISPERSION MEDIUM(5,3)
HEIFER(5,3)
ANTIBACTERIAL(5,2)
DIALYSIS(5,2)
STERILE POWDER(5,2)
ADJUVANT TECHNOLOGY(5,1)
AGE MONTH(5,1)
AGENT DELAYING ABSORPTION(5,1)
ALUMINUM MONOSTEARATE(5,1)
BULK VACCINE(5,1)
CAPTIVE WILD ANIMAL(5,1)
CHOICE ANTIGEN(5,1)
CHOICE DILUENT(5,1)
CIRCULATING ANTIBODY PRESENCE(5,1)
COMBINATION ADJUVANT VACCINEOR(5,1)
DEAE DEXTRAN DOSE(5,1)
DISINTEGRATION(5,1)
DOG CLOSE EXAMINATION(5,1)
DOSAGE UNIFORMITY(5,1)
DRUG DELIVERY(5,1)
EARLY IGM(5,1)
EXTEMPORANEOUS PREPARATION(5,1)
FILTERED STERILIZATION(5,1)
FUSION PROTEIN(5,1)
GAUGE NEEDLE(5,1)
GELATIN CAPSULE(5,1)
GLUCOSE POLYMER(5,1)
HOMOGENEOUS FRACTION(5,1)
IMMUNOGENIC PREPARATION(5,1)
IMMUNOSTIMULATING COMPLEX DERIVATIVE(5,1)
INERT DILUENT(5,1)
INJECTABLE COMPOSITION DELAYED RELEASE(5,1)
INJECTION SITE PHYSICAL PALPATION(5,1)
IONIC POLYSACCHARIDE MASS RATIO(5,1)
ISCOMATRIX BASED VACCINE(5,1)
LHRH COUPLING(5,1)
MAGNESIUM STEARATE(5,1)
MALE PIG(5,1)
NEGATIVELY CHARGED POLYSACCHARIDE COMPONENT(5,1)
PHARMACEUTICAL CARRIER(5,1)
POSITIVELY CHARGED IMMUNOSTIMULATING COMPLEX(5,1)
POTATO STARCH(5,1)
PRIMARY IMMUNIZATION(5,1)
PROLONGED ABSORPTION(5,1)
PROTEIN INCORPORATION(5,1)
PROTEIN REMAINDER(5,1)
REACTOGENICITY COMPLETE ABSENCE(5,1)
REPRODUCTIVE ACTIVITY(5,1)
SAPONIN FRACTION MIXTURE(5,1)
SAPONIN PREPARATION(5,1)
SCORE SEVERE SITE REACTION(5,1)
SECONDARY VACCINATION(5,1)
SEMI QUANTITATIVE SCALE(5,1)
SEVERE PAIN(5,1)
SEX SIGNIFICANT PROPORTION(5,1)
SITE REACTION DATA(5,1)
SOLUBLE ADJUVANT(5,1)
SOLUBLE DEXTRAN(5,1)
SOUTH AMERICAN TREE(5,1)
STERILE INJECTABLE SOLUTION PREPARATION(5,1)
STERILE MIXING VESSEL(5,1)
SUBSTITUTIONAL AMINOACID VARIANT(5,1)
TAIL VEIN(5,1)
TOXOID CONJUGATE SHOW(5,1)
UNITARY DOSAGE(5,1)
VACCINATION DAY(5,1)
VACCINE MANUFACTURE(5,1)
VACCINE PREPARATION(5,1)
VACCINE SITE(5,1)
VISIBLE ABSCESS FORMATION(5,1)
VISUAL INSPECTION(5,1)
WEEKLY INTERVAL(5,1)
COLTER(4,2)
DEAE DEXTRAN LEVEL(4,2)
EXCIPIENT(4,2)
MONKEY(4,2)
REPTILE(4,2)
SIMILARITY(4,2)
STERILE WATER(4,2)
TROCHE(4,2)
ULTRAFILTRATION(4,2)
ACTION PREVENTION(4,1)
ACTIVE INGREDIENT PLUS(4,1)
ADJUVANT COMPONENT ACTIVITY(4,1)
ADJUVANT COMPOUND(4,1)
AMINOACID INSERTIONAL DERIVATIVE(4,1)
ANTIGEN COMPLEX(4,1)
ANTIGEN CONTENT(4,1)
ANTIGEN SPECIFIC ELISA ASSAY(4,1)
ANTIGEN VOLUME(4,1)
BIBLIOGRAPHY(4,1)
CHOLESTEROL SOLUTION(4,1)
CLOSE VISUAL EXAMINATION(4,1)
COMBINATION ADJUVANT MLS(4,1)
COMPOSITION PERCENTAGE(4,1)
CONSISTENT IMMUNE RESPONSE(4,1)
DEAE DEXTRAN FINAL CONCENTRATION(4,1)
DEAE DEXTRAN VOLUME(4,1)
DISORDER TREATMENT(4,1)
EFFICACIOUS VACCINE DEVELOPMENT(4,1)
FREQUENT SITE REACTION(4,1)
IMMUNE RESPONSE DURATION(4,1)
IMMUNOSTIMULATING COMPLEX FINAL FORMULATION(4,1)
IMMUNOSTIMULATING COMPLEX PARTICLE(4,1)
INVNETION(4,1)
ISOTONIC AGENT(4,1)
LABORATORY TEST ANIMAL(4,1)
LHRH CARRIER(4,1)
LHRH CHEMICAL EQUIVALENT(4,1)
MAGNETIC STIRRER(4,1)
MAGNETIC STIRRING BAR(4,1)
MINIMUM TITER(4,1)
MODIFIED DEXTRAN(4,1)
NON NATURAL AMINOACID RESIDUE(4,1)
OUTDOOR RUN(4,1)
PARENTERAL(4,1)
PHOSPHOLIPID RATIO(4,1)
PHYLUM(4,1)
PLANT ORIGIN(4,1)
POLYSACHARIDE(4,1)
PRINCIPAL ACTIVE INGREDIENT(4,1)
PROPER FLUIDITY(4,1)
PROTEIN PREPARATION(4,1)
QUILLAJA SAPONARIA(4,1)
REACTOGENIC COMPONENT(4,1)
RECENT REVIEW(4,1)
REMAINING BPL(4,1)
SENSITIVE ANIMAL(4,1)
SIGNIFICANT ADJUVANT(4,1)
SORBIC ACID(4,1)
STERILE VEHICLE(4,1)
STRINGENT TEST(4,1)
STRONG IMMUNE RESPONSE(4,1)
TERM SAPONIN(4,1)
TERMINAL FUSION(4,1)
VACCINE COMPONENT(4,1)
WEAK ACTIVITY(4,1)
WHOLE FORMULATION(4,1)
WHOLE VIRUS(4,1)
EYE(3,3)
HORSE(3,3)
BOTTLE(3,2)
ELIXIR(3,2)
TOXICITY(3,2)
ALPHA LINKED(3,1)
AMINOACID SEQUENCE VARIANT(3,1)
AMINOACID SUBSTITUTION(3,1)
ANTIBODY RESPONSE DURATION(3,1)
BANTAM(3,1)
BICARBONATE(3,1)
BIOTECHNOLOGY(3,1)
BREAST CANCER(3,1)
CELL HELP(3,1)
CELL LYTIC EFFECT(3,1)
CENTRIFUGATION(3,1)
CHLOROBUTANOL(3,1)
CLOSE INSPECTION(3,1)
CONJUGATE VACCINE(3,1)
CORRECT CONCENTRATION(3,1)
CORRECT VOLUME(3,1)
COUNTERION(3,1)
DAY INTERVAL(3,1)
DEAE DEXTRAN MASS RATIO(3,1)
DEAE DEXTRAN RATIO(3,1)
DEAE GROUP(3,1)
DISSOLUTION(3,1)
DONKEY(3,1)
(US9149520)
ANIMAL(100,19)
IMMUNE RESPONSE(100,16)
LUTEINISING HORMONE RELEASING HORMONE(100,4)
DIPHTHERIA TOXOID CONJUGATE(100,2)
SAPONIN ADJUVANT(100,1)
IONIC POLYSACCHARIDE(57,9)
ADJUVANT(56,50)
TOXOID CONJUGATE(44,7)
SEVERITY INDICATION(39,1)
BODILY HEALTH(36,1)
DOSAGE UNIFORMITY(36,1)
SOLUBLE POLYSACCHARIDE(36,1)
SAPONIN COMPONENT(32,13)
SOLUBLE MOLECULE(32,1)
IONIC POLYSACCHARIDE COMPONENT(31,11)
SEVERE PAIN(31,1)
VACCINE MANUFACTURE(31,1)
ANIONIC MACROMOLECULE COMPONENT(28,1)
PARENTERAL(28,1)
VACCINE COMPOSITION DOSE(28,1)
DISEASE TREATMENT(27,1)
WHOLE FORMULATION(27,1)
DEAE DEXTRAN COMPONENT(26,3)
POLYSACCHARIDE(24,6)
IONIC MACROMOLECULE COMPONENT(24,3)
DISEASE CONDITION(24,1)
IMMUNOSTIMULATING COMPLEX COMPONENT(23,11)
STERILIZATION(23,1)
LHRH(21,35)
VACCINE(21,23)
PHOSPHOLIPID(21,2)
STEROL(21,1)
IMMUNOSTIMULATING COMPLEX(19,33)
DIPHTHERIA TOXOID(19,10)
IRRADIATION(19,1)
IONIC POLYSACCHARIDE MASS RATIO(18,2)
ADMINISTRATION(17,5)
SOLUBILITY(17,1)
LHRH DIPHTHERIA(16,7)
SAPONIN(15,7)
REACTION SITE(14,9)
DRY HEAT(13,1)
ANTIGEN RANGE(12,3)
BCA PROTEIN ASSAY(12,3)
IONIC POLYSACCHARIDE ADJUVANT(12,2)
IGG ISOTYPE SERUM TITER(12,1)
ISCOMATRIX ADJUVANTED VACCINE(12,1)
VACCINE COMPOSITION SINGLE DOSE(12,1)
DIPALMITOYL PHOSPHATIDYLCHOLINE(11,2)
INSOLUBLE MATERIAL(11,1)
ISCOM ADJUVANTED VACCINE(11,1)
DOSAGE UNIT(10,5)
DEAE DEXTRAN FORMULATION(10,4)
ISCOMATRIX FORMULATION(10,3)
BOVINE VIRAL DIARRHE(...)";Pharmaceuticals;Open
"1998-11-10
1999-11-04
2000-08-29
2000-10-31
2002-04-29";"CA2287775           A1 2000-05-10 [CA2287775]
STG: (A1) Application laid open
AP : 1999CA-2287775 1999-11-08
AU5837699           A  2000-05-11 [AU9958376]
STG: (A) Open to public inspection
AP : 1999AU-0058376 1999-11-09
JP2000139482        A  2000-05-23 [JP2000139482]
STG: (A) Published application
AP : 1999JP-0319340 1999-11-10
CN1254756           A  2000-05-31 [CN1254756]
STG: (A) Published application
AP : 1999CN-0123522 1999-11-10
EP1013757           A2 2000-06-28 [EP1013757]
STG: (A2) Application published without search report
AP : 1999EP-0308866 1999-11-08
BRPI9905352         A1 2000-11-21 [BR199905352]
STG: (A1) Published application
AP : 1999BR-0005352 1999-11-10
US6168942           A  2001-01-02 [US6168942]
STG: (A) Patents Granted before 2001-04-15
AP : 1999US-09433262 1999-11-04
US6168942           B1 2001-01-02 [US6168942]
STG: (B1) Granted patent as first publication
AP : 1999US-09433262 1999-11-04
FD :  Provisional Appl: US60/107,908 FDD=1998-11-10
FD : Provisional Appl: US60/107,908 FDD=1998-11-10 [1998US-60107908]
BR9905352           A  2001-02-06 [BR9905352]
STG: (A) Published application
AP : 1999BR-0005352 1999-11-10
ZA9907011           B  2001-05-09 [ZA9907011]
STG: (B)
AP : 1999ZA-0007011 1999-11-09
NZ500925            A  2001-06-29 [NZ-500925]
STG: (A) Published application
AP : 1999NZ-0500925 1999-11-09
AR019250            A1 2001-12-26 [AR--19250]
STG: (A1) Independent patent application
AP : 1999AR-0105650 1999-11-08
EP1013757           A3 2002-03-06 [EP1013757]
STG: (A3) Published search report
AP : 1999EP-0308866 1999-11-08
US6410032           B1 2002-06-25 [US6410032]
STG: (B1) Granted patent as first publication
AP : 2000US-09702330 2000-10-31
FD :  Division of: US09/433,262 FDD=1999-11-04 [1999US-09433262]
FD : Division of: US6168942 A 0 [US6168942]
FD : Provisional Appl: US60/107,908 FDD=1998-11-10 [1998US-60107908]
US6410299           B1 2002-06-25 [US6410299]
STG: (B1) Granted patent as first publication
AP : 2000US-09649796 2000-08-29
FD :  Division of: US09/433,262 FDD=1999-11-04 [1999US-09433262]
FD : Division of: US6168942 A 0 [US6168942]
FD : Provisional Appl: US60/107,908 FDD=1998-11-10 [1998US-60107908]
US20030165520       A1 2003-09-04 [US20030165520]
STG: (A1) Application published
AP : 2002US-10134288 2002-04-29
JP2003259885        A  2003-09-16 [JP2003259885]
STG: (A) Published application
AP : 2003JP-0022253 1999-11-10
AU765792            B2 2003-10-02 [AU-765792]
STG: (B2) Patent proceeded by OPI
AP : 1999AU-0058376 1999-11-09
TW585916            B  2004-05-01 [TW-585916]
STG: (B) Granted patent or patent of addition
AP : 1999TW-0119594 1999-11-09
CN1510130           A  2004-07-07 [CN1510130]
STG: (A) Published application
AP : 2003CN-0146677 1999-11-10
JP3602841           B2 2004-10-01 [JP3602841]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2003JP-0022253 1999-11-10
FD :  Division of: JP11319340 0 [1999JP-0319340]
JP3602759           B2 2004-10-01 [JP3602759]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 1999JP-0319340 1999-11-10
US6916477           B2 2005-07-12 [US6916477]
STG: (B2) Granted patent as second publication
AP : 2002US-10134288 2002-04-29
FD :  Division of: US09/702,330 FDD=2000-10-31 [2000US-09702330]
FD : Division of: US09/433,262 FDD=1999-11-04 [1999US-09433262]
FD : Division of: US6410032 A 0 [US6410032]
FD : Division of: US6168942 A 0 [US6168942]
FD : Provisional Appl: US60/107,908 FDD=1998-11-10 [1998US-60107908]
FD : Previous publication: US20030165520 A1 2003-09-04 [US20030165520]
CN1231578           C  2005-12-14 [CN1231578C]
STG: (C) Granted patent for invention
AP : 1999CN-0123522 1999-11-10
CN1247775           C  2006-03-29 [CN1247775C]
STG: (C) Granted patent for invention
AP : 2003CN-0146677 1999-11-10
FD :  Division of: CN99123522.3 FDD=1999-11-10 [1999CN-0123522]
HK1026718           A1 2006-04-21 [HK1026718]
STG: (A1) Patent application
AP : 2000HK-0105908 2000-09-20
HK1067383           A1 2006-08-18 [HK1067383]
STG: (A1) Patent application
AP : 2004HK-0110338 2004-12-30
BRPI9905352         A2 2010-01-19 [BR199905352]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 1999BR-0005352 1999-11-10";60018;"CA2287775           A1 2000-05-10 [CA2287775]
AU5837699           A  2000-05-11 [AU9958376]
JP2000139482        A  2000-05-23 [JP2000139482]
CN1254756           A  2000-05-31 [CN1254756]
EP1013757           A2 2000-06-28 [EP1013757]
BRPI9905352         A1 2000-11-21 [BR199905352]
US6168942           A  2001-01-02 [US6168942]
US6168942           B1 2001-01-02 [US6168942]
BR9905352           A  2001-02-06 [BR9905352]
ZA9907011           B  2001-05-09 [ZA9907011]
NZ500925            A  2001-06-29 [NZ-500925]
AR019250            A1 2001-12-26 [AR--19250]
EP1013757           A3 2002-03-06 [EP1013757]
US6410032           B1 2002-06-25 [US6410032]
US6410299           B1 2002-06-25 [US6410299]
US20030165520       A1 2003-09-04 [US20030165520]
JP2003259885        A  2003-09-16 [JP2003259885]
AU765792            B2 2003-10-02 [AU-765792]
TW585916            B  2004-05-01 [TW-585916]
CN1510130           A  2004-07-07 [CN1510130]
JP3602841           B2 2004-10-01 [JP3602841]
JP3602759           B2 2004-10-01 [JP3602759]
US6916477           B2 2005-07-12 [US6916477]
CN1231578           C  2005-12-14 [CN1231578C]
CN1247775           C  2006-03-29 [CN1247775C]
HK1026718           A1 2006-04-21 [HK1026718]
HK1067383           A1 2006-08-18 [HK1067383]
BRPI9905352         A2 2010-01-19 [BR199905352]";"1998US-60107908
1999US-09433262
2000US-09649796
2000US-09702330
2002US-10134288";;"PFIZER
PFIZER PRODUCTS";PFIZER;"(EP1013757)
US
(EP1013757)
US
(US6168942)
US
(US6410032)
US
(US6410299)
US
(US6916477)
US


(CA2287775)
US
(BR199905352)
US
(BR199905352)
US";"(EP1013757)
NAME=Pfizer Products Inc. Eastern Point Road , CITY=Groton, Connecticut 06340 , COUNTRY=US 

(EP1013757)
NAME=Pfizer Products Inc. Eastern Point Road Groton, Connecticut 06340 , COUNTRY=US 

(US6168942)
NAME=Pfizer Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

(US6410032)
NAME=Pfizer Inc , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

(US6410299)
NAME=Pfizer Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

NAME=Pfizer Products Inc. , CITY=Groton , STATE=CT , COUNTRY=US , ATYP=US Company 

(US6916477)
NAME=Pfizer Inc. , CITY=New York , STATE=NY , COUNTRY=US , ATYP=US Company 

(JP2003259885)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(JP3602841)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(JP2000139482)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(JP3602759)
NAME=PFIZER PRODUCTS INC. , REG=397067152 

(CA2287775)
NAME=PFIZER PRODUCTS INC. Eastern Point Road , CITY=GROTON , STATE=CT , POSTCODE=06340 , COUNTRY=US 

(BR199905352)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 

(BR199905352)
NAME=PFIZER PRODUCTS INC , COUNTRY=US 
";1;"CAO XUEMEI
SHEPPARD MICHAEL GEORGE";"(EP1013757)
US
(EP1013757)
US";"(EP1013757)
NAME=Cao, Xuemei 6 Catbird Lane , CITY=East Lyme, Connecticut 06333 , COUNTRY=US 

NAME=Sheppard, Michael George 29 Kingswood Drive , CITY=North Stonington, Connecticut 06359 , COUNTRY=US 

(EP1013757)
NAME=Cao, Xuemei 6 Catbird Lane East Lyme, Connecticut 06333 , COUNTRY=US 

NAME=Sheppard, Michael George 29 Kingswood Drive North Stonington, Connecticut 06359 , COUNTRY=US 
";"(EP1013757)
Attenuated forms of bovine viral diarrhea virus";"(EP1013757)
The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the N
 protease gene. The invention includes the attenuated viruses made by this method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.";"(CA2287775)
1. An attenuated bovine viral diarrhea (BVD) virus, wherein said virus has a genomic nucleic acid sequence comprising the sequence of SEQ ID NO:1 from nt 39 to nt 12116, or a degenerate variant thereof.
2. The attenuated BVD virus of claim 1, wherein said virus has a genomic nucleic acid sequence consisting essentially of the sequence of SEQ ID N0:1 from nt 39 to nt 12116, or a degenerate variant thereof.
3. The virus of claim 1, in substantially purified form.
4. A host cell infected with the virus of claim 1.
5. Progeny virus produced by the host cell of claim 4.
6. A vaccine camprising the attenuated BVD virus of claim 1 and a veterinarily accaptable carrier.
7. A nucleic acid molecule, comprising the sequence of SEQ ID NO:1 from nt 39 to nt 12116, or a degenerate variant thereof.
8. The nucleic acid molecule of claim 7, consisting essentially of the sequence of SEQ ID NO:1 from nt 39 to nt 12116, or a degenerate variant thereof.
9. The nucleic acid molecule of claim 7, in substantially purified form.
10. A vector comprising a distinct coding element consisting essentially of the nucleic acid molecule of claim 7.
11. The vector of claim 10, which is plasmid pBVDdN1 (ATCC No. 203354).
12. A host cell transformed or transfected with the nucleic acid molecule of claim 7 or the vector of claim 10.
13. Progeny BVD virus produced by the host cell of claim 12.
14. A vaccine comprising the nucleic acid molecule of claim 7, and a veterinarily acceptable carrier.
15. A method of modifying an isolated wild type BVD viral genome sa as to make it suitable for use in a vaccine, comprising mutating the genomic nucleic acid of said isolated wild type virus to inactivate the N pro protease gene.
16. The method of claim 15, wherein said inactivation of said N pro protease gene is accomplished by a procedure comprising: a) reverse transcribing the genomic RNA from said wild type BVD virus to form cDNA; b) cloning the cDNA of step a); c) mutating the N pro protease gene in the cloned cDNA of step b) so that said gene cannot produce a fully active gene product; and 32 d) cloning the mutated cDNA of step c).
17. The method of claim 16, wherein said N pro protease gene is inactivated by deleting all or part of its sequence from said wild type BVD viral genome.
18. A BVD viral genome made by the method of claim 15.
19. A vector comprising a distinct sequence element consisting essentially of the BVD viral genome of claim 18.
20. A host cell transfected with the viral genome of claim 18 or the vector of claim 19.
21. Progeny BVD virus produced by the host cell of ctaim 20.
22. A vaccine comprising the viral genome of claim 18, and a veterinarily acceptable carrier.
23. A method of attenuating a wild type BVD virus so as to make it suitable for use in a vaccine, comprising mutating the genomic nucleic acid of said virus to inactivate the N pro protease gene.
24. The method of claim 23, wherein attenuation is accomplished by a procedure comprising: a) isolating said wild type BVD virus; b) cloning the genomic nucleic acid of the isolated virus of step a); c) mutating the cloned genomic nucleic acid of step b) so as to inactivate the N pro protease gene; and d) transforming or transfecting the mutated nucleic acid of step c) into a host cell to produce attenuated virus.
25. The method of claim 24, wherein said N pro protease gene is inactivated by deleting all or part of its sequence from said wild type BVD viral genome.
26. An attenuated BVD virus made by the method of claim 23.
27. A host cell infected with the attenuated virus of claim 26.
28. The infected host cell of claim 27, wherein the host cell is an MDBK cell (ATCC CCL-22).
29. Progeny virus produced by the host cell of claim 28.
30. A vaccine comprising the attenuated BVD virus of claim 26, and a veterinartly acceptable carrier.
31. A method of inducing an immune response in cattle, comprising administering the vaccine of claim 6, 14, 22 or 30 to said cattle at a dosage sufficient to induce protective immunity against subsequent infection with BVD virus. 33
32. The method of claim 31, wherein the protective immunity results from both a humoral and cell-mediated immune response.
33. A method of inducing the production of antibody to BVD virus in an animal capable of making antibody, comprising administering: (a) the virus of claim 1; (b) the nucleic acid molecule of claim 7; (c) the vector of claim 10; (d) the viral genome of claim 18; (e) the vector of claim 19; or (f) the attenuated virus of claim 26, to, said animal at a dosage effective to induce said production of antibody.
34. The method of claim 33, wherein said antibody is produced in cattle.
35. The method of claim 33, further comprising isolating said antibody from said animal.
36. An antibody made by the method of claim 33. 34";"(EP1013757)
The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene.
The present invention is directed to methods of producing an attenuated form of bovine viral diarrhea (BVD) virus by inactivating a specific gene in the viral genome.
The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene.
In its first aspect, the present invention is based upon the development of a specific attenuated BVD viral strain.
In its first aspect, the present invention is based upon the development of a specific attenuated BVD viral strain.
The present invention is directed to methods of producing an attenuated form of bovine viral diarrhea (BVD) virus by inactivating a specific gene in the viral genome.";"(EP1013757)
For prokaryotic cells, the STBL2 strain of E. coli (gibco brl) has been found to give the best results for propagating the plasmid, and is generally preferred.
A clear need exists for new and effective vaccines to control the spread of the BVD virus.
Wschr. 81:481-487 (1974)) and are highly predisposed to infection with microorganisms causing diseases such as pneumonia or enteric disease (Barber, et al., Vet.
this protection is limited to one strain of homologous virus.
infection and this protection is limited to one strain of homologous virus.
this protection is limited to one strain of homologous virus.
Unfortunately, only one such vaccine appears to protect fetuses from infection and this protection is limited to one strain of homologous virus.
important diseases
Given that the disease caused by this virus is one of the most widespread and economically important diseases of cattle, such vaccines would represent a substantial advance in livestock farming.";"A61K-031/711
A61K-039/00
A61K-039/12
A61K-039/15
A61K-039/395
A61K-048/00
A61P-031/12
A61P-031/14
C07H-021/04
C07K-014/18
C07K-016/08
C12N-001/15
C12N-001/19
C12N-001/21
C12N-005/10
C12N-007/04
C12N-015/09
C12N-015/63";"(EP1013757)
1. An attenuated bovine viral diarrhea (BVD) virus, wherein said virus has a genomic nucleic acid sequence comprising the sequence of SEQ ID NO:1 from nt 39 to nt 12116, or a degenerate variant thereof.
7. A nucleic acid molecule, comprising the sequence of SEQ ID NO:1 from nt 39 to nt 12116, or a degenerate variant thereof.
15. A method of modifying an isolated wild type BVD viral genome so as to make it suitable for use in a vaccine, comprising mutating the genomic nucleic acid of said isolated wild type virus to inactivate the Npro protease gene.
23. A method of attenuating a wild type BVD virus so as to make it suitable for use in a vaccine, comprising mutating the genomic nucleic acid of said virus to inactivate the Npro protease gene.";"(EP1013757)
BOVINE VIRAL DIARRHEA VIRUS(100,44)
NPRO PROTEASE GENE(100,21)
ATTENUATED FORM(100,4)
HOMOLOGOUS VIRUS STRAIN(94,3)
ATTENUATED BVD VIRAL STRAIN(69,1)
VETERINARILY ACCEPTABLE CARRIER(48,8)
VIRAL GENOME(44,15)
VACCINE(35,38)
VIRUS(30,56)
DEGENERATE(30,5)
CATTLE IMMUNIZATION(29,1)
GASTROINTESTINAL DISEASE(29,1)
DISEASE(27,3)
BOVINE VIRAL DIARRHEA(26,45)
ATTENUATED VIRUS(26,9)
HOST CELL(25,14)
GENOMIC NUCLEIC ACID SEQUENCE(25,2)
GENOMIC NUCLEIC ACID(24,9)
PROGENY BOVINE VIRAL DIARRHEA(23,2)
ANTIBODY GENE(23,1)
BVD(20,2)
CLONED GENOMIC NUCLEIC ACID(19,1)
REVERSE TRANSCRIBING(19,1)
INFECTION(18,7)
ISOLATED VIRUS(17,1)
MICROORGANISM(17,1)
GENOMIC RNA(16,3)
BVDDN(16,2)
PNEUMONIA(16,1)
ANTIBODY PRODUCTION(15,7)
FETUS(15,1)
CATTLE(14,21)
BARBER(14,1)
STEP MUTATED CDNA(14,1)
GENE(13,10)
STEP CDNA CLONE(13,1)
BOVINE VIRAL DIARRHEA DN(12,35)
NUCLEIC ACID MOLECULE(12,8)
SERUM NEUTRALIZATION ASSAY(11,4)
PLASMID(10,11)
DOSAGE(10,7)
CELL MEDIATED IMMUNE RESPONSE(9,3)
CODING ELEMENT(9,3)
GIBCO(9,2)
PLASMID PVVNADL DNA(9,2)
PROKARYOTIC CELL(9,2)
INACTIVATED NPRO PROTEASE GENE(9,1)
INTESTINAL MUCOSA ULCERATION(9,1)
PROTECTIVE IMMUNITY RESULT(9,1)
VECTASTAIN ELITE ABC KIT(9,1)
WILD TYPE VIRUS ISOLATION(9,1)
VET(8,14)
POST TRANSFECTION(8,6)
MUTATED VIRAL GENOME(8,2)
CALF BIRTH(8,1)
DATA DEMONSTRATING SEROCONVERSION(8,1)
NPRO PROTEASE INACTIVATION(8,1)
PREGNANT CATTLE PLACENTA(8,1)
STEP NUCLEIC ACID MUTATION(8,1)
SENTINEL ANIMAL(7,3)
POSITIVE TITER(6,5)
CONFERENCE RE PROCEEDING(6,2)
IMMUNOHISTOCHEMISTRY ASSAY(6,2)
IMMUNOMETRIC ASSAY(6,2)
PRODUCTIVE INFECTION(6,2)
DNA FRAGMENT LIGATION(6,1)
E STRAIN(6,1)
EMBRYONIC BOVINE TRACHEA CELL(6,1)
FETAL EQUINE SERUM(6,1)
FULLY ACTIVE GENE PRODUCT(6,1)
GENE ENCODING VIRAL PROTEIN(6,1)
GENERAT ING ANTIBODY(6,1)
INFECTED RD MONOLAYER(6,1)
MEGASCRIPT REAGENT(6,1)
NCP VIRUS REPLICATION(6,1)
PARENTAL VIRUS RNA(6,1)
PROGENY VIRUS ATTENUATION(6,1)
PVVNADL DNA TEMPLATE(6,1)
REMINGTON PHARMACEUTICAL SCIENCE(6,1)
RESTRICTION ENZYME DIGESTION(6,1)
SERUM NEUTRALIZING(6,1)
ULTRASPEC RNA REAGENT(6,1)
WILD TYPE BVD VIRUS(6,1)
WILD TYPE INSULATION(6,1)
INFECTED ANIMAL(5,2)
INOCULATED ANIMAL(5,2)
NPRO CODING SEQUENCE(5,2)
NPRO GENE(5,2)
RADIOIMMUNE ASSAY(5,2)
RNA TRANSCRIPT(5,2)
FETAL BOVINE SERUM(5,1)
FRESH RD MONOLAYER(5,1)
IMMUNOLOGICAL DEFENSE(5,1)
LIPID AMINE ADJUVANT(5,1)
PESTIVIRUS GENUS(5,1)
PLASMID DNA TRANSFORMATION(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
PRIMER(4,9)
WILD TYPE(4,9)
PURIFIED FORM(4,4)
FOLD GREAT AFFINITY(4,2)
GIBCO BRL(4,2)
RANDOM MUTAGENESIS(4,2)
TRANSFECTED CELL(4,2)
ACCEPTED CONVENTION(4,1)
AGENT FACILITATING CELLULAR UPTAKE(4,1)
ANALYTICAL CENTRIFUGATION(4,1)
ANTIBODY TITER(4,1)
ANTIGEN QUANTITATION(4,1)
BOVINE KIDNEY CELL(4,1)
BOVINE RD CELL(4,1)
BOVINE TESTICULAR CELL(4,1)
BOVINE TURBINATE CELL(4,1)
BROAD TISSUE TROPISM ATTENUATION(4,1)
BVDV PREVENTION(4,1)
CATIONIC LIPID(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CHOLERA TOXIN(4,1)
CLASSICAL SWINE FEVER(4,1)
CODING SEQUENCE DELETION(4,1)
CP BIOTYPE(4,1)
DISEASE SEVERITY(4,1)
DNA REARRANGEMENT EVIDENCE(4,1)
EMERYVILLE CA(4,1)
EXTRA NUCLEOTIDE(4,1)
EXTRA OLIGONUCLEOTIDE(4,1)
FLAVIVIRIDAE FAMILY(4,1)
GENTLE ROCKING(4,1)
HETEROLOGOUS COLONY(4,1)
IMMUNIZATION DAY(4,1)
IMMUNOMODULATORY AGENT(4,1)
INFECTED CATTLE EXHIBIT(4,1)
INFECTION ABSOLUTE PREVENTION(4,1)
INTRA LYMPH NODE(4,1)
MACK PUBLISHING(4,1)
MANUFACTURER INSTRUCTION(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
MUTATED VIRUS(4,1)
NATURAL VIRUS GENOME(4,1)
NEUTRALIZING SERUM(4,1)
NPRO DELETION(4,1)
PARENTAL RNA(4,1)
PARENTERAL ADMINISTRATION(4,1)
PESTIVIRUS CDNA(4,1)
PLASMID ENCODING(4,1)
PLASMID PROPAGATION(4,1)
PROKARYOTIC HOST CELL(4,1)
PROTEOLYTIC CLEAVAGE(4,1)
PURITY ASSESSMENT(4,1)
PVVNADL TRANSFORMATION(4,1)
RD CELL MONOLAYER(4,1)
RNA DEPENDENT(4,1)
RNA POLYMERASE PROMOTER(4,1)
RNA TRANSFECTION(4,1)
SAPONIN FRACTION(4,1)
SCIENTIFIC PUBLICATION(4,1)
SELF NON SELF DISCRIMINATION SCIENCE(4,1)
SLOW REPLICATION(4,1)
UNIQUE RESTRICTION ENZYME(4,1)
UNIVERSITY BLVD(4,1)
UNLABELED ANTIBODY QUANTITY(4,1)
VACCINATED CATTLE(4,1)
VACCINATION DOSE(4,1)
VIRAL CHALLENGE(4,1)
VIRAL ENZYME(4,1)
VIRAL POLYPEPTIDE(4,1)
VIRAL REPLICATION(4,1)
VIRUS FETAL TRANSMISSION(4,1)
VIRUS PLAQUE(4,1)
VIRUS VACCINATED ANIMAL(4,1)
VIRUS VIRION(4,1)
DENATURATION(3,3)
VIRAL INFECTION(3,3)
ANTIBODY PRESENCE(3,2)
BOVINE VIRAL DIARRHEA PROTEIN(3,2)
PFU DNA POLYMERASE UNIT(3,2)
VIRUS PREPARATION(3,2)
AMPLIFICATION CYCLE(3,1)
ANTIBODY REACTION(3,1)
ATTENUATED BOVINE VIRAL DIARRHEA(3,1)
BOVINE VIRAL DIARRHEA VACCINE(3,1)
BP PLASMID(3,1)
CAMBRIDGE MA(3,1)
CELL EXTRACT(3,1)
CLINICAL SYNDROME VARIETY(3,1)
CONTAMINATING NUCLEIC ACID MOLECULE(3,1)
ENVELOPE PROTEIN(3,1)
GEL ELECTROPHORESIS(3,1)
GENETIC CODE DEGENERACY(3,1)
GENOMIC DNA(3,1)
HIGHLY HYDROPHOBIC PROTEIN(3,1)
IMMUNE RESPONSE INDUCTION(3,1)
IMMUNITY DURATION(3,1)
INFECTIVITY FALL(3,1)
INJECTED ANIMAL(3,1)
INJECTION SCHEDULE(3,1)
MAJOR GENOTYPE(3,1)
MINI DNA PURIFICATION(3,1)
MUTATED PLASMID PRODUCTION(3,1)
MUTATION INTRODUCTION(3,1)
NONSTRUCTURAL PROTEIN PROCESSING(3,1)
NUCLEIC ACID ENCODING(3,1)
OLIGONUCLEOTIDE SEQUENCE(3,1)
PARENTAL VIRUS REPLICATION RATE(3,1)
PLASMID SCHEMATIC REPRESENTATION(3,1)
PROMEGA CORP(3,1)
PROTEASE ACTIVITY(3,1)
RNA ENCODING(3,1)
RNA MOLECULE(3,1)
VACCINAL AGENT(3,1)
VACCINE ABILITY(3,1)
VECTOR FRAGMENT(3,1)
VECTOR LABORATORY(3,1)
VIRAL GENOME REGION(3,1)
VIRICIDAL AGENT(3,1)
VIRUS PARTICLE(3,1)
VIRUS STOCK(3,1)
ACETONE(2,3)
AGAROSE(2,3)
EUKARYOTIC CELL(2,3)
POLYMERASE CHAIN REACTION AMPLIFICATION(2,3)
SHEEP(2,3)
BIOCHEMISTRY(2,2)
BOVINE VIRAL DIARRHEA PRESENCE(2,2)
DEXTROSE(2,2)
FORMALDEHYDE(2,2)
INITIATION CODON(2,2)
MODIFIED LIVE VIRUS VACCINE(2,2)
PATHOGEN(2,2)
SITE DIRECTED MUTAGENESIS(2,2)
STABILIZER(2,2)
ACCESSION(2,1)
ALUMINUM HYDROXIDE GEL(2,1)
AMPLIFICATION REACTION(2,1)
AQUEOUS CARRIER(2,1)
AVRIDINE(2,1)
BIOLOGICAL FLUID(2,1)
BOVINE VIRAL DIARRHEA GENOME(2,1)
BOVINE VIRAL DIARRHEA SEQUENCE(2,1)
BOVINE VIRAL DIARRHEA STRAIN(2,1)
CELL LYSATE(2,1)
CHEMICAL MUTAGEN(2,1)
CLONED NUCLEIC ACID(2,1)
CODING REGION(2,1)
COFACTOR(2,1)
COMPLETE GENOMIC SEQUENCE(2,1)
CORE PROTEIN(2,1)
CORRELATION(2,1)
CULTURE MEDIUM(2,1)
CYTOKINE(2,1)
DIAGNOSTIC(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
EXTRA INSERTION(2,1)
FUNCTIONALLY EQUIVALENT(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
IMMUNOASSAY VARIETY(2,1)
LABORATORY SAMPLE(2,1)
MAMMALIAN CELL(2,1)
MONOCLONAL ANTIBODY TECHNOLOGY(2,1)
MURAMYL DIPEPTIDE(2,1)
MUTATED BOVINE VIRAL DIARRHEA(2,1)
MUTATED NUCLEIC ACID(2,1)
MUTATION PRODUCT(2,1)
NON TRANSLATED REGION(2,1)
OPTIMEM VOLUME(2,1)
PLASMID COMPLETE(2,1)
PLATINUM COMPLEX(2,1)
PORCINE CELL(2,1)
POST IMMUNIZATION(2,1)
POST VACCINATION(2,1)
PRIMARY IMMUNIZATION(2,1)
PROTECTIVE IMMUNE RESPONSE(2,1)
RE LATED(2,1)
SAFETY(2,1)
STANDARD DNA IMMUNIZATION(2,1)
SUSTAINED RELEASE(2,1)
TE BUFFER(2,1)
TRANSFECTION MIXTURE(2,1)
UNIFORM POPULATION(2,1)
VIRAL RNA SYNTHESIS(2,1)
VIRAL SEQUENCE(2,1)
YIELD DNA(2,1)
(US6168942)
VIRUS(100,50)
VACCINE(100,36)
NPRO PROTEASE GENE(100,21)
BOVINE VIRAL DIARRHEA(100,10)
VIRAL GENOME(100,9)
WILD TYPE(100,6)
ATTENUATED FORM(100,3)
BOVINE VIRAL DIARRHEA VIRUS(100,1)
WILD TYPE INSULATION(100,1)
ATTENUATED BVD VIRAL STRAIN(46,2)
BVD VIRUS SPREAD(46,1)
HOMOLOGOUS VIRUS STRAIN(44,1)
CLONED GENOMIC NUCLEIC ACID(34,1)
ATTENUATED VIRUS(31,10)
CATTLE ECONOMICALLY IMPORTANT DISEASE(30,1)
ISOLATED VIRUS(30,1)
CATTLE IMMUNIZATION(29,1)
GASTROINTESTINAL DISEASE(29,1)
GENOMIC NUCLEIC ACID(27,10)
MUTATED GENE(22,1)
DISEASE(19,2)
REVERSE TRANSCRIBING(19,1)
MICROORGANISM(17,1)
GENOMIC RNA(16,3)
PNEUMONIA(16,1)
FETUS(15,1)
STEP NUCLEIC ACID MUTATION(15,1)
INFECTION(14,6)
ATTENUATION(14,2)
BARBER(14,1)
HOST CELL(13,8)
BVD(13,6)
BVD VIRUS ATTENUATION(13,4)
STEP CDNA CLONE(13,1)
STBL(12,2)
SERUM NEUTRALIZATION ASSAY(11,4)
PLASMID(10,10)
GENE(10,6)
BVD VIRUS GENOME(9,2)
GIBCO(9,2)
PLASMID PVVNADL DNA(9,2)
PROKARYOTIC CELL(9,2)
BVD VIRUS NADL STRAIN(9,1)
CYTOPATHIC BVD VIRUS MARKER(9,1)
INACTIVATED NPRO PROTEASE GENE(9,1)
INTESTINAL MUCOSA ULCERATION(9,1)
VECTASTAIN ELITE ABC KIT(9,1)
WILD TYPE VIRUS ISOLATION(9,1)
VET(8,14)
POST TRANSFECTION(8,6)
STRAIN(8,3)
MUTATED VIRAL GENOME(8,2)
NPRO GENE DELETED BVD(8,2)
SERUM NEUTRALIZING TITER(8,2)
DATA DEMONSTRATING SEROCONVERSION(8,1)
NCP BIOTYPE VIRUS(8,1)
NPRO PROTEASE INACTIVATION(8,1)
PREGNANT CATTLE PLACENTA(8,1)
PCR AMPLIFICATION(7,3)
SENTINEL ANIMAL(7,3)
VETERINARILY ACCEPTABLE CARRIER(7,3)
CLEAR NEED(7,1)
POSITIVE TITER(6,5)
CONFERENCE RE PROCEEDING(6,2)
IMMUNOHISTOCHEMISTRY ASSAY(6,2)
IMMUNOMETRIC ASSAY(6,2)
PRODUCTIVE INFECTION(6,2)
BVD VIRAL GENOME SEQUENCE(6,1)
BVD VIRUS PLAQUE(6,1)
BVD VIRUS STRAIN(6,1)
DNA FRAGMENT LIGATION(6,1)
EMBRYONIC BOVINE TRACHEA CELL(6,1)
FETAL EQUINE SERUM(6,1)
GENE ENCODING VIRAL PROTEIN(6,1)
INFECTED RD MONOLAYER(6,1)
MEGASCRIPT REAGENT(6,1)
MUTATED BVD GENOME(6,1)
NCP VIRUS REPLICATION(6,1)
PARENTAL VIRUS RNA(6,1)
PROGENY VIRUS ATTENUATION(6,1)
PVVNADL DNA TEMPLATE(6,1)
RESTRICTION ENZYME DIGESTION(6,1)
ULTRASPEC RNA REAGENT(6,1)
MDBK CELL(5,4)
BVD PROTEIN(5,2)
COLI STBL(5,2)
INFECTED ANIMAL(5,2)
INOCULATED ANIMAL(5,2)
NPRO CODING SEQUENCE(5,2)
RADIOIMMUNE ASSAY(5,2)
RNA TRANSCRIPT(5,2)
RNA TRANSFECTION(5,2)
FETAL BOVINE SERUM(5,1)
FRESH RD MONOLAYER(5,1)
IMMUNOLOGICAL DEFENSE(5,1)
OLIGONUCLEOTIDE NADLE SEQUENCE(5,1)
PESTIVIRUS GENUS(5,1)
PLASMID DNA TRANSFORMATION(5,1)
PLASMID PBVDDN GENERATION(5,1)
SUCROSE GRADIENT CENTRIFUGATION(5,1)
SYNTHESIZED POLYPROTEIN(5,1)
VIRAL GENOME NTR REGION(5,1)
PRIMER(4,9)
ANTIBODY PRODUCTION(4,5)
ANTIBODY GENERATION(4,2)
FOLD GREAT AFFINITY(4,2)
GIBCO BRL(4,2)
RANDOM MUTAGENESIS(4,2)
TRANSFECTED CELL(4,2)
VIRAL CLONE(4,2)
ACCEPTED CONVENTION(4,1)
AGENT FACILITATING CELLULAR UPTAKE(4,1)
AMPHIGEN ADJUVANT(4,1)
ANALYTICAL CENTRIFUGATION(4,1)
ANIMAL DISEASE NATIONAL LABORATORY(4,1)
ANTIBODY TITER(4,1)
ANTIGEN QUANTITATION(4,1)
ATTENUATED BVD(4,1)
AVRIDINE LIPID(4,1)
BOVINE KIDNEY CELL(4,1)
BOVINE RD CELL(4,1)
BOVINE TESTICULAR CELL(4,1)
BOVINE TURBINATE CELL(4,1)
BROAD TISSUE TROPISM ATTENUATION(4,1)
BVD VACCINE(4,1)
BVD VIRAL DNA(4,1)
BVD VIRUS DETECTION(4,1)
BVD VIRUS NUCLEIC ACID(4,1)
BVD VIRUS PRESENCE(4,1)
BVD VIRUS SEQUENCE(4,1)
BVDDN ADMINISTRATION(4,1)
BVDDN GENOMIC SEQUENCE(4,1)
BVDV PREVENTION(4,1)
CATIONIC LIPID(4,1)
CHEMICALLY INDUCED MUTATION(4,1)
CHOLERA TOXIN(4,1)
CLASSICAL SWINE FEVER(4,1)
CODING SEQUENCE DELETION(4,1)
DISEASE SEVERITY(4,1)
DNA REARRANGEMENT EVIDENCE(4,1)
EMERYVILLE CALIF(4,1)
ENVELOPE GLYCOPROTEIN(4,1)
EXTRA NUCLEOTIDE(4,1)
EXTRA OLIGONUCLEOTIDE(4,1)
FLAVIVIRIDAE FAMILY(4,1)
GENTLE ROCKING(4,1)
HETEROLOGOUS COLONY(4,1)
IMMUNOMODULATORY AGENT(4,1)
INCOMPLETE ADJUVANT(4,1)
INFECTED CATTLE(4,1)
INFECTION ABSOLUTE PREVENTION(4,1)
INTRA LYMPH NODE(4,1)
MACK PUBLISHING(4,1)
MONOPHOSPHORYL LIPID(4,1)
MUCOSAL DISEASE OUTBREAK(4,1)
MUTATED BVDDN(4,1)
MUTATED VIRUS(4,1)
NATURAL VIRUS GENOME(4,1)
NEUTRALIZING SERUM(4,1)
NPRO DELETION(4,1)
PARENTAL RNA(4,1)
PARENTERAL ADMINISTRATION(4,1)
PBVDDN INITIATION CODON(4,1)
PCR FRAGMENT GENERATION(4,1)
PESTIVIRUS CDNA(4,1)
PLASMID ENCODING(4,1)
PLASMID PROPAGATION(4,1)
PROKARYOTIC HOST CELL(4,1)
PROTEOLYTIC CLEAVAGE(4,1)
PURITY ASSESSMENT(4,1)
PVVNADL AMPLIFICATION(4,1)
PVVNADL TRANSFORMATION(4,1)
RD CELL MONOLAYER(4,1)
RNA POLYMERASE PROMOTER(4,1)
RT PCR BEAD(4,1)
SAPONIN FRACTION(4,1)
SELF NON SELF DISCRIMINATION SCIENCE(4,1)
SLOW REPLICATION(4,1)
UNIQUE RESTRICTION ENZYME(4,1)
UNIVERSITY BLVD(4,1)
UNLABELED ANTIBODY QUANTITY(4,1)
VACCINATED CATTLE(4,1)
VACCINATION DOSE(4,1)
VECTOR FRAGMENT GENERATION(4,1)
VIRAL CHALLENGE(4,1)
VIRAL ENZYME(4,1)
VIRAL POLYPEPTIDE(4,1)
VIRAL REPLICATION(4,1)
VIRUS FETAL TRANSMISSION(4,1)
VIRUS VACCINATED ANIMAL(4,1)
VIRUS VIRION(4,1)
DOSAGE(3,5)
DENATURATION(3,3)
VIRAL INFECTION(3,3)
ANTIBODY PRESENCE(3,2)
BVD PRESENCE(3,2)
PFU DNA POLYMERASE UNIT(3,2)
VIRUS PREPARATION(3,2)
AMINE ADJUVANT(3,1)
AMPLIFICATION CYCLE(3,1)
ANTIBODY REACTION(3,1)
ATCC CCL(3,1)
BP PLASMID(3,1)
CELL EXTRACT(3,1)
CLINICAL SYNDROME VARIETY(3,1)
CONTAMINATING NUCLEIC ACID MOLECULE(3,1)
DESIGNATION VECTOR(3,1)
EFFICACY STUDY(3,1)
ENVELOPE PROTEIN(3,1)
GEL ELECTROPHORESIS(3,1)
GENETIC CODE DEGENERACY(3,1)
GENOMIC DNA(3,1)
HIGHLY HYDROPHOBIC PROTEIN(3,1)
IMMUNITY DURATION(3,1)
INFECTIVITY FALL(3,1)
INJECTED ANIMAL(3,1)
INJECTION SCHEDULE(3,1)
LIVE VIRUS(3,1)
MAJOR GENOTYPE(3,1)
MINI DNA PURIFICATION(3,1)
MUTATED PLASMID PRODUCTION(3,1)
MUTATION INTRODUCTION(3,1)
NONSTRUCTURAL PROTEIN PROCESSING(3,1)
NUCLEIC ACID ENCODING(3,1)
PARENTAL VIRUS REPLICATION RATE(3,1)
PROMEGA CORP(3,1)
PROTEASE ACTIVITY(3,1)
RNA ENCODING(3,1)
RNA MOLECULE(3,1)
SANDWICH ASSAY(3,1)
TERM PROTECTIVE IMMUNITY(3,1)
VACCINAL AGENT(3,1)
VACCINE ABILITY(3,1)
VECTOR LABORATORY(3,1)
VIRICIDAL AGENT(3,1)
VIRUS PARTICLE(3,1)
VIRUS STOCK(3,1)
ACETONE(2,3)
AGAROSE(2,3)
AMERICAN TYPE CULTURE COLLECTION(2,3)
EUKARYOTIC CELL(2,3)
SHEEP(2,3)
WILD TYPE BVD VIRUS(2,3)
BIOCHEMISTRY(2,2)
CELL MEDIATED IMMUNE RESPONSE(2,2)
CODING ELEMENT(2,2)
COLD SPRING(2,2)
DEGENERATE(2,2)
DEXTROSE(2,2)
DNA VACCINE(2,2)
PATHOGEN(2,2)
SITE DIRECTED MUTAGENESIS(2,2)
STABILIZER(2,2)
5NTR LOCATION(2,1)
ACCESSION(2,1)
ALUMINUM HYDROXIDE GEL(2,1)
AMPLIFICATION REACTION(2,1)
AQUEOUS CARRIER(2,1)
BIOLOGICAL FLUID(2,1)
BIRTH(2,1)
BVD SEQUENCE(2,1)
BVD SPECIFIC VIRAL PROTEIN(2,1)
BVD VIRUS SINGLE STRAIN(2,1)
BVDDN COMPLETE SEQUENCE(2,1)
BVDDN PRODUCTION(2,1)
BVDDN SLOW GROWTH(2,1)
BVDDNI(2,1)
CELL LYSATE(2,1)
CHEMICAL MUTAGEN(2,1)
CLONED NUCLEIC ACID(2,1)
CODING REGION(2,1)
COFACTOR(2,1)
COMPLETE BVDDN(2,1)
COMPLETE GENOMIC SEQUENCE(2,1)
CORE PROTEIN(2,1)
CORRELATION(2,1)
DIAGNOSTIC(2,1)
DOSE MULTIPLE ADMINISTRATION(2,1)
EXTRA INSERTION(2,1)
FUNCTION REDUCED RATE(2,1)
FUNCTIONALLY EQUIVALENT(2,1)
GENOTYPE ANALYSIS(2,1)
HEAT LABILE ENTEROTOXIN(2,1)
IMMUNE RESPONSE TERM INDUCTION(2,1)
IMMUNOASSAY VARIETY(2,1)
LABORATORY SAMPLE(2,1)
MAMMALIAN CELL(2,1)
MLV VACCINE SINGLE DOSE(2,1)
MONOCLONAL ANTIBODY TECHNOLOGY(2,1)
MURAMYL DIPEPTIDE(2,1)
MUTATED NUCLEIC ACID(2,1)
MUTATION PRODUCT(2,1)
NON TRANSLATED REGION(2,1)
OPTIMEM VOLUME(2,1)
PHENOTYPE ANALYSIS(2,1)
PLATINUM COMPLEX(2,1)
POLYMERASE CHAIN REACTION GENERATION(2,1)
PORCINE CELL(2,1)
POST IMMUNIZATION(2,1)
POST VACCINATION(2,1)
PRIMARY IMMUNIZATION(2,1)
PROTECTIVE IMMUNE RESPONSE(2,1)
SAFETY(2,1)
SELECTIVE PCR(2,1)
STANDARD DNA IMMUNIZATION(2,1)
SUSTAINED RELEASE(2,1)
TE BUFFER(2,1)
TERM ANTIBODY(2,1)
TRANSFECTION MIXTURE(2,1)
UNIFORM POPULATION(2,1)
VIRAL RNA SYNTHESIS(2,1)
YIELD DNA(2,1)
(US6410032)
VACCINE(100,40)
VETERINARILY ACCEPTABLE CARRIER(100,7)
BOVINE VIRAL DIARRHEA VIRUS(100,4)
ATTENUATED FORM(100,3)
NPRO PROTEASE GENE(96,16)
DEGENERATE VARIANT(89,2)
ATTENUATED BVD VIRAL STRAIN(75,2)
BVD VIRUS SPREAD(74,1)
HOMOLOGOUS VIRUS STRAIN(72,1)
VIRAL GENOME(69,8)
CATTLE ECONOMICALLY IMPORTANT DISEASE(49,1)
GASTROINTESTINAL DISEASE(48,1)
CATTLE IMMUNIZATION(47,1)
BOVINE VIRAL DIARRHEA(45,7)
PROKARYOLIC CELL(42,1)
VIRUS(40,50)
DEGENERATE(37,4)
GENOMIC NUCLEIC ACID SEQUENCE(37,1)
ATTENUATED VIRUS(33,9)
GENOMIC NUCLEIC ACID(33,9)
DISEASE(31,2)
AMINOACID SEQUENCE(28,2)
MICROORGANISM(28,1)
GENOMIC SEQUENCE(26,3)
PNEUMONIA(26,1)
FETUS(24,1)
INFECTION(23,6)
BARBER(23,1)
BVD VIRUS ATTENUATION(22,4)
NUCLEIC ACID MOLECULE(19,9)
STBL(19,2)
BVD(18,6)
SERUM NEUTRALIZATION ASSAY(18,4)
GENE(17,6)
PLASMID(16,9)
BVD VIRUS GENOME(15,2)
GIBCO(15,2)
PLASMID PVVNADL DNA(15,2)
CYTOPATHIC BVD VIRUS MARKER(15,1)
INTESTINAL MUCOSA ULCERATION(15,1)
VECTASTAIN ELITE ABC KIT(15,1)
STRAIN(14,3)
MUTATED VIRAL GENOME(14,2)
BVD VIRUS NADL STRAIN(14,1)
INACTIVATED NPRO PROTEASE GENE(14,1)
POST TRANSFECTION(13,6)
DATA DEMONSTRATING SEROCONVERSION(13,1)
NCP BIOTYPE VIRUS(13,1)
NPRO PROTEASE INACTIVATION(13,1)
PREGNANT CATTLE PLACENTA(13,1)
VET(12,14)
CLEAR NEED(12,1)
PCR AMPLIFICATION(11,3)
SENTINEL ANIMAL(11,3)
CONFERENCE RE PROCEEDING(11,2)
IMMUNOHISTOCHEMISTRY ASSAY(11,2)
IMMUNOMETRIC ASSAY(11,2)
BVD VIRUS PLAQUE(11,1)
INFECTED RD MONOLAYER(11,1)
MUTATED BVD GENOME(11,1)
NCP VIRUS REPLICATION(11,1)
PARENTAL VIRUS RNA(11,1)
ULTRASPEC RNA REAGENT(11,1)
POSITIVE TITER(10,5)
PRODUCTIVE INFECTION(10,2)
BVD VIRAL GENOME SEQUENCE(10,1)
BVD VIRUS STRAIN(10,1)
DNA FRAGMENT LIGATION(10,1)
EMBRYONIC BOVINE TRACHEA CELL(10,1)
FETAL EQUINE SERUM(10,1)
MEGASCRIPT REAGENT(10,1)
PROGENY VIRUS ATTENUATION(10,1)
PVVNADL DNA TEMPLATE(10,1)
RESTRICTION ENZYME DIGESTION(10,1)
SERUM NEUTRALIZING(10,1)
TYPE BOVINE VIRAL DIARRHEA(10,1)
MDBK CELL(9,4)
BVD PROTEIN(9,2)
COLI STBL(9,2)
INOCULATED ANIMAL(9,2)
NPRO CODING SEQUENCE(9,2)
NPRO GENE(9,2)
RNA TRANSCRIPT(9,2)
RNA TRANSFECTION(9,2)
FETAL BOVINE SERUM(9,1)
FRESH RD MONOLAYER(9,1)
IMMUNOLOGICAL DEFENSE(9,1)
NPRO DELECTION(9,1)
OLIGONUCLEOTIDE NADLE SEQUENCE(9,1)
PESTIVIRUS GENUS(9,1)
PLASMID DNA TRANSFORMATION(9,1)
PLASMID PBVDN GENERATION(9,1)
SUCROSE GRADIENT CENTRIFUGATION(9,1)
SYNTHESIZED POLYPROTEIN(9,1)
VIRAL GENOME 5NTR REGION(9,1)
INFECTED ANIMAL(8,2)
ANTIBODY GENERATION(7,2)
FOLD GREAT AFFINITY(7,2)
GENOMIC RNA(7,2)
RANDOM MUTAGENESIS(7,2)
TRANSFECTED CELL(7,2)
AGENT FACILITATING CELLULAR UPTAKE(7,1)
AMPHIGEN ADJUVANT(7,1)
ANTIGEN QUANTITATION(7,1)
ATTENUATED BVD(7,1)
AVRIDINE LIPID(7,1)
BOVINE TESTICULAR CELL(7,1)
BOVINE TURBINATE CELL(7,1)
BROAD TISSUE TROPISM ATTENUATION(7,1)
BVD VACCINE(7,1)
BVD VIRUS DETECTION(7,1)
BVDDN ADMINISTRATION(7,1)
BVDDN GENOMIC SEQUENCE(7,1)
CHEMICALLY INDUCED MUTATION(7,1)
CLASSICAL SWINE FEVER(7,1)
ENVELOPE GLYCOPROTEIN(7,1)
FLAVIVIRIDAE FAMILY(7,1)
HETEROLOGOUS COLONY(7,1)
INFECTION ABSOLUTE PREVENTION(7,1)
MONOPHOSPHONYL LIPID(7,1)
MUCOSAL DISEASE OUTBREAK(7,1)
MUTATED BVDDN(7,1)
NATURAL VIRUS GENOME(7,1)
PBVDDN INITIATION CODON(7,1)
PLASMID PBVDDN(7,1)
PLASMID PVBDDN(7,1)
PROTEOLYTIC CLEAVAGE(7,1)
PVVNADL AMPLIFICATION(7,1)
PVVNADL TRANSFORMATION(7,1)
RT PCR BEAD(7,1)
SELF NON SELF DISCRIMINATION SCIENCE(7,1)
UNIVERSITY BLVD(7,1)
UNLABELED ANTIBODY QUANTITY(7,1)
VACCINATED CATTLE(7,1)
VIRAL CHALLENGE(7,1)
VIRUS FETAL TRANSMISSION(7,1)
VIRUS VIRION(7,1)
DOSAGE(6,5)
WILD TYPE(6,4)
ANTIBODY PRESENCE(6,2)
BVD PRESENCE(6,2)
PFU DNA POLYMERASE UNIT(6,2)
VIRUS PREPARATION(6,2)
ACCEPTED CONVENTION(6,1)
ANALYTICAL CENTRIFUGATION(6,1)
ANIMAL DISEASE NATIONAL LABORATORY(6,1)
ANTIBODY TITER(6,1)
BOVINE KIDNEY CELL(6,1)
BOVINE RD CELL(6,1)
BVD VIRAL DNA(6,1)
BVD VIRUS NUCLEIC ACID(6,1)
BVD VIRUS PRESENCE(6,1)
BVD VIRUS SEQUENCE(6,1)
BVDV PREVENTION(6,1)
CATIONIC LIPID(6,1)
CHOLERA TOXIN(6,1)
CODING SEQUENCE DELETION(6,1)
DIRECT WIRAL RNA SYNTHESIS(6,1)
DISEASE SEVERITY(6,1)
DNA REARRANGEMENT EVIDENCE(6,1)
EXTRA NUCLEOTIDE(6,1)
EXTRA OLIGONUCLEOTIDE(6,1)
GENTLE ROCKING(6,1)
IMMUNOMODULATORY AGENT(6,1)
INCOMPLETE ADJUVANT(6,1)
INFECTED CATTLE(6,1)
INTRA LYMPH NODE(6,1)
MACK PUBLISHING(6,1)
MUTATED VIRUS(6,1)
NEUTRALIZING SERUM(6,1)
PARENTAL RNA(6,1)
PARENTERAL ADMINISTRATION(6,1)
PCR FRAGMENT GENERATION(6,1)
PLASMID ENCODING(6,1)
PLASMID PROPAGATION(6,1)
PROKARYOTIC HOST CELL(6,1)
PROMGEA CORP(6,1)
RADIOIMMUNE ASSAY(6,1)
RD CELL MONOLAYER(6,1)
RNA POLYMERASE PROMOTER(6,1)
SAPONIN FRACTION(6,1)
SCIENTIFIC PUBLICATION(6,1)
SLOW REPLICATION(6,1)
UNIQUE RESTRICTION ENZYME(6,1)
VACCINATION DOSE(6,1)
VECTOR FRAGMENT GENERATION(6,1)
VIRAL ENZYME(6,1)
VIRAL POLYPEPTIDE(6,1)
VIRAL REPLICATION(6,1)
VIRUS VACCINATED ANIMAL(6,1)
DENATURATION(5,3)
VIRAL INFECTION(5,3)
AMINE ADJUVANT(5,1)
AMPLIFICATION CYCLE(5,1)
ANTIBODY REACTION(5,1)
ATCC CCL(5,1)
BP PLASMID(5,1)
CELL EXTRACT(5,1)
CLINICAL SYNDROME VARIETY(5,1)
CONTAMINATING NUCLEIC ACID MOLECULE(5,1)
DESIGNATION VECTOR(5,1)
ENVELOPE PROTEIN(5,1)
EUKARYLOTIC CELL(5,1)
GEL ELECTROPHORESIS(5,1)
GENE ENCODING(5,1)
GENETIC CODE DEGENERACY(5,1)
GENOMIC DNA(5,1)
GIBCO BRL(5,1)
HIGHLY HYDROPHOBIC PROTEIN(5,1)
IMMUNITY DURATION(5,1)
INFECTIVITY FALL(5,1)
INJECTED ANIMAL(5,1)
INJECTION SCHEDULE(5,1)
LIVE VIRUS(5,1)
MAJOR GENOTYPE(5,1)
MINI DNA PURIFICATION(5,1)
MUTATED PLASMID PRODUCTION(5,1)
MUTATION INTRODUCTION(5,1)
NONSTRUCTURAL PROTEIN PROCESSING(5,1)
NUCLEIC ACID ENCODING(5,1)
PARENTAL VIRUS REPLICATION RATE(5,1)
PROCARYOTIC CELL(5,1)
PROTEASE ACTIVITY(5,1)
RNA ENCODING(5,1)
RNA MOLECULE(5,1)
SANDWICH ASSAY(5,1)
TERM PROTECTIVE IMMUNITY(5,1)
VACCINAL AGENT(5,1)
VACCINE ABILITY(5,1)
VECTOR LABORATORY(5,1)
VIRICIDAL AGENT(5,1)
VIRUS PARTICLE(5,1)
VIRUS STOCK(5,1)
BIOCHEMISTRY(4,2)
CELL MEDIATED IMMUNE RESPONSE(4,2)
CODING ELEMENT(4,2)
COLD SPRING(4,2)
DEXTROSE(4,2)
PATHOGEN(4,2)
SITE DIRECTED MUTAGENESIS(4,2)
STABILIZER(4,2)
5NTR LOCATION(4,1)
ALUMINUM HYDROXIDE GEL(4,1)
AMPLIFICATION REACTION(4,1)
BVD SEQUENCE(4,1)
BVD VIRUS SINGLE STRAIN(4,1)
BVDDN COMPLETE SEQUENCE(4,1)
BVDDN PRODUCTION(4,1)
BVDDN SLOW GROWTH(4,1)
CELL LYSATE(4,1)
CHEMICAL MUTAGEN(4,1)
COMPLETE BVDDN(4,1)
CORE PROTEIN(4,1)
DIAGNOSTIC(4,1)
DOSE MULTIPLE ADMINISTRATION(4,1)
EXTRA INSERTION(4,1)
FUNCTIONALLY EQUIVALENT(4,1)
GENOTYPE ANALYSIS(4,1)
HEAT LABILE ENTEROTOXIN(4,1)
IMMUNE RESPONSE TERM INDUCTION(4,1)
IMMUNOASSAY VARIETY(4,1)
LABORATORY SAMPLE(4,1)
MAMMALIAN CELL(4,1)
MLV VACCINE SINGLE DOSE(4,1)
MONOCLONAL ANTIBODY TECHNOLOGY(4,1)
MURAMYL DIPEPTIDE(4,1)
MUTATED NUCLEIC ACID(4,1)
MUTATION PRODUCT(4,1)
NON TRANSLATED REGION(4,1)
OPTIMEM VOLUME(4,1)
PHENOTYPE ANALYSIS(4,1)
PLATINUM COMPLEX(4,1)
POLYMERASE CHAIN REACTION GENERATION(4,1)
PORCINE CELL(4,1)
POST IMMUNIZATION(4,1)
POST VACCINATION(4,1)
PRIMARY IMMUNIZATION(4,1)
PRIMER SE(4,1)
PROTECTIVE IMMUNE RESPONSE(4,1)
PROVOKA ANTIBODY PRODUCTION(4,1)
SAFETY(4,1)
SELECTIVE PCR(4,1)
STANDARD DNA IMMUNIZATION(4,1)
SUSTAINED RELEASE(4,1)
TE BUFFER(4,1)
TERM ANTIBODY(4,1)
TRANSFECTION MIXTURE(4,1)
UNIFORM POPULATION(4,1)
YIELD DNA(4,1)
ACETONE(3,3)
AGAROSE(3,3)
AMERICAN TYPE CULTURE COLLECTION(3,3)
SHEEP(3,3)
WILD TYPE BVD VIRUS(3,3)
DNA VACCINE(3,2)
AQUEOUS CARRIER(3,1)
BATTLE(3,1)
BIOLOGICAL FLUID(3,1)
BIRTH(3,1)
BVD SPECIFIC VIRAL PROTEIN(3,1)
CLONED NUCLEIC ACID(3,1)
CODING REGION(3,1)
COFACTOR(3,1)
COMPLETE GENOMIC SEQUENCE(3,1)
CORRELATION(3,1)
CULTURE MEDIUM(3,1)
CYTOKINE(3,1)
(US6410299)
VACCINE(100,35)
NPRO PROTEASE GENE(100,15)
BOVINE VIRAL DIARRHEA(100,9)
NUCLEIC ACID MOLECULE(100,9)
VIRAL GENOME(100,8)
ATTENUATED FORM(100,3)
WILD TYPE INSULATION(100,2)
BOVINE VIRAL DIARRHEA VIRUS(100,1)
ATTENUATED BVD VIRAL STRAIN(99,2)
BVD VIRUS SPREAD(99,1)
HOMOLOGOUS VIRUS STRAIN(96,1)
DEGENERATE VARIANT(84,1)
CATTLE ECONOMICALLY IMPORTANT DISEASE(66,1)
GASTROINTESTINAL DISEASE(64,1)
CATTLE IMMUNIZATION(63,1)
VIRUS(46,46)
ATTENUATED VIRUS(44,9)
DISEASE(42,2)
DEGENERATE(39,4)
MICROORGANISM(37,1)
GENOMIC SEQUENCE(34,3)
PNEUMONIA(34,1)
FETUS(33,1)
BARBER(31,1)
INFECTION(30,6)
BVD VIRUS ATTENUATION(30,4)
GENOMIC NUCLEIC ACID(29,8)
AMINOACID SEQUENCE(27,1)
STBL(26,2)
SERUM NEUTRALIZATION ASSAY(24,4)
BVD(23,6)
GENE(22,6)
PLASMID(21,10)
BVD VIRUS GENOME(21,2)
GIBCO(21,2)
CYTOPATHIC BVD VIRUS MARKER(21,1)
INTESTINAL MUCOSA ULCERATION(21,1)
VECTASTAIN ELITE ABC KIT(21,1)
PLASMID PVVNADL DNA(20,2)
PROKARYOTIC CELL(20,2)
CODING ELEMENT(19,3)
STRAIN(19,3)
MUTATED VIRAL GENOME(19,2)
BVD VIRUS NADL STRAIN(19,1)
INACTIVATED NPRO PROTEASE GENE(19,1)
POST TRANSFECTION(18,6)
NCP BIOTYPE VIRUS(18,1)
NPRO PROTEASE INACTIVATION(18,1)
PREGNANT CATTLE PLACENTA(18,1)
VET(16,12)
CLEAR NEED(16,1)
PCR AMPLIFICATION(15,3)
SENTINEL ANIMAL(15,3)
VETERINARILY ACCEPTABLE CARRIER(15,3)
BVD VIRUS PLAQUE(15,1)
INFECTED RD MONOLAYER(15,1)
MUTATED BVD GENOME(15,1)
NCP VIRUS REPLICATION(15,1)
PARENTAL VIRUS RNA(15,1)
ULTRASPEC RNA REAGENT(15,1)
CONFERENCE RE PROCEEDING(14,2)
IMMUNOHISTOCHEMISTRY ASSAY(14,2)
IMMUNOMETRIC ASSAY(14,2)
POSITIVE TITER(13,5)
PRODUCTIVE INFECTION(13,2)
BVD VIRAL GENOME SEQUENCE(13,1)
BVD VIRUS STRAIN(13,1)
DNA FRAGMENT LIGATION(13,1)
EMBRYONIC BOVINE TRACHEA CELL(13,1)
FETAL EQUINE SERUM(13,1)
GENE ENCODING VIRAL PROTEIN(13,1)
MEGASCRIPT REAGENT(13,1)
PROGENY VIRUS ATTENUATION(13,1)
PVVNADL DNA TEMPLATE(13,1)
RESTRICTION ENZYME DIGESTION(13,1)
SERUM NEUTRALIZING(13,1)
MDBK CELL(12,4)
BVD PROTEIN(12,2)
COLI STBL(12,2)
INOCULATED ANIMAL(12,2)
NPRO CODING SEQUENCE(12,2)
NPRO GENE(12,2)
RADIOIMMUNE ASSAY(12,2)
RNA TRANSCRIPT(12,2)
RNA TRANSFECTION(12,2)
FETAL BOVINE SERUM(12,1)
FRESH RD MONOLAYER(12,1)
IMMUNOLOGICAL DEFENSE(12,1)
OLIGONUCLEOTIDE NADLE SEQUENCE(12,1)
PESTIVIRUS GENUS(12,1)
PLASMID DNA TRANSFORMATION(12,1)
PLASMID PBVDDN GENERATION(12,1)
SUCROSE GRADIENT CENTRIFUGATION(12,1)
SYNTHESIZED POLYPROTEIN(12,1)
VIRAL GENOME NTR REGION(12,1)
INFECTED ANIMAL(11,2)
PRIMER(10,9)
FOLD GREAT AFFINITY(10,2)
GENOMIC RNA(10,2)
GIBCO BRL(10,2)
RANDOM MUTAGENESIS(10,2)
TRANSFECTED CELL(10,2)
AGENT FACILITATING CELLULAR UPTAKE(10,1)
AMPHIGEN ADJUVANT(10,1)
ANTIGEN QUANTITATION(10,1)
ATTENUATED BVD(10,1)
AVRIDINE LIPID(10,1)
BOVINE TESTICULAR CELL(10,1)
BOVINE TURBINATE CELL(10,1)
BROAD TISSUE TROPISM ATTENUATION(10,1)
BVD VACCINE(10,1)
BVD VIRUS DETECTION(10,1)
BVDDN GENOMIC SEQUENCE(10,1)
CHEMICALLY INDUCED MUTATION(10,1)
CLASSICAL SWINE FEVER(10,1)
ENVELOPE GLYCOPROTEIN(10,1)
FLAVIVIRIDAE FAMILY(10,1)
HETEROLOGOUS COLONY(10,1)
INFECTION ABSOLUTE PREVENTION(10,1)
MONOPHOSPHORYL LIPID(10,1)
MUCOSAL DISEASE OUTBREAK(10,1)
MUTATED BVDDN(10,1)
NATURAL VIRUS GENOME(10,1)
NPRO DELETION(10,1)
PBVDDN INITIATION CODON(10,1)
PESTIVIRUS CDNA(10,1)
PROTEOLYTIC CLEAVAGE(10,1)
PVVNADL AMPLIFICATION(10,1)
PVVNADL TRANSFORMATION(10,1)
RT PCR BEAD(10,1)
SELF NON SELF DISCRIMINATION SCIENCE(10,1)
UNIVERSITY BLVD(10,1)
UNLABELED ANTIBODY QUANTITY(10,1)
VACCINATED CATTLE(10,1)
VIRAL CHALLENGE(10,1)
VIRUS FETAL TRANSMISSION(10,1)
VIRUS VIRION(10,1)
ANTIBODY PRODUCTION(9,5)
ANTIBODY GENERATION(9,2)
ACCEPTED CONVENTION(9,1)
ANALYTICAL CENTRIFUGATION(9,1)
ANIMAL DISEASE NATIONAL LABORATORY(9,1)
ANTIBODY TITER(9,1)
BOVINE KIDNEY CELL(9,1)
BOVINE RD CELL(9,1)
BVD VIRAL DNA(9,1)
BVD VIRUS NUCLEIC ACID(9,1)
BVD VIRUS PRESENCE(9,1)
BVD VIRUS SEQUENCE(9,1)
BVDV PREVENTION(9,1)
CATIONIC LIPID(9,1)
CHOLERA TOXIN(9,1)
CODING SEQUENCE DELETION(9,1)
DISEASE SEVERITY(9,1)
DNA REARRANGEMENT EVIDENCE(9,1)
EMERYVILLE CALIF(9,1)
EXTRA NUCLEOTIDE(9,1)
EXTRA OLIGONUCLEOTIDE(9,1)
GENTLE ROCKING(9,1)
IMMUNOMODULATORY AGENT(9,1)
INCOMPLETE ADJUVANT(9,1)
INFECTED CATTLE(9,1)
INTRA LYMPH NODE(9,1)
MACK PUBLISHING(9,1)
MUTATED VIRUS(9,1)
NEUTRALIZING SERUM(9,1)
PARENTAL RNA(9,1)
PARENTERAL ADMINISTRATION(9,1)
PCR FRAGMENT GENERATION(9,1)
PLASMID ENCODING(9,1)
PLASMID PROPAGATION(9,1)
PROKARYOTIC HOST CELL(9,1)
PURITY ASSESSMENT(9,1)
RD CELL MONOLAYER(9,1)
RNA POLYMERASE PROMOTER(9,1)
SAPONIN FRACTION(9,1)
SCIENTIFIC PUBLICATION(9,1)
SLOW REPLICATION(9,1)
UNIQUE RESTRICTION ENZYME(9,1)
VACCINATION DOSE(9,1)
VECTOR FRAGMENT GENERATION(9,1)
VIRAL ENZYME(9,1)
VIRAL POLYPEPTIDE(9,1)
VIRAL REPLICATION(9,1)
VIRUS VACCINATED ANIMAL(9,1)
DOSAGE(8,5)
ANTIBODY PRESENCE(8,2)
BVD PRESENCE(8,2)
PFU DNA POLYMERASE UNIT(8,2)
VIRUS PREPARATION(8,2)
DENATURATION(7,3)
VIRAL INFECTION(7,3)
AMINE ADJUVANT(7,1)
AMPLIFICATION CYCLE(7,1)
ANTIBODY REACTION(7,1)
ATCC CCL(7,1)
BP PLASMID(7,1)
CELL EXTRACT(7,1)
CLINICAL SYNDROME VARIETY(7,1)
CONTAMINATING NUCLEIC ACID MOLECULE(7,1)
DESIGNATION VECTOR(7,1)
ENVELOPE PROTEIN(7,1)
GEL ELECTROPHORESIS(7,1)
GENETIC CODE DEGENERACY(7,1)
GENOMIC DNA(7,1)
HIGHLY HYDROPHOBIC PROTEIN(7,1)
IMMUNITY DURATION(7,1)
INFECTIVITY FALL(7,1)
INJECTED ANIMAL(7,1)
INJECTION SCHEDULE(7,1)
LIVE VIRUS(7,1)
MAJOR GENOTYPE(7,1)
MINI DNA PURIFICATION(7,1)
MUTATED PLASMID PRODUCTION(7,1)
MUTATION INTRODUCTION(7,1)
NONSTRUCTURAL PROTEIN PROCESSING(7,1)
NUCLEIC ACID ENCODING(7,1)
PARENTAL VIRUS REPLICATION RATE(7,1)
PROMEGA CORP(7,1)
PROTEASE ACTIVITY(7,1)
RNA ENCODING(7,1)
RNA MOLECULE(7,1)
SANDWICH ASSAY(7,1)
TERM PROTECTIVE IMMUNITY(7,1)
VACCINAL AGENT(7,1)
VACCINE ABILITY(7,1)
VECTOR LABORATORY(7,1)
VIRICIDAL AGENT(7,1)
VIRUS PARTICLE(7,1)
VIRUS STOCK(7,1)
PURIFIED FORM(6,4)
BIOCHEMISTRY(6,2)
CELL MEDIATED IMMUNE RESPONSE(6,2)
COLD SPRING(6,2)
DEXTROSE(6,2)
PATHOGEN(6,2)
SITE DIRECTED MUTAGENESIS(6,2)
STABILIZER(6,2)
5NTR LOCATION(6,1)
ALUMINUM HYDROXIDE GEL(6,1)
AMPLIFICATION REACTION(6,1)
BVD SEQUENCE(6,1)
BVD VIRUS SINGLE STRAIN(6,1)
BVDDN COMPLETE SEQUENCE(6,1)
BVDDN PRODUCTION(6,1)
BVDDN SLOW GROWTH(6,1)
CELL LYSATE(6,1)
CHEMICAL MUTAGEN(6,1)
COMPLETE BVDDN(6,1)
CORE PROTEIN(6,1)
DIAGNOSTIC(6,1)
DOSE MULTIPLE ADMINISTRATION(6,1)
EXTRA INSERTION(6,1)
FUNCTIONALLY EQUIVALENT(6,1)
GENOTYPE ANALYSIS(6,1)
HEAT LABILE ENTEROTOXIN(6,1)
IMMUNE RESPONSE TERM INDUCTION(6,1)
IMMUNOASSAY VARIETY(6,1)
LABORATORY SAMPLE(6,1)
MAMMALIAN CELL(6,1)
MLV VACCINE SINGLE DOSE(6,1)
MONOCLONAL ANTIBODY TECHNOLOGY(6,1)
MURAMYL DIPEPTIDE(6,1)
MUTATED NUCLEIC ACID(6,1)
MUTATION PRODUCT(6,1)
NON TRANSLATED REGION(6,1)
OPTIMEM VOLUME(6,1)
PHENOTYPE ANALYSIS(6,1)
PLATINUM COMPLEX(6,1)
POLYMERASE CHAIN REACTION GENERATION(6,1)
PORCINE CELL(6,1)
POST IMMUNIZATION(6,1)
POST VACCINATION(6,1)
PRIMARY IMMUNIZATION(6,1)
PROTECTIVE IMMUNE RESPONSE(6,1)
SAFETY(6,1)
SELECTIVE PCR(6,1)
STANDARD DNA IMMUNIZATION(6,1)
SUSTAINED RELEASE(6,1)
TE BUFFER(6,1)
TERM ANTIBODY(6,1)
TRANSFECTION MIXTURE(6,1)
UNIFORM POPULATION(6,1)
VET RE(...)";Pharmaceuticals;Open
"1998-04-02
1998-10-26
1999-04-01
2002-08-12
2005-05-09
2007-05-01";"US20030113845       A1 2003-06-19 [US20030113845]
STG: (A1) Application published
AP : 2002US-10217613 2002-08-12
US20050266460       A1 2005-12-01 [US20050266460]
STG: (A1) Application published
AP : 2005US-11124215 2005-05-09
US6987023           B2 2006-01-17 [US6987023]
STG: (B2) Granted patent as second publication
AP : 2002US-10217613 2002-08-12
FD :  Continuation of: US09/283,402 FDD=1999-04-01 [1999US-09283402]
FD : CIP of: US09/178,851 FDD=1998-10-26 [1998US-09178851]  abandoned
FD : Provisional Appl: US60/080,414 FDD=1998-04-02 [1998US-60080414]
FD : Previous publication: US20030113845 A1 2003-06-19 [US20030113845]
US7232684           B2 2007-06-19 [US7232684]
STG: (B2) Granted patent as second publication
AP : 2005US-11124215 2005-05-09
FD :  Continuation of: US10/217,613 FDD=2002-08-12 [2002US-10217613]
FD : Continuation of: US09/283,402 FDD=1999-04-01 [1999US-09283402]
FD : CIP of: US09/178,851 FDD=1998-10-26 [1998US-09178851]  abandoned
FD : Continuation of: US6987023 A 2006-01-17 [US6987023]
FD : Provisional Appl: US60/080,414 FDD=1998-04-02 [1998US-60080414]
FD : Previous publication: US20050266460 A1 2005-12-01 [US20050266460]
US20070298461       A1 2007-12-27 [US20070298461]
STG: (A1) Application published
AP : 2007US-11799130 2007-05-01
US7604973           B2 2009-10-20 [US7604973]
STG: (B2) Granted patent as second publication
AP : 2007US-11799130 2007-05-01
FD :  Continuation of: US11/124,215 FDD=2005-05-09 [2005US-11124215]
FD : Continuation of: US10/217,613 FDD=2002-08-12 [2002US-10217613]
FD : Continuation of: US09/283,402 FDD=1999-04-01 [1999US-09283402]
FD : CIP of: US09/178,851 FDD=1998-10-26 [1998US-09178851]  abandoned
FD : Continuation of: US7232684 A 0 [US7232684]
FD : Continuation of: US6987023 A 2006-01-17 [US6987023]
FD : Provisional Appl: US60/080,414 FDD=1998-04-02 [1998US-60080414]
FD : Previous publication: US20070298461 A1 2007-12-27 [US20070298461]";43450084;"US20030113845       A1 2003-06-19 [US20030113845]
US20050266460       A1 2005-12-01 [US20050266460]
US6987023           B2 2006-01-17 [US6987023]
US7232684           B2 2007-06-19 [US7232684]
US20070298461       A1 2007-12-27 [US20070298461]
US7604973           B2 2009-10-20 [US7604973]";"1998US-09178851
1998US-60080414
1999US-09283402
2002US-10217613
2005US-11124215
2007US-11799130";;UNIVERSITY OF OKLAHOMA;UNIVERSITY OF OKLAHOMA;"(US6987023)
US
(US7232684)
US
(US7604973)
US";"(US6987023)
NAME=The Board of Regents of the University of Oklahoma , CITY=Norman , STATE=OK , COUNTRY=US , ATYP=US Company 

(US7232684)
NAME=The Board of Regents of the University of Oklahoma , CITY=Norman , STATE=OK , COUNTRY=US , ATYP=US Company 

(US7604973)
NAME=The Board of Regents of the University of Oklahoma , CITY=Norman , STATE=OK , COUNTRY=US , ATYP=US Company 
";1;DEANGELIS PAUL;"(US20070298461)
US
(US7604973)
US";"(US20070298461)
NAME=DeAngelis Paul , CITY=Edmond , STATE=OK , COUNTRY=US 

(US7604973)
NAME=DeAngelis Paul , CITY=Edmond , STATE=OK , COUNTRY=US 
";"(US7604973)
DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use";"(US7604973)
The present invention relates to a nucleic acid segment having a coding region segment encoding enzymatically active Pasteurella multocida hyaluronate synthase (PmHAS), and to the use of this nucleic acid segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic acid product.";"(US20030113845)
What we claim is:
1. A purified nucleic acid segment comprising a coding region encoding enzymatically active hyaluronate synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronate synthase of SEQ ID NO: 1.
2. The purified nucleic acid segment of claim 1, wherein the purified nucleic acid segment comprises a nucleotide sequence as set forth in SEQ ID NO: 2.
3. A recombinant vector selected from the group consisting of a plasmid, cosmid, phage, or virus vector and wherein the recombinant vector further comprises a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronan synthase of SEQ ID NO: 1.
4. The recombinant vector of claim 3, wherein the purified nucleic acid segment comprises a nucleotide sequence as set forth in SEQ ID NO: 2.
5. The recombinant vector of claim 3, wherein the plasmid further comprises an expression vector.
6. The recombinant vector of claim 5, wherein the expression vector comprises a promoter operatively linked to the coding region.
7. A recombinant host cell, wherein the recombinant host cell is a prokaryotic cell transformed with a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronan synthase of SEQ ID NO: 1.
8. The recombinant host cell of claim 7, wherein the purified nucleic acid segment comprises a nucleotide sequence as set forth in SEQ ID NO: 2.
9. The recombinant host cell of claim 8, wherein the host cell produces hyaluronic acid.
10. A recombinant host cell, wherein the recombinant host cell is a eukaryotic cell transfected with a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronan synthase of SEQ ID NO: 1.
11. The recombinant host cell of claim 10, wherein the purified nucleic acid segment comprises a nucleotide sequence as set forth in SEQ ID NO: 2.
12. The recombinant host cell of claim 11, wherein the host cell produces hyaluronic acid.
13. A recombinant host cell, wherein the recombinant host cell is transformed to introduce a recombinant vector into the recombinant host cell, wherein the recombinant vector comprises a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronan synthase of SEQ ID NO: 1.
14. The recombinant host cell of claim 13, wherein the purified nucleic acid segment comprises a nucleotide sequence as set forth in SEQ ID NO: 2.
15. The recombinant host cell of claim 14, wherein the host cell produces hyaluronic acid.
16. A recombinant host cell, wherein the recombinant host cell is transduced with a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronan synthase of SEQ ID NO: 1.
17. The recombinant host cell of claim 16, wherein the purified nucleic acid segment comprises a nucleotide sequence as set forth in SEQ ID NO: 2.
18. The recombinant host cell of claim 17, wherein the host cell produces hyaluronic acid.
19. A purified and isolated nucleic acid sequence encoding enzymatically active hyaluronan synthase, the nucleic acid sequence selected from the group consisting of: 
 (a) the nucleic acid sequence as set forth in SEQ ID NO: 2; and 
 (b) complementary nucleic acid sequences to the nucleic acid sequence as set forth in SEQ ID NO: 2 and which encode an enzymatically active hyaluronan synthase.
20. A purified and isolated nucleic acid segment consisting essentially of a nucleic acid segment encoding enzymatically active hyaluronan synthase from Pasturella, wherein the purified nucleic acid segment encodes the Pasturella hyaluronan synthase of SEQ ID NO: 1.
21. A procaryotic or eucaryotic host cell transformed or transfected with an isolated nucleic acid segment according to claim 1 in a manner allowing the host cell to express hyaluronic acid.
22. An isolated nucleic acid segment consisting essentially of a nucleic acid segment encoding hyaluronan synthase from Pasturella having a nucleic acid segment sufficiently duplicative of the nucleic acid segment as set forth in SEQ ID NO: 2 to allow possession of the biological property of coding for Pasturella hyaluronan synthase.
23. A cDNA sequence according to claim 22.
24. A procaryotic or eucaryotic host cell transformed or transfected with a nucleic acid segment according to claim 1, 19, 20, or 22 in a manner allowing the host cell to express hyaluronic acid.";"(US7604973)
The present invention relates to a novel HAS that produces HA.
In particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a PmHAS gene, that includes within its amino acid sequence an amino acid sequence in accordance with SEQ ID NO:1.
Moreover, in other particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a gene that includes within its amino acid sequence the amino acid sequence of an HAS gene or DNA, and in particular to an HAS gene or cDNA, corresponding to Pasteurella multocida HAS.
The invention discloses nucleic acid segments encoding an enzymatically active hyaluronate synthase from P. multocida PmHAS.";"(US7604973)
Thus, it will be appreciated by those of skill in the art that other means may be used to obtain the HAS gene or cDNA, in light of the present disclosure.
Due to certain advantages associated with the use of prokaryotic sources, one will likely realize the most advantages upon isolation of the HAS gene from the prokaryote P. multocida.
These are advantageous in that one can augment the Lacto coccus or Bacillus strain's ability to synthesize HA through gene dosaging (i.e., providing extra copies of the HA synthase gene by amplification) and/or inclusion of additional genes to increase the availability of HA precursors.
The disadvantages of these approaches are that the yield of product will also be decreased and it may be difficult to achieve reproducibility from day to day or batch to batch.
A major problem with such proteins is their clearance from the blood and a short biological half life.
One present solution to this problem is to couple a small molecule shield that prevents the protein from being cleared from the circulation too rapidly.
This practice, however, is very difficult to achieve reproducibility and one must meticulously repurify the hyaluronic acid to remove the hyaluronidase and unwanted digestion products.";"A61K-009/00
A61K-039/102
A61K-047/36
A61L-024/08
A61L-029/08
C07H-021/04
C12N-001/00
C12N-001/21
C12N-005/10
C12N-009/10
C12N-009/24
C12N-015/00
C12N-015/54
C12N-015/63
C12P-019/04
C12P-019/26
C12Q-001/68";"(US7604973)
1. A method for producing hyaluronic acid, comprising the steps of: introducing a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasteurella into a host organism, wherein the enzymatically active hyaluronan synthase is a single protein that polymerizes UDP-GlcA and UDP-GlcNAc to form hyaluronic acid, and wherein the nucleic acid segment is selected from the group consisting of: (a) the nucleic acid sequence as set forth in SEQ ID NO:2; (b) a nucleic acid segment encoding SEQ ID NO:1; and (c) a nucleic acid segment encoding SEQ ID NO:17; growing the host organism in a medium to secrete hyaluronic acid; and recovering the secreted hyaluronic acid.
4. A method for producing hyaluronic acid, comprising the steps of: introducing a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasteurella into a host organism, wherein the enzymatically active hyaluronan synthase is a single protein that polymerizes UDP-GlcA and UDP-GlcNAc to form hyaluronic acid, and wherein a complement of the nucleic acid segment is capable of hybridizing to the nucleic acid sequence of SEQ ID NO:2 under standard hybridization conditions comprising 1.2-1.8x HPB at 40-50 C.; growing the host organism in a medium to secrete hyaluronic acid; and recovering the secreted hyaluronic acid.
7. A method for producing hyaluronic acid, comprising the steps of: introducing a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasteurella into a host organism, wherein the enzymatically active hyaluronan synthase is a single protein that polymerizes UDP-GlcA and UDP-GlcNAc to form hyaluronic acid, and wherein the nucleic acid segment is at least 85% identical to SEQ ID NO:2; growing the host organism in a medium to secrete hyaluronic acid; and recovering the secreted hyaluronic acid.
10. A method for producing hyaluronic acid, comprising the steps of: introducing a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasteurella into a host organism, wherein the enzymatically active hyaluronan synthase is a single protein that polymerizes UDP-GlcA and UDP-GlcNAc to form hyaluronic acid, and wherein the enzymatically active hyaluronan synthase encoded by the purified nucleic acid segment is at least 89% identical to SEQ ID NO:1; growing the host organism in a medium to secrete hyaluronic acid; and recovering the secreted hyaluronic acid.
13. A method for producing hyaluronic acid, comprising the steps of: introducing a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from Pasteurella into a host organism, wherein the enzymatically active hyaluronan synthase is a single protein that polymerizes UDP-GlcA and UDP-GlcNAc to form hyaluronic acid, and wherein the hyaluronan synthase has SEQ ID NO:18 and therein, and wherein a complement of the nucleic acid segment is capable of hybridizing to the nucleic acid sequence of SEQ ID NO:2 under standard hybridization conditions comprising 1.2-1.8x HPB at 40-50 C.; growing the host organism in a medium to secrete hyaluronic acid; and recovering the secreted hyaluronic acid.
21. A recombinant host cell, wherein the recombinant host cell is a Bacillus cell comprising a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase, wherein the enzymatically active hyaluronan synthase is a single protein that polymerizes UDP-GlcA and UDP-GlcNAc to form hyaluronic acid (HA), and wherein the coding region is under control of a promoter, and wherein the coding region encoding enzymatically active hyaluronan synthase is selected from the group consisting of: (A) a coding region that is at least 85% identical to SEQ ID NO:2; and (B) a coding region wherein a complement thereof is capable of hybridizing to the nucleic acid sequence of SEQ ID NO:2 under standard hybridization conditions comprising 1.2-1.8x HPB at 40-50 C.";"(US20030113845)
PURIFIED NUCLEIC ACID(100,20)
NUCLEIC ACID SEQUENCE(100,13)
RECOMBINANT VECTOR(100,13)
RECOMBINANT HOST CELL(100,11)
PASTURELLA MULTOCIDA(100,10)
ENZYMATICALLY ACTIVE HYALURONAN SYNTHASE(100,8)
NUCLEIC ACID(100,7)
ISOLATED NUCLEIC ACID(100,3)
DNA ENCODING HYALURONAN SYNTHASE(100,1)
NUCLEIC ACID SEQUENCE ENCODING(100,1)
HYALURONAN SYNTHASE(76,9)
ENCODING HYALURONAN SYNTHASE(54,3)
PASTURELLA MULTOCIDA HYALURONATE SYNTHASE(45,1)
CODING REGION ENCODING(40,6)
EXPRESS HYALURONAN SYNTHASE(32,1)
ENZYMATICALLY ACTIVE HYALURONATE SYNTHASE(28,2)
HYALURONATE SYNTHASE(24,6)
TURKEY BLOODSTREAM(24,1)
ANIMAL PATHOGEN IDENTIFICATION(23,1)
NUCLEIC ACID SEGMENT ENCODING(21,2)
KNOCKOUT MUTANT STRAIN(21,1)
ISOLATED DNA(19,3)
VIRUS VECTOR(17,1)
BACTERIAL SPECIES(16,1)
MULTOCIDA INFECTION(16,1)
VACCINATING ANIMAL(16,1)
ACAPSULAR MUTANT(15,9)
MAKE HYALURONAN POLYMER(15,2)
FOWL CHOLERA(14,11)
PMHA GENE(14,2)
RECOMBINANT CONSTRUCT(14,2)
ACAPSULAR CELL(14,1)
FOREIGN HOST(14,1)
EXPRESSION VECTOR(13,3)
BORDETELLA BRONCHISEPTICA(13,1)
ECONOMICALLY IMPORTANT DISEASE(13,1)
NUCLEIC ACID SEGMENT(12,8)
PARENTAL STRAIN(12,3)
RECOMBINANT CELL PREPARATION(12,1)
MULTOCIDA(11,52)
EXPRESS HYALURONIC ACID(11,2)
POSSESSION(11,1)
PROKARYOTE(10,1)
BASE SUGAR(9,1)
PROKARYOTIC SOURCE(9,1)
GENE(8,30)
PLASMID(8,18)
UDP GLC DEHYDROGENASE(8,4)
PURITY(8,1)
SUBSTITUTE(8,1)
MAMMALIAN UDP GALNAC(7,3)
CDNA SEQUENCE(7,2)
COSMID(7,2)
DIAGNOSTIC TEST(7,2)
OVINE TESTICULAR HYALURONIDASE(7,2)
INTRAVENOUS INJECTION(7,1)
CAPSULE BIOSYNTHESIS(6,6)
ANTIBODY(6,5)
IMMUNE RESPONSE(6,5)
AMINOACID SEQUENCE(6,4)
EUKARYOTIC CELL(6,2)
FOWL AGRICULTURAL PATHOGEN(6,2)
PROKARYOTIC CELL(6,2)
FOWL CHOLERA ACUTE OUTBREAK(6,1)
MOD(6,1)
PARAMECIUM BURSARIA CHLORELLA VIRUS(6,1)
PASTURELLA MULTOCIDA INSERTIONAL MUTAGENESIS(6,1)
DNA SEQUENCE(5,7)
SYNTHASE GENE(5,6)
DISEASE(5,5)
PHAGE(5,4)
VACCINATION(5,4)
ENCAPSULATED REVERTANT(5,3)
DEATH(5,2)
KFAA HOMOLOG GENE(5,2)
SUGAR NUCLEOTIDE PRECURSOR SYNTHESIS(5,2)
MULTOCIDA POLYSACCHARIDE TRANSPORTER(5,1)
PASTURELLA MULTOCIDA CARTER(5,1)
PMHA ENZYMOLOGICAL CHARACTERIZATION(5,1)
DNA(4,20)
KDA PROTEIN(4,5)
SYNTHASE ACTIVITY(4,5)
HYALURONIC ACID PRODUCTION(4,4)
HYBRIDIZATION PROBE(4,4)
PROBABILITY SUM(4,4)
CDNA(4,3)
GALNAC TRANSFERASE(4,3)
HOMOLOGOUS RECOMBINATION(4,3)
MULTOCIDA MEMBRANE(4,3)
SOUTHERN BLOT(4,3)
CLONED HASS(4,2)
DIAGNOSTIC BACTERIAL TYPING PROBE(4,2)
ABSOLUTELY CONSERVED MOTIF(4,1)
ACAPSULAR KNOCKOUT MUTANT(4,1)
ACAPSULAR TN MUTANT(4,1)
ALTERED HYALURONATE SYNTHASE(4,1)
ANTIBIOTIC PREMATURE WITHDRAWAL(4,1)
AZIDO UDP GLCA(4,1)
BOVINE PAPILLOMA VIRUS ORIGIN(4,1)
BOVINE PNEUMATIC PASTEURELLOSIS(4,1)
BSTXI GENOMIC FRAGMENT(4,1)
CANDIDATE TRANSMEMBRANE HELIX(4,1)
CAPSULAR POLYSACCHARIDE TRANSPORT(4,1)
CAPSULE MUTANT ASSORTMENT(4,1)
CAPSULE POLYSACCHARIDE TRANSPORTER ANALOG(4,1)
CHRONIC FOWL CHOLERA(4,1)
CLONED DNA SEGMENT VERSATILITY(4,1)
CLONED PMHA ORF(4,1)
COLI KPS GENE HOMOLOG(4,1)
DOMESTIC ANIMAL PNEUMONIC LESION(4,1)
ENDOGENOUS CAPSULE GENE PROMOTER(4,1)
EUKARYOTIC HYALURONATE SYNTHESIS(4,1)
EXTRACELLULAR POLYSACCHARIDE CAPSULE(4,1)
FOOD GRADE LACTOCOCCUS(4,1)
FOWL CHOLERA CAES(4,1)
FOWL CHOLERA CAUSATIVE AGENT(4,1)
GENE DISRUPTION CONFIRMATION(4,1)
HOST DEFENSE EVASION(4,1)
KDA UDP GLUCOSE PYROPHOSPHORYLASE(4,1)
LIPOPOLYSACCHARIDE CARBOHYDRATE MOIETY(4,1)
LIVE AVIRULENT VACCINE(4,1)
LIVESTOCK FIELD DETERMINATION(4,1)
MODIFIED STRUCTURE(4,1)
MOLECULARLY CLONED MAMMALIAN ENZYME(4,1)
MULTOCIDA ACAPSULAR MUTANT(4,1)
NATIVE PHOTOAFFINITY LABELING(4,1)
PMHA GENE DISRUPTED VERSION(4,1)
PPM7A PLASMID TRUNCATED DERIVATIVE(4,1)
PROTEASE INHIBITOR PEPSTATIN(4,1)
RECOMBINANT HASA PLASMID(4,1)
STRAIN ACAPSULAR MUTANT(4,1)
STREPTOCOCCAL CAPSULE(4,1)
STREPTOCOCCUS BIOSYNTHESIS(4,1)
STREPTOMYCES HYALURONIDASE DIGESTION(4,1)
SUGAR NUCLEOTIDE PRECURSOR UDP(4,1)
TRIDIMENSIONAL BIOMATERIAL(4,1)
SIZE DISTRIBUTION(3,5)
PMHA DNA SEQUENCE(3,4)
BACILLUS STRAIN(3,3)
CAPSULE FORMATION(3,3)
MODIFIED SIZE(3,3)
NATIVE ENZYME(3,3)
POLYMER CAPSULE(3,3)
BACTERIAL CULTURE(3,2)
BUOYANT DENSITY CENTRIFUGATION(3,2)
CAPSULE ROLE(3,2)
COLI SURE CELL(3,2)
DISEASE PREVENTION(3,2)
DNA DISRUPTION(3,2)
EXTRACELLULAR CAPSULE(3,2)
HETEROLOGOUS BACTERIUM(3,2)
ISOLATED HOST(3,2)
LYASE DIGESTION(3,2)
MULTOCIDA BACTERIUM(3,2)
MULTOCIDA DNA(3,2)
MULTOCIDA ENZYME(3,2)
MULTOCIDA GENE(3,2)
MULTOCIDA GENOME(3,2)
PERCOLL CUSHION(3,2)
PMHA RESIDUE(3,2)
PPM7A INSERT(3,2)
PRECURSOR SUGAR(3,2)
PREDICTED MR(3,2)
PROKARYOTIC GENE(3,2)
RADIOMETRIC ASSAY(3,2)
RECOMBINANTLY INTRODUCED GENE(3,2)
TN TERMINUS(3,2)
VERTEBRATE HASS(3,2)
VIRULENCE ASSAY(3,2)
ACAPSULAR AVIRULENT(3,1)
ACAPSULAR BACTERIUM(3,1)
ACAPSULAR MICROBE(3,1)
ACAPSULAR STRAIN BUOYANT DENSITY(3,1)
ACAPSULAR SUBCLONE(3,1)
AGAROSE ELECTROPHORESIS(3,1)
AVIAN PASTEURELLOSIS(3,1)
BACTERIAL CAPSULAR SYNTHESIS(3,1)
BACTERIUM FATE(3,1)
BIOCOM PATIBLE FILM(3,1)
CAPSULAR SEROTYPE(3,1)
CAPSULE GENE ENCODING ENZYME(3,1)
CHIMERIC DNA MOLECULE(3,1)
CHIMERIC DNA TEMPLATE(3,1)
CHLORELLA INFECTION(3,1)
CHROMOSOMAL DNA LIGATED VECTOR(3,1)
CHROMOSOMAL DNA TEMPLATE(3,1)
CLASS IC GENETIC PROOF(3,1)
CLEVER EVOLUTIONARY ADAPTATION(3,1)
COLI KFAA PROTEIN(3,1)
COLONY MORPHOLOGY ALTERATION(3,1)
DESIGNING PCR PRIMER(3,1)
DISRUPTION SITE SEQUENCING(3,1)
FOWL CHOLERA DISEASE(3,1)
FOWL CHOLERA TREATMENT(3,1)
GENOMIC GENE COPY(3,1)
GLCA PHOTOINCORPORATION(3,1)
HAEMOPHILUS INFLUENZAE(3,1)
HETEROLOGOUS DNA PCR(3,1)
INDEPENDENT TRANSPOSON MUTANT PANEL(3,1)
INDIA INK STAIN(3,1)
INDIUM INK STAIN(3,1)
INTACT PMHA PROTEIN(3,1)
INTRINSICALLY SLOW ENZYME(3,1)
ITALIC LOWERCASE(3,1)
KINETIC OPTIMA(3,1)
LIVE FOWL DEATH(3,1)
MAMMALIAN HOST GENOMIC DNA(3,1)
MEMBRANE PREPARATION PHOTOAFFINITY LABELING(3,1)
MUCOID PHENOTYPE(3,1)
MULTOCIDA PMHA(3,1)
MUTANT CHROMOSOMAL DNA(3,1)
MUTANT REVERTANT(3,1)
NATURAL PASTURELLA MICROBE(3,1)
NEISSERIA MENINGITIDIS(3,1)
NONIRIDESCENT COLONY(3,1)
NONREPLICATING PLASMID(3,1)
OCCASIONAL REVERTANT(3,1)
PATHOGEN BLOCKING CAPSULE SYNTHESIS(3,1)
PATHOGENIC BACTERIUM CAPSULE(3,1)
PHOTOINCORPORATION SPECIFICITY(3,1)
PMHA POLYPEPTIDE MIDDLE(3,1)
PPM7A TRUNCATED DERIVATIVE(3,1)
PREIMMUNE HOST DEFENSE(3,1)
PROKARYOTIC ENZYME GENE(3,1)
PROTEIN FOLDING PREDICTION(3,1)
RADIOLABELED PRECURSOR INCORPORATION(3,1)
RECOMBINANT HUMAN PROTEIN STABILIZATION(3,1)
REPRESENTATIVE MICROCAPSULAR MUTANT(3,1)
RESTRICTION ENZYME HHAI(3,1)
SALMONELLA TYPHIMURIUM(3,1)
SEVERE NASAL LESION(3,1)
STREPTOCOCCUS THERMOPHILUS(3,1)
STREPTOMYCES HYALUROLYTICUS(3,1)
SUGAR NUCLEOTIDE CONCENTRATION TITRATION(3,1)
SWINE ATROPHIC RHINITIS(3,1)
SYNTHASE HOMOLOG(3,1)
TAGGED CHROMOSOMAL DNA(3,1)
TEMPLATE DNA HETEROLOGOUS(3,1)
TN MUTANT LANE(3,1)
TRANSPORTER PROTEIN PROBE(3,1)
TRULY ACAPSULAR STRAIN(3,1)
UNENCAPSULATED MUTANT(3,1)
UNINCORPORATED SUGAR(3,1)
UNRELATED GENOMIC DNA(3,1)
VIRALLY ENCODED ENZYME(3,1)
VIRULENT PARENTAL STRAIN(3,1)
MOLECULAR WEIGHT(2,7)
CATTLE(2,6)
HYALURONIC ACID POLYMER(2,4)
PHAGOCYTOSIS(2,4)
CHONDROITAN(2,3)
DRY COLONY(2,3)
EXOPOLYSACCHARIDE(2,3)
POLYSACCHARIDE PRODUCTION(2,3)
SHIPPING FEVER(2,3)
AGAROSE GEL(2,2)
ATTENUATED VACCINE POTENTIAL(2,2)
CAPSULE PRESENCE(2,2)
CELL PELLET(2,2)
COLI STRAIN(2,2)
CYCLE SEQUENCING REACTION(2,2)
DIGOXIGENIN LABELED PCR PRODUCT(2,2)
DNA CODING(2,2)
ENGINEERED CELL(2,2)
ENZYMATIC ACTIVITY(2,2)
ENZYME ACTIVITY(2,2)
GENETIC DEFECT NATURE(2,2)
MUTANT STRAIN(2,2)
OPTIMIZED VECTOR(2,2)
REPLICATION ORIGIN(2,2)
SOUTHERN ANALYSIS(2,2)
STRAIN INDEPENDENT(2,2)
UDP SUGAR PRECURSOR(2,2)
ULTRACENTRIFUGATION(2,2)
ULTRASONICATION(2,2)
33P TERMINATOR(2,1)
ACAPSULAR DERIVATIVE(2,1)
ACAPSULAR MUTANT SEPARATE COLONY(2,1)
ACAPSULAR VARIANT(2,1)
ACID RESIDUE CLUSTER(2,1)
ALMOST INSURMOUNTABLE BARRIER(2,1)
ALTERED SUGAR SUBSTRATE SPECIFICITY(2,1)
AMINO TERMINUS(2,1)
ANIMAL BREEDER(2,1)
ANIMAL KINGDOM MEMBER(2,1)
ANTIBIOTIC PROPHYLACTIC TREATMENT(2,1)
ARM TERMINUS PRIMER(2,1)
ASSAY BUFFER(2,1)
ATTENUATED VACCINE STRAIN(2,1)
AUTOIMMUNE REACTION REPERCUSSION(2,1)
AUTORADIOGRAM REGION(2,1)
AUXILIARY ENZYME(2,1)
AVIRULENT STRAIN(2,1)
BACTERIAL CAPSULE STUDY(2,1)
BACTERIAL GLYCOSYLTRANSFERASE VARIETY(2,1)
BACTERIAL HOST(2,1)
BACTERIAL MEMBRANE(2,1)
BACTERIUM ABILITY(2,1)
BIOLOGICAL PROTEIN ACTIVITY MAINTENANCE(2,1)
BIOLOGICALLY FUNCTIONAL EQUIVALENT PROTEIN(2,1)
BIRD PERCENTAGE(2,1)
BLASTP SEARCH(2,1)
BOVINE STRAIN(2,1)
BP LADDER(2,1)
BRAIN HEART INFUSION MEDIUM(2,1)
BSTXI DIGESTION(2,1)
CANDIDATE PLASMID(2,1)
CAPSULE ANTIGEN(2,1)
CAPSULE IMPORTANCE(2,1)
CAPSULE INHIBITING DRUG(2,1)
CAPSULE OPERON(2,1)
CAPSULE RADIUS(2,1)
CARBOHYDRATE POLYMER(2,1)
CARBOXYL TERMINI(2,1)
CARTER MAJOR CAPSULE COMPONENT(2,1)
CELLULAR DEBRIS(2,1)
CHIMERIC BAND(2,1)
CHIMERIC FRAGMENT(2,1)
CHIMERIC SEGMENT(2,1)
CHIMERIC TN(2,1)
CHOLERA STRAIN(2,1)
CHROMOSOMAL FRAGMENT(2,1)
CLONAL COLONY(2,1)
CLONED ENZYME(2,1)
CODON REDUNDANCY(2,1)
COLI HOMOLOG(2,1)
COLI MOLECULE(2,1)
COLI TRANSFORMANT(2,1)
COLI XLOLR CELL(2,1)
COMMERCIAL POULTRY(2,1)
COMPLEMENT MEDIATED LYSIS(2,1)
COMPLEMENTARITY RULE(2,1)
CONSENSUS SYMBOL(2,1)
CONSERVATIVE SUBSTITUTION(2,1)
CONTIGUOUS SEQUENCE REPLICATION(2,1)
COOMASSIE DYE(2,1)
COVALENTLY CROSSLINKING(2,1)
CRUDE MEMBRANE FRACTION(2,1)
CYTOPLASMIC DOMAIN(2,1)
DEAD VACCINE(2,1)
DEFECTIVE GENE(2,1)
DEHYDROGENASE ENZYME(2,1)
DEHYDROGENASE GENE(2,1)
DEHYDROGENASE HOMOLOG(2,1)
DESCENDING PAPER CHROMATOGRAPHY(2,1)
DETECTABLE CAPSULE(2,1)
DIFFICULTY ENGULFING(2,1)
DISEASE INTERVENTION(2,1)
DNA FRAGMENT(2,1)
DNA SEGMENT CODING REGION(2,1)
DOWNSTREAM GENE(2,1)
DRUG MIMICKING(2,1)
DXDD MOTIF(2,1)
EARLY TRIAL(2,1)
ECONOMICALLY DAMAGING DISEASE(2,1)
ENCAPSULATED PROGENY(2,1)
ENCAPSULATED STRAIN CELL(2,1)
ENDOCYTIC RECEPTOR(2,1)
ENZYME AFFINITY(2,1)
ENZYME DEGRADATION(2,1)
ENZYME IDENTIFICATION(2,1)
EPITOPE(2,1)
ESSENTIAL GENE(2,1)
EUKARYOTIC ENZYME(2,1)
EUKARYOTIC HOST(2,1)
EUKARYOTIC ORGANISM(2,1)
EXOGENOUS PROTEIN(2,1)
EXPOSED IMMUNOGEN(2,1)
EXTRA AMPLIFICATION(2,1)
EYE SURGERY(2,1)
EYE VITREOUS HUMOR(2,1)
FACILE RESOLUTION(2,1)
FIGHTING DISEASE(2,1)
FOWL STRAIN(2,1)
FRESHLY ADDED THIOGLYCOLATE(2,1)
FUNCTIONAL CAPSULE(2,1)
FUNCTIONAL CLONE(2,1)
FUNCTIONAL EQUIVALENCY(2,1)
FUNCTIONAL PMHA(2,1)
FUNCTIONAL SYNTHASE(2,1)
FUNCTIONALLY EQUIVALENT PROTEIN(2,1)
GEL FILTRATION CHROMATOGRAPHY(2,1)
GENE DOSAGING(2,1)
GENE ESSENTIAL(2,1)
GENE FUNCTION(2,1)
GENE KNOCKOUT PLASMID CONSTRUCTION(2,1)
GENE SYNTHESIS(2,1)
GENERATING ENZYME(2,1)
GENETIC CODE DEGENERACY(2,1)
GENETIC EVIDENCE(2,1)
GENETIC MANIPULATION(2,1)
GENOME ENCODING(2,1)
GLCNAC PROBE(2,1)
GRAM NEGATIVE BACTERIUM SPECIES(2,1)
GREEN COLORATION(2,1)
GROWING POLYSACCHARIDE(2,1)
HELPER PHAGE(2,1)
HHAI DIGESTION(2,1)
HHAI SITE(2,1)
HIGHLY VIRULENT TURKEY(2,1)
HOMOLOGOUS GENE(2,1)
HOST DNA SEQUENCING(2,1)
HOST MANIPULATION(2,1)
HOST ORGANISM(2,1)
HUMAN DEFENSE(2,1)
HUMAN PATHOGEN(2,1)
HYALURONAN CAPSULE(2,1)
HYALURONIC ACID MOLECULE SYNTHESIS(2,1)
HYALURONIC ACID OLIGOSACCHARIDE(2,1)
HYALURONIDASE TREATED RECOMBINANT CELL(2,1)
HYALURONIDASE TREATMENT(2,1)
INCORPORATION ASSAY(2,1)
INCORPORATION DATA(2,1)
INFECTED BIRD(2,1)
INTEGRAL MEMBRANE PROTEIN(2,1)
INTRINSIC ABILITY ALTERATION(2,1)
INTRON ABSENCE(2,1)
IRRELEVANT GENE(2,1)
KDA UDP GLUCOSE DEHYDROGENASE(2,1)
KFAA ANALOG(2,1)
KINETIC STUDY(2,1)
KNOCKOUT CASSETTE(2,1)
KNOCKOUT STRAIN(2,1)
LABORATORY STRAIN(2,1)
LAMBDA VIRUS(2,1)
LATE 1980S SHOW(2,1)
LB BROTH(2,1)
LIBRARY SCREENING(2,1)
LIVE ANIMAL TESTING(2,1)
LIVE CELL VACCINE(2,1)
LIVE TURKEY(2,1)
LYSOZYME DIGESTION(2,1)
MAXIMAL VELOCITY(2,1)
MEDIUM SIZED IRIDESCENT COLONY(2,1)
MICROBIAL PATHOGENESIS(2,1)
MICROBIAL RESISTANCE ISSUE(2,1)
MICROCAPSULAR STRAIN(2,1)
MICROORGANISM CLEARANCE(2,1)
MODEL PROTEIN(2,1)
MOLECULAR MIMICRY FOIL(2,1)
MORPHOLINO(2,1)
MUCOID TN(2,1)
MULTALIN ALIGNMENT(2,1)
MULTOCIDA AID(2,1)
MULTOCIDA CAPSULE PRODUCTION(2,1)
MULTOCIDA CELL(2,1)
MULTOCIDA POLYPEPTIDE(2,1)
MULTOCIDA SEQUENCE(2,1)
MULTOCIDA STRAIN(2,1)
MURINE HOMOLOG(2,1)
MUTAGENESIS ROUND(2,1)
MUTANT CHROMOSOME(2,1)
MUTANT DNA(2,1)
NONIMMUNOGENIC POLYMER(2,1)
NORMAL METABOLIC PATHWAY(2,1)
NOTABLE SEQUENCE SIMILARITY(2,1)
OBLIQUE LIGHTING(2,1)
OBSERVABLE CAPSULE(2,1)
OBSERVED REVERSION(2,1)
OCCASIONAL SPONTANEOUS MUTATION(2,1)
OPTION UTILITY(2,1)
PAPER CHROMATOGRAM ORIGIN(2,1)
PASTURELLA BACTERIAL PATHOGEN(2,1)
PATHOGEN CAPSULE(2,1)
PATHOGEN SPECTRUM(2,1)
PATHWAY MAJOR STRUCTURAL ENZYME(2,1)
PCR AMPLIFICATION(2,1)
PLAQUE HYBRIDIZATION(2,1)
PLASMID DELETION ANALYSIS(2,1)
PLASMID EXPRESSION(2,1)
PLASMID VECTOR(2,1)
PMHA DEPICTED REGION(2,1)
PMHA GENE PRODUCT(2,1)
PMHA GENE SEQUENCE INFORMATION(2,1)
PMHA HALF(2,1)
PMHA MOLECULAR CLONING(2,1)
PMHA SIGNIFICANT OVERALL SIMILARITY(2,1)
PMOL GLCA TRANSFER(2,1)
POLAR MUTATION(2,1)
POLYMERIZATION MACHINERY(2,1)
POLYPEPTIDE MAJORITY(2,1)
POLYPEPTIDE SPECIES(2,1)
POLYSACCHARIDE EXPORT(2,1)
POLYSACCHARIDE HYALURONIC ACID(2,1)
POLYSACCHARIDE SYNTHESIS(2,1)
POLYSIALIC ACID CAPSULE(2,1)
POULTRY INDUSTRY(2,1)
PPM 6E DNA(2,1)
PPMHA PLASMID(2,1)
PRECURSOR FORMATION DISRUPTION(2,1)
PRECURSOR POLYMERIZATION(2,1)
PREVALENT MOLECULE(2,1)
PREVALENT PATHOGEN(2,1)
PRIORITY DISEASE(2,1)
PROBE PHOTOINCORPORATION EXTENT(2,1)
PROKARYOTE ABILITY(2,1)
PROKARYOTIC CELLULAR ENVIRONMENT(2,1)
PROKARYOTIC ORGANISM(2,1)
PROMOTERLESS CHLORAMPHENICOL RESISTANCE GENE(2,1)
PRONASE TREATMENT(2,1)
PROTEASE INHIBITOR PRESENCE(2,1)
PROTECTIVE CAPSULE(2,1)
PROTECTIVE SHIELD(2,1)
PROTEIN ENCODING(2,1)
PROTEIN EXPRESSION(2,1)
PROTEIN SCIENCE(2,1)
PSTI RESTRICTION SITE(2,1)
PURIFIED DNA(2,1)
PYOGENES HASA(2,1)
PYOGENES MUTANT(2,1)
RADIOLABEL INCORPORATION(2,1)
RADIOLABELED UDP SUGAR ANALOG(2,1)
RECOMBINANT CELL CAPSULE(2,1)
RECOMBINANT GENE(2,1)
RECOMBINANT HOST(2,1)
RECOMBINANT LAMBDA(2,1)
RECOMBINANT PLASMID(2,1)
RECOMBINANT STRAIN(2,1)
REPORTER ENZYME FUSION ANALYSIS(2,1)
RESIDUE ORF(2,1)
RESTRICTION ENZYME SITE(2,1)
REVERSE COMPLEMENT(2,1)
REVERSION PHENOMENON(2,1)
REVERTANT CELL(2,1)
ROLE RECOGNITION(2,1)
SATURATION(2,1)
SAU3A LIBRARY(2,1)
SEGMENT FRAGMENT(2,1)
SEQUENCING PRIMER(2,1)
SEQUENCING TEMPLATE(2,1)
SERUM CALCIUM CHELATOR TREATMENT(2,1)
SEVERE ARTHRITIS TREATMENT(2,1)
SEVERE TRUNCATION(2,1)
SICK FLOCK(2,1)
SICKLY BIRD(2,1)
SIMILARITY PARAMETER(2,1)
SODIUM THIOGLYCOLATE(2,1)
SPONTANEOUS MUTANT(2,1)
STABLE ISOGENIC MUTANT(2,1)
STREPTOCOCCAL ENZYME(2,1)
STREPTOCOCCAL HASA SHORT REGION(2,1)
STREPTOCOCCAL MEMBRANE(2,1)
STRICT SANITATION(2,1)
STRINGENT HYBRIDIZATION CONDITION(2,1)
SUB THERAPEUTIC DOSE(2,1)
SUBCULTURED STRAIN(2,1)
SUGAR NUCLEOTIDE SUBSTRATE(2,1)
SUICIDE PLASMID(2,1)
SUPERNATANT FRACTION(2,1)
SWINE INDUSTRY(2,1)
SYNTHASE ENCODING DNA SEGMENT(2,1)
SYNTHASE ENZYME(2,1)
TAQ ENZYME(2,1)
TARGETED DRUG DELIVERY(2,1)
TARGETED INACTIVATION(2,1)
TERM RECOMBINANT VECTOR(2,1)
TERTIARY TEMPLATE(2,1)
THOUSAND FLOCK(2,1)
TITRATION DATA(2,1)
TMPRED PROGRAM(2,1)
TN COPY(2,1)
TN DISRUPTED SITE(2,1)
TN DISRUPTION SITE(2,1)
TN INSERTION EVENT(2,1)
TN TAGGED GENE(2,1)
TNH MUTANT(2,1)
TNL INSERTION(2,1)
TNL MUTANT(2,1)
TRANSFECTED COLONY(2,1)
TRANSMEMBRANE PROTEIN(2,1)
TRANSMEMBRANE REGION(2,1)
TRANSPORT MACHINERY(2,1)
TRANSPOSON TN(2,1)
TRAUMATIC ARTHRITIS(2,1)
TRUE ISOGENIC MUTANT(2,1)
TRUNCATED PMHA(2,1)
TRUNCATED SEQUENCE VERSION(2,1)
TRYPTOPHAN POLAR(2,1)
TURKEY INDUSTRY(2,1)
TURKEY MACROPHAGE(2,1)
TURKEY SERUM(2,1)
UDP ABSENCE(2,1)
UDP DERIVATIVE(2,1)
UDP GLCA CONCENTRATION(2,1)
UDP GLCA PRECURSOR(2,1)
UDP GLCNAC CONCENTRATION(2,1)
UDP SUGAR INCORPORATION(2,1)
ULTRASONIC DISRUPTION(2,1)
UNADULTERATED PARENT(2,1)
UNCHARACTERIZED GENE(2,1)
UNDERLINED LETTER(2,1)
UNENCAPSULATED VARIANT(2,1)
UNIQUE PMHA(2,1)
UNLABELED COMPETITOR(2,1)
VERTEBRATE ENZYME(2,1)
VERTEBRATE HOST(2,1)
VIGOROUS SHAKING(2,1)
VISUAL EXAMINATION(2,1)
WATSON CRICK(2,1)
WESTERN BLOT(2,1)
WET MORPHOLOGY(2,1)
XHOI SITE(2,1)
XLI BLUE MRF(2,1)
MGCL2(1,6)
MEDIUM PLATE(1,4)
PBS(1,4)
SPHA(1,3)
ADDED UDP(1,2)
ASSAY CONDITION(1,2)
BACTERIAL CAPSULE PRODUCTION(1,2)
BIOCHEMICAL LEVEL(1,2)
ELECTROPORATION(1,2)
ENCAPSULATION STATE(1,2)
FOWL CHOLERA PATHOGEN TYPE(1,2)
HAASE TREATED CELL(1,2)
IDENTICAL ASSAY(1,2)
IDENTICAL RESIDUE(1,2)
IRRADIATION(1,2)
KILOBASE(1,2)
LIGHT SPECTRUM ANALYSIS(1,2)
MOLECULAR BASIS(1,2)
MOLECULAR BIOLOGY(1,2)
NORMAL MICROBIAL GENE(1,2)
PHAGEMID(1,2)
POLYOMA(1,2)
REPEATED SUSPENSION(1,2)
REPRODUCIBILITY(1,2)
VERTEBRATE BODY(1,2)
AFFECTED JOINT(1,1)
ALTERNATING EXPOSURE(1,1)
AMINOACID SIMILARITY COEFFICIENT(1,1)
AMMONIUM ACETATE(1,1)
ANNUAL LOSS(1,1)
APPARENT LOCATION(1,1)
ARM PRIMER(1,1)
BACTERIUM SENSITIVE OUTER MEMBRANE(1,1)
BAND INTENSITY(1,1)
BIOCOMPATIBILITY(1,1)
BIOTECHNOLOGY PRODUCT(1,1)
BOVINE SERUM ALBUMIN STANDARD(1,1)
CELL LYSIS(1,1)
CHEMICAL MUTAGENESIS(1,1)
CHEMICALLY INDUCED MUTANT(1,1)
CHROMOSOME SUPPLY(1,1)
CLASSICAL TEST(1,1)
CLONAL SCREENING(1,1)
COLOCALIZATION(1,1)
COMPLEX COMPLEMENT(1,1)
COPY INSERTION(1,1)
CULTURE VOLUME(1,1)
DEPENDENT UDP(1,1)
DIGESTION PRODUCT(1,1)
DNA GENERATION(1,1)
DNA ISOLATION(1,1)
DNA PREPARATION(1,1)
DOUBLE CROSSOVER(1,1)
ECONOMIC LOSS(1,1)
ENCODING NUCLEIC ACID SEGMENT(1,1)
ENORMOUS DIFFERENCE(1,1)
ETHANESULFONIC ACID(1,1)
EXACT ROLE(1,1)
EXTRA COPY FORMATION(1,1)
FEEDLOT(1,1)
FLANKING SEQUENCE(1,1)
FREQUENCEY(1,1)
FUNCTIONAL CAPABILITY(1,1)
FUNCTIONAL COPY(1,1)
FUNCTIONAL PROTEIN(1,1)
GEL FILTRATION ANALYSIS(1,1)
GENE DNA SEQUENCE(1,1)
GENE PROBE(1,1)
GENERA VARIETY(1,1)
GENERATING MEMBRANE PREPARATION(1,1)
GENOMIC SEQUENCE(1,1)
GLYCOSAMINOGLYCAN(1,1)
GRAM NEGATIVE BACTERIA(1,1)
GREEN ALGAE HOST(1,1)
HEMOPHILUS INFLUENZAE(1,1)
HINDIII STANDARD(1,1)
HOST STRAIN(1,1)
HYALURONIC ACID COAT(1,1)
ICE COLD LYSOZYME TREATMENT(1,1)
IMMUNE RESPONSE DID(1,1)
INCUBATION MIXTURE(1,1)
INITIAL CHARACTERIZATION(1,1)
INTERNAL RESTRICTION SITE(1,1)
INVESTIGATION(1,1)
IONIC STRENGTH(1,1)
ISOPROPYLTHIOGALACTOSIDE(1,1)
KDA BAND(1,1)
KILLED CELL VACCINE(1,1)
KILLING ABILITY(1,1)
LABOR INTENSIVE INJECTION(1,1)
LAMBDA HINDIII MARKER POSITION(1,1)
LATE DOSE(1,1)
LEG END(1,1)
LOST SALE(1,1)
MAJOR PATHOGEN(1,1)
METAL SPECIFICITY STUDY(1,1)
MIN INCUBATION(1,1)
MOLECULAR EXPLANATION(1,1)
NORMAL POLYSACCHARIDE(1,1)
NUCLEOTIDE COMPARISON(1,1)
OBSERVED SUBSTITUTION(1,1)
OPTIMAL BUFFER(1,1)
PARTIAL ORF(1,1)
PCR ANALYSIS(1,1)
PCR CYCLE(1,1)
PHOTOAFFINITY LABELED PROTEIN SIZE(1,1)
PHOTOMICROGRAPH(1,1)
PMHA MIDDLE(1,1)
PMHA NUCLEIC ACID(1,1)
POLY HISTIDINE REGION(1,1)
POLYMER FAMILY(1,1)
POLYMER MOLECULE(1,1)
POSITIVE CLONE(1,1)
POTENTIAL REGULATORY GENE(1,1)
PROBE GENERATION(1,1)
PROSTHETIC GROUP INTRODUCTION(1,1)
PROTEIN RESIDUE(1,1)
RADIOLOGICAL(1,1)
REGION AMPLIFICATION(1,1)
REMAINING MANIPULATION(1,1)
RESISTANT STRAIN(1,1)
RT PCR(1,1)
STRAIN BI(1,1)
STRAND SEQUENCE(1,1)
SWINE PROMINENT CAUSE(1,1)
SYNTHASE DNA SEQUENCE(1,1)
TARGET GENE(1,1)
TERM BIOLOGICALLY FUNCTIONAL EQUIVALENT(1,1)
TERM DNA(1,1)
TEST ANIMAL(1,1)
TETRACYCLINE RESISTANCE GENE(1,1)
TN DERIVED MUTANT(1,1)
TN INSERTION LOCATION(1,1)
TN LOCATION(1,1)
TOPOLOGICAL ARRANGEMENT(1,1)
UNKNOWN FACTOR(1,1)
UNPREDICTABILITY(1,1)
WET APPEARANCE(1,1)
(US6987023)
PURIFIED NUCLEIC ACID(100,21)
RECOMBINANT VECTOR(100,13)
RECOMBINANT HOST CELL(100,11)
PASTEURELLA MULTOCIDA(100,9)
ENZYMATICALLY ACTIVE HYALURONAN SYNTHASE(100,6)
NUCLEIC ACID(100,6)
DNA ENCODING HYALURONAN SYNTHASE(100,1)
PASTEURELLA HYALURONAN(92,6)
PASTURELLA MULTOCIDA HYALURONATE SYNTHASE(83,1)
ENCODING HYALURONAN SYNTHASE(62,3)
CODING REGION ENCODING(46,6)
PASTEURELLA HYALURONATE(38,1)
EXPRESS HYALURONAN SYNTHASE(37,1)
ENZYMATICALLY ACTIVE HYALURONATE SYNTHASE(32,2)
PASTURELLA MULTOCIDA(28,1)
TURKEY BLOODSTREAM(28,1)
ANIMAL PATHOGEN IDENTIFICATION(26,1)
KNOCKOUT MUTANT STRAIN(24,1)
SYNTHASE(22,27)
HYALURONATE SYNTHASE(22,5)
RECOMBINANT CELL PREPARATION(22,1)
VIRUS VECTOR(20,1)
BACTERIAL SPECIES(19,1)
MULTOCIDA INFECTION(19,1)
VACCINATING ANIMAL(19,1)
ACAPSULAR MUTANT(18,9)
MAKE HYALURONAN POLYMER(18,2)
ACAPSULAR CELL(17,1)
NUCLEIC ACID SEGMENT ENCODING(17,1)
FOWL CHOLERA(16,11)
RECOMBINANT CONSTRUCT(16,2)
FOREIGN HOST(16,1)
PASTEURELLA(15,4)
EXPRESSION VECTOR(15,3)
BORDETELLA BRONCHISEPTICA(15,1)
ECONOMICALLY IMPORTANT DISEASE(15,1)
MULTOCIDA(13,52)
NUCLEIC ACID SEGMENT(13,6)
PARENTAL STRAIN(13,5)
PROKARYOTE(12,1)
CODING REGION(11,6)
PROKARYOTIC SOURCE(11,1)
PMHA(10,36)
UDP GLC DEHYDROGENASE(10,4)
BASE SUGAR(10,1)
PURITY(10,1)
PLASMID(9,18)
ACAPSULAR KNOCKOUT MUTANT(9,3)
COSMID(9,2)
EXPRESS HYALURONIC ACID(9,1)
SUBSTITUTE(9,1)
MAMMALIAN UDP GALNAC(8,3)
DIAGNOSTIC TEST(8,2)
INTRAVENOUS INJECTION(8,1)
GENE(7,30)
CAPSULE BIOSYNTHESIS(7,6)
ANTIBODY(7,5)
IMMUNE RESPONSE(7,5)
BOVINE TESTICULAR HYALURONIDASE(7,2)
EUKARYOTIC CELL(7,2)
FOWL AGRICULTURAL PATHOGEN(7,2)
PROKARYOTIC CELL(7,2)
MOD(7,1)
PARAMECIUM BURSARIA CHLORELLA VIRUS(7,1)
SYNTHASE GENE(6,6)
DISEASE(6,5)
HYALURONIC ACID PRODUCTION(6,4)
PHAGE(6,4)
VACCINATION(6,4)
ENCAPSULATED REVERTANT(6,3)
DEATH(6,2)
KFAA HOMOLOG GENE(6,2)
FOWL CHOLERA ACUTE OUTBREAK(6,1)
MULTOCIDA POLYSACCHARIDE TRANSPORTER(6,1)
PMHA ENZYMOLOGICAL CHARACTERIZATION(6,1)
KDA PROTEIN(5,5)
SYNTHASE ACTIVITY(5,5)
HYBRIDIZATION PROBE(5,4)
GALNAC TRANSFERASE(5,3)
HOMOLOGOUS RECOMBINATION(5,3)
SOUTHERN BLOT(5,3)
DIAGNOSTIC BACTERIAL TYPING PROBE(5,2)
MUCOID TRANSFORMANT(5,2)
SUGAR NUCLEOTIDE PRECURSOR SYNTHESIS(5,2)
ACAPSULAR TN MUTANT(5,1)
CANDIDATE TRANSMEMBRANE HELIX(5,1)
CAPSULE MUTANT ASSORTMENT(5,1)
CAPSULE POLYSACCHARIDE TRANSPORTER ANALOG(5,1)
COLI KPS GENE HOMOLOG(5,1)
ENDOGENOUS CAPSULE GENE PROMOTER(5,1)
EXTRACELLULAR POLYSACCHARIDE CAPSULE(5,1)
FOOD GRADE LACTOCOCCUS(5,1)
FOWL CHOLERA CAES(5,1)
FOWL CHOLERA CAUSATIVE AGENT(5,1)
ISOGENIC ACAPSULAR MUTANT(5,1)
KDA UDP GLUCOSE PYROPHOSPHORYLASE(5,1)
LIPOPOLYSACCHARIDE CARBOHYDRATE MOIETY(5,1)
LIVE AVIRULENT VACCINE(5,1)
LIVESTOCK FIELD DETERMINATION(5,1)
MOLECULARLY CLONED MAMMALIAN ENZYME(5,1)
MULTOCIDA ACAPSULAR MUTANT(5,1)
NATIVE PHOTOAFFINITY LABELING(5,1)
PMHA GENE DISRUPTED VERSION(5,1)
PPM7A PLASMID TRUNCATED DERIVATIVE(5,1)
PROTEASE INHIBITOR PEPSTATIN(5,1)
STREPTOCOCCAL CAPSULE(5,1)
STREPTOCOCCUS BIOSYNTHESIS(5,1)
STREPTOMYCES HYALURONIDASE DIGESTION(5,1)
SUGAR NUCLEOTIDE PRECURSOR UDP(5,1)
PROBABILITY SUM(4,4)
BACILLUS STRAIN(4,3)
MULTOCIDA MEMBRANE(4,3)
NATIVE ENZYME(4,3)
POLYMER CAPSULE(4,3)
BUOYANT DENSITY CENTRIFUGATION(4,2)
EXTRACELLULAR CAPSULE(4,2)
HETEROLOGOUS BACTERIUM(4,2)
LYASE DIGESTION(4,2)
MULTOCIDA BACTERIUM(4,2)
MULTOCIDA GENOME(4,2)
PERCOLL CUSHION(4,2)
RADIOMETRIC ASSAY(4,2)
TN TERMINUS(4,2)
VERTEBRATE HASS(4,2)
VIRULENCE ASSAY(4,2)
ACAPSULAR AVIRULENT(4,1)
ACAPSULAR STRAIN BUOYANT DENSITY(4,1)
ALTERED HYALURONATE SYNTHASE(4,1)
ANTIBIOTIC PREMATURE WITHDRAWAL(4,1)
AZIDO UDP GLCA(4,1)
BACTERIAL CAPSULAR SYNTHESIS(4,1)
BOVINE PAPILLOMA VIRUS ORIGIN(4,1)
BOVINE PNEUMATIC PASTEURELLOSIS(4,1)
BSTXI GENOMIC FRAGMENT(4,1)
CAPSULAR POLYSACCHARIDE TRANSPORT(4,1)
CAPSULE GENE ENCODING ENZYME(4,1)
CHROMOSOMAL DNA TEMPLATE(4,1)
CHRONIC FOWL CHOLERA(4,1)
CLASS IC GENETIC PROOF(4,1)
CLONED DNA SEGMENT VERSATILITY(4,1)
CLONED PMHA ORF(4,1)
DOMESTIC ANIMAL PNEUMONIC LESION(4,1)
EUKARYOTIC HYALURONATE SYNTHESIS(4,1)
FOWL CHOLERA DISEASE(4,1)
GENE DISRUPTION CONFIRMATION(4,1)
GLCA PHOTOINCORPORATION(4,1)
HETEROLOGOUS DNA PCR(4,1)
HOST DEFENSE EVASION(4,1)
INDIA INK STAIN(4,1)
KNOCKOUT MUTANT TEMPLATE(4,1)
LIVE FOWL DEATH(4,1)
MAMMALIAN HOST GENOMIC DNA(4,1)
MEMBRANE PREPARATION PHOTOAFFINITY LABELING(4,1)
MODIFIED STRUCTURE(4,1)
MUTANT CHROMOSOMAL DNA(4,1)
NEISSERIA MENINGITIDIS(4,1)
PASTEURELLA MULTOCIDA CARTER(4,1)
PASTEURELLA MULTOCIDA INSERTIONAL MUTAGENESIS(4,1)
PATHOGEN BLOCKING CAPSULE SYNTHESIS(4,1)
PMHA POLYPEPTIDE MIDDLE(4,1)
PMHA XHOI SITE(4,1)
PPM7A TRUNCATED DERIVATIVE(4,1)
PREIMMUNE HOST DEFENSE(4,1)
RADIOLABELED PRECURSOR INCORPORATION(4,1)
RECOMBINANT HASA PLASMID(4,1)
REPRESENTATIVE MICROCAPSULAR MUTANT(4,1)
RESTRICTION ENZYME HHAI(4,1)
SEVERE NASAL LESION(4,1)
STRAIN ACAPSULAR MUTANT(4,1)
TAGGED CHROMOSOMAL DNA(4,1)
TEMPLATE DNA HETEROLOGOUS(4,1)
TN MUTANT LANE(4,1)
TRIDIMENSIONAL BIOMATERIAL(4,1)
TRULY ACAPSULAR STRAIN(4,1)
UNRELATED GENOMIC DNA(4,1)
VIRALLY ENCODED ENZYME(4,1)
VIRULENT PARENTAL STRAIN(4,1)
SIZE DISTRIBUTION(3,5)
PMHA DNA SEQUENCE(3,4)
AGAROSE GEL(3,3)
CAPSULE FORMATION(3,3)
DRY COLONY(3,3)
EXOPOLYSACCHARIDE(3,3)
ISOLATED DNA(3,3)
MODIFIED SIZE(3,3)
POLYSACCHARIDE PRODUCTION(3,3)
BACTERIAL CULTURE(3,2)
CAPSULE ROLE(3,2)
COLI STRAIN(3,2)
COLI SURE CELL(3,2)
DISEASE PREVENTION(3,2)
DNA DISRUPTION(3,2)
ENZYMATIC ACTIVITY(3,2)
GENETIC DEFECT NATURE(3,2)
ISOLATED HOST(3,2)
MULTOCIDA DNA(3,2)
MULTOCIDA ENZYME(3,2)
MULTOCIDA GENE(3,2)
MUTANT STRAIN(3,2)
OPTIMIZED VECTOR(3,2)
PMHA RESIDUE(3,2)
PPM7A INSERT(3,2)
PRECURSOR SUGAR(3,2)
PREDICTED MR(3,2)
PROKARYOTIC GENE(3,2)
RECOMBINANTLY INTRODUCED GENE(3,2)
UDP SUGAR PRECURSOR(3,2)
33P TERMINATOR(3,1)
ACAPSULAR BACTERIUM(3,1)
ACAPSULAR DERIVATIVE(3,1)
ACAPSULAR MICROBE(3,1)
ACAPSULAR MUTANT SEPARATE COLONY(3,1)
ACAPSULAR SUBCLONE(3,1)
ACAPSULAR VARIANT(3,1)
ACID RESIDUE CLUSTER(3,1)
AGAROSE ELECTROPHORESIS(3,1)
ALMOST INSURMOUNTABLE BARRIER(3,1)
ANTIBIOTIC PROPHYLACTIC TREATMENT(3,1)
ARM TERMINUS PRIMER(3,1)
AVIAN PASTEURELLOSIS(3,1)
AVIRULENT STRAIN(3,1)
BACTERIAL GLYCOSYLTRANSFERASE VARIETY(3,1)
BACTERIUM FATE(3,1)
BIOCOM PATIBLE FILM(3,1)
BSTXI DIGESTION(3,1)
CANDIDATE PLASMID(3,1)
CAPSULAR SEROTYPE(3,1)
CAPSULE ANTIGEN(3,1)
CHIMERIC DNA MOLECULE(3,1)
CHLORELLA INFECTION(3,1)
CHROMOSOMAL DNA LIGATED VECTOR(3,1)
CHROMOSOMAL FRAGMENT(3,1)
CLEVER EVOLUTIONARY ADAPTATION(3,1)
CLONAL COLONY(3,1)
CLONED ENZYME(3,1)
CLONED HASS(3,1)
COLI KFAA PROTEIN(3,1)
COLI TRANSFORMANT(3,1)
COLI XLOLR CELL(3,1)
COLONY MORPHOLOGY ALTERATION(3,1)
COVALENTLY CROSSLINKING(3,1)
CYTOPLASMIC DOMAIN(3,1)
DEHYDROGENASE HOMOLOG(3,1)
DESIGNING PCR PRIMER(3,1)
DISRUPTION SITE SEQUENCING(3,1)
ECONOMICALLY DAMAGING DISEASE(3,1)
ENDOCYTIC RECEPTOR(3,1)
EYE VITREOUS HUMOR(3,1)
FOWL CHOLERA TREATMENT(3,1)
FUNCTIONAL CAPSULE(3,1)
GENOMIC GENE COPY(3,1)
GROWING POLYSACCHARIDE(3,1)
HAEMOPHILUS INFLUENZAE(3,1)
HHAI DIGESTION(3,1)
HIGHLY VIRULENT TURKEY(3,1)
HOST DNA SEQUENCING(3,1)
HYALURONAN CAPSULE(3,1)
HYALURONAN SYNTHASE(3,1)
INCORPORATION DATA(3,1)
INDEPENDENT TRANSPOSON MUTANT PANEL(3,1)
INDIUM INK STAIN(3,1)
INTACT PMHA PROTEIN(3,1)
INTRINSICALLY SLOW ENZYME(3,1)
IRRELEVANT GENE(3,1)
ITALIC LOWERCASE(3,1)
KINETIC OPTIMA(3,1)
KNOCKOUT CASSETTE(3,1)
LYSOZYME DIGESTION(3,1)
MICROBIAL PATHOGENESIS(3,1)
MICROCAPSULAR STRAIN(3,1)
MORPHOLINO(3,1)
MUCOID PHENOTYPE(3,1)
MULTOCIDA PMHA(3,1)
MULTOCIDA POLYPEPTIDE(3,1)
MURINE HOMOLOG(3,1)
MUTANT CHROMOSOME(3,1)
MUTANT REVERTANT(3,1)
NONIRIDESCENT COLONY(3,1)
NONREPLICATING PLASMID(3,1)
NOTABLE SEQUENCE SIMILARITY(3,1)
OBSERVABLE CAPSULE(3,1)
OCCASIONAL REVERTANT(3,1)
OCCASIONAL SPONTANEOUS MUTATION(3,1)
PAPER CHROMATOGRAM ORIGIN(3,1)
PASTEURELLA BACTERIAL PATHOGEN(3,1)
PASTEURELLA STRAIN(3,1)
PATHOGEN CAPSULE(3,1)
PATHOGENIC BACTERIUM CAPSULE(3,1)
PHOTOINCORPORATION SPECIFICITY(3,1)
PLAQUE HYBRIDIZATION(3,1)
POLYPEPTIDE MAJORITY(3,1)
POLYSACCHARIDE EXPORT(3,1)
PPM 6E DNA(3,1)
PPMHA PLASMID(3,1)
PREVALENT PATHOGEN(3,1)
PROBE PHOTOINCORPORATION EXTENT(3,1)
PROKARYOTIC CELLULAR ENVIRONMENT(3,1)
PROKARYOTIC ENZYME GENE(3,1)
PROKARYOTIC ORGANISM(3,1)
PROTEIN FOLDING PREDICTION(3,1)
PSTI RESTRICTION SITE(3,1)
PYOGENES HASA(3,1)
PYOGENES MUTANT(3,1)
RADIOLABEL INCORPORATION(3,1)
RADIOLABELED UDP SUGAR ANALOG(3,1)
RECOMBINANT CELL CAPSULE(3,1)
RECOMBINANT HUMAN PROTEIN STABILIZATION(3,1)
REPORTER ENZYME FUSION ANALYSIS(3,1)
RESTRICTION ENZYME SITE(3,1)
REVERSION PHENOMENON(3,1)
SALMONELLA TYPHIMURIUM(3,1)
SAU3A LIBRARY(3,1)
SICK FLOCK(3,1)
SICKLY BIRD(3,1)
SPONTANEOUS MUTANT(3,1)
STABLE ISOGENIC MUTANT(3,1)
STREPTOCOCCAL ENZYME(3,1)
STREPTOCOCCAL MEMBRANE(3,1)
STREPTOCOCCUS THERMOPHILUS(3,1)
STREPTOMYCES HYALUROLYTICUS(3,1)
STRICT SANITATION(3,1)
SUGAR NUCLEOTIDE CONCENTRATION TITRATION(3,1)
SUICIDE PLASMID(3,1)
SWINE ATROPHIC RHINITIS(3,1)
SYNTHASE HOMOLOG(3,1)
TARGETED INACTIVATION(3,1)
THOUSAND FLOCK(3,1)
TITRATION DATA(3,1)
TRANSFECTED COLONY(3,1)
TRANSPORTER PROTEIN PROBE(3,1)
TRAUMATIC ARTHRITIS(3,1)
TRUE ISOGENIC MUTANT(3,1)
TRUNCATED PMHA(3,1)
TURKEY MACROPHAGE(3,1)
UNADULTERATED PARENT(3,1)
UNCHARACTERIZED GENE(3,1)
UNENCAPSULATED MUTANT(3,1)
UNENCAPSULATED VARIANT(3,1)
UNINCORPORATED SUGAR(3,1)
UNLABELED COMPETITOR(3,1)
URELLA MICROBE(3,1)
NUCLEIC ACID SEQUENCE(2,9)
MOLECULAR WEIGHT(2,7)
CATTLE(2,6)
MGCL2(2,6)
HYALURONIC ACID POLYMER(2,4)
PHAGOCYTOSIS(2,4)
CHONDROITAN(2,3)
SHIPPING FEVER(2,3)
SPHA(2,3)
ATTENUATED VACCINE POTENTIAL(2,2)
BACTERIAL CAPSULE PRODUCTION(2,2)
CAPSULE PRESENCE(2,2)
CELL PELLET(2,2)
CYCLE SEQUENCING REACTION(2,2)
DIGOXIGENIN LABELED PCR PRODUCT(2,2)
DNA CODING(2,2)
ENGINEERED CELL(2,2)
ENZYME ACTIVITY(2,2)
PCR ANALYSIS(2,2)
PCR CYCLE(2,2)
REPLICATION ORIGIN(2,2)
SOUTHERN ANALYSIS(2,2)
STRAIN INDEPENDENT(2,2)
ULTRACENTRIFUGATION(2,2)
ULTRASONICATION(2,2)
ALTERED SUGAR SUBSTRATE SPECIFICITY(2,1)
AMINO TERMINUS(2,1)
ANIMAL BREEDER(2,1)
ANIMAL KINGDOM MEMBER(2,1)
ASSAY BUFFER(2,1)
ATTENUATED VACCINE STRAIN(2,1)
AUTOIMMUNE REACTION REPERCUSSION(2,1)
AUTORADIOGRAM REGION(2,1)
AUXILIARY ENZYME(2,1)
BACTERIAL CAPSULE STUDY(2,1)
BACTERIAL HOST(2,1)
BACTERIAL MEMBRANE(2,1)
BACTERIUM ABILITY(2,1)
BIOLOGICAL PROTEIN ACTIVITY MAINTENAN(...)";"Medical technology
Pharmaceuticals";Open
"1998-04-02
1998-10-26
1999-04-01";"WO9951265           A1 1999-10-14 [WO9951265]
STG: (A1) Published application with search report
AP : 1999WO-US07289 1999-04-01
CA2326821           A1 1999-10-14 [CA2326821]
STG: (A1) Application laid open
AP : 1999CA-2326821 1999-04-01
AU3548599           A  1999-10-25 [AU9935485]
STG: (A) Open to public inspection
AP : 1999AU-0035485 1999-04-01
WO9951265           A9 2000-04-13 [WO9951265]
STG: (A9) Complete corrected document
AP : 1999WO-US07289 1999-04-01
EP1073460           A1 2001-02-07 [EP1073460]
STG: (A1) Application published with search report
AP : 1999EP-0917339 1999-04-01
EP1073460           A4 2001-05-23 [EP1073460]
STG: (A4) Supplementary search report
AP : 1999EP-0917339 1999-04-01
CN1304317           A  2001-07-18 [CN1304317]
STG: (A) Published application
AP : 1999CN-0806942 1999-04-01
BR9909346           A  2001-09-11 [BR9909346]
STG: (A) Published application
AP : 1999BR-0009346 1999-04-01
BRPI9909346         A1 2001-09-11 [BRPI9909346]
STG: (A1) Published application
AP : 1999BR-0009346 1999-04-01
CZ20003576          A3 2001-09-12 [CZ200003576]
STG: (A3) Published application
AP : 2000CZ-0003576 1999-04-01
IL138803            A  2001-10-31 [IL-138803]
STG: (A) Application of patent for invention
AP : 1999IL-0138803 1999-04-01
JP2002510648        A  2002-04-09 [JP2002510648]
STG: (A) Published application
AP : 2000JP-0542035 1999-04-01
AU770903            B2 2004-03-04 [AU-770903]
STG: (B2) Patent proceeded by OPI
AP : 1999AU-0035485 1999-04-01
CN1327894           C  2007-07-25 [CN1327894C]
STG: (C) Granted patent for invention
AP : 1999CN-0806942 1999-04-01
EP1832662           A2 2007-09-12 [EP1832662]
STG: (A2) Application published without search report
AP : 2007EP-0007453 1999-04-01
EP1832662           A3 2007-11-07 [EP1832662]
STG: (A3) Published search report
AP : 2007EP-0007453 1999-04-01
CN101275143         A  2008-10-01 [CN101275143]
STG: (A) Published application
AP : 2007CN-0109863 1999-04-01
FD :  Division of: CN99806942.6 FDD=1999-04-01 [1999CN-0806942]
JP2008283974        A  2008-11-27 [JP2008283974]
STG: (A) Published application
AP : 2008JP-0146037 2008-06-03
JP4490581           B2 2010-04-09 [JP4490581]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2000JP-0542035 1999-04-01
CA2326821           C  2010-09-28 [CA2326821]
STG: (C) Patent (second level)
AP : 1999CA-2326821 1999-04-01
EP1832662           B1 2011-03-09 [EP1832662]
STG: (B1) Patent specification
AP : 2007EP-0007453 1999-04-01
FD :  Division of: EP99917339 FDD=1999-04-01 [1999EP-0917339]
FD : Division of: EP1073460 - 0 [EP1073460]
AT501275            T  2011-03-15 [ATE501275]
STG: (T) EP patent valid in AT
AP : AT07007453T 1999-04-01
DE69943276          D1 2011-04-21 [DE69943276]
STG: (D1) Grant (no unexamined application published) patent law 81
AP : 1999DE-6043276 1999-04-01
BRPI9909346         A2 2011-11-29 [BR9909346]
STG: (A2) Application for a patent of invention / pipeline patent published without search report
AP : 1999BR-0009346 1999-04-01
JP4887333           B2 2011-12-16 [JP4887333]
STG: (B2) Published granted patent (Second level)  from 01-03-1996 onwards (Published examined patent application (Second level) 1971-1996)
AP : 2008JP-0146037 2008-06-03
FD :  Division of: JP2000542035 FDD=1999-04-01 [2000JP-0542035]";71607548;"WO9951265           A1 1999-10-14 [WO9951265]
CA2326821           A1 1999-10-14 [CA2326821]
AU3548599           A  1999-10-25 [AU9935485]
WO9951265           A9 2000-04-13 [WO9951265]
EP1073460           A1 2001-02-07 [EP1073460]
EP1073460           A4 2001-05-23 [EP1073460]
CN1304317           A  2001-07-18 [CN1304317]
BR9909346           A  2001-09-11 [BR9909346]
BRPI9909346         A1 2001-09-11 [BRPI9909346]
CZ20003576          A3 2001-09-12 [CZ200003576]
IL138803            A  2001-10-31 [IL-138803]
JP2002510648        A  2002-04-09 [JP2002510648]
AU770903            B2 2004-03-04 [AU-770903]
CN1327894           C  2007-07-25 [CN1327894C]
EP1832662           A2 2007-09-12 [EP1832662]
EP1832662           A3 2007-11-07 [EP1832662]
CN101275143         A  2008-10-01 [CN101275143]
JP2008283974        A  2008-11-27 [JP2008283974]
JP4490581           B2 2010-04-09 [JP4490581]
CA2326821           C  2010-09-28 [CA2326821]
EP1832662           B1 2011-03-09 [EP1832662]
AT501275            T  2011-03-15 [ATE501275]
DE69943276          D1 2011-04-21 [DE69943276]
BRPI9909346         A2 2011-11-29 [BR9909346]
JP4887333           B2 2011-12-16 [JP4887333]";"1998US-09178851
1998US-60080414
1999EP-0917339
1999WO-US07289";"(EP1073460)
WO9951265
(JP4490581)
WO9951265
(IL-138803)
WO9951265
(AU-770903)
WO9951265
(CN1327894C)
WO9951265
(CA2326821)
WO9951265
(BR9909346)
WO9951265";"BOARD OF REGENTS OF THE SALT LAKE CITY UNIVERSITY OF OKLAHOMA
OKLAHOMA STATE UNIVERSITY
UNIVERSITY OF OKLAHOMA";OKLAHOMA STATE UNIVERSITY;"(EP1073460)
US
(EP1832662)
US
(EP1832662)
US
(EP1832662)
US
(WO9951265)
US


(CN1327894C)
US
(CA2326821)
US
(CA2326821)
US
(BRPI9909346)
US
(BR9909346)
US";"(EP1073460)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA University of Oklahoma, 1000 Asp Avenue , CITY=Norman, Oklahoma 73109 , COUNTRY=US 

(EP1832662)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA University of Oklahoma,  1000 Asp Avenue , CITY=Norman, Oklahoma 73109 , COUNTRY=US 

(EP1832662)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA University of Oklahoma, 1000 Asp Avenue Norman Oklahoma 73109 , COUNTRY=US 

(EP1832662)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA University of Oklahoma,  1000 Asp Avenue , CITY=Norman,Oklahoma 73109 , COUNTRY=US , REG=100235444 

(WO9951265)
NAME=BOARD OF REGENTS OF THE UNIVERSTIY OF OKLAHOMA [US / US]  1000 Asp Avenue Norman, OK 73109  , COUNTRY=US 

(JP4490581)
NAME=Board of Regents of The Salt Lake City University of Oklahoma , REG=500460793 

(JP2008283974)
NAME=BOARD OF REGENTS OF THE UNIV OF OKLAHOMA , REG=500460793 

(JP4887333)
NAME=Board of Regents of The Salt Lake City University of Oklahoma , REG=500460793 

(CN1327894C)
NAME=BOARD OF REGENTS OF UNIV. OF OKLAHOMA , COUNTRY=US 

(CA2326821)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 1000 Asp Avenue, NORMAN, OK, 78019 , COUNTRY=US 

(CA2326821)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 1000 Asp Avenue , CITY=NORMAN , STATE=OK , POSTCODE=78019 , COUNTRY=US 

(BRPI9909346)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA , COUNTRY=US 

(BR9909346)
NAME=THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA , COUNTRY=US 
";1;DEANGELIS PAUL;"(EP1832662)
US
(EP1832662)
US
(EP1832662)
US";"(EP1832662)
NAME=DeAngelis, Paul 706 Sunnybrook Drive Edmond, OK 73034 , COUNTRY=US 

NAME=Weigel, Paul H. 817 Hollowdale Edmond, OK 73003 , COUNTRY=US 

NAME=Kumari, Kshama 16220 Sugar Loaf Drive Edmond, OK 73013 , COUNTRY=US 

(EP1832662)
NAME=DeAngelis, Paul 706 Sunnybrook Drive Edmond, OK 73034 , COUNTRY=US 

(EP1832662)
NAME=DeAngelis, Paul 706 Sunnybrook Drive Edmond, OK 73034 , COUNTRY=US 
";"(EP1832662)
DNA encoding chondroitin synthase from Pasteurella multocida and methods of use";"(EP1832662)
The present invention relates to a nucleic acid segment having a coding region segment encoding enzymatically active bacterial multocida , and to the use of this nucleic acid segment in the preparation of recombinant cells which produce chondroitin synthase and chondroitin polymer.";"(WO9951265)
What we claim is :
1. A purified nucleic acid segment comprising a coding region encoding enzymatically active hyaluronate synthase from P. mul tocida .
2. The purified nucleic acid segment of claim 1, wherein the purified nucleic acid segment encodes the P. mul tocida hyaluronate synthase of SEQ ID N0:1.
3. The purified nucleic acid segment of claim 1, wherein the purified nucleic acid segment comprises a nucleotide sequence in accordance with SEQ ID NO:2.
4. A purified nucleic acid segment having a coding region encoding enzymatically active hyaluronate synthase, wherein the purified nucleic acid segment is capable of hybridizing to the nucleotide sequence of SEQ ID N0:2.
5. A purified nucleic acid segment having a coding region encoding enzymatically active hyaluronate synthase, wherein the purified nucleic acid segment has semiconservative or conservative amino acid codon changes when compared to the nucleotide sequence of SEQ ID NO: 2.
6. A recombinant vector selected from the group consisting of a plasmid, cosmid, phage, or virus vector and wherein the recombinant vector further comprises a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida .
 1 . The recombinant vector of claim 6, wherein the purified nucleic acid segment encodes the P. mul tocida hyaluronan synthase of SEQ ID N0:1.
8. The recombinant vector of claim 6, wherein the purified nucleic acid segment comprises a nucleotide sequence in accordance ith SEQ ID NO: 2.
9. The recombinant vector of claim 6, wherein the plasmid further comprises an expression vector.
10. The recombinant vector of claim 9, wherein the expression vector comprises a promoter operatively linked to the enzymatically active P. mul tocida hyaluronan synthase coding region.
11. A recombinant host cell, wherein the recombinant host cell is a prokaryotic cell transformed with a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida .
12. The recombinant host cell of claim 11, wherein the purified nucleic acid segment encodes the P. mul tocida hyaluronan synthase of SEQ ID N0:1.
13. The recombinant host cell of claim 11, wherein the purified nucleic acid segment comprises a nucleotide sequence in accordance with SEQ ID N0:2.
14. The recombinant host cell of claim 13, wherein the host cell produces hyaluronic acid.
15. The recombinant host cell of claim 11, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified structure.
16. The recombinant host cell of claim 11, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified size distribution.
17. A recombinant host cell, wherein the recombinant host cell is a eukaryotic cell transfected with a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida .
18. The recombinant host cell of claim 17, wherein the purified nucleic acid segment encodes the P. mul tocida hyaluronan synthase of SEQ ID N0:1.
19. The recombinant host cell of claim 17, wherein the purified nucleic acid segment comprises a nucleotide sequence in accordance with SEQ ID NO: 2.
20. The recombinant host cell of claim 19, wherein the host cell produces hyaluronic acid.
21. The recombinant host cell of claim 17, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified structure.
22. The recombinant host cell of claim 17, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified size distribution.
23. A recombinant host cell, wherein the recombinant host cell is electroporated to introduce a recombinant vector into the recombinant host cell, wherein the recombinant vector comprises a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida .
24. The recombinant host cell of claim 23, wherein the purified nucleic acid segment encodes the P. multocida hyaluronan synthase of SEQ ID N0:1.
25. The recombinant host cell of claim 23, wherein the purified nucleic acid segment comprises a nucleotide sequence in accordance with SEQ ID NO: 2.
26. The recombinant host cell of claim 25, wherein the host cell produces hyaluronic acid.
27. The recombinant host cell of claim 23, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified structure.
28. The recombinant host cell of claim 23, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified size distribution.
29. A recombinant host cell, wherein the recombinant host cell is transduced with a recombinant vector comprising a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida .
30. The recombinant host cell of claim 29, wherein the purified nucleic acid segment encodes the P. mul tocida hyaluronan synthase of SEQ ID N0:1.
31. The recombinant host cell of claim 29, wherein the purified nucleic acid segment comprises a nucleotide sequence in accordance with SEQ ID NO: 2.
32. The recombinant host cell of claim 31, wherein the host cell produces hyaluronic acid.
33. The recombinant host cell of claim 29, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified structure.
34. The recombinant host cell of claim 29, wherein the enzymatically active hyaluronan synthase is capable of producing a hyaluronic acid polymer having a modified size distribution.
35. A purified composition, wherein the purified composition comprises an enzymatically active hyaluronan synthase polypeptide from P. mul tocida .
36. A purified composition, wherein the purified composition comprises a polypeptide having an amino acid sequence in accordance with SEQ ID NO: 1.
37. A method for detecting a DNA species, comprising the steps of : obtaining a DNA sample; contacting the DNA sample with a purified nucleic acid segment in accordance with SEQ ID NO: 2; hybridizing the DNA sample and the purified nucleic acid segment thereby forming a hybridized complex; and detecting the complex.
38. A method for detecting a bacterial cell that expresses mRNA encoding P. mul tocida hyaluronan synthase, comprising the steps of: obtaining a bacterial cell sample; contacting at least one nucleic acid from the bacterial cell sample with purified nucleic acid segment in accordance with SEQ ID NO: 2; hybridizing the at least one nucleic acid and the purified nucleic acid segment thereby forming a hybridized complex; and detecting the hybridized complex, wherein the presence of the hybridized complex is indicative of a bacterial strain that expresses mRNA encoding P. mul tocida hyaluronan synthase .
39. A method for producing hyaluronic acid, comprising the steps of: introducing a purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida into a host organism, wherein the host organism contains nucleic acid segments encoding enzymes which produce UDP-GlcNAc and UDP-GlcA; growing the host organism in a medium to secrete hyaluronic acid; and recovering the secreted hyaluronic acid.
40. The method according to claim 39, wherein the step of recovering the hyaluronic acid comprises extracting the secreted hyaluronic acid from the medium.
41. The method according to claim 40, further comprising the step of purifying the extracted hyaluronic acid.
42. The method according to claim 39, wherein in the step of growing the host organism, the host organism secretes a structurally modified hyaluronic acid.
43. The method according to claim 39, wherein in the step of growing the host organism, the host organism secretes a hyaluronic acid having a modified size distribution.
44. A pharmaceutical composition comprising a preselected pharmaceutical drug and an effective amount of hyaluronic acid produced by hyaluronan synthase from P. multocida.
45. The pharmaceutical composition of claim 44, wherein the hyaluronic acid is produced by the P. mul tocida hyaluronan synthase of SEQ ID NO:l.
46. The pharmaceutical composition according to claim 44, wherein the molecular weight of the hyaluronic acid is modified thereby producing a modified molecular weight pharmaceutical composition capable of evading an immune response.
47. The pharmaceutical composition according to claim 44, wherein the molecular weight of the hyaluronic acid is modified thereby producing a modified molecular weight pharmaceutical composition capable of targeting a specific tissue or cell type within the patient having an affinity for the modified molecular weight pharmaceutical composition.
48. A purified and isolated nucleic acid sequence encoding enzymatically active hyaluronan synthase, the nucleic acid sequence selected from the group consisting of:
 (a) the nucleic acid sequence in accordance with SEQ ID NO: 2;
 (b) complementary nucleic acid sequences to the nucleic acid sequence in accordance with SEQ ID NO: 2; (c) nucleic acid sequences which will hybridize to the nucleic acid in accordance with SEQ ID NO: 2; and
 (d) nucleic acid sequences which will hybridize to the complementary nucleic acid sequences of SEQ ID NO:2.
49. A purified and isolated nucleic acid segment consisting essentially of a nucleic acid segment encoding enzymatically active hyaluronan synthase from P. multocida .
50. A procaryotic or eucaryotic host cell transformed or transfected with an isolated nucleic acid segment according to claim 1, 2, or 3 in a manner allowing the host cell to express hyaluronic acid.
51. An isolated nucleic acid segment consisting essentially of a nucleic acid segment encoding hyaluronan synthase from P. mul tocida having a nucleic acid segment sufficiently duplicative of the nucleic acid segment in accordance of SEQ ID NO: 2 to allow possession of the biological property of encoding for P. mul tocida hyaluronan synthase .
52. A cDNA sequence according to claim 51.
53. A procaryotic or eucaryotic host cell transformed or transfected with a nucleic acid segment according to claim 51 in a manner allowing the host cell to express hyaluronic acid.
54. A purified nucleic acid segment having a coding region encoding enzymatically active hyaluronan synthase from P. mul tocida wherein the purified nucleic acid segment is capable of hybridizing to the nucleotide sequence in accordance with SEQ ID NO: 2.
55. A purified nucleic acid segment having a coding region encoding enzymatically active hyaluronate synthase from P. mul tocida , the purified nucleic acid segment selected from the group consisting of:
 (A) the nucleic acid segment according to SEQ ID NO: 1;
 (B) the nucleotide sequence in accordance with SEQ ID NO : 2 ;
 (C) nucleic acid segments which hybridize to the nucleic acid segments defined in (A) or (B) or fragments thereof; and
 (D) nucleic acid segments which but for the degeneracy of the genetic code, or encoding of functionally equivalent amino acids, would hybridize to the nucleic acid segments defined in (A) , (B) , and (C) .
56. A method for creating a vaccine for P. mul tocida , comprising the steps of:
 - making a disrupted capsule gene cassette on a non- replicating plasmid;
 — introducing the disrupted gene cassette into a Pasturella strain having a chromosomal gene; - recombinating the Pasturella strain chromosomal gene with the disrupted gene cassette thereby creating mutant Pasturella strains;
 - screening the mutant Pasturella strains; and
 - selecting an appropriate mutant strain for use as a vaccine .
57. A live attenuated vaccine for Pasturella mul tocida , selected from the group consisting of:
 - a Pasturella strain with at least one disrupted capsular gene ;
 - a Pasturella strain with a disrupted capsular locus ;
 - a Pasturella strain with a disrupted polysaccharide biosynthesis gene;
 - a Pasturella strain with a disrupted polysaccharide synthase gene ; and
 - a Pasturella strain with a disrupted HA synthase gene.
58. A method for detecting Pasturella mul tocida infection in livestock, comprising the steps of:
 - providing a capsule gene probe or mixture of probes capable of hybridizing to a DNA extract of a bacterial sample taken from an animal;
 - incubating the capsule gene probe and the bacterial sample in a hybridization reaction chamber; and — providing a hybridization detection system capable of distinguishing complementarity between the bacterial sample .
59. A diagnostic test for detecting P. mul tocida in livestock, comprising:
 — a capsule gene PCR primer pair or a mixture of primer pairs capable of amplifying a DNA extract of a bacterial sample from an animal-derived sample;
 — means for performing thermal cycling PCR with the capsule gene PCR primer and bacterial samples thereby providing amplicons; and
 — means for detecting the amplicons; and
 — means for separating the amplicons into capsule specific groups .
60. The purified nucleic acid segment of claim 1, wherein the purified nucleic acid segment encodes the P. mul tocida chondroitin synthase of SEQ ID NO: 3.
61. A nucleic acid segment comprising a coding region encoding hyaluronate synthase .
62. A nucleic acid segment having a coding region encoding enzymatically active hyaluronate synthase.
63. A purified nucleic acid segment having a coding region encoding enzymatically active hyaluronate synthase.
64. A recombinant vector wherein the recombinant vector further comprises a nucleic acid segment having a coding region encoding hyaluronan synthase .
65. A recombinant host cell, wherein the recombinant host cell is transformed with a recombinant vector comprising a nucleic acid segment having a coding region encoding hyaluronan synthase .
66. A recombinant host cell, wherein the recombinant host cell is transfected with a recombinant vector comprising a nucleic acid segment having a coding region encoding hyaluronan synthase
67. A recombinant host cell, wherein the recombinant host cell is electroporated to introduce a recombinant vector into the recombinant host cell, wherein the recombinant vector comprises a nucleic acid segment having a coding region encoding hyaluronan synthase .
68. A recombinant host cell, wherein the recombinant host cell is transduced with a recombinant vector comprising a nucleic acid segment having a coding region encoding hyaluronan synthase .
69. A composition, wherein the composition comprises a hyaluronan synthase polypeptide.
70. A composition, wherein the composition comprises a polypeptide having an amino acid sequence in accordance with SEQ ID NO:l.
71. A method for detecting a DNA species, comprising the steps of : contacting a sample with a nucleic acid segment; and hybridizing the DNA sample and the nucleic acid segment thereby forming a hybridized complex.
72. A method for detecting a bacterial cell that expresses mRNA encoding hyaluronan synthase, comprising the steps of: contacting at least one nucleic acid from the bacterial cell sample with a nucleic acid segment; and hybridizing the at least one nucleic acid and the nucleic acid segment thereby forming a hybridized complex.
73. A method for producing hyaluronic acid, comprising the steps of : introducing a nucleic acid segment having a coding region encoding hyaluronan synthase into a host organism; and growing the host organism in a medium to secrete hyaluronic acid.
74. A pharmaceutical composition comprising a pharmaceutical drug and an effective amount of hyaluronic acid produced by hyaluronan synthase.
75. A nucleic acid sequence encoding hyaluronan synthase, the nucleic acid sequence selected from the group consisting of:
 (a) the nucleic acid sequence in accordance with SEQ ID NO: 2;
 (b) complementary nucleic acid sequences to the nucleic acid sequence in accordance with SEQ ID NO:2;
 (c) nucleic acid sequences which will hybridize to the nucleic acid in accordance with SEQ ID NO : 2 ; and
 (d) nucleic acid sequences which will hybridize to the complementary nucleic acid sequences of SEQ ID NO : 2.
76. A nucleic acid segment comprising a nucleic acid segment encoding hyaluronan synthase .
77. A host cell transformed or transfected with a nucleic acid segment according to claim 1, 2, or 3 in a manner allowing the host cell to express hyaluronic acid.
78. A nucleic acid segment comprising a nucleic acid segment encoding hyaluronan synthase having a nucleic acid segment sufficiently duplicative of the nucleic acid segment in accordance of SEQ ID NO : 2 to allow possession of the biological property of encoding for hyaluronan synthase .
79. A host cell transformed or transfected with a nucleic acid segment according to claim 78 in a manner allowing the host cell to express hyaluronic acid.
80. A nucleic acid segment having a coding region encoding hyaluronan synthase wherein the nucleic acid segment is capable of hybridizing to the nucleotide sequence in accordance with SEQ ID NO: 2.
81. A nucleic acid segment having a coding region encoding hyaluronate synthase, the nucleic acid segment selected from the group consisting of:
 (A) the nucleic acid segment according to SEQ ID NO: 1 ;
 (B) the nucleotide sequence in accordance with SEQ ID NO : 2 ; (C) nucleic acid segments which hybridize to the nucleic acid segments defined in (A) or (B) or fragments thereof; and
 (D) nucleic acid segments which but for the degeneracy of the genetic code, or encoding of functionally equivalent amino acids, would hybridize to the nucleic acid segments defined in (A) , (B) , and (C) .
82. A method for creating a vaccine comprising the steps of:
 - making a disrupted capsule gene cassette on a non- replicating plasmid;
 - introducing the disrupted gene cassette into a bacterial strain having a chromosomal gene;
 - recombinating the bacterial strain chromosomal gene with the disrupted gene cassette thereby creating mutant bacterial strains;
 - screening the mutant bacterial strains; and
 - selecting an appropriate mutant strain for use as a vaccine .
83. A vaccine selected from the group consisting of:
 - a bacterial strain with at least one disrupted capsular gene ;
 - a bacterial strain with a disrupted capsular locus;
 - a bacterial strain with a disrupted polysaccharide biosynthesis gene; - a bacterial strain with a disrupted polysaccharide synthase gene; and
 - a bacterial strain with a disrupted HA synthase gene.
84. A method for detecting bacterial infection, comprising the steps of :
 - providing a capsule gene probe or mixture of probes capable of hybridizing to a DNA extract of a bacterial sample taken from an animal;
 - incubating the capsule gene probe and the bacterial sample in a hybridization reaction chamber; and
 - providing a hybridization detection system capable of distinguishing complementarity between the bacterial sample .
85. A diagnostic test for detecting bacteria, comprising:
 - a capsule gene PCR primer pair or a mixture of primer pairs capable of amplifying a DNA extract of a bacterial sample from an animal-derived sample;
 - means for performing thermal cycling PCR with the capsule gene PCR primer and bacterial samples thereby providing amplicons; and
 - means for detecting the amplicons; and
 - means for separating the amplicons into capsule specific groups .";"(EP1832662)
The present invention relates to a novel HAS that produces HA.
The present invention relates to a DNA sequence encoding hyaluronan synthase from Pasturella multocida.
In particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a PmHAS gene, that includes within its amino acid sequence an amino acid sequence in accordance with SEQ ID NO:1.
Moreover, in other particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a gene that includes within its amino acid sequence the amino acid sequence of an HAS gene or DNA, and in particular to an HAS gene or cDNA, corresponding to Pasturella multocida HAS.
The present invention relates to a DNA sequence encoding hyaluronan synthase from Pasturella multocida.
More particularly, the present invention relates to a DNA sequence encoding hyaluronan synthase from Pasturella multocida which is capable of being placed into a recombinant construct so as to be able to express hyaluronan synthase in a foreign host.
The present invention also relates to methods of using a DNA sequence encoding hyaluronan synthase from Pasturella multocida to (1) make hyaluronan polymers of varying size distribution; (2) make hyaluronan polymers incorporating substitute or additional base sugars; (3) develop new and novel animal vaccines; and (4) develop new and novel diagnostic tests for the detection and identification of animal pathogens.
The present invention relates to a novel HAS that produces HA.";"(EP1832662)
To address these or other difficulties, there is a need for new methods and constructs that can be used to produce HA having one or more improved properties such as greater purity or ease of preparation.
In particular, there is a need to develop methodology for the production of larger amounts of relatively high molecular weight and relatively pure HA than is currently commercially available.
There is yet another need to be able to develop methodology for the production of HA having a modified size distribution (HA size) as well as HA having a modified structure (HA mod).
These antibodies are better able to bind to acapsular cells later in the immune response.
Due to certain advantages associated with the use of prokaryotic sources, one will likely realize the most advantages upon isolation of the HAS gene from the prokaryote P. multocida.
Fowl cholera is an economically important disease in North America.
Acapsular mutants of P. multocida do not thrive in the bloodstream of turkeys after intravenous injection, where encapsulated parental strains multiply quickly and cause death within 1 to 2 days.
This disease is also precipitated by Bordetella bronchiseptica, but the condition is worse when both bacterial species are present.";"A61K-039/00
A61K-039/02
A61K-039/102
A61K-047/36
A61P-031/04
C12N-001/00
C12N-001/15
C12N-001/19
C12N-001/21
C12N-005/10
C12N-009/00
C12N-009/10
C12N-015/09
C12N-015/52
C12N-015/54
C12N-015/63
C12P-019/04
C12P-019/26
C12Q-001/02
C12Q-001/68
G01N-033/48
G01N-033/53
G01N-033/566";"(EP1832662)
1. An isolated and purified nucleic acid segment encoding an enzymatically active chondroitin synthase, wherein the chondroitin synthase is a single protein that catalyzes the incorporation of both UDP-GlcA and UDP-GalNAc to form a chondroitin molecule, wherein the isolated and purified nucleic acid segment is any one of items (a) through (d): (a) a nucleic acid segment encoding the amino acid sequence of SEQ ID NO:3; (b) a nucleic acid segment having 80%-99% of nucleotides which are identical to (a); (c) a nucleic acid segment which hybridizes with a complementary strand of (a) at hybridization conditions of 1.2-1.8x HPB at 40-50 C; and (d) a nucleic acid segment which, but for the degeneracy of the genetic code, or encoding of functionally equivalent amino acids, would hybridize with a complementary strand of (a) at hybridization conditions of 1.2-1.8x HPB at 40-50 C.";"(EP1832662)
SYNTHASE(100,5)
ENCODING HYALURONAN SYNTHASE(100,3)
DNA ENCODING CHONDROITIN(100,1)
PASTEURELLA MULTOCIDA(100,1)
ENZYMATICALLY ACTIVE CHONDROITIN SYNTHASE(74,3)
PASTURELLA MULTOCIDA(70,9)
EXPRESS HYALURONAN SYNTHASE(55,1)
CHONDROITIN SYNTHASE(47,1)
UDP GALNAC(44,2)
TURKEY BLOODSTREAM(42,1)
ANIMAL PATHOGEN IDENTIFICATION(40,1)
CHONDROITIN MOLECULE(38,1)
RECOMBINANT VECTOR(34,8)
ISOLATED DNA(33,3)
STRAND(32,2)
BACTERIAL SPECIES(28,1)
MULTOCIDA INFECTION(28,1)
VACCINATING ANIMAL(28,1)
CHONDROITIN POLYMER(27,2)
MAKE HYALURONAN POLYMER(27,2)
ACAPSULAR MUTANT(26,7)
GENETIC CODE DEGENERACY(26,2)
THOUSAND FLOCK(26,1)
PMHA GENE(25,2)
NUCLEIC ACID SEGMENT ENCODING(25,1)
RECOMBINANT CONSTRUCT(24,2)
FOREIGN HOST(24,1)
FOWL CHOLERA(23,10)
NUCLEIC ACID SEGMENT(23,8)
HYALURONATE HYALURONIC ACID(23,1)
BORDETELLA BRONCHISEPTICA(22,1)
ECONOMICALLY IMPORTANT DISEASE(22,1)
PARENTAL STRAIN(21,3)
HYBRIDIZATION(19,7)
HYALURONAN(19,3)
MULTOCIDA(18,52)
AMINOACID SEQUENCE(18,6)
FUNCTIONALLY EQUIVALENT AMINOACID(18,1)
MICROBIAL RESISTANCE ISSUE(18,1)
PROKARYOTE(18,1)
PROKARYOTIC SOURCE(16,1)
MAMMALIAN UDP GALNAC(15,4)
RECOMBINANT HOST CELL(15,3)
BASE SUGAR(15,1)
GENE(14,36)
SUBSTITUTE(14,1)
NUCLEIC ACID(13,9)
DIGESTION PRODUCT(13,1)
NICOTINE POLACRILEX(13,1)
NUCLEOTIDE(12,6)
DIAGNOSTIC TEST(12,2)
OVINE TESTICULAR HYALURONIDASE(12,2)
INTRAVENOUS INJECTION(12,1)
REPRODUCIBILITY(12,1)
SINGLE PROTEIN(12,1)
INCORPORATION(11,8)
ACAPSULAR KNOCKOUT MUTANT(11,2)
INDEPENDENT TRANSPOSON MUTANT(11,1)
MOD(11,1)
PARAMECIUM BURSARIA CHLORELLA VIRUS(11,1)
PRODUCE CHONDROITIN(11,1)
HYALURONIC ACID BIOSYNTHESIS(10,10)
FOWL AGRICULTURAL PATHOGEN(10,2)
FOWL CHOLERA ACUTE OUTBREAK(10,1)
PASTURELLA MULTOCIDA INSERTIONAL MUTAGENESIS(10,1)
HYALURONIC ACID(9,60)
ENCAPSULATED REVERTANT(9,3)
CAPSULAR POLYSACCHARIDE TRANSPORT(9,2)
CDNA(9,2)
DEATH(9,2)
KFAA HOMOLOG GENE(9,2)
PHOTOAFFINITY LABELING AUTORADIOGRAM REPRESENTATION(9,1)
DNA SEQUENCE(8,8)
DISEASE(8,5)
HYBRIDIZATION PROBE(8,4)
GALNAC TRANSFERASE(8,3)
CHIMERIC DNA TEMPLATE(8,2)
SOUTHERN BLOT MAPPING(8,2)
SUGAR NUCLEOTIDE PRECURSOR SYNTHESIS(8,2)
BIOLOGICAL HALF LIFE(8,1)
COLI KPS GENE HOMOLOG(8,1)
EUKARYOTIC HYALURONATE SYNTHASE(8,1)
FOOD GRADE LACTOCOCCUS(8,1)
FOWL CHOLERA CAES(8,1)
ISOGENIC ACAPSULAR MUTANT(8,1)
MOLECULARLY CLONED MAMMALIAN ENZYME(8,1)
NATIVE WESTERN BLOT ANAYLSIS(8,1)
PASTURELLA MULTOCIDA CARTER(8,1)
PMHA PHOTAFFINITY LABELING(8,1)
PMHA PHOTOAFFINITY LABELING(8,1)
STREPTOMYCES HYALURONIDASE DIGESTION(8,1)
UDP GLCNAC DEPENDENT UDP(8,1)
DNA(7,13)
MULTOCIDA MEMBRANE(7,3)
DIAGNOSTIC BACTERIAL TYPING PROBE(7,2)
PPM TRUNCATED DERIVATIVE(7,2)
ACAPSULAR TN MUTANT(7,1)
CANDIDATE TRANSMEMBRANE HELIX(7,1)
CAPSULE BIOSYNTHESIS OPERON(7,1)
CAPSULE MUTANT ASSORTMENT(7,1)
ENDOGENOUS CAPSULE GENE PROMOTER(7,1)
ENTITLED HYALURONAN SYNTHASE GENE(7,1)
EXTRACELLULAR POLYSACCHARIDE CAPSULE(7,1)
FOWL CHOLERA CAUSATIVE AGENT(7,1)
LIPOPOLYSACCHARIDE CARBOHYDRATE MOIETY(7,1)
PMHA TN MUTANT(7,1)
PROTEASE INHIBITOR STATIN(7,1)
STREPTOCOCCAL CAPSULE(7,1)
SUGAR NUCLEOTIDE PRECURSOR UDP(7,1)
UDP GLC DEHYDROGENASE HOMOLOG(7,1)
HYALURONIC ACID SYNTHASE ACTIVITY(6,5)
HYALURONIC ACID SYNTHASE GENE(6,4)
KDA PROTEIN(6,4)
PROBABILITY SUM(6,4)
SIZE DISTRIBUTION(6,4)
BUOYANT DENSITY CENTRIFUGATION(6,2)
DISEASE PREVENTION(6,2)
EXTRACELLULAR CAPSULE(6,2)
GLCA TRANSFER PMOL(6,2)
HETEROLOGOUS BACTERIUM(6,2)
HOMOLOGOUS RECOMBINATION(6,2)
MULTOCIDA BACTERIUM(6,2)
MULTOCIDA GENOME(6,2)
RADIOMETRIC ASSAY(6,2)
TN DISRUPTION SITE(6,2)
TN TERMINUS(6,2)
UNDERLINED LETTER(6,2)
VERTEBRATE HASS(6,2)
VIRULENCE ASSAY(6,2)
VMAX ESTIMATION(6,2)
ACAPSULAR AVIRULENT(6,1)
ACAPSULAR STRAIN BUOYANT DENSITY(6,1)
ALTERED HYALURONATE SYNTHASE(6,1)
ANTIBIOTIC PREMATURE WITHDRAWAL(6,1)
AZIDO UDP GLCA(6,1)
BACTERIAL CAPSULAR SYNTHESIS(6,1)
BOVINE PAPILLOMA VIRUS ORIGIN(6,1)
BOVINE PNEUMATIC PASTEURELLOSIS(6,1)
BSTXI GENOMIC FRAGMENT(6,1)
CAPSULE GENE ENCODING ENZYME(6,1)
CHROMOSOMAL DNA LI(6,1)
CHROMOSOMAL DNA TEMPLATE(6,1)
CHRONIC FOWL CHOLERA(6,1)
CLASS IC GENETIC PROOF(6,1)
CLONED DNA SEGMENT VERSATILITY(6,1)
CLONED PMHA ORF(6,1)
DOMESTIC ANIMAL PNEUMONIC LESION(6,1)
ENZYMATICALLY ACTIVE HYALURONATE SYNTHASE(6,1)
FOWL CHOLERA DISEASE(6,1)
GENERAT ING MEMBRANE PREPARATION(6,1)
GLCA PHOTOINCORPORATION(6,1)
HETEROLOGOUS DNA PCR(6,1)
HOST DEFENSE EVASION(6,1)
INDIA INK STAIN(6,1)
KNOCKOUT MUTANT GENE(6,1)
LIVE FOWL DEATH(6,1)
MAMMALIAN HOST GENOMIC DNA(6,1)
MEMBRANE PREPARATION PHOTOAFFINITY LABELING(6,1)
MULTOCIDA ACAPSULAR MUTANT H(6,1)
MULTOCIDA DNA GENE(6,1)
MUTANT CHROMOSOMAL DNA(6,1)
NATURAL PASTURELLA MICROBE(6,1)
NEISSERIA MENINGITIDIS(6,1)
PATHOGEN BLOCKING CAPSULE SYNTHESIS(6,1)
PATHOGEN VIRULENT STRAIN(6,1)
PMHA POLYPEPTIDE MIDDLE(6,1)
POLYSACCHARIDE TRANSPORT HOMOLOG(6,1)
PROMOTERLESS CHLORAMPHENICOL RESISTANCE GENE(6,1)
RADIOLABELED PRECURSOR INCORPORATION(6,1)
RECOMBINANT HASA PLASMID(6,1)
RECOMBINANT PMHA PROTEIN(6,1)
REPRESENTATIVE MICROCAPSULAR MUTANT(6,1)
RESTRICTION ENZYME HHAI(6,1)
SEVERE NASAL LESION(6,1)
STRAIN ACAPSULAR MUTANT(6,1)
TAGGED CHROMOSOMAL DNA(6,1)
TEMPLATE DNA HETEROLOGOUS(6,1)
TN MUTANT LANE(6,1)
TRULY ACAPSULAR STRAIN(6,1)
UDP GLC DEHYDROGENASE ENZYME(6,1)
UNIQUE HYALURONAN SYNTHASE(6,1)
VIRALLY ENCODED ENZYME(6,1)
VIRULENT PARENTAL STRAIN(6,1)
MODIFIED SIZE(5,4)
MULTOCIDA HYALURONIC ACID(5,4)
PMHA DNA SEQUENCE(5,4)
CAPSULE FORMATION(5,3)
NATIVE ENZYME(5,3)
AUTHENTIC HYALURONIC ACID POLYSACCHARIDE(5,2)
BACTERIAL CULTURE(5,2)
COLI SURE CELL(5,2)
DISRUPTED VERSION(5,2)
DNA DISRUPTION(5,2)
HYALURONIC ACID LYASE DIGESTION(5,2)
ISOLATED HOST(5,2)
MODIFIED STRUCTURE(5,2)
MOLECULAR WEIGHT(5,2)
MULTOCIDA ENZYME(5,2)
MULTOCIDA GENE(5,2)
PMHA RESIDUE(5,2)
PREDICTED MR(5,2)
PROKARYOTIC GENE(5,2)
RECOMBINANTLY INTRODUCED GENE(5,2)
UDP GLUCOSE DEHYDROGENASE(5,2)
ACAPSULAR BACTERIUM(5,1)
ACAPSULAR MICROBE(5,1)
ACAPSULAR SUBCLONE(5,1)
AGAROSE ELECTROPHORESIS(5,1)
AVIAN PASTEURELLOSIS(5,1)
BACTERIUM FATE(5,1)
BIOCOM PATIBLE FILM(5,1)
CAPSULAR SEROTYPE(5,1)
CAPSULE GENE PROBE(5,1)
CHIMERIC DNA MOLECULE(5,1)
CHLORELLA INFECTION(5,1)
CLEVER EVOLUTIONARY ADAPTATION(5,1)
COLI KFAA PROTEIN(5,1)
COLONY MORPHOLOGY ALTERATION(5,1)
DESIGNING PCR PRIMER(5,1)
DISRUPTION SITE SEQUENCING(5,1)
FOWL CHOLERA TREATMENT(5,1)
GENOMIC GENE COPY(5,1)
HAEMOPHILUS INFLUENZAE(5,1)
INDIUM INK STAIN(5,1)
INTACT PMHA PROTEIN(5,1)
INTRINSICALLY SLOW ENZYME(5,1)
ITALIC LOWERCASE(5,1)
KINETIC OPTIMA(5,1)
LIVESTOCK P FIELD DETERMINATION(5,1)
MUCOID PHENOTYPE(5,1)
MULTOCIDA PMHA(5,1)
MUTANT REVERTANT(5,1)
NATIVE P PHOTOAFFINITY LABELING(5,1)
NONIRIDESCENT COLONY(5,1)
NONREPLICATING PLASMID(5,1)
OCCASIONAL REVERTANT(5,1)
PATHOGEN VIRULENCE(5,1)
PATHOGENIC BACTERIUM CAPSULE(5,1)
PCR ELECTROPHORETOGRAM(5,1)
PHOTOINCORPORATION SPECIFICITY(5,1)
PMHA ACTIVITY PH DEPENDANCE(5,1)
PMHA UDP SUGAR ANALOG(5,1)
POLYSACCHARIDE TRANSPORT MACHINERY(5,1)
PROKARYOTIC ENZYME GENE(5,1)
PROTEIN FOLDING PREDICTION(5,1)
RECOMBINANT HUMAN PROTEIN STABILIZATION(5,1)
SALMONELLA TYPHIMURIUM(5,1)
STREPTOCOCCUS THERMOPHILUS(5,1)
STREPTOMYCES HYALUROLYTICUS(5,1)
SUGAR NUCLEOTIDE CONCENTRATION TITRATION(5,1)
SWINE ATROPHIC RHINITIS(5,1)
SYNTHASE HOMOLOG(5,1)
TRANSPORTER PROTEIN PROBE(5,1)
UNENCAPSULATED MUTANT(5,1)
UNINCORPORATED SUGAR(5,1)
PHAGOCYTOSIS(4,4)
EXOPOLYSACCHARIDE(4,3)
BACILLUS STRAIN(4,2)
COLI STRAIN(4,2)
DNA KB(4,2)
ENZYMATIC ACTIVITY(4,2)
EXPRESSION VECTOR(4,2)
GENETIC DEFECT NATURE(4,2)
KDA UDP GLUCOSE(4,2)
MUTANT STRAIN(4,2)
OPTIMIZED VECTOR(4,2)
POLYMER CAPSULE(4,2)
POLYSACCHARIDE HYALURONIC ACID(4,2)
REPLICATION ORIGIN(4,2)
UDP GLCA CONCENTRATION(4,2)
UDP GLCNAC CONCENTRATION(4,2)
UDP SUGAR PRECURSOR(4,2)
ACAPSULAR MUTANT SEPARATE COLONY(4,1)
ACAPSULAR VARIANT(4,1)
ACID RESIDUE CLUSTER(4,1)
ALMOST INSURMOUNTABLE BARRIER(4,1)
ANIMAL BREEDER(4,1)
ANTIBIOTIC PROPHYLACTIC TREATMENT(4,1)
ANTIBODY GENE(4,1)
ARM TERMINUS PRIMER(4,1)
ATTENUATED VACCINE STRAIN(4,1)
AUTORADIOGRAM DEPICTING(4,1)
AVIRULENT STRAIN(4,1)
BACTERIAL GLYCOSYLTRANSFERASE VARIETY(4,1)
BACTERIAL HYALURONIC ACID POLYSACCHARIDE(4,1)
BIOLOGICAL PROTEIN ACTIVITY MAINTENANCE(4,1)
BIRD PERCENTAGE(4,1)
BSTXI DIGESTION(4,1)
CANDIDATE PLASMID(4,1)
CAPSULE ANTIGEN(4,1)
CAPSULE IMPORTANCE(4,1)
CAPSULE OPERON(4,1)
CAPSULE POLYSACCHARIDE(4,1)
CAPSULE RADIUS(4,1)
CAPSULE ROLE(4,1)
CARBOXYL TERMINI(4,1)
CHIMERIC FRAGMENT(4,1)
CHIMERIC TN(4,1)
CHOLERA STRAIN(4,1)
CHROMOSOMAL FRAGMENT(4,1)
CHROMOSOME SUPPLY UDP GLC(4,1)
CLONAL COLONY(4,1)
CLONED ENZYME(4,1)
CLONED HASS(4,1)
CODON REDUNDANCY(4,1)
COLI TRANSFORMANT(4,1)
COMPLEMENT MEDIATED LYSIS(4,1)
COMPLEMENTARITY RULE(4,1)
CONSENSUS SYMBOL(4,1)
CONTIGUOUS SEQUENCE REPLICATION(4,1)
COOMASSIE DYE(4,1)
COVALENTLY CROSSLINKING(4,1)
CRUDE MEMBRANE FRACTION(4,1)
CYTOPLASMIC DOMAIN(4,1)
DEAD VACCINE(4,1)
DEHYDROGENASE GENE(4,1)
DESCENDING PAPER CHROMATOGRAPHY(4,1)
DETECTABLE CAPSULE(4,1)
DIFFICULTY ENGULFING(4,1)
DISEASE INTERVENTION(4,1)
DNA FRAGMENT(4,1)
DRUG MIMICKING(4,1)
ECONOMICALLY DAMAGING DISEASE(4,1)
ENCAPSULATED PROGENY(4,1)
ENCAPSULATED STRAIN CELL(4,1)
ENDOCYTIC RECEPTOR(4,1)
ENZYME AFFINITY(4,1)
ENZYME DEGRADATION(4,1)
ENZYME IDENTIFICATION(4,1)
EPITOPE(4,1)
EUKARYOTIC ENZYME(4,1)
EUKARYOTIC ORGANISM(4,1)
EXOGENOUS PROTEIN(4,1)
EXTRACELLULAR HYALURONIC ACID CAPSULE(4,1)
EYE VITREOUS HUMOR(4,1)
FACILE RESOLUTION(4,1)
FIGHTING DISEASE(4,1)
FOWL STRAIN(4,1)
FUNCTIONAL CAPSULE(4,1)
GEL FILTRATION CHROMATOGRAPHY(4,1)
GENETIC EVIDENCE(4,1)
GENETIC MANIPULATION(4,1)
GROWING POLYSACCHARIDE(4,1)
HELPER PHAGE(4,1)
HHAI DIGESTION(4,1)
HIGHLY VIRULENT TURKEY(4,1)
HOMOLOGOUS GENE(4,1)
HOST DNA SEQUENCING(4,1)
HOST MANIPULATION(4,1)
HYALURONIC ACID CAPSULE BIOSYNTHESIS(4,1)
INCORPORATION ASSAY(4,1)
INCORPORATION DATA(4,1)
INFECTED BIRD(4,1)
INTRINSIC ABILITY ALTERATION(4,1)
IRRELEVANT GENE(4,1)
K ACAPSULAR DERIVATIVE(4,1)
KNOCKOUT CASSETTE(4,1)
KNOCKOUT STRAIN(4,1)
LIBRARY SCREENING(4,1)
LIVE ANIMAL TESTING(4,1)
LIVE TURKEY(4,1)
LYSOZYME DIGESTION(4,1)
METABOLIC PATHWAY(4,1)
MICROBIAL PATHOGENESIS(4,1)
MICROCAPSULAR STRAIN(4,1)
MICROORGANISM CLEARANCE(4,1)
MOLECULAR BIOLOGICAL CONFIRMATION(4,1)
MORPHOLINO(4,1)
MUCOID TN(4,1)
MULTOCIDA CAPSULE PRODUCTION(4,1)
MULTOCIDA POLYPEPTIDE(4,1)
MULTOCIDA STRAIN(4,1)
MURINE HOMOLOG(4,1)
MUTAGENESIS ROUND(4,1)
MUTANT CHROMOSOME(4,1)
NONIMMUNOGENIC POLYMER(4,1)
NOTABLE SEQUENCE SIMILARITY(4,1)
OBLIQUE LIGHTING(4,1)
OBSERVABLE CAPSULE(4,1)
OCCASIONAL SPONTANEOUS MUTATION(4,1)
P ISOGENIC MUTANT(4,1)
PAPER CHROMATOGRAM ORIGIN(4,1)
PASTURELLA BACTERIAL PATHOGEN(4,1)
PATHOGEN SPECTRUM(4,1)
PCR AMPLIFICATION(4,1)
PERCOLL CUSHION(4,1)
PHOTOMICROGRAPH DEMONSTRATING HYALURONIC ACID(4,1)
PLAQUE HYBRIDIZATION(4,1)
PLASMID DELETION ANALYSIS(4,1)
PLASMID EXPRESSION(4,1)
PMHA GENE PRODUCT(4,1)
POLYMERIZATION MACHINERY(4,1)
POLYPEPTIDE GALNAC(4,1)
POLYPEPTIDE MAJORITY(4,1)
POLYPEPTIDE SPECIES(4,1)
POLYSACCHARIDE EXPORT(4,1)
POLYSIALIC ACID CAPSULE(4,1)
PPMHA PLASMID(4,1)
PRECURSOR FORMATION DISRUPTION(4,1)
PRECURSOR POLYMERIZATION(4,1)
PRECURSOR SUGAR(4,1)
PREVALENT MOLECULE(4,1)
PREVALENT PATHOGEN(4,1)
PROBE PHOTOINCORPORATION EXTENT(4,1)
PROKARYOTIC CELLULAR ENVIRONMENT(4,1)
PROKARYOTIC ORGANISM(4,1)
PSTI RESTRICTION SITE(4,1)
PYOGENES HASA(4,1)
PYOGENES HYALURONIC ACID SYNTHASE(4,1)
PYOGENES MUTANT(4,1)
RADIOLABEL INCORPORATION(4,1)
RADIOLABELED UDP SUGAR ANALOG(4,1)
RE LATED GENUS(4,1)
RE LATED PROTEIN(4,1)
RECOMBINANT CELL CAPSULE(4,1)
RECOMBINANT GENE(4,1)
RECOMBINANT LAMBDA(4,1)
RECOMBINANT PLASMID(4,1)
RECOMBINANT STRAIN(4,1)
REPORTER ENZYME FUSION ANALYSIS(4,1)
RESTRICTION ENZYME SITE(4,1)
REVERSE COMPLEMENT(4,1)
REVERSION PHENOMENON(4,1)
SEGMENT FRAGMENT(4,1)
SEMI CONSERVATIVE SUBSTITUTION(4,1)
SEQUENCING PRIMER(4,1)
SEQUENCING TEMPLATE(4,1)
SEVERE ARTHRITIS TREATMENT(4,1)
SEVERE TRUNCATION(4,1)
SICK FLOCK(4,1)
SICKLY BIRD(4,1)
SPONTANEOUS MUTANT(4,1)
STREPTOCOCCAL ENZYME(4,1)
STREPTOCOCCAL MEMBRANE(4,1)
STRICT SANITATION(4,1)
SUB THERAPEUTIC DOSE(4,1)
SUBCULTURED STRAIN(4,1)
SUGAR NUCLEOTIDE SUBSTRATE(4,1)
SYNTHASE ENCODING DNA SEGMENT(4,1)
TARGETED DRUG DELIVERY(4,1)
TARGETED INACTIVATION(4,1)
TERTIARY TEMPLATE(4,1)
TETRACYCLINE RESISTANCE GENE(4,1)
TITRATION DATA(4,1)
TN COPY(4,1)
TN TAGGED GENE(4,1)
TNH MUTANT(4,1)
TNL MUTANT(4,1)
TRANSFECTED COLONY(4,1)
TRANSMEMBRANE PROTEIN(4,1)
TRANSPOSON TN(4,1)
TRAUMATIC ARTHRITIS(4,1)
TRUE ISOGENIC MUTANT(4,1)
TRUNCATED PMHA(4,1)
TRUNCATED SEQUENCE VERSION(4,1)
TURKEY MACROPHAGE(4,1)
TURKEY SERUM(4,1)
UDP GLCA PRECURSOR(4,1)
UDP GLCNAC DERIVATIVE(4,1)
UDP SUGAR INCORPORATION(4,1)
ULTRASONIC DISRUPTION(4,1)
UNADULTERATED PARENT(4,1)
UNCHARACTERIZED GENE(4,1)
UNENCAPSULATED VARIANT(4,1)
UNLABELED COMPETITOR(4,1)
VERTEBRATE ENZYME(4,1)
VERTEBRATE HOST(4,1)
VIGOROUS SHAKING(4,1)
WATSON CRICK(4,1)
NUCLEIC ACID SEQUENCE(3,8)
CATTLE(3,6)
HYALURONIC ACID PRODUCTION(3,6)
CHONDROITAN(3,3)
DIGOXIGENIN(3,3)
SHIPPING FEVER(3,3)
SPHA(3,3)
ATTENUATED VACCINE POTENTIAL(3,2)
CAPSULE PRESENCE(3,2)
CELL PELLET(3,2)
CYCLE SEQUENCING REACTION(3,2)
DNA CODING(3,2)
ENGINEERED CELL(3,2)
ENZYME ACTIVITY(3,2)
SOUTHERN ANALYSIS(3,2)
STREPTOMYCES HYALURONIC ACID(3,2)
ULTRACENTRIFUGATION(3,2)
ULTRASONICATION(3,2)
ALTERED SUGAR SUBSTRATE SPECIFICITY(3,1)
AMINO TERMINUS(3,1)
ANIMAL KINGDOM MEMBER(3,1)
ASSAY BUFFER(3,1)
AUTOIMMUNE REACTION REPERCUSSION(3,1)
AUTORADIOGRAM REGION(3,1)
AUXILIARY ENZYME(3,1)
BACTERIAL HOST(3,1)
BACTERIAL MEMBRANE(3,1)
BACTERIUM ABILITY(3,1)
BIOLOGICALLY FUNCTIONAL EQUIVALENT PROTEIN(3,1)
BOVINE STRAIN(3,1)
BP LADDER(3,1)
BRAIN HEART INFUSION MEDIUM(3,1)
CAPSULE INHIBITING DRUG(3,1)
CARBOHYDRATE POLYMER(3,1)
CARTER MAJOR CAPSULE COMPONENT(3,1)
CELLULAR DEBRIS(3,1)
CHIMERIC BAND(3,1)
CHIMERIC SEGMENT(3,1)
COLI MOLECULE(3,1)
COMMERCIAL POULTRY(3,1)
DNA SEGMENT CODING REGION(3,1)
DOWNSTREAM GENE(3,1)
DOWNSTREAM HYALURONIC ACID SYNTHASE(3,1)
EARLY TRIAL(3,1)
ESSENTIAL GENE(3,1)
EUKARYOTIC HOST(3,1)
EXPOSED IMMUNOGEN(3,1)
EXTRA AMPLIFICATION(3,1)
EYE SURGERY(3,1)
F CAPSULE BIOSYNTHESIS(3,1)
F KFAA HOMOLOG(3,1)
FRESHLY ADDED THIOGLYCOLATE(3,1)
FUNCTIONAL CLONE(3,1)
FUNCTIONAL COPY(3,1)
FUNCTIONAL EQUIVALENCY(3,1)
FUNCTIONAL PMHA(3,1)
FUNCTIONAL SYNTHASE(3,1)
FUNCTIONALLY EQUIVALENT PROTEIN(3,1)
GATED VECTOR(3,1)
GENE ESSENTIAL(3,1)
GENE FUNCTION(3,1)
GENE KNOCKOUT PLASMID CONSTRUCTION(3,1)
GENERAT ING ENZYME(3,1)
GENOME ENCODING(3,1)
GRAM NEGATIVE BACTERIUM SPECIES(3,1)
GREEN COLORATION(3,1)
HHAI SITE(3,1)
HOST ORGANISM(3,1)
HUMAN DEFENSE(3,1)
HUMAN PATHOGEN(3,1)
HYALURONIC ACID OLIGOSACCHARIDE(3,1)
HYALURONIC ACID SYNTHASE ENZYME(3,1)
HYALURONIDASE TREATED RECOMBINANT CELL(3,1)
HYALURONIDASE TREATMENT(3,1)
INTACT HYALURONIC ACID SYNTHASE(3,1)
INTEGRAL MEMBRANE PROTEIN(3,1)
INTRON ABSENCE(3,1)
KFAA ANALOG(3,1)
KINETIC STUDY(3,1)
LABORATORY STRAIN(3,1)
LACK UDP GLC(3,1)
LAMBDA VIRUS(3,1)
LB BROTH(3,1)
LIVE CELL VACCINE(3,1)
MAXIMAL VELOCITY(3,1)
MEDIUM SIZED IRIDESCENT COLONY(3,1)
MODEL PROTEIN(3,1)
MOLECULE SYNTHESIS(3,1)
MULTOCIDA AID(3,1)
MULTOCIDA CELL(3,1)
MULTOCIDA SEQUENCE(3,1)
MUTANT DNA(3,1)
MUTANT H DISRUPTION SITE(3,1)
OBSERVED REVERSION(3,1)
OPTION UTILITY(3,1)
PATHWAY MAJOR STRUCTURAL ENZYME(3,1)
PLASMID VECTOR(3,1)
PMHA DEPICTED REGION(3,1)
PMHA GENE SEQUENCE INFORMATION(3,1)
PMHA HALF(3,1)
PMHA SIGNIFICANT OVERALL SIMILARITY(3,1)
PMOL GLCA TRANSFER MG(3,1)
POLAR MUTATION(3,1)
POULTRY INDUSTRY(3,1)
PRIORITY DISEASE(3,1)
PROKARYOTE ABILITY(3,1)
PRONASE TREATMENT(3,1)
PROTEASE INHIBITOR PRESENCE(3,1)
PROTECTIVE CAPSULE(3,1)
PROTECTIVE SHIELD(3,1)
PROTEIN ENCODING(3,1)
PROTEIN EXPRESSION(3,1)
PROTEIN SCIENCE(3,1)
RE LATED POLYMER(3,1)
RESIDUE ORF(3,1)
REVERTANT CELL(3,1)
ROLE RECOGNITION(3,1)
SATURATION(3,1)
SERUM CALCIUM CHELATOR TREATMENT(3,1)
SIMILARITY PARAMETER(3,1)
STREPTOCOCCAL HASA SHORT REGION(3,1)
STRINGENT HYBRIDIZATION CONDITION(3,1)
SUPERNATANT FRACTION(3,1)
SWINE INDUSTRY(3,1)
TAQ ENZYME(3,1)
TN DISRUPTED SITE(3,1)
TN INSERTION EVENT(3,1)
TNL INSERTION(3,1)
TRANSMEMBRANE REGION(3,1)
TRANSPORTER ANALOG(3,1)
TURKEY INDUSTRY(3,1)
UDP GLCNAC ABSENCE(3,1)
UDP GLCNAC VARIED CONCENTRATION(3,1)
UNIQUE PMHA(3,1)
VISUAL EXAMINATION(3,1)
XHOI SITE(3,1)
XLI BLUE(3,1)
MOLECULAR WEIGHT HYALURONIC ACID(2,9)
MEDIUM PLATE(2,4)
DRYER(2,3)
MCI MOL(2,3)
METALLIC ELEMENT DEPENDENCY(2,3)
SHEEP(2,3)
ASE TREATED CELL(2,2)
ASSAY CONDITION(2,2)
ELECTROPORATION(2,2)
ENCAPSULATION STATE(2,2)
FOWL CHOLERA PATHOGEN TYPE(2,2)
HYALURONIC ACID CAPSULE PRODUCTION(2,2)
HYALURONIC ACID MOLECULE(2,2)
IDENTICAL ASSAY(2,2)
IDENTICAL RESIDUE(2,2)
IRRADIATION(2,2)
KILOBASE(2,2)
LIGHT SPECTRUM ANALYSIS(2,2)
MOLECULAR BASIS(2,2)
MOLECULAR BIOLOGY(2,2)
NORMAL MICROBIAL GENE(2,2)
PHAGEMID(2,2)
POLYOMA(2,2)
PSA(2,2)
REPEATED SUSPENSION(2,2)
VACCINATION(2,2)
VERTEBRATE BODY(2,2)
ABSCESS(2,1)
ACIDIC PH(2,1)
AFFECTED JOINT(2,1)
AGAROSE GEL(2,1)
ALTERNATING EXPOSURE(2,1)
AMINOACID SIMILARITY COEFFICIENT(2,1)
ANNUAL LOSS(2,1)
APPARENT LOCATION(2,1)
ARM PRIMER(2,1)
BACTERIAL CAPSULE PRODUCTION(2,1)
BACTERIUM NORMAL(2,1)
BACTERIUM SENSITIVE OUTER MEMBRANE(2,1)
BAND INTENSITY(2,1)
BIOCOMPATIBILITY(2,1)
BIOTECHNOLOGY PRODUCT(2,1)
BOVINE SERUM ALBUMIN STANDARD(2,1)
BROAD PH OPTIMUM(2,1)
CARTILAGE HYALURONIC ACID(2,1)
CDNA SEQUENCE(2,1)
CELL LYSIS(2,1)
CHEMICAL MUTAGENESIS(2,1)
CHEMICALLY INDUCED MUTANT(2,1)
CLASSICAL TEST(2,1)
CLONAL SCREENING(2,1)
COLOCALIZATION(2,1)
COMPLEX COMPLEMENT(2,1)
COPY INSERTION(2,1)
CULTURE VOLUME(2,1)
DNA EVENT MICROGRAM(2,1)
DNA GENERATION(2,1)
DNA ISOLATION(2,1)
DNA PREPARATION(2,1)
DOUBLE CROSSOVER(2,1)
DRY COLONY(2,1)
ECONOMIC LOSS(2,1)
ENCODING NUCLEIC ACID SEGMENT(2,1)
ENORMOUS DIFFERENCE(2,1)
EQUIVALENT HYALURONIC ACID SYNTHASE(2,1)
ETHANESULFONIC ACID(2,1)
EXACT ROLE(2,1)
EXTRA COPY FORMATION(2,1)
FEEDLOT(2,1)
FLANKING SEQUENCE(2,1)
FREQUENCEY(2,1)
FUNCTIONAL CAPABILITY(2,1)
FUNCTIONAL PROTEIN(2,1)
GEL FILTRATION ANALYSIS(2,1)
GENE DNA SEQUENCE(2,1)
GENERA VARIETY(2,1)
GENOMIC SEQUENCE(2,1)
GLYCOSAMINOGLYCAN(2,1)
GRAM NEGATIVE BACTERIA(2,1)
GREEN ALGAE HOST(2,1)
HEMOPHILUS INFLUENZAE(2,1)
HINDIII STANDARD(2,1)
HOST STRAIN(2,1)
HYALURONIC ACID COAT(2,1)
HYALURONIC ACID SYNTHESIS GENE(2,1)
ICE COLD LYSOZYME TREATMENT(2,1)
IMMUNE RESPONSE DID(2,1)
INCUBATION MIXTURE(2,1)
INTERNAL RESTRICTION SITE(2,1)
INVESTIGATION(2,1)
IONIC STRENGTH(2,1)
ISOPROPYLTHIOGALACTOSIDE(2,1)
KB PCR PRODUCT(2,1)
KDA BAND(2,1)
KILLED CELL VACCINE(2,1)
KILLING ABILITY(2,1)
LABOR INTENSIVE INJECTION(2,1)
LAMBDA HINDIII MARKER POSITION(2,1)
LATE DOSE(2,1)
LEG END(2,1)
LOST SALE(2,1)
MAJOR PATHOGEN(2,1)
METAL SPECIFICITY STUDY(2,1)
MG PROTEIN(2,1)
MIN INCUBATION(2,1)
MM THIOGLYCOLATE(2,1)
MOLECULAR EXPLANATION(2,1)
MUCIN O GLYCOSYLATION(2,1)
NASCENT HYALURONIC ACID CHAIN(2,1)
NATIVE K(2,1)
NONIMMUNOGENIC HYALURONIC ACID(2,1)
NORMAL POLYSACCHARIDE(2,1)
NUCLEOTIDE COMPARISON(2,1)
OBSERVED SUBSTITUTION(2,1)
OPTIMAL BUFFER(2,1)
P VIRULENCE(2,1)
PARTIAL ORF(2,1)
PCR ANALYSIS(2,1)
PCR CYCLE(2,1)
PHOTOAFFINITY LABELED PROTEIN SIZE(2,1)
PMHA MIDDLE(2,1)
PMHA NUCLEIC ACID(2,1)
POLYMER FAMILY(2,1)
POLYSACCHARIDE PRODUCTION(2,1)
POTENTIAL REGULATORY GENE(2,1)
PPM INSERT(2,1)
PPMHA CONSTRUCTION(2,1)
PROBE GENERATION(2,1)
PROSTHETIC GROUP INTRODUCTION(2,1)
PROTEIN RESIDUE(2,1)
PYROPHOSPHORYLASE(2,1)
RADIOLOGICAL(2,1)
RECOMBINANT P EXPRESSION(2,1)
REGION AMPLIFICATION(2,1)
REMAINING MANIPULATION(2,1)
RT PCR(2,1)
STRAIN BI(2,1)
STRAND SEQUENCE(2,1)
SWINE PROMINENT CAUSE(2,1)
TARGET GENE(2,1)
TEST ANIMAL(2,1)
TN DERIVED MUTANT(2,1)
TN INSERTION LOCATION(2,1)
TN LOCATION(2,1)
TOPOLOGICAL ARRANGEMENT(2,1)
UDP GLCNAC INCREASING CONCENTRATION(2,1)
UNKNOWN FACTOR(2,1)
UNPREDICTABILITY(2,1)
VERTEBRATE HYALURONIC ACID(2,1)
WHITE HALO(2,1)
(EP1832662)
SYNTHASE(100,5)
DNA ENCODING CHONDROITIN(100,1)
PASTEURELLA MULTOCIDA(100,1)
ENZYMATICALLY ACTIVE CHONDROITIN SYNTHASE(99,6)
ENCODING HYALURONAN SYNTHASE(85,3)
PASTURELLA MULTOCIDA(64,7)
CHONDROITIN SYNTHASE(58,2)
CHONDROITIN MOLECULE(47,2)
EXPRESS HYALURONAN SYNTHASE(47,1)
RECOMBINANT HOST CELL(43,8)
RECOMBINANT VECTOR(41,10)
CHONDROITIN POLYMER(40,4)
TURKEY BLOODSTREAM(36,1)
CHONDROITIN(34,9)
ANIMAL PATHOGEN IDENTIFICATION(34,1)
NUCLEIC ACID SEGMENT ENCODING(30,2)
ISOLATED DNA(28,3)
BACTERIAL SPECIES(24,1)
CHONDROITIN AMINOACID(24,1)
VACCINATING ANIMAL(24,1)
MAKE HYALURONAN POLYMER(23,2)
NUCLEIC ACID SEGMENT(22,9)
ACAPSULAR MUTANT(22,7)
PMHA GENE(21,2)
FOWL CHOLERA(20,10)
RECOMBINANT CONSTRUCT(20,2)
FOREIGN HOST(20,1)
BORDETELLA BRONCHISEPTICA(19,1)
ECONOMICALLY IMPORTANT DISEASE(19,1)
PARENTAL STRAIN(18,3)
PRODUCE CHONDROITIN(17,2)
MULTOCIDA(16,52)
NUCLEIC ACID(16,11)
AMINOACID SEQUENCE(16,7)
AUTOIMMUNE REACTION REPERCUSSION(16,1)
INCORPORATION(15,8)
NUCLEOTIDE(15,7)
SINGLE PROTEIN(15,2)
MICROBIAL RESISTANCE ISSUE(15,1)
PROKARYOTE(15,1)
BACILLUS CELL(14,1)
PROKARYOTIC SOURCE(14,1)
MAMMALIAN UDP GALNAC(13,4)
BASE SUGAR(13,1)
GENE(12,36)
SUBSTITUTE(12,1)
HYALURONAN(11,2)
NICOTINE POLACRILEX(11,1)
ACAPSULAR KNOCKOUT MUTANT(10,2)
OVINE TESTICULAR HYALURONIDASE(10,2)
INDEPENDENT TRANSPOSON MUTANT(10,1)
INTRAVENOUS INJECTION(10,1)
PARAMECIUM BURSARIA CHLORELLA VIRUS(10,1)
BATCH(9,2)
MOD(9,1)
HYALURONIC ACID BIOSYNTHESIS(8,10)
CAPSULAR POLYSACCHARIDE TRANSPORT(8,2)
DEATH(8,2)
KFAA HOMOLOG GENE(8,2)
REPRODUCIBILITY(8,2)
DIAGNOSTIC TEST(8,1)
FOWL CHOLERA ACUTE OUTBREAK(8,1)
PASTURELLA MULTOCIDA INSERTIONAL MUTAGENESIS(8,1)
PHOTOAFFINITY LABELING AUTORADIOGRAM REPRESENTATION(8,1)
DNA SEQUENCE(7,8)
DISEASE(7,5)
HYBRIDIZATION PROBE(7,4)
ENCAPSULATED REVERTANT(7,3)
GALNAC TRANSFERASE(7,3)
CDNA(7,2)
CHIMERIC DNA TEMPLATE(7,2)
SOUTHERN BLOT MAPPING(7,2)
SUGAR NUCLEOTIDE PRECURSOR SYNTHESIS(7,2)
BIOLOGICAL HALF LIFE(7,1)
COLI KPS GENE HOMOLOG(7,1)
EUKARYOTIC HYALURONATE SYNTHASE(7,1)
FOOD GRADE LACTOCOCCUS(7,1)
FOWL CHOLERA CAES(7,1)
ISOGENIC ACAPSULAR MUTANT(7,1)
MOLECULARLY CLONED MAMMALIAN ENZYME(7,1)
NATIVE WESTERN BLOT ANAYLSIS(7,1)
PASTURELLA MULTOCIDA CARTER(7,1)
PMHA PHOTAFFINITY LABELING(7,1)
PMHA PHOTOAFFINITY LABELING(7,1)
STREPTOMYCES HYALURONIDASE DIGESTION(7,1)
UDP GLCNAC DEPENDENT UDP(7,1)
HYALURONIC ACID(6,57)
DNA(6,14)
MULTOCIDA MEMBRANE(6,3)
HYALURONAN SYNTHASE(6,2)
PPM TRUNCATED DERIVATIVE(6,2)
ACAPSULAR TN MUTANT(6,1)
CANDIDATE TRANSMEMBRANE HELIX(6,1)
CAPSULE BIOSYNTHESIS OPERON(6,1)
CAPSULE MUTANT ASSORTMENT(6,1)
ENDOGENOUS CAPSULE GENE PROMOTER(6,1)
EXTRACELLULAR POLYSACCHARIDE CAPSULE(6,1)
FOWL AGRICULTURAL PATHOGEN(6,1)
FOWL CHOLERA CAUSATIVE AGENT(6,1)
LIPOPOLYSACCHARIDE CARBOHYDRATE MOIETY(6,1)
PMHA TN MUTANT(6,1)
PROTEASE INHIBITOR STATIN(6,1)
STREPTOCOCCAL CAPSULE(6,1)
SUGAR NUCLEOTIDE PRECURSOR UDP(6,1)
UDP GLC DEHYDROGENASE HOMOLOG(6,1)
HYALURONIC ACID SYNTHASE GENE(5,4)
KDA PROTEIN(5,4)
PROBABILITY SUM(5,4)
SIZE DISTRIBUTION(5,4)
NATIVE ENZYME(5,3)
AUTHENTIC HYALURONIC ACID POLYSACCHARIDE(5,2)
BACTERIAL CULTURE(5,2)
BUOYANT DENSITY CENTRIFUGATION(5,2)
COLI SURE CELL(5,2)
DISEASE PREVENTION(5,2)
DNA DISRUPTION(5,2)
EXTRACELLULAR CAPSULE(5,2)
GLCA TRANSFER PMOL(5,2)
HETEROLOGOUS BACTERIUM(5,2)
HYALURONIC ACID LYASE DIGESTION(5,2)
ISOLATED HOST(5,2)
MULTOCIDA ENZYME(5,2)
MULTOCIDA GENE(5,2)
MULTOCIDA GENOME(5,2)
PMHA RESIDUE(5,2)
PRECURSOR SUGAR(5,2)
PREDICTED MR(5,2)
PROKARYOTIC GENE(5,2)
RADIOMETRIC ASSAY(5,2)
RECOMBINANTLY INTRODUCED GENE(5,2)
TN DISRUPTION SITE(5,2)
TN TERMINUS(5,2)
UDP GLUCOSE DEHYDROGENASE(5,2)
UNDERLINED LETTER(5,2)
VERTEBRATE HASS(5,2)
VIRULENCE ASSAY(5,2)
VMAX ESTIMATION(5,2)
ACAPSULAR AVIRULENT(5,1)
ACAPSULAR STRAIN BUOYANT DENSITY(5,1)
ALTERED HYALURONATE SYNTHASE(5,1)
ANTIBIOTIC PREMATURE WITHDRAWAL(5,1)
AZIDO UDP GLCA(5,1)
BACTERIAL CAPSULAR SYNTHESIS(5,1)
BOVINE PAPILLOMA VIRUS ORIGIN(5,1)
BOVINE PNEUMATIC PASTEURELLOSIS(5,1)
BSTXI GENOMIC FRAGMENT(5,1)
CAPSULE GENE ENCODING ENZYME(5,1)
CHROMOSOMAL DNA LI(5,1)
CHROMOSOMAL DNA TEMPLATE(5,1)
CHRONIC FOWL CHOLERA(5,1)
CLASS IC GENETIC PROOF(5,1)
CLONED DNA SEGMENT VERSATILITY(5,1)
CLONED PMHA ORF(5,1)
DOMESTIC ANIMAL PNEUMONIC LESION(5,1)
ENZYMATICALLY ACTIVE HYALURONATE SYNTHASE(5,1)
FOWL CHOLERA DISEASE(5,1)
GENERAT ING MEMBRANE PREPARATION(5,1)
GLCA PHOTOINCORPORATION(5,1)
HETEROLOGOUS DNA PCR(5,1)
HOST DEFENSE EVASION(5,1)
INDIA INK STAIN(5,1)
KNOCKOUT MUTANT GENE(5,1)
LIVE FOWL DEATH(5,1)
MAMMALIAN HOST GENOMIC DNA(5,1)
MEMBRANE PREPARATION PHOTOAFFINITY LABELING(5,1)
MULTOCIDA ACAPSULAR MUTANT H(5,1)
MULTOCIDA DNA GENE(5,1)
MUTANT CHROMOSOMAL DNA(5,1)
NATURAL PASTURELLA MICROBE(5,1)
NEISSERIA MENINGITIDIS(5,1)
PATHOGEN BLOCKING CAPSULE SYNTHESIS(5,1)
PATHOGEN VIRULENT STRAIN(5,1)
PMHA POLYPEPTIDE MIDDLE(5,1)
POLYSACCHARIDE TRANSPORT HOMOLOG(5,1)
PROMOTERLESS CHLORAMPHENICOL RESISTANCE GENE(5,1)
RADIOLABELED PRECURSOR INCORPORATION(5,1)
RECOMBINANT HASA PLASMID(5,1)
RECOMBINANT PMHA PROTEIN(5,1)
REPRESENTATIVE MICROCAPSULAR MUTANT(5,1)
RESTRICTION ENZYME HHAI(5,1)
SEVERE NASAL LESION(5,1)
STRAIN ACAPSULAR MUTANT(5,1)
TAGGED CHROMOSOMAL DNA(5,1)
TEMPLATE DNA HETEROLOGOUS(5,1)
TN MUTANT LANE(5,1)
TRULY ACAPSULAR STRAIN(5,1)
UDP GLC DEHYDROGENASE ENZYME(5,1)
VIRALLY ENCODED ENZYME(5,1)
VIRULENT PARENTAL STRAIN(5,1)
HYALURONIC ACID SYNTHASE ACTIVITY(4,4)
MODIFIED SIZE(4,4)
MULTOCIDA HYALURONIC ACID(4,4)
CAPSULE FORMATION(4,3)
EXOPOLYSACCHARIDE(4,3)
BACILLUS STRAIN(4,2)
COLI STRAIN(4,2)
DNA KB(4,2)
ENZYMATIC ACTIVITY(4,2)
EXPRESSION VECTOR(4,2)
GENETIC DEFECT NATURE(4,2)
KDA UDP GLUCOSE(4,2)
MODIFIED STRUCTURE(4,2)
MOLECULAR WEIGHT(4,2)
MUTANT STRAIN(4,2)
OPTIMIZED VECTOR(4,2)
POLYMER CAPSULE(4,2)
UDP GLCNAC CONCENTRATION(4,2)
UDP SUGAR PRECURSOR(4,2)
ACAPSULAR BACTERIUM(4,1)
ACAPSULAR MICROBE(4,1)
ACAPSULAR MUTANT SEPARATE COLONY(4,1)
ACAPSULAR SUBCLONE(4,1)
ACAPSULAR VARIANT(4,1)
ACID RESIDUE CLUSTER(4,1)
AGAROSE ELECTROPHORESIS(4,1)
ALMOST INSURMOUNTABLE BARRIER(4,1)
ANTIBIOTIC PROPHYLACTIC TREATMENT(4,1)
ARM TERMINUS PRIMER(4,1)
AUTORADIOGRAM DEPICTING(4,1)
AVIAN PASTEURELLOSIS(4,1)
AVIRULENT STRAIN(4,1)
BACTERIAL GLYCOSYLTRANSFERASE VARIETY(4,1)
BACTERIUM FATE(4,1)
BIOCOM PATIBLE FILM(4,1)
BSTXI DIGESTION(4,1)
CANDIDATE PLASMID(4,1)
CAPSULAR SEROTYPE(4,1)
CAPSULE ANTIGEN(4,1)
CAPSULE GENE PROBE(4,1)
CAPSULE POLYSACCHARIDE(4,1)
CHIMERIC DNA MOLECULE(4,1)
CHROMOSOMAL FRAGMENT(4,1)
CLEVER EVOLUTIONARY ADAPTATION(4,1)
CLONAL COLONY(4,1)
CLONED ENZYME(4,1)
CLONED HASS(4,1)
COLI KFAA PROTEIN(4,1)
COLI TRANSFORMANT(4,1)
COLONY MORPHOLOGY ALTERATION(4,1)
COVALENTLY CROSSLINKING(4,1)
CYTOPLASMIC DOMAIN(4,1)
DESIGNING PCR PRIMER(4,1)
DIAGNOSTIC BACTERIAL TYPING PROBE(4,1)
DISRUPTION SITE SEQUENCING(4,1)
ECONOMICALLY DAMAGING DISEASE(4,1)
ENDOCYTIC RECEPTOR(4,1)
ENZYME CHARACTERIZATION(4,1)
EYE VITREOUS HUMOR(4,1)
FOWL CHOLERA TREATMENT(4,1)
FUNCTIONAL CAPSULE(4,1)
GENOMIC GENE COPY(4,1)
GROWING POLYSACCHARIDE(4,1)
HAEMOPHILUS INFLUENZAE(4,1)
HHAI DIGESTION(4,1)
HIGHLY VIRULENT TURKEY(4,1)
HOMOLOGOUS RECOMBINATION(4,1)
HOST DNA SEQUENCING(4,1)
INCORPORATION DATA(4,1)
INDIUM INK STAIN(4,1)
INTACT PMHA PROTEIN(4,1)
INTRINSICALLY SLOW ENZYME(4,1)
IRRELEVANT GENE(4,1)
ITALIC LOWERCASE(4,1)
KINETIC OPTIMA(4,1)
KNOCKOUT CASSETTE(4,1)
LYSOZYME DIGESTION(4,1)
MICROBIAL PATHOGENESIS(4,1)
MICROCAPSULAR STRAIN(4,1)
MOLECULAR BIOLOGICAL CONFIRMATION(4,1)
MORPHOLINO(4,1)
MUCOID PHENOTYPE(4,1)
MULTOCIDA BACTERIUM(4,1)
MULTOCIDA PMHA(4,1)
MULTOCIDA POLYPEPTIDE(4,1)
MULTOCIDA POLYSACCHARIDE(4,1)
MURINE HOMOLOG(4,1)
MUTANT CHROMOSOME(4,1)
MUTANT REVERTANT(4,1)
NATIVE P PHOTOAFFINITY LABELING(4,1)
NONIRIDESCENT COLONY(4,1)
NONREPLICATING PLASMID(4,1)
NOTABLE SEQUENCE SIMILARITY(4,1)
OBSERVABLE CAPSULE(4,1)
OCCASIONAL REVERTANT(4,1)
OCCASIONAL SPONTANEOUS MUTATION(4,1)
PAPER CHROMATOGRAM ORIGIN(4,1)
PASTURELLA BACTERIAL PATHOGEN(4,1)
PASTURELLA MULTICODA SERVE(4,1)
PATHOGEN VIRULENCE(4,1)
PATHOGENIC BACTERIUM CAPSULE(4,1)
PCR ELECTROPHORETOGRAM(4,1)
PERCOLL CUSHION(4,1)
PHOTOINCORPORATION SPECIFICITY(4,1)
PHOTOMICROGRAPH DEMONSTRATING HYALURONIC ACID(4,1)
PLAQUE HYBRIDIZATION(4,1)
PMHA ACTIVITY PH DEPENDANCE(4,1)
PMHA UDP SUGAR ANALOG(4,1)
POLYPEPTIDE GALNAC(4,1)
POLYPEPTIDE MAJORITY(4,1)
POLYSACCHARIDE EXPORT(4,1)
POLYSACCHARIDE TRANSPORT MACHINERY(4,1)
PPMHA PLASMID(4,1)
PREVALENT PATHOGEN(4,1)
PROBE PHOTOINCORPORATION EXTENT(4,1)
PROKARYOTIC CELLULAR ENVIRONMENT(4,1)
PROKARYOTIC ENZYME GENE(4,1)
PROKARYOTIC ORGANISM(4,1)
PROTEIN FOLDING PREDICTION(4,1)
PSTI RESTRICTION SITE(4,1)
PYOGENES HASA(4,1)
PYOGENES MUTANT(4,1)
RADIOLABEL INCORPORATION(4,1)
RADIOLABELED UDP SUGAR ANALOG(4,1)
RE LATED GENUS(4,1)
RECOMBINANT CELL CAPSULE(4,1)
RECOMBINANT HUMAN PROTEIN STABILIZATION(4,1)
REPORTER ENZYME FUSION ANALYSIS(4,1)
RESTRICTION ENZYME SITE(4,1)
REVERSION PHENOMENON(4,1)
SALMONELLA TYPHIMURIUM(4,1)
SEMI CONSERVATIVE SUBSTITUTION(4,1)
SICK FLOCK(4,1)
SICKLY BIRD(4,1)
SPONTANEOUS MUTANT(4,1)
STREPTOCOCCAL ENZYME(4,1)
STREPTOCOCCAL MEMBRANE(4,1)
STREPTOCOCCUS THERMOPHILUS(4,1)
STREPTOMYCES HYALUROLYTICUS(4,1)
STRICT SANITATION(4,1)
SUGAR NUCLEOTIDE CONCENTRATION TITRATION(4,1)
SWINE ATROPHIC RHINITIS(4,1)
SYNTHASE HOMOLOG(4,1)
TARGETED INACTIVATION(4,1)
THOUSAND FLOCK(4,1)
TITRATION DATA(4,1)
TRANSFECTED COLONY(4,1)
TRANSPORTER PROTEIN PROBE(4,1)
TRAUMATIC ARTHRITIS(4,1)
TRUE ISOGENIC MUTANT(4,1)
TRUNCATED PMHA(4,1)
TURKEY MACROPHAGE(4,1)
UNADULTERATED PARENT(4,1)
UNCHARACTERIZE(...)";"Analysis of biological materials
Pharmaceuticals";Open
1998-03-13;"US20020034522       A1 2002-03-21 [US20020034522]
STG: (A1) Application published
AP : 1999US-09291782 1999-04-14";43933212;US20020034522       A1 2002-03-21 [US20020034522];1998CA-2232119;;VETOQUINOL;VETOQUINOL;;;1;"ADLAM CHRIS
SCHREUER DAMIEN
SCHUHMACHER CATHERINE";"(US20020034522)
BE; FR";"(US20020034522)
NAME=ADLAM CHRIS , CITY=PIETREBAIS , COUNTRY=BE 

NAME=SCHREUER DAMIEN , CITY=MOFFANS ET VACHERESSE , COUNTRY=FR 

NAME=SCHUHMACHER CATHERINE , CITY=LURE , COUNTRY=FR 
";"(US20020034522)
Use of a strain of pasteurella haemolytica of a particular serotype for preparing a vaccine against bovine pasteurellosis due to pasteurella haemolytica";"(US20020034522)
A vaccine against bovine pasteurellosis due to Pasteurella haemolytica, characterised in that it comprises a first antigenic substance comprising at least one component chosen from the group consisting of: (a) The supernatant, concentrated if required, of a bacterial culture of Pasteurella haemolytica serotype A6, (b) An extract containing capsular antigens of Pasteurella haemolytica serotype A6, and (d) Whole bacterial bodies of Pasteurella haemolytica serotype A6, the said supernatant, the said extract and the said bacterial bodies being biologically inactivated.";"(US20020034522)
1. A vaccine against bovine pasteurellosis due to Pasteurella haemolytica, characterised in that it comprises a first antigenic substance comprising at least one component chosen from the group consisting of: 
 (a) The supernatant, concentrated if required, of a bacterial culture of Pasteurella haemolytica serotype A6, 
 (b) An extract containing capsular antigens of Pasteurella haemolytica serotype A6, and 
 (c) Whole bacterial bodies of Pasteurella haemolytica serotype A6, 
 the said supernatant, the said extract and the said bacterial bodies being biologically inactivated.
2. A vaccine according to claim 1, characterised in that it also comprises a second antigenic substance comprising at least one component chosen from the group made up of: 
 (a′) The supernatant, concentrated if required, of a bacterial culture of Pasteurella haemolytica serotype A1, 
 (b′) An extract containing capsular and/or membrane antigens of Pasteurella haemolytica serotype A1, 
 (c′) Whole bacterial bodies of Pasteurella haemolytica serotype A1, and 
 (d′) Fractions of the said bacterial bodies, 
 the said supernatant, the said extract, the said bacterial bodies and the said fractions being biologically inactivated.
3. A vaccine according to claim 1 or 2, characterised in that the said first antigenic substance comprises the supernatant of a culture of Pasteurella haemolytica serotype A6, the supernatant being concentrated and biologically inactivated.
4. A vaccine according to claim 2, characterised in that the said second antigenic substance comprises the supernatant of a culture of Pasteurella haemolytica serotype A1, the supernatant being concentrated and biologically inactivated.
5. A vaccine according to claim 1 or 2, characterised in that it also comprises an added leucotoxin of Pasteurella haemolytica other than the leucotoxin, if any, already present in the said first antigenic substance and/or the said second antigenic substance.
6. A vaccine according to claims 1 or 2, characterised in that the extract containing capsular antigens of Pasteurella haemolytica serotype A6 and the extract containing capsular antigens of Pasteurella haemolytica serotype A1 are respectively those obtained by extraction of cells of Pasteurella haemolytica serotype A6 or Pasteurella haemolytica serotype A1, using an aqueous solution of a mineral or organic salt.
7. A vaccine according to claim 1 or 2, characterised in that the said supernatant(s), extract(s) and whole bacterial bodies and the said fractions of bacterial bodies have been inactivated by formaldehyde or phenol.
8. A vaccine according to claim 1 or 2, characterised in that it also comprises at least one immunisation adjuvant.
9. A vaccine according to claim 8, characterised in that the said immunisation adjuvant is chosen from the group consisting of a saponin and aluminium hydroxide in gel form.
10. A concentrate of the supernatant of a bacterial culture of Pasteurella haemolytica serotype A6, the concentrate or the supernatant being inactivated or not.
11. A method of preparing the vaccine according to any of claims 1 to 9 wherein the first and the second antigenic substances are concentrated supernatants of bacterial culture, characterised in that it comprises the following operations: 
 (a) Cultivating a mother strain of Pasteurella haemolytica serotype A6, 
 (b) Separate cultivation of a mother strain of Pasteurella haemolytica serotype A1, 
 (c) Separation by filtration of at least a part of the bacterial cells of the supernatant obtained in operation (a) hereinbefore, 
 (d) Separation by filtration of at least a part of the bacterial cells of the supernatant obtained by operation (b) hereinbefore, 
 (e) Concentration of the supernatant obtained by operation (c) and of the supernatant obtained by operation (d) hereinbefore, 
 (f) Mixing the concentrates obtained by operation (e) hereinbefore in suitable proportions, 
 (g) Biological inactivation of the two concentrates obtained in operation (e) hereinbefore, before or after mixing them in operation (f) hereinbefore, 
 (h) Addition if required of one or more immunisation adjuvants to the mixture of inactivated concentrates obtained previously, 
 (i) Addition if required of Pasteurella haemolytica leucotoxin and 
 (j) Adjustment if required of the pH of the mixture obtained in operation (i) hereinbefore to the desired value.
12. A method of preparing the vaccine according to any of claims 1 to 9, wherein the first and the second antigenic substances are extracts containing capsular antigens, characterised in that it comprises the following operations: 
 (a) Cultivating a mother strain of Pasteurella haemolytica serotype A6 and separate cultivation of a mother strain of Pasteurella haemolytica serotype A1, 
 (b) Collecting the bacterial cells obtained in operation (a) hereinbefore, 
 (c) Extraction of the respective cells collected in operation (b), using an aqueous solution of a mineral or organic salt, 
 (d) Elimination of cellular material in order to recover an aqueous extract containing capsular antigens of Pasteurella haemolytica serotype A6 and an aqueous extract containing capsular antigens of Pasteurella haemolytica serotype A1, 
 (e) Purification of each extract, 
 (f) Mixing the purified extracts, 
 (g) Biological inactivation of the said extracts before or after mixing them in operation (f) hereinbefore, 
 (h) Addition if required of one or more immunisation adjuvants to the mixture of inactivated extracts obtained previously, 
 (i) Addition if required of Pasteurella haemolytica leucotoxin and 
 (j) Adjustment, if required, of the pH of the mixture obtained in operation (i) hereinbefore to the desired value.";"(US20020034522)
[0024] One object of the invention therefore is to use certain specific components of a strain of Pasteurella haemolytica serotype A6, either alone or together with a strain of Pasteurella haemolytica serotype A1, for preparing a vaccine against bovine pasteurellosis due to Pasteurella haemolytica.
[0001] The invention relates to use of a strain of Pasteurella haemolytica of a particular serotype for preparing a vaccine against bovine pasteurellosis due to Pasteurella haemolytica.
[0026] Accordingly the invention relates on the one hand to a vaccine against bovine pasteurellosis due to Pasteurella haemolytica, the vaccine being characterised in that it comprises a first antigenic substance comprising at least one component chosen from the group consisting of:";"(US20020034522)
However the authors did not specify either the method of sampling the strains or the pathological state of the animal or even the organ from which the samples were taken.
It is often difficult to reproduce pasteurellosis in these animals, since there is natural exposure to Pasteurella haemolytica organisms, which results in some resistance to the test.
However the test did produce disease, which again demonstrated the virulence of the serotype A6 strain used for the test.
[0002] Respiratory diseases of young bovines, mainly of the infectious enzootic broncho-pneumonia type, are a major problem in farms producing red and white meat.";A61K-039/102;"(US20020034522)
1. A vaccine against bovine pasteurellosis due to Pasteurella haemolytica, characterised in that it comprises a first antigenic substance comprising at least one component chosen from the group consisting of: (a) The supernatant, concentrated if required, of a bacterial culture of Pasteurella haemolytica serotype A6, (b) An extract containing capsular antigens of Pasteurella haemolytica serotype A6, and (c) Whole bacterial bodies of Pasteurella haemolytica serotype A6, the said supernatant, the said extract and the said bacterial bodies being biologically inactivated.
10. A concentrate of the supernatant of a bacterial culture of Pasteurella haemolytica serotype A6, the concentrate or the supernatant being inactivated or not.";"(US20020034522)
PASTEURELLA HAEMOLYTICA SEROTYPE(100,60)
VACCINE(100,40)
SUPERNATANT(100,27)
SEROTYPE(100,25)
PASTEURELLA HAEMOLYTICA(100,13)
BACTERIAL CULTURE(100,9)
BOVINE PASTEURELLOSIS(100,9)
CONCENTRATE(100,6)
PASTEURELLA HAEMOLYTICA STRAIN(100,3)
SUPERNATANT CONCENTRATE(100,1)
ANTIGENIC SUBSTANCE(43,20)
CAPSULAR ANTIGEN(43,14)
IMMUNIZATION ADJUVANT(35,7)
SEROTYPE VIRULENCE(30,1)
PASTEURELLA HAEMOLYTICA SEROTYPE STRAIN(29,10)
PASTEURELLA HAEMOLYTICA ORGANISM(29,1)
PASTEURELLA HAEMOLYTICA LEUCOTOXIN(28,4)
YOUNG BOVINE RESPIRATORY DISEASE(23,2)
SUPERNATANT BACTERIAL CELL(20,4)
BACTERIAL CULTURE SUPERNATANT(17,4)
MOTHER STRAIN SEPARATE CULTIVATION(16,4)
BACTERIAL BODY(15,8)
WHOLE BACTERIAL BODY(15,8)
FARM PRODUCT(15,1)
PASTEURELLA HAEMOLYTICA ADDED LEUCOTOXIN(13,3)
STRAIN COMPONENT(13,1)
PASTEURELLA HAEMOLYTICA SEROTYPE CULTURE(12,4)
ANIMAL STATE PATHOLOGY(12,2)
INACTIVATED CONCENTRATE MIXTURE(12,2)
NATURAL EXPOSURE(12,1)
AQUEOUS EXTRACT(11,5)
CELL EXTRACTION(11,3)
EXTRACT PURIFICATION(11,2)
INACTIVATED EXTRACT MIXTURE(11,2)
MEMBRANE ANTIGEN(11,2)
TEST DID(11,1)
AQUEOUS MINERAL SOLUTION(10,4)
PURIFIED EXTRACT(10,2)
BACTERIAL BODY FRACTION(10,1)
ORGAN(10,1)
STRAIN PASTEURELLA HAEMOLYTICA(9,6)
ORGANIC SALT(9,4)
PASTEURELLOSIS(9,3)
SUPERNATANT CONCENTRATION(9,3)
AUTHOR(9,2)
CONCENTRATED CULTURE SUPERNATANT(8,6)
DISEASE(7,2)
PASTEURELLA HAEMOLYTICA SEROTYPE PATHOGENICITY(7,1)
WHITE MEAT(7,1)
STRAIN(6,11)
ANIMAL(6,9)
VACCINE EFFICACY(6,4)
BACTERIAL CULTURE CONCENTRATED SUPERNATANT(6,2)
DANISH COMPANY SUPERFO(6,2)
VIRULENT PASTEURELLA HAEMOLYTICA(6,2)
BRONCHOPNEUMONIA TYPE(6,1)
SEROTYPE STRAIN(5,3)
CELLULAR MATERIAL ELIMINATION(5,2)
CAPSULAR ANTIGEN PRECIPITATION(5,1)
BIOTYPE(4,10)
PLACEBO(4,9)
COMMERCIAL VACCINE(4,3)
ALUMINUM HYDROXIDE AQUEOUS GEL(4,2)
BOVINE RESPIRATORY TRACT(4,2)
EXPERIMENTAL INFECTION(4,2)
NASAL PHARYNGEAL SWAB(4,2)
TRANSTRACHEAL INJECTION(4,2)
VACCINE DOSE(4,2)
CAPSULAR ANTIGEN RECOVERY(4,1)
CETYLTRIMETHYL AMMONIUM BROMIDE(4,1)
DEXTROSE STARCH BROTH(4,1)
NON TYPABLE PASTEURELLA HAEMOLYTICA(4,1)
PASTEURELLA HAEMOLYTICA CULTIVATION(4,1)
PASTEURELLA HAEMOLYTICA SEROTYPE CELL(4,1)
PASTEURELLA HAEMOLYTICA SEROTYPE DISTRIBUTION(4,1)
PASTEURELLA HAEMOLYTICA SEROTYPE FREQUENCY(4,1)
VACCINE LEUCOTOXIC ACTIVITY(4,1)
PASSIVE HAEMAGGLUTINATION(3,3)
SICK ANIMAL(3,2)
SODIUM SALICYLATE(3,2)
TWO CONCENTRATE BIOLOGICAL INACTIVATION(3,2)
YOUNG CALF(3,2)
ANNUAL CONGRESS(3,1)
BOVINE ORIGIN STRAIN(3,1)
DILUTION RECIPROCAL(3,1)
NASAL MUCUS EXAMINATION(3,1)
PASTEURELLA MUTLOCIDA(3,1)
QUILLAIA SAPONIN(3,1)
RECOMBINANT LEUCOTOXIN(3,1)
SEROTYPE PREVALENCE(3,1)
STRAIN CULTURE SUPERNATANT(3,1)
STUDY AUTHOR(3,1)
TRANSTRACHEAL SUCTION(3,1)
DEMONSTRATION(2,3)
ADJUVANT(2,2)
ARABINOSE(2,2)
BOVINE SAMPLE(2,2)
BRONCHUS(2,2)
CELL CULTURE BOTTLE(2,2)
CONCENTRATE VOLUME(2,2)
GELOSE MEDIUM(2,2)
LOGARITHMIC STAGE(2,2)
MORTALITY(2,2)
PRERUMINANT CALF(2,2)
SODIUM BICARBONATE SOLUTION(2,2)
TREHALOSE(2,2)
ANIMAL HUSBANDRY FAILURE(2,1)
ANIMAL SPECIES(2,1)
ATCC COLLECTION(2,1)
BACTERIA STUDY(2,1)
BIOLOGICAL GERM(2,1)
BOVINE SPECIES(2,1)
BRAIN HEART(2,1)
CELL SOLUBILIZATION(2,1)
CLINICAL EVALUATION(2,1)
CONCENTRATE QUANTITY(2,1)
CONCENTRATED SUPERNATANT MIXTURE(2,1)
DILUTED CONCENTRATE MIXTURE(2,1)
DOUBT REGARDING(2,1)
DSB BROTH(2,1)
EARLY STUDY(2,1)
FINAL LEUCOTOXIC ACTIVITY(2,1)
FREQUENTLY HEALTHY CARRIER(2,1)
HEALTHY ANIMAL NASAL CAVITY(2,1)
HEAT INACTIVATION(2,1)
INDUCED LESION(2,1)
INFUSION BROTH(2,1)
INTRAMUSCULAR DOSE(2,1)
INTRINSIC TOXICITY(2,1)
LEUCOTOXIN CONTENT(2,1)
LUNG EVALUATION(2,1)
LUNG FLORA(2,1)
MAJOR PATHOGENIC AGENT(2,1)
NAKED EYE(2,1)
NORTH IRELAND(2,1)
OLD CALF(2,1)
PASTEURELLA SAMPLE(2,1)
PERCENTAGE TOXICITY(2,1)
PETRI DISH(2,1)
PULMONARY SITE(2,1)
QUIL MOTHER SOLUTION(2,1)
SAMPLE DILUTION(2,1)
SAMPLE STRONG DILUTION(2,1)
SEROTYPE SAMPLE(2,1)
SEVERE PNEUMONIA(2,1)
SICK BOVINE(2,1)
SODIUM METABISULPHITE SOLUTION(2,1)
SPECIES ACCOUNTING(2,1)
STERILE AMPOULE(2,1)
STRAIN MULTIPLICATION(2,1)
SUPERNATANT QUANTITY(2,1)
SURVIVING CELL(2,1)
THOROUGH DIALYSIS(2,1)
TOXIC ACTIVITY PERCENTAGE(2,1)
TRACHEOBRONCHIAL SAMPLE(2,1)
TRADEMARK ALHYDROGEL(2,1)
TYPABLE SAMPLE(2,1)
VACCINE INJECTION(2,1)
VACCINE PREPARATION DOSE(2,1)
VACCINE PROTECTIVE CAPACITY(2,1)
UFC(1,4)
AQUEOUS FORMALDEHYDE SOLUTION(1,1)
BOVINE LEUKEMIA CELL(1,1)
CHEMICAL INACTIVATION(1,1)
CO2 ATMOSPHERE(1,1)
DECREASING TOXICITY(1,1)
DEOXYRIBONUCLEASE(1,1)
DIRECT HAEMAGGLUTINATION(1,1)
ENZYMATIC TREATMENT(1,1)
FINAL VACCINE(1,1)
FORMALDEHYDE AQUEOUS SOLUTION(1,1)
FUNDAMENTAL DIFFERENCE(1,1)
GEL FILTRATION(1,1)
IMMUNIZATION(1,1)
INFECTION EXTENT(1,1)
LIPOSACCHARIDE(1,1)
LOGARITHMIC GROWTH PHASE(1,1)
OVINE BASIS(1,1)";Pharmaceuticals;Open
